cancer_type	qtl_type	tag_SNP	LD	SNP_id	gene_id	gene_symbol	t-stat	p-value	FDR	beta	r	Traits	SNP_position	Gene_position
OV	cis	rs1577917	0.655	rs1059307	ENSG00000203875.9	SNHG5	21.8	1.37e-57	1.23e-51	0.89	0.82	Response to antipsychotic treatment;	chr6:85678170	chr6:85660950~85678736:-
OV	cis	rs1577917	0.655	rs9444352	ENSG00000203875.9	SNHG5	18.57	1.96e-47	7.56e-42	0.82	0.78	Response to antipsychotic treatment;	chr6:85547817	chr6:85660950~85678736:-
OV	cis	rs1577917	0.56	rs9450288	ENSG00000203875.9	SNHG5	17.42	9.97e-44	2.11e-38	0.8	0.76	Response to antipsychotic treatment;	chr6:85511868	chr6:85660950~85678736:-
OV	cis	rs62445005	1	rs62445005	ENSG00000211697.3	TRGV5	16.33	3.59e-40	4.84e-35	1.01	0.73	Shingles;	chr7:38346957	chr7:38343894~38350022:-
OV	cis	rs1577917	0.74	rs2475792	ENSG00000203875.9	SNHG5	16.29	4.78e-40	6.37e-35	0.81	0.73	Response to antipsychotic treatment;	chr6:85682384	chr6:85660950~85678736:-
OV	cis	rs1577917	0.74	rs9344542	ENSG00000203875.9	SNHG5	16.19	1.03e-39	1.33e-34	0.8	0.73	Response to antipsychotic treatment;	chr6:85684187	chr6:85660950~85678736:-
OV	cis	rs2882667	0.69	rs906695	ENSG00000253404.1	AC034243.1	15.91	8.44e-39	9.68e-34	0.9	0.73	Age-related hearing impairment (SNP x SNP interaction);	chr5:138803588	chr5:138744434~138753309:-
OV	cis	rs1577917	0.74	rs7752502	ENSG00000203875.9	SNHG5	15.73	3.34e-38	3.36e-33	0.8	0.72	Response to antipsychotic treatment;	chr6:85700933	chr6:85660950~85678736:-
OV	cis	rs507080	0.922	rs478371	ENSG00000255239.1	AP002954.6	15.61	8.04e-38	7.96e-33	0.86	0.72	Serum metabolite levels;	chr11:118694627	chr11:118688039~118690600:-
OV	cis	rs1577917	0.682	rs1173419	ENSG00000203875.9	SNHG5	-15.61	8.23e-38	8.08e-33	-0.78	-0.72	Response to antipsychotic treatment;	chr6:85692445	chr6:85660950~85678736:-
OV	cis	rs1577917	0.682	rs1173417	ENSG00000203875.9	SNHG5	15.4	4.05e-37	3.63e-32	0.79	0.71	Response to antipsychotic treatment;	chr6:85694223	chr6:85660950~85678736:-
OV	cis	rs507080	0.883	rs558593	ENSG00000255239.1	AP002954.6	15.39	4.38e-37	3.85e-32	0.86	0.71	Serum metabolite levels;	chr11:118691811	chr11:118688039~118690600:-
OV	cis	rs507080	0.922	rs558781	ENSG00000255239.1	AP002954.6	15.31	8.03e-37	6.81e-32	0.85	0.71	Serum metabolite levels;	chr11:118693688	chr11:118688039~118690600:-
OV	cis	rs507080	0.922	rs625513	ENSG00000255239.1	AP002954.6	15.27	1.05e-36	8.53e-32	0.85	0.71	Serum metabolite levels;	chr11:118685010	chr11:118688039~118690600:-
OV	cis	rs858239	0.601	rs7805206	ENSG00000230658.1	KLHL7-AS1	15.26	1.14e-36	9.07e-32	0.9	0.71	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23101228~23105703:-
OV	cis	rs507080	0.922	rs518028	ENSG00000255239.1	AP002954.6	15.25	1.25e-36	9.67e-32	0.86	0.71	Serum metabolite levels;	chr11:118694273	chr11:118688039~118690600:-
OV	cis	rs507080	0.922	rs519982	ENSG00000255239.1	AP002954.6	15.25	1.25e-36	9.67e-32	0.86	0.71	Serum metabolite levels;	chr11:118694522	chr11:118688039~118690600:-
OV	cis	rs507080	0.922	rs502601	ENSG00000255239.1	AP002954.6	15.25	1.25e-36	9.67e-32	0.86	0.71	Serum metabolite levels;	chr11:118694970	chr11:118688039~118690600:-
OV	cis	rs507080	0.922	rs7114458	ENSG00000255239.1	AP002954.6	15.25	1.25e-36	9.67e-32	0.86	0.71	Serum metabolite levels;	chr11:118695466	chr11:118688039~118690600:-
OV	cis	rs507080	0.922	rs7114216	ENSG00000255239.1	AP002954.6	15.25	1.25e-36	9.67e-32	0.86	0.71	Serum metabolite levels;	chr11:118695525	chr11:118688039~118690600:-
OV	cis	rs507080	0.922	rs582630	ENSG00000255239.1	AP002954.6	15.22	1.6e-36	1.22e-31	0.85	0.71	Serum metabolite levels;	chr11:118692090	chr11:118688039~118690600:-
OV	cis	rs507080	0.883	rs527475	ENSG00000255239.1	AP002954.6	15.22	1.6e-36	1.22e-31	0.85	0.71	Serum metabolite levels;	chr11:118692530	chr11:118688039~118690600:-
OV	cis	rs507080	0.922	rs585039	ENSG00000255239.1	AP002954.6	15.22	1.6e-36	1.22e-31	0.85	0.71	Serum metabolite levels;	chr11:118692672	chr11:118688039~118690600:-
OV	cis	rs507080	0.885	rs533144	ENSG00000255239.1	AP002954.6	15.21	1.71e-36	1.3e-31	0.85	0.71	Serum metabolite levels;	chr11:118688538	chr11:118688039~118690600:-
OV	cis	rs858239	0.541	rs4624924	ENSG00000230658.1	KLHL7-AS1	15.2	1.92e-36	1.46e-31	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23101228~23105703:-
OV	cis	rs507080	0.922	rs546890	ENSG00000255239.1	AP002954.6	15.18	2.08e-36	1.51e-31	0.85	0.71	Serum metabolite levels;	chr11:118686489	chr11:118688039~118690600:-
OV	cis	rs507080	0.883	rs693306	ENSG00000255239.1	AP002954.6	15.18	2.08e-36	1.51e-31	0.85	0.71	Serum metabolite levels;	chr11:118687624	chr11:118688039~118690600:-
OV	cis	rs507080	0.922	rs561845	ENSG00000255239.1	AP002954.6	15.18	2.08e-36	1.51e-31	0.85	0.71	Serum metabolite levels;	chr11:118688118	chr11:118688039~118690600:-
OV	cis	rs507080	0.922	rs638805	ENSG00000255239.1	AP002954.6	15.18	2.08e-36	1.51e-31	0.85	0.71	Serum metabolite levels;	chr11:118688180	chr11:118688039~118690600:-
OV	cis	rs507080	0.845	rs510408	ENSG00000255239.1	AP002954.6	15.18	2.08e-36	1.51e-31	0.85	0.71	Serum metabolite levels;	chr11:118688192	chr11:118688039~118690600:-
OV	cis	rs507080	0.845	rs509641	ENSG00000255239.1	AP002954.6	15.18	2.08e-36	1.51e-31	0.85	0.71	Serum metabolite levels;	chr11:118688243	chr11:118688039~118690600:-
OV	cis	rs507080	0.883	rs563549	ENSG00000255239.1	AP002954.6	15.18	2.08e-36	1.51e-31	0.85	0.71	Serum metabolite levels;	chr11:118688244	chr11:118688039~118690600:-
OV	cis	rs507080	0.883	rs12798453	ENSG00000255239.1	AP002954.6	15.18	2.08e-36	1.51e-31	0.85	0.71	Serum metabolite levels;	chr11:118690701	chr11:118688039~118690600:-
OV	cis	rs507080	0.961	rs34413584	ENSG00000255239.1	AP002954.6	15.17	2.28e-36	1.65e-31	0.85	0.71	Serum metabolite levels;	chr11:118675072	chr11:118688039~118690600:-
OV	cis	rs1577917	0.771	rs7762321	ENSG00000203875.9	SNHG5	15.17	2.3e-36	1.65e-31	0.79	0.71	Response to antipsychotic treatment;	chr6:85702428	chr6:85660950~85678736:-
OV	cis	rs507080	0.922	rs514143	ENSG00000255239.1	AP002954.6	15.17	2.33e-36	1.67e-31	0.85	0.71	Serum metabolite levels;	chr11:118687740	chr11:118688039~118690600:-
OV	cis	rs858239	0.601	rs6948469	ENSG00000230658.1	KLHL7-AS1	15.16	2.43e-36	1.73e-31	0.9	0.71	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23101228~23105703:-
OV	cis	rs507080	0.922	rs533646	ENSG00000255239.1	AP002954.6	15.14	2.91e-36	2.05e-31	0.86	0.71	Serum metabolite levels;	chr11:118696037	chr11:118688039~118690600:-
OV	cis	rs507080	0.922	rs642662	ENSG00000255239.1	AP002954.6	15.14	2.91e-36	2.05e-31	0.86	0.71	Serum metabolite levels;	chr11:118696311	chr11:118688039~118690600:-
OV	cis	rs507080	0.922	rs508640	ENSG00000255239.1	AP002954.6	15.13	3.23e-36	2.26e-31	0.85	0.71	Serum metabolite levels;	chr11:118693704	chr11:118688039~118690600:-
OV	cis	rs507080	0.922	rs471227	ENSG00000255239.1	AP002954.6	15.13	3.23e-36	2.26e-31	0.85	0.71	Serum metabolite levels;	chr11:118693892	chr11:118688039~118690600:-
OV	cis	rs507080	0.922	rs516153	ENSG00000255239.1	AP002954.6	15.13	3.23e-36	2.26e-31	0.85	0.71	Serum metabolite levels;	chr11:118694053	chr11:118688039~118690600:-
OV	cis	rs507080	0.922	rs555356	ENSG00000255239.1	AP002954.6	15.11	3.7e-36	2.56e-31	0.85	0.71	Serum metabolite levels;	chr11:118687369	chr11:118688039~118690600:-
OV	cis	rs507080	0.922	rs558907	ENSG00000255239.1	AP002954.6	15.08	4.63e-36	3.11e-31	0.85	0.71	Serum metabolite levels;	chr11:118687746	chr11:118688039~118690600:-
OV	cis	rs507080	0.885	rs7926959	ENSG00000255239.1	AP002954.6	15.08	4.63e-36	3.11e-31	0.85	0.71	Serum metabolite levels;	chr11:118689157	chr11:118688039~118690600:-
OV	cis	rs507080	0.663	rs7926970	ENSG00000255239.1	AP002954.6	15.08	4.63e-36	3.11e-31	0.85	0.71	Serum metabolite levels;	chr11:118689172	chr11:118688039~118690600:-
OV	cis	rs507080	0.885	rs4938530	ENSG00000255239.1	AP002954.6	15.08	4.63e-36	3.11e-31	0.85	0.71	Serum metabolite levels;	chr11:118689861	chr11:118688039~118690600:-
OV	cis	rs507080	0.845	rs667982	ENSG00000255239.1	AP002954.6	15.07	4.85e-36	3.23e-31	0.85	0.71	Serum metabolite levels;	chr11:118692058	chr11:118688039~118690600:-
OV	cis	rs507080	0.922	rs644867	ENSG00000255239.1	AP002954.6	15.07	4.87e-36	3.24e-31	0.86	0.71	Serum metabolite levels;	chr11:118696836	chr11:118688039~118690600:-
OV	cis	rs507080	0.885	rs693037	ENSG00000255239.1	AP002954.6	15.06	5.23e-36	3.45e-31	0.85	0.71	Serum metabolite levels;	chr11:118682617	chr11:118688039~118690600:-
OV	cis	rs858239	0.601	rs6962526	ENSG00000230658.1	KLHL7-AS1	15.05	5.88e-36	3.86e-31	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23101228~23105703:-
OV	cis	rs858239	0.539	rs6971673	ENSG00000230658.1	KLHL7-AS1	15.05	5.88e-36	3.86e-31	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23101228~23105703:-
OV	cis	rs507080	0.845	rs613377	ENSG00000255239.1	AP002954.6	15.04	6.35e-36	4.16e-31	0.85	0.71	Serum metabolite levels;	chr11:118685375	chr11:118688039~118690600:-
OV	cis	rs858239	0.6	rs2072368	ENSG00000230658.1	KLHL7-AS1	15.03	6.62e-36	4.31e-31	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23101228~23105703:-
OV	cis	rs507080	0.922	rs478296	ENSG00000255239.1	AP002954.6	15.01	7.54e-36	4.86e-31	0.87	0.71	Serum metabolite levels;	chr11:118696666	chr11:118688039~118690600:-
OV	cis	rs507080	0.922	rs493834	ENSG00000255239.1	AP002954.6	15.01	7.54e-36	4.86e-31	0.87	0.71	Serum metabolite levels;	chr11:118696735	chr11:118688039~118690600:-
OV	cis	rs507080	0.922	rs644498	ENSG00000255239.1	AP002954.6	15.01	7.54e-36	4.86e-31	0.87	0.71	Serum metabolite levels;	chr11:118696777	chr11:118688039~118690600:-
OV	cis	rs858239	0.601	rs10278700	ENSG00000230658.1	KLHL7-AS1	15.01	7.73e-36	4.96e-31	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23101228~23105703:-
OV	cis	rs858239	0.601	rs10263110	ENSG00000230658.1	KLHL7-AS1	15.01	7.73e-36	4.96e-31	0.91	0.71	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23101228~23105703:-
OV	cis	rs858239	0.601	rs6980224	ENSG00000230658.1	KLHL7-AS1	14.98	9.98e-36	6.34e-31	0.9	0.7	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23101228~23105703:-
OV	cis	rs858239	0.509	rs57611130	ENSG00000230658.1	KLHL7-AS1	14.98	9.99e-36	6.34e-31	0.93	0.7	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23101228~23105703:-
OV	cis	rs858239	0.601	rs11982002	ENSG00000230658.1	KLHL7-AS1	14.92	1.53e-35	9.55e-31	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23101228~23105703:-
OV	cis	rs858239	0.601	rs1558313	ENSG00000230658.1	KLHL7-AS1	14.92	1.54e-35	9.61e-31	0.9	0.7	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23101228~23105703:-
OV	cis	rs858239	0.6	rs7787110	ENSG00000230658.1	KLHL7-AS1	14.86	2.51e-35	1.46e-30	0.9	0.7	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23101228~23105703:-
OV	cis	rs507080	0.922	rs4589335	ENSG00000255239.1	AP002954.6	14.85	2.53e-35	1.46e-30	0.83	0.7	Serum metabolite levels;	chr11:118668431	chr11:118688039~118690600:-
OV	cis	rs858239	0.539	rs6955969	ENSG00000230658.1	KLHL7-AS1	14.84	2.72e-35	1.57e-30	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23101228~23105703:-
OV	cis	rs858239	0.601	rs2141307	ENSG00000230658.1	KLHL7-AS1	14.83	2.97e-35	1.71e-30	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23101228~23105703:-
OV	cis	rs507080	0.961	rs642530	ENSG00000255239.1	AP002954.6	14.82	3.3e-35	1.89e-30	0.83	0.7	Serum metabolite levels;	chr11:118680047	chr11:118688039~118690600:-
OV	cis	rs1577917	0.839	rs9450333	ENSG00000203875.9	SNHG5	-14.82	3.3e-35	1.89e-30	-0.78	-0.7	Response to antipsychotic treatment;	chr6:85810037	chr6:85660950~85678736:-
OV	cis	rs507080	0.807	rs7926944	ENSG00000255239.1	AP002954.6	14.82	3.35e-35	1.91e-30	0.85	0.7	Serum metabolite levels;	chr11:118689119	chr11:118688039~118690600:-
OV	cis	rs858239	0.6	rs10241208	ENSG00000230658.1	KLHL7-AS1	14.8	3.69e-35	2.05e-30	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23101228~23105703:-
OV	cis	rs858239	0.539	rs57864591	ENSG00000230658.1	KLHL7-AS1	14.77	4.79e-35	2.51e-30	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23101228~23105703:-
OV	cis	rs858239	0.539	rs4294098	ENSG00000230658.1	KLHL7-AS1	14.77	4.79e-35	2.51e-30	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23101228~23105703:-
OV	cis	rs858239	0.539	rs4504540	ENSG00000230658.1	KLHL7-AS1	14.77	4.79e-35	2.51e-30	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23101228~23105703:-
OV	cis	rs858239	0.509	rs6975524	ENSG00000230658.1	KLHL7-AS1	14.77	4.79e-35	2.51e-30	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23101228~23105703:-
OV	cis	rs858239	0.539	rs6955726	ENSG00000230658.1	KLHL7-AS1	14.77	4.79e-35	2.51e-30	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23101228~23105703:-
OV	cis	rs858239	0.539	rs6976957	ENSG00000230658.1	KLHL7-AS1	14.77	4.79e-35	2.51e-30	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23101228~23105703:-
OV	cis	rs507080	0.883	rs692750	ENSG00000255239.1	AP002954.6	14.77	4.9e-35	2.55e-30	0.83	0.7	Serum metabolite levels;	chr11:118667599	chr11:118688039~118690600:-
OV	cis	rs507080	0.961	rs520543	ENSG00000255239.1	AP002954.6	14.76	5.13e-35	2.66e-30	0.83	0.7	Serum metabolite levels;	chr11:118667448	chr11:118688039~118690600:-
OV	cis	rs507080	0.922	rs4936433	ENSG00000255239.1	AP002954.6	-14.75	5.36e-35	2.77e-30	-0.8	-0.7	Serum metabolite levels;	chr11:118681711	chr11:118688039~118690600:-
OV	cis	rs858239	0.601	rs10278776	ENSG00000230658.1	KLHL7-AS1	14.74	6.23e-35	3.22e-30	0.89	0.7	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23101228~23105703:-
OV	cis	rs507080	0.961	rs4457789	ENSG00000255239.1	AP002954.6	14.72	6.92e-35	3.55e-30	0.83	0.7	Serum metabolite levels;	chr11:118668461	chr11:118688039~118690600:-
OV	cis	rs858239	0.539	rs6956828	ENSG00000230658.1	KLHL7-AS1	14.71	7.62e-35	3.89e-30	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23101228~23105703:-
OV	cis	rs858239	0.539	rs4295546	ENSG00000230658.1	KLHL7-AS1	14.69	8.79e-35	4.43e-30	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23101228~23105703:-
OV	cis	rs858239	0.601	rs987257	ENSG00000230658.1	KLHL7-AS1	14.69	8.83e-35	4.44e-30	0.89	0.7	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23101228~23105703:-
OV	cis	rs858239	0.57	rs10235467	ENSG00000230658.1	KLHL7-AS1	14.68	9.28e-35	4.65e-30	0.89	0.7	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23101228~23105703:-
OV	cis	rs858239	0.601	rs764534	ENSG00000230658.1	KLHL7-AS1	14.67	1.03e-34	5.13e-30	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23101228~23105703:-
OV	cis	rs858239	0.601	rs929507	ENSG00000230658.1	KLHL7-AS1	14.67	1.03e-34	5.15e-30	0.89	0.7	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23101228~23105703:-
OV	cis	rs858239	0.601	rs929508	ENSG00000230658.1	KLHL7-AS1	14.67	1.03e-34	5.15e-30	0.89	0.7	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23101228~23105703:-
OV	cis	rs858239	0.539	rs7791200	ENSG00000230658.1	KLHL7-AS1	14.65	1.21e-34	6.02e-30	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23101228~23105703:-
OV	cis	rs858239	0.539	rs2103281	ENSG00000230658.1	KLHL7-AS1	14.63	1.33e-34	6.61e-30	0.91	0.7	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23101228~23105703:-
OV	cis	rs858239	0.601	rs4599714	ENSG00000230658.1	KLHL7-AS1	14.59	1.86e-34	9.14e-30	0.89	0.7	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23101228~23105703:-
OV	cis	rs507080	0.922	rs592280	ENSG00000255239.1	AP002954.6	14.57	2.1e-34	1.03e-29	0.83	0.7	Serum metabolite levels;	chr11:118682509	chr11:118688039~118690600:-
OV	cis	rs858239	0.6	rs10266123	ENSG00000230658.1	KLHL7-AS1	14.57	2.19e-34	1.07e-29	0.92	0.7	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23101228~23105703:-
OV	cis	rs858239	0.57	rs6968242	ENSG00000230658.1	KLHL7-AS1	14.57	2.23e-34	1.09e-29	0.89	0.7	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23101228~23105703:-
OV	cis	rs858239	0.601	rs15775	ENSG00000230658.1	KLHL7-AS1	14.55	2.53e-34	1.23e-29	0.89	0.69	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23101228~23105703:-
OV	cis	rs858239	0.601	rs2068459	ENSG00000230658.1	KLHL7-AS1	14.54	2.81e-34	1.36e-29	0.9	0.69	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23101228~23105703:-
OV	cis	rs858239	0.6	rs6461691	ENSG00000230658.1	KLHL7-AS1	14.53	3.04e-34	1.46e-29	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23101228~23105703:-
OV	cis	rs858239	0.6	rs2072369	ENSG00000230658.1	KLHL7-AS1	14.51	3.31e-34	1.58e-29	0.9	0.69	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23101228~23105703:-
OV	cis	rs858239	0.632	rs13438452	ENSG00000230658.1	KLHL7-AS1	14.51	3.44e-34	1.63e-29	0.88	0.69	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23101228~23105703:-
OV	cis	rs858239	0.601	rs1981665	ENSG00000230658.1	KLHL7-AS1	14.49	3.99e-34	1.87e-29	0.89	0.69	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23101228~23105703:-
OV	cis	rs858239	0.6	rs28646184	ENSG00000230658.1	KLHL7-AS1	14.47	4.55e-34	2.13e-29	0.89	0.69	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23101228~23105703:-
OV	cis	rs858239	0.6	rs10256524	ENSG00000230658.1	KLHL7-AS1	14.42	6.5e-34	2.99e-29	0.89	0.69	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23101228~23105703:-
OV	cis	rs858239	0.601	rs3735228	ENSG00000230658.1	KLHL7-AS1	14.42	6.75e-34	3.1e-29	0.88	0.69	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23101228~23105703:-
OV	cis	rs858239	0.601	rs73272053	ENSG00000230658.1	KLHL7-AS1	14.39	8.23e-34	3.76e-29	0.9	0.69	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23101228~23105703:-
OV	cis	rs507080	0.769	rs745663	ENSG00000255239.1	AP002954.6	14.39	8.27e-34	3.77e-29	0.83	0.69	Serum metabolite levels;	chr11:118658886	chr11:118688039~118690600:-
OV	cis	rs858239	0.57	rs10271613	ENSG00000230658.1	KLHL7-AS1	14.38	8.97e-34	4.08e-29	0.89	0.69	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23101228~23105703:-
OV	cis	rs858239	0.57	rs10242166	ENSG00000230658.1	KLHL7-AS1	14.38	8.97e-34	4.08e-29	0.89	0.69	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23101228~23105703:-
OV	cis	rs507080	0.961	rs673770	ENSG00000255239.1	AP002954.6	14.38	8.98e-34	4.08e-29	0.82	0.69	Serum metabolite levels;	chr11:118679892	chr11:118688039~118690600:-
OV	cis	rs507080	0.961	rs656505	ENSG00000255239.1	AP002954.6	14.38	9.48e-34	4.28e-29	0.82	0.69	Serum metabolite levels;	chr11:118679245	chr11:118688039~118690600:-
OV	cis	rs507080	0.961	rs660489	ENSG00000255239.1	AP002954.6	14.38	9.48e-34	4.28e-29	0.82	0.69	Serum metabolite levels;	chr11:118679255	chr11:118688039~118690600:-
OV	cis	rs507080	0.961	rs543327	ENSG00000255239.1	AP002954.6	14.38	9.48e-34	4.28e-29	0.82	0.69	Serum metabolite levels;	chr11:118679276	chr11:118688039~118690600:-
OV	cis	rs507080	0.961	rs543413	ENSG00000255239.1	AP002954.6	14.38	9.48e-34	4.28e-29	0.82	0.69	Serum metabolite levels;	chr11:118679308	chr11:118688039~118690600:-
OV	cis	rs507080	0.922	rs12788848	ENSG00000255239.1	AP002954.6	14.36	1.04e-33	4.63e-29	0.82	0.69	Serum metabolite levels;	chr11:118683079	chr11:118688039~118690600:-
OV	cis	rs507080	0.922	rs4474473	ENSG00000255239.1	AP002954.6	14.36	1.04e-33	4.63e-29	0.82	0.69	Serum metabolite levels;	chr11:118683180	chr11:118688039~118690600:-
OV	cis	rs507080	0.922	rs12796373	ENSG00000255239.1	AP002954.6	14.36	1.04e-33	4.63e-29	0.82	0.69	Serum metabolite levels;	chr11:118684230	chr11:118688039~118690600:-
OV	cis	rs507080	0.961	rs600969	ENSG00000255239.1	AP002954.6	14.36	1.07e-33	4.74e-29	0.82	0.69	Serum metabolite levels;	chr11:118675087	chr11:118688039~118690600:-
OV	cis	rs507080	0.922	rs12577485	ENSG00000255239.1	AP002954.6	14.36	1.07e-33	4.74e-29	0.82	0.69	Serum metabolite levels;	chr11:118676793	chr11:118688039~118690600:-
OV	cis	rs507080	0.922	rs525485	ENSG00000255239.1	AP002954.6	14.33	1.34e-33	5.87e-29	0.84	0.69	Serum metabolite levels;	chr11:118685045	chr11:118688039~118690600:-
OV	cis	rs507080	0.922	rs519848	ENSG00000255239.1	AP002954.6	14.32	1.4e-33	6.1e-29	0.82	0.69	Serum metabolite levels;	chr11:118682006	chr11:118688039~118690600:-
OV	cis	rs1577917	0.839	rs6454492	ENSG00000203875.9	SNHG5	-14.32	1.46e-33	6.36e-29	-0.81	-0.69	Response to antipsychotic treatment;	chr6:85773496	chr6:85660950~85678736:-
OV	cis	rs2739330	0.791	rs4822458	ENSG00000273295.1	AP000350.5	14.31	1.52e-33	6.59e-29	0.86	0.69	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23901432~23907068:-
OV	cis	rs507080	1	rs507080	ENSG00000255239.1	AP002954.6	14.3	1.67e-33	7.24e-29	0.82	0.69	Serum metabolite levels;	chr11:118678873	chr11:118688039~118690600:-
OV	cis	rs507080	0.883	rs656575	ENSG00000255239.1	AP002954.6	14.29	1.85e-33	7.94e-29	0.82	0.69	Serum metabolite levels;	chr11:118679199	chr11:118688039~118690600:-
OV	cis	rs507080	0.961	rs642497	ENSG00000255239.1	AP002954.6	14.27	2.12e-33	8.85e-29	0.82	0.69	Serum metabolite levels;	chr11:118680075	chr11:118688039~118690600:-
OV	cis	rs858239	0.601	rs10224327	ENSG00000230658.1	KLHL7-AS1	14.27	2.14e-33	8.95e-29	0.9	0.69	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23101228~23105703:-
OV	cis	rs858239	0.602	rs6953996	ENSG00000230658.1	KLHL7-AS1	14.27	2.17e-33	9.02e-29	0.89	0.69	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23101228~23105703:-
OV	cis	rs858239	0.539	rs10280815	ENSG00000230658.1	KLHL7-AS1	14.26	2.19e-33	9.02e-29	0.89	0.69	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23101228~23105703:-
OV	cis	rs858239	0.539	rs10225608	ENSG00000230658.1	KLHL7-AS1	14.26	2.19e-33	9.02e-29	0.89	0.69	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23101228~23105703:-
OV	cis	rs5850	0.557	rs10270788	ENSG00000230658.1	KLHL7-AS1	14.26	2.19e-33	9.02e-29	0.89	0.69	Blood protein levels;	chr7:23149381	chr7:23101228~23105703:-
OV	cis	rs858239	0.539	rs28716381	ENSG00000230658.1	KLHL7-AS1	14.26	2.19e-33	9.02e-29	0.89	0.69	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23101228~23105703:-
OV	cis	rs858239	0.539	rs1358442	ENSG00000230658.1	KLHL7-AS1	14.26	2.19e-33	9.02e-29	0.89	0.69	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23101228~23105703:-
OV	cis	rs507080	0.961	rs4938523	ENSG00000255239.1	AP002954.6	14.26	2.2e-33	9.08e-29	0.82	0.69	Serum metabolite levels;	chr11:118678129	chr11:118688039~118690600:-
OV	cis	rs858239	0.601	rs6461693	ENSG00000230658.1	KLHL7-AS1	-14.26	2.33e-33	9.57e-29	-0.91	-0.69	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23101228~23105703:-
OV	cis	rs507080	0.961	rs1784298	ENSG00000255239.1	AP002954.6	14.25	2.37e-33	9.68e-29	0.82	0.69	Serum metabolite levels;	chr11:118677956	chr11:118688039~118690600:-
OV	cis	rs507080	0.961	rs4938522	ENSG00000255239.1	AP002954.6	14.25	2.37e-33	9.68e-29	0.82	0.69	Serum metabolite levels;	chr11:118677962	chr11:118688039~118690600:-
OV	cis	rs507080	1	rs659969	ENSG00000255239.1	AP002954.6	14.25	2.37e-33	9.68e-29	0.82	0.69	Serum metabolite levels;	chr11:118679094	chr11:118688039~118690600:-
OV	cis	rs858239	0.601	rs10239760	ENSG00000230658.1	KLHL7-AS1	14.25	2.41e-33	9.83e-29	0.9	0.69	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23101228~23105703:-
OV	cis	rs858239	0.6	rs1115941	ENSG00000230658.1	KLHL7-AS1	14.24	2.7e-33	1.1e-28	0.9	0.69	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23101228~23105703:-
OV	cis	rs858239	0.508	rs2390754	ENSG00000230658.1	KLHL7-AS1	14.23	2.95e-33	1.2e-28	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23101228~23105703:-
OV	cis	rs858239	0.571	rs2390755	ENSG00000230658.1	KLHL7-AS1	14.22	3.03e-33	1.21e-28	0.89	0.69	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23101228~23105703:-
OV	cis	rs858239	0.539	rs4365988	ENSG00000230658.1	KLHL7-AS1	14.22	3.03e-33	1.21e-28	0.89	0.69	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23101228~23105703:-
OV	cis	rs858239	0.539	rs10279194	ENSG00000230658.1	KLHL7-AS1	14.22	3.03e-33	1.21e-28	0.89	0.69	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23101228~23105703:-
OV	cis	rs858239	0.539	rs3950345	ENSG00000230658.1	KLHL7-AS1	14.22	3.03e-33	1.21e-28	0.89	0.69	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23101228~23105703:-
OV	cis	rs858239	0.539	rs2178140	ENSG00000230658.1	KLHL7-AS1	14.22	3.03e-33	1.21e-28	0.89	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23101228~23105703:-
OV	cis	rs858239	0.539	rs2178139	ENSG00000230658.1	KLHL7-AS1	14.22	3.03e-33	1.21e-28	0.89	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23101228~23105703:-
OV	cis	rs858239	0.539	rs2141306	ENSG00000230658.1	KLHL7-AS1	14.22	3.03e-33	1.21e-28	0.89	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23101228~23105703:-
OV	cis	rs858239	0.539	rs6945510	ENSG00000230658.1	KLHL7-AS1	14.22	3.03e-33	1.21e-28	0.89	0.69	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23101228~23105703:-
OV	cis	rs858239	0.601	rs4140959	ENSG00000230658.1	KLHL7-AS1	14.21	3.35e-33	1.34e-28	0.89	0.69	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23101228~23105703:-
OV	cis	rs858239	0.6	rs4628176	ENSG00000230658.1	KLHL7-AS1	14.2	3.45e-33	1.38e-28	0.9	0.69	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23101228~23105703:-
OV	cis	rs858239	0.601	rs10255228	ENSG00000230658.1	KLHL7-AS1	14.19	3.79e-33	1.51e-28	0.88	0.69	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23101228~23105703:-
OV	cis	rs858239	0.539	rs28624974	ENSG00000230658.1	KLHL7-AS1	14.18	4.01e-33	1.59e-28	0.89	0.69	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23101228~23105703:-
OV	cis	rs858239	0.508	rs7805071	ENSG00000230658.1	KLHL7-AS1	14.18	4.08e-33	1.61e-28	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23101228~23105703:-
OV	cis	rs858239	0.508	rs7805085	ENSG00000230658.1	KLHL7-AS1	14.18	4.08e-33	1.61e-28	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23101228~23105703:-
OV	cis	rs858239	0.6	rs2014768	ENSG00000230658.1	KLHL7-AS1	14.18	4.11e-33	1.61e-28	0.9	0.69	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23101228~23105703:-
OV	cis	rs858239	0.6	rs10256361	ENSG00000230658.1	KLHL7-AS1	14.18	4.11e-33	1.61e-28	0.9	0.69	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23101228~23105703:-
OV	cis	rs858239	0.6	rs6978827	ENSG00000230658.1	KLHL7-AS1	14.18	4.11e-33	1.61e-28	0.9	0.69	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23101228~23105703:-
OV	cis	rs858239	0.6	rs7790157	ENSG00000230658.1	KLHL7-AS1	14.18	4.11e-33	1.61e-28	0.9	0.69	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23101228~23105703:-
OV	cis	rs2882667	0.69	rs160401	ENSG00000253404.1	AC034243.1	-14.18	4.22e-33	1.65e-28	-0.89	-0.69	Age-related hearing impairment (SNP x SNP interaction);	chr5:138725652	chr5:138744434~138753309:-
OV	cis	rs858239	0.539	rs2390757	ENSG00000230658.1	KLHL7-AS1	14.18	4.26e-33	1.66e-28	0.91	0.69	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23101228~23105703:-
OV	cis	rs1577917	0.654	rs9450284	ENSG00000203875.9	SNHG5	14.17	4.49e-33	1.75e-28	0.76	0.69	Response to antipsychotic treatment;	chr6:85489611	chr6:85660950~85678736:-
OV	cis	rs858239	0.539	rs870476	ENSG00000230658.1	KLHL7-AS1	14.17	4.59e-33	1.78e-28	0.88	0.69	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23101228~23105703:-
OV	cis	rs858239	0.6	rs10488077	ENSG00000230658.1	KLHL7-AS1	14.16	4.99e-33	1.94e-28	0.9	0.68	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23101228~23105703:-
OV	cis	rs858239	0.601	rs12539331	ENSG00000230658.1	KLHL7-AS1	14.15	5.15e-33	1.99e-28	0.89	0.68	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23101228~23105703:-
OV	cis	rs858239	0.539	rs2141305	ENSG00000230658.1	KLHL7-AS1	14.14	5.49e-33	2.12e-28	0.89	0.68	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23101228~23105703:-
OV	cis	rs858239	0.601	rs73272048	ENSG00000230658.1	KLHL7-AS1	14.13	6.22e-33	2.4e-28	0.88	0.68	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23101228~23105703:-
OV	cis	rs507080	0.922	rs4938524	ENSG00000255239.1	AP002954.6	14.11	7.23e-33	2.78e-28	0.81	0.68	Serum metabolite levels;	chr11:118681365	chr11:118688039~118690600:-
OV	cis	rs858239	0.539	rs6965833	ENSG00000230658.1	KLHL7-AS1	14.1	7.34e-33	2.82e-28	0.89	0.68	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23101228~23105703:-
OV	cis	rs858239	0.539	rs6949363	ENSG00000230658.1	KLHL7-AS1	14.1	7.34e-33	2.82e-28	0.89	0.68	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23101228~23105703:-
OV	cis	rs858239	0.539	rs4559148	ENSG00000230658.1	KLHL7-AS1	14.1	7.63e-33	2.91e-28	0.91	0.68	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23101228~23105703:-
OV	cis	rs858239	0.539	rs4377861	ENSG00000230658.1	KLHL7-AS1	14.1	7.63e-33	2.91e-28	0.91	0.68	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23101228~23105703:-
OV	cis	rs858239	0.539	rs10247268	ENSG00000230658.1	KLHL7-AS1	14.1	7.63e-33	2.91e-28	0.91	0.68	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23101228~23105703:-
OV	cis	rs858239	0.539	rs6461694	ENSG00000230658.1	KLHL7-AS1	14.1	7.63e-33	2.91e-28	0.91	0.68	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23101228~23105703:-
OV	cis	rs858239	0.6	rs6960001	ENSG00000230658.1	KLHL7-AS1	14.08	8.65e-33	3.28e-28	0.89	0.68	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23101228~23105703:-
OV	cis	rs858239	0.6	rs10237755	ENSG00000230658.1	KLHL7-AS1	14.08	8.65e-33	3.28e-28	0.89	0.68	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23101228~23105703:-
OV	cis	rs858239	0.6	rs6961131	ENSG00000230658.1	KLHL7-AS1	14.08	8.65e-33	3.28e-28	0.89	0.68	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23101228~23105703:-
OV	cis	rs858239	0.601	rs1034963	ENSG00000230658.1	KLHL7-AS1	14.05	1.09e-32	4.12e-28	0.87	0.68	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23101228~23105703:-
OV	cis	rs507080	0.769	rs11603616	ENSG00000255239.1	AP002954.6	14.02	1.39e-32	5.18e-28	0.82	0.68	Serum metabolite levels;	chr11:118625350	chr11:118688039~118690600:-
OV	cis	rs507080	0.769	rs571001	ENSG00000255239.1	AP002954.6	14.02	1.39e-32	5.18e-28	0.82	0.68	Serum metabolite levels;	chr11:118629457	chr11:118688039~118690600:-
OV	cis	rs507080	0.769	rs570952	ENSG00000255239.1	AP002954.6	14.02	1.39e-32	5.18e-28	0.82	0.68	Serum metabolite levels;	chr11:118629477	chr11:118688039~118690600:-
OV	cis	rs507080	0.769	rs645637	ENSG00000255239.1	AP002954.6	14.02	1.39e-32	5.18e-28	0.82	0.68	Serum metabolite levels;	chr11:118634373	chr11:118688039~118690600:-
OV	cis	rs507080	0.769	rs483283	ENSG00000255239.1	AP002954.6	14.02	1.39e-32	5.18e-28	0.82	0.68	Serum metabolite levels;	chr11:118635684	chr11:118688039~118690600:-
OV	cis	rs507080	0.769	rs570836	ENSG00000255239.1	AP002954.6	14.02	1.39e-32	5.18e-28	0.82	0.68	Serum metabolite levels;	chr11:118641444	chr11:118688039~118690600:-
OV	cis	rs858239	0.601	rs6971002	ENSG00000230658.1	KLHL7-AS1	14.01	1.45e-32	5.41e-28	0.86	0.68	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23101228~23105703:-
OV	cis	rs507080	0.769	rs2077173	ENSG00000255239.1	AP002954.6	14	1.59e-32	5.93e-28	0.82	0.68	Serum metabolite levels;	chr11:118621876	chr11:118688039~118690600:-
OV	cis	rs858239	0.6	rs9691762	ENSG00000230658.1	KLHL7-AS1	13.95	2.4e-32	8.82e-28	0.89	0.68	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23101228~23105703:-
OV	cis	rs858239	0.539	rs6975852	ENSG00000230658.1	KLHL7-AS1	13.94	2.63e-32	9.63e-28	0.91	0.68	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23101228~23105703:-
OV	cis	rs858239	0.665	rs6964665	ENSG00000230658.1	KLHL7-AS1	13.92	2.87e-32	1.05e-27	0.91	0.68	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23101228~23105703:-
OV	cis	rs12439619	0.705	rs17354185	ENSG00000278603.1	RP13-608F4.5	-13.91	3.16e-32	1.15e-27	-1.06	-0.68	Intelligence (multi-trait analysis);	chr15:82133829	chr15:82472203~82472426:+
OV	cis	rs507080	0.769	rs7389	ENSG00000255239.1	AP002954.6	-13.89	3.7e-32	1.35e-27	-0.8	-0.68	Serum metabolite levels;	chr11:118657756	chr11:118688039~118690600:-
OV	cis	rs1577917	0.629	rs7761762	ENSG00000203875.9	SNHG5	13.7	1.59e-31	5.71e-27	0.75	0.67	Response to antipsychotic treatment;	chr6:85496250	chr6:85660950~85678736:-
OV	cis	rs858239	0.6	rs10233039	ENSG00000230658.1	KLHL7-AS1	13.62	2.84e-31	1.02e-26	0.88	0.67	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23101228~23105703:-
OV	cis	rs507080	0.845	rs481903	ENSG00000255239.1	AP002954.6	13.61	3.02e-31	1.08e-26	0.83	0.67	Serum metabolite levels;	chr11:118697024	chr11:118688039~118690600:-
OV	cis	rs801193	0.591	rs2707839	ENSG00000222364.1	RNU6-96P	-13.58	3.69e-31	1.32e-26	-0.69	-0.67	Aortic root size;	chr7:66728097	chr7:66395191~66395286:+
OV	cis	rs507080	0.961	rs607527	ENSG00000255239.1	AP002954.6	-13.55	4.88e-31	1.73e-26	-0.78	-0.67	Serum metabolite levels;	chr11:118667478	chr11:118688039~118690600:-
OV	cis	rs1577917	0.958	rs11758508	ENSG00000203875.9	SNHG5	13.54	5.09e-31	1.8e-26	0.79	0.67	Response to antipsychotic treatment;	chr6:85797160	chr6:85660950~85678736:-
OV	cis	rs801193	0.66	rs2659914	ENSG00000222364.1	RNU6-96P	-13.51	6.49e-31	2.29e-26	-0.69	-0.67	Aortic root size;	chr7:66691927	chr7:66395191~66395286:+
OV	cis	rs858239	0.699	rs858260	ENSG00000230658.1	KLHL7-AS1	13.5	7.01e-31	2.47e-26	0.9	0.67	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23101228~23105703:-
OV	cis	rs801193	0.613	rs2659900	ENSG00000222364.1	RNU6-96P	-13.5	7.14e-31	2.5e-26	-0.69	-0.67	Aortic root size;	chr7:66719456	chr7:66395191~66395286:+
OV	cis	rs858239	0.6	rs4409314	ENSG00000230658.1	KLHL7-AS1	13.49	7.46e-31	2.61e-26	0.88	0.67	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23101228~23105703:-
OV	cis	rs9326248	0.773	rs1060211	ENSG00000254851.1	RP11-109L13.1	-13.47	8.8e-31	3.07e-26	-0.95	-0.67	Blood protein levels;	chr11:117169081	chr11:117135528~117138582:+
OV	cis	rs801193	0.636	rs2659895	ENSG00000222364.1	RNU6-96P	-13.45	1.03e-30	3.58e-26	-0.69	-0.67	Aortic root size;	chr7:66731484	chr7:66395191~66395286:+
OV	cis	rs858239	0.539	rs6461695	ENSG00000230658.1	KLHL7-AS1	13.45	1.06e-30	3.67e-26	0.9	0.67	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23101228~23105703:-
OV	cis	rs858239	0.6	rs10235786	ENSG00000230658.1	KLHL7-AS1	13.43	1.2e-30	4.13e-26	0.88	0.67	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23101228~23105703:-
OV	cis	rs875971	1	rs7792762	ENSG00000222364.1	RNU6-96P	-13.42	1.28e-30	4.42e-26	-0.68	-0.67	Aortic root size;	chr7:66539151	chr7:66395191~66395286:+
OV	cis	rs801193	0.66	rs2659897	ENSG00000222364.1	RNU6-96P	13.42	1.29e-30	4.44e-26	0.68	0.67	Aortic root size;	chr7:66722728	chr7:66395191~66395286:+
OV	cis	rs507080	0.769	rs527290	ENSG00000255239.1	AP002954.6	13.39	1.56e-30	5.37e-26	0.81	0.66	Serum metabolite levels;	chr11:118644898	chr11:118688039~118690600:-
OV	cis	rs9326248	0.861	rs7931335	ENSG00000254851.1	RP11-109L13.1	-13.38	1.72e-30	5.87e-26	-0.94	-0.66	Blood protein levels;	chr11:117166089	chr11:117135528~117138582:+
OV	cis	rs858239	0.539	rs10270695	ENSG00000230658.1	KLHL7-AS1	-13.35	2.15e-30	7.3e-26	-0.88	-0.66	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23101228~23105703:-
OV	cis	rs875971	0.965	rs28682868	ENSG00000222364.1	RNU6-96P	13.32	2.61e-30	8.86e-26	0.68	0.66	Aortic root size;	chr7:66224822	chr7:66395191~66395286:+
OV	cis	rs9326248	0.861	rs4938353	ENSG00000254851.1	RP11-109L13.1	-13.31	2.91e-30	9.82e-26	-0.92	-0.66	Blood protein levels;	chr11:117175481	chr11:117135528~117138582:+
OV	cis	rs801193	0.548	rs2659904	ENSG00000222364.1	RNU6-96P	-13.3	3.04e-30	1.02e-25	-0.69	-0.66	Aortic root size;	chr7:66713615	chr7:66395191~66395286:+
OV	cis	rs801193	0.66	rs10950049	ENSG00000222364.1	RNU6-96P	-13.3	3.11e-30	1.05e-25	-0.68	-0.66	Aortic root size;	chr7:66765873	chr7:66395191~66395286:+
OV	cis	rs2739330	0.76	rs5751761	ENSG00000273295.1	AP000350.5	-13.29	3.48e-30	1.17e-25	-0.74	-0.66	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23901432~23907068:-
OV	cis	rs801193	0.66	rs974239	ENSG00000222364.1	RNU6-96P	-13.28	3.77e-30	1.26e-25	-0.68	-0.66	Aortic root size;	chr7:66748504	chr7:66395191~66395286:+
OV	cis	rs801193	0.66	rs1016265	ENSG00000222364.1	RNU6-96P	-13.28	3.77e-30	1.26e-25	-0.68	-0.66	Aortic root size;	chr7:66749580	chr7:66395191~66395286:+
OV	cis	rs801193	0.66	rs4610622	ENSG00000222364.1	RNU6-96P	-13.28	3.77e-30	1.26e-25	-0.68	-0.66	Aortic root size;	chr7:66759510	chr7:66395191~66395286:+
OV	cis	rs1577917	0.883	rs6454505	ENSG00000203875.9	SNHG5	-13.26	4.25e-30	1.42e-25	-0.74	-0.66	Response to antipsychotic treatment;	chr6:85882644	chr6:85660950~85678736:-
OV	cis	rs875971	1	rs6963646	ENSG00000222364.1	RNU6-96P	13.26	4.31e-30	1.43e-25	0.67	0.66	Aortic root size;	chr7:66220780	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs2420820	ENSG00000222364.1	RNU6-96P	13.21	6.25e-30	2.06e-25	0.68	0.66	Aortic root size;	chr7:66626920	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs1544549	ENSG00000222364.1	RNU6-96P	13.19	7.08e-30	2.33e-25	0.68	0.66	Aortic root size;	chr7:66625676	chr7:66395191~66395286:+
OV	cis	rs9326248	0.768	rs4936366	ENSG00000254851.1	RP11-109L13.1	-13.18	7.71e-30	2.53e-25	-0.94	-0.66	Blood protein levels;	chr11:117156169	chr11:117135528~117138582:+
OV	cis	rs9326248	0.861	rs4938352	ENSG00000254851.1	RP11-109L13.1	-13.18	7.71e-30	2.53e-25	-0.94	-0.66	Blood protein levels;	chr11:117156765	chr11:117135528~117138582:+
OV	cis	rs875971	0.898	rs6977501	ENSG00000222364.1	RNU6-96P	13.15	9.82e-30	3.22e-25	0.67	0.66	Aortic root size;	chr7:66228355	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs1167612	ENSG00000222364.1	RNU6-96P	13.14	1.02e-29	3.33e-25	0.68	0.66	Aortic root size;	chr7:66102989	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs2220626	ENSG00000222364.1	RNU6-96P	13.14	1.04e-29	3.4e-25	0.68	0.66	Aortic root size;	chr7:66081075	chr7:66395191~66395286:+
OV	cis	rs875971	0.964	rs697969	ENSG00000222364.1	RNU6-96P	13.14	1.09e-29	3.52e-25	0.68	0.66	Aortic root size;	chr7:66093491	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs697970	ENSG00000222364.1	RNU6-96P	13.14	1.09e-29	3.52e-25	0.68	0.66	Aortic root size;	chr7:66095065	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs1182882	ENSG00000222364.1	RNU6-96P	13.14	1.09e-29	3.52e-25	0.68	0.66	Aortic root size;	chr7:66097076	chr7:66395191~66395286:+
OV	cis	rs858239	0.6	rs7456915	ENSG00000230658.1	KLHL7-AS1	13.09	1.53e-29	4.89e-25	0.86	0.66	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23101228~23105703:-
OV	cis	rs858239	0.6	rs13438179	ENSG00000230658.1	KLHL7-AS1	13.09	1.53e-29	4.89e-25	0.86	0.66	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23101228~23105703:-
OV	cis	rs9326248	0.861	rs1871757	ENSG00000254851.1	RP11-109L13.1	-13.08	1.64e-29	5.24e-25	-1	-0.66	Blood protein levels;	chr11:117159865	chr11:117135528~117138582:+
OV	cis	rs875971	1	rs11974219	ENSG00000222364.1	RNU6-96P	13.08	1.71e-29	5.41e-25	0.66	0.66	Aortic root size;	chr7:66182423	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs11974264	ENSG00000222364.1	RNU6-96P	13.08	1.71e-29	5.41e-25	0.66	0.66	Aortic root size;	chr7:66182595	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs1540651	ENSG00000222364.1	RNU6-96P	13.08	1.71e-29	5.41e-25	0.66	0.66	Aortic root size;	chr7:66185134	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs1565531	ENSG00000222364.1	RNU6-96P	13.08	1.71e-29	5.41e-25	0.66	0.66	Aortic root size;	chr7:66198126	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs55962648	ENSG00000222364.1	RNU6-96P	13.06	1.96e-29	6.18e-25	0.66	0.65	Aortic root size;	chr7:66160764	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs11971949	ENSG00000222364.1	RNU6-96P	13.06	1.96e-29	6.18e-25	0.66	0.65	Aortic root size;	chr7:66161027	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs2420168	ENSG00000222364.1	RNU6-96P	13.06	1.96e-29	6.18e-25	0.66	0.65	Aortic root size;	chr7:66165644	chr7:66395191~66395286:+
OV	cis	rs9326248	0.861	rs7120309	ENSG00000254851.1	RP11-109L13.1	-13.05	2.13e-29	6.7e-25	-0.93	-0.65	Blood protein levels;	chr11:117172100	chr11:117135528~117138582:+
OV	cis	rs9326248	0.861	rs7120449	ENSG00000254851.1	RP11-109L13.1	-13.05	2.13e-29	6.7e-25	-0.93	-0.65	Blood protein levels;	chr11:117172183	chr11:117135528~117138582:+
OV	cis	rs875971	0.965	rs6971509	ENSG00000222364.1	RNU6-96P	13.03	2.31e-29	7.27e-25	0.67	0.65	Aortic root size;	chr7:66249983	chr7:66395191~66395286:+
OV	cis	rs858239	0.6	rs7785842	ENSG00000230658.1	KLHL7-AS1	13.02	2.49e-29	7.8e-25	0.86	0.65	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23101228~23105703:-
OV	cis	rs801193	0.66	rs1962050	ENSG00000222364.1	RNU6-96P	13.02	2.55e-29	7.94e-25	0.66	0.65	Aortic root size;	chr7:66775021	chr7:66395191~66395286:+
OV	cis	rs9326248	0.727	rs4938347	ENSG00000254851.1	RP11-109L13.1	-13.01	2.75e-29	8.51e-25	-0.95	-0.65	Blood protein levels;	chr11:117151043	chr11:117135528~117138582:+
OV	cis	rs9326248	0.813	rs4938350	ENSG00000254851.1	RP11-109L13.1	-13.01	2.75e-29	8.51e-25	-0.95	-0.65	Blood protein levels;	chr11:117151560	chr11:117135528~117138582:+
OV	cis	rs875971	1	rs9986696	ENSG00000222364.1	RNU6-96P	12.99	3.15e-29	9.72e-25	0.68	0.65	Aortic root size;	chr7:66239589	chr7:66395191~66395286:+
OV	cis	rs801193	0.636	rs10233806	ENSG00000222364.1	RNU6-96P	12.98	3.46e-29	1.07e-24	0.68	0.65	Aortic root size;	chr7:66653261	chr7:66395191~66395286:+
OV	cis	rs858239	0.6	rs7776649	ENSG00000230658.1	KLHL7-AS1	12.97	3.81e-29	1.17e-24	0.87	0.65	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23101228~23105703:-
OV	cis	rs875971	0.965	rs10267430	ENSG00000222364.1	RNU6-96P	12.97	3.87e-29	1.19e-24	0.67	0.65	Aortic root size;	chr7:66278036	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs10257427	ENSG00000222364.1	RNU6-96P	12.97	3.87e-29	1.19e-24	0.67	0.65	Aortic root size;	chr7:66278221	chr7:66395191~66395286:+
OV	cis	rs507080	0.733	rs4486664	ENSG00000255239.1	AP002954.6	12.96	3.95e-29	1.2e-24	0.82	0.65	Serum metabolite levels;	chr11:118698358	chr11:118688039~118690600:-
OV	cis	rs875971	1	rs6946143	ENSG00000222364.1	RNU6-96P	-12.92	5.32e-29	1.6e-24	-0.66	-0.65	Aortic root size;	chr7:66114735	chr7:66395191~66395286:+
OV	cis	rs1577917	0.771	rs9450319	ENSG00000203875.9	SNHG5	12.92	5.34e-29	1.61e-24	0.75	0.65	Response to antipsychotic treatment;	chr6:85717607	chr6:85660950~85678736:-
OV	cis	rs507080	0.697	rs656287	ENSG00000255239.1	AP002954.6	12.92	5.54e-29	1.66e-24	0.82	0.65	Serum metabolite levels;	chr11:118701081	chr11:118688039~118690600:-
OV	cis	rs507080	0.733	rs570949	ENSG00000255239.1	AP002954.6	12.92	5.54e-29	1.66e-24	0.82	0.65	Serum metabolite levels;	chr11:118701202	chr11:118688039~118690600:-
OV	cis	rs858239	0.601	rs6966776	ENSG00000230658.1	KLHL7-AS1	12.92	5.6e-29	1.67e-24	0.86	0.65	Cerebrospinal fluid biomarker levels;	chr7:23126389	chr7:23101228~23105703:-
OV	cis	rs507080	0.733	rs7108144	ENSG00000255239.1	AP002954.6	12.91	5.89e-29	1.74e-24	0.82	0.65	Serum metabolite levels;	chr11:118698985	chr11:118688039~118690600:-
OV	cis	rs507080	0.663	rs523793	ENSG00000255239.1	AP002954.6	12.91	5.89e-29	1.74e-24	0.82	0.65	Serum metabolite levels;	chr11:118699988	chr11:118688039~118690600:-
OV	cis	rs507080	0.736	rs659564	ENSG00000255239.1	AP002954.6	12.91	5.89e-29	1.74e-24	0.82	0.65	Serum metabolite levels;	chr11:118700205	chr11:118688039~118690600:-
OV	cis	rs507080	0.736	rs642224	ENSG00000255239.1	AP002954.6	12.91	5.89e-29	1.74e-24	0.82	0.65	Serum metabolite levels;	chr11:118700210	chr11:118688039~118690600:-
OV	cis	rs507080	0.733	rs541631	ENSG00000255239.1	AP002954.6	12.91	5.89e-29	1.74e-24	0.82	0.65	Serum metabolite levels;	chr11:118700314	chr11:118688039~118690600:-
OV	cis	rs507080	0.736	rs658676	ENSG00000255239.1	AP002954.6	12.91	5.89e-29	1.74e-24	0.82	0.65	Serum metabolite levels;	chr11:118700414	chr11:118688039~118690600:-
OV	cis	rs507080	0.733	rs488141	ENSG00000255239.1	AP002954.6	12.91	5.89e-29	1.74e-24	0.82	0.65	Serum metabolite levels;	chr11:118700459	chr11:118688039~118690600:-
OV	cis	rs507080	0.733	rs657769	ENSG00000255239.1	AP002954.6	12.91	5.89e-29	1.74e-24	0.82	0.65	Serum metabolite levels;	chr11:118700607	chr11:118688039~118690600:-
OV	cis	rs507080	0.733	rs544452	ENSG00000255239.1	AP002954.6	12.91	5.89e-29	1.74e-24	0.82	0.65	Serum metabolite levels;	chr11:118700648	chr11:118688039~118690600:-
OV	cis	rs9326248	0.813	rs474488	ENSG00000254851.1	RP11-109L13.1	-12.9	6.11e-29	1.8e-24	-0.92	-0.65	Blood protein levels;	chr11:117198261	chr11:117135528~117138582:+
OV	cis	rs858239	0.6	rs1468592	ENSG00000230658.1	KLHL7-AS1	-12.89	6.96e-29	2.04e-24	-0.87	-0.65	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23101228~23105703:-
OV	cis	rs9326248	0.813	rs7115562	ENSG00000254851.1	RP11-109L13.1	-12.88	7.09e-29	2.07e-24	-0.94	-0.65	Blood protein levels;	chr11:117149754	chr11:117135528~117138582:+
OV	cis	rs9326248	0.652	rs7128382	ENSG00000254851.1	RP11-109L13.1	-12.88	7.09e-29	2.07e-24	-0.94	-0.65	Blood protein levels;	chr11:117152771	chr11:117135528~117138582:+
OV	cis	rs875971	1	rs4718307	ENSG00000222364.1	RNU6-96P	12.88	7.1e-29	2.07e-24	0.66	0.65	Aortic root size;	chr7:66146001	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs7801282	ENSG00000222364.1	RNU6-96P	12.88	7.1e-29	2.07e-24	0.66	0.65	Aortic root size;	chr7:66148700	chr7:66395191~66395286:+
OV	cis	rs875971	0.965	rs7794930	ENSG00000222364.1	RNU6-96P	12.88	7.19e-29	2.1e-24	0.67	0.65	Aortic root size;	chr7:66313559	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs875971	ENSG00000222364.1	RNU6-96P	12.87	7.88e-29	2.29e-24	0.66	0.65	Aortic root size;	chr7:66152608	chr7:66395191~66395286:+
OV	cis	rs1577917	0.538	rs6454483	ENSG00000203875.9	SNHG5	12.84	9.7e-29	2.81e-24	0.71	0.65	Response to antipsychotic treatment;	chr6:85708565	chr6:85660950~85678736:-
OV	cis	rs507080	0.697	rs653008	ENSG00000255239.1	AP002954.6	12.83	1.04e-28	3.02e-24	0.79	0.65	Serum metabolite levels;	chr11:118649775	chr11:118688039~118690600:-
OV	cis	rs1577917	0.739	rs9450318	ENSG00000203875.9	SNHG5	12.82	1.18e-28	3.38e-24	0.75	0.65	Response to antipsychotic treatment;	chr6:85717459	chr6:85660950~85678736:-
OV	cis	rs9326248	0.861	rs4938348	ENSG00000254851.1	RP11-109L13.1	-12.81	1.28e-28	3.67e-24	-0.94	-0.65	Blood protein levels;	chr11:117151161	chr11:117135528~117138582:+
OV	cis	rs507080	0.733	rs601318	ENSG00000255239.1	AP002954.6	12.8	1.33e-28	3.81e-24	0.79	0.65	Serum metabolite levels;	chr11:118648845	chr11:118688039~118690600:-
OV	cis	rs875971	1	rs10244498	ENSG00000222364.1	RNU6-96P	-12.8	1.34e-28	3.81e-24	-0.68	-0.65	Aortic root size;	chr7:66651069	chr7:66395191~66395286:+
OV	cis	rs1577917	0.771	rs7742201	ENSG00000203875.9	SNHG5	-12.8	1.35e-28	3.86e-24	-0.77	-0.65	Response to antipsychotic treatment;	chr6:85723212	chr6:85660950~85678736:-
OV	cis	rs1577917	0.727	rs9444361	ENSG00000203875.9	SNHG5	12.78	1.5e-28	4.27e-24	0.77	0.65	Response to antipsychotic treatment;	chr6:85691182	chr6:85660950~85678736:-
OV	cis	rs858239	0.632	rs7811903	ENSG00000230658.1	KLHL7-AS1	12.78	1.58e-28	4.49e-24	0.86	0.65	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23101228~23105703:-
OV	cis	rs875971	1	rs2087647	ENSG00000222364.1	RNU6-96P	12.77	1.64e-28	4.62e-24	0.65	0.65	Aortic root size;	chr7:66128201	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs6958484	ENSG00000222364.1	RNU6-96P	12.77	1.64e-28	4.62e-24	0.65	0.65	Aortic root size;	chr7:66134459	chr7:66395191~66395286:+
OV	cis	rs2882667	0.728	rs13181830	ENSG00000253404.1	AC034243.1	-12.77	1.65e-28	4.63e-24	-0.82	-0.65	Age-related hearing impairment (SNP x SNP interaction);	chr5:138944727	chr5:138744434~138753309:-
OV	cis	rs1577917	1	rs2816821	ENSG00000203875.9	SNHG5	-12.76	1.81e-28	5.06e-24	-0.73	-0.65	Response to antipsychotic treatment;	chr6:85947366	chr6:85660950~85678736:-
OV	cis	rs875971	1	rs6961717	ENSG00000222364.1	RNU6-96P	12.75	1.94e-28	5.4e-24	0.65	0.65	Aortic root size;	chr7:66122550	chr7:66395191~66395286:+
OV	cis	rs507080	0.733	rs611733	ENSG00000255239.1	AP002954.6	12.74	2.05e-28	5.67e-24	0.81	0.65	Serum metabolite levels;	chr11:118702051	chr11:118688039~118690600:-
OV	cis	rs507080	0.733	rs552079	ENSG00000255239.1	AP002954.6	12.74	2.05e-28	5.67e-24	0.81	0.65	Serum metabolite levels;	chr11:118702313	chr11:118688039~118690600:-
OV	cis	rs875971	1	rs6956179	ENSG00000222364.1	RNU6-96P	12.74	2.08e-28	5.75e-24	0.66	0.65	Aortic root size;	chr7:66341672	chr7:66395191~66395286:+
OV	cis	rs1577917	0.785	rs1885607	ENSG00000203875.9	SNHG5	12.73	2.23e-28	6.15e-24	0.78	0.65	Response to antipsychotic treatment;	chr6:85685187	chr6:85660950~85678736:-
OV	cis	rs875971	1	rs10215948	ENSG00000222364.1	RNU6-96P	12.72	2.43e-28	6.66e-24	0.66	0.65	Aortic root size;	chr7:66282799	chr7:66395191~66395286:+
OV	cis	rs875971	0.838	rs2173570	ENSG00000222364.1	RNU6-96P	12.72	2.43e-28	6.66e-24	0.66	0.65	Aortic root size;	chr7:66297976	chr7:66395191~66395286:+
OV	cis	rs875971	0.964	rs55748098	ENSG00000222364.1	RNU6-96P	12.72	2.43e-28	6.66e-24	0.66	0.65	Aortic root size;	chr7:66298631	chr7:66395191~66395286:+
OV	cis	rs875971	0.929	rs10950041	ENSG00000222364.1	RNU6-96P	-12.72	2.44e-28	6.68e-24	-0.66	-0.65	Aortic root size;	chr7:66508888	chr7:66395191~66395286:+
OV	cis	rs875971	0.929	rs6970860	ENSG00000222364.1	RNU6-96P	-12.72	2.44e-28	6.68e-24	-0.66	-0.65	Aortic root size;	chr7:66511647	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs6957199	ENSG00000222364.1	RNU6-96P	-12.72	2.44e-28	6.68e-24	-0.66	-0.65	Aortic root size;	chr7:66513532	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs937495	ENSG00000222364.1	RNU6-96P	12.71	2.56e-28	6.93e-24	0.66	0.64	Aortic root size;	chr7:66314811	chr7:66395191~66395286:+
OV	cis	rs875971	0.965	rs9969301	ENSG00000222364.1	RNU6-96P	12.71	2.56e-28	6.93e-24	0.66	0.64	Aortic root size;	chr7:66316668	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs2036264	ENSG00000222364.1	RNU6-96P	12.71	2.56e-28	6.93e-24	0.66	0.64	Aortic root size;	chr7:66334917	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs7783613	ENSG00000222364.1	RNU6-96P	12.71	2.56e-28	6.93e-24	0.66	0.64	Aortic root size;	chr7:66340274	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs12532998	ENSG00000222364.1	RNU6-96P	-12.7	2.88e-28	7.73e-24	-0.66	-0.64	Aortic root size;	chr7:66502472	chr7:66395191~66395286:+
OV	cis	rs875971	0.867	rs1002053	ENSG00000222364.1	RNU6-96P	12.7	2.89e-28	7.74e-24	0.66	0.64	Aortic root size;	chr7:66333558	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs6460292	ENSG00000222364.1	RNU6-96P	12.7	2.89e-28	7.74e-24	0.66	0.64	Aortic root size;	chr7:66345088	chr7:66395191~66395286:+
OV	cis	rs875971	0.83	rs4718358	ENSG00000222364.1	RNU6-96P	-12.7	2.92e-28	7.8e-24	-0.66	-0.64	Aortic root size;	chr7:66508681	chr7:66395191~66395286:+
OV	cis	rs1577917	0.958	rs9647601	ENSG00000203875.9	SNHG5	-12.69	2.98e-28	7.96e-24	-0.74	-0.64	Response to antipsychotic treatment;	chr6:85740109	chr6:85660950~85678736:-
OV	cis	rs875971	0.895	rs3857684	ENSG00000222364.1	RNU6-96P	-12.68	3.16e-28	8.37e-24	-0.66	-0.64	Aortic root size;	chr7:66473171	chr7:66395191~66395286:+
OV	cis	rs875971	0.964	rs6978429	ENSG00000222364.1	RNU6-96P	-12.68	3.16e-28	8.37e-24	-0.66	-0.64	Aortic root size;	chr7:66494889	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs4718357	ENSG00000222364.1	RNU6-96P	-12.68	3.16e-28	8.37e-24	-0.66	-0.64	Aortic root size;	chr7:66495891	chr7:66395191~66395286:+
OV	cis	rs875971	0.929	rs12535036	ENSG00000222364.1	RNU6-96P	-12.68	3.16e-28	8.37e-24	-0.66	-0.64	Aortic root size;	chr7:66499076	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs12533997	ENSG00000222364.1	RNU6-96P	-12.68	3.16e-28	8.37e-24	-0.66	-0.64	Aortic root size;	chr7:66500390	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs12698523	ENSG00000222364.1	RNU6-96P	-12.68	3.16e-28	8.37e-24	-0.66	-0.64	Aortic root size;	chr7:66503126	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs6970030	ENSG00000222364.1	RNU6-96P	-12.68	3.16e-28	8.37e-24	-0.66	-0.64	Aortic root size;	chr7:66503692	chr7:66395191~66395286:+
OV	cis	rs875971	0.928	rs6970357	ENSG00000222364.1	RNU6-96P	-12.68	3.16e-28	8.37e-24	-0.66	-0.64	Aortic root size;	chr7:66503891	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs3735148	ENSG00000222364.1	RNU6-96P	-12.68	3.16e-28	8.37e-24	-0.66	-0.64	Aortic root size;	chr7:66506022	chr7:66395191~66395286:+
OV	cis	rs858239	0.601	rs6969733	ENSG00000230658.1	KLHL7-AS1	12.68	3.2e-28	8.45e-24	0.83	0.64	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23101228~23105703:-
OV	cis	rs858239	0.601	rs4440529	ENSG00000230658.1	KLHL7-AS1	12.68	3.2e-28	8.45e-24	0.83	0.64	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23101228~23105703:-
OV	cis	rs1577917	1	rs6454513	ENSG00000203875.9	SNHG5	12.66	3.78e-28	9.88e-24	0.73	0.64	Response to antipsychotic treatment;	chr6:86010331	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs13199006	ENSG00000203875.9	SNHG5	-12.66	3.83e-28	9.89e-24	-0.72	-0.64	Response to antipsychotic treatment;	chr6:85898990	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs4707239	ENSG00000203875.9	SNHG5	-12.66	3.83e-28	9.89e-24	-0.72	-0.64	Response to antipsychotic treatment;	chr6:85900999	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs7766645	ENSG00000203875.9	SNHG5	-12.66	3.83e-28	9.89e-24	-0.72	-0.64	Response to antipsychotic treatment;	chr6:85912520	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs1911552	ENSG00000203875.9	SNHG5	-12.66	3.83e-28	9.89e-24	-0.72	-0.64	Response to antipsychotic treatment;	chr6:85928306	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs9647603	ENSG00000203875.9	SNHG5	-12.66	3.83e-28	9.89e-24	-0.72	-0.64	Response to antipsychotic treatment;	chr6:85929623	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs35385043	ENSG00000203875.9	SNHG5	-12.66	3.83e-28	9.89e-24	-0.72	-0.64	Response to antipsychotic treatment;	chr6:85938828	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs35760725	ENSG00000203875.9	SNHG5	-12.66	3.83e-28	9.89e-24	-0.72	-0.64	Response to antipsychotic treatment;	chr6:85939267	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs2660576	ENSG00000203875.9	SNHG5	-12.66	3.83e-28	9.89e-24	-0.72	-0.64	Response to antipsychotic treatment;	chr6:85941885	chr6:85660950~85678736:-
OV	cis	rs858239	0.511	rs10256996	ENSG00000230658.1	KLHL7-AS1	-12.66	3.89e-28	1e-23	-0.8	-0.64	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23101228~23105703:-
OV	cis	rs507080	0.733	rs673547	ENSG00000255239.1	AP002954.6	12.63	4.79e-28	1.23e-23	0.81	0.64	Serum metabolite levels;	chr11:118702630	chr11:118688039~118690600:-
OV	cis	rs9326248	0.813	rs588534	ENSG00000254851.1	RP11-109L13.1	-12.63	4.79e-28	1.23e-23	-0.9	-0.64	Blood protein levels;	chr11:117197788	chr11:117135528~117138582:+
OV	cis	rs858239	0.536	rs6956974	ENSG00000230658.1	KLHL7-AS1	-12.62	5.1e-28	1.3e-23	-0.86	-0.64	Cerebrospinal fluid biomarker levels;	chr7:23212699	chr7:23101228~23105703:-
OV	cis	rs875971	1	rs709595	ENSG00000222364.1	RNU6-96P	-12.62	5.23e-28	1.33e-23	-0.66	-0.64	Aortic root size;	chr7:66352346	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs811880	ENSG00000222364.1	RNU6-96P	-12.62	5.23e-28	1.33e-23	-0.66	-0.64	Aortic root size;	chr7:66353659	chr7:66395191~66395286:+
OV	cis	rs875971	0.964	rs778735	ENSG00000222364.1	RNU6-96P	-12.62	5.33e-28	1.36e-23	-0.66	-0.64	Aortic root size;	chr7:66349822	chr7:66395191~66395286:+
OV	cis	rs875971	0.965	rs697968	ENSG00000222364.1	RNU6-96P	12.61	5.65e-28	1.43e-23	0.67	0.64	Aortic root size;	chr7:66070046	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs1167411	ENSG00000222364.1	RNU6-96P	12.61	5.65e-28	1.43e-23	0.67	0.64	Aortic root size;	chr7:66074277	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs1183245	ENSG00000222364.1	RNU6-96P	12.61	5.65e-28	1.43e-23	0.67	0.64	Aortic root size;	chr7:66076198	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs1144895	ENSG00000222364.1	RNU6-96P	12.61	5.65e-28	1.43e-23	0.67	0.64	Aortic root size;	chr7:66076320	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs1144894	ENSG00000222364.1	RNU6-96P	12.61	5.65e-28	1.43e-23	0.67	0.64	Aortic root size;	chr7:66077907	chr7:66395191~66395286:+
OV	cis	rs1577917	1	rs2816815	ENSG00000203875.9	SNHG5	-12.6	6.11e-28	1.54e-23	-0.72	-0.64	Response to antipsychotic treatment;	chr6:85981938	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs2812972	ENSG00000203875.9	SNHG5	-12.59	6.33e-28	1.59e-23	-0.73	-0.64	Response to antipsychotic treatment;	chr6:85960162	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs12216074	ENSG00000203875.9	SNHG5	-12.59	6.42e-28	1.61e-23	-0.74	-0.64	Response to antipsychotic treatment;	chr6:85810284	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs6454488	ENSG00000203875.9	SNHG5	-12.59	6.65e-28	1.67e-23	-0.74	-0.64	Response to antipsychotic treatment;	chr6:85741124	chr6:85660950~85678736:-
OV	cis	rs875971	1	rs6945843	ENSG00000222364.1	RNU6-96P	12.57	7.3e-28	1.83e-23	0.66	0.64	Aortic root size;	chr7:66269796	chr7:66395191~66395286:+
OV	cis	rs875971	0.964	rs60193905	ENSG00000222364.1	RNU6-96P	-12.57	7.31e-28	1.83e-23	-0.65	-0.64	Aortic root size;	chr7:66506273	chr7:66395191~66395286:+
OV	cis	rs858239	0.601	rs764533	ENSG00000230658.1	KLHL7-AS1	12.56	7.75e-28	1.9e-23	0.83	0.64	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23101228~23105703:-
OV	cis	rs875971	1	rs778726	ENSG00000222364.1	RNU6-96P	-12.56	7.85e-28	1.9e-23	-0.66	-0.64	Aortic root size;	chr7:66363744	chr7:66395191~66395286:+
OV	cis	rs875971	0.964	rs778723	ENSG00000222364.1	RNU6-96P	-12.56	7.85e-28	1.9e-23	-0.66	-0.64	Aortic root size;	chr7:66364510	chr7:66395191~66395286:+
OV	cis	rs875971	0.767	rs1695815	ENSG00000222364.1	RNU6-96P	-12.56	7.85e-28	1.9e-23	-0.66	-0.64	Aortic root size;	chr7:66366357	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs778685	ENSG00000222364.1	RNU6-96P	-12.56	7.85e-28	1.9e-23	-0.66	-0.64	Aortic root size;	chr7:66371189	chr7:66395191~66395286:+
OV	cis	rs875971	0.929	rs778682	ENSG00000222364.1	RNU6-96P	-12.56	7.85e-28	1.9e-23	-0.66	-0.64	Aortic root size;	chr7:66372947	chr7:66395191~66395286:+
OV	cis	rs875971	0.964	rs11765965	ENSG00000222364.1	RNU6-96P	-12.56	7.85e-28	1.9e-23	-0.66	-0.64	Aortic root size;	chr7:66377234	chr7:66395191~66395286:+
OV	cis	rs875971	0.964	rs1643388	ENSG00000222364.1	RNU6-96P	-12.56	7.85e-28	1.9e-23	-0.66	-0.64	Aortic root size;	chr7:66379575	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs778722	ENSG00000222364.1	RNU6-96P	-12.56	7.85e-28	1.9e-23	-0.66	-0.64	Aortic root size;	chr7:66379841	chr7:66395191~66395286:+
OV	cis	rs875971	0.964	rs778721	ENSG00000222364.1	RNU6-96P	-12.56	7.85e-28	1.9e-23	-0.66	-0.64	Aortic root size;	chr7:66380410	chr7:66395191~66395286:+
OV	cis	rs875971	0.929	rs778712	ENSG00000222364.1	RNU6-96P	-12.56	7.85e-28	1.9e-23	-0.66	-0.64	Aortic root size;	chr7:66384991	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs778710	ENSG00000222364.1	RNU6-96P	-12.56	7.85e-28	1.9e-23	-0.66	-0.64	Aortic root size;	chr7:66389847	chr7:66395191~66395286:+
OV	cis	rs875971	0.964	rs778708	ENSG00000222364.1	RNU6-96P	-12.56	7.85e-28	1.9e-23	-0.66	-0.64	Aortic root size;	chr7:66391332	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs778706	ENSG00000222364.1	RNU6-96P	-12.56	7.85e-28	1.9e-23	-0.66	-0.64	Aortic root size;	chr7:66395437	chr7:66395191~66395286:+
OV	cis	rs875971	0.895	rs778700	ENSG00000222364.1	RNU6-96P	-12.56	7.85e-28	1.9e-23	-0.66	-0.64	Aortic root size;	chr7:66401463	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs778699	ENSG00000222364.1	RNU6-96P	-12.56	7.85e-28	1.9e-23	-0.66	-0.64	Aortic root size;	chr7:66403303	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs778696	ENSG00000222364.1	RNU6-96P	-12.56	7.85e-28	1.9e-23	-0.66	-0.64	Aortic root size;	chr7:66405826	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs778694	ENSG00000222364.1	RNU6-96P	-12.56	7.85e-28	1.9e-23	-0.66	-0.64	Aortic root size;	chr7:66406571	chr7:66395191~66395286:+
OV	cis	rs875971	0.929	rs778692	ENSG00000222364.1	RNU6-96P	-12.56	7.85e-28	1.9e-23	-0.66	-0.64	Aortic root size;	chr7:66407462	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs4718343	ENSG00000222364.1	RNU6-96P	-12.56	7.85e-28	1.9e-23	-0.66	-0.64	Aortic root size;	chr7:66409301	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs4718344	ENSG00000222364.1	RNU6-96P	-12.56	7.85e-28	1.9e-23	-0.66	-0.64	Aortic root size;	chr7:66409394	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs1968225	ENSG00000222364.1	RNU6-96P	-12.56	7.85e-28	1.9e-23	-0.66	-0.64	Aortic root size;	chr7:66409786	chr7:66395191~66395286:+
OV	cis	rs875971	0.737	rs7803424	ENSG00000222364.1	RNU6-96P	-12.56	7.85e-28	1.9e-23	-0.66	-0.64	Aortic root size;	chr7:66415618	chr7:66395191~66395286:+
OV	cis	rs875971	0.83	rs7799834	ENSG00000222364.1	RNU6-96P	-12.56	7.85e-28	1.9e-23	-0.66	-0.64	Aortic root size;	chr7:66415707	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs6460295	ENSG00000222364.1	RNU6-96P	-12.56	7.85e-28	1.9e-23	-0.66	-0.64	Aortic root size;	chr7:66417741	chr7:66395191~66395286:+
OV	cis	rs875971	0.964	rs6978721	ENSG00000222364.1	RNU6-96P	-12.56	7.85e-28	1.9e-23	-0.66	-0.64	Aortic root size;	chr7:66418217	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs6979382	ENSG00000222364.1	RNU6-96P	-12.56	7.85e-28	1.9e-23	-0.66	-0.64	Aortic root size;	chr7:66421388	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs6961990	ENSG00000222364.1	RNU6-96P	-12.56	7.85e-28	1.9e-23	-0.66	-0.64	Aortic root size;	chr7:66423583	chr7:66395191~66395286:+
OV	cis	rs1577917	0.518	rs2475787	ENSG00000203875.9	SNHG5	12.56	8.15e-28	1.97e-23	0.7	0.64	Response to antipsychotic treatment;	chr6:85705518	chr6:85660950~85678736:-
OV	cis	rs1577917	0.771	rs9362239	ENSG00000203875.9	SNHG5	12.55	8.35e-28	2.02e-23	0.74	0.64	Response to antipsychotic treatment;	chr6:85719545	chr6:85660950~85678736:-
OV	cis	rs858239	0.571	rs6953020	ENSG00000230658.1	KLHL7-AS1	12.55	8.96e-28	2.14e-23	0.83	0.64	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23101228~23105703:-
OV	cis	rs1577917	0.771	rs6454486	ENSG00000203875.9	SNHG5	12.54	9.08e-28	2.17e-23	0.74	0.64	Response to antipsychotic treatment;	chr6:85723869	chr6:85660950~85678736:-
OV	cis	rs1577917	0.917	rs1414201	ENSG00000203875.9	SNHG5	-12.54	9.19e-28	2.19e-23	-0.76	-0.64	Response to antipsychotic treatment;	chr6:85790598	chr6:85660950~85678736:-
OV	cis	rs1577917	0.916	rs4142546	ENSG00000203875.9	SNHG5	-12.53	1.02e-27	2.42e-23	-0.74	-0.64	Response to antipsychotic treatment;	chr6:85795593	chr6:85660950~85678736:-
OV	cis	rs1577917	0.518	rs6454482	ENSG00000203875.9	SNHG5	12.51	1.15e-27	2.69e-23	0.7	0.64	Response to antipsychotic treatment;	chr6:85708470	chr6:85660950~85678736:-
OV	cis	rs1577917	0.916	rs12206726	ENSG00000203875.9	SNHG5	-12.5	1.28e-27	2.97e-23	-0.75	-0.64	Response to antipsychotic treatment;	chr6:85789998	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs7453105	ENSG00000203875.9	SNHG5	-12.5	1.28e-27	2.97e-23	-0.75	-0.64	Response to antipsychotic treatment;	chr6:85791043	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs12209259	ENSG00000203875.9	SNHG5	-12.5	1.28e-27	2.97e-23	-0.75	-0.64	Response to antipsychotic treatment;	chr6:85792630	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs12191340	ENSG00000203875.9	SNHG5	-12.49	1.32e-27	3.05e-23	-0.73	-0.64	Response to antipsychotic treatment;	chr6:85811682	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs1414199	ENSG00000203875.9	SNHG5	-12.49	1.32e-27	3.05e-23	-0.73	-0.64	Response to antipsychotic treatment;	chr6:85812652	chr6:85660950~85678736:-
OV	cis	rs858239	0.6	rs6461692	ENSG00000230658.1	KLHL7-AS1	12.48	1.48e-27	3.4e-23	0.83	0.64	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23101228~23105703:-
OV	cis	rs1577917	1	rs16876529	ENSG00000203875.9	SNHG5	-12.47	1.58e-27	3.6e-23	-0.73	-0.64	Response to antipsychotic treatment;	chr6:85881484	chr6:85660950~85678736:-
OV	cis	rs1577917	0.771	rs3812133	ENSG00000203875.9	SNHG5	-12.46	1.63e-27	3.72e-23	-0.75	-0.64	Response to antipsychotic treatment;	chr6:85644693	chr6:85660950~85678736:-
OV	cis	rs1577917	0.876	rs4618490	ENSG00000203875.9	SNHG5	-12.46	1.67e-27	3.8e-23	-0.75	-0.64	Response to antipsychotic treatment;	chr6:85808685	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs6900436	ENSG00000203875.9	SNHG5	-12.46	1.69e-27	3.82e-23	-0.74	-0.64	Response to antipsychotic treatment;	chr6:85796570	chr6:85660950~85678736:-
OV	cis	rs1577917	0.687	rs1470531	ENSG00000203875.9	SNHG5	-12.46	1.69e-27	3.82e-23	-0.74	-0.64	Response to antipsychotic treatment;	chr6:85797651	chr6:85660950~85678736:-
OV	cis	rs875971	1	rs6958271	ENSG00000222364.1	RNU6-96P	-12.46	1.73e-27	3.92e-23	-0.66	-0.64	Aortic root size;	chr7:66514344	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs6958277	ENSG00000222364.1	RNU6-96P	-12.46	1.73e-27	3.92e-23	-0.66	-0.64	Aortic root size;	chr7:66514362	chr7:66395191~66395286:+
OV	cis	rs1577917	0.771	rs2484355	ENSG00000203875.9	SNHG5	-12.45	1.83e-27	4.15e-23	-0.75	-0.64	Response to antipsychotic treatment;	chr6:85684685	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs1337843	ENSG00000203875.9	SNHG5	-12.44	2.02e-27	4.55e-23	-0.73	-0.64	Response to antipsychotic treatment;	chr6:85965827	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs12190603	ENSG00000203875.9	SNHG5	-12.42	2.24e-27	5.02e-23	-0.75	-0.64	Response to antipsychotic treatment;	chr6:85766000	chr6:85660950~85678736:-
OV	cis	rs1577917	0.917	rs4707226	ENSG00000203875.9	SNHG5	-12.39	2.85e-27	6.36e-23	-0.74	-0.64	Response to antipsychotic treatment;	chr6:85818110	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs6923148	ENSG00000203875.9	SNHG5	12.39	2.86e-27	6.38e-23	0.73	0.64	Response to antipsychotic treatment;	chr6:86058068	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs34581302	ENSG00000203875.9	SNHG5	-12.38	2.99e-27	6.66e-23	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85996230	chr6:85660950~85678736:-
OV	cis	rs507080	0.733	rs4393358	ENSG00000255239.1	AP002954.6	12.38	3.11e-27	6.92e-23	0.79	0.63	Serum metabolite levels;	chr11:118698388	chr11:118688039~118690600:-
OV	cis	rs1577917	1	rs1962716	ENSG00000203875.9	SNHG5	-12.37	3.23e-27	7.15e-23	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85938718	chr6:85660950~85678736:-
OV	cis	rs858239	0.539	rs10254544	ENSG00000230658.1	KLHL7-AS1	12.37	3.25e-27	7.15e-23	0.86	0.63	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23101228~23105703:-
OV	cis	rs1577917	0.958	rs36042496	ENSG00000203875.9	SNHG5	-12.37	3.25e-27	7.15e-23	-0.73	-0.63	Response to antipsychotic treatment;	chr6:85814496	chr6:85660950~85678736:-
OV	cis	rs1577917	0.917	rs1584273	ENSG00000203875.9	SNHG5	-12.37	3.25e-27	7.15e-23	-0.73	-0.63	Response to antipsychotic treatment;	chr6:85814859	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs12198971	ENSG00000203875.9	SNHG5	-12.37	3.25e-27	7.15e-23	-0.73	-0.63	Response to antipsychotic treatment;	chr6:85815727	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs34230196	ENSG00000203875.9	SNHG5	-12.37	3.25e-27	7.15e-23	-0.73	-0.63	Response to antipsychotic treatment;	chr6:85816304	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs10455448	ENSG00000203875.9	SNHG5	-12.37	3.25e-27	7.15e-23	-0.73	-0.63	Response to antipsychotic treatment;	chr6:85823893	chr6:85660950~85678736:-
OV	cis	rs1577917	0.876	rs12212808	ENSG00000203875.9	SNHG5	-12.37	3.25e-27	7.15e-23	-0.73	-0.63	Response to antipsychotic treatment;	chr6:85824254	chr6:85660950~85678736:-
OV	cis	rs1577917	0.917	rs13196576	ENSG00000203875.9	SNHG5	-12.37	3.25e-27	7.15e-23	-0.73	-0.63	Response to antipsychotic treatment;	chr6:85824348	chr6:85660950~85678736:-
OV	cis	rs1577917	0.917	rs13213603	ENSG00000203875.9	SNHG5	-12.37	3.25e-27	7.15e-23	-0.73	-0.63	Response to antipsychotic treatment;	chr6:85825040	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs3857480	ENSG00000203875.9	SNHG5	-12.37	3.25e-27	7.15e-23	-0.73	-0.63	Response to antipsychotic treatment;	chr6:85825431	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs34994386	ENSG00000203875.9	SNHG5	-12.37	3.35e-27	7.35e-23	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85814417	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs11755642	ENSG00000203875.9	SNHG5	-12.36	3.62e-27	7.91e-23	-0.77	-0.63	Response to antipsychotic treatment;	chr6:85740348	chr6:85660950~85678736:-
OV	cis	rs1577917	0.771	rs9362237	ENSG00000203875.9	SNHG5	12.36	3.63e-27	7.94e-23	0.76	0.63	Response to antipsychotic treatment;	chr6:85699346	chr6:85660950~85678736:-
OV	cis	rs1577917	0.916	rs7759727	ENSG00000203875.9	SNHG5	-12.34	4.11e-27	8.94e-23	-0.75	-0.63	Response to antipsychotic treatment;	chr6:85809160	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs12213431	ENSG00000203875.9	SNHG5	-12.34	4.2e-27	9.13e-23	-0.76	-0.63	Response to antipsychotic treatment;	chr6:85791238	chr6:85660950~85678736:-
OV	cis	rs1577917	0.837	rs10944157	ENSG00000203875.9	SNHG5	-12.33	4.43e-27	9.62e-23	-0.73	-0.63	Response to antipsychotic treatment;	chr6:85867481	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs2324839	ENSG00000203875.9	SNHG5	-12.33	4.46e-27	9.68e-23	-0.73	-0.63	Response to antipsychotic treatment;	chr6:85827224	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs3900313	ENSG00000203875.9	SNHG5	-12.33	4.46e-27	9.68e-23	-0.73	-0.63	Response to antipsychotic treatment;	chr6:85827436	chr6:85660950~85678736:-
OV	cis	rs507080	0.733	rs517445	ENSG00000255239.1	AP002954.6	12.32	4.63e-27	9.99e-23	0.79	0.63	Serum metabolite levels;	chr11:118702826	chr11:118688039~118690600:-
OV	cis	rs507080	0.771	rs687664	ENSG00000255239.1	AP002954.6	12.32	4.63e-27	9.99e-23	0.79	0.63	Serum metabolite levels;	chr11:118703476	chr11:118688039~118690600:-
OV	cis	rs507080	0.771	rs523715	ENSG00000255239.1	AP002954.6	12.32	4.63e-27	9.99e-23	0.79	0.63	Serum metabolite levels;	chr11:118703479	chr11:118688039~118690600:-
OV	cis	rs1577917	1	rs12204015	ENSG00000203875.9	SNHG5	-12.32	4.66e-27	1e-22	-0.72	-0.63	Response to antipsychotic treatment;	chr6:85888616	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs12196230	ENSG00000203875.9	SNHG5	-12.28	6.31e-27	1.35e-22	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85810242	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs34281561	ENSG00000203875.9	SNHG5	-12.28	6.33e-27	1.35e-22	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85992154	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs35419329	ENSG00000203875.9	SNHG5	-12.28	6.33e-27	1.35e-22	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85992573	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs12216328	ENSG00000203875.9	SNHG5	-12.28	6.33e-27	1.35e-22	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85993700	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs12201571	ENSG00000203875.9	SNHG5	-12.26	7.67e-27	1.61e-22	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85900032	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs11759855	ENSG00000203875.9	SNHG5	-12.26	7.67e-27	1.61e-22	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85901123	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs1857964	ENSG00000203875.9	SNHG5	-12.26	7.67e-27	1.61e-22	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85926276	chr6:85660950~85678736:-
OV	cis	rs1577917	0.798	rs7772384	ENSG00000203875.9	SNHG5	-12.26	7.67e-27	1.61e-22	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85929962	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs13194429	ENSG00000203875.9	SNHG5	-12.26	7.67e-27	1.61e-22	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85936987	chr6:85660950~85678736:-
OV	cis	rs875971	0.825	rs801202	ENSG00000222364.1	RNU6-96P	12.25	8.1e-27	1.7e-22	0.64	0.63	Aortic root size;	chr7:66558942	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs801195	ENSG00000222364.1	RNU6-96P	12.25	8.1e-27	1.7e-22	0.64	0.63	Aortic root size;	chr7:66561128	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs801194	ENSG00000222364.1	RNU6-96P	12.25	8.1e-27	1.7e-22	0.64	0.63	Aortic root size;	chr7:66563508	chr7:66395191~66395286:+
OV	cis	rs1577917	1	rs791856	ENSG00000203875.9	SNHG5	12.25	8.36e-27	1.75e-22	0.73	0.63	Response to antipsychotic treatment;	chr6:85972123	chr6:85660950~85678736:-
OV	cis	rs858239	0.899	rs10085838	ENSG00000230658.1	KLHL7-AS1	12.24	8.79e-27	1.83e-22	0.85	0.63	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23101228~23105703:-
OV	cis	rs1577917	1	rs2166663	ENSG00000203875.9	SNHG5	-12.21	1.12e-26	2.3e-22	-0.72	-0.63	Response to antipsychotic treatment;	chr6:85884178	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs16876530	ENSG00000203875.9	SNHG5	-12.21	1.12e-26	2.3e-22	-0.72	-0.63	Response to antipsychotic treatment;	chr6:85885923	chr6:85660950~85678736:-
OV	cis	rs875971	0.862	rs801204	ENSG00000222364.1	RNU6-96P	12.21	1.12e-26	2.3e-22	0.64	0.63	Aortic root size;	chr7:66557934	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs801203	ENSG00000222364.1	RNU6-96P	12.21	1.12e-26	2.3e-22	0.64	0.63	Aortic root size;	chr7:66558025	chr7:66395191~66395286:+
OV	cis	rs1577917	1	rs4706254	ENSG00000203875.9	SNHG5	-12.2	1.18e-26	2.42e-22	-0.72	-0.63	Response to antipsychotic treatment;	chr6:85893095	chr6:85660950~85678736:-
OV	cis	rs1577917	0.652	rs75593931	ENSG00000203875.9	SNHG5	-12.19	1.23e-26	2.51e-22	-0.74	-0.63	Response to antipsychotic treatment;	chr6:86009821	chr6:85660950~85678736:-
OV	cis	rs1577917	0.959	rs12201739	ENSG00000203875.9	SNHG5	-12.19	1.23e-26	2.51e-22	-0.74	-0.63	Response to antipsychotic treatment;	chr6:86011021	chr6:85660950~85678736:-
OV	cis	rs8040855	0.559	rs6496801	ENSG00000259295.5	CSPG4P12	-12.19	1.27e-26	2.59e-22	-0.8	-0.63	Bulimia nervosa;	chr15:85185168	chr15:85191438~85213905:+
OV	cis	rs858239	0.601	rs11984129	ENSG00000230658.1	KLHL7-AS1	12.18	1.32e-26	2.7e-22	0.82	0.63	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23101228~23105703:-
OV	cis	rs875971	0.862	rs10256544	ENSG00000222364.1	RNU6-96P	-12.18	1.33e-26	2.7e-22	-0.66	-0.63	Aortic root size;	chr7:66210141	chr7:66395191~66395286:+
OV	cis	rs507080	0.733	rs489126	ENSG00000255239.1	AP002954.6	12.18	1.39e-26	2.81e-22	0.78	0.63	Serum metabolite levels;	chr11:118702038	chr11:118688039~118690600:-
OV	cis	rs875971	0.767	rs61348003	ENSG00000222364.1	RNU6-96P	-12.18	1.39e-26	2.81e-22	-0.64	-0.63	Aortic root size;	chr7:66540947	chr7:66395191~66395286:+
OV	cis	rs858239	0.509	rs6962213	ENSG00000230658.1	KLHL7-AS1	12.17	1.46e-26	2.94e-22	0.83	0.63	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23101228~23105703:-
OV	cis	rs858239	0.6	rs61292332	ENSG00000230658.1	KLHL7-AS1	12.15	1.74e-26	3.48e-22	0.83	0.63	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23101228~23105703:-
OV	cis	rs858239	0.6	rs4321896	ENSG00000230658.1	KLHL7-AS1	12.14	1.81e-26	3.61e-22	0.84	0.63	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23101228~23105703:-
OV	cis	rs1577917	0.958	rs12213331	ENSG00000203875.9	SNHG5	-12.14	1.83e-26	3.65e-22	-0.77	-0.63	Response to antipsychotic treatment;	chr6:85795079	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs1545376	ENSG00000203875.9	SNHG5	12.14	1.84e-26	3.68e-22	0.74	0.63	Response to antipsychotic treatment;	chr6:85794864	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs11756510	ENSG00000203875.9	SNHG5	-12.14	1.84e-26	3.68e-22	-0.73	-0.63	Response to antipsychotic treatment;	chr6:85990076	chr6:85660950~85678736:-
OV	cis	rs858239	0.6	rs59073109	ENSG00000230658.1	KLHL7-AS1	12.13	1.89e-26	3.77e-22	0.83	0.63	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23101228~23105703:-
OV	cis	rs858239	0.6	rs7788821	ENSG00000230658.1	KLHL7-AS1	12.13	1.89e-26	3.77e-22	0.83	0.63	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23101228~23105703:-
OV	cis	rs858239	0.6	rs6956595	ENSG00000230658.1	KLHL7-AS1	12.13	1.89e-26	3.77e-22	0.83	0.63	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23101228~23105703:-
OV	cis	rs875971	0.862	rs13232191	ENSG00000222364.1	RNU6-96P	-12.13	1.93e-26	3.81e-22	-0.64	-0.63	Aortic root size;	chr7:66521661	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs35378740	ENSG00000222364.1	RNU6-96P	-12.13	1.93e-26	3.81e-22	-0.64	-0.63	Aortic root size;	chr7:66522725	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs10950043	ENSG00000222364.1	RNU6-96P	-12.13	1.93e-26	3.81e-22	-0.64	-0.63	Aortic root size;	chr7:66523623	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs17747530	ENSG00000222364.1	RNU6-96P	-12.13	1.93e-26	3.81e-22	-0.64	-0.63	Aortic root size;	chr7:66529742	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs13226170	ENSG00000222364.1	RNU6-96P	-12.13	1.93e-26	3.81e-22	-0.64	-0.63	Aortic root size;	chr7:66534311	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs2420611	ENSG00000222364.1	RNU6-96P	-12.13	1.93e-26	3.81e-22	-0.64	-0.63	Aortic root size;	chr7:66534333	chr7:66395191~66395286:+
OV	cis	rs875971	0.861	rs801215	ENSG00000222364.1	RNU6-96P	12.13	1.93e-26	3.81e-22	0.64	0.63	Aortic root size;	chr7:66546951	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs13536	ENSG00000222364.1	RNU6-96P	12.13	1.93e-26	3.81e-22	0.64	0.63	Aortic root size;	chr7:66554203	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs801209	ENSG00000222364.1	RNU6-96P	12.13	1.93e-26	3.81e-22	0.64	0.63	Aortic root size;	chr7:66554403	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs801206	ENSG00000222364.1	RNU6-96P	12.13	1.93e-26	3.81e-22	0.64	0.63	Aortic root size;	chr7:66556979	chr7:66395191~66395286:+
OV	cis	rs507080	0.922	rs654792	ENSG00000255239.1	AP002954.6	-12.13	1.94e-26	3.82e-22	-0.74	-0.63	Serum metabolite levels;	chr11:118682287	chr11:118688039~118690600:-
OV	cis	rs801193	0.591	rs4506088	ENSG00000222364.1	RNU6-96P	12.13	1.96e-26	3.86e-22	0.64	0.63	Aortic root size;	chr7:66670470	chr7:66395191~66395286:+
OV	cis	rs1577917	0.958	rs34795473	ENSG00000203875.9	SNHG5	-12.13	2.01e-26	3.95e-22	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85752081	chr6:85660950~85678736:-
OV	cis	rs875971	0.862	rs6952182	ENSG00000222364.1	RNU6-96P	12.12	2.19e-26	4.29e-22	0.63	0.63	Aortic root size;	chr7:66218330	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs6964437	ENSG00000222364.1	RNU6-96P	12.12	2.19e-26	4.29e-22	0.63	0.63	Aortic root size;	chr7:66221457	chr7:66395191~66395286:+
OV	cis	rs1577917	1	rs12199516	ENSG00000203875.9	SNHG5	-12.11	2.27e-26	4.44e-22	-0.73	-0.63	Response to antipsychotic treatment;	chr6:86016503	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs12192992	ENSG00000203875.9	SNHG5	-12.11	2.35e-26	4.56e-22	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85900197	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs2324843	ENSG00000203875.9	SNHG5	-12.11	2.35e-26	4.56e-22	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85907783	chr6:85660950~85678736:-
OV	cis	rs1577917	0.917	rs35738006	ENSG00000203875.9	SNHG5	-12.11	2.35e-26	4.56e-22	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85936591	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs13196930	ENSG00000203875.9	SNHG5	-12.11	2.35e-26	4.56e-22	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85942527	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs12200330	ENSG00000203875.9	SNHG5	-12.11	2.35e-26	4.56e-22	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85946935	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs12208493	ENSG00000203875.9	SNHG5	-12.11	2.35e-26	4.56e-22	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85952549	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs12213149	ENSG00000203875.9	SNHG5	-12.11	2.35e-26	4.56e-22	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85958926	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs10455455	ENSG00000203875.9	SNHG5	-12.11	2.35e-26	4.56e-22	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85960496	chr6:85660950~85678736:-
OV	cis	rs858239	0.6	rs7341483	ENSG00000230658.1	KLHL7-AS1	-12.1	2.41e-26	4.66e-22	-0.82	-0.63	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23101228~23105703:-
OV	cis	rs1577917	0.837	rs806529	ENSG00000203875.9	SNHG5	-12.1	2.46e-26	4.73e-22	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85757403	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs6921315	ENSG00000203875.9	SNHG5	-12.1	2.46e-26	4.73e-22	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85761950	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs36096931	ENSG00000203875.9	SNHG5	-12.09	2.56e-26	4.89e-22	-0.71	-0.63	Response to antipsychotic treatment;	chr6:85983416	chr6:85660950~85678736:-
OV	cis	rs875971	0.862	rs6460302	ENSG00000222364.1	RNU6-96P	-12.09	2.56e-26	4.89e-22	-0.63	-0.63	Aortic root size;	chr7:66495270	chr7:66395191~66395286:+
OV	cis	rs858239	0.899	rs10262243	ENSG00000230658.1	KLHL7-AS1	12.09	2.57e-26	4.91e-22	0.84	0.63	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23101228~23105703:-
OV	cis	rs858239	0.899	rs1881203	ENSG00000230658.1	KLHL7-AS1	12.09	2.57e-26	4.91e-22	0.84	0.63	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23101228~23105703:-
OV	cis	rs858239	0.899	rs28458177	ENSG00000230658.1	KLHL7-AS1	12.09	2.57e-26	4.91e-22	0.84	0.63	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23101228~23105703:-
OV	cis	rs1577917	0.917	rs4098044	ENSG00000203875.9	SNHG5	-12.08	2.77e-26	5.28e-22	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85752348	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs12192033	ENSG00000203875.9	SNHG5	-12.08	2.77e-26	5.28e-22	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85762841	chr6:85660950~85678736:-
OV	cis	rs875971	0.755	rs76288834	ENSG00000222364.1	RNU6-96P	12.08	2.78e-26	5.29e-22	0.64	0.63	Aortic root size;	chr7:66604815	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs2024192	ENSG00000222364.1	RNU6-96P	12.07	2.98e-26	5.64e-22	0.63	0.63	Aortic root size;	chr7:66576460	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs4718377	ENSG00000222364.1	RNU6-96P	12.07	2.98e-26	5.64e-22	0.63	0.63	Aortic root size;	chr7:66584691	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs10278014	ENSG00000222364.1	RNU6-96P	12.07	2.98e-26	5.64e-22	0.63	0.63	Aortic root size;	chr7:66586277	chr7:66395191~66395286:+
OV	cis	rs1577917	1	rs12216203	ENSG00000203875.9	SNHG5	-12.07	3e-26	5.67e-22	-0.74	-0.63	Response to antipsychotic treatment;	chr6:85965583	chr6:85660950~85678736:-
OV	cis	rs1577917	0.916	rs12198730	ENSG00000203875.9	SNHG5	-12.07	3.01e-26	5.69e-22	-0.75	-0.63	Response to antipsychotic treatment;	chr6:85845420	chr6:85660950~85678736:-
OV	cis	rs875971	0.83	rs427973	ENSG00000222364.1	RNU6-96P	-12.07	3.06e-26	5.78e-22	-0.65	-0.63	Aortic root size;	chr7:66061661	chr7:66395191~66395286:+
OV	cis	rs858239	0.536	rs6961109	ENSG00000230658.1	KLHL7-AS1	12.06	3.18e-26	6.01e-22	0.83	0.63	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23101228~23105703:-
OV	cis	rs1577917	1	rs10498958	ENSG00000203875.9	SNHG5	12.06	3.25e-26	6.13e-22	0.74	0.62	Response to antipsychotic treatment;	chr6:85939987	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs2225754	ENSG00000203875.9	SNHG5	-12.06	3.3e-26	6.21e-22	-0.75	-0.62	Response to antipsychotic treatment;	chr6:85739980	chr6:85660950~85678736:-
OV	cis	rs875971	0.756	rs2901210	ENSG00000222364.1	RNU6-96P	12.06	3.4e-26	6.37e-22	0.64	0.62	Aortic root size;	chr7:66552518	chr7:66395191~66395286:+
OV	cis	rs1577917	0.958	rs10806337	ENSG00000203875.9	SNHG5	-12.04	3.69e-26	6.91e-22	-0.78	-0.62	Response to antipsychotic treatment;	chr6:85764531	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs2121594	ENSG00000203875.9	SNHG5	-12.04	3.9e-26	7.3e-22	-0.75	-0.62	Response to antipsychotic treatment;	chr6:85867136	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs2324817	ENSG00000203875.9	SNHG5	-12.03	4.06e-26	7.57e-22	-0.74	-0.62	Response to antipsychotic treatment;	chr6:85752936	chr6:85660950~85678736:-
OV	cis	rs875971	0.862	rs6955837	ENSG00000222364.1	RNU6-96P	12.03	4.11e-26	7.62e-22	0.63	0.62	Aortic root size;	chr7:66578155	chr7:66395191~66395286:+
OV	cis	rs875971	0.825	rs10281499	ENSG00000222364.1	RNU6-96P	12.03	4.11e-26	7.62e-22	0.63	0.62	Aortic root size;	chr7:66583979	chr7:66395191~66395286:+
OV	cis	rs1577917	0.958	rs10944147	ENSG00000203875.9	SNHG5	-12.03	4.11e-26	7.62e-22	-0.75	-0.62	Response to antipsychotic treatment;	chr6:85841068	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs13201730	ENSG00000203875.9	SNHG5	-12.03	4.11e-26	7.62e-22	-0.75	-0.62	Response to antipsychotic treatment;	chr6:85846929	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs12196377	ENSG00000203875.9	SNHG5	-12.03	4.11e-26	7.62e-22	-0.75	-0.62	Response to antipsychotic treatment;	chr6:85857057	chr6:85660950~85678736:-
OV	cis	rs875971	0.793	rs460678	ENSG00000222364.1	RNU6-96P	-12.02	4.32e-26	7.98e-22	-0.65	-0.62	Aortic root size;	chr7:66062213	chr7:66395191~66395286:+
OV	cis	rs1577917	0.958	rs12205492	ENSG00000203875.9	SNHG5	-12.02	4.57e-26	8.44e-22	-0.77	-0.62	Response to antipsychotic treatment;	chr6:85766258	chr6:85660950~85678736:-
OV	cis	rs875971	0.964	rs160635	ENSG00000222364.1	RNU6-96P	-12.01	4.71e-26	8.66e-22	-0.65	-0.62	Aortic root size;	chr7:66063931	chr7:66395191~66395286:+
OV	cis	rs1577917	0.958	rs13207173	ENSG00000203875.9	SNHG5	-12.01	4.81e-26	8.83e-22	-0.74	-0.62	Response to antipsychotic treatment;	chr6:85747804	chr6:85660950~85678736:-
OV	cis	rs875971	0.862	rs1968126	ENSG00000222364.1	RNU6-96P	12.01	4.87e-26	8.91e-22	0.64	0.62	Aortic root size;	chr7:66592017	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs6460306	ENSG00000222364.1	RNU6-96P	12.01	4.87e-26	8.91e-22	0.64	0.62	Aortic root size;	chr7:66595806	chr7:66395191~66395286:+
OV	cis	rs1577917	0.917	rs35283633	ENSG00000203875.9	SNHG5	-12	5.12e-26	9.35e-22	-0.74	-0.62	Response to antipsychotic treatment;	chr6:85981069	chr6:85660950~85678736:-
OV	cis	rs875971	0.862	rs12537823	ENSG00000222364.1	RNU6-96P	-12	5.16e-26	9.41e-22	-0.64	-0.62	Aortic root size;	chr7:66255897	chr7:66395191~66395286:+
OV	cis	rs1577917	1	rs955196	ENSG00000203875.9	SNHG5	12	5.17e-26	9.42e-22	0.74	0.62	Response to antipsychotic treatment;	chr6:86020233	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs12664335	ENSG00000203875.9	SNHG5	12	5.26e-26	9.56e-22	0.73	0.62	Response to antipsychotic treatment;	chr6:85888056	chr6:85660950~85678736:-
OV	cis	rs858239	0.867	rs10250602	ENSG00000230658.1	KLHL7-AS1	12	5.29e-26	9.61e-22	0.84	0.62	Cerebrospinal fluid biomarker levels;	chr7:23264082	chr7:23101228~23105703:-
OV	cis	rs875971	0.862	rs1875057	ENSG00000222364.1	RNU6-96P	11.99	5.41e-26	9.81e-22	0.63	0.62	Aortic root size;	chr7:66266868	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs6960446	ENSG00000222364.1	RNU6-96P	11.99	5.41e-26	9.81e-22	0.63	0.62	Aortic root size;	chr7:66268272	chr7:66395191~66395286:+
OV	cis	rs1577917	0.958	rs12193904	ENSG00000203875.9	SNHG5	-11.99	5.53e-26	1e-21	-0.75	-0.62	Response to antipsychotic treatment;	chr6:85742985	chr6:85660950~85678736:-
OV	cis	rs875971	0.862	rs6460282	ENSG00000222364.1	RNU6-96P	11.99	5.56e-26	1.01e-21	0.64	0.62	Aortic root size;	chr7:66226259	chr7:66395191~66395286:+
OV	cis	rs801193	0.591	rs721717	ENSG00000222364.1	RNU6-96P	11.98	5.98e-26	1.08e-21	0.64	0.62	Aortic root size;	chr7:66665305	chr7:66395191~66395286:+
OV	cis	rs801193	0.569	rs6951302	ENSG00000222364.1	RNU6-96P	11.98	5.98e-26	1.08e-21	0.64	0.62	Aortic root size;	chr7:66667525	chr7:66395191~66395286:+
OV	cis	rs1577917	1	rs12212733	ENSG00000203875.9	SNHG5	-11.98	6.1e-26	1.1e-21	-0.74	-0.62	Response to antipsychotic treatment;	chr6:86016295	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs11755864	ENSG00000203875.9	SNHG5	-11.97	6.26e-26	1.13e-21	-0.72	-0.62	Response to antipsychotic treatment;	chr6:85982073	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs72907388	ENSG00000203875.9	SNHG5	-11.97	6.41e-26	1.15e-21	-0.75	-0.62	Response to antipsychotic treatment;	chr6:85730489	chr6:85660950~85678736:-
OV	cis	rs801193	0.569	rs2707824	ENSG00000222364.1	RNU6-96P	-11.96	6.82e-26	1.22e-21	-0.63	-0.62	Aortic root size;	chr7:66724256	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs778736	ENSG00000222364.1	RNU6-96P	-11.96	7e-26	1.26e-21	-0.63	-0.62	Aortic root size;	chr7:66348861	chr7:66395191~66395286:+
OV	cis	rs2739330	0.791	rs4822458	ENSG00000225282.1	AP000350.6	11.96	7.14e-26	1.28e-21	0.77	0.62	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23926900~23929574:+
OV	cis	rs1577917	0.958	rs1591438	ENSG00000203875.9	SNHG5	-11.95	7.32e-26	1.31e-21	-0.75	-0.62	Response to antipsychotic treatment;	chr6:85815496	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs1591437	ENSG00000203875.9	SNHG5	-11.95	7.32e-26	1.31e-21	-0.75	-0.62	Response to antipsychotic treatment;	chr6:85815587	chr6:85660950~85678736:-
OV	cis	rs875971	0.895	rs6460278	ENSG00000222364.1	RNU6-96P	11.95	7.57e-26	1.35e-21	0.63	0.62	Aortic root size;	chr7:66197749	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs6460279	ENSG00000222364.1	RNU6-96P	11.95	7.57e-26	1.35e-21	0.63	0.62	Aortic root size;	chr7:66197774	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs28491091	ENSG00000222364.1	RNU6-96P	11.95	7.57e-26	1.35e-21	0.63	0.62	Aortic root size;	chr7:66204077	chr7:66395191~66395286:+
OV	cis	rs875971	0.789	rs10260426	ENSG00000222364.1	RNU6-96P	11.94	8.04e-26	1.43e-21	0.63	0.62	Aortic root size;	chr7:66271055	chr7:66395191~66395286:+
OV	cis	rs875971	0.79	rs10257911	ENSG00000222364.1	RNU6-96P	11.94	8.04e-26	1.43e-21	0.63	0.62	Aortic root size;	chr7:66278783	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs7796162	ENSG00000222364.1	RNU6-96P	11.94	8.04e-26	1.43e-21	0.63	0.62	Aortic root size;	chr7:66280771	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs6971059	ENSG00000222364.1	RNU6-96P	11.94	8.26e-26	1.46e-21	0.64	0.62	Aortic root size;	chr7:66602045	chr7:66395191~66395286:+
OV	cis	rs875971	0.789	rs7808013	ENSG00000222364.1	RNU6-96P	11.94	8.26e-26	1.46e-21	0.64	0.62	Aortic root size;	chr7:66606209	chr7:66395191~66395286:+
OV	cis	rs875971	0.825	rs7384021	ENSG00000222364.1	RNU6-96P	11.94	8.26e-26	1.46e-21	0.64	0.62	Aortic root size;	chr7:66612917	chr7:66395191~66395286:+
OV	cis	rs875971	0.825	rs66981195	ENSG00000222364.1	RNU6-96P	11.94	8.26e-26	1.46e-21	0.64	0.62	Aortic root size;	chr7:66614048	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs3926380	ENSG00000222364.1	RNU6-96P	11.94	8.26e-26	1.46e-21	0.64	0.62	Aortic root size;	chr7:66615658	chr7:66395191~66395286:+
OV	cis	rs875971	0.825	rs1860472	ENSG00000222364.1	RNU6-96P	11.94	8.26e-26	1.46e-21	0.64	0.62	Aortic root size;	chr7:66617736	chr7:66395191~66395286:+
OV	cis	rs9322193	0.884	rs7744105	ENSG00000231760.4	RP11-350J20.5	11.93	8.39e-26	1.48e-21	0.79	0.62	Lung cancer;	chr6:149849308	chr6:149796151~149826294:-
OV	cis	rs1577917	1	rs1415753	ENSG00000203875.9	SNHG5	-11.93	8.63e-26	1.51e-21	-0.75	-0.62	Response to antipsychotic treatment;	chr6:86043356	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs1577919	ENSG00000203875.9	SNHG5	-11.93	8.63e-26	1.51e-21	-0.75	-0.62	Response to antipsychotic treatment;	chr6:86047578	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs12203493	ENSG00000203875.9	SNHG5	-11.93	8.63e-26	1.51e-21	-0.75	-0.62	Response to antipsychotic treatment;	chr6:86048924	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs12203924	ENSG00000203875.9	SNHG5	-11.93	8.63e-26	1.51e-21	-0.75	-0.62	Response to antipsychotic treatment;	chr6:86066694	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs1018184	ENSG00000203875.9	SNHG5	11.93	8.79e-26	1.54e-21	0.72	0.62	Response to antipsychotic treatment;	chr6:85938757	chr6:85660950~85678736:-
OV	cis	rs875971	0.862	rs10282433	ENSG00000222364.1	RNU6-96P	11.92	9.01e-26	1.58e-21	0.63	0.62	Aortic root size;	chr7:66256452	chr7:66395191~66395286:+
OV	cis	rs1577917	0.958	rs13219504	ENSG00000203875.9	SNHG5	-11.92	9.06e-26	1.58e-21	-0.75	-0.62	Response to antipsychotic treatment;	chr6:85847199	chr6:85660950~85678736:-
OV	cis	rs875971	0.825	rs6951503	ENSG00000222364.1	RNU6-96P	11.92	9.12e-26	1.59e-21	0.63	0.62	Aortic root size;	chr7:66253949	chr7:66395191~66395286:+
OV	cis	rs1577917	0.958	rs11756615	ENSG00000203875.9	SNHG5	-11.92	9.29e-26	1.62e-21	-0.73	-0.62	Response to antipsychotic treatment;	chr6:85970117	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs10944168	ENSG00000203875.9	SNHG5	-11.92	9.29e-26	1.62e-21	-0.73	-0.62	Response to antipsychotic treatment;	chr6:85970438	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs10944170	ENSG00000203875.9	SNHG5	-11.92	9.56e-26	1.67e-21	-0.72	-0.62	Response to antipsychotic treatment;	chr6:85975751	chr6:85660950~85678736:-
OV	cis	rs6782228	0.675	rs6806687	ENSG00000242551.2	POU5F1P6	11.91	9.71e-26	1.69e-21	0.63	0.62	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128672946	chr3:128674735~128677005:-
OV	cis	rs1577917	1	rs12213740	ENSG00000203875.9	SNHG5	-11.91	9.9e-26	1.72e-21	-0.71	-0.62	Response to antipsychotic treatment;	chr6:85947015	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs12190604	ENSG00000203875.9	SNHG5	-11.9	1.05e-25	1.82e-21	-0.73	-0.62	Response to antipsychotic treatment;	chr6:86006497	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs4707223	ENSG00000203875.9	SNHG5	-11.9	1.1e-25	1.92e-21	-0.73	-0.62	Response to antipsychotic treatment;	chr6:85800084	chr6:85660950~85678736:-
OV	cis	rs1577917	0.876	rs1582126	ENSG00000203875.9	SNHG5	-11.88	1.21e-25	2.09e-21	-0.73	-0.62	Response to antipsychotic treatment;	chr6:85987487	chr6:85660950~85678736:-
OV	cis	rs801193	0.527	rs2707837	ENSG00000222364.1	RNU6-96P	-11.88	1.21e-25	2.1e-21	-0.63	-0.62	Aortic root size;	chr7:66716086	chr7:66395191~66395286:+
OV	cis	rs1577917	0.917	rs35038582	ENSG00000203875.9	SNHG5	-11.88	1.24e-25	2.13e-21	-0.72	-0.62	Response to antipsychotic treatment;	chr6:86011587	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs7760207	ENSG00000203875.9	SNHG5	-11.88	1.24e-25	2.13e-21	-0.72	-0.62	Response to antipsychotic treatment;	chr6:86011982	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs12207305	ENSG00000203875.9	SNHG5	-11.88	1.24e-25	2.13e-21	-0.72	-0.62	Response to antipsychotic treatment;	chr6:86013784	chr6:85660950~85678736:-
OV	cis	rs875971	0.862	rs4718383	ENSG00000222364.1	RNU6-96P	11.88	1.27e-25	2.18e-21	0.63	0.62	Aortic root size;	chr7:66643422	chr7:66395191~66395286:+
OV	cis	rs1577917	1	rs12205548	ENSG00000203875.9	SNHG5	-11.88	1.28e-25	2.19e-21	-0.75	-0.62	Response to antipsychotic treatment;	chr6:86050052	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs12665321	ENSG00000203875.9	SNHG5	-11.88	1.28e-25	2.19e-21	-0.75	-0.62	Response to antipsychotic treatment;	chr6:86059571	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs12196175	ENSG00000203875.9	SNHG5	-11.88	1.28e-25	2.19e-21	-0.75	-0.62	Response to antipsychotic treatment;	chr6:86069652	chr6:85660950~85678736:-
OV	cis	rs875971	0.862	rs1860469	ENSG00000222364.1	RNU6-96P	11.87	1.29e-25	2.22e-21	0.63	0.62	Aortic root size;	chr7:66641888	chr7:66395191~66395286:+
OV	cis	rs1577917	0.958	rs10944144	ENSG00000203875.9	SNHG5	-11.87	1.3e-25	2.22e-21	-0.75	-0.62	Response to antipsychotic treatment;	chr6:85828037	chr6:85660950~85678736:-
OV	cis	rs875971	1	rs709597	ENSG00000222364.1	RNU6-96P	11.87	1.31e-25	2.24e-21	0.64	0.62	Aortic root size;	chr7:66360996	chr7:66395191~66395286:+
OV	cis	rs858239	0.738	rs13225593	ENSG00000230658.1	KLHL7-AS1	11.86	1.45e-25	2.48e-21	0.85	0.62	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23101228~23105703:-
OV	cis	rs875971	0.862	rs10274883	ENSG00000222364.1	RNU6-96P	11.86	1.46e-25	2.48e-21	0.63	0.62	Aortic root size;	chr7:66651104	chr7:66395191~66395286:+
OV	cis	rs801193	0.569	rs881285	ENSG00000222364.1	RNU6-96P	11.86	1.46e-25	2.48e-21	0.63	0.62	Aortic root size;	chr7:66654433	chr7:66395191~66395286:+
OV	cis	rs801193	0.569	rs3846973	ENSG00000222364.1	RNU6-96P	11.86	1.46e-25	2.48e-21	0.63	0.62	Aortic root size;	chr7:66655048	chr7:66395191~66395286:+
OV	cis	rs801193	0.569	rs2013908	ENSG00000222364.1	RNU6-96P	11.86	1.46e-25	2.48e-21	0.63	0.62	Aortic root size;	chr7:66656082	chr7:66395191~66395286:+
OV	cis	rs801193	0.548	rs2109297	ENSG00000222364.1	RNU6-96P	11.86	1.46e-25	2.48e-21	0.63	0.62	Aortic root size;	chr7:66657397	chr7:66395191~66395286:+
OV	cis	rs801193	0.569	rs6978178	ENSG00000222364.1	RNU6-96P	11.86	1.46e-25	2.48e-21	0.63	0.62	Aortic root size;	chr7:66658097	chr7:66395191~66395286:+
OV	cis	rs801193	0.569	rs2659893	ENSG00000222364.1	RNU6-96P	-11.86	1.49e-25	2.52e-21	-0.63	-0.62	Aortic root size;	chr7:66735006	chr7:66395191~66395286:+
OV	cis	rs801193	0.569	rs2659892	ENSG00000222364.1	RNU6-96P	-11.86	1.49e-25	2.52e-21	-0.63	-0.62	Aortic root size;	chr7:66735318	chr7:66395191~66395286:+
OV	cis	rs801193	0.548	rs6975044	ENSG00000222364.1	RNU6-96P	-11.86	1.49e-25	2.53e-21	-0.63	-0.62	Aortic root size;	chr7:66762495	chr7:66395191~66395286:+
OV	cis	rs801193	0.548	rs2659891	ENSG00000222364.1	RNU6-96P	-11.85	1.5e-25	2.54e-21	-0.63	-0.62	Aortic root size;	chr7:66736127	chr7:66395191~66395286:+
OV	cis	rs1577917	0.958	rs34765423	ENSG00000203875.9	SNHG5	-11.85	1.53e-25	2.59e-21	-0.76	-0.62	Response to antipsychotic treatment;	chr6:85774730	chr6:85660950~85678736:-
OV	cis	rs875971	0.895	rs12698520	ENSG00000222364.1	RNU6-96P	-11.85	1.57e-25	2.64e-21	-0.64	-0.62	Aortic root size;	chr7:66453720	chr7:66395191~66395286:+
OV	cis	rs1577917	0.876	rs12201992	ENSG00000203875.9	SNHG5	-11.84	1.64e-25	2.73e-21	-0.72	-0.62	Response to antipsychotic treatment;	chr6:85908501	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs12201880	ENSG00000203875.9	SNHG5	-11.84	1.64e-25	2.73e-21	-0.72	-0.62	Response to antipsychotic treatment;	chr6:85917289	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs7756203	ENSG00000203875.9	SNHG5	-11.84	1.64e-25	2.73e-21	-0.72	-0.62	Response to antipsychotic treatment;	chr6:85917989	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs10944161	ENSG00000203875.9	SNHG5	-11.84	1.64e-25	2.73e-21	-0.72	-0.62	Response to antipsychotic treatment;	chr6:85920658	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs1857965	ENSG00000203875.9	SNHG5	-11.84	1.64e-25	2.73e-21	-0.72	-0.62	Response to antipsychotic treatment;	chr6:85921058	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs7771342	ENSG00000203875.9	SNHG5	-11.84	1.64e-25	2.73e-21	-0.72	-0.62	Response to antipsychotic treatment;	chr6:85922218	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs12154056	ENSG00000203875.9	SNHG5	-11.84	1.64e-25	2.73e-21	-0.72	-0.62	Response to antipsychotic treatment;	chr6:85924376	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs7747897	ENSG00000203875.9	SNHG5	-11.84	1.64e-25	2.73e-21	-0.72	-0.62	Response to antipsychotic treatment;	chr6:85937631	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs12199832	ENSG00000203875.9	SNHG5	-11.84	1.64e-25	2.73e-21	-0.72	-0.62	Response to antipsychotic treatment;	chr6:85943030	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs12207374	ENSG00000203875.9	SNHG5	-11.84	1.64e-25	2.73e-21	-0.72	-0.62	Response to antipsychotic treatment;	chr6:85946927	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs12201735	ENSG00000203875.9	SNHG5	-11.84	1.64e-25	2.73e-21	-0.72	-0.62	Response to antipsychotic treatment;	chr6:85947221	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs10455456	ENSG00000203875.9	SNHG5	-11.84	1.64e-25	2.73e-21	-0.72	-0.62	Response to antipsychotic treatment;	chr6:85960604	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs13213551	ENSG00000203875.9	SNHG5	-11.83	1.77e-25	2.92e-21	-0.71	-0.62	Response to antipsychotic treatment;	chr6:85898983	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs34622557	ENSG00000203875.9	SNHG5	-11.83	1.77e-25	2.92e-21	-0.71	-0.62	Response to antipsychotic treatment;	chr6:85921134	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs1911553	ENSG00000203875.9	SNHG5	-11.83	1.77e-25	2.92e-21	-0.71	-0.62	Response to antipsychotic treatment;	chr6:85921174	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs1995688	ENSG00000203875.9	SNHG5	-11.83	1.77e-25	2.92e-21	-0.71	-0.62	Response to antipsychotic treatment;	chr6:85922601	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs6940458	ENSG00000203875.9	SNHG5	-11.83	1.77e-25	2.92e-21	-0.71	-0.62	Response to antipsychotic treatment;	chr6:85935274	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs12205336	ENSG00000203875.9	SNHG5	-11.83	1.79e-25	2.94e-21	-0.73	-0.62	Response to antipsychotic treatment;	chr6:86012649	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs12209127	ENSG00000203875.9	SNHG5	-11.83	1.79e-25	2.94e-21	-0.73	-0.62	Response to antipsychotic treatment;	chr6:86014709	chr6:85660950~85678736:-
OV	cis	rs875971	0.83	rs427575	ENSG00000222364.1	RNU6-96P	-11.83	1.79e-25	2.94e-21	-0.65	-0.62	Aortic root size;	chr7:66054232	chr7:66395191~66395286:+
OV	cis	rs875971	0.8	rs427557	ENSG00000222364.1	RNU6-96P	-11.83	1.79e-25	2.94e-21	-0.65	-0.62	Aortic root size;	chr7:66054263	chr7:66395191~66395286:+
OV	cis	rs875971	0.83	rs587360	ENSG00000222364.1	RNU6-96P	-11.83	1.79e-25	2.94e-21	-0.65	-0.62	Aortic root size;	chr7:66057711	chr7:66395191~66395286:+
OV	cis	rs875971	0.564	rs313804	ENSG00000222364.1	RNU6-96P	-11.83	1.83e-25	3.01e-21	-0.65	-0.62	Aortic root size;	chr7:66049635	chr7:66395191~66395286:+
OV	cis	rs875971	0.662	rs448725	ENSG00000222364.1	RNU6-96P	-11.83	1.83e-25	3.01e-21	-0.65	-0.62	Aortic root size;	chr7:66049641	chr7:66395191~66395286:+
OV	cis	rs875971	0.658	rs432667	ENSG00000222364.1	RNU6-96P	-11.83	1.83e-25	3.01e-21	-0.65	-0.62	Aortic root size;	chr7:66049646	chr7:66395191~66395286:+
OV	cis	rs801193	0.569	rs2659908	ENSG00000222364.1	RNU6-96P	-11.83	1.86e-25	3.04e-21	-0.63	-0.62	Aortic root size;	chr7:66695835	chr7:66395191~66395286:+
OV	cis	rs801193	0.569	rs7782587	ENSG00000222364.1	RNU6-96P	-11.83	1.86e-25	3.04e-21	-0.63	-0.62	Aortic root size;	chr7:66701485	chr7:66395191~66395286:+
OV	cis	rs801193	0.569	rs4717315	ENSG00000222364.1	RNU6-96P	-11.83	1.86e-25	3.04e-21	-0.63	-0.62	Aortic root size;	chr7:66713338	chr7:66395191~66395286:+
OV	cis	rs1577917	0.958	rs12195776	ENSG00000203875.9	SNHG5	-11.81	2.12e-25	3.46e-21	-0.74	-0.62	Response to antipsychotic treatment;	chr6:85778881	chr6:85660950~85678736:-
OV	cis	rs875971	0.825	rs28480509	ENSG00000222364.1	RNU6-96P	11.8	2.18e-25	3.55e-21	0.63	0.62	Aortic root size;	chr7:66634237	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs9791712	ENSG00000222364.1	RNU6-96P	11.8	2.18e-25	3.55e-21	0.63	0.62	Aortic root size;	chr7:66640176	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs9791713	ENSG00000222364.1	RNU6-96P	11.8	2.18e-25	3.55e-21	0.63	0.62	Aortic root size;	chr7:66640211	chr7:66395191~66395286:+
OV	cis	rs1577917	1	rs955197	ENSG00000203875.9	SNHG5	-11.8	2.28e-25	3.72e-21	-0.74	-0.62	Response to antipsychotic treatment;	chr6:86019957	chr6:85660950~85678736:-
OV	cis	rs1577917	0.876	rs1582127	ENSG00000203875.9	SNHG5	-11.8	2.29e-25	3.72e-21	-0.71	-0.62	Response to antipsychotic treatment;	chr6:85987486	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs12199784	ENSG00000203875.9	SNHG5	-11.79	2.39e-25	3.89e-21	-0.73	-0.62	Response to antipsychotic treatment;	chr6:86017090	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs1335442	ENSG00000203875.9	SNHG5	-11.79	2.42e-25	3.92e-21	-0.77	-0.62	Response to antipsychotic treatment;	chr6:85756974	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs13213899	ENSG00000203875.9	SNHG5	-11.79	2.42e-25	3.92e-21	-0.77	-0.62	Response to antipsychotic treatment;	chr6:85763422	chr6:85660950~85678736:-
OV	cis	rs875971	0.862	rs1167408	ENSG00000222364.1	RNU6-96P	11.79	2.44e-25	3.94e-21	0.62	0.62	Aortic root size;	chr7:66091121	chr7:66395191~66395286:+
OV	cis	rs875971	0.83	rs1167406	ENSG00000222364.1	RNU6-96P	11.79	2.44e-25	3.94e-21	0.62	0.62	Aortic root size;	chr7:66091949	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs709609	ENSG00000222364.1	RNU6-96P	11.79	2.44e-25	3.94e-21	0.62	0.62	Aortic root size;	chr7:66095574	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs1167399	ENSG00000222364.1	RNU6-96P	11.79	2.44e-25	3.94e-21	0.62	0.62	Aortic root size;	chr7:66096890	chr7:66395191~66395286:+
OV	cis	rs875971	0.825	rs59466412	ENSG00000222364.1	RNU6-96P	11.79	2.44e-25	3.94e-21	0.62	0.62	Aortic root size;	chr7:66100371	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs57866200	ENSG00000222364.1	RNU6-96P	11.79	2.44e-25	3.94e-21	0.62	0.62	Aortic root size;	chr7:66100405	chr7:66395191~66395286:+
OV	cis	rs1577917	1	rs12190598	ENSG00000203875.9	SNHG5	-11.78	2.57e-25	4.15e-21	-0.72	-0.62	Response to antipsychotic treatment;	chr6:85976356	chr6:85660950~85678736:-
OV	cis	rs875971	1	rs3981131	ENSG00000222364.1	RNU6-96P	-11.77	2.81e-25	4.52e-21	-0.64	-0.62	Aortic root size;	chr7:66486690	chr7:66395191~66395286:+
OV	cis	rs858239	0.899	rs7794684	ENSG00000230658.1	KLHL7-AS1	11.77	2.86e-25	4.59e-21	0.81	0.62	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23101228~23105703:-
OV	cis	rs875971	1	rs6460296	ENSG00000222364.1	RNU6-96P	-11.76	3e-25	4.72e-21	-0.64	-0.62	Aortic root size;	chr7:66430152	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs4717292	ENSG00000222364.1	RNU6-96P	-11.76	3e-25	4.72e-21	-0.64	-0.62	Aortic root size;	chr7:66430611	chr7:66395191~66395286:+
OV	cis	rs875971	0.895	rs4718349	ENSG00000222364.1	RNU6-96P	-11.76	3e-25	4.72e-21	-0.64	-0.62	Aortic root size;	chr7:66444024	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs2420591	ENSG00000222364.1	RNU6-96P	-11.76	3e-25	4.72e-21	-0.64	-0.62	Aortic root size;	chr7:66447394	chr7:66395191~66395286:+
OV	cis	rs875971	0.895	rs10755833	ENSG00000222364.1	RNU6-96P	-11.76	3e-25	4.72e-21	-0.64	-0.62	Aortic root size;	chr7:66448930	chr7:66395191~66395286:+
OV	cis	rs875971	0.964	rs12668936	ENSG00000222364.1	RNU6-96P	-11.76	3e-25	4.72e-21	-0.64	-0.62	Aortic root size;	chr7:66449417	chr7:66395191~66395286:+
OV	cis	rs875971	0.895	rs7788984	ENSG00000222364.1	RNU6-96P	-11.76	3e-25	4.72e-21	-0.64	-0.62	Aortic root size;	chr7:66450629	chr7:66395191~66395286:+
OV	cis	rs875971	0.895	rs1833495	ENSG00000222364.1	RNU6-96P	-11.76	3e-25	4.72e-21	-0.64	-0.62	Aortic root size;	chr7:66456608	chr7:66395191~66395286:+
OV	cis	rs875971	0.964	rs6945032	ENSG00000222364.1	RNU6-96P	-11.76	3e-25	4.72e-21	-0.64	-0.62	Aortic root size;	chr7:66457499	chr7:66395191~66395286:+
OV	cis	rs875971	0.929	rs12673810	ENSG00000222364.1	RNU6-96P	-11.76	3e-25	4.72e-21	-0.64	-0.62	Aortic root size;	chr7:66458866	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs35149210	ENSG00000222364.1	RNU6-96P	-11.76	3e-25	4.72e-21	-0.64	-0.62	Aortic root size;	chr7:66464938	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs2042133	ENSG00000222364.1	RNU6-96P	-11.76	3e-25	4.72e-21	-0.64	-0.62	Aortic root size;	chr7:66466935	chr7:66395191~66395286:+
OV	cis	rs875971	0.964	rs2161065	ENSG00000222364.1	RNU6-96P	-11.76	3e-25	4.72e-21	-0.64	-0.62	Aortic root size;	chr7:66467918	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs6961155	ENSG00000222364.1	RNU6-96P	-11.76	3e-25	4.72e-21	-0.64	-0.62	Aortic root size;	chr7:66468308	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs7789768	ENSG00000222364.1	RNU6-96P	-11.76	3e-25	4.72e-21	-0.64	-0.62	Aortic root size;	chr7:66473993	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs12698521	ENSG00000222364.1	RNU6-96P	-11.76	3e-25	4.72e-21	-0.64	-0.62	Aortic root size;	chr7:66474502	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs1363055	ENSG00000222364.1	RNU6-96P	-11.76	3e-25	4.72e-21	-0.64	-0.62	Aortic root size;	chr7:66478288	chr7:66395191~66395286:+
OV	cis	rs875971	0.964	rs9691480	ENSG00000222364.1	RNU6-96P	-11.76	3e-25	4.72e-21	-0.64	-0.62	Aortic root size;	chr7:66479319	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs7789554	ENSG00000222364.1	RNU6-96P	-11.76	3e-25	4.72e-21	-0.64	-0.62	Aortic root size;	chr7:66481051	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs4717300	ENSG00000222364.1	RNU6-96P	-11.76	3e-25	4.72e-21	-0.64	-0.62	Aortic root size;	chr7:66482393	chr7:66395191~66395286:+
OV	cis	rs875971	0.895	rs1974769	ENSG00000222364.1	RNU6-96P	-11.76	3e-25	4.72e-21	-0.64	-0.62	Aortic root size;	chr7:66485627	chr7:66395191~66395286:+
OV	cis	rs875971	0.895	rs6460300	ENSG00000222364.1	RNU6-96P	-11.76	3e-25	4.72e-21	-0.64	-0.62	Aortic root size;	chr7:66487937	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs7803416	ENSG00000222364.1	RNU6-96P	-11.76	3e-25	4.72e-21	-0.64	-0.62	Aortic root size;	chr7:66489212	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs1981798	ENSG00000222364.1	RNU6-96P	-11.76	3e-25	4.72e-21	-0.64	-0.62	Aortic root size;	chr7:66489916	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs1981799	ENSG00000222364.1	RNU6-96P	-11.76	3e-25	4.72e-21	-0.64	-0.62	Aortic root size;	chr7:66490572	chr7:66395191~66395286:+
OV	cis	rs875971	0.964	rs2277911	ENSG00000222364.1	RNU6-96P	-11.76	3e-25	4.72e-21	-0.64	-0.62	Aortic root size;	chr7:66493638	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs880166	ENSG00000222364.1	RNU6-96P	11.75	3.2e-25	4.97e-21	0.62	0.62	Aortic root size;	chr7:66205775	chr7:66395191~66395286:+
OV	cis	rs858239	0.899	rs2268745	ENSG00000230658.1	KLHL7-AS1	11.75	3.22e-25	5.01e-21	0.82	0.62	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23101228~23105703:-
OV	cis	rs1577917	0.876	rs66986937	ENSG00000203875.9	SNHG5	-11.74	3.39e-25	5.27e-21	-0.74	-0.61	Response to antipsychotic treatment;	chr6:85822473	chr6:85660950~85678736:-
OV	cis	rs875971	0.798	rs12698522	ENSG00000222364.1	RNU6-96P	-11.74	3.48e-25	5.39e-21	-0.62	-0.61	Aortic root size;	chr7:66502354	chr7:66395191~66395286:+
OV	cis	rs875971	0.83	rs28714531	ENSG00000222364.1	RNU6-96P	-11.74	3.48e-25	5.39e-21	-0.62	-0.61	Aortic root size;	chr7:66503250	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs12698526	ENSG00000222364.1	RNU6-96P	-11.74	3.48e-25	5.39e-21	-0.62	-0.61	Aortic root size;	chr7:66504118	chr7:66395191~66395286:+
OV	cis	rs875971	0.964	rs6945019	ENSG00000222364.1	RNU6-96P	-11.74	3.48e-25	5.39e-21	-0.64	-0.61	Aortic root size;	chr7:66457471	chr7:66395191~66395286:+
OV	cis	rs801193	0.569	rs2707847	ENSG00000222364.1	RNU6-96P	-11.74	3.53e-25	5.46e-21	-0.63	-0.61	Aortic root size;	chr7:66737884	chr7:66395191~66395286:+
OV	cis	rs1577917	1	rs12215037	ENSG00000203875.9	SNHG5	-11.74	3.59e-25	5.55e-21	-0.74	-0.61	Response to antipsychotic treatment;	chr6:86017913	chr6:85660950~85678736:-
OV	cis	rs801193	0.569	rs13226966	ENSG00000222364.1	RNU6-96P	-11.73	3.88e-25	5.97e-21	-0.62	-0.61	Aortic root size;	chr7:66768636	chr7:66395191~66395286:+
OV	cis	rs801193	0.569	rs13242290	ENSG00000222364.1	RNU6-96P	11.73	3.89e-25	5.98e-21	0.64	0.61	Aortic root size;	chr7:66656898	chr7:66395191~66395286:+
OV	cis	rs2486288	0.656	rs7167146	ENSG00000259520.4	CTD-2651B20.3	-11.72	4.02e-25	6.17e-21	-0.78	-0.61	Glomerular filtration rate;	chr15:45279188	chr15:45251580~45279251:-
OV	cis	rs801193	0.569	rs35070132	ENSG00000222364.1	RNU6-96P	-11.72	4.08e-25	6.26e-21	-0.63	-0.61	Aortic root size;	chr7:66773096	chr7:66395191~66395286:+
OV	cis	rs1577917	1	rs1337850	ENSG00000203875.9	SNHG5	-11.71	4.49e-25	6.84e-21	-0.73	-0.61	Response to antipsychotic treatment;	chr6:86019385	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs12665542	ENSG00000203875.9	SNHG5	-11.7	4.57e-25	6.96e-21	-0.74	-0.61	Response to antipsychotic treatment;	chr6:85834725	chr6:85660950~85678736:-
OV	cis	rs801193	0.569	rs11772819	ENSG00000222364.1	RNU6-96P	-11.7	4.73e-25	7.19e-21	-0.62	-0.61	Aortic root size;	chr7:66752983	chr7:66395191~66395286:+
OV	cis	rs801193	0.569	rs11761542	ENSG00000222364.1	RNU6-96P	-11.7	4.73e-25	7.19e-21	-0.62	-0.61	Aortic root size;	chr7:66753209	chr7:66395191~66395286:+
OV	cis	rs801193	0.569	rs7800620	ENSG00000222364.1	RNU6-96P	-11.7	4.73e-25	7.19e-21	-0.62	-0.61	Aortic root size;	chr7:66758701	chr7:66395191~66395286:+
OV	cis	rs801193	0.548	rs7805152	ENSG00000222364.1	RNU6-96P	-11.7	4.8e-25	7.29e-21	-0.62	-0.61	Aortic root size;	chr7:66744266	chr7:66395191~66395286:+
OV	cis	rs6782228	0.675	rs9813845	ENSG00000242551.2	POU5F1P6	-11.7	4.84e-25	7.33e-21	-0.68	-0.61	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128680780	chr3:128674735~128677005:-
OV	cis	rs801193	0.569	rs10950050	ENSG00000222364.1	RNU6-96P	-11.69	4.93e-25	7.48e-21	-0.62	-0.61	Aortic root size;	chr7:66774601	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs7783779	ENSG00000222364.1	RNU6-96P	11.69	5.09e-25	7.71e-21	0.63	0.61	Aortic root size;	chr7:66331639	chr7:66395191~66395286:+
OV	cis	rs858239	0.738	rs7807879	ENSG00000230658.1	KLHL7-AS1	11.69	5.1e-25	7.72e-21	0.86	0.61	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23101228~23105703:-
OV	cis	rs1577917	0.958	rs2875456	ENSG00000203875.9	SNHG5	-11.69	5.1e-25	7.72e-21	-0.73	-0.61	Response to antipsychotic treatment;	chr6:85892566	chr6:85660950~85678736:-
OV	cis	rs875971	0.862	rs2901152	ENSG00000222364.1	RNU6-96P	11.68	5.29e-25	7.93e-21	0.63	0.61	Aortic root size;	chr7:66300017	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs10263690	ENSG00000222364.1	RNU6-96P	11.68	5.29e-25	7.93e-21	0.63	0.61	Aortic root size;	chr7:66301466	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs10250544	ENSG00000222364.1	RNU6-96P	11.68	5.29e-25	7.93e-21	0.63	0.61	Aortic root size;	chr7:66301574	chr7:66395191~66395286:+
OV	cis	rs875971	0.895	rs12531677	ENSG00000222364.1	RNU6-96P	11.68	5.29e-25	7.93e-21	0.63	0.61	Aortic root size;	chr7:66304099	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs7798630	ENSG00000222364.1	RNU6-96P	11.68	5.29e-25	7.93e-21	0.63	0.61	Aortic root size;	chr7:66306492	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs11984115	ENSG00000222364.1	RNU6-96P	11.68	5.29e-25	7.93e-21	0.63	0.61	Aortic root size;	chr7:66308872	chr7:66395191~66395286:+
OV	cis	rs875971	0.755	rs10228885	ENSG00000222364.1	RNU6-96P	11.68	5.29e-25	7.93e-21	0.63	0.61	Aortic root size;	chr7:66315542	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs3893216	ENSG00000222364.1	RNU6-96P	11.68	5.29e-25	7.93e-21	0.63	0.61	Aortic root size;	chr7:66325720	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs6958294	ENSG00000222364.1	RNU6-96P	11.68	5.29e-25	7.93e-21	0.63	0.61	Aortic root size;	chr7:66329809	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs2088655	ENSG00000222364.1	RNU6-96P	11.68	5.29e-25	7.93e-21	0.63	0.61	Aortic root size;	chr7:66330724	chr7:66395191~66395286:+
OV	cis	rs875971	0.895	rs10447522	ENSG00000222364.1	RNU6-96P	11.68	5.29e-25	7.93e-21	0.63	0.61	Aortic root size;	chr7:66331087	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs2088653	ENSG00000222364.1	RNU6-96P	11.68	5.29e-25	7.93e-21	0.63	0.61	Aortic root size;	chr7:66343621	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs6460293	ENSG00000222364.1	RNU6-96P	11.68	5.29e-25	7.93e-21	0.63	0.61	Aortic root size;	chr7:66345205	chr7:66395191~66395286:+
OV	cis	rs1577917	1	rs12207610	ENSG00000203875.9	SNHG5	-11.68	5.59e-25	8.36e-21	-0.71	-0.61	Response to antipsychotic treatment;	chr6:85978298	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs12203457	ENSG00000203875.9	SNHG5	-11.68	5.59e-25	8.36e-21	-0.71	-0.61	Response to antipsychotic treatment;	chr6:85979559	chr6:85660950~85678736:-
OV	cis	rs801193	0.569	rs2659907	ENSG00000222364.1	RNU6-96P	-11.67	5.74e-25	8.58e-21	-0.63	-0.61	Aortic root size;	chr7:66699045	chr7:66395191~66395286:+
OV	cis	rs875971	0.756	rs4718328	ENSG00000222364.1	RNU6-96P	11.67	5.76e-25	8.59e-21	0.62	0.61	Aortic root size;	chr7:66228350	chr7:66395191~66395286:+
OV	cis	rs9399135	0.967	rs9321481	ENSG00000232876.1	CTA-212D2.2	11.67	6.06e-25	9.02e-21	0.66	0.61	Red blood cell count;	chr6:135031510	chr6:135055033~135060550:+
OV	cis	rs1577917	0.958	rs67024565	ENSG00000203875.9	SNHG5	-11.66	6.2e-25	9.21e-21	-0.74	-0.61	Response to antipsychotic treatment;	chr6:85844279	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs10455158	ENSG00000203875.9	SNHG5	-11.66	6.32e-25	9.38e-21	-0.71	-0.61	Response to antipsychotic treatment;	chr6:85963107	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs12215903	ENSG00000203875.9	SNHG5	-11.66	6.32e-25	9.38e-21	-0.71	-0.61	Response to antipsychotic treatment;	chr6:85965310	chr6:85660950~85678736:-
OV	cis	rs1577917	0.959	rs34258068	ENSG00000203875.9	SNHG5	-11.66	6.32e-25	9.38e-21	-0.71	-0.61	Response to antipsychotic treatment;	chr6:85969731	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs11754330	ENSG00000203875.9	SNHG5	-11.66	6.43e-25	9.53e-21	-0.76	-0.61	Response to antipsychotic treatment;	chr6:85745352	chr6:85660950~85678736:-
OV	cis	rs875971	1	rs2077593	ENSG00000222364.1	RNU6-96P	-11.66	6.49e-25	9.61e-21	-0.64	-0.61	Aortic root size;	chr7:66427543	chr7:66395191~66395286:+
OV	cis	rs1577917	1	rs13217384	ENSG00000203875.9	SNHG5	-11.66	6.52e-25	9.66e-21	-0.7	-0.61	Response to antipsychotic treatment;	chr6:86010282	chr6:85660950~85678736:-
OV	cis	rs875971	0.862	rs11763189	ENSG00000222364.1	RNU6-96P	-11.65	6.95e-25	1.02e-20	-0.62	-0.61	Aortic root size;	chr7:66518542	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs2909688	ENSG00000222364.1	RNU6-96P	-11.64	7.19e-25	1.05e-20	-0.62	-0.61	Aortic root size;	chr7:66376625	chr7:66395191~66395286:+
OV	cis	rs875971	0.83	rs778711	ENSG00000222364.1	RNU6-96P	-11.64	7.19e-25	1.05e-20	-0.62	-0.61	Aortic root size;	chr7:66386670	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs1083554	ENSG00000222364.1	RNU6-96P	-11.64	7.19e-25	1.05e-20	-0.62	-0.61	Aortic root size;	chr7:66387354	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs778707	ENSG00000222364.1	RNU6-96P	-11.64	7.19e-25	1.05e-20	-0.62	-0.61	Aortic root size;	chr7:66392040	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs778705	ENSG00000222364.1	RNU6-96P	-11.64	7.19e-25	1.05e-20	-0.62	-0.61	Aortic root size;	chr7:66396128	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs778697	ENSG00000222364.1	RNU6-96P	-11.64	7.19e-25	1.05e-20	-0.62	-0.61	Aortic root size;	chr7:66405439	chr7:66395191~66395286:+
OV	cis	rs875971	0.798	rs7789615	ENSG00000222364.1	RNU6-96P	-11.64	7.19e-25	1.05e-20	-0.62	-0.61	Aortic root size;	chr7:66413674	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs6978028	ENSG00000222364.1	RNU6-96P	-11.64	7.19e-25	1.05e-20	-0.62	-0.61	Aortic root size;	chr7:66421313	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs6947339	ENSG00000222364.1	RNU6-96P	-11.64	7.19e-25	1.05e-20	-0.62	-0.61	Aortic root size;	chr7:66423483	chr7:66395191~66395286:+
OV	cis	rs1577917	0.958	rs36053156	ENSG00000203875.9	SNHG5	-11.63	7.66e-25	1.12e-20	-0.73	-0.61	Response to antipsychotic treatment;	chr6:85865791	chr6:85660950~85678736:-
OV	cis	rs6782228	0.606	rs7613073	ENSG00000242551.2	POU5F1P6	-11.63	7.96e-25	1.16e-20	-0.66	-0.61	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669660	chr3:128674735~128677005:-
OV	cis	rs875971	0.862	rs10276077	ENSG00000222364.1	RNU6-96P	11.63	8.02e-25	1.17e-20	0.62	0.61	Aortic root size;	chr7:66263424	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs6944374	ENSG00000222364.1	RNU6-96P	11.62	8.54e-25	1.24e-20	0.62	0.61	Aortic root size;	chr7:66221942	chr7:66395191~66395286:+
OV	cis	rs875971	0.929	rs34406470	ENSG00000222364.1	RNU6-96P	-11.62	8.63e-25	1.25e-20	-0.64	-0.61	Aortic root size;	chr7:66464969	chr7:66395191~66395286:+
OV	cis	rs858239	0.899	rs28635122	ENSG00000230658.1	KLHL7-AS1	11.61	8.89e-25	1.29e-20	0.81	0.61	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23101228~23105703:-
OV	cis	rs1577917	1	rs12661204	ENSG00000203875.9	SNHG5	-11.61	9.03e-25	1.31e-20	-0.72	-0.61	Response to antipsychotic treatment;	chr6:85968868	chr6:85660950~85678736:-
OV	cis	rs875971	0.862	rs4718330	ENSG00000222364.1	RNU6-96P	11.6	9.73e-25	1.41e-20	0.62	0.61	Aortic root size;	chr7:66250256	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs7781698	ENSG00000222364.1	RNU6-96P	-11.6	9.81e-25	1.42e-20	-0.63	-0.61	Aortic root size;	chr7:66431325	chr7:66395191~66395286:+
OV	cis	rs6782228	0.628	rs7641584	ENSG00000242551.2	POU5F1P6	-11.6	9.92e-25	1.44e-20	-0.66	-0.61	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128673787	chr3:128674735~128677005:-
OV	cis	rs875971	0.862	rs2420174	ENSG00000222364.1	RNU6-96P	11.6	1e-24	1.44e-20	0.61	0.61	Aortic root size;	chr7:66180374	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs2420173	ENSG00000222364.1	RNU6-96P	11.6	1e-24	1.44e-20	0.61	0.61	Aortic root size;	chr7:66180412	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs4718319	ENSG00000222364.1	RNU6-96P	11.6	1e-24	1.44e-20	0.61	0.61	Aortic root size;	chr7:66187797	chr7:66395191~66395286:+
OV	cis	rs875971	0.723	rs28391294	ENSG00000222364.1	RNU6-96P	11.6	1e-24	1.44e-20	0.61	0.61	Aortic root size;	chr7:66189328	chr7:66395191~66395286:+
OV	cis	rs875971	0.83	rs6967708	ENSG00000222364.1	RNU6-96P	11.6	1e-24	1.44e-20	0.61	0.61	Aortic root size;	chr7:66192326	chr7:66395191~66395286:+
OV	cis	rs875971	0.895	rs7782806	ENSG00000222364.1	RNU6-96P	11.6	1e-24	1.44e-20	0.61	0.61	Aortic root size;	chr7:66192910	chr7:66395191~66395286:+
OV	cis	rs1577917	0.958	rs12198876	ENSG00000203875.9	SNHG5	-11.59	1.08e-24	1.54e-20	-0.74	-0.61	Response to antipsychotic treatment;	chr6:85815758	chr6:85660950~85678736:-
OV	cis	rs875971	0.862	rs11773628	ENSG00000222364.1	RNU6-96P	11.58	1.11e-24	1.59e-20	0.62	0.61	Aortic root size;	chr7:66517644	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs7786892	ENSG00000222364.1	RNU6-96P	11.58	1.14e-24	1.63e-20	0.61	0.61	Aortic root size;	chr7:66163889	chr7:66395191~66395286:+
OV	cis	rs1577917	0.958	rs34622605	ENSG00000203875.9	SNHG5	-11.57	1.19e-24	1.7e-20	-0.75	-0.61	Response to antipsychotic treatment;	chr6:85746801	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs34106666	ENSG00000203875.9	SNHG5	-11.56	1.31e-24	1.87e-20	-0.71	-0.61	Response to antipsychotic treatment;	chr6:85966540	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs1337844	ENSG00000203875.9	SNHG5	-11.56	1.31e-24	1.87e-20	-0.71	-0.61	Response to antipsychotic treatment;	chr6:85967555	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs884841	ENSG00000203875.9	SNHG5	-11.56	1.31e-24	1.87e-20	-0.71	-0.61	Response to antipsychotic treatment;	chr6:85970582	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs884842	ENSG00000203875.9	SNHG5	-11.56	1.31e-24	1.87e-20	-0.71	-0.61	Response to antipsychotic treatment;	chr6:85970679	chr6:85660950~85678736:-
OV	cis	rs9399135	0.967	rs2150681	ENSG00000232876.1	CTA-212D2.2	11.55	1.37e-24	1.95e-20	0.66	0.61	Red blood cell count;	chr6:135054094	chr6:135055033~135060550:+
OV	cis	rs9326248	1	rs585849	ENSG00000254851.1	RP11-109L13.1	-11.55	1.43e-24	2.04e-20	-0.8	-0.61	Blood protein levels;	chr11:117198345	chr11:117135528~117138582:+
OV	cis	rs875971	0.929	rs4122249	ENSG00000222364.1	RNU6-96P	-11.54	1.54e-24	2.18e-20	-0.63	-0.61	Aortic root size;	chr7:66455949	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs6959268	ENSG00000222364.1	RNU6-96P	11.53	1.59e-24	2.24e-20	0.61	0.61	Aortic root size;	chr7:66347979	chr7:66395191~66395286:+
OV	cis	rs875971	0.893	rs62465470	ENSG00000222364.1	RNU6-96P	11.52	1.74e-24	2.45e-20	0.6	0.61	Aortic root size;	chr7:66136231	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs4368860	ENSG00000222364.1	RNU6-96P	11.52	1.74e-24	2.45e-20	0.6	0.61	Aortic root size;	chr7:66143495	chr7:66395191~66395286:+
OV	cis	rs858239	0.6	rs2003555	ENSG00000230658.1	KLHL7-AS1	11.52	1.77e-24	2.49e-20	0.8	0.61	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23101228~23105703:-
OV	cis	rs858239	0.6	rs10256359	ENSG00000230658.1	KLHL7-AS1	11.52	1.77e-24	2.49e-20	0.8	0.61	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23101228~23105703:-
OV	cis	rs858239	0.6	rs7784929	ENSG00000230658.1	KLHL7-AS1	11.52	1.77e-24	2.49e-20	0.8	0.61	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23101228~23105703:-
OV	cis	rs6782228	0.675	rs9841987	ENSG00000242551.2	POU5F1P6	-11.51	1.85e-24	2.6e-20	-0.66	-0.61	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128666299	chr3:128674735~128677005:-
OV	cis	rs6782228	0.675	rs56141228	ENSG00000242551.2	POU5F1P6	-11.51	1.85e-24	2.6e-20	-0.66	-0.61	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128667199	chr3:128674735~128677005:-
OV	cis	rs6782228	0.651	rs9852825	ENSG00000242551.2	POU5F1P6	-11.51	1.85e-24	2.6e-20	-0.66	-0.61	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128668514	chr3:128674735~128677005:-
OV	cis	rs875971	0.825	rs4587224	ENSG00000222364.1	RNU6-96P	11.51	1.96e-24	2.74e-20	0.62	0.61	Aortic root size;	chr7:66271195	chr7:66395191~66395286:+
OV	cis	rs875971	0.792	rs6971752	ENSG00000222364.1	RNU6-96P	11.51	1.96e-24	2.74e-20	0.62	0.61	Aortic root size;	chr7:66272999	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs10950033	ENSG00000222364.1	RNU6-96P	11.51	1.96e-24	2.74e-20	0.62	0.61	Aortic root size;	chr7:66274686	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs11760844	ENSG00000222364.1	RNU6-96P	11.51	1.96e-24	2.74e-20	0.62	0.61	Aortic root size;	chr7:66274896	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs4149461	ENSG00000222364.1	RNU6-96P	11.51	1.96e-24	2.74e-20	0.62	0.61	Aortic root size;	chr7:66279745	chr7:66395191~66395286:+
OV	cis	rs1577917	0.917	rs12202170	ENSG00000203875.9	SNHG5	-11.5	2.04e-24	2.85e-20	-0.73	-0.61	Response to antipsychotic treatment;	chr6:85880668	chr6:85660950~85678736:-
OV	cis	rs1577917	1	rs10455449	ENSG00000203875.9	SNHG5	-11.5	2.04e-24	2.85e-20	-0.73	-0.61	Response to antipsychotic treatment;	chr6:85882508	chr6:85660950~85678736:-
OV	cis	rs858239	0.6	rs7799422	ENSG00000230658.1	KLHL7-AS1	11.5	2.1e-24	2.93e-20	0.8	0.61	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23101228~23105703:-
OV	cis	rs875971	0.862	rs1612452	ENSG00000222364.1	RNU6-96P	11.49	2.2e-24	3.06e-20	0.61	0.61	Aortic root size;	chr7:66108909	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs1167390	ENSG00000222364.1	RNU6-96P	11.49	2.2e-24	3.06e-20	0.61	0.61	Aortic root size;	chr7:66110906	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs35034167	ENSG00000222364.1	RNU6-96P	11.49	2.2e-24	3.06e-20	0.61	0.61	Aortic root size;	chr7:66115179	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs1983372	ENSG00000222364.1	RNU6-96P	11.48	2.28e-24	3.17e-20	0.61	0.61	Aortic root size;	chr7:66146364	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs908915	ENSG00000222364.1	RNU6-96P	11.48	2.28e-24	3.17e-20	0.61	0.61	Aortic root size;	chr7:66149664	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs7809814	ENSG00000222364.1	RNU6-96P	11.48	2.28e-24	3.17e-20	0.61	0.61	Aortic root size;	chr7:66150410	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs28470208	ENSG00000222364.1	RNU6-96P	11.48	2.41e-24	3.34e-20	0.61	0.61	Aortic root size;	chr7:66119713	chr7:66395191~66395286:+
OV	cis	rs2487048	0.725	rs2246293	ENSG00000226334.1	RP11-217B7.2	11.47	2.46e-24	3.41e-20	0.73	0.61	Intraocular pressure;	chr9:104928557	chr9:104927553~104928892:+
OV	cis	rs1577917	0.958	rs10944137	ENSG00000203875.9	SNHG5	-11.47	2.56e-24	3.55e-20	-0.75	-0.61	Response to antipsychotic treatment;	chr6:85744596	chr6:85660950~85678736:-
OV	cis	rs858239	0.6	rs28483572	ENSG00000230658.1	KLHL7-AS1	11.46	2.78e-24	3.84e-20	0.8	0.61	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23101228~23105703:-
OV	cis	rs858239	0.6	rs6961406	ENSG00000230658.1	KLHL7-AS1	11.46	2.78e-24	3.84e-20	0.8	0.61	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23101228~23105703:-
OV	cis	rs858239	0.6	rs6461690	ENSG00000230658.1	KLHL7-AS1	11.46	2.78e-24	3.84e-20	0.8	0.61	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23101228~23105703:-
OV	cis	rs858239	0.6	rs6967419	ENSG00000230658.1	KLHL7-AS1	11.46	2.78e-24	3.84e-20	0.8	0.61	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23101228~23105703:-
OV	cis	rs875971	0.862	rs2460432	ENSG00000222364.1	RNU6-96P	11.46	2.82e-24	3.88e-20	0.61	0.61	Aortic root size;	chr7:66089398	chr7:66395191~66395286:+
OV	cis	rs1577917	1	rs10944169	ENSG00000203875.9	SNHG5	-11.44	3.04e-24	4.19e-20	-0.73	-0.6	Response to antipsychotic treatment;	chr6:85973318	chr6:85660950~85678736:-
OV	cis	rs858239	0.72	rs10227559	ENSG00000230658.1	KLHL7-AS1	11.44	3.13e-24	4.3e-20	0.83	0.6	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23101228~23105703:-
OV	cis	rs875971	0.862	rs778720	ENSG00000222364.1	RNU6-96P	11.43	3.29e-24	4.49e-20	0.6	0.6	Aortic root size;	chr7:66381288	chr7:66395191~66395286:+
OV	cis	rs875971	0.798	rs57739047	ENSG00000222364.1	RNU6-96P	-11.43	3.4e-24	4.63e-20	-0.61	-0.6	Aortic root size;	chr7:66507579	chr7:66395191~66395286:+
OV	cis	rs875971	0.83	rs6950137	ENSG00000222364.1	RNU6-96P	-11.43	3.4e-24	4.63e-20	-0.61	-0.6	Aortic root size;	chr7:66511623	chr7:66395191~66395286:+
OV	cis	rs1577917	0.538	rs7755996	ENSG00000203875.9	SNHG5	11.41	3.84e-24	5.21e-20	0.67	0.6	Response to antipsychotic treatment;	chr6:85714002	chr6:85660950~85678736:-
OV	cis	rs6782228	0.651	rs9289332	ENSG00000242551.2	POU5F1P6	-11.41	4.07e-24	5.45e-20	-0.66	-0.6	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669041	chr3:128674735~128677005:-
OV	cis	rs875971	0.798	rs6460304	ENSG00000222364.1	RNU6-96P	-11.4	4.19e-24	5.6e-20	-0.61	-0.6	Aortic root size;	chr7:66499741	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs6945775	ENSG00000222364.1	RNU6-96P	-11.4	4.19e-24	5.6e-20	-0.61	-0.6	Aortic root size;	chr7:66503987	chr7:66395191~66395286:+
OV	cis	rs2487048	0.725	rs2422493	ENSG00000226334.1	RP11-217B7.2	-11.38	4.74e-24	6.32e-20	-0.73	-0.6	Intraocular pressure;	chr9:104928714	chr9:104927553~104928892:+
OV	cis	rs1577917	0.958	rs12212480	ENSG00000203875.9	SNHG5	-11.38	4.8e-24	6.4e-20	-0.75	-0.6	Response to antipsychotic treatment;	chr6:85749059	chr6:85660950~85678736:-
OV	cis	rs9326248	1	rs7946257	ENSG00000254851.1	RP11-109L13.1	-11.38	4.87e-24	6.48e-20	-0.79	-0.6	Blood protein levels;	chr11:117182449	chr11:117135528~117138582:+
OV	cis	rs1577917	1	rs12663690	ENSG00000203875.9	SNHG5	11.37	5.13e-24	6.83e-20	0.7	0.6	Response to antipsychotic treatment;	chr6:85930444	chr6:85660950~85678736:-
OV	cis	rs9326248	1	rs664922	ENSG00000254851.1	RP11-109L13.1	-11.37	5.31e-24	7.06e-20	-0.79	-0.6	Blood protein levels;	chr11:117200179	chr11:117135528~117138582:+
OV	cis	rs9326248	1	rs664082	ENSG00000254851.1	RP11-109L13.1	-11.37	5.31e-24	7.06e-20	-0.79	-0.6	Blood protein levels;	chr11:117200354	chr11:117135528~117138582:+
OV	cis	rs9326248	0.954	rs521171	ENSG00000254851.1	RP11-109L13.1	-11.34	6.35e-24	8.4e-20	-0.78	-0.6	Blood protein levels;	chr11:117193977	chr11:117135528~117138582:+
OV	cis	rs9326248	0.861	rs4938343	ENSG00000254851.1	RP11-109L13.1	-11.34	6.46e-24	8.55e-20	-0.91	-0.6	Blood protein levels;	chr11:117132812	chr11:117135528~117138582:+
OV	cis	rs1577917	0.917	rs2197651	ENSG00000203875.9	SNHG5	-11.34	6.5e-24	8.59e-20	-0.76	-0.6	Response to antipsychotic treatment;	chr6:85785724	chr6:85660950~85678736:-
OV	cis	rs858239	0.899	rs2268747	ENSG00000230658.1	KLHL7-AS1	11.34	6.62e-24	8.75e-20	0.8	0.6	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23101228~23105703:-
OV	cis	rs858239	0.632	rs1985769	ENSG00000230658.1	KLHL7-AS1	11.34	6.63e-24	8.76e-20	0.79	0.6	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23101228~23105703:-
OV	cis	rs858239	0.6	rs7789237	ENSG00000230658.1	KLHL7-AS1	11.34	6.63e-24	8.76e-20	0.79	0.6	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23101228~23105703:-
OV	cis	rs1577917	1	rs12201741	ENSG00000203875.9	SNHG5	-11.33	6.83e-24	9.01e-20	-0.7	-0.6	Response to antipsychotic treatment;	chr6:85892901	chr6:85660950~85678736:-
OV	cis	rs1577917	0.958	rs11755048	ENSG00000203875.9	SNHG5	-11.33	6.95e-24	9.15e-20	-0.8	-0.6	Response to antipsychotic treatment;	chr6:85804616	chr6:85660950~85678736:-
OV	cis	rs9326248	0.954	rs10790177	ENSG00000254851.1	RP11-109L13.1	-11.32	7.59e-24	9.97e-20	-0.79	-0.6	Blood protein levels;	chr11:117177701	chr11:117135528~117138582:+
OV	cis	rs9326248	1	rs4938354	ENSG00000254851.1	RP11-109L13.1	-11.32	7.74e-24	1.01e-19	-0.79	-0.6	Blood protein levels;	chr11:117180449	chr11:117135528~117138582:+
OV	cis	rs875971	0.862	rs4236208	ENSG00000222364.1	RNU6-96P	11.3	8.49e-24	1.11e-19	0.61	0.6	Aortic root size;	chr7:66284091	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs10261398	ENSG00000222364.1	RNU6-96P	11.3	8.49e-24	1.11e-19	0.61	0.6	Aortic root size;	chr7:66285177	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs10224872	ENSG00000222364.1	RNU6-96P	11.3	8.49e-24	1.11e-19	0.61	0.6	Aortic root size;	chr7:66294786	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs709596	ENSG00000222364.1	RNU6-96P	-11.3	8.84e-24	1.15e-19	-0.6	-0.6	Aortic root size;	chr7:66360926	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs778686	ENSG00000222364.1	RNU6-96P	-11.3	8.84e-24	1.15e-19	-0.6	-0.6	Aortic root size;	chr7:66370923	chr7:66395191~66395286:+
OV	cis	rs6782228	0.675	rs2253151	ENSG00000242551.2	POU5F1P6	-11.28	1.02e-23	1.32e-19	-0.65	-0.6	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611294	chr3:128674735~128677005:-
OV	cis	rs875971	0.862	rs949930	ENSG00000222364.1	RNU6-96P	11.27	1.06e-23	1.37e-19	0.61	0.6	Aortic root size;	chr7:66301835	chr7:66395191~66395286:+
OV	cis	rs875971	0.928	rs2036263	ENSG00000222364.1	RNU6-96P	11.27	1.06e-23	1.37e-19	0.61	0.6	Aortic root size;	chr7:66335210	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs10240949	ENSG00000222364.1	RNU6-96P	11.27	1.06e-23	1.37e-19	0.61	0.6	Aortic root size;	chr7:66339430	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs7782704	ENSG00000222364.1	RNU6-96P	11.27	1.06e-23	1.37e-19	0.61	0.6	Aortic root size;	chr7:66340379	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs6460290	ENSG00000222364.1	RNU6-96P	11.27	1.06e-23	1.37e-19	0.61	0.6	Aortic root size;	chr7:66344119	chr7:66395191~66395286:+
OV	cis	rs9326248	0.906	rs171052	ENSG00000254851.1	RP11-109L13.1	11.27	1.13e-23	1.46e-19	0.81	0.6	Blood protein levels;	chr11:117211047	chr11:117135528~117138582:+
OV	cis	rs875971	0.862	rs778724	ENSG00000222364.1	RNU6-96P	-11.26	1.2e-23	1.53e-19	-0.6	-0.6	Aortic root size;	chr7:66364304	chr7:66395191~66395286:+
OV	cis	rs875971	0.767	rs1643394	ENSG00000222364.1	RNU6-96P	-11.26	1.2e-23	1.53e-19	-0.6	-0.6	Aortic root size;	chr7:66371107	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs778684	ENSG00000222364.1	RNU6-96P	-11.26	1.2e-23	1.53e-19	-0.6	-0.6	Aortic root size;	chr7:66371416	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs778680	ENSG00000222364.1	RNU6-96P	-11.26	1.2e-23	1.53e-19	-0.6	-0.6	Aortic root size;	chr7:66375427	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs11769079	ENSG00000222364.1	RNU6-96P	-11.26	1.2e-23	1.53e-19	-0.6	-0.6	Aortic root size;	chr7:66377141	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs1695820	ENSG00000222364.1	RNU6-96P	-11.26	1.2e-23	1.53e-19	-0.6	-0.6	Aortic root size;	chr7:66379576	chr7:66395191~66395286:+
OV	cis	rs875971	0.83	rs778715	ENSG00000222364.1	RNU6-96P	-11.26	1.2e-23	1.53e-19	-0.6	-0.6	Aortic root size;	chr7:66384222	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs778702	ENSG00000222364.1	RNU6-96P	-11.26	1.2e-23	1.53e-19	-0.6	-0.6	Aortic root size;	chr7:66399848	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs1643375	ENSG00000222364.1	RNU6-96P	-11.26	1.2e-23	1.53e-19	-0.6	-0.6	Aortic root size;	chr7:66407690	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs6962717	ENSG00000222364.1	RNU6-96P	-11.26	1.2e-23	1.53e-19	-0.6	-0.6	Aortic root size;	chr7:66418748	chr7:66395191~66395286:+
OV	cis	rs2487048	0.761	rs1800976	ENSG00000226334.1	RP11-217B7.2	-11.26	1.2e-23	1.53e-19	-0.73	-0.6	Intraocular pressure;	chr9:104928428	chr9:104927553~104928892:+
OV	cis	rs4423214	1	rs2002063	ENSG00000254682.1	RP11-660L16.2	11.26	1.2e-23	1.53e-19	0.71	0.6	Vitamin D levels;	chr11:71452430	chr11:71448674~71452157:+
OV	cis	rs4423214	1	rs11600860	ENSG00000254682.1	RP11-660L16.2	11.26	1.2e-23	1.53e-19	0.71	0.6	Vitamin D levels;	chr11:71452973	chr11:71448674~71452157:+
OV	cis	rs4423214	0.959	rs11606611	ENSG00000254682.1	RP11-660L16.2	11.26	1.2e-23	1.53e-19	0.71	0.6	Vitamin D levels;	chr11:71453000	chr11:71448674~71452157:+
OV	cis	rs4423214	1	rs11606612	ENSG00000254682.1	RP11-660L16.2	11.26	1.2e-23	1.53e-19	0.71	0.6	Vitamin D levels;	chr11:71453001	chr11:71448674~71452157:+
OV	cis	rs4423214	1	rs11606631	ENSG00000254682.1	RP11-660L16.2	11.26	1.2e-23	1.53e-19	0.71	0.6	Vitamin D levels;	chr11:71453075	chr11:71448674~71452157:+
OV	cis	rs875971	0.83	rs809025	ENSG00000222364.1	RNU6-96P	-11.25	1.23e-23	1.57e-19	-0.6	-0.6	Aortic root size;	chr7:66384832	chr7:66395191~66395286:+
OV	cis	rs6782228	0.675	rs6806687	ENSG00000277250.1	Metazoa_SRP	11.24	1.31e-23	1.67e-19	0.61	0.6	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128672946	chr3:128673681~128674021:-
OV	cis	rs1577917	0.916	rs12203358	ENSG00000203875.9	SNHG5	-11.24	1.31e-23	1.68e-19	-0.7	-0.6	Response to antipsychotic treatment;	chr6:85893506	chr6:85660950~85678736:-
OV	cis	rs9326248	0.798	rs10892079	ENSG00000254851.1	RP11-109L13.1	-11.24	1.33e-23	1.69e-19	-0.81	-0.6	Blood protein levels;	chr11:117146108	chr11:117135528~117138582:+
OV	cis	rs9326248	0.954	rs8521	ENSG00000254851.1	RP11-109L13.1	-11.23	1.43e-23	1.81e-19	-0.77	-0.6	Blood protein levels;	chr11:117196983	chr11:117135528~117138582:+
OV	cis	rs1577917	0.958	rs12192546	ENSG00000203875.9	SNHG5	11.22	1.53e-23	1.94e-19	0.74	0.6	Response to antipsychotic treatment;	chr6:85766766	chr6:85660950~85678736:-
OV	cis	rs2658782	0.951	rs117384439	ENSG00000279684.1	RP11-755E23.2	11.22	1.55e-23	1.96e-19	0.84	0.6	Pulmonary function decline;	chr11:93378312	chr11:93286629~93288903:-
OV	cis	rs858239	0.698	rs4265084	ENSG00000230658.1	KLHL7-AS1	11.22	1.6e-23	2.03e-19	0.81	0.6	Cerebrospinal fluid biomarker levels;	chr7:23367621	chr7:23101228~23105703:-
OV	cis	rs858239	0.6	rs28499396	ENSG00000230658.1	KLHL7-AS1	11.2	1.83e-23	2.31e-19	0.79	0.6	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23101228~23105703:-
OV	cis	rs875971	0.825	rs1000464	ENSG00000222364.1	RNU6-96P	11.19	1.98e-23	2.49e-19	0.61	0.6	Aortic root size;	chr7:66312922	chr7:66395191~66395286:+
OV	cis	rs2658782	0.951	rs72972357	ENSG00000279684.1	RP11-755E23.2	11.17	2.19e-23	2.76e-19	0.84	0.6	Pulmonary function decline;	chr11:93385674	chr11:93286629~93288903:-
OV	cis	rs4423214	1	rs12789751	ENSG00000254682.1	RP11-660L16.2	11.17	2.29e-23	2.86e-19	0.7	0.6	Vitamin D levels;	chr11:71453425	chr11:71448674~71452157:+
OV	cis	rs4423214	1	rs12791871	ENSG00000254682.1	RP11-660L16.2	11.17	2.29e-23	2.86e-19	0.7	0.6	Vitamin D levels;	chr11:71453498	chr11:71448674~71452157:+
OV	cis	rs4423214	1	rs7944926	ENSG00000254682.1	RP11-660L16.2	11.17	2.29e-23	2.86e-19	0.7	0.6	Vitamin D levels;	chr11:71454579	chr11:71448674~71452157:+
OV	cis	rs4423214	1	rs4944958	ENSG00000254682.1	RP11-660L16.2	11.17	2.29e-23	2.86e-19	0.7	0.6	Vitamin D levels;	chr11:71457027	chr11:71448674~71452157:+
OV	cis	rs4423214	1	rs12790010	ENSG00000254682.1	RP11-660L16.2	11.17	2.29e-23	2.86e-19	0.7	0.6	Vitamin D levels;	chr11:71459607	chr11:71448674~71452157:+
OV	cis	rs4423214	1	rs12806844	ENSG00000254682.1	RP11-660L16.2	11.17	2.29e-23	2.86e-19	0.7	0.6	Vitamin D levels;	chr11:71459724	chr11:71448674~71452157:+
OV	cis	rs4423214	1	rs12790558	ENSG00000254682.1	RP11-660L16.2	11.17	2.29e-23	2.86e-19	0.7	0.6	Vitamin D levels;	chr11:71459859	chr11:71448674~71452157:+
OV	cis	rs4423214	0.959	rs11233747	ENSG00000254682.1	RP11-660L16.2	11.17	2.29e-23	2.86e-19	0.7	0.6	Vitamin D levels;	chr11:71460596	chr11:71448674~71452157:+
OV	cis	rs4423214	1	rs11600569	ENSG00000254682.1	RP11-660L16.2	11.17	2.29e-23	2.86e-19	0.7	0.6	Vitamin D levels;	chr11:71462701	chr11:71448674~71452157:+
OV	cis	rs2882667	0.964	rs11958050	ENSG00000253404.1	AC034243.1	11.15	2.64e-23	3.3e-19	0.73	0.59	Age-related hearing impairment (SNP x SNP interaction);	chr5:138966139	chr5:138744434~138753309:-
OV	cis	rs875971	0.862	rs778734	ENSG00000222364.1	RNU6-96P	-11.14	2.78e-23	3.47e-19	-0.6	-0.59	Aortic root size;	chr7:66349862	chr7:66395191~66395286:+
OV	cis	rs4423214	0.959	rs12793224	ENSG00000254682.1	RP11-660L16.2	11.14	2.8e-23	3.49e-19	0.7	0.59	Vitamin D levels;	chr11:71457664	chr11:71448674~71452157:+
OV	cis	rs4423214	0.959	rs12794668	ENSG00000254682.1	RP11-660L16.2	11.14	2.8e-23	3.49e-19	0.7	0.59	Vitamin D levels;	chr11:71457669	chr11:71448674~71452157:+
OV	cis	rs7617773	0.817	rs11130162	ENSG00000229759.1	MRPS18AP1	11.14	2.81e-23	3.5e-19	0.61	0.59	Coronary artery disease;	chr3:48256121	chr3:48256350~48256938:-
OV	cis	rs9326248	0.953	rs488962	ENSG00000254851.1	RP11-109L13.1	11.13	3.09e-23	3.84e-19	0.8	0.59	Blood protein levels;	chr11:117201809	chr11:117135528~117138582:+
OV	cis	rs9326248	0.953	rs634960	ENSG00000254851.1	RP11-109L13.1	11.13	3.09e-23	3.84e-19	0.8	0.59	Blood protein levels;	chr11:117202247	chr11:117135528~117138582:+
OV	cis	rs9326248	0.954	rs4938349	ENSG00000254851.1	RP11-109L13.1	-11.11	3.56e-23	4.42e-19	-0.79	-0.59	Blood protein levels;	chr11:117151207	chr11:117135528~117138582:+
OV	cis	rs858239	0.899	rs5850	ENSG00000230658.1	KLHL7-AS1	11.1	3.66e-23	4.54e-19	0.78	0.59	Cerebrospinal fluid biomarker levels;	chr7:23274928	chr7:23101228~23105703:-
OV	cis	rs858239	0.806	rs10268610	ENSG00000230658.1	KLHL7-AS1	11.1	3.72e-23	4.61e-19	0.81	0.59	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23101228~23105703:-
OV	cis	rs7617773	0.817	rs11720622	ENSG00000229759.1	MRPS18AP1	11.09	4.15e-23	5.13e-19	0.61	0.59	Coronary artery disease;	chr3:48205189	chr3:48256350~48256938:-
OV	cis	rs875971	0.862	rs11765791	ENSG00000222364.1	RNU6-96P	-11.06	4.91e-23	6.06e-19	-0.61	-0.59	Aortic root size;	chr7:66471587	chr7:66395191~66395286:+
OV	cis	rs7617773	0.817	rs11130163	ENSG00000229759.1	MRPS18AP1	11.06	5e-23	6.17e-19	0.6	0.59	Coronary artery disease;	chr3:48271168	chr3:48256350~48256938:-
OV	cis	rs6782228	0.675	rs4443194	ENSG00000242551.2	POU5F1P6	-11.03	6.05e-23	7.45e-19	-0.65	-0.59	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664603	chr3:128674735~128677005:-
OV	cis	rs6782228	0.675	rs4857918	ENSG00000242551.2	POU5F1P6	-11.03	6.05e-23	7.45e-19	-0.65	-0.59	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128665117	chr3:128674735~128677005:-
OV	cis	rs4423214	1	rs12808368	ENSG00000254682.1	RP11-660L16.2	11.03	6.27e-23	7.71e-19	0.69	0.59	Vitamin D levels;	chr11:71459771	chr11:71448674~71452157:+
OV	cis	rs9326248	0.911	rs474339	ENSG00000254851.1	RP11-109L13.1	-11.03	6.45e-23	7.93e-19	-0.78	-0.59	Blood protein levels;	chr11:117188836	chr11:117135528~117138582:+
OV	cis	rs7617773	0.817	rs6806112	ENSG00000229759.1	MRPS18AP1	11.02	6.81e-23	8.36e-19	0.6	0.59	Coronary artery disease;	chr3:48234587	chr3:48256350~48256938:-
OV	cis	rs7617773	0.817	rs6787500	ENSG00000229759.1	MRPS18AP1	11.01	7.06e-23	8.66e-19	0.6	0.59	Coronary artery disease;	chr3:48257949	chr3:48256350~48256938:-
OV	cis	rs2836974	0.545	rs8128901	ENSG00000232608.1	TIMM9P2	-11.01	7.19e-23	8.8e-19	-0.7	-0.59	Cognitive function;	chr21:39338493	chr21:39216624~39217506:+
OV	cis	rs2836974	0.544	rs8128919	ENSG00000232608.1	TIMM9P2	-11.01	7.19e-23	8.8e-19	-0.7	-0.59	Cognitive function;	chr21:39339936	chr21:39216624~39217506:+
OV	cis	rs2658782	1	rs2658782	ENSG00000279684.1	RP11-755E23.2	-11	8.01e-23	9.8e-19	-0.81	-0.59	Pulmonary function decline;	chr11:93433565	chr11:93286629~93288903:-
OV	cis	rs2658782	1	rs2019814	ENSG00000279684.1	RP11-755E23.2	-11	8.01e-23	9.8e-19	-0.81	-0.59	Pulmonary function decline;	chr11:93435719	chr11:93286629~93288903:-
OV	cis	rs875971	0.862	rs6460307	ENSG00000222364.1	RNU6-96P	-10.98	9e-23	1.1e-18	-0.6	-0.59	Aortic root size;	chr7:66595884	chr7:66395191~66395286:+
OV	cis	rs507080	0.733	rs611733	ENSG00000255422.1	AP002954.4	-10.98	9.27e-23	1.13e-18	-0.72	-0.59	Serum metabolite levels;	chr11:118702051	chr11:118704607~118750263:+
OV	cis	rs507080	0.733	rs552079	ENSG00000255422.1	AP002954.4	-10.98	9.27e-23	1.13e-18	-0.72	-0.59	Serum metabolite levels;	chr11:118702313	chr11:118704607~118750263:+
OV	cis	rs507080	0.733	rs673547	ENSG00000255422.1	AP002954.4	-10.97	9.47e-23	1.15e-18	-0.72	-0.59	Serum metabolite levels;	chr11:118702630	chr11:118704607~118750263:+
OV	cis	rs12922317	0.681	rs2869492	ENSG00000260224.1	UBL5P4	10.97	9.65e-23	1.18e-18	0.64	0.59	Schizophrenia;	chr16:11977484	chr16:11968508~11968743:-
OV	cis	rs9326248	0.911	rs11216284	ENSG00000254851.1	RP11-109L13.1	-10.95	1.12e-22	1.36e-18	-0.8	-0.59	Blood protein levels;	chr11:117132344	chr11:117135528~117138582:+
OV	cis	rs2836974	0.563	rs6517522	ENSG00000232608.1	TIMM9P2	-10.94	1.15e-22	1.4e-18	-0.66	-0.59	Cognitive function;	chr21:39181919	chr21:39216624~39217506:+
OV	cis	rs1577917	0.958	rs12208227	ENSG00000203875.9	SNHG5	-10.94	1.17e-22	1.43e-18	-0.72	-0.59	Response to antipsychotic treatment;	chr6:85961226	chr6:85660950~85678736:-
OV	cis	rs507080	0.697	rs656287	ENSG00000255422.1	AP002954.4	-10.92	1.36e-22	1.65e-18	-0.72	-0.59	Serum metabolite levels;	chr11:118701081	chr11:118704607~118750263:+
OV	cis	rs507080	0.733	rs570949	ENSG00000255422.1	AP002954.4	-10.92	1.36e-22	1.65e-18	-0.72	-0.59	Serum metabolite levels;	chr11:118701202	chr11:118704607~118750263:+
OV	cis	rs9326248	1	rs3736120	ENSG00000254851.1	RP11-109L13.1	-10.92	1.38e-22	1.67e-18	-0.78	-0.59	Blood protein levels;	chr11:117161409	chr11:117135528~117138582:+
OV	cis	rs6782228	0.606	rs4857861	ENSG00000242551.2	POU5F1P6	-10.91	1.45e-22	1.75e-18	-0.64	-0.59	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687924	chr3:128674735~128677005:-
OV	cis	rs6782228	0.606	rs4857919	ENSG00000242551.2	POU5F1P6	-10.91	1.45e-22	1.75e-18	-0.64	-0.59	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128688652	chr3:128674735~128677005:-
OV	cis	rs875971	0.767	rs12668005	ENSG00000222364.1	RNU6-96P	-10.91	1.49e-22	1.8e-18	-0.6	-0.59	Aortic root size;	chr7:66444034	chr7:66395191~66395286:+
OV	cis	rs2658782	1	rs2605583	ENSG00000279684.1	RP11-755E23.2	-10.9	1.55e-22	1.88e-18	-0.81	-0.59	Pulmonary function decline;	chr11:93431791	chr11:93286629~93288903:-
OV	cis	rs2658782	1	rs2605582	ENSG00000279684.1	RP11-755E23.2	-10.9	1.57e-22	1.89e-18	-0.8	-0.59	Pulmonary function decline;	chr11:93430633	chr11:93286629~93288903:-
OV	cis	rs4423214	0.918	rs11233789	ENSG00000254682.1	RP11-660L16.2	10.9	1.62e-22	1.96e-18	0.68	0.59	Vitamin D levels;	chr11:71470039	chr11:71448674~71452157:+
OV	cis	rs6782228	0.675	rs2253151	ENSG00000277250.1	Metazoa_SRP	-10.88	1.8e-22	2.17e-18	-0.64	-0.59	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611294	chr3:128673681~128674021:-
OV	cis	rs4423214	1	rs28364617	ENSG00000254682.1	RP11-660L16.2	10.87	1.95e-22	2.35e-18	0.7	0.59	Vitamin D levels;	chr11:71448718	chr11:71448674~71452157:+
OV	cis	rs2836974	0.583	rs9981884	ENSG00000232608.1	TIMM9P2	-10.86	2.16e-22	2.59e-18	-0.68	-0.58	Cognitive function;	chr21:39213707	chr21:39216624~39217506:+
OV	cis	rs6782228	0.606	rs6775270	ENSG00000242551.2	POU5F1P6	-10.85	2.25e-22	2.69e-18	-0.64	-0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128684655	chr3:128674735~128677005:-
OV	cis	rs4423214	1	rs12785878	ENSG00000254682.1	RP11-660L16.2	10.85	2.26e-22	2.7e-18	0.69	0.58	Vitamin D levels;	chr11:71456403	chr11:71448674~71452157:+
OV	cis	rs9326248	1	rs9326248	ENSG00000254851.1	RP11-109L13.1	-10.82	2.85e-22	3.4e-18	-0.81	-0.58	Blood protein levels;	chr11:117128509	chr11:117135528~117138582:+
OV	cis	rs2658782	1	rs2658778	ENSG00000279684.1	RP11-755E23.2	-10.81	3e-22	3.57e-18	-0.81	-0.58	Pulmonary function decline;	chr11:93415782	chr11:93286629~93288903:-
OV	cis	rs2658782	1	rs2608216	ENSG00000279684.1	RP11-755E23.2	-10.81	3e-22	3.57e-18	-0.81	-0.58	Pulmonary function decline;	chr11:93416006	chr11:93286629~93288903:-
OV	cis	rs2658782	0.95	rs2446061	ENSG00000279684.1	RP11-755E23.2	-10.81	3e-22	3.57e-18	-0.81	-0.58	Pulmonary function decline;	chr11:93416111	chr11:93286629~93288903:-
OV	cis	rs2658782	0.951	rs72972364	ENSG00000279684.1	RP11-755E23.2	10.8	3.33e-22	3.95e-18	0.83	0.58	Pulmonary function decline;	chr11:93388962	chr11:93286629~93288903:-
OV	cis	rs7617773	0.638	rs7644414	ENSG00000229759.1	MRPS18AP1	10.79	3.53e-22	4.18e-18	0.61	0.58	Coronary artery disease;	chr3:48257589	chr3:48256350~48256938:-
OV	cis	rs6782228	0.606	rs6807019	ENSG00000242551.2	POU5F1P6	-10.78	3.74e-22	4.42e-18	-0.64	-0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687091	chr3:128674735~128677005:-
OV	cis	rs6782228	0.606	rs2811488	ENSG00000242551.2	POU5F1P6	-10.78	3.8e-22	4.49e-18	-0.63	-0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617674	chr3:128674735~128677005:-
OV	cis	rs4423214	1	rs7935125	ENSG00000254682.1	RP11-660L16.2	10.78	3.81e-22	4.5e-18	0.69	0.58	Vitamin D levels;	chr11:71473144	chr11:71448674~71452157:+
OV	cis	rs4423214	1	rs732934	ENSG00000254682.1	RP11-660L16.2	10.78	3.81e-22	4.5e-18	0.69	0.58	Vitamin D levels;	chr11:71475430	chr11:71448674~71452157:+
OV	cis	rs4423214	1	rs3794060	ENSG00000254682.1	RP11-660L16.2	10.77	3.93e-22	4.63e-18	0.69	0.58	Vitamin D levels;	chr11:71476633	chr11:71448674~71452157:+
OV	cis	rs9326248	1	rs10790175	ENSG00000254851.1	RP11-109L13.1	-10.77	4.08e-22	4.81e-18	-0.75	-0.58	Blood protein levels;	chr11:117164013	chr11:117135528~117138582:+
OV	cis	rs2658782	0.756	rs3019223	ENSG00000279684.1	RP11-755E23.2	-10.74	5.15e-22	6.04e-18	-0.81	-0.58	Pulmonary function decline;	chr11:93351016	chr11:93286629~93288903:-
OV	cis	rs1577917	0.958	rs12215232	ENSG00000203875.9	SNHG5	-10.73	5.49e-22	6.42e-18	-0.72	-0.58	Response to antipsychotic treatment;	chr6:86075712	chr6:85660950~85678736:-
OV	cis	rs507080	0.733	rs517445	ENSG00000255422.1	AP002954.4	-10.73	5.53e-22	6.47e-18	-0.7	-0.58	Serum metabolite levels;	chr11:118702826	chr11:118704607~118750263:+
OV	cis	rs507080	0.771	rs687664	ENSG00000255422.1	AP002954.4	-10.73	5.53e-22	6.47e-18	-0.7	-0.58	Serum metabolite levels;	chr11:118703476	chr11:118704607~118750263:+
OV	cis	rs507080	0.771	rs523715	ENSG00000255422.1	AP002954.4	-10.73	5.53e-22	6.47e-18	-0.7	-0.58	Serum metabolite levels;	chr11:118703479	chr11:118704607~118750263:+
OV	cis	rs6782228	0.628	rs7641584	ENSG00000277250.1	Metazoa_SRP	-10.72	5.95e-22	6.93e-18	-0.63	-0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128673787	chr3:128673681~128674021:-
OV	cis	rs6782228	0.606	rs7613073	ENSG00000277250.1	Metazoa_SRP	-10.71	6.37e-22	7.39e-18	-0.63	-0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669660	chr3:128673681~128674021:-
OV	cis	rs6782228	0.509	rs6780447	ENSG00000242551.2	POU5F1P6	-10.7	6.86e-22	7.96e-18	-0.63	-0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694965	chr3:128674735~128677005:-
OV	cis	rs6782228	0.527	rs7426806	ENSG00000242551.2	POU5F1P6	-10.69	7.09e-22	8.23e-18	-0.63	-0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694087	chr3:128674735~128677005:-
OV	cis	rs4423214	1	rs4944946	ENSG00000254682.1	RP11-660L16.2	10.69	7.18e-22	8.32e-18	0.7	0.58	Vitamin D levels;	chr11:71448383	chr11:71448674~71452157:+
OV	cis	rs858239	0.636	rs28706766	ENSG00000230658.1	KLHL7-AS1	10.68	7.93e-22	9.05e-18	0.74	0.58	Cerebrospinal fluid biomarker levels;	chr7:23130215	chr7:23101228~23105703:-
OV	cis	rs2658782	1	rs2605585	ENSG00000279684.1	RP11-755E23.2	-10.67	8.56e-22	9.75e-18	-0.81	-0.58	Pulmonary function decline;	chr11:93438696	chr11:93286629~93288903:-
OV	cis	rs6782228	0.585	rs6774515	ENSG00000242551.2	POU5F1P6	-10.66	8.87e-22	1.01e-17	-0.63	-0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128697035	chr3:128674735~128677005:-
OV	cis	rs6782228	0.565	rs12695509	ENSG00000242551.2	POU5F1P6	-10.66	8.87e-22	1.01e-17	-0.63	-0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128698201	chr3:128674735~128677005:-
OV	cis	rs2658782	0.951	rs2608215	ENSG00000279684.1	RP11-755E23.2	-10.65	9.91e-22	1.13e-17	-0.8	-0.58	Pulmonary function decline;	chr11:93415651	chr11:93286629~93288903:-
OV	cis	rs2658782	0.826	rs2925355	ENSG00000279684.1	RP11-755E23.2	-10.64	1.05e-21	1.19e-17	-0.81	-0.58	Pulmonary function decline;	chr11:93357721	chr11:93286629~93288903:-
OV	cis	rs2658782	0.826	rs1975820	ENSG00000279684.1	RP11-755E23.2	-10.63	1.11e-21	1.26e-17	-0.81	-0.58	Pulmonary function decline;	chr11:93348649	chr11:93286629~93288903:-
OV	cis	rs6782228	0.651	rs9289332	ENSG00000277250.1	Metazoa_SRP	-10.62	1.16e-21	1.32e-17	-0.64	-0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128669041	chr3:128673681~128674021:-
OV	cis	rs2658782	1	rs2658781	ENSG00000279684.1	RP11-755E23.2	10.62	1.17e-21	1.32e-17	0.78	0.58	Pulmonary function decline;	chr11:93433202	chr11:93286629~93288903:-
OV	cis	rs4423214	1	rs2282621	ENSG00000254682.1	RP11-660L16.2	10.62	1.18e-21	1.33e-17	0.67	0.58	Vitamin D levels;	chr11:71472428	chr11:71448674~71452157:+
OV	cis	rs4423214	1	rs2282620	ENSG00000254682.1	RP11-660L16.2	10.62	1.18e-21	1.33e-17	0.67	0.58	Vitamin D levels;	chr11:71472431	chr11:71448674~71452157:+
OV	cis	rs7617773	0.743	rs11716371	ENSG00000229759.1	MRPS18AP1	10.61	1.24e-21	1.4e-17	0.63	0.58	Coronary artery disease;	chr3:48321260	chr3:48256350~48256938:-
OV	cis	rs4423214	1	rs12278461	ENSG00000254682.1	RP11-660L16.2	10.61	1.25e-21	1.4e-17	0.67	0.58	Vitamin D levels;	chr11:71471139	chr11:71448674~71452157:+
OV	cis	rs6782228	0.527	rs6767383	ENSG00000242551.2	POU5F1P6	-10.6	1.4e-21	1.57e-17	-0.63	-0.58	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694744	chr3:128674735~128677005:-
OV	cis	rs875971	0.83	rs6976714	ENSG00000222364.1	RNU6-96P	-10.6	1.43e-21	1.6e-17	-0.59	-0.58	Aortic root size;	chr7:66426474	chr7:66395191~66395286:+
OV	cis	rs875971	0.651	rs2420596	ENSG00000222364.1	RNU6-96P	-10.59	1.44e-21	1.6e-17	-0.59	-0.58	Aortic root size;	chr7:66450996	chr7:66395191~66395286:+
OV	cis	rs875971	0.52	rs2420597	ENSG00000222364.1	RNU6-96P	-10.59	1.44e-21	1.6e-17	-0.59	-0.58	Aortic root size;	chr7:66450999	chr7:66395191~66395286:+
OV	cis	rs2658782	0.906	rs2658791	ENSG00000279684.1	RP11-755E23.2	-10.59	1.45e-21	1.62e-17	-0.82	-0.58	Pulmonary function decline;	chr11:93465817	chr11:93286629~93288903:-
OV	cis	rs7617773	0.78	rs7653152	ENSG00000229759.1	MRPS18AP1	10.58	1.61e-21	1.79e-17	0.62	0.57	Coronary artery disease;	chr3:48320607	chr3:48256350~48256938:-
OV	cis	rs507080	0.733	rs4486664	ENSG00000255422.1	AP002954.4	-10.58	1.62e-21	1.79e-17	-0.7	-0.57	Serum metabolite levels;	chr11:118698358	chr11:118704607~118750263:+
OV	cis	rs2658782	0.756	rs3019205	ENSG00000279684.1	RP11-755E23.2	-10.58	1.62e-21	1.79e-17	-0.8	-0.57	Pulmonary function decline;	chr11:93376387	chr11:93286629~93288903:-
OV	cis	rs507080	0.733	rs4393358	ENSG00000255422.1	AP002954.4	-10.58	1.63e-21	1.81e-17	-0.7	-0.57	Serum metabolite levels;	chr11:118698388	chr11:118704607~118750263:+
OV	cis	rs2658782	0.756	rs3019222	ENSG00000279684.1	RP11-755E23.2	-10.57	1.66e-21	1.84e-17	-0.8	-0.57	Pulmonary function decline;	chr11:93346552	chr11:93286629~93288903:-
OV	cis	rs1930961	0.85	rs5996945	ENSG00000272977.1	CTA-390C10.10	10.57	1.69e-21	1.86e-17	0.76	0.57	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25476218~25479971:+
OV	cis	rs507080	0.733	rs7108144	ENSG00000255422.1	AP002954.4	-10.57	1.69e-21	1.86e-17	-0.7	-0.57	Serum metabolite levels;	chr11:118698985	chr11:118704607~118750263:+
OV	cis	rs507080	0.663	rs523793	ENSG00000255422.1	AP002954.4	-10.57	1.69e-21	1.86e-17	-0.7	-0.57	Serum metabolite levels;	chr11:118699988	chr11:118704607~118750263:+
OV	cis	rs507080	0.736	rs659564	ENSG00000255422.1	AP002954.4	-10.57	1.69e-21	1.86e-17	-0.7	-0.57	Serum metabolite levels;	chr11:118700205	chr11:118704607~118750263:+
OV	cis	rs507080	0.736	rs642224	ENSG00000255422.1	AP002954.4	-10.57	1.69e-21	1.86e-17	-0.7	-0.57	Serum metabolite levels;	chr11:118700210	chr11:118704607~118750263:+
OV	cis	rs507080	0.733	rs541631	ENSG00000255422.1	AP002954.4	-10.57	1.69e-21	1.86e-17	-0.7	-0.57	Serum metabolite levels;	chr11:118700314	chr11:118704607~118750263:+
OV	cis	rs507080	0.736	rs658676	ENSG00000255422.1	AP002954.4	-10.57	1.69e-21	1.86e-17	-0.7	-0.57	Serum metabolite levels;	chr11:118700414	chr11:118704607~118750263:+
OV	cis	rs507080	0.733	rs488141	ENSG00000255422.1	AP002954.4	-10.57	1.69e-21	1.86e-17	-0.7	-0.57	Serum metabolite levels;	chr11:118700459	chr11:118704607~118750263:+
OV	cis	rs507080	0.733	rs657769	ENSG00000255422.1	AP002954.4	-10.57	1.69e-21	1.86e-17	-0.7	-0.57	Serum metabolite levels;	chr11:118700607	chr11:118704607~118750263:+
OV	cis	rs507080	0.733	rs544452	ENSG00000255422.1	AP002954.4	-10.57	1.69e-21	1.86e-17	-0.7	-0.57	Serum metabolite levels;	chr11:118700648	chr11:118704607~118750263:+
OV	cis	rs1891275	0.513	rs1539041	ENSG00000228701.1	TNKS2-AS1	-10.56	1.79e-21	1.95e-17	-0.66	-0.57	Intelligence (multi-trait analysis);	chr10:91817384	chr10:91782839~91798291:-
OV	cis	rs2658782	0.951	rs2608214	ENSG00000279684.1	RP11-755E23.2	-10.56	1.83e-21	2e-17	-0.78	-0.57	Pulmonary function decline;	chr11:93415499	chr11:93286629~93288903:-
OV	cis	rs6782228	0.585	rs2712392	ENSG00000242551.2	POU5F1P6	-10.55	1.93e-21	2.11e-17	-0.61	-0.57	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705414	chr3:128674735~128677005:-
OV	cis	rs7617773	0.78	rs7645425	ENSG00000229759.1	MRPS18AP1	10.54	2.06e-21	2.23e-17	0.62	0.57	Coronary artery disease;	chr3:48320879	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs6793223	ENSG00000229759.1	MRPS18AP1	10.54	2.06e-21	2.23e-17	0.62	0.57	Coronary artery disease;	chr3:48322611	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs4541431	ENSG00000229759.1	MRPS18AP1	10.54	2.06e-21	2.23e-17	0.62	0.57	Coronary artery disease;	chr3:48323728	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs11714944	ENSG00000229759.1	MRPS18AP1	10.54	2.06e-21	2.23e-17	0.62	0.57	Coronary artery disease;	chr3:48325481	chr3:48256350~48256938:-
OV	cis	rs7617773	0.743	rs13071960	ENSG00000229759.1	MRPS18AP1	10.54	2.06e-21	2.23e-17	0.62	0.57	Coronary artery disease;	chr3:48326047	chr3:48256350~48256938:-
OV	cis	rs7617773	0.743	rs4632568	ENSG00000229759.1	MRPS18AP1	10.54	2.06e-21	2.23e-17	0.62	0.57	Coronary artery disease;	chr3:48326329	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs11130164	ENSG00000229759.1	MRPS18AP1	10.54	2.06e-21	2.23e-17	0.62	0.57	Coronary artery disease;	chr3:48327544	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs7653336	ENSG00000229759.1	MRPS18AP1	10.54	2.06e-21	2.23e-17	0.62	0.57	Coronary artery disease;	chr3:48327974	chr3:48256350~48256938:-
OV	cis	rs7617773	0.747	rs34076262	ENSG00000229759.1	MRPS18AP1	10.54	2.06e-21	2.23e-17	0.62	0.57	Coronary artery disease;	chr3:48328926	chr3:48256350~48256938:-
OV	cis	rs858239	0.6	rs7776644	ENSG00000230658.1	KLHL7-AS1	10.54	2.07e-21	2.24e-17	0.77	0.57	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23101228~23105703:-
OV	cis	rs4423214	1	rs4944959	ENSG00000254682.1	RP11-660L16.2	-10.54	2.14e-21	2.31e-17	-0.67	-0.57	Vitamin D levels;	chr11:71457188	chr11:71448674~71452157:+
OV	cis	rs2658782	0.789	rs3020057	ENSG00000279684.1	RP11-755E23.2	-10.52	2.44e-21	2.63e-17	-0.8	-0.57	Pulmonary function decline;	chr11:93385349	chr11:93286629~93288903:-
OV	cis	rs858239	0.669	rs1006709	ENSG00000230658.1	KLHL7-AS1	10.51	2.59e-21	2.8e-17	0.73	0.57	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23101228~23105703:-
OV	cis	rs6782228	0.675	rs9841987	ENSG00000277250.1	Metazoa_SRP	-10.5	2.81e-21	3.02e-17	-0.63	-0.57	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128666299	chr3:128673681~128674021:-
OV	cis	rs6782228	0.675	rs56141228	ENSG00000277250.1	Metazoa_SRP	-10.5	2.81e-21	3.02e-17	-0.63	-0.57	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128667199	chr3:128673681~128674021:-
OV	cis	rs6782228	0.651	rs9852825	ENSG00000277250.1	Metazoa_SRP	-10.5	2.81e-21	3.02e-17	-0.63	-0.57	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128668514	chr3:128673681~128674021:-
OV	cis	rs858239	0.669	rs10950940	ENSG00000230658.1	KLHL7-AS1	-10.5	2.82e-21	3.02e-17	-0.74	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23157197	chr7:23101228~23105703:-
OV	cis	rs7617773	0.746	rs11713476	ENSG00000229759.1	MRPS18AP1	10.49	2.98e-21	3.2e-17	0.61	0.57	Coronary artery disease;	chr3:48333944	chr3:48256350~48256938:-
OV	cis	rs6782228	0.565	rs11719239	ENSG00000242551.2	POU5F1P6	-10.48	3.17e-21	3.39e-17	-0.62	-0.57	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700211	chr3:128674735~128677005:-
OV	cis	rs6782228	0.606	rs2001950	ENSG00000242551.2	POU5F1P6	-10.48	3.17e-21	3.39e-17	-0.62	-0.57	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700913	chr3:128674735~128677005:-
OV	cis	rs7617773	0.694	rs13099560	ENSG00000229759.1	MRPS18AP1	-10.48	3.18e-21	3.4e-17	-0.58	-0.57	Coronary artery disease;	chr3:48163278	chr3:48256350~48256938:-
OV	cis	rs10256972	0.616	rs4585652	ENSG00000229043.2	AC091729.9	-10.48	3.19e-21	3.41e-17	-0.68	-0.57	Endometriosis;Longevity;	chr7:1105760	chr7:1160374~1165267:+
OV	cis	rs4423214	1	rs909217	ENSG00000254682.1	RP11-660L16.2	10.48	3.28e-21	3.51e-17	0.67	0.57	Vitamin D levels;	chr11:71435531	chr11:71448674~71452157:+
OV	cis	rs6782228	0.675	rs9813845	ENSG00000277250.1	Metazoa_SRP	-10.48	3.33e-21	3.55e-17	-0.64	-0.57	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128680780	chr3:128673681~128674021:-
OV	cis	rs2658782	0.666	rs2925361	ENSG00000279684.1	RP11-755E23.2	-10.48	3.35e-21	3.58e-17	-0.8	-0.57	Pulmonary function decline;	chr11:93365657	chr11:93286629~93288903:-
OV	cis	rs7617773	0.78	rs13082158	ENSG00000229759.1	MRPS18AP1	10.46	3.7e-21	3.94e-17	0.62	0.57	Coronary artery disease;	chr3:48330980	chr3:48256350~48256938:-
OV	cis	rs2658782	0.789	rs56091149	ENSG00000279684.1	RP11-755E23.2	10.46	3.74e-21	3.98e-17	0.83	0.57	Pulmonary function decline;	chr11:93340474	chr11:93286629~93288903:-
OV	cis	rs858239	0.67	rs3807452	ENSG00000230658.1	KLHL7-AS1	-10.46	3.77e-21	4.01e-17	-0.74	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23101228~23105703:-
OV	cis	rs2658782	0.789	rs2658775	ENSG00000279684.1	RP11-755E23.2	-10.46	3.8e-21	4.04e-17	-0.8	-0.57	Pulmonary function decline;	chr11:93393633	chr11:93286629~93288903:-
OV	cis	rs2658782	0.789	rs2658773	ENSG00000279684.1	RP11-755E23.2	-10.46	3.8e-21	4.04e-17	-0.8	-0.57	Pulmonary function decline;	chr11:93393748	chr11:93286629~93288903:-
OV	cis	rs4423214	0.921	rs12807827	ENSG00000254682.1	RP11-660L16.2	10.45	4e-21	4.24e-17	0.67	0.57	Vitamin D levels;	chr11:71492744	chr11:71448674~71452157:+
OV	cis	rs7617773	0.746	rs7619865	ENSG00000229759.1	MRPS18AP1	10.44	4.28e-21	4.53e-17	0.57	0.57	Coronary artery disease;	chr3:48329090	chr3:48256350~48256938:-
OV	cis	rs9326248	1	rs4938344	ENSG00000254851.1	RP11-109L13.1	-10.44	4.39e-21	4.64e-17	-0.81	-0.57	Blood protein levels;	chr11:117133033	chr11:117135528~117138582:+
OV	cis	rs7617773	0.78	rs35411187	ENSG00000229759.1	MRPS18AP1	10.43	4.59e-21	4.84e-17	0.62	0.57	Coronary artery disease;	chr3:48318527	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs11714176	ENSG00000229759.1	MRPS18AP1	10.43	4.59e-21	4.84e-17	0.62	0.57	Coronary artery disease;	chr3:48319372	chr3:48256350~48256938:-
OV	cis	rs2836974	0.545	rs3167757	ENSG00000232608.1	TIMM9P2	-10.43	4.61e-21	4.85e-17	-0.68	-0.57	Cognitive function;	chr21:39342552	chr21:39216624~39217506:+
OV	cis	rs2836974	0.583	rs2776306	ENSG00000232608.1	TIMM9P2	-10.43	4.71e-21	4.96e-17	-0.67	-0.57	Cognitive function;	chr21:39341828	chr21:39216624~39217506:+
OV	cis	rs2739330	0.76	rs5751761	ENSG00000225282.1	AP000350.6	-10.43	4.72e-21	4.97e-17	-0.64	-0.57	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23926900~23929574:+
OV	cis	rs858239	0.699	rs1881201	ENSG00000230658.1	KLHL7-AS1	-10.42	4.94e-21	5.19e-17	-0.73	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23154394	chr7:23101228~23105703:-
OV	cis	rs7617773	0.78	rs11720026	ENSG00000229759.1	MRPS18AP1	10.42	4.99e-21	5.24e-17	0.62	0.57	Coronary artery disease;	chr3:48336431	chr3:48256350~48256938:-
OV	cis	rs7617773	0.743	rs11715876	ENSG00000229759.1	MRPS18AP1	10.42	4.99e-21	5.24e-17	0.62	0.57	Coronary artery disease;	chr3:48336432	chr3:48256350~48256938:-
OV	cis	rs2282300	0.739	rs1222211	ENSG00000254532.1	RP11-624D11.2	10.42	5.09e-21	5.34e-17	0.78	0.57	Morning vs. evening chronotype;	chr11:30340692	chr11:30044058~30084343:-
OV	cis	rs4423214	1	rs2852853	ENSG00000254682.1	RP11-660L16.2	10.41	5.35e-21	5.6e-17	0.66	0.57	Vitamin D levels;	chr11:71439171	chr11:71448674~71452157:+
OV	cis	rs2836974	0.583	rs2735307	ENSG00000232608.1	TIMM9P2	-10.38	6.78e-21	7.07e-17	-0.67	-0.57	Cognitive function;	chr21:39341432	chr21:39216624~39217506:+
OV	cis	rs7617773	0.676	rs13060020	ENSG00000229759.1	MRPS18AP1	10.38	6.8e-21	7.07e-17	0.62	0.57	Coronary artery disease;	chr3:48331156	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs11710257	ENSG00000229759.1	MRPS18AP1	10.38	6.8e-21	7.07e-17	0.62	0.57	Coronary artery disease;	chr3:48331724	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs71323395	ENSG00000229759.1	MRPS18AP1	10.38	6.8e-21	7.07e-17	0.62	0.57	Coronary artery disease;	chr3:48332587	chr3:48256350~48256938:-
OV	cis	rs7617773	0.743	rs71323397	ENSG00000229759.1	MRPS18AP1	10.38	6.8e-21	7.07e-17	0.62	0.57	Coronary artery disease;	chr3:48333384	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs13066044	ENSG00000229759.1	MRPS18AP1	10.38	6.8e-21	7.07e-17	0.62	0.57	Coronary artery disease;	chr3:48335786	chr3:48256350~48256938:-
OV	cis	rs7617773	0.778	rs11715776	ENSG00000229759.1	MRPS18AP1	10.38	6.8e-21	7.07e-17	0.62	0.57	Coronary artery disease;	chr3:48336121	chr3:48256350~48256938:-
OV	cis	rs7617773	0.778	rs11707997	ENSG00000229759.1	MRPS18AP1	10.38	6.8e-21	7.07e-17	0.62	0.57	Coronary artery disease;	chr3:48336385	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs11716848	ENSG00000229759.1	MRPS18AP1	10.38	6.8e-21	7.07e-17	0.62	0.57	Coronary artery disease;	chr3:48337010	chr3:48256350~48256938:-
OV	cis	rs2658782	0.789	rs3020073	ENSG00000279684.1	RP11-755E23.2	-10.37	7.33e-21	7.61e-17	-0.8	-0.57	Pulmonary function decline;	chr11:93370664	chr11:93286629~93288903:-
OV	cis	rs9326248	0.817	rs1242127	ENSG00000254851.1	RP11-109L13.1	10.36	7.35e-21	7.63e-17	0.78	0.57	Blood protein levels;	chr11:117205848	chr11:117135528~117138582:+
OV	cis	rs858239	0.67	rs6967526	ENSG00000230658.1	KLHL7-AS1	10.36	7.55e-21	7.84e-17	0.72	0.57	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23101228~23105703:-
OV	cis	rs2658782	0.789	rs2658776	ENSG00000279684.1	RP11-755E23.2	-10.34	8.8e-21	9.11e-17	-0.78	-0.57	Pulmonary function decline;	chr11:93414761	chr11:93286629~93288903:-
OV	cis	rs2658782	0.756	rs2658777	ENSG00000279684.1	RP11-755E23.2	-10.34	8.8e-21	9.11e-17	-0.78	-0.57	Pulmonary function decline;	chr11:93415257	chr11:93286629~93288903:-
OV	cis	rs2282300	0.739	rs16920406	ENSG00000254532.1	RP11-624D11.2	10.34	8.84e-21	9.15e-17	0.77	0.57	Morning vs. evening chronotype;	chr11:30194611	chr11:30044058~30084343:-
OV	cis	rs858239	0.699	rs955187	ENSG00000230658.1	KLHL7-AS1	-10.33	9.12e-21	9.43e-17	-0.72	-0.57	Cerebrospinal fluid biomarker levels;	chr7:23154986	chr7:23101228~23105703:-
OV	cis	rs2658782	0.789	rs1456238	ENSG00000279684.1	RP11-755E23.2	-10.31	1.06e-20	1.09e-16	-0.79	-0.56	Pulmonary function decline;	chr11:93384204	chr11:93286629~93288903:-
OV	cis	rs6782228	0.606	rs2811488	ENSG00000277250.1	Metazoa_SRP	-10.3	1.2e-20	1.23e-16	-0.61	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617674	chr3:128673681~128674021:-
OV	cis	rs7617773	0.78	rs13084616	ENSG00000229759.1	MRPS18AP1	-10.29	1.25e-20	1.29e-16	-0.62	-0.56	Coronary artery disease;	chr3:48298209	chr3:48256350~48256938:-
OV	cis	rs7617773	0.817	rs6796490	ENSG00000229759.1	MRPS18AP1	10.29	1.26e-20	1.29e-16	0.58	0.56	Coronary artery disease;	chr3:48195614	chr3:48256350~48256938:-
OV	cis	rs9326248	1	rs7107152	ENSG00000254851.1	RP11-109L13.1	10.29	1.29e-20	1.32e-16	0.73	0.56	Blood protein levels;	chr11:117185364	chr11:117135528~117138582:+
OV	cis	rs858239	0.6	rs6967475	ENSG00000230658.1	KLHL7-AS1	10.28	1.33e-20	1.36e-16	0.79	0.56	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23101228~23105703:-
OV	cis	rs9326248	0.689	rs4516002	ENSG00000254851.1	RP11-109L13.1	-10.28	1.37e-20	1.4e-16	-0.87	-0.56	Blood protein levels;	chr11:117128343	chr11:117135528~117138582:+
OV	cis	rs7617773	0.78	rs3197223	ENSG00000229759.1	MRPS18AP1	10.28	1.39e-20	1.42e-16	0.61	0.56	Coronary artery disease;	chr3:48294367	chr3:48256350~48256938:-
OV	cis	rs7617773	0.817	rs6800492	ENSG00000229759.1	MRPS18AP1	10.25	1.69e-20	1.72e-16	0.59	0.56	Coronary artery disease;	chr3:48282400	chr3:48256350~48256938:-
OV	cis	rs7617773	0.744	rs2125482	ENSG00000229759.1	MRPS18AP1	10.24	1.73e-20	1.76e-16	0.59	0.56	Coronary artery disease;	chr3:48281643	chr3:48256350~48256938:-
OV	cis	rs4423214	1	rs12797951	ENSG00000254682.1	RP11-660L16.2	-10.23	1.96e-20	1.98e-16	-0.65	-0.56	Vitamin D levels;	chr11:71432220	chr11:71448674~71452157:+
OV	cis	rs2282300	0.739	rs10835647	ENSG00000254532.1	RP11-624D11.2	10.21	2.14e-20	2.16e-16	0.77	0.56	Morning vs. evening chronotype;	chr11:30291721	chr11:30044058~30084343:-
OV	cis	rs507080	0.733	rs489126	ENSG00000255422.1	AP002954.4	-10.21	2.22e-20	2.25e-16	-0.67	-0.56	Serum metabolite levels;	chr11:118702038	chr11:118704607~118750263:+
OV	cis	rs7617773	0.78	rs13090538	ENSG00000229759.1	MRPS18AP1	10.21	2.26e-20	2.28e-16	0.6	0.56	Coronary artery disease;	chr3:48329279	chr3:48256350~48256938:-
OV	cis	rs10256972	0.591	rs6968988	ENSG00000229043.2	AC091729.9	-10.21	2.27e-20	2.29e-16	-0.65	-0.56	Endometriosis;Longevity;	chr7:1129983	chr7:1160374~1165267:+
OV	cis	rs17361889	0.778	rs6963052	ENSG00000224683.1	RPL36AP29	10.19	2.46e-20	2.47e-16	0.67	0.56	Pediatric bone mineral content (hip);	chr7:16171904	chr7:16208945~16209265:+
OV	cis	rs2882667	0.858	rs10900856	ENSG00000253404.1	AC034243.1	-10.19	2.46e-20	2.47e-16	-0.72	-0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139082057	chr5:138744434~138753309:-
OV	cis	rs2282300	0.739	rs1222216	ENSG00000254532.1	RP11-624D11.2	10.19	2.61e-20	2.61e-16	0.77	0.56	Morning vs. evening chronotype;	chr11:30324505	chr11:30044058~30084343:-
OV	cis	rs2282300	0.739	rs1222215	ENSG00000254532.1	RP11-624D11.2	10.19	2.61e-20	2.61e-16	0.77	0.56	Morning vs. evening chronotype;	chr11:30326049	chr11:30044058~30084343:-
OV	cis	rs2282300	0.696	rs1222214	ENSG00000254532.1	RP11-624D11.2	10.19	2.61e-20	2.61e-16	0.77	0.56	Morning vs. evening chronotype;	chr11:30326148	chr11:30044058~30084343:-
OV	cis	rs6782228	0.606	rs2811490	ENSG00000242551.2	POU5F1P6	-10.18	2.66e-20	2.65e-16	-0.59	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128632912	chr3:128674735~128677005:-
OV	cis	rs2282300	0.739	rs1765133	ENSG00000254532.1	RP11-624D11.2	10.18	2.79e-20	2.77e-16	0.77	0.56	Morning vs. evening chronotype;	chr11:30317853	chr11:30044058~30084343:-
OV	cis	rs6782228	0.606	rs10048945	ENSG00000242551.2	POU5F1P6	-10.17	2.83e-20	2.79e-16	-0.6	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128690837	chr3:128674735~128677005:-
OV	cis	rs6782228	0.509	rs2811495	ENSG00000242551.2	POU5F1P6	-10.17	2.84e-20	2.79e-16	-0.6	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641114	chr3:128674735~128677005:-
OV	cis	rs6782228	0.565	rs2811496	ENSG00000242551.2	POU5F1P6	-10.17	2.84e-20	2.79e-16	-0.6	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641115	chr3:128674735~128677005:-
OV	cis	rs9389248	0.69	rs6569982	ENSG00000232876.1	CTA-212D2.2	-10.17	2.85e-20	2.8e-16	-0.63	-0.56	High light scatter reticulocyte percentage of red cells;	chr6:134935357	chr6:135055033~135060550:+
OV	cis	rs7617773	0.78	rs13067450	ENSG00000229759.1	MRPS18AP1	10.17	2.87e-20	2.82e-16	0.61	0.56	Coronary artery disease;	chr3:48295716	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs4479622	ENSG00000229759.1	MRPS18AP1	10.17	2.87e-20	2.82e-16	0.61	0.56	Coronary artery disease;	chr3:48296683	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs34946886	ENSG00000229759.1	MRPS18AP1	10.17	2.87e-20	2.82e-16	0.61	0.56	Coronary artery disease;	chr3:48296997	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs34589064	ENSG00000229759.1	MRPS18AP1	10.17	2.87e-20	2.82e-16	0.61	0.56	Coronary artery disease;	chr3:48298059	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs2541	ENSG00000229759.1	MRPS18AP1	10.17	2.87e-20	2.82e-16	0.61	0.56	Coronary artery disease;	chr3:48298128	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs13085251	ENSG00000229759.1	MRPS18AP1	10.17	2.87e-20	2.82e-16	0.61	0.56	Coronary artery disease;	chr3:48298555	chr3:48256350~48256938:-
OV	cis	rs6782228	0.606	rs6439135	ENSG00000242551.2	POU5F1P6	-10.17	2.95e-20	2.89e-16	-0.6	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128639790	chr3:128674735~128677005:-
OV	cis	rs2282300	0.739	rs1933342	ENSG00000254532.1	RP11-624D11.2	-10.17	2.98e-20	2.92e-16	-0.77	-0.56	Morning vs. evening chronotype;	chr11:30291278	chr11:30044058~30084343:-
OV	cis	rs2282300	0.739	rs2225909	ENSG00000254532.1	RP11-624D11.2	-10.17	2.98e-20	2.92e-16	-0.77	-0.56	Morning vs. evening chronotype;	chr11:30308197	chr11:30044058~30084343:-
OV	cis	rs2282300	0.702	rs2211018	ENSG00000254532.1	RP11-624D11.2	-10.17	2.98e-20	2.92e-16	-0.77	-0.56	Morning vs. evening chronotype;	chr11:30308532	chr11:30044058~30084343:-
OV	cis	rs2282300	0.739	rs7926465	ENSG00000254532.1	RP11-624D11.2	-10.17	2.98e-20	2.92e-16	-0.77	-0.56	Morning vs. evening chronotype;	chr11:30311469	chr11:30044058~30084343:-
OV	cis	rs2282300	0.739	rs1616223	ENSG00000254532.1	RP11-624D11.2	10.17	2.98e-20	2.92e-16	0.77	0.56	Morning vs. evening chronotype;	chr11:30317236	chr11:30044058~30084343:-
OV	cis	rs2282300	0.739	rs1717772	ENSG00000254532.1	RP11-624D11.2	10.17	2.98e-20	2.92e-16	0.77	0.56	Morning vs. evening chronotype;	chr11:30318586	chr11:30044058~30084343:-
OV	cis	rs8040855	0.644	rs7495437	ENSG00000259295.5	CSPG4P12	-10.16	3.13e-20	3.06e-16	-0.69	-0.56	Bulimia nervosa;	chr15:85183059	chr15:85191438~85213905:+
OV	cis	rs17361889	0.752	rs62440374	ENSG00000224683.1	RPL36AP29	10.16	3.17e-20	3.1e-16	0.68	0.56	Pediatric bone mineral content (hip);	chr7:16172290	chr7:16208945~16209265:+
OV	cis	rs8040855	0.542	rs2342122	ENSG00000259295.5	CSPG4P12	-10.16	3.23e-20	3.16e-16	-0.69	-0.56	Bulimia nervosa;	chr15:85185304	chr15:85191438~85213905:+
OV	cis	rs8040855	0.644	rs2342120	ENSG00000259295.5	CSPG4P12	-10.16	3.23e-20	3.16e-16	-0.69	-0.56	Bulimia nervosa;	chr15:85185589	chr15:85191438~85213905:+
OV	cis	rs6782228	0.675	rs4443194	ENSG00000277250.1	Metazoa_SRP	-10.15	3.4e-20	3.31e-16	-0.62	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664603	chr3:128673681~128674021:-
OV	cis	rs6782228	0.675	rs4857918	ENSG00000277250.1	Metazoa_SRP	-10.15	3.4e-20	3.31e-16	-0.62	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128665117	chr3:128673681~128674021:-
OV	cis	rs9326248	1	rs664971	ENSG00000254851.1	RP11-109L13.1	10.14	3.53e-20	3.43e-16	0.71	0.56	Blood protein levels;	chr11:117200141	chr11:117135528~117138582:+
OV	cis	rs4423214	0.879	rs4945008	ENSG00000254682.1	RP11-660L16.2	10.14	3.56e-20	3.46e-16	0.65	0.56	Vitamin D levels;	chr11:71510202	chr11:71448674~71452157:+
OV	cis	rs8040855	0.621	rs6496796	ENSG00000259295.5	CSPG4P12	-10.12	4.03e-20	3.91e-16	-0.7	-0.56	Bulimia nervosa;	chr15:85183617	chr15:85191438~85213905:+
OV	cis	rs10256972	0.527	rs28671326	ENSG00000229043.2	AC091729.9	-10.12	4.24e-20	4.1e-16	-0.67	-0.56	Endometriosis;Longevity;	chr7:1135337	chr7:1160374~1165267:+
OV	cis	rs2658782	0.724	rs1869914	ENSG00000279684.1	RP11-755E23.2	-10.11	4.3e-20	4.16e-16	-0.78	-0.56	Pulmonary function decline;	chr11:93379326	chr11:93286629~93288903:-
OV	cis	rs7617773	0.817	rs9818937	ENSG00000229759.1	MRPS18AP1	10.11	4.31e-20	4.17e-16	0.58	0.56	Coronary artery disease;	chr3:48283791	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs9846818	ENSG00000229759.1	MRPS18AP1	10.11	4.32e-20	4.17e-16	0.56	0.56	Coronary artery disease;	chr3:48334195	chr3:48256350~48256938:-
OV	cis	rs7617773	0.817	rs11928691	ENSG00000229759.1	MRPS18AP1	10.11	4.36e-20	4.21e-16	0.59	0.56	Coronary artery disease;	chr3:48245275	chr3:48256350~48256938:-
OV	cis	rs2282300	0.739	rs1631451	ENSG00000254532.1	RP11-624D11.2	10.11	4.39e-20	4.23e-16	0.76	0.56	Morning vs. evening chronotype;	chr11:30327586	chr11:30044058~30084343:-
OV	cis	rs2282300	0.739	rs1717775	ENSG00000254532.1	RP11-624D11.2	10.11	4.39e-20	4.23e-16	0.76	0.56	Morning vs. evening chronotype;	chr11:30328707	chr11:30044058~30084343:-
OV	cis	rs2282300	0.739	rs1222208	ENSG00000254532.1	RP11-624D11.2	10.11	4.39e-20	4.23e-16	0.76	0.56	Morning vs. evening chronotype;	chr11:30339830	chr11:30044058~30084343:-
OV	cis	rs17361889	0.778	rs56033714	ENSG00000224683.1	RPL36AP29	10.11	4.51e-20	4.35e-16	0.68	0.56	Pediatric bone mineral content (hip);	chr7:16171442	chr7:16208945~16209265:+
OV	cis	rs6782228	0.606	rs58977394	ENSG00000242551.2	POU5F1P6	-10.11	4.56e-20	4.39e-16	-0.59	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619074	chr3:128674735~128677005:-
OV	cis	rs6782228	0.606	rs2712381	ENSG00000242551.2	POU5F1P6	-10.11	4.56e-20	4.39e-16	-0.59	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619757	chr3:128674735~128677005:-
OV	cis	rs7617773	0.817	rs17647717	ENSG00000229759.1	MRPS18AP1	10.1	4.66e-20	4.48e-16	0.62	0.56	Coronary artery disease;	chr3:48263966	chr3:48256350~48256938:-
OV	cis	rs2882667	0.858	rs6596460	ENSG00000253404.1	AC034243.1	10.1	4.67e-20	4.49e-16	0.66	0.56	Age-related hearing impairment (SNP x SNP interaction);	chr5:139078491	chr5:138744434~138753309:-
OV	cis	rs6782228	0.606	rs7627549	ENSG00000242551.2	POU5F1P6	-10.1	4.76e-20	4.58e-16	-0.59	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128634236	chr3:128674735~128677005:-
OV	cis	rs2658782	0.789	rs3019206	ENSG00000279684.1	RP11-755E23.2	-10.1	4.79e-20	4.6e-16	-0.78	-0.56	Pulmonary function decline;	chr11:93377907	chr11:93286629~93288903:-
OV	cis	rs6782228	0.606	rs2811500	ENSG00000242551.2	POU5F1P6	-10.1	4.9e-20	4.7e-16	-0.59	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128647413	chr3:128674735~128677005:-
OV	cis	rs2712381	0.797	rs62270806	ENSG00000277250.1	Metazoa_SRP	-10.09	5e-20	4.79e-16	-0.6	-0.56	Monocyte count;	chr3:128657426	chr3:128673681~128674021:-
OV	cis	rs7617773	0.743	rs6804986	ENSG00000229759.1	MRPS18AP1	10.08	5.59e-20	5.34e-16	0.59	0.56	Coronary artery disease;	chr3:48322105	chr3:48256350~48256938:-
OV	cis	rs2486288	0.656	rs1706767	ENSG00000259520.4	CTD-2651B20.3	10.08	5.61e-20	5.36e-16	0.71	0.56	Glomerular filtration rate;	chr15:45276901	chr15:45251580~45279251:-
OV	cis	rs2712381	0.797	rs62270806	ENSG00000242551.2	POU5F1P6	-10.07	5.79e-20	5.53e-16	-0.6	-0.56	Monocyte count;	chr3:128657426	chr3:128674735~128677005:-
OV	cis	rs6782228	0.606	rs6439135	ENSG00000277250.1	Metazoa_SRP	-10.07	5.88e-20	5.61e-16	-0.6	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128639790	chr3:128673681~128674021:-
OV	cis	rs6782228	0.585	rs2811492	ENSG00000242551.2	POU5F1P6	-10.07	6.08e-20	5.79e-16	-0.59	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128637436	chr3:128674735~128677005:-
OV	cis	rs6782228	0.606	rs1697	ENSG00000242551.2	POU5F1P6	-10.07	6.08e-20	5.79e-16	-0.59	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128638009	chr3:128674735~128677005:-
OV	cis	rs6782228	0.585	rs3122175	ENSG00000242551.2	POU5F1P6	-10.07	6.08e-20	5.79e-16	-0.59	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642433	chr3:128674735~128677005:-
OV	cis	rs6782228	0.606	rs7650156	ENSG00000242551.2	POU5F1P6	-10.07	6.08e-20	5.79e-16	-0.59	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642712	chr3:128674735~128677005:-
OV	cis	rs6782228	0.606	rs2811497	ENSG00000242551.2	POU5F1P6	-10.07	6.08e-20	5.79e-16	-0.59	-0.56	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128644489	chr3:128674735~128677005:-
OV	cis	rs4423214	0.921	rs11603330	ENSG00000254682.1	RP11-660L16.2	10.06	6.18e-20	5.88e-16	0.66	0.56	Vitamin D levels;	chr11:71442413	chr11:71448674~71452157:+
OV	cis	rs2658782	0.789	rs3020076	ENSG00000279684.1	RP11-755E23.2	-10.05	6.74e-20	6.39e-16	-0.77	-0.55	Pulmonary function decline;	chr11:93407892	chr11:93286629~93288903:-
OV	cis	rs7617773	0.817	rs9819094	ENSG00000229759.1	MRPS18AP1	10.05	6.79e-20	6.44e-16	0.55	0.55	Coronary artery disease;	chr3:48278068	chr3:48256350~48256938:-
OV	cis	rs6782228	0.606	rs1127030	ENSG00000242551.2	POU5F1P6	-10.04	7.11e-20	6.72e-16	-0.59	-0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128620110	chr3:128674735~128677005:-
OV	cis	rs6782228	0.509	rs4481172	ENSG00000242551.2	POU5F1P6	-10.04	7.31e-20	6.9e-16	-0.59	-0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128653814	chr3:128674735~128677005:-
OV	cis	rs7617773	0.709	rs4404473	ENSG00000229759.1	MRPS18AP1	10.03	7.72e-20	7.27e-16	0.61	0.55	Coronary artery disease;	chr3:48312136	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs35297395	ENSG00000229759.1	MRPS18AP1	10.02	8.14e-20	7.59e-16	0.6	0.55	Coronary artery disease;	chr3:48301392	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs36075665	ENSG00000229759.1	MRPS18AP1	10.02	8.14e-20	7.59e-16	0.6	0.55	Coronary artery disease;	chr3:48301597	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs35190747	ENSG00000229759.1	MRPS18AP1	10.02	8.14e-20	7.59e-16	0.6	0.55	Coronary artery disease;	chr3:48301800	chr3:48256350~48256938:-
OV	cis	rs7617773	0.743	rs7621785	ENSG00000229759.1	MRPS18AP1	10.02	8.14e-20	7.59e-16	0.6	0.55	Coronary artery disease;	chr3:48302218	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs4511915	ENSG00000229759.1	MRPS18AP1	10.02	8.14e-20	7.59e-16	0.6	0.55	Coronary artery disease;	chr3:48302368	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs13066758	ENSG00000229759.1	MRPS18AP1	10.02	8.14e-20	7.59e-16	0.6	0.55	Coronary artery disease;	chr3:48302387	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs4392440	ENSG00000229759.1	MRPS18AP1	10.02	8.14e-20	7.59e-16	0.6	0.55	Coronary artery disease;	chr3:48302430	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs13082859	ENSG00000229759.1	MRPS18AP1	10.02	8.14e-20	7.59e-16	0.6	0.55	Coronary artery disease;	chr3:48303185	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs36121690	ENSG00000229759.1	MRPS18AP1	10.02	8.14e-20	7.59e-16	0.6	0.55	Coronary artery disease;	chr3:48304021	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs35778847	ENSG00000229759.1	MRPS18AP1	10.02	8.14e-20	7.59e-16	0.6	0.55	Coronary artery disease;	chr3:48305495	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs34749846	ENSG00000229759.1	MRPS18AP1	10.02	8.14e-20	7.59e-16	0.6	0.55	Coronary artery disease;	chr3:48305678	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs7632297	ENSG00000229759.1	MRPS18AP1	10.02	8.14e-20	7.59e-16	0.6	0.55	Coronary artery disease;	chr3:48306673	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs79089926	ENSG00000229759.1	MRPS18AP1	10.02	8.14e-20	7.59e-16	0.6	0.55	Coronary artery disease;	chr3:48307074	chr3:48256350~48256938:-
OV	cis	rs7617773	0.643	rs78159520	ENSG00000229759.1	MRPS18AP1	10.02	8.14e-20	7.59e-16	0.6	0.55	Coronary artery disease;	chr3:48307533	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs4511916	ENSG00000229759.1	MRPS18AP1	10.02	8.14e-20	7.59e-16	0.6	0.55	Coronary artery disease;	chr3:48308876	chr3:48256350~48256938:-
OV	cis	rs7617773	0.815	rs7624450	ENSG00000229759.1	MRPS18AP1	10.02	8.14e-20	7.59e-16	0.6	0.55	Coronary artery disease;	chr3:48308885	chr3:48256350~48256938:-
OV	cis	rs7617773	0.815	rs6793150	ENSG00000229759.1	MRPS18AP1	10.02	8.14e-20	7.59e-16	0.6	0.55	Coronary artery disease;	chr3:48310070	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs6793239	ENSG00000229759.1	MRPS18AP1	10.02	8.14e-20	7.59e-16	0.6	0.55	Coronary artery disease;	chr3:48310128	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs6782166	ENSG00000229759.1	MRPS18AP1	10.02	8.14e-20	7.59e-16	0.6	0.55	Coronary artery disease;	chr3:48310193	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs4130522	ENSG00000229759.1	MRPS18AP1	10.02	8.14e-20	7.59e-16	0.6	0.55	Coronary artery disease;	chr3:48310823	chr3:48256350~48256938:-
OV	cis	rs7617773	0.674	rs13069029	ENSG00000229759.1	MRPS18AP1	10.02	8.14e-20	7.59e-16	0.6	0.55	Coronary artery disease;	chr3:48313534	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs13081169	ENSG00000229759.1	MRPS18AP1	10.02	8.14e-20	7.59e-16	0.6	0.55	Coronary artery disease;	chr3:48315307	chr3:48256350~48256938:-
OV	cis	rs7617773	0.817	rs35414021	ENSG00000229759.1	MRPS18AP1	10.02	8.16e-20	7.6e-16	0.61	0.55	Coronary artery disease;	chr3:48252034	chr3:48256350~48256938:-
OV	cis	rs6782228	0.527	rs2712371	ENSG00000242551.2	POU5F1P6	-10.02	8.4e-20	7.82e-16	-0.59	-0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128627371	chr3:128674735~128677005:-
OV	cis	rs6782228	0.509	rs2811495	ENSG00000277250.1	Metazoa_SRP	-10.02	8.55e-20	7.94e-16	-0.6	-0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641114	chr3:128673681~128674021:-
OV	cis	rs6782228	0.565	rs2811496	ENSG00000277250.1	Metazoa_SRP	-10.02	8.55e-20	7.94e-16	-0.6	-0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128641115	chr3:128673681~128674021:-
OV	cis	rs2282300	0.739	rs6484478	ENSG00000254532.1	RP11-624D11.2	-10.02	8.66e-20	8.03e-16	-0.77	-0.55	Morning vs. evening chronotype;	chr11:30284893	chr11:30044058~30084343:-
OV	cis	rs2282300	0.739	rs10742237	ENSG00000254532.1	RP11-624D11.2	-10.02	8.66e-20	8.03e-16	-0.77	-0.55	Morning vs. evening chronotype;	chr11:30289112	chr11:30044058~30084343:-
OV	cis	rs2282300	0.739	rs1933343	ENSG00000254532.1	RP11-624D11.2	-10.02	8.66e-20	8.03e-16	-0.77	-0.55	Morning vs. evening chronotype;	chr11:30289445	chr11:30044058~30084343:-
OV	cis	rs6782228	0.606	rs6787559	ENSG00000242551.2	POU5F1P6	-10.01	8.97e-20	8.32e-16	-0.59	-0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662243	chr3:128674735~128677005:-
OV	cis	rs7617773	0.817	rs11710861	ENSG00000229759.1	MRPS18AP1	10.01	9.15e-20	8.47e-16	0.59	0.55	Coronary artery disease;	chr3:48256070	chr3:48256350~48256938:-
OV	cis	rs7617773	0.817	rs13059037	ENSG00000229759.1	MRPS18AP1	10.01	9.27e-20	8.57e-16	0.61	0.55	Coronary artery disease;	chr3:48246389	chr3:48256350~48256938:-
OV	cis	rs7617773	0.815	rs9825637	ENSG00000229759.1	MRPS18AP1	10	9.35e-20	8.65e-16	0.59	0.55	Coronary artery disease;	chr3:48330792	chr3:48256350~48256938:-
OV	cis	rs7617773	0.817	rs9311421	ENSG00000229759.1	MRPS18AP1	10	9.46e-20	8.74e-16	0.58	0.55	Coronary artery disease;	chr3:48251588	chr3:48256350~48256938:-
OV	cis	rs10256972	0.567	rs2960835	ENSG00000229043.2	AC091729.9	-10	9.54e-20	8.81e-16	-0.65	-0.55	Endometriosis;Longevity;	chr7:1163327	chr7:1160374~1165267:+
OV	cis	rs8040855	0.644	rs4635318	ENSG00000259295.5	CSPG4P12	-10	9.88e-20	9.1e-16	-0.69	-0.55	Bulimia nervosa;	chr15:85183506	chr15:85191438~85213905:+
OV	cis	rs6782228	0.606	rs4634140	ENSG00000242551.2	POU5F1P6	10	9.93e-20	9.14e-16	0.58	0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705613	chr3:128674735~128677005:-
OV	cis	rs7246967	0.611	rs62120273	ENSG00000269509.1	BNIP3P34	9.99	1.04e-19	9.51e-16	1.04	0.55	Bronchopulmonary dysplasia;	chr19:22679518	chr19:22773853~22774424:+
OV	cis	rs7617773	0.779	rs9833309	ENSG00000229759.1	MRPS18AP1	9.98	1.12e-19	1.02e-15	0.58	0.55	Coronary artery disease;	chr3:48285960	chr3:48256350~48256938:-
OV	cis	rs7617773	0.817	rs9853804	ENSG00000229759.1	MRPS18AP1	9.98	1.12e-19	1.02e-15	0.58	0.55	Coronary artery disease;	chr3:48286239	chr3:48256350~48256938:-
OV	cis	rs7617773	0.817	rs9834095	ENSG00000229759.1	MRPS18AP1	9.98	1.12e-19	1.02e-15	0.58	0.55	Coronary artery disease;	chr3:48286261	chr3:48256350~48256938:-
OV	cis	rs7617773	0.817	rs4131361	ENSG00000229759.1	MRPS18AP1	9.98	1.12e-19	1.02e-15	0.58	0.55	Coronary artery disease;	chr3:48287322	chr3:48256350~48256938:-
OV	cis	rs7617773	0.817	rs6791930	ENSG00000229759.1	MRPS18AP1	9.98	1.12e-19	1.02e-15	0.58	0.55	Coronary artery disease;	chr3:48288410	chr3:48256350~48256938:-
OV	cis	rs7617773	0.817	rs6794644	ENSG00000229759.1	MRPS18AP1	9.98	1.12e-19	1.02e-15	0.58	0.55	Coronary artery disease;	chr3:48288547	chr3:48256350~48256938:-
OV	cis	rs6782228	0.606	rs2001703	ENSG00000242551.2	POU5F1P6	-9.98	1.12e-19	1.02e-15	-0.59	-0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664254	chr3:128674735~128677005:-
OV	cis	rs7617773	0.779	rs11718329	ENSG00000229759.1	MRPS18AP1	9.98	1.12e-19	1.02e-15	0.58	0.55	Coronary artery disease;	chr3:48268338	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs6442111	ENSG00000229759.1	MRPS18AP1	9.98	1.12e-19	1.02e-15	0.58	0.55	Coronary artery disease;	chr3:48270570	chr3:48256350~48256938:-
OV	cis	rs7617773	0.851	rs6775179	ENSG00000229759.1	MRPS18AP1	9.98	1.12e-19	1.02e-15	0.58	0.55	Coronary artery disease;	chr3:48271928	chr3:48256350~48256938:-
OV	cis	rs6782228	0.606	rs2712419	ENSG00000242551.2	POU5F1P6	-9.98	1.14e-19	1.03e-15	-0.59	-0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128622053	chr3:128674735~128677005:-
OV	cis	rs6782228	0.606	rs2712417	ENSG00000242551.2	POU5F1P6	-9.98	1.14e-19	1.03e-15	-0.59	-0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128626336	chr3:128674735~128677005:-
OV	cis	rs2658782	0.789	rs2259633	ENSG00000279684.1	RP11-755E23.2	-9.97	1.2e-19	1.08e-15	-0.76	-0.55	Pulmonary function decline;	chr11:93408414	chr11:93286629~93288903:-
OV	cis	rs7617773	0.817	rs34225441	ENSG00000229759.1	MRPS18AP1	9.97	1.21e-19	1.1e-15	0.6	0.55	Coronary artery disease;	chr3:48267401	chr3:48256350~48256938:-
OV	cis	rs6782228	0.606	rs2811489	ENSG00000242551.2	POU5F1P6	9.97	1.22e-19	1.11e-15	0.59	0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128618528	chr3:128674735~128677005:-
OV	cis	rs7617773	0.78	rs11706277	ENSG00000229759.1	MRPS18AP1	9.96	1.24e-19	1.12e-15	0.64	0.55	Coronary artery disease;	chr3:48318943	chr3:48256350~48256938:-
OV	cis	rs2836974	0.604	rs2854727	ENSG00000232608.1	TIMM9P2	-9.96	1.28e-19	1.16e-15	-0.66	-0.55	Cognitive function;	chr21:39341861	chr21:39216624~39217506:+
OV	cis	rs7617773	0.817	rs13100815	ENSG00000229759.1	MRPS18AP1	9.96	1.29e-19	1.17e-15	0.61	0.55	Coronary artery disease;	chr3:48245959	chr3:48256350~48256938:-
OV	cis	rs7617773	0.817	rs13072018	ENSG00000229759.1	MRPS18AP1	9.96	1.31e-19	1.18e-15	0.6	0.55	Coronary artery disease;	chr3:48278842	chr3:48256350~48256938:-
OV	cis	rs17361889	0.806	rs17367660	ENSG00000224683.1	RPL36AP29	9.96	1.32e-19	1.19e-15	0.68	0.55	Pediatric bone mineral content (hip);	chr7:16179008	chr7:16208945~16209265:+
OV	cis	rs7246967	0.551	rs62118775	ENSG00000269509.1	BNIP3P34	9.94	1.45e-19	1.31e-15	1.03	0.55	Bronchopulmonary dysplasia;	chr19:22644376	chr19:22773853~22774424:+
OV	cis	rs7617773	0.817	rs13068265	ENSG00000229759.1	MRPS18AP1	9.94	1.48e-19	1.33e-15	0.6	0.55	Coronary artery disease;	chr3:48260124	chr3:48256350~48256938:-
OV	cis	rs7617773	0.817	rs11709691	ENSG00000229759.1	MRPS18AP1	9.94	1.48e-19	1.33e-15	0.6	0.55	Coronary artery disease;	chr3:48262179	chr3:48256350~48256938:-
OV	cis	rs6782228	0.606	rs2811490	ENSG00000277250.1	Metazoa_SRP	-9.93	1.52e-19	1.37e-15	-0.59	-0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128632912	chr3:128673681~128674021:-
OV	cis	rs7617773	0.78	rs71323396	ENSG00000229759.1	MRPS18AP1	9.93	1.59e-19	1.43e-15	0.6	0.55	Coronary artery disease;	chr3:48333244	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs35297486	ENSG00000229759.1	MRPS18AP1	9.92	1.65e-19	1.48e-15	0.61	0.55	Coronary artery disease;	chr3:48336657	chr3:48256350~48256938:-
OV	cis	rs7617773	0.817	rs4131362	ENSG00000229759.1	MRPS18AP1	9.92	1.68e-19	1.5e-15	0.58	0.55	Coronary artery disease;	chr3:48287546	chr3:48256350~48256938:-
OV	cis	rs2282300	0.739	rs1222210	ENSG00000254532.1	RP11-624D11.2	-9.92	1.7e-19	1.52e-15	-0.74	-0.55	Morning vs. evening chronotype;	chr11:30340578	chr11:30044058~30084343:-
OV	cis	rs7617773	0.784	rs9850672	ENSG00000229759.1	MRPS18AP1	9.91	1.76e-19	1.57e-15	0.58	0.55	Coronary artery disease;	chr3:48259682	chr3:48256350~48256938:-
OV	cis	rs7617773	0.817	rs9847953	ENSG00000229759.1	MRPS18AP1	9.91	1.81e-19	1.61e-15	0.58	0.55	Coronary artery disease;	chr3:48241205	chr3:48256350~48256938:-
OV	cis	rs10256972	0.567	rs7782651	ENSG00000229043.2	AC091729.9	-9.91	1.82e-19	1.62e-15	-0.65	-0.55	Endometriosis;Longevity;	chr7:1120259	chr7:1160374~1165267:+
OV	cis	rs2980436	1	rs2980436	ENSG00000253981.4	ALG1L13P	-9.91	1.85e-19	1.65e-15	-0.67	-0.55	Schizophrenia;	chr8:8234503	chr8:8236003~8244667:-
OV	cis	rs4423214	1	rs7928249	ENSG00000254682.1	RP11-660L16.2	9.91	1.86e-19	1.66e-15	0.66	0.55	Vitamin D levels;	chr11:71450017	chr11:71448674~71452157:+
OV	cis	rs7617773	0.817	rs745116	ENSG00000229759.1	MRPS18AP1	9.9	1.93e-19	1.71e-15	0.58	0.55	Coronary artery disease;	chr3:48231046	chr3:48256350~48256938:-
OV	cis	rs7617773	0.746	rs4130995	ENSG00000229759.1	MRPS18AP1	9.89	2.02e-19	1.77e-15	0.56	0.55	Coronary artery disease;	chr3:48316765	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs11718350	ENSG00000229759.1	MRPS18AP1	9.89	2.09e-19	1.83e-15	0.6	0.55	Coronary artery disease;	chr3:48319502	chr3:48256350~48256938:-
OV	cis	rs1150668	0.799	rs2142730	ENSG00000216901.1	AL022393.7	9.89	2.14e-19	1.87e-15	0.62	0.55	Pubertal anthropometrics;	chr6:28298372	chr6:28176188~28176674:+
OV	cis	rs7617773	0.746	rs6796343	ENSG00000229759.1	MRPS18AP1	9.88	2.23e-19	1.94e-15	0.61	0.55	Coronary artery disease;	chr3:48240531	chr3:48256350~48256938:-
OV	cis	rs2282300	0.739	rs1765139	ENSG00000254532.1	RP11-624D11.2	9.88	2.29e-19	1.98e-15	0.74	0.55	Morning vs. evening chronotype;	chr11:30332178	chr11:30044058~30084343:-
OV	cis	rs858239	1	rs199348	ENSG00000230658.1	KLHL7-AS1	9.87	2.35e-19	2.03e-15	0.72	0.55	Cerebrospinal fluid biomarker levels;	chr7:23253479	chr7:23101228~23105703:-
OV	cis	rs6782228	0.606	rs2811500	ENSG00000277250.1	Metazoa_SRP	-9.86	2.51e-19	2.17e-15	-0.59	-0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128647413	chr3:128673681~128674021:-
OV	cis	rs1153858	1	rs11858495	ENSG00000259520.4	CTD-2651B20.3	9.86	2.65e-19	2.29e-15	0.67	0.55	Homoarginine levels;	chr15:45345464	chr15:45251580~45279251:-
OV	cis	rs2282300	0.653	rs67745574	ENSG00000254532.1	RP11-624D11.2	9.85	2.75e-19	2.37e-15	0.75	0.55	Morning vs. evening chronotype;	chr11:30213292	chr11:30044058~30084343:-
OV	cis	rs7617773	0.817	rs79310258	ENSG00000229759.1	MRPS18AP1	9.84	2.89e-19	2.48e-15	0.6	0.55	Coronary artery disease;	chr3:48218177	chr3:48256350~48256938:-
OV	cis	rs858239	0.73	rs10255155	ENSG00000230658.1	KLHL7-AS1	-9.84	2.96e-19	2.54e-15	-0.7	-0.55	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23101228~23105703:-
OV	cis	rs1150668	0.799	rs9301	ENSG00000216901.1	AL022393.7	9.84	3.02e-19	2.58e-15	0.62	0.55	Pubertal anthropometrics;	chr6:28324929	chr6:28176188~28176674:+
OV	cis	rs1150668	0.799	rs853684	ENSG00000216901.1	AL022393.7	9.84	3.02e-19	2.58e-15	0.62	0.55	Pubertal anthropometrics;	chr6:28326773	chr6:28176188~28176674:+
OV	cis	rs5850	0.602	rs1005786	ENSG00000230658.1	KLHL7-AS1	9.84	3.05e-19	2.61e-15	0.69	0.55	Blood protein levels;	chr7:23106218	chr7:23101228~23105703:-
OV	cis	rs6782228	0.509	rs4481172	ENSG00000277250.1	Metazoa_SRP	-9.83	3.14e-19	2.68e-15	-0.59	-0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128653814	chr3:128673681~128674021:-
OV	cis	rs10256972	0.591	rs10229680	ENSG00000229043.2	AC091729.9	-9.83	3.15e-19	2.69e-15	-0.64	-0.55	Endometriosis;Longevity;	chr7:1118929	chr7:1160374~1165267:+
OV	cis	rs1150668	0.768	rs1233713	ENSG00000216901.1	AL022393.7	9.82	3.32e-19	2.83e-15	0.6	0.55	Pubertal anthropometrics;	chr6:28230503	chr6:28176188~28176674:+
OV	cis	rs7617773	0.707	rs13061269	ENSG00000229759.1	MRPS18AP1	9.82	3.38e-19	2.88e-15	0.6	0.55	Coronary artery disease;	chr3:48331853	chr3:48256350~48256938:-
OV	cis	rs4423214	1	rs4944957	ENSG00000254682.1	RP11-660L16.2	-9.82	3.39e-19	2.88e-15	-0.65	-0.55	Vitamin D levels;	chr11:71456989	chr11:71448674~71452157:+
OV	cis	rs6782228	0.585	rs2811492	ENSG00000277250.1	Metazoa_SRP	-9.82	3.44e-19	2.91e-15	-0.59	-0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128637436	chr3:128673681~128674021:-
OV	cis	rs6782228	0.606	rs1697	ENSG00000277250.1	Metazoa_SRP	-9.82	3.44e-19	2.91e-15	-0.59	-0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128638009	chr3:128673681~128674021:-
OV	cis	rs6782228	0.585	rs3122175	ENSG00000277250.1	Metazoa_SRP	-9.82	3.44e-19	2.91e-15	-0.59	-0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642433	chr3:128673681~128674021:-
OV	cis	rs6782228	0.606	rs7650156	ENSG00000277250.1	Metazoa_SRP	-9.82	3.44e-19	2.91e-15	-0.59	-0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128642712	chr3:128673681~128674021:-
OV	cis	rs6782228	0.606	rs2811497	ENSG00000277250.1	Metazoa_SRP	-9.82	3.44e-19	2.91e-15	-0.59	-0.55	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128644489	chr3:128673681~128674021:-
OV	cis	rs2282300	0.739	rs1222219	ENSG00000254532.1	RP11-624D11.2	9.82	3.44e-19	2.91e-15	0.76	0.55	Morning vs. evening chronotype;	chr11:30322798	chr11:30044058~30084343:-
OV	cis	rs2739330	0.791	rs4822458	ENSG00000231271.1	AP000350.8	9.81	3.6e-19	3.05e-15	0.69	0.55	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23949918~23954042:+
OV	cis	rs9549260	0.709	rs4943795	ENSG00000229456.1	RLIMP1	-9.81	3.63e-19	3.07e-15	-0.69	-0.55	Red blood cell count;	chr13:40599296	chr13:40618738~40621348:+
OV	cis	rs7617773	0.78	rs3731489	ENSG00000229759.1	MRPS18AP1	9.8	3.85e-19	3.25e-15	0.6	0.55	Coronary artery disease;	chr3:48187416	chr3:48256350~48256938:-
OV	cis	rs1150668	0.799	rs1150707	ENSG00000216901.1	AL022393.7	9.8	3.85e-19	3.25e-15	0.6	0.55	Pubertal anthropometrics;	chr6:28229827	chr6:28176188~28176674:+
OV	cis	rs1150668	0.799	rs7206	ENSG00000216901.1	AL022393.7	9.8	3.85e-19	3.25e-15	0.6	0.55	Pubertal anthropometrics;	chr6:28233360	chr6:28176188~28176674:+
OV	cis	rs10256972	0.552	rs2949195	ENSG00000229043.2	AC091729.9	-9.79	4.32e-19	3.63e-15	-0.62	-0.54	Endometriosis;Longevity;	chr7:1163069	chr7:1160374~1165267:+
OV	cis	rs7617773	0.817	rs13094727	ENSG00000229759.1	MRPS18AP1	9.78	4.4e-19	3.69e-15	0.59	0.54	Coronary artery disease;	chr3:48281999	chr3:48256350~48256938:-
OV	cis	rs6782228	0.606	rs7627549	ENSG00000277250.1	Metazoa_SRP	-9.78	4.51e-19	3.79e-15	-0.59	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128634236	chr3:128673681~128674021:-
OV	cis	rs2836974	1	rs2836974	ENSG00000232608.1	TIMM9P2	9.78	4.52e-19	3.79e-15	0.63	0.54	Cognitive function;	chr21:39291255	chr21:39216624~39217506:+
OV	cis	rs10256972	0.552	rs2960830	ENSG00000229043.2	AC091729.9	-9.78	4.63e-19	3.88e-15	-0.63	-0.54	Endometriosis;Longevity;	chr7:1161005	chr7:1160374~1165267:+
OV	cis	rs858239	0.699	rs1881200	ENSG00000230658.1	KLHL7-AS1	-9.77	4.71e-19	3.95e-15	-0.71	-0.54	Cerebrospinal fluid biomarker levels;	chr7:23162018	chr7:23101228~23105703:-
OV	cis	rs10256972	0.591	rs6950319	ENSG00000229043.2	AC091729.9	-9.77	4.76e-19	3.99e-15	-0.64	-0.54	Endometriosis;Longevity;	chr7:1121688	chr7:1160374~1165267:+
OV	cis	rs2282300	0.653	rs12800124	ENSG00000254532.1	RP11-624D11.2	9.77	4.79e-19	4e-15	0.74	0.54	Morning vs. evening chronotype;	chr11:30218318	chr11:30044058~30084343:-
OV	cis	rs2282300	0.739	rs35883696	ENSG00000254532.1	RP11-624D11.2	9.77	4.79e-19	4e-15	0.74	0.54	Morning vs. evening chronotype;	chr11:30224860	chr11:30044058~30084343:-
OV	cis	rs2282300	0.696	rs12578061	ENSG00000254532.1	RP11-624D11.2	9.77	4.79e-19	4e-15	0.74	0.54	Morning vs. evening chronotype;	chr11:30227818	chr11:30044058~30084343:-
OV	cis	rs2282300	0.739	rs34224414	ENSG00000254532.1	RP11-624D11.2	9.77	4.79e-19	4e-15	0.74	0.54	Morning vs. evening chronotype;	chr11:30229494	chr11:30044058~30084343:-
OV	cis	rs2282300	0.739	rs12577729	ENSG00000254532.1	RP11-624D11.2	9.77	4.79e-19	4e-15	0.74	0.54	Morning vs. evening chronotype;	chr11:30235830	chr11:30044058~30084343:-
OV	cis	rs2282300	0.739	rs34044331	ENSG00000254532.1	RP11-624D11.2	9.77	4.79e-19	4e-15	0.74	0.54	Morning vs. evening chronotype;	chr11:30242939	chr11:30044058~30084343:-
OV	cis	rs2282300	0.739	rs7925340	ENSG00000254532.1	RP11-624D11.2	-9.77	4.79e-19	4e-15	-0.74	-0.54	Morning vs. evening chronotype;	chr11:30258861	chr11:30044058~30084343:-
OV	cis	rs2282300	0.702	rs4379811	ENSG00000254532.1	RP11-624D11.2	-9.77	4.79e-19	4e-15	-0.74	-0.54	Morning vs. evening chronotype;	chr11:30273213	chr11:30044058~30084343:-
OV	cis	rs2282300	0.739	rs3858428	ENSG00000254532.1	RP11-624D11.2	-9.77	4.79e-19	4e-15	-0.74	-0.54	Morning vs. evening chronotype;	chr11:30275003	chr11:30044058~30084343:-
OV	cis	rs4423214	0.879	rs12803256	ENSG00000254682.1	RP11-660L16.2	9.77	4.79e-19	4e-15	0.65	0.54	Vitamin D levels;	chr11:71421822	chr11:71448674~71452157:+
OV	cis	rs7617773	0.817	rs17786132	ENSG00000229759.1	MRPS18AP1	9.77	4.91e-19	4.09e-15	0.6	0.54	Coronary artery disease;	chr3:48207930	chr3:48256350~48256938:-
OV	cis	rs7617773	0.817	rs35456569	ENSG00000229759.1	MRPS18AP1	9.77	4.91e-19	4.09e-15	0.6	0.54	Coronary artery disease;	chr3:48209409	chr3:48256350~48256938:-
OV	cis	rs1150668	0.768	rs1150716	ENSG00000216901.1	AL022393.7	9.76	5e-19	4.16e-15	0.62	0.54	Pubertal anthropometrics;	chr6:28294921	chr6:28176188~28176674:+
OV	cis	rs7617773	0.817	rs6801801	ENSG00000229759.1	MRPS18AP1	9.76	5.02e-19	4.17e-15	0.57	0.54	Coronary artery disease;	chr3:48284943	chr3:48256350~48256938:-
OV	cis	rs2836974	0.899	rs68004583	ENSG00000232608.1	TIMM9P2	-9.75	5.61e-19	4.64e-15	-0.62	-0.54	Cognitive function;	chr21:39287661	chr21:39216624~39217506:+
OV	cis	rs2658782	0.901	rs2605611	ENSG00000279684.1	RP11-755E23.2	-9.73	6.17e-19	5.08e-15	-0.78	-0.54	Pulmonary function decline;	chr11:93496153	chr11:93286629~93288903:-
OV	cis	rs2658782	0.901	rs10466368	ENSG00000279684.1	RP11-755E23.2	-9.73	6.17e-19	5.08e-15	-0.78	-0.54	Pulmonary function decline;	chr11:93496590	chr11:93286629~93288903:-
OV	cis	rs2882667	0.964	rs11739351	ENSG00000253404.1	AC034243.1	9.73	6.24e-19	5.13e-15	0.65	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:138976053	chr5:138744434~138753309:-
OV	cis	rs6782228	0.527	rs2712371	ENSG00000277250.1	Metazoa_SRP	-9.73	6.29e-19	5.17e-15	-0.59	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128627371	chr3:128673681~128674021:-
OV	cis	rs7617773	0.817	rs3731513	ENSG00000229759.1	MRPS18AP1	9.73	6.3e-19	5.18e-15	0.59	0.54	Coronary artery disease;	chr3:48178047	chr3:48256350~48256938:-
OV	cis	rs2836974	0.966	rs2836977	ENSG00000232608.1	TIMM9P2	-9.73	6.46e-19	5.3e-15	-0.63	-0.54	Cognitive function;	chr21:39294140	chr21:39216624~39217506:+
OV	cis	rs2836974	0.865	rs34778912	ENSG00000232608.1	TIMM9P2	-9.73	6.46e-19	5.3e-15	-0.63	-0.54	Cognitive function;	chr21:39295111	chr21:39216624~39217506:+
OV	cis	rs2836974	0.865	rs7282624	ENSG00000232608.1	TIMM9P2	-9.73	6.46e-19	5.3e-15	-0.63	-0.54	Cognitive function;	chr21:39295114	chr21:39216624~39217506:+
OV	cis	rs2836974	0.931	rs13625	ENSG00000232608.1	TIMM9P2	-9.73	6.46e-19	5.3e-15	-0.63	-0.54	Cognitive function;	chr21:39297157	chr21:39216624~39217506:+
OV	cis	rs2282300	0.667	rs10734405	ENSG00000254532.1	RP11-624D11.2	-9.72	6.59e-19	5.31e-15	-0.74	-0.54	Morning vs. evening chronotype;	chr11:30252203	chr11:30044058~30084343:-
OV	cis	rs7617773	0.784	rs11715799	ENSG00000229759.1	MRPS18AP1	9.72	7e-19	5.62e-15	0.6	0.54	Coronary artery disease;	chr3:48213730	chr3:48256350~48256938:-
OV	cis	rs7617773	0.817	rs34728236	ENSG00000229759.1	MRPS18AP1	9.72	7e-19	5.62e-15	0.6	0.54	Coronary artery disease;	chr3:48217618	chr3:48256350~48256938:-
OV	cis	rs6782228	0.527	rs2811491	ENSG00000242551.2	POU5F1P6	-9.71	7.25e-19	5.8e-15	-0.59	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128635107	chr3:128674735~128677005:-
OV	cis	rs1150668	0.835	rs203869	ENSG00000216901.1	AL022393.7	9.7	7.66e-19	6.12e-15	0.6	0.54	Pubertal anthropometrics;	chr6:28073041	chr6:28176188~28176674:+
OV	cis	rs172166	0.56	rs203878	ENSG00000216901.1	AL022393.7	9.7	7.66e-19	6.12e-15	0.6	0.54	Cardiac Troponin-T levels;	chr6:28081218	chr6:28176188~28176674:+
OV	cis	rs10256972	0.552	rs2960831	ENSG00000229043.2	AC091729.9	-9.7	7.68e-19	6.14e-15	-0.63	-0.54	Endometriosis;Longevity;	chr7:1161556	chr7:1160374~1165267:+
OV	cis	rs9549260	0.755	rs9549252	ENSG00000229456.1	RLIMP1	9.7	7.77e-19	6.21e-15	0.61	0.54	Red blood cell count;	chr13:40656004	chr13:40618738~40621348:+
OV	cis	rs2282300	0.739	rs35229181	ENSG00000254532.1	RP11-624D11.2	9.69	8.1e-19	6.46e-15	0.74	0.54	Morning vs. evening chronotype;	chr11:30220151	chr11:30044058~30084343:-
OV	cis	rs2282300	0.739	rs34234618	ENSG00000254532.1	RP11-624D11.2	9.69	8.1e-19	6.46e-15	0.74	0.54	Morning vs. evening chronotype;	chr11:30220154	chr11:30044058~30084343:-
OV	cis	rs2282300	0.739	rs7942129	ENSG00000254532.1	RP11-624D11.2	9.69	8.25e-19	6.58e-15	0.73	0.54	Morning vs. evening chronotype;	chr11:30203145	chr11:30044058~30084343:-
OV	cis	rs2282300	0.739	rs34855782	ENSG00000254532.1	RP11-624D11.2	9.69	8.25e-19	6.58e-15	0.73	0.54	Morning vs. evening chronotype;	chr11:30203923	chr11:30044058~30084343:-
OV	cis	rs10256972	0.577	rs4999286	ENSG00000229043.2	AC091729.9	-9.69	8.46e-19	6.74e-15	-0.63	-0.54	Endometriosis;Longevity;	chr7:1159870	chr7:1160374~1165267:+
OV	cis	rs2882667	0.898	rs3828600	ENSG00000253404.1	AC034243.1	9.69	8.55e-19	6.8e-15	0.65	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139051170	chr5:138744434~138753309:-
OV	cis	rs6782228	0.606	rs6807019	ENSG00000277250.1	Metazoa_SRP	-9.69	8.61e-19	6.85e-15	-0.6	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687091	chr3:128673681~128674021:-
OV	cis	rs17361889	0.806	rs1949952	ENSG00000224683.1	RPL36AP29	-9.68	8.71e-19	6.92e-15	-0.63	-0.54	Pediatric bone mineral content (hip);	chr7:16189503	chr7:16208945~16209265:+
OV	cis	rs6782228	0.606	rs58977394	ENSG00000277250.1	Metazoa_SRP	-9.68	9e-19	7.15e-15	-0.58	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619074	chr3:128673681~128674021:-
OV	cis	rs6782228	0.606	rs2712381	ENSG00000277250.1	Metazoa_SRP	-9.68	9e-19	7.15e-15	-0.58	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619757	chr3:128673681~128674021:-
OV	cis	rs7617773	0.78	rs34523942	ENSG00000229759.1	MRPS18AP1	9.67	9.56e-19	7.58e-15	0.58	0.54	Coronary artery disease;	chr3:48301179	chr3:48256350~48256938:-
OV	cis	rs6782228	1	rs6775011	ENSG00000242551.2	POU5F1P6	9.66	1.02e-18	8.07e-15	0.65	0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128677640	chr3:128674735~128677005:-
OV	cis	rs7617773	0.817	rs3731555	ENSG00000229759.1	MRPS18AP1	9.66	1.02e-18	8.08e-15	0.58	0.54	Coronary artery disease;	chr3:48164612	chr3:48256350~48256938:-
OV	cis	rs2658782	0.901	rs11601056	ENSG00000279684.1	RP11-755E23.2	9.65	1.08e-18	8.5e-15	0.78	0.54	Pulmonary function decline;	chr11:93495995	chr11:93286629~93288903:-
OV	cis	rs6964833	0.935	rs7795281	ENSG00000123965.13	PMS2P5	9.65	1.1e-18	8.71e-15	0.8	0.54	Menarche (age at onset);	chr7:74708523	chr7:74894116~74897835:+
OV	cis	rs6964833	0.935	rs7795282	ENSG00000123965.13	PMS2P5	9.65	1.1e-18	8.71e-15	0.8	0.54	Menarche (age at onset);	chr7:74708526	chr7:74894116~74897835:+
OV	cis	rs2836974	0.8	rs73221174	ENSG00000232608.1	TIMM9P2	-9.65	1.11e-18	8.73e-15	-0.62	-0.54	Cognitive function;	chr21:39169013	chr21:39216624~39217506:+
OV	cis	rs10256972	0.552	rs2960837	ENSG00000229043.2	AC091729.9	-9.65	1.12e-18	8.83e-15	-0.62	-0.54	Endometriosis;Longevity;	chr7:1164321	chr7:1160374~1165267:+
OV	cis	rs10256972	0.553	rs4236381	ENSG00000229043.2	AC091729.9	-9.65	1.13e-18	8.87e-15	-0.63	-0.54	Endometriosis;Longevity;	chr7:1126087	chr7:1160374~1165267:+
OV	cis	rs7617773	0.817	rs936427	ENSG00000229759.1	MRPS18AP1	-9.65	1.13e-18	8.92e-15	-0.59	-0.54	Coronary artery disease;	chr3:48259584	chr3:48256350~48256938:-
OV	cis	rs6782228	1	rs12495411	ENSG00000242551.2	POU5F1P6	9.64	1.2e-18	9.4e-15	0.65	0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128676852	chr3:128674735~128677005:-
OV	cis	rs7617773	0.71	rs36064160	ENSG00000229759.1	MRPS18AP1	9.64	1.21e-18	9.44e-15	0.6	0.54	Coronary artery disease;	chr3:48201611	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs13079728	ENSG00000229759.1	MRPS18AP1	9.63	1.25e-18	9.75e-15	0.59	0.54	Coronary artery disease;	chr3:48297870	chr3:48256350~48256938:-
OV	cis	rs7246967	0.673	rs62119090	ENSG00000269509.1	BNIP3P34	9.63	1.29e-18	1e-14	0.95	0.54	Bronchopulmonary dysplasia;	chr19:22741112	chr19:22773853~22774424:+
OV	cis	rs2836974	0.965	rs8134733	ENSG00000232608.1	TIMM9P2	-9.63	1.3e-18	1.01e-14	-0.63	-0.54	Cognitive function;	chr21:39311533	chr21:39216624~39217506:+
OV	cis	rs858239	0.831	rs7796541	ENSG00000230658.1	KLHL7-AS1	9.62	1.36e-18	1.06e-14	0.79	0.54	Cerebrospinal fluid biomarker levels;	chr7:23349454	chr7:23101228~23105703:-
OV	cis	rs6782228	0.606	rs1127030	ENSG00000277250.1	Metazoa_SRP	-9.62	1.38e-18	1.07e-14	-0.58	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128620110	chr3:128673681~128674021:-
OV	cis	rs7617773	0.78	rs3731550	ENSG00000229759.1	MRPS18AP1	9.61	1.42e-18	1.1e-14	0.58	0.54	Coronary artery disease;	chr3:48165093	chr3:48256350~48256938:-
OV	cis	rs7617773	0.817	rs3731534	ENSG00000229759.1	MRPS18AP1	9.61	1.42e-18	1.1e-14	0.58	0.54	Coronary artery disease;	chr3:48170287	chr3:48256350~48256938:-
OV	cis	rs1150668	0.799	rs1150705	ENSG00000216901.1	AL022393.7	9.61	1.43e-18	1.11e-14	0.61	0.54	Pubertal anthropometrics;	chr6:28226008	chr6:28176188~28176674:+
OV	cis	rs7617773	0.817	rs3937	ENSG00000229759.1	MRPS18AP1	9.61	1.46e-18	1.13e-14	0.57	0.54	Coronary artery disease;	chr3:48270912	chr3:48256350~48256938:-
OV	cis	rs7617773	0.817	rs9837228	ENSG00000229759.1	MRPS18AP1	-9.6	1.57e-18	1.21e-14	-0.57	-0.54	Coronary artery disease;	chr3:48282976	chr3:48256350~48256938:-
OV	cis	rs6782228	0.527	rs2811491	ENSG00000277250.1	Metazoa_SRP	-9.59	1.63e-18	1.26e-14	-0.59	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128635107	chr3:128673681~128674021:-
OV	cis	rs6782228	0.606	rs2712419	ENSG00000277250.1	Metazoa_SRP	-9.59	1.66e-18	1.28e-14	-0.58	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128622053	chr3:128673681~128674021:-
OV	cis	rs6782228	0.606	rs2712417	ENSG00000277250.1	Metazoa_SRP	-9.59	1.66e-18	1.28e-14	-0.58	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128626336	chr3:128673681~128674021:-
OV	cis	rs2739330	0.791	rs4822458	ENSG00000250470.1	AP000351.3	9.59	1.67e-18	1.28e-14	0.71	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23976904~23977585:-
OV	cis	rs7617773	0.779	rs3731487	ENSG00000229759.1	MRPS18AP1	9.59	1.7e-18	1.3e-14	0.59	0.54	Coronary artery disease;	chr3:48188134	chr3:48256350~48256938:-
OV	cis	rs2882667	0.858	rs11744972	ENSG00000253404.1	AC034243.1	9.58	1.79e-18	1.36e-14	0.66	0.54	Age-related hearing impairment (SNP x SNP interaction);	chr5:139093100	chr5:138744434~138753309:-
OV	cis	rs2739330	0.587	rs4820571	ENSG00000225282.1	AP000350.6	9.58	1.81e-18	1.38e-14	0.63	0.54	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23926900~23929574:+
OV	cis	rs858239	0.932	rs199355	ENSG00000230658.1	KLHL7-AS1	9.57	1.87e-18	1.42e-14	0.69	0.54	Cerebrospinal fluid biomarker levels;	chr7:23256914	chr7:23101228~23105703:-
OV	cis	rs4423214	0.819	rs7938885	ENSG00000254682.1	RP11-660L16.2	9.56	1.99e-18	1.51e-14	0.63	0.54	Vitamin D levels;	chr11:71458997	chr11:71448674~71452157:+
OV	cis	rs4423214	0.959	rs12800438	ENSG00000254682.1	RP11-660L16.2	9.56	1.99e-18	1.51e-14	0.63	0.54	Vitamin D levels;	chr11:71459957	chr11:71448674~71452157:+
OV	cis	rs4423214	1	rs12807718	ENSG00000254682.1	RP11-660L16.2	9.56	1.99e-18	1.51e-14	0.63	0.54	Vitamin D levels;	chr11:71460124	chr11:71448674~71452157:+
OV	cis	rs4423214	1	rs4423214	ENSG00000254682.1	RP11-660L16.2	9.56	1.99e-18	1.51e-14	0.63	0.54	Vitamin D levels;	chr11:71462208	chr11:71448674~71452157:+
OV	cis	rs4423214	1	rs2276362	ENSG00000254682.1	RP11-660L16.2	9.56	1.99e-18	1.51e-14	0.63	0.54	Vitamin D levels;	chr11:71463406	chr11:71448674~71452157:+
OV	cis	rs2729354	0.953	rs1846567	ENSG00000265566.2	RN7SL605P	-9.56	2.03e-18	1.53e-14	-0.78	-0.54	Blood protein levels;	chr11:57590120	chr11:57528085~57528365:-
OV	cis	rs2282300	0.739	rs1222221	ENSG00000254532.1	RP11-624D11.2	9.56	2.09e-18	1.57e-14	0.72	0.54	Morning vs. evening chronotype;	chr11:30321191	chr11:30044058~30084343:-
OV	cis	rs2282300	0.739	rs10835648	ENSG00000254532.1	RP11-624D11.2	-9.56	2.09e-18	1.57e-14	-0.72	-0.54	Morning vs. evening chronotype;	chr11:30298959	chr11:30044058~30084343:-
OV	cis	rs2282300	0.739	rs7952339	ENSG00000254532.1	RP11-624D11.2	-9.56	2.09e-18	1.57e-14	-0.72	-0.54	Morning vs. evening chronotype;	chr11:30305797	chr11:30044058~30084343:-
OV	cis	rs6782228	0.606	rs2811489	ENSG00000277250.1	Metazoa_SRP	9.56	2.09e-18	1.58e-14	0.57	0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128618528	chr3:128673681~128674021:-
OV	cis	rs7617773	0.817	rs936426	ENSG00000229759.1	MRPS18AP1	9.54	2.3e-18	1.73e-14	0.55	0.54	Coronary artery disease;	chr3:48173763	chr3:48256350~48256938:-
OV	cis	rs6782228	0.606	rs6775270	ENSG00000277250.1	Metazoa_SRP	-9.54	2.32e-18	1.75e-14	-0.59	-0.54	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128684655	chr3:128673681~128674021:-
OV	cis	rs7617773	0.779	rs77957078	ENSG00000229759.1	MRPS18AP1	9.54	2.34e-18	1.76e-14	0.59	0.54	Coronary artery disease;	chr3:48289796	chr3:48256350~48256938:-
OV	cis	rs7617773	0.817	rs3729577	ENSG00000229759.1	MRPS18AP1	9.54	2.38e-18	1.78e-14	0.59	0.53	Coronary artery disease;	chr3:48187504	chr3:48256350~48256938:-
OV	cis	rs6964833	1	rs2301907	ENSG00000123965.13	PMS2P5	9.53	2.61e-18	1.95e-14	0.8	0.53	Menarche (age at onset);	chr7:74700517	chr7:74894116~74897835:+
OV	cis	rs2658782	0.901	rs11604909	ENSG00000279684.1	RP11-755E23.2	-9.52	2.65e-18	1.98e-14	-0.76	-0.53	Pulmonary function decline;	chr11:93485189	chr11:93286629~93288903:-
OV	cis	rs7617773	0.851	rs7647817	ENSG00000229759.1	MRPS18AP1	9.52	2.7e-18	2.01e-14	0.58	0.53	Coronary artery disease;	chr3:48195017	chr3:48256350~48256938:-
OV	cis	rs7617773	0.817	rs11707606	ENSG00000229759.1	MRPS18AP1	9.52	2.7e-18	2.01e-14	0.58	0.53	Coronary artery disease;	chr3:48195597	chr3:48256350~48256938:-
OV	cis	rs9326248	0.53	rs7112513	ENSG00000254851.1	RP11-109L13.1	-9.52	2.78e-18	2.07e-14	-0.87	-0.53	Blood protein levels;	chr11:117166645	chr11:117135528~117138582:+
OV	cis	rs7115242	0.514	rs4936367	ENSG00000254851.1	RP11-109L13.1	-9.52	2.78e-18	2.07e-14	-0.87	-0.53	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117171661	chr11:117135528~117138582:+
OV	cis	rs9326248	0.53	rs4604928	ENSG00000254851.1	RP11-109L13.1	-9.52	2.78e-18	2.07e-14	-0.87	-0.53	Blood protein levels;	chr11:117173487	chr11:117135528~117138582:+
OV	cis	rs2282300	0.739	rs67670125	ENSG00000254532.1	RP11-624D11.2	9.52	2.8e-18	2.08e-14	0.72	0.53	Morning vs. evening chronotype;	chr11:30193367	chr11:30044058~30084343:-
OV	cis	rs6782228	0.606	rs6787559	ENSG00000277250.1	Metazoa_SRP	-9.51	2.87e-18	2.12e-14	-0.58	-0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662243	chr3:128673681~128674021:-
OV	cis	rs2658782	0.694	rs3019221	ENSG00000279684.1	RP11-755E23.2	-9.51	2.89e-18	2.13e-14	-0.73	-0.53	Pulmonary function decline;	chr11:93346534	chr11:93286629~93288903:-
OV	cis	rs2882667	1	rs10515505	ENSG00000253404.1	AC034243.1	9.51	2.93e-18	2.17e-14	0.63	0.53	Age-related hearing impairment (SNP x SNP interaction);	chr5:138977457	chr5:138744434~138753309:-
OV	cis	rs7617773	0.817	rs3731497	ENSG00000229759.1	MRPS18AP1	9.51	2.94e-18	2.18e-14	0.58	0.53	Coronary artery disease;	chr3:48185063	chr3:48256350~48256938:-
OV	cis	rs6782228	1	rs11711038	ENSG00000242551.2	POU5F1P6	9.5	3.04e-18	2.24e-14	0.64	0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128675467	chr3:128674735~128677005:-
OV	cis	rs7617773	0.817	rs9830016	ENSG00000229759.1	MRPS18AP1	9.5	3.16e-18	2.33e-14	0.56	0.53	Coronary artery disease;	chr3:48241004	chr3:48256350~48256938:-
OV	cis	rs4423214	1	rs12792306	ENSG00000254682.1	RP11-660L16.2	9.5	3.19e-18	2.34e-14	0.63	0.53	Vitamin D levels;	chr11:71455946	chr11:71448674~71452157:+
OV	cis	rs4423214	1	rs4944955	ENSG00000254682.1	RP11-660L16.2	9.5	3.19e-18	2.34e-14	0.63	0.53	Vitamin D levels;	chr11:71456631	chr11:71448674~71452157:+
OV	cis	rs4423214	1	rs4944956	ENSG00000254682.1	RP11-660L16.2	9.5	3.19e-18	2.34e-14	0.63	0.53	Vitamin D levels;	chr11:71456719	chr11:71448674~71452157:+
OV	cis	rs4423214	1	rs2276361	ENSG00000254682.1	RP11-660L16.2	9.5	3.19e-18	2.34e-14	0.63	0.53	Vitamin D levels;	chr11:71458602	chr11:71448674~71452157:+
OV	cis	rs6964833	1	rs6964833	ENSG00000123965.13	PMS2P5	9.49	3.26e-18	2.39e-14	0.8	0.53	Menarche (age at onset);	chr7:74687575	chr7:74894116~74897835:+
OV	cis	rs6964833	1	rs35203738	ENSG00000123965.13	PMS2P5	9.49	3.26e-18	2.39e-14	0.8	0.53	Menarche (age at onset);	chr7:74690864	chr7:74894116~74897835:+
OV	cis	rs1150668	0.796	rs1124132	ENSG00000216901.1	AL022393.7	9.49	3.41e-18	2.5e-14	0.59	0.53	Pubertal anthropometrics;	chr6:28412544	chr6:28176188~28176674:+
OV	cis	rs6782228	0.606	rs10048945	ENSG00000277250.1	Metazoa_SRP	-9.48	3.45e-18	2.53e-14	-0.58	-0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128690837	chr3:128673681~128674021:-
OV	cis	rs7617773	0.78	rs34630841	ENSG00000229759.1	MRPS18AP1	9.48	3.46e-18	2.53e-14	0.59	0.53	Coronary artery disease;	chr3:48301771	chr3:48256350~48256938:-
OV	cis	rs7617773	0.78	rs77044321	ENSG00000229759.1	MRPS18AP1	9.48	3.46e-18	2.53e-14	0.59	0.53	Coronary artery disease;	chr3:48307824	chr3:48256350~48256938:-
OV	cis	rs7617773	0.743	rs13081633	ENSG00000229759.1	MRPS18AP1	9.48	3.46e-18	2.53e-14	0.59	0.53	Coronary artery disease;	chr3:48315791	chr3:48256350~48256938:-
OV	cis	rs6782228	0.606	rs9828893	ENSG00000242551.2	POU5F1P6	-9.48	3.65e-18	2.59e-14	-0.57	-0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128614082	chr3:128674735~128677005:-
OV	cis	rs10256972	0.552	rs6978842	ENSG00000229043.2	AC091729.9	-9.47	3.89e-18	2.75e-14	-0.6	-0.53	Endometriosis;Longevity;	chr7:1164963	chr7:1160374~1165267:+
OV	cis	rs9326248	0.53	rs2127905	ENSG00000254851.1	RP11-109L13.1	-9.46	4.03e-18	2.84e-14	-0.87	-0.53	Blood protein levels;	chr11:117155658	chr11:117135528~117138582:+
OV	cis	rs6782228	0.606	rs2001703	ENSG00000277250.1	Metazoa_SRP	-9.46	4.14e-18	2.92e-14	-0.58	-0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128664254	chr3:128673681~128674021:-
OV	cis	rs10256972	0.577	rs6962809	ENSG00000229043.2	AC091729.9	-9.46	4.2e-18	2.95e-14	-0.62	-0.53	Endometriosis;Longevity;	chr7:1169253	chr7:1160374~1165267:+
OV	cis	rs2836974	0.897	rs12481860	ENSG00000232608.1	TIMM9P2	-9.45	4.33e-18	3.03e-14	-0.6	-0.53	Cognitive function;	chr21:39165910	chr21:39216624~39217506:+
OV	cis	rs2836974	0.863	rs12483216	ENSG00000232608.1	TIMM9P2	-9.45	4.33e-18	3.03e-14	-0.6	-0.53	Cognitive function;	chr21:39167688	chr21:39216624~39217506:+
OV	cis	rs2836974	0.863	rs6517519	ENSG00000232608.1	TIMM9P2	-9.45	4.33e-18	3.03e-14	-0.6	-0.53	Cognitive function;	chr21:39168319	chr21:39216624~39217506:+
OV	cis	rs7617773	0.851	rs13068288	ENSG00000229759.1	MRPS18AP1	9.45	4.41e-18	3.08e-14	0.57	0.53	Coronary artery disease;	chr3:48290261	chr3:48256350~48256938:-
OV	cis	rs2658782	0.901	rs7116173	ENSG00000279684.1	RP11-755E23.2	9.44	4.79e-18	3.33e-14	0.75	0.53	Pulmonary function decline;	chr11:93489145	chr11:93286629~93288903:-
OV	cis	rs10256972	0.552	rs7805591	ENSG00000229043.2	AC091729.9	-9.43	4.85e-18	3.37e-14	-0.62	-0.53	Endometriosis;Longevity;	chr7:1171109	chr7:1160374~1165267:+
OV	cis	rs1150668	0.796	rs1005125	ENSG00000216901.1	AL022393.7	9.43	4.87e-18	3.38e-14	0.6	0.53	Pubertal anthropometrics;	chr6:28399578	chr6:28176188~28176674:+
OV	cis	rs1150668	0.796	rs213237	ENSG00000216901.1	AL022393.7	9.43	4.94e-18	3.43e-14	0.61	0.53	Pubertal anthropometrics;	chr6:28356161	chr6:28176188~28176674:+
OV	cis	rs2836974	0.897	rs2836927	ENSG00000232608.1	TIMM9P2	-9.43	5.01e-18	3.47e-14	-0.6	-0.53	Cognitive function;	chr21:39171290	chr21:39216624~39217506:+
OV	cis	rs2836974	0.897	rs2836929	ENSG00000232608.1	TIMM9P2	-9.43	5.01e-18	3.47e-14	-0.6	-0.53	Cognitive function;	chr21:39171885	chr21:39216624~39217506:+
OV	cis	rs2836974	0.899	rs8127087	ENSG00000232608.1	TIMM9P2	-9.43	5.01e-18	3.47e-14	-0.6	-0.53	Cognitive function;	chr21:39172576	chr21:39216624~39217506:+
OV	cis	rs2836974	0.897	rs2836932	ENSG00000232608.1	TIMM9P2	-9.43	5.01e-18	3.47e-14	-0.6	-0.53	Cognitive function;	chr21:39174791	chr21:39216624~39217506:+
OV	cis	rs507080	0.501	rs626645	ENSG00000255239.1	AP002954.6	9.43	5.18e-18	3.58e-14	0.63	0.53	Serum metabolite levels;	chr11:118704471	chr11:118688039~118690600:-
OV	cis	rs4423214	1	rs12422045	ENSG00000254682.1	RP11-660L16.2	9.42	5.25e-18	3.63e-14	0.63	0.53	Vitamin D levels;	chr11:71443774	chr11:71448674~71452157:+
OV	cis	rs507080	0.845	rs481903	ENSG00000255422.1	AP002954.4	-9.42	5.43e-18	3.75e-14	-0.64	-0.53	Serum metabolite levels;	chr11:118697024	chr11:118704607~118750263:+
OV	cis	rs2836950	0.565	rs4816617	ENSG00000232608.1	TIMM9P2	9.42	5.47e-18	3.77e-14	0.58	0.53	Menarche (age at onset);	chr21:39168764	chr21:39216624~39217506:+
OV	cis	rs7246967	0.551	rs62121805	ENSG00000269509.1	BNIP3P34	9.41	5.67e-18	3.89e-14	0.94	0.53	Bronchopulmonary dysplasia;	chr19:22726178	chr19:22773853~22774424:+
OV	cis	rs10256972	0.577	rs2949179	ENSG00000229043.2	AC091729.9	-9.41	5.69e-18	3.9e-14	-0.61	-0.53	Endometriosis;Longevity;	chr7:1170249	chr7:1160374~1165267:+
OV	cis	rs10256972	0.504	rs2949178	ENSG00000229043.2	AC091729.9	-9.41	5.69e-18	3.9e-14	-0.61	-0.53	Endometriosis;Longevity;	chr7:1170289	chr7:1160374~1165267:+
OV	cis	rs11235843	0.602	rs1830069	ENSG00000255928.1	RP11-456I15.2	-9.41	5.74e-18	3.94e-14	-0.74	-0.53	Hand grip strength;	chr11:73722184	chr11:73722349~73722694:+
OV	cis	rs9326248	0.53	rs1351452	ENSG00000254851.1	RP11-109L13.1	9.41	5.75e-18	3.94e-14	0.85	0.53	Blood protein levels;	chr11:117072638	chr11:117135528~117138582:+
OV	cis	rs2729354	0.903	rs1846568	ENSG00000265566.2	RN7SL605P	-9.41	5.82e-18	3.99e-14	-0.76	-0.53	Blood protein levels;	chr11:57590241	chr11:57528085~57528365:-
OV	cis	rs172166	0.516	rs1225710	ENSG00000216901.1	AL022393.7	-9.41	5.86e-18	4.01e-14	-0.6	-0.53	Cardiac Troponin-T levels;	chr6:28132862	chr6:28176188~28176674:+
OV	cis	rs6782228	0.585	rs9841161	ENSG00000242551.2	POU5F1P6	-9.4	6.21e-18	4.25e-14	-0.56	-0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613027	chr3:128674735~128677005:-
OV	cis	rs6782228	0.606	rs2712405	ENSG00000242551.2	POU5F1P6	-9.4	6.21e-18	4.25e-14	-0.56	-0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613239	chr3:128674735~128677005:-
OV	cis	rs10256972	0.567	rs2949185	ENSG00000229043.2	AC091729.9	-9.4	6.34e-18	4.33e-14	-0.62	-0.53	Endometriosis;Longevity;	chr7:1169377	chr7:1160374~1165267:+
OV	cis	rs6782228	0.606	rs2253144	ENSG00000277250.1	Metazoa_SRP	9.39	6.46e-18	4.41e-14	0.58	0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611077	chr3:128673681~128674021:-
OV	cis	rs4423214	1	rs2040323	ENSG00000254682.1	RP11-660L16.2	9.39	6.48e-18	4.42e-14	0.62	0.53	Vitamin D levels;	chr11:71461737	chr11:71448674~71452157:+
OV	cis	rs2836950	0.565	rs8134214	ENSG00000232608.1	TIMM9P2	9.39	6.67e-18	4.54e-14	0.58	0.53	Menarche (age at onset);	chr21:39170441	chr21:39216624~39217506:+
OV	cis	rs2836950	0.52	rs1980407	ENSG00000232608.1	TIMM9P2	9.39	6.67e-18	4.54e-14	0.58	0.53	Menarche (age at onset);	chr21:39172035	chr21:39216624~39217506:+
OV	cis	rs2836950	0.565	rs2836930	ENSG00000232608.1	TIMM9P2	9.39	6.67e-18	4.54e-14	0.58	0.53	Menarche (age at onset);	chr21:39173730	chr21:39216624~39217506:+
OV	cis	rs2836950	0.565	rs2836931	ENSG00000232608.1	TIMM9P2	9.39	6.67e-18	4.54e-14	0.58	0.53	Menarche (age at onset);	chr21:39174643	chr21:39216624~39217506:+
OV	cis	rs2836950	0.565	rs2836926	ENSG00000232608.1	TIMM9P2	9.39	6.72e-18	4.57e-14	0.58	0.53	Menarche (age at onset);	chr21:39164864	chr21:39216624~39217506:+
OV	cis	rs2836950	0.565	rs8131132	ENSG00000232608.1	TIMM9P2	9.39	6.72e-18	4.57e-14	0.58	0.53	Menarche (age at onset);	chr21:39166330	chr21:39216624~39217506:+
OV	cis	rs1150668	0.83	rs213240	ENSG00000216901.1	AL022393.7	9.38	6.84e-18	4.65e-14	0.6	0.53	Pubertal anthropometrics;	chr6:28348098	chr6:28176188~28176674:+
OV	cis	rs2836950	0.52	rs8130240	ENSG00000232608.1	TIMM9P2	9.38	6.93e-18	4.71e-14	0.58	0.53	Menarche (age at onset);	chr21:39166182	chr21:39216624~39217506:+
OV	cis	rs8105895	0.935	rs6511314	ENSG00000269742.1	BNIP3P29	-9.38	6.96e-18	4.73e-14	-0.77	-0.53	Body mass index (change over time);	chr19:22053593	chr19:22065828~22066398:-
OV	cis	rs7246967	0.611	rs56944174	ENSG00000269509.1	BNIP3P34	9.38	7.08e-18	4.8e-14	0.94	0.53	Bronchopulmonary dysplasia;	chr19:22738872	chr19:22773853~22774424:+
OV	cis	rs4423214	1	rs11233746	ENSG00000254682.1	RP11-660L16.2	9.37	7.45e-18	5.04e-14	0.62	0.53	Vitamin D levels;	chr11:71460394	chr11:71448674~71452157:+
OV	cis	rs801193	1	rs10234018	ENSG00000222364.1	RNU6-96P	9.37	7.49e-18	5.07e-14	0.53	0.53	Aortic root size;	chr7:66681297	chr7:66395191~66395286:+
OV	cis	rs2836974	0.899	rs34176878	ENSG00000232608.1	TIMM9P2	-9.37	7.55e-18	5.1e-14	-0.6	-0.53	Cognitive function;	chr21:39176929	chr21:39216624~39217506:+
OV	cis	rs1150668	0.796	rs2531832	ENSG00000216901.1	AL022393.7	9.36	8.11e-18	5.46e-14	0.59	0.53	Pubertal anthropometrics;	chr6:28421445	chr6:28176188~28176674:+
OV	cis	rs6782228	0.606	rs4857861	ENSG00000277250.1	Metazoa_SRP	-9.36	8.22e-18	5.51e-14	-0.58	-0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128687924	chr3:128673681~128674021:-
OV	cis	rs6782228	0.606	rs4857919	ENSG00000277250.1	Metazoa_SRP	-9.36	8.22e-18	5.51e-14	-0.58	-0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128688652	chr3:128673681~128674021:-
OV	cis	rs172166	0.561	rs149976	ENSG00000216901.1	AL022393.7	-9.36	8.34e-18	5.59e-14	-0.6	-0.53	Cardiac Troponin-T levels;	chr6:28019998	chr6:28176188~28176674:+
OV	cis	rs6782228	0.606	rs9828893	ENSG00000277250.1	Metazoa_SRP	-9.36	8.37e-18	5.6e-14	-0.57	-0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128614082	chr3:128673681~128674021:-
OV	cis	rs2836974	0.931	rs12151994	ENSG00000232608.1	TIMM9P2	-9.35	8.44e-18	5.64e-14	-0.62	-0.53	Cognitive function;	chr21:39318471	chr21:39216624~39217506:+
OV	cis	rs2836974	0.966	rs7283516	ENSG00000232608.1	TIMM9P2	-9.35	8.44e-18	5.64e-14	-0.62	-0.53	Cognitive function;	chr21:39318611	chr21:39216624~39217506:+
OV	cis	rs1150668	0.796	rs213236	ENSG00000216901.1	AL022393.7	9.35	8.79e-18	5.87e-14	0.61	0.53	Pubertal anthropometrics;	chr6:28356620	chr6:28176188~28176674:+
OV	cis	rs9326248	0.53	rs7940310	ENSG00000254851.1	RP11-109L13.1	-9.34	9.16e-18	6.09e-14	-0.87	-0.53	Blood protein levels;	chr11:117153765	chr11:117135528~117138582:+
OV	cis	rs9326248	0.53	rs7123517	ENSG00000254851.1	RP11-109L13.1	-9.34	9.16e-18	6.09e-14	-0.87	-0.53	Blood protein levels;	chr11:117157039	chr11:117135528~117138582:+
OV	cis	rs2836974	0.897	rs68090597	ENSG00000232608.1	TIMM9P2	-9.34	9.39e-18	6.23e-14	-0.6	-0.53	Cognitive function;	chr21:39163707	chr21:39216624~39217506:+
OV	cis	rs10256972	0.591	rs11766651	ENSG00000229043.2	AC091729.9	-9.34	9.42e-18	6.24e-14	-0.61	-0.53	Endometriosis;Longevity;	chr7:1122010	chr7:1160374~1165267:+
OV	cis	rs6964833	1	rs34324835	ENSG00000123965.13	PMS2P5	9.33	9.92e-18	6.56e-14	0.78	0.53	Menarche (age at onset);	chr7:74717986	chr7:74894116~74897835:+
OV	cis	rs7617773	0.746	rs4371540	ENSG00000229759.1	MRPS18AP1	9.32	1.06e-17	7e-14	0.58	0.53	Coronary artery disease;	chr3:48312053	chr3:48256350~48256938:-
OV	cis	rs2836974	0.796	rs77153312	ENSG00000232608.1	TIMM9P2	-9.32	1.09e-17	7.17e-14	-0.61	-0.53	Cognitive function;	chr21:39323573	chr21:39216624~39217506:+
OV	cis	rs2282300	0.739	rs34951229	ENSG00000254532.1	RP11-624D11.2	9.32	1.1e-17	7.21e-14	0.72	0.53	Morning vs. evening chronotype;	chr11:30243619	chr11:30044058~30084343:-
OV	cis	rs858239	0.669	rs6461687	ENSG00000230658.1	KLHL7-AS1	9.32	1.1e-17	7.24e-14	0.72	0.53	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23101228~23105703:-
OV	cis	rs2739330	0.587	rs4820571	ENSG00000273295.1	AP000350.5	9.31	1.11e-17	7.33e-14	0.62	0.53	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23901432~23907068:-
OV	cis	rs4423214	1	rs4944062	ENSG00000254682.1	RP11-660L16.2	9.31	1.12e-17	7.33e-14	0.63	0.53	Vitamin D levels;	chr11:71476248	chr11:71448674~71452157:+
OV	cis	rs11235843	0.636	rs2140892	ENSG00000255928.1	RP11-456I15.2	-9.31	1.14e-17	7.48e-14	-0.74	-0.53	Hand grip strength;	chr11:73711834	chr11:73722349~73722694:+
OV	cis	rs11673344	0.562	rs256740	ENSG00000226686.6	LINC01535	-9.31	1.14e-17	7.5e-14	-0.66	-0.53	Obesity-related traits;	chr19:37365451	chr19:37251912~37265535:+
OV	cis	rs1150668	0.83	rs2023493	ENSG00000216901.1	AL022393.7	9.31	1.17e-17	7.68e-14	0.59	0.53	Pubertal anthropometrics;	chr6:28432385	chr6:28176188~28176674:+
OV	cis	rs6782228	0.606	rs2712404	ENSG00000242551.2	POU5F1P6	9.3	1.19e-17	7.76e-14	0.56	0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613836	chr3:128674735~128677005:-
OV	cis	rs6782228	0.565	rs67445542	ENSG00000242551.2	POU5F1P6	-9.3	1.19e-17	7.78e-14	-0.56	-0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611683	chr3:128674735~128677005:-
OV	cis	rs11673344	0.58	rs320881	ENSG00000226686.6	LINC01535	9.3	1.19e-17	7.79e-14	0.66	0.53	Obesity-related traits;	chr19:37246948	chr19:37251912~37265535:+
OV	cis	rs8105895	0.935	rs6511321	ENSG00000269742.1	BNIP3P29	9.3	1.2e-17	7.82e-14	0.78	0.53	Body mass index (change over time);	chr19:22087266	chr19:22065828~22066398:-
OV	cis	rs8105895	0.877	rs8100768	ENSG00000269742.1	BNIP3P29	9.3	1.2e-17	7.82e-14	0.78	0.53	Body mass index (change over time);	chr19:22087666	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs2043319	ENSG00000269742.1	BNIP3P29	9.3	1.2e-17	7.82e-14	0.78	0.53	Body mass index (change over time);	chr19:22091793	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs28374572	ENSG00000269742.1	BNIP3P29	9.3	1.2e-17	7.82e-14	0.78	0.53	Body mass index (change over time);	chr19:22093676	chr19:22065828~22066398:-
OV	cis	rs8105895	0.733	rs10423457	ENSG00000269742.1	BNIP3P29	9.3	1.2e-17	7.82e-14	0.78	0.53	Body mass index (change over time);	chr19:22096465	chr19:22065828~22066398:-
OV	cis	rs6782228	0.606	rs2253144	ENSG00000242551.2	POU5F1P6	9.3	1.2e-17	7.87e-14	0.57	0.53	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611077	chr3:128674735~128677005:-
OV	cis	rs8105895	0.935	rs8111854	ENSG00000269742.1	BNIP3P29	9.3	1.23e-17	8.02e-14	0.79	0.53	Body mass index (change over time);	chr19:22057411	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs8110969	ENSG00000269742.1	BNIP3P29	9.3	1.23e-17	8.02e-14	0.79	0.53	Body mass index (change over time);	chr19:22057420	chr19:22065828~22066398:-
OV	cis	rs4423214	0.592	rs10898186	ENSG00000254682.1	RP11-660L16.2	-9.3	1.24e-17	8.11e-14	-0.74	-0.53	Vitamin D levels;	chr11:71477754	chr11:71448674~71452157:+
OV	cis	rs2836974	0.739	rs12482181	ENSG00000232608.1	TIMM9P2	-9.3	1.25e-17	8.14e-14	-0.59	-0.53	Cognitive function;	chr21:39176926	chr21:39216624~39217506:+
OV	cis	rs2836974	0.897	rs14194	ENSG00000232608.1	TIMM9P2	-9.3	1.25e-17	8.14e-14	-0.59	-0.53	Cognitive function;	chr21:39177540	chr21:39216624~39217506:+
OV	cis	rs2836974	0.831	rs6517521	ENSG00000232608.1	TIMM9P2	-9.3	1.25e-17	8.14e-14	-0.59	-0.53	Cognitive function;	chr21:39179662	chr21:39216624~39217506:+
OV	cis	rs2836974	0.829	rs34227163	ENSG00000232608.1	TIMM9P2	-9.3	1.25e-17	8.14e-14	-0.59	-0.53	Cognitive function;	chr21:39180017	chr21:39216624~39217506:+
OV	cis	rs8105895	0.935	rs10417916	ENSG00000269742.1	BNIP3P29	9.3	1.26e-17	8.16e-14	0.78	0.53	Body mass index (change over time);	chr19:22089813	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs1968446	ENSG00000269742.1	BNIP3P29	9.3	1.26e-17	8.16e-14	0.78	0.53	Body mass index (change over time);	chr19:22096245	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs7256462	ENSG00000269742.1	BNIP3P29	9.3	1.26e-17	8.16e-14	0.78	0.53	Body mass index (change over time);	chr19:22099191	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs10425828	ENSG00000269742.1	BNIP3P29	9.3	1.26e-17	8.16e-14	0.78	0.53	Body mass index (change over time);	chr19:22100275	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs8103374	ENSG00000269742.1	BNIP3P29	9.3	1.26e-17	8.16e-14	0.78	0.53	Body mass index (change over time);	chr19:22101517	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs8103279	ENSG00000269742.1	BNIP3P29	9.3	1.26e-17	8.16e-14	0.78	0.53	Body mass index (change over time);	chr19:22101538	chr19:22065828~22066398:-
OV	cis	rs8105895	0.867	rs8106762	ENSG00000269742.1	BNIP3P29	9.3	1.26e-17	8.16e-14	0.78	0.53	Body mass index (change over time);	chr19:22101934	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs10418804	ENSG00000269742.1	BNIP3P29	9.29	1.28e-17	8.31e-14	0.78	0.52	Body mass index (change over time);	chr19:22090213	chr19:22065828~22066398:-
OV	cis	rs2836974	0.965	rs34578707	ENSG00000232608.1	TIMM9P2	-9.29	1.32e-17	8.53e-14	-0.62	-0.52	Cognitive function;	chr21:39303241	chr21:39216624~39217506:+
OV	cis	rs6782228	0.585	rs9841161	ENSG00000277250.1	Metazoa_SRP	-9.29	1.33e-17	8.65e-14	-0.56	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613027	chr3:128673681~128674021:-
OV	cis	rs6782228	0.606	rs2712405	ENSG00000277250.1	Metazoa_SRP	-9.29	1.33e-17	8.65e-14	-0.56	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613239	chr3:128673681~128674021:-
OV	cis	rs9326248	0.53	rs2000615	ENSG00000254851.1	RP11-109L13.1	-9.29	1.34e-17	8.69e-14	-0.86	-0.52	Blood protein levels;	chr11:117045103	chr11:117135528~117138582:+
OV	cis	rs6782228	0.606	rs2712404	ENSG00000277250.1	Metazoa_SRP	9.29	1.35e-17	8.72e-14	0.56	0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128613836	chr3:128673681~128674021:-
OV	cis	rs1153858	1	rs1719247	ENSG00000259520.4	CTD-2651B20.3	-9.28	1.37e-17	8.9e-14	-0.63	-0.52	Homoarginine levels;	chr15:45328787	chr15:45251580~45279251:-
OV	cis	rs7246967	0.673	rs62122382	ENSG00000269509.1	BNIP3P34	9.28	1.4e-17	9.05e-14	0.92	0.52	Bronchopulmonary dysplasia;	chr19:22798046	chr19:22773853~22774424:+
OV	cis	rs2836974	0.867	rs77959119	ENSG00000232608.1	TIMM9P2	-9.28	1.43e-17	9.26e-14	-0.6	-0.52	Cognitive function;	chr21:39170842	chr21:39216624~39217506:+
OV	cis	rs6782228	0.876	rs34198449	ENSG00000242551.2	POU5F1P6	9.27	1.46e-17	9.44e-14	0.62	0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662427	chr3:128674735~128677005:-
OV	cis	rs9326248	0.53	rs6589589	ENSG00000254851.1	RP11-109L13.1	-9.27	1.46e-17	9.45e-14	-0.86	-0.52	Blood protein levels;	chr11:117061712	chr11:117135528~117138582:+
OV	cis	rs7115242	0.8	rs10736487	ENSG00000254851.1	RP11-109L13.1	-9.27	1.46e-17	9.45e-14	-0.86	-0.52	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117079516	chr11:117135528~117138582:+
OV	cis	rs9326248	0.53	rs2155583	ENSG00000254851.1	RP11-109L13.1	-9.27	1.51e-17	9.73e-14	-0.86	-0.52	Blood protein levels;	chr11:117044501	chr11:117135528~117138582:+
OV	cis	rs11673344	0.563	rs256744	ENSG00000226686.6	LINC01535	-9.27	1.52e-17	9.77e-14	-0.66	-0.52	Obesity-related traits;	chr19:37364586	chr19:37251912~37265535:+
OV	cis	rs4423214	1	rs2276360	ENSG00000254682.1	RP11-660L16.2	9.27	1.53e-17	9.83e-14	0.63	0.52	Vitamin D levels;	chr11:71458501	chr11:71448674~71452157:+
OV	cis	rs17361889	0.738	rs17288304	ENSG00000224683.1	RPL36AP29	9.27	1.53e-17	9.86e-14	0.64	0.52	Pediatric bone mineral content (hip);	chr7:16153112	chr7:16208945~16209265:+
OV	cis	rs2836950	0.565	rs3171465	ENSG00000232608.1	TIMM9P2	9.27	1.54e-17	9.89e-14	0.57	0.52	Menarche (age at onset);	chr21:39180381	chr21:39216624~39217506:+
OV	cis	rs172166	0.561	rs149971	ENSG00000216901.1	AL022393.7	9.26	1.56e-17	1e-13	0.59	0.52	Cardiac Troponin-T levels;	chr6:28014374	chr6:28176188~28176674:+
OV	cis	rs6782228	0.509	rs6780447	ENSG00000277250.1	Metazoa_SRP	-9.26	1.56e-17	1e-13	-0.58	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694965	chr3:128673681~128674021:-
OV	cis	rs858239	0.669	rs1990365	ENSG00000230658.1	KLHL7-AS1	9.26	1.58e-17	1.01e-13	0.71	0.52	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23101228~23105703:-
OV	cis	rs4423214	0.592	rs11233977	ENSG00000254682.1	RP11-660L16.2	-9.26	1.6e-17	1.03e-13	-0.75	-0.52	Vitamin D levels;	chr11:71510559	chr11:71448674~71452157:+
OV	cis	rs507080	0.501	rs494459	ENSG00000255239.1	AP002954.6	-9.25	1.66e-17	1.06e-13	-0.61	-0.52	Serum metabolite levels;	chr11:118703966	chr11:118688039~118690600:-
OV	cis	rs6782228	1	rs35871360	ENSG00000242551.2	POU5F1P6	9.24	1.82e-17	1.16e-13	0.62	0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617286	chr3:128674735~128677005:-
OV	cis	rs2836950	0.545	rs1888489	ENSG00000232608.1	TIMM9P2	9.24	1.82e-17	1.16e-13	0.58	0.52	Menarche (age at onset);	chr21:39161238	chr21:39216624~39217506:+
OV	cis	rs858239	0.932	rs1728320	ENSG00000230658.1	KLHL7-AS1	9.24	1.84e-17	1.17e-13	0.69	0.52	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23101228~23105703:-
OV	cis	rs2836974	0.965	rs6517538	ENSG00000232608.1	TIMM9P2	-9.23	1.9e-17	1.21e-13	-0.6	-0.52	Cognitive function;	chr21:39284316	chr21:39216624~39217506:+
OV	cis	rs7115242	0.8	rs7131536	ENSG00000254851.1	RP11-109L13.1	-9.23	1.92e-17	1.22e-13	-0.86	-0.52	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117128730	chr11:117135528~117138582:+
OV	cis	rs17361889	0.752	rs4721485	ENSG00000224683.1	RPL36AP29	9.23	1.96e-17	1.24e-13	0.6	0.52	Pediatric bone mineral content (hip);	chr7:16242848	chr7:16208945~16209265:+
OV	cis	rs6782228	1	rs7429360	ENSG00000242551.2	POU5F1P6	9.22	2.08e-17	1.31e-13	0.61	0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645954	chr3:128674735~128677005:-
OV	cis	rs6782228	1	rs35604103	ENSG00000242551.2	POU5F1P6	9.22	2.08e-17	1.31e-13	0.61	0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128616009	chr3:128674735~128677005:-
OV	cis	rs858239	0.614	rs10229956	ENSG00000230658.1	KLHL7-AS1	-9.22	2.12e-17	1.34e-13	-0.69	-0.52	Cerebrospinal fluid biomarker levels;	chr7:23363317	chr7:23101228~23105703:-
OV	cis	rs1150668	0.699	rs2394049	ENSG00000216901.1	AL022393.7	9.21	2.2e-17	1.39e-13	0.58	0.52	Pubertal anthropometrics;	chr6:28271903	chr6:28176188~28176674:+
OV	cis	rs17361889	0.806	rs62440376	ENSG00000224683.1	RPL36AP29	9.21	2.21e-17	1.39e-13	0.63	0.52	Pediatric bone mineral content (hip);	chr7:16193307	chr7:16208945~16209265:+
OV	cis	rs10256972	0.552	rs2949192	ENSG00000229043.2	AC091729.9	-9.21	2.22e-17	1.4e-13	-0.6	-0.52	Endometriosis;Longevity;	chr7:1164205	chr7:1160374~1165267:+
OV	cis	rs2729354	0.953	rs2649663	ENSG00000265566.2	RN7SL605P	-9.21	2.3e-17	1.45e-13	-0.72	-0.52	Blood protein levels;	chr11:57589832	chr11:57528085~57528365:-
OV	cis	rs6964833	1	rs17515241	ENSG00000123965.13	PMS2P5	-9.2	2.35e-17	1.48e-13	-0.77	-0.52	Menarche (age at onset);	chr7:74717695	chr7:74894116~74897835:+
OV	cis	rs4423214	0.65	rs4245442	ENSG00000254682.1	RP11-660L16.2	9.2	2.36e-17	1.48e-13	0.65	0.52	Vitamin D levels;	chr11:71509863	chr11:71448674~71452157:+
OV	cis	rs875971	1	rs6956179	ENSG00000226824.5	RP4-756H11.3	9.2	2.44e-17	1.53e-13	0.55	0.52	Aortic root size;	chr7:66341672	chr7:66654538~66669855:+
OV	cis	rs17361889	0.711	rs17287882	ENSG00000224683.1	RPL36AP29	9.2	2.45e-17	1.53e-13	0.65	0.52	Pediatric bone mineral content (hip);	chr7:16139249	chr7:16208945~16209265:+
OV	cis	rs6782228	0.565	rs11719239	ENSG00000277250.1	Metazoa_SRP	-9.19	2.54e-17	1.59e-13	-0.57	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700211	chr3:128673681~128674021:-
OV	cis	rs6782228	0.606	rs2001950	ENSG00000277250.1	Metazoa_SRP	-9.19	2.54e-17	1.59e-13	-0.57	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128700913	chr3:128673681~128674021:-
OV	cis	rs801193	0.66	rs1962050	ENSG00000226824.5	RP4-756H11.3	9.19	2.61e-17	1.63e-13	0.54	0.52	Aortic root size;	chr7:66775021	chr7:66654538~66669855:+
OV	cis	rs62388641	0.802	rs13202504	ENSG00000272279.1	RP11-157J24.2	9.19	2.66e-17	1.65e-13	0.85	0.52	Daytime sleep phenotypes;	chr6:1537640	chr6:1528364~1528911:-
OV	cis	rs6782228	0.565	rs67445542	ENSG00000277250.1	Metazoa_SRP	-9.18	2.74e-17	1.7e-13	-0.56	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611683	chr3:128673681~128674021:-
OV	cis	rs6782228	0.585	rs2712392	ENSG00000277250.1	Metazoa_SRP	-9.18	2.84e-17	1.76e-13	-0.56	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705414	chr3:128673681~128674021:-
OV	cis	rs2836950	0.565	rs7279497	ENSG00000232608.1	TIMM9P2	-9.17	2.86e-17	1.77e-13	-0.58	-0.52	Menarche (age at onset);	chr21:39159380	chr21:39216624~39217506:+
OV	cis	rs6782228	0.527	rs7426806	ENSG00000277250.1	Metazoa_SRP	-9.17	2.87e-17	1.78e-13	-0.57	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694087	chr3:128673681~128674021:-
OV	cis	rs9326248	0.53	rs7121347	ENSG00000254851.1	RP11-109L13.1	-9.17	2.96e-17	1.83e-13	-0.85	-0.52	Blood protein levels;	chr11:116996493	chr11:117135528~117138582:+
OV	cis	rs6782228	1	rs6782407	ENSG00000242551.2	POU5F1P6	9.16	3.06e-17	1.89e-13	0.63	0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619905	chr3:128674735~128677005:-
OV	cis	rs17361889	0.738	rs35150436	ENSG00000224683.1	RPL36AP29	9.16	3.07e-17	1.9e-13	0.63	0.52	Pediatric bone mineral content (hip);	chr7:16147313	chr7:16208945~16209265:+
OV	cis	rs17361889	0.711	rs1978253	ENSG00000224683.1	RPL36AP29	9.16	3.07e-17	1.9e-13	0.63	0.52	Pediatric bone mineral content (hip);	chr7:16151114	chr7:16208945~16209265:+
OV	cis	rs2836974	0.931	rs2836972	ENSG00000232608.1	TIMM9P2	-9.16	3.12e-17	1.91e-13	-0.59	-0.52	Cognitive function;	chr21:39280216	chr21:39216624~39217506:+
OV	cis	rs2836974	0.965	rs7354783	ENSG00000232608.1	TIMM9P2	-9.16	3.12e-17	1.91e-13	-0.59	-0.52	Cognitive function;	chr21:39281066	chr21:39216624~39217506:+
OV	cis	rs2836974	0.931	rs8132285	ENSG00000232608.1	TIMM9P2	-9.16	3.12e-17	1.91e-13	-0.59	-0.52	Cognitive function;	chr21:39283826	chr21:39216624~39217506:+
OV	cis	rs7617773	0.963	rs9822496	ENSG00000229759.1	MRPS18AP1	9.16	3.13e-17	1.91e-13	0.53	0.52	Coronary artery disease;	chr3:48139843	chr3:48256350~48256938:-
OV	cis	rs8105895	0.935	rs7259971	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22054517	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs6511316	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22054827	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs10406553	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22054999	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs10406653	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22055221	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs10407250	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22055349	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs10412953	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22055680	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs4510150	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22056867	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs4542784	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22056949	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs4257328	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22057288	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs10404669	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22058416	chr19:22065828~22066398:-
OV	cis	rs8105895	0.877	rs9973249	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22059358	chr19:22065828~22066398:-
OV	cis	rs8105895	0.877	rs2359833	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22059419	chr19:22065828~22066398:-
OV	cis	rs8105895	0.877	rs2163837	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22059434	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs2163835	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22059877	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs28857211	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22060302	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs28894669	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22060462	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs10406551	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22061718	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs10405613	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22061970	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs10405673	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22062088	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs10406485	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22062200	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs10406119	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22062207	chr19:22065828~22066398:-
OV	cis	rs8105895	0.877	rs28822164	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22062306	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs10408150	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22062423	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs7251884	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22062728	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs7252023	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22062844	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs7253053	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22062883	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs7252550	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22063215	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs10413784	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22063389	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs10407173	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22063861	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs8104144	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22064111	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs8103518	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22064150	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs8104630	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22064475	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs9653157	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22066688	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs9653142	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22066794	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs7247041	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22066988	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs7247147	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22067056	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs7247228	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22067334	chr19:22065828~22066398:-
OV	cis	rs8105895	0.877	rs7248305	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22067469	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs7250905	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22067941	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs2043317	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22068294	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs2043316	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22068402	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs8108651	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22068662	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs10420019	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22069103	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs10420042	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22069124	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs2043315	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22070021	chr19:22065828~22066398:-
OV	cis	rs8105895	0.778	rs10401922	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22070450	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs10422289	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22073258	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs10411275	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22076667	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs10411943	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22076980	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs62110990	ENSG00000269742.1	BNIP3P29	9.16	3.14e-17	1.91e-13	0.78	0.52	Body mass index (change over time);	chr19:22077639	chr19:22065828~22066398:-
OV	cis	rs6782228	1	rs6801509	ENSG00000242551.2	POU5F1P6	9.16	3.16e-17	1.92e-13	0.62	0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645426	chr3:128674735~128677005:-
OV	cis	rs1150668	0.764	rs9368565	ENSG00000216901.1	AL022393.7	-9.16	3.18e-17	1.93e-13	-0.58	-0.52	Pubertal anthropometrics;	chr6:28377433	chr6:28176188~28176674:+
OV	cis	rs1150668	0.796	rs1052215	ENSG00000216901.1	AL022393.7	-9.16	3.18e-17	1.93e-13	-0.58	-0.52	Pubertal anthropometrics;	chr6:28380381	chr6:28176188~28176674:+
OV	cis	rs7115242	0.8	rs4245168	ENSG00000254851.1	RP11-109L13.1	-9.16	3.22e-17	1.96e-13	-0.85	-0.52	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117011922	chr11:117135528~117138582:+
OV	cis	rs7115242	0.8	rs7931770	ENSG00000254851.1	RP11-109L13.1	-9.15	3.27e-17	1.98e-13	-0.85	-0.52	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116995574	chr11:117135528~117138582:+
OV	cis	rs11673344	0.642	rs55755939	ENSG00000226686.6	LINC01535	9.15	3.28e-17	1.99e-13	0.65	0.52	Obesity-related traits;	chr19:37353723	chr19:37251912~37265535:+
OV	cis	rs11673344	0.555	rs502546	ENSG00000226686.6	LINC01535	-9.15	3.28e-17	1.99e-13	-0.65	-0.52	Obesity-related traits;	chr19:37361788	chr19:37251912~37265535:+
OV	cis	rs8105895	0.799	rs10426159	ENSG00000269742.1	BNIP3P29	9.15	3.3e-17	2e-13	0.78	0.52	Body mass index (change over time);	chr19:22084522	chr19:22065828~22066398:-
OV	cis	rs8105895	0.932	rs28600030	ENSG00000269742.1	BNIP3P29	9.15	3.3e-17	2e-13	0.78	0.52	Body mass index (change over time);	chr19:22085641	chr19:22065828~22066398:-
OV	cis	rs17361889	0.778	rs1527198	ENSG00000224683.1	RPL36AP29	-9.15	3.35e-17	2.03e-13	-0.64	-0.52	Pediatric bone mineral content (hip);	chr7:16176520	chr7:16208945~16209265:+
OV	cis	rs2836974	0.897	rs2836923	ENSG00000232608.1	TIMM9P2	-9.15	3.48e-17	2.1e-13	-0.61	-0.52	Cognitive function;	chr21:39152310	chr21:39216624~39217506:+
OV	cis	rs11673344	0.642	rs11083420	ENSG00000226686.6	LINC01535	9.14	3.5e-17	2.12e-13	0.66	0.52	Obesity-related traits;	chr19:37317901	chr19:37251912~37265535:+
OV	cis	rs2658782	0.789	rs2605574	ENSG00000279684.1	RP11-755E23.2	-9.14	3.62e-17	2.19e-13	-0.7	-0.52	Pulmonary function decline;	chr11:93403278	chr11:93286629~93288903:-
OV	cis	rs801193	1	rs2055682	ENSG00000226824.5	RP4-756H11.3	-9.14	3.64e-17	2.2e-13	-0.55	-0.52	Aortic root size;	chr7:66795302	chr7:66654538~66669855:+
OV	cis	rs1150668	0.699	rs12214383	ENSG00000216901.1	AL022393.7	-9.14	3.67e-17	2.21e-13	-0.58	-0.52	Pubertal anthropometrics;	chr6:28255953	chr6:28176188~28176674:+
OV	cis	rs858239	0.632	rs6952947	ENSG00000230658.1	KLHL7-AS1	-9.14	3.72e-17	2.25e-13	-0.7	-0.52	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23101228~23105703:-
OV	cis	rs8040855	0.579	rs28521166	ENSG00000259295.5	CSPG4P12	-9.14	3.73e-17	2.25e-13	-0.63	-0.52	Bulimia nervosa;	chr15:85184801	chr15:85191438~85213905:+
OV	cis	rs6782228	1	rs7429360	ENSG00000277250.1	Metazoa_SRP	9.13	3.75e-17	2.26e-13	0.61	0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645954	chr3:128673681~128674021:-
OV	cis	rs7617773	1	rs12496784	ENSG00000229759.1	MRPS18AP1	-9.13	3.77e-17	2.27e-13	-0.53	-0.52	Coronary artery disease;	chr3:48144777	chr3:48256350~48256938:-
OV	cis	rs2836974	0.966	rs7283420	ENSG00000232608.1	TIMM9P2	-9.13	3.8e-17	2.29e-13	-0.61	-0.52	Cognitive function;	chr21:39294939	chr21:39216624~39217506:+
OV	cis	rs2836974	0.965	rs2836967	ENSG00000232608.1	TIMM9P2	-9.13	3.88e-17	2.33e-13	-0.59	-0.52	Cognitive function;	chr21:39267176	chr21:39216624~39217506:+
OV	cis	rs2836974	0.965	rs8130984	ENSG00000232608.1	TIMM9P2	-9.13	3.88e-17	2.33e-13	-0.59	-0.52	Cognitive function;	chr21:39268040	chr21:39216624~39217506:+
OV	cis	rs9399135	0.66	rs4472368	ENSG00000232876.1	CTA-212D2.2	-9.13	3.93e-17	2.36e-13	-0.57	-0.52	Red blood cell count;	chr6:134953094	chr6:135055033~135060550:+
OV	cis	rs2836974	0.897	rs7280375	ENSG00000232608.1	TIMM9P2	9.13	3.94e-17	2.37e-13	0.59	0.52	Cognitive function;	chr21:39180482	chr21:39216624~39217506:+
OV	cis	rs17361889	0.711	rs73056339	ENSG00000224683.1	RPL36AP29	9.12	4.07e-17	2.45e-13	0.63	0.52	Pediatric bone mineral content (hip);	chr7:16131751	chr7:16208945~16209265:+
OV	cis	rs4423214	1	rs1981412	ENSG00000254682.1	RP11-660L16.2	9.12	4.25e-17	2.55e-13	0.6	0.52	Vitamin D levels;	chr11:71427664	chr11:71448674~71452157:+
OV	cis	rs4423214	1	rs12419279	ENSG00000254682.1	RP11-660L16.2	9.12	4.25e-17	2.55e-13	0.6	0.52	Vitamin D levels;	chr11:71428015	chr11:71448674~71452157:+
OV	cis	rs4423214	1	rs12419334	ENSG00000254682.1	RP11-660L16.2	9.12	4.25e-17	2.55e-13	0.6	0.52	Vitamin D levels;	chr11:71428426	chr11:71448674~71452157:+
OV	cis	rs507080	0.922	rs533646	ENSG00000255422.1	AP002954.4	-9.11	4.44e-17	2.66e-13	-0.61	-0.52	Serum metabolite levels;	chr11:118696037	chr11:118704607~118750263:+
OV	cis	rs507080	0.922	rs642662	ENSG00000255422.1	AP002954.4	-9.11	4.44e-17	2.66e-13	-0.61	-0.52	Serum metabolite levels;	chr11:118696311	chr11:118704607~118750263:+
OV	cis	rs11673344	0.642	rs55926714	ENSG00000226686.6	LINC01535	9.11	4.47e-17	2.67e-13	0.65	0.52	Obesity-related traits;	chr19:37307974	chr19:37251912~37265535:+
OV	cis	rs11673344	0.642	rs12462487	ENSG00000226686.6	LINC01535	9.11	4.47e-17	2.67e-13	0.65	0.52	Obesity-related traits;	chr19:37311211	chr19:37251912~37265535:+
OV	cis	rs2836974	0.897	rs35391055	ENSG00000232608.1	TIMM9P2	-9.11	4.5e-17	2.69e-13	-0.6	-0.52	Cognitive function;	chr21:39153590	chr21:39216624~39217506:+
OV	cis	rs2836974	0.897	rs2836924	ENSG00000232608.1	TIMM9P2	-9.11	4.5e-17	2.69e-13	-0.6	-0.52	Cognitive function;	chr21:39153713	chr21:39216624~39217506:+
OV	cis	rs2836974	0.897	rs2836973	ENSG00000232608.1	TIMM9P2	-9.11	4.52e-17	2.7e-13	-0.59	-0.52	Cognitive function;	chr21:39283002	chr21:39216624~39217506:+
OV	cis	rs6782228	1	rs35871360	ENSG00000277250.1	Metazoa_SRP	9.1	4.65e-17	2.78e-13	0.62	0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128617286	chr3:128673681~128674021:-
OV	cis	rs6782228	1	rs11711038	ENSG00000277250.1	Metazoa_SRP	9.1	4.69e-17	2.8e-13	0.63	0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128675467	chr3:128673681~128674021:-
OV	cis	rs6782228	0.585	rs6774515	ENSG00000277250.1	Metazoa_SRP	-9.1	4.85e-17	2.89e-13	-0.57	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128697035	chr3:128673681~128674021:-
OV	cis	rs6782228	0.565	rs12695509	ENSG00000277250.1	Metazoa_SRP	-9.1	4.85e-17	2.89e-13	-0.57	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128698201	chr3:128673681~128674021:-
OV	cis	rs1150668	0.796	rs2247002	ENSG00000216901.1	AL022393.7	9.09	4.94e-17	2.94e-13	0.57	0.52	Pubertal anthropometrics;	chr6:28430174	chr6:28176188~28176674:+
OV	cis	rs2658782	0.547	rs3020064	ENSG00000279684.1	RP11-755E23.2	-9.09	5.05e-17	2.99e-13	-0.67	-0.52	Pulmonary function decline;	chr11:93327685	chr11:93286629~93288903:-
OV	cis	rs17361889	0.752	rs56161298	ENSG00000224683.1	RPL36AP29	9.09	5.06e-17	3e-13	0.62	0.52	Pediatric bone mineral content (hip);	chr7:16215537	chr7:16208945~16209265:+
OV	cis	rs11603023	0.874	rs577396	ENSG00000255239.1	AP002954.6	9.09	5.2e-17	3.07e-13	0.55	0.52	Cholesterol, total;	chr11:118628753	chr11:118688039~118690600:-
OV	cis	rs11603023	0.874	rs11216934	ENSG00000255239.1	AP002954.6	9.09	5.2e-17	3.07e-13	0.55	0.52	Cholesterol, total;	chr11:118630742	chr11:118688039~118690600:-
OV	cis	rs6782228	1	rs6775011	ENSG00000277250.1	Metazoa_SRP	9.09	5.22e-17	3.08e-13	0.63	0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128677640	chr3:128673681~128674021:-
OV	cis	rs6782228	1	rs35604103	ENSG00000277250.1	Metazoa_SRP	9.08	5.25e-17	3.1e-13	0.61	0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128616009	chr3:128673681~128674021:-
OV	cis	rs507080	0.922	rs518028	ENSG00000255422.1	AP002954.4	-9.08	5.29e-17	3.12e-13	-0.6	-0.52	Serum metabolite levels;	chr11:118694273	chr11:118704607~118750263:+
OV	cis	rs507080	0.922	rs519982	ENSG00000255422.1	AP002954.4	-9.08	5.29e-17	3.12e-13	-0.6	-0.52	Serum metabolite levels;	chr11:118694522	chr11:118704607~118750263:+
OV	cis	rs507080	0.922	rs502601	ENSG00000255422.1	AP002954.4	-9.08	5.29e-17	3.12e-13	-0.6	-0.52	Serum metabolite levels;	chr11:118694970	chr11:118704607~118750263:+
OV	cis	rs507080	0.922	rs7114458	ENSG00000255422.1	AP002954.4	-9.08	5.29e-17	3.12e-13	-0.6	-0.52	Serum metabolite levels;	chr11:118695466	chr11:118704607~118750263:+
OV	cis	rs507080	0.922	rs7114216	ENSG00000255422.1	AP002954.4	-9.08	5.29e-17	3.12e-13	-0.6	-0.52	Serum metabolite levels;	chr11:118695525	chr11:118704607~118750263:+
OV	cis	rs6964833	1	rs4717907	ENSG00000123965.13	PMS2P5	9.08	5.29e-17	3.12e-13	0.74	0.52	Menarche (age at onset);	chr7:74672169	chr7:74894116~74897835:+
OV	cis	rs507080	0.883	rs692750	ENSG00000255422.1	AP002954.4	-9.08	5.36e-17	3.16e-13	-0.59	-0.52	Serum metabolite levels;	chr11:118667599	chr11:118704607~118750263:+
OV	cis	rs6964833	1	rs36044436	ENSG00000123965.13	PMS2P5	9.08	5.37e-17	3.16e-13	0.77	0.52	Menarche (age at onset);	chr7:74675495	chr7:74894116~74897835:+
OV	cis	rs6782228	0.527	rs6767383	ENSG00000277250.1	Metazoa_SRP	-9.08	5.53e-17	3.25e-13	-0.57	-0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128694744	chr3:128673681~128674021:-
OV	cis	rs2836974	0.863	rs8128026	ENSG00000232608.1	TIMM9P2	-9.07	5.69e-17	3.34e-13	-0.6	-0.52	Cognitive function;	chr21:39161776	chr21:39216624~39217506:+
OV	cis	rs2836974	1	rs28360661	ENSG00000232608.1	TIMM9P2	-9.07	5.93e-17	3.48e-13	-0.61	-0.52	Cognitive function;	chr21:39310046	chr21:39216624~39217506:+
OV	cis	rs9326248	0.53	rs2471884	ENSG00000254851.1	RP11-109L13.1	-9.07	5.93e-17	3.48e-13	-0.87	-0.52	Blood protein levels;	chr11:117139604	chr11:117135528~117138582:+
OV	cis	rs2836950	0.52	rs59916147	ENSG00000232608.1	TIMM9P2	9.06	6.03e-17	3.54e-13	0.57	0.52	Menarche (age at onset);	chr21:39262776	chr21:39216624~39217506:+
OV	cis	rs1150668	0.699	rs1531681	ENSG00000216901.1	AL022393.7	9.06	6.1e-17	3.57e-13	0.57	0.52	Pubertal anthropometrics;	chr6:28259100	chr6:28176188~28176674:+
OV	cis	rs17361889	0.727	rs62440394	ENSG00000224683.1	RPL36AP29	9.06	6.16e-17	3.6e-13	0.61	0.52	Pediatric bone mineral content (hip);	chr7:16215008	chr7:16208945~16209265:+
OV	cis	rs6051080	1	rs6051080	ENSG00000274973.1	RP13-401N8.7	-9.06	6.29e-17	3.68e-13	-0.57	-0.52	Colorectal or endometrial cancer;	chr20:25995038	chr20:25845497~25845862:+
OV	cis	rs507080	0.922	rs508640	ENSG00000255422.1	AP002954.4	-9.06	6.31e-17	3.68e-13	-0.6	-0.52	Serum metabolite levels;	chr11:118693704	chr11:118704607~118750263:+
OV	cis	rs507080	0.922	rs471227	ENSG00000255422.1	AP002954.4	-9.06	6.31e-17	3.68e-13	-0.6	-0.52	Serum metabolite levels;	chr11:118693892	chr11:118704607~118750263:+
OV	cis	rs507080	0.922	rs516153	ENSG00000255422.1	AP002954.4	-9.06	6.31e-17	3.68e-13	-0.6	-0.52	Serum metabolite levels;	chr11:118694053	chr11:118704607~118750263:+
OV	cis	rs2836974	0.931	rs2836968	ENSG00000232608.1	TIMM9P2	-9.06	6.31e-17	3.68e-13	-0.59	-0.52	Cognitive function;	chr21:39270460	chr21:39216624~39217506:+
OV	cis	rs2836974	0.931	rs7283569	ENSG00000232608.1	TIMM9P2	-9.06	6.31e-17	3.68e-13	-0.59	-0.52	Cognitive function;	chr21:39272136	chr21:39216624~39217506:+
OV	cis	rs7617773	0.963	rs6766754	ENSG00000229759.1	MRPS18AP1	-9.06	6.4e-17	3.74e-13	-0.54	-0.52	Coronary artery disease;	chr3:48141099	chr3:48256350~48256938:-
OV	cis	rs7617773	0.832	rs6775114	ENSG00000229759.1	MRPS18AP1	-9.06	6.4e-17	3.74e-13	-0.54	-0.52	Coronary artery disease;	chr3:48141130	chr3:48256350~48256938:-
OV	cis	rs11235843	0.636	rs6592531	ENSG00000255928.1	RP11-456I15.2	-9.05	6.4e-17	3.74e-13	-0.71	-0.52	Hand grip strength;	chr11:73701309	chr11:73722349~73722694:+
OV	cis	rs4423214	0.57	rs7118246	ENSG00000254682.1	RP11-660L16.2	9.05	6.41e-17	3.74e-13	0.64	0.52	Vitamin D levels;	chr11:71520078	chr11:71448674~71452157:+
OV	cis	rs6782228	1	rs12495411	ENSG00000277250.1	Metazoa_SRP	9.05	6.42e-17	3.75e-13	0.62	0.52	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128676852	chr3:128673681~128674021:-
OV	cis	rs507080	0.883	rs558593	ENSG00000255422.1	AP002954.4	-9.05	6.49e-17	3.78e-13	-0.6	-0.52	Serum metabolite levels;	chr11:118691811	chr11:118704607~118750263:+
OV	cis	rs507080	0.922	rs478296	ENSG00000255422.1	AP002954.4	-9.05	6.53e-17	3.8e-13	-0.62	-0.52	Serum metabolite levels;	chr11:118696666	chr11:118704607~118750263:+
OV	cis	rs507080	0.922	rs493834	ENSG00000255422.1	AP002954.4	-9.05	6.53e-17	3.8e-13	-0.62	-0.52	Serum metabolite levels;	chr11:118696735	chr11:118704607~118750263:+
OV	cis	rs507080	0.922	rs644498	ENSG00000255422.1	AP002954.4	-9.05	6.53e-17	3.8e-13	-0.62	-0.52	Serum metabolite levels;	chr11:118696777	chr11:118704607~118750263:+
OV	cis	rs1150668	0.796	rs728122	ENSG00000216901.1	AL022393.7	9.04	6.97e-17	4.06e-13	0.57	0.51	Pubertal anthropometrics;	chr6:28431347	chr6:28176188~28176674:+
OV	cis	rs2836974	0.897	rs4817996	ENSG00000232608.1	TIMM9P2	-9.04	7.12e-17	4.13e-13	-0.6	-0.51	Cognitive function;	chr21:39153833	chr21:39216624~39217506:+
OV	cis	rs2836974	0.897	rs34394827	ENSG00000232608.1	TIMM9P2	-9.04	7.17e-17	4.16e-13	-0.6	-0.51	Cognitive function;	chr21:39156161	chr21:39216624~39217506:+
OV	cis	rs507080	0.885	rs693037	ENSG00000255422.1	AP002954.4	-9.04	7.22e-17	4.19e-13	-0.6	-0.51	Serum metabolite levels;	chr11:118682617	chr11:118704607~118750263:+
OV	cis	rs507080	0.885	rs533144	ENSG00000255422.1	AP002954.4	-9.03	7.58e-17	4.39e-13	-0.6	-0.51	Serum metabolite levels;	chr11:118688538	chr11:118704607~118750263:+
OV	cis	rs1387259	0.79	rs2732445	ENSG00000258273.1	RP11-370I10.4	-9.03	7.68e-17	4.45e-13	-0.6	-0.51	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48251750	chr12:48333755~48333901:-
OV	cis	rs2732480	0.5	rs2932093	ENSG00000258273.1	RP11-370I10.4	-9.03	7.68e-17	4.45e-13	-0.6	-0.51	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48254488	chr12:48333755~48333901:-
OV	cis	rs2658782	0.724	rs1563445	ENSG00000279684.1	RP11-755E23.2	-9.03	7.7e-17	4.46e-13	-0.72	-0.51	Pulmonary function decline;	chr11:93512876	chr11:93286629~93288903:-
OV	cis	rs10256972	0.516	rs12702081	ENSG00000229043.2	AC091729.9	-9.02	8.02e-17	4.64e-13	-0.6	-0.51	Endometriosis;Longevity;	chr7:1101892	chr7:1160374~1165267:+
OV	cis	rs801193	1	rs2420824	ENSG00000226824.5	RP4-756H11.3	9.02	8.08e-17	4.67e-13	0.55	0.51	Aortic root size;	chr7:66666129	chr7:66654538~66669855:+
OV	cis	rs11235843	0.602	rs7106773	ENSG00000255928.1	RP11-456I15.2	-9.02	8.14e-17	4.71e-13	-0.72	-0.51	Hand grip strength;	chr11:73672129	chr11:73722349~73722694:+
OV	cis	rs2836974	0.897	rs35386515	ENSG00000232608.1	TIMM9P2	-9.02	8.37e-17	4.83e-13	-0.6	-0.51	Cognitive function;	chr21:39160121	chr21:39216624~39217506:+
OV	cis	rs2836974	0.897	rs2836925	ENSG00000232608.1	TIMM9P2	-9.02	8.37e-17	4.83e-13	-0.6	-0.51	Cognitive function;	chr21:39160427	chr21:39216624~39217506:+
OV	cis	rs9326248	0.53	rs2000614	ENSG00000254851.1	RP11-109L13.1	-9.01	8.41e-17	4.85e-13	-0.82	-0.51	Blood protein levels;	chr11:117045026	chr11:117135528~117138582:+
OV	cis	rs9326248	0.53	rs2000616	ENSG00000254851.1	RP11-109L13.1	-9.01	8.41e-17	4.85e-13	-0.82	-0.51	Blood protein levels;	chr11:117045813	chr11:117135528~117138582:+
OV	cis	rs2487048	0.773	rs2472494	ENSG00000226334.1	RP11-217B7.2	-9.01	8.46e-17	4.88e-13	-0.63	-0.51	Intraocular pressure;	chr9:104933258	chr9:104927553~104928892:+
OV	cis	rs507080	0.922	rs546890	ENSG00000255422.1	AP002954.4	-9.01	8.65e-17	4.96e-13	-0.6	-0.51	Serum metabolite levels;	chr11:118686489	chr11:118704607~118750263:+
OV	cis	rs507080	0.883	rs693306	ENSG00000255422.1	AP002954.4	-9.01	8.65e-17	4.96e-13	-0.6	-0.51	Serum metabolite levels;	chr11:118687624	chr11:118704607~118750263:+
OV	cis	rs507080	0.922	rs561845	ENSG00000255422.1	AP002954.4	-9.01	8.65e-17	4.96e-13	-0.6	-0.51	Serum metabolite levels;	chr11:118688118	chr11:118704607~118750263:+
OV	cis	rs507080	0.922	rs638805	ENSG00000255422.1	AP002954.4	-9.01	8.65e-17	4.96e-13	-0.6	-0.51	Serum metabolite levels;	chr11:118688180	chr11:118704607~118750263:+
OV	cis	rs507080	0.845	rs510408	ENSG00000255422.1	AP002954.4	-9.01	8.65e-17	4.96e-13	-0.6	-0.51	Serum metabolite levels;	chr11:118688192	chr11:118704607~118750263:+
OV	cis	rs507080	0.845	rs509641	ENSG00000255422.1	AP002954.4	-9.01	8.65e-17	4.96e-13	-0.6	-0.51	Serum metabolite levels;	chr11:118688243	chr11:118704607~118750263:+
OV	cis	rs507080	0.883	rs563549	ENSG00000255422.1	AP002954.4	-9.01	8.65e-17	4.96e-13	-0.6	-0.51	Serum metabolite levels;	chr11:118688244	chr11:118704607~118750263:+
OV	cis	rs507080	0.883	rs12798453	ENSG00000255422.1	AP002954.4	-9.01	8.65e-17	4.96e-13	-0.6	-0.51	Serum metabolite levels;	chr11:118690701	chr11:118704607~118750263:+
OV	cis	rs507080	0.922	rs582630	ENSG00000255422.1	AP002954.4	-9.01	8.65e-17	4.96e-13	-0.6	-0.51	Serum metabolite levels;	chr11:118692090	chr11:118704607~118750263:+
OV	cis	rs507080	0.883	rs527475	ENSG00000255422.1	AP002954.4	-9.01	8.65e-17	4.96e-13	-0.6	-0.51	Serum metabolite levels;	chr11:118692530	chr11:118704607~118750263:+
OV	cis	rs507080	0.922	rs585039	ENSG00000255422.1	AP002954.4	-9.01	8.65e-17	4.96e-13	-0.6	-0.51	Serum metabolite levels;	chr11:118692672	chr11:118704607~118750263:+
OV	cis	rs9549260	0.755	rs2297627	ENSG00000229456.1	RLIMP1	9	8.99e-17	5.15e-13	0.54	0.51	Red blood cell count;	chr13:40659794	chr13:40618738~40621348:+
OV	cis	rs2836974	0.897	rs6517513	ENSG00000232608.1	TIMM9P2	-9	9e-17	5.15e-13	-0.6	-0.51	Cognitive function;	chr21:39154952	chr21:39216624~39217506:+
OV	cis	rs2836974	0.899	rs6517514	ENSG00000232608.1	TIMM9P2	-9	9e-17	5.15e-13	-0.6	-0.51	Cognitive function;	chr21:39155169	chr21:39216624~39217506:+
OV	cis	rs2836974	0.829	rs8128191	ENSG00000232608.1	TIMM9P2	-9	9e-17	5.15e-13	-0.6	-0.51	Cognitive function;	chr21:39155385	chr21:39216624~39217506:+
OV	cis	rs2836974	0.897	rs8132419	ENSG00000232608.1	TIMM9P2	-9	9e-17	5.15e-13	-0.6	-0.51	Cognitive function;	chr21:39155901	chr21:39216624~39217506:+
OV	cis	rs2836974	0.897	rs8132568	ENSG00000232608.1	TIMM9P2	-9	9e-17	5.15e-13	-0.6	-0.51	Cognitive function;	chr21:39155990	chr21:39216624~39217506:+
OV	cis	rs801193	1	rs2659909	ENSG00000226824.5	RP4-756H11.3	-9	9.05e-17	5.18e-13	-0.55	-0.51	Aortic root size;	chr7:66695292	chr7:66654538~66669855:+
OV	cis	rs507080	0.845	rs613377	ENSG00000255422.1	AP002954.4	-9	9.12e-17	5.22e-13	-0.6	-0.51	Serum metabolite levels;	chr11:118685375	chr11:118704607~118750263:+
OV	cis	rs6782228	0.606	rs4634140	ENSG00000277250.1	Metazoa_SRP	9	9.17e-17	5.24e-13	0.54	0.51	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128705613	chr3:128673681~128674021:-
OV	cis	rs507080	0.922	rs644867	ENSG00000255422.1	AP002954.4	-9	9.24e-17	5.28e-13	-0.61	-0.51	Serum metabolite levels;	chr11:118696836	chr11:118704607~118750263:+
OV	cis	rs2658782	0.547	rs3020054	ENSG00000279684.1	RP11-755E23.2	-9	9.49e-17	5.42e-13	-0.65	-0.51	Pulmonary function decline;	chr11:93322390	chr11:93286629~93288903:-
OV	cis	rs507080	0.961	rs34413584	ENSG00000255422.1	AP002954.4	-9	9.57e-17	5.46e-13	-0.6	-0.51	Serum metabolite levels;	chr11:118675072	chr11:118704607~118750263:+
OV	cis	rs2836950	0.545	rs11700449	ENSG00000232608.1	TIMM9P2	8.99	9.63e-17	5.49e-13	0.58	0.51	Menarche (age at onset);	chr21:39150493	chr21:39216624~39217506:+
OV	cis	rs801193	1	rs6958520	ENSG00000222364.1	RNU6-96P	-8.99	9.66e-17	5.51e-13	-0.53	-0.51	Aortic root size;	chr7:66686466	chr7:66395191~66395286:+
OV	cis	rs801193	1	rs7788576	ENSG00000222364.1	RNU6-96P	8.99	9.66e-17	5.51e-13	0.53	0.51	Aortic root size;	chr7:66683315	chr7:66395191~66395286:+
OV	cis	rs875971	0.628	rs6974355	ENSG00000226824.5	RP4-756H11.3	-8.99	9.67e-17	5.51e-13	-0.54	-0.51	Aortic root size;	chr7:66376994	chr7:66654538~66669855:+
OV	cis	rs17361889	0.727	rs1527208	ENSG00000224683.1	RPL36AP29	8.99	9.78e-17	5.57e-13	0.59	0.51	Pediatric bone mineral content (hip);	chr7:16241218	chr7:16208945~16209265:+
OV	cis	rs875971	0.964	rs778735	ENSG00000226824.5	RP4-756H11.3	-8.99	9.83e-17	5.6e-13	-0.54	-0.51	Aortic root size;	chr7:66349822	chr7:66654538~66669855:+
OV	cis	rs875971	0.66	rs801193	ENSG00000222364.1	RNU6-96P	8.99	9.88e-17	5.62e-13	0.52	0.51	Aortic root size;	chr7:66565625	chr7:66395191~66395286:+
OV	cis	rs17361889	0.727	rs17458603	ENSG00000224683.1	RPL36AP29	8.99	9.95e-17	5.65e-13	0.58	0.51	Pediatric bone mineral content (hip);	chr7:16239968	chr7:16208945~16209265:+
OV	cis	rs2729354	0.953	rs2848625	ENSG00000265566.2	RN7SL605P	-8.99	9.98e-17	5.67e-13	-0.79	-0.51	Blood protein levels;	chr11:57563177	chr11:57528085~57528365:-
OV	cis	rs7617773	0.963	rs12493256	ENSG00000229759.1	MRPS18AP1	-8.99	1.01e-16	5.73e-13	-0.54	-0.51	Coronary artery disease;	chr3:48135257	chr3:48256350~48256938:-
OV	cis	rs7397814	0.558	rs4764447	ENSG00000278635.1	CTD-2318O12.1	8.99	1.01e-16	5.74e-13	0.46	0.51	IgG glycosylation;	chr12:9426513	chr12:9415641~9416718:+
OV	cis	rs875971	1	rs709595	ENSG00000226824.5	RP4-756H11.3	-8.99	1.02e-16	5.78e-13	-0.54	-0.51	Aortic root size;	chr7:66352346	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs811880	ENSG00000226824.5	RP4-756H11.3	-8.99	1.02e-16	5.78e-13	-0.54	-0.51	Aortic root size;	chr7:66353659	chr7:66654538~66669855:+
OV	cis	rs2836974	0.897	rs11911112	ENSG00000232608.1	TIMM9P2	-8.98	1.04e-16	5.87e-13	-0.59	-0.51	Cognitive function;	chr21:39156420	chr21:39216624~39217506:+
OV	cis	rs2836974	0.831	rs11911149	ENSG00000232608.1	TIMM9P2	-8.98	1.04e-16	5.87e-13	-0.59	-0.51	Cognitive function;	chr21:39156449	chr21:39216624~39217506:+
OV	cis	rs17361889	0.671	rs73071825	ENSG00000224683.1	RPL36AP29	8.98	1.06e-16	5.97e-13	0.61	0.51	Pediatric bone mineral content (hip);	chr7:16109442	chr7:16208945~16209265:+
OV	cis	rs875971	0.867	rs1002053	ENSG00000226824.5	RP4-756H11.3	8.98	1.09e-16	6.13e-13	0.54	0.51	Aortic root size;	chr7:66333558	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs6460292	ENSG00000226824.5	RP4-756H11.3	8.98	1.09e-16	6.13e-13	0.54	0.51	Aortic root size;	chr7:66345088	chr7:66654538~66669855:+
OV	cis	rs801193	1	rs2420824	ENSG00000222364.1	RNU6-96P	8.98	1.09e-16	6.13e-13	0.53	0.51	Aortic root size;	chr7:66666129	chr7:66395191~66395286:+
OV	cis	rs1150668	0.83	rs2859365	ENSG00000216901.1	AL022393.7	-8.98	1.09e-16	6.16e-13	-0.57	-0.51	Pubertal anthropometrics;	chr6:28423688	chr6:28176188~28176674:+
OV	cis	rs2836974	0.897	rs13047678	ENSG00000232608.1	TIMM9P2	-8.97	1.1e-16	6.2e-13	-0.62	-0.51	Cognitive function;	chr21:39336927	chr21:39216624~39217506:+
OV	cis	rs2658782	0.547	rs3020052	ENSG00000279684.1	RP11-755E23.2	-8.97	1.11e-16	6.23e-13	-0.66	-0.51	Pulmonary function decline;	chr11:93322018	chr11:93286629~93288903:-
OV	cis	rs507080	0.922	rs592280	ENSG00000255422.1	AP002954.4	-8.97	1.12e-16	6.31e-13	-0.6	-0.51	Serum metabolite levels;	chr11:118682509	chr11:118704607~118750263:+
OV	cis	rs801193	0.66	rs2659897	ENSG00000226824.5	RP4-756H11.3	8.97	1.15e-16	6.5e-13	0.53	0.51	Aortic root size;	chr7:66722728	chr7:66654538~66669855:+
OV	cis	rs507080	0.922	rs558907	ENSG00000255422.1	AP002954.4	-8.96	1.17e-16	6.59e-13	-0.6	-0.51	Serum metabolite levels;	chr11:118687746	chr11:118704607~118750263:+
OV	cis	rs507080	0.885	rs7926959	ENSG00000255422.1	AP002954.4	-8.96	1.17e-16	6.59e-13	-0.6	-0.51	Serum metabolite levels;	chr11:118689157	chr11:118704607~118750263:+
OV	cis	rs507080	0.663	rs7926970	ENSG00000255422.1	AP002954.4	-8.96	1.17e-16	6.59e-13	-0.6	-0.51	Serum metabolite levels;	chr11:118689172	chr11:118704607~118750263:+
OV	cis	rs507080	0.885	rs4938530	ENSG00000255422.1	AP002954.4	-8.96	1.17e-16	6.59e-13	-0.6	-0.51	Serum metabolite levels;	chr11:118689861	chr11:118704607~118750263:+
OV	cis	rs875971	0.706	rs1643374	ENSG00000226824.5	RP4-756H11.3	-8.96	1.25e-16	7.01e-13	-0.54	-0.51	Aortic root size;	chr7:66407695	chr7:66654538~66669855:+
OV	cis	rs4423214	0.65	rs2186777	ENSG00000254682.1	RP11-660L16.2	8.95	1.25e-16	7.03e-13	0.63	0.51	Vitamin D levels;	chr11:71508757	chr11:71448674~71452157:+
OV	cis	rs801193	1	rs10274773	ENSG00000222364.1	RNU6-96P	8.95	1.28e-16	7.15e-13	0.53	0.51	Aortic root size;	chr7:66668591	chr7:66395191~66395286:+
OV	cis	rs801193	1	rs7785213	ENSG00000222364.1	RNU6-96P	8.95	1.28e-16	7.15e-13	0.53	0.51	Aortic root size;	chr7:66673991	chr7:66395191~66395286:+
OV	cis	rs11603023	0.772	rs540800	ENSG00000255239.1	AP002954.6	8.95	1.28e-16	7.2e-13	0.56	0.51	Cholesterol, total;	chr11:118694942	chr11:118688039~118690600:-
OV	cis	rs2658782	0.547	rs3020065	ENSG00000279684.1	RP11-755E23.2	-8.95	1.29e-16	7.21e-13	-0.66	-0.51	Pulmonary function decline;	chr11:93326733	chr11:93286629~93288903:-
OV	cis	rs2658782	0.526	rs3020062	ENSG00000279684.1	RP11-755E23.2	-8.95	1.29e-16	7.21e-13	-0.66	-0.51	Pulmonary function decline;	chr11:93327993	chr11:93286629~93288903:-
OV	cis	rs2729354	1	rs2848630	ENSG00000265566.2	RN7SL605P	-8.95	1.31e-16	7.32e-13	-0.77	-0.51	Blood protein levels;	chr11:57589434	chr11:57528085~57528365:-
OV	cis	rs2836950	0.545	rs8132424	ENSG00000232608.1	TIMM9P2	-8.95	1.31e-16	7.35e-13	-0.56	-0.51	Menarche (age at onset);	chr21:39212486	chr21:39216624~39217506:+
OV	cis	rs2658782	0.654	rs2605617	ENSG00000279684.1	RP11-755E23.2	-8.94	1.36e-16	7.59e-13	-0.71	-0.51	Pulmonary function decline;	chr11:93510167	chr11:93286629~93288903:-
OV	cis	rs801193	1	rs2286684	ENSG00000222364.1	RNU6-96P	8.94	1.36e-16	7.61e-13	0.53	0.51	Aortic root size;	chr7:66664843	chr7:66395191~66395286:+
OV	cis	rs801193	0.935	rs2286683	ENSG00000222364.1	RNU6-96P	8.94	1.36e-16	7.61e-13	0.53	0.51	Aortic root size;	chr7:66664856	chr7:66395191~66395286:+
OV	cis	rs7115242	0.8	rs519794	ENSG00000254851.1	RP11-109L13.1	-8.94	1.37e-16	7.64e-13	-0.83	-0.51	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116988737	chr11:117135528~117138582:+
OV	cis	rs853679	0.527	rs853683	ENSG00000216901.1	AL022393.7	8.94	1.37e-16	7.66e-13	0.6	0.51	Depression;	chr6:28327262	chr6:28176188~28176674:+
OV	cis	rs6782228	1	rs6801509	ENSG00000277250.1	Metazoa_SRP	8.94	1.37e-16	7.66e-13	0.61	0.51	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128645426	chr3:128673681~128674021:-
OV	cis	rs2729354	1	rs2729355	ENSG00000265566.2	RN7SL605P	-8.94	1.38e-16	7.72e-13	-0.76	-0.51	Blood protein levels;	chr11:57586510	chr11:57528085~57528365:-
OV	cis	rs2732480	0.538	rs1387259	ENSG00000258273.1	RP11-370I10.4	8.94	1.4e-16	7.79e-13	0.61	0.51	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309739	chr12:48333755~48333901:-
OV	cis	rs9326248	0.53	rs579890	ENSG00000254851.1	RP11-109L13.1	-8.94	1.4e-16	7.82e-13	-0.87	-0.51	Blood protein levels;	chr11:116928247	chr11:117135528~117138582:+
OV	cis	rs875971	0.965	rs697968	ENSG00000226824.5	RP4-756H11.3	8.94	1.41e-16	7.86e-13	0.54	0.51	Aortic root size;	chr7:66070046	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs1167411	ENSG00000226824.5	RP4-756H11.3	8.94	1.41e-16	7.86e-13	0.54	0.51	Aortic root size;	chr7:66074277	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs1183245	ENSG00000226824.5	RP4-756H11.3	8.94	1.41e-16	7.86e-13	0.54	0.51	Aortic root size;	chr7:66076198	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs1144895	ENSG00000226824.5	RP4-756H11.3	8.94	1.41e-16	7.86e-13	0.54	0.51	Aortic root size;	chr7:66076320	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs1144894	ENSG00000226824.5	RP4-756H11.3	8.94	1.41e-16	7.86e-13	0.54	0.51	Aortic root size;	chr7:66077907	chr7:66654538~66669855:+
OV	cis	rs11673344	0.642	rs73025481	ENSG00000226686.6	LINC01535	8.94	1.42e-16	7.91e-13	0.64	0.51	Obesity-related traits;	chr19:37346437	chr19:37251912~37265535:+
OV	cis	rs2729354	0.953	rs2649650	ENSG00000265566.2	RN7SL605P	-8.93	1.44e-16	7.99e-13	-0.79	-0.51	Blood protein levels;	chr11:57560094	chr11:57528085~57528365:-
OV	cis	rs2836974	0.931	rs13047663	ENSG00000232608.1	TIMM9P2	-8.93	1.45e-16	8.06e-13	-0.62	-0.51	Cognitive function;	chr21:39336892	chr21:39216624~39217506:+
OV	cis	rs11673344	0.624	rs862234	ENSG00000226686.6	LINC01535	-8.93	1.47e-16	8.14e-13	-0.66	-0.51	Obesity-related traits;	chr19:37237100	chr19:37251912~37265535:+
OV	cis	rs2729354	1	rs2729354	ENSG00000265566.2	RN7SL605P	-8.93	1.48e-16	8.21e-13	-0.76	-0.51	Blood protein levels;	chr11:57588497	chr11:57528085~57528365:-
OV	cis	rs4423214	0.592	rs7114252	ENSG00000254682.1	RP11-660L16.2	-8.93	1.48e-16	8.22e-13	-0.72	-0.51	Vitamin D levels;	chr11:71526560	chr11:71448674~71452157:+
OV	cis	rs2836974	0.681	rs8128827	ENSG00000232608.1	TIMM9P2	-8.93	1.52e-16	8.45e-13	-0.6	-0.51	Cognitive function;	chr21:39338621	chr21:39216624~39217506:+
OV	cis	rs2836974	0.897	rs2026267	ENSG00000232608.1	TIMM9P2	-8.93	1.52e-16	8.45e-13	-0.6	-0.51	Cognitive function;	chr21:39339551	chr21:39216624~39217506:+
OV	cis	rs2836974	0.897	rs35123057	ENSG00000232608.1	TIMM9P2	-8.93	1.52e-16	8.45e-13	-0.6	-0.51	Cognitive function;	chr21:39339763	chr21:39216624~39217506:+
OV	cis	rs801193	1	rs11773829	ENSG00000222364.1	RNU6-96P	8.93	1.52e-16	8.45e-13	0.53	0.51	Aortic root size;	chr7:66676087	chr7:66395191~66395286:+
OV	cis	rs507080	0.922	rs555356	ENSG00000255422.1	AP002954.4	-8.92	1.53e-16	8.49e-13	-0.59	-0.51	Serum metabolite levels;	chr11:118687369	chr11:118704607~118750263:+
OV	cis	rs2658782	0.547	rs3133454	ENSG00000279684.1	RP11-755E23.2	-8.92	1.53e-16	8.5e-13	-0.66	-0.51	Pulmonary function decline;	chr11:93325853	chr11:93286629~93288903:-
OV	cis	rs2836950	0.561	rs34705151	ENSG00000232608.1	TIMM9P2	8.92	1.55e-16	8.57e-13	0.56	0.51	Menarche (age at onset);	chr21:39181418	chr21:39216624~39217506:+
OV	cis	rs2729354	0.779	rs2454663	ENSG00000265566.2	RN7SL605P	-8.92	1.56e-16	8.66e-13	-0.75	-0.51	Blood protein levels;	chr11:57590610	chr11:57528085~57528365:-
OV	cis	rs8040855	0.599	rs4643289	ENSG00000259295.5	CSPG4P12	-8.92	1.6e-16	8.86e-13	-0.61	-0.51	Bulimia nervosa;	chr15:85183483	chr15:85191438~85213905:+
OV	cis	rs8040855	0.579	rs6496797	ENSG00000259295.5	CSPG4P12	-8.92	1.61e-16	8.87e-13	-0.62	-0.51	Bulimia nervosa;	chr15:85183624	chr15:85191438~85213905:+
OV	cis	rs2836950	0.52	rs2836966	ENSG00000232608.1	TIMM9P2	8.91	1.65e-16	9.08e-13	0.56	0.51	Menarche (age at onset);	chr21:39265595	chr21:39216624~39217506:+
OV	cis	rs7115242	0.8	rs493134	ENSG00000254851.1	RP11-109L13.1	-8.91	1.65e-16	9.11e-13	-0.84	-0.51	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116962963	chr11:117135528~117138582:+
OV	cis	rs507080	0.807	rs7926944	ENSG00000255422.1	AP002954.4	-8.91	1.66e-16	9.14e-13	-0.6	-0.51	Serum metabolite levels;	chr11:118689119	chr11:118704607~118750263:+
OV	cis	rs6903823	0.527	rs4713158	ENSG00000216901.1	AL022393.7	8.91	1.71e-16	9.39e-13	0.6	0.51	Pulmonary function;	chr6:28309994	chr6:28176188~28176674:+
OV	cis	rs1150668	0.796	rs2531825	ENSG00000216901.1	AL022393.7	8.91	1.71e-16	9.39e-13	0.57	0.51	Pubertal anthropometrics;	chr6:28381487	chr6:28176188~28176674:+
OV	cis	rs801193	1	rs17566701	ENSG00000226824.5	RP4-756H11.3	-8.91	1.75e-16	9.6e-13	-0.54	-0.51	Aortic root size;	chr7:66728196	chr7:66654538~66669855:+
OV	cis	rs2732480	0.5	rs12829841	ENSG00000258273.1	RP11-370I10.4	-8.9	1.81e-16	9.93e-13	-0.6	-0.51	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48234956	chr12:48333755~48333901:-
OV	cis	rs2732480	0.523	rs34286639	ENSG00000258273.1	RP11-370I10.4	-8.9	1.81e-16	9.93e-13	-0.6	-0.51	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48235261	chr12:48333755~48333901:-
OV	cis	rs1387259	0.929	rs11168484	ENSG00000258273.1	RP11-370I10.4	-8.9	1.81e-16	9.93e-13	-0.6	-0.51	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48239806	chr12:48333755~48333901:-
OV	cis	rs17361889	0.806	rs10487915	ENSG00000224683.1	RPL36AP29	8.9	1.85e-16	1.01e-12	0.63	0.51	Pediatric bone mineral content (hip);	chr7:16189396	chr7:16208945~16209265:+
OV	cis	rs11603023	0.874	rs483598	ENSG00000255239.1	AP002954.6	8.89	1.87e-16	1.03e-12	0.55	0.51	Cholesterol, total;	chr11:118638950	chr11:118688039~118690600:-
OV	cis	rs950027	0.549	rs1719250	ENSG00000259520.4	CTD-2651B20.3	-8.89	1.89e-16	1.03e-12	-0.66	-0.51	Response to fenofibrate (adiponectin levels);	chr15:45317575	chr15:45251580~45279251:-
OV	cis	rs801193	0.935	rs3800820	ENSG00000222364.1	RNU6-96P	8.89	1.89e-16	1.04e-12	0.53	0.51	Aortic root size;	chr7:66682191	chr7:66395191~66395286:+
OV	cis	rs801193	0.967	rs2707849	ENSG00000222364.1	RNU6-96P	-8.89	1.94e-16	1.06e-12	-0.52	-0.51	Aortic root size;	chr7:66687725	chr7:66395191~66395286:+
OV	cis	rs875971	0.666	rs13242072	ENSG00000226824.5	RP4-756H11.3	8.89	1.94e-16	1.06e-12	0.54	0.51	Aortic root size;	chr7:66301001	chr7:66654538~66669855:+
OV	cis	rs507080	0.922	rs558781	ENSG00000255422.1	AP002954.4	-8.89	1.95e-16	1.06e-12	-0.59	-0.51	Serum metabolite levels;	chr11:118693688	chr11:118704607~118750263:+
OV	cis	rs4423214	0.959	rs11606033	ENSG00000254682.1	RP11-660L16.2	8.89	1.95e-16	1.06e-12	0.6	0.51	Vitamin D levels;	chr11:71443158	chr11:71448674~71452157:+
OV	cis	rs4423214	1	rs1044482	ENSG00000254682.1	RP11-660L16.2	8.89	1.95e-16	1.06e-12	0.6	0.51	Vitamin D levels;	chr11:71444125	chr11:71448674~71452157:+
OV	cis	rs507080	0.922	rs625513	ENSG00000255422.1	AP002954.4	-8.89	1.95e-16	1.07e-12	-0.59	-0.51	Serum metabolite levels;	chr11:118685010	chr11:118704607~118750263:+
OV	cis	rs2729354	0.909	rs2729374	ENSG00000265566.2	RN7SL605P	-8.89	1.96e-16	1.07e-12	-0.79	-0.51	Blood protein levels;	chr11:57559454	chr11:57528085~57528365:-
OV	cis	rs875971	0.66	rs7807930	ENSG00000222364.1	RNU6-96P	8.89	1.97e-16	1.07e-12	0.52	0.51	Aortic root size;	chr7:66622178	chr7:66395191~66395286:+
OV	cis	rs875971	0.66	rs7807944	ENSG00000222364.1	RNU6-96P	8.89	1.97e-16	1.07e-12	0.52	0.51	Aortic root size;	chr7:66622208	chr7:66395191~66395286:+
OV	cis	rs7617773	0.963	rs12494304	ENSG00000229759.1	MRPS18AP1	-8.89	1.97e-16	1.07e-12	-0.54	-0.51	Coronary artery disease;	chr3:48136539	chr3:48256350~48256938:-
OV	cis	rs2836974	0.932	rs73221193	ENSG00000232608.1	TIMM9P2	-8.89	1.99e-16	1.09e-12	-0.58	-0.51	Cognitive function;	chr21:39182767	chr21:39216624~39217506:+
OV	cis	rs10256972	0.706	rs4285396	ENSG00000229043.2	AC091729.9	-8.88	2.01e-16	1.1e-12	-0.62	-0.51	Endometriosis;Longevity;	chr7:1084102	chr7:1160374~1165267:+
OV	cis	rs11235843	0.565	rs1723840	ENSG00000255928.1	RP11-456I15.2	8.88	2.04e-16	1.11e-12	0.7	0.51	Hand grip strength;	chr11:73762840	chr11:73722349~73722694:+
OV	cis	rs853679	0.527	rs853690	ENSG00000216901.1	AL022393.7	8.87	2.16e-16	1.18e-12	0.6	0.51	Depression;	chr6:28317705	chr6:28176188~28176674:+
OV	cis	rs853679	0.527	rs707907	ENSG00000216901.1	AL022393.7	8.87	2.16e-16	1.18e-12	0.6	0.51	Depression;	chr6:28323463	chr6:28176188~28176674:+
OV	cis	rs801193	0.935	rs2659916	ENSG00000222364.1	RNU6-96P	-8.87	2.16e-16	1.18e-12	-0.53	-0.51	Aortic root size;	chr7:66686365	chr7:66395191~66395286:+
OV	cis	rs4423214	0.592	rs10898191	ENSG00000254682.1	RP11-660L16.2	-8.87	2.19e-16	1.19e-12	-0.7	-0.51	Vitamin D levels;	chr11:71483555	chr11:71448674~71452157:+
OV	cis	rs9326248	0.53	rs10732856	ENSG00000254851.1	RP11-109L13.1	-8.87	2.24e-16	1.22e-12	-0.8	-0.51	Blood protein levels;	chr11:117036397	chr11:117135528~117138582:+
OV	cis	rs4423214	0.592	rs11234027	ENSG00000254682.1	RP11-660L16.2	-8.87	2.25e-16	1.22e-12	-0.72	-0.51	Vitamin D levels;	chr11:71523061	chr11:71448674~71452157:+
OV	cis	rs4423214	0.592	rs10898211	ENSG00000254682.1	RP11-660L16.2	-8.87	2.27e-16	1.23e-12	-0.72	-0.51	Vitamin D levels;	chr11:71499631	chr11:71448674~71452157:+
OV	cis	rs507080	0.845	rs667982	ENSG00000255422.1	AP002954.4	-8.87	2.28e-16	1.24e-12	-0.59	-0.51	Serum metabolite levels;	chr11:118692058	chr11:118704607~118750263:+
OV	cis	rs801193	1	rs2659915	ENSG00000222364.1	RNU6-96P	-8.86	2.29e-16	1.24e-12	-0.52	-0.51	Aortic root size;	chr7:66688114	chr7:66395191~66395286:+
OV	cis	rs801193	0.636	rs2659895	ENSG00000226824.5	RP4-756H11.3	-8.86	2.31e-16	1.25e-12	-0.54	-0.51	Aortic root size;	chr7:66731484	chr7:66654538~66669855:+
OV	cis	rs801193	0.591	rs2707839	ENSG00000226824.5	RP4-756H11.3	-8.86	2.32e-16	1.26e-12	-0.53	-0.51	Aortic root size;	chr7:66728097	chr7:66654538~66669855:+
OV	cis	rs6782228	0.876	rs34198449	ENSG00000277250.1	Metazoa_SRP	8.86	2.34e-16	1.27e-12	0.6	0.51	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128662427	chr3:128673681~128674021:-
OV	cis	rs2732480	0.538	rs1387260	ENSG00000258273.1	RP11-370I10.4	-8.86	2.35e-16	1.27e-12	-0.6	-0.51	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48309308	chr12:48333755~48333901:-
OV	cis	rs4423214	0.559	rs10898228	ENSG00000254682.1	RP11-660L16.2	-8.86	2.38e-16	1.29e-12	-0.71	-0.51	Vitamin D levels;	chr11:71517312	chr11:71448674~71452157:+
OV	cis	rs875971	1	rs937495	ENSG00000226824.5	RP4-756H11.3	8.86	2.39e-16	1.29e-12	0.53	0.51	Aortic root size;	chr7:66314811	chr7:66654538~66669855:+
OV	cis	rs875971	0.965	rs9969301	ENSG00000226824.5	RP4-756H11.3	8.86	2.39e-16	1.29e-12	0.53	0.51	Aortic root size;	chr7:66316668	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs2036264	ENSG00000226824.5	RP4-756H11.3	8.86	2.39e-16	1.29e-12	0.53	0.51	Aortic root size;	chr7:66334917	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs7783613	ENSG00000226824.5	RP4-756H11.3	8.86	2.39e-16	1.29e-12	0.53	0.51	Aortic root size;	chr7:66340274	chr7:66654538~66669855:+
OV	cis	rs507080	0.501	rs637563	ENSG00000255239.1	AP002954.6	8.86	2.44e-16	1.32e-12	0.59	0.51	Serum metabolite levels;	chr11:118704770	chr11:118688039~118690600:-
OV	cis	rs2729354	1	rs2649662	ENSG00000265566.2	RN7SL605P	8.85	2.51e-16	1.35e-12	0.74	0.51	Blood protein levels;	chr11:57585089	chr11:57528085~57528365:-
OV	cis	rs507080	0.922	rs514143	ENSG00000255422.1	AP002954.4	-8.84	2.64e-16	1.42e-12	-0.59	-0.51	Serum metabolite levels;	chr11:118687740	chr11:118704607~118750263:+
OV	cis	rs4853012	0.838	rs12619982	ENSG00000217702.2	RP11-287D1.4	8.84	2.67e-16	1.44e-12	0.79	0.51	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74130583~74135395:+
OV	cis	rs801193	1	rs6975195	ENSG00000222364.1	RNU6-96P	8.84	2.7e-16	1.45e-12	0.53	0.51	Aortic root size;	chr7:66659787	chr7:66395191~66395286:+
OV	cis	rs801193	1	rs3857688	ENSG00000222364.1	RNU6-96P	8.84	2.7e-16	1.45e-12	0.53	0.51	Aortic root size;	chr7:66662819	chr7:66395191~66395286:+
OV	cis	rs11603023	0.805	rs687190	ENSG00000255239.1	AP002954.6	8.84	2.72e-16	1.46e-12	0.56	0.51	Cholesterol, total;	chr11:118671674	chr11:118688039~118690600:-
OV	cis	rs11673344	0.642	rs12462708	ENSG00000226686.6	LINC01535	-8.84	2.75e-16	1.48e-12	-0.62	-0.51	Obesity-related traits;	chr19:37306676	chr19:37251912~37265535:+
OV	cis	rs4423214	0.547	rs11234030	ENSG00000254682.1	RP11-660L16.2	-8.83	2.79e-16	1.5e-12	-0.71	-0.51	Vitamin D levels;	chr11:71525921	chr11:71448674~71452157:+
OV	cis	rs3829251	0.786	rs7103591	ENSG00000254682.1	RP11-660L16.2	-8.83	2.79e-16	1.5e-12	-0.71	-0.51	Vitamin D levels;	chr11:71526573	chr11:71448674~71452157:+
OV	cis	rs4423214	0.592	rs7130829	ENSG00000254682.1	RP11-660L16.2	-8.83	2.79e-16	1.5e-12	-0.71	-0.51	Vitamin D levels;	chr11:71526656	chr11:71448674~71452157:+
OV	cis	rs17361889	0.766	rs17672493	ENSG00000224683.1	RPL36AP29	-8.83	2.82e-16	1.51e-12	-0.6	-0.51	Pediatric bone mineral content (hip);	chr7:16196559	chr7:16208945~16209265:+
OV	cis	rs801193	0.66	rs10950049	ENSG00000226824.5	RP4-756H11.3	-8.83	2.86e-16	1.53e-12	-0.53	-0.51	Aortic root size;	chr7:66765873	chr7:66654538~66669855:+
OV	cis	rs2836974	0.863	rs8132333	ENSG00000232608.1	TIMM9P2	-8.83	2.87e-16	1.54e-12	-0.58	-0.51	Cognitive function;	chr21:39155974	chr21:39216624~39217506:+
OV	cis	rs2836974	0.897	rs2836928	ENSG00000232608.1	TIMM9P2	-8.83	2.93e-16	1.57e-12	-0.58	-0.51	Cognitive function;	chr21:39171394	chr21:39216624~39217506:+
OV	cis	rs2836950	0.501	rs11702505	ENSG00000232608.1	TIMM9P2	8.83	2.97e-16	1.59e-12	0.58	0.51	Menarche (age at onset);	chr21:39328688	chr21:39216624~39217506:+
OV	cis	rs2836950	0.501	rs2836985	ENSG00000232608.1	TIMM9P2	8.83	2.97e-16	1.59e-12	0.58	0.51	Menarche (age at onset);	chr21:39329243	chr21:39216624~39217506:+
OV	cis	rs801193	0.967	rs2707841	ENSG00000222364.1	RNU6-96P	-8.83	2.98e-16	1.6e-12	-0.53	-0.51	Aortic root size;	chr7:66692033	chr7:66395191~66395286:+
OV	cis	rs801193	1	rs2659912	ENSG00000222364.1	RNU6-96P	-8.83	2.98e-16	1.6e-12	-0.53	-0.51	Aortic root size;	chr7:66693012	chr7:66395191~66395286:+
OV	cis	rs801193	1	rs2707836	ENSG00000222364.1	RNU6-96P	-8.83	2.98e-16	1.6e-12	-0.53	-0.51	Aortic root size;	chr7:66695448	chr7:66395191~66395286:+
OV	cis	rs801193	1	rs4717310	ENSG00000222364.1	RNU6-96P	-8.83	2.98e-16	1.6e-12	-0.53	-0.51	Aortic root size;	chr7:66696020	chr7:66395191~66395286:+
OV	cis	rs801193	0.844	rs7779971	ENSG00000222364.1	RNU6-96P	-8.83	2.98e-16	1.6e-12	-0.53	-0.51	Aortic root size;	chr7:66696803	chr7:66395191~66395286:+
OV	cis	rs494459	0.838	rs555649	ENSG00000255239.1	AP002954.6	8.82	3.04e-16	1.63e-12	0.58	0.51	Height;	chr11:118781100	chr11:118688039~118690600:-
OV	cis	rs875971	1	rs10215948	ENSG00000226824.5	RP4-756H11.3	8.82	3.09e-16	1.65e-12	0.53	0.51	Aortic root size;	chr7:66282799	chr7:66654538~66669855:+
OV	cis	rs875971	0.838	rs2173570	ENSG00000226824.5	RP4-756H11.3	8.82	3.09e-16	1.65e-12	0.53	0.51	Aortic root size;	chr7:66297976	chr7:66654538~66669855:+
OV	cis	rs875971	0.964	rs55748098	ENSG00000226824.5	RP4-756H11.3	8.82	3.09e-16	1.65e-12	0.53	0.51	Aortic root size;	chr7:66298631	chr7:66654538~66669855:+
OV	cis	rs2836974	0.831	rs34294410	ENSG00000232608.1	TIMM9P2	-8.82	3.09e-16	1.65e-12	-0.58	-0.51	Cognitive function;	chr21:39183234	chr21:39216624~39217506:+
OV	cis	rs7617773	0.963	rs6800730	ENSG00000229759.1	MRPS18AP1	8.82	3.14e-16	1.68e-12	0.57	0.51	Coronary artery disease;	chr3:48132720	chr3:48256350~48256938:-
OV	cis	rs875971	0.964	rs60193905	ENSG00000226824.5	RP4-756H11.3	-8.81	3.22e-16	1.71e-12	-0.53	-0.5	Aortic root size;	chr7:66506273	chr7:66654538~66669855:+
OV	cis	rs853679	0.527	rs1997660	ENSG00000216901.1	AL022393.7	8.81	3.23e-16	1.72e-12	0.6	0.5	Depression;	chr6:28301886	chr6:28176188~28176674:+
OV	cis	rs853679	0.527	rs9468333	ENSG00000216901.1	AL022393.7	8.81	3.23e-16	1.72e-12	0.6	0.5	Depression;	chr6:28303421	chr6:28176188~28176674:+
OV	cis	rs9326248	0.53	rs588918	ENSG00000254851.1	RP11-109L13.1	-8.81	3.24e-16	1.73e-12	-0.81	-0.5	Blood protein levels;	chr11:116985926	chr11:117135528~117138582:+
OV	cis	rs8040855	0.599	rs6496791	ENSG00000259295.5	CSPG4P12	-8.81	3.3e-16	1.76e-12	-0.61	-0.5	Bulimia nervosa;	chr15:85182428	chr15:85191438~85213905:+
OV	cis	rs2836950	0.545	rs8132143	ENSG00000232608.1	TIMM9P2	8.81	3.37e-16	1.79e-12	0.56	0.5	Menarche (age at onset);	chr21:39212332	chr21:39216624~39217506:+
OV	cis	rs875971	1	rs778726	ENSG00000226824.5	RP4-756H11.3	-8.81	3.38e-16	1.79e-12	-0.53	-0.5	Aortic root size;	chr7:66363744	chr7:66654538~66669855:+
OV	cis	rs875971	0.964	rs778723	ENSG00000226824.5	RP4-756H11.3	-8.81	3.38e-16	1.79e-12	-0.53	-0.5	Aortic root size;	chr7:66364510	chr7:66654538~66669855:+
OV	cis	rs875971	0.767	rs1695815	ENSG00000226824.5	RP4-756H11.3	-8.81	3.38e-16	1.79e-12	-0.53	-0.5	Aortic root size;	chr7:66366357	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs778685	ENSG00000226824.5	RP4-756H11.3	-8.81	3.38e-16	1.79e-12	-0.53	-0.5	Aortic root size;	chr7:66371189	chr7:66654538~66669855:+
OV	cis	rs875971	0.929	rs778682	ENSG00000226824.5	RP4-756H11.3	-8.81	3.38e-16	1.79e-12	-0.53	-0.5	Aortic root size;	chr7:66372947	chr7:66654538~66669855:+
OV	cis	rs875971	0.964	rs11765965	ENSG00000226824.5	RP4-756H11.3	-8.81	3.38e-16	1.79e-12	-0.53	-0.5	Aortic root size;	chr7:66377234	chr7:66654538~66669855:+
OV	cis	rs875971	0.964	rs1643388	ENSG00000226824.5	RP4-756H11.3	-8.81	3.38e-16	1.79e-12	-0.53	-0.5	Aortic root size;	chr7:66379575	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs778722	ENSG00000226824.5	RP4-756H11.3	-8.81	3.38e-16	1.79e-12	-0.53	-0.5	Aortic root size;	chr7:66379841	chr7:66654538~66669855:+
OV	cis	rs875971	0.964	rs778721	ENSG00000226824.5	RP4-756H11.3	-8.81	3.38e-16	1.79e-12	-0.53	-0.5	Aortic root size;	chr7:66380410	chr7:66654538~66669855:+
OV	cis	rs875971	0.929	rs778712	ENSG00000226824.5	RP4-756H11.3	-8.81	3.38e-16	1.79e-12	-0.53	-0.5	Aortic root size;	chr7:66384991	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs778710	ENSG00000226824.5	RP4-756H11.3	-8.81	3.38e-16	1.79e-12	-0.53	-0.5	Aortic root size;	chr7:66389847	chr7:66654538~66669855:+
OV	cis	rs875971	0.964	rs778708	ENSG00000226824.5	RP4-756H11.3	-8.81	3.38e-16	1.79e-12	-0.53	-0.5	Aortic root size;	chr7:66391332	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs778706	ENSG00000226824.5	RP4-756H11.3	-8.81	3.38e-16	1.79e-12	-0.53	-0.5	Aortic root size;	chr7:66395437	chr7:66654538~66669855:+
OV	cis	rs875971	0.895	rs778700	ENSG00000226824.5	RP4-756H11.3	-8.81	3.38e-16	1.79e-12	-0.53	-0.5	Aortic root size;	chr7:66401463	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs778699	ENSG00000226824.5	RP4-756H11.3	-8.81	3.38e-16	1.79e-12	-0.53	-0.5	Aortic root size;	chr7:66403303	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs778696	ENSG00000226824.5	RP4-756H11.3	-8.81	3.38e-16	1.79e-12	-0.53	-0.5	Aortic root size;	chr7:66405826	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs778694	ENSG00000226824.5	RP4-756H11.3	-8.81	3.38e-16	1.79e-12	-0.53	-0.5	Aortic root size;	chr7:66406571	chr7:66654538~66669855:+
OV	cis	rs875971	0.929	rs778692	ENSG00000226824.5	RP4-756H11.3	-8.81	3.38e-16	1.79e-12	-0.53	-0.5	Aortic root size;	chr7:66407462	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs4718343	ENSG00000226824.5	RP4-756H11.3	-8.81	3.38e-16	1.79e-12	-0.53	-0.5	Aortic root size;	chr7:66409301	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs4718344	ENSG00000226824.5	RP4-756H11.3	-8.81	3.38e-16	1.79e-12	-0.53	-0.5	Aortic root size;	chr7:66409394	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs1968225	ENSG00000226824.5	RP4-756H11.3	-8.81	3.38e-16	1.79e-12	-0.53	-0.5	Aortic root size;	chr7:66409786	chr7:66654538~66669855:+
OV	cis	rs875971	0.737	rs7803424	ENSG00000226824.5	RP4-756H11.3	-8.81	3.38e-16	1.79e-12	-0.53	-0.5	Aortic root size;	chr7:66415618	chr7:66654538~66669855:+
OV	cis	rs875971	0.83	rs7799834	ENSG00000226824.5	RP4-756H11.3	-8.81	3.38e-16	1.79e-12	-0.53	-0.5	Aortic root size;	chr7:66415707	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs6460295	ENSG00000226824.5	RP4-756H11.3	-8.81	3.38e-16	1.79e-12	-0.53	-0.5	Aortic root size;	chr7:66417741	chr7:66654538~66669855:+
OV	cis	rs875971	0.964	rs6978721	ENSG00000226824.5	RP4-756H11.3	-8.81	3.38e-16	1.79e-12	-0.53	-0.5	Aortic root size;	chr7:66418217	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs6979382	ENSG00000226824.5	RP4-756H11.3	-8.81	3.38e-16	1.79e-12	-0.53	-0.5	Aortic root size;	chr7:66421388	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs6961990	ENSG00000226824.5	RP4-756H11.3	-8.81	3.38e-16	1.79e-12	-0.53	-0.5	Aortic root size;	chr7:66423583	chr7:66654538~66669855:+
OV	cis	rs2658782	0.789	rs2605580	ENSG00000279684.1	RP11-755E23.2	-8.81	3.39e-16	1.79e-12	-0.68	-0.5	Pulmonary function decline;	chr11:93413888	chr11:93286629~93288903:-
OV	cis	rs801193	1	rs13239306	ENSG00000222364.1	RNU6-96P	8.81	3.41e-16	1.8e-12	0.54	0.5	Aortic root size;	chr7:66671030	chr7:66395191~66395286:+
OV	cis	rs494459	0.964	rs576283	ENSG00000255239.1	AP002954.6	8.8	3.46e-16	1.83e-12	0.59	0.5	Height;	chr11:118703185	chr11:118688039~118690600:-
OV	cis	rs494459	0.929	rs627391	ENSG00000255239.1	AP002954.6	8.8	3.46e-16	1.83e-12	0.59	0.5	Height;	chr11:118703207	chr11:118688039~118690600:-
OV	cis	rs507080	0.524	rs524409	ENSG00000255239.1	AP002954.6	8.8	3.46e-16	1.83e-12	0.59	0.5	Serum metabolite levels;	chr11:118703602	chr11:118688039~118690600:-
OV	cis	rs2836974	0.932	rs13048178	ENSG00000232608.1	TIMM9P2	-8.8	3.52e-16	1.85e-12	-0.58	-0.5	Cognitive function;	chr21:39189086	chr21:39216624~39217506:+
OV	cis	rs801193	1	rs2003301	ENSG00000222364.1	RNU6-96P	8.8	3.58e-16	1.88e-12	0.52	0.5	Aortic root size;	chr7:66682669	chr7:66395191~66395286:+
OV	cis	rs1150668	0.796	rs9468372	ENSG00000216901.1	AL022393.7	8.8	3.62e-16	1.9e-12	0.57	0.5	Pubertal anthropometrics;	chr6:28411584	chr6:28176188~28176674:+
OV	cis	rs507080	0.961	rs642497	ENSG00000255422.1	AP002954.4	-8.79	3.68e-16	1.93e-12	-0.58	-0.5	Serum metabolite levels;	chr11:118680075	chr11:118704607~118750263:+
OV	cis	rs7246967	0.611	rs2617780	ENSG00000269509.1	BNIP3P34	8.79	3.68e-16	1.93e-12	0.88	0.5	Bronchopulmonary dysplasia;	chr19:22809388	chr19:22773853~22774424:+
OV	cis	rs507080	0.501	rs625735	ENSG00000255239.1	AP002954.6	8.79	3.68e-16	1.93e-12	0.58	0.5	Serum metabolite levels;	chr11:118704710	chr11:118688039~118690600:-
OV	cis	rs17361889	0.752	rs1918266	ENSG00000224683.1	RPL36AP29	-8.79	3.69e-16	1.93e-12	-0.58	-0.5	Pediatric bone mineral content (hip);	chr7:16231996	chr7:16208945~16209265:+
OV	cis	rs2836974	0.965	rs2836965	ENSG00000232608.1	TIMM9P2	8.79	3.72e-16	1.95e-12	0.57	0.5	Cognitive function;	chr21:39261705	chr21:39216624~39217506:+
OV	cis	rs875971	0.965	rs28682868	ENSG00000226824.5	RP4-756H11.3	8.79	3.73e-16	1.96e-12	0.53	0.5	Aortic root size;	chr7:66224822	chr7:66654538~66669855:+
OV	cis	rs2836950	0.502	rs2150411	ENSG00000232608.1	TIMM9P2	8.79	3.73e-16	1.96e-12	0.56	0.5	Menarche (age at onset);	chr21:39202626	chr21:39216624~39217506:+
OV	cis	rs507080	0.922	rs478371	ENSG00000255422.1	AP002954.4	-8.79	3.74e-16	1.96e-12	-0.59	-0.5	Serum metabolite levels;	chr11:118694627	chr11:118704607~118750263:+
OV	cis	rs507080	0.922	rs4589335	ENSG00000255422.1	AP002954.4	-8.79	3.75e-16	1.96e-12	-0.58	-0.5	Serum metabolite levels;	chr11:118668431	chr11:118704607~118750263:+
OV	cis	rs2836950	0.509	rs11088466	ENSG00000232608.1	TIMM9P2	8.79	3.75e-16	1.97e-12	0.55	0.5	Menarche (age at onset);	chr21:39208091	chr21:39216624~39217506:+
OV	cis	rs11235843	0.636	rs10736793	ENSG00000255928.1	RP11-456I15.2	-8.79	3.79e-16	1.98e-12	-0.7	-0.5	Hand grip strength;	chr11:73691531	chr11:73722349~73722694:+
OV	cis	rs11235843	0.636	rs1464908	ENSG00000255928.1	RP11-456I15.2	-8.79	3.79e-16	1.98e-12	-0.7	-0.5	Hand grip strength;	chr11:73691634	chr11:73722349~73722694:+
OV	cis	rs2836950	0.565	rs7276046	ENSG00000232608.1	TIMM9P2	8.79	3.8e-16	1.99e-12	0.56	0.5	Menarche (age at onset);	chr21:39209367	chr21:39216624~39217506:+
OV	cis	rs2729354	1	rs2511983	ENSG00000265566.2	RN7SL605P	-8.79	3.83e-16	2e-12	-0.77	-0.5	Blood protein levels;	chr11:57579401	chr11:57528085~57528365:-
OV	cis	rs6782228	1	rs6782407	ENSG00000277250.1	Metazoa_SRP	8.79	3.84e-16	2.01e-12	0.61	0.5	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128619905	chr3:128673681~128674021:-
OV	cis	rs875971	0.66	rs2191268	ENSG00000222364.1	RNU6-96P	-8.79	3.85e-16	2.01e-12	-0.51	-0.5	Aortic root size;	chr7:66645237	chr7:66395191~66395286:+
OV	cis	rs10262624	0.504	rs4722255	ENSG00000234286.1	AC006026.13	-8.79	3.86e-16	2.01e-12	-0.57	-0.5	Schizophrenia;	chr7:23706453	chr7:23680195~23680786:-
OV	cis	rs2836950	0.545	rs4818001	ENSG00000232608.1	TIMM9P2	8.79	3.86e-16	2.01e-12	0.56	0.5	Menarche (age at onset);	chr21:39203162	chr21:39216624~39217506:+
OV	cis	rs2836974	0.897	rs1571709	ENSG00000232608.1	TIMM9P2	-8.79	3.87e-16	2.02e-12	-0.58	-0.5	Cognitive function;	chr21:39182054	chr21:39216624~39217506:+
OV	cis	rs801193	1	rs10252765	ENSG00000222364.1	RNU6-96P	-8.78	3.94e-16	2.06e-12	-0.53	-0.5	Aortic root size;	chr7:66763745	chr7:66395191~66395286:+
OV	cis	rs801193	1	rs6975195	ENSG00000226824.5	RP4-756H11.3	8.78	4.03e-16	2.1e-12	0.54	0.5	Aortic root size;	chr7:66659787	chr7:66654538~66669855:+
OV	cis	rs801193	1	rs3857688	ENSG00000226824.5	RP4-756H11.3	8.78	4.03e-16	2.1e-12	0.54	0.5	Aortic root size;	chr7:66662819	chr7:66654538~66669855:+
OV	cis	rs875971	0.66	rs2013222	ENSG00000222364.1	RNU6-96P	8.78	4.16e-16	2.16e-12	0.52	0.5	Aortic root size;	chr7:66570949	chr7:66395191~66395286:+
OV	cis	rs875971	0.965	rs6971509	ENSG00000226824.5	RP4-756H11.3	8.77	4.19e-16	2.18e-12	0.53	0.5	Aortic root size;	chr7:66249983	chr7:66654538~66669855:+
OV	cis	rs2581828	0.646	rs2564923	ENSG00000242142.1	SERBP1P3	8.77	4.38e-16	2.26e-12	0.55	0.5	Crohn's disease;	chr3:53069246	chr3:53064283~53065091:-
OV	cis	rs2836950	0.545	rs2836922	ENSG00000232608.1	TIMM9P2	8.77	4.39e-16	2.27e-12	0.57	0.5	Menarche (age at onset);	chr21:39144382	chr21:39216624~39217506:+
OV	cis	rs2836974	0.897	rs13052882	ENSG00000232608.1	TIMM9P2	-8.76	4.46e-16	2.3e-12	-0.58	-0.5	Cognitive function;	chr21:39183425	chr21:39216624~39217506:+
OV	cis	rs875971	0.66	rs801217	ENSG00000222364.1	RNU6-96P	8.76	4.48e-16	2.3e-12	0.52	0.5	Aortic root size;	chr7:66545590	chr7:66395191~66395286:+
OV	cis	rs875971	0.638	rs801216	ENSG00000222364.1	RNU6-96P	8.76	4.48e-16	2.3e-12	0.52	0.5	Aortic root size;	chr7:66546680	chr7:66395191~66395286:+
OV	cis	rs875971	0.66	rs801211	ENSG00000222364.1	RNU6-96P	8.76	4.48e-16	2.3e-12	0.52	0.5	Aortic root size;	chr7:66550702	chr7:66395191~66395286:+
OV	cis	rs875971	0.638	rs801205	ENSG00000222364.1	RNU6-96P	8.76	4.48e-16	2.3e-12	0.52	0.5	Aortic root size;	chr7:66557157	chr7:66395191~66395286:+
OV	cis	rs875971	0.617	rs810400	ENSG00000222364.1	RNU6-96P	8.76	4.48e-16	2.3e-12	0.52	0.5	Aortic root size;	chr7:66557902	chr7:66395191~66395286:+
OV	cis	rs875971	0.66	rs801192	ENSG00000222364.1	RNU6-96P	8.76	4.48e-16	2.3e-12	0.52	0.5	Aortic root size;	chr7:66566965	chr7:66395191~66395286:+
OV	cis	rs875971	0.66	rs801190	ENSG00000222364.1	RNU6-96P	8.76	4.48e-16	2.3e-12	0.52	0.5	Aortic root size;	chr7:66568046	chr7:66395191~66395286:+
OV	cis	rs875971	0.66	rs3857686	ENSG00000222364.1	RNU6-96P	8.76	4.48e-16	2.3e-12	0.52	0.5	Aortic root size;	chr7:66571204	chr7:66395191~66395286:+
OV	cis	rs875971	0.638	rs3898855	ENSG00000222364.1	RNU6-96P	8.76	4.48e-16	2.3e-12	0.52	0.5	Aortic root size;	chr7:66571411	chr7:66395191~66395286:+
OV	cis	rs875971	0.638	rs10278816	ENSG00000222364.1	RNU6-96P	8.76	4.48e-16	2.3e-12	0.52	0.5	Aortic root size;	chr7:66572000	chr7:66395191~66395286:+
OV	cis	rs875971	0.66	rs10281080	ENSG00000222364.1	RNU6-96P	8.76	4.48e-16	2.3e-12	0.52	0.5	Aortic root size;	chr7:66577454	chr7:66395191~66395286:+
OV	cis	rs875971	0.66	rs10950044	ENSG00000222364.1	RNU6-96P	8.76	4.48e-16	2.3e-12	0.52	0.5	Aortic root size;	chr7:66577989	chr7:66395191~66395286:+
OV	cis	rs875971	0.638	rs10249404	ENSG00000222364.1	RNU6-96P	8.76	4.48e-16	2.3e-12	0.52	0.5	Aortic root size;	chr7:66581737	chr7:66395191~66395286:+
OV	cis	rs875971	0.66	rs10215132	ENSG00000222364.1	RNU6-96P	8.76	4.48e-16	2.3e-12	0.52	0.5	Aortic root size;	chr7:66589419	chr7:66395191~66395286:+
OV	cis	rs875971	0.522	rs1968127	ENSG00000222364.1	RNU6-96P	8.76	4.48e-16	2.3e-12	0.52	0.5	Aortic root size;	chr7:66591816	chr7:66395191~66395286:+
OV	cis	rs875971	0.638	rs6460305	ENSG00000222364.1	RNU6-96P	8.76	4.48e-16	2.3e-12	0.52	0.5	Aortic root size;	chr7:66595421	chr7:66395191~66395286:+
OV	cis	rs875971	0.66	rs10272357	ENSG00000222364.1	RNU6-96P	8.76	4.48e-16	2.3e-12	0.52	0.5	Aortic root size;	chr7:66598087	chr7:66395191~66395286:+
OV	cis	rs875971	0.66	rs28698552	ENSG00000222364.1	RNU6-96P	-8.76	4.48e-16	2.3e-12	-0.52	-0.5	Aortic root size;	chr7:66540031	chr7:66395191~66395286:+
OV	cis	rs875971	0.66	rs62465434	ENSG00000222364.1	RNU6-96P	-8.76	4.48e-16	2.3e-12	-0.52	-0.5	Aortic root size;	chr7:66540165	chr7:66395191~66395286:+
OV	cis	rs875971	0.66	rs13224319	ENSG00000222364.1	RNU6-96P	-8.76	4.48e-16	2.3e-12	-0.52	-0.5	Aortic root size;	chr7:66542376	chr7:66395191~66395286:+
OV	cis	rs875971	0.619	rs12533585	ENSG00000222364.1	RNU6-96P	-8.76	4.51e-16	2.31e-12	-0.52	-0.5	Aortic root size;	chr7:66519618	chr7:66395191~66395286:+
OV	cis	rs4853012	0.838	rs72915068	ENSG00000217702.2	RP11-287D1.4	8.76	4.51e-16	2.31e-12	0.77	0.5	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74130583~74135395:+
OV	cis	rs2836974	0.836	rs1041440	ENSG00000232608.1	TIMM9P2	-8.76	4.56e-16	2.34e-12	-0.58	-0.5	Cognitive function;	chr21:39255399	chr21:39216624~39217506:+
OV	cis	rs4853012	0.838	rs4452177	ENSG00000217702.2	RP11-287D1.4	8.76	4.62e-16	2.37e-12	0.77	0.5	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74130583~74135395:+
OV	cis	rs801193	0.761	rs2659888	ENSG00000226824.5	RP4-756H11.3	-8.76	4.73e-16	2.42e-12	-0.54	-0.5	Aortic root size;	chr7:66765184	chr7:66654538~66669855:+
OV	cis	rs2836950	0.501	rs2836984	ENSG00000232608.1	TIMM9P2	8.75	4.78e-16	2.45e-12	0.57	0.5	Menarche (age at onset);	chr21:39329023	chr21:39216624~39217506:+
OV	cis	rs2836974	0.932	rs11910151	ENSG00000232608.1	TIMM9P2	-8.75	4.79e-16	2.45e-12	-0.57	-0.5	Cognitive function;	chr21:39188336	chr21:39216624~39217506:+
OV	cis	rs875971	0.558	rs4433015	ENSG00000226824.5	RP4-756H11.3	8.75	4.8e-16	2.45e-12	0.52	0.5	Aortic root size;	chr7:66174736	chr7:66654538~66669855:+
OV	cis	rs2836950	0.501	rs2056844	ENSG00000232608.1	TIMM9P2	8.75	4.83e-16	2.47e-12	0.55	0.5	Menarche (age at onset);	chr21:39298534	chr21:39216624~39217506:+
OV	cis	rs875971	0.619	rs10278371	ENSG00000222364.1	RNU6-96P	8.75	4.85e-16	2.48e-12	0.52	0.5	Aortic root size;	chr7:66586553	chr7:66395191~66395286:+
OV	cis	rs6782228	1	rs12635488	ENSG00000242551.2	POU5F1P6	8.75	4.86e-16	2.49e-12	0.61	0.5	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128633535	chr3:128674735~128677005:-
OV	cis	rs875971	0.66	rs79009421	ENSG00000222364.1	RNU6-96P	8.75	4.89e-16	2.5e-12	0.52	0.5	Aortic root size;	chr7:66603522	chr7:66395191~66395286:+
OV	cis	rs875971	0.66	rs6460308	ENSG00000222364.1	RNU6-96P	8.75	4.89e-16	2.5e-12	0.52	0.5	Aortic root size;	chr7:66619753	chr7:66395191~66395286:+
OV	cis	rs9368481	0.729	rs9379948	ENSG00000243307.2	POM121L6P	8.75	4.9e-16	2.5e-12	0.49	0.5	Autism spectrum disorder or schizophrenia;	chr6:26977004	chr6:26896952~26898777:+
OV	cis	rs2836974	0.932	rs2150415	ENSG00000232608.1	TIMM9P2	-8.75	4.9e-16	2.5e-12	-0.57	-0.5	Cognitive function;	chr21:39243441	chr21:39216624~39217506:+
OV	cis	rs2836974	0.836	rs8129355	ENSG00000232608.1	TIMM9P2	-8.75	4.95e-16	2.52e-12	-0.57	-0.5	Cognitive function;	chr21:39207943	chr21:39216624~39217506:+
OV	cis	rs2836974	0.899	rs34978594	ENSG00000232608.1	TIMM9P2	-8.75	4.95e-16	2.52e-12	-0.57	-0.5	Cognitive function;	chr21:39208077	chr21:39216624~39217506:+
OV	cis	rs875971	0.898	rs6977501	ENSG00000226824.5	RP4-756H11.3	8.75	4.97e-16	2.53e-12	0.53	0.5	Aortic root size;	chr7:66228355	chr7:66654538~66669855:+
OV	cis	rs1577917	0.545	rs9294338	ENSG00000203875.9	SNHG5	8.75	4.97e-16	2.53e-12	0.58	0.5	Response to antipsychotic treatment;	chr6:85764650	chr6:85660950~85678736:-
OV	cis	rs801193	1	rs62466793	ENSG00000222364.1	RNU6-96P	-8.75	4.99e-16	2.54e-12	-0.53	-0.5	Aortic root size;	chr7:66726530	chr7:66395191~66395286:+
OV	cis	rs801193	1	rs62466794	ENSG00000222364.1	RNU6-96P	-8.75	4.99e-16	2.54e-12	-0.53	-0.5	Aortic root size;	chr7:66726592	chr7:66395191~66395286:+
OV	cis	rs2836950	0.565	rs7278297	ENSG00000232608.1	TIMM9P2	8.75	5.06e-16	2.58e-12	0.55	0.5	Menarche (age at onset);	chr21:39253826	chr21:39216624~39217506:+
OV	cis	rs8105895	0.935	rs8108976	ENSG00000269742.1	BNIP3P29	8.74	5.1e-16	2.59e-12	0.75	0.5	Body mass index (change over time);	chr19:22068899	chr19:22065828~22066398:-
OV	cis	rs801193	1	rs2659909	ENSG00000222364.1	RNU6-96P	-8.74	5.11e-16	2.6e-12	-0.52	-0.5	Aortic root size;	chr7:66695292	chr7:66395191~66395286:+
OV	cis	rs4423214	0.592	rs10898193	ENSG00000254682.1	RP11-660L16.2	8.74	5.13e-16	2.61e-12	0.67	0.5	Vitamin D levels;	chr11:71486037	chr11:71448674~71452157:+
OV	cis	rs2658782	0.704	rs2605614	ENSG00000279684.1	RP11-755E23.2	-8.74	5.35e-16	2.72e-12	-0.7	-0.5	Pulmonary function decline;	chr11:93499579	chr11:93286629~93288903:-
OV	cis	rs2658782	0.615	rs2605615	ENSG00000279684.1	RP11-755E23.2	-8.74	5.35e-16	2.72e-12	-0.7	-0.5	Pulmonary function decline;	chr11:93499902	chr11:93286629~93288903:-
OV	cis	rs9368481	0.645	rs10456350	ENSG00000243307.2	POM121L6P	8.74	5.36e-16	2.72e-12	0.49	0.5	Autism spectrum disorder or schizophrenia;	chr6:27007802	chr6:26896952~26898777:+
OV	cis	rs2836974	0.932	rs6517526	ENSG00000232608.1	TIMM9P2	-8.74	5.37e-16	2.73e-12	-0.57	-0.5	Cognitive function;	chr21:39209604	chr21:39216624~39217506:+
OV	cis	rs6964833	1	rs4717906	ENSG00000123965.13	PMS2P5	8.73	5.45e-16	2.76e-12	0.73	0.5	Menarche (age at onset);	chr7:74671923	chr7:74894116~74897835:+
OV	cis	rs875971	1	rs9986696	ENSG00000226824.5	RP4-756H11.3	8.73	5.5e-16	2.79e-12	0.53	0.5	Aortic root size;	chr7:66239589	chr7:66654538~66669855:+
OV	cis	rs2732480	0.577	rs2732457	ENSG00000258273.1	RP11-370I10.4	8.73	5.51e-16	2.79e-12	0.58	0.5	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48364596	chr12:48333755~48333901:-
OV	cis	rs2836950	0.545	rs11701805	ENSG00000232608.1	TIMM9P2	8.73	5.52e-16	2.8e-12	0.55	0.5	Menarche (age at onset);	chr21:39246757	chr21:39216624~39217506:+
OV	cis	rs4713118	0.505	rs276371	ENSG00000216901.1	AL022393.7	8.73	5.52e-16	2.8e-12	0.56	0.5	Parkinson's disease;	chr6:27942930	chr6:28176188~28176674:+
OV	cis	rs2836974	0.897	rs35064900	ENSG00000232608.1	TIMM9P2	-8.73	5.53e-16	2.8e-12	-0.57	-0.5	Cognitive function;	chr21:39183566	chr21:39216624~39217506:+
OV	cis	rs2836974	0.897	rs36113648	ENSG00000232608.1	TIMM9P2	-8.73	5.53e-16	2.8e-12	-0.57	-0.5	Cognitive function;	chr21:39183571	chr21:39216624~39217506:+
OV	cis	rs7617773	0.925	rs7374376	ENSG00000229759.1	MRPS18AP1	-8.73	5.65e-16	2.85e-12	-0.54	-0.5	Coronary artery disease;	chr3:48131197	chr3:48256350~48256938:-
OV	cis	rs801193	0.967	rs34356500	ENSG00000222364.1	RNU6-96P	-8.73	5.67e-16	2.86e-12	-0.53	-0.5	Aortic root size;	chr7:66771620	chr7:66395191~66395286:+
OV	cis	rs875971	0.66	rs2013222	ENSG00000226824.5	RP4-756H11.3	8.73	5.69e-16	2.87e-12	0.53	0.5	Aortic root size;	chr7:66570949	chr7:66654538~66669855:+
OV	cis	rs2836974	0.932	rs6517523	ENSG00000232608.1	TIMM9P2	-8.73	5.73e-16	2.89e-12	-0.57	-0.5	Cognitive function;	chr21:39185406	chr21:39216624~39217506:+
OV	cis	rs853679	0.506	rs1150711	ENSG00000216901.1	AL022393.7	8.73	5.75e-16	2.9e-12	0.59	0.5	Depression;	chr6:28240757	chr6:28176188~28176674:+
OV	cis	rs801193	0.904	rs4718405	ENSG00000222364.1	RNU6-96P	-8.73	5.76e-16	2.91e-12	-0.52	-0.5	Aortic root size;	chr7:66789659	chr7:66395191~66395286:+
OV	cis	rs801193	1	rs2659906	ENSG00000222364.1	RNU6-96P	-8.72	5.85e-16	2.95e-12	-0.52	-0.5	Aortic root size;	chr7:66700323	chr7:66395191~66395286:+
OV	cis	rs801193	0.935	rs2659899	ENSG00000222364.1	RNU6-96P	-8.72	5.85e-16	2.95e-12	-0.52	-0.5	Aortic root size;	chr7:66721734	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs6946143	ENSG00000226824.5	RP4-756H11.3	-8.72	5.88e-16	2.96e-12	-0.52	-0.5	Aortic root size;	chr7:66114735	chr7:66654538~66669855:+
OV	cis	rs801193	0.935	rs11772264	ENSG00000222364.1	RNU6-96P	-8.72	5.88e-16	2.96e-12	-0.53	-0.5	Aortic root size;	chr7:66711400	chr7:66395191~66395286:+
OV	cis	rs801193	1	rs7782320	ENSG00000222364.1	RNU6-96P	-8.72	5.88e-16	2.96e-12	-0.53	-0.5	Aortic root size;	chr7:66712111	chr7:66395191~66395286:+
OV	cis	rs17361889	0.633	rs17359183	ENSG00000224683.1	RPL36AP29	8.72	5.92e-16	2.98e-12	0.6	0.5	Pediatric bone mineral content (hip);	chr7:16123149	chr7:16208945~16209265:+
OV	cis	rs17361889	0.711	rs17359294	ENSG00000224683.1	RPL36AP29	8.72	5.92e-16	2.98e-12	0.6	0.5	Pediatric bone mineral content (hip);	chr7:16124889	chr7:16208945~16209265:+
OV	cis	rs4853012	0.838	rs60705299	ENSG00000217702.2	RP11-287D1.4	8.72	5.97e-16	3e-12	0.76	0.5	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74130583~74135395:+
OV	cis	rs8040855	0.599	rs6496800	ENSG00000259295.5	CSPG4P12	-8.72	6.02e-16	3.03e-12	-0.6	-0.5	Bulimia nervosa;	chr15:85185055	chr15:85191438~85213905:+
OV	cis	rs507080	0.961	rs673770	ENSG00000255422.1	AP002954.4	-8.72	6.09e-16	3.06e-12	-0.58	-0.5	Serum metabolite levels;	chr11:118679892	chr11:118704607~118750263:+
OV	cis	rs507080	0.922	rs12788848	ENSG00000255422.1	AP002954.4	-8.72	6.12e-16	3.07e-12	-0.58	-0.5	Serum metabolite levels;	chr11:118683079	chr11:118704607~118750263:+
OV	cis	rs507080	0.922	rs4474473	ENSG00000255422.1	AP002954.4	-8.72	6.12e-16	3.07e-12	-0.58	-0.5	Serum metabolite levels;	chr11:118683180	chr11:118704607~118750263:+
OV	cis	rs507080	0.922	rs12796373	ENSG00000255422.1	AP002954.4	-8.72	6.12e-16	3.07e-12	-0.58	-0.5	Serum metabolite levels;	chr11:118684230	chr11:118704607~118750263:+
OV	cis	rs801193	1	rs4717319	ENSG00000226824.5	RP4-756H11.3	-8.72	6.12e-16	3.07e-12	-0.53	-0.5	Aortic root size;	chr7:66777606	chr7:66654538~66669855:+
OV	cis	rs801193	0.904	rs4718403	ENSG00000226824.5	RP4-756H11.3	-8.72	6.12e-16	3.07e-12	-0.53	-0.5	Aortic root size;	chr7:66777742	chr7:66654538~66669855:+
OV	cis	rs2836950	0.565	rs2150413	ENSG00000232608.1	TIMM9P2	8.72	6.17e-16	3.09e-12	0.56	0.5	Menarche (age at onset);	chr21:39242952	chr21:39216624~39217506:+
OV	cis	rs2836974	0.932	rs8128734	ENSG00000232608.1	TIMM9P2	-8.71	6.2e-16	3.11e-12	-0.57	-0.5	Cognitive function;	chr21:39197585	chr21:39216624~39217506:+
OV	cis	rs2836974	0.932	rs2234543	ENSG00000232608.1	TIMM9P2	-8.71	6.2e-16	3.11e-12	-0.57	-0.5	Cognitive function;	chr21:39200146	chr21:39216624~39217506:+
OV	cis	rs2836974	0.899	rs2836938	ENSG00000232608.1	TIMM9P2	-8.71	6.2e-16	3.11e-12	-0.57	-0.5	Cognitive function;	chr21:39202265	chr21:39216624~39217506:+
OV	cis	rs875971	0.638	rs7793569	ENSG00000222364.1	RNU6-96P	8.71	6.29e-16	3.15e-12	0.52	0.5	Aortic root size;	chr7:66651646	chr7:66395191~66395286:+
OV	cis	rs17361889	0.685	rs111795100	ENSG00000224683.1	RPL36AP29	8.71	6.36e-16	3.19e-12	0.6	0.5	Pediatric bone mineral content (hip);	chr7:16112093	chr7:16208945~16209265:+
OV	cis	rs801193	1	rs3778909	ENSG00000226824.5	RP4-756H11.3	-8.71	6.4e-16	3.2e-12	-0.53	-0.5	Aortic root size;	chr7:66790659	chr7:66654538~66669855:+
OV	cis	rs801193	1	rs2707845	ENSG00000226824.5	RP4-756H11.3	-8.71	6.4e-16	3.2e-12	-0.54	-0.5	Aortic root size;	chr7:66733811	chr7:66654538~66669855:+
OV	cis	rs4423214	0.559	rs11234042	ENSG00000254682.1	RP11-660L16.2	-8.71	6.42e-16	3.21e-12	-0.7	-0.5	Vitamin D levels;	chr11:71528040	chr11:71448674~71452157:+
OV	cis	rs507080	0.922	rs4938524	ENSG00000255422.1	AP002954.4	-8.71	6.43e-16	3.21e-12	-0.58	-0.5	Serum metabolite levels;	chr11:118681365	chr11:118704607~118750263:+
OV	cis	rs2658782	0.507	rs4457713	ENSG00000279684.1	RP11-755E23.2	-8.71	6.47e-16	3.23e-12	-0.66	-0.5	Pulmonary function decline;	chr11:93304264	chr11:93286629~93288903:-
OV	cis	rs2487048	0.804	rs2472496	ENSG00000226334.1	RP11-217B7.2	-8.7	6.71e-16	3.35e-12	-0.61	-0.5	Intraocular pressure;	chr9:104933072	chr9:104927553~104928892:+
OV	cis	rs2836950	0.585	rs1029004	ENSG00000232608.1	TIMM9P2	8.7	6.76e-16	3.37e-12	0.55	0.5	Menarche (age at onset);	chr21:39243417	chr21:39216624~39217506:+
OV	cis	rs9326248	0.817	rs6589598	ENSG00000254851.1	RP11-109L13.1	-8.7	6.77e-16	3.38e-12	-0.72	-0.5	Blood protein levels;	chr11:117131687	chr11:117135528~117138582:+
OV	cis	rs4423214	0.592	rs10898234	ENSG00000254682.1	RP11-660L16.2	-8.7	6.86e-16	3.41e-12	-0.71	-0.5	Vitamin D levels;	chr11:71525638	chr11:71448674~71452157:+
OV	cis	rs507080	0.961	rs600969	ENSG00000255422.1	AP002954.4	-8.7	6.89e-16	3.43e-12	-0.58	-0.5	Serum metabolite levels;	chr11:118675087	chr11:118704607~118750263:+
OV	cis	rs507080	0.922	rs12577485	ENSG00000255422.1	AP002954.4	-8.7	6.89e-16	3.43e-12	-0.58	-0.5	Serum metabolite levels;	chr11:118676793	chr11:118704607~118750263:+
OV	cis	rs9326248	0.53	rs2513093	ENSG00000254851.1	RP11-109L13.1	-8.7	6.91e-16	3.44e-12	-0.85	-0.5	Blood protein levels;	chr11:116935971	chr11:117135528~117138582:+
OV	cis	rs801193	1	rs1553609	ENSG00000226824.5	RP4-756H11.3	-8.7	6.95e-16	3.45e-12	-0.54	-0.5	Aortic root size;	chr7:66732152	chr7:66654538~66669855:+
OV	cis	rs801193	1	rs1553610	ENSG00000226824.5	RP4-756H11.3	-8.7	6.95e-16	3.45e-12	-0.54	-0.5	Aortic root size;	chr7:66732246	chr7:66654538~66669855:+
OV	cis	rs801193	0.935	rs11772264	ENSG00000226824.5	RP4-756H11.3	-8.69	7.16e-16	3.55e-12	-0.54	-0.5	Aortic root size;	chr7:66711400	chr7:66654538~66669855:+
OV	cis	rs801193	1	rs7782320	ENSG00000226824.5	RP4-756H11.3	-8.69	7.16e-16	3.55e-12	-0.54	-0.5	Aortic root size;	chr7:66712111	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs12532998	ENSG00000226824.5	RP4-756H11.3	-8.69	7.21e-16	3.58e-12	-0.52	-0.5	Aortic root size;	chr7:66502472	chr7:66654538~66669855:+
OV	cis	rs2658782	0.547	rs4753453	ENSG00000279684.1	RP11-755E23.2	-8.69	7.25e-16	3.6e-12	-0.66	-0.5	Pulmonary function decline;	chr11:93308008	chr11:93286629~93288903:-
OV	cis	rs4927850	1	rs4927850	ENSG00000231464.1	AC024937.4	-8.69	7.29e-16	3.61e-12	-0.61	-0.5	Pancreatic cancer;	chr3:196024759	chr3:195996738~195998233:+
OV	cis	rs2836974	0.897	rs8133146	ENSG00000232608.1	TIMM9P2	-8.69	7.36e-16	3.65e-12	-0.57	-0.5	Cognitive function;	chr21:39242372	chr21:39216624~39217506:+
OV	cis	rs6952407	1	rs6952407	ENSG00000222364.1	RNU6-96P	8.69	7.39e-16	3.66e-12	0.52	0.5	Cotinine glucuronidation;	chr7:66580525	chr7:66395191~66395286:+
OV	cis	rs875971	0.66	rs3764903	ENSG00000222364.1	RNU6-96P	8.69	7.44e-16	3.68e-12	0.52	0.5	Aortic root size;	chr7:66633495	chr7:66395191~66395286:+
OV	cis	rs2836950	0.501	rs35994303	ENSG00000232608.1	TIMM9P2	8.69	7.46e-16	3.7e-12	0.56	0.5	Menarche (age at onset);	chr21:39314094	chr21:39216624~39217506:+
OV	cis	rs2836974	0.897	rs1541102	ENSG00000232608.1	TIMM9P2	-8.69	7.49e-16	3.71e-12	-0.59	-0.5	Cognitive function;	chr21:39256839	chr21:39216624~39217506:+
OV	cis	rs875971	0.66	rs1860470	ENSG00000222364.1	RNU6-96P	8.69	7.5e-16	3.71e-12	0.52	0.5	Aortic root size;	chr7:66638707	chr7:66395191~66395286:+
OV	cis	rs17361889	0.685	rs62442360	ENSG00000224683.1	RPL36AP29	8.69	7.52e-16	3.72e-12	0.6	0.5	Pediatric bone mineral content (hip);	chr7:16103664	chr7:16208945~16209265:+
OV	cis	rs858239	1	rs858239	ENSG00000230658.1	KLHL7-AS1	8.69	7.52e-16	3.72e-12	0.66	0.5	Cerebrospinal fluid biomarker levels;	chr7:23246696	chr7:23101228~23105703:-
OV	cis	rs2836950	0.501	rs62223052	ENSG00000232608.1	TIMM9P2	8.68	7.78e-16	3.84e-12	0.59	0.5	Menarche (age at onset);	chr21:39336776	chr21:39216624~39217506:+
OV	cis	rs875971	0.619	rs2302918	ENSG00000222364.1	RNU6-96P	-8.68	7.81e-16	3.86e-12	-0.52	-0.5	Aortic root size;	chr7:66535945	chr7:66395191~66395286:+
OV	cis	rs2836974	0.863	rs1065242	ENSG00000232608.1	TIMM9P2	-8.68	7.83e-16	3.87e-12	-0.57	-0.5	Cognitive function;	chr21:39195790	chr21:39216624~39217506:+
OV	cis	rs6782228	0.883	rs11712115	ENSG00000242551.2	POU5F1P6	8.68	7.86e-16	3.88e-12	0.59	0.5	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128685426	chr3:128674735~128677005:-
OV	cis	rs875971	0.638	rs6960778	ENSG00000222364.1	RNU6-96P	8.68	7.88e-16	3.89e-12	0.53	0.5	Aortic root size;	chr7:66606610	chr7:66395191~66395286:+
OV	cis	rs801193	1	rs62466793	ENSG00000226824.5	RP4-756H11.3	-8.68	7.96e-16	3.93e-12	-0.54	-0.5	Aortic root size;	chr7:66726530	chr7:66654538~66669855:+
OV	cis	rs801193	1	rs62466794	ENSG00000226824.5	RP4-756H11.3	-8.68	7.96e-16	3.93e-12	-0.54	-0.5	Aortic root size;	chr7:66726592	chr7:66654538~66669855:+
OV	cis	rs875971	0.895	rs3857684	ENSG00000226824.5	RP4-756H11.3	-8.68	8.05e-16	3.96e-12	-0.52	-0.5	Aortic root size;	chr7:66473171	chr7:66654538~66669855:+
OV	cis	rs875971	0.964	rs6978429	ENSG00000226824.5	RP4-756H11.3	-8.68	8.05e-16	3.96e-12	-0.52	-0.5	Aortic root size;	chr7:66494889	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs4718357	ENSG00000226824.5	RP4-756H11.3	-8.68	8.05e-16	3.96e-12	-0.52	-0.5	Aortic root size;	chr7:66495891	chr7:66654538~66669855:+
OV	cis	rs875971	0.929	rs12535036	ENSG00000226824.5	RP4-756H11.3	-8.68	8.05e-16	3.96e-12	-0.52	-0.5	Aortic root size;	chr7:66499076	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs12533997	ENSG00000226824.5	RP4-756H11.3	-8.68	8.05e-16	3.96e-12	-0.52	-0.5	Aortic root size;	chr7:66500390	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs12698523	ENSG00000226824.5	RP4-756H11.3	-8.68	8.05e-16	3.96e-12	-0.52	-0.5	Aortic root size;	chr7:66503126	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs6970030	ENSG00000226824.5	RP4-756H11.3	-8.68	8.05e-16	3.96e-12	-0.52	-0.5	Aortic root size;	chr7:66503692	chr7:66654538~66669855:+
OV	cis	rs875971	0.928	rs6970357	ENSG00000226824.5	RP4-756H11.3	-8.68	8.05e-16	3.96e-12	-0.52	-0.5	Aortic root size;	chr7:66503891	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs3735148	ENSG00000226824.5	RP4-756H11.3	-8.68	8.05e-16	3.96e-12	-0.52	-0.5	Aortic root size;	chr7:66506022	chr7:66654538~66669855:+
OV	cis	rs2836950	0.501	rs13047518	ENSG00000232608.1	TIMM9P2	8.68	8.05e-16	3.96e-12	0.58	0.5	Menarche (age at onset);	chr21:39335381	chr21:39216624~39217506:+
OV	cis	rs875971	0.964	rs697969	ENSG00000226824.5	RP4-756H11.3	8.67	8.16e-16	4.01e-12	0.53	0.5	Aortic root size;	chr7:66093491	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs697970	ENSG00000226824.5	RP4-756H11.3	8.67	8.16e-16	4.01e-12	0.53	0.5	Aortic root size;	chr7:66095065	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs1182882	ENSG00000226824.5	RP4-756H11.3	8.67	8.16e-16	4.01e-12	0.53	0.5	Aortic root size;	chr7:66097076	chr7:66654538~66669855:+
OV	cis	rs17361889	0.752	rs6974124	ENSG00000224683.1	RPL36AP29	8.67	8.32e-16	4.08e-12	0.58	0.5	Pediatric bone mineral content (hip);	chr7:16234495	chr7:16208945~16209265:+
OV	cis	rs875971	0.642	rs35526611	ENSG00000222364.1	RNU6-96P	8.67	8.47e-16	4.15e-12	0.52	0.5	Aortic root size;	chr7:66629021	chr7:66395191~66395286:+
OV	cis	rs9368481	0.761	rs4713062	ENSG00000243307.2	POM121L6P	-8.67	8.48e-16	4.16e-12	-0.5	-0.5	Autism spectrum disorder or schizophrenia;	chr6:26980416	chr6:26896952~26898777:+
OV	cis	rs875971	0.66	rs1860468	ENSG00000222364.1	RNU6-96P	8.67	8.55e-16	4.19e-12	0.52	0.5	Aortic root size;	chr7:66642265	chr7:66395191~66395286:+
OV	cis	rs875971	0.638	rs35986979	ENSG00000222364.1	RNU6-96P	8.67	8.55e-16	4.19e-12	0.52	0.5	Aortic root size;	chr7:66624003	chr7:66395191~66395286:+
OV	cis	rs4423214	1	rs3750997	ENSG00000254682.1	RP11-660L16.2	8.66	8.61e-16	4.21e-12	0.59	0.5	Vitamin D levels;	chr11:71447795	chr11:71448674~71452157:+
OV	cis	rs17361889	0.752	rs10264415	ENSG00000224683.1	RPL36AP29	-8.66	8.65e-16	4.23e-12	-0.63	-0.5	Pediatric bone mineral content (hip);	chr7:16258087	chr7:16208945~16209265:+
OV	cis	rs875971	1	rs1167612	ENSG00000226824.5	RP4-756H11.3	8.66	8.7e-16	4.25e-12	0.53	0.5	Aortic root size;	chr7:66102989	chr7:66654538~66669855:+
OV	cis	rs2836950	0.545	rs11700813	ENSG00000232608.1	TIMM9P2	8.66	8.75e-16	4.27e-12	0.57	0.5	Menarche (age at onset);	chr21:39145543	chr21:39216624~39217506:+
OV	cis	rs507080	0.501	rs516503	ENSG00000255239.1	AP002954.6	8.66	8.78e-16	4.29e-12	0.58	0.5	Serum metabolite levels;	chr11:118709639	chr11:118688039~118690600:-
OV	cis	rs875971	1	rs2220626	ENSG00000226824.5	RP4-756H11.3	8.66	8.81e-16	4.3e-12	0.53	0.5	Aortic root size;	chr7:66081075	chr7:66654538~66669855:+
OV	cis	rs8105895	0.935	rs28635943	ENSG00000269742.1	BNIP3P29	8.66	9.04e-16	4.41e-12	0.74	0.5	Body mass index (change over time);	chr19:22085910	chr19:22065828~22066398:-
OV	cis	rs875971	0.929	rs10950041	ENSG00000226824.5	RP4-756H11.3	-8.66	9.15e-16	4.46e-12	-0.52	-0.5	Aortic root size;	chr7:66508888	chr7:66654538~66669855:+
OV	cis	rs875971	0.929	rs6970860	ENSG00000226824.5	RP4-756H11.3	-8.66	9.15e-16	4.46e-12	-0.52	-0.5	Aortic root size;	chr7:66511647	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs6957199	ENSG00000226824.5	RP4-756H11.3	-8.66	9.15e-16	4.46e-12	-0.52	-0.5	Aortic root size;	chr7:66513532	chr7:66654538~66669855:+
OV	cis	rs2836974	0.897	rs2836933	ENSG00000232608.1	TIMM9P2	-8.65	9.21e-16	4.49e-12	-0.57	-0.5	Cognitive function;	chr21:39192276	chr21:39216624~39217506:+
OV	cis	rs875971	0.83	rs4718358	ENSG00000226824.5	RP4-756H11.3	-8.65	9.28e-16	4.52e-12	-0.52	-0.5	Aortic root size;	chr7:66508681	chr7:66654538~66669855:+
OV	cis	rs2836974	0.831	rs4375956	ENSG00000232608.1	TIMM9P2	-8.65	9.37e-16	4.56e-12	-0.59	-0.5	Cognitive function;	chr21:39149862	chr21:39216624~39217506:+
OV	cis	rs875971	1	rs11974219	ENSG00000226824.5	RP4-756H11.3	8.65	9.39e-16	4.56e-12	0.52	0.5	Aortic root size;	chr7:66182423	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs11974264	ENSG00000226824.5	RP4-756H11.3	8.65	9.39e-16	4.56e-12	0.52	0.5	Aortic root size;	chr7:66182595	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs1540651	ENSG00000226824.5	RP4-756H11.3	8.65	9.39e-16	4.56e-12	0.52	0.5	Aortic root size;	chr7:66185134	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs1565531	ENSG00000226824.5	RP4-756H11.3	8.65	9.39e-16	4.56e-12	0.52	0.5	Aortic root size;	chr7:66198126	chr7:66654538~66669855:+
OV	cis	rs2836950	0.565	rs2836934	ENSG00000232608.1	TIMM9P2	8.65	9.39e-16	4.57e-12	0.55	0.5	Menarche (age at onset);	chr21:39192959	chr21:39216624~39217506:+
OV	cis	rs801193	0.66	rs974239	ENSG00000226824.5	RP4-756H11.3	-8.65	9.4e-16	4.57e-12	-0.53	-0.5	Aortic root size;	chr7:66748504	chr7:66654538~66669855:+
OV	cis	rs801193	0.66	rs1016265	ENSG00000226824.5	RP4-756H11.3	-8.65	9.4e-16	4.57e-12	-0.53	-0.5	Aortic root size;	chr7:66749580	chr7:66654538~66669855:+
OV	cis	rs801193	0.66	rs4610622	ENSG00000226824.5	RP4-756H11.3	-8.65	9.4e-16	4.57e-12	-0.53	-0.5	Aortic root size;	chr7:66759510	chr7:66654538~66669855:+
OV	cis	rs2836950	0.527	rs2836958	ENSG00000232608.1	TIMM9P2	8.65	9.43e-16	4.58e-12	0.55	0.5	Menarche (age at onset);	chr21:39251600	chr21:39216624~39217506:+
OV	cis	rs801193	1	rs2286684	ENSG00000226824.5	RP4-756H11.3	8.65	9.47e-16	4.6e-12	0.53	0.5	Aortic root size;	chr7:66664843	chr7:66654538~66669855:+
OV	cis	rs801193	0.935	rs2286683	ENSG00000226824.5	RP4-756H11.3	8.65	9.47e-16	4.6e-12	0.53	0.5	Aortic root size;	chr7:66664856	chr7:66654538~66669855:+
OV	cis	rs2836974	0.932	rs56306759	ENSG00000232608.1	TIMM9P2	-8.65	9.54e-16	4.63e-12	-0.57	-0.5	Cognitive function;	chr21:39236180	chr21:39216624~39217506:+
OV	cis	rs2658782	0.704	rs2658766	ENSG00000279684.1	RP11-755E23.2	-8.65	9.64e-16	4.68e-12	-0.69	-0.5	Pulmonary function decline;	chr11:93499063	chr11:93286629~93288903:-
OV	cis	rs801193	1	rs2659906	ENSG00000226824.5	RP4-756H11.3	-8.64	1.01e-15	4.87e-12	-0.53	-0.5	Aortic root size;	chr7:66700323	chr7:66654538~66669855:+
OV	cis	rs801193	0.935	rs2659899	ENSG00000226824.5	RP4-756H11.3	-8.64	1.01e-15	4.87e-12	-0.53	-0.5	Aortic root size;	chr7:66721734	chr7:66654538~66669855:+
OV	cis	rs507080	0.961	rs642530	ENSG00000255422.1	AP002954.4	-8.64	1.01e-15	4.89e-12	-0.57	-0.5	Serum metabolite levels;	chr11:118680047	chr11:118704607~118750263:+
OV	cis	rs801193	1	rs10274773	ENSG00000226824.5	RP4-756H11.3	8.64	1.02e-15	4.92e-12	0.53	0.5	Aortic root size;	chr7:66668591	chr7:66654538~66669855:+
OV	cis	rs801193	1	rs7785213	ENSG00000226824.5	RP4-756H11.3	8.64	1.02e-15	4.92e-12	0.53	0.5	Aortic root size;	chr7:66673991	chr7:66654538~66669855:+
OV	cis	rs4713118	0.505	rs156740	ENSG00000216901.1	AL022393.7	8.64	1.02e-15	4.94e-12	0.56	0.5	Parkinson's disease;	chr6:27992657	chr6:28176188~28176674:+
OV	cis	rs9368481	0.729	rs9379950	ENSG00000243307.2	POM121L6P	-8.64	1.03e-15	4.97e-12	-0.49	-0.5	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:26896952~26898777:+
OV	cis	rs9368481	1	rs9368481	ENSG00000243307.2	POM121L6P	-8.64	1.03e-15	4.97e-12	-0.49	-0.5	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:26896952~26898777:+
OV	cis	rs875971	0.642	rs35526611	ENSG00000226824.5	RP4-756H11.3	8.64	1.03e-15	4.98e-12	0.53	0.5	Aortic root size;	chr7:66629021	chr7:66654538~66669855:+
OV	cis	rs2836950	0.502	rs12627205	ENSG00000232608.1	TIMM9P2	8.64	1.03e-15	4.99e-12	0.55	0.5	Menarche (age at onset);	chr21:39258101	chr21:39216624~39217506:+
OV	cis	rs875971	0.638	rs35986979	ENSG00000226824.5	RP4-756H11.3	8.64	1.03e-15	5e-12	0.53	0.5	Aortic root size;	chr7:66624003	chr7:66654538~66669855:+
OV	cis	rs2836974	0.932	rs6517527	ENSG00000232608.1	TIMM9P2	-8.64	1.05e-15	5.06e-12	-0.57	-0.5	Cognitive function;	chr21:39209825	chr21:39216624~39217506:+
OV	cis	rs1150668	0.745	rs213238	ENSG00000216901.1	AL022393.7	8.63	1.06e-15	5.09e-12	0.58	0.5	Pubertal anthropometrics;	chr6:28354216	chr6:28176188~28176674:+
OV	cis	rs17361889	0.656	rs2058269	ENSG00000224683.1	RPL36AP29	8.63	1.06e-15	5.13e-12	0.58	0.5	Pediatric bone mineral content (hip);	chr7:16193629	chr7:16208945~16209265:+
OV	cis	rs875971	1	rs55962648	ENSG00000226824.5	RP4-756H11.3	8.63	1.07e-15	5.15e-12	0.51	0.5	Aortic root size;	chr7:66160764	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs11971949	ENSG00000226824.5	RP4-756H11.3	8.63	1.07e-15	5.15e-12	0.51	0.5	Aortic root size;	chr7:66161027	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs2420168	ENSG00000226824.5	RP4-756H11.3	8.63	1.07e-15	5.15e-12	0.51	0.5	Aortic root size;	chr7:66165644	chr7:66654538~66669855:+
OV	cis	rs2836974	0.831	rs2836964	ENSG00000232608.1	TIMM9P2	-8.63	1.07e-15	5.16e-12	-0.58	-0.5	Cognitive function;	chr21:39259080	chr21:39216624~39217506:+
OV	cis	rs17361889	0.752	rs62440451	ENSG00000224683.1	RPL36AP29	8.63	1.07e-15	5.17e-12	0.61	0.5	Pediatric bone mineral content (hip);	chr7:16259676	chr7:16208945~16209265:+
OV	cis	rs2658782	0.547	rs10765602	ENSG00000279684.1	RP11-755E23.2	-8.62	1.14e-15	5.49e-12	-0.65	-0.5	Pulmonary function decline;	chr11:93314999	chr11:93286629~93288903:-
OV	cis	rs875971	0.66	rs12698534	ENSG00000222364.1	RNU6-96P	-8.62	1.17e-15	5.59e-12	-0.51	-0.5	Aortic root size;	chr7:66521858	chr7:66395191~66395286:+
OV	cis	rs875971	1	rs6963646	ENSG00000226824.5	RP4-756H11.3	8.62	1.17e-15	5.62e-12	0.52	0.5	Aortic root size;	chr7:66220780	chr7:66654538~66669855:+
OV	cis	rs4423214	0.84	rs1629220	ENSG00000254682.1	RP11-660L16.2	-8.62	1.19e-15	5.7e-12	-0.63	-0.5	Vitamin D levels;	chr11:71463507	chr11:71448674~71452157:+
OV	cis	rs4423214	0.84	rs1792224	ENSG00000254682.1	RP11-660L16.2	-8.62	1.19e-15	5.7e-12	-0.63	-0.5	Vitamin D levels;	chr11:71465095	chr11:71448674~71452157:+
OV	cis	rs4423214	0.84	rs1792226	ENSG00000254682.1	RP11-660L16.2	-8.62	1.19e-15	5.7e-12	-0.63	-0.5	Vitamin D levels;	chr11:71465528	chr11:71448674~71452157:+
OV	cis	rs11603023	0.967	rs7936556	ENSG00000255239.1	AP002954.6	-8.61	1.2e-15	5.76e-12	-0.54	-0.5	Cholesterol, total;	chr11:118630582	chr11:118688039~118690600:-
OV	cis	rs4423214	0.765	rs2002064	ENSG00000254682.1	RP11-660L16.2	-8.61	1.2e-15	5.76e-12	-0.62	-0.5	Vitamin D levels;	chr11:71452374	chr11:71448674~71452157:+
OV	cis	rs801193	1	rs1553609	ENSG00000222364.1	RNU6-96P	-8.61	1.21e-15	5.78e-12	-0.52	-0.5	Aortic root size;	chr7:66732152	chr7:66395191~66395286:+
OV	cis	rs801193	1	rs1553610	ENSG00000222364.1	RNU6-96P	-8.61	1.21e-15	5.78e-12	-0.52	-0.5	Aortic root size;	chr7:66732246	chr7:66395191~66395286:+
OV	cis	rs2836974	0.932	rs35571600	ENSG00000232608.1	TIMM9P2	-8.61	1.24e-15	5.9e-12	-0.57	-0.5	Cognitive function;	chr21:39218698	chr21:39216624~39217506:+
OV	cis	rs12922317	0.556	rs11648938	ENSG00000260224.1	UBL5P4	8.61	1.24e-15	5.91e-12	0.53	0.5	Schizophrenia;	chr16:12000292	chr16:11968508~11968743:-
OV	cis	rs55794721	0.509	rs873308	ENSG00000261349.1	RP3-465N24.5	8.61	1.25e-15	5.95e-12	0.52	0.5	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25266102~25267136:-
OV	cis	rs875971	0.965	rs10267430	ENSG00000226824.5	RP4-756H11.3	8.61	1.25e-15	5.96e-12	0.52	0.5	Aortic root size;	chr7:66278036	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs10257427	ENSG00000226824.5	RP4-756H11.3	8.61	1.25e-15	5.96e-12	0.52	0.5	Aortic root size;	chr7:66278221	chr7:66654538~66669855:+
OV	cis	rs9326248	0.53	rs473188	ENSG00000254851.1	RP11-109L13.1	-8.61	1.27e-15	6.08e-12	-0.83	-0.5	Blood protein levels;	chr11:116941313	chr11:117135528~117138582:+
OV	cis	rs12922317	0.538	rs442234	ENSG00000260224.1	UBL5P4	8.61	1.27e-15	6.08e-12	0.52	0.5	Schizophrenia;	chr16:11978304	chr16:11968508~11968743:-
OV	cis	rs2836950	0.545	rs2836959	ENSG00000232608.1	TIMM9P2	8.6	1.28e-15	6.11e-12	0.54	0.5	Menarche (age at onset);	chr21:39251742	chr21:39216624~39217506:+
OV	cis	rs875971	0.66	rs3764903	ENSG00000226824.5	RP4-756H11.3	8.6	1.29e-15	6.14e-12	0.53	0.5	Aortic root size;	chr7:66633495	chr7:66654538~66669855:+
OV	cis	rs801193	1	rs2707845	ENSG00000222364.1	RNU6-96P	-8.6	1.3e-15	6.18e-12	-0.52	-0.5	Aortic root size;	chr7:66733811	chr7:66395191~66395286:+
OV	cis	rs875971	0.66	rs1860468	ENSG00000226824.5	RP4-756H11.3	8.6	1.3e-15	6.2e-12	0.53	0.5	Aortic root size;	chr7:66642265	chr7:66654538~66669855:+
OV	cis	rs801193	1	rs11773829	ENSG00000226824.5	RP4-756H11.3	8.6	1.31e-15	6.23e-12	0.53	0.5	Aortic root size;	chr7:66676087	chr7:66654538~66669855:+
OV	cis	rs801193	1	rs2659889	ENSG00000222364.1	RNU6-96P	-8.6	1.34e-15	6.35e-12	-0.52	-0.5	Aortic root size;	chr7:66752125	chr7:66395191~66395286:+
OV	cis	rs801193	1	rs3800812	ENSG00000222364.1	RNU6-96P	-8.6	1.34e-15	6.35e-12	-0.52	-0.5	Aortic root size;	chr7:66758474	chr7:66395191~66395286:+
OV	cis	rs801193	1	rs4279493	ENSG00000222364.1	RNU6-96P	-8.6	1.34e-15	6.35e-12	-0.52	-0.5	Aortic root size;	chr7:66761633	chr7:66395191~66395286:+
OV	cis	rs4423214	0.798	rs12224205	ENSG00000254682.1	RP11-660L16.2	-8.6	1.34e-15	6.38e-12	-0.61	-0.5	Vitamin D levels;	chr11:71469946	chr11:71448674~71452157:+
OV	cis	rs9326248	0.53	rs900012	ENSG00000254851.1	RP11-109L13.1	-8.6	1.35e-15	6.38e-12	-0.82	-0.5	Blood protein levels;	chr11:117095719	chr11:117135528~117138582:+
OV	cis	rs7847628	0.587	rs4837796	ENSG00000226752.6	PSMD5-AS1	8.6	1.35e-15	6.41e-12	0.59	0.5	Birth weight;	chr9:120848010	chr9:120824828~120854385:+
OV	cis	rs858239	1	rs858240	ENSG00000230658.1	KLHL7-AS1	8.59	1.37e-15	6.51e-12	0.65	0.5	Cerebrospinal fluid biomarker levels;	chr7:23244618	chr7:23101228~23105703:-
OV	cis	rs4853012	0.838	rs72911122	ENSG00000217702.2	RP11-287D1.4	8.59	1.4e-15	6.61e-12	0.75	0.5	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74130583~74135395:+
OV	cis	rs6964833	0.935	rs13238996	ENSG00000123965.13	PMS2P5	8.59	1.42e-15	6.73e-12	0.75	0.5	Menarche (age at onset);	chr7:74655318	chr7:74894116~74897835:+
OV	cis	rs875971	0.66	rs1860470	ENSG00000226824.5	RP4-756H11.3	8.59	1.44e-15	6.79e-12	0.53	0.5	Aortic root size;	chr7:66638707	chr7:66654538~66669855:+
OV	cis	rs2836950	0.565	rs8130320	ENSG00000232608.1	TIMM9P2	8.59	1.44e-15	6.82e-12	0.55	0.5	Menarche (age at onset);	chr21:39208332	chr21:39216624~39217506:+
OV	cis	rs2836950	0.52	rs11911087	ENSG00000232608.1	TIMM9P2	8.59	1.45e-15	6.85e-12	0.54	0.5	Menarche (age at onset);	chr21:39293266	chr21:39216624~39217506:+
OV	cis	rs2836974	0.931	rs2735306	ENSG00000232608.1	TIMM9P2	8.58	1.48e-15	6.98e-12	0.57	0.49	Cognitive function;	chr21:39341208	chr21:39216624~39217506:+
OV	cis	rs4853012	0.838	rs6707729	ENSG00000217702.2	RP11-287D1.4	8.58	1.49e-15	7.05e-12	0.75	0.49	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74130583~74135395:+
OV	cis	rs2836950	0.545	rs2836940	ENSG00000232608.1	TIMM9P2	8.58	1.5e-15	7.06e-12	0.55	0.49	Menarche (age at onset);	chr21:39216770	chr21:39216624~39217506:+
OV	cis	rs2836974	0.932	rs8129416	ENSG00000232608.1	TIMM9P2	-8.58	1.52e-15	7.16e-12	-0.57	-0.49	Cognitive function;	chr21:39245219	chr21:39216624~39217506:+
OV	cis	rs2836974	0.899	rs34433511	ENSG00000232608.1	TIMM9P2	-8.58	1.52e-15	7.16e-12	-0.57	-0.49	Cognitive function;	chr21:39246957	chr21:39216624~39217506:+
OV	cis	rs2836974	0.899	rs2836957	ENSG00000232608.1	TIMM9P2	-8.58	1.52e-15	7.16e-12	-0.57	-0.49	Cognitive function;	chr21:39251208	chr21:39216624~39217506:+
OV	cis	rs801193	1	rs2659889	ENSG00000226824.5	RP4-756H11.3	-8.58	1.53e-15	7.18e-12	-0.53	-0.49	Aortic root size;	chr7:66752125	chr7:66654538~66669855:+
OV	cis	rs801193	1	rs3800812	ENSG00000226824.5	RP4-756H11.3	-8.58	1.53e-15	7.18e-12	-0.53	-0.49	Aortic root size;	chr7:66758474	chr7:66654538~66669855:+
OV	cis	rs801193	1	rs4279493	ENSG00000226824.5	RP4-756H11.3	-8.58	1.53e-15	7.18e-12	-0.53	-0.49	Aortic root size;	chr7:66761633	chr7:66654538~66669855:+
OV	cis	rs8040855	0.599	rs4577058	ENSG00000259295.5	CSPG4P12	-8.57	1.58e-15	7.42e-12	-0.59	-0.49	Bulimia nervosa;	chr15:85183227	chr15:85191438~85213905:+
OV	cis	rs507080	0.961	rs520543	ENSG00000255422.1	AP002954.4	-8.57	1.62e-15	7.59e-12	-0.57	-0.49	Serum metabolite levels;	chr11:118667448	chr11:118704607~118750263:+
OV	cis	rs2836950	0.545	rs2836952	ENSG00000232608.1	TIMM9P2	8.57	1.63e-15	7.64e-12	0.54	0.49	Menarche (age at onset);	chr21:39244725	chr21:39216624~39217506:+
OV	cis	rs10256972	0.706	rs12701970	ENSG00000229043.2	AC091729.9	-8.57	1.63e-15	7.65e-12	-0.6	-0.49	Endometriosis;Longevity;	chr7:1082322	chr7:1160374~1165267:+
OV	cis	rs2658782	0.547	rs4344448	ENSG00000279684.1	RP11-755E23.2	-8.57	1.64e-15	7.72e-12	-0.65	-0.49	Pulmonary function decline;	chr11:93313881	chr11:93286629~93288903:-
OV	cis	rs2836974	0.899	rs114399588	ENSG00000232608.1	TIMM9P2	-8.57	1.64e-15	7.72e-12	-0.58	-0.49	Cognitive function;	chr21:39282032	chr21:39216624~39217506:+
OV	cis	rs2836974	0.965	rs8131126	ENSG00000232608.1	TIMM9P2	-8.57	1.64e-15	7.72e-12	-0.58	-0.49	Cognitive function;	chr21:39283828	chr21:39216624~39217506:+
OV	cis	rs801193	0.967	rs2420827	ENSG00000226824.5	RP4-756H11.3	8.57	1.66e-15	7.78e-12	0.52	0.49	Aortic root size;	chr7:66682114	chr7:66654538~66669855:+
OV	cis	rs9368481	0.761	rs4358615	ENSG00000243307.2	POM121L6P	8.56	1.67e-15	7.82e-12	0.48	0.49	Autism spectrum disorder or schizophrenia;	chr6:27030788	chr6:26896952~26898777:+
OV	cis	rs801193	0.66	rs2659914	ENSG00000226824.5	RP4-756H11.3	-8.56	1.68e-15	7.87e-12	-0.52	-0.49	Aortic root size;	chr7:66691927	chr7:66654538~66669855:+
OV	cis	rs801193	0.761	rs2659888	ENSG00000222364.1	RNU6-96P	-8.56	1.68e-15	7.88e-12	-0.52	-0.49	Aortic root size;	chr7:66765184	chr7:66395191~66395286:+
OV	cis	rs507080	0.922	rs519848	ENSG00000255422.1	AP002954.4	-8.56	1.7e-15	7.98e-12	-0.57	-0.49	Serum metabolite levels;	chr11:118682006	chr11:118704607~118750263:+
OV	cis	rs17361889	0.752	rs34750529	ENSG00000224683.1	RPL36AP29	8.56	1.7e-15	7.98e-12	0.59	0.49	Pediatric bone mineral content (hip);	chr7:16236950	chr7:16208945~16209265:+
OV	cis	rs4853012	0.838	rs59570457	ENSG00000217702.2	RP11-287D1.4	8.56	1.7e-15	7.98e-12	0.75	0.49	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74130583~74135395:+
OV	cis	rs8040855	0.599	rs1964724	ENSG00000259295.5	CSPG4P12	-8.56	1.72e-15	8.05e-12	-0.59	-0.49	Bulimia nervosa;	chr15:85183269	chr15:85191438~85213905:+
OV	cis	rs875971	0.66	rs10263935	ENSG00000222364.1	RNU6-96P	-8.56	1.72e-15	8.07e-12	-0.51	-0.49	Aortic root size;	chr7:66631041	chr7:66395191~66395286:+
OV	cis	rs2836950	0.565	rs2836942	ENSG00000232608.1	TIMM9P2	8.56	1.77e-15	8.3e-12	0.55	0.49	Menarche (age at onset);	chr21:39219455	chr21:39216624~39217506:+
OV	cis	rs858239	0.899	rs858271	ENSG00000230658.1	KLHL7-AS1	8.55	1.79e-15	8.36e-12	0.66	0.49	Cerebrospinal fluid biomarker levels;	chr7:23238664	chr7:23101228~23105703:-
OV	cis	rs4853012	0.838	rs6715351	ENSG00000217702.2	RP11-287D1.4	8.55	1.82e-15	8.49e-12	0.74	0.49	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74130583~74135395:+
OV	cis	rs4853012	0.838	rs61521879	ENSG00000217702.2	RP11-287D1.4	8.55	1.82e-15	8.49e-12	0.74	0.49	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74130583~74135395:+
OV	cis	rs8040855	0.599	rs6496792	ENSG00000259295.5	CSPG4P12	-8.55	1.82e-15	8.51e-12	-0.59	-0.49	Bulimia nervosa;	chr15:85182514	chr15:85191438~85213905:+
OV	cis	rs8040855	0.599	rs6496793	ENSG00000259295.5	CSPG4P12	-8.55	1.82e-15	8.51e-12	-0.59	-0.49	Bulimia nervosa;	chr15:85182515	chr15:85191438~85213905:+
OV	cis	rs8040855	0.599	rs6496795	ENSG00000259295.5	CSPG4P12	-8.55	1.82e-15	8.51e-12	-0.59	-0.49	Bulimia nervosa;	chr15:85182622	chr15:85191438~85213905:+
OV	cis	rs4853012	0.941	rs60291089	ENSG00000217702.2	RP11-287D1.4	8.55	1.84e-15	8.59e-12	0.76	0.49	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74130583~74135395:+
OV	cis	rs4853012	0.838	rs58759652	ENSG00000217702.2	RP11-287D1.4	8.55	1.84e-15	8.59e-12	0.76	0.49	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74130583~74135395:+
OV	cis	rs8040855	0.579	rs4843029	ENSG00000259295.5	CSPG4P12	-8.55	1.85e-15	8.63e-12	-0.59	-0.49	Bulimia nervosa;	chr15:85182164	chr15:85191438~85213905:+
OV	cis	rs858239	0.932	rs858272	ENSG00000230658.1	KLHL7-AS1	8.55	1.88e-15	8.75e-12	0.65	0.49	Cerebrospinal fluid biomarker levels;	chr7:23237166	chr7:23101228~23105703:-
OV	cis	rs801193	1	rs4717319	ENSG00000222364.1	RNU6-96P	-8.55	1.88e-15	8.77e-12	-0.51	-0.49	Aortic root size;	chr7:66777606	chr7:66395191~66395286:+
OV	cis	rs801193	0.904	rs4718403	ENSG00000222364.1	RNU6-96P	-8.55	1.88e-15	8.77e-12	-0.51	-0.49	Aortic root size;	chr7:66777742	chr7:66395191~66395286:+
OV	cis	rs17361889	0.633	rs1918267	ENSG00000224683.1	RPL36AP29	8.54	1.93e-15	9e-12	0.58	0.49	Pediatric bone mineral content (hip);	chr7:16231700	chr7:16208945~16209265:+
OV	cis	rs2836974	0.932	rs2836953	ENSG00000232608.1	TIMM9P2	-8.54	1.95e-15	9.07e-12	-0.57	-0.49	Cognitive function;	chr21:39245557	chr21:39216624~39217506:+
OV	cis	rs2836950	0.565	rs2150414	ENSG00000232608.1	TIMM9P2	8.54	1.96e-15	9.11e-12	0.54	0.49	Menarche (age at onset);	chr21:39243062	chr21:39216624~39217506:+
OV	cis	rs11723261	0.621	rs61794960	ENSG00000275426.1	CH17-262A2.1	8.54	1.96e-15	9.13e-12	0.86	0.49	Immune response to smallpox vaccine (IL-6);	chr4:156661	chr4:149738~150317:+
OV	cis	rs2836974	0.897	rs2836944	ENSG00000232608.1	TIMM9P2	-8.54	1.96e-15	9.13e-12	-0.57	-0.49	Cognitive function;	chr21:39221613	chr21:39216624~39217506:+
OV	cis	rs7115242	0.8	rs6589597	ENSG00000254851.1	RP11-109L13.1	8.54	1.98e-15	9.18e-12	0.82	0.49	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117127082	chr11:117135528~117138582:+
OV	cis	rs801193	0.613	rs2659900	ENSG00000226824.5	RP4-756H11.3	-8.54	1.98e-15	9.2e-12	-0.52	-0.49	Aortic root size;	chr7:66719456	chr7:66654538~66669855:+
OV	cis	rs4423214	0.61	rs12793607	ENSG00000254682.1	RP11-660L16.2	-8.54	1.99e-15	9.25e-12	-0.58	-0.49	Vitamin D levels;	chr11:71418270	chr11:71448674~71452157:+
OV	cis	rs7786410	1	rs7786410	ENSG00000226278.1	PSPHP1	8.54	2.02e-15	9.35e-12	0.91	0.49	Age-related hearing impairment;	chr7:55854630	chr7:55764797~55773288:+
OV	cis	rs801193	1	rs3778909	ENSG00000222364.1	RNU6-96P	-8.53	2.05e-15	9.5e-12	-0.51	-0.49	Aortic root size;	chr7:66790659	chr7:66395191~66395286:+
OV	cis	rs2732480	0.538	rs2732462	ENSG00000258273.1	RP11-370I10.4	-8.53	2.05e-15	9.5e-12	-0.59	-0.49	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48302601	chr12:48333755~48333901:-
OV	cis	rs875971	0.638	rs7793569	ENSG00000226824.5	RP4-756H11.3	8.53	2.07e-15	9.58e-12	0.53	0.49	Aortic root size;	chr7:66651646	chr7:66654538~66669855:+
OV	cis	rs1891275	0.54	rs10732773	ENSG00000228701.1	TNKS2-AS1	-8.53	2.09e-15	9.67e-12	-0.52	-0.49	Intelligence (multi-trait analysis);	chr10:91656468	chr10:91782839~91798291:-
OV	cis	rs507080	0.961	rs4457789	ENSG00000255422.1	AP002954.4	-8.53	2.09e-15	9.68e-12	-0.57	-0.49	Serum metabolite levels;	chr11:118668461	chr11:118704607~118750263:+
OV	cis	rs2882667	0.858	rs11750382	ENSG00000253404.1	AC034243.1	-8.53	2.12e-15	9.81e-12	-0.59	-0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121305	chr5:138744434~138753309:-
OV	cis	rs2739330	0.76	rs5751761	ENSG00000250470.1	AP000351.3	-8.53	2.13e-15	9.85e-12	-0.59	-0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23976904~23977585:-
OV	cis	rs2882667	0.858	rs11959851	ENSG00000253404.1	AC034243.1	8.52	2.16e-15	9.98e-12	0.63	0.49	Age-related hearing impairment (SNP x SNP interaction);	chr5:139085716	chr5:138744434~138753309:-
OV	cis	rs6952407	1	rs6952407	ENSG00000226824.5	RP4-756H11.3	8.52	2.17e-15	9.99e-12	0.52	0.49	Cotinine glucuronidation;	chr7:66580525	chr7:66654538~66669855:+
OV	cis	rs1075265	0.584	rs7558126	ENSG00000233266.1	HMGB1P31	8.52	2.17e-15	1e-11	0.6	0.49	Chronotype;Morning vs. evening chronotype;	chr2:54053847	chr2:54051334~54051760:+
OV	cis	rs4853012	0.793	rs6707619	ENSG00000217702.2	RP11-287D1.4	8.52	2.19e-15	1.01e-11	0.75	0.49	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74130583~74135395:+
OV	cis	rs858239	1	rs199347	ENSG00000230658.1	KLHL7-AS1	8.52	2.21e-15	1.02e-11	0.64	0.49	Cerebrospinal fluid biomarker levels;	chr7:23254127	chr7:23101228~23105703:-
OV	cis	rs875971	0.965	rs7794930	ENSG00000226824.5	RP4-756H11.3	8.52	2.22e-15	1.02e-11	0.52	0.49	Aortic root size;	chr7:66313559	chr7:66654538~66669855:+
OV	cis	rs801193	1	rs2003301	ENSG00000226824.5	RP4-756H11.3	8.52	2.28e-15	1.05e-11	0.52	0.49	Aortic root size;	chr7:66682669	chr7:66654538~66669855:+
OV	cis	rs801193	0.935	rs3800820	ENSG00000226824.5	RP4-756H11.3	8.52	2.3e-15	1.06e-11	0.52	0.49	Aortic root size;	chr7:66682191	chr7:66654538~66669855:+
OV	cis	rs2836950	0.501	rs11088470	ENSG00000232608.1	TIMM9P2	8.52	2.3e-15	1.06e-11	0.55	0.49	Menarche (age at onset);	chr21:39317236	chr21:39216624~39217506:+
OV	cis	rs2836950	0.501	rs2836983	ENSG00000232608.1	TIMM9P2	8.52	2.3e-15	1.06e-11	0.55	0.49	Menarche (age at onset);	chr21:39317410	chr21:39216624~39217506:+
OV	cis	rs2836950	0.52	rs8133927	ENSG00000232608.1	TIMM9P2	8.52	2.3e-15	1.06e-11	0.55	0.49	Menarche (age at onset);	chr21:39318035	chr21:39216624~39217506:+
OV	cis	rs2836950	0.52	rs8133928	ENSG00000232608.1	TIMM9P2	8.52	2.3e-15	1.06e-11	0.55	0.49	Menarche (age at onset);	chr21:39318037	chr21:39216624~39217506:+
OV	cis	rs801193	0.967	rs2707841	ENSG00000226824.5	RP4-756H11.3	-8.51	2.32e-15	1.06e-11	-0.52	-0.49	Aortic root size;	chr7:66692033	chr7:66654538~66669855:+
OV	cis	rs801193	1	rs2659912	ENSG00000226824.5	RP4-756H11.3	-8.51	2.32e-15	1.06e-11	-0.52	-0.49	Aortic root size;	chr7:66693012	chr7:66654538~66669855:+
OV	cis	rs801193	1	rs2707836	ENSG00000226824.5	RP4-756H11.3	-8.51	2.32e-15	1.06e-11	-0.52	-0.49	Aortic root size;	chr7:66695448	chr7:66654538~66669855:+
OV	cis	rs801193	1	rs4717310	ENSG00000226824.5	RP4-756H11.3	-8.51	2.32e-15	1.06e-11	-0.52	-0.49	Aortic root size;	chr7:66696020	chr7:66654538~66669855:+
OV	cis	rs801193	0.844	rs7779971	ENSG00000226824.5	RP4-756H11.3	-8.51	2.32e-15	1.06e-11	-0.52	-0.49	Aortic root size;	chr7:66696803	chr7:66654538~66669855:+
OV	cis	rs9326248	0.581	rs7120515	ENSG00000254851.1	RP11-109L13.1	-8.51	2.33e-15	1.06e-11	-0.56	-0.49	Blood protein levels;	chr11:117121210	chr11:117135528~117138582:+
OV	cis	rs2836974	0.653	rs8130556	ENSG00000232608.1	TIMM9P2	-8.51	2.34e-15	1.07e-11	-0.58	-0.49	Cognitive function;	chr21:39144946	chr21:39216624~39217506:+
OV	cis	rs11603023	0.967	rs4245184	ENSG00000255239.1	AP002954.6	-8.51	2.38e-15	1.09e-11	-0.54	-0.49	Cholesterol, total;	chr11:118639844	chr11:118688039~118690600:-
OV	cis	rs1075265	0.584	rs1833497	ENSG00000233266.1	HMGB1P31	8.51	2.39e-15	1.09e-11	0.6	0.49	Chronotype;Morning vs. evening chronotype;	chr2:54052186	chr2:54051334~54051760:+
OV	cis	rs2836974	0.897	rs34035316	ENSG00000232608.1	TIMM9P2	-8.51	2.4e-15	1.1e-11	-0.56	-0.49	Cognitive function;	chr21:39222097	chr21:39216624~39217506:+
OV	cis	rs2836974	0.897	rs2026265	ENSG00000232608.1	TIMM9P2	-8.51	2.4e-15	1.1e-11	-0.56	-0.49	Cognitive function;	chr21:39223591	chr21:39216624~39217506:+
OV	cis	rs2836974	0.897	rs1984022	ENSG00000232608.1	TIMM9P2	-8.51	2.4e-15	1.1e-11	-0.56	-0.49	Cognitive function;	chr21:39224159	chr21:39216624~39217506:+
OV	cis	rs2836974	0.897	rs8128102	ENSG00000232608.1	TIMM9P2	-8.51	2.4e-15	1.1e-11	-0.56	-0.49	Cognitive function;	chr21:39234488	chr21:39216624~39217506:+
OV	cis	rs801193	0.967	rs2707853	ENSG00000222364.1	RNU6-96P	-8.51	2.44e-15	1.11e-11	-0.51	-0.49	Aortic root size;	chr7:66749023	chr7:66395191~66395286:+
OV	cis	rs801193	1	rs2707850	ENSG00000222364.1	RNU6-96P	-8.51	2.45e-15	1.11e-11	-0.51	-0.49	Aortic root size;	chr7:66738883	chr7:66395191~66395286:+
OV	cis	rs801193	0.967	rs1110414	ENSG00000222364.1	RNU6-96P	-8.51	2.45e-15	1.11e-11	-0.51	-0.49	Aortic root size;	chr7:66740595	chr7:66395191~66395286:+
OV	cis	rs801193	1	rs7783924	ENSG00000222364.1	RNU6-96P	-8.51	2.45e-15	1.11e-11	-0.51	-0.49	Aortic root size;	chr7:66744070	chr7:66395191~66395286:+
OV	cis	rs801193	1	rs7789184	ENSG00000222364.1	RNU6-96P	-8.51	2.45e-15	1.11e-11	-0.51	-0.49	Aortic root size;	chr7:66745208	chr7:66395191~66395286:+
OV	cis	rs801193	1	rs2707856	ENSG00000222364.1	RNU6-96P	-8.51	2.45e-15	1.11e-11	-0.51	-0.49	Aortic root size;	chr7:66746023	chr7:66395191~66395286:+
OV	cis	rs801193	1	rs2707854	ENSG00000222364.1	RNU6-96P	-8.51	2.45e-15	1.11e-11	-0.51	-0.49	Aortic root size;	chr7:66747610	chr7:66395191~66395286:+
OV	cis	rs875971	0.577	rs35072105	ENSG00000226824.5	RP4-756H11.3	8.51	2.45e-15	1.11e-11	0.51	0.49	Aortic root size;	chr7:66144830	chr7:66654538~66669855:+
OV	cis	rs2732480	0.5	rs2450989	ENSG00000258273.1	RP11-370I10.4	8.5	2.46e-15	1.12e-11	0.57	0.49	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48259625	chr12:48333755~48333901:-
OV	cis	rs507080	0.961	rs4938523	ENSG00000255422.1	AP002954.4	-8.5	2.46e-15	1.12e-11	-0.57	-0.49	Serum metabolite levels;	chr11:118678129	chr11:118704607~118750263:+
OV	cis	rs2729354	0.817	rs2649667	ENSG00000265566.2	RN7SL605P	-8.5	2.51e-15	1.14e-11	-0.68	-0.49	Blood protein levels;	chr11:57503036	chr11:57528085~57528365:-
OV	cis	rs11603023	0.804	rs527619	ENSG00000255239.1	AP002954.6	-8.5	2.56e-15	1.16e-11	-0.55	-0.49	Cholesterol, total;	chr11:118692577	chr11:118688039~118690600:-
OV	cis	rs2836974	0.965	rs9941894	ENSG00000232608.1	TIMM9P2	-8.5	2.56e-15	1.16e-11	-0.58	-0.49	Cognitive function;	chr21:39262132	chr21:39216624~39217506:+
OV	cis	rs875971	0.964	rs160635	ENSG00000226824.5	RP4-756H11.3	-8.5	2.58e-15	1.17e-11	-0.53	-0.49	Aortic root size;	chr7:66063931	chr7:66654538~66669855:+
OV	cis	rs507080	0.883	rs656575	ENSG00000255422.1	AP002954.4	-8.5	2.6e-15	1.18e-11	-0.57	-0.49	Serum metabolite levels;	chr11:118679199	chr11:118704607~118750263:+
OV	cis	rs4423214	0.84	rs1792315	ENSG00000254682.1	RP11-660L16.2	-8.49	2.68e-15	1.22e-11	-0.62	-0.49	Vitamin D levels;	chr11:71454501	chr11:71448674~71452157:+
OV	cis	rs4423214	0.84	rs1790344	ENSG00000254682.1	RP11-660L16.2	-8.49	2.71e-15	1.23e-11	-0.61	-0.49	Vitamin D levels;	chr11:71465851	chr11:71448674~71452157:+
OV	cis	rs4423214	0.84	rs1790343	ENSG00000254682.1	RP11-660L16.2	-8.49	2.71e-15	1.23e-11	-0.61	-0.49	Vitamin D levels;	chr11:71466161	chr11:71448674~71452157:+
OV	cis	rs4423214	0.84	rs1792227	ENSG00000254682.1	RP11-660L16.2	-8.49	2.71e-15	1.23e-11	-0.61	-0.49	Vitamin D levels;	chr11:71466366	chr11:71448674~71452157:+
OV	cis	rs4423214	0.84	rs1790341	ENSG00000254682.1	RP11-660L16.2	-8.49	2.71e-15	1.23e-11	-0.61	-0.49	Vitamin D levels;	chr11:71466532	chr11:71448674~71452157:+
OV	cis	rs4423214	0.84	rs1540127	ENSG00000254682.1	RP11-660L16.2	-8.49	2.71e-15	1.23e-11	-0.61	-0.49	Vitamin D levels;	chr11:71467992	chr11:71448674~71452157:+
OV	cis	rs4423214	0.84	rs1792235	ENSG00000254682.1	RP11-660L16.2	-8.49	2.71e-15	1.23e-11	-0.61	-0.49	Vitamin D levels;	chr11:71470427	chr11:71448674~71452157:+
OV	cis	rs4423214	0.84	rs1619577	ENSG00000254682.1	RP11-660L16.2	-8.49	2.71e-15	1.23e-11	-0.61	-0.49	Vitamin D levels;	chr11:71470439	chr11:71448674~71452157:+
OV	cis	rs4423214	0.84	rs1792234	ENSG00000254682.1	RP11-660L16.2	-8.49	2.71e-15	1.23e-11	-0.61	-0.49	Vitamin D levels;	chr11:71470972	chr11:71448674~71452157:+
OV	cis	rs875971	1	rs875971	ENSG00000226824.5	RP4-756H11.3	8.49	2.75e-15	1.24e-11	0.51	0.49	Aortic root size;	chr7:66152608	chr7:66654538~66669855:+
OV	cis	rs801193	0.548	rs2659904	ENSG00000226824.5	RP4-756H11.3	-8.48	2.87e-15	1.3e-11	-0.52	-0.49	Aortic root size;	chr7:66713615	chr7:66654538~66669855:+
OV	cis	rs801193	0.967	rs2707853	ENSG00000226824.5	RP4-756H11.3	-8.48	2.93e-15	1.32e-11	-0.53	-0.49	Aortic root size;	chr7:66749023	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs4718307	ENSG00000226824.5	RP4-756H11.3	8.48	2.97e-15	1.34e-11	0.51	0.49	Aortic root size;	chr7:66146001	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs7801282	ENSG00000226824.5	RP4-756H11.3	8.48	2.97e-15	1.34e-11	0.51	0.49	Aortic root size;	chr7:66148700	chr7:66654538~66669855:+
OV	cis	rs17361889	0.727	rs61282805	ENSG00000224683.1	RPL36AP29	8.48	2.99e-15	1.35e-11	0.56	0.49	Pediatric bone mineral content (hip);	chr7:16236981	chr7:16208945~16209265:+
OV	cis	rs2739330	0.791	rs4822458	ENSG00000218537.1	MIF-AS1	8.47	3e-15	1.35e-11	0.62	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23894426~23898930:-
OV	cis	rs507080	0.961	rs1784298	ENSG00000255422.1	AP002954.4	-8.47	3.03e-15	1.36e-11	-0.57	-0.49	Serum metabolite levels;	chr11:118677956	chr11:118704607~118750263:+
OV	cis	rs507080	0.961	rs4938522	ENSG00000255422.1	AP002954.4	-8.47	3.03e-15	1.36e-11	-0.57	-0.49	Serum metabolite levels;	chr11:118677962	chr11:118704607~118750263:+
OV	cis	rs507080	1	rs659969	ENSG00000255422.1	AP002954.4	-8.47	3.03e-15	1.36e-11	-0.57	-0.49	Serum metabolite levels;	chr11:118679094	chr11:118704607~118750263:+
OV	cis	rs2836974	0.897	rs34599551	ENSG00000232608.1	TIMM9P2	-8.47	3.03e-15	1.36e-11	-0.56	-0.49	Cognitive function;	chr21:39222972	chr21:39216624~39217506:+
OV	cis	rs507080	0.961	rs656505	ENSG00000255422.1	AP002954.4	-8.47	3.11e-15	1.4e-11	-0.57	-0.49	Serum metabolite levels;	chr11:118679245	chr11:118704607~118750263:+
OV	cis	rs507080	0.961	rs660489	ENSG00000255422.1	AP002954.4	-8.47	3.11e-15	1.4e-11	-0.57	-0.49	Serum metabolite levels;	chr11:118679255	chr11:118704607~118750263:+
OV	cis	rs507080	0.961	rs543327	ENSG00000255422.1	AP002954.4	-8.47	3.11e-15	1.4e-11	-0.57	-0.49	Serum metabolite levels;	chr11:118679276	chr11:118704607~118750263:+
OV	cis	rs507080	0.961	rs543413	ENSG00000255422.1	AP002954.4	-8.47	3.11e-15	1.4e-11	-0.57	-0.49	Serum metabolite levels;	chr11:118679308	chr11:118704607~118750263:+
OV	cis	rs2836950	0.501	rs4818019	ENSG00000232608.1	TIMM9P2	8.47	3.11e-15	1.4e-11	0.55	0.49	Menarche (age at onset);	chr21:39322530	chr21:39216624~39217506:+
OV	cis	rs858239	0.676	rs3807459	ENSG00000230658.1	KLHL7-AS1	8.47	3.12e-15	1.4e-11	0.61	0.49	Cerebrospinal fluid biomarker levels;	chr7:23350132	chr7:23101228~23105703:-
OV	cis	rs17361889	0.778	rs2214626	ENSG00000224683.1	RPL36AP29	8.47	3.15e-15	1.41e-11	0.58	0.49	Pediatric bone mineral content (hip);	chr7:16276027	chr7:16208945~16209265:+
OV	cis	rs858239	0.932	rs1637190	ENSG00000230658.1	KLHL7-AS1	8.46	3.25e-15	1.45e-11	0.63	0.49	Cerebrospinal fluid biomarker levels;	chr7:23229446	chr7:23101228~23105703:-
OV	cis	rs875971	1	rs6958271	ENSG00000226824.5	RP4-756H11.3	-8.46	3.29e-15	1.47e-11	-0.52	-0.49	Aortic root size;	chr7:66514344	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs6958277	ENSG00000226824.5	RP4-756H11.3	-8.46	3.29e-15	1.47e-11	-0.52	-0.49	Aortic root size;	chr7:66514362	chr7:66654538~66669855:+
OV	cis	rs3931020	0.72	rs927904	ENSG00000272864.1	RP11-17E13.2	-8.46	3.32e-15	1.48e-11	-0.62	-0.49	Resistin levels;	chr1:74794644	chr1:74698769~74699333:-
OV	cis	rs801193	1	rs2707850	ENSG00000226824.5	RP4-756H11.3	-8.46	3.36e-15	1.5e-11	-0.52	-0.49	Aortic root size;	chr7:66738883	chr7:66654538~66669855:+
OV	cis	rs801193	0.967	rs1110414	ENSG00000226824.5	RP4-756H11.3	-8.46	3.36e-15	1.5e-11	-0.52	-0.49	Aortic root size;	chr7:66740595	chr7:66654538~66669855:+
OV	cis	rs801193	1	rs7783924	ENSG00000226824.5	RP4-756H11.3	-8.46	3.36e-15	1.5e-11	-0.52	-0.49	Aortic root size;	chr7:66744070	chr7:66654538~66669855:+
OV	cis	rs801193	1	rs7789184	ENSG00000226824.5	RP4-756H11.3	-8.46	3.36e-15	1.5e-11	-0.52	-0.49	Aortic root size;	chr7:66745208	chr7:66654538~66669855:+
OV	cis	rs801193	1	rs2707856	ENSG00000226824.5	RP4-756H11.3	-8.46	3.36e-15	1.5e-11	-0.52	-0.49	Aortic root size;	chr7:66746023	chr7:66654538~66669855:+
OV	cis	rs801193	1	rs2707854	ENSG00000226824.5	RP4-756H11.3	-8.46	3.36e-15	1.5e-11	-0.52	-0.49	Aortic root size;	chr7:66747610	chr7:66654538~66669855:+
OV	cis	rs801193	1	rs7788576	ENSG00000226824.5	RP4-756H11.3	8.46	3.4e-15	1.51e-11	0.52	0.49	Aortic root size;	chr7:66683315	chr7:66654538~66669855:+
OV	cis	rs801193	1	rs6958520	ENSG00000226824.5	RP4-756H11.3	-8.46	3.4e-15	1.51e-11	-0.52	-0.49	Aortic root size;	chr7:66686466	chr7:66654538~66669855:+
OV	cis	rs17361889	0.711	rs3857709	ENSG00000224683.1	RPL36AP29	8.45	3.51e-15	1.56e-11	0.59	0.49	Pediatric bone mineral content (hip);	chr7:16100477	chr7:16208945~16209265:+
OV	cis	rs2836950	0.501	rs2836980	ENSG00000232608.1	TIMM9P2	8.45	3.52e-15	1.56e-11	0.55	0.49	Menarche (age at onset);	chr21:39315692	chr21:39216624~39217506:+
OV	cis	rs17361889	0.752	rs62440450	ENSG00000224683.1	RPL36AP29	8.44	3.65e-15	1.62e-11	0.59	0.49	Pediatric bone mineral content (hip);	chr7:16257771	chr7:16208945~16209265:+
OV	cis	rs6782228	1	rs12635488	ENSG00000277250.1	Metazoa_SRP	8.44	3.73e-15	1.65e-11	0.6	0.49	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128633535	chr3:128673681~128674021:-
OV	cis	rs2836950	0.545	rs2836956	ENSG00000232608.1	TIMM9P2	-8.44	3.75e-15	1.66e-11	-0.55	-0.49	Menarche (age at onset);	chr21:39251092	chr21:39216624~39217506:+
OV	cis	rs2732480	0.577	rs2634684	ENSG00000258273.1	RP11-370I10.4	8.44	3.77e-15	1.67e-11	0.57	0.49	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48337092	chr12:48333755~48333901:-
OV	cis	rs858239	0.73	rs858279	ENSG00000230658.1	KLHL7-AS1	8.44	3.8e-15	1.68e-11	0.65	0.49	Cerebrospinal fluid biomarker levels;	chr7:23211386	chr7:23101228~23105703:-
OV	cis	rs2581828	0.656	rs2564940	ENSG00000242142.1	SERBP1P3	8.44	3.82e-15	1.69e-11	0.54	0.49	Crohn's disease;	chr3:53073553	chr3:53064283~53065091:-
OV	cis	rs6782228	1	rs34890930	ENSG00000277250.1	Metazoa_SRP	8.43	3.89e-15	1.72e-11	0.58	0.49	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128610380	chr3:128673681~128674021:-
OV	cis	rs1891275	0.551	rs1891271	ENSG00000228701.1	TNKS2-AS1	-8.43	3.9e-15	1.72e-11	-0.53	-0.49	Intelligence (multi-trait analysis);	chr10:91666566	chr10:91782839~91798291:-
OV	cis	rs801193	1	rs10252765	ENSG00000226824.5	RP4-756H11.3	-8.43	3.93e-15	1.73e-11	-0.52	-0.49	Aortic root size;	chr7:66763745	chr7:66654538~66669855:+
OV	cis	rs11603023	0.967	rs644273	ENSG00000255239.1	AP002954.6	-8.43	3.97e-15	1.75e-11	-0.53	-0.49	Cholesterol, total;	chr11:118640634	chr11:118688039~118690600:-
OV	cis	rs11603023	0.967	rs654423	ENSG00000255239.1	AP002954.6	-8.43	3.97e-15	1.75e-11	-0.53	-0.49	Cholesterol, total;	chr11:118641039	chr11:118688039~118690600:-
OV	cis	rs11690935	0.959	rs12692974	ENSG00000228389.1	AC068039.4	8.43	3.99e-15	1.76e-11	0.56	0.49	Schizophrenia;	chr2:171806746	chr2:171773482~171775844:+
OV	cis	rs2658782	0.724	rs2248655	ENSG00000279684.1	RP11-755E23.2	-8.43	4.04e-15	1.78e-11	-0.68	-0.49	Pulmonary function decline;	chr11:93521446	chr11:93286629~93288903:-
OV	cis	rs6964833	0.786	rs35633336	ENSG00000123965.13	PMS2P5	8.43	4.05e-15	1.78e-11	0.72	0.49	Menarche (age at onset);	chr7:74643961	chr7:74894116~74897835:+
OV	cis	rs6964833	0.935	rs34630792	ENSG00000123965.13	PMS2P5	8.43	4.05e-15	1.78e-11	0.72	0.49	Menarche (age at onset);	chr7:74646869	chr7:74894116~74897835:+
OV	cis	rs6964833	0.935	rs35735900	ENSG00000123965.13	PMS2P5	8.43	4.05e-15	1.78e-11	0.72	0.49	Menarche (age at onset);	chr7:74651887	chr7:74894116~74897835:+
OV	cis	rs6964833	0.872	rs4717903	ENSG00000123965.13	PMS2P5	8.43	4.05e-15	1.78e-11	0.72	0.49	Menarche (age at onset);	chr7:74653827	chr7:74894116~74897835:+
OV	cis	rs875971	0.505	rs1723275	ENSG00000222364.1	RNU6-96P	8.43	4.06e-15	1.79e-11	0.51	0.49	Aortic root size;	chr7:66039646	chr7:66395191~66395286:+
OV	cis	rs2729354	0.817	rs2848626	ENSG00000265566.2	RN7SL605P	-8.42	4.23e-15	1.86e-11	-0.77	-0.49	Blood protein levels;	chr11:57516515	chr11:57528085~57528365:-
OV	cis	rs875971	0.66	rs12698534	ENSG00000226824.5	RP4-756H11.3	-8.42	4.26e-15	1.87e-11	-0.52	-0.49	Aortic root size;	chr7:66521858	chr7:66654538~66669855:+
OV	cis	rs1891275	0.551	rs2421625	ENSG00000228701.1	TNKS2-AS1	-8.42	4.29e-15	1.88e-11	-0.51	-0.49	Intelligence (multi-trait analysis);	chr10:91656744	chr10:91782839~91798291:-
OV	cis	rs12922317	0.556	rs8062691	ENSG00000260224.1	UBL5P4	-8.42	4.29e-15	1.88e-11	-0.53	-0.49	Schizophrenia;	chr16:11997972	chr16:11968508~11968743:-
OV	cis	rs4853012	0.887	rs6737314	ENSG00000217702.2	RP11-287D1.4	8.42	4.39e-15	1.92e-11	0.8	0.49	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74130583~74135395:+
OV	cis	rs875971	1	rs2087647	ENSG00000226824.5	RP4-756H11.3	8.41	4.51e-15	1.97e-11	0.5	0.49	Aortic root size;	chr7:66128201	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs6958484	ENSG00000226824.5	RP4-756H11.3	8.41	4.51e-15	1.97e-11	0.5	0.49	Aortic root size;	chr7:66134459	chr7:66654538~66669855:+
OV	cis	rs1891275	0.551	rs4933692	ENSG00000228701.1	TNKS2-AS1	-8.41	4.51e-15	1.97e-11	-0.52	-0.49	Intelligence (multi-trait analysis);	chr10:91664876	chr10:91782839~91798291:-
OV	cis	rs1891275	0.551	rs7900863	ENSG00000228701.1	TNKS2-AS1	-8.41	4.51e-15	1.97e-11	-0.52	-0.49	Intelligence (multi-trait analysis);	chr10:91665737	chr10:91782839~91798291:-
OV	cis	rs1891275	0.588	rs6583782	ENSG00000228701.1	TNKS2-AS1	-8.41	4.51e-15	1.97e-11	-0.52	-0.49	Intelligence (multi-trait analysis);	chr10:91666022	chr10:91782839~91798291:-
OV	cis	rs2658782	0.639	rs2100552	ENSG00000279684.1	RP11-755E23.2	-8.41	4.55e-15	1.98e-11	-0.62	-0.49	Pulmonary function decline;	chr11:93449083	chr11:93286629~93288903:-
OV	cis	rs4423214	0.569	rs4944044	ENSG00000254682.1	RP11-660L16.2	8.41	4.55e-15	1.99e-11	0.58	0.49	Vitamin D levels;	chr11:71409167	chr11:71448674~71452157:+
OV	cis	rs17361889	0.711	rs7782485	ENSG00000224683.1	RPL36AP29	8.41	4.55e-15	1.99e-11	0.6	0.49	Pediatric bone mineral content (hip);	chr7:16272940	chr7:16208945~16209265:+
OV	cis	rs801193	0.935	rs2659916	ENSG00000226824.5	RP4-756H11.3	-8.41	4.56e-15	1.99e-11	-0.52	-0.49	Aortic root size;	chr7:66686365	chr7:66654538~66669855:+
OV	cis	rs507080	0.961	rs607527	ENSG00000255422.1	AP002954.4	8.41	4.59e-15	2e-11	0.56	0.49	Serum metabolite levels;	chr11:118667478	chr11:118704607~118750263:+
OV	cis	rs9326248	0.53	rs2513095	ENSG00000254851.1	RP11-109L13.1	-8.41	4.6e-15	2.01e-11	-0.84	-0.49	Blood protein levels;	chr11:116935553	chr11:117135528~117138582:+
OV	cis	rs7115242	0.669	rs1241658	ENSG00000254851.1	RP11-109L13.1	-8.41	4.6e-15	2.01e-11	-0.84	-0.49	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116948901	chr11:117135528~117138582:+
OV	cis	rs9326248	0.53	rs511676	ENSG00000254851.1	RP11-109L13.1	-8.41	4.6e-15	2.01e-11	-0.84	-0.49	Blood protein levels;	chr11:116954168	chr11:117135528~117138582:+
OV	cis	rs875971	1	rs6961717	ENSG00000226824.5	RP4-756H11.3	8.41	4.64e-15	2.02e-11	0.5	0.49	Aortic root size;	chr7:66122550	chr7:66654538~66669855:+
OV	cis	rs2739330	0.791	rs4822458	ENSG00000224205.1	AP000351.4	8.4	4.88e-15	2.12e-11	0.58	0.49	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23987320~23991421:-
OV	cis	rs1150668	0.83	rs2531831	ENSG00000216901.1	AL022393.7	8.39	5.05e-15	2.19e-11	0.54	0.49	Pubertal anthropometrics;	chr6:28420988	chr6:28176188~28176674:+
OV	cis	rs875971	0.619	rs12533585	ENSG00000226824.5	RP4-756H11.3	-8.39	5.08e-15	2.2e-11	-0.52	-0.49	Aortic root size;	chr7:66519618	chr7:66654538~66669855:+
OV	cis	rs4853012	0.887	rs77148265	ENSG00000217702.2	RP11-287D1.4	8.39	5.1e-15	2.21e-11	0.8	0.49	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74130583~74135395:+
OV	cis	rs875971	0.66	rs7807930	ENSG00000226824.5	RP4-756H11.3	8.39	5.12e-15	2.22e-11	0.51	0.49	Aortic root size;	chr7:66622178	chr7:66654538~66669855:+
OV	cis	rs875971	0.66	rs7807944	ENSG00000226824.5	RP4-756H11.3	8.39	5.12e-15	2.22e-11	0.51	0.49	Aortic root size;	chr7:66622208	chr7:66654538~66669855:+
OV	cis	rs1528149	0.93	rs62440852	ENSG00000224683.1	RPL36AP29	8.39	5.2e-15	2.25e-11	0.6	0.49	Sitting height ratio;	chr7:16077294	chr7:16208945~16209265:+
OV	cis	rs1528149	0.93	rs17357511	ENSG00000224683.1	RPL36AP29	8.39	5.2e-15	2.25e-11	0.6	0.49	Sitting height ratio;	chr7:16077339	chr7:16208945~16209265:+
OV	cis	rs875971	1	rs6945843	ENSG00000226824.5	RP4-756H11.3	8.39	5.2e-15	2.25e-11	0.51	0.49	Aortic root size;	chr7:66269796	chr7:66654538~66669855:+
OV	cis	rs875971	0.66	rs28698552	ENSG00000226824.5	RP4-756H11.3	-8.39	5.22e-15	2.25e-11	-0.52	-0.49	Aortic root size;	chr7:66540031	chr7:66654538~66669855:+
OV	cis	rs875971	0.66	rs62465434	ENSG00000226824.5	RP4-756H11.3	-8.39	5.22e-15	2.25e-11	-0.52	-0.49	Aortic root size;	chr7:66540165	chr7:66654538~66669855:+
OV	cis	rs875971	0.66	rs13224319	ENSG00000226824.5	RP4-756H11.3	-8.39	5.22e-15	2.25e-11	-0.52	-0.49	Aortic root size;	chr7:66542376	chr7:66654538~66669855:+
OV	cis	rs875971	0.66	rs801217	ENSG00000226824.5	RP4-756H11.3	8.39	5.22e-15	2.25e-11	0.52	0.49	Aortic root size;	chr7:66545590	chr7:66654538~66669855:+
OV	cis	rs875971	0.638	rs801216	ENSG00000226824.5	RP4-756H11.3	8.39	5.22e-15	2.25e-11	0.52	0.49	Aortic root size;	chr7:66546680	chr7:66654538~66669855:+
OV	cis	rs875971	0.66	rs801211	ENSG00000226824.5	RP4-756H11.3	8.39	5.22e-15	2.25e-11	0.52	0.49	Aortic root size;	chr7:66550702	chr7:66654538~66669855:+
OV	cis	rs875971	0.638	rs801205	ENSG00000226824.5	RP4-756H11.3	8.39	5.22e-15	2.25e-11	0.52	0.49	Aortic root size;	chr7:66557157	chr7:66654538~66669855:+
OV	cis	rs875971	0.617	rs810400	ENSG00000226824.5	RP4-756H11.3	8.39	5.22e-15	2.25e-11	0.52	0.49	Aortic root size;	chr7:66557902	chr7:66654538~66669855:+
OV	cis	rs875971	0.66	rs801192	ENSG00000226824.5	RP4-756H11.3	8.39	5.22e-15	2.25e-11	0.52	0.49	Aortic root size;	chr7:66566965	chr7:66654538~66669855:+
OV	cis	rs875971	0.66	rs801190	ENSG00000226824.5	RP4-756H11.3	8.39	5.22e-15	2.25e-11	0.52	0.49	Aortic root size;	chr7:66568046	chr7:66654538~66669855:+
OV	cis	rs875971	0.66	rs3857686	ENSG00000226824.5	RP4-756H11.3	8.39	5.22e-15	2.25e-11	0.52	0.49	Aortic root size;	chr7:66571204	chr7:66654538~66669855:+
OV	cis	rs875971	0.638	rs3898855	ENSG00000226824.5	RP4-756H11.3	8.39	5.22e-15	2.25e-11	0.52	0.49	Aortic root size;	chr7:66571411	chr7:66654538~66669855:+
OV	cis	rs875971	0.638	rs10278816	ENSG00000226824.5	RP4-756H11.3	8.39	5.22e-15	2.25e-11	0.52	0.49	Aortic root size;	chr7:66572000	chr7:66654538~66669855:+
OV	cis	rs875971	0.66	rs10281080	ENSG00000226824.5	RP4-756H11.3	8.39	5.22e-15	2.25e-11	0.52	0.49	Aortic root size;	chr7:66577454	chr7:66654538~66669855:+
OV	cis	rs875971	0.66	rs10950044	ENSG00000226824.5	RP4-756H11.3	8.39	5.22e-15	2.25e-11	0.52	0.49	Aortic root size;	chr7:66577989	chr7:66654538~66669855:+
OV	cis	rs875971	0.638	rs10249404	ENSG00000226824.5	RP4-756H11.3	8.39	5.22e-15	2.25e-11	0.52	0.49	Aortic root size;	chr7:66581737	chr7:66654538~66669855:+
OV	cis	rs875971	0.66	rs10215132	ENSG00000226824.5	RP4-756H11.3	8.39	5.22e-15	2.25e-11	0.52	0.49	Aortic root size;	chr7:66589419	chr7:66654538~66669855:+
OV	cis	rs875971	0.522	rs1968127	ENSG00000226824.5	RP4-756H11.3	8.39	5.22e-15	2.25e-11	0.52	0.49	Aortic root size;	chr7:66591816	chr7:66654538~66669855:+
OV	cis	rs875971	0.638	rs6460305	ENSG00000226824.5	RP4-756H11.3	8.39	5.22e-15	2.25e-11	0.52	0.49	Aortic root size;	chr7:66595421	chr7:66654538~66669855:+
OV	cis	rs875971	0.66	rs10272357	ENSG00000226824.5	RP4-756H11.3	8.39	5.22e-15	2.25e-11	0.52	0.49	Aortic root size;	chr7:66598087	chr7:66654538~66669855:+
OV	cis	rs875971	0.66	rs79009421	ENSG00000226824.5	RP4-756H11.3	8.39	5.3e-15	2.28e-11	0.52	0.49	Aortic root size;	chr7:66603522	chr7:66654538~66669855:+
OV	cis	rs875971	0.66	rs6460308	ENSG00000226824.5	RP4-756H11.3	8.39	5.3e-15	2.28e-11	0.52	0.49	Aortic root size;	chr7:66619753	chr7:66654538~66669855:+
OV	cis	rs875971	0.619	rs10278371	ENSG00000226824.5	RP4-756H11.3	8.39	5.33e-15	2.29e-11	0.52	0.49	Aortic root size;	chr7:66586553	chr7:66654538~66669855:+
OV	cis	rs858239	0.896	rs1637193	ENSG00000230658.1	KLHL7-AS1	8.39	5.36e-15	2.3e-11	0.65	0.49	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23101228~23105703:-
OV	cis	rs2836950	0.509	rs4816618	ENSG00000232608.1	TIMM9P2	8.38	5.4e-15	2.32e-11	0.54	0.49	Menarche (age at onset);	chr21:39227603	chr21:39216624~39217506:+
OV	cis	rs2836950	0.527	rs2836948	ENSG00000232608.1	TIMM9P2	8.38	5.4e-15	2.32e-11	0.54	0.49	Menarche (age at onset);	chr21:39227751	chr21:39216624~39217506:+
OV	cis	rs16828019	0.64	rs1140227	ENSG00000235358.1	RP11-399E6.1	8.38	5.41e-15	2.32e-11	0.93	0.49	Intelligence (multi-trait analysis);	chr1:41028139	chr1:41242373~41284861:+
OV	cis	rs16828019	0.777	rs16911	ENSG00000235358.1	RP11-399E6.1	8.38	5.41e-15	2.32e-11	0.93	0.49	Intelligence (multi-trait analysis);	chr1:41032349	chr1:41242373~41284861:+
OV	cis	rs7617773	0.925	rs6442105	ENSG00000229759.1	MRPS18AP1	-8.38	5.48e-15	2.34e-11	-0.52	-0.49	Coronary artery disease;	chr3:48140836	chr3:48256350~48256938:-
OV	cis	rs2658782	0.593	rs2243410	ENSG00000279684.1	RP11-755E23.2	-8.38	5.56e-15	2.37e-11	-0.66	-0.49	Pulmonary function decline;	chr11:93522353	chr11:93286629~93288903:-
OV	cis	rs2732480	0.5	rs2450991	ENSG00000258273.1	RP11-370I10.4	-8.38	5.57e-15	2.38e-11	-0.57	-0.49	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48257838	chr12:48333755~48333901:-
OV	cis	rs17361889	0.596	rs17286418	ENSG00000224683.1	RPL36AP29	8.38	5.59e-15	2.39e-11	0.59	0.49	Pediatric bone mineral content (hip);	chr7:16097894	chr7:16208945~16209265:+
OV	cis	rs9549260	0.564	rs9646110	ENSG00000229456.1	RLIMP1	-8.38	5.66e-15	2.41e-11	-0.52	-0.49	Red blood cell count;	chr13:40734165	chr13:40618738~40621348:+
OV	cis	rs17361889	0.711	rs17358277	ENSG00000224683.1	RPL36AP29	8.37	5.76e-15	2.46e-11	0.59	0.49	Pediatric bone mineral content (hip);	chr7:16093695	chr7:16208945~16209265:+
OV	cis	rs2117029	0.554	rs35884657	ENSG00000258017.1	RP11-386G11.10	-8.37	5.81e-15	2.47e-11	-0.59	-0.49	Intelligence (multi-trait analysis);	chr12:49137317	chr12:49127782~49147869:+
OV	cis	rs801193	0.967	rs2707849	ENSG00000226824.5	RP4-756H11.3	-8.37	5.96e-15	2.54e-11	-0.51	-0.49	Aortic root size;	chr7:66687725	chr7:66654538~66669855:+
OV	cis	rs2836950	0.501	rs4818018	ENSG00000232608.1	TIMM9P2	8.37	6.02e-15	2.56e-11	0.55	0.49	Menarche (age at onset);	chr21:39322146	chr21:39216624~39217506:+
OV	cis	rs9326248	0.581	rs7106437	ENSG00000254851.1	RP11-109L13.1	-8.36	6.14e-15	2.61e-11	-0.56	-0.49	Blood protein levels;	chr11:117121360	chr11:117135528~117138582:+
OV	cis	rs1075265	0.584	rs1559037	ENSG00000233266.1	HMGB1P31	8.36	6.16e-15	2.61e-11	0.6	0.49	Chronotype;Morning vs. evening chronotype;	chr2:54051448	chr2:54051334~54051760:+
OV	cis	rs1075265	0.584	rs7590846	ENSG00000233266.1	HMGB1P31	8.36	6.16e-15	2.61e-11	0.6	0.49	Chronotype;Morning vs. evening chronotype;	chr2:54051530	chr2:54051334~54051760:+
OV	cis	rs2732480	0.5	rs7315820	ENSG00000258273.1	RP11-370I10.4	-8.36	6.28e-15	2.66e-11	-0.58	-0.49	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48205155	chr12:48333755~48333901:-
OV	cis	rs16828019	0.777	rs2300658	ENSG00000235358.1	RP11-399E6.1	8.36	6.29e-15	2.67e-11	0.93	0.49	Intelligence (multi-trait analysis);	chr1:41039350	chr1:41242373~41284861:+
OV	cis	rs16828019	0.852	rs12729448	ENSG00000235358.1	RP11-399E6.1	8.36	6.29e-15	2.67e-11	0.93	0.49	Intelligence (multi-trait analysis);	chr1:41044162	chr1:41242373~41284861:+
OV	cis	rs16828019	0.852	rs2268678	ENSG00000235358.1	RP11-399E6.1	8.36	6.29e-15	2.67e-11	0.93	0.49	Intelligence (multi-trait analysis);	chr1:41045381	chr1:41242373~41284861:+
OV	cis	rs16828019	0.852	rs10489520	ENSG00000235358.1	RP11-399E6.1	8.36	6.29e-15	2.67e-11	0.93	0.49	Intelligence (multi-trait analysis);	chr1:41046083	chr1:41242373~41284861:+
OV	cis	rs16828019	0.852	rs12406620	ENSG00000235358.1	RP11-399E6.1	8.36	6.29e-15	2.67e-11	0.93	0.49	Intelligence (multi-trait analysis);	chr1:41046992	chr1:41242373~41284861:+
OV	cis	rs875971	0.54	rs35510581	ENSG00000226824.5	RP4-756H11.3	8.36	6.4e-15	2.71e-11	0.51	0.49	Aortic root size;	chr7:66113790	chr7:66654538~66669855:+
OV	cis	rs11673344	0.615	rs2921561	ENSG00000226686.6	LINC01535	8.36	6.48e-15	2.74e-11	0.6	0.49	Obesity-related traits;	chr19:37348969	chr19:37251912~37265535:+
OV	cis	rs4853012	0.941	rs78128123	ENSG00000217702.2	RP11-287D1.4	8.35	6.62e-15	2.8e-11	0.81	0.48	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74130583~74135395:+
OV	cis	rs17361889	0.711	rs1120230	ENSG00000224683.1	RPL36AP29	8.35	6.62e-15	2.8e-11	0.58	0.48	Pediatric bone mineral content (hip);	chr7:16110992	chr7:16208945~16209265:+
OV	cis	rs17361889	0.671	rs4282466	ENSG00000224683.1	RPL36AP29	8.35	6.62e-15	2.8e-11	0.58	0.48	Pediatric bone mineral content (hip);	chr7:16111878	chr7:16208945~16209265:+
OV	cis	rs17361889	0.671	rs987932	ENSG00000224683.1	RPL36AP29	8.35	6.62e-15	2.8e-11	0.58	0.48	Pediatric bone mineral content (hip);	chr7:16114696	chr7:16208945~16209265:+
OV	cis	rs17361889	0.632	rs987934	ENSG00000224683.1	RPL36AP29	8.35	6.62e-15	2.8e-11	0.58	0.48	Pediatric bone mineral content (hip);	chr7:16115124	chr7:16208945~16209265:+
OV	cis	rs12922317	0.538	rs446289	ENSG00000260224.1	UBL5P4	-8.35	6.71e-15	2.83e-11	-0.52	-0.48	Schizophrenia;	chr16:11976629	chr16:11968508~11968743:-
OV	cis	rs875971	0.793	rs460678	ENSG00000226824.5	RP4-756H11.3	-8.35	6.87e-15	2.9e-11	-0.52	-0.48	Aortic root size;	chr7:66062213	chr7:66654538~66669855:+
OV	cis	rs10256972	0.681	rs6979076	ENSG00000229043.2	AC091729.9	8.35	6.88e-15	2.9e-11	0.55	0.48	Endometriosis;Longevity;	chr7:1076611	chr7:1160374~1165267:+
OV	cis	rs16828019	0.789	rs36084778	ENSG00000235358.1	RP11-399E6.1	8.35	6.91e-15	2.91e-11	0.92	0.48	Intelligence (multi-trait analysis);	chr1:41013866	chr1:41242373~41284861:+
OV	cis	rs16828019	0.777	rs11209363	ENSG00000235358.1	RP11-399E6.1	8.35	6.91e-15	2.91e-11	0.92	0.48	Intelligence (multi-trait analysis);	chr1:41019405	chr1:41242373~41284861:+
OV	cis	rs9326248	0.53	rs510988	ENSG00000254851.1	RP11-109L13.1	-8.34	7.01e-15	2.95e-11	-0.84	-0.48	Blood protein levels;	chr11:116943088	chr11:117135528~117138582:+
OV	cis	rs4853012	0.941	rs2421752	ENSG00000217702.2	RP11-287D1.4	8.34	7.18e-15	3.02e-11	0.8	0.48	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74130583~74135395:+
OV	cis	rs11690935	1	rs1554166	ENSG00000228389.1	AC068039.4	8.34	7.21e-15	3.03e-11	0.53	0.48	Schizophrenia;	chr2:171685099	chr2:171773482~171775844:+
OV	cis	rs11690935	1	rs6433311	ENSG00000228389.1	AC068039.4	-8.34	7.29e-15	3.07e-11	-0.54	-0.48	Schizophrenia;	chr2:171692738	chr2:171773482~171775844:+
OV	cis	rs8040855	0.599	rs8037195	ENSG00000259295.5	CSPG4P12	-8.34	7.31e-15	3.07e-11	-0.57	-0.48	Bulimia nervosa;	chr15:85181455	chr15:85191438~85213905:+
OV	cis	rs858239	0.932	rs1624451	ENSG00000230658.1	KLHL7-AS1	-8.33	7.64e-15	3.21e-11	-0.65	-0.48	Cerebrospinal fluid biomarker levels;	chr7:23222816	chr7:23101228~23105703:-
OV	cis	rs1891275	0.515	rs10881945	ENSG00000228701.1	TNKS2-AS1	-8.33	7.67e-15	3.22e-11	-0.51	-0.48	Intelligence (multi-trait analysis);	chr10:91663826	chr10:91782839~91798291:-
OV	cis	rs1891275	0.551	rs2421629	ENSG00000228701.1	TNKS2-AS1	-8.33	7.67e-15	3.22e-11	-0.51	-0.48	Intelligence (multi-trait analysis);	chr10:91664018	chr10:91782839~91798291:-
OV	cis	rs858239	0.932	rs858275	ENSG00000230658.1	KLHL7-AS1	8.33	7.68e-15	3.22e-11	0.63	0.48	Cerebrospinal fluid biomarker levels;	chr7:23254525	chr7:23101228~23105703:-
OV	cis	rs2712431	0.554	rs9864772	ENSG00000242551.2	POU5F1P6	-8.33	7.76e-15	3.26e-11	-0.55	-0.48	Monocyte chemoattractant protein-1 levels;	chr3:128598096	chr3:128674735~128677005:-
OV	cis	rs2658782	0.724	rs2658769	ENSG00000279684.1	RP11-755E23.2	-8.33	7.82e-15	3.28e-11	-0.67	-0.48	Pulmonary function decline;	chr11:93518864	chr11:93286629~93288903:-
OV	cis	rs2658782	0.654	rs2605622	ENSG00000279684.1	RP11-755E23.2	-8.33	7.82e-15	3.28e-11	-0.66	-0.48	Pulmonary function decline;	chr11:93515076	chr11:93286629~93288903:-
OV	cis	rs2658782	0.654	rs2605623	ENSG00000279684.1	RP11-755E23.2	-8.33	7.82e-15	3.28e-11	-0.66	-0.48	Pulmonary function decline;	chr11:93516193	chr11:93286629~93288903:-
OV	cis	rs4853012	0.838	rs4429500	ENSG00000217702.2	RP11-287D1.4	8.32	7.97e-15	3.34e-11	0.71	0.48	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74130583~74135395:+
OV	cis	rs2836974	0.897	rs8132295	ENSG00000232608.1	TIMM9P2	8.32	8.01e-15	3.35e-11	0.55	0.48	Cognitive function;	chr21:39155848	chr21:39216624~39217506:+
OV	cis	rs875971	0.54	rs35510581	ENSG00000222364.1	RNU6-96P	8.32	8.05e-15	3.37e-11	0.49	0.48	Aortic root size;	chr7:66113790	chr7:66395191~66395286:+
OV	cis	rs875971	0.505	rs2462573	ENSG00000222364.1	RNU6-96P	8.32	8.1e-15	3.39e-11	0.5	0.48	Aortic root size;	chr7:66042405	chr7:66395191~66395286:+
OV	cis	rs875971	0.505	rs1167386	ENSG00000222364.1	RNU6-96P	8.32	8.1e-15	3.39e-11	0.5	0.48	Aortic root size;	chr7:66048109	chr7:66395191~66395286:+
OV	cis	rs875971	0.505	rs1167385	ENSG00000222364.1	RNU6-96P	8.32	8.1e-15	3.39e-11	0.5	0.48	Aortic root size;	chr7:66048321	chr7:66395191~66395286:+
OV	cis	rs858239	0.965	rs156429	ENSG00000230658.1	KLHL7-AS1	8.32	8.16e-15	3.41e-11	0.67	0.48	Cerebrospinal fluid biomarker levels;	chr7:23266401	chr7:23101228~23105703:-
OV	cis	rs858239	0.932	rs1728313	ENSG00000230658.1	KLHL7-AS1	8.32	8.22e-15	3.44e-11	0.63	0.48	Cerebrospinal fluid biomarker levels;	chr7:23231412	chr7:23101228~23105703:-
OV	cis	rs875971	1	rs1544549	ENSG00000226824.5	RP4-756H11.3	8.32	8.24e-15	3.44e-11	0.51	0.48	Aortic root size;	chr7:66625676	chr7:66654538~66669855:+
OV	cis	rs7396835	0.537	rs10892035	ENSG00000254851.1	RP11-109L13.1	-8.32	8.26e-15	3.45e-11	-0.68	-0.48	Quantitative traits;	chr11:116824222	chr11:117135528~117138582:+
OV	cis	rs875971	1	rs7792762	ENSG00000226824.5	RP4-756H11.3	-8.32	8.34e-15	3.48e-11	-0.51	-0.48	Aortic root size;	chr7:66539151	chr7:66654538~66669855:+
OV	cis	rs2117029	0.555	rs9788140	ENSG00000258017.1	RP11-386G11.10	-8.32	8.41e-15	3.51e-11	-0.59	-0.48	Intelligence (multi-trait analysis);	chr12:49126738	chr12:49127782~49147869:+
OV	cis	rs4423214	0.65	rs7940244	ENSG00000254682.1	RP11-660L16.2	-8.32	8.42e-15	3.51e-11	-0.55	-0.48	Vitamin D levels;	chr11:71510528	chr11:71448674~71452157:+
OV	cis	rs11690935	1	rs34542126	ENSG00000228389.1	AC068039.4	-8.31	8.56e-15	3.57e-11	-0.54	-0.48	Schizophrenia;	chr2:171686195	chr2:171773482~171775844:+
OV	cis	rs11168854	0.62	rs11168888	ENSG00000258017.1	RP11-386G11.10	-8.31	8.65e-15	3.61e-11	-0.59	-0.48	Body mass index;	chr12:49149614	chr12:49127782~49147869:+
OV	cis	rs11690935	0.959	rs1474074	ENSG00000228389.1	AC068039.4	8.31	8.75e-15	3.64e-11	0.56	0.48	Schizophrenia;	chr2:171803342	chr2:171773482~171775844:+
OV	cis	rs10262624	0.967	rs13235406	ENSG00000234286.1	AC006026.13	-8.31	8.79e-15	3.66e-11	-0.54	-0.48	Schizophrenia;	chr7:23879212	chr7:23680195~23680786:-
OV	cis	rs1891275	0.576	rs1891272	ENSG00000228701.1	TNKS2-AS1	-8.31	8.81e-15	3.66e-11	-0.51	-0.48	Intelligence (multi-trait analysis);	chr10:91666306	chr10:91782839~91798291:-
OV	cis	rs10262624	1	rs17347733	ENSG00000234286.1	AC006026.13	-8.31	8.86e-15	3.68e-11	-0.54	-0.48	Schizophrenia;	chr7:23878891	chr7:23680195~23680786:-
OV	cis	rs4423214	0.84	rs1792231	ENSG00000254682.1	RP11-660L16.2	-8.31	8.89e-15	3.69e-11	-0.61	-0.48	Vitamin D levels;	chr11:71471635	chr11:71448674~71452157:+
OV	cis	rs4423214	0.84	rs1790339	ENSG00000254682.1	RP11-660L16.2	-8.31	8.89e-15	3.69e-11	-0.61	-0.48	Vitamin D levels;	chr11:71471715	chr11:71448674~71452157:+
OV	cis	rs4423214	0.84	rs4435028	ENSG00000254682.1	RP11-660L16.2	-8.31	8.89e-15	3.69e-11	-0.61	-0.48	Vitamin D levels;	chr11:71472644	chr11:71448674~71452157:+
OV	cis	rs4423214	0.802	rs4616066	ENSG00000254682.1	RP11-660L16.2	-8.31	8.89e-15	3.69e-11	-0.61	-0.48	Vitamin D levels;	chr11:71472800	chr11:71448674~71452157:+
OV	cis	rs4423214	0.802	rs4402322	ENSG00000254682.1	RP11-660L16.2	-8.31	8.89e-15	3.69e-11	-0.61	-0.48	Vitamin D levels;	chr11:71472969	chr11:71448674~71452157:+
OV	cis	rs4423214	0.802	rs2276358	ENSG00000254682.1	RP11-660L16.2	-8.31	8.89e-15	3.69e-11	-0.61	-0.48	Vitamin D levels;	chr11:71473452	chr11:71448674~71452157:+
OV	cis	rs4423214	0.84	rs3794057	ENSG00000254682.1	RP11-660L16.2	-8.31	8.89e-15	3.69e-11	-0.61	-0.48	Vitamin D levels;	chr11:71475698	chr11:71448674~71452157:+
OV	cis	rs4423214	0.84	rs2017686	ENSG00000254682.1	RP11-660L16.2	-8.31	8.89e-15	3.69e-11	-0.61	-0.48	Vitamin D levels;	chr11:71476015	chr11:71448674~71452157:+
OV	cis	rs2732480	0.5	rs1552550	ENSG00000258273.1	RP11-370I10.4	-8.31	8.96e-15	3.72e-11	-0.57	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48249568	chr12:48333755~48333901:-
OV	cis	rs11690935	0.959	rs7608403	ENSG00000228389.1	AC068039.4	8.3	9.12e-15	3.78e-11	0.55	0.48	Schizophrenia;	chr2:171790255	chr2:171773482~171775844:+
OV	cis	rs4853012	0.838	rs2177707	ENSG00000217702.2	RP11-287D1.4	8.3	9.12e-15	3.78e-11	0.77	0.48	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74130583~74135395:+
OV	cis	rs11690935	0.959	rs6433314	ENSG00000228389.1	AC068039.4	8.3	9.22e-15	3.81e-11	0.56	0.48	Schizophrenia;	chr2:171804461	chr2:171773482~171775844:+
OV	cis	rs11723261	0.621	rs6599306	ENSG00000275426.1	CH17-262A2.1	-8.3	9.26e-15	3.83e-11	-0.76	-0.48	Immune response to smallpox vaccine (IL-6);	chr4:149655	chr4:149738~150317:+
OV	cis	rs875971	0.628	rs6974355	ENSG00000222364.1	RNU6-96P	-8.3	9.32e-15	3.85e-11	-0.5	-0.48	Aortic root size;	chr7:66376994	chr7:66395191~66395286:+
OV	cis	rs16828019	0.777	rs35044078	ENSG00000235358.1	RP11-399E6.1	8.29	9.67e-15	3.99e-11	0.93	0.48	Intelligence (multi-trait analysis);	chr1:41008728	chr1:41242373~41284861:+
OV	cis	rs16828019	0.777	rs3738369	ENSG00000235358.1	RP11-399E6.1	8.29	9.67e-15	3.99e-11	0.93	0.48	Intelligence (multi-trait analysis);	chr1:41020736	chr1:41242373~41284861:+
OV	cis	rs16828019	0.704	rs4996176	ENSG00000235358.1	RP11-399E6.1	8.29	9.67e-15	3.99e-11	0.93	0.48	Intelligence (multi-trait analysis);	chr1:41022496	chr1:41242373~41284861:+
OV	cis	rs16828019	0.777	rs35496942	ENSG00000235358.1	RP11-399E6.1	8.29	9.67e-15	3.99e-11	0.93	0.48	Intelligence (multi-trait analysis);	chr1:41023232	chr1:41242373~41284861:+
OV	cis	rs16828019	0.704	rs12031277	ENSG00000235358.1	RP11-399E6.1	8.29	9.67e-15	3.99e-11	0.93	0.48	Intelligence (multi-trait analysis);	chr1:41026129	chr1:41242373~41284861:+
OV	cis	rs2882667	0.898	rs6863347	ENSG00000253404.1	AC034243.1	8.29	9.98e-15	4.11e-11	0.6	0.48	Age-related hearing impairment (SNP x SNP interaction);	chr5:139025446	chr5:138744434~138753309:-
OV	cis	rs2836950	0.545	rs2297256	ENSG00000232608.1	TIMM9P2	8.29	1.01e-14	4.18e-11	0.54	0.48	Menarche (age at onset);	chr21:39186495	chr21:39216624~39217506:+
OV	cis	rs2732480	0.577	rs2732448	ENSG00000258273.1	RP11-370I10.4	-8.29	1.02e-14	4.18e-11	-0.57	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48336817	chr12:48333755~48333901:-
OV	cis	rs1387259	0.839	rs7486941	ENSG00000258273.1	RP11-370I10.4	8.29	1.02e-14	4.18e-11	0.56	0.48	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48184848	chr12:48333755~48333901:-
OV	cis	rs2836974	0.799	rs13047550	ENSG00000232608.1	TIMM9P2	-8.29	1.02e-14	4.21e-11	-0.57	-0.48	Cognitive function;	chr21:39143569	chr21:39216624~39217506:+
OV	cis	rs2658782	0.688	rs2658768	ENSG00000279684.1	RP11-755E23.2	-8.28	1.06e-14	4.34e-11	-0.67	-0.48	Pulmonary function decline;	chr11:93517661	chr11:93286629~93288903:-
OV	cis	rs507080	1	rs507080	ENSG00000255422.1	AP002954.4	-8.28	1.06e-14	4.36e-11	-0.56	-0.48	Serum metabolite levels;	chr11:118678873	chr11:118704607~118750263:+
OV	cis	rs4853012	0.941	rs7571083	ENSG00000217702.2	RP11-287D1.4	8.28	1.07e-14	4.4e-11	0.78	0.48	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74130583~74135395:+
OV	cis	rs2980439	0.818	rs2945249	ENSG00000253981.4	ALG1L13P	8.28	1.08e-14	4.41e-11	0.65	0.48	Neuroticism;	chr8:8237204	chr8:8236003~8244667:-
OV	cis	rs801193	0.901	rs4273746	ENSG00000226824.5	RP4-756H11.3	8.28	1.09e-14	4.48e-11	0.51	0.48	Aortic root size;	chr7:66836124	chr7:66654538~66669855:+
OV	cis	rs4423214	0.84	rs1792229	ENSG00000254682.1	RP11-660L16.2	-8.27	1.11e-14	4.56e-11	-0.61	-0.48	Vitamin D levels;	chr11:71468349	chr11:71448674~71452157:+
OV	cis	rs2732480	0.577	rs2732466	ENSG00000258273.1	RP11-370I10.4	-8.27	1.12e-14	4.57e-11	-0.57	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48338676	chr12:48333755~48333901:-
OV	cis	rs2732480	0.557	rs2634682	ENSG00000258273.1	RP11-370I10.4	-8.27	1.12e-14	4.57e-11	-0.57	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339160	chr12:48333755~48333901:-
OV	cis	rs801193	1	rs2659915	ENSG00000226824.5	RP4-756H11.3	-8.27	1.12e-14	4.58e-11	-0.51	-0.48	Aortic root size;	chr7:66688114	chr7:66654538~66669855:+
OV	cis	rs6782228	1	rs34890930	ENSG00000242551.2	POU5F1P6	8.27	1.13e-14	4.63e-11	0.56	0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128610380	chr3:128674735~128677005:-
OV	cis	rs2658782	0.526	rs7131487	ENSG00000279684.1	RP11-755E23.2	-8.27	1.14e-14	4.65e-11	-0.61	-0.48	Pulmonary function decline;	chr11:93452786	chr11:93286629~93288903:-
OV	cis	rs801193	0.636	rs10233806	ENSG00000226824.5	RP4-756H11.3	8.27	1.16e-14	4.73e-11	0.51	0.48	Aortic root size;	chr7:66653261	chr7:66654538~66669855:+
OV	cis	rs2117029	0.555	rs9788139	ENSG00000258017.1	RP11-386G11.10	-8.27	1.16e-14	4.76e-11	-0.59	-0.48	Intelligence (multi-trait analysis);	chr12:49126886	chr12:49127782~49147869:+
OV	cis	rs1891275	0.551	rs7908678	ENSG00000228701.1	TNKS2-AS1	8.26	1.22e-14	4.95e-11	0.5	0.48	Intelligence (multi-trait analysis);	chr10:91659253	chr10:91782839~91798291:-
OV	cis	rs2581828	0.656	rs1864367	ENSG00000242142.1	SERBP1P3	8.26	1.22e-14	4.95e-11	0.52	0.48	Crohn's disease;	chr3:53077688	chr3:53064283~53065091:-
OV	cis	rs2732480	0.557	rs2732441	ENSG00000258273.1	RP11-370I10.4	-8.26	1.24e-14	5.05e-11	-0.57	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48329541	chr12:48333755~48333901:-
OV	cis	rs11690935	1	rs6757773	ENSG00000228389.1	AC068039.4	-8.25	1.26e-14	5.14e-11	-0.54	-0.48	Schizophrenia;	chr2:171693120	chr2:171773482~171775844:+
OV	cis	rs6903823	0.508	rs1233660	ENSG00000216901.1	AL022393.7	8.25	1.26e-14	5.14e-11	0.56	0.48	Pulmonary function;	chr6:28292472	chr6:28176188~28176674:+
OV	cis	rs17361889	0.727	rs1527209	ENSG00000224683.1	RPL36AP29	8.25	1.28e-14	5.19e-11	0.56	0.48	Pediatric bone mineral content (hip);	chr7:16241462	chr7:16208945~16209265:+
OV	cis	rs875971	0.577	rs35072105	ENSG00000222364.1	RNU6-96P	8.25	1.3e-14	5.26e-11	0.49	0.48	Aortic root size;	chr7:66144830	chr7:66395191~66395286:+
OV	cis	rs2836950	0.565	rs2836945	ENSG00000232608.1	TIMM9P2	8.25	1.3e-14	5.29e-11	0.53	0.48	Menarche (age at onset);	chr21:39224831	chr21:39216624~39217506:+
OV	cis	rs12922317	0.535	rs8051349	ENSG00000260224.1	UBL5P4	-8.25	1.32e-14	5.37e-11	-0.53	-0.48	Schizophrenia;	chr16:12011666	chr16:11968508~11968743:-
OV	cis	rs4423214	0.55	rs4944885	ENSG00000254682.1	RP11-660L16.2	8.25	1.32e-14	5.38e-11	0.58	0.48	Vitamin D levels;	chr11:71403029	chr11:71448674~71452157:+
OV	cis	rs6903823	0.508	rs1150726	ENSG00000216901.1	AL022393.7	8.24	1.33e-14	5.41e-11	0.56	0.48	Pulmonary function;	chr6:28275265	chr6:28176188~28176674:+
OV	cis	rs10256972	0.758	rs2280724	ENSG00000229043.2	AC091729.9	-8.24	1.35e-14	5.48e-11	-0.62	-0.48	Endometriosis;Longevity;	chr7:1025084	chr7:1160374~1165267:+
OV	cis	rs2581828	0.656	rs11130338	ENSG00000242142.1	SERBP1P3	8.24	1.35e-14	5.48e-11	0.53	0.48	Crohn's disease;	chr3:53086908	chr3:53064283~53065091:-
OV	cis	rs1891275	0.576	rs7900117	ENSG00000228701.1	TNKS2-AS1	-8.24	1.39e-14	5.61e-11	-0.5	-0.48	Intelligence (multi-trait analysis);	chr10:91657530	chr10:91782839~91798291:-
OV	cis	rs1891275	0.551	rs4933213	ENSG00000228701.1	TNKS2-AS1	-8.24	1.39e-14	5.61e-11	-0.5	-0.48	Intelligence (multi-trait analysis);	chr10:91657947	chr10:91782839~91798291:-
OV	cis	rs1891275	0.506	rs4933214	ENSG00000228701.1	TNKS2-AS1	-8.24	1.39e-14	5.61e-11	-0.5	-0.48	Intelligence (multi-trait analysis);	chr10:91658004	chr10:91782839~91798291:-
OV	cis	rs1891275	0.515	rs7358148	ENSG00000228701.1	TNKS2-AS1	-8.24	1.39e-14	5.61e-11	-0.5	-0.48	Intelligence (multi-trait analysis);	chr10:91658775	chr10:91782839~91798291:-
OV	cis	rs1891275	0.601	rs7358034	ENSG00000228701.1	TNKS2-AS1	-8.24	1.39e-14	5.61e-11	-0.5	-0.48	Intelligence (multi-trait analysis);	chr10:91659007	chr10:91782839~91798291:-
OV	cis	rs1891275	0.551	rs7908547	ENSG00000228701.1	TNKS2-AS1	-8.24	1.39e-14	5.61e-11	-0.5	-0.48	Intelligence (multi-trait analysis);	chr10:91659230	chr10:91782839~91798291:-
OV	cis	rs1891275	0.551	rs2421626	ENSG00000228701.1	TNKS2-AS1	-8.24	1.39e-14	5.61e-11	-0.5	-0.48	Intelligence (multi-trait analysis);	chr10:91661177	chr10:91782839~91798291:-
OV	cis	rs1891275	0.551	rs2421627	ENSG00000228701.1	TNKS2-AS1	-8.24	1.39e-14	5.61e-11	-0.5	-0.48	Intelligence (multi-trait analysis);	chr10:91662226	chr10:91782839~91798291:-
OV	cis	rs4423214	0.84	rs1792233	ENSG00000254682.1	RP11-660L16.2	-8.24	1.39e-14	5.62e-11	-0.61	-0.48	Vitamin D levels;	chr11:71471133	chr11:71448674~71452157:+
OV	cis	rs4927850	1	rs7627706	ENSG00000231464.1	AC024937.4	8.24	1.39e-14	5.63e-11	0.58	0.48	Pancreatic cancer;	chr3:196026482	chr3:195996738~195998233:+
OV	cis	rs801193	0.904	rs4718405	ENSG00000226824.5	RP4-756H11.3	-8.24	1.4e-14	5.66e-11	-0.51	-0.48	Aortic root size;	chr7:66789659	chr7:66654538~66669855:+
OV	cis	rs4423214	0.592	rs7120029	ENSG00000254682.1	RP11-660L16.2	-8.24	1.41e-14	5.7e-11	-0.67	-0.48	Vitamin D levels;	chr11:71487911	chr11:71448674~71452157:+
OV	cis	rs858239	1	rs156421	ENSG00000230658.1	KLHL7-AS1	8.23	1.44e-14	5.82e-11	0.62	0.48	Cerebrospinal fluid biomarker levels;	chr7:23272868	chr7:23101228~23105703:-
OV	cis	rs2732480	0.5	rs12828309	ENSG00000258273.1	RP11-370I10.4	-8.23	1.44e-14	5.82e-11	-0.56	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48247377	chr12:48333755~48333901:-
OV	cis	rs11690935	1	rs11678984	ENSG00000228389.1	AC068039.4	-8.23	1.46e-14	5.9e-11	-0.54	-0.48	Schizophrenia;	chr2:171679338	chr2:171773482~171775844:+
OV	cis	rs4853012	0.838	rs4563249	ENSG00000217702.2	RP11-287D1.4	8.23	1.5e-14	6.03e-11	0.71	0.48	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74130583~74135395:+
OV	cis	rs11690935	1	rs312918	ENSG00000228389.1	AC068039.4	8.23	1.5e-14	6.07e-11	0.51	0.48	Schizophrenia;	chr2:171713077	chr2:171773482~171775844:+
OV	cis	rs2836950	0.565	rs2836943	ENSG00000232608.1	TIMM9P2	8.22	1.51e-14	6.1e-11	0.53	0.48	Menarche (age at onset);	chr21:39220685	chr21:39216624~39217506:+
OV	cis	rs2732480	0.5	rs2450986	ENSG00000258273.1	RP11-370I10.4	-8.22	1.59e-14	6.41e-11	-0.57	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48267905	chr12:48333755~48333901:-
OV	cis	rs1387259	0.929	rs2956703	ENSG00000258273.1	RP11-370I10.4	-8.22	1.59e-14	6.41e-11	-0.57	-0.48	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48276511	chr12:48333755~48333901:-
OV	cis	rs1387259	0.931	rs1107654	ENSG00000258273.1	RP11-370I10.4	-8.22	1.59e-14	6.41e-11	-0.57	-0.48	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48287314	chr12:48333755~48333901:-
OV	cis	rs17361889	0.698	rs1528136	ENSG00000224683.1	RPL36AP29	-8.22	1.6e-14	6.42e-11	-0.58	-0.48	Pediatric bone mineral content (hip);	chr7:16090018	chr7:16208945~16209265:+
OV	cis	rs875971	0.638	rs6960778	ENSG00000226824.5	RP4-756H11.3	8.21	1.62e-14	6.49e-11	0.52	0.48	Aortic root size;	chr7:66606610	chr7:66654538~66669855:+
OV	cis	rs10256972	0.713	rs10435026	ENSG00000229043.2	AC091729.9	-8.21	1.62e-14	6.51e-11	-0.59	-0.48	Endometriosis;Longevity;	chr7:1026312	chr7:1160374~1165267:+
OV	cis	rs1387259	0.839	rs7487682	ENSG00000258273.1	RP11-370I10.4	8.21	1.63e-14	6.52e-11	0.57	0.48	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48185882	chr12:48333755~48333901:-
OV	cis	rs9368481	0.761	rs12661756	ENSG00000243307.2	POM121L6P	8.21	1.63e-14	6.53e-11	0.49	0.48	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr6:26896952~26898777:+
OV	cis	rs2581828	0.656	rs11242	ENSG00000242142.1	SERBP1P3	-8.21	1.63e-14	6.53e-11	-0.52	-0.48	Crohn's disease;	chr3:53091906	chr3:53064283~53065091:-
OV	cis	rs875971	0.66	rs801193	ENSG00000226824.5	RP4-756H11.3	8.21	1.64e-14	6.56e-11	0.5	0.48	Aortic root size;	chr7:66565625	chr7:66654538~66669855:+
OV	cis	rs1387259	0.929	rs11168460	ENSG00000258273.1	RP11-370I10.4	-8.21	1.64e-14	6.56e-11	-0.57	-0.48	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48203582	chr12:48333755~48333901:-
OV	cis	rs2732480	0.5	rs7297824	ENSG00000258273.1	RP11-370I10.4	-8.21	1.64e-14	6.56e-11	-0.57	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48204867	chr12:48333755~48333901:-
OV	cis	rs2732480	0.5	rs11168464	ENSG00000258273.1	RP11-370I10.4	-8.21	1.64e-14	6.56e-11	-0.57	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48208332	chr12:48333755~48333901:-
OV	cis	rs6903823	0.508	rs1150724	ENSG00000216901.1	AL022393.7	8.21	1.64e-14	6.56e-11	0.56	0.48	Pulmonary function;	chr6:28282459	chr6:28176188~28176674:+
OV	cis	rs2117029	0.619	rs2241727	ENSG00000258017.1	RP11-386G11.10	-8.21	1.64e-14	6.56e-11	-0.59	-0.48	Intelligence (multi-trait analysis);	chr12:49131225	chr12:49127782~49147869:+
OV	cis	rs2836974	0.899	rs35774464	ENSG00000232608.1	TIMM9P2	-8.21	1.65e-14	6.58e-11	-0.56	-0.48	Cognitive function;	chr21:39208243	chr21:39216624~39217506:+
OV	cis	rs2836974	0.831	rs34592564	ENSG00000232608.1	TIMM9P2	-8.21	1.67e-14	6.65e-11	-0.57	-0.48	Cognitive function;	chr21:39144362	chr21:39216624~39217506:+
OV	cis	rs11168854	0.656	rs7969963	ENSG00000258017.1	RP11-386G11.10	-8.2	1.72e-14	6.86e-11	-0.58	-0.48	Body mass index;	chr12:49118222	chr12:49127782~49147869:+
OV	cis	rs17361889	0.613	rs4721484	ENSG00000224683.1	RPL36AP29	8.2	1.75e-14	6.97e-11	0.54	0.48	Pediatric bone mineral content (hip);	chr7:16242778	chr7:16208945~16209265:+
OV	cis	rs4853012	0.887	rs2280642	ENSG00000217702.2	RP11-287D1.4	8.2	1.76e-14	7.01e-11	0.76	0.48	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74130583~74135395:+
OV	cis	rs4853012	0.887	rs2122290	ENSG00000217702.2	RP11-287D1.4	8.2	1.76e-14	7.01e-11	0.76	0.48	Gestational age at birth (maternal effect);	chr2:74131774	chr2:74130583~74135395:+
OV	cis	rs17361889	0.778	rs56279207	ENSG00000224683.1	RPL36AP29	8.2	1.77e-14	7.05e-11	0.58	0.48	Pediatric bone mineral content (hip);	chr7:16275559	chr7:16208945~16209265:+
OV	cis	rs11690935	0.921	rs4668414	ENSG00000228389.1	AC068039.4	8.2	1.78e-14	7.06e-11	0.56	0.48	Schizophrenia;	chr2:171847781	chr2:171773482~171775844:+
OV	cis	rs11690935	0.959	rs7597387	ENSG00000228389.1	AC068039.4	8.2	1.8e-14	7.13e-11	0.54	0.48	Schizophrenia;	chr2:171720606	chr2:171773482~171775844:+
OV	cis	rs2658782	0.526	rs7127240	ENSG00000279684.1	RP11-755E23.2	-8.2	1.82e-14	7.21e-11	-0.61	-0.48	Pulmonary function decline;	chr11:93451726	chr11:93286629~93288903:-
OV	cis	rs1387259	0.929	rs2634666	ENSG00000258273.1	RP11-370I10.4	-8.19	1.89e-14	7.47e-11	-0.57	-0.48	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48269887	chr12:48333755~48333901:-
OV	cis	rs2581828	0.656	rs2581786	ENSG00000242142.1	SERBP1P3	8.19	1.89e-14	7.48e-11	0.53	0.48	Crohn's disease;	chr3:53092127	chr3:53064283~53065091:-
OV	cis	rs801193	0.967	rs3800823	ENSG00000226824.5	RP4-756H11.3	8.19	1.9e-14	7.48e-11	0.5	0.48	Aortic root size;	chr7:66682123	chr7:66654538~66669855:+
OV	cis	rs2581828	0.656	rs2564921	ENSG00000242142.1	SERBP1P3	-8.19	1.9e-14	7.48e-11	-0.53	-0.48	Crohn's disease;	chr3:53091569	chr3:53064283~53065091:-
OV	cis	rs875971	0.619	rs2302918	ENSG00000226824.5	RP4-756H11.3	-8.19	1.91e-14	7.54e-11	-0.51	-0.48	Aortic root size;	chr7:66535945	chr7:66654538~66669855:+
OV	cis	rs3091242	1	rs3091242	ENSG00000261349.1	RP3-465N24.5	-8.18	1.97e-14	7.76e-11	-0.51	-0.48	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25266102~25267136:-
OV	cis	rs3091242	0.967	rs3091240	ENSG00000261349.1	RP3-465N24.5	-8.18	1.97e-14	7.76e-11	-0.51	-0.48	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25266102~25267136:-
OV	cis	rs4423214	0.61	rs12789253	ENSG00000254682.1	RP11-660L16.2	8.18	2e-14	7.87e-11	0.57	0.48	Vitamin D levels;	chr11:71414719	chr11:71448674~71452157:+
OV	cis	rs2732480	0.5	rs7966829	ENSG00000258273.1	RP11-370I10.4	-8.18	2.02e-14	7.95e-11	-0.56	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48221820	chr12:48333755~48333901:-
OV	cis	rs55726902	0.506	rs1006476	ENSG00000276691.1	RP5-1057I20.5	8.18	2.03e-14	7.98e-11	0.6	0.48	Allergic disease (asthma, hay fever or eczema);	chr12:47785564	chr12:47788426~47788971:+
OV	cis	rs11690935	0.959	rs1113389	ENSG00000228389.1	AC068039.4	8.18	2.07e-14	8.15e-11	0.54	0.48	Schizophrenia;	chr2:171778855	chr2:171773482~171775844:+
OV	cis	rs2732480	0.5	rs1387257	ENSG00000258273.1	RP11-370I10.4	-8.17	2.1e-14	8.26e-11	-0.56	-0.48	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48242883	chr12:48333755~48333901:-
OV	cis	rs11673344	0.734	rs320887	ENSG00000226686.6	LINC01535	-8.17	2.11e-14	8.28e-11	-0.64	-0.48	Obesity-related traits;	chr19:37202536	chr19:37251912~37265535:+
OV	cis	rs875971	0.83	rs427973	ENSG00000226824.5	RP4-756H11.3	-8.17	2.12e-14	8.3e-11	-0.51	-0.48	Aortic root size;	chr7:66061661	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs2420820	ENSG00000226824.5	RP4-756H11.3	8.17	2.12e-14	8.32e-11	0.51	0.48	Aortic root size;	chr7:66626920	chr7:66654538~66669855:+
OV	cis	rs2564921	0.791	rs36033494	ENSG00000242142.1	SERBP1P3	8.17	2.14e-14	8.39e-11	0.54	0.48	Height;	chr3:53082835	chr3:53064283~53065091:-
OV	cis	rs3091242	0.933	rs12402120	ENSG00000261349.1	RP3-465N24.5	-8.17	2.16e-14	8.44e-11	-0.52	-0.48	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25266102~25267136:-
OV	cis	rs4713118	0.662	rs149969	ENSG00000220721.1	OR1F12	8.17	2.16e-14	8.45e-11	0.57	0.48	Parkinson's disease;	chr6:28009959	chr6:28073316~28074233:+
OV	cis	rs875971	0.666	rs13242072	ENSG00000222364.1	RNU6-96P	8.16	2.23e-14	8.7e-11	0.49	0.48	Aortic root size;	chr7:66301001	chr7:66395191~66395286:+
OV	cis	rs4423214	0.569	rs12806918	ENSG00000254682.1	RP11-660L16.2	8.16	2.24e-14	8.74e-11	0.56	0.48	Vitamin D levels;	chr11:71407972	chr11:71448674~71452157:+
OV	cis	rs858239	0.863	rs274058	ENSG00000230658.1	KLHL7-AS1	8.16	2.26e-14	8.84e-11	0.62	0.48	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr7:23101228~23105703:-
OV	cis	rs10262624	1	rs17347692	ENSG00000234286.1	AC006026.13	-8.16	2.29e-14	8.94e-11	-0.53	-0.48	Schizophrenia;	chr7:23878748	chr7:23680195~23680786:-
OV	cis	rs2581828	0.656	rs2336723	ENSG00000242142.1	SERBP1P3	8.16	2.31e-14	9.03e-11	0.52	0.48	Crohn's disease;	chr3:53072031	chr3:53064283~53065091:-
OV	cis	rs7246967	0.673	rs368144	ENSG00000269509.1	BNIP3P34	8.16	2.32e-14	9.06e-11	0.75	0.48	Bronchopulmonary dysplasia;	chr19:22817985	chr19:22773853~22774424:+
OV	cis	rs801193	1	rs13239306	ENSG00000226824.5	RP4-756H11.3	8.16	2.36e-14	9.2e-11	0.52	0.48	Aortic root size;	chr7:66671030	chr7:66654538~66669855:+
OV	cis	rs2581828	0.656	rs2581782	ENSG00000242142.1	SERBP1P3	8.15	2.44e-14	9.47e-11	0.53	0.48	Crohn's disease;	chr3:53088241	chr3:53064283~53065091:-
OV	cis	rs2581828	0.656	rs2581783	ENSG00000242142.1	SERBP1P3	8.15	2.44e-14	9.47e-11	0.53	0.48	Crohn's disease;	chr3:53088242	chr3:53064283~53065091:-
OV	cis	rs2581828	0.607	rs2581784	ENSG00000242142.1	SERBP1P3	8.15	2.44e-14	9.47e-11	0.53	0.48	Crohn's disease;	chr3:53088354	chr3:53064283~53065091:-
OV	cis	rs2581828	0.656	rs891368	ENSG00000242142.1	SERBP1P3	8.15	2.44e-14	9.47e-11	0.53	0.48	Crohn's disease;	chr3:53089257	chr3:53064283~53065091:-
OV	cis	rs2581828	0.656	rs1078968	ENSG00000242142.1	SERBP1P3	8.15	2.44e-14	9.47e-11	0.53	0.48	Crohn's disease;	chr3:53089470	chr3:53064283~53065091:-
OV	cis	rs507080	0.922	rs654792	ENSG00000255422.1	AP002954.4	8.15	2.45e-14	9.5e-11	0.55	0.48	Serum metabolite levels;	chr11:118682287	chr11:118704607~118750263:+
OV	cis	rs1150668	0.768	rs1150709	ENSG00000216901.1	AL022393.7	-8.15	2.49e-14	9.66e-11	-0.53	-0.48	Pubertal anthropometrics;	chr6:28239585	chr6:28176188~28176674:+
OV	cis	rs6782228	1	rs11718130	ENSG00000242551.2	POU5F1P6	8.15	2.52e-14	9.76e-11	0.58	0.48	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611184	chr3:128674735~128677005:-
OV	cis	rs875971	0.66	rs10263935	ENSG00000226824.5	RP4-756H11.3	-8.14	2.56e-14	9.9e-11	-0.5	-0.48	Aortic root size;	chr7:66631041	chr7:66654538~66669855:+
OV	cis	rs3091242	0.904	rs6661533	ENSG00000261349.1	RP3-465N24.5	-8.14	2.62e-14	1.01e-10	-0.5	-0.48	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25266102~25267136:-
OV	cis	rs858239	1	rs166663	ENSG00000230658.1	KLHL7-AS1	8.14	2.64e-14	1.02e-10	0.62	0.48	Cerebrospinal fluid biomarker levels;	chr7:23277123	chr7:23101228~23105703:-
OV	cis	rs7246967	0.866	rs62120785	ENSG00000269509.1	BNIP3P34	8.14	2.64e-14	1.02e-10	0.75	0.48	Bronchopulmonary dysplasia;	chr19:22861997	chr19:22773853~22774424:+
OV	cis	rs10262624	0.935	rs6966641	ENSG00000234286.1	AC006026.13	-8.13	2.73e-14	1.05e-10	-0.52	-0.48	Schizophrenia;	chr7:23866979	chr7:23680195~23680786:-
OV	cis	rs875971	0.66	rs2191268	ENSG00000226824.5	RP4-756H11.3	-8.13	2.75e-14	1.06e-10	-0.49	-0.47	Aortic root size;	chr7:66645237	chr7:66654538~66669855:+
OV	cis	rs11690935	0.959	rs7562356	ENSG00000228389.1	AC068039.4	8.13	2.82e-14	1.08e-10	0.54	0.47	Schizophrenia;	chr2:171770101	chr2:171773482~171775844:+
OV	cis	rs2581828	0.656	rs2253209	ENSG00000242142.1	SERBP1P3	8.13	2.84e-14	1.09e-10	0.52	0.47	Crohn's disease;	chr3:53081144	chr3:53064283~53065091:-
OV	cis	rs2581828	0.694	rs2336725	ENSG00000242142.1	SERBP1P3	8.13	2.84e-14	1.09e-10	0.52	0.47	Crohn's disease;	chr3:53084723	chr3:53064283~53065091:-
OV	cis	rs4423214	0.879	rs1790345	ENSG00000254682.1	RP11-660L16.2	-8.13	2.86e-14	1.1e-10	-0.58	-0.47	Vitamin D levels;	chr11:71434895	chr11:71448674~71452157:+
OV	cis	rs11690935	0.879	rs908671	ENSG00000228389.1	AC068039.4	8.12	2.9e-14	1.11e-10	0.55	0.47	Schizophrenia;	chr2:171833755	chr2:171773482~171775844:+
OV	cis	rs4927850	0.881	rs7630489	ENSG00000231464.1	AC024937.4	8.12	3e-14	1.14e-10	0.57	0.47	Pancreatic cancer;	chr3:196026530	chr3:195996738~195998233:+
OV	cis	rs4927850	1	rs7627868	ENSG00000231464.1	AC024937.4	8.12	3e-14	1.14e-10	0.57	0.47	Pancreatic cancer;	chr3:196026602	chr3:195996738~195998233:+
OV	cis	rs6903823	0.508	rs1778484	ENSG00000216901.1	AL022393.7	8.12	3.02e-14	1.15e-10	0.55	0.47	Pulmonary function;	chr6:28273021	chr6:28176188~28176674:+
OV	cis	rs2729354	0.768	rs2581922	ENSG00000265566.2	RN7SL605P	-8.11	3.06e-14	1.16e-10	-0.69	-0.47	Blood protein levels;	chr11:57497927	chr11:57528085~57528365:-
OV	cis	rs11168854	0.656	rs7969967	ENSG00000258017.1	RP11-386G11.10	8.11	3.08e-14	1.17e-10	0.57	0.47	Body mass index;	chr12:49118234	chr12:49127782~49147869:+
OV	cis	rs875971	0.862	rs778734	ENSG00000226824.5	RP4-756H11.3	-8.11	3.12e-14	1.18e-10	-0.49	-0.47	Aortic root size;	chr7:66349862	chr7:66654538~66669855:+
OV	cis	rs2980439	0.846	rs2980437	ENSG00000253981.4	ALG1L13P	-8.11	3.16e-14	1.2e-10	-0.64	-0.47	Neuroticism;	chr8:8237241	chr8:8236003~8244667:-
OV	cis	rs2581828	0.656	rs2581787	ENSG00000242142.1	SERBP1P3	8.11	3.21e-14	1.22e-10	0.53	0.47	Crohn's disease;	chr3:53093661	chr3:53064283~53065091:-
OV	cis	rs7246967	0.673	rs427709	ENSG00000269509.1	BNIP3P34	8.11	3.25e-14	1.23e-10	0.74	0.47	Bronchopulmonary dysplasia;	chr19:22815361	chr19:22773853~22774424:+
OV	cis	rs7246967	0.736	rs2617779	ENSG00000269509.1	BNIP3P34	8.11	3.25e-14	1.23e-10	0.74	0.47	Bronchopulmonary dysplasia;	chr19:22815519	chr19:22773853~22774424:+
OV	cis	rs801193	0.967	rs2420827	ENSG00000222364.1	RNU6-96P	8.11	3.25e-14	1.23e-10	0.48	0.47	Aortic root size;	chr7:66682114	chr7:66395191~66395286:+
OV	cis	rs2732480	0.5	rs2732461	ENSG00000258273.1	RP11-370I10.4	-8.11	3.25e-14	1.23e-10	-0.56	-0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48299019	chr12:48333755~48333901:-
OV	cis	rs801193	1	rs10234018	ENSG00000226824.5	RP4-756H11.3	8.11	3.26e-14	1.23e-10	0.49	0.47	Aortic root size;	chr7:66681297	chr7:66654538~66669855:+
OV	cis	rs2581828	0.656	rs34530577	ENSG00000242142.1	SERBP1P3	8.1	3.26e-14	1.24e-10	0.52	0.47	Crohn's disease;	chr3:53069780	chr3:53064283~53065091:-
OV	cis	rs3091242	0.935	rs3093632	ENSG00000261349.1	RP3-465N24.5	-8.1	3.27e-14	1.24e-10	-0.51	-0.47	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25266102~25267136:-
OV	cis	rs55794721	0.509	rs6699113	ENSG00000261349.1	RP3-465N24.5	-8.1	3.32e-14	1.25e-10	-0.5	-0.47	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25266102~25267136:-
OV	cis	rs55794721	0.509	rs7554255	ENSG00000261349.1	RP3-465N24.5	-8.1	3.32e-14	1.25e-10	-0.5	-0.47	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25266102~25267136:-
OV	cis	rs55794721	0.509	rs4649085	ENSG00000261349.1	RP3-465N24.5	-8.1	3.32e-14	1.25e-10	-0.5	-0.47	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25266102~25267136:-
OV	cis	rs1387259	0.859	rs2054905	ENSG00000258273.1	RP11-370I10.4	-8.1	3.33e-14	1.25e-10	-0.56	-0.47	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48294168	chr12:48333755~48333901:-
OV	cis	rs2729354	0.768	rs2848640	ENSG00000265566.2	RN7SL605P	-8.1	3.34e-14	1.26e-10	-0.7	-0.47	Blood protein levels;	chr11:57495207	chr11:57528085~57528365:-
OV	cis	rs10262624	0.504	rs59865844	ENSG00000234286.1	AC006026.13	8.1	3.36e-14	1.27e-10	0.53	0.47	Schizophrenia;	chr7:23693421	chr7:23680195~23680786:-
OV	cis	rs2739330	0.76	rs5751761	ENSG00000231271.1	AP000350.8	-8.1	3.36e-14	1.27e-10	-0.54	-0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23949918~23954042:+
OV	cis	rs875971	0.522	rs709604	ENSG00000222364.1	RNU6-96P	8.1	3.47e-14	1.3e-10	0.49	0.47	Aortic root size;	chr7:66032447	chr7:66395191~66395286:+
OV	cis	rs11690935	0.959	rs7355594	ENSG00000228389.1	AC068039.4	8.09	3.47e-14	1.31e-10	0.54	0.47	Schizophrenia;	chr2:171782938	chr2:171773482~171775844:+
OV	cis	rs11690935	0.959	rs10497374	ENSG00000228389.1	AC068039.4	8.09	3.47e-14	1.31e-10	0.54	0.47	Schizophrenia;	chr2:171784113	chr2:171773482~171775844:+
OV	cis	rs6782228	0.883	rs11712115	ENSG00000277250.1	Metazoa_SRP	8.09	3.48e-14	1.31e-10	0.56	0.47	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128685426	chr3:128673681~128674021:-
OV	cis	rs9326248	0.52	rs236919	ENSG00000254851.1	RP11-109L13.1	-8.09	3.56e-14	1.34e-10	-0.54	-0.47	Blood protein levels;	chr11:117224645	chr11:117135528~117138582:+
OV	cis	rs4423214	0.84	rs1123007	ENSG00000254682.1	RP11-660L16.2	-8.09	3.56e-14	1.34e-10	-0.61	-0.47	Vitamin D levels;	chr11:71474311	chr11:71448674~71452157:+
OV	cis	rs2732480	0.5	rs11168468	ENSG00000258273.1	RP11-370I10.4	-8.09	3.61e-14	1.35e-10	-0.56	-0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48218682	chr12:48333755~48333901:-
OV	cis	rs2117029	0.521	rs11168910	ENSG00000258017.1	RP11-386G11.10	-8.09	3.61e-14	1.36e-10	-0.57	-0.47	Intelligence (multi-trait analysis);	chr12:49192707	chr12:49127782~49147869:+
OV	cis	rs2739330	0.76	rs5751761	ENSG00000218537.1	MIF-AS1	-8.09	3.63e-14	1.36e-10	-0.54	-0.47	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23894426~23898930:-
OV	cis	rs875971	1	rs10244498	ENSG00000226824.5	RP4-756H11.3	-8.09	3.69e-14	1.38e-10	-0.51	-0.47	Aortic root size;	chr7:66651069	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs709597	ENSG00000226824.5	RP4-756H11.3	8.08	3.72e-14	1.39e-10	0.5	0.47	Aortic root size;	chr7:66360996	chr7:66654538~66669855:+
OV	cis	rs7115242	1	rs7115242	ENSG00000254851.1	RP11-109L13.1	8.08	3.82e-14	1.43e-10	0.9	0.47	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117037567	chr11:117135528~117138582:+
OV	cis	rs494459	0.756	rs570806	ENSG00000255239.1	AP002954.6	8.08	3.82e-14	1.43e-10	0.55	0.47	Height;	chr11:118786602	chr11:118688039~118690600:-
OV	cis	rs2836974	0.831	rs2836921	ENSG00000232608.1	TIMM9P2	-8.08	3.9e-14	1.46e-10	-0.56	-0.47	Cognitive function;	chr21:39144144	chr21:39216624~39217506:+
OV	cis	rs875971	0.83	rs427575	ENSG00000226824.5	RP4-756H11.3	-8.08	3.92e-14	1.46e-10	-0.51	-0.47	Aortic root size;	chr7:66054232	chr7:66654538~66669855:+
OV	cis	rs875971	0.8	rs427557	ENSG00000226824.5	RP4-756H11.3	-8.08	3.92e-14	1.46e-10	-0.51	-0.47	Aortic root size;	chr7:66054263	chr7:66654538~66669855:+
OV	cis	rs875971	0.83	rs587360	ENSG00000226824.5	RP4-756H11.3	-8.08	3.92e-14	1.46e-10	-0.51	-0.47	Aortic root size;	chr7:66057711	chr7:66654538~66669855:+
OV	cis	rs10262624	1	rs4722286	ENSG00000234286.1	AC006026.13	8.08	3.93e-14	1.47e-10	0.51	0.47	Schizophrenia;	chr7:23874005	chr7:23680195~23680786:-
OV	cis	rs11603023	0.625	rs633683	ENSG00000255239.1	AP002954.6	8.07	4e-14	1.49e-10	0.52	0.47	Cholesterol, total;	chr11:118634025	chr11:118688039~118690600:-
OV	cis	rs8040855	0.599	rs2342123	ENSG00000259295.5	CSPG4P12	8.07	4.09e-14	1.52e-10	0.56	0.47	Bulimia nervosa;	chr15:85181918	chr15:85191438~85213905:+
OV	cis	rs2581828	0.656	rs4687701	ENSG00000242142.1	SERBP1P3	-8.07	4.1e-14	1.53e-10	-0.52	-0.47	Crohn's disease;	chr3:53087260	chr3:53064283~53065091:-
OV	cis	rs2117029	0.521	rs1039225	ENSG00000258017.1	RP11-386G11.10	-8.07	4.11e-14	1.53e-10	-0.57	-0.47	Intelligence (multi-trait analysis);	chr12:49188909	chr12:49127782~49147869:+
OV	cis	rs2581828	0.656	rs2253685	ENSG00000242142.1	SERBP1P3	8.07	4.16e-14	1.55e-10	0.52	0.47	Crohn's disease;	chr3:53085687	chr3:53064283~53065091:-
OV	cis	rs2581828	0.656	rs2253796	ENSG00000242142.1	SERBP1P3	8.07	4.19e-14	1.56e-10	0.52	0.47	Crohn's disease;	chr3:53086082	chr3:53064283~53065091:-
OV	cis	rs853679	0.527	rs853693	ENSG00000216901.1	AL022393.7	8.06	4.22e-14	1.57e-10	0.56	0.47	Depression;	chr6:28314871	chr6:28176188~28176674:+
OV	cis	rs11690935	0.921	rs7355523	ENSG00000228389.1	AC068039.4	8.06	4.24e-14	1.58e-10	0.56	0.47	Schizophrenia;	chr2:171887911	chr2:171773482~171775844:+
OV	cis	rs6903823	0.508	rs1150718	ENSG00000216901.1	AL022393.7	8.06	4.25e-14	1.58e-10	0.56	0.47	Pulmonary function;	chr6:28289170	chr6:28176188~28176674:+
OV	cis	rs875971	0.564	rs313804	ENSG00000226824.5	RP4-756H11.3	-8.06	4.31e-14	1.6e-10	-0.51	-0.47	Aortic root size;	chr7:66049635	chr7:66654538~66669855:+
OV	cis	rs875971	0.662	rs448725	ENSG00000226824.5	RP4-756H11.3	-8.06	4.31e-14	1.6e-10	-0.51	-0.47	Aortic root size;	chr7:66049641	chr7:66654538~66669855:+
OV	cis	rs875971	0.658	rs432667	ENSG00000226824.5	RP4-756H11.3	-8.06	4.31e-14	1.6e-10	-0.51	-0.47	Aortic root size;	chr7:66049646	chr7:66654538~66669855:+
OV	cis	rs10256972	0.732	rs1574108	ENSG00000229043.2	AC091729.9	-8.06	4.36e-14	1.61e-10	-0.56	-0.47	Endometriosis;Longevity;	chr7:1066169	chr7:1160374~1165267:+
OV	cis	rs2581828	0.656	rs2253656	ENSG00000242142.1	SERBP1P3	8.06	4.36e-14	1.61e-10	0.52	0.47	Crohn's disease;	chr3:53085083	chr3:53064283~53065091:-
OV	cis	rs494459	0.838	rs12796102	ENSG00000255239.1	AP002954.6	8.06	4.38e-14	1.62e-10	0.55	0.47	Height;	chr11:118791319	chr11:118688039~118690600:-
OV	cis	rs875971	0.558	rs4433015	ENSG00000222364.1	RNU6-96P	8.06	4.39e-14	1.62e-10	0.48	0.47	Aortic root size;	chr7:66174736	chr7:66395191~66395286:+
OV	cis	rs11168854	0.719	rs11168902	ENSG00000258017.1	RP11-386G11.10	-8.06	4.44e-14	1.64e-10	-0.57	-0.47	Body mass index;	chr12:49174483	chr12:49127782~49147869:+
OV	cis	rs2117029	0.553	rs11168903	ENSG00000258017.1	RP11-386G11.10	-8.06	4.44e-14	1.64e-10	-0.57	-0.47	Intelligence (multi-trait analysis);	chr12:49174883	chr12:49127782~49147869:+
OV	cis	rs2729354	0.817	rs2250673	ENSG00000265566.2	RN7SL605P	-8.06	4.45e-14	1.64e-10	-0.69	-0.47	Blood protein levels;	chr11:57500697	chr11:57528085~57528365:-
OV	cis	rs11690935	0.959	rs10184866	ENSG00000228389.1	AC068039.4	8.05	4.5e-14	1.66e-10	0.53	0.47	Schizophrenia;	chr2:171752446	chr2:171773482~171775844:+
OV	cis	rs9368481	0.761	rs9357030	ENSG00000243307.2	POM121L6P	-8.05	4.51e-14	1.67e-10	-0.47	-0.47	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:26896952~26898777:+
OV	cis	rs2117029	0.586	rs11168874	ENSG00000258017.1	RP11-386G11.10	-8.05	4.52e-14	1.67e-10	-0.57	-0.47	Intelligence (multi-trait analysis);	chr12:49133753	chr12:49127782~49147869:+
OV	cis	rs2117029	0.521	rs11168885	ENSG00000258017.1	RP11-386G11.10	-8.05	4.52e-14	1.67e-10	-0.57	-0.47	Intelligence (multi-trait analysis);	chr12:49146204	chr12:49127782~49147869:+
OV	cis	rs875971	0.706	rs1643374	ENSG00000222364.1	RNU6-96P	-8.05	4.6e-14	1.69e-10	-0.49	-0.47	Aortic root size;	chr7:66407695	chr7:66395191~66395286:+
OV	cis	rs7246967	0.673	rs56209802	ENSG00000269509.1	BNIP3P34	8.05	4.66e-14	1.71e-10	0.75	0.47	Bronchopulmonary dysplasia;	chr19:22842750	chr19:22773853~22774424:+
OV	cis	rs7246967	0.8	rs8108944	ENSG00000269509.1	BNIP3P34	8.05	4.66e-14	1.71e-10	0.75	0.47	Bronchopulmonary dysplasia;	chr19:22855641	chr19:22773853~22774424:+
OV	cis	rs875971	0.577	rs34888281	ENSG00000222364.1	RNU6-96P	8.05	4.67e-14	1.72e-10	0.48	0.47	Aortic root size;	chr7:66120784	chr7:66395191~66395286:+
OV	cis	rs4423214	0.61	rs3763856	ENSG00000254682.1	RP11-660L16.2	8.05	4.73e-14	1.74e-10	0.56	0.47	Vitamin D levels;	chr11:71414299	chr11:71448674~71452157:+
OV	cis	rs801193	1	rs2055682	ENSG00000222364.1	RNU6-96P	-8.04	4.79e-14	1.76e-10	-0.49	-0.47	Aortic root size;	chr7:66795302	chr7:66395191~66395286:+
OV	cis	rs10256972	0.616	rs7806746	ENSG00000229043.2	AC091729.9	-8.04	4.85e-14	1.78e-10	-0.54	-0.47	Endometriosis;Longevity;	chr7:1035937	chr7:1160374~1165267:+
OV	cis	rs875971	0.577	rs34888281	ENSG00000226824.5	RP4-756H11.3	8.04	4.86e-14	1.78e-10	0.49	0.47	Aortic root size;	chr7:66120784	chr7:66654538~66669855:+
OV	cis	rs9549260	0.753	rs9532563	ENSG00000229456.1	RLIMP1	8.04	4.87e-14	1.79e-10	0.56	0.47	Red blood cell count;	chr13:40586133	chr13:40618738~40621348:+
OV	cis	rs494459	0.726	rs1784300	ENSG00000255239.1	AP002954.6	8.04	4.92e-14	1.8e-10	0.56	0.47	Height;	chr11:118808920	chr11:118688039~118690600:-
OV	cis	rs11690935	0.959	rs6705200	ENSG00000228389.1	AC068039.4	8.04	4.95e-14	1.81e-10	0.54	0.47	Schizophrenia;	chr2:171781090	chr2:171773482~171775844:+
OV	cis	rs11159086	0.793	rs1029701	ENSG00000259005.1	RP3-449M8.6	8.04	4.97e-14	1.82e-10	0.71	0.47	Advanced glycation end-product levels;	chr14:74474112	chr14:74474007~74474864:-
OV	cis	rs2658782	0.724	rs2605626	ENSG00000279684.1	RP11-755E23.2	-8.04	4.99e-14	1.83e-10	-0.63	-0.47	Pulmonary function decline;	chr11:93520737	chr11:93286629~93288903:-
OV	cis	rs10262624	1	rs7792262	ENSG00000234286.1	AC006026.13	8.04	5.03e-14	1.84e-10	0.52	0.47	Schizophrenia;	chr7:23876124	chr7:23680195~23680786:-
OV	cis	rs1075265	0.584	rs1862122	ENSG00000233266.1	HMGB1P31	-8.04	5.07e-14	1.85e-10	-0.58	-0.47	Chronotype;Morning vs. evening chronotype;	chr2:54052992	chr2:54051334~54051760:+
OV	cis	rs875971	0.862	rs949930	ENSG00000226824.5	RP4-756H11.3	8.03	5.14e-14	1.88e-10	0.49	0.47	Aortic root size;	chr7:66301835	chr7:66654538~66669855:+
OV	cis	rs875971	0.928	rs2036263	ENSG00000226824.5	RP4-756H11.3	8.03	5.14e-14	1.88e-10	0.49	0.47	Aortic root size;	chr7:66335210	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs10240949	ENSG00000226824.5	RP4-756H11.3	8.03	5.14e-14	1.88e-10	0.49	0.47	Aortic root size;	chr7:66339430	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs7782704	ENSG00000226824.5	RP4-756H11.3	8.03	5.14e-14	1.88e-10	0.49	0.47	Aortic root size;	chr7:66340379	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs6460290	ENSG00000226824.5	RP4-756H11.3	8.03	5.14e-14	1.88e-10	0.49	0.47	Aortic root size;	chr7:66344119	chr7:66654538~66669855:+
OV	cis	rs4423214	0.84	rs1790340	ENSG00000254682.1	RP11-660L16.2	-8.03	5.16e-14	1.88e-10	-0.61	-0.47	Vitamin D levels;	chr11:71471543	chr11:71448674~71452157:+
OV	cis	rs875971	1	rs3981131	ENSG00000226824.5	RP4-756H11.3	-8.03	5.21e-14	1.9e-10	-0.5	-0.47	Aortic root size;	chr7:66486690	chr7:66654538~66669855:+
OV	cis	rs765787	0.53	rs4774542	ENSG00000259520.4	CTD-2651B20.3	-8.03	5.32e-14	1.94e-10	-0.53	-0.47	Uric acid levels;	chr15:45233828	chr15:45251580~45279251:-
OV	cis	rs2836974	0.897	rs3945	ENSG00000232608.1	TIMM9P2	-8.02	5.52e-14	2.01e-10	-0.55	-0.47	Cognitive function;	chr21:39194141	chr21:39216624~39217506:+
OV	cis	rs875971	0.862	rs6944374	ENSG00000226824.5	RP4-756H11.3	8.02	5.69e-14	2.07e-10	0.49	0.47	Aortic root size;	chr7:66221942	chr7:66654538~66669855:+
OV	cis	rs1387259	0.931	rs11168474	ENSG00000258273.1	RP11-370I10.4	-8.01	5.79e-14	2.1e-10	-0.56	-0.47	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48227601	chr12:48333755~48333901:-
OV	cis	rs2729354	0.768	rs2848635	ENSG00000265566.2	RN7SL605P	-8.01	5.8e-14	2.1e-10	-0.69	-0.47	Blood protein levels;	chr11:57486458	chr11:57528085~57528365:-
OV	cis	rs2836974	0.932	rs2836955	ENSG00000232608.1	TIMM9P2	-8.01	5.88e-14	2.13e-10	-0.55	-0.47	Cognitive function;	chr21:39247961	chr21:39216624~39217506:+
OV	cis	rs875971	0.862	rs2901152	ENSG00000226824.5	RP4-756H11.3	8.01	5.95e-14	2.15e-10	0.49	0.47	Aortic root size;	chr7:66300017	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs10263690	ENSG00000226824.5	RP4-756H11.3	8.01	5.95e-14	2.15e-10	0.49	0.47	Aortic root size;	chr7:66301466	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs10250544	ENSG00000226824.5	RP4-756H11.3	8.01	5.95e-14	2.15e-10	0.49	0.47	Aortic root size;	chr7:66301574	chr7:66654538~66669855:+
OV	cis	rs875971	0.895	rs12531677	ENSG00000226824.5	RP4-756H11.3	8.01	5.95e-14	2.15e-10	0.49	0.47	Aortic root size;	chr7:66304099	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs7798630	ENSG00000226824.5	RP4-756H11.3	8.01	5.95e-14	2.15e-10	0.49	0.47	Aortic root size;	chr7:66306492	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs11984115	ENSG00000226824.5	RP4-756H11.3	8.01	5.95e-14	2.15e-10	0.49	0.47	Aortic root size;	chr7:66308872	chr7:66654538~66669855:+
OV	cis	rs875971	0.755	rs10228885	ENSG00000226824.5	RP4-756H11.3	8.01	5.95e-14	2.15e-10	0.49	0.47	Aortic root size;	chr7:66315542	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs3893216	ENSG00000226824.5	RP4-756H11.3	8.01	5.95e-14	2.15e-10	0.49	0.47	Aortic root size;	chr7:66325720	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs6958294	ENSG00000226824.5	RP4-756H11.3	8.01	5.95e-14	2.15e-10	0.49	0.47	Aortic root size;	chr7:66329809	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs2088655	ENSG00000226824.5	RP4-756H11.3	8.01	5.95e-14	2.15e-10	0.49	0.47	Aortic root size;	chr7:66330724	chr7:66654538~66669855:+
OV	cis	rs875971	0.895	rs10447522	ENSG00000226824.5	RP4-756H11.3	8.01	5.95e-14	2.15e-10	0.49	0.47	Aortic root size;	chr7:66331087	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs2088653	ENSG00000226824.5	RP4-756H11.3	8.01	5.95e-14	2.15e-10	0.49	0.47	Aortic root size;	chr7:66343621	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs6460293	ENSG00000226824.5	RP4-756H11.3	8.01	5.95e-14	2.15e-10	0.49	0.47	Aortic root size;	chr7:66345205	chr7:66654538~66669855:+
OV	cis	rs2117029	0.523	rs12227296	ENSG00000258017.1	RP11-386G11.10	-8.01	6.06e-14	2.18e-10	-0.57	-0.47	Intelligence (multi-trait analysis);	chr12:49136712	chr12:49127782~49147869:+
OV	cis	rs2117029	0.521	rs10875925	ENSG00000258017.1	RP11-386G11.10	-8.01	6.06e-14	2.18e-10	-0.57	-0.47	Intelligence (multi-trait analysis);	chr12:49142575	chr12:49127782~49147869:+
OV	cis	rs2117029	0.586	rs11168882	ENSG00000258017.1	RP11-386G11.10	-8.01	6.06e-14	2.18e-10	-0.57	-0.47	Intelligence (multi-trait analysis);	chr12:49143560	chr12:49127782~49147869:+
OV	cis	rs2117029	0.521	rs12227610	ENSG00000258017.1	RP11-386G11.10	-8.01	6.06e-14	2.18e-10	-0.57	-0.47	Intelligence (multi-trait analysis);	chr12:49146153	chr12:49127782~49147869:+
OV	cis	rs494459	0.691	rs607472	ENSG00000255239.1	AP002954.6	8.01	6.09e-14	2.19e-10	0.55	0.47	Height;	chr11:118809363	chr11:118688039~118690600:-
OV	cis	rs6903823	0.508	rs1150721	ENSG00000216901.1	AL022393.7	8.01	6.09e-14	2.19e-10	0.55	0.47	Pulmonary function;	chr6:28287263	chr6:28176188~28176674:+
OV	cis	rs4853012	0.838	rs60964317	ENSG00000217702.2	RP11-287D1.4	8	6.2e-14	2.23e-10	0.69	0.47	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74130583~74135395:+
OV	cis	rs55794721	0.509	rs12027110	ENSG00000261349.1	RP3-465N24.5	-8	6.32e-14	2.28e-10	-0.49	-0.47	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25266102~25267136:-
OV	cis	rs858239	0.863	rs274054	ENSG00000230658.1	KLHL7-AS1	7.99	6.85e-14	2.45e-10	0.61	0.47	Cerebrospinal fluid biomarker levels;	chr7:23350848	chr7:23101228~23105703:-
OV	cis	rs2408955	0.521	rs11168437	ENSG00000258273.1	RP11-370I10.4	-7.98	6.99e-14	2.5e-10	-0.57	-0.47	Glycated hemoglobin levels;	chr12:48172373	chr12:48333755~48333901:-
OV	cis	rs801193	0.967	rs3800823	ENSG00000222364.1	RNU6-96P	7.98	7.03e-14	2.52e-10	0.48	0.47	Aortic root size;	chr7:66682123	chr7:66395191~66395286:+
OV	cis	rs7267979	0.509	rs6115218	ENSG00000274973.1	RP13-401N8.7	-7.98	7.17e-14	2.56e-10	-0.58	-0.47	Liver enzyme levels (alkaline phosphatase);	chr20:25585849	chr20:25845497~25845862:+
OV	cis	rs11690935	0.851	rs9808259	ENSG00000228389.1	AC068039.4	7.98	7.2e-14	2.57e-10	0.54	0.47	Schizophrenia;	chr2:171792464	chr2:171773482~171775844:+
OV	cis	rs11690935	0.959	rs10167419	ENSG00000228389.1	AC068039.4	7.98	7.2e-14	2.57e-10	0.54	0.47	Schizophrenia;	chr2:171793316	chr2:171773482~171775844:+
OV	cis	rs1577917	0.545	rs9450325	ENSG00000203875.9	SNHG5	7.98	7.35e-14	2.62e-10	0.53	0.47	Response to antipsychotic treatment;	chr6:85766096	chr6:85660950~85678736:-
OV	cis	rs875971	0.862	rs4236208	ENSG00000226824.5	RP4-756H11.3	7.98	7.37e-14	2.63e-10	0.49	0.47	Aortic root size;	chr7:66284091	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs10261398	ENSG00000226824.5	RP4-756H11.3	7.98	7.37e-14	2.63e-10	0.49	0.47	Aortic root size;	chr7:66285177	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs10224872	ENSG00000226824.5	RP4-756H11.3	7.98	7.37e-14	2.63e-10	0.49	0.47	Aortic root size;	chr7:66294786	chr7:66654538~66669855:+
OV	cis	rs10262624	0.528	rs5029444	ENSG00000234286.1	AC006026.13	7.97	7.49e-14	2.67e-10	0.53	0.47	Schizophrenia;	chr7:23698176	chr7:23680195~23680786:-
OV	cis	rs875971	0.825	rs1000464	ENSG00000226824.5	RP4-756H11.3	7.97	7.56e-14	2.69e-10	0.49	0.47	Aortic root size;	chr7:66312922	chr7:66654538~66669855:+
OV	cis	rs858239	0.796	rs433395	ENSG00000230658.1	KLHL7-AS1	7.97	7.75e-14	2.75e-10	0.59	0.47	Cerebrospinal fluid biomarker levels;	chr7:23362336	chr7:23101228~23105703:-
OV	cis	rs11159086	0.793	rs1029703	ENSG00000259005.1	RP3-449M8.6	7.97	7.76e-14	2.75e-10	0.72	0.47	Advanced glycation end-product levels;	chr14:74473899	chr14:74474007~74474864:-
OV	cis	rs11159086	0.793	rs12432412	ENSG00000259005.1	RP3-449M8.6	7.97	7.76e-14	2.75e-10	0.72	0.47	Advanced glycation end-product levels;	chr14:74474294	chr14:74474007~74474864:-
OV	cis	rs11159086	0.793	rs1029700	ENSG00000259005.1	RP3-449M8.6	7.97	7.76e-14	2.75e-10	0.72	0.47	Advanced glycation end-product levels;	chr14:74474309	chr14:74474007~74474864:-
OV	cis	rs11159086	0.793	rs1029699	ENSG00000259005.1	RP3-449M8.6	7.97	7.76e-14	2.75e-10	0.72	0.47	Advanced glycation end-product levels;	chr14:74474790	chr14:74474007~74474864:-
OV	cis	rs2658782	0.654	rs2605620	ENSG00000279684.1	RP11-755E23.2	-7.97	7.81e-14	2.77e-10	-0.63	-0.47	Pulmonary function decline;	chr11:93514480	chr11:93286629~93288903:-
OV	cis	rs2836974	0.897	rs13049280	ENSG00000232608.1	TIMM9P2	-7.97	7.92e-14	2.81e-10	-0.55	-0.47	Cognitive function;	chr21:39222730	chr21:39216624~39217506:+
OV	cis	rs2117029	0.521	rs58336603	ENSG00000258017.1	RP11-386G11.10	-7.96	8.04e-14	2.85e-10	-0.55	-0.47	Intelligence (multi-trait analysis);	chr12:49163105	chr12:49127782~49147869:+
OV	cis	rs2117029	0.553	rs1991427	ENSG00000258017.1	RP11-386G11.10	-7.96	8.04e-14	2.85e-10	-0.55	-0.47	Intelligence (multi-trait analysis);	chr12:49164175	chr12:49127782~49147869:+
OV	cis	rs2117029	0.521	rs6580702	ENSG00000258017.1	RP11-386G11.10	-7.96	8.04e-14	2.85e-10	-0.55	-0.47	Intelligence (multi-trait analysis);	chr12:49169483	chr12:49127782~49147869:+
OV	cis	rs2732480	0.577	rs2732481	ENSG00000258273.1	RP11-370I10.4	-7.96	8.22e-14	2.91e-10	-0.56	-0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343202	chr12:48333755~48333901:-
OV	cis	rs2732480	0.557	rs2732484	ENSG00000258273.1	RP11-370I10.4	-7.96	8.22e-14	2.91e-10	-0.56	-0.47	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48343462	chr12:48333755~48333901:-
OV	cis	rs10256972	0.758	rs9801444	ENSG00000229043.2	AC091729.9	7.96	8.37e-14	2.96e-10	0.57	0.47	Endometriosis;Longevity;	chr7:1040808	chr7:1160374~1165267:+
OV	cis	rs1528149	1	rs1528149	ENSG00000224683.1	RPL36AP29	7.96	8.38e-14	2.96e-10	0.6	0.47	Sitting height ratio;	chr7:16067733	chr7:16208945~16209265:+
OV	cis	rs875971	0.862	rs4718330	ENSG00000226824.5	RP4-756H11.3	7.95	8.45e-14	2.98e-10	0.49	0.47	Aortic root size;	chr7:66250256	chr7:66654538~66669855:+
OV	cis	rs16828019	0.852	rs12729586	ENSG00000235358.1	RP11-399E6.1	7.95	8.46e-14	2.98e-10	0.89	0.47	Intelligence (multi-trait analysis);	chr1:41056705	chr1:41242373~41284861:+
OV	cis	rs16828019	0.704	rs34486565	ENSG00000235358.1	RP11-399E6.1	7.95	8.46e-14	2.98e-10	0.89	0.47	Intelligence (multi-trait analysis);	chr1:41056838	chr1:41242373~41284861:+
OV	cis	rs16828019	0.852	rs12742379	ENSG00000235358.1	RP11-399E6.1	7.95	8.46e-14	2.98e-10	0.89	0.47	Intelligence (multi-trait analysis);	chr1:41060709	chr1:41242373~41284861:+
OV	cis	rs12922317	0.86	rs2541583	ENSG00000260224.1	UBL5P4	7.95	8.65e-14	3.05e-10	0.51	0.47	Schizophrenia;	chr16:12037264	chr16:11968508~11968743:-
OV	cis	rs7396835	0.5	rs5092	ENSG00000254851.1	RP11-109L13.1	-7.95	8.67e-14	3.06e-10	-0.69	-0.47	Quantitative traits;	chr11:116822748	chr11:117135528~117138582:+
OV	cis	rs10262624	1	rs10262624	ENSG00000234286.1	AC006026.13	-7.95	8.73e-14	3.07e-10	-0.52	-0.47	Schizophrenia;	chr7:23876057	chr7:23680195~23680786:-
OV	cis	rs11690935	1	rs6721680	ENSG00000228389.1	AC068039.4	-7.95	8.73e-14	3.07e-10	-0.53	-0.47	Schizophrenia;	chr2:171687403	chr2:171773482~171775844:+
OV	cis	rs10262624	0.967	rs2390848	ENSG00000234286.1	AC006026.13	-7.95	8.74e-14	3.07e-10	-0.52	-0.47	Schizophrenia;	chr7:23872755	chr7:23680195~23680786:-
OV	cis	rs10262624	1	rs2023787	ENSG00000234286.1	AC006026.13	-7.95	8.74e-14	3.07e-10	-0.52	-0.47	Schizophrenia;	chr7:23875521	chr7:23680195~23680786:-
OV	cis	rs10262624	1	rs17347505	ENSG00000234286.1	AC006026.13	-7.95	8.74e-14	3.07e-10	-0.52	-0.47	Schizophrenia;	chr7:23875664	chr7:23680195~23680786:-
OV	cis	rs10262624	1	rs12671624	ENSG00000234286.1	AC006026.13	-7.95	8.74e-14	3.07e-10	-0.52	-0.47	Schizophrenia;	chr7:23875794	chr7:23680195~23680786:-
OV	cis	rs10262624	1	rs12671584	ENSG00000234286.1	AC006026.13	-7.95	8.74e-14	3.07e-10	-0.52	-0.47	Schizophrenia;	chr7:23875803	chr7:23680195~23680786:-
OV	cis	rs10262624	0.935	rs8180700	ENSG00000234286.1	AC006026.13	-7.95	8.77e-14	3.09e-10	-0.52	-0.47	Schizophrenia;	chr7:23870323	chr7:23680195~23680786:-
OV	cis	rs853679	0.527	rs213228	ENSG00000216901.1	AL022393.7	7.95	8.79e-14	3.09e-10	0.56	0.47	Depression;	chr6:28363475	chr6:28176188~28176674:+
OV	cis	rs11603023	0.967	rs494560	ENSG00000255239.1	AP002954.6	-7.95	8.81e-14	3.1e-10	-0.52	-0.47	Cholesterol, total;	chr11:118650844	chr11:118688039~118690600:-
OV	cis	rs875971	0.862	rs709596	ENSG00000226824.5	RP4-756H11.3	-7.95	8.98e-14	3.15e-10	-0.48	-0.47	Aortic root size;	chr7:66360926	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs778686	ENSG00000226824.5	RP4-756H11.3	-7.95	8.98e-14	3.15e-10	-0.48	-0.47	Aortic root size;	chr7:66370923	chr7:66654538~66669855:+
OV	cis	rs1707322	0.686	rs2991986	ENSG00000281133.1	AL355480.3	7.94	9.22e-14	3.24e-10	0.61	0.47	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr1:45580892~45580996:-
OV	cis	rs10262624	0.967	rs7792734	ENSG00000234286.1	AC006026.13	-7.94	9.27e-14	3.25e-10	-0.52	-0.47	Schizophrenia;	chr7:23876429	chr7:23680195~23680786:-
OV	cis	rs10262624	0.528	rs722294	ENSG00000234286.1	AC006026.13	7.94	9.42e-14	3.3e-10	0.53	0.47	Schizophrenia;	chr7:23706966	chr7:23680195~23680786:-
OV	cis	rs507080	0.922	rs4936433	ENSG00000255422.1	AP002954.4	7.94	9.49e-14	3.33e-10	0.52	0.47	Serum metabolite levels;	chr11:118681711	chr11:118704607~118750263:+
OV	cis	rs2729354	0.768	rs2729384	ENSG00000265566.2	RN7SL605P	-7.94	9.53e-14	3.34e-10	-0.69	-0.47	Blood protein levels;	chr11:57491144	chr11:57528085~57528365:-
OV	cis	rs858239	1	rs199357	ENSG00000230658.1	KLHL7-AS1	-7.94	9.54e-14	3.34e-10	-0.62	-0.47	Cerebrospinal fluid biomarker levels;	chr7:23248690	chr7:23101228~23105703:-
OV	cis	rs7246967	0.736	rs446058	ENSG00000269509.1	BNIP3P34	7.94	9.56e-14	3.35e-10	0.73	0.47	Bronchopulmonary dysplasia;	chr19:22817259	chr19:22773853~22774424:+
OV	cis	rs10262624	0.901	rs6966655	ENSG00000234286.1	AC006026.13	-7.93	9.58e-14	3.36e-10	-0.51	-0.47	Schizophrenia;	chr7:23867010	chr7:23680195~23680786:-
OV	cis	rs875971	0.862	rs2909688	ENSG00000226824.5	RP4-756H11.3	-7.93	9.63e-14	3.37e-10	-0.49	-0.47	Aortic root size;	chr7:66376625	chr7:66654538~66669855:+
OV	cis	rs875971	0.83	rs778711	ENSG00000226824.5	RP4-756H11.3	-7.93	9.63e-14	3.37e-10	-0.49	-0.47	Aortic root size;	chr7:66386670	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs1083554	ENSG00000226824.5	RP4-756H11.3	-7.93	9.63e-14	3.37e-10	-0.49	-0.47	Aortic root size;	chr7:66387354	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs778707	ENSG00000226824.5	RP4-756H11.3	-7.93	9.63e-14	3.37e-10	-0.49	-0.47	Aortic root size;	chr7:66392040	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs778705	ENSG00000226824.5	RP4-756H11.3	-7.93	9.63e-14	3.37e-10	-0.49	-0.47	Aortic root size;	chr7:66396128	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs778697	ENSG00000226824.5	RP4-756H11.3	-7.93	9.63e-14	3.37e-10	-0.49	-0.47	Aortic root size;	chr7:66405439	chr7:66654538~66669855:+
OV	cis	rs875971	0.798	rs7789615	ENSG00000226824.5	RP4-756H11.3	-7.93	9.63e-14	3.37e-10	-0.49	-0.47	Aortic root size;	chr7:66413674	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs6978028	ENSG00000226824.5	RP4-756H11.3	-7.93	9.63e-14	3.37e-10	-0.49	-0.47	Aortic root size;	chr7:66421313	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs6947339	ENSG00000226824.5	RP4-756H11.3	-7.93	9.63e-14	3.37e-10	-0.49	-0.47	Aortic root size;	chr7:66423483	chr7:66654538~66669855:+
OV	cis	rs801193	0.967	rs34356500	ENSG00000226824.5	RP4-756H11.3	-7.93	9.64e-14	3.37e-10	-0.5	-0.47	Aortic root size;	chr7:66771620	chr7:66654538~66669855:+
OV	cis	rs9326248	0.53	rs2075292	ENSG00000254851.1	RP11-109L13.1	-7.93	9.68e-14	3.38e-10	-0.83	-0.47	Blood protein levels;	chr11:116861796	chr11:117135528~117138582:+
OV	cis	rs875971	0.756	rs4718328	ENSG00000226824.5	RP4-756H11.3	7.93	9.8e-14	3.42e-10	0.48	0.47	Aortic root size;	chr7:66228350	chr7:66654538~66669855:+
OV	cis	rs11690935	0.959	rs12185567	ENSG00000228389.1	AC068039.4	-7.93	9.93e-14	3.46e-10	-0.54	-0.47	Schizophrenia;	chr2:171704219	chr2:171773482~171775844:+
OV	cis	rs801193	0.569	rs2659893	ENSG00000226824.5	RP4-756H11.3	-7.93	9.98e-14	3.47e-10	-0.49	-0.47	Aortic root size;	chr7:66735006	chr7:66654538~66669855:+
OV	cis	rs801193	0.569	rs2659892	ENSG00000226824.5	RP4-756H11.3	-7.93	9.98e-14	3.47e-10	-0.49	-0.47	Aortic root size;	chr7:66735318	chr7:66654538~66669855:+
OV	cis	rs11690935	1	rs2138348	ENSG00000228389.1	AC068039.4	-7.93	1.01e-13	3.52e-10	-0.52	-0.47	Schizophrenia;	chr2:171701662	chr2:171773482~171775844:+
OV	cis	rs11690935	0.959	rs3770452	ENSG00000228389.1	AC068039.4	7.93	1.01e-13	3.53e-10	0.53	0.47	Schizophrenia;	chr2:171812172	chr2:171773482~171775844:+
OV	cis	rs801193	0.548	rs2659891	ENSG00000226824.5	RP4-756H11.3	-7.93	1.02e-13	3.53e-10	-0.49	-0.47	Aortic root size;	chr7:66736127	chr7:66654538~66669855:+
OV	cis	rs11603023	0.874	rs613243	ENSG00000255239.1	AP002954.6	7.93	1.02e-13	3.54e-10	0.49	0.47	Cholesterol, total;	chr11:118643304	chr11:118688039~118690600:-
OV	cis	rs2729354	0.768	rs2584856	ENSG00000265566.2	RN7SL605P	-7.92	1.02e-13	3.55e-10	-0.68	-0.47	Blood protein levels;	chr11:57499839	chr11:57528085~57528365:-
OV	cis	rs9326248	0.53	rs6589575	ENSG00000254851.1	RP11-109L13.1	-7.92	1.02e-13	3.55e-10	-0.82	-0.47	Blood protein levels;	chr11:116862594	chr11:117135528~117138582:+
OV	cis	rs9326248	0.53	rs718847	ENSG00000254851.1	RP11-109L13.1	-7.92	1.02e-13	3.55e-10	-0.82	-0.47	Blood protein levels;	chr11:116863430	chr11:117135528~117138582:+
OV	cis	rs2117029	0.521	rs2114845	ENSG00000258017.1	RP11-386G11.10	-7.92	1.06e-13	3.69e-10	-0.55	-0.47	Intelligence (multi-trait analysis);	chr12:49164750	chr12:49127782~49147869:+
OV	cis	rs801193	0.569	rs13226966	ENSG00000226824.5	RP4-756H11.3	-7.92	1.07e-13	3.7e-10	-0.48	-0.47	Aortic root size;	chr7:66768636	chr7:66654538~66669855:+
OV	cis	rs11159086	0.729	rs8015872	ENSG00000259005.1	RP3-449M8.6	7.91	1.09e-13	3.78e-10	0.71	0.47	Advanced glycation end-product levels;	chr14:74475529	chr14:74474007~74474864:-
OV	cis	rs11159086	0.793	rs10147316	ENSG00000259005.1	RP3-449M8.6	7.91	1.09e-13	3.78e-10	0.71	0.47	Advanced glycation end-product levels;	chr14:74475688	chr14:74474007~74474864:-
OV	cis	rs11159086	0.838	rs10147963	ENSG00000259005.1	RP3-449M8.6	7.91	1.09e-13	3.78e-10	0.71	0.47	Advanced glycation end-product levels;	chr14:74476091	chr14:74474007~74474864:-
OV	cis	rs11159086	0.793	rs8021664	ENSG00000259005.1	RP3-449M8.6	7.91	1.09e-13	3.78e-10	0.71	0.47	Advanced glycation end-product levels;	chr14:74476592	chr14:74474007~74474864:-
OV	cis	rs11159086	0.793	rs10150696	ENSG00000259005.1	RP3-449M8.6	7.91	1.09e-13	3.78e-10	0.71	0.47	Advanced glycation end-product levels;	chr14:74476723	chr14:74474007~74474864:-
OV	cis	rs11159086	0.793	rs1860108	ENSG00000259005.1	RP3-449M8.6	7.91	1.09e-13	3.78e-10	0.71	0.47	Advanced glycation end-product levels;	chr14:74478562	chr14:74474007~74474864:-
OV	cis	rs801193	1	rs17566701	ENSG00000222364.1	RNU6-96P	-7.91	1.09e-13	3.79e-10	-0.49	-0.47	Aortic root size;	chr7:66728196	chr7:66395191~66395286:+
OV	cis	rs801193	0.569	rs2707824	ENSG00000226824.5	RP4-756H11.3	-7.91	1.1e-13	3.81e-10	-0.48	-0.46	Aortic root size;	chr7:66724256	chr7:66654538~66669855:+
OV	cis	rs801193	0.742	rs9969300	ENSG00000226824.5	RP4-756H11.3	7.91	1.15e-13	3.97e-10	0.5	0.46	Aortic root size;	chr7:66316659	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs6460282	ENSG00000226824.5	RP4-756H11.3	7.9	1.19e-13	4.08e-10	0.49	0.46	Aortic root size;	chr7:66226259	chr7:66654538~66669855:+
OV	cis	rs11690935	0.921	rs3770445	ENSG00000228389.1	AC068039.4	7.9	1.19e-13	4.1e-10	0.54	0.46	Schizophrenia;	chr2:171852409	chr2:171773482~171775844:+
OV	cis	rs7246967	0.736	rs423687	ENSG00000269509.1	BNIP3P34	7.9	1.19e-13	4.1e-10	0.73	0.46	Bronchopulmonary dysplasia;	chr19:22817943	chr19:22773853~22774424:+
OV	cis	rs7246967	0.736	rs386119	ENSG00000269509.1	BNIP3P34	7.9	1.19e-13	4.1e-10	0.73	0.46	Bronchopulmonary dysplasia;	chr19:22818016	chr19:22773853~22774424:+
OV	cis	rs11159086	0.793	rs11845370	ENSG00000259005.1	RP3-449M8.6	7.9	1.19e-13	4.1e-10	0.71	0.46	Advanced glycation end-product levels;	chr14:74481587	chr14:74474007~74474864:-
OV	cis	rs11159086	0.793	rs3784035	ENSG00000259005.1	RP3-449M8.6	7.9	1.19e-13	4.1e-10	0.71	0.46	Advanced glycation end-product levels;	chr14:74482221	chr14:74474007~74474864:-
OV	cis	rs11159086	0.793	rs12433382	ENSG00000259005.1	RP3-449M8.6	7.9	1.19e-13	4.1e-10	0.71	0.46	Advanced glycation end-product levels;	chr14:74482940	chr14:74474007~74474864:-
OV	cis	rs11159086	0.793	rs10148268	ENSG00000259005.1	RP3-449M8.6	7.9	1.19e-13	4.1e-10	0.71	0.46	Advanced glycation end-product levels;	chr14:74484261	chr14:74474007~74474864:-
OV	cis	rs11159086	0.793	rs11850070	ENSG00000259005.1	RP3-449M8.6	7.9	1.19e-13	4.1e-10	0.71	0.46	Advanced glycation end-product levels;	chr14:74487575	chr14:74474007~74474864:-
OV	cis	rs11159086	0.793	rs28378078	ENSG00000259005.1	RP3-449M8.6	7.9	1.19e-13	4.1e-10	0.71	0.46	Advanced glycation end-product levels;	chr14:74487940	chr14:74474007~74474864:-
OV	cis	rs11159086	0.793	rs9285594	ENSG00000259005.1	RP3-449M8.6	7.9	1.19e-13	4.1e-10	0.71	0.46	Advanced glycation end-product levels;	chr14:74489253	chr14:74474007~74474864:-
OV	cis	rs11159086	0.793	rs4903229	ENSG00000259005.1	RP3-449M8.6	7.9	1.19e-13	4.1e-10	0.71	0.46	Advanced glycation end-product levels;	chr14:74489865	chr14:74474007~74474864:-
OV	cis	rs11159086	0.793	rs8016972	ENSG00000259005.1	RP3-449M8.6	7.9	1.19e-13	4.1e-10	0.71	0.46	Advanced glycation end-product levels;	chr14:74491833	chr14:74474007~74474864:-
OV	cis	rs11159086	0.793	rs8015894	ENSG00000259005.1	RP3-449M8.6	7.9	1.19e-13	4.1e-10	0.71	0.46	Advanced glycation end-product levels;	chr14:74491917	chr14:74474007~74474864:-
OV	cis	rs1577917	0.545	rs1832070	ENSG00000203875.9	SNHG5	7.9	1.22e-13	4.2e-10	0.53	0.46	Response to antipsychotic treatment;	chr6:85773454	chr6:85660950~85678736:-
OV	cis	rs2729354	0.768	rs1001956	ENSG00000265566.2	RN7SL605P	-7.89	1.24e-13	4.25e-10	-0.68	-0.46	Blood protein levels;	chr11:57499476	chr11:57528085~57528365:-
OV	cis	rs1387259	0.899	rs7307566	ENSG00000258273.1	RP11-370I10.4	-7.89	1.25e-13	4.26e-10	-0.55	-0.46	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48210899	chr12:48333755~48333901:-
OV	cis	rs6782228	1	rs11718130	ENSG00000277250.1	Metazoa_SRP	7.89	1.25e-13	4.27e-10	0.57	0.46	Neutrophil count;Sum basophil neutrophil counts;Granulocyte count;Myeloid white cell count;Lymphocyte percentage of white cells;Monocyte count;White blood cell count;Sum neutrophil eosinophil counts;	chr3:128611184	chr3:128673681~128674021:-
OV	cis	rs2732480	0.537	rs1061986	ENSG00000258273.1	RP11-370I10.4	-7.89	1.26e-13	4.31e-10	-0.56	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342656	chr12:48333755~48333901:-
OV	cis	rs858239	0.862	rs1728292	ENSG00000230658.1	KLHL7-AS1	7.89	1.26e-13	4.32e-10	0.6	0.46	Cerebrospinal fluid biomarker levels;	chr7:23223855	chr7:23101228~23105703:-
OV	cis	rs2732480	0.517	rs2634676	ENSG00000258273.1	RP11-370I10.4	-7.89	1.28e-13	4.39e-10	-0.56	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344453	chr12:48333755~48333901:-
OV	cis	rs2732480	0.577	rs1489109	ENSG00000258273.1	RP11-370I10.4	-7.89	1.28e-13	4.39e-10	-0.56	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344997	chr12:48333755~48333901:-
OV	cis	rs2732480	0.577	rs1489108	ENSG00000258273.1	RP11-370I10.4	-7.89	1.28e-13	4.39e-10	-0.56	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344998	chr12:48333755~48333901:-
OV	cis	rs2729354	0.729	rs2729353	ENSG00000265566.2	RN7SL605P	-7.89	1.31e-13	4.47e-10	-0.69	-0.46	Blood protein levels;	chr11:57480530	chr11:57528085~57528365:-
OV	cis	rs10262624	1	rs10257777	ENSG00000234286.1	AC006026.13	-7.88	1.33e-13	4.53e-10	-0.52	-0.46	Schizophrenia;	chr7:23871362	chr7:23680195~23680786:-
OV	cis	rs9326248	0.861	rs11216172	ENSG00000254851.1	RP11-109L13.1	-7.88	1.34e-13	4.55e-10	-0.65	-0.46	Blood protein levels;	chr11:116879162	chr11:117135528~117138582:+
OV	cis	rs2729354	0.903	rs2729371	ENSG00000265566.2	RN7SL605P	-7.88	1.34e-13	4.58e-10	-0.7	-0.46	Blood protein levels;	chr11:57553849	chr11:57528085~57528365:-
OV	cis	rs2117029	0.521	rs12229524	ENSG00000258017.1	RP11-386G11.10	-7.88	1.35e-13	4.59e-10	-0.56	-0.46	Intelligence (multi-trait analysis);	chr12:49191570	chr12:49127782~49147869:+
OV	cis	rs11690935	1	rs312925	ENSG00000228389.1	AC068039.4	7.88	1.35e-13	4.6e-10	0.53	0.46	Schizophrenia;	chr2:171707412	chr2:171773482~171775844:+
OV	cis	rs801193	0.844	rs732465	ENSG00000222364.1	RNU6-96P	-7.88	1.35e-13	4.6e-10	-0.48	-0.46	Aortic root size;	chr7:66533463	chr7:66395191~66395286:+
OV	cis	rs801193	0.773	rs801207	ENSG00000222364.1	RNU6-96P	7.88	1.35e-13	4.6e-10	0.48	0.46	Aortic root size;	chr7:66555603	chr7:66395191~66395286:+
OV	cis	rs875971	0.543	rs801191	ENSG00000222364.1	RNU6-96P	7.88	1.35e-13	4.6e-10	0.48	0.46	Aortic root size;	chr7:66567968	chr7:66395191~66395286:+
OV	cis	rs875971	0.508	rs6947808	ENSG00000222364.1	RNU6-96P	7.88	1.35e-13	4.6e-10	0.48	0.46	Aortic root size;	chr7:66580095	chr7:66395191~66395286:+
OV	cis	rs11235843	0.714	rs7128512	ENSG00000255928.1	RP11-456I15.2	-7.88	1.39e-13	4.72e-10	-0.68	-0.46	Hand grip strength;	chr11:73661254	chr11:73722349~73722694:+
OV	cis	rs875971	0.83	rs809025	ENSG00000226824.5	RP4-756H11.3	-7.87	1.42e-13	4.8e-10	-0.48	-0.46	Aortic root size;	chr7:66384832	chr7:66654538~66669855:+
OV	cis	rs2729354	0.729	rs2258835	ENSG00000265566.2	RN7SL605P	-7.87	1.42e-13	4.8e-10	-0.69	-0.46	Blood protein levels;	chr11:57476115	chr11:57528085~57528365:-
OV	cis	rs10262624	0.935	rs4722283	ENSG00000234286.1	AC006026.13	7.87	1.43e-13	4.85e-10	0.5	0.46	Schizophrenia;	chr7:23866595	chr7:23680195~23680786:-
OV	cis	rs7246967	0.608	rs396440	ENSG00000269509.1	BNIP3P34	7.87	1.45e-13	4.93e-10	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22820164	chr19:22773853~22774424:+
OV	cis	rs7246967	0.608	rs433579	ENSG00000269509.1	BNIP3P34	7.87	1.45e-13	4.93e-10	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22820325	chr19:22773853~22774424:+
OV	cis	rs16828019	0.852	rs12045171	ENSG00000235358.1	RP11-399E6.1	7.87	1.46e-13	4.94e-10	0.83	0.46	Intelligence (multi-trait analysis);	chr1:41063133	chr1:41242373~41284861:+
OV	cis	rs875971	0.862	rs778724	ENSG00000226824.5	RP4-756H11.3	-7.87	1.46e-13	4.94e-10	-0.48	-0.46	Aortic root size;	chr7:66364304	chr7:66654538~66669855:+
OV	cis	rs875971	0.767	rs1643394	ENSG00000226824.5	RP4-756H11.3	-7.87	1.46e-13	4.94e-10	-0.48	-0.46	Aortic root size;	chr7:66371107	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs778684	ENSG00000226824.5	RP4-756H11.3	-7.87	1.46e-13	4.94e-10	-0.48	-0.46	Aortic root size;	chr7:66371416	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs778680	ENSG00000226824.5	RP4-756H11.3	-7.87	1.46e-13	4.94e-10	-0.48	-0.46	Aortic root size;	chr7:66375427	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs11769079	ENSG00000226824.5	RP4-756H11.3	-7.87	1.46e-13	4.94e-10	-0.48	-0.46	Aortic root size;	chr7:66377141	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs1695820	ENSG00000226824.5	RP4-756H11.3	-7.87	1.46e-13	4.94e-10	-0.48	-0.46	Aortic root size;	chr7:66379576	chr7:66654538~66669855:+
OV	cis	rs875971	0.83	rs778715	ENSG00000226824.5	RP4-756H11.3	-7.87	1.46e-13	4.94e-10	-0.48	-0.46	Aortic root size;	chr7:66384222	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs778702	ENSG00000226824.5	RP4-756H11.3	-7.87	1.46e-13	4.94e-10	-0.48	-0.46	Aortic root size;	chr7:66399848	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs1643375	ENSG00000226824.5	RP4-756H11.3	-7.87	1.46e-13	4.94e-10	-0.48	-0.46	Aortic root size;	chr7:66407690	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs6962717	ENSG00000226824.5	RP4-756H11.3	-7.87	1.46e-13	4.94e-10	-0.48	-0.46	Aortic root size;	chr7:66418748	chr7:66654538~66669855:+
OV	cis	rs17361889	0.671	rs1527201	ENSG00000224683.1	RPL36AP29	-7.87	1.48e-13	4.99e-10	-0.58	-0.46	Pediatric bone mineral content (hip);	chr7:16111403	chr7:16208945~16209265:+
OV	cis	rs4927850	1	rs7630875	ENSG00000231464.1	AC024937.4	7.86	1.49e-13	5.03e-10	0.56	0.46	Pancreatic cancer;	chr3:196026895	chr3:195996738~195998233:+
OV	cis	rs875971	0.508	rs10258739	ENSG00000226824.5	RP4-756H11.3	7.86	1.51e-13	5.08e-10	0.49	0.46	Aortic root size;	chr7:66597948	chr7:66654538~66669855:+
OV	cis	rs7617773	1	rs9832957	ENSG00000229759.1	MRPS18AP1	-7.86	1.51e-13	5.1e-10	-0.5	-0.46	Coronary artery disease;	chr3:48143776	chr3:48256350~48256938:-
OV	cis	rs2712431	0.554	rs2010054	ENSG00000242551.2	POU5F1P6	-7.86	1.51e-13	5.1e-10	-0.52	-0.46	Monocyte chemoattractant protein-1 levels;	chr3:128586459	chr3:128674735~128677005:-
OV	cis	rs2117029	0.554	rs12579015	ENSG00000258017.1	RP11-386G11.10	-7.86	1.53e-13	5.14e-10	-0.55	-0.46	Intelligence (multi-trait analysis);	chr12:49162648	chr12:49127782~49147869:+
OV	cis	rs2732480	0.577	rs2732486	ENSG00000258273.1	RP11-370I10.4	-7.86	1.54e-13	5.18e-10	-0.56	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48344051	chr12:48333755~48333901:-
OV	cis	rs875971	0.862	rs6460302	ENSG00000226824.5	RP4-756H11.3	-7.86	1.54e-13	5.18e-10	-0.47	-0.46	Aortic root size;	chr7:66495270	chr7:66654538~66669855:+
OV	cis	rs1075265	0.584	rs1862121	ENSG00000233266.1	HMGB1P31	7.86	1.54e-13	5.2e-10	0.57	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54058102	chr2:54051334~54051760:+
OV	cis	rs11690935	0.959	rs67204065	ENSG00000228389.1	AC068039.4	7.86	1.55e-13	5.2e-10	0.53	0.46	Schizophrenia;	chr2:171816114	chr2:171773482~171775844:+
OV	cis	rs7246967	0.673	rs4932784	ENSG00000269509.1	BNIP3P34	7.86	1.55e-13	5.22e-10	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22691449	chr19:22773853~22774424:+
OV	cis	rs11690935	0.921	rs6710698	ENSG00000228389.1	AC068039.4	7.86	1.56e-13	5.23e-10	0.52	0.46	Schizophrenia;	chr2:171739568	chr2:171773482~171775844:+
OV	cis	rs875971	0.798	rs6460304	ENSG00000226824.5	RP4-756H11.3	-7.86	1.57e-13	5.28e-10	-0.48	-0.46	Aortic root size;	chr7:66499741	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs6945775	ENSG00000226824.5	RP4-756H11.3	-7.86	1.57e-13	5.28e-10	-0.48	-0.46	Aortic root size;	chr7:66503987	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs2420174	ENSG00000226824.5	RP4-756H11.3	7.86	1.58e-13	5.31e-10	0.48	0.46	Aortic root size;	chr7:66180374	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs2420173	ENSG00000226824.5	RP4-756H11.3	7.86	1.58e-13	5.31e-10	0.48	0.46	Aortic root size;	chr7:66180412	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs4718319	ENSG00000226824.5	RP4-756H11.3	7.86	1.58e-13	5.31e-10	0.48	0.46	Aortic root size;	chr7:66187797	chr7:66654538~66669855:+
OV	cis	rs875971	0.723	rs28391294	ENSG00000226824.5	RP4-756H11.3	7.86	1.58e-13	5.31e-10	0.48	0.46	Aortic root size;	chr7:66189328	chr7:66654538~66669855:+
OV	cis	rs875971	0.83	rs6967708	ENSG00000226824.5	RP4-756H11.3	7.86	1.58e-13	5.31e-10	0.48	0.46	Aortic root size;	chr7:66192326	chr7:66654538~66669855:+
OV	cis	rs875971	0.895	rs7782806	ENSG00000226824.5	RP4-756H11.3	7.86	1.58e-13	5.31e-10	0.48	0.46	Aortic root size;	chr7:66192910	chr7:66654538~66669855:+
OV	cis	rs11690935	0.959	rs6724337	ENSG00000228389.1	AC068039.4	7.86	1.58e-13	5.31e-10	0.54	0.46	Schizophrenia;	chr2:171878819	chr2:171773482~171775844:+
OV	cis	rs2658782	0.738	rs2605628	ENSG00000279684.1	RP11-755E23.2	-7.85	1.6e-13	5.35e-10	-0.65	-0.46	Pulmonary function decline;	chr11:93528394	chr11:93286629~93288903:-
OV	cis	rs875971	0.508	rs10950045	ENSG00000222364.1	RNU6-96P	7.85	1.62e-13	5.41e-10	0.47	0.46	Aortic root size;	chr7:66601386	chr7:66395191~66395286:+
OV	cis	rs801193	0.839	rs6968619	ENSG00000222364.1	RNU6-96P	7.85	1.62e-13	5.41e-10	0.47	0.46	Aortic root size;	chr7:66603880	chr7:66395191~66395286:+
OV	cis	rs801193	0.839	rs12534943	ENSG00000222364.1	RNU6-96P	7.85	1.62e-13	5.41e-10	0.47	0.46	Aortic root size;	chr7:66605533	chr7:66395191~66395286:+
OV	cis	rs801193	0.805	rs12532355	ENSG00000222364.1	RNU6-96P	7.85	1.62e-13	5.41e-10	0.47	0.46	Aortic root size;	chr7:66605597	chr7:66395191~66395286:+
OV	cis	rs858239	1	rs156425	ENSG00000230658.1	KLHL7-AS1	-7.85	1.62e-13	5.41e-10	-0.6	-0.46	Cerebrospinal fluid biomarker levels;	chr7:23269500	chr7:23101228~23105703:-
OV	cis	rs875971	0.508	rs10242423	ENSG00000222364.1	RNU6-96P	7.85	1.63e-13	5.46e-10	0.47	0.46	Aortic root size;	chr7:66594188	chr7:66395191~66395286:+
OV	cis	rs875971	0.508	rs10253883	ENSG00000222364.1	RNU6-96P	7.85	1.63e-13	5.46e-10	0.47	0.46	Aortic root size;	chr7:66596151	chr7:66395191~66395286:+
OV	cis	rs875971	0.825	rs6951503	ENSG00000226824.5	RP4-756H11.3	7.85	1.64e-13	5.49e-10	0.48	0.46	Aortic root size;	chr7:66253949	chr7:66654538~66669855:+
OV	cis	rs9601248	0.529	rs2783125	ENSG00000227676.3	LINC01068	7.85	1.66e-13	5.53e-10	0.61	0.46	Major depressive disorder;	chr13:79583755	chr13:79566727~79571436:+
OV	cis	rs11159086	0.793	rs11621693	ENSG00000259005.1	RP3-449M8.6	7.85	1.67e-13	5.58e-10	0.72	0.46	Advanced glycation end-product levels;	chr14:74472631	chr14:74474007~74474864:-
OV	cis	rs11159086	0.793	rs1029702	ENSG00000259005.1	RP3-449M8.6	7.85	1.67e-13	5.58e-10	0.72	0.46	Advanced glycation end-product levels;	chr14:74473909	chr14:74474007~74474864:-
OV	cis	rs10256972	0.732	rs12701856	ENSG00000229043.2	AC091729.9	-7.85	1.68e-13	5.6e-10	-0.55	-0.46	Endometriosis;Longevity;	chr7:1068071	chr7:1160374~1165267:+
OV	cis	rs2836974	0.931	rs2776307	ENSG00000232608.1	TIMM9P2	7.85	1.68e-13	5.6e-10	0.55	0.46	Cognitive function;	chr21:39341907	chr21:39216624~39217506:+
OV	cis	rs4853012	0.941	rs4852329	ENSG00000217702.2	RP11-287D1.4	7.84	1.7e-13	5.68e-10	0.76	0.46	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74130583~74135395:+
OV	cis	rs11159086	0.793	rs10136668	ENSG00000259005.1	RP3-449M8.6	7.84	1.71e-13	5.68e-10	0.72	0.46	Advanced glycation end-product levels;	chr14:74492183	chr14:74474007~74474864:-
OV	cis	rs11159086	0.793	rs10139029	ENSG00000259005.1	RP3-449M8.6	7.84	1.71e-13	5.68e-10	0.72	0.46	Advanced glycation end-product levels;	chr14:74492284	chr14:74474007~74474864:-
OV	cis	rs11159086	0.793	rs17100414	ENSG00000259005.1	RP3-449M8.6	7.84	1.71e-13	5.68e-10	0.72	0.46	Advanced glycation end-product levels;	chr14:74467918	chr14:74474007~74474864:-
OV	cis	rs494459	0.838	rs566733	ENSG00000255239.1	AP002954.6	7.84	1.71e-13	5.69e-10	0.53	0.46	Height;	chr11:118737916	chr11:118688039~118690600:-
OV	cis	rs6991838	0.584	rs7823840	ENSG00000272010.1	CTD-3025N20.3	-7.84	1.74e-13	5.8e-10	-0.58	-0.46	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65591850~65592472:-
OV	cis	rs1528149	0.93	rs62440849	ENSG00000224683.1	RPL36AP29	7.84	1.75e-13	5.8e-10	0.59	0.46	Sitting height ratio;	chr7:16072349	chr7:16208945~16209265:+
OV	cis	rs1528149	0.866	rs1528147	ENSG00000224683.1	RPL36AP29	7.84	1.75e-13	5.8e-10	0.59	0.46	Sitting height ratio;	chr7:16073898	chr7:16208945~16209265:+
OV	cis	rs1528149	0.93	rs17357253	ENSG00000224683.1	RPL36AP29	7.84	1.75e-13	5.8e-10	0.59	0.46	Sitting height ratio;	chr7:16074339	chr7:16208945~16209265:+
OV	cis	rs875971	0.895	rs6460278	ENSG00000226824.5	RP4-756H11.3	7.84	1.76e-13	5.84e-10	0.48	0.46	Aortic root size;	chr7:66197749	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs6460279	ENSG00000226824.5	RP4-756H11.3	7.84	1.76e-13	5.84e-10	0.48	0.46	Aortic root size;	chr7:66197774	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs28491091	ENSG00000226824.5	RP4-756H11.3	7.84	1.76e-13	5.84e-10	0.48	0.46	Aortic root size;	chr7:66204077	chr7:66654538~66669855:+
OV	cis	rs10256972	0.721	rs2030959	ENSG00000229043.2	AC091729.9	-7.84	1.76e-13	5.85e-10	-0.57	-0.46	Endometriosis;Longevity;	chr7:1036270	chr7:1160374~1165267:+
OV	cis	rs3931020	0.745	rs10874274	ENSG00000272864.1	RP11-17E13.2	-7.84	1.77e-13	5.88e-10	-0.59	-0.46	Resistin levels;	chr1:74786450	chr1:74698769~74699333:-
OV	cis	rs875971	0.862	rs7786892	ENSG00000226824.5	RP4-756H11.3	7.84	1.78e-13	5.91e-10	0.47	0.46	Aortic root size;	chr7:66163889	chr7:66654538~66669855:+
OV	cis	rs7246967	0.673	rs4446014	ENSG00000269509.1	BNIP3P34	7.83	1.8e-13	5.97e-10	0.74	0.46	Bronchopulmonary dysplasia;	chr19:22714956	chr19:22773853~22774424:+
OV	cis	rs875971	0.862	rs6959268	ENSG00000226824.5	RP4-756H11.3	7.83	1.82e-13	6.03e-10	0.48	0.46	Aortic root size;	chr7:66347979	chr7:66654538~66669855:+
OV	cis	rs11159086	0.793	rs28612392	ENSG00000259005.1	RP3-449M8.6	7.83	1.83e-13	6.05e-10	0.72	0.46	Advanced glycation end-product levels;	chr14:74467894	chr14:74474007~74474864:-
OV	cis	rs875971	1	rs2077593	ENSG00000226824.5	RP4-756H11.3	-7.83	1.83e-13	6.06e-10	-0.49	-0.46	Aortic root size;	chr7:66427543	chr7:66654538~66669855:+
OV	cis	rs875971	0.798	rs12698522	ENSG00000226824.5	RP4-756H11.3	-7.83	1.84e-13	6.1e-10	-0.48	-0.46	Aortic root size;	chr7:66502354	chr7:66654538~66669855:+
OV	cis	rs875971	0.83	rs28714531	ENSG00000226824.5	RP4-756H11.3	-7.83	1.84e-13	6.1e-10	-0.48	-0.46	Aortic root size;	chr7:66503250	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs12698526	ENSG00000226824.5	RP4-756H11.3	-7.83	1.84e-13	6.1e-10	-0.48	-0.46	Aortic root size;	chr7:66504118	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs11773628	ENSG00000226824.5	RP4-756H11.3	7.83	1.85e-13	6.13e-10	0.48	0.46	Aortic root size;	chr7:66517644	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs10276077	ENSG00000226824.5	RP4-756H11.3	7.83	1.86e-13	6.15e-10	0.48	0.46	Aortic root size;	chr7:66263424	chr7:66654538~66669855:+
OV	cis	rs6991838	0.584	rs1053088	ENSG00000272010.1	CTD-3025N20.3	7.83	1.88e-13	6.19e-10	0.59	0.46	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65591850~65592472:-
OV	cis	rs10262624	0.967	rs35988560	ENSG00000234286.1	AC006026.13	-7.82	1.93e-13	6.37e-10	-0.52	-0.46	Schizophrenia;	chr7:23878561	chr7:23680195~23680786:-
OV	cis	rs875971	0.862	rs880166	ENSG00000226824.5	RP4-756H11.3	7.82	1.93e-13	6.37e-10	0.48	0.46	Aortic root size;	chr7:66205775	chr7:66654538~66669855:+
OV	cis	rs55794721	0.509	rs12027135	ENSG00000261349.1	RP3-465N24.5	-7.82	1.98e-13	6.49e-10	-0.49	-0.46	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25266102~25267136:-
OV	cis	rs10256972	0.786	rs3735686	ENSG00000229043.2	AC091729.9	-7.82	2.01e-13	6.59e-10	-0.56	-0.46	Endometriosis;Longevity;	chr7:1022891	chr7:1160374~1165267:+
OV	cis	rs875971	0.862	rs1875057	ENSG00000226824.5	RP4-756H11.3	7.82	2.02e-13	6.61e-10	0.48	0.46	Aortic root size;	chr7:66266868	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs6960446	ENSG00000226824.5	RP4-756H11.3	7.82	2.02e-13	6.61e-10	0.48	0.46	Aortic root size;	chr7:66268272	chr7:66654538~66669855:+
OV	cis	rs801193	0.569	rs10950050	ENSG00000226824.5	RP4-756H11.3	-7.82	2.02e-13	6.63e-10	-0.47	-0.46	Aortic root size;	chr7:66774601	chr7:66654538~66669855:+
OV	cis	rs7617773	0.963	rs12495221	ENSG00000229759.1	MRPS18AP1	-7.82	2.02e-13	6.63e-10	-0.49	-0.46	Coronary artery disease;	chr3:48137688	chr3:48256350~48256938:-
OV	cis	rs875971	0.929	rs4122249	ENSG00000226824.5	RP4-756H11.3	-7.81	2.04e-13	6.69e-10	-0.49	-0.46	Aortic root size;	chr7:66455949	chr7:66654538~66669855:+
OV	cis	rs7246967	0.736	rs428299	ENSG00000269509.1	BNIP3P34	7.81	2.05e-13	6.7e-10	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22813450	chr19:22773853~22774424:+
OV	cis	rs11690935	1	rs3795999	ENSG00000228389.1	AC068039.4	-7.81	2.06e-13	6.75e-10	-0.52	-0.46	Schizophrenia;	chr2:171687973	chr2:171773482~171775844:+
OV	cis	rs875971	0.825	rs4587224	ENSG00000226824.5	RP4-756H11.3	7.81	2.09e-13	6.84e-10	0.48	0.46	Aortic root size;	chr7:66271195	chr7:66654538~66669855:+
OV	cis	rs875971	0.792	rs6971752	ENSG00000226824.5	RP4-756H11.3	7.81	2.09e-13	6.84e-10	0.48	0.46	Aortic root size;	chr7:66272999	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs10950033	ENSG00000226824.5	RP4-756H11.3	7.81	2.09e-13	6.84e-10	0.48	0.46	Aortic root size;	chr7:66274686	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs11760844	ENSG00000226824.5	RP4-756H11.3	7.81	2.09e-13	6.84e-10	0.48	0.46	Aortic root size;	chr7:66274896	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs4149461	ENSG00000226824.5	RP4-756H11.3	7.81	2.09e-13	6.84e-10	0.48	0.46	Aortic root size;	chr7:66279745	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs6952182	ENSG00000226824.5	RP4-756H11.3	7.81	2.12e-13	6.93e-10	0.48	0.46	Aortic root size;	chr7:66218330	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs6964437	ENSG00000226824.5	RP4-756H11.3	7.81	2.12e-13	6.93e-10	0.48	0.46	Aortic root size;	chr7:66221457	chr7:66654538~66669855:+
OV	cis	rs7246967	0.736	rs453723	ENSG00000269509.1	BNIP3P34	7.81	2.12e-13	6.94e-10	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22815687	chr19:22773853~22774424:+
OV	cis	rs4853012	0.775	rs12465641	ENSG00000217702.2	RP11-287D1.4	-7.81	2.14e-13	6.99e-10	-0.73	-0.46	Gestational age at birth (maternal effect);	chr2:74110588	chr2:74130583~74135395:+
OV	cis	rs7246967	0.673	rs9676498	ENSG00000269509.1	BNIP3P34	7.81	2.16e-13	7.07e-10	0.7	0.46	Bronchopulmonary dysplasia;	chr19:22727708	chr19:22773853~22774424:+
OV	cis	rs2836974	0.897	rs13339986	ENSG00000232608.1	TIMM9P2	-7.8	2.19e-13	7.15e-10	-0.54	-0.46	Cognitive function;	chr21:39234056	chr21:39216624~39217506:+
OV	cis	rs7246967	0.736	rs436595	ENSG00000269509.1	BNIP3P34	7.8	2.2e-13	7.18e-10	0.75	0.46	Bronchopulmonary dysplasia;	chr19:22810243	chr19:22773853~22774424:+
OV	cis	rs11690935	0.694	rs312921	ENSG00000228389.1	AC068039.4	7.8	2.22e-13	7.22e-10	0.53	0.46	Schizophrenia;	chr2:171710715	chr2:171773482~171775844:+
OV	cis	rs9326248	0.569	rs4938315	ENSG00000254851.1	RP11-109L13.1	-7.8	2.25e-13	7.33e-10	-0.74	-0.46	Blood protein levels;	chr11:116860489	chr11:117135528~117138582:+
OV	cis	rs875971	0.789	rs10260426	ENSG00000226824.5	RP4-756H11.3	7.8	2.25e-13	7.34e-10	0.48	0.46	Aortic root size;	chr7:66271055	chr7:66654538~66669855:+
OV	cis	rs875971	0.79	rs10257911	ENSG00000226824.5	RP4-756H11.3	7.8	2.25e-13	7.34e-10	0.48	0.46	Aortic root size;	chr7:66278783	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs7796162	ENSG00000226824.5	RP4-756H11.3	7.8	2.25e-13	7.34e-10	0.48	0.46	Aortic root size;	chr7:66280771	chr7:66654538~66669855:+
OV	cis	rs875971	0.798	rs57739047	ENSG00000226824.5	RP4-756H11.3	-7.8	2.27e-13	7.39e-10	-0.48	-0.46	Aortic root size;	chr7:66507579	chr7:66654538~66669855:+
OV	cis	rs875971	0.83	rs6950137	ENSG00000226824.5	RP4-756H11.3	-7.8	2.27e-13	7.39e-10	-0.48	-0.46	Aortic root size;	chr7:66511623	chr7:66654538~66669855:+
OV	cis	rs6991838	0.584	rs7812446	ENSG00000272010.1	CTD-3025N20.3	-7.8	2.27e-13	7.39e-10	-0.58	-0.46	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65591850~65592472:-
OV	cis	rs6991838	0.557	rs7812390	ENSG00000272010.1	CTD-3025N20.3	-7.8	2.27e-13	7.39e-10	-0.58	-0.46	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs16932245	ENSG00000272010.1	CTD-3025N20.3	-7.8	2.27e-13	7.39e-10	-0.58	-0.46	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65591850~65592472:-
OV	cis	rs6991838	0.557	rs57419568	ENSG00000272010.1	CTD-3025N20.3	-7.8	2.27e-13	7.39e-10	-0.58	-0.46	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs16932250	ENSG00000272010.1	CTD-3025N20.3	-7.8	2.27e-13	7.39e-10	-0.58	-0.46	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65591850~65592472:-
OV	cis	rs875971	0.862	rs2024192	ENSG00000226824.5	RP4-756H11.3	7.8	2.3e-13	7.48e-10	0.48	0.46	Aortic root size;	chr7:66576460	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs4718377	ENSG00000226824.5	RP4-756H11.3	7.8	2.3e-13	7.48e-10	0.48	0.46	Aortic root size;	chr7:66584691	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs10278014	ENSG00000226824.5	RP4-756H11.3	7.8	2.3e-13	7.48e-10	0.48	0.46	Aortic root size;	chr7:66586277	chr7:66654538~66669855:+
OV	cis	rs11159086	0.793	rs10139122	ENSG00000259005.1	RP3-449M8.6	7.79	2.31e-13	7.5e-10	0.7	0.46	Advanced glycation end-product levels;	chr14:74492353	chr14:74474007~74474864:-
OV	cis	rs6991838	0.584	rs34494846	ENSG00000272010.1	CTD-3025N20.3	-7.79	2.32e-13	7.52e-10	-0.58	-0.46	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs1053087	ENSG00000272010.1	CTD-3025N20.3	-7.79	2.32e-13	7.52e-10	-0.58	-0.46	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs1053085	ENSG00000272010.1	CTD-3025N20.3	-7.79	2.32e-13	7.52e-10	-0.58	-0.46	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs4737747	ENSG00000272010.1	CTD-3025N20.3	-7.79	2.32e-13	7.52e-10	-0.58	-0.46	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs73236948	ENSG00000272010.1	CTD-3025N20.3	-7.79	2.32e-13	7.52e-10	-0.58	-0.46	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65591850~65592472:-
OV	cis	rs7246967	0.611	rs67531478	ENSG00000269509.1	BNIP3P34	7.79	2.32e-13	7.52e-10	0.73	0.46	Bronchopulmonary dysplasia;	chr19:22706702	chr19:22773853~22774424:+
OV	cis	rs7246967	0.604	rs8112577	ENSG00000269509.1	BNIP3P34	7.79	2.32e-13	7.52e-10	0.73	0.46	Bronchopulmonary dysplasia;	chr19:22710669	chr19:22773853~22774424:+
OV	cis	rs11723261	0.582	rs11248006	ENSG00000275426.1	CH17-262A2.1	7.79	2.34e-13	7.59e-10	0.8	0.46	Immune response to smallpox vaccine (IL-6);	chr4:172914	chr4:149738~150317:+
OV	cis	rs7246967	0.673	rs7250620	ENSG00000269509.1	BNIP3P34	7.79	2.35e-13	7.62e-10	0.73	0.46	Bronchopulmonary dysplasia;	chr19:22670324	chr19:22773853~22774424:+
OV	cis	rs11690935	0.959	rs35391289	ENSG00000228389.1	AC068039.4	7.79	2.37e-13	7.67e-10	0.53	0.46	Schizophrenia;	chr2:171778473	chr2:171773482~171775844:+
OV	cis	rs1075265	0.568	rs7604357	ENSG00000233266.1	HMGB1P31	7.79	2.37e-13	7.67e-10	0.55	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54074026	chr2:54051334~54051760:+
OV	cis	rs4713118	0.699	rs200969	ENSG00000220721.1	OR1F12	7.79	2.39e-13	7.75e-10	0.54	0.46	Parkinson's disease;	chr6:27891675	chr6:28073316~28074233:+
OV	cis	rs4853012	1	rs2280643	ENSG00000217702.2	RP11-287D1.4	7.79	2.44e-13	7.87e-10	0.72	0.46	Gestational age at birth (maternal effect);	chr2:74131159	chr2:74130583~74135395:+
OV	cis	rs4853012	0.887	rs2280644	ENSG00000217702.2	RP11-287D1.4	7.79	2.44e-13	7.87e-10	0.72	0.46	Gestational age at birth (maternal effect);	chr2:74131284	chr2:74130583~74135395:+
OV	cis	rs7246967	0.551	rs16998998	ENSG00000269509.1	BNIP3P34	7.78	2.49e-13	8.01e-10	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22728314	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs9677019	ENSG00000269509.1	BNIP3P34	7.78	2.49e-13	8.01e-10	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22729857	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs34676724	ENSG00000269509.1	BNIP3P34	7.78	2.49e-13	8.01e-10	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22735671	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs16999580	ENSG00000269509.1	BNIP3P34	7.78	2.49e-13	8.01e-10	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22740685	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs55684269	ENSG00000269509.1	BNIP3P34	7.78	2.49e-13	8.01e-10	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22741745	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs34003335	ENSG00000269509.1	BNIP3P34	7.78	2.49e-13	8.01e-10	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22742800	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs2194112	ENSG00000269509.1	BNIP3P34	7.78	2.49e-13	8.01e-10	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22743387	chr19:22773853~22774424:+
OV	cis	rs7246967	0.551	rs34907478	ENSG00000269509.1	BNIP3P34	7.78	2.49e-13	8.01e-10	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22746029	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs12985495	ENSG00000269509.1	BNIP3P34	7.78	2.49e-13	8.01e-10	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22747576	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs8103430	ENSG00000269509.1	BNIP3P34	7.78	2.49e-13	8.01e-10	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22748696	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs34174596	ENSG00000269509.1	BNIP3P34	7.78	2.49e-13	8.01e-10	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22750717	chr19:22773853~22774424:+
OV	cis	rs7246967	0.551	rs8103204	ENSG00000269509.1	BNIP3P34	7.78	2.49e-13	8.01e-10	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22753715	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs59621958	ENSG00000269509.1	BNIP3P34	7.78	2.49e-13	8.01e-10	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22757857	chr19:22773853~22774424:+
OV	cis	rs7246967	0.604	rs58653025	ENSG00000269509.1	BNIP3P34	7.78	2.49e-13	8.01e-10	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22758815	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs16999598	ENSG00000269509.1	BNIP3P34	7.78	2.49e-13	8.01e-10	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22760323	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs34671960	ENSG00000269509.1	BNIP3P34	7.78	2.49e-13	8.01e-10	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22765891	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs34726149	ENSG00000269509.1	BNIP3P34	7.78	2.49e-13	8.01e-10	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22769309	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs12985825	ENSG00000269509.1	BNIP3P34	7.78	2.49e-13	8.01e-10	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22770649	chr19:22773853~22774424:+
OV	cis	rs7246967	0.551	rs59127381	ENSG00000269509.1	BNIP3P34	7.78	2.5e-13	8.03e-10	0.73	0.46	Bronchopulmonary dysplasia;	chr19:22702233	chr19:22773853~22774424:+
OV	cis	rs7246967	0.551	rs73022749	ENSG00000269509.1	BNIP3P34	7.78	2.5e-13	8.03e-10	0.73	0.46	Bronchopulmonary dysplasia;	chr19:22704458	chr19:22773853~22774424:+
OV	cis	rs4423214	0.879	rs1792284	ENSG00000254682.1	RP11-660L16.2	7.78	2.5e-13	8.05e-10	0.55	0.46	Vitamin D levels;	chr11:71423920	chr11:71448674~71452157:+
OV	cis	rs11690935	0.959	rs66835971	ENSG00000228389.1	AC068039.4	7.78	2.5e-13	8.05e-10	0.53	0.46	Schizophrenia;	chr2:171820949	chr2:171773482~171775844:+
OV	cis	rs11690935	0.959	rs6759575	ENSG00000228389.1	AC068039.4	7.78	2.5e-13	8.05e-10	0.53	0.46	Schizophrenia;	chr2:171832558	chr2:171773482~171775844:+
OV	cis	rs11690935	0.921	rs908670	ENSG00000228389.1	AC068039.4	7.78	2.5e-13	8.05e-10	0.53	0.46	Schizophrenia;	chr2:171833670	chr2:171773482~171775844:+
OV	cis	rs853679	0.517	rs17711344	ENSG00000220721.1	OR1F12	-7.78	2.51e-13	8.06e-10	-0.52	-0.46	Depression;	chr6:28109824	chr6:28073316~28074233:+
OV	cis	rs875971	0.862	rs1167408	ENSG00000226824.5	RP4-756H11.3	7.78	2.51e-13	8.07e-10	0.48	0.46	Aortic root size;	chr7:66091121	chr7:66654538~66669855:+
OV	cis	rs875971	0.83	rs1167406	ENSG00000226824.5	RP4-756H11.3	7.78	2.51e-13	8.07e-10	0.48	0.46	Aortic root size;	chr7:66091949	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs709609	ENSG00000226824.5	RP4-756H11.3	7.78	2.51e-13	8.07e-10	0.48	0.46	Aortic root size;	chr7:66095574	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs1167399	ENSG00000226824.5	RP4-756H11.3	7.78	2.51e-13	8.07e-10	0.48	0.46	Aortic root size;	chr7:66096890	chr7:66654538~66669855:+
OV	cis	rs875971	0.825	rs59466412	ENSG00000226824.5	RP4-756H11.3	7.78	2.51e-13	8.07e-10	0.48	0.46	Aortic root size;	chr7:66100371	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs57866200	ENSG00000226824.5	RP4-756H11.3	7.78	2.51e-13	8.07e-10	0.48	0.46	Aortic root size;	chr7:66100405	chr7:66654538~66669855:+
OV	cis	rs2117029	0.619	rs9325145	ENSG00000258017.1	RP11-386G11.10	-7.78	2.55e-13	8.16e-10	-0.55	-0.46	Intelligence (multi-trait analysis);	chr12:49132101	chr12:49127782~49147869:+
OV	cis	rs2117029	0.586	rs10783307	ENSG00000258017.1	RP11-386G11.10	-7.78	2.55e-13	8.16e-10	-0.55	-0.46	Intelligence (multi-trait analysis);	chr12:49135822	chr12:49127782~49147869:+
OV	cis	rs2117029	0.554	rs12306494	ENSG00000258017.1	RP11-386G11.10	-7.78	2.55e-13	8.16e-10	-0.55	-0.46	Intelligence (multi-trait analysis);	chr12:49136998	chr12:49127782~49147869:+
OV	cis	rs2117029	0.586	rs10783308	ENSG00000258017.1	RP11-386G11.10	-7.78	2.55e-13	8.16e-10	-0.55	-0.46	Intelligence (multi-trait analysis);	chr12:49137675	chr12:49127782~49147869:+
OV	cis	rs2117029	0.586	rs11168884	ENSG00000258017.1	RP11-386G11.10	-7.78	2.55e-13	8.16e-10	-0.55	-0.46	Intelligence (multi-trait analysis);	chr12:49146109	chr12:49127782~49147869:+
OV	cis	rs11168854	0.719	rs11168890	ENSG00000258017.1	RP11-386G11.10	-7.78	2.55e-13	8.16e-10	-0.55	-0.46	Body mass index;	chr12:49150130	chr12:49127782~49147869:+
OV	cis	rs2117029	0.586	rs7954521	ENSG00000258017.1	RP11-386G11.10	-7.78	2.55e-13	8.16e-10	-0.55	-0.46	Intelligence (multi-trait analysis);	chr12:49151857	chr12:49127782~49147869:+
OV	cis	rs2117029	0.553	rs2162644	ENSG00000258017.1	RP11-386G11.10	-7.78	2.55e-13	8.16e-10	-0.55	-0.46	Intelligence (multi-trait analysis);	chr12:49154407	chr12:49127782~49147869:+
OV	cis	rs2117029	0.586	rs2114846	ENSG00000258017.1	RP11-386G11.10	-7.78	2.55e-13	8.16e-10	-0.55	-0.46	Intelligence (multi-trait analysis);	chr12:49154493	chr12:49127782~49147869:+
OV	cis	rs875971	0.862	rs778736	ENSG00000226824.5	RP4-756H11.3	-7.78	2.57e-13	8.24e-10	-0.48	-0.46	Aortic root size;	chr7:66348861	chr7:66654538~66669855:+
OV	cis	rs7246967	0.673	rs11881740	ENSG00000269509.1	BNIP3P34	7.78	2.58e-13	8.25e-10	0.73	0.46	Bronchopulmonary dysplasia;	chr19:22661042	chr19:22773853~22774424:+
OV	cis	rs4927850	1	rs7614767	ENSG00000231464.1	AC024937.4	7.77	2.62e-13	8.38e-10	0.55	0.46	Pancreatic cancer;	chr3:196026580	chr3:195996738~195998233:+
OV	cis	rs801193	0.569	rs2707847	ENSG00000226824.5	RP4-756H11.3	-7.77	2.62e-13	8.38e-10	-0.48	-0.46	Aortic root size;	chr7:66737884	chr7:66654538~66669855:+
OV	cis	rs7246967	0.673	rs34126042	ENSG00000269509.1	BNIP3P34	7.77	2.67e-13	8.54e-10	0.73	0.46	Bronchopulmonary dysplasia;	chr19:22726416	chr19:22773853~22774424:+
OV	cis	rs801193	0.548	rs7805152	ENSG00000226824.5	RP4-756H11.3	-7.77	2.68e-13	8.55e-10	-0.48	-0.46	Aortic root size;	chr7:66744266	chr7:66654538~66669855:+
OV	cis	rs858239	0.896	rs1637192	ENSG00000230658.1	KLHL7-AS1	7.77	2.68e-13	8.57e-10	0.62	0.46	Cerebrospinal fluid biomarker levels;	chr7:23220895	chr7:23101228~23105703:-
OV	cis	rs11690935	0.959	rs10803863	ENSG00000228389.1	AC068039.4	-7.77	2.71e-13	8.64e-10	-0.52	-0.46	Schizophrenia;	chr2:171678827	chr2:171773482~171775844:+
OV	cis	rs875971	0.862	rs2460432	ENSG00000226824.5	RP4-756H11.3	7.77	2.73e-13	8.7e-10	0.48	0.46	Aortic root size;	chr7:66089398	chr7:66654538~66669855:+
OV	cis	rs10256972	0.758	rs7799391	ENSG00000229043.2	AC091729.9	-7.77	2.73e-13	8.7e-10	-0.56	-0.46	Endometriosis;Longevity;	chr7:1042930	chr7:1160374~1165267:+
OV	cis	rs2729354	0.729	rs2848634	ENSG00000265566.2	RN7SL605P	-7.77	2.76e-13	8.8e-10	-0.67	-0.46	Blood protein levels;	chr11:57484855	chr11:57528085~57528365:-
OV	cis	rs16828019	0.929	rs8179465	ENSG00000235358.1	RP11-399E6.1	7.76	2.84e-13	9.04e-10	0.91	0.46	Intelligence (multi-trait analysis);	chr1:41236075	chr1:41242373~41284861:+
OV	cis	rs2732480	0.577	rs2634680	ENSG00000258273.1	RP11-370I10.4	-7.76	2.86e-13	9.09e-10	-0.55	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48340781	chr12:48333755~48333901:-
OV	cis	rs2732480	0.577	rs2634678	ENSG00000258273.1	RP11-370I10.4	-7.76	2.86e-13	9.09e-10	-0.55	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48341755	chr12:48333755~48333901:-
OV	cis	rs2732480	0.577	rs2732479	ENSG00000258273.1	RP11-370I10.4	-7.76	2.86e-13	9.09e-10	-0.55	-0.46	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342477	chr12:48333755~48333901:-
OV	cis	rs11690935	0.959	rs3770451	ENSG00000228389.1	AC068039.4	7.76	2.86e-13	9.1e-10	0.53	0.46	Schizophrenia;	chr2:171812205	chr2:171773482~171775844:+
OV	cis	rs1707322	0.721	rs10430124	ENSG00000281133.1	AL355480.3	-7.76	2.9e-13	9.2e-10	-0.59	-0.46	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr1:45580892~45580996:-
OV	cis	rs7569084	0.663	rs4671128	ENSG00000234255.7	AC012370.3	7.76	2.9e-13	9.21e-10	0.51	0.46	Sum eosinophil basophil counts;	chr2:65438130	chr2:65439888~65456571:-
OV	cis	rs2729354	0.729	rs2581923	ENSG00000265566.2	RN7SL605P	-7.75	2.98e-13	9.45e-10	-0.67	-0.46	Blood protein levels;	chr11:57482518	chr11:57528085~57528365:-
OV	cis	rs875971	0.862	rs10282433	ENSG00000226824.5	RP4-756H11.3	7.75	3.08e-13	9.74e-10	0.48	0.46	Aortic root size;	chr7:66256452	chr7:66654538~66669855:+
OV	cis	rs11723261	0.621	rs3829	ENSG00000275426.1	CH17-262A2.1	7.75	3.09e-13	9.76e-10	0.75	0.46	Immune response to smallpox vaccine (IL-6);	chr4:141070	chr4:149738~150317:+
OV	cis	rs11723261	0.621	rs57013142	ENSG00000275426.1	CH17-262A2.1	7.75	3.09e-13	9.76e-10	0.75	0.46	Immune response to smallpox vaccine (IL-6);	chr4:141956	chr4:149738~150317:+
OV	cis	rs11723261	0.564	rs61792258	ENSG00000275426.1	CH17-262A2.1	7.75	3.09e-13	9.76e-10	0.75	0.46	Immune response to smallpox vaccine (IL-6);	chr4:143482	chr4:149738~150317:+
OV	cis	rs7246967	0.611	rs8108452	ENSG00000269509.1	BNIP3P34	7.75	3.1e-13	9.78e-10	0.76	0.46	Bronchopulmonary dysplasia;	chr19:22670816	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs12973627	ENSG00000269509.1	BNIP3P34	7.75	3.1e-13	9.78e-10	0.76	0.46	Bronchopulmonary dysplasia;	chr19:22684903	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs62120304	ENSG00000269509.1	BNIP3P34	7.75	3.1e-13	9.78e-10	0.76	0.46	Bronchopulmonary dysplasia;	chr19:22689466	chr19:22773853~22774424:+
OV	cis	rs2117029	0.586	rs6580701	ENSG00000258017.1	RP11-386G11.10	-7.75	3.14e-13	9.9e-10	-0.55	-0.46	Intelligence (multi-trait analysis);	chr12:49163482	chr12:49127782~49147869:+
OV	cis	rs11690935	0.959	rs2674484	ENSG00000228389.1	AC068039.4	7.74	3.16e-13	9.96e-10	0.52	0.46	Schizophrenia;	chr2:171718102	chr2:171773482~171775844:+
OV	cis	rs2581828	0.656	rs2581800	ENSG00000242142.1	SERBP1P3	7.74	3.16e-13	9.96e-10	0.49	0.46	Crohn's disease;	chr3:53075336	chr3:53064283~53065091:-
OV	cis	rs6921919	0.583	rs9468370	ENSG00000216901.1	AL022393.7	7.74	3.22e-13	1.01e-09	0.54	0.46	Autism spectrum disorder or schizophrenia;	chr6:28401163	chr6:28176188~28176674:+
OV	cis	rs11723261	0.546	rs4315728	ENSG00000275426.1	CH17-262A2.1	7.74	3.23e-13	1.02e-09	0.75	0.46	Immune response to smallpox vaccine (IL-6);	chr4:147237	chr4:149738~150317:+
OV	cis	rs10262624	0.967	rs10229233	ENSG00000234286.1	AC006026.13	-7.74	3.3e-13	1.04e-09	-0.51	-0.46	Schizophrenia;	chr7:23867900	chr7:23680195~23680786:-
OV	cis	rs10262624	1	rs10245161	ENSG00000234286.1	AC006026.13	-7.74	3.3e-13	1.04e-09	-0.51	-0.46	Schizophrenia;	chr7:23868073	chr7:23680195~23680786:-
OV	cis	rs10262624	1	rs2106748	ENSG00000234286.1	AC006026.13	-7.74	3.3e-13	1.04e-09	-0.51	-0.46	Schizophrenia;	chr7:23871694	chr7:23680195~23680786:-
OV	cis	rs10262624	1	rs2106747	ENSG00000234286.1	AC006026.13	-7.74	3.3e-13	1.04e-09	-0.51	-0.46	Schizophrenia;	chr7:23871880	chr7:23680195~23680786:-
OV	cis	rs11690935	0.959	rs6722757	ENSG00000228389.1	AC068039.4	7.74	3.32e-13	1.04e-09	0.53	0.46	Schizophrenia;	chr2:171735453	chr2:171773482~171775844:+
OV	cis	rs10262624	1	rs10238070	ENSG00000234286.1	AC006026.13	-7.74	3.34e-13	1.05e-09	-0.51	-0.46	Schizophrenia;	chr7:23870172	chr7:23680195~23680786:-
OV	cis	rs10262624	1	rs2390847	ENSG00000234286.1	AC006026.13	-7.74	3.34e-13	1.05e-09	-0.51	-0.46	Schizophrenia;	chr7:23872082	chr7:23680195~23680786:-
OV	cis	rs10262624	1	rs2023786	ENSG00000234286.1	AC006026.13	-7.74	3.34e-13	1.05e-09	-0.51	-0.46	Schizophrenia;	chr7:23875534	chr7:23680195~23680786:-
OV	cis	rs11690935	1	rs12053003	ENSG00000228389.1	AC068039.4	-7.73	3.37e-13	1.06e-09	-0.52	-0.46	Schizophrenia;	chr2:171680840	chr2:171773482~171775844:+
OV	cis	rs2581828	0.656	rs2163167	ENSG00000242142.1	SERBP1P3	7.73	3.48e-13	1.09e-09	0.51	0.46	Crohn's disease;	chr3:53097756	chr3:53064283~53065091:-
OV	cis	rs2581828	0.541	rs2115781	ENSG00000242142.1	SERBP1P3	7.73	3.48e-13	1.09e-09	0.51	0.46	Crohn's disease;	chr3:53097813	chr3:53064283~53065091:-
OV	cis	rs1075265	0.584	rs4671178	ENSG00000233266.1	HMGB1P31	-7.73	3.48e-13	1.09e-09	-0.55	-0.46	Chronotype;Morning vs. evening chronotype;	chr2:54056356	chr2:54051334~54051760:+
OV	cis	rs1075265	0.568	rs10865277	ENSG00000233266.1	HMGB1P31	7.73	3.5e-13	1.1e-09	0.55	0.46	Chronotype;Morning vs. evening chronotype;	chr2:54074865	chr2:54051334~54051760:+
OV	cis	rs801193	0.569	rs11772819	ENSG00000226824.5	RP4-756H11.3	-7.73	3.52e-13	1.1e-09	-0.48	-0.46	Aortic root size;	chr7:66752983	chr7:66654538~66669855:+
OV	cis	rs801193	0.569	rs11761542	ENSG00000226824.5	RP4-756H11.3	-7.73	3.52e-13	1.1e-09	-0.48	-0.46	Aortic root size;	chr7:66753209	chr7:66654538~66669855:+
OV	cis	rs801193	0.569	rs7800620	ENSG00000226824.5	RP4-756H11.3	-7.73	3.52e-13	1.1e-09	-0.48	-0.46	Aortic root size;	chr7:66758701	chr7:66654538~66669855:+
OV	cis	rs2282300	0.956	rs654710	ENSG00000254532.1	RP11-624D11.2	-7.73	3.53e-13	1.1e-09	-0.61	-0.46	Morning vs. evening chronotype;	chr11:30372756	chr11:30044058~30084343:-
OV	cis	rs4423214	0.559	rs7949129	ENSG00000254682.1	RP11-660L16.2	-7.72	3.59e-13	1.12e-09	-0.64	-0.46	Vitamin D levels;	chr11:71482089	chr11:71448674~71452157:+
OV	cis	rs10262624	1	rs9769098	ENSG00000234286.1	AC006026.13	-7.72	3.6e-13	1.12e-09	-0.51	-0.46	Schizophrenia;	chr7:23877113	chr7:23680195~23680786:-
OV	cis	rs10262624	0.967	rs12333669	ENSG00000234286.1	AC006026.13	-7.72	3.6e-13	1.12e-09	-0.51	-0.46	Schizophrenia;	chr7:23877267	chr7:23680195~23680786:-
OV	cis	rs10262624	0.935	rs10487596	ENSG00000234286.1	AC006026.13	-7.72	3.6e-13	1.12e-09	-0.51	-0.46	Schizophrenia;	chr7:23877458	chr7:23680195~23680786:-
OV	cis	rs10262624	1	rs10950973	ENSG00000234286.1	AC006026.13	-7.72	3.6e-13	1.12e-09	-0.51	-0.46	Schizophrenia;	chr7:23877658	chr7:23680195~23680786:-
OV	cis	rs10262624	1	rs10950974	ENSG00000234286.1	AC006026.13	-7.72	3.6e-13	1.12e-09	-0.51	-0.46	Schizophrenia;	chr7:23877661	chr7:23680195~23680786:-
OV	cis	rs10262624	1	rs10950975	ENSG00000234286.1	AC006026.13	-7.72	3.6e-13	1.12e-09	-0.51	-0.46	Schizophrenia;	chr7:23877861	chr7:23680195~23680786:-
OV	cis	rs10262624	0.967	rs13244145	ENSG00000234286.1	AC006026.13	-7.72	3.6e-13	1.12e-09	-0.51	-0.46	Schizophrenia;	chr7:23878123	chr7:23680195~23680786:-
OV	cis	rs10262624	1	rs13244265	ENSG00000234286.1	AC006026.13	-7.72	3.6e-13	1.12e-09	-0.51	-0.46	Schizophrenia;	chr7:23878284	chr7:23680195~23680786:-
OV	cis	rs4423214	0.879	rs1790330	ENSG00000254682.1	RP11-660L16.2	-7.72	3.62e-13	1.13e-09	-0.56	-0.46	Vitamin D levels;	chr11:71436779	chr11:71448674~71452157:+
OV	cis	rs4423214	0.84	rs1790328	ENSG00000254682.1	RP11-660L16.2	-7.72	3.62e-13	1.13e-09	-0.56	-0.46	Vitamin D levels;	chr11:71436992	chr11:71448674~71452157:+
OV	cis	rs2564921	0.765	rs2581799	ENSG00000242142.1	SERBP1P3	-7.72	3.66e-13	1.14e-09	-0.51	-0.46	Height;	chr3:53074760	chr3:53064283~53065091:-
OV	cis	rs875971	0.862	rs6955837	ENSG00000226824.5	RP4-756H11.3	7.72	3.66e-13	1.14e-09	0.47	0.46	Aortic root size;	chr7:66578155	chr7:66654538~66669855:+
OV	cis	rs875971	0.825	rs10281499	ENSG00000226824.5	RP4-756H11.3	7.72	3.66e-13	1.14e-09	0.47	0.46	Aortic root size;	chr7:66583979	chr7:66654538~66669855:+
OV	cis	rs11690935	0.959	rs2292815	ENSG00000228389.1	AC068039.4	7.72	3.69e-13	1.15e-09	0.53	0.46	Schizophrenia;	chr2:171730141	chr2:171773482~171775844:+
OV	cis	rs11690935	0.838	rs10432423	ENSG00000228389.1	AC068039.4	7.72	3.74e-13	1.17e-09	0.52	0.46	Schizophrenia;	chr2:171896785	chr2:171773482~171775844:+
OV	cis	rs7246967	0.673	rs12974988	ENSG00000269509.1	BNIP3P34	7.72	3.75e-13	1.17e-09	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22743163	chr19:22773853~22774424:+
OV	cis	rs11723261	0.621	rs11733385	ENSG00000275426.1	CH17-262A2.1	7.72	3.75e-13	1.17e-09	0.74	0.46	Immune response to smallpox vaccine (IL-6);	chr4:146677	chr4:149738~150317:+
OV	cis	rs11159086	0.793	rs11625502	ENSG00000259005.1	RP3-449M8.6	7.71	3.87e-13	1.2e-09	0.71	0.46	Advanced glycation end-product levels;	chr14:74468309	chr14:74474007~74474864:-
OV	cis	rs875971	1	rs6460296	ENSG00000226824.5	RP4-756H11.3	-7.71	3.93e-13	1.22e-09	-0.48	-0.46	Aortic root size;	chr7:66430152	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs4717292	ENSG00000226824.5	RP4-756H11.3	-7.71	3.93e-13	1.22e-09	-0.48	-0.46	Aortic root size;	chr7:66430611	chr7:66654538~66669855:+
OV	cis	rs875971	0.895	rs4718349	ENSG00000226824.5	RP4-756H11.3	-7.71	3.93e-13	1.22e-09	-0.48	-0.46	Aortic root size;	chr7:66444024	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs2420591	ENSG00000226824.5	RP4-756H11.3	-7.71	3.93e-13	1.22e-09	-0.48	-0.46	Aortic root size;	chr7:66447394	chr7:66654538~66669855:+
OV	cis	rs875971	0.895	rs10755833	ENSG00000226824.5	RP4-756H11.3	-7.71	3.93e-13	1.22e-09	-0.48	-0.46	Aortic root size;	chr7:66448930	chr7:66654538~66669855:+
OV	cis	rs875971	0.964	rs12668936	ENSG00000226824.5	RP4-756H11.3	-7.71	3.93e-13	1.22e-09	-0.48	-0.46	Aortic root size;	chr7:66449417	chr7:66654538~66669855:+
OV	cis	rs875971	0.895	rs7788984	ENSG00000226824.5	RP4-756H11.3	-7.71	3.93e-13	1.22e-09	-0.48	-0.46	Aortic root size;	chr7:66450629	chr7:66654538~66669855:+
OV	cis	rs875971	0.895	rs1833495	ENSG00000226824.5	RP4-756H11.3	-7.71	3.93e-13	1.22e-09	-0.48	-0.46	Aortic root size;	chr7:66456608	chr7:66654538~66669855:+
OV	cis	rs875971	0.964	rs6945032	ENSG00000226824.5	RP4-756H11.3	-7.71	3.93e-13	1.22e-09	-0.48	-0.46	Aortic root size;	chr7:66457499	chr7:66654538~66669855:+
OV	cis	rs875971	0.929	rs12673810	ENSG00000226824.5	RP4-756H11.3	-7.71	3.93e-13	1.22e-09	-0.48	-0.46	Aortic root size;	chr7:66458866	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs35149210	ENSG00000226824.5	RP4-756H11.3	-7.71	3.93e-13	1.22e-09	-0.48	-0.46	Aortic root size;	chr7:66464938	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs2042133	ENSG00000226824.5	RP4-756H11.3	-7.71	3.93e-13	1.22e-09	-0.48	-0.46	Aortic root size;	chr7:66466935	chr7:66654538~66669855:+
OV	cis	rs875971	0.964	rs2161065	ENSG00000226824.5	RP4-756H11.3	-7.71	3.93e-13	1.22e-09	-0.48	-0.46	Aortic root size;	chr7:66467918	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs6961155	ENSG00000226824.5	RP4-756H11.3	-7.71	3.93e-13	1.22e-09	-0.48	-0.46	Aortic root size;	chr7:66468308	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs7789768	ENSG00000226824.5	RP4-756H11.3	-7.71	3.93e-13	1.22e-09	-0.48	-0.46	Aortic root size;	chr7:66473993	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs12698521	ENSG00000226824.5	RP4-756H11.3	-7.71	3.93e-13	1.22e-09	-0.48	-0.46	Aortic root size;	chr7:66474502	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs1363055	ENSG00000226824.5	RP4-756H11.3	-7.71	3.93e-13	1.22e-09	-0.48	-0.46	Aortic root size;	chr7:66478288	chr7:66654538~66669855:+
OV	cis	rs875971	0.964	rs9691480	ENSG00000226824.5	RP4-756H11.3	-7.71	3.93e-13	1.22e-09	-0.48	-0.46	Aortic root size;	chr7:66479319	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs7789554	ENSG00000226824.5	RP4-756H11.3	-7.71	3.93e-13	1.22e-09	-0.48	-0.46	Aortic root size;	chr7:66481051	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs4717300	ENSG00000226824.5	RP4-756H11.3	-7.71	3.93e-13	1.22e-09	-0.48	-0.46	Aortic root size;	chr7:66482393	chr7:66654538~66669855:+
OV	cis	rs875971	0.895	rs1974769	ENSG00000226824.5	RP4-756H11.3	-7.71	3.93e-13	1.22e-09	-0.48	-0.46	Aortic root size;	chr7:66485627	chr7:66654538~66669855:+
OV	cis	rs875971	0.895	rs6460300	ENSG00000226824.5	RP4-756H11.3	-7.71	3.93e-13	1.22e-09	-0.48	-0.46	Aortic root size;	chr7:66487937	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs7803416	ENSG00000226824.5	RP4-756H11.3	-7.71	3.93e-13	1.22e-09	-0.48	-0.46	Aortic root size;	chr7:66489212	chr7:66654538~66669855:+
OV	cis	rs875971	1	rs1981798	ENSG00000226824.5	RP4-756H11.3	-7.71	3.93e-13	1.22e-09	-0.48	-0.46	Aortic root size;	chr7:66489916	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs1981799	ENSG00000226824.5	RP4-756H11.3	-7.71	3.93e-13	1.22e-09	-0.48	-0.46	Aortic root size;	chr7:66490572	chr7:66654538~66669855:+
OV	cis	rs875971	0.964	rs2277911	ENSG00000226824.5	RP4-756H11.3	-7.71	3.93e-13	1.22e-09	-0.48	-0.46	Aortic root size;	chr7:66493638	chr7:66654538~66669855:+
OV	cis	rs7246967	0.673	rs62120125	ENSG00000269509.1	BNIP3P34	7.71	3.99e-13	1.23e-09	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22772297	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs6511383	ENSG00000269509.1	BNIP3P34	7.71	3.99e-13	1.23e-09	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22774098	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs2194113	ENSG00000269509.1	BNIP3P34	7.71	3.99e-13	1.23e-09	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22775273	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs62120457	ENSG00000269509.1	BNIP3P34	7.71	3.99e-13	1.23e-09	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22775717	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs55744741	ENSG00000269509.1	BNIP3P34	7.71	3.99e-13	1.23e-09	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22777171	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs4933036	ENSG00000269509.1	BNIP3P34	7.71	3.99e-13	1.23e-09	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22780267	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs35061555	ENSG00000269509.1	BNIP3P34	7.71	3.99e-13	1.23e-09	0.72	0.46	Bronchopulmonary dysplasia;	chr19:22780964	chr19:22773853~22774424:+
OV	cis	rs2882667	0.683	rs13188935	ENSG00000253404.1	AC034243.1	7.7	4.05e-13	1.25e-09	0.52	0.46	Age-related hearing impairment (SNP x SNP interaction);	chr5:139116536	chr5:138744434~138753309:-
OV	cis	rs4713118	0.699	rs200978	ENSG00000220721.1	OR1F12	7.7	4.05e-13	1.25e-09	0.54	0.46	Parkinson's disease;	chr6:27885390	chr6:28073316~28074233:+
OV	cis	rs2117029	0.521	rs7953169	ENSG00000258017.1	RP11-386G11.10	-7.7	4.06e-13	1.25e-09	-0.55	-0.46	Intelligence (multi-trait analysis);	chr12:49184389	chr12:49127782~49147869:+
OV	cis	rs7246967	0.551	rs12974117	ENSG00000269509.1	BNIP3P34	7.7	4.06e-13	1.25e-09	0.75	0.46	Bronchopulmonary dysplasia;	chr19:22685074	chr19:22773853~22774424:+
OV	cis	rs875971	0.862	rs1983372	ENSG00000226824.5	RP4-756H11.3	7.7	4.09e-13	1.26e-09	0.47	0.46	Aortic root size;	chr7:66146364	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs908915	ENSG00000226824.5	RP4-756H11.3	7.7	4.09e-13	1.26e-09	0.47	0.46	Aortic root size;	chr7:66149664	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs7809814	ENSG00000226824.5	RP4-756H11.3	7.7	4.09e-13	1.26e-09	0.47	0.46	Aortic root size;	chr7:66150410	chr7:66654538~66669855:+
OV	cis	rs2408955	0.521	rs1476607	ENSG00000258273.1	RP11-370I10.4	7.7	4.15e-13	1.28e-09	0.54	0.46	Glycated hemoglobin levels;	chr12:48131021	chr12:48333755~48333901:-
OV	cis	rs875971	0.929	rs34406470	ENSG00000226824.5	RP4-756H11.3	-7.7	4.2e-13	1.3e-09	-0.49	-0.46	Aortic root size;	chr7:66464969	chr7:66654538~66669855:+
OV	cis	rs11690935	0.959	rs10206062	ENSG00000228389.1	AC068039.4	7.7	4.21e-13	1.3e-09	0.52	0.46	Schizophrenia;	chr2:171720766	chr2:171773482~171775844:+
OV	cis	rs853679	0.517	rs9283884	ENSG00000220721.1	OR1F12	-7.7	4.23e-13	1.3e-09	-0.54	-0.45	Depression;	chr6:28167882	chr6:28073316~28074233:+
OV	cis	rs16828019	0.929	rs111309254	ENSG00000235358.1	RP11-399E6.1	7.7	4.23e-13	1.3e-09	0.91	0.45	Intelligence (multi-trait analysis);	chr1:41270328	chr1:41242373~41284861:+
OV	cis	rs16828019	0.929	rs4131949	ENSG00000235358.1	RP11-399E6.1	7.7	4.23e-13	1.3e-09	0.91	0.45	Intelligence (multi-trait analysis);	chr1:41272965	chr1:41242373~41284861:+
OV	cis	rs16828019	0.929	rs35813191	ENSG00000235358.1	RP11-399E6.1	7.7	4.23e-13	1.3e-09	0.91	0.45	Intelligence (multi-trait analysis);	chr1:41277128	chr1:41242373~41284861:+
OV	cis	rs2712381	0.517	rs62273237	ENSG00000242551.2	POU5F1P6	-7.7	4.27e-13	1.31e-09	-0.51	-0.45	Monocyte count;	chr3:128591264	chr3:128674735~128677005:-
OV	cis	rs4423214	0.592	rs78300366	ENSG00000254682.1	RP11-660L16.2	-7.69	4.33e-13	1.33e-09	-0.66	-0.45	Vitamin D levels;	chr11:71494468	chr11:71448674~71452157:+
OV	cis	rs1707322	0.686	rs3014242	ENSG00000281133.1	AL355480.3	7.69	4.36e-13	1.34e-09	0.6	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45580892~45580996:-
OV	cis	rs2836974	0.897	rs2776308	ENSG00000232608.1	TIMM9P2	-7.69	4.36e-13	1.34e-09	-0.56	-0.45	Cognitive function;	chr21:39343249	chr21:39216624~39217506:+
OV	cis	rs11690935	0.885	rs6727017	ENSG00000228389.1	AC068039.4	7.69	4.45e-13	1.37e-09	0.52	0.45	Schizophrenia;	chr2:171910337	chr2:171773482~171775844:+
OV	cis	rs494459	0.838	rs567680	ENSG00000255239.1	AP002954.6	7.69	4.51e-13	1.38e-09	0.53	0.45	Height;	chr11:118737823	chr11:118688039~118690600:-
OV	cis	rs7246967	0.673	rs2915932	ENSG00000269509.1	BNIP3P34	7.69	4.51e-13	1.38e-09	0.73	0.45	Bronchopulmonary dysplasia;	chr19:22660899	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs73020703	ENSG00000269509.1	BNIP3P34	7.69	4.51e-13	1.38e-09	0.73	0.45	Bronchopulmonary dysplasia;	chr19:22661537	chr19:22773853~22774424:+
OV	cis	rs7246967	0.8	rs8111895	ENSG00000269509.1	BNIP3P34	7.69	4.56e-13	1.4e-09	0.75	0.45	Bronchopulmonary dysplasia;	chr19:22890403	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs36029703	ENSG00000269509.1	BNIP3P34	7.68	4.59e-13	1.4e-09	0.7	0.45	Bronchopulmonary dysplasia;	chr19:22723386	chr19:22773853~22774424:+
OV	cis	rs7246967	0.551	rs7249473	ENSG00000269509.1	BNIP3P34	7.68	4.59e-13	1.4e-09	0.7	0.45	Bronchopulmonary dysplasia;	chr19:22723892	chr19:22773853~22774424:+
OV	cis	rs875971	0.505	rs2462573	ENSG00000236529.1	RP13-254B10.1	-7.68	4.63e-13	1.42e-09	-0.48	-0.45	Aortic root size;	chr7:66042405	chr7:65840212~65840596:+
OV	cis	rs875971	0.505	rs1167386	ENSG00000236529.1	RP13-254B10.1	-7.68	4.63e-13	1.42e-09	-0.48	-0.45	Aortic root size;	chr7:66048109	chr7:65840212~65840596:+
OV	cis	rs875971	0.505	rs1167385	ENSG00000236529.1	RP13-254B10.1	-7.68	4.63e-13	1.42e-09	-0.48	-0.45	Aortic root size;	chr7:66048321	chr7:65840212~65840596:+
OV	cis	rs11690935	0.959	rs7586207	ENSG00000228389.1	AC068039.4	7.68	4.67e-13	1.43e-09	0.53	0.45	Schizophrenia;	chr2:171814584	chr2:171773482~171775844:+
OV	cis	rs11763147	1	rs11763147	ENSG00000226824.5	RP4-756H11.3	7.68	4.69e-13	1.43e-09	0.46	0.45	Corneal structure;	chr7:65861834	chr7:66654538~66669855:+
OV	cis	rs6921919	0.638	rs7772827	ENSG00000216901.1	AL022393.7	7.68	4.72e-13	1.44e-09	0.55	0.45	Autism spectrum disorder or schizophrenia;	chr6:28333366	chr6:28176188~28176674:+
OV	cis	rs7115242	0.748	rs1035237	ENSG00000254851.1	RP11-109L13.1	-7.68	4.74e-13	1.45e-09	-0.79	-0.45	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116857134	chr11:117135528~117138582:+
OV	cis	rs6452524	0.532	rs27363	ENSG00000249664.1	CTD-2227C6.2	7.68	4.77e-13	1.46e-09	0.48	0.45	Hypertension (SNP x SNP interaction);	chr5:83040943	chr5:83012285~83013109:-
OV	cis	rs2658782	0.724	rs2605627	ENSG00000279684.1	RP11-755E23.2	-7.68	4.78e-13	1.46e-09	-0.63	-0.45	Pulmonary function decline;	chr11:93526349	chr11:93286629~93288903:-
OV	cis	rs6452524	0.508	rs256795	ENSG00000249664.1	CTD-2227C6.2	-7.68	4.84e-13	1.48e-09	-0.52	-0.45	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:83012285~83013109:-
OV	cis	rs7246967	0.611	rs62118823	ENSG00000269509.1	BNIP3P34	7.67	4.87e-13	1.48e-09	0.73	0.45	Bronchopulmonary dysplasia;	chr19:22661264	chr19:22773853~22774424:+
OV	cis	rs11690935	0.959	rs6745143	ENSG00000228389.1	AC068039.4	7.67	4.88e-13	1.49e-09	0.52	0.45	Schizophrenia;	chr2:171793872	chr2:171773482~171775844:+
OV	cis	rs875971	0.522	rs1917563	ENSG00000222364.1	RNU6-96P	7.67	4.89e-13	1.49e-09	0.45	0.45	Aortic root size;	chr7:65950660	chr7:66395191~66395286:+
OV	cis	rs2929278	0.617	rs3087657	ENSG00000249839.1	AC011330.5	-7.67	4.93e-13	1.5e-09	-0.55	-0.45	Schizophrenia;	chr15:43771661	chr15:43663654~43684339:-
OV	cis	rs3091242	0.967	rs3093614	ENSG00000261349.1	RP3-465N24.5	7.67	5.01e-13	1.52e-09	0.49	0.45	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25266102~25267136:-
OV	cis	rs9326248	0.574	rs1263173	ENSG00000254851.1	RP11-109L13.1	-7.67	5.03e-13	1.53e-09	-0.54	-0.45	Blood protein levels;	chr11:116810292	chr11:117135528~117138582:+
OV	cis	rs7246967	0.611	rs62118780	ENSG00000269509.1	BNIP3P34	7.67	5.07e-13	1.54e-09	0.73	0.45	Bronchopulmonary dysplasia;	chr19:22648312	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs4933019	ENSG00000269509.1	BNIP3P34	7.67	5.07e-13	1.54e-09	0.73	0.45	Bronchopulmonary dysplasia;	chr19:22649184	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs12983761	ENSG00000269509.1	BNIP3P34	7.67	5.07e-13	1.54e-09	0.73	0.45	Bronchopulmonary dysplasia;	chr19:22657795	chr19:22773853~22774424:+
OV	cis	rs875971	1	rs7781698	ENSG00000226824.5	RP4-756H11.3	-7.67	5.12e-13	1.56e-09	-0.48	-0.45	Aortic root size;	chr7:66431325	chr7:66654538~66669855:+
OV	cis	rs853679	0.517	rs2281588	ENSG00000220721.1	OR1F12	7.67	5.14e-13	1.56e-09	0.51	0.45	Depression;	chr6:28104824	chr6:28073316~28074233:+
OV	cis	rs3091242	0.934	rs686631	ENSG00000261349.1	RP3-465N24.5	-7.67	5.15e-13	1.56e-09	-0.52	-0.45	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25266102~25267136:-
OV	cis	rs1528149	0.836	rs740823	ENSG00000224683.1	RPL36AP29	7.66	5.18e-13	1.57e-09	0.58	0.45	Sitting height ratio;	chr7:16062778	chr7:16208945~16209265:+
OV	cis	rs17361889	0.634	rs1527210	ENSG00000224683.1	RPL36AP29	7.66	5.19e-13	1.57e-09	0.52	0.45	Pediatric bone mineral content (hip);	chr7:16236056	chr7:16208945~16209265:+
OV	cis	rs16828019	0.852	rs16827876	ENSG00000235358.1	RP11-399E6.1	7.66	5.2e-13	1.58e-09	0.88	0.45	Intelligence (multi-trait analysis);	chr1:41073864	chr1:41242373~41284861:+
OV	cis	rs2117029	0.587	rs1865157	ENSG00000258017.1	RP11-386G11.10	-7.66	5.21e-13	1.58e-09	-0.55	-0.45	Intelligence (multi-trait analysis);	chr12:49129003	chr12:49127782~49147869:+
OV	cis	rs875971	0.862	rs1612452	ENSG00000226824.5	RP4-756H11.3	7.66	5.23e-13	1.59e-09	0.46	0.45	Aortic root size;	chr7:66108909	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs1167390	ENSG00000226824.5	RP4-756H11.3	7.66	5.23e-13	1.59e-09	0.46	0.45	Aortic root size;	chr7:66110906	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs35034167	ENSG00000226824.5	RP4-756H11.3	7.66	5.23e-13	1.59e-09	0.46	0.45	Aortic root size;	chr7:66115179	chr7:66654538~66669855:+
OV	cis	rs2564921	0.73	rs2564929	ENSG00000242142.1	SERBP1P3	-7.66	5.24e-13	1.59e-09	-0.5	-0.45	Height;	chr3:53084188	chr3:53064283~53065091:-
OV	cis	rs11690935	0.959	rs6758704	ENSG00000228389.1	AC068039.4	7.66	5.25e-13	1.59e-09	0.52	0.45	Schizophrenia;	chr2:171798587	chr2:171773482~171775844:+
OV	cis	rs875971	0.862	rs28470208	ENSG00000226824.5	RP4-756H11.3	7.66	5.28e-13	1.6e-09	0.46	0.45	Aortic root size;	chr7:66119713	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs12537823	ENSG00000226824.5	RP4-756H11.3	-7.66	5.29e-13	1.6e-09	-0.48	-0.45	Aortic root size;	chr7:66255897	chr7:66654538~66669855:+
OV	cis	rs2117029	0.587	rs57853986	ENSG00000258017.1	RP11-386G11.10	-7.66	5.32e-13	1.61e-09	-0.55	-0.45	Intelligence (multi-trait analysis);	chr12:49124612	chr12:49127782~49147869:+
OV	cis	rs4423214	0.879	rs1630498	ENSG00000254682.1	RP11-660L16.2	-7.66	5.36e-13	1.62e-09	-0.56	-0.45	Vitamin D levels;	chr11:71439739	chr11:71448674~71452157:+
OV	cis	rs4423214	0.592	rs79634040	ENSG00000254682.1	RP11-660L16.2	-7.66	5.4e-13	1.63e-09	-0.65	-0.45	Vitamin D levels;	chr11:71519123	chr11:71448674~71452157:+
OV	cis	rs16828019	0.852	rs34979067	ENSG00000235358.1	RP11-399E6.1	7.65	5.58e-13	1.69e-09	0.88	0.45	Intelligence (multi-trait analysis);	chr1:41077412	chr1:41242373~41284861:+
OV	cis	rs16828019	0.852	rs35190461	ENSG00000235358.1	RP11-399E6.1	7.65	5.58e-13	1.69e-09	0.88	0.45	Intelligence (multi-trait analysis);	chr1:41077463	chr1:41242373~41284861:+
OV	cis	rs8018967	1	rs8018967	ENSG00000258695.2	RP3-414A15.2	-7.65	5.65e-13	1.7e-09	-0.52	-0.45	Blood metabolite ratios;	chr14:73510230	chr14:73522878~73530610:+
OV	cis	rs2117029	0.653	rs1476137	ENSG00000258017.1	RP11-386G11.10	-7.65	5.78e-13	1.74e-09	-0.55	-0.45	Intelligence (multi-trait analysis);	chr12:49129930	chr12:49127782~49147869:+
OV	cis	rs2117029	0.553	rs731350	ENSG00000258017.1	RP11-386G11.10	-7.65	5.78e-13	1.74e-09	-0.55	-0.45	Intelligence (multi-trait analysis);	chr12:49130804	chr12:49127782~49147869:+
OV	cis	rs875971	0.862	rs11763189	ENSG00000226824.5	RP4-756H11.3	-7.65	5.84e-13	1.76e-09	-0.47	-0.45	Aortic root size;	chr7:66518542	chr7:66654538~66669855:+
OV	cis	rs7246967	0.673	rs34682021	ENSG00000269509.1	BNIP3P34	7.65	5.85e-13	1.76e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22643926	chr19:22773853~22774424:+
OV	cis	rs7246967	0.551	rs34897132	ENSG00000269509.1	BNIP3P34	7.65	5.85e-13	1.76e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22644089	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs60021625	ENSG00000269509.1	BNIP3P34	7.65	5.85e-13	1.76e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22646752	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs59567211	ENSG00000269509.1	BNIP3P34	7.65	5.85e-13	1.76e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22647080	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs28787949	ENSG00000269509.1	BNIP3P34	7.65	5.85e-13	1.76e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22647554	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs67631531	ENSG00000269509.1	BNIP3P34	7.65	5.85e-13	1.76e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22647664	chr19:22773853~22774424:+
OV	cis	rs7246967	0.541	rs74169641	ENSG00000269509.1	BNIP3P34	7.65	5.85e-13	1.76e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22647774	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs56271774	ENSG00000269509.1	BNIP3P34	7.65	5.85e-13	1.76e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22648525	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs4414616	ENSG00000269509.1	BNIP3P34	7.65	5.85e-13	1.76e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22649609	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs4627499	ENSG00000269509.1	BNIP3P34	7.65	5.85e-13	1.76e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22649831	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs1835993	ENSG00000269509.1	BNIP3P34	7.65	5.85e-13	1.76e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22650235	chr19:22773853~22774424:+
OV	cis	rs7246967	0.551	rs1835994	ENSG00000269509.1	BNIP3P34	7.65	5.85e-13	1.76e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22650243	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs12984634	ENSG00000269509.1	BNIP3P34	7.65	5.85e-13	1.76e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22650942	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs12984903	ENSG00000269509.1	BNIP3P34	7.65	5.85e-13	1.76e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22651079	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs2361245	ENSG00000269509.1	BNIP3P34	7.65	5.85e-13	1.76e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22651728	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs2082445	ENSG00000269509.1	BNIP3P34	7.65	5.85e-13	1.76e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22651785	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs7250285	ENSG00000269509.1	BNIP3P34	7.65	5.85e-13	1.76e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22654306	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs66620859	ENSG00000269509.1	BNIP3P34	7.65	5.85e-13	1.76e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22654428	chr19:22773853~22774424:+
OV	cis	rs6921919	0.697	rs758398	ENSG00000216901.1	AL022393.7	7.64	5.9e-13	1.77e-09	0.57	0.45	Autism spectrum disorder or schizophrenia;	chr6:28352897	chr6:28176188~28176674:+
OV	cis	rs7246967	0.673	rs2885221	ENSG00000269509.1	BNIP3P34	7.64	6.03e-13	1.81e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22656585	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs2885222	ENSG00000269509.1	BNIP3P34	7.64	6.03e-13	1.81e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22657142	chr19:22773853~22774424:+
OV	cis	rs7396835	0.741	rs7396851	ENSG00000254851.1	RP11-109L13.1	7.64	6.1e-13	1.83e-09	0.7	0.45	Quantitative traits;	chr11:116813448	chr11:117135528~117138582:+
OV	cis	rs11690935	1	rs312924	ENSG00000228389.1	AC068039.4	-7.64	6.17e-13	1.85e-09	-0.52	-0.45	Schizophrenia;	chr2:171707511	chr2:171773482~171775844:+
OV	cis	rs7246967	0.611	rs56276210	ENSG00000269509.1	BNIP3P34	7.64	6.18e-13	1.85e-09	0.74	0.45	Bronchopulmonary dysplasia;	chr19:22716841	chr19:22773853~22774424:+
OV	cis	rs1707322	0.686	rs1547924	ENSG00000281133.1	AL355480.3	-7.64	6.21e-13	1.86e-09	-0.58	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr1:45580892~45580996:-
OV	cis	rs16828019	0.929	rs12029321	ENSG00000235358.1	RP11-399E6.1	7.64	6.22e-13	1.86e-09	0.88	0.45	Intelligence (multi-trait analysis);	chr1:41216858	chr1:41242373~41284861:+
OV	cis	rs16828019	0.929	rs11209734	ENSG00000235358.1	RP11-399E6.1	7.64	6.22e-13	1.86e-09	0.88	0.45	Intelligence (multi-trait analysis);	chr1:41232402	chr1:41242373~41284861:+
OV	cis	rs16828019	0.929	rs12037037	ENSG00000235358.1	RP11-399E6.1	7.64	6.22e-13	1.86e-09	0.88	0.45	Intelligence (multi-trait analysis);	chr1:41232584	chr1:41242373~41284861:+
OV	cis	rs16828019	0.929	rs2363805	ENSG00000235358.1	RP11-399E6.1	7.63	6.31e-13	1.88e-09	0.91	0.45	Intelligence (multi-trait analysis);	chr1:41253762	chr1:41242373~41284861:+
OV	cis	rs16828019	0.852	rs71648540	ENSG00000235358.1	RP11-399E6.1	7.63	6.31e-13	1.88e-09	0.91	0.45	Intelligence (multi-trait analysis);	chr1:41256623	chr1:41242373~41284861:+
OV	cis	rs7246967	0.611	rs16999571	ENSG00000269509.1	BNIP3P34	7.63	6.33e-13	1.89e-09	0.7	0.45	Bronchopulmonary dysplasia;	chr19:22721962	chr19:22773853~22774424:+
OV	cis	rs1707322	0.686	rs2275085	ENSG00000281133.1	AL355480.3	7.63	6.33e-13	1.89e-09	0.6	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr1:45580892~45580996:-
OV	cis	rs4713118	0.629	rs203888	ENSG00000220721.1	OR1F12	7.63	6.34e-13	1.89e-09	0.5	0.45	Parkinson's disease;	chr6:28053811	chr6:28073316~28074233:+
OV	cis	rs801193	0.591	rs721717	ENSG00000226824.5	RP4-756H11.3	7.63	6.43e-13	1.92e-09	0.48	0.45	Aortic root size;	chr7:66665305	chr7:66654538~66669855:+
OV	cis	rs801193	0.569	rs6951302	ENSG00000226824.5	RP4-756H11.3	7.63	6.43e-13	1.92e-09	0.48	0.45	Aortic root size;	chr7:66667525	chr7:66654538~66669855:+
OV	cis	rs2564921	0.73	rs1811351	ENSG00000242142.1	SERBP1P3	-7.63	6.48e-13	1.92e-09	-0.52	-0.45	Height;	chr3:53064759	chr3:53064283~53065091:-
OV	cis	rs7246967	0.551	rs7248993	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22666350	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs12980342	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22666555	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs3951784	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22669124	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs3951785	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22669126	chr19:22773853~22774424:+
OV	cis	rs7246967	0.551	rs7250608	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22670254	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs4244915	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22671336	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs8104052	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22675002	chr19:22773853~22774424:+
OV	cis	rs7246967	0.551	rs75360744	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22675154	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs12975767	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22680007	chr19:22773853~22774424:+
OV	cis	rs7246967	0.604	rs12975793	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22680042	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs57013651	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22680225	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs34795935	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22682386	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs7252925	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22683006	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs7253063	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22683095	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs7254097	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22683098	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs3902164	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22683479	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs6511374	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22683568	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs8103875	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22684060	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs4933024	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22684261	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs8104327	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22684357	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs8104564	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22684405	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs8107724	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22684612	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs12973264	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22684947	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs597906	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22685403	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs35335083	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22686790	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs8102172	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22687217	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs8102006	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22687301	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs3853652	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22689111	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs3853653	ENSG00000269509.1	BNIP3P34	7.63	6.5e-13	1.92e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22689130	chr19:22773853~22774424:+
OV	cis	rs6991838	0.584	rs6993876	ENSG00000272010.1	CTD-3025N20.3	7.63	6.51e-13	1.92e-09	0.57	0.45	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65591850~65592472:-
OV	cis	rs2117029	0.586	rs10875928	ENSG00000258017.1	RP11-386G11.10	-7.63	6.59e-13	1.95e-09	-0.54	-0.45	Intelligence (multi-trait analysis);	chr12:49162520	chr12:49127782~49147869:+
OV	cis	rs11690935	0.959	rs973889	ENSG00000228389.1	AC068039.4	7.63	6.6e-13	1.95e-09	0.52	0.45	Schizophrenia;	chr2:171723444	chr2:171773482~171775844:+
OV	cis	rs2282300	0.956	rs1717779	ENSG00000254532.1	RP11-624D11.2	7.63	6.62e-13	1.95e-09	0.63	0.45	Morning vs. evening chronotype;	chr11:30355151	chr11:30044058~30084343:-
OV	cis	rs875971	0.893	rs62465470	ENSG00000226824.5	RP4-756H11.3	7.62	6.66e-13	1.96e-09	0.46	0.45	Aortic root size;	chr7:66136231	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs4368860	ENSG00000226824.5	RP4-756H11.3	7.62	6.66e-13	1.96e-09	0.46	0.45	Aortic root size;	chr7:66143495	chr7:66654538~66669855:+
OV	cis	rs977987	0.705	rs4888377	ENSG00000261783.1	RP11-252K23.2	-7.62	6.67e-13	1.96e-09	-0.65	-0.45	Dupuytren's disease;	chr16:75291788	chr16:75379818~75381260:-
OV	cis	rs16828019	0.929	rs1032728	ENSG00000235358.1	RP11-399E6.1	7.62	6.71e-13	1.97e-09	0.88	0.45	Intelligence (multi-trait analysis);	chr1:41213894	chr1:41242373~41284861:+
OV	cis	rs16828019	0.929	rs35286837	ENSG00000235358.1	RP11-399E6.1	7.62	6.71e-13	1.97e-09	0.88	0.45	Intelligence (multi-trait analysis);	chr1:41217326	chr1:41242373~41284861:+
OV	cis	rs7246967	0.673	rs2099341	ENSG00000269509.1	BNIP3P34	7.62	6.81e-13	2e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22651558	chr19:22773853~22774424:+
OV	cis	rs4713118	0.662	rs9380045	ENSG00000220721.1	OR1F12	7.62	6.82e-13	2e-09	0.52	0.45	Parkinson's disease;	chr6:28057501	chr6:28073316~28074233:+
OV	cis	rs4713118	0.616	rs9348789	ENSG00000220721.1	OR1F12	7.62	6.82e-13	2e-09	0.52	0.45	Parkinson's disease;	chr6:28057708	chr6:28073316~28074233:+
OV	cis	rs4713118	0.662	rs9468274	ENSG00000220721.1	OR1F12	7.62	6.82e-13	2e-09	0.52	0.45	Parkinson's disease;	chr6:28058299	chr6:28073316~28074233:+
OV	cis	rs4713118	0.662	rs9468275	ENSG00000220721.1	OR1F12	7.62	6.82e-13	2e-09	0.52	0.45	Parkinson's disease;	chr6:28058358	chr6:28073316~28074233:+
OV	cis	rs4713118	0.662	rs9468276	ENSG00000220721.1	OR1F12	7.62	6.82e-13	2e-09	0.52	0.45	Parkinson's disease;	chr6:28059910	chr6:28073316~28074233:+
OV	cis	rs4713118	0.662	rs9468277	ENSG00000220721.1	OR1F12	7.62	6.82e-13	2e-09	0.52	0.45	Parkinson's disease;	chr6:28060612	chr6:28073316~28074233:+
OV	cis	rs4713118	0.662	rs9468278	ENSG00000220721.1	OR1F12	7.62	6.82e-13	2e-09	0.52	0.45	Parkinson's disease;	chr6:28060704	chr6:28073316~28074233:+
OV	cis	rs4713118	0.662	rs13218430	ENSG00000220721.1	OR1F12	7.62	6.82e-13	2e-09	0.52	0.45	Parkinson's disease;	chr6:28062059	chr6:28073316~28074233:+
OV	cis	rs4713118	0.662	rs9380046	ENSG00000220721.1	OR1F12	7.62	6.82e-13	2e-09	0.52	0.45	Parkinson's disease;	chr6:28062721	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs7755442	ENSG00000220721.1	OR1F12	7.62	6.82e-13	2e-09	0.51	0.45	Depression;	chr6:28071237	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs12174753	ENSG00000220721.1	OR1F12	7.62	6.82e-13	2e-09	0.51	0.45	Depression;	chr6:28074687	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs55747925	ENSG00000220721.1	OR1F12	7.62	6.82e-13	2e-09	0.51	0.45	Depression;	chr6:28076559	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs56310871	ENSG00000220721.1	OR1F12	7.62	6.82e-13	2e-09	0.51	0.45	Depression;	chr6:28076704	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs34716816	ENSG00000220721.1	OR1F12	7.62	6.82e-13	2e-09	0.51	0.45	Depression;	chr6:28078391	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9393884	ENSG00000220721.1	OR1F12	7.62	6.82e-13	2e-09	0.51	0.45	Depression;	chr6:28079011	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9380049	ENSG00000220721.1	OR1F12	7.62	6.82e-13	2e-09	0.51	0.45	Depression;	chr6:28080757	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9380050	ENSG00000220721.1	OR1F12	7.62	6.82e-13	2e-09	0.51	0.45	Depression;	chr6:28080760	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9393885	ENSG00000220721.1	OR1F12	7.62	6.82e-13	2e-09	0.51	0.45	Depression;	chr6:28082231	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9393886	ENSG00000220721.1	OR1F12	7.62	6.82e-13	2e-09	0.51	0.45	Depression;	chr6:28082261	chr6:28073316~28074233:+
OV	cis	rs4713118	0.515	rs9368549	ENSG00000220721.1	OR1F12	7.62	6.82e-13	2e-09	0.51	0.45	Parkinson's disease;	chr6:28082269	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs56364346	ENSG00000220721.1	OR1F12	7.62	6.82e-13	2e-09	0.51	0.45	Depression;	chr6:28082984	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9357061	ENSG00000220721.1	OR1F12	7.62	6.82e-13	2e-09	0.51	0.45	Depression;	chr6:28083994	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9368550	ENSG00000220721.1	OR1F12	7.62	6.82e-13	2e-09	0.51	0.45	Depression;	chr6:28084025	chr6:28073316~28074233:+
OV	cis	rs853679	0.542	rs2295594	ENSG00000220721.1	OR1F12	7.62	6.82e-13	2e-09	0.51	0.45	Depression;	chr6:28085319	chr6:28073316~28074233:+
OV	cis	rs875971	0.862	rs7783779	ENSG00000226824.5	RP4-756H11.3	7.62	6.82e-13	2e-09	0.48	0.45	Aortic root size;	chr7:66331639	chr7:66654538~66669855:+
OV	cis	rs853679	0.517	rs2273564	ENSG00000220721.1	OR1F12	7.62	6.88e-13	2.01e-09	0.51	0.45	Depression;	chr6:28089816	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs1853097	ENSG00000220721.1	OR1F12	7.62	6.88e-13	2.01e-09	0.51	0.45	Depression;	chr6:28090857	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9393887	ENSG00000220721.1	OR1F12	7.62	6.88e-13	2.01e-09	0.51	0.45	Depression;	chr6:28091242	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9393888	ENSG00000220721.1	OR1F12	7.62	6.88e-13	2.01e-09	0.51	0.45	Depression;	chr6:28091439	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs3734573	ENSG00000220721.1	OR1F12	7.62	6.88e-13	2.01e-09	0.51	0.45	Depression;	chr6:28091659	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9368551	ENSG00000220721.1	OR1F12	7.62	6.88e-13	2.01e-09	0.51	0.45	Depression;	chr6:28094014	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9393890	ENSG00000220721.1	OR1F12	7.62	6.88e-13	2.01e-09	0.51	0.45	Depression;	chr6:28096077	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9366715	ENSG00000220721.1	OR1F12	7.62	6.88e-13	2.01e-09	0.51	0.45	Depression;	chr6:28096855	chr6:28073316~28074233:+
OV	cis	rs853679	0.598	rs9380054	ENSG00000220721.1	OR1F12	7.62	6.88e-13	2.01e-09	0.51	0.45	Depression;	chr6:28099759	chr6:28073316~28074233:+
OV	cis	rs4713118	0.547	rs2116981	ENSG00000220721.1	OR1F12	7.62	6.88e-13	2.01e-09	0.51	0.45	Parkinson's disease;	chr6:28100173	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9368552	ENSG00000220721.1	OR1F12	7.62	6.88e-13	2.01e-09	0.51	0.45	Depression;	chr6:28100648	chr6:28073316~28074233:+
OV	cis	rs853679	0.542	rs34131763	ENSG00000220721.1	OR1F12	7.62	6.88e-13	2.01e-09	0.51	0.45	Depression;	chr6:28107222	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs35193936	ENSG00000220721.1	OR1F12	7.62	6.88e-13	2.01e-09	0.51	0.45	Depression;	chr6:28108492	chr6:28073316~28074233:+
OV	cis	rs1577917	0.545	rs7755958	ENSG00000203875.9	SNHG5	7.62	6.9e-13	2.02e-09	0.52	0.45	Response to antipsychotic treatment;	chr6:85778793	chr6:85660950~85678736:-
OV	cis	rs875971	0.522	rs1917563	ENSG00000226824.5	RP4-756H11.3	7.62	6.91e-13	2.02e-09	0.46	0.45	Aortic root size;	chr7:65950660	chr7:66654538~66669855:+
OV	cis	rs16828019	0.929	rs10524	ENSG00000235358.1	RP11-399E6.1	7.62	6.92e-13	2.02e-09	0.91	0.45	Intelligence (multi-trait analysis);	chr1:41260801	chr1:41242373~41284861:+
OV	cis	rs801193	0.844	rs2244022	ENSG00000226824.5	RP4-756H11.3	-7.62	6.92e-13	2.02e-09	-0.48	-0.45	Aortic root size;	chr7:66737443	chr7:66654538~66669855:+
OV	cis	rs6991838	0.557	rs7012578	ENSG00000272010.1	CTD-3025N20.3	-7.61	7.06e-13	2.06e-09	-0.57	-0.45	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65591850~65592472:-
OV	cis	rs11168854	0.651	rs12227770	ENSG00000258017.1	RP11-386G11.10	-7.61	7.09e-13	2.06e-09	-0.54	-0.45	Body mass index;	chr12:49183065	chr12:49127782~49147869:+
OV	cis	rs6991838	0.584	rs35790435	ENSG00000272010.1	CTD-3025N20.3	-7.61	7.09e-13	2.06e-09	-0.57	-0.45	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65591850~65592472:-
OV	cis	rs2282300	0.956	rs1222212	ENSG00000254532.1	RP11-624D11.2	7.61	7.16e-13	2.09e-09	0.63	0.45	Morning vs. evening chronotype;	chr11:30353096	chr11:30044058~30084343:-
OV	cis	rs875971	0.964	rs6945019	ENSG00000226824.5	RP4-756H11.3	-7.61	7.18e-13	2.09e-09	-0.48	-0.45	Aortic root size;	chr7:66457471	chr7:66654538~66669855:+
OV	cis	rs4423214	0.592	rs3829251	ENSG00000254682.1	RP11-660L16.2	-7.61	7.19e-13	2.09e-09	-0.63	-0.45	Vitamin D levels;	chr11:71483513	chr11:71448674~71452157:+
OV	cis	rs7569084	0.687	rs963539	ENSG00000234255.7	AC012370.3	-7.61	7.4e-13	2.14e-09	-0.51	-0.45	Sum eosinophil basophil counts;	chr2:65421413	chr2:65439888~65456571:-
OV	cis	rs4423214	0.879	rs1792264	ENSG00000254682.1	RP11-660L16.2	-7.61	7.48e-13	2.16e-09	-0.56	-0.45	Vitamin D levels;	chr11:71439201	chr11:71448674~71452157:+
OV	cis	rs801193	0.527	rs2707837	ENSG00000226824.5	RP4-756H11.3	-7.6	7.62e-13	2.2e-09	-0.47	-0.45	Aortic root size;	chr7:66716086	chr7:66654538~66669855:+
OV	cis	rs4423214	0.879	rs1790353	ENSG00000254682.1	RP11-660L16.2	-7.6	7.65e-13	2.2e-09	-0.55	-0.45	Vitamin D levels;	chr11:71425684	chr11:71448674~71452157:+
OV	cis	rs4423214	0.879	rs1792277	ENSG00000254682.1	RP11-660L16.2	-7.6	7.65e-13	2.2e-09	-0.55	-0.45	Vitamin D levels;	chr11:71427872	chr11:71448674~71452157:+
OV	cis	rs2836974	0.83	rs2735309	ENSG00000232608.1	TIMM9P2	-7.6	7.65e-13	2.2e-09	-0.56	-0.45	Cognitive function;	chr21:39343387	chr21:39216624~39217506:+
OV	cis	rs2117029	0.586	rs1874908	ENSG00000258017.1	RP11-386G11.10	-7.6	7.71e-13	2.22e-09	-0.54	-0.45	Intelligence (multi-trait analysis);	chr12:49190247	chr12:49127782~49147869:+
OV	cis	rs11690935	0.959	rs10166005	ENSG00000228389.1	AC068039.4	7.6	7.73e-13	2.22e-09	0.52	0.45	Schizophrenia;	chr2:171750784	chr2:171773482~171775844:+
OV	cis	rs4423214	0.879	rs1792283	ENSG00000254682.1	RP11-660L16.2	-7.6	7.75e-13	2.23e-09	-0.54	-0.45	Vitamin D levels;	chr11:71424090	chr11:71448674~71452157:+
OV	cis	rs4423214	0.879	rs1792282	ENSG00000254682.1	RP11-660L16.2	-7.6	7.75e-13	2.23e-09	-0.54	-0.45	Vitamin D levels;	chr11:71424120	chr11:71448674~71452157:+
OV	cis	rs7115242	0.925	rs7925256	ENSG00000254851.1	RP11-109L13.1	-7.6	7.76e-13	2.23e-09	-0.92	-0.45	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117174619	chr11:117135528~117138582:+
OV	cis	rs875971	0.522	rs10807697	ENSG00000226824.5	RP4-756H11.3	-7.6	7.94e-13	2.28e-09	-0.47	-0.45	Aortic root size;	chr7:65951183	chr7:66654538~66669855:+
OV	cis	rs801193	0.569	rs2659908	ENSG00000226824.5	RP4-756H11.3	-7.59	8.03e-13	2.3e-09	-0.47	-0.45	Aortic root size;	chr7:66695835	chr7:66654538~66669855:+
OV	cis	rs801193	0.569	rs7782587	ENSG00000226824.5	RP4-756H11.3	-7.59	8.03e-13	2.3e-09	-0.47	-0.45	Aortic root size;	chr7:66701485	chr7:66654538~66669855:+
OV	cis	rs801193	0.569	rs4717315	ENSG00000226824.5	RP4-756H11.3	-7.59	8.03e-13	2.3e-09	-0.47	-0.45	Aortic root size;	chr7:66713338	chr7:66654538~66669855:+
OV	cis	rs17711722	0.523	rs365896	ENSG00000236529.1	RP13-254B10.1	-7.59	8.37e-13	2.4e-09	-0.49	-0.45	Calcium levels;	chr7:66045710	chr7:65840212~65840596:+
OV	cis	rs2408955	0.522	rs11168408	ENSG00000258273.1	RP11-370I10.4	7.58	8.56e-13	2.45e-09	0.54	0.45	Glycated hemoglobin levels;	chr12:48104544	chr12:48333755~48333901:-
OV	cis	rs801193	0.844	rs732465	ENSG00000226824.5	RP4-756H11.3	-7.58	8.58e-13	2.45e-09	-0.47	-0.45	Aortic root size;	chr7:66533463	chr7:66654538~66669855:+
OV	cis	rs801193	0.773	rs801207	ENSG00000226824.5	RP4-756H11.3	7.58	8.58e-13	2.45e-09	0.47	0.45	Aortic root size;	chr7:66555603	chr7:66654538~66669855:+
OV	cis	rs875971	0.543	rs801191	ENSG00000226824.5	RP4-756H11.3	7.58	8.58e-13	2.45e-09	0.47	0.45	Aortic root size;	chr7:66567968	chr7:66654538~66669855:+
OV	cis	rs875971	0.508	rs6947808	ENSG00000226824.5	RP4-756H11.3	7.58	8.58e-13	2.45e-09	0.47	0.45	Aortic root size;	chr7:66580095	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs1968126	ENSG00000226824.5	RP4-756H11.3	7.58	8.65e-13	2.47e-09	0.47	0.45	Aortic root size;	chr7:66592017	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs6460306	ENSG00000226824.5	RP4-756H11.3	7.58	8.65e-13	2.47e-09	0.47	0.45	Aortic root size;	chr7:66595806	chr7:66654538~66669855:+
OV	cis	rs17711722	0.727	rs1880555	ENSG00000222364.1	RNU6-96P	-7.58	8.66e-13	2.47e-09	-0.46	-0.45	Calcium levels;	chr7:65967580	chr7:66395191~66395286:+
OV	cis	rs2153535	0.563	rs7739249	ENSG00000230939.1	RP11-314C16.1	-7.58	8.67e-13	2.47e-09	-0.52	-0.45	Motion sickness;	chr6:8534357	chr6:8784178~8785445:+
OV	cis	rs10262624	0.564	rs58051142	ENSG00000234286.1	AC006026.13	-7.58	8.96e-13	2.55e-09	-0.5	-0.45	Schizophrenia;	chr7:23866047	chr7:23680195~23680786:-
OV	cis	rs3091242	0.967	rs1053438	ENSG00000261349.1	RP3-465N24.5	7.58	8.99e-13	2.56e-09	0.48	0.45	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25266102~25267136:-
OV	cis	rs2564921	0.765	rs35333155	ENSG00000242142.1	SERBP1P3	7.57	9.06e-13	2.58e-09	0.5	0.45	Height;	chr3:53073764	chr3:53064283~53065091:-
OV	cis	rs2564921	0.73	rs58492539	ENSG00000242142.1	SERBP1P3	-7.57	9.06e-13	2.58e-09	-0.51	-0.45	Height;	chr3:53052712	chr3:53064283~53065091:-
OV	cis	rs2732480	0.577	rs2450994	ENSG00000258273.1	RP11-370I10.4	-7.57	9.1e-13	2.59e-09	-0.53	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48328049	chr12:48333755~48333901:-
OV	cis	rs494459	0.838	rs2510897	ENSG00000255239.1	AP002954.6	7.57	9.13e-13	2.6e-09	0.51	0.45	Height;	chr11:118773873	chr11:118688039~118690600:-
OV	cis	rs3091242	0.9	rs1811832	ENSG00000261349.1	RP3-465N24.5	-7.57	9.21e-13	2.62e-09	-0.49	-0.45	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25266102~25267136:-
OV	cis	rs8062405	1	rs62037371	ENSG00000259982.1	CDC37P1	7.57	9.22e-13	2.62e-09	0.55	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28700294~28701540:-
OV	cis	rs8062405	1	rs8055138	ENSG00000259982.1	CDC37P1	7.57	9.22e-13	2.62e-09	0.55	0.45	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28700294~28701540:-
OV	cis	rs7246967	0.673	rs55932152	ENSG00000269509.1	BNIP3P34	7.57	9.24e-13	2.62e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22690626	chr19:22773853~22774424:+
OV	cis	rs2732480	0.557	rs923397	ENSG00000258273.1	RP11-370I10.4	-7.57	9.26e-13	2.63e-09	-0.53	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48326609	chr12:48333755~48333901:-
OV	cis	rs2732480	0.557	rs2409004	ENSG00000258273.1	RP11-370I10.4	-7.57	9.26e-13	2.63e-09	-0.53	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48327668	chr12:48333755~48333901:-
OV	cis	rs7617773	0.925	rs34513961	ENSG00000229759.1	MRPS18AP1	7.57	9.3e-13	2.64e-09	0.53	0.45	Coronary artery disease;	chr3:48132163	chr3:48256350~48256938:-
OV	cis	rs17711722	0.701	rs781143	ENSG00000222364.1	RNU6-96P	-7.57	9.34e-13	2.65e-09	-0.46	-0.45	Calcium levels;	chr7:65974892	chr7:66395191~66395286:+
OV	cis	rs17711722	0.701	rs781145	ENSG00000222364.1	RNU6-96P	-7.57	9.34e-13	2.65e-09	-0.46	-0.45	Calcium levels;	chr7:65975383	chr7:66395191~66395286:+
OV	cis	rs801193	0.901	rs4273746	ENSG00000222364.1	RNU6-96P	7.57	9.51e-13	2.7e-09	0.47	0.45	Aortic root size;	chr7:66836124	chr7:66395191~66395286:+
OV	cis	rs3091242	1	rs9689	ENSG00000261349.1	RP3-465N24.5	-7.57	9.55e-13	2.71e-09	-0.47	-0.45	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25266102~25267136:-
OV	cis	rs853679	0.517	rs6932109	ENSG00000220721.1	OR1F12	-7.56	9.66e-13	2.74e-09	-0.53	-0.45	Depression;	chr6:28110525	chr6:28073316~28074233:+
OV	cis	rs1577917	0.545	rs9344548	ENSG00000203875.9	SNHG5	7.56	9.74e-13	2.76e-09	0.52	0.45	Response to antipsychotic treatment;	chr6:85777619	chr6:85660950~85678736:-
OV	cis	rs4713118	0.621	rs10484403	ENSG00000220721.1	OR1F12	7.56	9.87e-13	2.79e-09	0.53	0.45	Parkinson's disease;	chr6:28065745	chr6:28073316~28074233:+
OV	cis	rs7246967	0.673	rs7249003	ENSG00000269509.1	BNIP3P34	7.56	9.87e-13	2.79e-09	0.69	0.45	Bronchopulmonary dysplasia;	chr19:22705132	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs12971914	ENSG00000269509.1	BNIP3P34	7.56	9.87e-13	2.79e-09	0.69	0.45	Bronchopulmonary dysplasia;	chr19:22706096	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs8105441	ENSG00000269509.1	BNIP3P34	7.56	9.87e-13	2.79e-09	0.69	0.45	Bronchopulmonary dysplasia;	chr19:22708664	chr19:22773853~22774424:+
OV	cis	rs7246967	0.551	rs8112442	ENSG00000269509.1	BNIP3P34	7.56	9.87e-13	2.79e-09	0.69	0.45	Bronchopulmonary dysplasia;	chr19:22710567	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs73022763	ENSG00000269509.1	BNIP3P34	7.56	9.87e-13	2.79e-09	0.69	0.45	Bronchopulmonary dysplasia;	chr19:22711414	chr19:22773853~22774424:+
OV	cis	rs1707322	0.686	rs3014239	ENSG00000281133.1	AL355480.3	7.56	9.91e-13	2.8e-09	0.59	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45580892~45580996:-
OV	cis	rs1707322	0.686	rs3014236	ENSG00000281133.1	AL355480.3	7.56	9.91e-13	2.8e-09	0.59	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45580892~45580996:-
OV	cis	rs7246967	0.673	rs3951783	ENSG00000269509.1	BNIP3P34	7.56	9.95e-13	2.81e-09	0.71	0.45	Bronchopulmonary dysplasia;	chr19:22656462	chr19:22773853~22774424:+
OV	cis	rs7569084	0.687	rs1344891	ENSG00000234255.7	AC012370.3	7.56	9.97e-13	2.82e-09	0.49	0.45	Sum eosinophil basophil counts;	chr2:65458890	chr2:65439888~65456571:-
OV	cis	rs1577917	0.545	rs1335443	ENSG00000203875.9	SNHG5	-7.56	9.99e-13	2.82e-09	-0.52	-0.45	Response to antipsychotic treatment;	chr6:85769019	chr6:85660950~85678736:-
OV	cis	rs875971	0.522	rs9530	ENSG00000226824.5	RP4-756H11.3	-7.56	1.01e-12	2.85e-09	-0.47	-0.45	Aortic root size;	chr7:65960907	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs801204	ENSG00000226824.5	RP4-756H11.3	7.56	1.01e-12	2.85e-09	0.46	0.45	Aortic root size;	chr7:66557934	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs801203	ENSG00000226824.5	RP4-756H11.3	7.56	1.01e-12	2.85e-09	0.46	0.45	Aortic root size;	chr7:66558025	chr7:66654538~66669855:+
OV	cis	rs853679	0.517	rs4713135	ENSG00000220721.1	OR1F12	7.56	1.01e-12	2.85e-09	0.51	0.45	Depression;	chr6:28071808	chr6:28073316~28074233:+
OV	cis	rs11690935	0.959	rs4668412	ENSG00000228389.1	AC068039.4	7.56	1.01e-12	2.86e-09	0.52	0.45	Schizophrenia;	chr2:171763260	chr2:171773482~171775844:+
OV	cis	rs875971	0.862	rs13232191	ENSG00000226824.5	RP4-756H11.3	-7.55	1.02e-12	2.87e-09	-0.47	-0.45	Aortic root size;	chr7:66521661	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs35378740	ENSG00000226824.5	RP4-756H11.3	-7.55	1.02e-12	2.87e-09	-0.47	-0.45	Aortic root size;	chr7:66522725	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs10950043	ENSG00000226824.5	RP4-756H11.3	-7.55	1.02e-12	2.87e-09	-0.47	-0.45	Aortic root size;	chr7:66523623	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs17747530	ENSG00000226824.5	RP4-756H11.3	-7.55	1.02e-12	2.87e-09	-0.47	-0.45	Aortic root size;	chr7:66529742	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs13226170	ENSG00000226824.5	RP4-756H11.3	-7.55	1.02e-12	2.87e-09	-0.47	-0.45	Aortic root size;	chr7:66534311	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs2420611	ENSG00000226824.5	RP4-756H11.3	-7.55	1.02e-12	2.87e-09	-0.47	-0.45	Aortic root size;	chr7:66534333	chr7:66654538~66669855:+
OV	cis	rs875971	0.861	rs801215	ENSG00000226824.5	RP4-756H11.3	7.55	1.02e-12	2.87e-09	0.47	0.45	Aortic root size;	chr7:66546951	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs13536	ENSG00000226824.5	RP4-756H11.3	7.55	1.02e-12	2.87e-09	0.47	0.45	Aortic root size;	chr7:66554203	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs801209	ENSG00000226824.5	RP4-756H11.3	7.55	1.02e-12	2.87e-09	0.47	0.45	Aortic root size;	chr7:66554403	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs801206	ENSG00000226824.5	RP4-756H11.3	7.55	1.02e-12	2.87e-09	0.47	0.45	Aortic root size;	chr7:66556979	chr7:66654538~66669855:+
OV	cis	rs2117029	0.619	rs2753	ENSG00000258017.1	RP11-386G11.10	-7.55	1.02e-12	2.88e-09	-0.55	-0.45	Intelligence (multi-trait analysis);	chr12:49127889	chr12:49127782~49147869:+
OV	cis	rs3091242	0.9	rs669063	ENSG00000261349.1	RP3-465N24.5	-7.55	1.02e-12	2.88e-09	-0.5	-0.45	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25266102~25267136:-
OV	cis	rs6921919	0.697	rs6942030	ENSG00000216901.1	AL022393.7	7.55	1.03e-12	2.89e-09	0.54	0.45	Autism spectrum disorder or schizophrenia;	chr6:28348181	chr6:28176188~28176674:+
OV	cis	rs801193	0.569	rs2659907	ENSG00000226824.5	RP4-756H11.3	-7.55	1.03e-12	2.9e-09	-0.48	-0.45	Aortic root size;	chr7:66699045	chr7:66654538~66669855:+
OV	cis	rs875971	0.825	rs801202	ENSG00000226824.5	RP4-756H11.3	7.55	1.04e-12	2.92e-09	0.46	0.45	Aortic root size;	chr7:66558942	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs801195	ENSG00000226824.5	RP4-756H11.3	7.55	1.04e-12	2.92e-09	0.46	0.45	Aortic root size;	chr7:66561128	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs801194	ENSG00000226824.5	RP4-756H11.3	7.55	1.04e-12	2.92e-09	0.46	0.45	Aortic root size;	chr7:66563508	chr7:66654538~66669855:+
OV	cis	rs7688540	0.511	rs4522818	ENSG00000275426.1	CH17-262A2.1	7.55	1.04e-12	2.93e-09	0.83	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:187973	chr4:149738~150317:+
OV	cis	rs875971	0.767	rs61348003	ENSG00000226824.5	RP4-756H11.3	-7.55	1.05e-12	2.94e-09	-0.46	-0.45	Aortic root size;	chr7:66540947	chr7:66654538~66669855:+
OV	cis	rs7246967	0.673	rs73022717	ENSG00000269509.1	BNIP3P34	7.55	1.05e-12	2.94e-09	0.7	0.45	Bronchopulmonary dysplasia;	chr19:22694257	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs74664155	ENSG00000269509.1	BNIP3P34	7.55	1.05e-12	2.94e-09	0.7	0.45	Bronchopulmonary dysplasia;	chr19:22697530	chr19:22773853~22774424:+
OV	cis	rs2117029	0.554	rs2334931	ENSG00000258017.1	RP11-386G11.10	-7.55	1.05e-12	2.95e-09	-0.54	-0.45	Intelligence (multi-trait analysis);	chr12:49174130	chr12:49127782~49147869:+
OV	cis	rs2117029	0.586	rs10875929	ENSG00000258017.1	RP11-386G11.10	-7.55	1.05e-12	2.95e-09	-0.54	-0.45	Intelligence (multi-trait analysis);	chr12:49174605	chr12:49127782~49147869:+
OV	cis	rs2117029	0.554	rs2334930	ENSG00000258017.1	RP11-386G11.10	-7.55	1.05e-12	2.95e-09	-0.54	-0.45	Intelligence (multi-trait analysis);	chr12:49175528	chr12:49127782~49147869:+
OV	cis	rs2117029	0.586	rs11168904	ENSG00000258017.1	RP11-386G11.10	-7.55	1.05e-12	2.95e-09	-0.54	-0.45	Intelligence (multi-trait analysis);	chr12:49177234	chr12:49127782~49147869:+
OV	cis	rs2117029	0.586	rs10875931	ENSG00000258017.1	RP11-386G11.10	-7.55	1.05e-12	2.95e-09	-0.54	-0.45	Intelligence (multi-trait analysis);	chr12:49179513	chr12:49127782~49147869:+
OV	cis	rs2117029	0.554	rs7954530	ENSG00000258017.1	RP11-386G11.10	-7.55	1.05e-12	2.95e-09	-0.54	-0.45	Intelligence (multi-trait analysis);	chr12:49179742	chr12:49127782~49147869:+
OV	cis	rs2117029	0.586	rs7957998	ENSG00000258017.1	RP11-386G11.10	-7.55	1.05e-12	2.95e-09	-0.54	-0.45	Intelligence (multi-trait analysis);	chr12:49180240	chr12:49127782~49147869:+
OV	cis	rs2117029	0.553	rs11168909	ENSG00000258017.1	RP11-386G11.10	-7.55	1.05e-12	2.95e-09	-0.54	-0.45	Intelligence (multi-trait analysis);	chr12:49183092	chr12:49127782~49147869:+
OV	cis	rs2117029	0.521	rs1056875	ENSG00000258017.1	RP11-386G11.10	-7.55	1.05e-12	2.95e-09	-0.54	-0.45	Intelligence (multi-trait analysis);	chr12:49186397	chr12:49127782~49147869:+
OV	cis	rs4423214	0.625	rs78685409	ENSG00000254682.1	RP11-660L16.2	-7.55	1.05e-12	2.95e-09	-0.54	-0.45	Vitamin D levels;	chr11:71426337	chr11:71448674~71452157:+
OV	cis	rs1707322	0.686	rs1541131	ENSG00000281133.1	AL355480.3	7.55	1.07e-12	2.99e-09	0.59	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr1:45580892~45580996:-
OV	cis	rs17711722	0.74	rs7809991	ENSG00000226824.5	RP4-756H11.3	-7.55	1.07e-12	3.01e-09	-0.46	-0.45	Calcium levels;	chr7:65941231	chr7:66654538~66669855:+
OV	cis	rs875971	0.522	rs6960048	ENSG00000226824.5	RP4-756H11.3	-7.55	1.07e-12	3.01e-09	-0.46	-0.45	Aortic root size;	chr7:65943052	chr7:66654538~66669855:+
OV	cis	rs801193	0.844	rs2244022	ENSG00000222364.1	RNU6-96P	-7.55	1.08e-12	3.03e-09	-0.47	-0.45	Aortic root size;	chr7:66737443	chr7:66395191~66395286:+
OV	cis	rs16828019	0.929	rs35883594	ENSG00000235358.1	RP11-399E6.1	7.55	1.08e-12	3.03e-09	0.9	0.45	Intelligence (multi-trait analysis);	chr1:41278421	chr1:41242373~41284861:+
OV	cis	rs8040855	0.965	rs1961276	ENSG00000259295.5	CSPG4P12	7.54	1.09e-12	3.05e-09	0.54	0.45	Bulimia nervosa;	chr15:85170986	chr15:85191438~85213905:+
OV	cis	rs875971	0.522	rs7784623	ENSG00000222364.1	RNU6-96P	-7.54	1.09e-12	3.05e-09	-0.45	-0.45	Aortic root size;	chr7:65930047	chr7:66395191~66395286:+
OV	cis	rs875971	0.522	rs34973832	ENSG00000222364.1	RNU6-96P	-7.54	1.09e-12	3.05e-09	-0.45	-0.45	Aortic root size;	chr7:65931217	chr7:66395191~66395286:+
OV	cis	rs6921919	0.583	rs2041230	ENSG00000216901.1	AL022393.7	7.54	1.1e-12	3.06e-09	0.53	0.45	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28176188~28176674:+
OV	cis	rs11723261	0.509	rs61792240	ENSG00000275426.1	CH17-262A2.1	7.54	1.1e-12	3.08e-09	0.73	0.45	Immune response to smallpox vaccine (IL-6);	chr4:134876	chr4:149738~150317:+
OV	cis	rs2658782	0.724	rs2658770	ENSG00000279684.1	RP11-755E23.2	-7.54	1.11e-12	3.08e-09	-0.63	-0.45	Pulmonary function decline;	chr11:93528720	chr11:93286629~93288903:-
OV	cis	rs1707322	0.686	rs2991977	ENSG00000281133.1	AL355480.3	7.54	1.11e-12	3.09e-09	0.59	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45580892~45580996:-
OV	cis	rs1707322	0.656	rs2991981	ENSG00000281133.1	AL355480.3	7.54	1.11e-12	3.09e-09	0.59	0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45580892~45580996:-
OV	cis	rs853679	0.517	rs36078605	ENSG00000220721.1	OR1F12	7.54	1.11e-12	3.09e-09	0.51	0.45	Depression;	chr6:28110254	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9393891	ENSG00000220721.1	OR1F12	7.54	1.11e-12	3.09e-09	0.51	0.45	Depression;	chr6:28111382	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9468286	ENSG00000220721.1	OR1F12	7.54	1.11e-12	3.09e-09	0.51	0.45	Depression;	chr6:28111650	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9380055	ENSG00000220721.1	OR1F12	7.54	1.11e-12	3.09e-09	0.51	0.45	Depression;	chr6:28113851	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9368553	ENSG00000220721.1	OR1F12	7.54	1.11e-12	3.09e-09	0.51	0.45	Depression;	chr6:28114487	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9368554	ENSG00000220721.1	OR1F12	7.54	1.11e-12	3.09e-09	0.51	0.45	Depression;	chr6:28114933	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs4713137	ENSG00000220721.1	OR1F12	7.54	1.11e-12	3.09e-09	0.51	0.45	Depression;	chr6:28115743	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9348793	ENSG00000220721.1	OR1F12	7.54	1.11e-12	3.09e-09	0.51	0.45	Depression;	chr6:28116411	chr6:28073316~28074233:+
OV	cis	rs4713118	0.586	rs6905516	ENSG00000220721.1	OR1F12	7.54	1.11e-12	3.09e-09	0.51	0.45	Parkinson's disease;	chr6:28118700	chr6:28073316~28074233:+
OV	cis	rs4713118	0.586	rs6905522	ENSG00000220721.1	OR1F12	7.54	1.11e-12	3.09e-09	0.51	0.45	Parkinson's disease;	chr6:28118701	chr6:28073316~28074233:+
OV	cis	rs4713118	0.586	rs9468290	ENSG00000220721.1	OR1F12	7.54	1.11e-12	3.09e-09	0.51	0.45	Parkinson's disease;	chr6:28119896	chr6:28073316~28074233:+
OV	cis	rs4713118	0.662	rs9357060	ENSG00000220721.1	OR1F12	7.54	1.12e-12	3.1e-09	0.51	0.45	Parkinson's disease;	chr6:28056708	chr6:28073316~28074233:+
OV	cis	rs4713118	0.662	rs9468271	ENSG00000220721.1	OR1F12	7.54	1.12e-12	3.1e-09	0.51	0.45	Parkinson's disease;	chr6:28056792	chr6:28073316~28074233:+
OV	cis	rs2729354	0.52	rs2729377	ENSG00000265566.2	RN7SL605P	-7.54	1.12e-12	3.11e-09	-0.65	-0.45	Blood protein levels;	chr11:57482611	chr11:57528085~57528365:-
OV	cis	rs7246967	0.542	rs56355379	ENSG00000269509.1	BNIP3P34	7.54	1.12e-12	3.11e-09	0.68	0.45	Bronchopulmonary dysplasia;	chr19:22717653	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs34376806	ENSG00000269509.1	BNIP3P34	7.54	1.12e-12	3.11e-09	0.68	0.45	Bronchopulmonary dysplasia;	chr19:22718059	chr19:22773853~22774424:+
OV	cis	rs11690935	0.959	rs10194102	ENSG00000228389.1	AC068039.4	7.54	1.12e-12	3.11e-09	0.52	0.45	Schizophrenia;	chr2:171769633	chr2:171773482~171775844:+
OV	cis	rs11690935	0.918	rs11757	ENSG00000228389.1	AC068039.4	7.54	1.15e-12	3.2e-09	0.52	0.45	Schizophrenia;	chr2:171784535	chr2:171773482~171775844:+
OV	cis	rs8105895	0.935	rs78646027	ENSG00000269742.1	BNIP3P29	7.53	1.16e-12	3.21e-09	0.71	0.45	Body mass index (change over time);	chr19:22074608	chr19:22065828~22066398:-
OV	cis	rs17711722	0.74	rs7809991	ENSG00000222364.1	RNU6-96P	-7.53	1.16e-12	3.21e-09	-0.45	-0.45	Calcium levels;	chr7:65941231	chr7:66395191~66395286:+
OV	cis	rs875971	0.522	rs6960048	ENSG00000222364.1	RNU6-96P	-7.53	1.16e-12	3.21e-09	-0.45	-0.45	Aortic root size;	chr7:65943052	chr7:66395191~66395286:+
OV	cis	rs1707322	0.647	rs6686944	ENSG00000281133.1	AL355480.3	-7.53	1.16e-12	3.21e-09	-0.58	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr1:45580892~45580996:-
OV	cis	rs17711722	0.503	rs453835	ENSG00000236529.1	RP13-254B10.1	-7.53	1.16e-12	3.21e-09	-0.51	-0.45	Calcium levels;	chr7:66046172	chr7:65840212~65840596:+
OV	cis	rs853679	0.517	rs9380047	ENSG00000220721.1	OR1F12	7.53	1.16e-12	3.21e-09	0.51	0.45	Depression;	chr6:28070115	chr6:28073316~28074233:+
OV	cis	rs875971	0.505	rs6955582	ENSG00000222364.1	RNU6-96P	-7.53	1.17e-12	3.24e-09	-0.46	-0.45	Aortic root size;	chr7:65966699	chr7:66395191~66395286:+
OV	cis	rs73086581	0.787	rs68127408	ENSG00000229539.1	RP11-119B16.2	7.53	1.17e-12	3.25e-09	0.59	0.45	Response to antidepressants in depression;	chr20:3887800	chr20:3888239~3888868:-
OV	cis	rs73086581	0.787	rs67724338	ENSG00000229539.1	RP11-119B16.2	7.53	1.17e-12	3.25e-09	0.59	0.45	Response to antidepressants in depression;	chr20:3888410	chr20:3888239~3888868:-
OV	cis	rs73086581	0.787	rs67202952	ENSG00000229539.1	RP11-119B16.2	7.53	1.17e-12	3.25e-09	0.59	0.45	Response to antidepressants in depression;	chr20:3888452	chr20:3888239~3888868:-
OV	cis	rs9326248	0.648	rs11216257	ENSG00000254851.1	RP11-109L13.1	-7.53	1.17e-12	3.25e-09	-0.67	-0.45	Blood protein levels;	chr11:117061845	chr11:117135528~117138582:+
OV	cis	rs11690935	0.959	rs13419987	ENSG00000228389.1	AC068039.4	7.53	1.18e-12	3.27e-09	0.52	0.45	Schizophrenia;	chr2:171767404	chr2:171773482~171775844:+
OV	cis	rs494459	0.838	rs581045	ENSG00000255239.1	AP002954.6	7.53	1.19e-12	3.29e-09	0.51	0.45	Height;	chr11:118761813	chr11:118688039~118690600:-
OV	cis	rs1707322	0.721	rs10890333	ENSG00000281133.1	AL355480.3	-7.53	1.2e-12	3.31e-09	-0.58	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs12043945	ENSG00000281133.1	AL355480.3	-7.53	1.2e-12	3.31e-09	-0.58	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs12091503	ENSG00000281133.1	AL355480.3	-7.53	1.2e-12	3.31e-09	-0.58	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45580892~45580996:-
OV	cis	rs853679	0.517	rs9357063	ENSG00000220721.1	OR1F12	7.53	1.2e-12	3.32e-09	0.51	0.45	Depression;	chr6:28092227	chr6:28073316~28074233:+
OV	cis	rs7688540	0.511	rs61794969	ENSG00000275426.1	CH17-262A2.1	7.53	1.2e-12	3.32e-09	0.82	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:194242	chr4:149738~150317:+
OV	cis	rs7688540	0.511	rs77815676	ENSG00000275426.1	CH17-262A2.1	7.53	1.2e-12	3.32e-09	0.82	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:196080	chr4:149738~150317:+
OV	cis	rs7688540	0.511	rs76125013	ENSG00000275426.1	CH17-262A2.1	7.53	1.2e-12	3.32e-09	0.82	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:201493	chr4:149738~150317:+
OV	cis	rs11723261	0.545	rs6812799	ENSG00000275426.1	CH17-262A2.1	7.53	1.2e-12	3.32e-09	0.82	0.45	Immune response to smallpox vaccine (IL-6);	chr4:203545	chr4:149738~150317:+
OV	cis	rs7688540	0.511	rs6845131	ENSG00000275426.1	CH17-262A2.1	7.53	1.2e-12	3.32e-09	0.82	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:206358	chr4:149738~150317:+
OV	cis	rs7688540	0.511	rs11731623	ENSG00000275426.1	CH17-262A2.1	7.53	1.2e-12	3.32e-09	0.82	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:207221	chr4:149738~150317:+
OV	cis	rs7246967	0.611	rs3931771	ENSG00000269509.1	BNIP3P34	7.53	1.21e-12	3.34e-09	0.67	0.45	Bronchopulmonary dysplasia;	chr19:22714018	chr19:22773853~22774424:+
OV	cis	rs7246967	0.604	rs8107322	ENSG00000269509.1	BNIP3P34	7.53	1.21e-12	3.34e-09	0.67	0.45	Bronchopulmonary dysplasia;	chr19:22714630	chr19:22773853~22774424:+
OV	cis	rs853679	0.517	rs1340004	ENSG00000220721.1	OR1F12	7.52	1.23e-12	3.38e-09	0.51	0.45	Depression;	chr6:28135913	chr6:28073316~28074233:+
OV	cis	rs4423214	0.559	rs10898203	ENSG00000254682.1	RP11-660L16.2	-7.52	1.23e-12	3.39e-09	-0.65	-0.45	Vitamin D levels;	chr11:71492390	chr11:71448674~71452157:+
OV	cis	rs11690935	0.918	rs12692978	ENSG00000228389.1	AC068039.4	7.52	1.23e-12	3.4e-09	0.54	0.45	Schizophrenia;	chr2:171869471	chr2:171773482~171775844:+
OV	cis	rs1707322	0.721	rs11211163	ENSG00000281133.1	AL355480.3	-7.52	1.26e-12	3.46e-09	-0.58	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs12037803	ENSG00000281133.1	AL355480.3	-7.52	1.26e-12	3.46e-09	-0.58	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs11211165	ENSG00000281133.1	AL355480.3	-7.52	1.26e-12	3.46e-09	-0.58	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs11211166	ENSG00000281133.1	AL355480.3	-7.52	1.26e-12	3.46e-09	-0.58	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs10789470	ENSG00000281133.1	AL355480.3	-7.52	1.26e-12	3.46e-09	-0.58	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs61784796	ENSG00000281133.1	AL355480.3	-7.52	1.26e-12	3.46e-09	-0.58	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs10749856	ENSG00000281133.1	AL355480.3	-7.52	1.26e-12	3.46e-09	-0.58	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs10890344	ENSG00000281133.1	AL355480.3	-7.52	1.26e-12	3.46e-09	-0.58	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs4564187	ENSG00000281133.1	AL355480.3	-7.52	1.26e-12	3.46e-09	-0.58	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45580892~45580996:-
OV	cis	rs1707322	0.752	rs28438704	ENSG00000281133.1	AL355480.3	-7.52	1.26e-12	3.46e-09	-0.58	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs28442079	ENSG00000281133.1	AL355480.3	-7.52	1.26e-12	3.46e-09	-0.58	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45580892~45580996:-
OV	cis	rs11690935	0.959	rs6709156	ENSG00000228389.1	AC068039.4	7.52	1.26e-12	3.47e-09	0.51	0.45	Schizophrenia;	chr2:171735434	chr2:171773482~171775844:+
OV	cis	rs11690935	0.959	rs12692970	ENSG00000228389.1	AC068039.4	7.52	1.26e-12	3.47e-09	0.51	0.45	Schizophrenia;	chr2:171737687	chr2:171773482~171775844:+
OV	cis	rs1707322	0.686	rs1250	ENSG00000281133.1	AL355480.3	-7.52	1.26e-12	3.47e-09	-0.59	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr1:45580892~45580996:-
OV	cis	rs16828019	0.852	rs12022978	ENSG00000235358.1	RP11-399E6.1	7.52	1.28e-12	3.51e-09	0.87	0.45	Intelligence (multi-trait analysis);	chr1:41088416	chr1:41242373~41284861:+
OV	cis	rs4713118	0.621	rs4713132	ENSG00000220721.1	OR1F12	7.52	1.3e-12	3.55e-09	0.51	0.45	Parkinson's disease;	chr6:28066257	chr6:28073316~28074233:+
OV	cis	rs4713118	0.621	rs4713133	ENSG00000220721.1	OR1F12	7.52	1.3e-12	3.55e-09	0.51	0.45	Parkinson's disease;	chr6:28066263	chr6:28073316~28074233:+
OV	cis	rs4713118	0.621	rs4713134	ENSG00000220721.1	OR1F12	7.52	1.3e-12	3.55e-09	0.51	0.45	Parkinson's disease;	chr6:28066343	chr6:28073316~28074233:+
OV	cis	rs7688540	0.511	rs61794991	ENSG00000275426.1	CH17-262A2.1	7.51	1.3e-12	3.56e-09	0.82	0.45	Facial morphology (factor 6, height of vermillion lower lip);	chr4:204418	chr4:149738~150317:+
OV	cis	rs875971	0.522	rs4718285	ENSG00000222364.1	RNU6-96P	-7.51	1.3e-12	3.56e-09	-0.45	-0.45	Aortic root size;	chr7:65827018	chr7:66395191~66395286:+
OV	cis	rs875971	0.522	rs4718286	ENSG00000222364.1	RNU6-96P	-7.51	1.3e-12	3.56e-09	-0.45	-0.45	Aortic root size;	chr7:65827777	chr7:66395191~66395286:+
OV	cis	rs875971	0.522	rs4502988	ENSG00000222364.1	RNU6-96P	-7.51	1.3e-12	3.56e-09	-0.45	-0.45	Aortic root size;	chr7:65832759	chr7:66395191~66395286:+
OV	cis	rs17711722	0.585	rs6942660	ENSG00000222364.1	RNU6-96P	-7.51	1.3e-12	3.56e-09	-0.45	-0.45	Calcium levels;	chr7:65837419	chr7:66395191~66395286:+
OV	cis	rs17711722	0.64	rs13237956	ENSG00000222364.1	RNU6-96P	-7.51	1.3e-12	3.56e-09	-0.45	-0.45	Calcium levels;	chr7:65853042	chr7:66395191~66395286:+
OV	cis	rs6991838	0.584	rs4737748	ENSG00000272010.1	CTD-3025N20.3	7.51	1.32e-12	3.58e-09	0.56	0.45	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65591850~65592472:-
OV	cis	rs6991838	0.55	rs12335006	ENSG00000272010.1	CTD-3025N20.3	7.51	1.32e-12	3.58e-09	0.56	0.45	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs10957361	ENSG00000272010.1	CTD-3025N20.3	7.51	1.32e-12	3.58e-09	0.56	0.45	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65591850~65592472:-
OV	cis	rs6991838	0.612	rs12335276	ENSG00000272010.1	CTD-3025N20.3	7.51	1.32e-12	3.58e-09	0.56	0.45	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65591850~65592472:-
OV	cis	rs6991838	0.612	rs7832407	ENSG00000272010.1	CTD-3025N20.3	7.51	1.32e-12	3.58e-09	0.56	0.45	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65591850~65592472:-
OV	cis	rs6991838	0.551	rs7007505	ENSG00000272010.1	CTD-3025N20.3	7.51	1.32e-12	3.58e-09	0.56	0.45	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs7012856	ENSG00000272010.1	CTD-3025N20.3	7.51	1.32e-12	3.58e-09	0.56	0.45	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65591850~65592472:-
OV	cis	rs6991838	0.55	rs7817112	ENSG00000272010.1	CTD-3025N20.3	7.51	1.32e-12	3.58e-09	0.56	0.45	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs2048650	ENSG00000272010.1	CTD-3025N20.3	7.51	1.32e-12	3.58e-09	0.56	0.45	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs4737749	ENSG00000272010.1	CTD-3025N20.3	7.51	1.32e-12	3.58e-09	0.56	0.45	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs10092109	ENSG00000272010.1	CTD-3025N20.3	7.51	1.32e-12	3.58e-09	0.56	0.45	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs6997959	ENSG00000272010.1	CTD-3025N20.3	7.51	1.32e-12	3.58e-09	0.56	0.45	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs7814841	ENSG00000272010.1	CTD-3025N20.3	7.51	1.32e-12	3.58e-09	0.56	0.45	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs11985628	ENSG00000272010.1	CTD-3025N20.3	7.51	1.32e-12	3.58e-09	0.56	0.45	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65591850~65592472:-
OV	cis	rs6991838	0.557	rs13266834	ENSG00000272010.1	CTD-3025N20.3	7.51	1.32e-12	3.58e-09	0.56	0.45	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs13268343	ENSG00000272010.1	CTD-3025N20.3	7.51	1.32e-12	3.58e-09	0.56	0.45	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs7835313	ENSG00000272010.1	CTD-3025N20.3	7.51	1.32e-12	3.58e-09	0.56	0.45	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs3812412	ENSG00000272010.1	CTD-3025N20.3	7.51	1.32e-12	3.58e-09	0.56	0.45	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65591850~65592472:-
OV	cis	rs6991838	0.53	rs6472217	ENSG00000272010.1	CTD-3025N20.3	7.51	1.32e-12	3.58e-09	0.56	0.45	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs6472218	ENSG00000272010.1	CTD-3025N20.3	7.51	1.32e-12	3.58e-09	0.56	0.45	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs1533285	ENSG00000272010.1	CTD-3025N20.3	7.51	1.32e-12	3.58e-09	0.56	0.45	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs34226237	ENSG00000272010.1	CTD-3025N20.3	-7.51	1.32e-12	3.58e-09	-0.56	-0.45	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs6994213	ENSG00000272010.1	CTD-3025N20.3	-7.51	1.32e-12	3.58e-09	-0.56	-0.45	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs3765205	ENSG00000272010.1	CTD-3025N20.3	-7.51	1.32e-12	3.58e-09	-0.56	-0.45	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs7841652	ENSG00000272010.1	CTD-3025N20.3	-7.51	1.32e-12	3.58e-09	-0.56	-0.45	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65591850~65592472:-
OV	cis	rs6991838	0.53	rs35038843	ENSG00000272010.1	CTD-3025N20.3	-7.51	1.32e-12	3.58e-09	-0.56	-0.45	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65591850~65592472:-
OV	cis	rs801193	0.591	rs4506088	ENSG00000226824.5	RP4-756H11.3	7.51	1.33e-12	3.6e-09	0.47	0.45	Aortic root size;	chr7:66670470	chr7:66654538~66669855:+
OV	cis	rs1155848	0.892	rs9574424	ENSG00000227354.5	RBM26-AS1	-7.51	1.33e-12	3.61e-09	-0.71	-0.45	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79448541	chr13:79406309~79424328:+
OV	cis	rs2882667	0.505	rs6596465	ENSG00000253404.1	AC034243.1	-7.51	1.34e-12	3.62e-09	-0.5	-0.45	Age-related hearing impairment (SNP x SNP interaction);	chr5:139147337	chr5:138744434~138753309:-
OV	cis	rs7017914	0.934	rs17689585	ENSG00000223220.1	Y_RNA	7.51	1.34e-12	3.64e-09	0.46	0.45	Bone mineral density;	chr8:70906566	chr8:70780914~70781008:-
OV	cis	rs17507216	0.718	rs7165690	ENSG00000278603.1	RP13-608F4.5	7.51	1.35e-12	3.64e-09	0.62	0.45	Excessive daytime sleepiness;	chr15:82654804	chr15:82472203~82472426:+
OV	cis	rs875971	0.516	rs6945322	ENSG00000222364.1	RNU6-96P	-7.51	1.35e-12	3.64e-09	-0.45	-0.45	Aortic root size;	chr7:65871069	chr7:66395191~66395286:+
OV	cis	rs17711722	0.701	rs55773927	ENSG00000222364.1	RNU6-96P	-7.51	1.35e-12	3.64e-09	-0.45	-0.45	Calcium levels;	chr7:65872915	chr7:66395191~66395286:+
OV	cis	rs17711722	0.727	rs35850374	ENSG00000222364.1	RNU6-96P	-7.51	1.35e-12	3.64e-09	-0.45	-0.45	Calcium levels;	chr7:65892789	chr7:66395191~66395286:+
OV	cis	rs2564921	0.73	rs6781896	ENSG00000242142.1	SERBP1P3	-7.51	1.35e-12	3.66e-09	-0.51	-0.45	Height;	chr3:53047596	chr3:53064283~53065091:-
OV	cis	rs875971	0.522	rs1701760	ENSG00000236529.1	RP13-254B10.1	7.51	1.36e-12	3.66e-09	0.46	0.45	Aortic root size;	chr7:66008701	chr7:65840212~65840596:+
OV	cis	rs4423214	0.879	rs1792281	ENSG00000254682.1	RP11-660L16.2	-7.51	1.37e-12	3.69e-09	-0.54	-0.45	Vitamin D levels;	chr11:71424450	chr11:71448674~71452157:+
OV	cis	rs875971	0.895	rs12698520	ENSG00000226824.5	RP4-756H11.3	-7.5	1.39e-12	3.75e-09	-0.47	-0.45	Aortic root size;	chr7:66453720	chr7:66654538~66669855:+
OV	cis	rs17711722	0.522	rs4642526	ENSG00000236529.1	RP13-254B10.1	7.5	1.41e-12	3.81e-09	0.49	0.45	Calcium levels;	chr7:65751755	chr7:65840212~65840596:+
OV	cis	rs11690935	0.959	rs11897196	ENSG00000228389.1	AC068039.4	7.5	1.43e-12	3.85e-09	0.51	0.45	Schizophrenia;	chr2:171729085	chr2:171773482~171775844:+
OV	cis	rs11690935	0.959	rs10207085	ENSG00000228389.1	AC068039.4	7.5	1.43e-12	3.85e-09	0.51	0.45	Schizophrenia;	chr2:171729375	chr2:171773482~171775844:+
OV	cis	rs11690935	0.959	rs7604918	ENSG00000228389.1	AC068039.4	7.5	1.43e-12	3.85e-09	0.51	0.45	Schizophrenia;	chr2:171731584	chr2:171773482~171775844:+
OV	cis	rs1707322	0.65	rs4553239	ENSG00000281133.1	AL355480.3	-7.5	1.43e-12	3.86e-09	-0.58	-0.45	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr1:45580892~45580996:-
OV	cis	rs7246967	0.611	rs62118770	ENSG00000269509.1	BNIP3P34	7.5	1.43e-12	3.86e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22641227	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs62118771	ENSG00000269509.1	BNIP3P34	7.5	1.43e-12	3.86e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22641496	chr19:22773853~22774424:+
OV	cis	rs494459	0.838	rs555639	ENSG00000255239.1	AP002954.6	-7.5	1.44e-12	3.87e-09	-0.51	-0.45	Height;	chr11:118758322	chr11:118688039~118690600:-
OV	cis	rs11690935	0.959	rs11904009	ENSG00000228389.1	AC068039.4	7.5	1.45e-12	3.89e-09	0.51	0.45	Schizophrenia;	chr2:171770833	chr2:171773482~171775844:+
OV	cis	rs2732480	0.557	rs2732454	ENSG00000258273.1	RP11-370I10.4	-7.5	1.46e-12	3.91e-09	-0.53	-0.45	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48325894	chr12:48333755~48333901:-
OV	cis	rs7615952	0.932	rs13065725	ENSG00000171084.14	FAM86JP	7.5	1.46e-12	3.92e-09	0.75	0.45	Blood pressure (smoking interaction);	chr3:125913446	chr3:125916620~125930024:+
OV	cis	rs7615952	0.551	rs6438945	ENSG00000171084.14	FAM86JP	7.5	1.46e-12	3.92e-09	0.75	0.45	Blood pressure (smoking interaction);	chr3:125915630	chr3:125916620~125930024:+
OV	cis	rs875971	0.508	rs10242423	ENSG00000226824.5	RP4-756H11.3	7.5	1.46e-12	3.92e-09	0.47	0.45	Aortic root size;	chr7:66594188	chr7:66654538~66669855:+
OV	cis	rs875971	0.508	rs10253883	ENSG00000226824.5	RP4-756H11.3	7.5	1.46e-12	3.92e-09	0.47	0.45	Aortic root size;	chr7:66596151	chr7:66654538~66669855:+
OV	cis	rs875971	0.508	rs10950045	ENSG00000226824.5	RP4-756H11.3	7.5	1.47e-12	3.94e-09	0.47	0.45	Aortic root size;	chr7:66601386	chr7:66654538~66669855:+
OV	cis	rs801193	0.839	rs6968619	ENSG00000226824.5	RP4-756H11.3	7.5	1.47e-12	3.94e-09	0.47	0.45	Aortic root size;	chr7:66603880	chr7:66654538~66669855:+
OV	cis	rs801193	0.839	rs12534943	ENSG00000226824.5	RP4-756H11.3	7.5	1.47e-12	3.94e-09	0.47	0.45	Aortic root size;	chr7:66605533	chr7:66654538~66669855:+
OV	cis	rs801193	0.805	rs12532355	ENSG00000226824.5	RP4-756H11.3	7.5	1.47e-12	3.94e-09	0.47	0.45	Aortic root size;	chr7:66605597	chr7:66654538~66669855:+
OV	cis	rs73086581	0.947	rs73084531	ENSG00000229539.1	RP11-119B16.2	7.49	1.48e-12	3.96e-09	0.57	0.45	Response to antidepressants in depression;	chr20:3897782	chr20:3888239~3888868:-
OV	cis	rs7246967	0.673	rs117679583	ENSG00000269509.1	BNIP3P34	7.49	1.48e-12	3.96e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22862775	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs7258098	ENSG00000269509.1	BNIP3P34	7.49	1.48e-12	3.96e-09	0.72	0.45	Bronchopulmonary dysplasia;	chr19:22873927	chr19:22773853~22774424:+
OV	cis	rs4423214	0.879	rs736894	ENSG00000254682.1	RP11-660L16.2	7.49	1.5e-12	4.01e-09	0.55	0.45	Vitamin D levels;	chr11:71441212	chr11:71448674~71452157:+
OV	cis	rs875971	0.522	rs10807697	ENSG00000222364.1	RNU6-96P	-7.49	1.52e-12	4.07e-09	-0.45	-0.45	Aortic root size;	chr7:65951183	chr7:66395191~66395286:+
OV	cis	rs6921919	0.638	rs2108926	ENSG00000216901.1	AL022393.7	7.49	1.53e-12	4.1e-09	0.54	0.45	Autism spectrum disorder or schizophrenia;	chr6:28340970	chr6:28176188~28176674:+
OV	cis	rs2408955	0.504	rs11168441	ENSG00000258273.1	RP11-370I10.4	-7.49	1.54e-12	4.11e-09	-0.54	-0.45	Glycated hemoglobin levels;	chr12:48182271	chr12:48333755~48333901:-
OV	cis	rs17711722	0.727	rs1880555	ENSG00000226824.5	RP4-756H11.3	-7.49	1.54e-12	4.11e-09	-0.47	-0.45	Calcium levels;	chr7:65967580	chr7:66654538~66669855:+
OV	cis	rs875971	0.522	rs709604	ENSG00000236529.1	RP13-254B10.1	-7.49	1.56e-12	4.18e-09	-0.47	-0.44	Aortic root size;	chr7:66032447	chr7:65840212~65840596:+
OV	cis	rs1707322	0.686	rs2230658	ENSG00000281133.1	AL355480.3	7.48	1.57e-12	4.18e-09	0.58	0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr1:45580892~45580996:-
OV	cis	rs1707322	0.686	rs2230659	ENSG00000281133.1	AL355480.3	7.48	1.57e-12	4.18e-09	0.58	0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr1:45580892~45580996:-
OV	cis	rs875971	0.505	rs6955582	ENSG00000226824.5	RP4-756H11.3	-7.48	1.57e-12	4.18e-09	-0.47	-0.44	Aortic root size;	chr7:65966699	chr7:66654538~66669855:+
OV	cis	rs7246967	0.611	rs35355374	ENSG00000269509.1	BNIP3P34	7.48	1.57e-12	4.2e-09	0.72	0.44	Bronchopulmonary dysplasia;	chr19:22654899	chr19:22773853~22774424:+
OV	cis	rs11690935	0.959	rs10204501	ENSG00000228389.1	AC068039.4	7.48	1.58e-12	4.22e-09	0.51	0.44	Schizophrenia;	chr2:171732355	chr2:171773482~171775844:+
OV	cis	rs11690935	0.959	rs10204502	ENSG00000228389.1	AC068039.4	7.48	1.58e-12	4.22e-09	0.51	0.44	Schizophrenia;	chr2:171732356	chr2:171773482~171775844:+
OV	cis	rs11690935	0.959	rs10204622	ENSG00000228389.1	AC068039.4	7.48	1.58e-12	4.22e-09	0.51	0.44	Schizophrenia;	chr2:171732472	chr2:171773482~171775844:+
OV	cis	rs853679	0.517	rs1947862	ENSG00000220721.1	OR1F12	7.48	1.59e-12	4.24e-09	0.51	0.44	Depression;	chr6:28137418	chr6:28073316~28074233:+
OV	cis	rs11690935	0.959	rs4667694	ENSG00000228389.1	AC068039.4	7.48	1.59e-12	4.24e-09	0.52	0.44	Schizophrenia;	chr2:171748889	chr2:171773482~171775844:+
OV	cis	rs2658782	0.724	rs2248020	ENSG00000279684.1	RP11-755E23.2	-7.48	1.59e-12	4.25e-09	-0.59	-0.44	Pulmonary function decline;	chr11:93526799	chr11:93286629~93288903:-
OV	cis	rs875971	0.862	rs10274883	ENSG00000226824.5	RP4-756H11.3	7.48	1.59e-12	4.25e-09	0.47	0.44	Aortic root size;	chr7:66651104	chr7:66654538~66669855:+
OV	cis	rs801193	0.569	rs881285	ENSG00000226824.5	RP4-756H11.3	7.48	1.59e-12	4.25e-09	0.47	0.44	Aortic root size;	chr7:66654433	chr7:66654538~66669855:+
OV	cis	rs801193	0.569	rs3846973	ENSG00000226824.5	RP4-756H11.3	7.48	1.59e-12	4.25e-09	0.47	0.44	Aortic root size;	chr7:66655048	chr7:66654538~66669855:+
OV	cis	rs801193	0.569	rs2013908	ENSG00000226824.5	RP4-756H11.3	7.48	1.59e-12	4.25e-09	0.47	0.44	Aortic root size;	chr7:66656082	chr7:66654538~66669855:+
OV	cis	rs801193	0.548	rs2109297	ENSG00000226824.5	RP4-756H11.3	7.48	1.59e-12	4.25e-09	0.47	0.44	Aortic root size;	chr7:66657397	chr7:66654538~66669855:+
OV	cis	rs801193	0.569	rs6978178	ENSG00000226824.5	RP4-756H11.3	7.48	1.59e-12	4.25e-09	0.47	0.44	Aortic root size;	chr7:66658097	chr7:66654538~66669855:+
OV	cis	rs17711722	0.701	rs781143	ENSG00000226824.5	RP4-756H11.3	-7.48	1.6e-12	4.27e-09	-0.47	-0.44	Calcium levels;	chr7:65974892	chr7:66654538~66669855:+
OV	cis	rs17711722	0.701	rs781145	ENSG00000226824.5	RP4-756H11.3	-7.48	1.6e-12	4.27e-09	-0.47	-0.44	Calcium levels;	chr7:65975383	chr7:66654538~66669855:+
OV	cis	rs8062405	0.679	rs72793818	ENSG00000259982.1	CDC37P1	7.48	1.6e-12	4.27e-09	0.54	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28700294~28701540:-
OV	cis	rs1707322	0.686	rs3014251	ENSG00000281133.1	AL355480.3	7.48	1.62e-12	4.3e-09	0.58	0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45580892~45580996:-
OV	cis	rs2408955	0.522	rs3997	ENSG00000258273.1	RP11-370I10.4	7.48	1.62e-12	4.31e-09	0.54	0.44	Glycated hemoglobin levels;	chr12:48087804	chr12:48333755~48333901:-
OV	cis	rs7688540	0.511	rs10003260	ENSG00000275426.1	CH17-262A2.1	7.48	1.64e-12	4.36e-09	0.79	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:191053	chr4:149738~150317:+
OV	cis	rs11690935	0.959	rs12692973	ENSG00000228389.1	AC068039.4	-7.48	1.65e-12	4.38e-09	-0.51	-0.44	Schizophrenia;	chr2:171785547	chr2:171773482~171775844:+
OV	cis	rs7688540	0.511	rs75433628	ENSG00000275426.1	CH17-262A2.1	7.48	1.65e-12	4.39e-09	0.8	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:184563	chr4:149738~150317:+
OV	cis	rs875971	0.862	rs4718383	ENSG00000226824.5	RP4-756H11.3	7.47	1.67e-12	4.44e-09	0.46	0.44	Aortic root size;	chr7:66643422	chr7:66654538~66669855:+
OV	cis	rs507080	0.922	rs525485	ENSG00000255422.1	AP002954.4	-7.47	1.68e-12	4.45e-09	-0.53	-0.44	Serum metabolite levels;	chr11:118685045	chr11:118704607~118750263:+
OV	cis	rs2282300	0.956	rs1717773	ENSG00000254532.1	RP11-624D11.2	7.47	1.68e-12	4.46e-09	0.63	0.44	Morning vs. evening chronotype;	chr11:30361607	chr11:30044058~30084343:-
OV	cis	rs494459	0.838	rs488219	ENSG00000255239.1	AP002954.6	7.47	1.68e-12	4.47e-09	0.5	0.44	Height;	chr11:118749988	chr11:118688039~118690600:-
OV	cis	rs875971	0.54	rs1723268	ENSG00000236529.1	RP13-254B10.1	7.47	1.69e-12	4.48e-09	0.46	0.44	Aortic root size;	chr7:66008093	chr7:65840212~65840596:+
OV	cis	rs875971	0.825	rs28480509	ENSG00000226824.5	RP4-756H11.3	7.47	1.7e-12	4.52e-09	0.46	0.44	Aortic root size;	chr7:66634237	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs9791712	ENSG00000226824.5	RP4-756H11.3	7.47	1.7e-12	4.52e-09	0.46	0.44	Aortic root size;	chr7:66640176	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs9791713	ENSG00000226824.5	RP4-756H11.3	7.47	1.7e-12	4.52e-09	0.46	0.44	Aortic root size;	chr7:66640211	chr7:66654538~66669855:+
OV	cis	rs494459	0.657	rs614554	ENSG00000255239.1	AP002954.6	7.47	1.7e-12	4.52e-09	0.5	0.44	Height;	chr11:118764443	chr11:118688039~118690600:-
OV	cis	rs7115242	0.858	rs6589592	ENSG00000254851.1	RP11-109L13.1	-7.47	1.71e-12	4.54e-09	-0.92	-0.44	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:117087191	chr11:117135528~117138582:+
OV	cis	rs853679	0.517	rs9380052	ENSG00000220721.1	OR1F12	7.47	1.72e-12	4.55e-09	0.52	0.44	Depression;	chr6:28096845	chr6:28073316~28074233:+
OV	cis	rs6921919	0.638	rs1416920	ENSG00000216901.1	AL022393.7	7.47	1.72e-12	4.55e-09	0.54	0.44	Autism spectrum disorder or schizophrenia;	chr6:28335007	chr6:28176188~28176674:+
OV	cis	rs6921919	0.525	rs1361386	ENSG00000216901.1	AL022393.7	7.47	1.72e-12	4.55e-09	0.54	0.44	Autism spectrum disorder or schizophrenia;	chr6:28337827	chr6:28176188~28176674:+
OV	cis	rs6921919	0.638	rs6456815	ENSG00000216901.1	AL022393.7	7.47	1.72e-12	4.55e-09	0.54	0.44	Autism spectrum disorder or schizophrenia;	chr6:28338360	chr6:28176188~28176674:+
OV	cis	rs875971	0.862	rs10256544	ENSG00000226824.5	RP4-756H11.3	-7.47	1.72e-12	4.57e-09	-0.47	-0.44	Aortic root size;	chr7:66210141	chr7:66654538~66669855:+
OV	cis	rs4423214	0.592	rs10898223	ENSG00000254682.1	RP11-660L16.2	-7.47	1.77e-12	4.67e-09	-0.64	-0.44	Vitamin D levels;	chr11:71508218	chr11:71448674~71452157:+
OV	cis	rs7115242	0.844	rs645258	ENSG00000254851.1	RP11-109L13.1	-7.47	1.77e-12	4.68e-09	-0.88	-0.44	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116930485	chr11:117135528~117138582:+
OV	cis	rs4713118	0.629	rs203889	ENSG00000220721.1	OR1F12	7.47	1.77e-12	4.68e-09	0.51	0.44	Parkinson's disease;	chr6:28053997	chr6:28073316~28074233:+
OV	cis	rs8105895	0.935	rs7260331	ENSG00000269742.1	BNIP3P29	7.46	1.77e-12	4.69e-09	0.69	0.44	Body mass index (change over time);	chr19:22108969	chr19:22065828~22066398:-
OV	cis	rs7688540	0.511	rs6841415	ENSG00000275426.1	CH17-262A2.1	7.46	1.78e-12	4.7e-09	0.8	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:203594	chr4:149738~150317:+
OV	cis	rs10256972	1	rs10256972	ENSG00000229043.2	AC091729.9	7.46	1.78e-12	4.71e-09	0.49	0.44	Endometriosis;Longevity;	chr7:999367	chr7:1160374~1165267:+
OV	cis	rs494459	0.838	rs632124	ENSG00000255239.1	AP002954.6	7.46	1.79e-12	4.73e-09	0.51	0.44	Height;	chr11:118742526	chr11:118688039~118690600:-
OV	cis	rs875971	0.522	rs2949690	ENSG00000226824.5	RP4-756H11.3	7.46	1.8e-12	4.77e-09	0.46	0.44	Aortic root size;	chr7:66018255	chr7:66654538~66669855:+
OV	cis	rs73086581	0.947	rs56123574	ENSG00000229539.1	RP11-119B16.2	7.46	1.83e-12	4.83e-09	0.57	0.44	Response to antidepressants in depression;	chr20:3897434	chr20:3888239~3888868:-
OV	cis	rs875971	0.522	rs2949690	ENSG00000222364.1	RNU6-96P	7.46	1.84e-12	4.86e-09	0.45	0.44	Aortic root size;	chr7:66018255	chr7:66395191~66395286:+
OV	cis	rs9326248	0.59	rs2542063	ENSG00000254851.1	RP11-109L13.1	-7.46	1.85e-12	4.88e-09	-0.54	-0.44	Blood protein levels;	chr11:116814051	chr11:117135528~117138582:+
OV	cis	rs7246967	0.551	rs35740274	ENSG00000269509.1	BNIP3P34	7.46	1.85e-12	4.88e-09	0.71	0.44	Bronchopulmonary dysplasia;	chr19:22648611	chr19:22773853~22774424:+
OV	cis	rs1707322	0.686	rs2050376	ENSG00000281133.1	AL355480.3	-7.46	1.87e-12	4.93e-09	-0.56	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45580892~45580996:-
OV	cis	rs7246967	0.673	rs407989	ENSG00000269509.1	BNIP3P34	-7.46	1.88e-12	4.94e-09	-0.69	-0.44	Bronchopulmonary dysplasia;	chr19:22808784	chr19:22773853~22774424:+
OV	cis	rs1707322	0.721	rs4559551	ENSG00000281133.1	AL355480.3	-7.45	1.89e-12	4.97e-09	-0.58	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr1:45580892~45580996:-
OV	cis	rs1707322	0.691	rs61784803	ENSG00000281133.1	AL355480.3	7.45	1.91e-12	5.01e-09	0.57	0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45580892~45580996:-
OV	cis	rs1707322	0.663	rs3935296	ENSG00000281133.1	AL355480.3	7.45	1.91e-12	5.01e-09	0.57	0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs28817701	ENSG00000281133.1	AL355480.3	-7.45	1.91e-12	5.01e-09	-0.57	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45580892~45580996:-
OV	cis	rs1707322	0.691	rs28495425	ENSG00000281133.1	AL355480.3	-7.45	1.91e-12	5.01e-09	-0.57	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45580892~45580996:-
OV	cis	rs1707322	0.685	rs28617418	ENSG00000281133.1	AL355480.3	-7.45	1.91e-12	5.01e-09	-0.57	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45580892~45580996:-
OV	cis	rs1707322	0.682	rs28490344	ENSG00000281133.1	AL355480.3	-7.45	1.91e-12	5.01e-09	-0.57	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs28501477	ENSG00000281133.1	AL355480.3	-7.45	1.91e-12	5.01e-09	-0.57	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs28641748	ENSG00000281133.1	AL355480.3	-7.45	1.91e-12	5.01e-09	-0.57	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs6697821	ENSG00000281133.1	AL355480.3	-7.45	1.91e-12	5.01e-09	-0.57	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs4330955	ENSG00000281133.1	AL355480.3	-7.45	1.91e-12	5.01e-09	-0.57	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45580892~45580996:-
OV	cis	rs1707322	0.691	rs11211174	ENSG00000281133.1	AL355480.3	-7.45	1.91e-12	5.01e-09	-0.57	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45580892~45580996:-
OV	cis	rs1707322	0.691	rs12031182	ENSG00000281133.1	AL355480.3	-7.45	1.91e-12	5.01e-09	-0.57	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs10430123	ENSG00000281133.1	AL355480.3	-7.45	1.91e-12	5.01e-09	-0.57	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45580892~45580996:-
OV	cis	rs7569084	0.663	rs10190233	ENSG00000234255.7	AC012370.3	-7.45	1.91e-12	5.02e-09	-0.48	-0.44	Sum eosinophil basophil counts;	chr2:65413095	chr2:65439888~65456571:-
OV	cis	rs801193	0.569	rs13242290	ENSG00000226824.5	RP4-756H11.3	7.45	1.92e-12	5.03e-09	0.47	0.44	Aortic root size;	chr7:66656898	chr7:66654538~66669855:+
OV	cis	rs17711722	0.701	rs4467826	ENSG00000222364.1	RNU6-96P	-7.45	1.93e-12	5.07e-09	-0.44	-0.44	Calcium levels;	chr7:65903721	chr7:66395191~66395286:+
OV	cis	rs875971	0.522	rs1617484	ENSG00000236529.1	RP13-254B10.1	7.45	1.95e-12	5.12e-09	0.46	0.44	Aortic root size;	chr7:65998108	chr7:65840212~65840596:+
OV	cis	rs17711722	0.727	rs2658585	ENSG00000222364.1	RNU6-96P	-7.45	1.95e-12	5.12e-09	-0.45	-0.44	Calcium levels;	chr7:65996954	chr7:66395191~66395286:+
OV	cis	rs2564921	0.73	rs73082047	ENSG00000242142.1	SERBP1P3	-7.45	1.96e-12	5.13e-09	-0.51	-0.44	Height;	chr3:53070344	chr3:53064283~53065091:-
OV	cis	rs7017914	0.967	rs2933853	ENSG00000223220.1	Y_RNA	7.45	1.97e-12	5.16e-09	0.46	0.44	Bone mineral density;	chr8:70996987	chr8:70780914~70781008:-
OV	cis	rs4423214	0.879	rs10898144	ENSG00000254682.1	RP11-660L16.2	-7.45	1.98e-12	5.17e-09	-0.55	-0.44	Vitamin D levels;	chr11:71440494	chr11:71448674~71452157:+
OV	cis	rs997154	0.655	rs4981454	ENSG00000279656.1	RP11-298I3.6	7.45	1.99e-12	5.21e-09	0.57	0.44	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22952977	chr14:23023083~23024217:-
OV	cis	rs4713118	0.516	rs7739216	ENSG00000220721.1	OR1F12	7.45	1.99e-12	5.21e-09	0.51	0.44	Parkinson's disease;	chr6:28112168	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs35512245	ENSG00000220721.1	OR1F12	7.45	1.99e-12	5.21e-09	0.51	0.44	Depression;	chr6:28112175	chr6:28073316~28074233:+
OV	cis	rs1075265	0.568	rs959286	ENSG00000233266.1	HMGB1P31	7.44	2e-12	5.23e-09	0.54	0.44	Chronotype;Morning vs. evening chronotype;	chr2:54078941	chr2:54051334~54051760:+
OV	cis	rs1075265	0.547	rs11125520	ENSG00000233266.1	HMGB1P31	7.44	2.02e-12	5.28e-09	0.54	0.44	Chronotype;Morning vs. evening chronotype;	chr2:54076696	chr2:54051334~54051760:+
OV	cis	rs1707322	0.686	rs2991987	ENSG00000281133.1	AL355480.3	7.44	2.04e-12	5.31e-09	0.58	0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr1:45580892~45580996:-
OV	cis	rs17711722	1	rs17711722	ENSG00000236529.1	RP13-254B10.1	-7.44	2.05e-12	5.35e-09	-0.46	-0.44	Calcium levels;	chr7:65806210	chr7:65840212~65840596:+
OV	cis	rs7246967	0.673	rs12979264	ENSG00000269509.1	BNIP3P34	7.44	2.08e-12	5.43e-09	0.71	0.44	Bronchopulmonary dysplasia;	chr19:22682332	chr19:22773853~22774424:+
OV	cis	rs2658782	0.654	rs2248531	ENSG00000279684.1	RP11-755E23.2	-7.44	2.09e-12	5.46e-09	-0.59	-0.44	Pulmonary function decline;	chr11:93522197	chr11:93286629~93288903:-
OV	cis	rs853679	0.542	rs6934769	ENSG00000220721.1	OR1F12	7.44	2.11e-12	5.48e-09	0.51	0.44	Depression;	chr6:28123153	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs17711801	ENSG00000220721.1	OR1F12	7.44	2.11e-12	5.48e-09	0.51	0.44	Depression;	chr6:28124529	chr6:28073316~28074233:+
OV	cis	rs4713118	0.527	rs9461433	ENSG00000220721.1	OR1F12	7.44	2.11e-12	5.48e-09	0.51	0.44	Parkinson's disease;	chr6:28127394	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9468292	ENSG00000220721.1	OR1F12	7.44	2.11e-12	5.48e-09	0.51	0.44	Depression;	chr6:28127577	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs1947863	ENSG00000220721.1	OR1F12	7.44	2.11e-12	5.48e-09	0.51	0.44	Depression;	chr6:28131566	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs4713141	ENSG00000220721.1	OR1F12	7.44	2.11e-12	5.48e-09	0.51	0.44	Depression;	chr6:28133900	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9380056	ENSG00000220721.1	OR1F12	7.44	2.11e-12	5.48e-09	0.51	0.44	Depression;	chr6:28136698	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9380057	ENSG00000220721.1	OR1F12	7.44	2.11e-12	5.48e-09	0.51	0.44	Depression;	chr6:28136856	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs6941992	ENSG00000220721.1	OR1F12	7.44	2.11e-12	5.48e-09	0.51	0.44	Depression;	chr6:28138363	chr6:28073316~28074233:+
OV	cis	rs4713118	0.516	rs4713142	ENSG00000220721.1	OR1F12	7.44	2.11e-12	5.48e-09	0.51	0.44	Parkinson's disease;	chr6:28138569	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs4713143	ENSG00000220721.1	OR1F12	7.44	2.11e-12	5.48e-09	0.51	0.44	Depression;	chr6:28138981	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs4713144	ENSG00000220721.1	OR1F12	7.44	2.11e-12	5.48e-09	0.51	0.44	Depression;	chr6:28139012	chr6:28073316~28074233:+
OV	cis	rs7246967	0.611	rs73030508	ENSG00000269509.1	BNIP3P34	7.44	2.11e-12	5.48e-09	0.69	0.44	Bronchopulmonary dysplasia;	chr19:22643230	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs73030511	ENSG00000269509.1	BNIP3P34	7.44	2.11e-12	5.48e-09	0.69	0.44	Bronchopulmonary dysplasia;	chr19:22643232	chr19:22773853~22774424:+
OV	cis	rs507080	0.769	rs11603616	ENSG00000255422.1	AP002954.4	-7.44	2.12e-12	5.5e-09	-0.52	-0.44	Serum metabolite levels;	chr11:118625350	chr11:118704607~118750263:+
OV	cis	rs507080	0.769	rs571001	ENSG00000255422.1	AP002954.4	-7.44	2.12e-12	5.5e-09	-0.52	-0.44	Serum metabolite levels;	chr11:118629457	chr11:118704607~118750263:+
OV	cis	rs507080	0.769	rs570952	ENSG00000255422.1	AP002954.4	-7.44	2.12e-12	5.5e-09	-0.52	-0.44	Serum metabolite levels;	chr11:118629477	chr11:118704607~118750263:+
OV	cis	rs507080	0.769	rs645637	ENSG00000255422.1	AP002954.4	-7.44	2.12e-12	5.5e-09	-0.52	-0.44	Serum metabolite levels;	chr11:118634373	chr11:118704607~118750263:+
OV	cis	rs507080	0.769	rs483283	ENSG00000255422.1	AP002954.4	-7.44	2.12e-12	5.5e-09	-0.52	-0.44	Serum metabolite levels;	chr11:118635684	chr11:118704607~118750263:+
OV	cis	rs507080	0.769	rs570836	ENSG00000255422.1	AP002954.4	-7.44	2.12e-12	5.5e-09	-0.52	-0.44	Serum metabolite levels;	chr11:118641444	chr11:118704607~118750263:+
OV	cis	rs853679	0.542	rs9393892	ENSG00000220721.1	OR1F12	7.43	2.13e-12	5.52e-09	0.51	0.44	Depression;	chr6:28113616	chr6:28073316~28074233:+
OV	cis	rs1387259	0.723	rs2732488	ENSG00000258273.1	RP11-370I10.4	-7.43	2.14e-12	5.56e-09	-0.53	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48377661	chr12:48333755~48333901:-
OV	cis	rs1387259	0.758	rs2634670	ENSG00000258273.1	RP11-370I10.4	-7.43	2.14e-12	5.56e-09	-0.53	-0.44	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48378094	chr12:48333755~48333901:-
OV	cis	rs11159086	1	rs8006909	ENSG00000259005.1	RP3-449M8.6	7.43	2.15e-12	5.57e-09	0.72	0.44	Advanced glycation end-product levels;	chr14:74478085	chr14:74474007~74474864:-
OV	cis	rs875971	0.862	rs1860469	ENSG00000226824.5	RP4-756H11.3	7.43	2.15e-12	5.58e-09	0.46	0.44	Aortic root size;	chr7:66641888	chr7:66654538~66669855:+
OV	cis	rs6921919	0.638	rs9468344	ENSG00000216901.1	AL022393.7	7.43	2.17e-12	5.62e-09	0.53	0.44	Autism spectrum disorder or schizophrenia;	chr6:28341792	chr6:28176188~28176674:+
OV	cis	rs17711722	0.675	rs6947132	ENSG00000236529.1	RP13-254B10.1	-7.43	2.18e-12	5.65e-09	-0.46	-0.44	Calcium levels;	chr7:65808508	chr7:65840212~65840596:+
OV	cis	rs4713118	0.621	rs9368548	ENSG00000220721.1	OR1F12	7.43	2.19e-12	5.67e-09	0.52	0.44	Parkinson's disease;	chr6:28066959	chr6:28073316~28074233:+
OV	cis	rs6921919	0.583	rs6908137	ENSG00000216901.1	AL022393.7	7.43	2.19e-12	5.68e-09	0.52	0.44	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28176188~28176674:+
OV	cis	rs7246967	0.541	rs16999009	ENSG00000269509.1	BNIP3P34	-7.43	2.21e-12	5.72e-09	-0.7	-0.44	Bronchopulmonary dysplasia;	chr19:22726856	chr19:22773853~22774424:+
OV	cis	rs7246967	0.544	rs400275	ENSG00000269509.1	BNIP3P34	7.43	2.22e-12	5.74e-09	0.7	0.44	Bronchopulmonary dysplasia;	chr19:22833054	chr19:22773853~22774424:+
OV	cis	rs2658782	0.654	rs2248524	ENSG00000279684.1	RP11-755E23.2	-7.43	2.23e-12	5.77e-09	-0.59	-0.44	Pulmonary function decline;	chr11:93522549	chr11:93286629~93288903:-
OV	cis	rs875971	0.54	rs4717275	ENSG00000236529.1	RP13-254B10.1	-7.43	2.25e-12	5.82e-09	-0.46	-0.44	Aortic root size;	chr7:65800193	chr7:65840212~65840596:+
OV	cis	rs2836950	0.772	rs62222988	ENSG00000232608.1	TIMM9P2	7.42	2.26e-12	5.83e-09	0.55	0.44	Menarche (age at onset);	chr21:39197582	chr21:39216624~39217506:+
OV	cis	rs2282300	0.91	rs528292	ENSG00000254532.1	RP11-624D11.2	-7.42	2.27e-12	5.85e-09	-0.61	-0.44	Morning vs. evening chronotype;	chr11:30368163	chr11:30044058~30084343:-
OV	cis	rs875971	0.522	rs2008188	ENSG00000226824.5	RP4-756H11.3	-7.42	2.29e-12	5.91e-09	-0.46	-0.44	Aortic root size;	chr7:65964026	chr7:66654538~66669855:+
OV	cis	rs2581828	1	rs2581828	ENSG00000242142.1	SERBP1P3	7.42	2.3e-12	5.92e-09	0.5	0.44	Crohn's disease;	chr3:53099133	chr3:53064283~53065091:-
OV	cis	rs7396835	1	rs7396835	ENSG00000254851.1	RP11-109L13.1	-7.42	2.3e-12	5.92e-09	-0.7	-0.44	Quantitative traits;	chr11:116813312	chr11:117135528~117138582:+
OV	cis	rs7688540	0.511	rs11731927	ENSG00000275426.1	CH17-262A2.1	7.42	2.31e-12	5.95e-09	0.82	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:180316	chr4:149738~150317:+
OV	cis	rs875971	0.505	rs1723275	ENSG00000236529.1	RP13-254B10.1	-7.42	2.31e-12	5.96e-09	-0.47	-0.44	Aortic root size;	chr7:66039646	chr7:65840212~65840596:+
OV	cis	rs2712431	0.554	rs2010054	ENSG00000277250.1	Metazoa_SRP	-7.42	2.32e-12	5.97e-09	-0.5	-0.44	Monocyte chemoattractant protein-1 levels;	chr3:128586459	chr3:128673681~128674021:-
OV	cis	rs7246967	0.673	rs4933026	ENSG00000269509.1	BNIP3P34	7.42	2.32e-12	5.98e-09	0.67	0.44	Bronchopulmonary dysplasia;	chr19:22691690	chr19:22773853~22774424:+
OV	cis	rs11690935	0.885	rs6752812	ENSG00000228389.1	AC068039.4	7.42	2.36e-12	6.07e-09	0.5	0.44	Schizophrenia;	chr2:171986588	chr2:171773482~171775844:+
OV	cis	rs2282300	0.956	rs2685286	ENSG00000254532.1	RP11-624D11.2	7.42	2.36e-12	6.08e-09	0.61	0.44	Morning vs. evening chronotype;	chr11:30360041	chr11:30044058~30084343:-
OV	cis	rs1707322	0.721	rs10890336	ENSG00000281133.1	AL355480.3	-7.42	2.38e-12	6.1e-09	-0.56	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs11211151	ENSG00000281133.1	AL355480.3	-7.42	2.38e-12	6.1e-09	-0.56	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs12045096	ENSG00000281133.1	AL355480.3	-7.42	2.38e-12	6.1e-09	-0.56	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs4609469	ENSG00000281133.1	AL355480.3	-7.42	2.38e-12	6.1e-09	-0.56	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs12049027	ENSG00000281133.1	AL355480.3	-7.42	2.38e-12	6.1e-09	-0.56	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr1:45580892~45580996:-
OV	cis	rs1707322	0.752	rs10789467	ENSG00000281133.1	AL355480.3	-7.42	2.38e-12	6.1e-09	-0.56	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs10890337	ENSG00000281133.1	AL355480.3	-7.42	2.38e-12	6.1e-09	-0.56	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr1:45580892~45580996:-
OV	cis	rs1707322	0.752	rs3811435	ENSG00000281133.1	AL355480.3	-7.42	2.38e-12	6.1e-09	-0.56	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs9793568	ENSG00000281133.1	AL355480.3	-7.42	2.38e-12	6.1e-09	-0.56	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs11211157	ENSG00000281133.1	AL355480.3	-7.42	2.38e-12	6.1e-09	-0.56	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs11211158	ENSG00000281133.1	AL355480.3	-7.42	2.38e-12	6.1e-09	-0.56	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs6429575	ENSG00000281133.1	AL355480.3	-7.42	2.38e-12	6.1e-09	-0.56	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr1:45580892~45580996:-
OV	cis	rs1707322	0.685	rs6690926	ENSG00000281133.1	AL355480.3	-7.42	2.38e-12	6.1e-09	-0.56	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr1:45580892~45580996:-
OV	cis	rs1707322	0.752	rs8179402	ENSG00000281133.1	AL355480.3	-7.42	2.38e-12	6.1e-09	-0.56	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr1:45580892~45580996:-
OV	cis	rs1707322	0.752	rs8179296	ENSG00000281133.1	AL355480.3	-7.42	2.38e-12	6.1e-09	-0.56	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr1:45580892~45580996:-
OV	cis	rs875971	0.522	rs7784623	ENSG00000226824.5	RP4-756H11.3	-7.41	2.4e-12	6.16e-09	-0.45	-0.44	Aortic root size;	chr7:65930047	chr7:66654538~66669855:+
OV	cis	rs875971	0.522	rs34973832	ENSG00000226824.5	RP4-756H11.3	-7.41	2.4e-12	6.16e-09	-0.45	-0.44	Aortic root size;	chr7:65931217	chr7:66654538~66669855:+
OV	cis	rs9326248	0.581	rs10892072	ENSG00000254851.1	RP11-109L13.1	-7.41	2.41e-12	6.19e-09	-0.52	-0.44	Blood protein levels;	chr11:117089597	chr11:117135528~117138582:+
OV	cis	rs11690935	0.959	rs76324055	ENSG00000228389.1	AC068039.4	7.41	2.42e-12	6.2e-09	0.51	0.44	Schizophrenia;	chr2:171763640	chr2:171773482~171775844:+
OV	cis	rs11690935	0.959	rs77280952	ENSG00000228389.1	AC068039.4	7.41	2.42e-12	6.2e-09	0.51	0.44	Schizophrenia;	chr2:171763641	chr2:171773482~171775844:+
OV	cis	rs11690935	0.959	rs75922913	ENSG00000228389.1	AC068039.4	7.41	2.42e-12	6.2e-09	0.51	0.44	Schizophrenia;	chr2:171763642	chr2:171773482~171775844:+
OV	cis	rs507080	0.769	rs2077173	ENSG00000255422.1	AP002954.4	-7.41	2.44e-12	6.25e-09	-0.52	-0.44	Serum metabolite levels;	chr11:118621876	chr11:118704607~118750263:+
OV	cis	rs2581828	0.965	rs2581830	ENSG00000242142.1	SERBP1P3	7.41	2.46e-12	6.3e-09	0.5	0.44	Crohn's disease;	chr3:53100082	chr3:53064283~53065091:-
OV	cis	rs507080	0.769	rs527290	ENSG00000255422.1	AP002954.4	-7.41	2.49e-12	6.38e-09	-0.52	-0.44	Serum metabolite levels;	chr11:118644898	chr11:118704607~118750263:+
OV	cis	rs10256972	0.684	rs4724039	ENSG00000229043.2	AC091729.9	-7.41	2.5e-12	6.41e-09	-0.49	-0.44	Endometriosis;Longevity;	chr7:1071997	chr7:1160374~1165267:+
OV	cis	rs1707322	0.752	rs11211145	ENSG00000281133.1	AL355480.3	-7.41	2.51e-12	6.42e-09	-0.56	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr1:45580892~45580996:-
OV	cis	rs875971	0.508	rs10258739	ENSG00000222364.1	RNU6-96P	7.41	2.53e-12	6.46e-09	0.45	0.44	Aortic root size;	chr7:66597948	chr7:66395191~66395286:+
OV	cis	rs7246967	0.544	rs403717	ENSG00000269509.1	BNIP3P34	7.41	2.54e-12	6.5e-09	0.7	0.44	Bronchopulmonary dysplasia;	chr19:22826001	chr19:22773853~22774424:+
OV	cis	rs7246967	0.544	rs391308	ENSG00000269509.1	BNIP3P34	7.41	2.54e-12	6.5e-09	0.7	0.44	Bronchopulmonary dysplasia;	chr19:22826758	chr19:22773853~22774424:+
OV	cis	rs7246967	0.608	rs370734	ENSG00000269509.1	BNIP3P34	7.41	2.54e-12	6.5e-09	0.7	0.44	Bronchopulmonary dysplasia;	chr19:22829784	chr19:22773853~22774424:+
OV	cis	rs11690935	0.843	rs9784123	ENSG00000228389.1	AC068039.4	7.4	2.57e-12	6.57e-09	0.5	0.44	Schizophrenia;	chr2:171928495	chr2:171773482~171775844:+
OV	cis	rs2564921	0.693	rs2581798	ENSG00000242142.1	SERBP1P3	7.4	2.57e-12	6.57e-09	0.5	0.44	Height;	chr3:53073584	chr3:53064283~53065091:-
OV	cis	rs11690935	0.798	rs13018768	ENSG00000228389.1	AC068039.4	7.4	2.6e-12	6.64e-09	0.51	0.44	Schizophrenia;	chr2:171742082	chr2:171773482~171775844:+
OV	cis	rs875971	0.522	rs2949690	ENSG00000236529.1	RP13-254B10.1	-7.4	2.61e-12	6.66e-09	-0.46	-0.44	Aortic root size;	chr7:66018255	chr7:65840212~65840596:+
OV	cis	rs6921919	0.583	rs11755942	ENSG00000216901.1	AL022393.7	7.4	2.61e-12	6.67e-09	0.52	0.44	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28176188~28176674:+
OV	cis	rs11673344	0.734	rs1234250	ENSG00000226686.6	LINC01535	-7.4	2.62e-12	6.7e-09	-0.59	-0.44	Obesity-related traits;	chr19:37199518	chr19:37251912~37265535:+
OV	cis	rs7246967	0.673	rs7245540	ENSG00000269509.1	BNIP3P34	7.4	2.64e-12	6.73e-09	0.67	0.44	Bronchopulmonary dysplasia;	chr19:22698702	chr19:22773853~22774424:+
OV	cis	rs17711722	0.653	rs2460421	ENSG00000222364.1	RNU6-96P	7.4	2.64e-12	6.74e-09	0.46	0.44	Calcium levels;	chr7:66026136	chr7:66395191~66395286:+
OV	cis	rs7246967	0.866	rs111292710	ENSG00000269509.1	BNIP3P34	7.4	2.67e-12	6.81e-09	0.72	0.44	Bronchopulmonary dysplasia;	chr19:22884678	chr19:22773853~22774424:+
OV	cis	rs16828019	0.852	rs34386859	ENSG00000235358.1	RP11-399E6.1	7.4	2.68e-12	6.83e-09	0.86	0.44	Intelligence (multi-trait analysis);	chr1:41098352	chr1:41242373~41284861:+
OV	cis	rs7246967	0.604	rs8111899	ENSG00000269509.1	BNIP3P34	7.4	2.7e-12	6.89e-09	0.72	0.44	Bronchopulmonary dysplasia;	chr19:22716069	chr19:22773853~22774424:+
OV	cis	rs11763147	1	rs11763147	ENSG00000222364.1	RNU6-96P	7.39	2.71e-12	6.91e-09	0.44	0.44	Corneal structure;	chr7:65861834	chr7:66395191~66395286:+
OV	cis	rs7246967	0.611	rs73022711	ENSG00000269509.1	BNIP3P34	7.39	2.72e-12	6.91e-09	0.67	0.44	Bronchopulmonary dysplasia;	chr19:22692602	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs73022713	ENSG00000269509.1	BNIP3P34	7.39	2.72e-12	6.91e-09	0.67	0.44	Bronchopulmonary dysplasia;	chr19:22693420	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs57027767	ENSG00000269509.1	BNIP3P34	7.39	2.72e-12	6.91e-09	0.67	0.44	Bronchopulmonary dysplasia;	chr19:22693733	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs62120313	ENSG00000269509.1	BNIP3P34	7.39	2.72e-12	6.91e-09	0.67	0.44	Bronchopulmonary dysplasia;	chr19:22694381	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs7248107	ENSG00000269509.1	BNIP3P34	7.39	2.72e-12	6.91e-09	0.67	0.44	Bronchopulmonary dysplasia;	chr19:22695727	chr19:22773853~22774424:+
OV	cis	rs7246967	0.551	rs8102812	ENSG00000269509.1	BNIP3P34	7.39	2.72e-12	6.91e-09	0.67	0.44	Bronchopulmonary dysplasia;	chr19:22696441	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs8106215	ENSG00000269509.1	BNIP3P34	7.39	2.72e-12	6.91e-09	0.67	0.44	Bronchopulmonary dysplasia;	chr19:22696644	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs16994997	ENSG00000269509.1	BNIP3P34	7.39	2.72e-12	6.91e-09	0.67	0.44	Bronchopulmonary dysplasia;	chr19:22696808	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs34806882	ENSG00000269509.1	BNIP3P34	7.39	2.72e-12	6.91e-09	0.67	0.44	Bronchopulmonary dysplasia;	chr19:22697302	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs57736314	ENSG00000269509.1	BNIP3P34	7.39	2.72e-12	6.91e-09	0.67	0.44	Bronchopulmonary dysplasia;	chr19:22697470	chr19:22773853~22774424:+
OV	cis	rs7246967	0.604	rs58536761	ENSG00000269509.1	BNIP3P34	7.39	2.72e-12	6.91e-09	0.67	0.44	Bronchopulmonary dysplasia;	chr19:22697529	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs3853649	ENSG00000269509.1	BNIP3P34	7.39	2.72e-12	6.91e-09	0.67	0.44	Bronchopulmonary dysplasia;	chr19:22697658	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs3853650	ENSG00000269509.1	BNIP3P34	7.39	2.72e-12	6.91e-09	0.67	0.44	Bronchopulmonary dysplasia;	chr19:22697688	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs3844578	ENSG00000269509.1	BNIP3P34	7.39	2.72e-12	6.91e-09	0.67	0.44	Bronchopulmonary dysplasia;	chr19:22697808	chr19:22773853~22774424:+
OV	cis	rs7246967	0.551	rs3925175	ENSG00000269509.1	BNIP3P34	7.39	2.72e-12	6.91e-09	0.67	0.44	Bronchopulmonary dysplasia;	chr19:22698156	chr19:22773853~22774424:+
OV	cis	rs7246967	0.551	rs7257333	ENSG00000269509.1	BNIP3P34	7.39	2.72e-12	6.91e-09	0.67	0.44	Bronchopulmonary dysplasia;	chr19:22698347	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs34342502	ENSG00000269509.1	BNIP3P34	7.39	2.72e-12	6.91e-09	0.67	0.44	Bronchopulmonary dysplasia;	chr19:22698626	chr19:22773853~22774424:+
OV	cis	rs492146	0.819	rs677636	ENSG00000243236.5	GSTA9P	-7.39	2.73e-12	6.93e-09	-0.52	-0.44	Epilepsy (remission after treatment);	chr6:52972509	chr6:52939726~52957521:-
OV	cis	rs492146	0.819	rs584124	ENSG00000243236.5	GSTA9P	-7.39	2.73e-12	6.93e-09	-0.52	-0.44	Epilepsy (remission after treatment);	chr6:52973398	chr6:52939726~52957521:-
OV	cis	rs17711722	0.701	rs4467826	ENSG00000226824.5	RP4-756H11.3	-7.39	2.74e-12	6.95e-09	-0.45	-0.44	Calcium levels;	chr7:65903721	chr7:66654538~66669855:+
OV	cis	rs9918079	0.56	rs7438356	ENSG00000273133.1	RP11-799M12.2	-7.39	2.74e-12	6.95e-09	-0.5	-0.44	Obesity-related traits;	chr4:15623147	chr4:15563698~15564253:-
OV	cis	rs2712431	0.554	rs9864772	ENSG00000277250.1	Metazoa_SRP	-7.39	2.74e-12	6.96e-09	-0.5	-0.44	Monocyte chemoattractant protein-1 levels;	chr3:128598096	chr3:128673681~128674021:-
OV	cis	rs853679	0.517	rs3823180	ENSG00000220721.1	OR1F12	7.39	2.74e-12	6.97e-09	0.5	0.44	Depression;	chr6:28093966	chr6:28073316~28074233:+
OV	cis	rs875971	0.522	rs2008188	ENSG00000222364.1	RNU6-96P	-7.39	2.83e-12	7.17e-09	-0.45	-0.44	Aortic root size;	chr7:65964026	chr7:66395191~66395286:+
OV	cis	rs7397814	0.558	rs4764447	ENSG00000256673.1	RP11-599J14.2	7.39	2.83e-12	7.17e-09	0.44	0.44	IgG glycosylation;	chr12:9426513	chr12:9398355~9414851:-
OV	cis	rs7246967	0.611	rs7246424	ENSG00000269509.1	BNIP3P34	7.38	2.9e-12	7.31e-09	0.67	0.44	Bronchopulmonary dysplasia;	chr19:22699383	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs7249685	ENSG00000269509.1	BNIP3P34	7.38	2.9e-12	7.31e-09	0.67	0.44	Bronchopulmonary dysplasia;	chr19:22699577	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs2112610	ENSG00000269509.1	BNIP3P34	7.38	2.9e-12	7.32e-09	0.68	0.44	Bronchopulmonary dysplasia;	chr19:22734049	chr19:22773853~22774424:+
OV	cis	rs73086581	0.787	rs67633417	ENSG00000229539.1	RP11-119B16.2	7.38	2.92e-12	7.36e-09	0.59	0.44	Response to antidepressants in depression;	chr20:3887610	chr20:3888239~3888868:-
OV	cis	rs7615952	0.673	rs7632557	ENSG00000171084.14	FAM86JP	7.38	2.93e-12	7.37e-09	0.74	0.44	Blood pressure (smoking interaction);	chr3:125916038	chr3:125916620~125930024:+
OV	cis	rs7615952	0.932	rs9841157	ENSG00000171084.14	FAM86JP	7.38	2.93e-12	7.37e-09	0.74	0.44	Blood pressure (smoking interaction);	chr3:125916812	chr3:125916620~125930024:+
OV	cis	rs7615952	0.551	rs12695470	ENSG00000171084.14	FAM86JP	7.38	2.93e-12	7.37e-09	0.74	0.44	Blood pressure (smoking interaction);	chr3:125916875	chr3:125916620~125930024:+
OV	cis	rs7615952	0.932	rs13325495	ENSG00000171084.14	FAM86JP	7.38	2.93e-12	7.37e-09	0.74	0.44	Blood pressure (smoking interaction);	chr3:125918573	chr3:125916620~125930024:+
OV	cis	rs16828019	0.852	rs2300649	ENSG00000235358.1	RP11-399E6.1	7.38	2.93e-12	7.38e-09	0.86	0.44	Intelligence (multi-trait analysis);	chr1:41103531	chr1:41242373~41284861:+
OV	cis	rs16828019	0.852	rs3820090	ENSG00000235358.1	RP11-399E6.1	7.38	2.93e-12	7.38e-09	0.86	0.44	Intelligence (multi-trait analysis);	chr1:41107980	chr1:41242373~41284861:+
OV	cis	rs16828019	0.852	rs3904243	ENSG00000235358.1	RP11-399E6.1	7.38	2.93e-12	7.38e-09	0.86	0.44	Intelligence (multi-trait analysis);	chr1:41109180	chr1:41242373~41284861:+
OV	cis	rs16828019	0.852	rs11209545	ENSG00000235358.1	RP11-399E6.1	7.38	2.93e-12	7.38e-09	0.86	0.44	Intelligence (multi-trait analysis);	chr1:41110685	chr1:41242373~41284861:+
OV	cis	rs11690935	0.851	rs7581072	ENSG00000228389.1	AC068039.4	7.38	2.97e-12	7.47e-09	0.51	0.44	Schizophrenia;	chr2:171994938	chr2:171773482~171775844:+
OV	cis	rs17711722	0.675	rs6947132	ENSG00000222364.1	RNU6-96P	7.38	2.99e-12	7.51e-09	0.45	0.44	Calcium levels;	chr7:65808508	chr7:66395191~66395286:+
OV	cis	rs7246967	0.673	rs8103012	ENSG00000269509.1	BNIP3P34	7.38	3e-12	7.53e-09	0.67	0.44	Bronchopulmonary dysplasia;	chr19:22696483	chr19:22773853~22774424:+
OV	cis	rs875971	0.54	rs736270	ENSG00000236529.1	RP13-254B10.1	7.38	3e-12	7.53e-09	0.46	0.44	Aortic root size;	chr7:65963835	chr7:65840212~65840596:+
OV	cis	rs17361889	0.634	rs6954901	ENSG00000224683.1	RPL36AP29	-7.38	3.02e-12	7.6e-09	-0.54	-0.44	Pediatric bone mineral content (hip);	chr7:16267078	chr7:16208945~16209265:+
OV	cis	rs11159086	1	rs8006958	ENSG00000259005.1	RP3-449M8.6	7.38	3.03e-12	7.6e-09	0.7	0.44	Advanced glycation end-product levels;	chr14:74478148	chr14:74474007~74474864:-
OV	cis	rs2564921	0.73	rs2564939	ENSG00000242142.1	SERBP1P3	7.38	3.04e-12	7.63e-09	0.5	0.44	Height;	chr3:53072864	chr3:53064283~53065091:-
OV	cis	rs2153535	0.58	rs2327060	ENSG00000230939.1	RP11-314C16.1	-7.37	3.06e-12	7.68e-09	-0.5	-0.44	Motion sickness;	chr6:8446878	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs6929206	ENSG00000230939.1	RP11-314C16.1	-7.37	3.06e-12	7.68e-09	-0.5	-0.44	Motion sickness;	chr6:8447728	chr6:8784178~8785445:+
OV	cis	rs7246967	0.736	rs398945	ENSG00000269509.1	BNIP3P34	-7.37	3.09e-12	7.73e-09	-0.69	-0.44	Bronchopulmonary dysplasia;	chr19:22814314	chr19:22773853~22774424:+
OV	cis	rs11690935	0.851	rs10174055	ENSG00000228389.1	AC068039.4	7.37	3.22e-12	8.04e-09	0.51	0.44	Schizophrenia;	chr2:171993303	chr2:171773482~171775844:+
OV	cis	rs3091242	0.967	rs665372	ENSG00000261349.1	RP3-465N24.5	-7.37	3.24e-12	8.1e-09	-0.49	-0.44	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25266102~25267136:-
OV	cis	rs4423214	0.798	rs1894100	ENSG00000254682.1	RP11-660L16.2	-7.36	3.25e-12	8.12e-09	-0.56	-0.44	Vitamin D levels;	chr11:71419297	chr11:71448674~71452157:+
OV	cis	rs2729354	0.693	rs2584862	ENSG00000265566.2	RN7SL605P	-7.36	3.26e-12	8.15e-09	-0.64	-0.44	Blood protein levels;	chr11:57474483	chr11:57528085~57528365:-
OV	cis	rs11168854	0.595	rs11168857	ENSG00000258017.1	RP11-386G11.10	-7.36	3.27e-12	8.17e-09	-0.56	-0.44	Body mass index;	chr12:49096526	chr12:49127782~49147869:+
OV	cis	rs7246967	0.932	rs8101067	ENSG00000269509.1	BNIP3P34	7.36	3.31e-12	8.25e-09	0.72	0.44	Bronchopulmonary dysplasia;	chr19:22882375	chr19:22773853~22774424:+
OV	cis	rs6991838	0.584	rs7836349	ENSG00000272010.1	CTD-3025N20.3	-7.36	3.33e-12	8.3e-09	-0.55	-0.44	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65591850~65592472:-
OV	cis	rs4713118	0.587	rs61471148	ENSG00000220721.1	OR1F12	7.36	3.35e-12	8.35e-09	0.51	0.44	Parkinson's disease;	chr6:28069254	chr6:28073316~28074233:+
OV	cis	rs4713118	0.699	rs573179	ENSG00000220721.1	OR1F12	7.36	3.38e-12	8.42e-09	0.51	0.44	Parkinson's disease;	chr6:27881898	chr6:28073316~28074233:+
OV	cis	rs11690935	0.921	rs10200608	ENSG00000228389.1	AC068039.4	7.36	3.43e-12	8.54e-09	0.5	0.44	Schizophrenia;	chr2:171741419	chr2:171773482~171775844:+
OV	cis	rs7569084	1	rs7569084	ENSG00000234255.7	AC012370.3	-7.36	3.44e-12	8.56e-09	-0.48	-0.44	Sum eosinophil basophil counts;	chr2:65429835	chr2:65439888~65456571:-
OV	cis	rs875971	0.54	rs4717275	ENSG00000222364.1	RNU6-96P	7.36	3.44e-12	8.57e-09	0.45	0.44	Aortic root size;	chr7:65800193	chr7:66395191~66395286:+
OV	cis	rs7246967	0.608	rs2569728	ENSG00000269509.1	BNIP3P34	7.36	3.45e-12	8.58e-09	0.69	0.44	Bronchopulmonary dysplasia;	chr19:22831202	chr19:22773853~22774424:+
OV	cis	rs4713118	0.662	rs9393881	ENSG00000220721.1	OR1F12	7.35	3.47e-12	8.64e-09	0.5	0.44	Parkinson's disease;	chr6:28055973	chr6:28073316~28074233:+
OV	cis	rs7246967	0.736	rs411131	ENSG00000269509.1	BNIP3P34	7.35	3.48e-12	8.66e-09	0.69	0.44	Bronchopulmonary dysplasia;	chr19:22810637	chr19:22773853~22774424:+
OV	cis	rs17361889	0.634	rs7799150	ENSG00000224683.1	RPL36AP29	7.35	3.52e-12	8.76e-09	0.52	0.44	Pediatric bone mineral content (hip);	chr7:16258813	chr7:16208945~16209265:+
OV	cis	rs1707322	0.682	rs12037459	ENSG00000281133.1	AL355480.3	-7.35	3.56e-12	8.84e-09	-0.59	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr1:45580892~45580996:-
OV	cis	rs16828019	1	rs16828019	ENSG00000235358.1	RP11-399E6.1	7.35	3.56e-12	8.85e-09	0.9	0.44	Intelligence (multi-trait analysis);	chr1:41279363	chr1:41242373~41284861:+
OV	cis	rs7246967	0.544	rs420861	ENSG00000269509.1	BNIP3P34	7.35	3.59e-12	8.9e-09	0.69	0.44	Bronchopulmonary dysplasia;	chr19:22823102	chr19:22773853~22774424:+
OV	cis	rs4713118	0.629	rs203887	ENSG00000220721.1	OR1F12	7.35	3.61e-12	8.96e-09	0.51	0.44	Parkinson's disease;	chr6:28053491	chr6:28073316~28074233:+
OV	cis	rs6921919	0.583	rs6907950	ENSG00000216901.1	AL022393.7	7.35	3.61e-12	8.96e-09	0.53	0.44	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28176188~28176674:+
OV	cis	rs875971	0.522	rs1880556	ENSG00000222364.1	RNU6-96P	-7.35	3.62e-12	8.97e-09	-0.45	-0.44	Aortic root size;	chr7:65967557	chr7:66395191~66395286:+
OV	cis	rs875971	0.522	rs4718285	ENSG00000226824.5	RP4-756H11.3	-7.35	3.64e-12	9e-09	-0.45	-0.44	Aortic root size;	chr7:65827018	chr7:66654538~66669855:+
OV	cis	rs875971	0.522	rs4718286	ENSG00000226824.5	RP4-756H11.3	-7.35	3.64e-12	9e-09	-0.45	-0.44	Aortic root size;	chr7:65827777	chr7:66654538~66669855:+
OV	cis	rs875971	0.522	rs4502988	ENSG00000226824.5	RP4-756H11.3	-7.35	3.64e-12	9e-09	-0.45	-0.44	Aortic root size;	chr7:65832759	chr7:66654538~66669855:+
OV	cis	rs17711722	0.585	rs6942660	ENSG00000226824.5	RP4-756H11.3	-7.35	3.64e-12	9e-09	-0.45	-0.44	Calcium levels;	chr7:65837419	chr7:66654538~66669855:+
OV	cis	rs17711722	0.64	rs13237956	ENSG00000226824.5	RP4-756H11.3	-7.35	3.64e-12	9e-09	-0.45	-0.44	Calcium levels;	chr7:65853042	chr7:66654538~66669855:+
OV	cis	rs1075265	0.527	rs959285	ENSG00000233266.1	HMGB1P31	7.35	3.65e-12	9.03e-09	0.53	0.44	Chronotype;Morning vs. evening chronotype;	chr2:54078964	chr2:54051334~54051760:+
OV	cis	rs492146	0.765	rs670960	ENSG00000243236.5	GSTA9P	-7.34	3.7e-12	9.14e-09	-0.52	-0.44	Epilepsy (remission after treatment);	chr6:52978998	chr6:52939726~52957521:-
OV	cis	rs492146	0.765	rs672281	ENSG00000243236.5	GSTA9P	-7.34	3.7e-12	9.14e-09	-0.52	-0.44	Epilepsy (remission after treatment);	chr6:52979247	chr6:52939726~52957521:-
OV	cis	rs11690935	0.802	rs34636594	ENSG00000228389.1	AC068039.4	7.34	3.74e-12	9.24e-09	0.51	0.44	Schizophrenia;	chr2:172046366	chr2:171773482~171775844:+
OV	cis	rs7569084	1	rs13385171	ENSG00000234255.7	AC012370.3	-7.34	3.76e-12	9.29e-09	-0.48	-0.44	Sum eosinophil basophil counts;	chr2:65434709	chr2:65439888~65456571:-
OV	cis	rs494459	0.838	rs1784543	ENSG00000255239.1	AP002954.6	7.34	3.82e-12	9.42e-09	0.5	0.44	Height;	chr11:118760944	chr11:118688039~118690600:-
OV	cis	rs16828019	0.852	rs11209531	ENSG00000235358.1	RP11-399E6.1	7.34	3.82e-12	9.43e-09	0.85	0.44	Intelligence (multi-trait analysis);	chr1:41105349	chr1:41242373~41284861:+
OV	cis	rs875971	0.545	rs1796226	ENSG00000222364.1	RNU6-96P	-7.34	3.83e-12	9.45e-09	-0.51	-0.44	Aortic root size;	chr7:66622723	chr7:66395191~66395286:+
OV	cis	rs17711722	1	rs17711722	ENSG00000222364.1	RNU6-96P	7.34	3.84e-12	9.46e-09	0.45	0.44	Calcium levels;	chr7:65806210	chr7:66395191~66395286:+
OV	cis	rs4356975	0.518	rs4314347	ENSG00000248763.2	RP13-644M16.5	-7.34	3.85e-12	9.5e-09	-0.7	-0.44	Obesity-related traits;	chr4:69102209	chr4:69066395~69069888:+
OV	cis	rs1707322	0.717	rs3014245	ENSG00000281133.1	AL355480.3	7.33	3.9e-12	9.6e-09	0.59	0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr1:45580892~45580996:-
OV	cis	rs875971	0.522	rs9530	ENSG00000222364.1	RNU6-96P	-7.33	3.9e-12	9.61e-09	-0.45	-0.44	Aortic root size;	chr7:65960907	chr7:66395191~66395286:+
OV	cis	rs9322193	0.607	rs9322229	ENSG00000231760.4	RP11-350J20.5	7.33	3.93e-12	9.68e-09	0.6	0.44	Lung cancer;	chr6:149908949	chr6:149796151~149826294:-
OV	cis	rs7246967	0.608	rs453175	ENSG00000269509.1	BNIP3P34	7.33	3.94e-12	9.71e-09	0.69	0.44	Bronchopulmonary dysplasia;	chr19:22831285	chr19:22773853~22774424:+
OV	cis	rs7688540	0.511	rs61794965	ENSG00000275426.1	CH17-262A2.1	7.33	3.94e-12	9.71e-09	0.81	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:177880	chr4:149738~150317:+
OV	cis	rs1707322	0.721	rs6699418	ENSG00000281133.1	AL355480.3	-7.33	3.97e-12	9.74e-09	-0.56	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs4431884	ENSG00000281133.1	AL355480.3	-7.33	3.97e-12	9.74e-09	-0.56	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45580892~45580996:-
OV	cis	rs1707322	0.65	rs4660879	ENSG00000281133.1	AL355480.3	-7.33	3.97e-12	9.74e-09	-0.56	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45580892~45580996:-
OV	cis	rs494459	0.688	rs1048040	ENSG00000255239.1	AP002954.6	7.33	4.06e-12	9.95e-09	0.5	0.44	Height;	chr11:118747911	chr11:118688039~118690600:-
OV	cis	rs3091242	0.933	rs4649084	ENSG00000261349.1	RP3-465N24.5	-7.33	4.06e-12	9.95e-09	-0.48	-0.44	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25266102~25267136:-
OV	cis	rs875971	0.516	rs6945322	ENSG00000226824.5	RP4-756H11.3	-7.33	4.08e-12	9.95e-09	-0.45	-0.44	Aortic root size;	chr7:65871069	chr7:66654538~66669855:+
OV	cis	rs17711722	0.701	rs55773927	ENSG00000226824.5	RP4-756H11.3	-7.33	4.08e-12	9.95e-09	-0.45	-0.44	Calcium levels;	chr7:65872915	chr7:66654538~66669855:+
OV	cis	rs17711722	0.727	rs35850374	ENSG00000226824.5	RP4-756H11.3	-7.33	4.08e-12	9.95e-09	-0.45	-0.44	Calcium levels;	chr7:65892789	chr7:66654538~66669855:+
OV	cis	rs7017914	0.934	rs2639921	ENSG00000223220.1	Y_RNA	7.33	4.08e-12	9.96e-09	0.46	0.44	Bone mineral density;	chr8:70962599	chr8:70780914~70781008:-
OV	cis	rs2117029	0.555	rs7978448	ENSG00000258017.1	RP11-386G11.10	-7.32	4.14e-12	1.01e-08	-0.54	-0.44	Intelligence (multi-trait analysis);	chr12:49113157	chr12:49127782~49147869:+
OV	cis	rs11690935	0.843	rs9784070	ENSG00000228389.1	AC068039.4	7.32	4.17e-12	1.02e-08	0.5	0.44	Schizophrenia;	chr2:171928497	chr2:171773482~171775844:+
OV	cis	rs875971	0.522	rs7784623	ENSG00000236529.1	RP13-254B10.1	7.32	4.17e-12	1.02e-08	0.45	0.44	Aortic root size;	chr7:65930047	chr7:65840212~65840596:+
OV	cis	rs875971	0.522	rs34973832	ENSG00000236529.1	RP13-254B10.1	7.32	4.17e-12	1.02e-08	0.45	0.44	Aortic root size;	chr7:65931217	chr7:65840212~65840596:+
OV	cis	rs853679	0.517	rs3757187	ENSG00000220721.1	OR1F12	7.32	4.19e-12	1.02e-08	0.51	0.44	Depression;	chr6:28139876	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs3757185	ENSG00000220721.1	OR1F12	7.32	4.19e-12	1.02e-08	0.51	0.44	Depression;	chr6:28139998	chr6:28073316~28074233:+
OV	cis	rs10256972	0.685	rs10263665	ENSG00000229043.2	AC091729.9	-7.32	4.19e-12	1.02e-08	-0.49	-0.44	Endometriosis;Longevity;	chr7:1070992	chr7:1160374~1165267:+
OV	cis	rs1707322	0.685	rs11211177	ENSG00000281133.1	AL355480.3	-7.32	4.23e-12	1.03e-08	-0.55	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr1:45580892~45580996:-
OV	cis	rs8105895	0.799	rs6511327	ENSG00000269742.1	BNIP3P29	7.32	4.24e-12	1.03e-08	0.71	0.44	Body mass index (change over time);	chr19:22104097	chr19:22065828~22066398:-
OV	cis	rs507080	0.733	rs601318	ENSG00000255422.1	AP002954.4	-7.32	4.25e-12	1.03e-08	-0.52	-0.44	Serum metabolite levels;	chr11:118648845	chr11:118704607~118750263:+
OV	cis	rs8062405	1	rs3888190	ENSG00000259982.1	CDC37P1	7.32	4.26e-12	1.04e-08	0.54	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28700294~28701540:-
OV	cis	rs492146	0.819	rs5028437	ENSG00000243236.5	GSTA9P	7.32	4.27e-12	1.04e-08	0.52	0.44	Epilepsy (remission after treatment);	chr6:52970876	chr6:52939726~52957521:-
OV	cis	rs875971	0.522	rs781144	ENSG00000222364.1	RNU6-96P	-7.32	4.31e-12	1.05e-08	-0.44	-0.44	Aortic root size;	chr7:65975357	chr7:66395191~66395286:+
OV	cis	rs1707322	0.717	rs11211161	ENSG00000281133.1	AL355480.3	-7.32	4.34e-12	1.05e-08	-0.58	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr1:45580892~45580996:-
OV	cis	rs1707322	0.752	rs61784793	ENSG00000281133.1	AL355480.3	-7.32	4.34e-12	1.05e-08	-0.58	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr1:45580892~45580996:-
OV	cis	rs7017914	0.967	rs2639919	ENSG00000223220.1	Y_RNA	7.32	4.35e-12	1.06e-08	0.45	0.44	Bone mineral density;	chr8:70962893	chr8:70780914~70781008:-
OV	cis	rs7246967	0.673	rs4933027	ENSG00000269509.1	BNIP3P34	-7.31	4.42e-12	1.07e-08	-0.64	-0.44	Bronchopulmonary dysplasia;	chr19:22721170	chr19:22773853~22774424:+
OV	cis	rs7688540	0.547	rs11728864	ENSG00000275426.1	CH17-262A2.1	7.31	4.42e-12	1.07e-08	0.81	0.44	Facial morphology (factor 6, height of vermillion lower lip);	chr4:197518	chr4:149738~150317:+
OV	cis	rs3931020	0.772	rs1409785	ENSG00000272864.1	RP11-17E13.2	-7.31	4.43e-12	1.07e-08	-0.56	-0.44	Resistin levels;	chr1:74782438	chr1:74698769~74699333:-
OV	cis	rs9326248	0.53	rs6589576	ENSG00000254851.1	RP11-109L13.1	7.31	4.43e-12	1.08e-08	0.73	0.44	Blood protein levels;	chr11:116865072	chr11:117135528~117138582:+
OV	cis	rs2153535	0.58	rs2327064	ENSG00000230939.1	RP11-314C16.1	-7.31	4.45e-12	1.08e-08	-0.5	-0.44	Motion sickness;	chr6:8453819	chr6:8784178~8785445:+
OV	cis	rs11159086	1	rs4899514	ENSG00000259005.1	RP3-449M8.6	-7.31	4.46e-12	1.08e-08	-0.73	-0.44	Advanced glycation end-product levels;	chr14:74473467	chr14:74474007~74474864:-
OV	cis	rs2882667	0.66	rs3088052	ENSG00000253404.1	AC034243.1	7.31	4.48e-12	1.09e-08	0.49	0.44	Age-related hearing impairment (SNP x SNP interaction);	chr5:139121126	chr5:138744434~138753309:-
OV	cis	rs6700559	1	rs6656619	ENSG00000260088.1	RP11-92G12.3	7.31	4.54e-12	1.1e-08	0.45	0.44	Coronary artery disease;	chr1:200671664	chr1:200669507~200694250:+
OV	cis	rs858239	0.676	rs274032	ENSG00000230658.1	KLHL7-AS1	7.31	4.59e-12	1.11e-08	0.55	0.44	Cerebrospinal fluid biomarker levels;	chr7:23334940	chr7:23101228~23105703:-
OV	cis	rs73086581	0.947	rs67356712	ENSG00000229539.1	RP11-119B16.2	7.31	4.6e-12	1.11e-08	0.55	0.44	Response to antidepressants in depression;	chr20:3912239	chr20:3888239~3888868:-
OV	cis	rs1707322	0.721	rs10890343	ENSG00000281133.1	AL355480.3	-7.31	4.6e-12	1.11e-08	-0.56	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr1:45580892~45580996:-
OV	cis	rs1707322	0.717	rs1135812	ENSG00000281133.1	AL355480.3	-7.31	4.63e-12	1.12e-08	-0.58	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr1:45580892~45580996:-
OV	cis	rs1707322	0.752	rs6703748	ENSG00000281133.1	AL355480.3	-7.31	4.63e-12	1.12e-08	-0.58	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr1:45580892~45580996:-
OV	cis	rs17361889	0.613	rs62440449	ENSG00000224683.1	RPL36AP29	7.31	4.63e-12	1.12e-08	0.51	0.44	Pediatric bone mineral content (hip);	chr7:16257180	chr7:16208945~16209265:+
OV	cis	rs4713118	0.621	rs9295756	ENSG00000220721.1	OR1F12	7.31	4.64e-12	1.12e-08	0.51	0.44	Parkinson's disease;	chr6:28065618	chr6:28073316~28074233:+
OV	cis	rs3931020	0.772	rs1475396	ENSG00000272864.1	RP11-17E13.2	-7.31	4.65e-12	1.12e-08	-0.55	-0.44	Resistin levels;	chr1:74776712	chr1:74698769~74699333:-
OV	cis	rs2581828	0.965	rs35783750	ENSG00000242142.1	SERBP1P3	7.3	4.68e-12	1.13e-08	0.49	0.44	Crohn's disease;	chr3:53100847	chr3:53064283~53065091:-
OV	cis	rs2581828	0.965	rs34454739	ENSG00000242142.1	SERBP1P3	7.3	4.68e-12	1.13e-08	0.49	0.44	Crohn's disease;	chr3:53100955	chr3:53064283~53065091:-
OV	cis	rs2581828	0.965	rs2564961	ENSG00000242142.1	SERBP1P3	7.3	4.68e-12	1.13e-08	0.49	0.44	Crohn's disease;	chr3:53102445	chr3:53064283~53065091:-
OV	cis	rs2153535	0.58	rs718502	ENSG00000230939.1	RP11-314C16.1	-7.3	4.7e-12	1.13e-08	-0.5	-0.44	Motion sickness;	chr6:8527167	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs718503	ENSG00000230939.1	RP11-314C16.1	-7.3	4.7e-12	1.13e-08	-0.5	-0.44	Motion sickness;	chr6:8527230	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs6597335	ENSG00000230939.1	RP11-314C16.1	-7.3	4.7e-12	1.13e-08	-0.5	-0.44	Motion sickness;	chr6:8527481	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9328486	ENSG00000230939.1	RP11-314C16.1	-7.3	4.7e-12	1.13e-08	-0.5	-0.44	Motion sickness;	chr6:8527775	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs2183112	ENSG00000230939.1	RP11-314C16.1	-7.3	4.7e-12	1.13e-08	-0.5	-0.44	Motion sickness;	chr6:8527979	chr6:8784178~8785445:+
OV	cis	rs2153535	0.601	rs2143353	ENSG00000230939.1	RP11-314C16.1	-7.3	4.7e-12	1.13e-08	-0.5	-0.44	Motion sickness;	chr6:8529878	chr6:8784178~8785445:+
OV	cis	rs11690935	0.921	rs7594711	ENSG00000228389.1	AC068039.4	7.3	4.7e-12	1.13e-08	0.5	0.44	Schizophrenia;	chr2:172030734	chr2:171773482~171775844:+
OV	cis	rs507080	0.769	rs7389	ENSG00000255422.1	AP002954.4	7.3	4.71e-12	1.14e-08	0.5	0.44	Serum metabolite levels;	chr11:118657756	chr11:118704607~118750263:+
OV	cis	rs4356975	0.518	rs4694628	ENSG00000248763.2	RP13-644M16.5	-7.3	4.74e-12	1.14e-08	-0.69	-0.44	Obesity-related traits;	chr4:69104054	chr4:69066395~69069888:+
OV	cis	rs8062405	1	rs4451951	ENSG00000259982.1	CDC37P1	7.3	4.77e-12	1.15e-08	0.54	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28700294~28701540:-
OV	cis	rs2408955	0.501	rs8716	ENSG00000258273.1	RP11-370I10.4	-7.3	4.78e-12	1.15e-08	-0.52	-0.44	Glycated hemoglobin levels;	chr12:48145699	chr12:48333755~48333901:-
OV	cis	rs16828019	0.704	rs12024115	ENSG00000235358.1	RP11-399E6.1	7.3	4.83e-12	1.16e-08	0.84	0.44	Intelligence (multi-trait analysis);	chr1:41068685	chr1:41242373~41284861:+
OV	cis	rs2153535	0.58	rs6597332	ENSG00000230939.1	RP11-314C16.1	-7.3	4.86e-12	1.17e-08	-0.49	-0.44	Motion sickness;	chr6:8504515	chr6:8784178~8785445:+
OV	cis	rs6921919	0.609	rs1005127	ENSG00000216901.1	AL022393.7	7.3	4.86e-12	1.17e-08	0.52	0.44	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28176188~28176674:+
OV	cis	rs853679	0.515	rs4580862	ENSG00000216901.1	AL022393.7	7.3	4.86e-12	1.17e-08	0.52	0.44	Depression;	chr6:28399886	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs4357130	ENSG00000216901.1	AL022393.7	7.3	4.86e-12	1.17e-08	0.52	0.44	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28176188~28176674:+
OV	cis	rs6921919	0.609	rs9461455	ENSG00000216901.1	AL022393.7	7.3	4.87e-12	1.17e-08	0.55	0.44	Autism spectrum disorder or schizophrenia;	chr6:28361954	chr6:28176188~28176674:+
OV	cis	rs4853012	1	rs4853012	ENSG00000217702.2	RP11-287D1.4	7.3	4.9e-12	1.18e-08	0.77	0.44	Gestational age at birth (maternal effect);	chr2:74134163	chr2:74130583~74135395:+
OV	cis	rs7617773	0.539	rs13087050	ENSG00000229759.1	MRPS18AP1	7.3	4.93e-12	1.19e-08	0.44	0.44	Coronary artery disease;	chr3:48351310	chr3:48256350~48256938:-
OV	cis	rs7017914	0.934	rs7814274	ENSG00000223220.1	Y_RNA	-7.29	4.98e-12	1.2e-08	-0.45	-0.44	Bone mineral density;	chr8:70658176	chr8:70780914~70781008:-
OV	cis	rs9326248	0.581	rs11216267	ENSG00000254851.1	RP11-109L13.1	-7.29	4.98e-12	1.2e-08	-0.51	-0.44	Blood protein levels;	chr11:117081676	chr11:117135528~117138582:+
OV	cis	rs7017914	0.967	rs12679261	ENSG00000223220.1	Y_RNA	7.29	5.05e-12	1.21e-08	0.45	0.44	Bone mineral density;	chr8:70932414	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs10089583	ENSG00000223220.1	Y_RNA	7.29	5.05e-12	1.21e-08	0.45	0.44	Bone mineral density;	chr8:70937249	chr8:70780914~70781008:-
OV	cis	rs7617773	0.925	rs35942721	ENSG00000229759.1	MRPS18AP1	7.29	5.06e-12	1.22e-08	0.52	0.44	Coronary artery disease;	chr3:48131579	chr3:48256350~48256938:-
OV	cis	rs875971	0.522	rs2008188	ENSG00000236529.1	RP13-254B10.1	7.29	5.1e-12	1.23e-08	0.45	0.44	Aortic root size;	chr7:65964026	chr7:65840212~65840596:+
OV	cis	rs853679	0.517	rs16893666	ENSG00000220721.1	OR1F12	-7.29	5.15e-12	1.24e-08	-0.51	-0.44	Depression;	chr6:28086929	chr6:28073316~28074233:+
OV	cis	rs801193	0.569	rs35070132	ENSG00000226824.5	RP4-756H11.3	-7.29	5.18e-12	1.24e-08	-0.46	-0.44	Aortic root size;	chr7:66773096	chr7:66654538~66669855:+
OV	cis	rs8062405	1	rs62036620	ENSG00000259982.1	CDC37P1	7.29	5.25e-12	1.26e-08	0.54	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28700294~28701540:-
OV	cis	rs8062405	1	rs62036621	ENSG00000259982.1	CDC37P1	7.29	5.25e-12	1.26e-08	0.54	0.44	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28700294~28701540:-
OV	cis	rs875971	0.651	rs313829	ENSG00000222364.1	RNU6-96P	7.28	5.26e-12	1.26e-08	0.5	0.44	Aortic root size;	chr7:66087510	chr7:66395191~66395286:+
OV	cis	rs7569084	1	rs7583469	ENSG00000234255.7	AC012370.3	7.28	5.27e-12	1.26e-08	0.45	0.44	Sum eosinophil basophil counts;	chr2:65424222	chr2:65439888~65456571:-
OV	cis	rs507080	0.697	rs653008	ENSG00000255422.1	AP002954.4	-7.28	5.27e-12	1.26e-08	-0.51	-0.44	Serum metabolite levels;	chr11:118649775	chr11:118704607~118750263:+
OV	cis	rs7246967	0.611	rs8102927	ENSG00000269509.1	BNIP3P34	7.28	5.31e-12	1.27e-08	0.7	0.44	Bronchopulmonary dysplasia;	chr19:22696554	chr19:22773853~22774424:+
OV	cis	rs1707322	0.721	rs11211178	ENSG00000281133.1	AL355480.3	-7.28	5.35e-12	1.28e-08	-0.56	-0.44	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45580892~45580996:-
OV	cis	rs7044106	0.791	rs10984994	ENSG00000226752.6	PSMD5-AS1	7.28	5.38e-12	1.29e-08	0.51	0.44	Hip circumference adjusted for BMI;	chr9:120716491	chr9:120824828~120854385:+
OV	cis	rs73086581	1	rs73084575	ENSG00000229539.1	RP11-119B16.2	7.28	5.4e-12	1.29e-08	0.58	0.44	Response to antidepressants in depression;	chr20:3926121	chr20:3888239~3888868:-
OV	cis	rs9326248	0.581	rs7120706	ENSG00000254851.1	RP11-109L13.1	7.28	5.4e-12	1.29e-08	0.5	0.44	Blood protein levels;	chr11:116959371	chr11:117135528~117138582:+
OV	cis	rs492146	0.729	rs426013	ENSG00000243236.5	GSTA9P	-7.28	5.43e-12	1.3e-08	-0.51	-0.44	Epilepsy (remission after treatment);	chr6:52975947	chr6:52939726~52957521:-
OV	cis	rs492146	0.756	rs374275	ENSG00000243236.5	GSTA9P	-7.28	5.43e-12	1.3e-08	-0.51	-0.44	Epilepsy (remission after treatment);	chr6:52975999	chr6:52939726~52957521:-
OV	cis	rs7246967	0.673	rs2361260	ENSG00000269509.1	BNIP3P34	-7.28	5.44e-12	1.3e-08	-0.7	-0.44	Bronchopulmonary dysplasia;	chr19:22731342	chr19:22773853~22774424:+
OV	cis	rs62355901	0.545	rs16886256	ENSG00000271828.1	CTD-2310F14.1	-7.28	5.45e-12	1.3e-08	-0.73	-0.44	Breast cancer;	chr5:56765737	chr5:56927874~56929573:+
OV	cis	rs8005677	1	rs4982709	ENSG00000257285.4	RP11-298I3.1	7.28	5.46e-12	1.3e-08	0.51	0.44	Cognitive ability (multi-trait analysis);	chr14:22925490	chr14:22929609~22955562:+
OV	cis	rs748404	0.66	rs690367	ENSG00000205771.5	CATSPER2P1	7.28	5.47e-12	1.31e-08	0.55	0.43	Lung cancer;	chr15:43456106	chr15:43726918~43747094:-
OV	cis	rs1707322	0.717	rs1547925	ENSG00000281133.1	AL355480.3	7.28	5.52e-12	1.32e-08	0.59	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr1:45580892~45580996:-
OV	cis	rs7246967	0.736	rs2546463	ENSG00000269509.1	BNIP3P34	7.28	5.52e-12	1.32e-08	0.68	0.43	Bronchopulmonary dysplasia;	chr19:22811804	chr19:22773853~22774424:+
OV	cis	rs6700559	0.804	rs11588318	ENSG00000260088.1	RP11-92G12.3	-7.28	5.53e-12	1.32e-08	-0.45	-0.43	Coronary artery disease;	chr1:200669534	chr1:200669507~200694250:+
OV	cis	rs507080	0.769	rs745663	ENSG00000255422.1	AP002954.4	-7.28	5.53e-12	1.32e-08	-0.51	-0.43	Serum metabolite levels;	chr11:118658886	chr11:118704607~118750263:+
OV	cis	rs6921919	0.515	rs1339898	ENSG00000216901.1	AL022393.7	7.28	5.54e-12	1.32e-08	0.49	0.43	Autism spectrum disorder or schizophrenia;	chr6:28427729	chr6:28176188~28176674:+
OV	cis	rs7017914	0.967	rs1493198	ENSG00000223220.1	Y_RNA	7.27	5.59e-12	1.33e-08	0.45	0.43	Bone mineral density;	chr8:70939722	chr8:70780914~70781008:-
OV	cis	rs7017914	0.934	rs13255152	ENSG00000223220.1	Y_RNA	7.27	5.59e-12	1.33e-08	0.45	0.43	Bone mineral density;	chr8:70947384	chr8:70780914~70781008:-
OV	cis	rs7569084	0.687	rs6755006	ENSG00000234255.7	AC012370.3	-7.27	5.62e-12	1.34e-08	-0.49	-0.43	Sum eosinophil basophil counts;	chr2:65426008	chr2:65439888~65456571:-
OV	cis	rs7569084	0.687	rs6755128	ENSG00000234255.7	AC012370.3	-7.27	5.62e-12	1.34e-08	-0.49	-0.43	Sum eosinophil basophil counts;	chr2:65426065	chr2:65439888~65456571:-
OV	cis	rs11690935	0.885	rs10202823	ENSG00000228389.1	AC068039.4	7.27	5.63e-12	1.34e-08	0.49	0.43	Schizophrenia;	chr2:171923622	chr2:171773482~171775844:+
OV	cis	rs11690935	0.885	rs6750058	ENSG00000228389.1	AC068039.4	7.27	5.63e-12	1.34e-08	0.49	0.43	Schizophrenia;	chr2:171930399	chr2:171773482~171775844:+
OV	cis	rs17711722	0.701	rs781143	ENSG00000236529.1	RP13-254B10.1	7.27	5.67e-12	1.35e-08	0.45	0.43	Calcium levels;	chr7:65974892	chr7:65840212~65840596:+
OV	cis	rs17711722	0.701	rs781145	ENSG00000236529.1	RP13-254B10.1	7.27	5.67e-12	1.35e-08	0.45	0.43	Calcium levels;	chr7:65975383	chr7:65840212~65840596:+
OV	cis	rs2153535	0.601	rs7741024	ENSG00000230939.1	RP11-314C16.1	-7.27	5.7e-12	1.36e-08	-0.5	-0.43	Motion sickness;	chr6:8530080	chr6:8784178~8785445:+
OV	cis	rs6700559	0.903	rs6661240	ENSG00000260088.1	RP11-92G12.3	-7.27	5.73e-12	1.37e-08	-0.45	-0.43	Coronary artery disease;	chr1:200669719	chr1:200669507~200694250:+
OV	cis	rs6700559	0.967	rs6688581	ENSG00000260088.1	RP11-92G12.3	-7.27	5.73e-12	1.37e-08	-0.45	-0.43	Coronary artery disease;	chr1:200670028	chr1:200669507~200694250:+
OV	cis	rs2729354	0.817	rs2467327	ENSG00000265566.2	RN7SL605P	-7.27	5.79e-12	1.38e-08	-0.66	-0.43	Blood protein levels;	chr11:57511755	chr11:57528085~57528365:-
OV	cis	rs7246967	0.611	rs2361022	ENSG00000269509.1	BNIP3P34	7.27	5.84e-12	1.39e-08	0.67	0.43	Bronchopulmonary dysplasia;	chr19:22633731	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs2361023	ENSG00000269509.1	BNIP3P34	7.27	5.84e-12	1.39e-08	0.67	0.43	Bronchopulmonary dysplasia;	chr19:22634065	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs118059742	ENSG00000269509.1	BNIP3P34	7.27	5.84e-12	1.39e-08	0.67	0.43	Bronchopulmonary dysplasia;	chr19:22636644	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs56663398	ENSG00000269509.1	BNIP3P34	7.27	5.84e-12	1.39e-08	0.67	0.43	Bronchopulmonary dysplasia;	chr19:22637398	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs35731237	ENSG00000269509.1	BNIP3P34	7.27	5.84e-12	1.39e-08	0.67	0.43	Bronchopulmonary dysplasia;	chr19:22637708	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs12979173	ENSG00000269509.1	BNIP3P34	7.27	5.84e-12	1.39e-08	0.67	0.43	Bronchopulmonary dysplasia;	chr19:22637879	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs12979848	ENSG00000269509.1	BNIP3P34	7.27	5.84e-12	1.39e-08	0.67	0.43	Bronchopulmonary dysplasia;	chr19:22637996	chr19:22773853~22774424:+
OV	cis	rs7246967	0.551	rs6511367	ENSG00000269509.1	BNIP3P34	7.27	5.84e-12	1.39e-08	0.67	0.43	Bronchopulmonary dysplasia;	chr19:22638468	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs7250964	ENSG00000269509.1	BNIP3P34	7.27	5.84e-12	1.39e-08	0.67	0.43	Bronchopulmonary dysplasia;	chr19:22639692	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs7250343	ENSG00000269509.1	BNIP3P34	7.27	5.84e-12	1.39e-08	0.67	0.43	Bronchopulmonary dysplasia;	chr19:22640043	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs35007247	ENSG00000269509.1	BNIP3P34	7.27	5.84e-12	1.39e-08	0.67	0.43	Bronchopulmonary dysplasia;	chr19:22640121	chr19:22773853~22774424:+
OV	cis	rs2153535	0.58	rs6421948	ENSG00000230939.1	RP11-314C16.1	-7.27	5.88e-12	1.39e-08	-0.5	-0.43	Motion sickness;	chr6:8530787	chr6:8784178~8785445:+
OV	cis	rs4713118	0.662	rs156744	ENSG00000220721.1	OR1F12	7.27	5.9e-12	1.4e-08	0.52	0.43	Parkinson's disease;	chr6:27999496	chr6:28073316~28074233:+
OV	cis	rs7246967	0.608	rs437859	ENSG00000269509.1	BNIP3P34	-7.27	5.91e-12	1.4e-08	-0.67	-0.43	Bronchopulmonary dysplasia;	chr19:22824547	chr19:22773853~22774424:+
OV	cis	rs2153535	0.58	rs9406167	ENSG00000230939.1	RP11-314C16.1	-7.27	5.92e-12	1.4e-08	-0.49	-0.43	Motion sickness;	chr6:8502619	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs6597334	ENSG00000230939.1	RP11-314C16.1	-7.27	5.92e-12	1.4e-08	-0.49	-0.43	Motion sickness;	chr6:8504546	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs2327067	ENSG00000230939.1	RP11-314C16.1	-7.27	5.92e-12	1.4e-08	-0.49	-0.43	Motion sickness;	chr6:8518249	chr6:8784178~8785445:+
OV	cis	rs2153535	0.541	rs9328477	ENSG00000230939.1	RP11-314C16.1	-7.27	5.92e-12	1.4e-08	-0.49	-0.43	Motion sickness;	chr6:8518876	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9328478	ENSG00000230939.1	RP11-314C16.1	-7.27	5.92e-12	1.4e-08	-0.49	-0.43	Motion sickness;	chr6:8518950	chr6:8784178~8785445:+
OV	cis	rs4356975	0.518	rs78408800	ENSG00000248763.2	RP13-644M16.5	-7.27	5.93e-12	1.41e-08	-0.7	-0.43	Obesity-related traits;	chr4:69101657	chr4:69066395~69069888:+
OV	cis	rs1707322	0.721	rs4660314	ENSG00000281133.1	AL355480.3	-7.26	5.94e-12	1.41e-08	-0.57	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs12069121	ENSG00000281133.1	AL355480.3	-7.26	5.94e-12	1.41e-08	-0.57	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr1:45580892~45580996:-
OV	cis	rs1707322	0.686	rs61784833	ENSG00000281133.1	AL355480.3	-7.26	5.94e-12	1.41e-08	-0.57	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr1:45580892~45580996:-
OV	cis	rs150992	0.79	rs325220	ENSG00000248489.1	CTD-2007H13.3	7.26	6.06e-12	1.43e-08	0.59	0.43	Body mass index;	chr5:98968860	chr5:98929171~98995013:+
OV	cis	rs7569084	0.687	rs12614851	ENSG00000234255.7	AC012370.3	7.26	6.13e-12	1.45e-08	0.48	0.43	Sum eosinophil basophil counts;	chr2:65458050	chr2:65439888~65456571:-
OV	cis	rs11690935	1	rs35549875	ENSG00000228389.1	AC068039.4	-7.26	6.15e-12	1.45e-08	-0.5	-0.43	Schizophrenia;	chr2:171675882	chr2:171773482~171775844:+
OV	cis	rs2929278	0.736	rs2412823	ENSG00000249839.1	AC011330.5	7.26	6.18e-12	1.46e-08	0.53	0.43	Schizophrenia;	chr15:43935072	chr15:43663654~43684339:-
OV	cis	rs1707322	0.685	rs56177313	ENSG00000281133.1	AL355480.3	-7.26	6.2e-12	1.46e-08	-0.56	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45580892~45580996:-
OV	cis	rs875971	0.862	rs6971059	ENSG00000226824.5	RP4-756H11.3	7.26	6.21e-12	1.47e-08	0.46	0.43	Aortic root size;	chr7:66602045	chr7:66654538~66669855:+
OV	cis	rs875971	0.789	rs7808013	ENSG00000226824.5	RP4-756H11.3	7.26	6.21e-12	1.47e-08	0.46	0.43	Aortic root size;	chr7:66606209	chr7:66654538~66669855:+
OV	cis	rs875971	0.825	rs7384021	ENSG00000226824.5	RP4-756H11.3	7.26	6.21e-12	1.47e-08	0.46	0.43	Aortic root size;	chr7:66612917	chr7:66654538~66669855:+
OV	cis	rs875971	0.825	rs66981195	ENSG00000226824.5	RP4-756H11.3	7.26	6.21e-12	1.47e-08	0.46	0.43	Aortic root size;	chr7:66614048	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs3926380	ENSG00000226824.5	RP4-756H11.3	7.26	6.21e-12	1.47e-08	0.46	0.43	Aortic root size;	chr7:66615658	chr7:66654538~66669855:+
OV	cis	rs875971	0.825	rs1860472	ENSG00000226824.5	RP4-756H11.3	7.26	6.21e-12	1.47e-08	0.46	0.43	Aortic root size;	chr7:66617736	chr7:66654538~66669855:+
OV	cis	rs8105895	0.935	rs8110289	ENSG00000269742.1	BNIP3P29	7.26	6.25e-12	1.47e-08	0.71	0.43	Body mass index (change over time);	chr19:22056915	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs7252220	ENSG00000269742.1	BNIP3P29	7.26	6.25e-12	1.47e-08	0.71	0.43	Body mass index (change over time);	chr19:22062762	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs7252380	ENSG00000269742.1	BNIP3P29	7.26	6.25e-12	1.47e-08	0.71	0.43	Body mass index (change over time);	chr19:22062913	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs62110981	ENSG00000269742.1	BNIP3P29	7.26	6.25e-12	1.47e-08	0.71	0.43	Body mass index (change over time);	chr19:22063211	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs62110985	ENSG00000269742.1	BNIP3P29	7.26	6.25e-12	1.47e-08	0.71	0.43	Body mass index (change over time);	chr19:22073275	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs62110992	ENSG00000269742.1	BNIP3P29	7.26	6.25e-12	1.47e-08	0.71	0.43	Body mass index (change over time);	chr19:22078714	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs62111030	ENSG00000269742.1	BNIP3P29	7.26	6.25e-12	1.47e-08	0.71	0.43	Body mass index (change over time);	chr19:22096573	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs62111032	ENSG00000269742.1	BNIP3P29	7.26	6.25e-12	1.47e-08	0.71	0.43	Body mass index (change over time);	chr19:22098547	chr19:22065828~22066398:-
OV	cis	rs172166	0.694	rs203884	ENSG00000220721.1	OR1F12	7.26	6.26e-12	1.47e-08	0.47	0.43	Cardiac Troponin-T levels;	chr6:28109596	chr6:28073316~28074233:+
OV	cis	rs1707322	0.752	rs11211146	ENSG00000281133.1	AL355480.3	-7.26	6.29e-12	1.48e-08	-0.56	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr1:45580892~45580996:-
OV	cis	rs1707322	0.752	rs11211147	ENSG00000281133.1	AL355480.3	-7.26	6.29e-12	1.48e-08	-0.56	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr1:45580892~45580996:-
OV	cis	rs73086581	1	rs73086581	ENSG00000229539.1	RP11-119B16.2	7.25	6.3e-12	1.48e-08	0.56	0.43	Response to antidepressants in depression;	chr20:3996678	chr20:3888239~3888868:-
OV	cis	rs73086581	1	rs73088416	ENSG00000229539.1	RP11-119B16.2	7.25	6.3e-12	1.48e-08	0.56	0.43	Response to antidepressants in depression;	chr20:4014629	chr20:3888239~3888868:-
OV	cis	rs2408955	0.522	rs4760612	ENSG00000258273.1	RP11-370I10.4	7.25	6.31e-12	1.49e-08	0.52	0.43	Glycated hemoglobin levels;	chr12:48028073	chr12:48333755~48333901:-
OV	cis	rs2882667	0.66	rs6894907	ENSG00000253404.1	AC034243.1	7.25	6.32e-12	1.49e-08	0.51	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139106815	chr5:138744434~138753309:-
OV	cis	rs1707322	0.721	rs4660883	ENSG00000281133.1	AL355480.3	-7.25	6.34e-12	1.49e-08	-0.56	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr1:45580892~45580996:-
OV	cis	rs17711722	0.727	rs1880555	ENSG00000236529.1	RP13-254B10.1	7.25	6.36e-12	1.5e-08	0.45	0.43	Calcium levels;	chr7:65967580	chr7:65840212~65840596:+
OV	cis	rs875971	0.756	rs2901210	ENSG00000226824.5	RP4-756H11.3	7.25	6.38e-12	1.5e-08	0.46	0.43	Aortic root size;	chr7:66552518	chr7:66654538~66669855:+
OV	cis	rs7115242	0.92	rs6589574	ENSG00000254851.1	RP11-109L13.1	-7.25	6.4e-12	1.5e-08	-0.88	-0.43	Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;	chr11:116859922	chr11:117135528~117138582:+
OV	cis	rs7605378	0.528	rs281791	ENSG00000232732.8	AC073043.1	7.25	6.45e-12	1.52e-08	0.52	0.43	Osteoporosis;	chr2:199985679	chr2:199867396~199911159:-
OV	cis	rs7246967	0.673	rs34425596	ENSG00000269509.1	BNIP3P34	7.25	6.47e-12	1.52e-08	0.66	0.43	Bronchopulmonary dysplasia;	chr19:22716977	chr19:22773853~22774424:+
OV	cis	rs73086581	0.947	rs73084523	ENSG00000229539.1	RP11-119B16.2	7.25	6.53e-12	1.53e-08	0.55	0.43	Response to antidepressants in depression;	chr20:3894979	chr20:3888239~3888868:-
OV	cis	rs1707322	0.717	rs1135850	ENSG00000281133.1	AL355480.3	-7.25	6.54e-12	1.53e-08	-0.58	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45580892~45580996:-
OV	cis	rs1707322	0.655	rs3014240	ENSG00000281133.1	AL355480.3	7.25	6.54e-12	1.53e-08	0.58	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr1:45580892~45580996:-
OV	cis	rs1707322	0.686	rs3014235	ENSG00000281133.1	AL355480.3	7.25	6.54e-12	1.53e-08	0.58	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45580892~45580996:-
OV	cis	rs1707322	0.656	rs9429172	ENSG00000281133.1	AL355480.3	7.25	6.54e-12	1.53e-08	0.58	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr1:45580892~45580996:-
OV	cis	rs2117029	0.555	rs10783304	ENSG00000258017.1	RP11-386G11.10	-7.25	6.55e-12	1.54e-08	-0.54	-0.43	Intelligence (multi-trait analysis);	chr12:49106615	chr12:49127782~49147869:+
OV	cis	rs4423214	0.515	rs4944042	ENSG00000254682.1	RP11-660L16.2	7.25	6.56e-12	1.54e-08	0.52	0.43	Vitamin D levels;	chr11:71407742	chr11:71448674~71452157:+
OV	cis	rs7396835	0.8	rs6589572	ENSG00000254851.1	RP11-109L13.1	-7.25	6.6e-12	1.55e-08	-0.69	-0.43	Quantitative traits;	chr11:116810847	chr11:117135528~117138582:+
OV	cis	rs7396835	0.866	rs7927820	ENSG00000254851.1	RP11-109L13.1	-7.25	6.6e-12	1.55e-08	-0.69	-0.43	Quantitative traits;	chr11:116811440	chr11:117135528~117138582:+
OV	cis	rs2732480	0.577	rs2634681	ENSG00000258273.1	RP11-370I10.4	7.24	6.7e-12	1.57e-08	0.51	0.43	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48339301	chr12:48333755~48333901:-
OV	cis	rs6991838	0.584	rs14213	ENSG00000272010.1	CTD-3025N20.3	7.24	6.7e-12	1.57e-08	0.52	0.43	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65591850~65592472:-
OV	cis	rs8062405	1	rs62036617	ENSG00000259982.1	CDC37P1	7.24	6.71e-12	1.57e-08	0.54	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28700294~28701540:-
OV	cis	rs8062405	1	rs4788095	ENSG00000259982.1	CDC37P1	7.24	6.71e-12	1.57e-08	0.54	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28700294~28701540:-
OV	cis	rs8062405	0.964	rs72793809	ENSG00000259982.1	CDC37P1	7.24	6.71e-12	1.57e-08	0.54	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28700294~28701540:-
OV	cis	rs1707322	0.686	rs2991986	ENSG00000280836.1	AL355480.1	7.24	6.71e-12	1.57e-08	0.61	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615610	chr1:45581219~45581321:-
OV	cis	rs1707322	0.682	rs10890334	ENSG00000281133.1	AL355480.3	-7.24	6.73e-12	1.58e-08	-0.56	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr1:45580892~45580996:-
OV	cis	rs1707322	0.682	rs10890335	ENSG00000281133.1	AL355480.3	-7.24	6.73e-12	1.58e-08	-0.56	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr1:45580892~45580996:-
OV	cis	rs7246967	0.611	rs12978511	ENSG00000269509.1	BNIP3P34	7.24	6.76e-12	1.58e-08	0.67	0.43	Bronchopulmonary dysplasia;	chr19:22636414	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs12978964	ENSG00000269509.1	BNIP3P34	7.24	6.8e-12	1.59e-08	0.67	0.43	Bronchopulmonary dysplasia;	chr19:22636442	chr19:22773853~22774424:+
OV	cis	rs1707322	0.752	rs4660313	ENSG00000281133.1	AL355480.3	7.24	6.81e-12	1.59e-08	0.55	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45580892~45580996:-
OV	cis	rs11690935	0.959	rs6754817	ENSG00000228389.1	AC068039.4	7.24	6.82e-12	1.59e-08	0.5	0.43	Schizophrenia;	chr2:171806884	chr2:171773482~171775844:+
OV	cis	rs11690935	0.959	rs7572215	ENSG00000228389.1	AC068039.4	7.24	6.84e-12	1.6e-08	0.5	0.43	Schizophrenia;	chr2:171777718	chr2:171773482~171775844:+
OV	cis	rs875971	0.522	rs1617484	ENSG00000222364.1	RNU6-96P	-7.24	6.87e-12	1.61e-08	-0.44	-0.43	Aortic root size;	chr7:65998108	chr7:66395191~66395286:+
OV	cis	rs875971	0.522	rs781144	ENSG00000236529.1	RP13-254B10.1	7.24	6.92e-12	1.62e-08	0.45	0.43	Aortic root size;	chr7:65975357	chr7:65840212~65840596:+
OV	cis	rs7246967	0.866	rs438972	ENSG00000269509.1	BNIP3P34	7.24	6.97e-12	1.63e-08	0.63	0.43	Bronchopulmonary dysplasia;	chr19:22837025	chr19:22773853~22774424:+
OV	cis	rs7246967	0.604	rs12981846	ENSG00000269509.1	BNIP3P34	7.24	6.97e-12	1.63e-08	0.63	0.43	Bronchopulmonary dysplasia;	chr19:22838557	chr19:22773853~22774424:+
OV	cis	rs7246967	0.8	rs2362131	ENSG00000269509.1	BNIP3P34	7.24	6.97e-12	1.63e-08	0.63	0.43	Bronchopulmonary dysplasia;	chr19:22839634	chr19:22773853~22774424:+
OV	cis	rs2581828	0.896	rs12637287	ENSG00000242142.1	SERBP1P3	7.24	7.03e-12	1.64e-08	0.5	0.43	Crohn's disease;	chr3:53105425	chr3:53064283~53065091:-
OV	cis	rs2581828	0.931	rs2564942	ENSG00000242142.1	SERBP1P3	7.24	7.03e-12	1.64e-08	0.5	0.43	Crohn's disease;	chr3:53105490	chr3:53064283~53065091:-
OV	cis	rs2581828	0.931	rs2581774	ENSG00000242142.1	SERBP1P3	7.24	7.03e-12	1.64e-08	0.5	0.43	Crohn's disease;	chr3:53105491	chr3:53064283~53065091:-
OV	cis	rs7017914	0.967	rs1838393	ENSG00000223220.1	Y_RNA	7.24	7.03e-12	1.64e-08	0.45	0.43	Bone mineral density;	chr8:70790356	chr8:70780914~70781008:-
OV	cis	rs7017914	0.935	rs7826483	ENSG00000223220.1	Y_RNA	7.24	7.03e-12	1.64e-08	0.45	0.43	Bone mineral density;	chr8:70790658	chr8:70780914~70781008:-
OV	cis	rs1707322	0.721	rs7519900	ENSG00000281133.1	AL355480.3	-7.24	7.06e-12	1.65e-08	-0.57	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs10890346	ENSG00000281133.1	AL355480.3	7.23	7.18e-12	1.67e-08	0.56	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45580892~45580996:-
OV	cis	rs11168351	0.833	rs6580652	ENSG00000258273.1	RP11-370I10.4	7.23	7.19e-12	1.67e-08	0.52	0.43	Bipolar disorder and schizophrenia;	chr12:48053322	chr12:48333755~48333901:-
OV	cis	rs6921919	0.551	rs13201753	ENSG00000216901.1	AL022393.7	7.23	7.2e-12	1.67e-08	0.54	0.43	Autism spectrum disorder or schizophrenia;	chr6:28363351	chr6:28176188~28176674:+
OV	cis	rs4713118	0.629	rs203890	ENSG00000220721.1	OR1F12	7.23	7.2e-12	1.67e-08	0.5	0.43	Parkinson's disease;	chr6:28054470	chr6:28073316~28074233:+
OV	cis	rs3091242	0.933	rs35497030	ENSG00000261349.1	RP3-465N24.5	7.23	7.24e-12	1.68e-08	0.46	0.43	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25266102~25267136:-
OV	cis	rs1707322	0.716	rs6694889	ENSG00000281133.1	AL355480.3	-7.23	7.25e-12	1.69e-08	-0.56	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr1:45580892~45580996:-
OV	cis	rs1707322	0.682	rs12041197	ENSG00000281133.1	AL355480.3	-7.23	7.25e-12	1.69e-08	-0.56	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr1:45580892~45580996:-
OV	cis	rs1707322	0.717	rs12023439	ENSG00000281133.1	AL355480.3	-7.23	7.25e-12	1.69e-08	-0.56	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs6699418	ENSG00000280836.1	AL355480.1	-7.23	7.29e-12	1.69e-08	-0.59	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634509	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs4431884	ENSG00000280836.1	AL355480.1	-7.23	7.29e-12	1.69e-08	-0.59	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45635651	chr1:45581219~45581321:-
OV	cis	rs1707322	0.65	rs4660879	ENSG00000280836.1	AL355480.1	-7.23	7.29e-12	1.69e-08	-0.59	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45639729	chr1:45581219~45581321:-
OV	cis	rs875971	0.505	rs1723275	ENSG00000226824.5	RP4-756H11.3	7.23	7.29e-12	1.7e-08	0.46	0.43	Aortic root size;	chr7:66039646	chr7:66654538~66669855:+
OV	cis	rs8062405	1	rs3088215	ENSG00000259982.1	CDC37P1	7.23	7.31e-12	1.7e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28700294~28701540:-
OV	cis	rs8062405	1	rs28403629	ENSG00000259982.1	CDC37P1	7.23	7.31e-12	1.7e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28700294~28701540:-
OV	cis	rs8062405	1	rs61737565	ENSG00000259982.1	CDC37P1	7.23	7.31e-12	1.7e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28700294~28701540:-
OV	cis	rs8062405	1	rs4788099	ENSG00000259982.1	CDC37P1	7.23	7.31e-12	1.7e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28700294~28701540:-
OV	cis	rs8062405	1	rs9972693	ENSG00000259982.1	CDC37P1	7.23	7.31e-12	1.7e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28700294~28701540:-
OV	cis	rs8062405	0.964	rs9972768	ENSG00000259982.1	CDC37P1	7.23	7.31e-12	1.7e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28700294~28701540:-
OV	cis	rs8062405	0.965	rs62037363	ENSG00000259982.1	CDC37P1	7.23	7.31e-12	1.7e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28700294~28701540:-
OV	cis	rs8062405	1	rs7205323	ENSG00000259982.1	CDC37P1	7.23	7.31e-12	1.7e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28700294~28701540:-
OV	cis	rs8062405	1	rs4788101	ENSG00000259982.1	CDC37P1	7.23	7.31e-12	1.7e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28700294~28701540:-
OV	cis	rs8062405	1	rs62037364	ENSG00000259982.1	CDC37P1	7.23	7.31e-12	1.7e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28700294~28701540:-
OV	cis	rs8062405	1	rs62037365	ENSG00000259982.1	CDC37P1	7.23	7.31e-12	1.7e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28700294~28701540:-
OV	cis	rs8062405	0.929	rs11150609	ENSG00000259982.1	CDC37P1	7.23	7.31e-12	1.7e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28700294~28701540:-
OV	cis	rs8062405	0.737	rs11861132	ENSG00000259982.1	CDC37P1	7.23	7.31e-12	1.7e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28700294~28701540:-
OV	cis	rs8062405	1	rs11861174	ENSG00000259982.1	CDC37P1	7.23	7.31e-12	1.7e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28700294~28701540:-
OV	cis	rs8062405	1	rs4788102	ENSG00000259982.1	CDC37P1	7.23	7.31e-12	1.7e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28700294~28701540:-
OV	cis	rs8062405	1	rs62037367	ENSG00000259982.1	CDC37P1	7.23	7.31e-12	1.7e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28700294~28701540:-
OV	cis	rs8062405	1	rs7198606	ENSG00000259982.1	CDC37P1	7.23	7.31e-12	1.7e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28700294~28701540:-
OV	cis	rs8062405	0.929	rs11864750	ENSG00000259982.1	CDC37P1	7.23	7.31e-12	1.7e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28700294~28701540:-
OV	cis	rs8062405	0.964	rs7193733	ENSG00000259982.1	CDC37P1	7.23	7.31e-12	1.7e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28700294~28701540:-
OV	cis	rs8062405	1	rs8055982	ENSG00000259982.1	CDC37P1	7.23	7.31e-12	1.7e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28700294~28701540:-
OV	cis	rs8062405	1	rs7498665	ENSG00000259982.1	CDC37P1	7.23	7.31e-12	1.7e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28700294~28701540:-
OV	cis	rs8062405	0.964	rs11864107	ENSG00000259982.1	CDC37P1	7.23	7.31e-12	1.7e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28700294~28701540:-
OV	cis	rs950169	0.959	rs12911210	ENSG00000235370.6	DNM1P51	7.23	7.31e-12	1.7e-08	0.54	0.43	Schizophrenia;	chr15:84123331	chr15:84398316~84411701:-
OV	cis	rs6700559	0.683	rs4915450	ENSG00000260088.1	RP11-92G12.3	-7.23	7.38e-12	1.71e-08	-0.45	-0.43	Coronary artery disease;	chr1:200672461	chr1:200669507~200694250:+
OV	cis	rs6700559	1	rs10494821	ENSG00000260088.1	RP11-92G12.3	-7.23	7.38e-12	1.71e-08	-0.45	-0.43	Coronary artery disease;	chr1:200673357	chr1:200669507~200694250:+
OV	cis	rs6700559	1	rs6667172	ENSG00000260088.1	RP11-92G12.3	-7.23	7.38e-12	1.71e-08	-0.45	-0.43	Coronary artery disease;	chr1:200674710	chr1:200669507~200694250:+
OV	cis	rs1707322	0.656	rs3014210	ENSG00000281133.1	AL355480.3	7.23	7.4e-12	1.71e-08	0.55	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45580892~45580996:-
OV	cis	rs1707322	0.716	rs10890342	ENSG00000281133.1	AL355480.3	-7.23	7.41e-12	1.71e-08	-0.57	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr1:45580892~45580996:-
OV	cis	rs1707322	0.752	rs6658700	ENSG00000281133.1	AL355480.3	-7.23	7.41e-12	1.71e-08	-0.57	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr1:45580892~45580996:-
OV	cis	rs1707322	0.752	rs12047629	ENSG00000281133.1	AL355480.3	-7.23	7.41e-12	1.71e-08	-0.57	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr1:45580892~45580996:-
OV	cis	rs1707322	0.752	rs11211168	ENSG00000281133.1	AL355480.3	-7.23	7.41e-12	1.71e-08	-0.57	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr1:45580892~45580996:-
OV	cis	rs1707322	0.752	rs11211169	ENSG00000281133.1	AL355480.3	-7.23	7.41e-12	1.71e-08	-0.57	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr1:45580892~45580996:-
OV	cis	rs1707322	0.752	rs11211171	ENSG00000281133.1	AL355480.3	-7.23	7.41e-12	1.71e-08	-0.57	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr1:45580892~45580996:-
OV	cis	rs1707322	0.716	rs28370457	ENSG00000281133.1	AL355480.3	-7.23	7.41e-12	1.71e-08	-0.57	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr1:45580892~45580996:-
OV	cis	rs7615952	0.673	rs9821905	ENSG00000171084.14	FAM86JP	-7.23	7.44e-12	1.72e-08	-0.75	-0.43	Blood pressure (smoking interaction);	chr3:125902007	chr3:125916620~125930024:+
OV	cis	rs2712381	0.517	rs62273237	ENSG00000277250.1	Metazoa_SRP	-7.23	7.46e-12	1.72e-08	-0.49	-0.43	Monocyte count;	chr3:128591264	chr3:128673681~128674021:-
OV	cis	rs6700559	1	rs7527499	ENSG00000260088.1	RP11-92G12.3	-7.23	7.48e-12	1.73e-08	-0.45	-0.43	Coronary artery disease;	chr1:200676217	chr1:200669507~200694250:+
OV	cis	rs6700559	1	rs6427838	ENSG00000260088.1	RP11-92G12.3	-7.23	7.48e-12	1.73e-08	-0.45	-0.43	Coronary artery disease;	chr1:200676519	chr1:200669507~200694250:+
OV	cis	rs6700559	1	rs12061346	ENSG00000260088.1	RP11-92G12.3	-7.23	7.48e-12	1.73e-08	-0.45	-0.43	Coronary artery disease;	chr1:200677648	chr1:200669507~200694250:+
OV	cis	rs6700559	1	rs7533971	ENSG00000260088.1	RP11-92G12.3	-7.23	7.48e-12	1.73e-08	-0.45	-0.43	Coronary artery disease;	chr1:200678243	chr1:200669507~200694250:+
OV	cis	rs6700559	1	rs10919998	ENSG00000260088.1	RP11-92G12.3	-7.23	7.48e-12	1.73e-08	-0.45	-0.43	Coronary artery disease;	chr1:200679182	chr1:200669507~200694250:+
OV	cis	rs6700559	0.967	rs4072552	ENSG00000260088.1	RP11-92G12.3	-7.23	7.48e-12	1.73e-08	-0.45	-0.43	Coronary artery disease;	chr1:200680003	chr1:200669507~200694250:+
OV	cis	rs11159086	1	rs4903233	ENSG00000259005.1	RP3-449M8.6	7.23	7.52e-12	1.74e-08	0.7	0.43	Advanced glycation end-product levels;	chr14:74497291	chr14:74474007~74474864:-
OV	cis	rs1707322	0.721	rs11211181	ENSG00000281133.1	AL355480.3	-7.22	7.55e-12	1.74e-08	-0.54	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45580892~45580996:-
OV	cis	rs875971	0.862	rs778720	ENSG00000226824.5	RP4-756H11.3	7.22	7.56e-12	1.74e-08	0.44	0.43	Aortic root size;	chr7:66381288	chr7:66654538~66669855:+
OV	cis	rs7017914	0.935	rs56289931	ENSG00000223220.1	Y_RNA	7.22	7.58e-12	1.75e-08	0.45	0.43	Bone mineral density;	chr8:70925519	chr8:70780914~70781008:-
OV	cis	rs11690935	0.851	rs6433319	ENSG00000228389.1	AC068039.4	7.22	7.64e-12	1.76e-08	0.48	0.43	Schizophrenia;	chr2:171974442	chr2:171773482~171775844:+
OV	cis	rs1061377	0.76	rs7678457	ENSG00000249207.1	RP11-360F5.1	-7.22	7.65e-12	1.76e-08	-0.46	-0.43	Uric acid levels;	chr4:39136041	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs9996285	ENSG00000249207.1	RP11-360F5.1	-7.22	7.66e-12	1.77e-08	-0.46	-0.43	Uric acid levels;	chr4:39130556	chr4:39112677~39126818:-
OV	cis	rs1707322	0.721	rs10789468	ENSG00000281133.1	AL355480.3	-7.22	7.68e-12	1.77e-08	-0.55	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs6429574	ENSG00000281133.1	AL355480.3	-7.22	7.68e-12	1.77e-08	-0.55	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45580892~45580996:-
OV	cis	rs17711722	0.74	rs7809991	ENSG00000236529.1	RP13-254B10.1	7.22	7.7e-12	1.77e-08	0.44	0.43	Calcium levels;	chr7:65941231	chr7:65840212~65840596:+
OV	cis	rs875971	0.522	rs6960048	ENSG00000236529.1	RP13-254B10.1	7.22	7.7e-12	1.77e-08	0.44	0.43	Aortic root size;	chr7:65943052	chr7:65840212~65840596:+
OV	cis	rs875971	0.522	rs4718285	ENSG00000236529.1	RP13-254B10.1	7.22	7.73e-12	1.78e-08	0.44	0.43	Aortic root size;	chr7:65827018	chr7:65840212~65840596:+
OV	cis	rs875971	0.522	rs4718286	ENSG00000236529.1	RP13-254B10.1	7.22	7.73e-12	1.78e-08	0.44	0.43	Aortic root size;	chr7:65827777	chr7:65840212~65840596:+
OV	cis	rs875971	0.522	rs4502988	ENSG00000236529.1	RP13-254B10.1	7.22	7.73e-12	1.78e-08	0.44	0.43	Aortic root size;	chr7:65832759	chr7:65840212~65840596:+
OV	cis	rs17711722	0.585	rs6942660	ENSG00000236529.1	RP13-254B10.1	7.22	7.73e-12	1.78e-08	0.44	0.43	Calcium levels;	chr7:65837419	chr7:65840212~65840596:+
OV	cis	rs17711722	0.64	rs13237956	ENSG00000236529.1	RP13-254B10.1	7.22	7.73e-12	1.78e-08	0.44	0.43	Calcium levels;	chr7:65853042	chr7:65840212~65840596:+
OV	cis	rs875971	0.522	rs1880556	ENSG00000236529.1	RP13-254B10.1	7.22	7.74e-12	1.78e-08	0.45	0.43	Aortic root size;	chr7:65967557	chr7:65840212~65840596:+
OV	cis	rs1707322	0.682	rs3014241	ENSG00000281133.1	AL355480.3	7.22	7.78e-12	1.79e-08	0.58	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr1:45580892~45580996:-
OV	cis	rs6921919	0.583	rs9468368	ENSG00000216901.1	AL022393.7	7.22	7.84e-12	1.8e-08	0.51	0.43	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28176188~28176674:+
OV	cis	rs2153535	0.58	rs7743418	ENSG00000230939.1	RP11-314C16.1	-7.22	7.86e-12	1.81e-08	-0.49	-0.43	Motion sickness;	chr6:8437895	chr6:8784178~8785445:+
OV	cis	rs7569084	0.687	rs12993075	ENSG00000234255.7	AC012370.3	7.22	7.96e-12	1.83e-08	0.48	0.43	Sum eosinophil basophil counts;	chr2:65431010	chr2:65439888~65456571:-
OV	cis	rs853679	0.517	rs4713146	ENSG00000220721.1	OR1F12	7.21	8.03e-12	1.85e-08	0.51	0.43	Depression;	chr6:28143758	chr6:28073316~28074233:+
OV	cis	rs6700559	1	rs4311922	ENSG00000260088.1	RP11-92G12.3	-7.21	8.07e-12	1.85e-08	-0.45	-0.43	Coronary artery disease;	chr1:200674257	chr1:200669507~200694250:+
OV	cis	rs6700559	0.967	rs4447009	ENSG00000260088.1	RP11-92G12.3	-7.21	8.07e-12	1.85e-08	-0.45	-0.43	Coronary artery disease;	chr1:200674278	chr1:200669507~200694250:+
OV	cis	rs6700559	1	rs4265457	ENSG00000260088.1	RP11-92G12.3	-7.21	8.07e-12	1.85e-08	-0.45	-0.43	Coronary artery disease;	chr1:200674326	chr1:200669507~200694250:+
OV	cis	rs8062405	1	rs56404918	ENSG00000259982.1	CDC37P1	7.21	8.15e-12	1.87e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28700294~28701540:-
OV	cis	rs8062405	1	rs55719896	ENSG00000259982.1	CDC37P1	7.21	8.15e-12	1.87e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28700294~28701540:-
OV	cis	rs8062405	1	rs55830740	ENSG00000259982.1	CDC37P1	7.21	8.15e-12	1.87e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28700294~28701540:-
OV	cis	rs875971	0.516	rs6945322	ENSG00000236529.1	RP13-254B10.1	7.21	8.25e-12	1.89e-08	0.44	0.43	Aortic root size;	chr7:65871069	chr7:65840212~65840596:+
OV	cis	rs17711722	0.701	rs55773927	ENSG00000236529.1	RP13-254B10.1	7.21	8.25e-12	1.89e-08	0.44	0.43	Calcium levels;	chr7:65872915	chr7:65840212~65840596:+
OV	cis	rs17711722	0.727	rs35850374	ENSG00000236529.1	RP13-254B10.1	7.21	8.25e-12	1.89e-08	0.44	0.43	Calcium levels;	chr7:65892789	chr7:65840212~65840596:+
OV	cis	rs8062405	0.964	rs11860513	ENSG00000259982.1	CDC37P1	7.21	8.27e-12	1.9e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28700294~28701540:-
OV	cis	rs2153535	0.601	rs2143352	ENSG00000230939.1	RP11-314C16.1	-7.21	8.28e-12	1.9e-08	-0.5	-0.43	Motion sickness;	chr6:8530015	chr6:8784178~8785445:+
OV	cis	rs73086581	1	rs14047	ENSG00000229539.1	RP11-119B16.2	7.21	8.29e-12	1.9e-08	0.55	0.43	Response to antidepressants in depression;	chr20:3933568	chr20:3888239~3888868:-
OV	cis	rs875971	0.54	rs781152	ENSG00000236529.1	RP13-254B10.1	7.21	8.3e-12	1.9e-08	0.45	0.43	Aortic root size;	chr7:66014585	chr7:65840212~65840596:+
OV	cis	rs17711722	0.727	rs781151	ENSG00000236529.1	RP13-254B10.1	7.21	8.3e-12	1.9e-08	0.45	0.43	Calcium levels;	chr7:66014891	chr7:65840212~65840596:+
OV	cis	rs1707322	0.721	rs10789468	ENSG00000280836.1	AL355480.1	-7.21	8.31e-12	1.91e-08	-0.59	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658886	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs6429574	ENSG00000280836.1	AL355480.1	-7.21	8.31e-12	1.91e-08	-0.59	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668382	chr1:45581219~45581321:-
OV	cis	rs7017914	0.967	rs35207116	ENSG00000223220.1	Y_RNA	7.21	8.33e-12	1.91e-08	0.45	0.43	Bone mineral density;	chr8:70796736	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs62508819	ENSG00000223220.1	Y_RNA	7.21	8.33e-12	1.91e-08	0.45	0.43	Bone mineral density;	chr8:70805871	chr8:70780914~70781008:-
OV	cis	rs17711722	0.701	rs4467826	ENSG00000236529.1	RP13-254B10.1	7.21	8.4e-12	1.92e-08	0.44	0.43	Calcium levels;	chr7:65903721	chr7:65840212~65840596:+
OV	cis	rs7017914	0.967	rs17689955	ENSG00000223220.1	Y_RNA	7.21	8.4e-12	1.92e-08	0.45	0.43	Bone mineral density;	chr8:70936629	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs13255735	ENSG00000223220.1	Y_RNA	7.21	8.4e-12	1.92e-08	0.45	0.43	Bone mineral density;	chr8:70947504	chr8:70780914~70781008:-
OV	cis	rs8062405	0.964	rs78613234	ENSG00000259982.1	CDC37P1	7.21	8.41e-12	1.92e-08	0.52	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28700294~28701540:-
OV	cis	rs8062405	1	rs62036624	ENSG00000259982.1	CDC37P1	7.21	8.41e-12	1.92e-08	0.52	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28700294~28701540:-
OV	cis	rs8062405	1	rs55991577	ENSG00000259982.1	CDC37P1	7.21	8.41e-12	1.92e-08	0.52	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28700294~28701540:-
OV	cis	rs8062405	1	rs56358680	ENSG00000259982.1	CDC37P1	7.21	8.41e-12	1.92e-08	0.52	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28700294~28701540:-
OV	cis	rs8062405	1	rs62036626	ENSG00000259982.1	CDC37P1	7.21	8.41e-12	1.92e-08	0.52	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28700294~28701540:-
OV	cis	rs8062405	1	rs62036657	ENSG00000259982.1	CDC37P1	7.21	8.41e-12	1.92e-08	0.52	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28700294~28701540:-
OV	cis	rs8062405	1	rs12444171	ENSG00000259982.1	CDC37P1	7.21	8.41e-12	1.92e-08	0.52	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28700294~28701540:-
OV	cis	rs1707322	0.752	rs4586014	ENSG00000281133.1	AL355480.3	-7.21	8.43e-12	1.93e-08	-0.57	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr1:45580892~45580996:-
OV	cis	rs1707322	0.648	rs4439382	ENSG00000281133.1	AL355480.3	-7.21	8.43e-12	1.93e-08	-0.57	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr1:45580892~45580996:-
OV	cis	rs1707322	0.627	rs3014213	ENSG00000281133.1	AL355480.3	7.21	8.46e-12	1.93e-08	0.57	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45580892~45580996:-
OV	cis	rs1707322	0.686	rs2152078	ENSG00000281133.1	AL355480.3	7.21	8.46e-12	1.93e-08	0.57	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45580892~45580996:-
OV	cis	rs1707322	0.686	rs2991979	ENSG00000281133.1	AL355480.3	7.21	8.46e-12	1.93e-08	0.57	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45580892~45580996:-
OV	cis	rs2153535	0.58	rs6921036	ENSG00000230939.1	RP11-314C16.1	-7.2	8.49e-12	1.94e-08	-0.49	-0.43	Motion sickness;	chr6:8455167	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs6926759	ENSG00000230939.1	RP11-314C16.1	-7.2	8.49e-12	1.94e-08	-0.49	-0.43	Motion sickness;	chr6:8455943	chr6:8784178~8785445:+
OV	cis	rs3931020	0.772	rs11485555	ENSG00000272864.1	RP11-17E13.2	-7.2	8.5e-12	1.94e-08	-0.56	-0.43	Resistin levels;	chr1:74720825	chr1:74698769~74699333:-
OV	cis	rs3931020	0.679	rs28671241	ENSG00000272864.1	RP11-17E13.2	-7.2	8.56e-12	1.96e-08	-0.57	-0.43	Resistin levels;	chr1:74716197	chr1:74698769~74699333:-
OV	cis	rs1707322	0.752	rs28623463	ENSG00000281133.1	AL355480.3	-7.2	8.58e-12	1.96e-08	-0.57	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr1:45580892~45580996:-
OV	cis	rs73086581	0.838	rs41398349	ENSG00000229539.1	RP11-119B16.2	-7.2	8.59e-12	1.96e-08	-0.53	-0.43	Response to antidepressants in depression;	chr20:4043792	chr20:3888239~3888868:-
OV	cis	rs1707322	0.963	rs34907901	ENSG00000281133.1	AL355480.3	-7.2	8.62e-12	1.97e-08	-0.55	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45939542	chr1:45580892~45580996:-
OV	cis	rs875971	0.505	rs2462573	ENSG00000226824.5	RP4-756H11.3	7.2	8.66e-12	1.97e-08	0.45	0.43	Aortic root size;	chr7:66042405	chr7:66654538~66669855:+
OV	cis	rs875971	0.505	rs1167386	ENSG00000226824.5	RP4-756H11.3	7.2	8.66e-12	1.97e-08	0.45	0.43	Aortic root size;	chr7:66048109	chr7:66654538~66669855:+
OV	cis	rs875971	0.505	rs1167385	ENSG00000226824.5	RP4-756H11.3	7.2	8.66e-12	1.97e-08	0.45	0.43	Aortic root size;	chr7:66048321	chr7:66654538~66669855:+
OV	cis	rs10256972	0.616	rs6463001	ENSG00000229043.2	AC091729.9	-7.2	8.66e-12	1.97e-08	-0.48	-0.43	Endometriosis;Longevity;	chr7:1068636	chr7:1160374~1165267:+
OV	cis	rs4423214	0.559	rs10898201	ENSG00000254682.1	RP11-660L16.2	-7.2	8.74e-12	1.99e-08	-0.62	-0.43	Vitamin D levels;	chr11:71490481	chr11:71448674~71452157:+
OV	cis	rs997154	0.655	rs7147394	ENSG00000279656.1	RP11-298I3.6	7.2	8.78e-12	2e-08	0.56	0.43	Primary tooth development (time to first tooth eruption);Primary tooth development (number of teeth);	chr14:22941845	chr14:23023083~23024217:-
OV	cis	rs8062405	0.965	rs56040780	ENSG00000259982.1	CDC37P1	7.2	8.82e-12	2.01e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28700294~28701540:-
OV	cis	rs7246967	0.673	rs7247191	ENSG00000269509.1	BNIP3P34	7.2	8.87e-12	2.02e-08	0.66	0.43	Bronchopulmonary dysplasia;	chr19:22716783	chr19:22773853~22774424:+
OV	cis	rs2153535	0.542	rs915354	ENSG00000230939.1	RP11-314C16.1	-7.2	9e-12	2.05e-08	-0.49	-0.43	Motion sickness;	chr6:8440124	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs5001130	ENSG00000230939.1	RP11-314C16.1	-7.2	9e-12	2.05e-08	-0.49	-0.43	Motion sickness;	chr6:8442065	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs2327057	ENSG00000230939.1	RP11-314C16.1	-7.2	9e-12	2.05e-08	-0.49	-0.43	Motion sickness;	chr6:8443086	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1577466	ENSG00000230939.1	RP11-314C16.1	-7.2	9e-12	2.05e-08	-0.49	-0.43	Motion sickness;	chr6:8443959	chr6:8784178~8785445:+
OV	cis	rs875971	0.54	rs736270	ENSG00000226824.5	RP4-756H11.3	-7.19	9.03e-12	2.05e-08	-0.46	-0.43	Aortic root size;	chr7:65963835	chr7:66654538~66669855:+
OV	cis	rs875971	0.54	rs1723268	ENSG00000222364.1	RNU6-96P	-7.19	9.05e-12	2.06e-08	-0.44	-0.43	Aortic root size;	chr7:66008093	chr7:66395191~66395286:+
OV	cis	rs2153535	0.58	rs6914276	ENSG00000230939.1	RP11-314C16.1	7.19	9.08e-12	2.07e-08	0.5	0.43	Motion sickness;	chr6:8450202	chr6:8784178~8785445:+
OV	cis	rs801193	0.548	rs6975044	ENSG00000226824.5	RP4-756H11.3	-7.19	9.11e-12	2.07e-08	-0.45	-0.43	Aortic root size;	chr7:66762495	chr7:66654538~66669855:+
OV	cis	rs7017914	0.934	rs1389202	ENSG00000223220.1	Y_RNA	7.19	9.13e-12	2.08e-08	0.45	0.43	Bone mineral density;	chr8:70940050	chr8:70780914~70781008:-
OV	cis	rs6908034	0.654	rs6456272	ENSG00000228412.5	RP4-625H18.2	-7.19	9.14e-12	2.08e-08	-0.67	-0.43	Endometriosis;Deep ovarian and/or rectovaginal disease with dense adhesions;	chr6:19804805	chr6:19802164~19804752:-
OV	cis	rs4591358	0.648	rs16836855	ENSG00000223466.1	AC064834.2	-7.19	9.2e-12	2.09e-08	-0.62	-0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195522267	chr2:195533035~195538681:+
OV	cis	rs1707322	0.686	rs2991977	ENSG00000280836.1	AL355480.1	7.19	9.31e-12	2.11e-08	0.61	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45581219~45581321:-
OV	cis	rs1707322	0.656	rs2991981	ENSG00000280836.1	AL355480.1	7.19	9.31e-12	2.11e-08	0.61	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45581219~45581321:-
OV	cis	rs2153535	0.58	rs2327051	ENSG00000230939.1	RP11-314C16.1	7.19	9.42e-12	2.14e-08	0.49	0.43	Motion sickness;	chr6:8440917	chr6:8784178~8785445:+
OV	cis	rs8062405	1	rs1987472	ENSG00000259982.1	CDC37P1	7.19	9.45e-12	2.14e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28700294~28701540:-
OV	cis	rs8062405	0.895	rs56186137	ENSG00000259982.1	CDC37P1	7.19	9.45e-12	2.14e-08	0.53	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28700294~28701540:-
OV	cis	rs7569084	0.687	rs11126038	ENSG00000234255.7	AC012370.3	7.19	9.51e-12	2.16e-08	0.48	0.43	Sum eosinophil basophil counts;	chr2:65436100	chr2:65439888~65456571:-
OV	cis	rs2408955	0.522	rs4760679	ENSG00000258273.1	RP11-370I10.4	7.18	9.6e-12	2.17e-08	0.51	0.43	Glycated hemoglobin levels;	chr12:48067852	chr12:48333755~48333901:-
OV	cis	rs73086581	1	rs73084594	ENSG00000229539.1	RP11-119B16.2	7.18	9.69e-12	2.19e-08	0.55	0.43	Response to antidepressants in depression;	chr20:3935733	chr20:3888239~3888868:-
OV	cis	rs2980439	0.87	rs2945230	ENSG00000253981.4	ALG1L13P	7.18	9.71e-12	2.2e-08	0.42	0.43	Neuroticism;	chr8:8252414	chr8:8236003~8244667:-
OV	cis	rs2408955	0.522	rs6580650	ENSG00000258273.1	RP11-370I10.4	7.18	9.71e-12	2.2e-08	0.52	0.43	Glycated hemoglobin levels;	chr12:48024773	chr12:48333755~48333901:-
OV	cis	rs17608059	1	rs17608059	ENSG00000141028.6	CDRT15P1	-7.18	9.73e-12	2.2e-08	-0.53	-0.43	Temperament;	chr17:14007232	chr17:14024514~14025488:+
OV	cis	rs492146	0.765	rs367836	ENSG00000243236.5	GSTA9P	-7.18	9.75e-12	2.21e-08	-0.51	-0.43	Epilepsy (remission after treatment);	chr6:52978333	chr6:52939726~52957521:-
OV	cis	rs2564921	0.73	rs930122	ENSG00000242142.1	SERBP1P3	7.18	9.83e-12	2.22e-08	0.49	0.43	Height;	chr3:53085313	chr3:53064283~53065091:-
OV	cis	rs4591358	0.689	rs16837051	ENSG00000223466.1	AC064834.2	-7.18	9.87e-12	2.23e-08	-0.64	-0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195536281	chr2:195533035~195538681:+
OV	cis	rs7017914	0.902	rs7831792	ENSG00000223220.1	Y_RNA	7.18	9.88e-12	2.23e-08	0.46	0.43	Bone mineral density;	chr8:70653121	chr8:70780914~70781008:-
OV	cis	rs7017914	0.934	rs13255886	ENSG00000223220.1	Y_RNA	7.18	9.88e-12	2.23e-08	0.46	0.43	Bone mineral density;	chr8:70653719	chr8:70780914~70781008:-
OV	cis	rs7017914	0.902	rs34882924	ENSG00000223220.1	Y_RNA	7.18	9.88e-12	2.23e-08	0.46	0.43	Bone mineral density;	chr8:70654073	chr8:70780914~70781008:-
OV	cis	rs150992	0.861	rs467728	ENSG00000248489.1	CTD-2007H13.3	7.18	9.93e-12	2.25e-08	0.52	0.43	Body mass index;	chr5:98953863	chr5:98929171~98995013:+
OV	cis	rs73086581	1	rs17214949	ENSG00000229539.1	RP11-119B16.2	7.18	1e-11	2.26e-08	0.55	0.43	Response to antidepressants in depression;	chr20:3960305	chr20:3888239~3888868:-
OV	cis	rs73086581	1	rs17215054	ENSG00000229539.1	RP11-119B16.2	7.18	1e-11	2.26e-08	0.55	0.43	Response to antidepressants in depression;	chr20:3964132	chr20:3888239~3888868:-
OV	cis	rs73086581	1	rs17287486	ENSG00000229539.1	RP11-119B16.2	7.18	1e-11	2.26e-08	0.55	0.43	Response to antidepressants in depression;	chr20:3965620	chr20:3888239~3888868:-
OV	cis	rs73086581	1	rs73086540	ENSG00000229539.1	RP11-119B16.2	7.18	1e-11	2.26e-08	0.55	0.43	Response to antidepressants in depression;	chr20:3970203	chr20:3888239~3888868:-
OV	cis	rs73086581	1	rs73086544	ENSG00000229539.1	RP11-119B16.2	7.18	1e-11	2.26e-08	0.55	0.43	Response to antidepressants in depression;	chr20:3970281	chr20:3888239~3888868:-
OV	cis	rs73086581	1	rs2326289	ENSG00000229539.1	RP11-119B16.2	7.18	1e-11	2.26e-08	0.55	0.43	Response to antidepressants in depression;	chr20:3971653	chr20:3888239~3888868:-
OV	cis	rs73086581	1	rs73086549	ENSG00000229539.1	RP11-119B16.2	7.18	1e-11	2.26e-08	0.55	0.43	Response to antidepressants in depression;	chr20:3974015	chr20:3888239~3888868:-
OV	cis	rs73086581	1	rs113812453	ENSG00000229539.1	RP11-119B16.2	7.18	1e-11	2.26e-08	0.55	0.43	Response to antidepressants in depression;	chr20:3982546	chr20:3888239~3888868:-
OV	cis	rs73086581	0.947	rs17287577	ENSG00000229539.1	RP11-119B16.2	7.18	1e-11	2.26e-08	0.55	0.43	Response to antidepressants in depression;	chr20:3985607	chr20:3888239~3888868:-
OV	cis	rs16828019	0.852	rs71648534	ENSG00000235358.1	RP11-399E6.1	7.18	1e-11	2.26e-08	0.83	0.43	Intelligence (multi-trait analysis);	chr1:41148075	chr1:41242373~41284861:+
OV	cis	rs16828019	0.852	rs71648535	ENSG00000235358.1	RP11-399E6.1	7.18	1e-11	2.26e-08	0.83	0.43	Intelligence (multi-trait analysis);	chr1:41148078	chr1:41242373~41284861:+
OV	cis	rs2153535	0.563	rs1737586	ENSG00000230939.1	RP11-314C16.1	-7.18	1e-11	2.26e-08	-0.48	-0.43	Motion sickness;	chr6:8535664	chr6:8784178~8785445:+
OV	cis	rs4713118	0.516	rs6931858	ENSG00000220721.1	OR1F12	7.18	1.01e-11	2.27e-08	0.51	0.43	Parkinson's disease;	chr6:28110633	chr6:28073316~28074233:+
OV	cis	rs11723261	0.582	rs61792238	ENSG00000275426.1	CH17-262A2.1	7.18	1.01e-11	2.27e-08	0.71	0.43	Immune response to smallpox vaccine (IL-6);	chr4:112398	chr4:149738~150317:+
OV	cis	rs2153535	0.58	rs7745043	ENSG00000230939.1	RP11-314C16.1	-7.18	1.01e-11	2.28e-08	-0.48	-0.43	Motion sickness;	chr6:8513274	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9406170	ENSG00000230939.1	RP11-314C16.1	-7.18	1.01e-11	2.28e-08	-0.48	-0.43	Motion sickness;	chr6:8513920	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9379222	ENSG00000230939.1	RP11-314C16.1	-7.18	1.01e-11	2.28e-08	-0.48	-0.43	Motion sickness;	chr6:8514555	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9406172	ENSG00000230939.1	RP11-314C16.1	-7.18	1.01e-11	2.28e-08	-0.48	-0.43	Motion sickness;	chr6:8515231	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9406174	ENSG00000230939.1	RP11-314C16.1	-7.18	1.01e-11	2.28e-08	-0.48	-0.43	Motion sickness;	chr6:8516531	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs2143356	ENSG00000230939.1	RP11-314C16.1	-7.18	1.01e-11	2.28e-08	-0.48	-0.43	Motion sickness;	chr6:8517442	chr6:8784178~8785445:+
OV	cis	rs2836950	0.762	rs8134638	ENSG00000232608.1	TIMM9P2	7.17	1.02e-11	2.3e-08	0.53	0.43	Menarche (age at onset);	chr21:39272244	chr21:39216624~39217506:+
OV	cis	rs7017914	0.934	rs6987313	ENSG00000223220.1	Y_RNA	7.17	1.03e-11	2.31e-08	0.46	0.43	Bone mineral density;	chr8:70658754	chr8:70780914~70781008:-
OV	cis	rs7017914	0.902	rs35580034	ENSG00000223220.1	Y_RNA	7.17	1.03e-11	2.31e-08	0.46	0.43	Bone mineral density;	chr8:70659838	chr8:70780914~70781008:-
OV	cis	rs7017914	0.934	rs17760050	ENSG00000223220.1	Y_RNA	7.17	1.03e-11	2.31e-08	0.46	0.43	Bone mineral density;	chr8:70662016	chr8:70780914~70781008:-
OV	cis	rs7017914	0.934	rs35214141	ENSG00000223220.1	Y_RNA	7.17	1.03e-11	2.31e-08	0.46	0.43	Bone mineral density;	chr8:70662329	chr8:70780914~70781008:-
OV	cis	rs11690935	0.851	rs7573003	ENSG00000228389.1	AC068039.4	7.17	1.03e-11	2.32e-08	0.49	0.43	Schizophrenia;	chr2:171884905	chr2:171773482~171775844:+
OV	cis	rs7017914	1	rs13253842	ENSG00000223220.1	Y_RNA	7.17	1.04e-11	2.34e-08	0.45	0.43	Bone mineral density;	chr8:70713268	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs13254908	ENSG00000223220.1	Y_RNA	7.17	1.04e-11	2.34e-08	0.45	0.43	Bone mineral density;	chr8:70713863	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs13264669	ENSG00000223220.1	Y_RNA	7.17	1.04e-11	2.34e-08	0.45	0.43	Bone mineral density;	chr8:70714537	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs34508469	ENSG00000223220.1	Y_RNA	7.17	1.04e-11	2.34e-08	0.45	0.43	Bone mineral density;	chr8:70716228	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs6472539	ENSG00000223220.1	Y_RNA	7.17	1.04e-11	2.34e-08	0.45	0.43	Bone mineral density;	chr8:70717575	chr8:70780914~70781008:-
OV	cis	rs7017914	0.934	rs56043721	ENSG00000223220.1	Y_RNA	7.17	1.04e-11	2.34e-08	0.45	0.43	Bone mineral density;	chr8:70718192	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs3954897	ENSG00000223220.1	Y_RNA	7.17	1.04e-11	2.34e-08	0.45	0.43	Bone mineral density;	chr8:70723720	chr8:70780914~70781008:-
OV	cis	rs7017914	0.935	rs6981435	ENSG00000223220.1	Y_RNA	7.17	1.04e-11	2.34e-08	0.45	0.43	Bone mineral density;	chr8:70724913	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs6999739	ENSG00000223220.1	Y_RNA	7.17	1.04e-11	2.34e-08	0.45	0.43	Bone mineral density;	chr8:70724977	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs7013657	ENSG00000223220.1	Y_RNA	7.17	1.04e-11	2.34e-08	0.45	0.43	Bone mineral density;	chr8:70725324	chr8:70780914~70781008:-
OV	cis	rs7017914	0.934	rs7006615	ENSG00000223220.1	Y_RNA	7.17	1.04e-11	2.34e-08	0.45	0.43	Bone mineral density;	chr8:70727572	chr8:70780914~70781008:-
OV	cis	rs7017914	1	rs7007450	ENSG00000223220.1	Y_RNA	7.17	1.04e-11	2.34e-08	0.45	0.43	Bone mineral density;	chr8:70728034	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs11989553	ENSG00000223220.1	Y_RNA	7.17	1.04e-11	2.34e-08	0.45	0.43	Bone mineral density;	chr8:70728664	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs13272523	ENSG00000223220.1	Y_RNA	7.17	1.04e-11	2.34e-08	0.45	0.43	Bone mineral density;	chr8:70729237	chr8:70780914~70781008:-
OV	cis	rs7017914	0.934	rs62530826	ENSG00000223220.1	Y_RNA	7.17	1.04e-11	2.34e-08	0.45	0.43	Bone mineral density;	chr8:70729408	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs35295900	ENSG00000223220.1	Y_RNA	7.17	1.04e-11	2.34e-08	0.45	0.43	Bone mineral density;	chr8:70729826	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs35115527	ENSG00000223220.1	Y_RNA	7.17	1.04e-11	2.34e-08	0.45	0.43	Bone mineral density;	chr8:70730774	chr8:70780914~70781008:-
OV	cis	rs7017914	0.902	rs11991273	ENSG00000223220.1	Y_RNA	7.17	1.04e-11	2.34e-08	0.45	0.43	Bone mineral density;	chr8:70733625	chr8:70780914~70781008:-
OV	cis	rs7017914	0.869	rs11987511	ENSG00000223220.1	Y_RNA	7.17	1.04e-11	2.34e-08	0.45	0.43	Bone mineral density;	chr8:70733636	chr8:70780914~70781008:-
OV	cis	rs7017914	0.934	rs7015035	ENSG00000223220.1	Y_RNA	7.17	1.04e-11	2.34e-08	0.45	0.43	Bone mineral density;	chr8:70741366	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs6982406	ENSG00000223220.1	Y_RNA	7.17	1.04e-11	2.34e-08	0.45	0.43	Bone mineral density;	chr8:70742373	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs1902614	ENSG00000223220.1	Y_RNA	7.17	1.04e-11	2.34e-08	0.45	0.43	Bone mineral density;	chr8:70743932	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs34905858	ENSG00000223220.1	Y_RNA	7.17	1.04e-11	2.34e-08	0.45	0.43	Bone mineral density;	chr8:70747215	chr8:70780914~70781008:-
OV	cis	rs7017914	0.934	rs6998024	ENSG00000223220.1	Y_RNA	7.17	1.04e-11	2.34e-08	0.45	0.43	Bone mineral density;	chr8:70748605	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs35960437	ENSG00000223220.1	Y_RNA	7.17	1.04e-11	2.35e-08	0.45	0.43	Bone mineral density;	chr8:70749725	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs34409123	ENSG00000223220.1	Y_RNA	7.17	1.04e-11	2.35e-08	0.45	0.43	Bone mineral density;	chr8:70749881	chr8:70780914~70781008:-
OV	cis	rs11723261	0.621	rs11721745	ENSG00000275426.1	CH17-262A2.1	7.17	1.05e-11	2.35e-08	0.71	0.43	Immune response to smallpox vaccine (IL-6);	chr4:115052	chr4:149738~150317:+
OV	cis	rs4713118	0.662	rs149961	ENSG00000220721.1	OR1F12	7.17	1.05e-11	2.35e-08	0.51	0.43	Parkinson's disease;	chr6:28047791	chr6:28073316~28074233:+
OV	cis	rs875971	0.54	rs35510581	ENSG00000236529.1	RP13-254B10.1	-7.17	1.06e-11	2.37e-08	-0.44	-0.43	Aortic root size;	chr7:66113790	chr7:65840212~65840596:+
OV	cis	rs9326248	0.581	rs4938331	ENSG00000254851.1	RP11-109L13.1	-7.17	1.06e-11	2.37e-08	-0.5	-0.43	Blood protein levels;	chr11:117059966	chr11:117135528~117138582:+
OV	cis	rs9326248	0.51	rs4938332	ENSG00000254851.1	RP11-109L13.1	-7.17	1.06e-11	2.37e-08	-0.5	-0.43	Blood protein levels;	chr11:117060082	chr11:117135528~117138582:+
OV	cis	rs9326248	0.559	rs4938334	ENSG00000254851.1	RP11-109L13.1	-7.17	1.06e-11	2.37e-08	-0.5	-0.43	Blood protein levels;	chr11:117060326	chr11:117135528~117138582:+
OV	cis	rs9326248	0.581	rs6589590	ENSG00000254851.1	RP11-109L13.1	-7.17	1.06e-11	2.37e-08	-0.5	-0.43	Blood protein levels;	chr11:117065365	chr11:117135528~117138582:+
OV	cis	rs2153535	0.58	rs6421949	ENSG00000230939.1	RP11-314C16.1	-7.17	1.06e-11	2.37e-08	-0.49	-0.43	Motion sickness;	chr6:8531536	chr6:8784178~8785445:+
OV	cis	rs73086581	1	rs73086535	ENSG00000229539.1	RP11-119B16.2	7.17	1.06e-11	2.38e-08	0.55	0.43	Response to antidepressants in depression;	chr20:3963503	chr20:3888239~3888868:-
OV	cis	rs73086581	0.947	rs55794220	ENSG00000229539.1	RP11-119B16.2	7.17	1.06e-11	2.38e-08	0.55	0.43	Response to antidepressants in depression;	chr20:3975755	chr20:3888239~3888868:-
OV	cis	rs73086581	0.891	rs55871214	ENSG00000229539.1	RP11-119B16.2	7.17	1.06e-11	2.38e-08	0.55	0.43	Response to antidepressants in depression;	chr20:3985059	chr20:3888239~3888868:-
OV	cis	rs73086581	1	rs56069856	ENSG00000229539.1	RP11-119B16.2	7.17	1.06e-11	2.38e-08	0.55	0.43	Response to antidepressants in depression;	chr20:3985062	chr20:3888239~3888868:-
OV	cis	rs7017914	0.811	rs4272413	ENSG00000223220.1	Y_RNA	7.17	1.07e-11	2.39e-08	0.45	0.43	Bone mineral density;	chr8:70723952	chr8:70780914~70781008:-
OV	cis	rs7017914	0.934	rs10504479	ENSG00000223220.1	Y_RNA	7.17	1.07e-11	2.4e-08	0.46	0.43	Bone mineral density;	chr8:70665280	chr8:70780914~70781008:-
OV	cis	rs7017914	0.934	rs35109143	ENSG00000223220.1	Y_RNA	7.17	1.07e-11	2.4e-08	0.46	0.43	Bone mineral density;	chr8:70665665	chr8:70780914~70781008:-
OV	cis	rs7017914	0.902	rs13269513	ENSG00000223220.1	Y_RNA	7.17	1.07e-11	2.4e-08	0.46	0.43	Bone mineral density;	chr8:70665844	chr8:70780914~70781008:-
OV	cis	rs1707322	0.752	rs28550303	ENSG00000281133.1	AL355480.3	-7.17	1.07e-11	2.41e-08	-0.57	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr1:45580892~45580996:-
OV	cis	rs16828019	0.852	rs71648536	ENSG00000235358.1	RP11-399E6.1	7.17	1.08e-11	2.41e-08	0.83	0.43	Intelligence (multi-trait analysis);	chr1:41166336	chr1:41242373~41284861:+
OV	cis	rs494459	0.838	rs607125	ENSG00000255239.1	AP002954.6	7.17	1.08e-11	2.41e-08	0.5	0.43	Height;	chr11:118746590	chr11:118688039~118690600:-
OV	cis	rs7017914	0.967	rs6991329	ENSG00000223220.1	Y_RNA	7.17	1.08e-11	2.41e-08	0.46	0.43	Bone mineral density;	chr8:70681190	chr8:70780914~70781008:-
OV	cis	rs1707322	0.964	rs6675259	ENSG00000281133.1	AL355480.3	7.16	1.08e-11	2.42e-08	0.55	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46036623	chr1:45580892~45580996:-
OV	cis	rs7017914	0.967	rs4628281	ENSG00000223220.1	Y_RNA	7.16	1.08e-11	2.42e-08	0.45	0.43	Bone mineral density;	chr8:70926929	chr8:70780914~70781008:-
OV	cis	rs6991838	0.584	rs4737221	ENSG00000272010.1	CTD-3025N20.3	-7.16	1.09e-11	2.43e-08	-0.53	-0.43	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65591850~65592472:-
OV	cis	rs4713118	0.662	rs149947	ENSG00000220721.1	OR1F12	7.16	1.09e-11	2.43e-08	0.51	0.43	Parkinson's disease;	chr6:28004655	chr6:28073316~28074233:+
OV	cis	rs1707322	0.752	rs28890893	ENSG00000281133.1	AL355480.3	-7.16	1.09e-11	2.43e-08	-0.56	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr1:45580892~45580996:-
OV	cis	rs1707322	0.716	rs28375469	ENSG00000281133.1	AL355480.3	-7.16	1.09e-11	2.43e-08	-0.56	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr1:45580892~45580996:-
OV	cis	rs1707322	0.752	rs28545085	ENSG00000281133.1	AL355480.3	-7.16	1.09e-11	2.43e-08	-0.56	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr1:45580892~45580996:-
OV	cis	rs1707322	0.752	rs28719889	ENSG00000281133.1	AL355480.3	-7.16	1.09e-11	2.43e-08	-0.56	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr1:45580892~45580996:-
OV	cis	rs1707322	0.752	rs28812624	ENSG00000281133.1	AL355480.3	-7.16	1.09e-11	2.43e-08	-0.56	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr1:45580892~45580996:-
OV	cis	rs1707322	0.752	rs28507722	ENSG00000281133.1	AL355480.3	-7.16	1.09e-11	2.43e-08	-0.56	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr1:45580892~45580996:-
OV	cis	rs1707322	0.752	rs28568986	ENSG00000281133.1	AL355480.3	-7.16	1.09e-11	2.43e-08	-0.56	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr1:45580892~45580996:-
OV	cis	rs1707322	0.717	rs28396194	ENSG00000281133.1	AL355480.3	-7.16	1.09e-11	2.43e-08	-0.56	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr1:45580892~45580996:-
OV	cis	rs1707322	0.717	rs28752166	ENSG00000281133.1	AL355480.3	-7.16	1.09e-11	2.43e-08	-0.56	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr1:45580892~45580996:-
OV	cis	rs1707322	0.717	rs10890345	ENSG00000281133.1	AL355480.3	-7.16	1.09e-11	2.43e-08	-0.56	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs10789471	ENSG00000281133.1	AL355480.3	-7.16	1.09e-11	2.43e-08	-0.56	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr1:45580892~45580996:-
OV	cis	rs1707322	0.752	rs11211173	ENSG00000281133.1	AL355480.3	-7.16	1.09e-11	2.43e-08	-0.56	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr1:45580892~45580996:-
OV	cis	rs1707322	0.691	rs61784799	ENSG00000281133.1	AL355480.3	7.16	1.09e-11	2.43e-08	0.56	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr1:45580892~45580996:-
OV	cis	rs6991838	0.584	rs4275254	ENSG00000272010.1	CTD-3025N20.3	-7.16	1.09e-11	2.44e-08	-0.54	-0.43	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65591850~65592472:-
OV	cis	rs2729354	0.514	rs1967179	ENSG00000265566.2	RN7SL605P	-7.16	1.1e-11	2.45e-08	-0.57	-0.43	Blood protein levels;	chr11:57581010	chr11:57528085~57528365:-
OV	cis	rs1707322	0.717	rs3014246	ENSG00000281133.1	AL355480.3	7.16	1.11e-11	2.47e-08	0.57	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45580892~45580996:-
OV	cis	rs17711722	0.727	rs2658585	ENSG00000236529.1	RP13-254B10.1	7.16	1.11e-11	2.48e-08	0.45	0.43	Calcium levels;	chr7:65996954	chr7:65840212~65840596:+
OV	cis	rs875971	0.522	rs1880556	ENSG00000226824.5	RP4-756H11.3	-7.16	1.11e-11	2.48e-08	-0.45	-0.43	Aortic root size;	chr7:65967557	chr7:66654538~66669855:+
OV	cis	rs7617773	0.539	rs1471217	ENSG00000229759.1	MRPS18AP1	7.16	1.11e-11	2.48e-08	0.45	0.43	Coronary artery disease;	chr3:48343405	chr3:48256350~48256938:-
OV	cis	rs11159086	1	rs4903232	ENSG00000259005.1	RP3-449M8.6	7.16	1.11e-11	2.48e-08	0.69	0.43	Advanced glycation end-product levels;	chr14:74496585	chr14:74474007~74474864:-
OV	cis	rs875971	0.522	rs781144	ENSG00000226824.5	RP4-756H11.3	-7.16	1.12e-11	2.5e-08	-0.45	-0.43	Aortic root size;	chr7:65975357	chr7:66654538~66669855:+
OV	cis	rs7246967	0.608	rs2569725	ENSG00000269509.1	BNIP3P34	7.15	1.15e-11	2.56e-08	0.68	0.43	Bronchopulmonary dysplasia;	chr19:22833208	chr19:22773853~22774424:+
OV	cis	rs7605378	0.528	rs281787	ENSG00000232732.8	AC073043.1	7.15	1.15e-11	2.56e-08	0.52	0.43	Osteoporosis;	chr2:199919515	chr2:199867396~199911159:-
OV	cis	rs6700559	1	rs3806358	ENSG00000260088.1	RP11-92G12.3	-7.15	1.17e-11	2.59e-08	-0.45	-0.43	Coronary artery disease;	chr1:200670555	chr1:200669507~200694250:+
OV	cis	rs7246967	0.551	rs34563787	ENSG00000269509.1	BNIP3P34	7.15	1.17e-11	2.6e-08	0.71	0.43	Bronchopulmonary dysplasia;	chr19:22654934	chr19:22773853~22774424:+
OV	cis	rs11673344	0.566	rs185368	ENSG00000226686.6	LINC01535	-7.15	1.18e-11	2.62e-08	-0.49	-0.43	Obesity-related traits;	chr19:37381827	chr19:37251912~37265535:+
OV	cis	rs7017914	0.967	rs34042354	ENSG00000223220.1	Y_RNA	7.15	1.18e-11	2.62e-08	0.45	0.43	Bone mineral density;	chr8:70818726	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs13261712	ENSG00000223220.1	Y_RNA	7.15	1.18e-11	2.62e-08	0.45	0.43	Bone mineral density;	chr8:70820029	chr8:70780914~70781008:-
OV	cis	rs7017914	1	rs13252719	ENSG00000223220.1	Y_RNA	7.15	1.18e-11	2.62e-08	0.45	0.43	Bone mineral density;	chr8:70822334	chr8:70780914~70781008:-
OV	cis	rs7017914	0.934	rs13274062	ENSG00000223220.1	Y_RNA	7.15	1.18e-11	2.62e-08	0.45	0.43	Bone mineral density;	chr8:70824852	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs13274381	ENSG00000223220.1	Y_RNA	7.15	1.18e-11	2.62e-08	0.45	0.43	Bone mineral density;	chr8:70852859	chr8:70780914~70781008:-
OV	cis	rs17711722	0.523	rs313812	ENSG00000236529.1	RP13-254B10.1	-7.15	1.18e-11	2.62e-08	-0.48	-0.43	Calcium levels;	chr7:66040056	chr7:65840212~65840596:+
OV	cis	rs16828019	0.852	rs11209576	ENSG00000235358.1	RP11-399E6.1	7.15	1.18e-11	2.63e-08	0.83	0.43	Intelligence (multi-trait analysis);	chr1:41120357	chr1:41242373~41284861:+
OV	cis	rs2153535	0.58	rs9328484	ENSG00000230939.1	RP11-314C16.1	-7.15	1.19e-11	2.64e-08	-0.49	-0.43	Motion sickness;	chr6:8524610	chr6:8784178~8785445:+
OV	cis	rs2117029	0.556	rs1057725	ENSG00000258017.1	RP11-386G11.10	-7.15	1.19e-11	2.65e-08	-0.53	-0.43	Intelligence (multi-trait analysis);	chr12:49128795	chr12:49127782~49147869:+
OV	cis	rs1061377	0.965	rs7669376	ENSG00000249207.1	RP11-360F5.1	-7.15	1.19e-11	2.65e-08	-0.46	-0.43	Uric acid levels;	chr4:39116717	chr4:39112677~39126818:-
OV	cis	rs2658782	0.724	rs2605629	ENSG00000279684.1	RP11-755E23.2	7.15	1.19e-11	2.65e-08	0.58	0.43	Pulmonary function decline;	chr11:93530871	chr11:93286629~93288903:-
OV	cis	rs11690935	0.885	rs6725388	ENSG00000228389.1	AC068039.4	7.14	1.23e-11	2.72e-08	0.48	0.43	Schizophrenia;	chr2:171873505	chr2:171773482~171775844:+
OV	cis	rs16828019	0.852	rs3766324	ENSG00000235358.1	RP11-399E6.1	7.14	1.23e-11	2.72e-08	0.83	0.43	Intelligence (multi-trait analysis);	chr1:41122981	chr1:41242373~41284861:+
OV	cis	rs16828019	0.852	rs12759023	ENSG00000235358.1	RP11-399E6.1	7.14	1.23e-11	2.72e-08	0.83	0.43	Intelligence (multi-trait analysis);	chr1:41138306	chr1:41242373~41284861:+
OV	cis	rs16828019	0.852	rs34286980	ENSG00000235358.1	RP11-399E6.1	7.14	1.23e-11	2.72e-08	0.83	0.43	Intelligence (multi-trait analysis);	chr1:41142717	chr1:41242373~41284861:+
OV	cis	rs16828019	0.852	rs12048187	ENSG00000235358.1	RP11-399E6.1	7.14	1.23e-11	2.72e-08	0.83	0.43	Intelligence (multi-trait analysis);	chr1:41150511	chr1:41242373~41284861:+
OV	cis	rs16828019	0.852	rs12742803	ENSG00000235358.1	RP11-399E6.1	7.14	1.23e-11	2.72e-08	0.83	0.43	Intelligence (multi-trait analysis);	chr1:41182459	chr1:41242373~41284861:+
OV	cis	rs16828019	0.852	rs12408956	ENSG00000235358.1	RP11-399E6.1	7.14	1.23e-11	2.72e-08	0.83	0.43	Intelligence (multi-trait analysis);	chr1:41186280	chr1:41242373~41284861:+
OV	cis	rs16828019	0.852	rs35992757	ENSG00000235358.1	RP11-399E6.1	7.14	1.23e-11	2.72e-08	0.83	0.43	Intelligence (multi-trait analysis);	chr1:41187190	chr1:41242373~41284861:+
OV	cis	rs16828019	0.852	rs12044539	ENSG00000235358.1	RP11-399E6.1	7.14	1.23e-11	2.72e-08	0.83	0.43	Intelligence (multi-trait analysis);	chr1:41196060	chr1:41242373~41284861:+
OV	cis	rs16828019	0.852	rs12759050	ENSG00000235358.1	RP11-399E6.1	7.14	1.23e-11	2.72e-08	0.83	0.43	Intelligence (multi-trait analysis);	chr1:41198532	chr1:41242373~41284861:+
OV	cis	rs16828019	0.789	rs34216154	ENSG00000235358.1	RP11-399E6.1	7.14	1.23e-11	2.72e-08	0.83	0.43	Intelligence (multi-trait analysis);	chr1:41205235	chr1:41242373~41284861:+
OV	cis	rs7246967	0.932	rs34897621	ENSG00000269509.1	BNIP3P34	7.14	1.23e-11	2.72e-08	0.62	0.43	Bronchopulmonary dysplasia;	chr19:22844725	chr19:22773853~22774424:+
OV	cis	rs7246967	0.932	rs35948178	ENSG00000269509.1	BNIP3P34	7.14	1.23e-11	2.72e-08	0.62	0.43	Bronchopulmonary dysplasia;	chr19:22845717	chr19:22773853~22774424:+
OV	cis	rs7246967	0.932	rs35687548	ENSG00000269509.1	BNIP3P34	7.14	1.23e-11	2.72e-08	0.62	0.43	Bronchopulmonary dysplasia;	chr19:22846345	chr19:22773853~22774424:+
OV	cis	rs7246967	0.932	rs62120766	ENSG00000269509.1	BNIP3P34	7.14	1.23e-11	2.72e-08	0.62	0.43	Bronchopulmonary dysplasia;	chr19:22847145	chr19:22773853~22774424:+
OV	cis	rs7246967	0.932	rs35039856	ENSG00000269509.1	BNIP3P34	7.14	1.23e-11	2.72e-08	0.62	0.43	Bronchopulmonary dysplasia;	chr19:22848537	chr19:22773853~22774424:+
OV	cis	rs7246967	0.932	rs66737024	ENSG00000269509.1	BNIP3P34	7.14	1.23e-11	2.72e-08	0.62	0.43	Bronchopulmonary dysplasia;	chr19:22848884	chr19:22773853~22774424:+
OV	cis	rs7246967	0.866	rs4932694	ENSG00000269509.1	BNIP3P34	7.14	1.23e-11	2.72e-08	0.62	0.43	Bronchopulmonary dysplasia;	chr19:22849905	chr19:22773853~22774424:+
OV	cis	rs7246967	0.866	rs7250801	ENSG00000269509.1	BNIP3P34	7.14	1.23e-11	2.72e-08	0.62	0.43	Bronchopulmonary dysplasia;	chr19:22853155	chr19:22773853~22774424:+
OV	cis	rs7246967	0.932	rs4932793	ENSG00000269509.1	BNIP3P34	7.14	1.23e-11	2.72e-08	0.62	0.43	Bronchopulmonary dysplasia;	chr19:22853647	chr19:22773853~22774424:+
OV	cis	rs7246967	0.8	rs4932794	ENSG00000269509.1	BNIP3P34	7.14	1.23e-11	2.72e-08	0.62	0.43	Bronchopulmonary dysplasia;	chr19:22853754	chr19:22773853~22774424:+
OV	cis	rs7246967	0.932	rs62120772	ENSG00000269509.1	BNIP3P34	7.14	1.23e-11	2.72e-08	0.62	0.43	Bronchopulmonary dysplasia;	chr19:22854349	chr19:22773853~22774424:+
OV	cis	rs7246967	0.932	rs35007403	ENSG00000269509.1	BNIP3P34	7.14	1.23e-11	2.72e-08	0.62	0.43	Bronchopulmonary dysplasia;	chr19:22854645	chr19:22773853~22774424:+
OV	cis	rs7246967	0.932	rs8105614	ENSG00000269509.1	BNIP3P34	7.14	1.23e-11	2.72e-08	0.62	0.43	Bronchopulmonary dysplasia;	chr19:22855221	chr19:22773853~22774424:+
OV	cis	rs7246967	0.8	rs7256135	ENSG00000269509.1	BNIP3P34	7.14	1.23e-11	2.72e-08	0.62	0.43	Bronchopulmonary dysplasia;	chr19:22856319	chr19:22773853~22774424:+
OV	cis	rs7246967	0.932	rs58238799	ENSG00000269509.1	BNIP3P34	7.14	1.23e-11	2.72e-08	0.62	0.43	Bronchopulmonary dysplasia;	chr19:22857380	chr19:22773853~22774424:+
OV	cis	rs7246967	0.932	rs62120780	ENSG00000269509.1	BNIP3P34	7.14	1.23e-11	2.72e-08	0.62	0.43	Bronchopulmonary dysplasia;	chr19:22860912	chr19:22773853~22774424:+
OV	cis	rs7246967	0.866	rs34752785	ENSG00000269509.1	BNIP3P34	7.14	1.23e-11	2.72e-08	0.62	0.43	Bronchopulmonary dysplasia;	chr19:22861771	chr19:22773853~22774424:+
OV	cis	rs7246967	0.866	rs62120784	ENSG00000269509.1	BNIP3P34	7.14	1.23e-11	2.72e-08	0.62	0.43	Bronchopulmonary dysplasia;	chr19:22861933	chr19:22773853~22774424:+
OV	cis	rs7246967	0.866	rs35105042	ENSG00000269509.1	BNIP3P34	7.14	1.23e-11	2.72e-08	0.62	0.43	Bronchopulmonary dysplasia;	chr19:22865550	chr19:22773853~22774424:+
OV	cis	rs10256972	0.967	rs4723338	ENSG00000229043.2	AC091729.9	-7.14	1.24e-11	2.73e-08	-0.48	-0.43	Endometriosis;Longevity;	chr7:996605	chr7:1160374~1165267:+
OV	cis	rs11159086	1	rs11159086	ENSG00000259005.1	RP3-449M8.6	7.14	1.24e-11	2.74e-08	0.68	0.43	Advanced glycation end-product levels;	chr14:74495572	chr14:74474007~74474864:-
OV	cis	rs2153535	0.542	rs9505465	ENSG00000230939.1	RP11-314C16.1	-7.14	1.25e-11	2.75e-08	-0.48	-0.43	Motion sickness;	chr6:8510613	chr6:8784178~8785445:+
OV	cis	rs7017914	0.967	rs1348535	ENSG00000223220.1	Y_RNA	7.14	1.25e-11	2.76e-08	0.45	0.43	Bone mineral density;	chr8:70750506	chr8:70780914~70781008:-
OV	cis	rs875971	0.505	rs6955582	ENSG00000236529.1	RP13-254B10.1	7.14	1.26e-11	2.77e-08	0.45	0.43	Aortic root size;	chr7:65966699	chr7:65840212~65840596:+
OV	cis	rs9326248	0.581	rs7120963	ENSG00000254851.1	RP11-109L13.1	7.14	1.26e-11	2.77e-08	0.5	0.43	Blood protein levels;	chr11:116959545	chr11:117135528~117138582:+
OV	cis	rs1707322	1	rs785498	ENSG00000281133.1	AL355480.3	7.14	1.26e-11	2.78e-08	0.54	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr1:45580892~45580996:-
OV	cis	rs9326248	0.603	rs7396061	ENSG00000254851.1	RP11-109L13.1	-7.14	1.27e-11	2.79e-08	-0.51	-0.43	Blood protein levels;	chr11:116880158	chr11:117135528~117138582:+
OV	cis	rs7246967	0.673	rs8106180	ENSG00000269509.1	BNIP3P34	7.14	1.27e-11	2.8e-08	0.66	0.43	Bronchopulmonary dysplasia;	chr19:22696558	chr19:22773853~22774424:+
OV	cis	rs7615952	0.932	rs11922218	ENSG00000171084.14	FAM86JP	7.14	1.28e-11	2.81e-08	0.7	0.43	Blood pressure (smoking interaction);	chr3:125912446	chr3:125916620~125930024:+
OV	cis	rs7615952	0.866	rs11922276	ENSG00000171084.14	FAM86JP	7.14	1.28e-11	2.81e-08	0.7	0.43	Blood pressure (smoking interaction);	chr3:125912483	chr3:125916620~125930024:+
OV	cis	rs7017914	0.967	rs2732087	ENSG00000223220.1	Y_RNA	7.14	1.28e-11	2.82e-08	0.44	0.43	Bone mineral density;	chr8:70948204	chr8:70780914~70781008:-
OV	cis	rs2282300	0.956	rs594937	ENSG00000254532.1	RP11-624D11.2	-7.13	1.29e-11	2.84e-08	-0.6	-0.43	Morning vs. evening chronotype;	chr11:30368585	chr11:30044058~30084343:-
OV	cis	rs1707322	0.896	rs809774	ENSG00000281133.1	AL355480.3	7.13	1.3e-11	2.86e-08	0.54	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr1:45580892~45580996:-
OV	cis	rs73086581	0.838	rs56401022	ENSG00000229539.1	RP11-119B16.2	7.13	1.31e-11	2.89e-08	0.54	0.43	Response to antidepressants in depression;	chr20:4043634	chr20:3888239~3888868:-
OV	cis	rs7246967	0.673	rs937078	ENSG00000269509.1	BNIP3P34	7.13	1.32e-11	2.9e-08	0.66	0.43	Bronchopulmonary dysplasia;	chr19:22628865	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs12978794	ENSG00000269509.1	BNIP3P34	7.13	1.32e-11	2.9e-08	0.66	0.43	Bronchopulmonary dysplasia;	chr19:22629332	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs4932782	ENSG00000269509.1	BNIP3P34	7.13	1.32e-11	2.9e-08	0.66	0.43	Bronchopulmonary dysplasia;	chr19:22629999	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs4933017	ENSG00000269509.1	BNIP3P34	7.13	1.32e-11	2.9e-08	0.66	0.43	Bronchopulmonary dysplasia;	chr19:22630178	chr19:22773853~22774424:+
OV	cis	rs7246967	0.611	rs66866654	ENSG00000269509.1	BNIP3P34	7.13	1.32e-11	2.9e-08	0.66	0.43	Bronchopulmonary dysplasia;	chr19:22630937	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs73028776	ENSG00000269509.1	BNIP3P34	7.13	1.32e-11	2.9e-08	0.66	0.43	Bronchopulmonary dysplasia;	chr19:22630938	chr19:22773853~22774424:+
OV	cis	rs7246967	0.551	rs56968124	ENSG00000269509.1	BNIP3P34	7.13	1.32e-11	2.9e-08	0.66	0.43	Bronchopulmonary dysplasia;	chr19:22631647	chr19:22773853~22774424:+
OV	cis	rs7246967	0.551	rs57775631	ENSG00000269509.1	BNIP3P34	7.13	1.32e-11	2.9e-08	0.66	0.43	Bronchopulmonary dysplasia;	chr19:22631659	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs2361021	ENSG00000269509.1	BNIP3P34	7.13	1.32e-11	2.9e-08	0.66	0.43	Bronchopulmonary dysplasia;	chr19:22633522	chr19:22773853~22774424:+
OV	cis	rs2408955	0.5	rs12816820	ENSG00000258273.1	RP11-370I10.4	-7.13	1.32e-11	2.9e-08	-0.51	-0.43	Glycated hemoglobin levels;	chr12:48164542	chr12:48333755~48333901:-
OV	cis	rs1387259	0.57	rs12368659	ENSG00000258273.1	RP11-370I10.4	-7.13	1.32e-11	2.9e-08	-0.51	-0.43	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48168516	chr12:48333755~48333901:-
OV	cis	rs492146	1	rs375872	ENSG00000243236.5	GSTA9P	-7.13	1.33e-11	2.91e-08	-0.5	-0.43	Epilepsy (remission after treatment);	chr6:52970119	chr6:52939726~52957521:-
OV	cis	rs1707322	0.717	rs2253862	ENSG00000281133.1	AL355480.3	7.13	1.33e-11	2.91e-08	0.57	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr1:45580892~45580996:-
OV	cis	rs1707322	0.717	rs2991988	ENSG00000281133.1	AL355480.3	7.13	1.33e-11	2.91e-08	0.57	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr1:45580892~45580996:-
OV	cis	rs1707322	0.717	rs2991989	ENSG00000281133.1	AL355480.3	7.13	1.33e-11	2.91e-08	0.57	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr1:45580892~45580996:-
OV	cis	rs116927879	1	rs116927879	ENSG00000272556.1	RP11-638I8.1	-7.13	1.33e-11	2.93e-08	-0.69	-0.43	Subjective response to lithium treatment in bipolar disorder;	chr7:45825128	chr7:45814602~45815263:+
OV	cis	rs1707322	1	rs6677777	ENSG00000281133.1	AL355480.3	-7.13	1.34e-11	2.93e-08	-0.54	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46010164	chr1:45580892~45580996:-
OV	cis	rs7569084	0.64	rs11126039	ENSG00000234255.7	AC012370.3	7.13	1.34e-11	2.94e-08	0.47	0.43	Sum eosinophil basophil counts;	chr2:65457953	chr2:65439888~65456571:-
OV	cis	rs4713118	0.662	rs149946	ENSG00000220721.1	OR1F12	-7.13	1.34e-11	2.94e-08	-0.5	-0.43	Parkinson's disease;	chr6:28002253	chr6:28073316~28074233:+
OV	cis	rs875971	0.522	rs1701760	ENSG00000222364.1	RNU6-96P	-7.13	1.34e-11	2.94e-08	-0.44	-0.43	Aortic root size;	chr7:66008701	chr7:66395191~66395286:+
OV	cis	rs73086581	1	rs73088421	ENSG00000229539.1	RP11-119B16.2	7.13	1.35e-11	2.95e-08	0.56	0.43	Response to antidepressants in depression;	chr20:4017224	chr20:3888239~3888868:-
OV	cis	rs1061377	1	rs7685468	ENSG00000249207.1	RP11-360F5.1	-7.13	1.35e-11	2.96e-08	-0.46	-0.43	Uric acid levels;	chr4:39116649	chr4:39112677~39126818:-
OV	cis	rs7927771	0.965	rs3817335	ENSG00000280615.1	Y_RNA	-7.13	1.35e-11	2.96e-08	-0.53	-0.43	Subjective well-being;	chr11:47622339	chr11:47614898~47614994:-
OV	cis	rs73086581	1	rs73086505	ENSG00000229539.1	RP11-119B16.2	7.13	1.35e-11	2.96e-08	0.55	0.43	Response to antidepressants in depression;	chr20:3940924	chr20:3888239~3888868:-
OV	cis	rs73086581	1	rs73086508	ENSG00000229539.1	RP11-119B16.2	7.13	1.35e-11	2.96e-08	0.55	0.43	Response to antidepressants in depression;	chr20:3941068	chr20:3888239~3888868:-
OV	cis	rs73086581	1	rs73086510	ENSG00000229539.1	RP11-119B16.2	7.13	1.35e-11	2.96e-08	0.55	0.43	Response to antidepressants in depression;	chr20:3941484	chr20:3888239~3888868:-
OV	cis	rs73086581	1	rs73086512	ENSG00000229539.1	RP11-119B16.2	7.13	1.35e-11	2.96e-08	0.55	0.43	Response to antidepressants in depression;	chr20:3942125	chr20:3888239~3888868:-
OV	cis	rs73086581	1	rs17286768	ENSG00000229539.1	RP11-119B16.2	7.13	1.35e-11	2.96e-08	0.55	0.43	Response to antidepressants in depression;	chr20:3943922	chr20:3888239~3888868:-
OV	cis	rs73086581	1	rs17214621	ENSG00000229539.1	RP11-119B16.2	7.13	1.35e-11	2.96e-08	0.55	0.43	Response to antidepressants in depression;	chr20:3945277	chr20:3888239~3888868:-
OV	cis	rs150992	0.632	rs34490	ENSG00000248489.1	CTD-2007H13.3	7.13	1.36e-11	2.97e-08	0.52	0.43	Body mass index;	chr5:98974967	chr5:98929171~98995013:+
OV	cis	rs875971	0.522	rs1917563	ENSG00000236529.1	RP13-254B10.1	-7.12	1.37e-11	3e-08	-0.44	-0.43	Aortic root size;	chr7:65950660	chr7:65840212~65840596:+
OV	cis	rs1707322	0.721	rs10890343	ENSG00000280836.1	AL355480.1	-7.12	1.37e-11	3e-08	-0.59	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692250	chr1:45581219~45581321:-
OV	cis	rs492146	0.819	rs612483	ENSG00000243236.5	GSTA9P	7.12	1.37e-11	3.01e-08	0.51	0.43	Epilepsy (remission after treatment);	chr6:52975160	chr6:52939726~52957521:-
OV	cis	rs73086581	0.838	rs11907416	ENSG00000229539.1	RP11-119B16.2	7.12	1.38e-11	3.01e-08	0.55	0.43	Response to antidepressants in depression;	chr20:4024972	chr20:3888239~3888868:-
OV	cis	rs8105895	0.935	rs62110986	ENSG00000269742.1	BNIP3P29	7.12	1.38e-11	3.03e-08	0.71	0.43	Body mass index (change over time);	chr19:22073969	chr19:22065828~22066398:-
OV	cis	rs4423214	0.535	rs1540129	ENSG00000254682.1	RP11-660L16.2	7.12	1.4e-11	3.06e-08	0.55	0.43	Vitamin D levels;	chr11:71418477	chr11:71448674~71452157:+
OV	cis	rs1707322	0.721	rs11211149	ENSG00000281133.1	AL355480.3	-7.12	1.4e-11	3.06e-08	-0.55	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr1:45580892~45580996:-
OV	cis	rs1707322	0.752	rs11211152	ENSG00000281133.1	AL355480.3	-7.12	1.4e-11	3.06e-08	-0.55	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr1:45580892~45580996:-
OV	cis	rs1707322	0.752	rs4607935	ENSG00000281133.1	AL355480.3	-7.12	1.4e-11	3.06e-08	-0.55	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr1:45580892~45580996:-
OV	cis	rs1707322	0.681	rs12048866	ENSG00000281133.1	AL355480.3	-7.12	1.4e-11	3.06e-08	-0.55	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr1:45580892~45580996:-
OV	cis	rs1707322	0.752	rs3811436	ENSG00000281133.1	AL355480.3	-7.12	1.4e-11	3.06e-08	-0.55	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr1:45580892~45580996:-
OV	cis	rs1707322	0.752	rs12024590	ENSG00000281133.1	AL355480.3	-7.12	1.4e-11	3.06e-08	-0.55	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr1:45580892~45580996:-
OV	cis	rs1707322	0.752	rs12027622	ENSG00000281133.1	AL355480.3	-7.12	1.4e-11	3.06e-08	-0.55	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs4415615	ENSG00000281133.1	AL355480.3	-7.12	1.4e-11	3.06e-08	-0.55	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr1:45580892~45580996:-
OV	cis	rs1707322	0.752	rs7529699	ENSG00000281133.1	AL355480.3	-7.12	1.4e-11	3.06e-08	-0.55	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr1:45580892~45580996:-
OV	cis	rs1707322	0.716	rs6699444	ENSG00000281133.1	AL355480.3	-7.12	1.4e-11	3.06e-08	-0.55	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr1:45580892~45580996:-
OV	cis	rs1707322	0.752	rs10430105	ENSG00000281133.1	AL355480.3	-7.12	1.4e-11	3.06e-08	-0.55	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs10890341	ENSG00000281133.1	AL355480.3	-7.12	1.4e-11	3.06e-08	-0.55	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr1:45580892~45580996:-
OV	cis	rs1707322	0.686	rs1547924	ENSG00000280836.1	AL355480.1	-7.12	1.41e-11	3.07e-08	-0.59	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619440	chr1:45581219~45581321:-
OV	cis	rs2243480	0.708	rs35825036	ENSG00000222364.1	RNU6-96P	-7.12	1.41e-11	3.07e-08	-0.66	-0.43	Diabetic kidney disease;	chr7:66521515	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs13237037	ENSG00000222364.1	RNU6-96P	-7.12	1.41e-11	3.07e-08	-0.66	-0.43	Diabetic kidney disease;	chr7:66532895	chr7:66395191~66395286:+
OV	cis	rs2243480	0.901	rs13237344	ENSG00000222364.1	RNU6-96P	-7.12	1.41e-11	3.07e-08	-0.66	-0.43	Diabetic kidney disease;	chr7:66557269	chr7:66395191~66395286:+
OV	cis	rs3931020	0.745	rs1969111	ENSG00000272864.1	RP11-17E13.2	7.12	1.41e-11	3.07e-08	0.55	0.43	Resistin levels;	chr1:74797801	chr1:74698769~74699333:-
OV	cis	rs875971	0.522	rs10807697	ENSG00000236529.1	RP13-254B10.1	7.12	1.42e-11	3.09e-08	0.44	0.43	Aortic root size;	chr7:65951183	chr7:65840212~65840596:+
OV	cis	rs1075265	0.584	rs34769118	ENSG00000233266.1	HMGB1P31	7.12	1.42e-11	3.09e-08	0.52	0.43	Chronotype;Morning vs. evening chronotype;	chr2:54102173	chr2:54051334~54051760:+
OV	cis	rs1707322	1	rs10890382	ENSG00000281133.1	AL355480.3	-7.12	1.42e-11	3.1e-08	-0.55	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr1:45580892~45580996:-
OV	cis	rs1707322	0.717	rs1972410	ENSG00000281133.1	AL355480.3	-7.12	1.43e-11	3.11e-08	-0.56	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr1:45580892~45580996:-
OV	cis	rs7246967	0.8	rs2169794	ENSG00000269509.1	BNIP3P34	7.12	1.43e-11	3.12e-08	0.63	0.43	Bronchopulmonary dysplasia;	chr19:22842966	chr19:22773853~22774424:+
OV	cis	rs7246967	0.8	rs2061774	ENSG00000269509.1	BNIP3P34	7.12	1.43e-11	3.12e-08	0.63	0.43	Bronchopulmonary dysplasia;	chr19:22842973	chr19:22773853~22774424:+
OV	cis	rs977987	0.671	rs9922008	ENSG00000261783.1	RP11-252K23.2	-7.12	1.44e-11	3.13e-08	-0.61	-0.43	Dupuytren's disease;	chr16:75301508	chr16:75379818~75381260:-
OV	cis	rs11690935	0.851	rs6731562	ENSG00000228389.1	AC068039.4	7.12	1.45e-11	3.15e-08	0.47	0.43	Schizophrenia;	chr2:171941742	chr2:171773482~171775844:+
OV	cis	rs11690935	0.851	rs10201430	ENSG00000228389.1	AC068039.4	7.12	1.45e-11	3.15e-08	0.47	0.43	Schizophrenia;	chr2:171956715	chr2:171773482~171775844:+
OV	cis	rs7017914	0.967	rs7842851	ENSG00000223220.1	Y_RNA	7.11	1.47e-11	3.19e-08	0.44	0.43	Bone mineral density;	chr8:70751570	chr8:70780914~70781008:-
OV	cis	rs73086581	0.838	rs11906481	ENSG00000229539.1	RP11-119B16.2	7.11	1.48e-11	3.21e-08	0.53	0.43	Response to antidepressants in depression;	chr20:4048059	chr20:3888239~3888868:-
OV	cis	rs1707322	0.752	rs4660880	ENSG00000281133.1	AL355480.3	-7.11	1.49e-11	3.24e-08	-0.55	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr1:45580892~45580996:-
OV	cis	rs7246967	0.866	rs6511385	ENSG00000269509.1	BNIP3P34	7.11	1.5e-11	3.25e-08	0.64	0.43	Bronchopulmonary dysplasia;	chr19:22854134	chr19:22773853~22774424:+
OV	cis	rs7246967	0.932	rs35735434	ENSG00000269509.1	BNIP3P34	7.11	1.5e-11	3.25e-08	0.64	0.43	Bronchopulmonary dysplasia;	chr19:22856675	chr19:22773853~22774424:+
OV	cis	rs7246967	0.932	rs34373479	ENSG00000269509.1	BNIP3P34	7.11	1.5e-11	3.25e-08	0.64	0.43	Bronchopulmonary dysplasia;	chr19:22861060	chr19:22773853~22774424:+
OV	cis	rs7246967	0.932	rs7256599	ENSG00000269509.1	BNIP3P34	7.11	1.5e-11	3.25e-08	0.64	0.43	Bronchopulmonary dysplasia;	chr19:22863119	chr19:22773853~22774424:+
OV	cis	rs1061377	1	rs1061377	ENSG00000249207.1	RP11-360F5.1	-7.11	1.5e-11	3.25e-08	-0.45	-0.43	Uric acid levels;	chr4:39123130	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs13109200	ENSG00000249207.1	RP11-360F5.1	-7.11	1.5e-11	3.25e-08	-0.45	-0.43	Uric acid levels;	chr4:39124396	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs13144374	ENSG00000249207.1	RP11-360F5.1	-7.11	1.5e-11	3.25e-08	-0.45	-0.43	Uric acid levels;	chr4:39128859	chr4:39112677~39126818:-
OV	cis	rs1185460	0.967	rs2509121	ENSG00000271751.1	RP11-110I1.14	-7.11	1.5e-11	3.26e-08	-0.53	-0.43	Coronary artery disease;	chr11:119057542	chr11:119065263~119065677:-
OV	cis	rs2836974	0.568	rs428602	ENSG00000232608.1	TIMM9P2	-7.11	1.51e-11	3.27e-08	-0.45	-0.43	Cognitive function;	chr21:39175078	chr21:39216624~39217506:+
OV	cis	rs150992	0.861	rs428836	ENSG00000248489.1	CTD-2007H13.3	7.11	1.51e-11	3.28e-08	0.51	0.43	Body mass index;	chr5:98951673	chr5:98929171~98995013:+
OV	cis	rs2243480	0.803	rs13224048	ENSG00000222364.1	RNU6-96P	-7.11	1.52e-11	3.28e-08	-0.66	-0.43	Diabetic kidney disease;	chr7:66528779	chr7:66395191~66395286:+
OV	cis	rs1707322	0.752	rs12062535	ENSG00000281133.1	AL355480.3	-7.11	1.52e-11	3.3e-08	-0.56	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr1:45580892~45580996:-
OV	cis	rs2153535	0.56	rs9379214	ENSG00000230939.1	RP11-314C16.1	-7.11	1.52e-11	3.3e-08	-0.48	-0.43	Motion sickness;	chr6:8480637	chr6:8784178~8785445:+
OV	cis	rs875971	0.54	rs781152	ENSG00000226824.5	RP4-756H11.3	-7.1	1.56e-11	3.37e-08	-0.45	-0.43	Aortic root size;	chr7:66014585	chr7:66654538~66669855:+
OV	cis	rs17711722	0.727	rs781151	ENSG00000226824.5	RP4-756H11.3	-7.1	1.56e-11	3.37e-08	-0.45	-0.43	Calcium levels;	chr7:66014891	chr7:66654538~66669855:+
OV	cis	rs7017914	0.967	rs62530792	ENSG00000223220.1	Y_RNA	7.1	1.57e-11	3.39e-08	0.45	0.43	Bone mineral density;	chr8:70706532	chr8:70780914~70781008:-
OV	cis	rs7017914	0.902	rs35893260	ENSG00000223220.1	Y_RNA	7.1	1.57e-11	3.39e-08	0.45	0.43	Bone mineral density;	chr8:70707838	chr8:70780914~70781008:-
OV	cis	rs7246967	0.673	rs1433085	ENSG00000269509.1	BNIP3P34	7.1	1.57e-11	3.4e-08	0.66	0.43	Bronchopulmonary dysplasia;	chr19:22628297	chr19:22773853~22774424:+
OV	cis	rs2153535	0.58	rs7741403	ENSG00000230939.1	RP11-314C16.1	7.1	1.58e-11	3.41e-08	0.49	0.43	Motion sickness;	chr6:8530345	chr6:8784178~8785445:+
OV	cis	rs2882667	0.537	rs6887866	ENSG00000253404.1	AC034243.1	7.1	1.58e-11	3.41e-08	0.5	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139102007	chr5:138744434~138753309:-
OV	cis	rs453301	0.653	rs1562211	ENSG00000253893.2	FAM85B	7.1	1.59e-11	3.44e-08	0.48	0.43	Joint mobility (Beighton score);	chr8:9044914	chr8:8167819~8226614:-
OV	cis	rs2732480	0.538	rs2468943	ENSG00000258273.1	RP11-370I10.4	7.1	1.59e-11	3.44e-08	0.53	0.43	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48333755~48333901:-
OV	cis	rs2836974	0.568	rs452377	ENSG00000232608.1	TIMM9P2	-7.1	1.6e-11	3.45e-08	-0.45	-0.43	Cognitive function;	chr21:39165257	chr21:39216624~39217506:+
OV	cis	rs2836974	0.568	rs429955	ENSG00000232608.1	TIMM9P2	-7.1	1.6e-11	3.45e-08	-0.45	-0.43	Cognitive function;	chr21:39167834	chr21:39216624~39217506:+
OV	cis	rs2153535	0.58	rs9406158	ENSG00000230939.1	RP11-314C16.1	-7.1	1.6e-11	3.45e-08	-0.48	-0.43	Motion sickness;	chr6:8463919	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1335637	ENSG00000230939.1	RP11-314C16.1	-7.1	1.6e-11	3.45e-08	-0.48	-0.43	Motion sickness;	chr6:8464868	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9406162	ENSG00000230939.1	RP11-314C16.1	-7.1	1.6e-11	3.45e-08	-0.48	-0.43	Motion sickness;	chr6:8465963	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9393022	ENSG00000230939.1	RP11-314C16.1	-7.1	1.6e-11	3.45e-08	-0.48	-0.43	Motion sickness;	chr6:8466355	chr6:8784178~8785445:+
OV	cis	rs2153535	0.541	rs9392222	ENSG00000230939.1	RP11-314C16.1	-7.1	1.6e-11	3.45e-08	-0.48	-0.43	Motion sickness;	chr6:8467416	chr6:8784178~8785445:+
OV	cis	rs2153535	0.541	rs6932434	ENSG00000230939.1	RP11-314C16.1	-7.1	1.6e-11	3.45e-08	-0.48	-0.43	Motion sickness;	chr6:8467446	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1034273	ENSG00000230939.1	RP11-314C16.1	-7.1	1.6e-11	3.45e-08	-0.48	-0.43	Motion sickness;	chr6:8467912	chr6:8784178~8785445:+
OV	cis	rs2153535	0.541	rs9328471	ENSG00000230939.1	RP11-314C16.1	-7.1	1.6e-11	3.45e-08	-0.48	-0.43	Motion sickness;	chr6:8468609	chr6:8784178~8785445:+
OV	cis	rs2153535	0.601	rs9505451	ENSG00000230939.1	RP11-314C16.1	-7.1	1.6e-11	3.45e-08	-0.48	-0.43	Motion sickness;	chr6:8469717	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9393023	ENSG00000230939.1	RP11-314C16.1	-7.1	1.6e-11	3.45e-08	-0.48	-0.43	Motion sickness;	chr6:8469761	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1414346	ENSG00000230939.1	RP11-314C16.1	-7.1	1.6e-11	3.45e-08	-0.48	-0.43	Motion sickness;	chr6:8471341	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1932279	ENSG00000230939.1	RP11-314C16.1	-7.1	1.6e-11	3.45e-08	-0.48	-0.43	Motion sickness;	chr6:8473420	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs2152347	ENSG00000230939.1	RP11-314C16.1	-7.1	1.6e-11	3.45e-08	-0.48	-0.43	Motion sickness;	chr6:8474048	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9379213	ENSG00000230939.1	RP11-314C16.1	-7.1	1.6e-11	3.45e-08	-0.48	-0.43	Motion sickness;	chr6:8474712	chr6:8784178~8785445:+
OV	cis	rs11690935	0.885	rs7602037	ENSG00000228389.1	AC068039.4	7.1	1.6e-11	3.45e-08	0.48	0.43	Schizophrenia;	chr2:171961268	chr2:171773482~171775844:+
OV	cis	rs7246967	0.866	rs115497901	ENSG00000269509.1	BNIP3P34	7.1	1.6e-11	3.46e-08	0.64	0.43	Bronchopulmonary dysplasia;	chr19:22859959	chr19:22773853~22774424:+
OV	cis	rs4591358	0.773	rs16836736	ENSG00000223466.1	AC064834.2	-7.1	1.6e-11	3.46e-08	-0.58	-0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195511283	chr2:195533035~195538681:+
OV	cis	rs4591358	0.689	rs72925794	ENSG00000223466.1	AC064834.2	-7.1	1.6e-11	3.46e-08	-0.58	-0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195511813	chr2:195533035~195538681:+
OV	cis	rs4591358	0.773	rs72925795	ENSG00000223466.1	AC064834.2	-7.1	1.6e-11	3.46e-08	-0.58	-0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195511814	chr2:195533035~195538681:+
OV	cis	rs4591358	0.773	rs13035516	ENSG00000223466.1	AC064834.2	-7.1	1.6e-11	3.46e-08	-0.58	-0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195513234	chr2:195533035~195538681:+
OV	cis	rs4591358	0.773	rs34475459	ENSG00000223466.1	AC064834.2	-7.1	1.6e-11	3.46e-08	-0.58	-0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195515682	chr2:195533035~195538681:+
OV	cis	rs4591358	0.773	rs35070116	ENSG00000223466.1	AC064834.2	-7.1	1.6e-11	3.46e-08	-0.58	-0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195515729	chr2:195533035~195538681:+
OV	cis	rs875971	0.54	rs4717275	ENSG00000226824.5	RP4-756H11.3	7.1	1.6e-11	3.46e-08	0.45	0.43	Aortic root size;	chr7:65800193	chr7:66654538~66669855:+
OV	cis	rs7246967	0.673	rs60675447	ENSG00000269509.1	BNIP3P34	7.1	1.61e-11	3.46e-08	0.67	0.43	Bronchopulmonary dysplasia;	chr19:22628090	chr19:22773853~22774424:+
OV	cis	rs7246967	0.673	rs56725192	ENSG00000269509.1	BNIP3P34	7.1	1.61e-11	3.46e-08	0.67	0.43	Bronchopulmonary dysplasia;	chr19:22628136	chr19:22773853~22774424:+
OV	cis	rs7927771	0.725	rs11039265	ENSG00000280615.1	Y_RNA	-7.1	1.61e-11	3.47e-08	-0.53	-0.43	Subjective well-being;	chr11:47501662	chr11:47614898~47614994:-
OV	cis	rs4713118	0.629	rs149899	ENSG00000220721.1	OR1F12	7.1	1.62e-11	3.5e-08	0.51	0.43	Parkinson's disease;	chr6:28052201	chr6:28073316~28074233:+
OV	cis	rs4713118	0.629	rs172165	ENSG00000220721.1	OR1F12	7.1	1.62e-11	3.5e-08	0.51	0.43	Parkinson's disease;	chr6:28053036	chr6:28073316~28074233:+
OV	cis	rs4713118	0.597	rs172166	ENSG00000220721.1	OR1F12	7.1	1.62e-11	3.5e-08	0.51	0.43	Parkinson's disease;	chr6:28053042	chr6:28073316~28074233:+
OV	cis	rs2117029	0.619	rs10747562	ENSG00000258017.1	RP11-386G11.10	-7.1	1.63e-11	3.5e-08	-0.52	-0.43	Intelligence (multi-trait analysis);	chr12:49111401	chr12:49127782~49147869:+
OV	cis	rs2117029	0.619	rs11168862	ENSG00000258017.1	RP11-386G11.10	-7.1	1.63e-11	3.5e-08	-0.52	-0.43	Intelligence (multi-trait analysis);	chr12:49112175	chr12:49127782~49147869:+
OV	cis	rs1707322	0.686	rs3014242	ENSG00000280836.1	AL355480.1	7.09	1.64e-11	3.53e-08	0.6	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621905	chr1:45581219~45581321:-
OV	cis	rs853679	0.517	rs1904840	ENSG00000220721.1	OR1F12	7.09	1.65e-11	3.54e-08	0.5	0.43	Depression;	chr6:28140454	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9368555	ENSG00000220721.1	OR1F12	7.09	1.65e-11	3.54e-08	0.5	0.43	Depression;	chr6:28141189	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9393893	ENSG00000220721.1	OR1F12	7.09	1.65e-11	3.54e-08	0.5	0.43	Depression;	chr6:28141484	chr6:28073316~28074233:+
OV	cis	rs7017914	0.935	rs35564237	ENSG00000223220.1	Y_RNA	7.09	1.65e-11	3.55e-08	0.45	0.43	Bone mineral density;	chr8:70688239	chr8:70780914~70781008:-
OV	cis	rs7017914	0.934	rs62530772	ENSG00000223220.1	Y_RNA	7.09	1.65e-11	3.55e-08	0.45	0.43	Bone mineral density;	chr8:70689306	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs7814648	ENSG00000223220.1	Y_RNA	7.09	1.65e-11	3.55e-08	0.45	0.43	Bone mineral density;	chr8:70691749	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs1477944	ENSG00000223220.1	Y_RNA	7.09	1.65e-11	3.55e-08	0.45	0.43	Bone mineral density;	chr8:70703365	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs17760497	ENSG00000223220.1	Y_RNA	7.09	1.65e-11	3.55e-08	0.45	0.43	Bone mineral density;	chr8:70704810	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs34677078	ENSG00000223220.1	Y_RNA	7.09	1.65e-11	3.55e-08	0.45	0.43	Bone mineral density;	chr8:70705480	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs59992214	ENSG00000223220.1	Y_RNA	7.09	1.66e-11	3.56e-08	0.45	0.43	Bone mineral density;	chr8:70687310	chr8:70780914~70781008:-
OV	cis	rs2836974	0.568	rs414850	ENSG00000232608.1	TIMM9P2	-7.09	1.66e-11	3.56e-08	-0.45	-0.43	Cognitive function;	chr21:39171411	chr21:39216624~39217506:+
OV	cis	rs17711722	0.675	rs6947132	ENSG00000226824.5	RP4-756H11.3	7.09	1.66e-11	3.57e-08	0.44	0.43	Calcium levels;	chr7:65808508	chr7:66654538~66669855:+
OV	cis	rs2581828	0.965	rs2581829	ENSG00000242142.1	SERBP1P3	-7.09	1.67e-11	3.6e-08	-0.48	-0.43	Crohn's disease;	chr3:53099510	chr3:53064283~53065091:-
OV	cis	rs853679	0.517	rs9393894	ENSG00000220721.1	OR1F12	7.09	1.68e-11	3.61e-08	0.5	0.43	Depression;	chr6:28144784	chr6:28073316~28074233:+
OV	cis	rs2153535	0.58	rs9505457	ENSG00000230939.1	RP11-314C16.1	-7.09	1.69e-11	3.62e-08	-0.48	-0.43	Motion sickness;	chr6:8478909	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs2225765	ENSG00000230939.1	RP11-314C16.1	-7.09	1.69e-11	3.62e-08	-0.48	-0.43	Motion sickness;	chr6:8481552	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1577472	ENSG00000230939.1	RP11-314C16.1	-7.09	1.69e-11	3.62e-08	-0.48	-0.43	Motion sickness;	chr6:8485982	chr6:8784178~8785445:+
OV	cis	rs2153535	0.542	rs1120393	ENSG00000230939.1	RP11-314C16.1	-7.09	1.69e-11	3.62e-08	-0.48	-0.43	Motion sickness;	chr6:8486657	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9406165	ENSG00000230939.1	RP11-314C16.1	-7.09	1.69e-11	3.62e-08	-0.48	-0.43	Motion sickness;	chr6:8488604	chr6:8784178~8785445:+
OV	cis	rs2153535	0.563	rs4428546	ENSG00000230939.1	RP11-314C16.1	-7.09	1.69e-11	3.62e-08	-0.48	-0.43	Motion sickness;	chr6:8490143	chr6:8784178~8785445:+
OV	cis	rs2153535	0.505	rs1335629	ENSG00000230939.1	RP11-314C16.1	-7.09	1.69e-11	3.62e-08	-0.48	-0.43	Motion sickness;	chr6:8491630	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs763376	ENSG00000230939.1	RP11-314C16.1	-7.09	1.69e-11	3.62e-08	-0.48	-0.43	Motion sickness;	chr6:8492543	chr6:8784178~8785445:+
OV	cis	rs1061377	1	rs7675782	ENSG00000249207.1	RP11-360F5.1	-7.09	1.69e-11	3.62e-08	-0.45	-0.43	Uric acid levels;	chr4:39120048	chr4:39112677~39126818:-
OV	cis	rs10256972	0.967	rs1881122	ENSG00000229043.2	AC091729.9	-7.09	1.69e-11	3.62e-08	-0.48	-0.43	Endometriosis;Longevity;	chr7:1001310	chr7:1160374~1165267:+
OV	cis	rs853679	0.517	rs868987	ENSG00000220721.1	OR1F12	-7.09	1.69e-11	3.63e-08	-0.52	-0.43	Depression;	chr6:28142370	chr6:28073316~28074233:+
OV	cis	rs7017914	0.967	rs7825446	ENSG00000223220.1	Y_RNA	7.09	1.7e-11	3.64e-08	0.44	0.43	Bone mineral density;	chr8:70751939	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs6472543	ENSG00000223220.1	Y_RNA	7.09	1.7e-11	3.64e-08	0.44	0.43	Bone mineral density;	chr8:70752173	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs7819332	ENSG00000223220.1	Y_RNA	7.09	1.7e-11	3.64e-08	0.44	0.43	Bone mineral density;	chr8:70756030	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs7012404	ENSG00000223220.1	Y_RNA	7.09	1.7e-11	3.64e-08	0.44	0.43	Bone mineral density;	chr8:70756463	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs7018381	ENSG00000223220.1	Y_RNA	7.09	1.7e-11	3.64e-08	0.44	0.43	Bone mineral density;	chr8:70757882	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs13258584	ENSG00000223220.1	Y_RNA	7.09	1.7e-11	3.64e-08	0.44	0.43	Bone mineral density;	chr8:70759344	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs7014012	ENSG00000223220.1	Y_RNA	7.09	1.7e-11	3.64e-08	0.44	0.43	Bone mineral density;	chr8:70760508	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs1471114	ENSG00000223220.1	Y_RNA	7.09	1.7e-11	3.64e-08	0.44	0.43	Bone mineral density;	chr8:70763312	chr8:70780914~70781008:-
OV	cis	rs1707322	0.717	rs2275086	ENSG00000281133.1	AL355480.3	7.09	1.7e-11	3.64e-08	0.56	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45580892~45580996:-
OV	cis	rs875971	0.54	rs736270	ENSG00000222364.1	RNU6-96P	-7.09	1.7e-11	3.64e-08	-0.44	-0.43	Aortic root size;	chr7:65963835	chr7:66395191~66395286:+
OV	cis	rs7017914	0.934	rs7009297	ENSG00000223220.1	Y_RNA	7.09	1.7e-11	3.65e-08	0.44	0.43	Bone mineral density;	chr8:70760131	chr8:70780914~70781008:-
OV	cis	rs3931020	0.72	rs1327090	ENSG00000272864.1	RP11-17E13.2	-7.09	1.72e-11	3.68e-08	-0.56	-0.43	Resistin levels;	chr1:74800795	chr1:74698769~74699333:-
OV	cis	rs2408955	0.521	rs10875749	ENSG00000258273.1	RP11-370I10.4	7.09	1.73e-11	3.7e-08	0.5	0.43	Glycated hemoglobin levels;	chr12:48138134	chr12:48333755~48333901:-
OV	cis	rs73086581	0.838	rs73088426	ENSG00000229539.1	RP11-119B16.2	7.09	1.73e-11	3.7e-08	0.55	0.43	Response to antidepressants in depression;	chr20:4022636	chr20:3888239~3888868:-
OV	cis	rs17711722	0.653	rs2460421	ENSG00000236529.1	RP13-254B10.1	-7.08	1.74e-11	3.73e-08	-0.45	-0.43	Calcium levels;	chr7:66026136	chr7:65840212~65840596:+
OV	cis	rs1707322	0.686	rs1541131	ENSG00000280836.1	AL355480.1	7.08	1.75e-11	3.73e-08	0.6	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619262	chr1:45581219~45581321:-
OV	cis	rs7246967	0.932	rs35968517	ENSG00000269509.1	BNIP3P34	7.08	1.75e-11	3.75e-08	0.64	0.43	Bronchopulmonary dysplasia;	chr19:22844238	chr19:22773853~22774424:+
OV	cis	rs7246967	0.866	rs12984122	ENSG00000269509.1	BNIP3P34	7.08	1.76e-11	3.75e-08	0.64	0.43	Bronchopulmonary dysplasia;	chr19:22847872	chr19:22773853~22774424:+
OV	cis	rs8062405	0.72	rs9926245	ENSG00000259982.1	CDC37P1	7.08	1.76e-11	3.75e-08	0.5	0.43	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28700294~28701540:-
OV	cis	rs11159086	1	rs17100451	ENSG00000259005.1	RP3-449M8.6	7.08	1.76e-11	3.75e-08	0.68	0.43	Advanced glycation end-product levels;	chr14:74476210	chr14:74474007~74474864:-
OV	cis	rs7569084	0.687	rs4671663	ENSG00000234255.7	AC012370.3	7.08	1.76e-11	3.76e-08	0.48	0.43	Sum eosinophil basophil counts;	chr2:65434400	chr2:65439888~65456571:-
OV	cis	rs7569084	0.687	rs11692813	ENSG00000234255.7	AC012370.3	7.08	1.76e-11	3.76e-08	0.48	0.43	Sum eosinophil basophil counts;	chr2:65435172	chr2:65439888~65456571:-
OV	cis	rs2153535	0.505	rs1737583	ENSG00000230939.1	RP11-314C16.1	-7.08	1.76e-11	3.76e-08	-0.49	-0.43	Motion sickness;	chr6:8536579	chr6:8784178~8785445:+
OV	cis	rs2153535	0.563	rs3117071	ENSG00000230939.1	RP11-314C16.1	-7.08	1.76e-11	3.76e-08	-0.49	-0.43	Motion sickness;	chr6:8537675	chr6:8784178~8785445:+
OV	cis	rs2882667	0.556	rs6873733	ENSG00000253404.1	AC034243.1	7.08	1.76e-11	3.76e-08	0.48	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139067628	chr5:138744434~138753309:-
OV	cis	rs1707322	1	rs7538978	ENSG00000281133.1	AL355480.3	7.08	1.77e-11	3.78e-08	0.53	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039382	chr1:45580892~45580996:-
OV	cis	rs73086581	1	rs3746666	ENSG00000229539.1	RP11-119B16.2	7.08	1.77e-11	3.78e-08	0.54	0.43	Response to antidepressants in depression;	chr20:3930214	chr20:3888239~3888868:-
OV	cis	rs2153535	0.58	rs1855769	ENSG00000230939.1	RP11-314C16.1	-7.08	1.77e-11	3.78e-08	-0.48	-0.43	Motion sickness;	chr6:8472862	chr6:8784178~8785445:+
OV	cis	rs7017914	0.87	rs34282253	ENSG00000223220.1	Y_RNA	7.08	1.77e-11	3.78e-08	0.45	0.43	Bone mineral density;	chr8:70670131	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs2100908	ENSG00000223220.1	Y_RNA	7.08	1.77e-11	3.78e-08	0.45	0.43	Bone mineral density;	chr8:70671075	chr8:70780914~70781008:-
OV	cis	rs1707322	1	rs6672115	ENSG00000281133.1	AL355480.3	-7.08	1.78e-11	3.79e-08	-0.55	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807207	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs4134387	ENSG00000281133.1	AL355480.3	-7.08	1.78e-11	3.79e-08	-0.55	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs785490	ENSG00000281133.1	AL355480.3	7.08	1.79e-11	3.81e-08	0.54	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46111452	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs785493	ENSG00000281133.1	AL355480.3	7.08	1.79e-11	3.81e-08	0.54	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46119187	chr1:45580892~45580996:-
OV	cis	rs1707322	0.964	rs785496	ENSG00000281133.1	AL355480.3	7.08	1.79e-11	3.81e-08	0.54	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46122334	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs785497	ENSG00000281133.1	AL355480.3	7.08	1.79e-11	3.81e-08	0.54	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126231	chr1:45580892~45580996:-
OV	cis	rs1707322	0.964	rs785499	ENSG00000281133.1	AL355480.3	7.08	1.79e-11	3.81e-08	0.54	0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126748	chr1:45580892~45580996:-
OV	cis	rs1707322	0.686	rs1250	ENSG00000280836.1	AL355480.1	-7.08	1.79e-11	3.81e-08	-0.6	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628355	chr1:45581219~45581321:-
OV	cis	rs875971	0.755	rs76288834	ENSG00000226824.5	RP4-756H11.3	7.08	1.79e-11	3.81e-08	0.45	0.43	Aortic root size;	chr7:66604815	chr7:66654538~66669855:+
OV	cis	rs3091242	0.933	rs61775167	ENSG00000261349.1	RP3-465N24.5	7.08	1.79e-11	3.82e-08	0.45	0.43	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25266102~25267136:-
OV	cis	rs4591358	0.773	rs34480328	ENSG00000223466.1	AC064834.2	-7.08	1.8e-11	3.82e-08	-0.58	-0.43	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195510684	chr2:195533035~195538681:+
OV	cis	rs7017914	0.967	rs13271442	ENSG00000223220.1	Y_RNA	7.08	1.8e-11	3.82e-08	0.45	0.43	Bone mineral density;	chr8:70672934	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs34558600	ENSG00000223220.1	Y_RNA	7.08	1.8e-11	3.82e-08	0.45	0.43	Bone mineral density;	chr8:70673917	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs6472538	ENSG00000223220.1	Y_RNA	7.08	1.8e-11	3.82e-08	0.45	0.43	Bone mineral density;	chr8:70674736	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs7001162	ENSG00000223220.1	Y_RNA	7.08	1.8e-11	3.82e-08	0.45	0.43	Bone mineral density;	chr8:70675235	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs56112621	ENSG00000223220.1	Y_RNA	7.08	1.8e-11	3.82e-08	0.45	0.43	Bone mineral density;	chr8:70676159	chr8:70780914~70781008:-
OV	cis	rs7017914	1	rs7017914	ENSG00000223220.1	Y_RNA	7.08	1.8e-11	3.82e-08	0.45	0.43	Bone mineral density;	chr8:70678968	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs13256250	ENSG00000223220.1	Y_RNA	7.08	1.8e-11	3.82e-08	0.45	0.43	Bone mineral density;	chr8:70683958	chr8:70780914~70781008:-
OV	cis	rs1707322	1	rs10890381	ENSG00000281133.1	AL355480.3	-7.08	1.81e-11	3.85e-08	-0.55	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986099	chr1:45580892~45580996:-
OV	cis	rs1707322	0.827	rs12125508	ENSG00000281133.1	AL355480.3	-7.08	1.82e-11	3.88e-08	-0.54	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr1:45580892~45580996:-
OV	cis	rs1707322	0.826	rs10890349	ENSG00000281133.1	AL355480.3	-7.08	1.82e-11	3.88e-08	-0.54	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr1:45580892~45580996:-
OV	cis	rs1707322	0.758	rs10789474	ENSG00000281133.1	AL355480.3	-7.08	1.82e-11	3.88e-08	-0.54	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs7520123	ENSG00000281133.1	AL355480.3	-7.08	1.83e-11	3.89e-08	-0.54	-0.43	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr1:45580892~45580996:-
OV	cis	rs2882667	0.505	rs7721110	ENSG00000253404.1	AC034243.1	7.07	1.85e-11	3.92e-08	0.49	0.43	Age-related hearing impairment (SNP x SNP interaction);	chr5:139146817	chr5:138744434~138753309:-
OV	cis	rs1707322	0.964	rs785516	ENSG00000281133.1	AL355480.3	7.07	1.86e-11	3.96e-08	0.54	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46099086	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs785517	ENSG00000281133.1	AL355480.3	7.07	1.86e-11	3.96e-08	0.54	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46101863	chr1:45580892~45580996:-
OV	cis	rs7246967	1	rs35332070	ENSG00000269509.1	BNIP3P34	7.07	1.87e-11	3.96e-08	0.63	0.42	Bronchopulmonary dysplasia;	chr19:22851464	chr19:22773853~22774424:+
OV	cis	rs7246967	0.866	rs12972095	ENSG00000269509.1	BNIP3P34	7.07	1.87e-11	3.96e-08	0.63	0.42	Bronchopulmonary dysplasia;	chr19:22851708	chr19:22773853~22774424:+
OV	cis	rs7246967	0.551	rs7351072	ENSG00000269509.1	BNIP3P34	7.07	1.87e-11	3.96e-08	0.63	0.42	Bronchopulmonary dysplasia;	chr19:22861727	chr19:22773853~22774424:+
OV	cis	rs11159086	1	rs58384818	ENSG00000259005.1	RP3-449M8.6	7.07	1.87e-11	3.97e-08	0.68	0.42	Advanced glycation end-product levels;	chr14:74487045	chr14:74474007~74474864:-
OV	cis	rs11159086	1	rs17100588	ENSG00000259005.1	RP3-449M8.6	7.07	1.87e-11	3.97e-08	0.68	0.42	Advanced glycation end-product levels;	chr14:74487624	chr14:74474007~74474864:-
OV	cis	rs7569084	0.687	rs7577452	ENSG00000234255.7	AC012370.3	7.07	1.88e-11	3.98e-08	0.47	0.42	Sum eosinophil basophil counts;	chr2:65456694	chr2:65439888~65456571:-
OV	cis	rs8005677	0.962	rs8003934	ENSG00000257285.4	RP11-298I3.1	7.07	1.88e-11	3.98e-08	0.49	0.42	Cognitive ability (multi-trait analysis);	chr14:22931933	chr14:22929609~22955562:+
OV	cis	rs10510102	0.872	rs12246693	ENSG00000276742.1	RP11-500G22.4	7.07	1.9e-11	4.02e-08	0.68	0.42	Breast cancer;	chr10:121957373	chr10:121956782~121957098:+
OV	cis	rs10510102	0.872	rs12248806	ENSG00000276742.1	RP11-500G22.4	7.07	1.9e-11	4.02e-08	0.68	0.42	Breast cancer;	chr10:121958638	chr10:121956782~121957098:+
OV	cis	rs10510102	0.872	rs12255832	ENSG00000276742.1	RP11-500G22.4	7.07	1.9e-11	4.02e-08	0.68	0.42	Breast cancer;	chr10:121958762	chr10:121956782~121957098:+
OV	cis	rs10510102	0.872	rs12247367	ENSG00000276742.1	RP11-500G22.4	7.07	1.9e-11	4.02e-08	0.68	0.42	Breast cancer;	chr10:121961556	chr10:121956782~121957098:+
OV	cis	rs10510102	0.872	rs12240306	ENSG00000276742.1	RP11-500G22.4	7.07	1.9e-11	4.02e-08	0.68	0.42	Breast cancer;	chr10:121963391	chr10:121956782~121957098:+
OV	cis	rs10510102	0.872	rs12240308	ENSG00000276742.1	RP11-500G22.4	7.07	1.9e-11	4.02e-08	0.68	0.42	Breast cancer;	chr10:121963407	chr10:121956782~121957098:+
OV	cis	rs1707322	0.506	rs2991983	ENSG00000281133.1	AL355480.3	7.07	1.9e-11	4.02e-08	0.56	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr1:45580892~45580996:-
OV	cis	rs1707322	0.717	rs3014249	ENSG00000281133.1	AL355480.3	7.07	1.9e-11	4.02e-08	0.56	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr1:45580892~45580996:-
OV	cis	rs6991838	0.584	rs7459944	ENSG00000272010.1	CTD-3025N20.3	-7.07	1.9e-11	4.02e-08	-0.52	-0.42	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65591850~65592472:-
OV	cis	rs1707322	1	rs785484	ENSG00000281133.1	AL355480.3	7.07	1.9e-11	4.02e-08	0.54	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46108343	chr1:45580892~45580996:-
OV	cis	rs8005677	1	rs7155857	ENSG00000257285.4	RP11-298I3.1	7.07	1.91e-11	4.04e-08	0.49	0.42	Cognitive ability (multi-trait analysis);	chr14:22930850	chr14:22929609~22955562:+
OV	cis	rs1707322	0.964	rs785508	ENSG00000281133.1	AL355480.3	7.07	1.91e-11	4.04e-08	0.54	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr1:45580892~45580996:-
OV	cis	rs1707322	0.964	rs785509	ENSG00000281133.1	AL355480.3	7.07	1.91e-11	4.04e-08	0.54	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr1:45580892~45580996:-
OV	cis	rs1707322	0.929	rs785513	ENSG00000281133.1	AL355480.3	7.07	1.91e-11	4.04e-08	0.54	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46072648	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs12097761	ENSG00000281133.1	AL355480.3	-7.07	1.92e-11	4.05e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825490	chr1:45580892~45580996:-
OV	cis	rs4591358	0.648	rs56906982	ENSG00000223466.1	AC064834.2	-7.07	1.93e-11	4.08e-08	-0.58	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195512939	chr2:195533035~195538681:+
OV	cis	rs4591358	0.773	rs13035226	ENSG00000223466.1	AC064834.2	-7.07	1.93e-11	4.08e-08	-0.58	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195512957	chr2:195533035~195538681:+
OV	cis	rs2117029	0.555	rs3741621	ENSG00000258017.1	RP11-386G11.10	-7.07	1.94e-11	4.09e-08	-0.52	-0.42	Intelligence (multi-trait analysis);	chr12:49100242	chr12:49127782~49147869:+
OV	cis	rs2117029	0.555	rs2047101	ENSG00000258017.1	RP11-386G11.10	-7.07	1.94e-11	4.09e-08	-0.52	-0.42	Intelligence (multi-trait analysis);	chr12:49103860	chr12:49127782~49147869:+
OV	cis	rs8062405	0.698	rs7188071	ENSG00000259982.1	CDC37P1	-7.07	1.94e-11	4.11e-08	-0.54	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28906323	chr16:28700294~28701540:-
OV	cis	rs1707322	0.963	rs6429581	ENSG00000281133.1	AL355480.3	-7.07	1.95e-11	4.11e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853424	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs4660335	ENSG00000281133.1	AL355480.3	-7.07	1.95e-11	4.12e-08	-0.55	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr1:45580892~45580996:-
OV	cis	rs6991838	0.584	rs35941313	ENSG00000272010.1	CTD-3025N20.3	-7.06	1.95e-11	4.12e-08	-0.53	-0.42	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65591850~65592472:-
OV	cis	rs17711722	1	rs17711722	ENSG00000226824.5	RP4-756H11.3	7.06	1.96e-11	4.13e-08	0.45	0.42	Calcium levels;	chr7:65806210	chr7:66654538~66669855:+
OV	cis	rs853679	0.513	rs9468296	ENSG00000220721.1	OR1F12	7.06	1.96e-11	4.14e-08	0.5	0.42	Depression;	chr6:28145952	chr6:28073316~28074233:+
OV	cis	rs4591358	0.689	rs72927705	ENSG00000223466.1	AC064834.2	-7.06	1.97e-11	4.15e-08	-0.6	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195518341	chr2:195533035~195538681:+
OV	cis	rs4591358	0.689	rs72927707	ENSG00000223466.1	AC064834.2	-7.06	1.97e-11	4.15e-08	-0.6	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195518526	chr2:195533035~195538681:+
OV	cis	rs4591358	0.689	rs16836823	ENSG00000223466.1	AC064834.2	-7.06	1.97e-11	4.15e-08	-0.6	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195518785	chr2:195533035~195538681:+
OV	cis	rs4591358	0.689	rs57244991	ENSG00000223466.1	AC064834.2	-7.06	1.97e-11	4.15e-08	-0.6	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195519331	chr2:195533035~195538681:+
OV	cis	rs4591358	0.689	rs72927708	ENSG00000223466.1	AC064834.2	-7.06	1.97e-11	4.15e-08	-0.6	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195519789	chr2:195533035~195538681:+
OV	cis	rs4591358	0.689	rs72927711	ENSG00000223466.1	AC064834.2	-7.06	1.97e-11	4.15e-08	-0.6	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195520309	chr2:195533035~195538681:+
OV	cis	rs4591358	0.689	rs72927717	ENSG00000223466.1	AC064834.2	-7.06	1.97e-11	4.15e-08	-0.6	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195520887	chr2:195533035~195538681:+
OV	cis	rs6921919	0.583	rs9461459	ENSG00000216901.1	AL022393.7	7.06	1.97e-11	4.15e-08	0.5	0.42	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs28360638	ENSG00000216901.1	AL022393.7	7.06	1.97e-11	4.15e-08	0.5	0.42	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28176188~28176674:+
OV	cis	rs4423214	0.879	rs1790324	ENSG00000254682.1	RP11-660L16.2	-7.06	1.97e-11	4.16e-08	-0.52	-0.42	Vitamin D levels;	chr11:71439474	chr11:71448674~71452157:+
OV	cis	rs73086581	0.787	rs73084505	ENSG00000229539.1	RP11-119B16.2	7.06	1.97e-11	4.16e-08	0.57	0.42	Response to antidepressants in depression;	chr20:3876227	chr20:3888239~3888868:-
OV	cis	rs4591358	0.689	rs72927725	ENSG00000223466.1	AC064834.2	-7.06	1.97e-11	4.16e-08	-0.61	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195529140	chr2:195533035~195538681:+
OV	cis	rs4591358	0.689	rs7574191	ENSG00000223466.1	AC064834.2	-7.06	1.97e-11	4.16e-08	-0.61	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195529995	chr2:195533035~195538681:+
OV	cis	rs4591358	0.689	rs1500605	ENSG00000223466.1	AC064834.2	-7.06	1.97e-11	4.16e-08	-0.61	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195530584	chr2:195533035~195538681:+
OV	cis	rs4591358	0.648	rs1515877	ENSG00000223466.1	AC064834.2	-7.06	1.97e-11	4.16e-08	-0.61	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195530995	chr2:195533035~195538681:+
OV	cis	rs4591358	0.689	rs16836990	ENSG00000223466.1	AC064834.2	-7.06	1.97e-11	4.16e-08	-0.61	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195532968	chr2:195533035~195538681:+
OV	cis	rs4591358	0.689	rs16837006	ENSG00000223466.1	AC064834.2	-7.06	1.97e-11	4.16e-08	-0.61	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195533245	chr2:195533035~195538681:+
OV	cis	rs4591358	0.689	rs16837010	ENSG00000223466.1	AC064834.2	-7.06	1.97e-11	4.16e-08	-0.61	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195533302	chr2:195533035~195538681:+
OV	cis	rs2836974	0.666	rs12626405	ENSG00000232608.1	TIMM9P2	7.06	1.98e-11	4.17e-08	0.45	0.42	Cognitive function;	chr21:39291195	chr21:39216624~39217506:+
OV	cis	rs1707322	1	rs10789479	ENSG00000281133.1	AL355480.3	-7.06	2e-11	4.22e-08	-0.55	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886828	chr1:45580892~45580996:-
OV	cis	rs1707322	0.686	rs3014239	ENSG00000280836.1	AL355480.1	7.06	2.01e-11	4.22e-08	0.6	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624129	chr1:45581219~45581321:-
OV	cis	rs1707322	0.686	rs3014236	ENSG00000280836.1	AL355480.1	7.06	2.01e-11	4.22e-08	0.6	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625633	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs10890333	ENSG00000280836.1	AL355480.1	-7.06	2.02e-11	4.26e-08	-0.59	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs12043945	ENSG00000280836.1	AL355480.1	-7.06	2.02e-11	4.26e-08	-0.59	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs12091503	ENSG00000280836.1	AL355480.1	-7.06	2.02e-11	4.26e-08	-0.59	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs1707317	ENSG00000281133.1	AL355480.3	7.06	2.05e-11	4.31e-08	0.54	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044970	chr1:45580892~45580996:-
OV	cis	rs2836974	0.644	rs719230	ENSG00000232608.1	TIMM9P2	7.06	2.06e-11	4.32e-08	0.45	0.42	Cognitive function;	chr21:39304381	chr21:39216624~39217506:+
OV	cis	rs73086581	1	rs17286349	ENSG00000229539.1	RP11-119B16.2	7.06	2.06e-11	4.32e-08	0.54	0.42	Response to antidepressants in depression;	chr20:3933655	chr20:3888239~3888868:-
OV	cis	rs2153535	0.58	rs6905242	ENSG00000230939.1	RP11-314C16.1	-7.06	2.06e-11	4.32e-08	-0.48	-0.42	Motion sickness;	chr6:8471566	chr6:8784178~8785445:+
OV	cis	rs8105895	0.867	rs116220423	ENSG00000269742.1	BNIP3P29	7.06	2.06e-11	4.33e-08	0.69	0.42	Body mass index (change over time);	chr19:22054239	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs16998834	ENSG00000269742.1	BNIP3P29	7.06	2.06e-11	4.33e-08	0.69	0.42	Body mass index (change over time);	chr19:22084235	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs62110993	ENSG00000269742.1	BNIP3P29	7.06	2.06e-11	4.33e-08	0.69	0.42	Body mass index (change over time);	chr19:22085458	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs62111027	ENSG00000269742.1	BNIP3P29	7.06	2.06e-11	4.33e-08	0.69	0.42	Body mass index (change over time);	chr19:22086217	chr19:22065828~22066398:-
OV	cis	rs6700559	1	rs6700559	ENSG00000260088.1	RP11-92G12.3	7.06	2.07e-11	4.34e-08	0.44	0.42	Coronary artery disease;	chr1:200676945	chr1:200669507~200694250:+
OV	cis	rs1707322	0.686	rs2275085	ENSG00000280836.1	AL355480.1	7.05	2.07e-11	4.34e-08	0.6	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620180	chr1:45581219~45581321:-
OV	cis	rs3091242	0.933	rs909833	ENSG00000261349.1	RP3-465N24.5	-7.05	2.09e-11	4.39e-08	-0.46	-0.42	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25266102~25267136:-
OV	cis	rs1707322	0.65	rs4553239	ENSG00000280836.1	AL355480.1	-7.05	2.1e-11	4.4e-08	-0.59	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684814	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs1612419	ENSG00000281133.1	AL355480.3	7.05	2.11e-11	4.42e-08	0.54	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081273	chr1:45580892~45580996:-
OV	cis	rs17711722	0.522	rs62469933	ENSG00000236529.1	RP13-254B10.1	7.05	2.11e-11	4.43e-08	0.46	0.42	Calcium levels;	chr7:65800652	chr7:65840212~65840596:+
OV	cis	rs1707322	0.662	rs11211160	ENSG00000281133.1	AL355480.3	-7.05	2.12e-11	4.45e-08	-0.53	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr1:45580892~45580996:-
OV	cis	rs7927771	1	rs11039255	ENSG00000280615.1	Y_RNA	-7.05	2.13e-11	4.46e-08	-0.52	-0.42	Subjective well-being;	chr11:47474194	chr11:47614898~47614994:-
OV	cis	rs1707322	0.686	rs11211179	ENSG00000281133.1	AL355480.3	-7.05	2.13e-11	4.47e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs10157795	ENSG00000281133.1	AL355480.3	-7.05	2.13e-11	4.47e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr1:45580892~45580996:-
OV	cis	rs11168351	0.75	rs11168366	ENSG00000258273.1	RP11-370I10.4	7.05	2.14e-11	4.48e-08	0.52	0.42	Bipolar disorder and schizophrenia;	chr12:48027990	chr12:48333755~48333901:-
OV	cis	rs2153535	0.584	rs9502721	ENSG00000230939.1	RP11-314C16.1	-7.05	2.14e-11	4.49e-08	-0.49	-0.42	Motion sickness;	chr6:8541146	chr6:8784178~8785445:+
OV	cis	rs2153535	0.607	rs9502722	ENSG00000230939.1	RP11-314C16.1	-7.05	2.14e-11	4.49e-08	-0.49	-0.42	Motion sickness;	chr6:8541250	chr6:8784178~8785445:+
OV	cis	rs7569084	0.687	rs11675538	ENSG00000234255.7	AC012370.3	7.05	2.15e-11	4.5e-08	0.47	0.42	Sum eosinophil basophil counts;	chr2:65459327	chr2:65439888~65456571:-
OV	cis	rs2836974	0.568	rs377098	ENSG00000232608.1	TIMM9P2	7.05	2.18e-11	4.55e-08	0.45	0.42	Cognitive function;	chr21:39163290	chr21:39216624~39217506:+
OV	cis	rs2836974	0.568	rs371625	ENSG00000232608.1	TIMM9P2	7.05	2.18e-11	4.55e-08	0.45	0.42	Cognitive function;	chr21:39163345	chr21:39216624~39217506:+
OV	cis	rs875971	0.577	rs34888281	ENSG00000236529.1	RP13-254B10.1	-7.05	2.19e-11	4.58e-08	-0.44	-0.42	Aortic root size;	chr7:66120784	chr7:65840212~65840596:+
OV	cis	rs1707322	1	rs785467	ENSG00000281133.1	AL355480.3	7.04	2.2e-11	4.59e-08	0.54	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055887	chr1:45580892~45580996:-
OV	cis	rs7569084	0.687	rs1437462	ENSG00000234255.7	AC012370.3	7.04	2.22e-11	4.63e-08	0.48	0.42	Sum eosinophil basophil counts;	chr2:65449559	chr2:65439888~65456571:-
OV	cis	rs875971	0.545	rs6460281	ENSG00000222364.1	RNU6-96P	-7.04	2.23e-11	4.66e-08	-0.49	-0.42	Aortic root size;	chr7:66216128	chr7:66395191~66395286:+
OV	cis	rs10262624	0.901	rs6977550	ENSG00000234286.1	AC006026.13	-7.04	2.24e-11	4.68e-08	-0.49	-0.42	Schizophrenia;	chr7:23865825	chr7:23680195~23680786:-
OV	cis	rs8005677	0.926	rs34344888	ENSG00000257285.4	RP11-298I3.1	7.04	2.24e-11	4.68e-08	0.49	0.42	Cognitive ability (multi-trait analysis);	chr14:22918376	chr14:22929609~22955562:+
OV	cis	rs8005677	0.962	rs34917191	ENSG00000257285.4	RP11-298I3.1	7.04	2.24e-11	4.68e-08	0.49	0.42	Cognitive ability (multi-trait analysis);	chr14:22918419	chr14:22929609~22955562:+
OV	cis	rs8005677	1	rs1951119	ENSG00000257285.4	RP11-298I3.1	7.04	2.24e-11	4.68e-08	0.49	0.42	Cognitive ability (multi-trait analysis);	chr14:22919117	chr14:22929609~22955562:+
OV	cis	rs8005677	1	rs2295683	ENSG00000257285.4	RP11-298I3.1	7.04	2.24e-11	4.68e-08	0.49	0.42	Cognitive ability (multi-trait analysis);	chr14:22919173	chr14:22929609~22955562:+
OV	cis	rs8005677	1	rs4981449	ENSG00000257285.4	RP11-298I3.1	7.04	2.24e-11	4.68e-08	0.49	0.42	Cognitive ability (multi-trait analysis);	chr14:22919662	chr14:22929609~22955562:+
OV	cis	rs11168351	0.926	rs10875719	ENSG00000258273.1	RP11-370I10.4	-7.04	2.24e-11	4.68e-08	-0.5	-0.42	Bipolar disorder and schizophrenia;	chr12:48017375	chr12:48333755~48333901:-
OV	cis	rs1707322	0.717	rs3014237	ENSG00000281133.1	AL355480.3	7.04	2.25e-11	4.68e-08	0.57	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45580892~45580996:-
OV	cis	rs2153535	0.58	rs9406159	ENSG00000230939.1	RP11-314C16.1	-7.04	2.25e-11	4.68e-08	-0.48	-0.42	Motion sickness;	chr6:8464626	chr6:8784178~8785445:+
OV	cis	rs2836974	0.666	rs2836975	ENSG00000232608.1	TIMM9P2	7.04	2.25e-11	4.7e-08	0.45	0.42	Cognitive function;	chr21:39291694	chr21:39216624~39217506:+
OV	cis	rs7569084	0.663	rs11126037	ENSG00000234255.7	AC012370.3	7.04	2.26e-11	4.71e-08	0.47	0.42	Sum eosinophil basophil counts;	chr2:65436024	chr2:65439888~65456571:-
OV	cis	rs7569084	0.663	rs11694714	ENSG00000234255.7	AC012370.3	7.04	2.26e-11	4.71e-08	0.47	0.42	Sum eosinophil basophil counts;	chr2:65436802	chr2:65439888~65456571:-
OV	cis	rs1061377	1	rs36090629	ENSG00000249207.1	RP11-360F5.1	-7.04	2.26e-11	4.72e-08	-0.45	-0.42	Uric acid levels;	chr4:39137195	chr4:39112677~39126818:-
OV	cis	rs1061377	0.87	rs73238544	ENSG00000249207.1	RP11-360F5.1	-7.04	2.26e-11	4.72e-08	-0.45	-0.42	Uric acid levels;	chr4:39137343	chr4:39112677~39126818:-
OV	cis	rs7927771	1	rs10838738	ENSG00000280615.1	Y_RNA	-7.04	2.28e-11	4.74e-08	-0.53	-0.42	Subjective well-being;	chr11:47641497	chr11:47614898~47614994:-
OV	cis	rs2153535	0.541	rs4637688	ENSG00000230939.1	RP11-314C16.1	-7.04	2.28e-11	4.74e-08	-0.48	-0.42	Motion sickness;	chr6:8446268	chr6:8784178~8785445:+
OV	cis	rs7927771	0.965	rs1064608	ENSG00000280615.1	Y_RNA	-7.04	2.29e-11	4.76e-08	-0.52	-0.42	Subjective well-being;	chr11:47618877	chr11:47614898~47614994:-
OV	cis	rs1707322	0.721	rs10890336	ENSG00000280836.1	AL355480.1	-7.04	2.29e-11	4.76e-08	-0.58	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs11211151	ENSG00000280836.1	AL355480.1	-7.04	2.29e-11	4.76e-08	-0.58	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs12045096	ENSG00000280836.1	AL355480.1	-7.04	2.29e-11	4.76e-08	-0.58	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs4609469	ENSG00000280836.1	AL355480.1	-7.04	2.29e-11	4.76e-08	-0.58	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs12049027	ENSG00000280836.1	AL355480.1	-7.04	2.29e-11	4.76e-08	-0.58	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr1:45581219~45581321:-
OV	cis	rs1707322	0.752	rs10789467	ENSG00000280836.1	AL355480.1	-7.04	2.29e-11	4.76e-08	-0.58	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs10890337	ENSG00000280836.1	AL355480.1	-7.04	2.29e-11	4.76e-08	-0.58	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr1:45581219~45581321:-
OV	cis	rs1707322	0.752	rs3811435	ENSG00000280836.1	AL355480.1	-7.04	2.29e-11	4.76e-08	-0.58	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs9793568	ENSG00000280836.1	AL355480.1	-7.04	2.29e-11	4.76e-08	-0.58	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs11211157	ENSG00000280836.1	AL355480.1	-7.04	2.29e-11	4.76e-08	-0.58	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs11211158	ENSG00000280836.1	AL355480.1	-7.04	2.29e-11	4.76e-08	-0.58	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs6429575	ENSG00000280836.1	AL355480.1	-7.04	2.29e-11	4.76e-08	-0.58	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr1:45581219~45581321:-
OV	cis	rs1707322	0.685	rs6690926	ENSG00000280836.1	AL355480.1	-7.04	2.29e-11	4.76e-08	-0.58	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr1:45581219~45581321:-
OV	cis	rs1707322	0.752	rs8179402	ENSG00000280836.1	AL355480.1	-7.04	2.29e-11	4.76e-08	-0.58	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr1:45581219~45581321:-
OV	cis	rs1707322	0.752	rs8179296	ENSG00000280836.1	AL355480.1	-7.04	2.29e-11	4.76e-08	-0.58	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr1:45581219~45581321:-
OV	cis	rs7246967	0.608	rs428613	ENSG00000269509.1	BNIP3P34	7.04	2.3e-11	4.78e-08	0.64	0.42	Bronchopulmonary dysplasia;	chr19:22827117	chr19:22773853~22774424:+
OV	cis	rs2153535	0.58	rs9505467	ENSG00000230939.1	RP11-314C16.1	-7.04	2.3e-11	4.78e-08	-0.48	-0.42	Motion sickness;	chr6:8519986	chr6:8784178~8785445:+
OV	cis	rs1707322	1	rs4660334	ENSG00000281133.1	AL355480.3	-7.03	2.33e-11	4.83e-08	-0.53	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45996454	chr1:45580892~45580996:-
OV	cis	rs6991838	0.584	rs7463649	ENSG00000272010.1	CTD-3025N20.3	-7.03	2.33e-11	4.83e-08	-0.53	-0.42	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs7463740	ENSG00000272010.1	CTD-3025N20.3	-7.03	2.33e-11	4.83e-08	-0.53	-0.42	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs66467166	ENSG00000272010.1	CTD-3025N20.3	-7.03	2.33e-11	4.83e-08	-0.53	-0.42	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65591850~65592472:-
OV	cis	rs6991838	0.557	rs67685675	ENSG00000272010.1	CTD-3025N20.3	-7.03	2.33e-11	4.83e-08	-0.53	-0.42	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs66486920	ENSG00000272010.1	CTD-3025N20.3	-7.03	2.33e-11	4.83e-08	-0.53	-0.42	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs60023200	ENSG00000272010.1	CTD-3025N20.3	-7.03	2.33e-11	4.83e-08	-0.53	-0.42	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs61083799	ENSG00000272010.1	CTD-3025N20.3	-7.03	2.33e-11	4.83e-08	-0.53	-0.42	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs4449837	ENSG00000272010.1	CTD-3025N20.3	-7.03	2.33e-11	4.83e-08	-0.53	-0.42	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs57042777	ENSG00000272010.1	CTD-3025N20.3	-7.03	2.33e-11	4.83e-08	-0.53	-0.42	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65591850~65592472:-
OV	cis	rs2153535	0.58	rs962590	ENSG00000230939.1	RP11-314C16.1	-7.03	2.33e-11	4.83e-08	-0.48	-0.42	Motion sickness;	chr6:8450666	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs5001324	ENSG00000230939.1	RP11-314C16.1	-7.03	2.33e-11	4.83e-08	-0.48	-0.42	Motion sickness;	chr6:8451371	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs5001322	ENSG00000230939.1	RP11-314C16.1	-7.03	2.33e-11	4.83e-08	-0.48	-0.42	Motion sickness;	chr6:8451375	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs969422	ENSG00000230939.1	RP11-314C16.1	-7.03	2.33e-11	4.83e-08	-0.48	-0.42	Motion sickness;	chr6:8451547	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs969421	ENSG00000230939.1	RP11-314C16.1	-7.03	2.33e-11	4.83e-08	-0.48	-0.42	Motion sickness;	chr6:8451716	chr6:8784178~8785445:+
OV	cis	rs2153535	0.601	rs969420	ENSG00000230939.1	RP11-314C16.1	-7.03	2.33e-11	4.83e-08	-0.48	-0.42	Motion sickness;	chr6:8451733	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs7741456	ENSG00000230939.1	RP11-314C16.1	-7.03	2.33e-11	4.83e-08	-0.48	-0.42	Motion sickness;	chr6:8452191	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs7742689	ENSG00000230939.1	RP11-314C16.1	-7.03	2.33e-11	4.83e-08	-0.48	-0.42	Motion sickness;	chr6:8452200	chr6:8784178~8785445:+
OV	cis	rs11098499	1	rs1011054	ENSG00000245958.5	RP11-33B1.1	7.03	2.34e-11	4.86e-08	0.58	0.42	Corneal astigmatism;	chr4:119281232	chr4:119454791~119552025:+
OV	cis	rs492146	0.765	rs316133	ENSG00000243236.5	GSTA9P	-7.03	2.34e-11	4.86e-08	-0.51	-0.42	Epilepsy (remission after treatment);	chr6:52982753	chr6:52939726~52957521:-
OV	cis	rs7617773	0.539	rs17593974	ENSG00000229759.1	MRPS18AP1	7.03	2.36e-11	4.88e-08	0.44	0.42	Coronary artery disease;	chr3:48345844	chr3:48256350~48256938:-
OV	cis	rs7617773	0.514	rs11130166	ENSG00000229759.1	MRPS18AP1	7.03	2.36e-11	4.88e-08	0.44	0.42	Coronary artery disease;	chr3:48346566	chr3:48256350~48256938:-
OV	cis	rs7617773	0.563	rs62263035	ENSG00000229759.1	MRPS18AP1	7.03	2.36e-11	4.88e-08	0.44	0.42	Coronary artery disease;	chr3:48350079	chr3:48256350~48256938:-
OV	cis	rs2153535	0.58	rs1832100	ENSG00000230939.1	RP11-314C16.1	-7.03	2.39e-11	4.94e-08	-0.48	-0.42	Motion sickness;	chr6:8446723	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs2327058	ENSG00000230939.1	RP11-314C16.1	-7.03	2.39e-11	4.94e-08	-0.48	-0.42	Motion sickness;	chr6:8446785	chr6:8784178~8785445:+
OV	cis	rs2153535	0.601	rs2327059	ENSG00000230939.1	RP11-314C16.1	-7.03	2.39e-11	4.94e-08	-0.48	-0.42	Motion sickness;	chr6:8446838	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs2184582	ENSG00000230939.1	RP11-314C16.1	-7.03	2.39e-11	4.94e-08	-0.48	-0.42	Motion sickness;	chr6:8447560	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs2184583	ENSG00000230939.1	RP11-314C16.1	-7.03	2.39e-11	4.94e-08	-0.48	-0.42	Motion sickness;	chr6:8447575	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9505446	ENSG00000230939.1	RP11-314C16.1	-7.03	2.39e-11	4.94e-08	-0.48	-0.42	Motion sickness;	chr6:8448458	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1335633	ENSG00000230939.1	RP11-314C16.1	-7.03	2.39e-11	4.94e-08	-0.48	-0.42	Motion sickness;	chr6:8448567	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1115079	ENSG00000230939.1	RP11-314C16.1	-7.03	2.39e-11	4.94e-08	-0.48	-0.42	Motion sickness;	chr6:8449382	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1115078	ENSG00000230939.1	RP11-314C16.1	-7.03	2.39e-11	4.94e-08	-0.48	-0.42	Motion sickness;	chr6:8449405	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs6597322	ENSG00000230939.1	RP11-314C16.1	-7.03	2.39e-11	4.94e-08	-0.48	-0.42	Motion sickness;	chr6:8449719	chr6:8784178~8785445:+
OV	cis	rs6921919	0.583	rs7764722	ENSG00000216901.1	AL022393.7	7.03	2.41e-11	4.97e-08	0.49	0.42	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28176188~28176674:+
OV	cis	rs2836950	0.84	rs12482317	ENSG00000232608.1	TIMM9P2	7.03	2.41e-11	4.99e-08	0.51	0.42	Menarche (age at onset);	chr21:39216315	chr21:39216624~39217506:+
OV	cis	rs4713118	0.662	rs175954	ENSG00000220721.1	OR1F12	7.03	2.45e-11	5.05e-08	0.52	0.42	Parkinson's disease;	chr6:28043807	chr6:28073316~28074233:+
OV	cis	rs1707322	1	rs4660332	ENSG00000281133.1	AL355480.3	-7.03	2.45e-11	5.06e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995746	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs6665808	ENSG00000280836.1	AL355480.1	-7.03	2.45e-11	5.06e-08	-0.59	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr1:45581219~45581321:-
OV	cis	rs2836974	0.568	rs2142111	ENSG00000232608.1	TIMM9P2	-7.02	2.47e-11	5.09e-08	-0.45	-0.42	Cognitive function;	chr21:39177363	chr21:39216624~39217506:+
OV	cis	rs6700559	0.683	rs7548530	ENSG00000260088.1	RP11-92G12.3	-7.02	2.48e-11	5.1e-08	-0.44	-0.42	Coronary artery disease;	chr1:200687904	chr1:200669507~200694250:+
OV	cis	rs6700559	0.683	rs7526136	ENSG00000260088.1	RP11-92G12.3	-7.02	2.48e-11	5.1e-08	-0.44	-0.42	Coronary artery disease;	chr1:200687911	chr1:200669507~200694250:+
OV	cis	rs6700559	0.733	rs7526265	ENSG00000260088.1	RP11-92G12.3	-7.02	2.48e-11	5.1e-08	-0.44	-0.42	Coronary artery disease;	chr1:200687916	chr1:200669507~200694250:+
OV	cis	rs1707322	1	rs4074225	ENSG00000281133.1	AL355480.3	-7.02	2.51e-11	5.15e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs10789485	ENSG00000281133.1	AL355480.3	-7.02	2.51e-11	5.15e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr1:45580892~45580996:-
OV	cis	rs1707322	0.964	rs12067716	ENSG00000281133.1	AL355480.3	-7.02	2.51e-11	5.15e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr1:45580892~45580996:-
OV	cis	rs1061377	1	rs2890659	ENSG00000249207.1	RP11-360F5.1	-7.02	2.52e-11	5.19e-08	-0.45	-0.42	Uric acid levels;	chr4:39125401	chr4:39112677~39126818:-
OV	cis	rs1061377	0.932	rs35464499	ENSG00000249207.1	RP11-360F5.1	-7.02	2.52e-11	5.19e-08	-0.45	-0.42	Uric acid levels;	chr4:39127670	chr4:39112677~39126818:-
OV	cis	rs9813712	0.574	rs11718032	ENSG00000228252.7	COL6A4P2	7.02	2.53e-11	5.19e-08	0.46	0.42	Response to amphetamines;	chr3:130257749	chr3:130212823~130273806:+
OV	cis	rs1707322	1	rs10890350	ENSG00000281133.1	AL355480.3	-7.02	2.53e-11	5.19e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796706	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs4390216	ENSG00000281133.1	AL355480.3	-7.02	2.53e-11	5.19e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800784	chr1:45580892~45580996:-
OV	cis	rs1707322	0.964	rs10437063	ENSG00000281133.1	AL355480.3	-7.02	2.53e-11	5.19e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807994	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs6676982	ENSG00000281133.1	AL355480.3	-7.02	2.53e-11	5.19e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809729	chr1:45580892~45580996:-
OV	cis	rs1707322	0.927	rs11211194	ENSG00000281133.1	AL355480.3	-7.02	2.53e-11	5.19e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45816412	chr1:45580892~45580996:-
OV	cis	rs8005677	1	rs8006396	ENSG00000257285.4	RP11-298I3.1	7.02	2.54e-11	5.21e-08	0.49	0.42	Cognitive ability (multi-trait analysis);	chr14:22911641	chr14:22929609~22955562:+
OV	cis	rs8005677	1	rs4981446	ENSG00000257285.4	RP11-298I3.1	7.02	2.54e-11	5.21e-08	0.49	0.42	Cognitive ability (multi-trait analysis);	chr14:22912204	chr14:22929609~22955562:+
OV	cis	rs8005677	1	rs4982706	ENSG00000257285.4	RP11-298I3.1	7.02	2.54e-11	5.21e-08	0.49	0.42	Cognitive ability (multi-trait analysis);	chr14:22912488	chr14:22929609~22955562:+
OV	cis	rs8062405	0.792	rs12446550	ENSG00000259982.1	CDC37P1	7.02	2.56e-11	5.26e-08	0.5	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28700294~28701540:-
OV	cis	rs4591358	0.638	rs6732435	ENSG00000223466.1	AC064834.2	-7.02	2.57e-11	5.27e-08	-0.61	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195541501	chr2:195533035~195538681:+
OV	cis	rs6991838	0.556	rs7846527	ENSG00000272010.1	CTD-3025N20.3	-7.02	2.59e-11	5.31e-08	-0.52	-0.42	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs4320587	ENSG00000272010.1	CTD-3025N20.3	-7.02	2.59e-11	5.31e-08	-0.52	-0.42	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65591850~65592472:-
OV	cis	rs6991838	0.557	rs4737222	ENSG00000272010.1	CTD-3025N20.3	-7.02	2.59e-11	5.31e-08	-0.52	-0.42	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65591850~65592472:-
OV	cis	rs11673344	0.566	rs256735	ENSG00000226686.6	LINC01535	-7.02	2.6e-11	5.33e-08	-0.49	-0.42	Obesity-related traits;	chr19:37375141	chr19:37251912~37265535:+
OV	cis	rs11673344	0.566	rs185369	ENSG00000226686.6	LINC01535	-7.02	2.6e-11	5.33e-08	-0.49	-0.42	Obesity-related traits;	chr19:37376137	chr19:37251912~37265535:+
OV	cis	rs17711722	0.565	rs4275112	ENSG00000236529.1	RP13-254B10.1	-7.02	2.62e-11	5.36e-08	-0.47	-0.42	Calcium levels;	chr7:65733651	chr7:65840212~65840596:+
OV	cis	rs2153535	0.58	rs2327061	ENSG00000230939.1	RP11-314C16.1	-7.01	2.62e-11	5.37e-08	-0.47	-0.42	Motion sickness;	chr6:8446998	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs7453115	ENSG00000230939.1	RP11-314C16.1	-7.01	2.62e-11	5.37e-08	-0.47	-0.42	Motion sickness;	chr6:8447028	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs6910742	ENSG00000230939.1	RP11-314C16.1	-7.01	2.62e-11	5.37e-08	-0.47	-0.42	Motion sickness;	chr6:8448095	chr6:8784178~8785445:+
OV	cis	rs3136516	0.503	rs17787966	ENSG00000271350.1	CTD-2384B9.1	7.01	2.62e-11	5.37e-08	0.46	0.42	Venous thromboembolism;	chr11:47048874	chr11:47041027~47041945:-
OV	cis	rs2153535	0.58	rs4639392	ENSG00000230939.1	RP11-314C16.1	-7.01	2.63e-11	5.38e-08	-0.48	-0.42	Motion sickness;	chr6:8446314	chr6:8784178~8785445:+
OV	cis	rs4591358	0.689	rs34373729	ENSG00000223466.1	AC064834.2	-7.01	2.63e-11	5.38e-08	-0.61	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195543775	chr2:195533035~195538681:+
OV	cis	rs4591358	0.689	rs59639651	ENSG00000223466.1	AC064834.2	-7.01	2.63e-11	5.38e-08	-0.61	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195544426	chr2:195533035~195538681:+
OV	cis	rs4591358	0.689	rs72927766	ENSG00000223466.1	AC064834.2	-7.01	2.63e-11	5.38e-08	-0.61	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195545003	chr2:195533035~195538681:+
OV	cis	rs4591358	0.689	rs7580459	ENSG00000223466.1	AC064834.2	-7.01	2.63e-11	5.38e-08	-0.61	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195545963	chr2:195533035~195538681:+
OV	cis	rs4591358	0.689	rs57555936	ENSG00000223466.1	AC064834.2	-7.01	2.63e-11	5.38e-08	-0.61	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195546440	chr2:195533035~195538681:+
OV	cis	rs4591358	0.689	rs59017643	ENSG00000223466.1	AC064834.2	-7.01	2.63e-11	5.38e-08	-0.61	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195546835	chr2:195533035~195538681:+
OV	cis	rs1061377	1	rs13182	ENSG00000249207.1	RP11-360F5.1	-7.01	2.64e-11	5.39e-08	-0.45	-0.42	Uric acid levels;	chr4:39121293	chr4:39112677~39126818:-
OV	cis	rs4713118	0.662	rs149901	ENSG00000220721.1	OR1F12	7.01	2.64e-11	5.4e-08	0.5	0.42	Parkinson's disease;	chr6:27997725	chr6:28073316~28074233:+
OV	cis	rs4713118	0.662	rs464312	ENSG00000220721.1	OR1F12	7.01	2.64e-11	5.4e-08	0.5	0.42	Parkinson's disease;	chr6:27999813	chr6:28073316~28074233:+
OV	cis	rs4713118	0.662	rs469228	ENSG00000220721.1	OR1F12	7.01	2.64e-11	5.4e-08	0.5	0.42	Parkinson's disease;	chr6:28002926	chr6:28073316~28074233:+
OV	cis	rs4713118	0.54	rs469227	ENSG00000220721.1	OR1F12	7.01	2.64e-11	5.4e-08	0.5	0.42	Parkinson's disease;	chr6:28002927	chr6:28073316~28074233:+
OV	cis	rs8105895	0.877	rs62112919	ENSG00000269742.1	BNIP3P29	7.01	2.65e-11	5.42e-08	0.69	0.42	Body mass index (change over time);	chr19:22044343	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs62112920	ENSG00000269742.1	BNIP3P29	7.01	2.65e-11	5.42e-08	0.69	0.42	Body mass index (change over time);	chr19:22044347	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs75025987	ENSG00000269742.1	BNIP3P29	7.01	2.65e-11	5.42e-08	0.69	0.42	Body mass index (change over time);	chr19:22047867	chr19:22065828~22066398:-
OV	cis	rs1707322	0.963	rs12145287	ENSG00000281133.1	AL355480.3	-7.01	2.65e-11	5.42e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45859330	chr1:45580892~45580996:-
OV	cis	rs2153535	0.58	rs6927589	ENSG00000230939.1	RP11-314C16.1	7.01	2.66e-11	5.43e-08	0.48	0.42	Motion sickness;	chr6:8456399	chr6:8784178~8785445:+
OV	cis	rs7617773	0.563	rs13082269	ENSG00000229759.1	MRPS18AP1	7.01	2.67e-11	5.46e-08	0.44	0.42	Coronary artery disease;	chr3:48350784	chr3:48256350~48256938:-
OV	cis	rs7246967	0.673	rs16999519	ENSG00000269509.1	BNIP3P34	-7.01	2.67e-11	5.46e-08	-0.64	-0.42	Bronchopulmonary dysplasia;	chr19:22631274	chr19:22773853~22774424:+
OV	cis	rs875971	0.862	rs11765791	ENSG00000226824.5	RP4-756H11.3	-7.01	2.68e-11	5.47e-08	-0.44	-0.42	Aortic root size;	chr7:66471587	chr7:66654538~66669855:+
OV	cis	rs9326248	0.581	rs10502222	ENSG00000254851.1	RP11-109L13.1	-7.01	2.68e-11	5.47e-08	-0.49	-0.42	Blood protein levels;	chr11:116963014	chr11:117135528~117138582:+
OV	cis	rs9326248	0.559	rs10892052	ENSG00000254851.1	RP11-109L13.1	-7.01	2.68e-11	5.47e-08	-0.49	-0.42	Blood protein levels;	chr11:116963597	chr11:117135528~117138582:+
OV	cis	rs7208859	0.623	rs122898	ENSG00000280069.1	CTD-2349P21.3	7.01	2.68e-11	5.48e-08	0.43	0.42	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30738182~30740275:+
OV	cis	rs8005677	1	rs8014936	ENSG00000257285.4	RP11-298I3.1	7.01	2.68e-11	5.48e-08	0.49	0.42	Cognitive ability (multi-trait analysis);	chr14:22905936	chr14:22929609~22955562:+
OV	cis	rs8005677	1	rs8016061	ENSG00000257285.4	RP11-298I3.1	7.01	2.68e-11	5.48e-08	0.49	0.42	Cognitive ability (multi-trait analysis);	chr14:22906600	chr14:22929609~22955562:+
OV	cis	rs8005677	1	rs8005677	ENSG00000257285.4	RP11-298I3.1	7.01	2.68e-11	5.48e-08	0.49	0.42	Cognitive ability (multi-trait analysis);	chr14:22907469	chr14:22929609~22955562:+
OV	cis	rs73086581	0.741	rs17212649	ENSG00000229539.1	RP11-119B16.2	7.01	2.69e-11	5.49e-08	0.57	0.42	Response to antidepressants in depression;	chr20:3872446	chr20:3888239~3888868:-
OV	cis	rs1707322	0.964	rs7546237	ENSG00000281133.1	AL355480.3	-7.01	2.69e-11	5.49e-08	-0.53	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45819938	chr1:45580892~45580996:-
OV	cis	rs1707322	0.964	rs6697830	ENSG00000281133.1	AL355480.3	-7.01	2.69e-11	5.49e-08	-0.53	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45824805	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs12060274	ENSG00000281133.1	AL355480.3	-7.01	2.69e-11	5.49e-08	-0.53	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825390	chr1:45580892~45580996:-
OV	cis	rs1707322	0.963	rs11211202	ENSG00000281133.1	AL355480.3	-7.01	2.69e-11	5.49e-08	-0.53	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45826710	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs4660889	ENSG00000281133.1	AL355480.3	-7.01	2.69e-11	5.49e-08	-0.53	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45831659	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs10890353	ENSG00000281133.1	AL355480.3	-7.01	2.69e-11	5.49e-08	-0.53	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45832711	chr1:45580892~45580996:-
OV	cis	rs11159086	1	rs3759745	ENSG00000259005.1	RP3-449M8.6	7.01	2.7e-11	5.5e-08	0.68	0.42	Advanced glycation end-product levels;	chr14:74495967	chr14:74474007~74474864:-
OV	cis	rs1707322	0.963	rs10789478	ENSG00000281133.1	AL355480.3	-7.01	2.71e-11	5.52e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45884834	chr1:45580892~45580996:-
OV	cis	rs8005677	1	rs10148215	ENSG00000257285.4	RP11-298I3.1	7.01	2.72e-11	5.54e-08	0.49	0.42	Cognitive ability (multi-trait analysis);	chr14:22913136	chr14:22929609~22955562:+
OV	cis	rs2153535	0.541	rs6923558	ENSG00000230939.1	RP11-314C16.1	-7.01	2.74e-11	5.58e-08	-0.48	-0.42	Motion sickness;	chr6:8461234	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1577470	ENSG00000230939.1	RP11-314C16.1	-7.01	2.74e-11	5.58e-08	-0.48	-0.42	Motion sickness;	chr6:8462193	chr6:8784178~8785445:+
OV	cis	rs8062405	1	rs8062405	ENSG00000259982.1	CDC37P1	-7.01	2.74e-11	5.58e-08	-0.52	-0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28700294~28701540:-
OV	cis	rs1075265	0.547	rs6741891	ENSG00000233266.1	HMGB1P31	7.01	2.75e-11	5.6e-08	0.51	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54088529	chr2:54051334~54051760:+
OV	cis	rs11673344	0.566	rs256733	ENSG00000226686.6	LINC01535	7.01	2.75e-11	5.61e-08	0.49	0.42	Obesity-related traits;	chr19:37384729	chr19:37251912~37265535:+
OV	cis	rs11673344	0.583	rs7247090	ENSG00000226686.6	LINC01535	7.01	2.77e-11	5.64e-08	0.5	0.42	Obesity-related traits;	chr19:37522509	chr19:37251912~37265535:+
OV	cis	rs1707322	1	rs4073847	ENSG00000281133.1	AL355480.3	7.01	2.77e-11	5.64e-08	0.54	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45997340	chr1:45580892~45580996:-
OV	cis	rs17711722	0.522	rs6957759	ENSG00000236529.1	RP13-254B10.1	7	2.79e-11	5.68e-08	0.46	0.42	Calcium levels;	chr7:65806798	chr7:65840212~65840596:+
OV	cis	rs6991838	0.557	rs67046768	ENSG00000272010.1	CTD-3025N20.3	-7	2.8e-11	5.69e-08	-0.52	-0.42	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs4388482	ENSG00000272010.1	CTD-3025N20.3	-7	2.8e-11	5.69e-08	-0.52	-0.42	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs4637885	ENSG00000272010.1	CTD-3025N20.3	-7	2.8e-11	5.69e-08	-0.52	-0.42	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65591850~65592472:-
OV	cis	rs1707322	1	rs6675222	ENSG00000281133.1	AL355480.3	-7	2.81e-11	5.7e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45860904	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs1622208	ENSG00000281133.1	AL355480.3	7	2.82e-11	5.72e-08	0.54	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46032703	chr1:45580892~45580996:-
OV	cis	rs1707322	0.752	rs11488313	ENSG00000281133.1	AL355480.3	-7	2.83e-11	5.76e-08	-0.55	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs785507	ENSG00000281133.1	AL355480.3	7	2.86e-11	5.81e-08	0.54	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46075886	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs785510	ENSG00000281133.1	AL355480.3	7	2.87e-11	5.82e-08	0.54	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062946	chr1:45580892~45580996:-
OV	cis	rs8105895	0.935	rs8110975	ENSG00000269742.1	BNIP3P29	7	2.89e-11	5.86e-08	0.7	0.42	Body mass index (change over time);	chr19:22057431	chr19:22065828~22066398:-
OV	cis	rs7617773	0.539	rs13069884	ENSG00000229759.1	MRPS18AP1	7	2.92e-11	5.92e-08	0.44	0.42	Coronary artery disease;	chr3:48339658	chr3:48256350~48256938:-
OV	cis	rs7617773	0.539	rs2017859	ENSG00000229759.1	MRPS18AP1	7	2.92e-11	5.92e-08	0.44	0.42	Coronary artery disease;	chr3:48340771	chr3:48256350~48256938:-
OV	cis	rs7617773	0.501	rs12185901	ENSG00000229759.1	MRPS18AP1	7	2.92e-11	5.92e-08	0.44	0.42	Coronary artery disease;	chr3:48341429	chr3:48256350~48256938:-
OV	cis	rs7617773	0.539	rs13082217	ENSG00000229759.1	MRPS18AP1	7	2.92e-11	5.92e-08	0.44	0.42	Coronary artery disease;	chr3:48341774	chr3:48256350~48256938:-
OV	cis	rs7617773	0.539	rs11706939	ENSG00000229759.1	MRPS18AP1	7	2.92e-11	5.92e-08	0.44	0.42	Coronary artery disease;	chr3:48342502	chr3:48256350~48256938:-
OV	cis	rs7617773	0.539	rs11130165	ENSG00000229759.1	MRPS18AP1	7	2.92e-11	5.92e-08	0.44	0.42	Coronary artery disease;	chr3:48343231	chr3:48256350~48256938:-
OV	cis	rs1061377	1	rs2381284	ENSG00000249207.1	RP11-360F5.1	-7	2.93e-11	5.93e-08	-0.45	-0.42	Uric acid levels;	chr4:39117976	chr4:39112677~39126818:-
OV	cis	rs1061377	0.803	rs6857761	ENSG00000249207.1	RP11-360F5.1	-7	2.93e-11	5.93e-08	-0.45	-0.42	Uric acid levels;	chr4:39118353	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs9997089	ENSG00000249207.1	RP11-360F5.1	-7	2.93e-11	5.93e-08	-0.45	-0.42	Uric acid levels;	chr4:39119263	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs28465556	ENSG00000249207.1	RP11-360F5.1	-7	2.93e-11	5.93e-08	-0.45	-0.42	Uric acid levels;	chr4:39119569	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs10027813	ENSG00000249207.1	RP11-360F5.1	-7	2.93e-11	5.93e-08	-0.45	-0.42	Uric acid levels;	chr4:39119818	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs9990755	ENSG00000249207.1	RP11-360F5.1	-7	2.93e-11	5.93e-08	-0.45	-0.42	Uric acid levels;	chr4:39119819	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs7676008	ENSG00000249207.1	RP11-360F5.1	-7	2.93e-11	5.93e-08	-0.45	-0.42	Uric acid levels;	chr4:39120154	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs7655122	ENSG00000249207.1	RP11-360F5.1	-7	2.93e-11	5.93e-08	-0.45	-0.42	Uric acid levels;	chr4:39120396	chr4:39112677~39126818:-
OV	cis	rs7569084	0.687	rs934731	ENSG00000234255.7	AC012370.3	7	2.93e-11	5.94e-08	0.46	0.42	Sum eosinophil basophil counts;	chr2:65456353	chr2:65439888~65456571:-
OV	cis	rs1707322	1	rs12124847	ENSG00000281133.1	AL355480.3	-7	2.94e-11	5.95e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr1:45580892~45580996:-
OV	cis	rs1707322	0.686	rs2991987	ENSG00000280836.1	AL355480.1	6.99	2.95e-11	5.98e-08	0.6	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615750	chr1:45581219~45581321:-
OV	cis	rs7569084	0.687	rs35839762	ENSG00000234255.7	AC012370.3	6.99	2.96e-11	6e-08	0.47	0.42	Sum eosinophil basophil counts;	chr2:65441318	chr2:65439888~65456571:-
OV	cis	rs1707322	0.827	rs6694302	ENSG00000281133.1	AL355480.3	-6.99	2.99e-11	6.06e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr1:45580892~45580996:-
OV	cis	rs4563143	0.663	rs10406794	ENSG00000267243.4	AC005307.3	-6.99	3e-11	6.07e-08	-0.63	-0.42	Methadone dose in opioid dependence;	chr19:28737149	chr19:28435388~28727777:-
OV	cis	rs1707322	0.721	rs56255771	ENSG00000281133.1	AL355480.3	-6.99	3e-11	6.08e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr1:45580892~45580996:-
OV	cis	rs6921919	0.583	rs9468367	ENSG00000216901.1	AL022393.7	6.99	3.01e-11	6.08e-08	0.5	0.42	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28176188~28176674:+
OV	cis	rs2882667	0.537	rs7701338	ENSG00000253404.1	AC034243.1	6.99	3.01e-11	6.09e-08	0.48	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139070305	chr5:138744434~138753309:-
OV	cis	rs1707322	1	rs785478	ENSG00000281133.1	AL355480.3	6.99	3.03e-11	6.12e-08	0.54	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46025963	chr1:45580892~45580996:-
OV	cis	rs1707322	0.927	rs6690386	ENSG00000281133.1	AL355480.3	-6.99	3.03e-11	6.12e-08	-0.55	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr1:45580892~45580996:-
OV	cis	rs1707322	0.963	rs4630155	ENSG00000281133.1	AL355480.3	-6.99	3.03e-11	6.12e-08	-0.55	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr1:45580892~45580996:-
OV	cis	rs1707322	0.963	rs4508055	ENSG00000281133.1	AL355480.3	-6.99	3.03e-11	6.12e-08	-0.55	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr1:45580892~45580996:-
OV	cis	rs1707322	0.963	rs12076580	ENSG00000281133.1	AL355480.3	-6.99	3.03e-11	6.12e-08	-0.55	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr1:45580892~45580996:-
OV	cis	rs1707322	0.964	rs7512395	ENSG00000281133.1	AL355480.3	-6.99	3.03e-11	6.12e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45895505	chr1:45580892~45580996:-
OV	cis	rs2836974	0.568	rs8130795	ENSG00000232608.1	TIMM9P2	-6.99	3.03e-11	6.12e-08	-0.45	-0.42	Cognitive function;	chr21:39178057	chr21:39216624~39217506:+
OV	cis	rs7017914	0.902	rs1373480	ENSG00000223220.1	Y_RNA	6.99	3.04e-11	6.15e-08	0.44	0.42	Bone mineral density;	chr8:70774732	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs10448014	ENSG00000223220.1	Y_RNA	6.99	3.04e-11	6.15e-08	0.44	0.42	Bone mineral density;	chr8:70775930	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs7000647	ENSG00000223220.1	Y_RNA	6.99	3.04e-11	6.15e-08	0.44	0.42	Bone mineral density;	chr8:70776173	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs13254801	ENSG00000223220.1	Y_RNA	6.99	3.04e-11	6.15e-08	0.44	0.42	Bone mineral density;	chr8:70776749	chr8:70780914~70781008:-
OV	cis	rs7017914	0.783	rs13252584	ENSG00000223220.1	Y_RNA	6.99	3.04e-11	6.15e-08	0.44	0.42	Bone mineral density;	chr8:70776796	chr8:70780914~70781008:-
OV	cis	rs7017914	0.84	rs13254851	ENSG00000223220.1	Y_RNA	6.99	3.04e-11	6.15e-08	0.44	0.42	Bone mineral density;	chr8:70776799	chr8:70780914~70781008:-
OV	cis	rs875971	0.545	rs10950029	ENSG00000222364.1	RNU6-96P	-6.99	3.05e-11	6.16e-08	-0.48	-0.42	Aortic root size;	chr7:66169334	chr7:66395191~66395286:+
OV	cis	rs7569084	0.663	rs1437461	ENSG00000234255.7	AC012370.3	6.99	3.06e-11	6.18e-08	0.47	0.42	Sum eosinophil basophil counts;	chr2:65452578	chr2:65439888~65456571:-
OV	cis	rs7569084	0.687	rs7562559	ENSG00000234255.7	AC012370.3	6.99	3.06e-11	6.18e-08	0.47	0.42	Sum eosinophil basophil counts;	chr2:65452719	chr2:65439888~65456571:-
OV	cis	rs7927771	1	rs4752857	ENSG00000280615.1	Y_RNA	-6.99	3.07e-11	6.19e-08	-0.52	-0.42	Subjective well-being;	chr11:47634200	chr11:47614898~47614994:-
OV	cis	rs7927771	0.896	rs12794570	ENSG00000280615.1	Y_RNA	-6.99	3.07e-11	6.19e-08	-0.52	-0.42	Subjective well-being;	chr11:47636762	chr11:47614898~47614994:-
OV	cis	rs7301826	0.627	rs7315707	ENSG00000256250.1	RP11-989F5.1	6.99	3.07e-11	6.2e-08	0.48	0.42	Plasma plasminogen activator levels;	chr12:130788274	chr12:130810606~130812438:+
OV	cis	rs1707322	1	rs11211217	ENSG00000281133.1	AL355480.3	-6.99	3.08e-11	6.22e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45882557	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs7553924	ENSG00000281133.1	AL355480.3	-6.99	3.08e-11	6.22e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886952	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs4641257	ENSG00000281133.1	AL355480.3	-6.99	3.08e-11	6.22e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45887917	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs6693336	ENSG00000281133.1	AL355480.3	-6.99	3.08e-11	6.22e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45888923	chr1:45580892~45580996:-
OV	cis	rs2836974	0.644	rs61300849	ENSG00000232608.1	TIMM9P2	6.99	3.1e-11	6.25e-08	0.45	0.42	Cognitive function;	chr21:39308268	chr21:39216624~39217506:+
OV	cis	rs7017914	0.934	rs62508771	ENSG00000223220.1	Y_RNA	6.99	3.1e-11	6.25e-08	0.44	0.42	Bone mineral density;	chr8:70780453	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs6993170	ENSG00000223220.1	Y_RNA	6.99	3.1e-11	6.25e-08	0.44	0.42	Bone mineral density;	chr8:70781284	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs6998786	ENSG00000223220.1	Y_RNA	6.99	3.1e-11	6.25e-08	0.44	0.42	Bone mineral density;	chr8:70782395	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs12680988	ENSG00000223220.1	Y_RNA	6.99	3.1e-11	6.25e-08	0.44	0.42	Bone mineral density;	chr8:70783655	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs1596566	ENSG00000223220.1	Y_RNA	6.99	3.1e-11	6.25e-08	0.44	0.42	Bone mineral density;	chr8:70786341	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs6993115	ENSG00000223220.1	Y_RNA	6.99	3.1e-11	6.25e-08	0.44	0.42	Bone mineral density;	chr8:70786948	chr8:70780914~70781008:-
OV	cis	rs7017914	0.934	rs6992879	ENSG00000223220.1	Y_RNA	6.99	3.1e-11	6.25e-08	0.44	0.42	Bone mineral density;	chr8:70787048	chr8:70780914~70781008:-
OV	cis	rs4591358	0.689	rs72927760	ENSG00000223466.1	AC064834.2	-6.99	3.11e-11	6.27e-08	-0.61	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195544584	chr2:195533035~195538681:+
OV	cis	rs1061377	0.965	rs3733275	ENSG00000249207.1	RP11-360F5.1	-6.99	3.12e-11	6.28e-08	-0.45	-0.42	Uric acid levels;	chr4:39121077	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs9998867	ENSG00000249207.1	RP11-360F5.1	-6.99	3.12e-11	6.28e-08	-0.45	-0.42	Uric acid levels;	chr4:39117542	chr4:39112677~39126818:-
OV	cis	rs1707322	0.647	rs6686944	ENSG00000280836.1	AL355480.1	-6.98	3.13e-11	6.31e-08	-0.59	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr1:45581219~45581321:-
OV	cis	rs2581828	0.965	rs4337632	ENSG00000242142.1	SERBP1P3	6.98	3.14e-11	6.32e-08	0.48	0.42	Crohn's disease;	chr3:53103295	chr3:53064283~53065091:-
OV	cis	rs7017914	0.935	rs6472551	ENSG00000223220.1	Y_RNA	6.98	3.15e-11	6.34e-08	0.45	0.42	Bone mineral density;	chr8:70869614	chr8:70780914~70781008:-
OV	cis	rs11159086	0.941	rs12434836	ENSG00000259005.1	RP3-449M8.6	6.98	3.17e-11	6.37e-08	0.68	0.42	Advanced glycation end-product levels;	chr14:74468887	chr14:74474007~74474864:-
OV	cis	rs11159086	1	rs11626856	ENSG00000259005.1	RP3-449M8.6	6.98	3.17e-11	6.37e-08	0.68	0.42	Advanced glycation end-product levels;	chr14:74469665	chr14:74474007~74474864:-
OV	cis	rs1707322	1	rs10890355	ENSG00000281133.1	AL355480.3	-6.98	3.17e-11	6.37e-08	-0.53	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45851676	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs11211204	ENSG00000281133.1	AL355480.3	-6.98	3.17e-11	6.37e-08	-0.53	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45852192	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs7547189	ENSG00000281133.1	AL355480.3	-6.98	3.17e-11	6.37e-08	-0.53	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853842	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs7547284	ENSG00000281133.1	AL355480.3	-6.98	3.17e-11	6.37e-08	-0.53	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853893	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs11211205	ENSG00000281133.1	AL355480.3	-6.98	3.17e-11	6.37e-08	-0.53	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45856202	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs4660895	ENSG00000281133.1	AL355480.3	-6.98	3.17e-11	6.37e-08	-0.53	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864067	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs10158032	ENSG00000281133.1	AL355480.3	-6.98	3.17e-11	6.37e-08	-0.53	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867029	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs4660318	ENSG00000281133.1	AL355480.3	-6.98	3.17e-11	6.37e-08	-0.53	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45869204	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs10890360	ENSG00000281133.1	AL355480.3	-6.98	3.17e-11	6.37e-08	-0.53	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45872772	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs6682683	ENSG00000281133.1	AL355480.3	-6.98	3.17e-11	6.37e-08	-0.53	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45876665	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs4606257	ENSG00000281133.1	AL355480.3	-6.98	3.17e-11	6.38e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr1:45580892~45580996:-
OV	cis	rs875971	0.502	rs2946580	ENSG00000222364.1	RNU6-96P	6.98	3.17e-11	6.38e-08	0.49	0.42	Aortic root size;	chr7:66066855	chr7:66395191~66395286:+
OV	cis	rs3091242	0.867	rs602052	ENSG00000261349.1	RP3-465N24.5	-6.98	3.18e-11	6.39e-08	-0.48	-0.42	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25266102~25267136:-
OV	cis	rs6700559	0.873	rs6427840	ENSG00000260088.1	RP11-92G12.3	-6.98	3.19e-11	6.41e-08	-0.44	-0.42	Coronary artery disease;	chr1:200685659	chr1:200669507~200694250:+
OV	cis	rs1707322	0.721	rs11211163	ENSG00000280836.1	AL355480.1	-6.98	3.2e-11	6.41e-08	-0.59	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs12037803	ENSG00000280836.1	AL355480.1	-6.98	3.2e-11	6.41e-08	-0.59	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs11211165	ENSG00000280836.1	AL355480.1	-6.98	3.2e-11	6.41e-08	-0.59	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs11211166	ENSG00000280836.1	AL355480.1	-6.98	3.2e-11	6.41e-08	-0.59	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs10789470	ENSG00000280836.1	AL355480.1	-6.98	3.2e-11	6.41e-08	-0.59	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs61784796	ENSG00000280836.1	AL355480.1	-6.98	3.2e-11	6.41e-08	-0.59	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs10749856	ENSG00000280836.1	AL355480.1	-6.98	3.2e-11	6.41e-08	-0.59	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs10890344	ENSG00000280836.1	AL355480.1	-6.98	3.2e-11	6.41e-08	-0.59	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs4564187	ENSG00000280836.1	AL355480.1	-6.98	3.2e-11	6.41e-08	-0.59	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45581219~45581321:-
OV	cis	rs1707322	0.752	rs28438704	ENSG00000280836.1	AL355480.1	-6.98	3.2e-11	6.41e-08	-0.59	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs28442079	ENSG00000280836.1	AL355480.1	-6.98	3.2e-11	6.41e-08	-0.59	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45581219~45581321:-
OV	cis	rs8062405	0.754	rs62034323	ENSG00000259982.1	CDC37P1	6.98	3.21e-11	6.43e-08	0.5	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28700294~28701540:-
OV	cis	rs8062405	0.824	rs62034324	ENSG00000259982.1	CDC37P1	6.98	3.21e-11	6.43e-08	0.5	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28700294~28701540:-
OV	cis	rs8062405	0.824	rs62034326	ENSG00000259982.1	CDC37P1	6.98	3.21e-11	6.43e-08	0.5	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28700294~28701540:-
OV	cis	rs2882667	0.537	rs10057545	ENSG00000253404.1	AC034243.1	6.98	3.21e-11	6.44e-08	0.49	0.42	Age-related hearing impairment (SNP x SNP interaction);	chr5:139095319	chr5:138744434~138753309:-
OV	cis	rs8062405	0.824	rs28698667	ENSG00000259982.1	CDC37P1	6.98	3.22e-11	6.46e-08	0.5	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28700294~28701540:-
OV	cis	rs8105895	0.935	rs1560717	ENSG00000269742.1	BNIP3P29	6.98	3.22e-11	6.46e-08	0.67	0.42	Body mass index (change over time);	chr19:22109445	chr19:22065828~22066398:-
OV	cis	rs2408955	0.521	rs7301003	ENSG00000258273.1	RP11-370I10.4	-6.98	3.24e-11	6.49e-08	-0.5	-0.42	Glycated hemoglobin levels;	chr12:48156444	chr12:48333755~48333901:-
OV	cis	rs10510102	0.872	rs12259144	ENSG00000276742.1	RP11-500G22.4	6.98	3.26e-11	6.53e-08	0.69	0.42	Breast cancer;	chr10:121965433	chr10:121956782~121957098:+
OV	cis	rs7829975	0.742	rs12547493	ENSG00000253981.4	ALG1L13P	-6.98	3.26e-11	6.54e-08	-0.53	-0.42	Mood instability;	chr8:8804024	chr8:8236003~8244667:-
OV	cis	rs1707322	0.752	rs6678444	ENSG00000281133.1	AL355480.3	-6.98	3.27e-11	6.55e-08	-0.56	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr1:45580892~45580996:-
OV	cis	rs1707322	0.827	rs6683274	ENSG00000281133.1	AL355480.3	-6.98	3.27e-11	6.55e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr1:45580892~45580996:-
OV	cis	rs1707322	0.785	rs10890348	ENSG00000281133.1	AL355480.3	-6.98	3.27e-11	6.55e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr1:45580892~45580996:-
OV	cis	rs875971	0.54	rs781152	ENSG00000222364.1	RNU6-96P	-6.98	3.28e-11	6.56e-08	-0.43	-0.42	Aortic root size;	chr7:66014585	chr7:66395191~66395286:+
OV	cis	rs17711722	0.727	rs781151	ENSG00000222364.1	RNU6-96P	-6.98	3.28e-11	6.56e-08	-0.43	-0.42	Calcium levels;	chr7:66014891	chr7:66395191~66395286:+
OV	cis	rs1707322	0.686	rs1084086	ENSG00000281133.1	AL355480.3	6.98	3.28e-11	6.56e-08	0.54	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45580892~45580996:-
OV	cis	rs9322193	0.607	rs10457852	ENSG00000231760.4	RP11-350J20.5	6.98	3.28e-11	6.57e-08	0.58	0.42	Lung cancer;	chr6:149880584	chr6:149796151~149826294:-
OV	cis	rs73086581	1	rs73086588	ENSG00000229539.1	RP11-119B16.2	6.98	3.29e-11	6.59e-08	0.53	0.42	Response to antidepressants in depression;	chr20:4001577	chr20:3888239~3888868:-
OV	cis	rs73086581	1	rs73086595	ENSG00000229539.1	RP11-119B16.2	6.98	3.29e-11	6.59e-08	0.53	0.42	Response to antidepressants in depression;	chr20:4002801	chr20:3888239~3888868:-
OV	cis	rs73086581	1	rs73086597	ENSG00000229539.1	RP11-119B16.2	6.98	3.29e-11	6.59e-08	0.53	0.42	Response to antidepressants in depression;	chr20:4002924	chr20:3888239~3888868:-
OV	cis	rs73086581	1	rs34640283	ENSG00000229539.1	RP11-119B16.2	6.98	3.29e-11	6.59e-08	0.53	0.42	Response to antidepressants in depression;	chr20:4008929	chr20:3888239~3888868:-
OV	cis	rs7017914	0.967	rs6987007	ENSG00000223220.1	Y_RNA	6.97	3.34e-11	6.68e-08	0.44	0.42	Bone mineral density;	chr8:70688707	chr8:70780914~70781008:-
OV	cis	rs875971	0.651	rs2420596	ENSG00000226824.5	RP4-756H11.3	-6.97	3.35e-11	6.69e-08	-0.44	-0.42	Aortic root size;	chr7:66450996	chr7:66654538~66669855:+
OV	cis	rs875971	0.52	rs2420597	ENSG00000226824.5	RP4-756H11.3	-6.97	3.35e-11	6.69e-08	-0.44	-0.42	Aortic root size;	chr7:66450999	chr7:66654538~66669855:+
OV	cis	rs1075265	0.528	rs2018747	ENSG00000233266.1	HMGB1P31	6.97	3.37e-11	6.74e-08	0.5	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54082487	chr2:54051334~54051760:+
OV	cis	rs4591358	0.773	rs13008940	ENSG00000223466.1	AC064834.2	-6.97	3.38e-11	6.75e-08	-0.58	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195509828	chr2:195533035~195538681:+
OV	cis	rs4591358	0.689	rs7578371	ENSG00000223466.1	AC064834.2	-6.97	3.38e-11	6.75e-08	-0.58	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195510222	chr2:195533035~195538681:+
OV	cis	rs8005677	1	rs4982710	ENSG00000257285.4	RP11-298I3.1	6.97	3.38e-11	6.75e-08	0.49	0.42	Cognitive ability (multi-trait analysis);	chr14:22929693	chr14:22929609~22955562:+
OV	cis	rs492146	0.783	rs613764	ENSG00000243236.5	GSTA9P	-6.97	3.39e-11	6.77e-08	-0.52	-0.42	Epilepsy (remission after treatment);	chr6:52975437	chr6:52939726~52957521:-
OV	cis	rs9918079	0.56	rs7685083	ENSG00000273133.1	RP11-799M12.2	6.97	3.39e-11	6.77e-08	0.48	0.42	Obesity-related traits;	chr4:15609148	chr4:15563698~15564253:-
OV	cis	rs8062405	0.824	rs4788084	ENSG00000259982.1	CDC37P1	6.97	3.39e-11	6.78e-08	0.5	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28700294~28701540:-
OV	cis	rs1707322	0.963	rs10890373	ENSG00000281133.1	AL355480.3	-6.97	3.42e-11	6.82e-08	-0.56	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr1:45580892~45580996:-
OV	cis	rs2153535	0.58	rs7747306	ENSG00000230939.1	RP11-314C16.1	6.97	3.42e-11	6.82e-08	0.47	0.42	Motion sickness;	chr6:8453430	chr6:8784178~8785445:+
OV	cis	rs875971	0.522	rs709604	ENSG00000226824.5	RP4-756H11.3	6.97	3.43e-11	6.84e-08	0.44	0.42	Aortic root size;	chr7:66032447	chr7:66654538~66669855:+
OV	cis	rs4591358	0.689	rs2173773	ENSG00000223466.1	AC064834.2	-6.97	3.43e-11	6.85e-08	-0.6	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549701	chr2:195533035~195538681:+
OV	cis	rs4591358	0.689	rs72927784	ENSG00000223466.1	AC064834.2	-6.97	3.43e-11	6.85e-08	-0.6	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195550329	chr2:195533035~195538681:+
OV	cis	rs1061377	1	rs12499266	ENSG00000249207.1	RP11-360F5.1	6.97	3.44e-11	6.85e-08	0.45	0.42	Uric acid levels;	chr4:39118133	chr4:39112677~39126818:-
OV	cis	rs853679	0.55	rs9295762	ENSG00000220721.1	OR1F12	-6.97	3.44e-11	6.86e-08	-0.47	-0.42	Depression;	chr6:28187640	chr6:28073316~28074233:+
OV	cis	rs2408955	0.541	rs11168428	ENSG00000258273.1	RP11-370I10.4	6.97	3.44e-11	6.86e-08	0.51	0.42	Glycated hemoglobin levels;	chr12:48153345	chr12:48333755~48333901:-
OV	cis	rs9918079	0.56	rs6414767	ENSG00000273133.1	RP11-799M12.2	-6.97	3.45e-11	6.87e-08	-0.48	-0.42	Obesity-related traits;	chr4:15654098	chr4:15563698~15564253:-
OV	cis	rs9326248	0.539	rs10892058	ENSG00000254851.1	RP11-109L13.1	-6.97	3.45e-11	6.88e-08	-0.49	-0.42	Blood protein levels;	chr11:117005905	chr11:117135528~117138582:+
OV	cis	rs1707322	0.686	rs3014251	ENSG00000280836.1	AL355480.1	6.97	3.45e-11	6.88e-08	0.59	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45611756	chr1:45581219~45581321:-
OV	cis	rs875971	0.522	rs9530	ENSG00000236529.1	RP13-254B10.1	6.97	3.5e-11	6.96e-08	0.44	0.42	Aortic root size;	chr7:65960907	chr7:65840212~65840596:+
OV	cis	rs1789	0.903	rs4453929	ENSG00000273133.1	RP11-799M12.2	-6.97	3.5e-11	6.98e-08	-0.48	-0.42	Blood protein levels;	chr4:15670550	chr4:15563698~15564253:-
OV	cis	rs35160687	0.862	rs12476706	ENSG00000273080.1	RP11-301O19.1	6.96	3.52e-11	7e-08	0.43	0.42	Night sleep phenotypes;	chr2:86301247	chr2:86195590~86196049:+
OV	cis	rs73086581	1	rs56141565	ENSG00000229539.1	RP11-119B16.2	6.96	3.52e-11	7.01e-08	0.55	0.42	Response to antidepressants in depression;	chr20:4017956	chr20:3888239~3888868:-
OV	cis	rs7615952	0.8	rs11915699	ENSG00000171084.14	FAM86JP	6.96	3.53e-11	7.02e-08	0.68	0.42	Blood pressure (smoking interaction);	chr3:125913841	chr3:125916620~125930024:+
OV	cis	rs9326248	0.581	rs10892053	ENSG00000254851.1	RP11-109L13.1	-6.96	3.53e-11	7.02e-08	-0.49	-0.42	Blood protein levels;	chr11:116986287	chr11:117135528~117138582:+
OV	cis	rs7927771	1	rs1317149	ENSG00000280615.1	Y_RNA	-6.96	3.55e-11	7.06e-08	-0.52	-0.42	Subjective well-being;	chr11:47465333	chr11:47614898~47614994:-
OV	cis	rs7017914	0.967	rs12680166	ENSG00000223220.1	Y_RNA	6.96	3.55e-11	7.06e-08	0.44	0.42	Bone mineral density;	chr8:70766403	chr8:70780914~70781008:-
OV	cis	rs2153535	0.58	rs7743686	ENSG00000230939.1	RP11-314C16.1	-6.96	3.55e-11	7.06e-08	-0.48	-0.42	Motion sickness;	chr6:8525878	chr6:8784178~8785445:+
OV	cis	rs2153535	0.601	rs718504	ENSG00000230939.1	RP11-314C16.1	-6.96	3.55e-11	7.06e-08	-0.48	-0.42	Motion sickness;	chr6:8527279	chr6:8784178~8785445:+
OV	cis	rs2153535	0.601	rs7775274	ENSG00000230939.1	RP11-314C16.1	-6.96	3.55e-11	7.06e-08	-0.48	-0.42	Motion sickness;	chr6:8530070	chr6:8784178~8785445:+
OV	cis	rs1061377	0.722	rs34803689	ENSG00000249207.1	RP11-360F5.1	-6.96	3.56e-11	7.08e-08	-0.45	-0.42	Uric acid levels;	chr4:39116665	chr4:39112677~39126818:-
OV	cis	rs4591358	0.773	rs35261538	ENSG00000223466.1	AC064834.2	-6.96	3.56e-11	7.08e-08	-0.58	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195509681	chr2:195533035~195538681:+
OV	cis	rs7605378	0.528	rs7592587	ENSG00000232732.8	AC073043.1	-6.96	3.57e-11	7.1e-08	-0.51	-0.42	Osteoporosis;	chr2:199921793	chr2:199867396~199911159:-
OV	cis	rs875971	0.83	rs6976714	ENSG00000226824.5	RP4-756H11.3	-6.96	3.6e-11	7.15e-08	-0.44	-0.42	Aortic root size;	chr7:66426474	chr7:66654538~66669855:+
OV	cis	rs494459	0.964	rs576283	ENSG00000255422.1	AP002954.4	-6.96	3.6e-11	7.16e-08	-0.48	-0.42	Height;	chr11:118703185	chr11:118704607~118750263:+
OV	cis	rs494459	0.929	rs627391	ENSG00000255422.1	AP002954.4	-6.96	3.6e-11	7.16e-08	-0.48	-0.42	Height;	chr11:118703207	chr11:118704607~118750263:+
OV	cis	rs507080	0.524	rs524409	ENSG00000255422.1	AP002954.4	-6.96	3.6e-11	7.16e-08	-0.48	-0.42	Serum metabolite levels;	chr11:118703602	chr11:118704607~118750263:+
OV	cis	rs2564921	0.679	rs12635933	ENSG00000242142.1	SERBP1P3	-6.96	3.6e-11	7.16e-08	-0.48	-0.42	Height;	chr3:53015087	chr3:53064283~53065091:-
OV	cis	rs2153535	0.58	rs1410766	ENSG00000230939.1	RP11-314C16.1	-6.96	3.62e-11	7.18e-08	-0.48	-0.42	Motion sickness;	chr6:8525127	chr6:8784178~8785445:+
OV	cis	rs2153535	0.623	rs6597338	ENSG00000230939.1	RP11-314C16.1	-6.96	3.62e-11	7.19e-08	-0.48	-0.42	Motion sickness;	chr6:8533275	chr6:8784178~8785445:+
OV	cis	rs2408955	0.522	rs10875721	ENSG00000258273.1	RP11-370I10.4	6.96	3.64e-11	7.23e-08	0.5	0.42	Glycated hemoglobin levels;	chr12:48019810	chr12:48333755~48333901:-
OV	cis	rs2564921	0.73	rs62255895	ENSG00000242142.1	SERBP1P3	-6.96	3.66e-11	7.27e-08	-0.48	-0.42	Height;	chr3:53027969	chr3:53064283~53065091:-
OV	cis	rs2564921	0.73	rs73079924	ENSG00000242142.1	SERBP1P3	-6.96	3.66e-11	7.27e-08	-0.48	-0.42	Height;	chr3:53034139	chr3:53064283~53065091:-
OV	cis	rs2153535	0.601	rs9379224	ENSG00000230939.1	RP11-314C16.1	-6.96	3.69e-11	7.33e-08	-0.49	-0.42	Motion sickness;	chr6:8538180	chr6:8784178~8785445:+
OV	cis	rs4591358	0.689	rs17178460	ENSG00000223466.1	AC064834.2	-6.96	3.7e-11	7.33e-08	-0.61	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195555365	chr2:195533035~195538681:+
OV	cis	rs9918079	0.506	rs7696127	ENSG00000273133.1	RP11-799M12.2	-6.96	3.71e-11	7.35e-08	-0.48	-0.42	Obesity-related traits;	chr4:15641330	chr4:15563698~15564253:-
OV	cis	rs2243480	0.764	rs2460423	ENSG00000222364.1	RNU6-96P	-6.95	3.74e-11	7.41e-08	-0.65	-0.42	Diabetic kidney disease;	chr7:66136229	chr7:66395191~66395286:+
OV	cis	rs2153535	0.58	rs4140586	ENSG00000230939.1	RP11-314C16.1	-6.95	3.75e-11	7.42e-08	-0.47	-0.42	Motion sickness;	chr6:8502959	chr6:8784178~8785445:+
OV	cis	rs2153535	0.601	rs4140585	ENSG00000230939.1	RP11-314C16.1	-6.95	3.75e-11	7.42e-08	-0.47	-0.42	Motion sickness;	chr6:8503065	chr6:8784178~8785445:+
OV	cis	rs2153535	0.601	rs9393030	ENSG00000230939.1	RP11-314C16.1	-6.95	3.75e-11	7.42e-08	-0.47	-0.42	Motion sickness;	chr6:8516256	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9328479	ENSG00000230939.1	RP11-314C16.1	-6.95	3.75e-11	7.42e-08	-0.47	-0.42	Motion sickness;	chr6:8519413	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1119688	ENSG00000230939.1	RP11-314C16.1	-6.95	3.76e-11	7.44e-08	-0.48	-0.42	Motion sickness;	chr6:8460617	chr6:8784178~8785445:+
OV	cis	rs10510102	0.872	rs11814703	ENSG00000276742.1	RP11-500G22.4	6.95	3.76e-11	7.44e-08	0.67	0.42	Breast cancer;	chr10:121964774	chr10:121956782~121957098:+
OV	cis	rs10510102	0.872	rs12246728	ENSG00000276742.1	RP11-500G22.4	6.95	3.76e-11	7.44e-08	0.67	0.42	Breast cancer;	chr10:121966618	chr10:121956782~121957098:+
OV	cis	rs10510102	0.872	rs12261371	ENSG00000276742.1	RP11-500G22.4	6.95	3.76e-11	7.44e-08	0.67	0.42	Breast cancer;	chr10:121966686	chr10:121956782~121957098:+
OV	cis	rs10510102	0.872	rs11200292	ENSG00000276742.1	RP11-500G22.4	6.95	3.76e-11	7.44e-08	0.67	0.42	Breast cancer;	chr10:121967383	chr10:121956782~121957098:+
OV	cis	rs10510102	0.808	rs17102804	ENSG00000276742.1	RP11-500G22.4	6.95	3.76e-11	7.44e-08	0.67	0.42	Breast cancer;	chr10:121968365	chr10:121956782~121957098:+
OV	cis	rs10510102	0.872	rs12265369	ENSG00000276742.1	RP11-500G22.4	6.95	3.76e-11	7.44e-08	0.67	0.42	Breast cancer;	chr10:121968455	chr10:121956782~121957098:+
OV	cis	rs10510102	0.872	rs12265542	ENSG00000276742.1	RP11-500G22.4	6.95	3.76e-11	7.44e-08	0.67	0.42	Breast cancer;	chr10:121968740	chr10:121956782~121957098:+
OV	cis	rs10510102	0.872	rs11200293	ENSG00000276742.1	RP11-500G22.4	6.95	3.76e-11	7.44e-08	0.67	0.42	Breast cancer;	chr10:121969195	chr10:121956782~121957098:+
OV	cis	rs2153535	0.601	rs1928183	ENSG00000230939.1	RP11-314C16.1	-6.95	3.77e-11	7.46e-08	-0.48	-0.42	Motion sickness;	chr6:8529785	chr6:8784178~8785445:+
OV	cis	rs853679	0.517	rs9380058	ENSG00000220721.1	OR1F12	6.95	3.78e-11	7.47e-08	0.5	0.42	Depression;	chr6:28159666	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9393898	ENSG00000220721.1	OR1F12	6.95	3.78e-11	7.47e-08	0.5	0.42	Depression;	chr6:28162598	chr6:28073316~28074233:+
OV	cis	rs1707322	0.752	rs7541962	ENSG00000281133.1	AL355480.3	-6.95	3.79e-11	7.48e-08	-0.55	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr1:45580892~45580996:-
OV	cis	rs1061377	1	rs35437629	ENSG00000249207.1	RP11-360F5.1	-6.95	3.79e-11	7.48e-08	-0.44	-0.42	Uric acid levels;	chr4:39131712	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs7657926	ENSG00000249207.1	RP11-360F5.1	-6.95	3.79e-11	7.48e-08	-0.44	-0.42	Uric acid levels;	chr4:39132443	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs11096982	ENSG00000249207.1	RP11-360F5.1	-6.95	3.79e-11	7.48e-08	-0.44	-0.42	Uric acid levels;	chr4:39133247	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs11727875	ENSG00000249207.1	RP11-360F5.1	-6.95	3.79e-11	7.48e-08	-0.44	-0.42	Uric acid levels;	chr4:39133699	chr4:39112677~39126818:-
OV	cis	rs10256972	0.521	rs10280960	ENSG00000229043.2	AC091729.9	-6.95	3.86e-11	7.62e-08	-0.48	-0.42	Endometriosis;Longevity;	chr7:1064061	chr7:1160374~1165267:+
OV	cis	rs2243480	0.901	rs35823062	ENSG00000222364.1	RNU6-96P	-6.95	3.88e-11	7.64e-08	-0.64	-0.42	Diabetic kidney disease;	chr7:66500834	chr7:66395191~66395286:+
OV	cis	rs2153535	0.58	rs1360054	ENSG00000230939.1	RP11-314C16.1	-6.95	3.88e-11	7.64e-08	-0.48	-0.42	Motion sickness;	chr6:8520144	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9328483	ENSG00000230939.1	RP11-314C16.1	-6.95	3.88e-11	7.64e-08	-0.48	-0.42	Motion sickness;	chr6:8521062	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9393033	ENSG00000230939.1	RP11-314C16.1	-6.95	3.88e-11	7.64e-08	-0.48	-0.42	Motion sickness;	chr6:8521213	chr6:8784178~8785445:+
OV	cis	rs2153535	0.541	rs6938688	ENSG00000230939.1	RP11-314C16.1	-6.95	3.88e-11	7.64e-08	-0.48	-0.42	Motion sickness;	chr6:8521396	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs7743995	ENSG00000230939.1	RP11-314C16.1	-6.95	3.88e-11	7.64e-08	-0.47	-0.42	Motion sickness;	chr6:8495979	chr6:8784178~8785445:+
OV	cis	rs2836974	0.568	rs442972	ENSG00000232608.1	TIMM9P2	6.95	3.92e-11	7.71e-08	0.45	0.42	Cognitive function;	chr21:39162831	chr21:39216624~39217506:+
OV	cis	rs2117029	0.561	rs7957983	ENSG00000258017.1	RP11-386G11.10	-6.95	3.94e-11	7.75e-08	-0.51	-0.42	Intelligence (multi-trait analysis);	chr12:49115204	chr12:49127782~49147869:+
OV	cis	rs2117029	0.587	rs7958572	ENSG00000258017.1	RP11-386G11.10	-6.95	3.94e-11	7.75e-08	-0.51	-0.42	Intelligence (multi-trait analysis);	chr12:49115658	chr12:49127782~49147869:+
OV	cis	rs875971	0.767	rs12668005	ENSG00000226824.5	RP4-756H11.3	-6.94	3.96e-11	7.8e-08	-0.44	-0.42	Aortic root size;	chr7:66444034	chr7:66654538~66669855:+
OV	cis	rs2564921	0.73	rs56386026	ENSG00000242142.1	SERBP1P3	-6.94	3.98e-11	7.83e-08	-0.48	-0.42	Height;	chr3:53080524	chr3:53064283~53065091:-
OV	cis	rs1707322	1	rs7539800	ENSG00000281133.1	AL355480.3	6.94	4.06e-11	7.98e-08	0.54	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796457	chr1:45580892~45580996:-
OV	cis	rs2243480	0.901	rs34807232	ENSG00000222364.1	RNU6-96P	-6.94	4.07e-11	8e-08	-0.64	-0.42	Diabetic kidney disease;	chr7:66500146	chr7:66395191~66395286:+
OV	cis	rs11723261	0.546	rs57839456	ENSG00000275426.1	CH17-262A2.1	6.94	4.13e-11	8.12e-08	0.69	0.42	Immune response to smallpox vaccine (IL-6);	chr4:154494	chr4:149738~150317:+
OV	cis	rs875971	0.545	rs73142233	ENSG00000222364.1	RNU6-96P	-6.94	4.15e-11	8.15e-08	-0.48	-0.42	Aortic root size;	chr7:66221293	chr7:66395191~66395286:+
OV	cis	rs2564921	0.73	rs2564922	ENSG00000242142.1	SERBP1P3	6.94	4.15e-11	8.15e-08	0.47	0.42	Height;	chr3:53091453	chr3:53064283~53065091:-
OV	cis	rs7569084	0.687	rs1370394	ENSG00000234255.7	AC012370.3	6.94	4.15e-11	8.16e-08	0.47	0.42	Sum eosinophil basophil counts;	chr2:65453176	chr2:65439888~65456571:-
OV	cis	rs2153535	0.58	rs4960433	ENSG00000230939.1	RP11-314C16.1	-6.94	4.17e-11	8.18e-08	-0.47	-0.42	Motion sickness;	chr6:8523464	chr6:8784178~8785445:+
OV	cis	rs1707322	1	rs946527	ENSG00000281133.1	AL355480.3	-6.93	4.2e-11	8.24e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46020298	chr1:45580892~45580996:-
OV	cis	rs3931020	0.548	rs17618340	ENSG00000272864.1	RP11-17E13.2	-6.93	4.2e-11	8.24e-08	-0.53	-0.42	Resistin levels;	chr1:74781933	chr1:74698769~74699333:-
OV	cis	rs7017914	0.934	rs1993862	ENSG00000223220.1	Y_RNA	6.93	4.22e-11	8.28e-08	0.44	0.42	Bone mineral density;	chr8:70667127	chr8:70780914~70781008:-
OV	cis	rs6921919	0.583	rs9468355	ENSG00000216901.1	AL022393.7	6.93	4.22e-11	8.29e-08	0.48	0.42	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28176188~28176674:+
OV	cis	rs1075265	0.547	rs41385746	ENSG00000233266.1	HMGB1P31	-6.93	4.24e-11	8.31e-08	-0.5	-0.42	Chronotype;Morning vs. evening chronotype;	chr2:54077893	chr2:54051334~54051760:+
OV	cis	rs1707322	1	rs7532204	ENSG00000281133.1	AL355480.3	6.93	4.25e-11	8.34e-08	0.54	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019403	chr1:45580892~45580996:-
OV	cis	rs1707322	0.835	rs946525	ENSG00000281133.1	AL355480.3	6.93	4.25e-11	8.34e-08	0.54	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021605	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs946524	ENSG00000281133.1	AL355480.3	6.93	4.25e-11	8.34e-08	0.54	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021888	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs4660336	ENSG00000281133.1	AL355480.3	6.93	4.25e-11	8.34e-08	0.54	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46022304	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs4660906	ENSG00000281133.1	AL355480.3	-6.93	4.25e-11	8.34e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46005188	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs3922887	ENSG00000281133.1	AL355480.3	-6.93	4.25e-11	8.34e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008130	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs3922886	ENSG00000281133.1	AL355480.3	-6.93	4.25e-11	8.34e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008230	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs11211248	ENSG00000281133.1	AL355480.3	-6.93	4.25e-11	8.34e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46011172	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs10890376	ENSG00000281133.1	AL355480.3	-6.93	4.26e-11	8.35e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr1:45580892~45580996:-
OV	cis	rs1707322	0.789	rs10789473	ENSG00000281133.1	AL355480.3	-6.93	4.28e-11	8.39e-08	-0.53	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr1:45580892~45580996:-
OV	cis	rs875971	0.545	rs73136346	ENSG00000222364.1	RNU6-96P	6.93	4.29e-11	8.4e-08	0.49	0.42	Aortic root size;	chr7:66101095	chr7:66395191~66395286:+
OV	cis	rs2153535	0.58	rs7766852	ENSG00000230939.1	RP11-314C16.1	-6.93	4.3e-11	8.42e-08	-0.47	-0.42	Motion sickness;	chr6:8472184	chr6:8784178~8785445:+
OV	cis	rs6700559	0.873	rs7542840	ENSG00000260088.1	RP11-92G12.3	-6.93	4.3e-11	8.42e-08	-0.43	-0.42	Coronary artery disease;	chr1:200686558	chr1:200669507~200694250:+
OV	cis	rs6700559	0.873	rs7524025	ENSG00000260088.1	RP11-92G12.3	-6.93	4.3e-11	8.42e-08	-0.43	-0.42	Coronary artery disease;	chr1:200687859	chr1:200669507~200694250:+
OV	cis	rs6700559	0.815	rs7526365	ENSG00000260088.1	RP11-92G12.3	-6.93	4.3e-11	8.42e-08	-0.43	-0.42	Coronary artery disease;	chr1:200688020	chr1:200669507~200694250:+
OV	cis	rs6700559	0.873	rs7526482	ENSG00000260088.1	RP11-92G12.3	-6.93	4.3e-11	8.42e-08	-0.43	-0.42	Coronary artery disease;	chr1:200688310	chr1:200669507~200694250:+
OV	cis	rs6700559	0.873	rs7526853	ENSG00000260088.1	RP11-92G12.3	-6.93	4.3e-11	8.42e-08	-0.43	-0.42	Coronary artery disease;	chr1:200688529	chr1:200669507~200694250:+
OV	cis	rs6700559	0.844	rs61825137	ENSG00000260088.1	RP11-92G12.3	-6.93	4.3e-11	8.42e-08	-0.43	-0.42	Coronary artery disease;	chr1:200689267	chr1:200669507~200694250:+
OV	cis	rs6700559	0.873	rs7545177	ENSG00000260088.1	RP11-92G12.3	-6.93	4.3e-11	8.42e-08	-0.43	-0.42	Coronary artery disease;	chr1:200690727	chr1:200669507~200694250:+
OV	cis	rs6700559	0.873	rs7539646	ENSG00000260088.1	RP11-92G12.3	-6.93	4.3e-11	8.42e-08	-0.43	-0.42	Coronary artery disease;	chr1:200692534	chr1:200669507~200694250:+
OV	cis	rs6700559	0.873	rs7519383	ENSG00000260088.1	RP11-92G12.3	-6.93	4.3e-11	8.42e-08	-0.43	-0.42	Coronary artery disease;	chr1:200692968	chr1:200669507~200694250:+
OV	cis	rs6700559	0.815	rs12141497	ENSG00000260088.1	RP11-92G12.3	-6.93	4.3e-11	8.42e-08	-0.43	-0.42	Coronary artery disease;	chr1:200693389	chr1:200669507~200694250:+
OV	cis	rs6700559	0.873	rs12126708	ENSG00000260088.1	RP11-92G12.3	-6.93	4.3e-11	8.42e-08	-0.43	-0.42	Coronary artery disease;	chr1:200693397	chr1:200669507~200694250:+
OV	cis	rs6700559	0.873	rs10920008	ENSG00000260088.1	RP11-92G12.3	-6.93	4.3e-11	8.42e-08	-0.43	-0.42	Coronary artery disease;	chr1:200694546	chr1:200669507~200694250:+
OV	cis	rs55794721	0.509	rs11249248	ENSG00000261349.1	RP3-465N24.5	-6.93	4.31e-11	8.43e-08	-0.46	-0.42	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25266102~25267136:-
OV	cis	rs2243480	0.901	rs778730	ENSG00000222364.1	RNU6-96P	-6.93	4.33e-11	8.46e-08	-0.64	-0.42	Diabetic kidney disease;	chr7:66358338	chr7:66395191~66395286:+
OV	cis	rs9918079	0.56	rs7662032	ENSG00000273133.1	RP11-799M12.2	-6.93	4.33e-11	8.46e-08	-0.48	-0.42	Obesity-related traits;	chr4:15633791	chr4:15563698~15564253:-
OV	cis	rs9918079	0.56	rs12651550	ENSG00000273133.1	RP11-799M12.2	-6.93	4.33e-11	8.46e-08	-0.48	-0.42	Obesity-related traits;	chr4:15639395	chr4:15563698~15564253:-
OV	cis	rs1789	0.839	rs9997068	ENSG00000273133.1	RP11-799M12.2	-6.93	4.33e-11	8.46e-08	-0.48	-0.42	Blood protein levels;	chr4:15649367	chr4:15563698~15564253:-
OV	cis	rs875971	0.545	rs1638724	ENSG00000222364.1	RNU6-96P	6.93	4.34e-11	8.48e-08	0.49	0.42	Aortic root size;	chr7:66575494	chr7:66395191~66395286:+
OV	cis	rs11168351	0.864	rs12228750	ENSG00000258273.1	RP11-370I10.4	6.93	4.35e-11	8.49e-08	0.5	0.42	Bipolar disorder and schizophrenia;	chr12:48103214	chr12:48333755~48333901:-
OV	cis	rs11168351	0.864	rs10875743	ENSG00000258273.1	RP11-370I10.4	6.93	4.35e-11	8.49e-08	0.5	0.42	Bipolar disorder and schizophrenia;	chr12:48104630	chr12:48333755~48333901:-
OV	cis	rs1075265	0.584	rs11896781	ENSG00000233266.1	HMGB1P31	6.93	4.35e-11	8.5e-08	0.5	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54096987	chr2:54051334~54051760:+
OV	cis	rs1707322	0.721	rs6665808	ENSG00000281133.1	AL355480.3	-6.93	4.35e-11	8.5e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45696611	chr1:45580892~45580996:-
OV	cis	rs1789	0.786	rs6449161	ENSG00000273133.1	RP11-799M12.2	-6.93	4.37e-11	8.54e-08	-0.51	-0.42	Blood protein levels;	chr4:15691331	chr4:15563698~15564253:-
OV	cis	rs1707322	1	rs4660905	ENSG00000281133.1	AL355480.3	6.93	4.37e-11	8.54e-08	0.54	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995915	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs11211190	ENSG00000281133.1	AL355480.3	-6.93	4.41e-11	8.62e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800583	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs6429580	ENSG00000281133.1	AL355480.3	-6.93	4.41e-11	8.62e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809976	chr1:45580892~45580996:-
OV	cis	rs7927771	0.965	rs35184771	ENSG00000280615.1	Y_RNA	-6.93	4.42e-11	8.63e-08	-0.52	-0.42	Subjective well-being;	chr11:47453637	chr11:47614898~47614994:-
OV	cis	rs11673344	0.544	rs6508721	ENSG00000226686.6	LINC01535	-6.92	4.44e-11	8.67e-08	-0.49	-0.42	Obesity-related traits;	chr19:37419119	chr19:37251912~37265535:+
OV	cis	rs2408955	0.561	rs9971924	ENSG00000258273.1	RP11-370I10.4	6.92	4.45e-11	8.69e-08	0.5	0.42	Glycated hemoglobin levels;	chr12:48086049	chr12:48333755~48333901:-
OV	cis	rs2408955	0.522	rs7139330	ENSG00000258273.1	RP11-370I10.4	6.92	4.45e-11	8.69e-08	0.5	0.42	Glycated hemoglobin levels;	chr12:48089701	chr12:48333755~48333901:-
OV	cis	rs2408955	0.522	rs2051851	ENSG00000258273.1	RP11-370I10.4	6.92	4.45e-11	8.69e-08	0.5	0.42	Glycated hemoglobin levels;	chr12:48092157	chr12:48333755~48333901:-
OV	cis	rs2408955	0.522	rs973398	ENSG00000258273.1	RP11-370I10.4	6.92	4.45e-11	8.69e-08	0.5	0.42	Glycated hemoglobin levels;	chr12:48097265	chr12:48333755~48333901:-
OV	cis	rs3091242	1	rs9689	ENSG00000224183.1	SDHDP6	-6.92	4.47e-11	8.71e-08	-0.47	-0.42	Erythrocyte sedimentation rate;	chr1:25361785	chr1:25294164~25294643:-
OV	cis	rs2836974	0.613	rs2245455	ENSG00000232608.1	TIMM9P2	6.92	4.47e-11	8.72e-08	0.45	0.42	Cognitive function;	chr21:39176161	chr21:39216624~39217506:+
OV	cis	rs1707322	0.721	rs10430124	ENSG00000280836.1	AL355480.1	-6.92	4.48e-11	8.73e-08	-0.58	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755945	chr1:45581219~45581321:-
OV	cis	rs2153535	0.58	rs6912374	ENSG00000230939.1	RP11-314C16.1	-6.92	4.49e-11	8.75e-08	-0.46	-0.42	Motion sickness;	chr6:8456190	chr6:8784178~8785445:+
OV	cis	rs2564921	0.73	rs62255898	ENSG00000242142.1	SERBP1P3	-6.92	4.51e-11	8.8e-08	-0.48	-0.42	Height;	chr3:53029908	chr3:53064283~53065091:-
OV	cis	rs4713118	0.955	rs9468206	ENSG00000220721.1	OR1F12	6.92	4.53e-11	8.81e-08	0.46	0.42	Parkinson's disease;	chr6:27722674	chr6:28073316~28074233:+
OV	cis	rs875971	0.545	rs4718325	ENSG00000222364.1	RNU6-96P	-6.92	4.56e-11	8.89e-08	-0.48	-0.42	Aortic root size;	chr7:66215323	chr7:66395191~66395286:+
OV	cis	rs2836974	0.568	rs419469	ENSG00000232608.1	TIMM9P2	-6.92	4.57e-11	8.89e-08	-0.45	-0.42	Cognitive function;	chr21:39165308	chr21:39216624~39217506:+
OV	cis	rs3091242	0.933	rs34006994	ENSG00000261349.1	RP3-465N24.5	6.92	4.57e-11	8.9e-08	0.44	0.42	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25266102~25267136:-
OV	cis	rs3091242	0.9	rs4649086	ENSG00000261349.1	RP3-465N24.5	-6.92	4.57e-11	8.9e-08	-0.44	-0.42	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25266102~25267136:-
OV	cis	rs6700559	0.873	rs7526367	ENSG00000260088.1	RP11-92G12.3	-6.92	4.6e-11	8.95e-08	-0.44	-0.42	Coronary artery disease;	chr1:200688025	chr1:200669507~200694250:+
OV	cis	rs2836974	0.526	rs418359	ENSG00000232608.1	TIMM9P2	6.92	4.64e-11	9.02e-08	0.44	0.42	Cognitive function;	chr21:39164808	chr21:39216624~39217506:+
OV	cis	rs507080	0.501	rs626645	ENSG00000255422.1	AP002954.4	-6.92	4.69e-11	9.12e-08	-0.48	-0.42	Serum metabolite levels;	chr11:118704471	chr11:118704607~118750263:+
OV	cis	rs4713118	0.662	rs149948	ENSG00000220721.1	OR1F12	6.91	4.74e-11	9.19e-08	0.5	0.42	Parkinson's disease;	chr6:28007039	chr6:28073316~28074233:+
OV	cis	rs3091242	0.804	rs631133	ENSG00000261349.1	RP3-465N24.5	-6.91	4.74e-11	9.2e-08	-0.47	-0.42	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25266102~25267136:-
OV	cis	rs1789	0.872	rs4333182	ENSG00000273133.1	RP11-799M12.2	-6.91	4.74e-11	9.21e-08	-0.5	-0.42	Blood protein levels;	chr4:15683089	chr4:15563698~15564253:-
OV	cis	rs1707322	0.789	rs7540578	ENSG00000281133.1	AL355480.3	-6.91	4.78e-11	9.27e-08	-0.52	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr1:45580892~45580996:-
OV	cis	rs73086581	0.898	rs11906452	ENSG00000229539.1	RP11-119B16.2	6.91	4.78e-11	9.28e-08	0.52	0.42	Response to antidepressants in depression;	chr20:4000912	chr20:3888239~3888868:-
OV	cis	rs875971	0.577	rs35072105	ENSG00000236529.1	RP13-254B10.1	-6.91	4.83e-11	9.35e-08	-0.43	-0.42	Aortic root size;	chr7:66144830	chr7:65840212~65840596:+
OV	cis	rs2243480	1	rs316332	ENSG00000222364.1	RNU6-96P	-6.91	4.84e-11	9.37e-08	-0.64	-0.42	Diabetic kidney disease;	chr7:66139312	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs316330	ENSG00000222364.1	RNU6-96P	-6.91	4.84e-11	9.37e-08	-0.64	-0.42	Diabetic kidney disease;	chr7:66140385	chr7:66395191~66395286:+
OV	cis	rs1707322	0.721	rs11211181	ENSG00000280836.1	AL355480.1	-6.91	4.85e-11	9.39e-08	-0.56	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45771128	chr1:45581219~45581321:-
OV	cis	rs1061377	1	rs10026775	ENSG00000249207.1	RP11-360F5.1	-6.91	4.85e-11	9.39e-08	-0.45	-0.42	Uric acid levels;	chr4:39115155	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs3733276	ENSG00000249207.1	RP11-360F5.1	-6.91	4.85e-11	9.39e-08	-0.45	-0.42	Uric acid levels;	chr4:39115291	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs3733277	ENSG00000249207.1	RP11-360F5.1	-6.91	4.85e-11	9.39e-08	-0.45	-0.42	Uric acid levels;	chr4:39115483	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs3733278	ENSG00000249207.1	RP11-360F5.1	-6.91	4.85e-11	9.39e-08	-0.45	-0.42	Uric acid levels;	chr4:39115615	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs3733279	ENSG00000249207.1	RP11-360F5.1	-6.91	4.85e-11	9.39e-08	-0.45	-0.42	Uric acid levels;	chr4:39115625	chr4:39112677~39126818:-
OV	cis	rs11723261	0.582	rs7679573	ENSG00000275426.1	CH17-262A2.1	6.91	4.89e-11	9.46e-08	0.69	0.42	Immune response to smallpox vaccine (IL-6);	chr4:157810	chr4:149738~150317:+
OV	cis	rs2243480	0.901	rs778732	ENSG00000222364.1	RNU6-96P	-6.91	4.91e-11	9.5e-08	-0.65	-0.42	Diabetic kidney disease;	chr7:66357373	chr7:66395191~66395286:+
OV	cis	rs1707322	0.686	rs2230658	ENSG00000280836.1	AL355480.1	6.91	4.92e-11	9.52e-08	0.58	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613182	chr1:45581219~45581321:-
OV	cis	rs1707322	0.686	rs2230659	ENSG00000280836.1	AL355480.1	6.91	4.92e-11	9.52e-08	0.58	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613212	chr1:45581219~45581321:-
OV	cis	rs853679	0.517	rs9393895	ENSG00000220721.1	OR1F12	6.91	4.94e-11	9.54e-08	0.5	0.42	Depression;	chr6:28159843	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9357066	ENSG00000220721.1	OR1F12	6.91	4.94e-11	9.54e-08	0.5	0.42	Depression;	chr6:28162053	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9368556	ENSG00000220721.1	OR1F12	6.91	4.94e-11	9.54e-08	0.5	0.42	Depression;	chr6:28163375	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9368557	ENSG00000220721.1	OR1F12	6.91	4.94e-11	9.54e-08	0.5	0.42	Depression;	chr6:28163759	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9380059	ENSG00000220721.1	OR1F12	6.91	4.94e-11	9.54e-08	0.5	0.42	Depression;	chr6:28164580	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9380060	ENSG00000220721.1	OR1F12	6.91	4.94e-11	9.54e-08	0.5	0.42	Depression;	chr6:28164825	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs35227624	ENSG00000220721.1	OR1F12	6.91	4.94e-11	9.54e-08	0.5	0.42	Depression;	chr6:28164948	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9380061	ENSG00000220721.1	OR1F12	6.91	4.94e-11	9.54e-08	0.5	0.42	Depression;	chr6:28165025	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9368558	ENSG00000220721.1	OR1F12	6.91	4.94e-11	9.54e-08	0.5	0.42	Depression;	chr6:28165528	chr6:28073316~28074233:+
OV	cis	rs4713118	0.587	rs9393899	ENSG00000220721.1	OR1F12	6.91	4.94e-11	9.54e-08	0.5	0.42	Parkinson's disease;	chr6:28165750	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs4713150	ENSG00000220721.1	OR1F12	6.91	4.94e-11	9.54e-08	0.5	0.42	Depression;	chr6:28168434	chr6:28073316~28074233:+
OV	cis	rs4713118	0.527	rs4713151	ENSG00000220721.1	OR1F12	6.91	4.94e-11	9.54e-08	0.5	0.42	Parkinson's disease;	chr6:28168578	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9393901	ENSG00000220721.1	OR1F12	6.91	4.94e-11	9.54e-08	0.5	0.42	Depression;	chr6:28169019	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs3173443	ENSG00000220721.1	OR1F12	6.91	4.94e-11	9.54e-08	0.5	0.42	Depression;	chr6:28169249	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs4713152	ENSG00000220721.1	OR1F12	6.91	4.94e-11	9.54e-08	0.5	0.42	Depression;	chr6:28169676	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9348797	ENSG00000220721.1	OR1F12	6.91	4.94e-11	9.54e-08	0.5	0.42	Depression;	chr6:28169755	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9380062	ENSG00000220721.1	OR1F12	6.91	4.94e-11	9.54e-08	0.5	0.42	Depression;	chr6:28169791	chr6:28073316~28074233:+
OV	cis	rs853679	0.542	rs9380063	ENSG00000220721.1	OR1F12	6.91	4.94e-11	9.54e-08	0.5	0.42	Depression;	chr6:28170075	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs12332979	ENSG00000220721.1	OR1F12	6.91	4.94e-11	9.54e-08	0.5	0.42	Depression;	chr6:28173770	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs67878650	ENSG00000220721.1	OR1F12	6.91	4.94e-11	9.54e-08	0.5	0.42	Depression;	chr6:28174809	chr6:28073316~28074233:+
OV	cis	rs853679	0.569	rs9348798	ENSG00000220721.1	OR1F12	6.91	4.94e-11	9.54e-08	0.5	0.42	Depression;	chr6:28175233	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9380065	ENSG00000220721.1	OR1F12	6.91	4.94e-11	9.54e-08	0.5	0.42	Depression;	chr6:28176973	chr6:28073316~28074233:+
OV	cis	rs4713118	0.662	rs149900	ENSG00000220721.1	OR1F12	6.91	4.97e-11	9.57e-08	0.5	0.42	Parkinson's disease;	chr6:28046819	chr6:28073316~28074233:+
OV	cis	rs1185460	0.967	rs4454730	ENSG00000271751.1	RP11-110I1.14	-6.91	4.97e-11	9.57e-08	-0.49	-0.42	Coronary artery disease;	chr11:119066733	chr11:119065263~119065677:-
OV	cis	rs1185460	0.967	rs4545564	ENSG00000271751.1	RP11-110I1.14	-6.91	4.97e-11	9.57e-08	-0.49	-0.42	Coronary artery disease;	chr11:119066807	chr11:119065263~119065677:-
OV	cis	rs1185460	0.967	rs1784461	ENSG00000271751.1	RP11-110I1.14	-6.91	4.97e-11	9.57e-08	-0.49	-0.42	Coronary artery disease;	chr11:119067274	chr11:119065263~119065677:-
OV	cis	rs1707322	1	rs10890365	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893676	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs11211219	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893806	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs11211222	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45902085	chr1:45580892~45580996:-
OV	cis	rs1707322	0.928	rs7527244	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45903100	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs4524994	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45904591	chr1:45580892~45580996:-
OV	cis	rs1707322	0.963	rs9787412	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45905924	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs4660896	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45906744	chr1:45580892~45580996:-
OV	cis	rs1707322	0.928	rs10732844	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907016	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs12133129	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907676	chr1:45580892~45580996:-
OV	cis	rs1707322	0.963	rs4553121	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45909581	chr1:45580892~45580996:-
OV	cis	rs1707322	0.963	rs6690652	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45911020	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs6695421	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914535	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs11211223	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914933	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs6687301	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45917180	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs6657720	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45920597	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs7519181	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45922157	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs7526369	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45924888	chr1:45580892~45580996:-
OV	cis	rs1707322	0.963	rs10890371	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925225	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs10890372	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925348	chr1:45580892~45580996:-
OV	cis	rs1707322	0.928	rs6681068	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45932710	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs11211228	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934168	chr1:45580892~45580996:-
OV	cis	rs1707322	0.963	rs11211229	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934845	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs9803784	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45936235	chr1:45580892~45580996:-
OV	cis	rs1707322	0.963	rs12022335	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45937060	chr1:45580892~45580996:-
OV	cis	rs1707322	0.963	rs10789484	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941306	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs7527079	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45947778	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs34446427	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45951983	chr1:45580892~45580996:-
OV	cis	rs1707322	0.963	rs4660900	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45953933	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs4454479	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45957883	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs12077546	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966134	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs12124291	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966460	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs6671754	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968318	chr1:45580892~45580996:-
OV	cis	rs1707322	0.963	rs6666763	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45970779	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs4489497	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45973026	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs11211235	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45974703	chr1:45580892~45580996:-
OV	cis	rs1707322	0.893	rs9919275	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45975688	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs11211236	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45978095	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs4660328	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45979159	chr1:45580892~45580996:-
OV	cis	rs1707322	0.928	rs61785614	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45980375	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs9793167	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981128	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs11211237	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981657	chr1:45580892~45580996:-
OV	cis	rs1707322	0.963	rs11211238	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983743	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs10890380	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983797	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs4460583	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45984246	chr1:45580892~45580996:-
OV	cis	rs1707322	0.963	rs4459051	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45985531	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs11211239	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986275	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs6429588	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45988386	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs11211243	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45989761	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs11211244	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991001	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs4660903	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991929	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs4660331	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45993111	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs12097799	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45994214	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs6661500	ENSG00000281133.1	AL355480.3	-6.9	4.98e-11	9.57e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45999990	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs10890378	ENSG00000281133.1	AL355480.3	6.9	4.98e-11	9.57e-08	0.54	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45944985	chr1:45580892~45580996:-
OV	cis	rs950169	0.545	rs4842841	ENSG00000235370.6	DNM1P51	6.9	5e-11	9.61e-08	0.58	0.42	Schizophrenia;	chr15:83972373	chr15:84398316~84411701:-
OV	cis	rs7017914	0.902	rs10504481	ENSG00000223220.1	Y_RNA	6.9	5.05e-11	9.68e-08	0.43	0.42	Bone mineral density;	chr8:70787282	chr8:70780914~70781008:-
OV	cis	rs875971	0.545	rs313830	ENSG00000222364.1	RNU6-96P	6.9	5.06e-11	9.71e-08	0.49	0.42	Aortic root size;	chr7:66086944	chr7:66395191~66395286:+
OV	cis	rs1707322	1	rs11211232	ENSG00000281133.1	AL355480.3	-6.9	5.06e-11	9.71e-08	-0.53	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr1:45580892~45580996:-
OV	cis	rs2564921	0.704	rs56058643	ENSG00000242142.1	SERBP1P3	-6.9	5.06e-11	9.72e-08	-0.48	-0.42	Height;	chr3:53093751	chr3:53064283~53065091:-
OV	cis	rs1707322	0.691	rs11211175	ENSG00000280836.1	AL355480.1	-6.9	5.1e-11	9.77e-08	-0.57	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr1:45581219~45581321:-
OV	cis	rs7927771	0.929	rs66749409	ENSG00000280615.1	Y_RNA	-6.9	5.14e-11	9.84e-08	-0.51	-0.42	Subjective well-being;	chr11:47546522	chr11:47614898~47614994:-
OV	cis	rs7927771	0.894	rs12798346	ENSG00000280615.1	Y_RNA	-6.9	5.14e-11	9.84e-08	-0.51	-0.42	Subjective well-being;	chr11:47561569	chr11:47614898~47614994:-
OV	cis	rs7927771	0.965	rs56400411	ENSG00000280615.1	Y_RNA	-6.9	5.14e-11	9.84e-08	-0.51	-0.42	Subjective well-being;	chr11:47564824	chr11:47614898~47614994:-
OV	cis	rs7927771	1	rs35624992	ENSG00000280615.1	Y_RNA	-6.9	5.14e-11	9.84e-08	-0.51	-0.42	Subjective well-being;	chr11:47594246	chr11:47614898~47614994:-
OV	cis	rs7927771	1	rs12363232	ENSG00000280615.1	Y_RNA	-6.9	5.14e-11	9.84e-08	-0.51	-0.42	Subjective well-being;	chr11:47602338	chr11:47614898~47614994:-
OV	cis	rs1707322	0.721	rs4559551	ENSG00000280836.1	AL355480.1	-6.9	5.16e-11	9.86e-08	-0.58	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr1:45581219~45581321:-
OV	cis	rs2243480	1	rs316313	ENSG00000222364.1	RNU6-96P	-6.9	5.18e-11	9.9e-08	-0.64	-0.42	Diabetic kidney disease;	chr7:66128561	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs316312	ENSG00000222364.1	RNU6-96P	-6.9	5.18e-11	9.9e-08	-0.64	-0.42	Diabetic kidney disease;	chr7:66131504	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs419603	ENSG00000222364.1	RNU6-96P	-6.9	5.18e-11	9.9e-08	-0.64	-0.42	Diabetic kidney disease;	chr7:66132354	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs387676	ENSG00000222364.1	RNU6-96P	-6.9	5.18e-11	9.9e-08	-0.64	-0.42	Diabetic kidney disease;	chr7:66133233	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs13310597	ENSG00000222364.1	RNU6-96P	-6.9	5.18e-11	9.9e-08	-0.64	-0.42	Diabetic kidney disease;	chr7:66133553	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs431076	ENSG00000222364.1	RNU6-96P	-6.9	5.18e-11	9.9e-08	-0.64	-0.42	Diabetic kidney disease;	chr7:66135333	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs2257790	ENSG00000222364.1	RNU6-96P	-6.9	5.18e-11	9.9e-08	-0.64	-0.42	Diabetic kidney disease;	chr7:66135463	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs2460422	ENSG00000222364.1	RNU6-96P	-6.9	5.18e-11	9.9e-08	-0.64	-0.42	Diabetic kidney disease;	chr7:66136518	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs316334	ENSG00000222364.1	RNU6-96P	-6.9	5.18e-11	9.9e-08	-0.64	-0.42	Diabetic kidney disease;	chr7:66137139	chr7:66395191~66395286:+
OV	cis	rs2408955	0.568	rs12099462	ENSG00000258273.1	RP11-370I10.4	6.9	5.19e-11	9.91e-08	0.5	0.42	Glycated hemoglobin levels;	chr12:48109321	chr12:48333755~48333901:-
OV	cis	rs1075265	0.568	rs10865278	ENSG00000233266.1	HMGB1P31	6.9	5.22e-11	9.98e-08	0.51	0.42	Chronotype;Morning vs. evening chronotype;	chr2:54074902	chr2:54051334~54051760:+
OV	cis	rs1707322	0.682	rs28508523	ENSG00000281133.1	AL355480.3	-6.9	5.23e-11	9.98e-08	-0.54	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr1:45580892~45580996:-
OV	cis	rs1707322	0.721	rs61784800	ENSG00000281133.1	AL355480.3	6.9	5.23e-11	9.98e-08	0.54	0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr1:45580892~45580996:-
OV	cis	rs7017914	0.967	rs13257800	ENSG00000223220.1	Y_RNA	6.9	5.23e-11	9.99e-08	0.42	0.42	Bone mineral density;	chr8:70801898	chr8:70780914~70781008:-
OV	cis	rs6991838	0.584	rs7842085	ENSG00000272010.1	CTD-3025N20.3	6.89	5.29e-11	1.01e-07	0.54	0.42	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65591850~65592472:-
OV	cis	rs11673344	0.566	rs8109103	ENSG00000226686.6	LINC01535	6.89	5.29e-11	1.01e-07	0.49	0.42	Obesity-related traits;	chr19:37503209	chr19:37251912~37265535:+
OV	cis	rs8005677	1	rs1956881	ENSG00000257285.4	RP11-298I3.1	6.89	5.33e-11	1.02e-07	0.48	0.42	Cognitive ability (multi-trait analysis);	chr14:22924860	chr14:22929609~22955562:+
OV	cis	rs9326248	0.581	rs6589582	ENSG00000254851.1	RP11-109L13.1	-6.89	5.41e-11	1.03e-07	-0.49	-0.42	Blood protein levels;	chr11:116958484	chr11:117135528~117138582:+
OV	cis	rs7044106	0.762	rs10739570	ENSG00000226752.6	PSMD5-AS1	-6.89	5.41e-11	1.03e-07	-0.49	-0.42	Hip circumference adjusted for BMI;	chr9:120618944	chr9:120824828~120854385:+
OV	cis	rs2153535	0.58	rs4451187	ENSG00000230939.1	RP11-314C16.1	-6.89	5.42e-11	1.03e-07	-0.47	-0.42	Motion sickness;	chr6:8473677	chr6:8784178~8785445:+
OV	cis	rs2153535	0.504	rs4493781	ENSG00000230939.1	RP11-314C16.1	-6.89	5.42e-11	1.03e-07	-0.47	-0.42	Motion sickness;	chr6:8473708	chr6:8784178~8785445:+
OV	cis	rs2153535	0.541	rs5026687	ENSG00000230939.1	RP11-314C16.1	-6.89	5.42e-11	1.03e-07	-0.47	-0.42	Motion sickness;	chr6:8473724	chr6:8784178~8785445:+
OV	cis	rs7576126	0.563	rs1807337	ENSG00000234255.7	AC012370.3	-6.89	5.44e-11	1.04e-07	-0.46	-0.42	Severe influenza A (H1N1) infection;	chr2:65436033	chr2:65439888~65456571:-
OV	cis	rs8062405	1	rs80275162	ENSG00000259982.1	CDC37P1	6.89	5.47e-11	1.04e-07	0.51	0.42	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28700294~28701540:-
OV	cis	rs2153535	0.58	rs4587214	ENSG00000230939.1	RP11-314C16.1	-6.89	5.5e-11	1.05e-07	-0.47	-0.42	Motion sickness;	chr6:8453886	chr6:8784178~8785445:+
OV	cis	rs1707322	0.964	rs10890358	ENSG00000281133.1	AL355480.3	-6.89	5.5e-11	1.05e-07	-0.53	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853353	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs7531911	ENSG00000281133.1	AL355480.3	-6.89	5.5e-11	1.05e-07	-0.53	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864751	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs34694458	ENSG00000281133.1	AL355480.3	-6.89	5.5e-11	1.05e-07	-0.53	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867024	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs10890359	ENSG00000281133.1	AL355480.3	-6.89	5.5e-11	1.05e-07	-0.53	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45870963	chr1:45580892~45580996:-
OV	cis	rs6921919	0.583	rs16894060	ENSG00000216901.1	AL022393.7	6.89	5.51e-11	1.05e-07	0.5	0.42	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28176188~28176674:+
OV	cis	rs875971	0.545	rs313828	ENSG00000222364.1	RNU6-96P	6.89	5.52e-11	1.05e-07	0.48	0.42	Aortic root size;	chr7:66087627	chr7:66395191~66395286:+
OV	cis	rs875971	0.52	rs160645	ENSG00000222364.1	RNU6-96P	6.89	5.52e-11	1.05e-07	0.48	0.42	Aortic root size;	chr7:66091320	chr7:66395191~66395286:+
OV	cis	rs875971	0.789	rs28815324	ENSG00000222364.1	RNU6-96P	6.89	5.52e-11	1.05e-07	0.48	0.42	Aortic root size;	chr7:66100789	chr7:66395191~66395286:+
OV	cis	rs853679	0.517	rs9393896	ENSG00000220721.1	OR1F12	6.89	5.53e-11	1.05e-07	0.5	0.42	Depression;	chr6:28159925	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9393897	ENSG00000220721.1	OR1F12	6.89	5.53e-11	1.05e-07	0.5	0.42	Depression;	chr6:28159932	chr6:28073316~28074233:+
OV	cis	rs9918079	0.56	rs4557256	ENSG00000273133.1	RP11-799M12.2	-6.88	5.62e-11	1.07e-07	-0.47	-0.42	Obesity-related traits;	chr4:15625024	chr4:15563698~15564253:-
OV	cis	rs2153535	0.58	rs6941670	ENSG00000230939.1	RP11-314C16.1	-6.88	5.63e-11	1.07e-07	-0.47	-0.42	Motion sickness;	chr6:8446113	chr6:8784178~8785445:+
OV	cis	rs748404	0.66	rs690367	ENSG00000249839.1	AC011330.5	6.88	5.63e-11	1.07e-07	0.49	0.42	Lung cancer;	chr15:43456106	chr15:43663654~43684339:-
OV	cis	rs2153535	0.58	rs6920779	ENSG00000230939.1	RP11-314C16.1	-6.88	5.65e-11	1.07e-07	-0.47	-0.42	Motion sickness;	chr6:8437391	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs4960411	ENSG00000230939.1	RP11-314C16.1	-6.88	5.65e-11	1.07e-07	-0.47	-0.42	Motion sickness;	chr6:8437998	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs4960412	ENSG00000230939.1	RP11-314C16.1	-6.88	5.65e-11	1.07e-07	-0.47	-0.42	Motion sickness;	chr6:8438028	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs4960413	ENSG00000230939.1	RP11-314C16.1	-6.88	5.65e-11	1.07e-07	-0.47	-0.42	Motion sickness;	chr6:8438233	chr6:8784178~8785445:+
OV	cis	rs2153535	0.601	rs4960414	ENSG00000230939.1	RP11-314C16.1	-6.88	5.65e-11	1.07e-07	-0.47	-0.42	Motion sickness;	chr6:8438308	chr6:8784178~8785445:+
OV	cis	rs2153535	0.542	rs9393012	ENSG00000230939.1	RP11-314C16.1	-6.88	5.65e-11	1.07e-07	-0.47	-0.42	Motion sickness;	chr6:8439576	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1928184	ENSG00000230939.1	RP11-314C16.1	-6.88	5.67e-11	1.08e-07	-0.47	-0.42	Motion sickness;	chr6:8531875	chr6:8784178~8785445:+
OV	cis	rs17711722	0.727	rs2658585	ENSG00000226824.5	RP4-756H11.3	-6.88	5.67e-11	1.08e-07	-0.43	-0.42	Calcium levels;	chr7:65996954	chr7:66654538~66669855:+
OV	cis	rs2836950	0.959	rs4818008	ENSG00000232608.1	TIMM9P2	6.88	5.69e-11	1.08e-07	0.51	0.42	Menarche (age at onset);	chr21:39239516	chr21:39216624~39217506:+
OV	cis	rs9918079	0.506	rs10214	ENSG00000273133.1	RP11-799M12.2	6.88	5.7e-11	1.08e-07	0.48	0.42	Obesity-related traits;	chr4:15604808	chr4:15563698~15564253:-
OV	cis	rs2739330	0.791	rs4822458	ENSG00000099984.9	GSTT2	-6.88	5.7e-11	1.08e-07	-0.51	-0.42	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23980123~23983911:+
OV	cis	rs2243480	1	rs4149468	ENSG00000222364.1	RNU6-96P	-6.88	5.73e-11	1.09e-07	-0.64	-0.42	Diabetic kidney disease;	chr7:66360703	chr7:66395191~66395286:+
OV	cis	rs2153535	0.58	rs6921964	ENSG00000230939.1	RP11-314C16.1	-6.88	5.75e-11	1.09e-07	-0.47	-0.42	Motion sickness;	chr6:8446162	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs6597318	ENSG00000230939.1	RP11-314C16.1	-6.88	5.75e-11	1.09e-07	-0.48	-0.42	Motion sickness;	chr6:8437056	chr6:8784178~8785445:+
OV	cis	rs16828019	0.704	rs34660906	ENSG00000235358.1	RP11-399E6.1	6.88	5.75e-11	1.09e-07	0.97	0.42	Intelligence (multi-trait analysis);	chr1:41086296	chr1:41242373~41284861:+
OV	cis	rs2153535	0.504	rs5001323	ENSG00000230939.1	RP11-314C16.1	-6.88	5.77e-11	1.09e-07	-0.47	-0.42	Motion sickness;	chr6:8451372	chr6:8784178~8785445:+
OV	cis	rs507080	0.501	rs494459	ENSG00000255422.1	AP002954.4	6.88	5.8e-11	1.1e-07	0.47	0.42	Serum metabolite levels;	chr11:118703966	chr11:118704607~118750263:+
OV	cis	rs2929278	0.736	rs2412823	ENSG00000205771.5	CATSPER2P1	6.88	5.82e-11	1.1e-07	0.54	0.42	Schizophrenia;	chr15:43935072	chr15:43726918~43747094:-
OV	cis	rs4591358	0.731	rs34634374	ENSG00000223466.1	AC064834.2	-6.88	5.83e-11	1.1e-07	-0.58	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195509437	chr2:195533035~195538681:+
OV	cis	rs9918079	0.56	rs4698402	ENSG00000273133.1	RP11-799M12.2	-6.88	5.85e-11	1.11e-07	-0.48	-0.42	Obesity-related traits;	chr4:15628180	chr4:15563698~15564253:-
OV	cis	rs7017914	0.967	rs2732091	ENSG00000223220.1	Y_RNA	-6.88	5.88e-11	1.11e-07	-0.43	-0.42	Bone mineral density;	chr8:71006188	chr8:70780914~70781008:-
OV	cis	rs4591358	0.689	rs1913894	ENSG00000223466.1	AC064834.2	-6.88	5.89e-11	1.11e-07	-0.6	-0.42	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195534032	chr2:195533035~195538681:+
OV	cis	rs1061377	1	rs10018049	ENSG00000249207.1	RP11-360F5.1	-6.88	5.89e-11	1.12e-07	-0.45	-0.42	Uric acid levels;	chr4:39115781	chr4:39112677~39126818:-
OV	cis	rs2243480	0.901	rs778687	ENSG00000222364.1	RNU6-96P	-6.88	5.92e-11	1.12e-07	-0.64	-0.42	Diabetic kidney disease;	chr7:66370832	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs778679	ENSG00000222364.1	RNU6-96P	-6.88	5.92e-11	1.12e-07	-0.64	-0.42	Diabetic kidney disease;	chr7:66375924	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs778704	ENSG00000222364.1	RNU6-96P	-6.88	5.92e-11	1.12e-07	-0.64	-0.42	Diabetic kidney disease;	chr7:66398480	chr7:66395191~66395286:+
OV	cis	rs2243480	0.901	rs778693	ENSG00000222364.1	RNU6-96P	-6.88	5.92e-11	1.12e-07	-0.64	-0.42	Diabetic kidney disease;	chr7:66407358	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs778691	ENSG00000222364.1	RNU6-96P	-6.88	5.92e-11	1.12e-07	-0.64	-0.42	Diabetic kidney disease;	chr7:66408105	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs13235972	ENSG00000222364.1	RNU6-96P	-6.88	5.92e-11	1.12e-07	-0.64	-0.42	Diabetic kidney disease;	chr7:66418618	chr7:66395191~66395286:+
OV	cis	rs1707322	0.682	rs12037459	ENSG00000280836.1	AL355480.1	-6.87	5.96e-11	1.13e-07	-0.6	-0.42	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629287	chr1:45581219~45581321:-
OV	cis	rs1789	0.903	rs4616746	ENSG00000273133.1	RP11-799M12.2	-6.87	5.97e-11	1.13e-07	-0.48	-0.42	Blood protein levels;	chr4:15671475	chr4:15563698~15564253:-
OV	cis	rs2243480	1	rs778729	ENSG00000222364.1	RNU6-96P	-6.87	5.97e-11	1.13e-07	-0.64	-0.42	Diabetic kidney disease;	chr7:66359432	chr7:66395191~66395286:+
OV	cis	rs2836974	0.568	rs11910906	ENSG00000232608.1	TIMM9P2	6.87	5.98e-11	1.13e-07	0.44	0.42	Cognitive function;	chr21:39313736	chr21:39216624~39217506:+
OV	cis	rs3091242	0.933	rs10903129	ENSG00000261349.1	RP3-465N24.5	-6.87	6e-11	1.13e-07	-0.43	-0.42	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25266102~25267136:-
OV	cis	rs8062405	0.824	rs4788083	ENSG00000259982.1	CDC37P1	6.87	6.02e-11	1.14e-07	0.48	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28700294~28701540:-
OV	cis	rs11159086	1	rs4899516	ENSG00000259005.1	RP3-449M8.6	6.87	6.04e-11	1.14e-07	0.67	0.41	Advanced glycation end-product levels;	chr14:74492825	chr14:74474007~74474864:-
OV	cis	rs11159086	1	rs12433848	ENSG00000259005.1	RP3-449M8.6	6.87	6.04e-11	1.14e-07	0.67	0.41	Advanced glycation end-product levels;	chr14:74497570	chr14:74474007~74474864:-
OV	cis	rs2153535	0.623	rs2152346	ENSG00000230939.1	RP11-314C16.1	-6.87	6.05e-11	1.14e-07	-0.47	-0.41	Motion sickness;	chr6:8454419	chr6:8784178~8785445:+
OV	cis	rs2153535	0.562	rs6901765	ENSG00000230939.1	RP11-314C16.1	-6.87	6.05e-11	1.14e-07	-0.47	-0.41	Motion sickness;	chr6:8455203	chr6:8784178~8785445:+
OV	cis	rs2153535	0.601	rs9502715	ENSG00000230939.1	RP11-314C16.1	-6.87	6.05e-11	1.14e-07	-0.47	-0.41	Motion sickness;	chr6:8455476	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs6912193	ENSG00000230939.1	RP11-314C16.1	-6.87	6.05e-11	1.14e-07	-0.47	-0.41	Motion sickness;	chr6:8456073	chr6:8784178~8785445:+
OV	cis	rs2243480	1	rs34192067	ENSG00000222364.1	RNU6-96P	-6.87	6.06e-11	1.14e-07	-0.64	-0.41	Diabetic kidney disease;	chr7:66422670	chr7:66395191~66395286:+
OV	cis	rs2739330	0.76	rs5751761	ENSG00000224205.1	AP000351.4	-6.87	6.08e-11	1.15e-07	-0.44	-0.41	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23987320~23991421:-
OV	cis	rs3091242	0.933	rs11249250	ENSG00000261349.1	RP3-465N24.5	-6.87	6.09e-11	1.15e-07	-0.44	-0.41	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25266102~25267136:-
OV	cis	rs2836974	0.666	rs11910705	ENSG00000232608.1	TIMM9P2	6.87	6.1e-11	1.15e-07	0.45	0.41	Cognitive function;	chr21:39313678	chr21:39216624~39217506:+
OV	cis	rs2153535	0.601	rs9328487	ENSG00000230939.1	RP11-314C16.1	-6.87	6.12e-11	1.15e-07	-0.47	-0.41	Motion sickness;	chr6:8529145	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9328488	ENSG00000230939.1	RP11-314C16.1	-6.87	6.12e-11	1.15e-07	-0.47	-0.41	Motion sickness;	chr6:8529178	chr6:8784178~8785445:+
OV	cis	rs1707322	0.656	rs3014210	ENSG00000280836.1	AL355480.1	6.87	6.13e-11	1.16e-07	0.57	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45581219~45581321:-
OV	cis	rs7044106	0.791	rs2416797	ENSG00000226752.6	PSMD5-AS1	-6.87	6.18e-11	1.17e-07	-0.47	-0.41	Hip circumference adjusted for BMI;	chr9:120718322	chr9:120824828~120854385:+
OV	cis	rs7044106	0.791	rs2416798	ENSG00000226752.6	PSMD5-AS1	-6.87	6.18e-11	1.17e-07	-0.47	-0.41	Hip circumference adjusted for BMI;	chr9:120718325	chr9:120824828~120854385:+
OV	cis	rs1707322	1	rs785486	ENSG00000281133.1	AL355480.3	6.87	6.22e-11	1.17e-07	0.53	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46109476	chr1:45580892~45580996:-
OV	cis	rs1707322	0.865	rs785501	ENSG00000281133.1	AL355480.3	6.87	6.22e-11	1.17e-07	0.53	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46113939	chr1:45580892~45580996:-
OV	cis	rs1707322	0.929	rs785500	ENSG00000281133.1	AL355480.3	6.87	6.22e-11	1.17e-07	0.53	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46127372	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs785504	ENSG00000281133.1	AL355480.3	6.87	6.22e-11	1.17e-07	0.53	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46130024	chr1:45580892~45580996:-
OV	cis	rs8105895	0.736	rs2359835	ENSG00000269742.1	BNIP3P29	6.87	6.22e-11	1.17e-07	0.69	0.41	Body mass index (change over time);	chr19:22059888	chr19:22065828~22066398:-
OV	cis	rs8105895	0.733	rs62110979	ENSG00000269742.1	BNIP3P29	6.87	6.22e-11	1.17e-07	0.69	0.41	Body mass index (change over time);	chr19:22062350	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs62110987	ENSG00000269742.1	BNIP3P29	6.87	6.22e-11	1.17e-07	0.69	0.41	Body mass index (change over time);	chr19:22074493	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs62110988	ENSG00000269742.1	BNIP3P29	6.87	6.22e-11	1.17e-07	0.69	0.41	Body mass index (change over time);	chr19:22077154	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs62110989	ENSG00000269742.1	BNIP3P29	6.87	6.22e-11	1.17e-07	0.69	0.41	Body mass index (change over time);	chr19:22077497	chr19:22065828~22066398:-
OV	cis	rs1789	0.868	rs4631041	ENSG00000273133.1	RP11-799M12.2	-6.87	6.26e-11	1.18e-07	-0.48	-0.41	Blood protein levels;	chr4:15671772	chr4:15563698~15564253:-
OV	cis	rs6435862	0.593	rs34732883	ENSG00000229267.2	AC072062.1	6.86	6.29e-11	1.18e-07	0.48	0.41	Neuroblastoma (high-risk);	chr2:214809647	chr2:214810229~214963274:+
OV	cis	rs2153535	0.58	rs9378556	ENSG00000230939.1	RP11-314C16.1	-6.86	6.29e-11	1.18e-07	-0.46	-0.41	Motion sickness;	chr6:8514462	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9406171	ENSG00000230939.1	RP11-314C16.1	-6.86	6.29e-11	1.18e-07	-0.46	-0.41	Motion sickness;	chr6:8515129	chr6:8784178~8785445:+
OV	cis	rs2153535	0.54	rs9378557	ENSG00000230939.1	RP11-314C16.1	-6.86	6.29e-11	1.18e-07	-0.46	-0.41	Motion sickness;	chr6:8517148	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs2143355	ENSG00000230939.1	RP11-314C16.1	-6.86	6.29e-11	1.18e-07	-0.46	-0.41	Motion sickness;	chr6:8517623	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs2143354	ENSG00000230939.1	RP11-314C16.1	-6.86	6.29e-11	1.18e-07	-0.46	-0.41	Motion sickness;	chr6:8517674	chr6:8784178~8785445:+
OV	cis	rs2117029	0.555	rs7958241	ENSG00000258017.1	RP11-386G11.10	6.86	6.35e-11	1.19e-07	0.5	0.41	Intelligence (multi-trait analysis);	chr12:49115479	chr12:49127782~49147869:+
OV	cis	rs1707322	0.721	rs28817701	ENSG00000280836.1	AL355480.1	-6.86	6.35e-11	1.19e-07	-0.58	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45581219~45581321:-
OV	cis	rs1707322	0.691	rs28495425	ENSG00000280836.1	AL355480.1	-6.86	6.35e-11	1.19e-07	-0.58	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45581219~45581321:-
OV	cis	rs1707322	0.685	rs28617418	ENSG00000280836.1	AL355480.1	-6.86	6.35e-11	1.19e-07	-0.58	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45581219~45581321:-
OV	cis	rs1707322	0.682	rs28490344	ENSG00000280836.1	AL355480.1	-6.86	6.35e-11	1.19e-07	-0.58	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs28501477	ENSG00000280836.1	AL355480.1	-6.86	6.35e-11	1.19e-07	-0.58	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs28641748	ENSG00000280836.1	AL355480.1	-6.86	6.35e-11	1.19e-07	-0.58	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs6697821	ENSG00000280836.1	AL355480.1	-6.86	6.35e-11	1.19e-07	-0.58	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs4330955	ENSG00000280836.1	AL355480.1	-6.86	6.35e-11	1.19e-07	-0.58	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45581219~45581321:-
OV	cis	rs1707322	0.691	rs11211174	ENSG00000280836.1	AL355480.1	-6.86	6.35e-11	1.19e-07	-0.58	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45581219~45581321:-
OV	cis	rs1707322	0.691	rs12031182	ENSG00000280836.1	AL355480.1	-6.86	6.35e-11	1.19e-07	-0.58	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs10430123	ENSG00000280836.1	AL355480.1	-6.86	6.35e-11	1.19e-07	-0.58	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45581219~45581321:-
OV	cis	rs1707322	0.691	rs61784803	ENSG00000280836.1	AL355480.1	6.86	6.35e-11	1.19e-07	0.58	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45581219~45581321:-
OV	cis	rs1707322	0.663	rs3935296	ENSG00000280836.1	AL355480.1	6.86	6.35e-11	1.19e-07	0.58	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45581219~45581321:-
OV	cis	rs2153535	0.542	rs6912740	ENSG00000230939.1	RP11-314C16.1	-6.86	6.37e-11	1.19e-07	-0.47	-0.41	Motion sickness;	chr6:8439726	chr6:8784178~8785445:+
OV	cis	rs2153535	0.542	rs6905925	ENSG00000230939.1	RP11-314C16.1	-6.86	6.37e-11	1.19e-07	-0.47	-0.41	Motion sickness;	chr6:8439797	chr6:8784178~8785445:+
OV	cis	rs2153535	0.541	rs6905934	ENSG00000230939.1	RP11-314C16.1	-6.86	6.37e-11	1.19e-07	-0.47	-0.41	Motion sickness;	chr6:8439810	chr6:8784178~8785445:+
OV	cis	rs2153535	0.542	rs915353	ENSG00000230939.1	RP11-314C16.1	-6.86	6.37e-11	1.19e-07	-0.47	-0.41	Motion sickness;	chr6:8440137	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs2327050	ENSG00000230939.1	RP11-314C16.1	-6.86	6.37e-11	1.19e-07	-0.47	-0.41	Motion sickness;	chr6:8440397	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs4404802	ENSG00000230939.1	RP11-314C16.1	-6.86	6.37e-11	1.19e-07	-0.47	-0.41	Motion sickness;	chr6:8441819	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1932275	ENSG00000230939.1	RP11-314C16.1	-6.86	6.37e-11	1.19e-07	-0.47	-0.41	Motion sickness;	chr6:8442100	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1932276	ENSG00000230939.1	RP11-314C16.1	-6.86	6.37e-11	1.19e-07	-0.47	-0.41	Motion sickness;	chr6:8442360	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs915352	ENSG00000230939.1	RP11-314C16.1	-6.86	6.37e-11	1.19e-07	-0.47	-0.41	Motion sickness;	chr6:8442533	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs915351	ENSG00000230939.1	RP11-314C16.1	-6.86	6.37e-11	1.19e-07	-0.47	-0.41	Motion sickness;	chr6:8442560	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs2327056	ENSG00000230939.1	RP11-314C16.1	-6.86	6.37e-11	1.19e-07	-0.47	-0.41	Motion sickness;	chr6:8443072	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs3938660	ENSG00000230939.1	RP11-314C16.1	-6.86	6.37e-11	1.19e-07	-0.47	-0.41	Motion sickness;	chr6:8443102	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs915350	ENSG00000230939.1	RP11-314C16.1	-6.86	6.37e-11	1.19e-07	-0.47	-0.41	Motion sickness;	chr6:8443253	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1577467	ENSG00000230939.1	RP11-314C16.1	-6.86	6.37e-11	1.19e-07	-0.47	-0.41	Motion sickness;	chr6:8444008	chr6:8784178~8785445:+
OV	cis	rs2153535	0.601	rs1855765	ENSG00000230939.1	RP11-314C16.1	-6.86	6.37e-11	1.19e-07	-0.47	-0.41	Motion sickness;	chr6:8444092	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9406143	ENSG00000230939.1	RP11-314C16.1	-6.86	6.37e-11	1.19e-07	-0.47	-0.41	Motion sickness;	chr6:8444350	chr6:8784178~8785445:+
OV	cis	rs8105895	0.935	rs62111038	ENSG00000269742.1	BNIP3P29	6.86	6.37e-11	1.19e-07	0.69	0.41	Body mass index (change over time);	chr19:22103812	chr19:22065828~22066398:-
OV	cis	rs1707322	0.964	rs785483	ENSG00000281133.1	AL355480.3	6.86	6.39e-11	1.2e-07	0.53	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46093499	chr1:45580892~45580996:-
OV	cis	rs1707322	0.964	rs796773	ENSG00000281133.1	AL355480.3	6.86	6.39e-11	1.2e-07	0.53	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46098803	chr1:45580892~45580996:-
OV	cis	rs1707322	0.896	rs785518	ENSG00000281133.1	AL355480.3	6.86	6.39e-11	1.2e-07	0.53	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102750	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs785519	ENSG00000281133.1	AL355480.3	6.86	6.39e-11	1.2e-07	0.53	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102890	chr1:45580892~45580996:-
OV	cis	rs1707322	0.691	rs11211175	ENSG00000281133.1	AL355480.3	-6.86	6.41e-11	1.2e-07	-0.53	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755212	chr1:45580892~45580996:-
OV	cis	rs9918079	0.542	rs1789	ENSG00000273133.1	RP11-799M12.2	-6.86	6.42e-11	1.2e-07	-0.47	-0.41	Obesity-related traits;	chr4:15662912	chr4:15563698~15564253:-
OV	cis	rs2408955	0.521	rs10875753	ENSG00000258273.1	RP11-370I10.4	-6.86	6.42e-11	1.2e-07	-0.5	-0.41	Glycated hemoglobin levels;	chr12:48163358	chr12:48333755~48333901:-
OV	cis	rs7927771	0.965	rs34958982	ENSG00000280615.1	Y_RNA	-6.86	6.49e-11	1.21e-07	-0.51	-0.41	Subjective well-being;	chr11:47525494	chr11:47614898~47614994:-
OV	cis	rs10510102	0.872	rs116521083	ENSG00000276742.1	RP11-500G22.4	6.86	6.52e-11	1.22e-07	0.68	0.41	Breast cancer;	chr10:121950611	chr10:121956782~121957098:+
OV	cis	rs10510102	0.748	rs4589226	ENSG00000276742.1	RP11-500G22.4	6.86	6.52e-11	1.22e-07	0.68	0.41	Breast cancer;	chr10:121951073	chr10:121956782~121957098:+
OV	cis	rs10510102	0.81	rs34738294	ENSG00000276742.1	RP11-500G22.4	6.86	6.52e-11	1.22e-07	0.68	0.41	Breast cancer;	chr10:121951357	chr10:121956782~121957098:+
OV	cis	rs10510102	0.872	rs12258234	ENSG00000276742.1	RP11-500G22.4	6.86	6.52e-11	1.22e-07	0.68	0.41	Breast cancer;	chr10:121952828	chr10:121956782~121957098:+
OV	cis	rs10510102	0.515	rs11200285	ENSG00000276742.1	RP11-500G22.4	6.86	6.52e-11	1.22e-07	0.68	0.41	Breast cancer;	chr10:121953931	chr10:121956782~121957098:+
OV	cis	rs10510102	0.872	rs75831447	ENSG00000276742.1	RP11-500G22.4	6.86	6.52e-11	1.22e-07	0.68	0.41	Breast cancer;	chr10:121953963	chr10:121956782~121957098:+
OV	cis	rs10510102	0.63	rs79960726	ENSG00000276742.1	RP11-500G22.4	6.86	6.52e-11	1.22e-07	0.68	0.41	Breast cancer;	chr10:121954358	chr10:121956782~121957098:+
OV	cis	rs2153535	0.58	rs1328862	ENSG00000230939.1	RP11-314C16.1	-6.86	6.54e-11	1.22e-07	-0.47	-0.41	Motion sickness;	chr6:8526448	chr6:8784178~8785445:+
OV	cis	rs2836974	0.666	rs1888487	ENSG00000232608.1	TIMM9P2	6.86	6.58e-11	1.23e-07	0.44	0.41	Cognitive function;	chr21:39311333	chr21:39216624~39217506:+
OV	cis	rs1707322	1	rs10789486	ENSG00000281133.1	AL355480.3	-6.86	6.58e-11	1.23e-07	-0.53	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45942995	chr1:45580892~45580996:-
OV	cis	rs35160687	0.862	rs17737955	ENSG00000273080.1	RP11-301O19.1	6.86	6.66e-11	1.24e-07	0.42	0.41	Night sleep phenotypes;	chr2:86280891	chr2:86195590~86196049:+
OV	cis	rs2153535	0.58	rs6597337	ENSG00000230939.1	RP11-314C16.1	-6.86	6.66e-11	1.24e-07	-0.47	-0.41	Motion sickness;	chr6:8531419	chr6:8784178~8785445:+
OV	cis	rs4591358	0.648	rs7557471	ENSG00000223466.1	AC064834.2	-6.85	6.74e-11	1.26e-07	-0.59	-0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195520713	chr2:195533035~195538681:+
OV	cis	rs9813712	0.526	rs62281641	ENSG00000228252.7	COL6A4P2	-6.85	6.75e-11	1.26e-07	-0.47	-0.41	Response to amphetamines;	chr3:130235668	chr3:130212823~130273806:+
OV	cis	rs1707322	0.789	rs7540578	ENSG00000280836.1	AL355480.1	-6.85	6.76e-11	1.26e-07	-0.55	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45786472	chr1:45581219~45581321:-
OV	cis	rs2153535	0.541	rs945304	ENSG00000230939.1	RP11-314C16.1	-6.85	6.82e-11	1.27e-07	-0.47	-0.41	Motion sickness;	chr6:8442659	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1889715	ENSG00000230939.1	RP11-314C16.1	-6.85	6.82e-11	1.27e-07	-0.47	-0.41	Motion sickness;	chr6:8443242	chr6:8784178~8785445:+
OV	cis	rs1707322	1	rs4539075	ENSG00000281133.1	AL355480.3	-6.85	6.86e-11	1.28e-07	-0.53	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45892338	chr1:45580892~45580996:-
OV	cis	rs4713118	0.621	rs9295755	ENSG00000220721.1	OR1F12	-6.85	6.86e-11	1.28e-07	-0.48	-0.41	Parkinson's disease;	chr6:28065396	chr6:28073316~28074233:+
OV	cis	rs934734	0.571	rs7572922	ENSG00000234255.7	AC012370.3	-6.85	6.96e-11	1.29e-07	-0.46	-0.41	Rheumatoid arthritis;	chr2:65425022	chr2:65439888~65456571:-
OV	cis	rs2153535	0.58	rs7767756	ENSG00000230939.1	RP11-314C16.1	-6.85	6.98e-11	1.3e-07	-0.47	-0.41	Motion sickness;	chr6:8453195	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs7767926	ENSG00000230939.1	RP11-314C16.1	-6.85	6.98e-11	1.3e-07	-0.47	-0.41	Motion sickness;	chr6:8453324	chr6:8784178~8785445:+
OV	cis	rs7246967	1	rs12983770	ENSG00000269509.1	BNIP3P34	6.85	6.99e-11	1.3e-07	0.6	0.41	Bronchopulmonary dysplasia;	chr19:22840812	chr19:22773853~22774424:+
OV	cis	rs7246967	1	rs12980225	ENSG00000269509.1	BNIP3P34	6.85	6.99e-11	1.3e-07	0.6	0.41	Bronchopulmonary dysplasia;	chr19:22843943	chr19:22773853~22774424:+
OV	cis	rs11763147	1	rs11763147	ENSG00000236529.1	RP13-254B10.1	-6.85	6.99e-11	1.3e-07	-0.42	-0.41	Corneal structure;	chr7:65861834	chr7:65840212~65840596:+
OV	cis	rs2243480	1	rs422164	ENSG00000222364.1	RNU6-96P	-6.85	7e-11	1.3e-07	-0.64	-0.41	Diabetic kidney disease;	chr7:66121618	chr7:66395191~66395286:+
OV	cis	rs853679	0.517	rs9357065	ENSG00000220721.1	OR1F12	6.85	7.01e-11	1.3e-07	0.5	0.41	Depression;	chr6:28161802	chr6:28073316~28074233:+
OV	cis	rs7617773	0.539	rs13094496	ENSG00000229759.1	MRPS18AP1	6.85	7.03e-11	1.3e-07	0.44	0.41	Coronary artery disease;	chr3:48345560	chr3:48256350~48256938:-
OV	cis	rs67383717	0.527	rs12004422	ENSG00000175611.10	LINC00476	6.85	7.05e-11	1.31e-07	0.47	0.41	Parkinson's disease (pesticide exposure interaction);	chr9:95873393	chr9:95759231~95875977:-
OV	cis	rs1061377	1	rs28607301	ENSG00000249207.1	RP11-360F5.1	-6.84	7.07e-11	1.31e-07	-0.44	-0.41	Uric acid levels;	chr4:39136460	chr4:39112677~39126818:-
OV	cis	rs73086581	0.687	rs16989002	ENSG00000229539.1	RP11-119B16.2	6.84	7.1e-11	1.32e-07	0.56	0.41	Response to antidepressants in depression;	chr20:3870056	chr20:3888239~3888868:-
OV	cis	rs6921919	0.583	rs7764737	ENSG00000216901.1	AL022393.7	6.84	7.1e-11	1.32e-07	0.49	0.41	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs9461458	ENSG00000216901.1	AL022393.7	6.84	7.1e-11	1.32e-07	0.49	0.41	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28176188~28176674:+
OV	cis	rs6921919	0.609	rs9468365	ENSG00000216901.1	AL022393.7	6.84	7.1e-11	1.32e-07	0.49	0.41	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs1361385	ENSG00000216901.1	AL022393.7	6.84	7.1e-11	1.32e-07	0.49	0.41	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs1416918	ENSG00000216901.1	AL022393.7	6.84	7.1e-11	1.32e-07	0.49	0.41	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28176188~28176674:+
OV	cis	rs2882667	0.518	rs10041986	ENSG00000253404.1	AC034243.1	6.84	7.12e-11	1.32e-07	0.48	0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139088748	chr5:138744434~138753309:-
OV	cis	rs9918079	0.56	rs10008376	ENSG00000273133.1	RP11-799M12.2	6.84	7.13e-11	1.32e-07	0.48	0.41	Obesity-related traits;	chr4:15622332	chr4:15563698~15564253:-
OV	cis	rs1707322	1	rs1707337	ENSG00000281133.1	AL355480.3	6.84	7.16e-11	1.33e-07	0.52	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46043097	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs1768807	ENSG00000281133.1	AL355480.3	6.84	7.16e-11	1.33e-07	0.52	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044898	chr1:45580892~45580996:-
OV	cis	rs1707322	0.89	rs2297883	ENSG00000281133.1	AL355480.3	6.84	7.16e-11	1.33e-07	0.52	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46045815	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs1707338	ENSG00000281133.1	AL355480.3	6.84	7.16e-11	1.33e-07	0.52	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46046309	chr1:45580892~45580996:-
OV	cis	rs1707322	0.964	rs1707339	ENSG00000281133.1	AL355480.3	6.84	7.16e-11	1.33e-07	0.52	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46047507	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs1768818	ENSG00000281133.1	AL355480.3	6.84	7.16e-11	1.33e-07	0.52	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048614	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs1768817	ENSG00000281133.1	AL355480.3	6.84	7.16e-11	1.33e-07	0.52	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048862	chr1:45580892~45580996:-
OV	cis	rs7044106	0.791	rs4836830	ENSG00000226752.6	PSMD5-AS1	-6.84	7.2e-11	1.33e-07	-0.47	-0.41	Hip circumference adjusted for BMI;	chr9:120721390	chr9:120824828~120854385:+
OV	cis	rs1707322	0.964	rs1768802	ENSG00000281133.1	AL355480.3	6.84	7.21e-11	1.33e-07	0.53	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46082196	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs1588663	ENSG00000281133.1	AL355480.3	6.84	7.21e-11	1.33e-07	0.53	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083153	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs1768801	ENSG00000281133.1	AL355480.3	6.84	7.21e-11	1.33e-07	0.53	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083465	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs1768800	ENSG00000281133.1	AL355480.3	6.84	7.21e-11	1.33e-07	0.53	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083516	chr1:45580892~45580996:-
OV	cis	rs2117029	0.555	rs2279596	ENSG00000258017.1	RP11-386G11.10	-6.84	7.21e-11	1.33e-07	-0.51	-0.41	Intelligence (multi-trait analysis);	chr12:49104968	chr12:49127782~49147869:+
OV	cis	rs1707322	0.627	rs3014213	ENSG00000280836.1	AL355480.1	6.84	7.22e-11	1.34e-07	0.59	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45581219~45581321:-
OV	cis	rs1707322	0.686	rs2152078	ENSG00000280836.1	AL355480.1	6.84	7.22e-11	1.34e-07	0.59	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45581219~45581321:-
OV	cis	rs1707322	0.686	rs2991979	ENSG00000280836.1	AL355480.1	6.84	7.22e-11	1.34e-07	0.59	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45581219~45581321:-
OV	cis	rs2243480	0.901	rs12530490	ENSG00000222364.1	RNU6-96P	6.84	7.24e-11	1.34e-07	0.65	0.41	Diabetic kidney disease;	chr7:66226660	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs7778911	ENSG00000222364.1	RNU6-96P	6.84	7.24e-11	1.34e-07	0.65	0.41	Diabetic kidney disease;	chr7:66229519	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs1979823	ENSG00000222364.1	RNU6-96P	6.84	7.24e-11	1.34e-07	0.65	0.41	Diabetic kidney disease;	chr7:66239626	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs1796219	ENSG00000222364.1	RNU6-96P	6.84	7.24e-11	1.34e-07	0.49	0.41	Aortic root size;	chr7:66645977	chr7:66395191~66395286:+
OV	cis	rs7927771	1	rs12419692	ENSG00000280615.1	Y_RNA	6.84	7.33e-11	1.35e-07	0.51	0.41	Subjective well-being;	chr11:47603162	chr11:47614898~47614994:-
OV	cis	rs9813712	0.597	rs62281648	ENSG00000228252.7	COL6A4P2	-6.84	7.38e-11	1.36e-07	-0.46	-0.41	Response to amphetamines;	chr3:130244794	chr3:130212823~130273806:+
OV	cis	rs2836974	0.623	rs34240248	ENSG00000232608.1	TIMM9P2	6.84	7.41e-11	1.37e-07	0.44	0.41	Cognitive function;	chr21:39313313	chr21:39216624~39217506:+
OV	cis	rs73086581	0.687	rs73082600	ENSG00000229539.1	RP11-119B16.2	6.84	7.44e-11	1.37e-07	0.57	0.41	Response to antidepressants in depression;	chr20:3863718	chr20:3888239~3888868:-
OV	cis	rs2153535	0.505	rs9405395	ENSG00000230939.1	RP11-314C16.1	-6.84	7.45e-11	1.37e-07	-0.47	-0.41	Motion sickness;	chr6:8468389	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9392223	ENSG00000230939.1	RP11-314C16.1	-6.84	7.45e-11	1.37e-07	-0.47	-0.41	Motion sickness;	chr6:8468417	chr6:8784178~8785445:+
OV	cis	rs2564921	0.704	rs56155510	ENSG00000242142.1	SERBP1P3	-6.84	7.48e-11	1.38e-07	-0.47	-0.41	Height;	chr3:53009621	chr3:53064283~53065091:-
OV	cis	rs2836974	0.584	rs34436313	ENSG00000232608.1	TIMM9P2	6.83	7.52e-11	1.39e-07	0.44	0.41	Cognitive function;	chr21:39313320	chr21:39216624~39217506:+
OV	cis	rs2836974	0.666	rs35182074	ENSG00000232608.1	TIMM9P2	6.83	7.52e-11	1.39e-07	0.44	0.41	Cognitive function;	chr21:39313358	chr21:39216624~39217506:+
OV	cis	rs2564921	0.73	rs62255897	ENSG00000242142.1	SERBP1P3	-6.83	7.54e-11	1.39e-07	-0.48	-0.41	Height;	chr3:53029854	chr3:53064283~53065091:-
OV	cis	rs35160687	0.862	rs13024964	ENSG00000273080.1	RP11-301O19.1	6.83	7.56e-11	1.39e-07	0.42	0.41	Night sleep phenotypes;	chr2:86284745	chr2:86195590~86196049:+
OV	cis	rs1707322	1	rs785470	ENSG00000281133.1	AL355480.3	6.83	7.61e-11	1.4e-07	0.52	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46053950	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs785469	ENSG00000281133.1	AL355480.3	6.83	7.61e-11	1.4e-07	0.52	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055419	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs785468	ENSG00000281133.1	AL355480.3	6.83	7.61e-11	1.4e-07	0.52	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055845	chr1:45580892~45580996:-
OV	cis	rs2564921	0.704	rs57916015	ENSG00000242142.1	SERBP1P3	-6.83	7.61e-11	1.4e-07	-0.48	-0.41	Height;	chr3:52971094	chr3:53064283~53065091:-
OV	cis	rs7017914	0.934	rs7830550	ENSG00000223220.1	Y_RNA	6.83	7.64e-11	1.41e-07	0.44	0.41	Bone mineral density;	chr8:70658196	chr8:70780914~70781008:-
OV	cis	rs1185460	0.967	rs11217133	ENSG00000271751.1	RP11-110I1.14	-6.83	7.66e-11	1.41e-07	-0.52	-0.41	Coronary artery disease;	chr11:119057538	chr11:119065263~119065677:-
OV	cis	rs2153535	0.58	rs7767780	ENSG00000230939.1	RP11-314C16.1	-6.83	7.67e-11	1.41e-07	-0.46	-0.41	Motion sickness;	chr6:8453229	chr6:8784178~8785445:+
OV	cis	rs1707322	1	rs12403666	ENSG00000281133.1	AL355480.3	-6.83	7.67e-11	1.41e-07	-0.53	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45965949	chr1:45580892~45580996:-
OV	cis	rs2153535	0.58	rs2327062	ENSG00000230939.1	RP11-314C16.1	-6.83	7.68e-11	1.41e-07	-0.46	-0.41	Motion sickness;	chr6:8453625	chr6:8784178~8785445:+
OV	cis	rs2153535	0.601	rs2327054	ENSG00000230939.1	RP11-314C16.1	-6.83	7.68e-11	1.41e-07	-0.47	-0.41	Motion sickness;	chr6:8442897	chr6:8784178~8785445:+
OV	cis	rs2153535	0.623	rs2327055	ENSG00000230939.1	RP11-314C16.1	-6.83	7.68e-11	1.41e-07	-0.47	-0.41	Motion sickness;	chr6:8442912	chr6:8784178~8785445:+
OV	cis	rs875971	0.545	rs17138156	ENSG00000222364.1	RNU6-96P	-6.83	7.7e-11	1.42e-07	-0.49	-0.41	Aortic root size;	chr7:66249708	chr7:66395191~66395286:+
OV	cis	rs3931020	0.705	rs28482086	ENSG00000272864.1	RP11-17E13.2	-6.83	7.71e-11	1.42e-07	-0.54	-0.41	Resistin levels;	chr1:74760568	chr1:74698769~74699333:-
OV	cis	rs1185460	0.967	rs1784459	ENSG00000271751.1	RP11-110I1.14	-6.83	7.73e-11	1.42e-07	-0.48	-0.41	Coronary artery disease;	chr11:119067677	chr11:119065263~119065677:-
OV	cis	rs1185460	0.967	rs1786684	ENSG00000271751.1	RP11-110I1.14	-6.83	7.73e-11	1.42e-07	-0.48	-0.41	Coronary artery disease;	chr11:119067724	chr11:119065263~119065677:-
OV	cis	rs9813712	0.597	rs11711883	ENSG00000228252.7	COL6A4P2	-6.83	7.74e-11	1.42e-07	-0.46	-0.41	Response to amphetamines;	chr3:130241367	chr3:130212823~130273806:+
OV	cis	rs9813712	0.574	rs62281647	ENSG00000228252.7	COL6A4P2	-6.83	7.74e-11	1.42e-07	-0.46	-0.41	Response to amphetamines;	chr3:130242670	chr3:130212823~130273806:+
OV	cis	rs1707322	1	rs785480	ENSG00000281133.1	AL355480.3	-6.83	7.75e-11	1.42e-07	-0.52	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46026492	chr1:45580892~45580996:-
OV	cis	rs150992	0.821	rs326480	ENSG00000248489.1	CTD-2007H13.3	6.83	7.82e-11	1.44e-07	0.49	0.41	Body mass index;	chr5:98949263	chr5:98929171~98995013:+
OV	cis	rs8005677	1	rs4982712	ENSG00000257285.4	RP11-298I3.1	6.83	7.82e-11	1.44e-07	0.49	0.41	Cognitive ability (multi-trait analysis);	chr14:22934519	chr14:22929609~22955562:+
OV	cis	rs875971	0.502	rs2465121	ENSG00000222364.1	RNU6-96P	6.83	7.85e-11	1.44e-07	0.48	0.41	Aortic root size;	chr7:66156017	chr7:66395191~66395286:+
OV	cis	rs875971	0.862	rs6460307	ENSG00000226824.5	RP4-756H11.3	-6.83	7.88e-11	1.45e-07	-0.43	-0.41	Aortic root size;	chr7:66595884	chr7:66654538~66669855:+
OV	cis	rs1707322	0.721	rs61784800	ENSG00000280836.1	AL355480.1	6.83	7.89e-11	1.45e-07	0.57	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712440	chr1:45581219~45581321:-
OV	cis	rs1707322	0.682	rs28508523	ENSG00000280836.1	AL355480.1	-6.83	7.89e-11	1.45e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723953	chr1:45581219~45581321:-
OV	cis	rs10510102	0.872	rs28586586	ENSG00000276742.1	RP11-500G22.4	6.82	7.96e-11	1.46e-07	0.68	0.41	Breast cancer;	chr10:121950228	chr10:121956782~121957098:+
OV	cis	rs1707322	1	rs10890375	ENSG00000281133.1	AL355480.3	-6.82	7.99e-11	1.46e-07	-0.53	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940909	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs10890377	ENSG00000281133.1	AL355480.3	-6.82	7.99e-11	1.46e-07	-0.53	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940922	chr1:45580892~45580996:-
OV	cis	rs1707322	0.717	rs3014246	ENSG00000280836.1	AL355480.1	6.82	8.01e-11	1.47e-07	0.59	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45581219~45581321:-
OV	cis	rs35160687	0.829	rs13017143	ENSG00000273080.1	RP11-301O19.1	-6.82	8.03e-11	1.47e-07	-0.41	-0.41	Night sleep phenotypes;	chr2:86239426	chr2:86195590~86196049:+
OV	cis	rs1061377	1	rs1982009	ENSG00000249207.1	RP11-360F5.1	-6.82	8.03e-11	1.47e-07	-0.44	-0.41	Uric acid levels;	chr4:39123253	chr4:39112677~39126818:-
OV	cis	rs1061377	0.965	rs1138494	ENSG00000249207.1	RP11-360F5.1	-6.82	8.03e-11	1.47e-07	-0.44	-0.41	Uric acid levels;	chr4:39123315	chr4:39112677~39126818:-
OV	cis	rs1061377	0.965	rs1046655	ENSG00000249207.1	RP11-360F5.1	-6.82	8.03e-11	1.47e-07	-0.44	-0.41	Uric acid levels;	chr4:39126127	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs7694760	ENSG00000249207.1	RP11-360F5.1	-6.82	8.03e-11	1.47e-07	-0.44	-0.41	Uric acid levels;	chr4:39126481	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs34771104	ENSG00000249207.1	RP11-360F5.1	-6.82	8.03e-11	1.47e-07	-0.44	-0.41	Uric acid levels;	chr4:39127432	chr4:39112677~39126818:-
OV	cis	rs1061377	0.965	rs11728058	ENSG00000249207.1	RP11-360F5.1	-6.82	8.03e-11	1.47e-07	-0.44	-0.41	Uric acid levels;	chr4:39128224	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs17508864	ENSG00000249207.1	RP11-360F5.1	-6.82	8.03e-11	1.47e-07	-0.44	-0.41	Uric acid levels;	chr4:39129025	chr4:39112677~39126818:-
OV	cis	rs17711722	0.565	rs73372653	ENSG00000236529.1	RP13-254B10.1	6.82	8.07e-11	1.48e-07	0.45	0.41	Calcium levels;	chr7:65977808	chr7:65840212~65840596:+
OV	cis	rs4356975	0.541	rs6600892	ENSG00000248763.2	RP13-644M16.5	-6.82	8.08e-11	1.48e-07	-0.67	-0.41	Obesity-related traits;	chr4:69107521	chr4:69066395~69069888:+
OV	cis	rs853679	0.517	rs9295761	ENSG00000220721.1	OR1F12	6.82	8.12e-11	1.49e-07	0.5	0.41	Depression;	chr6:28180209	chr6:28073316~28074233:+
OV	cis	rs2153535	0.58	rs2327053	ENSG00000230939.1	RP11-314C16.1	-6.82	8.16e-11	1.49e-07	-0.46	-0.41	Motion sickness;	chr6:8442894	chr6:8784178~8785445:+
OV	cis	rs2564921	0.654	rs73087044	ENSG00000242142.1	SERBP1P3	-6.82	8.16e-11	1.49e-07	-0.48	-0.41	Height;	chr3:52975027	chr3:53064283~53065091:-
OV	cis	rs11673344	0.566	rs2385181	ENSG00000226686.6	LINC01535	-6.82	8.22e-11	1.5e-07	-0.49	-0.41	Obesity-related traits;	chr19:37395428	chr19:37251912~37265535:+
OV	cis	rs1707322	0.827	rs10890347	ENSG00000281133.1	AL355480.3	6.82	8.26e-11	1.51e-07	0.51	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45580892~45580996:-
OV	cis	rs1707322	0.717	rs11211161	ENSG00000280836.1	AL355480.1	-6.82	8.33e-11	1.52e-07	-0.58	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr1:45581219~45581321:-
OV	cis	rs1707322	0.752	rs61784793	ENSG00000280836.1	AL355480.1	-6.82	8.33e-11	1.52e-07	-0.58	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr1:45581219~45581321:-
OV	cis	rs2564921	0.666	rs11130335	ENSG00000242142.1	SERBP1P3	-6.81	8.39e-11	1.53e-07	-0.47	-0.41	Height;	chr3:52989619	chr3:53064283~53065091:-
OV	cis	rs1707322	1	rs4298677	ENSG00000281133.1	AL355480.3	-6.81	8.43e-11	1.54e-07	-0.53	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45840947	chr1:45580892~45580996:-
OV	cis	rs9813712	0.574	rs35856399	ENSG00000228252.7	COL6A4P2	-6.81	8.5e-11	1.55e-07	-0.46	-0.41	Response to amphetamines;	chr3:130241961	chr3:130212823~130273806:+
OV	cis	rs2243480	0.908	rs2460431	ENSG00000222364.1	RNU6-96P	6.81	8.56e-11	1.56e-07	0.65	0.41	Diabetic kidney disease;	chr7:66157859	chr7:66395191~66395286:+
OV	cis	rs2243480	0.711	rs2460426	ENSG00000222364.1	RNU6-96P	6.81	8.56e-11	1.56e-07	0.65	0.41	Diabetic kidney disease;	chr7:66158142	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs4718309	ENSG00000222364.1	RNU6-96P	6.81	8.56e-11	1.56e-07	0.65	0.41	Diabetic kidney disease;	chr7:66162777	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs6460274	ENSG00000222364.1	RNU6-96P	6.81	8.56e-11	1.56e-07	0.65	0.41	Diabetic kidney disease;	chr7:66163497	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs7787230	ENSG00000222364.1	RNU6-96P	6.81	8.56e-11	1.56e-07	0.65	0.41	Diabetic kidney disease;	chr7:66164112	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs316326	ENSG00000222364.1	RNU6-96P	-6.81	8.56e-11	1.56e-07	-0.65	-0.41	Diabetic kidney disease;	chr7:66144466	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs316325	ENSG00000222364.1	RNU6-96P	-6.81	8.56e-11	1.56e-07	-0.65	-0.41	Diabetic kidney disease;	chr7:66144531	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs316321	ENSG00000222364.1	RNU6-96P	-6.81	8.56e-11	1.56e-07	-0.65	-0.41	Diabetic kidney disease;	chr7:66146626	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs316318	ENSG00000222364.1	RNU6-96P	-6.81	8.56e-11	1.56e-07	-0.65	-0.41	Diabetic kidney disease;	chr7:66147917	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs316317	ENSG00000222364.1	RNU6-96P	-6.81	8.56e-11	1.56e-07	-0.65	-0.41	Diabetic kidney disease;	chr7:66148650	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs316304	ENSG00000222364.1	RNU6-96P	-6.81	8.56e-11	1.56e-07	-0.65	-0.41	Diabetic kidney disease;	chr7:66151907	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs2465120	ENSG00000222364.1	RNU6-96P	-6.81	8.56e-11	1.56e-07	-0.65	-0.41	Diabetic kidney disease;	chr7:66155987	chr7:66395191~66395286:+
OV	cis	rs6921919	0.583	rs7759191	ENSG00000216901.1	AL022393.7	6.81	8.57e-11	1.56e-07	0.49	0.41	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28176188~28176674:+
OV	cis	rs6435862	0.636	rs717548	ENSG00000229267.2	AC072062.1	6.81	8.68e-11	1.58e-07	0.47	0.41	Neuroblastoma (high-risk);	chr2:214812181	chr2:214810229~214963274:+
OV	cis	rs875971	0.545	rs67775320	ENSG00000222364.1	RNU6-96P	-6.81	8.69e-11	1.58e-07	-0.47	-0.41	Aortic root size;	chr7:66193792	chr7:66395191~66395286:+
OV	cis	rs1707322	0.662	rs11211160	ENSG00000280836.1	AL355480.1	-6.81	8.74e-11	1.59e-07	-0.56	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr1:45581219~45581321:-
OV	cis	rs9918079	0.56	rs10008975	ENSG00000273133.1	RP11-799M12.2	-6.81	8.8e-11	1.6e-07	-0.47	-0.41	Obesity-related traits;	chr4:15622948	chr4:15563698~15564253:-
OV	cis	rs1707322	0.721	rs7520123	ENSG00000280836.1	AL355480.1	-6.81	8.82e-11	1.6e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769547	chr1:45581219~45581321:-
OV	cis	rs1061377	1	rs1560397	ENSG00000249207.1	RP11-360F5.1	-6.8	8.91e-11	1.62e-07	-0.45	-0.41	Uric acid levels;	chr4:39112265	chr4:39112677~39126818:-
OV	cis	rs8105895	0.867	rs62111037	ENSG00000269742.1	BNIP3P29	6.8	8.98e-11	1.63e-07	0.68	0.41	Body mass index (change over time);	chr19:22103761	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs7254050	ENSG00000269742.1	BNIP3P29	6.8	8.98e-11	1.63e-07	0.68	0.41	Body mass index (change over time);	chr19:22103939	chr19:22065828~22066398:-
OV	cis	rs8040855	0.559	rs6496801	ENSG00000229212.6	RP11-561C5.4	-6.8	8.98e-11	1.63e-07	-0.53	-0.41	Bulimia nervosa;	chr15:85185168	chr15:85205440~85234795:-
OV	cis	rs67340775	0.541	rs169287	ENSG00000220721.1	OR1F12	6.8	9e-11	1.63e-07	0.52	0.41	Lung cancer in ever smokers;	chr6:27886982	chr6:28073316~28074233:+
OV	cis	rs67340775	0.541	rs200966	ENSG00000220721.1	OR1F12	6.8	9e-11	1.63e-07	0.52	0.41	Lung cancer in ever smokers;	chr6:27894374	chr6:28073316~28074233:+
OV	cis	rs2243480	1	rs6964245	ENSG00000222364.1	RNU6-96P	6.8	9e-11	1.63e-07	0.64	0.41	Diabetic kidney disease;	chr7:66253730	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs10807701	ENSG00000222364.1	RNU6-96P	6.8	9e-11	1.63e-07	0.64	0.41	Diabetic kidney disease;	chr7:66259699	chr7:66395191~66395286:+
OV	cis	rs2153535	0.58	rs9406169	ENSG00000230939.1	RP11-314C16.1	-6.8	9.01e-11	1.64e-07	-0.45	-0.41	Motion sickness;	chr6:8509237	chr6:8784178~8785445:+
OV	cis	rs1061377	0.965	rs7677729	ENSG00000249207.1	RP11-360F5.1	-6.8	9.04e-11	1.64e-07	-0.44	-0.41	Uric acid levels;	chr4:39120370	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs3796511	ENSG00000249207.1	RP11-360F5.1	-6.8	9.04e-11	1.64e-07	-0.44	-0.41	Uric acid levels;	chr4:39120586	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs3733274	ENSG00000249207.1	RP11-360F5.1	-6.8	9.04e-11	1.64e-07	-0.44	-0.41	Uric acid levels;	chr4:39120957	chr4:39112677~39126818:-
OV	cis	rs1075265	0.633	rs4671190	ENSG00000233266.1	HMGB1P31	6.8	9.05e-11	1.64e-07	0.49	0.41	Chronotype;Morning vs. evening chronotype;	chr2:54085604	chr2:54051334~54051760:+
OV	cis	rs7044106	0.762	rs10760107	ENSG00000226752.6	PSMD5-AS1	-6.8	9.07e-11	1.65e-07	-0.48	-0.41	Hip circumference adjusted for BMI;	chr9:120621352	chr9:120824828~120854385:+
OV	cis	rs1707322	1	rs7517560	ENSG00000281133.1	AL355480.3	-6.8	9.11e-11	1.65e-07	-0.53	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45960271	chr1:45580892~45580996:-
OV	cis	rs875971	0.545	rs1267814	ENSG00000222364.1	RNU6-96P	6.8	9.18e-11	1.66e-07	0.48	0.41	Aortic root size;	chr7:66579422	chr7:66395191~66395286:+
OV	cis	rs2243480	0.711	rs2420172	ENSG00000222364.1	RNU6-96P	6.8	9.21e-11	1.67e-07	0.65	0.41	Diabetic kidney disease;	chr7:66170354	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs2420171	ENSG00000222364.1	RNU6-96P	6.8	9.21e-11	1.67e-07	0.65	0.41	Diabetic kidney disease;	chr7:66172773	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs6974723	ENSG00000222364.1	RNU6-96P	6.8	9.21e-11	1.67e-07	0.65	0.41	Diabetic kidney disease;	chr7:66172952	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs9769882	ENSG00000222364.1	RNU6-96P	6.8	9.21e-11	1.67e-07	0.65	0.41	Diabetic kidney disease;	chr7:66177938	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs6966322	ENSG00000222364.1	RNU6-96P	6.8	9.21e-11	1.67e-07	0.65	0.41	Diabetic kidney disease;	chr7:66181767	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs4145008	ENSG00000222364.1	RNU6-96P	6.8	9.21e-11	1.67e-07	0.65	0.41	Diabetic kidney disease;	chr7:66182524	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs4718315	ENSG00000222364.1	RNU6-96P	6.8	9.21e-11	1.67e-07	0.65	0.41	Diabetic kidney disease;	chr7:66183554	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs4718316	ENSG00000222364.1	RNU6-96P	6.8	9.21e-11	1.67e-07	0.65	0.41	Diabetic kidney disease;	chr7:66183744	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs1873494	ENSG00000222364.1	RNU6-96P	6.8	9.21e-11	1.67e-07	0.65	0.41	Diabetic kidney disease;	chr7:66184912	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs6959002	ENSG00000222364.1	RNU6-96P	6.8	9.21e-11	1.67e-07	0.65	0.41	Diabetic kidney disease;	chr7:66185509	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs1547529	ENSG00000222364.1	RNU6-96P	-6.8	9.24e-11	1.67e-07	-0.48	-0.41	Aortic root size;	chr7:66258859	chr7:66395191~66395286:+
OV	cis	rs4591358	0.773	rs17781737	ENSG00000223466.1	AC064834.2	-6.8	9.28e-11	1.68e-07	-0.56	-0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195508251	chr2:195533035~195538681:+
OV	cis	rs9918079	0.542	rs6414765	ENSG00000273133.1	RP11-799M12.2	-6.8	9.29e-11	1.68e-07	-0.47	-0.41	Obesity-related traits;	chr4:15624870	chr4:15563698~15564253:-
OV	cis	rs875971	0.545	rs316305	ENSG00000222364.1	RNU6-96P	6.8	9.36e-11	1.69e-07	0.48	0.41	Aortic root size;	chr7:66152984	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs316306	ENSG00000222364.1	RNU6-96P	6.8	9.36e-11	1.69e-07	0.48	0.41	Aortic root size;	chr7:66153687	chr7:66395191~66395286:+
OV	cis	rs8105895	0.935	rs62111039	ENSG00000269742.1	BNIP3P29	6.8	9.37e-11	1.7e-07	0.68	0.41	Body mass index (change over time);	chr19:22104534	chr19:22065828~22066398:-
OV	cis	rs2153535	0.601	rs4140584	ENSG00000230939.1	RP11-314C16.1	6.79	9.5e-11	1.72e-07	0.48	0.41	Motion sickness;	chr6:8540381	chr6:8784178~8785445:+
OV	cis	rs1707322	0.963	rs1768815	ENSG00000281133.1	AL355480.3	6.79	9.57e-11	1.73e-07	0.53	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062931	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs2458400	ENSG00000281133.1	AL355480.3	6.79	9.57e-11	1.73e-07	0.53	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46065126	chr1:45580892~45580996:-
OV	cis	rs1707322	0.896	rs785512	ENSG00000281133.1	AL355480.3	6.79	9.57e-11	1.73e-07	0.53	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46068871	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs9429186	ENSG00000281133.1	AL355480.3	6.79	9.57e-11	1.73e-07	0.53	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074015	chr1:45580892~45580996:-
OV	cis	rs1707322	1	rs785506	ENSG00000281133.1	AL355480.3	6.79	9.57e-11	1.73e-07	0.53	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074980	chr1:45580892~45580996:-
OV	cis	rs2836974	0.644	rs2836986	ENSG00000232608.1	TIMM9P2	6.79	9.59e-11	1.73e-07	0.45	0.41	Cognitive function;	chr21:39330210	chr21:39216624~39217506:+
OV	cis	rs1061377	1	rs7685082	ENSG00000249207.1	RP11-360F5.1	-6.79	9.6e-11	1.73e-07	-0.44	-0.41	Uric acid levels;	chr4:39116472	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs7664078	ENSG00000249207.1	RP11-360F5.1	-6.79	9.6e-11	1.73e-07	-0.44	-0.41	Uric acid levels;	chr4:39116583	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs9998481	ENSG00000249207.1	RP11-360F5.1	-6.79	9.6e-11	1.73e-07	-0.44	-0.41	Uric acid levels;	chr4:39117215	chr4:39112677~39126818:-
OV	cis	rs8005677	1	rs2295685	ENSG00000257285.4	RP11-298I3.1	6.79	9.65e-11	1.74e-07	0.48	0.41	Cognitive ability (multi-trait analysis);	chr14:22928944	chr14:22929609~22955562:+
OV	cis	rs8005677	1	rs7145494	ENSG00000257285.4	RP11-298I3.1	6.79	9.65e-11	1.74e-07	0.48	0.41	Cognitive ability (multi-trait analysis);	chr14:22930581	chr14:22929609~22955562:+
OV	cis	rs1185460	0.967	rs11217137	ENSG00000271751.1	RP11-110I1.14	-6.79	9.65e-11	1.74e-07	-0.52	-0.41	Coronary artery disease;	chr11:119060319	chr11:119065263~119065677:-
OV	cis	rs3091242	0.933	rs10903130	ENSG00000261349.1	RP3-465N24.5	-6.79	9.66e-11	1.74e-07	-0.43	-0.41	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25266102~25267136:-
OV	cis	rs3091242	0.933	rs11249251	ENSG00000261349.1	RP3-465N24.5	-6.79	9.66e-11	1.74e-07	-0.43	-0.41	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25266102~25267136:-
OV	cis	rs2882667	0.522	rs7731574	ENSG00000253404.1	AC034243.1	-6.79	9.76e-11	1.76e-07	-0.47	-0.41	Age-related hearing impairment (SNP x SNP interaction);	chr5:139118503	chr5:138744434~138753309:-
OV	cis	rs4423214	0.592	rs1790349	ENSG00000254682.1	RP11-660L16.2	-6.79	9.78e-11	1.76e-07	-0.57	-0.41	Vitamin D levels;	chr11:71431304	chr11:71448674~71452157:+
OV	cis	rs2243480	1	rs316322	ENSG00000222364.1	RNU6-96P	-6.79	9.8e-11	1.77e-07	-0.66	-0.41	Diabetic kidney disease;	chr7:66146246	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs1499613	ENSG00000222364.1	RNU6-96P	6.79	9.86e-11	1.78e-07	0.64	0.41	Diabetic kidney disease;	chr7:66265873	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs1553174	ENSG00000222364.1	RNU6-96P	6.79	9.86e-11	1.78e-07	0.64	0.41	Diabetic kidney disease;	chr7:66266207	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs10950032	ENSG00000222364.1	RNU6-96P	6.79	9.86e-11	1.78e-07	0.64	0.41	Diabetic kidney disease;	chr7:66273604	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs6958420	ENSG00000222364.1	RNU6-96P	6.79	9.86e-11	1.78e-07	0.64	0.41	Diabetic kidney disease;	chr7:66286184	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs1392104	ENSG00000222364.1	RNU6-96P	6.79	9.86e-11	1.78e-07	0.64	0.41	Diabetic kidney disease;	chr7:66294120	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs4718333	ENSG00000222364.1	RNU6-96P	6.79	9.86e-11	1.78e-07	0.64	0.41	Diabetic kidney disease;	chr7:66307771	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs7792391	ENSG00000222364.1	RNU6-96P	6.79	9.86e-11	1.78e-07	0.64	0.41	Diabetic kidney disease;	chr7:66308442	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs10247526	ENSG00000222364.1	RNU6-96P	6.79	9.86e-11	1.78e-07	0.64	0.41	Diabetic kidney disease;	chr7:66315709	chr7:66395191~66395286:+
OV	cis	rs2243480	0.908	rs1532573	ENSG00000222364.1	RNU6-96P	6.79	9.86e-11	1.78e-07	0.64	0.41	Diabetic kidney disease;	chr7:66333815	chr7:66395191~66395286:+
OV	cis	rs2564921	0.73	rs60579898	ENSG00000242142.1	SERBP1P3	-6.79	9.86e-11	1.78e-07	-0.45	-0.41	Height;	chr3:53069965	chr3:53064283~53065091:-
OV	cis	rs11673344	0.566	rs1545755	ENSG00000226686.6	LINC01535	6.79	9.9e-11	1.78e-07	0.48	0.41	Obesity-related traits;	chr19:37490607	chr19:37251912~37265535:+
OV	cis	rs875971	0.502	rs1796227	ENSG00000222364.1	RNU6-96P	6.79	9.91e-11	1.78e-07	0.48	0.41	Aortic root size;	chr7:66622032	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs73142245	ENSG00000222364.1	RNU6-96P	-6.79	9.92e-11	1.79e-07	-0.48	-0.41	Aortic root size;	chr7:66226662	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs2460427	ENSG00000222364.1	RNU6-96P	6.79	9.92e-11	1.79e-07	0.47	0.41	Aortic root size;	chr7:66154218	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs10950025	ENSG00000222364.1	RNU6-96P	-6.79	9.92e-11	1.79e-07	-0.47	-0.41	Aortic root size;	chr7:66158946	chr7:66395191~66395286:+
OV	cis	rs875971	0.52	rs12666485	ENSG00000222364.1	RNU6-96P	-6.79	9.92e-11	1.79e-07	-0.47	-0.41	Aortic root size;	chr7:66160135	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs67688847	ENSG00000222364.1	RNU6-96P	-6.79	9.92e-11	1.79e-07	-0.47	-0.41	Aortic root size;	chr7:66161064	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs7787063	ENSG00000222364.1	RNU6-96P	-6.79	9.92e-11	1.79e-07	-0.47	-0.41	Aortic root size;	chr7:66164012	chr7:66395191~66395286:+
OV	cis	rs853679	0.517	rs16893666	ENSG00000219392.1	RP1-265C24.5	6.79	9.93e-11	1.79e-07	0.51	0.41	Depression;	chr6:28086929	chr6:28115628~28116551:+
OV	cis	rs1707322	0.752	rs11211146	ENSG00000280836.1	AL355480.1	-6.79	9.96e-11	1.79e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr1:45581219~45581321:-
OV	cis	rs1707322	0.752	rs11211147	ENSG00000280836.1	AL355480.1	-6.79	9.96e-11	1.79e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr1:45581219~45581321:-
OV	cis	rs4591358	0.773	rs17781713	ENSG00000223466.1	AC064834.2	-6.78	9.98e-11	1.8e-07	-0.57	-0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195506827	chr2:195533035~195538681:+
OV	cis	rs1061377	1	rs56119980	ENSG00000249207.1	RP11-360F5.1	-6.78	1e-10	1.8e-07	-0.44	-0.41	Uric acid levels;	chr4:39139390	chr4:39112677~39126818:-
OV	cis	rs934734	0.571	rs7565437	ENSG00000234255.7	AC012370.3	-6.78	1.01e-10	1.82e-07	-0.46	-0.41	Rheumatoid arthritis;	chr2:65419832	chr2:65439888~65456571:-
OV	cis	rs8062405	0.824	rs62034319	ENSG00000259982.1	CDC37P1	6.78	1.02e-10	1.83e-07	0.49	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28700294~28701540:-
OV	cis	rs853679	0.517	rs4711164	ENSG00000220721.1	OR1F12	6.78	1.02e-10	1.83e-07	0.49	0.41	Depression;	chr6:28147378	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs4711165	ENSG00000220721.1	OR1F12	6.78	1.02e-10	1.83e-07	0.49	0.41	Depression;	chr6:28147406	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs4713148	ENSG00000220721.1	OR1F12	6.78	1.02e-10	1.83e-07	0.49	0.41	Depression;	chr6:28148143	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9348794	ENSG00000220721.1	OR1F12	6.78	1.02e-10	1.83e-07	0.49	0.41	Depression;	chr6:28149979	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9468297	ENSG00000220721.1	OR1F12	6.78	1.02e-10	1.83e-07	0.49	0.41	Depression;	chr6:28151096	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9295758	ENSG00000220721.1	OR1F12	6.78	1.02e-10	1.83e-07	0.49	0.41	Depression;	chr6:28152885	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs17774663	ENSG00000220721.1	OR1F12	6.78	1.02e-10	1.83e-07	0.49	0.41	Depression;	chr6:28153120	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9468298	ENSG00000220721.1	OR1F12	6.78	1.02e-10	1.83e-07	0.49	0.41	Depression;	chr6:28154567	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9295759	ENSG00000220721.1	OR1F12	6.78	1.02e-10	1.83e-07	0.49	0.41	Depression;	chr6:28156691	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs9348796	ENSG00000220721.1	OR1F12	6.78	1.02e-10	1.83e-07	0.49	0.41	Depression;	chr6:28158424	chr6:28073316~28074233:+
OV	cis	rs853679	0.517	rs11552219	ENSG00000220721.1	OR1F12	6.78	1.02e-10	1.83e-07	0.49	0.41	Depression;	chr6:28159056	chr6:28073316~28074233:+
OV	cis	rs3931020	0.745	rs1980851	ENSG00000272864.1	RP11-17E13.2	-6.78	1.02e-10	1.84e-07	-0.54	-0.41	Resistin levels;	chr1:74803287	chr1:74698769~74699333:-
OV	cis	rs2564921	0.615	rs56129941	ENSG00000242142.1	SERBP1P3	-6.78	1.03e-10	1.84e-07	-0.47	-0.41	Height;	chr3:53007328	chr3:53064283~53065091:-
OV	cis	rs2836974	0.533	rs418298	ENSG00000232608.1	TIMM9P2	-6.78	1.04e-10	1.86e-07	-0.43	-0.41	Cognitive function;	chr21:39164728	chr21:39216624~39217506:+
OV	cis	rs2153535	0.563	rs1737584	ENSG00000230939.1	RP11-314C16.1	-6.78	1.04e-10	1.86e-07	-0.47	-0.41	Motion sickness;	chr6:8536509	chr6:8784178~8785445:+
OV	cis	rs2153535	0.526	rs9406179	ENSG00000230939.1	RP11-314C16.1	-6.78	1.04e-10	1.86e-07	-0.47	-0.41	Motion sickness;	chr6:8537991	chr6:8784178~8785445:+
OV	cis	rs1707322	0.752	rs4660880	ENSG00000280836.1	AL355480.1	-6.78	1.04e-10	1.86e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr1:45581219~45581321:-
OV	cis	rs11235843	0.929	rs68128239	ENSG00000255928.1	RP11-456I15.2	6.78	1.04e-10	1.86e-07	0.68	0.41	Hand grip strength;	chr11:73709547	chr11:73722349~73722694:+
OV	cis	rs11235843	0.929	rs67167213	ENSG00000255928.1	RP11-456I15.2	6.78	1.04e-10	1.86e-07	0.68	0.41	Hand grip strength;	chr11:73711163	chr11:73722349~73722694:+
OV	cis	rs1707322	0.686	rs11211179	ENSG00000280836.1	AL355480.1	-6.78	1.05e-10	1.89e-07	-0.56	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762410	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs10157795	ENSG00000280836.1	AL355480.1	-6.78	1.05e-10	1.89e-07	-0.56	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45762520	chr1:45581219~45581321:-
OV	cis	rs2153535	0.563	rs1737585	ENSG00000230939.1	RP11-314C16.1	6.77	1.06e-10	1.9e-07	0.48	0.41	Motion sickness;	chr6:8536361	chr6:8784178~8785445:+
OV	cis	rs1707322	0.716	rs6694889	ENSG00000280836.1	AL355480.1	-6.77	1.07e-10	1.91e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr1:45581219~45581321:-
OV	cis	rs1707322	0.682	rs12041197	ENSG00000280836.1	AL355480.1	-6.77	1.07e-10	1.91e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr1:45581219~45581321:-
OV	cis	rs1707322	0.717	rs12023439	ENSG00000280836.1	AL355480.1	-6.77	1.07e-10	1.91e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr1:45581219~45581321:-
OV	cis	rs2243480	1	rs1499614	ENSG00000222364.1	RNU6-96P	-6.77	1.07e-10	1.91e-07	-0.63	-0.41	Diabetic kidney disease;	chr7:66265811	chr7:66395191~66395286:+
OV	cis	rs8062405	0.823	rs7202948	ENSG00000259982.1	CDC37P1	6.77	1.07e-10	1.91e-07	0.48	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28700294~28701540:-
OV	cis	rs2153535	0.58	rs1577468	ENSG00000230939.1	RP11-314C16.1	-6.77	1.07e-10	1.92e-07	-0.47	-0.41	Motion sickness;	chr6:8444033	chr6:8784178~8785445:+
OV	cis	rs9918079	0.56	rs4698409	ENSG00000273133.1	RP11-799M12.2	-6.77	1.07e-10	1.92e-07	-0.47	-0.41	Obesity-related traits;	chr4:15658143	chr4:15563698~15564253:-
OV	cis	rs7615952	0.932	rs13321217	ENSG00000171084.14	FAM86JP	6.77	1.07e-10	1.92e-07	0.66	0.41	Blood pressure (smoking interaction);	chr3:125912928	chr3:125916620~125930024:+
OV	cis	rs12908161	0.959	rs2175567	ENSG00000259295.5	CSPG4P12	6.77	1.08e-10	1.93e-07	0.58	0.41	Schizophrenia;	chr15:84657715	chr15:85191438~85213905:+
OV	cis	rs2836974	0.644	rs11088472	ENSG00000232608.1	TIMM9P2	6.77	1.08e-10	1.93e-07	0.45	0.41	Cognitive function;	chr21:39327450	chr21:39216624~39217506:+
OV	cis	rs1707322	0.752	rs4586014	ENSG00000280836.1	AL355480.1	-6.77	1.09e-10	1.96e-07	-0.58	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr1:45581219~45581321:-
OV	cis	rs1707322	0.648	rs4439382	ENSG00000280836.1	AL355480.1	-6.77	1.09e-10	1.96e-07	-0.58	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr1:45581219~45581321:-
OV	cis	rs6991838	0.765	rs4424306	ENSG00000272010.1	CTD-3025N20.3	6.77	1.09e-10	1.96e-07	0.51	0.41	Intelligence (multi-trait analysis);	chr8:65618674	chr8:65591850~65592472:-
OV	cis	rs2836950	0.805	rs2836961	ENSG00000232608.1	TIMM9P2	6.77	1.1e-10	1.97e-07	0.49	0.41	Menarche (age at onset);	chr21:39255094	chr21:39216624~39217506:+
OV	cis	rs934734	0.532	rs55792977	ENSG00000234255.7	AC012370.3	-6.77	1.1e-10	1.97e-07	-0.44	-0.41	Rheumatoid arthritis;	chr2:65423730	chr2:65439888~65456571:-
OV	cis	rs10510102	0.808	rs11200296	ENSG00000276742.1	RP11-500G22.4	6.77	1.11e-10	1.98e-07	0.69	0.41	Breast cancer;	chr10:121971956	chr10:121956782~121957098:+
OV	cis	rs7044106	0.791	rs10984997	ENSG00000226752.6	PSMD5-AS1	-6.77	1.11e-10	1.98e-07	-0.47	-0.41	Hip circumference adjusted for BMI;	chr9:120718928	chr9:120824828~120854385:+
OV	cis	rs35160687	0.64	rs13015186	ENSG00000273080.1	RP11-301O19.1	6.77	1.11e-10	1.98e-07	0.42	0.41	Night sleep phenotypes;	chr2:86258455	chr2:86195590~86196049:+
OV	cis	rs2153535	0.58	rs9378551	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8463511	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9378552	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8463515	chr6:8784178~8785445:+
OV	cis	rs2153535	0.562	rs9379211	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8463694	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1319169	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8464223	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs965706	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8464475	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1335636	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8464814	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs986060	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8465195	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9393021	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8465890	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9406161	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8465911	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9405390	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8465976	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9405391	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8466315	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9406163	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8466409	chr6:8784178~8785445:+
OV	cis	rs2153535	0.504	rs9405393	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8467199	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs2184584	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8468174	chr6:8784178~8785445:+
OV	cis	rs2153535	0.541	rs7774752	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8468745	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9505450	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8469669	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9406164	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8469815	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs7341201	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8470037	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs7341206	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8470256	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs7341382	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8470316	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs7341383	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8470401	chr6:8784178~8785445:+
OV	cis	rs2153535	0.504	rs9328472	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8470615	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1414345	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8471304	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1414348	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8471707	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1414349	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8472057	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1414350	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8472098	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9392224	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8472381	chr6:8784178~8785445:+
OV	cis	rs2153535	0.542	rs9378553	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8472399	chr6:8784178~8785445:+
OV	cis	rs2153535	0.601	rs1855768	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8472736	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1932281	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8473532	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs6900007	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8473802	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs2184585	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8473935	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs2184586	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8473949	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs6902001	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8476822	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs4960423	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8476977	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1932282	ENSG00000230939.1	RP11-314C16.1	-6.77	1.11e-10	1.98e-07	-0.46	-0.41	Motion sickness;	chr6:8477097	chr6:8784178~8785445:+
OV	cis	rs7246967	0.866	rs12981220	ENSG00000269509.1	BNIP3P34	-6.77	1.12e-10	1.99e-07	-0.57	-0.41	Bronchopulmonary dysplasia;	chr19:22838598	chr19:22773853~22774424:+
OV	cis	rs875971	0.545	rs316324	ENSG00000222364.1	RNU6-96P	6.76	1.12e-10	1.99e-07	0.47	0.41	Aortic root size;	chr7:66145627	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs316323	ENSG00000222364.1	RNU6-96P	6.76	1.12e-10	1.99e-07	0.47	0.41	Aortic root size;	chr7:66146002	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs316316	ENSG00000222364.1	RNU6-96P	6.76	1.12e-10	1.99e-07	0.47	0.41	Aortic root size;	chr7:66149270	chr7:66395191~66395286:+
OV	cis	rs1707322	0.655	rs3014240	ENSG00000280836.1	AL355480.1	6.76	1.14e-10	2.01e-07	0.59	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr1:45581219~45581321:-
OV	cis	rs1707322	0.686	rs3014235	ENSG00000280836.1	AL355480.1	6.76	1.14e-10	2.01e-07	0.59	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45581219~45581321:-
OV	cis	rs1707322	0.656	rs9429172	ENSG00000280836.1	AL355480.1	6.76	1.14e-10	2.01e-07	0.59	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr1:45581219~45581321:-
OV	cis	rs1707322	0.717	rs1135850	ENSG00000280836.1	AL355480.1	-6.76	1.14e-10	2.01e-07	-0.59	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45581219~45581321:-
OV	cis	rs3931020	0.53	rs6668736	ENSG00000272864.1	RP11-17E13.2	-6.76	1.14e-10	2.02e-07	-0.52	-0.41	Resistin levels;	chr1:74768866	chr1:74698769~74699333:-
OV	cis	rs875971	0.545	rs2420456	ENSG00000222364.1	RNU6-96P	-6.76	1.14e-10	2.02e-07	-0.48	-0.41	Aortic root size;	chr7:66280619	chr7:66395191~66395286:+
OV	cis	rs2836974	0.627	rs9981301	ENSG00000232608.1	TIMM9P2	6.76	1.14e-10	2.02e-07	0.44	0.41	Cognitive function;	chr21:39314152	chr21:39216624~39217506:+
OV	cis	rs2836974	0.666	rs4624474	ENSG00000232608.1	TIMM9P2	6.76	1.14e-10	2.02e-07	0.44	0.41	Cognitive function;	chr21:39314401	chr21:39216624~39217506:+
OV	cis	rs934734	0.509	rs12185577	ENSG00000234255.7	AC012370.3	-6.76	1.14e-10	2.02e-07	-0.46	-0.41	Rheumatoid arthritis;	chr2:65432354	chr2:65439888~65456571:-
OV	cis	rs2564921	0.704	rs35671032	ENSG00000242142.1	SERBP1P3	-6.76	1.15e-10	2.04e-07	-0.47	-0.41	Height;	chr3:52972039	chr3:53064283~53065091:-
OV	cis	rs1707322	0.717	rs3014245	ENSG00000280836.1	AL355480.1	6.76	1.15e-10	2.04e-07	0.59	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45621241	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs11211200	ENSG00000281133.1	AL355480.3	-6.76	1.15e-10	2.04e-07	-0.51	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr1:45580892~45580996:-
OV	cis	rs10510102	0.748	rs11200297	ENSG00000276742.1	RP11-500G22.4	6.76	1.15e-10	2.04e-07	0.67	0.41	Breast cancer;	chr10:121972916	chr10:121956782~121957098:+
OV	cis	rs293748	0.66	rs61748200	ENSG00000250155.1	CTD-2353F22.1	-6.76	1.16e-10	2.05e-07	-0.62	-0.41	Obesity-related traits;	chr5:37036390	chr5:36666214~36725195:-
OV	cis	rs875971	0.558	rs4433015	ENSG00000236529.1	RP13-254B10.1	-6.76	1.16e-10	2.06e-07	-0.42	-0.41	Aortic root size;	chr7:66174736	chr7:65840212~65840596:+
OV	cis	rs73086581	0.947	rs11906612	ENSG00000229539.1	RP11-119B16.2	6.76	1.17e-10	2.06e-07	0.53	0.41	Response to antidepressants in depression;	chr20:3922987	chr20:3888239~3888868:-
OV	cis	rs6921919	0.583	rs4254981	ENSG00000216901.1	AL022393.7	6.76	1.17e-10	2.06e-07	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs6928771	ENSG00000216901.1	AL022393.7	6.76	1.17e-10	2.06e-07	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs6928773	ENSG00000216901.1	AL022393.7	6.76	1.17e-10	2.06e-07	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28176188~28176674:+
OV	cis	rs6921919	0.525	rs6929825	ENSG00000216901.1	AL022393.7	6.76	1.17e-10	2.06e-07	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs35599905	ENSG00000216901.1	AL022393.7	6.76	1.17e-10	2.06e-07	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs1124131	ENSG00000216901.1	AL022393.7	6.76	1.17e-10	2.06e-07	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs6899389	ENSG00000216901.1	AL022393.7	6.76	1.17e-10	2.06e-07	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs6922374	ENSG00000216901.1	AL022393.7	6.76	1.17e-10	2.06e-07	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs6899603	ENSG00000216901.1	AL022393.7	6.76	1.17e-10	2.06e-07	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs6922429	ENSG00000216901.1	AL022393.7	6.76	1.17e-10	2.06e-07	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28176188~28176674:+
OV	cis	rs2153535	0.58	rs9505455	ENSG00000230939.1	RP11-314C16.1	-6.76	1.17e-10	2.07e-07	-0.46	-0.41	Motion sickness;	chr6:8478389	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9379216	ENSG00000230939.1	RP11-314C16.1	-6.76	1.17e-10	2.07e-07	-0.46	-0.41	Motion sickness;	chr6:8481002	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs7450817	ENSG00000230939.1	RP11-314C16.1	-6.76	1.17e-10	2.07e-07	-0.46	-0.41	Motion sickness;	chr6:8481188	chr6:8784178~8785445:+
OV	cis	rs2153535	0.56	rs2210798	ENSG00000230939.1	RP11-314C16.1	-6.76	1.17e-10	2.07e-07	-0.46	-0.41	Motion sickness;	chr6:8481289	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs6597327	ENSG00000230939.1	RP11-314C16.1	-6.76	1.17e-10	2.07e-07	-0.46	-0.41	Motion sickness;	chr6:8481924	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs7753192	ENSG00000230939.1	RP11-314C16.1	-6.76	1.17e-10	2.07e-07	-0.46	-0.41	Motion sickness;	chr6:8482404	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs7763190	ENSG00000230939.1	RP11-314C16.1	-6.76	1.17e-10	2.07e-07	-0.46	-0.41	Motion sickness;	chr6:8483964	chr6:8784178~8785445:+
OV	cis	rs2153535	0.546	rs1335640	ENSG00000230939.1	RP11-314C16.1	-6.76	1.17e-10	2.07e-07	-0.46	-0.41	Motion sickness;	chr6:8485092	chr6:8784178~8785445:+
OV	cis	rs2153535	0.541	rs1414352	ENSG00000230939.1	RP11-314C16.1	-6.76	1.17e-10	2.07e-07	-0.46	-0.41	Motion sickness;	chr6:8485314	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1577471	ENSG00000230939.1	RP11-314C16.1	-6.76	1.17e-10	2.07e-07	-0.46	-0.41	Motion sickness;	chr6:8485672	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1120392	ENSG00000230939.1	RP11-314C16.1	-6.76	1.17e-10	2.07e-07	-0.46	-0.41	Motion sickness;	chr6:8486820	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1335641	ENSG00000230939.1	RP11-314C16.1	-6.76	1.17e-10	2.07e-07	-0.46	-0.41	Motion sickness;	chr6:8487627	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1335643	ENSG00000230939.1	RP11-314C16.1	-6.76	1.17e-10	2.07e-07	-0.46	-0.41	Motion sickness;	chr6:8487788	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9378554	ENSG00000230939.1	RP11-314C16.1	-6.76	1.17e-10	2.07e-07	-0.46	-0.41	Motion sickness;	chr6:8488235	chr6:8784178~8785445:+
OV	cis	rs4591358	0.773	rs17177580	ENSG00000223466.1	AC064834.2	6.76	1.17e-10	2.07e-07	0.54	0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195508426	chr2:195533035~195538681:+
OV	cis	rs3091242	0.933	rs9438905	ENSG00000261349.1	RP3-465N24.5	-6.76	1.17e-10	2.07e-07	-0.44	-0.41	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25266102~25267136:-
OV	cis	rs7927771	1	rs4752856	ENSG00000280615.1	Y_RNA	-6.76	1.17e-10	2.07e-07	-0.51	-0.41	Subjective well-being;	chr11:47626490	chr11:47614898~47614994:-
OV	cis	rs2153535	0.58	rs2225766	ENSG00000230939.1	RP11-314C16.1	-6.76	1.18e-10	2.08e-07	-0.46	-0.41	Motion sickness;	chr6:8481600	chr6:8784178~8785445:+
OV	cis	rs1707322	1	rs4073847	ENSG00000280836.1	AL355480.1	6.76	1.18e-10	2.08e-07	0.56	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45997340	chr1:45581219~45581321:-
OV	cis	rs1061377	1	rs1897136	ENSG00000249207.1	RP11-360F5.1	-6.76	1.18e-10	2.09e-07	-0.43	-0.41	Uric acid levels;	chr4:39131242	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs1897137	ENSG00000249207.1	RP11-360F5.1	-6.76	1.18e-10	2.09e-07	-0.43	-0.41	Uric acid levels;	chr4:39131387	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs7681116	ENSG00000249207.1	RP11-360F5.1	-6.76	1.18e-10	2.09e-07	-0.43	-0.41	Uric acid levels;	chr4:39133015	chr4:39112677~39126818:-
OV	cis	rs1061377	0.965	rs10018622	ENSG00000249207.1	RP11-360F5.1	-6.76	1.18e-10	2.09e-07	-0.43	-0.41	Uric acid levels;	chr4:39133944	chr4:39112677~39126818:-
OV	cis	rs6921919	0.515	rs1558205	ENSG00000216901.1	AL022393.7	-6.75	1.19e-10	2.09e-07	-0.47	-0.41	Autism spectrum disorder or schizophrenia;	chr6:28414485	chr6:28176188~28176674:+
OV	cis	rs8062405	0.824	rs7191618	ENSG00000259982.1	CDC37P1	6.75	1.19e-10	2.1e-07	0.48	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28700294~28701540:-
OV	cis	rs8062405	0.754	rs3859172	ENSG00000259982.1	CDC37P1	6.75	1.19e-10	2.1e-07	0.48	0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28700294~28701540:-
OV	cis	rs7246967	0.932	rs11882432	ENSG00000269509.1	BNIP3P34	6.75	1.19e-10	2.1e-07	0.58	0.41	Bronchopulmonary dysplasia;	chr19:22846901	chr19:22773853~22774424:+
OV	cis	rs7246967	0.799	rs12983185	ENSG00000269509.1	BNIP3P34	6.75	1.19e-10	2.1e-07	0.58	0.41	Bronchopulmonary dysplasia;	chr19:22847773	chr19:22773853~22774424:+
OV	cis	rs7246967	0.932	rs4932792	ENSG00000269509.1	BNIP3P34	6.75	1.19e-10	2.1e-07	0.58	0.41	Bronchopulmonary dysplasia;	chr19:22849647	chr19:22773853~22774424:+
OV	cis	rs7246967	0.932	rs34949383	ENSG00000269509.1	BNIP3P34	6.75	1.19e-10	2.1e-07	0.58	0.41	Bronchopulmonary dysplasia;	chr19:22851056	chr19:22773853~22774424:+
OV	cis	rs7246967	0.866	rs4932695	ENSG00000269509.1	BNIP3P34	6.75	1.19e-10	2.1e-07	0.58	0.41	Bronchopulmonary dysplasia;	chr19:22853575	chr19:22773853~22774424:+
OV	cis	rs7246967	0.8	rs12985313	ENSG00000269509.1	BNIP3P34	6.75	1.19e-10	2.1e-07	0.58	0.41	Bronchopulmonary dysplasia;	chr19:22854978	chr19:22773853~22774424:+
OV	cis	rs7246967	0.932	rs7257731	ENSG00000269509.1	BNIP3P34	6.75	1.19e-10	2.1e-07	0.58	0.41	Bronchopulmonary dysplasia;	chr19:22860001	chr19:22773853~22774424:+
OV	cis	rs1061377	1	rs1036036	ENSG00000249207.1	RP11-360F5.1	-6.75	1.2e-10	2.11e-07	-0.44	-0.41	Uric acid levels;	chr4:39111104	chr4:39112677~39126818:-
OV	cis	rs2836974	0.644	rs11088471	ENSG00000232608.1	TIMM9P2	6.75	1.2e-10	2.12e-07	0.45	0.41	Cognitive function;	chr21:39327387	chr21:39216624~39217506:+
OV	cis	rs1707322	0.721	rs11211149	ENSG00000280836.1	AL355480.1	-6.75	1.2e-10	2.12e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr1:45581219~45581321:-
OV	cis	rs1707322	0.752	rs11211152	ENSG00000280836.1	AL355480.1	-6.75	1.2e-10	2.12e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr1:45581219~45581321:-
OV	cis	rs1707322	0.752	rs4607935	ENSG00000280836.1	AL355480.1	-6.75	1.2e-10	2.12e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr1:45581219~45581321:-
OV	cis	rs1707322	0.681	rs12048866	ENSG00000280836.1	AL355480.1	-6.75	1.2e-10	2.12e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr1:45581219~45581321:-
OV	cis	rs1707322	0.752	rs3811436	ENSG00000280836.1	AL355480.1	-6.75	1.2e-10	2.12e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr1:45581219~45581321:-
OV	cis	rs1707322	0.752	rs12024590	ENSG00000280836.1	AL355480.1	-6.75	1.2e-10	2.12e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr1:45581219~45581321:-
OV	cis	rs1707322	0.752	rs12027622	ENSG00000280836.1	AL355480.1	-6.75	1.2e-10	2.12e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs4415615	ENSG00000280836.1	AL355480.1	-6.75	1.2e-10	2.12e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr1:45581219~45581321:-
OV	cis	rs1707322	0.752	rs7529699	ENSG00000280836.1	AL355480.1	-6.75	1.2e-10	2.12e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr1:45581219~45581321:-
OV	cis	rs1707322	0.716	rs6699444	ENSG00000280836.1	AL355480.1	-6.75	1.2e-10	2.12e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr1:45581219~45581321:-
OV	cis	rs1707322	0.752	rs10430105	ENSG00000280836.1	AL355480.1	-6.75	1.2e-10	2.12e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs10890341	ENSG00000280836.1	AL355480.1	-6.75	1.2e-10	2.12e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr1:45581219~45581321:-
OV	cis	rs1707322	0.717	rs1547925	ENSG00000280836.1	AL355480.1	6.75	1.21e-10	2.12e-07	0.59	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr1:45581219~45581321:-
OV	cis	rs2153535	0.58	rs7341381	ENSG00000230939.1	RP11-314C16.1	-6.75	1.22e-10	2.14e-07	-0.46	-0.41	Motion sickness;	chr6:8470304	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1414344	ENSG00000230939.1	RP11-314C16.1	-6.75	1.22e-10	2.14e-07	-0.46	-0.41	Motion sickness;	chr6:8471132	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs2152348	ENSG00000230939.1	RP11-314C16.1	-6.75	1.22e-10	2.14e-07	-0.46	-0.41	Motion sickness;	chr6:8474068	chr6:8784178~8785445:+
OV	cis	rs9918079	0.542	rs12499412	ENSG00000273133.1	RP11-799M12.2	6.75	1.22e-10	2.14e-07	0.47	0.41	Obesity-related traits;	chr4:15600629	chr4:15563698~15564253:-
OV	cis	rs9918079	0.58	rs13120905	ENSG00000273133.1	RP11-799M12.2	6.75	1.22e-10	2.14e-07	0.47	0.41	Obesity-related traits;	chr4:15610665	chr4:15563698~15564253:-
OV	cis	rs934734	0.532	rs12470883	ENSG00000234255.7	AC012370.3	-6.75	1.23e-10	2.16e-07	-0.44	-0.41	Rheumatoid arthritis;	chr2:65424717	chr2:65439888~65456571:-
OV	cis	rs1707322	0.682	rs10890334	ENSG00000280836.1	AL355480.1	-6.75	1.24e-10	2.17e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr1:45581219~45581321:-
OV	cis	rs1707322	0.682	rs10890335	ENSG00000280836.1	AL355480.1	-6.75	1.24e-10	2.17e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr1:45581219~45581321:-
OV	cis	rs7605378	0.528	rs281767	ENSG00000232732.8	AC073043.1	-6.75	1.24e-10	2.17e-07	-0.49	-0.41	Osteoporosis;	chr2:199958558	chr2:199867396~199911159:-
OV	cis	rs438465	1	rs454974	ENSG00000226194.4	RP1-137D17.1	6.75	1.24e-10	2.17e-07	0.62	0.41	Corneal astigmatism;	chr6:169412263	chr6:169369998~169388385:-
OV	cis	rs12819124	0.502	rs10875718	ENSG00000258273.1	RP11-370I10.4	-6.74	1.26e-10	2.2e-07	-0.49	-0.41	Glycated hemoglobin levels;	chr12:48017319	chr12:48333755~48333901:-
OV	cis	rs8105895	0.935	rs62111028	ENSG00000269742.1	BNIP3P29	6.74	1.26e-10	2.21e-07	0.68	0.41	Body mass index (change over time);	chr19:22089595	chr19:22065828~22066398:-
OV	cis	rs8105895	0.733	rs62111029	ENSG00000269742.1	BNIP3P29	6.74	1.26e-10	2.21e-07	0.68	0.41	Body mass index (change over time);	chr19:22093799	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs959908	ENSG00000269742.1	BNIP3P29	6.74	1.26e-10	2.21e-07	0.68	0.41	Body mass index (change over time);	chr19:22099091	chr19:22065828~22066398:-
OV	cis	rs8105895	0.867	rs12151358	ENSG00000269742.1	BNIP3P29	6.74	1.26e-10	2.21e-07	0.68	0.41	Body mass index (change over time);	chr19:22099806	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs62111034	ENSG00000269742.1	BNIP3P29	6.74	1.26e-10	2.21e-07	0.68	0.41	Body mass index (change over time);	chr19:22101918	chr19:22065828~22066398:-
OV	cis	rs10256972	0.967	rs7799110	ENSG00000229043.2	AC091729.9	-6.74	1.27e-10	2.22e-07	-0.46	-0.41	Endometriosis;Longevity;	chr7:999429	chr7:1160374~1165267:+
OV	cis	rs1707322	1	rs1707303	ENSG00000281133.1	AL355480.3	6.74	1.27e-10	2.22e-07	0.52	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46132601	chr1:45580892~45580996:-
OV	cis	rs2153535	0.58	rs6597326	ENSG00000230939.1	RP11-314C16.1	-6.74	1.28e-10	2.23e-07	-0.46	-0.41	Motion sickness;	chr6:8481786	chr6:8784178~8785445:+
OV	cis	rs2153535	0.541	rs1414353	ENSG00000230939.1	RP11-314C16.1	-6.74	1.28e-10	2.23e-07	-0.46	-0.41	Motion sickness;	chr6:8485409	chr6:8784178~8785445:+
OV	cis	rs2153535	0.525	rs1335644	ENSG00000230939.1	RP11-314C16.1	-6.74	1.28e-10	2.23e-07	-0.46	-0.41	Motion sickness;	chr6:8487808	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9393025	ENSG00000230939.1	RP11-314C16.1	-6.74	1.28e-10	2.23e-07	-0.46	-0.41	Motion sickness;	chr6:8490385	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1414340	ENSG00000230939.1	RP11-314C16.1	-6.74	1.28e-10	2.23e-07	-0.46	-0.41	Motion sickness;	chr6:8490906	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1335628	ENSG00000230939.1	RP11-314C16.1	-6.74	1.28e-10	2.23e-07	-0.46	-0.41	Motion sickness;	chr6:8491509	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs6597330	ENSG00000230939.1	RP11-314C16.1	-6.74	1.28e-10	2.23e-07	-0.46	-0.41	Motion sickness;	chr6:8491843	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs6941771	ENSG00000230939.1	RP11-314C16.1	-6.74	1.28e-10	2.23e-07	-0.46	-0.41	Motion sickness;	chr6:8494219	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs6937186	ENSG00000230939.1	RP11-314C16.1	-6.74	1.28e-10	2.23e-07	-0.46	-0.41	Motion sickness;	chr6:8494260	chr6:8784178~8785445:+
OV	cis	rs2836974	0.602	rs2037925	ENSG00000232608.1	TIMM9P2	6.74	1.29e-10	2.25e-07	0.44	0.41	Cognitive function;	chr21:39328005	chr21:39216624~39217506:+
OV	cis	rs8040855	0.644	rs4635318	ENSG00000229212.6	RP11-561C5.4	-6.74	1.3e-10	2.27e-07	-0.51	-0.41	Bulimia nervosa;	chr15:85183506	chr15:85205440~85234795:-
OV	cis	rs9813712	0.597	rs1453255	ENSG00000228252.7	COL6A4P2	-6.74	1.31e-10	2.29e-07	-0.45	-0.41	Response to amphetamines;	chr3:130258815	chr3:130212823~130273806:+
OV	cis	rs853679	0.517	rs3823180	ENSG00000219392.1	RP1-265C24.5	-6.74	1.33e-10	2.32e-07	-0.49	-0.41	Depression;	chr6:28093966	chr6:28115628~28116551:+
OV	cis	rs10256972	0.621	rs2280725	ENSG00000229043.2	AC091729.9	-6.73	1.34e-10	2.33e-07	-0.48	-0.41	Endometriosis;Longevity;	chr7:1047790	chr7:1160374~1165267:+
OV	cis	rs2243480	1	rs1796228	ENSG00000222364.1	RNU6-96P	-6.73	1.35e-10	2.35e-07	-0.64	-0.41	Diabetic kidney disease;	chr7:66568097	chr7:66395191~66395286:+
OV	cis	rs7396835	0.866	rs6589571	ENSG00000254851.1	RP11-109L13.1	-6.73	1.38e-10	2.39e-07	-0.64	-0.41	Quantitative traits;	chr11:116809702	chr11:117135528~117138582:+
OV	cis	rs875971	0.545	rs73142265	ENSG00000222364.1	RNU6-96P	-6.73	1.38e-10	2.4e-07	-0.47	-0.41	Aortic root size;	chr7:66234510	chr7:66395191~66395286:+
OV	cis	rs5742933	0.857	rs893784	ENSG00000253559.1	OSGEPL1-AS1	-6.73	1.39e-10	2.41e-07	-0.43	-0.41	Ferritin levels;	chr2:189671557	chr2:189762704~189765556:+
OV	cis	rs4591358	0.648	rs17177798	ENSG00000223466.1	AC064834.2	-6.73	1.4e-10	2.43e-07	-0.58	-0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195521352	chr2:195533035~195538681:+
OV	cis	rs2153535	0.58	rs1932284	ENSG00000230939.1	RP11-314C16.1	-6.73	1.41e-10	2.44e-07	-0.46	-0.41	Motion sickness;	chr6:8477461	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1932285	ENSG00000230939.1	RP11-314C16.1	-6.73	1.41e-10	2.44e-07	-0.46	-0.41	Motion sickness;	chr6:8477486	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs7775909	ENSG00000230939.1	RP11-314C16.1	-6.73	1.41e-10	2.44e-07	-0.46	-0.41	Motion sickness;	chr6:8477545	chr6:8784178~8785445:+
OV	cis	rs7615952	1	rs7615952	ENSG00000171084.14	FAM86JP	-6.72	1.41e-10	2.44e-07	-0.58	-0.41	Blood pressure (smoking interaction);	chr3:125930560	chr3:125916620~125930024:+
OV	cis	rs3136516	0.537	rs752850	ENSG00000271350.1	CTD-2384B9.1	-6.72	1.41e-10	2.44e-07	-0.46	-0.41	Venous thromboembolism;	chr11:47153599	chr11:47041027~47041945:-
OV	cis	rs2153535	0.526	rs7748404	ENSG00000230939.1	RP11-314C16.1	-6.72	1.41e-10	2.45e-07	-0.46	-0.41	Motion sickness;	chr6:8472267	chr6:8784178~8785445:+
OV	cis	rs2564921	0.704	rs62253649	ENSG00000242142.1	SERBP1P3	-6.72	1.42e-10	2.45e-07	-0.47	-0.41	Height;	chr3:52967831	chr3:53064283~53065091:-
OV	cis	rs875971	0.502	rs11769702	ENSG00000222364.1	RNU6-96P	-6.72	1.42e-10	2.46e-07	-0.47	-0.41	Aortic root size;	chr7:66255529	chr7:66395191~66395286:+
OV	cis	rs10510102	0.872	rs11200277	ENSG00000276742.1	RP11-500G22.4	6.72	1.43e-10	2.48e-07	0.66	0.41	Breast cancer;	chr10:121944295	chr10:121956782~121957098:+
OV	cis	rs2836974	0.623	rs7280326	ENSG00000232608.1	TIMM9P2	6.72	1.43e-10	2.48e-07	0.44	0.41	Cognitive function;	chr21:39328482	chr21:39216624~39217506:+
OV	cis	rs2153535	0.58	rs6905237	ENSG00000230939.1	RP11-314C16.1	-6.72	1.45e-10	2.51e-07	-0.46	-0.41	Motion sickness;	chr6:8471557	chr6:8784178~8785445:+
OV	cis	rs2153535	0.542	rs4440510	ENSG00000230939.1	RP11-314C16.1	-6.72	1.45e-10	2.51e-07	-0.46	-0.41	Motion sickness;	chr6:8471585	chr6:8784178~8785445:+
OV	cis	rs2153535	0.541	rs1414347	ENSG00000230939.1	RP11-314C16.1	-6.72	1.45e-10	2.51e-07	-0.46	-0.41	Motion sickness;	chr6:8471598	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1932280	ENSG00000230939.1	RP11-314C16.1	-6.72	1.46e-10	2.51e-07	-0.46	-0.41	Motion sickness;	chr6:8473421	chr6:8784178~8785445:+
OV	cis	rs2153535	0.584	rs9502723	ENSG00000230939.1	RP11-314C16.1	-6.72	1.46e-10	2.52e-07	-0.46	-0.41	Motion sickness;	chr6:8541271	chr6:8784178~8785445:+
OV	cis	rs10256972	0.521	rs7457418	ENSG00000229043.2	AC091729.9	-6.72	1.46e-10	2.52e-07	-0.45	-0.41	Endometriosis;Longevity;	chr7:1070619	chr7:1160374~1165267:+
OV	cis	rs2408955	0.561	rs11168365	ENSG00000258273.1	RP11-370I10.4	6.72	1.47e-10	2.54e-07	0.49	0.41	Glycated hemoglobin levels;	chr12:48027989	chr12:48333755~48333901:-
OV	cis	rs2153535	0.601	rs2015281	ENSG00000230939.1	RP11-314C16.1	-6.72	1.48e-10	2.55e-07	-0.46	-0.41	Motion sickness;	chr6:8539440	chr6:8784178~8785445:+
OV	cis	rs2153535	0.601	rs9505474	ENSG00000230939.1	RP11-314C16.1	-6.72	1.48e-10	2.55e-07	-0.46	-0.41	Motion sickness;	chr6:8539561	chr6:8784178~8785445:+
OV	cis	rs2153535	0.601	rs2327091	ENSG00000230939.1	RP11-314C16.1	-6.72	1.48e-10	2.55e-07	-0.46	-0.41	Motion sickness;	chr6:8540136	chr6:8784178~8785445:+
OV	cis	rs1707322	1	rs1707322	ENSG00000281133.1	AL355480.3	-6.72	1.48e-10	2.55e-07	-0.51	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039475	chr1:45580892~45580996:-
OV	cis	rs875971	0.545	rs221986	ENSG00000222364.1	RNU6-96P	6.72	1.48e-10	2.56e-07	0.47	0.41	Aortic root size;	chr7:66105323	chr7:66395191~66395286:+
OV	cis	rs4865169	0.791	rs11731868	ENSG00000269949.1	RP11-738E22.3	-6.71	1.5e-10	2.58e-07	-0.47	-0.41	Breast cancer;	chr4:57029048	chr4:56960927~56961373:-
OV	cis	rs2153535	0.58	rs6938071	ENSG00000230939.1	RP11-314C16.1	-6.71	1.5e-10	2.59e-07	-0.46	-0.41	Motion sickness;	chr6:8464612	chr6:8784178~8785445:+
OV	cis	rs2153535	0.601	rs9406160	ENSG00000230939.1	RP11-314C16.1	-6.71	1.5e-10	2.59e-07	-0.46	-0.41	Motion sickness;	chr6:8464674	chr6:8784178~8785445:+
OV	cis	rs7044106	0.708	rs1324472	ENSG00000226752.6	PSMD5-AS1	-6.71	1.51e-10	2.6e-07	-0.48	-0.41	Hip circumference adjusted for BMI;	chr9:120612832	chr9:120824828~120854385:+
OV	cis	rs1707322	0.963	rs34907901	ENSG00000280836.1	AL355480.1	-6.71	1.51e-10	2.6e-07	-0.56	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45939542	chr1:45581219~45581321:-
OV	cis	rs7617773	0.539	rs35460860	ENSG00000229759.1	MRPS18AP1	6.71	1.51e-10	2.61e-07	0.43	0.41	Coronary artery disease;	chr3:48350595	chr3:48256350~48256938:-
OV	cis	rs7617773	0.539	rs6779517	ENSG00000229759.1	MRPS18AP1	6.71	1.53e-10	2.63e-07	0.42	0.41	Coronary artery disease;	chr3:48342898	chr3:48256350~48256938:-
OV	cis	rs507080	0.501	rs637563	ENSG00000255422.1	AP002954.4	-6.71	1.53e-10	2.63e-07	-0.46	-0.41	Serum metabolite levels;	chr11:118704770	chr11:118704607~118750263:+
OV	cis	rs7927771	0.8	rs12146565	ENSG00000280615.1	Y_RNA	-6.71	1.53e-10	2.64e-07	-0.51	-0.41	Subjective well-being;	chr11:47377412	chr11:47614898~47614994:-
OV	cis	rs875971	0.545	rs73376401	ENSG00000222364.1	RNU6-96P	-6.71	1.54e-10	2.65e-07	-0.47	-0.41	Aortic root size;	chr7:66174841	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs6460276	ENSG00000222364.1	RNU6-96P	-6.71	1.54e-10	2.65e-07	-0.47	-0.41	Aortic root size;	chr7:66182290	chr7:66395191~66395286:+
OV	cis	rs2153535	0.601	rs9502719	ENSG00000230939.1	RP11-314C16.1	-6.71	1.54e-10	2.65e-07	-0.46	-0.41	Motion sickness;	chr6:8540799	chr6:8784178~8785445:+
OV	cis	rs2153535	0.547	rs9502720	ENSG00000230939.1	RP11-314C16.1	-6.71	1.54e-10	2.65e-07	-0.46	-0.41	Motion sickness;	chr6:8541129	chr6:8784178~8785445:+
OV	cis	rs2153535	0.601	rs9505472	ENSG00000230939.1	RP11-314C16.1	-6.71	1.56e-10	2.68e-07	-0.46	-0.41	Motion sickness;	chr6:8538532	chr6:8784178~8785445:+
OV	cis	rs2153535	0.601	rs9505473	ENSG00000230939.1	RP11-314C16.1	-6.71	1.56e-10	2.68e-07	-0.46	-0.41	Motion sickness;	chr6:8538544	chr6:8784178~8785445:+
OV	cis	rs1707322	0.752	rs6662164	ENSG00000281133.1	AL355480.3	-6.71	1.56e-10	2.68e-07	-0.51	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr1:45580892~45580996:-
OV	cis	rs1185460	0.967	rs1784460	ENSG00000271751.1	RP11-110I1.14	6.71	1.56e-10	2.68e-07	0.48	0.41	Coronary artery disease;	chr11:119067660	chr11:119065263~119065677:-
OV	cis	rs7246967	0.932	rs35446354	ENSG00000269509.1	BNIP3P34	6.7	1.58e-10	2.71e-07	0.58	0.41	Bronchopulmonary dysplasia;	chr19:22844522	chr19:22773853~22774424:+
OV	cis	rs73086581	0.838	rs73088424	ENSG00000229539.1	RP11-119B16.2	6.7	1.59e-10	2.73e-07	0.5	0.41	Response to antidepressants in depression;	chr20:4020359	chr20:3888239~3888868:-
OV	cis	rs875971	0.571	rs160641	ENSG00000222364.1	RNU6-96P	6.7	1.6e-10	2.74e-07	0.47	0.41	Aortic root size;	chr7:66112359	chr7:66395191~66395286:+
OV	cis	rs1075265	0.633	rs7591431	ENSG00000233266.1	HMGB1P31	6.7	1.6e-10	2.74e-07	0.52	0.41	Chronotype;Morning vs. evening chronotype;	chr2:53995028	chr2:54051334~54051760:+
OV	cis	rs7847628	0.765	rs7026635	ENSG00000226752.6	PSMD5-AS1	6.7	1.6e-10	2.75e-07	0.5	0.41	Birth weight;	chr9:120787749	chr9:120824828~120854385:+
OV	cis	rs293748	0.882	rs16903459	ENSG00000250155.1	CTD-2353F22.1	-6.7	1.62e-10	2.77e-07	-0.62	-0.41	Obesity-related traits;	chr5:37031314	chr5:36666214~36725195:-
OV	cis	rs1707322	1	rs12077974	ENSG00000281133.1	AL355480.3	-6.7	1.62e-10	2.78e-07	-0.53	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45918469	chr1:45580892~45580996:-
OV	cis	rs4591358	0.773	rs13002794	ENSG00000223466.1	AC064834.2	-6.7	1.62e-10	2.78e-07	-0.56	-0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195517175	chr2:195533035~195538681:+
OV	cis	rs6921919	0.583	rs1054372	ENSG00000216901.1	AL022393.7	6.7	1.63e-10	2.79e-07	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs9468354	ENSG00000216901.1	AL022393.7	6.7	1.63e-10	2.79e-07	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs7773051	ENSG00000216901.1	AL022393.7	6.7	1.63e-10	2.79e-07	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs12697938	ENSG00000216901.1	AL022393.7	6.7	1.63e-10	2.79e-07	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs13437294	ENSG00000216901.1	AL022393.7	6.7	1.63e-10	2.79e-07	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28176188~28176674:+
OV	cis	rs6921919	0.609	rs9468357	ENSG00000216901.1	AL022393.7	6.7	1.63e-10	2.79e-07	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs34513104	ENSG00000216901.1	AL022393.7	6.7	1.63e-10	2.79e-07	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs9461456	ENSG00000216901.1	AL022393.7	6.7	1.63e-10	2.79e-07	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28176188~28176674:+
OV	cis	rs6921919	0.525	rs9468360	ENSG00000216901.1	AL022393.7	6.7	1.63e-10	2.79e-07	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs16894021	ENSG00000216901.1	AL022393.7	6.7	1.63e-10	2.79e-07	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs11751693	ENSG00000216901.1	AL022393.7	6.7	1.63e-10	2.79e-07	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs7749736	ENSG00000216901.1	AL022393.7	6.7	1.63e-10	2.79e-07	0.48	0.41	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28176188~28176674:+
OV	cis	rs3091242	0.967	rs1053438	ENSG00000224183.1	SDHDP6	6.7	1.63e-10	2.79e-07	0.48	0.41	Erythrocyte sedimentation rate;	chr1:25361410	chr1:25294164~25294643:-
OV	cis	rs2836974	0.644	rs2836981	ENSG00000232608.1	TIMM9P2	6.7	1.63e-10	2.79e-07	0.43	0.41	Cognitive function;	chr21:39316439	chr21:39216624~39217506:+
OV	cis	rs2243480	1	rs1267820	ENSG00000222364.1	RNU6-96P	-6.7	1.64e-10	2.8e-07	-0.64	-0.41	Diabetic kidney disease;	chr7:66585308	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs2533288	ENSG00000222364.1	RNU6-96P	-6.7	1.64e-10	2.8e-07	-0.64	-0.41	Diabetic kidney disease;	chr7:66591724	chr7:66395191~66395286:+
OV	cis	rs1707322	0.716	rs10890342	ENSG00000280836.1	AL355480.1	-6.7	1.64e-10	2.8e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr1:45581219~45581321:-
OV	cis	rs1707322	0.752	rs6658700	ENSG00000280836.1	AL355480.1	-6.7	1.64e-10	2.8e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr1:45581219~45581321:-
OV	cis	rs1707322	0.752	rs12047629	ENSG00000280836.1	AL355480.1	-6.7	1.64e-10	2.8e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr1:45581219~45581321:-
OV	cis	rs1707322	0.752	rs11211168	ENSG00000280836.1	AL355480.1	-6.7	1.64e-10	2.8e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr1:45581219~45581321:-
OV	cis	rs1707322	0.752	rs11211169	ENSG00000280836.1	AL355480.1	-6.7	1.64e-10	2.8e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr1:45581219~45581321:-
OV	cis	rs1707322	0.752	rs11211171	ENSG00000280836.1	AL355480.1	-6.7	1.64e-10	2.8e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr1:45581219~45581321:-
OV	cis	rs1707322	0.716	rs28370457	ENSG00000280836.1	AL355480.1	-6.7	1.64e-10	2.8e-07	-0.57	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr1:45581219~45581321:-
OV	cis	rs2243480	1	rs6964530	ENSG00000222364.1	RNU6-96P	6.7	1.64e-10	2.8e-07	0.63	0.41	Diabetic kidney disease;	chr7:66253864	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs801199	ENSG00000222364.1	RNU6-96P	6.7	1.66e-10	2.83e-07	0.48	0.41	Aortic root size;	chr7:66560286	chr7:66395191~66395286:+
OV	cis	rs1707322	0.821	rs11211182	ENSG00000281133.1	AL355480.3	-6.7	1.66e-10	2.84e-07	-0.53	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45580892~45580996:-
OV	cis	rs4591358	0.773	rs35785148	ENSG00000223466.1	AC064834.2	-6.7	1.67e-10	2.84e-07	-0.56	-0.41	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195516751	chr2:195533035~195538681:+
OV	cis	rs1707322	0.717	rs2253862	ENSG00000280836.1	AL355480.1	6.7	1.67e-10	2.85e-07	0.58	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616288	chr1:45581219~45581321:-
OV	cis	rs1707322	0.717	rs2991988	ENSG00000280836.1	AL355480.1	6.7	1.67e-10	2.85e-07	0.58	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45616759	chr1:45581219~45581321:-
OV	cis	rs1707322	0.717	rs2991989	ENSG00000280836.1	AL355480.1	6.7	1.67e-10	2.85e-07	0.58	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45617293	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs56255771	ENSG00000280836.1	AL355480.1	-6.7	1.67e-10	2.85e-07	-0.56	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758647	chr1:45581219~45581321:-
OV	cis	rs2243480	1	rs1618893	ENSG00000222364.1	RNU6-96P	-6.69	1.67e-10	2.85e-07	-0.61	-0.41	Diabetic kidney disease;	chr7:66631132	chr7:66395191~66395286:+
OV	cis	rs6700559	0.873	rs7542210	ENSG00000260088.1	RP11-92G12.3	-6.69	1.68e-10	2.86e-07	-0.42	-0.41	Coronary artery disease;	chr1:200693087	chr1:200669507~200694250:+
OV	cis	rs3091242	0.935	rs4233043	ENSG00000261349.1	RP3-465N24.5	-6.69	1.69e-10	2.87e-07	-0.43	-0.41	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25266102~25267136:-
OV	cis	rs2153535	0.547	rs9505475	ENSG00000230939.1	RP11-314C16.1	-6.69	1.69e-10	2.88e-07	-0.46	-0.41	Motion sickness;	chr6:8542657	chr6:8784178~8785445:+
OV	cis	rs2153535	0.601	rs6906170	ENSG00000230939.1	RP11-314C16.1	-6.69	1.69e-10	2.88e-07	-0.46	-0.41	Motion sickness;	chr6:8542895	chr6:8784178~8785445:+
OV	cis	rs6921919	0.583	rs6922169	ENSG00000216901.1	AL022393.7	6.69	1.69e-10	2.88e-07	0.47	0.41	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28176188~28176674:+
OV	cis	rs6921919	0.559	rs13210866	ENSG00000216901.1	AL022393.7	6.69	1.69e-10	2.88e-07	0.47	0.41	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28176188~28176674:+
OV	cis	rs6921919	0.609	rs36018474	ENSG00000216901.1	AL022393.7	6.69	1.69e-10	2.88e-07	0.47	0.41	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs13201726	ENSG00000216901.1	AL022393.7	6.69	1.69e-10	2.88e-07	0.47	0.41	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs740622	ENSG00000216901.1	AL022393.7	6.69	1.69e-10	2.88e-07	0.47	0.41	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs16894108	ENSG00000216901.1	AL022393.7	6.69	1.69e-10	2.88e-07	0.47	0.41	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28176188~28176674:+
OV	cis	rs7617773	0.539	rs12486944	ENSG00000229759.1	MRPS18AP1	6.69	1.69e-10	2.88e-07	0.42	0.41	Coronary artery disease;	chr3:48348526	chr3:48256350~48256938:-
OV	cis	rs7605378	0.528	rs812760	ENSG00000232732.8	AC073043.1	-6.69	1.7e-10	2.89e-07	-0.5	-0.41	Osteoporosis;	chr2:199859649	chr2:199867396~199911159:-
OV	cis	rs7605378	0.528	rs281780	ENSG00000232732.8	AC073043.1	-6.69	1.7e-10	2.89e-07	-0.5	-0.41	Osteoporosis;	chr2:199891608	chr2:199867396~199911159:-
OV	cis	rs875971	0.545	rs12673308	ENSG00000222364.1	RNU6-96P	-6.69	1.72e-10	2.92e-07	-0.46	-0.41	Aortic root size;	chr7:66166374	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs67397473	ENSG00000222364.1	RNU6-96P	-6.69	1.72e-10	2.92e-07	-0.46	-0.41	Aortic root size;	chr7:66168318	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs10950027	ENSG00000222364.1	RNU6-96P	-6.69	1.72e-10	2.92e-07	-0.46	-0.41	Aortic root size;	chr7:66169164	chr7:66395191~66395286:+
OV	cis	rs11673344	0.583	rs10421436	ENSG00000226686.6	LINC01535	-6.69	1.72e-10	2.93e-07	-0.47	-0.41	Obesity-related traits;	chr19:37394601	chr19:37251912~37265535:+
OV	cis	rs2564921	0.73	rs12633064	ENSG00000242142.1	SERBP1P3	-6.69	1.73e-10	2.94e-07	-0.47	-0.41	Height;	chr3:53027361	chr3:53064283~53065091:-
OV	cis	rs11168351	1	rs11168351	ENSG00000258273.1	RP11-370I10.4	-6.69	1.73e-10	2.94e-07	-0.49	-0.41	Bipolar disorder and schizophrenia;	chr12:48009982	chr12:48333755~48333901:-
OV	cis	rs8062405	1	rs2008514	ENSG00000259982.1	CDC37P1	-6.69	1.73e-10	2.94e-07	-0.5	-0.41	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28700294~28701540:-
OV	cis	rs11673344	0.583	rs10425719	ENSG00000226686.6	LINC01535	-6.69	1.74e-10	2.96e-07	-0.47	-0.41	Obesity-related traits;	chr19:37459896	chr19:37251912~37265535:+
OV	cis	rs3091242	0.967	rs3093614	ENSG00000224183.1	SDHDP6	6.69	1.74e-10	2.96e-07	0.48	0.41	Erythrocyte sedimentation rate;	chr1:25351353	chr1:25294164~25294643:-
OV	cis	rs2836974	0.644	rs2410123	ENSG00000232608.1	TIMM9P2	6.69	1.75e-10	2.97e-07	0.45	0.41	Cognitive function;	chr21:39328167	chr21:39216624~39217506:+
OV	cis	rs3091242	0.933	rs7541095	ENSG00000261349.1	RP3-465N24.5	-6.69	1.76e-10	2.98e-07	-0.43	-0.41	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25266102~25267136:-
OV	cis	rs7927771	0.965	rs4752845	ENSG00000280615.1	Y_RNA	-6.69	1.76e-10	2.98e-07	-0.5	-0.41	Subjective well-being;	chr11:47518145	chr11:47614898~47614994:-
OV	cis	rs2153535	0.541	rs6908504	ENSG00000230939.1	RP11-314C16.1	-6.69	1.76e-10	2.98e-07	-0.45	-0.41	Motion sickness;	chr6:8456545	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs7755284	ENSG00000230939.1	RP11-314C16.1	-6.69	1.76e-10	2.98e-07	-0.45	-0.41	Motion sickness;	chr6:8457246	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs7769020	ENSG00000230939.1	RP11-314C16.1	-6.69	1.76e-10	2.98e-07	-0.45	-0.41	Motion sickness;	chr6:8457491	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9392220	ENSG00000230939.1	RP11-314C16.1	-6.69	1.76e-10	2.98e-07	-0.45	-0.41	Motion sickness;	chr6:8457713	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9379206	ENSG00000230939.1	RP11-314C16.1	-6.69	1.76e-10	2.98e-07	-0.45	-0.41	Motion sickness;	chr6:8457788	chr6:8784178~8785445:+
OV	cis	rs2153535	0.541	rs9405386	ENSG00000230939.1	RP11-314C16.1	-6.69	1.76e-10	2.98e-07	-0.45	-0.41	Motion sickness;	chr6:8457834	chr6:8784178~8785445:+
OV	cis	rs2153535	0.541	rs9379207	ENSG00000230939.1	RP11-314C16.1	-6.69	1.76e-10	2.98e-07	-0.45	-0.41	Motion sickness;	chr6:8457953	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9393016	ENSG00000230939.1	RP11-314C16.1	-6.69	1.76e-10	2.98e-07	-0.45	-0.41	Motion sickness;	chr6:8458340	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs4960421	ENSG00000230939.1	RP11-314C16.1	-6.69	1.76e-10	2.98e-07	-0.45	-0.41	Motion sickness;	chr6:8459059	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs4960422	ENSG00000230939.1	RP11-314C16.1	-6.69	1.76e-10	2.98e-07	-0.45	-0.41	Motion sickness;	chr6:8459076	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs7742794	ENSG00000230939.1	RP11-314C16.1	-6.69	1.76e-10	2.98e-07	-0.45	-0.41	Motion sickness;	chr6:8459490	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9505448	ENSG00000230939.1	RP11-314C16.1	-6.69	1.76e-10	2.98e-07	-0.45	-0.41	Motion sickness;	chr6:8459571	chr6:8784178~8785445:+
OV	cis	rs2980436	1	rs2980436	ENSG00000173295.6	FAM86B3P	-6.69	1.77e-10	2.99e-07	-0.48	-0.41	Schizophrenia;	chr8:8234503	chr8:8228595~8244865:+
OV	cis	rs875971	0.545	rs73376394	ENSG00000222364.1	RNU6-96P	-6.68	1.77e-10	3e-07	-0.46	-0.41	Aortic root size;	chr7:66172694	chr7:66395191~66395286:+
OV	cis	rs7927771	0.832	rs11605672	ENSG00000280615.1	Y_RNA	-6.68	1.78e-10	3.03e-07	-0.49	-0.41	Subjective well-being;	chr11:47392182	chr11:47614898~47614994:-
OV	cis	rs1499614	1	rs2659903	ENSG00000222364.1	RNU6-96P	-6.68	1.8e-10	3.05e-07	-0.65	-0.41	Gout;	chr7:66715944	chr7:66395191~66395286:+
OV	cis	rs4713118	0.866	rs9468217	ENSG00000220721.1	OR1F12	6.68	1.81e-10	3.06e-07	0.47	0.41	Parkinson's disease;	chr6:27758688	chr6:28073316~28074233:+
OV	cis	rs1707322	0.717	rs3014237	ENSG00000280836.1	AL355480.1	6.68	1.82e-10	3.08e-07	0.59	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs10890350	ENSG00000280836.1	AL355480.1	-6.68	1.82e-10	3.09e-07	-0.55	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796706	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs4390216	ENSG00000280836.1	AL355480.1	-6.68	1.82e-10	3.09e-07	-0.55	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800784	chr1:45581219~45581321:-
OV	cis	rs1707322	0.964	rs10437063	ENSG00000280836.1	AL355480.1	-6.68	1.82e-10	3.09e-07	-0.55	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807994	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs6676982	ENSG00000280836.1	AL355480.1	-6.68	1.82e-10	3.09e-07	-0.55	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809729	chr1:45581219~45581321:-
OV	cis	rs1707322	0.927	rs11211194	ENSG00000280836.1	AL355480.1	-6.68	1.82e-10	3.09e-07	-0.55	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45816412	chr1:45581219~45581321:-
OV	cis	rs2836974	0.533	rs4817999	ENSG00000232608.1	TIMM9P2	6.68	1.83e-10	3.1e-07	0.43	0.41	Cognitive function;	chr21:39182429	chr21:39216624~39217506:+
OV	cis	rs1707322	0.752	rs11211145	ENSG00000280836.1	AL355480.1	-6.68	1.83e-10	3.1e-07	-0.55	-0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr1:45581219~45581321:-
OV	cis	rs2564921	0.704	rs11130333	ENSG00000242142.1	SERBP1P3	-6.68	1.85e-10	3.12e-07	-0.47	-0.41	Height;	chr3:52977358	chr3:53064283~53065091:-
OV	cis	rs2153535	0.601	rs330105	ENSG00000230939.1	RP11-314C16.1	-6.68	1.85e-10	3.12e-07	-0.46	-0.41	Motion sickness;	chr6:8543748	chr6:8784178~8785445:+
OV	cis	rs853679	0.517	rs9357063	ENSG00000219392.1	RP1-265C24.5	-6.68	1.85e-10	3.13e-07	-0.49	-0.41	Depression;	chr6:28092227	chr6:28115628~28116551:+
OV	cis	rs2153535	0.58	rs6597325	ENSG00000230939.1	RP11-314C16.1	-6.68	1.86e-10	3.14e-07	-0.46	-0.41	Motion sickness;	chr6:8460820	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs6918391	ENSG00000230939.1	RP11-314C16.1	-6.68	1.86e-10	3.14e-07	-0.46	-0.41	Motion sickness;	chr6:8460945	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9379210	ENSG00000230939.1	RP11-314C16.1	-6.68	1.86e-10	3.14e-07	-0.46	-0.41	Motion sickness;	chr6:8461695	chr6:8784178~8785445:+
OV	cis	rs8005677	0.962	rs10130756	ENSG00000257285.4	RP11-298I3.1	6.68	1.87e-10	3.16e-07	0.47	0.41	Cognitive ability (multi-trait analysis);	chr14:22927391	chr14:22929609~22955562:+
OV	cis	rs1707322	1	rs785478	ENSG00000280836.1	AL355480.1	6.67	1.87e-10	3.16e-07	0.55	0.41	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46025963	chr1:45581219~45581321:-
OV	cis	rs2153535	0.58	rs7748455	ENSG00000230939.1	RP11-314C16.1	-6.67	1.89e-10	3.18e-07	-0.46	-0.4	Motion sickness;	chr6:8453392	chr6:8784178~8785445:+
OV	cis	rs875971	0.545	rs2707851	ENSG00000222364.1	RNU6-96P	6.67	1.9e-10	3.2e-07	0.48	0.4	Aortic root size;	chr7:66624178	chr7:66395191~66395286:+
OV	cis	rs11690935	0.788	rs10201053	ENSG00000228389.1	AC068039.4	6.67	1.9e-10	3.2e-07	0.47	0.4	Schizophrenia;	chr2:172024653	chr2:171773482~171775844:+
OV	cis	rs10256972	0.521	rs871019	ENSG00000229043.2	AC091729.9	-6.67	1.9e-10	3.21e-07	-0.45	-0.4	Endometriosis;Longevity;	chr7:1065594	chr7:1160374~1165267:+
OV	cis	rs9813712	0.548	rs9880123	ENSG00000228252.7	COL6A4P2	-6.67	1.91e-10	3.21e-07	-0.47	-0.4	Response to amphetamines;	chr3:130215275	chr3:130212823~130273806:+
OV	cis	rs2153535	0.58	rs7761937	ENSG00000230939.1	RP11-314C16.1	-6.67	1.91e-10	3.22e-07	-0.45	-0.4	Motion sickness;	chr6:8459201	chr6:8784178~8785445:+
OV	cis	rs1061377	1	rs35116118	ENSG00000249207.1	RP11-360F5.1	-6.67	1.91e-10	3.22e-07	-0.43	-0.4	Uric acid levels;	chr4:39127293	chr4:39112677~39126818:-
OV	cis	rs2243480	1	rs316329	ENSG00000222364.1	RNU6-96P	-6.67	1.92e-10	3.23e-07	-0.62	-0.4	Diabetic kidney disease;	chr7:66143429	chr7:66395191~66395286:+
OV	cis	rs10510102	0.872	rs10887032	ENSG00000276742.1	RP11-500G22.4	-6.67	1.93e-10	3.25e-07	-0.64	-0.4	Breast cancer;	chr10:121955887	chr10:121956782~121957098:+
OV	cis	rs1707322	1	rs946527	ENSG00000280836.1	AL355480.1	-6.67	1.93e-10	3.25e-07	-0.56	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46020298	chr1:45581219~45581321:-
OV	cis	rs6964833	0.554	rs2527366	ENSG00000123965.13	PMS2P5	-6.67	1.94e-10	3.27e-07	-0.55	-0.4	Menarche (age at onset);	chr7:74684615	chr7:74894116~74897835:+
OV	cis	rs11235843	0.853	rs11235925	ENSG00000255928.1	RP11-456I15.2	6.67	1.95e-10	3.28e-07	0.71	0.4	Hand grip strength;	chr11:73841598	chr11:73722349~73722694:+
OV	cis	rs7246967	0.673	rs55638152	ENSG00000269509.1	BNIP3P34	6.67	1.95e-10	3.28e-07	0.6	0.4	Bronchopulmonary dysplasia;	chr19:22872492	chr19:22773853~22774424:+
OV	cis	rs1707322	1	rs34444543	ENSG00000281133.1	AL355480.3	-6.67	1.96e-10	3.29e-07	-0.53	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893190	chr1:45580892~45580996:-
OV	cis	rs2243480	1	rs160639	ENSG00000222364.1	RNU6-96P	-6.67	1.96e-10	3.3e-07	-0.62	-0.4	Diabetic kidney disease;	chr7:66115000	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs313824	ENSG00000222364.1	RNU6-96P	-6.67	1.96e-10	3.3e-07	-0.62	-0.4	Diabetic kidney disease;	chr7:66116220	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs186378	ENSG00000222364.1	RNU6-96P	-6.67	1.96e-10	3.3e-07	-0.62	-0.4	Diabetic kidney disease;	chr7:66117071	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs160637	ENSG00000222364.1	RNU6-96P	-6.67	1.96e-10	3.3e-07	-0.62	-0.4	Diabetic kidney disease;	chr7:66119331	chr7:66395191~66395286:+
OV	cis	rs1707322	0.682	rs3014241	ENSG00000280836.1	AL355480.1	6.67	1.97e-10	3.31e-07	0.58	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr1:45581219~45581321:-
OV	cis	rs3091242	0.933	rs9438904	ENSG00000261349.1	RP3-465N24.5	-6.67	1.97e-10	3.32e-07	-0.45	-0.4	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25266102~25267136:-
OV	cis	rs7927771	0.864	rs755555	ENSG00000280615.1	Y_RNA	-6.67	1.98e-10	3.33e-07	-0.51	-0.4	Subjective well-being;	chr11:47410415	chr11:47614898~47614994:-
OV	cis	rs7927771	0.826	rs2293578	ENSG00000280615.1	Y_RNA	-6.67	1.98e-10	3.33e-07	-0.51	-0.4	Subjective well-being;	chr11:47415852	chr11:47614898~47614994:-
OV	cis	rs1061377	1	rs10030904	ENSG00000249207.1	RP11-360F5.1	-6.67	1.98e-10	3.33e-07	-0.44	-0.4	Uric acid levels;	chr4:39113603	chr4:39112677~39126818:-
OV	cis	rs8062405	0.691	rs11646653	ENSG00000259982.1	CDC37P1	-6.66	1.98e-10	3.34e-07	-0.5	-0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910828	chr16:28700294~28701540:-
OV	cis	rs875971	0.545	rs4441996	ENSG00000222364.1	RNU6-96P	6.66	1.99e-10	3.34e-07	0.47	0.4	Aortic root size;	chr7:66123233	chr7:66395191~66395286:+
OV	cis	rs7044106	0.537	rs10818474	ENSG00000226752.6	PSMD5-AS1	-6.66	1.99e-10	3.34e-07	-0.49	-0.4	Hip circumference adjusted for BMI;	chr9:120727686	chr9:120824828~120854385:+
OV	cis	rs293748	0.882	rs158794	ENSG00000250155.1	CTD-2353F22.1	-6.66	1.99e-10	3.34e-07	-0.61	-0.4	Obesity-related traits;	chr5:36882986	chr5:36666214~36725195:-
OV	cis	rs293748	0.882	rs151946	ENSG00000250155.1	CTD-2353F22.1	-6.66	1.99e-10	3.34e-07	-0.61	-0.4	Obesity-related traits;	chr5:36884064	chr5:36666214~36725195:-
OV	cis	rs293748	0.882	rs158793	ENSG00000250155.1	CTD-2353F22.1	-6.66	1.99e-10	3.34e-07	-0.61	-0.4	Obesity-related traits;	chr5:36884988	chr5:36666214~36725195:-
OV	cis	rs1707322	0.827	rs6683274	ENSG00000280836.1	AL355480.1	-6.66	1.99e-10	3.35e-07	-0.56	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45775966	chr1:45581219~45581321:-
OV	cis	rs1707322	0.785	rs10890348	ENSG00000280836.1	AL355480.1	-6.66	1.99e-10	3.35e-07	-0.56	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776751	chr1:45581219~45581321:-
OV	cis	rs875971	0.545	rs17138149	ENSG00000222364.1	RNU6-96P	-6.66	2e-10	3.35e-07	-0.46	-0.4	Aortic root size;	chr7:66228193	chr7:66395191~66395286:+
OV	cis	rs2153535	0.521	rs6939827	ENSG00000230939.1	RP11-314C16.1	-6.66	2.02e-10	3.39e-07	-0.45	-0.4	Motion sickness;	chr6:8461127	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9393019	ENSG00000230939.1	RP11-314C16.1	-6.66	2.02e-10	3.39e-07	-0.45	-0.4	Motion sickness;	chr6:8461858	chr6:8784178~8785445:+
OV	cis	rs7688540	0.771	rs17164747	ENSG00000275426.1	CH17-262A2.1	6.66	2.05e-10	3.43e-07	0.66	0.4	Facial morphology (factor 6, height of vermillion lower lip);	chr4:266798	chr4:149738~150317:+
OV	cis	rs7688540	0.771	rs79366248	ENSG00000275426.1	CH17-262A2.1	6.66	2.05e-10	3.43e-07	0.66	0.4	Facial morphology (factor 6, height of vermillion lower lip);	chr4:272870	chr4:149738~150317:+
OV	cis	rs17711722	0.51	rs11767457	ENSG00000236529.1	RP13-254B10.1	6.66	2.05e-10	3.44e-07	0.46	0.4	Calcium levels;	chr7:65825628	chr7:65840212~65840596:+
OV	cis	rs1061377	0.965	rs6833654	ENSG00000249207.1	RP11-360F5.1	-6.66	2.05e-10	3.44e-07	-0.44	-0.4	Uric acid levels;	chr4:39110701	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs1036038	ENSG00000249207.1	RP11-360F5.1	-6.66	2.05e-10	3.44e-07	-0.44	-0.4	Uric acid levels;	chr4:39111383	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs1560396	ENSG00000249207.1	RP11-360F5.1	-6.66	2.05e-10	3.44e-07	-0.44	-0.4	Uric acid levels;	chr4:39112092	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs2381285	ENSG00000249207.1	RP11-360F5.1	-6.66	2.05e-10	3.44e-07	-0.44	-0.4	Uric acid levels;	chr4:39112775	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs2163272	ENSG00000249207.1	RP11-360F5.1	-6.66	2.05e-10	3.44e-07	-0.44	-0.4	Uric acid levels;	chr4:39112790	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs2163273	ENSG00000249207.1	RP11-360F5.1	-6.66	2.05e-10	3.44e-07	-0.44	-0.4	Uric acid levels;	chr4:39112835	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs62310332	ENSG00000249207.1	RP11-360F5.1	-6.66	2.05e-10	3.44e-07	-0.44	-0.4	Uric acid levels;	chr4:39112939	chr4:39112677~39126818:-
OV	cis	rs1061377	0.965	rs3796510	ENSG00000249207.1	RP11-360F5.1	-6.66	2.05e-10	3.44e-07	-0.44	-0.4	Uric acid levels;	chr4:39113309	chr4:39112677~39126818:-
OV	cis	rs1061377	0.932	rs6855118	ENSG00000249207.1	RP11-360F5.1	-6.66	2.05e-10	3.44e-07	-0.44	-0.4	Uric acid levels;	chr4:39114322	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs6829234	ENSG00000249207.1	RP11-360F5.1	-6.66	2.05e-10	3.44e-07	-0.44	-0.4	Uric acid levels;	chr4:39114586	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs6812540	ENSG00000249207.1	RP11-360F5.1	-6.66	2.05e-10	3.44e-07	-0.44	-0.4	Uric acid levels;	chr4:39114803	chr4:39112677~39126818:-
OV	cis	rs875971	0.522	rs1617484	ENSG00000226824.5	RP4-756H11.3	-6.66	2.06e-10	3.45e-07	-0.42	-0.4	Aortic root size;	chr7:65998108	chr7:66654538~66669855:+
OV	cis	rs1707322	0.821	rs10749857	ENSG00000281133.1	AL355480.3	-6.66	2.06e-10	3.45e-07	-0.52	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr1:45580892~45580996:-
OV	cis	rs4713118	0.955	rs9468204	ENSG00000220721.1	OR1F12	6.66	2.08e-10	3.48e-07	0.45	0.4	Parkinson's disease;	chr6:27721030	chr6:28073316~28074233:+
OV	cis	rs17711722	0.653	rs2460421	ENSG00000226824.5	RP4-756H11.3	6.66	2.08e-10	3.49e-07	0.43	0.4	Calcium levels;	chr7:66026136	chr7:66654538~66669855:+
OV	cis	rs1707322	0.789	rs10789473	ENSG00000280836.1	AL355480.1	-6.66	2.1e-10	3.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782459	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs785465	ENSG00000281133.1	AL355480.3	-6.65	2.1e-10	3.51e-07	-0.52	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46056905	chr1:45580892~45580996:-
OV	cis	rs1707322	0.752	rs28623463	ENSG00000280836.1	AL355480.1	-6.65	2.11e-10	3.53e-07	-0.57	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr1:45581219~45581321:-
OV	cis	rs4591358	0.53	rs72927723	ENSG00000223466.1	AC064834.2	-6.65	2.12e-10	3.55e-07	-0.62	-0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195522498	chr2:195533035~195538681:+
OV	cis	rs6921919	0.609	rs67211468	ENSG00000216901.1	AL022393.7	6.65	2.13e-10	3.55e-07	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28176188~28176674:+
OV	cis	rs7246967	0.932	rs34622638	ENSG00000269509.1	BNIP3P34	6.65	2.13e-10	3.56e-07	0.62	0.4	Bronchopulmonary dysplasia;	chr19:22880850	chr19:22773853~22774424:+
OV	cis	rs2412819	0.545	rs17795279	ENSG00000249839.1	AC011330.5	6.65	2.14e-10	3.58e-07	0.57	0.4	Lung cancer;	chr15:43637180	chr15:43663654~43684339:-
OV	cis	rs875971	0.528	rs801213	ENSG00000222364.1	RNU6-96P	6.65	2.14e-10	3.58e-07	0.47	0.4	Aortic root size;	chr7:66549931	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs801212	ENSG00000222364.1	RNU6-96P	6.65	2.14e-10	3.58e-07	0.47	0.4	Aortic root size;	chr7:66550643	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs73152714	ENSG00000222364.1	RNU6-96P	-6.65	2.14e-10	3.58e-07	-0.47	-0.4	Aortic root size;	chr7:66534641	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs4718364	ENSG00000222364.1	RNU6-96P	-6.65	2.14e-10	3.58e-07	-0.47	-0.4	Aortic root size;	chr7:66536353	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs6961853	ENSG00000222364.1	RNU6-96P	-6.65	2.14e-10	3.58e-07	-0.47	-0.4	Aortic root size;	chr7:66537035	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs6970498	ENSG00000222364.1	RNU6-96P	-6.65	2.15e-10	3.58e-07	-0.47	-0.4	Aortic root size;	chr7:66275908	chr7:66395191~66395286:+
OV	cis	rs1707322	0.964	rs7546237	ENSG00000280836.1	AL355480.1	-6.65	2.15e-10	3.58e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45819938	chr1:45581219~45581321:-
OV	cis	rs1707322	0.964	rs6697830	ENSG00000280836.1	AL355480.1	-6.65	2.15e-10	3.58e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45824805	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs12060274	ENSG00000280836.1	AL355480.1	-6.65	2.15e-10	3.58e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825390	chr1:45581219~45581321:-
OV	cis	rs1707322	0.963	rs11211202	ENSG00000280836.1	AL355480.1	-6.65	2.15e-10	3.58e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45826710	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs4660889	ENSG00000280836.1	AL355480.1	-6.65	2.15e-10	3.58e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45831659	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs10890353	ENSG00000280836.1	AL355480.1	-6.65	2.15e-10	3.58e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45832711	chr1:45581219~45581321:-
OV	cis	rs2836974	0.644	rs2836982	ENSG00000232608.1	TIMM9P2	6.65	2.15e-10	3.59e-07	0.43	0.4	Cognitive function;	chr21:39317245	chr21:39216624~39217506:+
OV	cis	rs1707322	0.717	rs1135812	ENSG00000280836.1	AL355480.1	-6.65	2.15e-10	3.59e-07	-0.57	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45629600	chr1:45581219~45581321:-
OV	cis	rs1707322	0.752	rs6703748	ENSG00000280836.1	AL355480.1	-6.65	2.15e-10	3.59e-07	-0.57	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45630304	chr1:45581219~45581321:-
OV	cis	rs2243480	1	rs316331	ENSG00000222364.1	RNU6-96P	6.65	2.16e-10	3.6e-07	0.61	0.4	Diabetic kidney disease;	chr7:66139635	chr7:66395191~66395286:+
OV	cis	rs2836974	0.644	rs1882779	ENSG00000232608.1	TIMM9P2	6.65	2.16e-10	3.61e-07	0.44	0.4	Cognitive function;	chr21:39319012	chr21:39216624~39217506:+
OV	cis	rs950169	0.579	rs11633088	ENSG00000235370.6	DNM1P51	-6.65	2.17e-10	3.62e-07	-0.58	-0.4	Schizophrenia;	chr15:84003429	chr15:84398316~84411701:-
OV	cis	rs2243480	1	rs2243480	ENSG00000222364.1	RNU6-96P	-6.65	2.19e-10	3.65e-07	-0.61	-0.4	Diabetic kidney disease;	chr7:66134209	chr7:66395191~66395286:+
OV	cis	rs73086581	0.891	rs11907503	ENSG00000229539.1	RP11-119B16.2	6.65	2.19e-10	3.65e-07	0.51	0.4	Response to antidepressants in depression;	chr20:3906943	chr20:3888239~3888868:-
OV	cis	rs2243480	1	rs4718334	ENSG00000222364.1	RNU6-96P	6.65	2.21e-10	3.69e-07	0.63	0.4	Diabetic kidney disease;	chr7:66324467	chr7:66395191~66395286:+
OV	cis	rs1707322	0.721	rs10890346	ENSG00000280836.1	AL355480.1	6.65	2.22e-10	3.7e-07	0.56	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45581219~45581321:-
OV	cis	rs7246967	0.932	rs62120788	ENSG00000269509.1	BNIP3P34	6.65	2.22e-10	3.7e-07	0.6	0.4	Bronchopulmonary dysplasia;	chr19:22868210	chr19:22773853~22774424:+
OV	cis	rs7246967	0.932	rs4932799	ENSG00000269509.1	BNIP3P34	6.65	2.22e-10	3.7e-07	0.6	0.4	Bronchopulmonary dysplasia;	chr19:22868779	chr19:22773853~22774424:+
OV	cis	rs172166	0.694	rs188105	ENSG00000220721.1	OR1F12	6.64	2.23e-10	3.71e-07	0.44	0.4	Cardiac Troponin-T levels;	chr6:28103615	chr6:28073316~28074233:+
OV	cis	rs6991838	0.55	rs4737750	ENSG00000272010.1	CTD-3025N20.3	6.64	2.23e-10	3.72e-07	0.52	0.4	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65591850~65592472:-
OV	cis	rs7829975	0.659	rs4382480	ENSG00000253981.4	ALG1L13P	6.64	2.23e-10	3.72e-07	0.41	0.4	Mood instability;	chr8:8863963	chr8:8236003~8244667:-
OV	cis	rs2153535	0.546	rs9378559	ENSG00000230939.1	RP11-314C16.1	-6.64	2.23e-10	3.72e-07	-0.46	-0.4	Motion sickness;	chr6:8538825	chr6:8784178~8785445:+
OV	cis	rs3091242	0.933	rs35530120	ENSG00000261349.1	RP3-465N24.5	6.64	2.24e-10	3.74e-07	0.43	0.4	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25266102~25267136:-
OV	cis	rs2243480	1	rs6958289	ENSG00000222364.1	RNU6-96P	6.64	2.25e-10	3.75e-07	0.64	0.4	Diabetic kidney disease;	chr7:66192124	chr7:66395191~66395286:+
OV	cis	rs7017914	0.934	rs3110239	ENSG00000223220.1	Y_RNA	6.64	2.25e-10	3.75e-07	0.42	0.4	Bone mineral density;	chr8:71004510	chr8:70780914~70781008:-
OV	cis	rs3136516	0.537	rs752848	ENSG00000271350.1	CTD-2384B9.1	-6.64	2.26e-10	3.76e-07	-0.45	-0.4	Venous thromboembolism;	chr11:47153625	chr11:47041027~47041945:-
OV	cis	rs1061377	1	rs1036037	ENSG00000249207.1	RP11-360F5.1	-6.64	2.28e-10	3.79e-07	-0.44	-0.4	Uric acid levels;	chr4:39111272	chr4:39112677~39126818:-
OV	cis	rs3091242	0.902	rs36003018	ENSG00000261349.1	RP3-465N24.5	6.64	2.28e-10	3.79e-07	0.43	0.4	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25266102~25267136:-
OV	cis	rs3091242	0.933	rs35403885	ENSG00000261349.1	RP3-465N24.5	6.64	2.28e-10	3.79e-07	0.43	0.4	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25266102~25267136:-
OV	cis	rs1061377	1	rs9990742	ENSG00000249207.1	RP11-360F5.1	-6.64	2.29e-10	3.81e-07	-0.44	-0.4	Uric acid levels;	chr4:39119794	chr4:39112677~39126818:-
OV	cis	rs875971	0.545	rs1796222	ENSG00000222364.1	RNU6-96P	6.64	2.29e-10	3.81e-07	0.48	0.4	Aortic root size;	chr7:66592167	chr7:66395191~66395286:+
OV	cis	rs7017914	0.967	rs3098867	ENSG00000223220.1	Y_RNA	6.64	2.29e-10	3.81e-07	0.42	0.4	Bone mineral density;	chr8:71004636	chr8:70780914~70781008:-
OV	cis	rs7017914	0.934	rs2639904	ENSG00000223220.1	Y_RNA	6.64	2.29e-10	3.81e-07	0.42	0.4	Bone mineral density;	chr8:71004895	chr8:70780914~70781008:-
OV	cis	rs7017914	0.967	rs2639901	ENSG00000223220.1	Y_RNA	6.64	2.29e-10	3.81e-07	0.42	0.4	Bone mineral density;	chr8:71005516	chr8:70780914~70781008:-
OV	cis	rs6921919	0.583	rs2027361	ENSG00000216901.1	AL022393.7	6.64	2.29e-10	3.81e-07	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs4642462	ENSG00000216901.1	AL022393.7	6.64	2.29e-10	3.81e-07	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs3800328	ENSG00000216901.1	AL022393.7	6.64	2.29e-10	3.81e-07	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs35560946	ENSG00000216901.1	AL022393.7	6.64	2.29e-10	3.81e-07	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28176188~28176674:+
OV	cis	rs875971	0.545	rs2420612	ENSG00000222364.1	RNU6-96P	-6.64	2.3e-10	3.82e-07	-0.47	-0.4	Aortic root size;	chr7:66536825	chr7:66395191~66395286:+
OV	cis	rs2153535	0.58	rs1034272	ENSG00000230939.1	RP11-314C16.1	-6.64	2.3e-10	3.82e-07	-0.45	-0.4	Motion sickness;	chr6:8469102	chr6:8784178~8785445:+
OV	cis	rs2243480	1	rs316307	ENSG00000222364.1	RNU6-96P	-6.64	2.3e-10	3.82e-07	-0.62	-0.4	Diabetic kidney disease;	chr7:66105184	chr7:66395191~66395286:+
OV	cis	rs2243480	0.908	rs313822	ENSG00000222364.1	RNU6-96P	-6.64	2.3e-10	3.82e-07	-0.62	-0.4	Diabetic kidney disease;	chr7:66108952	chr7:66395191~66395286:+
OV	cis	rs8005677	1	rs1956880	ENSG00000257285.4	RP11-298I3.1	6.64	2.31e-10	3.83e-07	0.47	0.4	Cognitive ability (multi-trait analysis);	chr14:22924798	chr14:22929609~22955562:+
OV	cis	rs293748	0.882	rs13177875	ENSG00000250155.1	CTD-2353F22.1	-6.64	2.31e-10	3.83e-07	-0.6	-0.4	Obesity-related traits;	chr5:37078226	chr5:36666214~36725195:-
OV	cis	rs4563143	0.663	rs2218396	ENSG00000267243.4	AC005307.3	-6.64	2.32e-10	3.86e-07	-0.61	-0.4	Methadone dose in opioid dependence;	chr19:28745485	chr19:28435388~28727777:-
OV	cis	rs9813712	0.571	rs11715351	ENSG00000228252.7	COL6A4P2	-6.64	2.33e-10	3.86e-07	-0.46	-0.4	Response to amphetamines;	chr3:130214704	chr3:130212823~130273806:+
OV	cis	rs7605378	0.528	rs1704190	ENSG00000232732.8	AC073043.1	-6.64	2.33e-10	3.87e-07	-0.5	-0.4	Osteoporosis;	chr2:199895906	chr2:199867396~199911159:-
OV	cis	rs10256972	0.933	rs35696159	ENSG00000229043.2	AC091729.9	-6.64	2.34e-10	3.89e-07	-0.45	-0.4	Endometriosis;Longevity;	chr7:1007558	chr7:1160374~1165267:+
OV	cis	rs11168854	0.93	rs10783302	ENSG00000258017.1	RP11-386G11.10	6.64	2.35e-10	3.89e-07	0.48	0.4	Body mass index;	chr12:49104347	chr12:49127782~49147869:+
OV	cis	rs2243480	1	rs313820	ENSG00000222364.1	RNU6-96P	-6.64	2.35e-10	3.9e-07	-0.62	-0.4	Diabetic kidney disease;	chr7:66109479	chr7:66395191~66395286:+
OV	cis	rs934734	0.532	rs6752053	ENSG00000234255.7	AC012370.3	-6.64	2.35e-10	3.9e-07	-0.44	-0.4	Rheumatoid arthritis;	chr2:65439540	chr2:65439888~65456571:-
OV	cis	rs73086581	0.68	rs11908158	ENSG00000229539.1	RP11-119B16.2	6.63	2.35e-10	3.9e-07	0.51	0.4	Response to antidepressants in depression;	chr20:3956025	chr20:3888239~3888868:-
OV	cis	rs853679	0.517	rs2273564	ENSG00000219392.1	RP1-265C24.5	-6.63	2.37e-10	3.92e-07	-0.49	-0.4	Depression;	chr6:28089816	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs1853097	ENSG00000219392.1	RP1-265C24.5	-6.63	2.37e-10	3.92e-07	-0.49	-0.4	Depression;	chr6:28090857	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9393887	ENSG00000219392.1	RP1-265C24.5	-6.63	2.37e-10	3.92e-07	-0.49	-0.4	Depression;	chr6:28091242	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9393888	ENSG00000219392.1	RP1-265C24.5	-6.63	2.37e-10	3.92e-07	-0.49	-0.4	Depression;	chr6:28091439	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs3734573	ENSG00000219392.1	RP1-265C24.5	-6.63	2.37e-10	3.92e-07	-0.49	-0.4	Depression;	chr6:28091659	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9368551	ENSG00000219392.1	RP1-265C24.5	-6.63	2.37e-10	3.92e-07	-0.49	-0.4	Depression;	chr6:28094014	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9393890	ENSG00000219392.1	RP1-265C24.5	-6.63	2.37e-10	3.92e-07	-0.49	-0.4	Depression;	chr6:28096077	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9366715	ENSG00000219392.1	RP1-265C24.5	-6.63	2.37e-10	3.92e-07	-0.49	-0.4	Depression;	chr6:28096855	chr6:28115628~28116551:+
OV	cis	rs853679	0.598	rs9380054	ENSG00000219392.1	RP1-265C24.5	-6.63	2.37e-10	3.92e-07	-0.49	-0.4	Depression;	chr6:28099759	chr6:28115628~28116551:+
OV	cis	rs4713118	0.547	rs2116981	ENSG00000219392.1	RP1-265C24.5	-6.63	2.37e-10	3.92e-07	-0.49	-0.4	Parkinson's disease;	chr6:28100173	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9368552	ENSG00000219392.1	RP1-265C24.5	-6.63	2.37e-10	3.92e-07	-0.49	-0.4	Depression;	chr6:28100648	chr6:28115628~28116551:+
OV	cis	rs853679	0.542	rs34131763	ENSG00000219392.1	RP1-265C24.5	-6.63	2.37e-10	3.92e-07	-0.49	-0.4	Depression;	chr6:28107222	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs35193936	ENSG00000219392.1	RP1-265C24.5	-6.63	2.37e-10	3.92e-07	-0.49	-0.4	Depression;	chr6:28108492	chr6:28115628~28116551:+
OV	cis	rs6921919	0.525	rs9468361	ENSG00000216901.1	AL022393.7	6.63	2.38e-10	3.93e-07	0.48	0.4	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs7775132	ENSG00000216901.1	AL022393.7	6.63	2.38e-10	3.93e-07	0.48	0.4	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs3734563	ENSG00000216901.1	AL022393.7	6.63	2.38e-10	3.93e-07	0.48	0.4	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28176188~28176674:+
OV	cis	rs6921919	0.583	rs1591913	ENSG00000216901.1	AL022393.7	6.63	2.38e-10	3.93e-07	0.48	0.4	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28176188~28176674:+
OV	cis	rs7688540	0.771	rs74984113	ENSG00000275426.1	CH17-262A2.1	6.63	2.38e-10	3.94e-07	0.65	0.4	Facial morphology (factor 6, height of vermillion lower lip);	chr4:256733	chr4:149738~150317:+
OV	cis	rs2153535	0.58	rs9505454	ENSG00000230939.1	RP11-314C16.1	-6.63	2.4e-10	3.97e-07	-0.45	-0.4	Motion sickness;	chr6:8478299	chr6:8784178~8785445:+
OV	cis	rs1707322	0.686	rs2050376	ENSG00000280836.1	AL355480.1	-6.63	2.4e-10	3.98e-07	-0.54	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45581219~45581321:-
OV	cis	rs2564921	0.73	rs2253675	ENSG00000242142.1	SERBP1P3	-6.63	2.41e-10	3.99e-07	-0.46	-0.4	Height;	chr3:53085518	chr3:53064283~53065091:-
OV	cis	rs8105895	0.935	rs62112918	ENSG00000269742.1	BNIP3P29	6.63	2.42e-10	4e-07	0.67	0.4	Body mass index (change over time);	chr19:22044277	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs62112921	ENSG00000269742.1	BNIP3P29	6.63	2.42e-10	4e-07	0.67	0.4	Body mass index (change over time);	chr19:22044775	chr19:22065828~22066398:-
OV	cis	rs8105895	0.799	rs62112922	ENSG00000269742.1	BNIP3P29	6.63	2.42e-10	4e-07	0.67	0.4	Body mass index (change over time);	chr19:22045538	chr19:22065828~22066398:-
OV	cis	rs950169	0.58	rs11634320	ENSG00000235370.6	DNM1P51	-6.63	2.43e-10	4.01e-07	-0.49	-0.4	Schizophrenia;	chr15:84628952	chr15:84398316~84411701:-
OV	cis	rs858239	0.712	rs200717	ENSG00000230658.1	KLHL7-AS1	6.63	2.43e-10	4.02e-07	0.49	0.4	Cerebrospinal fluid biomarker levels;	chr7:23352652	chr7:23101228~23105703:-
OV	cis	rs8062405	0.789	rs151174	ENSG00000259982.1	CDC37P1	6.63	2.44e-10	4.04e-07	0.48	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28496748	chr16:28700294~28701540:-
OV	cis	rs6921919	0.525	rs16894095	ENSG00000216901.1	AL022393.7	6.63	2.44e-10	4.04e-07	0.49	0.4	Autism spectrum disorder or schizophrenia;	chr6:28422453	chr6:28176188~28176674:+
OV	cis	rs2153535	0.541	rs9505456	ENSG00000230939.1	RP11-314C16.1	-6.63	2.45e-10	4.05e-07	-0.45	-0.4	Motion sickness;	chr6:8478768	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9505458	ENSG00000230939.1	RP11-314C16.1	-6.63	2.45e-10	4.05e-07	-0.45	-0.4	Motion sickness;	chr6:8478982	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs9379215	ENSG00000230939.1	RP11-314C16.1	-6.63	2.45e-10	4.05e-07	-0.45	-0.4	Motion sickness;	chr6:8480992	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1832101	ENSG00000230939.1	RP11-314C16.1	-6.63	2.46e-10	4.07e-07	-0.45	-0.4	Motion sickness;	chr6:8459944	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1119690	ENSG00000230939.1	RP11-314C16.1	-6.63	2.46e-10	4.07e-07	-0.45	-0.4	Motion sickness;	chr6:8460427	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1119689	ENSG00000230939.1	RP11-314C16.1	-6.63	2.46e-10	4.07e-07	-0.45	-0.4	Motion sickness;	chr6:8460521	chr6:8784178~8785445:+
OV	cis	rs6921919	0.583	rs2071965	ENSG00000216901.1	AL022393.7	6.63	2.47e-10	4.07e-07	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28176188~28176674:+
OV	cis	rs2564921	0.704	rs62253606	ENSG00000242142.1	SERBP1P3	-6.63	2.49e-10	4.1e-07	-0.47	-0.4	Height;	chr3:52949886	chr3:53064283~53065091:-
OV	cis	rs6991838	0.584	rs10089708	ENSG00000272010.1	CTD-3025N20.3	6.62	2.49e-10	4.11e-07	0.52	0.4	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65591850~65592472:-
OV	cis	rs6991838	0.584	rs6991731	ENSG00000272010.1	CTD-3025N20.3	6.62	2.49e-10	4.11e-07	0.52	0.4	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65591850~65592472:-
OV	cis	rs10256972	0.869	rs4720158	ENSG00000229043.2	AC091729.9	-6.62	2.51e-10	4.13e-07	-0.45	-0.4	Endometriosis;Longevity;	chr7:1000689	chr7:1160374~1165267:+
OV	cis	rs1707322	1	rs11211190	ENSG00000280836.1	AL355480.1	-6.62	2.55e-10	4.2e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45800583	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs6429580	ENSG00000280836.1	AL355480.1	-6.62	2.55e-10	4.2e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45809976	chr1:45581219~45581321:-
OV	cis	rs875971	0.545	rs10261710	ENSG00000222364.1	RNU6-96P	-6.62	2.6e-10	4.27e-07	-0.48	-0.4	Aortic root size;	chr7:66249202	chr7:66395191~66395286:+
OV	cis	rs7017914	0.934	rs2732092	ENSG00000223220.1	Y_RNA	6.62	2.6e-10	4.28e-07	0.42	0.4	Bone mineral density;	chr8:71006364	chr8:70780914~70781008:-
OV	cis	rs2153535	0.58	rs2143357	ENSG00000230939.1	RP11-314C16.1	-6.62	2.6e-10	4.28e-07	-0.45	-0.4	Motion sickness;	chr6:8496963	chr6:8784178~8785445:+
OV	cis	rs1707322	1	rs10890355	ENSG00000280836.1	AL355480.1	-6.62	2.61e-10	4.28e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45851676	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs11211204	ENSG00000280836.1	AL355480.1	-6.62	2.61e-10	4.28e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45852192	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs7547189	ENSG00000280836.1	AL355480.1	-6.62	2.61e-10	4.28e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853842	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs7547284	ENSG00000280836.1	AL355480.1	-6.62	2.61e-10	4.28e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853893	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs11211205	ENSG00000280836.1	AL355480.1	-6.62	2.61e-10	4.28e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45856202	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs4660895	ENSG00000280836.1	AL355480.1	-6.62	2.61e-10	4.28e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864067	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs10158032	ENSG00000280836.1	AL355480.1	-6.62	2.61e-10	4.28e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867029	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs4660318	ENSG00000280836.1	AL355480.1	-6.62	2.61e-10	4.28e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45869204	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs10890360	ENSG00000280836.1	AL355480.1	-6.62	2.61e-10	4.28e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45872772	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs6682683	ENSG00000280836.1	AL355480.1	-6.62	2.61e-10	4.28e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45876665	chr1:45581219~45581321:-
OV	cis	rs227275	0.556	rs7676765	ENSG00000246560.2	RP11-10L12.4	-6.62	2.61e-10	4.28e-07	-0.48	-0.4	Allergic disease (asthma, hay fever or eczema);	chr4:103016776	chr4:102828055~102844075:+
OV	cis	rs2153535	0.601	rs1737581	ENSG00000230939.1	RP11-314C16.1	-6.62	2.61e-10	4.29e-07	-0.46	-0.4	Motion sickness;	chr6:8538905	chr6:8784178~8785445:+
OV	cis	rs853679	0.517	rs36078605	ENSG00000219392.1	RP1-265C24.5	-6.62	2.62e-10	4.3e-07	-0.49	-0.4	Depression;	chr6:28110254	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9393891	ENSG00000219392.1	RP1-265C24.5	-6.62	2.62e-10	4.3e-07	-0.49	-0.4	Depression;	chr6:28111382	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9468286	ENSG00000219392.1	RP1-265C24.5	-6.62	2.62e-10	4.3e-07	-0.49	-0.4	Depression;	chr6:28111650	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9380055	ENSG00000219392.1	RP1-265C24.5	-6.62	2.62e-10	4.3e-07	-0.49	-0.4	Depression;	chr6:28113851	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9368553	ENSG00000219392.1	RP1-265C24.5	-6.62	2.62e-10	4.3e-07	-0.49	-0.4	Depression;	chr6:28114487	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9368554	ENSG00000219392.1	RP1-265C24.5	-6.62	2.62e-10	4.3e-07	-0.49	-0.4	Depression;	chr6:28114933	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs4713137	ENSG00000219392.1	RP1-265C24.5	-6.62	2.62e-10	4.3e-07	-0.49	-0.4	Depression;	chr6:28115743	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9348793	ENSG00000219392.1	RP1-265C24.5	-6.62	2.62e-10	4.3e-07	-0.49	-0.4	Depression;	chr6:28116411	chr6:28115628~28116551:+
OV	cis	rs4713118	0.586	rs6905516	ENSG00000219392.1	RP1-265C24.5	-6.62	2.62e-10	4.3e-07	-0.49	-0.4	Parkinson's disease;	chr6:28118700	chr6:28115628~28116551:+
OV	cis	rs4713118	0.586	rs6905522	ENSG00000219392.1	RP1-265C24.5	-6.62	2.62e-10	4.3e-07	-0.49	-0.4	Parkinson's disease;	chr6:28118701	chr6:28115628~28116551:+
OV	cis	rs4713118	0.586	rs9468290	ENSG00000219392.1	RP1-265C24.5	-6.62	2.62e-10	4.3e-07	-0.49	-0.4	Parkinson's disease;	chr6:28119896	chr6:28115628~28116551:+
OV	cis	rs73086581	1	rs6107386	ENSG00000229539.1	RP11-119B16.2	6.62	2.63e-10	4.32e-07	0.52	0.4	Response to antidepressants in depression;	chr20:3992109	chr20:3888239~3888868:-
OV	cis	rs875971	0.502	rs6460311	ENSG00000222364.1	RNU6-96P	6.62	2.63e-10	4.32e-07	0.48	0.4	Aortic root size;	chr7:66646886	chr7:66395191~66395286:+
OV	cis	rs853679	0.517	rs4713135	ENSG00000219392.1	RP1-265C24.5	-6.61	2.64e-10	4.34e-07	-0.49	-0.4	Depression;	chr6:28071808	chr6:28115628~28116551:+
OV	cis	rs1707322	1	rs11211217	ENSG00000280836.1	AL355480.1	-6.61	2.66e-10	4.36e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45882557	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs7553924	ENSG00000280836.1	AL355480.1	-6.61	2.66e-10	4.36e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886952	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs4641257	ENSG00000280836.1	AL355480.1	-6.61	2.66e-10	4.36e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45887917	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs6693336	ENSG00000280836.1	AL355480.1	-6.61	2.66e-10	4.36e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45888923	chr1:45581219~45581321:-
OV	cis	rs7246967	0.932	rs4932800	ENSG00000269509.1	BNIP3P34	6.61	2.68e-10	4.39e-07	0.6	0.4	Bronchopulmonary dysplasia;	chr19:22868846	chr19:22773853~22774424:+
OV	cis	rs7246967	0.932	rs4932801	ENSG00000269509.1	BNIP3P34	6.61	2.68e-10	4.39e-07	0.6	0.4	Bronchopulmonary dysplasia;	chr19:22868851	chr19:22773853~22774424:+
OV	cis	rs2404602	0.622	rs1567671	ENSG00000259422.1	RP11-593F23.1	-6.61	2.68e-10	4.4e-07	-0.5	-0.4	Blood metabolite levels;	chr15:76916859	chr15:76174891~76181486:-
OV	cis	rs7044106	0.708	rs2416760	ENSG00000226752.6	PSMD5-AS1	-6.61	2.69e-10	4.41e-07	-0.47	-0.4	Hip circumference adjusted for BMI;	chr9:120612361	chr9:120824828~120854385:+
OV	cis	rs8062405	0.824	rs240702	ENSG00000259982.1	CDC37P1	6.61	2.72e-10	4.46e-07	0.48	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28700294~28701540:-
OV	cis	rs150992	0.609	rs366000	ENSG00000248489.1	CTD-2007H13.3	-6.61	2.77e-10	4.53e-07	-0.5	-0.4	Body mass index;	chr5:98991705	chr5:98929171~98995013:+
OV	cis	rs150992	0.632	rs162341	ENSG00000248489.1	CTD-2007H13.3	6.61	2.78e-10	4.54e-07	0.5	0.4	Body mass index;	chr5:98967230	chr5:98929171~98995013:+
OV	cis	rs73086581	0.945	rs6052222	ENSG00000229539.1	RP11-119B16.2	6.6	2.79e-10	4.57e-07	0.52	0.4	Response to antidepressants in depression;	chr20:3992146	chr20:3888239~3888868:-
OV	cis	rs11235843	0.853	rs11235922	ENSG00000255928.1	RP11-456I15.2	6.6	2.81e-10	4.6e-07	0.7	0.4	Hand grip strength;	chr11:73825653	chr11:73722349~73722694:+
OV	cis	rs2243480	1	rs958550	ENSG00000222364.1	RNU6-96P	6.6	2.83e-10	4.62e-07	0.62	0.4	Diabetic kidney disease;	chr7:66170692	chr7:66395191~66395286:+
OV	cis	rs7688540	0.771	rs78343340	ENSG00000275426.1	CH17-262A2.1	6.6	2.83e-10	4.62e-07	0.66	0.4	Facial morphology (factor 6, height of vermillion lower lip);	chr4:273648	chr4:149738~150317:+
OV	cis	rs1707322	1	rs4660906	ENSG00000280836.1	AL355480.1	-6.6	2.83e-10	4.63e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46005188	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs3922887	ENSG00000280836.1	AL355480.1	-6.6	2.83e-10	4.63e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008130	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs3922886	ENSG00000280836.1	AL355480.1	-6.6	2.83e-10	4.63e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46008230	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs11211248	ENSG00000280836.1	AL355480.1	-6.6	2.83e-10	4.63e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46011172	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs7532204	ENSG00000280836.1	AL355480.1	6.6	2.83e-10	4.63e-07	0.55	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019403	chr1:45581219~45581321:-
OV	cis	rs1707322	0.835	rs946525	ENSG00000280836.1	AL355480.1	6.6	2.83e-10	4.63e-07	0.55	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021605	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs946524	ENSG00000280836.1	AL355480.1	6.6	2.83e-10	4.63e-07	0.55	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46021888	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs4660336	ENSG00000280836.1	AL355480.1	6.6	2.83e-10	4.63e-07	0.55	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46022304	chr1:45581219~45581321:-
OV	cis	rs2836974	0.583	rs2410124	ENSG00000232608.1	TIMM9P2	6.6	2.84e-10	4.63e-07	0.44	0.4	Cognitive function;	chr21:39332834	chr21:39216624~39217506:+
OV	cis	rs2836974	0.583	rs9636957	ENSG00000232608.1	TIMM9P2	6.6	2.84e-10	4.63e-07	0.44	0.4	Cognitive function;	chr21:39333921	chr21:39216624~39217506:+
OV	cis	rs2836974	0.602	rs8130854	ENSG00000232608.1	TIMM9P2	6.6	2.84e-10	4.63e-07	0.44	0.4	Cognitive function;	chr21:39335115	chr21:39216624~39217506:+
OV	cis	rs6921919	0.806	rs213230	ENSG00000216901.1	AL022393.7	6.6	2.85e-10	4.65e-07	0.54	0.4	Autism spectrum disorder or schizophrenia;	chr6:28362487	chr6:28176188~28176674:+
OV	cis	rs7927771	0.832	rs11601173	ENSG00000280615.1	Y_RNA	-6.6	2.86e-10	4.67e-07	-0.49	-0.4	Subjective well-being;	chr11:47379507	chr11:47614898~47614994:-
OV	cis	rs7927771	0.832	rs11607981	ENSG00000280615.1	Y_RNA	-6.6	2.86e-10	4.67e-07	-0.49	-0.4	Subjective well-being;	chr11:47379509	chr11:47614898~47614994:-
OV	cis	rs7927771	0.832	rs11601603	ENSG00000280615.1	Y_RNA	-6.6	2.86e-10	4.67e-07	-0.49	-0.4	Subjective well-being;	chr11:47379620	chr11:47614898~47614994:-
OV	cis	rs9326248	0.581	rs10892048	ENSG00000254851.1	RP11-109L13.1	-6.6	2.86e-10	4.68e-07	-0.47	-0.4	Blood protein levels;	chr11:116943880	chr11:117135528~117138582:+
OV	cis	rs6452524	0.711	rs1478486	ENSG00000249664.1	CTD-2227C6.2	6.6	2.87e-10	4.69e-07	0.45	0.4	Hypertension (SNP x SNP interaction);	chr5:83081185	chr5:83012285~83013109:-
OV	cis	rs2153535	0.58	rs1932283	ENSG00000230939.1	RP11-314C16.1	-6.6	2.89e-10	4.72e-07	-0.45	-0.4	Motion sickness;	chr6:8477428	chr6:8784178~8785445:+
OV	cis	rs10510102	0.872	rs7906462	ENSG00000276742.1	RP11-500G22.4	6.6	2.9e-10	4.73e-07	0.64	0.4	Breast cancer;	chr10:121948098	chr10:121956782~121957098:+
OV	cis	rs6921919	0.583	rs7740351	ENSG00000216901.1	AL022393.7	6.6	2.9e-10	4.74e-07	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28176188~28176674:+
OV	cis	rs853679	0.55	rs1233707	ENSG00000220721.1	OR1F12	6.6	2.91e-10	4.75e-07	0.46	0.4	Depression;	chr6:28205175	chr6:28073316~28074233:+
OV	cis	rs2404602	0.647	rs7181506	ENSG00000259422.1	RP11-593F23.1	6.6	2.92e-10	4.75e-07	0.47	0.4	Blood metabolite levels;	chr15:76643336	chr15:76174891~76181486:-
OV	cis	rs11235843	0.929	rs11235864	ENSG00000255928.1	RP11-456I15.2	-6.6	2.92e-10	4.76e-07	-0.62	-0.4	Hand grip strength;	chr11:73697227	chr11:73722349~73722694:+
OV	cis	rs11690935	0.788	rs6715929	ENSG00000228389.1	AC068039.4	6.6	2.92e-10	4.77e-07	0.45	0.4	Schizophrenia;	chr2:172012600	chr2:171773482~171775844:+
OV	cis	rs2243480	1	rs10807702	ENSG00000222364.1	RNU6-96P	-6.6	2.93e-10	4.77e-07	-0.64	-0.4	Diabetic kidney disease;	chr7:66302856	chr7:66395191~66395286:+
OV	cis	rs1707322	1	rs10890375	ENSG00000280836.1	AL355480.1	-6.6	2.93e-10	4.77e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940909	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs10890377	ENSG00000280836.1	AL355480.1	-6.6	2.93e-10	4.77e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940922	chr1:45581219~45581321:-
OV	cis	rs853679	0.55	rs1233704	ENSG00000220721.1	OR1F12	-6.6	2.95e-10	4.8e-07	-0.49	-0.4	Depression;	chr6:28199145	chr6:28073316~28074233:+
OV	cis	rs4563143	0.663	rs10417671	ENSG00000267243.4	AC005307.3	-6.59	2.96e-10	4.82e-07	-0.61	-0.4	Methadone dose in opioid dependence;	chr19:28744428	chr19:28435388~28727777:-
OV	cis	rs2153535	0.58	rs4365970	ENSG00000230939.1	RP11-314C16.1	6.59	3e-10	4.88e-07	0.45	0.4	Motion sickness;	chr6:8453580	chr6:8784178~8785445:+
OV	cis	rs8005677	1	rs8006409	ENSG00000257285.4	RP11-298I3.1	6.59	3.01e-10	4.9e-07	0.47	0.4	Cognitive ability (multi-trait analysis);	chr14:22927302	chr14:22929609~22955562:+
OV	cis	rs2243480	1	rs2707844	ENSG00000222364.1	RNU6-96P	-6.59	3.03e-10	4.93e-07	-0.64	-0.4	Diabetic kidney disease;	chr7:66594522	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs1796220	ENSG00000222364.1	RNU6-96P	-6.59	3.03e-10	4.93e-07	-0.64	-0.4	Diabetic kidney disease;	chr7:66597113	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs2707831	ENSG00000222364.1	RNU6-96P	-6.59	3.03e-10	4.93e-07	-0.64	-0.4	Diabetic kidney disease;	chr7:66597524	chr7:66395191~66395286:+
OV	cis	rs2836974	0.602	rs2836987	ENSG00000232608.1	TIMM9P2	6.59	3.04e-10	4.94e-07	0.44	0.4	Cognitive function;	chr21:39334668	chr21:39216624~39217506:+
OV	cis	rs9813712	0.571	rs9836814	ENSG00000228252.7	COL6A4P2	6.59	3.04e-10	4.94e-07	0.46	0.4	Response to amphetamines;	chr3:130216054	chr3:130212823~130273806:+
OV	cis	rs9828933	0.832	rs2292662	ENSG00000280620.1	SCAANT1	6.59	3.07e-10	4.98e-07	0.61	0.4	Type 2 diabetes;	chr3:63911539	chr3:63911518~63911772:-
OV	cis	rs11235843	1	rs6590	ENSG00000255928.1	RP11-456I15.2	6.59	3.07e-10	4.99e-07	0.65	0.4	Hand grip strength;	chr11:73662507	chr11:73722349~73722694:+
OV	cis	rs875971	0.545	rs6979636	ENSG00000222364.1	RNU6-96P	-6.59	3.09e-10	5.01e-07	-0.45	-0.4	Aortic root size;	chr7:66276638	chr7:66395191~66395286:+
OV	cis	rs4713118	0.516	rs7739216	ENSG00000219392.1	RP1-265C24.5	-6.59	3.1e-10	5.04e-07	-0.49	-0.4	Parkinson's disease;	chr6:28112168	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs35512245	ENSG00000219392.1	RP1-265C24.5	-6.59	3.1e-10	5.04e-07	-0.49	-0.4	Depression;	chr6:28112175	chr6:28115628~28116551:+
OV	cis	rs73086581	0.735	rs6037730	ENSG00000229539.1	RP11-119B16.2	6.59	3.11e-10	5.05e-07	0.5	0.4	Response to antidepressants in depression;	chr20:4046171	chr20:3888239~3888868:-
OV	cis	rs73086581	0.838	rs6052265	ENSG00000229539.1	RP11-119B16.2	6.59	3.11e-10	5.05e-07	0.5	0.4	Response to antidepressants in depression;	chr20:4046188	chr20:3888239~3888868:-
OV	cis	rs8062405	0.824	rs153106	ENSG00000259982.1	CDC37P1	6.59	3.12e-10	5.06e-07	0.48	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28700294~28701540:-
OV	cis	rs1707322	0.691	rs61784799	ENSG00000280836.1	AL355480.1	6.58	3.12e-10	5.06e-07	0.56	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr1:45581219~45581321:-
OV	cis	rs1707322	0.752	rs28890893	ENSG00000280836.1	AL355480.1	-6.58	3.12e-10	5.06e-07	-0.56	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr1:45581219~45581321:-
OV	cis	rs1707322	0.716	rs28375469	ENSG00000280836.1	AL355480.1	-6.58	3.12e-10	5.06e-07	-0.56	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr1:45581219~45581321:-
OV	cis	rs1707322	0.752	rs28545085	ENSG00000280836.1	AL355480.1	-6.58	3.12e-10	5.06e-07	-0.56	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr1:45581219~45581321:-
OV	cis	rs1707322	0.752	rs28719889	ENSG00000280836.1	AL355480.1	-6.58	3.12e-10	5.06e-07	-0.56	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr1:45581219~45581321:-
OV	cis	rs1707322	0.752	rs28812624	ENSG00000280836.1	AL355480.1	-6.58	3.12e-10	5.06e-07	-0.56	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr1:45581219~45581321:-
OV	cis	rs1707322	0.752	rs28507722	ENSG00000280836.1	AL355480.1	-6.58	3.12e-10	5.06e-07	-0.56	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr1:45581219~45581321:-
OV	cis	rs1707322	0.752	rs28568986	ENSG00000280836.1	AL355480.1	-6.58	3.12e-10	5.06e-07	-0.56	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr1:45581219~45581321:-
OV	cis	rs1707322	0.717	rs28396194	ENSG00000280836.1	AL355480.1	-6.58	3.12e-10	5.06e-07	-0.56	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr1:45581219~45581321:-
OV	cis	rs1707322	0.717	rs28752166	ENSG00000280836.1	AL355480.1	-6.58	3.12e-10	5.06e-07	-0.56	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr1:45581219~45581321:-
OV	cis	rs1707322	0.717	rs10890345	ENSG00000280836.1	AL355480.1	-6.58	3.12e-10	5.06e-07	-0.56	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs10789471	ENSG00000280836.1	AL355480.1	-6.58	3.12e-10	5.06e-07	-0.56	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr1:45581219~45581321:-
OV	cis	rs1707322	0.752	rs11211173	ENSG00000280836.1	AL355480.1	-6.58	3.12e-10	5.06e-07	-0.56	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr1:45581219~45581321:-
OV	cis	rs507080	0.501	rs625735	ENSG00000255422.1	AP002954.4	-6.58	3.14e-10	5.09e-07	-0.45	-0.4	Serum metabolite levels;	chr11:118704710	chr11:118704607~118750263:+
OV	cis	rs2836974	0.644	rs4818017	ENSG00000232608.1	TIMM9P2	6.58	3.16e-10	5.11e-07	0.43	0.4	Cognitive function;	chr21:39318635	chr21:39216624~39217506:+
OV	cis	rs2243480	1	rs1546059	ENSG00000222364.1	RNU6-96P	6.58	3.17e-10	5.13e-07	0.63	0.4	Diabetic kidney disease;	chr7:66189722	chr7:66395191~66395286:+
OV	cis	rs765787	0.53	rs11636410	ENSG00000259520.4	CTD-2651B20.3	-6.58	3.18e-10	5.15e-07	-0.47	-0.4	Uric acid levels;	chr15:45243715	chr15:45251580~45279251:-
OV	cis	rs875971	0.66	rs10263935	ENSG00000236529.1	RP13-254B10.1	6.58	3.19e-10	5.16e-07	0.42	0.4	Aortic root size;	chr7:66631041	chr7:65840212~65840596:+
OV	cis	rs1061377	1	rs9999327	ENSG00000249207.1	RP11-360F5.1	-6.58	3.2e-10	5.17e-07	-0.44	-0.4	Uric acid levels;	chr4:39110111	chr4:39112677~39126818:-
OV	cis	rs11690935	0.851	rs10930502	ENSG00000228389.1	AC068039.4	6.58	3.2e-10	5.17e-07	0.46	0.4	Schizophrenia;	chr2:172025679	chr2:171773482~171775844:+
OV	cis	rs7927771	1	rs11039426	ENSG00000280615.1	Y_RNA	-6.58	3.23e-10	5.22e-07	-0.49	-0.4	Subjective well-being;	chr11:47841567	chr11:47614898~47614994:-
OV	cis	rs7927771	1	rs12418852	ENSG00000280615.1	Y_RNA	-6.58	3.23e-10	5.22e-07	-0.49	-0.4	Subjective well-being;	chr11:47847301	chr11:47614898~47614994:-
OV	cis	rs4591358	0.689	rs6759817	ENSG00000223466.1	AC064834.2	-6.58	3.24e-10	5.23e-07	-0.57	-0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195553739	chr2:195533035~195538681:+
OV	cis	rs4591358	0.689	rs6434785	ENSG00000223466.1	AC064834.2	-6.58	3.24e-10	5.23e-07	-0.57	-0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195554142	chr2:195533035~195538681:+
OV	cis	rs4591358	0.638	rs16837243	ENSG00000223466.1	AC064834.2	-6.58	3.24e-10	5.23e-07	-0.57	-0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195556458	chr2:195533035~195538681:+
OV	cis	rs2836974	0.605	rs2836971	ENSG00000232608.1	TIMM9P2	6.58	3.24e-10	5.24e-07	0.42	0.4	Cognitive function;	chr21:39280114	chr21:39216624~39217506:+
OV	cis	rs73086581	1	rs6107391	ENSG00000229539.1	RP11-119B16.2	6.58	3.25e-10	5.25e-07	0.51	0.4	Response to antidepressants in depression;	chr20:4002436	chr20:3888239~3888868:-
OV	cis	rs8062405	0.824	rs4788085	ENSG00000259982.1	CDC37P1	6.58	3.27e-10	5.27e-07	0.47	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28700294~28701540:-
OV	cis	rs8062405	0.824	rs28772958	ENSG00000259982.1	CDC37P1	6.58	3.27e-10	5.27e-07	0.47	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28700294~28701540:-
OV	cis	rs11235843	0.853	rs1869433	ENSG00000255928.1	RP11-456I15.2	6.58	3.27e-10	5.27e-07	0.69	0.4	Hand grip strength;	chr11:73828498	chr11:73722349~73722694:+
OV	cis	rs11235843	0.853	rs12365080	ENSG00000255928.1	RP11-456I15.2	6.58	3.27e-10	5.27e-07	0.69	0.4	Hand grip strength;	chr11:73836914	chr11:73722349~73722694:+
OV	cis	rs4563143	0.704	rs16961809	ENSG00000267243.4	AC005307.3	-6.58	3.29e-10	5.3e-07	-0.61	-0.4	Methadone dose in opioid dependence;	chr19:28735392	chr19:28435388~28727777:-
OV	cis	rs4591358	0.638	rs6704955	ENSG00000223466.1	AC064834.2	-6.57	3.31e-10	5.33e-07	-0.57	-0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195559393	chr2:195533035~195538681:+
OV	cis	rs494459	0.838	rs555649	ENSG00000255422.1	AP002954.4	-6.57	3.31e-10	5.33e-07	-0.44	-0.4	Height;	chr11:118781100	chr11:118704607~118750263:+
OV	cis	rs7017914	0.967	rs12675271	ENSG00000223220.1	Y_RNA	6.57	3.32e-10	5.36e-07	0.41	0.4	Bone mineral density;	chr8:70689774	chr8:70780914~70781008:-
OV	cis	rs11723261	0.564	rs60994255	ENSG00000275426.1	CH17-262A2.1	6.57	3.33e-10	5.37e-07	0.69	0.4	Immune response to smallpox vaccine (IL-6);	chr4:77554	chr4:149738~150317:+
OV	cis	rs875971	0.545	rs1638735	ENSG00000222364.1	RNU6-96P	-6.57	3.34e-10	5.39e-07	-0.43	-0.4	Aortic root size;	chr7:66630751	chr7:66395191~66395286:+
OV	cis	rs875971	0.571	rs160647	ENSG00000222364.1	RNU6-96P	6.57	3.37e-10	5.43e-07	0.47	0.4	Aortic root size;	chr7:66089365	chr7:66395191~66395286:+
OV	cis	rs8005677	1	rs11157930	ENSG00000257285.4	RP11-298I3.1	6.57	3.38e-10	5.45e-07	0.48	0.4	Cognitive ability (multi-trait analysis);	chr14:22933962	chr14:22929609~22955562:+
OV	cis	rs8005677	0.962	rs11157931	ENSG00000257285.4	RP11-298I3.1	6.57	3.38e-10	5.45e-07	0.48	0.4	Cognitive ability (multi-trait analysis);	chr14:22933984	chr14:22929609~22955562:+
OV	cis	rs2564921	0.666	rs62253656	ENSG00000242142.1	SERBP1P3	-6.57	3.39e-10	5.45e-07	-0.46	-0.4	Height;	chr3:52989412	chr3:53064283~53065091:-
OV	cis	rs2117029	0.555	rs10747561	ENSG00000258017.1	RP11-386G11.10	-6.57	3.39e-10	5.46e-07	-0.5	-0.4	Intelligence (multi-trait analysis);	chr12:49106726	chr12:49127782~49147869:+
OV	cis	rs10256972	0.9	rs7812072	ENSG00000229043.2	AC091729.9	-6.57	3.41e-10	5.48e-07	-0.46	-0.4	Endometriosis;Longevity;	chr7:1014226	chr7:1160374~1165267:+
OV	cis	rs11235843	0.853	rs4537782	ENSG00000255928.1	RP11-456I15.2	6.57	3.43e-10	5.51e-07	0.69	0.4	Hand grip strength;	chr11:73852846	chr11:73722349~73722694:+
OV	cis	rs1707322	1	rs10890378	ENSG00000280836.1	AL355480.1	6.57	3.44e-10	5.51e-07	0.55	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45944985	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs10890365	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893676	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs11211219	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893806	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs11211222	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45902085	chr1:45581219~45581321:-
OV	cis	rs1707322	0.928	rs7527244	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45903100	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs4524994	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45904591	chr1:45581219~45581321:-
OV	cis	rs1707322	0.963	rs9787412	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45905924	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs4660896	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45906744	chr1:45581219~45581321:-
OV	cis	rs1707322	0.928	rs10732844	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907016	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs12133129	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45907676	chr1:45581219~45581321:-
OV	cis	rs1707322	0.963	rs4553121	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45909581	chr1:45581219~45581321:-
OV	cis	rs1707322	0.963	rs6690652	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45911020	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs6695421	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914535	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs11211223	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45914933	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs6687301	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45917180	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs6657720	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45920597	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs7519181	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45922157	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs7526369	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45924888	chr1:45581219~45581321:-
OV	cis	rs1707322	0.963	rs10890371	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925225	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs10890372	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45925348	chr1:45581219~45581321:-
OV	cis	rs1707322	0.928	rs6681068	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45932710	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs11211228	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934168	chr1:45581219~45581321:-
OV	cis	rs1707322	0.963	rs11211229	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45934845	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs9803784	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45936235	chr1:45581219~45581321:-
OV	cis	rs1707322	0.963	rs12022335	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45937060	chr1:45581219~45581321:-
OV	cis	rs1707322	0.963	rs10789484	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941306	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs7527079	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45947778	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs34446427	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45951983	chr1:45581219~45581321:-
OV	cis	rs1707322	0.963	rs4660900	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45953933	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs4454479	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45957883	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs12077546	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966134	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs12124291	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45966460	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs6671754	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968318	chr1:45581219~45581321:-
OV	cis	rs1707322	0.963	rs6666763	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45970779	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs4489497	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45973026	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs11211235	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45974703	chr1:45581219~45581321:-
OV	cis	rs1707322	0.893	rs9919275	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45975688	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs11211236	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45978095	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs4660328	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45979159	chr1:45581219~45581321:-
OV	cis	rs1707322	0.928	rs61785614	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45980375	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs9793167	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981128	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs11211237	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45981657	chr1:45581219~45581321:-
OV	cis	rs1707322	0.963	rs11211238	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983743	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs10890380	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45983797	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs4460583	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45984246	chr1:45581219~45581321:-
OV	cis	rs1707322	0.963	rs4459051	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45985531	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs11211239	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986275	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs6429588	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45988386	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs11211243	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45989761	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs11211244	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991001	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs4660903	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45991929	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs4660331	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45993111	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs12097799	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45994214	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs6661500	ENSG00000280836.1	AL355480.1	-6.57	3.44e-10	5.51e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45999990	chr1:45581219~45581321:-
OV	cis	rs7615952	0.546	rs16836896	ENSG00000171084.14	FAM86JP	6.57	3.44e-10	5.52e-07	0.63	0.4	Blood pressure (smoking interaction);	chr3:125592418	chr3:125916620~125930024:+
OV	cis	rs2836974	0.605	rs2836988	ENSG00000232608.1	TIMM9P2	6.57	3.45e-10	5.52e-07	0.44	0.4	Cognitive function;	chr21:39336049	chr21:39216624~39217506:+
OV	cis	rs875971	0.545	rs13311962	ENSG00000222364.1	RNU6-96P	6.57	3.45e-10	5.54e-07	0.48	0.4	Aortic root size;	chr7:66603142	chr7:66395191~66395286:+
OV	cis	rs172166	0.611	rs203882	ENSG00000220721.1	OR1F12	6.57	3.46e-10	5.54e-07	0.44	0.4	Cardiac Troponin-T levels;	chr6:28110724	chr6:28073316~28074233:+
OV	cis	rs172166	0.694	rs1770131	ENSG00000220721.1	OR1F12	6.57	3.46e-10	5.54e-07	0.44	0.4	Cardiac Troponin-T levels;	chr6:28118635	chr6:28073316~28074233:+
OV	cis	rs1499614	1	rs1638731	ENSG00000222364.1	RNU6-96P	-6.57	3.46e-10	5.54e-07	-0.64	-0.4	Gout;	chr7:66679692	chr7:66395191~66395286:+
OV	cis	rs1499614	1	rs1882655	ENSG00000222364.1	RNU6-96P	6.57	3.46e-10	5.54e-07	0.64	0.4	Gout;	chr7:66682070	chr7:66395191~66395286:+
OV	cis	rs1499614	0.831	rs3800822	ENSG00000222364.1	RNU6-96P	6.57	3.46e-10	5.54e-07	0.64	0.4	Gout;	chr7:66682162	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs7783889	ENSG00000222364.1	RNU6-96P	-6.57	3.47e-10	5.56e-07	-0.47	-0.4	Aortic root size;	chr7:66283366	chr7:66395191~66395286:+
OV	cis	rs1185460	0.967	rs1786685	ENSG00000271751.1	RP11-110I1.14	-6.57	3.48e-10	5.57e-07	-0.48	-0.4	Coronary artery disease;	chr11:119068246	chr11:119065263~119065677:-
OV	cis	rs1185460	0.967	rs1784302	ENSG00000271751.1	RP11-110I1.14	-6.57	3.48e-10	5.57e-07	-0.48	-0.4	Coronary artery disease;	chr11:119070247	chr11:119065263~119065677:-
OV	cis	rs293748	0.825	rs468022	ENSG00000250155.1	CTD-2353F22.1	-6.57	3.48e-10	5.57e-07	-0.6	-0.4	Obesity-related traits;	chr5:36988150	chr5:36666214~36725195:-
OV	cis	rs9918079	0.56	rs4270584	ENSG00000273133.1	RP11-799M12.2	6.57	3.49e-10	5.58e-07	0.46	0.4	Obesity-related traits;	chr4:15599176	chr4:15563698~15564253:-
OV	cis	rs8062405	0.789	rs2106480	ENSG00000259982.1	CDC37P1	6.57	3.49e-10	5.59e-07	0.47	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28700294~28701540:-
OV	cis	rs7044106	0.791	rs10984995	ENSG00000226752.6	PSMD5-AS1	-6.57	3.49e-10	5.59e-07	-0.47	-0.4	Hip circumference adjusted for BMI;	chr9:120716932	chr9:120824828~120854385:+
OV	cis	rs62355901	0.509	rs10461615	ENSG00000271828.1	CTD-2310F14.1	6.56	3.5e-10	5.59e-07	0.74	0.4	Breast cancer;	chr5:56715913	chr5:56927874~56929573:+
OV	cis	rs4713118	0.955	rs9468203	ENSG00000220721.1	OR1F12	6.56	3.5e-10	5.6e-07	0.43	0.4	Parkinson's disease;	chr6:27720888	chr6:28073316~28074233:+
OV	cis	rs6921919	0.525	rs11760133	ENSG00000216901.1	AL022393.7	6.56	3.51e-10	5.61e-07	0.47	0.4	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28176188~28176674:+
OV	cis	rs7246967	0.932	rs4932798	ENSG00000269509.1	BNIP3P34	6.56	3.52e-10	5.62e-07	0.61	0.4	Bronchopulmonary dysplasia;	chr19:22868705	chr19:22773853~22774424:+
OV	cis	rs7927771	0.832	rs10838704	ENSG00000280615.1	Y_RNA	-6.56	3.54e-10	5.66e-07	-0.5	-0.4	Subjective well-being;	chr11:47403166	chr11:47614898~47614994:-
OV	cis	rs796364	0.625	rs1369843	ENSG00000232732.8	AC073043.1	-6.56	3.55e-10	5.66e-07	-0.55	-0.4	Schizophrenia;	chr2:200223448	chr2:199867396~199911159:-
OV	cis	rs853679	0.542	rs9393892	ENSG00000219392.1	RP1-265C24.5	-6.56	3.56e-10	5.69e-07	-0.49	-0.4	Depression;	chr6:28113616	chr6:28115628~28116551:+
OV	cis	rs875971	0.522	rs1701760	ENSG00000226824.5	RP4-756H11.3	-6.56	3.56e-10	5.69e-07	-0.42	-0.4	Aortic root size;	chr7:66008701	chr7:66654538~66669855:+
OV	cis	rs2153535	0.563	rs1796688	ENSG00000230939.1	RP11-314C16.1	-6.56	3.61e-10	5.75e-07	-0.46	-0.4	Motion sickness;	chr6:8536190	chr6:8784178~8785445:+
OV	cis	rs2153535	0.526	rs1796689	ENSG00000230939.1	RP11-314C16.1	-6.56	3.61e-10	5.75e-07	-0.46	-0.4	Motion sickness;	chr6:8536200	chr6:8784178~8785445:+
OV	cis	rs2153535	0.58	rs1414342	ENSG00000230939.1	RP11-314C16.1	-6.56	3.64e-10	5.8e-07	-0.45	-0.4	Motion sickness;	chr6:8462319	chr6:8784178~8785445:+
OV	cis	rs8062405	0.789	rs240704	ENSG00000259982.1	CDC37P1	6.56	3.64e-10	5.8e-07	0.47	0.4	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28700294~28701540:-
OV	cis	rs11235843	0.715	rs12421900	ENSG00000255928.1	RP11-456I15.2	6.56	3.64e-10	5.8e-07	0.69	0.4	Hand grip strength;	chr11:73840111	chr11:73722349~73722694:+
OV	cis	rs1707322	0.964	rs10890358	ENSG00000280836.1	AL355480.1	-6.56	3.64e-10	5.8e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853353	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs7531911	ENSG00000280836.1	AL355480.1	-6.56	3.64e-10	5.8e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45864751	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs34694458	ENSG00000280836.1	AL355480.1	-6.56	3.64e-10	5.8e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45867024	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs10890359	ENSG00000280836.1	AL355480.1	-6.56	3.64e-10	5.8e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45870963	chr1:45581219~45581321:-
OV	cis	rs2564921	0.73	rs62253602	ENSG00000242142.1	SERBP1P3	-6.56	3.65e-10	5.81e-07	-0.47	-0.4	Height;	chr3:52936861	chr3:53064283~53065091:-
OV	cis	rs2564921	0.704	rs62253603	ENSG00000242142.1	SERBP1P3	-6.56	3.65e-10	5.81e-07	-0.47	-0.4	Height;	chr3:52938846	chr3:53064283~53065091:-
OV	cis	rs2564921	0.704	rs62253604	ENSG00000242142.1	SERBP1P3	-6.56	3.65e-10	5.81e-07	-0.47	-0.4	Height;	chr3:52941053	chr3:53064283~53065091:-
OV	cis	rs3931020	1	rs12410060	ENSG00000272864.1	RP11-17E13.2	-6.56	3.66e-10	5.82e-07	-0.53	-0.4	Resistin levels;	chr1:74780164	chr1:74698769~74699333:-
OV	cis	rs7605378	0.567	rs717915	ENSG00000232732.8	AC073043.1	-6.56	3.68e-10	5.85e-07	-0.5	-0.4	Osteoporosis;	chr2:199850043	chr2:199867396~199911159:-
OV	cis	rs9813712	0.597	rs10934931	ENSG00000228252.7	COL6A4P2	-6.55	3.71e-10	5.9e-07	-0.45	-0.4	Response to amphetamines;	chr3:130261365	chr3:130212823~130273806:+
OV	cis	rs10740039	0.583	rs1904401	ENSG00000254271.1	RP11-131N11.4	-6.55	3.71e-10	5.91e-07	-0.51	-0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741809	chr10:60734342~60741828:+
OV	cis	rs7044106	0.708	rs991121	ENSG00000226752.6	PSMD5-AS1	-6.55	3.71e-10	5.91e-07	-0.47	-0.4	Hip circumference adjusted for BMI;	chr9:120608067	chr9:120824828~120854385:+
OV	cis	rs6991838	0.584	rs2175810	ENSG00000272010.1	CTD-3025N20.3	-6.55	3.72e-10	5.91e-07	-0.52	-0.4	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65591850~65592472:-
OV	cis	rs853679	0.517	rs7755442	ENSG00000219392.1	RP1-265C24.5	-6.55	3.75e-10	5.96e-07	-0.48	-0.4	Depression;	chr6:28071237	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs12174753	ENSG00000219392.1	RP1-265C24.5	-6.55	3.75e-10	5.96e-07	-0.48	-0.4	Depression;	chr6:28074687	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs55747925	ENSG00000219392.1	RP1-265C24.5	-6.55	3.75e-10	5.96e-07	-0.48	-0.4	Depression;	chr6:28076559	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs56310871	ENSG00000219392.1	RP1-265C24.5	-6.55	3.75e-10	5.96e-07	-0.48	-0.4	Depression;	chr6:28076704	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs34716816	ENSG00000219392.1	RP1-265C24.5	-6.55	3.75e-10	5.96e-07	-0.48	-0.4	Depression;	chr6:28078391	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9393884	ENSG00000219392.1	RP1-265C24.5	-6.55	3.75e-10	5.96e-07	-0.48	-0.4	Depression;	chr6:28079011	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9380049	ENSG00000219392.1	RP1-265C24.5	-6.55	3.75e-10	5.96e-07	-0.48	-0.4	Depression;	chr6:28080757	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9380050	ENSG00000219392.1	RP1-265C24.5	-6.55	3.75e-10	5.96e-07	-0.48	-0.4	Depression;	chr6:28080760	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9393885	ENSG00000219392.1	RP1-265C24.5	-6.55	3.75e-10	5.96e-07	-0.48	-0.4	Depression;	chr6:28082231	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9393886	ENSG00000219392.1	RP1-265C24.5	-6.55	3.75e-10	5.96e-07	-0.48	-0.4	Depression;	chr6:28082261	chr6:28115628~28116551:+
OV	cis	rs4713118	0.515	rs9368549	ENSG00000219392.1	RP1-265C24.5	-6.55	3.75e-10	5.96e-07	-0.48	-0.4	Parkinson's disease;	chr6:28082269	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs56364346	ENSG00000219392.1	RP1-265C24.5	-6.55	3.75e-10	5.96e-07	-0.48	-0.4	Depression;	chr6:28082984	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9357061	ENSG00000219392.1	RP1-265C24.5	-6.55	3.75e-10	5.96e-07	-0.48	-0.4	Depression;	chr6:28083994	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9368550	ENSG00000219392.1	RP1-265C24.5	-6.55	3.75e-10	5.96e-07	-0.48	-0.4	Depression;	chr6:28084025	chr6:28115628~28116551:+
OV	cis	rs853679	0.542	rs2295594	ENSG00000219392.1	RP1-265C24.5	-6.55	3.75e-10	5.96e-07	-0.48	-0.4	Depression;	chr6:28085319	chr6:28115628~28116551:+
OV	cis	rs293748	0.882	rs34525350	ENSG00000250155.1	CTD-2353F22.1	-6.55	3.77e-10	5.98e-07	-0.61	-0.4	Obesity-related traits;	chr5:37089535	chr5:36666214~36725195:-
OV	cis	rs1707322	0.506	rs2991983	ENSG00000280836.1	AL355480.1	6.55	3.77e-10	5.98e-07	0.57	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr1:45581219~45581321:-
OV	cis	rs1707322	0.717	rs3014249	ENSG00000280836.1	AL355480.1	6.55	3.77e-10	5.98e-07	0.57	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr1:45581219~45581321:-
OV	cis	rs11235843	0.866	rs72974869	ENSG00000255928.1	RP11-456I15.2	6.55	3.79e-10	6.01e-07	0.65	0.4	Hand grip strength;	chr11:73703801	chr11:73722349~73722694:+
OV	cis	rs853679	0.517	rs2281588	ENSG00000219392.1	RP1-265C24.5	-6.55	3.81e-10	6.04e-07	-0.48	-0.4	Depression;	chr6:28104824	chr6:28115628~28116551:+
OV	cis	rs11673344	0.864	rs79407399	ENSG00000226686.6	LINC01535	6.55	3.84e-10	6.09e-07	0.56	0.4	Obesity-related traits;	chr19:37000004	chr19:37251912~37265535:+
OV	cis	rs853679	0.542	rs6934769	ENSG00000219392.1	RP1-265C24.5	-6.55	3.87e-10	6.13e-07	-0.49	-0.4	Depression;	chr6:28123153	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs17711801	ENSG00000219392.1	RP1-265C24.5	-6.55	3.87e-10	6.13e-07	-0.49	-0.4	Depression;	chr6:28124529	chr6:28115628~28116551:+
OV	cis	rs4713118	0.527	rs9461433	ENSG00000219392.1	RP1-265C24.5	-6.55	3.87e-10	6.13e-07	-0.49	-0.4	Parkinson's disease;	chr6:28127394	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9468292	ENSG00000219392.1	RP1-265C24.5	-6.55	3.87e-10	6.13e-07	-0.49	-0.4	Depression;	chr6:28127577	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs1947863	ENSG00000219392.1	RP1-265C24.5	-6.55	3.87e-10	6.13e-07	-0.49	-0.4	Depression;	chr6:28131566	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs4713141	ENSG00000219392.1	RP1-265C24.5	-6.55	3.87e-10	6.13e-07	-0.49	-0.4	Depression;	chr6:28133900	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9380056	ENSG00000219392.1	RP1-265C24.5	-6.55	3.87e-10	6.13e-07	-0.49	-0.4	Depression;	chr6:28136698	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9380057	ENSG00000219392.1	RP1-265C24.5	-6.55	3.87e-10	6.13e-07	-0.49	-0.4	Depression;	chr6:28136856	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs6941992	ENSG00000219392.1	RP1-265C24.5	-6.55	3.87e-10	6.13e-07	-0.49	-0.4	Depression;	chr6:28138363	chr6:28115628~28116551:+
OV	cis	rs4713118	0.516	rs4713142	ENSG00000219392.1	RP1-265C24.5	-6.55	3.87e-10	6.13e-07	-0.49	-0.4	Parkinson's disease;	chr6:28138569	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs4713143	ENSG00000219392.1	RP1-265C24.5	-6.55	3.87e-10	6.13e-07	-0.49	-0.4	Depression;	chr6:28138981	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs4713144	ENSG00000219392.1	RP1-265C24.5	-6.55	3.87e-10	6.13e-07	-0.49	-0.4	Depression;	chr6:28139012	chr6:28115628~28116551:+
OV	cis	rs1707322	0.752	rs6662164	ENSG00000280836.1	AL355480.1	-6.55	3.89e-10	6.15e-07	-0.54	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr1:45581219~45581321:-
OV	cis	rs293748	0.882	rs245588	ENSG00000250155.1	CTD-2353F22.1	-6.55	3.89e-10	6.15e-07	-0.6	-0.4	Obesity-related traits;	chr5:36923108	chr5:36666214~36725195:-
OV	cis	rs293748	0.882	rs158802	ENSG00000250155.1	CTD-2353F22.1	-6.55	3.89e-10	6.15e-07	-0.6	-0.4	Obesity-related traits;	chr5:36941446	chr5:36666214~36725195:-
OV	cis	rs293748	0.882	rs293774	ENSG00000250155.1	CTD-2353F22.1	-6.55	3.89e-10	6.15e-07	-0.6	-0.4	Obesity-related traits;	chr5:36943166	chr5:36666214~36725195:-
OV	cis	rs875971	0.545	rs6950988	ENSG00000222364.1	RNU6-96P	-6.54	3.92e-10	6.21e-07	-0.47	-0.4	Aortic root size;	chr7:66511428	chr7:66395191~66395286:+
OV	cis	rs11235843	0.929	rs12366033	ENSG00000255928.1	RP11-456I15.2	6.54	3.93e-10	6.21e-07	0.65	0.4	Hand grip strength;	chr11:73667929	chr11:73722349~73722694:+
OV	cis	rs11235843	0.929	rs66481935	ENSG00000255928.1	RP11-456I15.2	6.54	3.93e-10	6.21e-07	0.65	0.4	Hand grip strength;	chr11:73669278	chr11:73722349~73722694:+
OV	cis	rs11235843	0.929	rs72974840	ENSG00000255928.1	RP11-456I15.2	6.54	3.93e-10	6.21e-07	0.65	0.4	Hand grip strength;	chr11:73669317	chr11:73722349~73722694:+
OV	cis	rs11235843	0.929	rs3825003	ENSG00000255928.1	RP11-456I15.2	6.54	3.93e-10	6.21e-07	0.65	0.4	Hand grip strength;	chr11:73678067	chr11:73722349~73722694:+
OV	cis	rs11235843	0.929	rs112650783	ENSG00000255928.1	RP11-456I15.2	6.54	3.93e-10	6.21e-07	0.65	0.4	Hand grip strength;	chr11:73678883	chr11:73722349~73722694:+
OV	cis	rs11235843	0.853	rs66556722	ENSG00000255928.1	RP11-456I15.2	6.54	3.93e-10	6.21e-07	0.65	0.4	Hand grip strength;	chr11:73691994	chr11:73722349~73722694:+
OV	cis	rs11235843	0.929	rs4944856	ENSG00000255928.1	RP11-456I15.2	6.54	3.93e-10	6.21e-07	0.65	0.4	Hand grip strength;	chr11:73694351	chr11:73722349~73722694:+
OV	cis	rs11235843	0.929	rs4944028	ENSG00000255928.1	RP11-456I15.2	6.54	3.93e-10	6.21e-07	0.65	0.4	Hand grip strength;	chr11:73696525	chr11:73722349~73722694:+
OV	cis	rs11235843	0.929	rs4944029	ENSG00000255928.1	RP11-456I15.2	6.54	3.93e-10	6.21e-07	0.65	0.4	Hand grip strength;	chr11:73696558	chr11:73722349~73722694:+
OV	cis	rs11235843	0.929	rs72974866	ENSG00000255928.1	RP11-456I15.2	6.54	3.93e-10	6.21e-07	0.65	0.4	Hand grip strength;	chr11:73701246	chr11:73722349~73722694:+
OV	cis	rs11235843	0.929	rs4944032	ENSG00000255928.1	RP11-456I15.2	-6.54	3.93e-10	6.21e-07	-0.65	-0.4	Hand grip strength;	chr11:73702076	chr11:73722349~73722694:+
OV	cis	rs1707322	0.752	rs4660313	ENSG00000280836.1	AL355480.1	6.54	3.94e-10	6.23e-07	0.55	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45581219~45581321:-
OV	cis	rs1185460	0.967	rs1177562	ENSG00000271751.1	RP11-110I1.14	-6.54	3.98e-10	6.28e-07	-0.5	-0.4	Coronary artery disease;	chr11:119078621	chr11:119065263~119065677:-
OV	cis	rs6452524	0.534	rs17284134	ENSG00000249664.1	CTD-2227C6.2	-6.54	3.98e-10	6.29e-07	-0.42	-0.4	Hypertension (SNP x SNP interaction);	chr5:83068325	chr5:83012285~83013109:-
OV	cis	rs2524005	1	rs2524005	ENSG00000227766.1	HCG4P5	-6.54	4.03e-10	6.36e-07	-0.54	-0.4	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29942075~29943067:-
OV	cis	rs1499614	1	rs2707832	ENSG00000222364.1	RNU6-96P	-6.54	4.05e-10	6.39e-07	-0.64	-0.4	Gout;	chr7:66671562	chr7:66395191~66395286:+
OV	cis	rs4591358	0.689	rs72927794	ENSG00000223466.1	AC064834.2	-6.54	4.08e-10	6.43e-07	-0.57	-0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195558607	chr2:195533035~195538681:+
OV	cis	rs2836974	0.563	rs997147	ENSG00000232608.1	TIMM9P2	6.54	4.11e-10	6.48e-07	0.43	0.4	Cognitive function;	chr21:39323399	chr21:39216624~39217506:+
OV	cis	rs7927771	0.931	rs12361256	ENSG00000280615.1	Y_RNA	-6.54	4.12e-10	6.5e-07	-0.49	-0.4	Subjective well-being;	chr11:47889271	chr11:47614898~47614994:-
OV	cis	rs7927771	0.965	rs17788930	ENSG00000280615.1	Y_RNA	-6.54	4.13e-10	6.51e-07	-0.49	-0.4	Subjective well-being;	chr11:47731223	chr11:47614898~47614994:-
OV	cis	rs2836974	0.666	rs4818015	ENSG00000232608.1	TIMM9P2	-6.54	4.14e-10	6.52e-07	-0.43	-0.4	Cognitive function;	chr21:39303567	chr21:39216624~39217506:+
OV	cis	rs2836974	0.674	rs1011413	ENSG00000232608.1	TIMM9P2	6.53	4.14e-10	6.52e-07	0.42	0.4	Cognitive function;	chr21:39266315	chr21:39216624~39217506:+
OV	cis	rs2836974	0.584	rs6517535	ENSG00000232608.1	TIMM9P2	6.53	4.15e-10	6.53e-07	0.42	0.4	Cognitive function;	chr21:39281426	chr21:39216624~39217506:+
OV	cis	rs2836974	0.627	rs7278985	ENSG00000232608.1	TIMM9P2	6.53	4.15e-10	6.53e-07	0.42	0.4	Cognitive function;	chr21:39281841	chr21:39216624~39217506:+
OV	cis	rs7617773	0.539	rs2017858	ENSG00000229759.1	MRPS18AP1	6.53	4.16e-10	6.55e-07	0.43	0.4	Coronary artery disease;	chr3:48340792	chr3:48256350~48256938:-
OV	cis	rs7044106	0.537	rs4434680	ENSG00000226752.6	PSMD5-AS1	-6.53	4.16e-10	6.55e-07	-0.49	-0.4	Hip circumference adjusted for BMI;	chr9:120727410	chr9:120824828~120854385:+
OV	cis	rs7044106	0.537	rs10739573	ENSG00000226752.6	PSMD5-AS1	-6.53	4.16e-10	6.55e-07	-0.49	-0.4	Hip circumference adjusted for BMI;	chr9:120727540	chr9:120824828~120854385:+
OV	cis	rs73086581	1	rs11906274	ENSG00000229539.1	RP11-119B16.2	6.53	4.17e-10	6.56e-07	0.51	0.4	Response to antidepressants in depression;	chr20:3964889	chr20:3888239~3888868:-
OV	cis	rs73086581	1	rs6052196	ENSG00000229539.1	RP11-119B16.2	6.53	4.17e-10	6.56e-07	0.51	0.4	Response to antidepressants in depression;	chr20:3965177	chr20:3888239~3888868:-
OV	cis	rs73086581	1	rs6116130	ENSG00000229539.1	RP11-119B16.2	6.53	4.17e-10	6.56e-07	0.51	0.4	Response to antidepressants in depression;	chr20:3966379	chr20:3888239~3888868:-
OV	cis	rs73086581	1	rs6052209	ENSG00000229539.1	RP11-119B16.2	6.53	4.17e-10	6.56e-07	0.51	0.4	Response to antidepressants in depression;	chr20:3981100	chr20:3888239~3888868:-
OV	cis	rs73086581	1	rs6052217	ENSG00000229539.1	RP11-119B16.2	6.53	4.17e-10	6.56e-07	0.51	0.4	Response to antidepressants in depression;	chr20:3989564	chr20:3888239~3888868:-
OV	cis	rs73086581	1	rs6052218	ENSG00000229539.1	RP11-119B16.2	6.53	4.17e-10	6.56e-07	0.51	0.4	Response to antidepressants in depression;	chr20:3989565	chr20:3888239~3888868:-
OV	cis	rs73086581	0.945	rs6052219	ENSG00000229539.1	RP11-119B16.2	6.53	4.17e-10	6.56e-07	0.51	0.4	Response to antidepressants in depression;	chr20:3989660	chr20:3888239~3888868:-
OV	cis	rs1707322	0.827	rs12125508	ENSG00000280836.1	AL355480.1	-6.53	4.19e-10	6.6e-07	-0.54	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45780338	chr1:45581219~45581321:-
OV	cis	rs1707322	0.826	rs10890349	ENSG00000280836.1	AL355480.1	-6.53	4.19e-10	6.6e-07	-0.54	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784283	chr1:45581219~45581321:-
OV	cis	rs1707322	0.758	rs10789474	ENSG00000280836.1	AL355480.1	-6.53	4.19e-10	6.6e-07	-0.54	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45784368	chr1:45581219~45581321:-
OV	cis	rs10510102	0.688	rs74570569	ENSG00000276742.1	RP11-500G22.4	6.53	4.21e-10	6.61e-07	0.64	0.4	Breast cancer;	chr10:121945347	chr10:121956782~121957098:+
OV	cis	rs10510102	0.872	rs7076727	ENSG00000276742.1	RP11-500G22.4	6.53	4.21e-10	6.61e-07	0.64	0.4	Breast cancer;	chr10:121947000	chr10:121956782~121957098:+
OV	cis	rs10510102	0.745	rs7076882	ENSG00000276742.1	RP11-500G22.4	6.53	4.21e-10	6.61e-07	0.64	0.4	Breast cancer;	chr10:121947039	chr10:121956782~121957098:+
OV	cis	rs10510102	0.872	rs7077035	ENSG00000276742.1	RP11-500G22.4	6.53	4.21e-10	6.61e-07	0.64	0.4	Breast cancer;	chr10:121947130	chr10:121956782~121957098:+
OV	cis	rs7044106	0.718	rs10616	ENSG00000226752.6	PSMD5-AS1	-6.53	4.21e-10	6.62e-07	-0.49	-0.4	Hip circumference adjusted for BMI;	chr9:120601255	chr9:120824828~120854385:+
OV	cis	rs4591358	0.689	rs6760142	ENSG00000223466.1	AC064834.2	-6.53	4.3e-10	6.75e-07	-0.56	-0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195553911	chr2:195533035~195538681:+
OV	cis	rs1707322	1	rs4539075	ENSG00000280836.1	AL355480.1	-6.53	4.31e-10	6.78e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45892338	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs4660905	ENSG00000280836.1	AL355480.1	6.53	4.32e-10	6.79e-07	0.55	0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995915	chr1:45581219~45581321:-
OV	cis	rs17711722	0.565	rs4717276	ENSG00000236529.1	RP13-254B10.1	6.53	4.33e-10	6.81e-07	0.43	0.4	Calcium levels;	chr7:65829754	chr7:65840212~65840596:+
OV	cis	rs150992	0.711	rs1069182	ENSG00000248489.1	CTD-2007H13.3	-6.53	4.34e-10	6.82e-07	-0.5	-0.4	Body mass index;	chr5:98806512	chr5:98929171~98995013:+
OV	cis	rs150992	0.673	rs992773	ENSG00000248489.1	CTD-2007H13.3	-6.53	4.34e-10	6.82e-07	-0.5	-0.4	Body mass index;	chr5:98808169	chr5:98929171~98995013:+
OV	cis	rs875971	0.545	rs1796217	ENSG00000222364.1	RNU6-96P	6.53	4.34e-10	6.82e-07	0.47	0.4	Aortic root size;	chr7:66620931	chr7:66395191~66395286:+
OV	cis	rs2153535	0.563	rs6942177	ENSG00000230939.1	RP11-314C16.1	6.52	4.4e-10	6.9e-07	0.47	0.4	Motion sickness;	chr6:8534227	chr6:8784178~8785445:+
OV	cis	rs853679	0.55	rs1233701	ENSG00000220721.1	OR1F12	-6.52	4.4e-10	6.9e-07	-0.47	-0.4	Depression;	chr6:28200948	chr6:28073316~28074233:+
OV	cis	rs7927771	1	rs34128973	ENSG00000280615.1	Y_RNA	-6.52	4.4e-10	6.9e-07	-0.49	-0.4	Subjective well-being;	chr11:47829824	chr11:47614898~47614994:-
OV	cis	rs7044106	0.791	rs7043969	ENSG00000226752.6	PSMD5-AS1	-6.52	4.4e-10	6.9e-07	-0.46	-0.4	Hip circumference adjusted for BMI;	chr9:120731711	chr9:120824828~120854385:+
OV	cis	rs9918079	0.56	rs6449153	ENSG00000273133.1	RP11-799M12.2	-6.52	4.43e-10	6.94e-07	-0.47	-0.4	Obesity-related traits;	chr4:15629593	chr4:15563698~15564253:-
OV	cis	rs8040855	0.621	rs6496796	ENSG00000229212.6	RP11-561C5.4	-6.52	4.45e-10	6.97e-07	-0.5	-0.4	Bulimia nervosa;	chr15:85183617	chr15:85205440~85234795:-
OV	cis	rs11235843	0.778	rs4944861	ENSG00000255928.1	RP11-456I15.2	6.52	4.45e-10	6.98e-07	0.64	0.4	Hand grip strength;	chr11:73719460	chr11:73722349~73722694:+
OV	cis	rs11235843	0.929	rs67488767	ENSG00000255928.1	RP11-456I15.2	6.52	4.45e-10	6.98e-07	0.64	0.4	Hand grip strength;	chr11:73721644	chr11:73722349~73722694:+
OV	cis	rs11235843	0.79	rs11235881	ENSG00000255928.1	RP11-456I15.2	6.52	4.45e-10	6.98e-07	0.64	0.4	Hand grip strength;	chr11:73727192	chr11:73722349~73722694:+
OV	cis	rs11235843	0.778	rs72976852	ENSG00000255928.1	RP11-456I15.2	6.52	4.45e-10	6.98e-07	0.64	0.4	Hand grip strength;	chr11:73731605	chr11:73722349~73722694:+
OV	cis	rs11235843	0.929	rs11235882	ENSG00000255928.1	RP11-456I15.2	6.52	4.45e-10	6.98e-07	0.64	0.4	Hand grip strength;	chr11:73731956	chr11:73722349~73722694:+
OV	cis	rs11235843	0.929	rs7939193	ENSG00000255928.1	RP11-456I15.2	6.52	4.45e-10	6.98e-07	0.64	0.4	Hand grip strength;	chr11:73735324	chr11:73722349~73722694:+
OV	cis	rs11235843	0.929	rs4944033	ENSG00000255928.1	RP11-456I15.2	6.52	4.45e-10	6.98e-07	0.64	0.4	Hand grip strength;	chr11:73737601	chr11:73722349~73722694:+
OV	cis	rs11235843	0.853	rs12365044	ENSG00000255928.1	RP11-456I15.2	6.52	4.45e-10	6.98e-07	0.64	0.4	Hand grip strength;	chr11:73741466	chr11:73722349~73722694:+
OV	cis	rs11235843	0.929	rs10898943	ENSG00000255928.1	RP11-456I15.2	6.52	4.45e-10	6.98e-07	0.64	0.4	Hand grip strength;	chr11:73752710	chr11:73722349~73722694:+
OV	cis	rs4591358	0.636	rs6712400	ENSG00000223466.1	AC064834.2	-6.52	4.47e-10	7e-07	-0.52	-0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195506646	chr2:195533035~195538681:+
OV	cis	rs8005677	1	rs1043209	ENSG00000257285.4	RP11-298I3.1	-6.52	4.48e-10	7.02e-07	-0.47	-0.4	Cognitive ability (multi-trait analysis);	chr14:22904777	chr14:22929609~22955562:+
OV	cis	rs875971	0.545	rs6460298	ENSG00000222364.1	RNU6-96P	-6.52	4.5e-10	7.04e-07	-0.46	-0.4	Aortic root size;	chr7:66442783	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs75577046	ENSG00000222364.1	RNU6-96P	-6.52	4.5e-10	7.04e-07	-0.46	-0.4	Aortic root size;	chr7:66493729	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs3735147	ENSG00000222364.1	RNU6-96P	-6.52	4.5e-10	7.04e-07	-0.46	-0.4	Aortic root size;	chr7:66505541	chr7:66395191~66395286:+
OV	cis	rs1707322	0.721	rs4660883	ENSG00000280836.1	AL355480.1	-6.52	4.5e-10	7.05e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr1:45581219~45581321:-
OV	cis	rs1499614	1	rs2659913	ENSG00000222364.1	RNU6-96P	-6.52	4.57e-10	7.14e-07	-0.64	-0.4	Gout;	chr7:66692349	chr7:66395191~66395286:+
OV	cis	rs1499614	1	rs2707840	ENSG00000222364.1	RNU6-96P	-6.52	4.57e-10	7.14e-07	-0.64	-0.4	Gout;	chr7:66693028	chr7:66395191~66395286:+
OV	cis	rs1499614	1	rs2659911	ENSG00000222364.1	RNU6-96P	-6.52	4.57e-10	7.14e-07	-0.64	-0.4	Gout;	chr7:66693433	chr7:66395191~66395286:+
OV	cis	rs1499614	1	rs2707838	ENSG00000222364.1	RNU6-96P	-6.52	4.57e-10	7.14e-07	-0.64	-0.4	Gout;	chr7:66694214	chr7:66395191~66395286:+
OV	cis	rs1499614	1	rs60326618	ENSG00000222364.1	RNU6-96P	-6.52	4.57e-10	7.14e-07	-0.64	-0.4	Gout;	chr7:66701371	chr7:66395191~66395286:+
OV	cis	rs1499614	1	rs2707830	ENSG00000222364.1	RNU6-96P	-6.52	4.57e-10	7.14e-07	-0.64	-0.4	Gout;	chr7:66702658	chr7:66395191~66395286:+
OV	cis	rs1499614	1	rs2707828	ENSG00000222364.1	RNU6-96P	-6.52	4.57e-10	7.14e-07	-0.64	-0.4	Gout;	chr7:66706390	chr7:66395191~66395286:+
OV	cis	rs1499614	0.803	rs1922723	ENSG00000222364.1	RNU6-96P	-6.52	4.57e-10	7.14e-07	-0.64	-0.4	Gout;	chr7:66710076	chr7:66395191~66395286:+
OV	cis	rs10740039	0.583	rs2127348	ENSG00000254271.1	RP11-131N11.4	-6.52	4.61e-10	7.2e-07	-0.51	-0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740945	chr10:60734342~60741828:+
OV	cis	rs10740039	0.583	rs2127349	ENSG00000254271.1	RP11-131N11.4	-6.52	4.61e-10	7.2e-07	-0.51	-0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740947	chr10:60734342~60741828:+
OV	cis	rs1707322	0.685	rs56177313	ENSG00000280836.1	AL355480.1	-6.52	4.62e-10	7.21e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45581219~45581321:-
OV	cis	rs950169	0.58	rs11634320	ENSG00000259295.5	CSPG4P12	-6.51	4.65e-10	7.25e-07	-0.54	-0.4	Schizophrenia;	chr15:84628952	chr15:85191438~85213905:+
OV	cis	rs293748	0.771	rs35011787	ENSG00000250155.1	CTD-2353F22.1	-6.51	4.65e-10	7.26e-07	-0.59	-0.4	Obesity-related traits;	chr5:37010302	chr5:36666214~36725195:-
OV	cis	rs293748	0.771	rs35701604	ENSG00000250155.1	CTD-2353F22.1	-6.51	4.65e-10	7.26e-07	-0.59	-0.4	Obesity-related traits;	chr5:37021831	chr5:36666214~36725195:-
OV	cis	rs11603023	0.874	rs613243	ENSG00000255422.1	AP002954.4	-6.51	4.67e-10	7.28e-07	-0.41	-0.4	Cholesterol, total;	chr11:118643304	chr11:118704607~118750263:+
OV	cis	rs2836974	0.526	rs1888488	ENSG00000232608.1	TIMM9P2	6.51	4.68e-10	7.29e-07	0.43	0.4	Cognitive function;	chr21:39314595	chr21:39216624~39217506:+
OV	cis	rs853679	0.55	rs1233699	ENSG00000219392.1	RP1-265C24.5	-6.51	4.68e-10	7.3e-07	-0.49	-0.4	Depression;	chr6:28201380	chr6:28115628~28116551:+
OV	cis	rs1061377	0.965	rs7690465	ENSG00000249207.1	RP11-360F5.1	-6.51	4.7e-10	7.33e-07	-0.44	-0.4	Uric acid levels;	chr4:39147015	chr4:39112677~39126818:-
OV	cis	rs7044106	0.708	rs959558	ENSG00000226752.6	PSMD5-AS1	-6.51	4.74e-10	7.38e-07	-0.46	-0.4	Hip circumference adjusted for BMI;	chr9:120606633	chr9:120824828~120854385:+
OV	cis	rs3931020	1	rs10874122	ENSG00000272864.1	RP11-17E13.2	-6.51	4.74e-10	7.39e-07	-0.52	-0.4	Resistin levels;	chr1:74770182	chr1:74698769~74699333:-
OV	cis	rs1707322	0.721	rs7519900	ENSG00000280836.1	AL355480.1	-6.51	4.79e-10	7.45e-07	-0.56	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45581219~45581321:-
OV	cis	rs293748	0.771	rs151945	ENSG00000250155.1	CTD-2353F22.1	-6.51	4.81e-10	7.49e-07	-0.58	-0.4	Obesity-related traits;	chr5:36838494	chr5:36666214~36725195:-
OV	cis	rs293748	0.771	rs181755	ENSG00000250155.1	CTD-2353F22.1	-6.51	4.81e-10	7.49e-07	-0.58	-0.4	Obesity-related traits;	chr5:36839162	chr5:36666214~36725195:-
OV	cis	rs293748	0.771	rs245587	ENSG00000250155.1	CTD-2353F22.1	-6.51	4.81e-10	7.49e-07	-0.58	-0.4	Obesity-related traits;	chr5:36839445	chr5:36666214~36725195:-
OV	cis	rs853679	0.517	rs9380047	ENSG00000219392.1	RP1-265C24.5	-6.51	4.84e-10	7.53e-07	-0.48	-0.4	Depression;	chr6:28070115	chr6:28115628~28116551:+
OV	cis	rs10510102	0.566	rs885543	ENSG00000276742.1	RP11-500G22.4	6.51	4.86e-10	7.57e-07	0.72	0.4	Breast cancer;	chr10:121973536	chr10:121956782~121957098:+
OV	cis	rs934734	0.532	rs1437466	ENSG00000234255.7	AC012370.3	-6.51	4.88e-10	7.59e-07	-0.43	-0.4	Rheumatoid arthritis;	chr2:65437216	chr2:65439888~65456571:-
OV	cis	rs1061377	1	rs6829450	ENSG00000249207.1	RP11-360F5.1	-6.5	4.96e-10	7.71e-07	-0.44	-0.4	Uric acid levels;	chr4:39114721	chr4:39112677~39126818:-
OV	cis	rs4591358	0.678	rs13015934	ENSG00000223466.1	AC064834.2	-6.5	4.97e-10	7.73e-07	-0.56	-0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195504897	chr2:195533035~195538681:+
OV	cis	rs11673344	0.77	rs34729406	ENSG00000226686.6	LINC01535	6.5	4.98e-10	7.74e-07	0.55	0.4	Obesity-related traits;	chr19:37012764	chr19:37251912~37265535:+
OV	cis	rs7927771	0.793	rs12803525	ENSG00000280615.1	Y_RNA	-6.5	5.01e-10	7.78e-07	-0.48	-0.4	Subjective well-being;	chr11:47391924	chr11:47614898~47614994:-
OV	cis	rs853679	0.517	rs6932109	ENSG00000219392.1	RP1-265C24.5	6.5	5.01e-10	7.78e-07	0.51	0.4	Depression;	chr6:28110525	chr6:28115628~28116551:+
OV	cis	rs7927771	0.864	rs11604680	ENSG00000280615.1	Y_RNA	-6.5	5.09e-10	7.9e-07	-0.5	-0.4	Subjective well-being;	chr11:47435988	chr11:47614898~47614994:-
OV	cis	rs10740039	0.583	rs4948264	ENSG00000254271.1	RP11-131N11.4	-6.5	5.13e-10	7.96e-07	-0.5	-0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740484	chr10:60734342~60741828:+
OV	cis	rs10740039	0.583	rs4948265	ENSG00000254271.1	RP11-131N11.4	-6.5	5.13e-10	7.96e-07	-0.5	-0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740495	chr10:60734342~60741828:+
OV	cis	rs10740039	0.583	rs7917700	ENSG00000254271.1	RP11-131N11.4	-6.5	5.13e-10	7.96e-07	-0.5	-0.4	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740596	chr10:60734342~60741828:+
OV	cis	rs67340775	0.541	rs200973	ENSG00000220721.1	OR1F12	6.5	5.15e-10	7.99e-07	0.5	0.4	Lung cancer in ever smokers;	chr6:27890643	chr6:28073316~28074233:+
OV	cis	rs62355901	0.599	rs12655060	ENSG00000271828.1	CTD-2310F14.1	6.5	5.15e-10	7.99e-07	0.75	0.4	Breast cancer;	chr5:56720808	chr5:56927874~56929573:+
OV	cis	rs1707322	1	rs10890370	ENSG00000281133.1	AL355480.3	-6.5	5.16e-10	8.01e-07	-0.49	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45923545	chr1:45580892~45580996:-
OV	cis	rs7688540	0.771	rs77234191	ENSG00000275426.1	CH17-262A2.1	6.5	5.17e-10	8.02e-07	0.66	0.4	Facial morphology (factor 6, height of vermillion lower lip);	chr4:264505	chr4:149738~150317:+
OV	cis	rs12908161	0.959	rs2175567	ENSG00000235370.6	DNM1P51	6.49	5.2e-10	8.07e-07	0.51	0.4	Schizophrenia;	chr15:84657715	chr15:84398316~84411701:-
OV	cis	rs1707322	0.721	rs11211178	ENSG00000280836.1	AL355480.1	-6.49	5.21e-10	8.08e-07	-0.55	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45581219~45581321:-
OV	cis	rs4591358	0.689	rs2102745	ENSG00000223466.1	AC064834.2	-6.49	5.22e-10	8.1e-07	-0.56	-0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195559315	chr2:195533035~195538681:+
OV	cis	rs7688540	0.771	rs11722521	ENSG00000275426.1	CH17-262A2.1	6.49	5.23e-10	8.1e-07	0.63	0.4	Facial morphology (factor 6, height of vermillion lower lip);	chr4:282976	chr4:149738~150317:+
OV	cis	rs7688540	0.771	rs7665727	ENSG00000275426.1	CH17-262A2.1	6.49	5.23e-10	8.1e-07	0.63	0.4	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283268	chr4:149738~150317:+
OV	cis	rs875971	0.545	rs73378304	ENSG00000222364.1	RNU6-96P	-6.49	5.26e-10	8.15e-07	-0.45	-0.4	Aortic root size;	chr7:66175760	chr7:66395191~66395286:+
OV	cis	rs73019876	0.901	rs424460	ENSG00000269742.1	BNIP3P29	-6.49	5.3e-10	8.21e-07	-0.47	-0.4	Testicular germ cell tumor;	chr19:22050890	chr19:22065828~22066398:-
OV	cis	rs1707322	0.827	rs6694302	ENSG00000280836.1	AL355480.1	-6.49	5.32e-10	8.24e-07	-0.54	-0.4	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45779973	chr1:45581219~45581321:-
OV	cis	rs3931020	1	rs3931020	ENSG00000272864.1	RP11-17E13.2	-6.49	5.35e-10	8.27e-07	-0.52	-0.4	Resistin levels;	chr1:74769633	chr1:74698769~74699333:-
OV	cis	rs853679	0.517	rs9283884	ENSG00000219392.1	RP1-265C24.5	6.49	5.4e-10	8.35e-07	0.5	0.4	Depression;	chr6:28167882	chr6:28115628~28116551:+
OV	cis	rs293748	0.771	rs158797	ENSG00000250155.1	CTD-2353F22.1	-6.49	5.43e-10	8.38e-07	-0.58	-0.4	Obesity-related traits;	chr5:36870318	chr5:36666214~36725195:-
OV	cis	rs293748	0.771	rs158792	ENSG00000250155.1	CTD-2353F22.1	-6.49	5.43e-10	8.38e-07	-0.58	-0.4	Obesity-related traits;	chr5:36889068	chr5:36666214~36725195:-
OV	cis	rs293748	0.771	rs293746	ENSG00000250155.1	CTD-2353F22.1	-6.49	5.43e-10	8.38e-07	-0.58	-0.4	Obesity-related traits;	chr5:36895168	chr5:36666214~36725195:-
OV	cis	rs293748	0.771	rs292160	ENSG00000250155.1	CTD-2353F22.1	-6.49	5.43e-10	8.38e-07	-0.58	-0.4	Obesity-related traits;	chr5:36895971	chr5:36666214~36725195:-
OV	cis	rs4591358	0.648	rs6732306	ENSG00000223466.1	AC064834.2	-6.49	5.45e-10	8.41e-07	-0.57	-0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195541396	chr2:195533035~195538681:+
OV	cis	rs4591358	0.689	rs2889034	ENSG00000223466.1	AC064834.2	-6.49	5.46e-10	8.44e-07	-0.57	-0.4	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195548022	chr2:195533035~195538681:+
OV	cis	rs17711722	0.528	rs73138179	ENSG00000236529.1	RP13-254B10.1	6.48	5.48e-10	8.45e-07	0.45	0.4	Calcium levels;	chr7:65829495	chr7:65840212~65840596:+
OV	cis	rs7044106	0.664	rs7861679	ENSG00000226752.6	PSMD5-AS1	6.48	5.51e-10	8.5e-07	0.49	0.4	Hip circumference adjusted for BMI;	chr9:120613311	chr9:120824828~120854385:+
OV	cis	rs10510102	0.872	rs7907815	ENSG00000276742.1	RP11-500G22.4	6.48	5.55e-10	8.55e-07	0.62	0.4	Breast cancer;	chr10:121965951	chr10:121956782~121957098:+
OV	cis	rs7017914	0.902	rs3098866	ENSG00000223220.1	Y_RNA	6.48	5.57e-10	8.59e-07	0.42	0.4	Bone mineral density;	chr8:71004339	chr8:70780914~70781008:-
OV	cis	rs853679	0.517	rs868987	ENSG00000219392.1	RP1-265C24.5	6.48	5.59e-10	8.62e-07	0.52	0.4	Depression;	chr6:28142370	chr6:28115628~28116551:+
OV	cis	rs875971	0.545	rs75840613	ENSG00000222364.1	RNU6-96P	-6.48	5.63e-10	8.68e-07	-0.46	-0.4	Aortic root size;	chr7:66376399	chr7:66395191~66395286:+
OV	cis	rs11235843	1	rs72974833	ENSG00000255928.1	RP11-456I15.2	6.48	5.65e-10	8.71e-07	0.65	0.4	Hand grip strength;	chr11:73664059	chr11:73722349~73722694:+
OV	cis	rs950169	0.545	rs4354897	ENSG00000235370.6	DNM1P51	6.48	5.67e-10	8.73e-07	0.56	0.4	Schizophrenia;	chr15:83976219	chr15:84398316~84411701:-
OV	cis	rs9813712	0.571	rs9855777	ENSG00000228252.7	COL6A4P2	6.48	5.68e-10	8.75e-07	0.43	0.4	Response to amphetamines;	chr3:130214805	chr3:130212823~130273806:+
OV	cis	rs8105895	0.935	rs1560716	ENSG00000269742.1	BNIP3P29	6.48	5.69e-10	8.76e-07	0.66	0.4	Body mass index (change over time);	chr19:22123099	chr19:22065828~22066398:-
OV	cis	rs492146	0.74	rs1032418	ENSG00000243236.5	GSTA9P	6.48	5.7e-10	8.78e-07	0.49	0.39	Epilepsy (remission after treatment);	chr6:52970159	chr6:52939726~52957521:-
OV	cis	rs8062405	1	rs7187776	ENSG00000259982.1	CDC37P1	6.48	5.73e-10	8.81e-07	0.47	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28700294~28701540:-
OV	cis	rs1185460	0.967	rs1786141	ENSG00000271751.1	RP11-110I1.14	-6.48	5.73e-10	8.82e-07	-0.47	-0.39	Coronary artery disease;	chr11:119067604	chr11:119065263~119065677:-
OV	cis	rs10740039	0.583	rs4948263	ENSG00000254271.1	RP11-131N11.4	-6.47	5.8e-10	8.93e-07	-0.5	-0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740132	chr10:60734342~60741828:+
OV	cis	rs801193	0.742	rs9969300	ENSG00000222364.1	RNU6-96P	6.47	5.81e-10	8.93e-07	0.41	0.39	Aortic root size;	chr7:66316659	chr7:66395191~66395286:+
OV	cis	rs1707322	0.717	rs2275086	ENSG00000280836.1	AL355480.1	6.47	5.83e-10	8.97e-07	0.56	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45581219~45581321:-
OV	cis	rs875971	0.545	rs11767262	ENSG00000222364.1	RNU6-96P	-6.47	5.84e-10	8.98e-07	-0.46	-0.39	Aortic root size;	chr7:66302237	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs66594357	ENSG00000222364.1	RNU6-96P	-6.47	5.84e-10	8.98e-07	-0.46	-0.39	Aortic root size;	chr7:66327797	chr7:66395191~66395286:+
OV	cis	rs1707322	0.686	rs1084086	ENSG00000280836.1	AL355480.1	6.47	5.84e-10	8.99e-07	0.55	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45581219~45581321:-
OV	cis	rs6921919	0.848	rs56131013	ENSG00000216901.1	AL022393.7	6.47	5.86e-10	9.01e-07	0.53	0.39	Autism spectrum disorder or schizophrenia;	chr6:28352900	chr6:28176188~28176674:+
OV	cis	rs1707322	0.721	rs4660314	ENSG00000280836.1	AL355480.1	-6.47	5.87e-10	9.03e-07	-0.55	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764213	chr1:45581219~45581321:-
OV	cis	rs1707322	0.721	rs12069121	ENSG00000280836.1	AL355480.1	-6.47	5.87e-10	9.03e-07	-0.55	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45766312	chr1:45581219~45581321:-
OV	cis	rs1707322	0.686	rs61784833	ENSG00000280836.1	AL355480.1	-6.47	5.87e-10	9.03e-07	-0.55	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45768100	chr1:45581219~45581321:-
OV	cis	rs2836974	0.627	rs8127986	ENSG00000232608.1	TIMM9P2	6.47	5.95e-10	9.14e-07	0.42	0.39	Cognitive function;	chr21:39315285	chr21:39216624~39217506:+
OV	cis	rs2833693	0.524	rs8129993	ENSG00000261610.1	AP000265.1	6.47	5.96e-10	9.15e-07	0.48	0.39	Temperament;	chr21:32268841	chr21:32259804~32261585:-
OV	cis	rs7017914	0.967	rs2639903	ENSG00000223220.1	Y_RNA	6.47	5.99e-10	9.19e-07	0.42	0.39	Bone mineral density;	chr8:71005209	chr8:70780914~70781008:-
OV	cis	rs9813712	0.526	rs13065659	ENSG00000228252.7	COL6A4P2	-6.46	6.13e-10	9.4e-07	-0.45	-0.39	Response to amphetamines;	chr3:130231945	chr3:130212823~130273806:+
OV	cis	rs2243480	1	rs160646	ENSG00000222364.1	RNU6-96P	-6.46	6.21e-10	9.52e-07	-0.62	-0.39	Diabetic kidney disease;	chr7:66091293	chr7:66395191~66395286:+
OV	cis	rs853679	0.517	rs1947862	ENSG00000219392.1	RP1-265C24.5	-6.46	6.27e-10	9.61e-07	-0.48	-0.39	Depression;	chr6:28137418	chr6:28115628~28116551:+
OV	cis	rs2243480	0.831	rs57294491	ENSG00000222364.1	RNU6-96P	6.46	6.31e-10	9.66e-07	0.64	0.39	Diabetic kidney disease;	chr7:66219914	chr7:66395191~66395286:+
OV	cis	rs1707322	1	rs785480	ENSG00000280836.1	AL355480.1	-6.46	6.33e-10	9.68e-07	-0.53	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46026492	chr1:45581219~45581321:-
OV	cis	rs875971	0.545	rs73146609	ENSG00000222364.1	RNU6-96P	-6.46	6.33e-10	9.68e-07	-0.46	-0.39	Aortic root size;	chr7:66302477	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs2173571	ENSG00000222364.1	RNU6-96P	-6.46	6.33e-10	9.68e-07	-0.46	-0.39	Aortic root size;	chr7:66305392	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs11770063	ENSG00000222364.1	RNU6-96P	-6.46	6.33e-10	9.68e-07	-0.46	-0.39	Aortic root size;	chr7:66318029	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs3936065	ENSG00000222364.1	RNU6-96P	-6.46	6.33e-10	9.68e-07	-0.46	-0.39	Aortic root size;	chr7:66325577	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs4718335	ENSG00000222364.1	RNU6-96P	-6.46	6.33e-10	9.68e-07	-0.46	-0.39	Aortic root size;	chr7:66339619	chr7:66395191~66395286:+
OV	cis	rs172166	0.694	rs1631552	ENSG00000220721.1	OR1F12	6.46	6.4e-10	9.79e-07	0.43	0.39	Cardiac Troponin-T levels;	chr6:28121921	chr6:28073316~28074233:+
OV	cis	rs172166	0.694	rs536704	ENSG00000220721.1	OR1F12	6.46	6.4e-10	9.79e-07	0.43	0.39	Cardiac Troponin-T levels;	chr6:28124825	chr6:28073316~28074233:+
OV	cis	rs7927771	1	rs34910028	ENSG00000280615.1	Y_RNA	-6.46	6.45e-10	9.83e-07	-0.48	-0.39	Subjective well-being;	chr11:47736897	chr11:47614898~47614994:-
OV	cis	rs11602339	1	rs11602339	ENSG00000280615.1	Y_RNA	-6.46	6.45e-10	9.83e-07	-0.48	-0.39	Body mass index;	chr11:47739919	chr11:47614898~47614994:-
OV	cis	rs7927771	1	rs12421210	ENSG00000280615.1	Y_RNA	-6.46	6.45e-10	9.83e-07	-0.48	-0.39	Subjective well-being;	chr11:47758034	chr11:47614898~47614994:-
OV	cis	rs7927771	1	rs7927771	ENSG00000280615.1	Y_RNA	-6.46	6.45e-10	9.83e-07	-0.48	-0.39	Subjective well-being;	chr11:47759754	chr11:47614898~47614994:-
OV	cis	rs7927771	1	rs12361031	ENSG00000280615.1	Y_RNA	-6.46	6.45e-10	9.83e-07	-0.48	-0.39	Subjective well-being;	chr11:47761524	chr11:47614898~47614994:-
OV	cis	rs7927771	1	rs7947730	ENSG00000280615.1	Y_RNA	-6.46	6.45e-10	9.83e-07	-0.48	-0.39	Subjective well-being;	chr11:47764632	chr11:47614898~47614994:-
OV	cis	rs7927771	1	rs35902101	ENSG00000280615.1	Y_RNA	-6.46	6.45e-10	9.83e-07	-0.48	-0.39	Subjective well-being;	chr11:47773617	chr11:47614898~47614994:-
OV	cis	rs11039389	1	rs11039389	ENSG00000280615.1	Y_RNA	-6.46	6.45e-10	9.83e-07	-0.48	-0.39	Neuroticism;	chr11:47774510	chr11:47614898~47614994:-
OV	cis	rs7927771	1	rs11039390	ENSG00000280615.1	Y_RNA	-6.46	6.45e-10	9.83e-07	-0.48	-0.39	Subjective well-being;	chr11:47774743	chr11:47614898~47614994:-
OV	cis	rs7927771	1	rs9909	ENSG00000280615.1	Y_RNA	-6.46	6.45e-10	9.83e-07	-0.48	-0.39	Subjective well-being;	chr11:47778223	chr11:47614898~47614994:-
OV	cis	rs7927771	1	rs7105282	ENSG00000280615.1	Y_RNA	-6.46	6.45e-10	9.83e-07	-0.48	-0.39	Subjective well-being;	chr11:47784062	chr11:47614898~47614994:-
OV	cis	rs7927771	1	rs12787330	ENSG00000280615.1	Y_RNA	-6.46	6.45e-10	9.83e-07	-0.48	-0.39	Subjective well-being;	chr11:47790759	chr11:47614898~47614994:-
OV	cis	rs7927771	1	rs7120333	ENSG00000280615.1	Y_RNA	-6.46	6.45e-10	9.83e-07	-0.48	-0.39	Subjective well-being;	chr11:47795889	chr11:47614898~47614994:-
OV	cis	rs7927771	1	rs11605774	ENSG00000280615.1	Y_RNA	-6.46	6.45e-10	9.83e-07	-0.48	-0.39	Subjective well-being;	chr11:47811241	chr11:47614898~47614994:-
OV	cis	rs7927771	1	rs11039412	ENSG00000280615.1	Y_RNA	-6.46	6.45e-10	9.83e-07	-0.48	-0.39	Subjective well-being;	chr11:47820029	chr11:47614898~47614994:-
OV	cis	rs7927771	0.965	rs11039416	ENSG00000280615.1	Y_RNA	-6.46	6.45e-10	9.83e-07	-0.48	-0.39	Subjective well-being;	chr11:47825159	chr11:47614898~47614994:-
OV	cis	rs7927771	0.965	rs35985502	ENSG00000280615.1	Y_RNA	-6.46	6.45e-10	9.83e-07	-0.48	-0.39	Subjective well-being;	chr11:47825876	chr11:47614898~47614994:-
OV	cis	rs853679	0.55	rs1233699	ENSG00000220721.1	OR1F12	6.46	6.45e-10	9.84e-07	0.46	0.39	Depression;	chr6:28201380	chr6:28073316~28074233:+
OV	cis	rs2836974	0.568	rs2836969	ENSG00000232608.1	TIMM9P2	6.45	6.49e-10	9.89e-07	0.42	0.39	Cognitive function;	chr21:39276339	chr21:39216624~39217506:+
OV	cis	rs1061377	1	rs4974998	ENSG00000249207.1	RP11-360F5.1	-6.45	6.52e-10	9.94e-07	-0.43	-0.39	Uric acid levels;	chr4:39109129	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs7673299	ENSG00000249207.1	RP11-360F5.1	-6.45	6.52e-10	9.94e-07	-0.43	-0.39	Uric acid levels;	chr4:39109138	chr4:39112677~39126818:-
OV	cis	rs1061377	1	rs4974997	ENSG00000249207.1	RP11-360F5.1	-6.45	6.52e-10	9.94e-07	-0.43	-0.39	Uric acid levels;	chr4:39109151	chr4:39112677~39126818:-
OV	cis	rs2243480	1	rs2420170	ENSG00000222364.1	RNU6-96P	6.45	6.53e-10	9.95e-07	0.63	0.39	Diabetic kidney disease;	chr7:66191066	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs7804223	ENSG00000222364.1	RNU6-96P	6.45	6.53e-10	9.95e-07	0.63	0.39	Diabetic kidney disease;	chr7:66199572	chr7:66395191~66395286:+
OV	cis	rs4591358	0.689	rs72927780	ENSG00000223466.1	AC064834.2	-6.45	6.54e-10	9.96e-07	-0.56	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195548569	chr2:195533035~195538681:+
OV	cis	rs7927771	0.965	rs4752881	ENSG00000280615.1	Y_RNA	-6.45	6.54e-10	9.96e-07	-0.5	-0.39	Subjective well-being;	chr11:47876983	chr11:47614898~47614994:-
OV	cis	rs4591358	0.689	rs55876968	ENSG00000223466.1	AC064834.2	-6.45	6.57e-10	1e-06	-0.56	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549015	chr2:195533035~195538681:+
OV	cis	rs4591358	0.689	rs55974440	ENSG00000223466.1	AC064834.2	-6.45	6.57e-10	1e-06	-0.56	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549056	chr2:195533035~195538681:+
OV	cis	rs4591358	0.689	rs12471810	ENSG00000223466.1	AC064834.2	-6.45	6.57e-10	1e-06	-0.56	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549969	chr2:195533035~195538681:+
OV	cis	rs4591358	0.689	rs2133860	ENSG00000223466.1	AC064834.2	-6.45	6.57e-10	1e-06	-0.56	-0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195551243	chr2:195533035~195538681:+
OV	cis	rs2243480	1	rs313813	ENSG00000222364.1	RNU6-96P	-6.45	6.58e-10	1e-06	-0.64	-0.39	Diabetic kidney disease;	chr7:66038513	chr7:66395191~66395286:+
OV	cis	rs10740039	0.549	rs9414741	ENSG00000254271.1	RP11-131N11.4	-6.45	6.62e-10	1.01e-06	-0.5	-0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60738510	chr10:60734342~60741828:+
OV	cis	rs10510102	0.872	rs11200267	ENSG00000276742.1	RP11-500G22.4	6.45	6.64e-10	1.01e-06	0.65	0.39	Breast cancer;	chr10:121929851	chr10:121956782~121957098:+
OV	cis	rs150992	0.655	rs327807	ENSG00000248489.1	CTD-2007H13.3	-6.45	6.67e-10	1.01e-06	-0.49	-0.39	Body mass index;	chr5:98942448	chr5:98929171~98995013:+
OV	cis	rs7044106	0.791	rs10985004	ENSG00000226752.6	PSMD5-AS1	-6.45	6.69e-10	1.02e-06	-0.45	-0.39	Hip circumference adjusted for BMI;	chr9:120722659	chr9:120824828~120854385:+
OV	cis	rs10256972	0.869	rs1007766	ENSG00000229043.2	AC091729.9	-6.45	6.7e-10	1.02e-06	-0.45	-0.39	Endometriosis;Longevity;	chr7:995267	chr7:1160374~1165267:+
OV	cis	rs801193	1	rs10252765	ENSG00000236529.1	RP13-254B10.1	6.45	6.74e-10	1.02e-06	0.42	0.39	Aortic root size;	chr7:66763745	chr7:65840212~65840596:+
OV	cis	rs2836974	0.644	rs9978775	ENSG00000232608.1	TIMM9P2	6.45	6.74e-10	1.02e-06	0.43	0.39	Cognitive function;	chr21:39322600	chr21:39216624~39217506:+
OV	cis	rs10510102	0.872	rs12248004	ENSG00000276742.1	RP11-500G22.4	6.45	6.76e-10	1.03e-06	0.69	0.39	Breast cancer;	chr10:121972215	chr10:121956782~121957098:+
OV	cis	rs7044106	0.762	rs10818471	ENSG00000226752.6	PSMD5-AS1	-6.45	6.79e-10	1.03e-06	-0.46	-0.39	Hip circumference adjusted for BMI;	chr9:120631767	chr9:120824828~120854385:+
OV	cis	rs7044106	0.762	rs7357638	ENSG00000226752.6	PSMD5-AS1	-6.44	6.9e-10	1.05e-06	-0.46	-0.39	Hip circumference adjusted for BMI;	chr9:120626926	chr9:120824828~120854385:+
OV	cis	rs7044106	0.718	rs1960421	ENSG00000226752.6	PSMD5-AS1	-6.44	6.9e-10	1.05e-06	-0.46	-0.39	Hip circumference adjusted for BMI;	chr9:120632616	chr9:120824828~120854385:+
OV	cis	rs7927771	0.864	rs4752838	ENSG00000280615.1	Y_RNA	-6.44	6.94e-10	1.05e-06	-0.48	-0.39	Subjective well-being;	chr11:47444454	chr11:47614898~47614994:-
OV	cis	rs438465	0.853	rs394053	ENSG00000226194.4	RP1-137D17.1	6.44	6.95e-10	1.05e-06	0.54	0.39	Corneal astigmatism;	chr6:169408609	chr6:169369998~169388385:-
OV	cis	rs172166	0.611	rs203883	ENSG00000220721.1	OR1F12	6.44	6.98e-10	1.06e-06	0.43	0.39	Cardiac Troponin-T levels;	chr6:28110578	chr6:28073316~28074233:+
OV	cis	rs2243480	1	rs410128	ENSG00000222364.1	RNU6-96P	-6.44	7e-10	1.06e-06	-0.64	-0.39	Diabetic kidney disease;	chr7:66138186	chr7:66395191~66395286:+
OV	cis	rs10740039	0.583	rs2127350	ENSG00000254271.1	RP11-131N11.4	-6.44	7.03e-10	1.07e-06	-0.5	-0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741079	chr10:60734342~60741828:+
OV	cis	rs10740039	0.583	rs2127351	ENSG00000254271.1	RP11-131N11.4	-6.44	7.03e-10	1.07e-06	-0.5	-0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60741425	chr10:60734342~60741828:+
OV	cis	rs1075265	0.547	rs10865279	ENSG00000233266.1	HMGB1P31	6.44	7.07e-10	1.07e-06	0.47	0.39	Chronotype;Morning vs. evening chronotype;	chr2:54097564	chr2:54051334~54051760:+
OV	cis	rs2153535	0.58	rs6913100	ENSG00000230939.1	RP11-314C16.1	-6.44	7.12e-10	1.08e-06	-0.44	-0.39	Motion sickness;	chr6:8456622	chr6:8784178~8785445:+
OV	cis	rs10740039	0.583	rs1904399	ENSG00000254271.1	RP11-131N11.4	-6.44	7.15e-10	1.08e-06	-0.5	-0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739240	chr10:60734342~60741828:+
OV	cis	rs10740039	0.583	rs1904400	ENSG00000254271.1	RP11-131N11.4	-6.44	7.15e-10	1.08e-06	-0.5	-0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739361	chr10:60734342~60741828:+
OV	cis	rs10740039	0.515	rs9414742	ENSG00000254271.1	RP11-131N11.4	-6.44	7.15e-10	1.08e-06	-0.5	-0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739769	chr10:60734342~60741828:+
OV	cis	rs10740039	0.583	rs9415609	ENSG00000254271.1	RP11-131N11.4	-6.44	7.15e-10	1.08e-06	-0.5	-0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60739832	chr10:60734342~60741828:+
OV	cis	rs796364	0.694	rs1653299	ENSG00000232732.8	AC073043.1	-6.44	7.18e-10	1.09e-06	-0.48	-0.39	Schizophrenia;	chr2:200210888	chr2:199867396~199911159:-
OV	cis	rs7605378	0.528	rs1704191	ENSG00000232732.8	AC073043.1	-6.44	7.18e-10	1.09e-06	-0.48	-0.39	Osteoporosis;	chr2:199951670	chr2:199867396~199911159:-
OV	cis	rs853679	0.513	rs13437444	ENSG00000219392.1	RP1-265C24.5	-6.44	7.19e-10	1.09e-06	-0.55	-0.39	Depression;	chr6:28103220	chr6:28115628~28116551:+
OV	cis	rs1499614	1	rs2141924	ENSG00000222364.1	RNU6-96P	-6.44	7.21e-10	1.09e-06	-0.65	-0.39	Gout;	chr7:66721259	chr7:66395191~66395286:+
OV	cis	rs2564921	0.704	rs12053904	ENSG00000242142.1	SERBP1P3	-6.44	7.22e-10	1.09e-06	-0.44	-0.39	Height;	chr3:52991821	chr3:53064283~53065091:-
OV	cis	rs2564921	0.679	rs2115779	ENSG00000242142.1	SERBP1P3	-6.44	7.22e-10	1.09e-06	-0.44	-0.39	Height;	chr3:52992698	chr3:53064283~53065091:-
OV	cis	rs2836974	0.568	rs7282604	ENSG00000232608.1	TIMM9P2	6.44	7.23e-10	1.09e-06	0.42	0.39	Cognitive function;	chr21:39164984	chr21:39216624~39217506:+
OV	cis	rs2243480	1	rs313814	ENSG00000222364.1	RNU6-96P	-6.43	7.25e-10	1.1e-06	-0.64	-0.39	Diabetic kidney disease;	chr7:66038306	chr7:66395191~66395286:+
OV	cis	rs853679	0.517	rs9380052	ENSG00000219392.1	RP1-265C24.5	-6.43	7.28e-10	1.1e-06	-0.49	-0.39	Depression;	chr6:28096845	chr6:28115628~28116551:+
OV	cis	rs4713118	0.911	rs9295746	ENSG00000220721.1	OR1F12	6.43	7.32e-10	1.11e-06	0.45	0.39	Parkinson's disease;	chr6:27762285	chr6:28073316~28074233:+
OV	cis	rs9918079	0.56	rs13147590	ENSG00000273133.1	RP11-799M12.2	6.43	7.36e-10	1.11e-06	0.45	0.39	Obesity-related traits;	chr4:15619565	chr4:15563698~15564253:-
OV	cis	rs5742933	0.711	rs12693551	ENSG00000253559.1	OSGEPL1-AS1	6.43	7.37e-10	1.11e-06	0.4	0.39	Ferritin levels;	chr2:189664505	chr2:189762704~189765556:+
OV	cis	rs2153535	0.601	rs7738877	ENSG00000230939.1	RP11-314C16.1	-6.43	7.38e-10	1.11e-06	-0.45	-0.39	Motion sickness;	chr6:8541997	chr6:8784178~8785445:+
OV	cis	rs853679	0.55	rs1233701	ENSG00000219392.1	RP1-265C24.5	6.43	7.47e-10	1.13e-06	0.49	0.39	Depression;	chr6:28200948	chr6:28115628~28116551:+
OV	cis	rs875971	0.545	rs35459055	ENSG00000222364.1	RNU6-96P	-6.43	7.5e-10	1.13e-06	-0.46	-0.39	Aortic root size;	chr7:66479399	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs316328	ENSG00000222364.1	RNU6-96P	6.43	7.52e-10	1.13e-06	0.43	0.39	Aortic root size;	chr7:66143851	chr7:66395191~66395286:+
OV	cis	rs853679	0.55	rs1237875	ENSG00000220721.1	OR1F12	-6.43	7.54e-10	1.14e-06	-0.45	-0.39	Depression;	chr6:28205232	chr6:28073316~28074233:+
OV	cis	rs1061377	1	rs12646251	ENSG00000249207.1	RP11-360F5.1	-6.43	7.58e-10	1.14e-06	-0.42	-0.39	Uric acid levels;	chr4:39132751	chr4:39112677~39126818:-
OV	cis	rs9326248	0.559	rs476399	ENSG00000254851.1	RP11-109L13.1	-6.43	7.61e-10	1.15e-06	-0.47	-0.39	Blood protein levels;	chr11:116863012	chr11:117135528~117138582:+
OV	cis	rs796364	0.568	rs11890894	ENSG00000232732.8	AC073043.1	-6.42	7.66e-10	1.15e-06	-0.47	-0.39	Schizophrenia;	chr2:200207332	chr2:199867396~199911159:-
OV	cis	rs2739330	0.791	rs4822458	ENSG00000228039.3	KB-1125A3.10	6.42	7.67e-10	1.16e-06	0.49	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:23963780~23964374:+
OV	cis	rs150992	0.632	rs326493	ENSG00000248489.1	CTD-2007H13.3	6.42	7.7e-10	1.16e-06	0.5	0.39	Body mass index;	chr5:98966251	chr5:98929171~98995013:+
OV	cis	rs10740039	0.583	rs2170005	ENSG00000254271.1	RP11-131N11.4	6.42	7.7e-10	1.16e-06	0.49	0.39	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60740842	chr10:60734342~60741828:+
OV	cis	rs11235843	1	rs2272248	ENSG00000255928.1	RP11-456I15.2	6.42	7.71e-10	1.16e-06	0.64	0.39	Hand grip strength;	chr11:73660897	chr11:73722349~73722694:+
OV	cis	rs11235843	1	rs4944852	ENSG00000255928.1	RP11-456I15.2	6.42	7.71e-10	1.16e-06	0.64	0.39	Hand grip strength;	chr11:73661062	chr11:73722349~73722694:+
OV	cis	rs11235843	1	rs11235843	ENSG00000255928.1	RP11-456I15.2	-6.42	7.71e-10	1.16e-06	-0.64	-0.39	Hand grip strength;	chr11:73662951	chr11:73722349~73722694:+
OV	cis	rs1707322	1	rs12077974	ENSG00000280836.1	AL355480.1	-6.42	7.73e-10	1.16e-06	-0.55	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45918469	chr1:45581219~45581321:-
OV	cis	rs3814244	0.528	rs12582272	ENSG00000255733.4	IFNG-AS1	6.42	7.75e-10	1.17e-06	0.39	0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:68006298	chr12:67989445~68234686:+
OV	cis	rs1707322	1	rs7538978	ENSG00000280836.1	AL355480.1	6.42	7.77e-10	1.17e-06	0.53	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039382	chr1:45581219~45581321:-
OV	cis	rs6991838	0.733	rs13281981	ENSG00000272010.1	CTD-3025N20.3	6.42	7.81e-10	1.17e-06	0.5	0.39	Intelligence (multi-trait analysis);	chr8:65611649	chr8:65591850~65592472:-
OV	cis	rs8105895	0.935	rs7252547	ENSG00000269742.1	BNIP3P29	6.42	7.86e-10	1.18e-06	0.66	0.39	Body mass index (change over time);	chr19:22122679	chr19:22065828~22066398:-
OV	cis	rs1707322	1	rs10789486	ENSG00000280836.1	AL355480.1	-6.42	7.88e-10	1.18e-06	-0.54	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45942995	chr1:45581219~45581321:-
OV	cis	rs5742933	0.725	rs1132360	ENSG00000253559.1	OSGEPL1-AS1	6.42	7.9e-10	1.19e-06	0.4	0.39	Ferritin levels;	chr2:189661498	chr2:189762704~189765556:+
OV	cis	rs9326248	0.559	rs484646	ENSG00000254851.1	RP11-109L13.1	-6.42	7.94e-10	1.19e-06	-0.48	-0.39	Blood protein levels;	chr11:116862140	chr11:117135528~117138582:+
OV	cis	rs875971	0.571	rs78668714	ENSG00000222364.1	RNU6-96P	-6.42	7.96e-10	1.19e-06	-0.46	-0.39	Aortic root size;	chr7:66474464	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs73150604	ENSG00000222364.1	RNU6-96P	-6.42	7.96e-10	1.19e-06	-0.46	-0.39	Aortic root size;	chr7:66480545	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs7810213	ENSG00000222364.1	RNU6-96P	-6.42	7.96e-10	1.19e-06	-0.46	-0.39	Aortic root size;	chr7:66481592	chr7:66395191~66395286:+
OV	cis	rs5742933	0.817	rs4667297	ENSG00000253559.1	OSGEPL1-AS1	6.41	8.13e-10	1.22e-06	0.4	0.39	Ferritin levels;	chr2:189664270	chr2:189762704~189765556:+
OV	cis	rs1707322	1	rs1613296	ENSG00000281133.1	AL355480.3	6.41	8.14e-10	1.22e-06	0.49	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081180	chr1:45580892~45580996:-
OV	cis	rs293748	0.771	rs294695	ENSG00000250155.1	CTD-2353F22.1	-6.41	8.14e-10	1.22e-06	-0.58	-0.39	Obesity-related traits;	chr5:36986586	chr5:36666214~36725195:-
OV	cis	rs2243480	1	rs437889	ENSG00000222364.1	RNU6-96P	-6.41	8.16e-10	1.22e-06	-0.64	-0.39	Diabetic kidney disease;	chr7:66044247	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs402418	ENSG00000222364.1	RNU6-96P	-6.41	8.16e-10	1.22e-06	-0.64	-0.39	Diabetic kidney disease;	chr7:66044482	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs431318	ENSG00000222364.1	RNU6-96P	-6.41	8.16e-10	1.22e-06	-0.64	-0.39	Diabetic kidney disease;	chr7:66046610	chr7:66395191~66395286:+
OV	cis	rs875971	0.54	rs1723268	ENSG00000226824.5	RP4-756H11.3	-6.41	8.19e-10	1.23e-06	-0.41	-0.39	Aortic root size;	chr7:66008093	chr7:66654538~66669855:+
OV	cis	rs4423214	0.524	rs4944046	ENSG00000254682.1	RP11-660L16.2	6.41	8.23e-10	1.23e-06	0.48	0.39	Vitamin D levels;	chr11:71412748	chr11:71448674~71452157:+
OV	cis	rs7688540	0.511	rs11735723	ENSG00000275426.1	CH17-262A2.1	6.41	8.28e-10	1.24e-06	0.79	0.39	Facial morphology (factor 6, height of vermillion lower lip);	chr4:205848	chr4:149738~150317:+
OV	cis	rs293748	1	rs293748	ENSG00000250155.1	CTD-2353F22.1	-6.41	8.32e-10	1.25e-06	-0.57	-0.39	Obesity-related traits;	chr5:36900741	chr5:36666214~36725195:-
OV	cis	rs7044106	0.791	rs7036196	ENSG00000226752.6	PSMD5-AS1	-6.41	8.37e-10	1.25e-06	-0.46	-0.39	Hip circumference adjusted for BMI;	chr9:120717179	chr9:120824828~120854385:+
OV	cis	rs7044106	0.791	rs7036766	ENSG00000226752.6	PSMD5-AS1	-6.41	8.37e-10	1.25e-06	-0.46	-0.39	Hip circumference adjusted for BMI;	chr9:120717343	chr9:120824828~120854385:+
OV	cis	rs3814244	0.528	rs61923060	ENSG00000255733.4	IFNG-AS1	6.41	8.39e-10	1.26e-06	0.39	0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997341	chr12:67989445~68234686:+
OV	cis	rs293748	0.771	rs158798	ENSG00000250155.1	CTD-2353F22.1	-6.41	8.42e-10	1.26e-06	-0.57	-0.39	Obesity-related traits;	chr5:36869157	chr5:36666214~36725195:-
OV	cis	rs1707322	1	rs4298677	ENSG00000280836.1	AL355480.1	-6.41	8.43e-10	1.26e-06	-0.54	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45840947	chr1:45581219~45581321:-
OV	cis	rs2243480	0.803	rs423187	ENSG00000222364.1	RNU6-96P	-6.41	8.5e-10	1.27e-06	-0.64	-0.39	Diabetic kidney disease;	chr7:66044512	chr7:66395191~66395286:+
OV	cis	rs7927771	1	rs10838747	ENSG00000280615.1	Y_RNA	-6.4	8.57e-10	1.28e-06	-0.48	-0.39	Subjective well-being;	chr11:47694772	chr11:47614898~47614994:-
OV	cis	rs9918079	0.56	rs4698406	ENSG00000273133.1	RP11-799M12.2	-6.4	8.59e-10	1.28e-06	-0.46	-0.39	Obesity-related traits;	chr4:15638994	chr4:15563698~15564253:-
OV	cis	rs494459	0.838	rs607125	ENSG00000255422.1	AP002954.4	-6.4	8.6e-10	1.28e-06	-0.44	-0.39	Height;	chr11:118746590	chr11:118704607~118750263:+
OV	cis	rs2745572	0.538	rs4587210	ENSG00000272279.1	RP11-157J24.2	6.4	8.65e-10	1.29e-06	0.48	0.39	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1542956	chr6:1528364~1528911:-
OV	cis	rs11690935	0.686	rs10165126	ENSG00000228389.1	AC068039.4	6.4	8.65e-10	1.29e-06	0.43	0.39	Schizophrenia;	chr2:171963793	chr2:171773482~171775844:+
OV	cis	rs7246967	1	rs11879853	ENSG00000269509.1	BNIP3P34	-6.4	8.7e-10	1.3e-06	-0.58	-0.39	Bronchopulmonary dysplasia;	chr19:22846632	chr19:22773853~22774424:+
OV	cis	rs7927771	0.931	rs4752801	ENSG00000280615.1	Y_RNA	-6.4	8.74e-10	1.3e-06	-0.49	-0.39	Subjective well-being;	chr11:47886089	chr11:47614898~47614994:-
OV	cis	rs11235843	0.734	rs11235920	ENSG00000255928.1	RP11-456I15.2	6.4	8.75e-10	1.31e-06	0.65	0.39	Hand grip strength;	chr11:73824841	chr11:73722349~73722694:+
OV	cis	rs8062405	0.965	rs8049439	ENSG00000259982.1	CDC37P1	6.4	8.76e-10	1.31e-06	0.48	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826194	chr16:28700294~28701540:-
OV	cis	rs7927771	0.8	rs55876153	ENSG00000280615.1	Y_RNA	-6.4	8.82e-10	1.32e-06	-0.47	-0.39	Subjective well-being;	chr11:47395085	chr11:47614898~47614994:-
OV	cis	rs3814244	0.528	rs10878723	ENSG00000255733.4	IFNG-AS1	6.4	8.89e-10	1.32e-06	0.39	0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005493	chr12:67989445~68234686:+
OV	cis	rs9918079	0.542	rs7688984	ENSG00000273133.1	RP11-799M12.2	-6.4	8.9e-10	1.33e-06	-0.46	-0.39	Obesity-related traits;	chr4:15655630	chr4:15563698~15564253:-
OV	cis	rs293748	0.771	rs292179	ENSG00000250155.1	CTD-2353F22.1	-6.4	8.92e-10	1.33e-06	-0.58	-0.39	Obesity-related traits;	chr5:36947511	chr5:36666214~36725195:-
OV	cis	rs293748	0.771	rs292181	ENSG00000250155.1	CTD-2353F22.1	-6.4	8.92e-10	1.33e-06	-0.58	-0.39	Obesity-related traits;	chr5:36952474	chr5:36666214~36725195:-
OV	cis	rs293748	0.771	rs292186	ENSG00000250155.1	CTD-2353F22.1	-6.4	8.92e-10	1.33e-06	-0.58	-0.39	Obesity-related traits;	chr5:36967320	chr5:36666214~36725195:-
OV	cis	rs2243480	1	rs465359	ENSG00000222364.1	RNU6-96P	-6.4	9.01e-10	1.34e-06	-0.62	-0.39	Diabetic kidney disease;	chr7:66093177	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs462853	ENSG00000222364.1	RNU6-96P	-6.4	9.01e-10	1.34e-06	-0.62	-0.39	Diabetic kidney disease;	chr7:66093180	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs160644	ENSG00000222364.1	RNU6-96P	-6.4	9.01e-10	1.34e-06	-0.62	-0.39	Diabetic kidney disease;	chr7:66093199	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs160642	ENSG00000222364.1	RNU6-96P	-6.4	9.01e-10	1.34e-06	-0.62	-0.39	Diabetic kidney disease;	chr7:66093386	chr7:66395191~66395286:+
OV	cis	rs2243480	0.614	rs34032527	ENSG00000222364.1	RNU6-96P	-6.4	9.01e-10	1.34e-06	-0.62	-0.39	Diabetic kidney disease;	chr7:66100154	chr7:66395191~66395286:+
OV	cis	rs7688540	0.771	rs61794996	ENSG00000275426.1	CH17-262A2.1	6.39	9.06e-10	1.35e-06	0.68	0.39	Facial morphology (factor 6, height of vermillion lower lip);	chr4:215539	chr4:149738~150317:+
OV	cis	rs8040855	0.644	rs7495437	ENSG00000229212.6	RP11-561C5.4	-6.39	9.09e-10	1.35e-06	-0.49	-0.39	Bulimia nervosa;	chr15:85183059	chr15:85205440~85234795:-
OV	cis	rs801193	0.591	rs9986881	ENSG00000236529.1	RP13-254B10.1	6.39	9.12e-10	1.35e-06	0.46	0.39	Aortic root size;	chr7:66708053	chr7:65840212~65840596:+
OV	cis	rs7044106	0.791	rs4617229	ENSG00000226752.6	PSMD5-AS1	-6.39	9.12e-10	1.36e-06	-0.44	-0.39	Hip circumference adjusted for BMI;	chr9:120718418	chr9:120824828~120854385:+
OV	cis	rs293748	0.771	rs16903490	ENSG00000250155.1	CTD-2353F22.1	-6.39	9.12e-10	1.36e-06	-0.57	-0.39	Obesity-related traits;	chr5:37067944	chr5:36666214~36725195:-
OV	cis	rs1707322	0.821	rs11211182	ENSG00000280836.1	AL355480.1	-6.39	9.12e-10	1.36e-06	-0.55	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45774498	chr1:45581219~45581321:-
OV	cis	rs3814244	0.528	rs7952790	ENSG00000255733.4	IFNG-AS1	6.39	9.14e-10	1.36e-06	0.4	0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:68012672	chr12:67989445~68234686:+
OV	cis	rs10510102	0.872	rs11200269	ENSG00000276742.1	RP11-500G22.4	6.39	9.31e-10	1.38e-06	0.63	0.39	Breast cancer;	chr10:121934021	chr10:121956782~121957098:+
OV	cis	rs10510102	0.872	rs11498944	ENSG00000276742.1	RP11-500G22.4	6.39	9.31e-10	1.38e-06	0.63	0.39	Breast cancer;	chr10:121938748	chr10:121956782~121957098:+
OV	cis	rs10510102	0.81	rs12267347	ENSG00000276742.1	RP11-500G22.4	6.39	9.31e-10	1.38e-06	0.63	0.39	Breast cancer;	chr10:121939110	chr10:121956782~121957098:+
OV	cis	rs10510102	0.808	rs12253007	ENSG00000276742.1	RP11-500G22.4	6.39	9.31e-10	1.38e-06	0.63	0.39	Breast cancer;	chr10:121939360	chr10:121956782~121957098:+
OV	cis	rs10510102	0.872	rs74318512	ENSG00000276742.1	RP11-500G22.4	6.39	9.31e-10	1.38e-06	0.63	0.39	Breast cancer;	chr10:121941465	chr10:121956782~121957098:+
OV	cis	rs10510102	0.872	rs12257207	ENSG00000276742.1	RP11-500G22.4	6.39	9.31e-10	1.38e-06	0.63	0.39	Breast cancer;	chr10:121941737	chr10:121956782~121957098:+
OV	cis	rs10510102	0.872	rs7916008	ENSG00000276742.1	RP11-500G22.4	6.39	9.31e-10	1.38e-06	0.63	0.39	Breast cancer;	chr10:121943578	chr10:121956782~121957098:+
OV	cis	rs10510102	0.872	rs7916380	ENSG00000276742.1	RP11-500G22.4	6.39	9.31e-10	1.38e-06	0.63	0.39	Breast cancer;	chr10:121943773	chr10:121956782~121957098:+
OV	cis	rs10510102	0.808	rs7920024	ENSG00000276742.1	RP11-500G22.4	6.39	9.31e-10	1.38e-06	0.63	0.39	Breast cancer;	chr10:121944063	chr10:121956782~121957098:+
OV	cis	rs3091242	0.933	rs926438	ENSG00000261349.1	RP3-465N24.5	-6.39	9.36e-10	1.39e-06	-0.44	-0.39	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25266102~25267136:-
OV	cis	rs875971	0.545	rs1909508	ENSG00000222364.1	RNU6-96P	-6.39	9.37e-10	1.39e-06	-0.46	-0.39	Aortic root size;	chr7:66301366	chr7:66395191~66395286:+
OV	cis	rs1707322	0.752	rs12062535	ENSG00000280836.1	AL355480.1	-6.39	9.38e-10	1.39e-06	-0.55	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr1:45581219~45581321:-
OV	cis	rs1707322	0.821	rs10749857	ENSG00000280836.1	AL355480.1	-6.39	9.39e-10	1.39e-06	-0.54	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45782471	chr1:45581219~45581321:-
OV	cis	rs2243480	1	rs427044	ENSG00000222364.1	RNU6-96P	-6.39	9.39e-10	1.39e-06	-0.63	-0.39	Diabetic kidney disease;	chr7:66043558	chr7:66395191~66395286:+
OV	cis	rs293748	0.713	rs158789	ENSG00000250155.1	CTD-2353F22.1	-6.39	9.39e-10	1.39e-06	-0.57	-0.39	Obesity-related traits;	chr5:36834955	chr5:36666214~36725195:-
OV	cis	rs1185460	1	rs1784305	ENSG00000271751.1	RP11-110I1.14	-6.39	9.41e-10	1.39e-06	-0.47	-0.39	Coronary artery disease;	chr11:119071338	chr11:119065263~119065677:-
OV	cis	rs7017914	0.967	rs17688313	ENSG00000223220.1	Y_RNA	-6.39	9.44e-10	1.4e-06	-0.41	-0.39	Bone mineral density;	chr8:70771629	chr8:70780914~70781008:-
OV	cis	rs875971	0.545	rs10950036	ENSG00000222364.1	RNU6-96P	-6.39	9.46e-10	1.4e-06	-0.46	-0.39	Aortic root size;	chr7:66353241	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs73148639	ENSG00000222364.1	RNU6-96P	-6.39	9.46e-10	1.4e-06	-0.46	-0.39	Aortic root size;	chr7:66390342	chr7:66395191~66395286:+
OV	cis	rs10256972	0.521	rs7811577	ENSG00000229043.2	AC091729.9	-6.39	9.52e-10	1.41e-06	-0.44	-0.39	Endometriosis;Longevity;	chr7:1063193	chr7:1160374~1165267:+
OV	cis	rs1707322	1	rs6675222	ENSG00000280836.1	AL355480.1	-6.38	9.61e-10	1.42e-06	-0.53	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45860904	chr1:45581219~45581321:-
OV	cis	rs8062405	0.789	rs180743	ENSG00000259982.1	CDC37P1	6.38	9.62e-10	1.42e-06	0.47	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28496323	chr16:28700294~28701540:-
OV	cis	rs2153535	0.518	rs9328485	ENSG00000230939.1	RP11-314C16.1	-6.38	9.64e-10	1.43e-06	-0.44	-0.39	Motion sickness;	chr6:8524831	chr6:8784178~8785445:+
OV	cis	rs10510102	0.872	rs79865971	ENSG00000276742.1	RP11-500G22.4	6.38	9.66e-10	1.43e-06	0.63	0.39	Breast cancer;	chr10:121941208	chr10:121956782~121957098:+
OV	cis	rs7044106	0.762	rs7849566	ENSG00000226752.6	PSMD5-AS1	-6.38	9.74e-10	1.44e-06	-0.46	-0.39	Hip circumference adjusted for BMI;	chr9:120698491	chr9:120824828~120854385:+
OV	cis	rs10510102	0.872	rs11200268	ENSG00000276742.1	RP11-500G22.4	6.38	9.74e-10	1.44e-06	0.63	0.39	Breast cancer;	chr10:121932661	chr10:121956782~121957098:+
OV	cis	rs7927771	0.832	rs1317164	ENSG00000280615.1	Y_RNA	-6.38	9.79e-10	1.45e-06	-0.47	-0.39	Subjective well-being;	chr11:47398206	chr11:47614898~47614994:-
OV	cis	rs950169	0.579	rs12913054	ENSG00000235370.6	DNM1P51	6.38	9.81e-10	1.45e-06	0.56	0.39	Schizophrenia;	chr15:83995704	chr15:84398316~84411701:-
OV	cis	rs875971	0.545	rs2279757	ENSG00000222364.1	RNU6-96P	-6.38	9.87e-10	1.46e-06	-0.46	-0.39	Aortic root size;	chr7:66363676	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs11766183	ENSG00000222364.1	RNU6-96P	-6.38	9.87e-10	1.46e-06	-0.46	-0.39	Aortic root size;	chr7:66374173	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs1065265	ENSG00000222364.1	RNU6-96P	-6.38	9.87e-10	1.46e-06	-0.46	-0.39	Aortic root size;	chr7:66376216	chr7:66395191~66395286:+
OV	cis	rs875971	0.545	rs7811204	ENSG00000222364.1	RNU6-96P	-6.38	9.87e-10	1.46e-06	-0.46	-0.39	Aortic root size;	chr7:66387213	chr7:66395191~66395286:+
OV	cis	rs1707322	1	rs12403666	ENSG00000280836.1	AL355480.1	-6.38	9.88e-10	1.46e-06	-0.54	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45965949	chr1:45581219~45581321:-
OV	cis	rs2243480	1	rs4718317	ENSG00000222364.1	RNU6-96P	6.38	9.9e-10	1.46e-06	0.6	0.39	Diabetic kidney disease;	chr7:66183914	chr7:66395191~66395286:+
OV	cis	rs1499614	1	rs1267817	ENSG00000222364.1	RNU6-96P	-6.38	9.9e-10	1.46e-06	-0.62	-0.39	Gout;	chr7:66645053	chr7:66395191~66395286:+
OV	cis	rs293748	0.771	rs158799	ENSG00000250155.1	CTD-2353F22.1	-6.38	9.9e-10	1.46e-06	-0.58	-0.39	Obesity-related traits;	chr5:36869149	chr5:36666214~36725195:-
OV	cis	rs1789	0.786	rs6414768	ENSG00000273133.1	RP11-799M12.2	-6.38	9.94e-10	1.47e-06	-0.46	-0.39	Blood protein levels;	chr4:15693740	chr4:15563698~15564253:-
OV	cis	rs293748	0.771	rs151947	ENSG00000250155.1	CTD-2353F22.1	-6.38	9.97e-10	1.47e-06	-0.57	-0.39	Obesity-related traits;	chr5:36865491	chr5:36666214~36725195:-
OV	cis	rs9326248	0.52	rs1446105	ENSG00000254851.1	RP11-109L13.1	-6.38	1e-09	1.48e-06	-0.46	-0.39	Blood protein levels;	chr11:116927828	chr11:117135528~117138582:+
OV	cis	rs293748	0.771	rs159141	ENSG00000250155.1	CTD-2353F22.1	-6.38	1.01e-09	1.48e-06	-0.57	-0.39	Obesity-related traits;	chr5:36925544	chr5:36666214~36725195:-
OV	cis	rs293748	0.771	rs159140	ENSG00000250155.1	CTD-2353F22.1	-6.38	1.01e-09	1.48e-06	-0.57	-0.39	Obesity-related traits;	chr5:36925903	chr5:36666214~36725195:-
OV	cis	rs6700559	0.873	rs7526031	ENSG00000260088.1	RP11-92G12.3	-6.37	1.01e-09	1.49e-06	-0.41	-0.39	Coronary artery disease;	chr1:200695174	chr1:200669507~200694250:+
OV	cis	rs4713118	0.869	rs9295743	ENSG00000220721.1	OR1F12	6.37	1.02e-09	1.5e-06	0.41	0.39	Parkinson's disease;	chr6:27747323	chr6:28073316~28074233:+
OV	cis	rs801193	0.613	rs2016325	ENSG00000226824.5	RP4-756H11.3	6.37	1.02e-09	1.5e-06	0.42	0.39	Aortic root size;	chr7:66858513	chr7:66654538~66669855:+
OV	cis	rs2243480	0.803	rs36127118	ENSG00000222364.1	RNU6-96P	-6.37	1.03e-09	1.51e-06	-0.61	-0.39	Diabetic kidney disease;	chr7:66100518	chr7:66395191~66395286:+
OV	cis	rs1499614	0.803	rs1796229	ENSG00000222364.1	RNU6-96P	-6.37	1.04e-09	1.52e-06	-0.62	-0.39	Gout;	chr7:66654674	chr7:66395191~66395286:+
OV	cis	rs1499614	0.901	rs3936	ENSG00000222364.1	RNU6-96P	-6.37	1.04e-09	1.52e-06	-0.62	-0.39	Gout;	chr7:66661502	chr7:66395191~66395286:+
OV	cis	rs8040855	0.542	rs2342122	ENSG00000229212.6	RP11-561C5.4	-6.37	1.04e-09	1.53e-06	-0.48	-0.39	Bulimia nervosa;	chr15:85185304	chr15:85205440~85234795:-
OV	cis	rs8040855	0.644	rs2342120	ENSG00000229212.6	RP11-561C5.4	-6.37	1.04e-09	1.53e-06	-0.48	-0.39	Bulimia nervosa;	chr15:85185589	chr15:85205440~85234795:-
OV	cis	rs6991838	0.798	rs62507575	ENSG00000272010.1	CTD-3025N20.3	6.37	1.04e-09	1.53e-06	0.48	0.39	Intelligence (multi-trait analysis);	chr8:65566486	chr8:65591850~65592472:-
OV	cis	rs1707322	0.927	rs6690386	ENSG00000280836.1	AL355480.1	-6.37	1.06e-09	1.55e-06	-0.55	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45787339	chr1:45581219~45581321:-
OV	cis	rs1707322	0.963	rs4630155	ENSG00000280836.1	AL355480.1	-6.37	1.06e-09	1.55e-06	-0.55	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45791438	chr1:45581219~45581321:-
OV	cis	rs1707322	0.963	rs4508055	ENSG00000280836.1	AL355480.1	-6.37	1.06e-09	1.55e-06	-0.55	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792059	chr1:45581219~45581321:-
OV	cis	rs1707322	0.963	rs12076580	ENSG00000280836.1	AL355480.1	-6.37	1.06e-09	1.55e-06	-0.55	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45792487	chr1:45581219~45581321:-
OV	cis	rs2243480	1	rs160633	ENSG00000222364.1	RNU6-96P	-6.37	1.06e-09	1.55e-06	-0.61	-0.39	Diabetic kidney disease;	chr7:66063241	chr7:66395191~66395286:+
OV	cis	rs2564921	0.704	rs62255931	ENSG00000242142.1	SERBP1P3	-6.36	1.07e-09	1.57e-06	-0.46	-0.39	Height;	chr3:53097932	chr3:53064283~53065091:-
OV	cis	rs10510102	0.872	rs12244199	ENSG00000276742.1	RP11-500G22.4	6.36	1.1e-09	1.61e-06	0.64	0.39	Breast cancer;	chr10:121965117	chr10:121956782~121957098:+
OV	cis	rs494459	0.688	rs1048040	ENSG00000255422.1	AP002954.4	-6.36	1.1e-09	1.61e-06	-0.43	-0.39	Height;	chr11:118747911	chr11:118704607~118750263:+
OV	cis	rs12134133	1	rs6673333	ENSG00000274245.1	RP11-357P18.2	6.36	1.1e-09	1.61e-06	0.53	0.39	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285802	chr1:207372559~207373252:+
OV	cis	rs7617773	0.539	rs12486935	ENSG00000229759.1	MRPS18AP1	6.36	1.1e-09	1.61e-06	0.41	0.39	Coronary artery disease;	chr3:48348674	chr3:48256350~48256938:-
OV	cis	rs7017914	0.593	rs2732140	ENSG00000223220.1	Y_RNA	6.36	1.12e-09	1.64e-06	0.42	0.39	Bone mineral density;	chr8:70998491	chr8:70780914~70781008:-
OV	cis	rs6700559	1	rs10800720	ENSG00000260088.1	RP11-92G12.3	-6.36	1.12e-09	1.64e-06	-0.42	-0.39	Coronary artery disease;	chr1:200679441	chr1:200669507~200694250:+
OV	cis	rs6700559	0.935	rs4072553	ENSG00000260088.1	RP11-92G12.3	-6.36	1.12e-09	1.64e-06	-0.42	-0.39	Coronary artery disease;	chr1:200680036	chr1:200669507~200694250:+
OV	cis	rs494459	0.838	rs1784543	ENSG00000255422.1	AP002954.4	-6.36	1.12e-09	1.64e-06	-0.44	-0.39	Height;	chr11:118760944	chr11:118704607~118750263:+
OV	cis	rs3931020	0.508	rs11485298	ENSG00000272864.1	RP11-17E13.2	-6.36	1.13e-09	1.65e-06	-0.51	-0.39	Resistin levels;	chr1:74752068	chr1:74698769~74699333:-
OV	cis	rs3931020	0.508	rs4145871	ENSG00000272864.1	RP11-17E13.2	-6.36	1.13e-09	1.65e-06	-0.51	-0.39	Resistin levels;	chr1:74753020	chr1:74698769~74699333:-
OV	cis	rs6921919	0.789	rs1119211	ENSG00000216901.1	AL022393.7	-6.36	1.13e-09	1.65e-06	-0.49	-0.39	Autism spectrum disorder or schizophrenia;	chr6:28341359	chr6:28176188~28176674:+
OV	cis	rs4380275	0.809	rs6753699	ENSG00000272342.1	RP13-539J13.1	6.35	1.13e-09	1.65e-06	0.43	0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:766081	chr2:739588~740164:-
OV	cis	rs4380275	0.782	rs60367761	ENSG00000272342.1	RP13-539J13.1	6.35	1.13e-09	1.65e-06	0.43	0.39	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:766414	chr2:739588~740164:-
OV	cis	rs2739330	0.587	rs4820571	ENSG00000218537.1	MIF-AS1	6.35	1.14e-09	1.67e-06	0.47	0.39	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23894426~23898930:-
OV	cis	rs11235843	0.853	rs1043234	ENSG00000255928.1	RP11-456I15.2	6.35	1.15e-09	1.67e-06	0.63	0.39	Hand grip strength;	chr11:73760716	chr11:73722349~73722694:+
OV	cis	rs11235843	0.929	rs3211165	ENSG00000255928.1	RP11-456I15.2	6.35	1.15e-09	1.67e-06	0.63	0.39	Hand grip strength;	chr11:73760733	chr11:73722349~73722694:+
OV	cis	rs1707322	1	rs11211200	ENSG00000280836.1	AL355480.1	-6.35	1.15e-09	1.68e-06	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45822680	chr1:45581219~45581321:-
OV	cis	rs6991838	0.765	rs10957358	ENSG00000272010.1	CTD-3025N20.3	6.35	1.15e-09	1.68e-06	0.49	0.39	Intelligence (multi-trait analysis);	chr8:65590067	chr8:65591850~65592472:-
OV	cis	rs11673344	0.74	rs113752815	ENSG00000226686.6	LINC01535	6.35	1.15e-09	1.68e-06	0.53	0.39	Obesity-related traits;	chr19:37043829	chr19:37251912~37265535:+
OV	cis	rs7615952	0.688	rs7624806	ENSG00000171084.14	FAM86JP	6.35	1.15e-09	1.69e-06	0.63	0.39	Blood pressure (smoking interaction);	chr3:125880231	chr3:125916620~125930024:+
OV	cis	rs7688540	0.723	rs17521834	ENSG00000275426.1	CH17-262A2.1	-6.35	1.15e-09	1.69e-06	-0.63	-0.39	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231660	chr4:149738~150317:+
OV	cis	rs9595066	0.627	rs4942287	ENSG00000227258.4	SMIM2-AS1	-6.35	1.16e-09	1.69e-06	-0.63	-0.39	Schizophrenia;	chr13:44160560	chr13:44110451~44240517:+
OV	cis	rs11723261	0.582	rs11248005	ENSG00000275426.1	CH17-262A2.1	6.35	1.16e-09	1.7e-06	0.64	0.39	Immune response to smallpox vaccine (IL-6);	chr4:172826	chr4:149738~150317:+
OV	cis	rs11723261	0.582	rs11733927	ENSG00000275426.1	CH17-262A2.1	6.35	1.16e-09	1.7e-06	0.64	0.39	Immune response to smallpox vaccine (IL-6);	chr4:173039	chr4:149738~150317:+
OV	cis	rs7044106	0.791	rs4836829	ENSG00000226752.6	PSMD5-AS1	-6.35	1.18e-09	1.72e-06	-0.44	-0.39	Hip circumference adjusted for BMI;	chr9:120720469	chr9:120824828~120854385:+
OV	cis	rs7044106	0.791	rs4837792	ENSG00000226752.6	PSMD5-AS1	-6.35	1.18e-09	1.72e-06	-0.44	-0.39	Hip circumference adjusted for BMI;	chr9:120721281	chr9:120824828~120854385:+
OV	cis	rs7044106	0.791	rs4837793	ENSG00000226752.6	PSMD5-AS1	-6.35	1.18e-09	1.72e-06	-0.44	-0.39	Hip circumference adjusted for BMI;	chr9:120721343	chr9:120824828~120854385:+
OV	cis	rs7044106	0.791	rs10985000	ENSG00000226752.6	PSMD5-AS1	-6.35	1.18e-09	1.72e-06	-0.44	-0.39	Hip circumference adjusted for BMI;	chr9:120721837	chr9:120824828~120854385:+
OV	cis	rs7044106	0.791	rs10818473	ENSG00000226752.6	PSMD5-AS1	-6.35	1.18e-09	1.72e-06	-0.44	-0.39	Hip circumference adjusted for BMI;	chr9:120721877	chr9:120824828~120854385:+
OV	cis	rs7044106	0.791	rs10985001	ENSG00000226752.6	PSMD5-AS1	-6.35	1.18e-09	1.72e-06	-0.44	-0.39	Hip circumference adjusted for BMI;	chr9:120721954	chr9:120824828~120854385:+
OV	cis	rs4713118	0.911	rs9461406	ENSG00000220721.1	OR1F12	-6.35	1.19e-09	1.73e-06	-0.45	-0.39	Parkinson's disease;	chr6:27751985	chr6:28073316~28074233:+
OV	cis	rs3814244	0.528	rs7306466	ENSG00000255733.4	IFNG-AS1	6.35	1.19e-09	1.74e-06	0.39	0.39	Itch intensity from mosquito bite adjusted by bite size;	chr12:68014942	chr12:67989445~68234686:+
OV	cis	rs6921919	0.789	rs11970439	ENSG00000216901.1	AL022393.7	6.35	1.19e-09	1.74e-06	0.5	0.39	Autism spectrum disorder or schizophrenia;	chr6:28335687	chr6:28176188~28176674:+
OV	cis	rs1707322	0.752	rs28550303	ENSG00000280836.1	AL355480.1	-6.35	1.19e-09	1.74e-06	-0.55	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr1:45581219~45581321:-
OV	cis	rs4713118	0.869	rs9283880	ENSG00000220721.1	OR1F12	6.34	1.21e-09	1.76e-06	0.41	0.39	Parkinson's disease;	chr6:27747464	chr6:28073316~28074233:+
OV	cis	rs6921919	0.848	rs6903823	ENSG00000216901.1	AL022393.7	6.34	1.21e-09	1.76e-06	0.51	0.39	Autism spectrum disorder or schizophrenia;	chr6:28354519	chr6:28176188~28176674:+
OV	cis	rs7044106	0.762	rs966396	ENSG00000226752.6	PSMD5-AS1	-6.34	1.22e-09	1.77e-06	-0.45	-0.39	Hip circumference adjusted for BMI;	chr9:120691003	chr9:120824828~120854385:+
OV	cis	rs7044106	0.762	rs1867254	ENSG00000226752.6	PSMD5-AS1	-6.34	1.23e-09	1.79e-06	-0.45	-0.39	Hip circumference adjusted for BMI;	chr9:120666800	chr9:120824828~120854385:+
OV	cis	rs4713118	0.869	rs9348775	ENSG00000220721.1	OR1F12	6.34	1.24e-09	1.8e-06	0.43	0.39	Parkinson's disease;	chr6:27727550	chr6:28073316~28074233:+
OV	cis	rs6921919	1	rs6922111	ENSG00000216901.1	AL022393.7	6.34	1.24e-09	1.81e-06	0.53	0.39	Autism spectrum disorder or schizophrenia;	chr6:28357531	chr6:28176188~28176674:+
OV	cis	rs4713118	0.869	rs2056925	ENSG00000220721.1	OR1F12	6.34	1.25e-09	1.82e-06	0.41	0.39	Parkinson's disease;	chr6:27723126	chr6:28073316~28074233:+
OV	cis	rs8062405	0.723	rs113208333	ENSG00000259982.1	CDC37P1	6.34	1.26e-09	1.83e-06	0.47	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28700294~28701540:-
OV	cis	rs8062405	0.691	rs743590	ENSG00000259982.1	CDC37P1	6.34	1.26e-09	1.83e-06	0.47	0.39	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28700294~28701540:-
OV	cis	rs7044106	0.791	rs2416799	ENSG00000226752.6	PSMD5-AS1	-6.34	1.26e-09	1.83e-06	-0.44	-0.39	Hip circumference adjusted for BMI;	chr9:120718588	chr9:120824828~120854385:+
OV	cis	rs7044106	0.791	rs10984998	ENSG00000226752.6	PSMD5-AS1	-6.34	1.26e-09	1.83e-06	-0.44	-0.39	Hip circumference adjusted for BMI;	chr9:120719238	chr9:120824828~120854385:+
OV	cis	rs7927771	1	rs4752873	ENSG00000280615.1	Y_RNA	-6.34	1.26e-09	1.83e-06	-0.47	-0.39	Subjective well-being;	chr11:47835968	chr11:47614898~47614994:-
OV	cis	rs73086581	1	rs3746665	ENSG00000229539.1	RP11-119B16.2	-6.33	1.27e-09	1.84e-06	-0.45	-0.39	Response to antidepressants in depression;	chr20:3929759	chr20:3888239~3888868:-
OV	cis	rs11235843	0.866	rs11235888	ENSG00000255928.1	RP11-456I15.2	6.33	1.27e-09	1.85e-06	0.63	0.39	Hand grip strength;	chr11:73759512	chr11:73722349~73722694:+
OV	cis	rs2243480	1	rs313832	ENSG00000222364.1	RNU6-96P	-6.33	1.28e-09	1.85e-06	-0.62	-0.39	Diabetic kidney disease;	chr7:66085904	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs313831	ENSG00000222364.1	RNU6-96P	-6.33	1.28e-09	1.85e-06	-0.62	-0.39	Diabetic kidney disease;	chr7:66086239	chr7:66395191~66395286:+
OV	cis	rs1707322	1	rs10890382	ENSG00000280836.1	AL355480.1	-6.33	1.28e-09	1.86e-06	-0.54	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46004002	chr1:45581219~45581321:-
OV	cis	rs7927771	0.832	rs935914	ENSG00000280615.1	Y_RNA	6.33	1.29e-09	1.87e-06	0.46	0.39	Subjective well-being;	chr11:47366048	chr11:47614898~47614994:-
OV	cis	rs796364	0.789	rs1653297	ENSG00000232732.8	AC073043.1	-6.33	1.29e-09	1.88e-06	-0.49	-0.39	Schizophrenia;	chr2:200210760	chr2:199867396~199911159:-
OV	cis	rs7044106	0.762	rs1530370	ENSG00000226752.6	PSMD5-AS1	-6.33	1.3e-09	1.88e-06	-0.45	-0.39	Hip circumference adjusted for BMI;	chr9:120662274	chr9:120824828~120854385:+
OV	cis	rs62355901	0.545	rs16886263	ENSG00000271828.1	CTD-2310F14.1	-6.33	1.3e-09	1.88e-06	-0.69	-0.39	Breast cancer;	chr5:56769680	chr5:56927874~56929573:+
OV	cis	rs11673344	0.801	rs56343212	ENSG00000226686.6	LINC01535	6.33	1.31e-09	1.89e-06	0.52	0.39	Obesity-related traits;	chr19:37167684	chr19:37251912~37265535:+
OV	cis	rs7927771	0.832	rs4752990	ENSG00000280615.1	Y_RNA	-6.33	1.31e-09	1.9e-06	-0.47	-0.39	Subjective well-being;	chr11:47388842	chr11:47614898~47614994:-
OV	cis	rs6921919	0.848	rs6903652	ENSG00000216901.1	AL022393.7	6.33	1.31e-09	1.9e-06	0.51	0.39	Autism spectrum disorder or schizophrenia;	chr6:28354343	chr6:28176188~28176674:+
OV	cis	rs3091242	0.933	rs11802413	ENSG00000261349.1	RP3-465N24.5	6.33	1.31e-09	1.9e-06	0.41	0.39	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25266102~25267136:-
OV	cis	rs7927771	0.965	rs12364432	ENSG00000280615.1	Y_RNA	-6.33	1.32e-09	1.91e-06	-0.48	-0.39	Subjective well-being;	chr11:47881331	chr11:47614898~47614994:-
OV	cis	rs853679	0.55	rs1233707	ENSG00000219392.1	RP1-265C24.5	-6.33	1.32e-09	1.91e-06	-0.48	-0.39	Depression;	chr6:28205175	chr6:28115628~28116551:+
OV	cis	rs7044106	0.762	rs7044226	ENSG00000226752.6	PSMD5-AS1	-6.33	1.32e-09	1.92e-06	-0.45	-0.39	Hip circumference adjusted for BMI;	chr9:120704050	chr9:120824828~120854385:+
OV	cis	rs11723261	0.582	rs11732336	ENSG00000275426.1	CH17-262A2.1	6.32	1.34e-09	1.93e-06	0.6	0.39	Immune response to smallpox vaccine (IL-6);	chr4:146728	chr4:149738~150317:+
OV	cis	rs1707322	0.896	rs946528	ENSG00000281133.1	AL355480.3	6.32	1.34e-09	1.93e-06	0.49	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019890	chr1:45580892~45580996:-
OV	cis	rs7927771	0.864	rs3781625	ENSG00000280615.1	Y_RNA	-6.32	1.34e-09	1.94e-06	-0.47	-0.39	Subjective well-being;	chr11:47421529	chr11:47614898~47614994:-
OV	cis	rs1707322	1	rs4660335	ENSG00000280836.1	AL355480.1	-6.32	1.34e-09	1.94e-06	-0.54	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46009046	chr1:45581219~45581321:-
OV	cis	rs2380205	0.5	rs688388	ENSG00000232807.2	RP11-536K7.3	-6.32	1.34e-09	1.94e-06	-0.4	-0.39	Breast cancer;	chr10:5918667	chr10:5934270~5945900:-
OV	cis	rs2564921	0.704	rs55950520	ENSG00000242142.1	SERBP1P3	-6.32	1.34e-09	1.94e-06	-0.46	-0.39	Height;	chr3:53094335	chr3:53064283~53065091:-
OV	cis	rs17361889	0.727	rs1295129	ENSG00000224683.1	RPL36AP29	-6.32	1.35e-09	1.94e-06	-0.45	-0.39	Pediatric bone mineral content (hip);	chr7:16277030	chr7:16208945~16209265:+
OV	cis	rs9326248	0.581	rs12225187	ENSG00000254851.1	RP11-109L13.1	-6.32	1.35e-09	1.95e-06	-0.46	-0.39	Blood protein levels;	chr11:116922515	chr11:117135528~117138582:+
OV	cis	rs4713118	0.512	rs2622319	ENSG00000220721.1	OR1F12	6.32	1.35e-09	1.96e-06	0.42	0.39	Parkinson's disease;	chr6:28152623	chr6:28073316~28074233:+
OV	cis	rs11673344	0.838	rs112401881	ENSG00000226686.6	LINC01535	6.32	1.36e-09	1.96e-06	0.53	0.39	Obesity-related traits;	chr19:37156092	chr19:37251912~37265535:+
OV	cis	rs12134133	1	rs28371597	ENSG00000274245.1	RP11-357P18.2	6.32	1.37e-09	1.97e-06	0.51	0.39	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207323551	chr1:207372559~207373252:+
OV	cis	rs4713118	0.621	rs10484403	ENSG00000219392.1	RP1-265C24.5	-6.32	1.38e-09	1.99e-06	-0.49	-0.39	Parkinson's disease;	chr6:28065745	chr6:28115628~28116551:+
OV	cis	rs7246967	0.866	rs35177997	ENSG00000269509.1	BNIP3P34	6.32	1.39e-09	2e-06	0.57	0.39	Bronchopulmonary dysplasia;	chr19:22877425	chr19:22773853~22774424:+
OV	cis	rs7246967	0.935	rs8112754	ENSG00000269509.1	BNIP3P34	6.32	1.39e-09	2e-06	0.57	0.39	Bronchopulmonary dysplasia;	chr19:22878068	chr19:22773853~22774424:+
OV	cis	rs7246967	1	rs8113312	ENSG00000269509.1	BNIP3P34	6.32	1.39e-09	2e-06	0.57	0.39	Bronchopulmonary dysplasia;	chr19:22878380	chr19:22773853~22774424:+
OV	cis	rs950169	0.58	rs2271431	ENSG00000259295.5	CSPG4P12	6.32	1.39e-09	2.01e-06	0.53	0.39	Schizophrenia;	chr15:84646233	chr15:85191438~85213905:+
OV	cis	rs1499614	1	rs1267818	ENSG00000222364.1	RNU6-96P	-6.32	1.39e-09	2.01e-06	-0.62	-0.39	Gout;	chr7:66642037	chr7:66395191~66395286:+
OV	cis	rs875971	0.642	rs35526611	ENSG00000236529.1	RP13-254B10.1	-6.32	1.39e-09	2.01e-06	-0.41	-0.39	Aortic root size;	chr7:66629021	chr7:65840212~65840596:+
OV	cis	rs7927771	0.864	rs55927797	ENSG00000280615.1	Y_RNA	-6.32	1.39e-09	2.01e-06	-0.47	-0.39	Subjective well-being;	chr11:47424741	chr11:47614898~47614994:-
OV	cis	rs62355901	0.551	rs72756073	ENSG00000271828.1	CTD-2310F14.1	6.32	1.39e-09	2.01e-06	0.77	0.39	Breast cancer;	chr5:56732554	chr5:56927874~56929573:+
OV	cis	rs62355901	0.551	rs61103728	ENSG00000271828.1	CTD-2310F14.1	6.32	1.39e-09	2.01e-06	0.77	0.39	Breast cancer;	chr5:56733066	chr5:56927874~56929573:+
OV	cis	rs7044106	0.791	rs3904196	ENSG00000226752.6	PSMD5-AS1	-6.32	1.4e-09	2.01e-06	-0.45	-0.39	Hip circumference adjusted for BMI;	chr9:120718091	chr9:120824828~120854385:+
OV	cis	rs611744	0.967	rs645241	ENSG00000253754.1	RP11-35G22.1	-6.32	1.4e-09	2.02e-06	-0.43	-0.39	Dupuytren's disease;	chr8:108178734	chr8:108226200~108227544:+
OV	cis	rs7246967	0.866	rs34294248	ENSG00000269509.1	BNIP3P34	6.32	1.4e-09	2.02e-06	0.57	0.39	Bronchopulmonary dysplasia;	chr19:22867667	chr19:22773853~22774424:+
OV	cis	rs2153535	0.518	rs913571	ENSG00000230939.1	RP11-314C16.1	-6.32	1.41e-09	2.03e-06	-0.43	-0.39	Motion sickness;	chr6:8591095	chr6:8784178~8785445:+
OV	cis	rs4660456	0.913	rs4660449	ENSG00000237899.1	RP4-739H11.3	6.31	1.41e-09	2.03e-06	0.57	0.39	Platelet count;	chr1:40739780	chr1:40669089~40687588:-
OV	cis	rs7927771	0.864	rs755553	ENSG00000280615.1	Y_RNA	6.31	1.42e-09	2.05e-06	0.46	0.39	Subjective well-being;	chr11:47410752	chr11:47614898~47614994:-
OV	cis	rs1707322	1	rs7517560	ENSG00000280836.1	AL355480.1	-6.31	1.43e-09	2.06e-06	-0.53	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45960271	chr1:45581219~45581321:-
OV	cis	rs11673344	0.832	rs56210764	ENSG00000226686.6	LINC01535	6.31	1.43e-09	2.06e-06	0.52	0.39	Obesity-related traits;	chr19:37125970	chr19:37251912~37265535:+
OV	cis	rs875971	0.638	rs35986979	ENSG00000236529.1	RP13-254B10.1	-6.31	1.43e-09	2.06e-06	-0.41	-0.39	Aortic root size;	chr7:66624003	chr7:65840212~65840596:+
OV	cis	rs1707322	1	rs4660334	ENSG00000280836.1	AL355480.1	-6.31	1.43e-09	2.06e-06	-0.52	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45996454	chr1:45581219~45581321:-
OV	cis	rs853679	0.55	rs6901017	ENSG00000220721.1	OR1F12	6.31	1.44e-09	2.07e-06	0.46	0.39	Depression;	chr6:28184805	chr6:28073316~28074233:+
OV	cis	rs1185460	0.967	rs1184902	ENSG00000271751.1	RP11-110I1.14	-6.31	1.44e-09	2.07e-06	-0.47	-0.39	Coronary artery disease;	chr11:119074627	chr11:119065263~119065677:-
OV	cis	rs853679	0.55	rs1150689	ENSG00000220721.1	OR1F12	6.31	1.45e-09	2.08e-06	0.46	0.39	Depression;	chr6:28197321	chr6:28073316~28074233:+
OV	cis	rs853679	0.55	rs1225599	ENSG00000220721.1	OR1F12	6.31	1.45e-09	2.08e-06	0.46	0.39	Depression;	chr6:28197412	chr6:28073316~28074233:+
OV	cis	rs853679	0.574	rs1233705	ENSG00000220721.1	OR1F12	6.31	1.45e-09	2.08e-06	0.46	0.39	Depression;	chr6:28198669	chr6:28073316~28074233:+
OV	cis	rs875971	0.66	rs1860468	ENSG00000236529.1	RP13-254B10.1	-6.31	1.45e-09	2.08e-06	-0.41	-0.39	Aortic root size;	chr7:66642265	chr7:65840212~65840596:+
OV	cis	rs7246967	1	rs936525	ENSG00000269509.1	BNIP3P34	6.31	1.46e-09	2.09e-06	0.56	0.39	Bronchopulmonary dysplasia;	chr19:22873387	chr19:22773853~22774424:+
OV	cis	rs11723261	0.621	rs7440274	ENSG00000275426.1	CH17-262A2.1	-6.31	1.47e-09	2.12e-06	-0.59	-0.39	Immune response to smallpox vaccine (IL-6);	chr4:161923	chr4:149738~150317:+
OV	cis	rs1707322	1	rs10890376	ENSG00000280836.1	AL355480.1	-6.31	1.48e-09	2.13e-06	-0.53	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45940910	chr1:45581219~45581321:-
OV	cis	rs3136516	0.537	rs2291444	ENSG00000271350.1	CTD-2384B9.1	6.3	1.49e-09	2.14e-06	0.42	0.39	Venous thromboembolism;	chr11:47157592	chr11:47041027~47041945:-
OV	cis	rs3136516	0.537	rs2291443	ENSG00000271350.1	CTD-2384B9.1	6.3	1.49e-09	2.14e-06	0.42	0.39	Venous thromboembolism;	chr11:47158310	chr11:47041027~47041945:-
OV	cis	rs7017914	0.652	rs2732118	ENSG00000223220.1	Y_RNA	6.3	1.49e-09	2.14e-06	0.42	0.39	Bone mineral density;	chr8:70996430	chr8:70780914~70781008:-
OV	cis	rs7927771	0.832	rs7924485	ENSG00000280615.1	Y_RNA	6.3	1.49e-09	2.14e-06	0.47	0.39	Subjective well-being;	chr11:47397578	chr11:47614898~47614994:-
OV	cis	rs11673344	0.832	rs56080874	ENSG00000226686.6	LINC01535	6.3	1.5e-09	2.16e-06	0.53	0.39	Obesity-related traits;	chr19:37085487	chr19:37251912~37265535:+
OV	cis	rs11673344	0.77	rs7257135	ENSG00000226686.6	LINC01535	6.3	1.5e-09	2.16e-06	0.53	0.39	Obesity-related traits;	chr19:37088726	chr19:37251912~37265535:+
OV	cis	rs1707322	0.964	rs6675259	ENSG00000280836.1	AL355480.1	6.3	1.51e-09	2.16e-06	0.53	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46036623	chr1:45581219~45581321:-
OV	cis	rs1707322	0.964	rs785508	ENSG00000280836.1	AL355480.1	6.3	1.51e-09	2.16e-06	0.52	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061487	chr1:45581219~45581321:-
OV	cis	rs1707322	0.964	rs785509	ENSG00000280836.1	AL355480.1	6.3	1.51e-09	2.16e-06	0.52	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46061628	chr1:45581219~45581321:-
OV	cis	rs1707322	0.929	rs785513	ENSG00000280836.1	AL355480.1	6.3	1.51e-09	2.16e-06	0.52	0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46072648	chr1:45581219~45581321:-
OV	cis	rs494459	0.838	rs2510897	ENSG00000255422.1	AP002954.4	-6.3	1.51e-09	2.17e-06	-0.43	-0.39	Height;	chr11:118773873	chr11:118704607~118750263:+
OV	cis	rs858239	0.6	rs7776649	ENSG00000230042.1	AK3P3	-6.3	1.52e-09	2.17e-06	-0.41	-0.39	Cerebrospinal fluid biomarker levels;	chr7:23079698	chr7:23129178~23129841:+
OV	cis	rs7927771	1	rs2290850	ENSG00000280615.1	Y_RNA	-6.3	1.52e-09	2.18e-06	-0.48	-0.39	Subjective well-being;	chr11:47786222	chr11:47614898~47614994:-
OV	cis	rs801193	1	rs2659915	ENSG00000236529.1	RP13-254B10.1	6.3	1.52e-09	2.18e-06	0.4	0.39	Aortic root size;	chr7:66688114	chr7:65840212~65840596:+
OV	cis	rs9532669	0.926	rs2039119	ENSG00000176268.5	CYCSP34	-6.3	1.52e-09	2.18e-06	-0.44	-0.39	Cervical cancer;	chr13:40872432	chr13:40863599~40863902:-
OV	cis	rs1790761	0.504	rs61894496	ENSG00000184224.3	C11orf72	6.3	1.52e-09	2.18e-06	0.43	0.39	Mean corpuscular volume;	chr11:67624436	chr11:67602880~67606706:-
OV	cis	rs4713118	0.869	rs9366700	ENSG00000220721.1	OR1F12	6.3	1.52e-09	2.18e-06	0.41	0.39	Parkinson's disease;	chr6:27729172	chr6:28073316~28074233:+
OV	cis	rs4713118	0.869	rs6456802	ENSG00000220721.1	OR1F12	6.3	1.52e-09	2.18e-06	0.41	0.39	Parkinson's disease;	chr6:27730576	chr6:28073316~28074233:+
OV	cis	rs4713118	0.869	rs9393851	ENSG00000220721.1	OR1F12	6.3	1.52e-09	2.18e-06	0.41	0.39	Parkinson's disease;	chr6:27731802	chr6:28073316~28074233:+
OV	cis	rs4713118	0.869	rs9461400	ENSG00000220721.1	OR1F12	6.3	1.52e-09	2.18e-06	0.41	0.39	Parkinson's disease;	chr6:27732780	chr6:28073316~28074233:+
OV	cis	rs4713118	0.869	rs9295742	ENSG00000220721.1	OR1F12	6.3	1.52e-09	2.18e-06	0.41	0.39	Parkinson's disease;	chr6:27735053	chr6:28073316~28074233:+
OV	cis	rs4713118	0.869	rs9461401	ENSG00000220721.1	OR1F12	6.3	1.52e-09	2.18e-06	0.41	0.39	Parkinson's disease;	chr6:27735512	chr6:28073316~28074233:+
OV	cis	rs4713118	0.869	rs6914924	ENSG00000220721.1	OR1F12	6.3	1.52e-09	2.18e-06	0.41	0.39	Parkinson's disease;	chr6:27743751	chr6:28073316~28074233:+
OV	cis	rs4713118	0.869	rs6930992	ENSG00000220721.1	OR1F12	6.3	1.52e-09	2.18e-06	0.41	0.39	Parkinson's disease;	chr6:27744341	chr6:28073316~28074233:+
OV	cis	rs4713118	0.869	rs6901520	ENSG00000220721.1	OR1F12	6.3	1.52e-09	2.18e-06	0.41	0.39	Parkinson's disease;	chr6:27746796	chr6:28073316~28074233:+
OV	cis	rs7044106	0.762	rs1158553	ENSG00000226752.6	PSMD5-AS1	-6.3	1.52e-09	2.18e-06	-0.45	-0.39	Hip circumference adjusted for BMI;	chr9:120638696	chr9:120824828~120854385:+
OV	cis	rs4713118	0.869	rs9283881	ENSG00000220721.1	OR1F12	6.3	1.52e-09	2.18e-06	0.41	0.39	Parkinson's disease;	chr6:27747476	chr6:28073316~28074233:+
OV	cis	rs4713118	0.869	rs9283882	ENSG00000220721.1	OR1F12	6.3	1.52e-09	2.18e-06	0.41	0.39	Parkinson's disease;	chr6:27747479	chr6:28073316~28074233:+
OV	cis	rs7615952	0.611	rs9681518	ENSG00000171084.14	FAM86JP	6.3	1.53e-09	2.19e-06	0.78	0.39	Blood pressure (smoking interaction);	chr3:125896287	chr3:125916620~125930024:+
OV	cis	rs1707322	1	rs34444543	ENSG00000280836.1	AL355480.1	-6.3	1.53e-09	2.19e-06	-0.54	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45893190	chr1:45581219~45581321:-
OV	cis	rs7615952	0.932	rs7629977	ENSG00000171084.14	FAM86JP	6.3	1.54e-09	2.2e-06	0.6	0.39	Blood pressure (smoking interaction);	chr3:125930730	chr3:125916620~125930024:+
OV	cis	rs293748	0.771	rs292196	ENSG00000250155.1	CTD-2353F22.1	6.3	1.54e-09	2.2e-06	0.55	0.39	Obesity-related traits;	chr5:36914077	chr5:36666214~36725195:-
OV	cis	rs293748	0.771	rs158410	ENSG00000250155.1	CTD-2353F22.1	-6.3	1.54e-09	2.2e-06	-0.57	-0.39	Obesity-related traits;	chr5:36858559	chr5:36666214~36725195:-
OV	cis	rs7849270	1	rs2541161	ENSG00000268707.1	RP11-247A12.7	6.3	1.55e-09	2.22e-06	0.42	0.39	Blood metabolite ratios;	chr9:129122523	chr9:129170434~129170940:+
OV	cis	rs875971	0.66	rs3764903	ENSG00000236529.1	RP13-254B10.1	-6.3	1.55e-09	2.22e-06	-0.41	-0.39	Aortic root size;	chr7:66633495	chr7:65840212~65840596:+
OV	cis	rs6558530	0.692	rs6558522	ENSG00000253982.1	CTD-2336O2.1	-6.3	1.56e-09	2.22e-06	-0.47	-0.39	Systolic blood pressure;	chr8:1754204	chr8:1761990~1764502:-
OV	cis	rs875971	0.66	rs1860470	ENSG00000236529.1	RP13-254B10.1	-6.3	1.56e-09	2.22e-06	-0.41	-0.39	Aortic root size;	chr7:66638707	chr7:65840212~65840596:+
OV	cis	rs2243480	0.615	rs34363376	ENSG00000222364.1	RNU6-96P	-6.3	1.56e-09	2.23e-06	-0.63	-0.39	Diabetic kidney disease;	chr7:66474549	chr7:66395191~66395286:+
OV	cis	rs7927771	0.69	rs35496532	ENSG00000280615.1	Y_RNA	-6.3	1.56e-09	2.23e-06	-0.47	-0.39	Subjective well-being;	chr11:47428787	chr11:47614898~47614994:-
OV	cis	rs4423214	0.592	rs11233933	ENSG00000254682.1	RP11-660L16.2	-6.29	1.58e-09	2.26e-06	-0.53	-0.39	Vitamin D levels;	chr11:71499024	chr11:71448674~71452157:+
OV	cis	rs12134133	1	rs7526831	ENSG00000274245.1	RP11-357P18.2	6.29	1.59e-09	2.27e-06	0.52	0.39	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265261	chr1:207372559~207373252:+
OV	cis	rs611744	0.781	rs656406	ENSG00000253754.1	RP11-35G22.1	-6.29	1.59e-09	2.27e-06	-0.44	-0.39	Dupuytren's disease;	chr8:108161614	chr8:108226200~108227544:+
OV	cis	rs11723261	0.621	rs7692530	ENSG00000275426.1	CH17-262A2.1	6.29	1.6e-09	2.28e-06	0.6	0.39	Immune response to smallpox vaccine (IL-6);	chr4:123563	chr4:149738~150317:+
OV	cis	rs853679	0.517	rs1340004	ENSG00000219392.1	RP1-265C24.5	-6.29	1.6e-09	2.29e-06	-0.47	-0.39	Depression;	chr6:28135913	chr6:28115628~28116551:+
OV	cis	rs7927771	0.864	rs11600581	ENSG00000280615.1	Y_RNA	-6.29	1.61e-09	2.29e-06	-0.47	-0.39	Subjective well-being;	chr11:47426946	chr11:47614898~47614994:-
OV	cis	rs293748	0.891	rs56261529	ENSG00000250155.1	CTD-2353F22.1	-6.29	1.61e-09	2.29e-06	-0.55	-0.39	Obesity-related traits;	chr5:37018714	chr5:36666214~36725195:-
OV	cis	rs1707322	1	rs6672115	ENSG00000280836.1	AL355480.1	-6.29	1.62e-09	2.31e-06	-0.53	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45807207	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs4134387	ENSG00000280836.1	AL355480.1	-6.29	1.62e-09	2.31e-06	-0.53	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45929486	chr1:45581219~45581321:-
OV	cis	rs4713118	0.869	rs9283883	ENSG00000220721.1	OR1F12	6.29	1.62e-09	2.31e-06	0.41	0.39	Parkinson's disease;	chr6:27747691	chr6:28073316~28074233:+
OV	cis	rs73019876	0.868	rs387343	ENSG00000269742.1	BNIP3P29	-6.29	1.62e-09	2.31e-06	-0.46	-0.39	Testicular germ cell tumor;	chr19:22052689	chr19:22065828~22066398:-
OV	cis	rs73019876	0.901	rs387315	ENSG00000269742.1	BNIP3P29	-6.29	1.62e-09	2.31e-06	-0.46	-0.39	Testicular germ cell tumor;	chr19:22052724	chr19:22065828~22066398:-
OV	cis	rs73019876	0.901	rs408312	ENSG00000269742.1	BNIP3P29	-6.29	1.62e-09	2.31e-06	-0.46	-0.39	Testicular germ cell tumor;	chr19:22052775	chr19:22065828~22066398:-
OV	cis	rs73019876	0.901	rs423926	ENSG00000269742.1	BNIP3P29	-6.29	1.62e-09	2.31e-06	-0.46	-0.39	Testicular germ cell tumor;	chr19:22052818	chr19:22065828~22066398:-
OV	cis	rs73019876	0.901	rs9653156	ENSG00000269742.1	BNIP3P29	6.29	1.62e-09	2.31e-06	0.46	0.39	Testicular germ cell tumor;	chr19:22066114	chr19:22065828~22066398:-
OV	cis	rs494459	0.838	rs12796102	ENSG00000255422.1	AP002954.4	-6.29	1.63e-09	2.33e-06	-0.44	-0.39	Height;	chr11:118791319	chr11:118704607~118750263:+
OV	cis	rs1707322	1	rs12097761	ENSG00000280836.1	AL355480.1	-6.29	1.64e-09	2.34e-06	-0.53	-0.39	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45825490	chr1:45581219~45581321:-
OV	cis	rs494459	0.756	rs570806	ENSG00000255422.1	AP002954.4	-6.29	1.64e-09	2.34e-06	-0.44	-0.39	Height;	chr11:118786602	chr11:118704607~118750263:+
OV	cis	rs853679	0.517	rs17711344	ENSG00000219392.1	RP1-265C24.5	6.29	1.65e-09	2.34e-06	0.47	0.39	Depression;	chr6:28109824	chr6:28115628~28116551:+
OV	cis	rs7927771	0.826	rs7925389	ENSG00000280615.1	Y_RNA	-6.29	1.65e-09	2.34e-06	-0.47	-0.39	Subjective well-being;	chr11:47445238	chr11:47614898~47614994:-
OV	cis	rs293748	0.771	rs167146	ENSG00000250155.1	CTD-2353F22.1	-6.28	1.68e-09	2.39e-06	-0.57	-0.38	Obesity-related traits;	chr5:36922204	chr5:36666214~36725195:-
OV	cis	rs7743045	0.625	rs9387628	ENSG00000253194.1	RP11-351A11.1	-6.28	1.68e-09	2.39e-06	-0.44	-0.38	Mean platelet volume;	chr6:119031853	chr6:118934785~119031541:+
OV	cis	rs7927771	0.864	rs2053979	ENSG00000280615.1	Y_RNA	-6.28	1.69e-09	2.4e-06	-0.47	-0.38	Subjective well-being;	chr11:47417893	chr11:47614898~47614994:-
OV	cis	rs7927771	0.832	rs896816	ENSG00000280615.1	Y_RNA	6.28	1.69e-09	2.4e-06	0.47	0.38	Subjective well-being;	chr11:47372787	chr11:47614898~47614994:-
OV	cis	rs7927771	0.832	rs7940536	ENSG00000280615.1	Y_RNA	6.28	1.69e-09	2.4e-06	0.47	0.38	Subjective well-being;	chr11:47373689	chr11:47614898~47614994:-
OV	cis	rs4713118	0.869	rs7773070	ENSG00000220721.1	OR1F12	6.28	1.7e-09	2.41e-06	0.41	0.38	Parkinson's disease;	chr6:27761048	chr6:28073316~28074233:+
OV	cis	rs1707322	0.752	rs11488313	ENSG00000280836.1	AL355480.1	-6.28	1.71e-09	2.42e-06	-0.54	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr1:45581219~45581321:-
OV	cis	rs9918079	0.524	rs4235379	ENSG00000273133.1	RP11-799M12.2	-6.28	1.73e-09	2.45e-06	-0.46	-0.38	Obesity-related traits;	chr4:15657655	chr4:15563698~15564253:-
OV	cis	rs7246967	0.932	rs1478457	ENSG00000269509.1	BNIP3P34	6.28	1.74e-09	2.46e-06	0.56	0.38	Bronchopulmonary dysplasia;	chr19:22882467	chr19:22773853~22774424:+
OV	cis	rs1707322	1	rs4074225	ENSG00000280836.1	AL355480.1	-6.28	1.74e-09	2.46e-06	-0.53	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45926692	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs10789485	ENSG00000280836.1	AL355480.1	-6.28	1.74e-09	2.46e-06	-0.53	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45941636	chr1:45581219~45581321:-
OV	cis	rs1707322	0.964	rs12067716	ENSG00000280836.1	AL355480.1	-6.28	1.74e-09	2.46e-06	-0.53	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45968756	chr1:45581219~45581321:-
OV	cis	rs7246967	0.932	rs35706770	ENSG00000269509.1	BNIP3P34	6.28	1.75e-09	2.47e-06	0.57	0.38	Bronchopulmonary dysplasia;	chr19:22876460	chr19:22773853~22774424:+
OV	cis	rs875971	0.545	rs12671152	ENSG00000222364.1	RNU6-96P	-6.27	1.76e-09	2.48e-06	-0.46	-0.38	Aortic root size;	chr7:66311140	chr7:66395191~66395286:+
OV	cis	rs2243480	0.708	rs13242216	ENSG00000222364.1	RNU6-96P	-6.27	1.76e-09	2.48e-06	-0.63	-0.38	Diabetic kidney disease;	chr7:66433290	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs67536397	ENSG00000222364.1	RNU6-96P	-6.27	1.76e-09	2.48e-06	-0.63	-0.38	Diabetic kidney disease;	chr7:66482930	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs58669269	ENSG00000222364.1	RNU6-96P	-6.27	1.76e-09	2.48e-06	-0.63	-0.38	Diabetic kidney disease;	chr7:66486966	chr7:66395191~66395286:+
OV	cis	rs7927771	0.864	rs60075622	ENSG00000280615.1	Y_RNA	-6.27	1.76e-09	2.49e-06	-0.47	-0.38	Subjective well-being;	chr11:47427550	chr11:47614898~47614994:-
OV	cis	rs7246967	1	rs7257127	ENSG00000269509.1	BNIP3P34	6.27	1.76e-09	2.49e-06	0.56	0.38	Bronchopulmonary dysplasia;	chr19:22873897	chr19:22773853~22774424:+
OV	cis	rs7927771	0.929	rs12787646	ENSG00000280615.1	Y_RNA	-6.27	1.78e-09	2.51e-06	-0.48	-0.38	Subjective well-being;	chr11:47648113	chr11:47614898~47614994:-
OV	cis	rs611744	0.87	rs633794	ENSG00000253754.1	RP11-35G22.1	-6.27	1.79e-09	2.53e-06	-0.44	-0.38	Dupuytren's disease;	chr8:108162473	chr8:108226200~108227544:+
OV	cis	rs7615952	0.604	rs9837847	ENSG00000171084.14	FAM86JP	6.27	1.81e-09	2.55e-06	0.77	0.38	Blood pressure (smoking interaction);	chr3:125905076	chr3:125916620~125930024:+
OV	cis	rs3091242	0.934	rs686631	ENSG00000224183.1	SDHDP6	-6.27	1.81e-09	2.55e-06	-0.48	-0.38	Erythrocyte sedimentation rate;	chr1:25393108	chr1:25294164~25294643:-
OV	cis	rs801193	1	rs3778909	ENSG00000236529.1	RP13-254B10.1	6.27	1.81e-09	2.56e-06	0.41	0.38	Aortic root size;	chr7:66790659	chr7:65840212~65840596:+
OV	cis	rs172166	0.694	rs203876	ENSG00000220721.1	OR1F12	6.27	1.82e-09	2.57e-06	0.41	0.38	Cardiac Troponin-T levels;	chr6:28078895	chr6:28073316~28074233:+
OV	cis	rs172166	0.694	rs203877	ENSG00000220721.1	OR1F12	6.27	1.82e-09	2.57e-06	0.41	0.38	Cardiac Troponin-T levels;	chr6:28080846	chr6:28073316~28074233:+
OV	cis	rs172166	0.694	rs203893	ENSG00000220721.1	OR1F12	6.27	1.82e-09	2.57e-06	0.41	0.38	Cardiac Troponin-T levels;	chr6:28094288	chr6:28073316~28074233:+
OV	cis	rs172166	0.652	rs476167	ENSG00000220721.1	OR1F12	6.27	1.82e-09	2.57e-06	0.41	0.38	Cardiac Troponin-T levels;	chr6:28098110	chr6:28073316~28074233:+
OV	cis	rs172166	0.694	rs203892	ENSG00000220721.1	OR1F12	6.27	1.82e-09	2.57e-06	0.41	0.38	Cardiac Troponin-T levels;	chr6:28099418	chr6:28073316~28074233:+
OV	cis	rs8005677	0.828	rs712486	ENSG00000257285.4	RP11-298I3.1	6.27	1.82e-09	2.57e-06	0.47	0.38	Cognitive ability (multi-trait analysis);	chr14:22955832	chr14:22929609~22955562:+
OV	cis	rs11235843	0.79	rs4944034	ENSG00000255928.1	RP11-456I15.2	6.27	1.83e-09	2.58e-06	0.63	0.38	Hand grip strength;	chr11:73792804	chr11:73722349~73722694:+
OV	cis	rs11235843	0.853	rs11235907	ENSG00000255928.1	RP11-456I15.2	6.27	1.83e-09	2.58e-06	0.63	0.38	Hand grip strength;	chr11:73794606	chr11:73722349~73722694:+
OV	cis	rs11235843	0.778	rs7929705	ENSG00000255928.1	RP11-456I15.2	6.27	1.83e-09	2.58e-06	0.63	0.38	Hand grip strength;	chr11:73795802	chr11:73722349~73722694:+
OV	cis	rs11235843	0.853	rs11235908	ENSG00000255928.1	RP11-456I15.2	6.27	1.83e-09	2.58e-06	0.63	0.38	Hand grip strength;	chr11:73796206	chr11:73722349~73722694:+
OV	cis	rs875971	0.66	rs2191268	ENSG00000236529.1	RP13-254B10.1	6.27	1.84e-09	2.59e-06	0.39	0.38	Aortic root size;	chr7:66645237	chr7:65840212~65840596:+
OV	cis	rs11603023	0.805	rs687190	ENSG00000255422.1	AP002954.4	-6.27	1.85e-09	2.6e-06	-0.41	-0.38	Cholesterol, total;	chr11:118671674	chr11:118704607~118750263:+
OV	cis	rs172166	0.694	rs1225716	ENSG00000220721.1	OR1F12	6.27	1.85e-09	2.61e-06	0.42	0.38	Cardiac Troponin-T levels;	chr6:28145968	chr6:28073316~28074233:+
OV	cis	rs10256972	0.621	rs2363285	ENSG00000229043.2	AC091729.9	-6.26	1.87e-09	2.63e-06	-0.43	-0.38	Endometriosis;Longevity;	chr7:1052008	chr7:1160374~1165267:+
OV	cis	rs7246967	1	rs11882498	ENSG00000269509.1	BNIP3P34	6.26	1.88e-09	2.64e-06	0.57	0.38	Bronchopulmonary dysplasia;	chr19:22877210	chr19:22773853~22774424:+
OV	cis	rs7246967	1	rs34629498	ENSG00000269509.1	BNIP3P34	6.26	1.88e-09	2.64e-06	0.57	0.38	Bronchopulmonary dysplasia;	chr19:22877918	chr19:22773853~22774424:+
OV	cis	rs875971	0.545	rs6969224	ENSG00000222364.1	RNU6-96P	-6.26	1.88e-09	2.65e-06	-0.46	-0.38	Aortic root size;	chr7:66370011	chr7:66395191~66395286:+
OV	cis	rs11235843	0.853	rs60020777	ENSG00000255928.1	RP11-456I15.2	6.26	1.9e-09	2.67e-06	0.63	0.38	Hand grip strength;	chr11:73771451	chr11:73722349~73722694:+
OV	cis	rs11235843	0.79	rs11235898	ENSG00000255928.1	RP11-456I15.2	6.26	1.9e-09	2.67e-06	0.63	0.38	Hand grip strength;	chr11:73776982	chr11:73722349~73722694:+
OV	cis	rs11235843	0.853	rs66610247	ENSG00000255928.1	RP11-456I15.2	6.26	1.9e-09	2.67e-06	0.63	0.38	Hand grip strength;	chr11:73786315	chr11:73722349~73722694:+
OV	cis	rs11235843	0.853	rs11235905	ENSG00000255928.1	RP11-456I15.2	6.26	1.9e-09	2.67e-06	0.63	0.38	Hand grip strength;	chr11:73786901	chr11:73722349~73722694:+
OV	cis	rs801193	1	rs4717319	ENSG00000236529.1	RP13-254B10.1	6.26	1.9e-09	2.67e-06	0.41	0.38	Aortic root size;	chr7:66777606	chr7:65840212~65840596:+
OV	cis	rs801193	0.904	rs4718403	ENSG00000236529.1	RP13-254B10.1	6.26	1.9e-09	2.67e-06	0.41	0.38	Aortic root size;	chr7:66777742	chr7:65840212~65840596:+
OV	cis	rs611744	0.806	rs2440387	ENSG00000253754.1	RP11-35G22.1	-6.26	1.9e-09	2.67e-06	-0.43	-0.38	Dupuytren's disease;	chr8:108054850	chr8:108226200~108227544:+
OV	cis	rs1061377	1	rs3796509	ENSG00000249207.1	RP11-360F5.1	-6.26	1.91e-09	2.69e-06	-0.42	-0.38	Uric acid levels;	chr4:39108566	chr4:39112677~39126818:-
OV	cis	rs1707322	1	rs10890381	ENSG00000280836.1	AL355480.1	-6.26	1.93e-09	2.71e-06	-0.53	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45986099	chr1:45581219~45581321:-
OV	cis	rs1061377	1	rs4974931	ENSG00000249207.1	RP11-360F5.1	-6.26	1.94e-09	2.72e-06	-0.42	-0.38	Uric acid levels;	chr4:39108896	chr4:39112677~39126818:-
OV	cis	rs3931020	0.962	rs2185695	ENSG00000272864.1	RP11-17E13.2	-6.26	1.94e-09	2.72e-06	-0.5	-0.38	Resistin levels;	chr1:74792197	chr1:74698769~74699333:-
OV	cis	rs7927771	0.965	rs12787112	ENSG00000280615.1	Y_RNA	-6.26	1.94e-09	2.72e-06	-0.47	-0.38	Subjective well-being;	chr11:47665595	chr11:47614898~47614994:-
OV	cis	rs1707322	0.963	rs6429581	ENSG00000280836.1	AL355480.1	-6.26	1.95e-09	2.73e-06	-0.53	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45853424	chr1:45581219~45581321:-
OV	cis	rs611744	0.967	rs584555	ENSG00000253754.1	RP11-35G22.1	-6.26	1.95e-09	2.73e-06	-0.43	-0.38	Dupuytren's disease;	chr8:108206383	chr8:108226200~108227544:+
OV	cis	rs3931020	0.508	rs28568334	ENSG00000272864.1	RP11-17E13.2	-6.25	1.96e-09	2.74e-06	-0.5	-0.38	Resistin levels;	chr1:74733615	chr1:74698769~74699333:-
OV	cis	rs7688540	0.771	rs11722197	ENSG00000275426.1	CH17-262A2.1	6.25	1.96e-09	2.75e-06	0.63	0.38	Facial morphology (factor 6, height of vermillion lower lip);	chr4:287918	chr4:149738~150317:+
OV	cis	rs7688540	0.771	rs11723261	ENSG00000275426.1	CH17-262A2.1	6.25	1.96e-09	2.75e-06	0.63	0.38	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288710	chr4:149738~150317:+
OV	cis	rs7587476	0.601	rs1129804	ENSG00000229267.2	AC072062.1	6.25	1.96e-09	2.75e-06	0.47	0.38	Neuroblastoma;	chr2:214809599	chr2:214810229~214963274:+
OV	cis	rs7587476	0.601	rs17489363	ENSG00000229267.2	AC072062.1	6.25	1.96e-09	2.75e-06	0.47	0.38	Neuroblastoma;	chr2:214809617	chr2:214810229~214963274:+
OV	cis	rs7246967	1	rs62120832	ENSG00000269509.1	BNIP3P34	6.25	1.97e-09	2.76e-06	0.58	0.38	Bronchopulmonary dysplasia;	chr19:22881462	chr19:22773853~22774424:+
OV	cis	rs9326248	0.581	rs7121898	ENSG00000254851.1	RP11-109L13.1	-6.25	1.97e-09	2.76e-06	-0.45	-0.38	Blood protein levels;	chr11:116926130	chr11:117135528~117138582:+
OV	cis	rs9326248	0.581	rs10790167	ENSG00000254851.1	RP11-109L13.1	-6.25	1.97e-09	2.76e-06	-0.45	-0.38	Blood protein levels;	chr11:116930227	chr11:117135528~117138582:+
OV	cis	rs11673344	0.9	rs11671112	ENSG00000226686.6	LINC01535	6.25	1.97e-09	2.76e-06	0.51	0.38	Obesity-related traits;	chr19:37169384	chr19:37251912~37265535:+
OV	cis	rs7688540	0.771	rs4582105	ENSG00000275426.1	CH17-262A2.1	6.25	1.98e-09	2.77e-06	0.64	0.38	Facial morphology (factor 6, height of vermillion lower lip);	chr4:252553	chr4:149738~150317:+
OV	cis	rs3091242	0.934	rs666686	ENSG00000261349.1	RP3-465N24.5	-6.25	1.98e-09	2.77e-06	-0.46	-0.38	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25266102~25267136:-
OV	cis	rs7927771	0.832	rs6485753	ENSG00000280615.1	Y_RNA	6.25	1.99e-09	2.78e-06	0.47	0.38	Subjective well-being;	chr11:47388649	chr11:47614898~47614994:-
OV	cis	rs7927771	0.832	rs4752993	ENSG00000280615.1	Y_RNA	6.25	1.99e-09	2.78e-06	0.47	0.38	Subjective well-being;	chr11:47389400	chr11:47614898~47614994:-
OV	cis	rs7927771	0.832	rs4752994	ENSG00000280615.1	Y_RNA	6.25	1.99e-09	2.78e-06	0.47	0.38	Subjective well-being;	chr11:47389514	chr11:47614898~47614994:-
OV	cis	rs7927771	0.832	rs10769262	ENSG00000280615.1	Y_RNA	6.25	1.99e-09	2.78e-06	0.47	0.38	Subjective well-being;	chr11:47390030	chr11:47614898~47614994:-
OV	cis	rs7615952	0.673	rs35955861	ENSG00000171084.14	FAM86JP	6.25	2.01e-09	2.8e-06	0.76	0.38	Blood pressure (smoking interaction);	chr3:125907358	chr3:125916620~125930024:+
OV	cis	rs7615952	0.673	rs35001498	ENSG00000171084.14	FAM86JP	6.25	2.01e-09	2.8e-06	0.76	0.38	Blood pressure (smoking interaction);	chr3:125909801	chr3:125916620~125930024:+
OV	cis	rs1707322	1	rs4660332	ENSG00000280836.1	AL355480.1	-6.25	2.01e-09	2.81e-06	-0.53	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45995746	chr1:45581219~45581321:-
OV	cis	rs10510102	0.872	rs7906271	ENSG00000276742.1	RP11-500G22.4	-6.25	2.01e-09	2.81e-06	-0.63	-0.38	Breast cancer;	chr10:121948207	chr10:121956782~121957098:+
OV	cis	rs7044106	0.762	rs3904197	ENSG00000226752.6	PSMD5-AS1	-6.25	2.03e-09	2.83e-06	-0.44	-0.38	Hip circumference adjusted for BMI;	chr9:120718100	chr9:120824828~120854385:+
OV	cis	rs11673344	0.832	rs76470527	ENSG00000226686.6	LINC01535	6.25	2.03e-09	2.84e-06	0.52	0.38	Obesity-related traits;	chr19:37035981	chr19:37251912~37265535:+
OV	cis	rs2243480	1	rs313803	ENSG00000222364.1	RNU6-96P	-6.25	2.04e-09	2.85e-06	-0.63	-0.38	Diabetic kidney disease;	chr7:66049744	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs313802	ENSG00000222364.1	RNU6-96P	-6.25	2.04e-09	2.85e-06	-0.63	-0.38	Diabetic kidney disease;	chr7:66051386	chr7:66395191~66395286:+
OV	cis	rs2243480	0.803	rs403089	ENSG00000222364.1	RNU6-96P	-6.25	2.04e-09	2.85e-06	-0.63	-0.38	Diabetic kidney disease;	chr7:66052736	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs458291	ENSG00000222364.1	RNU6-96P	-6.25	2.04e-09	2.85e-06	-0.63	-0.38	Diabetic kidney disease;	chr7:66055492	chr7:66395191~66395286:+
OV	cis	rs1707322	0.963	rs12145287	ENSG00000280836.1	AL355480.1	-6.25	2.05e-09	2.86e-06	-0.53	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45859330	chr1:45581219~45581321:-
OV	cis	rs7927771	0.698	rs34467936	ENSG00000280615.1	Y_RNA	-6.25	2.05e-09	2.86e-06	-0.48	-0.38	Subjective well-being;	chr11:47893747	chr11:47614898~47614994:-
OV	cis	rs4713118	0.869	rs6902689	ENSG00000220721.1	OR1F12	6.25	2.05e-09	2.87e-06	0.41	0.38	Parkinson's disease;	chr6:27741662	chr6:28073316~28074233:+
OV	cis	rs4713118	0.869	rs9468214	ENSG00000220721.1	OR1F12	6.25	2.05e-09	2.87e-06	0.41	0.38	Parkinson's disease;	chr6:27745520	chr6:28073316~28074233:+
OV	cis	rs11723261	0.582	rs6814287	ENSG00000275426.1	CH17-262A2.1	6.25	2.06e-09	2.88e-06	0.59	0.38	Immune response to smallpox vaccine (IL-6);	chr4:122443	chr4:149738~150317:+
OV	cis	rs11723261	0.582	rs3747693	ENSG00000275426.1	CH17-262A2.1	6.25	2.06e-09	2.88e-06	0.59	0.38	Immune response to smallpox vaccine (IL-6);	chr4:124493	chr4:149738~150317:+
OV	cis	rs4380275	0.782	rs11691064	ENSG00000272342.1	RP13-539J13.1	6.24	2.08e-09	2.9e-06	0.42	0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:755718	chr2:739588~740164:-
OV	cis	rs2243480	1	rs1638734	ENSG00000222364.1	RNU6-96P	-6.24	2.09e-09	2.91e-06	-0.61	-0.38	Diabetic kidney disease;	chr7:66632552	chr7:66395191~66395286:+
OV	cis	rs3931020	0.53	rs12125889	ENSG00000272864.1	RP11-17E13.2	-6.24	2.09e-09	2.91e-06	-0.49	-0.38	Resistin levels;	chr1:74776287	chr1:74698769~74699333:-
OV	cis	rs7615952	0.932	rs7630077	ENSG00000171084.14	FAM86JP	6.24	2.09e-09	2.91e-06	0.6	0.38	Blood pressure (smoking interaction);	chr3:125930833	chr3:125916620~125930024:+
OV	cis	rs4713118	0.869	rs6922574	ENSG00000220721.1	OR1F12	6.24	2.09e-09	2.92e-06	0.41	0.38	Parkinson's disease;	chr6:27725224	chr6:28073316~28074233:+
OV	cis	rs1707322	1	rs785498	ENSG00000280836.1	AL355480.1	6.24	2.1e-09	2.93e-06	0.52	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126742	chr1:45581219~45581321:-
OV	cis	rs1707322	0.717	rs1972410	ENSG00000280836.1	AL355480.1	-6.24	2.12e-09	2.95e-06	-0.54	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr1:45581219~45581321:-
OV	cis	rs7927771	0.864	rs112060627	ENSG00000280615.1	Y_RNA	-6.24	2.12e-09	2.96e-06	-0.46	-0.38	Subjective well-being;	chr11:47405405	chr11:47614898~47614994:-
OV	cis	rs7927771	0.864	rs7107726	ENSG00000280615.1	Y_RNA	-6.24	2.12e-09	2.96e-06	-0.46	-0.38	Subjective well-being;	chr11:47407694	chr11:47614898~47614994:-
OV	cis	rs1707322	1	rs10789479	ENSG00000280836.1	AL355480.1	-6.24	2.13e-09	2.96e-06	-0.53	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45886828	chr1:45581219~45581321:-
OV	cis	rs2243480	1	rs466983	ENSG00000222364.1	RNU6-96P	-6.24	2.13e-09	2.96e-06	-0.63	-0.38	Diabetic kidney disease;	chr7:66055509	chr7:66395191~66395286:+
OV	cis	rs801193	0.761	rs2659888	ENSG00000236529.1	RP13-254B10.1	6.24	2.14e-09	2.97e-06	0.41	0.38	Aortic root size;	chr7:66765184	chr7:65840212~65840596:+
OV	cis	rs1061377	0.965	rs12504238	ENSG00000249207.1	RP11-360F5.1	-6.24	2.14e-09	2.98e-06	-0.42	-0.38	Uric acid levels;	chr4:39142824	chr4:39112677~39126818:-
OV	cis	rs7615952	0.546	rs11717632	ENSG00000171084.14	FAM86JP	6.24	2.15e-09	2.98e-06	0.63	0.38	Blood pressure (smoking interaction);	chr3:125602286	chr3:125916620~125930024:+
OV	cis	rs7615952	0.546	rs2922197	ENSG00000171084.14	FAM86JP	6.24	2.15e-09	2.98e-06	0.63	0.38	Blood pressure (smoking interaction);	chr3:125603188	chr3:125916620~125930024:+
OV	cis	rs1707322	0.964	rs7512395	ENSG00000280836.1	AL355480.1	-6.24	2.15e-09	2.99e-06	-0.53	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45895505	chr1:45581219~45581321:-
OV	cis	rs1707322	0.752	rs7541962	ENSG00000280836.1	AL355480.1	-6.24	2.15e-09	3e-06	-0.54	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr1:45581219~45581321:-
OV	cis	rs7044106	0.762	rs10760110	ENSG00000226752.6	PSMD5-AS1	6.24	2.16e-09	3e-06	0.47	0.38	Hip circumference adjusted for BMI;	chr9:120650285	chr9:120824828~120854385:+
OV	cis	rs2581828	0.618	rs9838517	ENSG00000242142.1	SERBP1P3	-6.24	2.16e-09	3e-06	-0.46	-0.38	Crohn's disease;	chr3:53110347	chr3:53064283~53065091:-
OV	cis	rs7044106	0.762	rs7024046	ENSG00000226752.6	PSMD5-AS1	-6.24	2.16e-09	3e-06	-0.44	-0.38	Hip circumference adjusted for BMI;	chr9:120656900	chr9:120824828~120854385:+
OV	cis	rs7044106	0.762	rs4837789	ENSG00000226752.6	PSMD5-AS1	-6.24	2.16e-09	3e-06	-0.44	-0.38	Hip circumference adjusted for BMI;	chr9:120663978	chr9:120824828~120854385:+
OV	cis	rs8105895	0.935	rs62112362	ENSG00000269742.1	BNIP3P29	6.24	2.16e-09	3.01e-06	0.62	0.38	Body mass index (change over time);	chr19:22110311	chr19:22065828~22066398:-
OV	cis	rs8105895	0.935	rs62112364	ENSG00000269742.1	BNIP3P29	6.24	2.16e-09	3.01e-06	0.62	0.38	Body mass index (change over time);	chr19:22112101	chr19:22065828~22066398:-
OV	cis	rs4713118	0.588	rs200994	ENSG00000220721.1	OR1F12	-6.24	2.17e-09	3.01e-06	-0.43	-0.38	Parkinson's disease;	chr6:27846035	chr6:28073316~28074233:+
OV	cis	rs7615952	0.546	rs2922194	ENSG00000171084.14	FAM86JP	6.23	2.19e-09	3.05e-06	0.63	0.38	Blood pressure (smoking interaction);	chr3:125613419	chr3:125916620~125930024:+
OV	cis	rs6921919	0.583	rs740621	ENSG00000216901.1	AL022393.7	6.23	2.2e-09	3.05e-06	0.46	0.38	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28176188~28176674:+
OV	cis	rs1707322	0.963	rs10789478	ENSG00000280836.1	AL355480.1	-6.23	2.22e-09	3.08e-06	-0.53	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45884834	chr1:45581219~45581321:-
OV	cis	rs6700559	1	rs12076877	ENSG00000260088.1	RP11-92G12.3	-6.23	2.22e-09	3.08e-06	-0.41	-0.38	Coronary artery disease;	chr1:200674277	chr1:200669507~200694250:+
OV	cis	rs12022452	0.591	rs12042242	ENSG00000238287.1	RP11-656D10.3	6.23	2.22e-09	3.08e-06	0.63	0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40528201	chr1:40493157~40508661:-
OV	cis	rs7017914	0.652	rs10957533	ENSG00000223220.1	Y_RNA	-6.23	2.22e-09	3.08e-06	-0.41	-0.38	Bone mineral density;	chr8:70912872	chr8:70780914~70781008:-
OV	cis	rs8005677	0.798	rs61977741	ENSG00000257285.4	RP11-298I3.1	6.23	2.23e-09	3.09e-06	0.45	0.38	Cognitive ability (multi-trait analysis);	chr14:22931770	chr14:22929609~22955562:+
OV	cis	rs1707322	0.685	rs11211177	ENSG00000280836.1	AL355480.1	-6.23	2.26e-09	3.13e-06	-0.51	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr1:45581219~45581321:-
OV	cis	rs1499614	0.901	rs2178742	ENSG00000222364.1	RNU6-96P	-6.23	2.26e-09	3.13e-06	-0.63	-0.38	Gout;	chr7:66732812	chr7:66395191~66395286:+
OV	cis	rs4927850	0.723	rs7630825	ENSG00000231464.1	AC024937.4	6.23	2.27e-09	3.14e-06	0.45	0.38	Pancreatic cancer;	chr3:196026869	chr3:195996738~195998233:+
OV	cis	rs2153535	0.562	rs10458225	ENSG00000230939.1	RP11-314C16.1	6.23	2.28e-09	3.16e-06	0.44	0.38	Motion sickness;	chr6:8385771	chr6:8784178~8785445:+
OV	cis	rs7615952	0.611	rs7632305	ENSG00000171084.14	FAM86JP	6.23	2.29e-09	3.17e-06	0.76	0.38	Blood pressure (smoking interaction);	chr3:125915924	chr3:125916620~125930024:+
OV	cis	rs7615952	0.673	rs9841194	ENSG00000171084.14	FAM86JP	6.23	2.29e-09	3.17e-06	0.76	0.38	Blood pressure (smoking interaction);	chr3:125916896	chr3:125916620~125930024:+
OV	cis	rs11673344	0.832	rs11540540	ENSG00000226686.6	LINC01535	6.23	2.3e-09	3.18e-06	0.52	0.38	Obesity-related traits;	chr19:37129629	chr19:37251912~37265535:+
OV	cis	rs7927771	0.864	rs7937331	ENSG00000280615.1	Y_RNA	6.22	2.31e-09	3.19e-06	0.46	0.38	Subjective well-being;	chr11:47408907	chr11:47614898~47614994:-
OV	cis	rs7927771	0.864	rs755554	ENSG00000280615.1	Y_RNA	6.22	2.31e-09	3.19e-06	0.46	0.38	Subjective well-being;	chr11:47410483	chr11:47614898~47614994:-
OV	cis	rs7927771	0.864	rs2293577	ENSG00000280615.1	Y_RNA	6.22	2.31e-09	3.19e-06	0.46	0.38	Subjective well-being;	chr11:47415651	chr11:47614898~47614994:-
OV	cis	rs950169	0.579	rs881983	ENSG00000235370.6	DNM1P51	6.22	2.32e-09	3.21e-06	0.55	0.38	Schizophrenia;	chr15:83978556	chr15:84398316~84411701:-
OV	cis	rs4660456	0.913	rs7551747	ENSG00000237899.1	RP4-739H11.3	6.22	2.33e-09	3.22e-06	0.57	0.38	Platelet count;	chr1:40699407	chr1:40669089~40687588:-
OV	cis	rs131777	0.708	rs131749	ENSG00000205559.3	CHKB-AS1	6.22	2.34e-09	3.24e-06	0.48	0.38	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr22:50586195	chr22:50583026~50583877:+
OV	cis	rs1707322	0.613	rs1473840	ENSG00000281133.1	AL355480.3	6.22	2.35e-09	3.25e-06	0.47	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46135525	chr1:45580892~45580996:-
OV	cis	rs4713118	0.869	rs10214440	ENSG00000220721.1	OR1F12	6.22	2.36e-09	3.26e-06	0.41	0.38	Parkinson's disease;	chr6:27734661	chr6:28073316~28074233:+
OV	cis	rs11673344	0.75	rs78241494	ENSG00000226686.6	LINC01535	6.22	2.36e-09	3.26e-06	0.52	0.38	Obesity-related traits;	chr19:37158846	chr19:37251912~37265535:+
OV	cis	rs11673344	0.838	rs111827672	ENSG00000226686.6	LINC01535	6.22	2.36e-09	3.26e-06	0.52	0.38	Obesity-related traits;	chr19:37158964	chr19:37251912~37265535:+
OV	cis	rs8105895	0.733	rs62110861	ENSG00000269742.1	BNIP3P29	6.22	2.37e-09	3.27e-06	0.63	0.38	Body mass index (change over time);	chr19:21912962	chr19:22065828~22066398:-
OV	cis	rs8105895	0.799	rs62110863	ENSG00000269742.1	BNIP3P29	6.22	2.37e-09	3.27e-06	0.63	0.38	Body mass index (change over time);	chr19:21917706	chr19:22065828~22066398:-
OV	cis	rs875971	0.66	rs2013222	ENSG00000236529.1	RP13-254B10.1	-6.22	2.37e-09	3.28e-06	-0.4	-0.38	Aortic root size;	chr7:66570949	chr7:65840212~65840596:+
OV	cis	rs1707322	0.896	rs809774	ENSG00000280836.1	AL355480.1	6.22	2.38e-09	3.28e-06	0.51	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46094572	chr1:45581219~45581321:-
OV	cis	rs7615952	0.673	rs9289270	ENSG00000171084.14	FAM86JP	6.22	2.41e-09	3.32e-06	0.76	0.38	Blood pressure (smoking interaction);	chr3:125918136	chr3:125916620~125930024:+
OV	cis	rs3814244	0.528	rs11177002	ENSG00000255733.4	IFNG-AS1	6.22	2.41e-09	3.32e-06	0.39	0.38	Itch intensity from mosquito bite adjusted by bite size;	chr12:68003377	chr12:67989445~68234686:+
OV	cis	rs7927771	0.832	rs55677087	ENSG00000280615.1	Y_RNA	-6.22	2.41e-09	3.32e-06	-0.46	-0.38	Subjective well-being;	chr11:47376163	chr11:47614898~47614994:-
OV	cis	rs526231	0.543	rs42431	ENSG00000175749.11	EIF3KP1	-6.21	2.44e-09	3.36e-06	-0.48	-0.38	Primary biliary cholangitis;	chr5:103064359	chr5:103032376~103033031:+
OV	cis	rs1707322	1	rs12124847	ENSG00000280836.1	AL355480.1	-6.21	2.47e-09	3.4e-06	-0.53	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45915178	chr1:45581219~45581321:-
OV	cis	rs62355901	0.599	rs62355881	ENSG00000271828.1	CTD-2310F14.1	6.21	2.47e-09	3.41e-06	0.71	0.38	Breast cancer;	chr5:56737266	chr5:56927874~56929573:+
OV	cis	rs11098499	0.954	rs11098524	ENSG00000245958.5	RP11-33B1.1	-6.21	2.47e-09	3.41e-06	-0.43	-0.38	Corneal astigmatism;	chr4:119468877	chr4:119454791~119552025:+
OV	cis	rs11235843	0.853	rs10501412	ENSG00000255928.1	RP11-456I15.2	-6.21	2.48e-09	3.41e-06	-0.64	-0.38	Hand grip strength;	chr11:73830380	chr11:73722349~73722694:+
OV	cis	rs301901	0.683	rs34485458	ENSG00000250155.1	CTD-2353F22.1	-6.21	2.48e-09	3.41e-06	-0.48	-0.38	Height;	chr5:36861889	chr5:36666214~36725195:-
OV	cis	rs4713118	0.955	rs34752872	ENSG00000220721.1	OR1F12	6.21	2.48e-09	3.41e-06	0.42	0.38	Parkinson's disease;	chr6:27715465	chr6:28073316~28074233:+
OV	cis	rs4713118	0.955	rs9380010	ENSG00000220721.1	OR1F12	6.21	2.48e-09	3.41e-06	0.42	0.38	Parkinson's disease;	chr6:27715793	chr6:28073316~28074233:+
OV	cis	rs4713118	0.955	rs9368528	ENSG00000220721.1	OR1F12	6.21	2.48e-09	3.41e-06	0.42	0.38	Parkinson's disease;	chr6:27716019	chr6:28073316~28074233:+
OV	cis	rs4713118	0.955	rs9380011	ENSG00000220721.1	OR1F12	6.21	2.48e-09	3.41e-06	0.42	0.38	Parkinson's disease;	chr6:27716145	chr6:28073316~28074233:+
OV	cis	rs4713118	0.955	rs9368529	ENSG00000220721.1	OR1F12	6.21	2.48e-09	3.41e-06	0.42	0.38	Parkinson's disease;	chr6:27716852	chr6:28073316~28074233:+
OV	cis	rs4713118	0.955	rs9380012	ENSG00000220721.1	OR1F12	6.21	2.48e-09	3.41e-06	0.42	0.38	Parkinson's disease;	chr6:27716875	chr6:28073316~28074233:+
OV	cis	rs4713118	0.911	rs2394000	ENSG00000220721.1	OR1F12	6.21	2.48e-09	3.41e-06	0.42	0.38	Parkinson's disease;	chr6:27719212	chr6:28073316~28074233:+
OV	cis	rs4713118	0.955	rs9393847	ENSG00000220721.1	OR1F12	6.21	2.48e-09	3.41e-06	0.42	0.38	Parkinson's disease;	chr6:27720194	chr6:28073316~28074233:+
OV	cis	rs6921919	0.789	rs6912584	ENSG00000216901.1	AL022393.7	6.21	2.5e-09	3.43e-06	0.5	0.38	Autism spectrum disorder or schizophrenia;	chr6:28341813	chr6:28176188~28176674:+
OV	cis	rs1707322	1	rs4606257	ENSG00000280836.1	AL355480.1	-6.21	2.51e-09	3.45e-06	-0.52	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45841596	chr1:45581219~45581321:-
OV	cis	rs6952407	1	rs6952407	ENSG00000236529.1	RP13-254B10.1	-6.21	2.51e-09	3.46e-06	-0.4	-0.38	Cotinine glucuronidation;	chr7:66580525	chr7:65840212~65840596:+
OV	cis	rs73019876	0.901	rs415291	ENSG00000269742.1	BNIP3P29	-6.21	2.52e-09	3.47e-06	-0.45	-0.38	Testicular germ cell tumor;	chr19:22052505	chr19:22065828~22066398:-
OV	cis	rs1155848	0.892	rs1023293	ENSG00000227354.5	RBM26-AS1	6.21	2.54e-09	3.49e-06	0.64	0.38	Response to anti-TNF alpha therapy in inflammatory bowel disease;	chr13:79480285	chr13:79406309~79424328:+
OV	cis	rs853679	0.517	rs1904840	ENSG00000219392.1	RP1-265C24.5	-6.21	2.56e-09	3.52e-06	-0.48	-0.38	Depression;	chr6:28140454	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9368555	ENSG00000219392.1	RP1-265C24.5	-6.21	2.56e-09	3.52e-06	-0.48	-0.38	Depression;	chr6:28141189	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9393893	ENSG00000219392.1	RP1-265C24.5	-6.21	2.56e-09	3.52e-06	-0.48	-0.38	Depression;	chr6:28141484	chr6:28115628~28116551:+
OV	cis	rs7246967	1	rs936526	ENSG00000269509.1	BNIP3P34	6.2	2.61e-09	3.57e-06	0.56	0.38	Bronchopulmonary dysplasia;	chr19:22873185	chr19:22773853~22774424:+
OV	cis	rs7246967	1	rs7246967	ENSG00000269509.1	BNIP3P34	6.2	2.61e-09	3.57e-06	0.56	0.38	Bronchopulmonary dysplasia;	chr19:22873544	chr19:22773853~22774424:+
OV	cis	rs950169	0.58	rs2271431	ENSG00000235370.6	DNM1P51	6.2	2.62e-09	3.59e-06	0.47	0.38	Schizophrenia;	chr15:84646233	chr15:84398316~84411701:-
OV	cis	rs3931020	0.508	rs2345436	ENSG00000272864.1	RP11-17E13.2	-6.2	2.64e-09	3.61e-06	-0.5	-0.38	Resistin levels;	chr1:74733056	chr1:74698769~74699333:-
OV	cis	rs8113142	0.747	rs4141232	ENSG00000267243.4	AC005307.3	6.2	2.64e-09	3.62e-06	0.66	0.38	Femoral neck bone geometry and menarche (age at onset);	chr19:28544649	chr19:28435388~28727777:-
OV	cis	rs12134133	1	rs11584921	ENSG00000274245.1	RP11-357P18.2	6.2	2.64e-09	3.62e-06	0.51	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207268630	chr1:207372559~207373252:+
OV	cis	rs11159086	0.941	rs11846588	ENSG00000259005.1	RP3-449M8.6	6.2	2.65e-09	3.63e-06	0.64	0.38	Advanced glycation end-product levels;	chr14:74505398	chr14:74474007~74474864:-
OV	cis	rs7773456	0.533	rs9350190	ENSG00000228412.5	RP4-625H18.2	-6.2	2.66e-09	3.63e-06	-0.51	-0.38	Lupus nephritis in systemic lupus erythematosus;	chr6:19811429	chr6:19802164~19804752:-
OV	cis	rs1707322	0.752	rs6678444	ENSG00000280836.1	AL355480.1	-6.2	2.66e-09	3.64e-06	-0.54	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr1:45581219~45581321:-
OV	cis	rs9326248	0.559	rs573549	ENSG00000254851.1	RP11-109L13.1	-6.2	2.66e-09	3.64e-06	-0.46	-0.38	Blood protein levels;	chr11:116865963	chr11:117135528~117138582:+
OV	cis	rs7927771	0.832	rs10838697	ENSG00000280615.1	Y_RNA	-6.2	2.67e-09	3.65e-06	-0.45	-0.38	Subjective well-being;	chr11:47362933	chr11:47614898~47614994:-
OV	cis	rs853679	0.513	rs9468296	ENSG00000219392.1	RP1-265C24.5	-6.2	2.68e-09	3.67e-06	-0.48	-0.38	Depression;	chr6:28145952	chr6:28115628~28116551:+
OV	cis	rs11673344	0.864	rs1533736	ENSG00000226686.6	LINC01535	6.2	2.69e-09	3.67e-06	0.51	0.38	Obesity-related traits;	chr19:37164074	chr19:37251912~37265535:+
OV	cis	rs7927771	1	rs10838757	ENSG00000280615.1	Y_RNA	-6.2	2.7e-09	3.68e-06	-0.47	-0.38	Subjective well-being;	chr11:47741464	chr11:47614898~47614994:-
OV	cis	rs4563143	0.675	rs73029042	ENSG00000267243.4	AC005307.3	-6.2	2.7e-09	3.69e-06	-0.62	-0.38	Methadone dose in opioid dependence;	chr19:28777072	chr19:28435388~28727777:-
OV	cis	rs1707322	1	rs10890370	ENSG00000280836.1	AL355480.1	-6.2	2.7e-09	3.69e-06	-0.51	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45923545	chr1:45581219~45581321:-
OV	cis	rs9660180	0.967	rs11260623	ENSG00000231050.1	RP1-140A9.1	6.2	2.71e-09	3.7e-06	0.4	0.38	Body mass index;	chr1:1850017	chr1:1891471~1892658:+
OV	cis	rs611744	0.967	rs635624	ENSG00000253754.1	RP11-35G22.1	-6.19	2.71e-09	3.71e-06	-0.42	-0.38	Dupuytren's disease;	chr8:108185570	chr8:108226200~108227544:+
OV	cis	rs1707322	0.827	rs10890347	ENSG00000280836.1	AL355480.1	6.19	2.75e-09	3.75e-06	0.5	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45581219~45581321:-
OV	cis	rs12022452	0.63	rs3795346	ENSG00000238287.1	RP11-656D10.3	-6.19	2.75e-09	3.75e-06	-0.63	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40508753	chr1:40493157~40508661:-
OV	cis	rs801193	0.967	rs2707853	ENSG00000236529.1	RP13-254B10.1	6.19	2.79e-09	3.8e-06	0.4	0.38	Aortic root size;	chr7:66749023	chr7:65840212~65840596:+
OV	cis	rs494459	0.726	rs1784300	ENSG00000255422.1	AP002954.4	-6.19	2.79e-09	3.8e-06	-0.44	-0.38	Height;	chr11:118808920	chr11:118704607~118750263:+
OV	cis	rs73019876	0.901	rs424465	ENSG00000269742.1	BNIP3P29	-6.19	2.81e-09	3.83e-06	-0.45	-0.38	Testicular germ cell tumor;	chr19:22050876	chr19:22065828~22066398:-
OV	cis	rs73019876	0.901	rs440102	ENSG00000269742.1	BNIP3P29	-6.19	2.81e-09	3.83e-06	-0.45	-0.38	Testicular germ cell tumor;	chr19:22050966	chr19:22065828~22066398:-
OV	cis	rs1707322	1	rs7539800	ENSG00000280836.1	AL355480.1	6.19	2.81e-09	3.84e-06	0.53	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45796457	chr1:45581219~45581321:-
OV	cis	rs293748	0.891	rs292180	ENSG00000250155.1	CTD-2353F22.1	-6.19	2.82e-09	3.84e-06	-0.54	-0.38	Obesity-related traits;	chr5:36950157	chr5:36666214~36725195:-
OV	cis	rs7927771	0.864	rs2868459	ENSG00000280615.1	Y_RNA	-6.19	2.82e-09	3.84e-06	-0.46	-0.38	Subjective well-being;	chr11:47433421	chr11:47614898~47614994:-
OV	cis	rs611744	0.743	rs2514843	ENSG00000253754.1	RP11-35G22.1	-6.19	2.82e-09	3.84e-06	-0.44	-0.38	Dupuytren's disease;	chr8:108051206	chr8:108226200~108227544:+
OV	cis	rs2243480	1	rs383402	ENSG00000222364.1	RNU6-96P	6.19	2.86e-09	3.9e-06	0.56	0.38	Diabetic kidney disease;	chr7:66121666	chr7:66395191~66395286:+
OV	cis	rs6991838	0.612	rs7842162	ENSG00000272010.1	CTD-3025N20.3	6.18	2.86e-09	3.9e-06	0.49	0.38	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65591850~65592472:-
OV	cis	rs7615952	0.605	rs11708269	ENSG00000171084.14	FAM86JP	6.18	2.88e-09	3.92e-06	0.69	0.38	Blood pressure (smoking interaction);	chr3:125613306	chr3:125916620~125930024:+
OV	cis	rs801193	1	rs2659889	ENSG00000236529.1	RP13-254B10.1	6.18	2.9e-09	3.95e-06	0.41	0.38	Aortic root size;	chr7:66752125	chr7:65840212~65840596:+
OV	cis	rs801193	1	rs3800812	ENSG00000236529.1	RP13-254B10.1	6.18	2.9e-09	3.95e-06	0.41	0.38	Aortic root size;	chr7:66758474	chr7:65840212~65840596:+
OV	cis	rs801193	1	rs4279493	ENSG00000236529.1	RP13-254B10.1	6.18	2.9e-09	3.95e-06	0.41	0.38	Aortic root size;	chr7:66761633	chr7:65840212~65840596:+
OV	cis	rs494459	0.838	rs488219	ENSG00000278376.1	RP11-158I9.8	-6.18	2.91e-09	3.96e-06	-0.36	-0.38	Height;	chr11:118749988	chr11:118791254~118793137:+
OV	cis	rs801193	1	rs2707850	ENSG00000236529.1	RP13-254B10.1	6.18	2.91e-09	3.96e-06	0.4	0.38	Aortic root size;	chr7:66738883	chr7:65840212~65840596:+
OV	cis	rs801193	0.967	rs1110414	ENSG00000236529.1	RP13-254B10.1	6.18	2.91e-09	3.96e-06	0.4	0.38	Aortic root size;	chr7:66740595	chr7:65840212~65840596:+
OV	cis	rs801193	1	rs7783924	ENSG00000236529.1	RP13-254B10.1	6.18	2.91e-09	3.96e-06	0.4	0.38	Aortic root size;	chr7:66744070	chr7:65840212~65840596:+
OV	cis	rs801193	1	rs7789184	ENSG00000236529.1	RP13-254B10.1	6.18	2.91e-09	3.96e-06	0.4	0.38	Aortic root size;	chr7:66745208	chr7:65840212~65840596:+
OV	cis	rs801193	1	rs2707856	ENSG00000236529.1	RP13-254B10.1	6.18	2.91e-09	3.96e-06	0.4	0.38	Aortic root size;	chr7:66746023	chr7:65840212~65840596:+
OV	cis	rs801193	1	rs2707854	ENSG00000236529.1	RP13-254B10.1	6.18	2.91e-09	3.96e-06	0.4	0.38	Aortic root size;	chr7:66747610	chr7:65840212~65840596:+
OV	cis	rs13256369	0.901	rs12681298	ENSG00000253893.2	FAM85B	6.18	2.92e-09	3.97e-06	0.44	0.38	Obesity-related traits;	chr8:8708725	chr8:8167819~8226614:-
OV	cis	rs853679	0.517	rs3757187	ENSG00000219392.1	RP1-265C24.5	-6.18	2.94e-09	3.99e-06	-0.47	-0.38	Depression;	chr6:28139876	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs3757185	ENSG00000219392.1	RP1-265C24.5	-6.18	2.94e-09	3.99e-06	-0.47	-0.38	Depression;	chr6:28139998	chr6:28115628~28116551:+
OV	cis	rs875971	0.545	rs4718348	ENSG00000222364.1	RNU6-96P	-6.18	2.94e-09	3.99e-06	-0.45	-0.38	Aortic root size;	chr7:66441589	chr7:66395191~66395286:+
OV	cis	rs9660180	0.846	rs10907195	ENSG00000268575.1	RP1-283E3.8	6.18	2.94e-09	3.99e-06	0.36	0.38	Body mass index;	chr1:1781909	chr1:1702736~1737688:-
OV	cis	rs875971	0.638	rs7793569	ENSG00000236529.1	RP13-254B10.1	-6.18	2.95e-09	4e-06	-0.4	-0.38	Aortic root size;	chr7:66651646	chr7:65840212~65840596:+
OV	cis	rs73086581	1	rs17287822	ENSG00000229539.1	RP11-119B16.2	6.18	2.95e-09	4e-06	0.48	0.38	Response to antidepressants in depression;	chr20:3997889	chr20:3888239~3888868:-
OV	cis	rs7587476	0.601	rs17489231	ENSG00000229267.2	AC072062.1	6.18	2.95e-09	4.01e-06	0.46	0.38	Neuroblastoma;	chr2:214809015	chr2:214810229~214963274:+
OV	cis	rs494459	0.838	rs567680	ENSG00000255422.1	AP002954.4	-6.18	2.99e-09	4.06e-06	-0.43	-0.38	Height;	chr11:118737823	chr11:118704607~118750263:+
OV	cis	rs2739330	0.587	rs4820571	ENSG00000250470.1	AP000351.3	6.18	3e-09	4.08e-06	0.48	0.38	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23976904~23977585:-
OV	cis	rs4380275	0.782	rs4854276	ENSG00000272342.1	RP13-539J13.1	6.18	3.02e-09	4.09e-06	0.41	0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:764357	chr2:739588~740164:-
OV	cis	rs11603023	0.874	rs577396	ENSG00000255422.1	AP002954.4	-6.17	3.03e-09	4.1e-06	-0.39	-0.38	Cholesterol, total;	chr11:118628753	chr11:118704607~118750263:+
OV	cis	rs11603023	0.874	rs11216934	ENSG00000255422.1	AP002954.4	-6.17	3.03e-09	4.1e-06	-0.39	-0.38	Cholesterol, total;	chr11:118630742	chr11:118704607~118750263:+
OV	cis	rs12022452	0.591	rs4660415	ENSG00000238287.1	RP11-656D10.3	-6.17	3.03e-09	4.1e-06	-0.63	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40512819	chr1:40493157~40508661:-
OV	cis	rs12022452	0.556	rs11208298	ENSG00000238287.1	RP11-656D10.3	-6.17	3.03e-09	4.1e-06	-0.63	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40513206	chr1:40493157~40508661:-
OV	cis	rs12022452	0.591	rs61781641	ENSG00000238287.1	RP11-656D10.3	-6.17	3.03e-09	4.1e-06	-0.63	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40517412	chr1:40493157~40508661:-
OV	cis	rs12022452	0.591	rs11208315	ENSG00000238287.1	RP11-656D10.3	-6.17	3.03e-09	4.1e-06	-0.63	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40519730	chr1:40493157~40508661:-
OV	cis	rs12022452	0.591	rs12049435	ENSG00000238287.1	RP11-656D10.3	-6.17	3.03e-09	4.1e-06	-0.63	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40524888	chr1:40493157~40508661:-
OV	cis	rs12022452	0.556	rs12037288	ENSG00000238287.1	RP11-656D10.3	-6.17	3.03e-09	4.1e-06	-0.63	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40530625	chr1:40493157~40508661:-
OV	cis	rs12022452	0.591	rs1001400	ENSG00000238287.1	RP11-656D10.3	-6.17	3.03e-09	4.1e-06	-0.63	-0.38	Age-related hearing impairment (SNP x SNP interaction);	chr1:40533230	chr1:40493157~40508661:-
OV	cis	rs2581828	0.659	rs9845352	ENSG00000242142.1	SERBP1P3	-6.17	3.03e-09	4.11e-06	-0.46	-0.38	Crohn's disease;	chr3:53108205	chr3:53064283~53065091:-
OV	cis	rs2581828	0.659	rs9845484	ENSG00000242142.1	SERBP1P3	-6.17	3.03e-09	4.11e-06	-0.46	-0.38	Crohn's disease;	chr3:53108240	chr3:53064283~53065091:-
OV	cis	rs934734	0.532	rs7557569	ENSG00000234255.7	AC012370.3	-6.17	3.05e-09	4.13e-06	-0.42	-0.38	Rheumatoid arthritis;	chr2:65417427	chr2:65439888~65456571:-
OV	cis	rs934734	0.532	rs10166100	ENSG00000234255.7	AC012370.3	-6.17	3.05e-09	4.13e-06	-0.42	-0.38	Rheumatoid arthritis;	chr2:65418616	chr2:65439888~65456571:-
OV	cis	rs6088580	0.634	rs1890002	ENSG00000206582.1	Y_RNA	6.17	3.05e-09	4.13e-06	0.45	0.38	Glomerular filtration rate (creatinine);	chr20:34331413	chr20:34526510~34526606:-
OV	cis	rs7017914	0.628	rs12156041	ENSG00000223220.1	Y_RNA	6.17	3.08e-09	4.17e-06	0.42	0.38	Bone mineral density;	chr8:70914690	chr8:70780914~70781008:-
OV	cis	rs7927771	0.832	rs10769258	ENSG00000280615.1	Y_RNA	6.17	3.08e-09	4.17e-06	0.46	0.38	Subjective well-being;	chr11:47369488	chr11:47614898~47614994:-
OV	cis	rs801193	0.613	rs2016325	ENSG00000222364.1	RNU6-96P	6.17	3.1e-09	4.2e-06	0.39	0.38	Aortic root size;	chr7:66858513	chr7:66395191~66395286:+
OV	cis	rs62355901	0.545	rs72756091	ENSG00000271828.1	CTD-2310F14.1	6.17	3.12e-09	4.22e-06	0.68	0.38	Breast cancer;	chr5:56765903	chr5:56927874~56929573:+
OV	cis	rs8062405	1	rs7498555	ENSG00000259982.1	CDC37P1	6.17	3.12e-09	4.22e-06	0.48	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28700294~28701540:-
OV	cis	rs12802244	1	rs12802244	ENSG00000280615.1	Y_RNA	-6.17	3.14e-09	4.24e-06	-0.48	-0.38	Neuroticism;	chr11:47911114	chr11:47614898~47614994:-
OV	cis	rs12134133	1	rs1583090	ENSG00000274245.1	RP11-357P18.2	6.17	3.14e-09	4.25e-06	0.51	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207262438	chr1:207372559~207373252:+
OV	cis	rs2836974	0.568	rs4816620	ENSG00000232608.1	TIMM9P2	6.17	3.15e-09	4.25e-06	0.4	0.38	Cognitive function;	chr21:39241860	chr21:39216624~39217506:+
OV	cis	rs172166	0.694	rs2791332	ENSG00000220721.1	OR1F12	6.17	3.15e-09	4.26e-06	0.42	0.38	Cardiac Troponin-T levels;	chr6:28141010	chr6:28073316~28074233:+
OV	cis	rs7017914	0.652	rs2933859	ENSG00000223220.1	Y_RNA	6.17	3.16e-09	4.27e-06	0.42	0.38	Bone mineral density;	chr8:70993894	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs2933858	ENSG00000223220.1	Y_RNA	6.17	3.16e-09	4.27e-06	0.42	0.38	Bone mineral density;	chr8:70994109	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs2639948	ENSG00000223220.1	Y_RNA	6.17	3.16e-09	4.27e-06	0.42	0.38	Bone mineral density;	chr8:70996251	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs2732141	ENSG00000223220.1	Y_RNA	6.17	3.16e-09	4.27e-06	0.42	0.38	Bone mineral density;	chr8:70998672	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs2639947	ENSG00000223220.1	Y_RNA	6.17	3.16e-09	4.27e-06	0.42	0.38	Bone mineral density;	chr8:70999202	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs2732145	ENSG00000223220.1	Y_RNA	6.17	3.16e-09	4.27e-06	0.42	0.38	Bone mineral density;	chr8:70999834	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs2732146	ENSG00000223220.1	Y_RNA	6.17	3.16e-09	4.27e-06	0.42	0.38	Bone mineral density;	chr8:70999883	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs2732147	ENSG00000223220.1	Y_RNA	6.17	3.16e-09	4.27e-06	0.42	0.38	Bone mineral density;	chr8:71000179	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs2639946	ENSG00000223220.1	Y_RNA	6.17	3.16e-09	4.27e-06	0.42	0.38	Bone mineral density;	chr8:71000265	chr8:70780914~70781008:-
OV	cis	rs7017914	0.628	rs2732149	ENSG00000223220.1	Y_RNA	6.17	3.16e-09	4.27e-06	0.42	0.38	Bone mineral density;	chr8:71000267	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs2639945	ENSG00000223220.1	Y_RNA	6.17	3.16e-09	4.27e-06	0.42	0.38	Bone mineral density;	chr8:71000304	chr8:70780914~70781008:-
OV	cis	rs7017914	0.54	rs2639944	ENSG00000223220.1	Y_RNA	6.17	3.16e-09	4.27e-06	0.42	0.38	Bone mineral density;	chr8:71000512	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs2732088	ENSG00000223220.1	Y_RNA	6.17	3.16e-09	4.27e-06	0.42	0.38	Bone mineral density;	chr8:71000542	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs2639943	ENSG00000223220.1	Y_RNA	6.17	3.16e-09	4.27e-06	0.42	0.38	Bone mineral density;	chr8:71000905	chr8:70780914~70781008:-
OV	cis	rs73019876	0.869	rs402281	ENSG00000269742.1	BNIP3P29	-6.17	3.17e-09	4.29e-06	-0.44	-0.38	Testicular germ cell tumor;	chr19:22048510	chr19:22065828~22066398:-
OV	cis	rs73019876	0.901	rs423284	ENSG00000269742.1	BNIP3P29	-6.17	3.17e-09	4.29e-06	-0.44	-0.38	Testicular germ cell tumor;	chr19:22049576	chr19:22065828~22066398:-
OV	cis	rs73019876	0.901	rs390852	ENSG00000269742.1	BNIP3P29	-6.17	3.17e-09	4.29e-06	-0.44	-0.38	Testicular germ cell tumor;	chr19:22049774	chr19:22065828~22066398:-
OV	cis	rs73019876	0.901	rs399990	ENSG00000269742.1	BNIP3P29	-6.17	3.17e-09	4.29e-06	-0.44	-0.38	Testicular germ cell tumor;	chr19:22049994	chr19:22065828~22066398:-
OV	cis	rs73019876	0.901	rs430614	ENSG00000269742.1	BNIP3P29	-6.17	3.17e-09	4.29e-06	-0.44	-0.38	Testicular germ cell tumor;	chr19:22050232	chr19:22065828~22066398:-
OV	cis	rs73019876	0.901	rs507994	ENSG00000269742.1	BNIP3P29	-6.17	3.17e-09	4.29e-06	-0.44	-0.38	Testicular germ cell tumor;	chr19:22050257	chr19:22065828~22066398:-
OV	cis	rs73019876	0.836	rs548059	ENSG00000269742.1	BNIP3P29	-6.16	3.19e-09	4.31e-06	-0.44	-0.38	Testicular germ cell tumor;	chr19:22045289	chr19:22065828~22066398:-
OV	cis	rs73019876	0.747	rs7258834	ENSG00000269742.1	BNIP3P29	-6.16	3.19e-09	4.31e-06	-0.44	-0.38	Testicular germ cell tumor;	chr19:22045319	chr19:22065828~22066398:-
OV	cis	rs73019876	0.934	rs431346	ENSG00000269742.1	BNIP3P29	-6.16	3.19e-09	4.31e-06	-0.44	-0.38	Testicular germ cell tumor;	chr19:22045413	chr19:22065828~22066398:-
OV	cis	rs73019876	0.901	rs436194	ENSG00000269742.1	BNIP3P29	-6.16	3.19e-09	4.31e-06	-0.44	-0.38	Testicular germ cell tumor;	chr19:22045725	chr19:22065828~22066398:-
OV	cis	rs73019876	0.836	rs431474	ENSG00000269742.1	BNIP3P29	-6.16	3.19e-09	4.31e-06	-0.44	-0.38	Testicular germ cell tumor;	chr19:22045990	chr19:22065828~22066398:-
OV	cis	rs73019876	0.901	rs426299	ENSG00000269742.1	BNIP3P29	-6.16	3.19e-09	4.31e-06	-0.44	-0.38	Testicular germ cell tumor;	chr19:22046473	chr19:22065828~22066398:-
OV	cis	rs73019876	0.901	rs450298	ENSG00000269742.1	BNIP3P29	-6.16	3.19e-09	4.31e-06	-0.44	-0.38	Testicular germ cell tumor;	chr19:22047167	chr19:22065828~22066398:-
OV	cis	rs12134133	1	rs4844590	ENSG00000274245.1	RP11-357P18.2	6.16	3.2e-09	4.31e-06	0.5	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207322784	chr1:207372559~207373252:+
OV	cis	rs7044106	0.762	rs12003646	ENSG00000226752.6	PSMD5-AS1	-6.16	3.2e-09	4.31e-06	-0.44	-0.38	Hip circumference adjusted for BMI;	chr9:120708343	chr9:120824828~120854385:+
OV	cis	rs2836974	0.568	rs2183573	ENSG00000232608.1	TIMM9P2	6.16	3.21e-09	4.32e-06	0.4	0.38	Cognitive function;	chr21:39202379	chr21:39216624~39217506:+
OV	cis	rs7927771	0.756	rs10742803	ENSG00000280615.1	Y_RNA	6.16	3.21e-09	4.33e-06	0.45	0.38	Subjective well-being;	chr11:47418387	chr11:47614898~47614994:-
OV	cis	rs7927771	0.864	rs2293580	ENSG00000280615.1	Y_RNA	6.16	3.21e-09	4.33e-06	0.45	0.38	Subjective well-being;	chr11:47418732	chr11:47614898~47614994:-
OV	cis	rs293748	0.771	rs66868318	ENSG00000250155.1	CTD-2353F22.1	-6.16	3.21e-09	4.34e-06	-0.54	-0.38	Obesity-related traits;	chr5:36826119	chr5:36666214~36725195:-
OV	cis	rs875971	0.508	rs10258739	ENSG00000236529.1	RP13-254B10.1	-6.16	3.22e-09	4.35e-06	-0.4	-0.38	Aortic root size;	chr7:66597948	chr7:65840212~65840596:+
OV	cis	rs2286503	1	rs2286503	ENSG00000221740.1	SNORD93	6.16	3.23e-09	4.35e-06	0.44	0.38	Fibrinogen;	chr7:22816987	chr7:22856613~22856686:+
OV	cis	rs2286503	1	rs2286501	ENSG00000221740.1	SNORD93	6.16	3.23e-09	4.35e-06	0.44	0.38	Fibrinogen;	chr7:22817166	chr7:22856613~22856686:+
OV	cis	rs7615952	0.932	rs1976458	ENSG00000171084.14	FAM86JP	6.16	3.25e-09	4.37e-06	0.61	0.38	Blood pressure (smoking interaction);	chr3:125928669	chr3:125916620~125930024:+
OV	cis	rs11671005	0.504	rs3794963	ENSG00000269600.1	AC016629.3	6.16	3.25e-09	4.38e-06	0.47	0.38	Mean platelet volume;	chr19:58559684	chr19:58593896~58599355:-
OV	cis	rs12134133	1	rs61822697	ENSG00000274245.1	RP11-357P18.2	6.16	3.27e-09	4.41e-06	0.51	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207311819	chr1:207372559~207373252:+
OV	cis	rs875971	0.545	rs12670811	ENSG00000222364.1	RNU6-96P	-6.16	3.28e-09	4.42e-06	-0.45	-0.38	Aortic root size;	chr7:66358032	chr7:66395191~66395286:+
OV	cis	rs2836974	0.584	rs7276774	ENSG00000232608.1	TIMM9P2	6.16	3.29e-09	4.42e-06	0.4	0.38	Cognitive function;	chr21:39256799	chr21:39216624~39217506:+
OV	cis	rs293748	0.713	rs2937116	ENSG00000250155.1	CTD-2353F22.1	-6.16	3.29e-09	4.43e-06	-0.55	-0.38	Obesity-related traits;	chr5:36824900	chr5:36666214~36725195:-
OV	cis	rs73086581	1	rs6052220	ENSG00000229539.1	RP11-119B16.2	6.16	3.29e-09	4.43e-06	0.46	0.38	Response to antidepressants in depression;	chr20:3989947	chr20:3888239~3888868:-
OV	cis	rs11673344	0.832	rs112380313	ENSG00000226686.6	LINC01535	6.16	3.33e-09	4.48e-06	0.52	0.38	Obesity-related traits;	chr19:37027979	chr19:37251912~37265535:+
OV	cis	rs4660456	0.913	rs2744808	ENSG00000237899.1	RP4-739H11.3	-6.16	3.36e-09	4.51e-06	-0.58	-0.38	Platelet count;	chr1:40712271	chr1:40669089~40687588:-
OV	cis	rs8062405	0.755	rs62031607	ENSG00000259982.1	CDC37P1	6.16	3.36e-09	4.51e-06	0.48	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28700294~28701540:-
OV	cis	rs9660180	0.967	rs6687065	ENSG00000231050.1	RP1-140A9.1	6.16	3.36e-09	4.52e-06	0.4	0.38	Body mass index;	chr1:1847030	chr1:1891471~1892658:+
OV	cis	rs73086581	1	rs17215340	ENSG00000229539.1	RP11-119B16.2	-6.15	3.37e-09	4.53e-06	-0.48	-0.38	Response to antidepressants in depression;	chr20:3989526	chr20:3888239~3888868:-
OV	cis	rs7044106	0.762	rs3903886	ENSG00000226752.6	PSMD5-AS1	6.15	3.37e-09	4.53e-06	0.43	0.38	Hip circumference adjusted for BMI;	chr9:120621368	chr9:120824828~120854385:+
OV	cis	rs12134133	1	rs61822669	ENSG00000274245.1	RP11-357P18.2	6.15	3.38e-09	4.54e-06	0.51	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207247869	chr1:207372559~207373252:+
OV	cis	rs6991838	0.8	rs11786598	ENSG00000272010.1	CTD-3025N20.3	-6.15	3.38e-09	4.54e-06	-0.47	-0.38	Intelligence (multi-trait analysis);	chr8:65559944	chr8:65591850~65592472:-
OV	cis	rs11098499	0.866	rs10518329	ENSG00000245958.5	RP11-33B1.1	-6.15	3.38e-09	4.54e-06	-0.42	-0.38	Corneal astigmatism;	chr4:119480680	chr4:119454791~119552025:+
OV	cis	rs12134133	1	rs6658718	ENSG00000274245.1	RP11-357P18.2	6.15	3.39e-09	4.55e-06	0.46	0.38	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285561	chr1:207372559~207373252:+
OV	cis	rs11098499	0.661	rs10015965	ENSG00000245958.5	RP11-33B1.1	-6.15	3.39e-09	4.55e-06	-0.42	-0.38	Corneal astigmatism;	chr4:119347082	chr4:119454791~119552025:+
OV	cis	rs7615952	0.546	rs11711150	ENSG00000171084.14	FAM86JP	6.15	3.4e-09	4.56e-06	0.62	0.38	Blood pressure (smoking interaction);	chr3:125596819	chr3:125916620~125930024:+
OV	cis	rs4713118	0.621	rs9368548	ENSG00000219392.1	RP1-265C24.5	-6.15	3.4e-09	4.56e-06	-0.47	-0.38	Parkinson's disease;	chr6:28066959	chr6:28115628~28116551:+
OV	cis	rs7587476	0.601	rs13021937	ENSG00000229267.2	AC072062.1	6.15	3.4e-09	4.57e-06	0.47	0.38	Neuroblastoma;	chr2:214809213	chr2:214810229~214963274:+
OV	cis	rs7587476	0.531	rs35933323	ENSG00000229267.2	AC072062.1	6.15	3.4e-09	4.57e-06	0.47	0.38	Neuroblastoma;	chr2:214809366	chr2:214810229~214963274:+
OV	cis	rs2836974	0.59	rs11911822	ENSG00000232608.1	TIMM9P2	6.15	3.43e-09	4.6e-06	0.4	0.38	Cognitive function;	chr21:39235917	chr21:39216624~39217506:+
OV	cis	rs10740039	0.583	rs1904404	ENSG00000254271.1	RP11-131N11.4	-6.15	3.49e-09	4.67e-06	-0.49	-0.38	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60742428	chr10:60734342~60741828:+
OV	cis	rs11673344	0.77	rs74770693	ENSG00000226686.6	LINC01535	6.15	3.5e-09	4.68e-06	0.52	0.38	Obesity-related traits;	chr19:37135613	chr19:37251912~37265535:+
OV	cis	rs7044106	0.762	rs10760115	ENSG00000226752.6	PSMD5-AS1	-6.15	3.5e-09	4.68e-06	-0.45	-0.38	Hip circumference adjusted for BMI;	chr9:120714674	chr9:120824828~120854385:+
OV	cis	rs274567	0.599	rs11242110	ENSG00000233006.5	AC034220.3	-6.15	3.52e-09	4.71e-06	-0.41	-0.38	Blood metabolite levels;	chr5:132408085	chr5:132311285~132369916:-
OV	cis	rs7927771	1	rs10838748	ENSG00000280615.1	Y_RNA	-6.15	3.55e-09	4.75e-06	-0.47	-0.38	Subjective well-being;	chr11:47694829	chr11:47614898~47614994:-
OV	cis	rs34375054	0.526	rs4412800	ENSG00000279233.1	RP11-158L12.4	-6.15	3.55e-09	4.75e-06	-0.31	-0.38	Post bronchodilator FEV1/FVC ratio;	chr12:125190196	chr12:125138245~125141711:+
OV	cis	rs801193	1	rs13239306	ENSG00000236529.1	RP13-254B10.1	-6.14	3.56e-09	4.76e-06	-0.41	-0.38	Aortic root size;	chr7:66671030	chr7:65840212~65840596:+
OV	cis	rs4713118	0.868	rs2893928	ENSG00000220721.1	OR1F12	6.14	3.56e-09	4.77e-06	0.44	0.38	Parkinson's disease;	chr6:27770651	chr6:28073316~28074233:+
OV	cis	rs858239	0.632	rs7811903	ENSG00000230042.1	AK3P3	-6.14	3.58e-09	4.78e-06	-0.4	-0.38	Cerebrospinal fluid biomarker levels;	chr7:23079437	chr7:23129178~23129841:+
OV	cis	rs2833693	0.533	rs2833746	ENSG00000261610.1	AP000265.1	6.14	3.6e-09	4.82e-06	0.45	0.38	Temperament;	chr21:32252556	chr21:32259804~32261585:-
OV	cis	rs7773456	0.533	rs9368127	ENSG00000228412.5	RP4-625H18.2	-6.14	3.61e-09	4.82e-06	-0.51	-0.38	Lupus nephritis in systemic lupus erythematosus;	chr6:19811760	chr6:19802164~19804752:-
OV	cis	rs2153535	0.518	rs2183113	ENSG00000230939.1	RP11-314C16.1	-6.14	3.62e-09	4.84e-06	-0.42	-0.38	Motion sickness;	chr6:8528305	chr6:8784178~8785445:+
OV	cis	rs2153535	0.518	rs6597336	ENSG00000230939.1	RP11-314C16.1	-6.14	3.62e-09	4.84e-06	-0.42	-0.38	Motion sickness;	chr6:8530663	chr6:8784178~8785445:+
OV	cis	rs2153535	0.539	rs4960436	ENSG00000230939.1	RP11-314C16.1	-6.14	3.62e-09	4.84e-06	-0.42	-0.38	Motion sickness;	chr6:8532237	chr6:8784178~8785445:+
OV	cis	rs4563143	0.675	rs73029050	ENSG00000267243.4	AC005307.3	-6.14	3.63e-09	4.84e-06	-0.62	-0.38	Methadone dose in opioid dependence;	chr19:28785647	chr19:28435388~28727777:-
OV	cis	rs4713118	0.955	rs9393848	ENSG00000220721.1	OR1F12	6.14	3.63e-09	4.85e-06	0.43	0.38	Parkinson's disease;	chr6:27720590	chr6:28073316~28074233:+
OV	cis	rs4591358	0.68	rs4277541	ENSG00000223466.1	AC064834.2	-6.14	3.64e-09	4.87e-06	-0.5	-0.38	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195449705	chr2:195533035~195538681:+
OV	cis	rs7044106	0.762	rs1547268	ENSG00000226752.6	PSMD5-AS1	-6.14	3.65e-09	4.88e-06	-0.45	-0.38	Hip circumference adjusted for BMI;	chr9:120646410	chr9:120824828~120854385:+
OV	cis	rs7044106	0.762	rs1547267	ENSG00000226752.6	PSMD5-AS1	-6.14	3.65e-09	4.88e-06	-0.45	-0.38	Hip circumference adjusted for BMI;	chr9:120646458	chr9:120824828~120854385:+
OV	cis	rs7044106	0.762	rs4142158	ENSG00000226752.6	PSMD5-AS1	-6.14	3.65e-09	4.88e-06	-0.45	-0.38	Hip circumference adjusted for BMI;	chr9:120648541	chr9:120824828~120854385:+
OV	cis	rs934734	0.532	rs7569113	ENSG00000234255.7	AC012370.3	6.14	3.67e-09	4.9e-06	0.4	0.38	Rheumatoid arthritis;	chr2:65429907	chr2:65439888~65456571:-
OV	cis	rs2980439	0.846	rs2980437	ENSG00000173295.6	FAM86B3P	-6.14	3.68e-09	4.91e-06	-0.49	-0.38	Neuroticism;	chr8:8237241	chr8:8228595~8244865:+
OV	cis	rs992157	0.835	rs6707559	ENSG00000237281.1	CATIP-AS2	-6.14	3.68e-09	4.91e-06	-0.43	-0.38	Colorectal cancer;	chr2:218278050	chr2:218326889~218357966:-
OV	cis	rs7927771	0.864	rs4752999	ENSG00000280615.1	Y_RNA	-6.14	3.68e-09	4.92e-06	-0.45	-0.38	Subjective well-being;	chr11:47407014	chr11:47614898~47614994:-
OV	cis	rs7615952	1	rs7616044	ENSG00000171084.14	FAM86JP	6.14	3.7e-09	4.94e-06	0.59	0.38	Blood pressure (smoking interaction);	chr3:125930511	chr3:125916620~125930024:+
OV	cis	rs7615952	0.932	rs13314869	ENSG00000171084.14	FAM86JP	6.14	3.74e-09	4.99e-06	0.61	0.38	Blood pressure (smoking interaction);	chr3:125925826	chr3:125916620~125930024:+
OV	cis	rs8105895	0.935	rs988211	ENSG00000269742.1	BNIP3P29	6.14	3.75e-09	4.99e-06	0.62	0.38	Body mass index (change over time);	chr19:22119734	chr19:22065828~22066398:-
OV	cis	rs2282300	1	rs12796693	ENSG00000254532.1	RP11-624D11.2	6.13	3.83e-09	5.09e-06	0.51	0.38	Morning vs. evening chronotype;	chr11:30408036	chr11:30044058~30084343:-
OV	cis	rs4713118	0.868	rs9468220	ENSG00000220721.1	OR1F12	-6.13	3.85e-09	5.12e-06	-0.44	-0.38	Parkinson's disease;	chr6:27765197	chr6:28073316~28074233:+
OV	cis	rs4563143	0.675	rs55884228	ENSG00000267243.4	AC005307.3	-6.13	3.85e-09	5.12e-06	-0.61	-0.38	Methadone dose in opioid dependence;	chr19:28752990	chr19:28435388~28727777:-
OV	cis	rs4563143	0.675	rs56123392	ENSG00000267243.4	AC005307.3	-6.13	3.85e-09	5.12e-06	-0.61	-0.38	Methadone dose in opioid dependence;	chr19:28764724	chr19:28435388~28727777:-
OV	cis	rs4563143	0.647	rs73029014	ENSG00000267243.4	AC005307.3	-6.13	3.85e-09	5.12e-06	-0.61	-0.38	Methadone dose in opioid dependence;	chr19:28766748	chr19:28435388~28727777:-
OV	cis	rs7615952	0.741	rs13314845	ENSG00000171084.14	FAM86JP	6.13	3.87e-09	5.14e-06	0.61	0.38	Blood pressure (smoking interaction);	chr3:125925939	chr3:125916620~125930024:+
OV	cis	rs7615952	0.733	rs13314847	ENSG00000171084.14	FAM86JP	6.13	3.87e-09	5.14e-06	0.61	0.38	Blood pressure (smoking interaction);	chr3:125925945	chr3:125916620~125930024:+
OV	cis	rs7615952	0.932	rs13086087	ENSG00000171084.14	FAM86JP	6.13	3.87e-09	5.14e-06	0.61	0.38	Blood pressure (smoking interaction);	chr3:125927438	chr3:125916620~125930024:+
OV	cis	rs7615952	0.8	rs13086460	ENSG00000171084.14	FAM86JP	6.13	3.87e-09	5.14e-06	0.61	0.38	Blood pressure (smoking interaction);	chr3:125927574	chr3:125916620~125930024:+
OV	cis	rs7615952	0.866	rs1976459	ENSG00000171084.14	FAM86JP	6.13	3.87e-09	5.14e-06	0.61	0.38	Blood pressure (smoking interaction);	chr3:125928643	chr3:125916620~125930024:+
OV	cis	rs172166	0.694	rs9295760	ENSG00000220721.1	OR1F12	6.13	3.89e-09	5.18e-06	0.42	0.38	Cardiac Troponin-T levels;	chr6:28179607	chr6:28073316~28074233:+
OV	cis	rs4713118	0.513	rs1225591	ENSG00000220721.1	OR1F12	6.13	3.89e-09	5.18e-06	0.42	0.38	Parkinson's disease;	chr6:28180974	chr6:28073316~28074233:+
OV	cis	rs9660180	0.967	rs9660106	ENSG00000231050.1	RP1-140A9.1	6.13	3.92e-09	5.21e-06	0.39	0.38	Body mass index;	chr1:1866508	chr1:1891471~1892658:+
OV	cis	rs9660180	0.967	rs6603802	ENSG00000231050.1	RP1-140A9.1	6.13	3.95e-09	5.25e-06	0.4	0.38	Body mass index;	chr1:1881082	chr1:1891471~1892658:+
OV	cis	rs4563143	0.675	rs73025085	ENSG00000267243.4	AC005307.3	-6.12	3.96e-09	5.25e-06	-0.61	-0.38	Methadone dose in opioid dependence;	chr19:28756111	chr19:28435388~28727777:-
OV	cis	rs875971	0.66	rs801193	ENSG00000236529.1	RP13-254B10.1	-6.12	3.97e-09	5.26e-06	-0.39	-0.38	Aortic root size;	chr7:66565625	chr7:65840212~65840596:+
OV	cis	rs34779708	0.966	rs12257770	ENSG00000230534.5	RP11-297A16.2	6.12	3.99e-09	5.29e-06	0.46	0.38	Inflammatory bowel disease;Crohn's disease;	chr10:35228306	chr10:35098006~35127020:-
OV	cis	rs611744	0.967	rs2600614	ENSG00000253754.1	RP11-35G22.1	-6.12	3.99e-09	5.3e-06	-0.41	-0.38	Dupuytren's disease;	chr8:108185850	chr8:108226200~108227544:+
OV	cis	rs62355901	0.599	rs10513090	ENSG00000271828.1	CTD-2310F14.1	-6.12	4.01e-09	5.32e-06	-0.67	-0.38	Breast cancer;	chr5:56758238	chr5:56927874~56929573:+
OV	cis	rs4713118	0.869	rs9461405	ENSG00000220721.1	OR1F12	6.12	4.03e-09	5.35e-06	0.41	0.38	Parkinson's disease;	chr6:27751596	chr6:28073316~28074233:+
OV	cis	rs7615952	0.546	rs2979340	ENSG00000171084.14	FAM86JP	6.12	4.05e-09	5.37e-06	0.62	0.38	Blood pressure (smoking interaction);	chr3:125622540	chr3:125916620~125930024:+
OV	cis	rs7615952	0.546	rs2979338	ENSG00000171084.14	FAM86JP	6.12	4.05e-09	5.37e-06	0.62	0.38	Blood pressure (smoking interaction);	chr3:125624282	chr3:125916620~125930024:+
OV	cis	rs7615952	0.546	rs2922171	ENSG00000171084.14	FAM86JP	6.12	4.05e-09	5.37e-06	0.62	0.38	Blood pressure (smoking interaction);	chr3:125624349	chr3:125916620~125930024:+
OV	cis	rs7615952	0.546	rs112919177	ENSG00000171084.14	FAM86JP	6.12	4.05e-09	5.37e-06	0.62	0.38	Blood pressure (smoking interaction);	chr3:125627226	chr3:125916620~125930024:+
OV	cis	rs494459	0.838	rs488219	ENSG00000255422.1	AP002954.4	-6.12	4.09e-09	5.41e-06	-0.41	-0.38	Height;	chr11:118749988	chr11:118704607~118750263:+
OV	cis	rs7615952	0.673	rs3811677	ENSG00000171084.14	FAM86JP	6.12	4.1e-09	5.42e-06	0.59	0.38	Blood pressure (smoking interaction);	chr3:125929237	chr3:125916620~125930024:+
OV	cis	rs7615952	0.932	rs3811679	ENSG00000171084.14	FAM86JP	6.12	4.1e-09	5.42e-06	0.59	0.38	Blood pressure (smoking interaction);	chr3:125929440	chr3:125916620~125930024:+
OV	cis	rs8062405	0.756	rs151182	ENSG00000259982.1	CDC37P1	6.12	4.13e-09	5.46e-06	0.46	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28484431	chr16:28700294~28701540:-
OV	cis	rs7688540	0.771	rs11729365	ENSG00000275426.1	CH17-262A2.1	6.12	4.15e-09	5.49e-06	0.62	0.38	Facial morphology (factor 6, height of vermillion lower lip);	chr4:278735	chr4:149738~150317:+
OV	cis	rs7824557	0.767	rs6985460	ENSG00000255495.1	AC145124.2	6.11	4.19e-09	5.53e-06	0.46	0.38	Retinal vascular caliber;	chr8:11313578	chr8:12194467~12196280:+
OV	cis	rs875971	0.597	rs11763224	ENSG00000222364.1	RNU6-96P	-6.11	4.21e-09	5.56e-06	-0.45	-0.38	Aortic root size;	chr7:66518628	chr7:66395191~66395286:+
OV	cis	rs6964833	0.554	rs112506907	ENSG00000123965.13	PMS2P5	6.11	4.22e-09	5.58e-06	0.51	0.38	Menarche (age at onset);	chr7:74654407	chr7:74894116~74897835:+
OV	cis	rs875971	0.66	rs7807930	ENSG00000236529.1	RP13-254B10.1	-6.11	4.23e-09	5.59e-06	-0.39	-0.38	Aortic root size;	chr7:66622178	chr7:65840212~65840596:+
OV	cis	rs875971	0.66	rs7807944	ENSG00000236529.1	RP13-254B10.1	-6.11	4.23e-09	5.59e-06	-0.39	-0.38	Aortic root size;	chr7:66622208	chr7:65840212~65840596:+
OV	cis	rs2286503	1	rs2286503	ENSG00000228649.7	AC005682.5	6.11	4.25e-09	5.61e-06	0.44	0.38	Fibrinogen;	chr7:22816987	chr7:22854178~22861579:+
OV	cis	rs2286503	1	rs2286501	ENSG00000228649.7	AC005682.5	6.11	4.25e-09	5.61e-06	0.44	0.38	Fibrinogen;	chr7:22817166	chr7:22854178~22861579:+
OV	cis	rs2243480	1	rs3885839	ENSG00000222364.1	RNU6-96P	-6.11	4.26e-09	5.62e-06	-0.59	-0.38	Diabetic kidney disease;	chr7:65825416	chr7:66395191~66395286:+
OV	cis	rs2286503	0.966	rs2286507	ENSG00000228649.7	AC005682.5	6.11	4.28e-09	5.65e-06	0.44	0.38	Fibrinogen;	chr7:22815141	chr7:22854178~22861579:+
OV	cis	rs2581828	0.646	rs9861233	ENSG00000242142.1	SERBP1P3	-6.11	4.35e-09	5.74e-06	-0.45	-0.38	Crohn's disease;	chr3:53124815	chr3:53064283~53065091:-
OV	cis	rs853679	0.55	rs1237875	ENSG00000219392.1	RP1-265C24.5	6.11	4.39e-09	5.79e-06	0.46	0.38	Depression;	chr6:28205232	chr6:28115628~28116551:+
OV	cis	rs2404602	0.622	rs4886506	ENSG00000259422.1	RP11-593F23.1	6.11	4.4e-09	5.8e-06	0.42	0.38	Blood metabolite levels;	chr15:76914936	chr15:76174891~76181486:-
OV	cis	rs1707322	1	rs11211232	ENSG00000280836.1	AL355480.1	-6.11	4.41e-09	5.81e-06	-0.51	-0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45945474	chr1:45581219~45581321:-
OV	cis	rs7587476	0.601	rs6715570	ENSG00000229267.2	AC072062.1	6.11	4.41e-09	5.81e-06	0.46	0.38	Neuroblastoma;	chr2:214808716	chr2:214810229~214963274:+
OV	cis	rs6700559	0.935	rs10920001	ENSG00000260088.1	RP11-92G12.3	-6.1	4.42e-09	5.82e-06	-0.4	-0.38	Coronary artery disease;	chr1:200682420	chr1:200669507~200694250:+
OV	cis	rs950169	0.512	rs4374136	ENSG00000235370.6	DNM1P51	6.1	4.45e-09	5.87e-06	0.55	0.38	Schizophrenia;	chr15:83976255	chr15:84398316~84411701:-
OV	cis	rs875971	0.619	rs10278371	ENSG00000236529.1	RP13-254B10.1	-6.1	4.46e-09	5.88e-06	-0.4	-0.38	Aortic root size;	chr7:66586553	chr7:65840212~65840596:+
OV	cis	rs4713118	0.955	rs9468201	ENSG00000220721.1	OR1F12	6.1	4.49e-09	5.92e-06	0.42	0.38	Parkinson's disease;	chr6:27719256	chr6:28073316~28074233:+
OV	cis	rs73019876	0.901	rs367280	ENSG00000269742.1	BNIP3P29	-6.1	4.5e-09	5.93e-06	-0.44	-0.38	Testicular germ cell tumor;	chr19:22051986	chr19:22065828~22066398:-
OV	cis	rs4713118	0.513	rs149955	ENSG00000220721.1	OR1F12	6.1	4.52e-09	5.94e-06	0.41	0.38	Parkinson's disease;	chr6:28068447	chr6:28073316~28074233:+
OV	cis	rs8062405	0.723	rs35175818	ENSG00000259982.1	CDC37P1	6.1	4.52e-09	5.94e-06	0.47	0.38	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28700294~28701540:-
OV	cis	rs494459	0.838	rs555639	ENSG00000255422.1	AP002954.4	6.1	4.52e-09	5.95e-06	0.41	0.38	Height;	chr11:118758322	chr11:118704607~118750263:+
OV	cis	rs11671005	0.504	rs3794964	ENSG00000269600.1	AC016629.3	-6.1	4.53e-09	5.96e-06	-0.48	-0.38	Mean platelet volume;	chr19:58559549	chr19:58593896~58599355:-
OV	cis	rs73086581	1	rs17215529	ENSG00000229539.1	RP11-119B16.2	6.1	4.55e-09	5.98e-06	0.47	0.38	Response to antidepressants in depression;	chr20:3994755	chr20:3888239~3888868:-
OV	cis	rs2286503	0.901	rs10950922	ENSG00000228649.7	AC005682.5	6.1	4.56e-09	6e-06	0.44	0.38	Fibrinogen;	chr7:22814387	chr7:22854178~22861579:+
OV	cis	rs4713118	0.587	rs61471148	ENSG00000219392.1	RP1-265C24.5	-6.1	4.59e-09	6.03e-06	-0.47	-0.38	Parkinson's disease;	chr6:28069254	chr6:28115628~28116551:+
OV	cis	rs2243480	1	rs464895	ENSG00000222364.1	RNU6-96P	-6.1	4.6e-09	6.05e-06	-0.6	-0.38	Diabetic kidney disease;	chr7:66062119	chr7:66395191~66395286:+
OV	cis	rs11603023	0.874	rs483598	ENSG00000255422.1	AP002954.4	-6.1	4.61e-09	6.06e-06	-0.39	-0.38	Cholesterol, total;	chr11:118638950	chr11:118704607~118750263:+
OV	cis	rs9813712	0.571	rs9824426	ENSG00000228252.7	COL6A4P2	-6.1	4.61e-09	6.06e-06	-0.43	-0.38	Response to amphetamines;	chr3:130226115	chr3:130212823~130273806:+
OV	cis	rs1707322	1	rs1622208	ENSG00000280836.1	AL355480.1	6.1	4.64e-09	6.09e-06	0.52	0.38	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46032703	chr1:45581219~45581321:-
OV	cis	rs7927771	0.689	rs10734557	ENSG00000280615.1	Y_RNA	6.09	4.67e-09	6.13e-06	0.46	0.37	Subjective well-being;	chr11:47358510	chr11:47614898~47614994:-
OV	cis	rs2581828	0.646	rs6769931	ENSG00000242142.1	SERBP1P3	-6.09	4.7e-09	6.17e-06	-0.45	-0.37	Crohn's disease;	chr3:53126177	chr3:53064283~53065091:-
OV	cis	rs2581828	0.646	rs6809973	ENSG00000242142.1	SERBP1P3	-6.09	4.7e-09	6.17e-06	-0.45	-0.37	Crohn's disease;	chr3:53126200	chr3:53064283~53065091:-
OV	cis	rs2581828	0.608	rs6769944	ENSG00000242142.1	SERBP1P3	-6.09	4.7e-09	6.17e-06	-0.45	-0.37	Crohn's disease;	chr3:53126227	chr3:53064283~53065091:-
OV	cis	rs2581828	0.646	rs9858469	ENSG00000242142.1	SERBP1P3	-6.09	4.7e-09	6.17e-06	-0.45	-0.37	Crohn's disease;	chr3:53128390	chr3:53064283~53065091:-
OV	cis	rs2581828	0.646	rs9820324	ENSG00000242142.1	SERBP1P3	-6.09	4.7e-09	6.17e-06	-0.45	-0.37	Crohn's disease;	chr3:53128429	chr3:53064283~53065091:-
OV	cis	rs34375054	0.738	rs10846834	ENSG00000279233.1	RP11-158L12.4	6.09	4.72e-09	6.19e-06	0.3	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125141024	chr12:125138245~125141711:+
OV	cis	rs875971	0.66	rs28698552	ENSG00000236529.1	RP13-254B10.1	6.09	4.74e-09	6.21e-06	0.4	0.37	Aortic root size;	chr7:66540031	chr7:65840212~65840596:+
OV	cis	rs875971	0.66	rs62465434	ENSG00000236529.1	RP13-254B10.1	6.09	4.74e-09	6.21e-06	0.4	0.37	Aortic root size;	chr7:66540165	chr7:65840212~65840596:+
OV	cis	rs875971	0.66	rs13224319	ENSG00000236529.1	RP13-254B10.1	6.09	4.74e-09	6.21e-06	0.4	0.37	Aortic root size;	chr7:66542376	chr7:65840212~65840596:+
OV	cis	rs875971	0.66	rs801217	ENSG00000236529.1	RP13-254B10.1	-6.09	4.74e-09	6.21e-06	-0.4	-0.37	Aortic root size;	chr7:66545590	chr7:65840212~65840596:+
OV	cis	rs875971	0.638	rs801216	ENSG00000236529.1	RP13-254B10.1	-6.09	4.74e-09	6.21e-06	-0.4	-0.37	Aortic root size;	chr7:66546680	chr7:65840212~65840596:+
OV	cis	rs875971	0.66	rs801211	ENSG00000236529.1	RP13-254B10.1	-6.09	4.74e-09	6.21e-06	-0.4	-0.37	Aortic root size;	chr7:66550702	chr7:65840212~65840596:+
OV	cis	rs875971	0.638	rs801205	ENSG00000236529.1	RP13-254B10.1	-6.09	4.74e-09	6.21e-06	-0.4	-0.37	Aortic root size;	chr7:66557157	chr7:65840212~65840596:+
OV	cis	rs875971	0.617	rs810400	ENSG00000236529.1	RP13-254B10.1	-6.09	4.74e-09	6.21e-06	-0.4	-0.37	Aortic root size;	chr7:66557902	chr7:65840212~65840596:+
OV	cis	rs875971	0.66	rs801192	ENSG00000236529.1	RP13-254B10.1	-6.09	4.74e-09	6.21e-06	-0.4	-0.37	Aortic root size;	chr7:66566965	chr7:65840212~65840596:+
OV	cis	rs875971	0.66	rs801190	ENSG00000236529.1	RP13-254B10.1	-6.09	4.74e-09	6.21e-06	-0.4	-0.37	Aortic root size;	chr7:66568046	chr7:65840212~65840596:+
OV	cis	rs875971	0.66	rs3857686	ENSG00000236529.1	RP13-254B10.1	-6.09	4.74e-09	6.21e-06	-0.4	-0.37	Aortic root size;	chr7:66571204	chr7:65840212~65840596:+
OV	cis	rs875971	0.638	rs3898855	ENSG00000236529.1	RP13-254B10.1	-6.09	4.74e-09	6.21e-06	-0.4	-0.37	Aortic root size;	chr7:66571411	chr7:65840212~65840596:+
OV	cis	rs875971	0.638	rs10278816	ENSG00000236529.1	RP13-254B10.1	-6.09	4.74e-09	6.21e-06	-0.4	-0.37	Aortic root size;	chr7:66572000	chr7:65840212~65840596:+
OV	cis	rs875971	0.66	rs10281080	ENSG00000236529.1	RP13-254B10.1	-6.09	4.74e-09	6.21e-06	-0.4	-0.37	Aortic root size;	chr7:66577454	chr7:65840212~65840596:+
OV	cis	rs875971	0.66	rs10950044	ENSG00000236529.1	RP13-254B10.1	-6.09	4.74e-09	6.21e-06	-0.4	-0.37	Aortic root size;	chr7:66577989	chr7:65840212~65840596:+
OV	cis	rs875971	0.638	rs10249404	ENSG00000236529.1	RP13-254B10.1	-6.09	4.74e-09	6.21e-06	-0.4	-0.37	Aortic root size;	chr7:66581737	chr7:65840212~65840596:+
OV	cis	rs875971	0.66	rs10215132	ENSG00000236529.1	RP13-254B10.1	-6.09	4.74e-09	6.21e-06	-0.4	-0.37	Aortic root size;	chr7:66589419	chr7:65840212~65840596:+
OV	cis	rs875971	0.522	rs1968127	ENSG00000236529.1	RP13-254B10.1	-6.09	4.74e-09	6.21e-06	-0.4	-0.37	Aortic root size;	chr7:66591816	chr7:65840212~65840596:+
OV	cis	rs875971	0.638	rs6460305	ENSG00000236529.1	RP13-254B10.1	-6.09	4.74e-09	6.21e-06	-0.4	-0.37	Aortic root size;	chr7:66595421	chr7:65840212~65840596:+
OV	cis	rs875971	0.66	rs10272357	ENSG00000236529.1	RP13-254B10.1	-6.09	4.74e-09	6.21e-06	-0.4	-0.37	Aortic root size;	chr7:66598087	chr7:65840212~65840596:+
OV	cis	rs875971	0.619	rs12533585	ENSG00000236529.1	RP13-254B10.1	6.09	4.78e-09	6.25e-06	0.39	0.37	Aortic root size;	chr7:66519618	chr7:65840212~65840596:+
OV	cis	rs494459	0.657	rs614554	ENSG00000255422.1	AP002954.4	-6.09	4.79e-09	6.27e-06	-0.41	-0.37	Height;	chr11:118764443	chr11:118704607~118750263:+
OV	cis	rs875971	0.66	rs79009421	ENSG00000236529.1	RP13-254B10.1	-6.09	4.83e-09	6.31e-06	-0.39	-0.37	Aortic root size;	chr7:66603522	chr7:65840212~65840596:+
OV	cis	rs875971	0.66	rs6460308	ENSG00000236529.1	RP13-254B10.1	-6.09	4.83e-09	6.31e-06	-0.39	-0.37	Aortic root size;	chr7:66619753	chr7:65840212~65840596:+
OV	cis	rs11235843	0.853	rs72989228	ENSG00000255928.1	RP11-456I15.2	6.09	4.86e-09	6.35e-06	0.61	0.37	Hand grip strength;	chr11:73799237	chr11:73722349~73722694:+
OV	cis	rs11235843	0.853	rs11235910	ENSG00000255928.1	RP11-456I15.2	6.09	4.86e-09	6.35e-06	0.61	0.37	Hand grip strength;	chr11:73800187	chr11:73722349~73722694:+
OV	cis	rs8105895	0.735	rs17554694	ENSG00000269742.1	BNIP3P29	-6.09	4.9e-09	6.4e-06	-0.52	-0.37	Body mass index (change over time);	chr19:22134346	chr19:22065828~22066398:-
OV	cis	rs12999373	0.501	rs11127496	ENSG00000272342.1	RP13-539J13.1	6.08	4.91e-09	6.41e-06	0.41	0.37	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:694063	chr2:739588~740164:-
OV	cis	rs1707322	0.963	rs10890373	ENSG00000280836.1	AL355480.1	-6.08	4.92e-09	6.42e-06	-0.53	-0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45928083	chr1:45581219~45581321:-
OV	cis	rs853679	0.513	rs13437444	ENSG00000220721.1	OR1F12	6.08	4.94e-09	6.45e-06	0.49	0.37	Depression;	chr6:28103220	chr6:28073316~28074233:+
OV	cis	rs3814244	0.528	rs7962511	ENSG00000255733.4	IFNG-AS1	6.08	4.96e-09	6.47e-06	0.38	0.37	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002854	chr12:67989445~68234686:+
OV	cis	rs853679	0.55	rs9295762	ENSG00000219392.1	RP1-265C24.5	6.08	4.99e-09	6.51e-06	0.45	0.37	Depression;	chr6:28187640	chr6:28115628~28116551:+
OV	cis	rs611744	0.967	rs673015	ENSG00000253754.1	RP11-35G22.1	-6.08	5.05e-09	6.58e-06	-0.43	-0.37	Dupuytren's disease;	chr8:108179440	chr8:108226200~108227544:+
OV	cis	rs801193	0.844	rs732465	ENSG00000236529.1	RP13-254B10.1	6.08	5.09e-09	6.62e-06	0.39	0.37	Aortic root size;	chr7:66533463	chr7:65840212~65840596:+
OV	cis	rs801193	0.773	rs801207	ENSG00000236529.1	RP13-254B10.1	-6.08	5.09e-09	6.62e-06	-0.39	-0.37	Aortic root size;	chr7:66555603	chr7:65840212~65840596:+
OV	cis	rs875971	0.543	rs801191	ENSG00000236529.1	RP13-254B10.1	-6.08	5.09e-09	6.62e-06	-0.39	-0.37	Aortic root size;	chr7:66567968	chr7:65840212~65840596:+
OV	cis	rs875971	0.508	rs6947808	ENSG00000236529.1	RP13-254B10.1	-6.08	5.09e-09	6.62e-06	-0.39	-0.37	Aortic root size;	chr7:66580095	chr7:65840212~65840596:+
OV	cis	rs11673344	0.838	rs55856280	ENSG00000226686.6	LINC01535	6.08	5.1e-09	6.63e-06	0.52	0.37	Obesity-related traits;	chr19:37150747	chr19:37251912~37265535:+
OV	cis	rs7688540	0.771	rs11248009	ENSG00000275426.1	CH17-262A2.1	6.08	5.1e-09	6.63e-06	0.64	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:226360	chr4:149738~150317:+
OV	cis	rs7688540	0.771	rs61794997	ENSG00000275426.1	CH17-262A2.1	6.08	5.1e-09	6.63e-06	0.64	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:228314	chr4:149738~150317:+
OV	cis	rs7688540	0.771	rs11724417	ENSG00000275426.1	CH17-262A2.1	6.08	5.1e-09	6.63e-06	0.64	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:229563	chr4:149738~150317:+
OV	cis	rs7688540	0.771	rs11724176	ENSG00000275426.1	CH17-262A2.1	6.08	5.1e-09	6.63e-06	0.64	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231112	chr4:149738~150317:+
OV	cis	rs7688540	0.723	rs61794999	ENSG00000275426.1	CH17-262A2.1	6.08	5.1e-09	6.63e-06	0.64	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238578	chr4:149738~150317:+
OV	cis	rs7688540	0.609	rs77700883	ENSG00000275426.1	CH17-262A2.1	6.08	5.1e-09	6.63e-06	0.64	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238743	chr4:149738~150317:+
OV	cis	rs7688540	0.609	rs78896226	ENSG00000275426.1	CH17-262A2.1	6.08	5.1e-09	6.63e-06	0.64	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238744	chr4:149738~150317:+
OV	cis	rs7688540	0.771	rs7686546	ENSG00000275426.1	CH17-262A2.1	6.08	5.1e-09	6.63e-06	0.64	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:246825	chr4:149738~150317:+
OV	cis	rs7688540	0.771	rs61795001	ENSG00000275426.1	CH17-262A2.1	6.08	5.1e-09	6.63e-06	0.64	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:248268	chr4:149738~150317:+
OV	cis	rs7688540	0.771	rs61795002	ENSG00000275426.1	CH17-262A2.1	6.08	5.1e-09	6.63e-06	0.64	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:249008	chr4:149738~150317:+
OV	cis	rs494459	0.688	rs1048040	ENSG00000278376.1	RP11-158I9.8	-6.08	5.16e-09	6.71e-06	-0.36	-0.37	Height;	chr11:118747911	chr11:118791254~118793137:+
OV	cis	rs2836974	0.59	rs9974757	ENSG00000232608.1	TIMM9P2	6.08	5.17e-09	6.71e-06	0.4	0.37	Cognitive function;	chr21:39245318	chr21:39216624~39217506:+
OV	cis	rs1185460	0.967	rs3825061	ENSG00000271751.1	RP11-110I1.14	-6.07	5.18e-09	6.73e-06	-0.48	-0.37	Coronary artery disease;	chr11:119073965	chr11:119065263~119065677:-
OV	cis	rs7396835	0.551	rs10750098	ENSG00000254851.1	RP11-109L13.1	-6.07	5.21e-09	6.77e-06	-0.64	-0.37	Quantitative traits;	chr11:116834852	chr11:117135528~117138582:+
OV	cis	rs7927771	0.77	rs11039203	ENSG00000280615.1	Y_RNA	-6.07	5.22e-09	6.78e-06	-0.45	-0.37	Subjective well-being;	chr11:47363046	chr11:47614898~47614994:-
OV	cis	rs7927771	0.832	rs67116452	ENSG00000280615.1	Y_RNA	-6.07	5.22e-09	6.78e-06	-0.45	-0.37	Subjective well-being;	chr11:47363643	chr11:47614898~47614994:-
OV	cis	rs7927771	0.8	rs35996350	ENSG00000280615.1	Y_RNA	-6.07	5.22e-09	6.78e-06	-0.45	-0.37	Subjective well-being;	chr11:47367672	chr11:47614898~47614994:-
OV	cis	rs72807246	0.54	rs72807258	ENSG00000228701.1	TNKS2-AS1	6.07	5.23e-09	6.79e-06	0.54	0.37	Breast cancer;	chr10:92209153	chr10:91782839~91798291:-
OV	cis	rs7017914	0.617	rs2732144	ENSG00000223220.1	Y_RNA	6.07	5.23e-09	6.8e-06	0.42	0.37	Bone mineral density;	chr8:70954384	chr8:70780914~70781008:-
OV	cis	rs7017914	0.617	rs2639949	ENSG00000223220.1	Y_RNA	6.07	5.23e-09	6.8e-06	0.42	0.37	Bone mineral density;	chr8:70954781	chr8:70780914~70781008:-
OV	cis	rs7017914	0.617	rs2639950	ENSG00000223220.1	Y_RNA	6.07	5.23e-09	6.8e-06	0.42	0.37	Bone mineral density;	chr8:70954823	chr8:70780914~70781008:-
OV	cis	rs801193	1	rs2420824	ENSG00000236529.1	RP13-254B10.1	-6.07	5.25e-09	6.81e-06	-0.4	-0.37	Aortic root size;	chr7:66666129	chr7:65840212~65840596:+
OV	cis	rs7773456	0.576	rs6924929	ENSG00000228412.5	RP4-625H18.2	-6.07	5.25e-09	6.81e-06	-0.5	-0.37	Lupus nephritis in systemic lupus erythematosus;	chr6:19812381	chr6:19802164~19804752:-
OV	cis	rs3814244	0.569	rs11177008	ENSG00000255733.4	IFNG-AS1	6.07	5.25e-09	6.82e-06	0.37	0.37	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021024	chr12:67989445~68234686:+
OV	cis	rs67311347	1	rs9833430	ENSG00000223797.4	ENTPD3-AS1	6.07	5.26e-09	6.82e-06	0.42	0.37	Renal cell carcinoma;	chr3:40417552	chr3:40313802~40453329:-
OV	cis	rs12134133	0.888	rs11580394	ENSG00000274245.1	RP11-357P18.2	6.07	5.28e-09	6.85e-06	0.51	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207238567	chr1:207372559~207373252:+
OV	cis	rs12134133	0.962	rs7526658	ENSG00000274245.1	RP11-357P18.2	6.07	5.28e-09	6.85e-06	0.51	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240098	chr1:207372559~207373252:+
OV	cis	rs12134133	0.962	rs7516416	ENSG00000274245.1	RP11-357P18.2	6.07	5.28e-09	6.85e-06	0.51	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241050	chr1:207372559~207373252:+
OV	cis	rs12134133	0.962	rs6673890	ENSG00000274245.1	RP11-357P18.2	6.07	5.28e-09	6.85e-06	0.51	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241788	chr1:207372559~207373252:+
OV	cis	rs494459	0.838	rs632124	ENSG00000255422.1	AP002954.4	-6.07	5.29e-09	6.86e-06	-0.42	-0.37	Height;	chr11:118742526	chr11:118704607~118750263:+
OV	cis	rs853679	0.55	rs1150689	ENSG00000219392.1	RP1-265C24.5	-6.07	5.31e-09	6.88e-06	-0.48	-0.37	Depression;	chr6:28197321	chr6:28115628~28116551:+
OV	cis	rs853679	0.55	rs1225599	ENSG00000219392.1	RP1-265C24.5	-6.07	5.31e-09	6.88e-06	-0.48	-0.37	Depression;	chr6:28197412	chr6:28115628~28116551:+
OV	cis	rs853679	0.574	rs1233705	ENSG00000219392.1	RP1-265C24.5	-6.07	5.31e-09	6.88e-06	-0.48	-0.37	Depression;	chr6:28198669	chr6:28115628~28116551:+
OV	cis	rs12022452	0.591	rs6672398	ENSG00000238287.1	RP11-656D10.3	-6.07	5.33e-09	6.91e-06	-0.61	-0.37	Age-related hearing impairment (SNP x SNP interaction);	chr1:40536505	chr1:40493157~40508661:-
OV	cis	rs875971	0.508	rs10950045	ENSG00000236529.1	RP13-254B10.1	-6.07	5.34e-09	6.92e-06	-0.39	-0.37	Aortic root size;	chr7:66601386	chr7:65840212~65840596:+
OV	cis	rs801193	0.839	rs6968619	ENSG00000236529.1	RP13-254B10.1	-6.07	5.34e-09	6.92e-06	-0.39	-0.37	Aortic root size;	chr7:66603880	chr7:65840212~65840596:+
OV	cis	rs801193	0.839	rs12534943	ENSG00000236529.1	RP13-254B10.1	-6.07	5.34e-09	6.92e-06	-0.39	-0.37	Aortic root size;	chr7:66605533	chr7:65840212~65840596:+
OV	cis	rs801193	0.805	rs12532355	ENSG00000236529.1	RP13-254B10.1	-6.07	5.34e-09	6.92e-06	-0.39	-0.37	Aortic root size;	chr7:66605597	chr7:65840212~65840596:+
OV	cis	rs7626444	0.625	rs2948170	ENSG00000272359.1	U4	-6.07	5.35e-09	6.93e-06	-0.39	-0.37	Monocyte count;	chr3:196765660	chr3:196747192~196747324:-
OV	cis	rs172166	0.694	rs1150666	ENSG00000220721.1	OR1F12	6.07	5.35e-09	6.94e-06	0.41	0.37	Cardiac Troponin-T levels;	chr6:28156150	chr6:28073316~28074233:+
OV	cis	rs875971	0.508	rs10242423	ENSG00000236529.1	RP13-254B10.1	-6.07	5.35e-09	6.94e-06	-0.39	-0.37	Aortic root size;	chr7:66594188	chr7:65840212~65840596:+
OV	cis	rs875971	0.508	rs10253883	ENSG00000236529.1	RP13-254B10.1	-6.07	5.35e-09	6.94e-06	-0.39	-0.37	Aortic root size;	chr7:66596151	chr7:65840212~65840596:+
OV	cis	rs150992	0.711	rs170734	ENSG00000248489.1	CTD-2007H13.3	6.07	5.36e-09	6.94e-06	0.47	0.37	Body mass index;	chr5:98811337	chr5:98929171~98995013:+
OV	cis	rs2581828	0.646	rs9878875	ENSG00000242142.1	SERBP1P3	-6.07	5.38e-09	6.96e-06	-0.45	-0.37	Crohn's disease;	chr3:53122851	chr3:53064283~53065091:-
OV	cis	rs2581828	0.646	rs12630819	ENSG00000242142.1	SERBP1P3	-6.07	5.38e-09	6.96e-06	-0.45	-0.37	Crohn's disease;	chr3:53123286	chr3:53064283~53065091:-
OV	cis	rs2581828	0.646	rs12638996	ENSG00000242142.1	SERBP1P3	-6.07	5.38e-09	6.96e-06	-0.45	-0.37	Crohn's disease;	chr3:53123530	chr3:53064283~53065091:-
OV	cis	rs494459	0.838	rs12796102	ENSG00000278376.1	RP11-158I9.8	-6.07	5.39e-09	6.97e-06	-0.37	-0.37	Height;	chr11:118791319	chr11:118791254~118793137:+
OV	cis	rs1061377	0.965	rs12511857	ENSG00000249207.1	RP11-360F5.1	-6.07	5.39e-09	6.98e-06	-0.41	-0.37	Uric acid levels;	chr4:39143252	chr4:39112677~39126818:-
OV	cis	rs7615952	0.932	rs6438948	ENSG00000171084.14	FAM86JP	-6.07	5.41e-09	6.99e-06	-0.55	-0.37	Blood pressure (smoking interaction);	chr3:125931202	chr3:125916620~125930024:+
OV	cis	rs12134133	0.962	rs6682586	ENSG00000274245.1	RP11-357P18.2	6.07	5.42e-09	7.01e-06	0.51	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243122	chr1:207372559~207373252:+
OV	cis	rs12134133	0.962	rs6668560	ENSG00000274245.1	RP11-357P18.2	6.07	5.42e-09	7.01e-06	0.51	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207243462	chr1:207372559~207373252:+
OV	cis	rs10740039	0.583	rs2127352	ENSG00000254271.1	RP11-131N11.4	-6.07	5.42e-09	7.01e-06	-0.48	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60742129	chr10:60734342~60741828:+
OV	cis	rs9660180	0.967	rs2272908	ENSG00000231050.1	RP1-140A9.1	-6.07	5.44e-09	7.03e-06	-0.38	-0.37	Body mass index;	chr1:1790040	chr1:1891471~1892658:+
OV	cis	rs62355900	0.627	rs726501	ENSG00000271828.1	CTD-2310F14.1	6.07	5.44e-09	7.03e-06	0.68	0.37	Endometriosis;	chr5:56832039	chr5:56927874~56929573:+
OV	cis	rs62355900	0.627	rs58292679	ENSG00000271828.1	CTD-2310F14.1	6.07	5.44e-09	7.03e-06	0.68	0.37	Endometriosis;	chr5:56839989	chr5:56927874~56929573:+
OV	cis	rs11235843	0.853	rs7119528	ENSG00000255928.1	RP11-456I15.2	6.07	5.45e-09	7.05e-06	0.6	0.37	Hand grip strength;	chr11:73803717	chr11:73722349~73722694:+
OV	cis	rs11235843	0.853	rs17132369	ENSG00000255928.1	RP11-456I15.2	6.07	5.45e-09	7.05e-06	0.6	0.37	Hand grip strength;	chr11:73808030	chr11:73722349~73722694:+
OV	cis	rs11235843	0.853	rs55910552	ENSG00000255928.1	RP11-456I15.2	6.07	5.45e-09	7.05e-06	0.6	0.37	Hand grip strength;	chr11:73814872	chr11:73722349~73722694:+
OV	cis	rs796364	0.762	rs13030712	ENSG00000232732.8	AC073043.1	-6.07	5.46e-09	7.05e-06	-0.49	-0.37	Schizophrenia;	chr2:200108846	chr2:199867396~199911159:-
OV	cis	rs8105895	1	rs62112917	ENSG00000269742.1	BNIP3P29	6.06	5.47e-09	7.07e-06	0.61	0.37	Body mass index (change over time);	chr19:22043778	chr19:22065828~22066398:-
OV	cis	rs11673344	0.668	rs7248693	ENSG00000226686.6	LINC01535	6.06	5.47e-09	7.07e-06	0.52	0.37	Obesity-related traits;	chr19:36991864	chr19:37251912~37265535:+
OV	cis	rs2286503	0.966	rs2286507	ENSG00000221740.1	SNORD93	6.06	5.49e-09	7.09e-06	0.44	0.37	Fibrinogen;	chr7:22815141	chr7:22856613~22856686:+
OV	cis	rs4591358	0.68	rs12693771	ENSG00000223466.1	AC064834.2	-6.06	5.49e-09	7.09e-06	-0.51	-0.37	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195461651	chr2:195533035~195538681:+
OV	cis	rs1707322	0.896	rs946528	ENSG00000280836.1	AL355480.1	6.06	5.53e-09	7.14e-06	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46019890	chr1:45581219~45581321:-
OV	cis	rs8062405	0.755	rs55792032	ENSG00000259982.1	CDC37P1	6.06	5.54e-09	7.15e-06	0.45	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28700294~28701540:-
OV	cis	rs10510102	0.688	rs76573813	ENSG00000276742.1	RP11-500G22.4	6.06	5.56e-09	7.18e-06	0.6	0.37	Breast cancer;	chr10:121928955	chr10:121956782~121957098:+
OV	cis	rs8062405	0.756	rs151301	ENSG00000259982.1	CDC37P1	6.06	5.57e-09	7.19e-06	0.45	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28485738	chr16:28700294~28701540:-
OV	cis	rs2581828	0.646	rs2564944	ENSG00000242142.1	SERBP1P3	6.06	5.57e-09	7.19e-06	0.48	0.37	Crohn's disease;	chr3:53114439	chr3:53064283~53065091:-
OV	cis	rs72807246	1	rs72807246	ENSG00000228701.1	TNKS2-AS1	6.06	5.57e-09	7.19e-06	0.54	0.37	Breast cancer;	chr10:92172529	chr10:91782839~91798291:-
OV	cis	rs7688540	0.771	rs11723615	ENSG00000275426.1	CH17-262A2.1	6.06	5.61e-09	7.24e-06	0.59	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:283194	chr4:149738~150317:+
OV	cis	rs2286503	0.901	rs10950922	ENSG00000221740.1	SNORD93	6.06	5.64e-09	7.28e-06	0.43	0.37	Fibrinogen;	chr7:22814387	chr7:22856613~22856686:+
OV	cis	rs611744	0.967	rs673854	ENSG00000253754.1	RP11-35G22.1	-6.06	5.65e-09	7.28e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108179609	chr8:108226200~108227544:+
OV	cis	rs3814244	0.868	rs10878726	ENSG00000255733.4	IFNG-AS1	6.06	5.67e-09	7.31e-06	0.41	0.37	Itch intensity from mosquito bite adjusted by bite size;	chr12:68022865	chr12:67989445~68234686:+
OV	cis	rs8005677	0.828	rs8016027	ENSG00000257285.4	RP11-298I3.1	6.06	5.67e-09	7.31e-06	0.46	0.37	Cognitive ability (multi-trait analysis);	chr14:22950944	chr14:22929609~22955562:+
OV	cis	rs11098499	0.691	rs10028773	ENSG00000245958.5	RP11-33B1.1	6.06	5.69e-09	7.33e-06	0.42	0.37	Corneal astigmatism;	chr4:119344104	chr4:119454791~119552025:+
OV	cis	rs4380275	0.782	rs4468850	ENSG00000272342.1	RP13-539J13.1	6.06	5.69e-09	7.34e-06	0.42	0.37	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:749467	chr2:739588~740164:-
OV	cis	rs11671005	0.504	rs2305119	ENSG00000269600.1	AC016629.3	-6.06	5.72e-09	7.37e-06	-0.48	-0.37	Mean platelet volume;	chr19:58556256	chr19:58593896~58599355:-
OV	cis	rs7576126	1	rs7576126	ENSG00000234255.7	AC012370.3	-6.06	5.72e-09	7.37e-06	-0.41	-0.37	Severe influenza A (H1N1) infection;	chr2:65431235	chr2:65439888~65456571:-
OV	cis	rs62355900	0.627	rs16886400	ENSG00000271828.1	CTD-2310F14.1	6.06	5.74e-09	7.39e-06	0.68	0.37	Endometriosis;	chr5:56841605	chr5:56927874~56929573:+
OV	cis	rs8005677	0.798	rs4982711	ENSG00000257285.4	RP11-298I3.1	6.06	5.75e-09	7.41e-06	0.45	0.37	Cognitive ability (multi-trait analysis);	chr14:22929781	chr14:22929609~22955562:+
OV	cis	rs7688540	0.723	rs1986386	ENSG00000275426.1	CH17-262A2.1	6.05	5.8e-09	7.46e-06	0.64	0.37	Facial morphology (factor 6, height of vermillion lower lip);	chr4:235020	chr4:149738~150317:+
OV	cis	rs4591358	0.731	rs12693769	ENSG00000223466.1	AC064834.2	-6.05	5.8e-09	7.46e-06	-0.51	-0.37	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195453722	chr2:195533035~195538681:+
OV	cis	rs1707322	1	rs1707337	ENSG00000280836.1	AL355480.1	6.05	5.8e-09	7.47e-06	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46043097	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs1768807	ENSG00000280836.1	AL355480.1	6.05	5.8e-09	7.47e-06	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044898	chr1:45581219~45581321:-
OV	cis	rs1707322	0.89	rs2297883	ENSG00000280836.1	AL355480.1	6.05	5.8e-09	7.47e-06	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46045815	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs1707338	ENSG00000280836.1	AL355480.1	6.05	5.8e-09	7.47e-06	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46046309	chr1:45581219~45581321:-
OV	cis	rs1707322	0.964	rs1707339	ENSG00000280836.1	AL355480.1	6.05	5.8e-09	7.47e-06	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46047507	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs1768818	ENSG00000280836.1	AL355480.1	6.05	5.8e-09	7.47e-06	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048614	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs1768817	ENSG00000280836.1	AL355480.1	6.05	5.8e-09	7.47e-06	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46048862	chr1:45581219~45581321:-
OV	cis	rs4660456	0.913	rs2223486	ENSG00000237899.1	RP4-739H11.3	-6.05	5.81e-09	7.47e-06	-0.58	-0.37	Platelet count;	chr1:40693557	chr1:40669089~40687588:-
OV	cis	rs7626444	0.627	rs5021326	ENSG00000272359.1	U4	-6.05	5.81e-09	7.47e-06	-0.38	-0.37	Monocyte count;	chr3:196750757	chr3:196747192~196747324:-
OV	cis	rs875971	0.628	rs6974355	ENSG00000236529.1	RP13-254B10.1	6.05	5.83e-09	7.49e-06	0.39	0.37	Aortic root size;	chr7:66376994	chr7:65840212~65840596:+
OV	cis	rs12134133	1	rs2802235	ENSG00000274245.1	RP11-357P18.2	6.05	5.87e-09	7.54e-06	0.49	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207298454	chr1:207372559~207373252:+
OV	cis	rs2243480	0.901	rs313808	ENSG00000222364.1	RNU6-96P	-6.05	5.91e-09	7.59e-06	-0.59	-0.37	Diabetic kidney disease;	chr7:66034886	chr7:66395191~66395286:+
OV	cis	rs853679	0.517	rs9393894	ENSG00000219392.1	RP1-265C24.5	-6.05	5.95e-09	7.64e-06	-0.47	-0.37	Depression;	chr6:28144784	chr6:28115628~28116551:+
OV	cis	rs934734	0.532	rs2860773	ENSG00000234255.7	AC012370.3	-6.05	5.96e-09	7.65e-06	-0.41	-0.37	Rheumatoid arthritis;	chr2:65438507	chr2:65439888~65456571:-
OV	cis	rs4380275	0.782	rs4854369	ENSG00000272342.1	RP13-539J13.1	6.05	5.97e-09	7.66e-06	0.42	0.37	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:752530	chr2:739588~740164:-
OV	cis	rs875971	0.66	rs12698534	ENSG00000236529.1	RP13-254B10.1	6.05	5.99e-09	7.69e-06	0.39	0.37	Aortic root size;	chr7:66521858	chr7:65840212~65840596:+
OV	cis	rs992157	0.798	rs2382817	ENSG00000237281.1	CATIP-AS2	-6.05	6e-09	7.7e-06	-0.43	-0.37	Colorectal cancer;	chr2:218286495	chr2:218326889~218357966:-
OV	cis	rs67180937	0.922	rs17465982	ENSG00000272750.1	RP11-378J18.8	-6.05	6.07e-09	7.78e-06	-0.4	-0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664597	chr1:222658867~222661512:-
OV	cis	rs2243480	1	rs57057549	ENSG00000222364.1	RNU6-96P	-6.05	6.08e-09	7.78e-06	-0.58	-0.37	Diabetic kidney disease;	chr7:65940751	chr7:66395191~66395286:+
OV	cis	rs2243480	0.808	rs12698508	ENSG00000222364.1	RNU6-96P	-6.05	6.08e-09	7.78e-06	-0.58	-0.37	Diabetic kidney disease;	chr7:65946971	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs2961102	ENSG00000222364.1	RNU6-96P	-6.05	6.08e-09	7.78e-06	-0.58	-0.37	Diabetic kidney disease;	chr7:65959671	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs34970380	ENSG00000222364.1	RNU6-96P	-6.05	6.08e-09	7.78e-06	-0.58	-0.37	Diabetic kidney disease;	chr7:65966506	chr7:66395191~66395286:+
OV	cis	rs2243480	0.901	rs73148097	ENSG00000222364.1	RNU6-96P	-6.05	6.08e-09	7.78e-06	-0.58	-0.37	Diabetic kidney disease;	chr7:65966800	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs35820085	ENSG00000222364.1	RNU6-96P	-6.05	6.08e-09	7.78e-06	-0.58	-0.37	Diabetic kidney disease;	chr7:65977771	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs906134	ENSG00000222364.1	RNU6-96P	-6.05	6.08e-09	7.78e-06	-0.58	-0.37	Diabetic kidney disease;	chr7:65979301	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs1723270	ENSG00000222364.1	RNU6-96P	-6.05	6.08e-09	7.78e-06	-0.58	-0.37	Diabetic kidney disease;	chr7:66004843	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs1723269	ENSG00000222364.1	RNU6-96P	-6.05	6.08e-09	7.78e-06	-0.58	-0.37	Diabetic kidney disease;	chr7:66007799	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs781150	ENSG00000222364.1	RNU6-96P	-6.05	6.08e-09	7.78e-06	-0.58	-0.37	Diabetic kidney disease;	chr7:66015986	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs313798	ENSG00000222364.1	RNU6-96P	-6.05	6.08e-09	7.78e-06	-0.58	-0.37	Diabetic kidney disease;	chr7:66028044	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs35396113	ENSG00000222364.1	RNU6-96P	-6.05	6.08e-09	7.78e-06	-0.58	-0.37	Diabetic kidney disease;	chr7:66030474	chr7:66395191~66395286:+
OV	cis	rs8062405	0.723	rs762633	ENSG00000259982.1	CDC37P1	6.04	6.11e-09	7.82e-06	0.47	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28700294~28701540:-
OV	cis	rs8062405	0.723	rs62031562	ENSG00000259982.1	CDC37P1	6.04	6.11e-09	7.82e-06	0.47	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28700294~28701540:-
OV	cis	rs12134133	1	rs7522618	ENSG00000274245.1	RP11-357P18.2	6.04	6.12e-09	7.84e-06	0.5	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207244081	chr1:207372559~207373252:+
OV	cis	rs12134133	1	rs11580382	ENSG00000274245.1	RP11-357P18.2	6.04	6.12e-09	7.84e-06	0.5	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207245047	chr1:207372559~207373252:+
OV	cis	rs12134133	1	rs11580387	ENSG00000274245.1	RP11-357P18.2	6.04	6.12e-09	7.84e-06	0.5	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207245063	chr1:207372559~207373252:+
OV	cis	rs12134133	1	rs7518565	ENSG00000274245.1	RP11-357P18.2	6.04	6.12e-09	7.84e-06	0.5	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207246998	chr1:207372559~207373252:+
OV	cis	rs11673344	0.801	rs76806623	ENSG00000226686.6	LINC01535	6.04	6.13e-09	7.84e-06	0.51	0.37	Obesity-related traits;	chr19:37132525	chr19:37251912~37265535:+
OV	cis	rs1707322	1	rs785507	ENSG00000280836.1	AL355480.1	6.04	6.15e-09	7.87e-06	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46075886	chr1:45581219~45581321:-
OV	cis	rs507080	0.501	rs516503	ENSG00000255422.1	AP002954.4	-6.04	6.18e-09	7.91e-06	-0.42	-0.37	Serum metabolite levels;	chr11:118709639	chr11:118704607~118750263:+
OV	cis	rs62355900	0.627	rs16886403	ENSG00000271828.1	CTD-2310F14.1	6.04	6.19e-09	7.92e-06	0.65	0.37	Endometriosis;	chr5:56843419	chr5:56927874~56929573:+
OV	cis	rs67180937	0.645	rs2270707	ENSG00000272750.1	RP11-378J18.8	6.04	6.21e-09	7.95e-06	0.42	0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222664252	chr1:222658867~222661512:-
OV	cis	rs8105895	0.866	rs17701834	ENSG00000269742.1	BNIP3P29	-6.04	6.22e-09	7.95e-06	-0.59	-0.37	Body mass index (change over time);	chr19:21938656	chr19:22065828~22066398:-
OV	cis	rs801193	0.844	rs2244022	ENSG00000236529.1	RP13-254B10.1	6.04	6.22e-09	7.95e-06	0.39	0.37	Aortic root size;	chr7:66737443	chr7:65840212~65840596:+
OV	cis	rs4713118	0.869	rs4713121	ENSG00000220721.1	OR1F12	6.04	6.22e-09	7.96e-06	0.41	0.37	Parkinson's disease;	chr6:27754285	chr6:28073316~28074233:+
OV	cis	rs875971	0.638	rs6960778	ENSG00000236529.1	RP13-254B10.1	-6.04	6.22e-09	7.96e-06	-0.4	-0.37	Aortic root size;	chr7:66606610	chr7:65840212~65840596:+
OV	cis	rs2243480	0.901	rs73142137	ENSG00000222364.1	RNU6-96P	-6.04	6.22e-09	7.96e-06	-0.59	-0.37	Diabetic kidney disease;	chr7:65878455	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs13247184	ENSG00000222364.1	RNU6-96P	-6.04	6.22e-09	7.96e-06	-0.59	-0.37	Diabetic kidney disease;	chr7:65893941	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs35283677	ENSG00000222364.1	RNU6-96P	-6.04	6.22e-09	7.96e-06	-0.59	-0.37	Diabetic kidney disease;	chr7:65894246	chr7:66395191~66395286:+
OV	cis	rs526231	0.543	rs246900	ENSG00000175749.11	EIF3KP1	6.04	6.23e-09	7.96e-06	0.45	0.37	Primary biliary cholangitis;	chr5:103198928	chr5:103032376~103033031:+
OV	cis	rs526231	0.543	rs28025	ENSG00000175749.11	EIF3KP1	6.04	6.23e-09	7.96e-06	0.45	0.37	Primary biliary cholangitis;	chr5:103201678	chr5:103032376~103033031:+
OV	cis	rs7017914	0.652	rs2639910	ENSG00000223220.1	Y_RNA	6.04	6.23e-09	7.96e-06	0.42	0.37	Bone mineral density;	chr8:70949649	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs3098858	ENSG00000223220.1	Y_RNA	6.04	6.23e-09	7.96e-06	0.42	0.37	Bone mineral density;	chr8:70951038	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs3098859	ENSG00000223220.1	Y_RNA	6.04	6.23e-09	7.96e-06	0.42	0.37	Bone mineral density;	chr8:70952797	chr8:70780914~70781008:-
OV	cis	rs7017914	0.545	rs3110268	ENSG00000223220.1	Y_RNA	6.04	6.23e-09	7.96e-06	0.42	0.37	Bone mineral density;	chr8:70953933	chr8:70780914~70781008:-
OV	cis	rs1707322	0.963	rs1768815	ENSG00000280836.1	AL355480.1	6.04	6.26e-09	8e-06	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062931	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs2458400	ENSG00000280836.1	AL355480.1	6.04	6.26e-09	8e-06	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46065126	chr1:45581219~45581321:-
OV	cis	rs1707322	0.896	rs785512	ENSG00000280836.1	AL355480.1	6.04	6.26e-09	8e-06	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46068871	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs9429186	ENSG00000280836.1	AL355480.1	6.04	6.26e-09	8e-06	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074015	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs785506	ENSG00000280836.1	AL355480.1	6.04	6.26e-09	8e-06	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46074980	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs785470	ENSG00000280836.1	AL355480.1	6.04	6.28e-09	8.01e-06	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46053950	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs785469	ENSG00000280836.1	AL355480.1	6.04	6.28e-09	8.01e-06	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055419	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs785468	ENSG00000280836.1	AL355480.1	6.04	6.28e-09	8.01e-06	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055845	chr1:45581219~45581321:-
OV	cis	rs4660456	0.913	rs657149	ENSG00000237899.1	RP4-739H11.3	6.04	6.31e-09	8.05e-06	0.58	0.37	Platelet count;	chr1:40692486	chr1:40669089~40687588:-
OV	cis	rs1707322	1	rs1707303	ENSG00000280836.1	AL355480.1	6.04	6.31e-09	8.05e-06	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46132601	chr1:45581219~45581321:-
OV	cis	rs875971	0.619	rs2302918	ENSG00000236529.1	RP13-254B10.1	6.04	6.32e-09	8.06e-06	0.4	0.37	Aortic root size;	chr7:66535945	chr7:65840212~65840596:+
OV	cis	rs611744	0.967	rs635219	ENSG00000253754.1	RP11-35G22.1	-6.04	6.32e-09	8.06e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108217014	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs608115	ENSG00000253754.1	RP11-35G22.1	-6.04	6.32e-09	8.06e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108219719	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs475865	ENSG00000253754.1	RP11-35G22.1	-6.04	6.32e-09	8.06e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108223629	chr8:108226200~108227544:+
OV	cis	rs7927771	1	rs4752797	ENSG00000280615.1	Y_RNA	-6.04	6.33e-09	8.07e-06	-0.45	-0.37	Subjective well-being;	chr11:47852812	chr11:47614898~47614994:-
OV	cis	rs73086581	0.786	rs6037705	ENSG00000229539.1	RP11-119B16.2	6.04	6.39e-09	8.14e-06	0.47	0.37	Response to antidepressants in depression;	chr20:3972183	chr20:3888239~3888868:-
OV	cis	rs73086581	1	rs6037708	ENSG00000229539.1	RP11-119B16.2	6.04	6.39e-09	8.14e-06	0.47	0.37	Response to antidepressants in depression;	chr20:3980606	chr20:3888239~3888868:-
OV	cis	rs73086581	0.945	rs6037715	ENSG00000229539.1	RP11-119B16.2	6.04	6.39e-09	8.14e-06	0.47	0.37	Response to antidepressants in depression;	chr20:3991519	chr20:3888239~3888868:-
OV	cis	rs4713118	0.955	rs9468200	ENSG00000220721.1	OR1F12	6.04	6.4e-09	8.16e-06	0.42	0.37	Parkinson's disease;	chr6:27715284	chr6:28073316~28074233:+
OV	cis	rs7927771	0.832	rs7105851	ENSG00000280615.1	Y_RNA	6.03	6.43e-09	8.19e-06	0.45	0.37	Subjective well-being;	chr11:47361724	chr11:47614898~47614994:-
OV	cis	rs611744	0.935	rs679077	ENSG00000253754.1	RP11-35G22.1	-6.03	6.44e-09	8.2e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108232513	chr8:108226200~108227544:+
OV	cis	rs10028773	0.6	rs4001390	ENSG00000245958.5	RP11-33B1.1	-6.03	6.46e-09	8.22e-06	-0.41	-0.37	Educational attainment;	chr4:119344628	chr4:119454791~119552025:+
OV	cis	rs11098499	0.691	rs2136911	ENSG00000245958.5	RP11-33B1.1	-6.03	6.46e-09	8.22e-06	-0.41	-0.37	Corneal astigmatism;	chr4:119344704	chr4:119454791~119552025:+
OV	cis	rs11098499	0.554	rs2175381	ENSG00000245958.5	RP11-33B1.1	-6.03	6.46e-09	8.22e-06	-0.41	-0.37	Corneal astigmatism;	chr4:119344812	chr4:119454791~119552025:+
OV	cis	rs11098499	0.599	rs3864142	ENSG00000245958.5	RP11-33B1.1	-6.03	6.46e-09	8.22e-06	-0.41	-0.37	Corneal astigmatism;	chr4:119345036	chr4:119454791~119552025:+
OV	cis	rs11098499	0.605	rs6833140	ENSG00000245958.5	RP11-33B1.1	-6.03	6.46e-09	8.22e-06	-0.41	-0.37	Corneal astigmatism;	chr4:119345667	chr4:119454791~119552025:+
OV	cis	rs11098499	0.779	rs6815934	ENSG00000245958.5	RP11-33B1.1	-6.03	6.46e-09	8.22e-06	-0.41	-0.37	Corneal astigmatism;	chr4:119346155	chr4:119454791~119552025:+
OV	cis	rs10028773	0.568	rs6838457	ENSG00000245958.5	RP11-33B1.1	-6.03	6.46e-09	8.22e-06	-0.41	-0.37	Educational attainment;	chr4:119346212	chr4:119454791~119552025:+
OV	cis	rs438465	1	rs425239	ENSG00000226194.4	RP1-137D17.1	6.03	6.46e-09	8.22e-06	0.52	0.37	Corneal astigmatism;	chr6:169413663	chr6:169369998~169388385:-
OV	cis	rs1707322	1	rs1707317	ENSG00000280836.1	AL355480.1	6.03	6.47e-09	8.24e-06	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46044970	chr1:45581219~45581321:-
OV	cis	rs11098499	0.535	rs10005542	ENSG00000245958.5	RP11-33B1.1	-6.03	6.48e-09	8.25e-06	-0.41	-0.37	Corneal astigmatism;	chr4:119347147	chr4:119454791~119552025:+
OV	cis	rs55757919	1	rs55757919	ENSG00000231742.4	LINC01273	6.03	6.49e-09	8.25e-06	0.53	0.37	Monocyte percentage of white cells;	chr20:50132011	chr20:50172550~50176671:+
OV	cis	rs7017914	0.967	rs2732090	ENSG00000223220.1	Y_RNA	-6.03	6.51e-09	8.28e-06	-0.4	-0.37	Bone mineral density;	chr8:71006022	chr8:70780914~70781008:-
OV	cis	rs62355900	0.627	rs60985357	ENSG00000271828.1	CTD-2310F14.1	6.03	6.52e-09	8.3e-06	0.68	0.37	Endometriosis;	chr5:56827875	chr5:56927874~56929573:+
OV	cis	rs62355900	0.627	rs16886383	ENSG00000271828.1	CTD-2310F14.1	6.03	6.52e-09	8.3e-06	0.68	0.37	Endometriosis;	chr5:56829869	chr5:56927874~56929573:+
OV	cis	rs62355900	0.627	rs62358073	ENSG00000271828.1	CTD-2310F14.1	6.03	6.52e-09	8.3e-06	0.68	0.37	Endometriosis;	chr5:56831013	chr5:56927874~56929573:+
OV	cis	rs853679	0.517	rs4713146	ENSG00000219392.1	RP1-265C24.5	-6.03	6.53e-09	8.3e-06	-0.47	-0.37	Depression;	chr6:28143758	chr6:28115628~28116551:+
OV	cis	rs2836974	0.555	rs35909862	ENSG00000232608.1	TIMM9P2	6.03	6.55e-09	8.32e-06	0.4	0.37	Cognitive function;	chr21:39249232	chr21:39216624~39217506:+
OV	cis	rs8005677	0.828	rs57822749	ENSG00000257285.4	RP11-298I3.1	6.03	6.56e-09	8.34e-06	0.46	0.37	Cognitive ability (multi-trait analysis);	chr14:22940758	chr14:22929609~22955562:+
OV	cis	rs7829975	0.742	rs1533059	ENSG00000253893.2	FAM85B	6.03	6.58e-09	8.36e-06	0.4	0.37	Mood instability;	chr8:8827443	chr8:8167819~8226614:-
OV	cis	rs11976180	1	rs2961144	ENSG00000170356.8	OR2A20P	6.03	6.59e-09	8.38e-06	0.53	0.37	Obesity-related traits;	chr7:144050777	chr7:144250045~144252957:-
OV	cis	rs7017914	0.606	rs2639941	ENSG00000223220.1	Y_RNA	6.03	6.65e-09	8.44e-06	0.41	0.37	Bone mineral density;	chr8:71001670	chr8:70780914~70781008:-
OV	cis	rs7017914	0.644	rs2639940	ENSG00000223220.1	Y_RNA	6.03	6.65e-09	8.44e-06	0.41	0.37	Bone mineral density;	chr8:71001686	chr8:70780914~70781008:-
OV	cis	rs7017914	0.606	rs2639939	ENSG00000223220.1	Y_RNA	6.03	6.65e-09	8.44e-06	0.41	0.37	Bone mineral density;	chr8:71001688	chr8:70780914~70781008:-
OV	cis	rs7017914	0.628	rs2035925	ENSG00000223220.1	Y_RNA	6.03	6.65e-09	8.44e-06	0.41	0.37	Bone mineral density;	chr8:71001981	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs2639938	ENSG00000223220.1	Y_RNA	6.03	6.65e-09	8.44e-06	0.41	0.37	Bone mineral density;	chr8:71002117	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs2639937	ENSG00000223220.1	Y_RNA	6.03	6.65e-09	8.44e-06	0.41	0.37	Bone mineral density;	chr8:71002121	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs2035924	ENSG00000223220.1	Y_RNA	6.03	6.65e-09	8.44e-06	0.41	0.37	Bone mineral density;	chr8:71002218	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs36162059	ENSG00000223220.1	Y_RNA	6.03	6.65e-09	8.44e-06	0.41	0.37	Bone mineral density;	chr8:71002471	chr8:70780914~70781008:-
OV	cis	rs7017914	0.583	rs2639936	ENSG00000223220.1	Y_RNA	6.03	6.65e-09	8.44e-06	0.41	0.37	Bone mineral density;	chr8:71002500	chr8:70780914~70781008:-
OV	cis	rs7017914	0.628	rs2732089	ENSG00000223220.1	Y_RNA	6.03	6.65e-09	8.44e-06	0.41	0.37	Bone mineral density;	chr8:71002929	chr8:70780914~70781008:-
OV	cis	rs2243480	1	rs73150014	ENSG00000222364.1	RNU6-96P	-6.03	6.68e-09	8.47e-06	-0.58	-0.37	Diabetic kidney disease;	chr7:65985932	chr7:66395191~66395286:+
OV	cis	rs7626444	0.647	rs844546	ENSG00000272359.1	U4	-6.03	6.73e-09	8.54e-06	-0.38	-0.37	Monocyte count;	chr3:196748403	chr3:196747192~196747324:-
OV	cis	rs7626444	0.625	rs843540	ENSG00000272359.1	U4	-6.03	6.73e-09	8.54e-06	-0.38	-0.37	Monocyte count;	chr3:196748442	chr3:196747192~196747324:-
OV	cis	rs3931020	0.548	rs2134836	ENSG00000272864.1	RP11-17E13.2	-6.03	6.75e-09	8.55e-06	-0.48	-0.37	Resistin levels;	chr1:74805962	chr1:74698769~74699333:-
OV	cis	rs1707322	0.638	rs1707302	ENSG00000281133.1	AL355480.3	6.03	6.76e-09	8.57e-06	0.45	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46135245	chr1:45580892~45580996:-
OV	cis	rs7267979	0.789	rs6050472	ENSG00000274973.1	RP13-401N8.7	-6.02	6.79e-09	8.6e-06	-0.44	-0.37	Liver enzyme levels (alkaline phosphatase);	chr20:25239216	chr20:25845497~25845862:+
OV	cis	rs7829975	0.846	rs7005216	ENSG00000253893.2	FAM85B	6.02	6.79e-09	8.6e-06	0.38	0.37	Mood instability;	chr8:8689600	chr8:8167819~8226614:-
OV	cis	rs11671005	0.504	rs7257669	ENSG00000269600.1	AC016629.3	-6.02	6.79e-09	8.61e-06	-0.47	-0.37	Mean platelet volume;	chr19:58553572	chr19:58593896~58599355:-
OV	cis	rs2243480	1	rs1039664	ENSG00000222364.1	RNU6-96P	-6.02	6.79e-09	8.61e-06	-0.58	-0.37	Diabetic kidney disease;	chr7:65984729	chr7:66395191~66395286:+
OV	cis	rs1185460	0.934	rs10892328	ENSG00000271751.1	RP11-110I1.14	-6.02	6.82e-09	8.64e-06	-0.48	-0.37	Coronary artery disease;	chr11:119071944	chr11:119065263~119065677:-
OV	cis	rs9660180	0.967	rs10907191	ENSG00000231050.1	RP1-140A9.1	6.02	6.84e-09	8.67e-06	0.39	0.37	Body mass index;	chr1:1843381	chr1:1891471~1892658:+
OV	cis	rs73019876	0.901	rs417628	ENSG00000269742.1	BNIP3P29	-6.02	6.88e-09	8.71e-06	-0.44	-0.37	Testicular germ cell tumor;	chr19:22047992	chr19:22065828~22066398:-
OV	cis	rs2412819	0.571	rs56226333	ENSG00000249839.1	AC011330.5	-6.02	6.96e-09	8.81e-06	-0.53	-0.37	Lung cancer;	chr15:43632410	chr15:43663654~43684339:-
OV	cis	rs1707322	1	rs785467	ENSG00000280836.1	AL355480.1	6.02	7.02e-09	8.88e-06	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46055887	chr1:45581219~45581321:-
OV	cis	rs611744	0.967	rs682007	ENSG00000253754.1	RP11-35G22.1	-6.02	7.02e-09	8.88e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108198097	chr8:108226200~108227544:+
OV	cis	rs611744	0.934	rs682954	ENSG00000253754.1	RP11-35G22.1	-6.02	7.02e-09	8.88e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108198330	chr8:108226200~108227544:+
OV	cis	rs611744	0.836	rs684412	ENSG00000253754.1	RP11-35G22.1	-6.02	7.02e-09	8.88e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108198676	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs650437	ENSG00000253754.1	RP11-35G22.1	-6.02	7.02e-09	8.88e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108198698	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs650968	ENSG00000253754.1	RP11-35G22.1	-6.02	7.02e-09	8.88e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108198826	chr8:108226200~108227544:+
OV	cis	rs7044106	0.791	rs10985008	ENSG00000226752.6	PSMD5-AS1	-6.02	7.04e-09	8.89e-06	-0.42	-0.37	Hip circumference adjusted for BMI;	chr9:120730682	chr9:120824828~120854385:+
OV	cis	rs4563143	0.675	rs56322221	ENSG00000267243.4	AC005307.3	-6.02	7.07e-09	8.93e-06	-0.61	-0.37	Methadone dose in opioid dependence;	chr19:28779442	chr19:28435388~28727777:-
OV	cis	rs4563143	0.675	rs34113156	ENSG00000267243.4	AC005307.3	-6.02	7.07e-09	8.93e-06	-0.61	-0.37	Methadone dose in opioid dependence;	chr19:28779915	chr19:28435388~28727777:-
OV	cis	rs4563143	0.675	rs73029049	ENSG00000267243.4	AC005307.3	-6.02	7.07e-09	8.93e-06	-0.61	-0.37	Methadone dose in opioid dependence;	chr19:28784627	chr19:28435388~28727777:-
OV	cis	rs2739330	0.76	rs5751761	ENSG00000099984.9	GSTT2	6.02	7.08e-09	8.95e-06	0.41	0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23980123~23983911:+
OV	cis	rs200367988	1	rs200367988	ENSG00000271670.1	RP11-95I16.4	-6.01	7.17e-09	9.06e-06	-0.42	-0.37	Prostate-specific antigen levels (conditioned on lead SNPs);Prostate-specific antigen levels;	chr10:120915337	chr10:120879256~120880667:-
OV	cis	rs1707322	1	rs785510	ENSG00000280836.1	AL355480.1	6.01	7.18e-09	9.07e-06	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46062946	chr1:45581219~45581321:-
OV	cis	rs853679	0.527	rs9461443	ENSG00000219392.1	RP1-265C24.5	-6.01	7.2e-09	9.09e-06	-0.47	-0.37	Depression;	chr6:28226851	chr6:28115628~28116551:+
OV	cis	rs853679	0.55	rs34477097	ENSG00000219392.1	RP1-265C24.5	-6.01	7.2e-09	9.09e-06	-0.47	-0.37	Depression;	chr6:28229408	chr6:28115628~28116551:+
OV	cis	rs2286503	0.901	rs2286505	ENSG00000228649.7	AC005682.5	6.01	7.2e-09	9.09e-06	0.43	0.37	Fibrinogen;	chr7:22815221	chr7:22854178~22861579:+
OV	cis	rs4563143	0.675	rs56293553	ENSG00000267243.4	AC005307.3	-6.01	7.26e-09	9.16e-06	-0.6	-0.37	Methadone dose in opioid dependence;	chr19:28779548	chr19:28435388~28727777:-
OV	cis	rs950169	0.614	rs765524	ENSG00000235370.6	DNM1P51	6.01	7.28e-09	9.19e-06	0.5	0.37	Schizophrenia;	chr15:84013030	chr15:84398316~84411701:-
OV	cis	rs11976180	1	rs1320893	ENSG00000170356.8	OR2A20P	-6.01	7.32e-09	9.23e-06	-0.52	-0.37	Obesity-related traits;	chr7:144055019	chr7:144250045~144252957:-
OV	cis	rs9660180	0.783	rs1107910	ENSG00000268575.1	RP1-283E3.8	-6.01	7.34e-09	9.26e-06	-0.35	-0.37	Body mass index;	chr1:1760882	chr1:1702736~1737688:-
OV	cis	rs4713118	0.868	rs760587	ENSG00000220721.1	OR1F12	6.01	7.34e-09	9.26e-06	0.43	0.37	Parkinson's disease;	chr6:27772521	chr6:28073316~28074233:+
OV	cis	rs8105895	0.932	rs8105913	ENSG00000269742.1	BNIP3P29	6.01	7.35e-09	9.27e-06	0.62	0.37	Body mass index (change over time);	chr19:22018690	chr19:22065828~22066398:-
OV	cis	rs7684446	1	rs7684446	ENSG00000273133.1	RP11-799M12.2	6.01	7.41e-09	9.35e-06	0.42	0.37	Red blood cell count;	chr4:15591241	chr4:15563698~15564253:-
OV	cis	rs1789	0.653	rs13142069	ENSG00000273133.1	RP11-799M12.2	6.01	7.41e-09	9.35e-06	0.42	0.37	Blood protein levels;	chr4:15592069	chr4:15563698~15564253:-
OV	cis	rs4563143	0.577	rs73025093	ENSG00000267243.4	AC005307.3	-6.01	7.45e-09	9.37e-06	-0.6	-0.37	Methadone dose in opioid dependence;	chr19:28763711	chr19:28435388~28727777:-
OV	cis	rs611744	0.967	rs677288	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108165310	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs677330	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108165343	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs660816	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108165819	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs584716	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108166405	chr8:108226200~108227544:+
OV	cis	rs611744	0.934	rs673356	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108172930	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs689256	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108174169	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs597649	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108175489	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs598022	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108175530	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs598477	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108175645	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs602384	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108175956	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs610452	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108176034	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs612265	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108176421	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs613644	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108176765	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs628340	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108177196	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs627604	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108177590	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs631031	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108177803	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs641820	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108178488	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs671139	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108179031	chr8:108226200~108227544:+
OV	cis	rs611744	0.87	rs57723916	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108179204	chr8:108226200~108227544:+
OV	cis	rs611744	0.934	rs1668178	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108179471	chr8:108226200~108227544:+
OV	cis	rs611744	0.901	rs673981	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108179688	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs660065	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108179703	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs685690	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108179916	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs686584	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108180128	chr8:108226200~108227544:+
OV	cis	rs611744	0.934	rs672591	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108180224	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs594405	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108181378	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs595266	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108181555	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs597992	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108181579	chr8:108226200~108227544:+
OV	cis	rs611744	0.901	rs599357	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108181931	chr8:108226200~108227544:+
OV	cis	rs611744	0.868	rs612722	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108182621	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs628843	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108183886	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs653633	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108183922	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs651814	ENSG00000253754.1	RP11-35G22.1	-6.01	7.45e-09	9.37e-06	-0.41	-0.37	Dupuytren's disease;	chr8:108184342	chr8:108226200~108227544:+
OV	cis	rs494459	0.838	rs632124	ENSG00000278376.1	RP11-158I9.8	-6.01	7.46e-09	9.38e-06	-0.36	-0.37	Height;	chr11:118742526	chr11:118791254~118793137:+
OV	cis	rs6991838	0.798	rs6994889	ENSG00000272010.1	CTD-3025N20.3	6.01	7.48e-09	9.41e-06	0.45	0.37	Intelligence (multi-trait analysis);	chr8:65562547	chr8:65591850~65592472:-
OV	cis	rs4591358	0.68	rs12995102	ENSG00000223466.1	AC064834.2	-6.01	7.5e-09	9.42e-06	-0.51	-0.37	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195447752	chr2:195533035~195538681:+
OV	cis	rs2243480	1	rs73142166	ENSG00000222364.1	RNU6-96P	-6.01	7.51e-09	9.44e-06	-0.58	-0.37	Diabetic kidney disease;	chr7:65910845	chr7:66395191~66395286:+
OV	cis	rs2243480	0.908	rs55876148	ENSG00000222364.1	RNU6-96P	-6.01	7.51e-09	9.44e-06	-0.58	-0.37	Diabetic kidney disease;	chr7:65914813	chr7:66395191~66395286:+
OV	cis	rs7017914	0.652	rs2639911	ENSG00000223220.1	Y_RNA	6.01	7.52e-09	9.45e-06	0.41	0.37	Bone mineral density;	chr8:70948477	chr8:70780914~70781008:-
OV	cis	rs2739330	0.587	rs4820571	ENSG00000099984.9	GSTT2	-6.01	7.52e-09	9.45e-06	-0.43	-0.37	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23980123~23983911:+
OV	cis	rs7615952	0.599	rs12485717	ENSG00000171084.14	FAM86JP	-6	7.55e-09	9.49e-06	-0.5	-0.37	Blood pressure (smoking interaction);	chr3:125988232	chr3:125916620~125930024:+
OV	cis	rs67180937	0.961	rs17465940	ENSG00000272750.1	RP11-378J18.8	-6	7.6e-09	9.54e-06	-0.4	-0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222663654	chr1:222658867~222661512:-
OV	cis	rs7615952	0.546	rs4428131	ENSG00000171084.14	FAM86JP	6	7.62e-09	9.56e-06	0.61	0.37	Blood pressure (smoking interaction);	chr3:125627635	chr3:125916620~125930024:+
OV	cis	rs494459	0.838	rs607125	ENSG00000278376.1	RP11-158I9.8	-6	7.62e-09	9.57e-06	-0.36	-0.37	Height;	chr11:118746590	chr11:118791254~118793137:+
OV	cis	rs934734	0.532	rs10153675	ENSG00000234255.7	AC012370.3	-6	7.65e-09	9.6e-06	-0.41	-0.37	Rheumatoid arthritis;	chr2:65422446	chr2:65439888~65456571:-
OV	cis	rs2243480	1	rs35421653	ENSG00000222364.1	RNU6-96P	-6	7.65e-09	9.61e-06	-0.58	-0.37	Diabetic kidney disease;	chr7:65898442	chr7:66395191~66395286:+
OV	cis	rs7626444	0.625	rs2686596	ENSG00000272359.1	U4	-6	7.7e-09	9.66e-06	-0.38	-0.37	Monocyte count;	chr3:196748248	chr3:196747192~196747324:-
OV	cis	rs7626444	0.625	rs2686595	ENSG00000272359.1	U4	-6	7.7e-09	9.66e-06	-0.38	-0.37	Monocyte count;	chr3:196748271	chr3:196747192~196747324:-
OV	cis	rs2412819	0.571	rs62018900	ENSG00000249839.1	AC011330.5	-6	7.7e-09	9.66e-06	-0.53	-0.37	Lung cancer;	chr15:43633252	chr15:43663654~43684339:-
OV	cis	rs11673344	0.801	rs17707446	ENSG00000226686.6	LINC01535	-6	7.71e-09	9.67e-06	-0.52	-0.37	Obesity-related traits;	chr19:37092140	chr19:37251912~37265535:+
OV	cis	rs1263173	0.696	rs1263172	ENSG00000254851.1	RP11-109L13.1	-6	7.75e-09	9.72e-06	-0.44	-0.37	HDL cholesterol;	chr11:116810202	chr11:117135528~117138582:+
OV	cis	rs67180937	0.922	rs1133220	ENSG00000272750.1	RP11-378J18.8	-6	7.79e-09	9.77e-06	-0.4	-0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661461	chr1:222658867~222661512:-
OV	cis	rs2880765	0.566	rs17553790	ENSG00000259295.5	CSPG4P12	-6	7.82e-09	9.8e-06	-0.45	-0.37	Coronary artery disease;	chr15:85470434	chr15:85191438~85213905:+
OV	cis	rs8062405	0.755	rs2077031	ENSG00000259982.1	CDC37P1	6	7.82e-09	9.81e-06	0.46	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28700294~28701540:-
OV	cis	rs2243480	0.901	rs3813708	ENSG00000222364.1	RNU6-96P	-6	7.85e-09	9.83e-06	-0.59	-0.37	Diabetic kidney disease;	chr7:65840645	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs73142122	ENSG00000222364.1	RNU6-96P	-6	7.85e-09	9.83e-06	-0.59	-0.37	Diabetic kidney disease;	chr7:65846311	chr7:66395191~66395286:+
OV	cis	rs10463554	0.927	rs34798	ENSG00000175749.11	EIF3KP1	6	7.87e-09	9.85e-06	0.51	0.37	Parkinson's disease;	chr5:103090047	chr5:103032376~103033031:+
OV	cis	rs9660180	0.837	rs915292	ENSG00000231050.1	RP1-140A9.1	6	7.88e-09	9.87e-06	0.39	0.37	Body mass index;	chr1:1860718	chr1:1891471~1892658:+
OV	cis	rs11671005	0.61	rs4756	ENSG00000269600.1	AC016629.3	-6	7.93e-09	9.93e-06	-0.47	-0.37	Mean platelet volume;	chr19:58563286	chr19:58593896~58599355:-
OV	cis	rs611744	0.967	rs655722	ENSG00000253754.1	RP11-35G22.1	-6	7.93e-09	9.93e-06	-0.4	-0.37	Dupuytren's disease;	chr8:108185312	chr8:108226200~108227544:+
OV	cis	rs1707322	1	rs785490	ENSG00000280836.1	AL355480.1	5.99	7.97e-09	9.97e-06	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46111452	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs785493	ENSG00000280836.1	AL355480.1	5.99	7.97e-09	9.97e-06	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46119187	chr1:45581219~45581321:-
OV	cis	rs1707322	0.964	rs785496	ENSG00000280836.1	AL355480.1	5.99	7.97e-09	9.97e-06	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46122334	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs785497	ENSG00000280836.1	AL355480.1	5.99	7.97e-09	9.97e-06	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126231	chr1:45581219~45581321:-
OV	cis	rs1707322	0.964	rs785499	ENSG00000280836.1	AL355480.1	5.99	7.97e-09	9.97e-06	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46126748	chr1:45581219~45581321:-
OV	cis	rs2153535	0.518	rs9502728	ENSG00000230939.1	RP11-314C16.1	-5.99	7.99e-09	9.99e-06	-0.42	-0.37	Motion sickness;	chr6:8602710	chr6:8784178~8785445:+
OV	cis	rs12922317	0.589	rs350215	ENSG00000260224.1	UBL5P4	-5.99	8e-09	1e-05	-0.42	-0.37	Schizophrenia;	chr16:12057426	chr16:11968508~11968743:-
OV	cis	rs67180937	0.961	rs17465637	ENSG00000272750.1	RP11-378J18.8	5.99	8.06e-09	1.01e-05	0.41	0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650187	chr1:222658867~222661512:-
OV	cis	rs34375054	0.525	rs7133614	ENSG00000279233.1	RP11-158L12.4	5.99	8.06e-09	1.01e-05	0.31	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125121411	chr12:125138245~125141711:+
OV	cis	rs34375054	0.525	rs7133006	ENSG00000279233.1	RP11-158L12.4	5.99	8.06e-09	1.01e-05	0.31	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125121577	chr12:125138245~125141711:+
OV	cis	rs34375054	0.525	rs7133864	ENSG00000279233.1	RP11-158L12.4	5.99	8.06e-09	1.01e-05	0.31	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125121634	chr12:125138245~125141711:+
OV	cis	rs7044106	0.648	rs2031369	ENSG00000226752.6	PSMD5-AS1	-5.99	8.07e-09	1.01e-05	-0.45	-0.37	Hip circumference adjusted for BMI;	chr9:120598016	chr9:120824828~120854385:+
OV	cis	rs11235843	0.706	rs10898949	ENSG00000255928.1	RP11-456I15.2	-5.99	8.13e-09	1.02e-05	-0.65	-0.37	Hand grip strength;	chr11:73870627	chr11:73722349~73722694:+
OV	cis	rs12134133	1	rs28371583	ENSG00000274245.1	RP11-357P18.2	5.99	8.18e-09	1.02e-05	0.48	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207321334	chr1:207372559~207373252:+
OV	cis	rs8062405	1	rs72793812	ENSG00000259982.1	CDC37P1	5.99	8.21e-09	1.03e-05	0.46	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28700294~28701540:-
OV	cis	rs7044106	0.791	rs747819	ENSG00000226752.6	PSMD5-AS1	-5.99	8.22e-09	1.03e-05	-0.42	-0.37	Hip circumference adjusted for BMI;	chr9:120726163	chr9:120824828~120854385:+
OV	cis	rs7044106	0.791	rs735110	ENSG00000226752.6	PSMD5-AS1	-5.99	8.22e-09	1.03e-05	-0.42	-0.37	Hip circumference adjusted for BMI;	chr9:120726662	chr9:120824828~120854385:+
OV	cis	rs7044106	0.5	rs56725168	ENSG00000226752.6	PSMD5-AS1	-5.99	8.24e-09	1.03e-05	-0.42	-0.37	Hip circumference adjusted for BMI;	chr9:120730298	chr9:120824828~120854385:+
OV	cis	rs4713118	0.621	rs4713132	ENSG00000219392.1	RP1-265C24.5	-5.99	8.25e-09	1.03e-05	-0.45	-0.37	Parkinson's disease;	chr6:28066257	chr6:28115628~28116551:+
OV	cis	rs4713118	0.621	rs4713133	ENSG00000219392.1	RP1-265C24.5	-5.99	8.25e-09	1.03e-05	-0.45	-0.37	Parkinson's disease;	chr6:28066263	chr6:28115628~28116551:+
OV	cis	rs4713118	0.621	rs4713134	ENSG00000219392.1	RP1-265C24.5	-5.99	8.25e-09	1.03e-05	-0.45	-0.37	Parkinson's disease;	chr6:28066343	chr6:28115628~28116551:+
OV	cis	rs1707322	1	rs1612419	ENSG00000280836.1	AL355480.1	5.99	8.28e-09	1.03e-05	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081273	chr1:45581219~45581321:-
OV	cis	rs853679	0.517	rs9393896	ENSG00000219392.1	RP1-265C24.5	-5.99	8.28e-09	1.03e-05	-0.48	-0.37	Depression;	chr6:28159925	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9393897	ENSG00000219392.1	RP1-265C24.5	-5.99	8.28e-09	1.03e-05	-0.48	-0.37	Depression;	chr6:28159932	chr6:28115628~28116551:+
OV	cis	rs11159086	1	rs11159087	ENSG00000259005.1	RP3-449M8.6	5.99	8.3e-09	1.04e-05	0.62	0.37	Advanced glycation end-product levels;	chr14:74504671	chr14:74474007~74474864:-
OV	cis	rs611744	0.967	rs678387	ENSG00000253754.1	RP11-35G22.1	-5.99	8.31e-09	1.04e-05	-0.41	-0.37	Dupuytren's disease;	chr8:108230501	chr8:108226200~108227544:+
OV	cis	rs4563143	0.675	rs55976444	ENSG00000267243.4	AC005307.3	-5.99	8.35e-09	1.04e-05	-0.6	-0.37	Methadone dose in opioid dependence;	chr19:28774307	chr19:28435388~28727777:-
OV	cis	rs9660180	1	rs3737628	ENSG00000231050.1	RP1-140A9.1	5.99	8.35e-09	1.04e-05	0.37	0.37	Body mass index;	chr1:1791493	chr1:1891471~1892658:+
OV	cis	rs6772849	0.805	rs61159406	ENSG00000242551.2	POU5F1P6	-5.99	8.36e-09	1.04e-05	-0.42	-0.37	Monocyte percentage of white cells;Monocyte count;	chr3:128617166	chr3:128674735~128677005:-
OV	cis	rs6772849	0.805	rs13325747	ENSG00000242551.2	POU5F1P6	-5.99	8.36e-09	1.04e-05	-0.42	-0.37	Monocyte percentage of white cells;Monocyte count;	chr3:128617180	chr3:128674735~128677005:-
OV	cis	rs1707322	1	rs785486	ENSG00000280836.1	AL355480.1	5.99	8.36e-09	1.04e-05	0.5	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46109476	chr1:45581219~45581321:-
OV	cis	rs1707322	0.865	rs785501	ENSG00000280836.1	AL355480.1	5.99	8.36e-09	1.04e-05	0.5	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46113939	chr1:45581219~45581321:-
OV	cis	rs1707322	0.929	rs785500	ENSG00000280836.1	AL355480.1	5.99	8.36e-09	1.04e-05	0.5	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46127372	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs785504	ENSG00000280836.1	AL355480.1	5.99	8.36e-09	1.04e-05	0.5	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46130024	chr1:45581219~45581321:-
OV	cis	rs611744	0.806	rs2514846	ENSG00000253754.1	RP11-35G22.1	-5.98	8.38e-09	1.04e-05	-0.42	-0.37	Dupuytren's disease;	chr8:108054877	chr8:108226200~108227544:+
OV	cis	rs1185460	1	rs1614264	ENSG00000271751.1	RP11-110I1.14	-5.98	8.38e-09	1.04e-05	-0.45	-0.37	Coronary artery disease;	chr11:119071928	chr11:119065263~119065677:-
OV	cis	rs62355900	0.627	rs61141156	ENSG00000271828.1	CTD-2310F14.1	5.98	8.41e-09	1.05e-05	0.66	0.37	Endometriosis;	chr5:56842951	chr5:56927874~56929573:+
OV	cis	rs62355900	0.627	rs58151318	ENSG00000271828.1	CTD-2310F14.1	5.98	8.41e-09	1.05e-05	0.66	0.37	Endometriosis;	chr5:56843355	chr5:56927874~56929573:+
OV	cis	rs12999373	0.501	rs2867134	ENSG00000272342.1	RP13-539J13.1	-5.98	8.42e-09	1.05e-05	-0.4	-0.37	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:697499	chr2:739588~740164:-
OV	cis	rs4713118	0.824	rs7759217	ENSG00000220721.1	OR1F12	5.98	8.44e-09	1.05e-05	0.4	0.37	Parkinson's disease;	chr6:27762684	chr6:28073316~28074233:+
OV	cis	rs4713118	0.784	rs9468219	ENSG00000220721.1	OR1F12	5.98	8.44e-09	1.05e-05	0.4	0.37	Parkinson's disease;	chr6:27763976	chr6:28073316~28074233:+
OV	cis	rs957448	0.554	rs12541408	ENSG00000253704.1	RP11-267M23.4	5.98	8.44e-09	1.05e-05	0.46	0.37	Nonsyndromic cleft lip with cleft palate;	chr8:94573579	chr8:94553722~94569745:+
OV	cis	rs7487637	0.529	rs56389811	ENSG00000276691.1	RP5-1057I20.5	5.98	8.45e-09	1.05e-05	0.42	0.37	Mononucleosis;	chr12:47811575	chr12:47788426~47788971:+
OV	cis	rs934734	0.532	rs10184881	ENSG00000234255.7	AC012370.3	-5.98	8.46e-09	1.05e-05	-0.4	-0.37	Rheumatoid arthritis;	chr2:65457018	chr2:65439888~65456571:-
OV	cis	rs73086581	1	rs6107393	ENSG00000229539.1	RP11-119B16.2	5.98	8.53e-09	1.06e-05	0.47	0.37	Response to antidepressants in depression;	chr20:4007091	chr20:3888239~3888868:-
OV	cis	rs8062405	0.754	rs151179	ENSG00000278665.1	RP11-666O2.4	5.98	8.54e-09	1.06e-05	0.39	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28599241~28601881:-
OV	cis	rs1707322	0.964	rs1768802	ENSG00000280836.1	AL355480.1	5.98	8.55e-09	1.06e-05	0.5	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46082196	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs1588663	ENSG00000280836.1	AL355480.1	5.98	8.55e-09	1.06e-05	0.5	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083153	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs1768801	ENSG00000280836.1	AL355480.1	5.98	8.55e-09	1.06e-05	0.5	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083465	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs1768800	ENSG00000280836.1	AL355480.1	5.98	8.55e-09	1.06e-05	0.5	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46083516	chr1:45581219~45581321:-
OV	cis	rs62355900	0.627	rs16886429	ENSG00000271828.1	CTD-2310F14.1	5.98	8.6e-09	1.07e-05	0.68	0.37	Endometriosis;	chr5:56857265	chr5:56927874~56929573:+
OV	cis	rs934734	0.532	rs2028151	ENSG00000234255.7	AC012370.3	-5.98	8.61e-09	1.07e-05	-0.4	-0.37	Rheumatoid arthritis;	chr2:65428479	chr2:65439888~65456571:-
OV	cis	rs11723261	0.582	rs6830247	ENSG00000275426.1	CH17-262A2.1	5.98	8.68e-09	1.08e-05	0.6	0.37	Immune response to smallpox vaccine (IL-6);	chr4:156885	chr4:149738~150317:+
OV	cis	rs7811142	0.562	rs7786844	ENSG00000242294.5	STAG3L5P	5.98	8.68e-09	1.08e-05	0.38	0.37	Platelet count;	chr7:100336385	chr7:100336079~100351900:+
OV	cis	rs7811142	0.667	rs3873746	ENSG00000242294.5	STAG3L5P	5.98	8.68e-09	1.08e-05	0.38	0.37	Platelet count;	chr7:100337474	chr7:100336079~100351900:+
OV	cis	rs2581828	0.632	rs891369	ENSG00000242142.1	SERBP1P3	-5.98	8.69e-09	1.08e-05	-0.45	-0.37	Crohn's disease;	chr3:53102535	chr3:53064283~53065091:-
OV	cis	rs7605378	0.658	rs4673507	ENSG00000232732.8	AC073043.1	-5.98	8.71e-09	1.08e-05	-0.44	-0.37	Osteoporosis;	chr2:199845444	chr2:199867396~199911159:-
OV	cis	rs992157	1	rs2168704	ENSG00000237281.1	CATIP-AS2	-5.98	8.74e-09	1.09e-05	-0.42	-0.37	Colorectal cancer;	chr2:218277769	chr2:218326889~218357966:-
OV	cis	rs2243480	0.706	rs34466769	ENSG00000222364.1	RNU6-96P	-5.98	8.77e-09	1.09e-05	-0.52	-0.37	Diabetic kidney disease;	chr7:65988305	chr7:66395191~66395286:+
OV	cis	rs7017914	0.902	rs6472542	ENSG00000223220.1	Y_RNA	-5.98	8.8e-09	1.09e-05	-0.37	-0.37	Bone mineral density;	chr8:70741852	chr8:70780914~70781008:-
OV	cis	rs12134133	0.962	rs17258843	ENSG00000274245.1	RP11-357P18.2	5.98	8.8e-09	1.09e-05	0.5	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207241387	chr1:207372559~207373252:+
OV	cis	rs494459	0.838	rs555639	ENSG00000278376.1	RP11-158I9.8	5.97	8.85e-09	1.1e-05	0.35	0.37	Height;	chr11:118758322	chr11:118791254~118793137:+
OV	cis	rs2243480	1	rs56016656	ENSG00000222364.1	RNU6-96P	-5.97	8.86e-09	1.1e-05	-0.58	-0.37	Diabetic kidney disease;	chr7:65918494	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs56291018	ENSG00000222364.1	RNU6-96P	-5.97	8.86e-09	1.1e-05	-0.58	-0.37	Diabetic kidney disease;	chr7:65925352	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs36033484	ENSG00000222364.1	RNU6-96P	-5.97	8.86e-09	1.1e-05	-0.58	-0.37	Diabetic kidney disease;	chr7:65925571	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs34193460	ENSG00000222364.1	RNU6-96P	-5.97	8.86e-09	1.1e-05	-0.58	-0.37	Diabetic kidney disease;	chr7:65928123	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs34560516	ENSG00000222364.1	RNU6-96P	-5.97	8.86e-09	1.1e-05	-0.58	-0.37	Diabetic kidney disease;	chr7:65939105	chr7:66395191~66395286:+
OV	cis	rs934734	0.532	rs13383320	ENSG00000234255.7	AC012370.3	-5.97	8.91e-09	1.1e-05	-0.41	-0.37	Rheumatoid arthritis;	chr2:65418003	chr2:65439888~65456571:-
OV	cis	rs7626444	0.625	rs1798636	ENSG00000272359.1	U4	-5.97	8.92e-09	1.11e-05	-0.38	-0.37	Monocyte count;	chr3:196749733	chr3:196747192~196747324:-
OV	cis	rs7626444	0.625	rs1798637	ENSG00000272359.1	U4	-5.97	8.92e-09	1.11e-05	-0.38	-0.37	Monocyte count;	chr3:196749768	chr3:196747192~196747324:-
OV	cis	rs7626444	0.625	rs7638090	ENSG00000272359.1	U4	-5.97	8.92e-09	1.11e-05	-0.38	-0.37	Monocyte count;	chr3:196749965	chr3:196747192~196747324:-
OV	cis	rs7626444	0.625	rs2669637	ENSG00000272359.1	U4	-5.97	8.92e-09	1.11e-05	-0.38	-0.37	Monocyte count;	chr3:196750498	chr3:196747192~196747324:-
OV	cis	rs7626444	0.625	rs1718410	ENSG00000272359.1	U4	-5.97	8.92e-09	1.11e-05	-0.38	-0.37	Monocyte count;	chr3:196750789	chr3:196747192~196747324:-
OV	cis	rs853679	0.55	rs1233704	ENSG00000219392.1	RP1-265C24.5	5.97	8.99e-09	1.11e-05	0.48	0.37	Depression;	chr6:28199145	chr6:28115628~28116551:+
OV	cis	rs3931020	0.548	rs969435	ENSG00000272864.1	RP11-17E13.2	5.97	9.03e-09	1.12e-05	0.47	0.37	Resistin levels;	chr1:74808182	chr1:74698769~74699333:-
OV	cis	rs611744	0.967	rs2597654	ENSG00000253754.1	RP11-35G22.1	-5.97	9.08e-09	1.12e-05	-0.41	-0.37	Dupuytren's disease;	chr8:108208861	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs662714	ENSG00000253754.1	RP11-35G22.1	-5.97	9.08e-09	1.12e-05	-0.41	-0.37	Dupuytren's disease;	chr8:108209430	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs627019	ENSG00000253754.1	RP11-35G22.1	-5.97	9.08e-09	1.12e-05	-0.41	-0.37	Dupuytren's disease;	chr8:108210315	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs603889	ENSG00000253754.1	RP11-35G22.1	-5.97	9.08e-09	1.12e-05	-0.41	-0.37	Dupuytren's disease;	chr8:108212003	chr8:108226200~108227544:+
OV	cis	rs611744	0.934	rs672408	ENSG00000253754.1	RP11-35G22.1	-5.97	9.08e-09	1.12e-05	-0.41	-0.37	Dupuytren's disease;	chr8:108212161	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs641721	ENSG00000253754.1	RP11-35G22.1	-5.97	9.08e-09	1.12e-05	-0.41	-0.37	Dupuytren's disease;	chr8:108217911	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs653081	ENSG00000253754.1	RP11-35G22.1	-5.97	9.08e-09	1.12e-05	-0.41	-0.37	Dupuytren's disease;	chr8:108218154	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs536860	ENSG00000253754.1	RP11-35G22.1	-5.97	9.08e-09	1.12e-05	-0.41	-0.37	Dupuytren's disease;	chr8:108218493	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs686630	ENSG00000253754.1	RP11-35G22.1	-5.97	9.08e-09	1.12e-05	-0.41	-0.37	Dupuytren's disease;	chr8:108221010	chr8:108226200~108227544:+
OV	cis	rs611744	0.752	rs609197	ENSG00000253754.1	RP11-35G22.1	-5.97	9.08e-09	1.12e-05	-0.41	-0.37	Dupuytren's disease;	chr8:108221806	chr8:108226200~108227544:+
OV	cis	rs611744	0.901	rs639746	ENSG00000253754.1	RP11-35G22.1	-5.97	9.08e-09	1.12e-05	-0.41	-0.37	Dupuytren's disease;	chr8:108222596	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs636399	ENSG00000253754.1	RP11-35G22.1	-5.97	9.08e-09	1.12e-05	-0.41	-0.37	Dupuytren's disease;	chr8:108223340	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs637626	ENSG00000253754.1	RP11-35G22.1	-5.97	9.08e-09	1.12e-05	-0.41	-0.37	Dupuytren's disease;	chr8:108223556	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs702805	ENSG00000253754.1	RP11-35G22.1	-5.97	9.08e-09	1.12e-05	-0.41	-0.37	Dupuytren's disease;	chr8:108223700	chr8:108226200~108227544:+
OV	cis	rs611744	0.934	rs604698	ENSG00000253754.1	RP11-35G22.1	-5.97	9.08e-09	1.12e-05	-0.41	-0.37	Dupuytren's disease;	chr8:108226492	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs569701	ENSG00000253754.1	RP11-35G22.1	-5.97	9.08e-09	1.12e-05	-0.41	-0.37	Dupuytren's disease;	chr8:108226978	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs695028	ENSG00000253754.1	RP11-35G22.1	-5.97	9.08e-09	1.12e-05	-0.41	-0.37	Dupuytren's disease;	chr8:108227095	chr8:108226200~108227544:+
OV	cis	rs7580658	0.676	rs4150407	ENSG00000236682.1	AC068282.3	5.97	9.11e-09	1.13e-05	0.44	0.37	Protein C levels;	chr2:127292055	chr2:127389130~127400580:+
OV	cis	rs934734	0.532	rs7569257	ENSG00000234255.7	AC012370.3	-5.97	9.11e-09	1.13e-05	-0.41	-0.37	Rheumatoid arthritis;	chr2:65429842	chr2:65439888~65456571:-
OV	cis	rs1707322	0.964	rs785516	ENSG00000280836.1	AL355480.1	5.97	9.14e-09	1.13e-05	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46099086	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs785517	ENSG00000280836.1	AL355480.1	5.97	9.14e-09	1.13e-05	0.51	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46101863	chr1:45581219~45581321:-
OV	cis	rs34375054	0.526	rs883315	ENSG00000279233.1	RP11-158L12.4	5.97	9.17e-09	1.13e-05	0.3	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125192343	chr12:125138245~125141711:+
OV	cis	rs34375054	0.526	rs2343638	ENSG00000279233.1	RP11-158L12.4	5.97	9.17e-09	1.13e-05	0.3	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125192576	chr12:125138245~125141711:+
OV	cis	rs9322193	0.607	rs6557165	ENSG00000231760.4	RP11-350J20.5	-5.97	9.19e-09	1.13e-05	-0.47	-0.37	Lung cancer;	chr6:149906883	chr6:149796151~149826294:-
OV	cis	rs4591358	0.527	rs16836742	ENSG00000223466.1	AC064834.2	5.97	9.19e-09	1.13e-05	0.46	0.37	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195512919	chr2:195533035~195538681:+
OV	cis	rs611744	0.967	rs639059	ENSG00000253754.1	RP11-35G22.1	-5.97	9.2e-09	1.14e-05	-0.41	-0.37	Dupuytren's disease;	chr8:108223890	chr8:108226200~108227544:+
OV	cis	rs3931020	0.548	rs12145183	ENSG00000272864.1	RP11-17E13.2	-5.97	9.21e-09	1.14e-05	-0.47	-0.37	Resistin levels;	chr1:74806796	chr1:74698769~74699333:-
OV	cis	rs3931020	0.566	rs1409782	ENSG00000272864.1	RP11-17E13.2	-5.97	9.21e-09	1.14e-05	-0.47	-0.37	Resistin levels;	chr1:74807251	chr1:74698769~74699333:-
OV	cis	rs67180937	0.849	rs4575092	ENSG00000272750.1	RP11-378J18.8	-5.97	9.22e-09	1.14e-05	-0.4	-0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222661161	chr1:222658867~222661512:-
OV	cis	rs6088580	0.634	rs4277599	ENSG00000206582.1	Y_RNA	5.97	9.22e-09	1.14e-05	0.43	0.37	Glomerular filtration rate (creatinine);	chr20:34421099	chr20:34526510~34526606:-
OV	cis	rs2243480	1	rs73142162	ENSG00000222364.1	RNU6-96P	-5.97	9.24e-09	1.14e-05	-0.58	-0.37	Diabetic kidney disease;	chr7:65909309	chr7:66395191~66395286:+
OV	cis	rs1707322	0.638	rs1416706	ENSG00000281133.1	AL355480.3	5.96	9.31e-09	1.15e-05	0.45	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46137172	chr1:45580892~45580996:-
OV	cis	rs8062405	0.721	rs151181	ENSG00000259982.1	CDC37P1	5.96	9.37e-09	1.16e-05	0.44	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28700294~28701540:-
OV	cis	rs2833693	0.572	rs2040106	ENSG00000261610.1	AP000265.1	5.96	9.37e-09	1.16e-05	0.44	0.37	Temperament;	chr21:32242397	chr21:32259804~32261585:-
OV	cis	rs7017914	0.846	rs6472561	ENSG00000223220.1	Y_RNA	-5.96	9.42e-09	1.16e-05	-0.4	-0.37	Bone mineral density;	chr8:71042948	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs4074909	ENSG00000223220.1	Y_RNA	-5.96	9.42e-09	1.16e-05	-0.4	-0.37	Bone mineral density;	chr8:71043592	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs4078067	ENSG00000223220.1	Y_RNA	-5.96	9.42e-09	1.16e-05	-0.4	-0.37	Bone mineral density;	chr8:71044236	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs4504667	ENSG00000223220.1	Y_RNA	-5.96	9.42e-09	1.16e-05	-0.4	-0.37	Bone mineral density;	chr8:71044557	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs4571761	ENSG00000223220.1	Y_RNA	-5.96	9.42e-09	1.16e-05	-0.4	-0.37	Bone mineral density;	chr8:71044938	chr8:70780914~70781008:-
OV	cis	rs1707322	0.964	rs785483	ENSG00000280836.1	AL355480.1	5.96	9.45e-09	1.16e-05	0.5	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46093499	chr1:45581219~45581321:-
OV	cis	rs1707322	0.964	rs796773	ENSG00000280836.1	AL355480.1	5.96	9.45e-09	1.16e-05	0.5	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46098803	chr1:45581219~45581321:-
OV	cis	rs1707322	0.896	rs785518	ENSG00000280836.1	AL355480.1	5.96	9.45e-09	1.16e-05	0.5	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102750	chr1:45581219~45581321:-
OV	cis	rs1707322	1	rs785519	ENSG00000280836.1	AL355480.1	5.96	9.45e-09	1.16e-05	0.5	0.37	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46102890	chr1:45581219~45581321:-
OV	cis	rs8062405	0.754	rs151179	ENSG00000259982.1	CDC37P1	5.96	9.45e-09	1.16e-05	0.44	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28475735	chr16:28700294~28701540:-
OV	cis	rs858239	0.6	rs2014768	ENSG00000230042.1	AK3P3	-5.96	9.46e-09	1.16e-05	-0.39	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23082821	chr7:23129178~23129841:+
OV	cis	rs858239	0.6	rs10256361	ENSG00000230042.1	AK3P3	-5.96	9.46e-09	1.16e-05	-0.39	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23084266	chr7:23129178~23129841:+
OV	cis	rs858239	0.6	rs6978827	ENSG00000230042.1	AK3P3	-5.96	9.46e-09	1.16e-05	-0.39	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23085925	chr7:23129178~23129841:+
OV	cis	rs858239	0.6	rs7790157	ENSG00000230042.1	AK3P3	-5.96	9.46e-09	1.16e-05	-0.39	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23087379	chr7:23129178~23129841:+
OV	cis	rs62355901	0.551	rs12659430	ENSG00000271828.1	CTD-2310F14.1	5.96	9.47e-09	1.17e-05	0.7	0.37	Breast cancer;	chr5:56736792	chr5:56927874~56929573:+
OV	cis	rs853679	0.517	rs4711164	ENSG00000219392.1	RP1-265C24.5	-5.96	9.5e-09	1.17e-05	-0.47	-0.37	Depression;	chr6:28147378	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs4711165	ENSG00000219392.1	RP1-265C24.5	-5.96	9.5e-09	1.17e-05	-0.47	-0.37	Depression;	chr6:28147406	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs4713148	ENSG00000219392.1	RP1-265C24.5	-5.96	9.5e-09	1.17e-05	-0.47	-0.37	Depression;	chr6:28148143	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9348794	ENSG00000219392.1	RP1-265C24.5	-5.96	9.5e-09	1.17e-05	-0.47	-0.37	Depression;	chr6:28149979	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9468297	ENSG00000219392.1	RP1-265C24.5	-5.96	9.5e-09	1.17e-05	-0.47	-0.37	Depression;	chr6:28151096	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9295758	ENSG00000219392.1	RP1-265C24.5	-5.96	9.5e-09	1.17e-05	-0.47	-0.37	Depression;	chr6:28152885	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs17774663	ENSG00000219392.1	RP1-265C24.5	-5.96	9.5e-09	1.17e-05	-0.47	-0.37	Depression;	chr6:28153120	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9468298	ENSG00000219392.1	RP1-265C24.5	-5.96	9.5e-09	1.17e-05	-0.47	-0.37	Depression;	chr6:28154567	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9295759	ENSG00000219392.1	RP1-265C24.5	-5.96	9.5e-09	1.17e-05	-0.47	-0.37	Depression;	chr6:28156691	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9348796	ENSG00000219392.1	RP1-265C24.5	-5.96	9.5e-09	1.17e-05	-0.47	-0.37	Depression;	chr6:28158424	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs11552219	ENSG00000219392.1	RP1-265C24.5	-5.96	9.5e-09	1.17e-05	-0.47	-0.37	Depression;	chr6:28159056	chr6:28115628~28116551:+
OV	cis	rs7771547	0.642	rs1003250	ENSG00000240733.3	RN7SL502P	-5.96	9.56e-09	1.18e-05	-0.39	-0.37	Platelet distribution width;	chr6:36469635	chr6:36450912~36451201:-
OV	cis	rs7267979	0.702	rs449801	ENSG00000274973.1	RP13-401N8.7	-5.96	9.57e-09	1.18e-05	-0.43	-0.37	Liver enzyme levels (alkaline phosphatase);	chr20:25511211	chr20:25845497~25845862:+
OV	cis	rs7044106	0.708	rs10984992	ENSG00000226752.6	PSMD5-AS1	-5.96	9.58e-09	1.18e-05	-0.44	-0.37	Hip circumference adjusted for BMI;	chr9:120711138	chr9:120824828~120854385:+
OV	cis	rs853679	0.517	rs9357065	ENSG00000219392.1	RP1-265C24.5	-5.96	9.65e-09	1.19e-05	-0.47	-0.37	Depression;	chr6:28161802	chr6:28115628~28116551:+
OV	cis	rs801193	0.967	rs2707841	ENSG00000236529.1	RP13-254B10.1	5.96	9.68e-09	1.19e-05	0.39	0.37	Aortic root size;	chr7:66692033	chr7:65840212~65840596:+
OV	cis	rs801193	1	rs2659912	ENSG00000236529.1	RP13-254B10.1	5.96	9.68e-09	1.19e-05	0.39	0.37	Aortic root size;	chr7:66693012	chr7:65840212~65840596:+
OV	cis	rs801193	1	rs2707836	ENSG00000236529.1	RP13-254B10.1	5.96	9.68e-09	1.19e-05	0.39	0.37	Aortic root size;	chr7:66695448	chr7:65840212~65840596:+
OV	cis	rs801193	1	rs4717310	ENSG00000236529.1	RP13-254B10.1	5.96	9.68e-09	1.19e-05	0.39	0.37	Aortic root size;	chr7:66696020	chr7:65840212~65840596:+
OV	cis	rs801193	0.844	rs7779971	ENSG00000236529.1	RP13-254B10.1	5.96	9.68e-09	1.19e-05	0.39	0.37	Aortic root size;	chr7:66696803	chr7:65840212~65840596:+
OV	cis	rs11098499	0.954	rs13145352	ENSG00000245958.5	RP11-33B1.1	5.96	9.74e-09	1.2e-05	0.42	0.37	Corneal astigmatism;	chr4:119488808	chr4:119454791~119552025:+
OV	cis	rs494459	0.838	rs581045	ENSG00000255422.1	AP002954.4	-5.96	9.81e-09	1.2e-05	-0.41	-0.37	Height;	chr11:118761813	chr11:118704607~118750263:+
OV	cis	rs8062405	1	rs62036622	ENSG00000259982.1	CDC37P1	5.95	9.81e-09	1.2e-05	0.46	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28700294~28701540:-
OV	cis	rs16873450	0.903	rs12700464	ENSG00000234800.2	PCMTD1P3	5.95	9.86e-09	1.21e-05	0.37	0.37	Verbal memory performance (residualized delayed recall level);	chr7:23766910	chr7:23721311~23721782:-
OV	cis	rs16873450	0.934	rs12531019	ENSG00000234800.2	PCMTD1P3	5.95	9.86e-09	1.21e-05	0.37	0.37	Verbal memory performance (residualized delayed recall level);	chr7:23766983	chr7:23721311~23721782:-
OV	cis	rs16873450	0.934	rs12536120	ENSG00000234800.2	PCMTD1P3	5.95	9.86e-09	1.21e-05	0.37	0.37	Verbal memory performance (residualized delayed recall level);	chr7:23767035	chr7:23721311~23721782:-
OV	cis	rs11976180	1	rs2951369	ENSG00000170356.8	OR2A20P	-5.95	9.9e-09	1.21e-05	-0.52	-0.37	Obesity-related traits;	chr7:144055545	chr7:144250045~144252957:-
OV	cis	rs11976180	1	rs2951368	ENSG00000170356.8	OR2A20P	-5.95	9.9e-09	1.21e-05	-0.52	-0.37	Obesity-related traits;	chr7:144055728	chr7:144250045~144252957:-
OV	cis	rs11976180	1	rs2961115	ENSG00000170356.8	OR2A20P	-5.95	9.9e-09	1.21e-05	-0.52	-0.37	Obesity-related traits;	chr7:144056278	chr7:144250045~144252957:-
OV	cis	rs11976180	1	rs2951364	ENSG00000170356.8	OR2A20P	-5.95	9.9e-09	1.21e-05	-0.52	-0.37	Obesity-related traits;	chr7:144057390	chr7:144250045~144252957:-
OV	cis	rs11976180	1	rs2951363	ENSG00000170356.8	OR2A20P	-5.95	9.9e-09	1.21e-05	-0.52	-0.37	Obesity-related traits;	chr7:144057631	chr7:144250045~144252957:-
OV	cis	rs801193	1	rs2659909	ENSG00000236529.1	RP13-254B10.1	5.95	9.91e-09	1.21e-05	0.39	0.37	Aortic root size;	chr7:66695292	chr7:65840212~65840596:+
OV	cis	rs801193	1	rs11773829	ENSG00000236529.1	RP13-254B10.1	-5.95	9.95e-09	1.22e-05	-0.39	-0.37	Aortic root size;	chr7:66676087	chr7:65840212~65840596:+
OV	cis	rs4591358	0.731	rs12693768	ENSG00000223466.1	AC064834.2	-5.95	9.95e-09	1.22e-05	-0.51	-0.37	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195451897	chr2:195533035~195538681:+
OV	cis	rs2880765	0.545	rs17553734	ENSG00000259295.5	CSPG4P12	-5.95	9.96e-09	1.22e-05	-0.46	-0.37	Coronary artery disease;	chr15:85469828	chr15:85191438~85213905:+
OV	cis	rs3814244	0.528	rs12228471	ENSG00000255733.4	IFNG-AS1	5.95	9.97e-09	1.22e-05	0.37	0.37	Itch intensity from mosquito bite adjusted by bite size;	chr12:68027842	chr12:67989445~68234686:+
OV	cis	rs61990749	0.597	rs717683	ENSG00000239272.1	RPL21P10	5.95	9.97e-09	1.22e-05	0.51	0.37	Fibroblast growth factor basic levels;	chr14:77789110	chr14:77683202~77683989:-
OV	cis	rs61990749	0.544	rs1477259	ENSG00000239272.1	RPL21P10	5.95	9.97e-09	1.22e-05	0.51	0.37	Fibroblast growth factor basic levels;	chr14:77789795	chr14:77683202~77683989:-
OV	cis	rs7811142	0.83	rs6979910	ENSG00000242294.5	STAG3L5P	5.95	1e-08	1.23e-05	0.38	0.37	Platelet count;	chr7:100343007	chr7:100336079~100351900:+
OV	cis	rs7044106	0.734	rs12553070	ENSG00000226752.6	PSMD5-AS1	-5.95	1.01e-08	1.24e-05	-0.41	-0.37	Hip circumference adjusted for BMI;	chr9:120722988	chr9:120824828~120854385:+
OV	cis	rs7044106	0.791	rs12554440	ENSG00000226752.6	PSMD5-AS1	-5.95	1.01e-08	1.24e-05	-0.41	-0.37	Hip circumference adjusted for BMI;	chr9:120723055	chr9:120824828~120854385:+
OV	cis	rs67180937	0.645	rs1909197	ENSG00000272750.1	RP11-378J18.8	-5.95	1.01e-08	1.24e-05	-0.43	-0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222645879	chr1:222658867~222661512:-
OV	cis	rs2581828	0.618	rs7615099	ENSG00000242142.1	SERBP1P3	-5.95	1.01e-08	1.24e-05	-0.44	-0.37	Crohn's disease;	chr3:53109885	chr3:53064283~53065091:-
OV	cis	rs853679	0.517	rs9380058	ENSG00000219392.1	RP1-265C24.5	-5.95	1.02e-08	1.24e-05	-0.47	-0.37	Depression;	chr6:28159666	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9393898	ENSG00000219392.1	RP1-265C24.5	-5.95	1.02e-08	1.24e-05	-0.47	-0.37	Depression;	chr6:28162598	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9295761	ENSG00000219392.1	RP1-265C24.5	-5.95	1.02e-08	1.24e-05	-0.47	-0.37	Depression;	chr6:28180209	chr6:28115628~28116551:+
OV	cis	rs2729354	0.502	rs2848641	ENSG00000265566.2	RN7SL605P	-5.95	1.02e-08	1.24e-05	-0.5	-0.37	Blood protein levels;	chr11:57495595	chr11:57528085~57528365:-
OV	cis	rs4713118	0.629	rs203890	ENSG00000219392.1	RP1-265C24.5	-5.95	1.02e-08	1.24e-05	-0.45	-0.37	Parkinson's disease;	chr6:28054470	chr6:28115628~28116551:+
OV	cis	rs7626444	0.625	rs843541	ENSG00000272359.1	U4	-5.95	1.02e-08	1.25e-05	-0.37	-0.37	Monocyte count;	chr3:196748879	chr3:196747192~196747324:-
OV	cis	rs2282300	1	rs12575085	ENSG00000254532.1	RP11-624D11.2	5.95	1.02e-08	1.25e-05	0.5	0.37	Morning vs. evening chronotype;	chr11:30406715	chr11:30044058~30084343:-
OV	cis	rs5742933	0.857	rs7571089	ENSG00000253559.1	OSGEPL1-AS1	5.95	1.03e-08	1.25e-05	0.38	0.37	Ferritin levels;	chr2:189697067	chr2:189762704~189765556:+
OV	cis	rs9487094	0.67	rs729888	ENSG00000260273.1	RP11-425D10.10	-5.95	1.03e-08	1.25e-05	-0.39	-0.37	Height;	chr6:109636120	chr6:109382795~109383666:+
OV	cis	rs4713118	0.868	rs742047	ENSG00000220721.1	OR1F12	5.95	1.03e-08	1.26e-05	0.42	0.37	Parkinson's disease;	chr6:27771601	chr6:28073316~28074233:+
OV	cis	rs4660456	0.913	rs2744799	ENSG00000237899.1	RP4-739H11.3	5.95	1.03e-08	1.26e-05	0.55	0.37	Platelet count;	chr1:40719862	chr1:40669089~40687588:-
OV	cis	rs4660456	0.913	rs12727412	ENSG00000237899.1	RP4-739H11.3	-5.95	1.03e-08	1.26e-05	-0.55	-0.37	Platelet count;	chr1:40723243	chr1:40669089~40687588:-
OV	cis	rs4660456	0.913	rs4660448	ENSG00000237899.1	RP4-739H11.3	-5.95	1.03e-08	1.26e-05	-0.55	-0.37	Platelet count;	chr1:40724682	chr1:40669089~40687588:-
OV	cis	rs4660456	0.913	rs7532802	ENSG00000237899.1	RP4-739H11.3	-5.95	1.03e-08	1.26e-05	-0.55	-0.37	Platelet count;	chr1:40725528	chr1:40669089~40687588:-
OV	cis	rs4660456	0.913	rs2361648	ENSG00000237899.1	RP4-739H11.3	-5.95	1.03e-08	1.26e-05	-0.55	-0.37	Platelet count;	chr1:40726825	chr1:40669089~40687588:-
OV	cis	rs4660456	0.913	rs6675886	ENSG00000237899.1	RP4-739H11.3	-5.95	1.03e-08	1.26e-05	-0.55	-0.37	Platelet count;	chr1:40727955	chr1:40669089~40687588:-
OV	cis	rs4660456	0.83	rs12742219	ENSG00000237899.1	RP4-739H11.3	-5.95	1.03e-08	1.26e-05	-0.55	-0.37	Platelet count;	chr1:40728665	chr1:40669089~40687588:-
OV	cis	rs4660456	0.913	rs6668453	ENSG00000237899.1	RP4-739H11.3	-5.95	1.03e-08	1.26e-05	-0.55	-0.37	Platelet count;	chr1:40733299	chr1:40669089~40687588:-
OV	cis	rs4660456	0.913	rs35881320	ENSG00000237899.1	RP4-739H11.3	-5.95	1.03e-08	1.26e-05	-0.55	-0.37	Platelet count;	chr1:40733893	chr1:40669089~40687588:-
OV	cis	rs4660456	0.871	rs34512220	ENSG00000237899.1	RP4-739H11.3	-5.95	1.03e-08	1.26e-05	-0.55	-0.37	Platelet count;	chr1:40733912	chr1:40669089~40687588:-
OV	cis	rs4660456	0.913	rs6664044	ENSG00000237899.1	RP4-739H11.3	-5.95	1.03e-08	1.26e-05	-0.55	-0.37	Platelet count;	chr1:40735089	chr1:40669089~40687588:-
OV	cis	rs4660456	0.913	rs6702983	ENSG00000237899.1	RP4-739H11.3	-5.95	1.03e-08	1.26e-05	-0.55	-0.37	Platelet count;	chr1:40735585	chr1:40669089~40687588:-
OV	cis	rs4660456	0.913	rs12566733	ENSG00000237899.1	RP4-739H11.3	-5.95	1.03e-08	1.26e-05	-0.55	-0.37	Platelet count;	chr1:40736067	chr1:40669089~40687588:-
OV	cis	rs35160687	0.871	rs2278105	ENSG00000273080.1	RP11-301O19.1	5.94	1.04e-08	1.26e-05	0.36	0.37	Night sleep phenotypes;	chr2:86239393	chr2:86195590~86196049:+
OV	cis	rs7626444	0.625	rs7648479	ENSG00000272359.1	U4	-5.94	1.04e-08	1.27e-05	-0.37	-0.37	Monocyte count;	chr3:196750342	chr3:196747192~196747324:-
OV	cis	rs9487094	0.666	rs9480958	ENSG00000260273.1	RP11-425D10.10	-5.94	1.04e-08	1.27e-05	-0.38	-0.37	Height;	chr6:109432968	chr6:109382795~109383666:+
OV	cis	rs5742933	0.857	rs2289226	ENSG00000253559.1	OSGEPL1-AS1	-5.94	1.04e-08	1.27e-05	-0.37	-0.37	Ferritin levels;	chr2:189661479	chr2:189762704~189765556:+
OV	cis	rs853679	0.517	rs9393895	ENSG00000219392.1	RP1-265C24.5	-5.94	1.04e-08	1.27e-05	-0.47	-0.37	Depression;	chr6:28159843	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9357066	ENSG00000219392.1	RP1-265C24.5	-5.94	1.04e-08	1.27e-05	-0.47	-0.37	Depression;	chr6:28162053	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9368556	ENSG00000219392.1	RP1-265C24.5	-5.94	1.04e-08	1.27e-05	-0.47	-0.37	Depression;	chr6:28163375	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9368557	ENSG00000219392.1	RP1-265C24.5	-5.94	1.04e-08	1.27e-05	-0.47	-0.37	Depression;	chr6:28163759	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9380059	ENSG00000219392.1	RP1-265C24.5	-5.94	1.04e-08	1.27e-05	-0.47	-0.37	Depression;	chr6:28164580	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9380060	ENSG00000219392.1	RP1-265C24.5	-5.94	1.04e-08	1.27e-05	-0.47	-0.37	Depression;	chr6:28164825	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs35227624	ENSG00000219392.1	RP1-265C24.5	-5.94	1.04e-08	1.27e-05	-0.47	-0.37	Depression;	chr6:28164948	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9380061	ENSG00000219392.1	RP1-265C24.5	-5.94	1.04e-08	1.27e-05	-0.47	-0.37	Depression;	chr6:28165025	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9368558	ENSG00000219392.1	RP1-265C24.5	-5.94	1.04e-08	1.27e-05	-0.47	-0.37	Depression;	chr6:28165528	chr6:28115628~28116551:+
OV	cis	rs4713118	0.587	rs9393899	ENSG00000219392.1	RP1-265C24.5	-5.94	1.04e-08	1.27e-05	-0.47	-0.37	Parkinson's disease;	chr6:28165750	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs4713150	ENSG00000219392.1	RP1-265C24.5	-5.94	1.04e-08	1.27e-05	-0.47	-0.37	Depression;	chr6:28168434	chr6:28115628~28116551:+
OV	cis	rs4713118	0.527	rs4713151	ENSG00000219392.1	RP1-265C24.5	-5.94	1.04e-08	1.27e-05	-0.47	-0.37	Parkinson's disease;	chr6:28168578	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9393901	ENSG00000219392.1	RP1-265C24.5	-5.94	1.04e-08	1.27e-05	-0.47	-0.37	Depression;	chr6:28169019	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs3173443	ENSG00000219392.1	RP1-265C24.5	-5.94	1.04e-08	1.27e-05	-0.47	-0.37	Depression;	chr6:28169249	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs4713152	ENSG00000219392.1	RP1-265C24.5	-5.94	1.04e-08	1.27e-05	-0.47	-0.37	Depression;	chr6:28169676	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9348797	ENSG00000219392.1	RP1-265C24.5	-5.94	1.04e-08	1.27e-05	-0.47	-0.37	Depression;	chr6:28169755	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9380062	ENSG00000219392.1	RP1-265C24.5	-5.94	1.04e-08	1.27e-05	-0.47	-0.37	Depression;	chr6:28169791	chr6:28115628~28116551:+
OV	cis	rs853679	0.542	rs9380063	ENSG00000219392.1	RP1-265C24.5	-5.94	1.04e-08	1.27e-05	-0.47	-0.37	Depression;	chr6:28170075	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs12332979	ENSG00000219392.1	RP1-265C24.5	-5.94	1.04e-08	1.27e-05	-0.47	-0.37	Depression;	chr6:28173770	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs67878650	ENSG00000219392.1	RP1-265C24.5	-5.94	1.04e-08	1.27e-05	-0.47	-0.37	Depression;	chr6:28174809	chr6:28115628~28116551:+
OV	cis	rs853679	0.569	rs9348798	ENSG00000219392.1	RP1-265C24.5	-5.94	1.04e-08	1.27e-05	-0.47	-0.37	Depression;	chr6:28175233	chr6:28115628~28116551:+
OV	cis	rs853679	0.517	rs9380065	ENSG00000219392.1	RP1-265C24.5	-5.94	1.04e-08	1.27e-05	-0.47	-0.37	Depression;	chr6:28176973	chr6:28115628~28116551:+
OV	cis	rs67311347	1	rs73078123	ENSG00000223797.4	ENTPD3-AS1	5.94	1.05e-08	1.27e-05	0.42	0.37	Renal cell carcinoma;	chr3:40417472	chr3:40313802~40453329:-
OV	cis	rs7044106	0.791	rs735109	ENSG00000226752.6	PSMD5-AS1	-5.94	1.05e-08	1.28e-05	-0.41	-0.37	Hip circumference adjusted for BMI;	chr9:120726601	chr9:120824828~120854385:+
OV	cis	rs7626444	0.625	rs2669638	ENSG00000272359.1	U4	-5.94	1.05e-08	1.28e-05	-0.38	-0.37	Monocyte count;	chr3:196750527	chr3:196747192~196747324:-
OV	cis	rs7626444	0.625	rs2686593	ENSG00000272359.1	U4	-5.94	1.05e-08	1.28e-05	-0.38	-0.37	Monocyte count;	chr3:196750530	chr3:196747192~196747324:-
OV	cis	rs801193	0.901	rs4273746	ENSG00000236529.1	RP13-254B10.1	-5.94	1.06e-08	1.29e-05	-0.39	-0.37	Aortic root size;	chr7:66836124	chr7:65840212~65840596:+
OV	cis	rs10740039	0.583	rs9415611	ENSG00000254271.1	RP11-131N11.4	-5.94	1.07e-08	1.3e-05	-0.48	-0.37	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60743440	chr10:60734342~60741828:+
OV	cis	rs7017914	0.905	rs12542300	ENSG00000223220.1	Y_RNA	-5.94	1.07e-08	1.3e-05	-0.39	-0.37	Bone mineral density;	chr8:71039160	chr8:70780914~70781008:-
OV	cis	rs8005677	0.798	rs4982713	ENSG00000257285.4	RP11-298I3.1	5.94	1.07e-08	1.3e-05	0.45	0.37	Cognitive ability (multi-trait analysis);	chr14:22934893	chr14:22929609~22955562:+
OV	cis	rs8005677	0.798	rs35615180	ENSG00000257285.4	RP11-298I3.1	5.94	1.07e-08	1.3e-05	0.45	0.37	Cognitive ability (multi-trait analysis);	chr14:22935180	chr14:22929609~22955562:+
OV	cis	rs4380275	0.782	rs4335978	ENSG00000272342.1	RP13-539J13.1	5.94	1.07e-08	1.3e-05	0.42	0.37	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:750078	chr2:739588~740164:-
OV	cis	rs801193	1	rs2286684	ENSG00000236529.1	RP13-254B10.1	-5.94	1.08e-08	1.31e-05	-0.39	-0.37	Aortic root size;	chr7:66664843	chr7:65840212~65840596:+
OV	cis	rs801193	0.935	rs2286683	ENSG00000236529.1	RP13-254B10.1	-5.94	1.08e-08	1.31e-05	-0.39	-0.37	Aortic root size;	chr7:66664856	chr7:65840212~65840596:+
OV	cis	rs34375054	0.735	rs34961756	ENSG00000279233.1	RP11-158L12.4	5.94	1.08e-08	1.31e-05	0.29	0.37	Post bronchodilator FEV1/FVC ratio;	chr12:125144052	chr12:125138245~125141711:+
OV	cis	rs1185460	0.934	rs1006195	ENSG00000271751.1	RP11-110I1.14	5.94	1.08e-08	1.31e-05	0.44	0.37	Coronary artery disease;	chr11:119088159	chr11:119065263~119065677:-
OV	cis	rs7626444	0.565	rs7613010	ENSG00000272359.1	U4	-5.94	1.08e-08	1.31e-05	-0.38	-0.37	Monocyte count;	chr3:196763350	chr3:196747192~196747324:-
OV	cis	rs7626444	0.605	rs7642801	ENSG00000272359.1	U4	-5.94	1.08e-08	1.31e-05	-0.38	-0.37	Monocyte count;	chr3:196763435	chr3:196747192~196747324:-
OV	cis	rs1185460	0.967	rs1168568	ENSG00000271751.1	RP11-110I1.14	-5.94	1.09e-08	1.32e-05	-0.45	-0.37	Coronary artery disease;	chr11:119079089	chr11:119065263~119065677:-
OV	cis	rs1185460	0.967	rs1307145	ENSG00000271751.1	RP11-110I1.14	-5.94	1.09e-08	1.32e-05	-0.45	-0.37	Coronary artery disease;	chr11:119079507	chr11:119065263~119065677:-
OV	cis	rs4713118	0.513	rs149950	ENSG00000220721.1	OR1F12	5.94	1.09e-08	1.32e-05	0.39	0.37	Parkinson's disease;	chr6:28065261	chr6:28073316~28074233:+
OV	cis	rs4713118	0.513	rs149951	ENSG00000220721.1	OR1F12	5.94	1.09e-08	1.32e-05	0.39	0.37	Parkinson's disease;	chr6:28065309	chr6:28073316~28074233:+
OV	cis	rs853679	0.527	rs9461443	ENSG00000220721.1	OR1F12	5.94	1.09e-08	1.32e-05	0.43	0.37	Depression;	chr6:28226851	chr6:28073316~28074233:+
OV	cis	rs853679	0.55	rs34477097	ENSG00000220721.1	OR1F12	5.94	1.09e-08	1.32e-05	0.43	0.37	Depression;	chr6:28229408	chr6:28073316~28074233:+
OV	cis	rs8005677	0.828	rs35085068	ENSG00000257285.4	RP11-298I3.1	5.94	1.09e-08	1.32e-05	0.45	0.37	Cognitive ability (multi-trait analysis);	chr14:22940700	chr14:22929609~22955562:+
OV	cis	rs8005677	0.828	rs4981451	ENSG00000257285.4	RP11-298I3.1	5.94	1.09e-08	1.32e-05	0.45	0.37	Cognitive ability (multi-trait analysis);	chr14:22941072	chr14:22929609~22955562:+
OV	cis	rs8005677	0.798	rs4536383	ENSG00000257285.4	RP11-298I3.1	5.94	1.09e-08	1.32e-05	0.45	0.37	Cognitive ability (multi-trait analysis);	chr14:22941717	chr14:22929609~22955562:+
OV	cis	rs8005677	0.828	rs34584578	ENSG00000257285.4	RP11-298I3.1	5.94	1.09e-08	1.32e-05	0.45	0.37	Cognitive ability (multi-trait analysis);	chr14:22942481	chr14:22929609~22955562:+
OV	cis	rs7617773	0.817	rs9819094	ENSG00000228638.1	FCF1P2	-5.94	1.09e-08	1.32e-05	-0.43	-0.37	Coronary artery disease;	chr3:48278068	chr3:48290793~48291375:-
OV	cis	rs801193	1	rs10234018	ENSG00000236529.1	RP13-254B10.1	-5.93	1.09e-08	1.32e-05	-0.37	-0.37	Aortic root size;	chr7:66681297	chr7:65840212~65840596:+
OV	cis	rs11690935	0.688	rs7600835	ENSG00000228389.1	AC068039.4	5.93	1.1e-08	1.33e-05	0.39	0.37	Schizophrenia;	chr2:171665317	chr2:171773482~171775844:+
OV	cis	rs8062405	1	rs12325113	ENSG00000259982.1	CDC37P1	5.93	1.11e-08	1.34e-05	0.46	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28700294~28701540:-
OV	cis	rs56163509	1	rs56163509	ENSG00000259982.1	CDC37P1	5.93	1.11e-08	1.34e-05	0.46	0.37	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28700294~28701540:-
OV	cis	rs8062405	0.964	rs7187333	ENSG00000259982.1	CDC37P1	5.93	1.11e-08	1.34e-05	0.46	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28700294~28701540:-
OV	cis	rs8062405	1	rs62037369	ENSG00000259982.1	CDC37P1	5.93	1.11e-08	1.34e-05	0.46	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28700294~28701540:-
OV	cis	rs8062405	0.965	rs7359397	ENSG00000259982.1	CDC37P1	5.93	1.11e-08	1.34e-05	0.46	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28700294~28701540:-
OV	cis	rs7044106	0.762	rs13291660	ENSG00000226752.6	PSMD5-AS1	-5.93	1.11e-08	1.34e-05	-0.43	-0.37	Hip circumference adjusted for BMI;	chr9:120630470	chr9:120824828~120854385:+
OV	cis	rs8105895	1	rs2359811	ENSG00000269742.1	BNIP3P29	5.93	1.11e-08	1.34e-05	0.56	0.37	Body mass index (change over time);	chr19:21970074	chr19:22065828~22066398:-
OV	cis	rs7044106	0.791	rs10739572	ENSG00000226752.6	PSMD5-AS1	-5.93	1.11e-08	1.35e-05	-0.41	-0.37	Hip circumference adjusted for BMI;	chr9:120727537	chr9:120824828~120854385:+
OV	cis	rs7017914	0.628	rs55740254	ENSG00000223220.1	Y_RNA	5.93	1.12e-08	1.35e-05	0.41	0.37	Bone mineral density;	chr8:70928325	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs2017035	ENSG00000223220.1	Y_RNA	5.93	1.12e-08	1.35e-05	0.41	0.37	Bone mineral density;	chr8:70929571	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs10504487	ENSG00000223220.1	Y_RNA	5.93	1.12e-08	1.35e-05	0.41	0.37	Bone mineral density;	chr8:70931364	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs34366597	ENSG00000223220.1	Y_RNA	5.93	1.12e-08	1.35e-05	0.41	0.37	Bone mineral density;	chr8:70932658	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs7839977	ENSG00000223220.1	Y_RNA	5.93	1.12e-08	1.35e-05	0.41	0.37	Bone mineral density;	chr8:70933067	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs1493199	ENSG00000223220.1	Y_RNA	5.93	1.12e-08	1.35e-05	0.41	0.37	Bone mineral density;	chr8:70934269	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs7814774	ENSG00000223220.1	Y_RNA	5.93	1.12e-08	1.35e-05	0.41	0.37	Bone mineral density;	chr8:70934881	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs62506898	ENSG00000223220.1	Y_RNA	5.93	1.12e-08	1.35e-05	0.41	0.37	Bone mineral density;	chr8:70935267	chr8:70780914~70781008:-
OV	cis	rs7017914	0.616	rs17689943	ENSG00000223220.1	Y_RNA	5.93	1.12e-08	1.35e-05	0.41	0.37	Bone mineral density;	chr8:70936145	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs17689989	ENSG00000223220.1	Y_RNA	5.93	1.12e-08	1.35e-05	0.41	0.37	Bone mineral density;	chr8:70936769	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs17768191	ENSG00000223220.1	Y_RNA	5.93	1.12e-08	1.35e-05	0.41	0.37	Bone mineral density;	chr8:70939642	chr8:70780914~70781008:-
OV	cis	rs7017914	0.629	rs17690181	ENSG00000223220.1	Y_RNA	5.93	1.12e-08	1.35e-05	0.41	0.37	Bone mineral density;	chr8:70942231	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs13273873	ENSG00000223220.1	Y_RNA	5.93	1.12e-08	1.35e-05	0.41	0.37	Bone mineral density;	chr8:70942984	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs13280740	ENSG00000223220.1	Y_RNA	5.93	1.12e-08	1.35e-05	0.41	0.37	Bone mineral density;	chr8:70946286	chr8:70780914~70781008:-
OV	cis	rs853679	0.55	rs1225598	ENSG00000219392.1	RP1-265C24.5	-5.93	1.12e-08	1.35e-05	-0.47	-0.37	Depression;	chr6:28193021	chr6:28115628~28116551:+
OV	cis	rs7044106	0.718	rs1981021	ENSG00000226752.6	PSMD5-AS1	-5.93	1.12e-08	1.35e-05	-0.43	-0.37	Hip circumference adjusted for BMI;	chr9:120626115	chr9:120824828~120854385:+
OV	cis	rs7044106	0.734	rs1981020	ENSG00000226752.6	PSMD5-AS1	-5.93	1.12e-08	1.35e-05	-0.43	-0.37	Hip circumference adjusted for BMI;	chr9:120626186	chr9:120824828~120854385:+
OV	cis	rs853679	0.55	rs1225598	ENSG00000220721.1	OR1F12	5.93	1.12e-08	1.36e-05	0.44	0.37	Depression;	chr6:28193021	chr6:28073316~28074233:+
OV	cis	rs494459	0.756	rs570806	ENSG00000278376.1	RP11-158I9.8	-5.93	1.13e-08	1.36e-05	-0.36	-0.37	Height;	chr11:118786602	chr11:118791254~118793137:+
OV	cis	rs801193	1	rs10274773	ENSG00000236529.1	RP13-254B10.1	-5.93	1.13e-08	1.36e-05	-0.39	-0.37	Aortic root size;	chr7:66668591	chr7:65840212~65840596:+
OV	cis	rs801193	1	rs7785213	ENSG00000236529.1	RP13-254B10.1	-5.93	1.13e-08	1.36e-05	-0.39	-0.37	Aortic root size;	chr7:66673991	chr7:65840212~65840596:+
OV	cis	rs3814244	0.528	rs2870960	ENSG00000255733.4	IFNG-AS1	5.93	1.13e-08	1.36e-05	0.37	0.37	Itch intensity from mosquito bite adjusted by bite size;	chr12:68032848	chr12:67989445~68234686:+
OV	cis	rs4660456	0.913	rs3767950	ENSG00000237899.1	RP4-739H11.3	-5.93	1.14e-08	1.37e-05	-0.55	-0.37	Platelet count;	chr1:40767541	chr1:40669089~40687588:-
OV	cis	rs4660456	0.913	rs3754179	ENSG00000237899.1	RP4-739H11.3	-5.93	1.14e-08	1.37e-05	-0.55	-0.37	Platelet count;	chr1:40768464	chr1:40669089~40687588:-
OV	cis	rs853679	0.567	rs13196606	ENSG00000216901.1	AL022393.7	5.93	1.14e-08	1.37e-05	0.45	0.37	Depression;	chr6:28402301	chr6:28176188~28176674:+
OV	cis	rs2243480	1	rs160652	ENSG00000222364.1	RNU6-96P	-5.93	1.14e-08	1.37e-05	-0.59	-0.37	Diabetic kidney disease;	chr7:66073444	chr7:66395191~66395286:+
OV	cis	rs7044106	0.708	rs10760113	ENSG00000226752.6	PSMD5-AS1	-5.93	1.15e-08	1.38e-05	-0.43	-0.37	Hip circumference adjusted for BMI;	chr9:120711772	chr9:120824828~120854385:+
OV	cis	rs2732480	1	rs2732480	ENSG00000258273.1	RP11-370I10.4	5.93	1.15e-08	1.38e-05	0.43	0.37	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48342520	chr12:48333755~48333901:-
OV	cis	rs7301826	1	rs1609985	ENSG00000256250.1	RP11-989F5.1	-5.92	1.15e-08	1.39e-05	-0.37	-0.37	Plasma plasminogen activator levels;	chr12:130835625	chr12:130810606~130812438:+
OV	cis	rs494459	0.838	rs566733	ENSG00000255422.1	AP002954.4	-5.92	1.16e-08	1.4e-05	-0.41	-0.37	Height;	chr11:118737916	chr11:118704607~118750263:+
OV	cis	rs611744	0.658	rs2443775	ENSG00000253754.1	RP11-35G22.1	5.92	1.16e-08	1.4e-05	0.41	0.37	Dupuytren's disease;	chr8:108050253	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs596245	ENSG00000253754.1	RP11-35G22.1	-5.92	1.17e-08	1.41e-05	-0.4	-0.37	Dupuytren's disease;	chr8:108228593	chr8:108226200~108227544:+
OV	cis	rs4563143	0.675	rs112383987	ENSG00000267243.4	AC005307.3	-5.92	1.17e-08	1.41e-05	-0.6	-0.37	Methadone dose in opioid dependence;	chr19:28770174	chr19:28435388~28727777:-
OV	cis	rs7927771	0.697	rs11039307	ENSG00000280615.1	Y_RNA	-5.92	1.18e-08	1.42e-05	-0.42	-0.37	Subjective well-being;	chr11:47589600	chr11:47614898~47614994:-
OV	cis	rs12134133	1	rs7532664	ENSG00000274245.1	RP11-357P18.2	5.92	1.18e-08	1.42e-05	0.49	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207253598	chr1:207372559~207373252:+
OV	cis	rs12134133	1	rs55638602	ENSG00000274245.1	RP11-357P18.2	5.92	1.18e-08	1.42e-05	0.49	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207255597	chr1:207372559~207373252:+
OV	cis	rs12134133	1	rs4844588	ENSG00000274245.1	RP11-357P18.2	5.92	1.18e-08	1.42e-05	0.49	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207256323	chr1:207372559~207373252:+
OV	cis	rs12134133	0.927	rs4844589	ENSG00000274245.1	RP11-357P18.2	5.92	1.18e-08	1.42e-05	0.49	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207259285	chr1:207372559~207373252:+
OV	cis	rs12134133	1	rs6540893	ENSG00000274245.1	RP11-357P18.2	5.92	1.18e-08	1.42e-05	0.49	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207262382	chr1:207372559~207373252:+
OV	cis	rs12134133	1	rs61822674	ENSG00000274245.1	RP11-357P18.2	5.92	1.18e-08	1.42e-05	0.49	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207263378	chr1:207372559~207373252:+
OV	cis	rs12134133	1	rs10442696	ENSG00000274245.1	RP11-357P18.2	5.92	1.18e-08	1.42e-05	0.49	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207264783	chr1:207372559~207373252:+
OV	cis	rs12134133	1	rs7535532	ENSG00000274245.1	RP11-357P18.2	5.92	1.18e-08	1.42e-05	0.49	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207264991	chr1:207372559~207373252:+
OV	cis	rs12134133	1	rs7543117	ENSG00000274245.1	RP11-357P18.2	5.92	1.18e-08	1.42e-05	0.49	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265351	chr1:207372559~207373252:+
OV	cis	rs12134133	1	rs6684804	ENSG00000274245.1	RP11-357P18.2	5.92	1.18e-08	1.42e-05	0.49	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207265670	chr1:207372559~207373252:+
OV	cis	rs12134133	1	rs11582249	ENSG00000274245.1	RP11-357P18.2	5.92	1.18e-08	1.42e-05	0.49	0.37	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207268263	chr1:207372559~207373252:+
OV	cis	rs858239	0.6	rs1115941	ENSG00000230042.1	AK3P3	-5.92	1.18e-08	1.42e-05	-0.39	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23097569	chr7:23129178~23129841:+
OV	cis	rs3814244	0.569	rs2051993	ENSG00000255733.4	IFNG-AS1	5.92	1.19e-08	1.43e-05	0.37	0.37	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019898	chr12:67989445~68234686:+
OV	cis	rs7626444	0.584	rs7633044	ENSG00000272359.1	U4	-5.92	1.19e-08	1.43e-05	-0.38	-0.37	Monocyte count;	chr3:196763772	chr3:196747192~196747324:-
OV	cis	rs2286503	0.901	rs2286505	ENSG00000221740.1	SNORD93	5.92	1.19e-08	1.43e-05	0.43	0.37	Fibrinogen;	chr7:22815221	chr7:22856613~22856686:+
OV	cis	rs2243480	1	rs316327	ENSG00000222364.1	RNU6-96P	5.92	1.2e-08	1.44e-05	0.55	0.37	Diabetic kidney disease;	chr7:66144214	chr7:66395191~66395286:+
OV	cis	rs7927771	0.832	rs56030824	ENSG00000280615.1	Y_RNA	-5.92	1.2e-08	1.44e-05	-0.46	-0.37	Subjective well-being;	chr11:47375802	chr11:47614898~47614994:-
OV	cis	rs3091242	0.935	rs3093632	ENSG00000224183.1	SDHDP6	-5.92	1.2e-08	1.44e-05	-0.42	-0.37	Erythrocyte sedimentation rate;	chr1:25357521	chr1:25294164~25294643:-
OV	cis	rs7927771	0.832	rs1542321	ENSG00000280615.1	Y_RNA	5.92	1.2e-08	1.44e-05	0.45	0.37	Subjective well-being;	chr11:47358064	chr11:47614898~47614994:-
OV	cis	rs4713118	0.662	rs149970	ENSG00000280107.1	AL022393.9	-5.92	1.2e-08	1.44e-05	-0.48	-0.37	Parkinson's disease;	chr6:28012442	chr6:28170845~28172521:+
OV	cis	rs7267979	0.753	rs404148	ENSG00000274973.1	RP13-401N8.7	-5.92	1.2e-08	1.45e-05	-0.43	-0.37	Liver enzyme levels (alkaline phosphatase);	chr20:25467295	chr20:25845497~25845862:+
OV	cis	rs2858942	0.602	rs1211375	ENSG00000268836.1	LA16c-OS12.2	-5.92	1.21e-08	1.45e-05	-0.38	-0.37	Mean corpuscular hemoglobin;	chr16:190281	chr16:185748~186294:-
OV	cis	rs2581828	0.646	rs9867023	ENSG00000242142.1	SERBP1P3	5.92	1.21e-08	1.45e-05	0.43	0.37	Crohn's disease;	chr3:53126116	chr3:53064283~53065091:-
OV	cis	rs2412819	0.571	rs112667279	ENSG00000249839.1	AC011330.5	-5.92	1.21e-08	1.45e-05	-0.52	-0.37	Lung cancer;	chr15:43649258	chr15:43663654~43684339:-
OV	cis	rs4563143	0.514	rs73030738	ENSG00000267243.4	AC005307.3	-5.91	1.21e-08	1.46e-05	-0.64	-0.37	Methadone dose in opioid dependence;	chr19:28821421	chr19:28435388~28727777:-
OV	cis	rs2581828	0.539	rs114317830	ENSG00000242142.1	SERBP1P3	-5.91	1.21e-08	1.46e-05	-0.44	-0.37	Crohn's disease;	chr3:53126253	chr3:53064283~53065091:-
OV	cis	rs2581828	0.539	rs114670283	ENSG00000242142.1	SERBP1P3	-5.91	1.21e-08	1.46e-05	-0.44	-0.37	Crohn's disease;	chr3:53126254	chr3:53064283~53065091:-
OV	cis	rs8062405	0.895	rs62036658	ENSG00000259982.1	CDC37P1	5.91	1.22e-08	1.46e-05	0.45	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28700294~28701540:-
OV	cis	rs67180937	0.921	rs2291834	ENSG00000272750.1	RP11-378J18.8	-5.91	1.22e-08	1.46e-05	-0.4	-0.37	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658953	chr1:222658867~222661512:-
OV	cis	rs3091242	0.933	rs35497030	ENSG00000224183.1	SDHDP6	5.91	1.23e-08	1.47e-05	0.42	0.37	Erythrocyte sedimentation rate;	chr1:25456575	chr1:25294164~25294643:-
OV	cis	rs2286503	1	rs2286498	ENSG00000221740.1	SNORD93	-5.91	1.23e-08	1.48e-05	-0.42	-0.37	Fibrinogen;	chr7:22817885	chr7:22856613~22856686:+
OV	cis	rs8062405	1	rs72793811	ENSG00000259982.1	CDC37P1	5.91	1.25e-08	1.49e-05	0.45	0.37	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28700294~28701540:-
OV	cis	rs2581828	0.632	rs73088322	ENSG00000242142.1	SERBP1P3	-5.91	1.25e-08	1.49e-05	-0.45	-0.37	Crohn's disease;	chr3:53107500	chr3:53064283~53065091:-
OV	cis	rs2581828	0.659	rs73088327	ENSG00000242142.1	SERBP1P3	-5.91	1.25e-08	1.49e-05	-0.45	-0.37	Crohn's disease;	chr3:53107533	chr3:53064283~53065091:-
OV	cis	rs4563143	0.663	rs5025682	ENSG00000267243.4	AC005307.3	-5.91	1.26e-08	1.5e-05	-0.58	-0.37	Methadone dose in opioid dependence;	chr19:28747763	chr19:28435388~28727777:-
OV	cis	rs4563143	0.663	rs73025068	ENSG00000267243.4	AC005307.3	-5.91	1.26e-08	1.5e-05	-0.58	-0.37	Methadone dose in opioid dependence;	chr19:28748091	chr19:28435388~28727777:-
OV	cis	rs4563143	0.634	rs113736470	ENSG00000267243.4	AC005307.3	-5.91	1.26e-08	1.5e-05	-0.58	-0.37	Methadone dose in opioid dependence;	chr19:28749218	chr19:28435388~28727777:-
OV	cis	rs17361889	0.502	rs10807780	ENSG00000224683.1	RPL36AP29	-5.91	1.26e-08	1.51e-05	-0.42	-0.37	Pediatric bone mineral content (hip);	chr7:16179743	chr7:16208945~16209265:+
OV	cis	rs7044106	0.615	rs10818470	ENSG00000226752.6	PSMD5-AS1	-5.91	1.27e-08	1.52e-05	-0.44	-0.36	Hip circumference adjusted for BMI;	chr9:120596926	chr9:120824828~120854385:+
OV	cis	rs7615952	0.546	rs11718647	ENSG00000171084.14	FAM86JP	5.9	1.28e-08	1.53e-05	0.59	0.36	Blood pressure (smoking interaction);	chr3:125633178	chr3:125916620~125930024:+
OV	cis	rs73019876	0.901	rs394457	ENSG00000269742.1	BNIP3P29	-5.9	1.28e-08	1.53e-05	-0.43	-0.36	Testicular germ cell tumor;	chr19:22047626	chr19:22065828~22066398:-
OV	cis	rs13315649	0.562	rs6797317	ENSG00000277250.1	Metazoa_SRP	-5.9	1.28e-08	1.53e-05	-0.45	-0.36	Sum eosinophil basophil counts;	chr3:128684381	chr3:128673681~128674021:-
OV	cis	rs7487637	0.529	rs11168244	ENSG00000276691.1	RP5-1057I20.5	5.9	1.29e-08	1.54e-05	0.39	0.36	Mononucleosis;	chr12:47809158	chr12:47788426~47788971:+
OV	cis	rs1729407	0.647	rs2727791	ENSG00000254851.1	RP11-109L13.1	-5.9	1.29e-08	1.54e-05	-0.45	-0.36	Apolipoprotein A-IV levels;	chr11:116813846	chr11:117135528~117138582:+
OV	cis	rs3091242	1	rs3091242	ENSG00000224183.1	SDHDP6	-5.9	1.31e-08	1.56e-05	-0.42	-0.36	Erythrocyte sedimentation rate;	chr1:25348294	chr1:25294164~25294643:-
OV	cis	rs3091242	0.967	rs3091240	ENSG00000224183.1	SDHDP6	-5.9	1.31e-08	1.56e-05	-0.42	-0.36	Erythrocyte sedimentation rate;	chr1:25350444	chr1:25294164~25294643:-
OV	cis	rs4660456	0.83	rs12566786	ENSG00000237899.1	RP4-739H11.3	-5.9	1.31e-08	1.56e-05	-0.55	-0.36	Platelet count;	chr1:40742709	chr1:40669089~40687588:-
OV	cis	rs4660456	0.871	rs2274957	ENSG00000237899.1	RP4-739H11.3	-5.9	1.31e-08	1.56e-05	-0.55	-0.36	Platelet count;	chr1:40747290	chr1:40669089~40687588:-
OV	cis	rs4660456	0.913	rs4660173	ENSG00000237899.1	RP4-739H11.3	-5.9	1.31e-08	1.56e-05	-0.55	-0.36	Platelet count;	chr1:40747876	chr1:40669089~40687588:-
OV	cis	rs4660456	0.913	rs4660452	ENSG00000237899.1	RP4-739H11.3	-5.9	1.31e-08	1.56e-05	-0.55	-0.36	Platelet count;	chr1:40748519	chr1:40669089~40687588:-
OV	cis	rs4660456	0.913	rs12567925	ENSG00000237899.1	RP4-739H11.3	-5.9	1.31e-08	1.56e-05	-0.55	-0.36	Platelet count;	chr1:40751428	chr1:40669089~40687588:-
OV	cis	rs4660456	0.913	rs12728776	ENSG00000237899.1	RP4-739H11.3	-5.9	1.31e-08	1.56e-05	-0.55	-0.36	Platelet count;	chr1:40751718	chr1:40669089~40687588:-
OV	cis	rs4660456	0.913	rs12567755	ENSG00000237899.1	RP4-739H11.3	-5.9	1.31e-08	1.56e-05	-0.55	-0.36	Platelet count;	chr1:40751813	chr1:40669089~40687588:-
OV	cis	rs858239	0.6	rs6960001	ENSG00000230042.1	AK3P3	-5.9	1.32e-08	1.57e-05	-0.38	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23091257	chr7:23129178~23129841:+
OV	cis	rs858239	0.6	rs10237755	ENSG00000230042.1	AK3P3	-5.9	1.32e-08	1.57e-05	-0.38	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23091945	chr7:23129178~23129841:+
OV	cis	rs858239	0.6	rs6961131	ENSG00000230042.1	AK3P3	-5.9	1.32e-08	1.57e-05	-0.38	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23095171	chr7:23129178~23129841:+
OV	cis	rs7829975	0.54	rs2976909	ENSG00000253981.4	ALG1L13P	-5.9	1.32e-08	1.57e-05	-0.44	-0.36	Mood instability;	chr8:8489180	chr8:8236003~8244667:-
OV	cis	rs1707322	1	rs785484	ENSG00000280836.1	AL355480.1	5.9	1.32e-08	1.58e-05	0.5	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46108343	chr1:45581219~45581321:-
OV	cis	rs301901	0.581	rs292175	ENSG00000250155.1	CTD-2353F22.1	-5.9	1.32e-08	1.58e-05	-0.42	-0.36	Height;	chr5:36832512	chr5:36666214~36725195:-
OV	cis	rs7626444	0.625	rs2686590	ENSG00000272359.1	U4	-5.9	1.32e-08	1.58e-05	-0.38	-0.36	Monocyte count;	chr3:196765568	chr3:196747192~196747324:-
OV	cis	rs11235843	0.929	rs11235844	ENSG00000255928.1	RP11-456I15.2	5.9	1.33e-08	1.59e-05	0.58	0.36	Hand grip strength;	chr11:73668030	chr11:73722349~73722694:+
OV	cis	rs2243480	1	rs160655	ENSG00000222364.1	RNU6-96P	-5.9	1.33e-08	1.59e-05	-0.59	-0.36	Diabetic kidney disease;	chr7:66068227	chr7:66395191~66395286:+
OV	cis	rs2243480	0.803	rs160649	ENSG00000222364.1	RNU6-96P	-5.9	1.33e-08	1.59e-05	-0.59	-0.36	Diabetic kidney disease;	chr7:66078212	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs160648	ENSG00000222364.1	RNU6-96P	-5.9	1.33e-08	1.59e-05	-0.59	-0.36	Diabetic kidney disease;	chr7:66078397	chr7:66395191~66395286:+
OV	cis	rs61990749	0.597	rs4903643	ENSG00000239272.1	RPL21P10	5.9	1.33e-08	1.59e-05	0.51	0.36	Fibroblast growth factor basic levels;	chr14:77788448	chr14:77683202~77683989:-
OV	cis	rs61990749	0.597	rs1477260	ENSG00000239272.1	RPL21P10	5.9	1.33e-08	1.59e-05	0.51	0.36	Fibroblast growth factor basic levels;	chr14:77790475	chr14:77683202~77683989:-
OV	cis	rs61990749	0.597	rs1008988	ENSG00000239272.1	RPL21P10	5.9	1.33e-08	1.59e-05	0.51	0.36	Fibroblast growth factor basic levels;	chr14:77794452	chr14:77683202~77683989:-
OV	cis	rs12134133	1	rs10494889	ENSG00000274245.1	RP11-357P18.2	5.9	1.34e-08	1.59e-05	0.47	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207286963	chr1:207372559~207373252:+
OV	cis	rs12134133	1	rs1429904	ENSG00000274245.1	RP11-357P18.2	5.9	1.34e-08	1.59e-05	0.47	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207288539	chr1:207372559~207373252:+
OV	cis	rs12134133	1	rs2782854	ENSG00000274245.1	RP11-357P18.2	5.9	1.34e-08	1.59e-05	0.47	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207289369	chr1:207372559~207373252:+
OV	cis	rs6700559	0.967	rs12041320	ENSG00000260088.1	RP11-92G12.3	-5.9	1.34e-08	1.6e-05	-0.39	-0.36	Coronary artery disease;	chr1:200652107	chr1:200669507~200694250:+
OV	cis	rs611744	0.81	rs672161	ENSG00000253754.1	RP11-35G22.1	-5.9	1.35e-08	1.6e-05	-0.41	-0.36	Dupuytren's disease;	chr8:108151953	chr8:108226200~108227544:+
OV	cis	rs611744	0.839	rs672552	ENSG00000253754.1	RP11-35G22.1	-5.9	1.35e-08	1.6e-05	-0.41	-0.36	Dupuytren's disease;	chr8:108151994	chr8:108226200~108227544:+
OV	cis	rs611744	0.87	rs613261	ENSG00000253754.1	RP11-35G22.1	-5.9	1.35e-08	1.6e-05	-0.41	-0.36	Dupuytren's disease;	chr8:108153720	chr8:108226200~108227544:+
OV	cis	rs611744	0.87	rs613179	ENSG00000253754.1	RP11-35G22.1	-5.9	1.35e-08	1.6e-05	-0.41	-0.36	Dupuytren's disease;	chr8:108153777	chr8:108226200~108227544:+
OV	cis	rs9660180	0.967	rs6603803	ENSG00000231050.1	RP1-140A9.1	5.89	1.35e-08	1.61e-05	0.39	0.36	Body mass index;	chr1:1881249	chr1:1891471~1892658:+
OV	cis	rs7017914	0.606	rs2035928	ENSG00000223220.1	Y_RNA	5.89	1.35e-08	1.61e-05	0.41	0.36	Bone mineral density;	chr8:71001320	chr8:70780914~70781008:-
OV	cis	rs7017914	0.606	rs2035927	ENSG00000223220.1	Y_RNA	5.89	1.35e-08	1.61e-05	0.41	0.36	Bone mineral density;	chr8:71001325	chr8:70780914~70781008:-
OV	cis	rs7017914	0.606	rs2035926	ENSG00000223220.1	Y_RNA	5.89	1.35e-08	1.61e-05	0.41	0.36	Bone mineral density;	chr8:71001339	chr8:70780914~70781008:-
OV	cis	rs62355901	0.505	rs62355912	ENSG00000271828.1	CTD-2310F14.1	5.89	1.36e-08	1.62e-05	0.8	0.36	Breast cancer;	chr5:56788004	chr5:56927874~56929573:+
OV	cis	rs4713118	0.513	rs149954	ENSG00000220721.1	OR1F12	5.89	1.36e-08	1.62e-05	0.39	0.36	Parkinson's disease;	chr6:28067468	chr6:28073316~28074233:+
OV	cis	rs7688540	0.623	rs11735968	ENSG00000275426.1	CH17-262A2.1	5.89	1.36e-08	1.62e-05	0.63	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245031	chr4:149738~150317:+
OV	cis	rs611744	0.967	rs688746	ENSG00000253754.1	RP11-35G22.1	-5.89	1.36e-08	1.62e-05	-0.4	-0.36	Dupuytren's disease;	chr8:108213496	chr8:108226200~108227544:+
OV	cis	rs611744	0.934	rs609102	ENSG00000253754.1	RP11-35G22.1	-5.89	1.36e-08	1.62e-05	-0.4	-0.36	Dupuytren's disease;	chr8:108215177	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs859788	ENSG00000253754.1	RP11-35G22.1	-5.89	1.36e-08	1.62e-05	-0.4	-0.36	Dupuytren's disease;	chr8:108215341	chr8:108226200~108227544:+
OV	cis	rs611744	1	rs611744	ENSG00000253754.1	RP11-35G22.1	-5.89	1.36e-08	1.62e-05	-0.4	-0.36	Dupuytren's disease;	chr8:108215779	chr8:108226200~108227544:+
OV	cis	rs62355901	0.599	rs12656399	ENSG00000271828.1	CTD-2310F14.1	5.89	1.36e-08	1.62e-05	0.75	0.36	Breast cancer;	chr5:56731016	chr5:56927874~56929573:+
OV	cis	rs1075265	0.783	rs718872	ENSG00000233266.1	HMGB1P31	5.89	1.37e-08	1.63e-05	0.44	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53946569	chr2:54051334~54051760:+
OV	cis	rs4713118	0.662	rs149948	ENSG00000219392.1	RP1-265C24.5	-5.89	1.37e-08	1.63e-05	-0.46	-0.36	Parkinson's disease;	chr6:28007039	chr6:28115628~28116551:+
OV	cis	rs62355901	0.599	rs12657013	ENSG00000271828.1	CTD-2310F14.1	5.89	1.37e-08	1.64e-05	0.68	0.36	Breast cancer;	chr5:56739441	chr5:56927874~56929573:+
OV	cis	rs992157	0.932	rs56109829	ENSG00000237281.1	CATIP-AS2	-5.89	1.38e-08	1.64e-05	-0.42	-0.36	Colorectal cancer;	chr2:218285017	chr2:218326889~218357966:-
OV	cis	rs4660456	0.913	rs12040422	ENSG00000237899.1	RP4-739H11.3	5.89	1.38e-08	1.64e-05	0.57	0.36	Platelet count;	chr1:40669239	chr1:40669089~40687588:-
OV	cis	rs611744	0.647	rs2594358	ENSG00000253754.1	RP11-35G22.1	-5.89	1.38e-08	1.64e-05	-0.41	-0.36	Dupuytren's disease;	chr8:108243789	chr8:108226200~108227544:+
OV	cis	rs2243480	1	rs1964692	ENSG00000222364.1	RNU6-96P	-5.89	1.39e-08	1.65e-05	-0.57	-0.36	Diabetic kidney disease;	chr7:65989196	chr7:66395191~66395286:+
OV	cis	rs2243480	0.901	rs2456483	ENSG00000222364.1	RNU6-96P	-5.89	1.39e-08	1.65e-05	-0.57	-0.36	Diabetic kidney disease;	chr7:65996588	chr7:66395191~66395286:+
OV	cis	rs2243480	0.901	rs2949697	ENSG00000222364.1	RNU6-96P	-5.89	1.39e-08	1.65e-05	-0.57	-0.36	Diabetic kidney disease;	chr7:65999249	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs1701750	ENSG00000222364.1	RNU6-96P	-5.89	1.39e-08	1.65e-05	-0.57	-0.36	Diabetic kidney disease;	chr7:66002158	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs1701758	ENSG00000222364.1	RNU6-96P	-5.89	1.39e-08	1.65e-05	-0.57	-0.36	Diabetic kidney disease;	chr7:66005214	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs781157	ENSG00000222364.1	RNU6-96P	-5.89	1.39e-08	1.65e-05	-0.57	-0.36	Diabetic kidney disease;	chr7:66013324	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs781156	ENSG00000222364.1	RNU6-96P	-5.89	1.39e-08	1.65e-05	-0.57	-0.36	Diabetic kidney disease;	chr7:66014154	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs781149	ENSG00000222364.1	RNU6-96P	-5.89	1.39e-08	1.65e-05	-0.57	-0.36	Diabetic kidney disease;	chr7:66016297	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs451396	ENSG00000222364.1	RNU6-96P	-5.89	1.39e-08	1.65e-05	-0.57	-0.36	Diabetic kidney disease;	chr7:66019087	chr7:66395191~66395286:+
OV	cis	rs2243480	0.901	rs58207111	ENSG00000222364.1	RNU6-96P	-5.89	1.39e-08	1.65e-05	-0.57	-0.36	Diabetic kidney disease;	chr7:66021736	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs1167613	ENSG00000222364.1	RNU6-96P	-5.89	1.39e-08	1.65e-05	-0.57	-0.36	Diabetic kidney disease;	chr7:66022452	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs1715235	ENSG00000222364.1	RNU6-96P	-5.89	1.39e-08	1.65e-05	-0.57	-0.36	Diabetic kidney disease;	chr7:66023407	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs313799	ENSG00000222364.1	RNU6-96P	-5.89	1.39e-08	1.65e-05	-0.57	-0.36	Diabetic kidney disease;	chr7:66029343	chr7:66395191~66395286:+
OV	cis	rs7927771	0.793	rs3740686	ENSG00000280615.1	Y_RNA	5.89	1.39e-08	1.65e-05	0.45	0.36	Subjective well-being;	chr11:47354812	chr11:47614898~47614994:-
OV	cis	rs12134133	1	rs6660254	ENSG00000274245.1	RP11-357P18.2	5.89	1.39e-08	1.65e-05	0.49	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207272746	chr1:207372559~207373252:+
OV	cis	rs2282300	0.637	rs2065418	ENSG00000254532.1	RP11-624D11.2	5.89	1.4e-08	1.66e-05	0.41	0.36	Morning vs. evening chronotype;	chr11:30400521	chr11:30044058~30084343:-
OV	cis	rs67180937	0.884	rs2291832	ENSG00000272750.1	RP11-378J18.8	-5.89	1.4e-08	1.66e-05	-0.4	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222653139	chr1:222658867~222661512:-
OV	cis	rs4660456	0.913	rs16827569	ENSG00000237899.1	RP4-739H11.3	-5.89	1.4e-08	1.66e-05	-0.54	-0.36	Platelet count;	chr1:40761655	chr1:40669089~40687588:-
OV	cis	rs4713118	0.868	rs35069907	ENSG00000220721.1	OR1F12	5.89	1.4e-08	1.66e-05	0.42	0.36	Parkinson's disease;	chr6:27778913	chr6:28073316~28074233:+
OV	cis	rs143626010	1	rs143626010	ENSG00000259982.1	CDC37P1	5.89	1.41e-08	1.67e-05	0.44	0.36	Mosquito bite size;	chr16:28528081	chr16:28700294~28701540:-
OV	cis	rs4660456	0.871	rs669072	ENSG00000237899.1	RP4-739H11.3	5.89	1.41e-08	1.67e-05	0.57	0.36	Platelet count;	chr1:40679946	chr1:40669089~40687588:-
OV	cis	rs4660456	0.912	rs658806	ENSG00000237899.1	RP4-739H11.3	5.89	1.41e-08	1.67e-05	0.57	0.36	Platelet count;	chr1:40683312	chr1:40669089~40687588:-
OV	cis	rs4660456	0.913	rs489222	ENSG00000237899.1	RP4-739H11.3	5.89	1.41e-08	1.67e-05	0.57	0.36	Platelet count;	chr1:40683422	chr1:40669089~40687588:-
OV	cis	rs4660456	0.871	rs671704	ENSG00000237899.1	RP4-739H11.3	5.89	1.41e-08	1.67e-05	0.57	0.36	Platelet count;	chr1:40683974	chr1:40669089~40687588:-
OV	cis	rs4660456	0.826	rs507914	ENSG00000237899.1	RP4-739H11.3	5.89	1.41e-08	1.67e-05	0.57	0.36	Platelet count;	chr1:40686529	chr1:40669089~40687588:-
OV	cis	rs4660456	0.913	rs2780950	ENSG00000237899.1	RP4-739H11.3	5.89	1.41e-08	1.67e-05	0.57	0.36	Platelet count;	chr1:40686937	chr1:40669089~40687588:-
OV	cis	rs7615952	1	rs9289275	ENSG00000171084.14	FAM86JP	5.89	1.41e-08	1.67e-05	0.58	0.36	Blood pressure (smoking interaction);	chr3:125929816	chr3:125916620~125930024:+
OV	cis	rs4660456	0.564	rs34320811	ENSG00000237899.1	RP4-739H11.3	-5.89	1.41e-08	1.67e-05	-0.55	-0.36	Platelet count;	chr1:40763288	chr1:40669089~40687588:-
OV	cis	rs611744	0.967	rs637358	ENSG00000253754.1	RP11-35G22.1	-5.89	1.41e-08	1.68e-05	-0.4	-0.36	Dupuytren's disease;	chr8:108185225	chr8:108226200~108227544:+
OV	cis	rs611744	0.901	rs655320	ENSG00000253754.1	RP11-35G22.1	-5.89	1.41e-08	1.68e-05	-0.4	-0.36	Dupuytren's disease;	chr8:108185253	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs655707	ENSG00000253754.1	RP11-35G22.1	-5.89	1.41e-08	1.68e-05	-0.4	-0.36	Dupuytren's disease;	chr8:108185301	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs636904	ENSG00000253754.1	RP11-35G22.1	-5.89	1.41e-08	1.68e-05	-0.4	-0.36	Dupuytren's disease;	chr8:108185336	chr8:108226200~108227544:+
OV	cis	rs7302981	0.775	rs7301566	ENSG00000272368.2	RP4-605O3.4	-5.88	1.42e-08	1.68e-05	-0.41	-0.36	Systolic blood pressure;	chr12:50187864	chr12:50112197~50165618:+
OV	cis	rs8062405	0.964	rs62036614	ENSG00000259982.1	CDC37P1	5.88	1.42e-08	1.68e-05	0.46	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28700294~28701540:-
OV	cis	rs4713118	0.826	rs2893929	ENSG00000220721.1	OR1F12	5.88	1.43e-08	1.69e-05	0.42	0.36	Parkinson's disease;	chr6:27770953	chr6:28073316~28074233:+
OV	cis	rs4713118	0.666	rs4140646	ENSG00000220721.1	OR1F12	5.88	1.43e-08	1.69e-05	0.42	0.36	Parkinson's disease;	chr6:27771022	chr6:28073316~28074233:+
OV	cis	rs4713118	0.666	rs2893930	ENSG00000220721.1	OR1F12	5.88	1.43e-08	1.69e-05	0.42	0.36	Parkinson's disease;	chr6:27771027	chr6:28073316~28074233:+
OV	cis	rs67311347	0.784	rs13326389	ENSG00000223797.4	ENTPD3-AS1	5.88	1.43e-08	1.7e-05	0.4	0.36	Renal cell carcinoma;	chr3:40418233	chr3:40313802~40453329:-
OV	cis	rs7017914	0.652	rs754846	ENSG00000223220.1	Y_RNA	5.88	1.44e-08	1.7e-05	0.41	0.36	Bone mineral density;	chr8:70832304	chr8:70780914~70781008:-
OV	cis	rs10510102	0.872	rs12246693	ENSG00000226864.1	ATE1-AS1	5.88	1.44e-08	1.7e-05	0.59	0.36	Breast cancer;	chr10:121957373	chr10:121928312~121951965:+
OV	cis	rs10510102	0.872	rs12248806	ENSG00000226864.1	ATE1-AS1	5.88	1.44e-08	1.7e-05	0.59	0.36	Breast cancer;	chr10:121958638	chr10:121928312~121951965:+
OV	cis	rs10510102	0.872	rs12255832	ENSG00000226864.1	ATE1-AS1	5.88	1.44e-08	1.7e-05	0.59	0.36	Breast cancer;	chr10:121958762	chr10:121928312~121951965:+
OV	cis	rs10510102	0.872	rs12247367	ENSG00000226864.1	ATE1-AS1	5.88	1.44e-08	1.7e-05	0.59	0.36	Breast cancer;	chr10:121961556	chr10:121928312~121951965:+
OV	cis	rs10510102	0.872	rs12240306	ENSG00000226864.1	ATE1-AS1	5.88	1.44e-08	1.7e-05	0.59	0.36	Breast cancer;	chr10:121963391	chr10:121928312~121951965:+
OV	cis	rs10510102	0.872	rs12240308	ENSG00000226864.1	ATE1-AS1	5.88	1.44e-08	1.7e-05	0.59	0.36	Breast cancer;	chr10:121963407	chr10:121928312~121951965:+
OV	cis	rs992157	1	rs2292553	ENSG00000237281.1	CATIP-AS2	-5.88	1.44e-08	1.71e-05	-0.42	-0.36	Colorectal cancer;	chr2:218282080	chr2:218326889~218357966:-
OV	cis	rs62355901	0.505	rs115495921	ENSG00000271828.1	CTD-2310F14.1	5.88	1.44e-08	1.71e-05	0.69	0.36	Breast cancer;	chr5:56833021	chr5:56927874~56929573:+
OV	cis	rs61990749	0.597	rs4632066	ENSG00000239272.1	RPL21P10	-5.88	1.45e-08	1.71e-05	-0.49	-0.36	Fibroblast growth factor basic levels;	chr14:77780939	chr14:77683202~77683989:-
OV	cis	rs934734	0.532	rs2028150	ENSG00000234255.7	AC012370.3	-5.88	1.45e-08	1.71e-05	-0.4	-0.36	Rheumatoid arthritis;	chr2:65427878	chr2:65439888~65456571:-
OV	cis	rs2836974	0.644	rs7281853	ENSG00000232608.1	TIMM9P2	5.88	1.46e-08	1.72e-05	0.4	0.36	Cognitive function;	chr21:39321564	chr21:39216624~39217506:+
OV	cis	rs2833693	0.572	rs11088213	ENSG00000261610.1	AP000265.1	5.88	1.46e-08	1.72e-05	0.43	0.36	Temperament;	chr21:32241398	chr21:32259804~32261585:-
OV	cis	rs7811142	0.666	rs28401739	ENSG00000242294.5	STAG3L5P	5.88	1.47e-08	1.74e-05	0.38	0.36	Platelet count;	chr7:100308061	chr7:100336079~100351900:+
OV	cis	rs61990749	0.597	rs12896026	ENSG00000239272.1	RPL21P10	5.88	1.47e-08	1.74e-05	0.5	0.36	Fibroblast growth factor basic levels;	chr14:77778093	chr14:77683202~77683989:-
OV	cis	rs61990749	0.544	rs12435761	ENSG00000239272.1	RPL21P10	5.88	1.47e-08	1.74e-05	0.5	0.36	Fibroblast growth factor basic levels;	chr14:77779734	chr14:77683202~77683989:-
OV	cis	rs61990749	0.597	rs759808	ENSG00000239272.1	RPL21P10	5.88	1.47e-08	1.74e-05	0.5	0.36	Fibroblast growth factor basic levels;	chr14:77784502	chr14:77683202~77683989:-
OV	cis	rs4713118	0.662	rs149901	ENSG00000219392.1	RP1-265C24.5	-5.88	1.48e-08	1.74e-05	-0.46	-0.36	Parkinson's disease;	chr6:27997725	chr6:28115628~28116551:+
OV	cis	rs4713118	0.662	rs464312	ENSG00000219392.1	RP1-265C24.5	-5.88	1.48e-08	1.74e-05	-0.46	-0.36	Parkinson's disease;	chr6:27999813	chr6:28115628~28116551:+
OV	cis	rs4713118	0.662	rs469228	ENSG00000219392.1	RP1-265C24.5	-5.88	1.48e-08	1.74e-05	-0.46	-0.36	Parkinson's disease;	chr6:28002926	chr6:28115628~28116551:+
OV	cis	rs4713118	0.54	rs469227	ENSG00000219392.1	RP1-265C24.5	-5.88	1.48e-08	1.74e-05	-0.46	-0.36	Parkinson's disease;	chr6:28002927	chr6:28115628~28116551:+
OV	cis	rs7927771	0.756	rs2856661	ENSG00000280615.1	Y_RNA	5.88	1.48e-08	1.75e-05	0.46	0.36	Subjective well-being;	chr11:47353447	chr11:47614898~47614994:-
OV	cis	rs8062405	0.721	rs151303	ENSG00000259982.1	CDC37P1	5.88	1.48e-08	1.75e-05	0.44	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28700294~28701540:-
OV	cis	rs9487094	0.689	rs1476387	ENSG00000260273.1	RP11-425D10.10	5.88	1.49e-08	1.75e-05	0.37	0.36	Height;	chr6:109443332	chr6:109382795~109383666:+
OV	cis	rs7811142	0.775	rs1059129	ENSG00000242294.5	STAG3L5P	5.88	1.49e-08	1.75e-05	0.38	0.36	Platelet count;	chr7:100328899	chr7:100336079~100351900:+
OV	cis	rs796364	0.774	rs112564437	ENSG00000232732.8	AC073043.1	5.88	1.49e-08	1.75e-05	0.46	0.36	Schizophrenia;	chr2:200209325	chr2:199867396~199911159:-
OV	cis	rs7017914	0.69	rs12675094	ENSG00000223220.1	Y_RNA	5.88	1.49e-08	1.75e-05	0.41	0.36	Bone mineral density;	chr8:70884968	chr8:70780914~70781008:-
OV	cis	rs7017914	0.628	rs12675116	ENSG00000223220.1	Y_RNA	5.88	1.49e-08	1.75e-05	0.41	0.36	Bone mineral density;	chr8:70885056	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs13252230	ENSG00000223220.1	Y_RNA	5.88	1.49e-08	1.75e-05	0.41	0.36	Bone mineral density;	chr8:70886081	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs6996049	ENSG00000223220.1	Y_RNA	5.88	1.49e-08	1.75e-05	0.41	0.36	Bone mineral density;	chr8:70887771	chr8:70780914~70781008:-
OV	cis	rs7017914	0.629	rs35762981	ENSG00000223220.1	Y_RNA	5.88	1.49e-08	1.75e-05	0.41	0.36	Bone mineral density;	chr8:70889405	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs7841286	ENSG00000223220.1	Y_RNA	5.88	1.49e-08	1.75e-05	0.41	0.36	Bone mineral density;	chr8:70890908	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs4629903	ENSG00000223220.1	Y_RNA	5.88	1.49e-08	1.75e-05	0.41	0.36	Bone mineral density;	chr8:70892897	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs13271286	ENSG00000223220.1	Y_RNA	5.88	1.49e-08	1.75e-05	0.41	0.36	Bone mineral density;	chr8:70894364	chr8:70780914~70781008:-
OV	cis	rs4713118	0.868	rs7756968	ENSG00000220721.1	OR1F12	5.87	1.49e-08	1.76e-05	0.42	0.36	Parkinson's disease;	chr6:27767175	chr6:28073316~28074233:+
OV	cis	rs67311347	1	rs11539046	ENSG00000223797.4	ENTPD3-AS1	-5.87	1.5e-08	1.77e-05	-0.4	-0.36	Renal cell carcinoma;	chr3:40462318	chr3:40313802~40453329:-
OV	cis	rs62355901	0.653	rs16886206	ENSG00000271828.1	CTD-2310F14.1	5.87	1.5e-08	1.77e-05	0.67	0.36	Breast cancer;	chr5:56742321	chr5:56927874~56929573:+
OV	cis	rs7626444	0.584	rs844542	ENSG00000272359.1	U4	-5.87	1.51e-08	1.78e-05	-0.37	-0.36	Monocyte count;	chr3:196752432	chr3:196747192~196747324:-
OV	cis	rs1707322	1	rs1707322	ENSG00000280836.1	AL355480.1	-5.87	1.51e-08	1.78e-05	-0.49	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46039475	chr1:45581219~45581321:-
OV	cis	rs4660456	0.913	rs656230	ENSG00000237899.1	RP4-739H11.3	5.87	1.52e-08	1.78e-05	0.56	0.36	Platelet count;	chr1:40692701	chr1:40669089~40687588:-
OV	cis	rs4660456	0.913	rs2780953	ENSG00000237899.1	RP4-739H11.3	5.87	1.52e-08	1.78e-05	0.56	0.36	Platelet count;	chr1:40694105	chr1:40669089~40687588:-
OV	cis	rs4660456	0.913	rs6667368	ENSG00000237899.1	RP4-739H11.3	5.87	1.52e-08	1.78e-05	0.56	0.36	Platelet count;	chr1:40694887	chr1:40669089~40687588:-
OV	cis	rs67180937	0.922	rs10495198	ENSG00000272750.1	RP11-378J18.8	-5.87	1.52e-08	1.79e-05	-0.4	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222652375	chr1:222658867~222661512:-
OV	cis	rs34779708	0.931	rs17582416	ENSG00000230534.5	RP11-297A16.2	5.87	1.52e-08	1.79e-05	0.47	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:34998722	chr10:35098006~35127020:-
OV	cis	rs2188561	0.615	rs13226711	ENSG00000241764.3	AC002467.7	5.87	1.53e-08	1.79e-05	0.42	0.36	Alcohol consumption;	chr7:107754897	chr7:107742817~107744581:-
OV	cis	rs11976180	1	rs6464574	ENSG00000170356.8	OR2A20P	-5.87	1.53e-08	1.8e-05	-0.52	-0.36	Obesity-related traits;	chr7:144051164	chr7:144250045~144252957:-
OV	cis	rs1075265	0.692	rs805358	ENSG00000233266.1	HMGB1P31	5.87	1.54e-08	1.81e-05	0.44	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53934885	chr2:54051334~54051760:+
OV	cis	rs9660180	0.934	rs12729990	ENSG00000231050.1	RP1-140A9.1	5.87	1.54e-08	1.81e-05	0.38	0.36	Body mass index;	chr1:1880596	chr1:1891471~1892658:+
OV	cis	rs8105895	0.825	rs62112369	ENSG00000269742.1	BNIP3P29	5.87	1.55e-08	1.82e-05	0.55	0.36	Body mass index (change over time);	chr19:22131099	chr19:22065828~22066398:-
OV	cis	rs11168351	0.927	rs11168342	ENSG00000258273.1	RP11-370I10.4	-5.87	1.55e-08	1.82e-05	-0.45	-0.36	Bipolar disorder and schizophrenia;	chr12:47990014	chr12:48333755~48333901:-
OV	cis	rs11671005	0.61	rs11669345	ENSG00000269600.1	AC016629.3	-5.87	1.55e-08	1.82e-05	-0.5	-0.36	Mean platelet volume;	chr19:58550892	chr19:58593896~58599355:-
OV	cis	rs7626444	0.625	rs1104375	ENSG00000272359.1	U4	-5.87	1.56e-08	1.83e-05	-0.37	-0.36	Monocyte count;	chr3:196749172	chr3:196747192~196747324:-
OV	cis	rs7927771	0.8	rs11039200	ENSG00000280615.1	Y_RNA	-5.87	1.57e-08	1.84e-05	-0.46	-0.36	Subjective well-being;	chr11:47358095	chr11:47614898~47614994:-
OV	cis	rs2286503	1	rs2286498	ENSG00000228649.7	AC005682.5	-5.86	1.58e-08	1.85e-05	-0.42	-0.36	Fibrinogen;	chr7:22817885	chr7:22854178~22861579:+
OV	cis	rs4713118	0.516	rs6931858	ENSG00000219392.1	RP1-265C24.5	-5.86	1.58e-08	1.85e-05	-0.46	-0.36	Parkinson's disease;	chr6:28110633	chr6:28115628~28116551:+
OV	cis	rs7688540	0.771	rs61792116	ENSG00000275426.1	CH17-262A2.1	5.86	1.58e-08	1.85e-05	0.62	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:307288	chr4:149738~150317:+
OV	cis	rs7688540	0.771	rs4129956	ENSG00000275426.1	CH17-262A2.1	5.86	1.58e-08	1.85e-05	0.62	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:308219	chr4:149738~150317:+
OV	cis	rs55894132	1	rs55894132	ENSG00000257285.4	RP11-298I3.1	5.86	1.59e-08	1.87e-05	0.44	0.36	Intelligence (multi-trait analysis);	chr14:22939628	chr14:22929609~22955562:+
OV	cis	rs7267979	0.844	rs6050477	ENSG00000274973.1	RP13-401N8.7	5.86	1.59e-08	1.87e-05	0.42	0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25240911	chr20:25845497~25845862:+
OV	cis	rs611744	0.87	rs381742	ENSG00000253754.1	RP11-35G22.1	-5.86	1.6e-08	1.87e-05	-0.41	-0.36	Dupuytren's disease;	chr8:108129851	chr8:108226200~108227544:+
OV	cis	rs7927771	0.801	rs12798028	ENSG00000280615.1	Y_RNA	-5.86	1.6e-08	1.87e-05	-0.42	-0.36	Subjective well-being;	chr11:47583087	chr11:47614898~47614994:-
OV	cis	rs7927771	0.839	rs11039308	ENSG00000280615.1	Y_RNA	-5.86	1.6e-08	1.87e-05	-0.42	-0.36	Subjective well-being;	chr11:47600860	chr11:47614898~47614994:-
OV	cis	rs8062405	1	rs62036616	ENSG00000259982.1	CDC37P1	5.86	1.6e-08	1.87e-05	0.46	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28700294~28701540:-
OV	cis	rs11976180	1	rs2951360	ENSG00000170356.8	OR2A20P	-5.86	1.6e-08	1.87e-05	-0.51	-0.36	Obesity-related traits;	chr7:144060256	chr7:144250045~144252957:-
OV	cis	rs7017914	0.628	rs1389198	ENSG00000223220.1	Y_RNA	5.86	1.6e-08	1.87e-05	0.41	0.36	Bone mineral density;	chr8:70921872	chr8:70780914~70781008:-
OV	cis	rs494459	0.838	rs566733	ENSG00000278376.1	RP11-158I9.8	-5.86	1.61e-08	1.89e-05	-0.35	-0.36	Height;	chr11:118737916	chr11:118791254~118793137:+
OV	cis	rs1707322	1	rs785465	ENSG00000280836.1	AL355480.1	-5.86	1.62e-08	1.89e-05	-0.5	-0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46056905	chr1:45581219~45581321:-
OV	cis	rs7044106	0.762	rs4837790	ENSG00000226752.6	PSMD5-AS1	-5.86	1.62e-08	1.89e-05	-0.42	-0.36	Hip circumference adjusted for BMI;	chr9:120684047	chr9:120824828~120854385:+
OV	cis	rs2243480	1	rs1723267	ENSG00000222364.1	RNU6-96P	-5.86	1.62e-08	1.89e-05	-0.56	-0.36	Diabetic kidney disease;	chr7:66008327	chr7:66395191~66395286:+
OV	cis	rs3814244	0.868	rs11177007	ENSG00000255733.4	IFNG-AS1	5.86	1.62e-08	1.9e-05	0.35	0.36	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020964	chr12:67989445~68234686:+
OV	cis	rs4660456	0.913	rs16827552	ENSG00000237899.1	RP4-739H11.3	-5.86	1.63e-08	1.91e-05	-0.54	-0.36	Platelet count;	chr1:40758336	chr1:40669089~40687588:-
OV	cis	rs4660456	0.871	rs7549789	ENSG00000237899.1	RP4-739H11.3	-5.86	1.63e-08	1.91e-05	-0.54	-0.36	Platelet count;	chr1:40759362	chr1:40669089~40687588:-
OV	cis	rs3814244	0.528	rs56393928	ENSG00000255733.4	IFNG-AS1	5.86	1.64e-08	1.91e-05	0.36	0.36	Itch intensity from mosquito bite adjusted by bite size;	chr12:68029927	chr12:67989445~68234686:+
OV	cis	rs7688540	0.771	rs11730202	ENSG00000275426.1	CH17-262A2.1	5.86	1.64e-08	1.92e-05	0.6	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:216307	chr4:149738~150317:+
OV	cis	rs7626444	0.543	rs843528	ENSG00000272359.1	U4	-5.86	1.65e-08	1.93e-05	-0.37	-0.36	Monocyte count;	chr3:196753464	chr3:196747192~196747324:-
OV	cis	rs73086581	1	rs56324992	ENSG00000229539.1	RP11-119B16.2	5.85	1.66e-08	1.94e-05	0.45	0.36	Response to antidepressants in depression;	chr20:3997506	chr20:3888239~3888868:-
OV	cis	rs7044106	0.762	rs10491783	ENSG00000226752.6	PSMD5-AS1	-5.85	1.67e-08	1.95e-05	-0.42	-0.36	Hip circumference adjusted for BMI;	chr9:120687877	chr9:120824828~120854385:+
OV	cis	rs7044106	0.762	rs966397	ENSG00000226752.6	PSMD5-AS1	-5.85	1.67e-08	1.95e-05	-0.42	-0.36	Hip circumference adjusted for BMI;	chr9:120691034	chr9:120824828~120854385:+
OV	cis	rs7044106	0.762	rs10760112	ENSG00000226752.6	PSMD5-AS1	-5.85	1.67e-08	1.95e-05	-0.42	-0.36	Hip circumference adjusted for BMI;	chr9:120705292	chr9:120824828~120854385:+
OV	cis	rs611744	0.87	rs685358	ENSG00000253754.1	RP11-35G22.1	-5.85	1.69e-08	1.97e-05	-0.41	-0.36	Dupuytren's disease;	chr8:108149184	chr8:108226200~108227544:+
OV	cis	rs67311347	1	rs4128740	ENSG00000223797.4	ENTPD3-AS1	5.85	1.69e-08	1.97e-05	0.41	0.36	Renal cell carcinoma;	chr3:40478041	chr3:40313802~40453329:-
OV	cis	rs494459	0.838	rs2510897	ENSG00000278376.1	RP11-158I9.8	-5.85	1.69e-08	1.98e-05	-0.35	-0.36	Height;	chr11:118773873	chr11:118791254~118793137:+
OV	cis	rs2581828	0.646	rs3796351	ENSG00000242142.1	SERBP1P3	5.85	1.7e-08	1.98e-05	0.43	0.36	Crohn's disease;	chr3:53122049	chr3:53064283~53065091:-
OV	cis	rs13217239	0.646	rs10946888	ENSG00000243307.2	POM121L6P	5.85	1.7e-08	1.99e-05	0.36	0.36	Schizophrenia;	chr6:26983899	chr6:26896952~26898777:+
OV	cis	rs801193	0.967	rs2707849	ENSG00000236529.1	RP13-254B10.1	5.85	1.71e-08	2e-05	0.38	0.36	Aortic root size;	chr7:66687725	chr7:65840212~65840596:+
OV	cis	rs6700559	0.967	rs10919992	ENSG00000260088.1	RP11-92G12.3	-5.85	1.72e-08	2e-05	-0.39	-0.36	Coronary artery disease;	chr1:200638338	chr1:200669507~200694250:+
OV	cis	rs10740039	0.583	rs2127353	ENSG00000254271.1	RP11-131N11.4	-5.85	1.72e-08	2.01e-05	-0.47	-0.36	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60750206	chr10:60734342~60741828:+
OV	cis	rs7044106	0.708	rs920745	ENSG00000226752.6	PSMD5-AS1	-5.85	1.74e-08	2.02e-05	-0.42	-0.36	Hip circumference adjusted for BMI;	chr9:120667665	chr9:120824828~120854385:+
OV	cis	rs7044106	0.734	rs10491784	ENSG00000226752.6	PSMD5-AS1	-5.85	1.74e-08	2.02e-05	-0.42	-0.36	Hip circumference adjusted for BMI;	chr9:120670011	chr9:120824828~120854385:+
OV	cis	rs7044106	0.762	rs1886337	ENSG00000226752.6	PSMD5-AS1	-5.85	1.74e-08	2.02e-05	-0.42	-0.36	Hip circumference adjusted for BMI;	chr9:120681498	chr9:120824828~120854385:+
OV	cis	rs7044106	0.762	rs1411158	ENSG00000226752.6	PSMD5-AS1	-5.85	1.74e-08	2.02e-05	-0.42	-0.36	Hip circumference adjusted for BMI;	chr9:120702526	chr9:120824828~120854385:+
OV	cis	rs7626444	0.626	rs5021325	ENSG00000272359.1	U4	-5.85	1.74e-08	2.02e-05	-0.37	-0.36	Monocyte count;	chr3:196750758	chr3:196747192~196747324:-
OV	cis	rs8062405	0.755	rs4788073	ENSG00000259982.1	CDC37P1	5.85	1.74e-08	2.03e-05	0.43	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28700294~28701540:-
OV	cis	rs67180937	0.961	rs17163363	ENSG00000272750.1	RP11-378J18.8	-5.85	1.75e-08	2.03e-05	-0.4	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655362	chr1:222658867~222661512:-
OV	cis	rs35158675	1	rs35158675	ENSG00000272750.1	RP11-378J18.8	-5.85	1.75e-08	2.03e-05	-0.4	-0.36	Coronary artery disease;	chr1:222656208	chr1:222658867~222661512:-
OV	cis	rs4713118	0.662	rs9393881	ENSG00000280107.1	AL022393.9	-5.84	1.75e-08	2.03e-05	-0.45	-0.36	Parkinson's disease;	chr6:28055973	chr6:28170845~28172521:+
OV	cis	rs801193	1	rs7788576	ENSG00000236529.1	RP13-254B10.1	-5.84	1.75e-08	2.04e-05	-0.38	-0.36	Aortic root size;	chr7:66683315	chr7:65840212~65840596:+
OV	cis	rs801193	1	rs6958520	ENSG00000236529.1	RP13-254B10.1	5.84	1.75e-08	2.04e-05	0.38	0.36	Aortic root size;	chr7:66686466	chr7:65840212~65840596:+
OV	cis	rs10740039	0.548	rs9415607	ENSG00000254271.1	RP11-131N11.4	-5.84	1.75e-08	2.04e-05	-0.47	-0.36	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60737616	chr10:60734342~60741828:+
OV	cis	rs10510102	0.688	rs11812208	ENSG00000276742.1	RP11-500G22.4	5.84	1.75e-08	2.04e-05	0.59	0.36	Breast cancer;	chr10:121924831	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs77447688	ENSG00000276742.1	RP11-500G22.4	5.84	1.75e-08	2.04e-05	0.59	0.36	Breast cancer;	chr10:121925721	chr10:121956782~121957098:+
OV	cis	rs1729407	0.632	rs2071523	ENSG00000254851.1	RP11-109L13.1	-5.84	1.76e-08	2.04e-05	-0.47	-0.36	Apolipoprotein A-IV levels;	chr11:116826628	chr11:117135528~117138582:+
OV	cis	rs7428	0.527	rs7607284	ENSG00000246575.2	AC093162.5	5.84	1.76e-08	2.04e-05	0.36	0.36	Ear protrusion;	chr2:85320253	chr2:85315041~85316529:+
OV	cis	rs7428	0.527	rs4459734	ENSG00000246575.2	AC093162.5	5.84	1.76e-08	2.04e-05	0.36	0.36	Ear protrusion;	chr2:85320306	chr2:85315041~85316529:+
OV	cis	rs7428	0.527	rs1554110	ENSG00000246575.2	AC093162.5	5.84	1.76e-08	2.04e-05	0.36	0.36	Ear protrusion;	chr2:85320840	chr2:85315041~85316529:+
OV	cis	rs7428	0.545	rs7572750	ENSG00000246575.2	AC093162.5	5.84	1.76e-08	2.04e-05	0.36	0.36	Ear protrusion;	chr2:85325063	chr2:85315041~85316529:+
OV	cis	rs4660456	0.827	rs617413	ENSG00000237899.1	RP4-739H11.3	5.84	1.76e-08	2.04e-05	0.57	0.36	Platelet count;	chr1:40669846	chr1:40669089~40687588:-
OV	cis	rs4660456	0.869	rs616954	ENSG00000237899.1	RP4-739H11.3	5.84	1.76e-08	2.04e-05	0.57	0.36	Platelet count;	chr1:40669947	chr1:40669089~40687588:-
OV	cis	rs7688540	0.771	rs6599318	ENSG00000275426.1	CH17-262A2.1	5.84	1.76e-08	2.05e-05	0.62	0.36	Facial morphology (factor 6, height of vermillion lower lip);	chr4:250179	chr4:149738~150317:+
OV	cis	rs293748	0.891	rs6861906	ENSG00000250155.1	CTD-2353F22.1	-5.84	1.77e-08	2.06e-05	-0.48	-0.36	Obesity-related traits;	chr5:37075834	chr5:36666214~36725195:-
OV	cis	rs7017914	0.902	rs34856835	ENSG00000223220.1	Y_RNA	5.84	1.78e-08	2.06e-05	0.39	0.36	Bone mineral density;	chr8:71058376	chr8:70780914~70781008:-
OV	cis	rs6921919	1	rs6921919	ENSG00000216901.1	AL022393.7	5.84	1.78e-08	2.06e-05	0.5	0.36	Autism spectrum disorder or schizophrenia;	chr6:28357424	chr6:28176188~28176674:+
OV	cis	rs12134133	1	rs2490261	ENSG00000274245.1	RP11-357P18.2	5.84	1.78e-08	2.07e-05	0.48	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207304124	chr1:207372559~207373252:+
OV	cis	rs7626444	0.563	rs2686598	ENSG00000272359.1	U4	-5.84	1.8e-08	2.09e-05	-0.37	-0.36	Monocyte count;	chr3:196760848	chr3:196747192~196747324:-
OV	cis	rs4380275	0.782	rs11127506	ENSG00000272342.1	RP13-539J13.1	-5.84	1.8e-08	2.09e-05	-0.41	-0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:751300	chr2:739588~740164:-
OV	cis	rs7927771	0.864	rs3781627	ENSG00000280615.1	Y_RNA	5.84	1.81e-08	2.1e-05	0.46	0.36	Subjective well-being;	chr11:47419921	chr11:47614898~47614994:-
OV	cis	rs4660456	0.913	rs2780952	ENSG00000237899.1	RP4-739H11.3	5.84	1.81e-08	2.1e-05	0.55	0.36	Platelet count;	chr1:40689711	chr1:40669089~40687588:-
OV	cis	rs9487094	0.67	rs11755641	ENSG00000260273.1	RP11-425D10.10	5.84	1.81e-08	2.1e-05	0.38	0.36	Height;	chr6:109586733	chr6:109382795~109383666:+
OV	cis	rs1075265	0.588	rs1477258	ENSG00000233266.1	HMGB1P31	5.84	1.82e-08	2.11e-05	0.46	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54000031	chr2:54051334~54051760:+
OV	cis	rs2153535	0.585	rs980083	ENSG00000230939.1	RP11-314C16.1	5.84	1.82e-08	2.11e-05	0.39	0.36	Motion sickness;	chr6:8589683	chr6:8784178~8785445:+
OV	cis	rs7927771	0.832	rs4992357	ENSG00000280615.1	Y_RNA	-5.84	1.82e-08	2.11e-05	-0.44	-0.36	Subjective well-being;	chr11:47372087	chr11:47614898~47614994:-
OV	cis	rs67311347	0.876	rs13068097	ENSG00000223797.4	ENTPD3-AS1	-5.84	1.82e-08	2.12e-05	-0.4	-0.36	Renal cell carcinoma;	chr3:40462933	chr3:40313802~40453329:-
OV	cis	rs611744	0.837	rs403200	ENSG00000253754.1	RP11-35G22.1	-5.84	1.83e-08	2.12e-05	-0.4	-0.36	Dupuytren's disease;	chr8:108091147	chr8:108226200~108227544:+
OV	cis	rs4853012	0.539	rs9789534	ENSG00000217702.2	RP11-287D1.4	5.84	1.83e-08	2.12e-05	0.57	0.36	Gestational age at birth (maternal effect);	chr2:74135863	chr2:74130583~74135395:+
OV	cis	rs875971	0.666	rs13242072	ENSG00000236529.1	RP13-254B10.1	-5.84	1.83e-08	2.13e-05	-0.38	-0.36	Aortic root size;	chr7:66301001	chr7:65840212~65840596:+
OV	cis	rs12200782	0.505	rs9295696	ENSG00000241549.7	GUSBP2	5.84	1.84e-08	2.13e-05	0.43	0.36	Small cell lung carcinoma;	chr6:26550060	chr6:26871484~26956554:-
OV	cis	rs8062405	0.755	rs7186573	ENSG00000259982.1	CDC37P1	5.84	1.84e-08	2.13e-05	0.43	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28700294~28701540:-
OV	cis	rs67311347	1	rs6793596	ENSG00000223797.4	ENTPD3-AS1	5.83	1.85e-08	2.14e-05	0.41	0.36	Renal cell carcinoma;	chr3:40416304	chr3:40313802~40453329:-
OV	cis	rs11976180	1	rs13243677	ENSG00000170356.8	OR2A20P	-5.83	1.85e-08	2.14e-05	-0.51	-0.36	Obesity-related traits;	chr7:144049479	chr7:144250045~144252957:-
OV	cis	rs11976180	1	rs13226728	ENSG00000170356.8	OR2A20P	-5.83	1.85e-08	2.14e-05	-0.51	-0.36	Obesity-related traits;	chr7:144049485	chr7:144250045~144252957:-
OV	cis	rs801193	0.904	rs4718405	ENSG00000236529.1	RP13-254B10.1	5.83	1.85e-08	2.15e-05	0.38	0.36	Aortic root size;	chr7:66789659	chr7:65840212~65840596:+
OV	cis	rs8113142	0.614	rs11083645	ENSG00000267243.4	AC005307.3	5.83	1.86e-08	2.15e-05	0.54	0.36	Femoral neck bone geometry and menarche (age at onset);	chr19:28723093	chr19:28435388~28727777:-
OV	cis	rs3814244	0.832	rs11177006	ENSG00000255733.4	IFNG-AS1	5.83	1.86e-08	2.15e-05	0.36	0.36	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019317	chr12:67989445~68234686:+
OV	cis	rs293748	0.771	rs35135658	ENSG00000250155.1	CTD-2353F22.1	-5.83	1.86e-08	2.15e-05	-0.5	-0.36	Obesity-related traits;	chr5:36786777	chr5:36666214~36725195:-
OV	cis	rs293748	0.771	rs58952013	ENSG00000250155.1	CTD-2353F22.1	-5.83	1.86e-08	2.15e-05	-0.5	-0.36	Obesity-related traits;	chr5:36787362	chr5:36666214~36725195:-
OV	cis	rs293748	0.771	rs12659960	ENSG00000250155.1	CTD-2353F22.1	-5.83	1.86e-08	2.15e-05	-0.5	-0.36	Obesity-related traits;	chr5:36787913	chr5:36666214~36725195:-
OV	cis	rs2833693	0.572	rs4816428	ENSG00000261610.1	AP000265.1	5.83	1.87e-08	2.16e-05	0.43	0.36	Temperament;	chr21:32232689	chr21:32259804~32261585:-
OV	cis	rs858239	0.632	rs6952947	ENSG00000230042.1	AK3P3	5.83	1.87e-08	2.16e-05	0.39	0.36	Cerebrospinal fluid biomarker levels;	chr7:23081423	chr7:23129178~23129841:+
OV	cis	rs494459	0.657	rs614554	ENSG00000278376.1	RP11-158I9.8	-5.83	1.87e-08	2.17e-05	-0.34	-0.36	Height;	chr11:118764443	chr11:118791254~118793137:+
OV	cis	rs858239	0.6	rs10266123	ENSG00000230042.1	AK3P3	-5.83	1.88e-08	2.17e-05	-0.38	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23096868	chr7:23129178~23129841:+
OV	cis	rs801193	1	rs2659906	ENSG00000236529.1	RP13-254B10.1	5.83	1.88e-08	2.17e-05	0.38	0.36	Aortic root size;	chr7:66700323	chr7:65840212~65840596:+
OV	cis	rs801193	0.935	rs2659899	ENSG00000236529.1	RP13-254B10.1	5.83	1.88e-08	2.17e-05	0.38	0.36	Aortic root size;	chr7:66721734	chr7:65840212~65840596:+
OV	cis	rs8062405	0.755	rs17640009	ENSG00000259982.1	CDC37P1	5.83	1.88e-08	2.17e-05	0.43	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28700294~28701540:-
OV	cis	rs1185460	1	rs1185460	ENSG00000271751.1	RP11-110I1.14	5.83	1.89e-08	2.18e-05	0.46	0.36	Coronary artery disease;	chr11:119072723	chr11:119065263~119065677:-
OV	cis	rs2581828	0.646	rs9757079	ENSG00000242142.1	SERBP1P3	-5.83	1.89e-08	2.18e-05	-0.44	-0.36	Crohn's disease;	chr3:53121142	chr3:53064283~53065091:-
OV	cis	rs3091242	0.867	rs602052	ENSG00000224183.1	SDHDP6	-5.83	1.9e-08	2.19e-05	-0.44	-0.36	Erythrocyte sedimentation rate;	chr1:25395715	chr1:25294164~25294643:-
OV	cis	rs8062405	0.755	rs7193402	ENSG00000259982.1	CDC37P1	5.83	1.91e-08	2.21e-05	0.44	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28700294~28701540:-
OV	cis	rs853679	0.517	rs17711344	ENSG00000280107.1	AL022393.9	5.83	1.93e-08	2.23e-05	0.45	0.36	Depression;	chr6:28109824	chr6:28170845~28172521:+
OV	cis	rs4591358	0.731	rs10208012	ENSG00000223466.1	AC064834.2	5.82	1.94e-08	2.24e-05	0.49	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195452137	chr2:195533035~195538681:+
OV	cis	rs611744	0.967	rs686251	ENSG00000253754.1	RP11-35G22.1	-5.82	1.94e-08	2.24e-05	-0.4	-0.36	Dupuytren's disease;	chr8:108186678	chr8:108226200~108227544:+
OV	cis	rs13217239	0.646	rs10946897	ENSG00000243307.2	POM121L6P	5.82	1.95e-08	2.24e-05	0.36	0.36	Schizophrenia;	chr6:27027472	chr6:26896952~26898777:+
OV	cis	rs13217239	0.646	rs4403259	ENSG00000243307.2	POM121L6P	5.82	1.95e-08	2.24e-05	0.36	0.36	Schizophrenia;	chr6:27029838	chr6:26896952~26898777:+
OV	cis	rs7017914	0.616	rs55855305	ENSG00000223220.1	Y_RNA	5.82	1.96e-08	2.26e-05	0.41	0.36	Bone mineral density;	chr8:70790642	chr8:70780914~70781008:-
OV	cis	rs7017914	0.605	rs55865599	ENSG00000223220.1	Y_RNA	5.82	1.96e-08	2.26e-05	0.41	0.36	Bone mineral density;	chr8:70792351	chr8:70780914~70781008:-
OV	cis	rs62355901	0.545	rs58774999	ENSG00000271828.1	CTD-2310F14.1	5.82	1.96e-08	2.26e-05	0.68	0.36	Breast cancer;	chr5:56798018	chr5:56927874~56929573:+
OV	cis	rs1075265	0.756	rs805367	ENSG00000233266.1	HMGB1P31	5.82	1.96e-08	2.27e-05	0.44	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53943956	chr2:54051334~54051760:+
OV	cis	rs7017914	0.605	rs13267098	ENSG00000223220.1	Y_RNA	5.82	1.97e-08	2.27e-05	0.42	0.36	Bone mineral density;	chr8:70899651	chr8:70780914~70781008:-
OV	cis	rs7615952	0.673	rs34209763	ENSG00000171084.14	FAM86JP	5.82	1.97e-08	2.27e-05	0.68	0.36	Blood pressure (smoking interaction);	chr3:125880752	chr3:125916620~125930024:+
OV	cis	rs7615952	0.8	rs35390120	ENSG00000171084.14	FAM86JP	5.82	1.97e-08	2.27e-05	0.68	0.36	Blood pressure (smoking interaction);	chr3:125880966	chr3:125916620~125930024:+
OV	cis	rs7615952	0.611	rs2971298	ENSG00000171084.14	FAM86JP	5.82	1.97e-08	2.27e-05	0.68	0.36	Blood pressure (smoking interaction);	chr3:125883870	chr3:125916620~125930024:+
OV	cis	rs7044106	0.762	rs1470307	ENSG00000226752.6	PSMD5-AS1	-5.82	1.97e-08	2.27e-05	-0.42	-0.36	Hip circumference adjusted for BMI;	chr9:120670761	chr9:120824828~120854385:+
OV	cis	rs11690935	0.595	rs788171	ENSG00000228389.1	AC068039.4	-5.82	1.97e-08	2.27e-05	-0.4	-0.36	Schizophrenia;	chr2:172057104	chr2:171773482~171775844:+
OV	cis	rs801193	1	rs2003301	ENSG00000236529.1	RP13-254B10.1	-5.82	1.97e-08	2.27e-05	-0.38	-0.36	Aortic root size;	chr7:66682669	chr7:65840212~65840596:+
OV	cis	rs8062405	0.721	rs151303	ENSG00000278665.1	RP11-666O2.4	5.82	1.97e-08	2.27e-05	0.38	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28481189	chr16:28599241~28601881:-
OV	cis	rs11690935	0.571	rs1008151	ENSG00000228389.1	AC068039.4	-5.82	1.98e-08	2.29e-05	-0.41	-0.36	Schizophrenia;	chr2:172047370	chr2:171773482~171775844:+
OV	cis	rs10510102	0.516	rs12256693	ENSG00000276742.1	RP11-500G22.4	5.82	1.99e-08	2.29e-05	0.65	0.36	Breast cancer;	chr10:121976839	chr10:121956782~121957098:+
OV	cis	rs10510102	0.516	rs11200300	ENSG00000276742.1	RP11-500G22.4	5.82	1.99e-08	2.29e-05	0.65	0.36	Breast cancer;	chr10:121977489	chr10:121956782~121957098:+
OV	cis	rs438465	1	rs368028	ENSG00000226194.4	RP1-137D17.1	-5.82	2e-08	2.3e-05	-0.5	-0.36	Corneal astigmatism;	chr6:169411199	chr6:169369998~169388385:-
OV	cis	rs2980439	0.818	rs2945249	ENSG00000173295.6	FAM86B3P	5.82	2e-08	2.3e-05	0.47	0.36	Neuroticism;	chr8:8237204	chr8:8228595~8244865:+
OV	cis	rs7626444	0.625	rs9877495	ENSG00000272359.1	U4	-5.82	2.01e-08	2.31e-05	-0.37	-0.36	Monocyte count;	chr3:196756409	chr3:196747192~196747324:-
OV	cis	rs7626444	0.625	rs2686599	ENSG00000272359.1	U4	-5.82	2.01e-08	2.31e-05	-0.37	-0.36	Monocyte count;	chr3:196756923	chr3:196747192~196747324:-
OV	cis	rs7626444	0.625	rs1403101	ENSG00000272359.1	U4	-5.82	2.01e-08	2.31e-05	-0.37	-0.36	Monocyte count;	chr3:196758203	chr3:196747192~196747324:-
OV	cis	rs7626444	0.625	rs1486358	ENSG00000272359.1	U4	-5.82	2.01e-08	2.31e-05	-0.37	-0.36	Monocyte count;	chr3:196758719	chr3:196747192~196747324:-
OV	cis	rs11671005	0.61	rs8103813	ENSG00000269600.1	AC016629.3	-5.82	2.01e-08	2.31e-05	-0.51	-0.36	Mean platelet volume;	chr19:58561317	chr19:58593896~58599355:-
OV	cis	rs1185460	0.967	rs1786690	ENSG00000271751.1	RP11-110I1.14	-5.82	2.02e-08	2.32e-05	-0.44	-0.36	Coronary artery disease;	chr11:119071357	chr11:119065263~119065677:-
OV	cis	rs61990749	0.597	rs2112136	ENSG00000239272.1	RPL21P10	5.82	2.02e-08	2.32e-05	0.5	0.36	Fibroblast growth factor basic levels;	chr14:77782609	chr14:77683202~77683989:-
OV	cis	rs12681420	0.754	rs34471605	ENSG00000223220.1	Y_RNA	5.82	2.02e-08	2.33e-05	0.41	0.36	Erythrocyte cadmium concentration in never smokers;	chr8:70849983	chr8:70780914~70781008:-
OV	cis	rs611744	0.967	rs650401	ENSG00000253754.1	RP11-35G22.1	-5.82	2.03e-08	2.34e-05	-0.4	-0.36	Dupuytren's disease;	chr8:108184625	chr8:108226200~108227544:+
OV	cis	rs611744	0.934	rs2848619	ENSG00000253754.1	RP11-35G22.1	-5.82	2.03e-08	2.34e-05	-0.4	-0.36	Dupuytren's disease;	chr8:108185956	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs2212704	ENSG00000253754.1	RP11-35G22.1	-5.82	2.03e-08	2.34e-05	-0.4	-0.36	Dupuytren's disease;	chr8:108186186	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs684093	ENSG00000253754.1	RP11-35G22.1	-5.82	2.03e-08	2.34e-05	-0.4	-0.36	Dupuytren's disease;	chr8:108187126	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs684904	ENSG00000253754.1	RP11-35G22.1	-5.82	2.03e-08	2.34e-05	-0.4	-0.36	Dupuytren's disease;	chr8:108187188	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs686265	ENSG00000253754.1	RP11-35G22.1	-5.82	2.03e-08	2.34e-05	-0.4	-0.36	Dupuytren's disease;	chr8:108187534	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs591792	ENSG00000253754.1	RP11-35G22.1	-5.82	2.03e-08	2.34e-05	-0.4	-0.36	Dupuytren's disease;	chr8:108188217	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs2600615	ENSG00000253754.1	RP11-35G22.1	-5.82	2.03e-08	2.34e-05	-0.4	-0.36	Dupuytren's disease;	chr8:108188941	chr8:108226200~108227544:+
OV	cis	rs611744	0.87	rs638905	ENSG00000253754.1	RP11-35G22.1	-5.82	2.03e-08	2.34e-05	-0.4	-0.36	Dupuytren's disease;	chr8:108191177	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs666821	ENSG00000253754.1	RP11-35G22.1	-5.82	2.03e-08	2.34e-05	-0.4	-0.36	Dupuytren's disease;	chr8:108192084	chr8:108226200~108227544:+
OV	cis	rs611744	0.934	rs624311	ENSG00000253754.1	RP11-35G22.1	-5.82	2.03e-08	2.34e-05	-0.4	-0.36	Dupuytren's disease;	chr8:108192208	chr8:108226200~108227544:+
OV	cis	rs11671005	0.61	rs3794966	ENSG00000269600.1	AC016629.3	-5.82	2.04e-08	2.34e-05	-0.5	-0.36	Mean platelet volume;	chr19:58557629	chr19:58593896~58599355:-
OV	cis	rs67311347	1	rs11706148	ENSG00000223797.4	ENTPD3-AS1	5.82	2.04e-08	2.35e-05	0.41	0.36	Renal cell carcinoma;	chr3:40365752	chr3:40313802~40453329:-
OV	cis	rs10740039	0.729	rs6479728	ENSG00000254271.1	RP11-131N11.4	-5.82	2.04e-08	2.35e-05	-0.45	-0.36	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60731043	chr10:60734342~60741828:+
OV	cis	rs9487094	0.601	rs4945831	ENSG00000260273.1	RP11-425D10.10	5.81	2.05e-08	2.35e-05	0.36	0.36	Height;	chr6:109440234	chr6:109382795~109383666:+
OV	cis	rs858239	0.6	rs10256524	ENSG00000230042.1	AK3P3	-5.81	2.05e-08	2.35e-05	-0.37	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23105328	chr7:23129178~23129841:+
OV	cis	rs2153535	0.518	rs6912560	ENSG00000230939.1	RP11-314C16.1	-5.81	2.06e-08	2.36e-05	-0.4	-0.36	Motion sickness;	chr6:8563878	chr6:8784178~8785445:+
OV	cis	rs7044106	0.762	rs1158554	ENSG00000226752.6	PSMD5-AS1	-5.81	2.06e-08	2.36e-05	-0.42	-0.36	Hip circumference adjusted for BMI;	chr9:120638620	chr9:120824828~120854385:+
OV	cis	rs10256972	0.626	rs62433138	ENSG00000229043.2	AC091729.9	-5.81	2.06e-08	2.36e-05	-0.4	-0.36	Endometriosis;Longevity;	chr7:1011241	chr7:1160374~1165267:+
OV	cis	rs2581828	0.609	rs73088342	ENSG00000242142.1	SERBP1P3	-5.81	2.07e-08	2.37e-05	-0.44	-0.36	Crohn's disease;	chr3:53117648	chr3:53064283~53065091:-
OV	cis	rs2581828	0.646	rs6783748	ENSG00000242142.1	SERBP1P3	-5.81	2.07e-08	2.37e-05	-0.44	-0.36	Crohn's disease;	chr3:53119415	chr3:53064283~53065091:-
OV	cis	rs4591358	0.608	rs12693770	ENSG00000223466.1	AC064834.2	5.81	2.07e-08	2.37e-05	0.53	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195461422	chr2:195533035~195538681:+
OV	cis	rs7017914	0.69	rs13261146	ENSG00000223220.1	Y_RNA	5.81	2.08e-08	2.39e-05	0.41	0.36	Bone mineral density;	chr8:70814684	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs13263047	ENSG00000223220.1	Y_RNA	5.81	2.08e-08	2.39e-05	0.41	0.36	Bone mineral density;	chr8:70815061	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs62508827	ENSG00000223220.1	Y_RNA	5.81	2.08e-08	2.39e-05	0.41	0.36	Bone mineral density;	chr8:70815820	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs62508828	ENSG00000223220.1	Y_RNA	5.81	2.08e-08	2.39e-05	0.41	0.36	Bone mineral density;	chr8:70815974	chr8:70780914~70781008:-
OV	cis	rs801193	1	rs6975195	ENSG00000236529.1	RP13-254B10.1	-5.81	2.08e-08	2.39e-05	-0.39	-0.36	Aortic root size;	chr7:66659787	chr7:65840212~65840596:+
OV	cis	rs801193	1	rs3857688	ENSG00000236529.1	RP13-254B10.1	-5.81	2.08e-08	2.39e-05	-0.39	-0.36	Aortic root size;	chr7:66662819	chr7:65840212~65840596:+
OV	cis	rs4713118	0.513	rs9368547	ENSG00000220721.1	OR1F12	5.81	2.08e-08	2.39e-05	0.38	0.36	Parkinson's disease;	chr6:28060289	chr6:28073316~28074233:+
OV	cis	rs4713118	0.513	rs183244	ENSG00000220721.1	OR1F12	5.81	2.08e-08	2.39e-05	0.38	0.36	Parkinson's disease;	chr6:28064060	chr6:28073316~28074233:+
OV	cis	rs7017914	0.905	rs4738105	ENSG00000223220.1	Y_RNA	-5.81	2.09e-08	2.4e-05	-0.39	-0.36	Bone mineral density;	chr8:71046683	chr8:70780914~70781008:-
OV	cis	rs7829975	0.593	rs2921077	ENSG00000253893.2	FAM85B	-5.81	2.1e-08	2.4e-05	-0.39	-0.36	Mood instability;	chr8:8446992	chr8:8167819~8226614:-
OV	cis	rs10510102	0.872	rs116521083	ENSG00000226864.1	ATE1-AS1	5.81	2.1e-08	2.41e-05	0.6	0.36	Breast cancer;	chr10:121950611	chr10:121928312~121951965:+
OV	cis	rs10510102	0.748	rs4589226	ENSG00000226864.1	ATE1-AS1	5.81	2.1e-08	2.41e-05	0.6	0.36	Breast cancer;	chr10:121951073	chr10:121928312~121951965:+
OV	cis	rs10510102	0.81	rs34738294	ENSG00000226864.1	ATE1-AS1	5.81	2.1e-08	2.41e-05	0.6	0.36	Breast cancer;	chr10:121951357	chr10:121928312~121951965:+
OV	cis	rs10510102	0.872	rs12258234	ENSG00000226864.1	ATE1-AS1	5.81	2.1e-08	2.41e-05	0.6	0.36	Breast cancer;	chr10:121952828	chr10:121928312~121951965:+
OV	cis	rs10510102	0.515	rs11200285	ENSG00000226864.1	ATE1-AS1	5.81	2.1e-08	2.41e-05	0.6	0.36	Breast cancer;	chr10:121953931	chr10:121928312~121951965:+
OV	cis	rs10510102	0.872	rs75831447	ENSG00000226864.1	ATE1-AS1	5.81	2.1e-08	2.41e-05	0.6	0.36	Breast cancer;	chr10:121953963	chr10:121928312~121951965:+
OV	cis	rs10510102	0.63	rs79960726	ENSG00000226864.1	ATE1-AS1	5.81	2.1e-08	2.41e-05	0.6	0.36	Breast cancer;	chr10:121954358	chr10:121928312~121951965:+
OV	cis	rs992157	1	rs13429408	ENSG00000237281.1	CATIP-AS2	-5.81	2.13e-08	2.44e-05	-0.41	-0.36	Colorectal cancer;	chr2:218278137	chr2:218326889~218357966:-
OV	cis	rs801193	1	rs62466793	ENSG00000236529.1	RP13-254B10.1	5.81	2.13e-08	2.44e-05	0.38	0.36	Aortic root size;	chr7:66726530	chr7:65840212~65840596:+
OV	cis	rs801193	1	rs62466794	ENSG00000236529.1	RP13-254B10.1	5.81	2.13e-08	2.44e-05	0.38	0.36	Aortic root size;	chr7:66726592	chr7:65840212~65840596:+
OV	cis	rs858239	0.6	rs9691762	ENSG00000230042.1	AK3P3	-5.81	2.14e-08	2.45e-05	-0.38	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23086303	chr7:23129178~23129841:+
OV	cis	rs4660456	1	rs4660456	ENSG00000237899.1	RP4-739H11.3	-5.81	2.15e-08	2.45e-05	-0.53	-0.36	Platelet count;	chr1:40773839	chr1:40669089~40687588:-
OV	cis	rs4660456	0.956	rs4660457	ENSG00000237899.1	RP4-739H11.3	-5.81	2.15e-08	2.45e-05	-0.53	-0.36	Platelet count;	chr1:40774121	chr1:40669089~40687588:-
OV	cis	rs9813712	0.571	rs9855426	ENSG00000228252.7	COL6A4P2	5.81	2.15e-08	2.45e-05	0.42	0.36	Response to amphetamines;	chr3:130214475	chr3:130212823~130273806:+
OV	cis	rs1134634	1	rs1134634	ENSG00000273133.1	RP11-799M12.2	5.8	2.16e-08	2.46e-05	0.41	0.36	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15601446	chr4:15563698~15564253:-
OV	cis	rs4563143	0.514	rs112540771	ENSG00000267243.4	AC005307.3	-5.8	2.16e-08	2.46e-05	-0.64	-0.36	Methadone dose in opioid dependence;	chr19:28825193	chr19:28435388~28727777:-
OV	cis	rs11235843	0.706	rs12420099	ENSG00000255928.1	RP11-456I15.2	5.8	2.16e-08	2.46e-05	0.64	0.36	Hand grip strength;	chr11:73860796	chr11:73722349~73722694:+
OV	cis	rs11235843	0.706	rs12420751	ENSG00000255928.1	RP11-456I15.2	5.8	2.16e-08	2.46e-05	0.64	0.36	Hand grip strength;	chr11:73861364	chr11:73722349~73722694:+
OV	cis	rs11235843	0.706	rs17132411	ENSG00000255928.1	RP11-456I15.2	5.8	2.16e-08	2.46e-05	0.64	0.36	Hand grip strength;	chr11:73864275	chr11:73722349~73722694:+
OV	cis	rs11235843	0.706	rs72982926	ENSG00000255928.1	RP11-456I15.2	5.8	2.16e-08	2.46e-05	0.64	0.36	Hand grip strength;	chr11:73869383	chr11:73722349~73722694:+
OV	cis	rs11235843	0.706	rs4944869	ENSG00000255928.1	RP11-456I15.2	5.8	2.16e-08	2.46e-05	0.64	0.36	Hand grip strength;	chr11:73869735	chr11:73722349~73722694:+
OV	cis	rs4660456	0.913	rs2361650	ENSG00000237899.1	RP4-739H11.3	-5.8	2.17e-08	2.47e-05	-0.54	-0.36	Platelet count;	chr1:40764678	chr1:40669089~40687588:-
OV	cis	rs4660456	0.913	rs954654	ENSG00000237899.1	RP4-739H11.3	-5.8	2.17e-08	2.47e-05	-0.54	-0.36	Platelet count;	chr1:40764979	chr1:40669089~40687588:-
OV	cis	rs4660456	0.913	rs34212676	ENSG00000237899.1	RP4-739H11.3	-5.8	2.17e-08	2.47e-05	-0.54	-0.36	Platelet count;	chr1:40766522	chr1:40669089~40687588:-
OV	cis	rs2153535	0.606	rs11243253	ENSG00000230939.1	RP11-314C16.1	5.8	2.18e-08	2.49e-05	0.42	0.36	Motion sickness;	chr6:8379960	chr6:8784178~8785445:+
OV	cis	rs2739330	0.76	rs5751761	ENSG00000228039.3	KB-1125A3.10	-5.8	2.18e-08	2.49e-05	-0.4	-0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:23963780~23964374:+
OV	cis	rs4660456	0.826	rs3767952	ENSG00000237899.1	RP4-739H11.3	-5.8	2.19e-08	2.5e-05	-0.54	-0.36	Platelet count;	chr1:40765360	chr1:40669089~40687588:-
OV	cis	rs2243480	0.901	rs1701759	ENSG00000222364.1	RNU6-96P	-5.8	2.2e-08	2.51e-05	-0.56	-0.36	Diabetic kidney disease;	chr7:66005945	chr7:66395191~66395286:+
OV	cis	rs858239	0.6	rs7776644	ENSG00000230042.1	AK3P3	-5.8	2.2e-08	2.51e-05	-0.39	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23079688	chr7:23129178~23129841:+
OV	cis	rs7927771	0.839	rs3817334	ENSG00000280615.1	Y_RNA	-5.8	2.2e-08	2.51e-05	-0.42	-0.36	Subjective well-being;	chr11:47629441	chr11:47614898~47614994:-
OV	cis	rs7626444	0.625	rs843531	ENSG00000272359.1	U4	-5.8	2.21e-08	2.51e-05	-0.36	-0.36	Monocyte count;	chr3:196754900	chr3:196747192~196747324:-
OV	cis	rs7626444	0.628	rs1684464	ENSG00000272359.1	U4	-5.8	2.21e-08	2.51e-05	-0.36	-0.36	Monocyte count;	chr3:196758643	chr3:196747192~196747324:-
OV	cis	rs8062405	0.755	rs12447461	ENSG00000259982.1	CDC37P1	5.8	2.21e-08	2.52e-05	0.43	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28700294~28701540:-
OV	cis	rs8062405	0.755	rs111693583	ENSG00000259982.1	CDC37P1	5.8	2.21e-08	2.52e-05	0.43	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28700294~28701540:-
OV	cis	rs62355900	0.636	rs62355907	ENSG00000271828.1	CTD-2310F14.1	5.8	2.21e-08	2.52e-05	0.68	0.36	Endometriosis;	chr5:56775503	chr5:56927874~56929573:+
OV	cis	rs2188561	0.638	rs3735609	ENSG00000241764.3	AC002467.7	5.8	2.22e-08	2.53e-05	0.43	0.36	Alcohol consumption;	chr7:107743299	chr7:107742817~107744581:-
OV	cis	rs801193	1	rs2707845	ENSG00000236529.1	RP13-254B10.1	5.8	2.23e-08	2.54e-05	0.38	0.36	Aortic root size;	chr7:66733811	chr7:65840212~65840596:+
OV	cis	rs16873450	0.9	rs10231702	ENSG00000234800.2	PCMTD1P3	5.8	2.24e-08	2.55e-05	0.36	0.36	Verbal memory performance (residualized delayed recall level);	chr7:23757922	chr7:23721311~23721782:-
OV	cis	rs8005677	0.828	rs2295680	ENSG00000257285.4	RP11-298I3.1	-5.8	2.25e-08	2.56e-05	-0.41	-0.36	Cognitive ability (multi-trait analysis);	chr14:22905226	chr14:22929609~22955562:+
OV	cis	rs12134133	1	rs2782846	ENSG00000274245.1	RP11-357P18.2	5.8	2.26e-08	2.56e-05	0.47	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300495	chr1:207372559~207373252:+
OV	cis	rs67311347	1	rs4973993	ENSG00000223797.4	ENTPD3-AS1	5.8	2.26e-08	2.57e-05	0.4	0.36	Renal cell carcinoma;	chr3:40411469	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs4973994	ENSG00000223797.4	ENTPD3-AS1	5.8	2.26e-08	2.57e-05	0.4	0.36	Renal cell carcinoma;	chr3:40411533	chr3:40313802~40453329:-
OV	cis	rs11235843	0.706	rs17132397	ENSG00000255928.1	RP11-456I15.2	5.8	2.26e-08	2.57e-05	0.64	0.36	Hand grip strength;	chr11:73854872	chr11:73722349~73722694:+
OV	cis	rs11235843	0.706	rs11235931	ENSG00000255928.1	RP11-456I15.2	5.8	2.26e-08	2.57e-05	0.64	0.36	Hand grip strength;	chr11:73856475	chr11:73722349~73722694:+
OV	cis	rs11235843	0.706	rs10898947	ENSG00000255928.1	RP11-456I15.2	5.8	2.26e-08	2.57e-05	0.64	0.36	Hand grip strength;	chr11:73857937	chr11:73722349~73722694:+
OV	cis	rs6828577	0.56	rs2631147	ENSG00000269893.5	SNHG8	5.8	2.26e-08	2.57e-05	0.4	0.36	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118534699	chr4:118278709~118279823:+
OV	cis	rs2188561	0.697	rs10808154	ENSG00000241764.3	AC002467.7	5.8	2.26e-08	2.57e-05	0.43	0.36	Alcohol consumption;	chr7:107745951	chr7:107742817~107744581:-
OV	cis	rs4713118	0.621	rs9295755	ENSG00000219392.1	RP1-265C24.5	5.8	2.26e-08	2.57e-05	0.45	0.36	Parkinson's disease;	chr6:28065396	chr6:28115628~28116551:+
OV	cis	rs494459	0.691	rs607472	ENSG00000255422.1	AP002954.4	-5.8	2.27e-08	2.57e-05	-0.41	-0.36	Height;	chr11:118809363	chr11:118704607~118750263:+
OV	cis	rs8062405	0.755	rs4149398	ENSG00000259982.1	CDC37P1	5.79	2.27e-08	2.58e-05	0.45	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28700294~28701540:-
OV	cis	rs34779708	0.931	rs9663401	ENSG00000230534.5	RP11-297A16.2	5.79	2.27e-08	2.58e-05	0.49	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:34989921	chr10:35098006~35127020:-
OV	cis	rs301901	0.581	rs292174	ENSG00000250155.1	CTD-2353F22.1	-5.79	2.28e-08	2.59e-05	-0.42	-0.36	Height;	chr5:36832039	chr5:36666214~36725195:-
OV	cis	rs11235843	0.706	rs116388544	ENSG00000255928.1	RP11-456I15.2	5.79	2.29e-08	2.6e-05	0.64	0.36	Hand grip strength;	chr11:73882603	chr11:73722349~73722694:+
OV	cis	rs11235843	0.706	rs72982937	ENSG00000255928.1	RP11-456I15.2	5.79	2.29e-08	2.6e-05	0.64	0.36	Hand grip strength;	chr11:73885464	chr11:73722349~73722694:+
OV	cis	rs11235843	0.706	rs11235939	ENSG00000255928.1	RP11-456I15.2	5.79	2.29e-08	2.6e-05	0.64	0.36	Hand grip strength;	chr11:73892174	chr11:73722349~73722694:+
OV	cis	rs875971	0.522	rs7784623	ENSG00000224316.1	RP11-479O9.2	5.79	2.3e-08	2.61e-05	0.37	0.36	Aortic root size;	chr7:65930047	chr7:65773620~65802067:+
OV	cis	rs875971	0.522	rs34973832	ENSG00000224316.1	RP11-479O9.2	5.79	2.3e-08	2.61e-05	0.37	0.36	Aortic root size;	chr7:65931217	chr7:65773620~65802067:+
OV	cis	rs67180937	1	rs67180937	ENSG00000272750.1	RP11-378J18.8	-5.79	2.3e-08	2.61e-05	-0.4	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222650401	chr1:222658867~222661512:-
OV	cis	rs67180937	0.961	rs17011681	ENSG00000272750.1	RP11-378J18.8	-5.79	2.3e-08	2.61e-05	-0.4	-0.36	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222651746	chr1:222658867~222661512:-
OV	cis	rs858239	0.6	rs7456915	ENSG00000230042.1	AK3P3	-5.79	2.3e-08	2.61e-05	-0.38	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23103430	chr7:23129178~23129841:+
OV	cis	rs858239	0.6	rs13438179	ENSG00000230042.1	AK3P3	-5.79	2.3e-08	2.61e-05	-0.38	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23104232	chr7:23129178~23129841:+
OV	cis	rs1387259	0.619	rs7134565	ENSG00000258273.1	RP11-370I10.4	5.79	2.31e-08	2.62e-05	0.4	0.36	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48236241	chr12:48333755~48333901:-
OV	cis	rs7615952	0.8	rs12489350	ENSG00000171084.14	FAM86JP	5.79	2.31e-08	2.62e-05	0.56	0.36	Blood pressure (smoking interaction);	chr3:125925273	chr3:125916620~125930024:+
OV	cis	rs875971	0.522	rs1701760	ENSG00000224316.1	RP11-479O9.2	5.79	2.31e-08	2.62e-05	0.38	0.36	Aortic root size;	chr7:66008701	chr7:65773620~65802067:+
OV	cis	rs526231	0.543	rs7709726	ENSG00000175749.11	EIF3KP1	-5.79	2.31e-08	2.62e-05	-0.4	-0.36	Primary biliary cholangitis;	chr5:102991759	chr5:103032376~103033031:+
OV	cis	rs7615952	0.641	rs12488180	ENSG00000171084.14	FAM86JP	5.79	2.32e-08	2.63e-05	0.5	0.36	Blood pressure (smoking interaction);	chr3:126063393	chr3:125916620~125930024:+
OV	cis	rs7429990	0.813	rs7627568	ENSG00000229759.1	MRPS18AP1	-5.79	2.32e-08	2.63e-05	-0.37	-0.36	Educational attainment (years of education);	chr3:48051562	chr3:48256350~48256938:-
OV	cis	rs875971	0.505	rs2462573	ENSG00000224316.1	RP11-479O9.2	-5.79	2.33e-08	2.64e-05	-0.38	-0.36	Aortic root size;	chr7:66042405	chr7:65773620~65802067:+
OV	cis	rs875971	0.505	rs1167386	ENSG00000224316.1	RP11-479O9.2	-5.79	2.33e-08	2.64e-05	-0.38	-0.36	Aortic root size;	chr7:66048109	chr7:65773620~65802067:+
OV	cis	rs875971	0.505	rs1167385	ENSG00000224316.1	RP11-479O9.2	-5.79	2.33e-08	2.64e-05	-0.38	-0.36	Aortic root size;	chr7:66048321	chr7:65773620~65802067:+
OV	cis	rs875971	0.651	rs313829	ENSG00000226824.5	RP4-756H11.3	5.79	2.33e-08	2.64e-05	0.42	0.36	Aortic root size;	chr7:66087510	chr7:66654538~66669855:+
OV	cis	rs611744	0.901	rs2348801	ENSG00000253754.1	RP11-35G22.1	-5.79	2.33e-08	2.64e-05	-0.4	-0.36	Dupuytren's disease;	chr8:108155108	chr8:108226200~108227544:+
OV	cis	rs62355900	0.627	rs9292123	ENSG00000271828.1	CTD-2310F14.1	5.79	2.33e-08	2.64e-05	0.66	0.36	Endometriosis;	chr5:56807982	chr5:56927874~56929573:+
OV	cis	rs11690935	0.549	rs62183819	ENSG00000228389.1	AC068039.4	-5.79	2.33e-08	2.64e-05	-0.41	-0.36	Schizophrenia;	chr2:172039610	chr2:171773482~171775844:+
OV	cis	rs611744	0.967	rs662591	ENSG00000253754.1	RP11-35G22.1	-5.79	2.34e-08	2.65e-05	-0.39	-0.36	Dupuytren's disease;	chr8:108199129	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs702801	ENSG00000253754.1	RP11-35G22.1	-5.79	2.34e-08	2.65e-05	-0.39	-0.36	Dupuytren's disease;	chr8:108199573	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs677842	ENSG00000253754.1	RP11-35G22.1	-5.79	2.34e-08	2.65e-05	-0.39	-0.36	Dupuytren's disease;	chr8:108200239	chr8:108226200~108227544:+
OV	cis	rs611744	0.935	rs661036	ENSG00000253754.1	RP11-35G22.1	-5.79	2.34e-08	2.65e-05	-0.39	-0.36	Dupuytren's disease;	chr8:108200859	chr8:108226200~108227544:+
OV	cis	rs801193	1	rs1553609	ENSG00000236529.1	RP13-254B10.1	5.79	2.34e-08	2.65e-05	0.38	0.36	Aortic root size;	chr7:66732152	chr7:65840212~65840596:+
OV	cis	rs801193	1	rs1553610	ENSG00000236529.1	RP13-254B10.1	5.79	2.34e-08	2.65e-05	0.38	0.36	Aortic root size;	chr7:66732246	chr7:65840212~65840596:+
OV	cis	rs4591358	0.731	rs13031745	ENSG00000223466.1	AC064834.2	-5.79	2.35e-08	2.66e-05	-0.49	-0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195440458	chr2:195533035~195538681:+
OV	cis	rs2286503	0.966	rs6949233	ENSG00000228649.7	AC005682.5	5.79	2.35e-08	2.66e-05	0.42	0.36	Fibrinogen;	chr7:22818572	chr7:22854178~22861579:+
OV	cis	rs34375054	0.558	rs12578774	ENSG00000279233.1	RP11-158L12.4	-5.79	2.35e-08	2.66e-05	-0.31	-0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125197215	chr12:125138245~125141711:+
OV	cis	rs611744	0.967	rs645070	ENSG00000253754.1	RP11-35G22.1	-5.79	2.35e-08	2.66e-05	-0.39	-0.36	Dupuytren's disease;	chr8:108204116	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs702802	ENSG00000253754.1	RP11-35G22.1	-5.79	2.35e-08	2.66e-05	-0.39	-0.36	Dupuytren's disease;	chr8:108206009	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs681099	ENSG00000253754.1	RP11-35G22.1	-5.79	2.35e-08	2.66e-05	-0.39	-0.36	Dupuytren's disease;	chr8:108206663	chr8:108226200~108227544:+
OV	cis	rs4713118	0.621	rs9295756	ENSG00000219392.1	RP1-265C24.5	-5.79	2.36e-08	2.67e-05	-0.45	-0.36	Parkinson's disease;	chr6:28065618	chr6:28115628~28116551:+
OV	cis	rs67311347	1	rs2276870	ENSG00000223797.4	ENTPD3-AS1	-5.79	2.36e-08	2.67e-05	-0.4	-0.36	Renal cell carcinoma;	chr3:40457691	chr3:40313802~40453329:-
OV	cis	rs11976180	1	rs2371244	ENSG00000170356.8	OR2A20P	-5.79	2.37e-08	2.68e-05	-0.51	-0.36	Obesity-related traits;	chr7:144060518	chr7:144250045~144252957:-
OV	cis	rs11976180	1	rs4726669	ENSG00000170356.8	OR2A20P	-5.79	2.37e-08	2.68e-05	-0.51	-0.36	Obesity-related traits;	chr7:144061098	chr7:144250045~144252957:-
OV	cis	rs11976180	1	rs1320894	ENSG00000170356.8	OR2A20P	-5.79	2.37e-08	2.68e-05	-0.51	-0.36	Obesity-related traits;	chr7:144054709	chr7:144250045~144252957:-
OV	cis	rs4660456	0.913	rs6661855	ENSG00000237899.1	RP4-739H11.3	5.78	2.39e-08	2.7e-05	0.54	0.36	Platelet count;	chr1:40703245	chr1:40669089~40687588:-
OV	cis	rs4660456	0.913	rs7542019	ENSG00000237899.1	RP4-739H11.3	5.78	2.39e-08	2.7e-05	0.54	0.36	Platelet count;	chr1:40704039	chr1:40669089~40687588:-
OV	cis	rs4660456	0.913	rs1494	ENSG00000237899.1	RP4-739H11.3	5.78	2.39e-08	2.7e-05	0.54	0.36	Platelet count;	chr1:40706176	chr1:40669089~40687588:-
OV	cis	rs7017914	0.667	rs3098862	ENSG00000223220.1	Y_RNA	5.78	2.42e-08	2.73e-05	0.41	0.36	Bone mineral density;	chr8:70965706	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs2639914	ENSG00000223220.1	Y_RNA	5.78	2.42e-08	2.73e-05	0.41	0.36	Bone mineral density;	chr8:70967418	chr8:70780914~70781008:-
OV	cis	rs7017914	0.628	rs2732139	ENSG00000223220.1	Y_RNA	5.78	2.42e-08	2.73e-05	0.41	0.36	Bone mineral density;	chr8:70967802	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs2639913	ENSG00000223220.1	Y_RNA	5.78	2.42e-08	2.73e-05	0.41	0.36	Bone mineral density;	chr8:70967929	chr8:70780914~70781008:-
OV	cis	rs138319634	1	rs138319634	ENSG00000274973.1	RP13-401N8.7	-5.78	2.42e-08	2.74e-05	-0.59	-0.36	Red blood cell count;	chr20:25856855	chr20:25845497~25845862:+
OV	cis	rs11976180	1	rs7777389	ENSG00000170356.8	OR2A20P	-5.78	2.42e-08	2.74e-05	-0.51	-0.36	Obesity-related traits;	chr7:144047709	chr7:144250045~144252957:-
OV	cis	rs11976180	1	rs67239267	ENSG00000170356.8	OR2A20P	-5.78	2.42e-08	2.74e-05	-0.51	-0.36	Obesity-related traits;	chr7:144048023	chr7:144250045~144252957:-
OV	cis	rs116095464	1	rs56700778	ENSG00000277812.1	AC021087.1	5.78	2.43e-08	2.74e-05	0.88	0.36	Breast cancer;	chr5:313071	chr5:262769~262881:+
OV	cis	rs67311347	1	rs9822909	ENSG00000223797.4	ENTPD3-AS1	5.78	2.43e-08	2.74e-05	0.43	0.36	Renal cell carcinoma;	chr3:40415593	chr3:40313802~40453329:-
OV	cis	rs858239	0.6	rs10488077	ENSG00000230042.1	AK3P3	-5.78	2.43e-08	2.74e-05	-0.38	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23104563	chr7:23129178~23129841:+
OV	cis	rs2732480	0.967	rs2732469	ENSG00000258273.1	RP11-370I10.4	-5.78	2.43e-08	2.74e-05	-0.42	-0.36	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48319149	chr12:48333755~48333901:-
OV	cis	rs875971	0.706	rs1643374	ENSG00000236529.1	RP13-254B10.1	5.78	2.43e-08	2.74e-05	0.38	0.36	Aortic root size;	chr7:66407695	chr7:65840212~65840596:+
OV	cis	rs4591358	0.731	rs12693772	ENSG00000223466.1	AC064834.2	-5.78	2.43e-08	2.74e-05	-0.5	-0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195473636	chr2:195533035~195538681:+
OV	cis	rs1075265	0.818	rs12713253	ENSG00000233266.1	HMGB1P31	5.78	2.44e-08	2.75e-05	0.43	0.36	Chronotype;Morning vs. evening chronotype;	chr2:54037323	chr2:54051334~54051760:+
OV	cis	rs11976180	1	rs2951372	ENSG00000170356.8	OR2A20P	-5.78	2.44e-08	2.75e-05	-0.51	-0.36	Obesity-related traits;	chr7:144052410	chr7:144250045~144252957:-
OV	cis	rs17711722	0.701	rs4467826	ENSG00000224316.1	RP11-479O9.2	5.78	2.45e-08	2.77e-05	0.37	0.36	Calcium levels;	chr7:65903721	chr7:65773620~65802067:+
OV	cis	rs611744	0.905	rs677031	ENSG00000253754.1	RP11-35G22.1	-5.78	2.46e-08	2.77e-05	-0.4	-0.36	Dupuytren's disease;	chr8:108139840	chr8:108226200~108227544:+
OV	cis	rs1387259	0.619	rs2130095	ENSG00000258273.1	RP11-370I10.4	5.78	2.46e-08	2.77e-05	0.4	0.36	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48244972	chr12:48333755~48333901:-
OV	cis	rs801193	0.935	rs2659916	ENSG00000236529.1	RP13-254B10.1	5.78	2.46e-08	2.78e-05	0.38	0.36	Aortic root size;	chr7:66686365	chr7:65840212~65840596:+
OV	cis	rs611744	0.934	rs1989388	ENSG00000253754.1	RP11-35G22.1	-5.78	2.47e-08	2.78e-05	-0.39	-0.36	Dupuytren's disease;	chr8:108208040	chr8:108226200~108227544:+
OV	cis	rs7811142	0.779	rs28680963	ENSG00000242294.5	STAG3L5P	5.78	2.48e-08	2.79e-05	0.38	0.36	Platelet count;	chr7:100307852	chr7:100336079~100351900:+
OV	cis	rs611744	0.624	rs2514844	ENSG00000253754.1	RP11-35G22.1	-5.78	2.48e-08	2.79e-05	-0.4	-0.36	Dupuytren's disease;	chr8:108052581	chr8:108226200~108227544:+
OV	cis	rs611744	0.658	rs2443774	ENSG00000253754.1	RP11-35G22.1	-5.78	2.48e-08	2.79e-05	-0.4	-0.36	Dupuytren's disease;	chr8:108052729	chr8:108226200~108227544:+
OV	cis	rs4660456	0.913	rs16827532	ENSG00000237899.1	RP4-739H11.3	-5.78	2.48e-08	2.79e-05	-0.54	-0.36	Platelet count;	chr1:40755064	chr1:40669089~40687588:-
OV	cis	rs4660456	0.913	rs12729696	ENSG00000237899.1	RP4-739H11.3	-5.78	2.48e-08	2.79e-05	-0.54	-0.36	Platelet count;	chr1:40755099	chr1:40669089~40687588:-
OV	cis	rs55794721	0.509	rs873308	ENSG00000224183.1	SDHDP6	5.78	2.49e-08	2.8e-05	0.41	0.36	Mean corpuscular volume;Plateletcrit;	chr1:25432164	chr1:25294164~25294643:-
OV	cis	rs4380275	0.965	rs4375894	ENSG00000272342.1	RP13-539J13.1	5.78	2.49e-08	2.8e-05	0.4	0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772567	chr2:739588~740164:-
OV	cis	rs12134133	1	rs1782468	ENSG00000274245.1	RP11-357P18.2	5.78	2.49e-08	2.8e-05	0.47	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207297070	chr1:207372559~207373252:+
OV	cis	rs1426063	0.614	rs114761716	ENSG00000260265.1	RP11-44F21.5	5.78	2.51e-08	2.82e-05	0.67	0.36	QT interval;	chr4:75107209	chr4:75081702~75084717:-
OV	cis	rs1426063	0.614	rs115279737	ENSG00000260265.1	RP11-44F21.5	5.78	2.51e-08	2.82e-05	0.67	0.36	QT interval;	chr4:75107557	chr4:75081702~75084717:-
OV	cis	rs9660180	0.875	rs4648727	ENSG00000231050.1	RP1-140A9.1	-5.78	2.51e-08	2.82e-05	-0.37	-0.36	Body mass index;	chr1:1844830	chr1:1891471~1892658:+
OV	cis	rs11669181	1	rs11669181	ENSG00000267147.2	CTC-548K16.1	5.78	2.51e-08	2.82e-05	0.43	0.36	Conotruncal heart defects (maternal effects);	chr19:14334326	chr19:14333743~14343916:+
OV	cis	rs9487094	0.67	rs12199154	ENSG00000260273.1	RP11-425D10.10	-5.78	2.51e-08	2.83e-05	-0.38	-0.36	Height;	chr6:109501793	chr6:109382795~109383666:+
OV	cis	rs4591358	0.731	rs13036252	ENSG00000223466.1	AC064834.2	-5.77	2.52e-08	2.83e-05	-0.49	-0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195425834	chr2:195533035~195538681:+
OV	cis	rs4591358	0.68	rs7568240	ENSG00000223466.1	AC064834.2	-5.77	2.52e-08	2.83e-05	-0.49	-0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195428263	chr2:195533035~195538681:+
OV	cis	rs34779708	0.966	rs11010129	ENSG00000230534.5	RP11-297A16.2	5.77	2.52e-08	2.83e-05	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35221894	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs4934737	ENSG00000230534.5	RP11-297A16.2	5.77	2.52e-08	2.83e-05	0.46	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35223871	chr10:35098006~35127020:-
OV	cis	rs7428	0.527	rs6547612	ENSG00000246575.2	AC093162.5	5.77	2.52e-08	2.84e-05	0.35	0.36	Ear protrusion;	chr2:85324061	chr2:85315041~85316529:+
OV	cis	rs9487094	0.644	rs910730	ENSG00000260273.1	RP11-425D10.10	5.77	2.52e-08	2.84e-05	0.36	0.36	Height;	chr6:109447092	chr6:109382795~109383666:+
OV	cis	rs853679	0.628	rs9368560	ENSG00000219392.1	RP1-265C24.5	-5.77	2.53e-08	2.84e-05	-0.48	-0.36	Depression;	chr6:28192182	chr6:28115628~28116551:+
OV	cis	rs2243480	1	rs313809	ENSG00000222364.1	RNU6-96P	-5.77	2.54e-08	2.85e-05	-0.57	-0.36	Diabetic kidney disease;	chr7:66034996	chr7:66395191~66395286:+
OV	cis	rs9322193	0.884	rs7744105	ENSG00000216906.2	RP11-350J20.9	5.77	2.55e-08	2.86e-05	0.44	0.36	Lung cancer;	chr6:149849308	chr6:149904243~149906418:+
OV	cis	rs12134133	0.962	rs2564970	ENSG00000274245.1	RP11-357P18.2	5.77	2.55e-08	2.86e-05	0.47	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207290696	chr1:207372559~207373252:+
OV	cis	rs12134133	1	rs2782851	ENSG00000274245.1	RP11-357P18.2	5.77	2.55e-08	2.86e-05	0.47	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207291717	chr1:207372559~207373252:+
OV	cis	rs12134133	1	rs2782850	ENSG00000274245.1	RP11-357P18.2	5.77	2.55e-08	2.86e-05	0.47	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207292092	chr1:207372559~207373252:+
OV	cis	rs12134133	1	rs2782848	ENSG00000274245.1	RP11-357P18.2	5.77	2.55e-08	2.86e-05	0.47	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207293407	chr1:207372559~207373252:+
OV	cis	rs12134133	0.962	rs2039543	ENSG00000274245.1	RP11-357P18.2	5.77	2.55e-08	2.86e-05	0.47	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207294228	chr1:207372559~207373252:+
OV	cis	rs12134133	1	rs2802232	ENSG00000274245.1	RP11-357P18.2	5.77	2.55e-08	2.86e-05	0.47	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207294806	chr1:207372559~207373252:+
OV	cis	rs12134133	0.962	rs2782847	ENSG00000274245.1	RP11-357P18.2	5.77	2.55e-08	2.86e-05	0.47	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207295766	chr1:207372559~207373252:+
OV	cis	rs2153535	0.518	rs6925765	ENSG00000230939.1	RP11-314C16.1	-5.77	2.55e-08	2.86e-05	-0.4	-0.36	Motion sickness;	chr6:8566471	chr6:8784178~8785445:+
OV	cis	rs67311347	1	rs17078916	ENSG00000223797.4	ENTPD3-AS1	5.77	2.56e-08	2.87e-05	0.4	0.36	Renal cell carcinoma;	chr3:40403947	chr3:40313802~40453329:-
OV	cis	rs5742933	0.817	rs11679767	ENSG00000253559.1	OSGEPL1-AS1	5.77	2.56e-08	2.87e-05	0.37	0.36	Ferritin levels;	chr2:189681574	chr2:189762704~189765556:+
OV	cis	rs853679	0.55	rs6901017	ENSG00000219392.1	RP1-265C24.5	-5.77	2.58e-08	2.9e-05	-0.45	-0.36	Depression;	chr6:28184805	chr6:28115628~28116551:+
OV	cis	rs13315649	0.639	rs73196928	ENSG00000277250.1	Metazoa_SRP	-5.77	2.59e-08	2.91e-05	-0.44	-0.36	Sum eosinophil basophil counts;	chr3:128670583	chr3:128673681~128674021:-
OV	cis	rs801193	0.935	rs3800820	ENSG00000236529.1	RP13-254B10.1	-5.77	2.6e-08	2.91e-05	-0.38	-0.36	Aortic root size;	chr7:66682191	chr7:65840212~65840596:+
OV	cis	rs2581828	0.591	rs6445566	ENSG00000242142.1	SERBP1P3	-5.77	2.6e-08	2.92e-05	-0.45	-0.36	Crohn's disease;	chr3:53131611	chr3:53064283~53065091:-
OV	cis	rs2581828	0.618	rs13319872	ENSG00000242142.1	SERBP1P3	-5.77	2.6e-08	2.92e-05	-0.45	-0.36	Crohn's disease;	chr3:53132082	chr3:53064283~53065091:-
OV	cis	rs13256369	1	rs10110591	ENSG00000253893.2	FAM85B	5.77	2.62e-08	2.93e-05	0.41	0.36	Obesity-related traits;	chr8:8719098	chr8:8167819~8226614:-
OV	cis	rs10463554	0.892	rs17154860	ENSG00000175749.11	EIF3KP1	5.76	2.65e-08	2.97e-05	0.43	0.36	Parkinson's disease;	chr5:102955441	chr5:103032376~103033031:+
OV	cis	rs11235843	0.706	rs17132403	ENSG00000255928.1	RP11-456I15.2	5.76	2.65e-08	2.97e-05	0.64	0.36	Hand grip strength;	chr11:73858131	chr11:73722349~73722694:+
OV	cis	rs67311347	1	rs12633431	ENSG00000223797.4	ENTPD3-AS1	-5.76	2.66e-08	2.97e-05	-0.39	-0.36	Renal cell carcinoma;	chr3:40464249	chr3:40313802~40453329:-
OV	cis	rs67311347	0.956	rs6771527	ENSG00000223797.4	ENTPD3-AS1	-5.76	2.66e-08	2.97e-05	-0.39	-0.36	Renal cell carcinoma;	chr3:40465057	chr3:40313802~40453329:-
OV	cis	rs67311347	0.955	rs6782746	ENSG00000223797.4	ENTPD3-AS1	-5.76	2.66e-08	2.97e-05	-0.39	-0.36	Renal cell carcinoma;	chr3:40469101	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs7628247	ENSG00000223797.4	ENTPD3-AS1	-5.76	2.66e-08	2.97e-05	-0.39	-0.36	Renal cell carcinoma;	chr3:40471191	chr3:40313802~40453329:-
OV	cis	rs858239	0.6	rs10233039	ENSG00000230042.1	AK3P3	-5.76	2.66e-08	2.98e-05	-0.38	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23103494	chr7:23129178~23129841:+
OV	cis	rs11976180	1	rs2961118	ENSG00000170356.8	OR2A20P	-5.76	2.66e-08	2.98e-05	-0.51	-0.36	Obesity-related traits;	chr7:144058350	chr7:144250045~144252957:-
OV	cis	rs11976180	1	rs2961119	ENSG00000170356.8	OR2A20P	-5.76	2.66e-08	2.98e-05	-0.51	-0.36	Obesity-related traits;	chr7:144058759	chr7:144250045~144252957:-
OV	cis	rs7617773	0.817	rs9830016	ENSG00000228638.1	FCF1P2	-5.76	2.67e-08	2.98e-05	-0.44	-0.36	Coronary artery disease;	chr3:48241004	chr3:48290793~48291375:-
OV	cis	rs858239	0.6	rs10241208	ENSG00000230042.1	AK3P3	-5.76	2.69e-08	3.01e-05	-0.37	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23105295	chr7:23129178~23129841:+
OV	cis	rs4660456	0.826	rs2744802	ENSG00000237899.1	RP4-739H11.3	5.76	2.69e-08	3.01e-05	0.55	0.36	Platelet count;	chr1:40687577	chr1:40669089~40687588:-
OV	cis	rs7017914	0.628	rs13272343	ENSG00000223220.1	Y_RNA	5.76	2.7e-08	3.02e-05	0.4	0.36	Bone mineral density;	chr8:70882272	chr8:70780914~70781008:-
OV	cis	rs1707322	0.638	rs9429095	ENSG00000281133.1	AL355480.3	5.76	2.72e-08	3.04e-05	0.42	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46137676	chr1:45580892~45580996:-
OV	cis	rs858239	0.6	rs28646184	ENSG00000230042.1	AK3P3	-5.76	2.73e-08	3.05e-05	-0.37	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23099976	chr7:23129178~23129841:+
OV	cis	rs17711722	0.675	rs6947132	ENSG00000224316.1	RP11-479O9.2	-5.76	2.73e-08	3.05e-05	-0.37	-0.36	Calcium levels;	chr7:65808508	chr7:65773620~65802067:+
OV	cis	rs853679	0.517	rs16893666	ENSG00000280107.1	AL022393.9	5.76	2.73e-08	3.05e-05	0.45	0.36	Depression;	chr6:28086929	chr6:28170845~28172521:+
OV	cis	rs611744	0.87	rs596703	ENSG00000253754.1	RP11-35G22.1	5.76	2.74e-08	3.06e-05	0.4	0.36	Dupuytren's disease;	chr8:108147917	chr8:108226200~108227544:+
OV	cis	rs9828933	0.766	rs704372	ENSG00000280620.1	SCAANT1	-5.76	2.75e-08	3.07e-05	-0.56	-0.36	Type 2 diabetes;	chr3:63881777	chr3:63911518~63911772:-
OV	cis	rs992157	0.866	rs2292554	ENSG00000237281.1	CATIP-AS2	5.76	2.75e-08	3.07e-05	0.41	0.36	Colorectal cancer;	chr2:218282145	chr2:218326889~218357966:-
OV	cis	rs7017914	0.549	rs3098863	ENSG00000223220.1	Y_RNA	5.76	2.76e-08	3.08e-05	0.4	0.36	Bone mineral density;	chr8:70965931	chr8:70780914~70781008:-
OV	cis	rs934734	0.532	rs6546151	ENSG00000234255.7	AC012370.3	-5.76	2.76e-08	3.08e-05	-0.39	-0.36	Rheumatoid arthritis;	chr2:65449449	chr2:65439888~65456571:-
OV	cis	rs1930961	0.85	rs5996945	ENSG00000272798.1	CTA-390C10.9	5.76	2.76e-08	3.08e-05	0.42	0.36	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25436312~25436915:+
OV	cis	rs7811142	0.83	rs1063945	ENSG00000242294.5	STAG3L5P	5.76	2.78e-08	3.1e-05	0.37	0.36	Platelet count;	chr7:100332824	chr7:100336079~100351900:+
OV	cis	rs1707322	1	rs1613296	ENSG00000280836.1	AL355480.1	5.76	2.78e-08	3.1e-05	0.48	0.36	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46081180	chr1:45581219~45581321:-
OV	cis	rs7615952	0.546	rs2979333	ENSG00000171084.14	FAM86JP	5.76	2.78e-08	3.1e-05	0.59	0.36	Blood pressure (smoking interaction);	chr3:125641499	chr3:125916620~125930024:+
OV	cis	rs7615952	0.546	rs111812401	ENSG00000171084.14	FAM86JP	5.76	2.78e-08	3.1e-05	0.59	0.36	Blood pressure (smoking interaction);	chr3:125642651	chr3:125916620~125930024:+
OV	cis	rs7615952	0.546	rs2979350	ENSG00000171084.14	FAM86JP	5.76	2.78e-08	3.1e-05	0.59	0.36	Blood pressure (smoking interaction);	chr3:125643371	chr3:125916620~125930024:+
OV	cis	rs2581828	0.659	rs4282053	ENSG00000242142.1	SERBP1P3	-5.75	2.8e-08	3.12e-05	-0.44	-0.36	Crohn's disease;	chr3:53107949	chr3:53064283~53065091:-
OV	cis	rs1387259	0.64	rs10783243	ENSG00000258273.1	RP11-370I10.4	5.75	2.81e-08	3.14e-05	0.4	0.36	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48259220	chr12:48333755~48333901:-
OV	cis	rs67311347	1	rs11707278	ENSG00000223797.4	ENTPD3-AS1	5.75	2.82e-08	3.15e-05	0.4	0.36	Renal cell carcinoma;	chr3:40445584	chr3:40313802~40453329:-
OV	cis	rs8062405	0.755	rs4787456	ENSG00000259982.1	CDC37P1	5.75	2.83e-08	3.15e-05	0.44	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28700294~28701540:-
OV	cis	rs8062405	0.755	rs4788078	ENSG00000259982.1	CDC37P1	5.75	2.83e-08	3.15e-05	0.44	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28700294~28701540:-
OV	cis	rs8062405	0.755	rs62034350	ENSG00000259982.1	CDC37P1	5.75	2.83e-08	3.15e-05	0.44	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28700294~28701540:-
OV	cis	rs7017914	0.652	rs35323776	ENSG00000223220.1	Y_RNA	5.75	2.83e-08	3.15e-05	0.4	0.36	Bone mineral density;	chr8:70797931	chr8:70780914~70781008:-
OV	cis	rs7017914	0.69	rs35767277	ENSG00000223220.1	Y_RNA	5.75	2.83e-08	3.15e-05	0.4	0.36	Bone mineral density;	chr8:70806262	chr8:70780914~70781008:-
OV	cis	rs67311347	1	rs13073003	ENSG00000223797.4	ENTPD3-AS1	-5.75	2.83e-08	3.16e-05	-0.39	-0.36	Renal cell carcinoma;	chr3:40462835	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs6801185	ENSG00000223797.4	ENTPD3-AS1	-5.75	2.83e-08	3.16e-05	-0.39	-0.36	Renal cell carcinoma;	chr3:40463569	chr3:40313802~40453329:-
OV	cis	rs950169	0.959	rs12911210	ENSG00000225151.9	GOLGA2P7	-5.75	2.83e-08	3.16e-05	-0.46	-0.36	Schizophrenia;	chr15:84123331	chr15:84199311~84230136:-
OV	cis	rs2455601	0.744	rs7938995	ENSG00000254860.4	TMEM9B-AS1	5.75	2.84e-08	3.16e-05	0.44	0.36	Schizophrenia;	chr11:8954128	chr11:8964675~8977527:+
OV	cis	rs9291683	0.588	rs4280729	ENSG00000250413.1	RP11-448G15.1	-5.75	2.85e-08	3.17e-05	-0.4	-0.36	Bone mineral density;	chr4:10012237	chr4:10006482~10009725:+
OV	cis	rs9291683	0.552	rs10939656	ENSG00000250413.1	RP11-448G15.1	-5.75	2.85e-08	3.17e-05	-0.4	-0.36	Bone mineral density;	chr4:10013022	chr4:10006482~10009725:+
OV	cis	rs11168351	0.927	rs10875716	ENSG00000258273.1	RP11-370I10.4	-5.75	2.86e-08	3.18e-05	-0.45	-0.36	Bipolar disorder and schizophrenia;	chr12:47995240	chr12:48333755~48333901:-
OV	cis	rs9549260	0.604	rs9549273	ENSG00000229456.1	RLIMP1	-5.75	2.86e-08	3.18e-05	-0.47	-0.36	Red blood cell count;	chr13:40728011	chr13:40618738~40621348:+
OV	cis	rs7615952	0.611	rs35321002	ENSG00000171084.14	FAM86JP	5.75	2.86e-08	3.18e-05	0.69	0.36	Blood pressure (smoking interaction);	chr3:125893222	chr3:125916620~125930024:+
OV	cis	rs494459	0.838	rs567680	ENSG00000278376.1	RP11-158I9.8	-5.75	2.86e-08	3.18e-05	-0.35	-0.36	Height;	chr11:118737823	chr11:118791254~118793137:+
OV	cis	rs67311347	1	rs11129876	ENSG00000223797.4	ENTPD3-AS1	-5.75	2.86e-08	3.19e-05	-0.38	-0.36	Renal cell carcinoma;	chr3:40360145	chr3:40313802~40453329:-
OV	cis	rs34779708	0.931	rs11010130	ENSG00000230534.5	RP11-297A16.2	5.75	2.88e-08	3.2e-05	0.45	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35224379	chr10:35098006~35127020:-
OV	cis	rs34779708	0.897	rs11010131	ENSG00000230534.5	RP11-297A16.2	5.75	2.88e-08	3.2e-05	0.45	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:35224388	chr10:35098006~35127020:-
OV	cis	rs526231	0.578	rs2112886	ENSG00000175749.11	EIF3KP1	-5.75	2.88e-08	3.2e-05	-0.43	-0.36	Primary biliary cholangitis;	chr5:102915678	chr5:103032376~103033031:+
OV	cis	rs7017914	0.616	rs11987260	ENSG00000223220.1	Y_RNA	5.75	2.89e-08	3.21e-05	0.4	0.36	Bone mineral density;	chr8:70861647	chr8:70780914~70781008:-
OV	cis	rs2243480	1	rs313807	ENSG00000222364.1	RNU6-96P	-5.75	2.9e-08	3.22e-05	-0.57	-0.36	Diabetic kidney disease;	chr7:66034494	chr7:66395191~66395286:+
OV	cis	rs16873450	0.9	rs7782389	ENSG00000234800.2	PCMTD1P3	5.75	2.9e-08	3.22e-05	0.37	0.36	Verbal memory performance (residualized delayed recall level);	chr7:23788469	chr7:23721311~23721782:-
OV	cis	rs3091242	0.967	rs665372	ENSG00000224183.1	SDHDP6	-5.75	2.9e-08	3.23e-05	-0.43	-0.36	Erythrocyte sedimentation rate;	chr1:25392744	chr1:25294164~25294643:-
OV	cis	rs12908161	0.96	rs17599989	ENSG00000235370.6	DNM1P51	5.75	2.9e-08	3.23e-05	0.44	0.36	Schizophrenia;	chr15:84742305	chr15:84398316~84411701:-
OV	cis	rs858239	0.6	rs4628176	ENSG00000230042.1	AK3P3	-5.75	2.92e-08	3.24e-05	-0.38	-0.36	Cerebrospinal fluid biomarker levels;	chr7:23102947	chr7:23129178~23129841:+
OV	cis	rs7267979	0.657	rs6107073	ENSG00000274973.1	RP13-401N8.7	-5.75	2.92e-08	3.24e-05	-0.42	-0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25735727	chr20:25845497~25845862:+
OV	cis	rs4591358	0.549	rs10200021	ENSG00000223466.1	AC064834.2	-5.75	2.93e-08	3.25e-05	-0.46	-0.36	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195549863	chr2:195533035~195538681:+
OV	cis	rs116095464	0.558	rs10079760	ENSG00000250848.1	CTD-2083E4.5	-5.74	2.94e-08	3.27e-05	-0.44	-0.36	Breast cancer;	chr5:230663	chr5:288833~290321:-
OV	cis	rs7017914	0.902	rs6472562	ENSG00000223220.1	Y_RNA	5.74	2.95e-08	3.28e-05	0.39	0.36	Bone mineral density;	chr8:71057643	chr8:70780914~70781008:-
OV	cis	rs7017914	0.902	rs6472563	ENSG00000223220.1	Y_RNA	5.74	2.95e-08	3.28e-05	0.39	0.36	Bone mineral density;	chr8:71057672	chr8:70780914~70781008:-
OV	cis	rs17711722	0.74	rs7809991	ENSG00000224316.1	RP11-479O9.2	5.74	2.96e-08	3.29e-05	0.37	0.36	Calcium levels;	chr7:65941231	chr7:65773620~65802067:+
OV	cis	rs875971	0.522	rs6960048	ENSG00000224316.1	RP11-479O9.2	5.74	2.96e-08	3.29e-05	0.37	0.36	Aortic root size;	chr7:65943052	chr7:65773620~65802067:+
OV	cis	rs4660456	0.913	rs3767951	ENSG00000237899.1	RP4-739H11.3	-5.74	2.97e-08	3.3e-05	-0.53	-0.36	Platelet count;	chr1:40767359	chr1:40669089~40687588:-
OV	cis	rs67311347	1	rs73076046	ENSG00000223797.4	ENTPD3-AS1	5.74	2.98e-08	3.3e-05	0.4	0.36	Renal cell carcinoma;	chr3:40406233	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs11720360	ENSG00000223797.4	ENTPD3-AS1	5.74	2.98e-08	3.3e-05	0.4	0.36	Renal cell carcinoma;	chr3:40406906	chr3:40313802~40453329:-
OV	cis	rs293748	0.771	rs12659981	ENSG00000250155.1	CTD-2353F22.1	-5.74	2.98e-08	3.3e-05	-0.5	-0.36	Obesity-related traits;	chr5:36787996	chr5:36666214~36725195:-
OV	cis	rs293748	0.771	rs12659983	ENSG00000250155.1	CTD-2353F22.1	-5.74	2.98e-08	3.3e-05	-0.5	-0.36	Obesity-related traits;	chr5:36788002	chr5:36666214~36725195:-
OV	cis	rs733592	0.599	rs12819124	ENSG00000258273.1	RP11-370I10.4	-5.74	2.99e-08	3.31e-05	-0.42	-0.36	Plateletcrit;	chr12:48015271	chr12:48333755~48333901:-
OV	cis	rs7017914	0.616	rs12681114	ENSG00000223220.1	Y_RNA	5.74	2.99e-08	3.31e-05	0.4	0.36	Bone mineral density;	chr8:70750263	chr8:70780914~70781008:-
OV	cis	rs7017914	0.616	rs12679132	ENSG00000223220.1	Y_RNA	5.74	2.99e-08	3.31e-05	0.4	0.36	Bone mineral density;	chr8:70750270	chr8:70780914~70781008:-
OV	cis	rs12134133	1	rs2802237	ENSG00000274245.1	RP11-357P18.2	5.74	3e-08	3.32e-05	0.47	0.36	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207300825	chr1:207372559~207373252:+
OV	cis	rs2243480	0.666	rs1880311	ENSG00000222364.1	RNU6-96P	5.74	3e-08	3.32e-05	0.57	0.36	Diabetic kidney disease;	chr7:65811765	chr7:66395191~66395286:+
OV	cis	rs2739330	0.587	rs4820571	ENSG00000231271.1	AP000350.8	5.74	3e-08	3.32e-05	0.43	0.36	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23949918~23954042:+
OV	cis	rs26232	0.583	rs26434	ENSG00000175749.11	EIF3KP1	-5.74	3e-08	3.33e-05	-0.43	-0.36	Rheumatoid arthritis;	chr5:103027698	chr5:103032376~103033031:+
OV	cis	rs2581828	0.618	rs6792345	ENSG00000242142.1	SERBP1P3	-5.74	3e-08	3.33e-05	-0.45	-0.36	Crohn's disease;	chr3:53131178	chr3:53064283~53065091:-
OV	cis	rs2581828	0.618	rs6792363	ENSG00000242142.1	SERBP1P3	-5.74	3e-08	3.33e-05	-0.45	-0.36	Crohn's disease;	chr3:53131247	chr3:53064283~53065091:-
OV	cis	rs2581828	0.618	rs6445565	ENSG00000242142.1	SERBP1P3	-5.74	3e-08	3.33e-05	-0.45	-0.36	Crohn's disease;	chr3:53131448	chr3:53064283~53065091:-
OV	cis	rs2581828	0.618	rs6784207	ENSG00000242142.1	SERBP1P3	-5.74	3e-08	3.33e-05	-0.45	-0.36	Crohn's disease;	chr3:53133458	chr3:53064283~53065091:-
OV	cis	rs293748	0.771	rs12656269	ENSG00000250155.1	CTD-2353F22.1	5.74	3.01e-08	3.33e-05	0.49	0.36	Obesity-related traits;	chr5:36787776	chr5:36666214~36725195:-
OV	cis	rs7849270	0.879	rs10760587	ENSG00000268707.1	RP11-247A12.7	5.74	3.01e-08	3.34e-05	0.38	0.36	Blood metabolite ratios;	chr9:129083737	chr9:129170434~129170940:+
OV	cis	rs7927771	0.832	rs10838698	ENSG00000280615.1	Y_RNA	5.74	3.02e-08	3.34e-05	0.43	0.36	Subjective well-being;	chr11:47364372	chr11:47614898~47614994:-
OV	cis	rs7927771	0.832	rs10838699	ENSG00000280615.1	Y_RNA	5.74	3.02e-08	3.34e-05	0.43	0.36	Subjective well-being;	chr11:47364522	chr11:47614898~47614994:-
OV	cis	rs7684253	0.565	rs7680140	ENSG00000269949.1	RP11-738E22.3	-5.74	3.02e-08	3.34e-05	-0.44	-0.36	Migraine;	chr4:56957291	chr4:56960927~56961373:-
OV	cis	rs3931020	0.616	rs277381	ENSG00000272864.1	RP11-17E13.2	5.74	3.02e-08	3.35e-05	0.49	0.36	Resistin levels;	chr1:74801131	chr1:74698769~74699333:-
OV	cis	rs7017914	0.905	rs10091471	ENSG00000223220.1	Y_RNA	5.74	3.03e-08	3.35e-05	0.37	0.36	Bone mineral density;	chr8:71041520	chr8:70780914~70781008:-
OV	cis	rs71327718	1	rs71327718	ENSG00000171084.14	FAM86JP	5.74	3.03e-08	3.35e-05	0.72	0.36	Metabolite levels (HVA/5-HIAA ratio);	chr3:125874014	chr3:125916620~125930024:+
OV	cis	rs10740039	0.583	rs9415608	ENSG00000254271.1	RP11-131N11.4	-5.74	3.03e-08	3.36e-05	-0.46	-0.36	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60737680	chr10:60734342~60741828:+
OV	cis	rs7267979	0.789	rs2260197	ENSG00000274973.1	RP13-401N8.7	-5.74	3.04e-08	3.37e-05	-0.42	-0.36	Liver enzyme levels (alkaline phosphatase);	chr20:25303707	chr20:25845497~25845862:+
OV	cis	rs1729407	0.565	rs2849173	ENSG00000254851.1	RP11-109L13.1	-5.74	3.04e-08	3.37e-05	-0.46	-0.36	Apolipoprotein A-IV levels;	chr11:116826605	chr11:117135528~117138582:+
OV	cis	rs11168351	0.889	rs12817104	ENSG00000258273.1	RP11-370I10.4	-5.74	3.06e-08	3.38e-05	-0.44	-0.36	Bipolar disorder and schizophrenia;	chr12:47988790	chr12:48333755~48333901:-
OV	cis	rs611744	0.905	rs421695	ENSG00000253754.1	RP11-35G22.1	-5.74	3.07e-08	3.39e-05	-0.4	-0.36	Dupuytren's disease;	chr8:108105175	chr8:108226200~108227544:+
OV	cis	rs2455601	0.786	rs10279	ENSG00000254860.4	TMEM9B-AS1	5.74	3.07e-08	3.4e-05	0.44	0.36	Schizophrenia;	chr11:8947762	chr11:8964675~8977527:+
OV	cis	rs2243480	0.708	rs781141	ENSG00000222364.1	RNU6-96P	-5.74	3.08e-08	3.41e-05	-0.54	-0.36	Diabetic kidney disease;	chr7:65973566	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs781142	ENSG00000222364.1	RNU6-96P	-5.74	3.08e-08	3.41e-05	-0.54	-0.36	Diabetic kidney disease;	chr7:65973791	chr7:66395191~66395286:+
OV	cis	rs73086581	0.645	rs2103659	ENSG00000229539.1	RP11-119B16.2	-5.74	3.09e-08	3.42e-05	-0.36	-0.36	Response to antidepressants in depression;	chr20:4001925	chr20:3888239~3888868:-
OV	cis	rs10510102	0.623	rs10159856	ENSG00000276742.1	RP11-500G22.4	5.74	3.09e-08	3.42e-05	0.63	0.36	Breast cancer;	chr10:121988292	chr10:121956782~121957098:+
OV	cis	rs611744	0.87	rs2212703	ENSG00000253754.1	RP11-35G22.1	-5.74	3.09e-08	3.42e-05	-0.41	-0.36	Dupuytren's disease;	chr8:108186172	chr8:108226200~108227544:+
OV	cis	rs875971	0.522	rs781144	ENSG00000224316.1	RP11-479O9.2	5.73	3.09e-08	3.42e-05	0.37	0.36	Aortic root size;	chr7:65975357	chr7:65773620~65802067:+
OV	cis	rs10740039	0.583	rs9415612	ENSG00000254271.1	RP11-131N11.4	-5.73	3.12e-08	3.44e-05	-0.46	-0.36	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60746638	chr10:60734342~60741828:+
OV	cis	rs8062405	0.755	rs17707300	ENSG00000259982.1	CDC37P1	5.73	3.12e-08	3.45e-05	0.43	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28700294~28701540:-
OV	cis	rs4713118	0.662	rs149946	ENSG00000280107.1	AL022393.9	5.73	3.13e-08	3.45e-05	0.45	0.36	Parkinson's disease;	chr6:28002253	chr6:28170845~28172521:+
OV	cis	rs7580658	0.724	rs7568261	ENSG00000236682.1	AC068282.3	-5.73	3.13e-08	3.46e-05	-0.44	-0.36	Protein C levels;	chr2:127359748	chr2:127389130~127400580:+
OV	cis	rs17711722	1	rs17711722	ENSG00000224316.1	RP11-479O9.2	-5.73	3.14e-08	3.46e-05	-0.37	-0.36	Calcium levels;	chr7:65806210	chr7:65773620~65802067:+
OV	cis	rs34779708	0.931	rs79749947	ENSG00000230534.5	RP11-297A16.2	5.73	3.14e-08	3.47e-05	0.48	0.36	Inflammatory bowel disease;Crohn's disease;	chr10:34988153	chr10:35098006~35127020:-
OV	cis	rs7927771	0.839	rs7124681	ENSG00000280615.1	Y_RNA	-5.73	3.15e-08	3.48e-05	-0.41	-0.36	Subjective well-being;	chr11:47508395	chr11:47614898~47614994:-
OV	cis	rs494459	0.838	rs1784543	ENSG00000278376.1	RP11-158I9.8	-5.73	3.16e-08	3.49e-05	-0.34	-0.36	Height;	chr11:118760944	chr11:118791254~118793137:+
OV	cis	rs10510102	0.872	rs11814703	ENSG00000226864.1	ATE1-AS1	5.73	3.17e-08	3.49e-05	0.58	0.36	Breast cancer;	chr10:121964774	chr10:121928312~121951965:+
OV	cis	rs10510102	0.872	rs12246728	ENSG00000226864.1	ATE1-AS1	5.73	3.17e-08	3.49e-05	0.58	0.36	Breast cancer;	chr10:121966618	chr10:121928312~121951965:+
OV	cis	rs10510102	0.872	rs12261371	ENSG00000226864.1	ATE1-AS1	5.73	3.17e-08	3.49e-05	0.58	0.36	Breast cancer;	chr10:121966686	chr10:121928312~121951965:+
OV	cis	rs10510102	0.872	rs11200292	ENSG00000226864.1	ATE1-AS1	5.73	3.17e-08	3.49e-05	0.58	0.36	Breast cancer;	chr10:121967383	chr10:121928312~121951965:+
OV	cis	rs10510102	0.808	rs17102804	ENSG00000226864.1	ATE1-AS1	5.73	3.17e-08	3.49e-05	0.58	0.36	Breast cancer;	chr10:121968365	chr10:121928312~121951965:+
OV	cis	rs10510102	0.872	rs12265369	ENSG00000226864.1	ATE1-AS1	5.73	3.17e-08	3.49e-05	0.58	0.36	Breast cancer;	chr10:121968455	chr10:121928312~121951965:+
OV	cis	rs10510102	0.872	rs12265542	ENSG00000226864.1	ATE1-AS1	5.73	3.17e-08	3.49e-05	0.58	0.36	Breast cancer;	chr10:121968740	chr10:121928312~121951965:+
OV	cis	rs10510102	0.872	rs11200293	ENSG00000226864.1	ATE1-AS1	5.73	3.17e-08	3.49e-05	0.58	0.36	Breast cancer;	chr10:121969195	chr10:121928312~121951965:+
OV	cis	rs8062405	0.721	rs151181	ENSG00000278665.1	RP11-666O2.4	5.73	3.17e-08	3.5e-05	0.37	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28479196	chr16:28599241~28601881:-
OV	cis	rs9291683	0.632	rs11734786	ENSG00000250413.1	RP11-448G15.1	-5.73	3.18e-08	3.51e-05	-0.41	-0.36	Bone mineral density;	chr4:10039875	chr4:10006482~10009725:+
OV	cis	rs1075265	0.554	rs10168293	ENSG00000233266.1	HMGB1P31	5.73	3.2e-08	3.53e-05	0.44	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53973793	chr2:54051334~54051760:+
OV	cis	rs1075265	0.567	rs66773232	ENSG00000233266.1	HMGB1P31	5.73	3.2e-08	3.53e-05	0.44	0.36	Chronotype;Morning vs. evening chronotype;	chr2:53973970	chr2:54051334~54051760:+
OV	cis	rs4713118	0.621	rs9295755	ENSG00000280107.1	AL022393.9	5.73	3.21e-08	3.54e-05	0.45	0.36	Parkinson's disease;	chr6:28065396	chr6:28170845~28172521:+
OV	cis	rs875971	0.522	rs1880556	ENSG00000224316.1	RP11-479O9.2	5.73	3.23e-08	3.56e-05	0.37	0.36	Aortic root size;	chr7:65967557	chr7:65773620~65802067:+
OV	cis	rs875971	0.522	rs1917563	ENSG00000224316.1	RP11-479O9.2	-5.73	3.24e-08	3.56e-05	-0.37	-0.36	Aortic root size;	chr7:65950660	chr7:65773620~65802067:+
OV	cis	rs2999052	0.602	rs1625296	ENSG00000277250.1	Metazoa_SRP	5.73	3.24e-08	3.57e-05	0.46	0.36	Hypospadias;	chr3:128389139	chr3:128673681~128674021:-
OV	cis	rs67311347	1	rs11707673	ENSG00000223797.4	ENTPD3-AS1	5.73	3.24e-08	3.57e-05	0.39	0.36	Renal cell carcinoma;	chr3:40409113	chr3:40313802~40453329:-
OV	cis	rs3091242	0.933	rs12402120	ENSG00000224183.1	SDHDP6	-5.73	3.25e-08	3.57e-05	-0.42	-0.36	Erythrocyte sedimentation rate;	chr1:25425141	chr1:25294164~25294643:-
OV	cis	rs7811142	0.83	rs11771936	ENSG00000242294.5	STAG3L5P	5.72	3.26e-08	3.59e-05	0.37	0.36	Platelet count;	chr7:100345660	chr7:100336079~100351900:+
OV	cis	rs7811142	0.83	rs28495773	ENSG00000242294.5	STAG3L5P	5.72	3.26e-08	3.59e-05	0.37	0.36	Platelet count;	chr7:100345960	chr7:100336079~100351900:+
OV	cis	rs2282300	0.637	rs13642	ENSG00000254532.1	RP11-624D11.2	5.72	3.26e-08	3.59e-05	0.41	0.36	Morning vs. evening chronotype;	chr11:30410673	chr11:30044058~30084343:-
OV	cis	rs10510102	0.872	rs28586586	ENSG00000226864.1	ATE1-AS1	5.72	3.26e-08	3.59e-05	0.59	0.36	Breast cancer;	chr10:121950228	chr10:121928312~121951965:+
OV	cis	rs7017914	0.652	rs62532068	ENSG00000223220.1	Y_RNA	5.72	3.27e-08	3.59e-05	0.4	0.36	Bone mineral density;	chr8:70750952	chr8:70780914~70781008:-
OV	cis	rs7017914	0.617	rs111678999	ENSG00000223220.1	Y_RNA	5.72	3.27e-08	3.59e-05	0.4	0.36	Bone mineral density;	chr8:70755748	chr8:70780914~70781008:-
OV	cis	rs7017914	0.653	rs13273718	ENSG00000223220.1	Y_RNA	5.72	3.27e-08	3.59e-05	0.4	0.36	Bone mineral density;	chr8:70757485	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs17760766	ENSG00000223220.1	Y_RNA	5.72	3.27e-08	3.59e-05	0.4	0.36	Bone mineral density;	chr8:70758954	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs1444343	ENSG00000223220.1	Y_RNA	5.72	3.27e-08	3.59e-05	0.4	0.36	Bone mineral density;	chr8:70760749	chr8:70780914~70781008:-
OV	cis	rs7017914	0.69	rs35074484	ENSG00000223220.1	Y_RNA	5.72	3.27e-08	3.59e-05	0.4	0.36	Bone mineral density;	chr8:70762526	chr8:70780914~70781008:-
OV	cis	rs992157	0.965	rs62182826	ENSG00000237281.1	CATIP-AS2	-5.72	3.27e-08	3.59e-05	-0.4	-0.36	Colorectal cancer;	chr2:218284000	chr2:218326889~218357966:-
OV	cis	rs8062405	0.723	rs4788079	ENSG00000259982.1	CDC37P1	5.72	3.28e-08	3.6e-05	0.44	0.36	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28700294~28701540:-
OV	cis	rs875971	0.522	rs2949690	ENSG00000224316.1	RP11-479O9.2	-5.72	3.28e-08	3.6e-05	-0.37	-0.36	Aortic root size;	chr7:66018255	chr7:65773620~65802067:+
OV	cis	rs4660456	0.913	rs552147	ENSG00000237899.1	RP4-739H11.3	-5.72	3.28e-08	3.6e-05	-0.5	-0.36	Platelet count;	chr1:40689141	chr1:40669089~40687588:-
OV	cis	rs34375054	0.738	rs3751181	ENSG00000279233.1	RP11-158L12.4	5.72	3.29e-08	3.61e-05	0.29	0.36	Post bronchodilator FEV1/FVC ratio;	chr12:125141989	chr12:125138245~125141711:+
OV	cis	rs4761702	0.857	rs1135400	ENSG00000257322.4	RP11-511B23.2	5.72	3.31e-08	3.64e-05	0.39	0.36	Immature fraction of reticulocytes;	chr12:93315763	chr12:93003415~93215679:-
OV	cis	rs7626444	0.585	rs860050	ENSG00000272359.1	U4	-5.72	3.31e-08	3.64e-05	-0.37	-0.36	Monocyte count;	chr3:196747576	chr3:196747192~196747324:-
OV	cis	rs7302981	0.741	rs8181679	ENSG00000272368.2	RP4-605O3.4	-5.72	3.32e-08	3.65e-05	-0.4	-0.35	Systolic blood pressure;	chr12:50217237	chr12:50112197~50165618:+
OV	cis	rs7626444	0.625	rs843539	ENSG00000272359.1	U4	-5.72	3.32e-08	3.65e-05	-0.37	-0.35	Monocyte count;	chr3:196747985	chr3:196747192~196747324:-
OV	cis	rs7044106	0.762	rs10984974	ENSG00000226752.6	PSMD5-AS1	-5.72	3.33e-08	3.65e-05	-0.41	-0.35	Hip circumference adjusted for BMI;	chr9:120659278	chr9:120824828~120854385:+
OV	cis	rs2188561	0.697	rs6947099	ENSG00000241764.3	AC002467.7	5.72	3.33e-08	3.66e-05	0.42	0.35	Alcohol consumption;	chr7:107720471	chr7:107742817~107744581:-
OV	cis	rs494459	0.838	rs581045	ENSG00000278376.1	RP11-158I9.8	-5.72	3.33e-08	3.66e-05	-0.34	-0.35	Height;	chr11:118761813	chr11:118791254~118793137:+
OV	cis	rs796364	0.587	rs7588746	ENSG00000232732.8	AC073043.1	-5.72	3.34e-08	3.67e-05	-0.49	-0.35	Schizophrenia;	chr2:200121622	chr2:199867396~199911159:-
OV	cis	rs73086581	0.617	rs2300213	ENSG00000229539.1	RP11-119B16.2	-5.72	3.34e-08	3.67e-05	-0.37	-0.35	Response to antidepressants in depression;	chr20:4006076	chr20:3888239~3888868:-
OV	cis	rs7615952	0.673	rs115942855	ENSG00000171084.14	FAM86JP	5.72	3.34e-08	3.67e-05	0.74	0.35	Blood pressure (smoking interaction);	chr3:125883117	chr3:125916620~125930024:+
OV	cis	rs11690935	0.595	rs788170	ENSG00000228389.1	AC068039.4	-5.72	3.35e-08	3.67e-05	-0.4	-0.35	Schizophrenia;	chr2:172055230	chr2:171773482~171775844:+
OV	cis	rs2153535	0.585	rs7750891	ENSG00000230939.1	RP11-314C16.1	-5.72	3.35e-08	3.67e-05	-0.38	-0.35	Motion sickness;	chr6:8624613	chr6:8784178~8785445:+
OV	cis	rs7017914	0.652	rs11987148	ENSG00000223220.1	Y_RNA	5.72	3.36e-08	3.68e-05	0.4	0.35	Bone mineral density;	chr8:70749075	chr8:70780914~70781008:-
OV	cis	rs7688540	0.656	rs79657896	ENSG00000275426.1	CH17-262A2.1	5.72	3.36e-08	3.68e-05	0.6	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:305472	chr4:149738~150317:+
OV	cis	rs12134133	1	rs6660557	ENSG00000274245.1	RP11-357P18.2	5.72	3.36e-08	3.68e-05	0.46	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207281251	chr1:207372559~207373252:+
OV	cis	rs12134133	1	rs7521457	ENSG00000274245.1	RP11-357P18.2	5.72	3.36e-08	3.68e-05	0.46	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207283802	chr1:207372559~207373252:+
OV	cis	rs12134133	1	rs7553157	ENSG00000274245.1	RP11-357P18.2	5.72	3.36e-08	3.68e-05	0.46	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207283922	chr1:207372559~207373252:+
OV	cis	rs12134133	1	rs7553339	ENSG00000274245.1	RP11-357P18.2	5.72	3.36e-08	3.68e-05	0.46	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207284075	chr1:207372559~207373252:+
OV	cis	rs12134133	1	rs6668683	ENSG00000274245.1	RP11-357P18.2	5.72	3.36e-08	3.68e-05	0.46	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207285846	chr1:207372559~207373252:+
OV	cis	rs11673344	0.526	rs55754546	ENSG00000226686.6	LINC01535	5.72	3.38e-08	3.7e-05	0.46	0.35	Obesity-related traits;	chr19:37552860	chr19:37251912~37265535:+
OV	cis	rs7302981	0.741	rs4459386	ENSG00000272368.2	RP4-605O3.4	-5.72	3.38e-08	3.71e-05	-0.4	-0.35	Systolic blood pressure;	chr12:50201164	chr12:50112197~50165618:+
OV	cis	rs12134133	1	rs2782842	ENSG00000274245.1	RP11-357P18.2	5.72	3.39e-08	3.71e-05	0.46	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310231	chr1:207372559~207373252:+
OV	cis	rs765787	0.53	rs12439643	ENSG00000259520.4	CTD-2651B20.3	-5.72	3.39e-08	3.71e-05	-0.44	-0.35	Uric acid levels;	chr15:45237569	chr15:45251580~45279251:-
OV	cis	rs858239	0.6	rs7785842	ENSG00000230042.1	AK3P3	-5.72	3.42e-08	3.74e-05	-0.37	-0.35	Cerebrospinal fluid biomarker levels;	chr7:23102087	chr7:23129178~23129841:+
OV	cis	rs8062405	0.755	rs4788080	ENSG00000259982.1	CDC37P1	5.72	3.42e-08	3.75e-05	0.44	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28700294~28701540:-
OV	cis	rs7626444	0.625	rs843535	ENSG00000272359.1	U4	-5.72	3.43e-08	3.75e-05	-0.36	-0.35	Monocyte count;	chr3:196746193	chr3:196747192~196747324:-
OV	cis	rs7626444	0.647	rs843537	ENSG00000272359.1	U4	-5.72	3.43e-08	3.75e-05	-0.36	-0.35	Monocyte count;	chr3:196746532	chr3:196747192~196747324:-
OV	cis	rs7626444	0.625	rs1798634	ENSG00000272359.1	U4	-5.72	3.43e-08	3.75e-05	-0.36	-0.35	Monocyte count;	chr3:196747416	chr3:196747192~196747324:-
OV	cis	rs7626444	0.625	rs1798635	ENSG00000272359.1	U4	-5.72	3.43e-08	3.75e-05	-0.36	-0.35	Monocyte count;	chr3:196747418	chr3:196747192~196747324:-
OV	cis	rs7688540	0.771	rs10021364	ENSG00000275426.1	CH17-262A2.1	-5.71	3.45e-08	3.78e-05	-0.6	-0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:316902	chr4:149738~150317:+
OV	cis	rs1729407	0.659	rs2542050	ENSG00000254851.1	RP11-109L13.1	-5.71	3.45e-08	3.78e-05	-0.46	-0.35	Apolipoprotein A-IV levels;	chr11:116826401	chr11:117135528~117138582:+
OV	cis	rs4563143	0.647	rs34218744	ENSG00000267243.4	AC005307.3	-5.71	3.46e-08	3.78e-05	-0.58	-0.35	Methadone dose in opioid dependence;	chr19:28765914	chr19:28435388~28727777:-
OV	cis	rs4563143	0.647	rs117946634	ENSG00000267243.4	AC005307.3	-5.71	3.46e-08	3.78e-05	-0.58	-0.35	Methadone dose in opioid dependence;	chr19:28765915	chr19:28435388~28727777:-
OV	cis	rs4563143	0.647	rs117442062	ENSG00000267243.4	AC005307.3	-5.71	3.46e-08	3.78e-05	-0.58	-0.35	Methadone dose in opioid dependence;	chr19:28765916	chr19:28435388~28727777:-
OV	cis	rs4713118	0.513	rs149941	ENSG00000220721.1	OR1F12	5.71	3.46e-08	3.79e-05	0.41	0.35	Parkinson's disease;	chr6:28033255	chr6:28073316~28074233:+
OV	cis	rs13217239	0.646	rs6937880	ENSG00000243307.2	POM121L6P	5.71	3.47e-08	3.8e-05	0.35	0.35	Schizophrenia;	chr6:27032457	chr6:26896952~26898777:+
OV	cis	rs13217239	0.621	rs12527231	ENSG00000243307.2	POM121L6P	5.71	3.48e-08	3.8e-05	0.35	0.35	Schizophrenia;	chr6:27033509	chr6:26896952~26898777:+
OV	cis	rs13217239	0.646	rs12523820	ENSG00000243307.2	POM121L6P	5.71	3.48e-08	3.8e-05	0.35	0.35	Schizophrenia;	chr6:27033723	chr6:26896952~26898777:+
OV	cis	rs3091242	0.933	rs61775167	ENSG00000224183.1	SDHDP6	5.71	3.48e-08	3.81e-05	0.41	0.35	Erythrocyte sedimentation rate;	chr1:25454402	chr1:25294164~25294643:-
OV	cis	rs7017914	0.652	rs2035929	ENSG00000223220.1	Y_RNA	-5.71	3.5e-08	3.83e-05	-0.38	-0.35	Bone mineral density;	chr8:71001137	chr8:70780914~70781008:-
OV	cis	rs875971	0.54	rs4717275	ENSG00000224316.1	RP11-479O9.2	-5.71	3.5e-08	3.83e-05	-0.37	-0.35	Aortic root size;	chr7:65800193	chr7:65773620~65802067:+
OV	cis	rs4660456	0.913	rs2361651	ENSG00000237899.1	RP4-739H11.3	5.71	3.51e-08	3.84e-05	0.51	0.35	Platelet count;	chr1:40764542	chr1:40669089~40687588:-
OV	cis	rs4713118	0.868	rs10484401	ENSG00000220721.1	OR1F12	-5.71	3.51e-08	3.84e-05	-0.4	-0.35	Parkinson's disease;	chr6:27778811	chr6:28073316~28074233:+
OV	cis	rs13217239	0.646	rs10946898	ENSG00000243307.2	POM121L6P	5.71	3.52e-08	3.84e-05	0.35	0.35	Schizophrenia;	chr6:27036105	chr6:26896952~26898777:+
OV	cis	rs7017914	0.652	rs11994581	ENSG00000223220.1	Y_RNA	5.71	3.52e-08	3.84e-05	0.4	0.35	Bone mineral density;	chr8:70862172	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs34301443	ENSG00000223220.1	Y_RNA	5.71	3.52e-08	3.84e-05	0.4	0.35	Bone mineral density;	chr8:70863161	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs34768553	ENSG00000223220.1	Y_RNA	5.71	3.52e-08	3.84e-05	0.4	0.35	Bone mineral density;	chr8:70864755	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs35343840	ENSG00000223220.1	Y_RNA	5.71	3.52e-08	3.84e-05	0.4	0.35	Bone mineral density;	chr8:70865160	chr8:70780914~70781008:-
OV	cis	rs7017914	0.628	rs7015825	ENSG00000223220.1	Y_RNA	5.71	3.52e-08	3.84e-05	0.4	0.35	Bone mineral density;	chr8:70866438	chr8:70780914~70781008:-
OV	cis	rs11976180	1	rs1533268	ENSG00000170356.8	OR2A20P	-5.71	3.53e-08	3.85e-05	-0.5	-0.35	Obesity-related traits;	chr7:144069265	chr7:144250045~144252957:-
OV	cis	rs11976180	1	rs1533266	ENSG00000170356.8	OR2A20P	-5.71	3.53e-08	3.85e-05	-0.5	-0.35	Obesity-related traits;	chr7:144069621	chr7:144250045~144252957:-
OV	cis	rs6088580	0.634	rs1205345	ENSG00000206582.1	Y_RNA	5.71	3.53e-08	3.85e-05	0.43	0.35	Glomerular filtration rate (creatinine);	chr20:34326893	chr20:34526510~34526606:-
OV	cis	rs34779708	0.931	rs11010132	ENSG00000230534.5	RP11-297A16.2	5.71	3.55e-08	3.87e-05	0.45	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35228337	chr10:35098006~35127020:-
OV	cis	rs611744	0.87	rs429884	ENSG00000253754.1	RP11-35G22.1	-5.71	3.56e-08	3.88e-05	-0.4	-0.35	Dupuytren's disease;	chr8:108102894	chr8:108226200~108227544:+
OV	cis	rs611744	0.837	rs438191	ENSG00000253754.1	RP11-35G22.1	-5.71	3.56e-08	3.88e-05	-0.4	-0.35	Dupuytren's disease;	chr8:108111994	chr8:108226200~108227544:+
OV	cis	rs11976180	1	rs2961120	ENSG00000170356.8	OR2A20P	-5.71	3.56e-08	3.89e-05	-0.5	-0.35	Obesity-related traits;	chr7:144059492	chr7:144250045~144252957:-
OV	cis	rs611744	0.846	rs405534	ENSG00000253754.1	RP11-35G22.1	-5.71	3.57e-08	3.89e-05	-0.39	-0.35	Dupuytren's disease;	chr8:108142180	chr8:108226200~108227544:+
OV	cis	rs957448	1	rs7829886	ENSG00000253704.1	RP11-267M23.4	5.71	3.57e-08	3.89e-05	0.46	0.35	Nonsyndromic cleft lip with cleft palate;	chr8:94485160	chr8:94553722~94569745:+
OV	cis	rs611744	0.934	rs1452021	ENSG00000253754.1	RP11-35G22.1	-5.71	3.57e-08	3.89e-05	-0.39	-0.35	Dupuytren's disease;	chr8:108195657	chr8:108226200~108227544:+
OV	cis	rs611744	0.967	rs603571	ENSG00000253754.1	RP11-35G22.1	-5.71	3.57e-08	3.89e-05	-0.39	-0.35	Dupuytren's disease;	chr8:108201664	chr8:108226200~108227544:+
OV	cis	rs12682352	0.579	rs7006589	ENSG00000253893.2	FAM85B	-5.71	3.58e-08	3.9e-05	-0.4	-0.35	Neuroticism;	chr8:8810976	chr8:8167819~8226614:-
OV	cis	rs8062405	0.756	rs151182	ENSG00000278665.1	RP11-666O2.4	5.71	3.58e-08	3.9e-05	0.38	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28484431	chr16:28599241~28601881:-
OV	cis	rs16873450	0.9	rs6963050	ENSG00000234800.2	PCMTD1P3	5.71	3.58e-08	3.91e-05	0.37	0.35	Verbal memory performance (residualized delayed recall level);	chr7:23738590	chr7:23721311~23721782:-
OV	cis	rs1075265	0.633	rs10183655	ENSG00000233266.1	HMGB1P31	5.71	3.59e-08	3.91e-05	0.44	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53983644	chr2:54051334~54051760:+
OV	cis	rs67311347	1	rs73080137	ENSG00000223797.4	ENTPD3-AS1	5.71	3.59e-08	3.91e-05	0.39	0.35	Renal cell carcinoma;	chr3:40474921	chr3:40313802~40453329:-
OV	cis	rs2254546	0.516	rs7014565	ENSG00000255052.4	FAM66D	-5.71	3.59e-08	3.92e-05	-0.56	-0.35	Systemic lupus erythematosus;Kawasaki disease;	chr8:11539309	chr8:12115782~12177550:+
OV	cis	rs17711722	0.653	rs2460421	ENSG00000224316.1	RP11-479O9.2	-5.71	3.6e-08	3.92e-05	-0.38	-0.35	Calcium levels;	chr7:66026136	chr7:65773620~65802067:+
OV	cis	rs7626444	0.625	rs2931210	ENSG00000272359.1	U4	-5.7	3.62e-08	3.94e-05	-0.36	-0.35	Monocyte count;	chr3:196749805	chr3:196747192~196747324:-
OV	cis	rs2581828	0.646	rs13433700	ENSG00000242142.1	SERBP1P3	-5.7	3.62e-08	3.95e-05	-0.43	-0.35	Crohn's disease;	chr3:53113870	chr3:53064283~53065091:-
OV	cis	rs67311347	0.956	rs12633446	ENSG00000223797.4	ENTPD3-AS1	-5.7	3.63e-08	3.95e-05	-0.39	-0.35	Renal cell carcinoma;	chr3:40464170	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs7617989	ENSG00000223797.4	ENTPD3-AS1	-5.7	3.63e-08	3.95e-05	-0.39	-0.35	Renal cell carcinoma;	chr3:40470972	chr3:40313802~40453329:-
OV	cis	rs4713118	0.662	rs149947	ENSG00000219392.1	RP1-265C24.5	-5.7	3.63e-08	3.96e-05	-0.45	-0.35	Parkinson's disease;	chr6:28004655	chr6:28115628~28116551:+
OV	cis	rs7044106	0.762	rs1324473	ENSG00000226752.6	PSMD5-AS1	5.7	3.65e-08	3.97e-05	0.42	0.35	Hip circumference adjusted for BMI;	chr9:120642332	chr9:120824828~120854385:+
OV	cis	rs12134133	1	rs10494890	ENSG00000274245.1	RP11-357P18.2	-5.7	3.65e-08	3.97e-05	-0.47	-0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207251041	chr1:207372559~207373252:+
OV	cis	rs2153535	0.585	rs4960448	ENSG00000230939.1	RP11-314C16.1	-5.7	3.65e-08	3.97e-05	-0.38	-0.35	Motion sickness;	chr6:8624438	chr6:8784178~8785445:+
OV	cis	rs2115630	1	rs6496441	ENSG00000235370.6	DNM1P51	-5.7	3.65e-08	3.98e-05	-0.37	-0.35	P wave terminal force;	chr15:84820117	chr15:84398316~84411701:-
OV	cis	rs7267979	0.789	rs6083820	ENSG00000274973.1	RP13-401N8.7	5.7	3.66e-08	3.98e-05	0.42	0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25373542	chr20:25845497~25845862:+
OV	cis	rs7267979	0.789	rs62213729	ENSG00000274973.1	RP13-401N8.7	5.7	3.66e-08	3.98e-05	0.42	0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25382790	chr20:25845497~25845862:+
OV	cis	rs7811142	0.779	rs111312383	ENSG00000242294.5	STAG3L5P	5.7	3.67e-08	3.99e-05	0.38	0.35	Platelet count;	chr7:100307702	chr7:100336079~100351900:+
OV	cis	rs1075265	0.783	rs805359	ENSG00000233266.1	HMGB1P31	5.7	3.69e-08	4.01e-05	0.43	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53935317	chr2:54051334~54051760:+
OV	cis	rs4713118	0.513	rs149989	ENSG00000220721.1	OR1F12	5.7	3.7e-08	4.02e-05	0.41	0.35	Parkinson's disease;	chr6:28030406	chr6:28073316~28074233:+
OV	cis	rs7017914	0.905	rs2639960	ENSG00000223220.1	Y_RNA	5.7	3.7e-08	4.03e-05	0.37	0.35	Bone mineral density;	chr8:71009904	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs1908036	ENSG00000223220.1	Y_RNA	5.7	3.7e-08	4.03e-05	0.37	0.35	Bone mineral density;	chr8:71010089	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs1908035	ENSG00000223220.1	Y_RNA	5.7	3.7e-08	4.03e-05	0.37	0.35	Bone mineral density;	chr8:71010173	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs1908034	ENSG00000223220.1	Y_RNA	5.7	3.7e-08	4.03e-05	0.37	0.35	Bone mineral density;	chr8:71010319	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs2732104	ENSG00000223220.1	Y_RNA	5.7	3.7e-08	4.03e-05	0.37	0.35	Bone mineral density;	chr8:71011284	chr8:70780914~70781008:-
OV	cis	rs3091242	0.933	rs4649084	ENSG00000224183.1	SDHDP6	-5.7	3.72e-08	4.04e-05	-0.42	-0.35	Erythrocyte sedimentation rate;	chr1:25426126	chr1:25294164~25294643:-
OV	cis	rs977987	0.835	rs8046109	ENSG00000261783.1	RP11-252K23.2	-5.7	3.73e-08	4.05e-05	-0.45	-0.35	Dupuytren's disease;	chr16:75326198	chr16:75379818~75381260:-
OV	cis	rs7017914	0.905	rs2639958	ENSG00000223220.1	Y_RNA	5.7	3.73e-08	4.06e-05	0.37	0.35	Bone mineral density;	chr8:71009915	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs1908033	ENSG00000223220.1	Y_RNA	5.7	3.73e-08	4.06e-05	0.37	0.35	Bone mineral density;	chr8:71010564	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs2732103	ENSG00000223220.1	Y_RNA	5.7	3.73e-08	4.06e-05	0.37	0.35	Bone mineral density;	chr8:71011261	chr8:70780914~70781008:-
OV	cis	rs12134133	1	rs2564973	ENSG00000274245.1	RP11-357P18.2	5.7	3.76e-08	4.09e-05	0.47	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207306759	chr1:207372559~207373252:+
OV	cis	rs7017914	0.652	rs56108781	ENSG00000223220.1	Y_RNA	5.7	3.77e-08	4.09e-05	0.4	0.35	Bone mineral density;	chr8:70816519	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs34751830	ENSG00000223220.1	Y_RNA	5.7	3.77e-08	4.09e-05	0.4	0.35	Bone mineral density;	chr8:70818239	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs35318824	ENSG00000223220.1	Y_RNA	5.7	3.77e-08	4.09e-05	0.4	0.35	Bone mineral density;	chr8:70820387	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs13281838	ENSG00000223220.1	Y_RNA	5.7	3.77e-08	4.09e-05	0.4	0.35	Bone mineral density;	chr8:70822207	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs1822651	ENSG00000223220.1	Y_RNA	5.7	3.77e-08	4.09e-05	0.4	0.35	Bone mineral density;	chr8:70824426	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs6982838	ENSG00000223220.1	Y_RNA	5.7	3.77e-08	4.09e-05	0.4	0.35	Bone mineral density;	chr8:70830504	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs1457198	ENSG00000223220.1	Y_RNA	5.7	3.77e-08	4.09e-05	0.4	0.35	Bone mineral density;	chr8:70834934	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs35921782	ENSG00000223220.1	Y_RNA	5.7	3.77e-08	4.09e-05	0.4	0.35	Bone mineral density;	chr8:70836689	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs1156955	ENSG00000223220.1	Y_RNA	5.7	3.77e-08	4.09e-05	0.4	0.35	Bone mineral density;	chr8:70842724	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs35380538	ENSG00000223220.1	Y_RNA	5.7	3.77e-08	4.09e-05	0.4	0.35	Bone mineral density;	chr8:70845432	chr8:70780914~70781008:-
OV	cis	rs7017914	0.628	rs10957532	ENSG00000223220.1	Y_RNA	5.7	3.77e-08	4.09e-05	0.4	0.35	Bone mineral density;	chr8:70845775	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs62510667	ENSG00000223220.1	Y_RNA	5.7	3.77e-08	4.09e-05	0.4	0.35	Bone mineral density;	chr8:70850458	chr8:70780914~70781008:-
OV	cis	rs7017914	0.69	rs13274981	ENSG00000223220.1	Y_RNA	5.7	3.77e-08	4.09e-05	0.4	0.35	Bone mineral density;	chr8:70853045	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs6985251	ENSG00000223220.1	Y_RNA	5.7	3.77e-08	4.09e-05	0.4	0.35	Bone mineral density;	chr8:70853620	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs11991584	ENSG00000223220.1	Y_RNA	5.7	3.77e-08	4.09e-05	0.4	0.35	Bone mineral density;	chr8:70859112	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs11991605	ENSG00000223220.1	Y_RNA	5.7	3.77e-08	4.09e-05	0.4	0.35	Bone mineral density;	chr8:70859117	chr8:70780914~70781008:-
OV	cis	rs35160687	0.901	rs12478653	ENSG00000273080.1	RP11-301O19.1	-5.7	3.77e-08	4.09e-05	-0.34	-0.35	Night sleep phenotypes;	chr2:86308271	chr2:86195590~86196049:+
OV	cis	rs61990749	0.597	rs12887282	ENSG00000239272.1	RPL21P10	5.7	3.77e-08	4.1e-05	0.49	0.35	Fibroblast growth factor basic levels;	chr14:77734242	chr14:77683202~77683989:-
OV	cis	rs61990749	0.597	rs12887606	ENSG00000239272.1	RPL21P10	5.7	3.77e-08	4.1e-05	0.49	0.35	Fibroblast growth factor basic levels;	chr14:77734277	chr14:77683202~77683989:-
OV	cis	rs7684253	0.565	rs13108570	ENSG00000269949.1	RP11-738E22.3	-5.7	3.78e-08	4.1e-05	-0.43	-0.35	Migraine;	chr4:56940917	chr4:56960927~56961373:-
OV	cis	rs11673344	0.526	rs17303902	ENSG00000226686.6	LINC01535	5.7	3.79e-08	4.11e-05	0.46	0.35	Obesity-related traits;	chr19:37551912	chr19:37251912~37265535:+
OV	cis	rs62355901	0.599	rs62355875	ENSG00000271828.1	CTD-2310F14.1	5.69	3.8e-08	4.12e-05	0.71	0.35	Breast cancer;	chr5:56729353	chr5:56927874~56929573:+
OV	cis	rs62355901	0.599	rs62355876	ENSG00000271828.1	CTD-2310F14.1	5.69	3.8e-08	4.12e-05	0.71	0.35	Breast cancer;	chr5:56729373	chr5:56927874~56929573:+
OV	cis	rs34779708	0.897	rs9787566	ENSG00000230534.5	RP11-297A16.2	5.69	3.81e-08	4.13e-05	0.47	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:34990527	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs4351760	ENSG00000230534.5	RP11-297A16.2	5.69	3.81e-08	4.13e-05	0.47	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:34991326	chr10:35098006~35127020:-
OV	cis	rs34779708	0.898	rs4934695	ENSG00000230534.5	RP11-297A16.2	5.69	3.81e-08	4.13e-05	0.47	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:34991677	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs11597483	ENSG00000230534.5	RP11-297A16.2	5.69	3.81e-08	4.13e-05	0.47	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:34996189	chr10:35098006~35127020:-
OV	cis	rs35160687	0.901	rs10520415	ENSG00000273080.1	RP11-301O19.1	-5.69	3.84e-08	4.16e-05	-0.35	-0.35	Night sleep phenotypes;	chr2:86271615	chr2:86195590~86196049:+
OV	cis	rs9291683	0.595	rs35250962	ENSG00000250413.1	RP11-448G15.1	-5.69	3.87e-08	4.19e-05	-0.41	-0.35	Bone mineral density;	chr4:10046647	chr4:10006482~10009725:+
OV	cis	rs8005677	0.828	rs12589539	ENSG00000257285.4	RP11-298I3.1	5.69	3.88e-08	4.2e-05	0.43	0.35	Cognitive ability (multi-trait analysis);	chr14:22927471	chr14:22929609~22955562:+
OV	cis	rs7829975	0.711	rs12682352	ENSG00000253893.2	FAM85B	-5.69	3.88e-08	4.2e-05	-0.37	-0.35	Mood instability;	chr8:8788736	chr8:8167819~8226614:-
OV	cis	rs8062405	0.754	rs149299	ENSG00000259982.1	CDC37P1	5.69	3.88e-08	4.21e-05	0.43	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28700294~28701540:-
OV	cis	rs11690935	0.595	rs788166	ENSG00000228389.1	AC068039.4	-5.69	3.9e-08	4.22e-05	-0.4	-0.35	Schizophrenia;	chr2:172050761	chr2:171773482~171775844:+
OV	cis	rs62355901	0.599	rs751990	ENSG00000271828.1	CTD-2310F14.1	5.69	3.9e-08	4.23e-05	0.64	0.35	Breast cancer;	chr5:56743292	chr5:56927874~56929573:+
OV	cis	rs4713118	0.662	rs156744	ENSG00000219392.1	RP1-265C24.5	-5.69	3.91e-08	4.23e-05	-0.45	-0.35	Parkinson's disease;	chr6:27999496	chr6:28115628~28116551:+
OV	cis	rs7487637	0.529	rs11168245	ENSG00000276691.1	RP5-1057I20.5	5.69	3.94e-08	4.27e-05	0.39	0.35	Mononucleosis;	chr12:47810716	chr12:47788426~47788971:+
OV	cis	rs67340775	0.541	rs169287	ENSG00000280107.1	AL022393.9	-5.69	3.95e-08	4.27e-05	-0.49	-0.35	Lung cancer in ever smokers;	chr6:27886982	chr6:28170845~28172521:+
OV	cis	rs67340775	0.541	rs200966	ENSG00000280107.1	AL022393.9	-5.69	3.95e-08	4.27e-05	-0.49	-0.35	Lung cancer in ever smokers;	chr6:27894374	chr6:28170845~28172521:+
OV	cis	rs875971	0.54	rs736270	ENSG00000224316.1	RP11-479O9.2	5.69	3.95e-08	4.28e-05	0.37	0.35	Aortic root size;	chr7:65963835	chr7:65773620~65802067:+
OV	cis	rs67311347	1	rs7628796	ENSG00000223797.4	ENTPD3-AS1	-5.69	3.96e-08	4.28e-05	-0.39	-0.35	Renal cell carcinoma;	chr3:40465841	chr3:40313802~40453329:-
OV	cis	rs67311347	0.91	rs7651204	ENSG00000223797.4	ENTPD3-AS1	-5.69	3.96e-08	4.28e-05	-0.39	-0.35	Renal cell carcinoma;	chr3:40471344	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs7633809	ENSG00000223797.4	ENTPD3-AS1	-5.69	3.96e-08	4.28e-05	-0.39	-0.35	Renal cell carcinoma;	chr3:40476246	chr3:40313802~40453329:-
OV	cis	rs67311347	0.956	rs4974029	ENSG00000223797.4	ENTPD3-AS1	5.69	3.96e-08	4.28e-05	0.39	0.35	Renal cell carcinoma;	chr3:40479827	chr3:40313802~40453329:-
OV	cis	rs62355901	0.545	rs2113084	ENSG00000271828.1	CTD-2310F14.1	5.69	3.99e-08	4.31e-05	0.64	0.35	Breast cancer;	chr5:56737844	chr5:56927874~56929573:+
OV	cis	rs7429990	0.965	rs7430879	ENSG00000229759.1	MRPS18AP1	-5.68	4e-08	4.32e-05	-0.37	-0.35	Educational attainment (years of education);	chr3:47997224	chr3:48256350~48256938:-
OV	cis	rs7429990	0.932	rs4293721	ENSG00000229759.1	MRPS18AP1	-5.68	4e-08	4.32e-05	-0.37	-0.35	Educational attainment (years of education);	chr3:48003647	chr3:48256350~48256938:-
OV	cis	rs7429990	0.965	rs11130154	ENSG00000229759.1	MRPS18AP1	-5.68	4e-08	4.32e-05	-0.37	-0.35	Educational attainment (years of education);	chr3:48027752	chr3:48256350~48256938:-
OV	cis	rs7429990	0.965	rs5012971	ENSG00000229759.1	MRPS18AP1	-5.68	4e-08	4.32e-05	-0.37	-0.35	Educational attainment (years of education);	chr3:48033057	chr3:48256350~48256938:-
OV	cis	rs7429990	0.813	rs7637622	ENSG00000229759.1	MRPS18AP1	-5.68	4e-08	4.32e-05	-0.37	-0.35	Educational attainment (years of education);	chr3:48051561	chr3:48256350~48256938:-
OV	cis	rs7429990	0.965	rs7627645	ENSG00000229759.1	MRPS18AP1	-5.68	4e-08	4.32e-05	-0.37	-0.35	Educational attainment (years of education);	chr3:48051643	chr3:48256350~48256938:-
OV	cis	rs4713118	0.513	rs202908	ENSG00000220721.1	OR1F12	5.68	4.01e-08	4.33e-05	0.4	0.35	Parkinson's disease;	chr6:28043773	chr6:28073316~28074233:+
OV	cis	rs6051080	1	rs6051080	ENSG00000125804.12	FAM182A	5.68	4.02e-08	4.34e-05	0.39	0.35	Colorectal or endometrial cancer;	chr20:25995038	chr20:26054655~26086917:+
OV	cis	rs11671005	0.568	rs73068325	ENSG00000269600.1	AC016629.3	-5.68	4.02e-08	4.34e-05	-0.5	-0.35	Mean platelet volume;	chr19:58567729	chr19:58593896~58599355:-
OV	cis	rs11671005	0.568	rs73068329	ENSG00000269600.1	AC016629.3	-5.68	4.02e-08	4.34e-05	-0.5	-0.35	Mean platelet volume;	chr19:58568958	chr19:58593896~58599355:-
OV	cis	rs1075265	0.783	rs805450	ENSG00000233266.1	HMGB1P31	5.68	4.02e-08	4.35e-05	0.43	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53951772	chr2:54051334~54051760:+
OV	cis	rs7927771	0.832	rs11039212	ENSG00000280615.1	Y_RNA	5.68	4.03e-08	4.35e-05	0.43	0.35	Subjective well-being;	chr11:47371752	chr11:47614898~47614994:-
OV	cis	rs8062405	1	rs12446589	ENSG00000259982.1	CDC37P1	5.68	4.04e-08	4.36e-05	0.44	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28700294~28701540:-
OV	cis	rs3091242	0.804	rs631133	ENSG00000224183.1	SDHDP6	-5.68	4.04e-08	4.36e-05	-0.44	-0.35	Erythrocyte sedimentation rate;	chr1:25397655	chr1:25294164~25294643:-
OV	cis	rs2898290	0.5	rs11998678	ENSG00000255052.4	FAM66D	5.68	4.05e-08	4.37e-05	0.46	0.35	Systolic blood pressure;	chr8:11972641	chr8:12115782~12177550:+
OV	cis	rs7829975	0.871	rs572307	ENSG00000253981.4	ALG1L13P	-5.68	4.05e-08	4.37e-05	-0.36	-0.35	Mood instability;	chr8:8721301	chr8:8236003~8244667:-
OV	cis	rs13178541	0.81	rs4457070	ENSG00000250378.1	RP11-119J18.1	5.68	4.05e-08	4.37e-05	0.52	0.35	IgG glycosylation;	chr5:135814396	chr5:135812667~135826582:+
OV	cis	rs34779708	0.931	rs35886556	ENSG00000230534.5	RP11-297A16.2	5.68	4.06e-08	4.38e-05	0.47	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35046057	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs72789609	ENSG00000230534.5	RP11-297A16.2	5.68	4.06e-08	4.38e-05	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35017278	chr10:35098006~35127020:-
OV	cis	rs11976180	1	rs2371247	ENSG00000170356.8	OR2A20P	-5.68	4.06e-08	4.38e-05	-0.5	-0.35	Obesity-related traits;	chr7:144067086	chr7:144250045~144252957:-
OV	cis	rs11976180	1	rs2371248	ENSG00000170356.8	OR2A20P	-5.68	4.06e-08	4.38e-05	-0.5	-0.35	Obesity-related traits;	chr7:144067096	chr7:144250045~144252957:-
OV	cis	rs11671005	0.61	rs2305122	ENSG00000269600.1	AC016629.3	-5.68	4.06e-08	4.38e-05	-0.5	-0.35	Mean platelet volume;	chr19:58545385	chr19:58593896~58599355:-
OV	cis	rs1075265	0.584	rs10164409	ENSG00000233266.1	HMGB1P31	5.68	4.07e-08	4.39e-05	0.43	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53940867	chr2:54051334~54051760:+
OV	cis	rs11673344	0.665	rs74435359	ENSG00000226686.6	LINC01535	5.68	4.07e-08	4.39e-05	0.47	0.35	Obesity-related traits;	chr19:36955252	chr19:37251912~37265535:+
OV	cis	rs4713118	0.513	rs156738	ENSG00000220721.1	OR1F12	5.68	4.09e-08	4.41e-05	0.4	0.35	Parkinson's disease;	chr6:28046247	chr6:28073316~28074233:+
OV	cis	rs7017914	0.652	rs3098865	ENSG00000223220.1	Y_RNA	5.68	4.09e-08	4.41e-05	0.4	0.35	Bone mineral density;	chr8:71003749	chr8:70780914~70781008:-
OV	cis	rs67311347	1	rs9882171	ENSG00000223797.4	ENTPD3-AS1	5.68	4.09e-08	4.41e-05	0.39	0.35	Renal cell carcinoma;	chr3:40477330	chr3:40313802~40453329:-
OV	cis	rs10510102	0.872	rs12259144	ENSG00000226864.1	ATE1-AS1	5.68	4.09e-08	4.41e-05	0.59	0.35	Breast cancer;	chr10:121965433	chr10:121928312~121951965:+
OV	cis	rs7684253	0.565	rs7697176	ENSG00000269949.1	RP11-738E22.3	-5.68	4.11e-08	4.42e-05	-0.43	-0.35	Migraine;	chr4:56956882	chr4:56960927~56961373:-
OV	cis	rs611744	0.659	rs669584	ENSG00000253754.1	RP11-35G22.1	-5.68	4.11e-08	4.43e-05	-0.39	-0.35	Dupuytren's disease;	chr8:108125879	chr8:108226200~108227544:+
OV	cis	rs7429990	0.965	rs7430913	ENSG00000229759.1	MRPS18AP1	-5.68	4.12e-08	4.43e-05	-0.37	-0.35	Educational attainment (years of education);	chr3:47990867	chr3:48256350~48256938:-
OV	cis	rs61990749	0.544	rs176979	ENSG00000239272.1	RPL21P10	5.68	4.12e-08	4.44e-05	0.49	0.35	Fibroblast growth factor basic levels;	chr14:77731729	chr14:77683202~77683989:-
OV	cis	rs67311347	0.956	rs7640228	ENSG00000223797.4	ENTPD3-AS1	-5.68	4.13e-08	4.44e-05	-0.38	-0.35	Renal cell carcinoma;	chr3:40474699	chr3:40313802~40453329:-
OV	cis	rs7017914	0.702	rs36047866	ENSG00000223220.1	Y_RNA	5.68	4.14e-08	4.46e-05	0.4	0.35	Bone mineral density;	chr8:70644815	chr8:70780914~70781008:-
OV	cis	rs3814244	0.528	rs17104682	ENSG00000255733.4	IFNG-AS1	-5.68	4.15e-08	4.46e-05	-0.35	-0.35	Itch intensity from mosquito bite adjusted by bite size;	chr12:68033256	chr12:67989445~68234686:+
OV	cis	rs1075265	0.692	rs805361	ENSG00000233266.1	HMGB1P31	5.68	4.15e-08	4.46e-05	0.43	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53938709	chr2:54051334~54051760:+
OV	cis	rs858239	0.6	rs4409314	ENSG00000230042.1	AK3P3	-5.68	4.15e-08	4.47e-05	-0.37	-0.35	Cerebrospinal fluid biomarker levels;	chr7:23088333	chr7:23129178~23129841:+
OV	cis	rs6088580	0.634	rs2378133	ENSG00000206582.1	Y_RNA	5.68	4.17e-08	4.48e-05	0.42	0.35	Glomerular filtration rate (creatinine);	chr20:34331699	chr20:34526510~34526606:-
OV	cis	rs6088580	0.608	rs1205342	ENSG00000206582.1	Y_RNA	5.68	4.17e-08	4.48e-05	0.42	0.35	Glomerular filtration rate (creatinine);	chr20:34334036	chr20:34526510~34526606:-
OV	cis	rs7017914	0.628	rs2380691	ENSG00000223220.1	Y_RNA	5.68	4.17e-08	4.48e-05	0.4	0.35	Bone mineral density;	chr8:70872942	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs6998354	ENSG00000223220.1	Y_RNA	5.68	4.17e-08	4.48e-05	0.4	0.35	Bone mineral density;	chr8:70873934	chr8:70780914~70781008:-
OV	cis	rs7017914	0.644	rs12156377	ENSG00000223220.1	Y_RNA	5.68	4.17e-08	4.48e-05	0.4	0.35	Bone mineral density;	chr8:70875457	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs1908032	ENSG00000223220.1	Y_RNA	5.68	4.17e-08	4.48e-05	0.4	0.35	Bone mineral density;	chr8:70876735	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs7003788	ENSG00000223220.1	Y_RNA	5.68	4.17e-08	4.48e-05	0.4	0.35	Bone mineral density;	chr8:70876889	chr8:70780914~70781008:-
OV	cis	rs67311347	0.955	rs12487955	ENSG00000223797.4	ENTPD3-AS1	5.68	4.17e-08	4.48e-05	0.39	0.35	Renal cell carcinoma;	chr3:40371362	chr3:40313802~40453329:-
OV	cis	rs611744	0.839	rs638238	ENSG00000253754.1	RP11-35G22.1	-5.68	4.19e-08	4.5e-05	-0.4	-0.35	Dupuytren's disease;	chr8:108156923	chr8:108226200~108227544:+
OV	cis	rs7684253	0.565	rs13130605	ENSG00000269949.1	RP11-738E22.3	-5.67	4.22e-08	4.54e-05	-0.43	-0.35	Migraine;	chr4:56943905	chr4:56960927~56961373:-
OV	cis	rs11976180	1	rs2961117	ENSG00000170356.8	OR2A20P	-5.67	4.22e-08	4.54e-05	-0.48	-0.35	Obesity-related traits;	chr7:144058160	chr7:144250045~144252957:-
OV	cis	rs8062405	0.754	rs149299	ENSG00000278665.1	RP11-666O2.4	5.67	4.23e-08	4.54e-05	0.37	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28473820	chr16:28599241~28601881:-
OV	cis	rs2999052	0.509	rs1735537	ENSG00000242551.2	POU5F1P6	5.67	4.23e-08	4.55e-05	0.48	0.35	Hypospadias;	chr3:128403977	chr3:128674735~128677005:-
OV	cis	rs1075265	0.87	rs1421617	ENSG00000233266.1	HMGB1P31	5.67	4.23e-08	4.55e-05	0.41	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54032995	chr2:54051334~54051760:+
OV	cis	rs4713118	0.629	rs203889	ENSG00000219392.1	RP1-265C24.5	-5.67	4.23e-08	4.55e-05	-0.43	-0.35	Parkinson's disease;	chr6:28053997	chr6:28115628~28116551:+
OV	cis	rs7267979	0.738	rs2892409	ENSG00000274973.1	RP13-401N8.7	-5.67	4.24e-08	4.55e-05	-0.41	-0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25657502	chr20:25845497~25845862:+
OV	cis	rs4660456	0.869	rs7518344	ENSG00000237899.1	RP4-739H11.3	5.67	4.25e-08	4.56e-05	0.54	0.35	Platelet count;	chr1:40708327	chr1:40669089~40687588:-
OV	cis	rs4660456	0.827	rs10736404	ENSG00000237899.1	RP4-739H11.3	5.67	4.25e-08	4.56e-05	0.54	0.35	Platelet count;	chr1:40710331	chr1:40669089~40687588:-
OV	cis	rs11671005	0.61	rs3816329	ENSG00000269600.1	AC016629.3	-5.67	4.25e-08	4.57e-05	-0.5	-0.35	Mean platelet volume;	chr19:58547326	chr19:58593896~58599355:-
OV	cis	rs875971	0.522	rs1617484	ENSG00000224316.1	RP11-479O9.2	5.67	4.25e-08	4.57e-05	0.37	0.35	Aortic root size;	chr7:65998108	chr7:65773620~65802067:+
OV	cis	rs9291683	0.655	rs35750364	ENSG00000250413.1	RP11-448G15.1	-5.67	4.26e-08	4.57e-05	-0.4	-0.35	Bone mineral density;	chr4:10047425	chr4:10006482~10009725:+
OV	cis	rs1075265	0.87	rs17268179	ENSG00000233266.1	HMGB1P31	5.67	4.27e-08	4.58e-05	0.42	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54036876	chr2:54051334~54051760:+
OV	cis	rs801193	0.967	rs34356500	ENSG00000236529.1	RP13-254B10.1	5.67	4.27e-08	4.59e-05	0.38	0.35	Aortic root size;	chr7:66771620	chr7:65840212~65840596:+
OV	cis	rs9487094	0.689	rs1046943	ENSG00000260273.1	RP11-425D10.10	5.67	4.29e-08	4.61e-05	0.37	0.35	Height;	chr6:109462738	chr6:109382795~109383666:+
OV	cis	rs9291683	0.632	rs11734375	ENSG00000250413.1	RP11-448G15.1	-5.67	4.3e-08	4.61e-05	-0.4	-0.35	Bone mineral density;	chr4:10044674	chr4:10006482~10009725:+
OV	cis	rs67340775	0.541	rs200973	ENSG00000280107.1	AL022393.9	-5.67	4.3e-08	4.62e-05	-0.48	-0.35	Lung cancer in ever smokers;	chr6:27890643	chr6:28170845~28172521:+
OV	cis	rs4713118	0.868	rs2893928	ENSG00000219392.1	RP1-265C24.5	-5.67	4.31e-08	4.62e-05	-0.44	-0.35	Parkinson's disease;	chr6:27770651	chr6:28115628~28116551:+
OV	cis	rs9660180	0.78	rs12038111	ENSG00000268575.1	RP1-283E3.8	-5.67	4.32e-08	4.63e-05	-0.33	-0.35	Body mass index;	chr1:1772410	chr1:1702736~1737688:-
OV	cis	rs9660180	0.836	rs12038134	ENSG00000268575.1	RP1-283E3.8	-5.67	4.32e-08	4.63e-05	-0.33	-0.35	Body mass index;	chr1:1772426	chr1:1702736~1737688:-
OV	cis	rs7615952	0.673	rs16834637	ENSG00000171084.14	FAM86JP	5.67	4.32e-08	4.63e-05	0.69	0.35	Blood pressure (smoking interaction);	chr3:125886628	chr3:125916620~125930024:+
OV	cis	rs67311347	1	rs9875245	ENSG00000223797.4	ENTPD3-AS1	5.67	4.33e-08	4.64e-05	0.39	0.35	Renal cell carcinoma;	chr3:40400789	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs954589	ENSG00000223797.4	ENTPD3-AS1	5.67	4.33e-08	4.64e-05	0.39	0.35	Renal cell carcinoma;	chr3:40403054	chr3:40313802~40453329:-
OV	cis	rs2243480	0.711	rs1626926	ENSG00000222364.1	RNU6-96P	-5.67	4.35e-08	4.66e-05	-0.54	-0.35	Diabetic kidney disease;	chr7:65970805	chr7:66395191~66395286:+
OV	cis	rs67311347	1	rs6801859	ENSG00000223797.4	ENTPD3-AS1	-5.67	4.36e-08	4.67e-05	-0.39	-0.35	Renal cell carcinoma;	chr3:40451727	chr3:40313802~40453329:-
OV	cis	rs5742933	0.857	rs10931430	ENSG00000253559.1	OSGEPL1-AS1	5.67	4.37e-08	4.68e-05	0.37	0.35	Ferritin levels;	chr2:189677460	chr2:189762704~189765556:+
OV	cis	rs611744	0.819	rs424012	ENSG00000253754.1	RP11-35G22.1	-5.67	4.38e-08	4.7e-05	-0.4	-0.35	Dupuytren's disease;	chr8:108142424	chr8:108226200~108227544:+
OV	cis	rs8040855	0.965	rs1961276	ENSG00000229212.6	RP11-561C5.4	5.67	4.39e-08	4.7e-05	0.43	0.35	Bulimia nervosa;	chr15:85170986	chr15:85205440~85234795:-
OV	cis	rs7684253	0.565	rs12641030	ENSG00000269949.1	RP11-738E22.3	-5.67	4.4e-08	4.71e-05	-0.43	-0.35	Migraine;	chr4:56937339	chr4:56960927~56961373:-
OV	cis	rs7684253	0.565	rs6830774	ENSG00000269949.1	RP11-738E22.3	-5.67	4.4e-08	4.71e-05	-0.43	-0.35	Migraine;	chr4:56950140	chr4:56960927~56961373:-
OV	cis	rs67311347	1	rs11914297	ENSG00000223797.4	ENTPD3-AS1	5.67	4.41e-08	4.72e-05	0.39	0.35	Renal cell carcinoma;	chr3:40368579	chr3:40313802~40453329:-
OV	cis	rs1075265	0.875	rs12616212	ENSG00000233266.1	HMGB1P31	5.67	4.41e-08	4.72e-05	0.43	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54039109	chr2:54051334~54051760:+
OV	cis	rs7811142	0.83	rs6955367	ENSG00000242294.5	STAG3L5P	5.67	4.41e-08	4.72e-05	0.36	0.35	Platelet count;	chr7:100363571	chr7:100336079~100351900:+
OV	cis	rs8062405	0.755	rs4787457	ENSG00000259982.1	CDC37P1	5.67	4.42e-08	4.73e-05	0.43	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28700294~28701540:-
OV	cis	rs11976180	0.953	rs2951355	ENSG00000170356.8	OR2A20P	-5.66	4.43e-08	4.74e-05	-0.5	-0.35	Obesity-related traits;	chr7:144063469	chr7:144250045~144252957:-
OV	cis	rs11976180	1	rs2951354	ENSG00000170356.8	OR2A20P	-5.66	4.43e-08	4.74e-05	-0.5	-0.35	Obesity-related traits;	chr7:144063908	chr7:144250045~144252957:-
OV	cis	rs11976180	1	rs2951353	ENSG00000170356.8	OR2A20P	-5.66	4.43e-08	4.74e-05	-0.5	-0.35	Obesity-related traits;	chr7:144064023	chr7:144250045~144252957:-
OV	cis	rs11976180	1	rs2961125	ENSG00000170356.8	OR2A20P	-5.66	4.43e-08	4.74e-05	-0.5	-0.35	Obesity-related traits;	chr7:144064677	chr7:144250045~144252957:-
OV	cis	rs11976180	1	rs2961126	ENSG00000170356.8	OR2A20P	-5.66	4.43e-08	4.74e-05	-0.5	-0.35	Obesity-related traits;	chr7:144065643	chr7:144250045~144252957:-
OV	cis	rs11976180	0.953	rs2961127	ENSG00000170356.8	OR2A20P	-5.66	4.43e-08	4.74e-05	-0.5	-0.35	Obesity-related traits;	chr7:144065644	chr7:144250045~144252957:-
OV	cis	rs11976180	1	rs1919948	ENSG00000170356.8	OR2A20P	-5.66	4.43e-08	4.74e-05	-0.5	-0.35	Obesity-related traits;	chr7:144065750	chr7:144250045~144252957:-
OV	cis	rs11976180	1	rs2961128	ENSG00000170356.8	OR2A20P	-5.66	4.43e-08	4.74e-05	-0.5	-0.35	Obesity-related traits;	chr7:144066390	chr7:144250045~144252957:-
OV	cis	rs7017914	0.652	rs6984618	ENSG00000223220.1	Y_RNA	5.66	4.45e-08	4.76e-05	0.4	0.35	Bone mineral density;	chr8:70883334	chr8:70780914~70781008:-
OV	cis	rs67311347	1	rs12634013	ENSG00000223797.4	ENTPD3-AS1	5.66	4.46e-08	4.77e-05	0.4	0.35	Renal cell carcinoma;	chr3:40410897	chr3:40313802~40453329:-
OV	cis	rs7044106	0.69	rs10739569	ENSG00000226752.6	PSMD5-AS1	-5.66	4.46e-08	4.77e-05	-0.41	-0.35	Hip circumference adjusted for BMI;	chr9:120598749	chr9:120824828~120854385:+
OV	cis	rs172166	0.694	rs188105	ENSG00000219392.1	RP1-265C24.5	-5.66	4.47e-08	4.78e-05	-0.41	-0.35	Cardiac Troponin-T levels;	chr6:28103615	chr6:28115628~28116551:+
OV	cis	rs9660180	0.836	rs72634845	ENSG00000268575.1	RP1-283E3.8	-5.66	4.48e-08	4.79e-05	-0.33	-0.35	Body mass index;	chr1:1773460	chr1:1702736~1737688:-
OV	cis	rs9660180	0.868	rs72634846	ENSG00000268575.1	RP1-283E3.8	-5.66	4.48e-08	4.79e-05	-0.33	-0.35	Body mass index;	chr1:1773476	chr1:1702736~1737688:-
OV	cis	rs11603023	0.967	rs7936556	ENSG00000255422.1	AP002954.4	5.66	4.48e-08	4.79e-05	0.37	0.35	Cholesterol, total;	chr11:118630582	chr11:118704607~118750263:+
OV	cis	rs853679	0.513	rs13437444	ENSG00000280107.1	AL022393.9	-5.66	4.49e-08	4.8e-05	-0.51	-0.35	Depression;	chr6:28103220	chr6:28170845~28172521:+
OV	cis	rs2243480	0.803	rs55700941	ENSG00000222364.1	RNU6-96P	-5.66	4.49e-08	4.8e-05	-0.56	-0.35	Diabetic kidney disease;	chr7:65924813	chr7:66395191~66395286:+
OV	cis	rs7017914	0.905	rs2732102	ENSG00000223220.1	Y_RNA	-5.66	4.5e-08	4.81e-05	-0.36	-0.35	Bone mineral density;	chr8:71010637	chr8:70780914~70781008:-
OV	cis	rs7771547	0.573	rs619011	ENSG00000240733.3	RN7SL502P	5.66	4.51e-08	4.81e-05	0.38	0.35	Platelet distribution width;	chr6:36508815	chr6:36450912~36451201:-
OV	cis	rs4713118	0.629	rs203887	ENSG00000280107.1	AL022393.9	-5.66	4.51e-08	4.81e-05	-0.45	-0.35	Parkinson's disease;	chr6:28053491	chr6:28170845~28172521:+
OV	cis	rs2188561	0.697	rs739518	ENSG00000241764.3	AC002467.7	5.66	4.52e-08	4.82e-05	0.41	0.35	Alcohol consumption;	chr7:107743682	chr7:107742817~107744581:-
OV	cis	rs9487094	0.666	rs2277113	ENSG00000260273.1	RP11-425D10.10	5.66	4.52e-08	4.83e-05	0.37	0.35	Height;	chr6:109454233	chr6:109382795~109383666:+
OV	cis	rs853679	0.567	rs1005126	ENSG00000216901.1	AL022393.7	5.66	4.54e-08	4.84e-05	0.43	0.35	Depression;	chr6:28399846	chr6:28176188~28176674:+
OV	cis	rs67311347	1	rs2276871	ENSG00000223797.4	ENTPD3-AS1	5.66	4.56e-08	4.86e-05	0.38	0.35	Renal cell carcinoma;	chr3:40457782	chr3:40313802~40453329:-
OV	cis	rs4380275	1	rs4450634	ENSG00000272342.1	RP13-539J13.1	5.66	4.56e-08	4.87e-05	0.39	0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773257	chr2:739588~740164:-
OV	cis	rs4380275	1	rs4380275	ENSG00000272342.1	RP13-539J13.1	5.66	4.56e-08	4.87e-05	0.39	0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773278	chr2:739588~740164:-
OV	cis	rs4380275	1	rs6548253	ENSG00000272342.1	RP13-539J13.1	5.66	4.56e-08	4.87e-05	0.39	0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773655	chr2:739588~740164:-
OV	cis	rs4380275	1	rs73143802	ENSG00000272342.1	RP13-539J13.1	5.66	4.56e-08	4.87e-05	0.39	0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773826	chr2:739588~740164:-
OV	cis	rs4380275	1	rs4359695	ENSG00000272342.1	RP13-539J13.1	5.66	4.56e-08	4.87e-05	0.39	0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774214	chr2:739588~740164:-
OV	cis	rs4380275	0.931	rs4538239	ENSG00000272342.1	RP13-539J13.1	5.66	4.56e-08	4.87e-05	0.39	0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774238	chr2:739588~740164:-
OV	cis	rs7615952	0.605	rs34865555	ENSG00000171084.14	FAM86JP	5.66	4.57e-08	4.87e-05	0.66	0.35	Blood pressure (smoking interaction);	chr3:125585290	chr3:125916620~125930024:+
OV	cis	rs12134133	0.962	rs11120512	ENSG00000274245.1	RP11-357P18.2	-5.66	4.57e-08	4.87e-05	-0.47	-0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207240370	chr1:207372559~207373252:+
OV	cis	rs7267979	0.789	rs6083841	ENSG00000274973.1	RP13-401N8.7	5.66	4.57e-08	4.88e-05	0.41	0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25403928	chr20:25845497~25845862:+
OV	cis	rs10510102	0.688	rs74570569	ENSG00000226864.1	ATE1-AS1	5.66	4.58e-08	4.88e-05	0.58	0.35	Breast cancer;	chr10:121945347	chr10:121928312~121951965:+
OV	cis	rs10510102	0.872	rs7076727	ENSG00000226864.1	ATE1-AS1	5.66	4.58e-08	4.88e-05	0.58	0.35	Breast cancer;	chr10:121947000	chr10:121928312~121951965:+
OV	cis	rs10510102	0.745	rs7076882	ENSG00000226864.1	ATE1-AS1	5.66	4.58e-08	4.88e-05	0.58	0.35	Breast cancer;	chr10:121947039	chr10:121928312~121951965:+
OV	cis	rs10510102	0.872	rs7077035	ENSG00000226864.1	ATE1-AS1	5.66	4.58e-08	4.88e-05	0.58	0.35	Breast cancer;	chr10:121947130	chr10:121928312~121951965:+
OV	cis	rs2745572	0.557	rs2745569	ENSG00000272279.1	RP11-157J24.2	-5.66	4.58e-08	4.88e-05	-0.42	-0.35	Intraocular pressure;Glaucoma (primary open-angle);Glaucoma (high intraocular pressure);	chr6:1547396	chr6:1528364~1528911:-
OV	cis	rs957448	1	rs12543207	ENSG00000253704.1	RP11-267M23.4	5.66	4.61e-08	4.91e-05	0.47	0.35	Nonsyndromic cleft lip with cleft palate;	chr8:94485202	chr8:94553722~94569745:+
OV	cis	rs875971	0.505	rs1723275	ENSG00000224316.1	RP11-479O9.2	-5.66	4.62e-08	4.92e-05	-0.37	-0.35	Aortic root size;	chr7:66039646	chr7:65773620~65802067:+
OV	cis	rs2188561	0.697	rs34986332	ENSG00000241764.3	AC002467.7	5.66	4.62e-08	4.92e-05	0.42	0.35	Alcohol consumption;	chr7:107739010	chr7:107742817~107744581:-
OV	cis	rs2188561	0.638	rs28690459	ENSG00000241764.3	AC002467.7	5.66	4.62e-08	4.92e-05	0.42	0.35	Alcohol consumption;	chr7:107740258	chr7:107742817~107744581:-
OV	cis	rs853679	0.628	rs9368560	ENSG00000220721.1	OR1F12	5.66	4.63e-08	4.92e-05	0.44	0.35	Depression;	chr6:28192182	chr6:28073316~28074233:+
OV	cis	rs2188561	0.697	rs12705421	ENSG00000241764.3	AC002467.7	5.66	4.63e-08	4.93e-05	0.41	0.35	Alcohol consumption;	chr7:107760984	chr7:107742817~107744581:-
OV	cis	rs7615952	0.576	rs2276727	ENSG00000171084.14	FAM86JP	5.66	4.65e-08	4.94e-05	0.5	0.35	Blood pressure (smoking interaction);	chr3:126107400	chr3:125916620~125930024:+
OV	cis	rs9660180	1	rs9660180	ENSG00000231050.1	RP1-140A9.1	5.66	4.65e-08	4.94e-05	0.36	0.35	Body mass index;	chr1:1791592	chr1:1891471~1892658:+
OV	cis	rs611744	0.563	rs7815105	ENSG00000253754.1	RP11-35G22.1	-5.66	4.66e-08	4.96e-05	-0.41	-0.35	Dupuytren's disease;	chr8:108286565	chr8:108226200~108227544:+
OV	cis	rs34779708	0.931	rs11592404	ENSG00000230534.5	RP11-297A16.2	5.65	4.67e-08	4.96e-05	0.47	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:34984548	chr10:35098006~35127020:-
OV	cis	rs301901	0.698	rs4869505	ENSG00000250155.1	CTD-2353F22.1	5.65	4.68e-08	4.97e-05	0.43	0.35	Height;	chr5:37425888	chr5:36666214~36725195:-
OV	cis	rs7626444	0.625	rs1357287	ENSG00000272359.1	U4	-5.65	4.68e-08	4.98e-05	-0.36	-0.35	Monocyte count;	chr3:196758096	chr3:196747192~196747324:-
OV	cis	rs67311347	1	rs4973998	ENSG00000223797.4	ENTPD3-AS1	5.65	4.7e-08	5e-05	0.4	0.35	Renal cell carcinoma;	chr3:40418861	chr3:40313802~40453329:-
OV	cis	rs2188561	0.708	rs9718496	ENSG00000241764.3	AC002467.7	5.65	4.71e-08	5.01e-05	0.41	0.35	Alcohol consumption;	chr7:107730187	chr7:107742817~107744581:-
OV	cis	rs12022452	0.591	rs11208356	ENSG00000238287.1	RP11-656D10.3	-5.65	4.72e-08	5.01e-05	-0.59	-0.35	Age-related hearing impairment (SNP x SNP interaction);	chr1:40541259	chr1:40493157~40508661:-
OV	cis	rs1729407	0.695	rs1263176	ENSG00000254851.1	RP11-109L13.1	-5.65	4.72e-08	5.02e-05	-0.44	-0.35	Apolipoprotein A-IV levels;	chr11:116819407	chr11:117135528~117138582:+
OV	cis	rs11673344	0.864	rs56208574	ENSG00000226686.6	LINC01535	5.65	4.74e-08	5.03e-05	0.46	0.35	Obesity-related traits;	chr19:37007843	chr19:37251912~37265535:+
OV	cis	rs4713118	0.868	rs7756968	ENSG00000219392.1	RP1-265C24.5	-5.65	4.74e-08	5.04e-05	-0.43	-0.35	Parkinson's disease;	chr6:27767175	chr6:28115628~28116551:+
OV	cis	rs12134133	1	rs28371614	ENSG00000274245.1	RP11-357P18.2	5.65	4.74e-08	5.04e-05	0.45	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207331929	chr1:207372559~207373252:+
OV	cis	rs796364	0.512	rs1653290	ENSG00000232732.8	AC073043.1	-5.65	4.76e-08	5.05e-05	-0.52	-0.35	Schizophrenia;	chr2:200213442	chr2:199867396~199911159:-
OV	cis	rs3091242	0.933	rs10903129	ENSG00000224183.1	SDHDP6	-5.65	4.76e-08	5.05e-05	-0.4	-0.35	Erythrocyte sedimentation rate;	chr1:25442446	chr1:25294164~25294643:-
OV	cis	rs858239	0.6	rs2072369	ENSG00000230042.1	AK3P3	-5.65	4.78e-08	5.07e-05	-0.36	-0.35	Cerebrospinal fluid biomarker levels;	chr7:23106570	chr7:23129178~23129841:+
OV	cis	rs2243480	1	rs34815098	ENSG00000222364.1	RNU6-96P	-5.65	4.79e-08	5.08e-05	-0.54	-0.35	Diabetic kidney disease;	chr7:65827267	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs7456042	ENSG00000222364.1	RNU6-96P	-5.65	4.79e-08	5.08e-05	-0.54	-0.35	Diabetic kidney disease;	chr7:65834791	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs34703416	ENSG00000222364.1	RNU6-96P	-5.65	4.79e-08	5.08e-05	-0.54	-0.35	Diabetic kidney disease;	chr7:65835655	chr7:66395191~66395286:+
OV	cis	rs2243480	0.901	rs35256305	ENSG00000222364.1	RNU6-96P	-5.65	4.79e-08	5.08e-05	-0.54	-0.35	Diabetic kidney disease;	chr7:65841418	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs35825738	ENSG00000222364.1	RNU6-96P	-5.65	4.79e-08	5.08e-05	-0.54	-0.35	Diabetic kidney disease;	chr7:65853040	chr7:66395191~66395286:+
OV	cis	rs4380275	0.965	rs4315562	ENSG00000272342.1	RP13-539J13.1	5.65	4.8e-08	5.09e-05	0.39	0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772723	chr2:739588~740164:-
OV	cis	rs4713118	0.513	rs156734	ENSG00000220721.1	OR1F12	5.65	4.83e-08	5.12e-05	0.4	0.35	Parkinson's disease;	chr6:28039579	chr6:28073316~28074233:+
OV	cis	rs2688608	0.592	rs7923045	ENSG00000271816.1	BMS1P4	5.65	4.84e-08	5.13e-05	0.33	0.35	Inflammatory bowel disease;	chr10:73727740	chr10:73699151~73730487:-
OV	cis	rs7615952	0.8	rs2062773	ENSG00000171084.14	FAM86JP	5.65	4.84e-08	5.13e-05	0.56	0.35	Blood pressure (smoking interaction);	chr3:125920805	chr3:125916620~125930024:+
OV	cis	rs7615952	0.799	rs13315434	ENSG00000171084.14	FAM86JP	5.65	4.84e-08	5.13e-05	0.56	0.35	Blood pressure (smoking interaction);	chr3:125922551	chr3:125916620~125930024:+
OV	cis	rs7615952	0.866	rs13063119	ENSG00000171084.14	FAM86JP	5.65	4.84e-08	5.13e-05	0.56	0.35	Blood pressure (smoking interaction);	chr3:125925004	chr3:125916620~125930024:+
OV	cis	rs7615952	0.736	rs13063122	ENSG00000171084.14	FAM86JP	5.65	4.84e-08	5.13e-05	0.56	0.35	Blood pressure (smoking interaction);	chr3:125925017	chr3:125916620~125930024:+
OV	cis	rs514406	0.793	rs12402415	ENSG00000206627.1	RNU6-969P	-5.65	4.84e-08	5.13e-05	-0.36	-0.35	Monocyte count;	chr1:52752867	chr1:52805108~52805212:-
OV	cis	rs1075265	0.633	rs28653587	ENSG00000233266.1	HMGB1P31	5.65	4.84e-08	5.13e-05	0.44	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53992435	chr2:54051334~54051760:+
OV	cis	rs12922317	0.589	rs350216	ENSG00000260224.1	UBL5P4	5.65	4.84e-08	5.13e-05	0.39	0.35	Schizophrenia;	chr16:12057283	chr16:11968508~11968743:-
OV	cis	rs67311347	1	rs73080138	ENSG00000223797.4	ENTPD3-AS1	5.65	4.85e-08	5.14e-05	0.39	0.35	Renal cell carcinoma;	chr3:40474926	chr3:40313802~40453329:-
OV	cis	rs9660180	0.836	rs72634845	ENSG00000231050.1	RP1-140A9.1	5.65	4.86e-08	5.15e-05	0.37	0.35	Body mass index;	chr1:1773460	chr1:1891471~1892658:+
OV	cis	rs9660180	0.868	rs72634846	ENSG00000231050.1	RP1-140A9.1	5.65	4.86e-08	5.15e-05	0.37	0.35	Body mass index;	chr1:1773476	chr1:1891471~1892658:+
OV	cis	rs1075265	0.633	rs7564912	ENSG00000233266.1	HMGB1P31	5.65	4.86e-08	5.15e-05	0.44	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53995048	chr2:54051334~54051760:+
OV	cis	rs1075265	0.61	rs6746965	ENSG00000233266.1	HMGB1P31	5.65	4.86e-08	5.15e-05	0.44	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53996388	chr2:54051334~54051760:+
OV	cis	rs2688482	0.557	rs2550236	ENSG00000224769.1	AC069213.1	5.65	4.87e-08	5.16e-05	0.58	0.35	Lung disease severity in cystic fibrosis;	chr3:195795450	chr3:195614947~195620233:+
OV	cis	rs2243480	1	rs12698509	ENSG00000222364.1	RNU6-96P	-5.65	4.88e-08	5.16e-05	-0.53	-0.35	Diabetic kidney disease;	chr7:65953889	chr7:66395191~66395286:+
OV	cis	rs3091242	0.933	rs34006994	ENSG00000224183.1	SDHDP6	5.65	4.88e-08	5.17e-05	0.4	0.35	Erythrocyte sedimentation rate;	chr1:25454177	chr1:25294164~25294643:-
OV	cis	rs3091242	0.9	rs4649086	ENSG00000224183.1	SDHDP6	-5.65	4.88e-08	5.17e-05	-0.4	-0.35	Erythrocyte sedimentation rate;	chr1:25452476	chr1:25294164~25294643:-
OV	cis	rs1075265	0.87	rs1363062	ENSG00000233266.1	HMGB1P31	5.65	4.89e-08	5.17e-05	0.42	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54054625	chr2:54051334~54051760:+
OV	cis	rs8005677	1	rs1956880	ENSG00000279656.1	RP11-298I3.6	5.65	4.89e-08	5.18e-05	0.38	0.35	Cognitive ability (multi-trait analysis);	chr14:22924798	chr14:23023083~23024217:-
OV	cis	rs2999052	0.602	rs1625296	ENSG00000242551.2	POU5F1P6	5.65	4.9e-08	5.18e-05	0.45	0.35	Hypospadias;	chr3:128389139	chr3:128674735~128677005:-
OV	cis	rs2688608	0.592	rs11000760	ENSG00000271816.1	BMS1P4	5.64	4.92e-08	5.21e-05	0.33	0.35	Inflammatory bowel disease;	chr10:73733976	chr10:73699151~73730487:-
OV	cis	rs67311347	1	rs13095055	ENSG00000223797.4	ENTPD3-AS1	-5.64	4.96e-08	5.24e-05	-0.39	-0.35	Renal cell carcinoma;	chr3:40464175	chr3:40313802~40453329:-
OV	cis	rs67311347	0.956	rs9822870	ENSG00000223797.4	ENTPD3-AS1	-5.64	4.96e-08	5.24e-05	-0.39	-0.35	Renal cell carcinoma;	chr3:40473399	chr3:40313802~40453329:-
OV	cis	rs1075265	0.669	rs805317	ENSG00000233266.1	HMGB1P31	5.64	4.97e-08	5.26e-05	0.42	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53907867	chr2:54051334~54051760:+
OV	cis	rs1075265	0.692	rs805318	ENSG00000233266.1	HMGB1P31	5.64	4.97e-08	5.26e-05	0.42	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53907915	chr2:54051334~54051760:+
OV	cis	rs977987	0.806	rs4888405	ENSG00000261783.1	RP11-252K23.2	-5.64	4.98e-08	5.26e-05	-0.45	-0.35	Dupuytren's disease;	chr16:75394298	chr16:75379818~75381260:-
OV	cis	rs7771547	0.607	rs6923993	ENSG00000240733.3	RN7SL502P	5.64	4.98e-08	5.26e-05	0.38	0.35	Platelet distribution width;	chr6:36459499	chr6:36450912~36451201:-
OV	cis	rs783540	1	rs783540	ENSG00000278603.1	RP13-608F4.5	5.64	4.98e-08	5.26e-05	0.38	0.35	Schizophrenia;	chr15:82585958	chr15:82472203~82472426:+
OV	cis	rs1185460	0.804	rs13929	ENSG00000271751.1	RP11-110I1.14	-5.64	4.98e-08	5.27e-05	-0.43	-0.35	Coronary artery disease;	chr11:119045044	chr11:119065263~119065677:-
OV	cis	rs62355901	0.545	rs62355938	ENSG00000271828.1	CTD-2310F14.1	5.64	5.03e-08	5.32e-05	0.66	0.35	Breast cancer;	chr5:56798887	chr5:56927874~56929573:+
OV	cis	rs62355900	0.627	rs1862620	ENSG00000271828.1	CTD-2310F14.1	5.64	5.03e-08	5.32e-05	0.66	0.35	Endometriosis;	chr5:56802543	chr5:56927874~56929573:+
OV	cis	rs4713118	0.513	rs149897	ENSG00000220721.1	OR1F12	5.64	5.04e-08	5.32e-05	0.39	0.35	Parkinson's disease;	chr6:28038872	chr6:28073316~28074233:+
OV	cis	rs8005677	1	rs1043209	ENSG00000279656.1	RP11-298I3.6	-5.64	5.05e-08	5.33e-05	-0.38	-0.35	Cognitive ability (multi-trait analysis);	chr14:22904777	chr14:23023083~23024217:-
OV	cis	rs17711722	0.727	rs2658585	ENSG00000224316.1	RP11-479O9.2	5.64	5.07e-08	5.35e-05	0.37	0.35	Calcium levels;	chr7:65996954	chr7:65773620~65802067:+
OV	cis	rs11976180	1	rs1533267	ENSG00000170356.8	OR2A20P	-5.64	5.07e-08	5.35e-05	-0.49	-0.35	Obesity-related traits;	chr7:144069347	chr7:144250045~144252957:-
OV	cis	rs7771547	0.642	rs605684	ENSG00000240733.3	RN7SL502P	5.64	5.08e-08	5.36e-05	0.38	0.35	Platelet distribution width;	chr6:36525488	chr6:36450912~36451201:-
OV	cis	rs3931020	0.671	rs1327088	ENSG00000272864.1	RP11-17E13.2	-5.64	5.08e-08	5.36e-05	-0.43	-0.35	Resistin levels;	chr1:74789807	chr1:74698769~74699333:-
OV	cis	rs858239	0.6	rs6461691	ENSG00000230042.1	AK3P3	-5.64	5.08e-08	5.36e-05	-0.37	-0.35	Cerebrospinal fluid biomarker levels;	chr7:23099726	chr7:23129178~23129841:+
OV	cis	rs172166	0.611	rs203882	ENSG00000219392.1	RP1-265C24.5	-5.64	5.09e-08	5.37e-05	-0.41	-0.35	Cardiac Troponin-T levels;	chr6:28110724	chr6:28115628~28116551:+
OV	cis	rs172166	0.694	rs1770131	ENSG00000219392.1	RP1-265C24.5	-5.64	5.09e-08	5.37e-05	-0.41	-0.35	Cardiac Troponin-T levels;	chr6:28118635	chr6:28115628~28116551:+
OV	cis	rs11671005	0.652	rs11670864	ENSG00000269600.1	AC016629.3	-5.64	5.12e-08	5.4e-05	-0.49	-0.35	Mean platelet volume;	chr19:58519213	chr19:58593896~58599355:-
OV	cis	rs9291683	0.595	rs11731110	ENSG00000250413.1	RP11-448G15.1	-5.64	5.12e-08	5.4e-05	-0.4	-0.35	Bone mineral density;	chr4:10035722	chr4:10006482~10009725:+
OV	cis	rs9291683	0.595	rs10939665	ENSG00000250413.1	RP11-448G15.1	-5.64	5.12e-08	5.4e-05	-0.4	-0.35	Bone mineral density;	chr4:10036004	chr4:10006482~10009725:+
OV	cis	rs9291683	0.632	rs12508991	ENSG00000250413.1	RP11-448G15.1	-5.64	5.12e-08	5.4e-05	-0.4	-0.35	Bone mineral density;	chr4:10039480	chr4:10006482~10009725:+
OV	cis	rs9291683	0.632	rs7679916	ENSG00000250413.1	RP11-448G15.1	-5.64	5.12e-08	5.4e-05	-0.4	-0.35	Bone mineral density;	chr4:10040536	chr4:10006482~10009725:+
OV	cis	rs9291683	0.618	rs13137343	ENSG00000250413.1	RP11-448G15.1	-5.64	5.12e-08	5.4e-05	-0.4	-0.35	Bone mineral density;	chr4:10041404	chr4:10006482~10009725:+
OV	cis	rs11671005	0.568	rs55987239	ENSG00000269600.1	AC016629.3	-5.64	5.13e-08	5.4e-05	-0.5	-0.35	Mean platelet volume;	chr19:58573678	chr19:58593896~58599355:-
OV	cis	rs9660180	0.78	rs12038111	ENSG00000231050.1	RP1-140A9.1	5.64	5.13e-08	5.41e-05	0.36	0.35	Body mass index;	chr1:1772410	chr1:1891471~1892658:+
OV	cis	rs9660180	0.836	rs12038134	ENSG00000231050.1	RP1-140A9.1	5.64	5.13e-08	5.41e-05	0.36	0.35	Body mass index;	chr1:1772426	chr1:1891471~1892658:+
OV	cis	rs526231	0.578	rs6860588	ENSG00000175749.11	EIF3KP1	-5.64	5.16e-08	5.43e-05	-0.4	-0.35	Primary biliary cholangitis;	chr5:102944598	chr5:103032376~103033031:+
OV	cis	rs7017914	0.837	rs2732105	ENSG00000223220.1	Y_RNA	5.64	5.16e-08	5.44e-05	0.37	0.35	Bone mineral density;	chr8:71011410	chr8:70780914~70781008:-
OV	cis	rs67311347	1	rs4973989	ENSG00000223797.4	ENTPD3-AS1	5.63	5.16e-08	5.44e-05	0.39	0.35	Renal cell carcinoma;	chr3:40410052	chr3:40313802~40453329:-
OV	cis	rs1426063	0.614	rs17000261	ENSG00000260265.1	RP11-44F21.5	5.63	5.17e-08	5.45e-05	0.62	0.35	QT interval;	chr4:75108766	chr4:75081702~75084717:-
OV	cis	rs1075265	0.783	rs698858	ENSG00000233266.1	HMGB1P31	5.63	5.19e-08	5.47e-05	0.42	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53943333	chr2:54051334~54051760:+
OV	cis	rs9660180	0.935	rs2180311	ENSG00000231050.1	RP1-140A9.1	5.63	5.19e-08	5.47e-05	0.36	0.35	Body mass index;	chr1:1817295	chr1:1891471~1892658:+
OV	cis	rs9660180	0.967	rs6664664	ENSG00000231050.1	RP1-140A9.1	5.63	5.19e-08	5.47e-05	0.36	0.35	Body mass index;	chr1:1819825	chr1:1891471~1892658:+
OV	cis	rs801193	0.935	rs11772264	ENSG00000236529.1	RP13-254B10.1	5.63	5.24e-08	5.52e-05	0.37	0.35	Aortic root size;	chr7:66711400	chr7:65840212~65840596:+
OV	cis	rs801193	1	rs7782320	ENSG00000236529.1	RP13-254B10.1	5.63	5.24e-08	5.52e-05	0.37	0.35	Aortic root size;	chr7:66712111	chr7:65840212~65840596:+
OV	cis	rs2188561	0.697	rs66560125	ENSG00000241764.3	AC002467.7	5.63	5.25e-08	5.52e-05	0.41	0.35	Alcohol consumption;	chr7:107729589	chr7:107742817~107744581:-
OV	cis	rs7017914	0.652	rs11992027	ENSG00000223220.1	Y_RNA	5.63	5.26e-08	5.54e-05	0.4	0.35	Bone mineral density;	chr8:70776635	chr8:70780914~70781008:-
OV	cis	rs2179367	0.959	rs652807	ENSG00000231760.4	RP11-350J20.5	-5.63	5.27e-08	5.54e-05	-0.4	-0.35	Dupuytren's disease;	chr6:149416359	chr6:149796151~149826294:-
OV	cis	rs7017914	0.87	rs1353057	ENSG00000223220.1	Y_RNA	5.63	5.28e-08	5.55e-05	0.37	0.35	Bone mineral density;	chr8:71009862	chr8:70780914~70781008:-
OV	cis	rs7580658	0.75	rs6731176	ENSG00000236682.1	AC068282.3	-5.63	5.28e-08	5.55e-05	-0.43	-0.35	Protein C levels;	chr2:127313427	chr2:127389130~127400580:+
OV	cis	rs8040855	0.579	rs28521166	ENSG00000229212.6	RP11-561C5.4	-5.63	5.29e-08	5.56e-05	-0.43	-0.35	Bulimia nervosa;	chr15:85184801	chr15:85205440~85234795:-
OV	cis	rs4380275	1	rs7562792	ENSG00000272342.1	RP13-539J13.1	5.63	5.3e-08	5.57e-05	0.39	0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774469	chr2:739588~740164:-
OV	cis	rs7017914	0.935	rs2732093	ENSG00000223220.1	Y_RNA	5.63	5.31e-08	5.58e-05	0.37	0.35	Bone mineral density;	chr8:71006844	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs2639899	ENSG00000223220.1	Y_RNA	5.63	5.31e-08	5.58e-05	0.37	0.35	Bone mineral density;	chr8:71007227	chr8:70780914~70781008:-
OV	cis	rs7017914	0.875	rs2639897	ENSG00000223220.1	Y_RNA	5.63	5.31e-08	5.58e-05	0.37	0.35	Bone mineral density;	chr8:71008441	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs2639896	ENSG00000223220.1	Y_RNA	5.63	5.31e-08	5.58e-05	0.37	0.35	Bone mineral density;	chr8:71008548	chr8:70780914~70781008:-
OV	cis	rs1075265	0.527	rs10167891	ENSG00000233266.1	HMGB1P31	5.63	5.34e-08	5.61e-05	0.44	0.35	Chronotype;Morning vs. evening chronotype;	chr2:54003658	chr2:54051334~54051760:+
OV	cis	rs9660180	0.839	rs12040826	ENSG00000268575.1	RP1-283E3.8	-5.63	5.35e-08	5.62e-05	-0.32	-0.35	Body mass index;	chr1:1773848	chr1:1702736~1737688:-
OV	cis	rs9322193	0.607	rs4870078	ENSG00000231760.4	RP11-350J20.5	-5.63	5.36e-08	5.63e-05	-0.47	-0.35	Lung cancer;	chr6:149880676	chr6:149796151~149826294:-
OV	cis	rs4713118	0.824	rs9468223	ENSG00000220721.1	OR1F12	5.63	5.36e-08	5.63e-05	0.38	0.35	Parkinson's disease;	chr6:27772887	chr6:28073316~28074233:+
OV	cis	rs4713118	0.513	rs156739	ENSG00000220721.1	OR1F12	5.63	5.37e-08	5.64e-05	0.4	0.35	Parkinson's disease;	chr6:28045632	chr6:28073316~28074233:+
OV	cis	rs2153535	0.585	rs6900539	ENSG00000230939.1	RP11-314C16.1	-5.63	5.39e-08	5.66e-05	-0.38	-0.35	Motion sickness;	chr6:8592054	chr6:8784178~8785445:+
OV	cis	rs2153535	0.526	rs9505487	ENSG00000230939.1	RP11-314C16.1	-5.63	5.39e-08	5.66e-05	-0.38	-0.35	Motion sickness;	chr6:8593521	chr6:8784178~8785445:+
OV	cis	rs7927771	0.757	rs1057233	ENSG00000280615.1	Y_RNA	5.63	5.4e-08	5.67e-05	0.43	0.35	Subjective well-being;	chr11:47354897	chr11:47614898~47614994:-
OV	cis	rs8040855	0.599	rs4643289	ENSG00000229212.6	RP11-561C5.4	-5.63	5.41e-08	5.67e-05	-0.42	-0.35	Bulimia nervosa;	chr15:85183483	chr15:85205440~85234795:-
OV	cis	rs8062405	0.755	rs62034325	ENSG00000259982.1	CDC37P1	5.63	5.41e-08	5.67e-05	0.42	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28700294~28701540:-
OV	cis	rs7017914	0.652	rs958605	ENSG00000223220.1	Y_RNA	5.63	5.41e-08	5.67e-05	0.4	0.35	Bone mineral density;	chr8:70988356	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs2732122	ENSG00000223220.1	Y_RNA	5.63	5.41e-08	5.67e-05	0.4	0.35	Bone mineral density;	chr8:70988908	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs2639926	ENSG00000223220.1	Y_RNA	5.63	5.41e-08	5.67e-05	0.4	0.35	Bone mineral density;	chr8:70988976	chr8:70780914~70781008:-
OV	cis	rs8062405	1	rs12443881	ENSG00000259982.1	CDC37P1	5.63	5.42e-08	5.68e-05	0.43	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28700294~28701540:-
OV	cis	rs172166	0.694	rs203893	ENSG00000219392.1	RP1-265C24.5	-5.63	5.42e-08	5.69e-05	-0.4	-0.35	Cardiac Troponin-T levels;	chr6:28094288	chr6:28115628~28116551:+
OV	cis	rs172166	0.652	rs476167	ENSG00000219392.1	RP1-265C24.5	-5.63	5.42e-08	5.69e-05	-0.4	-0.35	Cardiac Troponin-T levels;	chr6:28098110	chr6:28115628~28116551:+
OV	cis	rs172166	0.694	rs203892	ENSG00000219392.1	RP1-265C24.5	-5.63	5.42e-08	5.69e-05	-0.4	-0.35	Cardiac Troponin-T levels;	chr6:28099418	chr6:28115628~28116551:+
OV	cis	rs2188561	0.697	rs13242107	ENSG00000241764.3	AC002467.7	5.63	5.43e-08	5.69e-05	0.41	0.35	Alcohol consumption;	chr7:107734800	chr7:107742817~107744581:-
OV	cis	rs34779708	0.931	rs35848945	ENSG00000230534.5	RP11-297A16.2	5.62	5.43e-08	5.69e-05	0.47	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:34998633	chr10:35098006~35127020:-
OV	cis	rs2153535	0.585	rs9328498	ENSG00000230939.1	RP11-314C16.1	-5.62	5.43e-08	5.69e-05	-0.37	-0.35	Motion sickness;	chr6:8623536	chr6:8784178~8785445:+
OV	cis	rs55794721	0.509	rs12027135	ENSG00000224183.1	SDHDP6	-5.62	5.44e-08	5.7e-05	-0.41	-0.35	Mean corpuscular volume;Plateletcrit;	chr1:25449242	chr1:25294164~25294643:-
OV	cis	rs4713118	0.662	rs9357060	ENSG00000219392.1	RP1-265C24.5	-5.62	5.45e-08	5.7e-05	-0.43	-0.35	Parkinson's disease;	chr6:28056708	chr6:28115628~28116551:+
OV	cis	rs4713118	0.662	rs9468271	ENSG00000219392.1	RP1-265C24.5	-5.62	5.45e-08	5.7e-05	-0.43	-0.35	Parkinson's disease;	chr6:28056792	chr6:28115628~28116551:+
OV	cis	rs11690935	0.655	rs12997093	ENSG00000228389.1	AC068039.4	-5.62	5.45e-08	5.71e-05	-0.4	-0.35	Schizophrenia;	chr2:171707928	chr2:171773482~171775844:+
OV	cis	rs5742933	0.817	rs2033870	ENSG00000253559.1	OSGEPL1-AS1	-5.62	5.45e-08	5.71e-05	-0.36	-0.35	Ferritin levels;	chr2:189739104	chr2:189762704~189765556:+
OV	cis	rs611744	0.967	rs630492	ENSG00000253754.1	RP11-35G22.1	5.62	5.46e-08	5.71e-05	0.37	0.35	Dupuytren's disease;	chr8:108203139	chr8:108226200~108227544:+
OV	cis	rs4805272	1	rs9304626	ENSG00000267243.4	AC005307.3	-5.62	5.46e-08	5.72e-05	-0.48	-0.35	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28829347	chr19:28435388~28727777:-
OV	cis	rs6991838	0.771	rs13282323	ENSG00000272010.1	CTD-3025N20.3	5.62	5.49e-08	5.74e-05	0.42	0.35	Intelligence (multi-trait analysis);	chr8:65560557	chr8:65591850~65592472:-
OV	cis	rs6991838	0.831	rs4394432	ENSG00000272010.1	CTD-3025N20.3	5.62	5.49e-08	5.74e-05	0.42	0.35	Intelligence (multi-trait analysis);	chr8:65560939	chr8:65591850~65592472:-
OV	cis	rs11690935	0.632	rs34531723	ENSG00000228389.1	AC068039.4	-5.62	5.5e-08	5.75e-05	-0.4	-0.35	Schizophrenia;	chr2:171707584	chr2:171773482~171775844:+
OV	cis	rs9291683	0.609	rs3796836	ENSG00000250413.1	RP11-448G15.1	-5.62	5.51e-08	5.77e-05	-0.4	-0.35	Bone mineral density;	chr4:10009721	chr4:10006482~10009725:+
OV	cis	rs9660180	0.935	rs9786942	ENSG00000231050.1	RP1-140A9.1	5.62	5.56e-08	5.81e-05	0.36	0.35	Body mass index;	chr1:1827774	chr1:1891471~1892658:+
OV	cis	rs9660180	0.934	rs34849348	ENSG00000231050.1	RP1-140A9.1	5.62	5.56e-08	5.81e-05	0.36	0.35	Body mass index;	chr1:1831318	chr1:1891471~1892658:+
OV	cis	rs7044106	0.762	rs10984972	ENSG00000226752.6	PSMD5-AS1	-5.62	5.58e-08	5.83e-05	-0.41	-0.35	Hip circumference adjusted for BMI;	chr9:120647586	chr9:120824828~120854385:+
OV	cis	rs7429990	0.965	rs7649981	ENSG00000229759.1	MRPS18AP1	5.62	5.61e-08	5.86e-05	0.37	0.35	Educational attainment (years of education);	chr3:47957847	chr3:48256350~48256938:-
OV	cis	rs7429990	0.965	rs2053767	ENSG00000229759.1	MRPS18AP1	5.62	5.61e-08	5.86e-05	0.37	0.35	Educational attainment (years of education);	chr3:47958184	chr3:48256350~48256938:-
OV	cis	rs796364	0.664	rs4673660	ENSG00000232732.8	AC073043.1	-5.62	5.62e-08	5.87e-05	-0.47	-0.35	Schizophrenia;	chr2:200050672	chr2:199867396~199911159:-
OV	cis	rs2286503	0.966	rs6949233	ENSG00000221740.1	SNORD93	5.62	5.63e-08	5.88e-05	0.41	0.35	Fibrinogen;	chr7:22818572	chr7:22856613~22856686:+
OV	cis	rs9660180	0.967	rs12044597	ENSG00000231050.1	RP1-140A9.1	5.62	5.64e-08	5.88e-05	0.36	0.35	Body mass index;	chr1:1777362	chr1:1891471~1892658:+
OV	cis	rs875971	0.54	rs1723268	ENSG00000224316.1	RP11-479O9.2	5.62	5.65e-08	5.89e-05	0.37	0.35	Aortic root size;	chr7:66008093	chr7:65773620~65802067:+
OV	cis	rs858239	0.6	rs10235786	ENSG00000230042.1	AK3P3	-5.62	5.65e-08	5.89e-05	-0.37	-0.35	Cerebrospinal fluid biomarker levels;	chr7:23100321	chr7:23129178~23129841:+
OV	cis	rs9487094	0.689	rs6939548	ENSG00000260273.1	RP11-425D10.10	5.62	5.68e-08	5.93e-05	0.37	0.35	Height;	chr6:109464011	chr6:109382795~109383666:+
OV	cis	rs9487094	0.666	rs3734652	ENSG00000260273.1	RP11-425D10.10	5.62	5.68e-08	5.93e-05	0.37	0.35	Height;	chr6:109465777	chr6:109382795~109383666:+
OV	cis	rs7615952	0.599	rs16834938	ENSG00000171084.14	FAM86JP	5.61	5.72e-08	5.97e-05	0.51	0.35	Blood pressure (smoking interaction);	chr3:125987203	chr3:125916620~125930024:+
OV	cis	rs7017914	0.652	rs2639928	ENSG00000223220.1	Y_RNA	5.61	5.72e-08	5.97e-05	0.4	0.35	Bone mineral density;	chr8:70971414	chr8:70780914~70781008:-
OV	cis	rs61990749	0.597	rs176971	ENSG00000239272.1	RPL21P10	5.61	5.74e-08	5.99e-05	0.49	0.35	Fibroblast growth factor basic levels;	chr14:77725256	chr14:77683202~77683989:-
OV	cis	rs7771547	0.642	rs629560	ENSG00000240733.3	RN7SL502P	5.61	5.79e-08	6.03e-05	0.38	0.35	Platelet distribution width;	chr6:36543614	chr6:36450912~36451201:-
OV	cis	rs2153535	0.585	rs1328873	ENSG00000230939.1	RP11-314C16.1	-5.61	5.79e-08	6.04e-05	-0.38	-0.35	Motion sickness;	chr6:8621171	chr6:8784178~8785445:+
OV	cis	rs2153535	0.585	rs9393047	ENSG00000230939.1	RP11-314C16.1	-5.61	5.79e-08	6.04e-05	-0.38	-0.35	Motion sickness;	chr6:8622373	chr6:8784178~8785445:+
OV	cis	rs2153535	0.585	rs9505495	ENSG00000230939.1	RP11-314C16.1	-5.61	5.79e-08	6.04e-05	-0.38	-0.35	Motion sickness;	chr6:8622963	chr6:8784178~8785445:+
OV	cis	rs2153535	0.585	rs9328499	ENSG00000230939.1	RP11-314C16.1	-5.61	5.79e-08	6.04e-05	-0.38	-0.35	Motion sickness;	chr6:8623546	chr6:8784178~8785445:+
OV	cis	rs73019876	0.502	rs4932954	ENSG00000269742.1	BNIP3P29	5.61	5.8e-08	6.04e-05	0.4	0.35	Testicular germ cell tumor;	chr19:22089652	chr19:22065828~22066398:-
OV	cis	rs73019876	0.502	rs9304994	ENSG00000269742.1	BNIP3P29	5.61	5.8e-08	6.04e-05	0.4	0.35	Testicular germ cell tumor;	chr19:22089941	chr19:22065828~22066398:-
OV	cis	rs611744	0.87	rs640068	ENSG00000253754.1	RP11-35G22.1	-5.61	5.8e-08	6.04e-05	-0.4	-0.35	Dupuytren's disease;	chr8:108145773	chr8:108226200~108227544:+
OV	cis	rs2188561	0.697	rs12539555	ENSG00000241764.3	AC002467.7	5.61	5.83e-08	6.07e-05	0.41	0.35	Alcohol consumption;	chr7:107764028	chr7:107742817~107744581:-
OV	cis	rs2243480	1	rs2462569	ENSG00000222364.1	RNU6-96P	5.61	5.83e-08	6.07e-05	0.54	0.35	Diabetic kidney disease;	chr7:66009859	chr7:66395191~66395286:+
OV	cis	rs4713118	0.824	rs9366702	ENSG00000220721.1	OR1F12	5.61	5.83e-08	6.07e-05	0.38	0.35	Parkinson's disease;	chr6:27766691	chr6:28073316~28074233:+
OV	cis	rs7017914	0.652	rs34719517	ENSG00000223220.1	Y_RNA	5.61	5.83e-08	6.07e-05	0.39	0.35	Bone mineral density;	chr8:70687866	chr8:70780914~70781008:-
OV	cis	rs7017914	0.667	rs34972504	ENSG00000223220.1	Y_RNA	5.61	5.83e-08	6.07e-05	0.39	0.35	Bone mineral density;	chr8:70689486	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs12681588	ENSG00000223220.1	Y_RNA	5.61	5.83e-08	6.07e-05	0.39	0.35	Bone mineral density;	chr8:70689652	chr8:70780914~70781008:-
OV	cis	rs7017914	0.628	rs7833211	ENSG00000223220.1	Y_RNA	5.61	5.83e-08	6.07e-05	0.39	0.35	Bone mineral density;	chr8:70691903	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs12156043	ENSG00000223220.1	Y_RNA	5.61	5.83e-08	6.07e-05	0.39	0.35	Bone mineral density;	chr8:70701808	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs7842091	ENSG00000223220.1	Y_RNA	5.61	5.83e-08	6.07e-05	0.39	0.35	Bone mineral density;	chr8:70702546	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs1477945	ENSG00000223220.1	Y_RNA	5.61	5.83e-08	6.07e-05	0.39	0.35	Bone mineral density;	chr8:70703318	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs17760532	ENSG00000223220.1	Y_RNA	5.61	5.83e-08	6.07e-05	0.39	0.35	Bone mineral density;	chr8:70708052	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs56173818	ENSG00000223220.1	Y_RNA	5.61	5.83e-08	6.07e-05	0.39	0.35	Bone mineral density;	chr8:70710138	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs56099911	ENSG00000223220.1	Y_RNA	5.61	5.83e-08	6.07e-05	0.39	0.35	Bone mineral density;	chr8:70710156	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs34643336	ENSG00000223220.1	Y_RNA	5.61	5.83e-08	6.07e-05	0.39	0.35	Bone mineral density;	chr8:70715718	chr8:70780914~70781008:-
OV	cis	rs7017914	0.629	rs35621553	ENSG00000223220.1	Y_RNA	5.61	5.83e-08	6.07e-05	0.39	0.35	Bone mineral density;	chr8:70715840	chr8:70780914~70781008:-
OV	cis	rs7017914	0.628	rs78322467	ENSG00000223220.1	Y_RNA	5.61	5.83e-08	6.07e-05	0.39	0.35	Bone mineral density;	chr8:70716439	chr8:70780914~70781008:-
OV	cis	rs7017914	0.605	rs13269410	ENSG00000223220.1	Y_RNA	5.61	5.83e-08	6.07e-05	0.39	0.35	Bone mineral density;	chr8:70725773	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs6987515	ENSG00000223220.1	Y_RNA	5.61	5.83e-08	6.07e-05	0.39	0.35	Bone mineral density;	chr8:70728067	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs56156614	ENSG00000223220.1	Y_RNA	5.61	5.83e-08	6.07e-05	0.39	0.35	Bone mineral density;	chr8:70730816	chr8:70780914~70781008:-
OV	cis	rs7017914	0.583	rs11986334	ENSG00000223220.1	Y_RNA	5.61	5.83e-08	6.07e-05	0.39	0.35	Bone mineral density;	chr8:70732239	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs56094661	ENSG00000223220.1	Y_RNA	5.61	5.83e-08	6.07e-05	0.39	0.35	Bone mineral density;	chr8:70732493	chr8:70780914~70781008:-
OV	cis	rs7017914	0.592	rs6980835	ENSG00000223220.1	Y_RNA	5.61	5.83e-08	6.07e-05	0.39	0.35	Bone mineral density;	chr8:70733691	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs2290702	ENSG00000223220.1	Y_RNA	5.61	5.83e-08	6.07e-05	0.39	0.35	Bone mineral density;	chr8:70734745	chr8:70780914~70781008:-
OV	cis	rs11976180	1	rs1540894	ENSG00000170356.8	OR2A20P	-5.61	5.83e-08	6.07e-05	-0.49	-0.35	Obesity-related traits;	chr7:144070583	chr7:144250045~144252957:-
OV	cis	rs4713118	0.662	rs9357060	ENSG00000280107.1	AL022393.9	-5.61	5.84e-08	6.07e-05	-0.43	-0.35	Parkinson's disease;	chr6:28056708	chr6:28170845~28172521:+
OV	cis	rs4713118	0.662	rs9468271	ENSG00000280107.1	AL022393.9	-5.61	5.84e-08	6.07e-05	-0.43	-0.35	Parkinson's disease;	chr6:28056792	chr6:28170845~28172521:+
OV	cis	rs7267979	0.789	rs6083810	ENSG00000274973.1	RP13-401N8.7	5.61	5.84e-08	6.08e-05	0.41	0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25349123	chr20:25845497~25845862:+
OV	cis	rs34779708	0.931	rs4934524	ENSG00000230534.5	RP11-297A16.2	5.61	5.85e-08	6.08e-05	0.47	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:34981993	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs4934693	ENSG00000230534.5	RP11-297A16.2	5.61	5.85e-08	6.08e-05	0.47	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:34982916	chr10:35098006~35127020:-
OV	cis	rs7267979	0.668	rs4815398	ENSG00000274973.1	RP13-401N8.7	5.61	5.85e-08	6.09e-05	0.42	0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25256702	chr20:25845497~25845862:+
OV	cis	rs34779708	0.897	rs4934529	ENSG00000230534.5	RP11-297A16.2	5.61	5.85e-08	6.09e-05	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35013448	chr10:35098006~35127020:-
OV	cis	rs34779708	0.897	rs12830	ENSG00000230534.5	RP11-297A16.2	5.61	5.85e-08	6.09e-05	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35013777	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs7920095	ENSG00000230534.5	RP11-297A16.2	5.61	5.85e-08	6.09e-05	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35014406	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs7908573	ENSG00000230534.5	RP11-297A16.2	5.61	5.86e-08	6.1e-05	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35020585	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs17583009	ENSG00000230534.5	RP11-297A16.2	5.61	5.86e-08	6.1e-05	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35031987	chr10:35098006~35127020:-
OV	cis	rs34779708	0.898	rs11595898	ENSG00000230534.5	RP11-297A16.2	5.61	5.86e-08	6.1e-05	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35037335	chr10:35098006~35127020:-
OV	cis	rs4713118	0.662	rs149947	ENSG00000280107.1	AL022393.9	-5.61	5.91e-08	6.14e-05	-0.45	-0.35	Parkinson's disease;	chr6:28004655	chr6:28170845~28172521:+
OV	cis	rs2921073	0.509	rs2976931	ENSG00000253893.2	FAM85B	-5.61	5.92e-08	6.15e-05	-0.37	-0.35	Parkinson's disease;	chr8:8399807	chr8:8167819~8226614:-
OV	cis	rs7189233	0.531	rs11859538	ENSG00000279344.1	RP11-44F14.7	5.61	5.92e-08	6.15e-05	0.32	0.35	Intelligence (multi-trait analysis);	chr16:53463133	chr16:53478957~53481550:-
OV	cis	rs1707322	1	rs6677777	ENSG00000280836.1	AL355480.1	-5.61	5.93e-08	6.16e-05	-0.47	-0.35	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:46010164	chr1:45581219~45581321:-
OV	cis	rs7617773	0.817	rs936426	ENSG00000228638.1	FCF1P2	-5.61	5.93e-08	6.16e-05	-0.42	-0.35	Coronary artery disease;	chr3:48173763	chr3:48290793~48291375:-
OV	cis	rs6700559	0.81	rs10399615	ENSG00000260088.1	RP11-92G12.3	5.61	5.93e-08	6.16e-05	0.37	0.35	Coronary artery disease;	chr1:200626145	chr1:200669507~200694250:+
OV	cis	rs875971	0.545	rs4718348	ENSG00000236529.1	RP13-254B10.1	5.61	5.96e-08	6.18e-05	0.42	0.35	Aortic root size;	chr7:66441589	chr7:65840212~65840596:+
OV	cis	rs858239	0.601	rs6461693	ENSG00000230042.1	AK3P3	5.61	6e-08	6.23e-05	0.37	0.35	Cerebrospinal fluid biomarker levels;	chr7:23120514	chr7:23129178~23129841:+
OV	cis	rs2153535	0.585	rs9379226	ENSG00000230939.1	RP11-314C16.1	-5.61	6e-08	6.23e-05	-0.38	-0.35	Motion sickness;	chr6:8584232	chr6:8784178~8785445:+
OV	cis	rs62355901	0.505	rs72759725	ENSG00000271828.1	CTD-2310F14.1	5.61	6e-08	6.23e-05	0.8	0.35	Breast cancer;	chr5:56941932	chr5:56927874~56929573:+
OV	cis	rs10510102	0.808	rs11200296	ENSG00000226864.1	ATE1-AS1	5.61	6.01e-08	6.23e-05	0.59	0.35	Breast cancer;	chr10:121971956	chr10:121928312~121951965:+
OV	cis	rs6991838	0.8	rs28547533	ENSG00000272010.1	CTD-3025N20.3	5.6	6.02e-08	6.25e-05	0.42	0.35	Intelligence (multi-trait analysis);	chr8:65559318	chr8:65591850~65592472:-
OV	cis	rs6991838	0.8	rs28626262	ENSG00000272010.1	CTD-3025N20.3	5.6	6.02e-08	6.25e-05	0.42	0.35	Intelligence (multi-trait analysis);	chr8:65559335	chr8:65591850~65592472:-
OV	cis	rs6991838	0.8	rs28709439	ENSG00000272010.1	CTD-3025N20.3	5.6	6.02e-08	6.25e-05	0.42	0.35	Intelligence (multi-trait analysis);	chr8:65559337	chr8:65591850~65592472:-
OV	cis	rs11673344	0.526	rs2291001	ENSG00000226686.6	LINC01535	5.6	6.03e-08	6.25e-05	0.45	0.35	Obesity-related traits;	chr19:37594431	chr19:37251912~37265535:+
OV	cis	rs11673344	0.518	rs73033134	ENSG00000226686.6	LINC01535	5.6	6.03e-08	6.25e-05	0.45	0.35	Obesity-related traits;	chr19:37596046	chr19:37251912~37265535:+
OV	cis	rs11673344	0.526	rs17305193	ENSG00000226686.6	LINC01535	5.6	6.03e-08	6.25e-05	0.45	0.35	Obesity-related traits;	chr19:37598764	chr19:37251912~37265535:+
OV	cis	rs34779708	0.931	rs66887762	ENSG00000230534.5	RP11-297A16.2	5.6	6.06e-08	6.28e-05	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35041649	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs59418206	ENSG00000230534.5	RP11-297A16.2	5.6	6.06e-08	6.28e-05	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35042696	chr10:35098006~35127020:-
OV	cis	rs611744	0.816	rs626211	ENSG00000253754.1	RP11-35G22.1	-5.6	6.06e-08	6.28e-05	-0.4	-0.35	Dupuytren's disease;	chr8:108177219	chr8:108226200~108227544:+
OV	cis	rs7017914	0.524	rs35544920	ENSG00000223220.1	Y_RNA	5.6	6.06e-08	6.28e-05	0.39	0.35	Bone mineral density;	chr8:70687552	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs12674966	ENSG00000223220.1	Y_RNA	5.6	6.07e-08	6.29e-05	0.39	0.35	Bone mineral density;	chr8:70772175	chr8:70780914~70781008:-
OV	cis	rs5742933	0.817	rs1233297	ENSG00000253559.1	OSGEPL1-AS1	-5.6	6.1e-08	6.32e-05	-0.36	-0.35	Ferritin levels;	chr2:189829449	chr2:189762704~189765556:+
OV	cis	rs11690935	0.571	rs13020884	ENSG00000228389.1	AC068039.4	-5.6	6.11e-08	6.32e-05	-0.39	-0.35	Schizophrenia;	chr2:172036795	chr2:171773482~171775844:+
OV	cis	rs11690935	0.527	rs7586556	ENSG00000228389.1	AC068039.4	-5.6	6.11e-08	6.32e-05	-0.39	-0.35	Schizophrenia;	chr2:172036983	chr2:171773482~171775844:+
OV	cis	rs11976180	1	rs1919950	ENSG00000170356.8	OR2A20P	-5.6	6.12e-08	6.33e-05	-0.49	-0.35	Obesity-related traits;	chr7:144070805	chr7:144250045~144252957:-
OV	cis	rs3931020	0.616	rs277380	ENSG00000272864.1	RP11-17E13.2	5.6	6.12e-08	6.34e-05	0.49	0.35	Resistin levels;	chr1:74797404	chr1:74698769~74699333:-
OV	cis	rs10510102	0.872	rs11200277	ENSG00000226864.1	ATE1-AS1	5.6	6.13e-08	6.34e-05	0.58	0.35	Breast cancer;	chr10:121944295	chr10:121928312~121951965:+
OV	cis	rs7615952	0.558	rs7641353	ENSG00000171084.14	FAM86JP	5.6	6.14e-08	6.35e-05	0.52	0.35	Blood pressure (smoking interaction);	chr3:125621035	chr3:125916620~125930024:+
OV	cis	rs7771547	0.607	rs584196	ENSG00000240733.3	RN7SL502P	5.6	6.15e-08	6.36e-05	0.37	0.35	Platelet distribution width;	chr6:36488466	chr6:36450912~36451201:-
OV	cis	rs7771547	0.605	rs659726	ENSG00000240733.3	RN7SL502P	5.6	6.15e-08	6.36e-05	0.37	0.35	Platelet distribution width;	chr6:36500014	chr6:36450912~36451201:-
OV	cis	rs10510102	0.516	rs10219133	ENSG00000276742.1	RP11-500G22.4	5.6	6.15e-08	6.36e-05	0.64	0.35	Breast cancer;	chr10:121987898	chr10:121956782~121957098:+
OV	cis	rs13217239	0.646	rs7451149	ENSG00000243307.2	POM121L6P	-5.6	6.17e-08	6.38e-05	-0.34	-0.35	Schizophrenia;	chr6:27089739	chr6:26896952~26898777:+
OV	cis	rs7688540	0.771	rs11248013	ENSG00000275426.1	CH17-262A2.1	5.6	6.19e-08	6.4e-05	0.59	0.35	Facial morphology (factor 6, height of vermillion lower lip);	chr4:317636	chr4:149738~150317:+
OV	cis	rs4713118	0.662	rs156744	ENSG00000280107.1	AL022393.9	-5.6	6.19e-08	6.4e-05	-0.45	-0.35	Parkinson's disease;	chr6:27999496	chr6:28170845~28172521:+
OV	cis	rs67180937	0.885	rs2133187	ENSG00000272750.1	RP11-378J18.8	-5.6	6.2e-08	6.41e-05	-0.37	-0.35	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640383	chr1:222658867~222661512:-
OV	cis	rs10510102	0.872	rs11200268	ENSG00000226864.1	ATE1-AS1	5.6	6.2e-08	6.41e-05	0.57	0.35	Breast cancer;	chr10:121932661	chr10:121928312~121951965:+
OV	cis	rs9660180	0.839	rs12040826	ENSG00000231050.1	RP1-140A9.1	5.6	6.21e-08	6.42e-05	0.36	0.35	Body mass index;	chr1:1773848	chr1:1891471~1892658:+
OV	cis	rs7847628	0.566	rs10739575	ENSG00000226752.6	PSMD5-AS1	5.6	6.22e-08	6.43e-05	0.47	0.35	Birth weight;	chr9:120843823	chr9:120824828~120854385:+
OV	cis	rs4660456	0.913	rs569159	ENSG00000237899.1	RP4-739H11.3	-5.6	6.22e-08	6.43e-05	-0.51	-0.35	Platelet count;	chr1:40701862	chr1:40669089~40687588:-
OV	cis	rs10510102	0.872	rs79865971	ENSG00000226864.1	ATE1-AS1	5.6	6.24e-08	6.45e-05	0.57	0.35	Breast cancer;	chr10:121941208	chr10:121928312~121951965:+
OV	cis	rs858239	0.6	rs1468592	ENSG00000230042.1	AK3P3	5.6	6.24e-08	6.45e-05	0.37	0.35	Cerebrospinal fluid biomarker levels;	chr7:23101028	chr7:23129178~23129841:+
OV	cis	rs4713118	0.662	rs149970	ENSG00000220721.1	OR1F12	5.6	6.27e-08	6.48e-05	0.42	0.35	Parkinson's disease;	chr6:28012442	chr6:28073316~28074233:+
OV	cis	rs11976180	1	rs2951308	ENSG00000170356.8	OR2A20P	5.6	6.28e-08	6.48e-05	0.49	0.35	Obesity-related traits;	chr7:144070056	chr7:144250045~144252957:-
OV	cis	rs1729407	0.774	rs2849167	ENSG00000254851.1	RP11-109L13.1	5.6	6.32e-08	6.53e-05	0.45	0.35	Apolipoprotein A-IV levels;	chr11:116814028	chr11:117135528~117138582:+
OV	cis	rs2243480	0.901	rs35087093	ENSG00000222364.1	RNU6-96P	-5.59	6.36e-08	6.56e-05	-0.53	-0.35	Diabetic kidney disease;	chr7:65940221	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs35046236	ENSG00000222364.1	RNU6-96P	-5.59	6.36e-08	6.56e-05	-0.53	-0.35	Diabetic kidney disease;	chr7:65943626	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs36068983	ENSG00000222364.1	RNU6-96P	-5.59	6.36e-08	6.56e-05	-0.53	-0.35	Diabetic kidney disease;	chr7:65944004	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs68189316	ENSG00000222364.1	RNU6-96P	-5.59	6.36e-08	6.56e-05	-0.53	-0.35	Diabetic kidney disease;	chr7:65944182	chr7:66395191~66395286:+
OV	cis	rs2243480	0.803	rs34804747	ENSG00000222364.1	RNU6-96P	-5.59	6.36e-08	6.56e-05	-0.53	-0.35	Diabetic kidney disease;	chr7:65947955	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs59794892	ENSG00000222364.1	RNU6-96P	-5.59	6.36e-08	6.56e-05	-0.53	-0.35	Diabetic kidney disease;	chr7:65950886	chr7:66395191~66395286:+
OV	cis	rs2243480	0.901	rs57126451	ENSG00000222364.1	RNU6-96P	-5.59	6.36e-08	6.56e-05	-0.53	-0.35	Diabetic kidney disease;	chr7:65951319	chr7:66395191~66395286:+
OV	cis	rs2243480	0.803	rs36004293	ENSG00000222364.1	RNU6-96P	-5.59	6.36e-08	6.56e-05	-0.53	-0.35	Diabetic kidney disease;	chr7:65951525	chr7:66395191~66395286:+
OV	cis	rs2243480	0.803	rs35268390	ENSG00000222364.1	RNU6-96P	-5.59	6.36e-08	6.56e-05	-0.53	-0.35	Diabetic kidney disease;	chr7:65951549	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs11538349	ENSG00000222364.1	RNU6-96P	-5.59	6.36e-08	6.56e-05	-0.53	-0.35	Diabetic kidney disease;	chr7:65956884	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs937108	ENSG00000222364.1	RNU6-96P	-5.59	6.36e-08	6.56e-05	-0.53	-0.35	Diabetic kidney disease;	chr7:65963465	chr7:66395191~66395286:+
OV	cis	rs9291683	0.588	rs2240724	ENSG00000250413.1	RP11-448G15.1	-5.59	6.41e-08	6.61e-05	-0.39	-0.35	Bone mineral density;	chr4:10019666	chr4:10006482~10009725:+
OV	cis	rs62355901	0.551	rs60856350	ENSG00000271828.1	CTD-2310F14.1	5.59	6.41e-08	6.61e-05	0.69	0.35	Breast cancer;	chr5:56727093	chr5:56927874~56929573:+
OV	cis	rs7811142	0.775	rs1636980	ENSG00000242294.5	STAG3L5P	-5.59	6.41e-08	6.61e-05	-0.37	-0.35	Platelet count;	chr7:100341241	chr7:100336079~100351900:+
OV	cis	rs35160687	1	rs35160687	ENSG00000273080.1	RP11-301O19.1	5.59	6.42e-08	6.61e-05	0.35	0.35	Night sleep phenotypes;	chr2:86244991	chr2:86195590~86196049:+
OV	cis	rs12022452	0.544	rs11208423	ENSG00000238287.1	RP11-656D10.3	-5.59	6.43e-08	6.62e-05	-0.6	-0.35	Age-related hearing impairment (SNP x SNP interaction);	chr1:40563942	chr1:40493157~40508661:-
OV	cis	rs67311347	1	rs28707772	ENSG00000223797.4	ENTPD3-AS1	5.59	6.43e-08	6.62e-05	0.4	0.35	Renal cell carcinoma;	chr3:40463175	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs73080126	ENSG00000223797.4	ENTPD3-AS1	5.59	6.43e-08	6.62e-05	0.4	0.35	Renal cell carcinoma;	chr3:40467662	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs28871903	ENSG00000223797.4	ENTPD3-AS1	5.59	6.43e-08	6.62e-05	0.4	0.35	Renal cell carcinoma;	chr3:40469603	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs56291770	ENSG00000223797.4	ENTPD3-AS1	5.59	6.43e-08	6.62e-05	0.4	0.35	Renal cell carcinoma;	chr3:40473879	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs56303661	ENSG00000223797.4	ENTPD3-AS1	5.59	6.43e-08	6.62e-05	0.4	0.35	Renal cell carcinoma;	chr3:40479287	chr3:40313802~40453329:-
OV	cis	rs7771547	0.642	rs9470309	ENSG00000240733.3	RN7SL502P	5.59	6.44e-08	6.63e-05	0.38	0.35	Platelet distribution width;	chr6:36541974	chr6:36450912~36451201:-
OV	cis	rs11673344	0.526	rs8101610	ENSG00000226686.6	LINC01535	-5.59	6.46e-08	6.65e-05	-0.45	-0.35	Obesity-related traits;	chr19:37566604	chr19:37251912~37265535:+
OV	cis	rs514406	0.861	rs7513052	ENSG00000206627.1	RNU6-969P	-5.59	6.48e-08	6.66e-05	-0.35	-0.35	Monocyte count;	chr1:52775688	chr1:52805108~52805212:-
OV	cis	rs9487094	0.666	rs3778478	ENSG00000260273.1	RP11-425D10.10	5.59	6.48e-08	6.67e-05	0.36	0.35	Height;	chr6:109470427	chr6:109382795~109383666:+
OV	cis	rs9487094	0.644	rs9791241	ENSG00000260273.1	RP11-425D10.10	5.59	6.48e-08	6.67e-05	0.36	0.35	Height;	chr6:109470900	chr6:109382795~109383666:+
OV	cis	rs4713118	0.629	rs203888	ENSG00000219392.1	RP1-265C24.5	-5.59	6.48e-08	6.67e-05	-0.42	-0.35	Parkinson's disease;	chr6:28053811	chr6:28115628~28116551:+
OV	cis	rs13315649	0.562	rs6797317	ENSG00000242551.2	POU5F1P6	-5.59	6.48e-08	6.67e-05	-0.43	-0.35	Sum eosinophil basophil counts;	chr3:128684381	chr3:128674735~128677005:-
OV	cis	rs7927771	0.864	rs3781626	ENSG00000280615.1	Y_RNA	-5.59	6.48e-08	6.67e-05	-0.41	-0.35	Subjective well-being;	chr11:47421342	chr11:47614898~47614994:-
OV	cis	rs514406	0.825	rs487453	ENSG00000206627.1	RNU6-969P	-5.59	6.49e-08	6.68e-05	-0.35	-0.35	Monocyte count;	chr1:52805553	chr1:52805108~52805212:-
OV	cis	rs67311347	1	rs12630072	ENSG00000223797.4	ENTPD3-AS1	5.59	6.49e-08	6.68e-05	0.4	0.35	Renal cell carcinoma;	chr3:40475699	chr3:40313802~40453329:-
OV	cis	rs526231	0.543	rs26820	ENSG00000175749.11	EIF3KP1	5.59	6.52e-08	6.7e-05	0.44	0.35	Primary biliary cholangitis;	chr5:103192391	chr5:103032376~103033031:+
OV	cis	rs526231	0.543	rs26819	ENSG00000175749.11	EIF3KP1	5.59	6.52e-08	6.7e-05	0.44	0.35	Primary biliary cholangitis;	chr5:103193700	chr5:103032376~103033031:+
OV	cis	rs526231	0.615	rs26818	ENSG00000175749.11	EIF3KP1	5.59	6.52e-08	6.7e-05	0.44	0.35	Primary biliary cholangitis;	chr5:103194018	chr5:103032376~103033031:+
OV	cis	rs9291683	0.679	rs13137795	ENSG00000250413.1	RP11-448G15.1	-5.59	6.52e-08	6.71e-05	-0.39	-0.35	Bone mineral density;	chr4:10049882	chr4:10006482~10009725:+
OV	cis	rs4380275	1	rs4854376	ENSG00000272342.1	RP13-539J13.1	5.59	6.53e-08	6.71e-05	0.4	0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:763683	chr2:739588~740164:-
OV	cis	rs9291683	0.588	rs3796842	ENSG00000250413.1	RP11-448G15.1	-5.59	6.53e-08	6.71e-05	-0.4	-0.35	Bone mineral density;	chr4:9994227	chr4:10006482~10009725:+
OV	cis	rs7017914	0.652	rs62508770	ENSG00000223220.1	Y_RNA	5.59	6.53e-08	6.71e-05	0.39	0.35	Bone mineral density;	chr8:70780269	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs55862702	ENSG00000223220.1	Y_RNA	5.59	6.53e-08	6.71e-05	0.39	0.35	Bone mineral density;	chr8:70781502	chr8:70780914~70781008:-
OV	cis	rs7017914	0.628	rs6998989	ENSG00000223220.1	Y_RNA	5.59	6.53e-08	6.71e-05	0.39	0.35	Bone mineral density;	chr8:70782296	chr8:70780914~70781008:-
OV	cis	rs7017914	0.628	rs6981149	ENSG00000223220.1	Y_RNA	5.59	6.53e-08	6.71e-05	0.39	0.35	Bone mineral density;	chr8:70782447	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs62508777	ENSG00000223220.1	Y_RNA	5.59	6.53e-08	6.71e-05	0.39	0.35	Bone mineral density;	chr8:70782769	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs6986479	ENSG00000223220.1	Y_RNA	5.59	6.53e-08	6.71e-05	0.39	0.35	Bone mineral density;	chr8:70785323	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs35115647	ENSG00000223220.1	Y_RNA	5.59	6.53e-08	6.71e-05	0.39	0.35	Bone mineral density;	chr8:70785777	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs1596565	ENSG00000223220.1	Y_RNA	5.59	6.53e-08	6.71e-05	0.39	0.35	Bone mineral density;	chr8:70786597	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs1444339	ENSG00000223220.1	Y_RNA	5.59	6.53e-08	6.71e-05	0.39	0.35	Bone mineral density;	chr8:70788407	chr8:70780914~70781008:-
OV	cis	rs7017914	0.628	rs7822474	ENSG00000223220.1	Y_RNA	5.59	6.53e-08	6.71e-05	0.39	0.35	Bone mineral density;	chr8:70793498	chr8:70780914~70781008:-
OV	cis	rs9487094	0.67	rs2024850	ENSG00000260273.1	RP11-425D10.10	-5.59	6.54e-08	6.72e-05	-0.38	-0.35	Height;	chr6:109497253	chr6:109382795~109383666:+
OV	cis	rs853679	0.517	rs3823180	ENSG00000280107.1	AL022393.9	-5.59	6.54e-08	6.72e-05	-0.43	-0.35	Depression;	chr6:28093966	chr6:28170845~28172521:+
OV	cis	rs1729407	0.649	rs2849176	ENSG00000254851.1	RP11-109L13.1	5.59	6.54e-08	6.72e-05	0.44	0.35	Apolipoprotein A-IV levels;	chr11:116826205	chr11:117135528~117138582:+
OV	cis	rs7017914	0.652	rs13250391	ENSG00000223220.1	Y_RNA	5.59	6.55e-08	6.73e-05	0.4	0.35	Bone mineral density;	chr8:70885537	chr8:70780914~70781008:-
OV	cis	rs7615952	0.611	rs2947646	ENSG00000171084.14	FAM86JP	-5.59	6.57e-08	6.75e-05	-0.7	-0.35	Blood pressure (smoking interaction);	chr3:125874759	chr3:125916620~125930024:+
OV	cis	rs4805272	0.582	rs11083652	ENSG00000267243.4	AC005307.3	5.59	6.57e-08	6.75e-05	0.44	0.35	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28740662	chr19:28435388~28727777:-
OV	cis	rs11673344	0.864	rs8106386	ENSG00000226686.6	LINC01535	-5.59	6.58e-08	6.75e-05	-0.45	-0.35	Obesity-related traits;	chr19:37012997	chr19:37251912~37265535:+
OV	cis	rs7017914	0.652	rs6994488	ENSG00000223220.1	Y_RNA	5.59	6.58e-08	6.75e-05	0.39	0.35	Bone mineral density;	chr8:70741229	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs35931247	ENSG00000223220.1	Y_RNA	5.59	6.58e-08	6.75e-05	0.39	0.35	Bone mineral density;	chr8:70743849	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs7015947	ENSG00000223220.1	Y_RNA	5.59	6.58e-08	6.75e-05	0.39	0.35	Bone mineral density;	chr8:70748711	chr8:70780914~70781008:-
OV	cis	rs61990749	0.597	rs8003691	ENSG00000239272.1	RPL21P10	5.59	6.61e-08	6.78e-05	0.48	0.35	Fibroblast growth factor basic levels;	chr14:77744882	chr14:77683202~77683989:-
OV	cis	rs61990749	0.597	rs2267768	ENSG00000239272.1	RPL21P10	5.59	6.61e-08	6.78e-05	0.48	0.35	Fibroblast growth factor basic levels;	chr14:77749671	chr14:77683202~77683989:-
OV	cis	rs61990749	0.597	rs1549119	ENSG00000239272.1	RPL21P10	5.59	6.61e-08	6.78e-05	0.48	0.35	Fibroblast growth factor basic levels;	chr14:77753469	chr14:77683202~77683989:-
OV	cis	rs61990749	0.597	rs1978416	ENSG00000239272.1	RPL21P10	5.59	6.61e-08	6.78e-05	0.48	0.35	Fibroblast growth factor basic levels;	chr14:77761558	chr14:77683202~77683989:-
OV	cis	rs61990749	0.544	rs3759728	ENSG00000239272.1	RPL21P10	5.59	6.61e-08	6.78e-05	0.48	0.35	Fibroblast growth factor basic levels;	chr14:77763816	chr14:77683202~77683989:-
OV	cis	rs4713118	0.621	rs9295756	ENSG00000280107.1	AL022393.9	-5.59	6.62e-08	6.79e-05	-0.44	-0.35	Parkinson's disease;	chr6:28065618	chr6:28170845~28172521:+
OV	cis	rs7811142	0.83	rs78256546	ENSG00000242294.5	STAG3L5P	5.58	6.67e-08	6.83e-05	0.36	0.35	Platelet count;	chr7:100355347	chr7:100336079~100351900:+
OV	cis	rs7811142	0.83	rs41280971	ENSG00000242294.5	STAG3L5P	5.58	6.67e-08	6.83e-05	0.36	0.35	Platelet count;	chr7:100356834	chr7:100336079~100351900:+
OV	cis	rs7811142	0.83	rs3087502	ENSG00000242294.5	STAG3L5P	5.58	6.67e-08	6.83e-05	0.36	0.35	Platelet count;	chr7:100357741	chr7:100336079~100351900:+
OV	cis	rs7968440	0.591	rs6580732	ENSG00000272368.2	RP4-605O3.4	-5.58	6.68e-08	6.84e-05	-0.38	-0.35	Fibrinogen;	chr12:50252496	chr12:50112197~50165618:+
OV	cis	rs10510102	0.872	rs11200269	ENSG00000226864.1	ATE1-AS1	5.58	6.69e-08	6.86e-05	0.57	0.35	Breast cancer;	chr10:121934021	chr10:121928312~121951965:+
OV	cis	rs10510102	0.872	rs11498944	ENSG00000226864.1	ATE1-AS1	5.58	6.69e-08	6.86e-05	0.57	0.35	Breast cancer;	chr10:121938748	chr10:121928312~121951965:+
OV	cis	rs10510102	0.81	rs12267347	ENSG00000226864.1	ATE1-AS1	5.58	6.69e-08	6.86e-05	0.57	0.35	Breast cancer;	chr10:121939110	chr10:121928312~121951965:+
OV	cis	rs10510102	0.808	rs12253007	ENSG00000226864.1	ATE1-AS1	5.58	6.69e-08	6.86e-05	0.57	0.35	Breast cancer;	chr10:121939360	chr10:121928312~121951965:+
OV	cis	rs10510102	0.872	rs74318512	ENSG00000226864.1	ATE1-AS1	5.58	6.69e-08	6.86e-05	0.57	0.35	Breast cancer;	chr10:121941465	chr10:121928312~121951965:+
OV	cis	rs10510102	0.872	rs12257207	ENSG00000226864.1	ATE1-AS1	5.58	6.69e-08	6.86e-05	0.57	0.35	Breast cancer;	chr10:121941737	chr10:121928312~121951965:+
OV	cis	rs10510102	0.872	rs7916008	ENSG00000226864.1	ATE1-AS1	5.58	6.69e-08	6.86e-05	0.57	0.35	Breast cancer;	chr10:121943578	chr10:121928312~121951965:+
OV	cis	rs10510102	0.872	rs7916380	ENSG00000226864.1	ATE1-AS1	5.58	6.69e-08	6.86e-05	0.57	0.35	Breast cancer;	chr10:121943773	chr10:121928312~121951965:+
OV	cis	rs10510102	0.808	rs7920024	ENSG00000226864.1	ATE1-AS1	5.58	6.69e-08	6.86e-05	0.57	0.35	Breast cancer;	chr10:121944063	chr10:121928312~121951965:+
OV	cis	rs611744	0.805	rs378515	ENSG00000253754.1	RP11-35G22.1	-5.58	6.69e-08	6.86e-05	-0.39	-0.35	Dupuytren's disease;	chr8:108092677	chr8:108226200~108227544:+
OV	cis	rs12200782	0.53	rs9379892	ENSG00000241549.7	GUSBP2	5.58	6.74e-08	6.9e-05	0.43	0.35	Small cell lung carcinoma;	chr6:26582186	chr6:26871484~26956554:-
OV	cis	rs9660180	0.967	rs61422524	ENSG00000231050.1	RP1-140A9.1	5.58	6.75e-08	6.91e-05	0.36	0.35	Body mass index;	chr1:1836126	chr1:1891471~1892658:+
OV	cis	rs7017914	0.905	rs2732094	ENSG00000223220.1	Y_RNA	5.58	6.76e-08	6.92e-05	0.37	0.35	Bone mineral density;	chr8:71007683	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs2732095	ENSG00000223220.1	Y_RNA	5.58	6.76e-08	6.92e-05	0.37	0.35	Bone mineral density;	chr8:71007711	chr8:70780914~70781008:-
OV	cis	rs7017914	0.87	rs2732096	ENSG00000223220.1	Y_RNA	5.58	6.76e-08	6.92e-05	0.37	0.35	Bone mineral density;	chr8:71007745	chr8:70780914~70781008:-
OV	cis	rs7017914	0.935	rs2732097	ENSG00000223220.1	Y_RNA	5.58	6.76e-08	6.92e-05	0.37	0.35	Bone mineral density;	chr8:71007778	chr8:70780914~70781008:-
OV	cis	rs4963124	0.886	rs10902216	ENSG00000279672.1	CMB9-55F22.1	5.58	6.77e-08	6.93e-05	0.42	0.35	Proteinuria and chronic kidney disease;	chr11:739392	chr11:779617~780755:+
OV	cis	rs10934853	0.561	rs760383	ENSG00000242551.2	POU5F1P6	5.58	6.77e-08	6.93e-05	0.46	0.35	Prostate cancer;Prostate cancer (SNP x SNP interaction);	chr3:128400722	chr3:128674735~128677005:-
OV	cis	rs12680842	0.883	rs13265241	ENSG00000253704.1	RP11-267M23.4	5.58	6.78e-08	6.93e-05	0.46	0.35	Body mass index;	chr8:94575129	chr8:94553722~94569745:+
OV	cis	rs7017914	0.702	rs13278019	ENSG00000223220.1	Y_RNA	5.58	6.78e-08	6.94e-05	0.4	0.35	Bone mineral density;	chr8:70621109	chr8:70780914~70781008:-
OV	cis	rs526231	0.543	rs27698	ENSG00000175749.11	EIF3KP1	-5.58	6.8e-08	6.95e-05	-0.44	-0.35	Primary biliary cholangitis;	chr5:103190474	chr5:103032376~103033031:+
OV	cis	rs7017914	0.69	rs10504492	ENSG00000223220.1	Y_RNA	5.58	6.84e-08	7e-05	0.39	0.35	Bone mineral density;	chr8:71065724	chr8:70780914~70781008:-
OV	cis	rs611744	0.87	rs423940	ENSG00000253754.1	RP11-35G22.1	-5.58	6.87e-08	7.02e-05	-0.39	-0.35	Dupuytren's disease;	chr8:108081350	chr8:108226200~108227544:+
OV	cis	rs7429990	0.965	rs4599334	ENSG00000229759.1	MRPS18AP1	-5.58	6.88e-08	7.03e-05	-0.37	-0.35	Educational attainment (years of education);	chr3:48024910	chr3:48256350~48256938:-
OV	cis	rs7684253	0.587	rs4339274	ENSG00000269949.1	RP11-738E22.3	5.58	6.89e-08	7.04e-05	0.42	0.35	Migraine;	chr4:56881468	chr4:56960927~56961373:-
OV	cis	rs7017914	0.652	rs56352991	ENSG00000223220.1	Y_RNA	5.58	6.89e-08	7.04e-05	0.39	0.35	Bone mineral density;	chr8:70655843	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs6994814	ENSG00000223220.1	Y_RNA	5.58	6.89e-08	7.04e-05	0.39	0.35	Bone mineral density;	chr8:70656903	chr8:70780914~70781008:-
OV	cis	rs7017914	0.628	rs7830515	ENSG00000223220.1	Y_RNA	5.58	6.89e-08	7.04e-05	0.39	0.35	Bone mineral density;	chr8:70657999	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs12674694	ENSG00000223220.1	Y_RNA	5.58	6.89e-08	7.04e-05	0.39	0.35	Bone mineral density;	chr8:70658599	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs13262205	ENSG00000223220.1	Y_RNA	5.58	6.89e-08	7.04e-05	0.39	0.35	Bone mineral density;	chr8:70659690	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs35863913	ENSG00000223220.1	Y_RNA	5.58	6.89e-08	7.04e-05	0.39	0.35	Bone mineral density;	chr8:70661024	chr8:70780914~70781008:-
OV	cis	rs2243480	1	rs34702770	ENSG00000222364.1	RNU6-96P	-5.58	6.9e-08	7.05e-05	-0.54	-0.35	Diabetic kidney disease;	chr7:65879836	chr7:66395191~66395286:+
OV	cis	rs2243480	0.803	rs35480979	ENSG00000222364.1	RNU6-96P	-5.58	6.9e-08	7.05e-05	-0.54	-0.35	Diabetic kidney disease;	chr7:65892097	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs34637256	ENSG00000222364.1	RNU6-96P	-5.58	6.9e-08	7.05e-05	-0.54	-0.35	Diabetic kidney disease;	chr7:65895144	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs35391607	ENSG00000222364.1	RNU6-96P	-5.58	6.9e-08	7.05e-05	-0.54	-0.35	Diabetic kidney disease;	chr7:65895842	chr7:66395191~66395286:+
OV	cis	rs7615952	0.736	rs11921945	ENSG00000171084.14	FAM86JP	5.58	6.91e-08	7.05e-05	0.55	0.35	Blood pressure (smoking interaction);	chr3:125924876	chr3:125916620~125930024:+
OV	cis	rs3814244	0.528	rs2860609	ENSG00000255733.4	IFNG-AS1	-5.58	6.92e-08	7.06e-05	-0.34	-0.35	Itch intensity from mosquito bite adjusted by bite size;	chr12:67997215	chr12:67989445~68234686:+
OV	cis	rs12134133	1	rs2782840	ENSG00000274245.1	RP11-357P18.2	5.58	6.92e-08	7.06e-05	0.45	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310838	chr1:207372559~207373252:+
OV	cis	rs11168351	0.927	rs7971880	ENSG00000258273.1	RP11-370I10.4	-5.58	6.95e-08	7.09e-05	-0.43	-0.35	Bipolar disorder and schizophrenia;	chr12:47997272	chr12:48333755~48333901:-
OV	cis	rs7829975	0.502	rs7820738	ENSG00000253893.2	FAM85B	5.58	6.95e-08	7.09e-05	0.36	0.35	Mood instability;	chr8:8845097	chr8:8167819~8226614:-
OV	cis	rs10510102	0.935	rs11200257	ENSG00000276742.1	RP11-500G22.4	5.58	6.96e-08	7.1e-05	0.57	0.35	Breast cancer;	chr10:121917232	chr10:121956782~121957098:+
OV	cis	rs11976180	1	rs2961132	ENSG00000170356.8	OR2A20P	-5.58	6.97e-08	7.11e-05	-0.49	-0.35	Obesity-related traits;	chr7:144071035	chr7:144250045~144252957:-
OV	cis	rs1075265	0.73	rs2111868	ENSG00000233266.1	HMGB1P31	5.58	6.98e-08	7.11e-05	0.42	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53958916	chr2:54051334~54051760:+
OV	cis	rs957448	0.554	rs10956919	ENSG00000253704.1	RP11-267M23.4	5.58	6.98e-08	7.12e-05	0.45	0.35	Nonsyndromic cleft lip with cleft palate;	chr8:94572945	chr8:94553722~94569745:+
OV	cis	rs957448	0.554	rs12540967	ENSG00000253704.1	RP11-267M23.4	5.58	6.98e-08	7.12e-05	0.45	0.35	Nonsyndromic cleft lip with cleft palate;	chr8:94576862	chr8:94553722~94569745:+
OV	cis	rs957448	0.554	rs4735297	ENSG00000253704.1	RP11-267M23.4	5.58	6.98e-08	7.12e-05	0.45	0.35	Nonsyndromic cleft lip with cleft palate;	chr8:94577112	chr8:94553722~94569745:+
OV	cis	rs957448	0.554	rs72674877	ENSG00000253704.1	RP11-267M23.4	5.58	6.98e-08	7.12e-05	0.45	0.35	Nonsyndromic cleft lip with cleft palate;	chr8:94580479	chr8:94553722~94569745:+
OV	cis	rs7429990	0.965	rs4858887	ENSG00000229759.1	MRPS18AP1	-5.58	6.98e-08	7.12e-05	-0.36	-0.35	Educational attainment (years of education);	chr3:48050527	chr3:48256350~48256938:-
OV	cis	rs293748	0.657	rs16903342	ENSG00000250155.1	CTD-2353F22.1	-5.58	6.98e-08	7.12e-05	-0.49	-0.35	Obesity-related traits;	chr5:36792480	chr5:36666214~36725195:-
OV	cis	rs293748	0.771	rs34920909	ENSG00000250155.1	CTD-2353F22.1	-5.58	6.98e-08	7.12e-05	-0.49	-0.35	Obesity-related traits;	chr5:36792614	chr5:36666214~36725195:-
OV	cis	rs293748	0.771	rs59889951	ENSG00000250155.1	CTD-2353F22.1	-5.58	6.98e-08	7.12e-05	-0.49	-0.35	Obesity-related traits;	chr5:36793150	chr5:36666214~36725195:-
OV	cis	rs293748	0.771	rs35899185	ENSG00000250155.1	CTD-2353F22.1	-5.58	6.98e-08	7.12e-05	-0.49	-0.35	Obesity-related traits;	chr5:36795884	chr5:36666214~36725195:-
OV	cis	rs61990749	0.597	rs117131659	ENSG00000239272.1	RPL21P10	-5.57	7.01e-08	7.15e-05	-0.48	-0.35	Fibroblast growth factor basic levels;	chr14:77664783	chr14:77683202~77683989:-
OV	cis	rs62355901	0.739	rs61055995	ENSG00000271828.1	CTD-2310F14.1	5.57	7.04e-08	7.17e-05	0.55	0.35	Breast cancer;	chr5:56723237	chr5:56927874~56929573:+
OV	cis	rs7829975	0.742	rs1533058	ENSG00000253981.4	ALG1L13P	5.57	7.04e-08	7.17e-05	0.38	0.35	Mood instability;	chr8:8827680	chr8:8236003~8244667:-
OV	cis	rs12134133	1	rs2661357	ENSG00000274245.1	RP11-357P18.2	5.57	7.04e-08	7.17e-05	0.45	0.35	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207310593	chr1:207372559~207373252:+
OV	cis	rs11723261	0.582	rs4634177	ENSG00000275426.1	CH17-262A2.1	5.57	7.05e-08	7.19e-05	0.53	0.35	Immune response to smallpox vaccine (IL-6);	chr4:143055	chr4:149738~150317:+
OV	cis	rs62355901	0.505	rs62358079	ENSG00000271828.1	CTD-2310F14.1	5.57	7.07e-08	7.2e-05	0.7	0.35	Breast cancer;	chr5:56858020	chr5:56927874~56929573:+
OV	cis	rs16886181	0.512	rs12652988	ENSG00000271828.1	CTD-2310F14.1	5.57	7.07e-08	7.2e-05	0.65	0.35	Breast cancer (early onset);	chr5:56739539	chr5:56927874~56929573:+
OV	cis	rs875971	0.929	rs34406470	ENSG00000236529.1	RP13-254B10.1	5.57	7.09e-08	7.22e-05	0.37	0.35	Aortic root size;	chr7:66464969	chr7:65840212~65840596:+
OV	cis	rs514406	0.755	rs11206015	ENSG00000206627.1	RNU6-969P	-5.57	7.09e-08	7.22e-05	-0.35	-0.35	Monocyte count;	chr1:52776515	chr1:52805108~52805212:-
OV	cis	rs514406	0.861	rs72637996	ENSG00000206627.1	RNU6-969P	-5.57	7.09e-08	7.22e-05	-0.35	-0.35	Monocyte count;	chr1:52783946	chr1:52805108~52805212:-
OV	cis	rs7267979	0.789	rs6076347	ENSG00000274973.1	RP13-401N8.7	5.57	7.1e-08	7.23e-05	0.41	0.35	Liver enzyme levels (alkaline phosphatase);	chr20:25418154	chr20:25845497~25845862:+
OV	cis	rs10510102	0.516	rs10887034	ENSG00000276742.1	RP11-500G22.4	5.57	7.1e-08	7.23e-05	0.63	0.35	Breast cancer;	chr10:121973996	chr10:121956782~121957098:+
OV	cis	rs1185460	0.904	rs1003081	ENSG00000271751.1	RP11-110I1.14	5.57	7.11e-08	7.24e-05	0.42	0.35	Coronary artery disease;	chr11:119043282	chr11:119065263~119065677:-
OV	cis	rs514406	0.825	rs7523761	ENSG00000206627.1	RNU6-969P	-5.57	7.11e-08	7.24e-05	-0.35	-0.35	Monocyte count;	chr1:52785243	chr1:52805108~52805212:-
OV	cis	rs67311347	0.956	rs9817233	ENSG00000223797.4	ENTPD3-AS1	5.57	7.12e-08	7.25e-05	0.39	0.35	Renal cell carcinoma;	chr3:40384127	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs9817142	ENSG00000223797.4	ENTPD3-AS1	5.57	7.12e-08	7.25e-05	0.39	0.35	Renal cell carcinoma;	chr3:40384283	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs9822644	ENSG00000223797.4	ENTPD3-AS1	5.57	7.12e-08	7.25e-05	0.39	0.35	Renal cell carcinoma;	chr3:40385118	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs12494022	ENSG00000223797.4	ENTPD3-AS1	5.57	7.12e-08	7.25e-05	0.39	0.35	Renal cell carcinoma;	chr3:40385161	chr3:40313802~40453329:-
OV	cis	rs10510102	0.872	rs7906271	ENSG00000226864.1	ATE1-AS1	-5.57	7.13e-08	7.25e-05	-0.58	-0.35	Breast cancer;	chr10:121948207	chr10:121928312~121951965:+
OV	cis	rs875971	0.522	rs2008188	ENSG00000224316.1	RP11-479O9.2	5.57	7.14e-08	7.26e-05	0.36	0.35	Aortic root size;	chr7:65964026	chr7:65773620~65802067:+
OV	cis	rs4380275	1	rs4268954	ENSG00000272342.1	RP13-539J13.1	5.57	7.14e-08	7.26e-05	0.38	0.35	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772834	chr2:739588~740164:-
OV	cis	rs7771547	0.642	rs12214285	ENSG00000240733.3	RN7SL502P	-5.57	7.16e-08	7.28e-05	-0.37	-0.35	Platelet distribution width;	chr6:36466902	chr6:36450912~36451201:-
OV	cis	rs7771547	0.607	rs632943	ENSG00000240733.3	RN7SL502P	5.57	7.16e-08	7.28e-05	0.37	0.35	Platelet distribution width;	chr6:36501344	chr6:36450912~36451201:-
OV	cis	rs7771547	0.573	rs621796	ENSG00000240733.3	RN7SL502P	5.57	7.16e-08	7.28e-05	0.37	0.35	Platelet distribution width;	chr6:36504482	chr6:36450912~36451201:-
OV	cis	rs4713118	0.662	rs9380045	ENSG00000280107.1	AL022393.9	-5.57	7.17e-08	7.28e-05	-0.43	-0.35	Parkinson's disease;	chr6:28057501	chr6:28170845~28172521:+
OV	cis	rs4713118	0.616	rs9348789	ENSG00000280107.1	AL022393.9	-5.57	7.17e-08	7.28e-05	-0.43	-0.35	Parkinson's disease;	chr6:28057708	chr6:28170845~28172521:+
OV	cis	rs4713118	0.662	rs9468274	ENSG00000280107.1	AL022393.9	-5.57	7.17e-08	7.28e-05	-0.43	-0.35	Parkinson's disease;	chr6:28058299	chr6:28170845~28172521:+
OV	cis	rs4713118	0.662	rs9468275	ENSG00000280107.1	AL022393.9	-5.57	7.17e-08	7.28e-05	-0.43	-0.35	Parkinson's disease;	chr6:28058358	chr6:28170845~28172521:+
OV	cis	rs4713118	0.662	rs9468276	ENSG00000280107.1	AL022393.9	-5.57	7.17e-08	7.28e-05	-0.43	-0.35	Parkinson's disease;	chr6:28059910	chr6:28170845~28172521:+
OV	cis	rs4713118	0.662	rs9468277	ENSG00000280107.1	AL022393.9	-5.57	7.17e-08	7.28e-05	-0.43	-0.35	Parkinson's disease;	chr6:28060612	chr6:28170845~28172521:+
OV	cis	rs4713118	0.662	rs9468278	ENSG00000280107.1	AL022393.9	-5.57	7.17e-08	7.28e-05	-0.43	-0.35	Parkinson's disease;	chr6:28060704	chr6:28170845~28172521:+
OV	cis	rs4713118	0.662	rs13218430	ENSG00000280107.1	AL022393.9	-5.57	7.17e-08	7.28e-05	-0.43	-0.35	Parkinson's disease;	chr6:28062059	chr6:28170845~28172521:+
OV	cis	rs4713118	0.662	rs9380046	ENSG00000280107.1	AL022393.9	-5.57	7.17e-08	7.28e-05	-0.43	-0.35	Parkinson's disease;	chr6:28062721	chr6:28170845~28172521:+
OV	cis	rs61990749	0.597	rs176946	ENSG00000239272.1	RPL21P10	5.57	7.17e-08	7.28e-05	0.48	0.35	Fibroblast growth factor basic levels;	chr14:77712096	chr14:77683202~77683989:-
OV	cis	rs4713118	0.866	rs2179094	ENSG00000220721.1	OR1F12	5.57	7.2e-08	7.31e-05	0.38	0.35	Parkinson's disease;	chr6:27774046	chr6:28073316~28074233:+
OV	cis	rs12908161	0.96	rs17599989	ENSG00000259295.5	CSPG4P12	5.57	7.22e-08	7.33e-05	0.47	0.35	Schizophrenia;	chr15:84742305	chr15:85191438~85213905:+
OV	cis	rs957448	0.607	rs12680842	ENSG00000253704.1	RP11-267M23.4	5.57	7.22e-08	7.33e-05	0.45	0.35	Nonsyndromic cleft lip with cleft palate;	chr8:94570378	chr8:94553722~94569745:+
OV	cis	rs957448	0.554	rs12680855	ENSG00000253704.1	RP11-267M23.4	5.57	7.22e-08	7.33e-05	0.45	0.35	Nonsyndromic cleft lip with cleft palate;	chr8:94570427	chr8:94553722~94569745:+
OV	cis	rs7615952	0.546	rs2979306	ENSG00000171084.14	FAM86JP	5.57	7.26e-08	7.37e-05	0.54	0.35	Blood pressure (smoking interaction);	chr3:125593286	chr3:125916620~125930024:+
OV	cis	rs9291683	0.632	rs10939669	ENSG00000250413.1	RP11-448G15.1	-5.57	7.3e-08	7.41e-05	-0.4	-0.35	Bone mineral density;	chr4:10044203	chr4:10006482~10009725:+
OV	cis	rs67311347	1	rs17078813	ENSG00000223797.4	ENTPD3-AS1	5.57	7.31e-08	7.42e-05	0.39	0.35	Renal cell carcinoma;	chr3:40392671	chr3:40313802~40453329:-
OV	cis	rs62355901	0.505	rs62355910	ENSG00000271828.1	CTD-2310F14.1	5.57	7.35e-08	7.45e-05	0.69	0.35	Breast cancer;	chr5:56784810	chr5:56927874~56929573:+
OV	cis	rs62355901	0.505	rs56309635	ENSG00000271828.1	CTD-2310F14.1	5.57	7.35e-08	7.45e-05	0.69	0.35	Breast cancer;	chr5:56789589	chr5:56927874~56929573:+
OV	cis	rs3814244	0.528	rs1468487	ENSG00000255733.4	IFNG-AS1	-5.57	7.35e-08	7.45e-05	-0.35	-0.35	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996602	chr12:67989445~68234686:+
OV	cis	rs11671005	0.651	rs55716128	ENSG00000269600.1	AC016629.3	-5.57	7.35e-08	7.45e-05	-0.49	-0.35	Mean platelet volume;	chr19:58537387	chr19:58593896~58599355:-
OV	cis	rs875971	0.522	rs4718285	ENSG00000224316.1	RP11-479O9.2	5.56	7.37e-08	7.47e-05	0.36	0.35	Aortic root size;	chr7:65827018	chr7:65773620~65802067:+
OV	cis	rs875971	0.522	rs4718286	ENSG00000224316.1	RP11-479O9.2	5.56	7.37e-08	7.47e-05	0.36	0.35	Aortic root size;	chr7:65827777	chr7:65773620~65802067:+
OV	cis	rs875971	0.522	rs4502988	ENSG00000224316.1	RP11-479O9.2	5.56	7.37e-08	7.47e-05	0.36	0.35	Aortic root size;	chr7:65832759	chr7:65773620~65802067:+
OV	cis	rs17711722	0.585	rs6942660	ENSG00000224316.1	RP11-479O9.2	5.56	7.37e-08	7.47e-05	0.36	0.35	Calcium levels;	chr7:65837419	chr7:65773620~65802067:+
OV	cis	rs17711722	0.64	rs13237956	ENSG00000224316.1	RP11-479O9.2	5.56	7.37e-08	7.47e-05	0.36	0.35	Calcium levels;	chr7:65853042	chr7:65773620~65802067:+
OV	cis	rs10463554	0.892	rs17154859	ENSG00000175749.11	EIF3KP1	-5.56	7.38e-08	7.48e-05	-0.4	-0.35	Parkinson's disease;	chr5:102955208	chr5:103032376~103033031:+
OV	cis	rs2282300	0.637	rs10767841	ENSG00000254532.1	RP11-624D11.2	5.56	7.42e-08	7.52e-05	0.4	0.35	Morning vs. evening chronotype;	chr11:30406728	chr11:30044058~30084343:-
OV	cis	rs2282300	0.637	rs7941828	ENSG00000254532.1	RP11-624D11.2	5.56	7.42e-08	7.52e-05	0.4	0.35	Morning vs. evening chronotype;	chr11:30408784	chr11:30044058~30084343:-
OV	cis	rs2282300	0.637	rs7942037	ENSG00000254532.1	RP11-624D11.2	5.56	7.42e-08	7.52e-05	0.4	0.35	Morning vs. evening chronotype;	chr11:30408785	chr11:30044058~30084343:-
OV	cis	rs34779708	0.931	rs11597392	ENSG00000230534.5	RP11-297A16.2	5.56	7.43e-08	7.53e-05	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:34999647	chr10:35098006~35127020:-
OV	cis	rs853679	0.538	rs13199081	ENSG00000216901.1	AL022393.7	5.56	7.48e-08	7.57e-05	0.45	0.35	Depression;	chr6:28364057	chr6:28176188~28176674:+
OV	cis	rs611744	0.647	rs631775	ENSG00000253754.1	RP11-35G22.1	-5.56	7.49e-08	7.58e-05	-0.39	-0.35	Dupuytren's disease;	chr8:108240517	chr8:108226200~108227544:+
OV	cis	rs9660180	0.967	rs12034740	ENSG00000231050.1	RP1-140A9.1	5.56	7.49e-08	7.58e-05	0.35	0.35	Body mass index;	chr1:1797530	chr1:1891471~1892658:+
OV	cis	rs3091242	0.933	rs9438905	ENSG00000224183.1	SDHDP6	-5.56	7.5e-08	7.59e-05	-0.4	-0.35	Erythrocyte sedimentation rate;	chr1:25437686	chr1:25294164~25294643:-
OV	cis	rs12594515	0.967	rs11857628	ENSG00000273972.1	CTD-2306A12.1	-5.56	7.51e-08	7.6e-05	-0.37	-0.35	Weight;Waist circumference;	chr15:45706008	chr15:45702640~45703183:+
OV	cis	rs9291683	0.561	rs3733584	ENSG00000250413.1	RP11-448G15.1	-5.56	7.52e-08	7.61e-05	-0.39	-0.35	Bone mineral density;	chr4:10034882	chr4:10006482~10009725:+
OV	cis	rs67311347	1	rs12488805	ENSG00000223797.4	ENTPD3-AS1	5.56	7.52e-08	7.61e-05	0.39	0.35	Renal cell carcinoma;	chr3:40381378	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs9854493	ENSG00000223797.4	ENTPD3-AS1	5.56	7.52e-08	7.61e-05	0.39	0.35	Renal cell carcinoma;	chr3:40382131	chr3:40313802~40453329:-
OV	cis	rs67180937	0.553	rs2088514	ENSG00000272750.1	RP11-378J18.8	-5.56	7.57e-08	7.65e-05	-0.43	-0.35	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222658030	chr1:222658867~222661512:-
OV	cis	rs611744	0.87	rs635941	ENSG00000253754.1	RP11-35G22.1	-5.56	7.61e-08	7.68e-05	-0.4	-0.35	Dupuytren's disease;	chr8:108223228	chr8:108226200~108227544:+
OV	cis	rs9291683	0.595	rs11722930	ENSG00000250413.1	RP11-448G15.1	-5.56	7.61e-08	7.68e-05	-0.39	-0.35	Bone mineral density;	chr4:10033830	chr4:10006482~10009725:+
OV	cis	rs9291683	0.538	rs11727199	ENSG00000250413.1	RP11-448G15.1	-5.56	7.61e-08	7.68e-05	-0.39	-0.35	Bone mineral density;	chr4:10034566	chr4:10006482~10009725:+
OV	cis	rs9291683	0.595	rs3733585	ENSG00000250413.1	RP11-448G15.1	-5.56	7.61e-08	7.68e-05	-0.39	-0.35	Bone mineral density;	chr4:10034715	chr4:10006482~10009725:+
OV	cis	rs16958445	1	rs16958445	ENSG00000260103.2	RP11-10O17.1	5.56	7.63e-08	7.7e-05	0.58	0.35	Exfoliation glaucoma or exfoliation syndrome;	chr15:73884216	chr15:74478070~74490286:-
OV	cis	rs4660456	0.913	rs556875	ENSG00000237899.1	RP4-739H11.3	-5.56	7.64e-08	7.72e-05	-0.52	-0.35	Platelet count;	chr1:40688571	chr1:40669089~40687588:-
OV	cis	rs4713118	0.662	rs9380045	ENSG00000219392.1	RP1-265C24.5	-5.56	7.65e-08	7.72e-05	-0.42	-0.35	Parkinson's disease;	chr6:28057501	chr6:28115628~28116551:+
OV	cis	rs4713118	0.616	rs9348789	ENSG00000219392.1	RP1-265C24.5	-5.56	7.65e-08	7.72e-05	-0.42	-0.35	Parkinson's disease;	chr6:28057708	chr6:28115628~28116551:+
OV	cis	rs4713118	0.662	rs9468274	ENSG00000219392.1	RP1-265C24.5	-5.56	7.65e-08	7.72e-05	-0.42	-0.35	Parkinson's disease;	chr6:28058299	chr6:28115628~28116551:+
OV	cis	rs4713118	0.662	rs9468275	ENSG00000219392.1	RP1-265C24.5	-5.56	7.65e-08	7.72e-05	-0.42	-0.35	Parkinson's disease;	chr6:28058358	chr6:28115628~28116551:+
OV	cis	rs4713118	0.662	rs9468276	ENSG00000219392.1	RP1-265C24.5	-5.56	7.65e-08	7.72e-05	-0.42	-0.35	Parkinson's disease;	chr6:28059910	chr6:28115628~28116551:+
OV	cis	rs4713118	0.662	rs9468277	ENSG00000219392.1	RP1-265C24.5	-5.56	7.65e-08	7.72e-05	-0.42	-0.35	Parkinson's disease;	chr6:28060612	chr6:28115628~28116551:+
OV	cis	rs4713118	0.662	rs9468278	ENSG00000219392.1	RP1-265C24.5	-5.56	7.65e-08	7.72e-05	-0.42	-0.35	Parkinson's disease;	chr6:28060704	chr6:28115628~28116551:+
OV	cis	rs4713118	0.662	rs13218430	ENSG00000219392.1	RP1-265C24.5	-5.56	7.65e-08	7.72e-05	-0.42	-0.35	Parkinson's disease;	chr6:28062059	chr6:28115628~28116551:+
OV	cis	rs4713118	0.662	rs9380046	ENSG00000219392.1	RP1-265C24.5	-5.56	7.65e-08	7.72e-05	-0.42	-0.35	Parkinson's disease;	chr6:28062721	chr6:28115628~28116551:+
OV	cis	rs10463554	0.963	rs257115	ENSG00000175749.11	EIF3KP1	5.56	7.65e-08	7.72e-05	0.4	0.35	Parkinson's disease;	chr5:103196107	chr5:103032376~103033031:+
OV	cis	rs67311347	0.713	rs9861194	ENSG00000223797.4	ENTPD3-AS1	5.56	7.66e-08	7.73e-05	0.38	0.35	Renal cell carcinoma;	chr3:40267734	chr3:40313802~40453329:-
OV	cis	rs7104764	0.507	rs6598054	ENSG00000277290.1	RP11-326C3.16	5.56	7.66e-08	7.73e-05	0.4	0.35	Menarche (age at onset);	chr11:254010	chr11:243099~243483:-
OV	cis	rs172166	0.611	rs203883	ENSG00000219392.1	RP1-265C24.5	-5.56	7.67e-08	7.73e-05	-0.4	-0.35	Cardiac Troponin-T levels;	chr6:28110578	chr6:28115628~28116551:+
OV	cis	rs55757919	1	rs55757919	ENSG00000237595.3	RP11-112L6.3	5.56	7.67e-08	7.74e-05	0.49	0.35	Monocyte percentage of white cells;	chr20:50132011	chr20:50162765~50166102:-
OV	cis	rs7017914	0.617	rs34917985	ENSG00000223220.1	Y_RNA	5.56	7.68e-08	7.74e-05	0.39	0.35	Bone mineral density;	chr8:70662426	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs6993326	ENSG00000223220.1	Y_RNA	5.56	7.68e-08	7.74e-05	0.39	0.35	Bone mineral density;	chr8:70663365	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs10504480	ENSG00000223220.1	Y_RNA	5.56	7.68e-08	7.74e-05	0.39	0.35	Bone mineral density;	chr8:70666012	chr8:70780914~70781008:-
OV	cis	rs301901	0.861	rs217797	ENSG00000250155.1	CTD-2353F22.1	-5.56	7.72e-08	7.78e-05	-0.4	-0.35	Height;	chr5:37318193	chr5:36666214~36725195:-
OV	cis	rs3931020	0.657	rs277376	ENSG00000272864.1	RP11-17E13.2	5.55	7.75e-08	7.8e-05	0.48	0.35	Resistin levels;	chr1:74776562	chr1:74698769~74699333:-
OV	cis	rs1075265	0.87	rs6724389	ENSG00000233266.1	HMGB1P31	5.55	7.8e-08	7.85e-05	0.42	0.35	Chronotype;Morning vs. evening chronotype;	chr2:53985698	chr2:54051334~54051760:+
OV	cis	rs9291683	0.609	rs13149985	ENSG00000250413.1	RP11-448G15.1	-5.55	7.8e-08	7.86e-05	-0.38	-0.35	Bone mineral density;	chr4:10026766	chr4:10006482~10009725:+
OV	cis	rs875971	0.522	rs709604	ENSG00000224316.1	RP11-479O9.2	-5.55	7.81e-08	7.86e-05	-0.37	-0.35	Aortic root size;	chr7:66032447	chr7:65773620~65802067:+
OV	cis	rs7580658	0.637	rs4662710	ENSG00000236682.1	AC068282.3	-5.55	7.82e-08	7.87e-05	-0.43	-0.35	Protein C levels;	chr2:127219241	chr2:127389130~127400580:+
OV	cis	rs34779708	0.931	rs4007289	ENSG00000230534.5	RP11-297A16.2	5.55	7.83e-08	7.88e-05	0.45	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:34980862	chr10:35098006~35127020:-
OV	cis	rs2188561	0.697	rs3735607	ENSG00000241764.3	AC002467.7	5.55	7.83e-08	7.88e-05	0.41	0.35	Alcohol consumption;	chr7:107743833	chr7:107742817~107744581:-
OV	cis	rs2455601	0.744	rs2568085	ENSG00000254860.4	TMEM9B-AS1	-5.55	7.86e-08	7.9e-05	-0.4	-0.35	Schizophrenia;	chr11:8954201	chr11:8964675~8977527:+
OV	cis	rs34779708	0.966	rs11599606	ENSG00000230534.5	RP11-297A16.2	5.55	7.87e-08	7.92e-05	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35117698	chr10:35098006~35127020:-
OV	cis	rs8040855	0.52	rs11629963	ENSG00000259295.5	CSPG4P12	-5.55	7.88e-08	7.92e-05	-0.53	-0.35	Bulimia nervosa;	chr15:84986808	chr15:85191438~85213905:+
OV	cis	rs611744	0.647	rs2597658	ENSG00000253754.1	RP11-35G22.1	-5.55	7.9e-08	7.93e-05	-0.39	-0.35	Dupuytren's disease;	chr8:108243785	chr8:108226200~108227544:+
OV	cis	rs2153535	0.553	rs2984099	ENSG00000230939.1	RP11-314C16.1	5.55	7.91e-08	7.95e-05	0.46	0.35	Motion sickness;	chr6:8637041	chr6:8784178~8785445:+
OV	cis	rs611744	0.87	rs634216	ENSG00000253754.1	RP11-35G22.1	-5.55	7.92e-08	7.96e-05	-0.4	-0.35	Dupuytren's disease;	chr8:108162574	chr8:108226200~108227544:+
OV	cis	rs1061377	0.748	rs1964345	ENSG00000249207.1	RP11-360F5.1	-5.55	7.92e-08	7.96e-05	-0.36	-0.35	Uric acid levels;	chr4:39104793	chr4:39112677~39126818:-
OV	cis	rs1061377	0.748	rs1964347	ENSG00000249207.1	RP11-360F5.1	-5.55	7.92e-08	7.96e-05	-0.36	-0.35	Uric acid levels;	chr4:39104956	chr4:39112677~39126818:-
OV	cis	rs1061377	0.748	rs4974933	ENSG00000249207.1	RP11-360F5.1	-5.55	7.92e-08	7.96e-05	-0.36	-0.35	Uric acid levels;	chr4:39105636	chr4:39112677~39126818:-
OV	cis	rs5742933	0.597	rs7568449	ENSG00000253559.1	OSGEPL1-AS1	5.55	7.93e-08	7.97e-05	0.37	0.35	Ferritin levels;	chr2:189656328	chr2:189762704~189765556:+
OV	cis	rs67180937	0.553	rs2133188	ENSG00000272750.1	RP11-378J18.8	5.55	7.95e-08	7.98e-05	0.42	0.35	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222640411	chr1:222658867~222661512:-
OV	cis	rs7684253	0.587	rs2170073	ENSG00000269949.1	RP11-738E22.3	-5.55	7.95e-08	7.98e-05	-0.42	-0.35	Migraine;	chr4:56880659	chr4:56960927~56961373:-
OV	cis	rs1426063	0.614	rs17000260	ENSG00000260265.1	RP11-44F21.5	5.55	7.99e-08	8.02e-05	0.66	0.35	QT interval;	chr4:75108576	chr4:75081702~75084717:-
OV	cis	rs2243480	1	rs67728539	ENSG00000222364.1	RNU6-96P	-5.55	7.99e-08	8.02e-05	-0.53	-0.35	Diabetic kidney disease;	chr7:65913137	chr7:66395191~66395286:+
OV	cis	rs10510102	0.872	rs7906462	ENSG00000226864.1	ATE1-AS1	5.55	7.99e-08	8.02e-05	0.56	0.35	Breast cancer;	chr10:121948098	chr10:121928312~121951965:+
OV	cis	rs7017914	0.652	rs12681420	ENSG00000223220.1	Y_RNA	5.55	7.99e-08	8.02e-05	0.4	0.35	Bone mineral density;	chr8:70680963	chr8:70780914~70781008:-
OV	cis	rs853679	0.55	rs1233701	ENSG00000280107.1	AL022393.9	5.55	8e-08	8.02e-05	0.44	0.35	Depression;	chr6:28200948	chr6:28170845~28172521:+
OV	cis	rs8062405	0.755	rs17707300	ENSG00000278665.1	RP11-666O2.4	5.55	8.01e-08	8.03e-05	0.37	0.35	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582026	chr16:28599241~28601881:-
OV	cis	rs611744	0.967	rs652485	ENSG00000253754.1	RP11-35G22.1	-5.55	8.02e-08	8.04e-05	-0.39	-0.35	Dupuytren's disease;	chr8:108190467	chr8:108226200~108227544:+
OV	cis	rs1150668	0.699	rs1531681	ENSG00000220721.1	OR1F12	5.55	8.02e-08	8.05e-05	0.34	0.35	Pubertal anthropometrics;	chr6:28259100	chr6:28073316~28074233:+
OV	cis	rs2153535	0.585	rs2208540	ENSG00000230939.1	RP11-314C16.1	-5.55	8.04e-08	8.06e-05	-0.37	-0.35	Motion sickness;	chr6:8627147	chr6:8784178~8785445:+
OV	cis	rs7771547	0.607	rs614028	ENSG00000240733.3	RN7SL502P	5.55	8.05e-08	8.07e-05	0.37	0.35	Platelet distribution width;	chr6:36516475	chr6:36450912~36451201:-
OV	cis	rs7771547	0.642	rs668499	ENSG00000240733.3	RN7SL502P	5.55	8.05e-08	8.07e-05	0.37	0.35	Platelet distribution width;	chr6:36528602	chr6:36450912~36451201:-
OV	cis	rs7771547	0.642	rs628213	ENSG00000240733.3	RN7SL502P	5.55	8.05e-08	8.07e-05	0.37	0.35	Platelet distribution width;	chr6:36540869	chr6:36450912~36451201:-
OV	cis	rs7615952	0.512	rs4679430	ENSG00000171084.14	FAM86JP	5.55	8.07e-08	8.09e-05	0.51	0.35	Blood pressure (smoking interaction);	chr3:125639049	chr3:125916620~125930024:+
OV	cis	rs7615952	0.512	rs34651730	ENSG00000171084.14	FAM86JP	5.55	8.07e-08	8.09e-05	0.51	0.35	Blood pressure (smoking interaction);	chr3:125639796	chr3:125916620~125930024:+
OV	cis	rs7615952	0.512	rs11929125	ENSG00000171084.14	FAM86JP	5.55	8.07e-08	8.09e-05	0.51	0.35	Blood pressure (smoking interaction);	chr3:125640599	chr3:125916620~125930024:+
OV	cis	rs7615952	0.512	rs2922175	ENSG00000171084.14	FAM86JP	5.55	8.07e-08	8.09e-05	0.51	0.35	Blood pressure (smoking interaction);	chr3:125642516	chr3:125916620~125930024:+
OV	cis	rs7615952	0.512	rs2979351	ENSG00000171084.14	FAM86JP	5.55	8.07e-08	8.09e-05	0.51	0.35	Blood pressure (smoking interaction);	chr3:125644755	chr3:125916620~125930024:+
OV	cis	rs35160687	0.901	rs67903513	ENSG00000273080.1	RP11-301O19.1	5.55	8.08e-08	8.1e-05	0.35	0.35	Night sleep phenotypes;	chr2:86284976	chr2:86195590~86196049:+
OV	cis	rs858239	0.601	rs1034963	ENSG00000230042.1	AK3P3	-5.55	8.1e-08	8.12e-05	-0.35	-0.35	Cerebrospinal fluid biomarker levels;	chr7:23108854	chr7:23129178~23129841:+
OV	cis	rs2153535	0.518	rs9393051	ENSG00000230939.1	RP11-314C16.1	-5.54	8.14e-08	8.15e-05	-0.39	-0.35	Motion sickness;	chr6:8638726	chr6:8784178~8785445:+
OV	cis	rs34779708	0.931	rs35317849	ENSG00000230534.5	RP11-297A16.2	5.54	8.15e-08	8.16e-05	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:34996793	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs4934697	ENSG00000230534.5	RP11-297A16.2	5.54	8.15e-08	8.16e-05	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:34998264	chr10:35098006~35127020:-
OV	cis	rs6940638	1	rs6940638	ENSG00000220721.1	OR1F12	5.54	8.15e-08	8.16e-05	0.44	0.35	Intelligence (multi-trait analysis);	chr6:27078471	chr6:28073316~28074233:+
OV	cis	rs67311347	1	rs9857824	ENSG00000223797.4	ENTPD3-AS1	5.54	8.15e-08	8.16e-05	0.38	0.35	Renal cell carcinoma;	chr3:40417921	chr3:40313802~40453329:-
OV	cis	rs11673344	0.864	rs79927931	ENSG00000226686.6	LINC01535	5.54	8.17e-08	8.18e-05	0.45	0.35	Obesity-related traits;	chr19:37012241	chr19:37251912~37265535:+
OV	cis	rs3931020	0.657	rs277368	ENSG00000272864.1	RP11-17E13.2	5.54	8.17e-08	8.18e-05	0.47	0.35	Resistin levels;	chr1:74764922	chr1:74698769~74699333:-
OV	cis	rs3931020	0.657	rs277369	ENSG00000272864.1	RP11-17E13.2	5.54	8.17e-08	8.18e-05	0.47	0.35	Resistin levels;	chr1:74768977	chr1:74698769~74699333:-
OV	cis	rs2153535	0.585	rs4960449	ENSG00000230939.1	RP11-314C16.1	-5.54	8.23e-08	8.23e-05	-0.37	-0.35	Motion sickness;	chr6:8625762	chr6:8784178~8785445:+
OV	cis	rs2153535	0.585	rs9393048	ENSG00000230939.1	RP11-314C16.1	-5.54	8.23e-08	8.23e-05	-0.37	-0.35	Motion sickness;	chr6:8626321	chr6:8784178~8785445:+
OV	cis	rs2153535	0.585	rs7766729	ENSG00000230939.1	RP11-314C16.1	-5.54	8.23e-08	8.23e-05	-0.37	-0.35	Motion sickness;	chr6:8627408	chr6:8784178~8785445:+
OV	cis	rs67311347	1	rs7641495	ENSG00000223797.4	ENTPD3-AS1	-5.54	8.28e-08	8.28e-05	-0.38	-0.35	Renal cell carcinoma;	chr3:40453199	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs962847	ENSG00000223797.4	ENTPD3-AS1	-5.54	8.28e-08	8.28e-05	-0.38	-0.35	Renal cell carcinoma;	chr3:40453665	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs1454497	ENSG00000223797.4	ENTPD3-AS1	-5.54	8.28e-08	8.28e-05	-0.38	-0.35	Renal cell carcinoma;	chr3:40454835	chr3:40313802~40453329:-
OV	cis	rs7017914	0.652	rs11987501	ENSG00000223220.1	Y_RNA	5.54	8.3e-08	8.3e-05	0.39	0.35	Bone mineral density;	chr8:70666283	chr8:70780914~70781008:-
OV	cis	rs1061377	0.748	rs6816202	ENSG00000249207.1	RP11-360F5.1	-5.54	8.33e-08	8.32e-05	-0.36	-0.35	Uric acid levels;	chr4:39106868	chr4:39112677~39126818:-
OV	cis	rs1061377	0.748	rs6842561	ENSG00000249207.1	RP11-360F5.1	-5.54	8.33e-08	8.32e-05	-0.36	-0.35	Uric acid levels;	chr4:39106873	chr4:39112677~39126818:-
OV	cis	rs34375054	0.738	rs10773145	ENSG00000279233.1	RP11-158L12.4	-5.54	8.37e-08	8.36e-05	-0.28	-0.35	Post bronchodilator FEV1/FVC ratio;	chr12:125141057	chr12:125138245~125141711:+
OV	cis	rs34779708	0.966	rs4934725	ENSG00000230534.5	RP11-297A16.2	5.54	8.39e-08	8.38e-05	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35109308	chr10:35098006~35127020:-
OV	cis	rs34779708	1	rs12769189	ENSG00000230534.5	RP11-297A16.2	5.54	8.39e-08	8.38e-05	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35110740	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs12774834	ENSG00000230534.5	RP11-297A16.2	5.54	8.39e-08	8.38e-05	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35111142	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs12775759	ENSG00000230534.5	RP11-297A16.2	5.54	8.39e-08	8.38e-05	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35111255	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs34296409	ENSG00000230534.5	RP11-297A16.2	5.54	8.39e-08	8.38e-05	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35115685	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs35777088	ENSG00000230534.5	RP11-297A16.2	5.54	8.39e-08	8.38e-05	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35120120	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs11592567	ENSG00000230534.5	RP11-297A16.2	5.54	8.39e-08	8.38e-05	0.46	0.35	Inflammatory bowel disease;Crohn's disease;	chr10:35120441	chr10:35098006~35127020:-
OV	cis	rs35160687	0.901	rs13020869	ENSG00000273080.1	RP11-301O19.1	5.54	8.4e-08	8.38e-05	0.35	0.35	Night sleep phenotypes;	chr2:86296237	chr2:86195590~86196049:+
OV	cis	rs858239	0.6	rs7787110	ENSG00000230042.1	AK3P3	-5.54	8.4e-08	8.39e-05	-0.36	-0.35	Cerebrospinal fluid biomarker levels;	chr7:23098855	chr7:23129178~23129841:+
OV	cis	rs6991838	0.584	rs7823840	ENSG00000200714.1	Y_RNA	-5.54	8.42e-08	8.4e-05	-0.44	-0.35	Intelligence (multi-trait analysis);	chr8:65606766	chr8:65592731~65592820:+
OV	cis	rs11673344	0.526	rs17244713	ENSG00000226686.6	LINC01535	5.54	8.42e-08	8.4e-05	0.44	0.35	Obesity-related traits;	chr19:37559938	chr19:37251912~37265535:+
OV	cis	rs11673344	0.526	rs17244769	ENSG00000226686.6	LINC01535	5.54	8.42e-08	8.4e-05	0.44	0.35	Obesity-related traits;	chr19:37562031	chr19:37251912~37265535:+
OV	cis	rs11673344	0.526	rs8111790	ENSG00000226686.6	LINC01535	5.54	8.42e-08	8.4e-05	0.44	0.35	Obesity-related traits;	chr19:37565861	chr19:37251912~37265535:+
OV	cis	rs11673344	0.526	rs55909413	ENSG00000226686.6	LINC01535	5.54	8.42e-08	8.4e-05	0.44	0.35	Obesity-related traits;	chr19:37578663	chr19:37251912~37265535:+
OV	cis	rs11673344	0.526	rs55865869	ENSG00000226686.6	LINC01535	5.54	8.42e-08	8.4e-05	0.44	0.35	Obesity-related traits;	chr19:37578683	chr19:37251912~37265535:+
OV	cis	rs11673344	0.502	rs17304703	ENSG00000226686.6	LINC01535	5.54	8.42e-08	8.4e-05	0.44	0.35	Obesity-related traits;	chr19:37582646	chr19:37251912~37265535:+
OV	cis	rs11673344	0.526	rs73033122	ENSG00000226686.6	LINC01535	5.54	8.42e-08	8.4e-05	0.44	0.35	Obesity-related traits;	chr19:37586006	chr19:37251912~37265535:+
OV	cis	rs11673344	0.526	rs2306201	ENSG00000226686.6	LINC01535	5.54	8.42e-08	8.4e-05	0.44	0.35	Obesity-related traits;	chr19:37586573	chr19:37251912~37265535:+
OV	cis	rs1075265	0.633	rs3731967	ENSG00000233266.1	HMGB1P31	-5.54	8.43e-08	8.41e-05	-0.43	-0.35	Chronotype;Morning vs. evening chronotype;	chr2:53975311	chr2:54051334~54051760:+
OV	cis	rs1185460	0.967	rs1177563	ENSG00000271751.1	RP11-110I1.14	-5.54	8.44e-08	8.42e-05	-0.42	-0.34	Coronary artery disease;	chr11:119078373	chr11:119065263~119065677:-
OV	cis	rs2999052	0.542	rs729847	ENSG00000242551.2	POU5F1P6	5.54	8.45e-08	8.42e-05	0.43	0.34	Hypospadias;	chr3:128391927	chr3:128674735~128677005:-
OV	cis	rs4805272	0.512	rs8106166	ENSG00000267243.4	AC005307.3	5.54	8.45e-08	8.43e-05	0.58	0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28848671	chr19:28435388~28727777:-
OV	cis	rs10934853	0.561	rs1702136	ENSG00000242551.2	POU5F1P6	5.54	8.46e-08	8.43e-05	0.47	0.34	Prostate cancer;Prostate cancer (SNP x SNP interaction);	chr3:128399868	chr3:128674735~128677005:-
OV	cis	rs62355901	0.505	rs61193961	ENSG00000271828.1	CTD-2310F14.1	5.54	8.46e-08	8.43e-05	0.67	0.34	Breast cancer;	chr5:56792343	chr5:56927874~56929573:+
OV	cis	rs4713118	0.629	rs203889	ENSG00000280107.1	AL022393.9	-5.54	8.46e-08	8.43e-05	-0.43	-0.34	Parkinson's disease;	chr6:28053997	chr6:28170845~28172521:+
OV	cis	rs2243480	1	rs35735127	ENSG00000222364.1	RNU6-96P	-5.54	8.47e-08	8.44e-05	-0.53	-0.34	Diabetic kidney disease;	chr7:65835436	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs73142121	ENSG00000222364.1	RNU6-96P	-5.54	8.47e-08	8.44e-05	-0.53	-0.34	Diabetic kidney disease;	chr7:65846219	chr7:66395191~66395286:+
OV	cis	rs2243480	0.803	rs34004500	ENSG00000222364.1	RNU6-96P	-5.54	8.47e-08	8.44e-05	-0.53	-0.34	Diabetic kidney disease;	chr7:65847191	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs13220979	ENSG00000222364.1	RNU6-96P	-5.54	8.48e-08	8.45e-05	-0.53	-0.34	Diabetic kidney disease;	chr7:65898217	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs34974928	ENSG00000222364.1	RNU6-96P	-5.54	8.48e-08	8.45e-05	-0.53	-0.34	Diabetic kidney disease;	chr7:65899019	chr7:66395191~66395286:+
OV	cis	rs61990749	0.597	rs9323650	ENSG00000239272.1	RPL21P10	5.54	8.48e-08	8.45e-05	0.44	0.34	Fibroblast growth factor basic levels;	chr14:77683993	chr14:77683202~77683989:-
OV	cis	rs992157	0.804	rs6758540	ENSG00000237281.1	CATIP-AS2	5.54	8.49e-08	8.46e-05	0.4	0.34	Colorectal cancer;	chr2:218273902	chr2:218326889~218357966:-
OV	cis	rs5742933	0.857	rs1233282	ENSG00000253559.1	OSGEPL1-AS1	-5.54	8.49e-08	8.46e-05	-0.36	-0.34	Ferritin levels;	chr2:189823518	chr2:189762704~189765556:+
OV	cis	rs7017914	0.875	rs2732107	ENSG00000223220.1	Y_RNA	5.54	8.49e-08	8.46e-05	0.37	0.34	Bone mineral density;	chr8:71013073	chr8:70780914~70781008:-
OV	cis	rs2999052	0.554	rs2659685	ENSG00000242551.2	POU5F1P6	5.54	8.51e-08	8.47e-05	0.46	0.34	Hypospadias;	chr3:128403553	chr3:128674735~128677005:-
OV	cis	rs4713118	0.824	rs9468225	ENSG00000220721.1	OR1F12	5.54	8.51e-08	8.47e-05	0.37	0.34	Parkinson's disease;	chr6:27777940	chr6:28073316~28074233:+
OV	cis	rs10483853	0.525	rs7158272	ENSG00000258695.2	RP3-414A15.2	5.54	8.52e-08	8.48e-05	0.47	0.34	Coronary artery calcification;	chr14:73476486	chr14:73522878~73530610:+
OV	cis	rs293748	0.771	rs35263618	ENSG00000250155.1	CTD-2353F22.1	-5.54	8.54e-08	8.49e-05	-0.48	-0.34	Obesity-related traits;	chr5:36795112	chr5:36666214~36725195:-
OV	cis	rs853679	0.517	rs9380052	ENSG00000280107.1	AL022393.9	-5.54	8.54e-08	8.5e-05	-0.44	-0.34	Depression;	chr6:28096845	chr6:28170845~28172521:+
OV	cis	rs16873450	1	rs16873450	ENSG00000234800.2	PCMTD1P3	-5.54	8.54e-08	8.5e-05	-0.35	-0.34	Verbal memory performance (residualized delayed recall level);	chr7:23767021	chr7:23721311~23721782:-
OV	cis	rs11976180	1	rs11975942	ENSG00000170356.8	OR2A20P	-5.54	8.55e-08	8.5e-05	-0.49	-0.34	Obesity-related traits;	chr7:144043487	chr7:144250045~144252957:-
OV	cis	rs11976180	1	rs11976037	ENSG00000170356.8	OR2A20P	-5.54	8.55e-08	8.5e-05	-0.49	-0.34	Obesity-related traits;	chr7:144043931	chr7:144250045~144252957:-
OV	cis	rs494459	0.964	rs576283	ENSG00000278376.1	RP11-158I9.8	-5.54	8.56e-08	8.51e-05	-0.34	-0.34	Height;	chr11:118703185	chr11:118791254~118793137:+
OV	cis	rs494459	0.929	rs627391	ENSG00000278376.1	RP11-158I9.8	-5.54	8.56e-08	8.51e-05	-0.34	-0.34	Height;	chr11:118703207	chr11:118791254~118793137:+
OV	cis	rs507080	0.524	rs524409	ENSG00000278376.1	RP11-158I9.8	-5.54	8.56e-08	8.51e-05	-0.34	-0.34	Serum metabolite levels;	chr11:118703602	chr11:118791254~118793137:+
OV	cis	rs34779708	0.931	rs2384283	ENSG00000230534.5	RP11-297A16.2	5.53	8.56e-08	8.52e-05	0.45	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35037861	chr10:35098006~35127020:-
OV	cis	rs61990749	0.597	rs2364584	ENSG00000239272.1	RPL21P10	-5.53	8.59e-08	8.55e-05	-0.47	-0.34	Fibroblast growth factor basic levels;	chr14:77685943	chr14:77683202~77683989:-
OV	cis	rs61990749	0.597	rs10136053	ENSG00000239272.1	RPL21P10	-5.53	8.59e-08	8.55e-05	-0.47	-0.34	Fibroblast growth factor basic levels;	chr14:77688862	chr14:77683202~77683989:-
OV	cis	rs8040855	0.579	rs6496797	ENSG00000229212.6	RP11-561C5.4	-5.53	8.62e-08	8.57e-05	-0.42	-0.34	Bulimia nervosa;	chr15:85183624	chr15:85205440~85234795:-
OV	cis	rs858239	0.6	rs2072368	ENSG00000230042.1	AK3P3	-5.53	8.62e-08	8.57e-05	-0.36	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23106493	chr7:23129178~23129841:+
OV	cis	rs7017914	0.652	rs62530770	ENSG00000223220.1	Y_RNA	5.53	8.63e-08	8.59e-05	0.39	0.34	Bone mineral density;	chr8:70688761	chr8:70780914~70781008:-
OV	cis	rs13178541	0.638	rs11242276	ENSG00000250378.1	RP11-119J18.1	-5.53	8.64e-08	8.59e-05	-0.49	-0.34	IgG glycosylation;	chr5:135777323	chr5:135812667~135826582:+
OV	cis	rs7811142	0.779	rs77370288	ENSG00000242294.5	STAG3L5P	5.53	8.69e-08	8.64e-05	0.36	0.34	Platelet count;	chr7:100350274	chr7:100336079~100351900:+
OV	cis	rs7811142	0.72	rs7795656	ENSG00000242294.5	STAG3L5P	5.53	8.69e-08	8.64e-05	0.36	0.34	Platelet count;	chr7:100352674	chr7:100336079~100351900:+
OV	cis	rs55794721	0.509	rs12027110	ENSG00000224183.1	SDHDP6	-5.53	8.69e-08	8.64e-05	-0.4	-0.34	Mean corpuscular volume;Plateletcrit;	chr1:25449191	chr1:25294164~25294643:-
OV	cis	rs11690935	0.632	rs34242651	ENSG00000228389.1	AC068039.4	-5.53	8.7e-08	8.65e-05	-0.39	-0.34	Schizophrenia;	chr2:171697489	chr2:171773482~171775844:+
OV	cis	rs10510102	0.872	rs11200267	ENSG00000226864.1	ATE1-AS1	5.53	8.72e-08	8.66e-05	0.58	0.34	Breast cancer;	chr10:121929851	chr10:121928312~121951965:+
OV	cis	rs172166	0.694	rs203876	ENSG00000219392.1	RP1-265C24.5	-5.53	8.72e-08	8.66e-05	-0.39	-0.34	Cardiac Troponin-T levels;	chr6:28078895	chr6:28115628~28116551:+
OV	cis	rs172166	0.694	rs203877	ENSG00000219392.1	RP1-265C24.5	-5.53	8.72e-08	8.66e-05	-0.39	-0.34	Cardiac Troponin-T levels;	chr6:28080846	chr6:28115628~28116551:+
OV	cis	rs9291683	0.595	rs13145442	ENSG00000250413.1	RP11-448G15.1	-5.53	8.72e-08	8.66e-05	-0.4	-0.34	Bone mineral density;	chr4:10035637	chr4:10006482~10009725:+
OV	cis	rs9291683	0.632	rs13137074	ENSG00000250413.1	RP11-448G15.1	-5.53	8.72e-08	8.66e-05	-0.4	-0.34	Bone mineral density;	chr4:10041218	chr4:10006482~10009725:+
OV	cis	rs9291683	0.632	rs13101785	ENSG00000250413.1	RP11-448G15.1	-5.53	8.72e-08	8.66e-05	-0.4	-0.34	Bone mineral density;	chr4:10041291	chr4:10006482~10009725:+
OV	cis	rs35160687	0.901	rs10200186	ENSG00000273080.1	RP11-301O19.1	5.53	8.73e-08	8.67e-05	0.34	0.34	Night sleep phenotypes;	chr2:86300300	chr2:86195590~86196049:+
OV	cis	rs35160687	0.842	rs10200526	ENSG00000273080.1	RP11-301O19.1	5.53	8.73e-08	8.67e-05	0.34	0.34	Night sleep phenotypes;	chr2:86300476	chr2:86195590~86196049:+
OV	cis	rs35160687	0.901	rs34048420	ENSG00000273080.1	RP11-301O19.1	5.53	8.73e-08	8.67e-05	0.34	0.34	Night sleep phenotypes;	chr2:86302625	chr2:86195590~86196049:+
OV	cis	rs35160687	0.901	rs34069316	ENSG00000273080.1	RP11-301O19.1	5.53	8.73e-08	8.67e-05	0.34	0.34	Night sleep phenotypes;	chr2:86302669	chr2:86195590~86196049:+
OV	cis	rs35160687	0.901	rs11127026	ENSG00000273080.1	RP11-301O19.1	5.53	8.73e-08	8.67e-05	0.34	0.34	Night sleep phenotypes;	chr2:86304625	chr2:86195590~86196049:+
OV	cis	rs35160687	0.901	rs12478575	ENSG00000273080.1	RP11-301O19.1	5.53	8.73e-08	8.67e-05	0.34	0.34	Night sleep phenotypes;	chr2:86308191	chr2:86195590~86196049:+
OV	cis	rs7580658	0.637	rs9636236	ENSG00000236682.1	AC068282.3	-5.53	8.73e-08	8.67e-05	-0.43	-0.34	Protein C levels;	chr2:127225365	chr2:127389130~127400580:+
OV	cis	rs2929278	0.617	rs3087657	ENSG00000205771.5	CATSPER2P1	-5.53	8.77e-08	8.7e-05	-0.45	-0.34	Schizophrenia;	chr15:43771661	chr15:43726918~43747094:-
OV	cis	rs67180937	0.961	rs2133189	ENSG00000272750.1	RP11-378J18.8	-5.53	8.77e-08	8.7e-05	-0.37	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641100	chr1:222658867~222661512:-
OV	cis	rs2153535	0.585	rs1983603	ENSG00000230939.1	RP11-314C16.1	-5.53	8.82e-08	8.75e-05	-0.38	-0.34	Motion sickness;	chr6:8580747	chr6:8784178~8785445:+
OV	cis	rs875971	0.516	rs6945322	ENSG00000224316.1	RP11-479O9.2	5.53	8.84e-08	8.77e-05	0.36	0.34	Aortic root size;	chr7:65871069	chr7:65773620~65802067:+
OV	cis	rs17711722	0.701	rs55773927	ENSG00000224316.1	RP11-479O9.2	5.53	8.84e-08	8.77e-05	0.36	0.34	Calcium levels;	chr7:65872915	chr7:65773620~65802067:+
OV	cis	rs17711722	0.727	rs35850374	ENSG00000224316.1	RP11-479O9.2	5.53	8.84e-08	8.77e-05	0.36	0.34	Calcium levels;	chr7:65892789	chr7:65773620~65802067:+
OV	cis	rs7684253	0.587	rs9685436	ENSG00000269949.1	RP11-738E22.3	-5.53	8.86e-08	8.78e-05	-0.4	-0.34	Migraine;	chr4:56881195	chr4:56960927~56961373:-
OV	cis	rs61990749	0.597	rs176952	ENSG00000239272.1	RPL21P10	5.53	8.89e-08	8.8e-05	0.48	0.34	Fibroblast growth factor basic levels;	chr14:77714393	chr14:77683202~77683989:-
OV	cis	rs61990749	0.544	rs2544566	ENSG00000239272.1	RPL21P10	5.53	8.89e-08	8.8e-05	0.48	0.34	Fibroblast growth factor basic levels;	chr14:77715395	chr14:77683202~77683989:-
OV	cis	rs61990749	0.544	rs2544567	ENSG00000239272.1	RPL21P10	5.53	8.89e-08	8.8e-05	0.48	0.34	Fibroblast growth factor basic levels;	chr14:77715396	chr14:77683202~77683989:-
OV	cis	rs611744	0.686	rs424976	ENSG00000253754.1	RP11-35G22.1	-5.53	8.91e-08	8.82e-05	-0.39	-0.34	Dupuytren's disease;	chr8:108108592	chr8:108226200~108227544:+
OV	cis	rs611744	0.87	rs416611	ENSG00000253754.1	RP11-35G22.1	-5.53	8.91e-08	8.82e-05	-0.39	-0.34	Dupuytren's disease;	chr8:108112365	chr8:108226200~108227544:+
OV	cis	rs611744	0.87	rs371878	ENSG00000253754.1	RP11-35G22.1	-5.53	8.91e-08	8.82e-05	-0.39	-0.34	Dupuytren's disease;	chr8:108118392	chr8:108226200~108227544:+
OV	cis	rs611744	0.805	rs453634	ENSG00000253754.1	RP11-35G22.1	-5.53	8.91e-08	8.82e-05	-0.39	-0.34	Dupuytren's disease;	chr8:108122873	chr8:108226200~108227544:+
OV	cis	rs875971	0.577	rs34888281	ENSG00000224316.1	RP11-479O9.2	-5.53	8.93e-08	8.84e-05	-0.36	-0.34	Aortic root size;	chr7:66120784	chr7:65773620~65802067:+
OV	cis	rs875971	1	rs3981131	ENSG00000236529.1	RP13-254B10.1	5.53	8.93e-08	8.84e-05	0.36	0.34	Aortic root size;	chr7:66486690	chr7:65840212~65840596:+
OV	cis	rs17711722	0.701	rs781143	ENSG00000224316.1	RP11-479O9.2	5.53	8.97e-08	8.88e-05	0.36	0.34	Calcium levels;	chr7:65974892	chr7:65773620~65802067:+
OV	cis	rs17711722	0.701	rs781145	ENSG00000224316.1	RP11-479O9.2	5.53	8.97e-08	8.88e-05	0.36	0.34	Calcium levels;	chr7:65975383	chr7:65773620~65802067:+
OV	cis	rs7684253	0.548	rs13106200	ENSG00000269949.1	RP11-738E22.3	-5.53	8.98e-08	8.88e-05	-0.43	-0.34	Migraine;	chr4:56852029	chr4:56960927~56961373:-
OV	cis	rs11976180	1	rs1919951	ENSG00000170356.8	OR2A20P	-5.53	8.98e-08	8.88e-05	-0.49	-0.34	Obesity-related traits;	chr7:144071798	chr7:144250045~144252957:-
OV	cis	rs116095464	1	rs7723693	ENSG00000277812.1	AC021087.1	5.52	9e-08	8.9e-05	0.79	0.34	Breast cancer;	chr5:305917	chr5:262769~262881:+
OV	cis	rs35160687	0.871	rs11127028	ENSG00000273080.1	RP11-301O19.1	5.52	9e-08	8.9e-05	0.34	0.34	Night sleep phenotypes;	chr2:86310386	chr2:86195590~86196049:+
OV	cis	rs4713118	0.739	rs2893931	ENSG00000220721.1	OR1F12	5.52	9.01e-08	8.91e-05	0.37	0.34	Parkinson's disease;	chr6:27780231	chr6:28073316~28074233:+
OV	cis	rs16873450	0.934	rs2193828	ENSG00000234800.2	PCMTD1P3	-5.52	9.01e-08	8.91e-05	-0.35	-0.34	Verbal memory performance (residualized delayed recall level);	chr7:23767458	chr7:23721311~23721782:-
OV	cis	rs7580658	0.637	rs9636235	ENSG00000236682.1	AC068282.3	-5.52	9.01e-08	8.91e-05	-0.42	-0.34	Protein C levels;	chr2:127223975	chr2:127389130~127400580:+
OV	cis	rs293748	0.657	rs72732585	ENSG00000250155.1	CTD-2353F22.1	-5.52	9.03e-08	8.93e-05	-0.48	-0.34	Obesity-related traits;	chr5:36792493	chr5:36666214~36725195:-
OV	cis	rs34779708	0.966	rs4934538	ENSG00000230534.5	RP11-297A16.2	5.52	9.04e-08	8.94e-05	0.46	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35183222	chr10:35098006~35127020:-
OV	cis	rs858239	0.601	rs4140959	ENSG00000230042.1	AK3P3	-5.52	9.06e-08	8.96e-05	-0.36	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23131157	chr7:23129178~23129841:+
OV	cis	rs11603023	0.967	rs4245184	ENSG00000255422.1	AP002954.4	5.52	9.07e-08	8.96e-05	0.37	0.34	Cholesterol, total;	chr11:118639844	chr11:118704607~118750263:+
OV	cis	rs301901	0.581	rs158409	ENSG00000250155.1	CTD-2353F22.1	-5.52	9.1e-08	8.99e-05	-0.4	-0.34	Height;	chr5:36848456	chr5:36666214~36725195:-
OV	cis	rs6700559	0.654	rs2809345	ENSG00000260088.1	RP11-92G12.3	5.52	9.1e-08	8.99e-05	0.35	0.34	Coronary artery disease;	chr1:200627135	chr1:200669507~200694250:+
OV	cis	rs4713118	0.824	rs742046	ENSG00000280107.1	AL022393.9	-5.52	9.11e-08	9.01e-05	-0.4	-0.34	Parkinson's disease;	chr6:27771475	chr6:28170845~28172521:+
OV	cis	rs12022452	0.506	rs11208363	ENSG00000238287.1	RP11-656D10.3	-5.52	9.13e-08	9.02e-05	-0.58	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr1:40544782	chr1:40493157~40508661:-
OV	cis	rs12022452	0.506	rs6673386	ENSG00000238287.1	RP11-656D10.3	-5.52	9.13e-08	9.02e-05	-0.58	-0.34	Age-related hearing impairment (SNP x SNP interaction);	chr1:40546207	chr1:40493157~40508661:-
OV	cis	rs2243480	0.831	rs7806717	ENSG00000222364.1	RNU6-96P	5.52	9.14e-08	9.02e-05	0.53	0.34	Diabetic kidney disease;	chr7:65928187	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs34136756	ENSG00000222364.1	RNU6-96P	-5.52	9.14e-08	9.02e-05	-0.53	-0.34	Diabetic kidney disease;	chr7:65916269	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs78803505	ENSG00000222364.1	RNU6-96P	-5.52	9.14e-08	9.02e-05	-0.53	-0.34	Diabetic kidney disease;	chr7:65917585	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs34933526	ENSG00000222364.1	RNU6-96P	-5.52	9.14e-08	9.02e-05	-0.53	-0.34	Diabetic kidney disease;	chr7:65918212	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs34577383	ENSG00000222364.1	RNU6-96P	-5.52	9.14e-08	9.02e-05	-0.53	-0.34	Diabetic kidney disease;	chr7:65920739	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs6949812	ENSG00000222364.1	RNU6-96P	-5.52	9.14e-08	9.02e-05	-0.53	-0.34	Diabetic kidney disease;	chr7:65922114	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs55895244	ENSG00000222364.1	RNU6-96P	-5.52	9.14e-08	9.02e-05	-0.53	-0.34	Diabetic kidney disease;	chr7:65922691	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs6970243	ENSG00000222364.1	RNU6-96P	-5.52	9.14e-08	9.02e-05	-0.53	-0.34	Diabetic kidney disease;	chr7:65923503	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs7794661	ENSG00000222364.1	RNU6-96P	-5.52	9.14e-08	9.02e-05	-0.53	-0.34	Diabetic kidney disease;	chr7:65924743	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs7795242	ENSG00000222364.1	RNU6-96P	-5.52	9.14e-08	9.02e-05	-0.53	-0.34	Diabetic kidney disease;	chr7:65925107	chr7:66395191~66395286:+
OV	cis	rs2243480	0.708	rs35310401	ENSG00000222364.1	RNU6-96P	-5.52	9.14e-08	9.02e-05	-0.53	-0.34	Diabetic kidney disease;	chr7:65925372	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs35058610	ENSG00000222364.1	RNU6-96P	-5.52	9.14e-08	9.02e-05	-0.53	-0.34	Diabetic kidney disease;	chr7:65925938	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs2177703	ENSG00000222364.1	RNU6-96P	-5.52	9.14e-08	9.02e-05	-0.53	-0.34	Diabetic kidney disease;	chr7:65926730	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs35432774	ENSG00000222364.1	RNU6-96P	-5.52	9.14e-08	9.02e-05	-0.53	-0.34	Diabetic kidney disease;	chr7:65928032	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs56985706	ENSG00000222364.1	RNU6-96P	-5.52	9.14e-08	9.02e-05	-0.53	-0.34	Diabetic kidney disease;	chr7:65929575	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs60683927	ENSG00000222364.1	RNU6-96P	-5.52	9.14e-08	9.02e-05	-0.53	-0.34	Diabetic kidney disease;	chr7:65929781	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs58062456	ENSG00000222364.1	RNU6-96P	-5.52	9.14e-08	9.02e-05	-0.53	-0.34	Diabetic kidney disease;	chr7:65929865	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs34529418	ENSG00000222364.1	RNU6-96P	-5.52	9.14e-08	9.02e-05	-0.53	-0.34	Diabetic kidney disease;	chr7:65938222	chr7:66395191~66395286:+
OV	cis	rs35160687	0.901	rs12620833	ENSG00000273080.1	RP11-301O19.1	5.52	9.18e-08	9.06e-05	0.35	0.34	Night sleep phenotypes;	chr2:86245747	chr2:86195590~86196049:+
OV	cis	rs13217239	0.574	rs9366680	ENSG00000243307.2	POM121L6P	5.52	9.19e-08	9.07e-05	0.34	0.34	Schizophrenia;	chr6:27038344	chr6:26896952~26898777:+
OV	cis	rs6088580	0.619	rs1205335	ENSG00000206582.1	Y_RNA	5.52	9.19e-08	9.07e-05	0.41	0.34	Glomerular filtration rate (creatinine);	chr20:34339701	chr20:34526510~34526606:-
OV	cis	rs4713118	0.621	rs10484403	ENSG00000280107.1	AL022393.9	-5.52	9.2e-08	9.08e-05	-0.44	-0.34	Parkinson's disease;	chr6:28065745	chr6:28170845~28172521:+
OV	cis	rs7811142	0.83	rs11761253	ENSG00000242294.5	STAG3L5P	5.52	9.2e-08	9.08e-05	0.36	0.34	Platelet count;	chr7:100341698	chr7:100336079~100351900:+
OV	cis	rs61990749	0.597	rs6574391	ENSG00000239272.1	RPL21P10	5.52	9.21e-08	9.08e-05	0.48	0.34	Fibroblast growth factor basic levels;	chr14:77741778	chr14:77683202~77683989:-
OV	cis	rs61990749	0.544	rs8003979	ENSG00000239272.1	RPL21P10	5.52	9.21e-08	9.08e-05	0.48	0.34	Fibroblast growth factor basic levels;	chr14:77744947	chr14:77683202~77683989:-
OV	cis	rs61990749	0.597	rs8016416	ENSG00000239272.1	RPL21P10	5.52	9.21e-08	9.08e-05	0.48	0.34	Fibroblast growth factor basic levels;	chr14:77746757	chr14:77683202~77683989:-
OV	cis	rs61990749	0.597	rs2032781	ENSG00000239272.1	RPL21P10	5.52	9.21e-08	9.08e-05	0.48	0.34	Fibroblast growth factor basic levels;	chr14:77748532	chr14:77683202~77683989:-
OV	cis	rs61990749	0.686	rs11159288	ENSG00000239272.1	RPL21P10	5.52	9.21e-08	9.08e-05	0.48	0.34	Fibroblast growth factor basic levels;	chr14:77750629	chr14:77683202~77683989:-
OV	cis	rs61990749	0.597	rs3783980	ENSG00000239272.1	RPL21P10	5.52	9.21e-08	9.08e-05	0.48	0.34	Fibroblast growth factor basic levels;	chr14:77753464	chr14:77683202~77683989:-
OV	cis	rs61990749	0.597	rs1477262	ENSG00000239272.1	RPL21P10	5.52	9.21e-08	9.08e-05	0.48	0.34	Fibroblast growth factor basic levels;	chr14:77760310	chr14:77683202~77683989:-
OV	cis	rs1075265	0.84	rs10084355	ENSG00000233266.1	HMGB1P31	5.52	9.21e-08	9.08e-05	0.41	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54021711	chr2:54051334~54051760:+
OV	cis	rs2153535	0.536	rs1328876	ENSG00000230939.1	RP11-314C16.1	-5.52	9.21e-08	9.08e-05	-0.37	-0.34	Motion sickness;	chr6:8620940	chr6:8784178~8785445:+
OV	cis	rs2153535	0.585	rs1328875	ENSG00000230939.1	RP11-314C16.1	-5.52	9.21e-08	9.08e-05	-0.37	-0.34	Motion sickness;	chr6:8620946	chr6:8784178~8785445:+
OV	cis	rs8062405	0.655	rs7184597	ENSG00000259982.1	CDC37P1	-5.52	9.22e-08	9.09e-05	-0.45	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28910488	chr16:28700294~28701540:-
OV	cis	rs35160687	0.901	rs12714180	ENSG00000273080.1	RP11-301O19.1	5.52	9.22e-08	9.09e-05	0.34	0.34	Night sleep phenotypes;	chr2:86298200	chr2:86195590~86196049:+
OV	cis	rs35160687	0.901	rs35281683	ENSG00000273080.1	RP11-301O19.1	5.52	9.22e-08	9.09e-05	0.34	0.34	Night sleep phenotypes;	chr2:86299249	chr2:86195590~86196049:+
OV	cis	rs7605378	0.688	rs769961	ENSG00000232732.8	AC073043.1	-5.52	9.24e-08	9.11e-05	-0.44	-0.34	Osteoporosis;	chr2:199847418	chr2:199867396~199911159:-
OV	cis	rs35160687	0.901	rs12472676	ENSG00000273080.1	RP11-301O19.1	5.52	9.24e-08	9.11e-05	0.35	0.34	Night sleep phenotypes;	chr2:86283692	chr2:86195590~86196049:+
OV	cis	rs2188561	0.697	rs6956243	ENSG00000241764.3	AC002467.7	5.52	9.25e-08	9.12e-05	0.41	0.34	Alcohol consumption;	chr7:107748466	chr7:107742817~107744581:-
OV	cis	rs2188561	0.666	rs13231387	ENSG00000241764.3	AC002467.7	5.52	9.25e-08	9.12e-05	0.41	0.34	Alcohol consumption;	chr7:107749534	chr7:107742817~107744581:-
OV	cis	rs10463554	1	rs12656131	ENSG00000175749.11	EIF3KP1	-5.52	9.25e-08	9.12e-05	-0.39	-0.34	Parkinson's disease;	chr5:102990174	chr5:103032376~103033031:+
OV	cis	rs16873450	0.527	rs12700462	ENSG00000234800.2	PCMTD1P3	-5.52	9.26e-08	9.13e-05	-0.35	-0.34	Verbal memory performance (residualized delayed recall level);	chr7:23753221	chr7:23721311~23721782:-
OV	cis	rs5742933	1	rs5743061	ENSG00000253559.1	OSGEPL1-AS1	5.52	9.28e-08	9.15e-05	0.37	0.34	Ferritin levels;	chr2:189829540	chr2:189762704~189765556:+
OV	cis	rs4713118	0.513	rs149942	ENSG00000220721.1	OR1F12	5.52	9.32e-08	9.18e-05	0.39	0.34	Parkinson's disease;	chr6:28033832	chr6:28073316~28074233:+
OV	cis	rs4713118	0.513	rs149945	ENSG00000220721.1	OR1F12	5.52	9.32e-08	9.18e-05	0.39	0.34	Parkinson's disease;	chr6:28035075	chr6:28073316~28074233:+
OV	cis	rs7615952	0.576	rs2276729	ENSG00000171084.14	FAM86JP	5.52	9.33e-08	9.19e-05	0.5	0.34	Blood pressure (smoking interaction);	chr3:126107371	chr3:125916620~125930024:+
OV	cis	rs7615952	0.599	rs7652883	ENSG00000171084.14	FAM86JP	5.52	9.36e-08	9.21e-05	0.48	0.34	Blood pressure (smoking interaction);	chr3:125989134	chr3:125916620~125930024:+
OV	cis	rs67180937	0.921	rs17163360	ENSG00000272750.1	RP11-378J18.8	-5.52	9.36e-08	9.21e-05	-0.38	-0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647448	chr1:222658867~222661512:-
OV	cis	rs6471393	0.893	rs2976350	ENSG00000253848.1	RP11-10N23.5	-5.52	9.38e-08	9.23e-05	-0.4	-0.34	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93716818	chr8:93741193~93744534:+
OV	cis	rs2282300	0.637	rs10742240	ENSG00000254532.1	RP11-624D11.2	5.52	9.4e-08	9.24e-05	0.4	0.34	Morning vs. evening chronotype;	chr11:30407891	chr11:30044058~30084343:-
OV	cis	rs8005677	1	rs4982709	ENSG00000279656.1	RP11-298I3.6	5.52	9.42e-08	9.26e-05	0.38	0.34	Cognitive ability (multi-trait analysis);	chr14:22925490	chr14:23023083~23024217:-
OV	cis	rs8062405	0.756	rs151301	ENSG00000278665.1	RP11-666O2.4	5.52	9.43e-08	9.27e-05	0.37	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28485738	chr16:28599241~28601881:-
OV	cis	rs62355901	0.505	rs62356565	ENSG00000271828.1	CTD-2310F14.1	5.52	9.44e-08	9.27e-05	0.66	0.34	Breast cancer;	chr5:56948139	chr5:56927874~56929573:+
OV	cis	rs2153535	0.518	rs9505510	ENSG00000230939.1	RP11-314C16.1	-5.52	9.44e-08	9.28e-05	-0.39	-0.34	Motion sickness;	chr6:8657603	chr6:8784178~8785445:+
OV	cis	rs34779708	0.931	rs4934704	ENSG00000230534.5	RP11-297A16.2	5.51	9.49e-08	9.32e-05	0.44	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35043236	chr10:35098006~35127020:-
OV	cis	rs3931020	0.688	rs452242	ENSG00000272864.1	RP11-17E13.2	5.51	9.51e-08	9.33e-05	0.47	0.34	Resistin levels;	chr1:74759941	chr1:74698769~74699333:-
OV	cis	rs73019876	0.502	rs2099347	ENSG00000269742.1	BNIP3P29	5.51	9.51e-08	9.33e-05	0.4	0.34	Testicular germ cell tumor;	chr19:22099812	chr19:22065828~22066398:-
OV	cis	rs2153535	0.518	rs9505503	ENSG00000230939.1	RP11-314C16.1	-5.51	9.55e-08	9.37e-05	-0.39	-0.34	Motion sickness;	chr6:8638572	chr6:8784178~8785445:+
OV	cis	rs11976180	1	rs11976180	ENSG00000170356.8	OR2A20P	-5.51	9.61e-08	9.42e-05	-0.49	-0.34	Obesity-related traits;	chr7:144044487	chr7:144250045~144252957:-
OV	cis	rs9291683	0.588	rs13121211	ENSG00000250413.1	RP11-448G15.1	-5.51	9.61e-08	9.43e-05	-0.38	-0.34	Bone mineral density;	chr4:9997915	chr4:10006482~10009725:+
OV	cis	rs34779708	0.931	rs12268745	ENSG00000230534.5	RP11-297A16.2	5.51	9.62e-08	9.44e-05	0.44	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35017061	chr10:35098006~35127020:-
OV	cis	rs4713118	0.513	rs149944	ENSG00000220721.1	OR1F12	5.51	9.63e-08	9.44e-05	0.39	0.34	Parkinson's disease;	chr6:28035040	chr6:28073316~28074233:+
OV	cis	rs67311347	0.911	rs58282210	ENSG00000223797.4	ENTPD3-AS1	5.51	9.65e-08	9.46e-05	0.39	0.34	Renal cell carcinoma;	chr3:40376452	chr3:40313802~40453329:-
OV	cis	rs55794721	0.509	rs6699113	ENSG00000224183.1	SDHDP6	-5.51	9.66e-08	9.47e-05	-0.39	-0.34	Mean corpuscular volume;Plateletcrit;	chr1:25451252	chr1:25294164~25294643:-
OV	cis	rs55794721	0.509	rs7554255	ENSG00000224183.1	SDHDP6	-5.51	9.66e-08	9.47e-05	-0.39	-0.34	Mean corpuscular volume;Plateletcrit;	chr1:25451615	chr1:25294164~25294643:-
OV	cis	rs55794721	0.509	rs4649085	ENSG00000224183.1	SDHDP6	-5.51	9.66e-08	9.47e-05	-0.39	-0.34	Mean corpuscular volume;Plateletcrit;	chr1:25452341	chr1:25294164~25294643:-
OV	cis	rs957448	1	rs10956915	ENSG00000253704.1	RP11-267M23.4	5.51	9.66e-08	9.47e-05	0.46	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94502362	chr8:94553722~94569745:+
OV	cis	rs957448	0.904	rs56302978	ENSG00000253704.1	RP11-267M23.4	5.51	9.66e-08	9.47e-05	0.46	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94505883	chr8:94553722~94569745:+
OV	cis	rs4713118	0.738	rs200465	ENSG00000220721.1	OR1F12	5.51	9.68e-08	9.48e-05	0.37	0.34	Parkinson's disease;	chr6:27789875	chr6:28073316~28074233:+
OV	cis	rs8062405	0.723	rs12445744	ENSG00000259982.1	CDC37P1	5.51	9.69e-08	9.49e-05	0.43	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28700294~28701540:-
OV	cis	rs8062405	0.755	rs4787455	ENSG00000259982.1	CDC37P1	5.51	9.69e-08	9.49e-05	0.43	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28700294~28701540:-
OV	cis	rs9291683	0.588	rs2240721	ENSG00000250413.1	RP11-448G15.1	-5.51	9.72e-08	9.52e-05	-0.38	-0.34	Bone mineral density;	chr4:10018940	chr4:10006482~10009725:+
OV	cis	rs9291683	0.588	rs2240722	ENSG00000250413.1	RP11-448G15.1	-5.51	9.72e-08	9.52e-05	-0.38	-0.34	Bone mineral density;	chr4:10019133	chr4:10006482~10009725:+
OV	cis	rs17711722	0.727	rs1880555	ENSG00000224316.1	RP11-479O9.2	5.51	9.72e-08	9.52e-05	0.36	0.34	Calcium levels;	chr7:65967580	chr7:65773620~65802067:+
OV	cis	rs9660180	0.875	rs4648727	ENSG00000268575.1	RP1-283E3.8	5.51	9.73e-08	9.53e-05	0.32	0.34	Body mass index;	chr1:1844830	chr1:1702736~1737688:-
OV	cis	rs1790761	0.692	rs614080	ENSG00000184224.3	C11orf72	5.51	9.75e-08	9.54e-05	0.39	0.34	Mean corpuscular volume;	chr11:67579816	chr11:67602880~67606706:-
OV	cis	rs4713118	0.662	rs149946	ENSG00000219392.1	RP1-265C24.5	5.51	9.76e-08	9.55e-05	0.43	0.34	Parkinson's disease;	chr6:28002253	chr6:28115628~28116551:+
OV	cis	rs7771547	0.642	rs595954	ENSG00000240733.3	RN7SL502P	5.51	9.76e-08	9.55e-05	0.37	0.34	Platelet distribution width;	chr6:36497057	chr6:36450912~36451201:-
OV	cis	rs6088580	0.634	rs6059866	ENSG00000206582.1	Y_RNA	-5.51	9.77e-08	9.56e-05	-0.4	-0.34	Glomerular filtration rate (creatinine);	chr20:34488005	chr20:34526510~34526606:-
OV	cis	rs4713118	0.696	rs2394002	ENSG00000220721.1	OR1F12	5.51	9.79e-08	9.58e-05	0.37	0.34	Parkinson's disease;	chr6:27780236	chr6:28073316~28074233:+
OV	cis	rs4805272	0.512	rs8105613	ENSG00000267243.4	AC005307.3	-5.51	9.8e-08	9.59e-05	-0.62	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28848244	chr19:28435388~28727777:-
OV	cis	rs1075265	0.87	rs6749817	ENSG00000233266.1	HMGB1P31	5.51	9.82e-08	9.6e-05	0.41	0.34	Chronotype;Morning vs. evening chronotype;	chr2:54032396	chr2:54051334~54051760:+
OV	cis	rs73019876	0.502	rs1019938	ENSG00000269742.1	BNIP3P29	-5.51	9.83e-08	9.61e-05	-0.4	-0.34	Testicular germ cell tumor;	chr19:22098152	chr19:22065828~22066398:-
OV	cis	rs4713118	0.513	rs149959	ENSG00000220721.1	OR1F12	5.51	9.84e-08	9.62e-05	0.38	0.34	Parkinson's disease;	chr6:28046076	chr6:28073316~28074233:+
OV	cis	rs7580658	0.637	rs1566822	ENSG00000236682.1	AC068282.3	-5.51	9.85e-08	9.63e-05	-0.42	-0.34	Protein C levels;	chr2:127229815	chr2:127389130~127400580:+
OV	cis	rs957448	0.948	rs11992893	ENSG00000253704.1	RP11-267M23.4	5.51	9.85e-08	9.63e-05	0.46	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94508473	chr8:94553722~94569745:+
OV	cis	rs957448	1	rs1055797	ENSG00000253704.1	RP11-267M23.4	5.51	9.85e-08	9.63e-05	0.46	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94511005	chr8:94553722~94569745:+
OV	cis	rs13178541	0.641	rs10077151	ENSG00000250378.1	RP11-119J18.1	-5.51	9.89e-08	9.66e-05	-0.48	-0.34	IgG glycosylation;	chr5:135805145	chr5:135812667~135826582:+
OV	cis	rs13178541	0.641	rs10077216	ENSG00000250378.1	RP11-119J18.1	-5.51	9.89e-08	9.66e-05	-0.48	-0.34	IgG glycosylation;	chr5:135805239	chr5:135812667~135826582:+
OV	cis	rs992157	1	rs992157	ENSG00000237281.1	CATIP-AS2	5.51	9.93e-08	9.7e-05	0.39	0.34	Colorectal cancer;	chr2:218290058	chr2:218326889~218357966:-
OV	cis	rs67311347	1	rs73078169	ENSG00000223797.4	ENTPD3-AS1	5.5	9.98e-08	9.74e-05	0.38	0.34	Renal cell carcinoma;	chr3:40442307	chr3:40313802~40453329:-
OV	cis	rs67180937	0.504	rs3008625	ENSG00000272750.1	RP11-378J18.8	5.5	1e-07	9.76e-05	0.46	0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222646680	chr1:222658867~222661512:-
OV	cis	rs514406	0.861	rs505444	ENSG00000206627.1	RNU6-969P	5.5	1e-07	9.79e-05	0.36	0.34	Monocyte count;	chr1:52786188	chr1:52805108~52805212:-
OV	cis	rs5742933	0.948	rs7592066	ENSG00000253559.1	OSGEPL1-AS1	5.5	1.01e-07	9.81e-05	0.35	0.34	Ferritin levels;	chr2:189778792	chr2:189762704~189765556:+
OV	cis	rs5742933	0.779	rs7595020	ENSG00000253559.1	OSGEPL1-AS1	5.5	1.01e-07	9.81e-05	0.35	0.34	Ferritin levels;	chr2:189778950	chr2:189762704~189765556:+
OV	cis	rs67311347	1	rs12492035	ENSG00000223797.4	ENTPD3-AS1	5.5	1.01e-07	9.84e-05	0.38	0.34	Renal cell carcinoma;	chr3:40425619	chr3:40313802~40453329:-
OV	cis	rs12594515	1	rs8032835	ENSG00000273972.1	CTD-2306A12.1	-5.5	1.01e-07	9.85e-05	-0.37	-0.34	Weight;Waist circumference;	chr15:45705699	chr15:45702640~45703183:+
OV	cis	rs12594515	1	rs8033148	ENSG00000273972.1	CTD-2306A12.1	-5.5	1.01e-07	9.85e-05	-0.37	-0.34	Weight;Waist circumference;	chr15:45705731	chr15:45702640~45703183:+
OV	cis	rs12594515	0.904	rs8032875	ENSG00000273972.1	CTD-2306A12.1	-5.5	1.01e-07	9.85e-05	-0.37	-0.34	Weight;Waist circumference;	chr15:45705812	chr15:45702640~45703183:+
OV	cis	rs12594515	0.874	rs8032878	ENSG00000273972.1	CTD-2306A12.1	-5.5	1.01e-07	9.85e-05	-0.37	-0.34	Weight;Waist circumference;	chr15:45705817	chr15:45702640~45703183:+
OV	cis	rs293748	0.771	rs13184774	ENSG00000250155.1	CTD-2353F22.1	-5.5	1.01e-07	9.86e-05	-0.48	-0.34	Obesity-related traits;	chr5:36803578	chr5:36666214~36725195:-
OV	cis	rs293748	0.713	rs292162	ENSG00000250155.1	CTD-2353F22.1	-5.5	1.01e-07	9.86e-05	-0.48	-0.34	Obesity-related traits;	chr5:36803778	chr5:36666214~36725195:-
OV	cis	rs293748	0.771	rs292166	ENSG00000250155.1	CTD-2353F22.1	-5.5	1.01e-07	9.86e-05	-0.48	-0.34	Obesity-related traits;	chr5:36805367	chr5:36666214~36725195:-
OV	cis	rs9291683	0.588	rs3756238	ENSG00000250413.1	RP11-448G15.1	-5.5	1.03e-07	9.98e-05	-0.38	-0.34	Bone mineral density;	chr4:10011578	chr4:10006482~10009725:+
OV	cis	rs9291683	0.588	rs3756237	ENSG00000250413.1	RP11-448G15.1	-5.5	1.03e-07	9.98e-05	-0.38	-0.34	Bone mineral density;	chr4:10011754	chr4:10006482~10009725:+
OV	cis	rs9291683	0.588	rs3756236	ENSG00000250413.1	RP11-448G15.1	-5.5	1.03e-07	9.98e-05	-0.38	-0.34	Bone mineral density;	chr4:10011839	chr4:10006482~10009725:+
OV	cis	rs9291683	0.552	rs10939655	ENSG00000250413.1	RP11-448G15.1	-5.5	1.03e-07	9.98e-05	-0.38	-0.34	Bone mineral density;	chr4:10013018	chr4:10006482~10009725:+
OV	cis	rs9291683	0.517	rs11736479	ENSG00000250413.1	RP11-448G15.1	-5.5	1.03e-07	9.98e-05	-0.38	-0.34	Bone mineral density;	chr4:10015763	chr4:10006482~10009725:+
OV	cis	rs9291683	0.588	rs13113730	ENSG00000250413.1	RP11-448G15.1	-5.5	1.03e-07	9.98e-05	-0.38	-0.34	Bone mineral density;	chr4:10016004	chr4:10006482~10009725:+
OV	cis	rs9291683	0.588	rs6857693	ENSG00000250413.1	RP11-448G15.1	-5.5	1.03e-07	9.98e-05	-0.38	-0.34	Bone mineral density;	chr4:10016811	chr4:10006482~10009725:+
OV	cis	rs9291683	0.588	rs6844329	ENSG00000250413.1	RP11-448G15.1	-5.5	1.03e-07	9.98e-05	-0.38	-0.34	Bone mineral density;	chr4:10016920	chr4:10006482~10009725:+
OV	cis	rs9291683	0.588	rs3796829	ENSG00000250413.1	RP11-448G15.1	-5.5	1.03e-07	9.98e-05	-0.38	-0.34	Bone mineral density;	chr4:10017514	chr4:10006482~10009725:+
OV	cis	rs3733585	0.773	rs13107466	ENSG00000250413.1	RP11-448G15.1	-5.5	1.03e-07	9.98e-05	-0.38	-0.34	Cleft plate (environmental tobacco smoke interaction);	chr4:10017766	chr4:10006482~10009725:+
OV	cis	rs9291683	0.588	rs13133766	ENSG00000250413.1	RP11-448G15.1	-5.5	1.03e-07	9.98e-05	-0.38	-0.34	Bone mineral density;	chr4:10018108	chr4:10006482~10009725:+
OV	cis	rs4713118	0.513	rs149958	ENSG00000220721.1	OR1F12	5.5	1.03e-07	9.99e-05	0.39	0.34	Parkinson's disease;	chr6:28045839	chr6:28073316~28074233:+
OV	cis	rs8005677	1	rs8014936	ENSG00000279656.1	RP11-298I3.6	5.5	1.03e-07	1e-04	0.37	0.34	Cognitive ability (multi-trait analysis);	chr14:22905936	chr14:23023083~23024217:-
OV	cis	rs8005677	1	rs8016061	ENSG00000279656.1	RP11-298I3.6	5.5	1.03e-07	1e-04	0.37	0.34	Cognitive ability (multi-trait analysis);	chr14:22906600	chr14:23023083~23024217:-
OV	cis	rs8005677	1	rs8005677	ENSG00000279656.1	RP11-298I3.6	5.5	1.03e-07	1e-04	0.37	0.34	Cognitive ability (multi-trait analysis);	chr14:22907469	chr14:23023083~23024217:-
OV	cis	rs858239	0.601	rs6966776	ENSG00000230042.1	AK3P3	-5.5	1.03e-07	1e-04	-0.36	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23126389	chr7:23129178~23129841:+
OV	cis	rs496547	0.654	rs688161	ENSG00000255239.1	AP002954.6	5.5	1.03e-07	1e-04	0.41	0.34	Hip minimal joint space width;	chr11:118807001	chr11:118688039~118690600:-
OV	cis	rs514406	0.861	rs11206011	ENSG00000206627.1	RNU6-969P	-5.5	1.03e-07	1e-04	-0.35	-0.34	Monocyte count;	chr1:52770238	chr1:52805108~52805212:-
OV	cis	rs9322193	0.607	rs9322229	ENSG00000216906.2	RP11-350J20.9	5.5	1.03e-07	1e-04	0.45	0.34	Lung cancer;	chr6:149908949	chr6:149904243~149906418:+
OV	cis	rs1150668	0.699	rs12214383	ENSG00000220721.1	OR1F12	-5.5	1.03e-07	1e-04	-0.34	-0.34	Pubertal anthropometrics;	chr6:28255953	chr6:28073316~28074233:+
OV	cis	rs67311347	1	rs73078158	ENSG00000223797.4	ENTPD3-AS1	5.5	1.03e-07	1e-04	0.38	0.34	Renal cell carcinoma;	chr3:40431076	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs73078164	ENSG00000223797.4	ENTPD3-AS1	5.5	1.03e-07	1e-04	0.38	0.34	Renal cell carcinoma;	chr3:40438798	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs1123019	ENSG00000223797.4	ENTPD3-AS1	5.5	1.03e-07	1e-04	0.38	0.34	Renal cell carcinoma;	chr3:40446789	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs2371186	ENSG00000223797.4	ENTPD3-AS1	5.5	1.03e-07	1e-04	0.38	0.34	Renal cell carcinoma;	chr3:40447222	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs9827461	ENSG00000223797.4	ENTPD3-AS1	5.5	1.03e-07	1e-04	0.38	0.34	Renal cell carcinoma;	chr3:40447860	chr3:40313802~40453329:-
OV	cis	rs7017914	0.702	rs62531711	ENSG00000223220.1	Y_RNA	5.5	1.04e-07	0.000101	0.39	0.34	Bone mineral density;	chr8:70618265	chr8:70780914~70781008:-
OV	cis	rs7017914	0.702	rs12678320	ENSG00000223220.1	Y_RNA	5.5	1.04e-07	0.000101	0.39	0.34	Bone mineral density;	chr8:70624957	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs6988053	ENSG00000223220.1	Y_RNA	5.5	1.04e-07	0.000101	0.39	0.34	Bone mineral density;	chr8:70634728	chr8:70780914~70781008:-
OV	cis	rs7017914	0.702	rs13258368	ENSG00000223220.1	Y_RNA	5.5	1.04e-07	0.000101	0.39	0.34	Bone mineral density;	chr8:70636516	chr8:70780914~70781008:-
OV	cis	rs9660180	0.967	rs12044597	ENSG00000268575.1	RP1-283E3.8	-5.5	1.04e-07	0.000102	-0.31	-0.34	Body mass index;	chr1:1777362	chr1:1702736~1737688:-
OV	cis	rs3814244	0.528	rs2906859	ENSG00000255733.4	IFNG-AS1	5.49	1.05e-07	0.000102	0.34	0.34	Itch intensity from mosquito bite adjusted by bite size;	chr12:68002355	chr12:67989445~68234686:+
OV	cis	rs1799810	0.523	rs11683986	ENSG00000236682.1	AC068282.3	5.49	1.05e-07	0.000102	0.44	0.34	Self-rated health;	chr2:127438822	chr2:127389130~127400580:+
OV	cis	rs526231	0.578	rs10515337	ENSG00000175749.11	EIF3KP1	-5.49	1.05e-07	0.000102	-0.42	-0.34	Primary biliary cholangitis;	chr5:102965664	chr5:103032376~103033031:+
OV	cis	rs7429990	0.901	rs6442091	ENSG00000229759.1	MRPS18AP1	-5.49	1.05e-07	0.000102	-0.37	-0.34	Educational attainment (years of education);	chr3:48001568	chr3:48256350~48256938:-
OV	cis	rs7429990	0.965	rs4858810	ENSG00000229759.1	MRPS18AP1	-5.49	1.05e-07	0.000102	-0.37	-0.34	Educational attainment (years of education);	chr3:48002247	chr3:48256350~48256938:-
OV	cis	rs7429990	0.965	rs4296617	ENSG00000229759.1	MRPS18AP1	-5.49	1.05e-07	0.000102	-0.37	-0.34	Educational attainment (years of education);	chr3:48026818	chr3:48256350~48256938:-
OV	cis	rs3091242	0.904	rs6661533	ENSG00000224183.1	SDHDP6	-5.49	1.05e-07	0.000102	-0.39	-0.34	Erythrocyte sedimentation rate;	chr1:25445224	chr1:25294164~25294643:-
OV	cis	rs11723261	0.527	rs11731581	ENSG00000275426.1	CH17-262A2.1	5.49	1.05e-07	0.000102	0.49	0.34	Immune response to smallpox vaccine (IL-6);	chr4:88044	chr4:149738~150317:+
OV	cis	rs11690935	0.632	rs12998411	ENSG00000228389.1	AC068039.4	-5.49	1.05e-07	0.000102	-0.39	-0.34	Schizophrenia;	chr2:171674197	chr2:171773482~171775844:+
OV	cis	rs3091242	0.933	rs7541095	ENSG00000224183.1	SDHDP6	-5.49	1.05e-07	0.000102	-0.4	-0.34	Erythrocyte sedimentation rate;	chr1:25434800	chr1:25294164~25294643:-
OV	cis	rs7580658	0.724	rs71414745	ENSG00000236682.1	AC068282.3	-5.49	1.05e-07	0.000102	-0.42	-0.34	Protein C levels;	chr2:127235012	chr2:127389130~127400580:+
OV	cis	rs11690935	0.655	rs1028127	ENSG00000228389.1	AC068039.4	-5.49	1.06e-07	0.000102	-0.39	-0.34	Schizophrenia;	chr2:171673526	chr2:171773482~171775844:+
OV	cis	rs7017914	0.905	rs2639898	ENSG00000223220.1	Y_RNA	5.49	1.06e-07	0.000102	0.36	0.34	Bone mineral density;	chr8:71008075	chr8:70780914~70781008:-
OV	cis	rs7017914	0.84	rs2732099	ENSG00000223220.1	Y_RNA	5.49	1.06e-07	0.000102	0.36	0.34	Bone mineral density;	chr8:71008815	chr8:70780914~70781008:-
OV	cis	rs10740039	1	rs10740039	ENSG00000254271.1	RP11-131N11.4	5.49	1.06e-07	0.000103	0.4	0.34	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60654924	chr10:60734342~60741828:+
OV	cis	rs73019876	0.502	rs4932748	ENSG00000269742.1	BNIP3P29	5.49	1.06e-07	0.000103	0.39	0.34	Testicular germ cell tumor;	chr19:22096516	chr19:22065828~22066398:-
OV	cis	rs73019876	0.502	rs2359995	ENSG00000269742.1	BNIP3P29	5.49	1.06e-07	0.000103	0.39	0.34	Testicular germ cell tumor;	chr19:22097258	chr19:22065828~22066398:-
OV	cis	rs73019876	0.522	rs6511323	ENSG00000269742.1	BNIP3P29	5.49	1.06e-07	0.000103	0.39	0.34	Testicular germ cell tumor;	chr19:22099112	chr19:22065828~22066398:-
OV	cis	rs73019876	0.502	rs4553749	ENSG00000269742.1	BNIP3P29	5.49	1.06e-07	0.000103	0.39	0.34	Testicular germ cell tumor;	chr19:22102261	chr19:22065828~22066398:-
OV	cis	rs2999052	0.542	rs3887841	ENSG00000242551.2	POU5F1P6	5.49	1.06e-07	0.000103	0.44	0.34	Hypospadias;	chr3:128391098	chr3:128674735~128677005:-
OV	cis	rs4865169	0.934	rs12650737	ENSG00000269949.1	RP11-738E22.3	-5.49	1.06e-07	0.000103	-0.4	-0.34	Breast cancer;	chr4:57026309	chr4:56960927~56961373:-
OV	cis	rs11603023	0.967	rs644273	ENSG00000255422.1	AP002954.4	5.49	1.06e-07	0.000103	0.36	0.34	Cholesterol, total;	chr11:118640634	chr11:118704607~118750263:+
OV	cis	rs11603023	0.967	rs654423	ENSG00000255422.1	AP002954.4	5.49	1.06e-07	0.000103	0.36	0.34	Cholesterol, total;	chr11:118641039	chr11:118704607~118750263:+
OV	cis	rs61990749	0.597	rs11623088	ENSG00000239272.1	RPL21P10	-5.49	1.06e-07	0.000103	-0.47	-0.34	Fibroblast growth factor basic levels;	chr14:77671392	chr14:77683202~77683989:-
OV	cis	rs61990749	0.597	rs13379065	ENSG00000239272.1	RPL21P10	-5.49	1.06e-07	0.000103	-0.47	-0.34	Fibroblast growth factor basic levels;	chr14:77674952	chr14:77683202~77683989:-
OV	cis	rs61990749	0.597	rs17106157	ENSG00000239272.1	RPL21P10	-5.49	1.06e-07	0.000103	-0.47	-0.34	Fibroblast growth factor basic levels;	chr14:77680535	chr14:77683202~77683989:-
OV	cis	rs61990749	0.597	rs2267759	ENSG00000239272.1	RPL21P10	-5.49	1.06e-07	0.000103	-0.47	-0.34	Fibroblast growth factor basic levels;	chr14:77681272	chr14:77683202~77683989:-
OV	cis	rs4713118	0.662	rs149948	ENSG00000280107.1	AL022393.9	-5.49	1.07e-07	0.000104	-0.44	-0.34	Parkinson's disease;	chr6:28007039	chr6:28170845~28172521:+
OV	cis	rs2188561	0.697	rs2237679	ENSG00000241764.3	AC002467.7	5.49	1.07e-07	0.000104	0.41	0.34	Alcohol consumption;	chr7:107693581	chr7:107742817~107744581:-
OV	cis	rs2188561	0.697	rs2072064	ENSG00000241764.3	AC002467.7	5.49	1.07e-07	0.000104	0.41	0.34	Alcohol consumption;	chr7:107694068	chr7:107742817~107744581:-
OV	cis	rs301901	0.734	rs10941321	ENSG00000250155.1	CTD-2353F22.1	-5.49	1.07e-07	0.000104	-0.4	-0.34	Height;	chr5:37213248	chr5:36666214~36725195:-
OV	cis	rs4713118	0.629	rs149899	ENSG00000219392.1	RP1-265C24.5	-5.49	1.07e-07	0.000104	-0.43	-0.34	Parkinson's disease;	chr6:28052201	chr6:28115628~28116551:+
OV	cis	rs4713118	0.629	rs172165	ENSG00000219392.1	RP1-265C24.5	-5.49	1.07e-07	0.000104	-0.43	-0.34	Parkinson's disease;	chr6:28053036	chr6:28115628~28116551:+
OV	cis	rs4713118	0.597	rs172166	ENSG00000219392.1	RP1-265C24.5	-5.49	1.07e-07	0.000104	-0.43	-0.34	Parkinson's disease;	chr6:28053042	chr6:28115628~28116551:+
OV	cis	rs611744	0.647	rs2594357	ENSG00000253754.1	RP11-35G22.1	-5.49	1.07e-07	0.000104	-0.38	-0.34	Dupuytren's disease;	chr8:108243760	chr8:108226200~108227544:+
OV	cis	rs34779708	0.966	rs10827487	ENSG00000230534.5	RP11-297A16.2	5.49	1.08e-07	0.000105	0.44	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35117950	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs1148245	ENSG00000230534.5	RP11-297A16.2	5.49	1.08e-07	0.000105	0.43	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35222966	chr10:35098006~35127020:-
OV	cis	rs8062405	0.755	rs62034358	ENSG00000259982.1	CDC37P1	5.49	1.09e-07	0.000105	0.42	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28700294~28701540:-
OV	cis	rs8062405	0.755	rs12445823	ENSG00000259982.1	CDC37P1	5.49	1.09e-07	0.000105	0.42	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28700294~28701540:-
OV	cis	rs11603023	0.804	rs527619	ENSG00000255422.1	AP002954.4	5.49	1.09e-07	0.000105	0.37	0.34	Cholesterol, total;	chr11:118692577	chr11:118704607~118750263:+
OV	cis	rs6088580	0.668	rs1205337	ENSG00000206582.1	Y_RNA	5.49	1.09e-07	0.000105	0.41	0.34	Glomerular filtration rate (creatinine);	chr20:34338235	chr20:34526510~34526606:-
OV	cis	rs2153535	0.585	rs58117210	ENSG00000230939.1	RP11-314C16.1	-5.49	1.09e-07	0.000105	-0.37	-0.34	Motion sickness;	chr6:8603881	chr6:8784178~8785445:+
OV	cis	rs2153535	0.585	rs9405400	ENSG00000230939.1	RP11-314C16.1	-5.49	1.09e-07	0.000105	-0.37	-0.34	Motion sickness;	chr6:8606895	chr6:8784178~8785445:+
OV	cis	rs7684253	0.548	rs62308071	ENSG00000269949.1	RP11-738E22.3	-5.49	1.09e-07	0.000106	-0.42	-0.34	Migraine;	chr4:56850720	chr4:56960927~56961373:-
OV	cis	rs9402743	0.671	rs9376115	ENSG00000231028.7	LINC00271	5.49	1.1e-07	0.000106	0.34	0.34	Systemic lupus erythematosus;	chr6:135616579	chr6:135497801~135716055:+
OV	cis	rs611744	0.631	rs681963	ENSG00000253754.1	RP11-35G22.1	-5.49	1.1e-07	0.000106	-0.38	-0.34	Dupuytren's disease;	chr8:108242803	chr8:108226200~108227544:+
OV	cis	rs611744	0.669	rs13251024	ENSG00000253754.1	RP11-35G22.1	-5.49	1.1e-07	0.000106	-0.38	-0.34	Dupuytren's disease;	chr8:108246104	chr8:108226200~108227544:+
OV	cis	rs8105895	1	rs79846980	ENSG00000269742.1	BNIP3P29	5.48	1.1e-07	0.000106	0.53	0.34	Body mass index (change over time);	chr19:21958541	chr19:22065828~22066398:-
OV	cis	rs6088580	0.634	rs4258875	ENSG00000206582.1	Y_RNA	5.48	1.1e-07	0.000106	0.41	0.34	Glomerular filtration rate (creatinine);	chr20:34337089	chr20:34526510~34526606:-
OV	cis	rs12134133	1	rs12134133	ENSG00000274245.1	RP11-357P18.2	5.48	1.1e-07	0.000106	0.44	0.34	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207284500	chr1:207372559~207373252:+
OV	cis	rs7429990	0.965	rs7653368	ENSG00000229759.1	MRPS18AP1	5.48	1.1e-07	0.000106	0.36	0.34	Educational attainment (years of education);	chr3:47943871	chr3:48256350~48256938:-
OV	cis	rs7811142	0.83	rs7341507	ENSG00000242294.5	STAG3L5P	5.48	1.1e-07	0.000107	0.35	0.34	Platelet count;	chr7:100353692	chr7:100336079~100351900:+
OV	cis	rs7302981	0.741	rs76919525	ENSG00000272368.2	RP4-605O3.4	-5.48	1.11e-07	0.000107	-0.4	-0.34	Systolic blood pressure;	chr12:50147950	chr12:50112197~50165618:+
OV	cis	rs2153535	0.518	rs9406187	ENSG00000230939.1	RP11-314C16.1	-5.48	1.11e-07	0.000107	-0.39	-0.34	Motion sickness;	chr6:8654376	chr6:8784178~8785445:+
OV	cis	rs875971	0.505	rs6955582	ENSG00000224316.1	RP11-479O9.2	5.48	1.11e-07	0.000107	0.36	0.34	Aortic root size;	chr7:65966699	chr7:65773620~65802067:+
OV	cis	rs4713118	0.662	rs149901	ENSG00000280107.1	AL022393.9	-5.48	1.12e-07	0.000107	-0.44	-0.34	Parkinson's disease;	chr6:27997725	chr6:28170845~28172521:+
OV	cis	rs4713118	0.662	rs464312	ENSG00000280107.1	AL022393.9	-5.48	1.12e-07	0.000107	-0.44	-0.34	Parkinson's disease;	chr6:27999813	chr6:28170845~28172521:+
OV	cis	rs4713118	0.662	rs469228	ENSG00000280107.1	AL022393.9	-5.48	1.12e-07	0.000107	-0.44	-0.34	Parkinson's disease;	chr6:28002926	chr6:28170845~28172521:+
OV	cis	rs4713118	0.54	rs469227	ENSG00000280107.1	AL022393.9	-5.48	1.12e-07	0.000107	-0.44	-0.34	Parkinson's disease;	chr6:28002927	chr6:28170845~28172521:+
OV	cis	rs11976180	1	rs2961134	ENSG00000170356.8	OR2A20P	-5.48	1.12e-07	0.000108	-0.46	-0.34	Obesity-related traits;	chr7:144073969	chr7:144250045~144252957:-
OV	cis	rs7188445	0.615	rs4340340	ENSG00000261390.4	RP11-345M22.2	-5.48	1.12e-07	0.000108	-0.39	-0.34	Urate levels;	chr16:79716720	chr16:79715232~79770563:-
OV	cis	rs7615952	0.512	rs2979336	ENSG00000171084.14	FAM86JP	5.48	1.12e-07	0.000108	0.51	0.34	Blood pressure (smoking interaction);	chr3:125638626	chr3:125916620~125930024:+
OV	cis	rs67311347	0.826	rs9863679	ENSG00000223797.4	ENTPD3-AS1	5.48	1.12e-07	0.000108	0.39	0.34	Renal cell carcinoma;	chr3:40398123	chr3:40313802~40453329:-
OV	cis	rs67311347	0.911	rs9863737	ENSG00000223797.4	ENTPD3-AS1	5.48	1.12e-07	0.000108	0.39	0.34	Renal cell carcinoma;	chr3:40398345	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs73076035	ENSG00000223797.4	ENTPD3-AS1	5.48	1.12e-07	0.000108	0.39	0.34	Renal cell carcinoma;	chr3:40398390	chr3:40313802~40453329:-
OV	cis	rs17767294	0.612	rs9461424	ENSG00000220721.1	OR1F12	5.48	1.14e-07	0.00011	0.54	0.34	Parkinson's disease;	chr6:27951623	chr6:28073316~28074233:+
OV	cis	rs17767294	0.612	rs9461425	ENSG00000220721.1	OR1F12	5.48	1.14e-07	0.00011	0.54	0.34	Parkinson's disease;	chr6:27951910	chr6:28073316~28074233:+
OV	cis	rs61990749	0.544	rs7151211	ENSG00000239272.1	RPL21P10	-5.48	1.14e-07	0.00011	-0.47	-0.34	Fibroblast growth factor basic levels;	chr14:77685558	chr14:77683202~77683989:-
OV	cis	rs61990749	0.597	rs72685264	ENSG00000239272.1	RPL21P10	-5.48	1.14e-07	0.00011	-0.47	-0.34	Fibroblast growth factor basic levels;	chr14:77686655	chr14:77683202~77683989:-
OV	cis	rs61990749	0.597	rs7147516	ENSG00000239272.1	RPL21P10	-5.48	1.14e-07	0.00011	-0.47	-0.34	Fibroblast growth factor basic levels;	chr14:77687637	chr14:77683202~77683989:-
OV	cis	rs9660180	0.783	rs1107910	ENSG00000231050.1	RP1-140A9.1	5.48	1.14e-07	0.00011	0.36	0.34	Body mass index;	chr1:1760882	chr1:1891471~1892658:+
OV	cis	rs853679	0.567	rs16894091	ENSG00000216901.1	AL022393.7	-5.48	1.15e-07	0.00011	-0.44	-0.34	Depression;	chr6:28422360	chr6:28176188~28176674:+
OV	cis	rs11976180	1	rs1919949	ENSG00000170356.8	OR2A20P	-5.48	1.15e-07	0.00011	-0.48	-0.34	Obesity-related traits;	chr7:144070630	chr7:144250045~144252957:-
OV	cis	rs7017914	0.652	rs62533063	ENSG00000223220.1	Y_RNA	5.48	1.15e-07	0.00011	0.39	0.34	Bone mineral density;	chr8:70673824	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs7831507	ENSG00000223220.1	Y_RNA	5.48	1.15e-07	0.00011	0.39	0.34	Bone mineral density;	chr8:70682991	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs13256093	ENSG00000223220.1	Y_RNA	5.48	1.15e-07	0.00011	0.39	0.34	Bone mineral density;	chr8:70684142	chr8:70780914~70781008:-
OV	cis	rs1075265	0.783	rs805424	ENSG00000233266.1	HMGB1P31	5.48	1.15e-07	0.00011	0.42	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53901098	chr2:54051334~54051760:+
OV	cis	rs67311347	1	rs12108041	ENSG00000223797.4	ENTPD3-AS1	5.48	1.15e-07	0.000111	0.38	0.34	Renal cell carcinoma;	chr3:40446044	chr3:40313802~40453329:-
OV	cis	rs3091242	0.902	rs36003018	ENSG00000224183.1	SDHDP6	5.48	1.15e-07	0.000111	0.39	0.34	Erythrocyte sedimentation rate;	chr1:25457827	chr1:25294164~25294643:-
OV	cis	rs3091242	0.933	rs35403885	ENSG00000224183.1	SDHDP6	5.48	1.15e-07	0.000111	0.39	0.34	Erythrocyte sedimentation rate;	chr1:25458060	chr1:25294164~25294643:-
OV	cis	rs1061377	0.748	rs11096977	ENSG00000249207.1	RP11-360F5.1	-5.47	1.16e-07	0.000111	-0.36	-0.34	Uric acid levels;	chr4:39106186	chr4:39112677~39126818:-
OV	cis	rs1061377	0.748	rs6810770	ENSG00000249207.1	RP11-360F5.1	-5.47	1.16e-07	0.000111	-0.36	-0.34	Uric acid levels;	chr4:39106545	chr4:39112677~39126818:-
OV	cis	rs1061377	0.748	rs6812316	ENSG00000249207.1	RP11-360F5.1	-5.47	1.16e-07	0.000111	-0.36	-0.34	Uric acid levels;	chr4:39106617	chr4:39112677~39126818:-
OV	cis	rs11690935	0.632	rs62184165	ENSG00000228389.1	AC068039.4	-5.47	1.16e-07	0.000111	-0.39	-0.34	Schizophrenia;	chr2:171701818	chr2:171773482~171775844:+
OV	cis	rs858239	0.6	rs2003555	ENSG00000230042.1	AK3P3	-5.47	1.16e-07	0.000112	-0.36	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23083296	chr7:23129178~23129841:+
OV	cis	rs858239	0.6	rs10256359	ENSG00000230042.1	AK3P3	-5.47	1.16e-07	0.000112	-0.36	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23084258	chr7:23129178~23129841:+
OV	cis	rs858239	0.6	rs7784929	ENSG00000230042.1	AK3P3	-5.47	1.16e-07	0.000112	-0.36	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23084658	chr7:23129178~23129841:+
OV	cis	rs4713118	0.826	rs2893929	ENSG00000219392.1	RP1-265C24.5	-5.47	1.17e-07	0.000112	-0.42	-0.34	Parkinson's disease;	chr6:27770953	chr6:28115628~28116551:+
OV	cis	rs4713118	0.666	rs4140646	ENSG00000219392.1	RP1-265C24.5	-5.47	1.17e-07	0.000112	-0.42	-0.34	Parkinson's disease;	chr6:27771022	chr6:28115628~28116551:+
OV	cis	rs4713118	0.666	rs2893930	ENSG00000219392.1	RP1-265C24.5	-5.47	1.17e-07	0.000112	-0.42	-0.34	Parkinson's disease;	chr6:27771027	chr6:28115628~28116551:+
OV	cis	rs858239	0.6	rs7799422	ENSG00000230042.1	AK3P3	-5.47	1.17e-07	0.000112	-0.36	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23088794	chr7:23129178~23129841:+
OV	cis	rs67311347	1	rs11714032	ENSG00000223797.4	ENTPD3-AS1	5.47	1.18e-07	0.000113	0.39	0.34	Renal cell carcinoma;	chr3:40390114	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs7634375	ENSG00000223797.4	ENTPD3-AS1	5.47	1.18e-07	0.000113	0.39	0.34	Renal cell carcinoma;	chr3:40390455	chr3:40313802~40453329:-
OV	cis	rs6569038	0.557	rs9401118	ENSG00000253194.1	RP11-351A11.1	-5.47	1.18e-07	0.000113	-0.38	-0.34	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119053584	chr6:118934785~119031541:+
OV	cis	rs7580658	0.614	rs7585198	ENSG00000236682.1	AC068282.3	5.47	1.18e-07	0.000113	0.43	0.34	Protein C levels;	chr2:127205059	chr2:127389130~127400580:+
OV	cis	rs4128705	0.958	rs6829492	ENSG00000249049.1	RP11-763F8.1	-5.47	1.18e-07	0.000113	-0.43	-0.34	Amyotrophic lateral sclerosis (sporadic);	chr4:91342298	chr4:91319034~91325306:-
OV	cis	rs5742933	0.857	rs1437891	ENSG00000253559.1	OSGEPL1-AS1	-5.47	1.18e-07	0.000113	-0.35	-0.34	Ferritin levels;	chr2:189697982	chr2:189762704~189765556:+
OV	cis	rs3091242	0.933	rs35530120	ENSG00000224183.1	SDHDP6	5.47	1.18e-07	0.000113	0.39	0.34	Erythrocyte sedimentation rate;	chr1:25458960	chr1:25294164~25294643:-
OV	cis	rs7017914	0.87	rs3098883	ENSG00000223220.1	Y_RNA	5.47	1.19e-07	0.000114	0.36	0.34	Bone mineral density;	chr8:71031332	chr8:70780914~70781008:-
OV	cis	rs6991838	0.673	rs7462352	ENSG00000272010.1	CTD-3025N20.3	5.47	1.19e-07	0.000114	0.42	0.34	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65591850~65592472:-
OV	cis	rs8005677	0.649	rs11629120	ENSG00000257285.4	RP11-298I3.1	-5.47	1.19e-07	0.000114	-0.41	-0.34	Cognitive ability (multi-trait analysis);	chr14:22989248	chr14:22929609~22955562:+
OV	cis	rs858239	0.601	rs10255228	ENSG00000230042.1	AK3P3	-5.47	1.2e-07	0.000114	-0.35	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23119244	chr7:23129178~23129841:+
OV	cis	rs6991838	0.831	rs11992528	ENSG00000272010.1	CTD-3025N20.3	5.47	1.2e-07	0.000115	0.41	0.34	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65591850~65592472:-
OV	cis	rs4061073	0.924	rs67060003	ENSG00000198711.5	SSBP3-AS1	-5.47	1.2e-07	0.000115	-0.27	-0.34	Body mass index;	chr1:54232568	chr1:54236440~54239063:+
OV	cis	rs10510102	0.872	rs10887032	ENSG00000226864.1	ATE1-AS1	-5.47	1.2e-07	0.000115	-0.55	-0.34	Breast cancer;	chr10:121955887	chr10:121928312~121951965:+
OV	cis	rs7626444	0.625	rs843529	ENSG00000272359.1	U4	5.47	1.2e-07	0.000115	0.36	0.34	Monocyte count;	chr3:196753724	chr3:196747192~196747324:-
OV	cis	rs611744	0.905	rs640950	ENSG00000253754.1	RP11-35G22.1	-5.47	1.2e-07	0.000115	-0.39	-0.34	Dupuytren's disease;	chr8:108145590	chr8:108226200~108227544:+
OV	cis	rs10510102	0.516	rs12242799	ENSG00000276742.1	RP11-500G22.4	5.47	1.21e-07	0.000116	0.61	0.34	Breast cancer;	chr10:121980067	chr10:121956782~121957098:+
OV	cis	rs55794721	0.509	rs11249248	ENSG00000224183.1	SDHDP6	-5.47	1.21e-07	0.000116	-0.4	-0.34	Mean corpuscular volume;Plateletcrit;	chr1:25426560	chr1:25294164~25294643:-
OV	cis	rs611744	0.647	rs7015513	ENSG00000253754.1	RP11-35G22.1	-5.47	1.21e-07	0.000116	-0.37	-0.34	Dupuytren's disease;	chr8:108250341	chr8:108226200~108227544:+
OV	cis	rs61990749	0.597	rs176955	ENSG00000239272.1	RPL21P10	5.47	1.21e-07	0.000116	0.48	0.34	Fibroblast growth factor basic levels;	chr14:77714877	chr14:77683202~77683989:-
OV	cis	rs61990749	0.544	rs176962	ENSG00000239272.1	RPL21P10	5.47	1.21e-07	0.000116	0.48	0.34	Fibroblast growth factor basic levels;	chr14:77719167	chr14:77683202~77683989:-
OV	cis	rs8005677	1	rs10148215	ENSG00000279656.1	RP11-298I3.6	5.46	1.22e-07	0.000116	0.37	0.34	Cognitive ability (multi-trait analysis);	chr14:22913136	chr14:23023083~23024217:-
OV	cis	rs8005677	1	rs8006396	ENSG00000279656.1	RP11-298I3.6	5.46	1.22e-07	0.000116	0.37	0.34	Cognitive ability (multi-trait analysis);	chr14:22911641	chr14:23023083~23024217:-
OV	cis	rs8005677	1	rs4981446	ENSG00000279656.1	RP11-298I3.6	5.46	1.22e-07	0.000116	0.37	0.34	Cognitive ability (multi-trait analysis);	chr14:22912204	chr14:23023083~23024217:-
OV	cis	rs8005677	1	rs4982706	ENSG00000279656.1	RP11-298I3.6	5.46	1.22e-07	0.000116	0.37	0.34	Cognitive ability (multi-trait analysis);	chr14:22912488	chr14:23023083~23024217:-
OV	cis	rs62355901	0.545	rs57850701	ENSG00000271828.1	CTD-2310F14.1	5.46	1.22e-07	0.000117	0.69	0.34	Breast cancer;	chr5:56728529	chr5:56927874~56929573:+
OV	cis	rs7615952	0.599	rs2270986	ENSG00000171084.14	FAM86JP	5.46	1.22e-07	0.000117	0.49	0.34	Blood pressure (smoking interaction);	chr3:125982256	chr3:125916620~125930024:+
OV	cis	rs7615952	0.599	rs12496921	ENSG00000171084.14	FAM86JP	5.46	1.22e-07	0.000117	0.49	0.34	Blood pressure (smoking interaction);	chr3:125983105	chr3:125916620~125930024:+
OV	cis	rs150992	0.592	rs10038192	ENSG00000248489.1	CTD-2007H13.3	5.46	1.22e-07	0.000117	0.4	0.34	Body mass index;	chr5:98989755	chr5:98929171~98995013:+
OV	cis	rs150992	0.571	rs10045959	ENSG00000248489.1	CTD-2007H13.3	5.46	1.22e-07	0.000117	0.4	0.34	Body mass index;	chr5:98989767	chr5:98929171~98995013:+
OV	cis	rs150992	0.571	rs10037147	ENSG00000248489.1	CTD-2007H13.3	5.46	1.22e-07	0.000117	0.4	0.34	Body mass index;	chr5:98989768	chr5:98929171~98995013:+
OV	cis	rs34779708	0.966	rs4934735	ENSG00000230534.5	RP11-297A16.2	-5.46	1.22e-07	0.000117	-0.44	-0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35207802	chr10:35098006~35127020:-
OV	cis	rs611744	0.647	rs4735053	ENSG00000253754.1	RP11-35G22.1	-5.46	1.23e-07	0.000117	-0.38	-0.34	Dupuytren's disease;	chr8:108248547	chr8:108226200~108227544:+
OV	cis	rs2688608	0.587	rs2894040	ENSG00000271816.1	BMS1P4	5.46	1.23e-07	0.000117	0.32	0.34	Inflammatory bowel disease;	chr10:73718401	chr10:73699151~73730487:-
OV	cis	rs2688608	0.592	rs3849967	ENSG00000271816.1	BMS1P4	5.46	1.23e-07	0.000117	0.32	0.34	Inflammatory bowel disease;	chr10:73723608	chr10:73699151~73730487:-
OV	cis	rs2688608	0.592	rs7909802	ENSG00000271816.1	BMS1P4	5.46	1.23e-07	0.000117	0.32	0.34	Inflammatory bowel disease;	chr10:73724428	chr10:73699151~73730487:-
OV	cis	rs4713118	0.513	rs149955	ENSG00000219392.1	RP1-265C24.5	-5.46	1.23e-07	0.000117	-0.39	-0.34	Parkinson's disease;	chr6:28068447	chr6:28115628~28116551:+
OV	cis	rs4713118	0.868	rs742047	ENSG00000219392.1	RP1-265C24.5	-5.46	1.23e-07	0.000117	-0.42	-0.34	Parkinson's disease;	chr6:27771601	chr6:28115628~28116551:+
OV	cis	rs293748	0.771	rs34701667	ENSG00000250155.1	CTD-2353F22.1	-5.46	1.23e-07	0.000118	-0.48	-0.34	Obesity-related traits;	chr5:36799375	chr5:36666214~36725195:-
OV	cis	rs293748	0.724	rs55668350	ENSG00000250155.1	CTD-2353F22.1	-5.46	1.23e-07	0.000118	-0.48	-0.34	Obesity-related traits;	chr5:36801181	chr5:36666214~36725195:-
OV	cis	rs293748	0.771	rs13174506	ENSG00000250155.1	CTD-2353F22.1	-5.46	1.23e-07	0.000118	-0.48	-0.34	Obesity-related traits;	chr5:36801678	chr5:36666214~36725195:-
OV	cis	rs293748	0.771	rs12654600	ENSG00000250155.1	CTD-2353F22.1	-5.46	1.23e-07	0.000118	-0.48	-0.34	Obesity-related traits;	chr5:36802066	chr5:36666214~36725195:-
OV	cis	rs293748	0.771	rs34139494	ENSG00000250155.1	CTD-2353F22.1	-5.46	1.23e-07	0.000118	-0.48	-0.34	Obesity-related traits;	chr5:36802466	chr5:36666214~36725195:-
OV	cis	rs293748	0.771	rs34092841	ENSG00000250155.1	CTD-2353F22.1	-5.46	1.23e-07	0.000118	-0.48	-0.34	Obesity-related traits;	chr5:36803462	chr5:36666214~36725195:-
OV	cis	rs293748	0.771	rs35660956	ENSG00000250155.1	CTD-2353F22.1	-5.46	1.23e-07	0.000118	-0.48	-0.34	Obesity-related traits;	chr5:36803648	chr5:36666214~36725195:-
OV	cis	rs293748	0.771	rs292163	ENSG00000250155.1	CTD-2353F22.1	-5.46	1.23e-07	0.000118	-0.48	-0.34	Obesity-related traits;	chr5:36803847	chr5:36666214~36725195:-
OV	cis	rs293748	0.771	rs172384	ENSG00000250155.1	CTD-2353F22.1	-5.46	1.23e-07	0.000118	-0.48	-0.34	Obesity-related traits;	chr5:36804123	chr5:36666214~36725195:-
OV	cis	rs293748	0.771	rs292164	ENSG00000250155.1	CTD-2353F22.1	-5.46	1.23e-07	0.000118	-0.48	-0.34	Obesity-related traits;	chr5:36804643	chr5:36666214~36725195:-
OV	cis	rs853679	0.513	rs9468296	ENSG00000280107.1	AL022393.9	-5.46	1.24e-07	0.000118	-0.44	-0.34	Depression;	chr6:28145952	chr6:28170845~28172521:+
OV	cis	rs7017914	0.628	rs2279128	ENSG00000223220.1	Y_RNA	5.46	1.24e-07	0.000118	0.38	0.34	Bone mineral density;	chr8:70669324	chr8:70780914~70781008:-
OV	cis	rs7017914	0.583	rs1477943	ENSG00000223220.1	Y_RNA	5.46	1.24e-07	0.000118	0.38	0.34	Bone mineral density;	chr8:70670528	chr8:70780914~70781008:-
OV	cis	rs2492286	0.518	rs2712412	ENSG00000277250.1	Metazoa_SRP	-5.46	1.24e-07	0.000118	-0.42	-0.34	Eosinophil counts;	chr3:128647208	chr3:128673681~128674021:-
OV	cis	rs1576263	0.934	rs330109	ENSG00000230939.1	RP11-314C16.1	-5.46	1.25e-07	0.000119	-0.36	-0.34	Photic sneeze reflex;	chr6:8545871	chr6:8784178~8785445:+
OV	cis	rs2688608	0.592	rs11000758	ENSG00000271816.1	BMS1P4	5.46	1.25e-07	0.000119	0.32	0.34	Inflammatory bowel disease;	chr10:73733852	chr10:73699151~73730487:-
OV	cis	rs2688608	0.592	rs10762560	ENSG00000271816.1	BMS1P4	5.46	1.25e-07	0.000119	0.32	0.34	Inflammatory bowel disease;	chr10:73735647	chr10:73699151~73730487:-
OV	cis	rs1790761	0.692	rs674783	ENSG00000184224.3	C11orf72	5.46	1.25e-07	0.000119	0.39	0.34	Mean corpuscular volume;	chr11:67571605	chr11:67602880~67606706:-
OV	cis	rs1790761	0.607	rs656652	ENSG00000184224.3	C11orf72	5.46	1.25e-07	0.000119	0.39	0.34	Mean corpuscular volume;	chr11:67576486	chr11:67602880~67606706:-
OV	cis	rs1790761	0.632	rs625978	ENSG00000184224.3	C11orf72	5.46	1.25e-07	0.000119	0.39	0.34	Mean corpuscular volume;	chr11:67577193	chr11:67602880~67606706:-
OV	cis	rs7773456	0.576	rs4140624	ENSG00000228412.5	RP4-625H18.2	-5.46	1.25e-07	0.000119	-0.45	-0.34	Lupus nephritis in systemic lupus erythematosus;	chr6:19818329	chr6:19802164~19804752:-
OV	cis	rs514406	0.727	rs61768342	ENSG00000206627.1	RNU6-969P	-5.46	1.25e-07	0.000119	-0.36	-0.34	Monocyte count;	chr1:52751356	chr1:52805108~52805212:-
OV	cis	rs514406	0.793	rs12081018	ENSG00000206627.1	RNU6-969P	-5.46	1.25e-07	0.000119	-0.36	-0.34	Monocyte count;	chr1:52751870	chr1:52805108~52805212:-
OV	cis	rs858239	0.6	rs28483572	ENSG00000230042.1	AK3P3	-5.46	1.25e-07	0.000119	-0.36	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23092166	chr7:23129178~23129841:+
OV	cis	rs858239	0.6	rs6961406	ENSG00000230042.1	AK3P3	-5.46	1.25e-07	0.000119	-0.36	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23095272	chr7:23129178~23129841:+
OV	cis	rs858239	0.6	rs6461690	ENSG00000230042.1	AK3P3	-5.46	1.25e-07	0.000119	-0.36	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23095915	chr7:23129178~23129841:+
OV	cis	rs858239	0.6	rs6967419	ENSG00000230042.1	AK3P3	-5.46	1.25e-07	0.000119	-0.36	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23096691	chr7:23129178~23129841:+
OV	cis	rs34779708	0.733	rs11597184	ENSG00000230534.5	RP11-297A16.2	5.46	1.26e-07	0.00012	0.45	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35108468	chr10:35098006~35127020:-
OV	cis	rs1150668	0.699	rs2394049	ENSG00000220721.1	OR1F12	5.46	1.26e-07	0.00012	0.34	0.34	Pubertal anthropometrics;	chr6:28271903	chr6:28073316~28074233:+
OV	cis	rs34779708	0.897	rs4934527	ENSG00000230534.5	RP11-297A16.2	5.46	1.26e-07	0.00012	0.44	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:34992190	chr10:35098006~35127020:-
OV	cis	rs7771547	0.607	rs9348997	ENSG00000240733.3	RN7SL502P	-5.46	1.26e-07	0.00012	-0.37	-0.34	Platelet distribution width;	chr6:36462783	chr6:36450912~36451201:-
OV	cis	rs8040855	0.599	rs6496791	ENSG00000229212.6	RP11-561C5.4	-5.46	1.26e-07	0.00012	-0.41	-0.34	Bulimia nervosa;	chr15:85182428	chr15:85205440~85234795:-
OV	cis	rs7684253	0.587	rs2002154	ENSG00000269949.1	RP11-738E22.3	-5.46	1.26e-07	0.00012	-0.41	-0.34	Migraine;	chr4:56879851	chr4:56960927~56961373:-
OV	cis	rs7684253	0.587	rs7670313	ENSG00000269949.1	RP11-738E22.3	-5.46	1.26e-07	0.00012	-0.41	-0.34	Migraine;	chr4:56880007	chr4:56960927~56961373:-
OV	cis	rs7684253	0.587	rs2170074	ENSG00000269949.1	RP11-738E22.3	-5.46	1.26e-07	0.00012	-0.41	-0.34	Migraine;	chr4:56880190	chr4:56960927~56961373:-
OV	cis	rs853679	0.517	rs2281588	ENSG00000280107.1	AL022393.9	-5.46	1.27e-07	0.00012	-0.42	-0.34	Depression;	chr6:28104824	chr6:28170845~28172521:+
OV	cis	rs35160687	0.901	rs12999029	ENSG00000273080.1	RP11-301O19.1	5.46	1.27e-07	0.00012	0.35	0.34	Night sleep phenotypes;	chr2:86275790	chr2:86195590~86196049:+
OV	cis	rs7044106	0.791	rs10985009	ENSG00000226752.6	PSMD5-AS1	5.46	1.27e-07	0.000121	0.39	0.34	Hip circumference adjusted for BMI;	chr9:120730761	chr9:120824828~120854385:+
OV	cis	rs2380205	0.546	rs649537	ENSG00000232807.2	RP11-536K7.3	-5.46	1.28e-07	0.000121	-0.35	-0.34	Breast cancer;	chr10:5903709	chr10:5934270~5945900:-
OV	cis	rs17445774	1	rs1509833	ENSG00000232732.8	AC073043.1	-5.46	1.28e-07	0.000121	-0.42	-0.34	LDL cholesterol to HDL cholesterol ratio;	chr2:200000502	chr2:199867396~199911159:-
OV	cis	rs4713118	0.662	rs149900	ENSG00000280107.1	AL022393.9	-5.46	1.28e-07	0.000121	-0.44	-0.34	Parkinson's disease;	chr6:28046819	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs2273564	ENSG00000280107.1	AL022393.9	-5.45	1.28e-07	0.000122	-0.42	-0.34	Depression;	chr6:28089816	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs1853097	ENSG00000280107.1	AL022393.9	-5.45	1.28e-07	0.000122	-0.42	-0.34	Depression;	chr6:28090857	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9393887	ENSG00000280107.1	AL022393.9	-5.45	1.28e-07	0.000122	-0.42	-0.34	Depression;	chr6:28091242	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9393888	ENSG00000280107.1	AL022393.9	-5.45	1.28e-07	0.000122	-0.42	-0.34	Depression;	chr6:28091439	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs3734573	ENSG00000280107.1	AL022393.9	-5.45	1.28e-07	0.000122	-0.42	-0.34	Depression;	chr6:28091659	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9368551	ENSG00000280107.1	AL022393.9	-5.45	1.28e-07	0.000122	-0.42	-0.34	Depression;	chr6:28094014	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9393890	ENSG00000280107.1	AL022393.9	-5.45	1.28e-07	0.000122	-0.42	-0.34	Depression;	chr6:28096077	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9366715	ENSG00000280107.1	AL022393.9	-5.45	1.28e-07	0.000122	-0.42	-0.34	Depression;	chr6:28096855	chr6:28170845~28172521:+
OV	cis	rs853679	0.598	rs9380054	ENSG00000280107.1	AL022393.9	-5.45	1.28e-07	0.000122	-0.42	-0.34	Depression;	chr6:28099759	chr6:28170845~28172521:+
OV	cis	rs4713118	0.547	rs2116981	ENSG00000280107.1	AL022393.9	-5.45	1.28e-07	0.000122	-0.42	-0.34	Parkinson's disease;	chr6:28100173	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9368552	ENSG00000280107.1	AL022393.9	-5.45	1.28e-07	0.000122	-0.42	-0.34	Depression;	chr6:28100648	chr6:28170845~28172521:+
OV	cis	rs853679	0.542	rs34131763	ENSG00000280107.1	AL022393.9	-5.45	1.28e-07	0.000122	-0.42	-0.34	Depression;	chr6:28107222	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs35193936	ENSG00000280107.1	AL022393.9	-5.45	1.28e-07	0.000122	-0.42	-0.34	Depression;	chr6:28108492	chr6:28170845~28172521:+
OV	cis	rs1122900	1	rs1122900	ENSG00000250155.1	CTD-2353F22.1	5.45	1.28e-07	0.000122	0.36	0.34	Aggressive periodontitis;	chr5:36689079	chr5:36666214~36725195:-
OV	cis	rs7017914	0.677	rs67781030	ENSG00000223220.1	Y_RNA	5.45	1.29e-07	0.000122	0.39	0.34	Bone mineral density;	chr8:70836619	chr8:70780914~70781008:-
OV	cis	rs1134634	0.52	rs12645849	ENSG00000273133.1	RP11-799M12.2	-5.45	1.29e-07	0.000123	-0.45	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15627457	chr4:15563698~15564253:-
OV	cis	rs5742933	0.597	rs12471663	ENSG00000253559.1	OSGEPL1-AS1	5.45	1.3e-07	0.000123	0.37	0.34	Ferritin levels;	chr2:189642372	chr2:189762704~189765556:+
OV	cis	rs5742933	0.597	rs6761923	ENSG00000253559.1	OSGEPL1-AS1	5.45	1.3e-07	0.000123	0.37	0.34	Ferritin levels;	chr2:189642873	chr2:189762704~189765556:+
OV	cis	rs4366055	1	rs4366055	ENSG00000253704.1	RP11-267M23.4	5.45	1.3e-07	0.000123	0.44	0.34	Body mass index;	chr8:94495100	chr8:94553722~94569745:+
OV	cis	rs3091242	0.933	rs10903130	ENSG00000224183.1	SDHDP6	-5.45	1.3e-07	0.000124	-0.39	-0.34	Erythrocyte sedimentation rate;	chr1:25442730	chr1:25294164~25294643:-
OV	cis	rs3091242	0.933	rs11249251	ENSG00000224183.1	SDHDP6	-5.45	1.3e-07	0.000124	-0.39	-0.34	Erythrocyte sedimentation rate;	chr1:25443697	chr1:25294164~25294643:-
OV	cis	rs514406	0.793	rs4500255	ENSG00000206627.1	RNU6-969P	-5.45	1.31e-07	0.000124	-0.35	-0.34	Monocyte count;	chr1:52747607	chr1:52805108~52805212:-
OV	cis	rs10510102	0.872	rs12244199	ENSG00000226864.1	ATE1-AS1	5.45	1.31e-07	0.000124	0.57	0.34	Breast cancer;	chr10:121965117	chr10:121928312~121951965:+
OV	cis	rs875971	1	rs7781698	ENSG00000236529.1	RP13-254B10.1	5.45	1.31e-07	0.000124	0.36	0.34	Aortic root size;	chr7:66431325	chr7:65840212~65840596:+
OV	cis	rs67311347	1	rs9874499	ENSG00000223797.4	ENTPD3-AS1	5.45	1.31e-07	0.000124	0.38	0.34	Renal cell carcinoma;	chr3:40400417	chr3:40313802~40453329:-
OV	cis	rs34779708	0.931	rs7923172	ENSG00000230534.5	RP11-297A16.2	5.45	1.31e-07	0.000124	0.43	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35020439	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs3740083	ENSG00000230534.5	RP11-297A16.2	5.45	1.31e-07	0.000124	0.43	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35031455	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs12261654	ENSG00000230534.5	RP11-297A16.2	5.45	1.31e-07	0.000124	0.43	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35033096	chr10:35098006~35127020:-
OV	cis	rs2898290	0.592	rs2736342	ENSG00000255556.2	RP11-351I21.6	-5.45	1.31e-07	0.000124	-0.37	-0.34	Systolic blood pressure;	chr8:11489780	chr8:12378679~12380265:-
OV	cis	rs17741873	0.72	rs2227568	ENSG00000224195.1	RP11-574K11.5	5.45	1.32e-07	0.000125	0.51	0.34	Paclitaxel disposition in epithelial ovarian cancer;	chr10:73914121	chr10:73813518~73814737:+
OV	cis	rs957448	1	rs957447	ENSG00000253704.1	RP11-267M23.4	5.45	1.32e-07	0.000125	0.46	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94528995	chr8:94553722~94569745:+
OV	cis	rs6844153	0.752	rs11737218	ENSG00000240005.4	RP11-293A21.1	5.45	1.32e-07	0.000125	0.4	0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26884151	chr4:26859806~26860599:-
OV	cis	rs1075265	0.597	rs11694711	ENSG00000233266.1	HMGB1P31	5.45	1.32e-07	0.000125	0.42	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53971924	chr2:54051334~54051760:+
OV	cis	rs2153535	0.518	rs9328493	ENSG00000230939.1	RP11-314C16.1	-5.45	1.33e-07	0.000126	-0.38	-0.34	Motion sickness;	chr6:8569066	chr6:8784178~8785445:+
OV	cis	rs2153535	0.518	rs9406181	ENSG00000230939.1	RP11-314C16.1	-5.45	1.33e-07	0.000126	-0.38	-0.34	Motion sickness;	chr6:8569069	chr6:8784178~8785445:+
OV	cis	rs8062405	0.688	rs3924376	ENSG00000259982.1	CDC37P1	-5.45	1.33e-07	0.000126	-0.45	-0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28914657	chr16:28700294~28701540:-
OV	cis	rs1134634	0.52	rs4698403	ENSG00000273133.1	RP11-799M12.2	-5.45	1.34e-07	0.000126	-0.45	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15628204	chr4:15563698~15564253:-
OV	cis	rs7429990	0.93	rs13075457	ENSG00000229759.1	MRPS18AP1	-5.45	1.34e-07	0.000127	-0.35	-0.34	Educational attainment (years of education);	chr3:48013063	chr3:48256350~48256938:-
OV	cis	rs7429990	0.93	rs11130152	ENSG00000229759.1	MRPS18AP1	-5.45	1.34e-07	0.000127	-0.35	-0.34	Educational attainment (years of education);	chr3:48014919	chr3:48256350~48256938:-
OV	cis	rs611744	0.87	rs429315	ENSG00000253754.1	RP11-35G22.1	5.45	1.34e-07	0.000127	0.42	0.34	Dupuytren's disease;	chr8:108081840	chr8:108226200~108227544:+
OV	cis	rs957448	1	rs1055800	ENSG00000253704.1	RP11-267M23.4	-5.45	1.34e-07	0.000127	-0.43	-0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94510810	chr8:94553722~94569745:+
OV	cis	rs17711722	0.503	rs453835	ENSG00000224316.1	RP11-479O9.2	-5.44	1.34e-07	0.000127	-0.39	-0.34	Calcium levels;	chr7:66046172	chr7:65773620~65802067:+
OV	cis	rs4713118	0.868	rs760587	ENSG00000219392.1	RP1-265C24.5	-5.44	1.35e-07	0.000127	-0.42	-0.34	Parkinson's disease;	chr6:27772521	chr6:28115628~28116551:+
OV	cis	rs957448	1	rs72674852	ENSG00000253704.1	RP11-267M23.4	5.44	1.35e-07	0.000127	0.46	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94536523	chr8:94553722~94569745:+
OV	cis	rs957448	1	rs16916874	ENSG00000253704.1	RP11-267M23.4	5.44	1.35e-07	0.000127	0.46	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94537749	chr8:94553722~94569745:+
OV	cis	rs13178541	0.641	rs2345447	ENSG00000250378.1	RP11-119J18.1	-5.44	1.35e-07	0.000128	-0.47	-0.34	IgG glycosylation;	chr5:135804058	chr5:135812667~135826582:+
OV	cis	rs13178541	0.641	rs10062107	ENSG00000250378.1	RP11-119J18.1	-5.44	1.35e-07	0.000128	-0.47	-0.34	IgG glycosylation;	chr5:135804913	chr5:135812667~135826582:+
OV	cis	rs7674212	0.507	rs10516495	ENSG00000246560.2	RP11-10L12.4	5.44	1.35e-07	0.000128	0.41	0.34	Type 2 diabetes;	chr4:102978933	chr4:102828055~102844075:+
OV	cis	rs4713118	0.868	rs35069907	ENSG00000219392.1	RP1-265C24.5	-5.44	1.35e-07	0.000128	-0.42	-0.34	Parkinson's disease;	chr6:27778913	chr6:28115628~28116551:+
OV	cis	rs13178541	0.641	rs2159660	ENSG00000250378.1	RP11-119J18.1	-5.44	1.35e-07	0.000128	-0.48	-0.34	IgG glycosylation;	chr5:135801356	chr5:135812667~135826582:+
OV	cis	rs13178541	0.641	rs2109670	ENSG00000250378.1	RP11-119J18.1	-5.44	1.35e-07	0.000128	-0.48	-0.34	IgG glycosylation;	chr5:135801529	chr5:135812667~135826582:+
OV	cis	rs13178541	0.641	rs2109669	ENSG00000250378.1	RP11-119J18.1	-5.44	1.35e-07	0.000128	-0.48	-0.34	IgG glycosylation;	chr5:135801688	chr5:135812667~135826582:+
OV	cis	rs2688608	0.53	rs71507081	ENSG00000271816.1	BMS1P4	5.44	1.36e-07	0.000128	0.32	0.34	Inflammatory bowel disease;	chr10:73733378	chr10:73699151~73730487:-
OV	cis	rs2675662	0.525	rs12264025	ENSG00000271816.1	BMS1P4	5.44	1.36e-07	0.000128	0.32	0.34	Psoriasis vulgaris;Psoriasis;	chr10:73734692	chr10:73699151~73730487:-
OV	cis	rs2688608	0.62	rs12253408	ENSG00000271816.1	BMS1P4	5.44	1.36e-07	0.000128	0.32	0.34	Inflammatory bowel disease;	chr10:73736198	chr10:73699151~73730487:-
OV	cis	rs2688608	0.592	rs12253429	ENSG00000271816.1	BMS1P4	5.44	1.36e-07	0.000128	0.32	0.34	Inflammatory bowel disease;	chr10:73736403	chr10:73699151~73730487:-
OV	cis	rs2688608	0.592	rs11000757	ENSG00000271816.1	BMS1P4	5.44	1.36e-07	0.000128	0.32	0.34	Inflammatory bowel disease;	chr10:73727057	chr10:73699151~73730487:-
OV	cis	rs2688608	0.592	rs11814282	ENSG00000271816.1	BMS1P4	5.44	1.36e-07	0.000128	0.32	0.34	Inflammatory bowel disease;	chr10:73730459	chr10:73699151~73730487:-
OV	cis	rs3814244	0.528	rs2906854	ENSG00000255733.4	IFNG-AS1	-5.44	1.36e-07	0.000128	-0.34	-0.34	Itch intensity from mosquito bite adjusted by bite size;	chr12:67993566	chr12:67989445~68234686:+
OV	cis	rs1790761	0.667	rs1254123	ENSG00000184224.3	C11orf72	5.44	1.36e-07	0.000128	0.38	0.34	Mean corpuscular volume;	chr11:67567341	chr11:67602880~67606706:-
OV	cis	rs1075265	0.87	rs7569370	ENSG00000233266.1	HMGB1P31	5.44	1.36e-07	0.000128	0.41	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53989212	chr2:54051334~54051760:+
OV	cis	rs804280	0.509	rs12719915	ENSG00000270154.1	RP11-419I17.1	-5.44	1.37e-07	0.000129	-0.4	-0.34	Myopia (pathological);	chr8:11928746	chr8:12476462~12477122:+
OV	cis	rs7580658	0.676	rs58475809	ENSG00000236682.1	AC068282.3	-5.44	1.37e-07	0.000129	-0.42	-0.34	Protein C levels;	chr2:127245074	chr2:127389130~127400580:+
OV	cis	rs9291683	0.552	rs11736410	ENSG00000250413.1	RP11-448G15.1	-5.44	1.37e-07	0.00013	-0.38	-0.34	Bone mineral density;	chr4:10015617	chr4:10006482~10009725:+
OV	cis	rs7811142	0.83	rs77861211	ENSG00000242294.5	STAG3L5P	5.44	1.38e-07	0.00013	0.36	0.34	Platelet count;	chr7:100364473	chr7:100336079~100351900:+
OV	cis	rs11690935	0.655	rs12052995	ENSG00000228389.1	AC068039.4	-5.44	1.38e-07	0.00013	-0.38	-0.34	Schizophrenia;	chr2:171680702	chr2:171773482~171775844:+
OV	cis	rs2243480	1	rs709607	ENSG00000222364.1	RNU6-96P	5.44	1.38e-07	0.00013	0.56	0.34	Diabetic kidney disease;	chr7:65984554	chr7:66395191~66395286:+
OV	cis	rs2833693	0.572	rs4817477	ENSG00000261610.1	AP000265.1	5.44	1.38e-07	0.00013	0.4	0.34	Temperament;	chr21:32213799	chr21:32259804~32261585:-
OV	cis	rs7429990	0.965	rs7642590	ENSG00000229759.1	MRPS18AP1	-5.44	1.39e-07	0.000131	-0.36	-0.34	Educational attainment (years of education);	chr3:48058260	chr3:48256350~48256938:-
OV	cis	rs4713118	0.662	rs149969	ENSG00000280107.1	AL022393.9	-5.44	1.39e-07	0.000131	-0.45	-0.34	Parkinson's disease;	chr6:28009959	chr6:28170845~28172521:+
OV	cis	rs4713118	0.662	rs149961	ENSG00000219392.1	RP1-265C24.5	-5.44	1.39e-07	0.000131	-0.43	-0.34	Parkinson's disease;	chr6:28047791	chr6:28115628~28116551:+
OV	cis	rs10510102	0.935	rs11200203	ENSG00000276742.1	RP11-500G22.4	5.44	1.39e-07	0.000131	0.57	0.34	Breast cancer;	chr10:121874014	chr10:121956782~121957098:+
OV	cis	rs7017914	0.69	rs17699084	ENSG00000223220.1	Y_RNA	-5.44	1.4e-07	0.000132	-0.39	-0.34	Bone mineral density;	chr8:71051176	chr8:70780914~70781008:-
OV	cis	rs7017914	0.69	rs55915640	ENSG00000223220.1	Y_RNA	5.44	1.4e-07	0.000132	0.39	0.34	Bone mineral density;	chr8:71052423	chr8:70780914~70781008:-
OV	cis	rs783540	0.867	rs11855735	ENSG00000278603.1	RP13-608F4.5	5.44	1.41e-07	0.000132	0.37	0.34	Schizophrenia;	chr15:82627794	chr15:82472203~82472426:+
OV	cis	rs7487637	0.566	rs875023	ENSG00000276691.1	RP5-1057I20.5	-5.44	1.41e-07	0.000132	-0.37	-0.34	Mononucleosis;	chr12:47800652	chr12:47788426~47788971:+
OV	cis	rs4908768	0.911	rs12121933	ENSG00000228423.2	RP4-633I8.4	5.44	1.41e-07	0.000132	0.39	0.34	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8717022	chr1:8805860~8807051:-
OV	cis	rs1729407	0.709	rs2098453	ENSG00000254851.1	RP11-109L13.1	-5.44	1.41e-07	0.000132	-0.43	-0.34	Apolipoprotein A-IV levels;	chr11:116825964	chr11:117135528~117138582:+
OV	cis	rs611744	0.905	rs408506	ENSG00000253754.1	RP11-35G22.1	5.43	1.41e-07	0.000133	0.37	0.34	Dupuytren's disease;	chr8:108142005	chr8:108226200~108227544:+
OV	cis	rs3091242	0.933	rs11249250	ENSG00000224183.1	SDHDP6	-5.43	1.41e-07	0.000133	-0.39	-0.34	Erythrocyte sedimentation rate;	chr1:25441118	chr1:25294164~25294643:-
OV	cis	rs61990749	0.597	rs1048147	ENSG00000239272.1	RPL21P10	-5.43	1.42e-07	0.000133	-0.47	-0.34	Fibroblast growth factor basic levels;	chr14:77673645	chr14:77683202~77683989:-
OV	cis	rs61990749	0.597	rs2267758	ENSG00000239272.1	RPL21P10	-5.43	1.42e-07	0.000133	-0.47	-0.34	Fibroblast growth factor basic levels;	chr14:77681086	chr14:77683202~77683989:-
OV	cis	rs61990749	0.597	rs2267761	ENSG00000239272.1	RPL21P10	-5.43	1.42e-07	0.000133	-0.47	-0.34	Fibroblast growth factor basic levels;	chr14:77681506	chr14:77683202~77683989:-
OV	cis	rs4713118	0.824	rs2179095	ENSG00000220721.1	OR1F12	-5.43	1.42e-07	0.000133	-0.37	-0.34	Parkinson's disease;	chr6:27783079	chr6:28073316~28074233:+
OV	cis	rs4713118	0.662	rs149900	ENSG00000219392.1	RP1-265C24.5	-5.43	1.42e-07	0.000134	-0.43	-0.34	Parkinson's disease;	chr6:28046819	chr6:28115628~28116551:+
OV	cis	rs8062405	0.69	rs7187604	ENSG00000259982.1	CDC37P1	5.43	1.42e-07	0.000134	0.42	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28700294~28701540:-
OV	cis	rs200986	1	rs200986	ENSG00000220721.1	OR1F12	5.43	1.43e-07	0.000134	0.36	0.34	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28073316~28074233:+
OV	cis	rs7968440	0.715	rs7967954	ENSG00000272368.2	RP4-605O3.4	-5.43	1.43e-07	0.000134	-0.37	-0.34	Fibrinogen;	chr12:50279701	chr12:50112197~50165618:+
OV	cis	rs8005677	1	rs7155857	ENSG00000279656.1	RP11-298I3.6	5.43	1.43e-07	0.000134	0.37	0.34	Cognitive ability (multi-trait analysis);	chr14:22930850	chr14:23023083~23024217:-
OV	cis	rs1790761	0.559	rs10896190	ENSG00000184224.3	C11orf72	5.43	1.43e-07	0.000134	0.38	0.34	Mean corpuscular volume;	chr11:67638652	chr11:67602880~67606706:-
OV	cis	rs796364	0.625	rs13035260	ENSG00000232732.8	AC073043.1	5.43	1.43e-07	0.000135	0.46	0.34	Schizophrenia;	chr2:200267654	chr2:199867396~199911159:-
OV	cis	rs2153535	0.585	rs1328874	ENSG00000230939.1	RP11-314C16.1	-5.43	1.43e-07	0.000135	-0.37	-0.34	Motion sickness;	chr6:8621010	chr6:8784178~8785445:+
OV	cis	rs7189233	0.531	rs1072911	ENSG00000279344.1	RP11-44F14.7	5.43	1.44e-07	0.000135	0.32	0.34	Intelligence (multi-trait analysis);	chr16:53465813	chr16:53478957~53481550:-
OV	cis	rs7302981	0.775	rs7301566	ENSG00000257298.1	RP3-405J10.3	-5.43	1.44e-07	0.000135	-0.32	-0.34	Systolic blood pressure;	chr12:50187864	chr12:50185580~50191363:-
OV	cis	rs11673344	0.698	rs56161518	ENSG00000226686.6	LINC01535	5.43	1.45e-07	0.000136	0.46	0.34	Obesity-related traits;	chr19:36978555	chr19:37251912~37265535:+
OV	cis	rs7811142	0.83	rs61735533	ENSG00000242294.5	STAG3L5P	5.43	1.45e-07	0.000136	0.36	0.34	Platelet count;	chr7:100358243	chr7:100336079~100351900:+
OV	cis	rs7811142	0.83	rs11761426	ENSG00000242294.5	STAG3L5P	5.43	1.45e-07	0.000136	0.36	0.34	Platelet count;	chr7:100359270	chr7:100336079~100351900:+
OV	cis	rs150992	0.678	rs161950	ENSG00000248489.1	CTD-2007H13.3	-5.43	1.45e-07	0.000136	-0.42	-0.34	Body mass index;	chr5:98924533	chr5:98929171~98995013:+
OV	cis	rs9532669	0.963	rs9532662	ENSG00000176268.5	CYCSP34	5.43	1.46e-07	0.000137	0.36	0.34	Cervical cancer;	chr13:40926215	chr13:40863599~40863902:-
OV	cis	rs507080	0.733	rs4393358	ENSG00000278376.1	RP11-158I9.8	-5.43	1.46e-07	0.000137	-0.36	-0.34	Serum metabolite levels;	chr11:118698388	chr11:118791254~118793137:+
OV	cis	rs67311347	1	rs9849992	ENSG00000223797.4	ENTPD3-AS1	5.43	1.46e-07	0.000137	0.38	0.34	Renal cell carcinoma;	chr3:40360649	chr3:40313802~40453329:-
OV	cis	rs4713118	0.824	rs2092075	ENSG00000220721.1	OR1F12	5.43	1.47e-07	0.000137	0.37	0.34	Parkinson's disease;	chr6:27781551	chr6:28073316~28074233:+
OV	cis	rs4713118	0.824	rs13211701	ENSG00000220721.1	OR1F12	5.43	1.47e-07	0.000137	0.37	0.34	Parkinson's disease;	chr6:27782300	chr6:28073316~28074233:+
OV	cis	rs4713118	0.824	rs9468229	ENSG00000220721.1	OR1F12	5.43	1.47e-07	0.000137	0.37	0.34	Parkinson's disease;	chr6:27782307	chr6:28073316~28074233:+
OV	cis	rs496547	0.686	rs524590	ENSG00000278376.1	RP11-158I9.8	-5.43	1.47e-07	0.000137	-0.33	-0.34	Hip minimal joint space width;	chr11:118769354	chr11:118791254~118793137:+
OV	cis	rs6772849	0.796	rs9841521	ENSG00000242551.2	POU5F1P6	-5.43	1.47e-07	0.000137	-0.4	-0.34	Monocyte percentage of white cells;Monocyte count;	chr3:128673431	chr3:128674735~128677005:-
OV	cis	rs4713118	0.662	rs9393881	ENSG00000219392.1	RP1-265C24.5	-5.43	1.47e-07	0.000138	-0.41	-0.34	Parkinson's disease;	chr6:28055973	chr6:28115628~28116551:+
OV	cis	rs7580658	0.895	rs9636237	ENSG00000236682.1	AC068282.3	-5.43	1.47e-07	0.000138	-0.43	-0.34	Protein C levels;	chr2:127318446	chr2:127389130~127400580:+
OV	cis	rs9291683	0.588	rs35438220	ENSG00000250413.1	RP11-448G15.1	-5.43	1.47e-07	0.000138	-0.38	-0.34	Bone mineral density;	chr4:9997774	chr4:10006482~10009725:+
OV	cis	rs1576263	0.934	rs330113	ENSG00000230939.1	RP11-314C16.1	-5.43	1.47e-07	0.000138	-0.37	-0.34	Photic sneeze reflex;	chr6:8546834	chr6:8784178~8785445:+
OV	cis	rs8005677	0.926	rs34344888	ENSG00000279656.1	RP11-298I3.6	5.43	1.48e-07	0.000138	0.37	0.34	Cognitive ability (multi-trait analysis);	chr14:22918376	chr14:23023083~23024217:-
OV	cis	rs8005677	0.962	rs34917191	ENSG00000279656.1	RP11-298I3.6	5.43	1.48e-07	0.000138	0.37	0.34	Cognitive ability (multi-trait analysis);	chr14:22918419	chr14:23023083~23024217:-
OV	cis	rs8005677	1	rs1951119	ENSG00000279656.1	RP11-298I3.6	5.43	1.48e-07	0.000138	0.37	0.34	Cognitive ability (multi-trait analysis);	chr14:22919117	chr14:23023083~23024217:-
OV	cis	rs8005677	1	rs2295683	ENSG00000279656.1	RP11-298I3.6	5.43	1.48e-07	0.000138	0.37	0.34	Cognitive ability (multi-trait analysis);	chr14:22919173	chr14:23023083~23024217:-
OV	cis	rs8005677	1	rs4981449	ENSG00000279656.1	RP11-298I3.6	5.43	1.48e-07	0.000138	0.37	0.34	Cognitive ability (multi-trait analysis);	chr14:22919662	chr14:23023083~23024217:-
OV	cis	rs875971	0.522	rs10807697	ENSG00000224316.1	RP11-479O9.2	5.43	1.48e-07	0.000138	0.35	0.34	Aortic root size;	chr7:65951183	chr7:65773620~65802067:+
OV	cis	rs1976403	0.633	rs1780324	ENSG00000227001.3	NBPF2P	5.43	1.48e-07	0.000138	0.37	0.34	Liver enzyme levels (alkaline phosphatase);	chr1:21495264	chr1:21424625~21427967:-
OV	cis	rs6700559	0.654	rs66717951	ENSG00000260088.1	RP11-92G12.3	5.42	1.48e-07	0.000139	0.35	0.34	Coronary artery disease;	chr1:200626437	chr1:200669507~200694250:+
OV	cis	rs6700559	0.654	rs2809346	ENSG00000260088.1	RP11-92G12.3	5.42	1.48e-07	0.000139	0.35	0.34	Coronary artery disease;	chr1:200627089	chr1:200669507~200694250:+
OV	cis	rs4713118	0.662	rs149970	ENSG00000219392.1	RP1-265C24.5	-5.42	1.49e-07	0.000139	-0.44	-0.34	Parkinson's disease;	chr6:28012442	chr6:28115628~28116551:+
OV	cis	rs7017914	0.905	rs1389206	ENSG00000223220.1	Y_RNA	5.42	1.49e-07	0.000139	0.36	0.34	Bone mineral density;	chr8:71012627	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs2639955	ENSG00000223220.1	Y_RNA	5.42	1.49e-07	0.000139	0.36	0.34	Bone mineral density;	chr8:71013107	chr8:70780914~70781008:-
OV	cis	rs7017914	0.869	rs2639954	ENSG00000223220.1	Y_RNA	5.42	1.49e-07	0.000139	0.36	0.34	Bone mineral density;	chr8:71013340	chr8:70780914~70781008:-
OV	cis	rs7017914	0.837	rs2639952	ENSG00000223220.1	Y_RNA	5.42	1.49e-07	0.000139	0.36	0.34	Bone mineral density;	chr8:71013495	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs2732108	ENSG00000223220.1	Y_RNA	5.42	1.49e-07	0.000139	0.36	0.34	Bone mineral density;	chr8:71013864	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs2732109	ENSG00000223220.1	Y_RNA	5.42	1.49e-07	0.000139	0.36	0.34	Bone mineral density;	chr8:71013988	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs1493203	ENSG00000223220.1	Y_RNA	5.42	1.49e-07	0.000139	0.36	0.34	Bone mineral density;	chr8:71014272	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs2732110	ENSG00000223220.1	Y_RNA	5.42	1.49e-07	0.000139	0.36	0.34	Bone mineral density;	chr8:71014576	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs2639951	ENSG00000223220.1	Y_RNA	5.42	1.49e-07	0.000139	0.36	0.34	Bone mineral density;	chr8:71014990	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs2732112	ENSG00000223220.1	Y_RNA	5.42	1.49e-07	0.000139	0.36	0.34	Bone mineral density;	chr8:71015606	chr8:70780914~70781008:-
OV	cis	rs7017914	0.811	rs1389204	ENSG00000223220.1	Y_RNA	5.42	1.49e-07	0.000139	0.36	0.34	Bone mineral density;	chr8:71016063	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs2732113	ENSG00000223220.1	Y_RNA	5.42	1.49e-07	0.000139	0.36	0.34	Bone mineral density;	chr8:71016314	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs2732114	ENSG00000223220.1	Y_RNA	5.42	1.49e-07	0.000139	0.36	0.34	Bone mineral density;	chr8:71016477	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs2732116	ENSG00000223220.1	Y_RNA	5.42	1.49e-07	0.000139	0.36	0.34	Bone mineral density;	chr8:71017092	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs2956610	ENSG00000223220.1	Y_RNA	5.42	1.49e-07	0.000139	0.36	0.34	Bone mineral density;	chr8:71017298	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs3098868	ENSG00000223220.1	Y_RNA	5.42	1.49e-07	0.000139	0.36	0.34	Bone mineral density;	chr8:71017457	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs3110246	ENSG00000223220.1	Y_RNA	5.42	1.49e-07	0.000139	0.36	0.34	Bone mineral density;	chr8:71022378	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs3110250	ENSG00000223220.1	Y_RNA	5.42	1.49e-07	0.000139	0.36	0.34	Bone mineral density;	chr8:71024149	chr8:70780914~70781008:-
OV	cis	rs2153535	0.518	rs9393054	ENSG00000230939.1	RP11-314C16.1	-5.42	1.5e-07	0.00014	-0.38	-0.34	Motion sickness;	chr6:8647209	chr6:8784178~8785445:+
OV	cis	rs514406	0.755	rs10888754	ENSG00000206627.1	RNU6-969P	-5.42	1.51e-07	0.000141	-0.35	-0.34	Monocyte count;	chr1:52763079	chr1:52805108~52805212:-
OV	cis	rs514406	0.861	rs10888755	ENSG00000206627.1	RNU6-969P	-5.42	1.51e-07	0.000141	-0.35	-0.34	Monocyte count;	chr1:52775157	chr1:52805108~52805212:-
OV	cis	rs7615952	0.641	rs4422257	ENSG00000171084.14	FAM86JP	5.42	1.51e-07	0.000141	0.49	0.34	Blood pressure (smoking interaction);	chr3:126055520	chr3:125916620~125930024:+
OV	cis	rs10246939	0.579	rs10464444	ENSG00000228775.6	WEE2-AS1	-5.42	1.51e-07	0.000141	-0.35	-0.34	Bitter taste perception;	chr7:141832387	chr7:141704338~141738346:-
OV	cis	rs8005677	1	rs1956881	ENSG00000279656.1	RP11-298I3.6	5.42	1.52e-07	0.000141	0.37	0.34	Cognitive ability (multi-trait analysis);	chr14:22924860	chr14:23023083~23024217:-
OV	cis	rs13178541	0.641	rs4976534	ENSG00000250378.1	RP11-119J18.1	-5.42	1.52e-07	0.000141	-0.47	-0.34	IgG glycosylation;	chr5:135798716	chr5:135812667~135826582:+
OV	cis	rs13178541	0.641	rs10900839	ENSG00000250378.1	RP11-119J18.1	-5.42	1.52e-07	0.000141	-0.47	-0.34	IgG glycosylation;	chr5:135798845	chr5:135812667~135826582:+
OV	cis	rs13178541	0.641	rs10900841	ENSG00000250378.1	RP11-119J18.1	-5.42	1.52e-07	0.000141	-0.47	-0.34	IgG glycosylation;	chr5:135799020	chr5:135812667~135826582:+
OV	cis	rs13178541	0.574	rs11738505	ENSG00000250378.1	RP11-119J18.1	-5.42	1.52e-07	0.000141	-0.47	-0.34	IgG glycosylation;	chr5:135800107	chr5:135812667~135826582:+
OV	cis	rs13178541	0.641	rs10076272	ENSG00000250378.1	RP11-119J18.1	-5.42	1.52e-07	0.000141	-0.47	-0.34	IgG glycosylation;	chr5:135800540	chr5:135812667~135826582:+
OV	cis	rs2243480	1	rs4548056	ENSG00000222364.1	RNU6-96P	-5.42	1.52e-07	0.000142	-0.52	-0.34	Diabetic kidney disease;	chr7:65833886	chr7:66395191~66395286:+
OV	cis	rs7615952	0.546	rs2976733	ENSG00000171084.14	FAM86JP	5.42	1.53e-07	0.000142	0.52	0.34	Blood pressure (smoking interaction);	chr3:125695294	chr3:125916620~125930024:+
OV	cis	rs10510102	0.516	rs78586895	ENSG00000276742.1	RP11-500G22.4	5.42	1.53e-07	0.000142	0.61	0.34	Breast cancer;	chr10:121977081	chr10:121956782~121957098:+
OV	cis	rs4908768	1	rs7523186	ENSG00000228423.2	RP4-633I8.4	-5.42	1.53e-07	0.000142	-0.38	-0.34	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8595436	chr1:8805860~8807051:-
OV	cis	rs16873450	0.507	rs2390825	ENSG00000234800.2	PCMTD1P3	5.42	1.53e-07	0.000142	0.35	0.34	Verbal memory performance (residualized delayed recall level);	chr7:23837194	chr7:23721311~23721782:-
OV	cis	rs11673344	0.864	rs55792845	ENSG00000226686.6	LINC01535	5.42	1.53e-07	0.000142	0.44	0.34	Obesity-related traits;	chr19:37007783	chr19:37251912~37265535:+
OV	cis	rs11673344	0.864	rs8107192	ENSG00000226686.6	LINC01535	5.42	1.53e-07	0.000142	0.44	0.34	Obesity-related traits;	chr19:37008725	chr19:37251912~37265535:+
OV	cis	rs11673344	0.864	rs11670216	ENSG00000226686.6	LINC01535	5.42	1.53e-07	0.000142	0.44	0.34	Obesity-related traits;	chr19:37012526	chr19:37251912~37265535:+
OV	cis	rs11673344	0.864	rs8104919	ENSG00000226686.6	LINC01535	5.42	1.53e-07	0.000142	0.44	0.34	Obesity-related traits;	chr19:37012881	chr19:37251912~37265535:+
OV	cis	rs7017914	0.905	rs2639957	ENSG00000223220.1	Y_RNA	5.42	1.53e-07	0.000143	0.36	0.34	Bone mineral density;	chr8:71010967	chr8:70780914~70781008:-
OV	cis	rs61990749	0.597	rs11624101	ENSG00000239272.1	RPL21P10	-5.42	1.53e-07	0.000143	-0.47	-0.34	Fibroblast growth factor basic levels;	chr14:77671716	chr14:77683202~77683989:-
OV	cis	rs853679	0.567	rs2232427	ENSG00000216901.1	AL022393.7	5.42	1.53e-07	0.000143	0.42	0.34	Depression;	chr6:28391932	chr6:28176188~28176674:+
OV	cis	rs67311347	1	rs11715214	ENSG00000223797.4	ENTPD3-AS1	5.42	1.54e-07	0.000143	0.38	0.34	Renal cell carcinoma;	chr3:40361513	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs9860162	ENSG00000223797.4	ENTPD3-AS1	5.42	1.54e-07	0.000143	0.38	0.34	Renal cell carcinoma;	chr3:40362384	chr3:40313802~40453329:-
OV	cis	rs3091242	0.933	rs909833	ENSG00000224183.1	SDHDP6	-5.42	1.54e-07	0.000143	-0.4	-0.34	Erythrocyte sedimentation rate;	chr1:25427649	chr1:25294164~25294643:-
OV	cis	rs796364	0.951	rs11680258	ENSG00000232732.8	AC073043.1	5.42	1.54e-07	0.000143	0.45	0.34	Schizophrenia;	chr2:200132253	chr2:199867396~199911159:-
OV	cis	rs8005677	0.962	rs8003934	ENSG00000279656.1	RP11-298I3.6	5.42	1.54e-07	0.000143	0.37	0.34	Cognitive ability (multi-trait analysis);	chr14:22931933	chr14:23023083~23024217:-
OV	cis	rs7309	0.81	rs11684253	ENSG00000227403.1	AC009299.3	-5.42	1.55e-07	0.000144	-0.45	-0.34	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161178025	chr2:161244739~161249050:+
OV	cis	rs796364	1	rs281771	ENSG00000232732.8	AC073043.1	5.42	1.55e-07	0.000144	0.5	0.34	Schizophrenia;	chr2:199947479	chr2:199867396~199911159:-
OV	cis	rs7580658	0.637	rs3902960	ENSG00000236682.1	AC068282.3	-5.42	1.55e-07	0.000144	-0.42	-0.34	Protein C levels;	chr2:127230666	chr2:127389130~127400580:+
OV	cis	rs2412819	0.571	rs17727853	ENSG00000249839.1	AC011330.5	-5.42	1.55e-07	0.000144	-0.47	-0.34	Lung cancer;	chr15:43630299	chr15:43663654~43684339:-
OV	cis	rs8113142	0.651	rs8104685	ENSG00000267243.4	AC005307.3	-5.42	1.55e-07	0.000144	-0.6	-0.34	Femoral neck bone geometry and menarche (age at onset);	chr19:28567927	chr19:28435388~28727777:-
OV	cis	rs875971	1	rs6460296	ENSG00000236529.1	RP13-254B10.1	5.42	1.55e-07	0.000144	0.36	0.34	Aortic root size;	chr7:66430152	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs4717292	ENSG00000236529.1	RP13-254B10.1	5.42	1.55e-07	0.000144	0.36	0.34	Aortic root size;	chr7:66430611	chr7:65840212~65840596:+
OV	cis	rs875971	0.895	rs4718349	ENSG00000236529.1	RP13-254B10.1	5.42	1.55e-07	0.000144	0.36	0.34	Aortic root size;	chr7:66444024	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs2420591	ENSG00000236529.1	RP13-254B10.1	5.42	1.55e-07	0.000144	0.36	0.34	Aortic root size;	chr7:66447394	chr7:65840212~65840596:+
OV	cis	rs875971	0.895	rs10755833	ENSG00000236529.1	RP13-254B10.1	5.42	1.55e-07	0.000144	0.36	0.34	Aortic root size;	chr7:66448930	chr7:65840212~65840596:+
OV	cis	rs875971	0.964	rs12668936	ENSG00000236529.1	RP13-254B10.1	5.42	1.55e-07	0.000144	0.36	0.34	Aortic root size;	chr7:66449417	chr7:65840212~65840596:+
OV	cis	rs875971	0.895	rs7788984	ENSG00000236529.1	RP13-254B10.1	5.42	1.55e-07	0.000144	0.36	0.34	Aortic root size;	chr7:66450629	chr7:65840212~65840596:+
OV	cis	rs875971	0.895	rs1833495	ENSG00000236529.1	RP13-254B10.1	5.42	1.55e-07	0.000144	0.36	0.34	Aortic root size;	chr7:66456608	chr7:65840212~65840596:+
OV	cis	rs875971	0.964	rs6945032	ENSG00000236529.1	RP13-254B10.1	5.42	1.55e-07	0.000144	0.36	0.34	Aortic root size;	chr7:66457499	chr7:65840212~65840596:+
OV	cis	rs875971	0.929	rs12673810	ENSG00000236529.1	RP13-254B10.1	5.42	1.55e-07	0.000144	0.36	0.34	Aortic root size;	chr7:66458866	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs35149210	ENSG00000236529.1	RP13-254B10.1	5.42	1.55e-07	0.000144	0.36	0.34	Aortic root size;	chr7:66464938	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs2042133	ENSG00000236529.1	RP13-254B10.1	5.42	1.55e-07	0.000144	0.36	0.34	Aortic root size;	chr7:66466935	chr7:65840212~65840596:+
OV	cis	rs875971	0.964	rs2161065	ENSG00000236529.1	RP13-254B10.1	5.42	1.55e-07	0.000144	0.36	0.34	Aortic root size;	chr7:66467918	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs6961155	ENSG00000236529.1	RP13-254B10.1	5.42	1.55e-07	0.000144	0.36	0.34	Aortic root size;	chr7:66468308	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs7789768	ENSG00000236529.1	RP13-254B10.1	5.42	1.55e-07	0.000144	0.36	0.34	Aortic root size;	chr7:66473993	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs12698521	ENSG00000236529.1	RP13-254B10.1	5.42	1.55e-07	0.000144	0.36	0.34	Aortic root size;	chr7:66474502	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs1363055	ENSG00000236529.1	RP13-254B10.1	5.42	1.55e-07	0.000144	0.36	0.34	Aortic root size;	chr7:66478288	chr7:65840212~65840596:+
OV	cis	rs875971	0.964	rs9691480	ENSG00000236529.1	RP13-254B10.1	5.42	1.55e-07	0.000144	0.36	0.34	Aortic root size;	chr7:66479319	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs7789554	ENSG00000236529.1	RP13-254B10.1	5.42	1.55e-07	0.000144	0.36	0.34	Aortic root size;	chr7:66481051	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs4717300	ENSG00000236529.1	RP13-254B10.1	5.42	1.55e-07	0.000144	0.36	0.34	Aortic root size;	chr7:66482393	chr7:65840212~65840596:+
OV	cis	rs875971	0.895	rs1974769	ENSG00000236529.1	RP13-254B10.1	5.42	1.55e-07	0.000144	0.36	0.34	Aortic root size;	chr7:66485627	chr7:65840212~65840596:+
OV	cis	rs875971	0.895	rs6460300	ENSG00000236529.1	RP13-254B10.1	5.42	1.55e-07	0.000144	0.36	0.34	Aortic root size;	chr7:66487937	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs7803416	ENSG00000236529.1	RP13-254B10.1	5.42	1.55e-07	0.000144	0.36	0.34	Aortic root size;	chr7:66489212	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs1981798	ENSG00000236529.1	RP13-254B10.1	5.42	1.55e-07	0.000144	0.36	0.34	Aortic root size;	chr7:66489916	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs1981799	ENSG00000236529.1	RP13-254B10.1	5.42	1.55e-07	0.000144	0.36	0.34	Aortic root size;	chr7:66490572	chr7:65840212~65840596:+
OV	cis	rs875971	0.964	rs2277911	ENSG00000236529.1	RP13-254B10.1	5.42	1.55e-07	0.000144	0.36	0.34	Aortic root size;	chr7:66493638	chr7:65840212~65840596:+
OV	cis	rs4713118	0.662	rs149961	ENSG00000280107.1	AL022393.9	-5.41	1.56e-07	0.000144	-0.44	-0.34	Parkinson's disease;	chr6:28047791	chr6:28170845~28172521:+
OV	cis	rs7811142	0.83	rs6975660	ENSG00000242294.5	STAG3L5P	5.41	1.56e-07	0.000144	0.36	0.34	Platelet count;	chr7:100377643	chr7:100336079~100351900:+
OV	cis	rs7811142	0.83	rs73401443	ENSG00000242294.5	STAG3L5P	5.41	1.56e-07	0.000144	0.36	0.34	Platelet count;	chr7:100379959	chr7:100336079~100351900:+
OV	cis	rs7811142	0.83	rs10085549	ENSG00000242294.5	STAG3L5P	5.41	1.56e-07	0.000144	0.36	0.34	Platelet count;	chr7:100385512	chr7:100336079~100351900:+
OV	cis	rs34375054	0.66	rs12578446	ENSG00000279233.1	RP11-158L12.4	5.41	1.56e-07	0.000145	0.3	0.34	Post bronchodilator FEV1/FVC ratio;	chr12:125121341	chr12:125138245~125141711:+
OV	cis	rs11723261	0.582	rs6599293	ENSG00000275426.1	CH17-262A2.1	5.41	1.57e-07	0.000145	0.52	0.34	Immune response to smallpox vaccine (IL-6);	chr4:139246	chr4:149738~150317:+
OV	cis	rs11920570	0.526	rs3828362	ENSG00000272758.4	RP11-299J3.8	5.41	1.58e-07	0.000146	0.31	0.34	Resting heart rate;	chr3:122412930	chr3:122416207~122443180:+
OV	cis	rs62355901	0.83	rs12653202	ENSG00000271828.1	CTD-2310F14.1	5.41	1.59e-07	0.000147	0.54	0.34	Breast cancer;	chr5:56721091	chr5:56927874~56929573:+
OV	cis	rs957448	1	rs2381885	ENSG00000253704.1	RP11-267M23.4	5.41	1.59e-07	0.000147	0.45	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94499974	chr8:94553722~94569745:+
OV	cis	rs172166	0.694	rs2791332	ENSG00000219392.1	RP1-265C24.5	-5.41	1.59e-07	0.000147	-0.4	-0.34	Cardiac Troponin-T levels;	chr6:28141010	chr6:28115628~28116551:+
OV	cis	rs7617773	0.817	rs6800492	ENSG00000228638.1	FCF1P2	-5.41	1.59e-07	0.000147	-0.41	-0.34	Coronary artery disease;	chr3:48282400	chr3:48290793~48291375:-
OV	cis	rs9291683	0.62	rs4444830	ENSG00000250413.1	RP11-448G15.1	5.41	1.59e-07	0.000147	0.39	0.34	Bone mineral density;	chr4:10123195	chr4:10006482~10009725:+
OV	cis	rs11603023	0.772	rs540800	ENSG00000255422.1	AP002954.4	-5.41	1.59e-07	0.000147	-0.36	-0.34	Cholesterol, total;	chr11:118694942	chr11:118704607~118750263:+
OV	cis	rs7829975	0.514	rs2979151	ENSG00000253981.4	ALG1L13P	-5.41	1.6e-07	0.000148	-0.34	-0.34	Mood instability;	chr8:8400509	chr8:8236003~8244667:-
OV	cis	rs8062405	0.722	rs3785354	ENSG00000259982.1	CDC37P1	5.41	1.6e-07	0.000148	0.42	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28700294~28701540:-
OV	cis	rs7302981	0.934	rs7294548	ENSG00000272368.2	RP4-605O3.4	-5.41	1.6e-07	0.000148	-0.38	-0.34	Systolic blood pressure;	chr12:50149418	chr12:50112197~50165618:+
OV	cis	rs7302981	0.967	rs6580729	ENSG00000272368.2	RP4-605O3.4	5.41	1.6e-07	0.000148	0.38	0.34	Systolic blood pressure;	chr12:50153255	chr12:50112197~50165618:+
OV	cis	rs7302981	0.967	rs11831413	ENSG00000272368.2	RP4-605O3.4	5.41	1.6e-07	0.000148	0.38	0.34	Systolic blood pressure;	chr12:50156600	chr12:50112197~50165618:+
OV	cis	rs4805272	0.512	rs4805278	ENSG00000267243.4	AC005307.3	-5.41	1.6e-07	0.000148	-0.61	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28845757	chr19:28435388~28727777:-
OV	cis	rs1891275	0.515	rs6583784	ENSG00000228701.1	TNKS2-AS1	5.41	1.6e-07	0.000148	0.36	0.34	Intelligence (multi-trait analysis);	chr10:91731819	chr10:91782839~91798291:-
OV	cis	rs293748	0.54	rs12655320	ENSG00000250155.1	CTD-2353F22.1	-5.41	1.6e-07	0.000148	-0.47	-0.34	Obesity-related traits;	chr5:37104756	chr5:36666214~36725195:-
OV	cis	rs2492286	0.518	rs2712418	ENSG00000277250.1	Metazoa_SRP	-5.41	1.61e-07	0.000148	-0.42	-0.34	Eosinophil counts;	chr3:128624793	chr3:128673681~128674021:-
OV	cis	rs7811142	0.83	rs11769057	ENSG00000242294.5	STAG3L5P	5.41	1.61e-07	0.000148	0.35	0.34	Platelet count;	chr7:100367038	chr7:100336079~100351900:+
OV	cis	rs2688608	0.592	rs3933085	ENSG00000271816.1	BMS1P4	5.41	1.61e-07	0.000149	0.32	0.34	Inflammatory bowel disease;	chr10:73723573	chr10:73699151~73730487:-
OV	cis	rs2688608	0.592	rs7909544	ENSG00000271816.1	BMS1P4	5.41	1.61e-07	0.000149	0.32	0.34	Inflammatory bowel disease;	chr10:73724246	chr10:73699151~73730487:-
OV	cis	rs2688608	0.592	rs10762559	ENSG00000271816.1	BMS1P4	5.41	1.62e-07	0.000149	0.32	0.34	Inflammatory bowel disease;	chr10:73726695	chr10:73699151~73730487:-
OV	cis	rs7811142	0.83	rs11768967	ENSG00000242294.5	STAG3L5P	5.41	1.62e-07	0.00015	0.35	0.34	Platelet count;	chr7:100370021	chr7:100336079~100351900:+
OV	cis	rs7811142	0.83	rs7792959	ENSG00000242294.5	STAG3L5P	5.41	1.62e-07	0.00015	0.35	0.34	Platelet count;	chr7:100374780	chr7:100336079~100351900:+
OV	cis	rs496547	0.721	rs2508570	ENSG00000255239.1	AP002954.6	5.41	1.63e-07	0.00015	0.4	0.34	Hip minimal joint space width;	chr11:118807900	chr11:118688039~118690600:-
OV	cis	rs496547	0.686	rs591756	ENSG00000255239.1	AP002954.6	5.41	1.63e-07	0.00015	0.4	0.34	Hip minimal joint space width;	chr11:118808172	chr11:118688039~118690600:-
OV	cis	rs10510102	0.935	rs78525391	ENSG00000276742.1	RP11-500G22.4	5.41	1.63e-07	0.00015	0.55	0.34	Breast cancer;	chr10:121901102	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs4627017	ENSG00000276742.1	RP11-500G22.4	5.41	1.63e-07	0.00015	0.55	0.34	Breast cancer;	chr10:121901878	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs7098562	ENSG00000276742.1	RP11-500G22.4	5.41	1.63e-07	0.00015	0.55	0.34	Breast cancer;	chr10:121902148	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs7098822	ENSG00000276742.1	RP11-500G22.4	5.41	1.63e-07	0.00015	0.55	0.34	Breast cancer;	chr10:121902157	chr10:121956782~121957098:+
OV	cis	rs10510102	0.81	rs11200240	ENSG00000276742.1	RP11-500G22.4	5.41	1.63e-07	0.00015	0.55	0.34	Breast cancer;	chr10:121903265	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs74914751	ENSG00000276742.1	RP11-500G22.4	5.41	1.63e-07	0.00015	0.55	0.34	Breast cancer;	chr10:121904496	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs11200242	ENSG00000276742.1	RP11-500G22.4	5.41	1.63e-07	0.00015	0.55	0.34	Breast cancer;	chr10:121905378	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs12246704	ENSG00000276742.1	RP11-500G22.4	5.41	1.63e-07	0.00015	0.55	0.34	Breast cancer;	chr10:121906165	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs11200243	ENSG00000276742.1	RP11-500G22.4	5.41	1.63e-07	0.00015	0.55	0.34	Breast cancer;	chr10:121906888	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs11200244	ENSG00000276742.1	RP11-500G22.4	5.41	1.63e-07	0.00015	0.55	0.34	Breast cancer;	chr10:121906944	chr10:121956782~121957098:+
OV	cis	rs875971	0.545	rs1796226	ENSG00000226824.5	RP4-756H11.3	-5.41	1.63e-07	0.000151	-0.4	-0.34	Aortic root size;	chr7:66622723	chr7:66654538~66669855:+
OV	cis	rs67180937	0.553	rs2936020	ENSG00000272750.1	RP11-378J18.8	5.41	1.64e-07	0.000151	0.43	0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222655754	chr1:222658867~222661512:-
OV	cis	rs7429990	0.965	rs319689	ENSG00000229759.1	MRPS18AP1	5.4	1.64e-07	0.000151	0.35	0.34	Educational attainment (years of education);	chr3:47886677	chr3:48256350~48256938:-
OV	cis	rs4660456	0.913	rs545218	ENSG00000237899.1	RP4-739H11.3	5.4	1.64e-07	0.000151	0.51	0.34	Platelet count;	chr1:40675313	chr1:40669089~40687588:-
OV	cis	rs3931020	0.688	rs405445	ENSG00000272864.1	RP11-17E13.2	5.4	1.64e-07	0.000151	0.47	0.34	Resistin levels;	chr1:74755466	chr1:74698769~74699333:-
OV	cis	rs7605378	0.752	rs769960	ENSG00000232732.8	AC073043.1	5.4	1.64e-07	0.000152	0.42	0.34	Osteoporosis;	chr2:199845983	chr2:199867396~199911159:-
OV	cis	rs3931020	0.688	rs277375	ENSG00000272864.1	RP11-17E13.2	-5.4	1.65e-07	0.000152	-0.46	-0.34	Resistin levels;	chr1:74738459	chr1:74698769~74699333:-
OV	cis	rs2333194	0.875	rs10220356	ENSG00000258695.2	RP3-414A15.2	5.4	1.65e-07	0.000152	0.37	0.34	Bipolar disorder with mood-incongruent psychosis;	chr14:73342768	chr14:73522878~73530610:+
OV	cis	rs73019876	0.502	rs1978718	ENSG00000269742.1	BNIP3P29	-5.4	1.65e-07	0.000152	-0.39	-0.34	Testicular germ cell tumor;	chr19:22110324	chr19:22065828~22066398:-
OV	cis	rs611744	0.647	rs7015240	ENSG00000253754.1	RP11-35G22.1	-5.4	1.65e-07	0.000152	-0.37	-0.34	Dupuytren's disease;	chr8:108249975	chr8:108226200~108227544:+
OV	cis	rs11763147	1	rs11763147	ENSG00000224316.1	RP11-479O9.2	-5.4	1.65e-07	0.000152	-0.35	-0.34	Corneal structure;	chr7:65861834	chr7:65773620~65802067:+
OV	cis	rs34779708	0.931	rs12776390	ENSG00000230534.5	RP11-297A16.2	5.4	1.65e-07	0.000152	0.44	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35102607	chr10:35098006~35127020:-
OV	cis	rs858239	0.601	rs73272048	ENSG00000230042.1	AK3P3	-5.4	1.66e-07	0.000153	-0.35	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23113034	chr7:23129178~23129841:+
OV	cis	rs62355900	0.627	rs61243567	ENSG00000271828.1	CTD-2310F14.1	5.4	1.66e-07	0.000153	0.61	0.34	Endometriosis;	chr5:56867986	chr5:56927874~56929573:+
OV	cis	rs11690935	0.632	rs1607254	ENSG00000228389.1	AC068039.4	-5.4	1.66e-07	0.000153	-0.38	-0.34	Schizophrenia;	chr2:171770042	chr2:171773482~171775844:+
OV	cis	rs6991838	0.584	rs7812446	ENSG00000200714.1	Y_RNA	-5.4	1.67e-07	0.000153	-0.43	-0.34	Intelligence (multi-trait analysis);	chr8:65593753	chr8:65592731~65592820:+
OV	cis	rs6991838	0.557	rs7812390	ENSG00000200714.1	Y_RNA	-5.4	1.67e-07	0.000153	-0.43	-0.34	Intelligence (multi-trait analysis);	chr8:65593982	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs16932245	ENSG00000200714.1	Y_RNA	-5.4	1.67e-07	0.000153	-0.43	-0.34	Intelligence (multi-trait analysis);	chr8:65597810	chr8:65592731~65592820:+
OV	cis	rs6991838	0.557	rs57419568	ENSG00000200714.1	Y_RNA	-5.4	1.67e-07	0.000153	-0.43	-0.34	Intelligence (multi-trait analysis);	chr8:65598633	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs16932250	ENSG00000200714.1	Y_RNA	-5.4	1.67e-07	0.000153	-0.43	-0.34	Intelligence (multi-trait analysis);	chr8:65598779	chr8:65592731~65592820:+
OV	cis	rs8105895	1	rs62112907	ENSG00000269742.1	BNIP3P29	5.4	1.67e-07	0.000154	0.53	0.34	Body mass index (change over time);	chr19:22026767	chr19:22065828~22066398:-
OV	cis	rs8105895	0.866	rs62112908	ENSG00000269742.1	BNIP3P29	5.4	1.67e-07	0.000154	0.53	0.34	Body mass index (change over time);	chr19:22031154	chr19:22065828~22066398:-
OV	cis	rs8105895	0.932	rs60548522	ENSG00000269742.1	BNIP3P29	5.4	1.67e-07	0.000154	0.53	0.34	Body mass index (change over time);	chr19:22032072	chr19:22065828~22066398:-
OV	cis	rs8105895	1	rs8105895	ENSG00000269742.1	BNIP3P29	5.4	1.67e-07	0.000154	0.53	0.34	Body mass index (change over time);	chr19:22032655	chr19:22065828~22066398:-
OV	cis	rs4805272	1	rs6509067	ENSG00000267243.4	AC005307.3	5.4	1.67e-07	0.000154	0.45	0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28835172	chr19:28435388~28727777:-
OV	cis	rs611744	0.647	rs615126	ENSG00000253754.1	RP11-35G22.1	-5.4	1.67e-07	0.000154	-0.38	-0.34	Dupuytren's disease;	chr8:108235390	chr8:108226200~108227544:+
OV	cis	rs611744	0.647	rs589347	ENSG00000253754.1	RP11-35G22.1	-5.4	1.67e-07	0.000154	-0.38	-0.34	Dupuytren's disease;	chr8:108241700	chr8:108226200~108227544:+
OV	cis	rs611744	0.647	rs615233	ENSG00000253754.1	RP11-35G22.1	-5.4	1.67e-07	0.000154	-0.38	-0.34	Dupuytren's disease;	chr8:108242033	chr8:108226200~108227544:+
OV	cis	rs611744	0.631	rs627392	ENSG00000253754.1	RP11-35G22.1	-5.4	1.67e-07	0.000154	-0.38	-0.34	Dupuytren's disease;	chr8:108242448	chr8:108226200~108227544:+
OV	cis	rs611744	0.647	rs579162	ENSG00000253754.1	RP11-35G22.1	-5.4	1.67e-07	0.000154	-0.38	-0.34	Dupuytren's disease;	chr8:108242613	chr8:108226200~108227544:+
OV	cis	rs853679	0.517	rs9357063	ENSG00000280107.1	AL022393.9	-5.4	1.67e-07	0.000154	-0.42	-0.34	Depression;	chr6:28092227	chr6:28170845~28172521:+
OV	cis	rs858239	0.601	rs15775	ENSG00000230042.1	AK3P3	-5.4	1.68e-07	0.000154	-0.35	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23125082	chr7:23129178~23129841:+
OV	cis	rs2153535	0.518	rs9392232	ENSG00000230939.1	RP11-314C16.1	-5.4	1.68e-07	0.000154	-0.38	-0.34	Motion sickness;	chr6:8636211	chr6:8784178~8785445:+
OV	cis	rs611744	0.87	rs650925	ENSG00000253754.1	RP11-35G22.1	-5.4	1.68e-07	0.000154	-0.39	-0.34	Dupuytren's disease;	chr8:108184496	chr8:108226200~108227544:+
OV	cis	rs17301013	0.507	rs2142864	ENSG00000227373.4	RP11-160H22.5	5.4	1.68e-07	0.000154	0.45	0.34	Systemic lupus erythematosus;	chr1:174304924	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs2860909	ENSG00000227373.4	RP11-160H22.5	5.4	1.68e-07	0.000154	0.45	0.34	Systemic lupus erythematosus;	chr1:174305211	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs6700482	ENSG00000227373.4	RP11-160H22.5	5.4	1.68e-07	0.000154	0.45	0.34	Systemic lupus erythematosus;	chr1:174306699	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs7553317	ENSG00000227373.4	RP11-160H22.5	5.4	1.68e-07	0.000154	0.45	0.34	Systemic lupus erythematosus;	chr1:174307182	chr1:174115300~174160004:-
OV	cis	rs853679	0.517	rs7755442	ENSG00000280107.1	AL022393.9	-5.4	1.68e-07	0.000154	-0.42	-0.34	Depression;	chr6:28071237	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs12174753	ENSG00000280107.1	AL022393.9	-5.4	1.68e-07	0.000154	-0.42	-0.34	Depression;	chr6:28074687	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs55747925	ENSG00000280107.1	AL022393.9	-5.4	1.68e-07	0.000154	-0.42	-0.34	Depression;	chr6:28076559	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs56310871	ENSG00000280107.1	AL022393.9	-5.4	1.68e-07	0.000154	-0.42	-0.34	Depression;	chr6:28076704	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs34716816	ENSG00000280107.1	AL022393.9	-5.4	1.68e-07	0.000154	-0.42	-0.34	Depression;	chr6:28078391	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9393884	ENSG00000280107.1	AL022393.9	-5.4	1.68e-07	0.000154	-0.42	-0.34	Depression;	chr6:28079011	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9380049	ENSG00000280107.1	AL022393.9	-5.4	1.68e-07	0.000154	-0.42	-0.34	Depression;	chr6:28080757	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9380050	ENSG00000280107.1	AL022393.9	-5.4	1.68e-07	0.000154	-0.42	-0.34	Depression;	chr6:28080760	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9393885	ENSG00000280107.1	AL022393.9	-5.4	1.68e-07	0.000154	-0.42	-0.34	Depression;	chr6:28082231	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9393886	ENSG00000280107.1	AL022393.9	-5.4	1.68e-07	0.000154	-0.42	-0.34	Depression;	chr6:28082261	chr6:28170845~28172521:+
OV	cis	rs4713118	0.515	rs9368549	ENSG00000280107.1	AL022393.9	-5.4	1.68e-07	0.000154	-0.42	-0.34	Parkinson's disease;	chr6:28082269	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs56364346	ENSG00000280107.1	AL022393.9	-5.4	1.68e-07	0.000154	-0.42	-0.34	Depression;	chr6:28082984	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9357061	ENSG00000280107.1	AL022393.9	-5.4	1.68e-07	0.000154	-0.42	-0.34	Depression;	chr6:28083994	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9368550	ENSG00000280107.1	AL022393.9	-5.4	1.68e-07	0.000154	-0.42	-0.34	Depression;	chr6:28084025	chr6:28170845~28172521:+
OV	cis	rs853679	0.542	rs2295594	ENSG00000280107.1	AL022393.9	-5.4	1.68e-07	0.000154	-0.42	-0.34	Depression;	chr6:28085319	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs4711164	ENSG00000280107.1	AL022393.9	-5.4	1.69e-07	0.000155	-0.44	-0.34	Depression;	chr6:28147378	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs4711165	ENSG00000280107.1	AL022393.9	-5.4	1.69e-07	0.000155	-0.44	-0.34	Depression;	chr6:28147406	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs4713148	ENSG00000280107.1	AL022393.9	-5.4	1.69e-07	0.000155	-0.44	-0.34	Depression;	chr6:28148143	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9348794	ENSG00000280107.1	AL022393.9	-5.4	1.69e-07	0.000155	-0.44	-0.34	Depression;	chr6:28149979	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9468297	ENSG00000280107.1	AL022393.9	-5.4	1.69e-07	0.000155	-0.44	-0.34	Depression;	chr6:28151096	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9295758	ENSG00000280107.1	AL022393.9	-5.4	1.69e-07	0.000155	-0.44	-0.34	Depression;	chr6:28152885	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs17774663	ENSG00000280107.1	AL022393.9	-5.4	1.69e-07	0.000155	-0.44	-0.34	Depression;	chr6:28153120	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9468298	ENSG00000280107.1	AL022393.9	-5.4	1.69e-07	0.000155	-0.44	-0.34	Depression;	chr6:28154567	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9295759	ENSG00000280107.1	AL022393.9	-5.4	1.69e-07	0.000155	-0.44	-0.34	Depression;	chr6:28156691	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9348796	ENSG00000280107.1	AL022393.9	-5.4	1.69e-07	0.000155	-0.44	-0.34	Depression;	chr6:28158424	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs11552219	ENSG00000280107.1	AL022393.9	-5.4	1.69e-07	0.000155	-0.44	-0.34	Depression;	chr6:28159056	chr6:28170845~28172521:+
OV	cis	rs5742933	0.817	rs3816196	ENSG00000253559.1	OSGEPL1-AS1	5.4	1.69e-07	0.000155	0.34	0.34	Ferritin levels;	chr2:189775749	chr2:189762704~189765556:+
OV	cis	rs11673344	0.864	rs1879497	ENSG00000226686.6	LINC01535	5.4	1.69e-07	0.000155	0.44	0.34	Obesity-related traits;	chr19:37141975	chr19:37251912~37265535:+
OV	cis	rs13178541	0.578	rs10463942	ENSG00000250378.1	RP11-119J18.1	-5.4	1.69e-07	0.000155	-0.47	-0.34	IgG glycosylation;	chr5:135803482	chr5:135812667~135826582:+
OV	cis	rs853679	0.55	rs1233699	ENSG00000280107.1	AL022393.9	-5.4	1.69e-07	0.000155	-0.43	-0.34	Depression;	chr6:28201380	chr6:28170845~28172521:+
OV	cis	rs9660180	0.967	rs61422524	ENSG00000268575.1	RP1-283E3.8	-5.4	1.69e-07	0.000155	-0.31	-0.34	Body mass index;	chr1:1836126	chr1:1702736~1737688:-
OV	cis	rs611744	0.81	rs619227	ENSG00000253754.1	RP11-35G22.1	-5.4	1.69e-07	0.000155	-0.39	-0.34	Dupuytren's disease;	chr8:108202871	chr8:108226200~108227544:+
OV	cis	rs4713118	0.513	rs149962	ENSG00000220721.1	OR1F12	5.4	1.69e-07	0.000155	0.37	0.34	Parkinson's disease;	chr6:28048140	chr6:28073316~28074233:+
OV	cis	rs172166	0.769	rs149965	ENSG00000220721.1	OR1F12	5.4	1.69e-07	0.000155	0.37	0.34	Cardiac Troponin-T levels;	chr6:28050911	chr6:28073316~28074233:+
OV	cis	rs116095464	0.85	rs6896163	ENSG00000277812.1	AC021087.1	5.4	1.69e-07	0.000155	0.72	0.34	Breast cancer;	chr5:303571	chr5:262769~262881:+
OV	cis	rs116095464	1	rs6555159	ENSG00000277812.1	AC021087.1	5.4	1.69e-07	0.000155	0.72	0.34	Breast cancer;	chr5:311447	chr5:262769~262881:+
OV	cis	rs6991838	0.584	rs1053088	ENSG00000200714.1	Y_RNA	5.4	1.69e-07	0.000155	0.44	0.34	Intelligence (multi-trait analysis);	chr8:65603548	chr8:65592731~65592820:+
OV	cis	rs7017914	0.652	rs4532626	ENSG00000223220.1	Y_RNA	-5.4	1.69e-07	0.000155	-0.38	-0.34	Bone mineral density;	chr8:71032660	chr8:70780914~70781008:-
OV	cis	rs1729407	0.625	rs2727789	ENSG00000254851.1	RP11-109L13.1	-5.4	1.7e-07	0.000156	-0.43	-0.34	Apolipoprotein A-IV levels;	chr11:116826171	chr11:117135528~117138582:+
OV	cis	rs853679	0.517	rs9380058	ENSG00000280107.1	AL022393.9	-5.4	1.7e-07	0.000156	-0.44	-0.34	Depression;	chr6:28159666	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9393898	ENSG00000280107.1	AL022393.9	-5.4	1.7e-07	0.000156	-0.44	-0.34	Depression;	chr6:28162598	chr6:28170845~28172521:+
OV	cis	rs611744	0.805	rs396149	ENSG00000253754.1	RP11-35G22.1	-5.4	1.7e-07	0.000156	-0.38	-0.34	Dupuytren's disease;	chr8:108096512	chr8:108226200~108227544:+
OV	cis	rs12200782	0.53	rs6929908	ENSG00000241549.7	GUSBP2	5.4	1.7e-07	0.000156	0.4	0.34	Small cell lung carcinoma;	chr6:26555061	chr6:26871484~26956554:-
OV	cis	rs853679	0.517	rs1904840	ENSG00000280107.1	AL022393.9	-5.4	1.7e-07	0.000156	-0.43	-0.34	Depression;	chr6:28140454	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9368555	ENSG00000280107.1	AL022393.9	-5.4	1.7e-07	0.000156	-0.43	-0.34	Depression;	chr6:28141189	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9393893	ENSG00000280107.1	AL022393.9	-5.4	1.7e-07	0.000156	-0.43	-0.34	Depression;	chr6:28141484	chr6:28170845~28172521:+
OV	cis	rs4660456	0.711	rs12409109	ENSG00000237899.1	RP4-739H11.3	-5.4	1.7e-07	0.000156	-0.51	-0.34	Platelet count;	chr1:40727216	chr1:40669089~40687588:-
OV	cis	rs6991838	0.584	rs34494846	ENSG00000200714.1	Y_RNA	-5.4	1.71e-07	0.000156	-0.43	-0.34	Intelligence (multi-trait analysis);	chr8:65602397	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs1053087	ENSG00000200714.1	Y_RNA	-5.4	1.71e-07	0.000156	-0.43	-0.34	Intelligence (multi-trait analysis);	chr8:65603630	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs1053085	ENSG00000200714.1	Y_RNA	-5.4	1.71e-07	0.000156	-0.43	-0.34	Intelligence (multi-trait analysis);	chr8:65603753	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs4737747	ENSG00000200714.1	Y_RNA	-5.4	1.71e-07	0.000156	-0.43	-0.34	Intelligence (multi-trait analysis);	chr8:65607024	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs73236948	ENSG00000200714.1	Y_RNA	-5.4	1.71e-07	0.000156	-0.43	-0.34	Intelligence (multi-trait analysis);	chr8:65609176	chr8:65592731~65592820:+
OV	cis	rs7189233	0.531	rs8056349	ENSG00000279344.1	RP11-44F14.7	5.4	1.71e-07	0.000156	0.32	0.34	Intelligence (multi-trait analysis);	chr16:53434114	chr16:53478957~53481550:-
OV	cis	rs3931020	0.688	rs525487	ENSG00000272864.1	RP11-17E13.2	5.4	1.71e-07	0.000157	0.47	0.34	Resistin levels;	chr1:74751736	chr1:74698769~74699333:-
OV	cis	rs172166	0.694	rs1631552	ENSG00000219392.1	RP1-265C24.5	-5.39	1.73e-07	0.000158	-0.39	-0.34	Cardiac Troponin-T levels;	chr6:28121921	chr6:28115628~28116551:+
OV	cis	rs172166	0.694	rs536704	ENSG00000219392.1	RP1-265C24.5	-5.39	1.73e-07	0.000158	-0.39	-0.34	Cardiac Troponin-T levels;	chr6:28124825	chr6:28115628~28116551:+
OV	cis	rs2836974	0.565	rs2836939	ENSG00000232608.1	TIMM9P2	-5.39	1.73e-07	0.000159	-0.46	-0.34	Cognitive function;	chr21:39206620	chr21:39216624~39217506:+
OV	cis	rs7429990	0.965	rs4858881	ENSG00000229759.1	MRPS18AP1	-5.39	1.74e-07	0.000159	-0.35	-0.34	Educational attainment (years of education);	chr3:48082306	chr3:48256350~48256938:-
OV	cis	rs34779708	0.931	rs4934700	ENSG00000230534.5	RP11-297A16.2	5.39	1.74e-07	0.000159	0.44	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35021914	chr10:35098006~35127020:-
OV	cis	rs875971	0.545	rs12670811	ENSG00000236529.1	RP13-254B10.1	5.39	1.74e-07	0.000159	0.41	0.34	Aortic root size;	chr7:66358032	chr7:65840212~65840596:+
OV	cis	rs494459	0.726	rs1784300	ENSG00000278376.1	RP11-158I9.8	-5.39	1.74e-07	0.000159	-0.33	-0.34	Height;	chr11:118808920	chr11:118791254~118793137:+
OV	cis	rs62355901	0.505	rs17661089	ENSG00000271828.1	CTD-2310F14.1	5.39	1.75e-07	0.00016	0.64	0.34	Breast cancer;	chr5:56810169	chr5:56927874~56929573:+
OV	cis	rs7626444	0.625	rs9826214	ENSG00000272359.1	U4	-5.39	1.75e-07	0.00016	-0.33	-0.34	Monocyte count;	chr3:196751342	chr3:196747192~196747324:-
OV	cis	rs10246939	0.543	rs9640204	ENSG00000228775.6	WEE2-AS1	5.39	1.75e-07	0.00016	0.35	0.34	Bitter taste perception;	chr7:141844300	chr7:141704338~141738346:-
OV	cis	rs7615952	0.576	rs1127717	ENSG00000171084.14	FAM86JP	5.39	1.75e-07	0.00016	0.49	0.34	Blood pressure (smoking interaction);	chr3:126107216	chr3:125916620~125930024:+
OV	cis	rs2380205	0.504	rs591878	ENSG00000232807.2	RP11-536K7.3	5.39	1.75e-07	0.00016	0.35	0.34	Breast cancer;	chr10:5893474	chr10:5934270~5945900:-
OV	cis	rs858239	0.57	rs10271613	ENSG00000230042.1	AK3P3	-5.39	1.75e-07	0.00016	-0.35	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23122967	chr7:23129178~23129841:+
OV	cis	rs858239	0.57	rs10242166	ENSG00000230042.1	AK3P3	-5.39	1.75e-07	0.00016	-0.35	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23123180	chr7:23129178~23129841:+
OV	cis	rs1134634	0.52	rs10008889	ENSG00000273133.1	RP11-799M12.2	-5.39	1.75e-07	0.00016	-0.45	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15622896	chr4:15563698~15564253:-
OV	cis	rs1134634	0.52	rs75099653	ENSG00000273133.1	RP11-799M12.2	-5.39	1.75e-07	0.00016	-0.45	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15626397	chr4:15563698~15564253:-
OV	cis	rs1167827	0.68	rs1167796	ENSG00000278416.1	PMS2L2	-5.39	1.75e-07	0.00016	-0.49	-0.34	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75344015~75359550:-
OV	cis	rs67311347	1	rs66841330	ENSG00000223797.4	ENTPD3-AS1	5.39	1.76e-07	0.00016	0.41	0.34	Renal cell carcinoma;	chr3:40489632	chr3:40313802~40453329:-
OV	cis	rs10510102	0.516	rs10437506	ENSG00000276742.1	RP11-500G22.4	5.39	1.76e-07	0.00016	0.61	0.34	Breast cancer;	chr10:121984011	chr10:121956782~121957098:+
OV	cis	rs10510102	0.516	rs74461504	ENSG00000276742.1	RP11-500G22.4	5.39	1.76e-07	0.00016	0.61	0.34	Breast cancer;	chr10:121986077	chr10:121956782~121957098:+
OV	cis	rs10510102	0.516	rs61071865	ENSG00000276742.1	RP11-500G22.4	5.39	1.76e-07	0.00016	0.61	0.34	Breast cancer;	chr10:121986236	chr10:121956782~121957098:+
OV	cis	rs10510102	0.516	rs10159589	ENSG00000276742.1	RP11-500G22.4	5.39	1.76e-07	0.00016	0.61	0.34	Breast cancer;	chr10:121986659	chr10:121956782~121957098:+
OV	cis	rs11235843	0.759	rs3741147	ENSG00000255928.1	RP11-456I15.2	5.39	1.76e-07	0.000161	0.51	0.34	Hand grip strength;	chr11:73655706	chr11:73722349~73722694:+
OV	cis	rs853679	0.517	rs9380047	ENSG00000280107.1	AL022393.9	-5.39	1.77e-07	0.000161	-0.42	-0.34	Depression;	chr6:28070115	chr6:28170845~28172521:+
OV	cis	rs10934853	0.568	rs2977561	ENSG00000242551.2	POU5F1P6	5.39	1.77e-07	0.000161	0.44	0.34	Prostate cancer;Prostate cancer (SNP x SNP interaction);	chr3:128387693	chr3:128674735~128677005:-
OV	cis	rs10510102	0.872	rs10887003	ENSG00000276742.1	RP11-500G22.4	5.39	1.77e-07	0.000161	0.56	0.34	Breast cancer;	chr10:121864660	chr10:121956782~121957098:+
OV	cis	rs853679	0.517	rs9295761	ENSG00000280107.1	AL022393.9	-5.39	1.77e-07	0.000161	-0.44	-0.34	Depression;	chr6:28180209	chr6:28170845~28172521:+
OV	cis	rs7968440	0.715	rs7957659	ENSG00000272368.2	RP4-605O3.4	-5.39	1.77e-07	0.000161	-0.37	-0.34	Fibrinogen;	chr12:50245027	chr12:50112197~50165618:+
OV	cis	rs1075265	0.783	rs6545376	ENSG00000233266.1	HMGB1P31	5.39	1.77e-07	0.000162	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53987685	chr2:54051334~54051760:+
OV	cis	rs2665103	0.715	rs16973457	ENSG00000278603.1	RP13-608F4.5	5.39	1.78e-07	0.000162	0.37	0.34	Intelligence (multi-trait analysis);	chr15:82271650	chr15:82472203~82472426:+
OV	cis	rs67311347	0.955	rs73078170	ENSG00000223797.4	ENTPD3-AS1	5.39	1.78e-07	0.000162	0.38	0.34	Renal cell carcinoma;	chr3:40442456	chr3:40313802~40453329:-
OV	cis	rs806321	0.755	rs2765762	ENSG00000237152.3	DLEU7-AS1	-5.39	1.78e-07	0.000162	-0.38	-0.34	Multiple sclerosis;	chr13:50207120	chr13:50807856~50849905:+
OV	cis	rs758324	0.606	rs247276	ENSG00000230612.2	AC004237.1	-5.39	1.78e-07	0.000163	-0.42	-0.34	Alzheimer's disease in APOE e4- carriers;	chr5:132133311	chr5:132688681~132723725:+
OV	cis	rs34779708	0.931	rs7079205	ENSG00000230534.5	RP11-297A16.2	5.39	1.79e-07	0.000163	0.43	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35035691	chr10:35098006~35127020:-
OV	cis	rs172166	0.637	rs1071893	ENSG00000220721.1	OR1F12	5.39	1.79e-07	0.000163	0.38	0.34	Cardiac Troponin-T levels;	chr6:28199857	chr6:28073316~28074233:+
OV	cis	rs62355901	0.505	rs72758017	ENSG00000271828.1	CTD-2310F14.1	5.39	1.8e-07	0.000164	0.66	0.34	Breast cancer;	chr5:56797732	chr5:56927874~56929573:+
OV	cis	rs11235843	0.706	rs11235933	ENSG00000255928.1	RP11-456I15.2	-5.39	1.81e-07	0.000164	-0.53	-0.34	Hand grip strength;	chr11:73865703	chr11:73722349~73722694:+
OV	cis	rs853679	0.567	rs3799499	ENSG00000216901.1	AL022393.7	5.38	1.81e-07	0.000164	0.42	0.34	Depression;	chr6:28386473	chr6:28176188~28176674:+
OV	cis	rs10246939	0.579	rs35647444	ENSG00000228775.6	WEE2-AS1	5.38	1.81e-07	0.000164	0.35	0.34	Bitter taste perception;	chr7:141833957	chr7:141704338~141738346:-
OV	cis	rs8105895	1	rs11881224	ENSG00000269742.1	BNIP3P29	5.38	1.81e-07	0.000165	0.53	0.34	Body mass index (change over time);	chr19:22037538	chr19:22065828~22066398:-
OV	cis	rs1061377	0.513	rs6840214	ENSG00000249207.1	RP11-360F5.1	5.38	1.82e-07	0.000165	0.4	0.34	Uric acid levels;	chr4:39118999	chr4:39112677~39126818:-
OV	cis	rs957448	1	rs1048029	ENSG00000253704.1	RP11-267M23.4	5.38	1.82e-07	0.000165	0.45	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94510149	chr8:94553722~94569745:+
OV	cis	rs116095464	1	rs6873902	ENSG00000277812.1	AC021087.1	5.38	1.82e-07	0.000165	0.72	0.34	Breast cancer;	chr5:313222	chr5:262769~262881:+
OV	cis	rs8105895	1	rs75167249	ENSG00000269742.1	BNIP3P29	5.38	1.82e-07	0.000166	0.51	0.34	Body mass index (change over time);	chr19:21945853	chr19:22065828~22066398:-
OV	cis	rs957448	1	rs72674843	ENSG00000253704.1	RP11-267M23.4	5.38	1.82e-07	0.000166	0.45	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94520772	chr8:94553722~94569745:+
OV	cis	rs2286503	1	rs2286499	ENSG00000221740.1	SNORD93	5.38	1.82e-07	0.000166	0.39	0.34	Fibrinogen;	chr7:22817858	chr7:22856613~22856686:+
OV	cis	rs957448	1	rs12678305	ENSG00000253704.1	RP11-267M23.4	5.38	1.83e-07	0.000166	0.45	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94508911	chr8:94553722~94569745:+
OV	cis	rs957448	0.948	rs1470153	ENSG00000253704.1	RP11-267M23.4	5.38	1.83e-07	0.000166	0.45	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94514587	chr8:94553722~94569745:+
OV	cis	rs853679	0.517	rs9393895	ENSG00000280107.1	AL022393.9	-5.38	1.83e-07	0.000166	-0.44	-0.34	Depression;	chr6:28159843	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9357066	ENSG00000280107.1	AL022393.9	-5.38	1.83e-07	0.000166	-0.44	-0.34	Depression;	chr6:28162053	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9368556	ENSG00000280107.1	AL022393.9	-5.38	1.83e-07	0.000166	-0.44	-0.34	Depression;	chr6:28163375	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9368557	ENSG00000280107.1	AL022393.9	-5.38	1.83e-07	0.000166	-0.44	-0.34	Depression;	chr6:28163759	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9380059	ENSG00000280107.1	AL022393.9	-5.38	1.83e-07	0.000166	-0.44	-0.34	Depression;	chr6:28164580	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9380060	ENSG00000280107.1	AL022393.9	-5.38	1.83e-07	0.000166	-0.44	-0.34	Depression;	chr6:28164825	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs35227624	ENSG00000280107.1	AL022393.9	-5.38	1.83e-07	0.000166	-0.44	-0.34	Depression;	chr6:28164948	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9380061	ENSG00000280107.1	AL022393.9	-5.38	1.83e-07	0.000166	-0.44	-0.34	Depression;	chr6:28165025	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9368558	ENSG00000280107.1	AL022393.9	-5.38	1.83e-07	0.000166	-0.44	-0.34	Depression;	chr6:28165528	chr6:28170845~28172521:+
OV	cis	rs4713118	0.587	rs9393899	ENSG00000280107.1	AL022393.9	-5.38	1.83e-07	0.000166	-0.44	-0.34	Parkinson's disease;	chr6:28165750	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs4713150	ENSG00000280107.1	AL022393.9	-5.38	1.83e-07	0.000166	-0.44	-0.34	Depression;	chr6:28168434	chr6:28170845~28172521:+
OV	cis	rs4713118	0.527	rs4713151	ENSG00000280107.1	AL022393.9	-5.38	1.83e-07	0.000166	-0.44	-0.34	Parkinson's disease;	chr6:28168578	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9393901	ENSG00000280107.1	AL022393.9	-5.38	1.83e-07	0.000166	-0.44	-0.34	Depression;	chr6:28169019	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs3173443	ENSG00000280107.1	AL022393.9	-5.38	1.83e-07	0.000166	-0.44	-0.34	Depression;	chr6:28169249	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs4713152	ENSG00000280107.1	AL022393.9	-5.38	1.83e-07	0.000166	-0.44	-0.34	Depression;	chr6:28169676	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9348797	ENSG00000280107.1	AL022393.9	-5.38	1.83e-07	0.000166	-0.44	-0.34	Depression;	chr6:28169755	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9380062	ENSG00000280107.1	AL022393.9	-5.38	1.83e-07	0.000166	-0.44	-0.34	Depression;	chr6:28169791	chr6:28170845~28172521:+
OV	cis	rs853679	0.542	rs9380063	ENSG00000280107.1	AL022393.9	-5.38	1.83e-07	0.000166	-0.44	-0.34	Depression;	chr6:28170075	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs12332979	ENSG00000280107.1	AL022393.9	-5.38	1.83e-07	0.000166	-0.44	-0.34	Depression;	chr6:28173770	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs67878650	ENSG00000280107.1	AL022393.9	-5.38	1.83e-07	0.000166	-0.44	-0.34	Depression;	chr6:28174809	chr6:28170845~28172521:+
OV	cis	rs853679	0.569	rs9348798	ENSG00000280107.1	AL022393.9	-5.38	1.83e-07	0.000166	-0.44	-0.34	Depression;	chr6:28175233	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9380065	ENSG00000280107.1	AL022393.9	-5.38	1.83e-07	0.000166	-0.44	-0.34	Depression;	chr6:28176973	chr6:28170845~28172521:+
OV	cis	rs9291683	0.588	rs12647117	ENSG00000250413.1	RP11-448G15.1	-5.38	1.83e-07	0.000166	-0.38	-0.34	Bone mineral density;	chr4:10020435	chr4:10006482~10009725:+
OV	cis	rs9291683	0.551	rs2276961	ENSG00000250413.1	RP11-448G15.1	-5.38	1.83e-07	0.000166	-0.38	-0.34	Bone mineral density;	chr4:10021357	chr4:10006482~10009725:+
OV	cis	rs9291683	0.588	rs12506364	ENSG00000250413.1	RP11-448G15.1	-5.38	1.83e-07	0.000166	-0.38	-0.34	Bone mineral density;	chr4:10021824	chr4:10006482~10009725:+
OV	cis	rs7615952	0.599	rs67566088	ENSG00000171084.14	FAM86JP	5.38	1.83e-07	0.000166	0.49	0.34	Blood pressure (smoking interaction);	chr3:126050130	chr3:125916620~125930024:+
OV	cis	rs7615952	0.641	rs12495947	ENSG00000171084.14	FAM86JP	5.38	1.83e-07	0.000166	0.49	0.34	Blood pressure (smoking interaction);	chr3:126052855	chr3:125916620~125930024:+
OV	cis	rs7615952	0.641	rs6805074	ENSG00000171084.14	FAM86JP	5.38	1.83e-07	0.000166	0.49	0.34	Blood pressure (smoking interaction);	chr3:126053431	chr3:125916620~125930024:+
OV	cis	rs7615952	0.641	rs66520539	ENSG00000171084.14	FAM86JP	5.38	1.83e-07	0.000166	0.49	0.34	Blood pressure (smoking interaction);	chr3:126061531	chr3:125916620~125930024:+
OV	cis	rs73019876	0.502	rs28456336	ENSG00000269742.1	BNIP3P29	5.38	1.83e-07	0.000166	0.39	0.34	Testicular germ cell tumor;	chr19:22085977	chr19:22065828~22066398:-
OV	cis	rs34779708	0.897	rs35784065	ENSG00000230534.5	RP11-297A16.2	5.38	1.83e-07	0.000166	0.45	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35064646	chr10:35098006~35127020:-
OV	cis	rs7617773	0.817	rs9837228	ENSG00000228638.1	FCF1P2	5.38	1.84e-07	0.000167	0.42	0.34	Coronary artery disease;	chr3:48282976	chr3:48290793~48291375:-
OV	cis	rs4243830	0.85	rs1064835	ENSG00000229519.2	RP11-58A11.2	-5.38	1.84e-07	0.000167	-0.48	-0.34	Body mass index;	chr1:6525479	chr1:6547905~6548619:+
OV	cis	rs4908768	0.579	rs12137865	ENSG00000228423.2	RP4-633I8.4	5.38	1.84e-07	0.000167	0.37	0.34	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8808347	chr1:8805860~8807051:-
OV	cis	rs1387259	0.698	rs4579969	ENSG00000258273.1	RP11-370I10.4	5.38	1.85e-07	0.000167	0.37	0.34	Obstructive sleep apnea trait (apnea hypopnea index);	chr12:48385779	chr12:48333755~48333901:-
OV	cis	rs55726902	1	rs55726902	ENSG00000276691.1	RP5-1057I20.5	5.38	1.86e-07	0.000168	0.38	0.34	Allergic disease (asthma, hay fever or eczema);	chr12:47803199	chr12:47788426~47788971:+
OV	cis	rs7580658	0.75	rs4497825	ENSG00000236682.1	AC068282.3	-5.38	1.86e-07	0.000168	-0.42	-0.34	Protein C levels;	chr2:127303477	chr2:127389130~127400580:+
OV	cis	rs2380205	0.546	rs636578	ENSG00000232807.2	RP11-536K7.3	-5.38	1.86e-07	0.000168	-0.34	-0.34	Breast cancer;	chr10:5896581	chr10:5934270~5945900:-
OV	cis	rs875971	0.54	rs35510581	ENSG00000224316.1	RP11-479O9.2	-5.38	1.87e-07	0.00017	-0.35	-0.34	Aortic root size;	chr7:66113790	chr7:65773620~65802067:+
OV	cis	rs507080	0.733	rs7108144	ENSG00000278376.1	RP11-158I9.8	-5.38	1.88e-07	0.00017	-0.36	-0.34	Serum metabolite levels;	chr11:118698985	chr11:118791254~118793137:+
OV	cis	rs507080	0.663	rs523793	ENSG00000278376.1	RP11-158I9.8	-5.38	1.88e-07	0.00017	-0.36	-0.34	Serum metabolite levels;	chr11:118699988	chr11:118791254~118793137:+
OV	cis	rs507080	0.736	rs659564	ENSG00000278376.1	RP11-158I9.8	-5.38	1.88e-07	0.00017	-0.36	-0.34	Serum metabolite levels;	chr11:118700205	chr11:118791254~118793137:+
OV	cis	rs507080	0.736	rs642224	ENSG00000278376.1	RP11-158I9.8	-5.38	1.88e-07	0.00017	-0.36	-0.34	Serum metabolite levels;	chr11:118700210	chr11:118791254~118793137:+
OV	cis	rs507080	0.733	rs541631	ENSG00000278376.1	RP11-158I9.8	-5.38	1.88e-07	0.00017	-0.36	-0.34	Serum metabolite levels;	chr11:118700314	chr11:118791254~118793137:+
OV	cis	rs507080	0.736	rs658676	ENSG00000278376.1	RP11-158I9.8	-5.38	1.88e-07	0.00017	-0.36	-0.34	Serum metabolite levels;	chr11:118700414	chr11:118791254~118793137:+
OV	cis	rs507080	0.733	rs488141	ENSG00000278376.1	RP11-158I9.8	-5.38	1.88e-07	0.00017	-0.36	-0.34	Serum metabolite levels;	chr11:118700459	chr11:118791254~118793137:+
OV	cis	rs507080	0.733	rs657769	ENSG00000278376.1	RP11-158I9.8	-5.38	1.88e-07	0.00017	-0.36	-0.34	Serum metabolite levels;	chr11:118700607	chr11:118791254~118793137:+
OV	cis	rs507080	0.733	rs544452	ENSG00000278376.1	RP11-158I9.8	-5.38	1.88e-07	0.00017	-0.36	-0.34	Serum metabolite levels;	chr11:118700648	chr11:118791254~118793137:+
OV	cis	rs1150668	0.745	rs213238	ENSG00000220721.1	OR1F12	5.38	1.88e-07	0.00017	0.35	0.34	Pubertal anthropometrics;	chr6:28354216	chr6:28073316~28074233:+
OV	cis	rs67180937	0.553	rs1498382	ENSG00000272750.1	RP11-378J18.8	5.38	1.88e-07	0.00017	0.43	0.34	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222641495	chr1:222658867~222661512:-
OV	cis	rs858239	0.601	rs6980224	ENSG00000230042.1	AK3P3	-5.38	1.89e-07	0.000171	-0.34	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23109518	chr7:23129178~23129841:+
OV	cis	rs3931020	0.688	rs455032	ENSG00000272864.1	RP11-17E13.2	5.38	1.89e-07	0.000171	0.46	0.34	Resistin levels;	chr1:74730804	chr1:74698769~74699333:-
OV	cis	rs3931020	0.688	rs1051122	ENSG00000272864.1	RP11-17E13.2	-5.38	1.89e-07	0.000171	-0.46	-0.34	Resistin levels;	chr1:74724768	chr1:74698769~74699333:-
OV	cis	rs3931020	0.688	rs968358	ENSG00000272864.1	RP11-17E13.2	-5.38	1.89e-07	0.000171	-0.46	-0.34	Resistin levels;	chr1:74728305	chr1:74698769~74699333:-
OV	cis	rs950027	1	rs950027	ENSG00000259520.4	CTD-2651B20.3	5.38	1.89e-07	0.000171	0.4	0.34	Response to fenofibrate (adiponectin levels);	chr15:45508837	chr15:45251580~45279251:-
OV	cis	rs611744	0.905	rs610891	ENSG00000253754.1	RP11-35G22.1	5.38	1.89e-07	0.000171	0.37	0.34	Dupuytren's disease;	chr8:108148774	chr8:108226200~108227544:+
OV	cis	rs8040855	0.579	rs4843029	ENSG00000229212.6	RP11-561C5.4	-5.38	1.89e-07	0.000171	-0.41	-0.34	Bulimia nervosa;	chr15:85182164	chr15:85205440~85234795:-
OV	cis	rs957448	1	rs1023767	ENSG00000253704.1	RP11-267M23.4	5.38	1.89e-07	0.000171	0.44	0.34	Nonsyndromic cleft lip with cleft palate;	chr8:94518741	chr8:94553722~94569745:+
OV	cis	rs17741873	0.72	rs2227562	ENSG00000224195.1	RP11-574K11.5	5.38	1.9e-07	0.000171	0.51	0.34	Paclitaxel disposition in epithelial ovarian cancer;	chr10:73913203	chr10:73813518~73814737:+
OV	cis	rs2243480	1	rs35542501	ENSG00000222364.1	RNU6-96P	-5.38	1.9e-07	0.000171	-0.52	-0.34	Diabetic kidney disease;	chr7:65966228	chr7:66395191~66395286:+
OV	cis	rs8062405	0.789	rs180743	ENSG00000278665.1	RP11-666O2.4	5.38	1.9e-07	0.000171	0.36	0.34	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28496323	chr16:28599241~28601881:-
OV	cis	rs611744	0.837	rs399131	ENSG00000253754.1	RP11-35G22.1	5.38	1.9e-07	0.000171	0.37	0.34	Dupuytren's disease;	chr8:108093057	chr8:108226200~108227544:+
OV	cis	rs494459	0.838	rs555649	ENSG00000278376.1	RP11-158I9.8	-5.37	1.9e-07	0.000171	-0.32	-0.34	Height;	chr11:118781100	chr11:118791254~118793137:+
OV	cis	rs853679	0.517	rs9393894	ENSG00000280107.1	AL022393.9	-5.37	1.9e-07	0.000172	-0.43	-0.34	Depression;	chr6:28144784	chr6:28170845~28172521:+
OV	cis	rs8105895	1	rs2359820	ENSG00000269742.1	BNIP3P29	5.37	1.9e-07	0.000172	0.53	0.34	Body mass index (change over time);	chr19:22025312	chr19:22065828~22066398:-
OV	cis	rs34779708	0.931	rs4934724	ENSG00000230534.5	RP11-297A16.2	5.37	1.9e-07	0.000172	0.45	0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35104741	chr10:35098006~35127020:-
OV	cis	rs1134634	0.52	rs7682586	ENSG00000273133.1	RP11-799M12.2	-5.37	1.91e-07	0.000172	-0.45	-0.34	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15624620	chr4:15563698~15564253:-
OV	cis	rs7309	0.935	rs6432674	ENSG00000227403.1	AC009299.3	-5.37	1.91e-07	0.000172	-0.45	-0.34	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161168811	chr2:161244739~161249050:+
OV	cis	rs4713118	0.513	rs149975	ENSG00000220721.1	OR1F12	5.37	1.91e-07	0.000173	0.39	0.34	Parkinson's disease;	chr6:28018562	chr6:28073316~28074233:+
OV	cis	rs8105895	1	rs8100042	ENSG00000269742.1	BNIP3P29	5.37	1.92e-07	0.000173	0.5	0.34	Body mass index (change over time);	chr19:21945039	chr19:22065828~22066398:-
OV	cis	rs875971	0.545	rs1638735	ENSG00000236529.1	RP13-254B10.1	5.37	1.94e-07	0.000175	0.37	0.34	Aortic root size;	chr7:66630751	chr7:65840212~65840596:+
OV	cis	rs858239	0.601	rs12539331	ENSG00000230042.1	AK3P3	-5.37	1.94e-07	0.000175	-0.35	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23111711	chr7:23129178~23129841:+
OV	cis	rs853679	0.517	rs9283884	ENSG00000280107.1	AL022393.9	5.37	1.94e-07	0.000175	0.43	0.34	Depression;	chr6:28167882	chr6:28170845~28172521:+
OV	cis	rs4713118	0.662	rs175954	ENSG00000280107.1	AL022393.9	-5.37	1.94e-07	0.000175	-0.45	-0.34	Parkinson's disease;	chr6:28043807	chr6:28170845~28172521:+
OV	cis	rs10510102	0.872	rs12248004	ENSG00000226864.1	ATE1-AS1	5.37	1.95e-07	0.000176	0.59	0.34	Breast cancer;	chr10:121972215	chr10:121928312~121951965:+
OV	cis	rs11603023	0.625	rs633683	ENSG00000255422.1	AP002954.4	-5.37	1.95e-07	0.000176	-0.36	-0.34	Cholesterol, total;	chr11:118634025	chr11:118704607~118750263:+
OV	cis	rs17445774	1	rs17445774	ENSG00000232732.8	AC073043.1	5.37	1.95e-07	0.000176	0.42	0.34	LDL cholesterol to HDL cholesterol ratio;	chr2:199994526	chr2:199867396~199911159:-
OV	cis	rs67311347	1	rs73078162	ENSG00000223797.4	ENTPD3-AS1	5.37	1.96e-07	0.000176	0.38	0.34	Renal cell carcinoma;	chr3:40435618	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs73078163	ENSG00000223797.4	ENTPD3-AS1	5.37	1.96e-07	0.000176	0.38	0.34	Renal cell carcinoma;	chr3:40438467	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs1004655	ENSG00000223797.4	ENTPD3-AS1	5.37	1.96e-07	0.000176	0.38	0.34	Renal cell carcinoma;	chr3:40448518	chr3:40313802~40453329:-
OV	cis	rs7580658	0.614	rs2896888	ENSG00000236682.1	AC068282.3	-5.37	1.96e-07	0.000177	-0.43	-0.34	Protein C levels;	chr2:127208235	chr2:127389130~127400580:+
OV	cis	rs6700559	0.81	rs7529962	ENSG00000260088.1	RP11-92G12.3	-5.37	1.97e-07	0.000177	-0.34	-0.34	Coronary artery disease;	chr1:200627849	chr1:200669507~200694250:+
OV	cis	rs10510102	0.688	rs76573813	ENSG00000226864.1	ATE1-AS1	5.37	1.97e-07	0.000177	0.55	0.34	Breast cancer;	chr10:121928955	chr10:121928312~121951965:+
OV	cis	rs858239	0.601	rs10239760	ENSG00000230042.1	AK3P3	-5.37	1.97e-07	0.000177	-0.35	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23110331	chr7:23129178~23129841:+
OV	cis	rs8040855	0.599	rs6496792	ENSG00000229212.6	RP11-561C5.4	-5.37	1.97e-07	0.000177	-0.4	-0.34	Bulimia nervosa;	chr15:85182514	chr15:85205440~85234795:-
OV	cis	rs8040855	0.599	rs6496793	ENSG00000229212.6	RP11-561C5.4	-5.37	1.97e-07	0.000177	-0.4	-0.34	Bulimia nervosa;	chr15:85182515	chr15:85205440~85234795:-
OV	cis	rs8040855	0.599	rs6496795	ENSG00000229212.6	RP11-561C5.4	-5.37	1.97e-07	0.000177	-0.4	-0.34	Bulimia nervosa;	chr15:85182622	chr15:85205440~85234795:-
OV	cis	rs2188561	0.697	rs4730258	ENSG00000241764.3	AC002467.7	5.37	1.98e-07	0.000178	0.38	0.34	Alcohol consumption;	chr7:107755787	chr7:107742817~107744581:-
OV	cis	rs9291683	0.588	rs35866697	ENSG00000250413.1	RP11-448G15.1	-5.37	1.98e-07	0.000178	-0.37	-0.34	Bone mineral density;	chr4:10016980	chr4:10006482~10009725:+
OV	cis	rs9291683	0.588	rs35099040	ENSG00000250413.1	RP11-448G15.1	-5.37	1.98e-07	0.000178	-0.37	-0.34	Bone mineral density;	chr4:10017215	chr4:10006482~10009725:+
OV	cis	rs3931020	0.688	rs277396	ENSG00000272864.1	RP11-17E13.2	5.37	1.98e-07	0.000178	0.46	0.34	Resistin levels;	chr1:74747964	chr1:74698769~74699333:-
OV	cis	rs2006771	0.618	rs470072	ENSG00000236132.1	CTA-440B3.1	-5.37	1.99e-07	0.000178	-0.41	-0.34	Nonsyndromic cleft lip with cleft palate;	chr22:31867145	chr22:31816379~31817491:-
OV	cis	rs6772849	0.805	rs61159406	ENSG00000277250.1	Metazoa_SRP	-5.37	1.99e-07	0.000178	-0.39	-0.34	Monocyte percentage of white cells;Monocyte count;	chr3:128617166	chr3:128673681~128674021:-
OV	cis	rs6772849	0.805	rs13325747	ENSG00000277250.1	Metazoa_SRP	-5.37	1.99e-07	0.000178	-0.39	-0.34	Monocyte percentage of white cells;Monocyte count;	chr3:128617180	chr3:128673681~128674021:-
OV	cis	rs7428	0.527	rs1061782	ENSG00000246575.2	AC093162.5	-5.37	1.99e-07	0.000179	-0.33	-0.34	Ear protrusion;	chr2:85319492	chr2:85315041~85316529:+
OV	cis	rs4713118	0.513	rs149972	ENSG00000220721.1	OR1F12	5.37	1.99e-07	0.000179	0.38	0.34	Parkinson's disease;	chr6:28015449	chr6:28073316~28074233:+
OV	cis	rs7615952	0.546	rs2979307	ENSG00000171084.14	FAM86JP	-5.36	1.99e-07	0.000179	-0.53	-0.34	Blood pressure (smoking interaction);	chr3:125590730	chr3:125916620~125930024:+
OV	cis	rs34779708	0.966	rs7077242	ENSG00000230534.5	RP11-297A16.2	-5.36	2e-07	0.000179	-0.43	-0.34	Inflammatory bowel disease;Crohn's disease;	chr10:35193037	chr10:35098006~35127020:-
OV	cis	rs62388641	0.539	rs56304710	ENSG00000272279.1	RP11-157J24.2	5.36	2e-07	0.000179	0.43	0.34	Daytime sleep phenotypes;	chr6:1542341	chr6:1528364~1528911:-
OV	cis	rs11673344	0.526	rs35153242	ENSG00000226686.6	LINC01535	-5.36	2e-07	0.000179	-0.44	-0.34	Obesity-related traits;	chr19:37660841	chr19:37251912~37265535:+
OV	cis	rs7429990	0.965	rs2882668	ENSG00000229759.1	MRPS18AP1	5.36	2e-07	0.00018	0.35	0.34	Educational attainment (years of education);	chr3:47938816	chr3:48256350~48256938:-
OV	cis	rs67311347	1	rs9865348	ENSG00000223797.4	ENTPD3-AS1	5.36	2.01e-07	0.00018	0.37	0.34	Renal cell carcinoma;	chr3:40356167	chr3:40313802~40453329:-
OV	cis	rs7580658	0.817	rs6761447	ENSG00000236682.1	AC068282.3	-5.36	2.01e-07	0.00018	-0.43	-0.34	Protein C levels;	chr2:127316997	chr2:127389130~127400580:+
OV	cis	rs2487032	0.573	rs2164560	ENSG00000226334.1	RP11-217B7.2	-5.36	2.01e-07	0.00018	-0.42	-0.34	Glaucoma (high intraocular pressure);	chr9:104945072	chr9:104927553~104928892:+
OV	cis	rs875971	0.83	rs6976714	ENSG00000236529.1	RP13-254B10.1	5.36	2.01e-07	0.000181	0.35	0.34	Aortic root size;	chr7:66426474	chr7:65840212~65840596:+
OV	cis	rs7617773	0.779	rs11718329	ENSG00000228638.1	FCF1P2	-5.36	2.02e-07	0.000181	-0.41	-0.34	Coronary artery disease;	chr3:48268338	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs6442111	ENSG00000228638.1	FCF1P2	-5.36	2.02e-07	0.000181	-0.41	-0.34	Coronary artery disease;	chr3:48270570	chr3:48290793~48291375:-
OV	cis	rs7617773	0.851	rs6775179	ENSG00000228638.1	FCF1P2	-5.36	2.02e-07	0.000181	-0.41	-0.34	Coronary artery disease;	chr3:48271928	chr3:48290793~48291375:-
OV	cis	rs4908768	0.871	rs11121221	ENSG00000228423.2	RP4-633I8.4	5.36	2.02e-07	0.000181	0.38	0.34	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8707470	chr1:8805860~8807051:-
OV	cis	rs2833693	0.519	rs2833699	ENSG00000261610.1	AP000265.1	5.36	2.02e-07	0.000181	0.38	0.34	Temperament;	chr21:32184240	chr21:32259804~32261585:-
OV	cis	rs875971	0.651	rs2420596	ENSG00000236529.1	RP13-254B10.1	5.36	2.03e-07	0.000182	0.35	0.34	Aortic root size;	chr7:66450996	chr7:65840212~65840596:+
OV	cis	rs875971	0.52	rs2420597	ENSG00000236529.1	RP13-254B10.1	5.36	2.03e-07	0.000182	0.35	0.34	Aortic root size;	chr7:66450999	chr7:65840212~65840596:+
OV	cis	rs6471393	0.861	rs2976374	ENSG00000253848.1	RP11-10N23.5	5.36	2.04e-07	0.000182	0.39	0.34	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93691945	chr8:93741193~93744534:+
OV	cis	rs4805272	0.539	rs1075733	ENSG00000267243.4	AC005307.3	-5.36	2.04e-07	0.000183	-0.54	-0.34	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28833553	chr19:28435388~28727777:-
OV	cis	rs853679	0.517	rs4713146	ENSG00000280107.1	AL022393.9	-5.36	2.05e-07	0.000183	-0.43	-0.34	Depression;	chr6:28143758	chr6:28170845~28172521:+
OV	cis	rs7116641	0.734	rs12417393	ENSG00000246250.2	RP11-613D13.5	5.36	2.05e-07	0.000183	0.39	0.34	Coronary artery disease;	chr11:43854164	chr11:43829709~43880726:-
OV	cis	rs67311347	1	rs4571217	ENSG00000223797.4	ENTPD3-AS1	5.36	2.05e-07	0.000184	0.37	0.34	Renal cell carcinoma;	chr3:40480482	chr3:40313802~40453329:-
OV	cis	rs611744	0.87	rs672243	ENSG00000253754.1	RP11-35G22.1	-5.36	2.05e-07	0.000184	-0.38	-0.34	Dupuytren's disease;	chr8:108086514	chr8:108226200~108227544:+
OV	cis	rs1075265	0.749	rs10203095	ENSG00000233266.1	HMGB1P31	5.36	2.05e-07	0.000184	0.4	0.34	Chronotype;Morning vs. evening chronotype;	chr2:53737150	chr2:54051334~54051760:+
OV	cis	rs853679	0.517	rs3757187	ENSG00000280107.1	AL022393.9	-5.36	2.06e-07	0.000184	-0.43	-0.34	Depression;	chr6:28139876	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs3757185	ENSG00000280107.1	AL022393.9	-5.36	2.06e-07	0.000184	-0.43	-0.34	Depression;	chr6:28139998	chr6:28170845~28172521:+
OV	cis	rs611744	0.503	rs13282220	ENSG00000253754.1	RP11-35G22.1	-5.36	2.06e-07	0.000184	-0.39	-0.34	Dupuytren's disease;	chr8:108250814	chr8:108226200~108227544:+
OV	cis	rs2153535	0.585	rs7739573	ENSG00000230939.1	RP11-314C16.1	5.36	2.06e-07	0.000184	0.36	0.34	Motion sickness;	chr6:8659671	chr6:8784178~8785445:+
OV	cis	rs2880765	0.835	rs7180923	ENSG00000229212.6	RP11-561C5.4	5.36	2.06e-07	0.000184	0.39	0.34	Coronary artery disease;	chr15:85507659	chr15:85205440~85234795:-
OV	cis	rs875971	0.522	rs9530	ENSG00000224316.1	RP11-479O9.2	5.36	2.07e-07	0.000185	0.35	0.34	Aortic root size;	chr7:65960907	chr7:65773620~65802067:+
OV	cis	rs858239	0.601	rs3735228	ENSG00000230042.1	AK3P3	-5.36	2.07e-07	0.000185	-0.34	-0.34	Cerebrospinal fluid biomarker levels;	chr7:23130808	chr7:23129178~23129841:+
OV	cis	rs2906856	0.848	rs3015001	ENSG00000255733.4	IFNG-AS1	-5.36	2.07e-07	0.000185	-0.34	-0.34	Mosquito bite size;	chr12:68003593	chr12:67989445~68234686:+
OV	cis	rs816535	1	rs816535	ENSG00000274973.1	RP13-401N8.7	-5.36	2.08e-07	0.000185	-0.47	-0.33	Parkinson disease and lewy body pathology;	chr20:26275360	chr20:25845497~25845862:+
OV	cis	rs10934853	0.568	rs2977561	ENSG00000277250.1	Metazoa_SRP	5.36	2.08e-07	0.000185	0.44	0.33	Prostate cancer;Prostate cancer (SNP x SNP interaction);	chr3:128387693	chr3:128673681~128674021:-
OV	cis	rs7302981	1	rs7308356	ENSG00000272368.2	RP4-605O3.4	-5.36	2.08e-07	0.000186	-0.38	-0.33	Systolic blood pressure;	chr12:50145828	chr12:50112197~50165618:+
OV	cis	rs7302981	0.934	rs7301649	ENSG00000272368.2	RP4-605O3.4	-5.36	2.08e-07	0.000186	-0.38	-0.33	Systolic blood pressure;	chr12:50147087	chr12:50112197~50165618:+
OV	cis	rs34779708	0.931	rs4934711	ENSG00000230534.5	RP11-297A16.2	5.36	2.09e-07	0.000186	0.44	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35071382	chr10:35098006~35127020:-
OV	cis	rs611744	0.837	rs422847	ENSG00000253754.1	RP11-35G22.1	5.36	2.09e-07	0.000186	0.37	0.33	Dupuytren's disease;	chr8:108091046	chr8:108226200~108227544:+
OV	cis	rs4805272	0.512	rs17772319	ENSG00000267243.4	AC005307.3	-5.36	2.09e-07	0.000187	-0.61	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28852157	chr19:28435388~28727777:-
OV	cis	rs4805272	0.512	rs765484	ENSG00000267243.4	AC005307.3	-5.36	2.09e-07	0.000187	-0.61	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28853756	chr19:28435388~28727777:-
OV	cis	rs7017914	0.905	rs2732106	ENSG00000223220.1	Y_RNA	5.35	2.09e-07	0.000187	0.35	0.33	Bone mineral density;	chr8:71011604	chr8:70780914~70781008:-
OV	cis	rs10246939	0.543	rs9640359	ENSG00000228775.6	WEE2-AS1	5.35	2.1e-07	0.000187	0.35	0.33	Bitter taste perception;	chr7:141844399	chr7:141704338~141738346:-
OV	cis	rs7615952	0.512	rs2979334	ENSG00000171084.14	FAM86JP	5.35	2.1e-07	0.000187	0.5	0.33	Blood pressure (smoking interaction);	chr3:125639980	chr3:125916620~125930024:+
OV	cis	rs7615952	0.512	rs11921452	ENSG00000171084.14	FAM86JP	5.35	2.1e-07	0.000187	0.5	0.33	Blood pressure (smoking interaction);	chr3:125640906	chr3:125916620~125930024:+
OV	cis	rs116095464	0.558	rs6872854	ENSG00000250848.1	CTD-2083E4.5	-5.35	2.1e-07	0.000187	-0.41	-0.33	Breast cancer;	chr5:208923	chr5:288833~290321:-
OV	cis	rs1797885	1	rs2589673	ENSG00000251774.1	RNU6-377P	5.35	2.1e-07	0.000187	0.31	0.33	Immature fraction of reticulocytes;	chr3:12475002	chr3:12514706~12514807:+
OV	cis	rs4713118	0.539	rs200951	ENSG00000220721.1	OR1F12	5.35	2.1e-07	0.000187	0.36	0.33	Parkinson's disease;	chr6:27868152	chr6:28073316~28074233:+
OV	cis	rs7017914	0.905	rs3098870	ENSG00000223220.1	Y_RNA	5.35	2.11e-07	0.000187	0.35	0.33	Bone mineral density;	chr8:71017700	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs3110240	ENSG00000223220.1	Y_RNA	5.35	2.11e-07	0.000187	0.35	0.33	Bone mineral density;	chr8:71017869	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs3098873	ENSG00000223220.1	Y_RNA	5.35	2.11e-07	0.000187	0.35	0.33	Bone mineral density;	chr8:71020351	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs3110241	ENSG00000223220.1	Y_RNA	5.35	2.11e-07	0.000187	0.35	0.33	Bone mineral density;	chr8:71020729	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs3110242	ENSG00000223220.1	Y_RNA	5.35	2.11e-07	0.000187	0.35	0.33	Bone mineral density;	chr8:71020732	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs3110243	ENSG00000223220.1	Y_RNA	5.35	2.11e-07	0.000187	0.35	0.33	Bone mineral density;	chr8:71020834	chr8:70780914~70781008:-
OV	cis	rs7017914	0.87	rs3098874	ENSG00000223220.1	Y_RNA	5.35	2.11e-07	0.000187	0.35	0.33	Bone mineral density;	chr8:71022103	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs3110247	ENSG00000223220.1	Y_RNA	5.35	2.11e-07	0.000187	0.35	0.33	Bone mineral density;	chr8:71022652	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs3110248	ENSG00000223220.1	Y_RNA	5.35	2.11e-07	0.000187	0.35	0.33	Bone mineral density;	chr8:71022700	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs3110249	ENSG00000223220.1	Y_RNA	5.35	2.11e-07	0.000187	0.35	0.33	Bone mineral density;	chr8:71023310	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs3098876	ENSG00000223220.1	Y_RNA	5.35	2.11e-07	0.000187	0.35	0.33	Bone mineral density;	chr8:71024009	chr8:70780914~70781008:-
OV	cis	rs7017914	0.87	rs3098877	ENSG00000223220.1	Y_RNA	5.35	2.11e-07	0.000187	0.35	0.33	Bone mineral density;	chr8:71024211	chr8:70780914~70781008:-
OV	cis	rs7017914	0.875	rs3110251	ENSG00000223220.1	Y_RNA	5.35	2.11e-07	0.000187	0.35	0.33	Bone mineral density;	chr8:71024739	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs3110252	ENSG00000223220.1	Y_RNA	5.35	2.11e-07	0.000187	0.35	0.33	Bone mineral density;	chr8:71024985	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs3110253	ENSG00000223220.1	Y_RNA	5.35	2.11e-07	0.000187	0.35	0.33	Bone mineral density;	chr8:71025318	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs3110254	ENSG00000223220.1	Y_RNA	5.35	2.11e-07	0.000187	0.35	0.33	Bone mineral density;	chr8:71025627	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs3110255	ENSG00000223220.1	Y_RNA	5.35	2.11e-07	0.000187	0.35	0.33	Bone mineral density;	chr8:71025815	chr8:70780914~70781008:-
OV	cis	rs7017914	0.87	rs3110256	ENSG00000223220.1	Y_RNA	5.35	2.11e-07	0.000187	0.35	0.33	Bone mineral density;	chr8:71025901	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs3110257	ENSG00000223220.1	Y_RNA	5.35	2.11e-07	0.000187	0.35	0.33	Bone mineral density;	chr8:71025916	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs3098879	ENSG00000223220.1	Y_RNA	5.35	2.11e-07	0.000187	0.35	0.33	Bone mineral density;	chr8:71026225	chr8:70780914~70781008:-
OV	cis	rs7017914	0.935	rs3110258	ENSG00000223220.1	Y_RNA	5.35	2.11e-07	0.000187	0.35	0.33	Bone mineral density;	chr8:71026297	chr8:70780914~70781008:-
OV	cis	rs7017914	0.87	rs3098880	ENSG00000223220.1	Y_RNA	5.35	2.11e-07	0.000187	0.35	0.33	Bone mineral density;	chr8:71026686	chr8:70780914~70781008:-
OV	cis	rs7017914	0.905	rs3098881	ENSG00000223220.1	Y_RNA	5.35	2.11e-07	0.000187	0.35	0.33	Bone mineral density;	chr8:71027455	chr8:70780914~70781008:-
OV	cis	rs2688608	0.592	rs7080579	ENSG00000271816.1	BMS1P4	5.35	2.11e-07	0.000188	0.31	0.33	Inflammatory bowel disease;	chr10:73744271	chr10:73699151~73730487:-
OV	cis	rs875971	0.964	rs6945019	ENSG00000236529.1	RP13-254B10.1	5.35	2.11e-07	0.000188	0.35	0.33	Aortic root size;	chr7:66457471	chr7:65840212~65840596:+
OV	cis	rs992157	1	rs736730	ENSG00000237281.1	CATIP-AS2	-5.35	2.11e-07	0.000188	-0.39	-0.33	Colorectal cancer;	chr2:218255532	chr2:218326889~218357966:-
OV	cis	rs992157	1	rs736731	ENSG00000237281.1	CATIP-AS2	-5.35	2.11e-07	0.000188	-0.39	-0.33	Colorectal cancer;	chr2:218255865	chr2:218326889~218357966:-
OV	cis	rs992157	1	rs10932766	ENSG00000237281.1	CATIP-AS2	-5.35	2.11e-07	0.000188	-0.39	-0.33	Colorectal cancer;	chr2:218257367	chr2:218326889~218357966:-
OV	cis	rs992157	1	rs3731859	ENSG00000237281.1	CATIP-AS2	-5.35	2.11e-07	0.000188	-0.39	-0.33	Colorectal cancer;	chr2:218259499	chr2:218326889~218357966:-
OV	cis	rs992157	1	rs11554825	ENSG00000237281.1	CATIP-AS2	-5.35	2.11e-07	0.000188	-0.39	-0.33	Colorectal cancer;	chr2:218261086	chr2:218326889~218357966:-
OV	cis	rs10510102	0.935	rs7906667	ENSG00000276742.1	RP11-500G22.4	5.35	2.11e-07	0.000188	0.53	0.33	Breast cancer;	chr10:121909142	chr10:121956782~121957098:+
OV	cis	rs116095464	0.558	rs73031482	ENSG00000250848.1	CTD-2083E4.5	-5.35	2.11e-07	0.000188	-0.41	-0.33	Breast cancer;	chr5:227479	chr5:288833~290321:-
OV	cis	rs2833693	0.656	rs2833697	ENSG00000261610.1	AP000265.1	5.35	2.12e-07	0.000188	0.4	0.33	Temperament;	chr21:32183825	chr21:32259804~32261585:-
OV	cis	rs4713118	0.824	rs742046	ENSG00000219392.1	RP1-265C24.5	-5.35	2.12e-07	0.000188	-0.38	-0.33	Parkinson's disease;	chr6:27771475	chr6:28115628~28116551:+
OV	cis	rs61990749	0.597	rs28534379	ENSG00000239272.1	RPL21P10	-5.35	2.12e-07	0.000188	-0.47	-0.33	Fibroblast growth factor basic levels;	chr14:77705797	chr14:77683202~77683989:-
OV	cis	rs61990749	0.597	rs176944	ENSG00000239272.1	RPL21P10	-5.35	2.12e-07	0.000188	-0.47	-0.33	Fibroblast growth factor basic levels;	chr14:77709868	chr14:77683202~77683989:-
OV	cis	rs4061073	1	rs4061073	ENSG00000198711.5	SSBP3-AS1	5.35	2.12e-07	0.000189	0.26	0.33	Body mass index;	chr1:54231070	chr1:54236440~54239063:+
OV	cis	rs853679	0.517	rs9357065	ENSG00000280107.1	AL022393.9	-5.35	2.12e-07	0.000189	-0.44	-0.33	Depression;	chr6:28161802	chr6:28170845~28172521:+
OV	cis	rs4805272	0.512	rs4805279	ENSG00000267243.4	AC005307.3	-5.35	2.12e-07	0.000189	-0.6	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28846059	chr19:28435388~28727777:-
OV	cis	rs4805272	0.512	rs12373558	ENSG00000267243.4	AC005307.3	-5.35	2.12e-07	0.000189	-0.6	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28846785	chr19:28435388~28727777:-
OV	cis	rs2243480	1	rs4718269	ENSG00000222364.1	RNU6-96P	5.35	2.13e-07	0.000189	0.57	0.33	Diabetic kidney disease;	chr7:65735810	chr7:66395191~66395286:+
OV	cis	rs10510102	0.935	rs11200263	ENSG00000276742.1	RP11-500G22.4	5.35	2.13e-07	0.000189	0.55	0.33	Breast cancer;	chr10:121922836	chr10:121956782~121957098:+
OV	cis	rs8040855	0.599	rs6496800	ENSG00000229212.6	RP11-561C5.4	-5.35	2.13e-07	0.000189	-0.4	-0.33	Bulimia nervosa;	chr15:85185055	chr15:85205440~85234795:-
OV	cis	rs34779708	0.833	rs12777517	ENSG00000230534.5	RP11-297A16.2	5.35	2.13e-07	0.00019	0.44	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35184999	chr10:35098006~35127020:-
OV	cis	rs957448	1	rs2381882	ENSG00000253704.1	RP11-267M23.4	5.35	2.14e-07	0.00019	0.46	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94535496	chr8:94553722~94569745:+
OV	cis	rs1134634	0.52	rs4698408	ENSG00000273133.1	RP11-799M12.2	-5.35	2.14e-07	0.00019	-0.44	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15657425	chr4:15563698~15564253:-
OV	cis	rs1930961	0.85	rs5996945	ENSG00000271138.1	IGLVIVOR22-1	5.35	2.14e-07	0.00019	0.39	0.33	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25437306~25437823:-
OV	cis	rs301901	0.828	rs4308503	ENSG00000250155.1	CTD-2353F22.1	5.35	2.14e-07	0.00019	0.39	0.33	Height;	chr5:37454091	chr5:36666214~36725195:-
OV	cis	rs7580658	0.857	rs2896980	ENSG00000236682.1	AC068282.3	-5.35	2.14e-07	0.00019	-0.43	-0.33	Protein C levels;	chr2:127382383	chr2:127389130~127400580:+
OV	cis	rs11690935	0.632	rs6723259	ENSG00000228389.1	AC068039.4	-5.35	2.14e-07	0.00019	-0.38	-0.33	Schizophrenia;	chr2:171766017	chr2:171773482~171775844:+
OV	cis	rs6940638	0.513	rs4424065	ENSG00000243307.2	POM121L6P	-5.35	2.14e-07	0.00019	-0.33	-0.33	Intelligence (multi-trait analysis);	chr6:27068677	chr6:26896952~26898777:+
OV	cis	rs7302981	0.967	rs12815871	ENSG00000272368.2	RP4-605O3.4	5.35	2.15e-07	0.00019	0.38	0.33	Systolic blood pressure;	chr12:50157165	chr12:50112197~50165618:+
OV	cis	rs801193	1	rs2055682	ENSG00000236529.1	RP13-254B10.1	5.35	2.15e-07	0.00019	0.35	0.33	Aortic root size;	chr7:66795302	chr7:65840212~65840596:+
OV	cis	rs9291683	0.585	rs12648479	ENSG00000250413.1	RP11-448G15.1	5.35	2.15e-07	0.000191	0.37	0.33	Bone mineral density;	chr4:10102947	chr4:10006482~10009725:+
OV	cis	rs858239	0.601	rs764534	ENSG00000230042.1	AK3P3	-5.35	2.15e-07	0.000191	-0.35	-0.33	Cerebrospinal fluid biomarker levels;	chr7:23114316	chr7:23129178~23129841:+
OV	cis	rs1790761	0.658	rs684928	ENSG00000184224.3	C11orf72	5.35	2.15e-07	0.000191	0.38	0.33	Mean corpuscular volume;	chr11:67562271	chr11:67602880~67606706:-
OV	cis	rs34779708	0.931	rs1926556	ENSG00000230534.5	RP11-297A16.2	5.35	2.16e-07	0.000191	0.45	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35055979	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs1926554	ENSG00000230534.5	RP11-297A16.2	5.35	2.16e-07	0.000191	0.45	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35056041	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs4934710	ENSG00000230534.5	RP11-297A16.2	5.35	2.16e-07	0.000191	0.45	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35061488	chr10:35098006~35127020:-
OV	cis	rs7617773	0.784	rs9850672	ENSG00000228638.1	FCF1P2	-5.35	2.16e-07	0.000191	-0.41	-0.33	Coronary artery disease;	chr3:48259682	chr3:48290793~48291375:-
OV	cis	rs9291683	0.551	rs2240720	ENSG00000250413.1	RP11-448G15.1	-5.35	2.16e-07	0.000192	-0.38	-0.33	Bone mineral density;	chr4:10018856	chr4:10006482~10009725:+
OV	cis	rs11673344	0.864	rs55921822	ENSG00000226686.6	LINC01535	5.35	2.16e-07	0.000192	0.44	0.33	Obesity-related traits;	chr19:37005910	chr19:37251912~37265535:+
OV	cis	rs1061377	0.513	rs2566162	ENSG00000249207.1	RP11-360F5.1	-5.35	2.17e-07	0.000192	-0.4	-0.33	Uric acid levels;	chr4:39126453	chr4:39112677~39126818:-
OV	cis	rs7617773	0.744	rs2125482	ENSG00000228638.1	FCF1P2	-5.35	2.18e-07	0.000192	-0.41	-0.33	Coronary artery disease;	chr3:48281643	chr3:48290793~48291375:-
OV	cis	rs34779708	0.931	rs11010083	ENSG00000230534.5	RP11-297A16.2	5.35	2.18e-07	0.000193	0.44	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35062603	chr10:35098006~35127020:-
OV	cis	rs11098499	0.863	rs1010739	ENSG00000245958.5	RP11-33B1.1	-5.35	2.18e-07	0.000193	-0.4	-0.33	Corneal astigmatism;	chr4:119542316	chr4:119454791~119552025:+
OV	cis	rs858239	0.601	rs4599714	ENSG00000230042.1	AK3P3	-5.35	2.19e-07	0.000194	-0.34	-0.33	Cerebrospinal fluid biomarker levels;	chr7:23129182	chr7:23129178~23129841:+
OV	cis	rs875971	1	rs2077593	ENSG00000236529.1	RP13-254B10.1	5.35	2.19e-07	0.000194	0.35	0.33	Aortic root size;	chr7:66427543	chr7:65840212~65840596:+
OV	cis	rs6088580	0.634	rs1205334	ENSG00000206582.1	Y_RNA	5.35	2.2e-07	0.000194	0.4	0.33	Glomerular filtration rate (creatinine);	chr20:34342563	chr20:34526510~34526606:-
OV	cis	rs858239	0.601	rs10278776	ENSG00000230042.1	AK3P3	-5.35	2.2e-07	0.000194	-0.34	-0.33	Cerebrospinal fluid biomarker levels;	chr7:23130140	chr7:23129178~23129841:+
OV	cis	rs2153535	0.585	rs1814213	ENSG00000230939.1	RP11-314C16.1	-5.34	2.2e-07	0.000195	-0.36	-0.33	Motion sickness;	chr6:8619632	chr6:8784178~8785445:+
OV	cis	rs2788869	0.887	rs1225763	ENSG00000247925.2	RP3-510L9.1	-5.34	2.2e-07	0.000195	-0.44	-0.33	Obstetric antiphospholipid syndrome;	chr6:10924010	chr6:11173452~11259099:+
OV	cis	rs35160687	0.901	rs35762338	ENSG00000273080.1	RP11-301O19.1	5.34	2.22e-07	0.000196	0.33	0.33	Night sleep phenotypes;	chr2:86286430	chr2:86195590~86196049:+
OV	cis	rs35160687	0.901	rs12714179	ENSG00000273080.1	RP11-301O19.1	5.34	2.22e-07	0.000196	0.33	0.33	Night sleep phenotypes;	chr2:86287835	chr2:86195590~86196049:+
OV	cis	rs4380275	0.965	rs4375894	ENSG00000223751.1	AC116609.2	5.34	2.22e-07	0.000196	0.38	0.33	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772567	chr2:742488~747767:+
OV	cis	rs7968440	0.808	rs66947035	ENSG00000257298.1	RP3-405J10.3	5.34	2.22e-07	0.000196	0.34	0.33	Fibrinogen;	chr12:50781260	chr12:50185580~50191363:-
OV	cis	rs9291683	0.679	rs2241483	ENSG00000250413.1	RP11-448G15.1	5.34	2.23e-07	0.000197	0.37	0.33	Bone mineral density;	chr4:10098207	chr4:10006482~10009725:+
OV	cis	rs7302981	0.667	rs1362984	ENSG00000272368.2	RP4-605O3.4	-5.34	2.23e-07	0.000197	-0.38	-0.33	Systolic blood pressure;	chr12:50206201	chr12:50112197~50165618:+
OV	cis	rs4853012	0.838	rs6715351	ENSG00000257800.1	FNBP1P1	5.34	2.24e-07	0.000197	0.46	0.33	Gestational age at birth (maternal effect);	chr2:74118992	chr2:74120680~74123218:+
OV	cis	rs4853012	0.838	rs61521879	ENSG00000257800.1	FNBP1P1	5.34	2.24e-07	0.000197	0.46	0.33	Gestational age at birth (maternal effect);	chr2:74119081	chr2:74120680~74123218:+
OV	cis	rs34779708	0.931	rs34375045	ENSG00000230534.5	RP11-297A16.2	5.34	2.24e-07	0.000197	0.45	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35073428	chr10:35098006~35127020:-
OV	cis	rs16873450	0.527	rs11982624	ENSG00000234800.2	PCMTD1P3	5.34	2.24e-07	0.000198	0.35	0.33	Verbal memory performance (residualized delayed recall level);	chr7:23834815	chr7:23721311~23721782:-
OV	cis	rs4713118	0.629	rs149899	ENSG00000280107.1	AL022393.9	-5.34	2.24e-07	0.000198	-0.43	-0.33	Parkinson's disease;	chr6:28052201	chr6:28170845~28172521:+
OV	cis	rs4713118	0.629	rs172165	ENSG00000280107.1	AL022393.9	-5.34	2.24e-07	0.000198	-0.43	-0.33	Parkinson's disease;	chr6:28053036	chr6:28170845~28172521:+
OV	cis	rs4713118	0.597	rs172166	ENSG00000280107.1	AL022393.9	-5.34	2.24e-07	0.000198	-0.43	-0.33	Parkinson's disease;	chr6:28053042	chr6:28170845~28172521:+
OV	cis	rs496547	0.557	rs516719	ENSG00000255239.1	AP002954.6	5.34	2.24e-07	0.000198	0.39	0.33	Hip minimal joint space width;	chr11:118808736	chr11:118688039~118690600:-
OV	cis	rs4908768	0.911	rs12567592	ENSG00000228423.2	RP4-633I8.4	5.34	2.24e-07	0.000198	0.38	0.33	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8728848	chr1:8805860~8807051:-
OV	cis	rs8086028	1	rs8086028	ENSG00000264714.1	RP11-21G15.1	5.34	2.25e-07	0.000198	0.41	0.33	Venous thromboembolism (SNP x SNP interaction);	chr18:10737781	chr18:10724619~10728539:+
OV	cis	rs73019876	0.502	rs7258192	ENSG00000269742.1	BNIP3P29	5.34	2.25e-07	0.000199	0.38	0.33	Testicular germ cell tumor;	chr19:22081856	chr19:22065828~22066398:-
OV	cis	rs73019876	0.523	rs6511320	ENSG00000269742.1	BNIP3P29	5.34	2.25e-07	0.000199	0.38	0.33	Testicular germ cell tumor;	chr19:22084320	chr19:22065828~22066398:-
OV	cis	rs10246939	0.579	rs9640205	ENSG00000228775.6	WEE2-AS1	5.34	2.25e-07	0.000199	0.35	0.33	Bitter taste perception;	chr7:141844400	chr7:141704338~141738346:-
OV	cis	rs2243480	1	rs160643	ENSG00000222364.1	RNU6-96P	-5.34	2.26e-07	0.000199	-0.49	-0.33	Diabetic kidney disease;	chr7:66093235	chr7:66395191~66395286:+
OV	cis	rs7576126	0.515	rs1866050	ENSG00000234255.7	AC012370.3	5.34	2.26e-07	0.000199	0.44	0.33	Severe influenza A (H1N1) infection;	chr2:65450595	chr2:65439888~65456571:-
OV	cis	rs4713118	0.539	rs200988	ENSG00000220721.1	OR1F12	5.34	2.26e-07	0.000199	0.36	0.33	Parkinson's disease;	chr6:27851575	chr6:28073316~28074233:+
OV	cis	rs611744	0.647	rs628206	ENSG00000253754.1	RP11-35G22.1	-5.34	2.26e-07	0.000199	-0.37	-0.33	Dupuytren's disease;	chr8:108235644	chr8:108226200~108227544:+
OV	cis	rs611744	0.647	rs864166	ENSG00000253754.1	RP11-35G22.1	-5.34	2.26e-07	0.000199	-0.37	-0.33	Dupuytren's disease;	chr8:108237071	chr8:108226200~108227544:+
OV	cis	rs611744	0.647	rs2848620	ENSG00000253754.1	RP11-35G22.1	-5.34	2.26e-07	0.000199	-0.37	-0.33	Dupuytren's disease;	chr8:108237322	chr8:108226200~108227544:+
OV	cis	rs611744	0.647	rs702808	ENSG00000253754.1	RP11-35G22.1	-5.34	2.26e-07	0.000199	-0.37	-0.33	Dupuytren's disease;	chr8:108240325	chr8:108226200~108227544:+
OV	cis	rs611744	0.608	rs667742	ENSG00000253754.1	RP11-35G22.1	-5.34	2.26e-07	0.000199	-0.37	-0.33	Dupuytren's disease;	chr8:108241774	chr8:108226200~108227544:+
OV	cis	rs11690935	0.549	rs796839	ENSG00000228389.1	AC068039.4	-5.34	2.26e-07	0.000199	-0.37	-0.33	Schizophrenia;	chr2:172051486	chr2:171773482~171775844:+
OV	cis	rs11690935	0.549	rs2129475	ENSG00000228389.1	AC068039.4	-5.34	2.26e-07	0.000199	-0.37	-0.33	Schizophrenia;	chr2:172052044	chr2:171773482~171775844:+
OV	cis	rs1790761	0.554	rs12787511	ENSG00000184224.3	C11orf72	-5.34	2.26e-07	2e-04	-0.44	-0.33	Mean corpuscular volume;	chr11:67634164	chr11:67602880~67606706:-
OV	cis	rs1790761	0.554	rs3758938	ENSG00000184224.3	C11orf72	-5.34	2.26e-07	2e-04	-0.44	-0.33	Mean corpuscular volume;	chr11:67634891	chr11:67602880~67606706:-
OV	cis	rs7617773	0.817	rs9818937	ENSG00000228638.1	FCF1P2	-5.34	2.26e-07	2e-04	-0.41	-0.33	Coronary artery disease;	chr3:48283791	chr3:48290793~48291375:-
OV	cis	rs73086581	0.568	rs6084541	ENSG00000229539.1	RP11-119B16.2	-5.34	2.27e-07	2e-04	-0.34	-0.33	Response to antidepressants in depression;	chr20:3982084	chr20:3888239~3888868:-
OV	cis	rs7017914	0.905	rs4434651	ENSG00000223220.1	Y_RNA	5.34	2.27e-07	2e-04	0.34	0.33	Bone mineral density;	chr8:71034952	chr8:70780914~70781008:-
OV	cis	rs11096990	0.613	rs6829660	ENSG00000249207.1	RP11-360F5.1	-5.34	2.27e-07	2e-04	-0.35	-0.33	Cognitive function;	chr4:39280943	chr4:39112677~39126818:-
OV	cis	rs4713118	0.505	rs276371	ENSG00000220721.1	OR1F12	5.34	2.28e-07	2e-04	0.33	0.33	Parkinson's disease;	chr6:27942930	chr6:28073316~28074233:+
OV	cis	rs7116641	0.734	rs3736505	ENSG00000246250.2	RP11-613D13.5	5.34	2.28e-07	0.000201	0.39	0.33	Coronary artery disease;	chr11:43854885	chr11:43829709~43880726:-
OV	cis	rs7116641	0.734	rs11555762	ENSG00000246250.2	RP11-613D13.5	5.34	2.28e-07	0.000201	0.39	0.33	Coronary artery disease;	chr11:43855148	chr11:43829709~43880726:-
OV	cis	rs9813712	0.597	rs10934931	ENSG00000253540.4	FAM86HP	-5.34	2.28e-07	0.000201	-0.35	-0.33	Response to amphetamines;	chr3:130261365	chr3:130099092~130111472:-
OV	cis	rs13315649	0.639	rs73196928	ENSG00000242551.2	POU5F1P6	-5.34	2.28e-07	0.000201	-0.41	-0.33	Sum eosinophil basophil counts;	chr3:128670583	chr3:128674735~128677005:-
OV	cis	rs875971	0.895	rs12698520	ENSG00000236529.1	RP13-254B10.1	5.34	2.29e-07	0.000201	0.35	0.33	Aortic root size;	chr7:66453720	chr7:65840212~65840596:+
OV	cis	rs116095464	0.558	rs6555058	ENSG00000250848.1	CTD-2083E4.5	5.34	2.29e-07	0.000201	0.4	0.33	Breast cancer;	chr5:226261	chr5:288833~290321:-
OV	cis	rs9399135	0.507	rs7766963	ENSG00000232876.1	CTA-212D2.2	5.34	2.29e-07	0.000202	0.36	0.33	Red blood cell count;	chr6:135111745	chr6:135055033~135060550:+
OV	cis	rs11157436	0.958	rs6572313	ENSG00000211812.1	TRAV26-2	-5.34	2.3e-07	0.000202	-0.38	-0.33	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22214070	chr14:22202583~22203368:+
OV	cis	rs34779708	0.966	rs4934539	ENSG00000230534.5	RP11-297A16.2	5.34	2.3e-07	0.000203	0.43	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35183271	chr10:35098006~35127020:-
OV	cis	rs7580658	0.895	rs62157549	ENSG00000236682.1	AC068282.3	-5.34	2.31e-07	0.000203	-0.42	-0.33	Protein C levels;	chr2:127308431	chr2:127389130~127400580:+
OV	cis	rs67311347	1	rs1047855	ENSG00000223797.4	ENTPD3-AS1	-5.33	2.31e-07	0.000203	-0.37	-0.33	Renal cell carcinoma;	chr3:40427405	chr3:40313802~40453329:-
OV	cis	rs7968440	0.707	rs1109726	ENSG00000257298.1	RP3-405J10.3	5.33	2.31e-07	0.000203	0.34	0.33	Fibrinogen;	chr12:50764765	chr12:50185580~50191363:-
OV	cis	rs853679	0.517	rs4713135	ENSG00000280107.1	AL022393.9	-5.33	2.31e-07	0.000203	-0.41	-0.33	Depression;	chr6:28071808	chr6:28170845~28172521:+
OV	cis	rs6088580	0.634	rs1205338	ENSG00000206582.1	Y_RNA	5.33	2.32e-07	0.000204	0.4	0.33	Glomerular filtration rate (creatinine);	chr20:34337819	chr20:34526510~34526606:-
OV	cis	rs4713118	0.513	rs149954	ENSG00000219392.1	RP1-265C24.5	-5.33	2.34e-07	0.000206	-0.38	-0.33	Parkinson's disease;	chr6:28067468	chr6:28115628~28116551:+
OV	cis	rs496547	0.719	rs472641	ENSG00000278376.1	RP11-158I9.8	-5.33	2.34e-07	0.000206	-0.32	-0.33	Hip minimal joint space width;	chr11:118746835	chr11:118791254~118793137:+
OV	cis	rs7017914	0.875	rs3098871	ENSG00000223220.1	Y_RNA	5.33	2.34e-07	0.000206	0.35	0.33	Bone mineral density;	chr8:71018180	chr8:70780914~70781008:-
OV	cis	rs34779708	0.931	rs35997236	ENSG00000230534.5	RP11-297A16.2	5.33	2.35e-07	0.000206	0.44	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35087762	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs4934719	ENSG00000230534.5	RP11-297A16.2	5.33	2.35e-07	0.000206	0.44	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35087841	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs4934720	ENSG00000230534.5	RP11-297A16.2	5.33	2.35e-07	0.000206	0.44	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35087872	chr10:35098006~35127020:-
OV	cis	rs34779708	0.897	rs34481177	ENSG00000230534.5	RP11-297A16.2	5.33	2.35e-07	0.000206	0.44	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35091985	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs11593858	ENSG00000230534.5	RP11-297A16.2	5.33	2.35e-07	0.000206	0.44	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35092445	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs4934723	ENSG00000230534.5	RP11-297A16.2	5.33	2.35e-07	0.000206	0.44	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35092835	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs72789690	ENSG00000230534.5	RP11-297A16.2	5.33	2.35e-07	0.000206	0.44	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35093889	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs68039650	ENSG00000230534.5	RP11-297A16.2	5.33	2.35e-07	0.000206	0.44	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35096571	chr10:35098006~35127020:-
OV	cis	rs34779708	0.897	rs12764820	ENSG00000230534.5	RP11-297A16.2	5.33	2.35e-07	0.000206	0.44	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35097393	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs67261877	ENSG00000230534.5	RP11-297A16.2	5.33	2.35e-07	0.000206	0.44	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35097412	chr10:35098006~35127020:-
OV	cis	rs8062405	0.755	rs4788074	ENSG00000259982.1	CDC37P1	-5.33	2.35e-07	0.000207	-0.41	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28700294~28701540:-
OV	cis	rs11603023	0.967	rs494560	ENSG00000255422.1	AP002954.4	5.33	2.36e-07	0.000207	0.36	0.33	Cholesterol, total;	chr11:118650844	chr11:118704607~118750263:+
OV	cis	rs858239	0.601	rs987257	ENSG00000230042.1	AK3P3	-5.33	2.36e-07	0.000207	-0.34	-0.33	Cerebrospinal fluid biomarker levels;	chr7:23108221	chr7:23129178~23129841:+
OV	cis	rs9660180	0.935	rs9786942	ENSG00000268575.1	RP1-283E3.8	-5.33	2.37e-07	0.000208	-0.31	-0.33	Body mass index;	chr1:1827774	chr1:1702736~1737688:-
OV	cis	rs9660180	0.934	rs34849348	ENSG00000268575.1	RP1-283E3.8	-5.33	2.37e-07	0.000208	-0.31	-0.33	Body mass index;	chr1:1831318	chr1:1702736~1737688:-
OV	cis	rs12200782	0.505	rs1535275	ENSG00000241549.7	GUSBP2	5.33	2.38e-07	0.000208	0.39	0.33	Small cell lung carcinoma;	chr6:26520539	chr6:26871484~26956554:-
OV	cis	rs4591358	0.569	rs6718998	ENSG00000223466.1	AC064834.2	-5.33	2.38e-07	0.000208	-0.51	-0.33	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195578245	chr2:195533035~195538681:+
OV	cis	rs11673344	1	rs11673344	ENSG00000226686.6	LINC01535	5.33	2.38e-07	0.000208	0.43	0.33	Obesity-related traits;	chr19:37194064	chr19:37251912~37265535:+
OV	cis	rs35160687	0.901	rs6714362	ENSG00000273080.1	RP11-301O19.1	-5.33	2.39e-07	0.000209	-0.34	-0.33	Night sleep phenotypes;	chr2:86249465	chr2:86195590~86196049:+
OV	cis	rs611744	0.806	rs374810	ENSG00000253754.1	RP11-35G22.1	-5.33	2.39e-07	0.000209	-0.38	-0.33	Dupuytren's disease;	chr8:108083801	chr8:108226200~108227544:+
OV	cis	rs7429990	0.932	rs7620736	ENSG00000229759.1	MRPS18AP1	-5.33	2.4e-07	0.00021	-0.35	-0.33	Educational attainment (years of education);	chr3:48068479	chr3:48256350~48256938:-
OV	cis	rs7429990	0.965	rs6791834	ENSG00000229759.1	MRPS18AP1	-5.33	2.4e-07	0.00021	-0.35	-0.33	Educational attainment (years of education);	chr3:48073598	chr3:48256350~48256938:-
OV	cis	rs7429990	0.965	rs35689209	ENSG00000229759.1	MRPS18AP1	-5.33	2.4e-07	0.00021	-0.35	-0.33	Educational attainment (years of education);	chr3:48078273	chr3:48256350~48256938:-
OV	cis	rs496547	0.719	rs1790189	ENSG00000278376.1	RP11-158I9.8	-5.33	2.4e-07	0.000211	-0.32	-0.33	Hip minimal joint space width;	chr11:118781617	chr11:118791254~118793137:+
OV	cis	rs4713118	0.621	rs4713132	ENSG00000280107.1	AL022393.9	-5.33	2.42e-07	0.000212	-0.41	-0.33	Parkinson's disease;	chr6:28066257	chr6:28170845~28172521:+
OV	cis	rs4713118	0.621	rs4713133	ENSG00000280107.1	AL022393.9	-5.33	2.42e-07	0.000212	-0.41	-0.33	Parkinson's disease;	chr6:28066263	chr6:28170845~28172521:+
OV	cis	rs4713118	0.621	rs4713134	ENSG00000280107.1	AL022393.9	-5.33	2.42e-07	0.000212	-0.41	-0.33	Parkinson's disease;	chr6:28066343	chr6:28170845~28172521:+
OV	cis	rs9660180	0.935	rs2180311	ENSG00000268575.1	RP1-283E3.8	-5.33	2.42e-07	0.000212	-0.31	-0.33	Body mass index;	chr1:1817295	chr1:1702736~1737688:-
OV	cis	rs9660180	0.967	rs6664664	ENSG00000268575.1	RP1-283E3.8	-5.33	2.42e-07	0.000212	-0.31	-0.33	Body mass index;	chr1:1819825	chr1:1702736~1737688:-
OV	cis	rs8005677	0.962	rs10130756	ENSG00000279656.1	RP11-298I3.6	5.33	2.42e-07	0.000212	0.36	0.33	Cognitive ability (multi-trait analysis);	chr14:22927391	chr14:23023083~23024217:-
OV	cis	rs853679	0.517	rs868987	ENSG00000280107.1	AL022393.9	5.33	2.42e-07	0.000212	0.44	0.33	Depression;	chr6:28142370	chr6:28170845~28172521:+
OV	cis	rs5742933	0.762	rs2033746	ENSG00000253559.1	OSGEPL1-AS1	5.33	2.42e-07	0.000212	0.34	0.33	Ferritin levels;	chr2:189734726	chr2:189762704~189765556:+
OV	cis	rs5742933	0.762	rs12992061	ENSG00000253559.1	OSGEPL1-AS1	5.33	2.42e-07	0.000212	0.34	0.33	Ferritin levels;	chr2:189736026	chr2:189762704~189765556:+
OV	cis	rs5742933	0.744	rs13002216	ENSG00000253559.1	OSGEPL1-AS1	5.33	2.42e-07	0.000212	0.34	0.33	Ferritin levels;	chr2:189746358	chr2:189762704~189765556:+
OV	cis	rs7580658	0.895	rs4662722	ENSG00000236682.1	AC068282.3	-5.33	2.42e-07	0.000212	-0.43	-0.33	Protein C levels;	chr2:127344993	chr2:127389130~127400580:+
OV	cis	rs7580658	0.895	rs4662580	ENSG00000236682.1	AC068282.3	-5.33	2.42e-07	0.000212	-0.43	-0.33	Protein C levels;	chr2:127345230	chr2:127389130~127400580:+
OV	cis	rs35160687	0.901	rs13017338	ENSG00000273080.1	RP11-301O19.1	5.32	2.43e-07	0.000212	0.34	0.33	Night sleep phenotypes;	chr2:86274430	chr2:86195590~86196049:+
OV	cis	rs1075265	0.783	rs805453	ENSG00000233266.1	HMGB1P31	5.32	2.43e-07	0.000212	0.4	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53955761	chr2:54051334~54051760:+
OV	cis	rs8040855	0.599	rs8037195	ENSG00000229212.6	RP11-561C5.4	-5.32	2.43e-07	0.000212	-0.4	-0.33	Bulimia nervosa;	chr15:85181455	chr15:85205440~85234795:-
OV	cis	rs611744	0.647	rs585077	ENSG00000253754.1	RP11-35G22.1	-5.32	2.43e-07	0.000213	-0.37	-0.33	Dupuytren's disease;	chr8:108233268	chr8:108226200~108227544:+
OV	cis	rs611744	0.608	rs612744	ENSG00000253754.1	RP11-35G22.1	-5.32	2.43e-07	0.000213	-0.37	-0.33	Dupuytren's disease;	chr8:108233762	chr8:108226200~108227544:+
OV	cis	rs611744	0.647	rs587340	ENSG00000253754.1	RP11-35G22.1	-5.32	2.43e-07	0.000213	-0.37	-0.33	Dupuytren's disease;	chr8:108233803	chr8:108226200~108227544:+
OV	cis	rs3091242	0.935	rs4233043	ENSG00000224183.1	SDHDP6	-5.32	2.44e-07	0.000213	-0.39	-0.33	Erythrocyte sedimentation rate;	chr1:25438992	chr1:25294164~25294643:-
OV	cis	rs1790761	0.692	rs1269981	ENSG00000184224.3	C11orf72	5.32	2.44e-07	0.000213	0.38	0.33	Mean corpuscular volume;	chr11:67567488	chr11:67602880~67606706:-
OV	cis	rs1790761	0.658	rs666328	ENSG00000184224.3	C11orf72	5.32	2.44e-07	0.000213	0.38	0.33	Mean corpuscular volume;	chr11:67568067	chr11:67602880~67606706:-
OV	cis	rs1790761	0.667	rs11227837	ENSG00000184224.3	C11orf72	5.32	2.44e-07	0.000213	0.38	0.33	Mean corpuscular volume;	chr11:67568953	chr11:67602880~67606706:-
OV	cis	rs7771547	0.573	rs7744363	ENSG00000240733.3	RN7SL502P	-5.32	2.44e-07	0.000214	-0.37	-0.33	Platelet distribution width;	chr6:36456888	chr6:36450912~36451201:-
OV	cis	rs34779708	0.966	rs12260130	ENSG00000230534.5	RP11-297A16.2	5.32	2.45e-07	0.000214	0.43	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35178743	chr10:35098006~35127020:-
OV	cis	rs7688540	0.771	rs7674560	ENSG00000275426.1	CH17-262A2.1	5.32	2.45e-07	0.000214	0.5	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:269530	chr4:149738~150317:+
OV	cis	rs1790761	0.692	rs10444362	ENSG00000184224.3	C11orf72	5.32	2.46e-07	0.000215	0.38	0.33	Mean corpuscular volume;	chr11:67565619	chr11:67602880~67606706:-
OV	cis	rs1790761	0.692	rs638140	ENSG00000184224.3	C11orf72	5.32	2.46e-07	0.000215	0.38	0.33	Mean corpuscular volume;	chr11:67566387	chr11:67602880~67606706:-
OV	cis	rs7580658	0.864	rs34832797	ENSG00000236682.1	AC068282.3	-5.32	2.46e-07	0.000215	-0.43	-0.33	Protein C levels;	chr2:127361865	chr2:127389130~127400580:+
OV	cis	rs7580658	0.895	rs7589451	ENSG00000236682.1	AC068282.3	-5.32	2.46e-07	0.000215	-0.43	-0.33	Protein C levels;	chr2:127371199	chr2:127389130~127400580:+
OV	cis	rs4713118	0.699	rs573179	ENSG00000280107.1	AL022393.9	-5.32	2.47e-07	0.000215	-0.42	-0.33	Parkinson's disease;	chr6:27881898	chr6:28170845~28172521:+
OV	cis	rs6558530	0.64	rs7844748	ENSG00000253982.1	CTD-2336O2.1	-5.32	2.47e-07	0.000215	-0.44	-0.33	Systolic blood pressure;	chr8:1754177	chr8:1761990~1764502:-
OV	cis	rs858239	0.632	rs1985769	ENSG00000230042.1	AK3P3	-5.32	2.47e-07	0.000216	-0.35	-0.33	Cerebrospinal fluid biomarker levels;	chr7:23082887	chr7:23129178~23129841:+
OV	cis	rs858239	0.6	rs7789237	ENSG00000230042.1	AK3P3	-5.32	2.47e-07	0.000216	-0.35	-0.33	Cerebrospinal fluid biomarker levels;	chr7:23085094	chr7:23129178~23129841:+
OV	cis	rs8062405	0.755	rs56209193	ENSG00000259982.1	CDC37P1	5.32	2.47e-07	0.000216	0.4	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28700294~28701540:-
OV	cis	rs7688540	0.771	rs61795006	ENSG00000275426.1	CH17-262A2.1	5.32	2.48e-07	0.000217	0.5	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:259812	chr4:149738~150317:+
OV	cis	rs7688540	0.771	rs61795007	ENSG00000275426.1	CH17-262A2.1	5.32	2.48e-07	0.000217	0.5	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:261475	chr4:149738~150317:+
OV	cis	rs8062405	0.755	rs1074631	ENSG00000278665.1	RP11-666O2.4	-5.32	2.49e-07	0.000217	-0.37	-0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28599241~28601881:-
OV	cis	rs11673344	0.864	rs7247589	ENSG00000226686.6	LINC01535	5.32	2.49e-07	0.000217	0.44	0.33	Obesity-related traits;	chr19:37019879	chr19:37251912~37265535:+
OV	cis	rs11673344	0.864	rs7256213	ENSG00000226686.6	LINC01535	5.32	2.49e-07	0.000217	0.44	0.33	Obesity-related traits;	chr19:37020589	chr19:37251912~37265535:+
OV	cis	rs7017914	0.652	rs2933847	ENSG00000223220.1	Y_RNA	5.32	2.49e-07	0.000218	0.38	0.33	Bone mineral density;	chr8:70972946	chr8:70780914~70781008:-
OV	cis	rs858239	0.601	rs1981665	ENSG00000230042.1	AK3P3	-5.32	2.5e-07	0.000218	-0.34	-0.33	Cerebrospinal fluid biomarker levels;	chr7:23128350	chr7:23129178~23129841:+
OV	cis	rs496547	0.686	rs487728	ENSG00000278376.1	RP11-158I9.8	-5.32	2.5e-07	0.000218	-0.32	-0.33	Hip minimal joint space width;	chr11:118750785	chr11:118791254~118793137:+
OV	cis	rs34779708	0.931	rs7099036	ENSG00000230534.5	RP11-297A16.2	5.32	2.51e-07	0.000218	0.44	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35060646	chr10:35098006~35127020:-
OV	cis	rs1790761	0.52	rs12800028	ENSG00000184224.3	C11orf72	-5.32	2.51e-07	0.000219	-0.45	-0.33	Mean corpuscular volume;	chr11:67635814	chr11:67602880~67606706:-
OV	cis	rs796364	1	rs11895190	ENSG00000232732.8	AC073043.1	5.32	2.51e-07	0.000219	0.5	0.33	Schizophrenia;	chr2:199973890	chr2:199867396~199911159:-
OV	cis	rs853679	0.567	rs6905380	ENSG00000216901.1	AL022393.7	5.32	2.51e-07	0.000219	0.4	0.33	Depression;	chr6:28407125	chr6:28176188~28176674:+
OV	cis	rs62355900	0.627	rs61663138	ENSG00000271828.1	CTD-2310F14.1	5.32	2.52e-07	0.00022	0.61	0.33	Endometriosis;	chr5:56899946	chr5:56927874~56929573:+
OV	cis	rs7615952	0.641	rs6438951	ENSG00000171084.14	FAM86JP	5.32	2.52e-07	0.00022	0.48	0.33	Blood pressure (smoking interaction);	chr3:125978156	chr3:125916620~125930024:+
OV	cis	rs8005677	1	rs2295685	ENSG00000279656.1	RP11-298I3.6	5.32	2.52e-07	0.00022	0.36	0.33	Cognitive ability (multi-trait analysis);	chr14:22928944	chr14:23023083~23024217:-
OV	cis	rs8005677	1	rs7145494	ENSG00000279656.1	RP11-298I3.6	5.32	2.52e-07	0.00022	0.36	0.33	Cognitive ability (multi-trait analysis);	chr14:22930581	chr14:23023083~23024217:-
OV	cis	rs34779708	0.897	rs4934716	ENSG00000230534.5	RP11-297A16.2	5.32	2.53e-07	0.00022	0.44	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35080371	chr10:35098006~35127020:-
OV	cis	rs7684253	0.548	rs922570	ENSG00000269949.1	RP11-738E22.3	-5.32	2.53e-07	0.00022	-0.4	-0.33	Migraine;	chr4:56851192	chr4:56960927~56961373:-
OV	cis	rs7684253	0.548	rs13108002	ENSG00000269949.1	RP11-738E22.3	-5.32	2.53e-07	0.00022	-0.4	-0.33	Migraine;	chr4:56852087	chr4:56960927~56961373:-
OV	cis	rs7580658	0.637	rs4560059	ENSG00000236682.1	AC068282.3	-5.32	2.53e-07	0.00022	-0.41	-0.33	Protein C levels;	chr2:127214652	chr2:127389130~127400580:+
OV	cis	rs7189233	0.55	rs4783811	ENSG00000279344.1	RP11-44F14.7	5.32	2.53e-07	0.00022	0.31	0.33	Intelligence (multi-trait analysis);	chr16:53449464	chr16:53478957~53481550:-
OV	cis	rs67383717	0.777	rs591486	ENSG00000175611.10	LINC00476	-5.32	2.53e-07	0.000221	-0.38	-0.33	Parkinson's disease (pesticide exposure interaction);	chr9:95887764	chr9:95759231~95875977:-
OV	cis	rs35160687	0.865	rs10189492	ENSG00000273080.1	RP11-301O19.1	5.32	2.53e-07	0.000221	0.34	0.33	Night sleep phenotypes;	chr2:86251779	chr2:86195590~86196049:+
OV	cis	rs7017914	0.652	rs2732138	ENSG00000223220.1	Y_RNA	5.32	2.54e-07	0.000221	0.38	0.33	Bone mineral density;	chr8:70971372	chr8:70780914~70781008:-
OV	cis	rs61990749	0.597	rs2299930	ENSG00000239272.1	RPL21P10	-5.31	2.55e-07	0.000222	-0.45	-0.33	Fibroblast growth factor basic levels;	chr14:77697379	chr14:77683202~77683989:-
OV	cis	rs35160687	0.901	rs12622200	ENSG00000273080.1	RP11-301O19.1	-5.31	2.56e-07	0.000222	-0.33	-0.33	Night sleep phenotypes;	chr2:86271472	chr2:86195590~86196049:+
OV	cis	rs1061377	0.748	rs12642261	ENSG00000249207.1	RP11-360F5.1	-5.31	2.56e-07	0.000223	-0.35	-0.33	Uric acid levels;	chr4:39096278	chr4:39112677~39126818:-
OV	cis	rs10510102	0.516	rs10159759	ENSG00000276742.1	RP11-500G22.4	5.31	2.57e-07	0.000223	0.6	0.33	Breast cancer;	chr10:121986533	chr10:121956782~121957098:+
OV	cis	rs7968440	0.722	rs11609941	ENSG00000257298.1	RP3-405J10.3	5.31	2.57e-07	0.000223	0.34	0.33	Fibrinogen;	chr12:50773835	chr12:50185580~50191363:-
OV	cis	rs7968440	0.75	rs67356137	ENSG00000257298.1	RP3-405J10.3	5.31	2.57e-07	0.000223	0.34	0.33	Fibrinogen;	chr12:50778044	chr12:50185580~50191363:-
OV	cis	rs35160687	0.798	rs6547674	ENSG00000273080.1	RP11-301O19.1	-5.31	2.57e-07	0.000224	-0.32	-0.33	Night sleep phenotypes;	chr2:86325796	chr2:86195590~86196049:+
OV	cis	rs35160687	0.798	rs11127029	ENSG00000273080.1	RP11-301O19.1	-5.31	2.57e-07	0.000224	-0.32	-0.33	Night sleep phenotypes;	chr2:86327502	chr2:86195590~86196049:+
OV	cis	rs2999052	0.602	rs2977562	ENSG00000277250.1	Metazoa_SRP	5.31	2.58e-07	0.000224	0.44	0.33	Hypospadias;	chr3:128387424	chr3:128673681~128674021:-
OV	cis	rs9291683	0.588	rs11732054	ENSG00000250413.1	RP11-448G15.1	-5.31	2.58e-07	0.000224	-0.37	-0.33	Bone mineral density;	chr4:9998253	chr4:10006482~10009725:+
OV	cis	rs11096990	0.634	rs12651217	ENSG00000249207.1	RP11-360F5.1	-5.31	2.59e-07	0.000224	-0.35	-0.33	Cognitive function;	chr4:39271964	chr4:39112677~39126818:-
OV	cis	rs10510102	0.935	rs12240893	ENSG00000276742.1	RP11-500G22.4	5.31	2.59e-07	0.000225	0.56	0.33	Breast cancer;	chr10:121870572	chr10:121956782~121957098:+
OV	cis	rs12922040	1	rs12922040	ENSG00000263335.1	AF001548.5	-5.31	2.59e-07	0.000225	-0.41	-0.33	Serum uric acid levels in response to allopurinol in gout;	chr16:15775609	chr16:15726674~15732993:+
OV	cis	rs853679	0.517	rs9393896	ENSG00000280107.1	AL022393.9	-5.31	2.6e-07	0.000225	-0.44	-0.33	Depression;	chr6:28159925	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9393897	ENSG00000280107.1	AL022393.9	-5.31	2.6e-07	0.000225	-0.44	-0.33	Depression;	chr6:28159932	chr6:28170845~28172521:+
OV	cis	rs34779708	0.966	rs1478463	ENSG00000230534.5	RP11-297A16.2	5.31	2.6e-07	0.000226	0.43	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35184107	chr10:35098006~35127020:-
OV	cis	rs7017914	0.87	rs2639953	ENSG00000223220.1	Y_RNA	5.31	2.6e-07	0.000226	0.35	0.33	Bone mineral density;	chr8:71013425	chr8:70780914~70781008:-
OV	cis	rs611744	0.506	rs13280454	ENSG00000253754.1	RP11-35G22.1	-5.31	2.61e-07	0.000226	-0.36	-0.33	Dupuytren's disease;	chr8:108251011	chr8:108226200~108227544:+
OV	cis	rs301901	0.772	rs7715883	ENSG00000250155.1	CTD-2353F22.1	-5.31	2.61e-07	0.000227	-0.39	-0.33	Height;	chr5:37238160	chr5:36666214~36725195:-
OV	cis	rs7829975	0.742	rs12547493	ENSG00000173295.6	FAM86B3P	-5.31	2.62e-07	0.000227	-0.4	-0.33	Mood instability;	chr8:8804024	chr8:8228595~8244865:+
OV	cis	rs6471393	0.964	rs2976366	ENSG00000253848.1	RP11-10N23.5	-5.31	2.62e-07	0.000227	-0.4	-0.33	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93708829	chr8:93741193~93744534:+
OV	cis	rs7428	0.545	rs1053561	ENSG00000246575.2	AC093162.5	5.31	2.62e-07	0.000227	0.33	0.33	Ear protrusion;	chr2:85318929	chr2:85315041~85316529:+
OV	cis	rs7688540	0.771	rs77078697	ENSG00000275426.1	CH17-262A2.1	5.31	2.63e-07	0.000228	0.5	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:258259	chr4:149738~150317:+
OV	cis	rs6772849	0.896	rs35535737	ENSG00000242551.2	POU5F1P6	-5.31	2.63e-07	0.000228	-0.39	-0.33	Monocyte percentage of white cells;Monocyte count;	chr3:128664563	chr3:128674735~128677005:-
OV	cis	rs13068223	0.904	rs13322900	ENSG00000243926.1	TIPARP-AS1	5.31	2.63e-07	0.000228	0.31	0.33	Age-related hearing impairment (SNP x SNP interaction);	chr3:156732229	chr3:156671862~156674378:-
OV	cis	rs73019876	0.502	rs6511326	ENSG00000269742.1	BNIP3P29	5.31	2.63e-07	0.000228	0.39	0.33	Testicular germ cell tumor;	chr19:22103877	chr19:22065828~22066398:-
OV	cis	rs7588746	0.868	rs12104649	ENSG00000232732.8	AC073043.1	5.31	2.64e-07	0.000228	0.44	0.33	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:200264109	chr2:199867396~199911159:-
OV	cis	rs2153535	0.536	rs78180822	ENSG00000230939.1	RP11-314C16.1	-5.31	2.64e-07	0.000229	-0.36	-0.33	Motion sickness;	chr6:8620941	chr6:8784178~8785445:+
OV	cis	rs8040855	0.599	rs4577058	ENSG00000229212.6	RP11-561C5.4	-5.31	2.64e-07	0.000229	-0.4	-0.33	Bulimia nervosa;	chr15:85183227	chr15:85205440~85234795:-
OV	cis	rs4908768	0.68	rs11121225	ENSG00000228423.2	RP4-633I8.4	5.31	2.64e-07	0.000229	0.41	0.33	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8756379	chr1:8805860~8807051:-
OV	cis	rs8062405	0.824	rs28698667	ENSG00000278665.1	RP11-666O2.4	5.31	2.65e-07	0.000229	0.35	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28521750	chr16:28599241~28601881:-
OV	cis	rs4243830	0.85	rs12410405	ENSG00000229519.2	RP11-58A11.2	-5.31	2.65e-07	0.000229	-0.42	-0.33	Body mass index;	chr1:6521223	chr1:6547905~6548619:+
OV	cis	rs1790761	0.52	rs12805884	ENSG00000184224.3	C11orf72	-5.31	2.66e-07	0.00023	-0.42	-0.33	Mean corpuscular volume;	chr11:67620506	chr11:67602880~67606706:-
OV	cis	rs55726902	1	rs73107993	ENSG00000276691.1	RP5-1057I20.5	5.31	2.66e-07	0.00023	0.37	0.33	Allergic disease (asthma, hay fever or eczema);	chr12:47802090	chr12:47788426~47788971:+
OV	cis	rs67311347	0.955	rs4974068	ENSG00000223797.4	ENTPD3-AS1	5.31	2.67e-07	0.000231	0.37	0.33	Renal cell carcinoma;	chr3:40335438	chr3:40313802~40453329:-
OV	cis	rs496547	0.686	rs477014	ENSG00000255239.1	AP002954.6	5.31	2.67e-07	0.000231	0.39	0.33	Hip minimal joint space width;	chr11:118808277	chr11:118688039~118690600:-
OV	cis	rs858239	0.601	rs2068459	ENSG00000230042.1	AK3P3	-5.3	2.68e-07	0.000232	-0.35	-0.33	Cerebrospinal fluid biomarker levels;	chr7:23114694	chr7:23129178~23129841:+
OV	cis	rs875971	0.929	rs4122249	ENSG00000236529.1	RP13-254B10.1	5.3	2.69e-07	0.000232	0.35	0.33	Aortic root size;	chr7:66455949	chr7:65840212~65840596:+
OV	cis	rs783540	0.809	rs3970696	ENSG00000278603.1	RP13-608F4.5	5.3	2.69e-07	0.000232	0.37	0.33	Schizophrenia;	chr15:82595006	chr15:82472203~82472426:+
OV	cis	rs7587476	0.784	rs13026390	ENSG00000229267.2	AC072062.1	5.3	2.69e-07	0.000232	0.43	0.33	Neuroblastoma;	chr2:214822351	chr2:214810229~214963274:+
OV	cis	rs34779708	0.931	rs11010077	ENSG00000230534.5	RP11-297A16.2	-5.3	2.69e-07	0.000233	-0.41	-0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35039160	chr10:35098006~35127020:-
OV	cis	rs6772849	0.93	rs12487604	ENSG00000242551.2	POU5F1P6	-5.3	2.69e-07	0.000233	-0.41	-0.33	Monocyte percentage of white cells;Monocyte count;	chr3:128618232	chr3:128674735~128677005:-
OV	cis	rs35160687	0.901	rs12472390	ENSG00000273080.1	RP11-301O19.1	5.3	2.7e-07	0.000233	0.34	0.33	Night sleep phenotypes;	chr2:86247960	chr2:86195590~86196049:+
OV	cis	rs67311347	1	rs28491638	ENSG00000223797.4	ENTPD3-AS1	5.3	2.71e-07	0.000234	0.38	0.33	Renal cell carcinoma;	chr3:40454772	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs28536038	ENSG00000223797.4	ENTPD3-AS1	5.3	2.71e-07	0.000234	0.38	0.33	Renal cell carcinoma;	chr3:40454891	chr3:40313802~40453329:-
OV	cis	rs67311347	0.955	rs2085114	ENSG00000223797.4	ENTPD3-AS1	5.3	2.71e-07	0.000234	0.38	0.33	Renal cell carcinoma;	chr3:40455946	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs2085115	ENSG00000223797.4	ENTPD3-AS1	5.3	2.71e-07	0.000234	0.38	0.33	Renal cell carcinoma;	chr3:40456049	chr3:40313802~40453329:-
OV	cis	rs611744	0.625	rs6469168	ENSG00000253754.1	RP11-35G22.1	-5.3	2.72e-07	0.000235	-0.36	-0.33	Dupuytren's disease;	chr8:108276170	chr8:108226200~108227544:+
OV	cis	rs7829975	0.711	rs4841051	ENSG00000253893.2	FAM85B	5.3	2.73e-07	0.000235	0.35	0.33	Mood instability;	chr8:8828136	chr8:8167819~8226614:-
OV	cis	rs8113142	0.668	rs55933947	ENSG00000267243.4	AC005307.3	-5.3	2.74e-07	0.000236	-0.54	-0.33	Femoral neck bone geometry and menarche (age at onset);	chr19:28613740	chr19:28435388~28727777:-
OV	cis	rs8040855	0.599	rs1964724	ENSG00000229212.6	RP11-561C5.4	-5.3	2.74e-07	0.000236	-0.4	-0.33	Bulimia nervosa;	chr15:85183269	chr15:85205440~85234795:-
OV	cis	rs6772849	0.931	rs60825080	ENSG00000242551.2	POU5F1P6	-5.3	2.74e-07	0.000236	-0.39	-0.33	Monocyte percentage of white cells;Monocyte count;	chr3:128665991	chr3:128674735~128677005:-
OV	cis	rs10740039	0.883	rs1561850	ENSG00000254271.1	RP11-131N11.4	5.3	2.74e-07	0.000236	0.41	0.33	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60631583	chr10:60734342~60741828:+
OV	cis	rs9291683	0.525	rs12506455	ENSG00000250413.1	RP11-448G15.1	-5.3	2.74e-07	0.000236	-0.37	-0.33	Bone mineral density;	chr4:10029945	chr4:10006482~10009725:+
OV	cis	rs3733585	0.783	rs13148371	ENSG00000250413.1	RP11-448G15.1	-5.3	2.74e-07	0.000236	-0.37	-0.33	Cleft plate (environmental tobacco smoke interaction);	chr4:10030937	chr4:10006482~10009725:+
OV	cis	rs6088580	0.634	rs4911151	ENSG00000206582.1	Y_RNA	5.3	2.76e-07	0.000237	0.39	0.33	Glomerular filtration rate (creatinine);	chr20:34344467	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6088471	ENSG00000206582.1	Y_RNA	5.3	2.76e-07	0.000237	0.39	0.33	Glomerular filtration rate (creatinine);	chr20:34344837	chr20:34526510~34526606:-
OV	cis	rs6991838	0.557	rs7012578	ENSG00000200714.1	Y_RNA	-5.3	2.76e-07	0.000237	-0.42	-0.33	Intelligence (multi-trait analysis);	chr8:65592592	chr8:65592731~65592820:+
OV	cis	rs6471393	0.964	rs2914941	ENSG00000253848.1	RP11-10N23.5	5.3	2.76e-07	0.000237	0.4	0.33	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93716983	chr8:93741193~93744534:+
OV	cis	rs6471393	0.861	rs2976372	ENSG00000253848.1	RP11-10N23.5	-5.3	2.77e-07	0.000238	-0.4	-0.33	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93690797	chr8:93741193~93744534:+
OV	cis	rs3931020	0.688	rs277374	ENSG00000272864.1	RP11-17E13.2	5.3	2.77e-07	0.000238	0.45	0.33	Resistin levels;	chr1:74734802	chr1:74698769~74699333:-
OV	cis	rs875971	0.545	rs35459055	ENSG00000236529.1	RP13-254B10.1	5.3	2.77e-07	0.000238	0.4	0.33	Aortic root size;	chr7:66479399	chr7:65840212~65840596:+
OV	cis	rs16873450	0.527	rs7792188	ENSG00000234800.2	PCMTD1P3	-5.3	2.78e-07	0.000239	-0.35	-0.33	Verbal memory performance (residualized delayed recall level);	chr7:23790140	chr7:23721311~23721782:-
OV	cis	rs4865169	1	rs4865169	ENSG00000269949.1	RP11-738E22.3	-5.3	2.78e-07	0.000239	-0.38	-0.33	Breast cancer;	chr4:57013626	chr4:56960927~56961373:-
OV	cis	rs5742933	0.597	rs6756913	ENSG00000253559.1	OSGEPL1-AS1	5.3	2.78e-07	0.000239	0.36	0.33	Ferritin levels;	chr2:189641040	chr2:189762704~189765556:+
OV	cis	rs4908768	0.579	rs7520572	ENSG00000228423.2	RP4-633I8.4	5.3	2.78e-07	0.000239	0.37	0.33	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8811631	chr1:8805860~8807051:-
OV	cis	rs4713118	0.516	rs6931858	ENSG00000280107.1	AL022393.9	-5.3	2.78e-07	0.000239	-0.43	-0.33	Parkinson's disease;	chr6:28110633	chr6:28170845~28172521:+
OV	cis	rs13068223	0.967	rs344035	ENSG00000243926.1	TIPARP-AS1	-5.3	2.79e-07	0.00024	-0.32	-0.33	Age-related hearing impairment (SNP x SNP interaction);	chr3:156743490	chr3:156671862~156674378:-
OV	cis	rs2253762	0.507	rs10159998	ENSG00000276742.1	RP11-500G22.4	5.3	2.79e-07	0.00024	0.56	0.33	Breast cancer;	chr10:121994550	chr10:121956782~121957098:+
OV	cis	rs2253762	0.54	rs11200311	ENSG00000276742.1	RP11-500G22.4	5.3	2.79e-07	0.00024	0.56	0.33	Breast cancer;	chr10:121995094	chr10:121956782~121957098:+
OV	cis	rs2253762	0.54	rs79069897	ENSG00000276742.1	RP11-500G22.4	5.3	2.79e-07	0.00024	0.56	0.33	Breast cancer;	chr10:121995680	chr10:121956782~121957098:+
OV	cis	rs2253762	0.54	rs77032313	ENSG00000276742.1	RP11-500G22.4	5.3	2.79e-07	0.00024	0.56	0.33	Breast cancer;	chr10:121995687	chr10:121956782~121957098:+
OV	cis	rs2253762	0.54	rs4752631	ENSG00000276742.1	RP11-500G22.4	5.3	2.79e-07	0.00024	0.56	0.33	Breast cancer;	chr10:121996442	chr10:121956782~121957098:+
OV	cis	rs2253762	0.54	rs11200313	ENSG00000276742.1	RP11-500G22.4	5.3	2.79e-07	0.00024	0.56	0.33	Breast cancer;	chr10:121996523	chr10:121956782~121957098:+
OV	cis	rs12594515	0.967	rs11854477	ENSG00000273972.1	CTD-2306A12.1	-5.3	2.8e-07	0.00024	-0.36	-0.33	Weight;Waist circumference;	chr15:45706147	chr15:45702640~45703183:+
OV	cis	rs1426063	0.614	rs76087197	ENSG00000260265.1	RP11-44F21.5	5.3	2.8e-07	0.000241	0.64	0.33	QT interval;	chr4:75134108	chr4:75081702~75084717:-
OV	cis	rs4908768	0.911	rs6693127	ENSG00000228423.2	RP4-633I8.4	5.3	2.8e-07	0.000241	0.38	0.33	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8714914	chr1:8805860~8807051:-
OV	cis	rs2153535	0.585	rs6597343	ENSG00000230939.1	RP11-314C16.1	-5.3	2.8e-07	0.000241	-0.36	-0.33	Motion sickness;	chr6:8620270	chr6:8784178~8785445:+
OV	cis	rs2688608	0.592	rs7076585	ENSG00000271816.1	BMS1P4	5.3	2.8e-07	0.000241	0.31	0.33	Inflammatory bowel disease;	chr10:73743934	chr10:73699151~73730487:-
OV	cis	rs7771547	0.507	rs6457918	ENSG00000240733.3	RN7SL502P	-5.3	2.81e-07	0.000241	-0.36	-0.33	Platelet distribution width;	chr6:36446531	chr6:36450912~36451201:-
OV	cis	rs8105895	0.932	rs12150930	ENSG00000269742.1	BNIP3P29	5.29	2.81e-07	0.000241	0.52	0.33	Body mass index (change over time);	chr19:22040885	chr19:22065828~22066398:-
OV	cis	rs10740039	1	rs10761541	ENSG00000254271.1	RP11-131N11.4	5.29	2.82e-07	0.000242	0.41	0.33	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655383	chr10:60734342~60741828:+
OV	cis	rs67311347	1	rs2276868	ENSG00000223797.4	ENTPD3-AS1	-5.29	2.82e-07	0.000242	-0.36	-0.33	Renal cell carcinoma;	chr3:40457354	chr3:40313802~40453329:-
OV	cis	rs2380205	0.546	rs633928	ENSG00000232807.2	RP11-536K7.3	-5.29	2.83e-07	0.000243	-0.34	-0.33	Breast cancer;	chr10:5902547	chr10:5934270~5945900:-
OV	cis	rs957448	1	rs72674866	ENSG00000253704.1	RP11-267M23.4	5.29	2.83e-07	0.000243	0.46	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94564619	chr8:94553722~94569745:+
OV	cis	rs957448	1	rs55897841	ENSG00000253704.1	RP11-267M23.4	5.29	2.83e-07	0.000243	0.46	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94565042	chr8:94553722~94569745:+
OV	cis	rs957448	0.948	rs72674867	ENSG00000253704.1	RP11-267M23.4	5.29	2.83e-07	0.000243	0.46	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94565973	chr8:94553722~94569745:+
OV	cis	rs10510102	0.872	rs7907815	ENSG00000226864.1	ATE1-AS1	5.29	2.84e-07	0.000243	0.53	0.33	Breast cancer;	chr10:121965951	chr10:121928312~121951965:+
OV	cis	rs7116641	0.771	rs7115970	ENSG00000246250.2	RP11-613D13.5	-5.29	2.84e-07	0.000243	-0.38	-0.33	Coronary artery disease;	chr11:43747745	chr11:43829709~43880726:-
OV	cis	rs7116641	0.663	rs10768976	ENSG00000246250.2	RP11-613D13.5	-5.29	2.84e-07	0.000243	-0.38	-0.33	Coronary artery disease;	chr11:43752263	chr11:43829709~43880726:-
OV	cis	rs7116641	0.697	rs4643069	ENSG00000246250.2	RP11-613D13.5	-5.29	2.84e-07	0.000243	-0.38	-0.33	Coronary artery disease;	chr11:43754184	chr11:43829709~43880726:-
OV	cis	rs7429990	0.965	rs6770467	ENSG00000229759.1	MRPS18AP1	-5.29	2.84e-07	0.000244	-0.34	-0.33	Educational attainment (years of education);	chr3:47977742	chr3:48256350~48256938:-
OV	cis	rs7429990	0.932	rs6770477	ENSG00000229759.1	MRPS18AP1	-5.29	2.84e-07	0.000244	-0.34	-0.33	Educational attainment (years of education);	chr3:47977768	chr3:48256350~48256938:-
OV	cis	rs7429990	0.965	rs28637561	ENSG00000229759.1	MRPS18AP1	-5.29	2.84e-07	0.000244	-0.34	-0.33	Educational attainment (years of education);	chr3:47979528	chr3:48256350~48256938:-
OV	cis	rs7429990	0.965	rs7427418	ENSG00000229759.1	MRPS18AP1	-5.29	2.84e-07	0.000244	-0.34	-0.33	Educational attainment (years of education);	chr3:47981217	chr3:48256350~48256938:-
OV	cis	rs7429990	0.965	rs13075795	ENSG00000229759.1	MRPS18AP1	-5.29	2.84e-07	0.000244	-0.34	-0.33	Educational attainment (years of education);	chr3:47983139	chr3:48256350~48256938:-
OV	cis	rs7429990	0.965	rs7431572	ENSG00000229759.1	MRPS18AP1	-5.29	2.84e-07	0.000244	-0.34	-0.33	Educational attainment (years of education);	chr3:47986361	chr3:48256350~48256938:-
OV	cis	rs7429990	0.965	rs13074973	ENSG00000229759.1	MRPS18AP1	-5.29	2.84e-07	0.000244	-0.34	-0.33	Educational attainment (years of education);	chr3:47986654	chr3:48256350~48256938:-
OV	cis	rs7429990	0.965	rs9811277	ENSG00000229759.1	MRPS18AP1	5.29	2.84e-07	0.000244	0.34	0.33	Educational attainment (years of education);	chr3:47970148	chr3:48256350~48256938:-
OV	cis	rs7429990	0.965	rs9814961	ENSG00000229759.1	MRPS18AP1	5.29	2.84e-07	0.000244	0.34	0.33	Educational attainment (years of education);	chr3:47976127	chr3:48256350~48256938:-
OV	cis	rs853679	0.517	rs36078605	ENSG00000280107.1	AL022393.9	-5.29	2.84e-07	0.000244	-0.41	-0.33	Depression;	chr6:28110254	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9393891	ENSG00000280107.1	AL022393.9	-5.29	2.84e-07	0.000244	-0.41	-0.33	Depression;	chr6:28111382	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9468286	ENSG00000280107.1	AL022393.9	-5.29	2.84e-07	0.000244	-0.41	-0.33	Depression;	chr6:28111650	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9380055	ENSG00000280107.1	AL022393.9	-5.29	2.84e-07	0.000244	-0.41	-0.33	Depression;	chr6:28113851	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9368553	ENSG00000280107.1	AL022393.9	-5.29	2.84e-07	0.000244	-0.41	-0.33	Depression;	chr6:28114487	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9368554	ENSG00000280107.1	AL022393.9	-5.29	2.84e-07	0.000244	-0.41	-0.33	Depression;	chr6:28114933	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs4713137	ENSG00000280107.1	AL022393.9	-5.29	2.84e-07	0.000244	-0.41	-0.33	Depression;	chr6:28115743	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9348793	ENSG00000280107.1	AL022393.9	-5.29	2.84e-07	0.000244	-0.41	-0.33	Depression;	chr6:28116411	chr6:28170845~28172521:+
OV	cis	rs4713118	0.586	rs6905516	ENSG00000280107.1	AL022393.9	-5.29	2.84e-07	0.000244	-0.41	-0.33	Parkinson's disease;	chr6:28118700	chr6:28170845~28172521:+
OV	cis	rs4713118	0.586	rs6905522	ENSG00000280107.1	AL022393.9	-5.29	2.84e-07	0.000244	-0.41	-0.33	Parkinson's disease;	chr6:28118701	chr6:28170845~28172521:+
OV	cis	rs4713118	0.586	rs9468290	ENSG00000280107.1	AL022393.9	-5.29	2.84e-07	0.000244	-0.41	-0.33	Parkinson's disease;	chr6:28119896	chr6:28170845~28172521:+
OV	cis	rs858239	0.632	rs13438452	ENSG00000230042.1	AK3P3	-5.29	2.85e-07	0.000244	-0.34	-0.33	Cerebrospinal fluid biomarker levels;	chr7:23134563	chr7:23129178~23129841:+
OV	cis	rs2739330	0.587	rs4820571	ENSG00000224205.1	AP000351.4	5.29	2.85e-07	0.000244	0.37	0.33	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23987320~23991421:-
OV	cis	rs1061377	0.513	rs2566166	ENSG00000249207.1	RP11-360F5.1	5.29	2.86e-07	0.000245	0.4	0.33	Uric acid levels;	chr4:39148404	chr4:39112677~39126818:-
OV	cis	rs7615952	0.576	rs4646748	ENSG00000171084.14	FAM86JP	5.29	2.86e-07	0.000245	0.49	0.33	Blood pressure (smoking interaction);	chr3:126107486	chr3:125916620~125930024:+
OV	cis	rs4713118	0.516	rs7739216	ENSG00000280107.1	AL022393.9	-5.29	2.87e-07	0.000246	-0.42	-0.33	Parkinson's disease;	chr6:28112168	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs35512245	ENSG00000280107.1	AL022393.9	-5.29	2.87e-07	0.000246	-0.42	-0.33	Depression;	chr6:28112175	chr6:28170845~28172521:+
OV	cis	rs2253762	0.54	rs10887036	ENSG00000276742.1	RP11-500G22.4	5.29	2.88e-07	0.000246	0.56	0.33	Breast cancer;	chr10:121997570	chr10:121956782~121957098:+
OV	cis	rs2253762	0.54	rs10887037	ENSG00000276742.1	RP11-500G22.4	5.29	2.88e-07	0.000246	0.56	0.33	Breast cancer;	chr10:121997572	chr10:121956782~121957098:+
OV	cis	rs34779708	0.75	rs35032841	ENSG00000230534.5	RP11-297A16.2	5.29	2.88e-07	0.000246	0.43	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35023759	chr10:35098006~35127020:-
OV	cis	rs34779708	0.742	rs35912711	ENSG00000230534.5	RP11-297A16.2	5.29	2.88e-07	0.000246	0.43	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35024068	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs4934702	ENSG00000230534.5	RP11-297A16.2	5.29	2.88e-07	0.000246	0.43	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35034146	chr10:35098006~35127020:-
OV	cis	rs7017914	0.905	rs2732115	ENSG00000223220.1	Y_RNA	5.29	2.88e-07	0.000247	0.35	0.33	Bone mineral density;	chr8:71016619	chr8:70780914~70781008:-
OV	cis	rs116095464	0.558	rs62347678	ENSG00000250848.1	CTD-2083E4.5	-5.29	2.89e-07	0.000247	-0.41	-0.33	Breast cancer;	chr5:227381	chr5:288833~290321:-
OV	cis	rs13315649	0.614	rs7609765	ENSG00000277250.1	Metazoa_SRP	-5.29	2.89e-07	0.000247	-0.43	-0.33	Sum eosinophil basophil counts;	chr3:128688295	chr3:128673681~128674021:-
OV	cis	rs13315649	0.724	rs28787069	ENSG00000277250.1	Metazoa_SRP	-5.29	2.89e-07	0.000247	-0.43	-0.33	Sum eosinophil basophil counts;	chr3:128695613	chr3:128673681~128674021:-
OV	cis	rs67383717	0.672	rs589458	ENSG00000175611.10	LINC00476	5.29	2.89e-07	0.000248	0.36	0.33	Parkinson's disease (pesticide exposure interaction);	chr9:95878389	chr9:95759231~95875977:-
OV	cis	rs17741873	0.72	rs16931023	ENSG00000224195.1	RP11-574K11.5	5.29	2.9e-07	0.000248	0.49	0.33	Paclitaxel disposition in epithelial ovarian cancer;	chr10:73924035	chr10:73813518~73814737:+
OV	cis	rs611744	0.625	rs11991891	ENSG00000253754.1	RP11-35G22.1	-5.29	2.9e-07	0.000248	-0.36	-0.33	Dupuytren's disease;	chr8:108282629	chr8:108226200~108227544:+
OV	cis	rs10463554	0.853	rs2432177	ENSG00000175749.11	EIF3KP1	5.29	2.91e-07	0.000249	0.39	0.33	Parkinson's disease;	chr5:103236172	chr5:103032376~103033031:+
OV	cis	rs4266144	0.592	rs1545854	ENSG00000244515.1	KRT18P34	5.29	2.93e-07	0.00025	0.43	0.33	Coronary artery disease;	chr3:157122349	chr3:157162663~157163932:-
OV	cis	rs12022452	0.506	rs61779163	ENSG00000238287.1	RP11-656D10.3	-5.29	2.93e-07	0.000251	-0.56	-0.33	Age-related hearing impairment (SNP x SNP interaction);	chr1:40549751	chr1:40493157~40508661:-
OV	cis	rs301901	1	rs158622	ENSG00000250155.1	CTD-2353F22.1	5.29	2.94e-07	0.000251	0.38	0.33	Height;	chr5:36887793	chr5:36666214~36725195:-
OV	cis	rs7587476	0.784	rs17424051	ENSG00000229267.2	AC072062.1	-5.29	2.94e-07	0.000251	-0.43	-0.33	Neuroblastoma;	chr2:214824268	chr2:214810229~214963274:+
OV	cis	rs8105895	1	rs117638181	ENSG00000269742.1	BNIP3P29	5.29	2.94e-07	0.000251	0.5	0.33	Body mass index (change over time);	chr19:21980212	chr19:22065828~22066398:-
OV	cis	rs34779708	0.966	rs12775799	ENSG00000230534.5	RP11-297A16.2	5.29	2.94e-07	0.000251	0.42	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35199336	chr10:35098006~35127020:-
OV	cis	rs10510102	0.608	rs4077606	ENSG00000226864.1	ATE1-AS1	-5.29	2.94e-07	0.000251	-0.48	-0.33	Breast cancer;	chr10:121849907	chr10:121928312~121951965:+
OV	cis	rs7017914	0.69	rs7013793	ENSG00000223220.1	Y_RNA	5.28	2.95e-07	0.000252	0.38	0.33	Bone mineral density;	chr8:71061317	chr8:70780914~70781008:-
OV	cis	rs7017914	0.69	rs35201629	ENSG00000223220.1	Y_RNA	5.28	2.95e-07	0.000252	0.38	0.33	Bone mineral density;	chr8:71062264	chr8:70780914~70781008:-
OV	cis	rs858239	0.6	rs28499396	ENSG00000230042.1	AK3P3	-5.28	2.96e-07	0.000252	-0.35	-0.33	Cerebrospinal fluid biomarker levels;	chr7:23084479	chr7:23129178~23129841:+
OV	cis	rs4853012	0.838	rs60705299	ENSG00000257800.1	FNBP1P1	5.28	2.96e-07	0.000253	0.46	0.33	Gestational age at birth (maternal effect);	chr2:74118243	chr2:74120680~74123218:+
OV	cis	rs858239	0.601	rs929507	ENSG00000230042.1	AK3P3	-5.28	2.97e-07	0.000253	-0.34	-0.33	Cerebrospinal fluid biomarker levels;	chr7:23127045	chr7:23129178~23129841:+
OV	cis	rs858239	0.601	rs929508	ENSG00000230042.1	AK3P3	-5.28	2.97e-07	0.000253	-0.34	-0.33	Cerebrospinal fluid biomarker levels;	chr7:23127090	chr7:23129178~23129841:+
OV	cis	rs11690935	0.731	rs10930491	ENSG00000228389.1	AC068039.4	-5.28	2.97e-07	0.000253	-0.37	-0.33	Schizophrenia;	chr2:171713314	chr2:171773482~171775844:+
OV	cis	rs7615952	0.641	rs7632497	ENSG00000171084.14	FAM86JP	5.28	2.98e-07	0.000254	0.48	0.33	Blood pressure (smoking interaction);	chr3:126064243	chr3:125916620~125930024:+
OV	cis	rs7615952	0.641	rs12487875	ENSG00000171084.14	FAM86JP	5.28	2.98e-07	0.000254	0.48	0.33	Blood pressure (smoking interaction);	chr3:126068381	chr3:125916620~125930024:+
OV	cis	rs875971	0.545	rs73376394	ENSG00000226824.5	RP4-756H11.3	-5.28	2.98e-07	0.000254	-0.39	-0.33	Aortic root size;	chr7:66172694	chr7:66654538~66669855:+
OV	cis	rs7615952	0.512	rs4234285	ENSG00000171084.14	FAM86JP	5.28	2.98e-07	0.000254	0.5	0.33	Blood pressure (smoking interaction);	chr3:125685633	chr3:125916620~125930024:+
OV	cis	rs7116641	0.737	rs10742688	ENSG00000246250.2	RP11-613D13.5	-5.28	2.99e-07	0.000254	-0.39	-0.33	Coronary artery disease;	chr11:43746704	chr11:43829709~43880726:-
OV	cis	rs7116641	0.697	rs7115919	ENSG00000246250.2	RP11-613D13.5	-5.28	2.99e-07	0.000254	-0.39	-0.33	Coronary artery disease;	chr11:43754931	chr11:43829709~43880726:-
OV	cis	rs611744	0.647	rs9969614	ENSG00000253754.1	RP11-35G22.1	-5.28	2.99e-07	0.000255	-0.36	-0.33	Dupuytren's disease;	chr8:108248352	chr8:108226200~108227544:+
OV	cis	rs1075265	0.589	rs2253760	ENSG00000233266.1	HMGB1P31	5.28	2.99e-07	0.000255	0.42	0.33	Chronotype;Morning vs. evening chronotype;	chr2:53806851	chr2:54051334~54051760:+
OV	cis	rs6088580	0.634	rs1205344	ENSG00000206582.1	Y_RNA	5.28	3e-07	0.000256	0.4	0.33	Glomerular filtration rate (creatinine);	chr20:34330492	chr20:34526510~34526606:-
OV	cis	rs6088580	0.668	rs1205340	ENSG00000206582.1	Y_RNA	5.28	3e-07	0.000256	0.4	0.33	Glomerular filtration rate (creatinine);	chr20:34336065	chr20:34526510~34526606:-
OV	cis	rs5742933	0.817	rs1233265	ENSG00000253559.1	OSGEPL1-AS1	-5.28	3.01e-07	0.000256	-0.34	-0.33	Ferritin levels;	chr2:189796390	chr2:189762704~189765556:+
OV	cis	rs8062405	0.824	rs62034319	ENSG00000278665.1	RP11-666O2.4	5.28	3.02e-07	0.000257	0.34	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520867	chr16:28599241~28601881:-
OV	cis	rs7617773	0.817	rs3937	ENSG00000228638.1	FCF1P2	-5.28	3.02e-07	0.000257	-0.41	-0.33	Coronary artery disease;	chr3:48270912	chr3:48290793~48291375:-
OV	cis	rs992157	1	rs6736362	ENSG00000237281.1	CATIP-AS2	-5.28	3.03e-07	0.000258	-0.39	-0.33	Colorectal cancer;	chr2:218250385	chr2:218326889~218357966:-
OV	cis	rs10510102	0.872	rs12264046	ENSG00000276742.1	RP11-500G22.4	5.28	3.03e-07	0.000258	0.54	0.33	Breast cancer;	chr10:121894996	chr10:121956782~121957098:+
OV	cis	rs875971	0.54	rs781152	ENSG00000224316.1	RP11-479O9.2	5.28	3.03e-07	0.000258	0.35	0.33	Aortic root size;	chr7:66014585	chr7:65773620~65802067:+
OV	cis	rs17711722	0.727	rs781151	ENSG00000224316.1	RP11-479O9.2	5.28	3.03e-07	0.000258	0.35	0.33	Calcium levels;	chr7:66014891	chr7:65773620~65802067:+
OV	cis	rs9291683	0.588	rs3733586	ENSG00000250413.1	RP11-448G15.1	-5.28	3.03e-07	0.000258	-0.36	-0.33	Bone mineral density;	chr4:9995910	chr4:10006482~10009725:+
OV	cis	rs858239	0.601	rs10224327	ENSG00000230042.1	AK3P3	-5.28	3.03e-07	0.000258	-0.35	-0.33	Cerebrospinal fluid biomarker levels;	chr7:23122201	chr7:23129178~23129841:+
OV	cis	rs7773456	0.576	rs12206194	ENSG00000228412.5	RP4-625H18.2	5.28	3.05e-07	0.000259	0.44	0.33	Lupus nephritis in systemic lupus erythematosus;	chr6:19819677	chr6:19802164~19804752:-
OV	cis	rs4591358	0.608	rs13003168	ENSG00000223466.1	AC064834.2	-5.28	3.06e-07	0.00026	-0.52	-0.33	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195496394	chr2:195533035~195538681:+
OV	cis	rs7688540	0.771	rs12505835	ENSG00000275426.1	CH17-262A2.1	5.28	3.07e-07	0.000261	0.56	0.33	Facial morphology (factor 6, height of vermillion lower lip);	chr4:303736	chr4:149738~150317:+
OV	cis	rs7617773	0.817	rs745116	ENSG00000228638.1	FCF1P2	-5.28	3.07e-07	0.000261	-0.41	-0.33	Coronary artery disease;	chr3:48231046	chr3:48290793~48291375:-
OV	cis	rs1134634	0.52	rs28522268	ENSG00000273133.1	RP11-799M12.2	-5.28	3.08e-07	0.000262	-0.44	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15601844	chr4:15563698~15564253:-
OV	cis	rs875971	0.767	rs12668005	ENSG00000236529.1	RP13-254B10.1	5.28	3.09e-07	0.000262	0.35	0.33	Aortic root size;	chr7:66444034	chr7:65840212~65840596:+
OV	cis	rs4763879	0.778	rs7977940	ENSG00000278635.1	CTD-2318O12.1	5.27	3.1e-07	0.000263	0.28	0.33	Type 1 diabetes;	chr12:9686320	chr12:9415641~9416718:+
OV	cis	rs9660180	0.967	rs10907191	ENSG00000268575.1	RP1-283E3.8	-5.27	3.11e-07	0.000264	-0.31	-0.33	Body mass index;	chr1:1843381	chr1:1702736~1737688:-
OV	cis	rs11673344	0.8	rs8108214	ENSG00000226686.6	LINC01535	-5.27	3.12e-07	0.000265	-0.43	-0.33	Obesity-related traits;	chr19:37025184	chr19:37251912~37265535:+
OV	cis	rs7580658	0.864	rs3088374	ENSG00000236682.1	AC068282.3	-5.27	3.12e-07	0.000265	-0.42	-0.33	Protein C levels;	chr2:127304472	chr2:127389130~127400580:+
OV	cis	rs7116641	0.734	rs7118906	ENSG00000246250.2	RP11-613D13.5	-5.27	3.13e-07	0.000265	-0.38	-0.33	Coronary artery disease;	chr11:43795770	chr11:43829709~43880726:-
OV	cis	rs34779708	0.931	rs34087268	ENSG00000230534.5	RP11-297A16.2	5.27	3.15e-07	0.000267	0.44	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35057796	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs58159560	ENSG00000230534.5	RP11-297A16.2	5.27	3.15e-07	0.000267	0.44	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35062321	chr10:35098006~35127020:-
OV	cis	rs9291683	0.609	rs55959894	ENSG00000250413.1	RP11-448G15.1	-5.27	3.15e-07	0.000267	-0.37	-0.33	Bone mineral density;	chr4:10024956	chr4:10006482~10009725:+
OV	cis	rs526231	0.511	rs34823	ENSG00000175749.11	EIF3KP1	-5.27	3.16e-07	0.000268	-0.39	-0.33	Primary biliary cholangitis;	chr5:103102587	chr5:103032376~103033031:+
OV	cis	rs6991838	0.584	rs35790435	ENSG00000200714.1	Y_RNA	-5.27	3.16e-07	0.000268	-0.42	-0.33	Intelligence (multi-trait analysis);	chr8:65590288	chr8:65592731~65592820:+
OV	cis	rs34779708	0.931	rs11596502	ENSG00000230534.5	RP11-297A16.2	5.27	3.17e-07	0.000268	0.44	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35098259	chr10:35098006~35127020:-
OV	cis	rs2188561	1	rs2188561	ENSG00000241764.3	AC002467.7	5.27	3.17e-07	0.000269	0.41	0.33	Alcohol consumption;	chr7:107695613	chr7:107742817~107744581:-
OV	cis	rs2188561	1	rs2712208	ENSG00000241764.3	AC002467.7	5.27	3.17e-07	0.000269	0.41	0.33	Alcohol consumption;	chr7:107703317	chr7:107742817~107744581:-
OV	cis	rs8062405	0.789	rs151174	ENSG00000278665.1	RP11-666O2.4	5.27	3.17e-07	0.000269	0.35	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28496748	chr16:28599241~28601881:-
OV	cis	rs9291683	0.655	rs3822242	ENSG00000250413.1	RP11-448G15.1	5.27	3.18e-07	0.00027	0.37	0.33	Bone mineral density;	chr4:10093280	chr4:10006482~10009725:+
OV	cis	rs301901	0.828	rs4304095	ENSG00000250155.1	CTD-2353F22.1	5.27	3.2e-07	0.00027	0.38	0.33	Height;	chr5:37454360	chr5:36666214~36725195:-
OV	cis	rs889312	0.532	rs16886181	ENSG00000271828.1	CTD-2310F14.1	5.27	3.2e-07	0.000271	0.55	0.33	Breast cancer (early onset);Breast cancer;	chr5:56733416	chr5:56927874~56929573:+
OV	cis	rs853679	0.517	rs1340004	ENSG00000280107.1	AL022393.9	-5.27	3.21e-07	0.000271	-0.41	-0.33	Depression;	chr6:28135913	chr6:28170845~28172521:+
OV	cis	rs62355900	0.627	rs59715006	ENSG00000271828.1	CTD-2310F14.1	5.27	3.21e-07	0.000271	0.6	0.33	Endometriosis;	chr5:56899820	chr5:56927874~56929573:+
OV	cis	rs16873450	0.527	rs1469000	ENSG00000234800.2	PCMTD1P3	5.27	3.21e-07	0.000271	0.33	0.33	Verbal memory performance (residualized delayed recall level);	chr7:23770986	chr7:23721311~23721782:-
OV	cis	rs61990749	0.597	rs176943	ENSG00000239272.1	RPL21P10	-5.27	3.22e-07	0.000272	-0.47	-0.33	Fibroblast growth factor basic levels;	chr14:77709454	chr14:77683202~77683989:-
OV	cis	rs5742933	0.857	rs1233284	ENSG00000253559.1	OSGEPL1-AS1	-5.27	3.22e-07	0.000272	-0.35	-0.33	Ferritin levels;	chr2:189825045	chr2:189762704~189765556:+
OV	cis	rs5742933	0.817	rs1233288	ENSG00000253559.1	OSGEPL1-AS1	-5.27	3.22e-07	0.000272	-0.35	-0.33	Ferritin levels;	chr2:189825999	chr2:189762704~189765556:+
OV	cis	rs4805272	1	rs7254988	ENSG00000267243.4	AC005307.3	-5.27	3.23e-07	0.000273	-0.44	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28835250	chr19:28435388~28727777:-
OV	cis	rs8062405	0.755	rs56209193	ENSG00000278665.1	RP11-666O2.4	5.27	3.24e-07	0.000273	0.35	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574315	chr16:28599241~28601881:-
OV	cis	rs7617773	0.817	rs9847953	ENSG00000228638.1	FCF1P2	-5.27	3.24e-07	0.000273	-0.41	-0.33	Coronary artery disease;	chr3:48241205	chr3:48290793~48291375:-
OV	cis	rs10916248	0.569	rs4654002	ENSG00000232628.4	RP11-365O16.3	5.27	3.24e-07	0.000274	0.4	0.33	QT interval (drug interaction);	chr1:224075680	chr1:224208747~224213279:-
OV	cis	rs67311347	0.955	rs11711994	ENSG00000223797.4	ENTPD3-AS1	5.26	3.25e-07	0.000274	0.37	0.33	Renal cell carcinoma;	chr3:40349595	chr3:40313802~40453329:-
OV	cis	rs7580658	0.857	rs11890187	ENSG00000236682.1	AC068282.3	-5.26	3.26e-07	0.000275	-0.42	-0.33	Protein C levels;	chr2:127326162	chr2:127389130~127400580:+
OV	cis	rs2286503	1	rs2286499	ENSG00000228649.7	AC005682.5	5.26	3.26e-07	0.000275	0.38	0.33	Fibrinogen;	chr7:22817858	chr7:22854178~22861579:+
OV	cis	rs16873450	0.9	rs2390811	ENSG00000234800.2	PCMTD1P3	-5.26	3.28e-07	0.000277	-0.33	-0.33	Verbal memory performance (residualized delayed recall level);	chr7:23757037	chr7:23721311~23721782:-
OV	cis	rs34779708	0.931	rs67976880	ENSG00000230534.5	RP11-297A16.2	5.26	3.28e-07	0.000277	0.44	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35083333	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs72789687	ENSG00000230534.5	RP11-297A16.2	5.26	3.28e-07	0.000277	0.44	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35083561	chr10:35098006~35127020:-
OV	cis	rs11673344	0.67	rs73039188	ENSG00000226686.6	LINC01535	5.26	3.28e-07	0.000277	0.43	0.33	Obesity-related traits;	chr19:36922449	chr19:37251912~37265535:+
OV	cis	rs9660180	0.967	rs2272908	ENSG00000268575.1	RP1-283E3.8	5.26	3.29e-07	0.000277	0.3	0.33	Body mass index;	chr1:1790040	chr1:1702736~1737688:-
OV	cis	rs11673344	0.864	rs11667146	ENSG00000226686.6	LINC01535	5.26	3.29e-07	0.000277	0.44	0.33	Obesity-related traits;	chr19:37004493	chr19:37251912~37265535:+
OV	cis	rs73019876	0.522	rs987711	ENSG00000269742.1	BNIP3P29	5.26	3.29e-07	0.000277	0.38	0.33	Testicular germ cell tumor;	chr19:22117205	chr19:22065828~22066398:-
OV	cis	rs2367970	0.57	rs7123583	ENSG00000254851.1	RP11-109L13.1	5.26	3.29e-07	0.000278	0.45	0.33	HDL cholesterol;	chr11:116729305	chr11:117135528~117138582:+
OV	cis	rs301901	0.796	rs62361483	ENSG00000250155.1	CTD-2353F22.1	5.26	3.29e-07	0.000278	0.38	0.33	Height;	chr5:37468413	chr5:36666214~36725195:-
OV	cis	rs35160687	0.901	rs17738096	ENSG00000273080.1	RP11-301O19.1	5.26	3.3e-07	0.000278	0.34	0.33	Night sleep phenotypes;	chr2:86286770	chr2:86195590~86196049:+
OV	cis	rs526231	0.578	rs6867392	ENSG00000175749.11	EIF3KP1	5.26	3.3e-07	0.000278	0.4	0.33	Primary biliary cholangitis;	chr5:102946183	chr5:103032376~103033031:+
OV	cis	rs875971	0.545	rs10950036	ENSG00000236529.1	RP13-254B10.1	5.26	3.3e-07	0.000278	0.4	0.33	Aortic root size;	chr7:66353241	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs73148639	ENSG00000236529.1	RP13-254B10.1	5.26	3.3e-07	0.000278	0.4	0.33	Aortic root size;	chr7:66390342	chr7:65840212~65840596:+
OV	cis	rs67311347	0.866	rs11712426	ENSG00000223797.4	ENTPD3-AS1	5.26	3.3e-07	0.000278	0.36	0.33	Renal cell carcinoma;	chr3:40288831	chr3:40313802~40453329:-
OV	cis	rs875971	0.577	rs35072105	ENSG00000224316.1	RP11-479O9.2	-5.26	3.31e-07	0.000279	-0.35	-0.33	Aortic root size;	chr7:66144830	chr7:65773620~65802067:+
OV	cis	rs11673344	0.864	rs703530	ENSG00000226686.6	LINC01535	5.26	3.32e-07	0.000279	0.43	0.33	Obesity-related traits;	chr19:37010016	chr19:37251912~37265535:+
OV	cis	rs11673344	0.864	rs826322	ENSG00000226686.6	LINC01535	5.26	3.32e-07	0.000279	0.43	0.33	Obesity-related traits;	chr19:37013694	chr19:37251912~37265535:+
OV	cis	rs11673344	0.8	rs826323	ENSG00000226686.6	LINC01535	5.26	3.32e-07	0.000279	0.43	0.33	Obesity-related traits;	chr19:37014051	chr19:37251912~37265535:+
OV	cis	rs7302981	0.702	rs2358538	ENSG00000272368.2	RP4-605O3.4	-5.26	3.32e-07	0.00028	-0.38	-0.33	Systolic blood pressure;	chr12:50192844	chr12:50112197~50165618:+
OV	cis	rs957448	0.554	rs12682601	ENSG00000253704.1	RP11-267M23.4	5.26	3.34e-07	0.000281	0.44	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94582492	chr8:94553722~94569745:+
OV	cis	rs17445774	0.857	rs6435043	ENSG00000232732.8	AC073043.1	-5.26	3.34e-07	0.000281	-0.43	-0.33	LDL cholesterol to HDL cholesterol ratio;	chr2:200036251	chr2:199867396~199911159:-
OV	cis	rs7188445	0.592	rs4404082	ENSG00000261390.4	RP11-345M22.2	5.26	3.34e-07	0.000281	0.38	0.33	Urate levels;	chr16:79716615	chr16:79715232~79770563:-
OV	cis	rs3758911	1	rs10789618	ENSG00000261098.1	RP11-819C21.1	-5.26	3.35e-07	0.000282	-0.31	-0.33	Coronary artery disease;	chr11:107319003	chr11:107312132~107316271:-
OV	cis	rs507080	0.733	rs517445	ENSG00000278376.1	RP11-158I9.8	-5.26	3.36e-07	0.000282	-0.34	-0.33	Serum metabolite levels;	chr11:118702826	chr11:118791254~118793137:+
OV	cis	rs507080	0.771	rs687664	ENSG00000278376.1	RP11-158I9.8	-5.26	3.36e-07	0.000282	-0.34	-0.33	Serum metabolite levels;	chr11:118703476	chr11:118791254~118793137:+
OV	cis	rs507080	0.771	rs523715	ENSG00000278376.1	RP11-158I9.8	-5.26	3.36e-07	0.000282	-0.34	-0.33	Serum metabolite levels;	chr11:118703479	chr11:118791254~118793137:+
OV	cis	rs11690935	0.589	rs2271758	ENSG00000228389.1	AC068039.4	-5.26	3.36e-07	0.000283	-0.38	-0.33	Schizophrenia;	chr2:171844647	chr2:171773482~171775844:+
OV	cis	rs4805272	0.512	rs7260055	ENSG00000267243.4	AC005307.3	-5.26	3.37e-07	0.000283	-0.6	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28850692	chr19:28435388~28727777:-
OV	cis	rs858239	0.57	rs10235467	ENSG00000230042.1	AK3P3	-5.26	3.37e-07	0.000283	-0.34	-0.33	Cerebrospinal fluid biomarker levels;	chr7:23109189	chr7:23129178~23129841:+
OV	cis	rs11673344	0.864	rs703535	ENSG00000226686.6	LINC01535	5.26	3.37e-07	0.000283	0.43	0.33	Obesity-related traits;	chr19:37014838	chr19:37251912~37265535:+
OV	cis	rs11673344	0.864	rs703537	ENSG00000226686.6	LINC01535	5.26	3.37e-07	0.000283	0.43	0.33	Obesity-related traits;	chr19:37016827	chr19:37251912~37265535:+
OV	cis	rs858239	0.57	rs6968242	ENSG00000230042.1	AK3P3	-5.26	3.39e-07	0.000285	-0.34	-0.33	Cerebrospinal fluid biomarker levels;	chr7:23127792	chr7:23129178~23129841:+
OV	cis	rs4380275	0.809	rs6753699	ENSG00000223751.1	AC116609.2	5.26	3.39e-07	0.000285	0.37	0.33	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:766081	chr2:742488~747767:+
OV	cis	rs4380275	0.782	rs60367761	ENSG00000223751.1	AC116609.2	5.26	3.39e-07	0.000285	0.37	0.33	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:766414	chr2:742488~747767:+
OV	cis	rs34779708	0.931	rs4934721	ENSG00000230534.5	RP11-297A16.2	5.26	3.4e-07	0.000285	0.44	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35088787	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs35136660	ENSG00000230534.5	RP11-297A16.2	5.26	3.4e-07	0.000285	0.44	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35097045	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs12768019	ENSG00000230534.5	RP11-297A16.2	5.26	3.4e-07	0.000285	0.44	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35100915	chr10:35098006~35127020:-
OV	cis	rs11690935	0.632	rs11690807	ENSG00000228389.1	AC068039.4	-5.25	3.42e-07	0.000287	-0.38	-0.33	Schizophrenia;	chr2:171771610	chr2:171773482~171775844:+
OV	cis	rs11992162	1	rs7460395	ENSG00000255556.2	RP11-351I21.6	5.25	3.43e-07	0.000287	0.38	0.33	Monocyte count;	chr8:11977866	chr8:12378679~12380265:-
OV	cis	rs7116641	0.734	rs6485462	ENSG00000246250.2	RP11-613D13.5	-5.25	3.44e-07	0.000288	-0.38	-0.33	Coronary artery disease;	chr11:43794650	chr11:43829709~43880726:-
OV	cis	rs7116641	0.734	rs7118659	ENSG00000246250.2	RP11-613D13.5	-5.25	3.44e-07	0.000288	-0.38	-0.33	Coronary artery disease;	chr11:43795575	chr11:43829709~43880726:-
OV	cis	rs11250098	0.547	rs2409764	ENSG00000255556.2	RP11-351I21.6	5.25	3.44e-07	0.000289	0.35	0.33	Morning vs. evening chronotype;	chr8:11423764	chr8:12378679~12380265:-
OV	cis	rs2243480	0.901	rs778730	ENSG00000226824.5	RP4-756H11.3	-5.25	3.47e-07	0.00029	-0.52	-0.33	Diabetic kidney disease;	chr7:66358338	chr7:66654538~66669855:+
OV	cis	rs1150668	0.83	rs2859365	ENSG00000220721.1	OR1F12	-5.25	3.47e-07	0.000291	-0.33	-0.33	Pubertal anthropometrics;	chr6:28423688	chr6:28073316~28074233:+
OV	cis	rs9291683	0.527	rs3822247	ENSG00000250413.1	RP11-448G15.1	5.25	3.49e-07	0.000292	0.4	0.33	Bone mineral density;	chr4:10093047	chr4:10006482~10009725:+
OV	cis	rs16958445	1	rs16958445	ENSG00000247240.6	UBL7-AS1	5.25	3.49e-07	0.000292	0.76	0.33	Exfoliation glaucoma or exfoliation syndrome;	chr15:73884216	chr15:74461265~74481302:+
OV	cis	rs4908768	0.556	rs11121230	ENSG00000228423.2	RP4-633I8.4	5.25	3.49e-07	0.000292	0.38	0.33	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8774647	chr1:8805860~8807051:-
OV	cis	rs7615952	0.576	rs2276726	ENSG00000171084.14	FAM86JP	5.25	3.49e-07	0.000292	0.47	0.33	Blood pressure (smoking interaction);	chr3:126107444	chr3:125916620~125930024:+
OV	cis	rs2999052	0.602	rs4241495	ENSG00000277250.1	Metazoa_SRP	-5.25	3.49e-07	0.000292	-0.41	-0.33	Hypospadias;	chr3:128392331	chr3:128673681~128674021:-
OV	cis	rs7309	0.87	rs2358016	ENSG00000227403.1	AC009299.3	5.25	3.5e-07	0.000293	0.41	0.33	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161150919	chr2:161244739~161249050:+
OV	cis	rs10510102	0.935	rs10887014	ENSG00000276742.1	RP11-500G22.4	5.25	3.51e-07	0.000293	0.54	0.33	Breast cancer;	chr10:121892322	chr10:121956782~121957098:+
OV	cis	rs10510102	0.872	rs11818735	ENSG00000276742.1	RP11-500G22.4	5.25	3.51e-07	0.000293	0.54	0.33	Breast cancer;	chr10:121892472	chr10:121956782~121957098:+
OV	cis	rs10510102	0.81	rs12259902	ENSG00000276742.1	RP11-500G22.4	5.25	3.51e-07	0.000293	0.54	0.33	Breast cancer;	chr10:121893017	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs11200228	ENSG00000276742.1	RP11-500G22.4	5.25	3.51e-07	0.000293	0.54	0.33	Breast cancer;	chr10:121893358	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs11200229	ENSG00000276742.1	RP11-500G22.4	5.25	3.51e-07	0.000293	0.54	0.33	Breast cancer;	chr10:121893519	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs10887016	ENSG00000276742.1	RP11-500G22.4	5.25	3.51e-07	0.000293	0.54	0.33	Breast cancer;	chr10:121893830	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs10887018	ENSG00000276742.1	RP11-500G22.4	5.25	3.51e-07	0.000293	0.54	0.33	Breast cancer;	chr10:121894457	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs11200230	ENSG00000276742.1	RP11-500G22.4	5.25	3.51e-07	0.000293	0.54	0.33	Breast cancer;	chr10:121895117	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs11200234	ENSG00000276742.1	RP11-500G22.4	5.25	3.51e-07	0.000293	0.54	0.33	Breast cancer;	chr10:121895851	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs12244951	ENSG00000276742.1	RP11-500G22.4	5.25	3.51e-07	0.000293	0.54	0.33	Breast cancer;	chr10:121896879	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs74362676	ENSG00000276742.1	RP11-500G22.4	5.25	3.51e-07	0.000293	0.54	0.33	Breast cancer;	chr10:121898216	chr10:121956782~121957098:+
OV	cis	rs10510102	0.872	rs3750837	ENSG00000276742.1	RP11-500G22.4	5.25	3.51e-07	0.000293	0.54	0.33	Breast cancer;	chr10:121899080	chr10:121956782~121957098:+
OV	cis	rs10510102	0.872	rs3750836	ENSG00000276742.1	RP11-500G22.4	5.25	3.51e-07	0.000293	0.54	0.33	Breast cancer;	chr10:121899087	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs11200237	ENSG00000276742.1	RP11-500G22.4	5.25	3.51e-07	0.000293	0.54	0.33	Breast cancer;	chr10:121900715	chr10:121956782~121957098:+
OV	cis	rs116095464	1	rs2015774	ENSG00000277812.1	AC021087.1	5.25	3.51e-07	0.000293	0.7	0.33	Breast cancer;	chr5:312843	chr5:262769~262881:+
OV	cis	rs7017914	0.652	rs2639931	ENSG00000223220.1	Y_RNA	5.25	3.52e-07	0.000294	0.38	0.33	Bone mineral density;	chr8:70974202	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs2639932	ENSG00000223220.1	Y_RNA	5.25	3.52e-07	0.000294	0.38	0.33	Bone mineral density;	chr8:70974216	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs2956615	ENSG00000223220.1	Y_RNA	5.25	3.52e-07	0.000294	0.38	0.33	Bone mineral density;	chr8:70974519	chr8:70780914~70781008:-
OV	cis	rs7017914	0.583	rs2732129	ENSG00000223220.1	Y_RNA	5.25	3.52e-07	0.000294	0.38	0.33	Bone mineral density;	chr8:70982734	chr8:70780914~70781008:-
OV	cis	rs7017914	0.652	rs2639912	ENSG00000223220.1	Y_RNA	5.25	3.52e-07	0.000294	0.38	0.33	Bone mineral density;	chr8:70983134	chr8:70780914~70781008:-
OV	cis	rs7017914	0.629	rs2956611	ENSG00000223220.1	Y_RNA	5.25	3.52e-07	0.000294	0.38	0.33	Bone mineral density;	chr8:70985633	chr8:70780914~70781008:-
OV	cis	rs7017914	0.629	rs2732126	ENSG00000223220.1	Y_RNA	5.25	3.52e-07	0.000294	0.38	0.33	Bone mineral density;	chr8:70986257	chr8:70780914~70781008:-
OV	cis	rs7017914	0.629	rs2732125	ENSG00000223220.1	Y_RNA	5.25	3.52e-07	0.000294	0.38	0.33	Bone mineral density;	chr8:70986266	chr8:70780914~70781008:-
OV	cis	rs611744	0.647	rs7016198	ENSG00000253754.1	RP11-35G22.1	-5.25	3.52e-07	0.000294	-0.36	-0.33	Dupuytren's disease;	chr8:108250523	chr8:108226200~108227544:+
OV	cis	rs611744	0.529	rs13282825	ENSG00000253754.1	RP11-35G22.1	-5.25	3.52e-07	0.000294	-0.36	-0.33	Dupuytren's disease;	chr8:108251008	chr8:108226200~108227544:+
OV	cis	rs611744	0.647	rs1584373	ENSG00000253754.1	RP11-35G22.1	-5.25	3.52e-07	0.000294	-0.36	-0.33	Dupuytren's disease;	chr8:108251170	chr8:108226200~108227544:+
OV	cis	rs611744	0.647	rs2859813	ENSG00000253754.1	RP11-35G22.1	-5.25	3.52e-07	0.000294	-0.36	-0.33	Dupuytren's disease;	chr8:108251268	chr8:108226200~108227544:+
OV	cis	rs3931020	0.626	rs277402	ENSG00000272864.1	RP11-17E13.2	5.25	3.55e-07	0.000296	0.45	0.33	Resistin levels;	chr1:74722637	chr1:74698769~74699333:-
OV	cis	rs7811142	0.83	rs6948685	ENSG00000242294.5	STAG3L5P	5.25	3.55e-07	0.000296	0.35	0.33	Platelet count;	chr7:100372565	chr7:100336079~100351900:+
OV	cis	rs7811142	0.83	rs7792525	ENSG00000242294.5	STAG3L5P	5.25	3.55e-07	0.000296	0.35	0.33	Platelet count;	chr7:100374499	chr7:100336079~100351900:+
OV	cis	rs301901	0.729	rs125682	ENSG00000250155.1	CTD-2353F22.1	-5.25	3.56e-07	0.000297	-0.37	-0.33	Height;	chr5:37337045	chr5:36666214~36725195:-
OV	cis	rs8062405	0.755	rs56272201	ENSG00000278665.1	RP11-666O2.4	5.25	3.56e-07	0.000297	0.36	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28599241~28601881:-
OV	cis	rs8062405	0.755	rs62034355	ENSG00000278665.1	RP11-666O2.4	5.25	3.56e-07	0.000297	0.36	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28599241~28601881:-
OV	cis	rs10740039	1	rs10740040	ENSG00000254271.1	RP11-131N11.4	5.25	3.56e-07	0.000297	0.4	0.33	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60654985	chr10:60734342~60741828:+
OV	cis	rs853679	0.517	rs1947862	ENSG00000280107.1	AL022393.9	-5.25	3.56e-07	0.000297	-0.41	-0.33	Depression;	chr6:28137418	chr6:28170845~28172521:+
OV	cis	rs34779708	0.966	rs11010122	ENSG00000230534.5	RP11-297A16.2	5.25	3.57e-07	0.000297	0.42	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35204590	chr10:35098006~35127020:-
OV	cis	rs34779708	0.9	rs73262807	ENSG00000230534.5	RP11-297A16.2	5.25	3.57e-07	0.000297	0.42	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35207458	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs4934736	ENSG00000230534.5	RP11-297A16.2	5.25	3.57e-07	0.000297	0.42	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35207940	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs17591781	ENSG00000230534.5	RP11-297A16.2	5.25	3.57e-07	0.000297	0.42	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35209610	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs17500582	ENSG00000230534.5	RP11-297A16.2	5.25	3.57e-07	0.000297	0.42	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35209860	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs11010125	ENSG00000230534.5	RP11-297A16.2	5.25	3.57e-07	0.000297	0.42	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35214025	chr10:35098006~35127020:-
OV	cis	rs4713118	0.662	rs175954	ENSG00000219392.1	RP1-265C24.5	-5.25	3.57e-07	0.000297	-0.43	-0.33	Parkinson's disease;	chr6:28043807	chr6:28115628~28116551:+
OV	cis	rs7617773	0.817	rs11710861	ENSG00000228638.1	FCF1P2	-5.25	3.57e-07	0.000297	-0.41	-0.33	Coronary artery disease;	chr3:48256070	chr3:48290793~48291375:-
OV	cis	rs2248020	0.501	rs2263368	ENSG00000279684.1	RP11-755E23.2	-5.25	3.57e-07	0.000298	-0.4	-0.33	Insulin levels in response to oral glucose tolerance test (30 minutes);	chr11:93531514	chr11:93286629~93288903:-
OV	cis	rs507080	0.501	rs637563	ENSG00000278376.1	RP11-158I9.8	-5.24	3.59e-07	0.000299	-0.32	-0.33	Serum metabolite levels;	chr11:118704770	chr11:118791254~118793137:+
OV	cis	rs853679	0.542	rs6934769	ENSG00000280107.1	AL022393.9	-5.24	3.59e-07	0.000299	-0.41	-0.33	Depression;	chr6:28123153	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs17711801	ENSG00000280107.1	AL022393.9	-5.24	3.59e-07	0.000299	-0.41	-0.33	Depression;	chr6:28124529	chr6:28170845~28172521:+
OV	cis	rs4713118	0.527	rs9461433	ENSG00000280107.1	AL022393.9	-5.24	3.59e-07	0.000299	-0.41	-0.33	Parkinson's disease;	chr6:28127394	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9468292	ENSG00000280107.1	AL022393.9	-5.24	3.59e-07	0.000299	-0.41	-0.33	Depression;	chr6:28127577	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs1947863	ENSG00000280107.1	AL022393.9	-5.24	3.59e-07	0.000299	-0.41	-0.33	Depression;	chr6:28131566	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs4713141	ENSG00000280107.1	AL022393.9	-5.24	3.59e-07	0.000299	-0.41	-0.33	Depression;	chr6:28133900	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9380056	ENSG00000280107.1	AL022393.9	-5.24	3.59e-07	0.000299	-0.41	-0.33	Depression;	chr6:28136698	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs9380057	ENSG00000280107.1	AL022393.9	-5.24	3.59e-07	0.000299	-0.41	-0.33	Depression;	chr6:28136856	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs6941992	ENSG00000280107.1	AL022393.9	-5.24	3.59e-07	0.000299	-0.41	-0.33	Depression;	chr6:28138363	chr6:28170845~28172521:+
OV	cis	rs4713118	0.516	rs4713142	ENSG00000280107.1	AL022393.9	-5.24	3.59e-07	0.000299	-0.41	-0.33	Parkinson's disease;	chr6:28138569	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs4713143	ENSG00000280107.1	AL022393.9	-5.24	3.59e-07	0.000299	-0.41	-0.33	Depression;	chr6:28138981	chr6:28170845~28172521:+
OV	cis	rs853679	0.517	rs4713144	ENSG00000280107.1	AL022393.9	-5.24	3.59e-07	0.000299	-0.41	-0.33	Depression;	chr6:28139012	chr6:28170845~28172521:+
OV	cis	rs4380275	0.782	rs4468850	ENSG00000223751.1	AC116609.2	5.24	3.59e-07	0.000299	0.38	0.33	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:749467	chr2:742488~747767:+
OV	cis	rs2286503	1	rs1029740	ENSG00000228649.7	AC005682.5	5.24	3.59e-07	0.000299	0.39	0.33	Fibrinogen;	chr7:22833967	chr7:22854178~22861579:+
OV	cis	rs16873450	0.527	rs6461743	ENSG00000234800.2	PCMTD1P3	5.24	3.6e-07	3e-04	0.34	0.33	Verbal memory performance (residualized delayed recall level);	chr7:23831972	chr7:23721311~23721782:-
OV	cis	rs16873450	0.527	rs2214236	ENSG00000234800.2	PCMTD1P3	5.24	3.6e-07	3e-04	0.34	0.33	Verbal memory performance (residualized delayed recall level);	chr7:23832790	chr7:23721311~23721782:-
OV	cis	rs4908768	0.579	rs75634300	ENSG00000228423.2	RP4-633I8.4	5.24	3.6e-07	3e-04	0.37	0.33	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8812396	chr1:8805860~8807051:-
OV	cis	rs1797885	1	rs709164	ENSG00000251774.1	RNU6-377P	5.24	3.61e-07	3e-04	0.31	0.33	Immature fraction of reticulocytes;	chr3:12472658	chr3:12514706~12514807:+
OV	cis	rs4713118	0.629	rs203890	ENSG00000280107.1	AL022393.9	-5.24	3.62e-07	0.000301	-0.41	-0.33	Parkinson's disease;	chr6:28054470	chr6:28170845~28172521:+
OV	cis	rs4805272	0.512	rs66830923	ENSG00000267243.4	AC005307.3	-5.24	3.63e-07	0.000302	-0.54	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28830370	chr19:28435388~28727777:-
OV	cis	rs611744	0.647	rs647907	ENSG00000253754.1	RP11-35G22.1	-5.24	3.63e-07	0.000302	-0.37	-0.33	Dupuytren's disease;	chr8:108239145	chr8:108226200~108227544:+
OV	cis	rs13315649	0.642	rs9811914	ENSG00000277250.1	Metazoa_SRP	-5.24	3.63e-07	0.000302	-0.43	-0.33	Sum eosinophil basophil counts;	chr3:128676517	chr3:128673681~128674021:-
OV	cis	rs7189233	0.531	rs1131220	ENSG00000279344.1	RP11-44F14.7	5.24	3.63e-07	0.000302	0.3	0.33	Intelligence (multi-trait analysis);	chr16:53470022	chr16:53478957~53481550:-
OV	cis	rs7189233	0.513	rs10748	ENSG00000279344.1	RP11-44F14.7	5.24	3.63e-07	0.000302	0.3	0.33	Intelligence (multi-trait analysis);	chr16:53470809	chr16:53478957~53481550:-
OV	cis	rs7189233	0.531	rs8045674	ENSG00000279344.1	RP11-44F14.7	5.24	3.63e-07	0.000302	0.3	0.33	Intelligence (multi-trait analysis);	chr16:53476024	chr16:53478957~53481550:-
OV	cis	rs6088580	0.634	rs2378134	ENSG00000206582.1	Y_RNA	5.24	3.63e-07	0.000302	0.39	0.33	Glomerular filtration rate (creatinine);	chr20:34350279	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs11700221	ENSG00000206582.1	Y_RNA	5.24	3.63e-07	0.000302	0.39	0.33	Glomerular filtration rate (creatinine);	chr20:34352514	chr20:34526510~34526606:-
OV	cis	rs2153535	0.518	rs1328868	ENSG00000230939.1	RP11-314C16.1	-5.24	3.63e-07	0.000302	-0.37	-0.33	Motion sickness;	chr6:8652345	chr6:8784178~8785445:+
OV	cis	rs34779708	0.931	rs35388511	ENSG00000230534.5	RP11-297A16.2	5.24	3.63e-07	0.000302	0.43	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35007688	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs34815241	ENSG00000230534.5	RP11-297A16.2	5.24	3.63e-07	0.000302	0.43	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35007748	chr10:35098006~35127020:-
OV	cis	rs7580658	0.676	rs12465955	ENSG00000236682.1	AC068282.3	-5.24	3.64e-07	0.000303	-0.41	-0.33	Protein C levels;	chr2:127249498	chr2:127389130~127400580:+
OV	cis	rs8062405	0.754	rs62034323	ENSG00000278665.1	RP11-666O2.4	5.24	3.64e-07	0.000303	0.34	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525152	chr16:28599241~28601881:-
OV	cis	rs8062405	0.824	rs62034324	ENSG00000278665.1	RP11-666O2.4	5.24	3.64e-07	0.000303	0.34	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28525441	chr16:28599241~28601881:-
OV	cis	rs8062405	0.824	rs62034326	ENSG00000278665.1	RP11-666O2.4	5.24	3.64e-07	0.000303	0.34	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527972	chr16:28599241~28601881:-
OV	cis	rs8062405	0.824	rs4788085	ENSG00000278665.1	RP11-666O2.4	5.24	3.65e-07	0.000303	0.34	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523682	chr16:28599241~28601881:-
OV	cis	rs8062405	0.824	rs28772958	ENSG00000278665.1	RP11-666O2.4	5.24	3.65e-07	0.000303	0.34	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28523984	chr16:28599241~28601881:-
OV	cis	rs853679	0.517	rs6932109	ENSG00000280107.1	AL022393.9	5.24	3.68e-07	0.000305	0.43	0.33	Depression;	chr6:28110525	chr6:28170845~28172521:+
OV	cis	rs301901	0.772	rs301878	ENSG00000250155.1	CTD-2353F22.1	-5.24	3.69e-07	0.000306	-0.38	-0.33	Height;	chr5:37097036	chr5:36666214~36725195:-
OV	cis	rs6496932	0.563	rs2344083	ENSG00000259295.5	CSPG4P12	-5.24	3.69e-07	0.000306	-0.39	-0.33	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85191438~85213905:+
OV	cis	rs10463554	0.927	rs34831	ENSG00000175749.11	EIF3KP1	5.24	3.69e-07	0.000306	0.39	0.33	Parkinson's disease;	chr5:103108385	chr5:103032376~103033031:+
OV	cis	rs7968440	0.838	rs7979165	ENSG00000257298.1	RP3-405J10.3	5.24	3.7e-07	0.000307	0.34	0.33	Fibrinogen;	chr12:50754774	chr12:50185580~50191363:-
OV	cis	rs1134634	0.52	rs28661857	ENSG00000273133.1	RP11-799M12.2	-5.24	3.7e-07	0.000307	-0.44	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15589842	chr4:15563698~15564253:-
OV	cis	rs62355900	0.627	rs72758096	ENSG00000271828.1	CTD-2310F14.1	5.24	3.72e-07	0.000308	0.6	0.33	Endometriosis;	chr5:56870367	chr5:56927874~56929573:+
OV	cis	rs7927592	0.913	rs11228292	ENSG00000212093.1	AP000807.1	5.24	3.72e-07	0.000309	0.41	0.33	Total body bone mineral density;	chr11:68612304	chr11:68506083~68506166:-
OV	cis	rs6088580	0.634	rs6059779	ENSG00000206582.1	Y_RNA	5.24	3.73e-07	0.000309	0.39	0.33	Glomerular filtration rate (creatinine);	chr20:34362519	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs3746455	ENSG00000206582.1	Y_RNA	5.24	3.73e-07	0.000309	0.39	0.33	Glomerular filtration rate (creatinine);	chr20:34369410	chr20:34526510~34526606:-
OV	cis	rs12922040	1	rs2075516	ENSG00000263335.1	AF001548.5	5.24	3.74e-07	0.00031	0.4	0.33	Serum uric acid levels in response to allopurinol in gout;	chr16:15775668	chr16:15726674~15732993:+
OV	cis	rs13217239	0.646	rs9393789	ENSG00000243307.2	POM121L6P	-5.23	3.76e-07	0.000311	-0.33	-0.33	Schizophrenia;	chr6:27099249	chr6:26896952~26898777:+
OV	cis	rs13217239	0.646	rs6456767	ENSG00000243307.2	POM121L6P	-5.23	3.76e-07	0.000311	-0.33	-0.33	Schizophrenia;	chr6:27102764	chr6:26896952~26898777:+
OV	cis	rs507080	0.733	rs4486664	ENSG00000278376.1	RP11-158I9.8	-5.23	3.76e-07	0.000311	-0.35	-0.33	Serum metabolite levels;	chr11:118698358	chr11:118791254~118793137:+
OV	cis	rs11690935	0.655	rs17614941	ENSG00000228389.1	AC068039.4	-5.23	3.77e-07	0.000312	-0.37	-0.33	Schizophrenia;	chr2:171684868	chr2:171773482~171775844:+
OV	cis	rs6452524	0.935	rs2386241	ENSG00000249664.1	CTD-2227C6.2	-5.23	3.78e-07	0.000312	-0.35	-0.33	Hypertension (SNP x SNP interaction);	chr5:83149872	chr5:83012285~83013109:-
OV	cis	rs4713118	0.868	rs10484401	ENSG00000280107.1	AL022393.9	5.23	3.78e-07	0.000313	0.4	0.33	Parkinson's disease;	chr6:27778811	chr6:28170845~28172521:+
OV	cis	rs957448	1	rs1992370	ENSG00000253704.1	RP11-267M23.4	5.23	3.78e-07	0.000313	0.44	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94546466	chr8:94553722~94569745:+
OV	cis	rs7684253	0.55	rs4566710	ENSG00000269949.1	RP11-738E22.3	-5.23	3.79e-07	0.000313	-0.4	-0.33	Migraine;	chr4:56879297	chr4:56960927~56961373:-
OV	cis	rs8005677	0.828	rs2295680	ENSG00000279656.1	RP11-298I3.6	-5.23	3.79e-07	0.000314	-0.35	-0.33	Cognitive ability (multi-trait analysis);	chr14:22905226	chr14:23023083~23024217:-
OV	cis	rs34779708	0.931	rs2148482	ENSG00000230534.5	RP11-297A16.2	5.23	3.8e-07	0.000314	0.43	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35059982	chr10:35098006~35127020:-
OV	cis	rs8005677	1	rs4982710	ENSG00000279656.1	RP11-298I3.6	5.23	3.8e-07	0.000314	0.36	0.33	Cognitive ability (multi-trait analysis);	chr14:22929693	chr14:23023083~23024217:-
OV	cis	rs11673344	0.932	rs76350084	ENSG00000226686.6	LINC01535	5.23	3.8e-07	0.000314	0.42	0.33	Obesity-related traits;	chr19:37187917	chr19:37251912~37265535:+
OV	cis	rs1061377	0.513	rs2566163	ENSG00000249207.1	RP11-360F5.1	-5.23	3.81e-07	0.000315	-0.41	-0.33	Uric acid levels;	chr4:39128345	chr4:39112677~39126818:-
OV	cis	rs7428	0.527	rs1053560	ENSG00000246575.2	AC093162.5	5.23	3.81e-07	0.000315	0.33	0.33	Ear protrusion;	chr2:85319069	chr2:85315041~85316529:+
OV	cis	rs7428	0.527	rs4832164	ENSG00000246575.2	AC093162.5	5.23	3.81e-07	0.000315	0.33	0.33	Ear protrusion;	chr2:85319809	chr2:85315041~85316529:+
OV	cis	rs1790761	0.667	rs4147581	ENSG00000184224.3	C11orf72	5.23	3.82e-07	0.000316	0.37	0.33	Mean corpuscular volume;	chr11:67584114	chr11:67602880~67606706:-
OV	cis	rs34779708	0.931	rs10508815	ENSG00000230534.5	RP11-297A16.2	5.23	3.82e-07	0.000316	0.42	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35043693	chr10:35098006~35127020:-
OV	cis	rs10510102	0.516	rs2420976	ENSG00000276742.1	RP11-500G22.4	-5.23	3.84e-07	0.000317	-0.57	-0.33	Breast cancer;	chr10:121986932	chr10:121956782~121957098:+
OV	cis	rs2492286	0.518	rs2811506	ENSG00000277250.1	Metazoa_SRP	-5.23	3.84e-07	0.000317	-0.42	-0.33	Eosinophil counts;	chr3:128610801	chr3:128673681~128674021:-
OV	cis	rs13217239	0.572	rs9379958	ENSG00000243307.2	POM121L6P	-5.23	3.84e-07	0.000317	-0.33	-0.33	Schizophrenia;	chr6:27098384	chr6:26896952~26898777:+
OV	cis	rs4908768	0.579	rs56280806	ENSG00000228423.2	RP4-633I8.4	5.23	3.84e-07	0.000317	0.37	0.33	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8815483	chr1:8805860~8807051:-
OV	cis	rs6471393	0.964	rs11549490	ENSG00000253848.1	RP11-10N23.5	-5.23	3.85e-07	0.000318	-0.39	-0.33	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93732822	chr8:93741193~93744534:+
OV	cis	rs4591358	1	rs4591358	ENSG00000223466.1	AC064834.2	-5.23	3.85e-07	0.000318	-0.42	-0.33	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195501166	chr2:195533035~195538681:+
OV	cis	rs4591358	1	rs6713576	ENSG00000223466.1	AC064834.2	-5.23	3.85e-07	0.000318	-0.42	-0.33	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195501522	chr2:195533035~195538681:+
OV	cis	rs4713118	0.512	rs2622319	ENSG00000219392.1	RP1-265C24.5	-5.23	3.86e-07	0.000319	-0.38	-0.33	Parkinson's disease;	chr6:28152623	chr6:28115628~28116551:+
OV	cis	rs4380275	0.782	rs4854369	ENSG00000223751.1	AC116609.2	5.23	3.87e-07	0.000319	0.38	0.33	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:752530	chr2:742488~747767:+
OV	cis	rs17711722	0.523	rs365896	ENSG00000224316.1	RP11-479O9.2	-5.23	3.87e-07	0.000319	-0.36	-0.33	Calcium levels;	chr7:66045710	chr7:65773620~65802067:+
OV	cis	rs4805272	0.539	rs7256211	ENSG00000267243.4	AC005307.3	-5.23	3.88e-07	0.00032	-0.56	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28842156	chr19:28435388~28727777:-
OV	cis	rs34779708	0.658	rs4934715	ENSG00000230534.5	RP11-297A16.2	5.23	3.89e-07	0.00032	0.43	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35076064	chr10:35098006~35127020:-
OV	cis	rs2253762	0.507	rs4752630	ENSG00000276742.1	RP11-500G22.4	5.23	3.89e-07	0.00032	0.52	0.33	Breast cancer;	chr10:121991440	chr10:121956782~121957098:+
OV	cis	rs116095464	0.558	rs2288459	ENSG00000250848.1	CTD-2083E4.5	-5.23	3.89e-07	0.00032	-0.41	-0.33	Breast cancer;	chr5:231028	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs2288458	ENSG00000250848.1	CTD-2083E4.5	-5.23	3.89e-07	0.00032	-0.41	-0.33	Breast cancer;	chr5:231145	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs2288457	ENSG00000250848.1	CTD-2083E4.5	-5.23	3.89e-07	0.00032	-0.41	-0.33	Breast cancer;	chr5:231155	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs7736600	ENSG00000250848.1	CTD-2083E4.5	-5.23	3.89e-07	0.00032	-0.41	-0.33	Breast cancer;	chr5:231222	chr5:288833~290321:-
OV	cis	rs7302981	0.967	rs35549836	ENSG00000272368.2	RP4-605O3.4	5.23	3.89e-07	0.00032	0.37	0.33	Systolic blood pressure;	chr12:50159419	chr12:50112197~50165618:+
OV	cis	rs7302981	0.967	rs35998534	ENSG00000272368.2	RP4-605O3.4	5.23	3.89e-07	0.00032	0.37	0.33	Systolic blood pressure;	chr12:50162999	chr12:50112197~50165618:+
OV	cis	rs13068223	1	rs9868587	ENSG00000243926.1	TIPARP-AS1	5.23	3.89e-07	0.00032	0.31	0.33	Age-related hearing impairment (SNP x SNP interaction);	chr3:156743800	chr3:156671862~156674378:-
OV	cis	rs11673344	0.526	rs57654288	ENSG00000226686.6	LINC01535	5.23	3.89e-07	0.000321	0.41	0.33	Obesity-related traits;	chr19:37587870	chr19:37251912~37265535:+
OV	cis	rs4908768	0.657	rs6693466	ENSG00000228423.2	RP4-633I8.4	5.23	3.9e-07	0.000321	0.37	0.33	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8757879	chr1:8805860~8807051:-
OV	cis	rs12594515	1	rs12594515	ENSG00000273972.1	CTD-2306A12.1	5.23	3.9e-07	0.000321	0.35	0.33	Weight;Waist circumference;	chr15:45692873	chr15:45702640~45703183:+
OV	cis	rs496547	0.686	rs2508916	ENSG00000278376.1	RP11-158I9.8	-5.23	3.91e-07	0.000322	-0.32	-0.33	Hip minimal joint space width;	chr11:118783942	chr11:118791254~118793137:+
OV	cis	rs9660180	1	rs9660180	ENSG00000268575.1	RP1-283E3.8	-5.23	3.92e-07	0.000322	-0.3	-0.33	Body mass index;	chr1:1791592	chr1:1702736~1737688:-
OV	cis	rs801193	0.967	rs3800823	ENSG00000236529.1	RP13-254B10.1	-5.23	3.92e-07	0.000323	-0.34	-0.33	Aortic root size;	chr7:66682123	chr7:65840212~65840596:+
OV	cis	rs301901	0.965	rs292195	ENSG00000250155.1	CTD-2353F22.1	-5.23	3.93e-07	0.000323	-0.38	-0.33	Height;	chr5:36941456	chr5:36666214~36725195:-
OV	cis	rs67311347	0.713	rs4974018	ENSG00000223797.4	ENTPD3-AS1	5.23	3.93e-07	0.000323	0.36	0.33	Renal cell carcinoma;	chr3:40265928	chr3:40313802~40453329:-
OV	cis	rs875971	0.502	rs2465121	ENSG00000226824.5	RP4-756H11.3	5.23	3.93e-07	0.000324	0.39	0.33	Aortic root size;	chr7:66156017	chr7:66654538~66669855:+
OV	cis	rs9813712	0.953	rs1453258	ENSG00000228252.7	COL6A4P2	5.23	3.94e-07	0.000324	0.42	0.33	Response to amphetamines;	chr3:130256454	chr3:130212823~130273806:+
OV	cis	rs10510102	0.516	rs11200301	ENSG00000276742.1	RP11-500G22.4	5.22	3.94e-07	0.000324	0.59	0.33	Breast cancer;	chr10:121977976	chr10:121956782~121957098:+
OV	cis	rs7580658	0.637	rs4580338	ENSG00000236682.1	AC068282.3	-5.22	3.95e-07	0.000325	-0.4	-0.33	Protein C levels;	chr2:127217361	chr2:127389130~127400580:+
OV	cis	rs853679	0.542	rs9393892	ENSG00000280107.1	AL022393.9	-5.22	3.95e-07	0.000325	-0.41	-0.33	Depression;	chr6:28113616	chr6:28170845~28172521:+
OV	cis	rs2833693	0.572	rs9982765	ENSG00000261610.1	AP000265.1	5.22	3.98e-07	0.000327	0.42	0.33	Temperament;	chr21:32204315	chr21:32259804~32261585:-
OV	cis	rs858239	0.601	rs73272053	ENSG00000230042.1	AK3P3	-5.22	3.98e-07	0.000327	-0.34	-0.33	Cerebrospinal fluid biomarker levels;	chr7:23115906	chr7:23129178~23129841:+
OV	cis	rs4853012	0.838	rs4429500	ENSG00000257800.1	FNBP1P1	5.22	3.98e-07	0.000327	0.45	0.33	Gestational age at birth (maternal effect);	chr2:74118209	chr2:74120680~74123218:+
OV	cis	rs10510102	0.935	rs11200258	ENSG00000276742.1	RP11-500G22.4	5.22	3.98e-07	0.000327	0.52	0.33	Breast cancer;	chr10:121918392	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs12264495	ENSG00000276742.1	RP11-500G22.4	5.22	3.98e-07	0.000327	0.52	0.33	Breast cancer;	chr10:121919967	chr10:121956782~121957098:+
OV	cis	rs17711722	0.522	rs4642526	ENSG00000224316.1	RP11-479O9.2	5.22	3.99e-07	0.000327	0.37	0.33	Calcium levels;	chr7:65751755	chr7:65773620~65802067:+
OV	cis	rs7429990	0.895	rs35790549	ENSG00000229759.1	MRPS18AP1	5.22	3.99e-07	0.000328	0.36	0.33	Educational attainment (years of education);	chr3:48029998	chr3:48256350~48256938:-
OV	cis	rs4713118	0.621	rs9368548	ENSG00000280107.1	AL022393.9	-5.22	4e-07	0.000328	-0.42	-0.33	Parkinson's disease;	chr6:28066959	chr6:28170845~28172521:+
OV	cis	rs7771547	0.573	rs566742	ENSG00000240733.3	RN7SL502P	5.22	4e-07	0.000328	0.35	0.33	Platelet distribution width;	chr6:36427891	chr6:36450912~36451201:-
OV	cis	rs67180937	0.553	rs2936023	ENSG00000272750.1	RP11-378J18.8	5.22	4e-07	0.000328	0.43	0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222656989	chr1:222658867~222661512:-
OV	cis	rs10510102	0.748	rs11200297	ENSG00000226864.1	ATE1-AS1	5.22	4.01e-07	0.000329	0.55	0.33	Breast cancer;	chr10:121972916	chr10:121928312~121951965:+
OV	cis	rs17741873	0.614	rs74617374	ENSG00000224195.1	RP11-574K11.5	5.22	4.01e-07	0.000329	0.49	0.33	Paclitaxel disposition in epithelial ovarian cancer;	chr10:73930301	chr10:73813518~73814737:+
OV	cis	rs172166	0.694	rs1225716	ENSG00000219392.1	RP1-265C24.5	-5.22	4.01e-07	0.000329	-0.38	-0.33	Cardiac Troponin-T levels;	chr6:28145968	chr6:28115628~28116551:+
OV	cis	rs10510102	0.935	rs7083278	ENSG00000276742.1	RP11-500G22.4	5.22	4.02e-07	0.00033	0.53	0.33	Breast cancer;	chr10:121853758	chr10:121956782~121957098:+
OV	cis	rs13068223	0.792	rs344034	ENSG00000243926.1	TIPARP-AS1	-5.22	4.02e-07	0.00033	-0.32	-0.33	Age-related hearing impairment (SNP x SNP interaction);	chr3:156745215	chr3:156671862~156674378:-
OV	cis	rs34779708	0.897	rs7897827	ENSG00000230534.5	RP11-297A16.2	5.22	4.02e-07	0.00033	0.43	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35097309	chr10:35098006~35127020:-
OV	cis	rs5742933	0.857	rs1233272	ENSG00000253559.1	OSGEPL1-AS1	-5.22	4.02e-07	0.00033	-0.35	-0.33	Ferritin levels;	chr2:189814968	chr2:189762704~189765556:+
OV	cis	rs10463554	0.927	rs34795	ENSG00000175749.11	EIF3KP1	5.22	4.03e-07	0.000331	0.4	0.33	Parkinson's disease;	chr5:103088716	chr5:103032376~103033031:+
OV	cis	rs10463554	0.927	rs34796	ENSG00000175749.11	EIF3KP1	5.22	4.03e-07	0.000331	0.4	0.33	Parkinson's disease;	chr5:103088725	chr5:103032376~103033031:+
OV	cis	rs10463554	0.927	rs34802	ENSG00000175749.11	EIF3KP1	5.22	4.03e-07	0.000331	0.4	0.33	Parkinson's disease;	chr5:103091301	chr5:103032376~103033031:+
OV	cis	rs7116641	0.734	rs4755744	ENSG00000246250.2	RP11-613D13.5	-5.22	4.04e-07	0.000331	-0.38	-0.33	Coronary artery disease;	chr11:43796180	chr11:43829709~43880726:-
OV	cis	rs61990749	0.597	rs8016447	ENSG00000239272.1	RPL21P10	5.22	4.04e-07	0.000331	0.45	0.33	Fibroblast growth factor basic levels;	chr14:77755725	chr14:77683202~77683989:-
OV	cis	rs11992162	0.636	rs11250182	ENSG00000206014.6	OR7E161P	5.22	4.04e-07	0.000332	0.39	0.33	Monocyte count;	chr8:11950067	chr8:11928597~11929563:-
OV	cis	rs3814244	0.54	rs2159064	ENSG00000255733.4	IFNG-AS1	-5.22	4.06e-07	0.000332	-0.32	-0.33	Itch intensity from mosquito bite adjusted by bite size;	chr12:68017126	chr12:67989445~68234686:+
OV	cis	rs11723261	0.582	rs11735742	ENSG00000275426.1	CH17-262A2.1	-5.22	4.06e-07	0.000332	-0.48	-0.33	Immune response to smallpox vaccine (IL-6);	chr4:148766	chr4:149738~150317:+
OV	cis	rs875971	0.545	rs6950988	ENSG00000236529.1	RP13-254B10.1	5.22	4.07e-07	0.000333	0.39	0.33	Aortic root size;	chr7:66511428	chr7:65840212~65840596:+
OV	cis	rs7429990	0.932	rs2166772	ENSG00000229759.1	MRPS18AP1	-5.22	4.07e-07	0.000334	-0.34	-0.33	Educational attainment (years of education);	chr3:48006384	chr3:48256350~48256938:-
OV	cis	rs1426063	0.614	rs17000262	ENSG00000260265.1	RP11-44F21.5	5.22	4.08e-07	0.000334	0.59	0.33	QT interval;	chr4:75108836	chr4:75081702~75084717:-
OV	cis	rs116095464	0.558	rs2162870	ENSG00000250848.1	CTD-2083E4.5	-5.22	4.09e-07	0.000334	-0.41	-0.33	Breast cancer;	chr5:228014	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs28729548	ENSG00000250848.1	CTD-2083E4.5	-5.22	4.09e-07	0.000334	-0.41	-0.33	Breast cancer;	chr5:228910	chr5:288833~290321:-
OV	cis	rs116095464	0.681	rs9687745	ENSG00000250848.1	CTD-2083E4.5	-5.22	4.09e-07	0.000334	-0.41	-0.33	Breast cancer;	chr5:229194	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs9688136	ENSG00000250848.1	CTD-2083E4.5	-5.22	4.09e-07	0.000334	-0.41	-0.33	Breast cancer;	chr5:229233	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs62347683	ENSG00000250848.1	CTD-2083E4.5	-5.22	4.09e-07	0.000334	-0.41	-0.33	Breast cancer;	chr5:230216	chr5:288833~290321:-
OV	cis	rs116095464	0.51	rs55750776	ENSG00000250848.1	CTD-2083E4.5	-5.22	4.09e-07	0.000334	-0.41	-0.33	Breast cancer;	chr5:230352	chr5:288833~290321:-
OV	cis	rs116095464	0.764	rs10069197	ENSG00000250848.1	CTD-2083E4.5	-5.22	4.09e-07	0.000334	-0.41	-0.33	Breast cancer;	chr5:230707	chr5:288833~290321:-
OV	cis	rs116095464	0.867	rs10074958	ENSG00000250848.1	CTD-2083E4.5	-5.22	4.09e-07	0.000334	-0.41	-0.33	Breast cancer;	chr5:230713	chr5:288833~290321:-
OV	cis	rs11673344	0.832	rs11084871	ENSG00000226686.6	LINC01535	5.22	4.09e-07	0.000335	0.43	0.33	Obesity-related traits;	chr19:37042023	chr19:37251912~37265535:+
OV	cis	rs12429206	0.52	rs1870839	ENSG00000233672.5	RNASEH2B-AS1	-5.22	4.09e-07	0.000335	-0.43	-0.33	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50899732	chr13:50862172~50910764:-
OV	cis	rs34779708	0.966	rs17591163	ENSG00000230534.5	RP11-297A16.2	5.22	4.1e-07	0.000335	0.43	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35176351	chr10:35098006~35127020:-
OV	cis	rs5742933	0.69	rs62183657	ENSG00000253559.1	OSGEPL1-AS1	-5.22	4.11e-07	0.000336	-0.43	-0.33	Ferritin levels;	chr2:189669448	chr2:189762704~189765556:+
OV	cis	rs957448	1	rs60655325	ENSG00000253704.1	RP11-267M23.4	5.22	4.13e-07	0.000337	0.44	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94552606	chr8:94553722~94569745:+
OV	cis	rs957448	1	rs16916881	ENSG00000253704.1	RP11-267M23.4	5.22	4.13e-07	0.000337	0.44	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94554042	chr8:94553722~94569745:+
OV	cis	rs10246939	0.579	rs12703413	ENSG00000228775.6	WEE2-AS1	-5.22	4.13e-07	0.000338	-0.33	-0.33	Bitter taste perception;	chr7:141847047	chr7:141704338~141738346:-
OV	cis	rs7580658	0.857	rs17015199	ENSG00000236682.1	AC068282.3	-5.22	4.13e-07	0.000338	-0.42	-0.33	Protein C levels;	chr2:127336477	chr2:127389130~127400580:+
OV	cis	rs67311347	0.869	rs6790495	ENSG00000223797.4	ENTPD3-AS1	5.21	4.14e-07	0.000339	0.37	0.33	Renal cell carcinoma;	chr3:40325279	chr3:40313802~40453329:-
OV	cis	rs67311347	0.869	rs7646899	ENSG00000223797.4	ENTPD3-AS1	5.21	4.14e-07	0.000339	0.37	0.33	Renal cell carcinoma;	chr3:40325491	chr3:40313802~40453329:-
OV	cis	rs2880765	0.545	rs17553734	ENSG00000229212.6	RP11-561C5.4	-5.21	4.14e-07	0.000339	-0.41	-0.33	Coronary artery disease;	chr15:85469828	chr15:85205440~85234795:-
OV	cis	rs7116641	0.663	rs10734517	ENSG00000246250.2	RP11-613D13.5	-5.21	4.14e-07	0.000339	-0.37	-0.33	Coronary artery disease;	chr11:43764183	chr11:43829709~43880726:-
OV	cis	rs7116641	0.734	rs1878765	ENSG00000246250.2	RP11-613D13.5	-5.21	4.14e-07	0.000339	-0.37	-0.33	Coronary artery disease;	chr11:43773042	chr11:43829709~43880726:-
OV	cis	rs7824557	0.767	rs3808513	ENSG00000255495.1	AC145124.2	-5.21	4.15e-07	0.000339	-0.4	-0.33	Retinal vascular caliber;	chr8:11299951	chr8:12194467~12196280:+
OV	cis	rs611744	0.604	rs6469170	ENSG00000253754.1	RP11-35G22.1	-5.21	4.15e-07	0.000339	-0.36	-0.33	Dupuytren's disease;	chr8:108293048	chr8:108226200~108227544:+
OV	cis	rs9813712	0.596	rs2587988	ENSG00000228252.7	COL6A4P2	-5.21	4.15e-07	0.000339	-0.34	-0.33	Response to amphetamines;	chr3:130201415	chr3:130212823~130273806:+
OV	cis	rs8005677	1	rs8006409	ENSG00000279656.1	RP11-298I3.6	5.21	4.16e-07	0.00034	0.36	0.33	Cognitive ability (multi-trait analysis);	chr14:22927302	chr14:23023083~23024217:-
OV	cis	rs6471393	0.964	rs2914953	ENSG00000253848.1	RP11-10N23.5	5.21	4.16e-07	0.00034	0.4	0.33	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93730122	chr8:93741193~93744534:+
OV	cis	rs1075265	0.933	rs918357	ENSG00000233266.1	HMGB1P31	5.21	4.16e-07	0.00034	0.38	0.33	Chronotype;Morning vs. evening chronotype;	chr2:54108826	chr2:54051334~54051760:+
OV	cis	rs4908768	0.657	rs10492963	ENSG00000228423.2	RP4-633I8.4	-5.21	4.16e-07	0.00034	-0.38	-0.33	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8750282	chr1:8805860~8807051:-
OV	cis	rs73201462	0.708	rs2811477	ENSG00000242551.2	POU5F1P6	5.21	4.16e-07	0.00034	0.68	0.33	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128179940	chr3:128674735~128677005:-
OV	cis	rs6088580	0.634	rs6087577	ENSG00000206582.1	Y_RNA	-5.21	4.17e-07	0.000341	-0.39	-0.33	Glomerular filtration rate (creatinine);	chr20:34367617	chr20:34526510~34526606:-
OV	cis	rs1862618	0.853	rs863840	ENSG00000271828.1	CTD-2310F14.1	5.21	4.18e-07	0.000341	0.49	0.33	Initial pursuit acceleration;	chr5:56833172	chr5:56927874~56929573:+
OV	cis	rs11690935	0.632	rs6433323	ENSG00000228389.1	AC068039.4	5.21	4.19e-07	0.000342	0.37	0.33	Schizophrenia;	chr2:172008155	chr2:171773482~171775844:+
OV	cis	rs4805272	0.512	rs7245724	ENSG00000267243.4	AC005307.3	-5.21	4.21e-07	0.000344	-0.6	-0.33	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28850772	chr19:28435388~28727777:-
OV	cis	rs7017914	0.652	rs1845217	ENSG00000223220.1	Y_RNA	5.21	4.21e-07	0.000344	0.37	0.33	Bone mineral density;	chr8:70985016	chr8:70780914~70781008:-
OV	cis	rs2243480	1	rs4718270	ENSG00000222364.1	RNU6-96P	-5.21	4.21e-07	0.000344	-0.56	-0.33	Diabetic kidney disease;	chr7:65737415	chr7:66395191~66395286:+
OV	cis	rs2243480	0.901	rs2900904	ENSG00000222364.1	RNU6-96P	-5.21	4.21e-07	0.000344	-0.56	-0.33	Diabetic kidney disease;	chr7:65739282	chr7:66395191~66395286:+
OV	cis	rs17767294	0.612	rs12332927	ENSG00000220721.1	OR1F12	5.21	4.22e-07	0.000344	0.5	0.33	Parkinson's disease;	chr6:27987337	chr6:28073316~28074233:+
OV	cis	rs4380275	0.965	rs4315562	ENSG00000223751.1	AC116609.2	5.21	4.23e-07	0.000345	0.37	0.33	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772723	chr2:742488~747767:+
OV	cis	rs13068223	0.905	rs344027	ENSG00000243926.1	TIPARP-AS1	-5.21	4.23e-07	0.000345	-0.32	-0.33	Age-related hearing impairment (SNP x SNP interaction);	chr3:156750604	chr3:156671862~156674378:-
OV	cis	rs3091242	0.933	rs9438904	ENSG00000224183.1	SDHDP6	-5.21	4.24e-07	0.000346	-0.39	-0.33	Erythrocyte sedimentation rate;	chr1:25430369	chr1:25294164~25294643:-
OV	cis	rs10740039	0.804	rs1837950	ENSG00000254271.1	RP11-131N11.4	-5.21	4.24e-07	0.000346	-0.4	-0.33	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60685207	chr10:60734342~60741828:+
OV	cis	rs1185460	0.565	rs10892325	ENSG00000271751.1	RP11-110I1.14	5.21	4.24e-07	0.000346	0.4	0.33	Coronary artery disease;	chr11:119041992	chr11:119065263~119065677:-
OV	cis	rs7309	0.935	rs11884495	ENSG00000227403.1	AC009299.3	-5.21	4.24e-07	0.000346	-0.44	-0.33	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161203458	chr2:161244739~161249050:+
OV	cis	rs7309	0.935	rs10930013	ENSG00000227403.1	AC009299.3	-5.21	4.24e-07	0.000346	-0.44	-0.33	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161213814	chr2:161244739~161249050:+
OV	cis	rs7173064	0.641	rs7496828	ENSG00000272888.4	LINC01578	-5.21	4.26e-07	0.000347	-0.43	-0.33	White matter hyperintensity burden;	chr15:93694392	chr15:92882707~92899701:+
OV	cis	rs67311347	0.955	rs4974067	ENSG00000223797.4	ENTPD3-AS1	5.21	4.26e-07	0.000347	0.35	0.33	Renal cell carcinoma;	chr3:40333060	chr3:40313802~40453329:-
OV	cis	rs7017914	0.629	rs2732111	ENSG00000223220.1	Y_RNA	5.21	4.26e-07	0.000347	0.37	0.33	Bone mineral density;	chr8:71015194	chr8:70780914~70781008:-
OV	cis	rs8105895	1	rs8104559	ENSG00000269742.1	BNIP3P29	5.21	4.27e-07	0.000348	0.51	0.33	Body mass index (change over time);	chr19:22022365	chr19:22065828~22066398:-
OV	cis	rs4380275	1	rs7562792	ENSG00000223751.1	AC116609.2	5.21	4.28e-07	0.000349	0.37	0.33	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774469	chr2:742488~747767:+
OV	cis	rs7017914	0.69	rs17699455	ENSG00000223220.1	Y_RNA	5.21	4.28e-07	0.000349	0.38	0.33	Bone mineral density;	chr8:71060138	chr8:70780914~70781008:-
OV	cis	rs11096990	0.634	rs2381372	ENSG00000249207.1	RP11-360F5.1	-5.21	4.29e-07	0.000349	-0.34	-0.33	Cognitive function;	chr4:39271471	chr4:39112677~39126818:-
OV	cis	rs4713118	0.587	rs61471148	ENSG00000280107.1	AL022393.9	-5.21	4.3e-07	0.00035	-0.41	-0.33	Parkinson's disease;	chr6:28069254	chr6:28170845~28172521:+
OV	cis	rs7617773	0.817	rs6801801	ENSG00000228638.1	FCF1P2	-5.21	4.3e-07	0.00035	-0.4	-0.33	Coronary artery disease;	chr3:48284943	chr3:48290793~48291375:-
OV	cis	rs7428	0.527	rs7608892	ENSG00000246575.2	AC093162.5	5.21	4.31e-07	0.000351	0.33	0.33	Ear protrusion;	chr2:85315595	chr2:85315041~85316529:+
OV	cis	rs2999052	0.602	rs2977562	ENSG00000242551.2	POU5F1P6	5.21	4.31e-07	0.000351	0.43	0.33	Hypospadias;	chr3:128387424	chr3:128674735~128677005:-
OV	cis	rs7615952	0.534	rs1503072	ENSG00000171084.14	FAM86JP	5.21	4.31e-07	0.000351	0.48	0.33	Blood pressure (smoking interaction);	chr3:126035848	chr3:125916620~125930024:+
OV	cis	rs7615952	0.599	rs7631268	ENSG00000171084.14	FAM86JP	5.21	4.31e-07	0.000351	0.48	0.33	Blood pressure (smoking interaction);	chr3:126036821	chr3:125916620~125930024:+
OV	cis	rs10510102	0.935	rs12245528	ENSG00000276742.1	RP11-500G22.4	-5.21	4.32e-07	0.000351	-0.53	-0.33	Breast cancer;	chr10:121881006	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs11818001	ENSG00000276742.1	RP11-500G22.4	-5.21	4.32e-07	0.000351	-0.53	-0.33	Breast cancer;	chr10:121884830	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs12243529	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121880321	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs12250677	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121880575	chr10:121956782~121957098:+
OV	cis	rs10510102	0.872	rs12243874	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121880788	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs7921873	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121881736	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs12258426	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121882189	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs12266380	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121882559	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs11200212	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121883145	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs11200213	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121883228	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs12247749	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121884196	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs12262776	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121884532	chr10:121956782~121957098:+
OV	cis	rs10510102	0.872	rs12264952	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121885673	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs12244866	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121886013	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs12266597	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121886062	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs12245018	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121886195	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs11200217	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121886372	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs11200218	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121886410	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs10887008	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121886714	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs12268872	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121887426	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs9630107	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121887713	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs10887010	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121888542	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs12251175	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121889015	chr10:121956782~121957098:+
OV	cis	rs10510102	0.872	rs11200220	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121889949	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs11200221	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121890134	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs10887011	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121890203	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs10887012	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121890454	chr10:121956782~121957098:+
OV	cis	rs10510102	0.872	rs11200222	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121891177	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs11200223	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121891416	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs10887013	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121891546	chr10:121956782~121957098:+
OV	cis	rs10510102	0.872	rs11200225	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121891948	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs11200226	ENSG00000276742.1	RP11-500G22.4	5.21	4.32e-07	0.000351	0.53	0.33	Breast cancer;	chr10:121891988	chr10:121956782~121957098:+
OV	cis	rs7116641	0.771	rs10768975	ENSG00000246250.2	RP11-613D13.5	-5.2	4.34e-07	0.000353	-0.38	-0.33	Coronary artery disease;	chr11:43732822	chr11:43829709~43880726:-
OV	cis	rs35160687	0.901	rs6713456	ENSG00000273080.1	RP11-301O19.1	5.2	4.34e-07	0.000353	0.33	0.33	Night sleep phenotypes;	chr2:86280530	chr2:86195590~86196049:+
OV	cis	rs607987	0.841	rs1765141	ENSG00000254532.1	RP11-624D11.2	5.2	4.34e-07	0.000353	0.39	0.33	Body mass index;	chr11:30342180	chr11:30044058~30084343:-
OV	cis	rs1185460	0.547	rs666741	ENSG00000271751.1	RP11-110I1.14	5.2	4.35e-07	0.000353	0.4	0.33	Coronary artery disease;	chr11:119040640	chr11:119065263~119065677:-
OV	cis	rs957448	1	rs28817653	ENSG00000253704.1	RP11-267M23.4	5.2	4.36e-07	0.000354	0.44	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94557822	chr8:94553722~94569745:+
OV	cis	rs1150668	0.796	rs1124132	ENSG00000220721.1	OR1F12	5.2	4.37e-07	0.000355	0.32	0.33	Pubertal anthropometrics;	chr6:28412544	chr6:28073316~28074233:+
OV	cis	rs10246939	0.579	rs6969430	ENSG00000228775.6	WEE2-AS1	5.2	4.37e-07	0.000355	0.34	0.33	Bitter taste perception;	chr7:141831340	chr7:141704338~141738346:-
OV	cis	rs3758911	1	rs11212164	ENSG00000261098.1	RP11-819C21.1	-5.2	4.38e-07	0.000355	-0.31	-0.33	Coronary artery disease;	chr11:107328113	chr11:107312132~107316271:-
OV	cis	rs301901	0.772	rs7711452	ENSG00000250155.1	CTD-2353F22.1	-5.2	4.38e-07	0.000356	-0.37	-0.33	Height;	chr5:37216735	chr5:36666214~36725195:-
OV	cis	rs2153535	0.518	rs9328473	ENSG00000230939.1	RP11-314C16.1	-5.2	4.39e-07	0.000356	-0.35	-0.33	Motion sickness;	chr6:8487092	chr6:8784178~8785445:+
OV	cis	rs116095464	1	rs6555160	ENSG00000277812.1	AC021087.1	-5.2	4.4e-07	0.000357	-0.69	-0.33	Breast cancer;	chr5:311554	chr5:262769~262881:+
OV	cis	rs7116641	0.738	rs4755741	ENSG00000246250.2	RP11-613D13.5	-5.2	4.41e-07	0.000357	-0.38	-0.33	Coronary artery disease;	chr11:43781704	chr11:43829709~43880726:-
OV	cis	rs10510102	0.516	rs3936070	ENSG00000276742.1	RP11-500G22.4	5.2	4.41e-07	0.000357	0.59	0.33	Breast cancer;	chr10:121974440	chr10:121956782~121957098:+
OV	cis	rs853679	0.55	rs9295762	ENSG00000280107.1	AL022393.9	5.2	4.41e-07	0.000358	0.4	0.33	Depression;	chr6:28187640	chr6:28170845~28172521:+
OV	cis	rs9291683	0.507	rs3796837	ENSG00000250413.1	RP11-448G15.1	-5.2	4.41e-07	0.000358	-0.39	-0.33	Bone mineral density;	chr4:10009697	chr4:10006482~10009725:+
OV	cis	rs453301	0.624	rs330049	ENSG00000253981.4	ALG1L13P	5.2	4.41e-07	0.000358	0.38	0.33	Joint mobility (Beighton score);	chr8:9229789	chr8:8236003~8244667:-
OV	cis	rs34779708	0.966	rs12775548	ENSG00000230534.5	RP11-297A16.2	5.2	4.41e-07	0.000358	0.43	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35190576	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs35079558	ENSG00000230534.5	RP11-297A16.2	5.2	4.41e-07	0.000358	0.43	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35190958	chr10:35098006~35127020:-
OV	cis	rs8062405	0.723	rs4788077	ENSG00000278665.1	RP11-666O2.4	5.2	4.43e-07	0.000359	0.36	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28599241~28601881:-
OV	cis	rs1891275	0.515	rs7911755	ENSG00000228701.1	TNKS2-AS1	-5.2	4.44e-07	0.000359	-0.35	-0.33	Intelligence (multi-trait analysis);	chr10:91730060	chr10:91782839~91798291:-
OV	cis	rs1185460	0.546	rs7114961	ENSG00000271751.1	RP11-110I1.14	5.2	4.44e-07	0.000359	0.41	0.33	Coronary artery disease;	chr11:119043677	chr11:119065263~119065677:-
OV	cis	rs6088580	0.634	rs4911152	ENSG00000206582.1	Y_RNA	5.2	4.44e-07	0.00036	0.39	0.33	Glomerular filtration rate (creatinine);	chr20:34367218	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs9789792	ENSG00000206582.1	Y_RNA	5.2	4.44e-07	0.00036	0.39	0.33	Glomerular filtration rate (creatinine);	chr20:34369903	chr20:34526510~34526606:-
OV	cis	rs11690935	0.632	rs9789538	ENSG00000228389.1	AC068039.4	-5.2	4.45e-07	0.000361	-0.37	-0.33	Schizophrenia;	chr2:171761964	chr2:171773482~171775844:+
OV	cis	rs7302981	0.667	rs7308692	ENSG00000272368.2	RP4-605O3.4	-5.2	4.46e-07	0.000361	-0.37	-0.33	Systolic blood pressure;	chr12:50233871	chr12:50112197~50165618:+
OV	cis	rs1790761	0.52	rs1551884	ENSG00000184224.3	C11orf72	-5.2	4.46e-07	0.000361	-0.41	-0.33	Mean corpuscular volume;	chr11:67632130	chr11:67602880~67606706:-
OV	cis	rs10740039	0.961	rs2083696	ENSG00000254271.1	RP11-131N11.4	5.2	4.47e-07	0.000362	0.4	0.33	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60656430	chr10:60734342~60741828:+
OV	cis	rs10740039	1	rs10821818	ENSG00000254271.1	RP11-131N11.4	5.2	4.47e-07	0.000362	0.4	0.33	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60657178	chr10:60734342~60741828:+
OV	cis	rs10740039	0.883	rs6479722	ENSG00000254271.1	RP11-131N11.4	5.2	4.47e-07	0.000362	0.4	0.33	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60657923	chr10:60734342~60741828:+
OV	cis	rs10740039	1	rs6479723	ENSG00000254271.1	RP11-131N11.4	5.2	4.47e-07	0.000362	0.4	0.33	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658127	chr10:60734342~60741828:+
OV	cis	rs10740039	1	rs10761545	ENSG00000254271.1	RP11-131N11.4	5.2	4.47e-07	0.000362	0.4	0.33	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658811	chr10:60734342~60741828:+
OV	cis	rs4908768	0.579	rs12142911	ENSG00000228423.2	RP4-633I8.4	5.2	4.47e-07	0.000362	0.37	0.33	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8797186	chr1:8805860~8807051:-
OV	cis	rs1891275	0.515	rs1418161	ENSG00000228701.1	TNKS2-AS1	-5.2	4.47e-07	0.000362	-0.35	-0.33	Intelligence (multi-trait analysis);	chr10:91724898	chr10:91782839~91798291:-
OV	cis	rs6471393	0.964	rs12056877	ENSG00000253848.1	RP11-10N23.5	-5.2	4.48e-07	0.000362	-0.39	-0.33	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93710234	chr8:93741193~93744534:+
OV	cis	rs6471393	0.964	rs2914944	ENSG00000253848.1	RP11-10N23.5	-5.2	4.48e-07	0.000362	-0.39	-0.33	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93711815	chr8:93741193~93744534:+
OV	cis	rs6471393	0.964	rs2914942	ENSG00000253848.1	RP11-10N23.5	-5.2	4.48e-07	0.000362	-0.39	-0.33	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93714189	chr8:93741193~93744534:+
OV	cis	rs10740039	0.883	rs7068934	ENSG00000254271.1	RP11-131N11.4	5.2	4.48e-07	0.000363	0.41	0.33	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60636490	chr10:60734342~60741828:+
OV	cis	rs10463554	0.927	rs34799	ENSG00000175749.11	EIF3KP1	5.2	4.48e-07	0.000363	0.4	0.33	Parkinson's disease;	chr5:103090498	chr5:103032376~103033031:+
OV	cis	rs10463554	0.927	rs34800	ENSG00000175749.11	EIF3KP1	5.2	4.48e-07	0.000363	0.4	0.33	Parkinson's disease;	chr5:103090799	chr5:103032376~103033031:+
OV	cis	rs526231	0.508	rs34805	ENSG00000175749.11	EIF3KP1	5.2	4.48e-07	0.000363	0.4	0.33	Primary biliary cholangitis;	chr5:103092608	chr5:103032376~103033031:+
OV	cis	rs10463554	0.927	rs34810	ENSG00000175749.11	EIF3KP1	5.2	4.48e-07	0.000363	0.4	0.33	Parkinson's disease;	chr5:103095045	chr5:103032376~103033031:+
OV	cis	rs957448	1	rs12679345	ENSG00000253704.1	RP11-267M23.4	5.2	4.5e-07	0.000364	0.42	0.33	Nonsyndromic cleft lip with cleft palate;	chr8:94552305	chr8:94553722~94569745:+
OV	cis	rs7829975	0.742	rs1533058	ENSG00000253893.2	FAM85B	-5.2	4.51e-07	0.000365	-0.37	-0.33	Mood instability;	chr8:8827680	chr8:8167819~8226614:-
OV	cis	rs7429990	0.932	rs7630685	ENSG00000229759.1	MRPS18AP1	-5.2	4.51e-07	0.000365	-0.35	-0.33	Educational attainment (years of education);	chr3:48089680	chr3:48256350~48256938:-
OV	cis	rs4713118	0.629	rs203887	ENSG00000219392.1	RP1-265C24.5	-5.2	4.52e-07	0.000365	-0.41	-0.33	Parkinson's disease;	chr6:28053491	chr6:28115628~28116551:+
OV	cis	rs10740039	1	rs10994460	ENSG00000254271.1	RP11-131N11.4	5.2	4.52e-07	0.000366	0.4	0.33	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60659033	chr10:60734342~60741828:+
OV	cis	rs611744	0.608	rs1448152	ENSG00000253754.1	RP11-35G22.1	-5.2	4.53e-07	0.000366	-0.35	-0.33	Dupuytren's disease;	chr8:108266020	chr8:108226200~108227544:+
OV	cis	rs611744	0.625	rs11779824	ENSG00000253754.1	RP11-35G22.1	-5.2	4.53e-07	0.000366	-0.35	-0.33	Dupuytren's disease;	chr8:108266460	chr8:108226200~108227544:+
OV	cis	rs7302981	0.741	rs10783342	ENSG00000272368.2	RP4-605O3.4	5.2	4.53e-07	0.000366	0.35	0.33	Systolic blood pressure;	chr12:50234683	chr12:50112197~50165618:+
OV	cis	rs9291683	0.588	rs12507330	ENSG00000250413.1	RP11-448G15.1	-5.2	4.54e-07	0.000367	-0.37	-0.33	Bone mineral density;	chr4:10000571	chr4:10006482~10009725:+
OV	cis	rs301901	0.698	rs217838	ENSG00000250155.1	CTD-2353F22.1	5.19	4.55e-07	0.000368	0.37	0.33	Height;	chr5:37376194	chr5:36666214~36725195:-
OV	cis	rs7116641	0.737	rs6485455	ENSG00000246250.2	RP11-613D13.5	-5.19	4.59e-07	0.00037	-0.38	-0.33	Coronary artery disease;	chr11:43732175	chr11:43829709~43880726:-
OV	cis	rs301901	1	rs158791	ENSG00000250155.1	CTD-2353F22.1	5.19	4.59e-07	0.00037	0.38	0.33	Height;	chr5:36948260	chr5:36666214~36725195:-
OV	cis	rs6991838	0.584	rs6993876	ENSG00000200714.1	Y_RNA	5.19	4.6e-07	0.000371	0.42	0.33	Intelligence (multi-trait analysis);	chr8:65601240	chr8:65592731~65592820:+
OV	cis	rs9291683	0.62	rs717615	ENSG00000250413.1	RP11-448G15.1	-5.19	4.61e-07	0.000372	-0.37	-0.33	Bone mineral density;	chr4:10103046	chr4:10006482~10009725:+
OV	cis	rs9291683	0.609	rs36084205	ENSG00000250413.1	RP11-448G15.1	-5.19	4.61e-07	0.000372	-0.36	-0.33	Bone mineral density;	chr4:10027054	chr4:10006482~10009725:+
OV	cis	rs9291683	0.609	rs13141233	ENSG00000250413.1	RP11-448G15.1	-5.19	4.61e-07	0.000372	-0.36	-0.33	Bone mineral density;	chr4:10027105	chr4:10006482~10009725:+
OV	cis	rs9291683	0.609	rs34709913	ENSG00000250413.1	RP11-448G15.1	-5.19	4.61e-07	0.000372	-0.36	-0.33	Bone mineral density;	chr4:10027331	chr4:10006482~10009725:+
OV	cis	rs2153535	0.585	rs7763881	ENSG00000230939.1	RP11-314C16.1	5.19	4.63e-07	0.000373	0.36	0.33	Motion sickness;	chr6:8653014	chr6:8784178~8785445:+
OV	cis	rs7615952	0.641	rs7618515	ENSG00000171084.14	FAM86JP	5.19	4.63e-07	0.000374	0.48	0.33	Blood pressure (smoking interaction);	chr3:126071735	chr3:125916620~125930024:+
OV	cis	rs9660180	0.967	rs12034740	ENSG00000268575.1	RP1-283E3.8	-5.19	4.63e-07	0.000374	-0.29	-0.33	Body mass index;	chr1:1797530	chr1:1702736~1737688:-
OV	cis	rs13315649	0.562	rs6439137	ENSG00000277250.1	Metazoa_SRP	-5.19	4.64e-07	0.000375	-0.42	-0.33	Sum eosinophil basophil counts;	chr3:128668107	chr3:128673681~128674021:-
OV	cis	rs611744	0.55	rs1448154	ENSG00000253754.1	RP11-35G22.1	-5.19	4.65e-07	0.000375	-0.35	-0.33	Dupuytren's disease;	chr8:108268824	chr8:108226200~108227544:+
OV	cis	rs6772849	0.93	rs9868579	ENSG00000242551.2	POU5F1P6	5.19	4.66e-07	0.000376	0.38	0.33	Monocyte percentage of white cells;Monocyte count;	chr3:128632211	chr3:128674735~128677005:-
OV	cis	rs6088580	0.601	rs6059827	ENSG00000206582.1	Y_RNA	-5.19	4.67e-07	0.000376	-0.38	-0.33	Glomerular filtration rate (creatinine);	chr20:34428552	chr20:34526510~34526606:-
OV	cis	rs10463554	0.892	rs3776874	ENSG00000175749.11	EIF3KP1	5.19	4.67e-07	0.000376	0.38	0.33	Parkinson's disease;	chr5:102946613	chr5:103032376~103033031:+
OV	cis	rs10463554	0.857	rs3776873	ENSG00000175749.11	EIF3KP1	5.19	4.67e-07	0.000376	0.38	0.33	Parkinson's disease;	chr5:102946768	chr5:103032376~103033031:+
OV	cis	rs2153535	0.585	rs1328858	ENSG00000230939.1	RP11-314C16.1	5.19	4.67e-07	0.000376	0.35	0.33	Motion sickness;	chr6:8563218	chr6:8784178~8785445:+
OV	cis	rs7189233	0.531	rs8062535	ENSG00000279344.1	RP11-44F14.7	5.19	4.67e-07	0.000376	0.3	0.33	Intelligence (multi-trait analysis);	chr16:53478576	chr16:53478957~53481550:-
OV	cis	rs9291683	0.679	rs3756225	ENSG00000250413.1	RP11-448G15.1	5.19	4.68e-07	0.000377	0.36	0.33	Bone mineral density;	chr4:10092509	chr4:10006482~10009725:+
OV	cis	rs889312	0.532	rs16886165	ENSG00000271828.1	CTD-2310F14.1	5.19	4.68e-07	0.000377	0.52	0.33	Breast cancer (early onset);Breast cancer;	chr5:56727256	chr5:56927874~56929573:+
OV	cis	rs11673344	0.868	rs1047333	ENSG00000226686.6	LINC01535	5.19	4.68e-07	0.000377	0.44	0.33	Obesity-related traits;	chr19:37151263	chr19:37251912~37265535:+
OV	cis	rs17301013	0.507	rs2760057	ENSG00000227373.4	RP11-160H22.5	5.19	4.7e-07	0.000378	0.41	0.33	Systemic lupus erythematosus;	chr1:174743384	chr1:174115300~174160004:-
OV	cis	rs7017914	0.905	rs1353058	ENSG00000223220.1	Y_RNA	5.19	4.71e-07	0.000379	0.34	0.33	Bone mineral density;	chr8:71009783	chr8:70780914~70781008:-
OV	cis	rs4964805	0.594	rs10861096	ENSG00000257681.1	RP11-341G23.4	5.19	4.71e-07	0.000379	0.37	0.33	Attention deficit hyperactivity disorder;	chr12:103775578	chr12:103746315~103768858:-
OV	cis	rs801193	0.967	rs2420827	ENSG00000236529.1	RP13-254B10.1	-5.19	4.72e-07	0.00038	-0.34	-0.33	Aortic root size;	chr7:66682114	chr7:65840212~65840596:+
OV	cis	rs7116641	0.737	rs10838175	ENSG00000246250.2	RP11-613D13.5	-5.19	4.73e-07	0.00038	-0.37	-0.33	Coronary artery disease;	chr11:43801335	chr11:43829709~43880726:-
OV	cis	rs7968440	0.808	rs6580769	ENSG00000257298.1	RP3-405J10.3	5.19	4.73e-07	0.000381	0.33	0.33	Fibrinogen;	chr12:50801738	chr12:50185580~50191363:-
OV	cis	rs7968440	0.808	rs66838741	ENSG00000257298.1	RP3-405J10.3	5.19	4.73e-07	0.000381	0.33	0.33	Fibrinogen;	chr12:50805231	chr12:50185580~50191363:-
OV	cis	rs7189233	0.531	rs9921587	ENSG00000279344.1	RP11-44F14.7	5.19	4.74e-07	0.000381	0.31	0.33	Intelligence (multi-trait analysis);	chr16:53441738	chr16:53478957~53481550:-
OV	cis	rs8113142	0.69	rs4805256	ENSG00000267243.4	AC005307.3	-5.19	4.74e-07	0.000381	-0.52	-0.33	Femoral neck bone geometry and menarche (age at onset);	chr19:28618452	chr19:28435388~28727777:-
OV	cis	rs8113142	0.651	rs56293350	ENSG00000267243.4	AC005307.3	-5.19	4.74e-07	0.000381	-0.52	-0.33	Femoral neck bone geometry and menarche (age at onset);	chr19:28618934	chr19:28435388~28727777:-
OV	cis	rs8113142	0.614	rs4804847	ENSG00000267243.4	AC005307.3	-5.19	4.74e-07	0.000381	-0.52	-0.33	Femoral neck bone geometry and menarche (age at onset);	chr19:28636489	chr19:28435388~28727777:-
OV	cis	rs8113142	0.614	rs1861173	ENSG00000267243.4	AC005307.3	-5.19	4.74e-07	0.000381	-0.52	-0.33	Femoral neck bone geometry and menarche (age at onset);	chr19:28637190	chr19:28435388~28727777:-
OV	cis	rs7116641	0.7	rs10768981	ENSG00000246250.2	RP11-613D13.5	-5.19	4.74e-07	0.000381	-0.37	-0.33	Coronary artery disease;	chr11:43810226	chr11:43829709~43880726:-
OV	cis	rs7116641	0.734	rs10400343	ENSG00000246250.2	RP11-613D13.5	-5.19	4.74e-07	0.000381	-0.37	-0.33	Coronary artery disease;	chr11:43810955	chr11:43829709~43880726:-
OV	cis	rs7116641	0.734	rs10742689	ENSG00000246250.2	RP11-613D13.5	-5.19	4.74e-07	0.000381	-0.37	-0.33	Coronary artery disease;	chr11:43815046	chr11:43829709~43880726:-
OV	cis	rs4713118	0.629	rs203888	ENSG00000280107.1	AL022393.9	-5.19	4.74e-07	0.000381	-0.4	-0.33	Parkinson's disease;	chr6:28053811	chr6:28170845~28172521:+
OV	cis	rs1185460	1	rs1799993	ENSG00000271751.1	RP11-110I1.14	5.19	4.75e-07	0.000382	0.39	0.33	Coronary artery disease;	chr11:119087417	chr11:119065263~119065677:-
OV	cis	rs8062405	0.824	rs153106	ENSG00000278665.1	RP11-666O2.4	5.19	4.76e-07	0.000383	0.34	0.33	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28515576	chr16:28599241~28601881:-
OV	cis	rs73019876	0.502	rs1560718	ENSG00000269742.1	BNIP3P29	-5.19	4.77e-07	0.000383	-0.38	-0.33	Testicular germ cell tumor;	chr19:22109410	chr19:22065828~22066398:-
OV	cis	rs853679	0.567	rs7740429	ENSG00000216901.1	AL022393.7	5.19	4.77e-07	0.000383	0.4	0.33	Depression;	chr6:28431469	chr6:28176188~28176674:+
OV	cis	rs2153535	0.585	rs1041279	ENSG00000230939.1	RP11-314C16.1	-5.19	4.77e-07	0.000383	-0.36	-0.33	Motion sickness;	chr6:8650293	chr6:8784178~8785445:+
OV	cis	rs7617773	0.817	rs9311421	ENSG00000228638.1	FCF1P2	-5.18	4.79e-07	0.000384	-0.4	-0.33	Coronary artery disease;	chr3:48251588	chr3:48290793~48291375:-
OV	cis	rs1113500	0.836	rs1122158	ENSG00000226822.1	RP11-356N1.2	5.18	4.79e-07	0.000385	0.39	0.33	Growth-regulated protein alpha levels;	chr1:108046046	chr1:108071482~108074519:+
OV	cis	rs7927592	0.913	rs12283755	ENSG00000212093.1	AP000807.1	5.18	4.8e-07	0.000385	0.42	0.33	Total body bone mineral density;	chr11:68604190	chr11:68506083~68506166:-
OV	cis	rs73019876	0.502	rs8100438	ENSG00000269742.1	BNIP3P29	-5.18	4.81e-07	0.000386	-0.37	-0.33	Testicular germ cell tumor;	chr19:22118201	chr19:22065828~22066398:-
OV	cis	rs234043	1	rs234043	ENSG00000223387.5	RP11-408H1.3	5.18	4.81e-07	0.000386	0.4	0.33	Renal cell carcinoma;	chr3:172595577	chr3:172560888~172595607:-
OV	cis	rs6700559	0.742	rs10399790	ENSG00000260088.1	RP11-92G12.3	-5.18	4.81e-07	0.000386	-0.35	-0.33	Coronary artery disease;	chr1:200626241	chr1:200669507~200694250:+
OV	cis	rs7116641	0.734	rs1518815	ENSG00000246250.2	RP11-613D13.5	-5.18	4.82e-07	0.000386	-0.37	-0.33	Coronary artery disease;	chr11:43803488	chr11:43829709~43880726:-
OV	cis	rs2153535	0.585	rs6932720	ENSG00000230939.1	RP11-314C16.1	-5.18	4.82e-07	0.000387	-0.36	-0.33	Motion sickness;	chr6:8644999	chr6:8784178~8785445:+
OV	cis	rs1134634	0.52	rs28419165	ENSG00000273133.1	RP11-799M12.2	-5.18	4.85e-07	0.000389	-0.43	-0.33	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15587722	chr4:15563698~15564253:-
OV	cis	rs7968440	0.808	rs67218241	ENSG00000257298.1	RP3-405J10.3	5.18	4.85e-07	0.000389	0.33	0.33	Fibrinogen;	chr12:50761639	chr12:50185580~50191363:-
OV	cis	rs7968440	0.778	rs111941917	ENSG00000257298.1	RP3-405J10.3	5.18	4.85e-07	0.000389	0.33	0.33	Fibrinogen;	chr12:50764479	chr12:50185580~50191363:-
OV	cis	rs12594515	1	rs11070467	ENSG00000273972.1	CTD-2306A12.1	5.18	4.85e-07	0.000389	0.35	0.33	Weight;Waist circumference;	chr15:45692803	chr15:45702640~45703183:+
OV	cis	rs1576263	0.934	rs330111	ENSG00000230939.1	RP11-314C16.1	-5.18	4.85e-07	0.000389	-0.35	-0.33	Photic sneeze reflex;	chr6:8546478	chr6:8784178~8785445:+
OV	cis	rs7429990	0.965	rs2166770	ENSG00000229759.1	MRPS18AP1	5.18	4.86e-07	0.00039	0.34	0.33	Educational attainment (years of education);	chr3:47964183	chr3:48256350~48256938:-
OV	cis	rs34779708	0.966	rs4934540	ENSG00000230534.5	RP11-297A16.2	5.18	4.86e-07	0.00039	0.42	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35185771	chr10:35098006~35127020:-
OV	cis	rs853679	0.55	rs1233707	ENSG00000280107.1	AL022393.9	-5.18	4.87e-07	0.00039	-0.41	-0.33	Depression;	chr6:28205175	chr6:28170845~28172521:+
OV	cis	rs611744	0.647	rs633901	ENSG00000253754.1	RP11-35G22.1	-5.18	4.87e-07	0.00039	-0.36	-0.33	Dupuytren's disease;	chr8:108230752	chr8:108226200~108227544:+
OV	cis	rs67180937	0.844	rs35626308	ENSG00000272750.1	RP11-378J18.8	-5.18	4.88e-07	0.000391	-0.35	-0.33	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222643014	chr1:222658867~222661512:-
OV	cis	rs2243480	1	rs6964245	ENSG00000226824.5	RP4-756H11.3	5.18	4.88e-07	0.000391	0.52	0.33	Diabetic kidney disease;	chr7:66253730	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs10807701	ENSG00000226824.5	RP4-756H11.3	5.18	4.88e-07	0.000391	0.52	0.33	Diabetic kidney disease;	chr7:66259699	chr7:66654538~66669855:+
OV	cis	rs55692468	0.54	rs4664586	ENSG00000213197.3	AC012066.1	-5.18	4.9e-07	0.000392	-0.33	-0.33	Intraocular pressure;	chr2:152467557	chr2:152389937~152390630:+
OV	cis	rs4380275	1	rs4450634	ENSG00000223751.1	AC116609.2	5.18	4.9e-07	0.000392	0.37	0.33	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773257	chr2:742488~747767:+
OV	cis	rs4380275	1	rs4380275	ENSG00000223751.1	AC116609.2	5.18	4.9e-07	0.000392	0.37	0.33	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773278	chr2:742488~747767:+
OV	cis	rs4380275	1	rs6548253	ENSG00000223751.1	AC116609.2	5.18	4.9e-07	0.000392	0.37	0.33	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773655	chr2:742488~747767:+
OV	cis	rs4380275	1	rs73143802	ENSG00000223751.1	AC116609.2	5.18	4.9e-07	0.000392	0.37	0.33	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:773826	chr2:742488~747767:+
OV	cis	rs4380275	1	rs4359695	ENSG00000223751.1	AC116609.2	5.18	4.9e-07	0.000392	0.37	0.33	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774214	chr2:742488~747767:+
OV	cis	rs4380275	0.931	rs4538239	ENSG00000223751.1	AC116609.2	5.18	4.9e-07	0.000392	0.37	0.33	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:774238	chr2:742488~747767:+
OV	cis	rs8113142	0.651	rs73026091	ENSG00000267243.4	AC005307.3	-5.18	4.9e-07	0.000392	-0.52	-0.33	Femoral neck bone geometry and menarche (age at onset);	chr19:28616111	chr19:28435388~28727777:-
OV	cis	rs8113142	0.651	rs16961698	ENSG00000267243.4	AC005307.3	-5.18	4.9e-07	0.000392	-0.52	-0.33	Femoral neck bone geometry and menarche (age at onset);	chr19:28620125	chr19:28435388~28727777:-
OV	cis	rs11096990	0.572	rs35040563	ENSG00000249207.1	RP11-360F5.1	-5.18	4.9e-07	0.000393	-0.35	-0.33	Cognitive function;	chr4:39154262	chr4:39112677~39126818:-
OV	cis	rs4713118	0.513	rs9368547	ENSG00000219392.1	RP1-265C24.5	-5.18	4.9e-07	0.000393	-0.37	-0.33	Parkinson's disease;	chr6:28060289	chr6:28115628~28116551:+
OV	cis	rs4713118	0.513	rs183244	ENSG00000219392.1	RP1-265C24.5	-5.18	4.9e-07	0.000393	-0.37	-0.33	Parkinson's disease;	chr6:28064060	chr6:28115628~28116551:+
OV	cis	rs301901	0.729	rs217781	ENSG00000250155.1	CTD-2353F22.1	-5.18	4.9e-07	0.000393	-0.37	-0.33	Height;	chr5:37344444	chr5:36666214~36725195:-
OV	cis	rs3758911	1	rs6588965	ENSG00000261098.1	RP11-819C21.1	-5.18	4.91e-07	0.000393	-0.31	-0.33	Coronary artery disease;	chr11:107330963	chr11:107312132~107316271:-
OV	cis	rs2153535	0.585	rs9378564	ENSG00000230939.1	RP11-314C16.1	-5.18	4.91e-07	0.000393	-0.36	-0.33	Motion sickness;	chr6:8639694	chr6:8784178~8785445:+
OV	cis	rs2153535	0.585	rs9379233	ENSG00000230939.1	RP11-314C16.1	-5.18	4.91e-07	0.000393	-0.36	-0.33	Motion sickness;	chr6:8639729	chr6:8784178~8785445:+
OV	cis	rs2153535	0.585	rs9505505	ENSG00000230939.1	RP11-314C16.1	-5.18	4.91e-07	0.000393	-0.36	-0.33	Motion sickness;	chr6:8640246	chr6:8784178~8785445:+
OV	cis	rs853679	0.567	rs7774981	ENSG00000216901.1	AL022393.7	5.18	4.91e-07	0.000393	0.4	0.33	Depression;	chr6:28379133	chr6:28176188~28176674:+
OV	cis	rs853679	0.567	rs7754960	ENSG00000216901.1	AL022393.7	5.18	4.91e-07	0.000393	0.4	0.33	Depression;	chr6:28379168	chr6:28176188~28176674:+
OV	cis	rs34779708	0.931	rs7079498	ENSG00000230534.5	RP11-297A16.2	5.18	4.91e-07	0.000393	0.43	0.33	Inflammatory bowel disease;Crohn's disease;	chr10:35086416	chr10:35098006~35127020:-
OV	cis	rs9813712	0.909	rs1453257	ENSG00000228252.7	COL6A4P2	-5.18	4.91e-07	0.000393	-0.42	-0.33	Response to amphetamines;	chr3:130258730	chr3:130212823~130273806:+
OV	cis	rs9813712	0.953	rs1453256	ENSG00000228252.7	COL6A4P2	-5.18	4.91e-07	0.000393	-0.42	-0.33	Response to amphetamines;	chr3:130258787	chr3:130212823~130273806:+
OV	cis	rs9813712	0.953	rs935916	ENSG00000228252.7	COL6A4P2	-5.18	4.91e-07	0.000393	-0.42	-0.33	Response to amphetamines;	chr3:130258931	chr3:130212823~130273806:+
OV	cis	rs3931020	0.657	rs7522428	ENSG00000272864.1	RP11-17E13.2	-5.18	4.91e-07	0.000393	-0.45	-0.33	Resistin levels;	chr1:74712676	chr1:74698769~74699333:-
OV	cis	rs55692468	0.52	rs62180799	ENSG00000213197.3	AC012066.1	5.18	4.92e-07	0.000394	0.33	0.33	Intraocular pressure;	chr2:152445594	chr2:152389937~152390630:+
OV	cis	rs67311347	0.911	rs6776044	ENSG00000223797.4	ENTPD3-AS1	5.18	4.93e-07	0.000394	0.36	0.33	Renal cell carcinoma;	chr3:40336012	chr3:40313802~40453329:-
OV	cis	rs67311347	0.911	rs6775936	ENSG00000223797.4	ENTPD3-AS1	5.18	4.94e-07	0.000395	0.36	0.33	Renal cell carcinoma;	chr3:40335908	chr3:40313802~40453329:-
OV	cis	rs7017914	0.69	rs17699685	ENSG00000223220.1	Y_RNA	5.18	4.96e-07	0.000396	0.37	0.32	Bone mineral density;	chr8:71066769	chr8:70780914~70781008:-
OV	cis	rs7017914	0.69	rs62506037	ENSG00000223220.1	Y_RNA	5.18	4.96e-07	0.000396	0.37	0.32	Bone mineral density;	chr8:71066959	chr8:70780914~70781008:-
OV	cis	rs7017914	0.69	rs11987409	ENSG00000223220.1	Y_RNA	5.18	4.96e-07	0.000396	0.37	0.32	Bone mineral density;	chr8:71067825	chr8:70780914~70781008:-
OV	cis	rs7017914	0.69	rs17699710	ENSG00000223220.1	Y_RNA	5.18	4.96e-07	0.000396	0.37	0.32	Bone mineral density;	chr8:71067975	chr8:70780914~70781008:-
OV	cis	rs9487094	0.626	rs12215077	ENSG00000260273.1	RP11-425D10.10	-5.18	4.96e-07	0.000396	-0.35	-0.32	Height;	chr6:109731677	chr6:109382795~109383666:+
OV	cis	rs8005677	0.828	rs12589539	ENSG00000279656.1	RP11-298I3.6	5.18	4.97e-07	0.000397	0.37	0.32	Cognitive ability (multi-trait analysis);	chr14:22927471	chr14:23023083~23024217:-
OV	cis	rs13178541	0.577	rs11748103	ENSG00000250378.1	RP11-119J18.1	-5.18	4.98e-07	0.000398	-0.45	-0.32	IgG glycosylation;	chr5:135789066	chr5:135812667~135826582:+
OV	cis	rs13178541	0.577	rs67427688	ENSG00000250378.1	RP11-119J18.1	-5.18	4.98e-07	0.000398	-0.45	-0.32	IgG glycosylation;	chr5:135789248	chr5:135812667~135826582:+
OV	cis	rs13178541	0.542	rs35475457	ENSG00000250378.1	RP11-119J18.1	-5.18	4.98e-07	0.000398	-0.45	-0.32	IgG glycosylation;	chr5:135789389	chr5:135812667~135826582:+
OV	cis	rs7811142	0.83	rs6945952	ENSG00000242294.5	STAG3L5P	5.18	4.98e-07	0.000398	0.35	0.32	Platelet count;	chr7:100384152	chr7:100336079~100351900:+
OV	cis	rs7811142	0.83	rs73401450	ENSG00000242294.5	STAG3L5P	5.18	4.98e-07	0.000398	0.35	0.32	Platelet count;	chr7:100384236	chr7:100336079~100351900:+
OV	cis	rs7811142	0.83	rs73401451	ENSG00000242294.5	STAG3L5P	5.18	4.98e-07	0.000398	0.35	0.32	Platelet count;	chr7:100384272	chr7:100336079~100351900:+
OV	cis	rs607987	0.871	rs2485398	ENSG00000254532.1	RP11-624D11.2	5.18	4.99e-07	0.000398	0.38	0.32	Body mass index;	chr11:30328147	chr11:30044058~30084343:-
OV	cis	rs607987	0.742	rs1717774	ENSG00000254532.1	RP11-624D11.2	5.18	4.99e-07	0.000398	0.38	0.32	Body mass index;	chr11:30328638	chr11:30044058~30084343:-
OV	cis	rs607987	0.871	rs1222205	ENSG00000254532.1	RP11-624D11.2	5.18	4.99e-07	0.000398	0.38	0.32	Body mass index;	chr11:30334510	chr11:30044058~30084343:-
OV	cis	rs2243480	1	rs6964530	ENSG00000226824.5	RP4-756H11.3	5.18	4.99e-07	0.000399	0.52	0.32	Diabetic kidney disease;	chr7:66253864	chr7:66654538~66669855:+
OV	cis	rs992157	0.835	rs12987219	ENSG00000237281.1	CATIP-AS2	5.18	4.99e-07	0.000399	0.38	0.32	Colorectal cancer;	chr2:218279426	chr2:218326889~218357966:-
OV	cis	rs8113142	0.651	rs58606095	ENSG00000267243.4	AC005307.3	-5.18	5e-07	0.000399	-0.53	-0.32	Femoral neck bone geometry and menarche (age at onset);	chr19:28605097	chr19:28435388~28727777:-
OV	cis	rs4713118	0.868	rs10484401	ENSG00000219392.1	RP1-265C24.5	5.18	5e-07	0.000399	0.39	0.32	Parkinson's disease;	chr6:27778811	chr6:28115628~28116551:+
OV	cis	rs4763879	0.778	rs11052497	ENSG00000278635.1	CTD-2318O12.1	5.17	5.02e-07	4e-04	0.28	0.32	Type 1 diabetes;	chr12:9696679	chr12:9415641~9416718:+
OV	cis	rs4763879	0.778	rs1056151	ENSG00000278635.1	CTD-2318O12.1	5.17	5.02e-07	4e-04	0.28	0.32	Type 1 diabetes;	chr12:9698427	chr12:9415641~9416718:+
OV	cis	rs526231	0.543	rs152123	ENSG00000175749.11	EIF3KP1	-5.17	5.02e-07	0.000401	-0.46	-0.32	Primary biliary cholangitis;	chr5:103196218	chr5:103032376~103033031:+
OV	cis	rs301901	0.569	rs217846	ENSG00000250155.1	CTD-2353F22.1	5.17	5.02e-07	0.000401	0.37	0.32	Height;	chr5:37367180	chr5:36666214~36725195:-
OV	cis	rs301901	0.698	rs217845	ENSG00000250155.1	CTD-2353F22.1	5.17	5.02e-07	0.000401	0.37	0.32	Height;	chr5:37367360	chr5:36666214~36725195:-
OV	cis	rs7626444	0.584	rs11711813	ENSG00000272359.1	U4	-5.17	5.03e-07	0.000401	-0.33	-0.32	Monocyte count;	chr3:196740467	chr3:196747192~196747324:-
OV	cis	rs607987	0.871	rs4359180	ENSG00000254532.1	RP11-624D11.2	5.17	5.05e-07	0.000402	0.38	0.32	Body mass index;	chr11:30281896	chr11:30044058~30084343:-
OV	cis	rs853679	0.567	rs9969098	ENSG00000216901.1	AL022393.7	5.17	5.05e-07	0.000402	0.39	0.32	Depression;	chr6:28430971	chr6:28176188~28176674:+
OV	cis	rs853679	0.567	rs16894106	ENSG00000216901.1	AL022393.7	5.17	5.05e-07	0.000402	0.39	0.32	Depression;	chr6:28432562	chr6:28176188~28176674:+
OV	cis	rs34779708	0.931	rs7923217	ENSG00000230534.5	RP11-297A16.2	5.17	5.05e-07	0.000403	0.41	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35020661	chr10:35098006~35127020:-
OV	cis	rs7429990	0.932	rs6442101	ENSG00000229759.1	MRPS18AP1	-5.17	5.05e-07	0.000403	-0.35	-0.32	Educational attainment (years of education);	chr3:48089403	chr3:48256350~48256938:-
OV	cis	rs607987	0.841	rs1222209	ENSG00000254532.1	RP11-624D11.2	5.17	5.06e-07	0.000403	0.38	0.32	Body mass index;	chr11:30340123	chr11:30044058~30084343:-
OV	cis	rs7615952	0.576	rs66671308	ENSG00000171084.14	FAM86JP	5.17	5.07e-07	0.000404	0.48	0.32	Blood pressure (smoking interaction);	chr3:126074683	chr3:125916620~125930024:+
OV	cis	rs4763879	0.729	rs10844472	ENSG00000278635.1	CTD-2318O12.1	5.17	5.07e-07	0.000404	0.28	0.32	Type 1 diabetes;	chr12:9691137	chr12:9415641~9416718:+
OV	cis	rs4713118	0.513	rs149950	ENSG00000219392.1	RP1-265C24.5	-5.17	5.07e-07	0.000404	-0.37	-0.32	Parkinson's disease;	chr6:28065261	chr6:28115628~28116551:+
OV	cis	rs4713118	0.513	rs149951	ENSG00000219392.1	RP1-265C24.5	-5.17	5.07e-07	0.000404	-0.37	-0.32	Parkinson's disease;	chr6:28065309	chr6:28115628~28116551:+
OV	cis	rs7615952	0.599	rs6779141	ENSG00000171084.14	FAM86JP	5.17	5.09e-07	0.000405	0.46	0.32	Blood pressure (smoking interaction);	chr3:125991152	chr3:125916620~125930024:+
OV	cis	rs7116641	0.636	rs7129046	ENSG00000246250.2	RP11-613D13.5	-5.17	5.09e-07	0.000406	-0.37	-0.32	Coronary artery disease;	chr11:43816001	chr11:43829709~43880726:-
OV	cis	rs7116641	0.734	rs10838180	ENSG00000246250.2	RP11-613D13.5	-5.17	5.09e-07	0.000406	-0.37	-0.32	Coronary artery disease;	chr11:43816767	chr11:43829709~43880726:-
OV	cis	rs11673344	0.966	rs111927298	ENSG00000226686.6	LINC01535	5.17	5.11e-07	0.000407	0.42	0.32	Obesity-related traits;	chr19:37193034	chr19:37251912~37265535:+
OV	cis	rs9813712	0.904	rs6439223	ENSG00000228252.7	COL6A4P2	5.17	5.13e-07	0.000408	0.42	0.32	Response to amphetamines;	chr3:130256697	chr3:130212823~130273806:+
OV	cis	rs13068223	1	rs34111024	ENSG00000243926.1	TIPARP-AS1	5.17	5.13e-07	0.000408	0.3	0.32	Age-related hearing impairment (SNP x SNP interaction);	chr3:156748947	chr3:156671862~156674378:-
OV	cis	rs13068223	1	rs36126086	ENSG00000243926.1	TIPARP-AS1	5.17	5.13e-07	0.000408	0.3	0.32	Age-related hearing impairment (SNP x SNP interaction);	chr3:156749028	chr3:156671862~156674378:-
OV	cis	rs12022452	0.506	rs12569328	ENSG00000238287.1	RP11-656D10.3	-5.17	5.13e-07	0.000409	-0.55	-0.32	Age-related hearing impairment (SNP x SNP interaction);	chr1:40553549	chr1:40493157~40508661:-
OV	cis	rs7587476	0.784	rs62202001	ENSG00000229267.2	AC072062.1	-5.17	5.14e-07	0.000409	-0.43	-0.32	Neuroblastoma;	chr2:214825635	chr2:214810229~214963274:+
OV	cis	rs7587476	0.736	rs62202002	ENSG00000229267.2	AC072062.1	-5.17	5.14e-07	0.000409	-0.43	-0.32	Neuroblastoma;	chr2:214825876	chr2:214810229~214963274:+
OV	cis	rs7587476	0.682	rs13009646	ENSG00000229267.2	AC072062.1	-5.17	5.14e-07	0.000409	-0.43	-0.32	Neuroblastoma;	chr2:214826535	chr2:214810229~214963274:+
OV	cis	rs7116641	0.734	rs6485456	ENSG00000246250.2	RP11-613D13.5	5.17	5.16e-07	0.000411	0.37	0.32	Coronary artery disease;	chr11:43745352	chr11:43829709~43880726:-
OV	cis	rs1075265	0.73	rs6711105	ENSG00000233266.1	HMGB1P31	5.17	5.17e-07	0.000411	0.4	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54017775	chr2:54051334~54051760:+
OV	cis	rs1075265	0.704	rs6711217	ENSG00000233266.1	HMGB1P31	5.17	5.17e-07	0.000411	0.4	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54017892	chr2:54051334~54051760:+
OV	cis	rs4805272	0.512	rs11879141	ENSG00000267243.4	AC005307.3	-5.17	5.18e-07	0.000412	-0.53	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28829428	chr19:28435388~28727777:-
OV	cis	rs4853012	0.941	rs60291089	ENSG00000257800.1	FNBP1P1	5.17	5.18e-07	0.000412	0.46	0.32	Gestational age at birth (maternal effect);	chr2:74117763	chr2:74120680~74123218:+
OV	cis	rs4853012	0.838	rs58759652	ENSG00000257800.1	FNBP1P1	5.17	5.18e-07	0.000412	0.46	0.32	Gestational age at birth (maternal effect);	chr2:74117775	chr2:74120680~74123218:+
OV	cis	rs9291683	0.588	rs34501273	ENSG00000250413.1	RP11-448G15.1	-5.17	5.19e-07	0.000412	-0.37	-0.32	Bone mineral density;	chr4:9995372	chr4:10006482~10009725:+
OV	cis	rs2098713	0.599	rs1812818	ENSG00000250155.1	CTD-2353F22.1	5.17	5.2e-07	0.000413	0.38	0.32	Telomere length;	chr5:37546652	chr5:36666214~36725195:-
OV	cis	rs8062405	0.757	rs2411453	ENSG00000259982.1	CDC37P1	-5.17	5.2e-07	0.000413	-0.4	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620700	chr16:28700294~28701540:-
OV	cis	rs7116641	0.771	rs7928134	ENSG00000246250.2	RP11-613D13.5	-5.17	5.22e-07	0.000414	-0.37	-0.32	Coronary artery disease;	chr11:43764763	chr11:43829709~43880726:-
OV	cis	rs9291683	0.546	rs13146686	ENSG00000250413.1	RP11-448G15.1	-5.17	5.22e-07	0.000415	-0.37	-0.32	Bone mineral density;	chr4:10033309	chr4:10006482~10009725:+
OV	cis	rs35160687	0.798	rs2367233	ENSG00000273080.1	RP11-301O19.1	-5.17	5.24e-07	0.000416	-0.32	-0.32	Night sleep phenotypes;	chr2:86314543	chr2:86195590~86196049:+
OV	cis	rs2253762	0.54	rs79547192	ENSG00000276742.1	RP11-500G22.4	5.17	5.24e-07	0.000416	0.56	0.32	Breast cancer;	chr10:121998664	chr10:121956782~121957098:+
OV	cis	rs8062405	0.789	rs2106480	ENSG00000278665.1	RP11-666O2.4	5.16	5.26e-07	0.000417	0.34	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28526650	chr16:28599241~28601881:-
OV	cis	rs7580658	0.676	rs4662717	ENSG00000236682.1	AC068282.3	-5.16	5.27e-07	0.000418	-0.4	-0.32	Protein C levels;	chr2:127255928	chr2:127389130~127400580:+
OV	cis	rs1134634	0.52	rs4393989	ENSG00000273133.1	RP11-799M12.2	-5.16	5.27e-07	0.000418	-0.43	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15614276	chr4:15563698~15564253:-
OV	cis	rs1134634	0.52	rs10034328	ENSG00000273133.1	RP11-799M12.2	-5.16	5.27e-07	0.000418	-0.43	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15616764	chr4:15563698~15564253:-
OV	cis	rs1134634	0.52	rs10003739	ENSG00000273133.1	RP11-799M12.2	-5.16	5.27e-07	0.000418	-0.43	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15617063	chr4:15563698~15564253:-
OV	cis	rs3091242	0.933	rs11802413	ENSG00000224183.1	SDHDP6	5.16	5.27e-07	0.000418	0.38	0.32	Erythrocyte sedimentation rate;	chr1:25434429	chr1:25294164~25294643:-
OV	cis	rs4728142	0.604	rs7783384	ENSG00000275106.1	RP11-309L24.10	-5.16	5.27e-07	0.000418	-0.42	-0.32	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129041243	chr7:128952527~128953316:-
OV	cis	rs10916248	0.569	rs7528528	ENSG00000232628.4	RP11-365O16.3	-5.16	5.28e-07	0.000419	-0.39	-0.32	QT interval (drug interaction);	chr1:224077615	chr1:224208747~224213279:-
OV	cis	rs11690935	0.632	rs2292816	ENSG00000228389.1	AC068039.4	-5.16	5.28e-07	0.000419	-0.37	-0.32	Schizophrenia;	chr2:171730204	chr2:171773482~171775844:+
OV	cis	rs2243480	1	rs1499613	ENSG00000226824.5	RP4-756H11.3	5.16	5.28e-07	0.000419	0.52	0.32	Diabetic kidney disease;	chr7:66265873	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs1553174	ENSG00000226824.5	RP4-756H11.3	5.16	5.28e-07	0.000419	0.52	0.32	Diabetic kidney disease;	chr7:66266207	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs10950032	ENSG00000226824.5	RP4-756H11.3	5.16	5.28e-07	0.000419	0.52	0.32	Diabetic kidney disease;	chr7:66273604	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs6958420	ENSG00000226824.5	RP4-756H11.3	5.16	5.28e-07	0.000419	0.52	0.32	Diabetic kidney disease;	chr7:66286184	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs1392104	ENSG00000226824.5	RP4-756H11.3	5.16	5.28e-07	0.000419	0.52	0.32	Diabetic kidney disease;	chr7:66294120	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs4718333	ENSG00000226824.5	RP4-756H11.3	5.16	5.28e-07	0.000419	0.52	0.32	Diabetic kidney disease;	chr7:66307771	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs7792391	ENSG00000226824.5	RP4-756H11.3	5.16	5.28e-07	0.000419	0.52	0.32	Diabetic kidney disease;	chr7:66308442	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs10247526	ENSG00000226824.5	RP4-756H11.3	5.16	5.28e-07	0.000419	0.52	0.32	Diabetic kidney disease;	chr7:66315709	chr7:66654538~66669855:+
OV	cis	rs2243480	0.908	rs1532573	ENSG00000226824.5	RP4-756H11.3	5.16	5.28e-07	0.000419	0.52	0.32	Diabetic kidney disease;	chr7:66333815	chr7:66654538~66669855:+
OV	cis	rs611744	0.647	rs1457211	ENSG00000253754.1	RP11-35G22.1	5.16	5.28e-07	0.000419	0.35	0.32	Dupuytren's disease;	chr8:108249089	chr8:108226200~108227544:+
OV	cis	rs875971	0.545	rs316305	ENSG00000226824.5	RP4-756H11.3	5.16	5.28e-07	0.000419	0.38	0.32	Aortic root size;	chr7:66152984	chr7:66654538~66669855:+
OV	cis	rs875971	0.545	rs316306	ENSG00000226824.5	RP4-756H11.3	5.16	5.28e-07	0.000419	0.38	0.32	Aortic root size;	chr7:66153687	chr7:66654538~66669855:+
OV	cis	rs4865169	0.967	rs10023088	ENSG00000269949.1	RP11-738E22.3	5.16	5.3e-07	0.00042	0.37	0.32	Breast cancer;	chr4:57018269	chr4:56960927~56961373:-
OV	cis	rs17301013	0.507	rs6701911	ENSG00000227373.4	RP11-160H22.5	5.16	5.3e-07	0.00042	0.43	0.32	Systemic lupus erythematosus;	chr1:174364755	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs61218633	ENSG00000227373.4	RP11-160H22.5	5.16	5.3e-07	0.00042	0.43	0.32	Systemic lupus erythematosus;	chr1:174375955	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs56148594	ENSG00000227373.4	RP11-160H22.5	5.16	5.3e-07	0.00042	0.43	0.32	Systemic lupus erythematosus;	chr1:174383932	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12091056	ENSG00000227373.4	RP11-160H22.5	5.16	5.3e-07	0.00042	0.43	0.32	Systemic lupus erythematosus;	chr1:174384470	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs57953555	ENSG00000227373.4	RP11-160H22.5	5.16	5.3e-07	0.00042	0.43	0.32	Systemic lupus erythematosus;	chr1:174384958	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs4651019	ENSG00000227373.4	RP11-160H22.5	5.16	5.3e-07	0.00042	0.43	0.32	Systemic lupus erythematosus;	chr1:174385079	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs10912775	ENSG00000227373.4	RP11-160H22.5	5.16	5.3e-07	0.00042	0.43	0.32	Systemic lupus erythematosus;	chr1:174388034	chr1:174115300~174160004:-
OV	cis	rs957448	1	rs72674861	ENSG00000253704.1	RP11-267M23.4	5.16	5.32e-07	0.000421	0.44	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94550051	chr8:94553722~94569745:+
OV	cis	rs1075265	0.704	rs10084374	ENSG00000233266.1	HMGB1P31	5.16	5.32e-07	0.000421	0.4	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54022175	chr2:54051334~54051760:+
OV	cis	rs7615952	0.599	rs6803160	ENSG00000171084.14	FAM86JP	5.16	5.32e-07	0.000422	0.46	0.32	Blood pressure (smoking interaction);	chr3:125990711	chr3:125916620~125930024:+
OV	cis	rs7615952	0.688	rs12485622	ENSG00000171084.14	FAM86JP	5.16	5.32e-07	0.000422	0.46	0.32	Blood pressure (smoking interaction);	chr3:125991896	chr3:125916620~125930024:+
OV	cis	rs465969	1	rs465969	ENSG00000255389.1	C6orf3	-5.16	5.32e-07	0.000422	-0.45	-0.32	Psoriasis;	chr6:111334327	chr6:111599875~111602295:+
OV	cis	rs7829975	0.846	rs6601724	ENSG00000253893.2	FAM85B	5.16	5.34e-07	0.000423	0.33	0.32	Mood instability;	chr8:8687362	chr8:8167819~8226614:-
OV	cis	rs611744	0.55	rs57045491	ENSG00000253754.1	RP11-35G22.1	-5.16	5.34e-07	0.000423	-0.35	-0.32	Dupuytren's disease;	chr8:108266891	chr8:108226200~108227544:+
OV	cis	rs611744	0.56	rs58605513	ENSG00000253754.1	RP11-35G22.1	-5.16	5.34e-07	0.000423	-0.35	-0.32	Dupuytren's disease;	chr8:108266893	chr8:108226200~108227544:+
OV	cis	rs11096990	0.593	rs4580660	ENSG00000249207.1	RP11-360F5.1	-5.16	5.37e-07	0.000425	-0.35	-0.32	Cognitive function;	chr4:39152216	chr4:39112677~39126818:-
OV	cis	rs11096990	0.551	rs2060005	ENSG00000249207.1	RP11-360F5.1	-5.16	5.37e-07	0.000425	-0.35	-0.32	Cognitive function;	chr4:39160901	chr4:39112677~39126818:-
OV	cis	rs1061377	0.501	rs62308278	ENSG00000249207.1	RP11-360F5.1	-5.16	5.37e-07	0.000425	-0.35	-0.32	Uric acid levels;	chr4:39161038	chr4:39112677~39126818:-
OV	cis	rs11096990	0.551	rs11724855	ENSG00000249207.1	RP11-360F5.1	-5.16	5.37e-07	0.000425	-0.35	-0.32	Cognitive function;	chr4:39163379	chr4:39112677~39126818:-
OV	cis	rs11673344	0.711	rs112857724	ENSG00000226686.6	LINC01535	5.16	5.37e-07	0.000425	0.42	0.32	Obesity-related traits;	chr19:37030176	chr19:37251912~37265535:+
OV	cis	rs1113500	0.836	rs1618973	ENSG00000226822.1	RP11-356N1.2	-5.16	5.37e-07	0.000425	-0.39	-0.32	Growth-regulated protein alpha levels;	chr1:108044145	chr1:108071482~108074519:+
OV	cis	rs34779708	0.931	rs34304999	ENSG00000230534.5	RP11-297A16.2	5.16	5.37e-07	0.000425	0.43	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35076777	chr10:35098006~35127020:-
OV	cis	rs733592	0.56	rs61918773	ENSG00000258273.1	RP11-370I10.4	5.16	5.39e-07	0.000426	0.39	0.32	Plateletcrit;	chr12:48027991	chr12:48333755~48333901:-
OV	cis	rs11157436	0.871	rs8003190	ENSG00000211812.1	TRAV26-2	-5.16	5.39e-07	0.000426	-0.38	-0.32	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22212096	chr14:22202583~22203368:+
OV	cis	rs6991838	0.584	rs34226237	ENSG00000200714.1	Y_RNA	-5.16	5.4e-07	0.000426	-0.41	-0.32	Intelligence (multi-trait analysis);	chr8:65600930	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs6994213	ENSG00000200714.1	Y_RNA	-5.16	5.4e-07	0.000426	-0.41	-0.32	Intelligence (multi-trait analysis);	chr8:65601497	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs3765205	ENSG00000200714.1	Y_RNA	-5.16	5.4e-07	0.000426	-0.41	-0.32	Intelligence (multi-trait analysis);	chr8:65605251	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs7841652	ENSG00000200714.1	Y_RNA	-5.16	5.4e-07	0.000426	-0.41	-0.32	Intelligence (multi-trait analysis);	chr8:65606392	chr8:65592731~65592820:+
OV	cis	rs6991838	0.53	rs35038843	ENSG00000200714.1	Y_RNA	-5.16	5.4e-07	0.000426	-0.41	-0.32	Intelligence (multi-trait analysis);	chr8:65610263	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs4737748	ENSG00000200714.1	Y_RNA	5.16	5.4e-07	0.000426	0.41	0.32	Intelligence (multi-trait analysis);	chr8:65613630	chr8:65592731~65592820:+
OV	cis	rs6991838	0.55	rs12335006	ENSG00000200714.1	Y_RNA	5.16	5.4e-07	0.000426	0.41	0.32	Intelligence (multi-trait analysis);	chr8:65619394	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs10957361	ENSG00000200714.1	Y_RNA	5.16	5.4e-07	0.000426	0.41	0.32	Intelligence (multi-trait analysis);	chr8:65619626	chr8:65592731~65592820:+
OV	cis	rs6991838	0.612	rs12335276	ENSG00000200714.1	Y_RNA	5.16	5.4e-07	0.000426	0.41	0.32	Intelligence (multi-trait analysis);	chr8:65619668	chr8:65592731~65592820:+
OV	cis	rs6991838	0.612	rs7832407	ENSG00000200714.1	Y_RNA	5.16	5.4e-07	0.000426	0.41	0.32	Intelligence (multi-trait analysis);	chr8:65621071	chr8:65592731~65592820:+
OV	cis	rs6991838	0.551	rs7007505	ENSG00000200714.1	Y_RNA	5.16	5.4e-07	0.000426	0.41	0.32	Intelligence (multi-trait analysis);	chr8:65621719	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs7012856	ENSG00000200714.1	Y_RNA	5.16	5.4e-07	0.000426	0.41	0.32	Intelligence (multi-trait analysis);	chr8:65622740	chr8:65592731~65592820:+
OV	cis	rs6991838	0.55	rs7817112	ENSG00000200714.1	Y_RNA	5.16	5.4e-07	0.000426	0.41	0.32	Intelligence (multi-trait analysis);	chr8:65624885	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs2048650	ENSG00000200714.1	Y_RNA	5.16	5.4e-07	0.000426	0.41	0.32	Intelligence (multi-trait analysis);	chr8:65625664	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs4737749	ENSG00000200714.1	Y_RNA	5.16	5.4e-07	0.000426	0.41	0.32	Intelligence (multi-trait analysis);	chr8:65627672	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs10092109	ENSG00000200714.1	Y_RNA	5.16	5.4e-07	0.000426	0.41	0.32	Intelligence (multi-trait analysis);	chr8:65627683	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs6997959	ENSG00000200714.1	Y_RNA	5.16	5.4e-07	0.000426	0.41	0.32	Intelligence (multi-trait analysis);	chr8:65628247	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs7814841	ENSG00000200714.1	Y_RNA	5.16	5.4e-07	0.000426	0.41	0.32	Intelligence (multi-trait analysis);	chr8:65629328	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs11985628	ENSG00000200714.1	Y_RNA	5.16	5.4e-07	0.000426	0.41	0.32	Intelligence (multi-trait analysis);	chr8:65630504	chr8:65592731~65592820:+
OV	cis	rs6991838	0.557	rs13266834	ENSG00000200714.1	Y_RNA	5.16	5.4e-07	0.000426	0.41	0.32	Intelligence (multi-trait analysis);	chr8:65631303	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs13268343	ENSG00000200714.1	Y_RNA	5.16	5.4e-07	0.000426	0.41	0.32	Intelligence (multi-trait analysis);	chr8:65631742	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs7835313	ENSG00000200714.1	Y_RNA	5.16	5.4e-07	0.000426	0.41	0.32	Intelligence (multi-trait analysis);	chr8:65633891	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs3812412	ENSG00000200714.1	Y_RNA	5.16	5.4e-07	0.000426	0.41	0.32	Intelligence (multi-trait analysis);	chr8:65634857	chr8:65592731~65592820:+
OV	cis	rs6991838	0.53	rs6472217	ENSG00000200714.1	Y_RNA	5.16	5.4e-07	0.000426	0.41	0.32	Intelligence (multi-trait analysis);	chr8:65635496	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs6472218	ENSG00000200714.1	Y_RNA	5.16	5.4e-07	0.000426	0.41	0.32	Intelligence (multi-trait analysis);	chr8:65635502	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs1533285	ENSG00000200714.1	Y_RNA	5.16	5.4e-07	0.000426	0.41	0.32	Intelligence (multi-trait analysis);	chr8:65637129	chr8:65592731~65592820:+
OV	cis	rs10740039	0.883	rs10740038	ENSG00000254271.1	RP11-131N11.4	5.16	5.4e-07	0.000426	0.41	0.32	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643479	chr10:60734342~60741828:+
OV	cis	rs7968440	0.736	rs10735827	ENSG00000257298.1	RP3-405J10.3	5.16	5.41e-07	0.000427	0.32	0.32	Fibrinogen;	chr12:50788629	chr12:50185580~50191363:-
OV	cis	rs13315649	0.525	rs62270822	ENSG00000277250.1	Metazoa_SRP	-5.16	5.41e-07	0.000427	-0.42	-0.32	Sum eosinophil basophil counts;	chr3:128683677	chr3:128673681~128674021:-
OV	cis	rs515186	1	rs515186	ENSG00000240733.3	RN7SL502P	5.16	5.41e-07	0.000427	0.35	0.32	Mean platelet volume;	chr6:36429715	chr6:36450912~36451201:-
OV	cis	rs7116641	0.734	rs58817325	ENSG00000246250.2	RP11-613D13.5	5.16	5.41e-07	0.000427	0.37	0.32	Coronary artery disease;	chr11:43853766	chr11:43829709~43880726:-
OV	cis	rs7927771	0.839	rs59360790	ENSG00000280615.1	Y_RNA	-5.16	5.43e-07	0.000429	-0.37	-0.32	Subjective well-being;	chr11:47647623	chr11:47614898~47614994:-
OV	cis	rs11992162	0.636	rs4841645	ENSG00000206014.6	OR7E161P	5.16	5.44e-07	0.000429	0.4	0.32	Monocyte count;	chr8:11941175	chr8:11928597~11929563:-
OV	cis	rs4713118	0.699	rs200978	ENSG00000280107.1	AL022393.9	-5.16	5.44e-07	0.000429	-0.42	-0.32	Parkinson's disease;	chr6:27885390	chr6:28170845~28172521:+
OV	cis	rs2188561	0.673	rs2712218	ENSG00000241764.3	AC002467.7	5.16	5.44e-07	0.000429	0.41	0.32	Alcohol consumption;	chr7:107716314	chr7:107742817~107744581:-
OV	cis	rs301901	0.772	rs301906	ENSG00000250155.1	CTD-2353F22.1	-5.16	5.45e-07	0.00043	-0.38	-0.32	Height;	chr5:37105504	chr5:36666214~36725195:-
OV	cis	rs1426063	0.748	rs6534607	ENSG00000260265.1	RP11-44F21.5	5.16	5.46e-07	0.00043	0.45	0.32	QT interval;	chr4:75106366	chr4:75081702~75084717:-
OV	cis	rs4713118	0.699	rs200969	ENSG00000280107.1	AL022393.9	-5.16	5.46e-07	0.000431	-0.42	-0.32	Parkinson's disease;	chr6:27891675	chr6:28170845~28172521:+
OV	cis	rs11992162	0.613	rs6998690	ENSG00000206014.6	OR7E161P	-5.16	5.47e-07	0.000431	-0.39	-0.32	Monocyte count;	chr8:11941287	chr8:11928597~11929563:-
OV	cis	rs301901	0.772	rs301909	ENSG00000250155.1	CTD-2353F22.1	-5.16	5.47e-07	0.000431	-0.38	-0.32	Height;	chr5:37102525	chr5:36666214~36725195:-
OV	cis	rs301901	0.772	rs301908	ENSG00000250155.1	CTD-2353F22.1	-5.16	5.47e-07	0.000431	-0.38	-0.32	Height;	chr5:37103704	chr5:36666214~36725195:-
OV	cis	rs12134133	0.752	rs4844579	ENSG00000274245.1	RP11-357P18.2	5.16	5.48e-07	0.000432	0.44	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207204546	chr1:207372559~207373252:+
OV	cis	rs6921919	1	rs35875412	ENSG00000216901.1	AL022393.7	5.16	5.48e-07	0.000432	0.48	0.32	Autism spectrum disorder or schizophrenia;	chr6:28364041	chr6:28176188~28176674:+
OV	cis	rs13068223	0.74	rs343999	ENSG00000243926.1	TIPARP-AS1	-5.16	5.48e-07	0.000432	-0.32	-0.32	Age-related hearing impairment (SNP x SNP interaction);	chr3:156734050	chr3:156671862~156674378:-
OV	cis	rs9660180	0.967	rs6603802	ENSG00000268575.1	RP1-283E3.8	-5.16	5.48e-07	0.000432	-0.3	-0.32	Body mass index;	chr1:1881082	chr1:1702736~1737688:-
OV	cis	rs8005677	0.741	rs1043675	ENSG00000257285.4	RP11-298I3.1	-5.16	5.5e-07	0.000433	-0.39	-0.32	Cognitive ability (multi-trait analysis);	chr14:22987106	chr14:22929609~22955562:+
OV	cis	rs8005677	0.649	rs11629120	ENSG00000279656.1	RP11-298I3.6	-5.16	5.5e-07	0.000433	-0.36	-0.32	Cognitive ability (multi-trait analysis);	chr14:22989248	chr14:23023083~23024217:-
OV	cis	rs7580658	0.637	rs12463909	ENSG00000236682.1	AC068282.3	5.16	5.5e-07	0.000433	0.39	0.32	Protein C levels;	chr2:127214162	chr2:127389130~127400580:+
OV	cis	rs301901	0.772	rs6887958	ENSG00000250155.1	CTD-2353F22.1	-5.16	5.5e-07	0.000434	-0.37	-0.32	Height;	chr5:37189717	chr5:36666214~36725195:-
OV	cis	rs11992162	0.636	rs4841642	ENSG00000206014.6	OR7E161P	-5.16	5.51e-07	0.000434	-0.39	-0.32	Monocyte count;	chr8:11940825	chr8:11928597~11929563:-
OV	cis	rs11992162	0.636	rs4841646	ENSG00000206014.6	OR7E161P	-5.16	5.51e-07	0.000434	-0.39	-0.32	Monocyte count;	chr8:11941198	chr8:11928597~11929563:-
OV	cis	rs116095464	0.558	rs10043002	ENSG00000250848.1	CTD-2083E4.5	-5.15	5.51e-07	0.000434	-0.41	-0.32	Breast cancer;	chr5:226638	chr5:288833~290321:-
OV	cis	rs875971	0.545	rs11767262	ENSG00000236529.1	RP13-254B10.1	5.15	5.52e-07	0.000435	0.39	0.32	Aortic root size;	chr7:66302237	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs66594357	ENSG00000236529.1	RP13-254B10.1	5.15	5.52e-07	0.000435	0.39	0.32	Aortic root size;	chr7:66327797	chr7:65840212~65840596:+
OV	cis	rs301901	1	rs158796	ENSG00000250155.1	CTD-2353F22.1	-5.15	5.52e-07	0.000435	-0.38	-0.32	Height;	chr5:36878678	chr5:36666214~36725195:-
OV	cis	rs301901	1	rs150380	ENSG00000250155.1	CTD-2353F22.1	-5.15	5.52e-07	0.000435	-0.38	-0.32	Height;	chr5:36880769	chr5:36666214~36725195:-
OV	cis	rs301901	1	rs158623	ENSG00000250155.1	CTD-2353F22.1	-5.15	5.52e-07	0.000435	-0.38	-0.32	Height;	chr5:36882917	chr5:36666214~36725195:-
OV	cis	rs1061377	0.513	rs2711994	ENSG00000249207.1	RP11-360F5.1	5.15	5.52e-07	0.000435	0.39	0.32	Uric acid levels;	chr4:39148121	chr4:39112677~39126818:-
OV	cis	rs7116641	0.734	rs939015	ENSG00000246250.2	RP11-613D13.5	5.15	5.53e-07	0.000436	0.36	0.32	Coronary artery disease;	chr11:43847101	chr11:43829709~43880726:-
OV	cis	rs34779708	0.966	rs17591857	ENSG00000230534.5	RP11-297A16.2	-5.15	5.53e-07	0.000436	-0.41	-0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35210115	chr10:35098006~35127020:-
OV	cis	rs116095464	0.867	rs7726582	ENSG00000250848.1	CTD-2083E4.5	-5.15	5.55e-07	0.000437	-0.41	-0.32	Breast cancer;	chr5:215234	chr5:288833~290321:-
OV	cis	rs172166	0.694	rs203884	ENSG00000219392.1	RP1-265C24.5	-5.15	5.55e-07	0.000437	-0.37	-0.32	Cardiac Troponin-T levels;	chr6:28109596	chr6:28115628~28116551:+
OV	cis	rs4128705	1	rs2870310	ENSG00000249049.1	RP11-763F8.1	-5.15	5.56e-07	0.000438	-0.39	-0.32	Amyotrophic lateral sclerosis (sporadic);	chr4:91361746	chr4:91319034~91325306:-
OV	cis	rs67180937	0.961	rs17163358	ENSG00000272750.1	RP11-378J18.8	-5.15	5.57e-07	0.000438	-0.35	-0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647297	chr1:222658867~222661512:-
OV	cis	rs4713118	0.868	rs9468220	ENSG00000219392.1	RP1-265C24.5	5.15	5.58e-07	0.000439	0.41	0.32	Parkinson's disease;	chr6:27765197	chr6:28115628~28116551:+
OV	cis	rs67311347	1	rs9968170	ENSG00000223797.4	ENTPD3-AS1	-5.15	5.58e-07	0.000439	-0.36	-0.32	Renal cell carcinoma;	chr3:40452783	chr3:40313802~40453329:-
OV	cis	rs9573567	0.881	rs6562898	ENSG00000261553.4	RP11-29G8.3	-5.15	5.58e-07	0.000439	-0.64	-0.32	Red blood cell count;Mean corpuscular volume;	chr13:75502232	chr13:75549773~75807120:+
OV	cis	rs7116641	0.771	rs10838158	ENSG00000246250.2	RP11-613D13.5	-5.15	5.58e-07	0.000439	-0.38	-0.32	Coronary artery disease;	chr11:43730972	chr11:43829709~43880726:-
OV	cis	rs4713118	0.699	rs573179	ENSG00000219392.1	RP1-265C24.5	-5.15	5.58e-07	0.000439	-0.41	-0.32	Parkinson's disease;	chr6:27881898	chr6:28115628~28116551:+
OV	cis	rs875971	0.502	rs2946580	ENSG00000226824.5	RP4-756H11.3	5.15	5.59e-07	0.000439	0.38	0.32	Aortic root size;	chr7:66066855	chr7:66654538~66669855:+
OV	cis	rs4761702	0.922	rs11106975	ENSG00000257322.4	RP11-511B23.2	-5.15	5.59e-07	0.00044	-0.37	-0.32	Immature fraction of reticulocytes;	chr12:93327178	chr12:93003415~93215679:-
OV	cis	rs7017914	0.644	rs6472564	ENSG00000223220.1	Y_RNA	5.15	5.6e-07	0.00044	0.37	0.32	Bone mineral density;	chr8:71066165	chr8:70780914~70781008:-
OV	cis	rs875971	0.862	rs11765791	ENSG00000236529.1	RP13-254B10.1	5.15	5.61e-07	0.000441	0.34	0.32	Aortic root size;	chr7:66471587	chr7:65840212~65840596:+
OV	cis	rs858239	0.601	rs6962526	ENSG00000230042.1	AK3P3	-5.15	5.62e-07	0.000442	-0.33	-0.32	Cerebrospinal fluid biomarker levels;	chr7:23118614	chr7:23129178~23129841:+
OV	cis	rs858239	0.539	rs6971673	ENSG00000230042.1	AK3P3	-5.15	5.62e-07	0.000442	-0.33	-0.32	Cerebrospinal fluid biomarker levels;	chr7:23119904	chr7:23129178~23129841:+
OV	cis	rs11673344	0.864	rs7259513	ENSG00000226686.6	LINC01535	5.15	5.62e-07	0.000442	0.41	0.32	Obesity-related traits;	chr19:37085802	chr19:37251912~37265535:+
OV	cis	rs11673344	0.864	rs7256876	ENSG00000226686.6	LINC01535	5.15	5.62e-07	0.000442	0.41	0.32	Obesity-related traits;	chr19:37088570	chr19:37251912~37265535:+
OV	cis	rs7116641	0.699	rs10838174	ENSG00000246250.2	RP11-613D13.5	-5.15	5.63e-07	0.000442	-0.37	-0.32	Coronary artery disease;	chr11:43801207	chr11:43829709~43880726:-
OV	cis	rs7017914	0.567	rs17758721	ENSG00000223220.1	Y_RNA	-5.15	5.64e-07	0.000443	-0.34	-0.32	Bone mineral density;	chr8:70552316	chr8:70780914~70781008:-
OV	cis	rs8062405	0.824	rs4788084	ENSG00000278665.1	RP11-666O2.4	5.15	5.65e-07	0.000444	0.34	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28528527	chr16:28599241~28601881:-
OV	cis	rs67311347	0.955	rs6764102	ENSG00000223797.4	ENTPD3-AS1	5.15	5.65e-07	0.000444	0.36	0.32	Renal cell carcinoma;	chr3:40336662	chr3:40313802~40453329:-
OV	cis	rs10510102	0.935	rs11200252	ENSG00000276742.1	RP11-500G22.4	5.15	5.65e-07	0.000444	0.52	0.32	Breast cancer;	chr10:121914728	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs12254184	ENSG00000276742.1	RP11-500G22.4	5.15	5.65e-07	0.000444	0.52	0.32	Breast cancer;	chr10:121914971	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs11200253	ENSG00000276742.1	RP11-500G22.4	5.15	5.65e-07	0.000444	0.52	0.32	Breast cancer;	chr10:121915114	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs11200254	ENSG00000276742.1	RP11-500G22.4	5.15	5.65e-07	0.000444	0.52	0.32	Breast cancer;	chr10:121915241	chr10:121956782~121957098:+
OV	cis	rs5742933	0.948	rs5743063	ENSG00000253559.1	OSGEPL1-AS1	5.15	5.66e-07	0.000444	0.35	0.32	Ferritin levels;	chr2:189829723	chr2:189762704~189765556:+
OV	cis	rs7927592	0.913	rs7109294	ENSG00000212093.1	AP000807.1	5.15	5.66e-07	0.000444	0.39	0.32	Total body bone mineral density;	chr11:68564625	chr11:68506083~68506166:-
OV	cis	rs875971	0.545	rs2460427	ENSG00000226824.5	RP4-756H11.3	5.15	5.67e-07	0.000445	0.38	0.32	Aortic root size;	chr7:66154218	chr7:66654538~66669855:+
OV	cis	rs875971	0.545	rs10950025	ENSG00000226824.5	RP4-756H11.3	-5.15	5.67e-07	0.000445	-0.38	-0.32	Aortic root size;	chr7:66158946	chr7:66654538~66669855:+
OV	cis	rs875971	0.52	rs12666485	ENSG00000226824.5	RP4-756H11.3	-5.15	5.67e-07	0.000445	-0.38	-0.32	Aortic root size;	chr7:66160135	chr7:66654538~66669855:+
OV	cis	rs875971	0.545	rs67688847	ENSG00000226824.5	RP4-756H11.3	-5.15	5.67e-07	0.000445	-0.38	-0.32	Aortic root size;	chr7:66161064	chr7:66654538~66669855:+
OV	cis	rs875971	0.545	rs7787063	ENSG00000226824.5	RP4-756H11.3	-5.15	5.67e-07	0.000445	-0.38	-0.32	Aortic root size;	chr7:66164012	chr7:66654538~66669855:+
OV	cis	rs2581828	0.618	rs1560332	ENSG00000242142.1	SERBP1P3	5.15	5.67e-07	0.000445	0.4	0.32	Crohn's disease;	chr3:53130787	chr3:53064283~53065091:-
OV	cis	rs13178541	0.641	rs4532359	ENSG00000250378.1	RP11-119J18.1	-5.15	5.69e-07	0.000447	-0.45	-0.32	IgG glycosylation;	chr5:135790641	chr5:135812667~135826582:+
OV	cis	rs2188561	0.697	rs13224313	ENSG00000241764.3	AC002467.7	5.15	5.69e-07	0.000447	0.38	0.32	Alcohol consumption;	chr7:107741907	chr7:107742817~107744581:-
OV	cis	rs496547	0.719	rs598373	ENSG00000255239.1	AP002954.6	5.15	5.71e-07	0.000448	0.38	0.32	Hip minimal joint space width;	chr11:118793668	chr11:118688039~118690600:-
OV	cis	rs7302981	0.967	rs7972842	ENSG00000272368.2	RP4-605O3.4	-5.15	5.71e-07	0.000448	-0.36	-0.32	Systolic blood pressure;	chr12:50122540	chr12:50112197~50165618:+
OV	cis	rs34779708	0.931	rs13377158	ENSG00000230534.5	RP11-297A16.2	-5.15	5.71e-07	0.000448	-0.41	-0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35081537	chr10:35098006~35127020:-
OV	cis	rs10992471	0.756	rs10115222	ENSG00000281156.1	MIR3651	5.15	5.71e-07	0.000448	0.36	0.32	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92365867	chr9:92292458~92292547:-
OV	cis	rs4761702	0.922	rs7960229	ENSG00000257322.4	RP11-511B23.2	-5.15	5.73e-07	0.00045	-0.37	-0.32	Immature fraction of reticulocytes;	chr12:93323943	chr12:93003415~93215679:-
OV	cis	rs7116641	0.734	rs1878850	ENSG00000246250.2	RP11-613D13.5	-5.15	5.75e-07	0.000451	-0.37	-0.32	Coronary artery disease;	chr11:43798926	chr11:43829709~43880726:-
OV	cis	rs7116641	0.734	rs1878851	ENSG00000246250.2	RP11-613D13.5	-5.15	5.75e-07	0.000451	-0.37	-0.32	Coronary artery disease;	chr11:43798974	chr11:43829709~43880726:-
OV	cis	rs7116641	0.734	rs4755747	ENSG00000246250.2	RP11-613D13.5	-5.15	5.75e-07	0.000451	-0.37	-0.32	Coronary artery disease;	chr11:43802413	chr11:43829709~43880726:-
OV	cis	rs9660180	0.967	rs6687065	ENSG00000268575.1	RP1-283E3.8	-5.14	5.79e-07	0.000453	-0.3	-0.32	Body mass index;	chr1:1847030	chr1:1702736~1737688:-
OV	cis	rs295490	0.688	rs184156	ENSG00000272656.1	RP11-219D15.3	-5.14	5.79e-07	0.000453	-0.44	-0.32	PR interval in Tripanosoma cruzi seropositivity;	chr3:139519526	chr3:139349024~139349371:-
OV	cis	rs6700559	0.81	rs10919990	ENSG00000260088.1	RP11-92G12.3	-5.14	5.79e-07	0.000453	-0.34	-0.32	Coronary artery disease;	chr1:200627076	chr1:200669507~200694250:+
OV	cis	rs6700559	0.81	rs10919991	ENSG00000260088.1	RP11-92G12.3	-5.14	5.79e-07	0.000453	-0.34	-0.32	Coronary artery disease;	chr1:200627217	chr1:200669507~200694250:+
OV	cis	rs67311347	1	rs17078511	ENSG00000223797.4	ENTPD3-AS1	5.14	5.79e-07	0.000454	0.36	0.32	Renal cell carcinoma;	chr3:40354763	chr3:40313802~40453329:-
OV	cis	rs1150668	0.768	rs1150716	ENSG00000220721.1	OR1F12	5.14	5.81e-07	0.000454	0.33	0.32	Pubertal anthropometrics;	chr6:28294921	chr6:28073316~28074233:+
OV	cis	rs7580658	0.676	rs2174270	ENSG00000236682.1	AC068282.3	-5.14	5.81e-07	0.000455	-0.4	-0.32	Protein C levels;	chr2:127248502	chr2:127389130~127400580:+
OV	cis	rs1499614	1	rs34250985	ENSG00000222364.1	RNU6-96P	-5.14	5.82e-07	0.000456	-0.58	-0.32	Gout;	chr7:66696075	chr7:66395191~66395286:+
OV	cis	rs8105895	1	rs57912102	ENSG00000269742.1	BNIP3P29	5.14	5.83e-07	0.000456	0.49	0.32	Body mass index (change over time);	chr19:21953241	chr19:22065828~22066398:-
OV	cis	rs8105895	1	rs1849004	ENSG00000269742.1	BNIP3P29	5.14	5.83e-07	0.000456	0.49	0.32	Body mass index (change over time);	chr19:21959653	chr19:22065828~22066398:-
OV	cis	rs8105895	1	rs11882234	ENSG00000269742.1	BNIP3P29	5.14	5.83e-07	0.000456	0.49	0.32	Body mass index (change over time);	chr19:21962925	chr19:22065828~22066398:-
OV	cis	rs2286503	0.65	rs1990279	ENSG00000228649.7	AC005682.5	5.14	5.84e-07	0.000457	0.39	0.32	Fibrinogen;	chr7:22851123	chr7:22854178~22861579:+
OV	cis	rs9291683	0.509	rs10939671	ENSG00000250413.1	RP11-448G15.1	-5.14	5.84e-07	0.000457	-0.38	-0.32	Bone mineral density;	chr4:10049191	chr4:10006482~10009725:+
OV	cis	rs4763879	0.778	rs7977940	ENSG00000256673.1	RP11-599J14.2	5.14	5.86e-07	0.000458	0.31	0.32	Type 1 diabetes;	chr12:9686320	chr12:9398355~9414851:-
OV	cis	rs293748	0.571	rs13171061	ENSG00000250155.1	CTD-2353F22.1	-5.14	5.87e-07	0.000459	-0.43	-0.32	Obesity-related traits;	chr5:37154591	chr5:36666214~36725195:-
OV	cis	rs13315649	0.639	rs7612926	ENSG00000277250.1	Metazoa_SRP	-5.14	5.88e-07	0.00046	-0.42	-0.32	Sum eosinophil basophil counts;	chr3:128689221	chr3:128673681~128674021:-
OV	cis	rs2999052	0.602	rs4241495	ENSG00000242551.2	POU5F1P6	-5.14	5.89e-07	0.00046	-0.4	-0.32	Hypospadias;	chr3:128392331	chr3:128674735~128677005:-
OV	cis	rs9291683	0.62	rs4383618	ENSG00000250413.1	RP11-448G15.1	5.14	5.89e-07	0.00046	0.36	0.32	Bone mineral density;	chr4:10123527	chr4:10006482~10009725:+
OV	cis	rs34779708	0.931	rs12773169	ENSG00000230534.5	RP11-297A16.2	5.14	5.89e-07	0.00046	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35077534	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs7099593	ENSG00000230534.5	RP11-297A16.2	5.14	5.89e-07	0.00046	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35077950	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs7084196	ENSG00000230534.5	RP11-297A16.2	5.14	5.89e-07	0.00046	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35078233	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs13376871	ENSG00000230534.5	RP11-297A16.2	5.14	5.89e-07	0.00046	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35080128	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs13376801	ENSG00000230534.5	RP11-297A16.2	5.14	5.89e-07	0.00046	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35081515	chr10:35098006~35127020:-
OV	cis	rs7017914	0.84	rs1481804	ENSG00000223220.1	Y_RNA	5.14	5.9e-07	0.000461	0.35	0.32	Bone mineral density;	chr8:71057195	chr8:70780914~70781008:-
OV	cis	rs301901	0.734	rs216385	ENSG00000250155.1	CTD-2353F22.1	-5.14	5.92e-07	0.000462	-0.37	-0.32	Height;	chr5:37275173	chr5:36666214~36725195:-
OV	cis	rs9291683	0.527	rs3822241	ENSG00000250413.1	RP11-448G15.1	5.14	5.92e-07	0.000462	0.38	0.32	Bone mineral density;	chr4:10093307	chr4:10006482~10009725:+
OV	cis	rs1185460	0.565	rs1043314	ENSG00000271751.1	RP11-110I1.14	5.14	5.92e-07	0.000462	0.41	0.32	Coronary artery disease;	chr11:119045232	chr11:119065263~119065677:-
OV	cis	rs7811142	0.83	rs118119933	ENSG00000242294.5	STAG3L5P	5.14	5.93e-07	0.000463	0.38	0.32	Platelet count;	chr7:100341427	chr7:100336079~100351900:+
OV	cis	rs4908768	0.579	rs55840223	ENSG00000228423.2	RP4-633I8.4	5.14	5.93e-07	0.000463	0.37	0.32	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8802728	chr1:8805860~8807051:-
OV	cis	rs66887589	0.777	rs4643791	ENSG00000245958.5	RP11-33B1.1	5.14	5.93e-07	0.000463	0.36	0.32	Diastolic blood pressure;	chr4:119344464	chr4:119454791~119552025:+
OV	cis	rs301901	0.556	rs13176996	ENSG00000250155.1	CTD-2353F22.1	-5.14	5.93e-07	0.000463	-0.42	-0.32	Height;	chr5:37178659	chr5:36666214~36725195:-
OV	cis	rs4713118	0.868	rs2893928	ENSG00000280107.1	AL022393.9	-5.14	5.94e-07	0.000463	-0.41	-0.32	Parkinson's disease;	chr6:27770651	chr6:28170845~28172521:+
OV	cis	rs11976180	1	rs6464573	ENSG00000170356.8	OR2A20P	5.14	5.95e-07	0.000464	0.45	0.32	Obesity-related traits;	chr7:144051005	chr7:144250045~144252957:-
OV	cis	rs301901	1	rs300065	ENSG00000250155.1	CTD-2353F22.1	-5.14	5.96e-07	0.000465	-0.38	-0.32	Height;	chr5:36997725	chr5:36666214~36725195:-
OV	cis	rs4908768	0.657	rs1353130	ENSG00000228423.2	RP4-633I8.4	5.14	5.96e-07	0.000465	0.37	0.32	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8762305	chr1:8805860~8807051:-
OV	cis	rs301901	1	rs292184	ENSG00000250155.1	CTD-2353F22.1	-5.14	5.97e-07	0.000465	-0.38	-0.32	Height;	chr5:36963703	chr5:36666214~36725195:-
OV	cis	rs301901	1	rs159755	ENSG00000250155.1	CTD-2353F22.1	-5.14	5.97e-07	0.000465	-0.38	-0.32	Height;	chr5:36995103	chr5:36666214~36725195:-
OV	cis	rs301901	0.698	rs217840	ENSG00000250155.1	CTD-2353F22.1	5.14	5.97e-07	0.000466	0.37	0.32	Height;	chr5:37373000	chr5:36666214~36725195:-
OV	cis	rs6088580	0.634	rs1205336	ENSG00000206582.1	Y_RNA	5.14	5.98e-07	0.000466	0.38	0.32	Glomerular filtration rate (creatinine);	chr20:34338530	chr20:34526510~34526606:-
OV	cis	rs875971	0.545	rs73378304	ENSG00000226824.5	RP4-756H11.3	-5.14	5.98e-07	0.000466	-0.38	-0.32	Aortic root size;	chr7:66175760	chr7:66654538~66669855:+
OV	cis	rs7945705	0.747	rs1980429	ENSG00000254860.4	TMEM9B-AS1	5.14	5.98e-07	0.000466	0.33	0.32	Hemoglobin concentration;	chr11:8988927	chr11:8964675~8977527:+
OV	cis	rs7116641	0.771	rs4755745	ENSG00000246250.2	RP11-613D13.5	-5.14	5.99e-07	0.000467	-0.37	-0.32	Coronary artery disease;	chr11:43799454	chr11:43829709~43880726:-
OV	cis	rs7429990	0.965	rs9846062	ENSG00000229759.1	MRPS18AP1	5.14	5.99e-07	0.000467	0.34	0.32	Educational attainment (years of education);	chr3:47957476	chr3:48256350~48256938:-
OV	cis	rs7429990	0.93	rs7374516	ENSG00000229759.1	MRPS18AP1	5.14	5.99e-07	0.000467	0.34	0.32	Educational attainment (years of education);	chr3:47961150	chr3:48256350~48256938:-
OV	cis	rs3814244	0.515	rs2906856	ENSG00000255733.4	IFNG-AS1	-5.14	6e-07	0.000467	-0.32	-0.32	Itch intensity from mosquito bite adjusted by bite size;	chr12:67996421	chr12:67989445~68234686:+
OV	cis	rs875971	0.545	rs316328	ENSG00000226824.5	RP4-756H11.3	5.14	6.01e-07	0.000468	0.37	0.32	Aortic root size;	chr7:66143851	chr7:66654538~66669855:+
OV	cis	rs12429206	0.52	rs75594262	ENSG00000233672.5	RNASEH2B-AS1	-5.14	6.02e-07	0.000469	-0.43	-0.32	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50900249	chr13:50862172~50910764:-
OV	cis	rs507080	0.733	rs673547	ENSG00000278376.1	RP11-158I9.8	-5.14	6.02e-07	0.000469	-0.34	-0.32	Serum metabolite levels;	chr11:118702630	chr11:118791254~118793137:+
OV	cis	rs301901	0.734	rs216387	ENSG00000250155.1	CTD-2353F22.1	-5.14	6.03e-07	0.000469	-0.37	-0.32	Height;	chr5:37276657	chr5:36666214~36725195:-
OV	cis	rs7771547	0.573	rs664370	ENSG00000240733.3	RN7SL502P	5.14	6.04e-07	0.000469	0.35	0.32	Platelet distribution width;	chr6:36426039	chr6:36450912~36451201:-
OV	cis	rs7771547	0.573	rs584418	ENSG00000240733.3	RN7SL502P	5.14	6.04e-07	0.000469	0.35	0.32	Platelet distribution width;	chr6:36427660	chr6:36450912~36451201:-
OV	cis	rs7771547	0.542	rs597153	ENSG00000240733.3	RN7SL502P	5.14	6.04e-07	0.000469	0.35	0.32	Platelet distribution width;	chr6:36428220	chr6:36450912~36451201:-
OV	cis	rs7771547	0.573	rs9470274	ENSG00000240733.3	RN7SL502P	5.14	6.04e-07	0.000469	0.35	0.32	Platelet distribution width;	chr6:36429452	chr6:36450912~36451201:-
OV	cis	rs7771547	0.573	rs517890	ENSG00000240733.3	RN7SL502P	5.14	6.04e-07	0.000469	0.35	0.32	Platelet distribution width;	chr6:36430009	chr6:36450912~36451201:-
OV	cis	rs7771547	0.573	rs629721	ENSG00000240733.3	RN7SL502P	5.14	6.04e-07	0.000469	0.35	0.32	Platelet distribution width;	chr6:36430452	chr6:36450912~36451201:-
OV	cis	rs7771547	0.573	rs544267	ENSG00000240733.3	RN7SL502P	5.14	6.04e-07	0.000469	0.35	0.32	Platelet distribution width;	chr6:36430525	chr6:36450912~36451201:-
OV	cis	rs11096990	0.593	rs35552004	ENSG00000249207.1	RP11-360F5.1	-5.14	6.04e-07	0.00047	-0.35	-0.32	Cognitive function;	chr4:39170914	chr4:39112677~39126818:-
OV	cis	rs11096990	0.552	rs7655170	ENSG00000249207.1	RP11-360F5.1	-5.14	6.04e-07	0.00047	-0.35	-0.32	Cognitive function;	chr4:39171984	chr4:39112677~39126818:-
OV	cis	rs67180937	0.553	rs3002148	ENSG00000272750.1	RP11-378J18.8	5.14	6.05e-07	0.000471	0.43	0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222637575	chr1:222658867~222661512:-
OV	cis	rs4713118	0.911	rs9295746	ENSG00000219392.1	RP1-265C24.5	-5.14	6.06e-07	0.000471	-0.4	-0.32	Parkinson's disease;	chr6:27762285	chr6:28115628~28116551:+
OV	cis	rs1150668	0.799	rs9301	ENSG00000220721.1	OR1F12	5.14	6.06e-07	0.000471	0.33	0.32	Pubertal anthropometrics;	chr6:28324929	chr6:28073316~28074233:+
OV	cis	rs1150668	0.799	rs853684	ENSG00000220721.1	OR1F12	5.14	6.06e-07	0.000471	0.33	0.32	Pubertal anthropometrics;	chr6:28326773	chr6:28073316~28074233:+
OV	cis	rs17301013	0.507	rs6693198	ENSG00000227373.4	RP11-160H22.5	5.14	6.06e-07	0.000471	0.43	0.32	Systemic lupus erythematosus;	chr1:174304301	chr1:174115300~174160004:-
OV	cis	rs34779708	0.931	rs7897457	ENSG00000230534.5	RP11-297A16.2	5.13	6.08e-07	0.000472	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35097112	chr10:35098006~35127020:-
OV	cis	rs7302981	0.899	rs1862043	ENSG00000272368.2	RP4-605O3.4	-5.13	6.08e-07	0.000473	-0.36	-0.32	Systolic blood pressure;	chr12:50182533	chr12:50112197~50165618:+
OV	cis	rs8062405	0.755	rs62034358	ENSG00000278665.1	RP11-666O2.4	5.13	6.09e-07	0.000473	0.35	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576276	chr16:28599241~28601881:-
OV	cis	rs8062405	0.755	rs12445823	ENSG00000278665.1	RP11-666O2.4	5.13	6.09e-07	0.000473	0.35	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576728	chr16:28599241~28601881:-
OV	cis	rs10510102	0.935	rs75339296	ENSG00000276742.1	RP11-500G22.4	5.13	6.1e-07	0.000474	0.53	0.32	Breast cancer;	chr10:121859895	chr10:121956782~121957098:+
OV	cis	rs875971	0.545	rs6460298	ENSG00000236529.1	RP13-254B10.1	5.13	6.12e-07	0.000475	0.38	0.32	Aortic root size;	chr7:66442783	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs75577046	ENSG00000236529.1	RP13-254B10.1	5.13	6.12e-07	0.000475	0.38	0.32	Aortic root size;	chr7:66493729	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs3735147	ENSG00000236529.1	RP13-254B10.1	5.13	6.12e-07	0.000475	0.38	0.32	Aortic root size;	chr7:66505541	chr7:65840212~65840596:+
OV	cis	rs8062405	0.824	rs240702	ENSG00000278665.1	RP11-666O2.4	5.13	6.13e-07	0.000476	0.34	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28520032	chr16:28599241~28601881:-
OV	cis	rs4865169	0.871	rs9918067	ENSG00000269949.1	RP11-738E22.3	-5.13	6.14e-07	0.000477	-0.37	-0.32	Breast cancer;	chr4:57004378	chr4:56960927~56961373:-
OV	cis	rs6772849	0.93	rs6768344	ENSG00000242551.2	POU5F1P6	-5.13	6.17e-07	0.000478	-0.37	-0.32	Monocyte percentage of white cells;Monocyte count;	chr3:128654713	chr3:128674735~128677005:-
OV	cis	rs6772849	0.93	rs13434160	ENSG00000242551.2	POU5F1P6	-5.13	6.17e-07	0.000478	-0.37	-0.32	Monocyte percentage of white cells;Monocyte count;	chr3:128655927	chr3:128674735~128677005:-
OV	cis	rs6772849	0.93	rs4857916	ENSG00000242551.2	POU5F1P6	-5.13	6.17e-07	0.000478	-0.37	-0.32	Monocyte percentage of white cells;Monocyte count;	chr3:128657171	chr3:128674735~128677005:-
OV	cis	rs1150668	0.796	rs2531832	ENSG00000220721.1	OR1F12	5.13	6.17e-07	0.000479	0.32	0.32	Pubertal anthropometrics;	chr6:28421445	chr6:28073316~28074233:+
OV	cis	rs4380275	0.782	rs11691064	ENSG00000223751.1	AC116609.2	5.13	6.17e-07	0.000479	0.36	0.32	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:755718	chr2:742488~747767:+
OV	cis	rs17301013	0.507	rs10912759	ENSG00000227373.4	RP11-160H22.5	5.13	6.18e-07	0.000479	0.42	0.32	Systemic lupus erythematosus;	chr1:174312178	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs6425278	ENSG00000227373.4	RP11-160H22.5	5.13	6.18e-07	0.000479	0.42	0.32	Systemic lupus erythematosus;	chr1:174313148	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12083548	ENSG00000227373.4	RP11-160H22.5	5.13	6.18e-07	0.000479	0.42	0.32	Systemic lupus erythematosus;	chr1:174319134	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12083814	ENSG00000227373.4	RP11-160H22.5	5.13	6.18e-07	0.000479	0.42	0.32	Systemic lupus erythematosus;	chr1:174319917	chr1:174115300~174160004:-
OV	cis	rs2380205	0.58	rs980230	ENSG00000232807.2	RP11-536K7.3	5.13	6.19e-07	0.000479	0.34	0.32	Breast cancer;	chr10:5863268	chr10:5934270~5945900:-
OV	cis	rs8062405	0.755	rs4788080	ENSG00000278665.1	RP11-666O2.4	5.13	6.2e-07	0.00048	0.35	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546760	chr16:28599241~28601881:-
OV	cis	rs3931020	0.657	rs10890142	ENSG00000272864.1	RP11-17E13.2	-5.13	6.2e-07	0.000481	-0.44	-0.32	Resistin levels;	chr1:74713445	chr1:74698769~74699333:-
OV	cis	rs496547	0.686	rs540180	ENSG00000278376.1	RP11-158I9.8	-5.13	6.21e-07	0.000481	-0.31	-0.32	Hip minimal joint space width;	chr11:118782920	chr11:118791254~118793137:+
OV	cis	rs13068223	0.74	rs344003	ENSG00000243926.1	TIPARP-AS1	-5.13	6.22e-07	0.000481	-0.32	-0.32	Age-related hearing impairment (SNP x SNP interaction);	chr3:156739931	chr3:156671862~156674378:-
OV	cis	rs10510102	0.688	rs11812208	ENSG00000226864.1	ATE1-AS1	5.13	6.22e-07	0.000482	0.53	0.32	Breast cancer;	chr10:121924831	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs77447688	ENSG00000226864.1	ATE1-AS1	5.13	6.22e-07	0.000482	0.53	0.32	Breast cancer;	chr10:121925721	chr10:121928312~121951965:+
OV	cis	rs11673344	0.528	rs578655	ENSG00000226686.6	LINC01535	5.13	6.23e-07	0.000482	0.4	0.32	Obesity-related traits;	chr19:36919855	chr19:37251912~37265535:+
OV	cis	rs638893	0.898	rs587816	ENSG00000255239.1	AP002954.6	5.13	6.23e-07	0.000483	0.49	0.32	Vitiligo;	chr11:118819162	chr11:118688039~118690600:-
OV	cis	rs638893	0.898	rs577121	ENSG00000255239.1	AP002954.6	5.13	6.23e-07	0.000483	0.49	0.32	Vitiligo;	chr11:118819841	chr11:118688039~118690600:-
OV	cis	rs1576263	0.967	rs9505478	ENSG00000230939.1	RP11-314C16.1	-5.13	6.24e-07	0.000483	-0.35	-0.32	Photic sneeze reflex;	chr6:8550303	chr6:8784178~8785445:+
OV	cis	rs1576263	0.967	rs162279	ENSG00000230939.1	RP11-314C16.1	-5.13	6.25e-07	0.000483	-0.35	-0.32	Photic sneeze reflex;	chr6:8556735	chr6:8784178~8785445:+
OV	cis	rs1576263	0.967	rs7755191	ENSG00000230939.1	RP11-314C16.1	-5.13	6.25e-07	0.000483	-0.35	-0.32	Photic sneeze reflex;	chr6:8558407	chr6:8784178~8785445:+
OV	cis	rs301901	1	rs158624	ENSG00000250155.1	CTD-2353F22.1	-5.13	6.25e-07	0.000484	-0.38	-0.32	Height;	chr5:36865567	chr5:36666214~36725195:-
OV	cis	rs10924970	0.601	rs4659647	ENSG00000236863.2	RPL23AP23	5.13	6.26e-07	0.000484	0.34	0.32	Asthma;	chr1:235215871	chr1:235295865~235296335:+
OV	cis	rs200895692	1	rs200895692	ENSG00000227533.4	SLC2A1-AS1	5.13	6.26e-07	0.000485	0.47	0.32	Monocyte count;	chr1:42956299	chr1:42959049~42983358:+
OV	cis	rs1976403	0.659	rs10799701	ENSG00000227001.3	NBPF2P	5.13	6.27e-07	0.000485	0.35	0.32	Liver enzyme levels (alkaline phosphatase);	chr1:21494497	chr1:21424625~21427967:-
OV	cis	rs10740039	0.842	rs7080024	ENSG00000254271.1	RP11-131N11.4	-5.13	6.27e-07	0.000485	-0.4	-0.32	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60632033	chr10:60734342~60741828:+
OV	cis	rs9828933	0.766	rs704361	ENSG00000280620.1	SCAANT1	-5.13	6.28e-07	0.000486	-0.57	-0.32	Type 2 diabetes;	chr3:63897995	chr3:63911518~63911772:-
OV	cis	rs301901	0.965	rs13158310	ENSG00000250155.1	CTD-2353F22.1	5.13	6.28e-07	0.000486	0.38	0.32	Height;	chr5:36789552	chr5:36666214~36725195:-
OV	cis	rs10992471	0.756	rs10123342	ENSG00000281156.1	MIR3651	-5.13	6.28e-07	0.000486	-0.36	-0.32	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92325542	chr9:92292458~92292547:-
OV	cis	rs9813712	0.953	rs6782280	ENSG00000228252.7	COL6A4P2	5.13	6.28e-07	0.000486	0.41	0.32	Response to amphetamines;	chr3:130245370	chr3:130212823~130273806:+
OV	cis	rs858239	0.602	rs6953996	ENSG00000230042.1	AK3P3	-5.13	6.32e-07	0.000488	-0.34	-0.32	Cerebrospinal fluid biomarker levels;	chr7:23136327	chr7:23129178~23129841:+
OV	cis	rs13178541	0.641	rs2345448	ENSG00000250378.1	RP11-119J18.1	5.13	6.32e-07	0.000488	0.44	0.32	IgG glycosylation;	chr5:135804128	chr5:135812667~135826582:+
OV	cis	rs858239	0.601	rs10278700	ENSG00000230042.1	AK3P3	-5.13	6.32e-07	0.000489	-0.33	-0.32	Cerebrospinal fluid biomarker levels;	chr7:23120910	chr7:23129178~23129841:+
OV	cis	rs858239	0.601	rs10263110	ENSG00000230042.1	AK3P3	-5.13	6.32e-07	0.000489	-0.33	-0.32	Cerebrospinal fluid biomarker levels;	chr7:23120932	chr7:23129178~23129841:+
OV	cis	rs6088590	0.561	rs3891369	ENSG00000206582.1	Y_RNA	-5.13	6.33e-07	0.00049	-0.39	-0.32	Coronary artery disease;	chr20:34573323	chr20:34526510~34526606:-
OV	cis	rs67311347	1	rs7642906	ENSG00000223797.4	ENTPD3-AS1	-5.13	6.34e-07	0.00049	-0.35	-0.32	Renal cell carcinoma;	chr3:40451142	chr3:40313802~40453329:-
OV	cis	rs10510102	0.935	rs11200260	ENSG00000276742.1	RP11-500G22.4	5.13	6.35e-07	0.00049	0.52	0.32	Breast cancer;	chr10:121920169	chr10:121956782~121957098:+
OV	cis	rs1797885	1	rs1797885	ENSG00000251774.1	RNU6-377P	5.13	6.36e-07	0.000491	0.3	0.32	Immature fraction of reticulocytes;	chr3:12475604	chr3:12514706~12514807:+
OV	cis	rs1797885	0.934	rs12714871	ENSG00000251774.1	RNU6-377P	5.13	6.36e-07	0.000491	0.3	0.32	Immature fraction of reticulocytes;	chr3:12477230	chr3:12514706~12514807:+
OV	cis	rs607987	0.806	rs1228479	ENSG00000254532.1	RP11-624D11.2	5.13	6.36e-07	0.000491	0.39	0.32	Body mass index;	chr11:30344019	chr11:30044058~30084343:-
OV	cis	rs7567389	0.74	rs4536600	ENSG00000236682.1	AC068282.3	-5.12	6.37e-07	0.000492	-0.43	-0.32	Self-rated health;	chr2:127244996	chr2:127389130~127400580:+
OV	cis	rs757081	0.658	rs214075	ENSG00000213779.4	RP11-452G18.1	5.12	6.37e-07	0.000492	0.4	0.32	Systolic blood pressure;	chr11:17278870	chr11:17193489~17194308:+
OV	cis	rs4908768	0.686	rs79644886	ENSG00000228423.2	RP4-633I8.4	5.12	6.37e-07	0.000492	0.37	0.32	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8743157	chr1:8805860~8807051:-
OV	cis	rs116095464	0.558	rs55664502	ENSG00000250848.1	CTD-2083E4.5	-5.12	6.39e-07	0.000493	-0.4	-0.32	Breast cancer;	chr5:270370	chr5:288833~290321:-
OV	cis	rs116095464	0.51	rs7723883	ENSG00000250848.1	CTD-2083E4.5	-5.12	6.39e-07	0.000493	-0.4	-0.32	Breast cancer;	chr5:270683	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs28558836	ENSG00000250848.1	CTD-2083E4.5	-5.12	6.39e-07	0.000493	-0.4	-0.32	Breast cancer;	chr5:285633	chr5:288833~290321:-
OV	cis	rs8062405	0.69	rs7187604	ENSG00000278665.1	RP11-666O2.4	5.12	6.39e-07	0.000493	0.35	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554632	chr16:28599241~28601881:-
OV	cis	rs853679	0.567	rs13209596	ENSG00000216901.1	AL022393.7	5.12	6.39e-07	0.000494	0.39	0.32	Depression;	chr6:28428413	chr6:28176188~28176674:+
OV	cis	rs7968440	0.651	rs7309519	ENSG00000272368.2	RP4-605O3.4	-5.12	6.4e-07	0.000494	-0.36	-0.32	Fibrinogen;	chr12:50258497	chr12:50112197~50165618:+
OV	cis	rs11157436	0.958	rs17183356	ENSG00000211812.1	TRAV26-2	-5.12	6.4e-07	0.000494	-0.38	-0.32	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22219101	chr14:22202583~22203368:+
OV	cis	rs7017914	0.652	rs13273773	ENSG00000223220.1	Y_RNA	5.12	6.42e-07	0.000495	0.36	0.32	Bone mineral density;	chr8:70867012	chr8:70780914~70781008:-
OV	cis	rs11690935	0.55	rs4280427	ENSG00000228389.1	AC068039.4	-5.12	6.42e-07	0.000495	-0.36	-0.32	Schizophrenia;	chr2:171956692	chr2:171773482~171775844:+
OV	cis	rs11690935	0.531	rs4280428	ENSG00000228389.1	AC068039.4	-5.12	6.42e-07	0.000495	-0.36	-0.32	Schizophrenia;	chr2:171956693	chr2:171773482~171775844:+
OV	cis	rs4713118	0.505	rs156740	ENSG00000220721.1	OR1F12	5.12	6.44e-07	0.000497	0.32	0.32	Parkinson's disease;	chr6:27992657	chr6:28073316~28074233:+
OV	cis	rs1797885	0.934	rs299650	ENSG00000251774.1	RNU6-377P	5.12	6.46e-07	0.000498	0.3	0.32	Immature fraction of reticulocytes;	chr3:12497096	chr3:12514706~12514807:+
OV	cis	rs2253762	0.54	rs10159634	ENSG00000276742.1	RP11-500G22.4	-5.12	6.47e-07	0.000499	-0.53	-0.32	Breast cancer;	chr10:121994520	chr10:121956782~121957098:+
OV	cis	rs8062405	0.72	rs9926245	ENSG00000278665.1	RP11-666O2.4	5.12	6.48e-07	0.000499	0.33	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544385	chr16:28599241~28601881:-
OV	cis	rs301901	0.675	rs2366274	ENSG00000250155.1	CTD-2353F22.1	-5.12	6.48e-07	0.000499	-0.37	-0.32	Height;	chr5:37266341	chr5:36666214~36725195:-
OV	cis	rs4908768	0.657	rs12144099	ENSG00000228423.2	RP4-633I8.4	5.12	6.5e-07	5e-04	0.36	0.32	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8756116	chr1:8805860~8807051:-
OV	cis	rs2833693	0.574	rs2211675	ENSG00000261610.1	AP000265.1	-5.12	6.5e-07	5e-04	-0.38	-0.32	Temperament;	chr21:32180793	chr21:32259804~32261585:-
OV	cis	rs11096990	0.634	rs6531703	ENSG00000249207.1	RP11-360F5.1	5.12	6.51e-07	0.000501	0.34	0.32	Cognitive function;	chr4:39281786	chr4:39112677~39126818:-
OV	cis	rs34779708	0.966	rs34605125	ENSG00000230534.5	RP11-297A16.2	5.12	6.51e-07	0.000501	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35122318	chr10:35098006~35127020:-
OV	cis	rs875971	0.545	rs313830	ENSG00000226824.5	RP4-756H11.3	5.12	6.52e-07	0.000501	0.38	0.32	Aortic root size;	chr7:66086944	chr7:66654538~66669855:+
OV	cis	rs494459	0.536	rs10790267	ENSG00000255239.1	AP002954.6	5.12	6.53e-07	0.000502	0.39	0.32	Height;	chr11:118856460	chr11:118688039~118690600:-
OV	cis	rs494459	0.536	rs11217067	ENSG00000255239.1	AP002954.6	5.12	6.53e-07	0.000502	0.39	0.32	Height;	chr11:118856623	chr11:118688039~118690600:-
OV	cis	rs2510897	0.675	rs4936442	ENSG00000255239.1	AP002954.6	5.12	6.53e-07	0.000502	0.39	0.32	Height;	chr11:118857611	chr11:118688039~118690600:-
OV	cis	rs875971	0.545	rs73152714	ENSG00000236529.1	RP13-254B10.1	5.12	6.53e-07	0.000502	0.38	0.32	Aortic root size;	chr7:66534641	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs4718364	ENSG00000236529.1	RP13-254B10.1	5.12	6.53e-07	0.000502	0.38	0.32	Aortic root size;	chr7:66536353	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs6961853	ENSG00000236529.1	RP13-254B10.1	5.12	6.53e-07	0.000502	0.38	0.32	Aortic root size;	chr7:66537035	chr7:65840212~65840596:+
OV	cis	rs875971	0.528	rs801213	ENSG00000236529.1	RP13-254B10.1	-5.12	6.53e-07	0.000502	-0.38	-0.32	Aortic root size;	chr7:66549931	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs801212	ENSG00000236529.1	RP13-254B10.1	-5.12	6.53e-07	0.000502	-0.38	-0.32	Aortic root size;	chr7:66550643	chr7:65840212~65840596:+
OV	cis	rs67311347	0.713	rs73073505	ENSG00000223797.4	ENTPD3-AS1	5.12	6.53e-07	0.000502	0.35	0.32	Renal cell carcinoma;	chr3:40269202	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs17078941	ENSG00000223797.4	ENTPD3-AS1	-5.12	6.54e-07	0.000502	-0.36	-0.32	Renal cell carcinoma;	chr3:40409397	chr3:40313802~40453329:-
OV	cis	rs34779708	0.966	rs1057108	ENSG00000230534.5	RP11-297A16.2	5.12	6.54e-07	0.000503	0.41	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35196021	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs7070427	ENSG00000230534.5	RP11-297A16.2	5.12	6.54e-07	0.000503	0.41	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35196761	chr10:35098006~35127020:-
OV	cis	rs7429990	0.965	rs319685	ENSG00000229759.1	MRPS18AP1	5.12	6.55e-07	0.000503	0.34	0.32	Educational attainment (years of education);	chr3:47890494	chr3:48256350~48256938:-
OV	cis	rs7429990	0.965	rs319684	ENSG00000229759.1	MRPS18AP1	5.12	6.55e-07	0.000503	0.34	0.32	Educational attainment (years of education);	chr3:47890784	chr3:48256350~48256938:-
OV	cis	rs7429990	0.932	rs810334	ENSG00000229759.1	MRPS18AP1	5.12	6.55e-07	0.000503	0.34	0.32	Educational attainment (years of education);	chr3:47893813	chr3:48256350~48256938:-
OV	cis	rs4713118	0.824	rs9468223	ENSG00000280107.1	AL022393.9	-5.12	6.55e-07	0.000503	-0.38	-0.32	Parkinson's disease;	chr6:27772887	chr6:28170845~28172521:+
OV	cis	rs4380275	0.782	rs4335978	ENSG00000223751.1	AC116609.2	5.12	6.55e-07	0.000503	0.37	0.32	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:750078	chr2:742488~747767:+
OV	cis	rs1790761	0.52	rs4930461	ENSG00000184224.3	C11orf72	5.12	6.56e-07	0.000504	0.41	0.32	Mean corpuscular volume;	chr11:67627424	chr11:67602880~67606706:-
OV	cis	rs496547	0.719	rs598373	ENSG00000278376.1	RP11-158I9.8	-5.12	6.57e-07	0.000504	-0.32	-0.32	Hip minimal joint space width;	chr11:118793668	chr11:118791254~118793137:+
OV	cis	rs293748	0.571	rs13169211	ENSG00000250155.1	CTD-2353F22.1	-5.12	6.57e-07	0.000505	-0.43	-0.32	Obesity-related traits;	chr5:37131567	chr5:36666214~36725195:-
OV	cis	rs293748	0.571	rs9632396	ENSG00000250155.1	CTD-2353F22.1	-5.12	6.57e-07	0.000505	-0.43	-0.32	Obesity-related traits;	chr5:37140229	chr5:36666214~36725195:-
OV	cis	rs293748	0.571	rs10512664	ENSG00000250155.1	CTD-2353F22.1	-5.12	6.57e-07	0.000505	-0.43	-0.32	Obesity-related traits;	chr5:37158021	chr5:36666214~36725195:-
OV	cis	rs2098713	0.512	rs13166974	ENSG00000250155.1	CTD-2353F22.1	-5.12	6.57e-07	0.000505	-0.43	-0.32	Telomere length;	chr5:37171263	chr5:36666214~36725195:-
OV	cis	rs13256369	0.708	rs10903310	ENSG00000253893.2	FAM85B	5.12	6.59e-07	0.000505	0.41	0.32	Obesity-related traits;	chr8:8732177	chr8:8167819~8226614:-
OV	cis	rs4713118	0.696	rs2394002	ENSG00000280107.1	AL022393.9	-5.12	6.6e-07	0.000506	-0.38	-0.32	Parkinson's disease;	chr6:27780236	chr6:28170845~28172521:+
OV	cis	rs4761702	1	rs4761701	ENSG00000257322.4	RP11-511B23.2	-5.12	6.62e-07	0.000508	-0.37	-0.32	Immature fraction of reticulocytes;	chr12:93315956	chr12:93003415~93215679:-
OV	cis	rs7968440	0.736	rs7978559	ENSG00000257298.1	RP3-405J10.3	5.12	6.62e-07	0.000508	0.33	0.32	Fibrinogen;	chr12:50794855	chr12:50185580~50191363:-
OV	cis	rs7968440	0.808	rs7958114	ENSG00000257298.1	RP3-405J10.3	5.12	6.62e-07	0.000508	0.33	0.32	Fibrinogen;	chr12:50796909	chr12:50185580~50191363:-
OV	cis	rs6088580	0.634	rs6059867	ENSG00000206582.1	Y_RNA	-5.12	6.63e-07	0.000508	-0.38	-0.32	Glomerular filtration rate (creatinine);	chr20:34490298	chr20:34526510~34526606:-
OV	cis	rs8062405	0.824	rs7191618	ENSG00000278665.1	RP11-666O2.4	5.12	6.64e-07	0.000509	0.33	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554346	chr16:28599241~28601881:-
OV	cis	rs8062405	0.754	rs3859172	ENSG00000278665.1	RP11-666O2.4	5.12	6.64e-07	0.000509	0.33	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554837	chr16:28599241~28601881:-
OV	cis	rs9813712	0.953	rs9847910	ENSG00000228252.7	COL6A4P2	5.12	6.64e-07	0.000509	0.41	0.32	Response to amphetamines;	chr3:130248174	chr3:130212823~130273806:+
OV	cis	rs4713118	0.868	rs760587	ENSG00000280107.1	AL022393.9	-5.12	6.65e-07	0.000509	-0.4	-0.32	Parkinson's disease;	chr6:27772521	chr6:28170845~28172521:+
OV	cis	rs875971	0.545	rs12671152	ENSG00000236529.1	RP13-254B10.1	5.12	6.65e-07	0.00051	0.39	0.32	Aortic root size;	chr7:66311140	chr7:65840212~65840596:+
OV	cis	rs6772849	0.83	rs7633674	ENSG00000242551.2	POU5F1P6	-5.12	6.65e-07	0.00051	-0.37	-0.32	Monocyte percentage of white cells;Monocyte count;	chr3:128636183	chr3:128674735~128677005:-
OV	cis	rs6772849	0.93	rs9873888	ENSG00000242551.2	POU5F1P6	-5.12	6.65e-07	0.00051	-0.37	-0.32	Monocyte percentage of white cells;Monocyte count;	chr3:128642144	chr3:128674735~128677005:-
OV	cis	rs1185460	1	rs15818	ENSG00000271751.1	RP11-110I1.14	-5.12	6.66e-07	0.00051	-0.41	-0.32	Coronary artery disease;	chr11:119081463	chr11:119065263~119065677:-
OV	cis	rs1426063	0.614	rs76931926	ENSG00000260265.1	RP11-44F21.5	5.12	6.66e-07	0.00051	0.61	0.32	QT interval;	chr4:75106902	chr4:75081702~75084717:-
OV	cis	rs17301013	0.507	rs1121537	ENSG00000227373.4	RP11-160H22.5	5.11	6.68e-07	0.000511	0.43	0.32	Systemic lupus erythematosus;	chr1:174307568	chr1:174115300~174160004:-
OV	cis	rs7968440	0.808	rs67934435	ENSG00000257298.1	RP3-405J10.3	5.11	6.69e-07	0.000512	0.32	0.32	Fibrinogen;	chr12:50823401	chr12:50185580~50191363:-
OV	cis	rs796364	1	rs10178177	ENSG00000232732.8	AC073043.1	-5.11	6.69e-07	0.000512	-0.48	-0.32	Schizophrenia;	chr2:199965270	chr2:199867396~199911159:-
OV	cis	rs796364	0.951	rs281776	ENSG00000232732.8	AC073043.1	-5.11	6.69e-07	0.000512	-0.48	-0.32	Schizophrenia;	chr2:199969559	chr2:199867396~199911159:-
OV	cis	rs1976403	0.633	rs1697422	ENSG00000227001.3	NBPF2P	5.11	6.71e-07	0.000513	0.35	0.32	Liver enzyme levels (alkaline phosphatase);	chr1:21495404	chr1:21424625~21427967:-
OV	cis	rs7309	0.935	rs1921309	ENSG00000227403.1	AC009299.3	-5.11	6.71e-07	0.000513	-0.43	-0.32	Educational attainment;Intelligence (multi-trait analysis);Cognitive ability (multi-trait analysis);	chr2:161192464	chr2:161244739~161249050:+
OV	cis	rs7617773	0.779	rs9833309	ENSG00000228638.1	FCF1P2	-5.11	6.72e-07	0.000514	-0.4	-0.32	Coronary artery disease;	chr3:48285960	chr3:48290793~48291375:-
OV	cis	rs7617773	0.817	rs9853804	ENSG00000228638.1	FCF1P2	-5.11	6.72e-07	0.000514	-0.4	-0.32	Coronary artery disease;	chr3:48286239	chr3:48290793~48291375:-
OV	cis	rs7617773	0.817	rs9834095	ENSG00000228638.1	FCF1P2	-5.11	6.72e-07	0.000514	-0.4	-0.32	Coronary artery disease;	chr3:48286261	chr3:48290793~48291375:-
OV	cis	rs7617773	0.817	rs4131361	ENSG00000228638.1	FCF1P2	-5.11	6.72e-07	0.000514	-0.4	-0.32	Coronary artery disease;	chr3:48287322	chr3:48290793~48291375:-
OV	cis	rs7617773	0.817	rs6791930	ENSG00000228638.1	FCF1P2	-5.11	6.72e-07	0.000514	-0.4	-0.32	Coronary artery disease;	chr3:48288410	chr3:48290793~48291375:-
OV	cis	rs7617773	0.817	rs6794644	ENSG00000228638.1	FCF1P2	-5.11	6.72e-07	0.000514	-0.4	-0.32	Coronary artery disease;	chr3:48288547	chr3:48290793~48291375:-
OV	cis	rs992157	0.775	rs7559428	ENSG00000237281.1	CATIP-AS2	5.11	6.73e-07	0.000515	0.37	0.32	Colorectal cancer;	chr2:218285515	chr2:218326889~218357966:-
OV	cis	rs957448	0.561	rs71532325	ENSG00000253704.1	RP11-267M23.4	5.11	6.75e-07	0.000516	0.42	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94615738	chr8:94553722~94569745:+
OV	cis	rs11157436	0.958	rs17255537	ENSG00000211812.1	TRAV26-2	-5.11	6.77e-07	0.000517	-0.38	-0.32	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22208225	chr14:22202583~22203368:+
OV	cis	rs7811142	0.83	rs76798830	ENSG00000242294.5	STAG3L5P	5.11	6.78e-07	0.000518	0.34	0.32	Platelet count;	chr7:100355205	chr7:100336079~100351900:+
OV	cis	rs7811142	0.775	rs6946768	ENSG00000242294.5	STAG3L5P	5.11	6.78e-07	0.000518	0.34	0.32	Platelet count;	chr7:100356770	chr7:100336079~100351900:+
OV	cis	rs992157	1	rs4674280	ENSG00000237281.1	CATIP-AS2	5.11	6.78e-07	0.000518	0.37	0.32	Colorectal cancer;	chr2:218276735	chr2:218326889~218357966:-
OV	cis	rs301901	0.965	rs3104057	ENSG00000250155.1	CTD-2353F22.1	-5.11	6.78e-07	0.000518	-0.38	-0.32	Height;	chr5:36982949	chr5:36666214~36725195:-
OV	cis	rs7945705	0.692	rs11042149	ENSG00000254860.4	TMEM9B-AS1	5.11	6.79e-07	0.000518	0.33	0.32	Hemoglobin concentration;	chr11:8989190	chr11:8964675~8977527:+
OV	cis	rs7945705	0.747	rs11042150	ENSG00000254860.4	TMEM9B-AS1	5.11	6.79e-07	0.000518	0.33	0.32	Hemoglobin concentration;	chr11:8989272	chr11:8964675~8977527:+
OV	cis	rs8062405	0.69	rs62034351	ENSG00000278665.1	RP11-666O2.4	5.11	6.79e-07	0.000519	0.36	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28599241~28601881:-
OV	cis	rs34779708	0.931	rs10466072	ENSG00000230534.5	RP11-297A16.2	5.11	6.8e-07	0.000519	0.41	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35113828	chr10:35098006~35127020:-
OV	cis	rs638893	1	rs583905	ENSG00000255239.1	AP002954.6	5.11	6.8e-07	0.000519	0.48	0.32	Vitiligo;	chr11:118825199	chr11:118688039~118690600:-
OV	cis	rs11096990	0.6	rs6835337	ENSG00000249207.1	RP11-360F5.1	5.11	6.8e-07	0.00052	0.34	0.32	Cognitive function;	chr4:39281189	chr4:39112677~39126818:-
OV	cis	rs7429990	0.901	rs7431567	ENSG00000229759.1	MRPS18AP1	-5.11	6.81e-07	0.00052	-0.34	-0.32	Educational attainment (years of education);	chr3:47986342	chr3:48256350~48256938:-
OV	cis	rs301901	1	rs296962	ENSG00000250155.1	CTD-2353F22.1	-5.11	6.81e-07	0.00052	-0.38	-0.32	Height;	chr5:36990381	chr5:36666214~36725195:-
OV	cis	rs1797885	0.934	rs299646	ENSG00000251774.1	RNU6-377P	5.11	6.85e-07	0.000523	0.3	0.32	Immature fraction of reticulocytes;	chr3:12498956	chr3:12514706~12514807:+
OV	cis	rs9660180	0.967	rs9660106	ENSG00000268575.1	RP1-283E3.8	-5.11	6.85e-07	0.000523	-0.3	-0.32	Body mass index;	chr1:1866508	chr1:1702736~1737688:-
OV	cis	rs11673344	0.797	rs3745768	ENSG00000226686.6	LINC01535	5.11	6.85e-07	0.000523	0.42	0.32	Obesity-related traits;	chr19:36997907	chr19:37251912~37265535:+
OV	cis	rs796364	1	rs281794	ENSG00000232732.8	AC073043.1	-5.11	6.86e-07	0.000523	-0.48	-0.32	Schizophrenia;	chr2:199981943	chr2:199867396~199911159:-
OV	cis	rs507080	0.733	rs611733	ENSG00000278376.1	RP11-158I9.8	-5.11	6.87e-07	0.000524	-0.34	-0.32	Serum metabolite levels;	chr11:118702051	chr11:118791254~118793137:+
OV	cis	rs507080	0.733	rs552079	ENSG00000278376.1	RP11-158I9.8	-5.11	6.87e-07	0.000524	-0.34	-0.32	Serum metabolite levels;	chr11:118702313	chr11:118791254~118793137:+
OV	cis	rs6471393	1	rs6997642	ENSG00000253848.1	RP11-10N23.5	-5.11	6.87e-07	0.000524	-0.4	-0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93703737	chr8:93741193~93744534:+
OV	cis	rs4128705	1	rs10516892	ENSG00000249049.1	RP11-763F8.1	5.11	6.87e-07	0.000524	0.39	0.32	Amyotrophic lateral sclerosis (sporadic);	chr4:91362969	chr4:91319034~91325306:-
OV	cis	rs17301013	0.507	rs10912753	ENSG00000227373.4	RP11-160H22.5	5.11	6.88e-07	0.000525	0.42	0.32	Systemic lupus erythematosus;	chr1:174265226	chr1:174115300~174160004:-
OV	cis	rs858239	0.601	rs1558313	ENSG00000230042.1	AK3P3	-5.11	6.88e-07	0.000525	-0.33	-0.32	Cerebrospinal fluid biomarker levels;	chr7:23116460	chr7:23129178~23129841:+
OV	cis	rs301901	1	rs159753	ENSG00000250155.1	CTD-2353F22.1	-5.11	6.88e-07	0.000525	-0.37	-0.32	Height;	chr5:37007527	chr5:36666214~36725195:-
OV	cis	rs301901	1	rs300060	ENSG00000250155.1	CTD-2353F22.1	-5.11	6.88e-07	0.000525	-0.37	-0.32	Height;	chr5:37019252	chr5:36666214~36725195:-
OV	cis	rs301901	1	rs300063	ENSG00000250155.1	CTD-2353F22.1	-5.11	6.88e-07	0.000525	-0.37	-0.32	Height;	chr5:37023796	chr5:36666214~36725195:-
OV	cis	rs9813712	0.595	rs1993217	ENSG00000228252.7	COL6A4P2	-5.11	6.89e-07	0.000525	-0.37	-0.32	Response to amphetamines;	chr3:130284832	chr3:130212823~130273806:+
OV	cis	rs9813712	0.595	rs16825656	ENSG00000228252.7	COL6A4P2	-5.11	6.89e-07	0.000525	-0.37	-0.32	Response to amphetamines;	chr3:130286225	chr3:130212823~130273806:+
OV	cis	rs875971	0.558	rs4433015	ENSG00000224316.1	RP11-479O9.2	-5.11	6.89e-07	0.000526	-0.34	-0.32	Aortic root size;	chr7:66174736	chr7:65773620~65802067:+
OV	cis	rs7116641	0.734	rs6485464	ENSG00000246250.2	RP11-613D13.5	-5.11	6.9e-07	0.000526	-0.37	-0.32	Coronary artery disease;	chr11:43803931	chr11:43829709~43880726:-
OV	cis	rs7771547	0.508	rs3798471	ENSG00000240733.3	RN7SL502P	5.11	6.9e-07	0.000526	0.35	0.32	Platelet distribution width;	chr6:36531794	chr6:36450912~36451201:-
OV	cis	rs301901	1	rs168662	ENSG00000250155.1	CTD-2353F22.1	-5.11	6.91e-07	0.000526	-0.37	-0.32	Height;	chr5:36925633	chr5:36666214~36725195:-
OV	cis	rs9291683	0.527	rs73212848	ENSG00000250413.1	RP11-448G15.1	5.11	6.91e-07	0.000527	0.38	0.32	Bone mineral density;	chr4:10091675	chr4:10006482~10009725:+
OV	cis	rs4266144	0.563	rs61124401	ENSG00000244515.1	KRT18P34	-5.11	6.91e-07	0.000527	-0.41	-0.32	Coronary artery disease;	chr3:157123130	chr3:157162663~157163932:-
OV	cis	rs4713118	0.826	rs2893929	ENSG00000280107.1	AL022393.9	-5.11	6.92e-07	0.000528	-0.4	-0.32	Parkinson's disease;	chr6:27770953	chr6:28170845~28172521:+
OV	cis	rs4713118	0.666	rs4140646	ENSG00000280107.1	AL022393.9	-5.11	6.92e-07	0.000528	-0.4	-0.32	Parkinson's disease;	chr6:27771022	chr6:28170845~28172521:+
OV	cis	rs4713118	0.666	rs2893930	ENSG00000280107.1	AL022393.9	-5.11	6.92e-07	0.000528	-0.4	-0.32	Parkinson's disease;	chr6:27771027	chr6:28170845~28172521:+
OV	cis	rs4128705	0.959	rs12508304	ENSG00000249049.1	RP11-763F8.1	5.11	6.93e-07	0.000528	0.41	0.32	Amyotrophic lateral sclerosis (sporadic);	chr4:91366033	chr4:91319034~91325306:-
OV	cis	rs4713118	0.911	rs9461406	ENSG00000219392.1	RP1-265C24.5	5.11	6.94e-07	0.000528	0.4	0.32	Parkinson's disease;	chr6:27751985	chr6:28115628~28116551:+
OV	cis	rs301901	0.828	rs151944	ENSG00000250155.1	CTD-2353F22.1	-5.11	6.95e-07	0.000529	-0.37	-0.32	Height;	chr5:36904297	chr5:36666214~36725195:-
OV	cis	rs2380205	0.503	rs685852	ENSG00000232807.2	RP11-536K7.3	-5.11	6.98e-07	0.000532	-0.33	-0.32	Breast cancer;	chr10:5892654	chr10:5934270~5945900:-
OV	cis	rs1979679	0.842	rs10459090	ENSG00000278733.1	RP11-425D17.1	5.11	6.98e-07	0.000532	0.38	0.32	Ossification of the posterior longitudinal ligament of the spine;	chr12:28188207	chr12:28185625~28186190:-
OV	cis	rs1150668	0.796	rs1005125	ENSG00000220721.1	OR1F12	5.11	6.98e-07	0.000532	0.32	0.32	Pubertal anthropometrics;	chr6:28399578	chr6:28073316~28074233:+
OV	cis	rs6088580	0.634	rs6059850	ENSG00000206582.1	Y_RNA	-5.1	7e-07	0.000533	-0.38	-0.32	Glomerular filtration rate (creatinine);	chr20:34456979	chr20:34526510~34526606:-
OV	cis	rs1979679	0.842	rs35098487	ENSG00000278733.1	RP11-425D17.1	5.1	7.03e-07	0.000535	0.37	0.32	Ossification of the posterior longitudinal ligament of the spine;	chr12:28191043	chr12:28185625~28186190:-
OV	cis	rs875971	0.545	rs313828	ENSG00000226824.5	RP4-756H11.3	5.1	7.03e-07	0.000535	0.38	0.32	Aortic root size;	chr7:66087627	chr7:66654538~66669855:+
OV	cis	rs875971	0.52	rs160645	ENSG00000226824.5	RP4-756H11.3	5.1	7.03e-07	0.000535	0.38	0.32	Aortic root size;	chr7:66091320	chr7:66654538~66669855:+
OV	cis	rs875971	0.789	rs28815324	ENSG00000226824.5	RP4-756H11.3	5.1	7.03e-07	0.000535	0.38	0.32	Aortic root size;	chr7:66100789	chr7:66654538~66669855:+
OV	cis	rs1790761	0.52	rs7124513	ENSG00000184224.3	C11orf72	-5.1	7.05e-07	0.000536	-0.4	-0.32	Mean corpuscular volume;	chr11:67628243	chr11:67602880~67606706:-
OV	cis	rs2980439	0.87	rs2945230	ENSG00000253893.2	FAM85B	-5.1	7.06e-07	0.000537	-0.33	-0.32	Neuroticism;	chr8:8252414	chr8:8167819~8226614:-
OV	cis	rs55692468	0.771	rs6744391	ENSG00000213197.3	AC012066.1	-5.1	7.06e-07	0.000537	-0.32	-0.32	Intraocular pressure;	chr2:152478100	chr2:152389937~152390630:+
OV	cis	rs611744	0.604	rs13248461	ENSG00000253754.1	RP11-35G22.1	-5.1	7.07e-07	0.000538	-0.35	-0.32	Dupuytren's disease;	chr8:108273604	chr8:108226200~108227544:+
OV	cis	rs7617773	0.817	rs3731555	ENSG00000228638.1	FCF1P2	-5.1	7.07e-07	0.000538	-0.4	-0.32	Coronary artery disease;	chr3:48164612	chr3:48290793~48291375:-
OV	cis	rs6471393	0.929	rs58575315	ENSG00000253848.1	RP11-10N23.5	5.1	7.07e-07	0.000538	0.39	0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93749495	chr8:93741193~93744534:+
OV	cis	rs6471393	0.929	rs62525162	ENSG00000253848.1	RP11-10N23.5	5.1	7.07e-07	0.000538	0.39	0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93749654	chr8:93741193~93744534:+
OV	cis	rs6471393	0.929	rs62525163	ENSG00000253848.1	RP11-10N23.5	5.1	7.07e-07	0.000538	0.39	0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93749824	chr8:93741193~93744534:+
OV	cis	rs6471393	0.929	rs62525164	ENSG00000253848.1	RP11-10N23.5	5.1	7.07e-07	0.000538	0.39	0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93750084	chr8:93741193~93744534:+
OV	cis	rs6471393	0.964	rs16916191	ENSG00000253848.1	RP11-10N23.5	5.1	7.07e-07	0.000538	0.37	0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93737337	chr8:93741193~93744534:+
OV	cis	rs9660180	0.967	rs11260623	ENSG00000268575.1	RP1-283E3.8	-5.1	7.08e-07	0.000538	-0.3	-0.32	Body mass index;	chr1:1850017	chr1:1702736~1737688:-
OV	cis	rs7567389	0.74	rs1604817	ENSG00000236682.1	AC068282.3	5.1	7.09e-07	0.000539	0.44	0.32	Self-rated health;	chr2:127242345	chr2:127389130~127400580:+
OV	cis	rs7429990	0.965	rs6772396	ENSG00000229759.1	MRPS18AP1	5.1	7.1e-07	0.00054	0.34	0.32	Educational attainment (years of education);	chr3:47918280	chr3:48256350~48256938:-
OV	cis	rs514406	0.763	rs6685599	ENSG00000206627.1	RNU6-969P	-5.1	7.1e-07	0.00054	-0.34	-0.32	Monocyte count;	chr1:52747500	chr1:52805108~52805212:-
OV	cis	rs514406	0.763	rs9988539	ENSG00000206627.1	RNU6-969P	-5.1	7.1e-07	0.00054	-0.34	-0.32	Monocyte count;	chr1:52748212	chr1:52805108~52805212:-
OV	cis	rs514406	0.8	rs4926930	ENSG00000206627.1	RNU6-969P	-5.1	7.1e-07	0.00054	-0.34	-0.32	Monocyte count;	chr1:52751663	chr1:52805108~52805212:-
OV	cis	rs6683071	1	rs2378606	ENSG00000272750.1	RP11-378J18.8	5.1	7.11e-07	0.00054	0.39	0.32	Cognitive performance;	chr1:222746406	chr1:222658867~222661512:-
OV	cis	rs301901	0.772	rs7735138	ENSG00000250155.1	CTD-2353F22.1	-5.1	7.11e-07	0.00054	-0.37	-0.32	Height;	chr5:37239138	chr5:36666214~36725195:-
OV	cis	rs7160336	0.555	rs7147523	ENSG00000259065.1	RP5-1021I20.1	5.1	7.11e-07	0.00054	0.39	0.32	Blood protein levels;	chr14:74034747	chr14:73787360~73803270:+
OV	cis	rs11673344	0.704	rs1667384	ENSG00000226686.6	LINC01535	5.1	7.14e-07	0.000542	0.4	0.32	Obesity-related traits;	chr19:36925852	chr19:37251912~37265535:+
OV	cis	rs11673344	0.83	rs3745770	ENSG00000226686.6	LINC01535	5.1	7.15e-07	0.000543	0.42	0.32	Obesity-related traits;	chr19:36997663	chr19:37251912~37265535:+
OV	cis	rs1134634	0.52	rs7661102	ENSG00000273133.1	RP11-799M12.2	-5.1	7.16e-07	0.000543	-0.42	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15596914	chr4:15563698~15564253:-
OV	cis	rs1134634	0.52	rs56041141	ENSG00000273133.1	RP11-799M12.2	-5.1	7.16e-07	0.000543	-0.42	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15598222	chr4:15563698~15564253:-
OV	cis	rs607987	0.871	rs1222218	ENSG00000254532.1	RP11-624D11.2	5.1	7.16e-07	0.000544	0.38	0.32	Body mass index;	chr11:30323214	chr11:30044058~30084343:-
OV	cis	rs73019876	0.502	rs452707	ENSG00000269742.1	BNIP3P29	-5.1	7.17e-07	0.000544	-0.36	-0.32	Testicular germ cell tumor;	chr19:22121343	chr19:22065828~22066398:-
OV	cis	rs7429990	0.901	rs7433678	ENSG00000229759.1	MRPS18AP1	-5.1	7.19e-07	0.000545	-0.33	-0.32	Educational attainment (years of education);	chr3:47995588	chr3:48256350~48256938:-
OV	cis	rs2243480	1	rs6460260	ENSG00000222364.1	RNU6-96P	5.1	7.2e-07	0.000545	0.55	0.32	Diabetic kidney disease;	chr7:65750468	chr7:66395191~66395286:+
OV	cis	rs2243480	1	rs6460261	ENSG00000222364.1	RNU6-96P	5.1	7.2e-07	0.000545	0.55	0.32	Diabetic kidney disease;	chr7:65750593	chr7:66395191~66395286:+
OV	cis	rs1891275	0.55	rs4933694	ENSG00000228701.1	TNKS2-AS1	-5.1	7.2e-07	0.000545	-0.35	-0.32	Intelligence (multi-trait analysis);	chr10:91739456	chr10:91782839~91798291:-
OV	cis	rs10510102	0.516	rs79528809	ENSG00000276742.1	RP11-500G22.4	5.1	7.2e-07	0.000546	0.58	0.32	Breast cancer;	chr10:121980309	chr10:121956782~121957098:+
OV	cis	rs8062405	1	rs12325113	ENSG00000278665.1	RP11-666O2.4	5.1	7.21e-07	0.000546	0.35	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28837347	chr16:28599241~28601881:-
OV	cis	rs56163509	1	rs56163509	ENSG00000278665.1	RP11-666O2.4	5.1	7.21e-07	0.000546	0.35	0.32	Tonsillectomy;Mean corpuscular volume;	chr16:28853150	chr16:28599241~28601881:-
OV	cis	rs8062405	0.964	rs7187333	ENSG00000278665.1	RP11-666O2.4	5.1	7.21e-07	0.000546	0.35	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854595	chr16:28599241~28601881:-
OV	cis	rs8062405	1	rs62037369	ENSG00000278665.1	RP11-666O2.4	5.1	7.21e-07	0.000546	0.35	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28872520	chr16:28599241~28601881:-
OV	cis	rs8062405	0.965	rs7359397	ENSG00000278665.1	RP11-666O2.4	5.1	7.21e-07	0.000546	0.35	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874338	chr16:28599241~28601881:-
OV	cis	rs875971	0.545	rs75840613	ENSG00000236529.1	RP13-254B10.1	5.1	7.23e-07	0.000547	0.38	0.32	Aortic root size;	chr7:66376399	chr7:65840212~65840596:+
OV	cis	rs9660180	0.837	rs915292	ENSG00000268575.1	RP1-283E3.8	-5.1	7.24e-07	0.000548	-0.3	-0.32	Body mass index;	chr1:1860718	chr1:1702736~1737688:-
OV	cis	rs4713118	0.588	rs200994	ENSG00000280107.1	AL022393.9	5.1	7.25e-07	0.000549	0.4	0.32	Parkinson's disease;	chr6:27846035	chr6:28170845~28172521:+
OV	cis	rs1979679	0.842	rs11049411	ENSG00000278733.1	RP11-425D17.1	5.1	7.25e-07	0.000549	0.37	0.32	Ossification of the posterior longitudinal ligament of the spine;	chr12:28184723	chr12:28185625~28186190:-
OV	cis	rs1979679	0.842	rs10459091	ENSG00000278733.1	RP11-425D17.1	5.1	7.25e-07	0.000549	0.37	0.32	Ossification of the posterior longitudinal ligament of the spine;	chr12:28188383	chr12:28185625~28186190:-
OV	cis	rs875971	0.545	rs73376401	ENSG00000226824.5	RP4-756H11.3	-5.1	7.25e-07	0.000549	-0.38	-0.32	Aortic root size;	chr7:66174841	chr7:66654538~66669855:+
OV	cis	rs875971	0.545	rs6460276	ENSG00000226824.5	RP4-756H11.3	-5.1	7.25e-07	0.000549	-0.38	-0.32	Aortic root size;	chr7:66182290	chr7:66654538~66669855:+
OV	cis	rs11673344	0.636	rs7255595	ENSG00000226686.6	LINC01535	5.1	7.26e-07	0.000549	0.42	0.32	Obesity-related traits;	chr19:36896260	chr19:37251912~37265535:+
OV	cis	rs6683071	0.501	rs3002146	ENSG00000272750.1	RP11-378J18.8	5.1	7.26e-07	0.00055	0.42	0.32	Cognitive performance;	chr1:222636066	chr1:222658867~222661512:-
OV	cis	rs67180937	0.553	rs1391557	ENSG00000272750.1	RP11-378J18.8	5.1	7.26e-07	0.00055	0.42	0.32	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222636274	chr1:222658867~222661512:-
OV	cis	rs1823913	0.927	rs13025919	ENSG00000227542.1	AC092614.2	5.1	7.27e-07	0.00055	0.39	0.32	Obesity-related traits;	chr2:191260175	chr2:191229165~191246172:-
OV	cis	rs7017914	0.652	rs17778232	ENSG00000223220.1	Y_RNA	5.1	7.28e-07	0.000551	0.37	0.32	Bone mineral density;	chr8:71079283	chr8:70780914~70781008:-
OV	cis	rs295490	0.748	rs78103472	ENSG00000272656.1	RP11-219D15.3	5.1	7.29e-07	0.000551	0.6	0.32	PR interval in Tripanosoma cruzi seropositivity;	chr3:139433304	chr3:139349024~139349371:-
OV	cis	rs11673344	0.526	rs1871196	ENSG00000226686.6	LINC01535	5.1	7.29e-07	0.000552	0.43	0.32	Obesity-related traits;	chr19:37656022	chr19:37251912~37265535:+
OV	cis	rs10510102	0.608	rs4752607	ENSG00000226864.1	ATE1-AS1	-5.1	7.3e-07	0.000552	-0.46	-0.32	Breast cancer;	chr10:121835426	chr10:121928312~121951965:+
OV	cis	rs507080	0.697	rs656287	ENSG00000278376.1	RP11-158I9.8	-5.1	7.3e-07	0.000552	-0.34	-0.32	Serum metabolite levels;	chr11:118701081	chr11:118791254~118793137:+
OV	cis	rs507080	0.733	rs570949	ENSG00000278376.1	RP11-158I9.8	-5.1	7.3e-07	0.000552	-0.34	-0.32	Serum metabolite levels;	chr11:118701202	chr11:118791254~118793137:+
OV	cis	rs301901	0.663	rs217847	ENSG00000250155.1	CTD-2353F22.1	5.1	7.31e-07	0.000553	0.36	0.32	Height;	chr5:37367135	chr5:36666214~36725195:-
OV	cis	rs4761702	1	rs4761702	ENSG00000257322.4	RP11-511B23.2	-5.1	7.31e-07	0.000553	-0.36	-0.32	Immature fraction of reticulocytes;	chr12:93316116	chr12:93003415~93215679:-
OV	cis	rs11096990	0.634	rs2381371	ENSG00000249207.1	RP11-360F5.1	-5.1	7.31e-07	0.000553	-0.34	-0.32	Cognitive function;	chr4:39271414	chr4:39112677~39126818:-
OV	cis	rs7786410	1	rs7786410	ENSG00000275875.1	RP11-613E4.5	5.1	7.31e-07	0.000553	0.55	0.32	Age-related hearing impairment;	chr7:55854630	chr7:55741525~55741869:+
OV	cis	rs62355900	0.627	rs16886463	ENSG00000271828.1	CTD-2310F14.1	5.1	7.32e-07	0.000553	0.59	0.32	Endometriosis;	chr5:56883514	chr5:56927874~56929573:+
OV	cis	rs62355900	0.627	rs62358106	ENSG00000271828.1	CTD-2310F14.1	5.1	7.32e-07	0.000553	0.59	0.32	Endometriosis;	chr5:56885542	chr5:56927874~56929573:+
OV	cis	rs62355900	0.627	rs3817119	ENSG00000271828.1	CTD-2310F14.1	5.1	7.32e-07	0.000553	0.59	0.32	Endometriosis;	chr5:56887916	chr5:56927874~56929573:+
OV	cis	rs11690935	0.55	rs11676438	ENSG00000228389.1	AC068039.4	-5.1	7.33e-07	0.000554	-0.35	-0.32	Schizophrenia;	chr2:171970147	chr2:171773482~171775844:+
OV	cis	rs10510102	0.872	rs11200261	ENSG00000276742.1	RP11-500G22.4	5.09	7.35e-07	0.000555	0.51	0.32	Breast cancer;	chr10:121921133	chr10:121956782~121957098:+
OV	cis	rs8005677	0.611	rs11624528	ENSG00000257285.4	RP11-298I3.1	5.09	7.36e-07	0.000556	0.38	0.32	Cognitive ability (multi-trait analysis);	chr14:22989947	chr14:22929609~22955562:+
OV	cis	rs11096990	0.613	rs12505690	ENSG00000249207.1	RP11-360F5.1	-5.09	7.36e-07	0.000556	-0.34	-0.32	Cognitive function;	chr4:39167425	chr4:39112677~39126818:-
OV	cis	rs11096990	0.634	rs2086752	ENSG00000249207.1	RP11-360F5.1	5.09	7.37e-07	0.000557	0.34	0.32	Cognitive function;	chr4:39280486	chr4:39112677~39126818:-
OV	cis	rs11096990	0.594	rs2381373	ENSG00000249207.1	RP11-360F5.1	5.09	7.37e-07	0.000557	0.34	0.32	Cognitive function;	chr4:39280683	chr4:39112677~39126818:-
OV	cis	rs11096990	0.634	rs60016848	ENSG00000249207.1	RP11-360F5.1	5.09	7.37e-07	0.000557	0.34	0.32	Cognitive function;	chr4:39281436	chr4:39112677~39126818:-
OV	cis	rs11096990	0.577	rs6830736	ENSG00000249207.1	RP11-360F5.1	5.09	7.37e-07	0.000557	0.34	0.32	Cognitive function;	chr4:39281467	chr4:39112677~39126818:-
OV	cis	rs11096990	0.634	rs6854358	ENSG00000249207.1	RP11-360F5.1	5.09	7.37e-07	0.000557	0.34	0.32	Cognitive function;	chr4:39281492	chr4:39112677~39126818:-
OV	cis	rs11096990	0.634	rs6852967	ENSG00000249207.1	RP11-360F5.1	5.09	7.37e-07	0.000557	0.34	0.32	Cognitive function;	chr4:39281526	chr4:39112677~39126818:-
OV	cis	rs11096990	0.634	rs6531704	ENSG00000249207.1	RP11-360F5.1	5.09	7.37e-07	0.000557	0.34	0.32	Cognitive function;	chr4:39282126	chr4:39112677~39126818:-
OV	cis	rs11096990	0.634	rs7654501	ENSG00000249207.1	RP11-360F5.1	5.09	7.37e-07	0.000557	0.34	0.32	Cognitive function;	chr4:39282364	chr4:39112677~39126818:-
OV	cis	rs4356975	0.518	rs4694628	ENSG00000251284.2	RP13-644M16.1	-5.09	7.38e-07	0.000557	-0.47	-0.32	Obesity-related traits;	chr4:69104054	chr4:69125274~69126451:+
OV	cis	rs7017914	0.905	rs3110244	ENSG00000223220.1	Y_RNA	-5.09	7.4e-07	0.000558	-0.34	-0.32	Bone mineral density;	chr8:71020962	chr8:70780914~70781008:-
OV	cis	rs858239	0.511	rs10256996	ENSG00000230042.1	AK3P3	5.09	7.4e-07	0.000559	0.32	0.32	Cerebrospinal fluid biomarker levels;	chr7:23105676	chr7:23129178~23129841:+
OV	cis	rs783540	0.967	rs7494860	ENSG00000278603.1	RP13-608F4.5	5.09	7.41e-07	0.000559	0.37	0.32	Schizophrenia;	chr15:82665667	chr15:82472203~82472426:+
OV	cis	rs17301013	0.507	rs72713537	ENSG00000227373.4	RP11-160H22.5	5.09	7.43e-07	0.00056	0.42	0.32	Systemic lupus erythematosus;	chr1:174354189	chr1:174115300~174160004:-
OV	cis	rs2833693	0.574	rs4143359	ENSG00000261610.1	AP000265.1	5.09	7.44e-07	0.000561	0.38	0.32	Temperament;	chr21:32179062	chr21:32259804~32261585:-
OV	cis	rs2833693	0.574	rs9653707	ENSG00000261610.1	AP000265.1	5.09	7.44e-07	0.000561	0.38	0.32	Temperament;	chr21:32179462	chr21:32259804~32261585:-
OV	cis	rs2833693	0.574	rs11088205	ENSG00000261610.1	AP000265.1	5.09	7.44e-07	0.000561	0.38	0.32	Temperament;	chr21:32179989	chr21:32259804~32261585:-
OV	cis	rs957448	1	rs12680965	ENSG00000253704.1	RP11-267M23.4	5.09	7.44e-07	0.000561	0.43	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94554069	chr8:94553722~94569745:+
OV	cis	rs6471393	1	rs6471393	ENSG00000253848.1	RP11-10N23.5	-5.09	7.45e-07	0.000562	-0.4	-0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93703063	chr8:93741193~93744534:+
OV	cis	rs8105895	1	rs17450788	ENSG00000269742.1	BNIP3P29	5.09	7.46e-07	0.000563	0.51	0.32	Body mass index (change over time);	chr19:22041953	chr19:22065828~22066398:-
OV	cis	rs858239	0.6	rs7341483	ENSG00000230042.1	AK3P3	5.09	7.46e-07	0.000563	0.34	0.32	Cerebrospinal fluid biomarker levels;	chr7:23088038	chr7:23129178~23129841:+
OV	cis	rs4805272	1	rs888828	ENSG00000267243.4	AC005307.3	-5.09	7.48e-07	0.000564	-0.43	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28834150	chr19:28435388~28727777:-
OV	cis	rs4805272	1	rs888827	ENSG00000267243.4	AC005307.3	-5.09	7.48e-07	0.000564	-0.43	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28834449	chr19:28435388~28727777:-
OV	cis	rs4805272	0.925	rs9304627	ENSG00000267243.4	AC005307.3	-5.09	7.48e-07	0.000564	-0.43	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28834549	chr19:28435388~28727777:-
OV	cis	rs4805272	1	rs7254025	ENSG00000267243.4	AC005307.3	-5.09	7.48e-07	0.000564	-0.43	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28835199	chr19:28435388~28727777:-
OV	cis	rs4805272	1	rs1363323	ENSG00000267243.4	AC005307.3	-5.09	7.48e-07	0.000564	-0.43	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28836045	chr19:28435388~28727777:-
OV	cis	rs1150668	0.83	rs213240	ENSG00000220721.1	OR1F12	5.09	7.49e-07	0.000564	0.32	0.32	Pubertal anthropometrics;	chr6:28348098	chr6:28073316~28074233:+
OV	cis	rs301901	0.895	rs292172	ENSG00000250155.1	CTD-2353F22.1	-5.09	7.49e-07	0.000564	-0.37	-0.32	Height;	chr5:36817237	chr5:36666214~36725195:-
OV	cis	rs116095464	0.558	rs57335027	ENSG00000250848.1	CTD-2083E4.5	-5.09	7.49e-07	0.000564	-0.4	-0.32	Breast cancer;	chr5:262792	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs6869925	ENSG00000250848.1	CTD-2083E4.5	-5.09	7.49e-07	0.000564	-0.4	-0.32	Breast cancer;	chr5:263921	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs6875291	ENSG00000250848.1	CTD-2083E4.5	-5.09	7.49e-07	0.000564	-0.4	-0.32	Breast cancer;	chr5:264077	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs6866776	ENSG00000250848.1	CTD-2083E4.5	-5.09	7.49e-07	0.000564	-0.4	-0.32	Breast cancer;	chr5:264380	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs6874745	ENSG00000250848.1	CTD-2083E4.5	-5.09	7.49e-07	0.000564	-0.4	-0.32	Breast cancer;	chr5:264412	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs7715108	ENSG00000250848.1	CTD-2083E4.5	-5.09	7.49e-07	0.000564	-0.4	-0.32	Breast cancer;	chr5:264546	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs7730700	ENSG00000250848.1	CTD-2083E4.5	-5.09	7.49e-07	0.000564	-0.4	-0.32	Breast cancer;	chr5:264598	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs10057674	ENSG00000250848.1	CTD-2083E4.5	-5.09	7.49e-07	0.000564	-0.4	-0.32	Breast cancer;	chr5:266698	chr5:288833~290321:-
OV	cis	rs7189233	0.531	rs9929873	ENSG00000279344.1	RP11-44F14.7	5.09	7.5e-07	0.000565	0.3	0.32	Intelligence (multi-trait analysis);	chr16:53456764	chr16:53478957~53481550:-
OV	cis	rs4253417	1	rs4253417	ENSG00000249679.1	RP11-279O9.4	5.09	7.5e-07	0.000565	0.34	0.32	Venous thromboembolism;Factor XI;	chr4:186277851	chr4:185471516~185472263:+
OV	cis	rs2153535	0.561	rs9406184	ENSG00000230939.1	RP11-314C16.1	-5.09	7.52e-07	0.000566	-0.35	-0.32	Motion sickness;	chr6:8642681	chr6:8784178~8785445:+
OV	cis	rs2153535	0.585	rs11243263	ENSG00000230939.1	RP11-314C16.1	-5.09	7.52e-07	0.000566	-0.35	-0.32	Motion sickness;	chr6:8642880	chr6:8784178~8785445:+
OV	cis	rs2153535	0.585	rs9392233	ENSG00000230939.1	RP11-314C16.1	-5.09	7.52e-07	0.000566	-0.35	-0.32	Motion sickness;	chr6:8645042	chr6:8784178~8785445:+
OV	cis	rs10510102	0.608	rs4077606	ENSG00000276742.1	RP11-500G22.4	-5.09	7.55e-07	0.000568	-0.45	-0.32	Breast cancer;	chr10:121849907	chr10:121956782~121957098:+
OV	cis	rs7189233	0.513	rs2908797	ENSG00000279344.1	RP11-44F14.7	5.09	7.55e-07	0.000568	0.3	0.32	Intelligence (multi-trait analysis);	chr16:53395261	chr16:53478957~53481550:-
OV	cis	rs7587476	0.862	rs13001462	ENSG00000229267.2	AC072062.1	-5.09	7.57e-07	0.000569	-0.43	-0.32	Neuroblastoma;	chr2:214813622	chr2:214810229~214963274:+
OV	cis	rs34779708	0.931	rs2001893	ENSG00000230534.5	RP11-297A16.2	5.09	7.58e-07	0.00057	0.41	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35011695	chr10:35098006~35127020:-
OV	cis	rs875971	0.571	rs160647	ENSG00000226824.5	RP4-756H11.3	5.09	7.61e-07	0.000571	0.38	0.32	Aortic root size;	chr7:66089365	chr7:66654538~66669855:+
OV	cis	rs10510102	0.935	rs11200183	ENSG00000276742.1	RP11-500G22.4	5.09	7.61e-07	0.000571	0.53	0.32	Breast cancer;	chr10:121829908	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs12255859	ENSG00000276742.1	RP11-500G22.4	5.09	7.61e-07	0.000571	0.53	0.32	Breast cancer;	chr10:121831661	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs7923634	ENSG00000276742.1	RP11-500G22.4	5.09	7.61e-07	0.000571	0.53	0.32	Breast cancer;	chr10:121832800	chr10:121956782~121957098:+
OV	cis	rs7567389	0.704	rs4662714	ENSG00000236682.1	AC068282.3	5.09	7.63e-07	0.000573	0.43	0.32	Self-rated health;	chr2:127237637	chr2:127389130~127400580:+
OV	cis	rs2153535	0.561	rs9405404	ENSG00000230939.1	RP11-314C16.1	-5.09	7.63e-07	0.000573	-0.35	-0.32	Motion sickness;	chr6:8646583	chr6:8784178~8785445:+
OV	cis	rs8040855	0.599	rs2342123	ENSG00000229212.6	RP11-561C5.4	5.09	7.64e-07	0.000574	0.38	0.32	Bulimia nervosa;	chr15:85181918	chr15:85205440~85234795:-
OV	cis	rs13178541	0.542	rs10900837	ENSG00000250378.1	RP11-119J18.1	-5.09	7.65e-07	0.000574	-0.44	-0.32	IgG glycosylation;	chr5:135790074	chr5:135812667~135826582:+
OV	cis	rs13178541	0.577	rs10900838	ENSG00000250378.1	RP11-119J18.1	-5.09	7.65e-07	0.000574	-0.44	-0.32	IgG glycosylation;	chr5:135790078	chr5:135812667~135826582:+
OV	cis	rs227275	0.525	rs3974604	ENSG00000246560.2	RP11-10L12.4	5.09	7.66e-07	0.000575	0.35	0.32	Allergic disease (asthma, hay fever or eczema);	chr4:102928601	chr4:102828055~102844075:+
OV	cis	rs62388641	0.547	rs2745610	ENSG00000272279.1	RP11-157J24.2	-5.09	7.67e-07	0.000575	-0.41	-0.32	Daytime sleep phenotypes;	chr6:1553741	chr6:1528364~1528911:-
OV	cis	rs9992667	0.955	rs11937257	ENSG00000231160.8	KLF3-AS1	5.08	7.71e-07	0.000578	0.41	0.32	Eosinophil percentage of granulocytes;	chr4:38643839	chr4:38612701~38664883:-
OV	cis	rs2243480	1	rs10807702	ENSG00000226824.5	RP4-756H11.3	-5.08	7.71e-07	0.000578	-0.52	-0.32	Diabetic kidney disease;	chr7:66302856	chr7:66654538~66669855:+
OV	cis	rs957448	1	rs957448	ENSG00000253704.1	RP11-267M23.4	5.08	7.72e-07	0.000579	0.42	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94529074	chr8:94553722~94569745:+
OV	cis	rs7429990	0.965	rs34380889	ENSG00000229759.1	MRPS18AP1	5.08	7.72e-07	0.000579	0.34	0.32	Educational attainment (years of education);	chr3:47905692	chr3:48256350~48256938:-
OV	cis	rs7429990	0.965	rs4858871	ENSG00000229759.1	MRPS18AP1	5.08	7.72e-07	0.000579	0.34	0.32	Educational attainment (years of education);	chr3:47911915	chr3:48256350~48256938:-
OV	cis	rs9291683	0.609	rs12500810	ENSG00000250413.1	RP11-448G15.1	-5.08	7.73e-07	0.000579	-0.36	-0.32	Bone mineral density;	chr4:10029444	chr4:10006482~10009725:+
OV	cis	rs1797885	0.902	rs1151988	ENSG00000251774.1	RNU6-377P	5.08	7.74e-07	0.00058	0.3	0.32	Immature fraction of reticulocytes;	chr3:12470013	chr3:12514706~12514807:+
OV	cis	rs11976180	0.569	rs12703565	ENSG00000273234.1	OR2A13P	-5.08	7.75e-07	0.00058	-0.48	-0.32	Obesity-related traits;	chr7:144057308	chr7:144142009~144142938:+
OV	cis	rs4380275	0.782	rs11127506	ENSG00000223751.1	AC116609.2	-5.08	7.77e-07	0.000582	-0.37	-0.32	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:751300	chr2:742488~747767:+
OV	cis	rs4713118	0.868	rs742047	ENSG00000280107.1	AL022393.9	-5.08	7.77e-07	0.000582	-0.4	-0.32	Parkinson's disease;	chr6:27771601	chr6:28170845~28172521:+
OV	cis	rs2153535	0.585	rs2224480	ENSG00000230939.1	RP11-314C16.1	-5.08	7.78e-07	0.000582	-0.35	-0.32	Motion sickness;	chr6:8647646	chr6:8784178~8785445:+
OV	cis	rs2153535	0.585	rs7770688	ENSG00000230939.1	RP11-314C16.1	-5.08	7.78e-07	0.000582	-0.35	-0.32	Motion sickness;	chr6:8648663	chr6:8784178~8785445:+
OV	cis	rs2153535	0.585	rs1328867	ENSG00000230939.1	RP11-314C16.1	-5.08	7.78e-07	0.000582	-0.35	-0.32	Motion sickness;	chr6:8652454	chr6:8784178~8785445:+
OV	cis	rs143626010	1	rs143626010	ENSG00000278665.1	RP11-666O2.4	5.08	7.79e-07	0.000583	0.33	0.32	Mosquito bite size;	chr16:28528081	chr16:28599241~28601881:-
OV	cis	rs2283792	0.812	rs240066	ENSG00000224086.5	LL22NC03-86G7.1	5.08	7.8e-07	0.000584	0.29	0.32	Multiple sclerosis;	chr22:21938623	chr22:21938293~21977632:+
OV	cis	rs1150668	0.796	rs2247002	ENSG00000220721.1	OR1F12	5.08	7.81e-07	0.000584	0.32	0.32	Pubertal anthropometrics;	chr6:28430174	chr6:28073316~28074233:+
OV	cis	rs7617773	0.817	rs11928691	ENSG00000228638.1	FCF1P2	-5.08	7.81e-07	0.000584	-0.4	-0.32	Coronary artery disease;	chr3:48245275	chr3:48290793~48291375:-
OV	cis	rs438465	1	rs2860563	ENSG00000226194.4	RP1-137D17.1	5.08	7.81e-07	0.000584	0.47	0.32	Corneal astigmatism;	chr6:169488146	chr6:169369998~169388385:-
OV	cis	rs150992	0.587	rs11949103	ENSG00000248489.1	CTD-2007H13.3	-5.08	7.81e-07	0.000584	-0.37	-0.32	Body mass index;	chr5:99011939	chr5:98929171~98995013:+
OV	cis	rs2153535	0.585	rs9393053	ENSG00000230939.1	RP11-314C16.1	-5.08	7.82e-07	0.000585	-0.35	-0.32	Motion sickness;	chr6:8644947	chr6:8784178~8785445:+
OV	cis	rs3136516	0.935	rs11038993	ENSG00000271350.1	CTD-2384B9.1	5.08	7.84e-07	0.000586	0.35	0.32	Venous thromboembolism;	chr11:46789366	chr11:47041027~47041945:-
OV	cis	rs2243480	1	rs1618893	ENSG00000226824.5	RP4-756H11.3	-5.08	7.84e-07	0.000586	-0.49	-0.32	Diabetic kidney disease;	chr7:66631132	chr7:66654538~66669855:+
OV	cis	rs17301013	0.507	rs6697959	ENSG00000227373.4	RP11-160H22.5	5.08	7.85e-07	0.000587	0.43	0.32	Systemic lupus erythematosus;	chr1:174285450	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12066504	ENSG00000227373.4	RP11-160H22.5	5.08	7.85e-07	0.000587	0.43	0.32	Systemic lupus erythematosus;	chr1:174288695	chr1:174115300~174160004:-
OV	cis	rs957448	1	rs72674855	ENSG00000253704.1	RP11-267M23.4	5.08	7.86e-07	0.000587	0.42	0.32	Nonsyndromic cleft lip with cleft palate;	chr8:94536706	chr8:94553722~94569745:+
OV	cis	rs62355901	0.505	rs3733951	ENSG00000271828.1	CTD-2310F14.1	-5.08	7.86e-07	0.000588	-0.61	-0.32	Breast cancer;	chr5:56833976	chr5:56927874~56929573:+
OV	cis	rs1823913	0.927	rs35339956	ENSG00000227542.1	AC092614.2	5.08	7.86e-07	0.000588	0.39	0.32	Obesity-related traits;	chr2:191261668	chr2:191229165~191246172:-
OV	cis	rs1823913	0.927	rs56209234	ENSG00000227542.1	AC092614.2	5.08	7.86e-07	0.000588	0.39	0.32	Obesity-related traits;	chr2:191261748	chr2:191229165~191246172:-
OV	cis	rs2153535	0.56	rs9405406	ENSG00000230939.1	RP11-314C16.1	-5.08	7.88e-07	0.000589	-0.35	-0.32	Motion sickness;	chr6:8654625	chr6:8784178~8785445:+
OV	cis	rs2153535	0.585	rs1998364	ENSG00000230939.1	RP11-314C16.1	-5.08	7.88e-07	0.000589	-0.35	-0.32	Motion sickness;	chr6:8657091	chr6:8784178~8785445:+
OV	cis	rs301901	0.581	rs292170	ENSG00000250155.1	CTD-2353F22.1	-5.08	7.88e-07	0.000589	-0.36	-0.32	Height;	chr5:36816559	chr5:36666214~36725195:-
OV	cis	rs301901	1	rs292194	ENSG00000250155.1	CTD-2353F22.1	5.08	7.89e-07	0.00059	0.35	0.32	Height;	chr5:36941665	chr5:36666214~36725195:-
OV	cis	rs10924970	0.649	rs4659656	ENSG00000236863.2	RPL23AP23	5.08	7.89e-07	0.00059	0.32	0.32	Asthma;	chr1:235220799	chr1:235295865~235296335:+
OV	cis	rs2188561	0.697	rs3735606	ENSG00000241764.3	AC002467.7	5.08	7.9e-07	0.00059	0.37	0.32	Alcohol consumption;	chr7:107743864	chr7:107742817~107744581:-
OV	cis	rs858239	0.6	rs59073109	ENSG00000230042.1	AK3P3	-5.08	7.91e-07	0.00059	-0.34	-0.32	Cerebrospinal fluid biomarker levels;	chr7:23093607	chr7:23129178~23129841:+
OV	cis	rs858239	0.6	rs7788821	ENSG00000230042.1	AK3P3	-5.08	7.91e-07	0.00059	-0.34	-0.32	Cerebrospinal fluid biomarker levels;	chr7:23094026	chr7:23129178~23129841:+
OV	cis	rs858239	0.6	rs6956595	ENSG00000230042.1	AK3P3	-5.08	7.91e-07	0.00059	-0.34	-0.32	Cerebrospinal fluid biomarker levels;	chr7:23094637	chr7:23129178~23129841:+
OV	cis	rs301901	0.796	rs4869520	ENSG00000250155.1	CTD-2353F22.1	5.08	7.92e-07	0.000591	0.38	0.32	Height;	chr5:37508981	chr5:36666214~36725195:-
OV	cis	rs301901	0.796	rs1517789	ENSG00000250155.1	CTD-2353F22.1	5.08	7.92e-07	0.000591	0.38	0.32	Height;	chr5:37510578	chr5:36666214~36725195:-
OV	cis	rs875971	0.545	rs7783889	ENSG00000236529.1	RP13-254B10.1	5.08	7.92e-07	0.000591	0.38	0.32	Aortic root size;	chr7:66283366	chr7:65840212~65840596:+
OV	cis	rs11157436	1	rs2293731	ENSG00000211812.1	TRAV26-2	-5.08	7.93e-07	0.000592	-0.4	-0.32	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22148880	chr14:22202583~22203368:+
OV	cis	rs796364	0.951	rs281793	ENSG00000232732.8	AC073043.1	-5.08	7.94e-07	0.000592	-0.47	-0.32	Schizophrenia;	chr2:199983267	chr2:199867396~199911159:-
OV	cis	rs2688608	0.592	rs12253482	ENSG00000271816.1	BMS1P4	5.08	7.95e-07	0.000593	0.3	0.32	Inflammatory bowel disease;	chr10:73736372	chr10:73699151~73730487:-
OV	cis	rs34779708	0.897	rs16935880	ENSG00000230534.5	RP11-297A16.2	5.08	7.95e-07	0.000593	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35126540	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs4934730	ENSG00000230534.5	RP11-297A16.2	5.08	7.95e-07	0.000593	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35126627	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs2045918	ENSG00000230534.5	RP11-297A16.2	5.08	7.95e-07	0.000593	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35129589	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs4294520	ENSG00000230534.5	RP11-297A16.2	5.08	7.95e-07	0.000593	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35133578	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs34876468	ENSG00000230534.5	RP11-297A16.2	5.08	7.95e-07	0.000593	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35135522	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs4934535	ENSG00000230534.5	RP11-297A16.2	5.08	7.95e-07	0.000593	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35143793	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs4934734	ENSG00000230534.5	RP11-297A16.2	5.08	7.95e-07	0.000593	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35145445	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs12769575	ENSG00000230534.5	RP11-297A16.2	5.08	7.95e-07	0.000593	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35146999	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs4934536	ENSG00000230534.5	RP11-297A16.2	5.08	7.95e-07	0.000593	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35152241	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs4934537	ENSG00000230534.5	RP11-297A16.2	5.08	7.95e-07	0.000593	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35152584	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs1545757	ENSG00000230534.5	RP11-297A16.2	5.08	7.95e-07	0.000593	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35156660	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs12784482	ENSG00000230534.5	RP11-297A16.2	5.08	7.95e-07	0.000593	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35157937	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs113170867	ENSG00000230534.5	RP11-297A16.2	5.08	7.95e-07	0.000593	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35161219	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs17499811	ENSG00000230534.5	RP11-297A16.2	5.08	7.95e-07	0.000593	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35167287	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs35146199	ENSG00000230534.5	RP11-297A16.2	5.08	7.95e-07	0.000593	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35172011	chr10:35098006~35127020:-
OV	cis	rs16873450	0.527	rs11982084	ENSG00000234800.2	PCMTD1P3	5.08	7.97e-07	0.000594	0.33	0.32	Verbal memory performance (residualized delayed recall level);	chr7:23743097	chr7:23721311~23721782:-
OV	cis	rs16873450	0.527	rs10950958	ENSG00000234800.2	PCMTD1P3	5.08	7.97e-07	0.000594	0.33	0.32	Verbal memory performance (residualized delayed recall level);	chr7:23748650	chr7:23721311~23721782:-
OV	cis	rs116095464	0.619	rs2303741	ENSG00000250848.1	CTD-2083E4.5	-5.08	7.97e-07	0.000594	-0.4	-0.32	Breast cancer;	chr5:218241	chr5:288833~290321:-
OV	cis	rs116095464	0.614	rs10067482	ENSG00000250848.1	CTD-2083E4.5	-5.08	7.97e-07	0.000594	-0.4	-0.32	Breast cancer;	chr5:219213	chr5:288833~290321:-
OV	cis	rs116095464	0.614	rs56299325	ENSG00000250848.1	CTD-2083E4.5	-5.08	7.97e-07	0.000594	-0.4	-0.32	Breast cancer;	chr5:220479	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs62346526	ENSG00000250848.1	CTD-2083E4.5	-5.08	7.97e-07	0.000594	-0.4	-0.32	Breast cancer;	chr5:220499	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs56043030	ENSG00000250848.1	CTD-2083E4.5	-5.08	7.97e-07	0.000594	-0.4	-0.32	Breast cancer;	chr5:220802	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs10067021	ENSG00000250848.1	CTD-2083E4.5	-5.08	7.97e-07	0.000594	-0.4	-0.32	Breast cancer;	chr5:221375	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs9312977	ENSG00000250848.1	CTD-2083E4.5	-5.08	7.97e-07	0.000594	-0.4	-0.32	Breast cancer;	chr5:221801	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs6881920	ENSG00000250848.1	CTD-2083E4.5	-5.08	7.97e-07	0.000594	-0.4	-0.32	Breast cancer;	chr5:222296	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs6878061	ENSG00000250848.1	CTD-2083E4.5	-5.08	7.97e-07	0.000594	-0.4	-0.32	Breast cancer;	chr5:222957	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs6882584	ENSG00000250848.1	CTD-2083E4.5	-5.08	7.97e-07	0.000594	-0.4	-0.32	Breast cancer;	chr5:223296	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs3213838	ENSG00000250848.1	CTD-2083E4.5	-5.08	7.97e-07	0.000594	-0.4	-0.32	Breast cancer;	chr5:223775	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs6555052	ENSG00000250848.1	CTD-2083E4.5	-5.08	7.97e-07	0.000594	-0.4	-0.32	Breast cancer;	chr5:224153	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs61689490	ENSG00000250848.1	CTD-2083E4.5	-5.08	7.97e-07	0.000594	-0.4	-0.32	Breast cancer;	chr5:224789	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs61492827	ENSG00000250848.1	CTD-2083E4.5	-5.08	7.97e-07	0.000594	-0.4	-0.32	Breast cancer;	chr5:225659	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs56342538	ENSG00000250848.1	CTD-2083E4.5	-5.08	7.97e-07	0.000594	-0.4	-0.32	Breast cancer;	chr5:225681	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs6555055	ENSG00000250848.1	CTD-2083E4.5	-5.08	7.97e-07	0.000594	-0.4	-0.32	Breast cancer;	chr5:226045	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs6555056	ENSG00000250848.1	CTD-2083E4.5	-5.08	7.97e-07	0.000594	-0.4	-0.32	Breast cancer;	chr5:226107	chr5:288833~290321:-
OV	cis	rs2188561	1	rs2712207	ENSG00000241764.3	AC002467.7	5.08	7.97e-07	0.000594	0.4	0.32	Alcohol consumption;	chr7:107711672	chr7:107742817~107744581:-
OV	cis	rs494459	0.536	rs57719838	ENSG00000255239.1	AP002954.6	5.08	7.98e-07	0.000594	0.39	0.32	Height;	chr11:118854014	chr11:118688039~118690600:-
OV	cis	rs10740039	0.883	rs10994468	ENSG00000254271.1	RP11-131N11.4	5.08	7.98e-07	0.000595	0.4	0.32	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60666533	chr10:60734342~60741828:+
OV	cis	rs8062405	1	rs72793811	ENSG00000278665.1	RP11-666O2.4	5.08	7.99e-07	0.000595	0.35	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828071	chr16:28599241~28601881:-
OV	cis	rs7116641	0.734	rs1518821	ENSG00000246250.2	RP11-613D13.5	-5.08	7.99e-07	0.000595	-0.36	-0.32	Coronary artery disease;	chr11:43850446	chr11:43829709~43880726:-
OV	cis	rs7771547	0.573	rs546272	ENSG00000240733.3	RN7SL502P	5.08	8.02e-07	0.000597	0.35	0.32	Platelet distribution width;	chr6:36430785	chr6:36450912~36451201:-
OV	cis	rs2243480	0.908	rs4718273	ENSG00000222364.1	RNU6-96P	5.08	8.03e-07	0.000598	0.55	0.32	Diabetic kidney disease;	chr7:65751112	chr7:66395191~66395286:+
OV	cis	rs992157	0.835	rs11677953	ENSG00000237281.1	CATIP-AS2	5.08	8.04e-07	0.000598	0.37	0.32	Colorectal cancer;	chr2:218256940	chr2:218326889~218357966:-
OV	cis	rs11690935	0.632	rs12991740	ENSG00000228389.1	AC068039.4	-5.08	8.05e-07	0.000599	-0.37	-0.32	Schizophrenia;	chr2:172021092	chr2:171773482~171775844:+
OV	cis	rs1150668	0.83	rs2531831	ENSG00000220721.1	OR1F12	5.07	8.08e-07	0.000601	0.32	0.32	Pubertal anthropometrics;	chr6:28420988	chr6:28073316~28074233:+
OV	cis	rs67311347	0.91	rs13089215	ENSG00000223797.4	ENTPD3-AS1	-5.07	8.09e-07	0.000601	-0.35	-0.32	Renal cell carcinoma;	chr3:40454403	chr3:40313802~40453329:-
OV	cis	rs57502260	0.704	rs60538784	ENSG00000212093.1	AP000807.1	5.07	8.1e-07	0.000602	0.53	0.32	Total body bone mineral density (age 45-60);	chr11:68619267	chr11:68506083~68506166:-
OV	cis	rs2253762	0.54	rs12249581	ENSG00000276742.1	RP11-500G22.4	5.07	8.11e-07	0.000603	0.58	0.32	Breast cancer;	chr10:122013486	chr10:121956782~121957098:+
OV	cis	rs875971	0.545	rs12673308	ENSG00000226824.5	RP4-756H11.3	-5.07	8.12e-07	0.000603	-0.37	-0.32	Aortic root size;	chr7:66166374	chr7:66654538~66669855:+
OV	cis	rs875971	0.545	rs67397473	ENSG00000226824.5	RP4-756H11.3	-5.07	8.12e-07	0.000603	-0.37	-0.32	Aortic root size;	chr7:66168318	chr7:66654538~66669855:+
OV	cis	rs875971	0.545	rs10950027	ENSG00000226824.5	RP4-756H11.3	-5.07	8.12e-07	0.000603	-0.37	-0.32	Aortic root size;	chr7:66169164	chr7:66654538~66669855:+
OV	cis	rs796825	0.597	rs6438576	ENSG00000240661.1	RP11-174O3.3	-5.07	8.12e-07	0.000603	-0.43	-0.32	HIV-1 susceptibility;	chr3:120338749	chr3:120349510~120367998:+
OV	cis	rs796825	0.553	rs939499	ENSG00000240661.1	RP11-174O3.3	-5.07	8.12e-07	0.000603	-0.43	-0.32	HIV-1 susceptibility;	chr3:120341555	chr3:120349510~120367998:+
OV	cis	rs796825	0.597	rs2138259	ENSG00000240661.1	RP11-174O3.3	-5.07	8.12e-07	0.000603	-0.43	-0.32	HIV-1 susceptibility;	chr3:120342387	chr3:120349510~120367998:+
OV	cis	rs796825	0.626	rs6438578	ENSG00000240661.1	RP11-174O3.3	-5.07	8.12e-07	0.000603	-0.43	-0.32	HIV-1 susceptibility;	chr3:120346322	chr3:120349510~120367998:+
OV	cis	rs796825	0.597	rs6438579	ENSG00000240661.1	RP11-174O3.3	-5.07	8.12e-07	0.000603	-0.43	-0.32	HIV-1 susceptibility;	chr3:120346362	chr3:120349510~120367998:+
OV	cis	rs8062405	0.723	rs12445744	ENSG00000278665.1	RP11-666O2.4	5.07	8.12e-07	0.000604	0.35	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28577074	chr16:28599241~28601881:-
OV	cis	rs8062405	0.755	rs4787455	ENSG00000278665.1	RP11-666O2.4	5.07	8.12e-07	0.000604	0.35	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28578134	chr16:28599241~28601881:-
OV	cis	rs7587476	1	rs2121285	ENSG00000229267.2	AC072062.1	5.07	8.14e-07	0.000604	0.44	0.32	Neuroblastoma;	chr2:214791444	chr2:214810229~214963274:+
OV	cis	rs7587476	1	rs1542173	ENSG00000229267.2	AC072062.1	5.07	8.14e-07	0.000604	0.44	0.32	Neuroblastoma;	chr2:214792836	chr2:214810229~214963274:+
OV	cis	rs1150668	0.799	rs2142730	ENSG00000220721.1	OR1F12	5.07	8.14e-07	0.000605	0.32	0.32	Pubertal anthropometrics;	chr6:28298372	chr6:28073316~28074233:+
OV	cis	rs7189233	0.531	rs1362429	ENSG00000279344.1	RP11-44F14.7	5.07	8.17e-07	0.000606	0.3	0.32	Intelligence (multi-trait analysis);	chr16:53445172	chr16:53478957~53481550:-
OV	cis	rs181553	0.664	rs10775491	ENSG00000266696.1	RP11-30L3.2	-5.07	8.17e-07	0.000607	-0.39	-0.32	Hip circumference adjusted for BMI;	chr18:49162097	chr18:49205912~49208781:+
OV	cis	rs34779708	0.931	rs17591135	ENSG00000230534.5	RP11-297A16.2	5.07	8.18e-07	0.000607	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35176262	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs55724039	ENSG00000230534.5	RP11-297A16.2	5.07	8.18e-07	0.000607	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35176469	chr10:35098006~35127020:-
OV	cis	rs7829975	0.84	rs572366	ENSG00000253981.4	ALG1L13P	5.07	8.18e-07	0.000607	0.33	0.32	Mood instability;	chr8:8721284	chr8:8236003~8244667:-
OV	cis	rs7189233	0.531	rs1074182	ENSG00000279344.1	RP11-44F14.7	5.07	8.18e-07	0.000607	0.3	0.32	Intelligence (multi-trait analysis);	chr16:53437445	chr16:53478957~53481550:-
OV	cis	rs2243480	0.901	rs12530490	ENSG00000226824.5	RP4-756H11.3	5.07	8.22e-07	0.00061	0.51	0.32	Diabetic kidney disease;	chr7:66226660	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs7778911	ENSG00000226824.5	RP4-756H11.3	5.07	8.22e-07	0.00061	0.51	0.32	Diabetic kidney disease;	chr7:66229519	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs1979823	ENSG00000226824.5	RP4-756H11.3	5.07	8.22e-07	0.00061	0.51	0.32	Diabetic kidney disease;	chr7:66239626	chr7:66654538~66669855:+
OV	cis	rs6700559	0.81	rs7521550	ENSG00000260088.1	RP11-92G12.3	-5.07	8.24e-07	0.000611	-0.34	-0.32	Coronary artery disease;	chr1:200623235	chr1:200669507~200694250:+
OV	cis	rs10510102	1	rs10886994	ENSG00000276742.1	RP11-500G22.4	5.07	8.25e-07	0.000611	0.52	0.32	Breast cancer;	chr10:121841075	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs11200187	ENSG00000276742.1	RP11-500G22.4	5.07	8.25e-07	0.000611	0.52	0.32	Breast cancer;	chr10:121843050	chr10:121956782~121957098:+
OV	cis	rs172166	0.516	rs1225710	ENSG00000220721.1	OR1F12	-5.07	8.25e-07	0.000611	-0.32	-0.32	Cardiac Troponin-T levels;	chr6:28132862	chr6:28073316~28074233:+
OV	cis	rs301901	1	rs292182	ENSG00000250155.1	CTD-2353F22.1	-5.07	8.28e-07	0.000613	-0.37	-0.32	Height;	chr5:36954710	chr5:36666214~36725195:-
OV	cis	rs301901	0.965	rs159749	ENSG00000250155.1	CTD-2353F22.1	-5.07	8.28e-07	0.000613	-0.37	-0.32	Height;	chr5:36968438	chr5:36666214~36725195:-
OV	cis	rs301901	1	rs6875748	ENSG00000250155.1	CTD-2353F22.1	5.07	8.29e-07	0.000614	0.37	0.32	Height;	chr5:37041491	chr5:36666214~36725195:-
OV	cis	rs6991838	0.584	rs7836349	ENSG00000200714.1	Y_RNA	-5.07	8.31e-07	0.000616	-0.4	-0.32	Intelligence (multi-trait analysis);	chr8:65591328	chr8:65592731~65592820:+
OV	cis	rs2153535	0.518	rs1998265	ENSG00000230939.1	RP11-314C16.1	-5.07	8.31e-07	0.000616	-0.36	-0.32	Motion sickness;	chr6:8651929	chr6:8784178~8785445:+
OV	cis	rs301901	1	rs159751	ENSG00000250155.1	CTD-2353F22.1	-5.07	8.33e-07	0.000616	-0.37	-0.32	Height;	chr5:36999896	chr5:36666214~36725195:-
OV	cis	rs301901	1	rs184182	ENSG00000250155.1	CTD-2353F22.1	-5.07	8.33e-07	0.000616	-0.37	-0.32	Height;	chr5:37005003	chr5:36666214~36725195:-
OV	cis	rs301901	1	rs300061	ENSG00000250155.1	CTD-2353F22.1	-5.07	8.33e-07	0.000616	-0.37	-0.32	Height;	chr5:37022673	chr5:36666214~36725195:-
OV	cis	rs853679	0.55	rs1237875	ENSG00000280107.1	AL022393.9	5.07	8.33e-07	0.000617	0.4	0.32	Depression;	chr6:28205232	chr6:28170845~28172521:+
OV	cis	rs1150668	0.799	rs1150707	ENSG00000220721.1	OR1F12	5.07	8.35e-07	0.000618	0.31	0.32	Pubertal anthropometrics;	chr6:28229827	chr6:28073316~28074233:+
OV	cis	rs1150668	0.799	rs7206	ENSG00000220721.1	OR1F12	5.07	8.35e-07	0.000618	0.31	0.32	Pubertal anthropometrics;	chr6:28233360	chr6:28073316~28074233:+
OV	cis	rs6088580	0.634	rs6088508	ENSG00000206582.1	Y_RNA	-5.07	8.36e-07	0.000618	-0.38	-0.32	Glomerular filtration rate (creatinine);	chr20:34472276	chr20:34526510~34526606:-
OV	cis	rs10924970	0.625	rs10925127	ENSG00000236863.2	RPL23AP23	5.07	8.37e-07	0.000619	0.33	0.32	Asthma;	chr1:235215344	chr1:235295865~235296335:+
OV	cis	rs6772849	0.93	rs9813197	ENSG00000242551.2	POU5F1P6	-5.07	8.38e-07	0.00062	-0.37	-0.32	Monocyte percentage of white cells;Monocyte count;	chr3:128650261	chr3:128674735~128677005:-
OV	cis	rs757081	0.658	rs214076	ENSG00000213779.4	RP11-452G18.1	5.07	8.39e-07	0.000621	0.38	0.32	Systolic blood pressure;	chr11:17278710	chr11:17193489~17194308:+
OV	cis	rs7116641	0.734	rs1518814	ENSG00000246250.2	RP11-613D13.5	5.07	8.4e-07	0.000621	0.36	0.32	Coronary artery disease;	chr11:43803083	chr11:43829709~43880726:-
OV	cis	rs6088580	0.634	rs2184836	ENSG00000206582.1	Y_RNA	5.07	8.41e-07	0.000621	0.38	0.32	Glomerular filtration rate (creatinine);	chr20:34375563	chr20:34526510~34526606:-
OV	cis	rs6088580	0.609	rs945674	ENSG00000206582.1	Y_RNA	5.07	8.41e-07	0.000621	0.38	0.32	Glomerular filtration rate (creatinine);	chr20:34376441	chr20:34526510~34526606:-
OV	cis	rs6088580	0.609	rs6058029	ENSG00000206582.1	Y_RNA	5.07	8.41e-07	0.000621	0.38	0.32	Glomerular filtration rate (creatinine);	chr20:34381837	chr20:34526510~34526606:-
OV	cis	rs6088580	0.608	rs2105109	ENSG00000206582.1	Y_RNA	5.07	8.41e-07	0.000621	0.38	0.32	Glomerular filtration rate (creatinine);	chr20:34384126	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6088488	ENSG00000206582.1	Y_RNA	5.07	8.41e-07	0.000621	0.38	0.32	Glomerular filtration rate (creatinine);	chr20:34404825	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs4911418	ENSG00000206582.1	Y_RNA	5.07	8.41e-07	0.000621	0.38	0.32	Glomerular filtration rate (creatinine);	chr20:34406451	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6579165	ENSG00000206582.1	Y_RNA	5.07	8.41e-07	0.000621	0.38	0.32	Glomerular filtration rate (creatinine);	chr20:34406909	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs4911419	ENSG00000206582.1	Y_RNA	5.07	8.41e-07	0.000621	0.38	0.32	Glomerular filtration rate (creatinine);	chr20:34408067	chr20:34526510~34526606:-
OV	cis	rs6088580	0.561	rs3761147	ENSG00000206582.1	Y_RNA	5.07	8.41e-07	0.000621	0.38	0.32	Glomerular filtration rate (creatinine);	chr20:34408883	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs4911421	ENSG00000206582.1	Y_RNA	5.07	8.41e-07	0.000621	0.38	0.32	Glomerular filtration rate (creatinine);	chr20:34411142	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs4911422	ENSG00000206582.1	Y_RNA	5.07	8.41e-07	0.000621	0.38	0.32	Glomerular filtration rate (creatinine);	chr20:34411539	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs2225837	ENSG00000206582.1	Y_RNA	5.07	8.41e-07	0.000621	0.38	0.32	Glomerular filtration rate (creatinine);	chr20:34417828	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs2424992	ENSG00000206582.1	Y_RNA	-5.07	8.41e-07	0.000621	-0.38	-0.32	Glomerular filtration rate (creatinine);	chr20:34424254	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6119497	ENSG00000206582.1	Y_RNA	-5.07	8.41e-07	0.000621	-0.38	-0.32	Glomerular filtration rate (creatinine);	chr20:34424723	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6059829	ENSG00000206582.1	Y_RNA	-5.07	8.41e-07	0.000621	-0.38	-0.32	Glomerular filtration rate (creatinine);	chr20:34429268	chr20:34526510~34526606:-
OV	cis	rs6088580	0.602	rs6059834	ENSG00000206582.1	Y_RNA	-5.07	8.41e-07	0.000621	-0.38	-0.32	Glomerular filtration rate (creatinine);	chr20:34431493	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6059835	ENSG00000206582.1	Y_RNA	-5.07	8.41e-07	0.000621	-0.38	-0.32	Glomerular filtration rate (creatinine);	chr20:34432335	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6120644	ENSG00000206582.1	Y_RNA	-5.07	8.41e-07	0.000621	-0.38	-0.32	Glomerular filtration rate (creatinine);	chr20:34436005	chr20:34526510~34526606:-
OV	cis	rs6088580	0.624	rs6120645	ENSG00000206582.1	Y_RNA	-5.07	8.41e-07	0.000621	-0.38	-0.32	Glomerular filtration rate (creatinine);	chr20:34437366	chr20:34526510~34526606:-
OV	cis	rs611744	0.647	rs1448151	ENSG00000253754.1	RP11-35G22.1	-5.07	8.41e-07	0.000622	-0.34	-0.32	Dupuytren's disease;	chr8:108264054	chr8:108226200~108227544:+
OV	cis	rs1075265	0.589	rs2542571	ENSG00000233266.1	HMGB1P31	5.07	8.42e-07	0.000622	0.4	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53814846	chr2:54051334~54051760:+
OV	cis	rs453301	0.686	rs11787026	ENSG00000253893.2	FAM85B	-5.07	8.42e-07	0.000623	-0.34	-0.32	Joint mobility (Beighton score);	chr8:9044861	chr8:8167819~8226614:-
OV	cis	rs2999052	0.602	rs7632169	ENSG00000277250.1	Metazoa_SRP	5.07	8.43e-07	0.000623	0.42	0.32	Hypospadias;	chr3:128395744	chr3:128673681~128674021:-
OV	cis	rs7017914	0.69	rs7825815	ENSG00000223220.1	Y_RNA	5.07	8.45e-07	0.000624	0.36	0.32	Bone mineral density;	chr8:71074170	chr8:70780914~70781008:-
OV	cis	rs7017914	0.558	rs4526394	ENSG00000223220.1	Y_RNA	5.07	8.45e-07	0.000624	0.36	0.32	Bone mineral density;	chr8:71076092	chr8:70780914~70781008:-
OV	cis	rs67311347	1	rs6762251	ENSG00000223797.4	ENTPD3-AS1	-5.07	8.45e-07	0.000624	-0.36	-0.32	Renal cell carcinoma;	chr3:40489645	chr3:40313802~40453329:-
OV	cis	rs1134634	0.52	rs73127647	ENSG00000273133.1	RP11-799M12.2	-5.06	8.45e-07	0.000624	-0.43	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15639969	chr4:15563698~15564253:-
OV	cis	rs1134634	0.52	rs872678	ENSG00000273133.1	RP11-799M12.2	-5.06	8.45e-07	0.000624	-0.43	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15654075	chr4:15563698~15564253:-
OV	cis	rs4713118	0.866	rs2179094	ENSG00000280107.1	AL022393.9	-5.06	8.46e-07	0.000625	-0.38	-0.32	Parkinson's disease;	chr6:27774046	chr6:28170845~28172521:+
OV	cis	rs858239	0.6	rs4321896	ENSG00000230042.1	AK3P3	-5.06	8.47e-07	0.000626	-0.34	-0.32	Cerebrospinal fluid biomarker levels;	chr7:23088437	chr7:23129178~23129841:+
OV	cis	rs11096990	0.634	rs3733281	ENSG00000249207.1	RP11-360F5.1	5.06	8.48e-07	0.000626	0.33	0.32	Cognitive function;	chr4:39270293	chr4:39112677~39126818:-
OV	cis	rs11673344	0.864	rs2562606	ENSG00000226686.6	LINC01535	5.06	8.51e-07	0.000628	0.42	0.32	Obesity-related traits;	chr19:37029628	chr19:37251912~37265535:+
OV	cis	rs11673344	0.864	rs2263167	ENSG00000226686.6	LINC01535	5.06	8.51e-07	0.000628	0.42	0.32	Obesity-related traits;	chr19:37030025	chr19:37251912~37265535:+
OV	cis	rs17301013	0.507	rs10912757	ENSG00000227373.4	RP11-160H22.5	5.06	8.52e-07	0.000629	0.43	0.32	Systemic lupus erythematosus;	chr1:174299064	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs10912758	ENSG00000227373.4	RP11-160H22.5	5.06	8.52e-07	0.000629	0.43	0.32	Systemic lupus erythematosus;	chr1:174300822	chr1:174115300~174160004:-
OV	cis	rs1134634	0.52	rs28528670	ENSG00000273133.1	RP11-799M12.2	-5.06	8.54e-07	0.00063	-0.42	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15591295	chr4:15563698~15564253:-
OV	cis	rs4805272	0.962	rs1363325	ENSG00000267243.4	AC005307.3	-5.06	8.56e-07	0.000631	-0.42	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28834759	chr19:28435388~28727777:-
OV	cis	rs6088580	0.634	rs6059905	ENSG00000206582.1	Y_RNA	-5.06	8.56e-07	0.000631	-0.38	-0.32	Glomerular filtration rate (creatinine);	chr20:34539142	chr20:34526510~34526606:-
OV	cis	rs1113500	0.965	rs10881495	ENSG00000226822.1	RP11-356N1.2	5.06	8.56e-07	0.000631	0.37	0.32	Growth-regulated protein alpha levels;	chr1:108068364	chr1:108071482~108074519:+
OV	cis	rs293748	0.515	rs12658479	ENSG00000250155.1	CTD-2353F22.1	5.06	8.56e-07	0.000631	0.42	0.32	Obesity-related traits;	chr5:37206519	chr5:36666214~36725195:-
OV	cis	rs293748	0.605	rs13188136	ENSG00000250155.1	CTD-2353F22.1	-5.06	8.57e-07	0.000632	-0.43	-0.32	Obesity-related traits;	chr5:37117132	chr5:36666214~36725195:-
OV	cis	rs73201462	0.708	rs34862979	ENSG00000277250.1	Metazoa_SRP	5.06	8.57e-07	0.000632	0.48	0.32	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128131521	chr3:128673681~128674021:-
OV	cis	rs7520050	0.966	rs11589562	ENSG00000281133.1	AL355480.3	-5.06	8.57e-07	0.000632	-0.35	-0.32	Reticulocyte count;Red blood cell count;	chr1:46001049	chr1:45580892~45580996:-
OV	cis	rs4761702	0.922	rs7976742	ENSG00000257322.4	RP11-511B23.2	-5.06	8.57e-07	0.000632	-0.37	-0.32	Immature fraction of reticulocytes;	chr12:93328025	chr12:93003415~93215679:-
OV	cis	rs11096990	0.593	rs6531700	ENSG00000249207.1	RP11-360F5.1	5.06	8.59e-07	0.000633	0.34	0.32	Cognitive function;	chr4:39269265	chr4:39112677~39126818:-
OV	cis	rs8062405	0.824	rs4788083	ENSG00000278665.1	RP11-666O2.4	5.06	8.6e-07	0.000634	0.33	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534128	chr16:28599241~28601881:-
OV	cis	rs73086581	0.524	rs2253977	ENSG00000229539.1	RP11-119B16.2	-5.06	8.6e-07	0.000634	-0.32	-0.32	Response to antidepressants in depression;	chr20:3958493	chr20:3888239~3888868:-
OV	cis	rs1113500	0.836	rs2801220	ENSG00000226822.1	RP11-356N1.2	-5.06	8.62e-07	0.000635	-0.39	-0.32	Growth-regulated protein alpha levels;	chr1:108042027	chr1:108071482~108074519:+
OV	cis	rs62034325	0.697	rs710410	ENSG00000278665.1	RP11-666O2.4	5.06	8.63e-07	0.000636	0.36	0.32	Body mass index;	chr16:28592021	chr16:28599241~28601881:-
OV	cis	rs10510102	0.935	rs79360006	ENSG00000276742.1	RP11-500G22.4	5.06	8.64e-07	0.000636	0.52	0.32	Breast cancer;	chr10:121912856	chr10:121956782~121957098:+
OV	cis	rs1185460	0.565	rs584115	ENSG00000271751.1	RP11-110I1.14	5.06	8.64e-07	0.000637	0.38	0.32	Coronary artery disease;	chr11:119068169	chr11:119065263~119065677:-
OV	cis	rs301901	0.698	rs217837	ENSG00000250155.1	CTD-2353F22.1	5.06	8.65e-07	0.000637	0.36	0.32	Height;	chr5:37376570	chr5:36666214~36725195:-
OV	cis	rs804280	0.509	rs12719915	ENSG00000255495.1	AC145124.2	-5.06	8.65e-07	0.000637	-0.42	-0.32	Myopia (pathological);	chr8:11928746	chr8:12194467~12196280:+
OV	cis	rs8062405	0.895	rs62036658	ENSG00000278665.1	RP11-666O2.4	5.06	8.66e-07	0.000638	0.35	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28839050	chr16:28599241~28601881:-
OV	cis	rs8062405	0.69	rs762634	ENSG00000278665.1	RP11-666O2.4	5.06	8.66e-07	0.000638	0.36	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28599241~28601881:-
OV	cis	rs611744	0.647	rs11785776	ENSG00000253754.1	RP11-35G22.1	-5.06	8.67e-07	0.000638	-0.34	-0.32	Dupuytren's disease;	chr8:108252704	chr8:108226200~108227544:+
OV	cis	rs611744	0.647	rs12675265	ENSG00000253754.1	RP11-35G22.1	-5.06	8.67e-07	0.000638	-0.34	-0.32	Dupuytren's disease;	chr8:108256576	chr8:108226200~108227544:+
OV	cis	rs611744	0.647	rs1609472	ENSG00000253754.1	RP11-35G22.1	-5.06	8.67e-07	0.000638	-0.34	-0.32	Dupuytren's disease;	chr8:108257003	chr8:108226200~108227544:+
OV	cis	rs7811142	0.83	rs75636500	ENSG00000242294.5	STAG3L5P	5.06	8.69e-07	0.00064	0.34	0.32	Platelet count;	chr7:100350034	chr7:100336079~100351900:+
OV	cis	rs62184315	0.638	rs12475694	ENSG00000253559.1	OSGEPL1-AS1	5.06	8.7e-07	0.00064	0.34	0.32	Alcohol dependence (age at onset);	chr2:189907882	chr2:189762704~189765556:+
OV	cis	rs7116641	0.7	rs6485466	ENSG00000246250.2	RP11-613D13.5	-5.06	8.71e-07	0.000641	-0.36	-0.32	Coronary artery disease;	chr11:43821651	chr11:43829709~43880726:-
OV	cis	rs7116641	0.636	rs10838185	ENSG00000246250.2	RP11-613D13.5	-5.06	8.71e-07	0.000641	-0.36	-0.32	Coronary artery disease;	chr11:43848389	chr11:43829709~43880726:-
OV	cis	rs7116641	0.737	rs11037676	ENSG00000246250.2	RP11-613D13.5	-5.06	8.71e-07	0.000641	-0.36	-0.32	Coronary artery disease;	chr11:43849662	chr11:43829709~43880726:-
OV	cis	rs7189233	0.531	rs8043918	ENSG00000279344.1	RP11-44F14.7	5.06	8.72e-07	0.000642	0.29	0.32	Intelligence (multi-trait analysis);	chr16:53479121	chr16:53478957~53481550:-
OV	cis	rs6772849	0.901	rs9849126	ENSG00000242551.2	POU5F1P6	5.06	8.72e-07	0.000642	0.37	0.32	Monocyte percentage of white cells;Monocyte count;	chr3:128593226	chr3:128674735~128677005:-
OV	cis	rs8062405	0.755	rs12447461	ENSG00000278665.1	RP11-666O2.4	5.06	8.74e-07	0.000643	0.33	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28571620	chr16:28599241~28601881:-
OV	cis	rs8062405	0.755	rs111693583	ENSG00000278665.1	RP11-666O2.4	5.06	8.74e-07	0.000643	0.33	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28572289	chr16:28599241~28601881:-
OV	cis	rs11157436	0.958	rs2075494	ENSG00000211812.1	TRAV26-2	-5.06	8.74e-07	0.000643	-0.37	-0.32	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22202564	chr14:22202583~22203368:+
OV	cis	rs11157436	0.958	rs2242542	ENSG00000211812.1	TRAV26-2	-5.06	8.74e-07	0.000643	-0.37	-0.32	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22203081	chr14:22202583~22203368:+
OV	cis	rs9291683	0.567	rs12499857	ENSG00000250413.1	RP11-448G15.1	-5.06	8.74e-07	0.000643	-0.37	-0.32	Bone mineral density;	chr4:9993752	chr4:10006482~10009725:+
OV	cis	rs67311347	0.866	rs2371183	ENSG00000223797.4	ENTPD3-AS1	-5.06	8.75e-07	0.000643	-0.34	-0.32	Renal cell carcinoma;	chr3:40292756	chr3:40313802~40453329:-
OV	cis	rs17301013	0.507	rs2281010	ENSG00000227373.4	RP11-160H22.5	5.06	8.75e-07	0.000643	0.43	0.32	Systemic lupus erythematosus;	chr1:174509917	chr1:174115300~174160004:-
OV	cis	rs34779708	0.931	rs12240347	ENSG00000230534.5	RP11-297A16.2	5.06	8.76e-07	0.000644	0.41	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35070547	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs4934533	ENSG00000230534.5	RP11-297A16.2	5.06	8.76e-07	0.000644	0.41	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35070691	chr10:35098006~35127020:-
OV	cis	rs607987	0.836	rs1222204	ENSG00000254532.1	RP11-624D11.2	5.06	8.78e-07	0.000646	0.38	0.32	Body mass index;	chr11:30311677	chr11:30044058~30084343:-
OV	cis	rs607987	0.836	rs1222203	ENSG00000254532.1	RP11-624D11.2	5.06	8.78e-07	0.000646	0.38	0.32	Body mass index;	chr11:30314787	chr11:30044058~30084343:-
OV	cis	rs607987	0.836	rs1222202	ENSG00000254532.1	RP11-624D11.2	5.06	8.78e-07	0.000646	0.38	0.32	Body mass index;	chr11:30315066	chr11:30044058~30084343:-
OV	cis	rs607987	0.871	rs7125524	ENSG00000254532.1	RP11-624D11.2	-5.06	8.78e-07	0.000646	-0.38	-0.32	Body mass index;	chr11:30309416	chr11:30044058~30084343:-
OV	cis	rs34779708	0.931	rs12771399	ENSG00000230534.5	RP11-297A16.2	5.06	8.81e-07	0.000647	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35163449	chr10:35098006~35127020:-
OV	cis	rs6088580	0.634	rs6059887	ENSG00000206582.1	Y_RNA	-5.06	8.83e-07	0.000649	-0.38	-0.32	Glomerular filtration rate (creatinine);	chr20:34513297	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6120669	ENSG00000206582.1	Y_RNA	-5.06	8.83e-07	0.000649	-0.38	-0.32	Glomerular filtration rate (creatinine);	chr20:34517223	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6059892	ENSG00000206582.1	Y_RNA	-5.06	8.83e-07	0.000649	-0.38	-0.32	Glomerular filtration rate (creatinine);	chr20:34517961	chr20:34526510~34526606:-
OV	cis	rs4763879	0.729	rs10844472	ENSG00000256673.1	RP11-599J14.2	5.06	8.84e-07	0.000649	0.3	0.32	Type 1 diabetes;	chr12:9691137	chr12:9398355~9414851:-
OV	cis	rs6772849	0.83	rs4857917	ENSG00000242551.2	POU5F1P6	-5.06	8.84e-07	0.000649	-0.37	-0.32	Monocyte percentage of white cells;Monocyte count;	chr3:128657335	chr3:128674735~128677005:-
OV	cis	rs6088590	0.561	rs6088528	ENSG00000206582.1	Y_RNA	-5.06	8.84e-07	0.000649	-0.38	-0.32	Coronary artery disease;	chr20:34568938	chr20:34526510~34526606:-
OV	cis	rs9309473	1	rs7594511	ENSG00000163016.8	ALMS1P	5.06	8.84e-07	0.000649	0.38	0.32	Metabolite levels;	chr2:73454512	chr2:73644919~73685576:+
OV	cis	rs8062405	0.755	rs7186573	ENSG00000278665.1	RP11-666O2.4	5.06	8.85e-07	0.00065	0.33	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28576068	chr16:28599241~28601881:-
OV	cis	rs7189233	0.531	rs7204496	ENSG00000279344.1	RP11-44F14.7	-5.06	8.86e-07	0.00065	-0.29	-0.32	Intelligence (multi-trait analysis);	chr16:53462686	chr16:53478957~53481550:-
OV	cis	rs13178541	0.542	rs12653449	ENSG00000250378.1	RP11-119J18.1	-5.05	8.88e-07	0.000652	-0.44	-0.32	IgG glycosylation;	chr5:135789750	chr5:135812667~135826582:+
OV	cis	rs13178541	0.577	rs12653452	ENSG00000250378.1	RP11-119J18.1	-5.05	8.88e-07	0.000652	-0.44	-0.32	IgG glycosylation;	chr5:135789785	chr5:135812667~135826582:+
OV	cis	rs13178541	0.577	rs12653438	ENSG00000250378.1	RP11-119J18.1	-5.05	8.88e-07	0.000652	-0.44	-0.32	IgG glycosylation;	chr5:135789834	chr5:135812667~135826582:+
OV	cis	rs875971	0.964	rs697969	ENSG00000236529.1	RP13-254B10.1	-5.05	8.88e-07	0.000652	-0.33	-0.32	Aortic root size;	chr7:66093491	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs697970	ENSG00000236529.1	RP13-254B10.1	-5.05	8.88e-07	0.000652	-0.33	-0.32	Aortic root size;	chr7:66095065	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs1182882	ENSG00000236529.1	RP13-254B10.1	-5.05	8.88e-07	0.000652	-0.33	-0.32	Aortic root size;	chr7:66097076	chr7:65840212~65840596:+
OV	cis	rs2688608	0.592	rs10762563	ENSG00000271816.1	BMS1P4	5.05	8.89e-07	0.000652	0.3	0.32	Inflammatory bowel disease;	chr10:73765044	chr10:73699151~73730487:-
OV	cis	rs2688608	0.592	rs10824032	ENSG00000271816.1	BMS1P4	5.05	8.89e-07	0.000652	0.3	0.32	Inflammatory bowel disease;	chr10:73768372	chr10:73699151~73730487:-
OV	cis	rs611744	0.647	rs676654	ENSG00000253754.1	RP11-35G22.1	-5.05	8.9e-07	0.000653	-0.35	-0.32	Dupuytren's disease;	chr8:108230074	chr8:108226200~108227544:+
OV	cis	rs2688608	0.588	rs10128205	ENSG00000271816.1	BMS1P4	5.05	8.91e-07	0.000653	0.3	0.32	Inflammatory bowel disease;	chr10:73709890	chr10:73699151~73730487:-
OV	cis	rs6088590	0.561	rs6088527	ENSG00000206582.1	Y_RNA	-5.05	8.92e-07	0.000654	-0.38	-0.32	Coronary artery disease;	chr20:34568037	chr20:34526510~34526606:-
OV	cis	rs6088590	0.561	rs6087600	ENSG00000206582.1	Y_RNA	-5.05	8.92e-07	0.000654	-0.38	-0.32	Coronary artery disease;	chr20:34569413	chr20:34526510~34526606:-
OV	cis	rs6088590	0.561	rs6059926	ENSG00000206582.1	Y_RNA	-5.05	8.92e-07	0.000654	-0.38	-0.32	Coronary artery disease;	chr20:34577000	chr20:34526510~34526606:-
OV	cis	rs6088580	0.713	rs1884669	ENSG00000206582.1	Y_RNA	-5.05	8.92e-07	0.000654	-0.38	-0.32	Glomerular filtration rate (creatinine);	chr20:34583483	chr20:34526510~34526606:-
OV	cis	rs6088590	0.561	rs2295444	ENSG00000206582.1	Y_RNA	-5.05	8.92e-07	0.000654	-0.38	-0.32	Coronary artery disease;	chr20:34586079	chr20:34526510~34526606:-
OV	cis	rs720475	1	rs720475	ENSG00000204959.4	ARHGEF34P	-5.05	8.92e-07	0.000654	-0.5	-0.32	Breast cancer;	chr7:144377836	chr7:144272445~144286966:-
OV	cis	rs6088580	0.602	rs6059840	ENSG00000206582.1	Y_RNA	-5.05	8.92e-07	0.000654	-0.38	-0.32	Glomerular filtration rate (creatinine);	chr20:34442600	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs3736762	ENSG00000206582.1	Y_RNA	-5.05	8.92e-07	0.000654	-0.38	-0.32	Glomerular filtration rate (creatinine);	chr20:34449531	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6058051	ENSG00000206582.1	Y_RNA	-5.05	8.92e-07	0.000654	-0.38	-0.32	Glomerular filtration rate (creatinine);	chr20:34457057	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6059860	ENSG00000206582.1	Y_RNA	-5.05	8.92e-07	0.000654	-0.38	-0.32	Glomerular filtration rate (creatinine);	chr20:34476025	chr20:34526510~34526606:-
OV	cis	rs34779708	0.966	rs12769484	ENSG00000230534.5	RP11-297A16.2	5.05	8.93e-07	0.000654	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35176818	chr10:35098006~35127020:-
OV	cis	rs6088580	0.634	rs6120650	ENSG00000206582.1	Y_RNA	-5.05	8.93e-07	0.000655	-0.38	-0.32	Glomerular filtration rate (creatinine);	chr20:34452168	chr20:34526510~34526606:-
OV	cis	rs4128705	0.958	rs2904380	ENSG00000249049.1	RP11-763F8.1	5.05	8.94e-07	0.000655	0.39	0.32	Amyotrophic lateral sclerosis (sporadic);	chr4:91361761	chr4:91319034~91325306:-
OV	cis	rs67311347	0.824	rs59922539	ENSG00000223797.4	ENTPD3-AS1	5.05	8.94e-07	0.000656	0.35	0.32	Renal cell carcinoma;	chr3:40295619	chr3:40313802~40453329:-
OV	cis	rs301901	0.772	rs301873	ENSG00000250155.1	CTD-2353F22.1	-5.05	8.95e-07	0.000656	-0.36	-0.32	Height;	chr5:37136896	chr5:36666214~36725195:-
OV	cis	rs301901	0.714	rs301869	ENSG00000250155.1	CTD-2353F22.1	-5.05	8.95e-07	0.000656	-0.36	-0.32	Height;	chr5:37140495	chr5:36666214~36725195:-
OV	cis	rs301901	0.772	rs2098713	ENSG00000250155.1	CTD-2353F22.1	-5.05	8.95e-07	0.000656	-0.36	-0.32	Height;	chr5:37144472	chr5:36666214~36725195:-
OV	cis	rs496547	0.588	rs473298	ENSG00000255239.1	AP002954.6	5.05	8.96e-07	0.000656	0.37	0.32	Hip minimal joint space width;	chr11:118808678	chr11:118688039~118690600:-
OV	cis	rs9813712	0.953	rs7619208	ENSG00000228252.7	COL6A4P2	-5.05	8.96e-07	0.000656	-0.41	-0.32	Response to amphetamines;	chr3:130258163	chr3:130212823~130273806:+
OV	cis	rs6088580	0.601	rs6059872	ENSG00000206582.1	Y_RNA	-5.05	8.97e-07	0.000657	-0.38	-0.32	Glomerular filtration rate (creatinine);	chr20:34494970	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6059878	ENSG00000206582.1	Y_RNA	-5.05	8.97e-07	0.000657	-0.38	-0.32	Glomerular filtration rate (creatinine);	chr20:34499361	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6120666	ENSG00000206582.1	Y_RNA	-5.05	8.97e-07	0.000657	-0.38	-0.32	Glomerular filtration rate (creatinine);	chr20:34502913	chr20:34526510~34526606:-
OV	cis	rs6088580	0.601	rs6120668	ENSG00000206582.1	Y_RNA	-5.05	8.97e-07	0.000657	-0.38	-0.32	Glomerular filtration rate (creatinine);	chr20:34511988	chr20:34526510~34526606:-
OV	cis	rs6088580	0.609	rs2378205	ENSG00000206582.1	Y_RNA	-5.05	8.97e-07	0.000657	-0.38	-0.32	Glomerular filtration rate (creatinine);	chr20:34522998	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6058073	ENSG00000206582.1	Y_RNA	-5.05	8.97e-07	0.000657	-0.38	-0.32	Glomerular filtration rate (creatinine);	chr20:34528678	chr20:34526510~34526606:-
OV	cis	rs11673344	0.832	rs76781063	ENSG00000226686.6	LINC01535	5.05	8.98e-07	0.000658	0.41	0.32	Obesity-related traits;	chr19:37036040	chr19:37251912~37265535:+
OV	cis	rs4805272	1	rs8113770	ENSG00000267243.4	AC005307.3	-5.05	8.98e-07	0.000658	-0.43	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28836829	chr19:28435388~28727777:-
OV	cis	rs6471393	0.862	rs11994625	ENSG00000253848.1	RP11-10N23.5	5.05	8.98e-07	0.000658	0.4	0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93760149	chr8:93741193~93744534:+
OV	cis	rs6471393	0.83	rs6981752	ENSG00000253848.1	RP11-10N23.5	5.05	8.98e-07	0.000658	0.4	0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93761046	chr8:93741193~93744534:+
OV	cis	rs10510102	0.872	rs78369301	ENSG00000276742.1	RP11-500G22.4	5.05	8.99e-07	0.000658	0.53	0.32	Breast cancer;	chr10:121858527	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs10466217	ENSG00000276742.1	RP11-500G22.4	5.05	8.99e-07	0.000658	0.53	0.32	Breast cancer;	chr10:121860362	chr10:121956782~121957098:+
OV	cis	rs7968440	0.808	rs2554862	ENSG00000257298.1	RP3-405J10.3	5.05	9.01e-07	0.00066	0.32	0.32	Fibrinogen;	chr12:50808263	chr12:50185580~50191363:-
OV	cis	rs1797885	0.934	rs1797874	ENSG00000251774.1	RNU6-377P	5.05	9.01e-07	0.00066	0.3	0.32	Immature fraction of reticulocytes;	chr3:12488093	chr3:12514706~12514807:+
OV	cis	rs1797885	0.902	rs905644	ENSG00000251774.1	RNU6-377P	5.05	9.01e-07	0.00066	0.3	0.32	Immature fraction of reticulocytes;	chr3:12489329	chr3:12514706~12514807:+
OV	cis	rs3758911	1	rs10789617	ENSG00000261098.1	RP11-819C21.1	-5.05	9.02e-07	0.00066	-0.3	-0.32	Coronary artery disease;	chr11:107318968	chr11:107312132~107316271:-
OV	cis	rs17301013	0.507	rs72717608	ENSG00000227373.4	RP11-160H22.5	5.05	9.03e-07	0.000661	0.42	0.32	Systemic lupus erythematosus;	chr1:174788316	chr1:174115300~174160004:-
OV	cis	rs607987	0.802	rs2786257	ENSG00000254532.1	RP11-624D11.2	5.05	9.06e-07	0.000662	0.37	0.32	Body mass index;	chr11:30319178	chr11:30044058~30084343:-
OV	cis	rs6471393	0.83	rs57803852	ENSG00000253848.1	RP11-10N23.5	5.05	9.06e-07	0.000662	0.39	0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93761156	chr8:93741193~93744534:+
OV	cis	rs875971	1	rs1167612	ENSG00000236529.1	RP13-254B10.1	-5.05	9.06e-07	0.000662	-0.33	-0.32	Aortic root size;	chr7:66102989	chr7:65840212~65840596:+
OV	cis	rs8062405	0.754	rs28410083	ENSG00000259982.1	CDC37P1	-5.05	9.06e-07	0.000663	-0.39	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28700294~28701540:-
OV	cis	rs8062405	0.789	rs1968751	ENSG00000259982.1	CDC37P1	-5.05	9.06e-07	0.000663	-0.39	-0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28700294~28701540:-
OV	cis	rs9291683	0.62	rs7699512	ENSG00000250413.1	RP11-448G15.1	5.05	9.07e-07	0.000663	0.36	0.32	Bone mineral density;	chr4:10124184	chr4:10006482~10009725:+
OV	cis	rs7974517	1	rs7974517	ENSG00000257298.1	RP3-405J10.3	-5.05	9.1e-07	0.000665	-0.3	-0.32	Male-pattern baldness;	chr12:50751299	chr12:50185580~50191363:-
OV	cis	rs607987	0.871	rs12793271	ENSG00000254532.1	RP11-624D11.2	-5.05	9.11e-07	0.000666	-0.37	-0.32	Body mass index;	chr11:30293038	chr11:30044058~30084343:-
OV	cis	rs4713118	0.513	rs149989	ENSG00000219392.1	RP1-265C24.5	-5.05	9.12e-07	0.000666	-0.39	-0.32	Parkinson's disease;	chr6:28030406	chr6:28115628~28116551:+
OV	cis	rs1891275	0.508	rs2096079	ENSG00000228701.1	TNKS2-AS1	-5.05	9.12e-07	0.000666	-0.34	-0.32	Intelligence (multi-trait analysis);	chr10:91736910	chr10:91782839~91798291:-
OV	cis	rs1891275	0.515	rs2153653	ENSG00000228701.1	TNKS2-AS1	-5.05	9.12e-07	0.000667	-0.35	-0.32	Intelligence (multi-trait analysis);	chr10:91736169	chr10:91782839~91798291:-
OV	cis	rs1891275	0.515	rs7475294	ENSG00000228701.1	TNKS2-AS1	-5.05	9.15e-07	0.000669	-0.34	-0.32	Intelligence (multi-trait analysis);	chr10:91748442	chr10:91782839~91798291:-
OV	cis	rs2898681	0.561	rs6855240	ENSG00000248375.1	RP11-177B4.1	-5.05	9.18e-07	0.00067	-0.57	-0.32	Optic nerve measurement (cup area);	chr4:52874620	chr4:52720081~52720831:-
OV	cis	rs2898681	0.521	rs6833350	ENSG00000248375.1	RP11-177B4.1	-5.05	9.18e-07	0.00067	-0.57	-0.32	Optic nerve measurement (cup area);	chr4:52874701	chr4:52720081~52720831:-
OV	cis	rs8062405	0.792	rs12446550	ENSG00000278665.1	RP11-666O2.4	5.05	9.18e-07	0.00067	0.33	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28532060	chr16:28599241~28601881:-
OV	cis	rs2253762	0.54	rs7358186	ENSG00000276742.1	RP11-500G22.4	5.05	9.18e-07	0.000671	0.55	0.32	Breast cancer;	chr10:122000816	chr10:121956782~121957098:+
OV	cis	rs6088590	0.561	rs764597	ENSG00000206582.1	Y_RNA	-5.05	9.21e-07	0.000672	-0.38	-0.32	Coronary artery disease;	chr20:34573421	chr20:34526510~34526606:-
OV	cis	rs4380275	1	rs4268954	ENSG00000223751.1	AC116609.2	5.05	9.21e-07	0.000672	0.36	0.32	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:772834	chr2:742488~747767:+
OV	cis	rs34779708	0.966	rs11010095	ENSG00000230534.5	RP11-297A16.2	5.05	9.21e-07	0.000673	0.41	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35107020	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs998658	ENSG00000230534.5	RP11-297A16.2	5.05	9.21e-07	0.000673	0.41	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35119726	chr10:35098006~35127020:-
OV	cis	rs801193	1	rs17566701	ENSG00000236529.1	RP13-254B10.1	5.05	9.22e-07	0.000673	0.34	0.32	Aortic root size;	chr7:66728196	chr7:65840212~65840596:+
OV	cis	rs9291683	0.527	rs11727087	ENSG00000250413.1	RP11-448G15.1	-5.05	9.23e-07	0.000673	-0.37	-0.32	Bone mineral density;	chr4:10094396	chr4:10006482~10009725:+
OV	cis	rs34779708	1	rs34779708	ENSG00000230534.5	RP11-297A16.2	5.05	9.23e-07	0.000673	0.41	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35177257	chr10:35098006~35127020:-
OV	cis	rs4805272	0.626	rs6509072	ENSG00000267243.4	AC005307.3	-5.05	9.23e-07	0.000674	-0.48	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28840796	chr19:28435388~28727777:-
OV	cis	rs9813712	0.953	rs896822	ENSG00000228252.7	COL6A4P2	-5.05	9.24e-07	0.000674	-0.41	-0.32	Response to amphetamines;	chr3:130259987	chr3:130212823~130273806:+
OV	cis	rs7302981	0.967	rs2178173	ENSG00000272368.2	RP4-605O3.4	-5.04	9.29e-07	0.000677	-0.36	-0.32	Systolic blood pressure;	chr12:50124146	chr12:50112197~50165618:+
OV	cis	rs7302981	0.967	rs7297421	ENSG00000272368.2	RP4-605O3.4	-5.04	9.29e-07	0.000677	-0.36	-0.32	Systolic blood pressure;	chr12:50125143	chr12:50112197~50165618:+
OV	cis	rs7302981	0.934	rs7279	ENSG00000272368.2	RP4-605O3.4	-5.04	9.29e-07	0.000677	-0.36	-0.32	Systolic blood pressure;	chr12:50130164	chr12:50112197~50165618:+
OV	cis	rs7302981	0.934	rs7532	ENSG00000272368.2	RP4-605O3.4	-5.04	9.29e-07	0.000677	-0.36	-0.32	Systolic blood pressure;	chr12:50130181	chr12:50112197~50165618:+
OV	cis	rs1134634	0.52	rs10022610	ENSG00000273133.1	RP11-799M12.2	-5.04	9.29e-07	0.000677	-0.43	-0.32	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15635864	chr4:15563698~15564253:-
OV	cis	rs116095464	0.51	rs60844864	ENSG00000250848.1	CTD-2083E4.5	-5.04	9.29e-07	0.000677	-0.4	-0.32	Breast cancer;	chr5:266885	chr5:288833~290321:-
OV	cis	rs16873450	0.527	rs6461738	ENSG00000234800.2	PCMTD1P3	5.04	9.29e-07	0.000677	0.33	0.32	Verbal memory performance (residualized delayed recall level);	chr7:23789557	chr7:23721311~23721782:-
OV	cis	rs3091242	0.9	rs1811832	ENSG00000224183.1	SDHDP6	-5.04	9.31e-07	0.000678	-0.37	-0.32	Erythrocyte sedimentation rate;	chr1:25427074	chr1:25294164~25294643:-
OV	cis	rs17301013	0.507	rs10494492	ENSG00000227373.4	RP11-160H22.5	-5.04	9.34e-07	0.00068	-0.4	-0.32	Systemic lupus erythematosus;	chr1:174723499	chr1:174115300~174160004:-
OV	cis	rs301901	0.734	rs216386	ENSG00000250155.1	CTD-2353F22.1	-5.04	9.34e-07	0.00068	-0.36	-0.32	Height;	chr5:37276224	chr5:36666214~36725195:-
OV	cis	rs4591358	0.654	rs6745113	ENSG00000223466.1	AC064834.2	-5.04	9.35e-07	0.00068	-0.38	-0.32	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195505888	chr2:195533035~195538681:+
OV	cis	rs7615952	0.599	rs6766327	ENSG00000171084.14	FAM86JP	5.04	9.35e-07	0.000681	0.46	0.32	Blood pressure (smoking interaction);	chr3:126004834	chr3:125916620~125930024:+
OV	cis	rs7615952	0.641	rs12491577	ENSG00000171084.14	FAM86JP	5.04	9.35e-07	0.000681	0.46	0.32	Blood pressure (smoking interaction);	chr3:126012288	chr3:125916620~125930024:+
OV	cis	rs7615952	0.599	rs1875683	ENSG00000171084.14	FAM86JP	5.04	9.35e-07	0.000681	0.46	0.32	Blood pressure (smoking interaction);	chr3:126013638	chr3:125916620~125930024:+
OV	cis	rs67311347	0.955	rs1129200	ENSG00000223797.4	ENTPD3-AS1	5.04	9.35e-07	0.000681	0.36	0.32	Renal cell carcinoma;	chr3:40490766	chr3:40313802~40453329:-
OV	cis	rs17023223	0.537	rs10923759	ENSG00000231365.4	RP11-418J17.1	5.04	9.36e-07	0.000681	0.42	0.32	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119149571	chr1:119140396~119275973:+
OV	cis	rs4763879	0.778	rs11052497	ENSG00000256673.1	RP11-599J14.2	5.04	9.37e-07	0.000682	0.3	0.32	Type 1 diabetes;	chr12:9696679	chr12:9398355~9414851:-
OV	cis	rs4763879	0.778	rs1056151	ENSG00000256673.1	RP11-599J14.2	5.04	9.37e-07	0.000682	0.3	0.32	Type 1 diabetes;	chr12:9698427	chr12:9398355~9414851:-
OV	cis	rs6088580	0.634	rs4911420	ENSG00000206582.1	Y_RNA	5.04	9.38e-07	0.000682	0.37	0.32	Glomerular filtration rate (creatinine);	chr20:34410848	chr20:34526510~34526606:-
OV	cis	rs8062405	0.823	rs7202948	ENSG00000278665.1	RP11-666O2.4	5.04	9.38e-07	0.000683	0.33	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28546968	chr16:28599241~28601881:-
OV	cis	rs8027521	0.501	rs2711588	ENSG00000280362.1	RP11-643A5.3	-5.04	9.39e-07	0.000683	-0.4	-0.32	Circulating chemerin levels;	chr15:53982129	chr15:53910769~53914712:+
OV	cis	rs858239	0.6	rs61292332	ENSG00000230042.1	AK3P3	-5.04	9.4e-07	0.000684	-0.34	-0.32	Cerebrospinal fluid biomarker levels;	chr7:23092243	chr7:23129178~23129841:+
OV	cis	rs2999052	0.602	rs7373685	ENSG00000277250.1	Metazoa_SRP	-5.04	9.42e-07	0.000685	-0.44	-0.32	Hypospadias;	chr3:128388177	chr3:128673681~128674021:-
OV	cis	rs4908768	0.594	rs11121228	ENSG00000228423.2	RP4-633I8.4	5.04	9.42e-07	0.000685	0.36	0.32	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8770583	chr1:8805860~8807051:-
OV	cis	rs4713118	0.739	rs2893931	ENSG00000280107.1	AL022393.9	-5.04	9.42e-07	0.000685	-0.37	-0.32	Parkinson's disease;	chr6:27780231	chr6:28170845~28172521:+
OV	cis	rs34779708	0.931	rs2384275	ENSG00000230534.5	RP11-297A16.2	5.04	9.44e-07	0.000686	0.41	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35008214	chr10:35098006~35127020:-
OV	cis	rs12429206	0.547	rs75419800	ENSG00000233672.5	RNASEH2B-AS1	-5.04	9.44e-07	0.000686	-0.42	-0.32	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50898897	chr13:50862172~50910764:-
OV	cis	rs34779708	0.966	rs12765038	ENSG00000230534.5	RP11-297A16.2	5.04	9.44e-07	0.000687	0.41	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35127585	chr10:35098006~35127020:-
OV	cis	rs8062405	0.755	rs4787457	ENSG00000278665.1	RP11-666O2.4	5.04	9.45e-07	0.000687	0.34	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28544079	chr16:28599241~28601881:-
OV	cis	rs9813712	0.571	rs9846596	ENSG00000228252.7	COL6A4P2	-5.04	9.48e-07	0.000689	-0.37	-0.32	Response to amphetamines;	chr3:130288318	chr3:130212823~130273806:+
OV	cis	rs9813712	0.595	rs1453239	ENSG00000228252.7	COL6A4P2	-5.04	9.48e-07	0.000689	-0.37	-0.32	Response to amphetamines;	chr3:130288915	chr3:130212823~130273806:+
OV	cis	rs9813712	0.523	rs9866942	ENSG00000228252.7	COL6A4P2	-5.04	9.48e-07	0.000689	-0.37	-0.32	Response to amphetamines;	chr3:130297796	chr3:130212823~130273806:+
OV	cis	rs11673344	0.526	rs73035160	ENSG00000226686.6	LINC01535	5.04	9.49e-07	0.00069	0.43	0.32	Obesity-related traits;	chr19:37655135	chr19:37251912~37265535:+
OV	cis	rs6928977	0.5	rs6925161	ENSG00000231028.7	LINC00271	-5.04	9.5e-07	0.00069	-0.32	-0.32	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135615496	chr6:135497801~135716055:+
OV	cis	rs611744	0.647	rs1379336	ENSG00000253754.1	RP11-35G22.1	-5.04	9.51e-07	0.000691	-0.34	-0.32	Dupuytren's disease;	chr8:108264377	chr8:108226200~108227544:+
OV	cis	rs10740039	0.804	rs894384	ENSG00000254271.1	RP11-131N11.4	5.04	9.53e-07	0.000692	0.4	0.32	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60692535	chr10:60734342~60741828:+
OV	cis	rs3758911	0.964	rs11212158	ENSG00000261098.1	RP11-819C21.1	-5.04	9.54e-07	0.000692	-0.31	-0.32	Coronary artery disease;	chr11:107325745	chr11:107312132~107316271:-
OV	cis	rs3758911	1	rs11212159	ENSG00000261098.1	RP11-819C21.1	-5.04	9.54e-07	0.000692	-0.31	-0.32	Coronary artery disease;	chr11:107326003	chr11:107312132~107316271:-
OV	cis	rs3758911	1	rs11212160	ENSG00000261098.1	RP11-819C21.1	-5.04	9.54e-07	0.000692	-0.31	-0.32	Coronary artery disease;	chr11:107326192	chr11:107312132~107316271:-
OV	cis	rs3758911	1	rs1046095	ENSG00000261098.1	RP11-819C21.1	-5.04	9.54e-07	0.000692	-0.31	-0.32	Coronary artery disease;	chr11:107326509	chr11:107312132~107316271:-
OV	cis	rs2836974	0.565	rs34304022	ENSG00000232608.1	TIMM9P2	-5.04	9.55e-07	0.000693	-0.45	-0.32	Cognitive function;	chr21:39207693	chr21:39216624~39217506:+
OV	cis	rs1797885	0.934	rs2648312	ENSG00000251774.1	RNU6-377P	-5.04	9.55e-07	0.000693	-0.3	-0.32	Immature fraction of reticulocytes;	chr3:12505648	chr3:12514706~12514807:+
OV	cis	rs853679	0.55	rs1233704	ENSG00000280107.1	AL022393.9	5.04	9.56e-07	0.000694	0.42	0.32	Depression;	chr6:28199145	chr6:28170845~28172521:+
OV	cis	rs301901	0.772	rs301863	ENSG00000250155.1	CTD-2353F22.1	-5.04	9.56e-07	0.000694	-0.36	-0.32	Height;	chr5:37133456	chr5:36666214~36725195:-
OV	cis	rs301901	0.743	rs301872	ENSG00000250155.1	CTD-2353F22.1	-5.04	9.56e-07	0.000694	-0.36	-0.32	Height;	chr5:37137756	chr5:36666214~36725195:-
OV	cis	rs611744	0.647	rs6981420	ENSG00000253754.1	RP11-35G22.1	-5.04	9.56e-07	0.000694	-0.34	-0.32	Dupuytren's disease;	chr8:108254465	chr8:108226200~108227544:+
OV	cis	rs611744	0.647	rs10106246	ENSG00000253754.1	RP11-35G22.1	-5.04	9.56e-07	0.000694	-0.34	-0.32	Dupuytren's disease;	chr8:108256481	chr8:108226200~108227544:+
OV	cis	rs7587476	0.906	rs2734674	ENSG00000229267.2	AC072062.1	5.04	9.57e-07	0.000694	0.43	0.32	Neuroblastoma;	chr2:214794171	chr2:214810229~214963274:+
OV	cis	rs1150668	0.768	rs1233713	ENSG00000220721.1	OR1F12	5.04	9.58e-07	0.000695	0.31	0.32	Pubertal anthropometrics;	chr6:28230503	chr6:28073316~28074233:+
OV	cis	rs17301013	0.507	rs6678209	ENSG00000227373.4	RP11-160H22.5	-5.04	9.6e-07	0.000696	-0.4	-0.32	Systemic lupus erythematosus;	chr1:174325607	chr1:174115300~174160004:-
OV	cis	rs6991838	0.584	rs4737221	ENSG00000200714.1	Y_RNA	-5.04	9.61e-07	0.000697	-0.4	-0.32	Intelligence (multi-trait analysis);	chr8:65569075	chr8:65592731~65592820:+
OV	cis	rs611744	0.647	rs1448150	ENSG00000253754.1	RP11-35G22.1	-5.04	9.61e-07	0.000697	-0.34	-0.32	Dupuytren's disease;	chr8:108263932	chr8:108226200~108227544:+
OV	cis	rs9291683	0.554	rs7668175	ENSG00000250413.1	RP11-448G15.1	5.04	9.62e-07	0.000698	0.35	0.32	Bone mineral density;	chr4:10124158	chr4:10006482~10009725:+
OV	cis	rs6991838	0.584	rs14213	ENSG00000200714.1	Y_RNA	5.04	9.62e-07	0.000698	0.39	0.32	Intelligence (multi-trait analysis);	chr8:65602719	chr8:65592731~65592820:+
OV	cis	rs7017914	0.652	rs3110263	ENSG00000223220.1	Y_RNA	5.04	9.63e-07	0.000698	0.37	0.32	Bone mineral density;	chr8:71030457	chr8:70780914~70781008:-
OV	cis	rs4713118	0.824	rs2092075	ENSG00000280107.1	AL022393.9	-5.04	9.64e-07	0.000699	-0.37	-0.32	Parkinson's disease;	chr6:27781551	chr6:28170845~28172521:+
OV	cis	rs4713118	0.824	rs13211701	ENSG00000280107.1	AL022393.9	-5.04	9.64e-07	0.000699	-0.37	-0.32	Parkinson's disease;	chr6:27782300	chr6:28170845~28172521:+
OV	cis	rs4713118	0.824	rs9468229	ENSG00000280107.1	AL022393.9	-5.04	9.64e-07	0.000699	-0.37	-0.32	Parkinson's disease;	chr6:27782307	chr6:28170845~28172521:+
OV	cis	rs875971	1	rs2220626	ENSG00000236529.1	RP13-254B10.1	-5.04	9.64e-07	0.000699	-0.33	-0.32	Aortic root size;	chr7:66081075	chr7:65840212~65840596:+
OV	cis	rs2999052	0.602	rs7632169	ENSG00000242551.2	POU5F1P6	5.04	9.65e-07	0.000699	0.42	0.32	Hypospadias;	chr3:128395744	chr3:128674735~128677005:-
OV	cis	rs7429990	0.965	rs4392441	ENSG00000229759.1	MRPS18AP1	-5.04	9.65e-07	0.000699	-0.33	-0.32	Educational attainment (years of education);	chr3:48036211	chr3:48256350~48256938:-
OV	cis	rs3814244	0.933	rs11610126	ENSG00000255733.4	IFNG-AS1	-5.04	9.67e-07	0.000701	-0.31	-0.32	Itch intensity from mosquito bite adjusted by bite size;	chr12:68026493	chr12:67989445~68234686:+
OV	cis	rs17361889	0.752	rs6956986	ENSG00000224683.1	RPL36AP29	-5.04	9.67e-07	0.000701	-0.36	-0.32	Pediatric bone mineral content (hip);	chr7:16230707	chr7:16208945~16209265:+
OV	cis	rs4713118	0.513	rs149962	ENSG00000219392.1	RP1-265C24.5	-5.04	9.68e-07	0.000701	-0.37	-0.32	Parkinson's disease;	chr6:28048140	chr6:28115628~28116551:+
OV	cis	rs172166	0.769	rs149965	ENSG00000219392.1	RP1-265C24.5	-5.04	9.68e-07	0.000701	-0.37	-0.32	Cardiac Troponin-T levels;	chr6:28050911	chr6:28115628~28116551:+
OV	cis	rs4639966	0.589	rs480958	ENSG00000255239.1	AP002954.6	5.04	9.68e-07	0.000701	0.37	0.32	Systemic lupus erythematosus;	chr11:118707281	chr11:118688039~118690600:-
OV	cis	rs7429990	0.965	rs800762	ENSG00000229759.1	MRPS18AP1	5.04	9.69e-07	0.000702	0.33	0.32	Educational attainment (years of education);	chr3:47864080	chr3:48256350~48256938:-
OV	cis	rs55894132	1	rs55894132	ENSG00000279656.1	RP11-298I3.6	5.04	9.69e-07	0.000702	0.36	0.32	Intelligence (multi-trait analysis);	chr14:22939628	chr14:23023083~23024217:-
OV	cis	rs7429990	0.965	rs7619882	ENSG00000229759.1	MRPS18AP1	5.04	9.71e-07	0.000703	0.33	0.32	Educational attainment (years of education);	chr3:47943334	chr3:48256350~48256938:-
OV	cis	rs13068223	0.935	rs1560414	ENSG00000243926.1	TIPARP-AS1	5.04	9.71e-07	0.000704	0.3	0.32	Age-related hearing impairment (SNP x SNP interaction);	chr3:156723960	chr3:156671862~156674378:-
OV	cis	rs17301013	0.606	rs72711443	ENSG00000227373.4	RP11-160H22.5	5.03	9.73e-07	0.000705	0.41	0.32	Systemic lupus erythematosus;	chr1:174090876	chr1:174115300~174160004:-
OV	cis	rs858239	0.541	rs4624924	ENSG00000230042.1	AK3P3	-5.03	9.74e-07	0.000705	-0.33	-0.32	Cerebrospinal fluid biomarker levels;	chr7:23129224	chr7:23129178~23129841:+
OV	cis	rs3814244	0.902	rs2870961	ENSG00000255733.4	IFNG-AS1	-5.03	9.76e-07	0.000706	-0.31	-0.32	Itch intensity from mosquito bite adjusted by bite size;	chr12:68024262	chr12:67989445~68234686:+
OV	cis	rs34779708	0.966	rs12762493	ENSG00000230534.5	RP11-297A16.2	5.03	9.78e-07	0.000708	0.41	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35182945	chr10:35098006~35127020:-
OV	cis	rs6088580	0.634	rs6088478	ENSG00000206582.1	Y_RNA	5.03	9.81e-07	0.000709	0.37	0.32	Glomerular filtration rate (creatinine);	chr20:34383913	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6088483	ENSG00000206582.1	Y_RNA	5.03	9.81e-07	0.000709	0.37	0.32	Glomerular filtration rate (creatinine);	chr20:34396908	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6088484	ENSG00000206582.1	Y_RNA	5.03	9.81e-07	0.000709	0.37	0.32	Glomerular filtration rate (creatinine);	chr20:34398155	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs4911423	ENSG00000206582.1	Y_RNA	5.03	9.81e-07	0.000709	0.37	0.32	Glomerular filtration rate (creatinine);	chr20:34411580	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6141471	ENSG00000206582.1	Y_RNA	5.03	9.81e-07	0.000709	0.37	0.32	Glomerular filtration rate (creatinine);	chr20:34418924	chr20:34526510~34526606:-
OV	cis	rs7617773	0.817	rs4131362	ENSG00000228638.1	FCF1P2	-5.03	9.81e-07	0.000709	-0.39	-0.32	Coronary artery disease;	chr3:48287546	chr3:48290793~48291375:-
OV	cis	rs7302981	0.899	rs4883481	ENSG00000272368.2	RP4-605O3.4	-5.03	9.83e-07	0.000711	-0.36	-0.32	Systolic blood pressure;	chr12:50180528	chr12:50112197~50165618:+
OV	cis	rs2253762	0.609	rs10887057	ENSG00000276742.1	RP11-500G22.4	5.03	9.89e-07	0.000715	0.48	0.32	Breast cancer;	chr10:122043799	chr10:121956782~121957098:+
OV	cis	rs7615952	0.609	rs13088451	ENSG00000171084.14	FAM86JP	5.03	9.89e-07	0.000715	0.48	0.32	Blood pressure (smoking interaction);	chr3:125834656	chr3:125916620~125930024:+
OV	cis	rs1075265	0.704	rs805402	ENSG00000233266.1	HMGB1P31	5.03	9.9e-07	0.000715	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53889212	chr2:54051334~54051760:+
OV	cis	rs1185460	0.565	rs1182922	ENSG00000271751.1	RP11-110I1.14	5.03	9.9e-07	0.000716	0.38	0.32	Coronary artery disease;	chr11:119062148	chr11:119065263~119065677:-
OV	cis	rs301901	1	rs159913	ENSG00000250155.1	CTD-2353F22.1	-5.03	9.91e-07	0.000716	-0.37	-0.32	Height;	chr5:37053881	chr5:36666214~36725195:-
OV	cis	rs17023223	0.508	rs12096448	ENSG00000231365.4	RP11-418J17.1	-5.03	9.94e-07	0.000718	-0.41	-0.32	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140767	chr1:119140396~119275973:+
OV	cis	rs17023223	0.537	rs4508058	ENSG00000231365.4	RP11-418J17.1	-5.03	9.94e-07	0.000718	-0.41	-0.32	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119141627	chr1:119140396~119275973:+
OV	cis	rs875971	0.545	rs316324	ENSG00000226824.5	RP4-756H11.3	5.03	9.94e-07	0.000718	0.37	0.32	Aortic root size;	chr7:66145627	chr7:66654538~66669855:+
OV	cis	rs875971	0.545	rs316323	ENSG00000226824.5	RP4-756H11.3	5.03	9.94e-07	0.000718	0.37	0.32	Aortic root size;	chr7:66146002	chr7:66654538~66669855:+
OV	cis	rs875971	0.545	rs316316	ENSG00000226824.5	RP4-756H11.3	5.03	9.94e-07	0.000718	0.37	0.32	Aortic root size;	chr7:66149270	chr7:66654538~66669855:+
OV	cis	rs1113500	0.799	rs1777459	ENSG00000226822.1	RP11-356N1.2	-5.03	9.94e-07	0.000718	-0.39	-0.32	Growth-regulated protein alpha levels;	chr1:108042377	chr1:108071482~108074519:+
OV	cis	rs7927592	0.913	rs948316	ENSG00000212093.1	AP000807.1	5.03	9.95e-07	0.000718	0.4	0.32	Total body bone mineral density;	chr11:68542202	chr11:68506083~68506166:-
OV	cis	rs7201929	1	rs12920514	ENSG00000259982.1	CDC37P1	-5.03	9.97e-07	0.00072	-0.42	-0.32	QT interval;	chr16:28824579	chr16:28700294~28701540:-
OV	cis	rs4356975	0.518	rs4314347	ENSG00000251284.2	RP13-644M16.1	-5.03	9.97e-07	0.00072	-0.47	-0.32	Obesity-related traits;	chr4:69102209	chr4:69125274~69126451:+
OV	cis	rs1150668	0.799	rs1150705	ENSG00000220721.1	OR1F12	5.03	1e-06	0.000722	0.32	0.32	Pubertal anthropometrics;	chr6:28226008	chr6:28073316~28074233:+
OV	cis	rs4805272	1	rs888826	ENSG00000267243.4	AC005307.3	-5.03	1e-06	0.000723	-0.42	-0.32	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28834512	chr19:28435388~28727777:-
OV	cis	rs7587476	0.689	rs10498025	ENSG00000229267.2	AC072062.1	-5.03	1e-06	0.000724	-0.44	-0.32	Neuroblastoma;	chr2:214884532	chr2:214810229~214963274:+
OV	cis	rs6088580	0.634	rs6120642	ENSG00000206582.1	Y_RNA	-5.03	1e-06	0.000724	-0.38	-0.32	Glomerular filtration rate (creatinine);	chr20:34424725	chr20:34526510~34526606:-
OV	cis	rs1150668	0.764	rs9368565	ENSG00000220721.1	OR1F12	-5.03	1.01e-06	0.000724	-0.32	-0.32	Pubertal anthropometrics;	chr6:28377433	chr6:28073316~28074233:+
OV	cis	rs1150668	0.796	rs1052215	ENSG00000220721.1	OR1F12	-5.03	1.01e-06	0.000724	-0.32	-0.32	Pubertal anthropometrics;	chr6:28380381	chr6:28073316~28074233:+
OV	cis	rs11673344	0.931	rs73622783	ENSG00000226686.6	LINC01535	5.03	1.01e-06	0.000725	0.4	0.32	Obesity-related traits;	chr19:37165155	chr19:37251912~37265535:+
OV	cis	rs2243480	1	rs778729	ENSG00000226824.5	RP4-756H11.3	-5.03	1.01e-06	0.000726	-0.5	-0.32	Diabetic kidney disease;	chr7:66359432	chr7:66654538~66669855:+
OV	cis	rs12134133	0.688	rs6540875	ENSG00000274245.1	RP11-357P18.2	5.03	1.01e-06	0.000727	0.43	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207221686	chr1:207372559~207373252:+
OV	cis	rs12134133	0.719	rs6696142	ENSG00000274245.1	RP11-357P18.2	5.03	1.01e-06	0.000727	0.43	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207228898	chr1:207372559~207373252:+
OV	cis	rs12134133	0.752	rs57003024	ENSG00000274245.1	RP11-357P18.2	5.03	1.01e-06	0.000727	0.43	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207230999	chr1:207372559~207373252:+
OV	cis	rs12134133	0.752	rs61821050	ENSG00000274245.1	RP11-357P18.2	5.03	1.01e-06	0.000727	0.43	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207235253	chr1:207372559~207373252:+
OV	cis	rs12134133	0.752	rs61821051	ENSG00000274245.1	RP11-357P18.2	5.03	1.01e-06	0.000727	0.43	0.32	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207235624	chr1:207372559~207373252:+
OV	cis	rs896854	0.654	rs13278601	ENSG00000253528.2	RP11-347C18.4	5.03	1.01e-06	0.000727	0.31	0.32	Type 2 diabetes;	chr8:94960746	chr8:94974573~94974853:-
OV	cis	rs1790761	0.667	rs598811	ENSG00000184224.3	C11orf72	5.03	1.01e-06	0.000728	0.36	0.32	Mean corpuscular volume;	chr11:67544205	chr11:67602880~67606706:-
OV	cis	rs4713118	0.866	rs9468217	ENSG00000219392.1	RP1-265C24.5	-5.03	1.01e-06	0.000728	-0.39	-0.32	Parkinson's disease;	chr6:27758688	chr6:28115628~28116551:+
OV	cis	rs9549260	0.755	rs9549236	ENSG00000229456.1	RLIMP1	-5.03	1.01e-06	0.000729	-0.39	-0.32	Red blood cell count;	chr13:40573021	chr13:40618738~40621348:+
OV	cis	rs34779708	0.931	rs2384287	ENSG00000230534.5	RP11-297A16.2	5.03	1.01e-06	0.000729	0.42	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35051631	chr10:35098006~35127020:-
OV	cis	rs2098713	0.599	rs12152831	ENSG00000250155.1	CTD-2353F22.1	5.03	1.01e-06	0.00073	0.36	0.32	Telomere length;	chr5:37555215	chr5:36666214~36725195:-
OV	cis	rs7587476	0.784	rs36086595	ENSG00000229267.2	AC072062.1	-5.03	1.01e-06	0.00073	-0.42	-0.32	Neuroblastoma;	chr2:214815569	chr2:214810229~214963274:+
OV	cis	rs875971	0.545	rs73136346	ENSG00000226824.5	RP4-756H11.3	5.03	1.02e-06	0.000731	0.38	0.32	Aortic root size;	chr7:66101095	chr7:66654538~66669855:+
OV	cis	rs4908768	0.579	rs11121237	ENSG00000228423.2	RP4-633I8.4	5.03	1.02e-06	0.000731	0.36	0.32	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8816333	chr1:8805860~8807051:-
OV	cis	rs7116641	0.737	rs10838162	ENSG00000246250.2	RP11-613D13.5	-5.03	1.02e-06	0.000731	-0.38	-0.32	Coronary artery disease;	chr11:43767672	chr11:43829709~43880726:-
OV	cis	rs7829975	0.659	rs4382480	ENSG00000173295.6	FAM86B3P	5.03	1.02e-06	0.000731	0.31	0.32	Mood instability;	chr8:8863963	chr8:8228595~8244865:+
OV	cis	rs34779708	0.931	rs6481935	ENSG00000230534.5	RP11-297A16.2	5.03	1.02e-06	0.000731	0.41	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35054031	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs2384289	ENSG00000230534.5	RP11-297A16.2	5.03	1.02e-06	0.000731	0.41	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35054597	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs12242882	ENSG00000230534.5	RP11-297A16.2	5.03	1.02e-06	0.000731	0.41	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35058932	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs11010082	ENSG00000230534.5	RP11-297A16.2	5.03	1.02e-06	0.000731	0.41	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35062227	chr10:35098006~35127020:-
OV	cis	rs9813712	0.597	rs1453255	ENSG00000253540.4	FAM86HP	-5.02	1.02e-06	0.000733	-0.33	-0.32	Response to amphetamines;	chr3:130258815	chr3:130099092~130111472:-
OV	cis	rs796364	0.906	rs281766	ENSG00000232732.8	AC073043.1	-5.02	1.02e-06	0.000734	-0.47	-0.32	Schizophrenia;	chr2:199955782	chr2:199867396~199911159:-
OV	cis	rs796364	1	rs166845	ENSG00000232732.8	AC073043.1	-5.02	1.02e-06	0.000734	-0.47	-0.32	Schizophrenia;	chr2:199958637	chr2:199867396~199911159:-
OV	cis	rs1790761	0.692	rs1148883	ENSG00000184224.3	C11orf72	5.02	1.02e-06	0.000734	0.36	0.32	Mean corpuscular volume;	chr11:67537215	chr11:67602880~67606706:-
OV	cis	rs9291683	0.62	rs11722946	ENSG00000250413.1	RP11-448G15.1	5.02	1.02e-06	0.000735	0.35	0.32	Bone mineral density;	chr4:10124366	chr4:10006482~10009725:+
OV	cis	rs13178541	0.81	rs878068	ENSG00000250378.1	RP11-119J18.1	5.02	1.02e-06	0.000736	0.46	0.32	IgG glycosylation;	chr5:135826667	chr5:135812667~135826582:+
OV	cis	rs1075265	0.704	rs9631059	ENSG00000233266.1	HMGB1P31	5.02	1.03e-06	0.000737	0.39	0.32	Chronotype;Morning vs. evening chronotype;	chr2:54015160	chr2:54051334~54051760:+
OV	cis	rs11671005	0.656	rs73066228	ENSG00000269600.1	AC016629.3	-5.02	1.03e-06	0.000737	-0.48	-0.32	Mean platelet volume;	chr19:58501829	chr19:58593896~58599355:-
OV	cis	rs4713118	0.868	rs35069907	ENSG00000280107.1	AL022393.9	-5.02	1.03e-06	0.000738	-0.4	-0.32	Parkinson's disease;	chr6:27778913	chr6:28170845~28172521:+
OV	cis	rs17301013	0.606	rs3086	ENSG00000227373.4	RP11-160H22.5	5.02	1.03e-06	0.000738	0.41	0.32	Systemic lupus erythematosus;	chr1:174167236	chr1:174115300~174160004:-
OV	cis	rs7116641	0.734	rs10768983	ENSG00000246250.2	RP11-613D13.5	5.02	1.03e-06	0.000739	0.36	0.32	Coronary artery disease;	chr11:43818385	chr11:43829709~43880726:-
OV	cis	rs34779708	0.966	rs12761675	ENSG00000230534.5	RP11-297A16.2	-5.02	1.03e-06	0.000739	-0.42	-0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35149409	chr10:35098006~35127020:-
OV	cis	rs1185460	0.565	rs538478	ENSG00000271751.1	RP11-110I1.14	5.02	1.03e-06	0.00074	0.38	0.32	Coronary artery disease;	chr11:119054629	chr11:119065263~119065677:-
OV	cis	rs6460942	0.511	rs10251790	ENSG00000226690.5	AC005281.1	5.02	1.03e-06	0.00074	0.57	0.32	Coronary artery disease;	chr7:12058075	chr7:12496429~12541910:+
OV	cis	rs6460942	0.511	rs10236264	ENSG00000226690.5	AC005281.1	5.02	1.03e-06	0.00074	0.57	0.32	Coronary artery disease;	chr7:12058138	chr7:12496429~12541910:+
OV	cis	rs301901	0.793	rs11750212	ENSG00000250155.1	CTD-2353F22.1	5.02	1.03e-06	0.00074	0.37	0.32	Height;	chr5:37463644	chr5:36666214~36725195:-
OV	cis	rs2921073	0.509	rs2976931	ENSG00000253981.4	ALG1L13P	5.02	1.03e-06	0.000741	0.32	0.32	Parkinson's disease;	chr8:8399807	chr8:8236003~8244667:-
OV	cis	rs2153535	0.585	rs1885203	ENSG00000230939.1	RP11-314C16.1	-5.02	1.03e-06	0.000742	-0.34	-0.32	Motion sickness;	chr6:8633646	chr6:8784178~8785445:+
OV	cis	rs2153535	0.537	rs9379232	ENSG00000230939.1	RP11-314C16.1	-5.02	1.03e-06	0.000742	-0.34	-0.32	Motion sickness;	chr6:8634176	chr6:8784178~8785445:+
OV	cis	rs796364	0.906	rs1658810	ENSG00000232732.8	AC073043.1	-5.02	1.03e-06	0.000742	-0.47	-0.32	Schizophrenia;	chr2:199951659	chr2:199867396~199911159:-
OV	cis	rs17301013	0.507	rs72717617	ENSG00000227373.4	RP11-160H22.5	5.02	1.04e-06	0.000743	0.42	0.32	Systemic lupus erythematosus;	chr1:174815514	chr1:174115300~174160004:-
OV	cis	rs6088580	0.66	rs6059893	ENSG00000206582.1	Y_RNA	-5.02	1.04e-06	0.000743	-0.37	-0.32	Glomerular filtration rate (creatinine);	chr20:34518092	chr20:34526510~34526606:-
OV	cis	rs7829975	0.514	rs2979151	ENSG00000253893.2	FAM85B	5.02	1.04e-06	0.000743	0.33	0.32	Mood instability;	chr8:8400509	chr8:8167819~8226614:-
OV	cis	rs7811142	0.72	rs112622797	ENSG00000242294.5	STAG3L5P	5.02	1.04e-06	0.000744	0.35	0.32	Platelet count;	chr7:100319793	chr7:100336079~100351900:+
OV	cis	rs796364	0.951	rs7608668	ENSG00000232732.8	AC073043.1	5.02	1.04e-06	0.000744	0.41	0.32	Schizophrenia;	chr2:200135294	chr2:199867396~199911159:-
OV	cis	rs10246939	0.543	rs9640358	ENSG00000228775.6	WEE2-AS1	5.02	1.04e-06	0.000745	0.32	0.32	Bitter taste perception;	chr7:141844082	chr7:141704338~141738346:-
OV	cis	rs10510102	0.516	rs11200306	ENSG00000276742.1	RP11-500G22.4	5.02	1.04e-06	0.000746	0.54	0.32	Breast cancer;	chr10:121980862	chr10:121956782~121957098:+
OV	cis	rs796364	1	rs281759	ENSG00000232732.8	AC073043.1	-5.02	1.04e-06	0.000747	-0.46	-0.32	Schizophrenia;	chr2:199922996	chr2:199867396~199911159:-
OV	cis	rs796364	1	rs281760	ENSG00000232732.8	AC073043.1	-5.02	1.04e-06	0.000747	-0.46	-0.32	Schizophrenia;	chr2:199923081	chr2:199867396~199911159:-
OV	cis	rs796364	1	rs281762	ENSG00000232732.8	AC073043.1	-5.02	1.04e-06	0.000747	-0.46	-0.32	Schizophrenia;	chr2:199934478	chr2:199867396~199911159:-
OV	cis	rs796364	0.951	rs281769	ENSG00000232732.8	AC073043.1	-5.02	1.04e-06	0.000747	-0.46	-0.32	Schizophrenia;	chr2:199944986	chr2:199867396~199911159:-
OV	cis	rs796364	1	rs281774	ENSG00000232732.8	AC073043.1	-5.02	1.04e-06	0.000747	-0.46	-0.32	Schizophrenia;	chr2:199949849	chr2:199867396~199911159:-
OV	cis	rs796364	0.789	rs176008	ENSG00000232732.8	AC073043.1	-5.02	1.04e-06	0.000747	-0.46	-0.32	Schizophrenia;	chr2:199949997	chr2:199867396~199911159:-
OV	cis	rs9660180	0.846	rs10907195	ENSG00000231050.1	RP1-140A9.1	-5.02	1.04e-06	0.000748	-0.34	-0.32	Body mass index;	chr1:1781909	chr1:1891471~1892658:+
OV	cis	rs6088580	0.609	rs6059845	ENSG00000206582.1	Y_RNA	-5.02	1.04e-06	0.000748	-0.37	-0.32	Glomerular filtration rate (creatinine);	chr20:34448695	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6059851	ENSG00000206582.1	Y_RNA	-5.02	1.04e-06	0.000748	-0.37	-0.32	Glomerular filtration rate (creatinine);	chr20:34460140	chr20:34526510~34526606:-
OV	cis	rs10510102	0.566	rs885543	ENSG00000226864.1	ATE1-AS1	5.02	1.05e-06	0.000749	0.58	0.32	Breast cancer;	chr10:121973536	chr10:121928312~121951965:+
OV	cis	rs17711722	0.523	rs313812	ENSG00000224316.1	RP11-479O9.2	-5.02	1.05e-06	0.000749	-0.36	-0.32	Calcium levels;	chr7:66040056	chr7:65773620~65802067:+
OV	cis	rs67311347	1	rs7625736	ENSG00000223797.4	ENTPD3-AS1	-5.02	1.05e-06	0.00075	-0.34	-0.32	Renal cell carcinoma;	chr3:40399854	chr3:40313802~40453329:-
OV	cis	rs6088580	0.634	rs6059868	ENSG00000206582.1	Y_RNA	-5.02	1.05e-06	0.000751	-0.37	-0.32	Glomerular filtration rate (creatinine);	chr20:34491655	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6059890	ENSG00000206582.1	Y_RNA	-5.02	1.05e-06	0.000751	-0.37	-0.32	Glomerular filtration rate (creatinine);	chr20:34513848	chr20:34526510~34526606:-
OV	cis	rs6088580	0.66	rs6087592	ENSG00000206582.1	Y_RNA	-5.02	1.05e-06	0.000751	-0.37	-0.32	Glomerular filtration rate (creatinine);	chr20:34526698	chr20:34526510~34526606:-
OV	cis	rs11157436	0.958	rs12432733	ENSG00000211812.1	TRAV26-2	-5.02	1.05e-06	0.000753	-0.38	-0.32	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22230741	chr14:22202583~22203368:+
OV	cis	rs7771547	0.573	rs546353	ENSG00000240733.3	RN7SL502P	5.02	1.05e-06	0.000753	0.34	0.32	Platelet distribution width;	chr6:36430820	chr6:36450912~36451201:-
OV	cis	rs7771547	0.573	rs10440841	ENSG00000240733.3	RN7SL502P	-5.02	1.05e-06	0.000753	-0.34	-0.32	Platelet distribution width;	chr6:36431309	chr6:36450912~36451201:-
OV	cis	rs7771547	0.573	rs9470278	ENSG00000240733.3	RN7SL502P	-5.02	1.05e-06	0.000753	-0.34	-0.32	Platelet distribution width;	chr6:36431462	chr6:36450912~36451201:-
OV	cis	rs2153535	0.585	rs9393050	ENSG00000230939.1	RP11-314C16.1	-5.02	1.05e-06	0.000754	-0.34	-0.32	Motion sickness;	chr6:8635219	chr6:8784178~8785445:+
OV	cis	rs9660180	0.934	rs12729990	ENSG00000268575.1	RP1-283E3.8	-5.02	1.06e-06	0.000755	-0.3	-0.32	Body mass index;	chr1:1880596	chr1:1702736~1737688:-
OV	cis	rs496547	0.686	rs540180	ENSG00000255239.1	AP002954.6	5.02	1.06e-06	0.000756	0.36	0.32	Hip minimal joint space width;	chr11:118782920	chr11:118688039~118690600:-
OV	cis	rs172166	0.694	rs1150666	ENSG00000219392.1	RP1-265C24.5	-5.02	1.06e-06	0.000756	-0.37	-0.32	Cardiac Troponin-T levels;	chr6:28156150	chr6:28115628~28116551:+
OV	cis	rs7580658	0.864	rs4150454	ENSG00000236682.1	AC068282.3	-5.02	1.06e-06	0.000757	-0.4	-0.32	Protein C levels;	chr2:127280968	chr2:127389130~127400580:+
OV	cis	rs853679	0.55	rs1150689	ENSG00000280107.1	AL022393.9	-5.02	1.06e-06	0.000758	-0.41	-0.32	Depression;	chr6:28197321	chr6:28170845~28172521:+
OV	cis	rs853679	0.55	rs1225599	ENSG00000280107.1	AL022393.9	-5.02	1.06e-06	0.000758	-0.41	-0.32	Depression;	chr6:28197412	chr6:28170845~28172521:+
OV	cis	rs853679	0.574	rs1233705	ENSG00000280107.1	AL022393.9	-5.02	1.06e-06	0.000758	-0.41	-0.32	Depression;	chr6:28198669	chr6:28170845~28172521:+
OV	cis	rs6991838	0.798	rs62507575	ENSG00000200714.1	Y_RNA	5.02	1.06e-06	0.000759	0.4	0.32	Intelligence (multi-trait analysis);	chr8:65566486	chr8:65592731~65592820:+
OV	cis	rs301901	0.531	rs292171	ENSG00000250155.1	CTD-2353F22.1	-5.02	1.07e-06	0.000762	-0.36	-0.32	Height;	chr5:36816591	chr5:36666214~36725195:-
OV	cis	rs6088580	0.634	rs6087579	ENSG00000206582.1	Y_RNA	5.02	1.07e-06	0.000762	0.38	0.32	Glomerular filtration rate (creatinine);	chr20:34397349	chr20:34526510~34526606:-
OV	cis	rs2999052	0.602	rs7373685	ENSG00000242551.2	POU5F1P6	-5.02	1.07e-06	0.000764	-0.43	-0.32	Hypospadias;	chr3:128388177	chr3:128674735~128677005:-
OV	cis	rs6991838	0.584	rs4275254	ENSG00000200714.1	Y_RNA	-5.01	1.07e-06	0.000765	-0.4	-0.32	Intelligence (multi-trait analysis);	chr8:65589129	chr8:65592731~65592820:+
OV	cis	rs1075265	0.87	rs7569214	ENSG00000233266.1	HMGB1P31	5.01	1.07e-06	0.000765	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53989049	chr2:54051334~54051760:+
OV	cis	rs1075265	0.729	rs10201364	ENSG00000233266.1	HMGB1P31	5.01	1.07e-06	0.000765	0.38	0.32	Chronotype;Morning vs. evening chronotype;	chr2:53990220	chr2:54051334~54051760:+
OV	cis	rs6772849	0.93	rs12630379	ENSG00000242551.2	POU5F1P6	-5.01	1.07e-06	0.000765	-0.36	-0.32	Monocyte percentage of white cells;Monocyte count;	chr3:128651361	chr3:128674735~128677005:-
OV	cis	rs1150668	0.835	rs203869	ENSG00000220721.1	OR1F12	5.01	1.07e-06	0.000767	0.31	0.32	Pubertal anthropometrics;	chr6:28073041	chr6:28073316~28074233:+
OV	cis	rs172166	0.56	rs203878	ENSG00000220721.1	OR1F12	5.01	1.07e-06	0.000767	0.31	0.32	Cardiac Troponin-T levels;	chr6:28081218	chr6:28073316~28074233:+
OV	cis	rs7116641	0.734	rs2037297	ENSG00000246250.2	RP11-613D13.5	-5.01	1.08e-06	0.000768	-0.36	-0.32	Coronary artery disease;	chr11:43825155	chr11:43829709~43880726:-
OV	cis	rs858239	0.601	rs6948469	ENSG00000230042.1	AK3P3	-5.01	1.08e-06	0.000769	-0.32	-0.32	Cerebrospinal fluid biomarker levels;	chr7:23135147	chr7:23129178~23129841:+
OV	cis	rs34779708	0.931	rs12248333	ENSG00000230534.5	RP11-297A16.2	5.01	1.08e-06	0.000769	0.41	0.32	Inflammatory bowel disease;Crohn's disease;	chr10:35074049	chr10:35098006~35127020:-
OV	cis	rs11673344	0.528	rs573294	ENSG00000226686.6	LINC01535	5.01	1.08e-06	0.000769	0.38	0.32	Obesity-related traits;	chr19:36919260	chr19:37251912~37265535:+
OV	cis	rs11673344	0.528	rs476194	ENSG00000226686.6	LINC01535	5.01	1.08e-06	0.000769	0.38	0.32	Obesity-related traits;	chr19:36919831	chr19:37251912~37265535:+
OV	cis	rs11673344	0.528	rs579452	ENSG00000226686.6	LINC01535	5.01	1.08e-06	0.000769	0.38	0.32	Obesity-related traits;	chr19:36919936	chr19:37251912~37265535:+
OV	cis	rs11673344	0.528	rs491326	ENSG00000226686.6	LINC01535	5.01	1.08e-06	0.000769	0.38	0.32	Obesity-related traits;	chr19:36920037	chr19:37251912~37265535:+
OV	cis	rs11673344	0.528	rs563786	ENSG00000226686.6	LINC01535	5.01	1.08e-06	0.000769	0.38	0.32	Obesity-related traits;	chr19:36922012	chr19:37251912~37265535:+
OV	cis	rs4964805	0.505	rs15918	ENSG00000257681.1	RP11-341G23.4	5.01	1.08e-06	0.00077	0.35	0.32	Attention deficit hyperactivity disorder;	chr12:103773246	chr12:103746315~103768858:-
OV	cis	rs7428	0.502	rs3184781	ENSG00000246575.2	AC093162.5	5.01	1.08e-06	0.000771	0.31	0.32	Ear protrusion;	chr2:85322404	chr2:85315041~85316529:+
OV	cis	rs7428	0.527	rs3184780	ENSG00000246575.2	AC093162.5	5.01	1.08e-06	0.000771	0.31	0.32	Ear protrusion;	chr2:85322424	chr2:85315041~85316529:+
OV	cis	rs7428	0.545	rs2366404	ENSG00000246575.2	AC093162.5	5.01	1.08e-06	0.000771	0.31	0.32	Ear protrusion;	chr2:85324656	chr2:85315041~85316529:+
OV	cis	rs611744	0.647	rs689275	ENSG00000253754.1	RP11-35G22.1	-5.01	1.08e-06	0.000771	-0.35	-0.32	Dupuytren's disease;	chr8:108229593	chr8:108226200~108227544:+
OV	cis	rs1729407	0.741	rs1263177	ENSG00000254851.1	RP11-109L13.1	-5.01	1.08e-06	0.000771	-0.4	-0.32	Apolipoprotein A-IV levels;	chr11:116819996	chr11:117135528~117138582:+
OV	cis	rs496547	0.721	rs2508570	ENSG00000278376.1	RP11-158I9.8	-5.01	1.08e-06	0.000772	-0.31	-0.32	Hip minimal joint space width;	chr11:118807900	chr11:118791254~118793137:+
OV	cis	rs496547	0.686	rs591756	ENSG00000278376.1	RP11-158I9.8	-5.01	1.08e-06	0.000772	-0.31	-0.32	Hip minimal joint space width;	chr11:118808172	chr11:118791254~118793137:+
OV	cis	rs496547	0.756	rs562059	ENSG00000255239.1	AP002954.6	5.01	1.08e-06	0.000773	0.38	0.32	Hip minimal joint space width;	chr11:118731349	chr11:118688039~118690600:-
OV	cis	rs1113500	0.966	rs11185249	ENSG00000226822.1	RP11-356N1.2	5.01	1.09e-06	0.000775	0.37	0.32	Growth-regulated protein alpha levels;	chr1:108069024	chr1:108071482~108074519:+
OV	cis	rs172166	0.694	rs9295760	ENSG00000219392.1	RP1-265C24.5	-5.01	1.09e-06	0.000777	-0.37	-0.32	Cardiac Troponin-T levels;	chr6:28179607	chr6:28115628~28116551:+
OV	cis	rs4713118	0.513	rs1225591	ENSG00000219392.1	RP1-265C24.5	-5.01	1.09e-06	0.000777	-0.37	-0.32	Parkinson's disease;	chr6:28180974	chr6:28115628~28116551:+
OV	cis	rs1061377	0.748	rs13117988	ENSG00000249207.1	RP11-360F5.1	-5.01	1.09e-06	0.000778	-0.33	-0.32	Uric acid levels;	chr4:39092219	chr4:39112677~39126818:-
OV	cis	rs4964805	0.586	rs934846	ENSG00000257681.1	RP11-341G23.4	5.01	1.09e-06	0.000779	0.34	0.32	Attention deficit hyperactivity disorder;	chr12:103791519	chr12:103746315~103768858:-
OV	cis	rs116095464	0.614	rs62344339	ENSG00000250848.1	CTD-2083E4.5	-5.01	1.09e-06	0.000779	-0.39	-0.32	Breast cancer;	chr5:252880	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs9687898	ENSG00000250848.1	CTD-2083E4.5	-5.01	1.09e-06	0.000779	-0.39	-0.32	Breast cancer;	chr5:253837	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs9688045	ENSG00000250848.1	CTD-2083E4.5	-5.01	1.09e-06	0.000779	-0.39	-0.32	Breast cancer;	chr5:253920	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs112343653	ENSG00000250848.1	CTD-2083E4.5	-5.01	1.09e-06	0.000779	-0.39	-0.32	Breast cancer;	chr5:257059	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs73024831	ENSG00000250848.1	CTD-2083E4.5	-5.01	1.09e-06	0.000779	-0.39	-0.32	Breast cancer;	chr5:257077	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs62344345	ENSG00000250848.1	CTD-2083E4.5	-5.01	1.09e-06	0.000779	-0.39	-0.32	Breast cancer;	chr5:257305	chr5:288833~290321:-
OV	cis	rs13178541	0.81	rs4327594	ENSG00000250378.1	RP11-119J18.1	-5.01	1.1e-06	0.000781	-0.48	-0.32	IgG glycosylation;	chr5:135774638	chr5:135812667~135826582:+
OV	cis	rs8062405	0.723	rs4788079	ENSG00000278665.1	RP11-666O2.4	5.01	1.1e-06	0.000781	0.34	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548042	chr16:28599241~28601881:-
OV	cis	rs8062405	0.755	rs55792032	ENSG00000278665.1	RP11-666O2.4	5.01	1.1e-06	0.000781	0.33	0.32	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28588090	chr16:28599241~28601881:-
OV	cis	rs514406	0.763	rs7535088	ENSG00000206627.1	RNU6-969P	-5.01	1.1e-06	0.000781	-0.34	-0.32	Monocyte count;	chr1:52749370	chr1:52805108~52805212:-
OV	cis	rs11673344	0.832	rs8104296	ENSG00000226686.6	LINC01535	5.01	1.1e-06	0.000784	0.41	0.32	Obesity-related traits;	chr19:37025634	chr19:37251912~37265535:+
OV	cis	rs10992471	0.756	rs10992319	ENSG00000281156.1	MIR3651	-5.01	1.1e-06	0.000784	-0.35	-0.32	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92365613	chr9:92292458~92292547:-
OV	cis	rs1113500	1	rs1113500	ENSG00000226822.1	RP11-356N1.2	-5.01	1.1e-06	0.000786	-0.38	-0.32	Growth-regulated protein alpha levels;	chr1:108052820	chr1:108071482~108074519:+
OV	cis	rs7017914	0.69	rs13263370	ENSG00000223220.1	Y_RNA	5.01	1.11e-06	0.000786	0.37	0.32	Bone mineral density;	chr8:71057299	chr8:70780914~70781008:-
OV	cis	rs4713118	0.513	rs149944	ENSG00000219392.1	RP1-265C24.5	-5.01	1.11e-06	0.000787	-0.38	-0.32	Parkinson's disease;	chr6:28035040	chr6:28115628~28116551:+
OV	cis	rs17023223	0.581	rs11811859	ENSG00000231365.4	RP11-418J17.1	-5.01	1.11e-06	0.000788	-0.41	-0.32	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165057	chr1:119140396~119275973:+
OV	cis	rs12594515	1	rs12595137	ENSG00000273972.1	CTD-2306A12.1	-5.01	1.11e-06	0.000788	-0.33	-0.32	Weight;Waist circumference;	chr15:45693907	chr15:45702640~45703183:+
OV	cis	rs12594515	0.967	rs12595138	ENSG00000273972.1	CTD-2306A12.1	-5.01	1.11e-06	0.000788	-0.33	-0.32	Weight;Waist circumference;	chr15:45693910	chr15:45702640~45703183:+
OV	cis	rs6991838	0.765	rs4424306	ENSG00000200714.1	Y_RNA	5.01	1.11e-06	0.000788	0.4	0.32	Intelligence (multi-trait analysis);	chr8:65618674	chr8:65592731~65592820:+
OV	cis	rs11673344	0.966	rs56330606	ENSG00000226686.6	LINC01535	5.01	1.11e-06	0.00079	0.4	0.32	Obesity-related traits;	chr19:37183051	chr19:37251912~37265535:+
OV	cis	rs12594515	1	rs12906442	ENSG00000273972.1	CTD-2306A12.1	-5.01	1.11e-06	0.00079	-0.33	-0.32	Weight;Waist circumference;	chr15:45693056	chr15:45702640~45703183:+
OV	cis	rs12594515	1	rs12911309	ENSG00000273972.1	CTD-2306A12.1	-5.01	1.11e-06	0.00079	-0.33	-0.32	Weight;Waist circumference;	chr15:45693521	chr15:45702640~45703183:+
OV	cis	rs2243480	1	rs4149468	ENSG00000226824.5	RP4-756H11.3	-5.01	1.12e-06	0.000793	-0.49	-0.32	Diabetic kidney disease;	chr7:66360703	chr7:66654538~66669855:+
OV	cis	rs607987	0.871	rs35665615	ENSG00000254532.1	RP11-624D11.2	-5.01	1.12e-06	0.000793	-0.37	-0.32	Body mass index;	chr11:30290972	chr11:30044058~30084343:-
OV	cis	rs607987	0.871	rs12805098	ENSG00000254532.1	RP11-624D11.2	-5.01	1.12e-06	0.000793	-0.37	-0.32	Body mass index;	chr11:30291196	chr11:30044058~30084343:-
OV	cis	rs607987	0.871	rs11031041	ENSG00000254532.1	RP11-624D11.2	-5.01	1.12e-06	0.000793	-0.37	-0.32	Body mass index;	chr11:30297173	chr11:30044058~30084343:-
OV	cis	rs607987	0.871	rs61626579	ENSG00000254532.1	RP11-624D11.2	-5.01	1.12e-06	0.000793	-0.37	-0.32	Body mass index;	chr11:30297885	chr11:30044058~30084343:-
OV	cis	rs607987	0.836	rs12361937	ENSG00000254532.1	RP11-624D11.2	-5.01	1.12e-06	0.000793	-0.37	-0.32	Body mass index;	chr11:30305615	chr11:30044058~30084343:-
OV	cis	rs7267979	0.866	rs2424699	ENSG00000274973.1	RP13-401N8.7	-5.01	1.12e-06	0.000794	-0.37	-0.32	Liver enzyme levels (alkaline phosphatase);	chr20:25276826	chr20:25845497~25845862:+
OV	cis	rs301901	0.965	rs2886201	ENSG00000250155.1	CTD-2353F22.1	-5.01	1.12e-06	0.000794	-0.37	-0.32	Height;	chr5:36796728	chr5:36666214~36725195:-
OV	cis	rs12594515	1	rs58368732	ENSG00000273972.1	CTD-2306A12.1	-5.01	1.12e-06	0.000795	-0.33	-0.32	Weight;Waist circumference;	chr15:45698333	chr15:45702640~45703183:+
OV	cis	rs13178541	0.511	rs28373574	ENSG00000250378.1	RP11-119J18.1	-5	1.12e-06	0.000795	-0.45	-0.32	IgG glycosylation;	chr5:135789626	chr5:135812667~135826582:+
OV	cis	rs9291683	0.597	rs11723016	ENSG00000250413.1	RP11-448G15.1	5	1.12e-06	0.000796	0.35	0.32	Bone mineral density;	chr4:10124565	chr4:10006482~10009725:+
OV	cis	rs10916248	0.55	rs7544572	ENSG00000232628.4	RP11-365O16.3	-5	1.12e-06	0.000796	-0.38	-0.32	QT interval (drug interaction);	chr1:224077515	chr1:224208747~224213279:-
OV	cis	rs56114371	0.777	rs200483	ENSG00000220721.1	OR1F12	5	1.12e-06	0.000797	0.51	0.32	Breast cancer;	chr6:27807046	chr6:28073316~28074233:+
OV	cis	rs1979679	0.842	rs1841964	ENSG00000278733.1	RP11-425D17.1	-5	1.13e-06	0.000799	-0.36	-0.32	Ossification of the posterior longitudinal ligament of the spine;	chr12:28190100	chr12:28185625~28186190:-
OV	cis	rs7617773	0.851	rs13068288	ENSG00000228638.1	FCF1P2	-5	1.13e-06	0.000799	-0.4	-0.32	Coronary artery disease;	chr3:48290261	chr3:48290793~48291375:-
OV	cis	rs4243830	0.85	rs10746502	ENSG00000229519.2	RP11-58A11.2	5	1.13e-06	0.000799	0.4	0.32	Body mass index;	chr1:6547139	chr1:6547905~6548619:+
OV	cis	rs3758911	0.894	rs6588964	ENSG00000261098.1	RP11-819C21.1	-5	1.13e-06	8e-04	-0.3	-0.32	Coronary artery disease;	chr11:107330725	chr11:107312132~107316271:-
OV	cis	rs465969	0.744	rs3851228	ENSG00000255389.1	C6orf3	5	1.13e-06	8e-04	0.51	0.32	Psoriasis;	chr6:111526988	chr6:111599875~111602295:+
OV	cis	rs6471393	0.964	rs2914940	ENSG00000253848.1	RP11-10N23.5	5	1.13e-06	0.000802	0.38	0.32	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93719598	chr8:93741193~93744534:+
OV	cis	rs4763879	0.778	rs1044771	ENSG00000278635.1	CTD-2318O12.1	5	1.13e-06	0.000803	0.27	0.32	Type 1 diabetes;	chr12:9699333	chr12:9415641~9416718:+
OV	cis	rs494459	0.536	rs11217063	ENSG00000255239.1	AP002954.6	5	1.13e-06	0.000803	0.38	0.32	Height;	chr11:118855233	chr11:118688039~118690600:-
OV	cis	rs796364	1	rs4410273	ENSG00000232732.8	AC073043.1	-5	1.13e-06	0.000803	-0.47	-0.32	Schizophrenia;	chr2:199953535	chr2:199867396~199911159:-
OV	cis	rs2188561	0.697	rs7787927	ENSG00000241764.3	AC002467.7	5	1.14e-06	0.000806	0.36	0.32	Alcohol consumption;	chr7:107763915	chr7:107742817~107744581:-
OV	cis	rs1150668	0.796	rs2531825	ENSG00000220721.1	OR1F12	5	1.14e-06	0.000808	0.32	0.32	Pubertal anthropometrics;	chr6:28381487	chr6:28073316~28074233:+
OV	cis	rs2153535	0.584	rs55945625	ENSG00000230939.1	RP11-314C16.1	5	1.14e-06	0.00081	0.36	0.31	Motion sickness;	chr6:8371134	chr6:8784178~8785445:+
OV	cis	rs2153535	0.584	rs62395677	ENSG00000230939.1	RP11-314C16.1	5	1.14e-06	0.00081	0.36	0.31	Motion sickness;	chr6:8371356	chr6:8784178~8785445:+
OV	cis	rs2153535	0.584	rs62395678	ENSG00000230939.1	RP11-314C16.1	5	1.14e-06	0.00081	0.36	0.31	Motion sickness;	chr6:8371456	chr6:8784178~8785445:+
OV	cis	rs507080	0.501	rs625735	ENSG00000278376.1	RP11-158I9.8	-5	1.14e-06	0.00081	-0.31	-0.31	Serum metabolite levels;	chr11:118704710	chr11:118791254~118793137:+
OV	cis	rs6772849	0.93	rs4467479	ENSG00000242551.2	POU5F1P6	-5	1.14e-06	0.00081	-0.36	-0.31	Monocyte percentage of white cells;Monocyte count;	chr3:128650212	chr3:128674735~128677005:-
OV	cis	rs34779708	0.966	rs35814343	ENSG00000230534.5	RP11-297A16.2	5	1.15e-06	0.000812	0.41	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35138786	chr10:35098006~35127020:-
OV	cis	rs3091242	0.9	rs669063	ENSG00000224183.1	SDHDP6	-5	1.15e-06	0.000812	-0.38	-0.31	Erythrocyte sedimentation rate;	chr1:25394663	chr1:25294164~25294643:-
OV	cis	rs8062405	0.755	rs17640009	ENSG00000278665.1	RP11-666O2.4	5	1.15e-06	0.000812	0.33	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28584379	chr16:28599241~28601881:-
OV	cis	rs1150668	0.745	rs213238	ENSG00000204709.4	LINC01556	5	1.15e-06	0.000812	0.38	0.31	Pubertal anthropometrics;	chr6:28354216	chr6:28943877~28944537:+
OV	cis	rs8113142	0.614	rs4805257	ENSG00000267243.4	AC005307.3	5	1.15e-06	0.000813	0.49	0.31	Femoral neck bone geometry and menarche (age at onset);	chr19:28639558	chr19:28435388~28727777:-
OV	cis	rs7587476	0.822	rs6726763	ENSG00000229267.2	AC072062.1	-5	1.15e-06	0.000813	-0.42	-0.31	Neuroblastoma;	chr2:214816856	chr2:214810229~214963274:+
OV	cis	rs2286503	1	rs1029740	ENSG00000221740.1	SNORD93	5	1.15e-06	0.000813	0.37	0.31	Fibrinogen;	chr7:22833967	chr7:22856613~22856686:+
OV	cis	rs8062405	0.755	rs4788073	ENSG00000278665.1	RP11-666O2.4	5	1.15e-06	0.000814	0.33	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28583228	chr16:28599241~28601881:-
OV	cis	rs27434	0.51	rs27038	ENSG00000272109.1	CTD-2260A17.3	-5	1.15e-06	0.000814	-0.5	-0.31	Ankylosing spondylitis;	chr5:96777250	chr5:96804353~96806105:+
OV	cis	rs4713118	0.696	rs2394002	ENSG00000219392.1	RP1-265C24.5	-5	1.15e-06	0.000815	-0.37	-0.31	Parkinson's disease;	chr6:27780236	chr6:28115628~28116551:+
OV	cis	rs853679	0.546	rs200995	ENSG00000220721.1	OR1F12	-5	1.15e-06	0.000815	-0.5	-0.31	Depression;	chr6:27845916	chr6:28073316~28074233:+
OV	cis	rs858239	0.601	rs11982002	ENSG00000230042.1	AK3P3	-5	1.15e-06	0.000815	-0.33	-0.31	Cerebrospinal fluid biomarker levels;	chr7:23123651	chr7:23129178~23129841:+
OV	cis	rs17301013	0.507	rs72715237	ENSG00000227373.4	RP11-160H22.5	5	1.16e-06	0.000816	0.42	0.31	Systemic lupus erythematosus;	chr1:174550527	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs16847335	ENSG00000227373.4	RP11-160H22.5	5	1.16e-06	0.000816	0.42	0.31	Systemic lupus erythematosus;	chr1:174682746	chr1:174115300~174160004:-
OV	cis	rs1075265	0.729	rs7571086	ENSG00000233266.1	HMGB1P31	5	1.16e-06	0.00082	0.38	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54007899	chr2:54051334~54051760:+
OV	cis	rs73019876	0.502	rs7258080	ENSG00000269742.1	BNIP3P29	5	1.16e-06	0.00082	0.37	0.31	Testicular germ cell tumor;	chr19:22074823	chr19:22065828~22066398:-
OV	cis	rs73019876	0.502	rs10403779	ENSG00000269742.1	BNIP3P29	5	1.16e-06	0.00082	0.37	0.31	Testicular germ cell tumor;	chr19:22075594	chr19:22065828~22066398:-
OV	cis	rs4713118	0.824	rs9468225	ENSG00000280107.1	AL022393.9	-5	1.16e-06	0.00082	-0.37	-0.31	Parkinson's disease;	chr6:27777940	chr6:28170845~28172521:+
OV	cis	rs7587476	0.784	rs13032278	ENSG00000229267.2	AC072062.1	-5	1.16e-06	0.00082	-0.42	-0.31	Neuroblastoma;	chr2:214833310	chr2:214810229~214963274:+
OV	cis	rs611744	0.573	rs629996	ENSG00000253754.1	RP11-35G22.1	-5	1.16e-06	0.000822	-0.36	-0.31	Dupuytren's disease;	chr8:108242977	chr8:108226200~108227544:+
OV	cis	rs1891275	0.515	rs1361552	ENSG00000228701.1	TNKS2-AS1	-5	1.17e-06	0.000825	-0.34	-0.31	Intelligence (multi-trait analysis);	chr10:91774867	chr10:91782839~91798291:-
OV	cis	rs116095464	0.614	rs4371799	ENSG00000250848.1	CTD-2083E4.5	-5	1.17e-06	0.000825	-0.39	-0.31	Breast cancer;	chr5:268077	chr5:288833~290321:-
OV	cis	rs2098713	0.535	rs1126290	ENSG00000250155.1	CTD-2353F22.1	5	1.17e-06	0.000825	0.37	0.31	Telomere length;	chr5:37588398	chr5:36666214~36725195:-
OV	cis	rs73019876	0.502	rs8107039	ENSG00000269742.1	BNIP3P29	5	1.17e-06	0.000826	0.37	0.31	Testicular germ cell tumor;	chr19:22056188	chr19:22065828~22066398:-
OV	cis	rs73019876	0.502	rs4244913	ENSG00000269742.1	BNIP3P29	5	1.17e-06	0.000826	0.37	0.31	Testicular germ cell tumor;	chr19:22057117	chr19:22065828~22066398:-
OV	cis	rs73019876	0.522	rs2043318	ENSG00000269742.1	BNIP3P29	5	1.17e-06	0.000826	0.37	0.31	Testicular germ cell tumor;	chr19:22058813	chr19:22065828~22066398:-
OV	cis	rs73019876	0.502	rs6511318	ENSG00000269742.1	BNIP3P29	5	1.17e-06	0.000826	0.37	0.31	Testicular germ cell tumor;	chr19:22062943	chr19:22065828~22066398:-
OV	cis	rs73019876	0.502	rs4932953	ENSG00000269742.1	BNIP3P29	5	1.17e-06	0.000826	0.37	0.31	Testicular germ cell tumor;	chr19:22066243	chr19:22065828~22066398:-
OV	cis	rs73019876	0.502	rs7251108	ENSG00000269742.1	BNIP3P29	5	1.17e-06	0.000826	0.37	0.31	Testicular germ cell tumor;	chr19:22067887	chr19:22065828~22066398:-
OV	cis	rs73019876	0.502	rs28881618	ENSG00000269742.1	BNIP3P29	5	1.17e-06	0.000826	0.37	0.31	Testicular germ cell tumor;	chr19:22071890	chr19:22065828~22066398:-
OV	cis	rs73019876	0.502	rs3752163	ENSG00000269742.1	BNIP3P29	5	1.17e-06	0.000826	0.37	0.31	Testicular germ cell tumor;	chr19:22073594	chr19:22065828~22066398:-
OV	cis	rs73019876	0.502	rs7254363	ENSG00000269742.1	BNIP3P29	5	1.17e-06	0.000826	0.37	0.31	Testicular germ cell tumor;	chr19:22074246	chr19:22065828~22066398:-
OV	cis	rs3733585	0.673	rs6840802	ENSG00000250413.1	RP11-448G15.1	-4.99	1.17e-06	0.000827	-0.36	-0.31	Cleft plate (environmental tobacco smoke interaction);	chr4:9964009	chr4:10006482~10009725:+
OV	cis	rs17301013	0.531	rs55688014	ENSG00000227373.4	RP11-160H22.5	4.99	1.18e-06	0.000829	0.42	0.31	Systemic lupus erythematosus;	chr1:174693321	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs55667039	ENSG00000227373.4	RP11-160H22.5	4.99	1.18e-06	0.000829	0.42	0.31	Systemic lupus erythematosus;	chr1:174698699	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs72715281	ENSG00000227373.4	RP11-160H22.5	4.99	1.18e-06	0.000829	0.42	0.31	Systemic lupus erythematosus;	chr1:174711533	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs2861005	ENSG00000227373.4	RP11-160H22.5	4.99	1.18e-06	0.000829	0.42	0.31	Systemic lupus erythematosus;	chr1:174711832	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs72715294	ENSG00000227373.4	RP11-160H22.5	4.99	1.18e-06	0.000829	0.42	0.31	Systemic lupus erythematosus;	chr1:174754922	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs1813136	ENSG00000227373.4	RP11-160H22.5	4.99	1.18e-06	0.000829	0.42	0.31	Systemic lupus erythematosus;	chr1:174756656	chr1:174115300~174160004:-
OV	cis	rs3733585	0.775	rs13124007	ENSG00000250413.1	RP11-448G15.1	-4.99	1.18e-06	0.000829	-0.37	-0.31	Cleft plate (environmental tobacco smoke interaction);	chr4:10042307	chr4:10006482~10009725:+
OV	cis	rs9291683	0.566	rs13144709	ENSG00000250413.1	RP11-448G15.1	-4.99	1.18e-06	0.000829	-0.37	-0.31	Bone mineral density;	chr4:10042558	chr4:10006482~10009725:+
OV	cis	rs9291683	0.546	rs13110307	ENSG00000250413.1	RP11-448G15.1	-4.99	1.18e-06	0.000829	-0.37	-0.31	Bone mineral density;	chr4:10042740	chr4:10006482~10009725:+
OV	cis	rs4380275	0.782	rs4854276	ENSG00000223751.1	AC116609.2	4.99	1.18e-06	0.00083	0.35	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:764357	chr2:742488~747767:+
OV	cis	rs16873450	0.527	rs10234251	ENSG00000234800.2	PCMTD1P3	4.99	1.18e-06	0.000832	0.32	0.31	Verbal memory performance (residualized delayed recall level);	chr7:23741022	chr7:23721311~23721782:-
OV	cis	rs6088580	0.634	rs6087587	ENSG00000206582.1	Y_RNA	-4.99	1.18e-06	0.000832	-0.37	-0.31	Glomerular filtration rate (creatinine);	chr20:34470823	chr20:34526510~34526606:-
OV	cis	rs6088580	0.57	rs6058057	ENSG00000206582.1	Y_RNA	-4.99	1.18e-06	0.000832	-0.37	-0.31	Glomerular filtration rate (creatinine);	chr20:34477478	chr20:34526510~34526606:-
OV	cis	rs6471393	0.895	rs4255106	ENSG00000253848.1	RP11-10N23.5	4.99	1.19e-06	0.000835	0.38	0.31	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93766367	chr8:93741193~93744534:+
OV	cis	rs4061073	1	rs2297026	ENSG00000198711.5	SSBP3-AS1	-4.99	1.19e-06	0.000835	-0.25	-0.31	Body mass index;	chr1:54228541	chr1:54236440~54239063:+
OV	cis	rs7927592	0.913	rs4988291	ENSG00000212093.1	AP000807.1	4.99	1.19e-06	0.000835	0.4	0.31	Total body bone mineral density;	chr11:68614139	chr11:68506083~68506166:-
OV	cis	rs7927592	0.871	rs12941	ENSG00000212093.1	AP000807.1	4.99	1.19e-06	0.000835	0.4	0.31	Total body bone mineral density;	chr11:68614725	chr11:68506083~68506166:-
OV	cis	rs7927592	0.913	rs11228293	ENSG00000212093.1	AP000807.1	4.99	1.19e-06	0.000835	0.4	0.31	Total body bone mineral density;	chr11:68617178	chr11:68506083~68506166:-
OV	cis	rs992157	0.965	rs13427681	ENSG00000237281.1	CATIP-AS2	-4.99	1.19e-06	0.000837	-0.37	-0.31	Colorectal cancer;	chr2:218302840	chr2:218326889~218357966:-
OV	cis	rs8062405	1	rs72793812	ENSG00000278665.1	RP11-666O2.4	4.99	1.19e-06	0.000838	0.34	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28829060	chr16:28599241~28601881:-
OV	cis	rs9291683	0.552	rs17187075	ENSG00000250413.1	RP11-448G15.1	-4.99	1.19e-06	0.000838	-0.36	-0.31	Bone mineral density;	chr4:9988704	chr4:10006482~10009725:+
OV	cis	rs7811142	0.83	rs11765869	ENSG00000242294.5	STAG3L5P	4.99	1.19e-06	0.000839	0.34	0.31	Platelet count;	chr7:100367166	chr7:100336079~100351900:+
OV	cis	rs8062405	1	rs12443881	ENSG00000278665.1	RP11-666O2.4	4.99	1.2e-06	0.000844	0.34	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28830456	chr16:28599241~28601881:-
OV	cis	rs1075265	0.756	rs805423	ENSG00000233266.1	HMGB1P31	4.99	1.2e-06	0.000846	0.39	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53899904	chr2:54051334~54051760:+
OV	cis	rs8005677	0.828	rs712486	ENSG00000279656.1	RP11-298I3.6	4.99	1.2e-06	0.000847	0.36	0.31	Cognitive ability (multi-trait analysis);	chr14:22955832	chr14:23023083~23024217:-
OV	cis	rs1858037	0.867	rs1039765	ENSG00000234255.7	AC012370.3	-4.99	1.21e-06	0.000848	-0.34	-0.31	Rheumatoid arthritis;	chr2:65387228	chr2:65439888~65456571:-
OV	cis	rs7116641	0.734	rs7101808	ENSG00000246250.2	RP11-613D13.5	-4.99	1.21e-06	0.000848	-0.36	-0.31	Coronary artery disease;	chr11:43822029	chr11:43829709~43880726:-
OV	cis	rs7116641	0.734	rs1464229	ENSG00000246250.2	RP11-613D13.5	-4.99	1.21e-06	0.000848	-0.36	-0.31	Coronary artery disease;	chr11:43826788	chr11:43829709~43880726:-
OV	cis	rs7116641	0.734	rs7935296	ENSG00000246250.2	RP11-613D13.5	-4.99	1.21e-06	0.000848	-0.36	-0.31	Coronary artery disease;	chr11:43829924	chr11:43829709~43880726:-
OV	cis	rs7116641	0.7	rs6485470	ENSG00000246250.2	RP11-613D13.5	-4.99	1.21e-06	0.000848	-0.36	-0.31	Coronary artery disease;	chr11:43830253	chr11:43829709~43880726:-
OV	cis	rs7116641	0.734	rs11037663	ENSG00000246250.2	RP11-613D13.5	-4.99	1.21e-06	0.000848	-0.36	-0.31	Coronary artery disease;	chr11:43832359	chr11:43829709~43880726:-
OV	cis	rs7116641	0.734	rs6485473	ENSG00000246250.2	RP11-613D13.5	-4.99	1.21e-06	0.000848	-0.36	-0.31	Coronary artery disease;	chr11:43834805	chr11:43829709~43880726:-
OV	cis	rs7116641	0.734	rs7931097	ENSG00000246250.2	RP11-613D13.5	-4.99	1.21e-06	0.000848	-0.36	-0.31	Coronary artery disease;	chr11:43835868	chr11:43829709~43880726:-
OV	cis	rs7116641	0.734	rs7934707	ENSG00000246250.2	RP11-613D13.5	-4.99	1.21e-06	0.000848	-0.36	-0.31	Coronary artery disease;	chr11:43836378	chr11:43829709~43880726:-
OV	cis	rs7116641	0.734	rs10734518	ENSG00000246250.2	RP11-613D13.5	-4.99	1.21e-06	0.000848	-0.36	-0.31	Coronary artery disease;	chr11:43840198	chr11:43829709~43880726:-
OV	cis	rs7116641	0.734	rs7111450	ENSG00000246250.2	RP11-613D13.5	-4.99	1.21e-06	0.000848	-0.36	-0.31	Coronary artery disease;	chr11:43841480	chr11:43829709~43880726:-
OV	cis	rs7116641	0.699	rs1914773	ENSG00000246250.2	RP11-613D13.5	-4.99	1.21e-06	0.000848	-0.36	-0.31	Coronary artery disease;	chr11:43844744	chr11:43829709~43880726:-
OV	cis	rs11096990	0.634	rs3733287	ENSG00000249207.1	RP11-360F5.1	-4.99	1.21e-06	0.000849	-0.34	-0.31	Cognitive function;	chr4:39215732	chr4:39112677~39126818:-
OV	cis	rs9660180	1	rs3737628	ENSG00000268575.1	RP1-283E3.8	-4.99	1.21e-06	0.000849	-0.28	-0.31	Body mass index;	chr1:1791493	chr1:1702736~1737688:-
OV	cis	rs34421088	0.532	rs1545073	ENSG00000255495.1	AC145124.2	4.99	1.21e-06	0.00085	0.38	0.31	Neuroticism;	chr8:11310191	chr8:12194467~12196280:+
OV	cis	rs7945705	0.747	rs2568045	ENSG00000254860.4	TMEM9B-AS1	4.99	1.21e-06	0.00085	0.32	0.31	Hemoglobin concentration;	chr11:8982513	chr11:8964675~8977527:+
OV	cis	rs17301013	0.606	rs10912754	ENSG00000227373.4	RP11-160H22.5	4.99	1.21e-06	0.00085	0.41	0.31	Systemic lupus erythematosus;	chr1:174273667	chr1:174115300~174160004:-
OV	cis	rs6471393	0.964	rs56282609	ENSG00000253848.1	RP11-10N23.5	4.99	1.21e-06	0.000851	0.39	0.31	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93737852	chr8:93741193~93744534:+
OV	cis	rs896854	0.654	rs16893776	ENSG00000253528.2	RP11-347C18.4	4.99	1.21e-06	0.000851	0.3	0.31	Type 2 diabetes;	chr8:94961376	chr8:94974573~94974853:-
OV	cis	rs875971	0.965	rs697968	ENSG00000236529.1	RP13-254B10.1	-4.99	1.21e-06	0.000851	-0.33	-0.31	Aortic root size;	chr7:66070046	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs1167411	ENSG00000236529.1	RP13-254B10.1	-4.99	1.21e-06	0.000851	-0.33	-0.31	Aortic root size;	chr7:66074277	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs1183245	ENSG00000236529.1	RP13-254B10.1	-4.99	1.21e-06	0.000851	-0.33	-0.31	Aortic root size;	chr7:66076198	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs1144895	ENSG00000236529.1	RP13-254B10.1	-4.99	1.21e-06	0.000851	-0.33	-0.31	Aortic root size;	chr7:66076320	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs1144894	ENSG00000236529.1	RP13-254B10.1	-4.99	1.21e-06	0.000851	-0.33	-0.31	Aortic root size;	chr7:66077907	chr7:65840212~65840596:+
OV	cis	rs11157436	0.958	rs1041859	ENSG00000211812.1	TRAV26-2	-4.99	1.21e-06	0.000852	-0.37	-0.31	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22204878	chr14:22202583~22203368:+
OV	cis	rs11157436	0.958	rs1041860	ENSG00000211812.1	TRAV26-2	-4.99	1.21e-06	0.000852	-0.37	-0.31	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22204897	chr14:22202583~22203368:+
OV	cis	rs2243480	0.901	rs35823062	ENSG00000226824.5	RP4-756H11.3	-4.99	1.21e-06	0.000853	-0.49	-0.31	Diabetic kidney disease;	chr7:66500834	chr7:66654538~66669855:+
OV	cis	rs7160336	0.555	rs8021337	ENSG00000259065.1	RP5-1021I20.1	-4.99	1.22e-06	0.000854	-0.39	-0.31	Blood protein levels;	chr14:74184738	chr14:73787360~73803270:+
OV	cis	rs4061073	0.961	rs9012	ENSG00000198711.5	SSBP3-AS1	-4.99	1.22e-06	0.000854	-0.25	-0.31	Body mass index;	chr1:54225792	chr1:54236440~54239063:+
OV	cis	rs8062405	0.722	rs3785354	ENSG00000278665.1	RP11-666O2.4	4.99	1.22e-06	0.000854	0.34	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28539346	chr16:28599241~28601881:-
OV	cis	rs2153535	0.553	rs2984099	ENSG00000230939.1	RP11-314C16.1	-4.99	1.22e-06	0.000855	-0.34	-0.31	Motion sickness;	chr6:8637041	chr6:8784178~8785445:+
OV	cis	rs507080	0.501	rs516503	ENSG00000278376.1	RP11-158I9.8	-4.99	1.22e-06	0.000855	-0.31	-0.31	Serum metabolite levels;	chr11:118709639	chr11:118791254~118793137:+
OV	cis	rs2688608	0.617	rs6480709	ENSG00000271816.1	BMS1P4	4.99	1.22e-06	0.000856	0.3	0.31	Inflammatory bowel disease;	chr10:73719367	chr10:73699151~73730487:-
OV	cis	rs2688608	0.618	rs28553894	ENSG00000271816.1	BMS1P4	4.99	1.22e-06	0.000856	0.3	0.31	Inflammatory bowel disease;	chr10:73730085	chr10:73699151~73730487:-
OV	cis	rs2688608	0.618	rs28718766	ENSG00000271816.1	BMS1P4	4.99	1.22e-06	0.000856	0.3	0.31	Inflammatory bowel disease;	chr10:73730086	chr10:73699151~73730487:-
OV	cis	rs2098713	0.562	rs55794983	ENSG00000250155.1	CTD-2353F22.1	4.99	1.22e-06	0.000858	0.37	0.31	Telomere length;	chr5:37549046	chr5:36666214~36725195:-
OV	cis	rs11157436	0.958	rs17183308	ENSG00000211812.1	TRAV26-2	-4.99	1.22e-06	0.000858	-0.37	-0.31	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22195090	chr14:22202583~22203368:+
OV	cis	rs4728142	0.604	rs4731541	ENSG00000275106.1	RP11-309L24.10	-4.99	1.22e-06	0.000858	-0.41	-0.31	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129038182	chr7:128952527~128953316:-
OV	cis	rs3136516	0.772	rs7947747	ENSG00000271350.1	CTD-2384B9.1	-4.99	1.23e-06	0.000859	-0.34	-0.31	Venous thromboembolism;	chr11:46831288	chr11:47041027~47041945:-
OV	cis	rs6471393	0.964	rs16916186	ENSG00000253848.1	RP11-10N23.5	4.99	1.23e-06	0.000859	0.38	0.31	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93733158	chr8:93741193~93744534:+
OV	cis	rs7116641	0.734	rs10742690	ENSG00000246250.2	RP11-613D13.5	-4.99	1.23e-06	0.000859	-0.35	-0.31	Coronary artery disease;	chr11:43846102	chr11:43829709~43880726:-
OV	cis	rs11096990	0.634	rs745642	ENSG00000249207.1	RP11-360F5.1	4.98	1.23e-06	0.000861	0.33	0.31	Cognitive function;	chr4:39279642	chr4:39112677~39126818:-
OV	cis	rs638893	0.947	rs515707	ENSG00000255239.1	AP002954.6	4.98	1.23e-06	0.000861	0.48	0.31	Vitiligo;	chr11:118814772	chr11:118688039~118690600:-
OV	cis	rs796364	0.951	rs3098341	ENSG00000232732.8	AC073043.1	-4.98	1.23e-06	0.000862	-0.46	-0.31	Schizophrenia;	chr2:199927775	chr2:199867396~199911159:-
OV	cis	rs796364	0.951	rs971232	ENSG00000232732.8	AC073043.1	-4.98	1.23e-06	0.000862	-0.46	-0.31	Schizophrenia;	chr2:199928158	chr2:199867396~199911159:-
OV	cis	rs796364	1	rs281763	ENSG00000232732.8	AC073043.1	-4.98	1.23e-06	0.000862	-0.46	-0.31	Schizophrenia;	chr2:199930147	chr2:199867396~199911159:-
OV	cis	rs10992471	0.702	rs10820967	ENSG00000281156.1	MIR3651	-4.98	1.24e-06	0.000864	-0.36	-0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92339447	chr9:92292458~92292547:-
OV	cis	rs11096990	0.656	rs7686161	ENSG00000249207.1	RP11-360F5.1	4.98	1.24e-06	0.000866	0.34	0.31	Cognitive function;	chr4:39283201	chr4:39112677~39126818:-
OV	cis	rs8100891	0.537	rs3746016	ENSG00000267213.4	AC007773.2	-4.98	1.24e-06	0.000866	-0.46	-0.31	Neuroticism;	chr19:32386353	chr19:32390050~32405560:-
OV	cis	rs6772849	0.896	rs4557179	ENSG00000242551.2	POU5F1P6	-4.98	1.24e-06	0.000866	-0.36	-0.31	Monocyte percentage of white cells;Monocyte count;	chr3:128647883	chr3:128674735~128677005:-
OV	cis	rs13178541	0.748	rs9327727	ENSG00000250378.1	RP11-119J18.1	-4.98	1.24e-06	0.000867	-0.45	-0.31	IgG glycosylation;	chr5:135725997	chr5:135812667~135826582:+
OV	cis	rs9532669	0.926	rs9525418	ENSG00000176268.5	CYCSP34	-4.98	1.24e-06	0.000868	-0.36	-0.31	Cervical cancer;	chr13:40879081	chr13:40863599~40863902:-
OV	cis	rs1075265	0.836	rs10208233	ENSG00000233266.1	HMGB1P31	4.98	1.24e-06	0.000869	0.4	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54066433	chr2:54051334~54051760:+
OV	cis	rs7968440	0.736	rs1561422	ENSG00000257298.1	RP3-405J10.3	-4.98	1.24e-06	0.000869	-0.3	-0.31	Fibrinogen;	chr12:50794614	chr12:50185580~50191363:-
OV	cis	rs10924970	0.687	rs4433382	ENSG00000236863.2	RPL23AP23	4.98	1.24e-06	0.000869	0.33	0.31	Asthma;	chr1:235201678	chr1:235295865~235296335:+
OV	cis	rs9990333	0.562	rs73210005	ENSG00000231464.1	AC024937.4	4.98	1.25e-06	0.00087	0.36	0.31	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100441	chr3:195996738~195998233:+
OV	cis	rs9990333	0.562	rs58079878	ENSG00000231464.1	AC024937.4	4.98	1.25e-06	0.00087	0.36	0.31	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196100620	chr3:195996738~195998233:+
OV	cis	rs13068223	0.819	rs8792	ENSG00000243926.1	TIPARP-AS1	-4.98	1.25e-06	0.000871	-0.29	-0.31	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747639	chr3:156671862~156674378:-
OV	cis	rs607987	0.713	rs2947888	ENSG00000254532.1	RP11-624D11.2	-4.98	1.25e-06	0.000871	-0.37	-0.31	Body mass index;	chr11:30319088	chr11:30044058~30084343:-
OV	cis	rs607987	0.871	rs1222220	ENSG00000254532.1	RP11-624D11.2	4.98	1.25e-06	0.000871	0.37	0.31	Body mass index;	chr11:30322378	chr11:30044058~30084343:-
OV	cis	rs607987	0.871	rs642126	ENSG00000254532.1	RP11-624D11.2	4.98	1.25e-06	0.000872	0.37	0.31	Body mass index;	chr11:30244823	chr11:30044058~30084343:-
OV	cis	rs607987	0.841	rs515997	ENSG00000254532.1	RP11-624D11.2	4.98	1.25e-06	0.000872	0.37	0.31	Body mass index;	chr11:30245491	chr11:30044058~30084343:-
OV	cis	rs607987	0.871	rs675635	ENSG00000254532.1	RP11-624D11.2	4.98	1.25e-06	0.000872	0.37	0.31	Body mass index;	chr11:30249859	chr11:30044058~30084343:-
OV	cis	rs607987	0.871	rs60968445	ENSG00000254532.1	RP11-624D11.2	-4.98	1.25e-06	0.000872	-0.37	-0.31	Body mass index;	chr11:30253290	chr11:30044058~30084343:-
OV	cis	rs607987	0.836	rs1933347	ENSG00000254532.1	RP11-624D11.2	-4.98	1.25e-06	0.000872	-0.37	-0.31	Body mass index;	chr11:30258062	chr11:30044058~30084343:-
OV	cis	rs607987	0.836	rs4267046	ENSG00000254532.1	RP11-624D11.2	-4.98	1.25e-06	0.000872	-0.37	-0.31	Body mass index;	chr11:30261232	chr11:30044058~30084343:-
OV	cis	rs607987	0.841	rs4923632	ENSG00000254532.1	RP11-624D11.2	-4.98	1.25e-06	0.000872	-0.37	-0.31	Body mass index;	chr11:30280476	chr11:30044058~30084343:-
OV	cis	rs2280018	0.526	rs2966129	ENSG00000260735.1	RP11-72I8.1	4.98	1.25e-06	0.000872	0.39	0.31	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059070	chr16:15094411~15109197:+
OV	cis	rs8062405	0.755	rs4787456	ENSG00000278665.1	RP11-666O2.4	4.98	1.25e-06	0.000872	0.34	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548252	chr16:28599241~28601881:-
OV	cis	rs8062405	0.755	rs4788078	ENSG00000278665.1	RP11-666O2.4	4.98	1.25e-06	0.000872	0.34	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28548660	chr16:28599241~28601881:-
OV	cis	rs8062405	0.755	rs62034350	ENSG00000278665.1	RP11-666O2.4	4.98	1.25e-06	0.000872	0.34	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28550935	chr16:28599241~28601881:-
OV	cis	rs875971	0.545	rs4441996	ENSG00000226824.5	RP4-756H11.3	4.98	1.26e-06	0.000875	0.37	0.31	Aortic root size;	chr7:66123233	chr7:66654538~66669855:+
OV	cis	rs11673344	0.864	rs2562595	ENSG00000226686.6	LINC01535	4.98	1.26e-06	0.000875	0.41	0.31	Obesity-related traits;	chr19:37023964	chr19:37251912~37265535:+
OV	cis	rs11673344	0.832	rs8101407	ENSG00000226686.6	LINC01535	4.98	1.26e-06	0.000875	0.41	0.31	Obesity-related traits;	chr19:37024444	chr19:37251912~37265535:+
OV	cis	rs496547	0.654	rs688161	ENSG00000278376.1	RP11-158I9.8	-4.98	1.26e-06	0.000877	-0.31	-0.31	Hip minimal joint space width;	chr11:118807001	chr11:118791254~118793137:+
OV	cis	rs796364	1	rs1509835	ENSG00000232732.8	AC073043.1	-4.98	1.26e-06	0.000877	-0.43	-0.31	Schizophrenia;	chr2:199950086	chr2:199867396~199911159:-
OV	cis	rs7923609	0.578	rs10761789	ENSG00000232075.1	MRPL35P2	-4.98	1.26e-06	0.000877	-0.32	-0.31	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63636804	chr10:63634317~63634827:-
OV	cis	rs875971	0.545	rs801199	ENSG00000236529.1	RP13-254B10.1	-4.98	1.26e-06	0.000877	-0.37	-0.31	Aortic root size;	chr7:66560286	chr7:65840212~65840596:+
OV	cis	rs2243480	0.901	rs778687	ENSG00000226824.5	RP4-756H11.3	-4.98	1.26e-06	0.000877	-0.49	-0.31	Diabetic kidney disease;	chr7:66370832	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs778679	ENSG00000226824.5	RP4-756H11.3	-4.98	1.26e-06	0.000877	-0.49	-0.31	Diabetic kidney disease;	chr7:66375924	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs778704	ENSG00000226824.5	RP4-756H11.3	-4.98	1.26e-06	0.000877	-0.49	-0.31	Diabetic kidney disease;	chr7:66398480	chr7:66654538~66669855:+
OV	cis	rs2243480	0.901	rs778693	ENSG00000226824.5	RP4-756H11.3	-4.98	1.26e-06	0.000877	-0.49	-0.31	Diabetic kidney disease;	chr7:66407358	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs778691	ENSG00000226824.5	RP4-756H11.3	-4.98	1.26e-06	0.000877	-0.49	-0.31	Diabetic kidney disease;	chr7:66408105	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs13235972	ENSG00000226824.5	RP4-756H11.3	-4.98	1.26e-06	0.000877	-0.49	-0.31	Diabetic kidney disease;	chr7:66418618	chr7:66654538~66669855:+
OV	cis	rs853679	0.545	rs35949109	ENSG00000280107.1	AL022393.9	-4.98	1.26e-06	0.000878	-0.51	-0.31	Depression;	chr6:28058148	chr6:28170845~28172521:+
OV	cis	rs11096990	0.634	rs7659894	ENSG00000249207.1	RP11-360F5.1	4.98	1.26e-06	0.000878	0.34	0.31	Cognitive function;	chr4:39282815	chr4:39112677~39126818:-
OV	cis	rs17301013	0.507	rs2183202	ENSG00000227373.4	RP11-160H22.5	4.98	1.26e-06	0.000878	0.42	0.31	Systemic lupus erythematosus;	chr1:174824553	chr1:174115300~174160004:-
OV	cis	rs2243480	1	rs34192067	ENSG00000226824.5	RP4-756H11.3	-4.98	1.27e-06	0.000882	-0.49	-0.31	Diabetic kidney disease;	chr7:66422670	chr7:66654538~66669855:+
OV	cis	rs796364	1	rs1658807	ENSG00000232732.8	AC073043.1	-4.98	1.27e-06	0.000882	-0.46	-0.31	Schizophrenia;	chr2:199902789	chr2:199867396~199911159:-
OV	cis	rs2153535	0.585	rs9405403	ENSG00000230939.1	RP11-314C16.1	-4.98	1.27e-06	0.000883	-0.34	-0.31	Motion sickness;	chr6:8636061	chr6:8784178~8785445:+
OV	cis	rs2153535	0.56	rs7748421	ENSG00000230939.1	RP11-314C16.1	-4.98	1.27e-06	0.000883	-0.34	-0.31	Motion sickness;	chr6:8636271	chr6:8784178~8785445:+
OV	cis	rs301901	0.698	rs62360226	ENSG00000250155.1	CTD-2353F22.1	4.98	1.27e-06	0.000884	0.35	0.31	Height;	chr5:37428489	chr5:36666214~36725195:-
OV	cis	rs301901	0.698	rs11948801	ENSG00000250155.1	CTD-2353F22.1	4.98	1.27e-06	0.000884	0.35	0.31	Height;	chr5:37430113	chr5:36666214~36725195:-
OV	cis	rs11690935	0.632	rs17581284	ENSG00000228389.1	AC068039.4	-4.98	1.27e-06	0.000886	-0.35	-0.31	Schizophrenia;	chr2:171802866	chr2:171773482~171775844:+
OV	cis	rs2688608	0.56	rs10128354	ENSG00000271816.1	BMS1P4	4.98	1.27e-06	0.000886	0.29	0.31	Inflammatory bowel disease;	chr10:73710287	chr10:73699151~73730487:-
OV	cis	rs896854	0.654	rs13281625	ENSG00000253528.2	RP11-347C18.4	4.98	1.27e-06	0.000886	0.3	0.31	Type 2 diabetes;	chr8:94960510	chr8:94974573~94974853:-
OV	cis	rs896854	0.625	rs13281709	ENSG00000253528.2	RP11-347C18.4	4.98	1.27e-06	0.000886	0.3	0.31	Type 2 diabetes;	chr8:94960591	chr8:94974573~94974853:-
OV	cis	rs896854	0.625	rs4735335	ENSG00000253528.2	RP11-347C18.4	4.98	1.27e-06	0.000886	0.3	0.31	Type 2 diabetes;	chr8:94961099	chr8:94974573~94974853:-
OV	cis	rs896854	0.654	rs4735337	ENSG00000253528.2	RP11-347C18.4	4.98	1.27e-06	0.000886	0.3	0.31	Type 2 diabetes;	chr8:94961237	chr8:94974573~94974853:-
OV	cis	rs301901	0.965	rs158803	ENSG00000250155.1	CTD-2353F22.1	-4.98	1.28e-06	0.000886	-0.37	-0.31	Height;	chr5:36911514	chr5:36666214~36725195:-
OV	cis	rs2098713	0.535	rs11748123	ENSG00000250155.1	CTD-2353F22.1	4.98	1.28e-06	0.000888	0.37	0.31	Telomere length;	chr5:37575317	chr5:36666214~36725195:-
OV	cis	rs6088590	0.582	rs6059909	ENSG00000206582.1	Y_RNA	-4.98	1.28e-06	0.000889	-0.38	-0.31	Coronary artery disease;	chr20:34551887	chr20:34526510~34526606:-
OV	cis	rs7829975	0.871	rs572307	ENSG00000253893.2	FAM85B	4.98	1.28e-06	0.000889	0.33	0.31	Mood instability;	chr8:8721301	chr8:8167819~8226614:-
OV	cis	rs67311347	0.868	rs10865895	ENSG00000223797.4	ENTPD3-AS1	4.98	1.28e-06	0.00089	0.35	0.31	Renal cell carcinoma;	chr3:40337186	chr3:40313802~40453329:-
OV	cis	rs1075265	0.749	rs6738369	ENSG00000233266.1	HMGB1P31	4.98	1.29e-06	0.000892	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53756547	chr2:54051334~54051760:+
OV	cis	rs992157	1	rs4674280	ENSG00000261338.2	RP11-378A13.1	-4.98	1.29e-06	0.000894	-0.36	-0.31	Colorectal cancer;	chr2:218276735	chr2:218255319~218257366:+
OV	cis	rs496547	0.756	rs562059	ENSG00000278376.1	RP11-158I9.8	-4.98	1.29e-06	0.000894	-0.32	-0.31	Hip minimal joint space width;	chr11:118731349	chr11:118791254~118793137:+
OV	cis	rs16873450	0.527	rs12539789	ENSG00000234800.2	PCMTD1P3	4.97	1.29e-06	0.000895	0.32	0.31	Verbal memory performance (residualized delayed recall level);	chr7:23736797	chr7:23721311~23721782:-
OV	cis	rs607987	0.713	rs2947888	ENSG00000254532.1	RP11-624D11.2	4.97	1.29e-06	0.000896	0.37	0.31	Body mass index;	chr11:30319088	chr11:30044058~30084343:-
OV	cis	rs116095464	0.558	rs7713524	ENSG00000250848.1	CTD-2083E4.5	4.97	1.29e-06	0.000897	0.38	0.31	Breast cancer;	chr5:276085	chr5:288833~290321:-
OV	cis	rs7945705	0.692	rs2742470	ENSG00000254860.4	TMEM9B-AS1	4.97	1.3e-06	0.000898	0.32	0.31	Hemoglobin concentration;	chr11:8982455	chr11:8964675~8977527:+
OV	cis	rs2153535	0.585	rs9379236	ENSG00000230939.1	RP11-314C16.1	-4.97	1.3e-06	0.000899	-0.34	-0.31	Motion sickness;	chr6:8651792	chr6:8784178~8785445:+
OV	cis	rs2153535	0.56	rs1328866	ENSG00000230939.1	RP11-314C16.1	-4.97	1.3e-06	0.000899	-0.34	-0.31	Motion sickness;	chr6:8653283	chr6:8784178~8785445:+
OV	cis	rs2153535	0.585	rs1328865	ENSG00000230939.1	RP11-314C16.1	-4.97	1.3e-06	0.000899	-0.34	-0.31	Motion sickness;	chr6:8653454	chr6:8784178~8785445:+
OV	cis	rs34779708	0.966	rs7913615	ENSG00000230534.5	RP11-297A16.2	4.97	1.3e-06	0.000899	0.41	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35134029	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs35126129	ENSG00000230534.5	RP11-297A16.2	4.97	1.3e-06	0.000899	0.41	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35163213	chr10:35098006~35127020:-
OV	cis	rs293748	0.571	rs13184464	ENSG00000250155.1	CTD-2353F22.1	-4.97	1.3e-06	0.000901	-0.43	-0.31	Obesity-related traits;	chr5:37191983	chr5:36666214~36725195:-
OV	cis	rs8005677	1	rs11157930	ENSG00000279656.1	RP11-298I3.6	4.97	1.3e-06	0.000901	0.35	0.31	Cognitive ability (multi-trait analysis);	chr14:22933962	chr14:23023083~23024217:-
OV	cis	rs8005677	0.962	rs11157931	ENSG00000279656.1	RP11-298I3.6	4.97	1.3e-06	0.000901	0.35	0.31	Cognitive ability (multi-trait analysis);	chr14:22933984	chr14:23023083~23024217:-
OV	cis	rs8062405	0.69	rs6498089	ENSG00000259982.1	CDC37P1	-4.97	1.3e-06	0.000901	-0.38	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28700294~28701540:-
OV	cis	rs116095464	0.558	rs1812843	ENSG00000250848.1	CTD-2083E4.5	-4.97	1.3e-06	0.000902	-0.39	-0.31	Breast cancer;	chr5:267543	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs12173244	ENSG00000250848.1	CTD-2083E4.5	-4.97	1.3e-06	0.000902	-0.39	-0.31	Breast cancer;	chr5:269409	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs56127718	ENSG00000250848.1	CTD-2083E4.5	-4.97	1.3e-06	0.000902	-0.39	-0.31	Breast cancer;	chr5:270158	chr5:288833~290321:-
OV	cis	rs116095464	0.614	rs10061564	ENSG00000250848.1	CTD-2083E4.5	-4.97	1.3e-06	0.000902	-0.39	-0.31	Breast cancer;	chr5:271214	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs59113266	ENSG00000250848.1	CTD-2083E4.5	-4.97	1.3e-06	0.000902	-0.39	-0.31	Breast cancer;	chr5:279850	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs11959126	ENSG00000250848.1	CTD-2083E4.5	-4.97	1.3e-06	0.000902	-0.39	-0.31	Breast cancer;	chr5:283765	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs7356696	ENSG00000250848.1	CTD-2083E4.5	-4.97	1.3e-06	0.000902	-0.39	-0.31	Breast cancer;	chr5:284136	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs7356561	ENSG00000250848.1	CTD-2083E4.5	-4.97	1.3e-06	0.000902	-0.39	-0.31	Breast cancer;	chr5:284266	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs59284383	ENSG00000250848.1	CTD-2083E4.5	-4.97	1.3e-06	0.000902	-0.39	-0.31	Breast cancer;	chr5:284410	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs7731089	ENSG00000250848.1	CTD-2083E4.5	-4.97	1.3e-06	0.000902	-0.39	-0.31	Breast cancer;	chr5:290307	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs7703803	ENSG00000250848.1	CTD-2083E4.5	-4.97	1.3e-06	0.000902	-0.39	-0.31	Breast cancer;	chr5:292196	chr5:288833~290321:-
OV	cis	rs6071166	0.869	rs6027422	ENSG00000174365.18	SNHG11	4.97	1.3e-06	0.000903	0.38	0.31	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38703838	chr20:38446578~38450921:+
OV	cis	rs7428	0.545	rs4832163	ENSG00000246575.2	AC093162.5	4.97	1.31e-06	0.000904	0.31	0.31	Ear protrusion;	chr2:85313960	chr2:85315041~85316529:+
OV	cis	rs2153535	0.585	rs9328500	ENSG00000230939.1	RP11-314C16.1	4.97	1.31e-06	0.000904	0.34	0.31	Motion sickness;	chr6:8658838	chr6:8784178~8785445:+
OV	cis	rs7189233	0.531	rs13332406	ENSG00000279344.1	RP11-44F14.7	4.97	1.31e-06	0.000905	0.29	0.31	Intelligence (multi-trait analysis);	chr16:53455793	chr16:53478957~53481550:-
OV	cis	rs6991838	0.584	rs7459944	ENSG00000200714.1	Y_RNA	-4.97	1.31e-06	0.000905	-0.39	-0.31	Intelligence (multi-trait analysis);	chr8:65566040	chr8:65592731~65592820:+
OV	cis	rs2098713	0.599	rs62359042	ENSG00000250155.1	CTD-2353F22.1	4.97	1.31e-06	0.000907	0.36	0.31	Telomere length;	chr5:37577604	chr5:36666214~36725195:-
OV	cis	rs7927592	0.913	rs7106010	ENSG00000212093.1	AP000807.1	4.97	1.31e-06	0.000908	0.4	0.31	Total body bone mineral density;	chr11:68597744	chr11:68506083~68506166:-
OV	cis	rs7927592	0.913	rs3758643	ENSG00000212093.1	AP000807.1	4.97	1.31e-06	0.000908	0.4	0.31	Total body bone mineral density;	chr11:68599725	chr11:68506083~68506166:-
OV	cis	rs992157	0.835	rs2271543	ENSG00000237281.1	CATIP-AS2	4.97	1.31e-06	0.000909	0.36	0.31	Colorectal cancer;	chr2:218277768	chr2:218326889~218357966:-
OV	cis	rs992157	0.717	rs3817266	ENSG00000237281.1	CATIP-AS2	4.97	1.31e-06	0.000909	0.36	0.31	Colorectal cancer;	chr2:218277871	chr2:218326889~218357966:-
OV	cis	rs992157	0.835	rs2292551	ENSG00000237281.1	CATIP-AS2	4.97	1.31e-06	0.000909	0.36	0.31	Colorectal cancer;	chr2:218278506	chr2:218326889~218357966:-
OV	cis	rs992157	0.835	rs12987180	ENSG00000237281.1	CATIP-AS2	4.97	1.31e-06	0.000909	0.36	0.31	Colorectal cancer;	chr2:218279366	chr2:218326889~218357966:-
OV	cis	rs992157	0.835	rs4674283	ENSG00000237281.1	CATIP-AS2	4.97	1.31e-06	0.000909	0.36	0.31	Colorectal cancer;	chr2:218279531	chr2:218326889~218357966:-
OV	cis	rs992157	0.835	rs2045434	ENSG00000237281.1	CATIP-AS2	4.97	1.31e-06	0.000909	0.36	0.31	Colorectal cancer;	chr2:218279775	chr2:218326889~218357966:-
OV	cis	rs7927592	0.956	rs10896341	ENSG00000212093.1	AP000807.1	4.97	1.31e-06	0.000909	0.4	0.31	Total body bone mineral density;	chr11:68545712	chr11:68506083~68506166:-
OV	cis	rs7927592	0.913	rs67947146	ENSG00000212093.1	AP000807.1	4.97	1.31e-06	0.000909	0.4	0.31	Total body bone mineral density;	chr11:68547512	chr11:68506083~68506166:-
OV	cis	rs7927592	0.913	rs7104345	ENSG00000212093.1	AP000807.1	4.97	1.31e-06	0.000909	0.4	0.31	Total body bone mineral density;	chr11:68549304	chr11:68506083~68506166:-
OV	cis	rs7927592	0.871	rs11228284	ENSG00000212093.1	AP000807.1	4.97	1.31e-06	0.000909	0.4	0.31	Total body bone mineral density;	chr11:68555299	chr11:68506083~68506166:-
OV	cis	rs607987	0.871	rs1782508	ENSG00000254532.1	RP11-624D11.2	4.97	1.31e-06	0.000909	0.36	0.31	Body mass index;	chr11:30222248	chr11:30044058~30084343:-
OV	cis	rs7189233	0.531	rs9931702	ENSG00000279344.1	RP11-44F14.7	4.97	1.31e-06	0.000909	0.3	0.31	Intelligence (multi-trait analysis);	chr16:53492639	chr16:53478957~53481550:-
OV	cis	rs17023223	0.537	rs61319010	ENSG00000231365.4	RP11-418J17.1	-4.97	1.32e-06	0.00091	-0.41	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119200388	chr1:119140396~119275973:+
OV	cis	rs1729407	0.706	rs595049	ENSG00000254851.1	RP11-109L13.1	-4.97	1.32e-06	0.000912	-0.4	-0.31	Apolipoprotein A-IV levels;	chr11:116828729	chr11:117135528~117138582:+
OV	cis	rs7615952	0.599	rs2279821	ENSG00000171084.14	FAM86JP	4.97	1.32e-06	0.000912	0.46	0.31	Blood pressure (smoking interaction);	chr3:126015465	chr3:125916620~125930024:+
OV	cis	rs34779708	0.966	rs2045917	ENSG00000230534.5	RP11-297A16.2	4.97	1.32e-06	0.000912	0.4	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35129598	chr10:35098006~35127020:-
OV	cis	rs1528149	0.576	rs10277151	ENSG00000224683.1	RPL36AP29	4.97	1.32e-06	0.000913	0.39	0.31	Sitting height ratio;	chr7:16075788	chr7:16208945~16209265:+
OV	cis	rs7580658	0.864	rs4150441	ENSG00000236682.1	AC068282.3	-4.97	1.32e-06	0.000913	-0.4	-0.31	Protein C levels;	chr2:127283339	chr2:127389130~127400580:+
OV	cis	rs17301013	0.606	rs12082461	ENSG00000227373.4	RP11-160H22.5	4.97	1.32e-06	0.000913	0.41	0.31	Systemic lupus erythematosus;	chr1:174169876	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs10912737	ENSG00000227373.4	RP11-160H22.5	4.97	1.32e-06	0.000913	0.41	0.31	Systemic lupus erythematosus;	chr1:174172999	chr1:174115300~174160004:-
OV	cis	rs17301013	0.531	rs12079687	ENSG00000227373.4	RP11-160H22.5	4.97	1.32e-06	0.000913	0.41	0.31	Systemic lupus erythematosus;	chr1:174175545	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs12087808	ENSG00000227373.4	RP11-160H22.5	4.97	1.32e-06	0.000913	0.41	0.31	Systemic lupus erythematosus;	chr1:174178848	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs10912740	ENSG00000227373.4	RP11-160H22.5	4.97	1.32e-06	0.000913	0.41	0.31	Systemic lupus erythematosus;	chr1:174180224	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs724888	ENSG00000227373.4	RP11-160H22.5	4.97	1.32e-06	0.000913	0.41	0.31	Systemic lupus erythematosus;	chr1:174180403	chr1:174115300~174160004:-
OV	cis	rs7927771	0.725	rs11570094	ENSG00000280615.1	Y_RNA	4.97	1.32e-06	0.000914	0.4	0.31	Subjective well-being;	chr11:47338155	chr11:47614898~47614994:-
OV	cis	rs7587476	0.784	rs34112702	ENSG00000229267.2	AC072062.1	-4.97	1.32e-06	0.000915	-0.42	-0.31	Neuroblastoma;	chr2:214831278	chr2:214810229~214963274:+
OV	cis	rs7587476	0.784	rs13008641	ENSG00000229267.2	AC072062.1	-4.97	1.32e-06	0.000915	-0.42	-0.31	Neuroblastoma;	chr2:214833309	chr2:214810229~214963274:+
OV	cis	rs6772849	0.896	rs9816260	ENSG00000242551.2	POU5F1P6	-4.97	1.33e-06	0.000915	-0.36	-0.31	Monocyte percentage of white cells;Monocyte count;	chr3:128633240	chr3:128674735~128677005:-
OV	cis	rs8062405	0.789	rs240704	ENSG00000278665.1	RP11-666O2.4	4.97	1.33e-06	0.000917	0.33	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28518628	chr16:28599241~28601881:-
OV	cis	rs7849270	0.801	rs10819474	ENSG00000268707.1	RP11-247A12.7	-4.97	1.33e-06	0.000919	-0.34	-0.31	Blood metabolite ratios;	chr9:129168215	chr9:129170434~129170940:+
OV	cis	rs2153535	0.585	rs1328870	ENSG00000230939.1	RP11-314C16.1	-4.97	1.33e-06	0.00092	-0.34	-0.31	Motion sickness;	chr6:8637803	chr6:8784178~8785445:+
OV	cis	rs7617773	0.78	rs3731550	ENSG00000228638.1	FCF1P2	-4.97	1.33e-06	0.00092	-0.4	-0.31	Coronary artery disease;	chr3:48165093	chr3:48290793~48291375:-
OV	cis	rs7617773	0.817	rs3731534	ENSG00000228638.1	FCF1P2	-4.97	1.33e-06	0.00092	-0.4	-0.31	Coronary artery disease;	chr3:48170287	chr3:48290793~48291375:-
OV	cis	rs6088580	0.634	rs6059897	ENSG00000206582.1	Y_RNA	-4.97	1.33e-06	0.00092	-0.37	-0.31	Glomerular filtration rate (creatinine);	chr20:34525419	chr20:34526510~34526606:-
OV	cis	rs875971	0.571	rs160641	ENSG00000226824.5	RP4-756H11.3	4.97	1.33e-06	0.000921	0.37	0.31	Aortic root size;	chr7:66112359	chr7:66654538~66669855:+
OV	cis	rs17301013	0.507	rs72717616	ENSG00000227373.4	RP11-160H22.5	4.97	1.34e-06	0.000921	0.42	0.31	Systemic lupus erythematosus;	chr1:174812711	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs72717618	ENSG00000227373.4	RP11-160H22.5	4.97	1.34e-06	0.000921	0.42	0.31	Systemic lupus erythematosus;	chr1:174816839	chr1:174115300~174160004:-
OV	cis	rs3091242	0.933	rs926438	ENSG00000224183.1	SDHDP6	-4.97	1.34e-06	0.000922	-0.38	-0.31	Erythrocyte sedimentation rate;	chr1:25427147	chr1:25294164~25294643:-
OV	cis	rs301901	0.634	rs4869429	ENSG00000250155.1	CTD-2353F22.1	4.97	1.34e-06	0.000922	0.35	0.31	Height;	chr5:37407777	chr5:36666214~36725195:-
OV	cis	rs6088580	0.634	rs945673	ENSG00000206582.1	Y_RNA	4.97	1.34e-06	0.000922	0.37	0.31	Glomerular filtration rate (creatinine);	chr20:34376459	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs1890000	ENSG00000206582.1	Y_RNA	4.97	1.34e-06	0.000922	0.37	0.31	Glomerular filtration rate (creatinine);	chr20:34380506	chr20:34526510~34526606:-
OV	cis	rs10992471	0.756	rs3758229	ENSG00000281156.1	MIR3651	-4.97	1.34e-06	0.000923	-0.35	-0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92316570	chr9:92292458~92292547:-
OV	cis	rs3814244	0.515	rs2906862	ENSG00000255733.4	IFNG-AS1	-4.97	1.34e-06	0.000923	-0.31	-0.31	Itch intensity from mosquito bite adjusted by bite size;	chr12:68005371	chr12:67989445~68234686:+
OV	cis	rs34779708	0.931	rs11010101	ENSG00000230534.5	RP11-297A16.2	4.97	1.34e-06	0.000924	0.4	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35122117	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs11010102	ENSG00000230534.5	RP11-297A16.2	4.97	1.34e-06	0.000924	0.4	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35122138	chr10:35098006~35127020:-
OV	cis	rs17301013	0.507	rs4652797	ENSG00000227373.4	RP11-160H22.5	4.97	1.34e-06	0.000924	0.42	0.31	Systemic lupus erythematosus;	chr1:174791236	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs7521109	ENSG00000227373.4	RP11-160H22.5	4.97	1.34e-06	0.000924	0.42	0.31	Systemic lupus erythematosus;	chr1:174802629	chr1:174115300~174160004:-
OV	cis	rs7017914	0.652	rs950903	ENSG00000223220.1	Y_RNA	4.97	1.34e-06	0.000925	0.35	0.31	Bone mineral density;	chr8:70988539	chr8:70780914~70781008:-
OV	cis	rs116095464	0.558	rs9654452	ENSG00000250848.1	CTD-2083E4.5	-4.97	1.34e-06	0.000925	-0.39	-0.31	Breast cancer;	chr5:299446	chr5:288833~290321:-
OV	cis	rs1797885	0.564	rs959088	ENSG00000251774.1	RNU6-377P	4.97	1.34e-06	0.000925	0.3	0.31	Immature fraction of reticulocytes;	chr3:12540639	chr3:12514706~12514807:+
OV	cis	rs9287719	0.601	rs12692412	ENSG00000243819.4	RN7SL832P	-4.97	1.34e-06	0.000927	-0.31	-0.31	Prostate cancer;	chr2:10579928	chr2:10690344~10692099:+
OV	cis	rs17301013	0.606	rs7547766	ENSG00000227373.4	RP11-160H22.5	4.97	1.35e-06	0.000929	0.41	0.31	Systemic lupus erythematosus;	chr1:174180977	chr1:174115300~174160004:-
OV	cis	rs34779708	0.966	rs10827492	ENSG00000230534.5	RP11-297A16.2	-4.97	1.35e-06	0.00093	-0.4	-0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35140897	chr10:35098006~35127020:-
OV	cis	rs11157436	0.958	rs61972231	ENSG00000211812.1	TRAV26-2	-4.96	1.35e-06	0.00093	-0.37	-0.31	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22206508	chr14:22202583~22203368:+
OV	cis	rs9298506	1	rs28615248	ENSG00000254142.2	RP11-53M11.3	4.96	1.35e-06	0.000931	0.44	0.31	Intracranial aneurysm;	chr8:54538633	chr8:54554361~54561927:+
OV	cis	rs3758911	1	rs3758911	ENSG00000261098.1	RP11-819C21.1	-4.96	1.35e-06	0.000932	-0.3	-0.31	Coronary artery disease;	chr11:107326914	chr11:107312132~107316271:-
OV	cis	rs1979679	0.808	rs71452082	ENSG00000278733.1	RP11-425D17.1	4.96	1.35e-06	0.000932	0.37	0.31	Ossification of the posterior longitudinal ligament of the spine;	chr12:28221647	chr12:28185625~28186190:-
OV	cis	rs858239	0.699	rs858260	ENSG00000230042.1	AK3P3	-4.96	1.36e-06	0.000934	-0.34	-0.31	Cerebrospinal fluid biomarker levels;	chr7:23173315	chr7:23129178~23129841:+
OV	cis	rs11673344	0.796	rs16971886	ENSG00000226686.6	LINC01535	4.96	1.36e-06	0.000935	0.41	0.31	Obesity-related traits;	chr19:36997073	chr19:37251912~37265535:+
OV	cis	rs2492286	0.518	rs2712418	ENSG00000242551.2	POU5F1P6	-4.96	1.36e-06	0.000936	-0.39	-0.31	Eosinophil counts;	chr3:128624793	chr3:128674735~128677005:-
OV	cis	rs1576263	0.967	rs7753991	ENSG00000230939.1	RP11-314C16.1	-4.96	1.36e-06	0.000936	-0.34	-0.31	Photic sneeze reflex;	chr6:8561195	chr6:8784178~8785445:+
OV	cis	rs13068223	0.74	rs237250	ENSG00000243926.1	TIPARP-AS1	4.96	1.36e-06	0.000936	0.3	0.31	Age-related hearing impairment (SNP x SNP interaction);	chr3:156726594	chr3:156671862~156674378:-
OV	cis	rs8113142	0.614	rs59394095	ENSG00000267243.4	AC005307.3	-4.96	1.36e-06	0.000936	-0.51	-0.31	Femoral neck bone geometry and menarche (age at onset);	chr19:28701205	chr19:28435388~28727777:-
OV	cis	rs8100891	0.537	rs4805755	ENSG00000267213.4	AC007773.2	4.96	1.36e-06	0.000938	0.47	0.31	Neuroticism;	chr19:32363564	chr19:32390050~32405560:-
OV	cis	rs7615952	0.736	rs9862893	ENSG00000171084.14	FAM86JP	4.96	1.36e-06	0.000939	0.58	0.31	Blood pressure (smoking interaction);	chr3:125968131	chr3:125916620~125930024:+
OV	cis	rs4713118	0.824	rs9366702	ENSG00000280107.1	AL022393.9	-4.96	1.37e-06	0.000941	-0.37	-0.31	Parkinson's disease;	chr6:27766691	chr6:28170845~28172521:+
OV	cis	rs6860806	0.507	rs272878	ENSG00000233006.5	AC034220.3	-4.96	1.37e-06	0.000942	-0.33	-0.31	Breast cancer;	chr5:132336076	chr5:132311285~132369916:-
OV	cis	rs2253762	0.54	rs79586669	ENSG00000276742.1	RP11-500G22.4	4.96	1.37e-06	0.000942	0.56	0.31	Breast cancer;	chr10:122015153	chr10:121956782~121957098:+
OV	cis	rs11673344	0.796	rs9676450	ENSG00000226686.6	LINC01535	4.96	1.37e-06	0.000943	0.41	0.31	Obesity-related traits;	chr19:36998505	chr19:37251912~37265535:+
OV	cis	rs17301013	0.507	rs6684688	ENSG00000227373.4	RP11-160H22.5	4.96	1.37e-06	0.000943	0.41	0.31	Systemic lupus erythematosus;	chr1:174357180	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs926349	ENSG00000227373.4	RP11-160H22.5	4.96	1.37e-06	0.000943	0.41	0.31	Systemic lupus erythematosus;	chr1:174368408	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs10912772	ENSG00000227373.4	RP11-160H22.5	4.96	1.37e-06	0.000943	0.41	0.31	Systemic lupus erythematosus;	chr1:174370832	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12073751	ENSG00000227373.4	RP11-160H22.5	4.96	1.37e-06	0.000943	0.41	0.31	Systemic lupus erythematosus;	chr1:174373177	chr1:174115300~174160004:-
OV	cis	rs12440434	1	rs12440434	ENSG00000275580.1	RP11-295H24.4	4.96	1.37e-06	0.000944	0.42	0.31	Major depressive disorder;	chr15:48930049	chr15:49343608~49344254:+
OV	cis	rs301901	1	rs300058	ENSG00000250155.1	CTD-2353F22.1	-4.96	1.38e-06	0.000945	-0.36	-0.31	Height;	chr5:37053874	chr5:36666214~36725195:-
OV	cis	rs8100891	0.537	rs10405382	ENSG00000267213.4	AC007773.2	-4.96	1.38e-06	0.000945	-0.46	-0.31	Neuroticism;	chr19:32405810	chr19:32390050~32405560:-
OV	cis	rs875971	0.545	rs17138149	ENSG00000236529.1	RP13-254B10.1	4.96	1.38e-06	0.000947	0.36	0.31	Aortic root size;	chr7:66228193	chr7:65840212~65840596:+
OV	cis	rs6088590	0.502	rs6059861	ENSG00000206582.1	Y_RNA	-4.96	1.38e-06	0.000947	-0.37	-0.31	Coronary artery disease;	chr20:34480758	chr20:34526510~34526606:-
OV	cis	rs796364	1	rs281788	ENSG00000232732.8	AC073043.1	-4.96	1.38e-06	0.000948	-0.46	-0.31	Schizophrenia;	chr2:199918982	chr2:199867396~199911159:-
OV	cis	rs7429990	0.965	rs184388	ENSG00000229759.1	MRPS18AP1	4.96	1.38e-06	0.000948	0.34	0.31	Educational attainment (years of education);	chr3:47898136	chr3:48256350~48256938:-
OV	cis	rs7429990	0.965	rs319696	ENSG00000229759.1	MRPS18AP1	4.96	1.38e-06	0.000948	0.34	0.31	Educational attainment (years of education);	chr3:47902371	chr3:48256350~48256938:-
OV	cis	rs6772849	0.93	rs12487604	ENSG00000277250.1	Metazoa_SRP	-4.96	1.38e-06	0.00095	-0.39	-0.31	Monocyte percentage of white cells;Monocyte count;	chr3:128618232	chr3:128673681~128674021:-
OV	cis	rs7429990	1	rs1665982	ENSG00000229759.1	MRPS18AP1	-4.96	1.38e-06	0.00095	-0.34	-0.31	Educational attainment (years of education);	chr3:47863589	chr3:48256350~48256938:-
OV	cis	rs1075265	0.548	rs805448	ENSG00000233266.1	HMGB1P31	4.96	1.39e-06	0.000952	0.4	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53950055	chr2:54051334~54051760:+
OV	cis	rs7116641	0.697	rs7110437	ENSG00000246250.2	RP11-613D13.5	-4.96	1.39e-06	0.000954	-0.4	-0.31	Coronary artery disease;	chr11:43759003	chr11:43829709~43880726:-
OV	cis	rs7773456	0.74	rs4140625	ENSG00000228412.5	RP4-625H18.2	-4.96	1.39e-06	0.000954	-0.39	-0.31	Lupus nephritis in systemic lupus erythematosus;	chr6:19818109	chr6:19802164~19804752:-
OV	cis	rs6088580	0.542	rs6059882	ENSG00000206582.1	Y_RNA	-4.96	1.39e-06	0.000956	-0.37	-0.31	Glomerular filtration rate (creatinine);	chr20:34502362	chr20:34526510~34526606:-
OV	cis	rs116095464	0.558	rs28635197	ENSG00000250848.1	CTD-2083E4.5	-4.96	1.39e-06	0.000956	-0.39	-0.31	Breast cancer;	chr5:278956	chr5:288833~290321:-
OV	cis	rs2243480	0.901	rs34807232	ENSG00000226824.5	RP4-756H11.3	-4.96	1.4e-06	0.000958	-0.49	-0.31	Diabetic kidney disease;	chr7:66500146	chr7:66654538~66669855:+
OV	cis	rs7615952	0.512	rs4646765	ENSG00000171084.14	FAM86JP	4.96	1.4e-06	0.000958	0.46	0.31	Blood pressure (smoking interaction);	chr3:126101864	chr3:125916620~125930024:+
OV	cis	rs7615952	0.576	rs4646763	ENSG00000171084.14	FAM86JP	4.96	1.4e-06	0.000958	0.46	0.31	Blood pressure (smoking interaction);	chr3:126103286	chr3:125916620~125930024:+
OV	cis	rs7615952	0.576	rs4646759	ENSG00000171084.14	FAM86JP	4.96	1.4e-06	0.000958	0.46	0.31	Blood pressure (smoking interaction);	chr3:126104103	chr3:125916620~125930024:+
OV	cis	rs1075265	0.749	rs2357693	ENSG00000233266.1	HMGB1P31	4.96	1.4e-06	0.00096	0.38	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53735699	chr2:54051334~54051760:+
OV	cis	rs1075265	0.704	rs10181999	ENSG00000233266.1	HMGB1P31	4.96	1.4e-06	0.000961	0.39	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54025360	chr2:54051334~54051760:+
OV	cis	rs11690935	0.61	rs3770458	ENSG00000228389.1	AC068039.4	-4.96	1.4e-06	0.000962	-0.36	-0.31	Schizophrenia;	chr2:171794777	chr2:171773482~171775844:+
OV	cis	rs11690935	0.632	rs35854151	ENSG00000228389.1	AC068039.4	-4.96	1.4e-06	0.000962	-0.36	-0.31	Schizophrenia;	chr2:171800929	chr2:171773482~171775844:+
OV	cis	rs7829975	0.84	rs572366	ENSG00000253893.2	FAM85B	-4.96	1.4e-06	0.000963	-0.34	-0.31	Mood instability;	chr8:8721284	chr8:8167819~8226614:-
OV	cis	rs7201929	0.801	rs9933198	ENSG00000259982.1	CDC37P1	-4.96	1.4e-06	0.000963	-0.41	-0.31	QT interval;	chr16:28877088	chr16:28700294~28701540:-
OV	cis	rs7189233	0.55	rs4784312	ENSG00000279344.1	RP11-44F14.7	4.96	1.41e-06	0.000963	0.29	0.31	Intelligence (multi-trait analysis);	chr16:53464490	chr16:53478957~53481550:-
OV	cis	rs61990749	0.597	rs59848135	ENSG00000239272.1	RPL21P10	-4.96	1.41e-06	0.000964	-0.46	-0.31	Fibroblast growth factor basic levels;	chr14:77662657	chr14:77683202~77683989:-
OV	cis	rs507080	0.501	rs626645	ENSG00000278376.1	RP11-158I9.8	-4.96	1.41e-06	0.000965	-0.31	-0.31	Serum metabolite levels;	chr11:118704471	chr11:118791254~118793137:+
OV	cis	rs10740039	0.883	rs2393676	ENSG00000254271.1	RP11-131N11.4	4.96	1.41e-06	0.000965	0.39	0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60630500	chr10:60734342~60741828:+
OV	cis	rs4713118	0.824	rs9366702	ENSG00000219392.1	RP1-265C24.5	-4.96	1.41e-06	0.000965	-0.36	-0.31	Parkinson's disease;	chr6:27766691	chr6:28115628~28116551:+
OV	cis	rs796364	1	rs4263095	ENSG00000232732.8	AC073043.1	4.96	1.41e-06	0.000966	0.46	0.31	Schizophrenia;	chr2:199965414	chr2:199867396~199911159:-
OV	cis	rs7580658	0.724	rs6712213	ENSG00000236682.1	AC068282.3	-4.96	1.41e-06	0.000967	-0.4	-0.31	Protein C levels;	chr2:127240654	chr2:127389130~127400580:+
OV	cis	rs7968440	0.591	rs6580732	ENSG00000257298.1	RP3-405J10.3	-4.96	1.41e-06	0.000967	-0.28	-0.31	Fibrinogen;	chr12:50252496	chr12:50185580~50191363:-
OV	cis	rs6088580	0.634	rs4911153	ENSG00000206582.1	Y_RNA	4.96	1.41e-06	0.000968	0.37	0.31	Glomerular filtration rate (creatinine);	chr20:34373741	chr20:34526510~34526606:-
OV	cis	rs7927592	0.871	rs55953412	ENSG00000212093.1	AP000807.1	4.95	1.41e-06	0.000969	0.39	0.31	Total body bone mineral density;	chr11:68560815	chr11:68506083~68506166:-
OV	cis	rs7927592	0.913	rs7102898	ENSG00000212093.1	AP000807.1	4.95	1.41e-06	0.000969	0.39	0.31	Total body bone mineral density;	chr11:68561402	chr11:68506083~68506166:-
OV	cis	rs17301013	0.507	rs1474575	ENSG00000227373.4	RP11-160H22.5	-4.95	1.41e-06	0.000969	-0.41	-0.31	Systemic lupus erythematosus;	chr1:174569563	chr1:174115300~174160004:-
OV	cis	rs8100891	0.537	rs16967141	ENSG00000267213.4	AC007773.2	-4.95	1.42e-06	0.00097	-0.48	-0.31	Neuroticism;	chr19:32480317	chr19:32390050~32405560:-
OV	cis	rs9298506	1	rs4552882	ENSG00000254142.2	RP11-53M11.3	4.95	1.42e-06	0.000972	0.43	0.31	Intracranial aneurysm;	chr8:54549764	chr8:54554361~54561927:+
OV	cis	rs10992471	0.756	rs7043152	ENSG00000281156.1	MIR3651	-4.95	1.42e-06	0.000973	-0.35	-0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92376217	chr9:92292458~92292547:-
OV	cis	rs116095464	0.558	rs1541822	ENSG00000250848.1	CTD-2083E4.5	4.95	1.43e-06	0.000977	0.38	0.31	Breast cancer;	chr5:269119	chr5:288833~290321:-
OV	cis	rs9291683	0.609	rs7678012	ENSG00000250413.1	RP11-448G15.1	-4.95	1.43e-06	0.000978	-0.36	-0.31	Bone mineral density;	chr4:9992148	chr4:10006482~10009725:+
OV	cis	rs17301013	0.507	rs72715262	ENSG00000227373.4	RP11-160H22.5	4.95	1.43e-06	0.000978	0.42	0.31	Systemic lupus erythematosus;	chr1:174607088	chr1:174115300~174160004:-
OV	cis	rs6471393	0.929	rs56108220	ENSG00000253848.1	RP11-10N23.5	4.95	1.43e-06	0.000978	0.37	0.31	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93736965	chr8:93741193~93744534:+
OV	cis	rs3758911	0.894	rs11212162	ENSG00000261098.1	RP11-819C21.1	-4.95	1.43e-06	0.000981	-0.3	-0.31	Coronary artery disease;	chr11:107327884	chr11:107312132~107316271:-
OV	cis	rs34779708	0.966	rs10827493	ENSG00000230534.5	RP11-297A16.2	4.95	1.43e-06	0.000981	0.4	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35166048	chr10:35098006~35127020:-
OV	cis	rs11690935	0.589	rs6729945	ENSG00000228389.1	AC068039.4	-4.95	1.43e-06	0.000981	-0.35	-0.31	Schizophrenia;	chr2:171999788	chr2:171773482~171775844:+
OV	cis	rs7968440	0.736	rs10747592	ENSG00000257298.1	RP3-405J10.3	-4.95	1.44e-06	0.000982	-0.3	-0.31	Fibrinogen;	chr12:50788339	chr12:50185580~50191363:-
OV	cis	rs11673344	0.864	rs8108727	ENSG00000226686.6	LINC01535	4.95	1.44e-06	0.000982	0.4	0.31	Obesity-related traits;	chr19:37090622	chr19:37251912~37265535:+
OV	cis	rs2243480	1	rs1499614	ENSG00000226824.5	RP4-756H11.3	-4.95	1.44e-06	0.000982	-0.49	-0.31	Diabetic kidney disease;	chr7:66265811	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs4718334	ENSG00000226824.5	RP4-756H11.3	4.95	1.44e-06	0.000982	0.5	0.31	Diabetic kidney disease;	chr7:66324467	chr7:66654538~66669855:+
OV	cis	rs62355900	0.627	rs16886449	ENSG00000271828.1	CTD-2310F14.1	4.95	1.44e-06	0.000983	0.58	0.31	Endometriosis;	chr5:56880479	chr5:56927874~56929573:+
OV	cis	rs62355900	0.627	rs895380	ENSG00000271828.1	CTD-2310F14.1	4.95	1.44e-06	0.000983	0.58	0.31	Endometriosis;	chr5:56881321	chr5:56927874~56929573:+
OV	cis	rs1528149	0.504	rs1527215	ENSG00000224683.1	RPL36AP29	-4.95	1.44e-06	0.000984	-0.36	-0.31	Sitting height ratio;	chr7:16127184	chr7:16208945~16209265:+
OV	cis	rs6088580	0.584	rs2378203	ENSG00000206582.1	Y_RNA	4.95	1.44e-06	0.000985	0.37	0.31	Glomerular filtration rate (creatinine);	chr20:34406040	chr20:34526510~34526606:-
OV	cis	rs14027	0.921	rs16893140	ENSG00000279347.1	RP11-85I17.2	-4.95	1.44e-06	0.000986	-0.32	-0.31	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119767007	chr8:119838736~119840385:-
OV	cis	rs607987	0.871	rs673740	ENSG00000254532.1	RP11-624D11.2	4.95	1.44e-06	0.000986	0.36	0.31	Body mass index;	chr11:30250298	chr11:30044058~30084343:-
OV	cis	rs607987	0.871	rs34487664	ENSG00000254532.1	RP11-624D11.2	-4.95	1.44e-06	0.000986	-0.36	-0.31	Body mass index;	chr11:30253804	chr11:30044058~30084343:-
OV	cis	rs607987	0.836	rs4531442	ENSG00000254532.1	RP11-624D11.2	-4.95	1.44e-06	0.000986	-0.36	-0.31	Body mass index;	chr11:30257282	chr11:30044058~30084343:-
OV	cis	rs607987	0.871	rs1933345	ENSG00000254532.1	RP11-624D11.2	-4.95	1.44e-06	0.000986	-0.36	-0.31	Body mass index;	chr11:30257721	chr11:30044058~30084343:-
OV	cis	rs607987	0.871	rs1933346	ENSG00000254532.1	RP11-624D11.2	-4.95	1.44e-06	0.000986	-0.36	-0.31	Body mass index;	chr11:30257807	chr11:30044058~30084343:-
OV	cis	rs607987	0.871	rs7924960	ENSG00000254532.1	RP11-624D11.2	-4.95	1.44e-06	0.000986	-0.36	-0.31	Body mass index;	chr11:30258528	chr11:30044058~30084343:-
OV	cis	rs607987	0.841	rs11031014	ENSG00000254532.1	RP11-624D11.2	-4.95	1.44e-06	0.000986	-0.36	-0.31	Body mass index;	chr11:30259519	chr11:30044058~30084343:-
OV	cis	rs607987	0.871	rs4244552	ENSG00000254532.1	RP11-624D11.2	-4.95	1.44e-06	0.000986	-0.36	-0.31	Body mass index;	chr11:30260727	chr11:30044058~30084343:-
OV	cis	rs607987	0.871	rs11031024	ENSG00000254532.1	RP11-624D11.2	-4.95	1.44e-06	0.000986	-0.36	-0.31	Body mass index;	chr11:30270629	chr11:30044058~30084343:-
OV	cis	rs607987	0.871	rs11031025	ENSG00000254532.1	RP11-624D11.2	-4.95	1.44e-06	0.000986	-0.36	-0.31	Body mass index;	chr11:30270803	chr11:30044058~30084343:-
OV	cis	rs607987	0.871	rs10835643	ENSG00000254532.1	RP11-624D11.2	-4.95	1.44e-06	0.000986	-0.36	-0.31	Body mass index;	chr11:30272782	chr11:30044058~30084343:-
OV	cis	rs607987	0.871	rs4923629	ENSG00000254532.1	RP11-624D11.2	-4.95	1.44e-06	0.000986	-0.36	-0.31	Body mass index;	chr11:30273685	chr11:30044058~30084343:-
OV	cis	rs607987	0.836	rs11031027	ENSG00000254532.1	RP11-624D11.2	-4.95	1.44e-06	0.000986	-0.36	-0.31	Body mass index;	chr11:30275827	chr11:30044058~30084343:-
OV	cis	rs607987	0.841	rs12363576	ENSG00000254532.1	RP11-624D11.2	-4.95	1.44e-06	0.000986	-0.36	-0.31	Body mass index;	chr11:30280060	chr11:30044058~30084343:-
OV	cis	rs607987	0.871	rs4923631	ENSG00000254532.1	RP11-624D11.2	-4.95	1.44e-06	0.000986	-0.36	-0.31	Body mass index;	chr11:30280321	chr11:30044058~30084343:-
OV	cis	rs607987	0.841	rs11031028	ENSG00000254532.1	RP11-624D11.2	-4.95	1.44e-06	0.000986	-0.36	-0.31	Body mass index;	chr11:30281376	chr11:30044058~30084343:-
OV	cis	rs607987	0.841	rs11031030	ENSG00000254532.1	RP11-624D11.2	-4.95	1.44e-06	0.000986	-0.36	-0.31	Body mass index;	chr11:30282908	chr11:30044058~30084343:-
OV	cis	rs11096990	0.634	rs746678	ENSG00000249207.1	RP11-360F5.1	4.95	1.45e-06	0.000988	0.33	0.31	Cognitive function;	chr4:39279035	chr4:39112677~39126818:-
OV	cis	rs11690935	0.55	rs62183784	ENSG00000228389.1	AC068039.4	-4.95	1.45e-06	0.000988	-0.35	-0.31	Schizophrenia;	chr2:172001789	chr2:171773482~171775844:+
OV	cis	rs11690935	0.55	rs62183785	ENSG00000228389.1	AC068039.4	-4.95	1.45e-06	0.000988	-0.35	-0.31	Schizophrenia;	chr2:172002068	chr2:171773482~171775844:+
OV	cis	rs7927592	0.913	rs11228276	ENSG00000212093.1	AP000807.1	4.95	1.45e-06	0.000988	0.4	0.31	Total body bone mineral density;	chr11:68540057	chr11:68506083~68506166:-
OV	cis	rs7927592	0.913	rs67005337	ENSG00000212093.1	AP000807.1	4.95	1.45e-06	0.000988	0.4	0.31	Total body bone mineral density;	chr11:68540290	chr11:68506083~68506166:-
OV	cis	rs67311347	1	rs11714912	ENSG00000223797.4	ENTPD3-AS1	-4.95	1.45e-06	0.000988	-0.35	-0.31	Renal cell carcinoma;	chr3:40452574	chr3:40313802~40453329:-
OV	cis	rs6921919	0.945	rs16901847	ENSG00000216901.1	AL022393.7	4.95	1.45e-06	0.000989	0.43	0.31	Autism spectrum disorder or schizophrenia;	chr6:28408074	chr6:28176188~28176674:+
OV	cis	rs17301013	0.606	rs12354141	ENSG00000227373.4	RP11-160H22.5	4.95	1.45e-06	0.00099	0.41	0.31	Systemic lupus erythematosus;	chr1:174166078	chr1:174115300~174160004:-
OV	cis	rs13068223	0.819	rs11917436	ENSG00000243926.1	TIPARP-AS1	4.95	1.45e-06	0.00099	0.29	0.31	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747839	chr3:156671862~156674378:-
OV	cis	rs201673768	1	rs201673768	ENSG00000258273.1	RP11-370I10.4	-4.95	1.45e-06	0.000991	-0.4	-0.31	Platelet count;	chr12:48305834	chr12:48333755~48333901:-
OV	cis	rs2153535	0.585	rs4959494	ENSG00000230939.1	RP11-314C16.1	-4.95	1.45e-06	0.000991	-0.34	-0.31	Motion sickness;	chr6:8640935	chr6:8784178~8785445:+
OV	cis	rs2153535	0.585	rs4959495	ENSG00000230939.1	RP11-314C16.1	-4.95	1.45e-06	0.000991	-0.34	-0.31	Motion sickness;	chr6:8641186	chr6:8784178~8785445:+
OV	cis	rs2153535	0.585	rs11243264	ENSG00000230939.1	RP11-314C16.1	-4.95	1.45e-06	0.000991	-0.34	-0.31	Motion sickness;	chr6:8642912	chr6:8784178~8785445:+
OV	cis	rs2153535	0.585	rs11243265	ENSG00000230939.1	RP11-314C16.1	-4.95	1.45e-06	0.000991	-0.34	-0.31	Motion sickness;	chr6:8642925	chr6:8784178~8785445:+
OV	cis	rs2153535	0.585	rs9406185	ENSG00000230939.1	RP11-314C16.1	-4.95	1.45e-06	0.000991	-0.34	-0.31	Motion sickness;	chr6:8644491	chr6:8784178~8785445:+
OV	cis	rs1501911	0.611	rs1875529	ENSG00000248489.1	CTD-2007H13.3	-4.95	1.45e-06	0.000992	-0.39	-0.31	Lung function (FEV1/FVC);	chr5:99033350	chr5:98929171~98995013:+
OV	cis	rs12682352	0.715	rs332039	ENSG00000253893.2	FAM85B	-4.95	1.45e-06	0.000992	-0.35	-0.31	Neuroticism;	chr8:8866141	chr8:8167819~8226614:-
OV	cis	rs7927592	0.913	rs2282563	ENSG00000212093.1	AP000807.1	4.95	1.46e-06	0.000995	0.4	0.31	Total body bone mineral density;	chr11:68565732	chr11:68506083~68506166:-
OV	cis	rs875971	0.545	rs221986	ENSG00000226824.5	RP4-756H11.3	4.95	1.46e-06	0.000995	0.37	0.31	Aortic root size;	chr7:66105323	chr7:66654538~66669855:+
OV	cis	rs6088590	0.561	rs6059934	ENSG00000206582.1	Y_RNA	-4.95	1.46e-06	0.000995	-0.38	-0.31	Coronary artery disease;	chr20:34590520	chr20:34526510~34526606:-
OV	cis	rs11690935	0.531	rs62183800	ENSG00000228389.1	AC068039.4	-4.95	1.46e-06	0.000996	-0.35	-0.31	Schizophrenia;	chr2:172002365	chr2:171773482~171775844:+
OV	cis	rs11690935	0.55	rs62183801	ENSG00000228389.1	AC068039.4	-4.95	1.46e-06	0.000996	-0.35	-0.31	Schizophrenia;	chr2:172002567	chr2:171773482~171775844:+
OV	cis	rs11690935	0.55	rs6718013	ENSG00000228389.1	AC068039.4	-4.95	1.46e-06	0.000996	-0.35	-0.31	Schizophrenia;	chr2:172004277	chr2:171773482~171775844:+
OV	cis	rs7302981	0.667	rs7136648	ENSG00000272368.2	RP4-605O3.4	4.95	1.46e-06	0.000996	0.35	0.31	Systolic blood pressure;	chr12:50231039	chr12:50112197~50165618:+
OV	cis	rs11157436	0.918	rs7159024	ENSG00000211812.1	TRAV26-2	-4.95	1.46e-06	0.000997	-0.35	-0.31	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22228760	chr14:22202583~22203368:+
OV	cis	rs796364	0.951	rs12620298	ENSG00000232732.8	AC073043.1	4.95	1.46e-06	0.000997	0.43	0.31	Schizophrenia;	chr2:200182461	chr2:199867396~199911159:-
OV	cis	rs526231	0.543	rs34379	ENSG00000175749.11	EIF3KP1	-4.95	1.46e-06	0.000997	-0.36	-0.31	Primary biliary cholangitis;	chr5:103062994	chr5:103032376~103033031:+
OV	cis	rs17301013	0.606	rs10912728	ENSG00000227373.4	RP11-160H22.5	4.95	1.46e-06	0.000998	0.41	0.31	Systemic lupus erythematosus;	chr1:174093234	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs4652168	ENSG00000227373.4	RP11-160H22.5	4.95	1.46e-06	0.000998	0.41	0.31	Systemic lupus erythematosus;	chr1:174095077	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs28831202	ENSG00000227373.4	RP11-160H22.5	4.95	1.46e-06	0.000998	0.41	0.31	Systemic lupus erythematosus;	chr1:174099231	chr1:174115300~174160004:-
OV	cis	rs8005677	1	rs4982712	ENSG00000279656.1	RP11-298I3.6	4.95	1.47e-06	0.001	0.34	0.31	Cognitive ability (multi-trait analysis);	chr14:22934519	chr14:23023083~23024217:-
OV	cis	rs11096990	0.593	rs7685619	ENSG00000249207.1	RP11-360F5.1	-4.95	1.47e-06	0.001	-0.33	-0.31	Cognitive function;	chr4:39211779	chr4:39112677~39126818:-
OV	cis	rs4853012	0.793	rs6707619	ENSG00000257800.1	FNBP1P1	4.95	1.47e-06	0.001	0.44	0.31	Gestational age at birth (maternal effect);	chr2:74117529	chr2:74120680~74123218:+
OV	cis	rs3814244	0.933	rs10748093	ENSG00000255733.4	IFNG-AS1	-4.95	1.47e-06	0.001	-0.3	-0.31	Itch intensity from mosquito bite adjusted by bite size;	chr12:68024469	chr12:67989445~68234686:+
OV	cis	rs2739330	0.791	rs4822458	ENSG00000235689.1	AP000351.13	4.95	1.47e-06	0.001	0.36	0.31	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23923472	chr22:24006305~24008258:-
OV	cis	rs7428	0.545	rs17026212	ENSG00000246575.2	AC093162.5	4.95	1.47e-06	0.001	0.31	0.31	Ear protrusion;	chr2:85324573	chr2:85315041~85316529:+
OV	cis	rs992157	0.835	rs7559416	ENSG00000261338.2	RP11-378A13.1	-4.95	1.48e-06	0.00101	-0.36	-0.31	Colorectal cancer;	chr2:218285488	chr2:218255319~218257366:+
OV	cis	rs9813712	0.571	rs6795143	ENSG00000228252.7	COL6A4P2	-4.95	1.48e-06	0.00101	-0.36	-0.31	Response to amphetamines;	chr3:130224355	chr3:130212823~130273806:+
OV	cis	rs9813712	0.571	rs9289366	ENSG00000228252.7	COL6A4P2	-4.95	1.48e-06	0.00101	-0.36	-0.31	Response to amphetamines;	chr3:130225267	chr3:130212823~130273806:+
OV	cis	rs9813712	0.571	rs9289367	ENSG00000228252.7	COL6A4P2	-4.95	1.48e-06	0.00101	-0.36	-0.31	Response to amphetamines;	chr3:130225286	chr3:130212823~130273806:+
OV	cis	rs9813712	0.571	rs9289368	ENSG00000228252.7	COL6A4P2	-4.95	1.48e-06	0.00101	-0.36	-0.31	Response to amphetamines;	chr3:130225562	chr3:130212823~130273806:+
OV	cis	rs9813712	0.571	rs6774141	ENSG00000228252.7	COL6A4P2	-4.95	1.48e-06	0.00101	-0.36	-0.31	Response to amphetamines;	chr3:130225599	chr3:130212823~130273806:+
OV	cis	rs875971	0.545	rs1547529	ENSG00000236529.1	RP13-254B10.1	4.95	1.48e-06	0.00101	0.37	0.31	Aortic root size;	chr7:66258859	chr7:65840212~65840596:+
OV	cis	rs67311347	0.955	rs9821036	ENSG00000223797.4	ENTPD3-AS1	4.95	1.48e-06	0.00101	0.34	0.31	Renal cell carcinoma;	chr3:40337516	chr3:40313802~40453329:-
OV	cis	rs2153535	0.553	rs6932565	ENSG00000230939.1	RP11-314C16.1	-4.95	1.48e-06	0.00101	-0.34	-0.31	Motion sickness;	chr6:8644926	chr6:8784178~8785445:+
OV	cis	rs1185460	0.547	rs667584	ENSG00000271751.1	RP11-110I1.14	4.94	1.48e-06	0.00101	0.38	0.31	Coronary artery disease;	chr11:119040834	chr11:119065263~119065677:-
OV	cis	rs1185460	0.565	rs657685	ENSG00000271751.1	RP11-110I1.14	4.94	1.48e-06	0.00101	0.38	0.31	Coronary artery disease;	chr11:119042272	chr11:119065263~119065677:-
OV	cis	rs2153535	0.585	rs9379237	ENSG00000230939.1	RP11-314C16.1	-4.94	1.48e-06	0.00101	-0.34	-0.31	Motion sickness;	chr6:8654330	chr6:8784178~8785445:+
OV	cis	rs2153535	0.609	rs1328864	ENSG00000230939.1	RP11-314C16.1	-4.94	1.48e-06	0.00101	-0.34	-0.31	Motion sickness;	chr6:8656048	chr6:8784178~8785445:+
OV	cis	rs2153535	0.585	rs7450731	ENSG00000230939.1	RP11-314C16.1	-4.94	1.48e-06	0.00101	-0.34	-0.31	Motion sickness;	chr6:8656501	chr6:8784178~8785445:+
OV	cis	rs7302981	0.702	rs2358538	ENSG00000257298.1	RP3-405J10.3	-4.94	1.48e-06	0.00101	-0.3	-0.31	Systolic blood pressure;	chr12:50192844	chr12:50185580~50191363:-
OV	cis	rs4805272	0.539	rs1422212	ENSG00000267243.4	AC005307.3	-4.94	1.49e-06	0.00101	-0.56	-0.31	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28839284	chr19:28435388~28727777:-
OV	cis	rs10740039	0.804	rs4948424	ENSG00000254271.1	RP11-131N11.4	4.94	1.49e-06	0.00101	0.4	0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60681812	chr10:60734342~60741828:+
OV	cis	rs7189233	0.531	rs7202621	ENSG00000279344.1	RP11-44F14.7	4.94	1.49e-06	0.00101	0.29	0.31	Intelligence (multi-trait analysis);	chr16:53452125	chr16:53478957~53481550:-
OV	cis	rs7968440	0.808	rs829112	ENSG00000257298.1	RP3-405J10.3	-4.94	1.49e-06	0.00101	-0.31	-0.31	Fibrinogen;	chr12:50813921	chr12:50185580~50191363:-
OV	cis	rs301901	0.772	rs301874	ENSG00000250155.1	CTD-2353F22.1	-4.94	1.49e-06	0.00101	-0.36	-0.31	Height;	chr5:37094189	chr5:36666214~36725195:-
OV	cis	rs3814244	1	rs3814244	ENSG00000255733.4	IFNG-AS1	-4.94	1.49e-06	0.00102	-0.3	-0.31	Itch intensity from mosquito bite adjusted by bite size;	chr12:68019691	chr12:67989445~68234686:+
OV	cis	rs17023223	0.537	rs12081198	ENSG00000231365.4	RP11-418J17.1	-4.94	1.49e-06	0.00102	-0.41	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143481	chr1:119140396~119275973:+
OV	cis	rs17023223	0.537	rs12086686	ENSG00000231365.4	RP11-418J17.1	-4.94	1.49e-06	0.00102	-0.41	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146461	chr1:119140396~119275973:+
OV	cis	rs17023223	0.537	rs12097967	ENSG00000231365.4	RP11-418J17.1	-4.94	1.49e-06	0.00102	-0.41	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119160290	chr1:119140396~119275973:+
OV	cis	rs17023223	0.537	rs12064137	ENSG00000231365.4	RP11-418J17.1	-4.94	1.49e-06	0.00102	-0.41	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119167126	chr1:119140396~119275973:+
OV	cis	rs17023223	0.509	rs61806978	ENSG00000231365.4	RP11-418J17.1	-4.94	1.49e-06	0.00102	-0.41	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119170592	chr1:119140396~119275973:+
OV	cis	rs17023223	0.537	rs12065809	ENSG00000231365.4	RP11-418J17.1	-4.94	1.49e-06	0.00102	-0.41	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119181912	chr1:119140396~119275973:+
OV	cis	rs17023223	0.553	rs11484962	ENSG00000231365.4	RP11-418J17.1	-4.94	1.49e-06	0.00102	-0.41	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182563	chr1:119140396~119275973:+
OV	cis	rs17023223	0.537	rs66715579	ENSG00000231365.4	RP11-418J17.1	-4.94	1.49e-06	0.00102	-0.41	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182809	chr1:119140396~119275973:+
OV	cis	rs17023223	0.537	rs11487668	ENSG00000231365.4	RP11-418J17.1	-4.94	1.49e-06	0.00102	-0.41	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184173	chr1:119140396~119275973:+
OV	cis	rs17023223	0.537	rs10923766	ENSG00000231365.4	RP11-418J17.1	-4.94	1.49e-06	0.00102	-0.41	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119184309	chr1:119140396~119275973:+
OV	cis	rs17023223	0.537	rs61806983	ENSG00000231365.4	RP11-418J17.1	-4.94	1.49e-06	0.00102	-0.41	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119188901	chr1:119140396~119275973:+
OV	cis	rs17023223	0.537	rs12087987	ENSG00000231365.4	RP11-418J17.1	-4.94	1.49e-06	0.00102	-0.41	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119192198	chr1:119140396~119275973:+
OV	cis	rs1150668	0.83	rs2023493	ENSG00000220721.1	OR1F12	4.94	1.5e-06	0.00102	0.31	0.31	Pubertal anthropometrics;	chr6:28432385	chr6:28073316~28074233:+
OV	cis	rs9291683	0.597	rs11722989	ENSG00000250413.1	RP11-448G15.1	4.94	1.5e-06	0.00102	0.35	0.31	Bone mineral density;	chr4:10124515	chr4:10006482~10009725:+
OV	cis	rs9291683	0.546	rs7442336	ENSG00000250413.1	RP11-448G15.1	-4.94	1.5e-06	0.00102	-0.36	-0.31	Bone mineral density;	chr4:10044159	chr4:10006482~10009725:+
OV	cis	rs11157436	1	rs72638482	ENSG00000211812.1	TRAV26-2	-4.94	1.5e-06	0.00102	-0.4	-0.31	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22153322	chr14:22202583~22203368:+
OV	cis	rs1862618	0.526	rs2591963	ENSG00000271828.1	CTD-2310F14.1	-4.94	1.5e-06	0.00102	-0.53	-0.31	Initial pursuit acceleration;	chr5:56941308	chr5:56927874~56929573:+
OV	cis	rs1862618	0.573	rs2591962	ENSG00000271828.1	CTD-2310F14.1	-4.94	1.5e-06	0.00102	-0.53	-0.31	Initial pursuit acceleration;	chr5:56941328	chr5:56927874~56929573:+
OV	cis	rs1862618	0.573	rs1550821	ENSG00000271828.1	CTD-2310F14.1	-4.94	1.5e-06	0.00102	-0.53	-0.31	Initial pursuit acceleration;	chr5:56946496	chr5:56927874~56929573:+
OV	cis	rs7116641	0.734	rs7131110	ENSG00000246250.2	RP11-613D13.5	-4.94	1.5e-06	0.00102	-0.35	-0.31	Coronary artery disease;	chr11:43825300	chr11:43829709~43880726:-
OV	cis	rs7116641	0.734	rs1464230	ENSG00000246250.2	RP11-613D13.5	-4.94	1.5e-06	0.00102	-0.35	-0.31	Coronary artery disease;	chr11:43827204	chr11:43829709~43880726:-
OV	cis	rs7116641	0.734	rs2139154	ENSG00000246250.2	RP11-613D13.5	-4.94	1.5e-06	0.00102	-0.35	-0.31	Coronary artery disease;	chr11:43837132	chr11:43829709~43880726:-
OV	cis	rs7116641	0.734	rs9971535	ENSG00000246250.2	RP11-613D13.5	-4.94	1.5e-06	0.00102	-0.35	-0.31	Coronary artery disease;	chr11:43840775	chr11:43829709~43880726:-
OV	cis	rs9291683	0.507	rs6845554	ENSG00000250413.1	RP11-448G15.1	-4.94	1.51e-06	0.00102	-0.36	-0.31	Bone mineral density;	chr4:10011549	chr4:10006482~10009725:+
OV	cis	rs17301013	0.507	rs72713532	ENSG00000227373.4	RP11-160H22.5	4.94	1.51e-06	0.00102	0.4	0.31	Systemic lupus erythematosus;	chr1:174337826	chr1:174115300~174160004:-
OV	cis	rs9309473	1	rs6711033	ENSG00000163016.8	ALMS1P	4.94	1.51e-06	0.00102	0.37	0.31	Metabolite levels;	chr2:73519516	chr2:73644919~73685576:+
OV	cis	rs4713118	0.513	rs149959	ENSG00000219392.1	RP1-265C24.5	-4.94	1.51e-06	0.00102	-0.37	-0.31	Parkinson's disease;	chr6:28046076	chr6:28115628~28116551:+
OV	cis	rs7923609	0.578	rs10740138	ENSG00000232075.1	MRPL35P2	-4.94	1.51e-06	0.00102	-0.32	-0.31	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63635373	chr10:63634317~63634827:-
OV	cis	rs45509595	0.841	rs200485	ENSG00000220721.1	OR1F12	4.94	1.52e-06	0.00103	0.5	0.31	Breast cancer;	chr6:27807919	chr6:28073316~28074233:+
OV	cis	rs45509595	0.841	rs370155	ENSG00000220721.1	OR1F12	4.94	1.52e-06	0.00103	0.5	0.31	Breast cancer;	chr6:27814253	chr6:28073316~28074233:+
OV	cis	rs67311347	1	rs1119179	ENSG00000223797.4	ENTPD3-AS1	-4.94	1.52e-06	0.00103	-0.36	-0.31	Renal cell carcinoma;	chr3:40383438	chr3:40313802~40453329:-
OV	cis	rs1729407	0.786	rs5100	ENSG00000254851.1	RP11-109L13.1	-4.94	1.52e-06	0.00103	-0.39	-0.31	Apolipoprotein A-IV levels;	chr11:116821978	chr11:117135528~117138582:+
OV	cis	rs875971	0.545	rs1638735	ENSG00000237310.1	GS1-124K5.4	4.94	1.52e-06	0.00103	0.33	0.31	Aortic root size;	chr7:66630751	chr7:66493706~66495474:+
OV	cis	rs4713118	0.866	rs9468217	ENSG00000280107.1	AL022393.9	-4.94	1.52e-06	0.00103	-0.39	-0.31	Parkinson's disease;	chr6:27758688	chr6:28170845~28172521:+
OV	cis	rs17301013	0.507	rs12074107	ENSG00000227373.4	RP11-160H22.5	-4.94	1.52e-06	0.00103	-0.39	-0.31	Systemic lupus erythematosus;	chr1:174307926	chr1:174115300~174160004:-
OV	cis	rs875971	0.545	rs2707851	ENSG00000236529.1	RP13-254B10.1	-4.94	1.53e-06	0.00104	-0.37	-0.31	Aortic root size;	chr7:66624178	chr7:65840212~65840596:+
OV	cis	rs1075265	0.73	rs11893270	ENSG00000233266.1	HMGB1P31	4.94	1.53e-06	0.00104	0.39	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54019828	chr2:54051334~54051760:+
OV	cis	rs7690543	0.581	rs11943139	ENSG00000248049.5	UBA6-AS1	-4.94	1.53e-06	0.00104	-0.48	-0.31	Glucose homeostasis traits;	chr4:67126659	chr4:67701280~68080952:+
OV	cis	rs16873450	0.571	rs10268973	ENSG00000234800.2	PCMTD1P3	4.94	1.53e-06	0.00104	0.31	0.31	Verbal memory performance (residualized delayed recall level);	chr7:23763696	chr7:23721311~23721782:-
OV	cis	rs6558530	0.73	rs4875958	ENSG00000253982.1	CTD-2336O2.1	-4.94	1.53e-06	0.00104	-0.34	-0.31	Systolic blood pressure;	chr8:1772924	chr8:1761990~1764502:-
OV	cis	rs34779708	0.931	rs2490663	ENSG00000230534.5	RP11-297A16.2	-4.94	1.53e-06	0.00104	-0.41	-0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35040807	chr10:35098006~35127020:-
OV	cis	rs10992471	0.756	rs1121979	ENSG00000281156.1	MIR3651	-4.94	1.54e-06	0.00104	-0.35	-0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92377936	chr9:92292458~92292547:-
OV	cis	rs10992471	0.756	rs11792342	ENSG00000281156.1	MIR3651	-4.94	1.54e-06	0.00104	-0.35	-0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92381386	chr9:92292458~92292547:-
OV	cis	rs7429990	0.932	rs34025851	ENSG00000229759.1	MRPS18AP1	4.94	1.54e-06	0.00104	0.34	0.31	Educational attainment (years of education);	chr3:47912243	chr3:48256350~48256938:-
OV	cis	rs4718428	1	rs12534637	ENSG00000226824.5	RP4-756H11.3	-4.94	1.54e-06	0.00104	-0.36	-0.31	Corneal structure;	chr7:66862667	chr7:66654538~66669855:+
OV	cis	rs992157	0.835	rs4674282	ENSG00000237281.1	CATIP-AS2	4.94	1.54e-06	0.00104	0.36	0.31	Colorectal cancer;	chr2:218279507	chr2:218326889~218357966:-
OV	cis	rs6435862	0.593	rs34732883	ENSG00000227769.6	AC072062.3	4.94	1.54e-06	0.00104	0.38	0.31	Neuroblastoma (high-risk);	chr2:214809647	chr2:215004782~215085488:+
OV	cis	rs4713118	0.662	rs149969	ENSG00000219392.1	RP1-265C24.5	-4.94	1.54e-06	0.00104	-0.4	-0.31	Parkinson's disease;	chr6:28009959	chr6:28115628~28116551:+
OV	cis	rs10486158	0.582	rs887605	ENSG00000187953.9	PMS2CL	-4.94	1.54e-06	0.00104	-0.39	-0.31	Bipolar disorder and schizophrenia;	chr7:7348302	chr7:6710128~6753862:+
OV	cis	rs7335046	1	rs1927726	ENSG00000280710.1	RP11-214F16.8	-4.94	1.55e-06	0.00105	-0.41	-0.31	Basal cell carcinoma;	chr13:99260629	chr13:99498524~99501315:+
OV	cis	rs11690935	0.589	rs62183782	ENSG00000228389.1	AC068039.4	-4.94	1.55e-06	0.00105	-0.35	-0.31	Schizophrenia;	chr2:172000102	chr2:171773482~171775844:+
OV	cis	rs496547	0.686	rs477014	ENSG00000278376.1	RP11-158I9.8	-4.94	1.55e-06	0.00105	-0.31	-0.31	Hip minimal joint space width;	chr11:118808277	chr11:118791254~118793137:+
OV	cis	rs295490	0.688	rs184157	ENSG00000272656.1	RP11-219D15.3	4.94	1.55e-06	0.00105	0.43	0.31	PR interval in Tripanosoma cruzi seropositivity;	chr3:139523324	chr3:139349024~139349371:-
OV	cis	rs607987	0.871	rs35458722	ENSG00000254532.1	RP11-624D11.2	-4.93	1.55e-06	0.00105	-0.37	-0.31	Body mass index;	chr11:30253594	chr11:30044058~30084343:-
OV	cis	rs6991838	0.584	rs35941313	ENSG00000200714.1	Y_RNA	-4.93	1.55e-06	0.00105	-0.39	-0.31	Intelligence (multi-trait analysis);	chr8:65587498	chr8:65592731~65592820:+
OV	cis	rs301901	1	rs300064	ENSG00000250155.1	CTD-2353F22.1	4.93	1.56e-06	0.00105	0.36	0.31	Height;	chr5:37025769	chr5:36666214~36725195:-
OV	cis	rs1061377	0.748	rs35904472	ENSG00000249207.1	RP11-360F5.1	-4.93	1.56e-06	0.00105	-0.32	-0.31	Uric acid levels;	chr4:39094901	chr4:39112677~39126818:-
OV	cis	rs1061377	0.748	rs10856841	ENSG00000249207.1	RP11-360F5.1	-4.93	1.56e-06	0.00105	-0.32	-0.31	Uric acid levels;	chr4:39095240	chr4:39112677~39126818:-
OV	cis	rs10246939	0.543	rs11765575	ENSG00000228775.6	WEE2-AS1	4.93	1.56e-06	0.00105	0.32	0.31	Bitter taste perception;	chr7:141838168	chr7:141704338~141738346:-
OV	cis	rs6558530	0.692	rs7818406	ENSG00000253982.1	CTD-2336O2.1	4.93	1.56e-06	0.00105	0.4	0.31	Systolic blood pressure;	chr8:1753084	chr8:1761990~1764502:-
OV	cis	rs6558530	0.692	rs10105317	ENSG00000253982.1	CTD-2336O2.1	4.93	1.56e-06	0.00105	0.4	0.31	Systolic blood pressure;	chr8:1753266	chr8:1761990~1764502:-
OV	cis	rs4853012	0.838	rs72915068	ENSG00000257800.1	FNBP1P1	4.93	1.56e-06	0.00105	0.44	0.31	Gestational age at birth (maternal effect);	chr2:74129058	chr2:74120680~74123218:+
OV	cis	rs17711722	0.565	rs73372653	ENSG00000224316.1	RP11-479O9.2	4.93	1.56e-06	0.00105	0.35	0.31	Calcium levels;	chr7:65977808	chr7:65773620~65802067:+
OV	cis	rs992157	1	rs6736362	ENSG00000261338.2	RP11-378A13.1	4.93	1.56e-06	0.00106	0.37	0.31	Colorectal cancer;	chr2:218250385	chr2:218255319~218257366:+
OV	cis	rs319690	1	rs319690	ENSG00000229759.1	MRPS18AP1	4.93	1.56e-06	0.00106	0.33	0.31	Diastolic blood pressure;Systolic blood pressure;Blood pressure;	chr3:47885994	chr3:48256350~48256938:-
OV	cis	rs13068223	0.716	rs344067	ENSG00000243926.1	TIPARP-AS1	-4.93	1.56e-06	0.00106	-0.3	-0.31	Age-related hearing impairment (SNP x SNP interaction);	chr3:156723825	chr3:156671862~156674378:-
OV	cis	rs301901	0.796	rs4869527	ENSG00000250155.1	CTD-2353F22.1	4.93	1.56e-06	0.00106	0.36	0.31	Height;	chr5:37533964	chr5:36666214~36725195:-
OV	cis	rs301901	0.796	rs6872681	ENSG00000250155.1	CTD-2353F22.1	4.93	1.56e-06	0.00106	0.36	0.31	Height;	chr5:37535278	chr5:36666214~36725195:-
OV	cis	rs301901	0.761	rs1533521	ENSG00000250155.1	CTD-2353F22.1	4.93	1.56e-06	0.00106	0.36	0.31	Height;	chr5:37540355	chr5:36666214~36725195:-
OV	cis	rs8100891	0.537	rs113427979	ENSG00000267213.4	AC007773.2	-4.93	1.57e-06	0.00106	-0.47	-0.31	Neuroticism;	chr19:32364502	chr19:32390050~32405560:-
OV	cis	rs9487094	0.922	rs10782162	ENSG00000260273.1	RP11-425D10.10	-4.93	1.57e-06	0.00106	-0.36	-0.31	Height;	chr6:109485060	chr6:109382795~109383666:+
OV	cis	rs10510102	0.608	rs4752607	ENSG00000276742.1	RP11-500G22.4	-4.93	1.57e-06	0.00106	-0.44	-0.31	Breast cancer;	chr10:121835426	chr10:121956782~121957098:+
OV	cis	rs7615952	0.512	rs1077621	ENSG00000171084.14	FAM86JP	4.93	1.57e-06	0.00106	0.46	0.31	Blood pressure (smoking interaction);	chr3:126100956	chr3:125916620~125930024:+
OV	cis	rs9291683	0.51	rs4318649	ENSG00000250413.1	RP11-448G15.1	-4.93	1.57e-06	0.00106	-0.36	-0.31	Bone mineral density;	chr4:10015191	chr4:10006482~10009725:+
OV	cis	rs3733585	0.746	rs4318650	ENSG00000250413.1	RP11-448G15.1	-4.93	1.57e-06	0.00106	-0.36	-0.31	Cleft plate (environmental tobacco smoke interaction);	chr4:10015244	chr4:10006482~10009725:+
OV	cis	rs9291683	0.526	rs6827785	ENSG00000250413.1	RP11-448G15.1	-4.93	1.57e-06	0.00106	-0.36	-0.31	Bone mineral density;	chr4:10016581	chr4:10006482~10009725:+
OV	cis	rs11098499	0.954	rs6849561	ENSG00000245958.5	RP11-33B1.1	4.93	1.57e-06	0.00106	0.37	0.31	Corneal astigmatism;	chr4:119488539	chr4:119454791~119552025:+
OV	cis	rs62355900	0.627	rs3736430	ENSG00000271828.1	CTD-2310F14.1	4.93	1.57e-06	0.00106	0.57	0.31	Endometriosis;	chr5:56884653	chr5:56927874~56929573:+
OV	cis	rs7587476	0.822	rs13018304	ENSG00000229267.2	AC072062.1	-4.93	1.58e-06	0.00106	-0.41	-0.31	Neuroblastoma;	chr2:214817494	chr2:214810229~214963274:+
OV	cis	rs4128705	1	rs4128704	ENSG00000249049.1	RP11-763F8.1	4.93	1.58e-06	0.00106	0.37	0.31	Amyotrophic lateral sclerosis (sporadic);	chr4:91362540	chr4:91319034~91325306:-
OV	cis	rs514406	0.929	rs554301	ENSG00000206627.1	RNU6-969P	-4.93	1.58e-06	0.00107	-0.32	-0.31	Monocyte count;	chr1:52856276	chr1:52805108~52805212:-
OV	cis	rs1426063	0.614	rs78784058	ENSG00000260265.1	RP11-44F21.5	4.93	1.58e-06	0.00107	0.58	0.31	QT interval;	chr4:75108738	chr4:75081702~75084717:-
OV	cis	rs4654783	0.505	rs7544210	ENSG00000228397.1	RP1-224A6.3	-4.93	1.58e-06	0.00107	-0.35	-0.31	Endometriosis;	chr1:22128649	chr1:22023994~22024968:-
OV	cis	rs16873450	0.527	rs1017192	ENSG00000234800.2	PCMTD1P3	-4.93	1.58e-06	0.00107	-0.32	-0.31	Verbal memory performance (residualized delayed recall level);	chr7:23770067	chr7:23721311~23721782:-
OV	cis	rs4356975	0.518	rs78408800	ENSG00000251284.2	RP13-644M16.1	-4.93	1.58e-06	0.00107	-0.46	-0.31	Obesity-related traits;	chr4:69101657	chr4:69125274~69126451:+
OV	cis	rs7189233	0.531	rs9941254	ENSG00000279344.1	RP11-44F14.7	4.93	1.59e-06	0.00107	0.29	0.31	Intelligence (multi-trait analysis);	chr16:53453306	chr16:53478957~53481550:-
OV	cis	rs7189233	0.531	rs7194730	ENSG00000279344.1	RP11-44F14.7	4.93	1.59e-06	0.00107	0.29	0.31	Intelligence (multi-trait analysis);	chr16:53455278	chr16:53478957~53481550:-
OV	cis	rs514406	0.929	rs557715	ENSG00000206627.1	RNU6-969P	4.93	1.59e-06	0.00107	0.32	0.31	Monocyte count;	chr1:52855921	chr1:52805108~52805212:-
OV	cis	rs8100891	0.537	rs2302773	ENSG00000267213.4	AC007773.2	-4.93	1.59e-06	0.00107	-0.47	-0.31	Neuroticism;	chr19:32436405	chr19:32390050~32405560:-
OV	cis	rs8100891	0.537	rs738093	ENSG00000267213.4	AC007773.2	-4.93	1.59e-06	0.00107	-0.47	-0.31	Neuroticism;	chr19:32439601	chr19:32390050~32405560:-
OV	cis	rs4908768	0.555	rs55939938	ENSG00000228423.2	RP4-633I8.4	4.93	1.59e-06	0.00107	0.34	0.31	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8803605	chr1:8805860~8807051:-
OV	cis	rs7429990	0.965	rs2631721	ENSG00000229759.1	MRPS18AP1	4.93	1.59e-06	0.00107	0.33	0.31	Educational attainment (years of education);	chr3:47881807	chr3:48256350~48256938:-
OV	cis	rs11157436	0.958	rs3811277	ENSG00000211812.1	TRAV26-2	-4.93	1.6e-06	0.00107	-0.39	-0.31	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22190419	chr14:22202583~22203368:+
OV	cis	rs2404602	0.583	rs2176623	ENSG00000259422.1	RP11-593F23.1	4.93	1.6e-06	0.00108	0.34	0.31	Blood metabolite levels;	chr15:76276238	chr15:76174891~76181486:-
OV	cis	rs9813712	0.953	rs9871734	ENSG00000228252.7	COL6A4P2	4.93	1.6e-06	0.00108	0.39	0.31	Response to amphetamines;	chr3:130240756	chr3:130212823~130273806:+
OV	cis	rs2253762	0.507	rs12264894	ENSG00000276742.1	RP11-500G22.4	4.93	1.6e-06	0.00108	0.53	0.31	Breast cancer;	chr10:121992087	chr10:121956782~121957098:+
OV	cis	rs1134634	0.52	rs1473166	ENSG00000273133.1	RP11-799M12.2	-4.93	1.6e-06	0.00108	-0.43	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15555868	chr4:15563698~15564253:-
OV	cis	rs1134634	0.52	rs2160044	ENSG00000273133.1	RP11-799M12.2	-4.93	1.6e-06	0.00108	-0.43	-0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15556720	chr4:15563698~15564253:-
OV	cis	rs7116641	0.699	rs6485469	ENSG00000246250.2	RP11-613D13.5	-4.93	1.6e-06	0.00108	-0.35	-0.31	Coronary artery disease;	chr11:43827743	chr11:43829709~43880726:-
OV	cis	rs7116641	0.734	rs2139153	ENSG00000246250.2	RP11-613D13.5	-4.93	1.6e-06	0.00108	-0.35	-0.31	Coronary artery disease;	chr11:43837004	chr11:43829709~43880726:-
OV	cis	rs4713118	0.513	rs149972	ENSG00000219392.1	RP1-265C24.5	-4.93	1.61e-06	0.00108	-0.38	-0.31	Parkinson's disease;	chr6:28015449	chr6:28115628~28116551:+
OV	cis	rs62034325	0.697	rs710410	ENSG00000259982.1	CDC37P1	4.93	1.61e-06	0.00108	0.4	0.31	Body mass index;	chr16:28592021	chr16:28700294~28701540:-
OV	cis	rs11673344	0.832	rs77772684	ENSG00000226686.6	LINC01535	4.93	1.61e-06	0.00108	0.41	0.31	Obesity-related traits;	chr19:37055838	chr19:37251912~37265535:+
OV	cis	rs34779708	0.931	rs4934709	ENSG00000230534.5	RP11-297A16.2	-4.93	1.61e-06	0.00108	-0.41	-0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35050396	chr10:35098006~35127020:-
OV	cis	rs11690935	0.55	rs55653103	ENSG00000228389.1	AC068039.4	-4.93	1.61e-06	0.00108	-0.35	-0.31	Schizophrenia;	chr2:171996909	chr2:171773482~171775844:+
OV	cis	rs1979679	0.842	rs981494	ENSG00000278733.1	RP11-425D17.1	-4.93	1.61e-06	0.00109	-0.37	-0.31	Ossification of the posterior longitudinal ligament of the spine;	chr12:28172916	chr12:28185625~28186190:-
OV	cis	rs301901	1	rs210540	ENSG00000250155.1	CTD-2353F22.1	-4.93	1.61e-06	0.00109	-0.36	-0.31	Height;	chr5:36804263	chr5:36666214~36725195:-
OV	cis	rs7017914	0.644	rs55970604	ENSG00000223220.1	Y_RNA	4.93	1.61e-06	0.00109	0.36	0.31	Bone mineral density;	chr8:71065538	chr8:70780914~70781008:-
OV	cis	rs17023223	0.537	rs12081327	ENSG00000231365.4	RP11-418J17.1	-4.93	1.62e-06	0.00109	-0.41	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119143735	chr1:119140396~119275973:+
OV	cis	rs17023223	0.537	rs12085616	ENSG00000231365.4	RP11-418J17.1	-4.93	1.62e-06	0.00109	-0.41	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119146525	chr1:119140396~119275973:+
OV	cis	rs17023223	0.537	rs6677107	ENSG00000231365.4	RP11-418J17.1	-4.93	1.62e-06	0.00109	-0.41	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166142	chr1:119140396~119275973:+
OV	cis	rs17023223	0.537	rs12064033	ENSG00000231365.4	RP11-418J17.1	-4.93	1.62e-06	0.00109	-0.41	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119166935	chr1:119140396~119275973:+
OV	cis	rs17023223	0.509	rs56195272	ENSG00000231365.4	RP11-418J17.1	-4.93	1.62e-06	0.00109	-0.41	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119171374	chr1:119140396~119275973:+
OV	cis	rs17023223	0.537	rs55836852	ENSG00000231365.4	RP11-418J17.1	-4.93	1.62e-06	0.00109	-0.41	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119182778	chr1:119140396~119275973:+
OV	cis	rs896854	0.54	rs2011567	ENSG00000253528.2	RP11-347C18.4	4.93	1.62e-06	0.00109	0.3	0.31	Type 2 diabetes;	chr8:94959692	chr8:94974573~94974853:-
OV	cis	rs11673344	0.808	rs57916401	ENSG00000226686.6	LINC01535	4.93	1.62e-06	0.00109	0.4	0.31	Obesity-related traits;	chr19:37153149	chr19:37251912~37265535:+
OV	cis	rs6772849	0.896	rs4857859	ENSG00000242551.2	POU5F1P6	-4.93	1.62e-06	0.00109	-0.36	-0.31	Monocyte percentage of white cells;Monocyte count;	chr3:128629171	chr3:128674735~128677005:-
OV	cis	rs7429990	0.965	rs319682	ENSG00000229759.1	MRPS18AP1	4.93	1.62e-06	0.00109	0.33	0.31	Educational attainment (years of education);	chr3:47873628	chr3:48256350~48256938:-
OV	cis	rs875971	0.545	rs17138156	ENSG00000236529.1	RP13-254B10.1	4.93	1.62e-06	0.00109	0.37	0.31	Aortic root size;	chr7:66249708	chr7:65840212~65840596:+
OV	cis	rs4763879	0.778	rs2895989	ENSG00000278635.1	CTD-2318O12.1	4.93	1.62e-06	0.00109	0.26	0.31	Type 1 diabetes;	chr12:9688735	chr12:9415641~9416718:+
OV	cis	rs4908768	0.717	rs12119207	ENSG00000228423.2	RP4-633I8.4	4.92	1.63e-06	0.00109	0.36	0.31	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8769440	chr1:8805860~8807051:-
OV	cis	rs4908768	0.639	rs4908512	ENSG00000228423.2	RP4-633I8.4	4.92	1.63e-06	0.00109	0.36	0.31	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8770307	chr1:8805860~8807051:-
OV	cis	rs4908768	0.594	rs11121227	ENSG00000228423.2	RP4-633I8.4	4.92	1.63e-06	0.00109	0.36	0.31	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8770581	chr1:8805860~8807051:-
OV	cis	rs4763879	0.739	rs12582584	ENSG00000278635.1	CTD-2318O12.1	4.92	1.63e-06	0.00109	0.27	0.31	Type 1 diabetes;	chr12:9671542	chr12:9415641~9416718:+
OV	cis	rs11976180	0.569	rs12703565	ENSG00000170356.8	OR2A20P	-4.92	1.63e-06	0.00109	-0.55	-0.31	Obesity-related traits;	chr7:144057308	chr7:144250045~144252957:-
OV	cis	rs6471393	0.895	rs58103546	ENSG00000253848.1	RP11-10N23.5	4.92	1.63e-06	0.0011	0.39	0.31	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93749483	chr8:93741193~93744534:+
OV	cis	rs10992471	0.756	rs7027595	ENSG00000281156.1	MIR3651	-4.92	1.63e-06	0.0011	-0.35	-0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92369271	chr9:92292458~92292547:-
OV	cis	rs2239557	1	rs2358628	ENSG00000259065.1	RP5-1021I20.1	4.92	1.63e-06	0.0011	0.38	0.31	Common traits (Other);	chr14:74165054	chr14:73787360~73803270:+
OV	cis	rs3733585	0.781	rs57250714	ENSG00000250413.1	RP11-448G15.1	-4.92	1.63e-06	0.0011	-0.34	-0.31	Cleft plate (environmental tobacco smoke interaction);	chr4:9982905	chr4:10006482~10009725:+
OV	cis	rs7017914	0.652	rs441890	ENSG00000223220.1	Y_RNA	4.92	1.63e-06	0.0011	0.31	0.31	Bone mineral density;	chr8:70652432	chr8:70780914~70781008:-
OV	cis	rs1061377	0.71	rs12503506	ENSG00000249207.1	RP11-360F5.1	-4.92	1.63e-06	0.0011	-0.32	-0.31	Uric acid levels;	chr4:39082553	chr4:39112677~39126818:-
OV	cis	rs4664293	0.51	rs1968343	ENSG00000226266.5	AC009961.3	4.92	1.64e-06	0.0011	0.37	0.31	Monocyte percentage of white cells;	chr2:159712247	chr2:159670708~159712435:-
OV	cis	rs858239	0.738	rs13225593	ENSG00000230042.1	AK3P3	-4.92	1.64e-06	0.0011	-0.34	-0.31	Cerebrospinal fluid biomarker levels;	chr7:23220688	chr7:23129178~23129841:+
OV	cis	rs10992471	0.729	rs6479418	ENSG00000281156.1	MIR3651	-4.92	1.64e-06	0.0011	-0.34	-0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92302480	chr9:92292458~92292547:-
OV	cis	rs11096990	0.576	rs2008679	ENSG00000249207.1	RP11-360F5.1	4.92	1.64e-06	0.0011	0.33	0.31	Cognitive function;	chr4:39266385	chr4:39112677~39126818:-
OV	cis	rs4908768	0.657	rs3938719	ENSG00000228423.2	RP4-633I8.4	4.92	1.65e-06	0.0011	0.35	0.31	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8744938	chr1:8805860~8807051:-
OV	cis	rs12594515	1	rs8039622	ENSG00000273972.1	CTD-2306A12.1	-4.92	1.65e-06	0.00111	-0.33	-0.31	Weight;Waist circumference;	chr15:45694233	chr15:45702640~45703183:+
OV	cis	rs12594515	1	rs8039974	ENSG00000273972.1	CTD-2306A12.1	-4.92	1.65e-06	0.00111	-0.33	-0.31	Weight;Waist circumference;	chr15:45694467	chr15:45702640~45703183:+
OV	cis	rs12594515	1	rs6493167	ENSG00000273972.1	CTD-2306A12.1	-4.92	1.65e-06	0.00111	-0.33	-0.31	Weight;Waist circumference;	chr15:45694611	chr15:45702640~45703183:+
OV	cis	rs12594515	1	rs6493168	ENSG00000273972.1	CTD-2306A12.1	-4.92	1.65e-06	0.00111	-0.33	-0.31	Weight;Waist circumference;	chr15:45694613	chr15:45702640~45703183:+
OV	cis	rs8062405	0.755	rs62031607	ENSG00000278665.1	RP11-666O2.4	4.92	1.65e-06	0.00111	0.34	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620209	chr16:28599241~28601881:-
OV	cis	rs34375054	1	rs3751178	ENSG00000279233.1	RP11-158L12.4	-4.92	1.66e-06	0.00111	-0.25	-0.31	Post bronchodilator FEV1/FVC ratio;	chr12:125179811	chr12:125138245~125141711:+
OV	cis	rs12594515	1	rs6493170	ENSG00000273972.1	CTD-2306A12.1	-4.92	1.66e-06	0.00111	-0.33	-0.31	Weight;Waist circumference;	chr15:45694821	chr15:45702640~45703183:+
OV	cis	rs12594515	1	rs6493172	ENSG00000273972.1	CTD-2306A12.1	-4.92	1.66e-06	0.00111	-0.33	-0.31	Weight;Waist circumference;	chr15:45695015	chr15:45702640~45703183:+
OV	cis	rs12594515	1	rs8025258	ENSG00000273972.1	CTD-2306A12.1	-4.92	1.66e-06	0.00111	-0.33	-0.31	Weight;Waist circumference;	chr15:45695356	chr15:45702640~45703183:+
OV	cis	rs12594515	1	rs8027000	ENSG00000273972.1	CTD-2306A12.1	-4.92	1.66e-06	0.00111	-0.33	-0.31	Weight;Waist circumference;	chr15:45695597	chr15:45702640~45703183:+
OV	cis	rs12594515	1	rs8026221	ENSG00000273972.1	CTD-2306A12.1	-4.92	1.66e-06	0.00111	-0.33	-0.31	Weight;Waist circumference;	chr15:45695712	chr15:45702640~45703183:+
OV	cis	rs12594515	1	rs8031128	ENSG00000273972.1	CTD-2306A12.1	-4.92	1.66e-06	0.00111	-0.33	-0.31	Weight;Waist circumference;	chr15:45696330	chr15:45702640~45703183:+
OV	cis	rs12594515	1	rs8032361	ENSG00000273972.1	CTD-2306A12.1	-4.92	1.66e-06	0.00111	-0.33	-0.31	Weight;Waist circumference;	chr15:45696355	chr15:45702640~45703183:+
OV	cis	rs12594515	0.967	rs71405295	ENSG00000273972.1	CTD-2306A12.1	-4.92	1.66e-06	0.00111	-0.33	-0.31	Weight;Waist circumference;	chr15:45696723	chr15:45702640~45703183:+
OV	cis	rs12594515	0.506	rs74199860	ENSG00000273972.1	CTD-2306A12.1	-4.92	1.66e-06	0.00111	-0.33	-0.31	Weight;Waist circumference;	chr15:45696992	chr15:45702640~45703183:+
OV	cis	rs12594515	1	rs6493175	ENSG00000273972.1	CTD-2306A12.1	-4.92	1.66e-06	0.00111	-0.33	-0.31	Weight;Waist circumference;	chr15:45697700	chr15:45702640~45703183:+
OV	cis	rs12594515	1	rs6493176	ENSG00000273972.1	CTD-2306A12.1	-4.92	1.66e-06	0.00111	-0.33	-0.31	Weight;Waist circumference;	chr15:45697828	chr15:45702640~45703183:+
OV	cis	rs12594515	0.967	rs8039088	ENSG00000273972.1	CTD-2306A12.1	-4.92	1.66e-06	0.00111	-0.33	-0.31	Weight;Waist circumference;	chr15:45697980	chr15:45702640~45703183:+
OV	cis	rs12594515	1	rs8038320	ENSG00000273972.1	CTD-2306A12.1	-4.92	1.66e-06	0.00111	-0.33	-0.31	Weight;Waist circumference;	chr15:45698069	chr15:45702640~45703183:+
OV	cis	rs12594515	1	rs8038058	ENSG00000273972.1	CTD-2306A12.1	-4.92	1.66e-06	0.00111	-0.33	-0.31	Weight;Waist circumference;	chr15:45698074	chr15:45702640~45703183:+
OV	cis	rs12594515	0.967	rs67854274	ENSG00000273972.1	CTD-2306A12.1	-4.92	1.66e-06	0.00111	-0.33	-0.31	Weight;Waist circumference;	chr15:45698320	chr15:45702640~45703183:+
OV	cis	rs12594515	1	rs7172161	ENSG00000273972.1	CTD-2306A12.1	-4.92	1.66e-06	0.00111	-0.33	-0.31	Weight;Waist circumference;	chr15:45698582	chr15:45702640~45703183:+
OV	cis	rs12594515	1	rs7173144	ENSG00000273972.1	CTD-2306A12.1	-4.92	1.66e-06	0.00111	-0.33	-0.31	Weight;Waist circumference;	chr15:45698998	chr15:45702640~45703183:+
OV	cis	rs9291683	0.704	rs11726271	ENSG00000250413.1	RP11-448G15.1	4.92	1.66e-06	0.00111	0.35	0.31	Bone mineral density;	chr4:10096568	chr4:10006482~10009725:+
OV	cis	rs2230624	1	rs76823085	ENSG00000242349.4	NPPA-AS1	-4.92	1.66e-06	0.00111	-0.58	-0.31	Mosquito bite size;	chr1:11823491	chr1:11841017~11848079:+
OV	cis	rs293748	0.54	rs12652735	ENSG00000250155.1	CTD-2353F22.1	-4.92	1.66e-06	0.00111	-0.42	-0.31	Obesity-related traits;	chr5:37230629	chr5:36666214~36725195:-
OV	cis	rs293748	0.571	rs13171414	ENSG00000250155.1	CTD-2353F22.1	-4.92	1.66e-06	0.00111	-0.42	-0.31	Obesity-related traits;	chr5:37231977	chr5:36666214~36725195:-
OV	cis	rs293748	0.571	rs13181187	ENSG00000250155.1	CTD-2353F22.1	-4.92	1.66e-06	0.00111	-0.42	-0.31	Obesity-related traits;	chr5:37239275	chr5:36666214~36725195:-
OV	cis	rs7189233	0.531	rs7204758	ENSG00000279344.1	RP11-44F14.7	4.92	1.66e-06	0.00111	0.29	0.31	Intelligence (multi-trait analysis);	chr16:53448453	chr16:53478957~53481550:-
OV	cis	rs7189233	0.531	rs9921627	ENSG00000279344.1	RP11-44F14.7	4.92	1.66e-06	0.00111	0.29	0.31	Intelligence (multi-trait analysis);	chr16:53448780	chr16:53478957~53481550:-
OV	cis	rs295490	0.748	rs77342235	ENSG00000272656.1	RP11-219D15.3	4.92	1.66e-06	0.00111	0.57	0.31	PR interval in Tripanosoma cruzi seropositivity;	chr3:139419212	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs76778175	ENSG00000272656.1	RP11-219D15.3	4.92	1.66e-06	0.00111	0.57	0.31	PR interval in Tripanosoma cruzi seropositivity;	chr3:139440213	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs78230813	ENSG00000272656.1	RP11-219D15.3	4.92	1.66e-06	0.00111	0.57	0.31	PR interval in Tripanosoma cruzi seropositivity;	chr3:139441345	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs77995988	ENSG00000272656.1	RP11-219D15.3	4.92	1.66e-06	0.00111	0.57	0.31	PR interval in Tripanosoma cruzi seropositivity;	chr3:139456686	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs79361389	ENSG00000272656.1	RP11-219D15.3	4.92	1.66e-06	0.00111	0.57	0.31	PR interval in Tripanosoma cruzi seropositivity;	chr3:139458517	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs78251555	ENSG00000272656.1	RP11-219D15.3	4.92	1.66e-06	0.00111	0.57	0.31	PR interval in Tripanosoma cruzi seropositivity;	chr3:139460159	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs17494356	ENSG00000272656.1	RP11-219D15.3	4.92	1.66e-06	0.00111	0.57	0.31	PR interval in Tripanosoma cruzi seropositivity;	chr3:139465126	chr3:139349024~139349371:-
OV	cis	rs7771547	0.573	rs522179	ENSG00000240733.3	RN7SL502P	4.92	1.66e-06	0.00111	0.33	0.31	Platelet distribution width;	chr6:36423828	chr6:36450912~36451201:-
OV	cis	rs7771547	0.573	rs629297	ENSG00000240733.3	RN7SL502P	4.92	1.66e-06	0.00111	0.33	0.31	Platelet distribution width;	chr6:36430369	chr6:36450912~36451201:-
OV	cis	rs4713118	0.738	rs200465	ENSG00000280107.1	AL022393.9	-4.92	1.66e-06	0.00111	-0.37	-0.31	Parkinson's disease;	chr6:27789875	chr6:28170845~28172521:+
OV	cis	rs4272382	1	rs4272382	ENSG00000253426.4	RP11-10A14.4	-4.92	1.67e-06	0.00111	-0.54	-0.31	Response to cytidine analogues (gemcitabine);	chr8:8575978	chr8:9151742~9168136:+
OV	cis	rs11096990	0.593	rs35937374	ENSG00000249207.1	RP11-360F5.1	-4.92	1.67e-06	0.00112	-0.33	-0.31	Cognitive function;	chr4:39184735	chr4:39112677~39126818:-
OV	cis	rs11096990	0.574	rs34070258	ENSG00000249207.1	RP11-360F5.1	-4.92	1.67e-06	0.00112	-0.33	-0.31	Cognitive function;	chr4:39188132	chr4:39112677~39126818:-
OV	cis	rs11096990	0.613	rs35391082	ENSG00000249207.1	RP11-360F5.1	-4.92	1.67e-06	0.00112	-0.33	-0.31	Cognitive function;	chr4:39191033	chr4:39112677~39126818:-
OV	cis	rs11096990	0.613	rs4974990	ENSG00000249207.1	RP11-360F5.1	-4.92	1.67e-06	0.00112	-0.33	-0.31	Cognitive function;	chr4:39191645	chr4:39112677~39126818:-
OV	cis	rs796364	1	rs1704186	ENSG00000232732.8	AC073043.1	-4.92	1.67e-06	0.00112	-0.45	-0.31	Schizophrenia;	chr2:199904816	chr2:199867396~199911159:-
OV	cis	rs293748	0.54	rs6879284	ENSG00000250155.1	CTD-2353F22.1	-4.92	1.67e-06	0.00112	-0.41	-0.31	Obesity-related traits;	chr5:37230185	chr5:36666214~36725195:-
OV	cis	rs1075265	0.704	rs805405	ENSG00000233266.1	HMGB1P31	4.92	1.68e-06	0.00112	0.38	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53891014	chr2:54051334~54051760:+
OV	cis	rs301901	1	rs300055	ENSG00000250155.1	CTD-2353F22.1	-4.92	1.68e-06	0.00112	-0.36	-0.31	Height;	chr5:37072722	chr5:36666214~36725195:-
OV	cis	rs17301013	0.507	rs2146564	ENSG00000227373.4	RP11-160H22.5	4.92	1.68e-06	0.00112	0.42	0.31	Systemic lupus erythematosus;	chr1:174716214	chr1:174115300~174160004:-
OV	cis	rs896854	0.654	rs6982393	ENSG00000253528.2	RP11-347C18.4	4.92	1.68e-06	0.00112	0.29	0.31	Type 2 diabetes;	chr8:94968480	chr8:94974573~94974853:-
OV	cis	rs673078	0.607	rs1060964	ENSG00000275759.1	RP11-131L12.3	-4.92	1.69e-06	0.00113	-0.45	-0.31	Glucose homeostasis traits;	chr12:118414906	chr12:118428281~118428870:+
OV	cis	rs494459	0.536	rs11217065	ENSG00000255239.1	AP002954.6	4.92	1.69e-06	0.00113	0.37	0.31	Height;	chr11:118855938	chr11:118688039~118690600:-
OV	cis	rs4964805	0.594	rs10861095	ENSG00000257681.1	RP11-341G23.4	4.92	1.69e-06	0.00113	0.35	0.31	Attention deficit hyperactivity disorder;	chr12:103771609	chr12:103746315~103768858:-
OV	cis	rs4964805	0.505	rs4981032	ENSG00000257681.1	RP11-341G23.4	4.92	1.69e-06	0.00113	0.35	0.31	Attention deficit hyperactivity disorder;	chr12:103772086	chr12:103746315~103768858:-
OV	cis	rs4964805	0.594	rs9132	ENSG00000257681.1	RP11-341G23.4	4.92	1.69e-06	0.00113	0.35	0.31	Attention deficit hyperactivity disorder;	chr12:103772465	chr12:103746315~103768858:-
OV	cis	rs858239	0.738	rs7807879	ENSG00000230042.1	AK3P3	-4.92	1.69e-06	0.00113	-0.35	-0.31	Cerebrospinal fluid biomarker levels;	chr7:23220969	chr7:23129178~23129841:+
OV	cis	rs7615952	0.599	rs60847438	ENSG00000171084.14	FAM86JP	4.92	1.69e-06	0.00113	0.46	0.31	Blood pressure (smoking interaction);	chr3:126027162	chr3:125916620~125930024:+
OV	cis	rs1790761	0.667	rs658768	ENSG00000184224.3	C11orf72	4.92	1.7e-06	0.00113	0.35	0.31	Mean corpuscular volume;	chr11:67570337	chr11:67602880~67606706:-
OV	cis	rs1790761	0.667	rs591434	ENSG00000184224.3	C11orf72	4.92	1.7e-06	0.00113	0.35	0.31	Mean corpuscular volume;	chr11:67570343	chr11:67602880~67606706:-
OV	cis	rs57502260	0.704	rs55975204	ENSG00000212093.1	AP000807.1	4.92	1.7e-06	0.00113	0.53	0.31	Total body bone mineral density (age 45-60);	chr11:68481656	chr11:68506083~68506166:-
OV	cis	rs57502260	0.704	rs2186937	ENSG00000212093.1	AP000807.1	4.92	1.7e-06	0.00113	0.53	0.31	Total body bone mineral density (age 45-60);	chr11:68489379	chr11:68506083~68506166:-
OV	cis	rs783540	0.934	rs8043401	ENSG00000278603.1	RP13-608F4.5	4.91	1.7e-06	0.00114	0.35	0.31	Schizophrenia;	chr15:82687507	chr15:82472203~82472426:+
OV	cis	rs116095464	0.558	rs7714335	ENSG00000250848.1	CTD-2083E4.5	-4.91	1.71e-06	0.00114	-0.39	-0.31	Breast cancer;	chr5:263398	chr5:288833~290321:-
OV	cis	rs301901	0.796	rs11742177	ENSG00000250155.1	CTD-2353F22.1	4.91	1.71e-06	0.00114	0.37	0.31	Height;	chr5:37504063	chr5:36666214~36725195:-
OV	cis	rs301901	0.796	rs1829292	ENSG00000250155.1	CTD-2353F22.1	4.91	1.71e-06	0.00114	0.37	0.31	Height;	chr5:37505544	chr5:36666214~36725195:-
OV	cis	rs1891275	0.515	rs7092745	ENSG00000228701.1	TNKS2-AS1	-4.91	1.71e-06	0.00114	-0.34	-0.31	Intelligence (multi-trait analysis);	chr10:91724063	chr10:91782839~91798291:-
OV	cis	rs12200782	0.505	rs7765920	ENSG00000241549.7	GUSBP2	4.91	1.72e-06	0.00114	0.36	0.31	Small cell lung carcinoma;	chr6:26514543	chr6:26871484~26956554:-
OV	cis	rs8100891	0.537	rs4805758	ENSG00000267213.4	AC007773.2	-4.91	1.72e-06	0.00114	-0.47	-0.31	Neuroticism;	chr19:32375518	chr19:32390050~32405560:-
OV	cis	rs1850744	0.826	rs7685513	ENSG00000163612.10	FAM86KP	4.91	1.72e-06	0.00115	0.76	0.31	Economic and political preferences;	chr4:9726975	chr4:9153296~9165451:+
OV	cis	rs853679	0.55	rs6901017	ENSG00000280107.1	AL022393.9	-4.91	1.72e-06	0.00115	-0.4	-0.31	Depression;	chr6:28184805	chr6:28170845~28172521:+
OV	cis	rs17301013	0.507	rs7517516	ENSG00000227373.4	RP11-160H22.5	4.91	1.72e-06	0.00115	0.41	0.31	Systemic lupus erythematosus;	chr1:174346187	chr1:174115300~174160004:-
OV	cis	rs7688540	0.771	rs10027325	ENSG00000275426.1	CH17-262A2.1	4.91	1.72e-06	0.00115	0.45	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:288819	chr4:149738~150317:+
OV	cis	rs1671400	1	rs919586	ENSG00000250794.2	ALG1L12P	4.91	1.72e-06	0.00115	0.47	0.31	Obesity-related traits;	chr8:13317162	chr8:12421032~12425000:+
OV	cis	rs1891275	0.515	rs11186666	ENSG00000228701.1	TNKS2-AS1	-4.91	1.73e-06	0.00115	-0.34	-0.31	Intelligence (multi-trait analysis);	chr10:91718162	chr10:91782839~91798291:-
OV	cis	rs607987	0.871	rs689233	ENSG00000254532.1	RP11-624D11.2	4.91	1.73e-06	0.00115	0.36	0.31	Body mass index;	chr11:30249120	chr11:30044058~30084343:-
OV	cis	rs607987	0.836	rs645161	ENSG00000254532.1	RP11-624D11.2	4.91	1.73e-06	0.00115	0.36	0.31	Body mass index;	chr11:30250679	chr11:30044058~30084343:-
OV	cis	rs858239	0.6	rs6461692	ENSG00000230042.1	AK3P3	-4.91	1.73e-06	0.00115	-0.32	-0.31	Cerebrospinal fluid biomarker levels;	chr7:23100076	chr7:23129178~23129841:+
OV	cis	rs4948102	0.595	rs7793921	ENSG00000275875.1	RP11-613E4.5	-4.91	1.73e-06	0.00115	-0.32	-0.31	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr7:55741525~55741869:+
OV	cis	rs4948102	0.595	rs10255049	ENSG00000275875.1	RP11-613E4.5	-4.91	1.73e-06	0.00115	-0.32	-0.31	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr7:55741525~55741869:+
OV	cis	rs8177876	0.822	rs79926943	ENSG00000261838.4	RP11-303E16.6	4.91	1.73e-06	0.00115	0.59	0.31	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81072005	chr16:81069854~81076598:+
OV	cis	rs17301013	0.606	rs4233169	ENSG00000227373.4	RP11-160H22.5	4.91	1.73e-06	0.00115	0.41	0.31	Systemic lupus erythematosus;	chr1:174118986	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs1853321	ENSG00000227373.4	RP11-160H22.5	4.91	1.73e-06	0.00115	0.41	0.31	Systemic lupus erythematosus;	chr1:174125295	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs6694208	ENSG00000227373.4	RP11-160H22.5	4.91	1.73e-06	0.00115	0.41	0.31	Systemic lupus erythematosus;	chr1:174127631	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs727912	ENSG00000227373.4	RP11-160H22.5	4.91	1.73e-06	0.00115	0.41	0.31	Systemic lupus erythematosus;	chr1:174132729	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs4650950	ENSG00000227373.4	RP11-160H22.5	4.91	1.73e-06	0.00115	0.41	0.31	Systemic lupus erythematosus;	chr1:174134264	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs4650951	ENSG00000227373.4	RP11-160H22.5	4.91	1.73e-06	0.00115	0.41	0.31	Systemic lupus erythematosus;	chr1:174134368	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs4652191	ENSG00000227373.4	RP11-160H22.5	4.91	1.73e-06	0.00115	0.41	0.31	Systemic lupus erythematosus;	chr1:174135473	chr1:174115300~174160004:-
OV	cis	rs10924970	0.649	rs10802583	ENSG00000236863.2	RPL23AP23	4.91	1.73e-06	0.00115	0.31	0.31	Asthma;	chr1:235275372	chr1:235295865~235296335:+
OV	cis	rs1185460	0.547	rs10892323	ENSG00000271751.1	RP11-110I1.14	4.91	1.73e-06	0.00115	0.38	0.31	Coronary artery disease;	chr11:119032048	chr11:119065263~119065677:-
OV	cis	rs7587476	1	rs7587476	ENSG00000229267.2	AC072062.1	4.91	1.73e-06	0.00115	0.42	0.31	Neuroblastoma;	chr2:214789163	chr2:214810229~214963274:+
OV	cis	rs8113142	0.614	rs16961775	ENSG00000267243.4	AC005307.3	-4.91	1.73e-06	0.00115	-0.51	-0.31	Femoral neck bone geometry and menarche (age at onset);	chr19:28706090	chr19:28435388~28727777:-
OV	cis	rs858239	0.601	rs6971002	ENSG00000230042.1	AK3P3	-4.91	1.74e-06	0.00115	-0.31	-0.31	Cerebrospinal fluid biomarker levels;	chr7:23132685	chr7:23129178~23129841:+
OV	cis	rs8100891	0.537	rs10410770	ENSG00000267213.4	AC007773.2	-4.91	1.74e-06	0.00116	-0.47	-0.31	Neuroticism;	chr19:32411498	chr19:32390050~32405560:-
OV	cis	rs62184315	0.575	rs256546	ENSG00000253559.1	OSGEPL1-AS1	-4.91	1.74e-06	0.00116	-0.33	-0.31	Alcohol dependence (age at onset);	chr2:189886437	chr2:189762704~189765556:+
OV	cis	rs3733585	0.699	rs7683283	ENSG00000250413.1	RP11-448G15.1	4.91	1.74e-06	0.00116	0.34	0.31	Cleft plate (environmental tobacco smoke interaction);	chr4:9968350	chr4:10006482~10009725:+
OV	cis	rs3733585	0.699	rs28610447	ENSG00000250413.1	RP11-448G15.1	4.91	1.74e-06	0.00116	0.34	0.31	Cleft plate (environmental tobacco smoke interaction);	chr4:9969893	chr4:10006482~10009725:+
OV	cis	rs3733585	0.624	rs58130873	ENSG00000250413.1	RP11-448G15.1	4.91	1.74e-06	0.00116	0.34	0.31	Cleft plate (environmental tobacco smoke interaction);	chr4:9970457	chr4:10006482~10009725:+
OV	cis	rs1891275	0.515	rs4244930	ENSG00000228701.1	TNKS2-AS1	-4.91	1.74e-06	0.00116	-0.34	-0.31	Intelligence (multi-trait analysis);	chr10:91707092	chr10:91782839~91798291:-
OV	cis	rs17264034	0.861	rs431288	ENSG00000250786.1	SNHG18	4.91	1.74e-06	0.00116	0.49	0.31	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9549347	chr5:9546200~9550609:+
OV	cis	rs611744	0.538	rs59930666	ENSG00000253754.1	RP11-35G22.1	-4.91	1.74e-06	0.00116	-0.35	-0.31	Dupuytren's disease;	chr8:108250067	chr8:108226200~108227544:+
OV	cis	rs17301013	0.507	rs60811893	ENSG00000227373.4	RP11-160H22.5	4.91	1.74e-06	0.00116	0.41	0.31	Systemic lupus erythematosus;	chr1:174765968	chr1:174115300~174160004:-
OV	cis	rs4805272	1	rs4804854	ENSG00000267243.4	AC005307.3	-4.91	1.74e-06	0.00116	-0.41	-0.31	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28829151	chr19:28435388~28727777:-
OV	cis	rs4805272	1	rs10412433	ENSG00000267243.4	AC005307.3	-4.91	1.74e-06	0.00116	-0.41	-0.31	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28829256	chr19:28435388~28727777:-
OV	cis	rs4805272	1	rs10411061	ENSG00000267243.4	AC005307.3	-4.91	1.74e-06	0.00116	-0.41	-0.31	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28829299	chr19:28435388~28727777:-
OV	cis	rs4805272	1	rs10419348	ENSG00000267243.4	AC005307.3	-4.91	1.74e-06	0.00116	-0.41	-0.31	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28829480	chr19:28435388~28727777:-
OV	cis	rs4805272	1	rs11672592	ENSG00000267243.4	AC005307.3	-4.91	1.74e-06	0.00116	-0.41	-0.31	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28829891	chr19:28435388~28727777:-
OV	cis	rs4805272	1	rs2042193	ENSG00000267243.4	AC005307.3	-4.91	1.74e-06	0.00116	-0.41	-0.31	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28830018	chr19:28435388~28727777:-
OV	cis	rs7927592	0.913	rs12284933	ENSG00000212093.1	AP000807.1	4.91	1.75e-06	0.00116	0.4	0.31	Total body bone mineral density;	chr11:68552021	chr11:68506083~68506166:-
OV	cis	rs10934853	0.561	rs760383	ENSG00000277250.1	Metazoa_SRP	4.91	1.75e-06	0.00116	0.42	0.31	Prostate cancer;Prostate cancer (SNP x SNP interaction);	chr3:128400722	chr3:128673681~128674021:-
OV	cis	rs2188561	0.806	rs2712210	ENSG00000241764.3	AC002467.7	4.91	1.75e-06	0.00116	0.35	0.31	Alcohol consumption;	chr7:107687407	chr7:107742817~107744581:-
OV	cis	rs875971	0.545	rs10950029	ENSG00000226824.5	RP4-756H11.3	-4.91	1.75e-06	0.00116	-0.36	-0.31	Aortic root size;	chr7:66169334	chr7:66654538~66669855:+
OV	cis	rs1576263	0.967	rs162280	ENSG00000230939.1	RP11-314C16.1	-4.91	1.75e-06	0.00116	-0.33	-0.31	Photic sneeze reflex;	chr6:8555456	chr6:8784178~8785445:+
OV	cis	rs853679	0.55	rs1225598	ENSG00000280107.1	AL022393.9	-4.91	1.75e-06	0.00116	-0.41	-0.31	Depression;	chr6:28193021	chr6:28170845~28172521:+
OV	cis	rs7923609	0.578	rs3858121	ENSG00000232075.1	MRPL35P2	-4.91	1.75e-06	0.00117	-0.32	-0.31	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63640237	chr10:63634317~63634827:-
OV	cis	rs14027	0.921	rs1433951	ENSG00000279347.1	RP11-85I17.2	-4.91	1.76e-06	0.00117	-0.32	-0.31	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119777362	chr8:119838736~119840385:-
OV	cis	rs9813712	0.574	rs11718032	ENSG00000253540.4	FAM86HP	4.91	1.76e-06	0.00117	0.32	0.31	Response to amphetamines;	chr3:130257749	chr3:130099092~130111472:-
OV	cis	rs992157	0.835	rs10932768	ENSG00000237281.1	CATIP-AS2	4.91	1.77e-06	0.00117	0.36	0.31	Colorectal cancer;	chr2:218281476	chr2:218326889~218357966:-
OV	cis	rs2280018	0.526	rs2966128	ENSG00000260735.1	RP11-72I8.1	-4.91	1.77e-06	0.00118	-0.38	-0.31	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15059532	chr16:15094411~15109197:+
OV	cis	rs9506514	0.509	rs9509279	ENSG00000222726.1	RNU2-7P	4.91	1.77e-06	0.00118	0.37	0.31	Coronary artery calcification;	chr13:20559580	chr13:20612161~20612338:+
OV	cis	rs2098713	0.549	rs62359033	ENSG00000250155.1	CTD-2353F22.1	4.91	1.78e-06	0.00118	0.36	0.31	Telomere length;	chr5:37549741	chr5:36666214~36725195:-
OV	cis	rs2098713	0.599	rs12652658	ENSG00000250155.1	CTD-2353F22.1	4.91	1.78e-06	0.00118	0.36	0.31	Telomere length;	chr5:37555461	chr5:36666214~36725195:-
OV	cis	rs6088580	0.634	rs6059880	ENSG00000206582.1	Y_RNA	-4.91	1.78e-06	0.00118	-0.37	-0.31	Glomerular filtration rate (creatinine);	chr20:34500864	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6088498	ENSG00000206582.1	Y_RNA	-4.9	1.79e-06	0.00119	-0.38	-0.31	Glomerular filtration rate (creatinine);	chr20:34432640	chr20:34526510~34526606:-
OV	cis	rs3733585	0.631	rs4697925	ENSG00000250413.1	RP11-448G15.1	4.9	1.79e-06	0.00119	0.37	0.31	Cleft plate (environmental tobacco smoke interaction);	chr4:10122706	chr4:10006482~10009725:+
OV	cis	rs6772849	0.93	rs55987729	ENSG00000242551.2	POU5F1P6	-4.9	1.79e-06	0.00119	-0.36	-0.31	Monocyte percentage of white cells;Monocyte count;	chr3:128621267	chr3:128674735~128677005:-
OV	cis	rs12073359	0.954	rs10494264	ENSG00000223945.2	RP11-458I7.1	4.9	1.79e-06	0.00119	0.46	0.31	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150121510	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs2039800	ENSG00000223945.2	RP11-458I7.1	4.9	1.79e-06	0.00119	0.46	0.31	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150123635	chr1:150053864~150055034:+
OV	cis	rs4713118	0.824	rs2179095	ENSG00000280107.1	AL022393.9	4.9	1.79e-06	0.00119	0.37	0.31	Parkinson's disease;	chr6:27783079	chr6:28170845~28172521:+
OV	cis	rs17711722	0.522	rs62469933	ENSG00000224316.1	RP11-479O9.2	4.9	1.79e-06	0.00119	0.34	0.31	Calcium levels;	chr7:65800652	chr7:65773620~65802067:+
OV	cis	rs4272382	1	rs4272382	ENSG00000173295.6	FAM86B3P	-4.9	1.79e-06	0.00119	-0.47	-0.31	Response to cytidine analogues (gemcitabine);	chr8:8575978	chr8:8228595~8244865:+
OV	cis	rs7189233	0.531	rs1072910	ENSG00000279344.1	RP11-44F14.7	4.9	1.8e-06	0.00119	0.28	0.31	Intelligence (multi-trait analysis);	chr16:53465687	chr16:53478957~53481550:-
OV	cis	rs6991838	0.584	rs7463649	ENSG00000200714.1	Y_RNA	-4.9	1.8e-06	0.00119	-0.39	-0.31	Intelligence (multi-trait analysis);	chr8:65573760	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs7463740	ENSG00000200714.1	Y_RNA	-4.9	1.8e-06	0.00119	-0.39	-0.31	Intelligence (multi-trait analysis);	chr8:65573950	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs66467166	ENSG00000200714.1	Y_RNA	-4.9	1.8e-06	0.00119	-0.39	-0.31	Intelligence (multi-trait analysis);	chr8:65574165	chr8:65592731~65592820:+
OV	cis	rs6991838	0.557	rs67685675	ENSG00000200714.1	Y_RNA	-4.9	1.8e-06	0.00119	-0.39	-0.31	Intelligence (multi-trait analysis);	chr8:65574371	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs66486920	ENSG00000200714.1	Y_RNA	-4.9	1.8e-06	0.00119	-0.39	-0.31	Intelligence (multi-trait analysis);	chr8:65574458	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs60023200	ENSG00000200714.1	Y_RNA	-4.9	1.8e-06	0.00119	-0.39	-0.31	Intelligence (multi-trait analysis);	chr8:65574547	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs61083799	ENSG00000200714.1	Y_RNA	-4.9	1.8e-06	0.00119	-0.39	-0.31	Intelligence (multi-trait analysis);	chr8:65574868	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs4449837	ENSG00000200714.1	Y_RNA	-4.9	1.8e-06	0.00119	-0.39	-0.31	Intelligence (multi-trait analysis);	chr8:65575917	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs57042777	ENSG00000200714.1	Y_RNA	-4.9	1.8e-06	0.00119	-0.39	-0.31	Intelligence (multi-trait analysis);	chr8:65576855	chr8:65592731~65592820:+
OV	cis	rs11096990	0.634	rs6531702	ENSG00000249207.1	RP11-360F5.1	-4.9	1.8e-06	0.00119	-0.32	-0.31	Cognitive function;	chr4:39273774	chr4:39112677~39126818:-
OV	cis	rs607987	0.871	rs1782507	ENSG00000254532.1	RP11-624D11.2	4.9	1.8e-06	0.00119	0.36	0.31	Body mass index;	chr11:30222321	chr11:30044058~30084343:-
OV	cis	rs607987	0.871	rs653452	ENSG00000254532.1	RP11-624D11.2	4.9	1.8e-06	0.00119	0.36	0.31	Body mass index;	chr11:30222688	chr11:30044058~30084343:-
OV	cis	rs116095464	0.558	rs13357299	ENSG00000250848.1	CTD-2083E4.5	-4.9	1.8e-06	0.00119	-0.38	-0.31	Breast cancer;	chr5:242096	chr5:288833~290321:-
OV	cis	rs34779708	0.771	rs12098283	ENSG00000230534.5	RP11-297A16.2	4.9	1.8e-06	0.00119	0.4	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35189187	chr10:35098006~35127020:-
OV	cis	rs514406	0.929	rs11206035	ENSG00000206627.1	RNU6-969P	4.9	1.8e-06	0.00119	0.32	0.31	Monocyte count;	chr1:52857899	chr1:52805108~52805212:-
OV	cis	rs514406	0.929	rs12410420	ENSG00000206627.1	RNU6-969P	4.9	1.8e-06	0.00119	0.32	0.31	Monocyte count;	chr1:52858082	chr1:52805108~52805212:-
OV	cis	rs514406	0.929	rs2607095	ENSG00000206627.1	RNU6-969P	4.9	1.8e-06	0.00119	0.32	0.31	Monocyte count;	chr1:52859967	chr1:52805108~52805212:-
OV	cis	rs10510102	0.935	rs11200201	ENSG00000276742.1	RP11-500G22.4	4.9	1.81e-06	0.0012	0.54	0.31	Breast cancer;	chr10:121864790	chr10:121956782~121957098:+
OV	cis	rs57502260	0.704	rs12286536	ENSG00000212093.1	AP000807.1	4.9	1.81e-06	0.0012	0.53	0.31	Total body bone mineral density (age 45-60);	chr11:68522766	chr11:68506083~68506166:-
OV	cis	rs11671005	0.656	rs11672609	ENSG00000269600.1	AC016629.3	-4.9	1.81e-06	0.0012	-0.48	-0.31	Mean platelet volume;	chr19:58495557	chr19:58593896~58599355:-
OV	cis	rs17301013	0.606	rs6425277	ENSG00000227373.4	RP11-160H22.5	4.9	1.81e-06	0.0012	0.4	0.31	Systemic lupus erythematosus;	chr1:174296153	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs12074276	ENSG00000227373.4	RP11-160H22.5	4.9	1.81e-06	0.0012	0.4	0.31	Systemic lupus erythematosus;	chr1:174302167	chr1:174115300~174160004:-
OV	cis	rs34779708	0.966	rs12773647	ENSG00000230534.5	RP11-297A16.2	4.9	1.81e-06	0.0012	0.4	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35151399	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs34630580	ENSG00000230534.5	RP11-297A16.2	4.9	1.81e-06	0.0012	0.4	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35160300	chr10:35098006~35127020:-
OV	cis	rs792448	0.798	rs612414	ENSG00000201544.1	SNORA16B	4.9	1.81e-06	0.0012	0.39	0.31	White blood cell count (basophil);	chr1:212428834	chr1:212352816~212352950:+
OV	cis	rs7580658	0.864	rs10928761	ENSG00000236682.1	AC068282.3	-4.9	1.81e-06	0.0012	-0.4	-0.31	Protein C levels;	chr2:127245671	chr2:127389130~127400580:+
OV	cis	rs796825	0.597	rs1092829	ENSG00000240661.1	RP11-174O3.3	-4.9	1.81e-06	0.0012	-0.44	-0.31	HIV-1 susceptibility;	chr3:120318714	chr3:120349510~120367998:+
OV	cis	rs3136516	1	rs3136516	ENSG00000271350.1	CTD-2384B9.1	-4.9	1.82e-06	0.0012	-0.34	-0.31	Venous thromboembolism;	chr11:46739206	chr11:47041027~47041945:-
OV	cis	rs1797885	0.966	rs1619599	ENSG00000251774.1	RNU6-377P	4.9	1.82e-06	0.0012	0.29	0.31	Immature fraction of reticulocytes;	chr3:12462791	chr3:12514706~12514807:+
OV	cis	rs1797885	0.902	rs1699346	ENSG00000251774.1	RNU6-377P	4.9	1.82e-06	0.0012	0.29	0.31	Immature fraction of reticulocytes;	chr3:12462796	chr3:12514706~12514807:+
OV	cis	rs301901	1	rs301901	ENSG00000250155.1	CTD-2353F22.1	-4.9	1.82e-06	0.0012	-0.36	-0.31	Height;	chr5:37046524	chr5:36666214~36725195:-
OV	cis	rs875971	0.965	rs7794930	ENSG00000236529.1	RP13-254B10.1	-4.9	1.82e-06	0.00121	-0.32	-0.31	Aortic root size;	chr7:66313559	chr7:65840212~65840596:+
OV	cis	rs17301013	0.507	rs10912789	ENSG00000227373.4	RP11-160H22.5	4.9	1.83e-06	0.00121	0.4	0.31	Systemic lupus erythematosus;	chr1:174465616	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs6684141	ENSG00000227373.4	RP11-160H22.5	4.9	1.83e-06	0.00121	0.4	0.31	Systemic lupus erythematosus;	chr1:174467305	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12058377	ENSG00000227373.4	RP11-160H22.5	4.9	1.83e-06	0.00121	0.4	0.31	Systemic lupus erythematosus;	chr1:174470971	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs6656925	ENSG00000227373.4	RP11-160H22.5	4.9	1.83e-06	0.00121	0.4	0.31	Systemic lupus erythematosus;	chr1:174474161	chr1:174115300~174160004:-
OV	cis	rs473651	0.935	rs1103770	ENSG00000229915.1	AC016999.2	-4.9	1.83e-06	0.00121	-0.39	-0.31	Multiple system atrophy;	chr2:238430640	chr2:238427077~238427729:-
OV	cis	rs473651	0.935	rs10170056	ENSG00000229915.1	AC016999.2	-4.9	1.83e-06	0.00121	-0.39	-0.31	Multiple system atrophy;	chr2:238430650	chr2:238427077~238427729:-
OV	cis	rs473651	0.935	rs559579	ENSG00000229915.1	AC016999.2	-4.9	1.83e-06	0.00121	-0.39	-0.31	Multiple system atrophy;	chr2:238430860	chr2:238427077~238427729:-
OV	cis	rs473651	0.935	rs558924	ENSG00000229915.1	AC016999.2	-4.9	1.83e-06	0.00121	-0.39	-0.31	Multiple system atrophy;	chr2:238430870	chr2:238427077~238427729:-
OV	cis	rs10510102	0.935	rs7907871	ENSG00000276742.1	RP11-500G22.4	4.9	1.83e-06	0.00121	0.49	0.31	Breast cancer;	chr10:121878185	chr10:121956782~121957098:+
OV	cis	rs992157	0.835	rs7585702	ENSG00000237281.1	CATIP-AS2	4.9	1.84e-06	0.00121	0.36	0.31	Colorectal cancer;	chr2:218281884	chr2:218326889~218357966:-
OV	cis	rs992157	0.835	rs2292555	ENSG00000237281.1	CATIP-AS2	4.9	1.84e-06	0.00121	0.36	0.31	Colorectal cancer;	chr2:218282159	chr2:218326889~218357966:-
OV	cis	rs992157	0.835	rs10932769	ENSG00000237281.1	CATIP-AS2	4.9	1.84e-06	0.00121	0.36	0.31	Colorectal cancer;	chr2:218282522	chr2:218326889~218357966:-
OV	cis	rs992157	0.835	rs6729058	ENSG00000237281.1	CATIP-AS2	4.9	1.84e-06	0.00121	0.36	0.31	Colorectal cancer;	chr2:218283646	chr2:218326889~218357966:-
OV	cis	rs992157	0.804	rs7559525	ENSG00000237281.1	CATIP-AS2	4.9	1.84e-06	0.00121	0.36	0.31	Colorectal cancer;	chr2:218285584	chr2:218326889~218357966:-
OV	cis	rs4713118	0.868	rs7756968	ENSG00000280107.1	AL022393.9	-4.9	1.84e-06	0.00121	-0.39	-0.31	Parkinson's disease;	chr6:27767175	chr6:28170845~28172521:+
OV	cis	rs1150668	0.796	rs728122	ENSG00000220721.1	OR1F12	4.9	1.84e-06	0.00121	0.31	0.31	Pubertal anthropometrics;	chr6:28431347	chr6:28073316~28074233:+
OV	cis	rs6991838	0.733	rs13281981	ENSG00000200714.1	Y_RNA	4.9	1.84e-06	0.00121	0.4	0.31	Intelligence (multi-trait analysis);	chr8:65611649	chr8:65592731~65592820:+
OV	cis	rs7927592	0.871	rs17603185	ENSG00000212093.1	AP000807.1	4.9	1.84e-06	0.00121	0.4	0.31	Total body bone mineral density;	chr11:68608773	chr11:68506083~68506166:-
OV	cis	rs853679	0.546	rs200990	ENSG00000220721.1	OR1F12	4.9	1.84e-06	0.00122	0.48	0.31	Depression;	chr6:27848045	chr6:28073316~28074233:+
OV	cis	rs11673344	0.931	rs1234251	ENSG00000226686.6	LINC01535	4.9	1.84e-06	0.00122	0.39	0.31	Obesity-related traits;	chr19:37180354	chr19:37251912~37265535:+
OV	cis	rs4763879	0.778	rs1044771	ENSG00000256673.1	RP11-599J14.2	4.9	1.84e-06	0.00122	0.3	0.31	Type 1 diabetes;	chr12:9699333	chr12:9398355~9414851:-
OV	cis	rs858239	0.665	rs6964665	ENSG00000230042.1	AK3P3	-4.9	1.85e-06	0.00122	-0.33	-0.31	Cerebrospinal fluid biomarker levels;	chr7:23171733	chr7:23129178~23129841:+
OV	cis	rs34779708	0.897	rs7900480	ENSG00000230534.5	RP11-297A16.2	-4.9	1.85e-06	0.00122	-0.4	-0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35049771	chr10:35098006~35127020:-
OV	cis	rs2833693	0.574	rs9978000	ENSG00000261610.1	AP000265.1	4.9	1.85e-06	0.00122	0.37	0.31	Temperament;	chr21:32176510	chr21:32259804~32261585:-
OV	cis	rs11992162	1	rs7460395	ENSG00000270154.1	RP11-419I17.1	4.9	1.85e-06	0.00122	0.33	0.31	Monocyte count;	chr8:11977866	chr8:12476462~12477122:+
OV	cis	rs1729407	0.786	rs5096	ENSG00000254851.1	RP11-109L13.1	-4.9	1.85e-06	0.00122	-0.39	-0.31	Apolipoprotein A-IV levels;	chr11:116822379	chr11:117135528~117138582:+
OV	cis	rs17301013	0.507	rs72715300	ENSG00000227373.4	RP11-160H22.5	4.9	1.85e-06	0.00122	0.41	0.31	Systemic lupus erythematosus;	chr1:174768405	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs55844798	ENSG00000227373.4	RP11-160H22.5	4.9	1.85e-06	0.00122	0.41	0.31	Systemic lupus erythematosus;	chr1:174768973	chr1:174115300~174160004:-
OV	cis	rs2280018	0.526	rs2941257	ENSG00000260735.1	RP11-72I8.1	-4.9	1.85e-06	0.00122	-0.37	-0.31	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15072588	chr16:15094411~15109197:+
OV	cis	rs7771547	0.508	rs1570368	ENSG00000240733.3	RN7SL502P	4.9	1.85e-06	0.00122	0.34	0.31	Platelet distribution width;	chr6:36469359	chr6:36450912~36451201:-
OV	cis	rs6991838	0.557	rs67046768	ENSG00000200714.1	Y_RNA	-4.9	1.85e-06	0.00122	-0.39	-0.31	Intelligence (multi-trait analysis);	chr8:65577486	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs4388482	ENSG00000200714.1	Y_RNA	-4.9	1.85e-06	0.00122	-0.39	-0.31	Intelligence (multi-trait analysis);	chr8:65583968	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs4637885	ENSG00000200714.1	Y_RNA	-4.9	1.85e-06	0.00122	-0.39	-0.31	Intelligence (multi-trait analysis);	chr8:65584849	chr8:65592731~65592820:+
OV	cis	rs17301013	0.606	rs72711487	ENSG00000227373.4	RP11-160H22.5	4.9	1.86e-06	0.00122	0.41	0.31	Systemic lupus erythematosus;	chr1:174189002	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs10912746	ENSG00000227373.4	RP11-160H22.5	4.9	1.86e-06	0.00122	0.41	0.31	Systemic lupus erythematosus;	chr1:174210205	chr1:174115300~174160004:-
OV	cis	rs7615952	0.599	rs12486459	ENSG00000171084.14	FAM86JP	4.9	1.86e-06	0.00123	0.45	0.31	Blood pressure (smoking interaction);	chr3:126022622	chr3:125916620~125930024:+
OV	cis	rs7615952	0.599	rs67575510	ENSG00000171084.14	FAM86JP	4.9	1.86e-06	0.00123	0.45	0.31	Blood pressure (smoking interaction);	chr3:126023512	chr3:125916620~125930024:+
OV	cis	rs116095464	0.542	rs28650039	ENSG00000250848.1	CTD-2083E4.5	-4.9	1.86e-06	0.00123	-0.38	-0.31	Breast cancer;	chr5:273839	chr5:288833~290321:-
OV	cis	rs17301013	0.507	rs2860955	ENSG00000227373.4	RP11-160H22.5	-4.9	1.86e-06	0.00123	-0.4	-0.31	Systemic lupus erythematosus;	chr1:174391380	chr1:174115300~174160004:-
OV	cis	rs8100891	0.537	rs28562777	ENSG00000267213.4	AC007773.2	-4.9	1.86e-06	0.00123	-0.46	-0.31	Neuroticism;	chr19:32409913	chr19:32390050~32405560:-
OV	cis	rs7615952	0.641	rs61048217	ENSG00000171084.14	FAM86JP	4.9	1.86e-06	0.00123	0.46	0.31	Blood pressure (smoking interaction);	chr3:126089062	chr3:125916620~125930024:+
OV	cis	rs7615952	0.641	rs60839048	ENSG00000171084.14	FAM86JP	4.9	1.86e-06	0.00123	0.46	0.31	Blood pressure (smoking interaction);	chr3:126089095	chr3:125916620~125930024:+
OV	cis	rs7615952	0.641	rs7640158	ENSG00000171084.14	FAM86JP	4.9	1.86e-06	0.00123	0.46	0.31	Blood pressure (smoking interaction);	chr3:126089168	chr3:125916620~125930024:+
OV	cis	rs7615952	0.641	rs2365019	ENSG00000171084.14	FAM86JP	4.9	1.86e-06	0.00123	0.46	0.31	Blood pressure (smoking interaction);	chr3:126089292	chr3:125916620~125930024:+
OV	cis	rs6991838	0.556	rs7846527	ENSG00000200714.1	Y_RNA	-4.89	1.87e-06	0.00123	-0.39	-0.31	Intelligence (multi-trait analysis);	chr8:65586522	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs4320587	ENSG00000200714.1	Y_RNA	-4.89	1.87e-06	0.00123	-0.39	-0.31	Intelligence (multi-trait analysis);	chr8:65586991	chr8:65592731~65592820:+
OV	cis	rs6991838	0.557	rs4737222	ENSG00000200714.1	Y_RNA	-4.89	1.87e-06	0.00123	-0.39	-0.31	Intelligence (multi-trait analysis);	chr8:65587878	chr8:65592731~65592820:+
OV	cis	rs6088580	0.608	rs8114616	ENSG00000206582.1	Y_RNA	4.89	1.87e-06	0.00123	0.37	0.31	Glomerular filtration rate (creatinine);	chr20:34381286	chr20:34526510~34526606:-
OV	cis	rs55692468	0.771	rs10191361	ENSG00000213197.3	AC012066.1	-4.89	1.87e-06	0.00123	-0.32	-0.31	Intraocular pressure;	chr2:152484334	chr2:152389937~152390630:+
OV	cis	rs116095464	0.558	rs62347677	ENSG00000250848.1	CTD-2083E4.5	-4.89	1.87e-06	0.00123	-0.4	-0.31	Breast cancer;	chr5:227338	chr5:288833~290321:-
OV	cis	rs7017914	0.69	rs62506036	ENSG00000223220.1	Y_RNA	4.89	1.88e-06	0.00124	0.36	0.31	Bone mineral density;	chr8:71066890	chr8:70780914~70781008:-
OV	cis	rs4805272	0.962	rs8101324	ENSG00000267243.4	AC005307.3	-4.89	1.88e-06	0.00124	-0.42	-0.31	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28840622	chr19:28435388~28727777:-
OV	cis	rs4805272	1	rs56131999	ENSG00000267243.4	AC005307.3	-4.89	1.88e-06	0.00124	-0.41	-0.31	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28828690	chr19:28435388~28727777:-
OV	cis	rs4805272	0.962	rs55811684	ENSG00000267243.4	AC005307.3	-4.89	1.88e-06	0.00124	-0.41	-0.31	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28828842	chr19:28435388~28727777:-
OV	cis	rs7605378	1	rs2689766	ENSG00000232732.8	AC073043.1	-4.89	1.89e-06	0.00125	-0.38	-0.31	Osteoporosis;	chr2:199832816	chr2:199867396~199911159:-
OV	cis	rs1185460	1	rs7938944	ENSG00000271751.1	RP11-110I1.14	-4.89	1.89e-06	0.00125	-0.38	-0.31	Coronary artery disease;	chr11:119083356	chr11:119065263~119065677:-
OV	cis	rs57502260	0.704	rs17149179	ENSG00000212093.1	AP000807.1	4.89	1.9e-06	0.00125	0.52	0.31	Total body bone mineral density (age 45-60);	chr11:68584254	chr11:68506083~68506166:-
OV	cis	rs17301013	0.507	rs10912777	ENSG00000227373.4	RP11-160H22.5	4.89	1.9e-06	0.00125	0.4	0.31	Systemic lupus erythematosus;	chr1:174393764	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs10912778	ENSG00000227373.4	RP11-160H22.5	4.89	1.9e-06	0.00125	0.4	0.31	Systemic lupus erythematosus;	chr1:174393827	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs2205937	ENSG00000227373.4	RP11-160H22.5	4.89	1.9e-06	0.00125	0.4	0.31	Systemic lupus erythematosus;	chr1:174394440	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12084291	ENSG00000227373.4	RP11-160H22.5	4.89	1.9e-06	0.00125	0.4	0.31	Systemic lupus erythematosus;	chr1:174395721	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs2901815	ENSG00000227373.4	RP11-160H22.5	4.89	1.9e-06	0.00125	0.4	0.31	Systemic lupus erythematosus;	chr1:174397404	chr1:174115300~174160004:-
OV	cis	rs853679	0.882	rs4713140	ENSG00000219392.1	RP1-265C24.5	-4.89	1.91e-06	0.00125	-0.5	-0.31	Depression;	chr6:28129415	chr6:28115628~28116551:+
OV	cis	rs61403071	0.778	rs12443866	ENSG00000270006.2	RP11-178L8.7	4.89	1.91e-06	0.00125	0.36	0.31	Coronary artery disease;	chr16:86668825	chr16:87317509~87318043:+
OV	cis	rs796364	0.951	rs6722092	ENSG00000232732.8	AC073043.1	-4.89	1.91e-06	0.00126	-0.4	-0.31	Schizophrenia;	chr2:200194648	chr2:199867396~199911159:-
OV	cis	rs4728142	0.625	rs4731533	ENSG00000275106.1	RP11-309L24.10	-4.89	1.92e-06	0.00126	-0.4	-0.31	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128962088	chr7:128952527~128953316:-
OV	cis	rs796364	0.951	rs2881593	ENSG00000232732.8	AC073043.1	4.89	1.92e-06	0.00126	0.41	0.31	Schizophrenia;	chr2:200135624	chr2:199867396~199911159:-
OV	cis	rs853679	0.607	rs201002	ENSG00000220721.1	OR1F12	4.89	1.92e-06	0.00126	0.48	0.31	Depression;	chr6:27840414	chr6:28073316~28074233:+
OV	cis	rs9291683	0.566	rs13122689	ENSG00000250413.1	RP11-448G15.1	-4.89	1.92e-06	0.00126	-0.36	-0.31	Bone mineral density;	chr4:10043024	chr4:10006482~10009725:+
OV	cis	rs9291683	0.546	rs13129453	ENSG00000250413.1	RP11-448G15.1	-4.89	1.92e-06	0.00126	-0.36	-0.31	Bone mineral density;	chr4:10043160	chr4:10006482~10009725:+
OV	cis	rs9291683	0.546	rs12504565	ENSG00000250413.1	RP11-448G15.1	-4.89	1.92e-06	0.00126	-0.36	-0.31	Bone mineral density;	chr4:10043521	chr4:10006482~10009725:+
OV	cis	rs992157	0.798	rs7557709	ENSG00000237281.1	CATIP-AS2	-4.89	1.92e-06	0.00126	-0.36	-0.31	Colorectal cancer;	chr2:218302806	chr2:218326889~218357966:-
OV	cis	rs6991838	0.8	rs11786598	ENSG00000200714.1	Y_RNA	-4.89	1.93e-06	0.00126	-0.39	-0.31	Intelligence (multi-trait analysis);	chr8:65559944	chr8:65592731~65592820:+
OV	cis	rs1075265	0.605	rs805418	ENSG00000233266.1	HMGB1P31	4.89	1.93e-06	0.00126	0.38	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53898634	chr2:54051334~54051760:+
OV	cis	rs1499614	1	rs1638731	ENSG00000226824.5	RP4-756H11.3	-4.89	1.93e-06	0.00126	-0.51	-0.31	Gout;	chr7:66679692	chr7:66654538~66669855:+
OV	cis	rs1499614	1	rs1882655	ENSG00000226824.5	RP4-756H11.3	4.89	1.93e-06	0.00126	0.51	0.31	Gout;	chr7:66682070	chr7:66654538~66669855:+
OV	cis	rs1499614	0.831	rs3800822	ENSG00000226824.5	RP4-756H11.3	4.89	1.93e-06	0.00126	0.51	0.31	Gout;	chr7:66682162	chr7:66654538~66669855:+
OV	cis	rs11096990	0.634	rs11096988	ENSG00000249207.1	RP11-360F5.1	-4.89	1.93e-06	0.00126	-0.32	-0.31	Cognitive function;	chr4:39264081	chr4:39112677~39126818:-
OV	cis	rs7968440	0.715	rs7957659	ENSG00000257298.1	RP3-405J10.3	-4.89	1.93e-06	0.00126	-0.28	-0.31	Fibrinogen;	chr12:50245027	chr12:50185580~50191363:-
OV	cis	rs7587476	0.643	rs6714373	ENSG00000229267.2	AC072062.1	-4.89	1.93e-06	0.00126	-0.42	-0.31	Neuroblastoma;	chr2:214854290	chr2:214810229~214963274:+
OV	cis	rs11096990	0.634	rs17431358	ENSG00000249207.1	RP11-360F5.1	4.89	1.93e-06	0.00126	0.32	0.31	Cognitive function;	chr4:39275676	chr4:39112677~39126818:-
OV	cis	rs11096990	0.634	rs12648082	ENSG00000249207.1	RP11-360F5.1	4.89	1.93e-06	0.00126	0.32	0.31	Cognitive function;	chr4:39278104	chr4:39112677~39126818:-
OV	cis	rs17301013	0.507	rs10912791	ENSG00000227373.4	RP11-160H22.5	4.89	1.93e-06	0.00126	0.4	0.31	Systemic lupus erythematosus;	chr1:174479298	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12079334	ENSG00000227373.4	RP11-160H22.5	4.89	1.93e-06	0.00126	0.4	0.31	Systemic lupus erythematosus;	chr1:174480815	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12065454	ENSG00000227373.4	RP11-160H22.5	4.89	1.93e-06	0.00126	0.4	0.31	Systemic lupus erythematosus;	chr1:174492226	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs4652494	ENSG00000227373.4	RP11-160H22.5	4.89	1.93e-06	0.00126	0.4	0.31	Systemic lupus erythematosus;	chr1:174495861	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs7537823	ENSG00000227373.4	RP11-160H22.5	4.89	1.93e-06	0.00126	0.4	0.31	Systemic lupus erythematosus;	chr1:174502222	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs2281011	ENSG00000227373.4	RP11-160H22.5	4.89	1.93e-06	0.00126	0.4	0.31	Systemic lupus erythematosus;	chr1:174509890	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs2072759	ENSG00000227373.4	RP11-160H22.5	4.89	1.93e-06	0.00126	0.4	0.31	Systemic lupus erythematosus;	chr1:174510189	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs4652513	ENSG00000227373.4	RP11-160H22.5	4.89	1.93e-06	0.00126	0.4	0.31	Systemic lupus erythematosus;	chr1:174515794	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs6665535	ENSG00000227373.4	RP11-160H22.5	4.89	1.93e-06	0.00126	0.4	0.31	Systemic lupus erythematosus;	chr1:174522480	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12084948	ENSG00000227373.4	RP11-160H22.5	4.89	1.93e-06	0.00126	0.4	0.31	Systemic lupus erythematosus;	chr1:174525776	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs11809482	ENSG00000227373.4	RP11-160H22.5	4.89	1.93e-06	0.00126	0.4	0.31	Systemic lupus erythematosus;	chr1:174530269	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs909533	ENSG00000227373.4	RP11-160H22.5	4.89	1.93e-06	0.00126	0.4	0.31	Systemic lupus erythematosus;	chr1:174531428	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs72715224	ENSG00000227373.4	RP11-160H22.5	4.89	1.93e-06	0.00126	0.4	0.31	Systemic lupus erythematosus;	chr1:174534256	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12093966	ENSG00000227373.4	RP11-160H22.5	4.89	1.93e-06	0.00126	0.4	0.31	Systemic lupus erythematosus;	chr1:174535120	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs7550472	ENSG00000227373.4	RP11-160H22.5	4.89	1.93e-06	0.00126	0.4	0.31	Systemic lupus erythematosus;	chr1:174536442	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs11484645	ENSG00000227373.4	RP11-160H22.5	4.89	1.93e-06	0.00126	0.4	0.31	Systemic lupus erythematosus;	chr1:174542993	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12063545	ENSG00000227373.4	RP11-160H22.5	4.89	1.93e-06	0.00126	0.4	0.31	Systemic lupus erythematosus;	chr1:174552863	chr1:174115300~174160004:-
OV	cis	rs7201929	1	rs7499878	ENSG00000259982.1	CDC37P1	-4.89	1.93e-06	0.00127	-0.4	-0.31	QT interval;	chr16:28857143	chr16:28700294~28701540:-
OV	cis	rs8105895	0.8	rs62112872	ENSG00000269742.1	BNIP3P29	4.89	1.94e-06	0.00127	0.48	0.31	Body mass index (change over time);	chr19:22009623	chr19:22065828~22066398:-
OV	cis	rs1729407	0.814	rs2071521	ENSG00000254851.1	RP11-109L13.1	4.89	1.94e-06	0.00127	0.4	0.31	Apolipoprotein A-IV levels;	chr11:116827132	chr11:117135528~117138582:+
OV	cis	rs10924970	0.624	rs2297803	ENSG00000236863.2	RPL23AP23	4.89	1.94e-06	0.00127	0.32	0.31	Asthma;	chr1:235246709	chr1:235295865~235296335:+
OV	cis	rs7829975	0.56	rs17154599	ENSG00000253981.4	ALG1L13P	-4.89	1.94e-06	0.00127	-0.36	-0.31	Mood instability;	chr8:8693908	chr8:8236003~8244667:-
OV	cis	rs1113500	0.933	rs10881500	ENSG00000226822.1	RP11-356N1.2	4.89	1.94e-06	0.00127	0.37	0.31	Growth-regulated protein alpha levels;	chr1:108096273	chr1:108071482~108074519:+
OV	cis	rs1113500	0.897	rs10785832	ENSG00000226822.1	RP11-356N1.2	4.89	1.94e-06	0.00127	0.37	0.31	Growth-regulated protein alpha levels;	chr1:108096277	chr1:108071482~108074519:+
OV	cis	rs1113500	0.933	rs10785833	ENSG00000226822.1	RP11-356N1.2	4.89	1.94e-06	0.00127	0.37	0.31	Growth-regulated protein alpha levels;	chr1:108096460	chr1:108071482~108074519:+
OV	cis	rs1113500	0.702	rs11185262	ENSG00000226822.1	RP11-356N1.2	4.89	1.94e-06	0.00127	0.37	0.31	Growth-regulated protein alpha levels;	chr1:108097120	chr1:108071482~108074519:+
OV	cis	rs6991838	0.584	rs7842085	ENSG00000200714.1	Y_RNA	4.89	1.95e-06	0.00128	0.41	0.31	Intelligence (multi-trait analysis);	chr8:65636787	chr8:65592731~65592820:+
OV	cis	rs9828933	0.752	rs28675788	ENSG00000280620.1	SCAANT1	4.89	1.95e-06	0.00128	0.57	0.31	Type 2 diabetes;	chr3:63956512	chr3:63911518~63911772:-
OV	cis	rs34779708	0.931	rs34954932	ENSG00000230534.5	RP11-297A16.2	4.89	1.95e-06	0.00128	0.4	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35121879	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs34776628	ENSG00000230534.5	RP11-297A16.2	4.89	1.95e-06	0.00128	0.4	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35137396	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs17499247	ENSG00000230534.5	RP11-297A16.2	4.89	1.95e-06	0.00128	0.4	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35137827	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs10827491	ENSG00000230534.5	RP11-297A16.2	4.89	1.95e-06	0.00128	0.4	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35138467	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs4934732	ENSG00000230534.5	RP11-297A16.2	4.89	1.95e-06	0.00128	0.4	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35142756	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs878264	ENSG00000230534.5	RP11-297A16.2	4.89	1.95e-06	0.00128	0.4	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35151653	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs12782948	ENSG00000230534.5	RP11-297A16.2	4.89	1.95e-06	0.00128	0.4	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35161679	chr10:35098006~35127020:-
OV	cis	rs34779708	0.897	rs9665538	ENSG00000230534.5	RP11-297A16.2	4.89	1.95e-06	0.00128	0.4	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35172110	chr10:35098006~35127020:-
OV	cis	rs992157	0.835	rs13005100	ENSG00000237281.1	CATIP-AS2	4.89	1.95e-06	0.00128	0.36	0.31	Colorectal cancer;	chr2:218287044	chr2:218326889~218357966:-
OV	cis	rs992157	0.835	rs13031757	ENSG00000237281.1	CATIP-AS2	4.89	1.95e-06	0.00128	0.36	0.31	Colorectal cancer;	chr2:218287203	chr2:218326889~218357966:-
OV	cis	rs992157	0.835	rs34353396	ENSG00000237281.1	CATIP-AS2	4.89	1.95e-06	0.00128	0.36	0.31	Colorectal cancer;	chr2:218289259	chr2:218326889~218357966:-
OV	cis	rs2098713	0.561	rs55960353	ENSG00000250155.1	CTD-2353F22.1	4.89	1.95e-06	0.00128	0.37	0.31	Telomere length;	chr5:37599484	chr5:36666214~36725195:-
OV	cis	rs17301013	0.507	rs72715259	ENSG00000227373.4	RP11-160H22.5	4.89	1.95e-06	0.00128	0.42	0.31	Systemic lupus erythematosus;	chr1:174604590	chr1:174115300~174160004:-
OV	cis	rs4713118	0.662	rs149970	ENSG00000226314.6	ZNF192P1	-4.89	1.95e-06	0.00128	-0.43	-0.31	Parkinson's disease;	chr6:28012442	chr6:28161781~28169594:+
OV	cis	rs1790761	0.692	rs611663	ENSG00000184224.3	C11orf72	4.89	1.95e-06	0.00128	0.36	0.31	Mean corpuscular volume;	chr11:67544750	chr11:67602880~67606706:-
OV	cis	rs853679	0.546	rs175597	ENSG00000220721.1	OR1F12	4.88	1.95e-06	0.00128	0.5	0.31	Depression;	chr6:27842848	chr6:28073316~28074233:+
OV	cis	rs8062405	1	rs80275162	ENSG00000278665.1	RP11-666O2.4	4.88	1.96e-06	0.00128	0.33	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28852196	chr16:28599241~28601881:-
OV	cis	rs17301013	0.507	rs6687616	ENSG00000227373.4	RP11-160H22.5	4.88	1.96e-06	0.00128	0.42	0.31	Systemic lupus erythematosus;	chr1:174840322	chr1:174115300~174160004:-
OV	cis	rs2906856	0.921	rs1019076	ENSG00000255733.4	IFNG-AS1	-4.88	1.96e-06	0.00129	-0.31	-0.31	Mosquito bite size;	chr12:68004338	chr12:67989445~68234686:+
OV	cis	rs494459	0.691	rs607472	ENSG00000278376.1	RP11-158I9.8	-4.88	1.96e-06	0.00129	-0.31	-0.31	Height;	chr11:118809363	chr11:118791254~118793137:+
OV	cis	rs7188445	0.592	rs17767281	ENSG00000261390.4	RP11-345M22.2	-4.88	1.97e-06	0.00129	-0.35	-0.31	Urate levels;	chr16:79708544	chr16:79715232~79770563:-
OV	cis	rs514406	0.895	rs1925673	ENSG00000206627.1	RNU6-969P	4.88	1.97e-06	0.00129	0.31	0.31	Monocyte count;	chr1:52861312	chr1:52805108~52805212:-
OV	cis	rs8062405	0.69	rs762634	ENSG00000259982.1	CDC37P1	4.88	1.97e-06	0.00129	0.4	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28592014	chr16:28700294~28701540:-
OV	cis	rs607987	0.836	rs4267043	ENSG00000254532.1	RP11-624D11.2	-4.88	1.97e-06	0.00129	-0.36	-0.31	Body mass index;	chr11:30272222	chr11:30044058~30084343:-
OV	cis	rs607987	0.776	rs11031032	ENSG00000254532.1	RP11-624D11.2	-4.88	1.97e-06	0.00129	-0.36	-0.31	Body mass index;	chr11:30283179	chr11:30044058~30084343:-
OV	cis	rs6991838	0.798	rs6994889	ENSG00000200714.1	Y_RNA	4.88	1.97e-06	0.00129	0.38	0.31	Intelligence (multi-trait analysis);	chr8:65562547	chr8:65592731~65592820:+
OV	cis	rs6928977	0.5	rs9494308	ENSG00000231028.7	LINC00271	4.88	1.97e-06	0.00129	0.31	0.31	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135627666	chr6:135497801~135716055:+
OV	cis	rs9393777	0.528	rs34843552	ENSG00000243307.2	POM121L6P	-4.88	1.97e-06	0.00129	-0.35	-0.31	Intelligence (multi-trait analysis);	chr6:27274136	chr6:26896952~26898777:+
OV	cis	rs73201462	0.803	rs2955084	ENSG00000242551.2	POU5F1P6	-4.88	1.98e-06	0.00129	-0.64	-0.31	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128242462	chr3:128674735~128677005:-
OV	cis	rs607987	0.836	rs7108615	ENSG00000254532.1	RP11-624D11.2	-4.88	1.98e-06	0.0013	-0.36	-0.31	Body mass index;	chr11:30276262	chr11:30044058~30084343:-
OV	cis	rs34779708	0.931	rs2244100	ENSG00000230534.5	RP11-297A16.2	-4.88	1.99e-06	0.0013	-0.39	-0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35034708	chr10:35098006~35127020:-
OV	cis	rs7429990	0.93	rs71323371	ENSG00000229759.1	MRPS18AP1	4.88	1.99e-06	0.0013	0.34	0.31	Educational attainment (years of education);	chr3:47904327	chr3:48256350~48256938:-
OV	cis	rs6088590	0.523	rs6059913	ENSG00000206582.1	Y_RNA	-4.88	1.99e-06	0.0013	-0.37	-0.31	Coronary artery disease;	chr20:34555484	chr20:34526510~34526606:-
OV	cis	rs6088590	0.561	rs6059918	ENSG00000206582.1	Y_RNA	-4.88	1.99e-06	0.0013	-0.37	-0.31	Coronary artery disease;	chr20:34562699	chr20:34526510~34526606:-
OV	cis	rs7580658	0.521	rs2404535	ENSG00000236682.1	AC068282.3	4.88	1.99e-06	0.0013	0.38	0.31	Protein C levels;	chr2:127190133	chr2:127389130~127400580:+
OV	cis	rs853679	0.628	rs9368560	ENSG00000280107.1	AL022393.9	-4.88	2e-06	0.0013	-0.42	-0.31	Depression;	chr6:28192182	chr6:28170845~28172521:+
OV	cis	rs8100891	0.537	rs2302772	ENSG00000267213.4	AC007773.2	-4.88	2e-06	0.00131	-0.46	-0.31	Neuroticism;	chr19:32411144	chr19:32390050~32405560:-
OV	cis	rs858239	0.6	rs6967475	ENSG00000230042.1	AK3P3	-4.88	2e-06	0.00131	-0.35	-0.31	Cerebrospinal fluid biomarker levels;	chr7:23089363	chr7:23129178~23129841:+
OV	cis	rs7615952	0.576	rs17523380	ENSG00000250012.1	RP11-124N2.1	-4.88	2.01e-06	0.00131	-0.36	-0.31	Blood pressure (smoking interaction);	chr3:126084031	chr3:126084220~126095349:+
OV	cis	rs17301013	0.507	rs10912762	ENSG00000227373.4	RP11-160H22.5	4.88	2.01e-06	0.00131	0.4	0.31	Systemic lupus erythematosus;	chr1:174312477	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs10912763	ENSG00000227373.4	RP11-160H22.5	4.88	2.01e-06	0.00131	0.4	0.31	Systemic lupus erythematosus;	chr1:174316083	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs10912764	ENSG00000227373.4	RP11-160H22.5	4.88	2.01e-06	0.00131	0.4	0.31	Systemic lupus erythematosus;	chr1:174316085	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12097252	ENSG00000227373.4	RP11-160H22.5	4.88	2.01e-06	0.00131	0.4	0.31	Systemic lupus erythematosus;	chr1:174318374	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs10912765	ENSG00000227373.4	RP11-160H22.5	4.88	2.01e-06	0.00131	0.4	0.31	Systemic lupus erythematosus;	chr1:174322812	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs4651008	ENSG00000227373.4	RP11-160H22.5	4.88	2.01e-06	0.00131	0.4	0.31	Systemic lupus erythematosus;	chr1:174342681	chr1:174115300~174160004:-
OV	cis	rs10992471	0.756	rs7848055	ENSG00000281156.1	MIR3651	-4.88	2.01e-06	0.00131	-0.34	-0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92353210	chr9:92292458~92292547:-
OV	cis	rs8005677	0.798	rs61977741	ENSG00000279656.1	RP11-298I3.6	4.88	2.02e-06	0.00131	0.34	0.31	Cognitive ability (multi-trait analysis);	chr14:22931770	chr14:23023083~23024217:-
OV	cis	rs4713118	0.699	rs200978	ENSG00000219392.1	RP1-265C24.5	-4.88	2.02e-06	0.00132	-0.39	-0.31	Parkinson's disease;	chr6:27885390	chr6:28115628~28116551:+
OV	cis	rs6088590	0.561	rs11167239	ENSG00000206582.1	Y_RNA	-4.88	2.02e-06	0.00132	-0.37	-0.31	Coronary artery disease;	chr20:34552668	chr20:34526510~34526606:-
OV	cis	rs9876781	0.559	rs1841178	ENSG00000229759.1	MRPS18AP1	4.88	2.03e-06	0.00132	0.31	0.31	Longevity;	chr3:48355556	chr3:48256350~48256938:-
OV	cis	rs858239	0.665	rs858305	ENSG00000230658.1	KLHL7-AS1	-4.88	2.03e-06	0.00132	-0.45	-0.31	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23101228~23105703:-
OV	cis	rs17301013	0.581	rs1591944	ENSG00000227373.4	RP11-160H22.5	4.88	2.03e-06	0.00132	0.41	0.31	Systemic lupus erythematosus;	chr1:174204917	chr1:174115300~174160004:-
OV	cis	rs17023223	0.537	rs12083510	ENSG00000231365.4	RP11-418J17.1	-4.88	2.03e-06	0.00132	-0.4	-0.31	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119203997	chr1:119140396~119275973:+
OV	cis	rs796364	0.951	rs59695400	ENSG00000232732.8	AC073043.1	4.88	2.03e-06	0.00132	0.41	0.31	Schizophrenia;	chr2:200156602	chr2:199867396~199911159:-
OV	cis	rs853679	0.882	rs4713140	ENSG00000280107.1	AL022393.9	-4.88	2.03e-06	0.00133	-0.51	-0.31	Depression;	chr6:28129415	chr6:28170845~28172521:+
OV	cis	rs9467773	0.62	rs2451741	ENSG00000243307.2	POM121L6P	4.88	2.04e-06	0.00133	0.31	0.31	Intelligence (multi-trait analysis);	chr6:26629176	chr6:26896952~26898777:+
OV	cis	rs12134133	0.752	rs6540874	ENSG00000274245.1	RP11-357P18.2	4.88	2.04e-06	0.00133	0.42	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207221638	chr1:207372559~207373252:+
OV	cis	rs12134133	0.752	rs6683677	ENSG00000274245.1	RP11-357P18.2	4.88	2.04e-06	0.00133	0.42	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207228335	chr1:207372559~207373252:+
OV	cis	rs7160336	0.628	rs12893501	ENSG00000259065.1	RP5-1021I20.1	4.88	2.04e-06	0.00133	0.37	0.31	Blood protein levels;	chr14:73990459	chr14:73787360~73803270:+
OV	cis	rs2279440	0.759	rs7642020	ENSG00000206573.7	THUMPD3-AS1	4.88	2.04e-06	0.00133	0.37	0.31	Glucose homeostasis traits;	chr3:9480796	chr3:9349689~9398579:-
OV	cis	rs6088590	0.523	rs6058084	ENSG00000206582.1	Y_RNA	-4.88	2.04e-06	0.00133	-0.37	-0.31	Coronary artery disease;	chr20:34596000	chr20:34526510~34526606:-
OV	cis	rs10978777	0.515	rs28848858	ENSG00000276883.1	AL137852.1	4.88	2.04e-06	0.00133	0.4	0.31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107278492	chr9:107292369~107292456:-
OV	cis	rs14027	0.921	rs2136374	ENSG00000279347.1	RP11-85I17.2	-4.88	2.04e-06	0.00133	-0.31	-0.31	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119765046	chr8:119838736~119840385:-
OV	cis	rs14027	0.881	rs4871578	ENSG00000279347.1	RP11-85I17.2	-4.88	2.04e-06	0.00133	-0.31	-0.31	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119767615	chr8:119838736~119840385:-
OV	cis	rs14027	0.921	rs10110601	ENSG00000279347.1	RP11-85I17.2	-4.88	2.04e-06	0.00133	-0.31	-0.31	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119774866	chr8:119838736~119840385:-
OV	cis	rs6088590	0.561	rs6059932	ENSG00000206582.1	Y_RNA	-4.87	2.05e-06	0.00133	-0.37	-0.31	Coronary artery disease;	chr20:34587662	chr20:34526510~34526606:-
OV	cis	rs6088590	0.561	rs6087605	ENSG00000206582.1	Y_RNA	-4.87	2.05e-06	0.00133	-0.37	-0.31	Coronary artery disease;	chr20:34592820	chr20:34526510~34526606:-
OV	cis	rs116095464	0.558	rs55776650	ENSG00000250848.1	CTD-2083E4.5	-4.87	2.05e-06	0.00134	-0.38	-0.31	Breast cancer;	chr5:273711	chr5:288833~290321:-
OV	cis	rs2253762	0.645	rs11200366	ENSG00000276742.1	RP11-500G22.4	-4.87	2.05e-06	0.00134	-0.46	-0.31	Breast cancer;	chr10:122044170	chr10:121956782~121957098:+
OV	cis	rs4713118	0.513	rs149897	ENSG00000219392.1	RP1-265C24.5	-4.87	2.06e-06	0.00134	-0.37	-0.31	Parkinson's disease;	chr6:28038872	chr6:28115628~28116551:+
OV	cis	rs2098713	0.586	rs61435914	ENSG00000250155.1	CTD-2353F22.1	4.87	2.06e-06	0.00134	0.37	0.31	Telomere length;	chr5:37607239	chr5:36666214~36725195:-
OV	cis	rs293748	0.571	rs12652882	ENSG00000250155.1	CTD-2353F22.1	-4.87	2.06e-06	0.00134	-0.41	-0.31	Obesity-related traits;	chr5:37188340	chr5:36666214~36725195:-
OV	cis	rs783540	1	rs1259180	ENSG00000278603.1	RP13-608F4.5	-4.87	2.06e-06	0.00134	-0.34	-0.31	Schizophrenia;	chr15:82575930	chr15:82472203~82472426:+
OV	cis	rs7927592	0.913	rs7118897	ENSG00000212093.1	AP000807.1	4.87	2.07e-06	0.00134	0.39	0.31	Total body bone mineral density;	chr11:68593212	chr11:68506083~68506166:-
OV	cis	rs11903757	0.738	rs10931515	ENSG00000281467.1	Clostridiales-1	-4.87	2.07e-06	0.00134	-0.42	-0.31	Colorectal cancer;	chr2:191710385	chr2:191699476~191699631:-
OV	cis	rs17711722	0.51	rs11767457	ENSG00000224316.1	RP11-479O9.2	4.87	2.07e-06	0.00134	0.36	0.31	Calcium levels;	chr7:65825628	chr7:65773620~65802067:+
OV	cis	rs2522056	1	rs7730247	ENSG00000233006.5	AC034220.3	-4.87	2.07e-06	0.00135	-0.37	-0.31	Fibrinogen;Lymphocyte counts;	chr5:132445596	chr5:132311285~132369916:-
OV	cis	rs2522056	0.932	rs1012793	ENSG00000233006.5	AC034220.3	-4.87	2.07e-06	0.00135	-0.37	-0.31	Fibrinogen;Lymphocyte counts;	chr5:132445653	chr5:132311285~132369916:-
OV	cis	rs9291683	0.655	rs55941493	ENSG00000250413.1	RP11-448G15.1	4.87	2.07e-06	0.00135	0.35	0.31	Bone mineral density;	chr4:10098717	chr4:10006482~10009725:+
OV	cis	rs2098713	0.561	rs11949124	ENSG00000250155.1	CTD-2353F22.1	4.87	2.07e-06	0.00135	0.36	0.31	Telomere length;	chr5:37590362	chr5:36666214~36725195:-
OV	cis	rs3136516	0.935	rs4506602	ENSG00000271350.1	CTD-2384B9.1	-4.87	2.07e-06	0.00135	-0.33	-0.31	Venous thromboembolism;	chr11:46794083	chr11:47041027~47041945:-
OV	cis	rs6088590	0.523	rs6088536	ENSG00000206582.1	Y_RNA	-4.87	2.07e-06	0.00135	-0.37	-0.31	Coronary artery disease;	chr20:34601302	chr20:34526510~34526606:-
OV	cis	rs10510102	0.935	rs7906667	ENSG00000226864.1	ATE1-AS1	4.87	2.08e-06	0.00135	0.49	0.31	Breast cancer;	chr10:121909142	chr10:121928312~121951965:+
OV	cis	rs73019876	0.502	rs632709	ENSG00000269742.1	BNIP3P29	-4.87	2.08e-06	0.00135	-0.36	-0.31	Testicular germ cell tumor;	chr19:22050294	chr19:22065828~22066398:-
OV	cis	rs4728142	0.564	rs10954213	ENSG00000275106.1	RP11-309L24.10	-4.87	2.08e-06	0.00135	-0.4	-0.31	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128949373	chr7:128952527~128953316:-
OV	cis	rs4728142	0.604	rs13242262	ENSG00000275106.1	RP11-309L24.10	-4.87	2.08e-06	0.00135	-0.4	-0.31	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128951310	chr7:128952527~128953316:-
OV	cis	rs611744	0.573	rs674580	ENSG00000253754.1	RP11-35G22.1	-4.87	2.08e-06	0.00135	-0.35	-0.31	Dupuytren's disease;	chr8:108239461	chr8:108226200~108227544:+
OV	cis	rs9291683	0.507	rs6827754	ENSG00000250413.1	RP11-448G15.1	4.87	2.08e-06	0.00135	0.35	0.31	Bone mineral density;	chr4:10016529	chr4:10006482~10009725:+
OV	cis	rs1790761	0.501	rs4930210	ENSG00000184224.3	C11orf72	-4.87	2.09e-06	0.00136	-0.33	-0.31	Mean corpuscular volume;	chr11:67637255	chr11:67602880~67606706:-
OV	cis	rs293748	0.54	rs13163937	ENSG00000250155.1	CTD-2353F22.1	-4.87	2.09e-06	0.00136	-0.42	-0.31	Obesity-related traits;	chr5:37253547	chr5:36666214~36725195:-
OV	cis	rs11096990	0.593	rs7662880	ENSG00000249207.1	RP11-360F5.1	4.87	2.09e-06	0.00136	0.33	0.31	Cognitive function;	chr4:39283604	chr4:39112677~39126818:-
OV	cis	rs142472947	1	rs142472947	ENSG00000228423.2	RP4-633I8.4	4.87	2.09e-06	0.00136	0.39	0.31	White blood cell count;	chr1:8460430	chr1:8805860~8807051:-
OV	cis	rs6460942	0.841	rs17444203	ENSG00000226690.5	AC005281.1	-4.87	2.09e-06	0.00136	-0.49	-0.31	Coronary artery disease;	chr7:12422238	chr7:12496429~12541910:+
OV	cis	rs4380275	1	rs4854376	ENSG00000223751.1	AC116609.2	4.87	2.09e-06	0.00136	0.36	0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (doxorubicin);	chr2:763683	chr2:742488~747767:+
OV	cis	rs7688540	0.771	rs1986557	ENSG00000275426.1	CH17-262A2.1	4.87	2.1e-06	0.00136	0.46	0.31	Facial morphology (factor 6, height of vermillion lower lip);	chr4:289329	chr4:149738~150317:+
OV	cis	rs1789	0.592	rs1558572	ENSG00000273133.1	RP11-799M12.2	-4.87	2.1e-06	0.00136	-0.37	-0.31	Blood protein levels;	chr4:15537121	chr4:15563698~15564253:-
OV	cis	rs17301013	0.507	rs4652511	ENSG00000227373.4	RP11-160H22.5	4.87	2.1e-06	0.00136	0.4	0.31	Systemic lupus erythematosus;	chr1:174515500	chr1:174115300~174160004:-
OV	cis	rs1075265	0.572	rs3770405	ENSG00000233266.1	HMGB1P31	4.87	2.1e-06	0.00136	0.35	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53694884	chr2:54051334~54051760:+
OV	cis	rs7302981	0.741	rs8181679	ENSG00000257298.1	RP3-405J10.3	-4.87	2.1e-06	0.00136	-0.29	-0.31	Systolic blood pressure;	chr12:50217237	chr12:50185580~50191363:-
OV	cis	rs7829975	0.54	rs2976909	ENSG00000173295.6	FAM86B3P	-4.87	2.1e-06	0.00136	-0.36	-0.31	Mood instability;	chr8:8489180	chr8:8228595~8244865:+
OV	cis	rs34779708	0.868	rs2384352	ENSG00000230534.5	RP11-297A16.2	4.87	2.1e-06	0.00136	0.4	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35203904	chr10:35098006~35127020:-
OV	cis	rs4908768	0.817	rs11577530	ENSG00000228423.2	RP4-633I8.4	4.87	2.11e-06	0.00137	0.4	0.31	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8683385	chr1:8805860~8807051:-
OV	cis	rs9291683	0.609	rs4622999	ENSG00000250413.1	RP11-448G15.1	-4.87	2.11e-06	0.00137	-0.35	-0.31	Bone mineral density;	chr4:10001771	chr4:10006482~10009725:+
OV	cis	rs4853012	0.887	rs2280642	ENSG00000257800.1	FNBP1P1	4.87	2.11e-06	0.00137	0.45	0.31	Gestational age at birth (maternal effect);	chr2:74131125	chr2:74120680~74123218:+
OV	cis	rs4853012	0.887	rs2122290	ENSG00000257800.1	FNBP1P1	4.87	2.11e-06	0.00137	0.45	0.31	Gestational age at birth (maternal effect);	chr2:74131774	chr2:74120680~74123218:+
OV	cis	rs2243480	0.708	rs35825036	ENSG00000226824.5	RP4-756H11.3	-4.87	2.11e-06	0.00137	-0.48	-0.31	Diabetic kidney disease;	chr7:66521515	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs13237037	ENSG00000226824.5	RP4-756H11.3	-4.87	2.11e-06	0.00137	-0.48	-0.31	Diabetic kidney disease;	chr7:66532895	chr7:66654538~66669855:+
OV	cis	rs2243480	0.901	rs13237344	ENSG00000226824.5	RP4-756H11.3	-4.87	2.11e-06	0.00137	-0.48	-0.31	Diabetic kidney disease;	chr7:66557269	chr7:66654538~66669855:+
OV	cis	rs7580658	0.545	rs67996371	ENSG00000236682.1	AC068282.3	-4.87	2.11e-06	0.00137	-0.38	-0.31	Protein C levels;	chr2:127195841	chr2:127389130~127400580:+
OV	cis	rs11673344	0.764	rs513406	ENSG00000226686.6	LINC01535	4.87	2.11e-06	0.00137	0.38	0.31	Obesity-related traits;	chr19:36948245	chr19:37251912~37265535:+
OV	cis	rs11673344	0.734	rs496872	ENSG00000226686.6	LINC01535	4.87	2.11e-06	0.00137	0.38	0.31	Obesity-related traits;	chr19:36948579	chr19:37251912~37265535:+
OV	cis	rs4713118	0.513	rs149941	ENSG00000219392.1	RP1-265C24.5	-4.87	2.11e-06	0.00137	-0.38	-0.31	Parkinson's disease;	chr6:28033255	chr6:28115628~28116551:+
OV	cis	rs1075265	0.722	rs2111623	ENSG00000233266.1	HMGB1P31	-4.87	2.12e-06	0.00137	-0.36	-0.31	Chronotype;Morning vs. evening chronotype;	chr2:53757820	chr2:54051334~54051760:+
OV	cis	rs8062405	0.69	rs6498089	ENSG00000278665.1	RP11-666O2.4	-4.87	2.12e-06	0.00137	-0.33	-0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28617979	chr16:28599241~28601881:-
OV	cis	rs17301013	0.507	rs116545832	ENSG00000227373.4	RP11-160H22.5	4.87	2.12e-06	0.00137	0.41	0.31	Systemic lupus erythematosus;	chr1:174438725	chr1:174115300~174160004:-
OV	cis	rs2098713	0.561	rs4869440	ENSG00000250155.1	CTD-2353F22.1	4.87	2.12e-06	0.00137	0.36	0.31	Telomere length;	chr5:37600839	chr5:36666214~36725195:-
OV	cis	rs3758911	1	rs10789616	ENSG00000261098.1	RP11-819C21.1	-4.87	2.12e-06	0.00138	-0.29	-0.31	Coronary artery disease;	chr11:107318365	chr11:107312132~107316271:-
OV	cis	rs1555322	0.53	rs2425044	ENSG00000279253.1	RP4-614O4.13	-4.87	2.12e-06	0.00138	-0.39	-0.31	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35262727~35264187:-
OV	cis	rs875971	0.545	rs13311962	ENSG00000236529.1	RP13-254B10.1	-4.87	2.13e-06	0.00138	-0.37	-0.31	Aortic root size;	chr7:66603142	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs6958271	ENSG00000236529.1	RP13-254B10.1	4.87	2.13e-06	0.00138	0.32	0.31	Aortic root size;	chr7:66514344	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs6958277	ENSG00000236529.1	RP13-254B10.1	4.87	2.13e-06	0.00138	0.32	0.31	Aortic root size;	chr7:66514362	chr7:65840212~65840596:+
OV	cis	rs7302981	0.741	rs4459386	ENSG00000257298.1	RP3-405J10.3	-4.87	2.13e-06	0.00138	-0.29	-0.31	Systolic blood pressure;	chr12:50201164	chr12:50185580~50191363:-
OV	cis	rs2404602	0.692	rs4886503	ENSG00000259422.1	RP11-593F23.1	-4.87	2.13e-06	0.00138	-0.32	-0.31	Blood metabolite levels;	chr15:76816533	chr15:76174891~76181486:-
OV	cis	rs4964805	0.594	rs4981036	ENSG00000257681.1	RP11-341G23.4	4.87	2.14e-06	0.00138	0.34	0.31	Attention deficit hyperactivity disorder;	chr12:103770566	chr12:103746315~103768858:-
OV	cis	rs12701220	0.655	rs7778968	ENSG00000229043.2	AC091729.9	-4.87	2.14e-06	0.00138	-0.38	-0.31	Bronchopulmonary dysplasia;	chr7:1104986	chr7:1160374~1165267:+
OV	cis	rs301901	1	rs301859	ENSG00000250155.1	CTD-2353F22.1	-4.87	2.14e-06	0.00138	-0.36	-0.31	Height;	chr5:37045739	chr5:36666214~36725195:-
OV	cis	rs301901	1	rs188541	ENSG00000250155.1	CTD-2353F22.1	-4.87	2.14e-06	0.00138	-0.36	-0.31	Height;	chr5:37061159	chr5:36666214~36725195:-
OV	cis	rs12073359	0.955	rs1824848	ENSG00000223945.2	RP11-458I7.1	4.87	2.14e-06	0.00138	0.45	0.31	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150167382	chr1:150053864~150055034:+
OV	cis	rs4853012	0.838	rs6707729	ENSG00000257800.1	FNBP1P1	4.87	2.14e-06	0.00138	0.43	0.31	Gestational age at birth (maternal effect);	chr2:74117558	chr2:74120680~74123218:+
OV	cis	rs992157	0.764	rs10932774	ENSG00000237281.1	CATIP-AS2	-4.86	2.14e-06	0.00138	-0.36	-0.31	Colorectal cancer;	chr2:218326846	chr2:218326889~218357966:-
OV	cis	rs6700559	0.81	rs2808248	ENSG00000260088.1	RP11-92G12.3	4.86	2.15e-06	0.00139	0.32	0.31	Coronary artery disease;	chr1:200623147	chr1:200669507~200694250:+
OV	cis	rs6700559	0.81	rs2808250	ENSG00000260088.1	RP11-92G12.3	-4.86	2.15e-06	0.00139	-0.32	-0.31	Coronary artery disease;	chr1:200623419	chr1:200669507~200694250:+
OV	cis	rs4865169	0.934	rs3796531	ENSG00000269949.1	RP11-738E22.3	-4.86	2.15e-06	0.00139	-0.35	-0.31	Breast cancer;	chr4:56984680	chr4:56960927~56961373:-
OV	cis	rs1790761	0.692	rs10896179	ENSG00000184224.3	C11orf72	4.86	2.15e-06	0.00139	0.35	0.31	Mean corpuscular volume;	chr11:67549457	chr11:67602880~67606706:-
OV	cis	rs301901	1	rs388098	ENSG00000250155.1	CTD-2353F22.1	-4.86	2.15e-06	0.00139	-0.36	-0.31	Height;	chr5:37068442	chr5:36666214~36725195:-
OV	cis	rs992157	0.835	rs2292550	ENSG00000237281.1	CATIP-AS2	4.86	2.15e-06	0.00139	0.36	0.31	Colorectal cancer;	chr2:218275565	chr2:218326889~218357966:-
OV	cis	rs7615952	0.576	rs6780025	ENSG00000171084.14	FAM86JP	4.86	2.15e-06	0.00139	0.45	0.31	Blood pressure (smoking interaction);	chr3:126096781	chr3:125916620~125930024:+
OV	cis	rs7615952	0.576	rs6804482	ENSG00000171084.14	FAM86JP	4.86	2.15e-06	0.00139	0.45	0.31	Blood pressure (smoking interaction);	chr3:126096919	chr3:125916620~125930024:+
OV	cis	rs875971	0.862	rs1167408	ENSG00000236529.1	RP13-254B10.1	-4.86	2.15e-06	0.00139	-0.32	-0.31	Aortic root size;	chr7:66091121	chr7:65840212~65840596:+
OV	cis	rs875971	0.83	rs1167406	ENSG00000236529.1	RP13-254B10.1	-4.86	2.15e-06	0.00139	-0.32	-0.31	Aortic root size;	chr7:66091949	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs709609	ENSG00000236529.1	RP13-254B10.1	-4.86	2.15e-06	0.00139	-0.32	-0.31	Aortic root size;	chr7:66095574	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs1167399	ENSG00000236529.1	RP13-254B10.1	-4.86	2.15e-06	0.00139	-0.32	-0.31	Aortic root size;	chr7:66096890	chr7:65840212~65840596:+
OV	cis	rs875971	0.825	rs59466412	ENSG00000236529.1	RP13-254B10.1	-4.86	2.15e-06	0.00139	-0.32	-0.31	Aortic root size;	chr7:66100371	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs57866200	ENSG00000236529.1	RP13-254B10.1	-4.86	2.15e-06	0.00139	-0.32	-0.31	Aortic root size;	chr7:66100405	chr7:65840212~65840596:+
OV	cis	rs2098713	0.561	rs62359058	ENSG00000250155.1	CTD-2353F22.1	4.86	2.16e-06	0.00139	0.37	0.31	Telomere length;	chr5:37592593	chr5:36666214~36725195:-
OV	cis	rs2098713	0.561	rs12655908	ENSG00000250155.1	CTD-2353F22.1	4.86	2.16e-06	0.00139	0.37	0.31	Telomere length;	chr5:37595793	chr5:36666214~36725195:-
OV	cis	rs2098713	0.561	rs4869530	ENSG00000250155.1	CTD-2353F22.1	4.86	2.16e-06	0.00139	0.37	0.31	Telomere length;	chr5:37598468	chr5:36666214~36725195:-
OV	cis	rs1075265	0.626	rs805320	ENSG00000233266.1	HMGB1P31	4.86	2.16e-06	0.0014	0.38	0.31	Chronotype;Morning vs. evening chronotype;	chr2:53911305	chr2:54051334~54051760:+
OV	cis	rs858239	0.539	rs10254544	ENSG00000230042.1	AK3P3	-4.86	2.16e-06	0.0014	-0.33	-0.31	Cerebrospinal fluid biomarker levels;	chr7:23180616	chr7:23129178~23129841:+
OV	cis	rs2243480	0.706	rs6460257	ENSG00000222364.1	RNU6-96P	-4.86	2.17e-06	0.0014	-0.45	-0.31	Diabetic kidney disease;	chr7:65731813	chr7:66395191~66395286:+
OV	cis	rs11673344	0.704	rs1726719	ENSG00000226686.6	LINC01535	4.86	2.17e-06	0.0014	0.38	0.31	Obesity-related traits;	chr19:36927130	chr19:37251912~37265535:+
OV	cis	rs10829156	0.898	rs4748504	ENSG00000225527.1	RP11-383B4.4	-4.86	2.17e-06	0.0014	-0.41	-0.31	Sudden cardiac arrest;	chr10:18651868	chr10:18531849~18533336:-
OV	cis	rs875971	0.545	rs1909508	ENSG00000236529.1	RP13-254B10.1	4.86	2.17e-06	0.0014	0.36	0.31	Aortic root size;	chr7:66301366	chr7:65840212~65840596:+
OV	cis	rs875971	0.964	rs60193905	ENSG00000236529.1	RP13-254B10.1	4.86	2.17e-06	0.0014	0.32	0.31	Aortic root size;	chr7:66506273	chr7:65840212~65840596:+
OV	cis	rs55692468	0.539	rs4664110	ENSG00000213197.3	AC012066.1	-4.86	2.17e-06	0.0014	-0.32	-0.31	Intraocular pressure;	chr2:152461900	chr2:152389937~152390630:+
OV	cis	rs7189233	0.531	rs9302648	ENSG00000279344.1	RP11-44F14.7	4.86	2.18e-06	0.00141	0.29	0.31	Intelligence (multi-trait analysis);	chr16:53493869	chr16:53478957~53481550:-
OV	cis	rs796364	0.616	rs6718118	ENSG00000232732.8	AC073043.1	4.86	2.18e-06	0.00141	0.44	0.31	Schizophrenia;	chr2:199827129	chr2:199867396~199911159:-
OV	cis	rs8062405	1	rs62036622	ENSG00000278665.1	RP11-666O2.4	4.86	2.18e-06	0.00141	0.34	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28825882	chr16:28599241~28601881:-
OV	cis	rs858239	0.539	rs28624974	ENSG00000230042.1	AK3P3	-4.86	2.18e-06	0.00141	-0.32	-0.31	Cerebrospinal fluid biomarker levels;	chr7:23149317	chr7:23129178~23129841:+
OV	cis	rs11157436	0.846	rs12435431	ENSG00000211812.1	TRAV26-2	-4.86	2.18e-06	0.00141	-0.34	-0.31	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22230301	chr14:22202583~22203368:+
OV	cis	rs34779708	0.931	rs12767414	ENSG00000230534.5	RP11-297A16.2	4.86	2.18e-06	0.00141	0.4	0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35101265	chr10:35098006~35127020:-
OV	cis	rs875971	0.83	rs427973	ENSG00000236529.1	RP13-254B10.1	4.86	2.18e-06	0.00141	0.33	0.31	Aortic root size;	chr7:66061661	chr7:65840212~65840596:+
OV	cis	rs11096990	0.613	rs1451821	ENSG00000249207.1	RP11-360F5.1	4.86	2.18e-06	0.00141	0.33	0.31	Cognitive function;	chr4:39178797	chr4:39112677~39126818:-
OV	cis	rs507080	0.733	rs489126	ENSG00000278376.1	RP11-158I9.8	-4.86	2.19e-06	0.00141	-0.32	-0.31	Serum metabolite levels;	chr11:118702038	chr11:118791254~118793137:+
OV	cis	rs9291683	0.588	rs17246745	ENSG00000250413.1	RP11-448G15.1	-4.86	2.19e-06	0.00141	-0.35	-0.31	Bone mineral density;	chr4:9992959	chr4:10006482~10009725:+
OV	cis	rs17301013	0.507	rs28628056	ENSG00000227373.4	RP11-160H22.5	4.86	2.19e-06	0.00141	0.4	0.31	Systemic lupus erythematosus;	chr1:174369545	chr1:174115300~174160004:-
OV	cis	rs1555322	0.505	rs639763	ENSG00000279253.1	RP4-614O4.13	-4.86	2.19e-06	0.00141	-0.39	-0.31	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35262727~35264187:-
OV	cis	rs2921073	0.605	rs2976933	ENSG00000253893.2	FAM85B	-4.86	2.19e-06	0.00141	-0.35	-0.31	Parkinson's disease;	chr8:8397365	chr8:8167819~8226614:-
OV	cis	rs10793273	1	rs10793273	ENSG00000246174.6	KCTD21-AS1	-4.86	2.19e-06	0.00141	-0.31	-0.31	Pelvic organ prolapse;	chr11:78031549	chr11:78139771~78175323:+
OV	cis	rs4718428	0.96	rs6460317	ENSG00000226824.5	RP4-756H11.3	-4.86	2.2e-06	0.00142	-0.35	-0.31	Corneal structure;	chr7:66925268	chr7:66654538~66669855:+
OV	cis	rs7811142	0.83	rs705866	ENSG00000242294.5	STAG3L5P	4.86	2.2e-06	0.00142	0.34	0.31	Platelet count;	chr7:100367662	chr7:100336079~100351900:+
OV	cis	rs11673344	0.704	rs1644710	ENSG00000226686.6	LINC01535	4.86	2.2e-06	0.00142	0.38	0.31	Obesity-related traits;	chr19:36926160	chr19:37251912~37265535:+
OV	cis	rs875971	0.545	rs1267814	ENSG00000236529.1	RP13-254B10.1	-4.86	2.21e-06	0.00142	-0.37	-0.31	Aortic root size;	chr7:66579422	chr7:65840212~65840596:+
OV	cis	rs13178541	0.745	rs7380109	ENSG00000250378.1	RP11-119J18.1	-4.86	2.21e-06	0.00142	-0.43	-0.31	IgG glycosylation;	chr5:135751385	chr5:135812667~135826582:+
OV	cis	rs7771547	0.573	rs547026	ENSG00000240733.3	RN7SL502P	4.86	2.21e-06	0.00142	0.33	0.31	Platelet distribution width;	chr6:36430839	chr6:36450912~36451201:-
OV	cis	rs4805272	0.962	rs1363328	ENSG00000267243.4	AC005307.3	-4.86	2.21e-06	0.00143	-0.41	-0.31	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28834656	chr19:28435388~28727777:-
OV	cis	rs858239	0.539	rs2141305	ENSG00000230042.1	AK3P3	-4.86	2.21e-06	0.00143	-0.32	-0.31	Cerebrospinal fluid biomarker levels;	chr7:23152280	chr7:23129178~23129841:+
OV	cis	rs4908768	0.817	rs11587482	ENSG00000228423.2	RP4-633I8.4	4.86	2.22e-06	0.00143	0.39	0.31	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8683136	chr1:8805860~8807051:-
OV	cis	rs1797885	0.934	rs299654	ENSG00000251774.1	RNU6-377P	4.86	2.22e-06	0.00143	0.29	0.31	Immature fraction of reticulocytes;	chr3:12508579	chr3:12514706~12514807:+
OV	cis	rs896854	0.654	rs28591375	ENSG00000253528.2	RP11-347C18.4	4.86	2.22e-06	0.00143	0.29	0.31	Type 2 diabetes;	chr8:94961409	chr8:94974573~94974853:-
OV	cis	rs896854	0.654	rs4735339	ENSG00000253528.2	RP11-347C18.4	4.86	2.22e-06	0.00143	0.29	0.31	Type 2 diabetes;	chr8:94962145	chr8:94974573~94974853:-
OV	cis	rs896854	0.654	rs28716845	ENSG00000253528.2	RP11-347C18.4	4.86	2.22e-06	0.00143	0.29	0.31	Type 2 diabetes;	chr8:94962257	chr8:94974573~94974853:-
OV	cis	rs896854	0.596	rs7823059	ENSG00000253528.2	RP11-347C18.4	4.86	2.22e-06	0.00143	0.29	0.31	Type 2 diabetes;	chr8:94962733	chr8:94974573~94974853:-
OV	cis	rs896854	0.653	rs13266313	ENSG00000253528.2	RP11-347C18.4	4.86	2.22e-06	0.00143	0.29	0.31	Type 2 diabetes;	chr8:94963074	chr8:94974573~94974853:-
OV	cis	rs896854	0.654	rs4735340	ENSG00000253528.2	RP11-347C18.4	4.86	2.22e-06	0.00143	0.29	0.31	Type 2 diabetes;	chr8:94964023	chr8:94974573~94974853:-
OV	cis	rs34779708	0.931	rs11010067	ENSG00000230534.5	RP11-297A16.2	-4.86	2.22e-06	0.00143	-0.4	-0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35006503	chr10:35098006~35127020:-
OV	cis	rs4718428	1	rs4718428	ENSG00000226824.5	RP4-756H11.3	-4.86	2.22e-06	0.00143	-0.36	-0.31	Corneal structure;	chr7:66956459	chr7:66654538~66669855:+
OV	cis	rs11671005	0.656	rs55652736	ENSG00000269600.1	AC016629.3	-4.86	2.22e-06	0.00143	-0.48	-0.31	Mean platelet volume;	chr19:58496199	chr19:58593896~58599355:-
OV	cis	rs12594515	1	rs6493169	ENSG00000273972.1	CTD-2306A12.1	4.86	2.22e-06	0.00143	0.32	0.31	Weight;Waist circumference;	chr15:45694796	chr15:45702640~45703183:+
OV	cis	rs17711722	0.522	rs6957759	ENSG00000224316.1	RP11-479O9.2	4.86	2.22e-06	0.00143	0.34	0.31	Calcium levels;	chr7:65806798	chr7:65773620~65802067:+
OV	cis	rs1075265	0.568	rs805416	ENSG00000233266.1	HMGB1P31	-4.86	2.22e-06	0.00143	-0.38	-0.31	Chronotype;Morning vs. evening chronotype;	chr2:53898121	chr2:54051334~54051760:+
OV	cis	rs67311347	1	rs56992941	ENSG00000223797.4	ENTPD3-AS1	4.86	2.23e-06	0.00143	0.34	0.31	Renal cell carcinoma;	chr3:40430943	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs4974017	ENSG00000223797.4	ENTPD3-AS1	4.86	2.23e-06	0.00143	0.34	0.31	Renal cell carcinoma;	chr3:40432028	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs6762997	ENSG00000223797.4	ENTPD3-AS1	4.86	2.23e-06	0.00143	0.34	0.31	Renal cell carcinoma;	chr3:40436660	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs977652	ENSG00000223797.4	ENTPD3-AS1	4.86	2.23e-06	0.00143	0.34	0.31	Renal cell carcinoma;	chr3:40437678	chr3:40313802~40453329:-
OV	cis	rs13113518	0.812	rs12500686	ENSG00000223305.1	RN7SKP30	4.86	2.23e-06	0.00143	0.37	0.31	Height;	chr4:55457922	chr4:55540502~55540835:-
OV	cis	rs875971	1	rs6956179	ENSG00000236529.1	RP13-254B10.1	-4.86	2.23e-06	0.00143	-0.32	-0.31	Aortic root size;	chr7:66341672	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs67775320	ENSG00000236529.1	RP13-254B10.1	4.86	2.23e-06	0.00144	0.36	0.31	Aortic root size;	chr7:66193792	chr7:65840212~65840596:+
OV	cis	rs7208859	0.623	rs122898	ENSG00000264538.5	SUZ12P1	4.86	2.24e-06	0.00144	0.31	0.31	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30709299~30790908:+
OV	cis	rs116095464	0.614	rs28736753	ENSG00000250848.1	CTD-2083E4.5	-4.86	2.24e-06	0.00144	-0.39	-0.31	Breast cancer;	chr5:273966	chr5:288833~290321:-
OV	cis	rs17301013	0.606	rs6670425	ENSG00000227373.4	RP11-160H22.5	4.86	2.24e-06	0.00144	0.4	0.31	Systemic lupus erythematosus;	chr1:174144204	chr1:174115300~174160004:-
OV	cis	rs17301013	0.581	rs6685499	ENSG00000227373.4	RP11-160H22.5	4.86	2.24e-06	0.00144	0.4	0.31	Systemic lupus erythematosus;	chr1:174144237	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs4652193	ENSG00000227373.4	RP11-160H22.5	4.86	2.24e-06	0.00144	0.4	0.31	Systemic lupus erythematosus;	chr1:174144554	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs16846717	ENSG00000227373.4	RP11-160H22.5	4.86	2.24e-06	0.00144	0.4	0.31	Systemic lupus erythematosus;	chr1:174152180	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs16846718	ENSG00000227373.4	RP11-160H22.5	4.86	2.24e-06	0.00144	0.4	0.31	Systemic lupus erythematosus;	chr1:174152782	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs10912735	ENSG00000227373.4	RP11-160H22.5	4.86	2.24e-06	0.00144	0.4	0.31	Systemic lupus erythematosus;	chr1:174159002	chr1:174115300~174160004:-
OV	cis	rs9859260	0.744	rs539816	ENSG00000231464.1	AC024937.4	-4.85	2.24e-06	0.00144	-0.38	-0.31	Mean corpuscular volume;	chr3:196057205	chr3:195996738~195998233:+
OV	cis	rs9859260	0.744	rs492349	ENSG00000231464.1	AC024937.4	-4.85	2.24e-06	0.00144	-0.38	-0.31	Mean corpuscular volume;	chr3:196057321	chr3:195996738~195998233:+
OV	cis	rs9859260	0.744	rs492288	ENSG00000231464.1	AC024937.4	-4.85	2.24e-06	0.00144	-0.38	-0.31	Mean corpuscular volume;	chr3:196057339	chr3:195996738~195998233:+
OV	cis	rs34779708	0.931	rs2505631	ENSG00000230534.5	RP11-297A16.2	-4.85	2.25e-06	0.00144	-0.4	-0.31	Inflammatory bowel disease;Crohn's disease;	chr10:35079457	chr10:35098006~35127020:-
OV	cis	rs6435862	0.636	rs717548	ENSG00000227769.6	AC072062.3	4.85	2.25e-06	0.00144	0.37	0.31	Neuroblastoma (high-risk);	chr2:214812181	chr2:215004782~215085488:+
OV	cis	rs796364	0.715	rs1106399	ENSG00000232732.8	AC073043.1	4.85	2.25e-06	0.00144	0.44	0.31	Schizophrenia;	chr2:200139114	chr2:199867396~199911159:-
OV	cis	rs796364	0.806	rs1106400	ENSG00000232732.8	AC073043.1	4.85	2.25e-06	0.00144	0.44	0.31	Schizophrenia;	chr2:200139366	chr2:199867396~199911159:-
OV	cis	rs796364	0.806	rs74938253	ENSG00000232732.8	AC073043.1	4.85	2.25e-06	0.00144	0.44	0.31	Schizophrenia;	chr2:200143663	chr2:199867396~199911159:-
OV	cis	rs7968440	1	rs2731443	ENSG00000257298.1	RP3-405J10.3	4.85	2.25e-06	0.00145	0.3	0.31	Fibrinogen;	chr12:50700355	chr12:50185580~50191363:-
OV	cis	rs1576263	0.967	rs1796698	ENSG00000230939.1	RP11-314C16.1	-4.85	2.25e-06	0.00145	-0.34	-0.31	Photic sneeze reflex;	chr6:8552236	chr6:8784178~8785445:+
OV	cis	rs1576263	0.967	rs162282	ENSG00000230939.1	RP11-314C16.1	-4.85	2.25e-06	0.00145	-0.34	-0.31	Photic sneeze reflex;	chr6:8552800	chr6:8784178~8785445:+
OV	cis	rs2179367	0.887	rs2789488	ENSG00000231760.4	RP11-350J20.5	-4.85	2.25e-06	0.00145	-0.36	-0.31	Dupuytren's disease;	chr6:149404154	chr6:149796151~149826294:-
OV	cis	rs9291683	0.546	rs10939672	ENSG00000250413.1	RP11-448G15.1	-4.85	2.26e-06	0.00145	-0.36	-0.31	Bone mineral density;	chr4:10050512	chr4:10006482~10009725:+
OV	cis	rs11096990	0.613	rs6840578	ENSG00000249207.1	RP11-360F5.1	-4.85	2.26e-06	0.00145	-0.33	-0.31	Cognitive function;	chr4:39206996	chr4:39112677~39126818:-
OV	cis	rs11096990	0.613	rs7690414	ENSG00000249207.1	RP11-360F5.1	-4.85	2.26e-06	0.00145	-0.33	-0.31	Cognitive function;	chr4:39210669	chr4:39112677~39126818:-
OV	cis	rs11673344	0.764	rs826304	ENSG00000226686.6	LINC01535	4.85	2.26e-06	0.00145	0.38	0.31	Obesity-related traits;	chr19:36952681	chr19:37251912~37265535:+
OV	cis	rs875971	0.545	rs73142233	ENSG00000226824.5	RP4-756H11.3	-4.85	2.26e-06	0.00145	-0.36	-0.31	Aortic root size;	chr7:66221293	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs1612452	ENSG00000236529.1	RP13-254B10.1	-4.85	2.26e-06	0.00145	-0.31	-0.31	Aortic root size;	chr7:66108909	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs1167390	ENSG00000236529.1	RP13-254B10.1	-4.85	2.26e-06	0.00145	-0.31	-0.31	Aortic root size;	chr7:66110906	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs35034167	ENSG00000236529.1	RP13-254B10.1	-4.85	2.26e-06	0.00145	-0.31	-0.31	Aortic root size;	chr7:66115179	chr7:65840212~65840596:+
OV	cis	rs7429990	0.965	rs34750113	ENSG00000229759.1	MRPS18AP1	4.85	2.27e-06	0.00145	0.33	0.31	Educational attainment (years of education);	chr3:47944902	chr3:48256350~48256938:-
OV	cis	rs7927592	0.913	rs3740631	ENSG00000212093.1	AP000807.1	4.85	2.27e-06	0.00146	0.39	0.31	Total body bone mineral density;	chr11:68574254	chr11:68506083~68506166:-
OV	cis	rs7927592	0.913	rs3824850	ENSG00000212093.1	AP000807.1	4.85	2.27e-06	0.00146	0.39	0.31	Total body bone mineral density;	chr11:68574405	chr11:68506083~68506166:-
OV	cis	rs7927592	0.913	rs3740629	ENSG00000212093.1	AP000807.1	4.85	2.27e-06	0.00146	0.39	0.31	Total body bone mineral density;	chr11:68576125	chr11:68506083~68506166:-
OV	cis	rs7927592	0.913	rs11228287	ENSG00000212093.1	AP000807.1	4.85	2.27e-06	0.00146	0.39	0.31	Total body bone mineral density;	chr11:68582286	chr11:68506083~68506166:-
OV	cis	rs7927592	0.913	rs10896346	ENSG00000212093.1	AP000807.1	4.85	2.27e-06	0.00146	0.39	0.31	Total body bone mineral density;	chr11:68585203	chr11:68506083~68506166:-
OV	cis	rs7927592	0.913	rs10896347	ENSG00000212093.1	AP000807.1	4.85	2.27e-06	0.00146	0.39	0.31	Total body bone mineral density;	chr11:68585659	chr11:68506083~68506166:-
OV	cis	rs7927592	0.913	rs6591344	ENSG00000212093.1	AP000807.1	4.85	2.27e-06	0.00146	0.39	0.31	Total body bone mineral density;	chr11:68593405	chr11:68506083~68506166:-
OV	cis	rs7927592	0.913	rs7127948	ENSG00000212093.1	AP000807.1	4.85	2.27e-06	0.00146	0.39	0.31	Total body bone mineral density;	chr11:68595594	chr11:68506083~68506166:-
OV	cis	rs1185460	0.547	rs34150933	ENSG00000271751.1	RP11-110I1.14	4.85	2.28e-06	0.00146	0.37	0.31	Coronary artery disease;	chr11:119040329	chr11:119065263~119065677:-
OV	cis	rs10924970	0.649	rs4659653	ENSG00000236863.2	RPL23AP23	4.85	2.28e-06	0.00146	0.31	0.31	Asthma;	chr1:235219460	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs3795250	ENSG00000236863.2	RPL23AP23	4.85	2.28e-06	0.00146	0.31	0.31	Asthma;	chr1:235220036	chr1:235295865~235296335:+
OV	cis	rs10924970	0.601	rs3765797	ENSG00000236863.2	RPL23AP23	4.85	2.28e-06	0.00146	0.31	0.31	Asthma;	chr1:235223685	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs12743844	ENSG00000236863.2	RPL23AP23	4.85	2.28e-06	0.00146	0.31	0.31	Asthma;	chr1:235225918	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs12032572	ENSG00000236863.2	RPL23AP23	4.85	2.28e-06	0.00146	0.31	0.31	Asthma;	chr1:235226039	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs10495361	ENSG00000236863.2	RPL23AP23	4.85	2.28e-06	0.00146	0.31	0.31	Asthma;	chr1:235226233	chr1:235295865~235296335:+
OV	cis	rs10924970	0.601	rs11581323	ENSG00000236863.2	RPL23AP23	4.85	2.28e-06	0.00146	0.31	0.31	Asthma;	chr1:235232608	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs12034913	ENSG00000236863.2	RPL23AP23	4.85	2.28e-06	0.00146	0.31	0.31	Asthma;	chr1:235236017	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs10925195	ENSG00000236863.2	RPL23AP23	4.85	2.28e-06	0.00146	0.31	0.31	Asthma;	chr1:235238027	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs2185019	ENSG00000236863.2	RPL23AP23	4.85	2.28e-06	0.00146	0.31	0.31	Asthma;	chr1:235238818	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs12760850	ENSG00000236863.2	RPL23AP23	4.85	2.28e-06	0.00146	0.31	0.31	Asthma;	chr1:235241930	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs2185018	ENSG00000236863.2	RPL23AP23	4.85	2.28e-06	0.00146	0.31	0.31	Asthma;	chr1:235245095	chr1:235295865~235296335:+
OV	cis	rs8054556	0.692	rs4788199	ENSG00000261367.1	RP11-455F5.4	-4.85	2.28e-06	0.00146	-0.33	-0.31	Autism spectrum disorder or schizophrenia;	chr16:29959536	chr16:30107675~30110541:+
OV	cis	rs1113500	0.897	rs55980437	ENSG00000226822.1	RP11-356N1.2	4.85	2.29e-06	0.00146	0.37	0.31	Growth-regulated protein alpha levels;	chr1:108096876	chr1:108071482~108074519:+
OV	cis	rs7017914	0.652	rs7014185	ENSG00000223220.1	Y_RNA	4.85	2.29e-06	0.00146	0.35	0.31	Bone mineral density;	chr8:71082558	chr8:70780914~70781008:-
OV	cis	rs8062405	1	rs12446589	ENSG00000278665.1	RP11-666O2.4	4.85	2.29e-06	0.00147	0.33	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859641	chr16:28599241~28601881:-
OV	cis	rs9880192	0.516	rs2713575	ENSG00000277250.1	Metazoa_SRP	-4.85	2.29e-06	0.00147	-0.34	-0.31	White blood cell count;Eosinophil percentage of white cells;Monocyte count;Neutrophil percentage of granulocytes;Monocyte-lymphocyte ratio;Eosinophil percentage of granulocytes;Eosinophil counts;	chr3:128575512	chr3:128673681~128674021:-
OV	cis	rs11214589	0.747	rs11214577	ENSG00000270179.1	RP11-159N11.4	4.85	2.29e-06	0.00147	0.32	0.31	Neuroticism;	chr11:113333544	chr11:113368478~113369117:+
OV	cis	rs10740039	0.804	rs1372714	ENSG00000254271.1	RP11-131N11.4	4.85	2.3e-06	0.00147	0.38	0.31	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60686640	chr10:60734342~60741828:+
OV	cis	rs293748	0.54	rs10461978	ENSG00000250155.1	CTD-2353F22.1	-4.85	2.3e-06	0.00147	-0.42	-0.31	Obesity-related traits;	chr5:37274810	chr5:36666214~36725195:-
OV	cis	rs2253762	0.507	rs10159582	ENSG00000276742.1	RP11-500G22.4	4.85	2.3e-06	0.00147	0.51	0.31	Breast cancer;	chr10:121993110	chr10:121956782~121957098:+
OV	cis	rs2253762	0.507	rs10159583	ENSG00000276742.1	RP11-500G22.4	4.85	2.3e-06	0.00147	0.51	0.31	Breast cancer;	chr10:121993154	chr10:121956782~121957098:+
OV	cis	rs2253762	0.507	rs75383663	ENSG00000276742.1	RP11-500G22.4	4.85	2.3e-06	0.00147	0.51	0.31	Breast cancer;	chr10:121993340	chr10:121956782~121957098:+
OV	cis	rs1061377	0.674	rs34506243	ENSG00000249207.1	RP11-360F5.1	-4.85	2.3e-06	0.00147	-0.32	-0.31	Uric acid levels;	chr4:39082702	chr4:39112677~39126818:-
OV	cis	rs4814920	0.818	rs4813376	ENSG00000275142.1	RP5-999L4.2	4.85	2.3e-06	0.00147	0.49	0.31	Bipolar disorder (body mass index interaction);	chr20:19870811	chr20:19871891~19872284:+
OV	cis	rs4853012	0.838	rs59570457	ENSG00000257800.1	FNBP1P1	4.85	2.31e-06	0.00147	0.43	0.31	Gestational age at birth (maternal effect);	chr2:74117155	chr2:74120680~74123218:+
OV	cis	rs9298506	1	rs10104997	ENSG00000254142.2	RP11-53M11.3	4.85	2.31e-06	0.00147	0.41	0.31	Intracranial aneurysm;	chr8:54527508	chr8:54554361~54561927:+
OV	cis	rs9298506	1	rs28503706	ENSG00000254142.2	RP11-53M11.3	4.85	2.31e-06	0.00147	0.41	0.31	Intracranial aneurysm;	chr8:54529239	chr8:54554361~54561927:+
OV	cis	rs234043	1	rs234051	ENSG00000223387.5	RP11-408H1.3	-4.85	2.31e-06	0.00148	-0.37	-0.31	Renal cell carcinoma;	chr3:172593922	chr3:172560888~172595607:-
OV	cis	rs2111504	0.945	rs1861780	ENSG00000267213.4	AC007773.2	-4.85	2.32e-06	0.00148	-0.46	-0.31	Bipolar disorder;	chr19:32372138	chr19:32390050~32405560:-
OV	cis	rs1538970	0.504	rs3790585	ENSG00000280836.1	AL355480.1	-4.85	2.32e-06	0.00148	-0.52	-0.31	Platelet count;	chr1:45557684	chr1:45581219~45581321:-
OV	cis	rs116095464	0.558	rs9687621	ENSG00000250848.1	CTD-2083E4.5	-4.85	2.32e-06	0.00148	-0.4	-0.31	Breast cancer;	chr5:229079	chr5:288833~290321:-
OV	cis	rs1555322	0.53	rs2425053	ENSG00000279253.1	RP4-614O4.13	-4.85	2.32e-06	0.00148	-0.37	-0.31	Attention deficit hyperactivity disorder;	chr20:35294017	chr20:35262727~35264187:-
OV	cis	rs4908768	0.859	rs12131717	ENSG00000228423.2	RP4-633I8.4	4.85	2.32e-06	0.00148	0.38	0.31	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8658026	chr1:8805860~8807051:-
OV	cis	rs1150668	0.796	rs213236	ENSG00000220721.1	OR1F12	4.85	2.32e-06	0.00148	0.31	0.31	Pubertal anthropometrics;	chr6:28356620	chr6:28073316~28074233:+
OV	cis	rs57502260	0.704	rs72936570	ENSG00000212093.1	AP000807.1	4.85	2.32e-06	0.00148	0.53	0.31	Total body bone mineral density (age 45-60);	chr11:68539671	chr11:68506083~68506166:-
OV	cis	rs1723838	0.826	rs1880643	ENSG00000255928.1	RP11-456I15.2	4.85	2.32e-06	0.00148	0.56	0.31	Obesity-related traits;	chr11:73701969	chr11:73722349~73722694:+
OV	cis	rs17301013	0.507	rs3920486	ENSG00000227373.4	RP11-160H22.5	4.85	2.32e-06	0.00148	0.4	0.31	Systemic lupus erythematosus;	chr1:174567714	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12079118	ENSG00000227373.4	RP11-160H22.5	4.85	2.32e-06	0.00148	0.4	0.31	Systemic lupus erythematosus;	chr1:174568885	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12079879	ENSG00000227373.4	RP11-160H22.5	4.85	2.32e-06	0.00148	0.4	0.31	Systemic lupus erythematosus;	chr1:174571877	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs2092084	ENSG00000227373.4	RP11-160H22.5	4.85	2.32e-06	0.00148	0.4	0.31	Systemic lupus erythematosus;	chr1:174581547	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs10489264	ENSG00000227373.4	RP11-160H22.5	4.85	2.32e-06	0.00148	0.4	0.31	Systemic lupus erythematosus;	chr1:174584310	chr1:174115300~174160004:-
OV	cis	rs116095464	1	rs28416084	ENSG00000250848.1	CTD-2083E4.5	-4.85	2.33e-06	0.00148	-0.41	-0.31	Breast cancer;	chr5:217525	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs9312978	ENSG00000250848.1	CTD-2083E4.5	-4.85	2.33e-06	0.00148	-0.41	-0.31	Breast cancer;	chr5:221815	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs9312979	ENSG00000250848.1	CTD-2083E4.5	-4.85	2.33e-06	0.00148	-0.41	-0.31	Breast cancer;	chr5:221942	chr5:288833~290321:-
OV	cis	rs9595066	0.627	rs4942287	ENSG00000230731.2	RP11-478K15.6	-4.85	2.33e-06	0.00148	-0.46	-0.31	Schizophrenia;	chr13:44160560	chr13:44234118~44243192:-
OV	cis	rs1823913	0.599	rs67781530	ENSG00000227542.1	AC092614.2	4.85	2.33e-06	0.00148	0.34	0.31	Obesity-related traits;	chr2:191295608	chr2:191229165~191246172:-
OV	cis	rs858239	0.539	rs7791200	ENSG00000230042.1	AK3P3	-4.85	2.33e-06	0.00148	-0.32	-0.31	Cerebrospinal fluid biomarker levels;	chr7:23142502	chr7:23129178~23129841:+
OV	cis	rs116095464	0.558	rs1971229	ENSG00000250848.1	CTD-2083E4.5	-4.85	2.33e-06	0.00148	-0.38	-0.31	Breast cancer;	chr5:268072	chr5:288833~290321:-
OV	cis	rs17301013	0.507	rs332767	ENSG00000227373.4	RP11-160H22.5	4.85	2.33e-06	0.00149	0.39	0.31	Systemic lupus erythematosus;	chr1:174686386	chr1:174115300~174160004:-
OV	cis	rs496547	0.686	rs2508916	ENSG00000255239.1	AP002954.6	4.85	2.33e-06	0.00149	0.35	0.31	Hip minimal joint space width;	chr11:118783942	chr11:118688039~118690600:-
OV	cis	rs5742933	0.69	rs6726636	ENSG00000253559.1	OSGEPL1-AS1	-4.85	2.33e-06	0.00149	-0.41	-0.31	Ferritin levels;	chr2:189653095	chr2:189762704~189765556:+
OV	cis	rs4713118	0.955	rs9468200	ENSG00000219392.1	RP1-265C24.5	-4.85	2.33e-06	0.00149	-0.37	-0.31	Parkinson's disease;	chr6:27715284	chr6:28115628~28116551:+
OV	cis	rs12130219	0.5	rs4845743	ENSG00000237975.5	FLG-AS1	-4.85	2.34e-06	0.00149	-0.4	-0.31	Inflammatory skin disease;	chr1:152211673	chr1:152168125~152445456:+
OV	cis	rs7580658	0.963	rs12991768	ENSG00000236682.1	AC068282.3	-4.85	2.34e-06	0.00149	-0.41	-0.31	Protein C levels;	chr2:127388669	chr2:127389130~127400580:+
OV	cis	rs28571765	1	rs28571765	ENSG00000254142.2	RP11-53M11.3	4.85	2.34e-06	0.00149	0.41	0.31	Multiple myeloma;	chr8:54536721	chr8:54554361~54561927:+
OV	cis	rs293748	0.571	rs10042473	ENSG00000250155.1	CTD-2353F22.1	-4.85	2.34e-06	0.00149	-0.41	-0.31	Obesity-related traits;	chr5:37243651	chr5:36666214~36725195:-
OV	cis	rs6772849	0.896	rs61112519	ENSG00000242551.2	POU5F1P6	-4.85	2.34e-06	0.00149	-0.35	-0.31	Monocyte percentage of white cells;Monocyte count;	chr3:128619333	chr3:128674735~128677005:-
OV	cis	rs7429990	0.965	rs35199727	ENSG00000229759.1	MRPS18AP1	4.84	2.35e-06	0.00149	0.34	0.31	Educational attainment (years of education);	chr3:47905218	chr3:48256350~48256938:-
OV	cis	rs7116641	0.734	rs1518822	ENSG00000246250.2	RP11-613D13.5	-4.84	2.35e-06	0.00149	-0.35	-0.31	Coronary artery disease;	chr11:43850247	chr11:43829709~43880726:-
OV	cis	rs17301013	0.507	rs55748748	ENSG00000227373.4	RP11-160H22.5	4.84	2.35e-06	0.00149	0.41	0.31	Systemic lupus erythematosus;	chr1:174546252	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs41266050	ENSG00000227373.4	RP11-160H22.5	4.84	2.35e-06	0.00149	0.41	0.31	Systemic lupus erythematosus;	chr1:174547861	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs72715240	ENSG00000227373.4	RP11-160H22.5	4.84	2.35e-06	0.00149	0.41	0.31	Systemic lupus erythematosus;	chr1:174560838	chr1:174115300~174160004:-
OV	cis	rs9990333	0.562	rs56224853	ENSG00000231464.1	AC024937.4	4.84	2.35e-06	0.0015	0.35	0.31	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196102005	chr3:195996738~195998233:+
OV	cis	rs9990333	0.544	rs73210008	ENSG00000231464.1	AC024937.4	4.84	2.35e-06	0.0015	0.35	0.31	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196102260	chr3:195996738~195998233:+
OV	cis	rs7927592	0.913	rs6591340	ENSG00000212093.1	AP000807.1	4.84	2.35e-06	0.0015	0.39	0.31	Total body bone mineral density;	chr11:68530168	chr11:68506083~68506166:-
OV	cis	rs7580658	0.509	rs12477653	ENSG00000236682.1	AC068282.3	-4.84	2.35e-06	0.0015	-0.37	-0.31	Protein C levels;	chr2:127194505	chr2:127389130~127400580:+
OV	cis	rs7580658	0.545	rs13001179	ENSG00000236682.1	AC068282.3	-4.84	2.35e-06	0.0015	-0.37	-0.31	Protein C levels;	chr2:127194617	chr2:127389130~127400580:+
OV	cis	rs7580658	0.545	rs13001184	ENSG00000236682.1	AC068282.3	-4.84	2.35e-06	0.0015	-0.37	-0.31	Protein C levels;	chr2:127194630	chr2:127389130~127400580:+
OV	cis	rs6772849	0.662	rs12494372	ENSG00000242551.2	POU5F1P6	-4.84	2.36e-06	0.0015	-0.36	-0.31	Monocyte percentage of white cells;Monocyte count;	chr3:128682850	chr3:128674735~128677005:-
OV	cis	rs2880765	0.566	rs17553790	ENSG00000229212.6	RP11-561C5.4	-4.84	2.36e-06	0.0015	-0.37	-0.31	Coronary artery disease;	chr15:85470434	chr15:85205440~85234795:-
OV	cis	rs875971	1	rs10244498	ENSG00000236529.1	RP13-254B10.1	4.84	2.36e-06	0.0015	0.33	0.31	Aortic root size;	chr7:66651069	chr7:65840212~65840596:+
OV	cis	rs6772849	0.93	rs68090762	ENSG00000242551.2	POU5F1P6	-4.84	2.36e-06	0.0015	-0.35	-0.31	Monocyte percentage of white cells;Monocyte count;	chr3:128625064	chr3:128674735~128677005:-
OV	cis	rs6772849	0.93	rs1962040	ENSG00000242551.2	POU5F1P6	-4.84	2.36e-06	0.0015	-0.36	-0.31	Monocyte percentage of white cells;Monocyte count;	chr3:128605318	chr3:128674735~128677005:-
OV	cis	rs13178541	0.577	rs67621798	ENSG00000250378.1	RP11-119J18.1	-4.84	2.36e-06	0.0015	-0.42	-0.31	IgG glycosylation;	chr5:135789568	chr5:135812667~135826582:+
OV	cis	rs34375054	0.66	rs900411	ENSG00000279233.1	RP11-158L12.4	4.84	2.36e-06	0.0015	0.27	0.31	Post bronchodilator FEV1/FVC ratio;	chr12:125128293	chr12:125138245~125141711:+
OV	cis	rs2980439	0.87	rs2945230	ENSG00000173295.6	FAM86B3P	4.84	2.37e-06	0.00151	0.29	0.31	Neuroticism;	chr8:8252414	chr8:8228595~8244865:+
OV	cis	rs4761702	0.661	rs12423139	ENSG00000257322.4	RP11-511B23.2	-4.84	2.38e-06	0.00151	-0.35	-0.31	Immature fraction of reticulocytes;	chr12:93336482	chr12:93003415~93215679:-
OV	cis	rs796364	0.616	rs6710393	ENSG00000232732.8	AC073043.1	-4.84	2.38e-06	0.00151	-0.46	-0.31	Schizophrenia;	chr2:199832523	chr2:199867396~199911159:-
OV	cis	rs9813712	0.571	rs9866568	ENSG00000228252.7	COL6A4P2	-4.84	2.38e-06	0.00151	-0.35	-0.31	Response to amphetamines;	chr3:130297539	chr3:130212823~130273806:+
OV	cis	rs116095464	0.558	rs10052012	ENSG00000250848.1	CTD-2083E4.5	-4.84	2.38e-06	0.00151	-0.38	-0.31	Breast cancer;	chr5:231793	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs10077076	ENSG00000250848.1	CTD-2083E4.5	-4.84	2.38e-06	0.00151	-0.38	-0.31	Breast cancer;	chr5:231825	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs10080225	ENSG00000250848.1	CTD-2083E4.5	-4.84	2.38e-06	0.00151	-0.38	-0.31	Breast cancer;	chr5:232060	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs10475136	ENSG00000250848.1	CTD-2083E4.5	-4.84	2.38e-06	0.00151	-0.38	-0.31	Breast cancer;	chr5:232681	chr5:288833~290321:-
OV	cis	rs875971	0.545	rs2707851	ENSG00000237310.1	GS1-124K5.4	-4.84	2.39e-06	0.00152	-0.36	-0.31	Aortic root size;	chr7:66624178	chr7:66493706~66495474:+
OV	cis	rs67180937	0.553	rs3008629	ENSG00000272750.1	RP11-378J18.8	4.84	2.4e-06	0.00152	0.42	0.31	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222662588	chr1:222658867~222661512:-
OV	cis	rs7927592	0.913	rs10896338	ENSG00000212093.1	AP000807.1	4.84	2.4e-06	0.00152	0.39	0.31	Total body bone mineral density;	chr11:68531892	chr11:68506083~68506166:-
OV	cis	rs7927592	0.913	rs7115374	ENSG00000212093.1	AP000807.1	4.84	2.4e-06	0.00152	0.39	0.31	Total body bone mineral density;	chr11:68532608	chr11:68506083~68506166:-
OV	cis	rs7927592	0.913	rs67605986	ENSG00000212093.1	AP000807.1	4.84	2.4e-06	0.00152	0.39	0.31	Total body bone mineral density;	chr11:68533487	chr11:68506083~68506166:-
OV	cis	rs7927592	0.913	rs12285993	ENSG00000212093.1	AP000807.1	4.84	2.4e-06	0.00152	0.39	0.31	Total body bone mineral density;	chr11:68535070	chr11:68506083~68506166:-
OV	cis	rs1440372	1	rs893902	ENSG00000259673.4	IQCH-AS1	-4.84	2.4e-06	0.00152	-0.42	-0.31	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);Waist-hip ratio;	chr15:66722404	chr15:67403619~67521844:-
OV	cis	rs12134133	0.752	rs6673080	ENSG00000274245.1	RP11-357P18.2	4.84	2.4e-06	0.00152	0.42	0.31	Blood protein levels;Posterior cortical atrophy and Alzheimer's disease;	chr1:207216859	chr1:207372559~207373252:+
OV	cis	rs11673344	0.864	rs7260386	ENSG00000226686.6	LINC01535	4.84	2.4e-06	0.00152	0.4	0.31	Obesity-related traits;	chr19:37158656	chr19:37251912~37265535:+
OV	cis	rs11673344	0.801	rs112263309	ENSG00000226686.6	LINC01535	4.84	2.4e-06	0.00152	0.4	0.31	Obesity-related traits;	chr19:37160333	chr19:37251912~37265535:+
OV	cis	rs57502260	0.704	rs72936599	ENSG00000212093.1	AP000807.1	4.84	2.4e-06	0.00152	0.54	0.31	Total body bone mineral density (age 45-60);	chr11:68552937	chr11:68506083~68506166:-
OV	cis	rs853679	0.546	rs200490	ENSG00000220721.1	OR1F12	4.84	2.4e-06	0.00152	0.49	0.31	Depression;	chr6:27829157	chr6:28073316~28074233:+
OV	cis	rs8062405	1	rs7498555	ENSG00000278665.1	RP11-666O2.4	4.84	2.41e-06	0.00152	0.34	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28882250	chr16:28599241~28601881:-
OV	cis	rs796364	0.906	rs281789	ENSG00000232732.8	AC073043.1	-4.84	2.41e-06	0.00152	-0.45	-0.31	Schizophrenia;	chr2:199915975	chr2:199867396~199911159:-
OV	cis	rs7428	0.545	rs9248	ENSG00000246575.2	AC093162.5	4.84	2.41e-06	0.00153	0.3	0.31	Ear protrusion;	chr2:85310189	chr2:85315041~85316529:+
OV	cis	rs9859260	0.744	rs557527	ENSG00000231464.1	AC024937.4	-4.84	2.41e-06	0.00153	-0.37	-0.31	Mean corpuscular volume;	chr3:196053838	chr3:195996738~195998233:+
OV	cis	rs301901	0.772	rs6451313	ENSG00000250155.1	CTD-2353F22.1	-4.84	2.42e-06	0.00153	-0.35	-0.31	Height;	chr5:37182208	chr5:36666214~36725195:-
OV	cis	rs1969253	0.712	rs843365	ENSG00000243584.1	RP11-14I2.2	-4.84	2.42e-06	0.00153	-0.34	-0.31	Major depressive disorder;	chr3:184182941	chr3:183613620~183616742:+
OV	cis	rs4713118	0.824	rs2179095	ENSG00000219392.1	RP1-265C24.5	4.84	2.42e-06	0.00153	0.36	0.31	Parkinson's disease;	chr6:27783079	chr6:28115628~28116551:+
OV	cis	rs3733585	0.648	rs13103497	ENSG00000250413.1	RP11-448G15.1	-4.84	2.43e-06	0.00154	-0.35	-0.31	Cleft plate (environmental tobacco smoke interaction);	chr4:9977638	chr4:10006482~10009725:+
OV	cis	rs9291683	0.546	rs13139055	ENSG00000250413.1	RP11-448G15.1	-4.84	2.43e-06	0.00154	-0.36	-0.31	Bone mineral density;	chr4:10037300	chr4:10006482~10009725:+
OV	cis	rs11157436	0.914	rs7142794	ENSG00000211812.1	TRAV26-2	-4.84	2.43e-06	0.00154	-0.37	-0.31	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22238175	chr14:22202583~22203368:+
OV	cis	rs12594515	1	rs11070464	ENSG00000273972.1	CTD-2306A12.1	-4.84	2.43e-06	0.00154	-0.32	-0.31	Weight;Waist circumference;	chr15:45692578	chr15:45702640~45703183:+
OV	cis	rs12594515	0.967	rs11070465	ENSG00000273972.1	CTD-2306A12.1	-4.84	2.43e-06	0.00154	-0.32	-0.31	Weight;Waist circumference;	chr15:45692701	chr15:45702640~45703183:+
OV	cis	rs12594515	0.967	rs11070466	ENSG00000273972.1	CTD-2306A12.1	-4.84	2.43e-06	0.00154	-0.32	-0.31	Weight;Waist circumference;	chr15:45692757	chr15:45702640~45703183:+
OV	cis	rs11673344	0.704	rs1726724	ENSG00000226686.6	LINC01535	4.84	2.43e-06	0.00154	0.38	0.31	Obesity-related traits;	chr19:36925890	chr19:37251912~37265535:+
OV	cis	rs1823913	0.599	rs17414109	ENSG00000227542.1	AC092614.2	4.84	2.43e-06	0.00154	0.35	0.31	Obesity-related traits;	chr2:191310675	chr2:191229165~191246172:-
OV	cis	rs1823913	0.538	rs35311234	ENSG00000227542.1	AC092614.2	4.84	2.43e-06	0.00154	0.35	0.31	Obesity-related traits;	chr2:191316952	chr2:191229165~191246172:-
OV	cis	rs11690935	0.55	rs7584187	ENSG00000228389.1	AC068039.4	4.84	2.44e-06	0.00155	0.34	0.31	Schizophrenia;	chr2:172001198	chr2:171773482~171775844:+
OV	cis	rs62355901	0.545	rs16886260	ENSG00000271828.1	CTD-2310F14.1	-4.84	2.45e-06	0.00155	-0.53	-0.31	Breast cancer;	chr5:56769629	chr5:56927874~56929573:+
OV	cis	rs1075265	0.744	rs10203576	ENSG00000233266.1	HMGB1P31	4.84	2.45e-06	0.00155	0.37	0.31	Chronotype;Morning vs. evening chronotype;	chr2:54060939	chr2:54051334~54051760:+
OV	cis	rs8062405	0.69	rs62034351	ENSG00000259982.1	CDC37P1	4.83	2.46e-06	0.00155	0.39	0.31	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28554168	chr16:28700294~28701540:-
OV	cis	rs1528149	0.504	rs12537888	ENSG00000224683.1	RPL36AP29	-4.83	2.46e-06	0.00155	-0.35	-0.31	Sitting height ratio;	chr7:16127873	chr7:16208945~16209265:+
OV	cis	rs67311347	0.822	rs9826847	ENSG00000223797.4	ENTPD3-AS1	4.83	2.46e-06	0.00155	0.34	0.31	Renal cell carcinoma;	chr3:40303821	chr3:40313802~40453329:-
OV	cis	rs10992471	0.756	rs10992303	ENSG00000281156.1	MIR3651	-4.83	2.46e-06	0.00155	-0.34	-0.31	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92320522	chr9:92292458~92292547:-
OV	cis	rs2243480	0.803	rs13224048	ENSG00000226824.5	RP4-756H11.3	-4.83	2.46e-06	0.00156	-0.48	-0.31	Diabetic kidney disease;	chr7:66528779	chr7:66654538~66669855:+
OV	cis	rs7189233	0.531	rs4281707	ENSG00000279344.1	RP11-44F14.7	4.83	2.46e-06	0.00156	0.29	0.31	Intelligence (multi-trait analysis);	chr16:53468034	chr16:53478957~53481550:-
OV	cis	rs7580658	0.534	rs2089109	ENSG00000236682.1	AC068282.3	-4.83	2.47e-06	0.00156	-0.37	-0.31	Protein C levels;	chr2:127193882	chr2:127389130~127400580:+
OV	cis	rs875971	0.545	rs6460281	ENSG00000226824.5	RP4-756H11.3	-4.83	2.47e-06	0.00156	-0.36	-0.31	Aortic root size;	chr7:66216128	chr7:66654538~66669855:+
OV	cis	rs1113500	0.932	rs1343205	ENSG00000226822.1	RP11-356N1.2	4.83	2.47e-06	0.00156	0.36	0.31	Growth-regulated protein alpha levels;	chr1:108055251	chr1:108071482~108074519:+
OV	cis	rs11096990	0.634	rs7666632	ENSG00000249207.1	RP11-360F5.1	-4.83	2.47e-06	0.00156	-0.33	-0.31	Cognitive function;	chr4:39238568	chr4:39112677~39126818:-
OV	cis	rs17264034	0.861	rs414396	ENSG00000250786.1	SNHG18	4.83	2.48e-06	0.00157	0.48	0.31	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9550596	chr5:9546200~9550609:+
OV	cis	rs172166	0.561	rs149976	ENSG00000220721.1	OR1F12	-4.83	2.49e-06	0.00157	-0.31	-0.31	Cardiac Troponin-T levels;	chr6:28019998	chr6:28073316~28074233:+
OV	cis	rs3733585	0.699	rs4473653	ENSG00000250413.1	RP11-448G15.1	4.83	2.49e-06	0.00157	0.35	0.31	Cleft plate (environmental tobacco smoke interaction);	chr4:9969434	chr4:10006482~10009725:+
OV	cis	rs4591358	1	rs4850619	ENSG00000223466.1	AC064834.2	-4.83	2.49e-06	0.00157	-0.38	-0.31	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195468634	chr2:195533035~195538681:+
OV	cis	rs875971	0.964	rs160635	ENSG00000236529.1	RP13-254B10.1	4.83	2.49e-06	0.00157	0.32	0.31	Aortic root size;	chr7:66063931	chr7:65840212~65840596:+
OV	cis	rs9859260	0.71	rs419068	ENSG00000231464.1	AC024937.4	-4.83	2.5e-06	0.00158	-0.38	-0.31	Mean corpuscular volume;	chr3:196055305	chr3:195996738~195998233:+
OV	cis	rs9859260	0.71	rs366268	ENSG00000231464.1	AC024937.4	-4.83	2.5e-06	0.00158	-0.38	-0.31	Mean corpuscular volume;	chr3:196055306	chr3:195996738~195998233:+
OV	cis	rs9859260	0.744	rs419059	ENSG00000231464.1	AC024937.4	-4.83	2.5e-06	0.00158	-0.38	-0.31	Mean corpuscular volume;	chr3:196055313	chr3:195996738~195998233:+
OV	cis	rs301901	0.796	rs62359002	ENSG00000250155.1	CTD-2353F22.1	4.83	2.5e-06	0.00158	0.36	0.31	Height;	chr5:37499677	chr5:36666214~36725195:-
OV	cis	rs2788869	0.752	rs1225759	ENSG00000247925.2	RP3-510L9.1	-4.83	2.51e-06	0.00158	-0.41	-0.31	Obstetric antiphospholipid syndrome;	chr6:10923294	chr6:11173452~11259099:+
OV	cis	rs2098713	0.535	rs56288111	ENSG00000250155.1	CTD-2353F22.1	4.83	2.51e-06	0.00158	0.36	0.31	Telomere length;	chr5:37619340	chr5:36666214~36725195:-
OV	cis	rs2098713	0.535	rs2176478	ENSG00000250155.1	CTD-2353F22.1	4.83	2.51e-06	0.00158	0.36	0.31	Telomere length;	chr5:37626939	chr5:36666214~36725195:-
OV	cis	rs35141484	1	rs35141484	ENSG00000249348.1	UGDH-AS1	-4.83	2.51e-06	0.00158	-0.58	-0.31	Asthma (childhood onset);	chr4:39086721	chr4:39528019~39594707:+
OV	cis	rs607987	0.871	rs521271	ENSG00000254532.1	RP11-624D11.2	4.83	2.51e-06	0.00158	0.36	0.31	Body mass index;	chr11:30218923	chr11:30044058~30084343:-
OV	cis	rs2098713	0.535	rs56044522	ENSG00000250155.1	CTD-2353F22.1	4.83	2.51e-06	0.00158	0.36	0.31	Telomere length;	chr5:37582698	chr5:36666214~36725195:-
OV	cis	rs16873450	0.548	rs6953133	ENSG00000234800.2	PCMTD1P3	4.83	2.52e-06	0.00159	0.32	0.31	Verbal memory performance (residualized delayed recall level);	chr7:23761171	chr7:23721311~23721782:-
OV	cis	rs57502260	0.573	rs11228294	ENSG00000212093.1	AP000807.1	4.83	2.52e-06	0.00159	0.41	0.31	Total body bone mineral density (age 45-60);	chr11:68621099	chr11:68506083~68506166:-
OV	cis	rs10978777	0.515	rs12555417	ENSG00000276883.1	AL137852.1	4.83	2.53e-06	0.00159	0.39	0.31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107278761	chr9:107292369~107292456:-
OV	cis	rs10978777	0.515	rs10816480	ENSG00000276883.1	AL137852.1	4.83	2.53e-06	0.00159	0.39	0.31	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107279917	chr9:107292369~107292456:-
OV	cis	rs4713118	0.513	rs149942	ENSG00000219392.1	RP1-265C24.5	-4.83	2.53e-06	0.00159	-0.37	-0.31	Parkinson's disease;	chr6:28033832	chr6:28115628~28116551:+
OV	cis	rs4713118	0.513	rs149945	ENSG00000219392.1	RP1-265C24.5	-4.83	2.53e-06	0.00159	-0.37	-0.31	Parkinson's disease;	chr6:28035075	chr6:28115628~28116551:+
OV	cis	rs7587476	0.689	rs78989396	ENSG00000229267.2	AC072062.1	-4.83	2.53e-06	0.00159	-0.41	-0.31	Neuroblastoma;	chr2:214850092	chr2:214810229~214963274:+
OV	cis	rs17301013	0.507	rs7414200	ENSG00000227373.4	RP11-160H22.5	4.83	2.53e-06	0.00159	0.4	0.31	Systemic lupus erythematosus;	chr1:174569820	chr1:174115300~174160004:-
OV	cis	rs17711722	0.528	rs73138179	ENSG00000224316.1	RP11-479O9.2	4.83	2.53e-06	0.0016	0.35	0.31	Calcium levels;	chr7:65829495	chr7:65773620~65802067:+
OV	cis	rs17711722	0.565	rs4275112	ENSG00000224316.1	RP11-479O9.2	-4.83	2.54e-06	0.0016	-0.34	-0.31	Calcium levels;	chr7:65733651	chr7:65773620~65802067:+
OV	cis	rs10924970	0.649	rs12040676	ENSG00000236863.2	RPL23AP23	-4.83	2.54e-06	0.0016	-0.3	-0.31	Asthma;	chr1:235315493	chr1:235295865~235296335:+
OV	cis	rs9828933	0.516	rs704371	ENSG00000280620.1	SCAANT1	-4.83	2.54e-06	0.0016	-0.45	-0.31	Type 2 diabetes;	chr3:63881852	chr3:63911518~63911772:-
OV	cis	rs347685	0.564	rs6806443	ENSG00000249417.1	RP11-438D8.2	4.83	2.54e-06	0.0016	0.48	0.31	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;	chr3:142023343	chr3:141267353~141367137:-
OV	cis	rs2861422	0.516	rs2862122	ENSG00000249417.1	RP11-438D8.2	4.83	2.54e-06	0.0016	0.48	0.31	Glomerular filtration rate (creatinine);	chr3:142023510	chr3:141267353~141367137:-
OV	cis	rs347685	0.529	rs7619506	ENSG00000249417.1	RP11-438D8.2	4.83	2.54e-06	0.0016	0.48	0.31	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;	chr3:142024553	chr3:141267353~141367137:-
OV	cis	rs347685	0.518	rs6803884	ENSG00000249417.1	RP11-438D8.2	4.83	2.54e-06	0.0016	0.48	0.31	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;	chr3:142026100	chr3:141267353~141367137:-
OV	cis	rs347685	0.518	rs4683417	ENSG00000249417.1	RP11-438D8.2	4.83	2.54e-06	0.0016	0.48	0.31	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;	chr3:142026948	chr3:141267353~141367137:-
OV	cis	rs3733585	0.648	rs67820465	ENSG00000250413.1	RP11-448G15.1	4.83	2.55e-06	0.0016	0.34	0.31	Cleft plate (environmental tobacco smoke interaction);	chr4:9974249	chr4:10006482~10009725:+
OV	cis	rs67311347	1	rs4973878	ENSG00000223797.4	ENTPD3-AS1	4.83	2.55e-06	0.0016	0.32	0.31	Renal cell carcinoma;	chr3:40366074	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs4246666	ENSG00000223797.4	ENTPD3-AS1	4.83	2.55e-06	0.0016	0.32	0.31	Renal cell carcinoma;	chr3:40366179	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs2887995	ENSG00000223797.4	ENTPD3-AS1	4.83	2.55e-06	0.0016	0.32	0.31	Renal cell carcinoma;	chr3:40367538	chr3:40313802~40453329:-
OV	cis	rs4713118	0.699	rs200969	ENSG00000219392.1	RP1-265C24.5	-4.83	2.55e-06	0.00161	-0.38	-0.31	Parkinson's disease;	chr6:27891675	chr6:28115628~28116551:+
OV	cis	rs17301013	0.507	rs1883262	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174401104	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs2860959	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174403704	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs10912779	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174404311	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12090860	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174405166	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12064126	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174405312	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs10798310	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174408581	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs11799704	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174413640	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs2901817	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174414479	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs16828481	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174415979	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs6701534	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174418612	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs10798312	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174419089	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs4652422	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174419501	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs4233181	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174419697	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs10489258	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174420447	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs10798313	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174420995	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12065326	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174426892	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs10912786	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174427609	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12074416	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174430109	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12069134	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174434287	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs6677262	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174434539	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs60409344	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174438724	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs72713584	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174439129	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12077381	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174439566	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs74126805	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174440226	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12078960	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174440891	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12079011	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174441055	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12080407	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174441964	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12097931	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174454841	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs969472	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174458562	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs10798314	ENSG00000227373.4	RP11-160H22.5	4.83	2.55e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174458958	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs7535987	ENSG00000227373.4	RP11-160H22.5	4.83	2.56e-06	0.00161	0.4	0.31	Systemic lupus erythematosus;	chr1:174240840	chr1:174115300~174160004:-
OV	cis	rs6088580	0.634	rs6142153	ENSG00000206582.1	Y_RNA	4.83	2.56e-06	0.00161	0.36	0.31	Glomerular filtration rate (creatinine);	chr20:34380941	chr20:34526510~34526606:-
OV	cis	rs293748	0.54	rs13166829	ENSG00000250155.1	CTD-2353F22.1	-4.83	2.56e-06	0.00161	-0.42	-0.31	Obesity-related traits;	chr5:37222124	chr5:36666214~36725195:-
OV	cis	rs853679	0.882	rs3757188	ENSG00000219392.1	RP1-265C24.5	-4.82	2.57e-06	0.00162	-0.5	-0.3	Depression;	chr6:28139579	chr6:28115628~28116551:+
OV	cis	rs783540	1	rs6603033	ENSG00000278603.1	RP13-608F4.5	4.82	2.58e-06	0.00162	0.35	0.3	Schizophrenia;	chr15:82667123	chr15:82472203~82472426:+
OV	cis	rs896854	0.625	rs4735336	ENSG00000253528.2	RP11-347C18.4	-4.82	2.58e-06	0.00162	-0.3	-0.3	Type 2 diabetes;	chr8:94961182	chr8:94974573~94974853:-
OV	cis	rs301901	0.686	rs158795	ENSG00000250155.1	CTD-2353F22.1	-4.82	2.58e-06	0.00162	-0.39	-0.3	Height;	chr5:36882886	chr5:36666214~36725195:-
OV	cis	rs11157436	1	rs11157440	ENSG00000211812.1	TRAV26-2	-4.82	2.58e-06	0.00162	-0.37	-0.3	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22181757	chr14:22202583~22203368:+
OV	cis	rs7927592	0.956	rs948315	ENSG00000212093.1	AP000807.1	4.82	2.58e-06	0.00162	0.38	0.3	Total body bone mineral density;	chr11:68541672	chr11:68506083~68506166:-
OV	cis	rs6088590	0.542	rs6059956	ENSG00000206582.1	Y_RNA	-4.82	2.59e-06	0.00162	-0.36	-0.3	Coronary artery disease;	chr20:34632266	chr20:34526510~34526606:-
OV	cis	rs507080	0.501	rs494459	ENSG00000278376.1	RP11-158I9.8	4.82	2.59e-06	0.00163	0.3	0.3	Serum metabolite levels;	chr11:118703966	chr11:118791254~118793137:+
OV	cis	rs9287719	0.967	rs4669596	ENSG00000234818.1	AC092687.5	4.82	2.59e-06	0.00163	0.33	0.3	Prostate cancer;	chr2:10580446	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs4284804	ENSG00000234818.1	AC092687.5	4.82	2.59e-06	0.00163	0.33	0.3	Prostate cancer;	chr2:10581998	chr2:10589166~10604830:+
OV	cis	rs9287719	0.935	rs10803723	ENSG00000234818.1	AC092687.5	4.82	2.59e-06	0.00163	0.33	0.3	Prostate cancer;	chr2:10582751	chr2:10589166~10604830:+
OV	cis	rs9287719	0.935	rs6751075	ENSG00000234818.1	AC092687.5	4.82	2.59e-06	0.00163	0.33	0.3	Prostate cancer;	chr2:10583420	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs12622765	ENSG00000234818.1	AC092687.5	4.82	2.59e-06	0.00163	0.33	0.3	Prostate cancer;	chr2:10588205	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs759402	ENSG00000234818.1	AC092687.5	4.82	2.59e-06	0.00163	0.33	0.3	Prostate cancer;	chr2:10589428	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs759403	ENSG00000234818.1	AC092687.5	4.82	2.59e-06	0.00163	0.33	0.3	Prostate cancer;	chr2:10589771	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs11674433	ENSG00000234818.1	AC092687.5	4.82	2.59e-06	0.00163	0.33	0.3	Prostate cancer;	chr2:10590713	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs2024431	ENSG00000234818.1	AC092687.5	4.82	2.59e-06	0.00163	0.33	0.3	Prostate cancer;	chr2:10591201	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs2287061	ENSG00000234818.1	AC092687.5	4.82	2.59e-06	0.00163	0.33	0.3	Prostate cancer;	chr2:10603027	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs2287062	ENSG00000234818.1	AC092687.5	4.82	2.59e-06	0.00163	0.33	0.3	Prostate cancer;	chr2:10603065	chr2:10589166~10604830:+
OV	cis	rs9287719	0.935	rs1309	ENSG00000234818.1	AC092687.5	4.82	2.59e-06	0.00163	0.33	0.3	Prostate cancer;	chr2:10603420	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs3815521	ENSG00000234818.1	AC092687.5	4.82	2.59e-06	0.00163	0.33	0.3	Prostate cancer;	chr2:10603528	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs10929686	ENSG00000234818.1	AC092687.5	4.82	2.59e-06	0.00163	0.33	0.3	Prostate cancer;	chr2:10603579	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs4470306	ENSG00000234818.1	AC092687.5	4.82	2.59e-06	0.00163	0.33	0.3	Prostate cancer;	chr2:10603872	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs4613248	ENSG00000234818.1	AC092687.5	4.82	2.59e-06	0.00163	0.33	0.3	Prostate cancer;	chr2:10603925	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs10191883	ENSG00000234818.1	AC092687.5	4.82	2.59e-06	0.00163	0.33	0.3	Prostate cancer;	chr2:10604010	chr2:10589166~10604830:+
OV	cis	rs9287719	0.934	rs4629131	ENSG00000234818.1	AC092687.5	4.82	2.59e-06	0.00163	0.33	0.3	Prostate cancer;	chr2:10604033	chr2:10589166~10604830:+
OV	cis	rs9287719	0.901	rs4555317	ENSG00000234818.1	AC092687.5	4.82	2.59e-06	0.00163	0.33	0.3	Prostate cancer;	chr2:10604121	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs4555318	ENSG00000234818.1	AC092687.5	4.82	2.59e-06	0.00163	0.33	0.3	Prostate cancer;	chr2:10604169	chr2:10589166~10604830:+
OV	cis	rs9287719	0.934	rs4622695	ENSG00000234818.1	AC092687.5	4.82	2.59e-06	0.00163	0.33	0.3	Prostate cancer;	chr2:10604201	chr2:10589166~10604830:+
OV	cis	rs9287719	0.934	rs6432111	ENSG00000234818.1	AC092687.5	4.82	2.59e-06	0.00163	0.33	0.3	Prostate cancer;	chr2:10604494	chr2:10589166~10604830:+
OV	cis	rs875971	0.545	rs2420456	ENSG00000236529.1	RP13-254B10.1	4.82	2.6e-06	0.00163	0.36	0.3	Aortic root size;	chr7:66280619	chr7:65840212~65840596:+
OV	cis	rs4747241	0.556	rs4495815	ENSG00000226163.1	RP11-167P22.3	4.82	2.6e-06	0.00163	0.34	0.3	Heschl's gyrus morphology;	chr10:72309220	chr10:72501746~72502956:+
OV	cis	rs733592	0.507	rs7138917	ENSG00000258273.1	RP11-370I10.4	4.82	2.6e-06	0.00163	0.37	0.3	Plateletcrit;	chr12:48061472	chr12:48333755~48333901:-
OV	cis	rs13315649	0.614	rs7609765	ENSG00000242551.2	POU5F1P6	-4.82	2.61e-06	0.00163	-0.39	-0.3	Sum eosinophil basophil counts;	chr3:128688295	chr3:128674735~128677005:-
OV	cis	rs13315649	0.724	rs28787069	ENSG00000242551.2	POU5F1P6	-4.82	2.61e-06	0.00163	-0.39	-0.3	Sum eosinophil basophil counts;	chr3:128695613	chr3:128674735~128677005:-
OV	cis	rs17301013	0.531	rs6678286	ENSG00000227373.4	RP11-160H22.5	4.82	2.62e-06	0.00164	0.4	0.3	Systemic lupus erythematosus;	chr1:174200481	chr1:174115300~174160004:-
OV	cis	rs11673344	0.765	rs826296	ENSG00000226686.6	LINC01535	4.82	2.62e-06	0.00164	0.38	0.3	Obesity-related traits;	chr19:36947384	chr19:37251912~37265535:+
OV	cis	rs9309473	1	rs7584575	ENSG00000163016.8	ALMS1P	4.82	2.62e-06	0.00164	0.37	0.3	Metabolite levels;	chr2:73439274	chr2:73644919~73685576:+
OV	cis	rs9287719	0.967	rs6432112	ENSG00000234818.1	AC092687.5	-4.82	2.62e-06	0.00164	-0.33	-0.3	Prostate cancer;	chr2:10604748	chr2:10589166~10604830:+
OV	cis	rs957448	1	rs56716157	ENSG00000253704.1	RP11-267M23.4	4.82	2.62e-06	0.00164	0.43	0.3	Nonsyndromic cleft lip with cleft palate;	chr8:94530644	chr8:94553722~94569745:+
OV	cis	rs67311347	0.866	rs56331709	ENSG00000223797.4	ENTPD3-AS1	4.82	2.62e-06	0.00164	0.34	0.3	Renal cell carcinoma;	chr3:40315067	chr3:40313802~40453329:-
OV	cis	rs301901	0.828	rs10941337	ENSG00000250155.1	CTD-2353F22.1	4.82	2.63e-06	0.00165	0.36	0.3	Height;	chr5:37474023	chr5:36666214~36725195:-
OV	cis	rs10924970	0.649	rs4659676	ENSG00000236863.2	RPL23AP23	4.82	2.63e-06	0.00165	0.31	0.3	Asthma;	chr1:235233262	chr1:235295865~235296335:+
OV	cis	rs875971	0.83	rs427575	ENSG00000236529.1	RP13-254B10.1	4.82	2.63e-06	0.00165	0.33	0.3	Aortic root size;	chr7:66054232	chr7:65840212~65840596:+
OV	cis	rs875971	0.8	rs427557	ENSG00000236529.1	RP13-254B10.1	4.82	2.63e-06	0.00165	0.33	0.3	Aortic root size;	chr7:66054263	chr7:65840212~65840596:+
OV	cis	rs875971	0.83	rs587360	ENSG00000236529.1	RP13-254B10.1	4.82	2.63e-06	0.00165	0.33	0.3	Aortic root size;	chr7:66057711	chr7:65840212~65840596:+
OV	cis	rs8062405	0.755	rs62034325	ENSG00000278665.1	RP11-666O2.4	4.82	2.64e-06	0.00165	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28527319	chr16:28599241~28601881:-
OV	cis	rs3758911	1	rs10789611	ENSG00000261098.1	RP11-819C21.1	-4.82	2.64e-06	0.00165	-0.29	-0.3	Coronary artery disease;	chr11:107316810	chr11:107312132~107316271:-
OV	cis	rs3758911	1	rs10789612	ENSG00000261098.1	RP11-819C21.1	-4.82	2.64e-06	0.00165	-0.29	-0.3	Coronary artery disease;	chr11:107316931	chr11:107312132~107316271:-
OV	cis	rs3758911	1	rs10890707	ENSG00000261098.1	RP11-819C21.1	-4.82	2.64e-06	0.00165	-0.29	-0.3	Coronary artery disease;	chr11:107317153	chr11:107312132~107316271:-
OV	cis	rs3758911	1	rs10890708	ENSG00000261098.1	RP11-819C21.1	-4.82	2.64e-06	0.00165	-0.29	-0.3	Coronary artery disease;	chr11:107317315	chr11:107312132~107316271:-
OV	cis	rs3758911	0.964	rs10890709	ENSG00000261098.1	RP11-819C21.1	-4.82	2.64e-06	0.00165	-0.29	-0.3	Coronary artery disease;	chr11:107317378	chr11:107312132~107316271:-
OV	cis	rs3758911	0.964	rs10890711	ENSG00000261098.1	RP11-819C21.1	-4.82	2.64e-06	0.00165	-0.29	-0.3	Coronary artery disease;	chr11:107317424	chr11:107312132~107316271:-
OV	cis	rs3758911	0.964	rs12290112	ENSG00000261098.1	RP11-819C21.1	-4.82	2.64e-06	0.00165	-0.29	-0.3	Coronary artery disease;	chr11:107317487	chr11:107312132~107316271:-
OV	cis	rs3758911	0.964	rs12270655	ENSG00000261098.1	RP11-819C21.1	-4.82	2.64e-06	0.00165	-0.29	-0.3	Coronary artery disease;	chr11:107317507	chr11:107312132~107316271:-
OV	cis	rs3758911	0.964	rs10890712	ENSG00000261098.1	RP11-819C21.1	-4.82	2.64e-06	0.00165	-0.29	-0.3	Coronary artery disease;	chr11:107317583	chr11:107312132~107316271:-
OV	cis	rs611744	0.517	rs62537573	ENSG00000253754.1	RP11-35G22.1	-4.82	2.64e-06	0.00165	-0.33	-0.3	Dupuytren's disease;	chr8:108257052	chr8:108226200~108227544:+
OV	cis	rs611744	0.538	rs2298605	ENSG00000253754.1	RP11-35G22.1	-4.82	2.64e-06	0.00165	-0.33	-0.3	Dupuytren's disease;	chr8:108259777	chr8:108226200~108227544:+
OV	cis	rs611744	0.538	rs13257548	ENSG00000253754.1	RP11-35G22.1	-4.82	2.64e-06	0.00165	-0.33	-0.3	Dupuytren's disease;	chr8:108260956	chr8:108226200~108227544:+
OV	cis	rs7927592	0.731	rs10896350	ENSG00000212093.1	AP000807.1	4.82	2.64e-06	0.00165	0.35	0.3	Total body bone mineral density;	chr11:68618905	chr11:68506083~68506166:-
OV	cis	rs9287719	0.901	rs10210859	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10593803	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs715247	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10596165	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs715246	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10596229	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs2010073	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10596352	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs2010080	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10596426	chr2:10589166~10604830:+
OV	cis	rs9287719	0.901	rs6432109	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10596695	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs7592691	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10597300	chr2:10589166~10604830:+
OV	cis	rs9287719	0.934	rs6432110	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10597892	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs7605461	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10598008	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs7593496	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10598050	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs7608498	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10598302	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs7582775	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10598323	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs6750891	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10598437	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs6733416	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10598558	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs6751398	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10598846	chr2:10589166~10604830:+
OV	cis	rs9287719	0.901	rs13034017	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10599466	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs13034061	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10599525	chr2:10589166~10604830:+
OV	cis	rs9287719	0.935	rs7600495	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10599674	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs7600587	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10599725	chr2:10589166~10604830:+
OV	cis	rs9287719	0.839	rs7600695	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10599819	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs7587114	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10599837	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs7600728	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10599873	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs7600820	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10599918	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs7587231	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10599967	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs4668691	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10600368	chr2:10589166~10604830:+
OV	cis	rs9287719	0.934	rs10181806	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10601015	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs11687023	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10601286	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs10454738	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10601923	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs6706542	ENSG00000234818.1	AC092687.5	4.82	2.64e-06	0.00165	0.33	0.3	Prostate cancer;	chr2:10602365	chr2:10589166~10604830:+
OV	cis	rs17023223	0.537	rs10923767	ENSG00000231365.4	RP11-418J17.1	-4.82	2.64e-06	0.00165	-0.4	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119189724	chr1:119140396~119275973:+
OV	cis	rs8062405	0.754	rs28410083	ENSG00000278665.1	RP11-666O2.4	-4.82	2.64e-06	0.00165	-0.32	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620039	chr16:28599241~28601881:-
OV	cis	rs8062405	0.789	rs1968751	ENSG00000278665.1	RP11-666O2.4	-4.82	2.64e-06	0.00165	-0.32	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620438	chr16:28599241~28601881:-
OV	cis	rs875971	0.545	rs10950029	ENSG00000236529.1	RP13-254B10.1	4.82	2.64e-06	0.00165	0.35	0.3	Aortic root size;	chr7:66169334	chr7:65840212~65840596:+
OV	cis	rs17264034	0.861	rs1508798	ENSG00000250786.1	SNHG18	-4.82	2.64e-06	0.00165	-0.46	-0.3	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9556582	chr5:9546200~9550609:+
OV	cis	rs9859260	0.71	rs41298097	ENSG00000231464.1	AC024937.4	-4.82	2.64e-06	0.00165	-0.37	-0.3	Mean corpuscular volume;	chr3:196052284	chr3:195996738~195998233:+
OV	cis	rs9859260	0.71	rs34906439	ENSG00000231464.1	AC024937.4	-4.82	2.64e-06	0.00165	-0.37	-0.3	Mean corpuscular volume;	chr3:196052835	chr3:195996738~195998233:+
OV	cis	rs6991838	0.765	rs10957358	ENSG00000200714.1	Y_RNA	4.82	2.64e-06	0.00165	0.39	0.3	Intelligence (multi-trait analysis);	chr8:65590067	chr8:65592731~65592820:+
OV	cis	rs10992471	0.729	rs7042335	ENSG00000281156.1	MIR3651	-4.82	2.65e-06	0.00165	-0.34	-0.3	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92360265	chr9:92292458~92292547:-
OV	cis	rs7520050	0.807	rs4353138	ENSG00000280836.1	AL355480.1	4.82	2.65e-06	0.00165	0.37	0.3	Reticulocyte count;Red blood cell count;	chr1:45754131	chr1:45581219~45581321:-
OV	cis	rs7176527	1	rs3762169	ENSG00000225151.9	GOLGA2P7	4.82	2.65e-06	0.00166	0.42	0.3	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:84199311~84230136:-
OV	cis	rs1113500	1	rs1777483	ENSG00000226822.1	RP11-356N1.2	-4.82	2.65e-06	0.00166	-0.35	-0.3	Growth-regulated protein alpha levels;	chr1:108066786	chr1:108071482~108074519:+
OV	cis	rs2919917	1	rs1545228	ENSG00000254352.1	RP11-578O24.2	-4.82	2.65e-06	0.00166	-0.38	-0.3	Lymphocyte counts;	chr8:78732202	chr8:78723796~78724136:-
OV	cis	rs2153535	0.585	rs9406183	ENSG00000230939.1	RP11-314C16.1	4.82	2.65e-06	0.00166	0.33	0.3	Motion sickness;	chr6:8639538	chr6:8784178~8785445:+
OV	cis	rs10924970	0.663	rs12749180	ENSG00000236863.2	RPL23AP23	4.82	2.65e-06	0.00166	0.31	0.3	Asthma;	chr1:235200790	chr1:235295865~235296335:+
OV	cis	rs10924970	0.687	rs4553178	ENSG00000236863.2	RPL23AP23	4.82	2.65e-06	0.00166	0.31	0.3	Asthma;	chr1:235201228	chr1:235295865~235296335:+
OV	cis	rs73201462	1	rs2687723	ENSG00000277250.1	Metazoa_SRP	4.82	2.65e-06	0.00166	0.46	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128146716	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs73192978	ENSG00000277250.1	Metazoa_SRP	4.82	2.65e-06	0.00166	0.46	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128149432	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs73192979	ENSG00000277250.1	Metazoa_SRP	4.82	2.65e-06	0.00166	0.46	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128149478	chr3:128673681~128674021:-
OV	cis	rs73201462	0.901	rs34749881	ENSG00000277250.1	Metazoa_SRP	4.82	2.65e-06	0.00166	0.46	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128151426	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs11711710	ENSG00000277250.1	Metazoa_SRP	4.82	2.65e-06	0.00166	0.46	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128153663	chr3:128673681~128674021:-
OV	cis	rs11719546	1	rs11719546	ENSG00000277250.1	Metazoa_SRP	4.82	2.65e-06	0.00166	0.46	0.3	Post bronchodilator FEV1;	chr3:128153759	chr3:128673681~128674021:-
OV	cis	rs9287719	0.967	rs4519489	ENSG00000234818.1	AC092687.5	4.82	2.66e-06	0.00166	0.33	0.3	Prostate cancer;	chr2:10598961	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs4453662	ENSG00000234818.1	AC092687.5	4.82	2.66e-06	0.00166	0.33	0.3	Prostate cancer;	chr2:10599002	chr2:10589166~10604830:+
OV	cis	rs12073359	0.955	rs4926391	ENSG00000223945.2	RP11-458I7.1	4.82	2.66e-06	0.00166	0.45	0.3	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150168687	chr1:150053864~150055034:+
OV	cis	rs853679	0.546	rs200996	ENSG00000220721.1	OR1F12	4.82	2.67e-06	0.00167	0.49	0.3	Depression;	chr6:27844050	chr6:28073316~28074233:+
OV	cis	rs1075265	0.73	rs7597188	ENSG00000233266.1	HMGB1P31	4.82	2.67e-06	0.00167	0.38	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54014732	chr2:54051334~54051760:+
OV	cis	rs875971	0.895	rs3857684	ENSG00000236529.1	RP13-254B10.1	4.82	2.68e-06	0.00167	0.32	0.3	Aortic root size;	chr7:66473171	chr7:65840212~65840596:+
OV	cis	rs875971	0.964	rs6978429	ENSG00000236529.1	RP13-254B10.1	4.82	2.68e-06	0.00167	0.32	0.3	Aortic root size;	chr7:66494889	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs4718357	ENSG00000236529.1	RP13-254B10.1	4.82	2.68e-06	0.00167	0.32	0.3	Aortic root size;	chr7:66495891	chr7:65840212~65840596:+
OV	cis	rs875971	0.929	rs12535036	ENSG00000236529.1	RP13-254B10.1	4.82	2.68e-06	0.00167	0.32	0.3	Aortic root size;	chr7:66499076	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs12533997	ENSG00000236529.1	RP13-254B10.1	4.82	2.68e-06	0.00167	0.32	0.3	Aortic root size;	chr7:66500390	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs12698523	ENSG00000236529.1	RP13-254B10.1	4.82	2.68e-06	0.00167	0.32	0.3	Aortic root size;	chr7:66503126	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs6970030	ENSG00000236529.1	RP13-254B10.1	4.82	2.68e-06	0.00167	0.32	0.3	Aortic root size;	chr7:66503692	chr7:65840212~65840596:+
OV	cis	rs875971	0.928	rs6970357	ENSG00000236529.1	RP13-254B10.1	4.82	2.68e-06	0.00167	0.32	0.3	Aortic root size;	chr7:66503891	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs3735148	ENSG00000236529.1	RP13-254B10.1	4.82	2.68e-06	0.00167	0.32	0.3	Aortic root size;	chr7:66506022	chr7:65840212~65840596:+
OV	cis	rs2999052	0.661	rs3021461	ENSG00000242551.2	POU5F1P6	4.82	2.68e-06	0.00167	0.43	0.3	Hypospadias;	chr3:128376809	chr3:128674735~128677005:-
OV	cis	rs2999052	0.661	rs2977565	ENSG00000242551.2	POU5F1P6	4.82	2.68e-06	0.00167	0.43	0.3	Hypospadias;	chr3:128376924	chr3:128674735~128677005:-
OV	cis	rs17301013	0.606	rs4650939	ENSG00000227373.4	RP11-160H22.5	4.82	2.69e-06	0.00168	0.4	0.3	Systemic lupus erythematosus;	chr1:174096823	chr1:174115300~174160004:-
OV	cis	rs45509595	0.822	rs200484	ENSG00000220721.1	OR1F12	4.81	2.69e-06	0.00168	0.51	0.3	Breast cancer;	chr6:27807896	chr6:28073316~28074233:+
OV	cis	rs45509595	0.841	rs9368531	ENSG00000220721.1	OR1F12	4.81	2.69e-06	0.00168	0.51	0.3	Breast cancer;	chr6:27814094	chr6:28073316~28074233:+
OV	cis	rs45509595	0.749	rs401763	ENSG00000220721.1	OR1F12	4.81	2.69e-06	0.00168	0.51	0.3	Breast cancer;	chr6:27814750	chr6:28073316~28074233:+
OV	cis	rs45509595	0.659	rs390764	ENSG00000220721.1	OR1F12	4.81	2.69e-06	0.00168	0.51	0.3	Breast cancer;	chr6:27814757	chr6:28073316~28074233:+
OV	cis	rs45509595	0.841	rs401754	ENSG00000220721.1	OR1F12	4.81	2.69e-06	0.00168	0.51	0.3	Breast cancer;	chr6:27814760	chr6:28073316~28074233:+
OV	cis	rs45509595	0.841	rs2747054	ENSG00000220721.1	OR1F12	4.81	2.69e-06	0.00168	0.51	0.3	Breast cancer;	chr6:27815581	chr6:28073316~28074233:+
OV	cis	rs45509595	0.841	rs200501	ENSG00000220721.1	OR1F12	4.81	2.69e-06	0.00168	0.51	0.3	Breast cancer;	chr6:27821164	chr6:28073316~28074233:+
OV	cis	rs8040855	0.825	rs3964197	ENSG00000259295.5	CSPG4P12	4.81	2.69e-06	0.00168	0.44	0.3	Bulimia nervosa;	chr15:85178681	chr15:85191438~85213905:+
OV	cis	rs858239	0.539	rs2103281	ENSG00000230042.1	AK3P3	-4.81	2.7e-06	0.00168	-0.32	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23154612	chr7:23129178~23129841:+
OV	cis	rs9298506	1	rs4455806	ENSG00000254142.2	RP11-53M11.3	4.81	2.7e-06	0.00168	0.41	0.3	Intracranial aneurysm;	chr8:54545313	chr8:54554361~54561927:+
OV	cis	rs9298506	1	rs10097401	ENSG00000254142.2	RP11-53M11.3	4.81	2.7e-06	0.00168	0.41	0.3	Intracranial aneurysm;	chr8:54548255	chr8:54554361~54561927:+
OV	cis	rs9322193	0.607	rs10457852	ENSG00000216906.2	RP11-350J20.9	4.81	2.7e-06	0.00168	0.41	0.3	Lung cancer;	chr6:149880584	chr6:149904243~149906418:+
OV	cis	rs4713118	0.869	rs4713121	ENSG00000280107.1	AL022393.9	-4.81	2.7e-06	0.00168	-0.36	-0.3	Parkinson's disease;	chr6:27754285	chr6:28170845~28172521:+
OV	cis	rs875971	0.545	rs1796222	ENSG00000226824.5	RP4-756H11.3	4.81	2.7e-06	0.00168	0.37	0.3	Aortic root size;	chr7:66592167	chr7:66654538~66669855:+
OV	cis	rs7968440	0.808	rs1613835	ENSG00000257298.1	RP3-405J10.3	4.81	2.7e-06	0.00168	0.31	0.3	Fibrinogen;	chr12:50811283	chr12:50185580~50191363:-
OV	cis	rs7968440	0.808	rs1659387	ENSG00000257298.1	RP3-405J10.3	4.81	2.7e-06	0.00168	0.31	0.3	Fibrinogen;	chr12:50811284	chr12:50185580~50191363:-
OV	cis	rs2280018	0.526	rs1510148	ENSG00000260735.1	RP11-72I8.1	-4.81	2.7e-06	0.00168	-0.37	-0.3	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);Plasma omega-6 polyunsaturated fatty acid levels (linoleic acid);	chr16:15073522	chr16:15094411~15109197:+
OV	cis	rs73201462	1	rs73201462	ENSG00000277250.1	Metazoa_SRP	4.81	2.71e-06	0.00169	0.5	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128340450	chr3:128673681~128674021:-
OV	cis	rs301901	0.772	rs10061157	ENSG00000250155.1	CTD-2353F22.1	4.81	2.71e-06	0.00169	0.34	0.3	Height;	chr5:37161516	chr5:36666214~36725195:-
OV	cis	rs1134634	0.52	rs4280724	ENSG00000273133.1	RP11-799M12.2	-4.81	2.72e-06	0.00169	-0.41	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15574128	chr4:15563698~15564253:-
OV	cis	rs1134634	0.52	rs7665390	ENSG00000273133.1	RP11-799M12.2	-4.81	2.72e-06	0.00169	-0.41	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15576115	chr4:15563698~15564253:-
OV	cis	rs7017914	0.905	rs2639956	ENSG00000223220.1	Y_RNA	4.81	2.72e-06	0.00169	0.32	0.3	Bone mineral density;	chr8:71011856	chr8:70780914~70781008:-
OV	cis	rs9859260	0.614	rs493661	ENSG00000231464.1	AC024937.4	-4.81	2.72e-06	0.00169	-0.38	-0.3	Mean corpuscular volume;	chr3:196059618	chr3:195996738~195998233:+
OV	cis	rs1528149	0.576	rs1881242	ENSG00000224683.1	RPL36AP29	-4.81	2.72e-06	0.00169	-0.36	-0.3	Sitting height ratio;	chr7:16073822	chr7:16208945~16209265:+
OV	cis	rs896854	0.654	rs10429443	ENSG00000253528.2	RP11-347C18.4	4.81	2.73e-06	0.0017	0.29	0.3	Type 2 diabetes;	chr8:94958936	chr8:94974573~94974853:-
OV	cis	rs896854	0.654	rs896846	ENSG00000253528.2	RP11-347C18.4	4.81	2.73e-06	0.0017	0.29	0.3	Type 2 diabetes;	chr8:94960225	chr8:94974573~94974853:-
OV	cis	rs896854	0.654	rs896847	ENSG00000253528.2	RP11-347C18.4	4.81	2.73e-06	0.0017	0.29	0.3	Type 2 diabetes;	chr8:94960323	chr8:94974573~94974853:-
OV	cis	rs875971	0.83	rs4718358	ENSG00000236529.1	RP13-254B10.1	4.81	2.73e-06	0.0017	0.32	0.3	Aortic root size;	chr7:66508681	chr7:65840212~65840596:+
OV	cis	rs9813712	0.855	rs6806152	ENSG00000228252.7	COL6A4P2	-4.81	2.73e-06	0.0017	-0.36	-0.3	Response to amphetamines;	chr3:130245358	chr3:130212823~130273806:+
OV	cis	rs8059260	0.736	rs16957883	ENSG00000274038.1	RP11-66H6.4	-4.81	2.73e-06	0.0017	-0.6	-0.3	Alcohol consumption over the past year;	chr16:10994788	chr16:11056556~11057034:+
OV	cis	rs3758911	1	rs12286342	ENSG00000261098.1	RP11-819C21.1	-4.81	2.73e-06	0.0017	-0.29	-0.3	Coronary artery disease;	chr11:107315568	chr11:107312132~107316271:-
OV	cis	rs3758911	1	rs12273125	ENSG00000261098.1	RP11-819C21.1	-4.81	2.73e-06	0.0017	-0.29	-0.3	Coronary artery disease;	chr11:107315602	chr11:107312132~107316271:-
OV	cis	rs62458065	0.85	rs28677012	ENSG00000226468.2	AC018641.7	4.81	2.73e-06	0.0017	0.47	0.3	Metabolite levels (HVA/MHPG ratio);	chr7:32430199	chr7:32456963~32457758:-
OV	cis	rs875971	0.651	rs313829	ENSG00000236529.1	RP13-254B10.1	-4.81	2.73e-06	0.0017	-0.36	-0.3	Aortic root size;	chr7:66087510	chr7:65840212~65840596:+
OV	cis	rs7580658	0.864	rs1566823	ENSG00000236682.1	AC068282.3	-4.81	2.74e-06	0.0017	-0.39	-0.3	Protein C levels;	chr2:127260616	chr2:127389130~127400580:+
OV	cis	rs638893	1	rs638893	ENSG00000255239.1	AP002954.6	4.81	2.74e-06	0.0017	0.45	0.3	Vitiligo;	chr11:118827828	chr11:118688039~118690600:-
OV	cis	rs7429990	0.965	rs1550914	ENSG00000229759.1	MRPS18AP1	4.81	2.74e-06	0.0017	0.32	0.3	Educational attainment (years of education);	chr3:47953678	chr3:48256350~48256938:-
OV	cis	rs12681420	0.668	rs1493202	ENSG00000223220.1	Y_RNA	4.81	2.74e-06	0.0017	0.31	0.3	Erythrocyte cadmium concentration in never smokers;	chr8:70993352	chr8:70780914~70781008:-
OV	cis	rs10510102	0.935	rs11200257	ENSG00000226864.1	ATE1-AS1	4.81	2.75e-06	0.00171	0.5	0.3	Breast cancer;	chr10:121917232	chr10:121928312~121951965:+
OV	cis	rs11992162	0.551	rs35010200	ENSG00000206014.6	OR7E161P	4.81	2.76e-06	0.00171	0.36	0.3	Monocyte count;	chr8:11928146	chr8:11928597~11929563:-
OV	cis	rs804280	0.662	rs11250164	ENSG00000270154.1	RP11-419I17.1	-4.81	2.76e-06	0.00171	-0.32	-0.3	Myopia (pathological);	chr8:11753177	chr8:12476462~12477122:+
OV	cis	rs1979679	0.842	rs36097532	ENSG00000278733.1	RP11-425D17.1	4.81	2.76e-06	0.00172	0.36	0.3	Ossification of the posterior longitudinal ligament of the spine;	chr12:28228557	chr12:28185625~28186190:-
OV	cis	rs67311347	0.506	rs55962832	ENSG00000223797.4	ENTPD3-AS1	4.81	2.76e-06	0.00172	0.33	0.3	Renal cell carcinoma;	chr3:40202960	chr3:40313802~40453329:-
OV	cis	rs9309473	0.95	rs10169213	ENSG00000163016.8	ALMS1P	4.81	2.76e-06	0.00172	0.35	0.3	Metabolite levels;	chr2:73560107	chr2:73644919~73685576:+
OV	cis	rs7189233	0.531	rs7203132	ENSG00000279344.1	RP11-44F14.7	-4.81	2.77e-06	0.00172	-0.28	-0.3	Intelligence (multi-trait analysis);	chr16:53395863	chr16:53478957~53481550:-
OV	cis	rs67311347	0.577	rs1317217	ENSG00000223797.4	ENTPD3-AS1	4.81	2.77e-06	0.00172	0.32	0.3	Renal cell carcinoma;	chr3:40230206	chr3:40313802~40453329:-
OV	cis	rs7302981	0.845	rs56709084	ENSG00000272368.2	RP4-605O3.4	4.81	2.77e-06	0.00172	0.34	0.3	Systolic blood pressure;	chr12:50170107	chr12:50112197~50165618:+
OV	cis	rs4728142	0.604	rs10229001	ENSG00000275106.1	RP11-309L24.10	-4.81	2.77e-06	0.00172	-0.4	-0.3	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128959343	chr7:128952527~128953316:-
OV	cis	rs11673344	0.864	rs2562587	ENSG00000226686.6	LINC01535	4.81	2.77e-06	0.00172	0.39	0.3	Obesity-related traits;	chr19:37019357	chr19:37251912~37265535:+
OV	cis	rs301901	1	rs300049	ENSG00000250155.1	CTD-2353F22.1	-4.81	2.77e-06	0.00172	-0.36	-0.3	Height;	chr5:37083971	chr5:36666214~36725195:-
OV	cis	rs6772849	0.93	rs7639400	ENSG00000242551.2	POU5F1P6	-4.81	2.77e-06	0.00172	-0.36	-0.3	Monocyte percentage of white cells;Monocyte count;	chr3:128604513	chr3:128674735~128677005:-
OV	cis	rs12594515	0.967	rs11856523	ENSG00000273972.1	CTD-2306A12.1	-4.81	2.78e-06	0.00172	-0.32	-0.3	Weight;Waist circumference;	chr15:45697297	chr15:45702640~45703183:+
OV	cis	rs8100891	0.537	rs1030094	ENSG00000267213.4	AC007773.2	-4.81	2.78e-06	0.00172	-0.45	-0.3	Neuroticism;	chr19:32419525	chr19:32390050~32405560:-
OV	cis	rs875971	0.564	rs313804	ENSG00000236529.1	RP13-254B10.1	4.81	2.78e-06	0.00173	0.33	0.3	Aortic root size;	chr7:66049635	chr7:65840212~65840596:+
OV	cis	rs875971	0.662	rs448725	ENSG00000236529.1	RP13-254B10.1	4.81	2.78e-06	0.00173	0.33	0.3	Aortic root size;	chr7:66049641	chr7:65840212~65840596:+
OV	cis	rs875971	0.658	rs432667	ENSG00000236529.1	RP13-254B10.1	4.81	2.78e-06	0.00173	0.33	0.3	Aortic root size;	chr7:66049646	chr7:65840212~65840596:+
OV	cis	rs17301013	0.606	rs12080535	ENSG00000227373.4	RP11-160H22.5	4.81	2.78e-06	0.00173	0.39	0.3	Systemic lupus erythematosus;	chr1:174569832	chr1:174115300~174160004:-
OV	cis	rs17301013	0.54	rs61624206	ENSG00000227373.4	RP11-160H22.5	4.81	2.78e-06	0.00173	0.39	0.3	Systemic lupus erythematosus;	chr1:174578374	chr1:174115300~174160004:-
OV	cis	rs1075265	0.716	rs7573991	ENSG00000233266.1	HMGB1P31	4.81	2.78e-06	0.00173	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53726830	chr2:54051334~54051760:+
OV	cis	rs875971	0.545	rs13311962	ENSG00000237310.1	GS1-124K5.4	-4.81	2.79e-06	0.00173	-0.36	-0.3	Aortic root size;	chr7:66603142	chr7:66493706~66495474:+
OV	cis	rs1569175	0.655	rs166847	ENSG00000232732.8	AC073043.1	4.81	2.79e-06	0.00173	0.67	0.3	Response to treatment for acute lymphoblastic leukemia;	chr2:199975889	chr2:199867396~199911159:-
OV	cis	rs992157	1	rs13003334	ENSG00000261338.2	RP11-378A13.1	4.81	2.79e-06	0.00173	0.35	0.3	Colorectal cancer;	chr2:218260198	chr2:218255319~218257366:+
OV	cis	rs3758911	0.964	rs10789614	ENSG00000261098.1	RP11-819C21.1	-4.81	2.8e-06	0.00173	-0.29	-0.3	Coronary artery disease;	chr11:107318047	chr11:107312132~107316271:-
OV	cis	rs3758911	1	rs10789615	ENSG00000261098.1	RP11-819C21.1	-4.81	2.8e-06	0.00173	-0.29	-0.3	Coronary artery disease;	chr11:107318088	chr11:107312132~107316271:-
OV	cis	rs347685	0.564	rs907293	ENSG00000249417.1	RP11-438D8.2	4.81	2.8e-06	0.00174	0.48	0.3	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;	chr3:142020727	chr3:141267353~141367137:-
OV	cis	rs7617773	0.817	rs3731513	ENSG00000228638.1	FCF1P2	-4.81	2.8e-06	0.00174	-0.39	-0.3	Coronary artery disease;	chr3:48178047	chr3:48290793~48291375:-
OV	cis	rs10740039	0.883	rs34168977	ENSG00000254271.1	RP11-131N11.4	4.81	2.81e-06	0.00174	0.39	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60632916	chr10:60734342~60741828:+
OV	cis	rs875971	0.867	rs1002053	ENSG00000236529.1	RP13-254B10.1	-4.81	2.81e-06	0.00174	-0.32	-0.3	Aortic root size;	chr7:66333558	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs6460292	ENSG00000236529.1	RP13-254B10.1	-4.81	2.81e-06	0.00174	-0.32	-0.3	Aortic root size;	chr7:66345088	chr7:65840212~65840596:+
OV	cis	rs17301013	0.606	rs11487399	ENSG00000227373.4	RP11-160H22.5	4.81	2.81e-06	0.00174	0.39	0.3	Systemic lupus erythematosus;	chr1:174527129	chr1:174115300~174160004:-
OV	cis	rs875971	1	rs12532998	ENSG00000236529.1	RP13-254B10.1	4.8	2.82e-06	0.00174	0.32	0.3	Aortic root size;	chr7:66502472	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs67775320	ENSG00000226824.5	RP4-756H11.3	-4.8	2.82e-06	0.00174	-0.36	-0.3	Aortic root size;	chr7:66193792	chr7:66654538~66669855:+
OV	cis	rs6471393	0.964	rs3813853	ENSG00000253848.1	RP11-10N23.5	4.8	2.82e-06	0.00175	0.37	0.3	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93740526	chr8:93741193~93744534:+
OV	cis	rs6471393	0.929	rs7016930	ENSG00000253848.1	RP11-10N23.5	4.8	2.82e-06	0.00175	0.37	0.3	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93743185	chr8:93741193~93744534:+
OV	cis	rs6471393	0.929	rs7017036	ENSG00000253848.1	RP11-10N23.5	4.8	2.82e-06	0.00175	0.37	0.3	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93743216	chr8:93741193~93744534:+
OV	cis	rs6471393	0.929	rs4734251	ENSG00000253848.1	RP11-10N23.5	4.8	2.82e-06	0.00175	0.37	0.3	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93744195	chr8:93741193~93744534:+
OV	cis	rs6471393	0.929	rs4734252	ENSG00000253848.1	RP11-10N23.5	4.8	2.82e-06	0.00175	0.37	0.3	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93744286	chr8:93741193~93744534:+
OV	cis	rs6471393	0.929	rs4464937	ENSG00000253848.1	RP11-10N23.5	4.8	2.82e-06	0.00175	0.37	0.3	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93744689	chr8:93741193~93744534:+
OV	cis	rs13315649	0.525	rs62270822	ENSG00000242551.2	POU5F1P6	-4.8	2.82e-06	0.00175	-0.39	-0.3	Sum eosinophil basophil counts;	chr3:128683677	chr3:128674735~128677005:-
OV	cis	rs295490	0.748	rs75472377	ENSG00000272656.1	RP11-219D15.3	4.8	2.82e-06	0.00175	0.55	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139439365	chr3:139349024~139349371:-
OV	cis	rs858239	0.539	rs10280815	ENSG00000230042.1	AK3P3	-4.8	2.83e-06	0.00175	-0.32	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23148751	chr7:23129178~23129841:+
OV	cis	rs858239	0.539	rs10225608	ENSG00000230042.1	AK3P3	-4.8	2.83e-06	0.00175	-0.32	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23149289	chr7:23129178~23129841:+
OV	cis	rs5850	0.557	rs10270788	ENSG00000230042.1	AK3P3	-4.8	2.83e-06	0.00175	-0.32	-0.3	Blood protein levels;	chr7:23149381	chr7:23129178~23129841:+
OV	cis	rs858239	0.539	rs28716381	ENSG00000230042.1	AK3P3	-4.8	2.83e-06	0.00175	-0.32	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23149396	chr7:23129178~23129841:+
OV	cis	rs858239	0.539	rs1358442	ENSG00000230042.1	AK3P3	-4.8	2.83e-06	0.00175	-0.32	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23150120	chr7:23129178~23129841:+
OV	cis	rs1555322	0.53	rs2425042	ENSG00000126005.14	MMP24-AS1	-4.8	2.83e-06	0.00175	-0.43	-0.3	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35216462~35278131:-
OV	cis	rs1555322	0.53	rs7004	ENSG00000126005.14	MMP24-AS1	-4.8	2.83e-06	0.00175	-0.43	-0.3	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35216462~35278131:-
OV	cis	rs17301013	0.54	rs72713601	ENSG00000227373.4	RP11-160H22.5	4.8	2.83e-06	0.00175	0.39	0.3	Systemic lupus erythematosus;	chr1:174482987	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs9729907	ENSG00000227373.4	RP11-160H22.5	4.8	2.83e-06	0.00175	0.39	0.3	Systemic lupus erythematosus;	chr1:174483607	chr1:174115300~174160004:-
OV	cis	rs17301013	0.581	rs2901818	ENSG00000227373.4	RP11-160H22.5	4.8	2.83e-06	0.00175	0.39	0.3	Systemic lupus erythematosus;	chr1:174486239	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs6658315	ENSG00000227373.4	RP11-160H22.5	4.8	2.83e-06	0.00175	0.39	0.3	Systemic lupus erythematosus;	chr1:174489961	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs12064743	ENSG00000227373.4	RP11-160H22.5	4.8	2.83e-06	0.00175	0.39	0.3	Systemic lupus erythematosus;	chr1:174496646	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs7536102	ENSG00000227373.4	RP11-160H22.5	4.8	2.83e-06	0.00175	0.39	0.3	Systemic lupus erythematosus;	chr1:174496801	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs7522253	ENSG00000227373.4	RP11-160H22.5	4.8	2.83e-06	0.00175	0.39	0.3	Systemic lupus erythematosus;	chr1:174496980	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs4652500	ENSG00000227373.4	RP11-160H22.5	4.8	2.83e-06	0.00175	0.39	0.3	Systemic lupus erythematosus;	chr1:174500656	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12071794	ENSG00000227373.4	RP11-160H22.5	4.8	2.83e-06	0.00175	0.39	0.3	Systemic lupus erythematosus;	chr1:174500767	chr1:174115300~174160004:-
OV	cis	rs17301013	0.556	rs7535845	ENSG00000227373.4	RP11-160H22.5	4.8	2.83e-06	0.00175	0.39	0.3	Systemic lupus erythematosus;	chr1:174502672	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs10912798	ENSG00000227373.4	RP11-160H22.5	4.8	2.83e-06	0.00175	0.39	0.3	Systemic lupus erythematosus;	chr1:174511420	chr1:174115300~174160004:-
OV	cis	rs17301013	0.581	rs10912799	ENSG00000227373.4	RP11-160H22.5	4.8	2.83e-06	0.00175	0.39	0.3	Systemic lupus erythematosus;	chr1:174511422	chr1:174115300~174160004:-
OV	cis	rs17301013	0.556	rs10912800	ENSG00000227373.4	RP11-160H22.5	4.8	2.83e-06	0.00175	0.39	0.3	Systemic lupus erythematosus;	chr1:174513939	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs56213002	ENSG00000227373.4	RP11-160H22.5	4.8	2.83e-06	0.00175	0.39	0.3	Systemic lupus erythematosus;	chr1:174516512	chr1:174115300~174160004:-
OV	cis	rs17301013	0.541	rs10798319	ENSG00000227373.4	RP11-160H22.5	4.8	2.83e-06	0.00175	0.39	0.3	Systemic lupus erythematosus;	chr1:174516983	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs9730220	ENSG00000227373.4	RP11-160H22.5	4.8	2.83e-06	0.00175	0.39	0.3	Systemic lupus erythematosus;	chr1:174519092	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs12062170	ENSG00000227373.4	RP11-160H22.5	4.8	2.83e-06	0.00175	0.39	0.3	Systemic lupus erythematosus;	chr1:174528420	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs12062483	ENSG00000227373.4	RP11-160H22.5	4.8	2.83e-06	0.00175	0.39	0.3	Systemic lupus erythematosus;	chr1:174529089	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs6681970	ENSG00000227373.4	RP11-160H22.5	4.8	2.83e-06	0.00175	0.39	0.3	Systemic lupus erythematosus;	chr1:174532698	chr1:174115300~174160004:-
OV	cis	rs6471393	0.964	rs1051914	ENSG00000253848.1	RP11-10N23.5	4.8	2.83e-06	0.00175	0.38	0.3	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93728838	chr8:93741193~93744534:+
OV	cis	rs6471393	0.964	rs2914952	ENSG00000253848.1	RP11-10N23.5	4.8	2.83e-06	0.00175	0.38	0.3	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93729524	chr8:93741193~93744534:+
OV	cis	rs6700559	0.81	rs2809344	ENSG00000260088.1	RP11-92G12.3	4.8	2.83e-06	0.00175	0.32	0.3	Coronary artery disease;	chr1:200627478	chr1:200669507~200694250:+
OV	cis	rs7520050	0.751	rs2230657	ENSG00000281133.1	AL355480.3	4.8	2.83e-06	0.00175	0.35	0.3	Reticulocyte count;Red blood cell count;	chr1:45607817	chr1:45580892~45580996:-
OV	cis	rs473651	0.904	rs10929275	ENSG00000229915.1	AC016999.2	-4.8	2.84e-06	0.00175	-0.38	-0.3	Multiple system atrophy;	chr2:238414528	chr2:238427077~238427729:-
OV	cis	rs7927592	0.913	rs2236708	ENSG00000212093.1	AP000807.1	4.8	2.84e-06	0.00175	0.39	0.3	Total body bone mineral density;	chr11:68610577	chr11:68506083~68506166:-
OV	cis	rs9318086	0.712	rs9318099	ENSG00000205861.10	C1QTNF9B-AS1	4.8	2.84e-06	0.00175	0.37	0.3	Myopia (pathological);	chr13:23868323	chr13:23888889~23897263:+
OV	cis	rs4805272	1	rs1422213	ENSG00000267243.4	AC005307.3	-4.8	2.84e-06	0.00175	-0.41	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28839227	chr19:28435388~28727777:-
OV	cis	rs11976180	0.517	rs6949375	ENSG00000273234.1	OR2A13P	-4.8	2.84e-06	0.00175	-0.43	-0.3	Obesity-related traits;	chr7:144076758	chr7:144142009~144142938:+
OV	cis	rs9309473	0.95	rs6740766	ENSG00000163016.8	ALMS1P	4.8	2.84e-06	0.00175	0.35	0.3	Metabolite levels;	chr2:73553786	chr2:73644919~73685576:+
OV	cis	rs9309473	1	rs13431267	ENSG00000163016.8	ALMS1P	4.8	2.84e-06	0.00175	0.35	0.3	Metabolite levels;	chr2:73555073	chr2:73644919~73685576:+
OV	cis	rs9309473	1	rs10207220	ENSG00000163016.8	ALMS1P	4.8	2.84e-06	0.00175	0.35	0.3	Metabolite levels;	chr2:73557919	chr2:73644919~73685576:+
OV	cis	rs295490	0.748	rs59628512	ENSG00000272656.1	RP11-219D15.3	4.8	2.84e-06	0.00175	0.56	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139472550	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs115673919	ENSG00000272656.1	RP11-219D15.3	4.8	2.84e-06	0.00175	0.56	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139489239	chr3:139349024~139349371:-
OV	cis	rs73086581	0.592	rs2300217	ENSG00000229539.1	RP11-119B16.2	4.8	2.84e-06	0.00176	0.31	0.3	Response to antidepressants in depression;	chr20:3957928	chr20:3888239~3888868:-
OV	cis	rs9309473	1	rs9309473	ENSG00000163016.8	ALMS1P	4.8	2.84e-06	0.00176	0.36	0.3	Metabolite levels;	chr2:73516855	chr2:73644919~73685576:+
OV	cis	rs4853012	0.838	rs2177707	ENSG00000257800.1	FNBP1P1	4.8	2.85e-06	0.00176	0.45	0.3	Gestational age at birth (maternal effect);	chr2:74129723	chr2:74120680~74123218:+
OV	cis	rs875971	0.545	rs1909508	ENSG00000226824.5	RP4-756H11.3	-4.8	2.85e-06	0.00176	-0.36	-0.3	Aortic root size;	chr7:66301366	chr7:66654538~66669855:+
OV	cis	rs858239	0.539	rs6965833	ENSG00000230042.1	AK3P3	-4.8	2.85e-06	0.00176	-0.32	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23152747	chr7:23129178~23129841:+
OV	cis	rs858239	0.539	rs6949363	ENSG00000230042.1	AK3P3	-4.8	2.85e-06	0.00176	-0.32	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23152775	chr7:23129178~23129841:+
OV	cis	rs17301013	0.507	rs411665	ENSG00000227373.4	RP11-160H22.5	4.8	2.85e-06	0.00176	0.39	0.3	Systemic lupus erythematosus;	chr1:174656563	chr1:174115300~174160004:-
OV	cis	rs4938303	0.633	rs61906081	ENSG00000254851.1	RP11-109L13.1	4.8	2.85e-06	0.00176	0.5	0.3	Triglycerides;	chr11:116666342	chr11:117135528~117138582:+
OV	cis	rs783540	0.846	rs2099259	ENSG00000278603.1	RP13-608F4.5	4.8	2.86e-06	0.00176	0.35	0.3	Schizophrenia;	chr15:82654937	chr15:82472203~82472426:+
OV	cis	rs62458065	0.85	rs28693551	ENSG00000226468.2	AC018641.7	4.8	2.86e-06	0.00176	0.47	0.3	Metabolite levels (HVA/MHPG ratio);	chr7:32429775	chr7:32456963~32457758:-
OV	cis	rs10740039	0.804	rs894383	ENSG00000254271.1	RP11-131N11.4	4.8	2.86e-06	0.00176	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60683359	chr10:60734342~60741828:+
OV	cis	rs7968440	0.801	rs7960015	ENSG00000257298.1	RP3-405J10.3	4.8	2.86e-06	0.00177	0.31	0.3	Fibrinogen;	chr12:50751411	chr12:50185580~50191363:-
OV	cis	rs3733585	0.699	rs7663079	ENSG00000250413.1	RP11-448G15.1	4.8	2.86e-06	0.00177	0.34	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9965147	chr4:10006482~10009725:+
OV	cis	rs3733585	0.699	rs7657340	ENSG00000250413.1	RP11-448G15.1	4.8	2.86e-06	0.00177	0.34	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9965148	chr4:10006482~10009725:+
OV	cis	rs3733585	0.699	rs7663097	ENSG00000250413.1	RP11-448G15.1	4.8	2.86e-06	0.00177	0.34	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9965167	chr4:10006482~10009725:+
OV	cis	rs7968440	0.736	rs10783388	ENSG00000257298.1	RP3-405J10.3	4.8	2.87e-06	0.00177	0.29	0.3	Fibrinogen;	chr12:50787916	chr12:50185580~50191363:-
OV	cis	rs17301013	0.606	rs7530265	ENSG00000227373.4	RP11-160H22.5	4.8	2.87e-06	0.00177	0.39	0.3	Systemic lupus erythematosus;	chr1:174564603	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs12083628	ENSG00000227373.4	RP11-160H22.5	4.8	2.87e-06	0.00177	0.39	0.3	Systemic lupus erythematosus;	chr1:174572097	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs6691118	ENSG00000227373.4	RP11-160H22.5	4.8	2.87e-06	0.00177	0.39	0.3	Systemic lupus erythematosus;	chr1:174577798	chr1:174115300~174160004:-
OV	cis	rs17301013	0.581	rs12082139	ENSG00000227373.4	RP11-160H22.5	4.8	2.87e-06	0.00177	0.39	0.3	Systemic lupus erythematosus;	chr1:174589043	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs12067463	ENSG00000227373.4	RP11-160H22.5	4.8	2.87e-06	0.00177	0.39	0.3	Systemic lupus erythematosus;	chr1:174625437	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs10912823	ENSG00000227373.4	RP11-160H22.5	4.8	2.87e-06	0.00177	0.39	0.3	Systemic lupus erythematosus;	chr1:174625602	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs6677874	ENSG00000227373.4	RP11-160H22.5	4.8	2.87e-06	0.00177	0.39	0.3	Systemic lupus erythematosus;	chr1:174628410	chr1:174115300~174160004:-
OV	cis	rs875971	0.929	rs10950041	ENSG00000236529.1	RP13-254B10.1	4.8	2.87e-06	0.00177	0.32	0.3	Aortic root size;	chr7:66508888	chr7:65840212~65840596:+
OV	cis	rs875971	0.929	rs6970860	ENSG00000236529.1	RP13-254B10.1	4.8	2.87e-06	0.00177	0.32	0.3	Aortic root size;	chr7:66511647	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs6957199	ENSG00000236529.1	RP13-254B10.1	4.8	2.87e-06	0.00177	0.32	0.3	Aortic root size;	chr7:66513532	chr7:65840212~65840596:+
OV	cis	rs858239	0.571	rs2390755	ENSG00000230042.1	AK3P3	-4.8	2.87e-06	0.00177	-0.32	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23151097	chr7:23129178~23129841:+
OV	cis	rs858239	0.539	rs4365988	ENSG00000230042.1	AK3P3	-4.8	2.87e-06	0.00177	-0.32	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23151252	chr7:23129178~23129841:+
OV	cis	rs858239	0.539	rs10279194	ENSG00000230042.1	AK3P3	-4.8	2.87e-06	0.00177	-0.32	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23151464	chr7:23129178~23129841:+
OV	cis	rs858239	0.539	rs3950345	ENSG00000230042.1	AK3P3	-4.8	2.87e-06	0.00177	-0.32	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23151495	chr7:23129178~23129841:+
OV	cis	rs858239	0.539	rs2178140	ENSG00000230042.1	AK3P3	-4.8	2.87e-06	0.00177	-0.32	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23152006	chr7:23129178~23129841:+
OV	cis	rs858239	0.539	rs2178139	ENSG00000230042.1	AK3P3	-4.8	2.87e-06	0.00177	-0.32	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23152017	chr7:23129178~23129841:+
OV	cis	rs858239	0.539	rs2141306	ENSG00000230042.1	AK3P3	-4.8	2.87e-06	0.00177	-0.32	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23152045	chr7:23129178~23129841:+
OV	cis	rs858239	0.539	rs6945510	ENSG00000230042.1	AK3P3	-4.8	2.87e-06	0.00177	-0.32	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23152621	chr7:23129178~23129841:+
OV	cis	rs17301013	0.507	rs11805578	ENSG00000227373.4	RP11-160H22.5	4.8	2.88e-06	0.00177	0.41	0.3	Systemic lupus erythematosus;	chr1:174573174	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs4652652	ENSG00000227373.4	RP11-160H22.5	4.8	2.88e-06	0.00177	0.41	0.3	Systemic lupus erythematosus;	chr1:174596582	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs4651103	ENSG00000227373.4	RP11-160H22.5	4.8	2.88e-06	0.00177	0.41	0.3	Systemic lupus erythematosus;	chr1:174596750	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs4615901	ENSG00000227373.4	RP11-160H22.5	4.8	2.88e-06	0.00177	0.41	0.3	Systemic lupus erythematosus;	chr1:174609432	chr1:174115300~174160004:-
OV	cis	rs1789	0.706	rs7696938	ENSG00000273133.1	RP11-799M12.2	4.8	2.88e-06	0.00178	0.39	0.3	Blood protein levels;	chr4:15701954	chr4:15563698~15564253:-
OV	cis	rs4713118	0.739	rs2893931	ENSG00000219392.1	RP1-265C24.5	-4.8	2.89e-06	0.00178	-0.35	-0.3	Parkinson's disease;	chr6:27780231	chr6:28115628~28116551:+
OV	cis	rs4938303	0.633	rs12799441	ENSG00000254851.1	RP11-109L13.1	4.8	2.89e-06	0.00178	0.5	0.3	Triglycerides;	chr11:116687799	chr11:117135528~117138582:+
OV	cis	rs4639966	0.569	rs603486	ENSG00000255239.1	AP002954.6	4.8	2.9e-06	0.00179	0.34	0.3	Systemic lupus erythematosus;	chr11:118716638	chr11:118688039~118690600:-
OV	cis	rs3814244	0.933	rs12423194	ENSG00000255733.4	IFNG-AS1	4.8	2.9e-06	0.00179	0.29	0.3	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020387	chr12:67989445~68234686:+
OV	cis	rs17301013	0.606	rs12086693	ENSG00000227373.4	RP11-160H22.5	4.8	2.91e-06	0.00179	0.39	0.3	Systemic lupus erythematosus;	chr1:174527651	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs6668096	ENSG00000227373.4	RP11-160H22.5	4.8	2.91e-06	0.00179	0.39	0.3	Systemic lupus erythematosus;	chr1:174537343	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs6692173	ENSG00000227373.4	RP11-160H22.5	4.8	2.91e-06	0.00179	0.39	0.3	Systemic lupus erythematosus;	chr1:174544474	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs333423	ENSG00000227373.4	RP11-160H22.5	4.8	2.91e-06	0.00179	0.39	0.3	Systemic lupus erythematosus;	chr1:174666557	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs333437	ENSG00000227373.4	RP11-160H22.5	4.8	2.91e-06	0.00179	0.39	0.3	Systemic lupus erythematosus;	chr1:174672224	chr1:174115300~174160004:-
OV	cis	rs7520050	0.778	rs2934857	ENSG00000281133.1	AL355480.3	-4.8	2.91e-06	0.00179	-0.33	-0.3	Reticulocyte count;Red blood cell count;	chr1:45573940	chr1:45580892~45580996:-
OV	cis	rs4266144	0.821	rs56237906	ENSG00000244515.1	KRT18P34	-4.8	2.93e-06	0.0018	-0.39	-0.3	Coronary artery disease;	chr3:157134684	chr3:157162663~157163932:-
OV	cis	rs67311347	0.824	rs73073561	ENSG00000223797.4	ENTPD3-AS1	4.8	2.93e-06	0.0018	0.34	0.3	Renal cell carcinoma;	chr3:40315807	chr3:40313802~40453329:-
OV	cis	rs7968440	0.715	rs7967954	ENSG00000257298.1	RP3-405J10.3	-4.8	2.93e-06	0.0018	-0.28	-0.3	Fibrinogen;	chr12:50279701	chr12:50185580~50191363:-
OV	cis	rs9859260	0.744	rs406271	ENSG00000231464.1	AC024937.4	-4.8	2.93e-06	0.0018	-0.37	-0.3	Mean corpuscular volume;	chr3:196050105	chr3:195996738~195998233:+
OV	cis	rs6860806	0.507	rs2631362	ENSG00000233006.5	AC034220.3	-4.8	2.93e-06	0.0018	-0.33	-0.3	Breast cancer;	chr5:132371601	chr5:132311285~132369916:-
OV	cis	rs7927592	0.731	rs2156463	ENSG00000212093.1	AP000807.1	4.8	2.93e-06	0.0018	0.35	0.3	Total body bone mineral density;	chr11:68618843	chr11:68506083~68506166:-
OV	cis	rs295490	0.748	rs77016755	ENSG00000272656.1	RP11-219D15.3	4.8	2.93e-06	0.0018	0.55	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139392125	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs61034702	ENSG00000272656.1	RP11-219D15.3	4.8	2.93e-06	0.0018	0.55	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139395105	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs115177972	ENSG00000272656.1	RP11-219D15.3	4.8	2.93e-06	0.0018	0.55	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139410696	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs77876369	ENSG00000272656.1	RP11-219D15.3	4.8	2.93e-06	0.0018	0.55	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139412070	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs77131232	ENSG00000272656.1	RP11-219D15.3	4.8	2.93e-06	0.0018	0.55	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139415468	chr3:139349024~139349371:-
OV	cis	rs295490	0.588	rs75694829	ENSG00000272656.1	RP11-219D15.3	4.8	2.93e-06	0.0018	0.55	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139416582	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs76520271	ENSG00000272656.1	RP11-219D15.3	4.8	2.93e-06	0.0018	0.55	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139422441	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs77343695	ENSG00000272656.1	RP11-219D15.3	4.8	2.93e-06	0.0018	0.55	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139430617	chr3:139349024~139349371:-
OV	cis	rs295490	0.667	rs79661321	ENSG00000272656.1	RP11-219D15.3	4.8	2.93e-06	0.0018	0.55	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139434762	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs77036655	ENSG00000272656.1	RP11-219D15.3	4.8	2.93e-06	0.0018	0.55	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139436231	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs76522909	ENSG00000272656.1	RP11-219D15.3	4.8	2.93e-06	0.0018	0.55	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139444006	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs2289348	ENSG00000272656.1	RP11-219D15.3	4.8	2.93e-06	0.0018	0.55	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139445424	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs61680644	ENSG00000272656.1	RP11-219D15.3	4.8	2.93e-06	0.0018	0.55	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139455729	chr3:139349024~139349371:-
OV	cis	rs295490	0.667	rs79829464	ENSG00000272656.1	RP11-219D15.3	4.8	2.93e-06	0.0018	0.55	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139456842	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs77347345	ENSG00000272656.1	RP11-219D15.3	4.8	2.93e-06	0.0018	0.55	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139459863	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs17560106	ENSG00000272656.1	RP11-219D15.3	4.8	2.93e-06	0.0018	0.55	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139461388	chr3:139349024~139349371:-
OV	cis	rs295490	0.667	rs2289350	ENSG00000272656.1	RP11-219D15.3	4.8	2.93e-06	0.0018	0.55	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139462436	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs80323892	ENSG00000272656.1	RP11-219D15.3	4.8	2.93e-06	0.0018	0.55	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139464658	chr3:139349024~139349371:-
OV	cis	rs11157436	0.918	rs1983519	ENSG00000211812.1	TRAV26-2	-4.8	2.94e-06	0.0018	-0.39	-0.3	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150310	chr14:22202583~22203368:+
OV	cis	rs2253762	0.507	rs11200310	ENSG00000276742.1	RP11-500G22.4	4.8	2.94e-06	0.00181	0.5	0.3	Breast cancer;	chr10:121989944	chr10:121956782~121957098:+
OV	cis	rs10992471	0.756	rs2516568	ENSG00000281156.1	MIR3651	-4.8	2.94e-06	0.00181	-0.34	-0.3	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92425098	chr9:92292458~92292547:-
OV	cis	rs7043114	0.525	rs4744136	ENSG00000281156.1	MIR3651	4.8	2.94e-06	0.00181	0.34	0.3	Height;	chr9:92512742	chr9:92292458~92292547:-
OV	cis	rs13178541	0.745	rs3963615	ENSG00000250378.1	RP11-119J18.1	-4.79	2.95e-06	0.00181	-0.42	-0.3	IgG glycosylation;	chr5:135750292	chr5:135812667~135826582:+
OV	cis	rs992157	1	rs736730	ENSG00000261338.2	RP11-378A13.1	4.79	2.96e-06	0.00181	0.36	0.3	Colorectal cancer;	chr2:218255532	chr2:218255319~218257366:+
OV	cis	rs992157	1	rs736731	ENSG00000261338.2	RP11-378A13.1	4.79	2.96e-06	0.00181	0.36	0.3	Colorectal cancer;	chr2:218255865	chr2:218255319~218257366:+
OV	cis	rs992157	1	rs10932766	ENSG00000261338.2	RP11-378A13.1	4.79	2.96e-06	0.00181	0.36	0.3	Colorectal cancer;	chr2:218257367	chr2:218255319~218257366:+
OV	cis	rs992157	1	rs3731859	ENSG00000261338.2	RP11-378A13.1	4.79	2.96e-06	0.00181	0.36	0.3	Colorectal cancer;	chr2:218259499	chr2:218255319~218257366:+
OV	cis	rs992157	1	rs11554825	ENSG00000261338.2	RP11-378A13.1	4.79	2.96e-06	0.00181	0.36	0.3	Colorectal cancer;	chr2:218261086	chr2:218255319~218257366:+
OV	cis	rs7927592	0.871	rs113020558	ENSG00000212093.1	AP000807.1	4.79	2.96e-06	0.00181	0.39	0.3	Total body bone mineral density;	chr11:68529364	chr11:68506083~68506166:-
OV	cis	rs10510102	0.935	rs10510101	ENSG00000276742.1	RP11-500G22.4	4.79	2.96e-06	0.00182	0.49	0.3	Breast cancer;	chr10:121898614	chr10:121956782~121957098:+
OV	cis	rs4713118	0.824	rs742046	ENSG00000220721.1	OR1F12	4.79	2.97e-06	0.00182	0.32	0.3	Parkinson's disease;	chr6:27771475	chr6:28073316~28074233:+
OV	cis	rs7580658	0.724	rs12623948	ENSG00000236682.1	AC068282.3	-4.79	2.97e-06	0.00182	-0.39	-0.3	Protein C levels;	chr2:127243766	chr2:127389130~127400580:+
OV	cis	rs10740039	0.804	rs2028563	ENSG00000254271.1	RP11-131N11.4	-4.79	2.98e-06	0.00182	-0.37	-0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60677139	chr10:60734342~60741828:+
OV	cis	rs11992162	0.56	rs13256329	ENSG00000206014.6	OR7E161P	4.79	2.98e-06	0.00182	0.36	0.3	Monocyte count;	chr8:11924705	chr8:11928597~11929563:-
OV	cis	rs10435719	0.638	rs67146188	ENSG00000206014.6	OR7E161P	4.79	2.98e-06	0.00182	0.36	0.3	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11924924	chr8:11928597~11929563:-
OV	cis	rs10435719	0.58	rs13260712	ENSG00000206014.6	OR7E161P	4.79	2.98e-06	0.00182	0.36	0.3	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11925061	chr8:11928597~11929563:-
OV	cis	rs11992162	0.551	rs13268217	ENSG00000206014.6	OR7E161P	4.79	2.98e-06	0.00182	0.36	0.3	Monocyte count;	chr8:11925100	chr8:11928597~11929563:-
OV	cis	rs11992162	0.573	rs13264994	ENSG00000206014.6	OR7E161P	4.79	2.98e-06	0.00182	0.36	0.3	Monocyte count;	chr8:11925250	chr8:11928597~11929563:-
OV	cis	rs11992162	0.573	rs13275808	ENSG00000206014.6	OR7E161P	4.79	2.98e-06	0.00182	0.36	0.3	Monocyte count;	chr8:11925306	chr8:11928597~11929563:-
OV	cis	rs1113500	0.933	rs10881497	ENSG00000226822.1	RP11-356N1.2	-4.79	2.99e-06	0.00183	-0.36	-0.3	Growth-regulated protein alpha levels;	chr1:108091893	chr1:108071482~108074519:+
OV	cis	rs10510102	0.935	rs11200258	ENSG00000226864.1	ATE1-AS1	4.79	2.99e-06	0.00183	0.49	0.3	Breast cancer;	chr10:121918392	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs12264495	ENSG00000226864.1	ATE1-AS1	4.79	2.99e-06	0.00183	0.49	0.3	Breast cancer;	chr10:121919967	chr10:121928312~121951965:+
OV	cis	rs6088580	0.634	rs6058070	ENSG00000206582.1	Y_RNA	-4.79	2.99e-06	0.00183	-0.36	-0.3	Glomerular filtration rate (creatinine);	chr20:34515716	chr20:34526510~34526606:-
OV	cis	rs2188561	0.697	rs7782475	ENSG00000241764.3	AC002467.7	-4.79	3e-06	0.00183	-0.35	-0.3	Alcohol consumption;	chr7:107745806	chr7:107742817~107744581:-
OV	cis	rs10510102	0.935	rs11200252	ENSG00000226864.1	ATE1-AS1	4.79	3e-06	0.00183	0.49	0.3	Breast cancer;	chr10:121914728	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs12254184	ENSG00000226864.1	ATE1-AS1	4.79	3e-06	0.00183	0.49	0.3	Breast cancer;	chr10:121914971	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs11200253	ENSG00000226864.1	ATE1-AS1	4.79	3e-06	0.00183	0.49	0.3	Breast cancer;	chr10:121915114	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs11200254	ENSG00000226864.1	ATE1-AS1	4.79	3e-06	0.00183	0.49	0.3	Breast cancer;	chr10:121915241	chr10:121928312~121951965:+
OV	cis	rs7302981	0.9	rs836179	ENSG00000272368.2	RP4-605O3.4	4.79	3e-06	0.00184	0.34	0.3	Systolic blood pressure;	chr12:50109299	chr12:50112197~50165618:+
OV	cis	rs7302981	0.9	rs836180	ENSG00000272368.2	RP4-605O3.4	4.79	3e-06	0.00184	0.34	0.3	Systolic blood pressure;	chr12:50109486	chr12:50112197~50165618:+
OV	cis	rs301901	0.796	rs3941788	ENSG00000250155.1	CTD-2353F22.1	4.79	3e-06	0.00184	0.36	0.3	Height;	chr5:37498809	chr5:36666214~36725195:-
OV	cis	rs7615952	0.576	rs12497295	ENSG00000171084.14	FAM86JP	4.79	3.01e-06	0.00184	0.45	0.3	Blood pressure (smoking interaction);	chr3:126099807	chr3:125916620~125930024:+
OV	cis	rs6088580	0.634	rs6059824	ENSG00000206582.1	Y_RNA	-4.79	3.01e-06	0.00184	-0.36	-0.3	Glomerular filtration rate (creatinine);	chr20:34426737	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6058041	ENSG00000206582.1	Y_RNA	-4.79	3.01e-06	0.00184	-0.36	-0.3	Glomerular filtration rate (creatinine);	chr20:34430202	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6058052	ENSG00000206582.1	Y_RNA	-4.79	3.01e-06	0.00184	-0.36	-0.3	Glomerular filtration rate (creatinine);	chr20:34459279	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6087588	ENSG00000206582.1	Y_RNA	-4.79	3.01e-06	0.00184	-0.36	-0.3	Glomerular filtration rate (creatinine);	chr20:34478564	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs13041646	ENSG00000206582.1	Y_RNA	-4.79	3.01e-06	0.00184	-0.36	-0.3	Glomerular filtration rate (creatinine);	chr20:34495076	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6088475	ENSG00000206582.1	Y_RNA	4.79	3.01e-06	0.00184	0.36	0.3	Glomerular filtration rate (creatinine);	chr20:34377181	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6142164	ENSG00000206582.1	Y_RNA	4.79	3.01e-06	0.00184	0.36	0.3	Glomerular filtration rate (creatinine);	chr20:34418791	chr20:34526510~34526606:-
OV	cis	rs6788497	0.643	rs56882053	ENSG00000242551.2	POU5F1P6	4.79	3.01e-06	0.00184	0.59	0.3	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr3:128406968	chr3:128674735~128677005:-
OV	cis	rs881375	0.967	rs7046108	ENSG00000226752.6	PSMD5-AS1	4.79	3.01e-06	0.00184	0.34	0.3	Rheumatoid arthritis;	chr9:120898061	chr9:120824828~120854385:+
OV	cis	rs1150668	0.796	rs9468372	ENSG00000220721.1	OR1F12	4.79	3.01e-06	0.00184	0.31	0.3	Pubertal anthropometrics;	chr6:28411584	chr6:28073316~28074233:+
OV	cis	rs11673344	0.704	rs484001	ENSG00000226686.6	LINC01535	4.79	3.02e-06	0.00184	0.37	0.3	Obesity-related traits;	chr19:36931320	chr19:37251912~37265535:+
OV	cis	rs4805272	0.626	rs12610050	ENSG00000267243.4	AC005307.3	-4.79	3.02e-06	0.00185	-0.48	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28840417	chr19:28435388~28727777:-
OV	cis	rs4805272	0.626	rs12608533	ENSG00000267243.4	AC005307.3	-4.79	3.02e-06	0.00185	-0.48	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28840498	chr19:28435388~28727777:-
OV	cis	rs172166	0.561	rs149971	ENSG00000220721.1	OR1F12	4.79	3.02e-06	0.00185	0.31	0.3	Cardiac Troponin-T levels;	chr6:28014374	chr6:28073316~28074233:+
OV	cis	rs11157436	0.958	rs764161	ENSG00000211812.1	TRAV26-2	-4.79	3.02e-06	0.00185	-0.36	-0.3	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231182	chr14:22202583~22203368:+
OV	cis	rs10740039	0.842	rs7915540	ENSG00000254271.1	RP11-131N11.4	4.79	3.02e-06	0.00185	0.39	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60646538	chr10:60734342~60741828:+
OV	cis	rs10740039	0.883	rs7905018	ENSG00000254271.1	RP11-131N11.4	4.79	3.02e-06	0.00185	0.39	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60647585	chr10:60734342~60741828:+
OV	cis	rs10740039	0.883	rs7920170	ENSG00000254271.1	RP11-131N11.4	4.79	3.02e-06	0.00185	0.39	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60647766	chr10:60734342~60741828:+
OV	cis	rs10740039	0.842	rs10761537	ENSG00000254271.1	RP11-131N11.4	4.79	3.02e-06	0.00185	0.39	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60649263	chr10:60734342~60741828:+
OV	cis	rs10740039	0.883	rs10761538	ENSG00000254271.1	RP11-131N11.4	4.79	3.02e-06	0.00185	0.39	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60649463	chr10:60734342~60741828:+
OV	cis	rs1150668	0.796	rs213237	ENSG00000220721.1	OR1F12	4.79	3.03e-06	0.00185	0.31	0.3	Pubertal anthropometrics;	chr6:28356161	chr6:28073316~28074233:+
OV	cis	rs10510102	1	rs11200181	ENSG00000276742.1	RP11-500G22.4	4.79	3.04e-06	0.00185	0.47	0.3	Breast cancer;	chr10:121828528	chr10:121956782~121957098:+
OV	cis	rs10510102	1	rs7923678	ENSG00000276742.1	RP11-500G22.4	4.79	3.04e-06	0.00185	0.47	0.3	Breast cancer;	chr10:121832546	chr10:121956782~121957098:+
OV	cis	rs10510102	1	rs6585764	ENSG00000276742.1	RP11-500G22.4	4.79	3.04e-06	0.00185	0.47	0.3	Breast cancer;	chr10:121837308	chr10:121956782~121957098:+
OV	cis	rs10510102	0.935	rs12253283	ENSG00000276742.1	RP11-500G22.4	-4.79	3.04e-06	0.00185	-0.47	-0.3	Breast cancer;	chr10:121909740	chr10:121956782~121957098:+
OV	cis	rs17301013	0.606	rs1417186	ENSG00000227373.4	RP11-160H22.5	-4.79	3.05e-06	0.00186	-0.39	-0.3	Systemic lupus erythematosus;	chr1:174171090	chr1:174115300~174160004:-
OV	cis	rs8062405	1	rs62036616	ENSG00000278665.1	RP11-666O2.4	4.79	3.05e-06	0.00186	0.33	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28599241~28601881:-
OV	cis	rs6921919	0.945	rs7765989	ENSG00000216901.1	AL022393.7	4.79	3.05e-06	0.00186	0.41	0.3	Autism spectrum disorder or schizophrenia;	chr6:28432518	chr6:28176188~28176674:+
OV	cis	rs10740039	0.842	rs7069157	ENSG00000254271.1	RP11-131N11.4	4.79	3.05e-06	0.00186	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60629475	chr10:60734342~60741828:+
OV	cis	rs7520050	0.645	rs1768809	ENSG00000281133.1	AL355480.3	4.79	3.05e-06	0.00186	0.36	0.3	Reticulocyte count;Red blood cell count;	chr1:46037164	chr1:45580892~45580996:-
OV	cis	rs7927592	0.956	rs7944870	ENSG00000212093.1	AP000807.1	4.79	3.05e-06	0.00186	0.38	0.3	Total body bone mineral density;	chr11:68541640	chr11:68506083~68506166:-
OV	cis	rs8100891	0.537	rs28729153	ENSG00000267213.4	AC007773.2	-4.79	3.05e-06	0.00186	-0.46	-0.3	Neuroticism;	chr19:32416672	chr19:32390050~32405560:-
OV	cis	rs10829156	0.699	rs6482516	ENSG00000225527.1	RP11-383B4.4	-4.79	3.05e-06	0.00186	-0.37	-0.3	Sudden cardiac arrest;	chr10:18550421	chr10:18531849~18533336:-
OV	cis	rs10829156	0.66	rs10828901	ENSG00000225527.1	RP11-383B4.4	-4.79	3.05e-06	0.00186	-0.37	-0.3	Sudden cardiac arrest;	chr10:18552161	chr10:18531849~18533336:-
OV	cis	rs783540	0.967	rs1145172	ENSG00000278603.1	RP13-608F4.5	-4.79	3.05e-06	0.00186	-0.34	-0.3	Schizophrenia;	chr15:82554866	chr15:82472203~82472426:+
OV	cis	rs7824557	0.547	rs2409745	ENSG00000255495.1	AC145124.2	4.79	3.06e-06	0.00187	0.35	0.3	Retinal vascular caliber;	chr8:11219126	chr8:12194467~12196280:+
OV	cis	rs73201462	0.803	rs2811478	ENSG00000277250.1	Metazoa_SRP	4.79	3.06e-06	0.00187	0.46	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128180781	chr3:128673681~128674021:-
OV	cis	rs11673344	0.704	rs1644711	ENSG00000226686.6	LINC01535	4.79	3.07e-06	0.00187	0.37	0.3	Obesity-related traits;	chr19:36926420	chr19:37251912~37265535:+
OV	cis	rs11673344	0.704	rs826262	ENSG00000226686.6	LINC01535	4.79	3.07e-06	0.00187	0.37	0.3	Obesity-related traits;	chr19:36928540	chr19:37251912~37265535:+
OV	cis	rs11673344	0.704	rs485034	ENSG00000226686.6	LINC01535	4.79	3.07e-06	0.00187	0.37	0.3	Obesity-related traits;	chr19:36931455	chr19:37251912~37265535:+
OV	cis	rs11673344	0.704	rs517110	ENSG00000226686.6	LINC01535	4.79	3.07e-06	0.00187	0.37	0.3	Obesity-related traits;	chr19:36931492	chr19:37251912~37265535:+
OV	cis	rs11673344	0.734	rs2551047	ENSG00000226686.6	LINC01535	4.79	3.07e-06	0.00187	0.37	0.3	Obesity-related traits;	chr19:36935174	chr19:37251912~37265535:+
OV	cis	rs11673344	0.704	rs551717	ENSG00000226686.6	LINC01535	4.79	3.07e-06	0.00187	0.37	0.3	Obesity-related traits;	chr19:36936977	chr19:37251912~37265535:+
OV	cis	rs11673344	0.704	rs826290	ENSG00000226686.6	LINC01535	4.79	3.07e-06	0.00187	0.37	0.3	Obesity-related traits;	chr19:36937543	chr19:37251912~37265535:+
OV	cis	rs11673344	0.67	rs505717	ENSG00000226686.6	LINC01535	4.79	3.07e-06	0.00187	0.37	0.3	Obesity-related traits;	chr19:36939414	chr19:37251912~37265535:+
OV	cis	rs11673344	0.704	rs544543	ENSG00000226686.6	LINC01535	4.79	3.07e-06	0.00187	0.37	0.3	Obesity-related traits;	chr19:36939921	chr19:37251912~37265535:+
OV	cis	rs11673344	0.67	rs568654	ENSG00000226686.6	LINC01535	4.79	3.07e-06	0.00187	0.37	0.3	Obesity-related traits;	chr19:36940285	chr19:37251912~37265535:+
OV	cis	rs11673344	0.633	rs519606	ENSG00000226686.6	LINC01535	4.79	3.07e-06	0.00187	0.37	0.3	Obesity-related traits;	chr19:36942327	chr19:37251912~37265535:+
OV	cis	rs11673344	0.67	rs35011739	ENSG00000226686.6	LINC01535	4.79	3.07e-06	0.00187	0.37	0.3	Obesity-related traits;	chr19:36943328	chr19:37251912~37265535:+
OV	cis	rs11673344	0.704	rs540451	ENSG00000226686.6	LINC01535	4.79	3.07e-06	0.00187	0.37	0.3	Obesity-related traits;	chr19:36944619	chr19:37251912~37265535:+
OV	cis	rs7429990	0.965	rs11707679	ENSG00000229759.1	MRPS18AP1	4.79	3.07e-06	0.00187	0.33	0.3	Educational attainment (years of education);	chr3:47915016	chr3:48256350~48256938:-
OV	cis	rs4938303	0.633	rs567209	ENSG00000254851.1	RP11-109L13.1	4.79	3.08e-06	0.00187	0.5	0.3	Triglycerides;	chr11:116664111	chr11:117135528~117138582:+
OV	cis	rs1858037	0.867	rs2118305	ENSG00000234255.7	AC012370.3	4.79	3.08e-06	0.00188	0.34	0.3	Rheumatoid arthritis;	chr2:65378086	chr2:65439888~65456571:-
OV	cis	rs1075265	0.73	rs7597189	ENSG00000233266.1	HMGB1P31	4.78	3.09e-06	0.00188	0.37	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54014733	chr2:54051334~54051760:+
OV	cis	rs6772849	0.901	rs9289330	ENSG00000242551.2	POU5F1P6	-4.78	3.09e-06	0.00188	-0.35	-0.3	Monocyte percentage of white cells;Monocyte count;	chr3:128592224	chr3:128674735~128677005:-
OV	cis	rs2153535	0.585	rs9393052	ENSG00000230939.1	RP11-314C16.1	-4.78	3.09e-06	0.00189	-0.33	-0.3	Motion sickness;	chr6:8644832	chr6:8784178~8785445:+
OV	cis	rs1075265	0.73	rs805391	ENSG00000233266.1	HMGB1P31	-4.78	3.1e-06	0.00189	-0.36	-0.3	Chronotype;Morning vs. evening chronotype;	chr2:53877181	chr2:54051334~54051760:+
OV	cis	rs9287719	0.649	rs12476554	ENSG00000243819.4	RN7SL832P	4.78	3.1e-06	0.00189	0.3	0.3	Prostate cancer;	chr2:10587621	chr2:10690344~10692099:+
OV	cis	rs12429206	0.512	rs9535530	ENSG00000233672.5	RNASEH2B-AS1	-4.78	3.11e-06	0.00189	-0.4	-0.3	Prostate-specific antigen levels (conditioned on lead SNPs);	chr13:50925136	chr13:50862172~50910764:-
OV	cis	rs875971	0.545	rs2279757	ENSG00000226824.5	RP4-756H11.3	-4.78	3.11e-06	0.0019	-0.36	-0.3	Aortic root size;	chr7:66363676	chr7:66654538~66669855:+
OV	cis	rs875971	0.545	rs11766183	ENSG00000226824.5	RP4-756H11.3	-4.78	3.11e-06	0.0019	-0.36	-0.3	Aortic root size;	chr7:66374173	chr7:66654538~66669855:+
OV	cis	rs875971	0.545	rs1065265	ENSG00000226824.5	RP4-756H11.3	-4.78	3.11e-06	0.0019	-0.36	-0.3	Aortic root size;	chr7:66376216	chr7:66654538~66669855:+
OV	cis	rs875971	0.545	rs7811204	ENSG00000226824.5	RP4-756H11.3	-4.78	3.11e-06	0.0019	-0.36	-0.3	Aortic root size;	chr7:66387213	chr7:66654538~66669855:+
OV	cis	rs10510102	0.935	rs11200263	ENSG00000226864.1	ATE1-AS1	4.78	3.12e-06	0.0019	0.5	0.3	Breast cancer;	chr10:121922836	chr10:121928312~121951965:+
OV	cis	rs1113500	0.836	rs1539553	ENSG00000226822.1	RP11-356N1.2	-4.78	3.12e-06	0.0019	-0.36	-0.3	Growth-regulated protein alpha levels;	chr1:108047376	chr1:108071482~108074519:+
OV	cis	rs2153535	0.585	rs7753781	ENSG00000230939.1	RP11-314C16.1	-4.78	3.12e-06	0.0019	-0.33	-0.3	Motion sickness;	chr6:8637268	chr6:8784178~8785445:+
OV	cis	rs73086581	0.592	rs6037702	ENSG00000229539.1	RP11-119B16.2	-4.78	3.13e-06	0.0019	-0.31	-0.3	Response to antidepressants in depression;	chr20:3955745	chr20:3888239~3888868:-
OV	cis	rs7017914	0.622	rs34022947	ENSG00000223220.1	Y_RNA	4.78	3.13e-06	0.00191	0.35	0.3	Bone mineral density;	chr8:71072373	chr8:70780914~70781008:-
OV	cis	rs1075265	0.669	rs805330	ENSG00000233266.1	HMGB1P31	4.78	3.13e-06	0.00191	0.37	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53921194	chr2:54051334~54051760:+
OV	cis	rs992157	1	rs2292553	ENSG00000261338.2	RP11-378A13.1	4.78	3.14e-06	0.00191	0.35	0.3	Colorectal cancer;	chr2:218282080	chr2:218255319~218257366:+
OV	cis	rs17301013	0.507	rs17842156	ENSG00000227373.4	RP11-160H22.5	4.78	3.14e-06	0.00191	0.41	0.3	Systemic lupus erythematosus;	chr1:174715050	chr1:174115300~174160004:-
OV	cis	rs934734	0.789	rs268122	ENSG00000234255.7	AC012370.3	-4.78	3.14e-06	0.00191	-0.33	-0.3	Rheumatoid arthritis;	chr2:65374975	chr2:65439888~65456571:-
OV	cis	rs17301013	0.606	rs459078	ENSG00000227373.4	RP11-160H22.5	4.78	3.15e-06	0.00191	0.38	0.3	Systemic lupus erythematosus;	chr1:174733772	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs162815	ENSG00000227373.4	RP11-160H22.5	4.78	3.15e-06	0.00191	0.38	0.3	Systemic lupus erythematosus;	chr1:174738792	chr1:174115300~174160004:-
OV	cis	rs7829975	0.593	rs2921077	ENSG00000253981.4	ALG1L13P	4.78	3.15e-06	0.00191	0.31	0.3	Mood instability;	chr8:8446992	chr8:8236003~8244667:-
OV	cis	rs4908768	1	rs4908768	ENSG00000228423.2	RP4-633I8.4	4.78	3.15e-06	0.00191	0.37	0.3	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8594705	chr1:8805860~8807051:-
OV	cis	rs9880211	0.948	rs6806123	ENSG00000239213.4	NCK1-AS1	4.78	3.15e-06	0.00191	0.36	0.3	Height;Body mass index;	chr3:136586634	chr3:136841726~136862054:-
OV	cis	rs1113500	0.933	rs11185261	ENSG00000226822.1	RP11-356N1.2	4.78	3.15e-06	0.00192	0.36	0.3	Growth-regulated protein alpha levels;	chr1:108096081	chr1:108071482~108074519:+
OV	cis	rs1113500	0.897	rs4628530	ENSG00000226822.1	RP11-356N1.2	4.78	3.15e-06	0.00192	0.36	0.3	Growth-regulated protein alpha levels;	chr1:108096086	chr1:108071482~108074519:+
OV	cis	rs2098713	0.535	rs1589116	ENSG00000250155.1	CTD-2353F22.1	4.78	3.15e-06	0.00192	0.36	0.3	Telomere length;	chr5:37629567	chr5:36666214~36725195:-
OV	cis	rs13315649	0.642	rs9811914	ENSG00000242551.2	POU5F1P6	-4.78	3.15e-06	0.00192	-0.39	-0.3	Sum eosinophil basophil counts;	chr3:128676517	chr3:128674735~128677005:-
OV	cis	rs4853012	0.838	rs72911122	ENSG00000257800.1	FNBP1P1	4.78	3.16e-06	0.00192	0.42	0.3	Gestational age at birth (maternal effect);	chr2:74116992	chr2:74120680~74123218:+
OV	cis	rs1858037	0.867	rs72621551	ENSG00000234255.7	AC012370.3	4.78	3.17e-06	0.00192	0.34	0.3	Rheumatoid arthritis;	chr2:65388087	chr2:65439888~65456571:-
OV	cis	rs10829156	0.699	rs4747353	ENSG00000225527.1	RP11-383B4.4	-4.78	3.17e-06	0.00192	-0.37	-0.3	Sudden cardiac arrest;	chr10:18548028	chr10:18531849~18533336:-
OV	cis	rs17301013	0.606	rs332764	ENSG00000227373.4	RP11-160H22.5	4.78	3.17e-06	0.00192	0.38	0.3	Systemic lupus erythematosus;	chr1:174693056	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs332763	ENSG00000227373.4	RP11-160H22.5	4.78	3.17e-06	0.00192	0.38	0.3	Systemic lupus erythematosus;	chr1:174693482	chr1:174115300~174160004:-
OV	cis	rs17301013	0.581	rs332772	ENSG00000227373.4	RP11-160H22.5	4.78	3.17e-06	0.00192	0.38	0.3	Systemic lupus erythematosus;	chr1:174695740	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs333471	ENSG00000227373.4	RP11-160H22.5	4.78	3.17e-06	0.00192	0.38	0.3	Systemic lupus erythematosus;	chr1:174705062	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs332784	ENSG00000227373.4	RP11-160H22.5	4.78	3.17e-06	0.00192	0.38	0.3	Systemic lupus erythematosus;	chr1:174719927	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs332798	ENSG00000227373.4	RP11-160H22.5	4.78	3.17e-06	0.00192	0.38	0.3	Systemic lupus erythematosus;	chr1:174729096	chr1:174115300~174160004:-
OV	cis	rs8062405	0.755	rs4788074	ENSG00000278665.1	RP11-666O2.4	-4.78	3.17e-06	0.00192	-0.33	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28582276	chr16:28599241~28601881:-
OV	cis	rs9298506	1	rs28457828	ENSG00000254142.2	RP11-53M11.3	4.78	3.17e-06	0.00193	0.4	0.3	Intracranial aneurysm;	chr8:54538582	chr8:54554361~54561927:+
OV	cis	rs875971	0.545	rs12671152	ENSG00000226824.5	RP4-756H11.3	-4.78	3.18e-06	0.00193	-0.37	-0.3	Aortic root size;	chr7:66311140	chr7:66654538~66669855:+
OV	cis	rs17301013	0.507	rs333422	ENSG00000227373.4	RP11-160H22.5	-4.78	3.18e-06	0.00193	-0.39	-0.3	Systemic lupus erythematosus;	chr1:174664167	chr1:174115300~174160004:-
OV	cis	rs607987	0.756	rs571174	ENSG00000254532.1	RP11-624D11.2	4.78	3.18e-06	0.00193	0.38	0.3	Body mass index;	chr11:30373402	chr11:30044058~30084343:-
OV	cis	rs4964805	0.594	rs11111759	ENSG00000257681.1	RP11-341G23.4	4.78	3.18e-06	0.00193	0.34	0.3	Attention deficit hyperactivity disorder;	chr12:103769405	chr12:103746315~103768858:-
OV	cis	rs7429990	1	rs1684942	ENSG00000229759.1	MRPS18AP1	4.78	3.19e-06	0.00194	0.32	0.3	Educational attainment (years of education);	chr3:47859213	chr3:48256350~48256938:-
OV	cis	rs116095464	0.558	rs73029475	ENSG00000250848.1	CTD-2083E4.5	-4.78	3.21e-06	0.00194	-0.4	-0.3	Breast cancer;	chr5:206854	chr5:288833~290321:-
OV	cis	rs451390	1	rs451390	ENSG00000237232.6	ZNF295-AS1	4.78	3.21e-06	0.00195	0.66	0.3	Tuberculosis;	chr21:41923401	chr21:42009194~42024924:+
OV	cis	rs4853012	0.838	rs4452177	ENSG00000257800.1	FNBP1P1	4.78	3.21e-06	0.00195	0.43	0.3	Gestational age at birth (maternal effect);	chr2:74118079	chr2:74120680~74123218:+
OV	cis	rs11159086	0.793	rs17100414	ENSG00000270000.1	RP3-449M8.9	4.78	3.22e-06	0.00195	0.45	0.3	Advanced glycation end-product levels;	chr14:74467918	chr14:74471930~74472360:-
OV	cis	rs10924970	0.649	rs12729988	ENSG00000236863.2	RPL23AP23	4.77	3.22e-06	0.00196	0.31	0.3	Asthma;	chr1:235209265	chr1:235295865~235296335:+
OV	cis	rs796364	0.813	rs7565417	ENSG00000232732.8	AC073043.1	-4.77	3.23e-06	0.00196	-0.4	-0.3	Schizophrenia;	chr2:200192768	chr2:199867396~199911159:-
OV	cis	rs7927592	0.763	rs3740628	ENSG00000212093.1	AP000807.1	4.77	3.23e-06	0.00196	0.35	0.3	Total body bone mineral density;	chr11:68613947	chr11:68506083~68506166:-
OV	cis	rs796825	0.597	rs787210	ENSG00000240661.1	RP11-174O3.3	-4.77	3.23e-06	0.00196	-0.42	-0.3	HIV-1 susceptibility;	chr3:120321280	chr3:120349510~120367998:+
OV	cis	rs4713118	0.866	rs2179094	ENSG00000219392.1	RP1-265C24.5	-4.77	3.23e-06	0.00196	-0.35	-0.3	Parkinson's disease;	chr6:27774046	chr6:28115628~28116551:+
OV	cis	rs875971	0.862	rs28470208	ENSG00000236529.1	RP13-254B10.1	-4.77	3.23e-06	0.00196	-0.31	-0.3	Aortic root size;	chr7:66119713	chr7:65840212~65840596:+
OV	cis	rs11690935	0.55	rs6730085	ENSG00000228389.1	AC068039.4	-4.77	3.24e-06	0.00196	-0.34	-0.3	Schizophrenia;	chr2:171999938	chr2:171773482~171775844:+
OV	cis	rs7927771	0.693	rs2856650	ENSG00000280615.1	Y_RNA	-4.77	3.24e-06	0.00196	-0.4	-0.3	Subjective well-being;	chr11:47343648	chr11:47614898~47614994:-
OV	cis	rs7580658	0.724	rs6712446	ENSG00000236682.1	AC068282.3	-4.77	3.24e-06	0.00196	-0.38	-0.3	Protein C levels;	chr2:127240823	chr2:127389130~127400580:+
OV	cis	rs7580658	0.724	rs6712551	ENSG00000236682.1	AC068282.3	-4.77	3.24e-06	0.00196	-0.38	-0.3	Protein C levels;	chr2:127240909	chr2:127389130~127400580:+
OV	cis	rs17301013	0.606	rs7536987	ENSG00000227373.4	RP11-160H22.5	4.77	3.24e-06	0.00196	0.39	0.3	Systemic lupus erythematosus;	chr1:174367978	chr1:174115300~174160004:-
OV	cis	rs17301013	0.556	rs10912774	ENSG00000227373.4	RP11-160H22.5	4.77	3.24e-06	0.00196	0.39	0.3	Systemic lupus erythematosus;	chr1:174387706	chr1:174115300~174160004:-
OV	cis	rs67311347	0.955	rs4973999	ENSG00000223797.4	ENTPD3-AS1	4.77	3.24e-06	0.00196	0.32	0.3	Renal cell carcinoma;	chr3:40418892	chr3:40313802~40453329:-
OV	cis	rs301901	0.965	rs13180309	ENSG00000250155.1	CTD-2353F22.1	-4.77	3.24e-06	0.00197	-0.35	-0.3	Height;	chr5:36789899	chr5:36666214~36725195:-
OV	cis	rs4908768	0.911	rs953535	ENSG00000228423.2	RP4-633I8.4	4.77	3.25e-06	0.00197	0.35	0.3	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8716660	chr1:8805860~8807051:-
OV	cis	rs3758911	0.894	rs10890718	ENSG00000261098.1	RP11-819C21.1	-4.77	3.25e-06	0.00197	-0.29	-0.3	Coronary artery disease;	chr11:107326257	chr11:107312132~107316271:-
OV	cis	rs4763879	0.739	rs12582584	ENSG00000256673.1	RP11-599J14.2	4.77	3.25e-06	0.00197	0.3	0.3	Type 1 diabetes;	chr12:9671542	chr12:9398355~9414851:-
OV	cis	rs4713118	0.824	rs2092075	ENSG00000219392.1	RP1-265C24.5	-4.77	3.25e-06	0.00197	-0.35	-0.3	Parkinson's disease;	chr6:27781551	chr6:28115628~28116551:+
OV	cis	rs4713118	0.824	rs13211701	ENSG00000219392.1	RP1-265C24.5	-4.77	3.25e-06	0.00197	-0.35	-0.3	Parkinson's disease;	chr6:27782300	chr6:28115628~28116551:+
OV	cis	rs4713118	0.824	rs9468229	ENSG00000219392.1	RP1-265C24.5	-4.77	3.25e-06	0.00197	-0.35	-0.3	Parkinson's disease;	chr6:27782307	chr6:28115628~28116551:+
OV	cis	rs1113500	0.862	rs11185264	ENSG00000226822.1	RP11-356N1.2	4.77	3.25e-06	0.00197	0.37	0.3	Growth-regulated protein alpha levels;	chr1:108097884	chr1:108071482~108074519:+
OV	cis	rs6088590	0.648	rs6058105	ENSG00000206582.1	Y_RNA	-4.77	3.26e-06	0.00197	-0.37	-0.3	Coronary artery disease;	chr20:34683915	chr20:34526510~34526606:-
OV	cis	rs4728142	0.525	rs4731534	ENSG00000275106.1	RP11-309L24.10	-4.77	3.26e-06	0.00197	-0.39	-0.3	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128965540	chr7:128952527~128953316:-
OV	cis	rs2000999	0.514	rs17604676	ENSG00000260015.1	RP11-510M2.5	-4.77	3.27e-06	0.00198	-0.5	-0.3	LDL cholesterol levels;Blood protein levels;Total cholesterol levels;LDL cholesterol;Haptoglobin levels;Cholesterol, total;	chr16:72188085	chr16:71539834~71541825:-
OV	cis	rs4713118	0.513	rs156739	ENSG00000219392.1	RP1-265C24.5	-4.77	3.27e-06	0.00198	-0.37	-0.3	Parkinson's disease;	chr6:28045632	chr6:28115628~28116551:+
OV	cis	rs7811142	0.83	rs6965458	ENSG00000242294.5	STAG3L5P	4.77	3.27e-06	0.00198	0.33	0.3	Platelet count;	chr7:100375779	chr7:100336079~100351900:+
OV	cis	rs10740039	0.883	rs10994446	ENSG00000254271.1	RP11-131N11.4	4.77	3.28e-06	0.00198	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639433	chr10:60734342~60741828:+
OV	cis	rs10740039	0.883	rs2119912	ENSG00000254271.1	RP11-131N11.4	4.77	3.28e-06	0.00198	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639754	chr10:60734342~60741828:+
OV	cis	rs301901	0.772	rs301867	ENSG00000250155.1	CTD-2353F22.1	-4.77	3.28e-06	0.00198	-0.34	-0.3	Height;	chr5:37130754	chr5:36666214~36725195:-
OV	cis	rs301901	0.743	rs10073054	ENSG00000250155.1	CTD-2353F22.1	-4.77	3.28e-06	0.00198	-0.34	-0.3	Height;	chr5:37172281	chr5:36666214~36725195:-
OV	cis	rs67180937	0.733	rs61824331	ENSG00000272750.1	RP11-378J18.8	-4.77	3.28e-06	0.00199	-0.32	-0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222708030	chr1:222658867~222661512:-
OV	cis	rs7927592	0.956	rs11228258	ENSG00000212093.1	AP000807.1	-4.77	3.28e-06	0.00199	-0.37	-0.3	Total body bone mineral density;	chr11:68486860	chr11:68506083~68506166:-
OV	cis	rs796364	0.616	rs2689765	ENSG00000232732.8	AC073043.1	-4.77	3.28e-06	0.00199	-0.45	-0.3	Schizophrenia;	chr2:199831629	chr2:199867396~199911159:-
OV	cis	rs796364	0.539	rs6738494	ENSG00000232732.8	AC073043.1	-4.77	3.28e-06	0.00199	-0.45	-0.3	Schizophrenia;	chr2:199832335	chr2:199867396~199911159:-
OV	cis	rs7520050	0.778	rs2088102	ENSG00000281133.1	AL355480.3	4.77	3.29e-06	0.00199	0.34	0.3	Reticulocyte count;Red blood cell count;	chr1:45567302	chr1:45580892~45580996:-
OV	cis	rs6088580	0.634	rs7271970	ENSG00000206582.1	Y_RNA	4.77	3.29e-06	0.00199	0.36	0.3	Glomerular filtration rate (creatinine);	chr20:34399860	chr20:34526510~34526606:-
OV	cis	rs2492286	0.597	rs2712384	ENSG00000277250.1	Metazoa_SRP	-4.77	3.3e-06	0.00199	-0.4	-0.3	Eosinophil counts;	chr3:128615429	chr3:128673681~128674021:-
OV	cis	rs13068223	0.669	rs168247	ENSG00000243926.1	TIPARP-AS1	-4.77	3.3e-06	0.002	-0.29	-0.3	Age-related hearing impairment (SNP x SNP interaction);	chr3:156722397	chr3:156671862~156674378:-
OV	cis	rs875971	0.798	rs6460304	ENSG00000236529.1	RP13-254B10.1	4.77	3.3e-06	0.002	0.31	0.3	Aortic root size;	chr7:66499741	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs6945775	ENSG00000236529.1	RP13-254B10.1	4.77	3.3e-06	0.002	0.31	0.3	Aortic root size;	chr7:66503987	chr7:65840212~65840596:+
OV	cis	rs10510102	0.935	rs11200260	ENSG00000226864.1	ATE1-AS1	4.77	3.3e-06	0.002	0.49	0.3	Breast cancer;	chr10:121920169	chr10:121928312~121951965:+
OV	cis	rs27434	0.66	rs26493	ENSG00000272109.1	CTD-2260A17.3	-4.77	3.31e-06	0.002	-0.5	-0.3	Ankylosing spondylitis;	chr5:96819615	chr5:96804353~96806105:+
OV	cis	rs473651	0.901	rs563282	ENSG00000229915.1	AC016999.2	-4.77	3.31e-06	0.002	-0.38	-0.3	Multiple system atrophy;	chr2:238421095	chr2:238427077~238427729:-
OV	cis	rs2262909	0.548	rs6511312	ENSG00000268598.1	VN1R80P	4.77	3.31e-06	0.002	0.35	0.3	Chagas cardiomyopathy in Tripanosoma cruzi seropositivity;	chr19:22022547	chr19:21063924~21064261:+
OV	cis	rs17301013	0.507	rs3862941	ENSG00000227373.4	RP11-160H22.5	4.77	3.31e-06	0.002	0.41	0.3	Systemic lupus erythematosus;	chr1:174689418	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs17842157	ENSG00000227373.4	RP11-160H22.5	4.77	3.31e-06	0.002	0.41	0.3	Systemic lupus erythematosus;	chr1:174719442	chr1:174115300~174160004:-
OV	cis	rs796364	0.806	rs34510964	ENSG00000232732.8	AC073043.1	4.77	3.32e-06	0.00201	0.43	0.3	Schizophrenia;	chr2:200145953	chr2:199867396~199911159:-
OV	cis	rs4713118	0.824	rs9468223	ENSG00000219392.1	RP1-265C24.5	-4.77	3.32e-06	0.00201	-0.35	-0.3	Parkinson's disease;	chr6:27772887	chr6:28115628~28116551:+
OV	cis	rs12073359	1	rs3925724	ENSG00000223945.2	RP11-458I7.1	4.77	3.34e-06	0.00201	0.45	0.3	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150108151	chr1:150053864~150055034:+
OV	cis	rs4713118	0.869	rs7773070	ENSG00000280107.1	AL022393.9	-4.77	3.35e-06	0.00202	-0.35	-0.3	Parkinson's disease;	chr6:27761048	chr6:28170845~28172521:+
OV	cis	rs9287719	0.967	rs10929682	ENSG00000234818.1	AC092687.5	4.77	3.35e-06	0.00202	0.32	0.3	Prostate cancer;	chr2:10592063	chr2:10589166~10604830:+
OV	cis	rs17301013	0.606	rs2103640	ENSG00000227373.4	RP11-160H22.5	4.77	3.35e-06	0.00202	0.4	0.3	Systemic lupus erythematosus;	chr1:174219147	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs56338048	ENSG00000227373.4	RP11-160H22.5	4.77	3.35e-06	0.00202	0.4	0.3	Systemic lupus erythematosus;	chr1:174220266	chr1:174115300~174160004:-
OV	cis	rs347685	0.529	rs963396	ENSG00000249417.1	RP11-438D8.2	4.77	3.35e-06	0.00202	0.48	0.3	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;	chr3:142031697	chr3:141267353~141367137:-
OV	cis	rs4938303	0.718	rs10892020	ENSG00000254851.1	RP11-109L13.1	-4.77	3.35e-06	0.00202	-0.45	-0.3	Triglycerides;	chr11:116718936	chr11:117135528~117138582:+
OV	cis	rs17301013	0.507	rs12065527	ENSG00000227373.4	RP11-160H22.5	4.77	3.35e-06	0.00202	0.39	0.3	Systemic lupus erythematosus;	chr1:174627066	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12064403	ENSG00000227373.4	RP11-160H22.5	4.77	3.35e-06	0.00202	0.39	0.3	Systemic lupus erythematosus;	chr1:174627067	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12065825	ENSG00000227373.4	RP11-160H22.5	4.77	3.35e-06	0.00202	0.39	0.3	Systemic lupus erythematosus;	chr1:174627902	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs6667107	ENSG00000227373.4	RP11-160H22.5	4.77	3.35e-06	0.00202	0.39	0.3	Systemic lupus erythematosus;	chr1:174628667	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs10912828	ENSG00000227373.4	RP11-160H22.5	4.77	3.35e-06	0.00202	0.39	0.3	Systemic lupus erythematosus;	chr1:174635701	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs10912829	ENSG00000227373.4	RP11-160H22.5	4.77	3.35e-06	0.00202	0.39	0.3	Systemic lupus erythematosus;	chr1:174635894	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs6689153	ENSG00000227373.4	RP11-160H22.5	4.77	3.35e-06	0.00202	0.39	0.3	Systemic lupus erythematosus;	chr1:174639550	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs395109	ENSG00000227373.4	RP11-160H22.5	4.77	3.35e-06	0.00202	0.39	0.3	Systemic lupus erythematosus;	chr1:174641233	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs2760058	ENSG00000227373.4	RP11-160H22.5	4.77	3.35e-06	0.00202	0.39	0.3	Systemic lupus erythematosus;	chr1:174641320	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs333454	ENSG00000227373.4	RP11-160H22.5	4.77	3.35e-06	0.00202	0.39	0.3	Systemic lupus erythematosus;	chr1:174653939	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs333452	ENSG00000227373.4	RP11-160H22.5	4.77	3.35e-06	0.00202	0.39	0.3	Systemic lupus erythematosus;	chr1:174654718	chr1:174115300~174160004:-
OV	cis	rs796364	0.806	rs112305133	ENSG00000232732.8	AC073043.1	4.77	3.36e-06	0.00202	0.43	0.3	Schizophrenia;	chr2:200145657	chr2:199867396~199911159:-
OV	cis	rs796364	0.806	rs34582889	ENSG00000232732.8	AC073043.1	4.77	3.36e-06	0.00202	0.43	0.3	Schizophrenia;	chr2:200145804	chr2:199867396~199911159:-
OV	cis	rs9309473	0.95	rs10178678	ENSG00000163016.8	ALMS1P	4.77	3.37e-06	0.00203	0.36	0.3	Metabolite levels;	chr2:73535109	chr2:73644919~73685576:+
OV	cis	rs875971	0.793	rs460678	ENSG00000236529.1	RP13-254B10.1	4.76	3.37e-06	0.00203	0.32	0.3	Aortic root size;	chr7:66062213	chr7:65840212~65840596:+
OV	cis	rs17301013	0.507	rs72715204	ENSG00000227373.4	RP11-160H22.5	4.76	3.37e-06	0.00203	0.41	0.3	Systemic lupus erythematosus;	chr1:174492787	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs11807229	ENSG00000227373.4	RP11-160H22.5	4.76	3.37e-06	0.00203	0.41	0.3	Systemic lupus erythematosus;	chr1:174519456	chr1:174115300~174160004:-
OV	cis	rs1797885	0.934	rs299658	ENSG00000251774.1	RNU6-377P	4.76	3.38e-06	0.00204	0.28	0.3	Immature fraction of reticulocytes;	chr3:12510585	chr3:12514706~12514807:+
OV	cis	rs7615952	0.543	rs4645102	ENSG00000171084.14	FAM86JP	4.76	3.38e-06	0.00204	0.47	0.3	Blood pressure (smoking interaction);	chr3:125705597	chr3:125916620~125930024:+
OV	cis	rs1891275	0.515	rs7093728	ENSG00000228701.1	TNKS2-AS1	-4.76	3.39e-06	0.00204	-0.33	-0.3	Intelligence (multi-trait analysis);	chr10:91683860	chr10:91782839~91798291:-
OV	cis	rs1891275	0.515	rs10786010	ENSG00000228701.1	TNKS2-AS1	-4.76	3.39e-06	0.00204	-0.33	-0.3	Intelligence (multi-trait analysis);	chr10:91684016	chr10:91782839~91798291:-
OV	cis	rs1891275	0.515	rs1986941	ENSG00000228701.1	TNKS2-AS1	-4.76	3.39e-06	0.00204	-0.33	-0.3	Intelligence (multi-trait analysis);	chr10:91684586	chr10:91782839~91798291:-
OV	cis	rs1891275	0.515	rs7098763	ENSG00000228701.1	TNKS2-AS1	-4.76	3.39e-06	0.00204	-0.33	-0.3	Intelligence (multi-trait analysis);	chr10:91685070	chr10:91782839~91798291:-
OV	cis	rs1891275	0.508	rs7099557	ENSG00000228701.1	TNKS2-AS1	-4.76	3.39e-06	0.00204	-0.33	-0.3	Intelligence (multi-trait analysis);	chr10:91685607	chr10:91782839~91798291:-
OV	cis	rs2153535	0.967	rs10484750	ENSG00000230939.1	RP11-314C16.1	4.76	3.39e-06	0.00204	0.35	0.3	Motion sickness;	chr6:8378376	chr6:8784178~8785445:+
OV	cis	rs7617773	0.817	rs13068265	ENSG00000228638.1	FCF1P2	-4.76	3.4e-06	0.00205	-0.38	-0.3	Coronary artery disease;	chr3:48260124	chr3:48290793~48291375:-
OV	cis	rs7617773	0.817	rs11709691	ENSG00000228638.1	FCF1P2	-4.76	3.4e-06	0.00205	-0.38	-0.3	Coronary artery disease;	chr3:48262179	chr3:48290793~48291375:-
OV	cis	rs76934034	0.522	rs117488236	ENSG00000264204.2	AGAP7P	-4.76	3.4e-06	0.00205	-0.53	-0.3	Prostate cancer;	chr10:45546587	chr10:46109621~46131358:+
OV	cis	rs17301013	0.581	rs12081445	ENSG00000227373.4	RP11-160H22.5	4.76	3.4e-06	0.00205	0.4	0.3	Systemic lupus erythematosus;	chr1:174226923	chr1:174115300~174160004:-
OV	cis	rs10740039	0.883	rs1442540	ENSG00000254271.1	RP11-131N11.4	-4.76	3.4e-06	0.00205	-0.37	-0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60653548	chr10:60734342~60741828:+
OV	cis	rs1134634	0.52	rs741180	ENSG00000273133.1	RP11-799M12.2	-4.76	3.4e-06	0.00205	-0.41	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15561787	chr4:15563698~15564253:-
OV	cis	rs17023223	0.537	rs4590715	ENSG00000231365.4	RP11-418J17.1	-4.76	3.41e-06	0.00205	-0.39	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119207578	chr1:119140396~119275973:+
OV	cis	rs11690935	0.589	rs62182403	ENSG00000228389.1	AC068039.4	-4.76	3.41e-06	0.00205	-0.34	-0.3	Schizophrenia;	chr2:171890672	chr2:171773482~171775844:+
OV	cis	rs10246939	0.543	rs9640357	ENSG00000228775.6	WEE2-AS1	4.76	3.41e-06	0.00205	0.31	0.3	Bitter taste perception;	chr7:141843298	chr7:141704338~141738346:-
OV	cis	rs116095464	0.558	rs7708182	ENSG00000250848.1	CTD-2083E4.5	-4.76	3.41e-06	0.00205	-0.37	-0.3	Breast cancer;	chr5:234673	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs10058428	ENSG00000250848.1	CTD-2083E4.5	-4.76	3.41e-06	0.00205	-0.37	-0.3	Breast cancer;	chr5:235493	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs10036253	ENSG00000250848.1	CTD-2083E4.5	-4.76	3.41e-06	0.00205	-0.37	-0.3	Breast cancer;	chr5:238404	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs10075018	ENSG00000250848.1	CTD-2083E4.5	-4.76	3.41e-06	0.00205	-0.37	-0.3	Breast cancer;	chr5:239060	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs10076655	ENSG00000250848.1	CTD-2083E4.5	-4.76	3.41e-06	0.00205	-0.37	-0.3	Breast cancer;	chr5:239349	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs10057492	ENSG00000250848.1	CTD-2083E4.5	-4.76	3.41e-06	0.00205	-0.37	-0.3	Breast cancer;	chr5:239388	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs28418643	ENSG00000250848.1	CTD-2083E4.5	-4.76	3.41e-06	0.00205	-0.37	-0.3	Breast cancer;	chr5:240744	chr5:288833~290321:-
OV	cis	rs62355901	0.8	rs10461612	ENSG00000271828.1	CTD-2310F14.1	4.76	3.42e-06	0.00205	0.46	0.3	Breast cancer;	chr5:56708004	chr5:56927874~56929573:+
OV	cis	rs62355901	0.8	rs7709971	ENSG00000271828.1	CTD-2310F14.1	4.76	3.42e-06	0.00205	0.46	0.3	Breast cancer;	chr5:56711512	chr5:56927874~56929573:+
OV	cis	rs10978777	0.515	rs12342066	ENSG00000276883.1	AL137852.1	4.76	3.42e-06	0.00205	0.4	0.3	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107262772	chr9:107292369~107292456:-
OV	cis	rs875971	0.545	rs75840613	ENSG00000226824.5	RP4-756H11.3	-4.76	3.42e-06	0.00206	-0.36	-0.3	Aortic root size;	chr7:66376399	chr7:66654538~66669855:+
OV	cis	rs1862618	0.573	rs2034245	ENSG00000271828.1	CTD-2310F14.1	-4.76	3.42e-06	0.00206	-0.53	-0.3	Initial pursuit acceleration;	chr5:56947858	chr5:56927874~56929573:+
OV	cis	rs11673344	0.764	rs529468	ENSG00000226686.6	LINC01535	4.76	3.42e-06	0.00206	0.37	0.3	Obesity-related traits;	chr19:36955298	chr19:37251912~37265535:+
OV	cis	rs11673344	0.764	rs524802	ENSG00000226686.6	LINC01535	4.76	3.42e-06	0.00206	0.37	0.3	Obesity-related traits;	chr19:36956045	chr19:37251912~37265535:+
OV	cis	rs9813712	0.574	rs35856399	ENSG00000253540.4	FAM86HP	-4.76	3.43e-06	0.00206	-0.32	-0.3	Response to amphetamines;	chr3:130241961	chr3:130099092~130111472:-
OV	cis	rs9309473	1	rs10190219	ENSG00000163016.8	ALMS1P	4.76	3.43e-06	0.00206	0.37	0.3	Metabolite levels;	chr2:73431203	chr2:73644919~73685576:+
OV	cis	rs17301013	0.507	rs333438	ENSG00000227373.4	RP11-160H22.5	4.76	3.43e-06	0.00206	0.39	0.3	Systemic lupus erythematosus;	chr1:174672782	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs2771401	ENSG00000227373.4	RP11-160H22.5	4.76	3.43e-06	0.00206	0.39	0.3	Systemic lupus erythematosus;	chr1:174678302	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs464540	ENSG00000227373.4	RP11-160H22.5	4.76	3.43e-06	0.00206	0.39	0.3	Systemic lupus erythematosus;	chr1:174679250	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs467437	ENSG00000227373.4	RP11-160H22.5	4.76	3.43e-06	0.00206	0.39	0.3	Systemic lupus erythematosus;	chr1:174679861	chr1:174115300~174160004:-
OV	cis	rs853679	0.882	rs4713139	ENSG00000219392.1	RP1-265C24.5	-4.76	3.43e-06	0.00206	-0.49	-0.3	Depression;	chr6:28124907	chr6:28115628~28116551:+
OV	cis	rs11673344	0.931	rs7256746	ENSG00000226686.6	LINC01535	4.76	3.44e-06	0.00207	0.37	0.3	Obesity-related traits;	chr19:37175073	chr19:37251912~37265535:+
OV	cis	rs7927592	0.956	rs10896343	ENSG00000212093.1	AP000807.1	4.76	3.44e-06	0.00207	0.38	0.3	Total body bone mineral density;	chr11:68550392	chr11:68506083~68506166:-
OV	cis	rs8100891	0.506	rs4804992	ENSG00000267213.4	AC007773.2	-4.76	3.45e-06	0.00207	-0.45	-0.3	Neuroticism;	chr19:32367885	chr19:32390050~32405560:-
OV	cis	rs11159086	0.793	rs10139122	ENSG00000270000.1	RP3-449M8.9	4.76	3.45e-06	0.00207	0.44	0.3	Advanced glycation end-product levels;	chr14:74492353	chr14:74471930~74472360:-
OV	cis	rs67311347	1	rs9829800	ENSG00000223797.4	ENTPD3-AS1	4.76	3.45e-06	0.00207	0.32	0.3	Renal cell carcinoma;	chr3:40402436	chr3:40313802~40453329:-
OV	cis	rs7927592	0.871	rs871212	ENSG00000212093.1	AP000807.1	4.76	3.46e-06	0.00207	0.38	0.3	Total body bone mineral density;	chr11:68581227	chr11:68506083~68506166:-
OV	cis	rs9309473	0.606	rs1589576	ENSG00000163016.8	ALMS1P	4.76	3.46e-06	0.00208	0.39	0.3	Metabolite levels;	chr2:73511677	chr2:73644919~73685576:+
OV	cis	rs17301013	0.507	rs72715260	ENSG00000227373.4	RP11-160H22.5	4.76	3.46e-06	0.00208	0.41	0.3	Systemic lupus erythematosus;	chr1:174604995	chr1:174115300~174160004:-
OV	cis	rs7746199	0.736	rs10484399	ENSG00000220721.1	OR1F12	4.76	3.48e-06	0.00209	0.52	0.3	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:28073316~28074233:+
OV	cis	rs1185460	1	rs7127212	ENSG00000271751.1	RP11-110I1.14	4.76	3.48e-06	0.00209	0.4	0.3	Coronary artery disease;	chr11:119082492	chr11:119065263~119065677:-
OV	cis	rs7580658	0.521	rs35577992	ENSG00000236682.1	AC068282.3	-4.76	3.48e-06	0.00209	-0.37	-0.3	Protein C levels;	chr2:127183748	chr2:127389130~127400580:+
OV	cis	rs1113500	0.897	rs11185263	ENSG00000226822.1	RP11-356N1.2	4.76	3.48e-06	0.00209	0.35	0.3	Growth-regulated protein alpha levels;	chr1:108097182	chr1:108071482~108074519:+
OV	cis	rs227275	0.525	rs7698608	ENSG00000246560.2	RP11-10L12.4	4.76	3.49e-06	0.00209	0.33	0.3	Allergic disease (asthma, hay fever or eczema);	chr4:103016817	chr4:102828055~102844075:+
OV	cis	rs17301013	0.606	rs11802158	ENSG00000227373.4	RP11-160H22.5	4.76	3.49e-06	0.00209	0.4	0.3	Systemic lupus erythematosus;	chr1:174223973	chr1:174115300~174160004:-
OV	cis	rs6088580	0.634	rs6087580	ENSG00000206582.1	Y_RNA	4.76	3.49e-06	0.00209	0.36	0.3	Glomerular filtration rate (creatinine);	chr20:34404786	chr20:34526510~34526606:-
OV	cis	rs295490	0.748	rs58234450	ENSG00000272656.1	RP11-219D15.3	4.76	3.49e-06	0.00209	0.55	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139481465	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs114423015	ENSG00000272656.1	RP11-219D15.3	4.76	3.49e-06	0.00209	0.55	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139488980	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs80175427	ENSG00000272656.1	RP11-219D15.3	4.76	3.49e-06	0.00209	0.55	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139498904	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs17494482	ENSG00000272656.1	RP11-219D15.3	4.76	3.49e-06	0.00209	0.55	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139499028	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs2882080	ENSG00000272656.1	RP11-219D15.3	4.76	3.49e-06	0.00209	0.55	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139499109	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs2882081	ENSG00000272656.1	RP11-219D15.3	4.76	3.49e-06	0.00209	0.55	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139499427	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs7428398	ENSG00000272656.1	RP11-219D15.3	4.76	3.49e-06	0.00209	0.55	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139499687	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs77398474	ENSG00000272656.1	RP11-219D15.3	4.76	3.49e-06	0.00209	0.55	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139502307	chr3:139349024~139349371:-
OV	cis	rs2919917	0.956	rs10112388	ENSG00000254352.1	RP11-578O24.2	4.76	3.49e-06	0.00209	0.37	0.3	Lymphocyte counts;	chr8:78691512	chr8:78723796~78724136:-
OV	cis	rs2919917	1	rs6980663	ENSG00000254352.1	RP11-578O24.2	4.76	3.49e-06	0.00209	0.37	0.3	Lymphocyte counts;	chr8:78691589	chr8:78723796~78724136:-
OV	cis	rs2919917	1	rs7001074	ENSG00000254352.1	RP11-578O24.2	4.76	3.49e-06	0.00209	0.37	0.3	Lymphocyte counts;	chr8:78691689	chr8:78723796~78724136:-
OV	cis	rs11673344	0.618	rs4420645	ENSG00000226686.6	LINC01535	4.76	3.5e-06	0.0021	0.39	0.3	Obesity-related traits;	chr19:37054086	chr19:37251912~37265535:+
OV	cis	rs11673344	0.832	rs2011475	ENSG00000226686.6	LINC01535	4.76	3.5e-06	0.0021	0.39	0.3	Obesity-related traits;	chr19:37054712	chr19:37251912~37265535:+
OV	cis	rs7617773	0.817	rs13094727	ENSG00000228638.1	FCF1P2	-4.76	3.5e-06	0.0021	-0.38	-0.3	Coronary artery disease;	chr3:48281999	chr3:48290793~48291375:-
OV	cis	rs9309473	0.95	rs17009149	ENSG00000163016.8	ALMS1P	4.76	3.5e-06	0.0021	0.34	0.3	Metabolite levels;	chr2:73563241	chr2:73644919~73685576:+
OV	cis	rs17301013	0.507	rs1793320	ENSG00000227373.4	RP11-160H22.5	4.76	3.5e-06	0.0021	0.38	0.3	Systemic lupus erythematosus;	chr1:174796308	chr1:174115300~174160004:-
OV	cis	rs1150668	0.83	rs2859365	ENSG00000204709.4	LINC01556	-4.76	3.51e-06	0.0021	-0.34	-0.3	Pubertal anthropometrics;	chr6:28423688	chr6:28943877~28944537:+
OV	cis	rs2380205	0.546	rs635532	ENSG00000232807.2	RP11-536K7.3	-4.76	3.51e-06	0.0021	-0.32	-0.3	Breast cancer;	chr10:5928365	chr10:5934270~5945900:-
OV	cis	rs3758911	0.929	rs55837508	ENSG00000261098.1	RP11-819C21.1	-4.76	3.51e-06	0.0021	-0.29	-0.3	Coronary artery disease;	chr11:107323756	chr11:107312132~107316271:-
OV	cis	rs3758911	1	rs10890716	ENSG00000261098.1	RP11-819C21.1	-4.76	3.51e-06	0.0021	-0.29	-0.3	Coronary artery disease;	chr11:107324310	chr11:107312132~107316271:-
OV	cis	rs3758911	1	rs10789619	ENSG00000261098.1	RP11-819C21.1	-4.76	3.51e-06	0.0021	-0.29	-0.3	Coronary artery disease;	chr11:107324570	chr11:107312132~107316271:-
OV	cis	rs3758911	0.964	rs11212157	ENSG00000261098.1	RP11-819C21.1	-4.76	3.51e-06	0.0021	-0.29	-0.3	Coronary artery disease;	chr11:107324572	chr11:107312132~107316271:-
OV	cis	rs3758911	1	rs10749901	ENSG00000261098.1	RP11-819C21.1	-4.76	3.51e-06	0.0021	-0.29	-0.3	Coronary artery disease;	chr11:107324776	chr11:107312132~107316271:-
OV	cis	rs55704346	0.654	rs12498160	ENSG00000281501.1	SEPSECS-AS1	4.76	3.51e-06	0.0021	0.32	0.3	Tonsillectomy;	chr4:25168324	chr4:25160641~25201440:+
OV	cis	rs8062405	0.789	rs1968752	ENSG00000278665.1	RP11-666O2.4	4.76	3.52e-06	0.00211	0.31	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28599241~28601881:-
OV	cis	rs301901	0.965	rs13170811	ENSG00000250155.1	CTD-2353F22.1	-4.75	3.53e-06	0.00212	-0.35	-0.3	Height;	chr5:36795628	chr5:36666214~36725195:-
OV	cis	rs804280	0.662	rs11784693	ENSG00000270154.1	RP11-419I17.1	-4.75	3.53e-06	0.00212	-0.33	-0.3	Myopia (pathological);	chr8:11753165	chr8:12476462~12477122:+
OV	cis	rs3733585	0.699	rs6449172	ENSG00000250413.1	RP11-448G15.1	4.75	3.53e-06	0.00212	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9964412	chr4:10006482~10009725:+
OV	cis	rs875971	0.545	rs1638735	ENSG00000226824.5	RP4-756H11.3	-4.75	3.54e-06	0.00212	-0.33	-0.3	Aortic root size;	chr7:66630751	chr7:66654538~66669855:+
OV	cis	rs881375	0.967	rs1860823	ENSG00000226752.6	PSMD5-AS1	-4.75	3.54e-06	0.00212	-0.34	-0.3	Rheumatoid arthritis;	chr9:120897026	chr9:120824828~120854385:+
OV	cis	rs881375	0.967	rs1860824	ENSG00000226752.6	PSMD5-AS1	-4.75	3.54e-06	0.00212	-0.34	-0.3	Rheumatoid arthritis;	chr9:120897061	chr9:120824828~120854385:+
OV	cis	rs8100891	0.537	rs16967057	ENSG00000267213.4	AC007773.2	4.75	3.54e-06	0.00212	0.45	0.3	Neuroticism;	chr19:32423172	chr19:32390050~32405560:-
OV	cis	rs17264034	0.861	rs11749803	ENSG00000250786.1	SNHG18	4.75	3.54e-06	0.00212	0.47	0.3	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9553456	chr5:9546200~9550609:+
OV	cis	rs10759883	0.539	rs966217	ENSG00000175611.10	LINC00476	4.75	3.54e-06	0.00212	0.37	0.3	Nicotine dependence;	chr9:95943247	chr9:95759231~95875977:-
OV	cis	rs4591358	0.571	rs4850366	ENSG00000223466.1	AC064834.2	-4.75	3.55e-06	0.00213	-0.36	-0.3	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195538742	chr2:195533035~195538681:+
OV	cis	rs3733585	0.699	rs6852441	ENSG00000250413.1	RP11-448G15.1	4.75	3.56e-06	0.00213	0.34	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9972120	chr4:10006482~10009725:+
OV	cis	rs1862618	0.511	rs2591952	ENSG00000271828.1	CTD-2310F14.1	4.75	3.56e-06	0.00213	0.47	0.3	Initial pursuit acceleration;	chr5:56824942	chr5:56927874~56929573:+
OV	cis	rs4718428	1	rs868961	ENSG00000226824.5	RP4-756H11.3	-4.75	3.56e-06	0.00213	-0.37	-0.3	Corneal structure;	chr7:66972221	chr7:66654538~66669855:+
OV	cis	rs12073359	0.955	rs1105209	ENSG00000223945.2	RP11-458I7.1	4.75	3.56e-06	0.00213	0.44	0.3	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150180625	chr1:150053864~150055034:+
OV	cis	rs6772849	0.93	rs4857914	ENSG00000242551.2	POU5F1P6	-4.75	3.57e-06	0.00213	-0.35	-0.3	Monocyte percentage of white cells;Monocyte count;	chr3:128631841	chr3:128674735~128677005:-
OV	cis	rs733592	0.507	rs3825403	ENSG00000258273.1	RP11-370I10.4	4.75	3.57e-06	0.00213	0.37	0.3	Plateletcrit;	chr12:48063376	chr12:48333755~48333901:-
OV	cis	rs4805272	1	rs4805276	ENSG00000267243.4	AC005307.3	-4.75	3.57e-06	0.00214	-0.41	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28836987	chr19:28435388~28727777:-
OV	cis	rs8062405	0.69	rs4787458	ENSG00000278665.1	RP11-666O2.4	4.75	3.57e-06	0.00214	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28599241~28601881:-
OV	cis	rs301901	1	rs13176880	ENSG00000250155.1	CTD-2353F22.1	-4.75	3.58e-06	0.00214	-0.36	-0.3	Height;	chr5:37081780	chr5:36666214~36725195:-
OV	cis	rs1528149	0.504	rs10227232	ENSG00000224683.1	RPL36AP29	-4.75	3.58e-06	0.00214	-0.35	-0.3	Sitting height ratio;	chr7:16138475	chr7:16208945~16209265:+
OV	cis	rs8005677	0.828	rs8016027	ENSG00000279656.1	RP11-298I3.6	4.75	3.59e-06	0.00214	0.34	0.3	Cognitive ability (multi-trait analysis);	chr14:22950944	chr14:23023083~23024217:-
OV	cis	rs2253762	0.54	rs75670246	ENSG00000276742.1	RP11-500G22.4	4.75	3.59e-06	0.00215	0.51	0.3	Breast cancer;	chr10:122032687	chr10:121956782~121957098:+
OV	cis	rs8062405	0.964	rs62036614	ENSG00000278665.1	RP11-666O2.4	4.75	3.59e-06	0.00215	0.33	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28599241~28601881:-
OV	cis	rs1062177	0.901	rs1549622	ENSG00000253921.1	CTB-113P19.3	-4.75	3.6e-06	0.00215	-0.42	-0.3	Preschool internalizing problems;	chr5:151886488	chr5:151753992~151767247:+
OV	cis	rs17301013	0.507	rs4652460	ENSG00000227373.4	RP11-160H22.5	4.75	3.61e-06	0.00215	0.39	0.3	Systemic lupus erythematosus;	chr1:174459499	chr1:174115300~174160004:-
OV	cis	rs1061377	0.748	rs12649085	ENSG00000249207.1	RP11-360F5.1	-4.75	3.61e-06	0.00215	-0.32	-0.3	Uric acid levels;	chr4:39106459	chr4:39112677~39126818:-
OV	cis	rs17301013	0.507	rs34409674	ENSG00000227373.4	RP11-160H22.5	-4.75	3.61e-06	0.00216	-0.4	-0.3	Systemic lupus erythematosus;	chr1:174560246	chr1:174115300~174160004:-
OV	cis	rs172166	0.694	rs203893	ENSG00000280107.1	AL022393.9	-4.75	3.62e-06	0.00216	-0.35	-0.3	Cardiac Troponin-T levels;	chr6:28094288	chr6:28170845~28172521:+
OV	cis	rs172166	0.652	rs476167	ENSG00000280107.1	AL022393.9	-4.75	3.62e-06	0.00216	-0.35	-0.3	Cardiac Troponin-T levels;	chr6:28098110	chr6:28170845~28172521:+
OV	cis	rs172166	0.694	rs203892	ENSG00000280107.1	AL022393.9	-4.75	3.62e-06	0.00216	-0.35	-0.3	Cardiac Troponin-T levels;	chr6:28099418	chr6:28170845~28172521:+
OV	cis	rs301901	0.766	rs12521993	ENSG00000250155.1	CTD-2353F22.1	4.75	3.62e-06	0.00216	0.35	0.3	Height;	chr5:37488095	chr5:36666214~36725195:-
OV	cis	rs301901	0.662	rs7726960	ENSG00000250155.1	CTD-2353F22.1	4.75	3.62e-06	0.00216	0.35	0.3	Height;	chr5:37490184	chr5:36666214~36725195:-
OV	cis	rs11096990	0.634	rs2276888	ENSG00000249207.1	RP11-360F5.1	4.75	3.62e-06	0.00216	0.31	0.3	Cognitive function;	chr4:39278287	chr4:39112677~39126818:-
OV	cis	rs2284219	0.565	rs2284217	ENSG00000226874.1	AC005154.8	-4.75	3.63e-06	0.00216	-0.36	-0.3	Type 2 diabetes;	chr7:30673992	chr7:30544053~30544431:+
OV	cis	rs61160187	0.583	rs6449503	ENSG00000272308.1	RP11-231G3.1	4.75	3.63e-06	0.00217	0.34	0.3	Educational attainment (years of education);Educational attainment (college completion);	chr5:60799445	chr5:60866457~60866935:-
OV	cis	rs4713118	0.513	rs149975	ENSG00000219392.1	RP1-265C24.5	-4.75	3.63e-06	0.00217	-0.37	-0.3	Parkinson's disease;	chr6:28018562	chr6:28115628~28116551:+
OV	cis	rs4713118	0.869	rs9283883	ENSG00000280107.1	AL022393.9	-4.75	3.64e-06	0.00217	-0.35	-0.3	Parkinson's disease;	chr6:27747691	chr6:28170845~28172521:+
OV	cis	rs4713118	0.955	rs9468201	ENSG00000219392.1	RP1-265C24.5	-4.75	3.64e-06	0.00217	-0.36	-0.3	Parkinson's disease;	chr6:27719256	chr6:28115628~28116551:+
OV	cis	rs1134634	0.52	rs11943107	ENSG00000273133.1	RP11-799M12.2	-4.75	3.65e-06	0.00218	-0.4	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15573042	chr4:15563698~15564253:-
OV	cis	rs1140227	0.502	rs10789304	ENSG00000235358.1	RP11-399E6.1	4.75	3.65e-06	0.00218	0.45	0.3	Intelligence (multi-trait analysis);	chr1:41121740	chr1:41242373~41284861:+
OV	cis	rs875971	0.798	rs57739047	ENSG00000236529.1	RP13-254B10.1	4.75	3.66e-06	0.00218	0.31	0.3	Aortic root size;	chr7:66507579	chr7:65840212~65840596:+
OV	cis	rs875971	0.83	rs6950137	ENSG00000236529.1	RP13-254B10.1	4.75	3.66e-06	0.00218	0.31	0.3	Aortic root size;	chr7:66511623	chr7:65840212~65840596:+
OV	cis	rs17301013	0.507	rs392307	ENSG00000227373.4	RP11-160H22.5	4.75	3.66e-06	0.00218	0.39	0.3	Systemic lupus erythematosus;	chr1:174744243	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs3117838	ENSG00000227373.4	RP11-160H22.5	4.75	3.66e-06	0.00218	0.39	0.3	Systemic lupus erythematosus;	chr1:174749205	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs1923818	ENSG00000227373.4	RP11-160H22.5	4.75	3.66e-06	0.00218	0.39	0.3	Systemic lupus erythematosus;	chr1:174749737	chr1:174115300~174160004:-
OV	cis	rs116095464	0.558	rs7725227	ENSG00000250848.1	CTD-2083E4.5	-4.75	3.66e-06	0.00218	-0.37	-0.3	Breast cancer;	chr5:233402	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs7710005	ENSG00000250848.1	CTD-2083E4.5	-4.75	3.66e-06	0.00218	-0.37	-0.3	Breast cancer;	chr5:233457	chr5:288833~290321:-
OV	cis	rs116095464	0.681	rs10060016	ENSG00000250848.1	CTD-2083E4.5	-4.75	3.67e-06	0.00218	-0.37	-0.3	Breast cancer;	chr5:240985	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs10057299	ENSG00000250848.1	CTD-2083E4.5	-4.75	3.67e-06	0.00218	-0.37	-0.3	Breast cancer;	chr5:242020	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs13354585	ENSG00000250848.1	CTD-2083E4.5	-4.75	3.67e-06	0.00218	-0.37	-0.3	Breast cancer;	chr5:242148	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs13356367	ENSG00000250848.1	CTD-2083E4.5	-4.75	3.67e-06	0.00218	-0.37	-0.3	Breast cancer;	chr5:242280	chr5:288833~290321:-
OV	cis	rs116095464	0.85	rs10055295	ENSG00000250848.1	CTD-2083E4.5	-4.75	3.67e-06	0.00218	-0.37	-0.3	Breast cancer;	chr5:243634	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs10055354	ENSG00000250848.1	CTD-2083E4.5	-4.75	3.67e-06	0.00218	-0.37	-0.3	Breast cancer;	chr5:243679	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs60251075	ENSG00000250848.1	CTD-2083E4.5	-4.75	3.67e-06	0.00218	-0.37	-0.3	Breast cancer;	chr5:245177	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs62344300	ENSG00000250848.1	CTD-2083E4.5	-4.75	3.67e-06	0.00218	-0.37	-0.3	Breast cancer;	chr5:246221	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs10462754	ENSG00000250848.1	CTD-2083E4.5	-4.75	3.67e-06	0.00218	-0.37	-0.3	Breast cancer;	chr5:246554	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs10462755	ENSG00000250848.1	CTD-2083E4.5	-4.75	3.67e-06	0.00218	-0.37	-0.3	Breast cancer;	chr5:246633	chr5:288833~290321:-
OV	cis	rs6772849	1	rs9848975	ENSG00000242551.2	POU5F1P6	-4.75	3.67e-06	0.00219	-0.36	-0.3	Monocyte percentage of white cells;Monocyte count;	chr3:128593140	chr3:128674735~128677005:-
OV	cis	rs1075265	0.68	rs6715488	ENSG00000233266.1	HMGB1P31	4.75	3.67e-06	0.00219	0.37	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54004130	chr2:54051334~54051760:+
OV	cis	rs3733585	0.638	rs7377625	ENSG00000250413.1	RP11-448G15.1	4.75	3.68e-06	0.00219	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9951475	chr4:10006482~10009725:+
OV	cis	rs172166	0.694	rs188105	ENSG00000280107.1	AL022393.9	-4.75	3.68e-06	0.00219	-0.35	-0.3	Cardiac Troponin-T levels;	chr6:28103615	chr6:28170845~28172521:+
OV	cis	rs67311347	0.869	rs9832311	ENSG00000223797.4	ENTPD3-AS1	4.75	3.68e-06	0.00219	0.33	0.3	Renal cell carcinoma;	chr3:40339831	chr3:40313802~40453329:-
OV	cis	rs57502260	0.79	rs7128942	ENSG00000212093.1	AP000807.1	4.75	3.69e-06	0.00219	0.46	0.3	Total body bone mineral density (age 45-60);	chr11:68620516	chr11:68506083~68506166:-
OV	cis	rs9979383	0.538	rs2242734	ENSG00000228107.1	AP000692.9	-4.75	3.69e-06	0.00219	-0.3	-0.3	Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr21:35417281	chr21:36360630~36362040:+
OV	cis	rs8062405	0.965	rs56040780	ENSG00000278665.1	RP11-666O2.4	4.74	3.69e-06	0.0022	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850560	chr16:28599241~28601881:-
OV	cis	rs2253762	0.54	rs11200357	ENSG00000276742.1	RP11-500G22.4	4.74	3.69e-06	0.0022	0.51	0.3	Breast cancer;	chr10:122034390	chr10:121956782~121957098:+
OV	cis	rs7927592	0.913	rs7123564	ENSG00000212093.1	AP000807.1	4.74	3.69e-06	0.0022	0.39	0.3	Total body bone mineral density;	chr11:68594696	chr11:68506083~68506166:-
OV	cis	rs301901	0.514	rs10073063	ENSG00000250155.1	CTD-2353F22.1	-4.74	3.7e-06	0.0022	-0.38	-0.3	Height;	chr5:37259873	chr5:36666214~36725195:-
OV	cis	rs1862618	0.802	rs832560	ENSG00000271828.1	CTD-2310F14.1	4.74	3.7e-06	0.0022	0.46	0.3	Initial pursuit acceleration;	chr5:56828596	chr5:56927874~56929573:+
OV	cis	rs9291683	0.53	rs17246501	ENSG00000250413.1	RP11-448G15.1	-4.74	3.7e-06	0.0022	-0.32	-0.3	Bone mineral density;	chr4:9984086	chr4:10006482~10009725:+
OV	cis	rs1426063	0.614	rs17000264	ENSG00000260265.1	RP11-44F21.5	4.74	3.7e-06	0.0022	0.57	0.3	QT interval;	chr4:75108962	chr4:75081702~75084717:-
OV	cis	rs8062405	1	rs3088215	ENSG00000278665.1	RP11-666O2.4	4.74	3.71e-06	0.0022	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28842675	chr16:28599241~28601881:-
OV	cis	rs8062405	1	rs28403629	ENSG00000278665.1	RP11-666O2.4	4.74	3.71e-06	0.0022	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28843448	chr16:28599241~28601881:-
OV	cis	rs8062405	1	rs61737565	ENSG00000278665.1	RP11-666O2.4	4.74	3.71e-06	0.0022	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844201	chr16:28599241~28601881:-
OV	cis	rs8062405	1	rs4788099	ENSG00000278665.1	RP11-666O2.4	4.74	3.71e-06	0.0022	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28844406	chr16:28599241~28601881:-
OV	cis	rs8062405	1	rs9972693	ENSG00000278665.1	RP11-666O2.4	4.74	3.71e-06	0.0022	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28848481	chr16:28599241~28601881:-
OV	cis	rs8062405	0.964	rs9972768	ENSG00000278665.1	RP11-666O2.4	4.74	3.71e-06	0.0022	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28850413	chr16:28599241~28601881:-
OV	cis	rs8062405	0.965	rs62037363	ENSG00000278665.1	RP11-666O2.4	4.74	3.71e-06	0.0022	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28853721	chr16:28599241~28601881:-
OV	cis	rs8062405	1	rs7205323	ENSG00000278665.1	RP11-666O2.4	4.74	3.71e-06	0.0022	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28854571	chr16:28599241~28601881:-
OV	cis	rs8062405	1	rs4788101	ENSG00000278665.1	RP11-666O2.4	4.74	3.71e-06	0.0022	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28856483	chr16:28599241~28601881:-
OV	cis	rs8062405	1	rs62037364	ENSG00000278665.1	RP11-666O2.4	4.74	3.71e-06	0.0022	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857374	chr16:28599241~28601881:-
OV	cis	rs8062405	1	rs62037365	ENSG00000278665.1	RP11-666O2.4	4.74	3.71e-06	0.0022	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28857641	chr16:28599241~28601881:-
OV	cis	rs8062405	0.929	rs11150609	ENSG00000278665.1	RP11-666O2.4	4.74	3.71e-06	0.0022	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28859275	chr16:28599241~28601881:-
OV	cis	rs8062405	0.737	rs11861132	ENSG00000278665.1	RP11-666O2.4	4.74	3.71e-06	0.0022	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860539	chr16:28599241~28601881:-
OV	cis	rs8062405	1	rs11861174	ENSG00000278665.1	RP11-666O2.4	4.74	3.71e-06	0.0022	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28860668	chr16:28599241~28601881:-
OV	cis	rs8062405	1	rs4788102	ENSG00000278665.1	RP11-666O2.4	4.74	3.71e-06	0.0022	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28862077	chr16:28599241~28601881:-
OV	cis	rs8062405	1	rs62037367	ENSG00000278665.1	RP11-666O2.4	4.74	3.71e-06	0.0022	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863226	chr16:28599241~28601881:-
OV	cis	rs8062405	1	rs7198606	ENSG00000278665.1	RP11-666O2.4	4.74	3.71e-06	0.0022	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863801	chr16:28599241~28601881:-
OV	cis	rs8062405	0.929	rs11864750	ENSG00000278665.1	RP11-666O2.4	4.74	3.71e-06	0.0022	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28863883	chr16:28599241~28601881:-
OV	cis	rs8062405	0.964	rs7193733	ENSG00000278665.1	RP11-666O2.4	4.74	3.71e-06	0.0022	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28864161	chr16:28599241~28601881:-
OV	cis	rs8062405	1	rs8055982	ENSG00000278665.1	RP11-666O2.4	4.74	3.71e-06	0.0022	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28869881	chr16:28599241~28601881:-
OV	cis	rs8062405	1	rs7498665	ENSG00000278665.1	RP11-666O2.4	4.74	3.71e-06	0.0022	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28871920	chr16:28599241~28601881:-
OV	cis	rs8062405	0.964	rs11864107	ENSG00000278665.1	RP11-666O2.4	4.74	3.71e-06	0.0022	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28874610	chr16:28599241~28601881:-
OV	cis	rs1113500	0.933	rs10881498	ENSG00000226822.1	RP11-356N1.2	4.74	3.71e-06	0.0022	0.36	0.3	Growth-regulated protein alpha levels;	chr1:108092362	chr1:108071482~108074519:+
OV	cis	rs3758911	0.861	rs11212163	ENSG00000261098.1	RP11-819C21.1	-4.74	3.71e-06	0.00221	-0.3	-0.3	Coronary artery disease;	chr11:107328005	chr11:107312132~107316271:-
OV	cis	rs4908768	0.871	rs4908775	ENSG00000228423.2	RP4-633I8.4	4.74	3.72e-06	0.00221	0.36	0.3	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8734351	chr1:8805860~8807051:-
OV	cis	rs67311347	0.577	rs11712626	ENSG00000223797.4	ENTPD3-AS1	4.74	3.72e-06	0.00221	0.32	0.3	Renal cell carcinoma;	chr3:40218436	chr3:40313802~40453329:-
OV	cis	rs67311347	0.577	rs11129870	ENSG00000223797.4	ENTPD3-AS1	4.74	3.72e-06	0.00221	0.32	0.3	Renal cell carcinoma;	chr3:40218915	chr3:40313802~40453329:-
OV	cis	rs1528149	0.504	rs6943936	ENSG00000224683.1	RPL36AP29	-4.74	3.72e-06	0.00221	-0.34	-0.3	Sitting height ratio;	chr7:16128648	chr7:16208945~16209265:+
OV	cis	rs1528149	0.504	rs6968537	ENSG00000224683.1	RPL36AP29	-4.74	3.72e-06	0.00221	-0.34	-0.3	Sitting height ratio;	chr7:16129083	chr7:16208945~16209265:+
OV	cis	rs1723838	0.59	rs7396121	ENSG00000255928.1	RP11-456I15.2	4.74	3.72e-06	0.00221	0.7	0.3	Obesity-related traits;	chr11:73691025	chr11:73722349~73722694:+
OV	cis	rs1723838	0.826	rs77411374	ENSG00000255928.1	RP11-456I15.2	4.74	3.72e-06	0.00221	0.7	0.3	Obesity-related traits;	chr11:73785245	chr11:73722349~73722694:+
OV	cis	rs1150668	0.768	rs1150716	ENSG00000204709.4	LINC01556	4.74	3.72e-06	0.00221	0.35	0.3	Pubertal anthropometrics;	chr6:28294921	chr6:28943877~28944537:+
OV	cis	rs301901	0.828	rs62361485	ENSG00000250155.1	CTD-2353F22.1	4.74	3.72e-06	0.00221	0.35	0.3	Height;	chr5:37474739	chr5:36666214~36725195:-
OV	cis	rs301901	0.828	rs56007618	ENSG00000250155.1	CTD-2353F22.1	4.74	3.72e-06	0.00221	0.35	0.3	Height;	chr5:37475788	chr5:36666214~36725195:-
OV	cis	rs301901	0.828	rs55731764	ENSG00000250155.1	CTD-2353F22.1	4.74	3.72e-06	0.00221	0.35	0.3	Height;	chr5:37475789	chr5:36666214~36725195:-
OV	cis	rs875971	1	rs778726	ENSG00000236529.1	RP13-254B10.1	4.74	3.72e-06	0.00221	0.31	0.3	Aortic root size;	chr7:66363744	chr7:65840212~65840596:+
OV	cis	rs875971	0.964	rs778723	ENSG00000236529.1	RP13-254B10.1	4.74	3.72e-06	0.00221	0.31	0.3	Aortic root size;	chr7:66364510	chr7:65840212~65840596:+
OV	cis	rs875971	0.767	rs1695815	ENSG00000236529.1	RP13-254B10.1	4.74	3.72e-06	0.00221	0.31	0.3	Aortic root size;	chr7:66366357	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs778685	ENSG00000236529.1	RP13-254B10.1	4.74	3.72e-06	0.00221	0.31	0.3	Aortic root size;	chr7:66371189	chr7:65840212~65840596:+
OV	cis	rs875971	0.929	rs778682	ENSG00000236529.1	RP13-254B10.1	4.74	3.72e-06	0.00221	0.31	0.3	Aortic root size;	chr7:66372947	chr7:65840212~65840596:+
OV	cis	rs875971	0.964	rs11765965	ENSG00000236529.1	RP13-254B10.1	4.74	3.72e-06	0.00221	0.31	0.3	Aortic root size;	chr7:66377234	chr7:65840212~65840596:+
OV	cis	rs875971	0.964	rs1643388	ENSG00000236529.1	RP13-254B10.1	4.74	3.72e-06	0.00221	0.31	0.3	Aortic root size;	chr7:66379575	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs778722	ENSG00000236529.1	RP13-254B10.1	4.74	3.72e-06	0.00221	0.31	0.3	Aortic root size;	chr7:66379841	chr7:65840212~65840596:+
OV	cis	rs875971	0.964	rs778721	ENSG00000236529.1	RP13-254B10.1	4.74	3.72e-06	0.00221	0.31	0.3	Aortic root size;	chr7:66380410	chr7:65840212~65840596:+
OV	cis	rs875971	0.929	rs778712	ENSG00000236529.1	RP13-254B10.1	4.74	3.72e-06	0.00221	0.31	0.3	Aortic root size;	chr7:66384991	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs778710	ENSG00000236529.1	RP13-254B10.1	4.74	3.72e-06	0.00221	0.31	0.3	Aortic root size;	chr7:66389847	chr7:65840212~65840596:+
OV	cis	rs875971	0.964	rs778708	ENSG00000236529.1	RP13-254B10.1	4.74	3.72e-06	0.00221	0.31	0.3	Aortic root size;	chr7:66391332	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs778706	ENSG00000236529.1	RP13-254B10.1	4.74	3.72e-06	0.00221	0.31	0.3	Aortic root size;	chr7:66395437	chr7:65840212~65840596:+
OV	cis	rs875971	0.895	rs778700	ENSG00000236529.1	RP13-254B10.1	4.74	3.72e-06	0.00221	0.31	0.3	Aortic root size;	chr7:66401463	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs778699	ENSG00000236529.1	RP13-254B10.1	4.74	3.72e-06	0.00221	0.31	0.3	Aortic root size;	chr7:66403303	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs778696	ENSG00000236529.1	RP13-254B10.1	4.74	3.72e-06	0.00221	0.31	0.3	Aortic root size;	chr7:66405826	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs778694	ENSG00000236529.1	RP13-254B10.1	4.74	3.72e-06	0.00221	0.31	0.3	Aortic root size;	chr7:66406571	chr7:65840212~65840596:+
OV	cis	rs875971	0.929	rs778692	ENSG00000236529.1	RP13-254B10.1	4.74	3.72e-06	0.00221	0.31	0.3	Aortic root size;	chr7:66407462	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs4718343	ENSG00000236529.1	RP13-254B10.1	4.74	3.72e-06	0.00221	0.31	0.3	Aortic root size;	chr7:66409301	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs4718344	ENSG00000236529.1	RP13-254B10.1	4.74	3.72e-06	0.00221	0.31	0.3	Aortic root size;	chr7:66409394	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs1968225	ENSG00000236529.1	RP13-254B10.1	4.74	3.72e-06	0.00221	0.31	0.3	Aortic root size;	chr7:66409786	chr7:65840212~65840596:+
OV	cis	rs875971	0.737	rs7803424	ENSG00000236529.1	RP13-254B10.1	4.74	3.72e-06	0.00221	0.31	0.3	Aortic root size;	chr7:66415618	chr7:65840212~65840596:+
OV	cis	rs875971	0.83	rs7799834	ENSG00000236529.1	RP13-254B10.1	4.74	3.72e-06	0.00221	0.31	0.3	Aortic root size;	chr7:66415707	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs6460295	ENSG00000236529.1	RP13-254B10.1	4.74	3.72e-06	0.00221	0.31	0.3	Aortic root size;	chr7:66417741	chr7:65840212~65840596:+
OV	cis	rs875971	0.964	rs6978721	ENSG00000236529.1	RP13-254B10.1	4.74	3.72e-06	0.00221	0.31	0.3	Aortic root size;	chr7:66418217	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs6979382	ENSG00000236529.1	RP13-254B10.1	4.74	3.72e-06	0.00221	0.31	0.3	Aortic root size;	chr7:66421388	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs6961990	ENSG00000236529.1	RP13-254B10.1	4.74	3.72e-06	0.00221	0.31	0.3	Aortic root size;	chr7:66423583	chr7:65840212~65840596:+
OV	cis	rs10829156	0.898	rs10741120	ENSG00000225527.1	RP11-383B4.4	-4.74	3.72e-06	0.00221	-0.42	-0.3	Sudden cardiac arrest;	chr10:18641063	chr10:18531849~18533336:-
OV	cis	rs9309473	0.95	rs6735946	ENSG00000163016.8	ALMS1P	4.74	3.72e-06	0.00221	0.34	0.3	Metabolite levels;	chr2:73562931	chr2:73644919~73685576:+
OV	cis	rs7580658	0.545	rs885276	ENSG00000236682.1	AC068282.3	-4.74	3.73e-06	0.00221	-0.37	-0.3	Protein C levels;	chr2:127193328	chr2:127389130~127400580:+
OV	cis	rs11673344	0.764	rs547483	ENSG00000226686.6	LINC01535	-4.74	3.74e-06	0.00222	-0.37	-0.3	Obesity-related traits;	chr19:36950463	chr19:37251912~37265535:+
OV	cis	rs11159086	0.793	rs1029701	ENSG00000270000.1	RP3-449M8.9	4.74	3.74e-06	0.00222	0.43	0.3	Advanced glycation end-product levels;	chr14:74474112	chr14:74471930~74472360:-
OV	cis	rs1797885	0.564	rs2454435	ENSG00000251774.1	RNU6-377P	4.74	3.74e-06	0.00222	0.29	0.3	Immature fraction of reticulocytes;	chr3:12544741	chr3:12514706~12514807:+
OV	cis	rs853679	0.599	rs202906	ENSG00000280107.1	AL022393.9	4.74	3.74e-06	0.00222	0.48	0.3	Depression;	chr6:28043874	chr6:28170845~28172521:+
OV	cis	rs1862618	0.853	rs2432195	ENSG00000271828.1	CTD-2310F14.1	4.74	3.74e-06	0.00222	0.46	0.3	Initial pursuit acceleration;	chr5:56824586	chr5:56927874~56929573:+
OV	cis	rs73201462	1	rs10934850	ENSG00000277250.1	Metazoa_SRP	4.74	3.74e-06	0.00222	0.46	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128168114	chr3:128673681~128674021:-
OV	cis	rs1823913	0.599	rs67342262	ENSG00000227542.1	AC092614.2	4.74	3.75e-06	0.00222	0.33	0.3	Obesity-related traits;	chr2:191295612	chr2:191229165~191246172:-
OV	cis	rs3733585	0.699	rs7676733	ENSG00000250413.1	RP11-448G15.1	4.74	3.75e-06	0.00222	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9965332	chr4:10006482~10009725:+
OV	cis	rs3733585	0.699	rs10017674	ENSG00000250413.1	RP11-448G15.1	4.74	3.75e-06	0.00222	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9965429	chr4:10006482~10009725:+
OV	cis	rs3733585	0.673	rs7434391	ENSG00000250413.1	RP11-448G15.1	4.74	3.75e-06	0.00222	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9966058	chr4:10006482~10009725:+
OV	cis	rs3733585	0.699	rs6449176	ENSG00000250413.1	RP11-448G15.1	4.74	3.75e-06	0.00222	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9966219	chr4:10006482~10009725:+
OV	cis	rs3733585	0.699	rs6449179	ENSG00000250413.1	RP11-448G15.1	4.74	3.75e-06	0.00222	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9967493	chr4:10006482~10009725:+
OV	cis	rs3733585	0.699	rs7677710	ENSG00000250413.1	RP11-448G15.1	4.74	3.75e-06	0.00222	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9967893	chr4:10006482~10009725:+
OV	cis	rs7259965	0.839	rs1872125	ENSG00000277744.1	CTC-435M10.12	-4.74	3.75e-06	0.00222	-0.28	-0.3	Midgestational circulating levels of organochlorine pesticides;Midgestational circulating levels of PBDEs;	chr19:40995811	chr19:41373971~41374419:+
OV	cis	rs13068223	0.584	rs345986	ENSG00000243926.1	TIPARP-AS1	-4.74	3.76e-06	0.00223	-0.29	-0.3	Age-related hearing impairment (SNP x SNP interaction);	chr3:156677540	chr3:156671862~156674378:-
OV	cis	rs11157436	0.958	rs17255510	ENSG00000211812.1	TRAV26-2	4.74	3.76e-06	0.00223	0.34	0.3	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22194962	chr14:22202583~22203368:+
OV	cis	rs2239620	0.838	rs9370135	ENSG00000216775.2	RP1-152L7.5	-4.74	3.76e-06	0.00223	-0.3	-0.3	LDL cholesterol levels;	chr6:52589187	chr6:52665148~52669155:+
OV	cis	rs1113500	0.933	rs10785834	ENSG00000226822.1	RP11-356N1.2	4.74	3.77e-06	0.00223	0.36	0.3	Growth-regulated protein alpha levels;	chr1:108096479	chr1:108071482~108074519:+
OV	cis	rs1150668	0.768	rs1150709	ENSG00000220721.1	OR1F12	-4.74	3.77e-06	0.00223	-0.3	-0.3	Pubertal anthropometrics;	chr6:28239585	chr6:28073316~28074233:+
OV	cis	rs514406	0.893	rs512723	ENSG00000206627.1	RNU6-969P	-4.74	3.77e-06	0.00223	-0.31	-0.3	Monocyte count;	chr1:52878208	chr1:52805108~52805212:-
OV	cis	rs7201929	1	rs7201929	ENSG00000259982.1	CDC37P1	4.74	3.78e-06	0.00224	0.37	0.3	QT interval;	chr16:28860645	chr16:28700294~28701540:-
OV	cis	rs17301013	0.507	rs398350	ENSG00000227373.4	RP11-160H22.5	4.74	3.79e-06	0.00224	0.38	0.3	Systemic lupus erythematosus;	chr1:174706168	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs3117843	ENSG00000227373.4	RP11-160H22.5	4.74	3.79e-06	0.00224	0.38	0.3	Systemic lupus erythematosus;	chr1:174711581	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs332786	ENSG00000227373.4	RP11-160H22.5	4.74	3.79e-06	0.00224	0.38	0.3	Systemic lupus erythematosus;	chr1:174713584	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs332779	ENSG00000227373.4	RP11-160H22.5	4.74	3.79e-06	0.00224	0.38	0.3	Systemic lupus erythematosus;	chr1:174716623	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs332781	ENSG00000227373.4	RP11-160H22.5	4.74	3.79e-06	0.00224	0.38	0.3	Systemic lupus erythematosus;	chr1:174718483	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs193082	ENSG00000227373.4	RP11-160H22.5	4.74	3.79e-06	0.00224	0.38	0.3	Systemic lupus erythematosus;	chr1:174725439	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs2568098	ENSG00000227373.4	RP11-160H22.5	4.74	3.79e-06	0.00224	0.38	0.3	Systemic lupus erythematosus;	chr1:174732183	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs460878	ENSG00000227373.4	RP11-160H22.5	4.74	3.79e-06	0.00224	0.38	0.3	Systemic lupus erythematosus;	chr1:174732645	chr1:174115300~174160004:-
OV	cis	rs3733585	0.664	rs17185870	ENSG00000250413.1	RP11-448G15.1	4.74	3.79e-06	0.00224	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9956590	chr4:10006482~10009725:+
OV	cis	rs17301013	0.507	rs2568096	ENSG00000227373.4	RP11-160H22.5	4.74	3.8e-06	0.00225	0.38	0.3	Systemic lupus erythematosus;	chr1:174735463	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs333436	ENSG00000227373.4	RP11-160H22.5	4.74	3.8e-06	0.00225	0.38	0.3	Systemic lupus erythematosus;	chr1:174739069	chr1:174115300~174160004:-
OV	cis	rs875971	0.545	rs1638724	ENSG00000236529.1	RP13-254B10.1	-4.74	3.8e-06	0.00225	-0.36	-0.3	Aortic root size;	chr7:66575494	chr7:65840212~65840596:+
OV	cis	rs11673344	0.864	rs12151313	ENSG00000226686.6	LINC01535	4.74	3.8e-06	0.00225	0.39	0.3	Obesity-related traits;	chr19:37072309	chr19:37251912~37265535:+
OV	cis	rs295490	0.748	rs17394620	ENSG00000272656.1	RP11-219D15.3	4.74	3.8e-06	0.00225	0.59	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139348541	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs17316181	ENSG00000272656.1	RP11-219D15.3	4.74	3.8e-06	0.00225	0.59	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139350851	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs61613889	ENSG00000272656.1	RP11-219D15.3	4.74	3.8e-06	0.00225	0.59	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139352279	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs59958973	ENSG00000272656.1	RP11-219D15.3	4.74	3.8e-06	0.00225	0.59	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139352385	chr3:139349024~139349371:-
OV	cis	rs1723838	0.826	rs118089862	ENSG00000255928.1	RP11-456I15.2	4.74	3.8e-06	0.00225	0.7	0.3	Obesity-related traits;	chr11:73717724	chr11:73722349~73722694:+
OV	cis	rs1075265	0.811	rs805322	ENSG00000233266.1	HMGB1P31	-4.74	3.8e-06	0.00225	-0.4	-0.3	Chronotype;Morning vs. evening chronotype;	chr2:53912758	chr2:54051334~54051760:+
OV	cis	rs3733585	0.725	rs6449201	ENSG00000250413.1	RP11-448G15.1	4.74	3.8e-06	0.00225	0.34	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9972270	chr4:10006482~10009725:+
OV	cis	rs796364	0.906	rs6740981	ENSG00000232732.8	AC073043.1	-4.74	3.81e-06	0.00225	-0.39	-0.3	Schizophrenia;	chr2:200195493	chr2:199867396~199911159:-
OV	cis	rs796364	0.901	rs13030683	ENSG00000232732.8	AC073043.1	-4.74	3.81e-06	0.00225	-0.39	-0.3	Schizophrenia;	chr2:200196812	chr2:199867396~199911159:-
OV	cis	rs796364	0.951	rs11897245	ENSG00000232732.8	AC073043.1	-4.74	3.81e-06	0.00225	-0.39	-0.3	Schizophrenia;	chr2:200198921	chr2:199867396~199911159:-
OV	cis	rs8027521	0.936	rs1478175	ENSG00000280362.1	RP11-643A5.3	4.74	3.82e-06	0.00226	0.36	0.3	Circulating chemerin levels;	chr15:53964529	chr15:53910769~53914712:+
OV	cis	rs4664293	0.585	rs13019325	ENSG00000226266.5	AC009961.3	4.74	3.82e-06	0.00226	0.36	0.3	Monocyte percentage of white cells;	chr2:159772479	chr2:159670708~159712435:-
OV	cis	rs17301013	0.606	rs6676161	ENSG00000227373.4	RP11-160H22.5	4.74	3.82e-06	0.00226	0.39	0.3	Systemic lupus erythematosus;	chr1:174138555	chr1:174115300~174160004:-
OV	cis	rs7429990	0.76	rs319694	ENSG00000229759.1	MRPS18AP1	4.74	3.82e-06	0.00226	0.32	0.3	Educational attainment (years of education);	chr3:47843463	chr3:48256350~48256938:-
OV	cis	rs853679	0.599	rs149949	ENSG00000280107.1	AL022393.9	-4.74	3.82e-06	0.00226	-0.51	-0.3	Depression;	chr6:28043738	chr6:28170845~28172521:+
OV	cis	rs875971	1	rs937495	ENSG00000236529.1	RP13-254B10.1	-4.74	3.83e-06	0.00226	-0.31	-0.3	Aortic root size;	chr7:66314811	chr7:65840212~65840596:+
OV	cis	rs875971	0.965	rs9969301	ENSG00000236529.1	RP13-254B10.1	-4.74	3.83e-06	0.00226	-0.31	-0.3	Aortic root size;	chr7:66316668	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs2036264	ENSG00000236529.1	RP13-254B10.1	-4.74	3.83e-06	0.00226	-0.31	-0.3	Aortic root size;	chr7:66334917	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs7783613	ENSG00000236529.1	RP13-254B10.1	-4.74	3.83e-06	0.00226	-0.31	-0.3	Aortic root size;	chr7:66340274	chr7:65840212~65840596:+
OV	cis	rs10510102	0.507	rs12244092	ENSG00000276742.1	RP11-500G22.4	4.74	3.83e-06	0.00226	0.53	0.3	Breast cancer;	chr10:122005769	chr10:121956782~121957098:+
OV	cis	rs4713118	0.824	rs9468225	ENSG00000219392.1	RP1-265C24.5	-4.74	3.84e-06	0.00227	-0.35	-0.3	Parkinson's disease;	chr6:27777940	chr6:28115628~28116551:+
OV	cis	rs4664293	0.585	rs10460301	ENSG00000226266.5	AC009961.3	4.74	3.84e-06	0.00227	0.36	0.3	Monocyte percentage of white cells;	chr2:159778566	chr2:159670708~159712435:-
OV	cis	rs9291683	1	rs9291683	ENSG00000250413.1	RP11-448G15.1	-4.74	3.85e-06	0.00227	-0.33	-0.3	Bone mineral density;	chr4:10322536	chr4:10006482~10009725:+
OV	cis	rs796364	0.901	rs4673762	ENSG00000232732.8	AC073043.1	-4.74	3.85e-06	0.00227	-0.39	-0.3	Schizophrenia;	chr2:200200448	chr2:199867396~199911159:-
OV	cis	rs796364	0.951	rs35618222	ENSG00000232732.8	AC073043.1	-4.74	3.85e-06	0.00227	-0.39	-0.3	Schizophrenia;	chr2:200201054	chr2:199867396~199911159:-
OV	cis	rs796364	0.813	rs4672686	ENSG00000232732.8	AC073043.1	-4.73	3.86e-06	0.00228	-0.39	-0.3	Schizophrenia;	chr2:200200321	chr2:199867396~199911159:-
OV	cis	rs796364	0.951	rs36086821	ENSG00000232732.8	AC073043.1	-4.73	3.86e-06	0.00228	-0.39	-0.3	Schizophrenia;	chr2:200202713	chr2:199867396~199911159:-
OV	cis	rs796364	0.951	rs7586284	ENSG00000232732.8	AC073043.1	-4.73	3.86e-06	0.00228	-0.39	-0.3	Schizophrenia;	chr2:200203279	chr2:199867396~199911159:-
OV	cis	rs796364	0.951	rs7586320	ENSG00000232732.8	AC073043.1	-4.73	3.86e-06	0.00228	-0.39	-0.3	Schizophrenia;	chr2:200203486	chr2:199867396~199911159:-
OV	cis	rs57502260	0.68	rs55654976	ENSG00000212093.1	AP000807.1	4.73	3.87e-06	0.00228	0.49	0.3	Total body bone mineral density (age 45-60);	chr11:68626073	chr11:68506083~68506166:-
OV	cis	rs496547	0.557	rs516719	ENSG00000278376.1	RP11-158I9.8	-4.73	3.87e-06	0.00228	-0.29	-0.3	Hip minimal joint space width;	chr11:118808736	chr11:118791254~118793137:+
OV	cis	rs1891275	0.515	rs10881957	ENSG00000228701.1	TNKS2-AS1	-4.73	3.87e-06	0.00228	-0.33	-0.3	Intelligence (multi-trait analysis);	chr10:91742119	chr10:91782839~91798291:-
OV	cis	rs55692468	0.804	rs10169514	ENSG00000213197.3	AC012066.1	-4.73	3.87e-06	0.00228	-0.31	-0.3	Intraocular pressure;	chr2:152470643	chr2:152389937~152390630:+
OV	cis	rs55692468	0.804	rs6742066	ENSG00000213197.3	AC012066.1	-4.73	3.87e-06	0.00228	-0.31	-0.3	Intraocular pressure;	chr2:152472649	chr2:152389937~152390630:+
OV	cis	rs9990333	0.622	rs57783901	ENSG00000231464.1	AC024937.4	4.73	3.87e-06	0.00228	0.34	0.3	Iron status biomarkers (transferrin levels);Iron status biomarkers (transferrin saturation);	chr3:196089486	chr3:195996738~195998233:+
OV	cis	rs9859260	0.744	rs3933	ENSG00000231464.1	AC024937.4	-4.73	3.87e-06	0.00228	-0.37	-0.3	Mean corpuscular volume;	chr3:196058126	chr3:195996738~195998233:+
OV	cis	rs13113518	0.812	rs11945371	ENSG00000223305.1	RN7SKP30	4.73	3.87e-06	0.00228	0.34	0.3	Height;	chr4:55409063	chr4:55540502~55540835:-
OV	cis	rs854765	0.964	rs854764	ENSG00000197815.4	RP1-253P7.4	4.73	3.88e-06	0.00229	0.24	0.3	Total body bone mineral density;	chr17:18108436	chr17:17858227~17860041:+
OV	cis	rs748404	0.55	rs12912505	ENSG00000249839.1	AC011330.5	-4.73	3.88e-06	0.00229	-0.42	-0.3	Lung cancer;	chr15:43525206	chr15:43663654~43684339:-
OV	cis	rs67311347	1	rs9835219	ENSG00000223797.4	ENTPD3-AS1	4.73	3.88e-06	0.00229	0.32	0.3	Renal cell carcinoma;	chr3:40382602	chr3:40313802~40453329:-
OV	cis	rs1979679	0.842	rs12049916	ENSG00000278733.1	RP11-425D17.1	4.73	3.89e-06	0.00229	0.36	0.3	Ossification of the posterior longitudinal ligament of the spine;	chr12:28207052	chr12:28185625~28186190:-
OV	cis	rs67311347	1	rs7642552	ENSG00000223797.4	ENTPD3-AS1	4.73	3.89e-06	0.00229	0.32	0.3	Renal cell carcinoma;	chr3:40383325	chr3:40313802~40453329:-
OV	cis	rs6893300	0.961	rs113829727	ENSG00000254035.1	RP11-281O15.4	4.73	3.89e-06	0.00229	0.37	0.3	Resting heart rate;	chr5:179764895	chr5:178969390~178990116:+
OV	cis	rs6893300	0.961	rs3797776	ENSG00000254035.1	RP11-281O15.4	4.73	3.89e-06	0.00229	0.37	0.3	Resting heart rate;	chr5:179766597	chr5:178969390~178990116:+
OV	cis	rs494459	0.504	rs7929520	ENSG00000255239.1	AP002954.6	4.73	3.89e-06	0.00229	0.36	0.3	Height;	chr11:118859432	chr11:118688039~118690600:-
OV	cis	rs494459	0.536	rs34561290	ENSG00000255239.1	AP002954.6	4.73	3.89e-06	0.00229	0.36	0.3	Height;	chr11:118860890	chr11:118688039~118690600:-
OV	cis	rs494459	0.536	rs11217072	ENSG00000255239.1	AP002954.6	4.73	3.89e-06	0.00229	0.36	0.3	Height;	chr11:118861053	chr11:118688039~118690600:-
OV	cis	rs896854	0.812	rs4582532	ENSG00000253528.2	RP11-347C18.4	4.73	3.89e-06	0.00229	0.29	0.3	Type 2 diabetes;	chr8:94957029	chr8:94974573~94974853:-
OV	cis	rs896854	0.812	rs2340586	ENSG00000253528.2	RP11-347C18.4	4.73	3.89e-06	0.00229	0.29	0.3	Type 2 diabetes;	chr8:94957033	chr8:94974573~94974853:-
OV	cis	rs11157436	0.958	rs12433649	ENSG00000211812.1	TRAV26-2	-4.73	3.9e-06	0.00229	-0.36	-0.3	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231828	chr14:22202583~22203368:+
OV	cis	rs55704346	0.654	rs11937742	ENSG00000281501.1	SEPSECS-AS1	4.73	3.9e-06	0.0023	0.32	0.3	Tonsillectomy;	chr4:25162050	chr4:25160641~25201440:+
OV	cis	rs7927592	0.626	rs11228279	ENSG00000212093.1	AP000807.1	-4.73	3.9e-06	0.0023	-0.35	-0.3	Total body bone mineral density;	chr11:68542212	chr11:68506083~68506166:-
OV	cis	rs57502260	0.679	rs72936524	ENSG00000212093.1	AP000807.1	4.73	3.9e-06	0.0023	0.53	0.3	Total body bone mineral density (age 45-60);	chr11:68508430	chr11:68506083~68506166:-
OV	cis	rs473651	0.935	rs541128	ENSG00000229915.1	AC016999.2	-4.73	3.91e-06	0.0023	-0.37	-0.3	Multiple system atrophy;	chr2:238427808	chr2:238427077~238427729:-
OV	cis	rs875971	0.545	rs4718325	ENSG00000226824.5	RP4-756H11.3	-4.73	3.91e-06	0.0023	-0.36	-0.3	Aortic root size;	chr7:66215323	chr7:66654538~66669855:+
OV	cis	rs875971	0.83	rs809025	ENSG00000236529.1	RP13-254B10.1	4.73	3.91e-06	0.0023	0.31	0.3	Aortic root size;	chr7:66384832	chr7:65840212~65840596:+
OV	cis	rs858239	0.601	rs2141307	ENSG00000230042.1	AK3P3	-4.73	3.92e-06	0.00231	-0.31	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23151805	chr7:23129178~23129841:+
OV	cis	rs10740039	0.671	rs7919726	ENSG00000254271.1	RP11-131N11.4	4.73	3.94e-06	0.00232	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60689748	chr10:60734342~60741828:+
OV	cis	rs10740039	0.804	rs10821824	ENSG00000254271.1	RP11-131N11.4	4.73	3.94e-06	0.00232	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60690449	chr10:60734342~60741828:+
OV	cis	rs5742933	0.512	rs80277863	ENSG00000253559.1	OSGEPL1-AS1	-4.73	3.94e-06	0.00232	-0.34	-0.3	Ferritin levels;	chr2:189766733	chr2:189762704~189765556:+
OV	cis	rs17301013	0.659	rs59649440	ENSG00000227373.4	RP11-160H22.5	4.73	3.94e-06	0.00232	0.38	0.3	Systemic lupus erythematosus;	chr1:174332024	chr1:174115300~174160004:-
OV	cis	rs853679	0.882	rs4713139	ENSG00000280107.1	AL022393.9	-4.73	3.94e-06	0.00232	-0.5	-0.3	Depression;	chr6:28124907	chr6:28170845~28172521:+
OV	cis	rs858239	0.806	rs10268610	ENSG00000230042.1	AK3P3	-4.73	3.95e-06	0.00232	-0.33	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23235145	chr7:23129178~23129841:+
OV	cis	rs1555322	0.53	rs6060347	ENSG00000279253.1	RP4-614O4.13	-4.73	3.95e-06	0.00232	-0.37	-0.3	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35262727~35264187:-
OV	cis	rs11992162	0.591	rs4240678	ENSG00000270154.1	RP11-419I17.1	-4.73	3.95e-06	0.00232	-0.34	-0.3	Monocyte count;	chr8:11944917	chr8:12476462~12477122:+
OV	cis	rs8062405	1	rs56404918	ENSG00000278665.1	RP11-666O2.4	4.73	3.96e-06	0.00232	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835519	chr16:28599241~28601881:-
OV	cis	rs8062405	1	rs55719896	ENSG00000278665.1	RP11-666O2.4	4.73	3.96e-06	0.00232	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835545	chr16:28599241~28601881:-
OV	cis	rs8062405	1	rs55830740	ENSG00000278665.1	RP11-666O2.4	4.73	3.96e-06	0.00232	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28835828	chr16:28599241~28601881:-
OV	cis	rs71520386	0.607	rs11767419	ENSG00000228649.7	AC005682.5	-4.73	3.96e-06	0.00233	-0.36	-0.3	Fibrinogen levels;	chr7:22839364	chr7:22854178~22861579:+
OV	cis	rs6088580	0.634	rs6059856	ENSG00000206582.1	Y_RNA	-4.73	3.96e-06	0.00233	-0.36	-0.3	Glomerular filtration rate (creatinine);	chr20:34470149	chr20:34526510~34526606:-
OV	cis	rs7520050	0.667	rs11211176	ENSG00000280836.1	AL355480.1	4.73	3.96e-06	0.00233	0.37	0.3	Reticulocyte count;Red blood cell count;	chr1:45757414	chr1:45581219~45581321:-
OV	cis	rs4763879	0.865	rs4763839	ENSG00000256673.1	RP11-599J14.2	4.73	3.96e-06	0.00233	0.29	0.3	Type 1 diabetes;	chr12:9730104	chr12:9398355~9414851:-
OV	cis	rs7189233	0.531	rs56126229	ENSG00000279344.1	RP11-44F14.7	4.73	3.96e-06	0.00233	0.27	0.3	Intelligence (multi-trait analysis);	chr16:53476775	chr16:53478957~53481550:-
OV	cis	rs3733585	0.673	rs9994266	ENSG00000250413.1	RP11-448G15.1	4.73	3.97e-06	0.00233	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9952826	chr4:10006482~10009725:+
OV	cis	rs10924970	0.649	rs2093406	ENSG00000236863.2	RPL23AP23	4.73	3.97e-06	0.00233	0.3	0.3	Asthma;	chr1:235208230	chr1:235295865~235296335:+
OV	cis	rs6471393	0.964	rs10504930	ENSG00000253848.1	RP11-10N23.5	-4.73	3.97e-06	0.00233	-0.37	-0.3	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93732585	chr8:93741193~93744534:+
OV	cis	rs875971	0.545	rs1267814	ENSG00000226824.5	RP4-756H11.3	4.73	3.98e-06	0.00234	0.36	0.3	Aortic root size;	chr7:66579422	chr7:66654538~66669855:+
OV	cis	rs7811142	1	rs1000215	ENSG00000242294.5	STAG3L5P	4.73	3.98e-06	0.00234	0.31	0.3	Platelet count;	chr7:100406920	chr7:100336079~100351900:+
OV	cis	rs17301013	0.632	rs12079214	ENSG00000227373.4	RP11-160H22.5	4.73	3.98e-06	0.00234	0.39	0.3	Systemic lupus erythematosus;	chr1:174149572	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs12065785	ENSG00000227373.4	RP11-160H22.5	4.73	3.98e-06	0.00234	0.39	0.3	Systemic lupus erythematosus;	chr1:174151296	chr1:174115300~174160004:-
OV	cis	rs757081	0.658	rs105290	ENSG00000213779.4	RP11-452G18.1	4.73	3.99e-06	0.00234	0.34	0.3	Systolic blood pressure;	chr11:17270521	chr11:17193489~17194308:+
OV	cis	rs9487094	0.961	rs7773095	ENSG00000260273.1	RP11-425D10.10	-4.73	3.99e-06	0.00234	-0.33	-0.3	Height;	chr6:109405874	chr6:109382795~109383666:+
OV	cis	rs875971	1	rs10215948	ENSG00000236529.1	RP13-254B10.1	-4.73	3.99e-06	0.00234	-0.31	-0.3	Aortic root size;	chr7:66282799	chr7:65840212~65840596:+
OV	cis	rs875971	0.838	rs2173570	ENSG00000236529.1	RP13-254B10.1	-4.73	3.99e-06	0.00234	-0.31	-0.3	Aortic root size;	chr7:66297976	chr7:65840212~65840596:+
OV	cis	rs875971	0.964	rs55748098	ENSG00000236529.1	RP13-254B10.1	-4.73	3.99e-06	0.00234	-0.31	-0.3	Aortic root size;	chr7:66298631	chr7:65840212~65840596:+
OV	cis	rs11159086	0.793	rs10136668	ENSG00000270000.1	RP3-449M8.9	4.73	4e-06	0.00235	0.44	0.3	Advanced glycation end-product levels;	chr14:74492183	chr14:74471930~74472360:-
OV	cis	rs11159086	0.793	rs10139029	ENSG00000270000.1	RP3-449M8.9	4.73	4e-06	0.00235	0.44	0.3	Advanced glycation end-product levels;	chr14:74492284	chr14:74471930~74472360:-
OV	cis	rs11671005	0.656	rs11671092	ENSG00000269600.1	AC016629.3	-4.73	4e-06	0.00235	-0.47	-0.3	Mean platelet volume;	chr19:58497742	chr19:58593896~58599355:-
OV	cis	rs11671005	0.656	rs55928441	ENSG00000269600.1	AC016629.3	-4.73	4e-06	0.00235	-0.47	-0.3	Mean platelet volume;	chr19:58498307	chr19:58593896~58599355:-
OV	cis	rs2153535	0.585	rs9379234	ENSG00000230939.1	RP11-314C16.1	-4.73	4.01e-06	0.00235	-0.33	-0.3	Motion sickness;	chr6:8643520	chr6:8784178~8785445:+
OV	cis	rs7617773	0.817	rs17786132	ENSG00000228638.1	FCF1P2	-4.73	4.01e-06	0.00235	-0.38	-0.3	Coronary artery disease;	chr3:48207930	chr3:48290793~48291375:-
OV	cis	rs7617773	0.817	rs35456569	ENSG00000228638.1	FCF1P2	-4.73	4.01e-06	0.00235	-0.38	-0.3	Coronary artery disease;	chr3:48209409	chr3:48290793~48291375:-
OV	cis	rs10510102	0.872	rs56108883	ENSG00000276742.1	RP11-500G22.4	4.73	4.01e-06	0.00235	0.48	0.3	Breast cancer;	chr10:121825567	chr10:121956782~121957098:+
OV	cis	rs733592	0.524	rs10875726	ENSG00000258273.1	RP11-370I10.4	4.73	4.01e-06	0.00235	0.36	0.3	Plateletcrit;	chr12:48032209	chr12:48333755~48333901:-
OV	cis	rs733592	0.524	rs10875727	ENSG00000258273.1	RP11-370I10.4	4.73	4.01e-06	0.00235	0.36	0.3	Plateletcrit;	chr12:48032360	chr12:48333755~48333901:-
OV	cis	rs853679	0.505	rs200992	ENSG00000220721.1	OR1F12	4.73	4.02e-06	0.00236	0.46	0.3	Depression;	chr6:27846899	chr6:28073316~28074233:+
OV	cis	rs10510102	0.935	rs79360006	ENSG00000226864.1	ATE1-AS1	4.73	4.02e-06	0.00236	0.49	0.3	Breast cancer;	chr10:121912856	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs78525391	ENSG00000226864.1	ATE1-AS1	4.73	4.03e-06	0.00236	0.5	0.3	Breast cancer;	chr10:121901102	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs4627017	ENSG00000226864.1	ATE1-AS1	4.73	4.03e-06	0.00236	0.5	0.3	Breast cancer;	chr10:121901878	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs7098562	ENSG00000226864.1	ATE1-AS1	4.73	4.03e-06	0.00236	0.5	0.3	Breast cancer;	chr10:121902148	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs7098822	ENSG00000226864.1	ATE1-AS1	4.73	4.03e-06	0.00236	0.5	0.3	Breast cancer;	chr10:121902157	chr10:121928312~121951965:+
OV	cis	rs10510102	0.81	rs11200240	ENSG00000226864.1	ATE1-AS1	4.73	4.03e-06	0.00236	0.5	0.3	Breast cancer;	chr10:121903265	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs74914751	ENSG00000226864.1	ATE1-AS1	4.73	4.03e-06	0.00236	0.5	0.3	Breast cancer;	chr10:121904496	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs11200242	ENSG00000226864.1	ATE1-AS1	4.73	4.03e-06	0.00236	0.5	0.3	Breast cancer;	chr10:121905378	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs12246704	ENSG00000226864.1	ATE1-AS1	4.73	4.03e-06	0.00236	0.5	0.3	Breast cancer;	chr10:121906165	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs11200243	ENSG00000226864.1	ATE1-AS1	4.73	4.03e-06	0.00236	0.5	0.3	Breast cancer;	chr10:121906888	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs11200244	ENSG00000226864.1	ATE1-AS1	4.73	4.03e-06	0.00236	0.5	0.3	Breast cancer;	chr10:121906944	chr10:121928312~121951965:+
OV	cis	rs9876781	0.56	rs2362451	ENSG00000229759.1	MRPS18AP1	-4.73	4.03e-06	0.00236	-0.3	-0.3	Longevity;	chr3:48358338	chr3:48256350~48256938:-
OV	cis	rs8100891	0.537	rs28672356	ENSG00000267213.4	AC007773.2	-4.73	4.03e-06	0.00236	-0.45	-0.3	Neuroticism;	chr19:32416937	chr19:32390050~32405560:-
OV	cis	rs12787909	1	rs12787909	ENSG00000250699.1	AP000892.4	4.72	4.04e-06	0.00237	0.65	0.3	Lipoprotein (a) - cholesterol levels;	chr11:117675767	chr11:117316362~117328038:-
OV	cis	rs1499614	0.901	rs2178742	ENSG00000226824.5	RP4-756H11.3	-4.72	4.05e-06	0.00237	-0.5	-0.3	Gout;	chr7:66732812	chr7:66654538~66669855:+
OV	cis	rs8062405	0.755	rs2077031	ENSG00000278665.1	RP11-666O2.4	4.72	4.05e-06	0.00237	0.33	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28591847	chr16:28599241~28601881:-
OV	cis	rs13068223	0.584	rs345985	ENSG00000243926.1	TIPARP-AS1	-4.72	4.05e-06	0.00237	-0.28	-0.3	Age-related hearing impairment (SNP x SNP interaction);	chr3:156679385	chr3:156671862~156674378:-
OV	cis	rs8062405	0.964	rs78613234	ENSG00000278665.1	RP11-666O2.4	4.72	4.05e-06	0.00237	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828104	chr16:28599241~28601881:-
OV	cis	rs8062405	1	rs62036624	ENSG00000278665.1	RP11-666O2.4	4.72	4.05e-06	0.00237	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28828609	chr16:28599241~28601881:-
OV	cis	rs8062405	1	rs55991577	ENSG00000278665.1	RP11-666O2.4	4.72	4.05e-06	0.00237	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831704	chr16:28599241~28601881:-
OV	cis	rs8062405	1	rs56358680	ENSG00000278665.1	RP11-666O2.4	4.72	4.05e-06	0.00237	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28831797	chr16:28599241~28601881:-
OV	cis	rs8062405	1	rs62036626	ENSG00000278665.1	RP11-666O2.4	4.72	4.05e-06	0.00237	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28832963	chr16:28599241~28601881:-
OV	cis	rs8062405	1	rs62036657	ENSG00000278665.1	RP11-666O2.4	4.72	4.05e-06	0.00237	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833044	chr16:28599241~28601881:-
OV	cis	rs8062405	1	rs12444171	ENSG00000278665.1	RP11-666O2.4	4.72	4.05e-06	0.00237	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28833930	chr16:28599241~28601881:-
OV	cis	rs796364	0.951	rs7565005	ENSG00000232732.8	AC073043.1	4.72	4.06e-06	0.00238	0.38	0.3	Schizophrenia;	chr2:200148554	chr2:199867396~199911159:-
OV	cis	rs3733585	0.648	rs35954357	ENSG00000250413.1	RP11-448G15.1	-4.72	4.06e-06	0.00238	-0.34	-0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9977134	chr4:10006482~10009725:+
OV	cis	rs6921919	0.887	rs16894116	ENSG00000216901.1	AL022393.7	4.72	4.06e-06	0.00238	0.41	0.3	Autism spectrum disorder or schizophrenia;	chr6:28447190	chr6:28176188~28176674:+
OV	cis	rs11157436	0.958	rs764160	ENSG00000211812.1	TRAV26-2	-4.72	4.07e-06	0.00238	-0.35	-0.3	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22231098	chr14:22202583~22203368:+
OV	cis	rs4713118	0.824	rs7759217	ENSG00000280107.1	AL022393.9	-4.72	4.07e-06	0.00238	-0.35	-0.3	Parkinson's disease;	chr6:27762684	chr6:28170845~28172521:+
OV	cis	rs4713118	0.784	rs9468219	ENSG00000280107.1	AL022393.9	-4.72	4.07e-06	0.00238	-0.35	-0.3	Parkinson's disease;	chr6:27763976	chr6:28170845~28172521:+
OV	cis	rs17264034	1	rs414829	ENSG00000250786.1	SNHG18	4.72	4.07e-06	0.00238	0.47	0.3	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9552413	chr5:9546200~9550609:+
OV	cis	rs875971	0.545	rs73146609	ENSG00000226824.5	RP4-756H11.3	-4.72	4.08e-06	0.00239	-0.36	-0.3	Aortic root size;	chr7:66302477	chr7:66654538~66669855:+
OV	cis	rs875971	0.545	rs2173571	ENSG00000226824.5	RP4-756H11.3	-4.72	4.08e-06	0.00239	-0.36	-0.3	Aortic root size;	chr7:66305392	chr7:66654538~66669855:+
OV	cis	rs875971	0.545	rs11770063	ENSG00000226824.5	RP4-756H11.3	-4.72	4.08e-06	0.00239	-0.36	-0.3	Aortic root size;	chr7:66318029	chr7:66654538~66669855:+
OV	cis	rs875971	0.545	rs3936065	ENSG00000226824.5	RP4-756H11.3	-4.72	4.08e-06	0.00239	-0.36	-0.3	Aortic root size;	chr7:66325577	chr7:66654538~66669855:+
OV	cis	rs875971	0.545	rs4718335	ENSG00000226824.5	RP4-756H11.3	-4.72	4.08e-06	0.00239	-0.36	-0.3	Aortic root size;	chr7:66339619	chr7:66654538~66669855:+
OV	cis	rs17301013	0.531	rs332806	ENSG00000227373.4	RP11-160H22.5	4.72	4.09e-06	0.00239	0.39	0.3	Systemic lupus erythematosus;	chr1:174653645	chr1:174115300~174160004:-
OV	cis	rs17023223	0.537	rs12092807	ENSG00000231365.4	RP11-418J17.1	4.72	4.09e-06	0.00239	0.39	0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119208021	chr1:119140396~119275973:+
OV	cis	rs858239	0.509	rs57611130	ENSG00000230042.1	AK3P3	-4.72	4.09e-06	0.00239	-0.31	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23144933	chr7:23129178~23129841:+
OV	cis	rs1555322	0.53	rs8122819	ENSG00000279253.1	RP4-614O4.13	-4.72	4.09e-06	0.00239	-0.36	-0.3	Attention deficit hyperactivity disorder;	chr20:35293783	chr20:35262727~35264187:-
OV	cis	rs10510102	0.872	rs11200261	ENSG00000226864.1	ATE1-AS1	4.72	4.1e-06	0.0024	0.48	0.3	Breast cancer;	chr10:121921133	chr10:121928312~121951965:+
OV	cis	rs1729407	0.706	rs1268354	ENSG00000254851.1	RP11-109L13.1	-4.72	4.11e-06	0.0024	-0.37	-0.3	Apolipoprotein A-IV levels;	chr11:116819862	chr11:117135528~117138582:+
OV	cis	rs56114371	0.777	rs200482	ENSG00000220721.1	OR1F12	4.72	4.11e-06	0.0024	0.48	0.3	Breast cancer;	chr6:27806126	chr6:28073316~28074233:+
OV	cis	rs4938303	0.756	rs12802944	ENSG00000254851.1	RP11-109L13.1	4.72	4.11e-06	0.0024	0.48	0.3	Triglycerides;	chr11:116705684	chr11:117135528~117138582:+
OV	cis	rs9828933	0.766	rs864975	ENSG00000280620.1	SCAANT1	-4.72	4.11e-06	0.0024	-0.56	-0.3	Type 2 diabetes;	chr3:63899939	chr3:63911518~63911772:-
OV	cis	rs3758911	0.964	rs10749896	ENSG00000261098.1	RP11-819C21.1	-4.72	4.12e-06	0.0024	-0.29	-0.3	Coronary artery disease;	chr11:107314102	chr11:107312132~107316271:-
OV	cis	rs3758911	0.964	rs10789608	ENSG00000261098.1	RP11-819C21.1	-4.72	4.12e-06	0.0024	-0.29	-0.3	Coronary artery disease;	chr11:107314132	chr11:107312132~107316271:-
OV	cis	rs896854	0.654	rs1453377	ENSG00000253528.2	RP11-347C18.4	4.72	4.12e-06	0.0024	0.28	0.3	Type 2 diabetes;	chr8:94957719	chr8:94974573~94974853:-
OV	cis	rs6088580	0.602	rs6058064	ENSG00000206582.1	Y_RNA	-4.72	4.12e-06	0.0024	-0.36	-0.3	Glomerular filtration rate (creatinine);	chr20:34498817	chr20:34526510~34526606:-
OV	cis	rs67311347	0.822	rs11709089	ENSG00000223797.4	ENTPD3-AS1	4.72	4.12e-06	0.00241	0.33	0.3	Renal cell carcinoma;	chr3:40309993	chr3:40313802~40453329:-
OV	cis	rs67311347	0.866	rs9826419	ENSG00000223797.4	ENTPD3-AS1	4.72	4.12e-06	0.00241	0.33	0.3	Renal cell carcinoma;	chr3:40310560	chr3:40313802~40453329:-
OV	cis	rs67311347	0.866	rs3214006	ENSG00000223797.4	ENTPD3-AS1	4.72	4.12e-06	0.00241	0.33	0.3	Renal cell carcinoma;	chr3:40310643	chr3:40313802~40453329:-
OV	cis	rs17264034	0.861	rs56344213	ENSG00000250786.1	SNHG18	4.72	4.13e-06	0.00241	0.46	0.3	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9553756	chr5:9546200~9550609:+
OV	cis	rs17301013	0.606	rs16846938	ENSG00000227373.4	RP11-160H22.5	4.72	4.14e-06	0.00241	0.39	0.3	Systemic lupus erythematosus;	chr1:174400537	chr1:174115300~174160004:-
OV	cis	rs17301013	0.632	rs10912782	ENSG00000227373.4	RP11-160H22.5	4.72	4.14e-06	0.00241	0.39	0.3	Systemic lupus erythematosus;	chr1:174418758	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs5015737	ENSG00000227373.4	RP11-160H22.5	4.72	4.14e-06	0.00241	0.39	0.3	Systemic lupus erythematosus;	chr1:174452857	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs12089182	ENSG00000227373.4	RP11-160H22.5	4.72	4.14e-06	0.00241	0.39	0.3	Systemic lupus erythematosus;	chr1:174463816	chr1:174115300~174160004:-
OV	cis	rs10510102	0.935	rs7083278	ENSG00000226864.1	ATE1-AS1	4.72	4.14e-06	0.00242	0.49	0.3	Breast cancer;	chr10:121853758	chr10:121928312~121951965:+
OV	cis	rs875971	0.545	rs1796217	ENSG00000237310.1	GS1-124K5.4	-4.72	4.15e-06	0.00242	-0.35	-0.3	Aortic root size;	chr7:66620931	chr7:66493706~66495474:+
OV	cis	rs1134634	0.52	rs73125606	ENSG00000273133.1	RP11-799M12.2	-4.72	4.15e-06	0.00242	-0.42	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15545691	chr4:15563698~15564253:-
OV	cis	rs1134634	0.52	rs10025837	ENSG00000273133.1	RP11-799M12.2	-4.72	4.15e-06	0.00242	-0.42	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15548362	chr4:15563698~15564253:-
OV	cis	rs2243480	1	rs1618893	ENSG00000273142.1	RP11-458F8.4	-4.72	4.16e-06	0.00242	-0.34	-0.3	Diabetic kidney disease;	chr7:66631132	chr7:66902857~66906297:+
OV	cis	rs13113518	0.812	rs1522114	ENSG00000223305.1	RN7SKP30	4.72	4.16e-06	0.00242	0.35	0.3	Height;	chr4:55489895	chr4:55540502~55540835:-
OV	cis	rs17301013	0.507	rs11806996	ENSG00000227373.4	RP11-160H22.5	4.72	4.16e-06	0.00242	0.41	0.3	Systemic lupus erythematosus;	chr1:174654784	chr1:174115300~174160004:-
OV	cis	rs9925964	0.748	rs4889603	ENSG00000278922.1	AC002310.14	4.72	4.16e-06	0.00243	0.34	0.3	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30970904	chr16:30526918~30528294:+
OV	cis	rs13113518	0.812	rs56055342	ENSG00000223305.1	RN7SKP30	4.72	4.17e-06	0.00243	0.35	0.3	Height;	chr4:55540928	chr4:55540502~55540835:-
OV	cis	rs7429990	1	rs319680	ENSG00000229759.1	MRPS18AP1	4.72	4.17e-06	0.00243	0.32	0.3	Educational attainment (years of education);	chr3:47856817	chr3:48256350~48256938:-
OV	cis	rs4713118	0.869	rs6902689	ENSG00000280107.1	AL022393.9	-4.72	4.17e-06	0.00243	-0.35	-0.3	Parkinson's disease;	chr6:27741662	chr6:28170845~28172521:+
OV	cis	rs4713118	0.869	rs9468214	ENSG00000280107.1	AL022393.9	-4.72	4.17e-06	0.00243	-0.35	-0.3	Parkinson's disease;	chr6:27745520	chr6:28170845~28172521:+
OV	cis	rs473651	0.935	rs477041	ENSG00000229915.1	AC016999.2	4.72	4.17e-06	0.00243	0.37	0.3	Multiple system atrophy;	chr2:238447354	chr2:238427077~238427729:-
OV	cis	rs7429990	0.965	rs4858880	ENSG00000229759.1	MRPS18AP1	-4.72	4.18e-06	0.00244	-0.31	-0.3	Educational attainment (years of education);	chr3:48062959	chr3:48256350~48256938:-
OV	cis	rs7429990	0.965	rs7426976	ENSG00000229759.1	MRPS18AP1	-4.72	4.18e-06	0.00244	-0.31	-0.3	Educational attainment (years of education);	chr3:47981083	chr3:48256350~48256938:-
OV	cis	rs7429990	0.965	rs1013431	ENSG00000229759.1	MRPS18AP1	-4.72	4.18e-06	0.00244	-0.31	-0.3	Educational attainment (years of education);	chr3:47987628	chr3:48256350~48256938:-
OV	cis	rs7429990	0.932	rs9862913	ENSG00000229759.1	MRPS18AP1	4.72	4.18e-06	0.00244	0.31	0.3	Educational attainment (years of education);	chr3:47974682	chr3:48256350~48256938:-
OV	cis	rs7829975	0.659	rs4382480	ENSG00000253893.2	FAM85B	-4.72	4.18e-06	0.00244	-0.32	-0.3	Mood instability;	chr8:8863963	chr8:8167819~8226614:-
OV	cis	rs3758911	0.964	rs7358296	ENSG00000261098.1	RP11-819C21.1	-4.72	4.19e-06	0.00244	-0.29	-0.3	Coronary artery disease;	chr11:107403212	chr11:107312132~107316271:-
OV	cis	rs67311347	0.955	rs11719205	ENSG00000223797.4	ENTPD3-AS1	4.72	4.19e-06	0.00244	0.32	0.3	Renal cell carcinoma;	chr3:40375767	chr3:40313802~40453329:-
OV	cis	rs8062405	0.69	rs4787458	ENSG00000259982.1	CDC37P1	4.72	4.19e-06	0.00244	0.37	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28519966	chr16:28700294~28701540:-
OV	cis	rs875971	0.571	rs78668714	ENSG00000226824.5	RP4-756H11.3	-4.72	4.19e-06	0.00244	-0.36	-0.3	Aortic root size;	chr7:66474464	chr7:66654538~66669855:+
OV	cis	rs875971	0.545	rs73150604	ENSG00000226824.5	RP4-756H11.3	-4.72	4.19e-06	0.00244	-0.36	-0.3	Aortic root size;	chr7:66480545	chr7:66654538~66669855:+
OV	cis	rs875971	0.545	rs7810213	ENSG00000226824.5	RP4-756H11.3	-4.72	4.19e-06	0.00244	-0.36	-0.3	Aortic root size;	chr7:66481592	chr7:66654538~66669855:+
OV	cis	rs17301013	0.507	rs12082012	ENSG00000227373.4	RP11-160H22.5	4.72	4.19e-06	0.00244	0.39	0.3	Systemic lupus erythematosus;	chr1:174588729	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12085652	ENSG00000227373.4	RP11-160H22.5	4.72	4.19e-06	0.00244	0.39	0.3	Systemic lupus erythematosus;	chr1:174588864	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs4451598	ENSG00000227373.4	RP11-160H22.5	4.72	4.19e-06	0.00244	0.39	0.3	Systemic lupus erythematosus;	chr1:174606576	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs10912817	ENSG00000227373.4	RP11-160H22.5	4.72	4.19e-06	0.00244	0.39	0.3	Systemic lupus erythematosus;	chr1:174615581	chr1:174115300~174160004:-
OV	cis	rs6772849	0.775	rs60092972	ENSG00000242551.2	POU5F1P6	-4.72	4.2e-06	0.00244	-0.37	-0.3	Monocyte percentage of white cells;Monocyte count;	chr3:128703333	chr3:128674735~128677005:-
OV	cis	rs2919917	0.915	rs2046339	ENSG00000254352.1	RP11-578O24.2	4.72	4.2e-06	0.00244	0.37	0.3	Lymphocyte counts;	chr8:78724283	chr8:78723796~78724136:-
OV	cis	rs2919917	1	rs1441438	ENSG00000254352.1	RP11-578O24.2	-4.72	4.2e-06	0.00244	-0.37	-0.3	Lymphocyte counts;	chr8:78729534	chr8:78723796~78724136:-
OV	cis	rs2919917	1	rs894221	ENSG00000254352.1	RP11-578O24.2	-4.72	4.2e-06	0.00244	-0.37	-0.3	Lymphocyte counts;	chr8:78736822	chr8:78723796~78724136:-
OV	cis	rs1061377	0.513	rs2712000	ENSG00000249207.1	RP11-360F5.1	-4.72	4.2e-06	0.00245	-0.36	-0.3	Uric acid levels;	chr4:39135462	chr4:39112677~39126818:-
OV	cis	rs7927592	0.913	rs7925275	ENSG00000212093.1	AP000807.1	4.72	4.2e-06	0.00245	0.38	0.3	Total body bone mineral density;	chr11:68522965	chr11:68506083~68506166:-
OV	cis	rs14027	0.921	rs12542706	ENSG00000279347.1	RP11-85I17.2	-4.72	4.21e-06	0.00245	-0.31	-0.3	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119831539	chr8:119838736~119840385:-
OV	cis	rs14027	0.921	rs10505374	ENSG00000279347.1	RP11-85I17.2	-4.72	4.21e-06	0.00245	-0.31	-0.3	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119832350	chr8:119838736~119840385:-
OV	cis	rs7580658	0.724	rs4662711	ENSG00000236682.1	AC068282.3	-4.72	4.21e-06	0.00245	-0.38	-0.3	Protein C levels;	chr2:127233264	chr2:127389130~127400580:+
OV	cis	rs875971	0.545	rs10950036	ENSG00000226824.5	RP4-756H11.3	-4.72	4.22e-06	0.00245	-0.36	-0.3	Aortic root size;	chr7:66353241	chr7:66654538~66669855:+
OV	cis	rs875971	0.545	rs73148639	ENSG00000226824.5	RP4-756H11.3	-4.72	4.22e-06	0.00245	-0.36	-0.3	Aortic root size;	chr7:66390342	chr7:66654538~66669855:+
OV	cis	rs848490	0.674	rs17807185	ENSG00000214293.7	APTR	4.71	4.23e-06	0.00246	0.38	0.3	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77678978	chr7:77657660~77696265:-
OV	cis	rs17301013	0.606	rs6692437	ENSG00000227373.4	RP11-160H22.5	4.71	4.23e-06	0.00246	0.4	0.3	Systemic lupus erythematosus;	chr1:174213771	chr1:174115300~174160004:-
OV	cis	rs67340775	0.541	rs169287	ENSG00000219392.1	RP1-265C24.5	-4.71	4.23e-06	0.00246	-0.4	-0.3	Lung cancer in ever smokers;	chr6:27886982	chr6:28115628~28116551:+
OV	cis	rs67340775	0.541	rs200966	ENSG00000219392.1	RP1-265C24.5	-4.71	4.23e-06	0.00246	-0.4	-0.3	Lung cancer in ever smokers;	chr6:27894374	chr6:28115628~28116551:+
OV	cis	rs295490	0.748	rs3772876	ENSG00000272656.1	RP11-219D15.3	4.71	4.24e-06	0.00247	0.54	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139469035	chr3:139349024~139349371:-
OV	cis	rs34779708	0.966	rs2126984	ENSG00000230534.5	RP11-297A16.2	4.71	4.24e-06	0.00247	0.38	0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35121363	chr10:35098006~35127020:-
OV	cis	rs8100891	0.537	rs10415145	ENSG00000267213.4	AC007773.2	4.71	4.25e-06	0.00247	0.43	0.3	Neuroticism;	chr19:32350147	chr19:32390050~32405560:-
OV	cis	rs9309473	1	rs6755241	ENSG00000163016.8	ALMS1P	4.71	4.25e-06	0.00247	0.36	0.3	Metabolite levels;	chr2:73414236	chr2:73644919~73685576:+
OV	cis	rs17301013	0.606	rs1793307	ENSG00000227373.4	RP11-160H22.5	-4.71	4.25e-06	0.00247	-0.38	-0.3	Systemic lupus erythematosus;	chr1:174758716	chr1:174115300~174160004:-
OV	cis	rs17301013	0.62	rs1793310	ENSG00000227373.4	RP11-160H22.5	-4.71	4.25e-06	0.00247	-0.38	-0.3	Systemic lupus erythematosus;	chr1:174770786	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs1618408	ENSG00000227373.4	RP11-160H22.5	-4.71	4.25e-06	0.00247	-0.38	-0.3	Systemic lupus erythematosus;	chr1:174777402	chr1:174115300~174160004:-
OV	cis	rs116095464	0.558	rs10059907	ENSG00000250848.1	CTD-2083E4.5	-4.71	4.25e-06	0.00247	-0.4	-0.3	Breast cancer;	chr5:205245	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs10060089	ENSG00000250848.1	CTD-2083E4.5	-4.71	4.25e-06	0.00247	-0.4	-0.3	Breast cancer;	chr5:205450	chr5:288833~290321:-
OV	cis	rs7017914	0.667	rs3816745	ENSG00000223220.1	Y_RNA	-4.71	4.25e-06	0.00247	-0.35	-0.3	Bone mineral density;	chr8:70594399	chr8:70780914~70781008:-
OV	cis	rs853679	0.607	rs200489	ENSG00000220721.1	OR1F12	4.71	4.26e-06	0.00248	0.5	0.3	Depression;	chr6:27830479	chr6:28073316~28074233:+
OV	cis	rs858239	0.539	rs870476	ENSG00000230042.1	AK3P3	-4.71	4.26e-06	0.00248	-0.31	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23153652	chr7:23129178~23129841:+
OV	cis	rs7189233	0.531	rs62048526	ENSG00000279344.1	RP11-44F14.7	4.71	4.26e-06	0.00248	0.27	0.3	Intelligence (multi-trait analysis);	chr16:53478014	chr16:53478957~53481550:-
OV	cis	rs858239	0.539	rs57864591	ENSG00000230042.1	AK3P3	-4.71	4.27e-06	0.00248	-0.31	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23144805	chr7:23129178~23129841:+
OV	cis	rs858239	0.539	rs4294098	ENSG00000230042.1	AK3P3	-4.71	4.27e-06	0.00248	-0.31	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23146376	chr7:23129178~23129841:+
OV	cis	rs858239	0.539	rs4504540	ENSG00000230042.1	AK3P3	-4.71	4.27e-06	0.00248	-0.31	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23146579	chr7:23129178~23129841:+
OV	cis	rs858239	0.509	rs6975524	ENSG00000230042.1	AK3P3	-4.71	4.27e-06	0.00248	-0.31	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23146833	chr7:23129178~23129841:+
OV	cis	rs858239	0.539	rs6955726	ENSG00000230042.1	AK3P3	-4.71	4.27e-06	0.00248	-0.31	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23147072	chr7:23129178~23129841:+
OV	cis	rs858239	0.539	rs6976957	ENSG00000230042.1	AK3P3	-4.71	4.27e-06	0.00248	-0.31	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23147714	chr7:23129178~23129841:+
OV	cis	rs9287719	0.674	rs1387566	ENSG00000234818.1	AC092687.5	-4.71	4.27e-06	0.00248	-0.35	-0.3	Prostate cancer;	chr2:10688524	chr2:10589166~10604830:+
OV	cis	rs4927850	1	rs4927850	ENSG00000242086.7	LINC00969	-4.71	4.28e-06	0.00249	-0.31	-0.3	Pancreatic cancer;	chr3:196024759	chr3:195658062~195739964:+
OV	cis	rs992157	0.835	rs4674282	ENSG00000261338.2	RP11-378A13.1	-4.71	4.28e-06	0.00249	-0.35	-0.3	Colorectal cancer;	chr2:218279507	chr2:218255319~218257366:+
OV	cis	rs295490	0.748	rs75256094	ENSG00000272656.1	RP11-219D15.3	4.71	4.28e-06	0.00249	0.59	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139349504	chr3:139349024~139349371:-
OV	cis	rs2492286	0.597	rs6802078	ENSG00000277250.1	Metazoa_SRP	-4.71	4.28e-06	0.00249	-0.39	-0.3	Eosinophil counts;	chr3:128639910	chr3:128673681~128674021:-
OV	cis	rs17301013	0.606	rs12079689	ENSG00000227373.4	RP11-160H22.5	4.71	4.29e-06	0.00249	0.4	0.3	Systemic lupus erythematosus;	chr1:174240514	chr1:174115300~174160004:-
OV	cis	rs17301013	0.581	rs7551605	ENSG00000227373.4	RP11-160H22.5	4.71	4.29e-06	0.00249	0.4	0.3	Systemic lupus erythematosus;	chr1:174245718	chr1:174115300~174160004:-
OV	cis	rs67311347	1	rs7631893	ENSG00000223797.4	ENTPD3-AS1	4.71	4.29e-06	0.00249	0.33	0.3	Renal cell carcinoma;	chr3:40399378	chr3:40313802~40453329:-
OV	cis	rs301901	0.514	rs11954689	ENSG00000250155.1	CTD-2353F22.1	-4.71	4.3e-06	0.00249	-0.38	-0.3	Height;	chr5:37269214	chr5:36666214~36725195:-
OV	cis	rs2286503	0.78	rs12113458	ENSG00000221740.1	SNORD93	4.71	4.31e-06	0.0025	0.37	0.3	Fibrinogen;	chr7:22816009	chr7:22856613~22856686:+
OV	cis	rs4908768	0.906	rs11121213	ENSG00000228423.2	RP4-633I8.4	4.71	4.33e-06	0.00251	0.37	0.3	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8668128	chr1:8805860~8807051:-
OV	cis	rs4908768	0.725	rs11121214	ENSG00000228423.2	RP4-633I8.4	4.71	4.33e-06	0.00251	0.37	0.3	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8668606	chr1:8805860~8807051:-
OV	cis	rs4718428	0.924	rs6971897	ENSG00000226824.5	RP4-756H11.3	-4.71	4.33e-06	0.00251	-0.34	-0.3	Corneal structure;	chr7:66947787	chr7:66654538~66669855:+
OV	cis	rs1576263	0.727	rs6936670	ENSG00000230939.1	RP11-314C16.1	-4.71	4.33e-06	0.00251	-0.32	-0.3	Photic sneeze reflex;	chr6:8691656	chr6:8784178~8785445:+
OV	cis	rs2098713	0.535	rs10941358	ENSG00000250155.1	CTD-2353F22.1	4.71	4.33e-06	0.00251	0.35	0.3	Telomere length;	chr5:37637276	chr5:36666214~36725195:-
OV	cis	rs783540	0.967	rs1145173	ENSG00000278603.1	RP13-608F4.5	-4.71	4.34e-06	0.00252	-0.34	-0.3	Schizophrenia;	chr15:82554675	chr15:82472203~82472426:+
OV	cis	rs9291683	0.507	rs6849273	ENSG00000250413.1	RP11-448G15.1	-4.71	4.34e-06	0.00252	-0.34	-0.3	Bone mineral density;	chr4:10019971	chr4:10006482~10009725:+
OV	cis	rs3758911	0.964	rs10890715	ENSG00000261098.1	RP11-819C21.1	-4.71	4.35e-06	0.00252	-0.28	-0.3	Coronary artery disease;	chr11:107322457	chr11:107312132~107316271:-
OV	cis	rs3758911	1	rs12146472	ENSG00000261098.1	RP11-819C21.1	-4.71	4.35e-06	0.00252	-0.28	-0.3	Coronary artery disease;	chr11:107323450	chr11:107312132~107316271:-
OV	cis	rs3758911	1	rs12146473	ENSG00000261098.1	RP11-819C21.1	-4.71	4.35e-06	0.00252	-0.28	-0.3	Coronary artery disease;	chr11:107323540	chr11:107312132~107316271:-
OV	cis	rs7927592	0.913	rs4316515	ENSG00000212093.1	AP000807.1	-4.71	4.35e-06	0.00252	-0.38	-0.3	Total body bone mineral density;	chr11:68541372	chr11:68506083~68506166:-
OV	cis	rs733592	0.524	rs10875741	ENSG00000258273.1	RP11-370I10.4	4.71	4.36e-06	0.00252	0.36	0.3	Plateletcrit;	chr12:48099139	chr12:48333755~48333901:-
OV	cis	rs8100891	0.537	rs2111504	ENSG00000267213.4	AC007773.2	-4.71	4.36e-06	0.00253	-0.44	-0.3	Neuroticism;	chr19:32426549	chr19:32390050~32405560:-
OV	cis	rs1891275	0.515	rs1080496	ENSG00000228701.1	TNKS2-AS1	4.71	4.36e-06	0.00253	0.32	0.3	Intelligence (multi-trait analysis);	chr10:91684505	chr10:91782839~91798291:-
OV	cis	rs6460942	0.778	rs74993124	ENSG00000226690.5	AC005281.1	4.71	4.37e-06	0.00253	0.46	0.3	Coronary artery disease;	chr7:12423291	chr7:12496429~12541910:+
OV	cis	rs6460942	0.778	rs76030612	ENSG00000226690.5	AC005281.1	4.71	4.37e-06	0.00253	0.46	0.3	Coronary artery disease;	chr7:12423311	chr7:12496429~12541910:+
OV	cis	rs6460942	0.687	rs74753576	ENSG00000226690.5	AC005281.1	4.71	4.37e-06	0.00253	0.46	0.3	Coronary artery disease;	chr7:12424300	chr7:12496429~12541910:+
OV	cis	rs1858037	0.867	rs4671658	ENSG00000234255.7	AC012370.3	-4.71	4.37e-06	0.00253	-0.32	-0.3	Rheumatoid arthritis;	chr2:65334258	chr2:65439888~65456571:-
OV	cis	rs11062987	0.522	rs11063036	ENSG00000243507.1	RP11-476M19.1	-4.71	4.37e-06	0.00253	-0.69	-0.3	Alzheimer disease and age of onset;	chr12:4203543	chr12:3468950~3469296:+
OV	cis	rs10829156	0.625	rs10828906	ENSG00000225527.1	RP11-383B4.4	-4.71	4.37e-06	0.00253	-0.37	-0.3	Sudden cardiac arrest;	chr10:18552866	chr10:18531849~18533336:-
OV	cis	rs7829975	0.686	rs907180	ENSG00000253893.2	FAM85B	-4.71	4.38e-06	0.00254	-0.33	-0.3	Mood instability;	chr8:8845317	chr8:8167819~8226614:-
OV	cis	rs9309473	1	rs13421462	ENSG00000163016.8	ALMS1P	4.71	4.38e-06	0.00254	0.34	0.3	Metabolite levels;	chr2:73492748	chr2:73644919~73685576:+
OV	cis	rs67311347	0.955	rs6599100	ENSG00000223797.4	ENTPD3-AS1	4.71	4.38e-06	0.00254	0.32	0.3	Renal cell carcinoma;	chr3:40405871	chr3:40313802~40453329:-
OV	cis	rs17301013	0.507	rs10489256	ENSG00000227373.4	RP11-160H22.5	4.71	4.39e-06	0.00254	0.41	0.3	Systemic lupus erythematosus;	chr1:174359663	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs4651016	ENSG00000227373.4	RP11-160H22.5	4.71	4.39e-06	0.00254	0.41	0.3	Systemic lupus erythematosus;	chr1:174375146	chr1:174115300~174160004:-
OV	cis	rs11690935	0.61	rs59844139	ENSG00000228389.1	AC068039.4	-4.71	4.39e-06	0.00254	-0.33	-0.3	Schizophrenia;	chr2:171875473	chr2:171773482~171775844:+
OV	cis	rs11157436	1	rs61972228	ENSG00000211812.1	TRAV26-2	-4.71	4.4e-06	0.00254	-0.36	-0.3	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22179460	chr14:22202583~22203368:+
OV	cis	rs11157436	1	rs12587157	ENSG00000211812.1	TRAV26-2	-4.71	4.4e-06	0.00254	-0.36	-0.3	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22181476	chr14:22202583~22203368:+
OV	cis	rs11157436	0.915	rs11622938	ENSG00000211812.1	TRAV26-2	-4.71	4.4e-06	0.00254	-0.36	-0.3	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22183456	chr14:22202583~22203368:+
OV	cis	rs11157436	1	rs75648426	ENSG00000211812.1	TRAV26-2	-4.71	4.4e-06	0.00254	-0.36	-0.3	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22184044	chr14:22202583~22203368:+
OV	cis	rs17301013	0.606	rs724889	ENSG00000227373.4	RP11-160H22.5	-4.71	4.4e-06	0.00254	-0.4	-0.3	Systemic lupus erythematosus;	chr1:174180326	chr1:174115300~174160004:-
OV	cis	rs875971	0.545	rs17138149	ENSG00000237310.1	GS1-124K5.4	4.71	4.4e-06	0.00254	0.33	0.3	Aortic root size;	chr7:66228193	chr7:66493706~66495474:+
OV	cis	rs9291683	0.588	rs4697705	ENSG00000250413.1	RP11-448G15.1	4.71	4.4e-06	0.00255	0.34	0.3	Bone mineral density;	chr4:10106503	chr4:10006482~10009725:+
OV	cis	rs875971	0.862	rs709596	ENSG00000236529.1	RP13-254B10.1	4.71	4.4e-06	0.00255	0.31	0.3	Aortic root size;	chr7:66360926	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs778686	ENSG00000236529.1	RP13-254B10.1	4.71	4.4e-06	0.00255	0.31	0.3	Aortic root size;	chr7:66370923	chr7:65840212~65840596:+
OV	cis	rs13068223	1	rs13068223	ENSG00000243926.1	TIPARP-AS1	4.71	4.41e-06	0.00255	0.28	0.3	Age-related hearing impairment (SNP x SNP interaction);	chr3:156753166	chr3:156671862~156674378:-
OV	cis	rs11159086	0.729	rs8015872	ENSG00000270000.1	RP3-449M8.9	4.71	4.41e-06	0.00255	0.43	0.3	Advanced glycation end-product levels;	chr14:74475529	chr14:74471930~74472360:-
OV	cis	rs11159086	0.793	rs10147316	ENSG00000270000.1	RP3-449M8.9	4.71	4.41e-06	0.00255	0.43	0.3	Advanced glycation end-product levels;	chr14:74475688	chr14:74471930~74472360:-
OV	cis	rs11159086	0.838	rs10147963	ENSG00000270000.1	RP3-449M8.9	4.71	4.41e-06	0.00255	0.43	0.3	Advanced glycation end-product levels;	chr14:74476091	chr14:74471930~74472360:-
OV	cis	rs11159086	0.793	rs8021664	ENSG00000270000.1	RP3-449M8.9	4.71	4.41e-06	0.00255	0.43	0.3	Advanced glycation end-product levels;	chr14:74476592	chr14:74471930~74472360:-
OV	cis	rs11159086	0.793	rs10150696	ENSG00000270000.1	RP3-449M8.9	4.71	4.41e-06	0.00255	0.43	0.3	Advanced glycation end-product levels;	chr14:74476723	chr14:74471930~74472360:-
OV	cis	rs11159086	0.793	rs1860108	ENSG00000270000.1	RP3-449M8.9	4.71	4.41e-06	0.00255	0.43	0.3	Advanced glycation end-product levels;	chr14:74478562	chr14:74471930~74472360:-
OV	cis	rs8062405	0.755	rs1074631	ENSG00000259982.1	CDC37P1	-4.7	4.41e-06	0.00255	-0.38	-0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28542787	chr16:28700294~28701540:-
OV	cis	rs1113500	0.73	rs1343203	ENSG00000226822.1	RP11-356N1.2	4.7	4.42e-06	0.00255	0.35	0.3	Growth-regulated protein alpha levels;	chr1:108048560	chr1:108071482~108074519:+
OV	cis	rs875971	0.545	rs1638724	ENSG00000226824.5	RP4-756H11.3	4.7	4.42e-06	0.00256	0.36	0.3	Aortic root size;	chr7:66575494	chr7:66654538~66669855:+
OV	cis	rs2412819	0.545	rs17795279	ENSG00000205771.5	CATSPER2P1	4.7	4.42e-06	0.00256	0.45	0.3	Lung cancer;	chr15:43637180	chr15:43726918~43747094:-
OV	cis	rs783540	0.935	rs2278355	ENSG00000278603.1	RP13-608F4.5	4.7	4.42e-06	0.00256	0.34	0.3	Schizophrenia;	chr15:82662403	chr15:82472203~82472426:+
OV	cis	rs62103177	0.525	rs4799116	ENSG00000261126.6	RP11-795F19.1	-4.7	4.42e-06	0.00256	-0.39	-0.3	Opioid sensitivity;	chr18:79976735	chr18:80046900~80095482:+
OV	cis	rs2688482	0.557	rs3103952	ENSG00000224769.1	AC069213.1	4.7	4.42e-06	0.00256	0.52	0.3	Lung disease severity in cystic fibrosis;	chr3:195795819	chr3:195614947~195620233:+
OV	cis	rs17301013	0.507	rs11802092	ENSG00000227373.4	RP11-160H22.5	4.7	4.43e-06	0.00256	0.39	0.3	Systemic lupus erythematosus;	chr1:174601773	chr1:174115300~174160004:-
OV	cis	rs7617773	0.817	rs13072018	ENSG00000228638.1	FCF1P2	-4.7	4.43e-06	0.00256	-0.38	-0.3	Coronary artery disease;	chr3:48278842	chr3:48290793~48291375:-
OV	cis	rs295490	0.748	rs74636199	ENSG00000272656.1	RP11-219D15.3	4.7	4.43e-06	0.00256	0.54	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139493679	chr3:139349024~139349371:-
OV	cis	rs45509595	0.841	rs17751184	ENSG00000220721.1	OR1F12	4.7	4.43e-06	0.00256	0.61	0.3	Breast cancer;	chr6:27807250	chr6:28073316~28074233:+
OV	cis	rs11673344	0.764	rs826303	ENSG00000226686.6	LINC01535	4.7	4.44e-06	0.00256	0.37	0.3	Obesity-related traits;	chr19:36951549	chr19:37251912~37265535:+
OV	cis	rs4948102	0.642	rs766333	ENSG00000275875.1	RP11-613E4.5	-4.7	4.44e-06	0.00256	-0.32	-0.3	Plasma homocysteine levels (post-methionine load test);	chr7:56059011	chr7:55741525~55741869:+
OV	cis	rs9925964	0.744	rs12716979	ENSG00000278922.1	AC002310.14	-4.7	4.44e-06	0.00257	-0.34	-0.3	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31000500	chr16:30526918~30528294:+
OV	cis	rs4948102	0.597	rs12669623	ENSG00000275875.1	RP11-613E4.5	-4.7	4.44e-06	0.00257	-0.32	-0.3	Plasma homocysteine levels (post-methionine load test);	chr7:56071486	chr7:55741525~55741869:+
OV	cis	rs10510102	0.516	rs12244921	ENSG00000276742.1	RP11-500G22.4	4.7	4.44e-06	0.00257	0.49	0.3	Breast cancer;	chr10:121990342	chr10:121956782~121957098:+
OV	cis	rs4938303	0.633	rs528806	ENSG00000254851.1	RP11-109L13.1	4.7	4.45e-06	0.00257	0.51	0.3	Triglycerides;	chr11:116659197	chr11:117135528~117138582:+
OV	cis	rs853679	0.546	rs200949	ENSG00000220721.1	OR1F12	4.7	4.45e-06	0.00257	0.43	0.3	Depression;	chr6:27867657	chr6:28073316~28074233:+
OV	cis	rs13113518	0.783	rs11133389	ENSG00000223305.1	RN7SKP30	4.7	4.45e-06	0.00257	0.35	0.3	Height;	chr4:55486718	chr4:55540502~55540835:-
OV	cis	rs13113518	0.812	rs4865001	ENSG00000223305.1	RN7SKP30	4.7	4.45e-06	0.00257	0.35	0.3	Height;	chr4:55490176	chr4:55540502~55540835:-
OV	cis	rs13113518	0.812	rs4864543	ENSG00000223305.1	RN7SKP30	4.7	4.45e-06	0.00257	0.35	0.3	Height;	chr4:55490228	chr4:55540502~55540835:-
OV	cis	rs13113518	0.812	rs6825774	ENSG00000223305.1	RN7SKP30	4.7	4.45e-06	0.00257	0.35	0.3	Height;	chr4:55491150	chr4:55540502~55540835:-
OV	cis	rs13113518	0.812	rs3805153	ENSG00000223305.1	RN7SKP30	4.7	4.45e-06	0.00257	0.35	0.3	Height;	chr4:55493557	chr4:55540502~55540835:-
OV	cis	rs13113518	0.756	rs7658446	ENSG00000223305.1	RN7SKP30	4.7	4.45e-06	0.00257	0.35	0.3	Height;	chr4:55495262	chr4:55540502~55540835:-
OV	cis	rs13113518	0.776	rs13124436	ENSG00000223305.1	RN7SKP30	4.7	4.45e-06	0.00257	0.35	0.3	Height;	chr4:55502504	chr4:55540502~55540835:-
OV	cis	rs11159086	0.793	rs11845370	ENSG00000270000.1	RP3-449M8.9	4.7	4.45e-06	0.00257	0.43	0.3	Advanced glycation end-product levels;	chr14:74481587	chr14:74471930~74472360:-
OV	cis	rs11159086	0.793	rs3784035	ENSG00000270000.1	RP3-449M8.9	4.7	4.45e-06	0.00257	0.43	0.3	Advanced glycation end-product levels;	chr14:74482221	chr14:74471930~74472360:-
OV	cis	rs11159086	0.793	rs12433382	ENSG00000270000.1	RP3-449M8.9	4.7	4.45e-06	0.00257	0.43	0.3	Advanced glycation end-product levels;	chr14:74482940	chr14:74471930~74472360:-
OV	cis	rs11159086	0.793	rs10148268	ENSG00000270000.1	RP3-449M8.9	4.7	4.45e-06	0.00257	0.43	0.3	Advanced glycation end-product levels;	chr14:74484261	chr14:74471930~74472360:-
OV	cis	rs11159086	0.793	rs11850070	ENSG00000270000.1	RP3-449M8.9	4.7	4.45e-06	0.00257	0.43	0.3	Advanced glycation end-product levels;	chr14:74487575	chr14:74471930~74472360:-
OV	cis	rs11159086	0.793	rs28378078	ENSG00000270000.1	RP3-449M8.9	4.7	4.45e-06	0.00257	0.43	0.3	Advanced glycation end-product levels;	chr14:74487940	chr14:74471930~74472360:-
OV	cis	rs11159086	0.793	rs9285594	ENSG00000270000.1	RP3-449M8.9	4.7	4.45e-06	0.00257	0.43	0.3	Advanced glycation end-product levels;	chr14:74489253	chr14:74471930~74472360:-
OV	cis	rs11159086	0.793	rs4903229	ENSG00000270000.1	RP3-449M8.9	4.7	4.45e-06	0.00257	0.43	0.3	Advanced glycation end-product levels;	chr14:74489865	chr14:74471930~74472360:-
OV	cis	rs11159086	0.793	rs8016972	ENSG00000270000.1	RP3-449M8.9	4.7	4.45e-06	0.00257	0.43	0.3	Advanced glycation end-product levels;	chr14:74491833	chr14:74471930~74472360:-
OV	cis	rs11159086	0.793	rs8015894	ENSG00000270000.1	RP3-449M8.9	4.7	4.45e-06	0.00257	0.43	0.3	Advanced glycation end-product levels;	chr14:74491917	chr14:74471930~74472360:-
OV	cis	rs13315649	0.639	rs7612926	ENSG00000242551.2	POU5F1P6	-4.7	4.47e-06	0.00258	-0.39	-0.3	Sum eosinophil basophil counts;	chr3:128689221	chr3:128674735~128677005:-
OV	cis	rs4908768	0.534	rs11586056	ENSG00000228423.2	RP4-633I8.4	4.7	4.47e-06	0.00258	0.36	0.3	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8785140	chr1:8805860~8807051:-
OV	cis	rs1150668	0.83	rs213240	ENSG00000204709.4	LINC01556	4.7	4.48e-06	0.00258	0.35	0.3	Pubertal anthropometrics;	chr6:28348098	chr6:28943877~28944537:+
OV	cis	rs1979679	0.659	rs11049461	ENSG00000278733.1	RP11-425D17.1	4.7	4.48e-06	0.00258	0.38	0.3	Ossification of the posterior longitudinal ligament of the spine;	chr12:28207688	chr12:28185625~28186190:-
OV	cis	rs9291683	0.526	rs12506122	ENSG00000250413.1	RP11-448G15.1	-4.7	4.49e-06	0.00259	-0.34	-0.3	Bone mineral density;	chr4:10031914	chr4:10006482~10009725:+
OV	cis	rs9291683	0.507	rs3775940	ENSG00000250413.1	RP11-448G15.1	-4.7	4.49e-06	0.00259	-0.34	-0.3	Bone mineral density;	chr4:10023539	chr4:10006482~10009725:+
OV	cis	rs6907340	0.517	rs9465531	ENSG00000237404.1	RP3-471C18.2	-4.7	4.49e-06	0.00259	-0.38	-0.3	Endometriosis;	chr6:19798418	chr6:19689825~19753113:-
OV	cis	rs2243480	0.522	rs431168	ENSG00000222364.1	RNU6-96P	-4.7	4.49e-06	0.00259	-0.53	-0.3	Diabetic kidney disease;	chr7:66046617	chr7:66395191~66395286:+
OV	cis	rs992157	0.835	rs13005100	ENSG00000261338.2	RP11-378A13.1	-4.7	4.5e-06	0.00259	-0.35	-0.3	Colorectal cancer;	chr2:218287044	chr2:218255319~218257366:+
OV	cis	rs992157	0.835	rs13031757	ENSG00000261338.2	RP11-378A13.1	-4.7	4.5e-06	0.00259	-0.35	-0.3	Colorectal cancer;	chr2:218287203	chr2:218255319~218257366:+
OV	cis	rs992157	0.835	rs34353396	ENSG00000261338.2	RP11-378A13.1	-4.7	4.5e-06	0.00259	-0.35	-0.3	Colorectal cancer;	chr2:218289259	chr2:218255319~218257366:+
OV	cis	rs7617773	0.78	rs3731489	ENSG00000228638.1	FCF1P2	-4.7	4.5e-06	0.00259	-0.38	-0.3	Coronary artery disease;	chr3:48187416	chr3:48290793~48291375:-
OV	cis	rs6471393	0.964	rs2914959	ENSG00000253848.1	RP11-10N23.5	4.7	4.5e-06	0.00259	0.39	0.3	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93727117	chr8:93741193~93744534:+
OV	cis	rs10740039	0.883	rs7088404	ENSG00000254271.1	RP11-131N11.4	4.7	4.5e-06	0.00259	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60633320	chr10:60734342~60741828:+
OV	cis	rs10740039	0.883	rs1837946	ENSG00000254271.1	RP11-131N11.4	4.7	4.5e-06	0.00259	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60633676	chr10:60734342~60741828:+
OV	cis	rs10740039	0.883	rs1837945	ENSG00000254271.1	RP11-131N11.4	4.7	4.5e-06	0.00259	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60633757	chr10:60734342~60741828:+
OV	cis	rs10740039	0.883	rs7089287	ENSG00000254271.1	RP11-131N11.4	4.7	4.5e-06	0.00259	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634006	chr10:60734342~60741828:+
OV	cis	rs10740039	0.883	rs7089720	ENSG00000254271.1	RP11-131N11.4	4.7	4.5e-06	0.00259	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634063	chr10:60734342~60741828:+
OV	cis	rs10740039	0.883	rs7093573	ENSG00000254271.1	RP11-131N11.4	4.7	4.5e-06	0.00259	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634611	chr10:60734342~60741828:+
OV	cis	rs10740039	0.804	rs7093882	ENSG00000254271.1	RP11-131N11.4	4.7	4.5e-06	0.00259	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60634863	chr10:60734342~60741828:+
OV	cis	rs10740039	0.883	rs7097818	ENSG00000254271.1	RP11-131N11.4	4.7	4.5e-06	0.00259	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60635106	chr10:60734342~60741828:+
OV	cis	rs10740039	0.842	rs2119913	ENSG00000254271.1	RP11-131N11.4	4.7	4.5e-06	0.00259	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60635631	chr10:60734342~60741828:+
OV	cis	rs10740039	0.586	rs7068462	ENSG00000254271.1	RP11-131N11.4	4.7	4.5e-06	0.00259	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60636240	chr10:60734342~60741828:+
OV	cis	rs10740039	0.883	rs7069814	ENSG00000254271.1	RP11-131N11.4	4.7	4.5e-06	0.00259	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60637001	chr10:60734342~60741828:+
OV	cis	rs10740039	0.883	rs10821809	ENSG00000254271.1	RP11-131N11.4	4.7	4.5e-06	0.00259	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60637612	chr10:60734342~60741828:+
OV	cis	rs10740039	0.883	rs10740037	ENSG00000254271.1	RP11-131N11.4	4.7	4.5e-06	0.00259	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60637747	chr10:60734342~60741828:+
OV	cis	rs10740039	0.804	rs10761531	ENSG00000254271.1	RP11-131N11.4	4.7	4.5e-06	0.00259	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60638177	chr10:60734342~60741828:+
OV	cis	rs10740039	0.883	rs10761533	ENSG00000254271.1	RP11-131N11.4	4.7	4.5e-06	0.00259	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60638573	chr10:60734342~60741828:+
OV	cis	rs10740039	0.846	rs2165690	ENSG00000254271.1	RP11-131N11.4	4.7	4.5e-06	0.00259	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639609	chr10:60734342~60741828:+
OV	cis	rs10740039	0.883	rs2119911	ENSG00000254271.1	RP11-131N11.4	4.7	4.5e-06	0.00259	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60639808	chr10:60734342~60741828:+
OV	cis	rs10740039	0.883	rs7918897	ENSG00000254271.1	RP11-131N11.4	4.7	4.5e-06	0.00259	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643754	chr10:60734342~60741828:+
OV	cis	rs10740039	0.883	rs7902632	ENSG00000254271.1	RP11-131N11.4	4.7	4.5e-06	0.00259	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643811	chr10:60734342~60741828:+
OV	cis	rs10740039	0.804	rs7902456	ENSG00000254271.1	RP11-131N11.4	4.7	4.5e-06	0.00259	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60643937	chr10:60734342~60741828:+
OV	cis	rs10740039	0.96	rs10761536	ENSG00000254271.1	RP11-131N11.4	4.7	4.5e-06	0.00259	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60644657	chr10:60734342~60741828:+
OV	cis	rs10740039	0.734	rs10821815	ENSG00000254271.1	RP11-131N11.4	4.7	4.5e-06	0.00259	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60644843	chr10:60734342~60741828:+
OV	cis	rs10740039	0.883	rs10994455	ENSG00000254271.1	RP11-131N11.4	4.7	4.5e-06	0.00259	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60645589	chr10:60734342~60741828:+
OV	cis	rs10740039	0.96	rs10443928	ENSG00000254271.1	RP11-131N11.4	4.7	4.5e-06	0.00259	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60645718	chr10:60734342~60741828:+
OV	cis	rs10740039	0.883	rs10443929	ENSG00000254271.1	RP11-131N11.4	4.7	4.5e-06	0.00259	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60645852	chr10:60734342~60741828:+
OV	cis	rs295490	0.667	rs76728176	ENSG00000272656.1	RP11-219D15.3	4.7	4.51e-06	0.0026	0.54	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139441574	chr3:139349024~139349371:-
OV	cis	rs9880211	1	rs6768743	ENSG00000239213.4	NCK1-AS1	-4.7	4.51e-06	0.0026	-0.35	-0.3	Height;Body mass index;	chr3:136486165	chr3:136841726~136862054:-
OV	cis	rs8113142	0.943	rs73014990	ENSG00000267243.4	AC005307.3	-4.7	4.51e-06	0.0026	-0.54	-0.3	Femoral neck bone geometry and menarche (age at onset);	chr19:28515609	chr19:28435388~28727777:-
OV	cis	rs11096990	0.613	rs4974995	ENSG00000249207.1	RP11-360F5.1	4.7	4.51e-06	0.0026	0.33	0.3	Cognitive function;	chr4:39216503	chr4:39112677~39126818:-
OV	cis	rs992157	0.835	rs2271543	ENSG00000261338.2	RP11-378A13.1	-4.7	4.53e-06	0.00261	-0.35	-0.3	Colorectal cancer;	chr2:218277768	chr2:218255319~218257366:+
OV	cis	rs992157	0.717	rs3817266	ENSG00000261338.2	RP11-378A13.1	-4.7	4.53e-06	0.00261	-0.35	-0.3	Colorectal cancer;	chr2:218277871	chr2:218255319~218257366:+
OV	cis	rs992157	0.835	rs2292551	ENSG00000261338.2	RP11-378A13.1	-4.7	4.53e-06	0.00261	-0.35	-0.3	Colorectal cancer;	chr2:218278506	chr2:218255319~218257366:+
OV	cis	rs992157	0.835	rs12987180	ENSG00000261338.2	RP11-378A13.1	-4.7	4.53e-06	0.00261	-0.35	-0.3	Colorectal cancer;	chr2:218279366	chr2:218255319~218257366:+
OV	cis	rs992157	0.835	rs4674283	ENSG00000261338.2	RP11-378A13.1	-4.7	4.53e-06	0.00261	-0.35	-0.3	Colorectal cancer;	chr2:218279531	chr2:218255319~218257366:+
OV	cis	rs992157	0.835	rs2045434	ENSG00000261338.2	RP11-378A13.1	-4.7	4.53e-06	0.00261	-0.35	-0.3	Colorectal cancer;	chr2:218279775	chr2:218255319~218257366:+
OV	cis	rs2999052	0.713	rs1702119	ENSG00000277250.1	Metazoa_SRP	4.7	4.54e-06	0.00261	0.38	0.3	Hypospadias;	chr3:128375650	chr3:128673681~128674021:-
OV	cis	rs1113500	0.933	rs4590700	ENSG00000226822.1	RP11-356N1.2	4.7	4.54e-06	0.00261	0.36	0.3	Growth-regulated protein alpha levels;	chr1:108095722	chr1:108071482~108074519:+
OV	cis	rs8113142	0.943	rs75698649	ENSG00000267243.4	AC005307.3	-4.7	4.54e-06	0.00261	-0.55	-0.3	Femoral neck bone geometry and menarche (age at onset);	chr19:28509753	chr19:28435388~28727777:-
OV	cis	rs8113142	0.943	rs56675947	ENSG00000267243.4	AC005307.3	-4.7	4.54e-06	0.00261	-0.55	-0.3	Femoral neck bone geometry and menarche (age at onset);	chr19:28512160	chr19:28435388~28727777:-
OV	cis	rs2999052	0.805	rs1735546	ENSG00000277250.1	Metazoa_SRP	4.7	4.54e-06	0.00261	0.38	0.3	Hypospadias;	chr3:128356555	chr3:128673681~128674021:-
OV	cis	rs67180937	0.733	rs35725247	ENSG00000272750.1	RP11-378J18.8	-4.7	4.54e-06	0.00261	-0.32	-0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222706825	chr1:222658867~222661512:-
OV	cis	rs17301013	0.507	rs6677243	ENSG00000227373.4	RP11-160H22.5	4.7	4.55e-06	0.00261	0.38	0.3	Systemic lupus erythematosus;	chr1:174339471	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs10912766	ENSG00000227373.4	RP11-160H22.5	4.7	4.55e-06	0.00261	0.38	0.3	Systemic lupus erythematosus;	chr1:174341129	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12059307	ENSG00000227373.4	RP11-160H22.5	4.7	4.55e-06	0.00261	0.38	0.3	Systemic lupus erythematosus;	chr1:174342105	chr1:174115300~174160004:-
OV	cis	rs7580658	0.963	rs4233584	ENSG00000236682.1	AC068282.3	-4.7	4.55e-06	0.00262	-0.39	-0.3	Protein C levels;	chr2:127302587	chr2:127389130~127400580:+
OV	cis	rs1185460	1	rs4614	ENSG00000271751.1	RP11-110I1.14	-4.7	4.55e-06	0.00262	-0.39	-0.3	Coronary artery disease;	chr11:119081661	chr11:119065263~119065677:-
OV	cis	rs13068223	0.607	rs184695	ENSG00000243926.1	TIPARP-AS1	-4.7	4.56e-06	0.00262	-0.28	-0.3	Age-related hearing impairment (SNP x SNP interaction);	chr3:156679600	chr3:156671862~156674378:-
OV	cis	rs11096990	0.634	rs10010352	ENSG00000249207.1	RP11-360F5.1	-4.7	4.57e-06	0.00263	-0.32	-0.3	Cognitive function;	chr4:39240657	chr4:39112677~39126818:-
OV	cis	rs7043114	0.544	rs12335553	ENSG00000281156.1	MIR3651	-4.7	4.57e-06	0.00263	-0.32	-0.3	Height;	chr9:92535589	chr9:92292458~92292547:-
OV	cis	rs7043114	0.563	rs987554	ENSG00000281156.1	MIR3651	-4.7	4.57e-06	0.00263	-0.32	-0.3	Height;	chr9:92536456	chr9:92292458~92292547:-
OV	cis	rs10992471	0.651	rs13296623	ENSG00000281156.1	MIR3651	-4.7	4.57e-06	0.00263	-0.32	-0.3	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92539345	chr9:92292458~92292547:-
OV	cis	rs1044573	0.514	rs2268879	ENSG00000274973.1	RP13-401N8.7	4.7	4.58e-06	0.00263	0.37	0.3	Allergic rhinitis;	chr20:25197169	chr20:25845497~25845862:+
OV	cis	rs10771431	1	rs11611670	ENSG00000111788.10	RP11-22B23.1	4.7	4.58e-06	0.00263	0.27	0.3	Breast size;	chr12:9232939	chr12:9277235~9313241:+
OV	cis	rs875971	0.862	rs778724	ENSG00000236529.1	RP13-254B10.1	4.7	4.59e-06	0.00264	0.3	0.3	Aortic root size;	chr7:66364304	chr7:65840212~65840596:+
OV	cis	rs875971	0.767	rs1643394	ENSG00000236529.1	RP13-254B10.1	4.7	4.59e-06	0.00264	0.3	0.3	Aortic root size;	chr7:66371107	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs778684	ENSG00000236529.1	RP13-254B10.1	4.7	4.59e-06	0.00264	0.3	0.3	Aortic root size;	chr7:66371416	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs778680	ENSG00000236529.1	RP13-254B10.1	4.7	4.59e-06	0.00264	0.3	0.3	Aortic root size;	chr7:66375427	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs11769079	ENSG00000236529.1	RP13-254B10.1	4.7	4.59e-06	0.00264	0.3	0.3	Aortic root size;	chr7:66377141	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs1695820	ENSG00000236529.1	RP13-254B10.1	4.7	4.59e-06	0.00264	0.3	0.3	Aortic root size;	chr7:66379576	chr7:65840212~65840596:+
OV	cis	rs875971	0.83	rs778715	ENSG00000236529.1	RP13-254B10.1	4.7	4.59e-06	0.00264	0.3	0.3	Aortic root size;	chr7:66384222	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs778702	ENSG00000236529.1	RP13-254B10.1	4.7	4.59e-06	0.00264	0.3	0.3	Aortic root size;	chr7:66399848	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs1643375	ENSG00000236529.1	RP13-254B10.1	4.7	4.59e-06	0.00264	0.3	0.3	Aortic root size;	chr7:66407690	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs6962717	ENSG00000236529.1	RP13-254B10.1	4.7	4.59e-06	0.00264	0.3	0.3	Aortic root size;	chr7:66418748	chr7:65840212~65840596:+
OV	cis	rs1862618	0.853	rs252916	ENSG00000271828.1	CTD-2310F14.1	4.7	4.6e-06	0.00264	0.46	0.3	Initial pursuit acceleration;	chr5:56825961	chr5:56927874~56929573:+
OV	cis	rs9287719	0.87	rs728135	ENSG00000234818.1	AC092687.5	4.7	4.6e-06	0.00264	0.32	0.3	Prostate cancer;	chr2:10605006	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs963831	ENSG00000234818.1	AC092687.5	4.7	4.6e-06	0.00264	0.32	0.3	Prostate cancer;	chr2:10605058	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs728134	ENSG00000234818.1	AC092687.5	4.7	4.6e-06	0.00264	0.32	0.3	Prostate cancer;	chr2:10605061	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs2884233	ENSG00000234818.1	AC092687.5	4.7	4.6e-06	0.00264	0.32	0.3	Prostate cancer;	chr2:10605177	chr2:10589166~10604830:+
OV	cis	rs9287719	0.839	rs12692415	ENSG00000234818.1	AC092687.5	4.7	4.6e-06	0.00264	0.32	0.3	Prostate cancer;	chr2:10605348	chr2:10589166~10604830:+
OV	cis	rs9287719	0.934	rs12692416	ENSG00000234818.1	AC092687.5	4.7	4.6e-06	0.00264	0.32	0.3	Prostate cancer;	chr2:10605501	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs12692417	ENSG00000234818.1	AC092687.5	4.7	4.6e-06	0.00264	0.32	0.3	Prostate cancer;	chr2:10605592	chr2:10589166~10604830:+
OV	cis	rs9287719	0.934	rs12692418	ENSG00000234818.1	AC092687.5	4.7	4.6e-06	0.00264	0.32	0.3	Prostate cancer;	chr2:10605744	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs6755548	ENSG00000234818.1	AC092687.5	4.7	4.6e-06	0.00264	0.32	0.3	Prostate cancer;	chr2:10606000	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs6761678	ENSG00000234818.1	AC092687.5	4.7	4.6e-06	0.00264	0.32	0.3	Prostate cancer;	chr2:10606215	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs6759100	ENSG00000234818.1	AC092687.5	4.7	4.6e-06	0.00264	0.32	0.3	Prostate cancer;	chr2:10606584	chr2:10589166~10604830:+
OV	cis	rs8113142	0.887	rs73016915	ENSG00000267243.4	AC005307.3	-4.7	4.61e-06	0.00264	-0.55	-0.3	Femoral neck bone geometry and menarche (age at onset);	chr19:28522707	chr19:28435388~28727777:-
OV	cis	rs8113142	0.832	rs59220969	ENSG00000267243.4	AC005307.3	-4.7	4.61e-06	0.00264	-0.55	-0.3	Femoral neck bone geometry and menarche (age at onset);	chr19:28525985	chr19:28435388~28727777:-
OV	cis	rs10829156	0.699	rs10828879	ENSG00000225527.1	RP11-383B4.4	-4.7	4.61e-06	0.00264	-0.37	-0.3	Sudden cardiac arrest;	chr10:18546425	chr10:18531849~18533336:-
OV	cis	rs7829975	0.711	rs12682352	ENSG00000253981.4	ALG1L13P	4.69	4.61e-06	0.00265	0.3	0.3	Mood instability;	chr8:8788736	chr8:8236003~8244667:-
OV	cis	rs2243480	0.901	rs778732	ENSG00000226824.5	RP4-756H11.3	-4.69	4.62e-06	0.00265	-0.48	-0.3	Diabetic kidney disease;	chr7:66357373	chr7:66654538~66669855:+
OV	cis	rs4713118	0.513	rs156734	ENSG00000219392.1	RP1-265C24.5	-4.69	4.62e-06	0.00265	-0.36	-0.3	Parkinson's disease;	chr6:28039579	chr6:28115628~28116551:+
OV	cis	rs67311347	0.577	rs1880763	ENSG00000223797.4	ENTPD3-AS1	-4.69	4.62e-06	0.00265	-0.31	-0.3	Renal cell carcinoma;	chr3:40241764	chr3:40313802~40453329:-
OV	cis	rs1499614	1	rs2659903	ENSG00000226824.5	RP4-756H11.3	-4.69	4.63e-06	0.00265	-0.49	-0.3	Gout;	chr7:66715944	chr7:66654538~66669855:+
OV	cis	rs1075265	0.933	rs7607066	ENSG00000233266.1	HMGB1P31	4.69	4.63e-06	0.00266	0.35	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54110054	chr2:54051334~54051760:+
OV	cis	rs875971	0.545	rs6460298	ENSG00000226824.5	RP4-756H11.3	-4.69	4.63e-06	0.00266	-0.36	-0.3	Aortic root size;	chr7:66442783	chr7:66654538~66669855:+
OV	cis	rs875971	0.545	rs75577046	ENSG00000226824.5	RP4-756H11.3	-4.69	4.63e-06	0.00266	-0.36	-0.3	Aortic root size;	chr7:66493729	chr7:66654538~66669855:+
OV	cis	rs875971	0.545	rs3735147	ENSG00000226824.5	RP4-756H11.3	-4.69	4.63e-06	0.00266	-0.36	-0.3	Aortic root size;	chr7:66505541	chr7:66654538~66669855:+
OV	cis	rs67311347	0.605	rs1880762	ENSG00000223797.4	ENTPD3-AS1	4.69	4.63e-06	0.00266	0.32	0.3	Renal cell carcinoma;	chr3:40241724	chr3:40313802~40453329:-
OV	cis	rs73201462	1	rs13095660	ENSG00000277250.1	Metazoa_SRP	4.69	4.63e-06	0.00266	0.46	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128129313	chr3:128673681~128674021:-
OV	cis	rs73201462	0.708	rs6788497	ENSG00000277250.1	Metazoa_SRP	4.69	4.63e-06	0.00266	0.46	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128129545	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs6439116	ENSG00000277250.1	Metazoa_SRP	4.69	4.63e-06	0.00266	0.46	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128130224	chr3:128673681~128674021:-
OV	cis	rs13059975	1	rs13059975	ENSG00000277250.1	Metazoa_SRP	4.69	4.63e-06	0.00266	0.46	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128130841	chr3:128673681~128674021:-
OV	cis	rs34174370	1	rs34174370	ENSG00000277250.1	Metazoa_SRP	4.69	4.63e-06	0.00266	0.46	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128130901	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs11714619	ENSG00000277250.1	Metazoa_SRP	4.69	4.63e-06	0.00266	0.46	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128131233	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs6783253	ENSG00000277250.1	Metazoa_SRP	4.69	4.63e-06	0.00266	0.46	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128132718	chr3:128673681~128674021:-
OV	cis	rs73201462	0.901	rs35347185	ENSG00000277250.1	Metazoa_SRP	4.69	4.63e-06	0.00266	0.46	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128135684	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs6797834	ENSG00000277250.1	Metazoa_SRP	4.69	4.63e-06	0.00266	0.46	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128137557	chr3:128673681~128674021:-
OV	cis	rs73201462	0.708	rs11709725	ENSG00000277250.1	Metazoa_SRP	4.69	4.63e-06	0.00266	0.46	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128139090	chr3:128673681~128674021:-
OV	cis	rs73201462	0.808	rs34689870	ENSG00000277250.1	Metazoa_SRP	4.69	4.63e-06	0.00266	0.46	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128141636	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs34817706	ENSG00000277250.1	Metazoa_SRP	4.69	4.63e-06	0.00266	0.46	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128142215	chr3:128673681~128674021:-
OV	cis	rs6800225	1	rs6800225	ENSG00000277250.1	Metazoa_SRP	4.69	4.63e-06	0.00266	0.46	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128143335	chr3:128673681~128674021:-
OV	cis	rs9309473	0.95	rs1918863	ENSG00000163016.8	ALMS1P	4.69	4.64e-06	0.00266	0.35	0.3	Metabolite levels;	chr2:73417353	chr2:73644919~73685576:+
OV	cis	rs1891275	0.509	rs34190234	ENSG00000228701.1	TNKS2-AS1	-4.69	4.64e-06	0.00266	-0.33	-0.3	Intelligence (multi-trait analysis);	chr10:91683317	chr10:91782839~91798291:-
OV	cis	rs1891275	0.509	rs76313529	ENSG00000228701.1	TNKS2-AS1	-4.69	4.64e-06	0.00266	-0.33	-0.3	Intelligence (multi-trait analysis);	chr10:91683319	chr10:91782839~91798291:-
OV	cis	rs1134634	0.52	rs3822298	ENSG00000273133.1	RP11-799M12.2	-4.69	4.64e-06	0.00266	-0.4	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15554780	chr4:15563698~15564253:-
OV	cis	rs8113142	1	rs12461451	ENSG00000267243.4	AC005307.3	-4.69	4.64e-06	0.00266	-0.55	-0.3	Femoral neck bone geometry and menarche (age at onset);	chr19:28526582	chr19:28435388~28727777:-
OV	cis	rs875971	1	rs2087647	ENSG00000236529.1	RP13-254B10.1	-4.69	4.65e-06	0.00266	-0.31	-0.3	Aortic root size;	chr7:66128201	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs6958484	ENSG00000236529.1	RP13-254B10.1	-4.69	4.65e-06	0.00266	-0.31	-0.3	Aortic root size;	chr7:66134459	chr7:65840212~65840596:+
OV	cis	rs1150668	0.796	rs9468372	ENSG00000204709.4	LINC01556	4.69	4.65e-06	0.00266	0.34	0.3	Pubertal anthropometrics;	chr6:28411584	chr6:28943877~28944537:+
OV	cis	rs11096990	0.634	rs11736790	ENSG00000249207.1	RP11-360F5.1	-4.69	4.65e-06	0.00266	-0.31	-0.3	Cognitive function;	chr4:39254704	chr4:39112677~39126818:-
OV	cis	rs11096990	0.634	rs1451818	ENSG00000249207.1	RP11-360F5.1	-4.69	4.65e-06	0.00266	-0.31	-0.3	Cognitive function;	chr4:39257151	chr4:39112677~39126818:-
OV	cis	rs1075265	0.704	rs13417926	ENSG00000233266.1	HMGB1P31	4.69	4.66e-06	0.00267	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53825520	chr2:54051334~54051760:+
OV	cis	rs1075265	0.933	rs2287642	ENSG00000233266.1	HMGB1P31	4.69	4.66e-06	0.00267	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:54108447	chr2:54051334~54051760:+
OV	cis	rs11039131	0.929	rs1685404	ENSG00000271350.1	CTD-2384B9.1	-4.69	4.67e-06	0.00267	-0.36	-0.3	Schizophrenia;	chr11:47222114	chr11:47041027~47041945:-
OV	cis	rs9287719	0.967	rs6735074	ENSG00000234818.1	AC092687.5	-4.69	4.67e-06	0.00267	-0.32	-0.3	Prostate cancer;	chr2:10594640	chr2:10589166~10604830:+
OV	cis	rs1891275	0.515	rs1592051	ENSG00000228701.1	TNKS2-AS1	4.69	4.67e-06	0.00267	0.33	0.3	Intelligence (multi-trait analysis);	chr10:91782429	chr10:91782839~91798291:-
OV	cis	rs3733585	0.638	rs28715627	ENSG00000250413.1	RP11-448G15.1	4.69	4.68e-06	0.00268	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9956516	chr4:10006482~10009725:+
OV	cis	rs3733585	0.664	rs17245436	ENSG00000250413.1	RP11-448G15.1	4.69	4.68e-06	0.00268	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9956545	chr4:10006482~10009725:+
OV	cis	rs3733585	0.638	rs17185835	ENSG00000250413.1	RP11-448G15.1	4.69	4.68e-06	0.00268	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9956556	chr4:10006482~10009725:+
OV	cis	rs7927592	0.717	rs7126451	ENSG00000212093.1	AP000807.1	-4.69	4.68e-06	0.00268	-0.35	-0.3	Total body bone mineral density;	chr11:68489918	chr11:68506083~68506166:-
OV	cis	rs3733585	0.725	rs10939636	ENSG00000250413.1	RP11-448G15.1	4.69	4.68e-06	0.00268	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9971016	chr4:10006482~10009725:+
OV	cis	rs4805272	1	rs4805272	ENSG00000267243.4	AC005307.3	-4.69	4.68e-06	0.00268	-0.4	-0.3	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28828799	chr19:28435388~28727777:-
OV	cis	rs6991838	0.778	rs11779601	ENSG00000272010.1	CTD-3025N20.3	4.69	4.68e-06	0.00268	0.38	0.3	Intelligence (multi-trait analysis);	chr8:65550241	chr8:65591850~65592472:-
OV	cis	rs301901	0.965	rs1466862	ENSG00000250155.1	CTD-2353F22.1	-4.69	4.69e-06	0.00268	-0.35	-0.3	Height;	chr5:36791710	chr5:36666214~36725195:-
OV	cis	rs4908768	0.657	rs11121229	ENSG00000228423.2	RP4-633I8.4	-4.69	4.69e-06	0.00268	-0.34	-0.3	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8771224	chr1:8805860~8807051:-
OV	cis	rs7927592	0.763	rs10896351	ENSG00000212093.1	AP000807.1	4.69	4.69e-06	0.00268	0.35	0.3	Total body bone mineral density;	chr11:68619428	chr11:68506083~68506166:-
OV	cis	rs9487094	0.813	rs12528712	ENSG00000260273.1	RP11-425D10.10	4.69	4.69e-06	0.00268	0.34	0.3	Height;	chr6:109339681	chr6:109382795~109383666:+
OV	cis	rs9309473	0.95	rs10198549	ENSG00000163016.8	ALMS1P	4.69	4.7e-06	0.00269	0.34	0.3	Metabolite levels;	chr2:73567277	chr2:73644919~73685576:+
OV	cis	rs9309473	1	rs9653557	ENSG00000163016.8	ALMS1P	4.69	4.7e-06	0.00269	0.34	0.3	Metabolite levels;	chr2:73568835	chr2:73644919~73685576:+
OV	cis	rs9309473	0.848	rs17009159	ENSG00000163016.8	ALMS1P	4.69	4.7e-06	0.00269	0.34	0.3	Metabolite levels;	chr2:73570635	chr2:73644919~73685576:+
OV	cis	rs9309473	1	rs7583255	ENSG00000163016.8	ALMS1P	4.69	4.7e-06	0.00269	0.34	0.3	Metabolite levels;	chr2:73570869	chr2:73644919~73685576:+
OV	cis	rs9309473	1	rs7586463	ENSG00000163016.8	ALMS1P	4.69	4.7e-06	0.00269	0.34	0.3	Metabolite levels;	chr2:73571349	chr2:73644919~73685576:+
OV	cis	rs9309473	0.948	rs10173534	ENSG00000163016.8	ALMS1P	4.69	4.7e-06	0.00269	0.34	0.3	Metabolite levels;	chr2:73586305	chr2:73644919~73685576:+
OV	cis	rs733592	0.507	rs7304428	ENSG00000258273.1	RP11-370I10.4	4.69	4.7e-06	0.00269	0.36	0.3	Plateletcrit;	chr12:48100492	chr12:48333755~48333901:-
OV	cis	rs7617773	0.779	rs3731487	ENSG00000228638.1	FCF1P2	-4.69	4.7e-06	0.00269	-0.38	-0.3	Coronary artery disease;	chr3:48188134	chr3:48290793~48291375:-
OV	cis	rs11673344	0.704	rs571340	ENSG00000226686.6	LINC01535	4.69	4.7e-06	0.00269	0.37	0.3	Obesity-related traits;	chr19:36933981	chr19:37251912~37265535:+
OV	cis	rs6991838	0.55	rs4737750	ENSG00000200714.1	Y_RNA	4.69	4.72e-06	0.0027	0.39	0.3	Intelligence (multi-trait analysis);	chr8:65638724	chr8:65592731~65592820:+
OV	cis	rs73201462	0.901	rs2955133	ENSG00000277250.1	Metazoa_SRP	-4.69	4.72e-06	0.0027	-0.45	-0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128226479	chr3:128673681~128674021:-
OV	cis	rs10759883	0.563	rs694230	ENSG00000175611.10	LINC00476	4.69	4.73e-06	0.0027	0.36	0.3	Nicotine dependence;	chr9:95954227	chr9:95759231~95875977:-
OV	cis	rs992157	1	rs2168704	ENSG00000261338.2	RP11-378A13.1	4.69	4.73e-06	0.0027	0.34	0.3	Colorectal cancer;	chr2:218277769	chr2:218255319~218257366:+
OV	cis	rs1976403	0.51	rs1697421	ENSG00000227001.3	NBPF2P	4.69	4.73e-06	0.0027	0.34	0.3	Liver enzyme levels (alkaline phosphatase);	chr1:21496799	chr1:21424625~21427967:-
OV	cis	rs6088580	0.609	rs6059844	ENSG00000206582.1	Y_RNA	-4.69	4.74e-06	0.00271	-0.35	-0.3	Glomerular filtration rate (creatinine);	chr20:34448677	chr20:34526510~34526606:-
OV	cis	rs881375	0.678	rs2416804	ENSG00000226752.6	PSMD5-AS1	4.69	4.74e-06	0.00271	0.33	0.3	Rheumatoid arthritis;	chr9:120914118	chr9:120824828~120854385:+
OV	cis	rs473651	0.935	rs540636	ENSG00000229915.1	AC016999.2	-4.69	4.74e-06	0.00271	-0.38	-0.3	Multiple system atrophy;	chr2:238449700	chr2:238427077~238427729:-
OV	cis	rs7829975	0.711	rs4841051	ENSG00000253981.4	ALG1L13P	-4.69	4.74e-06	0.00271	-0.3	-0.3	Mood instability;	chr8:8828136	chr8:8236003~8244667:-
OV	cis	rs1681630	0.545	rs1228001	ENSG00000280615.1	Y_RNA	-4.69	4.74e-06	0.00271	-0.35	-0.3	Height;	chr11:47965442	chr11:47614898~47614994:-
OV	cis	rs2836974	0.583	rs9981884	ENSG00000237373.1	BRWD1-IT1	-4.69	4.75e-06	0.00271	-0.33	-0.3	Cognitive function;	chr21:39213707	chr21:39217093~39219805:-
OV	cis	rs7927592	0.731	rs11228288	ENSG00000212093.1	AP000807.1	4.69	4.75e-06	0.00271	0.35	0.3	Total body bone mineral density;	chr11:68586082	chr11:68506083~68506166:-
OV	cis	rs2253762	0.54	rs10887051	ENSG00000276742.1	RP11-500G22.4	4.69	4.76e-06	0.00272	0.5	0.3	Breast cancer;	chr10:122026030	chr10:121956782~121957098:+
OV	cis	rs7580658	0.545	rs12477559	ENSG00000236682.1	AC068282.3	-4.69	4.76e-06	0.00272	-0.36	-0.3	Protein C levels;	chr2:127194221	chr2:127389130~127400580:+
OV	cis	rs7927592	0.913	rs7107622	ENSG00000212093.1	AP000807.1	4.69	4.76e-06	0.00272	0.37	0.3	Total body bone mineral density;	chr11:68606715	chr11:68506083~68506166:-
OV	cis	rs13113518	0.812	rs6830409	ENSG00000223305.1	RN7SKP30	4.69	4.76e-06	0.00272	0.35	0.3	Height;	chr4:55522229	chr4:55540502~55540835:-
OV	cis	rs13113518	0.841	rs7699867	ENSG00000223305.1	RN7SKP30	4.69	4.77e-06	0.00272	0.35	0.3	Height;	chr4:55483718	chr4:55540502~55540835:-
OV	cis	rs6558530	0.836	rs7461159	ENSG00000253982.1	CTD-2336O2.1	4.69	4.77e-06	0.00273	0.37	0.3	Systolic blood pressure;	chr8:1768450	chr8:1761990~1764502:-
OV	cis	rs73201462	1	rs61044849	ENSG00000277250.1	Metazoa_SRP	4.69	4.78e-06	0.00273	0.49	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128346623	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs57735707	ENSG00000277250.1	Metazoa_SRP	4.69	4.78e-06	0.00273	0.49	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128346972	chr3:128673681~128674021:-
OV	cis	rs1555322	0.53	rs2425044	ENSG00000126005.14	MMP24-AS1	-4.69	4.79e-06	0.00273	-0.41	-0.3	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35216462~35278131:-
OV	cis	rs4964805	0.594	rs4964830	ENSG00000257681.1	RP11-341G23.4	-4.69	4.8e-06	0.00274	-0.33	-0.3	Attention deficit hyperactivity disorder;	chr12:103775130	chr12:103746315~103768858:-
OV	cis	rs1134634	0.52	rs16892152	ENSG00000273133.1	RP11-799M12.2	-4.69	4.8e-06	0.00274	-0.41	-0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15559630	chr4:15563698~15564253:-
OV	cis	rs1113500	0.933	rs11185260	ENSG00000226822.1	RP11-356N1.2	-4.69	4.8e-06	0.00274	-0.36	-0.3	Growth-regulated protein alpha levels;	chr1:108092457	chr1:108071482~108074519:+
OV	cis	rs8054556	0.647	rs11863174	ENSG00000261367.1	RP11-455F5.4	-4.69	4.8e-06	0.00274	-0.33	-0.3	Autism spectrum disorder or schizophrenia;	chr16:30008054	chr16:30107675~30110541:+
OV	cis	rs11690935	0.55	rs6746701	ENSG00000228389.1	AC068039.4	-4.69	4.8e-06	0.00274	-0.34	-0.3	Schizophrenia;	chr2:172004347	chr2:171773482~171775844:+
OV	cis	rs611744	0.647	rs674391	ENSG00000253754.1	RP11-35G22.1	-4.69	4.81e-06	0.00274	-0.33	-0.3	Dupuytren's disease;	chr8:108230574	chr8:108226200~108227544:+
OV	cis	rs4713118	0.621	rs9295755	ENSG00000226314.6	ZNF192P1	4.69	4.81e-06	0.00274	0.4	0.3	Parkinson's disease;	chr6:28065396	chr6:28161781~28169594:+
OV	cis	rs9287719	0.967	rs6432114	ENSG00000234818.1	AC092687.5	4.69	4.82e-06	0.00275	0.32	0.3	Prostate cancer;	chr2:10604804	chr2:10589166~10604830:+
OV	cis	rs3758911	0.894	rs11212166	ENSG00000261098.1	RP11-819C21.1	-4.69	4.82e-06	0.00275	-0.29	-0.3	Coronary artery disease;	chr11:107331878	chr11:107312132~107316271:-
OV	cis	rs3758911	0.894	rs7358308	ENSG00000261098.1	RP11-819C21.1	-4.69	4.82e-06	0.00275	-0.29	-0.3	Coronary artery disease;	chr11:107333178	chr11:107312132~107316271:-
OV	cis	rs1150668	0.796	rs1124132	ENSG00000204709.4	LINC01556	4.68	4.83e-06	0.00275	0.34	0.3	Pubertal anthropometrics;	chr6:28412544	chr6:28943877~28944537:+
OV	cis	rs11157436	1	rs12587166	ENSG00000211812.1	TRAV26-2	-4.68	4.83e-06	0.00275	-0.36	-0.3	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22165492	chr14:22202583~22203368:+
OV	cis	rs12073359	1	rs4926407	ENSG00000223945.2	RP11-458I7.1	4.68	4.83e-06	0.00275	0.44	0.3	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150115706	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs6666959	ENSG00000223945.2	RP11-458I7.1	4.68	4.83e-06	0.00275	0.44	0.3	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150116837	chr1:150053864~150055034:+
OV	cis	rs812925	0.512	rs1177309	ENSG00000271889.1	RP11-493E12.1	4.68	4.83e-06	0.00275	0.34	0.3	Immature fraction of reticulocytes;	chr2:61158113	chr2:61151433~61162105:-
OV	cis	rs13256369	0.951	rs12679360	ENSG00000253893.2	FAM85B	4.68	4.84e-06	0.00276	0.35	0.3	Obesity-related traits;	chr8:8708759	chr8:8167819~8226614:-
OV	cis	rs11671005	0.736	rs11668201	ENSG00000269600.1	AC016629.3	-4.68	4.84e-06	0.00276	-0.42	-0.3	Mean platelet volume;	chr19:58492265	chr19:58593896~58599355:-
OV	cis	rs2380205	0.601	rs4293039	ENSG00000232807.2	RP11-536K7.3	4.68	4.84e-06	0.00276	0.31	0.3	Breast cancer;	chr10:5856261	chr10:5934270~5945900:-
OV	cis	rs6772849	0.768	rs4521246	ENSG00000242551.2	POU5F1P6	4.68	4.85e-06	0.00276	0.36	0.3	Monocyte percentage of white cells;Monocyte count;	chr3:128702323	chr3:128674735~128677005:-
OV	cis	rs172166	0.694	rs203876	ENSG00000280107.1	AL022393.9	-4.68	4.85e-06	0.00276	-0.35	-0.3	Cardiac Troponin-T levels;	chr6:28078895	chr6:28170845~28172521:+
OV	cis	rs172166	0.694	rs203877	ENSG00000280107.1	AL022393.9	-4.68	4.85e-06	0.00276	-0.35	-0.3	Cardiac Troponin-T levels;	chr6:28080846	chr6:28170845~28172521:+
OV	cis	rs2999052	0.805	rs1735549	ENSG00000242551.2	POU5F1P6	4.68	4.86e-06	0.00276	0.41	0.3	Hypospadias;	chr3:128352966	chr3:128674735~128677005:-
OV	cis	rs9309473	1	rs10179134	ENSG00000163016.8	ALMS1P	4.68	4.86e-06	0.00277	0.36	0.3	Metabolite levels;	chr2:73410391	chr2:73644919~73685576:+
OV	cis	rs853679	0.546	rs200989	ENSG00000220721.1	OR1F12	4.68	4.86e-06	0.00277	0.49	0.3	Depression;	chr6:27848664	chr6:28073316~28074233:+
OV	cis	rs7580658	0.963	rs9789510	ENSG00000236682.1	AC068282.3	-4.68	4.86e-06	0.00277	-0.39	-0.3	Protein C levels;	chr2:127379436	chr2:127389130~127400580:+
OV	cis	rs7580658	0.926	rs4662725	ENSG00000236682.1	AC068282.3	-4.68	4.86e-06	0.00277	-0.39	-0.3	Protein C levels;	chr2:127383744	chr2:127389130~127400580:+
OV	cis	rs10829156	0.679	rs4747352	ENSG00000225527.1	RP11-383B4.4	-4.68	4.87e-06	0.00277	-0.4	-0.3	Sudden cardiac arrest;	chr10:18539734	chr10:18531849~18533336:-
OV	cis	rs6772849	1	rs60228913	ENSG00000242551.2	POU5F1P6	-4.68	4.87e-06	0.00277	-0.36	-0.3	Monocyte percentage of white cells;Monocyte count;	chr3:128592488	chr3:128674735~128677005:-
OV	cis	rs7927592	0.763	rs10896340	ENSG00000212093.1	AP000807.1	-4.68	4.88e-06	0.00278	-0.34	-0.3	Total body bone mineral density;	chr11:68545177	chr11:68506083~68506166:-
OV	cis	rs992157	0.835	rs10932768	ENSG00000261338.2	RP11-378A13.1	-4.68	4.89e-06	0.00278	-0.35	-0.3	Colorectal cancer;	chr2:218281476	chr2:218255319~218257366:+
OV	cis	rs1797885	0.844	rs1699351	ENSG00000251774.1	RNU6-377P	4.68	4.9e-06	0.00278	0.28	0.3	Immature fraction of reticulocytes;	chr3:12518818	chr3:12514706~12514807:+
OV	cis	rs7189233	0.55	rs9938788	ENSG00000279344.1	RP11-44F14.7	4.68	4.9e-06	0.00279	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53447510	chr16:53478957~53481550:-
OV	cis	rs4908768	0.657	rs4908778	ENSG00000228423.2	RP4-633I8.4	4.68	4.9e-06	0.00279	0.34	0.3	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8744829	chr1:8805860~8807051:-
OV	cis	rs10740039	0.842	rs1442541	ENSG00000254271.1	RP11-131N11.4	4.68	4.91e-06	0.00279	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60626285	chr10:60734342~60741828:+
OV	cis	rs10740039	0.883	rs1867081	ENSG00000254271.1	RP11-131N11.4	4.68	4.91e-06	0.00279	0.38	0.3	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60626569	chr10:60734342~60741828:+
OV	cis	rs11168351	0.517	rs10875754	ENSG00000258273.1	RP11-370I10.4	-4.68	4.91e-06	0.00279	-0.37	-0.3	Bipolar disorder and schizophrenia;	chr12:48164139	chr12:48333755~48333901:-
OV	cis	rs11673344	0.582	rs114437741	ENSG00000226686.6	LINC01535	4.68	4.91e-06	0.00279	0.37	0.3	Obesity-related traits;	chr19:36955379	chr19:37251912~37265535:+
OV	cis	rs7043114	0.507	rs7037075	ENSG00000281156.1	MIR3651	-4.68	4.92e-06	0.0028	-0.33	-0.3	Height;	chr9:92454331	chr9:92292458~92292547:-
OV	cis	rs875971	0.545	rs10950029	ENSG00000237310.1	GS1-124K5.4	4.68	4.92e-06	0.0028	0.34	0.3	Aortic root size;	chr7:66169334	chr7:66493706~66495474:+
OV	cis	rs4713118	0.869	rs7773070	ENSG00000219392.1	RP1-265C24.5	-4.68	4.93e-06	0.0028	-0.34	-0.3	Parkinson's disease;	chr6:27761048	chr6:28115628~28116551:+
OV	cis	rs875971	0.798	rs12698522	ENSG00000236529.1	RP13-254B10.1	4.68	4.93e-06	0.0028	0.31	0.3	Aortic root size;	chr7:66502354	chr7:65840212~65840596:+
OV	cis	rs875971	0.83	rs28714531	ENSG00000236529.1	RP13-254B10.1	4.68	4.93e-06	0.0028	0.31	0.3	Aortic root size;	chr7:66503250	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs12698526	ENSG00000236529.1	RP13-254B10.1	4.68	4.93e-06	0.0028	0.31	0.3	Aortic root size;	chr7:66504118	chr7:65840212~65840596:+
OV	cis	rs7201929	1	rs8061877	ENSG00000259982.1	CDC37P1	-4.68	4.93e-06	0.0028	-0.4	-0.3	QT interval;	chr16:28845498	chr16:28700294~28701540:-
OV	cis	rs4747241	0.774	rs10762507	ENSG00000226163.1	RP11-167P22.3	4.68	4.94e-06	0.00281	0.34	0.3	Heschl's gyrus morphology;	chr10:72298713	chr10:72501746~72502956:+
OV	cis	rs7302981	0.967	rs7136570	ENSG00000272368.2	RP4-605O3.4	-4.68	4.94e-06	0.00281	-0.33	-0.3	Systolic blood pressure;	chr12:50136153	chr12:50112197~50165618:+
OV	cis	rs116095464	0.558	rs6866632	ENSG00000250848.1	CTD-2083E4.5	-4.68	4.94e-06	0.00281	-0.39	-0.3	Breast cancer;	chr5:264314	chr5:288833~290321:-
OV	cis	rs875971	1	rs6961717	ENSG00000236529.1	RP13-254B10.1	-4.68	4.94e-06	0.00281	-0.3	-0.3	Aortic root size;	chr7:66122550	chr7:65840212~65840596:+
OV	cis	rs295490	0.748	rs41356949	ENSG00000272656.1	RP11-219D15.3	4.68	4.94e-06	0.00281	0.54	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139469580	chr3:139349024~139349371:-
OV	cis	rs295490	0.667	rs78684868	ENSG00000272656.1	RP11-219D15.3	4.68	4.94e-06	0.00281	0.54	0.3	PR interval in Tripanosoma cruzi seropositivity;	chr3:139485651	chr3:139349024~139349371:-
OV	cis	rs9309473	1	rs13383871	ENSG00000163016.8	ALMS1P	4.68	4.95e-06	0.00281	0.36	0.3	Metabolite levels;	chr2:73404651	chr2:73644919~73685576:+
OV	cis	rs17023223	0.553	rs56234947	ENSG00000231365.4	RP11-418J17.1	-4.68	4.95e-06	0.00281	-0.39	-0.3	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119165121	chr1:119140396~119275973:+
OV	cis	rs1862618	0.525	rs2662016	ENSG00000271828.1	CTD-2310F14.1	-4.68	4.95e-06	0.00281	-0.5	-0.3	Initial pursuit acceleration;	chr5:56973220	chr5:56927874~56929573:+
OV	cis	rs1797885	0.934	rs1797889	ENSG00000251774.1	RNU6-377P	4.68	4.96e-06	0.00281	0.28	0.3	Immature fraction of reticulocytes;	chr3:12517887	chr3:12514706~12514807:+
OV	cis	rs1167832	0.59	rs71560454	ENSG00000278416.1	PMS2L2	-4.68	4.96e-06	0.00281	-0.46	-0.3	Ankle injury;	chr7:75465453	chr7:75344015~75359550:-
OV	cis	rs12073359	1	rs10749674	ENSG00000223945.2	RP11-458I7.1	4.68	4.96e-06	0.00281	0.44	0.3	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150104955	chr1:150053864~150055034:+
OV	cis	rs875971	1	rs709595	ENSG00000236529.1	RP13-254B10.1	4.68	4.96e-06	0.00282	0.31	0.3	Aortic root size;	chr7:66352346	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs811880	ENSG00000236529.1	RP13-254B10.1	4.68	4.96e-06	0.00282	0.31	0.3	Aortic root size;	chr7:66353659	chr7:65840212~65840596:+
OV	cis	rs1823913	0.599	rs4146103	ENSG00000227542.1	AC092614.2	4.68	4.97e-06	0.00282	0.33	0.3	Obesity-related traits;	chr2:191272000	chr2:191229165~191246172:-
OV	cis	rs8062405	0.755	rs7193402	ENSG00000278665.1	RP11-666O2.4	4.68	4.97e-06	0.00282	0.32	0.3	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28574806	chr16:28599241~28601881:-
OV	cis	rs13230714	0.858	rs2888075	ENSG00000204959.4	ARHGEF34P	4.68	4.97e-06	0.00282	0.39	0.3	Breast cancer;	chr7:144456786	chr7:144272445~144286966:-
OV	cis	rs875971	0.964	rs778735	ENSG00000236529.1	RP13-254B10.1	4.68	4.98e-06	0.00283	0.31	0.3	Aortic root size;	chr7:66349822	chr7:65840212~65840596:+
OV	cis	rs1499614	1	rs2659913	ENSG00000226824.5	RP4-756H11.3	-4.68	4.99e-06	0.00283	-0.49	-0.3	Gout;	chr7:66692349	chr7:66654538~66669855:+
OV	cis	rs1499614	1	rs2707840	ENSG00000226824.5	RP4-756H11.3	-4.68	4.99e-06	0.00283	-0.49	-0.3	Gout;	chr7:66693028	chr7:66654538~66669855:+
OV	cis	rs1499614	1	rs2659911	ENSG00000226824.5	RP4-756H11.3	-4.68	4.99e-06	0.00283	-0.49	-0.3	Gout;	chr7:66693433	chr7:66654538~66669855:+
OV	cis	rs1499614	1	rs2707838	ENSG00000226824.5	RP4-756H11.3	-4.68	4.99e-06	0.00283	-0.49	-0.3	Gout;	chr7:66694214	chr7:66654538~66669855:+
OV	cis	rs1499614	1	rs60326618	ENSG00000226824.5	RP4-756H11.3	-4.68	4.99e-06	0.00283	-0.49	-0.3	Gout;	chr7:66701371	chr7:66654538~66669855:+
OV	cis	rs1499614	1	rs2707830	ENSG00000226824.5	RP4-756H11.3	-4.68	4.99e-06	0.00283	-0.49	-0.3	Gout;	chr7:66702658	chr7:66654538~66669855:+
OV	cis	rs1499614	1	rs2707828	ENSG00000226824.5	RP4-756H11.3	-4.68	4.99e-06	0.00283	-0.49	-0.3	Gout;	chr7:66706390	chr7:66654538~66669855:+
OV	cis	rs1499614	0.803	rs1922723	ENSG00000226824.5	RP4-756H11.3	-4.68	4.99e-06	0.00283	-0.49	-0.3	Gout;	chr7:66710076	chr7:66654538~66669855:+
OV	cis	rs17301013	0.507	rs1754354	ENSG00000227373.4	RP11-160H22.5	-4.68	4.99e-06	0.00283	-0.39	-0.3	Systemic lupus erythematosus;	chr1:174817196	chr1:174115300~174160004:-
OV	cis	rs3733585	0.638	rs13145554	ENSG00000250413.1	RP11-448G15.1	-4.68	4.99e-06	0.00283	-0.33	-0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9977965	chr4:10006482~10009725:+
OV	cis	rs8054556	1	rs4788195	ENSG00000261367.1	RP11-455F5.4	-4.68	4.99e-06	0.00283	-0.33	-0.3	Autism spectrum disorder or schizophrenia;	chr16:29949272	chr16:30107675~30110541:+
OV	cis	rs10924970	0.649	rs4659480	ENSG00000236863.2	RPL23AP23	4.68	5e-06	0.00283	0.31	0.3	Asthma;	chr1:235271857	chr1:235295865~235296335:+
OV	cis	rs10924970	0.687	rs10802441	ENSG00000236863.2	RPL23AP23	4.68	5.01e-06	0.00284	0.31	0.3	Asthma;	chr1:235194383	chr1:235295865~235296335:+
OV	cis	rs6088580	0.634	rs6088502	ENSG00000206582.1	Y_RNA	-4.68	5.02e-06	0.00284	-0.35	-0.3	Glomerular filtration rate (creatinine);	chr20:34449839	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6059875	ENSG00000206582.1	Y_RNA	-4.68	5.02e-06	0.00284	-0.35	-0.3	Glomerular filtration rate (creatinine);	chr20:34498285	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6088512	ENSG00000206582.1	Y_RNA	-4.68	5.02e-06	0.00284	-0.35	-0.3	Glomerular filtration rate (creatinine);	chr20:34508086	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6059896	ENSG00000206582.1	Y_RNA	-4.68	5.02e-06	0.00284	-0.35	-0.3	Glomerular filtration rate (creatinine);	chr20:34523978	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6141465	ENSG00000206582.1	Y_RNA	4.68	5.02e-06	0.00284	0.35	0.3	Glomerular filtration rate (creatinine);	chr20:34379508	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6142157	ENSG00000206582.1	Y_RNA	4.68	5.02e-06	0.00284	0.35	0.3	Glomerular filtration rate (creatinine);	chr20:34396366	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs6142159	ENSG00000206582.1	Y_RNA	4.68	5.02e-06	0.00284	0.35	0.3	Glomerular filtration rate (creatinine);	chr20:34405229	chr20:34526510~34526606:-
OV	cis	rs733592	0.507	rs56129148	ENSG00000258273.1	RP11-370I10.4	4.68	5.02e-06	0.00284	0.36	0.3	Plateletcrit;	chr12:48091747	chr12:48333755~48333901:-
OV	cis	rs2919917	1	rs2953475	ENSG00000254352.1	RP11-578O24.2	-4.68	5.02e-06	0.00284	-0.35	-0.3	Lymphocyte counts;	chr8:78725903	chr8:78723796~78724136:-
OV	cis	rs7829975	0.502	rs7820738	ENSG00000253981.4	ALG1L13P	-4.68	5.02e-06	0.00285	-0.29	-0.3	Mood instability;	chr8:8845097	chr8:8236003~8244667:-
OV	cis	rs11168351	0.591	rs4258439	ENSG00000258273.1	RP11-370I10.4	4.68	5.03e-06	0.00285	0.36	0.3	Bipolar disorder and schizophrenia;	chr12:48074869	chr12:48333755~48333901:-
OV	cis	rs733592	0.507	rs10747529	ENSG00000258273.1	RP11-370I10.4	4.68	5.03e-06	0.00285	0.36	0.3	Plateletcrit;	chr12:48079586	chr12:48333755~48333901:-
OV	cis	rs2243480	0.522	rs73150635	ENSG00000222364.1	RNU6-96P	-4.68	5.03e-06	0.00285	-0.53	-0.3	Diabetic kidney disease;	chr7:66507503	chr7:66395191~66395286:+
OV	cis	rs10916248	0.569	rs7528514	ENSG00000232628.4	RP11-365O16.3	4.68	5.03e-06	0.00285	0.36	0.3	QT interval (drug interaction);	chr1:224077561	chr1:224208747~224213279:-
OV	cis	rs17301013	0.507	rs332801	ENSG00000227373.4	RP11-160H22.5	4.68	5.03e-06	0.00285	0.38	0.3	Systemic lupus erythematosus;	chr1:174753192	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs332800	ENSG00000227373.4	RP11-160H22.5	4.68	5.03e-06	0.00285	0.38	0.3	Systemic lupus erythematosus;	chr1:174753467	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs1793292	ENSG00000227373.4	RP11-160H22.5	-4.68	5.03e-06	0.00285	-0.38	-0.3	Systemic lupus erythematosus;	chr1:174778185	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs1793298	ENSG00000227373.4	RP11-160H22.5	-4.68	5.03e-06	0.00285	-0.38	-0.3	Systemic lupus erythematosus;	chr1:174784601	chr1:174115300~174160004:-
OV	cis	rs7773456	0.711	rs9358277	ENSG00000228412.5	RP4-625H18.2	-4.68	5.04e-06	0.00285	-0.39	-0.3	Lupus nephritis in systemic lupus erythematosus;	chr6:19816398	chr6:19802164~19804752:-
OV	cis	rs7429990	0.965	rs1061003	ENSG00000229759.1	MRPS18AP1	4.68	5.04e-06	0.00285	0.31	0.3	Educational attainment (years of education);	chr3:47851089	chr3:48256350~48256938:-
OV	cis	rs7617773	0.851	rs7647817	ENSG00000228638.1	FCF1P2	-4.68	5.04e-06	0.00285	-0.38	-0.3	Coronary artery disease;	chr3:48195017	chr3:48290793~48291375:-
OV	cis	rs7617773	0.817	rs11707606	ENSG00000228638.1	FCF1P2	-4.68	5.04e-06	0.00285	-0.38	-0.3	Coronary artery disease;	chr3:48195597	chr3:48290793~48291375:-
OV	cis	rs1113500	0.933	rs12035689	ENSG00000226822.1	RP11-356N1.2	4.67	5.05e-06	0.00286	0.36	0.3	Growth-regulated protein alpha levels;	chr1:108094134	chr1:108071482~108074519:+
OV	cis	rs1113500	0.862	rs3853494	ENSG00000226822.1	RP11-356N1.2	4.67	5.05e-06	0.00286	0.36	0.3	Growth-regulated protein alpha levels;	chr1:108094712	chr1:108071482~108074519:+
OV	cis	rs7200543	1	rs35574015	ENSG00000270580.4	PKD1P6	4.67	5.05e-06	0.00286	0.31	0.3	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15052204	chr16:15104723~15131601:-
OV	cis	rs1185460	0.565	rs2276060	ENSG00000271751.1	RP11-110I1.14	4.67	5.05e-06	0.00286	0.36	0.3	Coronary artery disease;	chr11:119048420	chr11:119065263~119065677:-
OV	cis	rs1862618	0.853	rs252919	ENSG00000271828.1	CTD-2310F14.1	4.67	5.06e-06	0.00286	0.46	0.3	Initial pursuit acceleration;	chr5:56828284	chr5:56927874~56929573:+
OV	cis	rs67180937	0.583	rs61827168	ENSG00000272750.1	RP11-378J18.8	4.67	5.07e-06	0.00287	0.37	0.3	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222634138	chr1:222658867~222661512:-
OV	cis	rs2492286	0.518	rs2712412	ENSG00000242551.2	POU5F1P6	-4.67	5.08e-06	0.00287	-0.36	-0.3	Eosinophil counts;	chr3:128647208	chr3:128674735~128677005:-
OV	cis	rs1150668	0.796	rs2247002	ENSG00000204709.4	LINC01556	4.67	5.08e-06	0.00287	0.34	0.3	Pubertal anthropometrics;	chr6:28430174	chr6:28943877~28944537:+
OV	cis	rs7043114	0.563	rs7848391	ENSG00000281156.1	MIR3651	-4.67	5.08e-06	0.00287	-0.32	-0.3	Height;	chr9:92575238	chr9:92292458~92292547:-
OV	cis	rs10463554	0.963	rs1011454	ENSG00000175749.11	EIF3KP1	4.67	5.09e-06	0.00288	0.34	0.3	Parkinson's disease;	chr5:103032551	chr5:103032376~103033031:+
OV	cis	rs1167832	0.535	rs12112145	ENSG00000278416.1	PMS2L2	-4.67	5.09e-06	0.00288	-0.46	-0.3	Ankle injury;	chr7:75439557	chr7:75344015~75359550:-
OV	cis	rs1167832	0.673	rs34048280	ENSG00000278416.1	PMS2L2	-4.67	5.09e-06	0.00288	-0.46	-0.3	Ankle injury;	chr7:75466111	chr7:75344015~75359550:-
OV	cis	rs875971	0.545	rs316305	ENSG00000236529.1	RP13-254B10.1	-4.67	5.1e-06	0.00288	-0.35	-0.3	Aortic root size;	chr7:66152984	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs316306	ENSG00000236529.1	RP13-254B10.1	-4.67	5.1e-06	0.00288	-0.35	-0.3	Aortic root size;	chr7:66153687	chr7:65840212~65840596:+
OV	cis	rs10899021	0.92	rs11236181	ENSG00000279353.1	RP11-864N7.4	4.67	5.11e-06	0.00289	0.48	0.3	Response to metformin (IC50);	chr11:74634778	chr11:74698231~74699658:-
OV	cis	rs992157	0.835	rs7585702	ENSG00000261338.2	RP11-378A13.1	-4.67	5.11e-06	0.00289	-0.35	-0.3	Colorectal cancer;	chr2:218281884	chr2:218255319~218257366:+
OV	cis	rs992157	0.835	rs2292555	ENSG00000261338.2	RP11-378A13.1	-4.67	5.11e-06	0.00289	-0.35	-0.3	Colorectal cancer;	chr2:218282159	chr2:218255319~218257366:+
OV	cis	rs992157	0.835	rs10932769	ENSG00000261338.2	RP11-378A13.1	-4.67	5.11e-06	0.00289	-0.35	-0.3	Colorectal cancer;	chr2:218282522	chr2:218255319~218257366:+
OV	cis	rs992157	0.835	rs6729058	ENSG00000261338.2	RP11-378A13.1	-4.67	5.11e-06	0.00289	-0.35	-0.3	Colorectal cancer;	chr2:218283646	chr2:218255319~218257366:+
OV	cis	rs992157	0.804	rs7559525	ENSG00000261338.2	RP11-378A13.1	-4.67	5.11e-06	0.00289	-0.35	-0.3	Colorectal cancer;	chr2:218285584	chr2:218255319~218257366:+
OV	cis	rs1862618	0.853	rs252909	ENSG00000271828.1	CTD-2310F14.1	4.67	5.11e-06	0.00289	0.46	0.3	Initial pursuit acceleration;	chr5:56825304	chr5:56927874~56929573:+
OV	cis	rs1858037	0.836	rs1396209	ENSG00000234255.7	AC012370.3	4.67	5.11e-06	0.00289	0.34	0.3	Rheumatoid arthritis;	chr2:65374100	chr2:65439888~65456571:-
OV	cis	rs1134634	0.52	rs13121363	ENSG00000273133.1	RP11-799M12.2	4.67	5.12e-06	0.00289	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15567369	chr4:15563698~15564253:-
OV	cis	rs1134634	0.52	rs13116304	ENSG00000273133.1	RP11-799M12.2	4.67	5.12e-06	0.00289	0.4	0.3	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15567523	chr4:15563698~15564253:-
OV	cis	rs10510102	0.935	rs11200203	ENSG00000226864.1	ATE1-AS1	4.67	5.12e-06	0.00289	0.5	0.3	Breast cancer;	chr10:121874014	chr10:121928312~121951965:+
OV	cis	rs7605378	1	rs769957	ENSG00000232732.8	AC073043.1	-4.67	5.12e-06	0.00289	-0.36	-0.3	Osteoporosis;	chr2:199830801	chr2:199867396~199911159:-
OV	cis	rs10759883	0.539	rs10988755	ENSG00000175611.10	LINC00476	4.67	5.13e-06	0.0029	0.36	0.3	Nicotine dependence;	chr9:95944085	chr9:95759231~95875977:-
OV	cis	rs10759883	0.587	rs603947	ENSG00000175611.10	LINC00476	4.67	5.13e-06	0.0029	0.36	0.3	Nicotine dependence;	chr9:95944647	chr9:95759231~95875977:-
OV	cis	rs10759883	0.563	rs7847983	ENSG00000175611.10	LINC00476	4.67	5.13e-06	0.0029	0.36	0.3	Nicotine dependence;	chr9:95948046	chr9:95759231~95875977:-
OV	cis	rs10759883	0.563	rs10819650	ENSG00000175611.10	LINC00476	4.67	5.13e-06	0.0029	0.36	0.3	Nicotine dependence;	chr9:95951161	chr9:95759231~95875977:-
OV	cis	rs10759883	0.563	rs10760679	ENSG00000175611.10	LINC00476	4.67	5.13e-06	0.0029	0.36	0.3	Nicotine dependence;	chr9:95951511	chr9:95759231~95875977:-
OV	cis	rs3733585	0.673	rs4455410	ENSG00000250413.1	RP11-448G15.1	-4.67	5.13e-06	0.0029	-0.33	-0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9951673	chr4:10006482~10009725:+
OV	cis	rs853679	0.546	rs34295134	ENSG00000220721.1	OR1F12	4.67	5.14e-06	0.0029	0.48	0.3	Depression;	chr6:27860373	chr6:28073316~28074233:+
OV	cis	rs853679	0.546	rs200948	ENSG00000220721.1	OR1F12	4.67	5.14e-06	0.0029	0.48	0.3	Depression;	chr6:27867494	chr6:28073316~28074233:+
OV	cis	rs853679	0.546	rs200950	ENSG00000220721.1	OR1F12	4.67	5.14e-06	0.0029	0.48	0.3	Depression;	chr6:27867994	chr6:28073316~28074233:+
OV	cis	rs1858037	0.836	rs17475335	ENSG00000234255.7	AC012370.3	4.67	5.14e-06	0.0029	0.33	0.3	Rheumatoid arthritis;	chr2:65378646	chr2:65439888~65456571:-
OV	cis	rs473651	0.935	rs578510	ENSG00000229915.1	AC016999.2	-4.67	5.15e-06	0.0029	-0.37	-0.3	Multiple system atrophy;	chr2:238434499	chr2:238427077~238427729:-
OV	cis	rs8005677	0.798	rs4982711	ENSG00000279656.1	RP11-298I3.6	4.67	5.15e-06	0.00291	0.33	0.3	Cognitive ability (multi-trait analysis);	chr14:22929781	chr14:23023083~23024217:-
OV	cis	rs17301013	0.556	rs1754353	ENSG00000227373.4	RP11-160H22.5	-4.67	5.16e-06	0.00291	-0.38	-0.3	Systemic lupus erythematosus;	chr1:174822229	chr1:174115300~174160004:-
OV	cis	rs67311347	1	rs4973997	ENSG00000223797.4	ENTPD3-AS1	4.67	5.16e-06	0.00291	0.31	0.3	Renal cell carcinoma;	chr3:40418654	chr3:40313802~40453329:-
OV	cis	rs11159086	0.793	rs1029703	ENSG00000270000.1	RP3-449M8.9	4.67	5.16e-06	0.00291	0.44	0.3	Advanced glycation end-product levels;	chr14:74473899	chr14:74471930~74472360:-
OV	cis	rs11159086	0.793	rs12432412	ENSG00000270000.1	RP3-449M8.9	4.67	5.16e-06	0.00291	0.44	0.3	Advanced glycation end-product levels;	chr14:74474294	chr14:74471930~74472360:-
OV	cis	rs11159086	0.793	rs1029700	ENSG00000270000.1	RP3-449M8.9	4.67	5.16e-06	0.00291	0.44	0.3	Advanced glycation end-product levels;	chr14:74474309	chr14:74471930~74472360:-
OV	cis	rs11159086	0.793	rs1029699	ENSG00000270000.1	RP3-449M8.9	4.67	5.16e-06	0.00291	0.44	0.3	Advanced glycation end-product levels;	chr14:74474790	chr14:74471930~74472360:-
OV	cis	rs34779708	0.966	rs2505639	ENSG00000230534.5	RP11-297A16.2	-4.67	5.16e-06	0.00291	-0.38	-0.3	Inflammatory bowel disease;Crohn's disease;	chr10:35185493	chr10:35098006~35127020:-
OV	cis	rs8005677	0.611	rs11624528	ENSG00000279656.1	RP11-298I3.6	4.67	5.16e-06	0.00291	0.32	0.3	Cognitive ability (multi-trait analysis);	chr14:22989947	chr14:23023083~23024217:-
OV	cis	rs1569175	1	rs281777	ENSG00000232732.8	AC073043.1	4.67	5.17e-06	0.00291	0.61	0.3	Response to treatment for acute lymphoblastic leukemia;	chr2:199974890	chr2:199867396~199911159:-
OV	cis	rs67311347	0.549	rs60249586	ENSG00000223797.4	ENTPD3-AS1	4.67	5.17e-06	0.00292	0.31	0.3	Renal cell carcinoma;	chr3:40205168	chr3:40313802~40453329:-
OV	cis	rs1797885	0.585	rs2255655	ENSG00000251774.1	RNU6-377P	4.67	5.19e-06	0.00292	0.29	0.3	Immature fraction of reticulocytes;	chr3:12557340	chr3:12514706~12514807:+
OV	cis	rs4865169	0.595	rs9998008	ENSG00000269949.1	RP11-738E22.3	4.67	5.2e-06	0.00293	0.34	0.3	Breast cancer;	chr4:56899886	chr4:56960927~56961373:-
OV	cis	rs10246939	0.505	rs34726057	ENSG00000228775.6	WEE2-AS1	4.67	5.2e-06	0.00293	0.33	0.3	Bitter taste perception;	chr7:141832117	chr7:141704338~141738346:-
OV	cis	rs812925	0.515	rs1177308	ENSG00000271889.1	RP11-493E12.1	4.67	5.2e-06	0.00293	0.34	0.3	Immature fraction of reticulocytes;	chr2:61160119	chr2:61151433~61162105:-
OV	cis	rs812925	0.553	rs1177307	ENSG00000271889.1	RP11-493E12.1	4.67	5.2e-06	0.00293	0.34	0.3	Immature fraction of reticulocytes;	chr2:61160253	chr2:61151433~61162105:-
OV	cis	rs812925	0.512	rs1729674	ENSG00000271889.1	RP11-493E12.1	4.67	5.2e-06	0.00293	0.34	0.3	Immature fraction of reticulocytes;	chr2:61162602	chr2:61151433~61162105:-
OV	cis	rs4747241	0.626	rs4409753	ENSG00000226163.1	RP11-167P22.3	4.67	5.2e-06	0.00293	0.33	0.3	Heschl's gyrus morphology;	chr10:72309368	chr10:72501746~72502956:+
OV	cis	rs6723108	0.627	rs2166480	ENSG00000224043.6	CCNT2-AS1	4.67	5.21e-06	0.00293	0.36	0.3	Type 2 diabetes;	chr2:134879768	chr2:134735464~134918710:-
OV	cis	rs9309473	1	rs62151652	ENSG00000163016.8	ALMS1P	4.67	5.21e-06	0.00293	0.35	0.3	Metabolite levels;	chr2:73473004	chr2:73644919~73685576:+
OV	cis	rs17301013	0.531	rs1793318	ENSG00000227373.4	RP11-160H22.5	-4.67	5.21e-06	0.00293	-0.38	-0.3	Systemic lupus erythematosus;	chr1:174824678	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs1793316	ENSG00000227373.4	RP11-160H22.5	4.67	5.21e-06	0.00293	0.38	0.3	Systemic lupus erythematosus;	chr1:174825006	chr1:174115300~174160004:-
OV	cis	rs7116641	0.734	rs10838186	ENSG00000246250.2	RP11-613D13.5	-4.67	5.21e-06	0.00293	-0.33	-0.3	Coronary artery disease;	chr11:43848430	chr11:43829709~43880726:-
OV	cis	rs11723261	0.582	rs4582104	ENSG00000275426.1	CH17-262A2.1	4.67	5.22e-06	0.00294	0.45	0.3	Immune response to smallpox vaccine (IL-6);	chr4:143160	chr4:149738~150317:+
OV	cis	rs8059260	0.604	rs76969865	ENSG00000274038.1	RP11-66H6.4	-4.67	5.22e-06	0.00294	-0.6	-0.3	Alcohol consumption over the past year;	chr16:11050092	chr16:11056556~11057034:+
OV	cis	rs875971	0.545	rs6969224	ENSG00000226824.5	RP4-756H11.3	-4.67	5.22e-06	0.00294	-0.36	-0.3	Aortic root size;	chr7:66370011	chr7:66654538~66669855:+
OV	cis	rs853679	0.882	rs3757188	ENSG00000280107.1	AL022393.9	-4.67	5.23e-06	0.00294	-0.49	-0.3	Depression;	chr6:28139579	chr6:28170845~28172521:+
OV	cis	rs992157	0.717	rs11692780	ENSG00000237281.1	CATIP-AS2	4.67	5.23e-06	0.00294	0.35	0.3	Colorectal cancer;	chr2:218284440	chr2:218326889~218357966:-
OV	cis	rs4853012	1	rs4853012	ENSG00000257800.1	FNBP1P1	4.67	5.24e-06	0.00295	0.48	0.3	Gestational age at birth (maternal effect);	chr2:74134163	chr2:74120680~74123218:+
OV	cis	rs3733585	0.598	rs28677023	ENSG00000250413.1	RP11-448G15.1	4.67	5.24e-06	0.00295	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9956702	chr4:10006482~10009725:+
OV	cis	rs3733585	0.664	rs28602527	ENSG00000250413.1	RP11-448G15.1	4.67	5.24e-06	0.00295	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9956703	chr4:10006482~10009725:+
OV	cis	rs3733585	0.699	rs6815001	ENSG00000250413.1	RP11-448G15.1	4.67	5.24e-06	0.00295	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9957038	chr4:10006482~10009725:+
OV	cis	rs3733585	0.673	rs6849729	ENSG00000250413.1	RP11-448G15.1	4.67	5.24e-06	0.00295	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9957108	chr4:10006482~10009725:+
OV	cis	rs3733585	0.673	rs6843873	ENSG00000250413.1	RP11-448G15.1	4.67	5.24e-06	0.00295	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9957164	chr4:10006482~10009725:+
OV	cis	rs3733585	0.673	rs6850143	ENSG00000250413.1	RP11-448G15.1	4.67	5.24e-06	0.00295	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9957300	chr4:10006482~10009725:+
OV	cis	rs3733585	0.699	rs6844316	ENSG00000250413.1	RP11-448G15.1	4.67	5.24e-06	0.00295	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9957353	chr4:10006482~10009725:+
OV	cis	rs3733585	0.699	rs6834893	ENSG00000250413.1	RP11-448G15.1	4.67	5.24e-06	0.00295	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9957499	chr4:10006482~10009725:+
OV	cis	rs3733585	0.699	rs6844787	ENSG00000250413.1	RP11-448G15.1	4.67	5.24e-06	0.00295	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9957609	chr4:10006482~10009725:+
OV	cis	rs3733585	0.648	rs28513781	ENSG00000250413.1	RP11-448G15.1	4.67	5.24e-06	0.00295	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9957710	chr4:10006482~10009725:+
OV	cis	rs3733585	0.699	rs4515163	ENSG00000250413.1	RP11-448G15.1	4.67	5.24e-06	0.00295	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9957979	chr4:10006482~10009725:+
OV	cis	rs3733585	0.699	rs62294331	ENSG00000250413.1	RP11-448G15.1	4.67	5.24e-06	0.00295	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9958265	chr4:10006482~10009725:+
OV	cis	rs3733585	0.699	rs62294332	ENSG00000250413.1	RP11-448G15.1	4.67	5.24e-06	0.00295	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9958365	chr4:10006482~10009725:+
OV	cis	rs3733585	0.699	rs57574512	ENSG00000250413.1	RP11-448G15.1	4.67	5.24e-06	0.00295	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9958558	chr4:10006482~10009725:+
OV	cis	rs3733585	0.699	rs6449159	ENSG00000250413.1	RP11-448G15.1	4.67	5.24e-06	0.00295	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9958874	chr4:10006482~10009725:+
OV	cis	rs3733585	0.699	rs7699609	ENSG00000250413.1	RP11-448G15.1	4.67	5.24e-06	0.00295	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9959435	chr4:10006482~10009725:+
OV	cis	rs3733585	0.673	rs7672947	ENSG00000250413.1	RP11-448G15.1	4.67	5.24e-06	0.00295	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9959744	chr4:10006482~10009725:+
OV	cis	rs3733585	0.699	rs4588456	ENSG00000250413.1	RP11-448G15.1	4.67	5.24e-06	0.00295	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9962271	chr4:10006482~10009725:+
OV	cis	rs3733585	0.673	rs6836706	ENSG00000250413.1	RP11-448G15.1	4.67	5.24e-06	0.00295	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9962627	chr4:10006482~10009725:+
OV	cis	rs3733585	0.673	rs10018204	ENSG00000250413.1	RP11-448G15.1	4.67	5.24e-06	0.00295	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9962946	chr4:10006482~10009725:+
OV	cis	rs3733585	0.699	rs28613263	ENSG00000250413.1	RP11-448G15.1	4.67	5.24e-06	0.00295	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9963256	chr4:10006482~10009725:+
OV	cis	rs2919917	0.688	rs3780003	ENSG00000254352.1	RP11-578O24.2	4.67	5.26e-06	0.00296	0.33	0.3	Lymphocyte counts;	chr8:78696019	chr8:78723796~78724136:-
OV	cis	rs733592	0.524	rs10875744	ENSG00000258273.1	RP11-370I10.4	-4.67	5.26e-06	0.00296	-0.36	-0.3	Plateletcrit;	chr12:48104657	chr12:48333755~48333901:-
OV	cis	rs7429990	0.864	rs1403579	ENSG00000229759.1	MRPS18AP1	4.67	5.26e-06	0.00296	0.34	0.3	Educational attainment (years of education);	chr3:47617889	chr3:48256350~48256938:-
OV	cis	rs2919917	1	rs2369440	ENSG00000254352.1	RP11-578O24.2	4.67	5.27e-06	0.00296	0.35	0.3	Lymphocyte counts;	chr8:78709474	chr8:78723796~78724136:-
OV	cis	rs3733585	0.673	rs116046986	ENSG00000250413.1	RP11-448G15.1	4.66	5.27e-06	0.00296	0.33	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9956170	chr4:10006482~10009725:+
OV	cis	rs733592	0.507	rs7299704	ENSG00000258273.1	RP11-370I10.4	-4.66	5.28e-06	0.00296	-0.36	-0.3	Plateletcrit;	chr12:48050705	chr12:48333755~48333901:-
OV	cis	rs9309473	1	rs1881245	ENSG00000163016.8	ALMS1P	4.66	5.28e-06	0.00296	0.36	0.3	Metabolite levels;	chr2:73422800	chr2:73644919~73685576:+
OV	cis	rs2253762	0.54	rs11200351	ENSG00000276742.1	RP11-500G22.4	4.66	5.29e-06	0.00297	0.5	0.3	Breast cancer;	chr10:122029957	chr10:121956782~121957098:+
OV	cis	rs2253762	0.54	rs11200353	ENSG00000276742.1	RP11-500G22.4	4.66	5.29e-06	0.00297	0.5	0.3	Breast cancer;	chr10:122030181	chr10:121956782~121957098:+
OV	cis	rs2253762	0.54	rs10887053	ENSG00000276742.1	RP11-500G22.4	4.66	5.29e-06	0.00297	0.5	0.3	Breast cancer;	chr10:122030997	chr10:121956782~121957098:+
OV	cis	rs7302981	0.741	rs10783342	ENSG00000257298.1	RP3-405J10.3	4.66	5.29e-06	0.00297	0.27	0.3	Systolic blood pressure;	chr12:50234683	chr12:50185580~50191363:-
OV	cis	rs73201462	1	rs34409786	ENSG00000277250.1	Metazoa_SRP	4.66	5.29e-06	0.00297	0.45	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128169332	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs13067650	ENSG00000277250.1	Metazoa_SRP	4.66	5.29e-06	0.00297	0.45	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128170699	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs11706455	ENSG00000277250.1	Metazoa_SRP	4.66	5.29e-06	0.00297	0.45	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128173148	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs11712798	ENSG00000277250.1	Metazoa_SRP	4.66	5.29e-06	0.00297	0.45	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128175451	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2811511	ENSG00000277250.1	Metazoa_SRP	4.66	5.29e-06	0.00297	0.45	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128194145	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2687730	ENSG00000277250.1	Metazoa_SRP	4.66	5.29e-06	0.00297	0.45	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128196614	chr3:128673681~128674021:-
OV	cis	rs73201462	0.901	rs2811486	ENSG00000277250.1	Metazoa_SRP	4.66	5.29e-06	0.00297	0.45	0.3	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128201232	chr3:128673681~128674021:-
OV	cis	rs3758911	0.828	rs10789605	ENSG00000261098.1	RP11-819C21.1	-4.66	5.29e-06	0.00297	-0.29	-0.3	Coronary artery disease;	chr11:107313859	chr11:107312132~107316271:-
OV	cis	rs3758911	0.828	rs10789606	ENSG00000261098.1	RP11-819C21.1	-4.66	5.29e-06	0.00297	-0.29	-0.3	Coronary artery disease;	chr11:107313862	chr11:107312132~107316271:-
OV	cis	rs11098499	0.863	rs17050695	ENSG00000245958.5	RP11-33B1.1	-4.66	5.3e-06	0.00297	-0.34	-0.3	Corneal astigmatism;	chr4:119568372	chr4:119454791~119552025:+
OV	cis	rs875971	1	rs4718307	ENSG00000236529.1	RP13-254B10.1	-4.66	5.3e-06	0.00297	-0.31	-0.3	Aortic root size;	chr7:66146001	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs7801282	ENSG00000236529.1	RP13-254B10.1	-4.66	5.3e-06	0.00297	-0.31	-0.3	Aortic root size;	chr7:66148700	chr7:65840212~65840596:+
OV	cis	rs3733585	0.673	rs4235347	ENSG00000250413.1	RP11-448G15.1	4.66	5.31e-06	0.00298	0.32	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9950332	chr4:10006482~10009725:+
OV	cis	rs3733585	0.673	rs4235348	ENSG00000250413.1	RP11-448G15.1	4.66	5.31e-06	0.00298	0.32	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9950344	chr4:10006482~10009725:+
OV	cis	rs3733585	0.673	rs4697914	ENSG00000250413.1	RP11-448G15.1	4.66	5.31e-06	0.00298	0.32	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9950642	chr4:10006482~10009725:+
OV	cis	rs3733585	0.624	rs7376154	ENSG00000250413.1	RP11-448G15.1	4.66	5.31e-06	0.00298	0.32	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9950963	chr4:10006482~10009725:+
OV	cis	rs3733585	0.648	rs7376155	ENSG00000250413.1	RP11-448G15.1	4.66	5.31e-06	0.00298	0.32	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9950964	chr4:10006482~10009725:+
OV	cis	rs3733585	0.673	rs7376505	ENSG00000250413.1	RP11-448G15.1	4.66	5.31e-06	0.00298	0.32	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9951120	chr4:10006482~10009725:+
OV	cis	rs3733585	0.673	rs7377578	ENSG00000250413.1	RP11-448G15.1	4.66	5.31e-06	0.00298	0.32	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9951151	chr4:10006482~10009725:+
OV	cis	rs3733585	0.624	rs76574510	ENSG00000250413.1	RP11-448G15.1	4.66	5.31e-06	0.00298	0.32	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9951628	chr4:10006482~10009725:+
OV	cis	rs3733585	0.577	rs5014939	ENSG00000250413.1	RP11-448G15.1	4.66	5.31e-06	0.00298	0.32	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9951629	chr4:10006482~10009725:+
OV	cis	rs3733585	0.673	rs4560411	ENSG00000250413.1	RP11-448G15.1	4.66	5.31e-06	0.00298	0.32	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9951737	chr4:10006482~10009725:+
OV	cis	rs3733585	0.673	rs4407505	ENSG00000250413.1	RP11-448G15.1	4.66	5.31e-06	0.00298	0.32	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9951743	chr4:10006482~10009725:+
OV	cis	rs3733585	0.673	rs4467563	ENSG00000250413.1	RP11-448G15.1	4.66	5.31e-06	0.00298	0.32	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9951836	chr4:10006482~10009725:+
OV	cis	rs3733585	0.673	rs4467564	ENSG00000250413.1	RP11-448G15.1	4.66	5.31e-06	0.00298	0.32	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9951848	chr4:10006482~10009725:+
OV	cis	rs3733585	0.673	rs4292332	ENSG00000250413.1	RP11-448G15.1	4.66	5.31e-06	0.00298	0.32	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9952206	chr4:10006482~10009725:+
OV	cis	rs3733585	0.673	rs4292333	ENSG00000250413.1	RP11-448G15.1	4.66	5.31e-06	0.00298	0.32	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9952247	chr4:10006482~10009725:+
OV	cis	rs3733585	0.673	rs4447861	ENSG00000250413.1	RP11-448G15.1	4.66	5.31e-06	0.00298	0.32	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9952316	chr4:10006482~10009725:+
OV	cis	rs3733585	0.673	rs4459990	ENSG00000250413.1	RP11-448G15.1	4.66	5.31e-06	0.00298	0.32	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9952381	chr4:10006482~10009725:+
OV	cis	rs3733585	0.673	rs4495037	ENSG00000250413.1	RP11-448G15.1	4.66	5.31e-06	0.00298	0.32	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9952426	chr4:10006482~10009725:+
OV	cis	rs3733585	0.673	rs4627861	ENSG00000250413.1	RP11-448G15.1	4.66	5.31e-06	0.00298	0.32	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9952614	chr4:10006482~10009725:+
OV	cis	rs3733585	0.648	rs7378305	ENSG00000250413.1	RP11-448G15.1	4.66	5.31e-06	0.00298	0.32	0.3	Cleft plate (environmental tobacco smoke interaction);	chr4:9953269	chr4:10006482~10009725:+
OV	cis	rs992157	0.965	rs13427681	ENSG00000261338.2	RP11-378A13.1	4.66	5.31e-06	0.00298	0.35	0.3	Colorectal cancer;	chr2:218302840	chr2:218255319~218257366:+
OV	cis	rs1555322	0.53	rs6058224	ENSG00000279253.1	RP4-614O4.13	-4.66	5.31e-06	0.00298	-0.35	-0.3	Attention deficit hyperactivity disorder;	chr20:35293971	chr20:35262727~35264187:-
OV	cis	rs4713118	0.513	rs149958	ENSG00000219392.1	RP1-265C24.5	-4.66	5.32e-06	0.00298	-0.36	-0.3	Parkinson's disease;	chr6:28045839	chr6:28115628~28116551:+
OV	cis	rs4718428	1	rs4718421	ENSG00000226824.5	RP4-756H11.3	-4.66	5.33e-06	0.00299	-0.34	-0.3	Corneal structure;	chr7:66885313	chr7:66654538~66669855:+
OV	cis	rs875971	0.756	rs2901210	ENSG00000236529.1	RP13-254B10.1	-4.66	5.33e-06	0.00299	-0.31	-0.3	Aortic root size;	chr7:66552518	chr7:65840212~65840596:+
OV	cis	rs3758911	0.894	rs12285491	ENSG00000261098.1	RP11-819C21.1	-4.66	5.35e-06	0.003	-0.29	-0.3	Coronary artery disease;	chr11:107340319	chr11:107312132~107316271:-
OV	cis	rs3758911	0.894	rs12286915	ENSG00000261098.1	RP11-819C21.1	-4.66	5.35e-06	0.003	-0.29	-0.3	Coronary artery disease;	chr11:107340608	chr11:107312132~107316271:-
OV	cis	rs3758911	0.894	rs10890723	ENSG00000261098.1	RP11-819C21.1	-4.66	5.35e-06	0.003	-0.29	-0.3	Coronary artery disease;	chr11:107342510	chr11:107312132~107316271:-
OV	cis	rs3758911	0.894	rs7350479	ENSG00000261098.1	RP11-819C21.1	-4.66	5.35e-06	0.003	-0.29	-0.3	Coronary artery disease;	chr11:107342553	chr11:107312132~107316271:-
OV	cis	rs3758911	0.894	rs56393657	ENSG00000261098.1	RP11-819C21.1	-4.66	5.35e-06	0.003	-0.29	-0.3	Coronary artery disease;	chr11:107342902	chr11:107312132~107316271:-
OV	cis	rs832187	0.629	rs59971314	ENSG00000280620.1	SCAANT1	4.66	5.35e-06	0.003	0.37	0.3	Schizophrenia;	chr3:63928942	chr3:63911518~63911772:-
OV	cis	rs4664293	0.605	rs12991516	ENSG00000226266.5	AC009961.3	-4.66	5.35e-06	0.003	-0.35	-0.3	Monocyte percentage of white cells;	chr2:159585554	chr2:159670708~159712435:-
OV	cis	rs4930103	0.619	rs10769945	ENSG00000232987.1	LINC01219	-4.66	5.36e-06	0.003	-0.3	-0.3	DNA methylation (variation);DNA methylation (parent-of-origin);	chr11:1963897	chr11:1991096~1993469:+
OV	cis	rs881375	1	rs6478486	ENSG00000226752.6	PSMD5-AS1	-4.66	5.37e-06	0.003	-0.34	-0.3	Rheumatoid arthritis;	chr9:120893051	chr9:120824828~120854385:+
OV	cis	rs1797885	0.934	rs709162	ENSG00000251774.1	RNU6-377P	4.66	5.37e-06	0.003	0.27	0.3	Immature fraction of reticulocytes;	chr3:12479681	chr3:12514706~12514807:+
OV	cis	rs62458065	0.85	rs6462362	ENSG00000226468.2	AC018641.7	4.66	5.37e-06	0.00301	0.44	0.3	Metabolite levels (HVA/MHPG ratio);	chr7:32425121	chr7:32456963~32457758:-
OV	cis	rs6772849	0.804	rs4857920	ENSG00000242551.2	POU5F1P6	-4.66	5.37e-06	0.00301	-0.34	-0.3	Monocyte percentage of white cells;Monocyte count;	chr3:128688780	chr3:128674735~128677005:-
OV	cis	rs57502260	0.573	rs11228295	ENSG00000212093.1	AP000807.1	4.66	5.38e-06	0.00301	0.4	0.3	Total body bone mineral density (age 45-60);	chr11:68621120	chr11:68506083~68506166:-
OV	cis	rs875971	0.545	rs6969224	ENSG00000236529.1	RP13-254B10.1	4.66	5.38e-06	0.00301	0.36	0.3	Aortic root size;	chr7:66370011	chr7:65840212~65840596:+
OV	cis	rs17301013	0.581	rs12080977	ENSG00000227373.4	RP11-160H22.5	4.66	5.38e-06	0.00301	0.39	0.3	Systemic lupus erythematosus;	chr1:174247026	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs72713503	ENSG00000227373.4	RP11-160H22.5	4.66	5.38e-06	0.00301	0.39	0.3	Systemic lupus erythematosus;	chr1:174247553	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs16846816	ENSG00000227373.4	RP11-160H22.5	4.66	5.38e-06	0.00301	0.39	0.3	Systemic lupus erythematosus;	chr1:174251602	chr1:174115300~174160004:-
OV	cis	rs17301013	0.581	rs12083540	ENSG00000227373.4	RP11-160H22.5	4.66	5.38e-06	0.00301	0.39	0.3	Systemic lupus erythematosus;	chr1:174254096	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs12085311	ENSG00000227373.4	RP11-160H22.5	4.66	5.38e-06	0.00301	0.39	0.3	Systemic lupus erythematosus;	chr1:174256097	chr1:174115300~174160004:-
OV	cis	rs4908768	0.629	rs12410886	ENSG00000228423.2	RP4-633I8.4	4.66	5.38e-06	0.00301	0.34	0.3	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8818750	chr1:8805860~8807051:-
OV	cis	rs4908768	0.582	rs12410893	ENSG00000228423.2	RP4-633I8.4	4.66	5.38e-06	0.00301	0.34	0.3	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8818826	chr1:8805860~8807051:-
OV	cis	rs7927592	0.763	rs2513277	ENSG00000212093.1	AP000807.1	4.66	5.39e-06	0.00301	0.34	0.3	Total body bone mineral density;	chr11:68593419	chr11:68506083~68506166:-
OV	cis	rs7927592	0.763	rs4340059	ENSG00000212093.1	AP000807.1	4.66	5.39e-06	0.00301	0.34	0.3	Total body bone mineral density;	chr11:68594965	chr11:68506083~68506166:-
OV	cis	rs992157	0.932	rs56109829	ENSG00000261338.2	RP11-378A13.1	4.66	5.4e-06	0.00302	0.34	0.3	Colorectal cancer;	chr2:218285017	chr2:218255319~218257366:+
OV	cis	rs17301013	0.531	rs4650958	ENSG00000227373.4	RP11-160H22.5	4.66	5.4e-06	0.00302	0.38	0.3	Systemic lupus erythematosus;	chr1:174178378	chr1:174115300~174160004:-
OV	cis	rs1858037	0.836	rs2576923	ENSG00000234255.7	AC012370.3	-4.66	5.41e-06	0.00302	-0.33	-0.3	Rheumatoid arthritis;	chr2:65406750	chr2:65439888~65456571:-
OV	cis	rs1858037	0.867	rs55945621	ENSG00000234255.7	AC012370.3	4.66	5.41e-06	0.00302	0.33	0.3	Rheumatoid arthritis;	chr2:65388220	chr2:65439888~65456571:-
OV	cis	rs1858037	0.867	rs964505	ENSG00000234255.7	AC012370.3	4.66	5.41e-06	0.00302	0.33	0.3	Rheumatoid arthritis;	chr2:65396055	chr2:65439888~65456571:-
OV	cis	rs875971	0.66	rs10263935	ENSG00000224316.1	RP11-479O9.2	4.66	5.41e-06	0.00302	0.31	0.3	Aortic root size;	chr7:66631041	chr7:65773620~65802067:+
OV	cis	rs2492286	0.597	rs7647337	ENSG00000277250.1	Metazoa_SRP	-4.66	5.41e-06	0.00302	-0.39	-0.3	Eosinophil counts;	chr3:128628353	chr3:128673681~128674021:-
OV	cis	rs2492286	0.569	rs9848287	ENSG00000277250.1	Metazoa_SRP	-4.66	5.41e-06	0.00302	-0.39	-0.3	Eosinophil counts;	chr3:128628799	chr3:128673681~128674021:-
OV	cis	rs2492286	0.569	rs2712383	ENSG00000277250.1	Metazoa_SRP	-4.66	5.41e-06	0.00302	-0.39	-0.3	Eosinophil counts;	chr3:128629033	chr3:128673681~128674021:-
OV	cis	rs4713118	0.614	rs9468209	ENSG00000220721.1	OR1F12	4.66	5.41e-06	0.00302	0.3	0.3	Parkinson's disease;	chr6:27726642	chr6:28073316~28074233:+
OV	cis	rs3758911	0.894	rs10749902	ENSG00000261098.1	RP11-819C21.1	-4.66	5.42e-06	0.00303	-0.28	-0.3	Coronary artery disease;	chr11:107324855	chr11:107312132~107316271:-
OV	cis	rs473651	0.935	rs508483	ENSG00000229915.1	AC016999.2	-4.66	5.43e-06	0.00303	-0.37	-0.3	Multiple system atrophy;	chr2:238431068	chr2:238427077~238427729:-
OV	cis	rs2492286	0.569	rs9289331	ENSG00000277250.1	Metazoa_SRP	-4.66	5.44e-06	0.00304	-0.39	-0.3	Eosinophil counts;	chr3:128635173	chr3:128673681~128674021:-
OV	cis	rs7189233	0.531	rs17800577	ENSG00000279344.1	RP11-44F14.7	4.66	5.46e-06	0.00305	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53442892	chr16:53478957~53481550:-
OV	cis	rs17301013	0.606	rs10912750	ENSG00000227373.4	RP11-160H22.5	4.66	5.47e-06	0.00306	0.39	0.3	Systemic lupus erythematosus;	chr1:174253637	chr1:174115300~174160004:-
OV	cis	rs10924970	0.649	rs11801073	ENSG00000236863.2	RPL23AP23	4.66	5.48e-06	0.00306	0.3	0.3	Asthma;	chr1:235294794	chr1:235295865~235296335:+
OV	cis	rs6088580	0.634	rs62212172	ENSG00000206582.1	Y_RNA	4.66	5.48e-06	0.00306	0.35	0.3	Glomerular filtration rate (creatinine);	chr20:34399899	chr20:34526510~34526606:-
OV	cis	rs6088580	0.634	rs4142007	ENSG00000206582.1	Y_RNA	4.66	5.48e-06	0.00306	0.35	0.3	Glomerular filtration rate (creatinine);	chr20:34402244	chr20:34526510~34526606:-
OV	cis	rs858239	0.601	rs764533	ENSG00000230042.1	AK3P3	-4.66	5.48e-06	0.00306	-0.31	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23114256	chr7:23129178~23129841:+
OV	cis	rs7567389	0.51	rs1473623	ENSG00000236682.1	AC068282.3	4.66	5.49e-06	0.00307	0.39	0.3	Self-rated health;	chr2:127438644	chr2:127389130~127400580:+
OV	cis	rs875971	0.502	rs6460311	ENSG00000226824.5	RP4-756H11.3	4.66	5.49e-06	0.00307	0.36	0.3	Aortic root size;	chr7:66646886	chr7:66654538~66669855:+
OV	cis	rs7189233	0.55	rs9927982	ENSG00000279344.1	RP11-44F14.7	4.66	5.5e-06	0.00307	0.28	0.3	Intelligence (multi-trait analysis);	chr16:53440196	chr16:53478957~53481550:-
OV	cis	rs875971	0.545	rs11767262	ENSG00000226824.5	RP4-756H11.3	-4.66	5.5e-06	0.00307	-0.35	-0.3	Aortic root size;	chr7:66302237	chr7:66654538~66669855:+
OV	cis	rs875971	0.545	rs66594357	ENSG00000226824.5	RP4-756H11.3	-4.66	5.5e-06	0.00307	-0.35	-0.3	Aortic root size;	chr7:66327797	chr7:66654538~66669855:+
OV	cis	rs7189233	0.531	rs16952246	ENSG00000279344.1	RP11-44F14.7	4.66	5.51e-06	0.00307	0.27	0.3	Intelligence (multi-trait analysis);	chr16:53446797	chr16:53478957~53481550:-
OV	cis	rs2492286	0.597	rs1126828	ENSG00000277250.1	Metazoa_SRP	-4.66	5.51e-06	0.00307	-0.37	-0.3	Eosinophil counts;	chr3:128625943	chr3:128673681~128674021:-
OV	cis	rs55692468	0.761	rs62180804	ENSG00000213197.3	AC012066.1	4.65	5.51e-06	0.00307	0.32	0.3	Intraocular pressure;	chr2:152502998	chr2:152389937~152390630:+
OV	cis	rs55692468	0.848	rs55882252	ENSG00000213197.3	AC012066.1	4.65	5.51e-06	0.00307	0.32	0.3	Intraocular pressure;	chr2:152505186	chr2:152389937~152390630:+
OV	cis	rs17301013	0.606	rs12077529	ENSG00000227373.4	RP11-160H22.5	4.65	5.52e-06	0.00308	0.38	0.3	Systemic lupus erythematosus;	chr1:174549874	chr1:174115300~174160004:-
OV	cis	rs1150668	0.796	rs2531832	ENSG00000204709.4	LINC01556	4.65	5.52e-06	0.00308	0.34	0.3	Pubertal anthropometrics;	chr6:28421445	chr6:28943877~28944537:+
OV	cis	rs2999052	0.708	rs6785384	ENSG00000242551.2	POU5F1P6	4.65	5.53e-06	0.00308	0.41	0.3	Hypospadias;	chr3:128358759	chr3:128674735~128677005:-
OV	cis	rs2999052	0.708	rs1735545	ENSG00000242551.2	POU5F1P6	4.65	5.53e-06	0.00308	0.41	0.3	Hypospadias;	chr3:128362417	chr3:128674735~128677005:-
OV	cis	rs1555322	0.505	rs639763	ENSG00000126005.14	MMP24-AS1	-4.65	5.54e-06	0.00309	-0.42	-0.3	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35216462~35278131:-
OV	cis	rs55692468	0.848	rs12471183	ENSG00000213197.3	AC012066.1	4.65	5.54e-06	0.00309	0.32	0.3	Intraocular pressure;	chr2:152510313	chr2:152389937~152390630:+
OV	cis	rs301901	0.698	rs2886593	ENSG00000250155.1	CTD-2353F22.1	4.65	5.54e-06	0.00309	0.33	0.3	Height;	chr5:37427041	chr5:36666214~36725195:-
OV	cis	rs3758911	0.861	rs10890710	ENSG00000261098.1	RP11-819C21.1	-4.65	5.54e-06	0.00309	-0.28	-0.3	Coronary artery disease;	chr11:107317423	chr11:107312132~107316271:-
OV	cis	rs9925964	0.933	rs2359612	ENSG00000278922.1	AC002310.14	4.65	5.54e-06	0.00309	0.33	0.3	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31092475	chr16:30526918~30528294:+
OV	cis	rs9287719	0.967	rs6744599	ENSG00000234818.1	AC092687.5	-4.65	5.55e-06	0.00309	-0.31	-0.3	Prostate cancer;	chr2:10606887	chr2:10589166~10604830:+
OV	cis	rs858239	0.539	rs4559148	ENSG00000230042.1	AK3P3	-4.65	5.55e-06	0.00309	-0.31	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23146348	chr7:23129178~23129841:+
OV	cis	rs858239	0.539	rs4377861	ENSG00000230042.1	AK3P3	-4.65	5.55e-06	0.00309	-0.31	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23146350	chr7:23129178~23129841:+
OV	cis	rs858239	0.539	rs10247268	ENSG00000230042.1	AK3P3	-4.65	5.55e-06	0.00309	-0.31	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23147560	chr7:23129178~23129841:+
OV	cis	rs858239	0.539	rs6461694	ENSG00000230042.1	AK3P3	-4.65	5.55e-06	0.00309	-0.31	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23148160	chr7:23129178~23129841:+
OV	cis	rs4713118	0.955	rs9468206	ENSG00000219392.1	RP1-265C24.5	-4.65	5.55e-06	0.00309	-0.35	-0.3	Parkinson's disease;	chr6:27722674	chr6:28115628~28116551:+
OV	cis	rs7017914	0.652	rs13264053	ENSG00000223220.1	Y_RNA	4.65	5.55e-06	0.00309	0.33	0.3	Bone mineral density;	chr8:71079101	chr8:70780914~70781008:-
OV	cis	rs858239	0.539	rs4295546	ENSG00000230042.1	AK3P3	-4.65	5.55e-06	0.00309	-0.31	-0.3	Cerebrospinal fluid biomarker levels;	chr7:23151402	chr7:23129178~23129841:+
OV	cis	rs992157	1	rs13429408	ENSG00000261338.2	RP11-378A13.1	4.65	5.56e-06	0.00309	0.34	0.3	Colorectal cancer;	chr2:218278137	chr2:218255319~218257366:+
OV	cis	rs9660180	0.967	rs6603803	ENSG00000268575.1	RP1-283E3.8	-4.65	5.58e-06	0.00311	-0.28	-0.3	Body mass index;	chr1:1881249	chr1:1702736~1737688:-
OV	cis	rs11159086	0.793	rs11621693	ENSG00000270000.1	RP3-449M8.9	4.65	5.59e-06	0.00311	0.44	0.3	Advanced glycation end-product levels;	chr14:74472631	chr14:74471930~74472360:-
OV	cis	rs11159086	0.793	rs1029702	ENSG00000270000.1	RP3-449M8.9	4.65	5.59e-06	0.00311	0.44	0.3	Advanced glycation end-product levels;	chr14:74473909	chr14:74471930~74472360:-
OV	cis	rs881375	1	rs7037140	ENSG00000226752.6	PSMD5-AS1	-4.65	5.59e-06	0.00311	-0.34	-0.3	Rheumatoid arthritis;	chr9:120894049	chr9:120824828~120854385:+
OV	cis	rs4713118	0.869	rs10214440	ENSG00000280107.1	AL022393.9	-4.65	5.59e-06	0.00311	-0.34	-0.3	Parkinson's disease;	chr6:27734661	chr6:28170845~28172521:+
OV	cis	rs7580658	0.963	rs62157555	ENSG00000236682.1	AC068282.3	-4.65	5.59e-06	0.00311	-0.39	-0.3	Protein C levels;	chr2:127349600	chr2:127389130~127400580:+
OV	cis	rs1075265	0.783	rs805438	ENSG00000233266.1	HMGB1P31	4.65	5.59e-06	0.00311	0.36	0.3	Chronotype;Morning vs. evening chronotype;	chr2:53829051	chr2:54051334~54051760:+
OV	cis	rs2919917	0.628	rs6990105	ENSG00000254352.1	RP11-578O24.2	4.65	5.6e-06	0.00312	0.39	0.29	Lymphocyte counts;	chr8:78689652	chr8:78723796~78724136:-
OV	cis	rs2919917	0.628	rs6981103	ENSG00000254352.1	RP11-578O24.2	4.65	5.6e-06	0.00312	0.39	0.29	Lymphocyte counts;	chr8:78691702	chr8:78723796~78724136:-
OV	cis	rs10510102	0.872	rs10887003	ENSG00000226864.1	ATE1-AS1	4.65	5.61e-06	0.00312	0.5	0.29	Breast cancer;	chr10:121864660	chr10:121928312~121951965:+
OV	cis	rs7605378	1	rs769958	ENSG00000232732.8	AC073043.1	-4.65	5.61e-06	0.00312	-0.36	-0.29	Osteoporosis;	chr2:199831178	chr2:199867396~199911159:-
OV	cis	rs5742933	1	rs1550388	ENSG00000253559.1	OSGEPL1-AS1	4.65	5.62e-06	0.00313	0.33	0.29	Ferritin levels;	chr2:189739054	chr2:189762704~189765556:+
OV	cis	rs13113518	0.513	rs13132085	ENSG00000223305.1	RN7SKP30	-4.65	5.63e-06	0.00313	-0.36	-0.29	Height;	chr4:55593918	chr4:55540502~55540835:-
OV	cis	rs4713118	0.869	rs6922574	ENSG00000280107.1	AL022393.9	-4.65	5.63e-06	0.00313	-0.34	-0.29	Parkinson's disease;	chr6:27725224	chr6:28170845~28172521:+
OV	cis	rs7617773	0.817	rs35414021	ENSG00000228638.1	FCF1P2	-4.65	5.64e-06	0.00314	-0.38	-0.29	Coronary artery disease;	chr3:48252034	chr3:48290793~48291375:-
OV	cis	rs2070488	1	rs1002676	ENSG00000229589.1	ACVR2B-AS1	-4.65	5.65e-06	0.00314	-0.32	-0.29	Electrocardiographic conduction measures;	chr3:38403441	chr3:38451027~38454820:-
OV	cis	rs10829156	0.699	rs1917209	ENSG00000225527.1	RP11-383B4.4	-4.65	5.66e-06	0.00315	-0.37	-0.29	Sudden cardiac arrest;	chr10:18543631	chr10:18531849~18533336:-
OV	cis	rs10829156	0.66	rs10764587	ENSG00000225527.1	RP11-383B4.4	-4.65	5.66e-06	0.00315	-0.37	-0.29	Sudden cardiac arrest;	chr10:18548901	chr10:18531849~18533336:-
OV	cis	rs2919917	0.662	rs1483572	ENSG00000254352.1	RP11-578O24.2	4.65	5.66e-06	0.00315	0.33	0.29	Lymphocyte counts;	chr8:78723008	chr8:78723796~78724136:-
OV	cis	rs801193	1	rs10252765	ENSG00000224316.1	RP11-479O9.2	4.65	5.67e-06	0.00315	0.32	0.29	Aortic root size;	chr7:66763745	chr7:65773620~65802067:+
OV	cis	rs1969253	0.712	rs843343	ENSG00000243584.1	RP11-14I2.2	-4.65	5.67e-06	0.00315	-0.33	-0.29	Major depressive disorder;	chr3:184190114	chr3:183613620~183616742:+
OV	cis	rs875971	0.893	rs62465470	ENSG00000236529.1	RP13-254B10.1	-4.65	5.67e-06	0.00315	-0.3	-0.29	Aortic root size;	chr7:66136231	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs4368860	ENSG00000236529.1	RP13-254B10.1	-4.65	5.67e-06	0.00315	-0.3	-0.29	Aortic root size;	chr7:66143495	chr7:65840212~65840596:+
OV	cis	rs9311474	1	rs7614727	ENSG00000243224.1	RP5-1157M23.2	-4.65	5.67e-06	0.00315	-0.32	-0.29	Electroencephalogram traits;	chr3:52261879	chr3:52239258~52241097:+
OV	cis	rs796364	0.616	rs7589545	ENSG00000232732.8	AC073043.1	-4.65	5.68e-06	0.00315	-0.43	-0.29	Schizophrenia;	chr2:199811379	chr2:199867396~199911159:-
OV	cis	rs796364	0.616	rs2030653	ENSG00000232732.8	AC073043.1	-4.65	5.68e-06	0.00315	-0.43	-0.29	Schizophrenia;	chr2:199812902	chr2:199867396~199911159:-
OV	cis	rs796364	0.577	rs7574287	ENSG00000232732.8	AC073043.1	-4.65	5.68e-06	0.00315	-0.43	-0.29	Schizophrenia;	chr2:199816276	chr2:199867396~199911159:-
OV	cis	rs796364	0.616	rs7574313	ENSG00000232732.8	AC073043.1	-4.65	5.68e-06	0.00315	-0.43	-0.29	Schizophrenia;	chr2:199816317	chr2:199867396~199911159:-
OV	cis	rs796364	0.616	rs1523818	ENSG00000232732.8	AC073043.1	-4.65	5.68e-06	0.00315	-0.43	-0.29	Schizophrenia;	chr2:199819981	chr2:199867396~199911159:-
OV	cis	rs796364	0.616	rs2689762	ENSG00000232732.8	AC073043.1	-4.65	5.68e-06	0.00315	-0.43	-0.29	Schizophrenia;	chr2:199822481	chr2:199867396~199911159:-
OV	cis	rs796364	0.616	rs2103094	ENSG00000232732.8	AC073043.1	-4.65	5.68e-06	0.00315	-0.43	-0.29	Schizophrenia;	chr2:199823231	chr2:199867396~199911159:-
OV	cis	rs7617773	0.817	rs936427	ENSG00000228638.1	FCF1P2	4.65	5.68e-06	0.00316	0.38	0.29	Coronary artery disease;	chr3:48259584	chr3:48290793~48291375:-
OV	cis	rs875971	0.545	rs35459055	ENSG00000226824.5	RP4-756H11.3	-4.65	5.69e-06	0.00316	-0.35	-0.29	Aortic root size;	chr7:66479399	chr7:66654538~66669855:+
OV	cis	rs473651	0.904	rs62196716	ENSG00000229915.1	AC016999.2	-4.65	5.69e-06	0.00316	-0.37	-0.29	Multiple system atrophy;	chr2:238448336	chr2:238427077~238427729:-
OV	cis	rs4938303	0.633	rs12801136	ENSG00000254851.1	RP11-109L13.1	4.65	5.69e-06	0.00316	0.49	0.29	Triglycerides;	chr11:116677632	chr11:117135528~117138582:+
OV	cis	rs4938303	0.633	rs61906104	ENSG00000254851.1	RP11-109L13.1	4.65	5.69e-06	0.00316	0.49	0.29	Triglycerides;	chr11:116679398	chr11:117135528~117138582:+
OV	cis	rs4938303	0.671	rs35352977	ENSG00000254851.1	RP11-109L13.1	4.65	5.69e-06	0.00316	0.49	0.29	Triglycerides;	chr11:116681756	chr11:117135528~117138582:+
OV	cis	rs7259376	0.875	rs10409520	ENSG00000269742.1	BNIP3P29	4.65	5.69e-06	0.00316	0.34	0.29	Menopause (age at onset);	chr19:22329675	chr19:22065828~22066398:-
OV	cis	rs7580658	0.963	rs12479003	ENSG00000236682.1	AC068282.3	-4.65	5.7e-06	0.00316	-0.39	-0.29	Protein C levels;	chr2:127360977	chr2:127389130~127400580:+
OV	cis	rs7580658	0.963	rs10803585	ENSG00000236682.1	AC068282.3	-4.65	5.7e-06	0.00316	-0.39	-0.29	Protein C levels;	chr2:127372532	chr2:127389130~127400580:+
OV	cis	rs7580658	0.963	rs12052483	ENSG00000236682.1	AC068282.3	-4.65	5.7e-06	0.00316	-0.39	-0.29	Protein C levels;	chr2:127379244	chr2:127389130~127400580:+
OV	cis	rs11096990	0.634	rs4975001	ENSG00000249207.1	RP11-360F5.1	4.65	5.7e-06	0.00316	0.31	0.29	Cognitive function;	chr4:39264844	chr4:39112677~39126818:-
OV	cis	rs9309473	1	rs56154726	ENSG00000163016.8	ALMS1P	4.65	5.7e-06	0.00316	0.34	0.29	Metabolite levels;	chr2:73494640	chr2:73644919~73685576:+
OV	cis	rs67311347	0.956	rs13066971	ENSG00000223797.4	ENTPD3-AS1	-4.65	5.7e-06	0.00317	-0.32	-0.29	Renal cell carcinoma;	chr3:40421019	chr3:40313802~40453329:-
OV	cis	rs11250098	0.547	rs2409764	ENSG00000255495.1	AC145124.2	4.65	5.72e-06	0.00317	0.32	0.29	Morning vs. evening chronotype;	chr8:11423764	chr8:12194467~12196280:+
OV	cis	rs116095464	0.558	rs10065584	ENSG00000250848.1	CTD-2083E4.5	-4.65	5.72e-06	0.00317	-0.39	-0.29	Breast cancer;	chr5:253882	chr5:288833~290321:-
OV	cis	rs3733585	0.648	rs13125029	ENSG00000250413.1	RP11-448G15.1	-4.65	5.72e-06	0.00317	-0.33	-0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:9980405	chr4:10006482~10009725:+
OV	cis	rs7968440	0.966	rs7977742	ENSG00000257298.1	RP3-405J10.3	4.65	5.73e-06	0.00318	0.3	0.29	Fibrinogen;	chr12:50736424	chr12:50185580~50191363:-
OV	cis	rs796364	0.806	rs74706215	ENSG00000232732.8	AC073043.1	4.65	5.73e-06	0.00318	0.48	0.29	Schizophrenia;	chr2:200076644	chr2:199867396~199911159:-
OV	cis	rs796364	0.806	rs56216998	ENSG00000232732.8	AC073043.1	4.65	5.73e-06	0.00318	0.48	0.29	Schizophrenia;	chr2:200079610	chr2:199867396~199911159:-
OV	cis	rs1113500	0.573	rs10748507	ENSG00000226822.1	RP11-356N1.2	4.65	5.73e-06	0.00318	0.36	0.29	Growth-regulated protein alpha levels;	chr1:108088899	chr1:108071482~108074519:+
OV	cis	rs4718428	1	rs868961	ENSG00000222364.1	RNU6-96P	-4.65	5.74e-06	0.00318	-0.36	-0.29	Corneal structure;	chr7:66972221	chr7:66395191~66395286:+
OV	cis	rs4713118	0.513	rs202908	ENSG00000219392.1	RP1-265C24.5	-4.65	5.74e-06	0.00318	-0.36	-0.29	Parkinson's disease;	chr6:28043773	chr6:28115628~28116551:+
OV	cis	rs1858037	0.867	rs6727013	ENSG00000234255.7	AC012370.3	4.65	5.74e-06	0.00318	0.33	0.29	Rheumatoid arthritis;	chr2:65331241	chr2:65439888~65456571:-
OV	cis	rs7927592	1	rs7927592	ENSG00000212093.1	AP000807.1	4.65	5.75e-06	0.00318	0.37	0.29	Total body bone mineral density;	chr11:68602492	chr11:68506083~68506166:-
OV	cis	rs7124681	0.565	rs2203712	ENSG00000280615.1	Y_RNA	4.65	5.75e-06	0.00318	0.32	0.29	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47513412	chr11:47614898~47614994:-
OV	cis	rs2788869	0.887	rs1767777	ENSG00000247925.2	RP3-510L9.1	-4.65	5.75e-06	0.00319	-0.4	-0.29	Obstetric antiphospholipid syndrome;	chr6:10925570	chr6:11173452~11259099:+
OV	cis	rs9309473	0.898	rs10197755	ENSG00000163016.8	ALMS1P	4.65	5.75e-06	0.00319	0.34	0.29	Metabolite levels;	chr2:73570496	chr2:73644919~73685576:+
OV	cis	rs796364	1	rs11680723	ENSG00000232732.8	AC073043.1	4.65	5.75e-06	0.00319	0.46	0.29	Schizophrenia;	chr2:199946234	chr2:199867396~199911159:-
OV	cis	rs9813712	0.526	rs62281641	ENSG00000253540.4	FAM86HP	-4.65	5.76e-06	0.00319	-0.32	-0.29	Response to amphetamines;	chr3:130235668	chr3:130099092~130111472:-
OV	cis	rs1185460	0.546	rs2508948	ENSG00000271751.1	RP11-110I1.14	4.65	5.76e-06	0.00319	0.36	0.29	Coronary artery disease;	chr11:119080932	chr11:119065263~119065677:-
OV	cis	rs73201462	1	rs67575175	ENSG00000277250.1	Metazoa_SRP	4.64	5.76e-06	0.00319	0.45	0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128161383	chr3:128673681~128674021:-
OV	cis	rs9309473	1	rs6745368	ENSG00000163016.8	ALMS1P	4.64	5.77e-06	0.0032	0.34	0.29	Metabolite levels;	chr2:73582847	chr2:73644919~73685576:+
OV	cis	rs10510102	1	rs10886994	ENSG00000226864.1	ATE1-AS1	4.64	5.77e-06	0.0032	0.49	0.29	Breast cancer;	chr10:121841075	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs11200187	ENSG00000226864.1	ATE1-AS1	4.64	5.77e-06	0.0032	0.49	0.29	Breast cancer;	chr10:121843050	chr10:121928312~121951965:+
OV	cis	rs4713118	0.513	rs156738	ENSG00000219392.1	RP1-265C24.5	-4.64	5.77e-06	0.0032	-0.35	-0.29	Parkinson's disease;	chr6:28046247	chr6:28115628~28116551:+
OV	cis	rs4713118	0.869	rs9283880	ENSG00000280107.1	AL022393.9	-4.64	5.77e-06	0.0032	-0.34	-0.29	Parkinson's disease;	chr6:27747464	chr6:28170845~28172521:+
OV	cis	rs4853012	0.838	rs60964317	ENSG00000257800.1	FNBP1P1	4.64	5.78e-06	0.0032	0.4	0.29	Gestational age at birth (maternal effect);	chr2:74116296	chr2:74120680~74123218:+
OV	cis	rs11157436	0.958	rs2204963	ENSG00000211812.1	TRAV26-2	-4.64	5.79e-06	0.0032	-0.36	-0.29	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22187871	chr14:22202583~22203368:+
OV	cis	rs11157436	0.958	rs61972229	ENSG00000211812.1	TRAV26-2	-4.64	5.79e-06	0.0032	-0.36	-0.29	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22189754	chr14:22202583~22203368:+
OV	cis	rs11157436	0.958	rs17183301	ENSG00000211812.1	TRAV26-2	-4.64	5.79e-06	0.0032	-0.36	-0.29	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22190003	chr14:22202583~22203368:+
OV	cis	rs875971	0.545	rs12670811	ENSG00000226824.5	RP4-756H11.3	-4.64	5.79e-06	0.0032	-0.36	-0.29	Aortic root size;	chr7:66358032	chr7:66654538~66669855:+
OV	cis	rs17301013	0.507	rs72713586	ENSG00000227373.4	RP11-160H22.5	4.64	5.79e-06	0.00321	0.41	0.29	Systemic lupus erythematosus;	chr1:174441265	chr1:174115300~174160004:-
OV	cis	rs11096990	0.634	rs4975002	ENSG00000249207.1	RP11-360F5.1	4.64	5.8e-06	0.00321	0.31	0.29	Cognitive function;	chr4:39286733	chr4:39112677~39126818:-
OV	cis	rs73201462	1	rs57699322	ENSG00000277250.1	Metazoa_SRP	4.64	5.8e-06	0.00321	0.47	0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128346470	chr3:128673681~128674021:-
OV	cis	rs10924970	0.649	rs11799507	ENSG00000236863.2	RPL23AP23	4.64	5.8e-06	0.00321	0.3	0.29	Asthma;	chr1:235270784	chr1:235295865~235296335:+
OV	cis	rs10924970	0.625	rs10925287	ENSG00000236863.2	RPL23AP23	4.64	5.8e-06	0.00321	0.3	0.29	Asthma;	chr1:235271155	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs1933248	ENSG00000236863.2	RPL23AP23	4.64	5.8e-06	0.00321	0.3	0.29	Asthma;	chr1:235276008	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs10925306	ENSG00000236863.2	RPL23AP23	4.64	5.8e-06	0.00321	0.3	0.29	Asthma;	chr1:235279461	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs12760766	ENSG00000236863.2	RPL23AP23	4.64	5.8e-06	0.00321	0.3	0.29	Asthma;	chr1:235282763	chr1:235295865~235296335:+
OV	cis	rs4728142	0.604	rs7807018	ENSG00000275106.1	RP11-309L24.10	-4.64	5.81e-06	0.00321	-0.38	-0.29	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000134	chr7:128952527~128953316:-
OV	cis	rs7927771	0.524	rs10742814	ENSG00000280615.1	Y_RNA	4.64	5.82e-06	0.00322	0.32	0.29	Subjective well-being;	chr11:47532785	chr11:47614898~47614994:-
OV	cis	rs10510102	0.935	rs11200183	ENSG00000226864.1	ATE1-AS1	4.64	5.82e-06	0.00322	0.49	0.29	Breast cancer;	chr10:121829908	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs12255859	ENSG00000226864.1	ATE1-AS1	4.64	5.82e-06	0.00322	0.49	0.29	Breast cancer;	chr10:121831661	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs7923634	ENSG00000226864.1	ATE1-AS1	4.64	5.82e-06	0.00322	0.49	0.29	Breast cancer;	chr10:121832800	chr10:121928312~121951965:+
OV	cis	rs2098713	0.561	rs57015453	ENSG00000250155.1	CTD-2353F22.1	4.64	5.83e-06	0.00322	0.35	0.29	Telomere length;	chr5:37596878	chr5:36666214~36725195:-
OV	cis	rs7429990	0.965	rs1060407	ENSG00000229759.1	MRPS18AP1	4.64	5.83e-06	0.00322	0.32	0.29	Educational attainment (years of education);	chr3:47916547	chr3:48256350~48256938:-
OV	cis	rs7536700	0.915	rs10082235	ENSG00000272030.1	RP1-178F15.4	4.64	5.84e-06	0.00323	0.54	0.29	Multiple myeloma (IgH translocation);	chr1:153684174	chr1:153631438~153634397:-
OV	cis	rs55692468	0.606	rs1878632	ENSG00000213197.3	AC012066.1	-4.64	5.85e-06	0.00323	-0.3	-0.29	Intraocular pressure;	chr2:152466644	chr2:152389937~152390630:+
OV	cis	rs7617773	0.78	rs34523942	ENSG00000228638.1	FCF1P2	-4.64	5.85e-06	0.00323	-0.37	-0.29	Coronary artery disease;	chr3:48301179	chr3:48290793~48291375:-
OV	cis	rs2522056	1	rs6874639	ENSG00000233006.5	AC034220.3	4.64	5.86e-06	0.00324	0.35	0.29	Fibrinogen;Lymphocyte counts;	chr5:132443024	chr5:132311285~132369916:-
OV	cis	rs17711722	0.565	rs4275112	ENSG00000226824.5	RP4-756H11.3	4.64	5.86e-06	0.00324	0.33	0.29	Calcium levels;	chr7:65733651	chr7:66654538~66669855:+
OV	cis	rs73201462	1	rs2955129	ENSG00000277250.1	Metazoa_SRP	-4.64	5.87e-06	0.00324	-0.45	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128210364	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2955130	ENSG00000277250.1	Metazoa_SRP	-4.64	5.87e-06	0.00324	-0.45	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128218971	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2811549	ENSG00000277250.1	Metazoa_SRP	-4.64	5.87e-06	0.00324	-0.45	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128219865	chr3:128673681~128674021:-
OV	cis	rs7746199	0.736	rs13202295	ENSG00000220721.1	OR1F12	4.64	5.87e-06	0.00324	0.55	0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:28073316~28074233:+
OV	cis	rs55692468	0.606	rs6759772	ENSG00000213197.3	AC012066.1	-4.64	5.87e-06	0.00324	-0.3	-0.29	Intraocular pressure;	chr2:152466210	chr2:152389937~152390630:+
OV	cis	rs17264034	0.821	rs60322708	ENSG00000250786.1	SNHG18	4.64	5.87e-06	0.00324	0.45	0.29	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9555837	chr5:9546200~9550609:+
OV	cis	rs34779708	0.931	rs10437420	ENSG00000230534.5	RP11-297A16.2	-4.64	5.88e-06	0.00325	-0.38	-0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35046116	chr10:35098006~35127020:-
OV	cis	rs7617773	0.817	rs34225441	ENSG00000228638.1	FCF1P2	-4.64	5.89e-06	0.00325	-0.38	-0.29	Coronary artery disease;	chr3:48267401	chr3:48290793~48291375:-
OV	cis	rs1858037	0.867	rs876933	ENSG00000234255.7	AC012370.3	4.64	5.89e-06	0.00325	0.33	0.29	Rheumatoid arthritis;	chr2:65382303	chr2:65439888~65456571:-
OV	cis	rs7927592	0.956	rs7106259	ENSG00000212093.1	AP000807.1	4.64	5.89e-06	0.00325	0.38	0.29	Total body bone mineral density;	chr11:68531044	chr11:68506083~68506166:-
OV	cis	rs14027	0.921	rs13270831	ENSG00000279347.1	RP11-85I17.2	-4.64	5.89e-06	0.00325	-0.3	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119755071	chr8:119838736~119840385:-
OV	cis	rs17301013	0.507	rs2987872	ENSG00000227373.4	RP11-160H22.5	-4.64	5.91e-06	0.00326	-0.38	-0.29	Systemic lupus erythematosus;	chr1:174840935	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs1793305	ENSG00000227373.4	RP11-160H22.5	-4.64	5.91e-06	0.00326	-0.38	-0.29	Systemic lupus erythematosus;	chr1:174841124	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs1894201	ENSG00000227373.4	RP11-160H22.5	-4.64	5.91e-06	0.00326	-0.38	-0.29	Systemic lupus erythematosus;	chr1:174841452	chr1:174115300~174160004:-
OV	cis	rs14027	0.921	rs16893101	ENSG00000279347.1	RP11-85I17.2	-4.64	5.92e-06	0.00326	-0.3	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119750669	chr8:119838736~119840385:-
OV	cis	rs13113518	0.812	rs11133385	ENSG00000223305.1	RN7SKP30	4.64	5.92e-06	0.00326	0.34	0.29	Height;	chr4:55460485	chr4:55540502~55540835:-
OV	cis	rs12073359	0.955	rs4926411	ENSG00000223945.2	RP11-458I7.1	4.64	5.92e-06	0.00326	0.44	0.29	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150165577	chr1:150053864~150055034:+
OV	cis	rs73201462	1	rs13069054	ENSG00000277250.1	Metazoa_SRP	4.64	5.92e-06	0.00326	0.45	0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128137139	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs6810006	ENSG00000277250.1	Metazoa_SRP	4.64	5.92e-06	0.00326	0.45	0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128137215	chr3:128673681~128674021:-
OV	cis	rs73201462	0.901	rs56175090	ENSG00000277250.1	Metazoa_SRP	4.64	5.92e-06	0.00326	0.45	0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128141237	chr3:128673681~128674021:-
OV	cis	rs73201462	0.808	rs34372443	ENSG00000277250.1	Metazoa_SRP	4.64	5.92e-06	0.00326	0.45	0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128141651	chr3:128673681~128674021:-
OV	cis	rs7927592	0.956	rs12277225	ENSG00000212093.1	AP000807.1	4.64	5.92e-06	0.00326	0.37	0.29	Total body bone mineral density;	chr11:68573499	chr11:68506083~68506166:-
OV	cis	rs7927592	0.956	rs60212556	ENSG00000212093.1	AP000807.1	4.64	5.92e-06	0.00326	0.37	0.29	Total body bone mineral density;	chr11:68538026	chr11:68506083~68506166:-
OV	cis	rs7927592	0.956	rs12271290	ENSG00000212093.1	AP000807.1	-4.64	5.93e-06	0.00327	-0.37	-0.29	Total body bone mineral density;	chr11:68558768	chr11:68506083~68506166:-
OV	cis	rs3733585	0.631	rs4697924	ENSG00000250413.1	RP11-448G15.1	4.64	5.93e-06	0.00327	0.38	0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:10122615	chr4:10006482~10009725:+
OV	cis	rs2492286	0.597	rs2712372	ENSG00000277250.1	Metazoa_SRP	-4.64	5.93e-06	0.00327	-0.39	-0.29	Eosinophil counts;	chr3:128604994	chr3:128673681~128674021:-
OV	cis	rs2492286	0.597	rs2712407	ENSG00000277250.1	Metazoa_SRP	-4.64	5.93e-06	0.00327	-0.39	-0.29	Eosinophil counts;	chr3:128607964	chr3:128673681~128674021:-
OV	cis	rs3733585	0.699	rs60045583	ENSG00000250413.1	RP11-448G15.1	4.64	5.94e-06	0.00327	0.33	0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:9970326	chr4:10006482~10009725:+
OV	cis	rs6471393	0.798	rs62525169	ENSG00000253848.1	RP11-10N23.5	4.64	5.94e-06	0.00328	0.38	0.29	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93804169	chr8:93741193~93744534:+
OV	cis	rs9925964	0.804	rs9926533	ENSG00000278922.1	AC002310.14	-4.64	5.95e-06	0.00328	-0.32	-0.29	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31002858	chr16:30526918~30528294:+
OV	cis	rs8059260	0.668	rs75637865	ENSG00000274038.1	RP11-66H6.4	-4.64	5.95e-06	0.00328	-0.58	-0.29	Alcohol consumption over the past year;	chr16:10982439	chr16:11056556~11057034:+
OV	cis	rs8059260	0.736	rs7202408	ENSG00000274038.1	RP11-66H6.4	-4.64	5.95e-06	0.00328	-0.58	-0.29	Alcohol consumption over the past year;	chr16:10984758	chr16:11056556~11057034:+
OV	cis	rs9880192	0.516	rs2713575	ENSG00000242551.2	POU5F1P6	-4.64	5.96e-06	0.00328	-0.33	-0.29	White blood cell count;Eosinophil percentage of white cells;Monocyte count;Neutrophil percentage of granulocytes;Monocyte-lymphocyte ratio;Eosinophil percentage of granulocytes;Eosinophil counts;	chr3:128575512	chr3:128674735~128677005:-
OV	cis	rs11673344	0.764	rs10424584	ENSG00000226686.6	LINC01535	4.64	5.97e-06	0.00329	0.38	0.29	Obesity-related traits;	chr19:36975986	chr19:37251912~37265535:+
OV	cis	rs10246939	0.543	rs35836873	ENSG00000228775.6	WEE2-AS1	4.64	5.97e-06	0.00329	0.3	0.29	Bitter taste perception;	chr7:141844010	chr7:141704338~141738346:-
OV	cis	rs875971	0.545	rs12673308	ENSG00000237310.1	GS1-124K5.4	4.64	5.98e-06	0.00329	0.33	0.29	Aortic root size;	chr7:66166374	chr7:66493706~66495474:+
OV	cis	rs875971	0.545	rs67397473	ENSG00000237310.1	GS1-124K5.4	4.64	5.98e-06	0.00329	0.33	0.29	Aortic root size;	chr7:66168318	chr7:66493706~66495474:+
OV	cis	rs875971	0.545	rs10950027	ENSG00000237310.1	GS1-124K5.4	4.64	5.98e-06	0.00329	0.33	0.29	Aortic root size;	chr7:66169164	chr7:66493706~66495474:+
OV	cis	rs783540	1	rs1267657	ENSG00000278603.1	RP13-608F4.5	-4.64	5.98e-06	0.00329	-0.34	-0.29	Schizophrenia;	chr15:82546501	chr15:82472203~82472426:+
OV	cis	rs783540	1	rs803688	ENSG00000278603.1	RP13-608F4.5	-4.64	5.98e-06	0.00329	-0.34	-0.29	Schizophrenia;	chr15:82548043	chr15:82472203~82472426:+
OV	cis	rs2661868	0.918	rs2636314	ENSG00000228423.2	RP4-633I8.4	4.64	5.98e-06	0.00329	0.34	0.29	Life satisfaction;	chr1:8380583	chr1:8805860~8807051:-
OV	cis	rs3733585	0.604	rs73215003	ENSG00000250413.1	RP11-448G15.1	4.64	5.98e-06	0.00329	0.35	0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:10124693	chr4:10006482~10009725:+
OV	cis	rs2286503	0.78	rs2286506	ENSG00000221740.1	SNORD93	4.64	5.99e-06	0.0033	0.37	0.29	Fibrinogen;	chr7:22815196	chr7:22856613~22856686:+
OV	cis	rs2286503	0.752	rs2286504	ENSG00000221740.1	SNORD93	4.64	5.99e-06	0.0033	0.37	0.29	Fibrinogen;	chr7:22815228	chr7:22856613~22856686:+
OV	cis	rs896854	0.654	rs2011566	ENSG00000253528.2	RP11-347C18.4	4.64	5.99e-06	0.0033	0.29	0.29	Type 2 diabetes;	chr8:94959693	chr8:94974573~94974853:-
OV	cis	rs6088590	0.687	rs73106933	ENSG00000206582.1	Y_RNA	-4.64	6e-06	0.0033	-0.36	-0.29	Coronary artery disease;	chr20:34699621	chr20:34526510~34526606:-
OV	cis	rs7968440	1	rs2700485	ENSG00000257298.1	RP3-405J10.3	4.64	6e-06	0.0033	0.28	0.29	Fibrinogen;	chr12:50710209	chr12:50185580~50191363:-
OV	cis	rs7968440	1	rs2250752	ENSG00000257298.1	RP3-405J10.3	4.64	6e-06	0.0033	0.28	0.29	Fibrinogen;	chr12:50712308	chr12:50185580~50191363:-
OV	cis	rs7968440	1	rs2731434	ENSG00000257298.1	RP3-405J10.3	4.64	6e-06	0.0033	0.28	0.29	Fibrinogen;	chr12:50716092	chr12:50185580~50191363:-
OV	cis	rs9287719	0.674	rs6432130	ENSG00000234818.1	AC092687.5	-4.64	6e-06	0.0033	-0.35	-0.29	Prostate cancer;	chr2:10681431	chr2:10589166~10604830:+
OV	cis	rs9287719	0.674	rs11691060	ENSG00000234818.1	AC092687.5	-4.64	6e-06	0.0033	-0.35	-0.29	Prostate cancer;	chr2:10686935	chr2:10589166~10604830:+
OV	cis	rs9287719	0.674	rs11684157	ENSG00000234818.1	AC092687.5	-4.64	6e-06	0.0033	-0.35	-0.29	Prostate cancer;	chr2:10687031	chr2:10589166~10604830:+
OV	cis	rs853679	0.546	rs200981	ENSG00000220721.1	OR1F12	4.64	6e-06	0.0033	0.45	0.29	Depression;	chr6:27865396	chr6:28073316~28074233:+
OV	cis	rs301901	0.897	rs12657771	ENSG00000250155.1	CTD-2353F22.1	-4.63	6.03e-06	0.00332	-0.35	-0.29	Height;	chr5:36787860	chr5:36666214~36725195:-
OV	cis	rs2243480	0.522	rs778717	ENSG00000222364.1	RNU6-96P	-4.63	6.04e-06	0.00332	-0.52	-0.29	Diabetic kidney disease;	chr7:66383164	chr7:66395191~66395286:+
OV	cis	rs9298506	1	rs10103996	ENSG00000254142.2	RP11-53M11.3	4.63	6.04e-06	0.00332	0.4	0.29	Intracranial aneurysm;	chr8:54509864	chr8:54554361~54561927:+
OV	cis	rs7927592	0.913	rs12272917	ENSG00000212093.1	AP000807.1	4.63	6.05e-06	0.00332	0.38	0.29	Total body bone mineral density;	chr11:68495902	chr11:68506083~68506166:-
OV	cis	rs7927592	0.913	rs59056571	ENSG00000212093.1	AP000807.1	4.63	6.05e-06	0.00332	0.38	0.29	Total body bone mineral density;	chr11:68505505	chr11:68506083~68506166:-
OV	cis	rs7927592	0.913	rs66752716	ENSG00000212093.1	AP000807.1	4.63	6.05e-06	0.00332	0.38	0.29	Total body bone mineral density;	chr11:68506158	chr11:68506083~68506166:-
OV	cis	rs7927592	0.913	rs11228262	ENSG00000212093.1	AP000807.1	4.63	6.05e-06	0.00332	0.38	0.29	Total body bone mineral density;	chr11:68507439	chr11:68506083~68506166:-
OV	cis	rs7927592	0.913	rs55883802	ENSG00000212093.1	AP000807.1	4.63	6.05e-06	0.00332	0.38	0.29	Total body bone mineral density;	chr11:68511361	chr11:68506083~68506166:-
OV	cis	rs7927592	0.913	rs11228268	ENSG00000212093.1	AP000807.1	4.63	6.05e-06	0.00332	0.38	0.29	Total body bone mineral density;	chr11:68519979	chr11:68506083~68506166:-
OV	cis	rs7927592	0.913	rs4084149	ENSG00000212093.1	AP000807.1	4.63	6.05e-06	0.00332	0.38	0.29	Total body bone mineral density;	chr11:68521099	chr11:68506083~68506166:-
OV	cis	rs67311347	1	rs112619360	ENSG00000223797.4	ENTPD3-AS1	4.63	6.07e-06	0.00333	0.32	0.29	Renal cell carcinoma;	chr3:40391154	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs72861689	ENSG00000223797.4	ENTPD3-AS1	4.63	6.07e-06	0.00333	0.32	0.29	Renal cell carcinoma;	chr3:40394399	chr3:40313802~40453329:-
OV	cis	rs957448	0.561	rs4734282	ENSG00000253704.1	RP11-267M23.4	4.63	6.07e-06	0.00333	0.38	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94603827	chr8:94553722~94569745:+
OV	cis	rs8054556	1	rs7190185	ENSG00000261367.1	RP11-455F5.4	-4.63	6.07e-06	0.00333	-0.33	-0.29	Autism spectrum disorder or schizophrenia;	chr16:29951031	chr16:30107675~30110541:+
OV	cis	rs992157	0.71	rs56364928	ENSG00000237281.1	CATIP-AS2	-4.63	6.07e-06	0.00333	-0.35	-0.29	Colorectal cancer;	chr2:218194335	chr2:218326889~218357966:-
OV	cis	rs9925964	0.933	rs2303223	ENSG00000278922.1	AC002310.14	-4.63	6.07e-06	0.00334	-0.33	-0.29	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31063854	chr16:30526918~30528294:+
OV	cis	rs9925964	0.933	rs881929	ENSG00000278922.1	AC002310.14	-4.63	6.07e-06	0.00334	-0.33	-0.29	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31068050	chr16:30526918~30528294:+
OV	cis	rs10510102	0.872	rs12264046	ENSG00000226864.1	ATE1-AS1	4.63	6.08e-06	0.00334	0.49	0.29	Breast cancer;	chr10:121894996	chr10:121928312~121951965:+
OV	cis	rs2492286	0.597	rs2811487	ENSG00000277250.1	Metazoa_SRP	-4.63	6.08e-06	0.00334	-0.38	-0.29	Eosinophil counts;	chr3:128613036	chr3:128673681~128674021:-
OV	cis	rs4763879	0.778	rs9332411	ENSG00000278635.1	CTD-2318O12.1	4.63	6.08e-06	0.00334	0.25	0.29	Type 1 diabetes;	chr12:9681749	chr12:9415641~9416718:+
OV	cis	rs6907340	0.517	rs9465533	ENSG00000237404.1	RP3-471C18.2	-4.63	6.09e-06	0.00334	-0.38	-0.29	Endometriosis;	chr6:19801477	chr6:19689825~19753113:-
OV	cis	rs6071524	0.508	rs2247983	ENSG00000277581.1	RP4-616B8.6	4.63	6.09e-06	0.00334	0.35	0.29	Autism spectrum disorder or schizophrenia;	chr20:38769266	chr20:38962472~38962993:+
OV	cis	rs9880211	1	rs28718456	ENSG00000239213.4	NCK1-AS1	4.63	6.09e-06	0.00334	0.35	0.29	Height;Body mass index;	chr3:136485164	chr3:136841726~136862054:-
OV	cis	rs2380205	0.58	rs907687	ENSG00000232807.2	RP11-536K7.3	-4.63	6.09e-06	0.00335	-0.3	-0.29	Breast cancer;	chr10:5858799	chr10:5934270~5945900:-
OV	cis	rs3758911	0.964	rs10789607	ENSG00000261098.1	RP11-819C21.1	-4.63	6.1e-06	0.00335	-0.28	-0.29	Coronary artery disease;	chr11:107314128	chr11:107312132~107316271:-
OV	cis	rs3758911	1	rs2046903	ENSG00000261098.1	RP11-819C21.1	-4.63	6.1e-06	0.00335	-0.28	-0.29	Coronary artery disease;	chr11:107315208	chr11:107312132~107316271:-
OV	cis	rs3758911	1	rs10890705	ENSG00000261098.1	RP11-819C21.1	-4.63	6.1e-06	0.00335	-0.28	-0.29	Coronary artery disease;	chr11:107315308	chr11:107312132~107316271:-
OV	cis	rs3758911	1	rs4387327	ENSG00000261098.1	RP11-819C21.1	-4.63	6.1e-06	0.00335	-0.28	-0.29	Coronary artery disease;	chr11:107315334	chr11:107312132~107316271:-
OV	cis	rs7580658	0.926	rs79789049	ENSG00000236682.1	AC068282.3	-4.63	6.1e-06	0.00335	-0.39	-0.29	Protein C levels;	chr2:127387896	chr2:127389130~127400580:+
OV	cis	rs858239	0.539	rs6956828	ENSG00000230042.1	AK3P3	-4.63	6.1e-06	0.00335	-0.31	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23147728	chr7:23129178~23129841:+
OV	cis	rs4713118	0.869	rs9295743	ENSG00000280107.1	AL022393.9	-4.63	6.11e-06	0.00335	-0.34	-0.29	Parkinson's disease;	chr6:27747323	chr6:28170845~28172521:+
OV	cis	rs10740039	0.883	rs1442546	ENSG00000254271.1	RP11-131N11.4	4.63	6.11e-06	0.00335	0.37	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60650240	chr10:60734342~60741828:+
OV	cis	rs10740039	0.883	rs1442545	ENSG00000254271.1	RP11-131N11.4	4.63	6.11e-06	0.00335	0.37	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60650268	chr10:60734342~60741828:+
OV	cis	rs9287719	0.674	rs759399	ENSG00000234818.1	AC092687.5	-4.63	6.12e-06	0.00336	-0.35	-0.29	Prostate cancer;	chr2:10656757	chr2:10589166~10604830:+
OV	cis	rs9287719	0.674	rs10929690	ENSG00000234818.1	AC092687.5	-4.63	6.12e-06	0.00336	-0.35	-0.29	Prostate cancer;	chr2:10665848	chr2:10589166~10604830:+
OV	cis	rs4805272	0.539	rs17591634	ENSG00000267243.4	AC005307.3	4.63	6.12e-06	0.00336	0.49	0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28840721	chr19:28435388~28727777:-
OV	cis	rs4908768	1	rs12134896	ENSG00000228423.2	RP4-633I8.4	4.63	6.14e-06	0.00337	0.37	0.29	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8596168	chr1:8805860~8807051:-
OV	cis	rs992157	0.687	rs10206984	ENSG00000237281.1	CATIP-AS2	-4.63	6.15e-06	0.00337	-0.34	-0.29	Colorectal cancer;	chr2:218202257	chr2:218326889~218357966:-
OV	cis	rs858239	0.539	rs6461695	ENSG00000230042.1	AK3P3	-4.63	6.15e-06	0.00337	-0.32	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23158165	chr7:23129178~23129841:+
OV	cis	rs2243480	1	rs464895	ENSG00000226824.5	RP4-756H11.3	-4.63	6.15e-06	0.00337	-0.48	-0.29	Diabetic kidney disease;	chr7:66062119	chr7:66654538~66669855:+
OV	cis	rs14027	0.921	rs12707880	ENSG00000279347.1	RP11-85I17.2	-4.63	6.16e-06	0.00337	-0.31	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119829051	chr8:119838736~119840385:-
OV	cis	rs992157	0.835	rs12987219	ENSG00000261338.2	RP11-378A13.1	-4.63	6.16e-06	0.00338	-0.34	-0.29	Colorectal cancer;	chr2:218279426	chr2:218255319~218257366:+
OV	cis	rs3733585	0.699	rs6856127	ENSG00000250413.1	RP11-448G15.1	4.63	6.18e-06	0.00338	0.32	0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:9963819	chr4:10006482~10009725:+
OV	cis	rs783540	0.967	rs4779044	ENSG00000278603.1	RP13-608F4.5	4.63	6.18e-06	0.00339	0.33	0.29	Schizophrenia;	chr15:82670601	chr15:82472203~82472426:+
OV	cis	rs301901	0.772	rs6860727	ENSG00000250155.1	CTD-2353F22.1	-4.63	6.19e-06	0.00339	-0.33	-0.29	Height;	chr5:37179239	chr5:36666214~36725195:-
OV	cis	rs875971	0.862	rs2460432	ENSG00000236529.1	RP13-254B10.1	-4.63	6.19e-06	0.00339	-0.3	-0.29	Aortic root size;	chr7:66089398	chr7:65840212~65840596:+
OV	cis	rs10978777	0.889	rs10978769	ENSG00000276883.1	AL137852.1	4.63	6.19e-06	0.00339	0.33	0.29	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107245862	chr9:107292369~107292456:-
OV	cis	rs3758911	0.894	rs10789620	ENSG00000261098.1	RP11-819C21.1	-4.63	6.2e-06	0.0034	-0.29	-0.29	Coronary artery disease;	chr11:107334700	chr11:107312132~107316271:-
OV	cis	rs1823913	0.637	rs1378162	ENSG00000227542.1	AC092614.2	4.63	6.2e-06	0.0034	0.32	0.29	Obesity-related traits;	chr2:191298523	chr2:191229165~191246172:-
OV	cis	rs1075265	0.901	rs1118618	ENSG00000233266.1	HMGB1P31	4.63	6.21e-06	0.0034	0.37	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54099333	chr2:54051334~54051760:+
OV	cis	rs1075265	0.933	rs929734	ENSG00000233266.1	HMGB1P31	4.63	6.21e-06	0.0034	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54111158	chr2:54051334~54051760:+
OV	cis	rs1681630	0.545	rs12790666	ENSG00000280615.1	Y_RNA	-4.63	6.22e-06	0.0034	-0.34	-0.29	Height;	chr11:47961925	chr11:47614898~47614994:-
OV	cis	rs853679	0.882	rs9468287	ENSG00000280107.1	AL022393.9	-4.63	6.23e-06	0.00341	-0.5	-0.29	Depression;	chr6:28111963	chr6:28170845~28172521:+
OV	cis	rs6471393	0.792	rs7839522	ENSG00000253848.1	RP11-10N23.5	-4.63	6.23e-06	0.00341	-0.38	-0.29	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93827906	chr8:93741193~93744534:+
OV	cis	rs7617773	0.694	rs13099560	ENSG00000228638.1	FCF1P2	4.63	6.23e-06	0.00341	0.35	0.29	Coronary artery disease;	chr3:48163278	chr3:48290793~48291375:-
OV	cis	rs1569175	1	rs3094761	ENSG00000232732.8	AC073043.1	4.63	6.23e-06	0.00341	0.56	0.29	Response to treatment for acute lymphoblastic leukemia;	chr2:200069767	chr2:199867396~199911159:-
OV	cis	rs812925	0.512	rs7558954	ENSG00000271889.1	RP11-493E12.1	4.63	6.23e-06	0.00341	0.34	0.29	Immature fraction of reticulocytes;	chr2:61157771	chr2:61151433~61162105:-
OV	cis	rs7429990	0.965	rs777015	ENSG00000229759.1	MRPS18AP1	4.63	6.24e-06	0.00341	0.32	0.29	Educational attainment (years of education);	chr3:47895582	chr3:48256350~48256938:-
OV	cis	rs1134634	0.52	rs16892140	ENSG00000273133.1	RP11-799M12.2	-4.63	6.24e-06	0.00342	-0.4	-0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15546927	chr4:15563698~15564253:-
OV	cis	rs853679	0.824	rs34712084	ENSG00000280107.1	AL022393.9	-4.63	6.24e-06	0.00342	-0.51	-0.29	Depression;	chr6:28076050	chr6:28170845~28172521:+
OV	cis	rs853679	0.824	rs1321505	ENSG00000280107.1	AL022393.9	-4.63	6.24e-06	0.00342	-0.51	-0.29	Depression;	chr6:28085045	chr6:28170845~28172521:+
OV	cis	rs17301013	0.507	rs6689327	ENSG00000227373.4	RP11-160H22.5	4.63	6.26e-06	0.00342	0.37	0.29	Systemic lupus erythematosus;	chr1:174464274	chr1:174115300~174160004:-
OV	cis	rs6772849	1	rs2713605	ENSG00000242551.2	POU5F1P6	-4.63	6.26e-06	0.00343	-0.35	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128588617	chr3:128674735~128677005:-
OV	cis	rs6772849	1	rs2712373	ENSG00000242551.2	POU5F1P6	-4.63	6.26e-06	0.00343	-0.35	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128589212	chr3:128674735~128677005:-
OV	cis	rs6772849	1	rs2712378	ENSG00000242551.2	POU5F1P6	-4.63	6.26e-06	0.00343	-0.35	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128589951	chr3:128674735~128677005:-
OV	cis	rs6772849	0.965	rs67790930	ENSG00000242551.2	POU5F1P6	-4.63	6.26e-06	0.00343	-0.35	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128591193	chr3:128674735~128677005:-
OV	cis	rs6772849	0.965	rs4286447	ENSG00000242551.2	POU5F1P6	-4.63	6.26e-06	0.00343	-0.35	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128591746	chr3:128674735~128677005:-
OV	cis	rs992157	0.735	rs13392177	ENSG00000237281.1	CATIP-AS2	4.63	6.27e-06	0.00343	0.34	0.29	Colorectal cancer;	chr2:218248233	chr2:218326889~218357966:-
OV	cis	rs1075265	0.933	rs11888384	ENSG00000233266.1	HMGB1P31	4.63	6.27e-06	0.00343	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54110984	chr2:54051334~54051760:+
OV	cis	rs853679	0.882	rs9461432	ENSG00000280107.1	AL022393.9	-4.63	6.28e-06	0.00343	-0.5	-0.29	Depression;	chr6:28119105	chr6:28170845~28172521:+
OV	cis	rs3733585	0.699	rs6449202	ENSG00000250413.1	RP11-448G15.1	4.63	6.28e-06	0.00343	0.33	0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:9972419	chr4:10006482~10009725:+
OV	cis	rs4713118	0.662	rs9393881	ENSG00000226314.6	ZNF192P1	-4.63	6.29e-06	0.00344	-0.38	-0.29	Parkinson's disease;	chr6:28055973	chr6:28161781~28169594:+
OV	cis	rs1969253	0.712	rs843367	ENSG00000243584.1	RP11-14I2.2	-4.63	6.29e-06	0.00344	-0.33	-0.29	Major depressive disorder;	chr3:184182550	chr3:183613620~183616742:+
OV	cis	rs1969253	0.712	rs843364	ENSG00000243584.1	RP11-14I2.2	-4.63	6.29e-06	0.00344	-0.33	-0.29	Major depressive disorder;	chr3:184183048	chr3:183613620~183616742:+
OV	cis	rs1969253	0.712	rs6443954	ENSG00000243584.1	RP11-14I2.2	-4.63	6.29e-06	0.00344	-0.33	-0.29	Major depressive disorder;	chr3:184185013	chr3:183613620~183616742:+
OV	cis	rs1969253	0.712	rs2942057	ENSG00000243584.1	RP11-14I2.2	-4.63	6.29e-06	0.00344	-0.33	-0.29	Major depressive disorder;	chr3:184187080	chr3:183613620~183616742:+
OV	cis	rs858239	0.601	rs11984129	ENSG00000230042.1	AK3P3	-4.63	6.29e-06	0.00344	-0.31	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23113058	chr7:23129178~23129841:+
OV	cis	rs172166	0.637	rs1071893	ENSG00000219392.1	RP1-265C24.5	-4.63	6.29e-06	0.00344	-0.35	-0.29	Cardiac Troponin-T levels;	chr6:28199857	chr6:28115628~28116551:+
OV	cis	rs17772222	0.582	rs12050316	ENSG00000258789.1	RP11-507K2.3	-4.63	6.29e-06	0.00344	-0.31	-0.29	Coronary artery calcification;	chr14:88522097	chr14:88551597~88552493:+
OV	cis	rs992157	0.965	rs62182826	ENSG00000261338.2	RP11-378A13.1	4.63	6.29e-06	0.00344	0.34	0.29	Colorectal cancer;	chr2:218284000	chr2:218255319~218257366:+
OV	cis	rs7429990	0.965	rs9854454	ENSG00000229759.1	MRPS18AP1	-4.62	6.29e-06	0.00344	-0.3	-0.29	Educational attainment (years of education);	chr3:47971307	chr3:48256350~48256938:-
OV	cis	rs34779708	0.966	rs2045915	ENSG00000230534.5	RP11-297A16.2	4.62	6.29e-06	0.00344	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35129688	chr10:35098006~35127020:-
OV	cis	rs34779708	0.931	rs4934731	ENSG00000230534.5	RP11-297A16.2	4.62	6.29e-06	0.00344	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35142708	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs57081218	ENSG00000230534.5	RP11-297A16.2	4.62	6.29e-06	0.00344	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35145680	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs6481941	ENSG00000230534.5	RP11-297A16.2	4.62	6.29e-06	0.00344	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35151213	chr10:35098006~35127020:-
OV	cis	rs34779708	0.966	rs10508816	ENSG00000230534.5	RP11-297A16.2	4.62	6.29e-06	0.00344	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35171048	chr10:35098006~35127020:-
OV	cis	rs6772849	1	rs2712379	ENSG00000242551.2	POU5F1P6	-4.62	6.3e-06	0.00344	-0.35	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128590217	chr3:128674735~128677005:-
OV	cis	rs473651	0.967	rs483042	ENSG00000229915.1	AC016999.2	-4.62	6.31e-06	0.00344	-0.37	-0.29	Multiple system atrophy;	chr2:238426679	chr2:238427077~238427729:-
OV	cis	rs1576263	0.967	rs9328489	ENSG00000230939.1	RP11-314C16.1	4.62	6.31e-06	0.00344	0.32	0.29	Photic sneeze reflex;	chr6:8561884	chr6:8784178~8785445:+
OV	cis	rs17023223	0.537	rs3934789	ENSG00000231365.4	RP11-418J17.1	-4.62	6.31e-06	0.00345	-0.39	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119140440	chr1:119140396~119275973:+
OV	cis	rs1012068	0.686	rs5753818	ENSG00000236132.1	CTA-440B3.1	4.62	6.31e-06	0.00345	0.34	0.29	Chronic hepatitis C infection;	chr22:31917947	chr22:31816379~31817491:-
OV	cis	rs2833693	0.572	rs2833711	ENSG00000261610.1	AP000265.1	4.62	6.31e-06	0.00345	0.38	0.29	Temperament;	chr21:32191022	chr21:32259804~32261585:-
OV	cis	rs3733585	0.631	rs7699671	ENSG00000250413.1	RP11-448G15.1	4.62	6.32e-06	0.00345	0.35	0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:10124250	chr4:10006482~10009725:+
OV	cis	rs1555322	0.53	rs2425042	ENSG00000279253.1	RP4-614O4.13	-4.62	6.32e-06	0.00345	-0.37	-0.29	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35262727~35264187:-
OV	cis	rs1555322	0.53	rs7004	ENSG00000279253.1	RP4-614O4.13	-4.62	6.32e-06	0.00345	-0.37	-0.29	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35262727~35264187:-
OV	cis	rs10510102	0.935	rs12240893	ENSG00000226864.1	ATE1-AS1	4.62	6.33e-06	0.00346	0.5	0.29	Breast cancer;	chr10:121870572	chr10:121928312~121951965:+
OV	cis	rs875971	0.571	rs78668714	ENSG00000236529.1	RP13-254B10.1	4.62	6.33e-06	0.00346	0.35	0.29	Aortic root size;	chr7:66474464	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs73150604	ENSG00000236529.1	RP13-254B10.1	4.62	6.33e-06	0.00346	0.35	0.29	Aortic root size;	chr7:66480545	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs7810213	ENSG00000236529.1	RP13-254B10.1	4.62	6.33e-06	0.00346	0.35	0.29	Aortic root size;	chr7:66481592	chr7:65840212~65840596:+
OV	cis	rs9287719	0.699	rs4669602	ENSG00000234818.1	AC092687.5	4.62	6.33e-06	0.00346	0.32	0.29	Prostate cancer;	chr2:10647841	chr2:10589166~10604830:+
OV	cis	rs875971	0.545	rs67775320	ENSG00000237310.1	GS1-124K5.4	4.62	6.33e-06	0.00346	0.34	0.29	Aortic root size;	chr7:66193792	chr7:66493706~66495474:+
OV	cis	rs7520050	0.966	rs11589562	ENSG00000280836.1	AL355480.1	-4.62	6.34e-06	0.00346	-0.34	-0.29	Reticulocyte count;Red blood cell count;	chr1:46001049	chr1:45581219~45581321:-
OV	cis	rs6558530	0.666	rs7005699	ENSG00000253982.1	CTD-2336O2.1	4.62	6.34e-06	0.00346	0.37	0.29	Systolic blood pressure;	chr8:1752454	chr8:1761990~1764502:-
OV	cis	rs9287719	1	rs9287719	ENSG00000234818.1	AC092687.5	4.62	6.34e-06	0.00346	0.31	0.29	Prostate cancer;	chr2:10570604	chr2:10589166~10604830:+
OV	cis	rs473651	0.777	rs550890	ENSG00000229915.1	AC016999.2	-4.62	6.35e-06	0.00346	-0.36	-0.29	Multiple system atrophy;	chr2:238423914	chr2:238427077~238427729:-
OV	cis	rs7189233	0.55	rs13330182	ENSG00000279344.1	RP11-44F14.7	4.62	6.35e-06	0.00346	0.27	0.29	Intelligence (multi-trait analysis);	chr16:53438473	chr16:53478957~53481550:-
OV	cis	rs11690935	0.632	rs6737308	ENSG00000228389.1	AC068039.4	-4.62	6.35e-06	0.00347	-0.33	-0.29	Schizophrenia;	chr2:172007137	chr2:171773482~171775844:+
OV	cis	rs116095464	0.51	rs73016876	ENSG00000250848.1	CTD-2083E4.5	-4.62	6.36e-06	0.00347	-0.36	-0.29	Breast cancer;	chr5:244360	chr5:288833~290321:-
OV	cis	rs11690935	0.632	rs62183783	ENSG00000228389.1	AC068039.4	-4.62	6.37e-06	0.00347	-0.33	-0.29	Schizophrenia;	chr2:172000868	chr2:171773482~171775844:+
OV	cis	rs796364	0.806	rs6743396	ENSG00000232732.8	AC073043.1	-4.62	6.37e-06	0.00347	-0.47	-0.29	Schizophrenia;	chr2:199995415	chr2:199867396~199911159:-
OV	cis	rs796364	0.806	rs6435040	ENSG00000232732.8	AC073043.1	-4.62	6.37e-06	0.00347	-0.47	-0.29	Schizophrenia;	chr2:199996438	chr2:199867396~199911159:-
OV	cis	rs796364	0.806	rs4673634	ENSG00000232732.8	AC073043.1	-4.62	6.37e-06	0.00347	-0.47	-0.29	Schizophrenia;	chr2:199998626	chr2:199867396~199911159:-
OV	cis	rs796364	0.806	rs6435041	ENSG00000232732.8	AC073043.1	-4.62	6.37e-06	0.00347	-0.47	-0.29	Schizophrenia;	chr2:200002421	chr2:199867396~199911159:-
OV	cis	rs796364	0.806	rs1605900	ENSG00000232732.8	AC073043.1	-4.62	6.37e-06	0.00347	-0.47	-0.29	Schizophrenia;	chr2:200005474	chr2:199867396~199911159:-
OV	cis	rs5742933	0.557	rs1233276	ENSG00000253559.1	OSGEPL1-AS1	-4.62	6.37e-06	0.00347	-0.33	-0.29	Ferritin levels;	chr2:189820056	chr2:189762704~189765556:+
OV	cis	rs611744	0.583	rs1448148	ENSG00000253754.1	RP11-35G22.1	-4.62	6.37e-06	0.00347	-0.32	-0.29	Dupuytren's disease;	chr8:108320845	chr8:108226200~108227544:+
OV	cis	rs875971	0.862	rs11763189	ENSG00000236529.1	RP13-254B10.1	4.62	6.38e-06	0.00348	0.3	0.29	Aortic root size;	chr7:66518542	chr7:65840212~65840596:+
OV	cis	rs11098499	0.863	rs10019674	ENSG00000245958.5	RP11-33B1.1	4.62	6.38e-06	0.00348	0.35	0.29	Corneal astigmatism;	chr4:119522334	chr4:119454791~119552025:+
OV	cis	rs1569175	1	rs3115424	ENSG00000232732.8	AC073043.1	4.62	6.39e-06	0.00348	0.55	0.29	Response to treatment for acute lymphoblastic leukemia;	chr2:200067573	chr2:199867396~199911159:-
OV	cis	rs2919917	0.688	rs6993386	ENSG00000254352.1	RP11-578O24.2	-4.62	6.4e-06	0.00349	-0.32	-0.29	Lymphocyte counts;	chr8:78741910	chr8:78723796~78724136:-
OV	cis	rs858239	0.508	rs2390754	ENSG00000230042.1	AK3P3	-4.62	6.4e-06	0.00349	-0.31	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23150875	chr7:23129178~23129841:+
OV	cis	rs8114671	0.967	rs2180568	ENSG00000269202.1	RP4-614O4.12	4.62	6.4e-06	0.00349	0.29	0.29	Height;	chr20:35206991	chr20:35201747~35203288:-
OV	cis	rs116095464	0.558	rs113796397	ENSG00000250848.1	CTD-2083E4.5	-4.62	6.41e-06	0.00349	-0.36	-0.29	Breast cancer;	chr5:246388	chr5:288833~290321:-
OV	cis	rs4948102	0.599	rs2230197	ENSG00000275875.1	RP11-613E4.5	-4.62	6.41e-06	0.00349	-0.32	-0.29	Plasma homocysteine levels (post-methionine load test);	chr7:56058667	chr7:55741525~55741869:+
OV	cis	rs17301013	0.632	rs1653636	ENSG00000227373.4	RP11-160H22.5	-4.62	6.41e-06	0.00349	-0.37	-0.29	Systemic lupus erythematosus;	chr1:174767739	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs1754360	ENSG00000227373.4	RP11-160H22.5	-4.62	6.41e-06	0.00349	-0.37	-0.29	Systemic lupus erythematosus;	chr1:174775825	chr1:174115300~174160004:-
OV	cis	rs8113142	0.943	rs73014997	ENSG00000267243.4	AC005307.3	-4.62	6.41e-06	0.00349	-0.55	-0.29	Femoral neck bone geometry and menarche (age at onset);	chr19:28518105	chr19:28435388~28727777:-
OV	cis	rs13113518	0.783	rs6843997	ENSG00000223305.1	RN7SKP30	4.62	6.42e-06	0.0035	0.34	0.29	Height;	chr4:55508982	chr4:55540502~55540835:-
OV	cis	rs13113518	0.783	rs12508367	ENSG00000223305.1	RN7SKP30	4.62	6.42e-06	0.0035	0.34	0.29	Height;	chr4:55509442	chr4:55540502~55540835:-
OV	cis	rs13113518	0.812	rs2272073	ENSG00000223305.1	RN7SKP30	4.62	6.42e-06	0.0035	0.34	0.29	Height;	chr4:55510177	chr4:55540502~55540835:-
OV	cis	rs1797885	0.816	rs2596829	ENSG00000251774.1	RNU6-377P	4.62	6.42e-06	0.0035	0.28	0.29	Immature fraction of reticulocytes;	chr3:12522140	chr3:12514706~12514807:+
OV	cis	rs1797885	0.844	rs2655260	ENSG00000251774.1	RNU6-377P	4.62	6.42e-06	0.0035	0.28	0.29	Immature fraction of reticulocytes;	chr3:12522141	chr3:12514706~12514807:+
OV	cis	rs295490	0.748	rs78490940	ENSG00000272656.1	RP11-219D15.3	4.62	6.42e-06	0.0035	0.58	0.29	PR interval in Tripanosoma cruzi seropositivity;	chr3:139370333	chr3:139349024~139349371:-
OV	cis	rs7083	0.935	rs523366	ENSG00000278768.1	BACE1-AS	4.62	6.42e-06	0.0035	0.3	0.29	Blood protein levels;	chr11:117248836	chr11:117290874~117293571:+
OV	cis	rs10246939	0.579	rs58093678	ENSG00000228775.6	WEE2-AS1	4.62	6.43e-06	0.0035	0.31	0.29	Bitter taste perception;	chr7:141856719	chr7:141704338~141738346:-
OV	cis	rs875971	1	rs2420820	ENSG00000236529.1	RP13-254B10.1	-4.62	6.44e-06	0.00351	-0.31	-0.29	Aortic root size;	chr7:66626920	chr7:65840212~65840596:+
OV	cis	rs4713118	0.869	rs4713121	ENSG00000219392.1	RP1-265C24.5	-4.62	6.46e-06	0.00352	-0.34	-0.29	Parkinson's disease;	chr6:27754285	chr6:28115628~28116551:+
OV	cis	rs7189233	0.571	rs4146344	ENSG00000279344.1	RP11-44F14.7	4.62	6.47e-06	0.00352	0.27	0.29	Intelligence (multi-trait analysis);	chr16:53435050	chr16:53478957~53481550:-
OV	cis	rs11096990	0.613	rs2060805	ENSG00000249207.1	RP11-360F5.1	-4.62	6.48e-06	0.00353	-0.31	-0.29	Cognitive function;	chr4:39232788	chr4:39112677~39126818:-
OV	cis	rs7580658	0.963	rs867304	ENSG00000236682.1	AC068282.3	-4.62	6.48e-06	0.00353	-0.38	-0.29	Protein C levels;	chr2:127320912	chr2:127389130~127400580:+
OV	cis	rs796364	0.616	rs769956	ENSG00000232732.8	AC073043.1	4.62	6.48e-06	0.00353	0.45	0.29	Schizophrenia;	chr2:199828997	chr2:199867396~199911159:-
OV	cis	rs14027	0.921	rs1567359	ENSG00000279347.1	RP11-85I17.2	-4.62	6.48e-06	0.00353	-0.3	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119778378	chr8:119838736~119840385:-
OV	cis	rs14027	0.921	rs2043430	ENSG00000279347.1	RP11-85I17.2	-4.62	6.48e-06	0.00353	-0.3	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119779741	chr8:119838736~119840385:-
OV	cis	rs14027	0.921	rs12543087	ENSG00000279347.1	RP11-85I17.2	-4.62	6.48e-06	0.00353	-0.3	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119784207	chr8:119838736~119840385:-
OV	cis	rs14027	0.921	rs10101278	ENSG00000279347.1	RP11-85I17.2	-4.62	6.48e-06	0.00353	-0.3	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119784799	chr8:119838736~119840385:-
OV	cis	rs14027	0.921	rs1976575	ENSG00000279347.1	RP11-85I17.2	-4.62	6.48e-06	0.00353	-0.3	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119788618	chr8:119838736~119840385:-
OV	cis	rs14027	0.921	rs7837589	ENSG00000279347.1	RP11-85I17.2	-4.62	6.48e-06	0.00353	-0.3	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119789401	chr8:119838736~119840385:-
OV	cis	rs14027	0.921	rs67905698	ENSG00000279347.1	RP11-85I17.2	-4.62	6.48e-06	0.00353	-0.3	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119792186	chr8:119838736~119840385:-
OV	cis	rs14027	0.921	rs28756749	ENSG00000279347.1	RP11-85I17.2	-4.62	6.48e-06	0.00353	-0.3	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119803164	chr8:119838736~119840385:-
OV	cis	rs934734	0.563	rs11126034	ENSG00000234255.7	AC012370.3	-4.62	6.48e-06	0.00353	-0.31	-0.29	Rheumatoid arthritis;	chr2:65353087	chr2:65439888~65456571:-
OV	cis	rs1075265	0.722	rs7596349	ENSG00000233266.1	HMGB1P31	4.62	6.49e-06	0.00353	0.36	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53709123	chr2:54051334~54051760:+
OV	cis	rs6772849	0.775	rs9828414	ENSG00000242551.2	POU5F1P6	-4.62	6.49e-06	0.00353	-0.35	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128693874	chr3:128674735~128677005:-
OV	cis	rs6772849	0.804	rs9832430	ENSG00000242551.2	POU5F1P6	-4.62	6.49e-06	0.00353	-0.35	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128694054	chr3:128674735~128677005:-
OV	cis	rs7580658	0.929	rs13029237	ENSG00000236682.1	AC068282.3	-4.62	6.5e-06	0.00353	-0.39	-0.29	Protein C levels;	chr2:127390278	chr2:127389130~127400580:+
OV	cis	rs8054556	0.647	rs11649149	ENSG00000261367.1	RP11-455F5.4	-4.62	6.5e-06	0.00354	-0.31	-0.29	Autism spectrum disorder or schizophrenia;	chr16:29997323	chr16:30107675~30110541:+
OV	cis	rs875971	0.862	rs2909688	ENSG00000236529.1	RP13-254B10.1	4.62	6.51e-06	0.00354	0.3	0.29	Aortic root size;	chr7:66376625	chr7:65840212~65840596:+
OV	cis	rs875971	0.83	rs778711	ENSG00000236529.1	RP13-254B10.1	4.62	6.51e-06	0.00354	0.3	0.29	Aortic root size;	chr7:66386670	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs1083554	ENSG00000236529.1	RP13-254B10.1	4.62	6.51e-06	0.00354	0.3	0.29	Aortic root size;	chr7:66387354	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs778707	ENSG00000236529.1	RP13-254B10.1	4.62	6.51e-06	0.00354	0.3	0.29	Aortic root size;	chr7:66392040	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs778705	ENSG00000236529.1	RP13-254B10.1	4.62	6.51e-06	0.00354	0.3	0.29	Aortic root size;	chr7:66396128	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs778697	ENSG00000236529.1	RP13-254B10.1	4.62	6.51e-06	0.00354	0.3	0.29	Aortic root size;	chr7:66405439	chr7:65840212~65840596:+
OV	cis	rs875971	0.798	rs7789615	ENSG00000236529.1	RP13-254B10.1	4.62	6.51e-06	0.00354	0.3	0.29	Aortic root size;	chr7:66413674	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs6978028	ENSG00000236529.1	RP13-254B10.1	4.62	6.51e-06	0.00354	0.3	0.29	Aortic root size;	chr7:66421313	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs6947339	ENSG00000236529.1	RP13-254B10.1	4.62	6.51e-06	0.00354	0.3	0.29	Aortic root size;	chr7:66423483	chr7:65840212~65840596:+
OV	cis	rs1858037	0.867	rs1553675	ENSG00000234255.7	AC012370.3	-4.62	6.51e-06	0.00354	-0.32	-0.29	Rheumatoid arthritis;	chr2:65343173	chr2:65439888~65456571:-
OV	cis	rs1528149	0.504	rs1990364	ENSG00000224683.1	RPL36AP29	4.62	6.52e-06	0.00354	0.33	0.29	Sitting height ratio;	chr7:16129300	chr7:16208945~16209265:+
OV	cis	rs8054556	0.669	rs4787491	ENSG00000261367.1	RP11-455F5.4	-4.62	6.52e-06	0.00354	-0.31	-0.29	Autism spectrum disorder or schizophrenia;	chr16:30004016	chr16:30107675~30110541:+
OV	cis	rs858239	0.539	rs2390757	ENSG00000230042.1	AK3P3	-4.62	6.52e-06	0.00354	-0.31	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23151873	chr7:23129178~23129841:+
OV	cis	rs17301013	0.507	rs1653630	ENSG00000227373.4	RP11-160H22.5	-4.62	6.52e-06	0.00354	-0.38	-0.29	Systemic lupus erythematosus;	chr1:174791810	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs913688	ENSG00000227373.4	RP11-160H22.5	-4.62	6.52e-06	0.00354	-0.38	-0.29	Systemic lupus erythematosus;	chr1:174805080	chr1:174115300~174160004:-
OV	cis	rs9601248	0.627	rs2146593	ENSG00000227676.3	LINC01068	4.62	6.52e-06	0.00354	0.37	0.29	Major depressive disorder;	chr13:79605977	chr13:79566727~79571436:+
OV	cis	rs9660180	0.967	rs61422524	ENSG00000215914.4	MMP23A	-4.62	6.53e-06	0.00354	-0.34	-0.29	Body mass index;	chr1:1836126	chr1:1699942~1701782:+
OV	cis	rs4713118	0.911	rs9461406	ENSG00000280107.1	AL022393.9	4.62	6.53e-06	0.00354	0.37	0.29	Parkinson's disease;	chr6:27751985	chr6:28170845~28172521:+
OV	cis	rs10829156	0.699	rs10764584	ENSG00000225527.1	RP11-383B4.4	4.62	6.54e-06	0.00355	0.36	0.29	Sudden cardiac arrest;	chr10:18546396	chr10:18531849~18533336:-
OV	cis	rs10851478	0.515	rs12439429	ENSG00000259545.2	RP11-325E5.4	4.62	6.54e-06	0.00355	0.33	0.29	Oral cavity cancer;	chr15:49442437	chr15:49177610~49178741:-
OV	cis	rs875971	0.545	rs4441996	ENSG00000236529.1	RP13-254B10.1	-4.62	6.55e-06	0.00355	-0.34	-0.29	Aortic root size;	chr7:66123233	chr7:65840212~65840596:+
OV	cis	rs7302981	0.667	rs7308692	ENSG00000257298.1	RP3-405J10.3	-4.62	6.55e-06	0.00355	-0.27	-0.29	Systolic blood pressure;	chr12:50233871	chr12:50185580~50191363:-
OV	cis	rs17301013	0.507	rs2901820	ENSG00000227373.4	RP11-160H22.5	4.62	6.55e-06	0.00355	0.4	0.29	Systemic lupus erythematosus;	chr1:174505201	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs4652512	ENSG00000227373.4	RP11-160H22.5	4.62	6.55e-06	0.00355	0.4	0.29	Systemic lupus erythematosus;	chr1:174515519	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs57512497	ENSG00000227373.4	RP11-160H22.5	4.62	6.55e-06	0.00355	0.4	0.29	Systemic lupus erythematosus;	chr1:174518346	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs72715218	ENSG00000227373.4	RP11-160H22.5	4.62	6.55e-06	0.00355	0.4	0.29	Systemic lupus erythematosus;	chr1:174529056	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs2060158	ENSG00000227373.4	RP11-160H22.5	4.62	6.55e-06	0.00355	0.4	0.29	Systemic lupus erythematosus;	chr1:174667379	chr1:174115300~174160004:-
OV	cis	rs9309473	0.95	rs7596773	ENSG00000163016.8	ALMS1P	4.62	6.55e-06	0.00356	0.36	0.29	Metabolite levels;	chr2:73618873	chr2:73644919~73685576:+
OV	cis	rs14027	0.921	rs4871634	ENSG00000279347.1	RP11-85I17.2	-4.62	6.56e-06	0.00356	-0.3	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119806243	chr8:119838736~119840385:-
OV	cis	rs1797885	0.651	rs1552485	ENSG00000251774.1	RNU6-377P	-4.62	6.56e-06	0.00356	-0.28	-0.29	Immature fraction of reticulocytes;	chr3:12538784	chr3:12514706~12514807:+
OV	cis	rs17711722	0.565	rs4717276	ENSG00000226824.5	RP4-756H11.3	-4.62	6.56e-06	0.00356	-0.32	-0.29	Calcium levels;	chr7:65829754	chr7:66654538~66669855:+
OV	cis	rs875971	0.545	rs12670811	ENSG00000237310.1	GS1-124K5.4	4.62	6.57e-06	0.00356	0.35	0.29	Aortic root size;	chr7:66358032	chr7:66493706~66495474:+
OV	cis	rs10829156	0.66	rs11014830	ENSG00000225527.1	RP11-383B4.4	-4.62	6.57e-06	0.00356	-0.36	-0.29	Sudden cardiac arrest;	chr10:18551504	chr10:18531849~18533336:-
OV	cis	rs4713118	0.869	rs9366700	ENSG00000280107.1	AL022393.9	-4.61	6.58e-06	0.00357	-0.34	-0.29	Parkinson's disease;	chr6:27729172	chr6:28170845~28172521:+
OV	cis	rs4713118	0.869	rs6456802	ENSG00000280107.1	AL022393.9	-4.61	6.58e-06	0.00357	-0.34	-0.29	Parkinson's disease;	chr6:27730576	chr6:28170845~28172521:+
OV	cis	rs4713118	0.869	rs9393851	ENSG00000280107.1	AL022393.9	-4.61	6.58e-06	0.00357	-0.34	-0.29	Parkinson's disease;	chr6:27731802	chr6:28170845~28172521:+
OV	cis	rs4713118	0.869	rs9461400	ENSG00000280107.1	AL022393.9	-4.61	6.58e-06	0.00357	-0.34	-0.29	Parkinson's disease;	chr6:27732780	chr6:28170845~28172521:+
OV	cis	rs4713118	0.869	rs9295742	ENSG00000280107.1	AL022393.9	-4.61	6.58e-06	0.00357	-0.34	-0.29	Parkinson's disease;	chr6:27735053	chr6:28170845~28172521:+
OV	cis	rs4713118	0.869	rs9461401	ENSG00000280107.1	AL022393.9	-4.61	6.58e-06	0.00357	-0.34	-0.29	Parkinson's disease;	chr6:27735512	chr6:28170845~28172521:+
OV	cis	rs4713118	0.869	rs6914924	ENSG00000280107.1	AL022393.9	-4.61	6.58e-06	0.00357	-0.34	-0.29	Parkinson's disease;	chr6:27743751	chr6:28170845~28172521:+
OV	cis	rs4713118	0.869	rs6930992	ENSG00000280107.1	AL022393.9	-4.61	6.58e-06	0.00357	-0.34	-0.29	Parkinson's disease;	chr6:27744341	chr6:28170845~28172521:+
OV	cis	rs4713118	0.869	rs6901520	ENSG00000280107.1	AL022393.9	-4.61	6.58e-06	0.00357	-0.34	-0.29	Parkinson's disease;	chr6:27746796	chr6:28170845~28172521:+
OV	cis	rs7927592	0.672	rs10501398	ENSG00000212093.1	AP000807.1	-4.61	6.59e-06	0.00357	-0.34	-0.29	Total body bone mineral density;	chr11:68564247	chr11:68506083~68506166:-
OV	cis	rs2239547	0.603	rs6805298	ENSG00000242142.1	SERBP1P3	-4.61	6.59e-06	0.00357	-0.37	-0.29	Schizophrenia;	chr3:53062536	chr3:53064283~53065091:-
OV	cis	rs1823913	0.599	rs17412635	ENSG00000227542.1	AC092614.2	-4.61	6.59e-06	0.00357	-0.32	-0.29	Obesity-related traits;	chr2:191294834	chr2:191229165~191246172:-
OV	cis	rs853679	0.546	rs200952	ENSG00000220721.1	OR1F12	4.61	6.6e-06	0.00358	0.48	0.29	Depression;	chr6:27869198	chr6:28073316~28074233:+
OV	cis	rs853679	0.546	rs200954	ENSG00000220721.1	OR1F12	4.61	6.6e-06	0.00358	0.48	0.29	Depression;	chr6:27870986	chr6:28073316~28074233:+
OV	cis	rs9309473	1	rs7580825	ENSG00000163016.8	ALMS1P	4.61	6.6e-06	0.00358	0.35	0.29	Metabolite levels;	chr2:73408020	chr2:73644919~73685576:+
OV	cis	rs7302981	0.667	rs1362984	ENSG00000257298.1	RP3-405J10.3	-4.61	6.61e-06	0.00358	-0.28	-0.29	Systolic blood pressure;	chr12:50206201	chr12:50185580~50191363:-
OV	cis	rs1891275	0.515	rs2421694	ENSG00000228701.1	TNKS2-AS1	-4.61	6.61e-06	0.00358	-0.33	-0.29	Intelligence (multi-trait analysis);	chr10:91756347	chr10:91782839~91798291:-
OV	cis	rs9322193	0.607	rs6557165	ENSG00000216906.2	RP11-350J20.9	-4.61	6.61e-06	0.00358	-0.36	-0.29	Lung cancer;	chr6:149906883	chr6:149904243~149906418:+
OV	cis	rs7580658	0.545	rs13006847	ENSG00000236682.1	AC068282.3	4.61	6.61e-06	0.00358	0.35	0.29	Protein C levels;	chr2:127194687	chr2:127389130~127400580:+
OV	cis	rs796364	0.951	rs11675980	ENSG00000232732.8	AC073043.1	4.61	6.63e-06	0.00359	0.4	0.29	Schizophrenia;	chr2:200186427	chr2:199867396~199911159:-
OV	cis	rs17301013	0.507	rs2142863	ENSG00000227373.4	RP11-160H22.5	4.61	6.64e-06	0.0036	0.4	0.29	Systemic lupus erythematosus;	chr1:174301582	chr1:174115300~174160004:-
OV	cis	rs10829156	0.66	rs7918933	ENSG00000225527.1	RP11-383B4.4	-4.61	6.65e-06	0.0036	-0.37	-0.29	Sudden cardiac arrest;	chr10:18517434	chr10:18531849~18533336:-
OV	cis	rs1555322	0.505	rs591590	ENSG00000269202.1	RP4-614O4.12	4.61	6.65e-06	0.0036	0.34	0.29	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35201747~35203288:-
OV	cis	rs14027	0.921	rs16893113	ENSG00000279347.1	RP11-85I17.2	-4.61	6.65e-06	0.0036	-0.3	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119756447	chr8:119838736~119840385:-
OV	cis	rs14027	0.921	rs2326377	ENSG00000279347.1	RP11-85I17.2	-4.61	6.65e-06	0.0036	-0.3	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119756696	chr8:119838736~119840385:-
OV	cis	rs14027	0.921	rs13257002	ENSG00000279347.1	RP11-85I17.2	-4.61	6.65e-06	0.0036	-0.3	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119757489	chr8:119838736~119840385:-
OV	cis	rs14027	0.921	rs62526565	ENSG00000279347.1	RP11-85I17.2	-4.61	6.65e-06	0.0036	-0.3	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119759301	chr8:119838736~119840385:-
OV	cis	rs9309473	1	rs7572722	ENSG00000163016.8	ALMS1P	4.61	6.66e-06	0.00361	0.33	0.29	Metabolite levels;	chr2:73497548	chr2:73644919~73685576:+
OV	cis	rs2185570	0.611	rs3980257	ENSG00000234724.1	HDAC1P1	4.61	6.66e-06	0.00361	0.55	0.29	Dehydroepiandrosterone sulphate levels;	chr10:94967155	chr10:94137748~94139500:+
OV	cis	rs4918798	0.602	rs112365911	ENSG00000234724.1	HDAC1P1	4.61	6.66e-06	0.00361	0.55	0.29	Warfarin maintenance dose;	chr10:94969279	chr10:94137748~94139500:+
OV	cis	rs4918798	0.649	rs4351748	ENSG00000234724.1	HDAC1P1	4.61	6.66e-06	0.00361	0.55	0.29	Warfarin maintenance dose;	chr10:94972574	chr10:94137748~94139500:+
OV	cis	rs4918798	0.696	rs1934966	ENSG00000234724.1	HDAC1P1	4.61	6.66e-06	0.00361	0.55	0.29	Warfarin maintenance dose;	chr10:94979135	chr10:94137748~94139500:+
OV	cis	rs4918798	0.649	rs9332216	ENSG00000234724.1	HDAC1P1	4.61	6.66e-06	0.00361	0.55	0.29	Warfarin maintenance dose;	chr10:94983417	chr10:94137748~94139500:+
OV	cis	rs4918798	0.696	rs9332222	ENSG00000234724.1	HDAC1P1	4.61	6.66e-06	0.00361	0.55	0.29	Warfarin maintenance dose;	chr10:94984307	chr10:94137748~94139500:+
OV	cis	rs4918798	0.696	rs61886802	ENSG00000234724.1	HDAC1P1	4.61	6.66e-06	0.00361	0.55	0.29	Warfarin maintenance dose;	chr10:94985312	chr10:94137748~94139500:+
OV	cis	rs4918798	0.696	rs4918795	ENSG00000234724.1	HDAC1P1	4.61	6.66e-06	0.00361	0.55	0.29	Warfarin maintenance dose;	chr10:94987770	chr10:94137748~94139500:+
OV	cis	rs11096990	0.593	rs1026235	ENSG00000249207.1	RP11-360F5.1	-4.61	6.67e-06	0.00361	-0.31	-0.29	Cognitive function;	chr4:39226629	chr4:39112677~39126818:-
OV	cis	rs875971	0.545	rs1796217	ENSG00000236529.1	RP13-254B10.1	-4.61	6.67e-06	0.00361	-0.35	-0.29	Aortic root size;	chr7:66620931	chr7:65840212~65840596:+
OV	cis	rs9287719	0.81	rs7601748	ENSG00000234818.1	AC092687.5	4.61	6.68e-06	0.00361	0.33	0.29	Prostate cancer;	chr2:10645320	chr2:10589166~10604830:+
OV	cis	rs17264034	0.821	rs605126	ENSG00000250786.1	SNHG18	4.61	6.68e-06	0.00361	0.45	0.29	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9541754	chr5:9546200~9550609:+
OV	cis	rs1555322	0.53	rs932562	ENSG00000269202.1	RP4-614O4.12	-4.61	6.69e-06	0.00361	-0.34	-0.29	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35201747~35203288:-
OV	cis	rs1555322	0.53	rs2275275	ENSG00000269202.1	RP4-614O4.12	-4.61	6.69e-06	0.00361	-0.34	-0.29	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35201747~35203288:-
OV	cis	rs4664293	0.585	rs35081473	ENSG00000226266.5	AC009961.3	4.61	6.69e-06	0.00362	0.36	0.29	Monocyte percentage of white cells;	chr2:159679970	chr2:159670708~159712435:-
OV	cis	rs4664293	0.605	rs7556888	ENSG00000226266.5	AC009961.3	4.61	6.69e-06	0.00362	0.36	0.29	Monocyte percentage of white cells;	chr2:159683750	chr2:159670708~159712435:-
OV	cis	rs934734	0.789	rs906579	ENSG00000234255.7	AC012370.3	-4.61	6.7e-06	0.00362	-0.32	-0.29	Rheumatoid arthritis;	chr2:65374464	chr2:65439888~65456571:-
OV	cis	rs934734	0.789	rs906578	ENSG00000234255.7	AC012370.3	-4.61	6.7e-06	0.00362	-0.32	-0.29	Rheumatoid arthritis;	chr2:65374466	chr2:65439888~65456571:-
OV	cis	rs875971	0.545	rs6460281	ENSG00000236529.1	RP13-254B10.1	4.61	6.7e-06	0.00362	0.34	0.29	Aortic root size;	chr7:66216128	chr7:65840212~65840596:+
OV	cis	rs2919917	1	rs1054283	ENSG00000254352.1	RP11-578O24.2	4.61	6.7e-06	0.00362	0.36	0.29	Lymphocyte counts;	chr8:78698475	chr8:78723796~78724136:-
OV	cis	rs9309473	0.748	rs2421552	ENSG00000163016.8	ALMS1P	4.61	6.7e-06	0.00362	0.35	0.29	Metabolite levels;	chr2:73531676	chr2:73644919~73685576:+
OV	cis	rs9309473	0.948	rs10199224	ENSG00000163016.8	ALMS1P	4.61	6.7e-06	0.00362	0.35	0.29	Metabolite levels;	chr2:73534319	chr2:73644919~73685576:+
OV	cis	rs8054556	1	rs8054556	ENSG00000261367.1	RP11-455F5.4	-4.61	6.71e-06	0.00362	-0.33	-0.29	Autism spectrum disorder or schizophrenia;	chr16:29946895	chr16:30107675~30110541:+
OV	cis	rs7617773	0.925	rs34513961	ENSG00000228638.1	FCF1P2	-4.61	6.71e-06	0.00362	-0.4	-0.29	Coronary artery disease;	chr3:48132163	chr3:48290793~48291375:-
OV	cis	rs17301013	0.507	rs2860725	ENSG00000227373.4	RP11-160H22.5	-4.61	6.71e-06	0.00362	-0.38	-0.29	Systemic lupus erythematosus;	chr1:174815447	chr1:174115300~174160004:-
OV	cis	rs1584120	0.62	rs11046816	ENSG00000274885.1	RP11-268P4.6	-4.61	6.72e-06	0.00363	-0.35	-0.29	Pelvic organ prolapse (moderate/severe);	chr12:23128414	chr12:22638464~22638943:+
OV	cis	rs10899021	1	rs11236211	ENSG00000279353.1	RP11-864N7.4	4.61	6.72e-06	0.00363	0.6	0.29	Response to metformin (IC50);	chr11:74682166	chr11:74698231~74699658:-
OV	cis	rs875971	0.545	rs73142265	ENSG00000226824.5	RP4-756H11.3	-4.61	6.72e-06	0.00363	-0.35	-0.29	Aortic root size;	chr7:66234510	chr7:66654538~66669855:+
OV	cis	rs2015599	0.623	rs3782505	ENSG00000257176.2	RP11-996F15.2	4.61	6.73e-06	0.00363	0.36	0.29	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29280418~29317848:-
OV	cis	rs9287719	0.967	rs7570118	ENSG00000234818.1	AC092687.5	4.61	6.73e-06	0.00363	0.31	0.29	Prostate cancer;	chr2:10577881	chr2:10589166~10604830:+
OV	cis	rs9925964	0.933	rs10871454	ENSG00000278922.1	AC002310.14	-4.61	6.73e-06	0.00363	-0.33	-0.29	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31036758	chr16:30526918~30528294:+
OV	cis	rs9925964	0.933	rs12448321	ENSG00000278922.1	AC002310.14	-4.61	6.73e-06	0.00363	-0.33	-0.29	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31036959	chr16:30526918~30528294:+
OV	cis	rs9473147	0.516	rs9349413	ENSG00000270761.1	RP11-385F7.1	-4.61	6.74e-06	0.00364	-0.34	-0.29	Platelet distribution width;Mean platelet volume;	chr6:47543755	chr6:47477243~47477572:-
OV	cis	rs10510102	0.935	rs12245528	ENSG00000226864.1	ATE1-AS1	-4.61	6.76e-06	0.00364	-0.48	-0.29	Breast cancer;	chr10:121881006	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs11818001	ENSG00000226864.1	ATE1-AS1	-4.61	6.76e-06	0.00364	-0.48	-0.29	Breast cancer;	chr10:121884830	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs12243529	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121880321	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs12250677	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121880575	chr10:121928312~121951965:+
OV	cis	rs10510102	0.872	rs12243874	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121880788	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs7921873	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121881736	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs12258426	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121882189	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs12266380	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121882559	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs11200212	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121883145	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs11200213	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121883228	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs12247749	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121884196	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs12262776	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121884532	chr10:121928312~121951965:+
OV	cis	rs10510102	0.872	rs12264952	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121885673	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs12244866	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121886013	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs12266597	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121886062	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs12245018	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121886195	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs11200217	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121886372	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs11200218	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121886410	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs10887008	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121886714	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs12268872	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121887426	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs9630107	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121887713	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs10887010	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121888542	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs12251175	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121889015	chr10:121928312~121951965:+
OV	cis	rs10510102	0.872	rs11200220	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121889949	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs11200221	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121890134	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs10887011	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121890203	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs10887012	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121890454	chr10:121928312~121951965:+
OV	cis	rs10510102	0.872	rs11200222	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121891177	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs11200223	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121891416	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs10887013	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121891546	chr10:121928312~121951965:+
OV	cis	rs10510102	0.872	rs11200225	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121891948	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs11200226	ENSG00000226864.1	ATE1-AS1	4.61	6.76e-06	0.00364	0.48	0.29	Breast cancer;	chr10:121891988	chr10:121928312~121951965:+
OV	cis	rs8062405	0.723	rs113208333	ENSG00000278665.1	RP11-666O2.4	4.61	6.76e-06	0.00365	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28594839	chr16:28599241~28601881:-
OV	cis	rs8062405	0.691	rs743590	ENSG00000278665.1	RP11-666O2.4	4.61	6.76e-06	0.00365	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28596909	chr16:28599241~28601881:-
OV	cis	rs56114371	0.777	rs200481	ENSG00000220721.1	OR1F12	4.61	6.76e-06	0.00365	0.46	0.29	Breast cancer;	chr6:27806054	chr6:28073316~28074233:+
OV	cis	rs3733585	0.699	rs6449178	ENSG00000250413.1	RP11-448G15.1	-4.61	6.76e-06	0.00365	-0.32	-0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:9967060	chr4:10006482~10009725:+
OV	cis	rs10931896	0.531	rs295117	ENSG00000232732.8	AC073043.1	-4.61	6.78e-06	0.00365	-0.34	-0.29	Systolic blood pressure;	chr2:200282105	chr2:199867396~199911159:-
OV	cis	rs875971	0.545	rs17138156	ENSG00000226824.5	RP4-756H11.3	-4.61	6.78e-06	0.00365	-0.35	-0.29	Aortic root size;	chr7:66249708	chr7:66654538~66669855:+
OV	cis	rs1979679	0.842	rs1118097	ENSG00000278733.1	RP11-425D17.1	4.61	6.78e-06	0.00366	0.35	0.29	Ossification of the posterior longitudinal ligament of the spine;	chr12:28177156	chr12:28185625~28186190:-
OV	cis	rs13113518	0.729	rs13120134	ENSG00000223305.1	RN7SKP30	4.61	6.79e-06	0.00366	0.35	0.29	Height;	chr4:55415153	chr4:55540502~55540835:-
OV	cis	rs875971	0.545	rs73142245	ENSG00000226824.5	RP4-756H11.3	-4.61	6.79e-06	0.00366	-0.35	-0.29	Aortic root size;	chr7:66226662	chr7:66654538~66669855:+
OV	cis	rs853679	0.713	rs200991	ENSG00000220721.1	OR1F12	-4.61	6.79e-06	0.00366	-0.4	-0.29	Depression;	chr6:27847716	chr6:28073316~28074233:+
OV	cis	rs1538970	0.962	rs2487442	ENSG00000280836.1	AL355480.1	4.61	6.81e-06	0.00367	0.41	0.29	Platelet count;	chr1:45391504	chr1:45581219~45581321:-
OV	cis	rs4908768	0.859	rs4908770	ENSG00000228423.2	RP4-633I8.4	4.61	6.81e-06	0.00367	0.37	0.29	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8651313	chr1:8805860~8807051:-
OV	cis	rs10246939	0.505	rs12703409	ENSG00000228775.6	WEE2-AS1	4.61	6.82e-06	0.00367	0.33	0.29	Bitter taste perception;	chr7:141812058	chr7:141704338~141738346:-
OV	cis	rs7302981	0.967	rs6580729	ENSG00000257298.1	RP3-405J10.3	4.61	6.83e-06	0.00368	0.27	0.29	Systolic blood pressure;	chr12:50153255	chr12:50185580~50191363:-
OV	cis	rs7302981	0.967	rs11831413	ENSG00000257298.1	RP3-405J10.3	4.61	6.83e-06	0.00368	0.27	0.29	Systolic blood pressure;	chr12:50156600	chr12:50185580~50191363:-
OV	cis	rs7302981	0.934	rs7294548	ENSG00000257298.1	RP3-405J10.3	-4.61	6.83e-06	0.00368	-0.27	-0.29	Systolic blood pressure;	chr12:50149418	chr12:50185580~50191363:-
OV	cis	rs6860806	0.507	rs169256	ENSG00000233006.5	AC034220.3	4.61	6.83e-06	0.00368	0.32	0.29	Breast cancer;	chr5:132352840	chr5:132311285~132369916:-
OV	cis	rs2015599	0.549	rs7134796	ENSG00000257176.2	RP11-996F15.2	4.61	6.83e-06	0.00368	0.36	0.29	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29280418~29317848:-
OV	cis	rs875971	0.862	rs778720	ENSG00000236529.1	RP13-254B10.1	-4.61	6.83e-06	0.00368	-0.3	-0.29	Aortic root size;	chr7:66381288	chr7:65840212~65840596:+
OV	cis	rs10924970	0.649	rs10925099	ENSG00000236863.2	RPL23AP23	4.61	6.84e-06	0.00368	0.3	0.29	Asthma;	chr1:235203587	chr1:235295865~235296335:+
OV	cis	rs17301013	0.507	rs41472847	ENSG00000227373.4	RP11-160H22.5	-4.61	6.84e-06	0.00368	-0.39	-0.29	Systemic lupus erythematosus;	chr1:174475342	chr1:174115300~174160004:-
OV	cis	rs733592	0.56	rs2158515	ENSG00000258273.1	RP11-370I10.4	4.61	6.84e-06	0.00368	0.35	0.29	Plateletcrit;	chr12:48113885	chr12:48333755~48333901:-
OV	cis	rs7043114	0.525	rs2025388	ENSG00000281156.1	MIR3651	-4.61	6.85e-06	0.00369	-0.32	-0.29	Height;	chr9:92366458	chr9:92292458~92292547:-
OV	cis	rs2919917	1	rs1466526	ENSG00000254352.1	RP11-578O24.2	-4.61	6.87e-06	0.0037	-0.38	-0.29	Lymphocyte counts;	chr8:78643239	chr8:78723796~78724136:-
OV	cis	rs2274471	0.645	rs3824432	ENSG00000234534.1	CSNK1G2P1	4.61	6.87e-06	0.0037	0.38	0.29	Crohn's disease;	chr9:5091675	chr9:5040945~5041940:+
OV	cis	rs796364	0.95	rs56155997	ENSG00000232732.8	AC073043.1	4.6	6.87e-06	0.0037	0.45	0.29	Schizophrenia;	chr2:199903768	chr2:199867396~199911159:-
OV	cis	rs796364	1	rs35594306	ENSG00000232732.8	AC073043.1	4.6	6.87e-06	0.0037	0.45	0.29	Schizophrenia;	chr2:199910402	chr2:199867396~199911159:-
OV	cis	rs6844153	0.887	rs60890366	ENSG00000240005.4	RP11-293A21.1	-4.6	6.88e-06	0.0037	-0.4	-0.29	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26938615	chr4:26859806~26860599:-
OV	cis	rs496547	0.588	rs473298	ENSG00000278376.1	RP11-158I9.8	-4.6	6.88e-06	0.0037	-0.29	-0.29	Hip minimal joint space width;	chr11:118808678	chr11:118791254~118793137:+
OV	cis	rs17711722	0.522	rs4642526	ENSG00000226824.5	RP4-756H11.3	-4.6	6.88e-06	0.0037	-0.33	-0.29	Calcium levels;	chr7:65751755	chr7:66654538~66669855:+
OV	cis	rs2179367	0.6	rs9498354	ENSG00000231760.4	RP11-350J20.5	-4.6	6.88e-06	0.0037	-0.37	-0.29	Dupuytren's disease;	chr6:149441715	chr6:149796151~149826294:-
OV	cis	rs611744	0.506	rs4735054	ENSG00000253754.1	RP11-35G22.1	4.6	6.89e-06	0.00371	0.32	0.29	Dupuytren's disease;	chr8:108249551	chr8:108226200~108227544:+
OV	cis	rs7617773	0.817	rs13059037	ENSG00000228638.1	FCF1P2	-4.6	6.89e-06	0.00371	-0.38	-0.29	Coronary artery disease;	chr3:48246389	chr3:48290793~48291375:-
OV	cis	rs1134634	0.52	rs4280723	ENSG00000273133.1	RP11-799M12.2	4.6	6.9e-06	0.00371	0.4	0.29	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15574095	chr4:15563698~15564253:-
OV	cis	rs9298506	1	rs10102164	ENSG00000254142.2	RP11-53M11.3	4.6	6.9e-06	0.00371	0.38	0.29	Intracranial aneurysm;	chr8:54509054	chr8:54554361~54561927:+
OV	cis	rs9298506	1	rs56204645	ENSG00000254142.2	RP11-53M11.3	4.6	6.9e-06	0.00371	0.38	0.29	Intracranial aneurysm;	chr8:54509209	chr8:54554361~54561927:+
OV	cis	rs6772849	1	rs6772849	ENSG00000242551.2	POU5F1P6	-4.6	6.9e-06	0.00371	-0.35	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128587575	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs58986862	ENSG00000277250.1	Metazoa_SRP	4.6	6.92e-06	0.00372	0.47	0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128342846	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs56850662	ENSG00000277250.1	Metazoa_SRP	4.6	6.92e-06	0.00372	0.47	0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128343079	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs60399786	ENSG00000277250.1	Metazoa_SRP	4.6	6.92e-06	0.00372	0.47	0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128343227	chr3:128673681~128674021:-
OV	cis	rs67180937	0.542	rs61824282	ENSG00000272750.1	RP11-378J18.8	-4.6	6.94e-06	0.00373	-0.28	-0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222647869	chr1:222658867~222661512:-
OV	cis	rs473651	0.935	rs541013	ENSG00000229915.1	AC016999.2	-4.6	6.94e-06	0.00373	-0.37	-0.29	Multiple system atrophy;	chr2:238427851	chr2:238427077~238427729:-
OV	cis	rs473651	0.904	rs508274	ENSG00000229915.1	AC016999.2	-4.6	6.94e-06	0.00373	-0.37	-0.29	Multiple system atrophy;	chr2:238429082	chr2:238427077~238427729:-
OV	cis	rs10935480	0.904	rs13065271	ENSG00000239445.4	ST3GAL6-AS1	-4.6	6.95e-06	0.00373	-0.36	-0.29	Blood protein levels;	chr3:98715649	chr3:98714330~98732651:-
OV	cis	rs8100891	0.537	rs1001446	ENSG00000267213.4	AC007773.2	-4.6	6.95e-06	0.00373	-0.43	-0.29	Neuroticism;	chr19:32410051	chr19:32390050~32405560:-
OV	cis	rs2115630	1	rs6496441	ENSG00000225151.9	GOLGA2P7	4.6	6.96e-06	0.00374	0.31	0.29	P wave terminal force;	chr15:84820117	chr15:84199311~84230136:-
OV	cis	rs858239	0.508	rs7805071	ENSG00000230042.1	AK3P3	-4.6	7e-06	0.00376	-0.31	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23150593	chr7:23129178~23129841:+
OV	cis	rs858239	0.508	rs7805085	ENSG00000230042.1	AK3P3	-4.6	7e-06	0.00376	-0.31	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23150624	chr7:23129178~23129841:+
OV	cis	rs10510102	0.935	rs10887014	ENSG00000226864.1	ATE1-AS1	4.6	7e-06	0.00376	0.48	0.29	Breast cancer;	chr10:121892322	chr10:121928312~121951965:+
OV	cis	rs10510102	0.872	rs11818735	ENSG00000226864.1	ATE1-AS1	4.6	7e-06	0.00376	0.48	0.29	Breast cancer;	chr10:121892472	chr10:121928312~121951965:+
OV	cis	rs10510102	0.81	rs12259902	ENSG00000226864.1	ATE1-AS1	4.6	7e-06	0.00376	0.48	0.29	Breast cancer;	chr10:121893017	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs11200228	ENSG00000226864.1	ATE1-AS1	4.6	7e-06	0.00376	0.48	0.29	Breast cancer;	chr10:121893358	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs11200229	ENSG00000226864.1	ATE1-AS1	4.6	7e-06	0.00376	0.48	0.29	Breast cancer;	chr10:121893519	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs10887016	ENSG00000226864.1	ATE1-AS1	4.6	7e-06	0.00376	0.48	0.29	Breast cancer;	chr10:121893830	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs10887018	ENSG00000226864.1	ATE1-AS1	4.6	7e-06	0.00376	0.48	0.29	Breast cancer;	chr10:121894457	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs11200230	ENSG00000226864.1	ATE1-AS1	4.6	7e-06	0.00376	0.48	0.29	Breast cancer;	chr10:121895117	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs11200234	ENSG00000226864.1	ATE1-AS1	4.6	7e-06	0.00376	0.48	0.29	Breast cancer;	chr10:121895851	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs12244951	ENSG00000226864.1	ATE1-AS1	4.6	7e-06	0.00376	0.48	0.29	Breast cancer;	chr10:121896879	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs74362676	ENSG00000226864.1	ATE1-AS1	4.6	7e-06	0.00376	0.48	0.29	Breast cancer;	chr10:121898216	chr10:121928312~121951965:+
OV	cis	rs10510102	0.872	rs3750837	ENSG00000226864.1	ATE1-AS1	4.6	7e-06	0.00376	0.48	0.29	Breast cancer;	chr10:121899080	chr10:121928312~121951965:+
OV	cis	rs10510102	0.872	rs3750836	ENSG00000226864.1	ATE1-AS1	4.6	7e-06	0.00376	0.48	0.29	Breast cancer;	chr10:121899087	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs11200237	ENSG00000226864.1	ATE1-AS1	4.6	7e-06	0.00376	0.48	0.29	Breast cancer;	chr10:121900715	chr10:121928312~121951965:+
OV	cis	rs473651	1	rs473651	ENSG00000229915.1	AC016999.2	-4.6	7e-06	0.00376	-0.36	-0.29	Multiple system atrophy;	chr2:238426760	chr2:238427077~238427729:-
OV	cis	rs473651	0.935	rs474478	ENSG00000229915.1	AC016999.2	-4.6	7e-06	0.00376	-0.36	-0.29	Multiple system atrophy;	chr2:238426832	chr2:238427077~238427729:-
OV	cis	rs7587476	0.906	rs62201985	ENSG00000229267.2	AC072062.1	-4.6	7.01e-06	0.00376	-0.41	-0.29	Neuroblastoma;	chr2:214793914	chr2:214810229~214963274:+
OV	cis	rs7043114	0.563	rs10820986	ENSG00000281156.1	MIR3651	-4.6	7.04e-06	0.00377	-0.31	-0.29	Height;	chr9:92550679	chr9:92292458~92292547:-
OV	cis	rs7927592	0.956	rs7116899	ENSG00000212093.1	AP000807.1	4.6	7.04e-06	0.00377	0.37	0.29	Total body bone mineral density;	chr11:68618067	chr11:68506083~68506166:-
OV	cis	rs7927592	0.956	rs7102273	ENSG00000212093.1	AP000807.1	4.6	7.04e-06	0.00377	0.37	0.29	Total body bone mineral density;	chr11:68618111	chr11:68506083~68506166:-
OV	cis	rs9309473	0.898	rs10185080	ENSG00000163016.8	ALMS1P	4.6	7.05e-06	0.00378	0.33	0.29	Metabolite levels;	chr2:73570380	chr2:73644919~73685576:+
OV	cis	rs8099594	0.51	rs7233575	ENSG00000266696.1	RP11-30L3.2	4.6	7.05e-06	0.00378	0.37	0.29	Height;	chr18:49168712	chr18:49205912~49208781:+
OV	cis	rs2919917	0.955	rs1441850	ENSG00000254352.1	RP11-578O24.2	-4.6	7.05e-06	0.00378	-0.37	-0.29	Lymphocyte counts;	chr8:78745431	chr8:78723796~78724136:-
OV	cis	rs4356975	0.541	rs6600892	ENSG00000251284.2	RP13-644M16.1	-4.6	7.05e-06	0.00378	-0.44	-0.29	Obesity-related traits;	chr4:69107521	chr4:69125274~69126451:+
OV	cis	rs7267979	0.604	rs242130	ENSG00000274973.1	RP13-401N8.7	4.6	7.05e-06	0.00378	0.33	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25613384	chr20:25845497~25845862:+
OV	cis	rs2919917	1	rs7010897	ENSG00000254352.1	RP11-578O24.2	4.6	7.06e-06	0.00378	0.36	0.29	Lymphocyte counts;	chr8:78708119	chr8:78723796~78724136:-
OV	cis	rs875971	0.545	rs6460281	ENSG00000237310.1	GS1-124K5.4	4.6	7.06e-06	0.00378	0.33	0.29	Aortic root size;	chr7:66216128	chr7:66493706~66495474:+
OV	cis	rs3733585	0.673	rs6449156	ENSG00000250413.1	RP11-448G15.1	4.6	7.08e-06	0.00379	0.33	0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:9955088	chr4:10006482~10009725:+
OV	cis	rs8062405	0.723	rs762633	ENSG00000278665.1	RP11-666O2.4	4.6	7.08e-06	0.00379	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597020	chr16:28599241~28601881:-
OV	cis	rs8062405	0.723	rs62031562	ENSG00000278665.1	RP11-666O2.4	4.6	7.08e-06	0.00379	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28598008	chr16:28599241~28601881:-
OV	cis	rs301901	0.664	rs4504403	ENSG00000250155.1	CTD-2353F22.1	4.6	7.08e-06	0.00379	0.35	0.29	Height;	chr5:37481330	chr5:36666214~36725195:-
OV	cis	rs9532669	0.926	rs7799	ENSG00000229456.1	RLIMP1	4.6	7.09e-06	0.00379	0.31	0.29	Cervical cancer;	chr13:40958916	chr13:40618738~40621348:+
OV	cis	rs295137	0.836	rs1217456	ENSG00000232732.8	AC073043.1	-4.6	7.09e-06	0.0038	-0.34	-0.29	Asthma (bronchodilator response);	chr2:200227556	chr2:199867396~199911159:-
OV	cis	rs12220898	0.688	rs7915976	ENSG00000235939.1	RP11-123B3.2	4.6	7.1e-06	0.0038	0.51	0.29	Inflammatory biomarkers;	chr10:49351157	chr10:49419277~49472903:+
OV	cis	rs992157	0.717	rs11692780	ENSG00000261338.2	RP11-378A13.1	-4.6	7.1e-06	0.0038	-0.35	-0.29	Colorectal cancer;	chr2:218284440	chr2:218255319~218257366:+
OV	cis	rs4713118	0.911	rs9295746	ENSG00000280107.1	AL022393.9	-4.6	7.1e-06	0.0038	-0.37	-0.29	Parkinson's disease;	chr6:27762285	chr6:28170845~28172521:+
OV	cis	rs1150668	0.799	rs2142730	ENSG00000204709.4	LINC01556	4.6	7.11e-06	0.00381	0.34	0.29	Pubertal anthropometrics;	chr6:28298372	chr6:28943877~28944537:+
OV	cis	rs10740039	0.766	rs2119917	ENSG00000254271.1	RP11-131N11.4	4.6	7.11e-06	0.00381	0.36	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60677626	chr10:60734342~60741828:+
OV	cis	rs150992	0.587	rs4703052	ENSG00000248489.1	CTD-2007H13.3	-4.6	7.12e-06	0.00381	-0.34	-0.29	Body mass index;	chr5:99008818	chr5:98929171~98995013:+
OV	cis	rs8054556	0.669	rs9972866	ENSG00000261367.1	RP11-455F5.4	-4.6	7.12e-06	0.00381	-0.31	-0.29	Autism spectrum disorder or schizophrenia;	chr16:30007661	chr16:30107675~30110541:+
OV	cis	rs3808502	0.527	rs2736374	ENSG00000255495.1	AC145124.2	-4.6	7.13e-06	0.00381	-0.32	-0.29	Neuroticism;	chr8:11256319	chr8:12194467~12196280:+
OV	cis	rs6538678	0.895	rs1436124	ENSG00000199506.1	RNU6-247P	-4.6	7.13e-06	0.00381	-0.39	-0.29	Lupus nephritis in systemic lupus erythematosus;	chr12:95889654	chr12:95792529~95792635:-
OV	cis	rs875971	0.545	rs10261710	ENSG00000226824.5	RP4-756H11.3	-4.6	7.13e-06	0.00381	-0.36	-0.29	Aortic root size;	chr7:66249202	chr7:66654538~66669855:+
OV	cis	rs7580658	0.963	rs2090574	ENSG00000236682.1	AC068282.3	-4.6	7.14e-06	0.00382	-0.39	-0.29	Protein C levels;	chr2:127373815	chr2:127389130~127400580:+
OV	cis	rs13068223	0.562	rs346003	ENSG00000243926.1	TIPARP-AS1	-4.6	7.16e-06	0.00383	-0.28	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr3:156705283	chr3:156671862~156674378:-
OV	cis	rs853679	0.599	rs149990	ENSG00000280107.1	AL022393.9	-4.6	7.16e-06	0.00383	-0.5	-0.29	Depression;	chr6:28030480	chr6:28170845~28172521:+
OV	cis	rs853679	0.599	rs149943	ENSG00000280107.1	AL022393.9	-4.6	7.16e-06	0.00383	-0.5	-0.29	Depression;	chr6:28034610	chr6:28170845~28172521:+
OV	cis	rs858239	0.539	rs6955969	ENSG00000230042.1	AK3P3	-4.6	7.16e-06	0.00383	-0.3	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23147080	chr7:23129178~23129841:+
OV	cis	rs896854	0.624	rs9297949	ENSG00000253528.2	RP11-347C18.4	4.6	7.17e-06	0.00383	0.28	0.29	Type 2 diabetes;	chr8:94957217	chr8:94974573~94974853:-
OV	cis	rs1979679	0.918	rs2348234	ENSG00000278733.1	RP11-425D17.1	4.6	7.18e-06	0.00384	0.35	0.29	Ossification of the posterior longitudinal ligament of the spine;	chr12:28354126	chr12:28185625~28186190:-
OV	cis	rs1979679	0.918	rs1586868	ENSG00000278733.1	RP11-425D17.1	4.6	7.18e-06	0.00384	0.35	0.29	Ossification of the posterior longitudinal ligament of the spine;	chr12:28368176	chr12:28185625~28186190:-
OV	cis	rs1979679	0.918	rs1586867	ENSG00000278733.1	RP11-425D17.1	4.6	7.18e-06	0.00384	0.35	0.29	Ossification of the posterior longitudinal ligament of the spine;	chr12:28368345	chr12:28185625~28186190:-
OV	cis	rs1979679	0.918	rs78500430	ENSG00000278733.1	RP11-425D17.1	4.6	7.18e-06	0.00384	0.35	0.29	Ossification of the posterior longitudinal ligament of the spine;	chr12:28369828	chr12:28185625~28186190:-
OV	cis	rs1979679	0.918	rs7977429	ENSG00000278733.1	RP11-425D17.1	4.6	7.18e-06	0.00384	0.35	0.29	Ossification of the posterior longitudinal ligament of the spine;	chr12:28370376	chr12:28185625~28186190:-
OV	cis	rs1979679	0.918	rs11049562	ENSG00000278733.1	RP11-425D17.1	4.6	7.18e-06	0.00384	0.35	0.29	Ossification of the posterior longitudinal ligament of the spine;	chr12:28375576	chr12:28185625~28186190:-
OV	cis	rs10924970	0.649	rs3765795	ENSG00000236863.2	RPL23AP23	-4.59	7.19e-06	0.00384	-0.31	-0.29	Asthma;	chr1:235212504	chr1:235295865~235296335:+
OV	cis	rs896854	0.902	rs726816	ENSG00000253528.2	RP11-347C18.4	4.59	7.19e-06	0.00384	0.28	0.29	Type 2 diabetes;	chr8:94956185	chr8:94974573~94974853:-
OV	cis	rs1555322	0.53	rs6060347	ENSG00000126005.14	MMP24-AS1	-4.59	7.2e-06	0.00385	-0.4	-0.29	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35216462~35278131:-
OV	cis	rs4908768	0.911	rs79769442	ENSG00000228423.2	RP4-633I8.4	4.59	7.2e-06	0.00385	0.37	0.29	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8598418	chr1:8805860~8807051:-
OV	cis	rs2243480	1	rs160633	ENSG00000226824.5	RP4-756H11.3	-4.59	7.21e-06	0.00385	-0.47	-0.29	Diabetic kidney disease;	chr7:66063241	chr7:66654538~66669855:+
OV	cis	rs1979679	0.842	rs11049373	ENSG00000278733.1	RP11-425D17.1	4.59	7.24e-06	0.00387	0.35	0.29	Ossification of the posterior longitudinal ligament of the spine;	chr12:28148881	chr12:28185625~28186190:-
OV	cis	rs181553	0.532	rs2044550	ENSG00000266696.1	RP11-30L3.2	-4.59	7.25e-06	0.00387	-0.35	-0.29	Hip circumference adjusted for BMI;	chr18:49055730	chr18:49205912~49208781:+
OV	cis	rs1979679	0.918	rs2169755	ENSG00000278733.1	RP11-425D17.1	4.59	7.25e-06	0.00387	0.35	0.29	Ossification of the posterior longitudinal ligament of the spine;	chr12:28338224	chr12:28185625~28186190:-
OV	cis	rs62458065	0.85	rs7785999	ENSG00000226468.2	AC018641.7	4.59	7.26e-06	0.00387	0.4	0.29	Metabolite levels (HVA/MHPG ratio);	chr7:32421650	chr7:32456963~32457758:-
OV	cis	rs13178541	0.81	rs2304075	ENSG00000250378.1	RP11-119J18.1	-4.59	7.27e-06	0.00388	-0.44	-0.29	IgG glycosylation;	chr5:135842435	chr5:135812667~135826582:+
OV	cis	rs7043114	0.525	rs7023004	ENSG00000281156.1	MIR3651	-4.59	7.28e-06	0.00389	-0.32	-0.29	Height;	chr9:92336430	chr9:92292458~92292547:-
OV	cis	rs295490	0.748	rs75634125	ENSG00000272656.1	RP11-219D15.3	4.59	7.29e-06	0.00389	0.58	0.29	PR interval in Tripanosoma cruzi seropositivity;	chr3:139371639	chr3:139349024~139349371:-
OV	cis	rs9309473	1	rs11674602	ENSG00000163016.8	ALMS1P	4.59	7.3e-06	0.00389	0.33	0.29	Metabolite levels;	chr2:73496058	chr2:73644919~73685576:+
OV	cis	rs116095464	0.558	rs10056628	ENSG00000250848.1	CTD-2083E4.5	-4.59	7.3e-06	0.00389	-0.38	-0.29	Breast cancer;	chr5:279397	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs56298907	ENSG00000250848.1	CTD-2083E4.5	-4.59	7.3e-06	0.00389	-0.38	-0.29	Breast cancer;	chr5:283165	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs7356535	ENSG00000250848.1	CTD-2083E4.5	-4.59	7.3e-06	0.00389	-0.38	-0.29	Breast cancer;	chr5:284002	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs55833259	ENSG00000250848.1	CTD-2083E4.5	-4.59	7.3e-06	0.00389	-0.38	-0.29	Breast cancer;	chr5:286613	chr5:288833~290321:-
OV	cis	rs73201462	1	rs2811414	ENSG00000277250.1	Metazoa_SRP	-4.59	7.31e-06	0.0039	-0.43	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128272334	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2811530	ENSG00000277250.1	Metazoa_SRP	-4.59	7.31e-06	0.0039	-0.43	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128274323	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2811528	ENSG00000277250.1	Metazoa_SRP	-4.59	7.31e-06	0.0039	-0.43	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128275593	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2811381	ENSG00000277250.1	Metazoa_SRP	-4.59	7.31e-06	0.0039	-0.43	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128279069	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs6765233	ENSG00000277250.1	Metazoa_SRP	-4.59	7.31e-06	0.0039	-0.43	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128284007	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2811536	ENSG00000277250.1	Metazoa_SRP	-4.59	7.31e-06	0.0039	-0.43	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128270076	chr3:128673681~128674021:-
OV	cis	rs7116641	0.961	rs34390003	ENSG00000246250.2	RP11-613D13.5	4.59	7.31e-06	0.0039	0.33	0.29	Coronary artery disease;	chr11:43696893	chr11:43829709~43880726:-
OV	cis	rs1979679	0.842	rs4931727	ENSG00000278733.1	RP11-425D17.1	4.59	7.32e-06	0.00391	0.35	0.29	Ossification of the posterior longitudinal ligament of the spine;	chr12:28146186	chr12:28185625~28186190:-
OV	cis	rs10986311	0.747	rs10760344	ENSG00000227200.1	RP11-121A14.3	-4.59	7.33e-06	0.00391	-0.27	-0.29	Vitiligo;	chr9:124264003	chr9:124262876~124265809:+
OV	cis	rs10759883	0.563	rs10819668	ENSG00000175611.10	LINC00476	4.59	7.33e-06	0.00391	0.35	0.29	Nicotine dependence;	chr9:95959848	chr9:95759231~95875977:-
OV	cis	rs10759883	0.539	rs10988817	ENSG00000175611.10	LINC00476	4.59	7.33e-06	0.00391	0.35	0.29	Nicotine dependence;	chr9:95960364	chr9:95759231~95875977:-
OV	cis	rs473651	0.716	rs548179	ENSG00000229915.1	AC016999.2	-4.59	7.34e-06	0.00391	-0.38	-0.29	Multiple system atrophy;	chr2:238411864	chr2:238427077~238427729:-
OV	cis	rs67311347	1	rs6795475	ENSG00000223797.4	ENTPD3-AS1	4.59	7.34e-06	0.00391	0.31	0.29	Renal cell carcinoma;	chr3:40447790	chr3:40313802~40453329:-
OV	cis	rs172166	0.611	rs203882	ENSG00000280107.1	AL022393.9	-4.59	7.34e-06	0.00391	-0.35	-0.29	Cardiac Troponin-T levels;	chr6:28110724	chr6:28170845~28172521:+
OV	cis	rs172166	0.694	rs1770131	ENSG00000280107.1	AL022393.9	-4.59	7.34e-06	0.00391	-0.35	-0.29	Cardiac Troponin-T levels;	chr6:28118635	chr6:28170845~28172521:+
OV	cis	rs3733585	0.673	rs4311316	ENSG00000250413.1	RP11-448G15.1	-4.59	7.35e-06	0.00392	-0.32	-0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:9954347	chr4:10006482~10009725:+
OV	cis	rs875971	0.545	rs73378304	ENSG00000236529.1	RP13-254B10.1	4.59	7.35e-06	0.00392	0.34	0.29	Aortic root size;	chr7:66175760	chr7:65840212~65840596:+
OV	cis	rs4713118	0.512	rs2622319	ENSG00000280107.1	AL022393.9	-4.59	7.36e-06	0.00392	-0.35	-0.29	Parkinson's disease;	chr6:28152623	chr6:28170845~28172521:+
OV	cis	rs73201462	1	rs56287882	ENSG00000277250.1	Metazoa_SRP	4.59	7.38e-06	0.00393	0.46	0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128311500	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs73197383	ENSG00000277250.1	Metazoa_SRP	4.59	7.38e-06	0.00393	0.46	0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128311631	chr3:128673681~128674021:-
OV	cis	rs2688608	0.592	rs7908825	ENSG00000271816.1	BMS1P4	-4.59	7.38e-06	0.00393	-0.27	-0.29	Inflammatory bowel disease;	chr10:73794783	chr10:73699151~73730487:-
OV	cis	rs875971	0.545	rs2279757	ENSG00000236529.1	RP13-254B10.1	4.59	7.39e-06	0.00393	0.35	0.29	Aortic root size;	chr7:66363676	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs11766183	ENSG00000236529.1	RP13-254B10.1	4.59	7.39e-06	0.00393	0.35	0.29	Aortic root size;	chr7:66374173	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs1065265	ENSG00000236529.1	RP13-254B10.1	4.59	7.39e-06	0.00393	0.35	0.29	Aortic root size;	chr7:66376216	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs7811204	ENSG00000236529.1	RP13-254B10.1	4.59	7.39e-06	0.00393	0.35	0.29	Aortic root size;	chr7:66387213	chr7:65840212~65840596:+
OV	cis	rs10829156	1	rs10829156	ENSG00000225527.1	RP11-383B4.4	-4.59	7.39e-06	0.00394	-0.38	-0.29	Sudden cardiac arrest;	chr10:18661626	chr10:18531849~18533336:-
OV	cis	rs10027350	0.857	rs3796793	ENSG00000281501.1	SEPSECS-AS1	4.59	7.39e-06	0.00394	0.34	0.29	Childhood ear infection;	chr4:25142945	chr4:25160641~25201440:+
OV	cis	rs9876781	0.507	rs1824362	ENSG00000229759.1	MRPS18AP1	-4.59	7.4e-06	0.00394	-0.29	-0.29	Longevity;	chr3:48360459	chr3:48256350~48256938:-
OV	cis	rs1584120	0.57	rs7974302	ENSG00000274885.1	RP11-268P4.6	-4.59	7.4e-06	0.00394	-0.34	-0.29	Pelvic organ prolapse (moderate/severe);	chr12:23106584	chr12:22638464~22638943:+
OV	cis	rs875971	0.545	rs313828	ENSG00000236529.1	RP13-254B10.1	-4.59	7.4e-06	0.00394	-0.35	-0.29	Aortic root size;	chr7:66087627	chr7:65840212~65840596:+
OV	cis	rs875971	0.52	rs160645	ENSG00000236529.1	RP13-254B10.1	-4.59	7.4e-06	0.00394	-0.35	-0.29	Aortic root size;	chr7:66091320	chr7:65840212~65840596:+
OV	cis	rs875971	0.789	rs28815324	ENSG00000236529.1	RP13-254B10.1	-4.59	7.4e-06	0.00394	-0.35	-0.29	Aortic root size;	chr7:66100789	chr7:65840212~65840596:+
OV	cis	rs17264034	0.821	rs460234	ENSG00000250786.1	SNHG18	4.59	7.41e-06	0.00394	0.45	0.29	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9543022	chr5:9546200~9550609:+
OV	cis	rs796364	1	rs281785	ENSG00000232732.8	AC073043.1	-4.59	7.42e-06	0.00395	-0.43	-0.29	Schizophrenia;	chr2:199884843	chr2:199867396~199911159:-
OV	cis	rs7927592	0.956	rs7124078	ENSG00000212093.1	AP000807.1	4.59	7.43e-06	0.00395	0.37	0.29	Total body bone mineral density;	chr11:68531165	chr11:68506083~68506166:-
OV	cis	rs1979679	0.842	rs7316299	ENSG00000278733.1	RP11-425D17.1	4.59	7.44e-06	0.00396	0.35	0.29	Ossification of the posterior longitudinal ligament of the spine;	chr12:28179757	chr12:28185625~28186190:-
OV	cis	rs11159086	0.793	rs28612392	ENSG00000270000.1	RP3-449M8.9	4.59	7.46e-06	0.00396	0.43	0.29	Advanced glycation end-product levels;	chr14:74467894	chr14:74471930~74472360:-
OV	cis	rs3733585	0.673	rs9994937	ENSG00000250413.1	RP11-448G15.1	4.59	7.46e-06	0.00396	0.33	0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:9963175	chr4:10006482~10009725:+
OV	cis	rs2348418	0.639	rs10459087	ENSG00000247934.4	RP11-967K21.1	4.59	7.46e-06	0.00396	0.29	0.29	Lung function (FEV1);Lung function (FVC);	chr12:28115904	chr12:28163298~28190738:-
OV	cis	rs116095464	0.51	rs10057501	ENSG00000250848.1	CTD-2083E4.5	-4.59	7.48e-06	0.00397	-0.36	-0.29	Breast cancer;	chr5:239430	chr5:288833~290321:-
OV	cis	rs7617773	0.784	rs11715799	ENSG00000228638.1	FCF1P2	-4.59	7.48e-06	0.00397	-0.38	-0.29	Coronary artery disease;	chr3:48213730	chr3:48290793~48291375:-
OV	cis	rs7617773	0.817	rs34728236	ENSG00000228638.1	FCF1P2	-4.59	7.48e-06	0.00397	-0.38	-0.29	Coronary artery disease;	chr3:48217618	chr3:48290793~48291375:-
OV	cis	rs1823913	0.599	rs13020656	ENSG00000227542.1	AC092614.2	4.59	7.48e-06	0.00398	0.33	0.29	Obesity-related traits;	chr2:191314197	chr2:191229165~191246172:-
OV	cis	rs17301013	0.606	rs2860907	ENSG00000227373.4	RP11-160H22.5	4.59	7.5e-06	0.00398	0.37	0.29	Systemic lupus erythematosus;	chr1:174203246	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs4607949	ENSG00000227373.4	RP11-160H22.5	4.59	7.5e-06	0.00398	0.37	0.29	Systemic lupus erythematosus;	chr1:174212218	chr1:174115300~174160004:-
OV	cis	rs73201462	1	rs2811523	ENSG00000277250.1	Metazoa_SRP	4.59	7.5e-06	0.00398	0.45	0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128292554	chr3:128673681~128674021:-
OV	cis	rs957448	0.561	rs58663902	ENSG00000253704.1	RP11-267M23.4	4.59	7.5e-06	0.00398	0.37	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94610177	chr8:94553722~94569745:+
OV	cis	rs7667	0.812	rs12042240	ENSG00000240490.3	RN7SL277P	-4.59	7.5e-06	0.00398	-0.35	-0.29	Crohn's disease and psoriasis;	chr1:19442077	chr1:19424384~19424671:+
OV	cis	rs3758911	0.828	rs1490946	ENSG00000261098.1	RP11-819C21.1	-4.58	7.51e-06	0.00399	-0.28	-0.29	Coronary artery disease;	chr11:107325374	chr11:107312132~107316271:-
OV	cis	rs796364	0.901	rs35572201	ENSG00000232732.8	AC073043.1	4.58	7.52e-06	0.00399	0.41	0.29	Schizophrenia;	chr2:200170370	chr2:199867396~199911159:-
OV	cis	rs2898681	0.618	rs7677726	ENSG00000248375.1	RP11-177B4.1	4.58	7.52e-06	0.00399	0.51	0.29	Optic nerve measurement (cup area);	chr4:52873095	chr4:52720081~52720831:-
OV	cis	rs796364	0.616	rs2140486	ENSG00000232732.8	AC073043.1	-4.58	7.52e-06	0.00399	-0.43	-0.29	Schizophrenia;	chr2:199825379	chr2:199867396~199911159:-
OV	cis	rs796364	0.616	rs769955	ENSG00000232732.8	AC073043.1	-4.58	7.52e-06	0.00399	-0.43	-0.29	Schizophrenia;	chr2:199827872	chr2:199867396~199911159:-
OV	cis	rs9925964	0.9	rs56813533	ENSG00000278922.1	AC002310.14	-4.58	7.53e-06	0.004	-0.33	-0.29	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31059160	chr16:30526918~30528294:+
OV	cis	rs9880211	1	rs17364492	ENSG00000239213.4	NCK1-AS1	-4.58	7.53e-06	0.004	-0.34	-0.29	Height;Body mass index;	chr3:136485595	chr3:136841726~136862054:-
OV	cis	rs4713118	0.955	rs34752872	ENSG00000219392.1	RP1-265C24.5	-4.58	7.54e-06	0.004	-0.35	-0.29	Parkinson's disease;	chr6:27715465	chr6:28115628~28116551:+
OV	cis	rs4713118	0.955	rs9380010	ENSG00000219392.1	RP1-265C24.5	-4.58	7.54e-06	0.004	-0.35	-0.29	Parkinson's disease;	chr6:27715793	chr6:28115628~28116551:+
OV	cis	rs4713118	0.955	rs9368528	ENSG00000219392.1	RP1-265C24.5	-4.58	7.54e-06	0.004	-0.35	-0.29	Parkinson's disease;	chr6:27716019	chr6:28115628~28116551:+
OV	cis	rs4713118	0.955	rs9380011	ENSG00000219392.1	RP1-265C24.5	-4.58	7.54e-06	0.004	-0.35	-0.29	Parkinson's disease;	chr6:27716145	chr6:28115628~28116551:+
OV	cis	rs4713118	0.955	rs9368529	ENSG00000219392.1	RP1-265C24.5	-4.58	7.54e-06	0.004	-0.35	-0.29	Parkinson's disease;	chr6:27716852	chr6:28115628~28116551:+
OV	cis	rs4713118	0.955	rs9380012	ENSG00000219392.1	RP1-265C24.5	-4.58	7.54e-06	0.004	-0.35	-0.29	Parkinson's disease;	chr6:27716875	chr6:28115628~28116551:+
OV	cis	rs4713118	0.911	rs2394000	ENSG00000219392.1	RP1-265C24.5	-4.58	7.54e-06	0.004	-0.35	-0.29	Parkinson's disease;	chr6:27719212	chr6:28115628~28116551:+
OV	cis	rs4713118	0.955	rs9393847	ENSG00000219392.1	RP1-265C24.5	-4.58	7.54e-06	0.004	-0.35	-0.29	Parkinson's disease;	chr6:27720194	chr6:28115628~28116551:+
OV	cis	rs11992162	0.551	rs35010200	ENSG00000270154.1	RP11-419I17.1	-4.58	7.54e-06	0.004	-0.3	-0.29	Monocyte count;	chr8:11928146	chr8:12476462~12477122:+
OV	cis	rs4728142	0.584	rs7796963	ENSG00000275106.1	RP11-309L24.10	-4.58	7.55e-06	0.004	-0.37	-0.29	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128988947	chr7:128952527~128953316:-
OV	cis	rs1555322	0.53	rs2425044	ENSG00000269202.1	RP4-614O4.12	-4.58	7.56e-06	0.00401	-0.34	-0.29	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35201747~35203288:-
OV	cis	rs1823913	0.599	rs2124095	ENSG00000227542.1	AC092614.2	4.58	7.59e-06	0.00402	0.32	0.29	Obesity-related traits;	chr2:191301728	chr2:191229165~191246172:-
OV	cis	rs72615157	0.716	rs75779608	ENSG00000242294.5	STAG3L5P	4.58	7.59e-06	0.00402	0.29	0.29	Lung function (FEV1/FVC);	chr7:100171334	chr7:100336079~100351900:+
OV	cis	rs7617773	0.817	rs3731497	ENSG00000228638.1	FCF1P2	-4.58	7.59e-06	0.00402	-0.37	-0.29	Coronary artery disease;	chr3:48185063	chr3:48290793~48291375:-
OV	cis	rs875971	0.545	rs316324	ENSG00000236529.1	RP13-254B10.1	-4.58	7.6e-06	0.00403	-0.34	-0.29	Aortic root size;	chr7:66145627	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs316323	ENSG00000236529.1	RP13-254B10.1	-4.58	7.6e-06	0.00403	-0.34	-0.29	Aortic root size;	chr7:66146002	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs316316	ENSG00000236529.1	RP13-254B10.1	-4.58	7.6e-06	0.00403	-0.34	-0.29	Aortic root size;	chr7:66149270	chr7:65840212~65840596:+
OV	cis	rs1075265	0.749	rs2692518	ENSG00000233266.1	HMGB1P31	4.58	7.61e-06	0.00403	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53804746	chr2:54051334~54051760:+
OV	cis	rs9309473	1	rs7564890	ENSG00000163016.8	ALMS1P	4.58	7.61e-06	0.00403	0.35	0.29	Metabolite levels;	chr2:73414725	chr2:73644919~73685576:+
OV	cis	rs10992471	0.756	rs2761681	ENSG00000281156.1	MIR3651	-4.58	7.62e-06	0.00404	-0.32	-0.29	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92424655	chr9:92292458~92292547:-
OV	cis	rs7968440	0.651	rs7309519	ENSG00000257298.1	RP3-405J10.3	-4.58	7.62e-06	0.00404	-0.27	-0.29	Fibrinogen;	chr12:50258497	chr12:50185580~50191363:-
OV	cis	rs875971	0.545	rs73152714	ENSG00000237310.1	GS1-124K5.4	4.58	7.63e-06	0.00404	0.34	0.29	Aortic root size;	chr7:66534641	chr7:66493706~66495474:+
OV	cis	rs875971	0.545	rs4718364	ENSG00000237310.1	GS1-124K5.4	4.58	7.63e-06	0.00404	0.34	0.29	Aortic root size;	chr7:66536353	chr7:66493706~66495474:+
OV	cis	rs875971	0.545	rs6961853	ENSG00000237310.1	GS1-124K5.4	4.58	7.63e-06	0.00404	0.34	0.29	Aortic root size;	chr7:66537035	chr7:66493706~66495474:+
OV	cis	rs875971	0.528	rs801213	ENSG00000237310.1	GS1-124K5.4	-4.58	7.63e-06	0.00404	-0.34	-0.29	Aortic root size;	chr7:66549931	chr7:66493706~66495474:+
OV	cis	rs875971	0.545	rs801212	ENSG00000237310.1	GS1-124K5.4	-4.58	7.63e-06	0.00404	-0.34	-0.29	Aortic root size;	chr7:66550643	chr7:66493706~66495474:+
OV	cis	rs2919917	0.628	rs12544041	ENSG00000254352.1	RP11-578O24.2	-4.58	7.64e-06	0.00404	-0.4	-0.29	Lymphocyte counts;	chr8:78731404	chr8:78723796~78724136:-
OV	cis	rs1789	0.503	rs13133213	ENSG00000273133.1	RP11-799M12.2	-4.58	7.64e-06	0.00405	-0.34	-0.29	Blood protein levels;	chr4:15645171	chr4:15563698~15564253:-
OV	cis	rs10246939	0.505	rs9640203	ENSG00000228775.6	WEE2-AS1	4.58	7.64e-06	0.00405	0.33	0.29	Bitter taste perception;	chr7:141844295	chr7:141704338~141738346:-
OV	cis	rs7043114	0.525	rs7864630	ENSG00000281156.1	MIR3651	-4.58	7.65e-06	0.00405	-0.32	-0.29	Height;	chr9:92505278	chr9:92292458~92292547:-
OV	cis	rs9309473	1	rs1114380	ENSG00000163016.8	ALMS1P	4.58	7.65e-06	0.00405	0.33	0.29	Metabolite levels;	chr2:73577581	chr2:73644919~73685576:+
OV	cis	rs9309473	1	rs10169714	ENSG00000163016.8	ALMS1P	4.58	7.65e-06	0.00405	0.33	0.29	Metabolite levels;	chr2:73581646	chr2:73644919~73685576:+
OV	cis	rs9309473	1	rs7582606	ENSG00000163016.8	ALMS1P	4.58	7.65e-06	0.00405	0.33	0.29	Metabolite levels;	chr2:73586818	chr2:73644919~73685576:+
OV	cis	rs4728142	0.584	rs6965542	ENSG00000275106.1	RP11-309L24.10	-4.58	7.66e-06	0.00406	-0.38	-0.29	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129015864	chr7:128952527~128953316:-
OV	cis	rs34779708	0.966	rs1213392	ENSG00000230534.5	RP11-297A16.2	4.58	7.66e-06	0.00406	0.37	0.29	Inflammatory bowel disease;Crohn's disease;	chr10:35141357	chr10:35098006~35127020:-
OV	cis	rs7588746	0.521	rs73054585	ENSG00000232732.8	AC073043.1	4.58	7.67e-06	0.00406	0.38	0.29	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:200279663	chr2:199867396~199911159:-
OV	cis	rs1979679	0.842	rs2127315	ENSG00000278733.1	RP11-425D17.1	4.58	7.68e-06	0.00407	0.35	0.29	Ossification of the posterior longitudinal ligament of the spine;	chr12:28156247	chr12:28185625~28186190:-
OV	cis	rs11673344	0.764	rs10403679	ENSG00000226686.6	LINC01535	4.58	7.68e-06	0.00407	0.37	0.29	Obesity-related traits;	chr19:36980810	chr19:37251912~37265535:+
OV	cis	rs11673344	0.764	rs13345491	ENSG00000226686.6	LINC01535	4.58	7.68e-06	0.00407	0.37	0.29	Obesity-related traits;	chr19:36982197	chr19:37251912~37265535:+
OV	cis	rs7569084	0.566	rs7584295	ENSG00000234255.7	AC012370.3	4.58	7.7e-06	0.00408	0.31	0.29	Sum eosinophil basophil counts;	chr2:65353940	chr2:65439888~65456571:-
OV	cis	rs934734	0.563	rs11695373	ENSG00000234255.7	AC012370.3	4.58	7.7e-06	0.00408	0.31	0.29	Rheumatoid arthritis;	chr2:65354066	chr2:65439888~65456571:-
OV	cis	rs6460942	0.915	rs17541464	ENSG00000226690.5	AC005281.1	4.58	7.71e-06	0.00408	0.45	0.29	Coronary artery disease;	chr7:12423049	chr7:12496429~12541910:+
OV	cis	rs875971	0.965	rs10267430	ENSG00000236529.1	RP13-254B10.1	-4.58	7.71e-06	0.00408	-0.3	-0.29	Aortic root size;	chr7:66278036	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs10257427	ENSG00000236529.1	RP13-254B10.1	-4.58	7.71e-06	0.00408	-0.3	-0.29	Aortic root size;	chr7:66278221	chr7:65840212~65840596:+
OV	cis	rs4713118	0.662	rs156744	ENSG00000226314.6	ZNF192P1	-4.58	7.71e-06	0.00408	-0.4	-0.29	Parkinson's disease;	chr6:27999496	chr6:28161781~28169594:+
OV	cis	rs853679	0.546	rs200953	ENSG00000220721.1	OR1F12	4.58	7.72e-06	0.00408	0.44	0.29	Depression;	chr6:27869489	chr6:28073316~28074233:+
OV	cis	rs9287719	0.967	rs6432113	ENSG00000234818.1	AC092687.5	-4.58	7.73e-06	0.00409	-0.31	-0.29	Prostate cancer;	chr2:10604763	chr2:10589166~10604830:+
OV	cis	rs6088590	0.735	rs6088618	ENSG00000206582.1	Y_RNA	-4.58	7.73e-06	0.00409	-0.36	-0.29	Coronary artery disease;	chr20:34821547	chr20:34526510~34526606:-
OV	cis	rs10129255	0.518	rs10150460	ENSG00000223648.3	IGHV3-64	-4.58	7.73e-06	0.00409	-0.29	-0.29	Kawasaki disease;	chr14:106677179	chr14:106643132~106658258:-
OV	cis	rs3758911	1	rs1046094	ENSG00000261098.1	RP11-819C21.1	-4.58	7.74e-06	0.00409	-0.29	-0.29	Coronary artery disease;	chr11:107326530	chr11:107312132~107316271:-
OV	cis	rs10992471	0.597	rs11789163	ENSG00000281156.1	MIR3651	-4.58	7.75e-06	0.0041	-0.32	-0.29	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92472691	chr9:92292458~92292547:-
OV	cis	rs116095464	0.558	rs6879656	ENSG00000250848.1	CTD-2083E4.5	-4.58	7.76e-06	0.0041	-0.39	-0.29	Breast cancer;	chr5:264313	chr5:288833~290321:-
OV	cis	rs9880211	0.898	rs6770476	ENSG00000239213.4	NCK1-AS1	4.58	7.76e-06	0.0041	0.35	0.29	Height;Body mass index;	chr3:136355078	chr3:136841726~136862054:-
OV	cis	rs1823913	0.599	rs34840299	ENSG00000227542.1	AC092614.2	4.58	7.76e-06	0.0041	0.32	0.29	Obesity-related traits;	chr2:191280379	chr2:191229165~191246172:-
OV	cis	rs293748	0.571	rs13177573	ENSG00000250155.1	CTD-2353F22.1	4.58	7.76e-06	0.0041	0.38	0.29	Obesity-related traits;	chr5:37233335	chr5:36666214~36725195:-
OV	cis	rs4713118	0.621	rs9295756	ENSG00000226314.6	ZNF192P1	-4.58	7.77e-06	0.00411	-0.39	-0.29	Parkinson's disease;	chr6:28065618	chr6:28161781~28169594:+
OV	cis	rs293748	0.571	rs16903531	ENSG00000250155.1	CTD-2353F22.1	-4.58	7.77e-06	0.00411	-0.38	-0.29	Obesity-related traits;	chr5:37197058	chr5:36666214~36725195:-
OV	cis	rs4763879	0.634	rs12424826	ENSG00000278635.1	CTD-2318O12.1	4.58	7.81e-06	0.00412	0.24	0.29	Type 1 diabetes;	chr12:9701981	chr12:9415641~9416718:+
OV	cis	rs17301013	0.507	rs1622802	ENSG00000227373.4	RP11-160H22.5	-4.58	7.81e-06	0.00412	-0.37	-0.29	Systemic lupus erythematosus;	chr1:174766066	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs1329281	ENSG00000227373.4	RP11-160H22.5	-4.58	7.81e-06	0.00412	-0.37	-0.29	Systemic lupus erythematosus;	chr1:174766432	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs6696465	ENSG00000227373.4	RP11-160H22.5	-4.58	7.81e-06	0.00412	-0.37	-0.29	Systemic lupus erythematosus;	chr1:174769700	chr1:174115300~174160004:-
OV	cis	rs17301013	0.531	rs1653634	ENSG00000227373.4	RP11-160H22.5	-4.58	7.81e-06	0.00412	-0.37	-0.29	Systemic lupus erythematosus;	chr1:174783348	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs10798324	ENSG00000227373.4	RP11-160H22.5	-4.58	7.81e-06	0.00412	-0.37	-0.29	Systemic lupus erythematosus;	chr1:174787485	chr1:174115300~174160004:-
OV	cis	rs875971	0.545	rs313830	ENSG00000236529.1	RP13-254B10.1	-4.58	7.82e-06	0.00413	-0.34	-0.29	Aortic root size;	chr7:66086944	chr7:65840212~65840596:+
OV	cis	rs16873450	0.527	rs7807397	ENSG00000234800.2	PCMTD1P3	-4.58	7.83e-06	0.00413	-0.3	-0.29	Verbal memory performance (residualized delayed recall level);	chr7:23758366	chr7:23721311~23721782:-
OV	cis	rs16873450	0.506	rs4566942	ENSG00000234800.2	PCMTD1P3	-4.58	7.83e-06	0.00413	-0.3	-0.29	Verbal memory performance (residualized delayed recall level);	chr7:23759488	chr7:23721311~23721782:-
OV	cis	rs16873450	0.527	rs28406908	ENSG00000234800.2	PCMTD1P3	-4.58	7.83e-06	0.00413	-0.3	-0.29	Verbal memory performance (residualized delayed recall level);	chr7:23759574	chr7:23721311~23721782:-
OV	cis	rs2688608	0.592	rs13013	ENSG00000271816.1	BMS1P4	4.58	7.83e-06	0.00414	0.27	0.29	Inflammatory bowel disease;	chr10:73802403	chr10:73699151~73730487:-
OV	cis	rs9880211	1	rs17200216	ENSG00000239213.4	NCK1-AS1	4.57	7.85e-06	0.00414	0.36	0.29	Height;Body mass index;	chr3:136348390	chr3:136841726~136862054:-
OV	cis	rs4713118	0.662	rs9380045	ENSG00000226314.6	ZNF192P1	-4.57	7.85e-06	0.00414	-0.38	-0.29	Parkinson's disease;	chr6:28057501	chr6:28161781~28169594:+
OV	cis	rs4713118	0.616	rs9348789	ENSG00000226314.6	ZNF192P1	-4.57	7.85e-06	0.00414	-0.38	-0.29	Parkinson's disease;	chr6:28057708	chr6:28161781~28169594:+
OV	cis	rs4713118	0.662	rs9468274	ENSG00000226314.6	ZNF192P1	-4.57	7.85e-06	0.00414	-0.38	-0.29	Parkinson's disease;	chr6:28058299	chr6:28161781~28169594:+
OV	cis	rs4713118	0.662	rs9468275	ENSG00000226314.6	ZNF192P1	-4.57	7.85e-06	0.00414	-0.38	-0.29	Parkinson's disease;	chr6:28058358	chr6:28161781~28169594:+
OV	cis	rs4713118	0.662	rs9468276	ENSG00000226314.6	ZNF192P1	-4.57	7.85e-06	0.00414	-0.38	-0.29	Parkinson's disease;	chr6:28059910	chr6:28161781~28169594:+
OV	cis	rs4713118	0.662	rs9468277	ENSG00000226314.6	ZNF192P1	-4.57	7.85e-06	0.00414	-0.38	-0.29	Parkinson's disease;	chr6:28060612	chr6:28161781~28169594:+
OV	cis	rs4713118	0.662	rs9468278	ENSG00000226314.6	ZNF192P1	-4.57	7.85e-06	0.00414	-0.38	-0.29	Parkinson's disease;	chr6:28060704	chr6:28161781~28169594:+
OV	cis	rs4713118	0.662	rs13218430	ENSG00000226314.6	ZNF192P1	-4.57	7.85e-06	0.00414	-0.38	-0.29	Parkinson's disease;	chr6:28062059	chr6:28161781~28169594:+
OV	cis	rs4713118	0.662	rs9380046	ENSG00000226314.6	ZNF192P1	-4.57	7.85e-06	0.00414	-0.38	-0.29	Parkinson's disease;	chr6:28062721	chr6:28161781~28169594:+
OV	cis	rs9287719	0.967	rs6748036	ENSG00000234818.1	AC092687.5	4.57	7.85e-06	0.00414	0.31	0.29	Prostate cancer;	chr2:10577363	chr2:10589166~10604830:+
OV	cis	rs7083	0.653	rs573442	ENSG00000278768.1	BACE1-AS	4.57	7.85e-06	0.00414	0.3	0.29	Blood protein levels;	chr11:117307204	chr11:117290874~117293571:+
OV	cis	rs1075265	0.933	rs7562055	ENSG00000233266.1	HMGB1P31	4.57	7.86e-06	0.00415	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54112694	chr2:54051334~54051760:+
OV	cis	rs796364	0.806	rs76568708	ENSG00000232732.8	AC073043.1	4.57	7.87e-06	0.00415	0.47	0.29	Schizophrenia;	chr2:200064808	chr2:199867396~199911159:-
OV	cis	rs2274471	0.699	rs10974985	ENSG00000234534.1	CSNK1G2P1	-4.57	7.87e-06	0.00415	-0.36	-0.29	Crohn's disease;	chr9:5156061	chr9:5040945~5041940:+
OV	cis	rs1707322	0.686	rs1084086	ENSG00000234329.1	RP11-767N6.2	-4.57	7.87e-06	0.00415	-0.3	-0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45651039~45651826:-
OV	cis	rs2999052	0.673	rs1735538	ENSG00000277250.1	Metazoa_SRP	4.57	7.88e-06	0.00415	0.37	0.29	Hypospadias;	chr3:128373259	chr3:128673681~128674021:-
OV	cis	rs149866169	1	rs149866169	ENSG00000220721.1	OR1F12	4.57	7.89e-06	0.00416	0.53	0.29	Subjective well-being (multi-trait analysis);Lung cancer;Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Squamous cell lung carcinoma;	chr6:27473944	chr6:28073316~28074233:+
OV	cis	rs1862618	0.525	rs2662021	ENSG00000271828.1	CTD-2310F14.1	-4.57	7.89e-06	0.00416	-0.47	-0.29	Initial pursuit acceleration;	chr5:56965864	chr5:56927874~56929573:+
OV	cis	rs9309473	1	rs13398956	ENSG00000163016.8	ALMS1P	4.57	7.89e-06	0.00416	0.34	0.29	Metabolite levels;	chr2:73493131	chr2:73644919~73685576:+
OV	cis	rs7580658	0.963	rs12463451	ENSG00000236682.1	AC068282.3	-4.57	7.9e-06	0.00416	-0.38	-0.29	Protein C levels;	chr2:127296307	chr2:127389130~127400580:+
OV	cis	rs2919917	1	rs11986947	ENSG00000254352.1	RP11-578O24.2	4.57	7.91e-06	0.00416	0.36	0.29	Lymphocyte counts;	chr8:78708957	chr8:78723796~78724136:-
OV	cis	rs2919917	1	rs2717539	ENSG00000254352.1	RP11-578O24.2	4.57	7.91e-06	0.00416	0.36	0.29	Lymphocyte counts;	chr8:78716804	chr8:78723796~78724136:-
OV	cis	rs875971	0.545	rs6950988	ENSG00000226824.5	RP4-756H11.3	-4.57	7.91e-06	0.00417	-0.35	-0.29	Aortic root size;	chr7:66511428	chr7:66654538~66669855:+
OV	cis	rs6772849	0.93	rs4857912	ENSG00000242551.2	POU5F1P6	-4.57	7.91e-06	0.00417	-0.34	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128610381	chr3:128674735~128677005:-
OV	cis	rs1979679	0.842	rs4931729	ENSG00000278733.1	RP11-425D17.1	4.57	7.92e-06	0.00417	0.35	0.29	Ossification of the posterior longitudinal ligament of the spine;	chr12:28146306	chr12:28185625~28186190:-
OV	cis	rs875971	0.862	rs949930	ENSG00000236529.1	RP13-254B10.1	-4.57	7.93e-06	0.00417	-0.3	-0.29	Aortic root size;	chr7:66301835	chr7:65840212~65840596:+
OV	cis	rs875971	0.928	rs2036263	ENSG00000236529.1	RP13-254B10.1	-4.57	7.93e-06	0.00417	-0.3	-0.29	Aortic root size;	chr7:66335210	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs10240949	ENSG00000236529.1	RP13-254B10.1	-4.57	7.93e-06	0.00417	-0.3	-0.29	Aortic root size;	chr7:66339430	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs7782704	ENSG00000236529.1	RP13-254B10.1	-4.57	7.93e-06	0.00417	-0.3	-0.29	Aortic root size;	chr7:66340379	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs6460290	ENSG00000236529.1	RP13-254B10.1	-4.57	7.93e-06	0.00417	-0.3	-0.29	Aortic root size;	chr7:66344119	chr7:65840212~65840596:+
OV	cis	rs17767294	0.708	rs72847370	ENSG00000220721.1	OR1F12	4.57	7.93e-06	0.00417	0.54	0.29	Parkinson's disease;	chr6:27881646	chr6:28073316~28074233:+
OV	cis	rs17767294	0.708	rs113741085	ENSG00000220721.1	OR1F12	4.57	7.93e-06	0.00417	0.54	0.29	Parkinson's disease;	chr6:27882204	chr6:28073316~28074233:+
OV	cis	rs4664293	0.546	rs12469866	ENSG00000226266.5	AC009961.3	4.57	7.94e-06	0.00418	0.35	0.29	Monocyte percentage of white cells;	chr2:159766119	chr2:159670708~159712435:-
OV	cis	rs7124681	0.584	rs12226590	ENSG00000280615.1	Y_RNA	4.57	7.96e-06	0.00419	0.32	0.29	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47550256	chr11:47614898~47614994:-
OV	cis	rs7429990	0.866	rs3732529	ENSG00000229759.1	MRPS18AP1	4.57	7.96e-06	0.00419	0.3	0.29	Educational attainment (years of education);	chr3:47928619	chr3:48256350~48256938:-
OV	cis	rs7429990	0.932	rs60446735	ENSG00000229759.1	MRPS18AP1	4.57	7.96e-06	0.00419	0.3	0.29	Educational attainment (years of education);	chr3:47929958	chr3:48256350~48256938:-
OV	cis	rs73201462	1	rs11716941	ENSG00000277250.1	Metazoa_SRP	-4.57	7.97e-06	0.00419	-0.43	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128156531	chr3:128673681~128674021:-
OV	cis	rs4713118	0.505	rs156740	ENSG00000204709.4	LINC01556	4.57	7.97e-06	0.00419	0.34	0.29	Parkinson's disease;	chr6:27992657	chr6:28943877~28944537:+
OV	cis	rs7587476	0.501	rs11888027	ENSG00000229267.2	AC072062.1	4.57	7.97e-06	0.00419	0.33	0.29	Neuroblastoma;	chr2:214774888	chr2:214810229~214963274:+
OV	cis	rs9287719	0.81	rs1990612	ENSG00000234818.1	AC092687.5	4.57	7.97e-06	0.00419	0.32	0.29	Prostate cancer;	chr2:10641818	chr2:10589166~10604830:+
OV	cis	rs10924970	0.601	rs12751195	ENSG00000236863.2	RPL23AP23	4.57	7.98e-06	0.00419	0.3	0.29	Asthma;	chr1:235285880	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs3845565	ENSG00000236863.2	RPL23AP23	4.57	7.98e-06	0.00419	0.3	0.29	Asthma;	chr1:235286332	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs12748827	ENSG00000236863.2	RPL23AP23	4.57	7.98e-06	0.00419	0.3	0.29	Asthma;	chr1:235287372	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs1317238	ENSG00000236863.2	RPL23AP23	4.57	7.98e-06	0.00419	0.3	0.29	Asthma;	chr1:235294265	chr1:235295865~235296335:+
OV	cis	rs10924970	0.578	rs12031118	ENSG00000236863.2	RPL23AP23	4.57	7.98e-06	0.00419	0.3	0.29	Asthma;	chr1:235300572	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs12736498	ENSG00000236863.2	RPL23AP23	4.57	7.98e-06	0.00419	0.3	0.29	Asthma;	chr1:235301305	chr1:235295865~235296335:+
OV	cis	rs10924970	0.625	rs61836167	ENSG00000236863.2	RPL23AP23	4.57	7.98e-06	0.00419	0.3	0.29	Asthma;	chr1:235301744	chr1:235295865~235296335:+
OV	cis	rs4713118	0.628	rs9295740	ENSG00000220721.1	OR1F12	4.57	7.98e-06	0.0042	0.35	0.29	Parkinson's disease;	chr6:27721723	chr6:28073316~28074233:+
OV	cis	rs2833693	0.572	rs2833715	ENSG00000261610.1	AP000265.1	4.57	7.98e-06	0.0042	0.37	0.29	Temperament;	chr21:32192268	chr21:32259804~32261585:-
OV	cis	rs4713118	0.869	rs9283881	ENSG00000280107.1	AL022393.9	-4.57	7.98e-06	0.0042	-0.34	-0.29	Parkinson's disease;	chr6:27747476	chr6:28170845~28172521:+
OV	cis	rs4713118	0.869	rs9283882	ENSG00000280107.1	AL022393.9	-4.57	7.98e-06	0.0042	-0.34	-0.29	Parkinson's disease;	chr6:27747479	chr6:28170845~28172521:+
OV	cis	rs2522056	1	rs11242113	ENSG00000233006.5	AC034220.3	-4.57	7.98e-06	0.0042	-0.35	-0.29	Fibrinogen;Lymphocyte counts;	chr5:132441542	chr5:132311285~132369916:-
OV	cis	rs9287719	0.781	rs12472807	ENSG00000234818.1	AC092687.5	4.57	7.99e-06	0.0042	0.32	0.29	Prostate cancer;	chr2:10641479	chr2:10589166~10604830:+
OV	cis	rs17301013	0.507	rs16847337	ENSG00000227373.4	RP11-160H22.5	-4.57	8e-06	0.00421	-0.4	-0.29	Systemic lupus erythematosus;	chr1:174683121	chr1:174115300~174160004:-
OV	cis	rs3733585	0.534	rs7375642	ENSG00000250413.1	RP11-448G15.1	4.57	8e-06	0.00421	0.32	0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:9953612	chr4:10006482~10009725:+
OV	cis	rs3733585	0.578	rs6837224	ENSG00000250413.1	RP11-448G15.1	4.57	8e-06	0.00421	0.32	0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:9953631	chr4:10006482~10009725:+
OV	cis	rs3733585	0.578	rs4466042	ENSG00000250413.1	RP11-448G15.1	4.57	8e-06	0.00421	0.32	0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:9953743	chr4:10006482~10009725:+
OV	cis	rs3733585	0.726	rs4306953	ENSG00000250413.1	RP11-448G15.1	4.57	8e-06	0.00421	0.32	0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:9954152	chr4:10006482~10009725:+
OV	cis	rs3733585	0.673	rs4519796	ENSG00000250413.1	RP11-448G15.1	4.57	8e-06	0.00421	0.32	0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:9954312	chr4:10006482~10009725:+
OV	cis	rs172166	0.694	rs1225716	ENSG00000280107.1	AL022393.9	-4.57	8.01e-06	0.00421	-0.35	-0.29	Cardiac Troponin-T levels;	chr6:28145968	chr6:28170845~28172521:+
OV	cis	rs4964805	0.657	rs1866293	ENSG00000257681.1	RP11-341G23.4	4.57	8.01e-06	0.00421	0.32	0.29	Attention deficit hyperactivity disorder;	chr12:103792877	chr12:103746315~103768858:-
OV	cis	rs4964805	0.657	rs1866294	ENSG00000257681.1	RP11-341G23.4	4.57	8.01e-06	0.00421	0.32	0.29	Attention deficit hyperactivity disorder;	chr12:103793017	chr12:103746315~103768858:-
OV	cis	rs3733585	0.605	rs7656624	ENSG00000250413.1	RP11-448G15.1	4.57	8.02e-06	0.00421	0.36	0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:10119473	chr4:10006482~10009725:+
OV	cis	rs638893	1	rs73005500	ENSG00000255239.1	AP002954.6	-4.57	8.02e-06	0.00421	-0.46	-0.29	Vitiligo;	chr11:118826666	chr11:118688039~118690600:-
OV	cis	rs62244186	0.715	rs10212378	ENSG00000214820.3	MPRIPP1	4.57	8.02e-06	0.00421	0.27	0.29	Depressive symptoms;	chr3:44625794	chr3:44579938~44581026:-
OV	cis	rs875971	0.545	rs10950025	ENSG00000236529.1	RP13-254B10.1	4.57	8.02e-06	0.00421	0.34	0.29	Aortic root size;	chr7:66158946	chr7:65840212~65840596:+
OV	cis	rs875971	0.52	rs12666485	ENSG00000236529.1	RP13-254B10.1	4.57	8.02e-06	0.00421	0.34	0.29	Aortic root size;	chr7:66160135	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs67688847	ENSG00000236529.1	RP13-254B10.1	4.57	8.02e-06	0.00421	0.34	0.29	Aortic root size;	chr7:66161064	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs7787063	ENSG00000236529.1	RP13-254B10.1	4.57	8.02e-06	0.00421	0.34	0.29	Aortic root size;	chr7:66164012	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs2460427	ENSG00000236529.1	RP13-254B10.1	-4.57	8.02e-06	0.00421	-0.34	-0.29	Aortic root size;	chr7:66154218	chr7:65840212~65840596:+
OV	cis	rs4763879	0.739	rs2114871	ENSG00000278635.1	CTD-2318O12.1	4.57	8.02e-06	0.00421	0.25	0.29	Type 1 diabetes;	chr12:9676842	chr12:9415641~9416718:+
OV	cis	rs875971	0.545	rs12673308	ENSG00000236529.1	RP13-254B10.1	4.57	8.03e-06	0.00421	0.34	0.29	Aortic root size;	chr7:66166374	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs67397473	ENSG00000236529.1	RP13-254B10.1	4.57	8.03e-06	0.00421	0.34	0.29	Aortic root size;	chr7:66168318	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs10950027	ENSG00000236529.1	RP13-254B10.1	4.57	8.03e-06	0.00421	0.34	0.29	Aortic root size;	chr7:66169164	chr7:65840212~65840596:+
OV	cis	rs7172809	0.599	rs17471480	ENSG00000230459.3	RP11-741G21.1	-4.57	8.03e-06	0.00422	-0.37	-0.29	Glucose homeostasis traits;	chr15:77463208	chr15:77278465~77278774:+
OV	cis	rs11159086	0.793	rs11625502	ENSG00000270000.1	RP3-449M8.9	4.57	8.04e-06	0.00422	0.43	0.29	Advanced glycation end-product levels;	chr14:74468309	chr14:74471930~74472360:-
OV	cis	rs1823913	0.599	rs13001899	ENSG00000227542.1	AC092614.2	4.57	8.04e-06	0.00422	0.32	0.29	Obesity-related traits;	chr2:191285442	chr2:191229165~191246172:-
OV	cis	rs853679	0.766	rs9368561	ENSG00000280107.1	AL022393.9	-4.57	8.04e-06	0.00422	-0.5	-0.29	Depression;	chr6:28200565	chr6:28170845~28172521:+
OV	cis	rs1538970	0.884	rs781226	ENSG00000280836.1	AL355480.1	4.57	8.05e-06	0.00422	0.4	0.29	Platelet count;	chr1:45406990	chr1:45581219~45581321:-
OV	cis	rs473651	0.935	rs472357	ENSG00000229915.1	AC016999.2	4.57	8.05e-06	0.00422	0.36	0.29	Multiple system atrophy;	chr2:238446813	chr2:238427077~238427729:-
OV	cis	rs896854	0.936	rs10108430	ENSG00000253528.2	RP11-347C18.4	4.57	8.06e-06	0.00423	0.28	0.29	Type 2 diabetes;	chr8:94949566	chr8:94974573~94974853:-
OV	cis	rs6772849	0.901	rs9849126	ENSG00000277250.1	Metazoa_SRP	4.57	8.07e-06	0.00423	0.34	0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128593226	chr3:128673681~128674021:-
OV	cis	rs7043114	0.525	rs7869742	ENSG00000281156.1	MIR3651	-4.57	8.08e-06	0.00424	-0.32	-0.29	Height;	chr9:92493892	chr9:92292458~92292547:-
OV	cis	rs8054556	0.647	rs4787488	ENSG00000261367.1	RP11-455F5.4	4.57	8.09e-06	0.00424	0.31	0.29	Autism spectrum disorder or schizophrenia;	chr16:29984482	chr16:30107675~30110541:+
OV	cis	rs4747241	0.662	rs9415068	ENSG00000226163.1	RP11-167P22.3	-4.57	8.1e-06	0.00424	-0.33	-0.29	Heschl's gyrus morphology;	chr10:72353575	chr10:72501746~72502956:+
OV	cis	rs2898290	0.5	rs11998678	ENSG00000254866.2	DEFB109P3	4.57	8.1e-06	0.00425	0.4	0.29	Systolic blood pressure;	chr8:11972641	chr8:12150895~12151134:-
OV	cis	rs896854	0.875	rs4735333	ENSG00000253528.2	RP11-347C18.4	4.57	8.12e-06	0.00426	0.28	0.29	Type 2 diabetes;	chr8:94942846	chr8:94974573~94974853:-
OV	cis	rs853679	0.882	rs4713140	ENSG00000226314.6	ZNF192P1	-4.57	8.12e-06	0.00426	-0.5	-0.29	Depression;	chr6:28129415	chr6:28161781~28169594:+
OV	cis	rs957448	0.561	rs34471170	ENSG00000253704.1	RP11-267M23.4	4.57	8.14e-06	0.00426	0.38	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94601135	chr8:94553722~94569745:+
OV	cis	rs957448	0.561	rs9642927	ENSG00000253704.1	RP11-267M23.4	4.57	8.14e-06	0.00426	0.38	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94601414	chr8:94553722~94569745:+
OV	cis	rs957448	0.529	rs9642928	ENSG00000253704.1	RP11-267M23.4	4.57	8.14e-06	0.00426	0.38	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94601698	chr8:94553722~94569745:+
OV	cis	rs957448	0.561	rs1808488	ENSG00000253704.1	RP11-267M23.4	4.57	8.14e-06	0.00426	0.38	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94602636	chr8:94553722~94569745:+
OV	cis	rs957448	0.583	rs754275	ENSG00000253704.1	RP11-267M23.4	4.57	8.14e-06	0.00426	0.38	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94602741	chr8:94553722~94569745:+
OV	cis	rs957448	0.561	rs1426172	ENSG00000253704.1	RP11-267M23.4	4.57	8.14e-06	0.00426	0.38	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94602988	chr8:94553722~94569745:+
OV	cis	rs2274471	0.645	rs10974955	ENSG00000234534.1	CSNK1G2P1	4.57	8.14e-06	0.00427	0.37	0.29	Crohn's disease;	chr9:5090641	chr9:5040945~5041940:+
OV	cis	rs7899628	1	rs7899628	ENSG00000226864.1	ATE1-AS1	-4.57	8.14e-06	0.00427	-0.38	-0.29	Breast cancer;	chr10:121904429	chr10:121928312~121951965:+
OV	cis	rs10829156	0.625	rs7082235	ENSG00000225527.1	RP11-383B4.4	-4.57	8.15e-06	0.00427	-0.37	-0.29	Sudden cardiac arrest;	chr10:18536765	chr10:18531849~18533336:-
OV	cis	rs6772849	1	rs2734037	ENSG00000242551.2	POU5F1P6	-4.57	8.16e-06	0.00427	-0.34	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128590041	chr3:128674735~128677005:-
OV	cis	rs8054556	1	rs11642046	ENSG00000261367.1	RP11-455F5.4	-4.57	8.17e-06	0.00428	-0.32	-0.29	Autism spectrum disorder or schizophrenia;	chr16:29981787	chr16:30107675~30110541:+
OV	cis	rs8054556	1	rs9925915	ENSG00000261367.1	RP11-455F5.4	-4.57	8.17e-06	0.00428	-0.32	-0.29	Autism spectrum disorder or schizophrenia;	chr16:29982365	chr16:30107675~30110541:+
OV	cis	rs875971	1	rs6946143	ENSG00000236529.1	RP13-254B10.1	4.57	8.17e-06	0.00428	0.3	0.29	Aortic root size;	chr7:66114735	chr7:65840212~65840596:+
OV	cis	rs17301013	0.581	rs11801385	ENSG00000227373.4	RP11-160H22.5	4.57	8.18e-06	0.00428	0.39	0.29	Systemic lupus erythematosus;	chr1:174089454	chr1:174115300~174160004:-
OV	cis	rs2919917	0.793	rs2625664	ENSG00000254352.1	RP11-578O24.2	4.57	8.19e-06	0.00428	0.36	0.29	Lymphocyte counts;	chr8:78718373	chr8:78723796~78724136:-
OV	cis	rs2919917	1	rs1026920	ENSG00000254352.1	RP11-578O24.2	4.57	8.19e-06	0.00428	0.36	0.29	Lymphocyte counts;	chr8:78719775	chr8:78723796~78724136:-
OV	cis	rs2919917	1	rs2717538	ENSG00000254352.1	RP11-578O24.2	4.57	8.19e-06	0.00428	0.36	0.29	Lymphocyte counts;	chr8:78720914	chr8:78723796~78724136:-
OV	cis	rs853679	0.882	rs9468300	ENSG00000280107.1	AL022393.9	-4.56	8.2e-06	0.00429	-0.5	-0.29	Depression;	chr6:28159062	chr6:28170845~28172521:+
OV	cis	rs853679	0.825	rs8180562	ENSG00000280107.1	AL022393.9	-4.56	8.2e-06	0.00429	-0.5	-0.29	Depression;	chr6:28173682	chr6:28170845~28172521:+
OV	cis	rs17264034	0.821	rs422309	ENSG00000250786.1	SNHG18	4.56	8.2e-06	0.00429	0.45	0.29	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9544284	chr5:9546200~9550609:+
OV	cis	rs8062405	1	rs62037371	ENSG00000278665.1	RP11-666O2.4	4.56	8.21e-06	0.00429	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878810	chr16:28599241~28601881:-
OV	cis	rs8062405	1	rs8055138	ENSG00000278665.1	RP11-666O2.4	4.56	8.21e-06	0.00429	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28880144	chr16:28599241~28601881:-
OV	cis	rs8100891	0.537	rs2012353	ENSG00000267213.4	AC007773.2	-4.56	8.21e-06	0.0043	-0.44	-0.29	Neuroticism;	chr19:32408387	chr19:32390050~32405560:-
OV	cis	rs473651	0.935	rs482775	ENSG00000229915.1	AC016999.2	-4.56	8.21e-06	0.0043	-0.36	-0.29	Multiple system atrophy;	chr2:238426762	chr2:238427077~238427729:-
OV	cis	rs10934853	0.561	rs1702136	ENSG00000277250.1	Metazoa_SRP	4.56	8.22e-06	0.0043	0.4	0.29	Prostate cancer;Prostate cancer (SNP x SNP interaction);	chr3:128399868	chr3:128673681~128674021:-
OV	cis	rs217727	0.524	rs7483477	ENSG00000232987.1	LINC01219	-4.56	8.22e-06	0.0043	-0.36	-0.29	Breast cancer;	chr11:1899025	chr11:1991096~1993469:+
OV	cis	rs11157436	1	rs3811278	ENSG00000211812.1	TRAV26-2	-4.56	8.23e-06	0.0043	-0.35	-0.29	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22186227	chr14:22202583~22203368:+
OV	cis	rs783540	0.843	rs9652567	ENSG00000278603.1	RP13-608F4.5	4.56	8.23e-06	0.0043	0.34	0.29	Schizophrenia;	chr15:82699762	chr15:82472203~82472426:+
OV	cis	rs783540	0.934	rs4779050	ENSG00000278603.1	RP13-608F4.5	4.56	8.23e-06	0.0043	0.34	0.29	Schizophrenia;	chr15:82699986	chr15:82472203~82472426:+
OV	cis	rs1113500	0.933	rs11185259	ENSG00000226822.1	RP11-356N1.2	-4.56	8.23e-06	0.0043	-0.36	-0.29	Growth-regulated protein alpha levels;	chr1:108092440	chr1:108071482~108074519:+
OV	cis	rs4713118	0.662	rs149946	ENSG00000226314.6	ZNF192P1	4.56	8.23e-06	0.0043	0.39	0.29	Parkinson's disease;	chr6:28002253	chr6:28161781~28169594:+
OV	cis	rs1555322	0.53	rs2297789	ENSG00000126005.14	MMP24-AS1	-4.56	8.24e-06	0.0043	-0.4	-0.29	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35216462~35278131:-
OV	cis	rs10954213	0.525	rs11770589	ENSG00000275106.1	RP11-309L24.10	-4.56	8.25e-06	0.00431	-0.35	-0.29	Sjögren's syndrome;	chr7:128949434	chr7:128952527~128953316:-
OV	cis	rs9291683	0.546	rs4529049	ENSG00000250413.1	RP11-448G15.1	-4.56	8.25e-06	0.00431	-0.34	-0.29	Bone mineral density;	chr4:10043765	chr4:10006482~10009725:+
OV	cis	rs2688608	0.592	rs10824031	ENSG00000271816.1	BMS1P4	4.56	8.25e-06	0.00431	0.27	0.29	Inflammatory bowel disease;	chr10:73749515	chr10:73699151~73730487:-
OV	cis	rs2688608	0.62	rs7076525	ENSG00000271816.1	BMS1P4	4.56	8.25e-06	0.00431	0.27	0.29	Inflammatory bowel disease;	chr10:73753039	chr10:73699151~73730487:-
OV	cis	rs9660180	0.967	rs12034740	ENSG00000215914.4	MMP23A	-4.56	8.26e-06	0.00431	-0.33	-0.29	Body mass index;	chr1:1797530	chr1:1699942~1701782:+
OV	cis	rs8027521	0.846	rs2725580	ENSG00000280362.1	RP11-643A5.3	4.56	8.26e-06	0.00432	0.33	0.29	Circulating chemerin levels;	chr15:53970517	chr15:53910769~53914712:+
OV	cis	rs4713118	0.662	rs149947	ENSG00000226314.6	ZNF192P1	-4.56	8.27e-06	0.00432	-0.4	-0.29	Parkinson's disease;	chr6:28004655	chr6:28161781~28169594:+
OV	cis	rs17301013	0.581	rs56158362	ENSG00000227373.4	RP11-160H22.5	4.56	8.27e-06	0.00432	0.39	0.29	Systemic lupus erythematosus;	chr1:174166437	chr1:174115300~174160004:-
OV	cis	rs3814244	0.788	rs3741647	ENSG00000255733.4	IFNG-AS1	-4.56	8.28e-06	0.00432	-0.28	-0.29	Itch intensity from mosquito bite adjusted by bite size;	chr12:68028249	chr12:67989445~68234686:+
OV	cis	rs3733585	0.753	rs12500805	ENSG00000250413.1	RP11-448G15.1	-4.56	8.3e-06	0.00433	-0.33	-0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:10016355	chr4:10006482~10009725:+
OV	cis	rs72615157	0.561	rs113401658	ENSG00000242294.5	STAG3L5P	4.56	8.31e-06	0.00434	0.28	0.29	Lung function (FEV1/FVC);	chr7:100260882	chr7:100336079~100351900:+
OV	cis	rs72615157	0.561	rs113844570	ENSG00000242294.5	STAG3L5P	4.56	8.31e-06	0.00434	0.28	0.29	Lung function (FEV1/FVC);	chr7:100276155	chr7:100336079~100351900:+
OV	cis	rs896854	0.818	rs896855	ENSG00000253528.2	RP11-347C18.4	4.56	8.31e-06	0.00434	0.28	0.29	Type 2 diabetes;	chr8:94947580	chr8:94974573~94974853:-
OV	cis	rs7520050	0.667	rs11211176	ENSG00000281133.1	AL355480.3	4.56	8.31e-06	0.00434	0.33	0.29	Reticulocyte count;Red blood cell count;	chr1:45757414	chr1:45580892~45580996:-
OV	cis	rs4908768	0.535	rs2708628	ENSG00000228423.2	RP4-633I8.4	4.56	8.31e-06	0.00434	0.34	0.29	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8390388	chr1:8805860~8807051:-
OV	cis	rs4908768	0.535	rs2784738	ENSG00000228423.2	RP4-633I8.4	4.56	8.31e-06	0.00434	0.34	0.29	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8406157	chr1:8805860~8807051:-
OV	cis	rs4908768	0.535	rs2748456	ENSG00000228423.2	RP4-633I8.4	4.56	8.31e-06	0.00434	0.34	0.29	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8406690	chr1:8805860~8807051:-
OV	cis	rs4908768	0.535	rs2661868	ENSG00000228423.2	RP4-633I8.4	4.56	8.31e-06	0.00434	0.34	0.29	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8409729	chr1:8805860~8807051:-
OV	cis	rs10246939	0.505	rs6967189	ENSG00000228775.6	WEE2-AS1	4.56	8.32e-06	0.00434	0.33	0.29	Bitter taste perception;	chr7:141826220	chr7:141704338~141738346:-
OV	cis	rs1150668	0.799	rs9301	ENSG00000204709.4	LINC01556	4.56	8.33e-06	0.00435	0.34	0.29	Pubertal anthropometrics;	chr6:28324929	chr6:28943877~28944537:+
OV	cis	rs1150668	0.799	rs853684	ENSG00000204709.4	LINC01556	4.56	8.33e-06	0.00435	0.34	0.29	Pubertal anthropometrics;	chr6:28326773	chr6:28943877~28944537:+
OV	cis	rs875971	0.825	rs28480509	ENSG00000236529.1	RP13-254B10.1	-4.56	8.33e-06	0.00435	-0.3	-0.29	Aortic root size;	chr7:66634237	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs9791712	ENSG00000236529.1	RP13-254B10.1	-4.56	8.33e-06	0.00435	-0.3	-0.29	Aortic root size;	chr7:66640176	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs9791713	ENSG00000236529.1	RP13-254B10.1	-4.56	8.33e-06	0.00435	-0.3	-0.29	Aortic root size;	chr7:66640211	chr7:65840212~65840596:+
OV	cis	rs7927592	0.546	rs497261	ENSG00000212093.1	AP000807.1	4.56	8.33e-06	0.00435	0.34	0.29	Total body bone mineral density;	chr11:68424776	chr11:68506083~68506166:-
OV	cis	rs7927592	0.546	rs599083	ENSG00000212093.1	AP000807.1	4.56	8.33e-06	0.00435	0.34	0.29	Total body bone mineral density;	chr11:68424878	chr11:68506083~68506166:-
OV	cis	rs7927592	0.546	rs683978	ENSG00000212093.1	AP000807.1	4.56	8.33e-06	0.00435	0.34	0.29	Total body bone mineral density;	chr11:68424953	chr11:68506083~68506166:-
OV	cis	rs7927592	0.546	rs554734	ENSG00000212093.1	AP000807.1	4.56	8.33e-06	0.00435	0.34	0.29	Total body bone mineral density;	chr11:68425050	chr11:68506083~68506166:-
OV	cis	rs875971	0.545	rs7783889	ENSG00000226824.5	RP4-756H11.3	-4.56	8.35e-06	0.00435	-0.35	-0.29	Aortic root size;	chr7:66283366	chr7:66654538~66669855:+
OV	cis	rs4713118	0.629	rs203887	ENSG00000226314.6	ZNF192P1	-4.56	8.35e-06	0.00436	-0.39	-0.29	Parkinson's disease;	chr6:28053491	chr6:28161781~28169594:+
OV	cis	rs55726902	0.761	rs2544030	ENSG00000276691.1	RP5-1057I20.5	4.56	8.35e-06	0.00436	0.29	0.29	Allergic disease (asthma, hay fever or eczema);	chr12:47801668	chr12:47788426~47788971:+
OV	cis	rs9393777	0.92	rs34150729	ENSG00000220721.1	OR1F12	4.56	8.35e-06	0.00436	0.54	0.29	Intelligence (multi-trait analysis);	chr6:27420975	chr6:28073316~28074233:+
OV	cis	rs9393777	0.92	rs13191227	ENSG00000220721.1	OR1F12	4.56	8.35e-06	0.00436	0.54	0.29	Intelligence (multi-trait analysis);	chr6:27422336	chr6:28073316~28074233:+
OV	cis	rs9368481	0.761	rs9357030	ENSG00000261584.1	RP11-457M11.5	-4.56	8.36e-06	0.00436	-0.33	-0.29	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:26686241~26687964:+
OV	cis	rs4591358	0.618	rs4850625	ENSG00000223466.1	AC064834.2	4.56	8.36e-06	0.00436	0.35	0.29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195522138	chr2:195533035~195538681:+
OV	cis	rs1862618	0.853	rs252915	ENSG00000271828.1	CTD-2310F14.1	-4.56	8.37e-06	0.00436	-0.45	-0.29	Initial pursuit acceleration;	chr5:56825927	chr5:56927874~56929573:+
OV	cis	rs3733585	0.673	rs7378340	ENSG00000250413.1	RP11-448G15.1	4.56	8.37e-06	0.00437	0.32	0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:9953574	chr4:10006482~10009725:+
OV	cis	rs73201462	1	rs13071740	ENSG00000277250.1	Metazoa_SRP	4.56	8.37e-06	0.00437	0.45	0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128162725	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs13077790	ENSG00000277250.1	Metazoa_SRP	4.56	8.37e-06	0.00437	0.45	0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128163815	chr3:128673681~128674021:-
OV	cis	rs4964805	0.526	rs934845	ENSG00000257681.1	RP11-341G23.4	4.56	8.37e-06	0.00437	0.31	0.29	Attention deficit hyperactivity disorder;	chr12:103791479	chr12:103746315~103768858:-
OV	cis	rs875971	1	rs7792762	ENSG00000236529.1	RP13-254B10.1	4.56	8.38e-06	0.00437	0.3	0.29	Aortic root size;	chr7:66539151	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs4718348	ENSG00000226824.5	RP4-756H11.3	-4.56	8.38e-06	0.00437	-0.35	-0.29	Aortic root size;	chr7:66441589	chr7:66654538~66669855:+
OV	cis	rs4853012	0.838	rs12619982	ENSG00000257800.1	FNBP1P1	4.56	8.38e-06	0.00437	0.42	0.29	Gestational age at birth (maternal effect);	chr2:74128895	chr2:74120680~74123218:+
OV	cis	rs6538678	0.777	rs10745736	ENSG00000199506.1	RNU6-247P	-4.56	8.39e-06	0.00437	-0.38	-0.29	Lupus nephritis in systemic lupus erythematosus;	chr12:95889308	chr12:95792529~95792635:-
OV	cis	rs1499614	1	rs2141924	ENSG00000226824.5	RP4-756H11.3	-4.56	8.39e-06	0.00437	-0.49	-0.29	Gout;	chr7:66721259	chr7:66654538~66669855:+
OV	cis	rs3733585	0.673	rs4312757	ENSG00000250413.1	RP11-448G15.1	4.56	8.4e-06	0.00438	0.32	0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:9954521	chr4:10006482~10009725:+
OV	cis	rs3733585	0.673	rs6814664	ENSG00000250413.1	RP11-448G15.1	4.56	8.4e-06	0.00438	0.32	0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:9954604	chr4:10006482~10009725:+
OV	cis	rs3733585	0.588	rs6449154	ENSG00000250413.1	RP11-448G15.1	4.56	8.4e-06	0.00438	0.32	0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:9954780	chr4:10006482~10009725:+
OV	cis	rs3733585	0.638	rs6414766	ENSG00000250413.1	RP11-448G15.1	4.56	8.4e-06	0.00438	0.32	0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:9954850	chr4:10006482~10009725:+
OV	cis	rs3733585	0.638	rs6449155	ENSG00000250413.1	RP11-448G15.1	4.56	8.4e-06	0.00438	0.32	0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:9954923	chr4:10006482~10009725:+
OV	cis	rs2070488	0.93	rs2370840	ENSG00000229589.1	ACVR2B-AS1	4.56	8.4e-06	0.00438	0.32	0.29	Electrocardiographic conduction measures;	chr3:38488334	chr3:38451027~38454820:-
OV	cis	rs611744	0.647	rs11774904	ENSG00000253754.1	RP11-35G22.1	-4.56	8.4e-06	0.00438	-0.31	-0.29	Dupuytren's disease;	chr8:108261206	chr8:108226200~108227544:+
OV	cis	rs7172809	0.573	rs17468413	ENSG00000230459.3	RP11-741G21.1	4.56	8.41e-06	0.00438	0.38	0.29	Glucose homeostasis traits;	chr15:77252168	chr15:77278465~77278774:+
OV	cis	rs7829975	0.533	rs13274028	ENSG00000253981.4	ALG1L13P	4.56	8.41e-06	0.00438	0.31	0.29	Mood instability;	chr8:8871683	chr8:8236003~8244667:-
OV	cis	rs1979679	0.918	rs10771429	ENSG00000278733.1	RP11-425D17.1	-4.56	8.42e-06	0.00439	-0.35	-0.29	Ossification of the posterior longitudinal ligament of the spine;	chr12:28468573	chr12:28185625~28186190:-
OV	cis	rs1979679	0.918	rs10771430	ENSG00000278733.1	RP11-425D17.1	-4.56	8.42e-06	0.00439	-0.35	-0.29	Ossification of the posterior longitudinal ligament of the spine;	chr12:28470505	chr12:28185625~28186190:-
OV	cis	rs17711722	0.565	rs4717276	ENSG00000224316.1	RP11-479O9.2	4.56	8.42e-06	0.00439	0.32	0.29	Calcium levels;	chr7:65829754	chr7:65773620~65802067:+
OV	cis	rs10510102	0.935	rs7907871	ENSG00000226864.1	ATE1-AS1	4.56	8.43e-06	0.00439	0.46	0.29	Breast cancer;	chr10:121878185	chr10:121928312~121951965:+
OV	cis	rs73201462	1	rs2811392	ENSG00000277250.1	Metazoa_SRP	-4.56	8.44e-06	0.00439	-0.45	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128305133	chr3:128673681~128674021:-
OV	cis	rs1150668	0.796	rs2531825	ENSG00000204709.4	LINC01556	4.56	8.44e-06	0.0044	0.33	0.29	Pubertal anthropometrics;	chr6:28381487	chr6:28943877~28944537:+
OV	cis	rs992157	1	rs13003334	ENSG00000237281.1	CATIP-AS2	-4.56	8.45e-06	0.0044	-0.33	-0.29	Colorectal cancer;	chr2:218260198	chr2:218326889~218357966:-
OV	cis	rs934734	0.544	rs4671127	ENSG00000234255.7	AC012370.3	4.56	8.45e-06	0.0044	0.31	0.29	Rheumatoid arthritis;	chr2:65335836	chr2:65439888~65456571:-
OV	cis	rs13113518	0.812	rs13116035	ENSG00000223305.1	RN7SKP30	4.56	8.45e-06	0.0044	0.34	0.29	Height;	chr4:55561218	chr4:55540502~55540835:-
OV	cis	rs6991838	0.584	rs10089708	ENSG00000200714.1	Y_RNA	4.56	8.45e-06	0.0044	0.38	0.29	Intelligence (multi-trait analysis);	chr8:65642927	chr8:65592731~65592820:+
OV	cis	rs6991838	0.584	rs6991731	ENSG00000200714.1	Y_RNA	4.56	8.45e-06	0.0044	0.38	0.29	Intelligence (multi-trait analysis);	chr8:65643232	chr8:65592731~65592820:+
OV	cis	rs1723838	0.826	rs6592528	ENSG00000255928.1	RP11-456I15.2	4.56	8.48e-06	0.00442	0.64	0.29	Obesity-related traits;	chr11:73666305	chr11:73722349~73722694:+
OV	cis	rs875971	1	rs875971	ENSG00000236529.1	RP13-254B10.1	-4.56	8.49e-06	0.00442	-0.3	-0.29	Aortic root size;	chr7:66152608	chr7:65840212~65840596:+
OV	cis	rs1979679	0.842	rs7138497	ENSG00000278733.1	RP11-425D17.1	4.56	8.5e-06	0.00442	0.34	0.29	Ossification of the posterior longitudinal ligament of the spine;	chr12:28242918	chr12:28185625~28186190:-
OV	cis	rs11976180	0.517	rs6949375	ENSG00000170356.8	OR2A20P	-4.56	8.5e-06	0.00442	-0.48	-0.29	Obesity-related traits;	chr7:144076758	chr7:144250045~144252957:-
OV	cis	rs9393777	0.92	rs13207689	ENSG00000220721.1	OR1F12	4.56	8.5e-06	0.00442	0.54	0.29	Intelligence (multi-trait analysis);	chr6:27401925	chr6:28073316~28074233:+
OV	cis	rs10510102	1	rs10510102	ENSG00000276742.1	RP11-500G22.4	-4.56	8.5e-06	0.00442	-0.49	-0.29	Breast cancer;	chr10:121865675	chr10:121956782~121957098:+
OV	cis	rs7520050	0.807	rs4353138	ENSG00000281133.1	AL355480.3	4.56	8.51e-06	0.00443	0.33	0.29	Reticulocyte count;Red blood cell count;	chr1:45754131	chr1:45580892~45580996:-
OV	cis	rs1969253	0.712	rs3792305	ENSG00000243584.1	RP11-14I2.2	-4.56	8.52e-06	0.00443	-0.33	-0.29	Major depressive disorder;	chr3:184187189	chr3:183613620~183616742:+
OV	cis	rs1969253	0.712	rs843345	ENSG00000243584.1	RP11-14I2.2	-4.56	8.52e-06	0.00443	-0.33	-0.29	Major depressive disorder;	chr3:184188727	chr3:183613620~183616742:+
OV	cis	rs1969253	0.712	rs843344	ENSG00000243584.1	RP11-14I2.2	-4.56	8.52e-06	0.00443	-0.33	-0.29	Major depressive disorder;	chr3:184189244	chr3:183613620~183616742:+
OV	cis	rs116095464	0.558	rs62346508	ENSG00000250848.1	CTD-2083E4.5	-4.56	8.52e-06	0.00443	-0.38	-0.29	Breast cancer;	chr5:203553	chr5:288833~290321:-
OV	cis	rs7615952	0.558	rs17334039	ENSG00000171084.14	FAM86JP	4.56	8.53e-06	0.00443	0.46	0.29	Blood pressure (smoking interaction);	chr3:125821465	chr3:125916620~125930024:+
OV	cis	rs8054556	0.647	rs4077410	ENSG00000261367.1	RP11-455F5.4	-4.56	8.54e-06	0.00444	-0.31	-0.29	Autism spectrum disorder or schizophrenia;	chr16:29986879	chr16:30107675~30110541:+
OV	cis	rs8062405	1	rs62036617	ENSG00000278665.1	RP11-666O2.4	4.56	8.54e-06	0.00444	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28816177	chr16:28599241~28601881:-
OV	cis	rs8062405	1	rs4788095	ENSG00000278665.1	RP11-666O2.4	4.56	8.54e-06	0.00444	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28820038	chr16:28599241~28601881:-
OV	cis	rs8062405	0.964	rs72793809	ENSG00000278665.1	RP11-666O2.4	4.56	8.54e-06	0.00444	0.32	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821061	chr16:28599241~28601881:-
OV	cis	rs13230714	0.858	rs714429	ENSG00000204959.4	ARHGEF34P	-4.56	8.55e-06	0.00444	-0.39	-0.29	Breast cancer;	chr7:144456641	chr7:144272445~144286966:-
OV	cis	rs4591358	0.684	rs35306440	ENSG00000223466.1	AC064834.2	4.55	8.55e-06	0.00445	0.35	0.29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195507507	chr2:195533035~195538681:+
OV	cis	rs496547	0.719	rs1790189	ENSG00000255239.1	AP002954.6	4.55	8.55e-06	0.00445	0.33	0.29	Hip minimal joint space width;	chr11:118781617	chr11:118688039~118690600:-
OV	cis	rs73201462	1	rs34955225	ENSG00000277250.1	Metazoa_SRP	4.55	8.56e-06	0.00445	0.47	0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128106235	chr3:128673681~128674021:-
OV	cis	rs12073359	1	rs72694957	ENSG00000223945.2	RP11-458I7.1	-4.55	8.57e-06	0.00445	-0.47	-0.29	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150163093	chr1:150053864~150055034:+
OV	cis	rs7580658	0.963	rs12622436	ENSG00000236682.1	AC068282.3	-4.55	8.58e-06	0.00446	-0.38	-0.29	Protein C levels;	chr2:127324106	chr2:127389130~127400580:+
OV	cis	rs2070488	0.896	rs11914389	ENSG00000229589.1	ACVR2B-AS1	4.55	8.59e-06	0.00446	0.32	0.29	Electrocardiographic conduction measures;	chr3:38485724	chr3:38451027~38454820:-
OV	cis	rs4763879	0.778	rs2895989	ENSG00000256673.1	RP11-599J14.2	4.55	8.6e-06	0.00447	0.27	0.29	Type 1 diabetes;	chr12:9688735	chr12:9398355~9414851:-
OV	cis	rs7968440	1	rs2251603	ENSG00000272368.2	RP4-605O3.4	-4.55	8.6e-06	0.00447	-0.34	-0.29	Fibrinogen;	chr12:50655870	chr12:50112197~50165618:+
OV	cis	rs875971	0.545	rs801199	ENSG00000237310.1	GS1-124K5.4	-4.55	8.61e-06	0.00447	-0.34	-0.29	Aortic root size;	chr7:66560286	chr7:66493706~66495474:+
OV	cis	rs295490	0.748	rs77705963	ENSG00000272656.1	RP11-219D15.3	4.55	8.61e-06	0.00447	0.56	0.29	PR interval in Tripanosoma cruzi seropositivity;	chr3:139341843	chr3:139349024~139349371:-
OV	cis	rs812925	0.533	rs35507645	ENSG00000271889.1	RP11-493E12.1	4.55	8.62e-06	0.00447	0.33	0.29	Immature fraction of reticulocytes;	chr2:61169631	chr2:61151433~61162105:-
OV	cis	rs4964805	0.71	rs1866296	ENSG00000257681.1	RP11-341G23.4	4.55	8.62e-06	0.00447	0.32	0.29	Attention deficit hyperactivity disorder;	chr12:103793314	chr12:103746315~103768858:-
OV	cis	rs1075265	0.548	rs2542575	ENSG00000233266.1	HMGB1P31	4.55	8.62e-06	0.00447	0.37	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53821221	chr2:54051334~54051760:+
OV	cis	rs9884765	0.965	rs4508848	ENSG00000249049.1	RP11-763F8.1	-4.55	8.62e-06	0.00448	-0.32	-0.29	Breast cancer;	chr4:91694428	chr4:91319034~91325306:-
OV	cis	rs473651	0.74	rs502349	ENSG00000229915.1	AC016999.2	-4.55	8.63e-06	0.00448	-0.37	-0.29	Multiple system atrophy;	chr2:238409748	chr2:238427077~238427729:-
OV	cis	rs4664293	0.605	rs890095	ENSG00000226266.5	AC009961.3	4.55	8.64e-06	0.00449	0.35	0.29	Monocyte percentage of white cells;	chr2:159604708	chr2:159670708~159712435:-
OV	cis	rs992157	0.697	rs13384682	ENSG00000237281.1	CATIP-AS2	-4.55	8.66e-06	0.00449	-0.34	-0.29	Colorectal cancer;	chr2:218204414	chr2:218326889~218357966:-
OV	cis	rs992157	0.71	rs7569907	ENSG00000237281.1	CATIP-AS2	-4.55	8.66e-06	0.00449	-0.34	-0.29	Colorectal cancer;	chr2:218205828	chr2:218326889~218357966:-
OV	cis	rs7302981	0.741	rs76919525	ENSG00000257298.1	RP3-405J10.3	-4.55	8.66e-06	0.00449	-0.28	-0.29	Systolic blood pressure;	chr12:50147950	chr12:50185580~50191363:-
OV	cis	rs8054556	0.935	rs4788203	ENSG00000261367.1	RP11-455F5.4	-4.55	8.67e-06	0.0045	-0.32	-0.29	Autism spectrum disorder or schizophrenia;	chr16:29967506	chr16:30107675~30110541:+
OV	cis	rs7121800	0.603	rs4922835	ENSG00000254532.1	RP11-624D11.2	-4.55	8.67e-06	0.0045	-0.37	-0.29	Pit-and-Fissure caries;	chr11:30517771	chr11:30044058~30084343:-
OV	cis	rs7520050	0.778	rs2991985	ENSG00000281133.1	AL355480.3	4.55	8.68e-06	0.0045	0.33	0.29	Reticulocyte count;Red blood cell count;	chr1:45614858	chr1:45580892~45580996:-
OV	cis	rs7927592	0.731	rs7108376	ENSG00000212093.1	AP000807.1	-4.55	8.68e-06	0.0045	-0.34	-0.29	Total body bone mineral density;	chr11:68580402	chr11:68506083~68506166:-
OV	cis	rs7617773	0.817	rs3729577	ENSG00000228638.1	FCF1P2	-4.55	8.69e-06	0.00451	-0.37	-0.29	Coronary artery disease;	chr3:48187504	chr3:48290793~48291375:-
OV	cis	rs3091242	0.934	rs666686	ENSG00000224183.1	SDHDP6	-4.55	8.69e-06	0.00451	-0.38	-0.29	Erythrocyte sedimentation rate;	chr1:25393020	chr1:25294164~25294643:-
OV	cis	rs2999052	0.554	rs2659685	ENSG00000277250.1	Metazoa_SRP	4.55	8.69e-06	0.00451	0.39	0.29	Hypospadias;	chr3:128403553	chr3:128673681~128674021:-
OV	cis	rs4853012	1	rs2280643	ENSG00000257800.1	FNBP1P1	4.55	8.7e-06	0.00451	0.42	0.29	Gestational age at birth (maternal effect);	chr2:74131159	chr2:74120680~74123218:+
OV	cis	rs4853012	0.887	rs2280644	ENSG00000257800.1	FNBP1P1	4.55	8.7e-06	0.00451	0.42	0.29	Gestational age at birth (maternal effect);	chr2:74131284	chr2:74120680~74123218:+
OV	cis	rs4728142	0.604	rs4731536	ENSG00000275106.1	RP11-309L24.10	-4.55	8.7e-06	0.00451	-0.38	-0.29	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129000239	chr7:128952527~128953316:-
OV	cis	rs4713118	0.955	rs9468206	ENSG00000280107.1	AL022393.9	-4.55	8.73e-06	0.00452	-0.35	-0.29	Parkinson's disease;	chr6:27722674	chr6:28170845~28172521:+
OV	cis	rs4964805	0.594	rs3812805	ENSG00000257681.1	RP11-341G23.4	4.55	8.75e-06	0.00453	0.32	0.29	Attention deficit hyperactivity disorder;	chr12:103777094	chr12:103746315~103768858:-
OV	cis	rs473651	0.935	rs520765	ENSG00000229915.1	AC016999.2	-4.55	8.75e-06	0.00453	-0.36	-0.29	Multiple system atrophy;	chr2:238446071	chr2:238427077~238427729:-
OV	cis	rs9925964	0.748	rs11640961	ENSG00000278922.1	AC002310.14	-4.55	8.75e-06	0.00453	-0.33	-0.29	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30968497	chr16:30526918~30528294:+
OV	cis	rs8059260	0.668	rs74423828	ENSG00000274038.1	RP11-66H6.4	-4.55	8.76e-06	0.00454	-0.58	-0.29	Alcohol consumption over the past year;	chr16:10975574	chr16:11056556~11057034:+
OV	cis	rs6027072	0.59	rs6027091	ENSG00000196756.10	SNHG17	4.55	8.76e-06	0.00454	0.8	0.29	Modified Stumvoll Insulin Sensitivity Index (BMI interaction);	chr20:38658704	chr20:38420588~38435353:-
OV	cis	rs4128705	0.959	rs12186312	ENSG00000249049.1	RP11-763F8.1	-4.55	8.76e-06	0.00454	-0.36	-0.29	Amyotrophic lateral sclerosis (sporadic);	chr4:91368188	chr4:91319034~91325306:-
OV	cis	rs6991838	0.8	rs28547533	ENSG00000200714.1	Y_RNA	4.55	8.76e-06	0.00454	0.35	0.29	Intelligence (multi-trait analysis);	chr8:65559318	chr8:65592731~65592820:+
OV	cis	rs6991838	0.8	rs28626262	ENSG00000200714.1	Y_RNA	4.55	8.76e-06	0.00454	0.35	0.29	Intelligence (multi-trait analysis);	chr8:65559335	chr8:65592731~65592820:+
OV	cis	rs6991838	0.8	rs28709439	ENSG00000200714.1	Y_RNA	4.55	8.76e-06	0.00454	0.35	0.29	Intelligence (multi-trait analysis);	chr8:65559337	chr8:65592731~65592820:+
OV	cis	rs875971	0.862	rs4236208	ENSG00000236529.1	RP13-254B10.1	-4.55	8.77e-06	0.00454	-0.3	-0.29	Aortic root size;	chr7:66284091	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs10261398	ENSG00000236529.1	RP13-254B10.1	-4.55	8.77e-06	0.00454	-0.3	-0.29	Aortic root size;	chr7:66285177	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs10224872	ENSG00000236529.1	RP13-254B10.1	-4.55	8.77e-06	0.00454	-0.3	-0.29	Aortic root size;	chr7:66294786	chr7:65840212~65840596:+
OV	cis	rs9309473	0.948	rs11884776	ENSG00000163016.8	ALMS1P	4.55	8.78e-06	0.00454	0.32	0.29	Metabolite levels;	chr2:73519796	chr2:73644919~73685576:+
OV	cis	rs875971	1	rs55962648	ENSG00000236529.1	RP13-254B10.1	-4.55	8.78e-06	0.00455	-0.3	-0.29	Aortic root size;	chr7:66160764	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs11971949	ENSG00000236529.1	RP13-254B10.1	-4.55	8.78e-06	0.00455	-0.3	-0.29	Aortic root size;	chr7:66161027	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs2420168	ENSG00000236529.1	RP13-254B10.1	-4.55	8.78e-06	0.00455	-0.3	-0.29	Aortic root size;	chr7:66165644	chr7:65840212~65840596:+
OV	cis	rs7617773	0.638	rs7644414	ENSG00000228638.1	FCF1P2	-4.55	8.79e-06	0.00455	-0.36	-0.29	Coronary artery disease;	chr3:48257589	chr3:48290793~48291375:-
OV	cis	rs10510102	0.935	rs75339296	ENSG00000226864.1	ATE1-AS1	4.55	8.79e-06	0.00455	0.48	0.29	Breast cancer;	chr10:121859895	chr10:121928312~121951965:+
OV	cis	rs8062405	0.723	rs4788077	ENSG00000259982.1	CDC37P1	4.55	8.79e-06	0.00455	0.36	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558443	chr16:28700294~28701540:-
OV	cis	rs9595066	0.715	rs9567366	ENSG00000227258.4	SMIM2-AS1	-4.55	8.8e-06	0.00455	-0.5	-0.29	Schizophrenia;	chr13:44108837	chr13:44110451~44240517:+
OV	cis	rs2239620	1	rs9370134	ENSG00000216775.2	RP1-152L7.5	-4.55	8.8e-06	0.00455	-0.28	-0.29	LDL cholesterol levels;	chr6:52588810	chr6:52665148~52669155:+
OV	cis	rs875971	0.545	rs2420612	ENSG00000226824.5	RP4-756H11.3	-4.55	8.81e-06	0.00456	-0.35	-0.29	Aortic root size;	chr7:66536825	chr7:66654538~66669855:+
OV	cis	rs116095464	0.558	rs6878087	ENSG00000250848.1	CTD-2083E4.5	4.55	8.81e-06	0.00456	0.35	0.29	Breast cancer;	chr5:223002	chr5:288833~290321:-
OV	cis	rs7927771	0.524	rs10838732	ENSG00000280615.1	Y_RNA	4.55	8.81e-06	0.00456	0.32	0.29	Subjective well-being;	chr11:47586388	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs6485763	ENSG00000280615.1	Y_RNA	4.55	8.81e-06	0.00456	0.32	0.29	Subjective well-being;	chr11:47605750	chr11:47614898~47614994:-
OV	cis	rs1150668	0.796	rs728122	ENSG00000204709.4	LINC01556	4.55	8.82e-06	0.00456	0.33	0.29	Pubertal anthropometrics;	chr6:28431347	chr6:28943877~28944537:+
OV	cis	rs17301013	0.507	rs16846949	ENSG00000227373.4	RP11-160H22.5	4.55	8.83e-06	0.00456	0.4	0.29	Systemic lupus erythematosus;	chr1:174402071	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs7413513	ENSG00000227373.4	RP11-160H22.5	4.55	8.83e-06	0.00456	0.4	0.29	Systemic lupus erythematosus;	chr1:174403163	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs11799535	ENSG00000227373.4	RP11-160H22.5	4.55	8.83e-06	0.00456	0.4	0.29	Systemic lupus erythematosus;	chr1:174415790	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs72713591	ENSG00000227373.4	RP11-160H22.5	4.55	8.83e-06	0.00456	0.4	0.29	Systemic lupus erythematosus;	chr1:174442956	chr1:174115300~174160004:-
OV	cis	rs67311347	1	rs1466236	ENSG00000223797.4	ENTPD3-AS1	4.55	8.84e-06	0.00457	0.31	0.29	Renal cell carcinoma;	chr3:40420671	chr3:40313802~40453329:-
OV	cis	rs7104764	0.507	rs6598056	ENSG00000277290.1	RP11-326C3.16	4.55	8.85e-06	0.00457	0.32	0.29	Menarche (age at onset);	chr11:252283	chr11:243099~243483:-
OV	cis	rs13113518	0.812	rs13140173	ENSG00000223305.1	RN7SKP30	4.55	8.85e-06	0.00457	0.34	0.29	Height;	chr4:55527164	chr4:55540502~55540835:-
OV	cis	rs13113518	0.812	rs2035692	ENSG00000223305.1	RN7SKP30	4.55	8.85e-06	0.00457	0.34	0.29	Height;	chr4:55528801	chr4:55540502~55540835:-
OV	cis	rs13113518	0.812	rs4507426	ENSG00000223305.1	RN7SKP30	4.55	8.85e-06	0.00457	0.34	0.29	Height;	chr4:55529387	chr4:55540502~55540835:-
OV	cis	rs13113518	0.812	rs2035691	ENSG00000223305.1	RN7SKP30	4.55	8.85e-06	0.00457	0.34	0.29	Height;	chr4:55529786	chr4:55540502~55540835:-
OV	cis	rs13113518	0.756	rs11939652	ENSG00000223305.1	RN7SKP30	4.55	8.85e-06	0.00457	0.34	0.29	Height;	chr4:55532542	chr4:55540502~55540835:-
OV	cis	rs9287719	0.967	rs12464817	ENSG00000234818.1	AC092687.5	4.55	8.85e-06	0.00458	0.3	0.29	Prostate cancer;	chr2:10567086	chr2:10589166~10604830:+
OV	cis	rs858239	0.601	rs6969733	ENSG00000230042.1	AK3P3	-4.55	8.86e-06	0.00458	-0.3	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23128758	chr7:23129178~23129841:+
OV	cis	rs858239	0.601	rs4440529	ENSG00000230042.1	AK3P3	-4.55	8.86e-06	0.00458	-0.3	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23129132	chr7:23129178~23129841:+
OV	cis	rs9287719	0.967	rs4669593	ENSG00000234818.1	AC092687.5	4.55	8.88e-06	0.00458	0.3	0.29	Prostate cancer;	chr2:10561782	chr2:10589166~10604830:+
OV	cis	rs6991838	0.771	rs13282323	ENSG00000200714.1	Y_RNA	4.55	8.88e-06	0.00459	0.35	0.29	Intelligence (multi-trait analysis);	chr8:65560557	chr8:65592731~65592820:+
OV	cis	rs6991838	0.831	rs4394432	ENSG00000200714.1	Y_RNA	4.55	8.88e-06	0.00459	0.35	0.29	Intelligence (multi-trait analysis);	chr8:65560939	chr8:65592731~65592820:+
OV	cis	rs73201462	1	rs2811525	ENSG00000277250.1	Metazoa_SRP	-4.55	8.89e-06	0.00459	-0.42	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128280587	chr3:128673681~128674021:-
OV	cis	rs2919917	0.915	rs2953477	ENSG00000254352.1	RP11-578O24.2	4.55	8.9e-06	0.00459	0.34	0.29	Lymphocyte counts;	chr8:78712370	chr8:78723796~78724136:-
OV	cis	rs6788497	0.643	rs11718942	ENSG00000242551.2	POU5F1P6	4.55	8.9e-06	0.0046	0.58	0.29	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr3:128402552	chr3:128674735~128677005:-
OV	cis	rs6788497	0.643	rs11715947	ENSG00000242551.2	POU5F1P6	4.55	8.9e-06	0.0046	0.58	0.29	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr3:128403737	chr3:128674735~128677005:-
OV	cis	rs6788497	0.643	rs58233283	ENSG00000242551.2	POU5F1P6	4.55	8.9e-06	0.0046	0.58	0.29	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr3:128406849	chr3:128674735~128677005:-
OV	cis	rs116095464	0.558	rs10065239	ENSG00000250848.1	CTD-2083E4.5	-4.55	8.91e-06	0.0046	-0.38	-0.29	Breast cancer;	chr5:275173	chr5:288833~290321:-
OV	cis	rs10486158	0.582	rs887605	ENSG00000219545.8	UMAD1	-4.55	8.91e-06	0.0046	-0.45	-0.29	Bipolar disorder and schizophrenia;	chr7:7348302	chr7:7640711~8004059:+
OV	cis	rs4763879	0.739	rs7310460	ENSG00000278635.1	CTD-2318O12.1	4.55	8.92e-06	0.0046	0.24	0.29	Type 1 diabetes;	chr12:9688177	chr12:9415641~9416718:+
OV	cis	rs1555322	0.53	rs932562	ENSG00000279253.1	RP4-614O4.13	-4.55	8.93e-06	0.00461	-0.36	-0.29	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35262727~35264187:-
OV	cis	rs1555322	0.53	rs2275275	ENSG00000279253.1	RP4-614O4.13	-4.55	8.93e-06	0.00461	-0.36	-0.29	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35262727~35264187:-
OV	cis	rs10129255	0.5	rs2105989	ENSG00000223648.3	IGHV3-64	4.54	8.94e-06	0.00461	0.29	0.29	Kawasaki disease;	chr14:106682199	chr14:106643132~106658258:-
OV	cis	rs1075265	0.626	rs805412	ENSG00000233266.1	HMGB1P31	4.54	8.94e-06	0.00461	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53893683	chr2:54051334~54051760:+
OV	cis	rs875971	0.597	rs11763224	ENSG00000226824.5	RP4-756H11.3	-4.54	8.95e-06	0.00462	-0.35	-0.29	Aortic root size;	chr7:66518628	chr7:66654538~66669855:+
OV	cis	rs6772849	0.896	rs35535737	ENSG00000277250.1	Metazoa_SRP	-4.54	8.96e-06	0.00462	-0.34	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128664563	chr3:128673681~128674021:-
OV	cis	rs9291683	0.588	rs17247314	ENSG00000250413.1	RP11-448G15.1	-4.54	8.96e-06	0.00462	-0.33	-0.29	Bone mineral density;	chr4:10003119	chr4:10006482~10009725:+
OV	cis	rs8062405	0.723	rs35175818	ENSG00000278665.1	RP11-666O2.4	4.54	8.97e-06	0.00463	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597425	chr16:28599241~28601881:-
OV	cis	rs4728142	0.564	rs11767711	ENSG00000275106.1	RP11-309L24.10	-4.54	8.97e-06	0.00463	-0.37	-0.29	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129011778	chr7:128952527~128953316:-
OV	cis	rs8054556	1	rs3814884	ENSG00000261367.1	RP11-455F5.4	-4.54	8.98e-06	0.00463	-0.32	-0.29	Autism spectrum disorder or schizophrenia;	chr16:29983415	chr16:30107675~30110541:+
OV	cis	rs73201462	1	rs2955095	ENSG00000277250.1	Metazoa_SRP	4.54	8.99e-06	0.00463	0.43	0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128258822	chr3:128673681~128674021:-
OV	cis	rs9828933	0.752	rs832192	ENSG00000280620.1	SCAANT1	-4.54	8.99e-06	0.00463	-0.54	-0.29	Type 2 diabetes;	chr3:63867747	chr3:63911518~63911772:-
OV	cis	rs611744	0.647	rs13280487	ENSG00000253754.1	RP11-35G22.1	-4.54	9e-06	0.00464	-0.31	-0.29	Dupuytren's disease;	chr8:108258034	chr8:108226200~108227544:+
OV	cis	rs875971	0.502	rs11769702	ENSG00000226824.5	RP4-756H11.3	-4.54	9e-06	0.00464	-0.34	-0.29	Aortic root size;	chr7:66255529	chr7:66654538~66669855:+
OV	cis	rs7927592	0.763	rs7119422	ENSG00000212093.1	AP000807.1	-4.54	9.01e-06	0.00464	-0.33	-0.29	Total body bone mineral density;	chr11:68563686	chr11:68506083~68506166:-
OV	cis	rs739525	0.518	rs178268	ENSG00000236540.6	AC006547.13	4.54	9.01e-06	0.00464	0.3	0.29	Testicular germ cell tumor;	chr22:20975977	chr22:20058030~20070569:-
OV	cis	rs875971	0.861	rs801215	ENSG00000236529.1	RP13-254B10.1	-4.54	9.01e-06	0.00464	-0.3	-0.29	Aortic root size;	chr7:66546951	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs13536	ENSG00000236529.1	RP13-254B10.1	-4.54	9.01e-06	0.00464	-0.3	-0.29	Aortic root size;	chr7:66554203	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs801209	ENSG00000236529.1	RP13-254B10.1	-4.54	9.01e-06	0.00464	-0.3	-0.29	Aortic root size;	chr7:66554403	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs801206	ENSG00000236529.1	RP13-254B10.1	-4.54	9.01e-06	0.00464	-0.3	-0.29	Aortic root size;	chr7:66556979	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs13232191	ENSG00000236529.1	RP13-254B10.1	4.54	9.01e-06	0.00464	0.3	0.29	Aortic root size;	chr7:66521661	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs35378740	ENSG00000236529.1	RP13-254B10.1	4.54	9.01e-06	0.00464	0.3	0.29	Aortic root size;	chr7:66522725	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs10950043	ENSG00000236529.1	RP13-254B10.1	4.54	9.01e-06	0.00464	0.3	0.29	Aortic root size;	chr7:66523623	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs17747530	ENSG00000236529.1	RP13-254B10.1	4.54	9.01e-06	0.00464	0.3	0.29	Aortic root size;	chr7:66529742	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs13226170	ENSG00000236529.1	RP13-254B10.1	4.54	9.01e-06	0.00464	0.3	0.29	Aortic root size;	chr7:66534311	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs2420611	ENSG00000236529.1	RP13-254B10.1	4.54	9.01e-06	0.00464	0.3	0.29	Aortic root size;	chr7:66534333	chr7:65840212~65840596:+
OV	cis	rs1555322	0.53	rs2425043	ENSG00000279253.1	RP4-614O4.13	-4.54	9.02e-06	0.00464	-0.36	-0.29	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35262727~35264187:-
OV	cis	rs10740039	0.729	rs7091383	ENSG00000254271.1	RP11-131N11.4	4.54	9.02e-06	0.00465	0.36	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60676419	chr10:60734342~60741828:+
OV	cis	rs13315649	0.562	rs6439137	ENSG00000242551.2	POU5F1P6	-4.54	9.03e-06	0.00465	-0.37	-0.29	Sum eosinophil basophil counts;	chr3:128668107	chr3:128674735~128677005:-
OV	cis	rs4747241	0.556	rs4433500	ENSG00000226163.1	RP11-167P22.3	4.54	9.03e-06	0.00465	0.32	0.29	Heschl's gyrus morphology;	chr10:72309240	chr10:72501746~72502956:+
OV	cis	rs11096990	0.855	rs4974986	ENSG00000249207.1	RP11-360F5.1	4.54	9.04e-06	0.00465	0.33	0.29	Cognitive function;	chr4:39165308	chr4:39112677~39126818:-
OV	cis	rs875971	0.571	rs160641	ENSG00000236529.1	RP13-254B10.1	-4.54	9.04e-06	0.00465	-0.34	-0.29	Aortic root size;	chr7:66112359	chr7:65840212~65840596:+
OV	cis	rs7043114	0.525	rs10992374	ENSG00000281156.1	MIR3651	-4.54	9.04e-06	0.00466	-0.31	-0.29	Height;	chr9:92574045	chr9:92292458~92292547:-
OV	cis	rs8062405	0.755	rs4788076	ENSG00000259982.1	CDC37P1	4.54	9.07e-06	0.00467	0.35	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28700294~28701540:-
OV	cis	rs73201462	1	rs2811527	ENSG00000277250.1	Metazoa_SRP	-4.54	9.09e-06	0.00468	-0.42	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128275761	chr3:128673681~128674021:-
OV	cis	rs2243480	1	rs313813	ENSG00000226824.5	RP4-756H11.3	-4.54	9.1e-06	0.00468	-0.48	-0.29	Diabetic kidney disease;	chr7:66038513	chr7:66654538~66669855:+
OV	cis	rs7429990	0.864	rs1464614	ENSG00000229759.1	MRPS18AP1	4.54	9.12e-06	0.00469	0.29	0.29	Educational attainment (years of education);	chr3:47612885	chr3:48256350~48256938:-
OV	cis	rs875971	0.767	rs12668005	ENSG00000237310.1	GS1-124K5.4	4.54	9.14e-06	0.0047	0.3	0.29	Aortic root size;	chr7:66444034	chr7:66493706~66495474:+
OV	cis	rs13068223	0.74	rs344028	ENSG00000243926.1	TIPARP-AS1	4.54	9.15e-06	0.0047	0.28	0.29	Age-related hearing impairment (SNP x SNP interaction);	chr3:156747980	chr3:156671862~156674378:-
OV	cis	rs875971	1	rs1544549	ENSG00000236529.1	RP13-254B10.1	-4.54	9.15e-06	0.0047	-0.3	-0.29	Aortic root size;	chr7:66625676	chr7:65840212~65840596:+
OV	cis	rs17301013	0.507	rs10912822	ENSG00000227373.4	RP11-160H22.5	4.54	9.15e-06	0.00471	0.38	0.29	Systemic lupus erythematosus;	chr1:174624490	chr1:174115300~174160004:-
OV	cis	rs6471393	0.798	rs55680024	ENSG00000253848.1	RP11-10N23.5	4.54	9.16e-06	0.00471	0.38	0.29	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:93836533	chr8:93741193~93744534:+
OV	cis	rs7746199	0.736	rs13202291	ENSG00000220721.1	OR1F12	4.54	9.17e-06	0.00471	0.53	0.29	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:28073316~28074233:+
OV	cis	rs10181042	0.581	rs1177285	ENSG00000271889.1	RP11-493E12.1	4.54	9.17e-06	0.00471	0.33	0.29	Crohn's disease;	chr2:61123002	chr2:61151433~61162105:-
OV	cis	rs6788497	0.643	rs11705709	ENSG00000242551.2	POU5F1P6	-4.54	9.18e-06	0.00472	-0.54	-0.29	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr3:128401031	chr3:128674735~128677005:-
OV	cis	rs3758911	0.894	rs11212156	ENSG00000261098.1	RP11-819C21.1	-4.54	9.18e-06	0.00472	-0.28	-0.29	Coronary artery disease;	chr11:107323381	chr11:107312132~107316271:-
OV	cis	rs875971	0.83	rs6976714	ENSG00000237310.1	GS1-124K5.4	4.54	9.19e-06	0.00472	0.29	0.29	Aortic root size;	chr7:66426474	chr7:66493706~66495474:+
OV	cis	rs9828933	0.752	rs73117082	ENSG00000280620.1	SCAANT1	4.54	9.2e-06	0.00473	0.53	0.29	Type 2 diabetes;	chr3:63961889	chr3:63911518~63911772:-
OV	cis	rs13113518	0.729	rs11133377	ENSG00000223305.1	RN7SKP30	4.54	9.2e-06	0.00473	0.35	0.29	Height;	chr4:55413708	chr4:55540502~55540835:-
OV	cis	rs673078	0.607	rs7309484	ENSG00000275759.1	RP11-131L12.3	-4.54	9.21e-06	0.00473	-0.46	-0.29	Glucose homeostasis traits;	chr12:118400833	chr12:118428281~118428870:+
OV	cis	rs796364	0.806	rs203766	ENSG00000232732.8	AC073043.1	4.54	9.22e-06	0.00474	0.44	0.29	Schizophrenia;	chr2:200037949	chr2:199867396~199911159:-
OV	cis	rs796364	0.806	rs203765	ENSG00000232732.8	AC073043.1	4.54	9.22e-06	0.00474	0.44	0.29	Schizophrenia;	chr2:200038297	chr2:199867396~199911159:-
OV	cis	rs796364	0.806	rs188102	ENSG00000232732.8	AC073043.1	4.54	9.22e-06	0.00474	0.44	0.29	Schizophrenia;	chr2:200038466	chr2:199867396~199911159:-
OV	cis	rs7116641	0.961	rs12577642	ENSG00000246250.2	RP11-613D13.5	4.54	9.23e-06	0.00474	0.33	0.29	Coronary artery disease;	chr11:43706984	chr11:43829709~43880726:-
OV	cis	rs7116641	0.961	rs56130800	ENSG00000246250.2	RP11-613D13.5	4.54	9.23e-06	0.00474	0.33	0.29	Coronary artery disease;	chr11:43708303	chr11:43829709~43880726:-
OV	cis	rs7116641	0.922	rs1878767	ENSG00000246250.2	RP11-613D13.5	4.54	9.23e-06	0.00474	0.33	0.29	Coronary artery disease;	chr11:43708437	chr11:43829709~43880726:-
OV	cis	rs1113500	0.614	rs1343192	ENSG00000226822.1	RP11-356N1.2	4.54	9.23e-06	0.00474	0.35	0.29	Growth-regulated protein alpha levels;	chr1:108071266	chr1:108071482~108074519:+
OV	cis	rs875971	0.545	rs1547529	ENSG00000226824.5	RP4-756H11.3	-4.54	9.27e-06	0.00476	-0.35	-0.29	Aortic root size;	chr7:66258859	chr7:66654538~66669855:+
OV	cis	rs7259376	0.875	rs1091182	ENSG00000269742.1	BNIP3P29	-4.54	9.27e-06	0.00476	-0.34	-0.29	Menopause (age at onset);	chr19:22292820	chr19:22065828~22066398:-
OV	cis	rs1062177	0.901	rs1549622	ENSG00000213433.5	RPLP1P6	-4.54	9.27e-06	0.00476	-0.36	-0.29	Preschool internalizing problems;	chr5:151886488	chr5:151765859~151766378:-
OV	cis	rs881375	0.631	rs10739577	ENSG00000226752.6	PSMD5-AS1	-4.54	9.27e-06	0.00476	-0.3	-0.29	Rheumatoid arthritis;	chr9:120906576	chr9:120824828~120854385:+
OV	cis	rs67311347	1	rs12638199	ENSG00000223797.4	ENTPD3-AS1	4.54	9.28e-06	0.00476	0.31	0.29	Renal cell carcinoma;	chr3:40433794	chr3:40313802~40453329:-
OV	cis	rs73201462	1	rs2955096	ENSG00000277250.1	Metazoa_SRP	4.54	9.28e-06	0.00476	0.42	0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128259023	chr3:128673681~128674021:-
OV	cis	rs73201462	0.908	rs2955098	ENSG00000277250.1	Metazoa_SRP	-4.54	9.28e-06	0.00476	-0.42	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128260658	chr3:128673681~128674021:-
OV	cis	rs73201462	0.901	rs2811400	ENSG00000277250.1	Metazoa_SRP	-4.54	9.28e-06	0.00476	-0.42	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128269024	chr3:128673681~128674021:-
OV	cis	rs2919917	0.628	rs1036751	ENSG00000254352.1	RP11-578O24.2	-4.54	9.28e-06	0.00476	-0.39	-0.29	Lymphocyte counts;	chr8:78729671	chr8:78723796~78724136:-
OV	cis	rs2919917	0.628	rs894222	ENSG00000254352.1	RP11-578O24.2	-4.54	9.28e-06	0.00476	-0.39	-0.29	Lymphocyte counts;	chr8:78737034	chr8:78723796~78724136:-
OV	cis	rs7587476	1	rs3768707	ENSG00000229267.2	AC072062.1	-4.54	9.28e-06	0.00476	-0.37	-0.29	Neuroblastoma;	chr2:214780411	chr2:214810229~214963274:+
OV	cis	rs875971	0.545	rs6950988	ENSG00000237310.1	GS1-124K5.4	4.54	9.29e-06	0.00476	0.34	0.29	Aortic root size;	chr7:66511428	chr7:66493706~66495474:+
OV	cis	rs8059260	0.736	rs12149904	ENSG00000274038.1	RP11-66H6.4	-4.54	9.29e-06	0.00477	-0.57	-0.29	Alcohol consumption over the past year;	chr16:10991789	chr16:11056556~11057034:+
OV	cis	rs7302981	1	rs7302981	ENSG00000272368.2	RP4-605O3.4	-4.54	9.3e-06	0.00477	-0.33	-0.29	Systolic blood pressure;	chr12:50144032	chr12:50112197~50165618:+
OV	cis	rs1790761	0.505	rs4320958	ENSG00000184224.3	C11orf72	-4.54	9.31e-06	0.00478	-0.33	-0.29	Mean corpuscular volume;	chr11:67542863	chr11:67602880~67606706:-
OV	cis	rs875971	0.825	rs1000464	ENSG00000236529.1	RP13-254B10.1	-4.53	9.33e-06	0.00478	-0.3	-0.29	Aortic root size;	chr7:66312922	chr7:65840212~65840596:+
OV	cis	rs9309473	0.898	rs28879089	ENSG00000163016.8	ALMS1P	4.53	9.33e-06	0.00478	0.33	0.29	Metabolite levels;	chr2:73585759	chr2:73644919~73685576:+
OV	cis	rs9309473	0.948	rs7603647	ENSG00000163016.8	ALMS1P	4.53	9.33e-06	0.00478	0.33	0.29	Metabolite levels;	chr2:73590111	chr2:73644919~73685576:+
OV	cis	rs9309473	1	rs7558944	ENSG00000163016.8	ALMS1P	4.53	9.34e-06	0.00479	0.33	0.29	Metabolite levels;	chr2:73583782	chr2:73644919~73685576:+
OV	cis	rs9309473	1	rs13432605	ENSG00000163016.8	ALMS1P	4.53	9.34e-06	0.00479	0.33	0.29	Metabolite levels;	chr2:73583854	chr2:73644919~73685576:+
OV	cis	rs9309473	0.848	rs9750915	ENSG00000163016.8	ALMS1P	4.53	9.34e-06	0.00479	0.33	0.29	Metabolite levels;	chr2:73584753	chr2:73644919~73685576:+
OV	cis	rs4591358	1	rs7571836	ENSG00000223466.1	AC064834.2	-4.53	9.34e-06	0.00479	-0.36	-0.29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195475768	chr2:195533035~195538681:+
OV	cis	rs858239	0.536	rs6961109	ENSG00000230042.1	AK3P3	-4.53	9.34e-06	0.00479	-0.31	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23212794	chr7:23129178~23129841:+
OV	cis	rs13113518	0.812	rs2412648	ENSG00000223305.1	RN7SKP30	4.53	9.34e-06	0.00479	0.33	0.29	Height;	chr4:55454900	chr4:55540502~55540835:-
OV	cis	rs13113518	0.812	rs12512737	ENSG00000223305.1	RN7SKP30	4.53	9.34e-06	0.00479	0.33	0.29	Height;	chr4:55454938	chr4:55540502~55540835:-
OV	cis	rs13113518	0.812	rs13125984	ENSG00000223305.1	RN7SKP30	4.53	9.34e-06	0.00479	0.33	0.29	Height;	chr4:55455102	chr4:55540502~55540835:-
OV	cis	rs453301	0.686	rs13252797	ENSG00000253893.2	FAM85B	-4.53	9.37e-06	0.0048	-0.31	-0.29	Joint mobility (Beighton score);	chr8:9003920	chr8:8167819~8226614:-
OV	cis	rs732765	1	rs10134885	ENSG00000258439.1	RP11-173A8.2	-4.53	9.38e-06	0.0048	-0.38	-0.29	Non-small cell lung cancer;	chr14:74906772	chr14:74658049~74658590:+
OV	cis	rs16863064	0.66	rs1007308	ENSG00000279891.1	FLJ42393	-4.53	9.41e-06	0.00482	-0.27	-0.29	Schizophrenia;	chr3:188171935	chr3:188178543~188180812:+
OV	cis	rs11903757	1	rs4477849	ENSG00000281467.1	Clostridiales-1	4.53	9.41e-06	0.00482	0.46	0.29	Colorectal cancer;	chr2:191716203	chr2:191699476~191699631:-
OV	cis	rs67340775	0.541	rs200973	ENSG00000219392.1	RP1-265C24.5	-4.53	9.41e-06	0.00482	-0.39	-0.29	Lung cancer in ever smokers;	chr6:27890643	chr6:28115628~28116551:+
OV	cis	rs7580658	0.963	rs6732279	ENSG00000236682.1	AC068282.3	-4.53	9.42e-06	0.00482	-0.38	-0.29	Protein C levels;	chr2:127331964	chr2:127389130~127400580:+
OV	cis	rs7043114	0.525	rs4744134	ENSG00000281156.1	MIR3651	4.53	9.42e-06	0.00482	0.32	0.29	Height;	chr9:92484551	chr9:92292458~92292547:-
OV	cis	rs181553	0.664	rs1965843	ENSG00000266696.1	RP11-30L3.2	4.53	9.43e-06	0.00483	0.34	0.29	Hip circumference adjusted for BMI;	chr18:49155947	chr18:49205912~49208781:+
OV	cis	rs17301013	0.507	rs74128393	ENSG00000227373.4	RP11-160H22.5	4.53	9.44e-06	0.00483	0.4	0.29	Systemic lupus erythematosus;	chr1:174407961	chr1:174115300~174160004:-
OV	cis	rs1569175	0.522	rs2347286	ENSG00000232732.8	AC073043.1	4.53	9.44e-06	0.00483	0.49	0.29	Response to treatment for acute lymphoblastic leukemia;	chr2:200081670	chr2:199867396~199911159:-
OV	cis	rs4747241	0.771	rs7075993	ENSG00000226163.1	RP11-167P22.3	4.53	9.45e-06	0.00484	0.33	0.29	Heschl's gyrus morphology;	chr10:72294832	chr10:72501746~72502956:+
OV	cis	rs875971	0.545	rs6970498	ENSG00000226824.5	RP4-756H11.3	-4.53	9.45e-06	0.00484	-0.35	-0.29	Aortic root size;	chr7:66275908	chr7:66654538~66669855:+
OV	cis	rs7771547	0.855	rs9368942	ENSG00000240733.3	RN7SL502P	4.53	9.47e-06	0.00484	0.31	0.29	Platelet distribution width;	chr6:36598736	chr6:36450912~36451201:-
OV	cis	rs957448	0.539	rs9643346	ENSG00000253704.1	RP11-267M23.4	4.53	9.47e-06	0.00484	0.37	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94601587	chr8:94553722~94569745:+
OV	cis	rs1150668	0.83	rs2023493	ENSG00000204709.4	LINC01556	4.53	9.49e-06	0.00485	0.33	0.29	Pubertal anthropometrics;	chr6:28432385	chr6:28943877~28944537:+
OV	cis	rs1538970	0.961	rs4660854	ENSG00000280836.1	AL355480.1	-4.53	9.49e-06	0.00485	-0.39	-0.29	Platelet count;	chr1:45388415	chr1:45581219~45581321:-
OV	cis	rs881375	0.678	rs10760125	ENSG00000226752.6	PSMD5-AS1	-4.53	9.51e-06	0.00486	-0.3	-0.29	Rheumatoid arthritis;	chr9:120900312	chr9:120824828~120854385:+
OV	cis	rs17301013	0.507	rs12076548	ENSG00000227373.4	RP11-160H22.5	-4.53	9.52e-06	0.00487	-0.39	-0.29	Systemic lupus erythematosus;	chr1:174479005	chr1:174115300~174160004:-
OV	cis	rs875971	0.862	rs4718383	ENSG00000236529.1	RP13-254B10.1	-4.53	9.53e-06	0.00487	-0.3	-0.29	Aortic root size;	chr7:66643422	chr7:65840212~65840596:+
OV	cis	rs13113518	0.812	rs12500456	ENSG00000223305.1	RN7SKP30	4.53	9.53e-06	0.00487	0.34	0.29	Height;	chr4:55561053	chr4:55540502~55540835:-
OV	cis	rs13113518	0.783	rs2171618	ENSG00000223305.1	RN7SKP30	4.53	9.53e-06	0.00487	0.34	0.29	Height;	chr4:55564241	chr4:55540502~55540835:-
OV	cis	rs2836974	0.563	rs6517522	ENSG00000237373.1	BRWD1-IT1	-4.53	9.53e-06	0.00487	-0.31	-0.29	Cognitive function;	chr21:39181919	chr21:39217093~39219805:-
OV	cis	rs881375	0.678	rs9886724	ENSG00000226752.6	PSMD5-AS1	-4.53	9.54e-06	0.00487	-0.3	-0.29	Rheumatoid arthritis;	chr9:120902741	chr9:120824828~120854385:+
OV	cis	rs992157	0.71	rs13026485	ENSG00000237281.1	CATIP-AS2	4.53	9.54e-06	0.00488	0.33	0.29	Colorectal cancer;	chr2:218193261	chr2:218326889~218357966:-
OV	cis	rs11096990	0.855	rs2566170	ENSG00000249207.1	RP11-360F5.1	4.53	9.55e-06	0.00488	0.34	0.29	Cognitive function;	chr4:39150757	chr4:39112677~39126818:-
OV	cis	rs514406	0.893	rs2897561	ENSG00000206627.1	RNU6-969P	4.53	9.56e-06	0.00488	0.3	0.29	Monocyte count;	chr1:52923075	chr1:52805108~52805212:-
OV	cis	rs514406	0.893	rs1242330	ENSG00000206627.1	RNU6-969P	4.53	9.56e-06	0.00488	0.3	0.29	Monocyte count;	chr1:52931170	chr1:52805108~52805212:-
OV	cis	rs514406	0.825	rs1242328	ENSG00000206627.1	RNU6-969P	4.53	9.56e-06	0.00488	0.3	0.29	Monocyte count;	chr1:52931197	chr1:52805108~52805212:-
OV	cis	rs1150668	0.764	rs9368565	ENSG00000204709.4	LINC01556	-4.53	9.57e-06	0.00489	-0.33	-0.29	Pubertal anthropometrics;	chr6:28377433	chr6:28943877~28944537:+
OV	cis	rs1150668	0.796	rs1052215	ENSG00000204709.4	LINC01556	-4.53	9.57e-06	0.00489	-0.33	-0.29	Pubertal anthropometrics;	chr6:28380381	chr6:28943877~28944537:+
OV	cis	rs4713118	0.824	rs7759217	ENSG00000219392.1	RP1-265C24.5	-4.53	9.57e-06	0.00489	-0.33	-0.29	Parkinson's disease;	chr6:27762684	chr6:28115628~28116551:+
OV	cis	rs4713118	0.784	rs9468219	ENSG00000219392.1	RP1-265C24.5	-4.53	9.57e-06	0.00489	-0.33	-0.29	Parkinson's disease;	chr6:27763976	chr6:28115628~28116551:+
OV	cis	rs9467773	0.62	rs2451741	ENSG00000261584.1	RP11-457M11.5	4.53	9.57e-06	0.00489	0.32	0.29	Intelligence (multi-trait analysis);	chr6:26629176	chr6:26686241~26687964:+
OV	cis	rs8054556	0.967	rs7193532	ENSG00000261367.1	RP11-455F5.4	-4.53	9.57e-06	0.00489	-0.32	-0.29	Autism spectrum disorder or schizophrenia;	chr16:29951481	chr16:30107675~30110541:+
OV	cis	rs8054556	0.967	rs11150576	ENSG00000261367.1	RP11-455F5.4	-4.53	9.57e-06	0.00489	-0.32	-0.29	Autism spectrum disorder or schizophrenia;	chr16:29954175	chr16:30107675~30110541:+
OV	cis	rs875971	0.862	rs1860469	ENSG00000236529.1	RP13-254B10.1	-4.53	9.57e-06	0.00489	-0.3	-0.29	Aortic root size;	chr7:66641888	chr7:65840212~65840596:+
OV	cis	rs7200543	1	rs55727637	ENSG00000270580.4	PKD1P6	4.53	9.59e-06	0.0049	0.3	0.29	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15051395	chr16:15104723~15131601:-
OV	cis	rs525592	1	rs525592	ENSG00000212093.1	AP000807.1	4.53	9.6e-06	0.0049	0.33	0.29	Bone mineral density;	chr11:68427636	chr11:68506083~68506166:-
OV	cis	rs73201462	1	rs2811537	ENSG00000277250.1	Metazoa_SRP	4.53	9.61e-06	0.0049	0.42	0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128269081	chr3:128673681~128674021:-
OV	cis	rs73201462	0.831	rs2999036	ENSG00000277250.1	Metazoa_SRP	-4.53	9.61e-06	0.0049	-0.44	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128301858	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2811390	ENSG00000277250.1	Metazoa_SRP	-4.53	9.61e-06	0.0049	-0.44	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128302638	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2811391	ENSG00000277250.1	Metazoa_SRP	-4.53	9.61e-06	0.0049	-0.44	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128303525	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2811393	ENSG00000277250.1	Metazoa_SRP	-4.53	9.61e-06	0.0049	-0.44	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128305156	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2037965	ENSG00000277250.1	Metazoa_SRP	-4.53	9.61e-06	0.0049	-0.44	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128306201	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2811397	ENSG00000277250.1	Metazoa_SRP	-4.53	9.61e-06	0.0049	-0.44	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128308394	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs6805582	ENSG00000277250.1	Metazoa_SRP	4.53	9.61e-06	0.0049	0.44	0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128310165	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs6805621	ENSG00000277250.1	Metazoa_SRP	4.53	9.61e-06	0.0049	0.44	0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128310361	chr3:128673681~128674021:-
OV	cis	rs28735056	0.609	rs4799099	ENSG00000261126.6	RP11-795F19.1	4.53	9.61e-06	0.00491	0.3	0.29	Schizophrenia;	chr18:79879585	chr18:80046900~80095482:+
OV	cis	rs7043114	0.507	rs10761154	ENSG00000281156.1	MIR3651	-4.53	9.63e-06	0.00491	-0.32	-0.29	Height;	chr9:92381804	chr9:92292458~92292547:-
OV	cis	rs7043114	0.525	rs1053446	ENSG00000281156.1	MIR3651	-4.53	9.63e-06	0.00491	-0.32	-0.29	Height;	chr9:92384479	chr9:92292458~92292547:-
OV	cis	rs7927592	0.731	rs11228275	ENSG00000212093.1	AP000807.1	-4.53	9.64e-06	0.00492	-0.33	-0.29	Total body bone mineral density;	chr11:68536512	chr11:68506083~68506166:-
OV	cis	rs73186030	0.92	rs17265703	ENSG00000272758.4	RP11-299J3.8	-4.53	9.66e-06	0.00493	-0.33	-0.29	Serum parathyroid hormone levels;	chr3:122329797	chr3:122416207~122443180:+
OV	cis	rs858239	0.571	rs6953020	ENSG00000230042.1	AK3P3	-4.53	9.67e-06	0.00493	-0.3	-0.29	Cerebrospinal fluid biomarker levels;	chr7:23132513	chr7:23129178~23129841:+
OV	cis	rs11649653	0.502	rs62057232	ENSG00000278922.1	AC002310.14	-4.53	9.68e-06	0.00493	-0.33	-0.29	Triglycerides;	chr16:30809545	chr16:30526918~30528294:+
OV	cis	rs875971	0.651	rs2420596	ENSG00000237310.1	GS1-124K5.4	4.53	9.68e-06	0.00493	0.29	0.29	Aortic root size;	chr7:66450996	chr7:66493706~66495474:+
OV	cis	rs875971	0.52	rs2420597	ENSG00000237310.1	GS1-124K5.4	4.53	9.68e-06	0.00493	0.29	0.29	Aortic root size;	chr7:66450999	chr7:66493706~66495474:+
OV	cis	rs8113142	0.943	rs12459719	ENSG00000267243.4	AC005307.3	-4.53	9.69e-06	0.00494	-0.54	-0.29	Femoral neck bone geometry and menarche (age at onset);	chr19:28533247	chr19:28435388~28727777:-
OV	cis	rs8113142	0.943	rs73016948	ENSG00000267243.4	AC005307.3	-4.53	9.69e-06	0.00494	-0.54	-0.29	Femoral neck bone geometry and menarche (age at onset);	chr19:28533740	chr19:28435388~28727777:-
OV	cis	rs8113142	0.943	rs112856667	ENSG00000267243.4	AC005307.3	-4.53	9.69e-06	0.00494	-0.54	-0.29	Femoral neck bone geometry and menarche (age at onset);	chr19:28533945	chr19:28435388~28727777:-
OV	cis	rs8113142	1	rs73016957	ENSG00000267243.4	AC005307.3	-4.53	9.69e-06	0.00494	-0.54	-0.29	Femoral neck bone geometry and menarche (age at onset);	chr19:28538056	chr19:28435388~28727777:-
OV	cis	rs8113142	1	rs73016960	ENSG00000267243.4	AC005307.3	-4.53	9.69e-06	0.00494	-0.54	-0.29	Femoral neck bone geometry and menarche (age at onset);	chr19:28538112	chr19:28435388~28727777:-
OV	cis	rs8054556	0.669	rs12931955	ENSG00000261367.1	RP11-455F5.4	-4.53	9.69e-06	0.00494	-0.31	-0.29	Autism spectrum disorder or schizophrenia;	chr16:30001745	chr16:30107675~30110541:+
OV	cis	rs6788497	0.643	rs11720784	ENSG00000242551.2	POU5F1P6	4.53	9.7e-06	0.00494	0.57	0.29	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr3:128388296	chr3:128674735~128677005:-
OV	cis	rs607987	0.756	rs1765135	ENSG00000254532.1	RP11-624D11.2	4.53	9.71e-06	0.00495	0.35	0.29	Body mass index;	chr11:30355235	chr11:30044058~30084343:-
OV	cis	rs6772849	1	rs6798431	ENSG00000242551.2	POU5F1P6	-4.53	9.71e-06	0.00495	-0.34	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128584530	chr3:128674735~128677005:-
OV	cis	rs6772849	1	rs9836257	ENSG00000242551.2	POU5F1P6	-4.53	9.71e-06	0.00495	-0.34	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128584640	chr3:128674735~128677005:-
OV	cis	rs7246657	0.765	rs10402455	ENSG00000226686.6	LINC01535	-4.53	9.72e-06	0.00495	-0.48	-0.29	Coronary artery calcification;	chr19:37237805	chr19:37251912~37265535:+
OV	cis	rs7605378	1	rs7605378	ENSG00000232732.8	AC073043.1	-4.53	9.72e-06	0.00495	-0.35	-0.29	Osteoporosis;	chr2:199812203	chr2:199867396~199911159:-
OV	cis	rs7605378	1	rs10194076	ENSG00000232732.8	AC073043.1	-4.53	9.72e-06	0.00495	-0.35	-0.29	Osteoporosis;	chr2:199812940	chr2:199867396~199911159:-
OV	cis	rs67311347	1	rs10510708	ENSG00000223797.4	ENTPD3-AS1	4.53	9.72e-06	0.00495	0.3	0.29	Renal cell carcinoma;	chr3:40363279	chr3:40313802~40453329:-
OV	cis	rs10246939	0.505	rs892354	ENSG00000228775.6	WEE2-AS1	4.53	9.73e-06	0.00496	0.32	0.29	Bitter taste perception;	chr7:141844934	chr7:141704338~141738346:-
OV	cis	rs8062405	1	rs3888190	ENSG00000278665.1	RP11-666O2.4	4.53	9.73e-06	0.00496	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28878165	chr16:28599241~28601881:-
OV	cis	rs1979679	0.837	rs2881860	ENSG00000278733.1	RP11-425D17.1	4.53	9.73e-06	0.00496	0.34	0.29	Ossification of the posterior longitudinal ligament of the spine;	chr12:28363268	chr12:28185625~28186190:-
OV	cis	rs4713118	0.662	rs9357060	ENSG00000226314.6	ZNF192P1	-4.53	9.73e-06	0.00496	-0.38	-0.29	Parkinson's disease;	chr6:28056708	chr6:28161781~28169594:+
OV	cis	rs4713118	0.662	rs9468271	ENSG00000226314.6	ZNF192P1	-4.53	9.73e-06	0.00496	-0.38	-0.29	Parkinson's disease;	chr6:28056792	chr6:28161781~28169594:+
OV	cis	rs3733585	0.699	rs7437120	ENSG00000250413.1	RP11-448G15.1	4.52	9.76e-06	0.00497	0.32	0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:9966059	chr4:10006482~10009725:+
OV	cis	rs881375	0.967	rs7875829	ENSG00000226752.6	PSMD5-AS1	-4.52	9.76e-06	0.00497	-0.32	-0.29	Rheumatoid arthritis;	chr9:120898120	chr9:120824828~120854385:+
OV	cis	rs881375	0.867	rs10818484	ENSG00000226752.6	PSMD5-AS1	-4.52	9.76e-06	0.00497	-0.32	-0.29	Rheumatoid arthritis;	chr9:120898916	chr9:120824828~120854385:+
OV	cis	rs9287719	0.781	rs6714413	ENSG00000234818.1	AC092687.5	4.52	9.76e-06	0.00497	0.32	0.29	Prostate cancer;	chr2:10618733	chr2:10589166~10604830:+
OV	cis	rs9287719	0.746	rs6742448	ENSG00000234818.1	AC092687.5	4.52	9.76e-06	0.00497	0.32	0.29	Prostate cancer;	chr2:10619000	chr2:10589166~10604830:+
OV	cis	rs9287719	0.781	rs6714795	ENSG00000234818.1	AC092687.5	4.52	9.76e-06	0.00497	0.32	0.29	Prostate cancer;	chr2:10619008	chr2:10589166~10604830:+
OV	cis	rs9287719	0.781	rs6732671	ENSG00000234818.1	AC092687.5	4.52	9.76e-06	0.00497	0.32	0.29	Prostate cancer;	chr2:10619023	chr2:10589166~10604830:+
OV	cis	rs9287719	0.753	rs2018512	ENSG00000234818.1	AC092687.5	4.52	9.76e-06	0.00497	0.32	0.29	Prostate cancer;	chr2:10619153	chr2:10589166~10604830:+
OV	cis	rs67311347	0.577	rs2887951	ENSG00000223797.4	ENTPD3-AS1	4.52	9.77e-06	0.00497	0.3	0.29	Renal cell carcinoma;	chr3:40240613	chr3:40313802~40453329:-
OV	cis	rs1797885	0.934	rs709165	ENSG00000251774.1	RNU6-377P	4.52	9.78e-06	0.00498	0.27	0.29	Immature fraction of reticulocytes;	chr3:12472625	chr3:12514706~12514807:+
OV	cis	rs9880211	1	rs9837158	ENSG00000239213.4	NCK1-AS1	4.52	9.78e-06	0.00498	0.36	0.29	Height;Body mass index;	chr3:136354321	chr3:136841726~136862054:-
OV	cis	rs6788497	0.643	rs60672471	ENSG00000242551.2	POU5F1P6	4.52	9.78e-06	0.00498	0.52	0.29	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr3:128406875	chr3:128674735~128677005:-
OV	cis	rs2243480	1	rs313814	ENSG00000226824.5	RP4-756H11.3	-4.52	9.8e-06	0.00498	-0.48	-0.29	Diabetic kidney disease;	chr7:66038306	chr7:66654538~66669855:+
OV	cis	rs1075265	1	rs1075265	ENSG00000233266.1	HMGB1P31	4.52	9.8e-06	0.00498	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54127790	chr2:54051334~54051760:+
OV	cis	rs17301013	0.507	rs3118988	ENSG00000227373.4	RP11-160H22.5	-4.52	9.8e-06	0.00499	-0.37	-0.29	Systemic lupus erythematosus;	chr1:174819245	chr1:174115300~174160004:-
OV	cis	rs2243480	1	rs160652	ENSG00000226824.5	RP4-756H11.3	-4.52	9.81e-06	0.00499	-0.48	-0.29	Diabetic kidney disease;	chr7:66073444	chr7:66654538~66669855:+
OV	cis	rs10829156	0.699	rs7911922	ENSG00000225527.1	RP11-383B4.4	-4.52	9.81e-06	0.00499	-0.36	-0.29	Sudden cardiac arrest;	chr10:18542768	chr10:18531849~18533336:-
OV	cis	rs9847710	0.733	rs2581790	ENSG00000242142.1	SERBP1P3	4.52	9.81e-06	0.00499	0.35	0.29	Ulcerative colitis;	chr3:53067764	chr3:53064283~53065091:-
OV	cis	rs6772849	1	rs9839508	ENSG00000242551.2	POU5F1P6	4.52	9.82e-06	0.00499	0.34	0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128591951	chr3:128674735~128677005:-
OV	cis	rs783540	0.934	rs10400906	ENSG00000278603.1	RP13-608F4.5	4.52	9.84e-06	0.005	0.32	0.29	Schizophrenia;	chr15:82628387	chr15:82472203~82472426:+
OV	cis	rs7617773	0.817	rs79310258	ENSG00000228638.1	FCF1P2	-4.52	9.84e-06	0.005	-0.37	-0.29	Coronary artery disease;	chr3:48218177	chr3:48290793~48291375:-
OV	cis	rs1979679	0.842	rs34043014	ENSG00000278733.1	RP11-425D17.1	4.52	9.84e-06	0.00501	0.34	0.29	Ossification of the posterior longitudinal ligament of the spine;	chr12:28171359	chr12:28185625~28186190:-
OV	cis	rs1979679	0.842	rs10492370	ENSG00000278733.1	RP11-425D17.1	4.52	9.84e-06	0.00501	0.34	0.29	Ossification of the posterior longitudinal ligament of the spine;	chr12:28171900	chr12:28185625~28186190:-
OV	cis	rs7043114	0.563	rs10820988	ENSG00000281156.1	MIR3651	-4.52	9.85e-06	0.00501	-0.31	-0.29	Height;	chr9:92554726	chr9:92292458~92292547:-
OV	cis	rs7043114	0.544	rs4302908	ENSG00000281156.1	MIR3651	-4.52	9.85e-06	0.00501	-0.31	-0.29	Height;	chr9:92559359	chr9:92292458~92292547:-
OV	cis	rs14027	0.921	rs10109901	ENSG00000279347.1	RP11-85I17.2	-4.52	9.86e-06	0.00501	-0.3	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119817287	chr8:119838736~119840385:-
OV	cis	rs14027	0.921	rs10109951	ENSG00000279347.1	RP11-85I17.2	-4.52	9.86e-06	0.00501	-0.3	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119817519	chr8:119838736~119840385:-
OV	cis	rs14027	0.883	rs4871642	ENSG00000279347.1	RP11-85I17.2	-4.52	9.86e-06	0.00501	-0.3	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119818813	chr8:119838736~119840385:-
OV	cis	rs14027	0.921	rs2634	ENSG00000279347.1	RP11-85I17.2	-4.52	9.86e-06	0.00501	-0.3	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119819869	chr8:119838736~119840385:-
OV	cis	rs14027	0.921	rs4870955	ENSG00000279347.1	RP11-85I17.2	-4.52	9.86e-06	0.00501	-0.3	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119821929	chr8:119838736~119840385:-
OV	cis	rs14027	0.921	rs34718068	ENSG00000279347.1	RP11-85I17.2	-4.52	9.86e-06	0.00501	-0.3	-0.29	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119822368	chr8:119838736~119840385:-
OV	cis	rs6893300	0.961	rs11741570	ENSG00000254035.1	RP11-281O15.4	4.52	9.88e-06	0.00502	0.35	0.29	Resting heart rate;	chr5:179781909	chr5:178969390~178990116:+
OV	cis	rs6893300	0.961	rs11744616	ENSG00000254035.1	RP11-281O15.4	4.52	9.88e-06	0.00502	0.35	0.29	Resting heart rate;	chr5:179782112	chr5:178969390~178990116:+
OV	cis	rs11159086	1	rs4903233	ENSG00000270000.1	RP3-449M8.9	4.52	9.88e-06	0.00502	0.44	0.29	Advanced glycation end-product levels;	chr14:74497291	chr14:74471930~74472360:-
OV	cis	rs992157	0.775	rs7559428	ENSG00000261338.2	RP11-378A13.1	-4.52	9.89e-06	0.00503	-0.34	-0.29	Colorectal cancer;	chr2:218285515	chr2:218255319~218257366:+
OV	cis	rs473651	0.935	rs35080527	ENSG00000229915.1	AC016999.2	-4.52	9.9e-06	0.00503	-0.37	-0.29	Multiple system atrophy;	chr2:238442746	chr2:238427077~238427729:-
OV	cis	rs7555523	0.887	rs4657471	ENSG00000224358.1	RP11-466F5.8	-4.52	9.9e-06	0.00503	-0.4	-0.29	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165717636	chr1:165768929~165775176:+
OV	cis	rs7200543	0.583	rs4985149	ENSG00000270580.4	PKD1P6	4.52	9.94e-06	0.00505	0.3	0.29	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15053481	chr16:15104723~15131601:-
OV	cis	rs1555322	0.53	rs2425042	ENSG00000269202.1	RP4-614O4.12	-4.52	9.95e-06	0.00505	-0.34	-0.29	Attention deficit hyperactivity disorder;	chr20:35278092	chr20:35201747~35203288:-
OV	cis	rs1555322	0.53	rs7004	ENSG00000269202.1	RP4-614O4.12	-4.52	9.95e-06	0.00505	-0.34	-0.29	Attention deficit hyperactivity disorder;	chr20:35278950	chr20:35201747~35203288:-
OV	cis	rs4865169	0.691	rs1056364	ENSG00000269949.1	RP11-738E22.3	-4.52	9.96e-06	0.00505	-0.34	-0.29	Breast cancer;	chr4:57023511	chr4:56960927~56961373:-
OV	cis	rs1075265	0.901	rs2048749	ENSG00000233266.1	HMGB1P31	4.52	9.97e-06	0.00506	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54130483	chr2:54051334~54051760:+
OV	cis	rs11096990	0.855	rs2566172	ENSG00000249207.1	RP11-360F5.1	4.52	9.97e-06	0.00506	0.34	0.29	Cognitive function;	chr4:39150943	chr4:39112677~39126818:-
OV	cis	rs1508798	0.539	rs3798092	ENSG00000250786.1	SNHG18	-4.52	9.99e-06	0.00507	-0.36	-0.29	Coronary artery disease;	chr5:9541581	chr5:9546200~9550609:+
OV	cis	rs7771547	0.821	rs10947613	ENSG00000240733.3	RN7SL502P	4.52	1e-05	0.00507	0.32	0.29	Platelet distribution width;	chr6:36604563	chr6:36450912~36451201:-
OV	cis	rs7771547	0.821	rs7755461	ENSG00000240733.3	RN7SL502P	4.52	1e-05	0.00507	0.32	0.29	Platelet distribution width;	chr6:36607055	chr6:36450912~36451201:-
OV	cis	rs2919917	0.628	rs2717540	ENSG00000254352.1	RP11-578O24.2	4.52	1e-05	0.00507	0.38	0.29	Lymphocyte counts;	chr8:78710128	chr8:78723796~78724136:-
OV	cis	rs6460942	0.749	rs79221452	ENSG00000226690.5	AC005281.1	4.52	1e-05	0.00507	0.55	0.29	Coronary artery disease;	chr7:12163271	chr7:12496429~12541910:+
OV	cis	rs4713118	0.662	rs149901	ENSG00000226314.6	ZNF192P1	-4.52	1e-05	0.00508	-0.39	-0.29	Parkinson's disease;	chr6:27997725	chr6:28161781~28169594:+
OV	cis	rs4713118	0.662	rs464312	ENSG00000226314.6	ZNF192P1	-4.52	1e-05	0.00508	-0.39	-0.29	Parkinson's disease;	chr6:27999813	chr6:28161781~28169594:+
OV	cis	rs4713118	0.662	rs469228	ENSG00000226314.6	ZNF192P1	-4.52	1e-05	0.00508	-0.39	-0.29	Parkinson's disease;	chr6:28002926	chr6:28161781~28169594:+
OV	cis	rs4713118	0.54	rs469227	ENSG00000226314.6	ZNF192P1	-4.52	1e-05	0.00508	-0.39	-0.29	Parkinson's disease;	chr6:28002927	chr6:28161781~28169594:+
OV	cis	rs7043114	0.525	rs7850432	ENSG00000281156.1	MIR3651	-4.52	1e-05	0.00508	-0.32	-0.29	Height;	chr9:92368228	chr9:92292458~92292547:-
OV	cis	rs10829156	0.947	rs10764661	ENSG00000225527.1	RP11-383B4.4	-4.52	1e-05	0.00508	-0.4	-0.29	Sudden cardiac arrest;	chr10:18659018	chr10:18531849~18533336:-
OV	cis	rs1044826	1	rs747346	ENSG00000250433.1	CLSTN2-AS1	-4.52	1e-05	0.00508	-0.33	-0.29	Obesity-related traits;	chr3:139513072	chr3:140505611~140508789:-
OV	cis	rs73201462	1	rs2955091	ENSG00000277250.1	Metazoa_SRP	-4.52	1e-05	0.00509	-0.45	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128252518	chr3:128673681~128674021:-
OV	cis	rs7160336	0.713	rs7161293	ENSG00000259065.1	RP5-1021I20.1	4.52	1e-05	0.00509	0.34	0.29	Blood protein levels;	chr14:74031655	chr14:73787360~73803270:+
OV	cis	rs13217239	0.646	rs7451149	ENSG00000261584.1	RP11-457M11.5	-4.52	1e-05	0.00509	-0.32	-0.29	Schizophrenia;	chr6:27089739	chr6:26686241~26687964:+
OV	cis	rs4713118	0.513	rs149955	ENSG00000280107.1	AL022393.9	-4.52	1.01e-05	0.0051	-0.34	-0.29	Parkinson's disease;	chr6:28068447	chr6:28170845~28172521:+
OV	cis	rs10510102	0.872	rs78369301	ENSG00000226864.1	ATE1-AS1	4.52	1.01e-05	0.0051	0.48	0.29	Breast cancer;	chr10:121858527	chr10:121928312~121951965:+
OV	cis	rs10510102	0.935	rs10466217	ENSG00000226864.1	ATE1-AS1	4.52	1.01e-05	0.0051	0.48	0.29	Breast cancer;	chr10:121860362	chr10:121928312~121951965:+
OV	cis	rs1075265	0.704	rs805410	ENSG00000233266.1	HMGB1P31	4.52	1.01e-05	0.0051	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53893360	chr2:54051334~54051760:+
OV	cis	rs7429990	0.833	rs3755638	ENSG00000229759.1	MRPS18AP1	-4.52	1.01e-05	0.0051	-0.3	-0.29	Educational attainment (years of education);	chr3:47580841	chr3:48256350~48256938:-
OV	cis	rs1075265	0.568	rs2542577	ENSG00000233266.1	HMGB1P31	4.52	1.01e-05	0.00511	0.36	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53822111	chr2:54051334~54051760:+
OV	cis	rs73201462	1	rs2811396	ENSG00000277250.1	Metazoa_SRP	-4.52	1.01e-05	0.00512	-0.41	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128268513	chr3:128673681~128674021:-
OV	cis	rs67311347	0.524	rs11129869	ENSG00000223797.4	ENTPD3-AS1	4.52	1.01e-05	0.00512	0.3	0.29	Renal cell carcinoma;	chr3:40218247	chr3:40313802~40453329:-
OV	cis	rs7617773	0.746	rs6796343	ENSG00000228638.1	FCF1P2	-4.52	1.01e-05	0.00512	-0.37	-0.29	Coronary artery disease;	chr3:48240531	chr3:48290793~48291375:-
OV	cis	rs2015599	0.623	rs3782510	ENSG00000275476.1	RP11-996F15.4	4.52	1.01e-05	0.00513	0.36	0.29	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29277397~29277882:-
OV	cis	rs875971	0.545	rs221986	ENSG00000236529.1	RP13-254B10.1	-4.52	1.01e-05	0.00513	-0.34	-0.29	Aortic root size;	chr7:66105323	chr7:65840212~65840596:+
OV	cis	rs10924970	0.649	rs10925128	ENSG00000236863.2	RPL23AP23	4.52	1.01e-05	0.00514	0.3	0.29	Asthma;	chr1:235215452	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs12022924	ENSG00000236863.2	RPL23AP23	4.52	1.01e-05	0.00514	0.3	0.29	Asthma;	chr1:235216832	chr1:235295865~235296335:+
OV	cis	rs73201462	1	rs7374227	ENSG00000277250.1	Metazoa_SRP	4.52	1.02e-05	0.00514	0.43	0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128282672	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2811522	ENSG00000277250.1	Metazoa_SRP	-4.52	1.02e-05	0.00514	-0.43	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128292580	chr3:128673681~128674021:-
OV	cis	rs1790761	0.587	rs4930431	ENSG00000184224.3	C11orf72	-4.52	1.02e-05	0.00514	-0.34	-0.29	Mean corpuscular volume;	chr11:67526837	chr11:67602880~67606706:-
OV	cis	rs7927592	0.513	rs630225	ENSG00000212093.1	AP000807.1	4.52	1.02e-05	0.00514	0.33	0.29	Total body bone mineral density;	chr11:68427143	chr11:68506083~68506166:-
OV	cis	rs9287719	0.649	rs11684537	ENSG00000243819.4	RN7SL832P	4.52	1.02e-05	0.00514	0.29	0.29	Prostate cancer;	chr2:10594706	chr2:10690344~10692099:+
OV	cis	rs172166	0.694	rs1150666	ENSG00000280107.1	AL022393.9	-4.52	1.02e-05	0.00514	-0.35	-0.29	Cardiac Troponin-T levels;	chr6:28156150	chr6:28170845~28172521:+
OV	cis	rs12456021	0.723	rs8083368	ENSG00000267787.4	RP11-35G9.5	4.52	1.02e-05	0.00515	0.36	0.29	Multiple sclerosis;	chr18:58552358	chr18:57639455~57738044:+
OV	cis	rs8177876	0.822	rs12443549	ENSG00000261838.4	RP11-303E16.6	-4.51	1.02e-05	0.00515	-0.61	-0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81070596	chr16:81069854~81076598:+
OV	cis	rs2999052	0.805	rs1735546	ENSG00000242551.2	POU5F1P6	4.51	1.02e-05	0.00515	0.37	0.29	Hypospadias;	chr3:128356555	chr3:128674735~128677005:-
OV	cis	rs72615157	0.634	rs74774557	ENSG00000242294.5	STAG3L5P	4.51	1.02e-05	0.00515	0.27	0.29	Lung function (FEV1/FVC);	chr7:100212802	chr7:100336079~100351900:+
OV	cis	rs875971	0.545	rs2420456	ENSG00000226824.5	RP4-756H11.3	-4.51	1.02e-05	0.00516	-0.34	-0.29	Aortic root size;	chr7:66280619	chr7:66654538~66669855:+
OV	cis	rs7968440	1	rs7977690	ENSG00000257298.1	RP3-405J10.3	4.51	1.02e-05	0.00516	0.28	0.29	Fibrinogen;	chr12:50736631	chr12:50185580~50191363:-
OV	cis	rs4845570	1	rs17568246	ENSG00000203288.3	RP11-98D18.9	-4.51	1.02e-05	0.00516	-0.5	-0.29	Coronary artery disease;	chr1:151763980	chr1:151790804~151794402:+
OV	cis	rs6052484	0.523	rs11087634	ENSG00000229539.1	RP11-119B16.2	4.51	1.02e-05	0.00516	0.3	0.29	Sense of smell;	chr20:4340734	chr20:3888239~3888868:-
OV	cis	rs4713118	0.824	rs742046	ENSG00000226314.6	ZNF192P1	-4.51	1.02e-05	0.00517	-0.35	-0.29	Parkinson's disease;	chr6:27771475	chr6:28161781~28169594:+
OV	cis	rs4763879	0.634	rs12424826	ENSG00000256673.1	RP11-599J14.2	4.51	1.02e-05	0.00517	0.27	0.29	Type 1 diabetes;	chr12:9701981	chr12:9398355~9414851:-
OV	cis	rs17301013	0.507	rs2064150	ENSG00000227373.4	RP11-160H22.5	-4.51	1.02e-05	0.00517	-0.39	-0.29	Systemic lupus erythematosus;	chr1:174339289	chr1:174115300~174160004:-
OV	cis	rs9291683	0.566	rs13115776	ENSG00000250413.1	RP11-448G15.1	-4.51	1.02e-05	0.00518	-0.34	-0.29	Bone mineral density;	chr4:10038565	chr4:10006482~10009725:+
OV	cis	rs796364	0.865	rs769948	ENSG00000232732.8	AC073043.1	-4.51	1.02e-05	0.00518	-0.43	-0.29	Schizophrenia;	chr2:199863752	chr2:199867396~199911159:-
OV	cis	rs796364	1	rs769949	ENSG00000232732.8	AC073043.1	-4.51	1.02e-05	0.00518	-0.43	-0.29	Schizophrenia;	chr2:199864835	chr2:199867396~199911159:-
OV	cis	rs796364	1	rs769950	ENSG00000232732.8	AC073043.1	-4.51	1.02e-05	0.00518	-0.43	-0.29	Schizophrenia;	chr2:199865305	chr2:199867396~199911159:-
OV	cis	rs796364	0.951	rs769952	ENSG00000232732.8	AC073043.1	-4.51	1.02e-05	0.00518	-0.43	-0.29	Schizophrenia;	chr2:199869645	chr2:199867396~199911159:-
OV	cis	rs796364	0.906	rs281784	ENSG00000232732.8	AC073043.1	-4.51	1.02e-05	0.00518	-0.43	-0.29	Schizophrenia;	chr2:199885026	chr2:199867396~199911159:-
OV	cis	rs796364	0.95	rs188146	ENSG00000232732.8	AC073043.1	-4.51	1.02e-05	0.00518	-0.43	-0.29	Schizophrenia;	chr2:199885721	chr2:199867396~199911159:-
OV	cis	rs796364	1	rs281783	ENSG00000232732.8	AC073043.1	-4.51	1.02e-05	0.00518	-0.43	-0.29	Schizophrenia;	chr2:199886859	chr2:199867396~199911159:-
OV	cis	rs1823913	0.599	rs17511445	ENSG00000227542.1	AC092614.2	-4.51	1.03e-05	0.00518	-0.32	-0.29	Obesity-related traits;	chr2:191279831	chr2:191229165~191246172:-
OV	cis	rs9925964	0.933	rs9929899	ENSG00000278922.1	AC002310.14	-4.51	1.03e-05	0.00519	-0.32	-0.29	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31051380	chr16:30526918~30528294:+
OV	cis	rs9925964	0.933	rs4889530	ENSG00000278922.1	AC002310.14	-4.51	1.03e-05	0.00519	-0.32	-0.29	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31054597	chr16:30526918~30528294:+
OV	cis	rs1858037	0.867	rs871974	ENSG00000234255.7	AC012370.3	-4.51	1.03e-05	0.00519	-0.32	-0.29	Rheumatoid arthritis;	chr2:65330153	chr2:65439888~65456571:-
OV	cis	rs2562784	0.587	rs2562763	ENSG00000235370.6	DNM1P51	4.51	1.03e-05	0.00519	0.53	0.29	Height;	chr15:83596468	chr15:84398316~84411701:-
OV	cis	rs7617773	0.779	rs77957078	ENSG00000228638.1	FCF1P2	-4.51	1.03e-05	0.00519	-0.37	-0.29	Coronary artery disease;	chr3:48289796	chr3:48290793~48291375:-
OV	cis	rs6558530	0.932	rs6558531	ENSG00000253982.1	CTD-2336O2.1	4.51	1.03e-05	0.00519	0.33	0.29	Systolic blood pressure;	chr8:1759400	chr8:1761990~1764502:-
OV	cis	rs10246939	0.529	rs60165685	ENSG00000228775.6	WEE2-AS1	4.51	1.03e-05	0.00519	0.31	0.29	Bitter taste perception;	chr7:141861190	chr7:141704338~141738346:-
OV	cis	rs67180937	0.7	rs4282830	ENSG00000272750.1	RP11-378J18.8	-4.51	1.03e-05	0.00519	-0.31	-0.29	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222738618	chr1:222658867~222661512:-
OV	cis	rs7726839	0.54	rs56325086	ENSG00000271781.1	CTD-2589H19.6	-4.51	1.03e-05	0.00519	-0.45	-0.29	Obesity-related traits;	chr5:640613	chr5:675826~676616:+
OV	cis	rs7726839	0.54	rs3792720	ENSG00000271781.1	CTD-2589H19.6	-4.51	1.03e-05	0.00519	-0.45	-0.29	Obesity-related traits;	chr5:642913	chr5:675826~676616:+
OV	cis	rs7043114	0.525	rs9299404	ENSG00000281156.1	MIR3651	4.51	1.03e-05	0.0052	0.32	0.29	Height;	chr9:92408056	chr9:92292458~92292547:-
OV	cis	rs172166	0.611	rs203883	ENSG00000280107.1	AL022393.9	-4.51	1.03e-05	0.00521	-0.34	-0.29	Cardiac Troponin-T levels;	chr6:28110578	chr6:28170845~28172521:+
OV	cis	rs7927592	0.956	rs2155730	ENSG00000212093.1	AP000807.1	4.51	1.03e-05	0.00521	0.36	0.29	Total body bone mineral density;	chr11:68562006	chr11:68506083~68506166:-
OV	cis	rs11083475	1	rs3786839	ENSG00000267892.1	CTD-2540F13.2	4.51	1.03e-05	0.00521	0.32	0.29	Heart rate;	chr19:38691925	chr19:38738284~38739863:+
OV	cis	rs7580658	0.963	rs4233583	ENSG00000236682.1	AC068282.3	-4.51	1.03e-05	0.00522	-0.37	-0.29	Protein C levels;	chr2:127302492	chr2:127389130~127400580:+
OV	cis	rs180730	0.519	rs1470696	ENSG00000251609.2	SETP12	4.51	1.03e-05	0.00522	0.33	0.29	Fasting plasma glucose;	chr4:120921412	chr4:120895494~120897083:-
OV	cis	rs11673344	0.73	rs826314	ENSG00000226686.6	LINC01535	4.51	1.03e-05	0.00522	0.36	0.29	Obesity-related traits;	chr19:36959533	chr19:37251912~37265535:+
OV	cis	rs1075265	0.84	rs2884254	ENSG00000233266.1	HMGB1P31	4.51	1.03e-05	0.00522	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53979326	chr2:54051334~54051760:+
OV	cis	rs6772849	0.775	rs12486377	ENSG00000242551.2	POU5F1P6	-4.51	1.03e-05	0.00523	-0.34	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128696010	chr3:128674735~128677005:-
OV	cis	rs71520386	0.632	rs12535331	ENSG00000228649.7	AC005682.5	4.51	1.04e-05	0.00523	0.34	0.29	Fibrinogen levels;	chr7:22838485	chr7:22854178~22861579:+
OV	cis	rs801193	0.569	rs10950050	ENSG00000236529.1	RP13-254B10.1	4.51	1.04e-05	0.00524	0.29	0.29	Aortic root size;	chr7:66774601	chr7:65840212~65840596:+
OV	cis	rs2015599	0.563	rs11050168	ENSG00000257176.2	RP11-996F15.2	4.51	1.04e-05	0.00524	0.35	0.29	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29280418~29317848:-
OV	cis	rs2898290	0.5	rs11998678	ENSG00000255046.1	RP11-297N6.4	4.51	1.04e-05	0.00524	0.35	0.29	Systolic blood pressure;	chr8:11972641	chr8:11797928~11802568:-
OV	cis	rs11673344	0.764	rs474017	ENSG00000226686.6	LINC01535	4.51	1.04e-05	0.00525	0.35	0.29	Obesity-related traits;	chr19:36963217	chr19:37251912~37265535:+
OV	cis	rs17023223	0.537	rs10923756	ENSG00000231365.4	RP11-418J17.1	-4.51	1.04e-05	0.00525	-0.39	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119132025	chr1:119140396~119275973:+
OV	cis	rs796364	0.625	rs4673837	ENSG00000232732.8	AC073043.1	-4.51	1.04e-05	0.00526	-0.39	-0.29	Schizophrenia;	chr2:200266436	chr2:199867396~199911159:-
OV	cis	rs73201462	1	rs2811534	ENSG00000277250.1	Metazoa_SRP	-4.51	1.04e-05	0.00526	-0.42	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128272265	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2811533	ENSG00000277250.1	Metazoa_SRP	-4.51	1.04e-05	0.00526	-0.42	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128272886	chr3:128673681~128674021:-
OV	cis	rs73201462	0.901	rs2811532	ENSG00000277250.1	Metazoa_SRP	-4.51	1.04e-05	0.00526	-0.42	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128273327	chr3:128673681~128674021:-
OV	cis	rs73201462	0.908	rs2811531	ENSG00000277250.1	Metazoa_SRP	-4.51	1.04e-05	0.00526	-0.42	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128273652	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2955100	ENSG00000277250.1	Metazoa_SRP	-4.51	1.04e-05	0.00526	-0.42	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128274482	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2999062	ENSG00000277250.1	Metazoa_SRP	-4.51	1.04e-05	0.00526	-0.42	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128274763	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2811526	ENSG00000277250.1	Metazoa_SRP	-4.51	1.04e-05	0.00526	-0.42	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128276875	chr3:128673681~128674021:-
OV	cis	rs73201462	0.908	rs2811373	ENSG00000277250.1	Metazoa_SRP	-4.51	1.04e-05	0.00526	-0.42	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128278586	chr3:128673681~128674021:-
OV	cis	rs73201462	0.831	rs2811524	ENSG00000277250.1	Metazoa_SRP	-4.51	1.04e-05	0.00526	-0.42	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128281112	chr3:128673681~128674021:-
OV	cis	rs73201462	0.908	rs2811386	ENSG00000277250.1	Metazoa_SRP	-4.51	1.04e-05	0.00526	-0.42	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128281172	chr3:128673681~128674021:-
OV	cis	rs73201462	0.908	rs4593050	ENSG00000277250.1	Metazoa_SRP	-4.51	1.04e-05	0.00526	-0.42	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128285688	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs6439124	ENSG00000277250.1	Metazoa_SRP	-4.51	1.04e-05	0.00526	-0.42	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128288623	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs7373998	ENSG00000277250.1	Metazoa_SRP	-4.51	1.04e-05	0.00526	-0.42	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128289380	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2955101	ENSG00000277250.1	Metazoa_SRP	-4.51	1.04e-05	0.00526	-0.42	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128290769	chr3:128673681~128674021:-
OV	cis	rs73201462	0.908	rs2811520	ENSG00000277250.1	Metazoa_SRP	-4.51	1.04e-05	0.00526	-0.42	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128293434	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2811519	ENSG00000277250.1	Metazoa_SRP	-4.51	1.04e-05	0.00526	-0.42	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128294033	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2811518	ENSG00000277250.1	Metazoa_SRP	-4.51	1.04e-05	0.00526	-0.42	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128294802	chr3:128673681~128674021:-
OV	cis	rs8054556	0.633	rs12928610	ENSG00000261367.1	RP11-455F5.4	-4.51	1.05e-05	0.00527	-0.31	-0.29	Autism spectrum disorder or schizophrenia;	chr16:30004701	chr16:30107675~30110541:+
OV	cis	rs17301013	0.606	rs1407127	ENSG00000227373.4	RP11-160H22.5	-4.51	1.05e-05	0.00528	-0.39	-0.29	Systemic lupus erythematosus;	chr1:174119548	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs56152378	ENSG00000227373.4	RP11-160H22.5	4.51	1.05e-05	0.00528	0.39	0.29	Systemic lupus erythematosus;	chr1:174106480	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs4652179	ENSG00000227373.4	RP11-160H22.5	4.51	1.05e-05	0.00528	0.39	0.29	Systemic lupus erythematosus;	chr1:174107185	chr1:174115300~174160004:-
OV	cis	rs17301013	0.581	rs17353198	ENSG00000227373.4	RP11-160H22.5	4.51	1.05e-05	0.00528	0.39	0.29	Systemic lupus erythematosus;	chr1:174107439	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs17350991	ENSG00000227373.4	RP11-160H22.5	4.51	1.05e-05	0.00528	0.39	0.29	Systemic lupus erythematosus;	chr1:174114330	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs57407575	ENSG00000227373.4	RP11-160H22.5	4.51	1.05e-05	0.00528	0.39	0.29	Systemic lupus erythematosus;	chr1:174115504	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs6656491	ENSG00000227373.4	RP11-160H22.5	4.51	1.05e-05	0.00528	0.39	0.29	Systemic lupus erythematosus;	chr1:174127524	chr1:174115300~174160004:-
OV	cis	rs17301013	0.581	rs72711457	ENSG00000227373.4	RP11-160H22.5	4.51	1.05e-05	0.00528	0.39	0.29	Systemic lupus erythematosus;	chr1:174135385	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs6668008	ENSG00000227373.4	RP11-160H22.5	4.51	1.05e-05	0.00528	0.39	0.29	Systemic lupus erythematosus;	chr1:174138752	chr1:174115300~174160004:-
OV	cis	rs1979679	0.879	rs1581630	ENSG00000278733.1	RP11-425D17.1	-4.51	1.05e-05	0.00528	-0.35	-0.29	Ossification of the posterior longitudinal ligament of the spine;	chr12:28466378	chr12:28185625~28186190:-
OV	cis	rs853679	0.517	rs16893666	ENSG00000226314.6	ZNF192P1	4.51	1.05e-05	0.00528	0.38	0.29	Depression;	chr6:28086929	chr6:28161781~28169594:+
OV	cis	rs62244186	0.715	rs11130032	ENSG00000214820.3	MPRIPP1	4.51	1.05e-05	0.00528	0.26	0.29	Depressive symptoms;	chr3:44662591	chr3:44579938~44581026:-
OV	cis	rs1584120	0.57	rs17459026	ENSG00000274885.1	RP11-268P4.6	-4.51	1.05e-05	0.00528	-0.33	-0.29	Pelvic organ prolapse (moderate/severe);	chr12:23107065	chr12:22638464~22638943:+
OV	cis	rs4908768	1	rs11121203	ENSG00000228423.2	RP4-633I8.4	4.51	1.05e-05	0.00528	0.35	0.29	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8588181	chr1:8805860~8807051:-
OV	cis	rs1113500	0.933	rs10494089	ENSG00000226822.1	RP11-356N1.2	4.51	1.05e-05	0.00528	0.34	0.29	Growth-regulated protein alpha levels;	chr1:108084073	chr1:108071482~108074519:+
OV	cis	rs1113500	0.933	rs745795	ENSG00000226822.1	RP11-356N1.2	4.51	1.05e-05	0.00528	0.34	0.29	Growth-regulated protein alpha levels;	chr1:108086723	chr1:108071482~108074519:+
OV	cis	rs1113500	0.933	rs2077259	ENSG00000226822.1	RP11-356N1.2	4.51	1.05e-05	0.00528	0.34	0.29	Growth-regulated protein alpha levels;	chr1:108086929	chr1:108071482~108074519:+
OV	cis	rs1113500	0.933	rs3909076	ENSG00000226822.1	RP11-356N1.2	4.51	1.05e-05	0.00528	0.34	0.29	Growth-regulated protein alpha levels;	chr1:108089138	chr1:108071482~108074519:+
OV	cis	rs1113500	0.933	rs3893034	ENSG00000226822.1	RP11-356N1.2	4.51	1.05e-05	0.00528	0.34	0.29	Growth-regulated protein alpha levels;	chr1:108089556	chr1:108071482~108074519:+
OV	cis	rs1113500	0.933	rs12132785	ENSG00000226822.1	RP11-356N1.2	4.51	1.05e-05	0.00528	0.34	0.29	Growth-regulated protein alpha levels;	chr1:108090461	chr1:108071482~108074519:+
OV	cis	rs992157	0.731	rs1399132	ENSG00000261338.2	RP11-378A13.1	4.51	1.05e-05	0.00529	0.34	0.29	Colorectal cancer;	chr2:218295047	chr2:218255319~218257366:+
OV	cis	rs4763879	0.634	rs2098298	ENSG00000256673.1	RP11-599J14.2	4.51	1.05e-05	0.00529	0.27	0.29	Type 1 diabetes;	chr12:9707473	chr12:9398355~9414851:-
OV	cis	rs4763879	0.594	rs12427310	ENSG00000256673.1	RP11-599J14.2	4.51	1.05e-05	0.00529	0.27	0.29	Type 1 diabetes;	chr12:9707539	chr12:9398355~9414851:-
OV	cis	rs992157	0.796	rs55680399	ENSG00000261338.2	RP11-378A13.1	4.51	1.05e-05	0.00529	0.34	0.29	Colorectal cancer;	chr2:218295898	chr2:218255319~218257366:+
OV	cis	rs4869313	0.846	rs11135484	ENSG00000247121.5	CTD-2260A17.2	-4.51	1.05e-05	0.00529	-0.34	-0.29	Pediatric autoimmune diseases;	chr5:96886185	chr5:96814028~96935809:-
OV	cis	rs4964805	0.58	rs10861097	ENSG00000257681.1	RP11-341G23.4	4.51	1.05e-05	0.0053	0.32	0.29	Attention deficit hyperactivity disorder;	chr12:103776696	chr12:103746315~103768858:-
OV	cis	rs4908768	0.581	rs2784739	ENSG00000228423.2	RP4-633I8.4	4.51	1.05e-05	0.0053	0.33	0.29	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8437498	chr1:8805860~8807051:-
OV	cis	rs4718428	1	rs4718428	ENSG00000222364.1	RNU6-96P	-4.51	1.05e-05	0.0053	-0.33	-0.29	Corneal structure;	chr7:66956459	chr7:66395191~66395286:+
OV	cis	rs881375	0.654	rs10760126	ENSG00000226752.6	PSMD5-AS1	-4.51	1.05e-05	0.00531	-0.3	-0.29	Rheumatoid arthritis;	chr9:120900340	chr9:120824828~120854385:+
OV	cis	rs881375	0.678	rs4836834	ENSG00000226752.6	PSMD5-AS1	-4.51	1.05e-05	0.00531	-0.3	-0.29	Rheumatoid arthritis;	chr9:120903623	chr9:120824828~120854385:+
OV	cis	rs11673344	0.764	rs16971873	ENSG00000226686.6	LINC01535	4.51	1.05e-05	0.00531	0.37	0.29	Obesity-related traits;	chr19:36978521	chr19:37251912~37265535:+
OV	cis	rs62012628	0.527	rs12438008	ENSG00000261143.1	ADAMTS7P3	-4.51	1.05e-05	0.00531	-0.32	-0.29	Diastolic blood pressure;	chr15:78792338	chr15:77976042~77993057:+
OV	cis	rs9291683	0.53	rs4235346	ENSG00000250413.1	RP11-448G15.1	4.51	1.06e-05	0.00531	0.31	0.29	Bone mineral density;	chr4:9943672	chr4:10006482~10009725:+
OV	cis	rs4934494	0.911	rs7098233	ENSG00000240996.1	RP11-80H5.7	4.51	1.06e-05	0.00531	0.37	0.29	Red blood cell count;	chr10:89663111	chr10:89694295~89697928:-
OV	cis	rs8062405	0.755	rs56272201	ENSG00000259982.1	CDC37P1	4.51	1.06e-05	0.00531	0.36	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569364	chr16:28700294~28701540:-
OV	cis	rs8062405	0.755	rs62034355	ENSG00000259982.1	CDC37P1	4.51	1.06e-05	0.00531	0.36	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28569717	chr16:28700294~28701540:-
OV	cis	rs2439831	0.85	rs12702	ENSG00000205771.5	CATSPER2P1	4.51	1.06e-05	0.00532	0.43	0.29	Lung cancer in ever smokers;	chr15:43801729	chr15:43726918~43747094:-
OV	cis	rs1113500	0.933	rs1414674	ENSG00000226822.1	RP11-356N1.2	4.51	1.06e-05	0.00532	0.34	0.29	Growth-regulated protein alpha levels;	chr1:108083325	chr1:108071482~108074519:+
OV	cis	rs7605378	1	rs7577763	ENSG00000232732.8	AC073043.1	-4.51	1.06e-05	0.00532	-0.35	-0.29	Osteoporosis;	chr2:199817030	chr2:199867396~199911159:-
OV	cis	rs7605378	1	rs2577852	ENSG00000232732.8	AC073043.1	-4.51	1.06e-05	0.00532	-0.35	-0.29	Osteoporosis;	chr2:199822525	chr2:199867396~199911159:-
OV	cis	rs10924970	0.625	rs12757645	ENSG00000236863.2	RPL23AP23	4.51	1.06e-05	0.00533	0.3	0.29	Asthma;	chr1:235334489	chr1:235295865~235296335:+
OV	cis	rs8054556	1	rs4788204	ENSG00000261367.1	RP11-455F5.4	-4.51	1.06e-05	0.00533	-0.35	-0.29	Autism spectrum disorder or schizophrenia;	chr16:29983897	chr16:30107675~30110541:+
OV	cis	rs62244186	0.748	rs2888410	ENSG00000214820.3	MPRIPP1	4.51	1.06e-05	0.00533	0.26	0.29	Depressive symptoms;	chr3:44613984	chr3:44579938~44581026:-
OV	cis	rs7043114	0.544	rs7852510	ENSG00000281156.1	MIR3651	-4.51	1.06e-05	0.00533	-0.31	-0.29	Height;	chr9:92554077	chr9:92292458~92292547:-
OV	cis	rs7267979	0.546	rs8115804	ENSG00000274973.1	RP13-401N8.7	4.51	1.06e-05	0.00533	0.34	0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25458147	chr20:25845497~25845862:+
OV	cis	rs7043114	0.525	rs8067	ENSG00000281156.1	MIR3651	-4.51	1.06e-05	0.00533	-0.32	-0.29	Height;	chr9:92456547	chr9:92292458~92292547:-
OV	cis	rs10899021	1	rs11236201	ENSG00000279353.1	RP11-864N7.4	4.5	1.06e-05	0.00534	0.59	0.29	Response to metformin (IC50);	chr11:74664588	chr11:74698231~74699658:-
OV	cis	rs10899021	1	rs11236202	ENSG00000279353.1	RP11-864N7.4	4.5	1.06e-05	0.00534	0.59	0.29	Response to metformin (IC50);	chr11:74665647	chr11:74698231~74699658:-
OV	cis	rs4713118	0.662	rs149900	ENSG00000226314.6	ZNF192P1	-4.5	1.06e-05	0.00534	-0.39	-0.29	Parkinson's disease;	chr6:28046819	chr6:28161781~28169594:+
OV	cis	rs1538970	1	rs1417578	ENSG00000280836.1	AL355480.1	-4.5	1.06e-05	0.00534	-0.4	-0.29	Platelet count;	chr1:45384918	chr1:45581219~45581321:-
OV	cis	rs295490	0.748	rs75866638	ENSG00000272656.1	RP11-219D15.3	4.5	1.06e-05	0.00534	0.56	0.29	PR interval in Tripanosoma cruzi seropositivity;	chr3:139338830	chr3:139349024~139349371:-
OV	cis	rs8099594	0.51	rs1893528	ENSG00000266696.1	RP11-30L3.2	4.5	1.06e-05	0.00534	0.37	0.29	Height;	chr18:49169720	chr18:49205912~49208781:+
OV	cis	rs11673344	0.764	rs565721	ENSG00000226686.6	LINC01535	4.5	1.06e-05	0.00535	0.36	0.29	Obesity-related traits;	chr19:36964929	chr19:37251912~37265535:+
OV	cis	rs853679	0.546	rs71537572	ENSG00000220721.1	OR1F12	4.5	1.06e-05	0.00535	0.63	0.29	Depression;	chr6:28002937	chr6:28073316~28074233:+
OV	cis	rs3733585	0.605	rs4697926	ENSG00000250413.1	RP11-448G15.1	-4.5	1.07e-05	0.00536	-0.34	-0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:10122943	chr4:10006482~10009725:+
OV	cis	rs881375	0.715	rs11794516	ENSG00000226752.6	PSMD5-AS1	-4.5	1.07e-05	0.00536	-0.3	-0.29	Rheumatoid arthritis;	chr9:120877952	chr9:120824828~120854385:+
OV	cis	rs2227564	0.533	rs3870402	ENSG00000271816.1	BMS1P4	4.5	1.07e-05	0.00536	0.29	0.29	Crohn's disease;Inflammatory bowel disease;	chr10:73714029	chr10:73699151~73730487:-
OV	cis	rs2227564	0.62	rs4746143	ENSG00000271816.1	BMS1P4	4.5	1.07e-05	0.00536	0.29	0.29	Crohn's disease;Inflammatory bowel disease;	chr10:73717540	chr10:73699151~73730487:-
OV	cis	rs7927771	0.524	rs2242081	ENSG00000280615.1	Y_RNA	4.5	1.07e-05	0.00536	0.31	0.29	Subjective well-being;	chr11:47478715	chr11:47614898~47614994:-
OV	cis	rs17301013	0.606	rs77379897	ENSG00000227373.4	RP11-160H22.5	4.5	1.07e-05	0.00537	0.39	0.29	Systemic lupus erythematosus;	chr1:174169373	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs56375942	ENSG00000227373.4	RP11-160H22.5	4.5	1.07e-05	0.00537	0.39	0.29	Systemic lupus erythematosus;	chr1:174176206	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs56404641	ENSG00000227373.4	RP11-160H22.5	4.5	1.07e-05	0.00537	0.39	0.29	Systemic lupus erythematosus;	chr1:174176323	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs56239105	ENSG00000227373.4	RP11-160H22.5	4.5	1.07e-05	0.00537	0.39	0.29	Systemic lupus erythematosus;	chr1:174179346	chr1:174115300~174160004:-
OV	cis	rs7259376	0.875	rs2116919	ENSG00000269742.1	BNIP3P29	4.5	1.07e-05	0.00537	0.33	0.29	Menopause (age at onset);	chr19:22308904	chr19:22065828~22066398:-
OV	cis	rs4713118	0.662	rs149948	ENSG00000226314.6	ZNF192P1	-4.5	1.07e-05	0.00538	-0.39	-0.29	Parkinson's disease;	chr6:28007039	chr6:28161781~28169594:+
OV	cis	rs796364	0.806	rs11691873	ENSG00000232732.8	AC073043.1	4.5	1.07e-05	0.00538	0.46	0.29	Schizophrenia;	chr2:200101614	chr2:199867396~199911159:-
OV	cis	rs796364	0.806	rs10931887	ENSG00000232732.8	AC073043.1	4.5	1.07e-05	0.00538	0.46	0.29	Schizophrenia;	chr2:200104182	chr2:199867396~199911159:-
OV	cis	rs957448	0.796	rs72674824	ENSG00000253704.1	RP11-267M23.4	4.5	1.07e-05	0.00538	0.42	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94477053	chr8:94553722~94569745:+
OV	cis	rs1979679	0.918	rs10771427	ENSG00000278733.1	RP11-425D17.1	4.5	1.07e-05	0.00538	0.36	0.29	Ossification of the posterior longitudinal ligament of the spine;	chr12:28452493	chr12:28185625~28186190:-
OV	cis	rs295490	0.748	rs80248005	ENSG00000272656.1	RP11-219D15.3	4.5	1.07e-05	0.00538	0.56	0.29	PR interval in Tripanosoma cruzi seropositivity;	chr3:139347834	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs77869711	ENSG00000272656.1	RP11-219D15.3	4.5	1.07e-05	0.00538	0.56	0.29	PR interval in Tripanosoma cruzi seropositivity;	chr3:139348416	chr3:139349024~139349371:-
OV	cis	rs9309473	1	rs6705489	ENSG00000163016.8	ALMS1P	4.5	1.07e-05	0.00538	0.35	0.29	Metabolite levels;	chr2:73421683	chr2:73644919~73685576:+
OV	cis	rs7968440	1	rs2731443	ENSG00000272368.2	RP4-605O3.4	4.5	1.07e-05	0.00538	0.34	0.29	Fibrinogen;	chr12:50700355	chr12:50112197~50165618:+
OV	cis	rs8062405	0.679	rs72793818	ENSG00000278665.1	RP11-666O2.4	4.5	1.07e-05	0.00538	0.31	0.29	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28881816	chr16:28599241~28601881:-
OV	cis	rs4713118	0.955	rs9393848	ENSG00000219392.1	RP1-265C24.5	-4.5	1.07e-05	0.00539	-0.35	-0.29	Parkinson's disease;	chr6:27720590	chr6:28115628~28116551:+
OV	cis	rs1555322	0.53	rs2425047	ENSG00000126005.14	MMP24-AS1	4.5	1.07e-05	0.00539	0.38	0.29	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35216462~35278131:-
OV	cis	rs172166	0.694	rs9295760	ENSG00000280107.1	AL022393.9	-4.5	1.08e-05	0.00539	-0.35	-0.29	Cardiac Troponin-T levels;	chr6:28179607	chr6:28170845~28172521:+
OV	cis	rs4713118	0.513	rs1225591	ENSG00000280107.1	AL022393.9	-4.5	1.08e-05	0.00539	-0.35	-0.29	Parkinson's disease;	chr6:28180974	chr6:28170845~28172521:+
OV	cis	rs757081	0.658	rs214101	ENSG00000213779.4	RP11-452G18.1	4.5	1.08e-05	0.00539	0.32	0.29	Systolic blood pressure;	chr11:17267807	chr11:17193489~17194308:+
OV	cis	rs4243830	1	rs41278014	ENSG00000229519.2	RP11-58A11.2	-4.5	1.08e-05	0.0054	-0.4	-0.29	Body mass index;	chr1:6519593	chr1:6547905~6548619:+
OV	cis	rs6772849	0.83	rs7633674	ENSG00000277250.1	Metazoa_SRP	-4.5	1.08e-05	0.0054	-0.33	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128636183	chr3:128673681~128674021:-
OV	cis	rs6772849	0.93	rs9873888	ENSG00000277250.1	Metazoa_SRP	-4.5	1.08e-05	0.0054	-0.33	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128642144	chr3:128673681~128674021:-
OV	cis	rs13068223	1	rs13095806	ENSG00000243926.1	TIPARP-AS1	-4.5	1.08e-05	0.0054	-0.27	-0.29	Age-related hearing impairment (SNP x SNP interaction);	chr3:156738271	chr3:156671862~156674378:-
OV	cis	rs2661868	0.788	rs2708631	ENSG00000228423.2	RP4-633I8.4	4.5	1.08e-05	0.00541	0.33	0.29	Life satisfaction;	chr1:8403450	chr1:8805860~8807051:-
OV	cis	rs7667	0.812	rs12407089	ENSG00000240490.3	RN7SL277P	-4.5	1.08e-05	0.00541	-0.34	-0.29	Crohn's disease and psoriasis;	chr1:19441320	chr1:19424384~19424671:+
OV	cis	rs2492286	0.518	rs2811506	ENSG00000242551.2	POU5F1P6	-4.5	1.08e-05	0.00541	-0.37	-0.29	Eosinophil counts;	chr3:128610801	chr3:128674735~128677005:-
OV	cis	rs62244186	0.714	rs2293600	ENSG00000214820.3	MPRIPP1	-4.5	1.08e-05	0.00541	-0.26	-0.29	Depressive symptoms;	chr3:44557611	chr3:44579938~44581026:-
OV	cis	rs1555322	0.53	rs6060341	ENSG00000126005.14	MMP24-AS1	4.5	1.08e-05	0.00542	0.39	0.29	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35216462~35278131:-
OV	cis	rs17301013	0.606	rs1793315	ENSG00000227373.4	RP11-160H22.5	-4.5	1.08e-05	0.00542	-0.37	-0.29	Systemic lupus erythematosus;	chr1:174808923	chr1:174115300~174160004:-
OV	cis	rs875971	0.502	rs1796227	ENSG00000237310.1	GS1-124K5.4	-4.5	1.08e-05	0.00542	-0.33	-0.29	Aortic root size;	chr7:66622032	chr7:66493706~66495474:+
OV	cis	rs10510102	0.872	rs56108883	ENSG00000226864.1	ATE1-AS1	4.5	1.08e-05	0.00542	0.46	0.29	Breast cancer;	chr10:121825567	chr10:121928312~121951965:+
OV	cis	rs875971	0.545	rs73136346	ENSG00000236529.1	RP13-254B10.1	-4.5	1.08e-05	0.00542	-0.34	-0.29	Aortic root size;	chr7:66101095	chr7:65840212~65840596:+
OV	cis	rs4763879	0.739	rs2895988	ENSG00000278635.1	CTD-2318O12.1	4.5	1.08e-05	0.00542	0.25	0.29	Type 1 diabetes;	chr12:9675831	chr12:9415641~9416718:+
OV	cis	rs875971	0.545	rs10950036	ENSG00000237310.1	GS1-124K5.4	4.5	1.08e-05	0.00543	0.34	0.29	Aortic root size;	chr7:66353241	chr7:66493706~66495474:+
OV	cis	rs875971	0.545	rs73148639	ENSG00000237310.1	GS1-124K5.4	4.5	1.08e-05	0.00543	0.34	0.29	Aortic root size;	chr7:66390342	chr7:66493706~66495474:+
OV	cis	rs11690935	0.632	rs12052246	ENSG00000228389.1	AC068039.4	-4.5	1.08e-05	0.00543	-0.32	-0.29	Schizophrenia;	chr2:172030703	chr2:171773482~171775844:+
OV	cis	rs9880211	0.8	rs34324561	ENSG00000239213.4	NCK1-AS1	4.5	1.08e-05	0.00543	0.36	0.29	Height;Body mass index;	chr3:136382400	chr3:136841726~136862054:-
OV	cis	rs7957197	0.938	rs55879344	ENSG00000200795.1	RNU4-1	4.5	1.08e-05	0.00543	0.41	0.29	Type 2 diabetes;	chr12:121007193	chr12:120293097~120293237:-
OV	cis	rs4713118	0.869	rs9461405	ENSG00000280107.1	AL022393.9	-4.5	1.09e-05	0.00543	-0.34	-0.29	Parkinson's disease;	chr6:27751596	chr6:28170845~28172521:+
OV	cis	rs853679	0.556	rs34706883	ENSG00000220721.1	OR1F12	4.5	1.09e-05	0.00544	0.56	0.29	Depression;	chr6:27837477	chr6:28073316~28074233:+
OV	cis	rs67340775	0.748	rs13212651	ENSG00000220721.1	OR1F12	4.5	1.09e-05	0.00544	0.56	0.29	Lung cancer in ever smokers;	chr6:27839207	chr6:28073316~28074233:+
OV	cis	rs73201462	1	rs73201462	ENSG00000242551.2	POU5F1P6	4.5	1.09e-05	0.00544	0.47	0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128340450	chr3:128674735~128677005:-
OV	cis	rs4814920	0.818	rs6081790	ENSG00000275142.1	RP5-999L4.2	-4.5	1.09e-05	0.00544	-0.51	-0.29	Bipolar disorder (body mass index interaction);	chr20:19882273	chr20:19871891~19872284:+
OV	cis	rs875971	0.862	rs778734	ENSG00000236529.1	RP13-254B10.1	4.5	1.09e-05	0.00544	0.3	0.29	Aortic root size;	chr7:66349862	chr7:65840212~65840596:+
OV	cis	rs9309473	0.948	rs2421550	ENSG00000163016.8	ALMS1P	4.5	1.09e-05	0.00545	0.35	0.29	Metabolite levels;	chr2:73431558	chr2:73644919~73685576:+
OV	cis	rs3733585	0.699	rs6449177	ENSG00000250413.1	RP11-448G15.1	4.5	1.09e-05	0.00545	0.32	0.29	Cleft plate (environmental tobacco smoke interaction);	chr4:9966426	chr4:10006482~10009725:+
OV	cis	rs13113518	0.812	rs12505880	ENSG00000223305.1	RN7SKP30	4.5	1.09e-05	0.00545	0.32	0.29	Height;	chr4:55440988	chr4:55540502~55540835:-
OV	cis	rs2919917	1	rs2919917	ENSG00000254352.1	RP11-578O24.2	-4.5	1.09e-05	0.00546	-0.35	-0.29	Lymphocyte counts;	chr8:78745028	chr8:78723796~78724136:-
OV	cis	rs7043114	0.525	rs10116241	ENSG00000281156.1	MIR3651	-4.5	1.09e-05	0.00546	-0.31	-0.29	Height;	chr9:92478264	chr9:92292458~92292547:-
OV	cis	rs62244186	0.632	rs1402751	ENSG00000214820.3	MPRIPP1	4.5	1.09e-05	0.00546	0.25	0.29	Depressive symptoms;	chr3:44552538	chr3:44579938~44581026:-
OV	cis	rs1891275	0.515	rs7092884	ENSG00000228701.1	TNKS2-AS1	4.5	1.09e-05	0.00546	0.33	0.29	Intelligence (multi-trait analysis);	chr10:91724115	chr10:91782839~91798291:-
OV	cis	rs4713118	0.869	rs9348775	ENSG00000280107.1	AL022393.9	-4.5	1.09e-05	0.00547	-0.35	-0.29	Parkinson's disease;	chr6:27727550	chr6:28170845~28172521:+
OV	cis	rs13113518	0.783	rs6843722	ENSG00000223305.1	RN7SKP30	4.5	1.09e-05	0.00547	0.33	0.29	Height;	chr4:55465165	chr4:55540502~55540835:-
OV	cis	rs4747241	0.593	rs10740401	ENSG00000226163.1	RP11-167P22.3	4.5	1.1e-05	0.00548	0.32	0.29	Heschl's gyrus morphology;	chr10:72306639	chr10:72501746~72502956:+
OV	cis	rs4747241	0.593	rs3924190	ENSG00000226163.1	RP11-167P22.3	4.5	1.1e-05	0.00548	0.32	0.29	Heschl's gyrus morphology;	chr10:72308318	chr10:72501746~72502956:+
OV	cis	rs4747241	0.626	rs4275534	ENSG00000226163.1	RP11-167P22.3	4.5	1.1e-05	0.00548	0.32	0.29	Heschl's gyrus morphology;	chr10:72308393	chr10:72501746~72502956:+
OV	cis	rs4713118	0.588	rs200994	ENSG00000219392.1	RP1-265C24.5	4.5	1.1e-05	0.00548	0.35	0.29	Parkinson's disease;	chr6:27846035	chr6:28115628~28116551:+
OV	cis	rs67311347	0.911	rs6773917	ENSG00000223797.4	ENTPD3-AS1	4.5	1.1e-05	0.00548	0.31	0.29	Renal cell carcinoma;	chr3:40427763	chr3:40313802~40453329:-
OV	cis	rs10829156	0.898	rs7095666	ENSG00000225527.1	RP11-383B4.4	4.5	1.1e-05	0.00549	0.37	0.29	Sudden cardiac arrest;	chr10:18650538	chr10:18531849~18533336:-
OV	cis	rs801193	0.636	rs10233806	ENSG00000236529.1	RP13-254B10.1	-4.5	1.1e-05	0.00549	-0.3	-0.29	Aortic root size;	chr7:66653261	chr7:65840212~65840596:+
OV	cis	rs7605378	1	rs796363	ENSG00000232732.8	AC073043.1	-4.5	1.1e-05	0.0055	-0.35	-0.29	Osteoporosis;	chr2:199828945	chr2:199867396~199911159:-
OV	cis	rs6772849	0.775	rs66822528	ENSG00000242551.2	POU5F1P6	-4.5	1.1e-05	0.0055	-0.34	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128696254	chr3:128674735~128677005:-
OV	cis	rs7927592	0.763	rs11822059	ENSG00000212093.1	AP000807.1	4.5	1.1e-05	0.0055	0.33	0.29	Total body bone mineral density;	chr11:68533354	chr11:68506083~68506166:-
OV	cis	rs2919917	0.628	rs10109359	ENSG00000254352.1	RP11-578O24.2	4.5	1.1e-05	0.0055	0.38	0.29	Lymphocyte counts;	chr8:78694369	chr8:78723796~78724136:-
OV	cis	rs1707322	0.752	rs11211145	ENSG00000234329.1	RP11-767N6.2	4.5	1.1e-05	0.00551	0.29	0.29	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr1:45651039~45651826:-
OV	cis	rs6772849	1	rs6798431	ENSG00000277250.1	Metazoa_SRP	-4.5	1.1e-05	0.00551	-0.35	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128584530	chr3:128673681~128674021:-
OV	cis	rs6772849	1	rs9836257	ENSG00000277250.1	Metazoa_SRP	-4.5	1.1e-05	0.00551	-0.35	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128584640	chr3:128673681~128674021:-
OV	cis	rs8059260	0.736	rs78121798	ENSG00000274038.1	RP11-66H6.4	-4.5	1.1e-05	0.00552	-0.56	-0.29	Alcohol consumption over the past year;	chr16:10984224	chr16:11056556~11057034:+
OV	cis	rs1979679	0.842	rs7139154	ENSG00000278733.1	RP11-425D17.1	4.5	1.11e-05	0.00552	0.34	0.29	Ossification of the posterior longitudinal ligament of the spine;	chr12:28181603	chr12:28185625~28186190:-
OV	cis	rs295137	0.836	rs1217429	ENSG00000232732.8	AC073043.1	-4.5	1.11e-05	0.00553	-0.33	-0.29	Asthma (bronchodilator response);	chr2:200229428	chr2:199867396~199911159:-
OV	cis	rs9322193	0.607	rs9322229	ENSG00000268592.3	RAET1E-AS1	4.49	1.11e-05	0.00554	0.36	0.29	Lung cancer;	chr6:149908949	chr6:149863494~149919507:+
OV	cis	rs4938303	0.633	rs1960036	ENSG00000254851.1	RP11-109L13.1	4.49	1.11e-05	0.00554	0.47	0.29	Triglycerides;	chr11:116676692	chr11:117135528~117138582:+
OV	cis	rs4938303	0.633	rs35963862	ENSG00000254851.1	RP11-109L13.1	4.49	1.11e-05	0.00554	0.47	0.29	Triglycerides;	chr11:116679180	chr11:117135528~117138582:+
OV	cis	rs9298506	1	rs9298506	ENSG00000254142.2	RP11-53M11.3	4.49	1.11e-05	0.00554	0.36	0.29	Intracranial aneurysm;	chr8:54524964	chr8:54554361~54561927:+
OV	cis	rs71520386	0.607	rs11767419	ENSG00000221740.1	SNORD93	-4.49	1.11e-05	0.00555	-0.34	-0.29	Fibrinogen levels;	chr7:22839364	chr7:22856613~22856686:+
OV	cis	rs2015599	0.623	rs1072724	ENSG00000257176.2	RP11-996F15.2	4.49	1.11e-05	0.00555	0.36	0.29	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29280418~29317848:-
OV	cis	rs2015599	0.623	rs7358667	ENSG00000257176.2	RP11-996F15.2	4.49	1.11e-05	0.00555	0.36	0.29	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29280418~29317848:-
OV	cis	rs10851478	0.515	rs28375625	ENSG00000259545.2	RP11-325E5.4	4.49	1.11e-05	0.00555	0.32	0.29	Oral cavity cancer;	chr15:49450297	chr15:49177610~49178741:-
OV	cis	rs801193	0.761	rs2659888	ENSG00000224316.1	RP11-479O9.2	4.49	1.11e-05	0.00555	0.31	0.29	Aortic root size;	chr7:66765184	chr7:65773620~65802067:+
OV	cis	rs796364	0.76	rs11690371	ENSG00000232732.8	AC073043.1	4.49	1.11e-05	0.00555	0.47	0.29	Schizophrenia;	chr2:200124893	chr2:199867396~199911159:-
OV	cis	rs1538970	0.847	rs781230	ENSG00000280836.1	AL355480.1	4.49	1.11e-05	0.00556	0.39	0.29	Platelet count;	chr1:45415079	chr1:45581219~45581321:-
OV	cis	rs1538970	0.847	rs1771550	ENSG00000280836.1	AL355480.1	4.49	1.11e-05	0.00556	0.39	0.29	Platelet count;	chr1:45417893	chr1:45581219~45581321:-
OV	cis	rs875971	0.545	rs7783889	ENSG00000237310.1	GS1-124K5.4	4.49	1.11e-05	0.00556	0.33	0.29	Aortic root size;	chr7:66283366	chr7:66493706~66495474:+
OV	cis	rs7927592	0.513	rs607887	ENSG00000212093.1	AP000807.1	4.49	1.11e-05	0.00556	0.33	0.29	Total body bone mineral density;	chr11:68429493	chr11:68506083~68506166:-
OV	cis	rs473651	0.692	rs579511	ENSG00000229915.1	AC016999.2	-4.49	1.11e-05	0.00556	-0.36	-0.29	Multiple system atrophy;	chr2:238426273	chr2:238427077~238427729:-
OV	cis	rs7429990	0.864	rs6774170	ENSG00000229759.1	MRPS18AP1	-4.49	1.11e-05	0.00556	-0.3	-0.29	Educational attainment (years of education);	chr3:47615977	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs1403578	ENSG00000229759.1	MRPS18AP1	-4.49	1.11e-05	0.00556	-0.3	-0.29	Educational attainment (years of education);	chr3:47617997	chr3:48256350~48256938:-
OV	cis	rs7429990	0.833	rs883661	ENSG00000229759.1	MRPS18AP1	-4.49	1.11e-05	0.00556	-0.3	-0.29	Educational attainment (years of education);	chr3:47618611	chr3:48256350~48256938:-
OV	cis	rs7429990	0.833	rs870622	ENSG00000229759.1	MRPS18AP1	-4.49	1.11e-05	0.00556	-0.3	-0.29	Educational attainment (years of education);	chr3:47618683	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs868255	ENSG00000229759.1	MRPS18AP1	-4.49	1.11e-05	0.00556	-0.3	-0.29	Educational attainment (years of education);	chr3:47619074	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs4858842	ENSG00000229759.1	MRPS18AP1	-4.49	1.11e-05	0.00556	-0.3	-0.29	Educational attainment (years of education);	chr3:47619574	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs11130144	ENSG00000229759.1	MRPS18AP1	-4.49	1.11e-05	0.00556	-0.3	-0.29	Educational attainment (years of education);	chr3:47626444	chr3:48256350~48256938:-
OV	cis	rs73201462	1	rs11721213	ENSG00000277250.1	Metazoa_SRP	-4.49	1.11e-05	0.00556	-0.45	-0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128348598	chr3:128673681~128674021:-
OV	cis	rs6788497	0.643	rs11717030	ENSG00000242551.2	POU5F1P6	4.49	1.12e-05	0.00556	0.57	0.29	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr3:128404445	chr3:128674735~128677005:-
OV	cis	rs9368481	0.729	rs9379950	ENSG00000261584.1	RP11-457M11.5	-4.49	1.12e-05	0.00556	-0.32	-0.29	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:26686241~26687964:+
OV	cis	rs9368481	1	rs9368481	ENSG00000261584.1	RP11-457M11.5	-4.49	1.12e-05	0.00556	-0.32	-0.29	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:26686241~26687964:+
OV	cis	rs7188445	0.787	rs7189954	ENSG00000261390.4	RP11-345M22.2	4.49	1.12e-05	0.00557	0.35	0.29	Urate levels;	chr16:79701150	chr16:79715232~79770563:-
OV	cis	rs9925964	0.869	rs2288004	ENSG00000278922.1	AC002310.14	-4.49	1.12e-05	0.00557	-0.31	-0.29	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31042719	chr16:30526918~30528294:+
OV	cis	rs801193	0.844	rs732465	ENSG00000224316.1	RP11-479O9.2	4.49	1.12e-05	0.00557	0.3	0.29	Aortic root size;	chr7:66533463	chr7:65773620~65802067:+
OV	cis	rs801193	0.773	rs801207	ENSG00000224316.1	RP11-479O9.2	-4.49	1.12e-05	0.00557	-0.3	-0.29	Aortic root size;	chr7:66555603	chr7:65773620~65802067:+
OV	cis	rs875971	0.543	rs801191	ENSG00000224316.1	RP11-479O9.2	-4.49	1.12e-05	0.00557	-0.3	-0.29	Aortic root size;	chr7:66567968	chr7:65773620~65802067:+
OV	cis	rs875971	0.508	rs6947808	ENSG00000224316.1	RP11-479O9.2	-4.49	1.12e-05	0.00557	-0.3	-0.29	Aortic root size;	chr7:66580095	chr7:65773620~65802067:+
OV	cis	rs7829975	0.533	rs13274028	ENSG00000253893.2	FAM85B	-4.49	1.12e-05	0.00557	-0.32	-0.29	Mood instability;	chr8:8871683	chr8:8167819~8226614:-
OV	cis	rs896854	0.654	rs13274945	ENSG00000253528.2	RP11-347C18.4	4.49	1.12e-05	0.00557	0.27	0.29	Type 2 diabetes;	chr8:94974398	chr8:94974573~94974853:-
OV	cis	rs9309473	1	rs6740223	ENSG00000163016.8	ALMS1P	4.49	1.12e-05	0.00557	0.34	0.29	Metabolite levels;	chr2:73426204	chr2:73644919~73685576:+
OV	cis	rs9309473	1	rs6707722	ENSG00000163016.8	ALMS1P	4.49	1.12e-05	0.00557	0.34	0.29	Metabolite levels;	chr2:73427235	chr2:73644919~73685576:+
OV	cis	rs1075265	0.901	rs9808326	ENSG00000233266.1	HMGB1P31	4.49	1.12e-05	0.00558	0.35	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54115971	chr2:54051334~54051760:+
OV	cis	rs17742757	0.522	rs899364	ENSG00000255052.4	FAM66D	4.49	1.12e-05	0.00558	0.38	0.29	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr8:11472035	chr8:12115782~12177550:+
OV	cis	rs6772849	1	rs2712379	ENSG00000277250.1	Metazoa_SRP	-4.49	1.12e-05	0.00558	-0.34	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128590217	chr3:128673681~128674021:-
OV	cis	rs8177876	0.731	rs76093926	ENSG00000261838.4	RP11-303E16.6	4.49	1.12e-05	0.00558	0.54	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81078920	chr16:81069854~81076598:+
OV	cis	rs8177876	0.731	rs10514512	ENSG00000261838.4	RP11-303E16.6	4.49	1.12e-05	0.00558	0.54	0.29	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080350	chr16:81069854~81076598:+
OV	cis	rs9925964	0.933	rs749671	ENSG00000278922.1	AC002310.14	-4.49	1.12e-05	0.00558	-0.33	-0.29	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31077026	chr16:30526918~30528294:+
OV	cis	rs853679	0.882	rs9380064	ENSG00000280107.1	AL022393.9	-4.49	1.12e-05	0.00559	-0.5	-0.29	Depression;	chr6:28175340	chr6:28170845~28172521:+
OV	cis	rs7043114	0.525	rs10820969	ENSG00000281156.1	MIR3651	-4.49	1.12e-05	0.00559	-0.32	-0.29	Height;	chr9:92344396	chr9:92292458~92292547:-
OV	cis	rs7043114	0.525	rs6479419	ENSG00000281156.1	MIR3651	-4.49	1.12e-05	0.00559	-0.32	-0.29	Height;	chr9:92347720	chr9:92292458~92292547:-
OV	cis	rs7043114	0.525	rs7020874	ENSG00000281156.1	MIR3651	-4.49	1.12e-05	0.00559	-0.32	-0.29	Height;	chr9:92350278	chr9:92292458~92292547:-
OV	cis	rs7043114	0.525	rs7047089	ENSG00000281156.1	MIR3651	-4.49	1.12e-05	0.00559	-0.32	-0.29	Height;	chr9:92355698	chr9:92292458~92292547:-
OV	cis	rs992157	0.798	rs2382818	ENSG00000261338.2	RP11-378A13.1	-4.49	1.12e-05	0.00559	-0.34	-0.29	Colorectal cancer;	chr2:218291184	chr2:218255319~218257366:+
OV	cis	rs992157	0.798	rs2382819	ENSG00000261338.2	RP11-378A13.1	-4.49	1.12e-05	0.00559	-0.34	-0.29	Colorectal cancer;	chr2:218291186	chr2:218255319~218257366:+
OV	cis	rs4713118	0.868	rs9468220	ENSG00000280107.1	AL022393.9	4.49	1.12e-05	0.0056	0.37	0.29	Parkinson's disease;	chr6:27765197	chr6:28170845~28172521:+
OV	cis	rs4639966	0.569	rs603486	ENSG00000278376.1	RP11-158I9.8	-4.49	1.12e-05	0.0056	-0.27	-0.29	Systemic lupus erythematosus;	chr11:118716638	chr11:118791254~118793137:+
OV	cis	rs8054556	0.647	rs4788211	ENSG00000261367.1	RP11-455F5.4	-4.49	1.12e-05	0.0056	-0.3	-0.29	Autism spectrum disorder or schizophrenia;	chr16:30004244	chr16:30107675~30110541:+
OV	cis	rs875971	0.545	rs73146609	ENSG00000236529.1	RP13-254B10.1	4.49	1.13e-05	0.00561	0.34	0.29	Aortic root size;	chr7:66302477	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs2173571	ENSG00000236529.1	RP13-254B10.1	4.49	1.13e-05	0.00561	0.34	0.29	Aortic root size;	chr7:66305392	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs11770063	ENSG00000236529.1	RP13-254B10.1	4.49	1.13e-05	0.00561	0.34	0.29	Aortic root size;	chr7:66318029	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs3936065	ENSG00000236529.1	RP13-254B10.1	4.49	1.13e-05	0.00561	0.34	0.29	Aortic root size;	chr7:66325577	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs4718335	ENSG00000236529.1	RP13-254B10.1	4.49	1.13e-05	0.00561	0.34	0.29	Aortic root size;	chr7:66339619	chr7:65840212~65840596:+
OV	cis	rs881375	0.678	rs10118357	ENSG00000226752.6	PSMD5-AS1	-4.49	1.13e-05	0.00561	-0.3	-0.29	Rheumatoid arthritis;	chr9:120917790	chr9:120824828~120854385:+
OV	cis	rs9309473	1	rs6736866	ENSG00000163016.8	ALMS1P	4.49	1.13e-05	0.00561	0.36	0.29	Metabolite levels;	chr2:73434858	chr2:73644919~73685576:+
OV	cis	rs13113518	0.812	rs2048564	ENSG00000223305.1	RN7SKP30	4.49	1.13e-05	0.00561	0.33	0.29	Height;	chr4:55407965	chr4:55540502~55540835:-
OV	cis	rs853679	0.607	rs67101035	ENSG00000220721.1	OR1F12	4.49	1.13e-05	0.00561	0.58	0.29	Depression;	chr6:27831109	chr6:28073316~28074233:+
OV	cis	rs4908768	0.906	rs55830087	ENSG00000228423.2	RP4-633I8.4	4.49	1.13e-05	0.00561	0.35	0.29	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8621491	chr1:8805860~8807051:-
OV	cis	rs4908768	0.906	rs11121207	ENSG00000228423.2	RP4-633I8.4	4.49	1.13e-05	0.00561	0.35	0.29	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8621789	chr1:8805860~8807051:-
OV	cis	rs10740039	0.883	rs10761542	ENSG00000254271.1	RP11-131N11.4	4.49	1.13e-05	0.00562	0.35	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655465	chr10:60734342~60741828:+
OV	cis	rs10740039	1	rs10761543	ENSG00000254271.1	RP11-131N11.4	4.49	1.13e-05	0.00562	0.35	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655633	chr10:60734342~60741828:+
OV	cis	rs10740039	0.883	rs10761544	ENSG00000254271.1	RP11-131N11.4	4.49	1.13e-05	0.00562	0.35	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655647	chr10:60734342~60741828:+
OV	cis	rs10740039	0.804	rs7900848	ENSG00000254271.1	RP11-131N11.4	4.49	1.13e-05	0.00562	0.35	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60655893	chr10:60734342~60741828:+
OV	cis	rs10740039	0.883	rs7898504	ENSG00000254271.1	RP11-131N11.4	4.49	1.13e-05	0.00562	0.35	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658233	chr10:60734342~60741828:+
OV	cis	rs10740039	0.671	rs7913549	ENSG00000254271.1	RP11-131N11.4	4.49	1.13e-05	0.00562	0.35	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658474	chr10:60734342~60741828:+
OV	cis	rs10740039	0.842	rs10821819	ENSG00000254271.1	RP11-131N11.4	4.49	1.13e-05	0.00562	0.35	0.29	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60658857	chr10:60734342~60741828:+
OV	cis	rs9813712	0.597	rs11711883	ENSG00000253540.4	FAM86HP	-4.49	1.13e-05	0.00562	-0.3	-0.29	Response to amphetamines;	chr3:130241367	chr3:130099092~130111472:-
OV	cis	rs9813712	0.574	rs62281647	ENSG00000253540.4	FAM86HP	-4.49	1.13e-05	0.00562	-0.3	-0.29	Response to amphetamines;	chr3:130242670	chr3:130099092~130111472:-
OV	cis	rs2980436	1	rs2980436	ENSG00000253893.2	FAM85B	4.49	1.13e-05	0.00563	0.37	0.29	Schizophrenia;	chr8:8234503	chr8:8167819~8226614:-
OV	cis	rs6088590	0.648	rs6059991	ENSG00000206582.1	Y_RNA	-4.49	1.13e-05	0.00563	-0.35	-0.29	Coronary artery disease;	chr20:34693032	chr20:34526510~34526606:-
OV	cis	rs875971	0.862	rs1983372	ENSG00000236529.1	RP13-254B10.1	-4.49	1.13e-05	0.00563	-0.29	-0.29	Aortic root size;	chr7:66146364	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs908915	ENSG00000236529.1	RP13-254B10.1	-4.49	1.13e-05	0.00563	-0.29	-0.29	Aortic root size;	chr7:66149664	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs7809814	ENSG00000236529.1	RP13-254B10.1	-4.49	1.13e-05	0.00563	-0.29	-0.29	Aortic root size;	chr7:66150410	chr7:65840212~65840596:+
OV	cis	rs7580658	0.891	rs55998967	ENSG00000236682.1	AC068282.3	-4.49	1.13e-05	0.00563	-0.37	-0.29	Protein C levels;	chr2:127291098	chr2:127389130~127400580:+
OV	cis	rs7968440	0.933	rs7308872	ENSG00000257298.1	RP3-405J10.3	-4.49	1.14e-05	0.00565	-0.26	-0.29	Fibrinogen;	chr12:50726391	chr12:50185580~50191363:-
OV	cis	rs295490	0.748	rs77327267	ENSG00000272656.1	RP11-219D15.3	4.49	1.14e-05	0.00565	0.56	0.29	PR interval in Tripanosoma cruzi seropositivity;	chr3:139341667	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs74877536	ENSG00000272656.1	RP11-219D15.3	4.49	1.14e-05	0.00565	0.56	0.29	PR interval in Tripanosoma cruzi seropositivity;	chr3:139344277	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs1602628	ENSG00000272656.1	RP11-219D15.3	4.49	1.14e-05	0.00565	0.56	0.29	PR interval in Tripanosoma cruzi seropositivity;	chr3:139345532	chr3:139349024~139349371:-
OV	cis	rs295490	0.667	rs59960641	ENSG00000272656.1	RP11-219D15.3	4.49	1.14e-05	0.00565	0.56	0.29	PR interval in Tripanosoma cruzi seropositivity;	chr3:139346587	chr3:139349024~139349371:-
OV	cis	rs1555322	0.53	rs2425043	ENSG00000269202.1	RP4-614O4.12	-4.49	1.14e-05	0.00565	-0.33	-0.29	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35201747~35203288:-
OV	cis	rs1113500	0.933	rs11185255	ENSG00000226822.1	RP11-356N1.2	4.49	1.14e-05	0.00566	0.34	0.29	Growth-regulated protein alpha levels;	chr1:108090569	chr1:108071482~108074519:+
OV	cis	rs1113500	0.933	rs11185256	ENSG00000226822.1	RP11-356N1.2	4.49	1.14e-05	0.00566	0.34	0.29	Growth-regulated protein alpha levels;	chr1:108091335	chr1:108071482~108074519:+
OV	cis	rs533581	0.866	rs475796	ENSG00000261373.1	VPS9D1-AS1	-4.49	1.14e-05	0.00567	-0.36	-0.29	Social autistic-like traits;	chr16:88904368	chr16:89711856~89718165:+
OV	cis	rs7726839	0.574	rs12522955	ENSG00000271781.1	CTD-2589H19.6	-4.49	1.14e-05	0.00567	-0.44	-0.29	Obesity-related traits;	chr5:639116	chr5:675826~676616:+
OV	cis	rs812925	0.533	rs60997156	ENSG00000271889.1	RP11-493E12.1	4.49	1.14e-05	0.00567	0.33	0.29	Immature fraction of reticulocytes;	chr2:61169404	chr2:61151433~61162105:-
OV	cis	rs875971	0.545	rs801199	ENSG00000226824.5	RP4-756H11.3	4.49	1.14e-05	0.00567	0.34	0.29	Aortic root size;	chr7:66560286	chr7:66654538~66669855:+
OV	cis	rs7587476	0.599	rs61073893	ENSG00000229267.2	AC072062.1	-4.49	1.14e-05	0.00567	-0.41	-0.29	Neuroblastoma;	chr2:214880090	chr2:214810229~214963274:+
OV	cis	rs3758911	0.788	rs10890704	ENSG00000261098.1	RP11-819C21.1	-4.49	1.14e-05	0.00568	-0.28	-0.29	Coronary artery disease;	chr11:107312779	chr11:107312132~107316271:-
OV	cis	rs2841233	0.692	rs2028416	ENSG00000258701.1	LINC00638	4.49	1.14e-05	0.00568	0.33	0.29	IgG glycosylation;	chr14:104882215	chr14:104821201~104823718:+
OV	cis	rs607987	0.756	rs1235089	ENSG00000254532.1	RP11-624D11.2	-4.49	1.14e-05	0.00568	-0.33	-0.29	Body mass index;	chr11:30353769	chr11:30044058~30084343:-
OV	cis	rs4713118	0.869	rs2056925	ENSG00000280107.1	AL022393.9	-4.49	1.14e-05	0.00568	-0.33	-0.29	Parkinson's disease;	chr6:27723126	chr6:28170845~28172521:+
OV	cis	rs875971	0.545	rs6979636	ENSG00000226824.5	RP4-756H11.3	-4.49	1.14e-05	0.00568	-0.33	-0.29	Aortic root size;	chr7:66276638	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs6460307	ENSG00000237310.1	GS1-124K5.4	4.49	1.14e-05	0.00569	0.29	0.29	Aortic root size;	chr7:66595884	chr7:66493706~66495474:+
OV	cis	rs7083	0.716	rs687740	ENSG00000278768.1	BACE1-AS	-4.49	1.15e-05	0.00569	-0.29	-0.29	Blood protein levels;	chr11:117306887	chr11:117290874~117293571:+
OV	cis	rs1823913	0.599	rs10497713	ENSG00000227542.1	AC092614.2	4.49	1.15e-05	0.00569	0.32	0.29	Obesity-related traits;	chr2:191279312	chr2:191229165~191246172:-
OV	cis	rs10510102	0.935	rs12253283	ENSG00000226864.1	ATE1-AS1	-4.49	1.15e-05	0.00569	-0.45	-0.29	Breast cancer;	chr10:121909740	chr10:121928312~121951965:+
OV	cis	rs7927592	0.956	rs11228269	ENSG00000212093.1	AP000807.1	4.49	1.15e-05	0.00569	0.36	0.29	Total body bone mineral density;	chr11:68522328	chr11:68506083~68506166:-
OV	cis	rs7605378	1	rs797163	ENSG00000232732.8	AC073043.1	-4.49	1.15e-05	0.0057	-0.35	-0.29	Osteoporosis;	chr2:199831664	chr2:199867396~199911159:-
OV	cis	rs875971	0.545	rs1267814	ENSG00000237310.1	GS1-124K5.4	-4.49	1.15e-05	0.0057	-0.33	-0.29	Aortic root size;	chr7:66579422	chr7:66493706~66495474:+
OV	cis	rs10759883	0.563	rs623438	ENSG00000175611.10	LINC00476	4.49	1.15e-05	0.0057	0.35	0.29	Nicotine dependence;	chr9:95938114	chr9:95759231~95875977:-
OV	cis	rs7302981	0.809	rs66768395	ENSG00000272368.2	RP4-605O3.4	4.49	1.15e-05	0.0057	0.32	0.29	Systolic blood pressure;	chr12:50174482	chr12:50112197~50165618:+
OV	cis	rs7302981	0.809	rs1044370	ENSG00000272368.2	RP4-605O3.4	4.49	1.15e-05	0.0057	0.32	0.29	Systolic blood pressure;	chr12:50176827	chr12:50112197~50165618:+
OV	cis	rs7520050	0.966	rs1707321	ENSG00000281133.1	AL355480.3	4.49	1.15e-05	0.00571	0.32	0.29	Reticulocyte count;Red blood cell count;	chr1:46039637	chr1:45580892~45580996:-
OV	cis	rs7429990	0.965	rs62260764	ENSG00000229759.1	MRPS18AP1	4.49	1.15e-05	0.00571	0.32	0.29	Educational attainment (years of education);	chr3:47949010	chr3:48256350~48256938:-
OV	cis	rs7429990	0.932	rs6803741	ENSG00000229759.1	MRPS18AP1	-4.49	1.15e-05	0.00571	-0.3	-0.29	Educational attainment (years of education);	chr3:48082050	chr3:48256350~48256938:-
OV	cis	rs11673344	0.764	rs519551	ENSG00000226686.6	LINC01535	4.49	1.15e-05	0.00571	0.37	0.29	Obesity-related traits;	chr19:36965046	chr19:37251912~37265535:+
OV	cis	rs875971	0.545	rs17138156	ENSG00000237310.1	GS1-124K5.4	4.49	1.15e-05	0.00571	0.33	0.29	Aortic root size;	chr7:66249708	chr7:66493706~66495474:+
OV	cis	rs10829156	0.57	rs7904365	ENSG00000225527.1	RP11-383B4.4	-4.49	1.15e-05	0.00571	-0.38	-0.29	Sudden cardiac arrest;	chr10:18542375	chr10:18531849~18533336:-
OV	cis	rs2919917	0.614	rs10102877	ENSG00000254352.1	RP11-578O24.2	4.49	1.15e-05	0.00572	0.32	0.29	Lymphocyte counts;	chr8:78686127	chr8:78723796~78724136:-
OV	cis	rs67311347	1	rs951560	ENSG00000223797.4	ENTPD3-AS1	4.49	1.15e-05	0.00572	0.3	0.29	Renal cell carcinoma;	chr3:40421980	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs7612015	ENSG00000223797.4	ENTPD3-AS1	4.49	1.15e-05	0.00572	0.3	0.29	Renal cell carcinoma;	chr3:40358483	chr3:40313802~40453329:-
OV	cis	rs172166	0.694	rs1631552	ENSG00000280107.1	AL022393.9	-4.49	1.15e-05	0.00572	-0.34	-0.29	Cardiac Troponin-T levels;	chr6:28121921	chr6:28170845~28172521:+
OV	cis	rs172166	0.694	rs536704	ENSG00000280107.1	AL022393.9	-4.49	1.15e-05	0.00572	-0.34	-0.29	Cardiac Troponin-T levels;	chr6:28124825	chr6:28170845~28172521:+
OV	cis	rs7302981	0.667	rs7136648	ENSG00000257298.1	RP3-405J10.3	4.49	1.15e-05	0.00572	0.27	0.29	Systolic blood pressure;	chr12:50231039	chr12:50185580~50191363:-
OV	cis	rs9487094	0.961	rs3807005	ENSG00000260273.1	RP11-425D10.10	4.49	1.15e-05	0.00572	0.32	0.29	Height;	chr6:109469907	chr6:109382795~109383666:+
OV	cis	rs957448	0.561	rs12679785	ENSG00000253704.1	RP11-267M23.4	4.49	1.15e-05	0.00572	0.37	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94593349	chr8:94553722~94569745:+
OV	cis	rs957448	0.561	rs13258635	ENSG00000253704.1	RP11-267M23.4	4.49	1.15e-05	0.00572	0.37	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94595629	chr8:94553722~94569745:+
OV	cis	rs12680842	0.842	rs34691145	ENSG00000253704.1	RP11-267M23.4	4.49	1.15e-05	0.00572	0.37	0.29	Body mass index;	chr8:94597715	chr8:94553722~94569745:+
OV	cis	rs957448	0.561	rs7459558	ENSG00000253704.1	RP11-267M23.4	4.49	1.15e-05	0.00572	0.37	0.29	Nonsyndromic cleft lip with cleft palate;	chr8:94598618	chr8:94553722~94569745:+
OV	cis	rs1113500	0.933	rs4517375	ENSG00000226822.1	RP11-356N1.2	-4.49	1.15e-05	0.00572	-0.34	-0.29	Growth-regulated protein alpha levels;	chr1:108095708	chr1:108071482~108074519:+
OV	cis	rs853679	0.882	rs9468300	ENSG00000219392.1	RP1-265C24.5	-4.49	1.16e-05	0.00573	-0.48	-0.29	Depression;	chr6:28159062	chr6:28115628~28116551:+
OV	cis	rs853679	0.825	rs8180562	ENSG00000219392.1	RP1-265C24.5	-4.49	1.16e-05	0.00573	-0.48	-0.29	Depression;	chr6:28173682	chr6:28115628~28116551:+
OV	cis	rs6772849	0.93	rs6768344	ENSG00000277250.1	Metazoa_SRP	-4.49	1.16e-05	0.00574	-0.33	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128654713	chr3:128673681~128674021:-
OV	cis	rs6772849	0.93	rs13434160	ENSG00000277250.1	Metazoa_SRP	-4.49	1.16e-05	0.00574	-0.33	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128655927	chr3:128673681~128674021:-
OV	cis	rs6772849	0.93	rs4857916	ENSG00000277250.1	Metazoa_SRP	-4.49	1.16e-05	0.00574	-0.33	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128657171	chr3:128673681~128674021:-
OV	cis	rs4788196	1	rs4788196	ENSG00000261367.1	RP11-455F5.4	-4.49	1.16e-05	0.00574	-0.31	-0.29	Pubertal anthropometrics;	chr16:29956113	chr16:30107675~30110541:+
OV	cis	rs875971	0.545	rs1796219	ENSG00000226824.5	RP4-756H11.3	4.48	1.16e-05	0.00574	0.35	0.29	Aortic root size;	chr7:66645977	chr7:66654538~66669855:+
OV	cis	rs9298506	1	rs10087526	ENSG00000254142.2	RP11-53M11.3	4.48	1.16e-05	0.00575	0.38	0.29	Intracranial aneurysm;	chr8:54520591	chr8:54554361~54561927:+
OV	cis	rs9298506	1	rs10112582	ENSG00000254142.2	RP11-53M11.3	4.48	1.16e-05	0.00575	0.38	0.29	Intracranial aneurysm;	chr8:54520592	chr8:54554361~54561927:+
OV	cis	rs1511299	0.597	rs2063454	ENSG00000249417.1	RP11-438D8.2	-4.48	1.16e-05	0.00575	-0.43	-0.29	Glomerular filtration rate;	chr3:141996529	chr3:141267353~141367137:-
OV	cis	rs7945705	0.902	rs10769979	ENSG00000254860.4	TMEM9B-AS1	-4.48	1.16e-05	0.00576	-0.3	-0.29	Hemoglobin concentration;	chr11:8989112	chr11:8964675~8977527:+
OV	cis	rs11096990	0.821	rs2711991	ENSG00000249207.1	RP11-360F5.1	4.48	1.16e-05	0.00576	0.33	0.29	Cognitive function;	chr4:39149733	chr4:39112677~39126818:-
OV	cis	rs11096990	0.855	rs2566168	ENSG00000249207.1	RP11-360F5.1	4.48	1.16e-05	0.00576	0.33	0.29	Cognitive function;	chr4:39150053	chr4:39112677~39126818:-
OV	cis	rs4948102	0.667	rs7811270	ENSG00000275875.1	RP11-613E4.5	-4.48	1.16e-05	0.00576	-0.31	-0.29	Plasma homocysteine levels (post-methionine load test);	chr7:56072297	chr7:55741525~55741869:+
OV	cis	rs17023223	0.537	rs12085308	ENSG00000231365.4	RP11-418J17.1	-4.48	1.16e-05	0.00577	-0.38	-0.29	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119134930	chr1:119140396~119275973:+
OV	cis	rs9660180	1	rs9660180	ENSG00000215914.4	MMP23A	-4.48	1.16e-05	0.00577	-0.32	-0.29	Body mass index;	chr1:1791592	chr1:1699942~1701782:+
OV	cis	rs1150668	0.796	rs213236	ENSG00000204709.4	LINC01556	4.48	1.16e-05	0.00577	0.34	0.29	Pubertal anthropometrics;	chr6:28356620	chr6:28943877~28944537:+
OV	cis	rs507080	0.845	rs481903	ENSG00000278376.1	RP11-158I9.8	-4.48	1.16e-05	0.00577	-0.3	-0.29	Serum metabolite levels;	chr11:118697024	chr11:118791254~118793137:+
OV	cis	rs1075265	0.568	rs3095756	ENSG00000233266.1	HMGB1P31	4.48	1.17e-05	0.00578	0.36	0.29	Chronotype;Morning vs. evening chronotype;	chr2:53822332	chr2:54051334~54051760:+
OV	cis	rs875971	0.545	rs35459055	ENSG00000237310.1	GS1-124K5.4	4.48	1.17e-05	0.00578	0.33	0.29	Aortic root size;	chr7:66479399	chr7:66493706~66495474:+
OV	cis	rs1075265	0.935	rs6545384	ENSG00000233266.1	HMGB1P31	4.48	1.17e-05	0.00578	0.34	0.29	Chronotype;Morning vs. evening chronotype;	chr2:54073927	chr2:54051334~54051760:+
OV	cis	rs9925964	0.869	rs749670	ENSG00000278922.1	AC002310.14	-4.48	1.17e-05	0.00579	-0.33	-0.29	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31077304	chr16:30526918~30528294:+
OV	cis	rs7043114	0.507	rs6479420	ENSG00000281156.1	MIR3651	-4.48	1.17e-05	0.00579	-0.32	-0.29	Height;	chr9:92354124	chr9:92292458~92292547:-
OV	cis	rs881375	0.967	rs1930778	ENSG00000226752.6	PSMD5-AS1	-4.48	1.17e-05	0.00579	-0.31	-0.29	Rheumatoid arthritis;	chr9:120879091	chr9:120824828~120854385:+
OV	cis	rs881375	1	rs10760118	ENSG00000226752.6	PSMD5-AS1	-4.48	1.17e-05	0.00579	-0.31	-0.29	Rheumatoid arthritis;	chr9:120879338	chr9:120824828~120854385:+
OV	cis	rs875971	1	rs6945843	ENSG00000236529.1	RP13-254B10.1	-4.48	1.17e-05	0.00579	-0.3	-0.29	Aortic root size;	chr7:66269796	chr7:65840212~65840596:+
OV	cis	rs2015599	0.623	rs3782510	ENSG00000257176.2	RP11-996F15.2	4.48	1.17e-05	0.00579	0.35	0.29	Platelet count;Mean platelet volume;	chr12:29301176	chr12:29280418~29317848:-
OV	cis	rs4591358	0.871	rs1500608	ENSG00000223466.1	AC064834.2	-4.48	1.17e-05	0.00579	-0.34	-0.29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195482075	chr2:195533035~195538681:+
OV	cis	rs4591358	0.834	rs4850621	ENSG00000223466.1	AC064834.2	-4.48	1.17e-05	0.00579	-0.34	-0.29	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195484850	chr2:195533035~195538681:+
OV	cis	rs4728142	0.604	rs6969930	ENSG00000275106.1	RP11-309L24.10	-4.48	1.17e-05	0.00579	-0.37	-0.29	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128990259	chr7:128952527~128953316:-
OV	cis	rs4908768	0.596	rs4908516	ENSG00000228423.2	RP4-633I8.4	4.48	1.17e-05	0.00579	0.35	0.29	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8819551	chr1:8805860~8807051:-
OV	cis	rs11096990	0.634	rs1057807	ENSG00000249207.1	RP11-360F5.1	4.48	1.17e-05	0.0058	0.3	0.29	Cognitive function;	chr4:39287853	chr4:39112677~39126818:-
OV	cis	rs4918798	0.696	rs56044736	ENSG00000234724.1	HDAC1P1	4.48	1.17e-05	0.0058	0.53	0.29	Warfarin maintenance dose;	chr10:94974213	chr10:94137748~94139500:+
OV	cis	rs4918798	0.696	rs72818642	ENSG00000234724.1	HDAC1P1	4.48	1.17e-05	0.0058	0.53	0.29	Warfarin maintenance dose;	chr10:94976294	chr10:94137748~94139500:+
OV	cis	rs4918798	0.696	rs2153629	ENSG00000234724.1	HDAC1P1	4.48	1.17e-05	0.0058	0.53	0.29	Warfarin maintenance dose;	chr10:94982038	chr10:94137748~94139500:+
OV	cis	rs9309473	0.95	rs2947860	ENSG00000163016.8	ALMS1P	4.48	1.17e-05	0.0058	0.34	0.29	Metabolite levels;	chr2:73628259	chr2:73644919~73685576:+
OV	cis	rs6940638	0.688	rs9393795	ENSG00000220721.1	OR1F12	4.48	1.17e-05	0.0058	0.31	0.29	Intelligence (multi-trait analysis);	chr6:27249940	chr6:28073316~28074233:+
OV	cis	rs1167832	0.645	rs1167828	ENSG00000278416.1	PMS2L2	-4.48	1.17e-05	0.0058	-0.45	-0.29	Ankle injury;	chr7:75534076	chr7:75344015~75359550:-
OV	cis	rs783540	1	rs11637433	ENSG00000278603.1	RP13-608F4.5	4.48	1.17e-05	0.0058	0.33	0.29	Schizophrenia;	chr15:82652585	chr15:82472203~82472426:+
OV	cis	rs6772849	0.775	rs67105978	ENSG00000242551.2	POU5F1P6	-4.48	1.18e-05	0.00581	-0.34	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128696337	chr3:128674735~128677005:-
OV	cis	rs6772849	0.768	rs9820741	ENSG00000242551.2	POU5F1P6	-4.48	1.18e-05	0.00581	-0.34	-0.29	Monocyte percentage of white cells;Monocyte count;	chr3:128697237	chr3:128674735~128677005:-
OV	cis	rs58521262	0.652	rs4024169	ENSG00000269509.1	BNIP3P34	4.48	1.18e-05	0.00582	0.36	0.29	Testicular germ cell tumor;	chr19:22718861	chr19:22773853~22774424:+
OV	cis	rs853679	0.607	rs66886492	ENSG00000220721.1	OR1F12	4.48	1.18e-05	0.00582	0.56	0.29	Depression;	chr6:28121953	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs35345226	ENSG00000220721.1	OR1F12	4.48	1.18e-05	0.00582	0.56	0.29	Depression;	chr6:28123802	chr6:28073316~28074233:+
OV	cis	rs514406	0.644	rs6661196	ENSG00000206627.1	RNU6-969P	-4.48	1.18e-05	0.00582	-0.3	-0.29	Monocyte count;	chr1:52737992	chr1:52805108~52805212:-
OV	cis	rs8054556	1	rs4788200	ENSG00000261367.1	RP11-455F5.4	-4.48	1.18e-05	0.00582	-0.32	-0.29	Autism spectrum disorder or schizophrenia;	chr16:29959944	chr16:30107675~30110541:+
OV	cis	rs8054556	1	rs4788201	ENSG00000261367.1	RP11-455F5.4	-4.48	1.18e-05	0.00582	-0.32	-0.29	Autism spectrum disorder or schizophrenia;	chr16:29961369	chr16:30107675~30110541:+
OV	cis	rs8054556	1	rs6565173	ENSG00000261367.1	RP11-455F5.4	-4.48	1.18e-05	0.00582	-0.32	-0.29	Autism spectrum disorder or schizophrenia;	chr16:29962846	chr16:30107675~30110541:+
OV	cis	rs4908768	0.906	rs56163601	ENSG00000228423.2	RP4-633I8.4	4.48	1.18e-05	0.00582	0.36	0.29	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8691838	chr1:8805860~8807051:-
OV	cis	rs875971	0.862	rs11765791	ENSG00000237310.1	GS1-124K5.4	4.48	1.18e-05	0.00582	0.29	0.29	Aortic root size;	chr7:66471587	chr7:66493706~66495474:+
OV	cis	rs7267979	0.932	rs6107052	ENSG00000274973.1	RP13-401N8.7	-4.48	1.18e-05	0.00583	-0.32	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25550202	chr20:25845497~25845862:+
OV	cis	rs7267979	0.932	rs928121	ENSG00000274973.1	RP13-401N8.7	-4.48	1.18e-05	0.00583	-0.32	-0.29	Liver enzyme levels (alkaline phosphatase);	chr20:25554182	chr20:25845497~25845862:+
OV	cis	rs853679	0.546	rs493161	ENSG00000220721.1	OR1F12	4.48	1.18e-05	0.00583	0.47	0.29	Depression;	chr6:27882936	chr6:28073316~28074233:+
OV	cis	rs875971	0.545	rs73152714	ENSG00000226824.5	RP4-756H11.3	-4.48	1.18e-05	0.00583	-0.34	-0.29	Aortic root size;	chr7:66534641	chr7:66654538~66669855:+
OV	cis	rs875971	0.545	rs4718364	ENSG00000226824.5	RP4-756H11.3	-4.48	1.18e-05	0.00583	-0.34	-0.29	Aortic root size;	chr7:66536353	chr7:66654538~66669855:+
OV	cis	rs875971	0.545	rs6961853	ENSG00000226824.5	RP4-756H11.3	-4.48	1.18e-05	0.00583	-0.34	-0.29	Aortic root size;	chr7:66537035	chr7:66654538~66669855:+
OV	cis	rs875971	0.528	rs801213	ENSG00000226824.5	RP4-756H11.3	4.48	1.18e-05	0.00583	0.34	0.29	Aortic root size;	chr7:66549931	chr7:66654538~66669855:+
OV	cis	rs875971	0.545	rs801212	ENSG00000226824.5	RP4-756H11.3	4.48	1.18e-05	0.00583	0.34	0.29	Aortic root size;	chr7:66550643	chr7:66654538~66669855:+
OV	cis	rs9880211	0.898	rs13434116	ENSG00000239213.4	NCK1-AS1	4.48	1.18e-05	0.00583	0.35	0.29	Height;Body mass index;	chr3:136634232	chr3:136841726~136862054:-
OV	cis	rs9368481	0.729	rs9379950	ENSG00000241549.7	GUSBP2	-4.48	1.18e-05	0.00584	-0.28	-0.29	Autism spectrum disorder or schizophrenia;	chr6:26993769	chr6:26871484~26956554:-
OV	cis	rs9368481	1	rs9368481	ENSG00000241549.7	GUSBP2	-4.48	1.18e-05	0.00584	-0.28	-0.29	Autism spectrum disorder or schizophrenia;	chr6:26993982	chr6:26871484~26956554:-
OV	cis	rs1561570	0.934	rs10752286	ENSG00000228330.1	RP11-730A19.5	-4.48	1.18e-05	0.00584	-0.31	-0.29	Paget's disease;	chr10:13118103	chr10:13142185~13142977:-
OV	cis	rs7667	0.812	rs12091047	ENSG00000240490.3	RN7SL277P	-4.48	1.18e-05	0.00584	-0.34	-0.29	Crohn's disease and psoriasis;	chr1:19445431	chr1:19424384~19424671:+
OV	cis	rs28735056	0.572	rs4799100	ENSG00000261126.6	RP11-795F19.1	-4.48	1.18e-05	0.00584	-0.3	-0.29	Schizophrenia;	chr18:79880207	chr18:80046900~80095482:+
OV	cis	rs896854	0.967	rs13257021	ENSG00000253528.2	RP11-347C18.4	4.48	1.18e-05	0.00584	0.28	0.29	Type 2 diabetes;	chr8:94953467	chr8:94974573~94974853:-
OV	cis	rs896854	0.967	rs10808671	ENSG00000253528.2	RP11-347C18.4	4.48	1.18e-05	0.00584	0.28	0.29	Type 2 diabetes;	chr8:94955144	chr8:94974573~94974853:-
OV	cis	rs896854	0.967	rs10956933	ENSG00000253528.2	RP11-347C18.4	4.48	1.18e-05	0.00584	0.28	0.29	Type 2 diabetes;	chr8:94955460	chr8:94974573~94974853:-
OV	cis	rs73201462	1	rs2999061	ENSG00000277250.1	Metazoa_SRP	4.48	1.18e-05	0.00585	0.42	0.29	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128274780	chr3:128673681~128674021:-
OV	cis	rs6500602	0.727	rs7193136	ENSG00000280063.1	RP11-295D4.3	4.48	1.18e-05	0.00585	0.22	0.29	Schizophrenia;	chr16:4530033	chr16:4346694~4348648:-
OV	cis	rs853679	0.546	rs200977	ENSG00000220721.1	OR1F12	4.48	1.18e-05	0.00585	0.47	0.29	Depression;	chr6:27886523	chr6:28073316~28074233:+
OV	cis	rs67311347	1	rs9874006	ENSG00000223797.4	ENTPD3-AS1	4.48	1.18e-05	0.00585	0.31	0.29	Renal cell carcinoma;	chr3:40430105	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs34762643	ENSG00000223797.4	ENTPD3-AS1	4.48	1.18e-05	0.00585	0.31	0.29	Renal cell carcinoma;	chr3:40433942	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs9841335	ENSG00000223797.4	ENTPD3-AS1	4.48	1.18e-05	0.00585	0.31	0.29	Renal cell carcinoma;	chr3:40434367	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs28434528	ENSG00000223797.4	ENTPD3-AS1	4.48	1.18e-05	0.00585	0.31	0.29	Renal cell carcinoma;	chr3:40443402	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs11716675	ENSG00000223797.4	ENTPD3-AS1	4.48	1.18e-05	0.00585	0.31	0.29	Renal cell carcinoma;	chr3:40443789	chr3:40313802~40453329:-
OV	cis	rs1584120	0.503	rs11046804	ENSG00000274885.1	RP11-268P4.6	-4.48	1.19e-05	0.00585	-0.33	-0.28	Pelvic organ prolapse (moderate/severe);	chr12:23117772	chr12:22638464~22638943:+
OV	cis	rs11096990	0.634	rs12648793	ENSG00000249207.1	RP11-360F5.1	4.48	1.19e-05	0.00585	0.3	0.28	Cognitive function;	chr4:39284473	chr4:39112677~39126818:-
OV	cis	rs4713118	0.568	rs9468213	ENSG00000220721.1	OR1F12	4.48	1.19e-05	0.00585	0.29	0.28	Parkinson's disease;	chr6:27738401	chr6:28073316~28074233:+
OV	cis	rs473651	0.904	rs501333	ENSG00000229915.1	AC016999.2	-4.48	1.19e-05	0.00585	-0.36	-0.28	Multiple system atrophy;	chr2:238427404	chr2:238427077~238427729:-
OV	cis	rs10924970	0.687	rs10802438	ENSG00000236863.2	RPL23AP23	4.48	1.19e-05	0.00586	0.3	0.28	Asthma;	chr1:235194228	chr1:235295865~235296335:+
OV	cis	rs17301013	0.606	rs17350956	ENSG00000227373.4	RP11-160H22.5	4.48	1.19e-05	0.00586	0.39	0.28	Systemic lupus erythematosus;	chr1:174093863	chr1:174115300~174160004:-
OV	cis	rs12681963	0.686	rs11557703	ENSG00000271869.1	RP11-51J9.5	-4.48	1.19e-05	0.00587	-0.44	-0.28	Migraine;	chr8:30104435	chr8:30155830~30156232:-
OV	cis	rs1020064	0.636	rs1529975	ENSG00000235319.1	AC012360.4	-4.48	1.19e-05	0.00587	-0.35	-0.28	AIDS;	chr2:105313444	chr2:105324210~105330529:+
OV	cis	rs13113518	0.812	rs11932712	ENSG00000223305.1	RN7SKP30	4.48	1.19e-05	0.00587	0.33	0.28	Height;	chr4:55436423	chr4:55540502~55540835:-
OV	cis	rs13113518	0.812	rs12501746	ENSG00000223305.1	RN7SKP30	4.48	1.19e-05	0.00587	0.33	0.28	Height;	chr4:55437438	chr4:55540502~55540835:-
OV	cis	rs2239557	1	rs2358633	ENSG00000259065.1	RP5-1021I20.1	4.48	1.19e-05	0.00588	0.34	0.28	Common traits (Other);	chr14:74180715	chr14:73787360~73803270:+
OV	cis	rs6460942	0.597	rs6944517	ENSG00000226690.5	AC005281.1	4.48	1.19e-05	0.00588	0.49	0.28	Coronary artery disease;	chr7:12475657	chr7:12496429~12541910:+
OV	cis	rs6460942	0.597	rs6968664	ENSG00000226690.5	AC005281.1	4.48	1.19e-05	0.00588	0.49	0.28	Coronary artery disease;	chr7:12475867	chr7:12496429~12541910:+
OV	cis	rs7617773	0.71	rs36064160	ENSG00000228638.1	FCF1P2	-4.48	1.19e-05	0.00589	-0.37	-0.28	Coronary artery disease;	chr3:48201611	chr3:48290793~48291375:-
OV	cis	rs8005677	0.798	rs4982713	ENSG00000279656.1	RP11-298I3.6	4.48	1.19e-05	0.00589	0.32	0.28	Cognitive ability (multi-trait analysis);	chr14:22934893	chr14:23023083~23024217:-
OV	cis	rs8005677	0.798	rs35615180	ENSG00000279656.1	RP11-298I3.6	4.48	1.19e-05	0.00589	0.32	0.28	Cognitive ability (multi-trait analysis);	chr14:22935180	chr14:23023083~23024217:-
OV	cis	rs1569175	0.522	rs10221945	ENSG00000232732.8	AC073043.1	4.48	1.19e-05	0.00589	0.45	0.28	Response to treatment for acute lymphoblastic leukemia;	chr2:200011124	chr2:199867396~199911159:-
OV	cis	rs1569175	0.522	rs2202923	ENSG00000232732.8	AC073043.1	4.48	1.19e-05	0.00589	0.45	0.28	Response to treatment for acute lymphoblastic leukemia;	chr2:200015081	chr2:199867396~199911159:-
OV	cis	rs1538970	1	rs2492840	ENSG00000280836.1	AL355480.1	-4.48	1.2e-05	0.0059	-0.39	-0.28	Platelet count;	chr1:45384120	chr1:45581219~45581321:-
OV	cis	rs2999052	0.509	rs1735537	ENSG00000277250.1	Metazoa_SRP	4.48	1.2e-05	0.0059	0.39	0.28	Hypospadias;	chr3:128403977	chr3:128673681~128674021:-
OV	cis	rs757110	0.526	rs757081	ENSG00000213779.4	RP11-452G18.1	4.48	1.2e-05	0.0059	0.36	0.28	Type 2 diabetes;	chr11:17330136	chr11:17193489~17194308:+
OV	cis	rs9813712	0.595	rs12490957	ENSG00000228252.7	COL6A4P2	4.48	1.2e-05	0.0059	0.32	0.28	Response to amphetamines;	chr3:130287851	chr3:130212823~130273806:+
OV	cis	rs7605378	0.964	rs2689763	ENSG00000232732.8	AC073043.1	-4.48	1.2e-05	0.00591	-0.35	-0.28	Osteoporosis;	chr2:199824832	chr2:199867396~199911159:-
OV	cis	rs7615952	0.688	rs17334074	ENSG00000171084.14	FAM86JP	-4.48	1.2e-05	0.00591	-0.44	-0.28	Blood pressure (smoking interaction);	chr3:125821617	chr3:125916620~125930024:+
OV	cis	rs73201462	1	rs2955126	ENSG00000277250.1	Metazoa_SRP	-4.48	1.2e-05	0.00591	-0.43	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128207411	chr3:128673681~128674021:-
OV	cis	rs9816784	0.566	rs11720913	ENSG00000231464.1	AC024937.4	4.48	1.2e-05	0.00592	0.33	0.28	Mean corpuscular hemoglobin;	chr3:196105689	chr3:195996738~195998233:+
OV	cis	rs6772849	0.93	rs7639400	ENSG00000277250.1	Metazoa_SRP	-4.48	1.2e-05	0.00592	-0.34	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128604513	chr3:128673681~128674021:-
OV	cis	rs17711722	0.522	rs6957759	ENSG00000226824.5	RP4-756H11.3	-4.48	1.2e-05	0.00592	-0.32	-0.28	Calcium levels;	chr7:65806798	chr7:66654538~66669855:+
OV	cis	rs3930017	1	rs3930017	ENSG00000225726.1	AC007000.10	-4.48	1.2e-05	0.00592	-0.27	-0.28	Body mass index;	chr7:77091265	chr7:77071751~77072237:-
OV	cis	rs4713118	0.955	rs9468204	ENSG00000280107.1	AL022393.9	-4.48	1.2e-05	0.00592	-0.35	-0.28	Parkinson's disease;	chr6:27721030	chr6:28170845~28172521:+
OV	cis	rs3814244	0.966	rs10784666	ENSG00000255733.4	IFNG-AS1	-4.48	1.2e-05	0.00592	-0.27	-0.28	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021923	chr12:67989445~68234686:+
OV	cis	rs3814244	0.966	rs10784667	ENSG00000255733.4	IFNG-AS1	-4.48	1.2e-05	0.00592	-0.27	-0.28	Itch intensity from mosquito bite adjusted by bite size;	chr12:68021996	chr12:67989445~68234686:+
OV	cis	rs6940638	0.688	rs9295730	ENSG00000220721.1	OR1F12	4.48	1.2e-05	0.00593	0.3	0.28	Intelligence (multi-trait analysis);	chr6:27161027	chr6:28073316~28074233:+
OV	cis	rs1528149	0.504	rs7795348	ENSG00000272537.1	GS1-166A23.1	-4.48	1.2e-05	0.00593	-0.32	-0.28	Sitting height ratio;	chr7:16110647	chr7:16471184~16471373:+
OV	cis	rs17301013	0.606	rs1894198	ENSG00000227373.4	RP11-160H22.5	-4.48	1.2e-05	0.00593	-0.36	-0.28	Systemic lupus erythematosus;	chr1:174835393	chr1:174115300~174160004:-
OV	cis	rs17301013	0.659	rs1894199	ENSG00000227373.4	RP11-160H22.5	-4.48	1.2e-05	0.00593	-0.36	-0.28	Systemic lupus erythematosus;	chr1:174835545	chr1:174115300~174160004:-
OV	cis	rs1790761	0.505	rs7106423	ENSG00000184224.3	C11orf72	-4.48	1.21e-05	0.00595	-0.32	-0.28	Mean corpuscular volume;	chr11:67546673	chr11:67602880~67606706:-
OV	cis	rs8054556	1	rs4787489	ENSG00000261367.1	RP11-455F5.4	-4.48	1.21e-05	0.00595	-0.32	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29984559	chr16:30107675~30110541:+
OV	cis	rs875971	0.767	rs61348003	ENSG00000236529.1	RP13-254B10.1	4.47	1.21e-05	0.00596	0.29	0.28	Aortic root size;	chr7:66540947	chr7:65840212~65840596:+
OV	cis	rs607987	0.756	rs1765134	ENSG00000254532.1	RP11-624D11.2	4.47	1.21e-05	0.00597	0.34	0.28	Body mass index;	chr11:30354497	chr11:30044058~30084343:-
OV	cis	rs67311347	1	rs2168111	ENSG00000223797.4	ENTPD3-AS1	4.47	1.21e-05	0.00598	0.3	0.28	Renal cell carcinoma;	chr3:40353834	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs9834052	ENSG00000223797.4	ENTPD3-AS1	4.47	1.21e-05	0.00598	0.3	0.28	Renal cell carcinoma;	chr3:40357569	chr3:40313802~40453329:-
OV	cis	rs67311347	0.955	rs6773383	ENSG00000223797.4	ENTPD3-AS1	4.47	1.21e-05	0.00598	0.3	0.28	Renal cell carcinoma;	chr3:40335921	chr3:40313802~40453329:-
OV	cis	rs172166	0.694	rs203884	ENSG00000280107.1	AL022393.9	-4.47	1.22e-05	0.00599	-0.33	-0.28	Cardiac Troponin-T levels;	chr6:28109596	chr6:28170845~28172521:+
OV	cis	rs67311347	1	rs13324109	ENSG00000223797.4	ENTPD3-AS1	4.47	1.22e-05	0.00599	0.3	0.28	Renal cell carcinoma;	chr3:40419276	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs1466237	ENSG00000223797.4	ENTPD3-AS1	4.47	1.22e-05	0.00599	0.3	0.28	Renal cell carcinoma;	chr3:40420535	chr3:40313802~40453329:-
OV	cis	rs1150668	0.796	rs213237	ENSG00000204709.4	LINC01556	4.47	1.22e-05	0.006	0.34	0.28	Pubertal anthropometrics;	chr6:28356161	chr6:28943877~28944537:+
OV	cis	rs9660180	0.78	rs12038111	ENSG00000215914.4	MMP23A	-4.47	1.22e-05	0.006	-0.33	-0.28	Body mass index;	chr1:1772410	chr1:1699942~1701782:+
OV	cis	rs9660180	0.836	rs12038134	ENSG00000215914.4	MMP23A	-4.47	1.22e-05	0.006	-0.33	-0.28	Body mass index;	chr1:1772426	chr1:1699942~1701782:+
OV	cis	rs829883	0.664	rs829876	ENSG00000227825.4	SLC9A7P1	4.47	1.22e-05	0.006	0.29	0.28	Colorectal adenoma (advanced);	chr12:98448360	chr12:98453835~98457145:-
OV	cis	rs7968440	0.931	rs2251024	ENSG00000257298.1	RP3-405J10.3	4.47	1.22e-05	0.006	0.27	0.28	Fibrinogen;	chr12:50709850	chr12:50185580~50191363:-
OV	cis	rs62445005	1	rs62445005	ENSG00000211699.2	TRGV3	4.47	1.22e-05	0.006	0.33	0.28	Shingles;	chr7:38346957	chr7:38358512~38359162:-
OV	cis	rs10931896	0.531	rs295118	ENSG00000232732.8	AC073043.1	-4.47	1.22e-05	0.00601	-0.33	-0.28	Systolic blood pressure;	chr2:200279281	chr2:199867396~199911159:-
OV	cis	rs9287719	0.615	rs12613769	ENSG00000243819.4	RN7SL832P	4.47	1.22e-05	0.00601	0.3	0.28	Prostate cancer;	chr2:10602164	chr2:10690344~10692099:+
OV	cis	rs2015599	0.549	rs7134796	ENSG00000275476.1	RP11-996F15.4	4.47	1.22e-05	0.00602	0.37	0.28	Platelet count;Mean platelet volume;	chr12:29294361	chr12:29277397~29277882:-
OV	cis	rs2274471	0.645	rs12237834	ENSG00000234534.1	CSNK1G2P1	4.47	1.22e-05	0.00602	0.37	0.28	Crohn's disease;	chr9:5093646	chr9:5040945~5041940:+
OV	cis	rs829883	0.664	rs829864	ENSG00000227825.4	SLC9A7P1	4.47	1.23e-05	0.00602	0.3	0.28	Colorectal adenoma (advanced);	chr12:98456417	chr12:98453835~98457145:-
OV	cis	rs829883	0.664	rs1096148	ENSG00000227825.4	SLC9A7P1	4.47	1.23e-05	0.00602	0.3	0.28	Colorectal adenoma (advanced);	chr12:98457227	chr12:98453835~98457145:-
OV	cis	rs829883	0.664	rs865509	ENSG00000227825.4	SLC9A7P1	4.47	1.23e-05	0.00602	0.3	0.28	Colorectal adenoma (advanced);	chr12:98460666	chr12:98453835~98457145:-
OV	cis	rs829883	0.639	rs829898	ENSG00000227825.4	SLC9A7P1	4.47	1.23e-05	0.00602	0.3	0.28	Colorectal adenoma (advanced);	chr12:98463897	chr12:98453835~98457145:-
OV	cis	rs875971	0.508	rs10242423	ENSG00000224316.1	RP11-479O9.2	-4.47	1.23e-05	0.00603	-0.3	-0.28	Aortic root size;	chr7:66594188	chr7:65773620~65802067:+
OV	cis	rs875971	0.508	rs10253883	ENSG00000224316.1	RP11-479O9.2	-4.47	1.23e-05	0.00603	-0.3	-0.28	Aortic root size;	chr7:66596151	chr7:65773620~65802067:+
OV	cis	rs611744	0.523	rs13253581	ENSG00000253754.1	RP11-35G22.1	-4.47	1.23e-05	0.00603	-0.31	-0.28	Dupuytren's disease;	chr8:108330876	chr8:108226200~108227544:+
OV	cis	rs853679	0.546	rs35819751	ENSG00000220721.1	OR1F12	4.47	1.23e-05	0.00603	0.56	0.28	Depression;	chr6:27842791	chr6:28073316~28074233:+
OV	cis	rs12701220	0.655	rs10241018	ENSG00000229043.2	AC091729.9	-4.47	1.23e-05	0.00603	-0.36	-0.28	Bronchopulmonary dysplasia;	chr7:1105138	chr7:1160374~1165267:+
OV	cis	rs7429990	0.965	rs796566	ENSG00000229759.1	MRPS18AP1	4.47	1.23e-05	0.00603	0.3	0.28	Educational attainment (years of education);	chr3:47896864	chr3:48256350~48256938:-
OV	cis	rs9309473	1	rs7598396	ENSG00000163016.8	ALMS1P	4.47	1.23e-05	0.00603	0.32	0.28	Metabolite levels;	chr2:73425500	chr2:73644919~73685576:+
OV	cis	rs7119	0.651	rs12917431	ENSG00000259362.2	RP11-307C19.1	-4.47	1.23e-05	0.00604	-0.33	-0.28	Type 2 diabetes;	chr15:77557842	chr15:77525540~77534110:+
OV	cis	rs17301013	0.507	rs61528155	ENSG00000227373.4	RP11-160H22.5	4.47	1.23e-05	0.00604	0.39	0.28	Systemic lupus erythematosus;	chr1:174276140	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12066700	ENSG00000227373.4	RP11-160H22.5	4.47	1.23e-05	0.00604	0.39	0.28	Systemic lupus erythematosus;	chr1:174282054	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs12060460	ENSG00000227373.4	RP11-160H22.5	4.47	1.23e-05	0.00604	0.39	0.28	Systemic lupus erythematosus;	chr1:174284513	chr1:174115300~174160004:-
OV	cis	rs7512898	0.5	rs10753881	ENSG00000260088.1	RP11-92G12.3	-4.47	1.23e-05	0.00604	-0.32	-0.28	Electrocardiographic conduction measures;	chr1:200796185	chr1:200669507~200694250:+
OV	cis	rs875971	0.508	rs10950045	ENSG00000224316.1	RP11-479O9.2	-4.47	1.23e-05	0.00605	-0.3	-0.28	Aortic root size;	chr7:66601386	chr7:65773620~65802067:+
OV	cis	rs801193	0.839	rs6968619	ENSG00000224316.1	RP11-479O9.2	-4.47	1.23e-05	0.00605	-0.3	-0.28	Aortic root size;	chr7:66603880	chr7:65773620~65802067:+
OV	cis	rs801193	0.839	rs12534943	ENSG00000224316.1	RP11-479O9.2	-4.47	1.23e-05	0.00605	-0.3	-0.28	Aortic root size;	chr7:66605533	chr7:65773620~65802067:+
OV	cis	rs801193	0.805	rs12532355	ENSG00000224316.1	RP11-479O9.2	-4.47	1.23e-05	0.00605	-0.3	-0.28	Aortic root size;	chr7:66605597	chr7:65773620~65802067:+
OV	cis	rs934734	0.563	rs1858036	ENSG00000234255.7	AC012370.3	4.47	1.23e-05	0.00605	0.31	0.28	Rheumatoid arthritis;	chr2:65371107	chr2:65439888~65456571:-
OV	cis	rs934734	0.563	rs1858037	ENSG00000234255.7	AC012370.3	4.47	1.23e-05	0.00605	0.31	0.28	Rheumatoid arthritis;	chr2:65371166	chr2:65439888~65456571:-
OV	cis	rs11118620	0.622	rs11118618	ENSG00000238078.1	LINC01352	4.47	1.23e-05	0.00605	0.39	0.28	Heart failure;	chr1:220838204	chr1:220829255~220832429:+
OV	cis	rs6772849	0.708	rs12491942	ENSG00000242551.2	POU5F1P6	-4.47	1.23e-05	0.00605	-0.34	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128702626	chr3:128674735~128677005:-
OV	cis	rs2243480	0.522	rs12698511	ENSG00000222364.1	RNU6-96P	-4.47	1.23e-05	0.00606	-0.5	-0.28	Diabetic kidney disease;	chr7:66009932	chr7:66395191~66395286:+
OV	cis	rs6860806	0.507	rs156322	ENSG00000233006.5	AC034220.3	4.47	1.23e-05	0.00606	0.31	0.28	Breast cancer;	chr5:132318232	chr5:132311285~132369916:-
OV	cis	rs7688540	0.771	rs4549329	ENSG00000275426.1	CH17-262A2.1	4.47	1.24e-05	0.00606	0.45	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245996	chr4:149738~150317:+
OV	cis	rs12073359	1	rs3208509	ENSG00000223945.2	RP11-458I7.1	4.47	1.24e-05	0.00607	0.42	0.28	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150157141	chr1:150053864~150055034:+
OV	cis	rs2243480	1	rs160655	ENSG00000226824.5	RP4-756H11.3	-4.47	1.24e-05	0.00607	-0.47	-0.28	Diabetic kidney disease;	chr7:66068227	chr7:66654538~66669855:+
OV	cis	rs2243480	0.803	rs160649	ENSG00000226824.5	RP4-756H11.3	-4.47	1.24e-05	0.00607	-0.47	-0.28	Diabetic kidney disease;	chr7:66078212	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs160648	ENSG00000226824.5	RP4-756H11.3	-4.47	1.24e-05	0.00607	-0.47	-0.28	Diabetic kidney disease;	chr7:66078397	chr7:66654538~66669855:+
OV	cis	rs10924970	0.649	rs12036412	ENSG00000236863.2	RPL23AP23	4.47	1.24e-05	0.00607	0.3	0.28	Asthma;	chr1:235235497	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs6673756	ENSG00000236863.2	RPL23AP23	4.47	1.24e-05	0.00607	0.3	0.28	Asthma;	chr1:235248819	chr1:235295865~235296335:+
OV	cis	rs7116641	0.961	rs7928523	ENSG00000246250.2	RP11-613D13.5	4.47	1.24e-05	0.00607	0.32	0.28	Coronary artery disease;	chr11:43697551	chr11:43829709~43880726:-
OV	cis	rs8062405	0.789	rs1968752	ENSG00000259982.1	CDC37P1	4.47	1.24e-05	0.00608	0.34	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28620264	chr16:28700294~28701540:-
OV	cis	rs1823913	0.599	rs2168166	ENSG00000227542.1	AC092614.2	4.47	1.24e-05	0.00608	0.31	0.28	Obesity-related traits;	chr2:191288063	chr2:191229165~191246172:-
OV	cis	rs6772849	0.93	rs1962040	ENSG00000277250.1	Metazoa_SRP	-4.47	1.24e-05	0.00609	-0.34	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128605318	chr3:128673681~128674021:-
OV	cis	rs7829975	0.577	rs940030	ENSG00000253893.2	FAM85B	4.47	1.24e-05	0.0061	0.32	0.28	Mood instability;	chr8:8689418	chr8:8167819~8226614:-
OV	cis	rs7429990	0.833	rs2293226	ENSG00000229759.1	MRPS18AP1	4.47	1.24e-05	0.0061	0.3	0.28	Educational attainment (years of education);	chr3:47585292	chr3:48256350~48256938:-
OV	cis	rs67311347	0.955	rs11717036	ENSG00000223797.4	ENTPD3-AS1	-4.47	1.25e-05	0.00611	-0.3	-0.28	Renal cell carcinoma;	chr3:40338087	chr3:40313802~40453329:-
OV	cis	rs7520050	0.778	rs3014216	ENSG00000281133.1	AL355480.3	-4.47	1.25e-05	0.00612	-0.32	-0.28	Reticulocyte count;Red blood cell count;	chr1:45570088	chr1:45580892~45580996:-
OV	cis	rs875971	0.545	rs73376401	ENSG00000236529.1	RP13-254B10.1	4.47	1.25e-05	0.00613	0.33	0.28	Aortic root size;	chr7:66174841	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs6460276	ENSG00000236529.1	RP13-254B10.1	4.47	1.25e-05	0.00613	0.33	0.28	Aortic root size;	chr7:66182290	chr7:65840212~65840596:+
OV	cis	rs13068223	0.84	rs11709829	ENSG00000243926.1	TIPARP-AS1	4.47	1.25e-05	0.00613	0.26	0.28	Age-related hearing impairment (SNP x SNP interaction);	chr3:156716300	chr3:156671862~156674378:-
OV	cis	rs9309473	0.95	rs13431529	ENSG00000163016.8	ALMS1P	4.47	1.25e-05	0.00614	0.34	0.28	Metabolite levels;	chr2:73648914	chr2:73644919~73685576:+
OV	cis	rs9309473	0.95	rs13408433	ENSG00000163016.8	ALMS1P	4.47	1.25e-05	0.00614	0.34	0.28	Metabolite levels;	chr2:73655945	chr2:73644919~73685576:+
OV	cis	rs7812879	0.852	rs998682	ENSG00000255052.4	FAM66D	4.47	1.25e-05	0.00614	0.41	0.28	Systemic lupus erythematosus;	chr8:11495543	chr8:12115782~12177550:+
OV	cis	rs11903757	1	rs6717663	ENSG00000281467.1	Clostridiales-1	-4.47	1.25e-05	0.00614	-0.49	-0.28	Colorectal cancer;	chr2:191724659	chr2:191699476~191699631:-
OV	cis	rs11903757	1	rs6717668	ENSG00000281467.1	Clostridiales-1	-4.47	1.25e-05	0.00614	-0.49	-0.28	Colorectal cancer;	chr2:191724673	chr2:191699476~191699631:-
OV	cis	rs638893	1	rs28827279	ENSG00000255239.1	AP002954.6	4.47	1.25e-05	0.00614	0.43	0.28	Vitiligo;	chr11:118830054	chr11:118688039~118690600:-
OV	cis	rs1555322	0.53	rs6060341	ENSG00000269202.1	RP4-614O4.12	4.47	1.25e-05	0.00614	0.33	0.28	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35201747~35203288:-
OV	cis	rs1075265	0.933	rs7560947	ENSG00000233266.1	HMGB1P31	4.47	1.25e-05	0.00615	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54087473	chr2:54051334~54051760:+
OV	cis	rs11096990	0.855	rs2711989	ENSG00000249207.1	RP11-360F5.1	4.47	1.26e-05	0.00615	0.34	0.28	Cognitive function;	chr4:39150416	chr4:39112677~39126818:-
OV	cis	rs11096990	0.855	rs2566169	ENSG00000249207.1	RP11-360F5.1	4.47	1.26e-05	0.00615	0.34	0.28	Cognitive function;	chr4:39150420	chr4:39112677~39126818:-
OV	cis	rs172166	0.694	rs2791332	ENSG00000280107.1	AL022393.9	-4.47	1.26e-05	0.00615	-0.34	-0.28	Cardiac Troponin-T levels;	chr6:28141010	chr6:28170845~28172521:+
OV	cis	rs514406	0.607	rs6665324	ENSG00000206627.1	RNU6-969P	-4.47	1.26e-05	0.00616	-0.3	-0.28	Monocyte count;	chr1:52735938	chr1:52805108~52805212:-
OV	cis	rs514406	0.644	rs7552663	ENSG00000206627.1	RNU6-969P	-4.47	1.26e-05	0.00616	-0.3	-0.28	Monocyte count;	chr1:52738680	chr1:52805108~52805212:-
OV	cis	rs514406	0.644	rs7529978	ENSG00000206627.1	RNU6-969P	-4.47	1.26e-05	0.00616	-0.3	-0.28	Monocyte count;	chr1:52739033	chr1:52805108~52805212:-
OV	cis	rs514406	0.644	rs7530078	ENSG00000206627.1	RNU6-969P	-4.47	1.26e-05	0.00616	-0.3	-0.28	Monocyte count;	chr1:52739189	chr1:52805108~52805212:-
OV	cis	rs140174	0.763	rs131421	ENSG00000273000.4	KB-1572G7.2	4.47	1.26e-05	0.00617	0.26	0.28	Migraine;	chr22:23579015	chr22:23652860~23717347:-
OV	cis	rs7927592	0.913	rs10896329	ENSG00000212093.1	AP000807.1	4.46	1.26e-05	0.00618	0.36	0.28	Total body bone mineral density;	chr11:68482561	chr11:68506083~68506166:-
OV	cis	rs10924970	0.747	rs10218726	ENSG00000236863.2	RPL23AP23	4.46	1.26e-05	0.00618	0.29	0.28	Asthma;	chr1:235255384	chr1:235295865~235296335:+
OV	cis	rs13113518	0.783	rs12504300	ENSG00000223305.1	RN7SKP30	4.46	1.26e-05	0.00618	0.34	0.28	Height;	chr4:55482360	chr4:55540502~55540835:-
OV	cis	rs7259376	0.902	rs10409947	ENSG00000269742.1	BNIP3P29	4.46	1.26e-05	0.00618	0.33	0.28	Menopause (age at onset);	chr19:22329716	chr19:22065828~22066398:-
OV	cis	rs7259376	0.875	rs1991830	ENSG00000269742.1	BNIP3P29	4.46	1.26e-05	0.00618	0.33	0.28	Menopause (age at onset);	chr19:22331928	chr19:22065828~22066398:-
OV	cis	rs8005677	0.828	rs35085068	ENSG00000279656.1	RP11-298I3.6	4.46	1.26e-05	0.00618	0.32	0.28	Cognitive ability (multi-trait analysis);	chr14:22940700	chr14:23023083~23024217:-
OV	cis	rs8005677	0.828	rs4981451	ENSG00000279656.1	RP11-298I3.6	4.46	1.26e-05	0.00618	0.32	0.28	Cognitive ability (multi-trait analysis);	chr14:22941072	chr14:23023083~23024217:-
OV	cis	rs8005677	0.798	rs4536383	ENSG00000279656.1	RP11-298I3.6	4.46	1.26e-05	0.00618	0.32	0.28	Cognitive ability (multi-trait analysis);	chr14:22941717	chr14:23023083~23024217:-
OV	cis	rs8005677	0.828	rs34584578	ENSG00000279656.1	RP11-298I3.6	4.46	1.26e-05	0.00618	0.32	0.28	Cognitive ability (multi-trait analysis);	chr14:22942481	chr14:23023083~23024217:-
OV	cis	rs796364	1	rs796364	ENSG00000232732.8	AC073043.1	-4.46	1.26e-05	0.00619	-0.42	-0.28	Schizophrenia;	chr2:199851396	chr2:199867396~199911159:-
OV	cis	rs11098499	0.955	rs11944880	ENSG00000245958.5	RP11-33B1.1	4.46	1.26e-05	0.00619	0.32	0.28	Corneal astigmatism;	chr4:119238179	chr4:119454791~119552025:+
OV	cis	rs11673344	0.734	rs1667343	ENSG00000226686.6	LINC01535	4.46	1.27e-05	0.00619	0.36	0.28	Obesity-related traits;	chr19:36978196	chr19:37251912~37265535:+
OV	cis	rs7043114	0.525	rs710162	ENSG00000281156.1	MIR3651	4.46	1.27e-05	0.0062	0.31	0.28	Height;	chr9:92297508	chr9:92292458~92292547:-
OV	cis	rs4493873	0.812	rs10956792	ENSG00000253738.1	OTUD6B-AS1	-4.46	1.27e-05	0.0062	-0.35	-0.28	Migraine - clinic-based;	chr8:91097510	chr8:91059909~91070189:-
OV	cis	rs7043114	0.525	rs10761161	ENSG00000281156.1	MIR3651	-4.46	1.27e-05	0.0062	-0.31	-0.28	Height;	chr9:92500060	chr9:92292458~92292547:-
OV	cis	rs2412819	0.571	rs2930531	ENSG00000249839.1	AC011330.5	4.46	1.27e-05	0.0062	0.41	0.28	Lung cancer;	chr15:43829372	chr15:43663654~43684339:-
OV	cis	rs7617773	0.817	rs13100815	ENSG00000228638.1	FCF1P2	-4.46	1.27e-05	0.00621	-0.37	-0.28	Coronary artery disease;	chr3:48245959	chr3:48290793~48291375:-
OV	cis	rs1823913	0.599	rs58106487	ENSG00000227542.1	AC092614.2	4.46	1.27e-05	0.00621	0.31	0.28	Obesity-related traits;	chr2:191292404	chr2:191229165~191246172:-
OV	cis	rs13068223	0.607	rs193197	ENSG00000243926.1	TIPARP-AS1	-4.46	1.27e-05	0.00621	-0.27	-0.28	Age-related hearing impairment (SNP x SNP interaction);	chr3:156693943	chr3:156671862~156674378:-
OV	cis	rs1979679	0.879	rs980920	ENSG00000278733.1	RP11-425D17.1	4.46	1.27e-05	0.00622	0.34	0.28	Ossification of the posterior longitudinal ligament of the spine;	chr12:28316178	chr12:28185625~28186190:-
OV	cis	rs1979679	0.918	rs11049529	ENSG00000278733.1	RP11-425D17.1	4.46	1.27e-05	0.00622	0.34	0.28	Ossification of the posterior longitudinal ligament of the spine;	chr12:28318571	chr12:28185625~28186190:-
OV	cis	rs783540	0.843	rs28374463	ENSG00000278603.1	RP13-608F4.5	-4.46	1.27e-05	0.00622	-0.32	-0.28	Schizophrenia;	chr15:82630613	chr15:82472203~82472426:+
OV	cis	rs9880211	1	rs4038586	ENSG00000239213.4	NCK1-AS1	4.46	1.27e-05	0.00622	0.35	0.28	Height;Body mass index;	chr3:136644449	chr3:136841726~136862054:-
OV	cis	rs9880211	1	rs6767889	ENSG00000239213.4	NCK1-AS1	4.46	1.27e-05	0.00622	0.35	0.28	Height;Body mass index;	chr3:136646613	chr3:136841726~136862054:-
OV	cis	rs9880211	0.898	rs35304385	ENSG00000239213.4	NCK1-AS1	4.46	1.27e-05	0.00622	0.35	0.28	Height;Body mass index;	chr3:136667411	chr3:136841726~136862054:-
OV	cis	rs9880211	0.898	rs28877020	ENSG00000239213.4	NCK1-AS1	4.46	1.27e-05	0.00622	0.35	0.28	Height;Body mass index;	chr3:136676874	chr3:136841726~136862054:-
OV	cis	rs9880211	0.904	rs9857833	ENSG00000239213.4	NCK1-AS1	4.46	1.27e-05	0.00622	0.35	0.28	Height;Body mass index;	chr3:136685625	chr3:136841726~136862054:-
OV	cis	rs8059260	0.668	rs4781029	ENSG00000274038.1	RP11-66H6.4	-4.46	1.27e-05	0.00622	-0.56	-0.28	Alcohol consumption over the past year;	chr16:10983717	chr16:11056556~11057034:+
OV	cis	rs17301013	0.606	rs913687	ENSG00000227373.4	RP11-160H22.5	4.46	1.27e-05	0.00622	0.36	0.28	Systemic lupus erythematosus;	chr1:174805993	chr1:174115300~174160004:-
OV	cis	rs7520050	0.807	rs4660312	ENSG00000281133.1	AL355480.3	-4.46	1.27e-05	0.00623	-0.32	-0.28	Reticulocyte count;Red blood cell count;	chr1:45644900	chr1:45580892~45580996:-
OV	cis	rs1790761	0.505	rs7938563	ENSG00000184224.3	C11orf72	-4.46	1.27e-05	0.00623	-0.32	-0.28	Mean corpuscular volume;	chr11:67536660	chr11:67602880~67606706:-
OV	cis	rs7615952	0.688	rs12638240	ENSG00000171084.14	FAM86JP	4.46	1.28e-05	0.00623	0.45	0.28	Blood pressure (smoking interaction);	chr3:125822395	chr3:125916620~125930024:+
OV	cis	rs7615952	0.688	rs12638224	ENSG00000171084.14	FAM86JP	4.46	1.28e-05	0.00623	0.45	0.28	Blood pressure (smoking interaction);	chr3:125822477	chr3:125916620~125930024:+
OV	cis	rs2562784	0.638	rs2585064	ENSG00000235370.6	DNM1P51	4.46	1.28e-05	0.00623	0.5	0.28	Height;	chr15:83594757	chr15:84398316~84411701:-
OV	cis	rs783540	1	rs7496954	ENSG00000278603.1	RP13-608F4.5	4.46	1.28e-05	0.00623	0.32	0.28	Schizophrenia;	chr15:82676784	chr15:82472203~82472426:+
OV	cis	rs1858037	0.867	rs61226353	ENSG00000234255.7	AC012370.3	4.46	1.28e-05	0.00624	0.32	0.28	Rheumatoid arthritis;	chr2:65363637	chr2:65439888~65456571:-
OV	cis	rs35160687	0.842	rs1863052	ENSG00000273080.1	RP11-301O19.1	4.46	1.28e-05	0.00625	0.27	0.28	Night sleep phenotypes;	chr2:86332235	chr2:86195590~86196049:+
OV	cis	rs295490	0.748	rs74340696	ENSG00000272656.1	RP11-219D15.3	4.46	1.28e-05	0.00625	0.56	0.28	PR interval in Tripanosoma cruzi seropositivity;	chr3:139341859	chr3:139349024~139349371:-
OV	cis	rs7615952	0.599	rs6438953	ENSG00000171084.14	FAM86JP	4.46	1.28e-05	0.00625	0.39	0.28	Blood pressure (smoking interaction);	chr3:126006108	chr3:125916620~125930024:+
OV	cis	rs7615952	0.599	rs1044215	ENSG00000171084.14	FAM86JP	4.46	1.28e-05	0.00625	0.39	0.28	Blood pressure (smoking interaction);	chr3:126006716	chr3:125916620~125930024:+
OV	cis	rs62244186	0.715	rs13321717	ENSG00000214820.3	MPRIPP1	4.46	1.28e-05	0.00625	0.26	0.28	Depressive symptoms;	chr3:44625963	chr3:44579938~44581026:-
OV	cis	rs55726902	0.761	rs2544029	ENSG00000276691.1	RP5-1057I20.5	4.46	1.28e-05	0.00625	0.28	0.28	Allergic disease (asthma, hay fever or eczema);	chr12:47801174	chr12:47788426~47788971:+
OV	cis	rs992157	0.798	rs2382818	ENSG00000237281.1	CATIP-AS2	4.46	1.29e-05	0.00627	0.34	0.28	Colorectal cancer;	chr2:218291184	chr2:218326889~218357966:-
OV	cis	rs992157	0.798	rs2382819	ENSG00000237281.1	CATIP-AS2	4.46	1.29e-05	0.00627	0.34	0.28	Colorectal cancer;	chr2:218291186	chr2:218326889~218357966:-
OV	cis	rs7927592	0.913	rs7116994	ENSG00000212093.1	AP000807.1	4.46	1.29e-05	0.00628	0.35	0.28	Total body bone mineral density;	chr11:68487159	chr11:68506083~68506166:-
OV	cis	rs11992162	0.591	rs4240678	ENSG00000251402.3	FAM90A25P	-4.46	1.29e-05	0.00628	-0.35	-0.28	Monocyte count;	chr8:11944917	chr8:12415080~12418090:-
OV	cis	rs7302981	0.967	rs12815871	ENSG00000257298.1	RP3-405J10.3	4.46	1.29e-05	0.00629	0.27	0.28	Systolic blood pressure;	chr12:50157165	chr12:50185580~50191363:-
OV	cis	rs9660180	0.836	rs72634845	ENSG00000215914.4	MMP23A	-4.46	1.29e-05	0.00629	-0.33	-0.28	Body mass index;	chr1:1773460	chr1:1699942~1701782:+
OV	cis	rs9660180	0.868	rs72634846	ENSG00000215914.4	MMP23A	-4.46	1.29e-05	0.00629	-0.33	-0.28	Body mass index;	chr1:1773476	chr1:1699942~1701782:+
OV	cis	rs4908768	0.871	rs4908508	ENSG00000228423.2	RP4-633I8.4	4.46	1.29e-05	0.00629	0.33	0.28	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8740721	chr1:8805860~8807051:-
OV	cis	rs73201462	1	rs2999069	ENSG00000277250.1	Metazoa_SRP	-4.46	1.29e-05	0.00629	-0.41	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128252766	chr3:128673681~128674021:-
OV	cis	rs73201462	0.908	rs2955092	ENSG00000277250.1	Metazoa_SRP	-4.46	1.29e-05	0.00629	-0.41	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128253685	chr3:128673681~128674021:-
OV	cis	rs73201462	0.908	rs2955094	ENSG00000277250.1	Metazoa_SRP	-4.46	1.29e-05	0.00629	-0.41	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128258080	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2999068	ENSG00000277250.1	Metazoa_SRP	-4.46	1.29e-05	0.00629	-0.41	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128259135	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2955097	ENSG00000277250.1	Metazoa_SRP	-4.46	1.29e-05	0.00629	-0.41	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128259662	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2999067	ENSG00000277250.1	Metazoa_SRP	-4.46	1.29e-05	0.00629	-0.41	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128259688	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2955099	ENSG00000277250.1	Metazoa_SRP	-4.46	1.29e-05	0.00629	-0.41	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128260811	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2999066	ENSG00000277250.1	Metazoa_SRP	-4.46	1.29e-05	0.00629	-0.41	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128261443	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2999065	ENSG00000277250.1	Metazoa_SRP	-4.46	1.29e-05	0.00629	-0.41	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128262595	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2811545	ENSG00000277250.1	Metazoa_SRP	-4.46	1.29e-05	0.00629	-0.41	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128264305	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2811544	ENSG00000277250.1	Metazoa_SRP	-4.46	1.29e-05	0.00629	-0.41	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128264652	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2811543	ENSG00000277250.1	Metazoa_SRP	-4.46	1.29e-05	0.00629	-0.41	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128264953	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2811542	ENSG00000277250.1	Metazoa_SRP	-4.46	1.29e-05	0.00629	-0.41	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128264957	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2811541	ENSG00000277250.1	Metazoa_SRP	-4.46	1.29e-05	0.00629	-0.41	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128265951	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2811540	ENSG00000277250.1	Metazoa_SRP	-4.46	1.29e-05	0.00629	-0.41	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128266726	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2811538	ENSG00000277250.1	Metazoa_SRP	-4.46	1.29e-05	0.00629	-0.41	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128267788	chr3:128673681~128674021:-
OV	cis	rs57502260	0.573	rs12291008	ENSG00000212093.1	AP000807.1	4.46	1.29e-05	0.00629	0.37	0.28	Total body bone mineral density (age 45-60);	chr11:68621604	chr11:68506083~68506166:-
OV	cis	rs1185460	0.565	rs540261	ENSG00000271751.1	RP11-110I1.14	4.46	1.29e-05	0.0063	0.35	0.28	Coronary artery disease;	chr11:119076924	chr11:119065263~119065677:-
OV	cis	rs4908768	0.657	rs4908510	ENSG00000228423.2	RP4-633I8.4	-4.46	1.29e-05	0.0063	-0.33	-0.28	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8746286	chr1:8805860~8807051:-
OV	cis	rs6772849	0.796	rs9841521	ENSG00000277250.1	Metazoa_SRP	-4.46	1.29e-05	0.00631	-0.33	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128673431	chr3:128673681~128674021:-
OV	cis	rs6460942	0.597	rs17544637	ENSG00000226690.5	AC005281.1	4.46	1.29e-05	0.00631	0.49	0.28	Coronary artery disease;	chr7:12482245	chr7:12496429~12541910:+
OV	cis	rs2688608	0.592	rs2306328	ENSG00000271816.1	BMS1P4	4.46	1.29e-05	0.00631	0.26	0.28	Inflammatory bowel disease;	chr10:73819752	chr10:73699151~73730487:-
OV	cis	rs2688608	0.62	rs7098444	ENSG00000271816.1	BMS1P4	4.46	1.29e-05	0.00631	0.26	0.28	Inflammatory bowel disease;	chr10:73820284	chr10:73699151~73730487:-
OV	cis	rs7746199	0.736	rs58616630	ENSG00000280107.1	AL022393.9	-4.46	1.29e-05	0.00631	-0.59	-0.28	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:28170845~28172521:+
OV	cis	rs10750165	0.644	rs11217471	ENSG00000254428.1	RP11-110I1.11	-4.46	1.3e-05	0.00632	-0.24	-0.28	Aggressiveness in attention deficit hyperactivity disorder;	chr11:119759932	chr11:119003742~119004893:-
OV	cis	rs1584120	0.57	rs10842123	ENSG00000274885.1	RP11-268P4.6	-4.46	1.3e-05	0.00632	-0.33	-0.28	Pelvic organ prolapse (moderate/severe);	chr12:23113358	chr12:22638464~22638943:+
OV	cis	rs4763879	0.502	rs11052552	ENSG00000256673.1	RP11-599J14.2	-4.46	1.3e-05	0.00633	-0.26	-0.28	Type 1 diabetes;	chr12:9703362	chr12:9398355~9414851:-
OV	cis	rs2788869	0.887	rs1225731	ENSG00000247925.2	RP3-510L9.1	-4.46	1.3e-05	0.00633	-0.38	-0.28	Obstetric antiphospholipid syndrome;	chr6:10932260	chr6:11173452~11259099:+
OV	cis	rs8062405	1	rs62036620	ENSG00000278665.1	RP11-666O2.4	4.46	1.3e-05	0.00633	0.31	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821776	chr16:28599241~28601881:-
OV	cis	rs8062405	1	rs62036621	ENSG00000278665.1	RP11-666O2.4	4.46	1.3e-05	0.00633	0.31	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28821978	chr16:28599241~28601881:-
OV	cis	rs17301013	0.507	rs1613634	ENSG00000227373.4	RP11-160H22.5	-4.46	1.3e-05	0.00633	-0.35	-0.28	Systemic lupus erythematosus;	chr1:174803184	chr1:174115300~174160004:-
OV	cis	rs7569084	0.522	rs906577	ENSG00000234255.7	AC012370.3	4.46	1.3e-05	0.00634	0.31	0.28	Sum eosinophil basophil counts;	chr2:65369523	chr2:65439888~65456571:-
OV	cis	rs934734	0.563	rs11126035	ENSG00000234255.7	AC012370.3	4.46	1.3e-05	0.00634	0.31	0.28	Rheumatoid arthritis;	chr2:65369932	chr2:65439888~65456571:-
OV	cis	rs10829156	0.738	rs4748502	ENSG00000225527.1	RP11-383B4.4	-4.46	1.3e-05	0.00634	-0.38	-0.28	Sudden cardiac arrest;	chr10:18647032	chr10:18531849~18533336:-
OV	cis	rs9287719	0.837	rs4331474	ENSG00000234818.1	AC092687.5	4.46	1.3e-05	0.00635	0.3	0.28	Prostate cancer;	chr2:10615457	chr2:10589166~10604830:+
OV	cis	rs10740039	0.81	rs4440977	ENSG00000254271.1	RP11-131N11.4	4.46	1.3e-05	0.00635	0.36	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60618163	chr10:60734342~60741828:+
OV	cis	rs3930017	1	rs3930016	ENSG00000225726.1	AC007000.10	-4.46	1.3e-05	0.00635	-0.27	-0.28	Body mass index;	chr7:77091132	chr7:77071751~77072237:-
OV	cis	rs9880211	1	rs13092193	ENSG00000239213.4	NCK1-AS1	4.46	1.3e-05	0.00635	0.34	0.28	Height;Body mass index;	chr3:136521524	chr3:136841726~136862054:-
OV	cis	rs9880211	1	rs6771002	ENSG00000239213.4	NCK1-AS1	4.46	1.3e-05	0.00635	0.34	0.28	Height;Body mass index;	chr3:136522186	chr3:136841726~136862054:-
OV	cis	rs14027	0.921	rs12542794	ENSG00000279347.1	RP11-85I17.2	-4.46	1.31e-05	0.00635	-0.29	-0.28	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119826153	chr8:119838736~119840385:-
OV	cis	rs514406	0.893	rs1242326	ENSG00000206627.1	RNU6-969P	4.46	1.31e-05	0.00636	0.29	0.28	Monocyte count;	chr1:52933432	chr1:52805108~52805212:-
OV	cis	rs11096990	0.634	rs17754	ENSG00000249207.1	RP11-360F5.1	-4.46	1.31e-05	0.00636	-0.3	-0.28	Cognitive function;	chr4:39287688	chr4:39112677~39126818:-
OV	cis	rs10740039	0.842	rs10761539	ENSG00000254271.1	RP11-131N11.4	4.46	1.31e-05	0.00636	0.35	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60649733	chr10:60734342~60741828:+
OV	cis	rs10740039	0.883	rs7476720	ENSG00000254271.1	RP11-131N11.4	4.46	1.31e-05	0.00636	0.35	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60650610	chr10:60734342~60741828:+
OV	cis	rs10740039	0.883	rs1975442	ENSG00000254271.1	RP11-131N11.4	4.46	1.31e-05	0.00636	0.35	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60651161	chr10:60734342~60741828:+
OV	cis	rs10740039	0.842	rs7090892	ENSG00000254271.1	RP11-131N11.4	4.46	1.31e-05	0.00636	0.35	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60652093	chr10:60734342~60741828:+
OV	cis	rs10740039	0.804	rs7094818	ENSG00000254271.1	RP11-131N11.4	4.46	1.31e-05	0.00636	0.35	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60652213	chr10:60734342~60741828:+
OV	cis	rs10740039	0.883	rs1470237	ENSG00000254271.1	RP11-131N11.4	4.46	1.31e-05	0.00636	0.35	0.28	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60653381	chr10:60734342~60741828:+
OV	cis	rs17301013	0.581	rs4652204	ENSG00000227373.4	RP11-160H22.5	4.46	1.31e-05	0.00636	0.38	0.28	Systemic lupus erythematosus;	chr1:174150682	chr1:174115300~174160004:-
OV	cis	rs853679	0.599	rs156743	ENSG00000280107.1	AL022393.9	-4.46	1.31e-05	0.00636	-0.47	-0.28	Depression;	chr6:27999311	chr6:28170845~28172521:+
OV	cis	rs957448	0.687	rs10104041	ENSG00000253704.1	RP11-267M23.4	4.46	1.31e-05	0.00636	0.34	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94559374	chr8:94553722~94569745:+
OV	cis	rs7017914	0.69	rs10090230	ENSG00000223220.1	Y_RNA	4.46	1.31e-05	0.00637	0.3	0.28	Bone mineral density;	chr8:70884778	chr8:70780914~70781008:-
OV	cis	rs7017914	0.69	rs10090471	ENSG00000223220.1	Y_RNA	4.46	1.31e-05	0.00637	0.3	0.28	Bone mineral density;	chr8:70885034	chr8:70780914~70781008:-
OV	cis	rs853679	0.517	rs3823180	ENSG00000226314.6	ZNF192P1	-4.46	1.31e-05	0.00637	-0.37	-0.28	Depression;	chr6:28093966	chr6:28161781~28169594:+
OV	cis	rs7267979	0.932	rs424487	ENSG00000274973.1	RP13-401N8.7	-4.46	1.31e-05	0.00637	-0.32	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25487495	chr20:25845497~25845862:+
OV	cis	rs853679	0.607	rs13194781	ENSG00000220721.1	OR1F12	4.46	1.31e-05	0.00637	0.56	0.28	Depression;	chr6:27847861	chr6:28073316~28074233:+
OV	cis	rs4713118	0.738	rs200465	ENSG00000219392.1	RP1-265C24.5	-4.46	1.31e-05	0.00637	-0.33	-0.28	Parkinson's disease;	chr6:27789875	chr6:28115628~28116551:+
OV	cis	rs116095464	0.558	rs62346506	ENSG00000250848.1	CTD-2083E4.5	-4.46	1.31e-05	0.00638	-0.37	-0.28	Breast cancer;	chr5:201479	chr5:288833~290321:-
OV	cis	rs116095464	0.558	rs9312956	ENSG00000250848.1	CTD-2083E4.5	-4.46	1.31e-05	0.00638	-0.37	-0.28	Breast cancer;	chr5:201697	chr5:288833~290321:-
OV	cis	rs67311347	0.521	rs2887963	ENSG00000223797.4	ENTPD3-AS1	-4.46	1.31e-05	0.00638	-0.3	-0.28	Renal cell carcinoma;	chr3:40201975	chr3:40313802~40453329:-
OV	cis	rs853679	0.517	rs17711344	ENSG00000226314.6	ZNF192P1	4.46	1.31e-05	0.00639	0.37	0.28	Depression;	chr6:28109824	chr6:28161781~28169594:+
OV	cis	rs7746199	0.736	rs13193542	ENSG00000220721.1	OR1F12	4.46	1.31e-05	0.00639	0.54	0.28	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:28073316~28074233:+
OV	cis	rs7746199	0.736	rs13193480	ENSG00000220721.1	OR1F12	4.46	1.31e-05	0.00639	0.54	0.28	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:28073316~28074233:+
OV	cis	rs7267979	0.808	rs84816	ENSG00000274973.1	RP13-401N8.7	-4.46	1.31e-05	0.00639	-0.31	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25479283	chr20:25845497~25845862:+
OV	cis	rs9298506	1	rs28600710	ENSG00000254142.2	RP11-53M11.3	4.46	1.31e-05	0.00639	0.37	0.28	Intracranial aneurysm;	chr8:54524233	chr8:54554361~54561927:+
OV	cis	rs1707322	0.685	rs11211177	ENSG00000234329.1	RP11-767N6.2	4.46	1.32e-05	0.00639	0.28	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr1:45651039~45651826:-
OV	cis	rs10992471	0.631	rs2296667	ENSG00000281156.1	MIR3651	-4.46	1.32e-05	0.00639	-0.31	-0.28	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92512056	chr9:92292458~92292547:-
OV	cis	rs875971	0.545	rs11767262	ENSG00000237310.1	GS1-124K5.4	4.46	1.32e-05	0.00639	0.33	0.28	Aortic root size;	chr7:66302237	chr7:66493706~66495474:+
OV	cis	rs875971	0.545	rs66594357	ENSG00000237310.1	GS1-124K5.4	4.46	1.32e-05	0.00639	0.33	0.28	Aortic root size;	chr7:66327797	chr7:66493706~66495474:+
OV	cis	rs875971	0.502	rs6460311	ENSG00000236529.1	RP13-254B10.1	-4.46	1.32e-05	0.00639	-0.34	-0.28	Aortic root size;	chr7:66646886	chr7:65840212~65840596:+
OV	cis	rs62244186	0.748	rs6441861	ENSG00000214820.3	MPRIPP1	4.46	1.32e-05	0.00639	0.25	0.28	Depressive symptoms;	chr3:44610795	chr3:44579938~44581026:-
OV	cis	rs7429990	0.864	rs11130143	ENSG00000229759.1	MRPS18AP1	-4.46	1.32e-05	0.0064	-0.3	-0.28	Educational attainment (years of education);	chr3:47614943	chr3:48256350~48256938:-
OV	cis	rs9880211	0.898	rs34031772	ENSG00000239213.4	NCK1-AS1	4.46	1.32e-05	0.0064	0.35	0.28	Height;Body mass index;	chr3:136299299	chr3:136841726~136862054:-
OV	cis	rs10986311	0.649	rs10818936	ENSG00000227200.1	RP11-121A14.3	-4.45	1.32e-05	0.00641	-0.25	-0.28	Vitiligo;	chr9:124244067	chr9:124262876~124265809:+
OV	cis	rs6088590	0.71	rs6059992	ENSG00000206582.1	Y_RNA	-4.45	1.32e-05	0.00641	-0.34	-0.28	Coronary artery disease;	chr20:34694471	chr20:34526510~34526606:-
OV	cis	rs875971	0.862	rs6944374	ENSG00000236529.1	RP13-254B10.1	-4.45	1.32e-05	0.00641	-0.29	-0.28	Aortic root size;	chr7:66221942	chr7:65840212~65840596:+
OV	cis	rs11096990	0.634	rs7564	ENSG00000249207.1	RP11-360F5.1	4.45	1.32e-05	0.00642	0.3	0.28	Cognitive function;	chr4:39285702	chr4:39112677~39126818:-
OV	cis	rs829883	0.738	rs249854	ENSG00000227825.4	SLC9A7P1	4.45	1.32e-05	0.00642	0.29	0.28	Colorectal adenoma (advanced);	chr12:98468994	chr12:98453835~98457145:-
OV	cis	rs67311347	1	rs2305522	ENSG00000223797.4	ENTPD3-AS1	4.45	1.32e-05	0.00643	0.3	0.28	Renal cell carcinoma;	chr3:40387867	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs7636719	ENSG00000223797.4	ENTPD3-AS1	4.45	1.32e-05	0.00643	0.3	0.28	Renal cell carcinoma;	chr3:40390593	chr3:40313802~40453329:-
OV	cis	rs992157	0.866	rs2292554	ENSG00000261338.2	RP11-378A13.1	-4.45	1.32e-05	0.00643	-0.33	-0.28	Colorectal cancer;	chr2:218282145	chr2:218255319~218257366:+
OV	cis	rs853679	0.545	rs35949109	ENSG00000226314.6	ZNF192P1	-4.45	1.32e-05	0.00643	-0.49	-0.28	Depression;	chr6:28058148	chr6:28161781~28169594:+
OV	cis	rs4964805	0.657	rs11111781	ENSG00000257681.1	RP11-341G23.4	4.45	1.32e-05	0.00643	0.31	0.28	Attention deficit hyperactivity disorder;	chr12:103793662	chr12:103746315~103768858:-
OV	cis	rs1862618	0.853	rs2548665	ENSG00000271828.1	CTD-2310F14.1	4.45	1.33e-05	0.00644	0.44	0.28	Initial pursuit acceleration;	chr5:56835978	chr5:56927874~56929573:+
OV	cis	rs1862618	0.802	rs2591949	ENSG00000271828.1	CTD-2310F14.1	4.45	1.33e-05	0.00644	0.44	0.28	Initial pursuit acceleration;	chr5:56836800	chr5:56927874~56929573:+
OV	cis	rs1862618	0.853	rs2548664	ENSG00000271828.1	CTD-2310F14.1	4.45	1.33e-05	0.00644	0.44	0.28	Initial pursuit acceleration;	chr5:56837728	chr5:56927874~56929573:+
OV	cis	rs7927771	0.524	rs10742817	ENSG00000280615.1	Y_RNA	-4.45	1.33e-05	0.00644	-0.3	-0.28	Subjective well-being;	chr11:47667791	chr11:47614898~47614994:-
OV	cis	rs6088590	0.603	rs6579186	ENSG00000206582.1	Y_RNA	-4.45	1.33e-05	0.00644	-0.34	-0.28	Coronary artery disease;	chr20:34694394	chr20:34526510~34526606:-
OV	cis	rs875971	0.545	rs2420612	ENSG00000236529.1	RP13-254B10.1	4.45	1.33e-05	0.00646	0.34	0.28	Aortic root size;	chr7:66536825	chr7:65840212~65840596:+
OV	cis	rs875971	0.638	rs35986979	ENSG00000224316.1	RP11-479O9.2	-4.45	1.33e-05	0.00646	-0.3	-0.28	Aortic root size;	chr7:66624003	chr7:65773620~65802067:+
OV	cis	rs9287719	0.649	rs10929683	ENSG00000243819.4	RN7SL832P	-4.45	1.33e-05	0.00646	-0.28	-0.28	Prostate cancer;	chr2:10592082	chr2:10690344~10692099:+
OV	cis	rs6558530	0.932	rs7842425	ENSG00000253982.1	CTD-2336O2.1	4.45	1.33e-05	0.00646	0.32	0.28	Systolic blood pressure;	chr8:1757875	chr8:1761990~1764502:-
OV	cis	rs13113518	0.812	rs6849474	ENSG00000223305.1	RN7SKP30	4.45	1.33e-05	0.00646	0.33	0.28	Height;	chr4:55452295	chr4:55540502~55540835:-
OV	cis	rs13113518	0.812	rs4864996	ENSG00000223305.1	RN7SKP30	4.45	1.33e-05	0.00646	0.33	0.28	Height;	chr4:55452921	chr4:55540502~55540835:-
OV	cis	rs3758911	0.894	rs1490947	ENSG00000261098.1	RP11-819C21.1	-4.45	1.33e-05	0.00646	-0.28	-0.28	Coronary artery disease;	chr11:107325294	chr11:107312132~107316271:-
OV	cis	rs62184315	0.536	rs2278591	ENSG00000253559.1	OSGEPL1-AS1	-4.45	1.33e-05	0.00646	-0.39	-0.28	Alcohol dependence (age at onset);	chr2:189755778	chr2:189762704~189765556:+
OV	cis	rs62184315	0.536	rs16831972	ENSG00000253559.1	OSGEPL1-AS1	-4.45	1.33e-05	0.00646	-0.39	-0.28	Alcohol dependence (age at onset);	chr2:189756707	chr2:189762704~189765556:+
OV	cis	rs992157	0.796	rs55680399	ENSG00000237281.1	CATIP-AS2	-4.45	1.33e-05	0.00646	-0.33	-0.28	Colorectal cancer;	chr2:218295898	chr2:218326889~218357966:-
OV	cis	rs875971	0.508	rs10258739	ENSG00000224316.1	RP11-479O9.2	-4.45	1.33e-05	0.00646	-0.3	-0.28	Aortic root size;	chr7:66597948	chr7:65773620~65802067:+
OV	cis	rs1858037	0.867	rs4671660	ENSG00000234255.7	AC012370.3	4.45	1.33e-05	0.00647	0.32	0.28	Rheumatoid arthritis;	chr2:65349302	chr2:65439888~65456571:-
OV	cis	rs9287719	0.967	rs7355649	ENSG00000234818.1	AC092687.5	4.45	1.33e-05	0.00647	0.3	0.28	Prostate cancer;	chr2:10607968	chr2:10589166~10604830:+
OV	cis	rs8054556	1	rs3814881	ENSG00000261367.1	RP11-455F5.4	-4.45	1.33e-05	0.00647	-0.31	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29989580	chr16:30107675~30110541:+
OV	cis	rs875971	0.545	rs2420456	ENSG00000237310.1	GS1-124K5.4	4.45	1.33e-05	0.00647	0.33	0.28	Aortic root size;	chr7:66280619	chr7:66493706~66495474:+
OV	cis	rs853679	0.607	rs201002	ENSG00000280107.1	AL022393.9	-4.45	1.33e-05	0.00647	-0.48	-0.28	Depression;	chr6:27840414	chr6:28170845~28172521:+
OV	cis	rs11159086	1	rs4899514	ENSG00000270000.1	RP3-449M8.9	-4.45	1.34e-05	0.00647	-0.45	-0.28	Advanced glycation end-product levels;	chr14:74473467	chr14:74471930~74472360:-
OV	cis	rs372883	0.58	rs2254038	ENSG00000226935.5	LINC00161	-4.45	1.34e-05	0.00648	-0.3	-0.28	Pancreatic cancer;	chr21:29373402	chr21:28539318~28540355:+
OV	cis	rs875971	0.642	rs35526611	ENSG00000224316.1	RP11-479O9.2	-4.45	1.34e-05	0.00648	-0.3	-0.28	Aortic root size;	chr7:66629021	chr7:65773620~65802067:+
OV	cis	rs2243480	0.764	rs2460423	ENSG00000226824.5	RP4-756H11.3	-4.45	1.34e-05	0.00648	-0.45	-0.28	Diabetic kidney disease;	chr7:66136229	chr7:66654538~66669855:+
OV	cis	rs7259376	0.875	rs1975175	ENSG00000269742.1	BNIP3P29	4.45	1.34e-05	0.00649	0.33	0.28	Menopause (age at onset);	chr19:22332437	chr19:22065828~22066398:-
OV	cis	rs1075265	0.73	rs7601692	ENSG00000233266.1	HMGB1P31	4.45	1.34e-05	0.0065	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53705532	chr2:54051334~54051760:+
OV	cis	rs1555322	0.53	rs932562	ENSG00000126005.14	MMP24-AS1	-4.45	1.34e-05	0.0065	-0.39	-0.28	Attention deficit hyperactivity disorder;	chr20:35283507	chr20:35216462~35278131:-
OV	cis	rs1555322	0.53	rs2275275	ENSG00000126005.14	MMP24-AS1	-4.45	1.34e-05	0.0065	-0.39	-0.28	Attention deficit hyperactivity disorder;	chr20:35284508	chr20:35216462~35278131:-
OV	cis	rs6142102	0.602	rs2268086	ENSG00000276073.1	RP5-1125A11.7	4.45	1.34e-05	0.0065	0.33	0.28	Skin pigmentation;	chr20:34060932	chr20:33985617~33988989:-
OV	cis	rs1823913	0.637	rs4853584	ENSG00000227542.1	AC092614.2	-4.45	1.35e-05	0.00651	-0.32	-0.28	Obesity-related traits;	chr2:191310596	chr2:191229165~191246172:-
OV	cis	rs801193	1	rs2659889	ENSG00000224316.1	RP11-479O9.2	4.45	1.35e-05	0.00652	0.31	0.28	Aortic root size;	chr7:66752125	chr7:65773620~65802067:+
OV	cis	rs801193	1	rs3800812	ENSG00000224316.1	RP11-479O9.2	4.45	1.35e-05	0.00652	0.31	0.28	Aortic root size;	chr7:66758474	chr7:65773620~65802067:+
OV	cis	rs801193	1	rs4279493	ENSG00000224316.1	RP11-479O9.2	4.45	1.35e-05	0.00652	0.31	0.28	Aortic root size;	chr7:66761633	chr7:65773620~65802067:+
OV	cis	rs10759883	0.587	rs2405134	ENSG00000175611.10	LINC00476	-4.45	1.35e-05	0.00652	-0.37	-0.28	Nicotine dependence;	chr9:95795179	chr9:95759231~95875977:-
OV	cis	rs796364	1	rs35220450	ENSG00000232732.8	AC073043.1	4.45	1.35e-05	0.00652	0.44	0.28	Schizophrenia;	chr2:199916014	chr2:199867396~199911159:-
OV	cis	rs6907340	0.517	rs6939160	ENSG00000237404.1	RP3-471C18.2	-4.45	1.35e-05	0.00653	-0.36	-0.28	Endometriosis;	chr6:19802086	chr6:19689825~19753113:-
OV	cis	rs2919917	0.666	rs10957898	ENSG00000254352.1	RP11-578O24.2	-4.45	1.35e-05	0.00653	-0.38	-0.28	Lymphocyte counts;	chr8:78705078	chr8:78723796~78724136:-
OV	cis	rs3733585	0.699	rs7658170	ENSG00000250413.1	RP11-448G15.1	-4.45	1.35e-05	0.00653	-0.31	-0.28	Cleft plate (environmental tobacco smoke interaction);	chr4:9964969	chr4:10006482~10009725:+
OV	cis	rs3733585	0.673	rs7376948	ENSG00000250413.1	RP11-448G15.1	4.45	1.35e-05	0.00653	0.31	0.28	Cleft plate (environmental tobacco smoke interaction);	chr4:9953084	chr4:10006482~10009725:+
OV	cis	rs4763879	0.634	rs61915472	ENSG00000278635.1	CTD-2318O12.1	4.45	1.35e-05	0.00653	0.24	0.28	Type 1 diabetes;	chr12:9700995	chr12:9415641~9416718:+
OV	cis	rs2070488	0.965	rs7373828	ENSG00000229589.1	ACVR2B-AS1	4.45	1.35e-05	0.00654	0.31	0.28	Electrocardiographic conduction measures;	chr3:38482820	chr3:38451027~38454820:-
OV	cis	rs8062405	1	rs1987472	ENSG00000278665.1	RP11-666O2.4	4.45	1.36e-05	0.00655	0.31	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814456	chr16:28599241~28601881:-
OV	cis	rs8062405	0.895	rs56186137	ENSG00000278665.1	RP11-666O2.4	4.45	1.36e-05	0.00655	0.31	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814632	chr16:28599241~28601881:-
OV	cis	rs3733585	0.699	rs10001964	ENSG00000250413.1	RP11-448G15.1	4.45	1.36e-05	0.00655	0.32	0.28	Cleft plate (environmental tobacco smoke interaction);	chr4:9957651	chr4:10006482~10009725:+
OV	cis	rs3733585	0.699	rs6449158	ENSG00000250413.1	RP11-448G15.1	4.45	1.36e-05	0.00655	0.32	0.28	Cleft plate (environmental tobacco smoke interaction);	chr4:9958835	chr4:10006482~10009725:+
OV	cis	rs3733585	0.699	rs17245723	ENSG00000250413.1	RP11-448G15.1	4.45	1.36e-05	0.00655	0.32	0.28	Cleft plate (environmental tobacco smoke interaction);	chr4:9960594	chr4:10006482~10009725:+
OV	cis	rs3733585	0.637	rs6850684	ENSG00000250413.1	RP11-448G15.1	4.45	1.36e-05	0.00655	0.32	0.28	Cleft plate (environmental tobacco smoke interaction);	chr4:9962756	chr4:10006482~10009725:+
OV	cis	rs507080	0.922	rs654792	ENSG00000278376.1	RP11-158I9.8	4.45	1.36e-05	0.00655	0.28	0.28	Serum metabolite levels;	chr11:118682287	chr11:118791254~118793137:+
OV	cis	rs6940638	0.513	rs4424065	ENSG00000261584.1	RP11-457M11.5	-4.45	1.36e-05	0.00656	-0.32	-0.28	Intelligence (multi-trait analysis);	chr6:27068677	chr6:26686241~26687964:+
OV	cis	rs11096990	0.855	rs2566173	ENSG00000249207.1	RP11-360F5.1	4.45	1.36e-05	0.00656	0.33	0.28	Cognitive function;	chr4:39151111	chr4:39112677~39126818:-
OV	cis	rs11096990	0.855	rs2711988	ENSG00000249207.1	RP11-360F5.1	4.45	1.36e-05	0.00656	0.33	0.28	Cognitive function;	chr4:39151128	chr4:39112677~39126818:-
OV	cis	rs11096990	0.855	rs2043102	ENSG00000249207.1	RP11-360F5.1	4.45	1.36e-05	0.00656	0.33	0.28	Cognitive function;	chr4:39151292	chr4:39112677~39126818:-
OV	cis	rs11096990	0.855	rs2711986	ENSG00000249207.1	RP11-360F5.1	4.45	1.36e-05	0.00656	0.33	0.28	Cognitive function;	chr4:39152258	chr4:39112677~39126818:-
OV	cis	rs181553	0.629	rs12232591	ENSG00000266696.1	RP11-30L3.2	4.45	1.36e-05	0.00656	0.36	0.28	Hip circumference adjusted for BMI;	chr18:49164091	chr18:49205912~49208781:+
OV	cis	rs181553	0.699	rs12970381	ENSG00000266696.1	RP11-30L3.2	4.45	1.36e-05	0.00656	0.36	0.28	Hip circumference adjusted for BMI;	chr18:49167450	chr18:49205912~49208781:+
OV	cis	rs9309473	0.847	rs13538	ENSG00000163016.8	ALMS1P	4.45	1.36e-05	0.00656	0.34	0.28	Metabolite levels;	chr2:73641201	chr2:73644919~73685576:+
OV	cis	rs9309473	1	rs13428235	ENSG00000163016.8	ALMS1P	4.45	1.36e-05	0.00657	0.33	0.28	Metabolite levels;	chr2:73406302	chr2:73644919~73685576:+
OV	cis	rs4747241	0.626	rs4300326	ENSG00000226163.1	RP11-167P22.3	-4.45	1.36e-05	0.00657	-0.32	-0.28	Heschl's gyrus morphology;	chr10:72308938	chr10:72501746~72502956:+
OV	cis	rs858239	0.539	rs6975852	ENSG00000230042.1	AK3P3	-4.45	1.36e-05	0.00658	-0.3	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23147035	chr7:23129178~23129841:+
OV	cis	rs10129255	0.536	rs10139058	ENSG00000223648.3	IGHV3-64	4.45	1.36e-05	0.00658	0.28	0.28	Kawasaki disease;	chr14:106685899	chr14:106643132~106658258:-
OV	cis	rs1555322	0.505	rs591590	ENSG00000126005.14	MMP24-AS1	4.45	1.36e-05	0.00658	0.39	0.28	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35216462~35278131:-
OV	cis	rs7043114	0.525	rs1053441	ENSG00000281156.1	MIR3651	-4.45	1.36e-05	0.00658	-0.31	-0.28	Height;	chr9:92385558	chr9:92292458~92292547:-
OV	cis	rs11096990	0.634	rs2062229	ENSG00000249207.1	RP11-360F5.1	-4.45	1.36e-05	0.00658	-0.3	-0.28	Cognitive function;	chr4:39285146	chr4:39112677~39126818:-
OV	cis	rs67311347	1	rs6599102	ENSG00000223797.4	ENTPD3-AS1	4.45	1.36e-05	0.00659	0.3	0.28	Renal cell carcinoma;	chr3:40426915	chr3:40313802~40453329:-
OV	cis	rs6952407	1	rs6952407	ENSG00000224316.1	RP11-479O9.2	-4.45	1.36e-05	0.00659	-0.3	-0.28	Cotinine glucuronidation;	chr7:66580525	chr7:65773620~65802067:+
OV	cis	rs2243480	0.803	rs55700941	ENSG00000226824.5	RP4-756H11.3	-4.45	1.37e-05	0.00659	-0.46	-0.28	Diabetic kidney disease;	chr7:65924813	chr7:66654538~66669855:+
OV	cis	rs9925964	0.9	rs9934438	ENSG00000278922.1	AC002310.14	-4.45	1.37e-05	0.00659	-0.32	-0.28	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31093557	chr16:30526918~30528294:+
OV	cis	rs9925964	0.933	rs9923231	ENSG00000278922.1	AC002310.14	-4.45	1.37e-05	0.00659	-0.32	-0.28	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31096368	chr16:30526918~30528294:+
OV	cis	rs4908768	0.859	rs55802878	ENSG00000228423.2	RP4-633I8.4	4.45	1.37e-05	0.0066	0.34	0.28	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8606352	chr1:8805860~8807051:-
OV	cis	rs57502260	0.79	rs7129320	ENSG00000212093.1	AP000807.1	4.45	1.37e-05	0.0066	0.45	0.28	Total body bone mineral density (age 45-60);	chr11:68620752	chr11:68506083~68506166:-
OV	cis	rs7429990	0.864	rs6442081	ENSG00000229759.1	MRPS18AP1	-4.45	1.37e-05	0.0066	-0.31	-0.28	Educational attainment (years of education);	chr3:47728890	chr3:48256350~48256938:-
OV	cis	rs12713280	0.955	rs67025912	ENSG00000272156.1	RP11-477N3.1	4.45	1.37e-05	0.00661	0.4	0.28	Economic and political preferences;	chr2:54860403	chr2:54082554~54085066:+
OV	cis	rs875971	0.545	rs1547529	ENSG00000237310.1	GS1-124K5.4	4.45	1.37e-05	0.00661	0.33	0.28	Aortic root size;	chr7:66258859	chr7:66493706~66495474:+
OV	cis	rs1185460	0.546	rs474201	ENSG00000271751.1	RP11-110I1.14	-4.45	1.37e-05	0.00661	-0.34	-0.28	Coronary artery disease;	chr11:119087519	chr11:119065263~119065677:-
OV	cis	rs10510102	0.935	rs10510101	ENSG00000226864.1	ATE1-AS1	4.45	1.37e-05	0.00661	0.47	0.28	Breast cancer;	chr10:121898614	chr10:121928312~121951965:+
OV	cis	rs9326248	1	rs10790175	ENSG00000280143.1	AP000892.6	4.45	1.37e-05	0.00662	0.3	0.28	Blood protein levels;	chr11:117164013	chr11:117204967~117210292:+
OV	cis	rs2028299	0.919	rs3759831	ENSG00000259677.1	RP11-493E3.1	4.45	1.37e-05	0.00663	0.32	0.28	Type 2 diabetes;	chr15:89871410	chr15:89876540~89877285:+
OV	cis	rs6991838	0.778	rs11782837	ENSG00000272010.1	CTD-3025N20.3	4.45	1.37e-05	0.00663	0.36	0.28	Intelligence (multi-trait analysis);	chr8:65550328	chr8:65591850~65592472:-
OV	cis	rs9287719	0.967	rs6727768	ENSG00000234818.1	AC092687.5	4.44	1.38e-05	0.00663	0.3	0.28	Prostate cancer;	chr2:10617353	chr2:10589166~10604830:+
OV	cis	rs2070488	0.93	rs928813	ENSG00000229589.1	ACVR2B-AS1	4.44	1.38e-05	0.00663	0.31	0.28	Electrocardiographic conduction measures;	chr3:38487046	chr3:38451027~38454820:-
OV	cis	rs2070488	0.965	rs7433277	ENSG00000229589.1	ACVR2B-AS1	4.44	1.38e-05	0.00663	0.31	0.28	Electrocardiographic conduction measures;	chr3:38488327	chr3:38451027~38454820:-
OV	cis	rs992157	0.731	rs1399132	ENSG00000237281.1	CATIP-AS2	-4.44	1.38e-05	0.00663	-0.33	-0.28	Colorectal cancer;	chr2:218295047	chr2:218326889~218357966:-
OV	cis	rs2436845	0.627	rs1897787	ENSG00000253385.1	KB-1254G8.1	4.44	1.38e-05	0.00664	0.36	0.28	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102850195	chr8:102854455~102856075:+
OV	cis	rs853679	0.546	rs36116761	ENSG00000220721.1	OR1F12	4.44	1.38e-05	0.00664	0.56	0.28	Depression;	chr6:27850704	chr6:28073316~28074233:+
OV	cis	rs853679	0.546	rs34194357	ENSG00000220721.1	OR1F12	4.44	1.38e-05	0.00664	0.56	0.28	Depression;	chr6:27850757	chr6:28073316~28074233:+
OV	cis	rs4713118	0.869	rs9283881	ENSG00000219392.1	RP1-265C24.5	-4.44	1.38e-05	0.00665	-0.32	-0.28	Parkinson's disease;	chr6:27747476	chr6:28115628~28116551:+
OV	cis	rs4713118	0.869	rs9283882	ENSG00000219392.1	RP1-265C24.5	-4.44	1.38e-05	0.00665	-0.32	-0.28	Parkinson's disease;	chr6:27747479	chr6:28115628~28116551:+
OV	cis	rs4938303	0.633	rs35681250	ENSG00000254851.1	RP11-109L13.1	4.44	1.38e-05	0.00665	0.46	0.28	Triglycerides;	chr11:116684670	chr11:117135528~117138582:+
OV	cis	rs5742933	0.69	rs62183656	ENSG00000253559.1	OSGEPL1-AS1	-4.44	1.38e-05	0.00666	-0.39	-0.28	Ferritin levels;	chr2:189669387	chr2:189762704~189765556:+
OV	cis	rs5742933	0.69	rs62183658	ENSG00000253559.1	OSGEPL1-AS1	-4.44	1.38e-05	0.00666	-0.39	-0.28	Ferritin levels;	chr2:189669491	chr2:189762704~189765556:+
OV	cis	rs7615952	0.599	rs6438955	ENSG00000171084.14	FAM86JP	4.44	1.38e-05	0.00666	0.39	0.28	Blood pressure (smoking interaction);	chr3:126011490	chr3:125916620~125930024:+
OV	cis	rs62244186	0.627	rs12386385	ENSG00000214820.3	MPRIPP1	4.44	1.38e-05	0.00666	0.26	0.28	Depressive symptoms;	chr3:44416048	chr3:44579938~44581026:-
OV	cis	rs2286503	0.65	rs1990279	ENSG00000221740.1	SNORD93	4.44	1.38e-05	0.00667	0.34	0.28	Fibrinogen;	chr7:22851123	chr7:22856613~22856686:+
OV	cis	rs875971	0.66	rs1860468	ENSG00000224316.1	RP11-479O9.2	-4.44	1.38e-05	0.00667	-0.3	-0.28	Aortic root size;	chr7:66642265	chr7:65773620~65802067:+
OV	cis	rs496547	0.686	rs487728	ENSG00000255239.1	AP002954.6	4.44	1.39e-05	0.00667	0.32	0.28	Hip minimal joint space width;	chr11:118750785	chr11:118688039~118690600:-
OV	cis	rs473651	0.837	rs563458	ENSG00000229915.1	AC016999.2	-4.44	1.39e-05	0.00668	-0.36	-0.28	Multiple system atrophy;	chr2:238436972	chr2:238427077~238427729:-
OV	cis	rs757081	0.669	rs542274	ENSG00000213779.4	RP11-452G18.1	4.44	1.39e-05	0.00668	0.31	0.28	Systolic blood pressure;	chr11:17185886	chr11:17193489~17194308:+
OV	cis	rs992157	0.798	rs4996257	ENSG00000261338.2	RP11-378A13.1	4.44	1.39e-05	0.00668	0.34	0.28	Colorectal cancer;	chr2:218298113	chr2:218255319~218257366:+
OV	cis	rs7580658	0.545	rs885275	ENSG00000236682.1	AC068282.3	-4.44	1.39e-05	0.00669	-0.34	-0.28	Protein C levels;	chr2:127193519	chr2:127389130~127400580:+
OV	cis	rs2070488	0.965	rs1046048	ENSG00000229589.1	ACVR2B-AS1	4.44	1.39e-05	0.00669	0.31	0.28	Electrocardiographic conduction measures;	chr3:38483251	chr3:38451027~38454820:-
OV	cis	rs2070488	0.965	rs7642472	ENSG00000229589.1	ACVR2B-AS1	4.44	1.39e-05	0.00669	0.31	0.28	Electrocardiographic conduction measures;	chr3:38484076	chr3:38451027~38454820:-
OV	cis	rs2070488	0.965	rs7640050	ENSG00000229589.1	ACVR2B-AS1	4.44	1.39e-05	0.00669	0.31	0.28	Electrocardiographic conduction measures;	chr3:38484373	chr3:38451027~38454820:-
OV	cis	rs992157	0.71	rs6752254	ENSG00000237281.1	CATIP-AS2	-4.44	1.39e-05	0.0067	-0.32	-0.28	Colorectal cancer;	chr2:218194020	chr2:218326889~218357966:-
OV	cis	rs9287719	0.967	rs6759714	ENSG00000234818.1	AC092687.5	4.44	1.39e-05	0.0067	0.3	0.28	Prostate cancer;	chr2:10607081	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs6744854	ENSG00000234818.1	AC092687.5	4.44	1.39e-05	0.0067	0.3	0.28	Prostate cancer;	chr2:10607120	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs6759740	ENSG00000234818.1	AC092687.5	4.44	1.39e-05	0.0067	0.3	0.28	Prostate cancer;	chr2:10607145	chr2:10589166~10604830:+
OV	cis	rs1020064	0.609	rs2576748	ENSG00000235319.1	AC012360.4	4.44	1.39e-05	0.0067	0.36	0.28	AIDS;	chr2:105294801	chr2:105324210~105330529:+
OV	cis	rs896854	0.625	rs7823886	ENSG00000253528.2	RP11-347C18.4	4.44	1.4e-05	0.00671	0.27	0.28	Type 2 diabetes;	chr8:94974231	chr8:94974573~94974853:-
OV	cis	rs8062405	0.755	rs4788076	ENSG00000278665.1	RP11-666O2.4	4.44	1.4e-05	0.00672	0.3	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28558684	chr16:28599241~28601881:-
OV	cis	rs875971	0.862	rs6944374	ENSG00000237310.1	GS1-124K5.4	-4.44	1.4e-05	0.00672	-0.29	-0.28	Aortic root size;	chr7:66221942	chr7:66493706~66495474:+
OV	cis	rs6772849	1	rs2713605	ENSG00000277250.1	Metazoa_SRP	-4.44	1.4e-05	0.00672	-0.34	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128588617	chr3:128673681~128674021:-
OV	cis	rs6772849	1	rs2712373	ENSG00000277250.1	Metazoa_SRP	-4.44	1.4e-05	0.00672	-0.34	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128589212	chr3:128673681~128674021:-
OV	cis	rs6772849	1	rs2712378	ENSG00000277250.1	Metazoa_SRP	-4.44	1.4e-05	0.00672	-0.34	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128589951	chr3:128673681~128674021:-
OV	cis	rs6772849	0.965	rs67790930	ENSG00000277250.1	Metazoa_SRP	-4.44	1.4e-05	0.00672	-0.34	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128591193	chr3:128673681~128674021:-
OV	cis	rs6772849	0.965	rs4286447	ENSG00000277250.1	Metazoa_SRP	-4.44	1.4e-05	0.00672	-0.34	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128591746	chr3:128673681~128674021:-
OV	cis	rs10924970	0.687	rs3765792	ENSG00000236863.2	RPL23AP23	4.44	1.4e-05	0.00672	0.3	0.28	Asthma;	chr1:235192617	chr1:235295865~235296335:+
OV	cis	rs10147992	1	rs10147992	ENSG00000258744.1	RP11-80A15.1	4.44	1.4e-05	0.00672	0.36	0.28	White blood cell types;	chr14:25034593	chr14:24501594~24508688:+
OV	cis	rs4908768	1	rs12122666	ENSG00000228423.2	RP4-633I8.4	-4.44	1.4e-05	0.00672	-0.35	-0.28	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8681379	chr1:8805860~8807051:-
OV	cis	rs17301013	0.507	rs3118990	ENSG00000227373.4	RP11-160H22.5	-4.44	1.4e-05	0.00672	-0.37	-0.28	Systemic lupus erythematosus;	chr1:174818586	chr1:174115300~174160004:-
OV	cis	rs7950696	1	rs7950696	ENSG00000280615.1	Y_RNA	4.44	1.4e-05	0.00673	0.31	0.28	Platelet count;	chr11:47459981	chr11:47614898~47614994:-
OV	cis	rs14027	0.921	rs35496588	ENSG00000279347.1	RP11-85I17.2	4.44	1.4e-05	0.00673	0.3	0.28	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119842461	chr8:119838736~119840385:-
OV	cis	rs4296809	0.505	rs72751803	ENSG00000249779.1	RP11-447H19.3	-4.44	1.4e-05	0.00673	-0.54	-0.28	Brain structure;	chr5:44066255	chr5:43206709~43207811:+
OV	cis	rs10462065	0.892	rs10462064	ENSG00000249779.1	RP11-447H19.3	-4.44	1.4e-05	0.00673	-0.54	-0.28	Nonsyndromic cleft lip with cleft palate;	chr5:44066707	chr5:43206709~43207811:+
OV	cis	rs10759883	0.539	rs684455	ENSG00000175611.10	LINC00476	4.44	1.4e-05	0.00673	0.34	0.28	Nicotine dependence;	chr9:95964061	chr9:95759231~95875977:-
OV	cis	rs2289700	1	rs16970287	ENSG00000279235.1	RP11-16K12.2	-4.44	1.4e-05	0.00674	-0.4	-0.28	Bipolar disorder;	chr15:78935915	chr15:78906127~78906809:+
OV	cis	rs4713118	0.629	rs203889	ENSG00000226314.6	ZNF192P1	-4.44	1.4e-05	0.00674	-0.37	-0.28	Parkinson's disease;	chr6:28053997	chr6:28161781~28169594:+
OV	cis	rs4713118	0.869	rs9283880	ENSG00000219392.1	RP1-265C24.5	-4.44	1.4e-05	0.00674	-0.32	-0.28	Parkinson's disease;	chr6:27747464	chr6:28115628~28116551:+
OV	cis	rs1969253	0.712	rs843342	ENSG00000243584.1	RP11-14I2.2	-4.44	1.4e-05	0.00674	-0.32	-0.28	Major depressive disorder;	chr3:184190214	chr3:183613620~183616742:+
OV	cis	rs3733585	0.699	rs6449171	ENSG00000250413.1	RP11-448G15.1	-4.44	1.4e-05	0.00675	-0.33	-0.28	Cleft plate (environmental tobacco smoke interaction);	chr4:9964374	chr4:10006482~10009725:+
OV	cis	rs875971	1	rs11974219	ENSG00000236529.1	RP13-254B10.1	-4.44	1.4e-05	0.00675	-0.29	-0.28	Aortic root size;	chr7:66182423	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs11974264	ENSG00000236529.1	RP13-254B10.1	-4.44	1.4e-05	0.00675	-0.29	-0.28	Aortic root size;	chr7:66182595	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs1540651	ENSG00000236529.1	RP13-254B10.1	-4.44	1.4e-05	0.00675	-0.29	-0.28	Aortic root size;	chr7:66185134	chr7:65840212~65840596:+
OV	cis	rs875971	1	rs1565531	ENSG00000236529.1	RP13-254B10.1	-4.44	1.4e-05	0.00675	-0.29	-0.28	Aortic root size;	chr7:66198126	chr7:65840212~65840596:+
OV	cis	rs875971	0.597	rs11763224	ENSG00000236529.1	RP13-254B10.1	4.44	1.41e-05	0.00675	0.34	0.28	Aortic root size;	chr7:66518628	chr7:65840212~65840596:+
OV	cis	rs7617773	0.78	rs34630841	ENSG00000228638.1	FCF1P2	-4.44	1.41e-05	0.00676	-0.37	-0.28	Coronary artery disease;	chr3:48301771	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs77044321	ENSG00000228638.1	FCF1P2	-4.44	1.41e-05	0.00676	-0.37	-0.28	Coronary artery disease;	chr3:48307824	chr3:48290793~48291375:-
OV	cis	rs7617773	0.743	rs13081633	ENSG00000228638.1	FCF1P2	-4.44	1.41e-05	0.00676	-0.37	-0.28	Coronary artery disease;	chr3:48315791	chr3:48290793~48291375:-
OV	cis	rs1538970	0.884	rs781232	ENSG00000280836.1	AL355480.1	4.44	1.41e-05	0.00677	0.39	0.28	Platelet count;	chr1:45424727	chr1:45581219~45581321:-
OV	cis	rs875971	0.502	rs2946580	ENSG00000236529.1	RP13-254B10.1	-4.44	1.41e-05	0.00677	-0.33	-0.28	Aortic root size;	chr7:66066855	chr7:65840212~65840596:+
OV	cis	rs2243480	1	rs316329	ENSG00000226824.5	RP4-756H11.3	-4.44	1.41e-05	0.00677	-0.44	-0.28	Diabetic kidney disease;	chr7:66143429	chr7:66654538~66669855:+
OV	cis	rs7520050	0.966	rs7556436	ENSG00000281133.1	AL355480.3	-4.44	1.41e-05	0.00678	-0.31	-0.28	Reticulocyte count;Red blood cell count;	chr1:45898208	chr1:45580892~45580996:-
OV	cis	rs7043114	0.525	rs10761153	ENSG00000281156.1	MIR3651	-4.44	1.41e-05	0.00678	-0.31	-0.28	Height;	chr9:92368487	chr9:92292458~92292547:-
OV	cis	rs7043114	0.525	rs10283572	ENSG00000281156.1	MIR3651	-4.44	1.41e-05	0.00678	-0.31	-0.28	Height;	chr9:92370792	chr9:92292458~92292547:-
OV	cis	rs7615952	0.599	rs66532274	ENSG00000171084.14	FAM86JP	4.44	1.41e-05	0.00679	0.39	0.28	Blood pressure (smoking interaction);	chr3:126013002	chr3:125916620~125930024:+
OV	cis	rs1020064	0.636	rs2679876	ENSG00000235319.1	AC012360.4	-4.44	1.42e-05	0.0068	-0.35	-0.28	AIDS;	chr2:105321650	chr2:105324210~105330529:+
OV	cis	rs13068223	0.568	rs7636965	ENSG00000243926.1	TIPARP-AS1	4.44	1.42e-05	0.0068	0.27	0.28	Age-related hearing impairment (SNP x SNP interaction);	chr3:156700615	chr3:156671862~156674378:-
OV	cis	rs757081	0.648	rs11024231	ENSG00000213779.4	RP11-452G18.1	4.44	1.42e-05	0.00681	0.32	0.28	Systolic blood pressure;	chr11:17265703	chr11:17193489~17194308:+
OV	cis	rs9309473	0.898	rs10201159	ENSG00000163016.8	ALMS1P	4.44	1.42e-05	0.00681	0.34	0.28	Metabolite levels;	chr2:73631838	chr2:73644919~73685576:+
OV	cis	rs853679	0.546	rs483143	ENSG00000220721.1	OR1F12	4.44	1.42e-05	0.00681	0.44	0.28	Depression;	chr6:27878966	chr6:28073316~28074233:+
OV	cis	rs7927592	0.956	rs2510384	ENSG00000212093.1	AP000807.1	4.44	1.42e-05	0.00682	0.36	0.28	Total body bone mineral density;	chr11:68624369	chr11:68506083~68506166:-
OV	cis	rs66823261	0.778	rs2906332	ENSG00000223508.5	RPL23AP53	4.44	1.42e-05	0.00682	0.42	0.28	Breast cancer (estrogen-receptor negative);Breast cancer;	chr8:244943	chr8:213186~232231:-
OV	cis	rs9311474	1	rs6445358	ENSG00000243224.1	RP5-1157M23.2	-4.44	1.42e-05	0.00683	-0.3	-0.28	Electroencephalogram traits;	chr3:52274829	chr3:52239258~52241097:+
OV	cis	rs9660180	0.935	rs2180311	ENSG00000215914.4	MMP23A	-4.44	1.42e-05	0.00683	-0.33	-0.28	Body mass index;	chr1:1817295	chr1:1699942~1701782:+
OV	cis	rs9660180	0.967	rs6664664	ENSG00000215914.4	MMP23A	-4.44	1.42e-05	0.00683	-0.33	-0.28	Body mass index;	chr1:1819825	chr1:1699942~1701782:+
OV	cis	rs12815613	1	rs12815613	ENSG00000200795.1	RNU4-1	4.44	1.43e-05	0.00683	0.35	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr12:120969453	chr12:120293097~120293237:-
OV	cis	rs1979679	0.918	rs7312574	ENSG00000278733.1	RP11-425D17.1	-4.44	1.43e-05	0.00683	-0.34	-0.28	Ossification of the posterior longitudinal ligament of the spine;	chr12:28514977	chr12:28185625~28186190:-
OV	cis	rs9287719	0.774	rs4997811	ENSG00000234818.1	AC092687.5	4.44	1.43e-05	0.00684	0.3	0.28	Prostate cancer;	chr2:10615412	chr2:10589166~10604830:+
OV	cis	rs9287719	0.745	rs4997810	ENSG00000234818.1	AC092687.5	4.44	1.43e-05	0.00684	0.3	0.28	Prostate cancer;	chr2:10615414	chr2:10589166~10604830:+
OV	cis	rs9287719	0.745	rs4997809	ENSG00000234818.1	AC092687.5	4.44	1.43e-05	0.00684	0.3	0.28	Prostate cancer;	chr2:10615416	chr2:10589166~10604830:+
OV	cis	rs875971	0.66	rs3764903	ENSG00000224316.1	RP11-479O9.2	-4.44	1.43e-05	0.00684	-0.3	-0.28	Aortic root size;	chr7:66633495	chr7:65773620~65802067:+
OV	cis	rs7927592	0.956	rs7104877	ENSG00000212093.1	AP000807.1	-4.44	1.43e-05	0.00684	-0.36	-0.28	Total body bone mineral density;	chr11:68610134	chr11:68506083~68506166:-
OV	cis	rs8114671	0.967	rs1577924	ENSG00000269202.1	RP4-614O4.12	4.44	1.43e-05	0.00685	0.28	0.28	Height;	chr20:35196485	chr20:35201747~35203288:-
OV	cis	rs10924970	0.625	rs12044028	ENSG00000236863.2	RPL23AP23	4.44	1.43e-05	0.00685	0.29	0.28	Asthma;	chr1:235329657	chr1:235295865~235296335:+
OV	cis	rs1538970	0.781	rs12049503	ENSG00000280836.1	AL355480.1	-4.44	1.43e-05	0.00685	-0.42	-0.28	Platelet count;	chr1:45555884	chr1:45581219~45581321:-
OV	cis	rs10129255	0.5	rs1974468	ENSG00000223648.3	IGHV3-64	4.44	1.43e-05	0.00685	0.28	0.28	Kawasaki disease;	chr14:106686149	chr14:106643132~106658258:-
OV	cis	rs1858037	0.867	rs67817304	ENSG00000234255.7	AC012370.3	4.44	1.43e-05	0.00686	0.32	0.28	Rheumatoid arthritis;	chr2:65346982	chr2:65439888~65456571:-
OV	cis	rs62184315	0.536	rs2289405	ENSG00000253559.1	OSGEPL1-AS1	-4.44	1.43e-05	0.00686	-0.39	-0.28	Alcohol dependence (age at onset);	chr2:189771313	chr2:189762704~189765556:+
OV	cis	rs17023223	0.509	rs7542832	ENSG00000231365.4	RP11-418J17.1	-4.44	1.43e-05	0.00686	-0.38	-0.28	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119220106	chr1:119140396~119275973:+
OV	cis	rs1979679	0.842	rs4931730	ENSG00000278733.1	RP11-425D17.1	4.44	1.43e-05	0.00687	0.34	0.28	Ossification of the posterior longitudinal ligament of the spine;	chr12:28146343	chr12:28185625~28186190:-
OV	cis	rs11673344	0.764	rs569371	ENSG00000226686.6	LINC01535	4.43	1.44e-05	0.00687	0.34	0.28	Obesity-related traits;	chr19:36963095	chr19:37251912~37265535:+
OV	cis	rs2861422	0.569	rs34579489	ENSG00000249417.1	RP11-438D8.2	-4.43	1.44e-05	0.00688	-0.44	-0.28	Glomerular filtration rate (creatinine);	chr3:142006889	chr3:141267353~141367137:-
OV	cis	rs347685	0.529	rs35486283	ENSG00000249417.1	RP11-438D8.2	-4.43	1.44e-05	0.00688	-0.44	-0.28	Glomerular filtration rate in non diabetics (creatinine);Chronic kidney disease;	chr3:142009002	chr3:141267353~141367137:-
OV	cis	rs7746199	0.736	rs13209332	ENSG00000280107.1	AL022393.9	-4.43	1.44e-05	0.00689	-0.58	-0.28	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:28170845~28172521:+
OV	cis	rs7746199	0.736	rs34965299	ENSG00000280107.1	AL022393.9	-4.43	1.44e-05	0.00689	-0.58	-0.28	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr6:28170845~28172521:+
OV	cis	rs7927592	0.956	rs10896334	ENSG00000212093.1	AP000807.1	4.43	1.44e-05	0.00689	0.36	0.28	Total body bone mineral density;	chr11:68514026	chr11:68506083~68506166:-
OV	cis	rs7927592	0.956	rs10896337	ENSG00000212093.1	AP000807.1	4.43	1.44e-05	0.00689	0.36	0.28	Total body bone mineral density;	chr11:68516768	chr11:68506083~68506166:-
OV	cis	rs875971	0.638	rs7793569	ENSG00000224316.1	RP11-479O9.2	-4.43	1.44e-05	0.00689	-0.3	-0.28	Aortic root size;	chr7:66651646	chr7:65773620~65802067:+
OV	cis	rs599083	0.573	rs3018713	ENSG00000212093.1	AP000807.1	4.43	1.44e-05	0.0069	0.32	0.28	Bone mineral density (spine);	chr11:68623518	chr11:68506083~68506166:-
OV	cis	rs7605378	1	rs2346662	ENSG00000232732.8	AC073043.1	-4.43	1.44e-05	0.0069	-0.34	-0.28	Osteoporosis;	chr2:199814435	chr2:199867396~199911159:-
OV	cis	rs957448	0.507	rs1984711	ENSG00000253704.1	RP11-267M23.4	4.43	1.44e-05	0.00691	0.36	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94600276	chr8:94553722~94569745:+
OV	cis	rs10771431	1	rs10771431	ENSG00000111788.10	RP11-22B23.1	4.43	1.44e-05	0.00691	0.25	0.28	Breast size;	chr12:9228263	chr12:9277235~9313241:+
OV	cis	rs875971	0.66	rs1860470	ENSG00000224316.1	RP11-479O9.2	-4.43	1.44e-05	0.00691	-0.3	-0.28	Aortic root size;	chr7:66638707	chr7:65773620~65802067:+
OV	cis	rs11096990	0.75	rs2465242	ENSG00000249207.1	RP11-360F5.1	4.43	1.45e-05	0.00691	0.33	0.28	Cognitive function;	chr4:39153796	chr4:39112677~39126818:-
OV	cis	rs11096990	0.855	rs2465243	ENSG00000249207.1	RP11-360F5.1	4.43	1.45e-05	0.00691	0.33	0.28	Cognitive function;	chr4:39154036	chr4:39112677~39126818:-
OV	cis	rs11096990	0.855	rs2566176	ENSG00000249207.1	RP11-360F5.1	4.43	1.45e-05	0.00691	0.33	0.28	Cognitive function;	chr4:39154373	chr4:39112677~39126818:-
OV	cis	rs11096990	0.855	rs2566177	ENSG00000249207.1	RP11-360F5.1	4.43	1.45e-05	0.00691	0.33	0.28	Cognitive function;	chr4:39154558	chr4:39112677~39126818:-
OV	cis	rs11096990	0.855	rs2566178	ENSG00000249207.1	RP11-360F5.1	4.43	1.45e-05	0.00691	0.33	0.28	Cognitive function;	chr4:39155194	chr4:39112677~39126818:-
OV	cis	rs11096990	0.819	rs2435528	ENSG00000249207.1	RP11-360F5.1	4.43	1.45e-05	0.00691	0.33	0.28	Cognitive function;	chr4:39155916	chr4:39112677~39126818:-
OV	cis	rs11096990	0.855	rs2711933	ENSG00000249207.1	RP11-360F5.1	4.43	1.45e-05	0.00691	0.33	0.28	Cognitive function;	chr4:39156090	chr4:39112677~39126818:-
OV	cis	rs11096990	0.855	rs2711934	ENSG00000249207.1	RP11-360F5.1	4.43	1.45e-05	0.00691	0.33	0.28	Cognitive function;	chr4:39156254	chr4:39112677~39126818:-
OV	cis	rs11096990	0.855	rs2566179	ENSG00000249207.1	RP11-360F5.1	4.43	1.45e-05	0.00691	0.33	0.28	Cognitive function;	chr4:39156413	chr4:39112677~39126818:-
OV	cis	rs11096990	0.855	rs2566180	ENSG00000249207.1	RP11-360F5.1	4.43	1.45e-05	0.00691	0.33	0.28	Cognitive function;	chr4:39157381	chr4:39112677~39126818:-
OV	cis	rs11096990	0.855	rs2566181	ENSG00000249207.1	RP11-360F5.1	4.43	1.45e-05	0.00691	0.33	0.28	Cognitive function;	chr4:39157987	chr4:39112677~39126818:-
OV	cis	rs11096990	0.819	rs1367297	ENSG00000249207.1	RP11-360F5.1	4.43	1.45e-05	0.00691	0.33	0.28	Cognitive function;	chr4:39159614	chr4:39112677~39126818:-
OV	cis	rs11096990	0.855	rs2566183	ENSG00000249207.1	RP11-360F5.1	4.43	1.45e-05	0.00691	0.33	0.28	Cognitive function;	chr4:39162288	chr4:39112677~39126818:-
OV	cis	rs11096990	0.855	rs2566184	ENSG00000249207.1	RP11-360F5.1	4.43	1.45e-05	0.00691	0.33	0.28	Cognitive function;	chr4:39162700	chr4:39112677~39126818:-
OV	cis	rs2239620	1	rs2239620	ENSG00000216775.2	RP1-152L7.5	-4.43	1.45e-05	0.00691	-0.28	-0.28	LDL cholesterol levels;	chr6:52587787	chr6:52665148~52669155:+
OV	cis	rs6772849	0.901	rs9289330	ENSG00000277250.1	Metazoa_SRP	-4.43	1.45e-05	0.00692	-0.32	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128592224	chr3:128673681~128674021:-
OV	cis	rs801193	0.742	rs9969300	ENSG00000236529.1	RP13-254B10.1	-4.43	1.45e-05	0.00692	-0.3	-0.28	Aortic root size;	chr7:66316659	chr7:65840212~65840596:+
OV	cis	rs1823913	0.526	rs36028476	ENSG00000227542.1	AC092614.2	4.43	1.45e-05	0.00692	0.32	0.28	Obesity-related traits;	chr2:191300595	chr2:191229165~191246172:-
OV	cis	rs10510102	0.872	rs3862129	ENSG00000276742.1	RP11-500G22.4	4.43	1.45e-05	0.00693	0.44	0.28	Breast cancer;	chr10:121824460	chr10:121956782~121957098:+
OV	cis	rs7829975	0.846	rs6601724	ENSG00000253981.4	ALG1L13P	-4.43	1.45e-05	0.00693	-0.27	-0.28	Mood instability;	chr8:8687362	chr8:8236003~8244667:-
OV	cis	rs73201462	1	rs2811387	ENSG00000277250.1	Metazoa_SRP	-4.43	1.45e-05	0.00694	-0.42	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128296335	chr3:128673681~128674021:-
OV	cis	rs875971	0.862	rs10274883	ENSG00000236529.1	RP13-254B10.1	-4.43	1.45e-05	0.00694	-0.29	-0.28	Aortic root size;	chr7:66651104	chr7:65840212~65840596:+
OV	cis	rs801193	0.569	rs881285	ENSG00000236529.1	RP13-254B10.1	-4.43	1.45e-05	0.00694	-0.29	-0.28	Aortic root size;	chr7:66654433	chr7:65840212~65840596:+
OV	cis	rs801193	0.569	rs3846973	ENSG00000236529.1	RP13-254B10.1	-4.43	1.45e-05	0.00694	-0.29	-0.28	Aortic root size;	chr7:66655048	chr7:65840212~65840596:+
OV	cis	rs801193	0.569	rs2013908	ENSG00000236529.1	RP13-254B10.1	-4.43	1.45e-05	0.00694	-0.29	-0.28	Aortic root size;	chr7:66656082	chr7:65840212~65840596:+
OV	cis	rs801193	0.548	rs2109297	ENSG00000236529.1	RP13-254B10.1	-4.43	1.45e-05	0.00694	-0.29	-0.28	Aortic root size;	chr7:66657397	chr7:65840212~65840596:+
OV	cis	rs801193	0.569	rs6978178	ENSG00000236529.1	RP13-254B10.1	-4.43	1.45e-05	0.00694	-0.29	-0.28	Aortic root size;	chr7:66658097	chr7:65840212~65840596:+
OV	cis	rs694739	0.93	rs574087	ENSG00000236935.1	AP003774.1	4.43	1.45e-05	0.00694	0.38	0.28	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64335476	chr11:64325050~64329504:-
OV	cis	rs7615952	0.599	rs2333408	ENSG00000171084.14	FAM86JP	4.43	1.45e-05	0.00694	0.39	0.28	Blood pressure (smoking interaction);	chr3:126013255	chr3:125916620~125930024:+
OV	cis	rs4128705	1	rs4128705	ENSG00000249049.1	RP11-763F8.1	4.43	1.45e-05	0.00695	0.32	0.28	Amyotrophic lateral sclerosis (sporadic);	chr4:91362620	chr4:91319034~91325306:-
OV	cis	rs4591358	0.765	rs9288249	ENSG00000223466.1	AC064834.2	-4.43	1.45e-05	0.00695	-0.32	-0.28	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195452555	chr2:195533035~195538681:+
OV	cis	rs1584120	0.62	rs11046807	ENSG00000274885.1	RP11-268P4.6	-4.43	1.46e-05	0.00695	-0.32	-0.28	Pelvic organ prolapse (moderate/severe);	chr12:23121069	chr12:22638464~22638943:+
OV	cis	rs1198872	0.526	rs57282335	ENSG00000272275.1	RP11-791G15.2	-4.43	1.46e-05	0.00695	-0.39	-0.28	Cardiac Troponin-T levels;	chr2:10788081	chr2:10767875~10770058:-
OV	cis	rs9287719	0.967	rs12467642	ENSG00000234818.1	AC092687.5	4.43	1.46e-05	0.00695	0.3	0.28	Prostate cancer;	chr2:10621358	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs12464908	ENSG00000234818.1	AC092687.5	4.43	1.46e-05	0.00695	0.3	0.28	Prostate cancer;	chr2:10621370	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs7563816	ENSG00000234818.1	AC092687.5	4.43	1.46e-05	0.00695	0.3	0.28	Prostate cancer;	chr2:10623274	chr2:10589166~10604830:+
OV	cis	rs10978777	1	rs9969728	ENSG00000276883.1	AL137852.1	-4.43	1.46e-05	0.00697	-0.31	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107277353	chr9:107292369~107292456:-
OV	cis	rs4713118	0.662	rs149969	ENSG00000226314.6	ZNF192P1	-4.43	1.46e-05	0.00697	-0.39	-0.28	Parkinson's disease;	chr6:28009959	chr6:28161781~28169594:+
OV	cis	rs1862618	0.573	rs832532	ENSG00000271828.1	CTD-2310F14.1	4.43	1.46e-05	0.00697	0.48	0.28	Initial pursuit acceleration;	chr5:56926111	chr5:56927874~56929573:+
OV	cis	rs875971	0.545	rs17138149	ENSG00000226824.5	RP4-756H11.3	-4.43	1.46e-05	0.00698	-0.33	-0.28	Aortic root size;	chr7:66228193	chr7:66654538~66669855:+
OV	cis	rs10924970	0.649	rs12747368	ENSG00000236863.2	RPL23AP23	4.43	1.46e-05	0.00698	0.29	0.28	Asthma;	chr1:235303372	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs2382568	ENSG00000236863.2	RPL23AP23	4.43	1.46e-05	0.00698	0.29	0.28	Asthma;	chr1:235305565	chr1:235295865~235296335:+
OV	cis	rs10924970	0.601	rs11804525	ENSG00000236863.2	RPL23AP23	4.43	1.46e-05	0.00698	0.29	0.28	Asthma;	chr1:235307380	chr1:235295865~235296335:+
OV	cis	rs7667	0.728	rs10458381	ENSG00000240490.3	RN7SL277P	-4.43	1.46e-05	0.00698	-0.34	-0.28	Crohn's disease and psoriasis;	chr1:19442749	chr1:19424384~19424671:+
OV	cis	rs17301013	0.507	rs72713528	ENSG00000227373.4	RP11-160H22.5	4.43	1.46e-05	0.00699	0.38	0.28	Systemic lupus erythematosus;	chr1:174319862	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs17300775	ENSG00000227373.4	RP11-160H22.5	4.43	1.46e-05	0.00699	0.38	0.28	Systemic lupus erythematosus;	chr1:174191901	chr1:174115300~174160004:-
OV	cis	rs17301013	0.566	rs72711492	ENSG00000227373.4	RP11-160H22.5	4.43	1.46e-05	0.00699	0.38	0.28	Systemic lupus erythematosus;	chr1:174195464	chr1:174115300~174160004:-
OV	cis	rs9287719	0.601	rs10178751	ENSG00000243819.4	RN7SL832P	4.43	1.46e-05	0.00699	0.29	0.28	Prostate cancer;	chr2:10594077	chr2:10690344~10692099:+
OV	cis	rs9393777	0.92	rs34953377	ENSG00000243307.2	POM121L6P	-4.43	1.46e-05	0.00699	-0.49	-0.28	Intelligence (multi-trait analysis);	chr6:27413881	chr6:26896952~26898777:+
OV	cis	rs9393777	0.778	rs66841633	ENSG00000243307.2	POM121L6P	-4.43	1.46e-05	0.00699	-0.49	-0.28	Intelligence (multi-trait analysis);	chr6:27414607	chr6:26896952~26898777:+
OV	cis	rs2412819	0.571	rs56226333	ENSG00000205771.5	CATSPER2P1	-4.43	1.47e-05	0.00699	-0.43	-0.28	Lung cancer;	chr15:43632410	chr15:43726918~43747094:-
OV	cis	rs9660180	0.935	rs9786942	ENSG00000215914.4	MMP23A	-4.43	1.47e-05	0.00699	-0.33	-0.28	Body mass index;	chr1:1827774	chr1:1699942~1701782:+
OV	cis	rs9660180	0.934	rs34849348	ENSG00000215914.4	MMP23A	-4.43	1.47e-05	0.00699	-0.33	-0.28	Body mass index;	chr1:1831318	chr1:1699942~1701782:+
OV	cis	rs181553	0.664	rs8094480	ENSG00000266696.1	RP11-30L3.2	4.43	1.47e-05	0.00699	0.35	0.28	Hip circumference adjusted for BMI;	chr18:49161306	chr18:49205912~49208781:+
OV	cis	rs858239	0.539	rs10270695	ENSG00000230042.1	AK3P3	4.43	1.47e-05	0.00699	0.3	0.28	Cerebrospinal fluid biomarker levels;	chr7:23149369	chr7:23129178~23129841:+
OV	cis	rs4948102	0.551	rs4275190	ENSG00000275875.1	RP11-613E4.5	-4.43	1.47e-05	0.00701	-0.31	-0.28	Plasma homocysteine levels (post-methionine load test);	chr7:56036695	chr7:55741525~55741869:+
OV	cis	rs12492269	0.702	rs41381644	ENSG00000240429.1	LRRFIP1P1	4.43	1.47e-05	0.00701	0.46	0.28	Plasma clusterin levels;	chr3:178443826	chr3:179259028~179261273:-
OV	cis	rs7302981	1	rs7308356	ENSG00000257298.1	RP3-405J10.3	-4.43	1.47e-05	0.00701	-0.26	-0.28	Systolic blood pressure;	chr12:50145828	chr12:50185580~50191363:-
OV	cis	rs7302981	0.934	rs7301649	ENSG00000257298.1	RP3-405J10.3	-4.43	1.47e-05	0.00701	-0.26	-0.28	Systolic blood pressure;	chr12:50147087	chr12:50185580~50191363:-
OV	cis	rs3733585	0.699	rs7435196	ENSG00000250413.1	RP11-448G15.1	4.43	1.47e-05	0.00701	0.31	0.28	Cleft plate (environmental tobacco smoke interaction);	chr4:9965932	chr4:10006482~10009725:+
OV	cis	rs6772849	0.93	rs9868579	ENSG00000277250.1	Metazoa_SRP	4.43	1.47e-05	0.00702	0.33	0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128632211	chr3:128673681~128674021:-
OV	cis	rs10759883	0.563	rs690056	ENSG00000175611.10	LINC00476	4.43	1.47e-05	0.00703	0.34	0.28	Nicotine dependence;	chr9:95938704	chr9:95759231~95875977:-
OV	cis	rs1823913	0.562	rs17347499	ENSG00000227542.1	AC092614.2	4.43	1.47e-05	0.00703	0.31	0.28	Obesity-related traits;	chr2:191301116	chr2:191229165~191246172:-
OV	cis	rs17301013	0.507	rs12067852	ENSG00000227373.4	RP11-160H22.5	-4.43	1.48e-05	0.00704	-0.39	-0.28	Systemic lupus erythematosus;	chr1:174302481	chr1:174115300~174160004:-
OV	cis	rs638893	1	rs649338	ENSG00000255239.1	AP002954.6	4.43	1.48e-05	0.00704	0.44	0.28	Vitiligo;	chr11:118834945	chr11:118688039~118690600:-
OV	cis	rs8001976	0.622	rs9534835	ENSG00000229111.1	MED4-AS1	-4.43	1.48e-05	0.00704	-0.35	-0.28	Aging (time to event);	chr13:47806635	chr13:48077137~48079991:+
OV	cis	rs992157	0.798	rs1017698	ENSG00000261338.2	RP11-378A13.1	-4.43	1.48e-05	0.00704	-0.33	-0.28	Colorectal cancer;	chr2:218305802	chr2:218255319~218257366:+
OV	cis	rs875971	0.545	rs4718348	ENSG00000237310.1	GS1-124K5.4	4.43	1.48e-05	0.00704	0.33	0.28	Aortic root size;	chr7:66441589	chr7:66493706~66495474:+
OV	cis	rs992157	0.798	rs10932772	ENSG00000261338.2	RP11-378A13.1	4.43	1.48e-05	0.00705	0.33	0.28	Colorectal cancer;	chr2:218312425	chr2:218255319~218257366:+
OV	cis	rs875971	0.862	rs778720	ENSG00000237310.1	GS1-124K5.4	-4.43	1.48e-05	0.00705	-0.28	-0.28	Aortic root size;	chr7:66381288	chr7:66493706~66495474:+
OV	cis	rs73201462	1	rs2955089	ENSG00000277250.1	Metazoa_SRP	-4.43	1.48e-05	0.00705	-0.41	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128250487	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2955090	ENSG00000277250.1	Metazoa_SRP	-4.43	1.48e-05	0.00705	-0.41	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128250528	chr3:128673681~128674021:-
OV	cis	rs1969253	0.712	rs843336	ENSG00000243584.1	RP11-14I2.2	4.43	1.48e-05	0.00707	0.3	0.28	Major depressive disorder;	chr3:184194551	chr3:183613620~183616742:+
OV	cis	rs116095464	0.558	rs34629844	ENSG00000250848.1	CTD-2083E4.5	-4.43	1.49e-05	0.00707	-0.37	-0.28	Breast cancer;	chr5:200714	chr5:288833~290321:-
OV	cis	rs67311347	0.91	rs7617361	ENSG00000223797.4	ENTPD3-AS1	4.43	1.49e-05	0.00708	0.29	0.28	Renal cell carcinoma;	chr3:40331768	chr3:40313802~40453329:-
OV	cis	rs7121800	0.888	rs16920802	ENSG00000254532.1	RP11-624D11.2	-4.43	1.49e-05	0.00708	-0.32	-0.28	Pit-and-Fissure caries;	chr11:30490926	chr11:30044058~30084343:-
OV	cis	rs13068223	0.584	rs344018	ENSG00000243926.1	TIPARP-AS1	-4.43	1.49e-05	0.00708	-0.27	-0.28	Age-related hearing impairment (SNP x SNP interaction);	chr3:156698204	chr3:156671862~156674378:-
OV	cis	rs4713118	0.662	rs175954	ENSG00000226314.6	ZNF192P1	-4.43	1.49e-05	0.00708	-0.4	-0.28	Parkinson's disease;	chr6:28043807	chr6:28161781~28169594:+
OV	cis	rs7160336	0.515	rs7152352	ENSG00000259065.1	RP5-1021I20.1	-4.43	1.49e-05	0.0071	-0.32	-0.28	Blood protein levels;	chr14:74144568	chr14:73787360~73803270:+
OV	cis	rs875971	0.862	rs7783779	ENSG00000236529.1	RP13-254B10.1	-4.43	1.49e-05	0.00711	-0.3	-0.28	Aortic root size;	chr7:66331639	chr7:65840212~65840596:+
OV	cis	rs1134634	0.52	rs2041671	ENSG00000273133.1	RP11-799M12.2	-4.43	1.49e-05	0.00711	-0.37	-0.28	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr4:15550575	chr4:15563698~15564253:-
OV	cis	rs881375	0.933	rs7859805	ENSG00000226752.6	PSMD5-AS1	-4.43	1.5e-05	0.00711	-0.32	-0.28	Rheumatoid arthritis;	chr9:120901845	chr9:120824828~120854385:+
OV	cis	rs881375	0.933	rs10818485	ENSG00000226752.6	PSMD5-AS1	-4.43	1.5e-05	0.00711	-0.32	-0.28	Rheumatoid arthritis;	chr9:120905538	chr9:120824828~120854385:+
OV	cis	rs881375	0.967	rs10435843	ENSG00000226752.6	PSMD5-AS1	-4.43	1.5e-05	0.00711	-0.32	-0.28	Rheumatoid arthritis;	chr9:120905755	chr9:120824828~120854385:+
OV	cis	rs881375	0.967	rs10435844	ENSG00000226752.6	PSMD5-AS1	-4.43	1.5e-05	0.00711	-0.32	-0.28	Rheumatoid arthritis;	chr9:120905921	chr9:120824828~120854385:+
OV	cis	rs881375	0.967	rs7848332	ENSG00000226752.6	PSMD5-AS1	-4.43	1.5e-05	0.00711	-0.32	-0.28	Rheumatoid arthritis;	chr9:120907218	chr9:120824828~120854385:+
OV	cis	rs6893300	0.961	rs62406219	ENSG00000254035.1	RP11-281O15.4	4.43	1.5e-05	0.00711	0.34	0.28	Resting heart rate;	chr5:179784628	chr5:178969390~178990116:+
OV	cis	rs10931896	0.531	rs296801	ENSG00000232732.8	AC073043.1	-4.43	1.5e-05	0.00712	-0.32	-0.28	Systolic blood pressure;	chr2:200278089	chr2:199867396~199911159:-
OV	cis	rs8054556	1	rs4583255	ENSG00000261367.1	RP11-455F5.4	-4.43	1.5e-05	0.00712	-0.32	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29977620	chr16:30107675~30110541:+
OV	cis	rs957448	0.698	rs116348949	ENSG00000253704.1	RP11-267M23.4	4.43	1.5e-05	0.00712	0.34	0.28	Nonsyndromic cleft lip with cleft palate;	chr8:94557488	chr8:94553722~94569745:+
OV	cis	rs8054556	0.967	rs12918652	ENSG00000261367.1	RP11-455F5.4	-4.43	1.5e-05	0.00712	-0.31	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29953036	chr16:30107675~30110541:+
OV	cis	rs3814244	0.788	rs3741649	ENSG00000255733.4	IFNG-AS1	-4.42	1.5e-05	0.00712	-0.27	-0.28	Itch intensity from mosquito bite adjusted by bite size;	chr12:68028351	chr12:67989445~68234686:+
OV	cis	rs3814244	0.788	rs11177014	ENSG00000255733.4	IFNG-AS1	-4.42	1.5e-05	0.00712	-0.27	-0.28	Itch intensity from mosquito bite adjusted by bite size;	chr12:68031871	chr12:67989445~68234686:+
OV	cis	rs1797885	0.564	rs2596820	ENSG00000251774.1	RNU6-377P	4.42	1.5e-05	0.00712	0.27	0.28	Immature fraction of reticulocytes;	chr3:12560442	chr3:12514706~12514807:+
OV	cis	rs189798	0.807	rs330909	ENSG00000254340.1	RP11-10A14.3	4.42	1.5e-05	0.00713	0.42	0.28	Myopia (pathological);	chr8:9137877	chr8:9141424~9145435:+
OV	cis	rs1862618	0.853	rs33325	ENSG00000271828.1	CTD-2310F14.1	4.42	1.5e-05	0.00713	0.45	0.28	Initial pursuit acceleration;	chr5:56846720	chr5:56927874~56929573:+
OV	cis	rs1862618	0.802	rs42769	ENSG00000271828.1	CTD-2310F14.1	4.42	1.5e-05	0.00713	0.45	0.28	Initial pursuit acceleration;	chr5:56848325	chr5:56927874~56929573:+
OV	cis	rs2999052	0.542	rs3887841	ENSG00000277250.1	Metazoa_SRP	4.42	1.5e-05	0.00715	0.37	0.28	Hypospadias;	chr3:128391098	chr3:128673681~128674021:-
OV	cis	rs2274471	0.54	rs10815162	ENSG00000234534.1	CSNK1G2P1	4.42	1.5e-05	0.00715	0.36	0.28	Crohn's disease;	chr9:5122291	chr9:5040945~5041940:+
OV	cis	rs67311347	1	rs9332450	ENSG00000223797.4	ENTPD3-AS1	-4.42	1.51e-05	0.00715	-0.31	-0.28	Renal cell carcinoma;	chr3:40416550	chr3:40313802~40453329:-
OV	cis	rs992157	0.735	rs13393821	ENSG00000237281.1	CATIP-AS2	-4.42	1.51e-05	0.00716	-0.33	-0.28	Colorectal cancer;	chr2:218212019	chr2:218326889~218357966:-
OV	cis	rs13113518	0.812	rs4865003	ENSG00000223305.1	RN7SKP30	4.42	1.51e-05	0.00716	0.33	0.28	Height;	chr4:55514802	chr4:55540502~55540835:-
OV	cis	rs13113518	0.756	rs12510275	ENSG00000223305.1	RN7SKP30	4.42	1.51e-05	0.00716	0.33	0.28	Height;	chr4:55516548	chr4:55540502~55540835:-
OV	cis	rs13113518	0.812	rs12510327	ENSG00000223305.1	RN7SKP30	4.42	1.51e-05	0.00716	0.33	0.28	Height;	chr4:55516744	chr4:55540502~55540835:-
OV	cis	rs13113518	0.812	rs11939580	ENSG00000223305.1	RN7SKP30	4.42	1.51e-05	0.00716	0.33	0.28	Height;	chr4:55517185	chr4:55540502~55540835:-
OV	cis	rs1029966	0.697	rs2908662	ENSG00000262712.1	RP11-295D4.1	4.42	1.51e-05	0.00716	0.36	0.28	Cancer;	chr16:4932012	chr16:4335870~4337818:-
OV	cis	rs6460942	0.597	rs7808537	ENSG00000226690.5	AC005281.1	4.42	1.51e-05	0.00717	0.49	0.28	Coronary artery disease;	chr7:12481287	chr7:12496429~12541910:+
OV	cis	rs875971	0.825	rs4587224	ENSG00000236529.1	RP13-254B10.1	-4.42	1.51e-05	0.00717	-0.29	-0.28	Aortic root size;	chr7:66271195	chr7:65840212~65840596:+
OV	cis	rs875971	0.792	rs6971752	ENSG00000236529.1	RP13-254B10.1	-4.42	1.51e-05	0.00717	-0.29	-0.28	Aortic root size;	chr7:66272999	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs10950033	ENSG00000236529.1	RP13-254B10.1	-4.42	1.51e-05	0.00717	-0.29	-0.28	Aortic root size;	chr7:66274686	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs11760844	ENSG00000236529.1	RP13-254B10.1	-4.42	1.51e-05	0.00717	-0.29	-0.28	Aortic root size;	chr7:66274896	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs4149461	ENSG00000236529.1	RP13-254B10.1	-4.42	1.51e-05	0.00717	-0.29	-0.28	Aortic root size;	chr7:66279745	chr7:65840212~65840596:+
OV	cis	rs1584120	0.62	rs12321859	ENSG00000274885.1	RP11-268P4.6	-4.42	1.51e-05	0.00718	-0.33	-0.28	Pelvic organ prolapse (moderate/severe);	chr12:23122099	chr12:22638464~22638943:+
OV	cis	rs67311347	0.911	rs9849224	ENSG00000223797.4	ENTPD3-AS1	4.42	1.51e-05	0.00719	0.3	0.28	Renal cell carcinoma;	chr3:40351071	chr3:40313802~40453329:-
OV	cis	rs496547	0.686	rs524590	ENSG00000255239.1	AP002954.6	4.42	1.51e-05	0.00719	0.32	0.28	Hip minimal joint space width;	chr11:118769354	chr11:118688039~118690600:-
OV	cis	rs4713118	0.955	rs9468204	ENSG00000219392.1	RP1-265C24.5	-4.42	1.52e-05	0.0072	-0.34	-0.28	Parkinson's disease;	chr6:27721030	chr6:28115628~28116551:+
OV	cis	rs896854	0.654	rs10104909	ENSG00000253528.2	RP11-347C18.4	4.42	1.52e-05	0.0072	0.27	0.28	Type 2 diabetes;	chr8:94965745	chr8:94974573~94974853:-
OV	cis	rs4763879	0.634	rs61915472	ENSG00000256673.1	RP11-599J14.2	4.42	1.52e-05	0.0072	0.27	0.28	Type 1 diabetes;	chr12:9700995	chr12:9398355~9414851:-
OV	cis	rs2274471	0.699	rs10815160	ENSG00000234534.1	CSNK1G2P1	4.42	1.52e-05	0.00721	0.35	0.28	Crohn's disease;	chr9:5116616	chr9:5040945~5041940:+
OV	cis	rs1113500	0.614	rs12565953	ENSG00000226822.1	RP11-356N1.2	4.42	1.52e-05	0.00721	0.35	0.28	Growth-regulated protein alpha levels;	chr1:108064465	chr1:108071482~108074519:+
OV	cis	rs1113500	0.614	rs61797342	ENSG00000226822.1	RP11-356N1.2	4.42	1.52e-05	0.00721	0.35	0.28	Growth-regulated protein alpha levels;	chr1:108065763	chr1:108071482~108074519:+
OV	cis	rs1797885	0.564	rs2633443	ENSG00000251774.1	RNU6-377P	4.42	1.52e-05	0.00721	0.27	0.28	Immature fraction of reticulocytes;	chr3:12559338	chr3:12514706~12514807:+
OV	cis	rs11098499	0.863	rs7699064	ENSG00000245958.5	RP11-33B1.1	4.42	1.52e-05	0.00722	0.34	0.28	Corneal astigmatism;	chr4:119507154	chr4:119454791~119552025:+
OV	cis	rs4713118	0.513	rs149950	ENSG00000280107.1	AL022393.9	-4.42	1.52e-05	0.00722	-0.32	-0.28	Parkinson's disease;	chr6:28065261	chr6:28170845~28172521:+
OV	cis	rs4713118	0.513	rs149951	ENSG00000280107.1	AL022393.9	-4.42	1.52e-05	0.00722	-0.32	-0.28	Parkinson's disease;	chr6:28065309	chr6:28170845~28172521:+
OV	cis	rs7580658	0.929	rs4150477	ENSG00000236682.1	AC068282.3	4.42	1.52e-05	0.00722	0.36	0.28	Protein C levels;	chr2:127274970	chr2:127389130~127400580:+
OV	cis	rs7017914	0.629	rs2732120	ENSG00000223220.1	Y_RNA	4.42	1.52e-05	0.00722	0.3	0.28	Bone mineral density;	chr8:70992758	chr8:70780914~70781008:-
OV	cis	rs7017914	0.714	rs2732119	ENSG00000223220.1	Y_RNA	4.42	1.52e-05	0.00722	0.3	0.28	Bone mineral density;	chr8:70996142	chr8:70780914~70781008:-
OV	cis	rs11098499	0.863	rs1552095	ENSG00000249244.1	RP11-548H18.2	4.42	1.52e-05	0.00723	0.4	0.28	Corneal astigmatism;	chr4:119539151	chr4:119391831~119395335:-
OV	cis	rs17301013	0.606	rs10912747	ENSG00000227373.4	RP11-160H22.5	-4.42	1.52e-05	0.00723	-0.37	-0.28	Systemic lupus erythematosus;	chr1:174224564	chr1:174115300~174160004:-
OV	cis	rs496547	0.719	rs472641	ENSG00000255239.1	AP002954.6	4.42	1.52e-05	0.00723	0.32	0.28	Hip minimal joint space width;	chr11:118746835	chr11:118688039~118690600:-
OV	cis	rs875971	0.545	rs73376401	ENSG00000237310.1	GS1-124K5.4	4.42	1.52e-05	0.00723	0.32	0.28	Aortic root size;	chr7:66174841	chr7:66493706~66495474:+
OV	cis	rs875971	0.545	rs6460276	ENSG00000237310.1	GS1-124K5.4	4.42	1.52e-05	0.00723	0.32	0.28	Aortic root size;	chr7:66182290	chr7:66493706~66495474:+
OV	cis	rs6052484	0.523	rs10854263	ENSG00000229539.1	RP11-119B16.2	4.42	1.53e-05	0.00725	0.32	0.28	Sense of smell;	chr20:4339157	chr20:3888239~3888868:-
OV	cis	rs992157	0.661	rs17653757	ENSG00000237281.1	CATIP-AS2	-4.42	1.53e-05	0.00725	-0.33	-0.28	Colorectal cancer;	chr2:218244641	chr2:218326889~218357966:-
OV	cis	rs992157	0.71	rs12996912	ENSG00000237281.1	CATIP-AS2	-4.42	1.53e-05	0.00725	-0.33	-0.28	Colorectal cancer;	chr2:218245832	chr2:218326889~218357966:-
OV	cis	rs116095464	0.614	rs62344292	ENSG00000250848.1	CTD-2083E4.5	-4.42	1.53e-05	0.00725	-0.36	-0.28	Breast cancer;	chr5:244515	chr5:288833~290321:-
OV	cis	rs116095464	0.614	rs78905930	ENSG00000250848.1	CTD-2083E4.5	-4.42	1.53e-05	0.00725	-0.36	-0.28	Breast cancer;	chr5:246445	chr5:288833~290321:-
OV	cis	rs875971	0.545	rs2707851	ENSG00000226824.5	RP4-756H11.3	4.42	1.53e-05	0.00725	0.34	0.28	Aortic root size;	chr7:66624178	chr7:66654538~66669855:+
OV	cis	rs7968440	1	rs2251603	ENSG00000257298.1	RP3-405J10.3	-4.42	1.53e-05	0.00726	-0.27	-0.28	Fibrinogen;	chr12:50655870	chr12:50185580~50191363:-
OV	cis	rs8105895	1	rs6511313	ENSG00000269742.1	BNIP3P29	4.42	1.53e-05	0.00726	0.41	0.28	Body mass index (change over time);	chr19:22033103	chr19:22065828~22066398:-
OV	cis	rs17301013	0.507	rs464635	ENSG00000227373.4	RP11-160H22.5	4.42	1.53e-05	0.00727	0.36	0.28	Systemic lupus erythematosus;	chr1:174732730	chr1:174115300~174160004:-
OV	cis	rs62184315	0.536	rs56137655	ENSG00000253559.1	OSGEPL1-AS1	-4.42	1.53e-05	0.00727	-0.39	-0.28	Alcohol dependence (age at onset);	chr2:189675844	chr2:189762704~189765556:+
OV	cis	rs7587476	0.906	rs17487827	ENSG00000229267.2	AC072062.1	-4.42	1.53e-05	0.00727	-0.37	-0.28	Neuroblastoma;	chr2:214779611	chr2:214810229~214963274:+
OV	cis	rs7520050	0.807	rs4468203	ENSG00000281133.1	AL355480.3	-4.42	1.53e-05	0.00727	-0.31	-0.28	Reticulocyte count;Red blood cell count;	chr1:45647600	chr1:45580892~45580996:-
OV	cis	rs7520050	0.807	rs6656279	ENSG00000281133.1	AL355480.3	-4.42	1.53e-05	0.00727	-0.31	-0.28	Reticulocyte count;Red blood cell count;	chr1:45658416	chr1:45580892~45580996:-
OV	cis	rs7520050	0.807	rs6671802	ENSG00000281133.1	AL355480.3	-4.42	1.53e-05	0.00727	-0.31	-0.28	Reticulocyte count;Red blood cell count;	chr1:45658991	chr1:45580892~45580996:-
OV	cis	rs896854	0.654	rs13248607	ENSG00000253528.2	RP11-347C18.4	4.42	1.53e-05	0.00728	0.27	0.28	Type 2 diabetes;	chr8:94974409	chr8:94974573~94974853:-
OV	cis	rs4254863	1	rs11741921	ENSG00000247796.2	CTD-2366F13.1	-4.42	1.54e-05	0.00728	-0.46	-0.28	Breast cancer;	chr5:53374532	chr5:53109842~53115126:+
OV	cis	rs9880211	0.848	rs71336069	ENSG00000239213.4	NCK1-AS1	4.42	1.54e-05	0.00728	0.35	0.28	Height;Body mass index;	chr3:136633024	chr3:136841726~136862054:-
OV	cis	rs9880211	1	rs28750366	ENSG00000239213.4	NCK1-AS1	4.42	1.54e-05	0.00728	0.35	0.28	Height;Body mass index;	chr3:136642213	chr3:136841726~136862054:-
OV	cis	rs9880211	0.846	rs73230043	ENSG00000239213.4	NCK1-AS1	4.42	1.54e-05	0.00728	0.35	0.28	Height;Body mass index;	chr3:136688317	chr3:136841726~136862054:-
OV	cis	rs7017914	0.69	rs13248937	ENSG00000223220.1	Y_RNA	4.42	1.54e-05	0.00728	0.3	0.28	Bone mineral density;	chr8:70906514	chr8:70780914~70781008:-
OV	cis	rs796364	0.806	rs203769	ENSG00000232732.8	AC073043.1	4.42	1.54e-05	0.00728	0.45	0.28	Schizophrenia;	chr2:200036143	chr2:199867396~199911159:-
OV	cis	rs6772849	0.93	rs9813197	ENSG00000277250.1	Metazoa_SRP	-4.42	1.54e-05	0.00728	-0.33	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128650261	chr3:128673681~128674021:-
OV	cis	rs829883	0.664	rs829874	ENSG00000227825.4	SLC9A7P1	4.42	1.54e-05	0.00729	0.29	0.28	Colorectal adenoma (advanced);	chr12:98446837	chr12:98453835~98457145:-
OV	cis	rs2243480	1	rs316331	ENSG00000226824.5	RP4-756H11.3	4.42	1.54e-05	0.00729	0.43	0.28	Diabetic kidney disease;	chr7:66139635	chr7:66654538~66669855:+
OV	cis	rs73201462	1	rs11710704	ENSG00000277250.1	Metazoa_SRP	4.42	1.54e-05	0.00729	0.44	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128328393	chr3:128673681~128674021:-
OV	cis	rs6921919	0.945	rs61289879	ENSG00000216901.1	AL022393.7	4.42	1.54e-05	0.00729	0.4	0.28	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28176188~28176674:+
OV	cis	rs11723261	0.621	rs6599307	ENSG00000275426.1	CH17-262A2.1	4.42	1.54e-05	0.0073	0.41	0.28	Immune response to smallpox vaccine (IL-6);	chr4:149993	chr4:149738~150317:+
OV	cis	rs62184315	0.536	rs62184265	ENSG00000253559.1	OSGEPL1-AS1	-4.42	1.54e-05	0.0073	-0.39	-0.28	Alcohol dependence (age at onset);	chr2:189756231	chr2:189762704~189765556:+
OV	cis	rs875971	0.862	rs6959268	ENSG00000236529.1	RP13-254B10.1	-4.42	1.54e-05	0.0073	-0.29	-0.28	Aortic root size;	chr7:66347979	chr7:65840212~65840596:+
OV	cis	rs7771547	0.855	rs1406945	ENSG00000240733.3	RN7SL502P	4.42	1.54e-05	0.00731	0.31	0.28	Platelet distribution width;	chr6:36594664	chr6:36450912~36451201:-
OV	cis	rs10899021	1	rs11236190	ENSG00000279353.1	RP11-864N7.4	4.42	1.54e-05	0.00731	0.55	0.28	Response to metformin (IC50);	chr11:74655710	chr11:74698231~74699658:-
OV	cis	rs10924970	0.625	rs10802624	ENSG00000236863.2	RPL23AP23	4.42	1.54e-05	0.00731	0.3	0.28	Asthma;	chr1:235331656	chr1:235295865~235296335:+
OV	cis	rs1113500	0.73	rs1777456	ENSG00000226822.1	RP11-356N1.2	-4.42	1.55e-05	0.00732	-0.33	-0.28	Growth-regulated protein alpha levels;	chr1:108045850	chr1:108071482~108074519:+
OV	cis	rs7968440	0.966	rs1521516	ENSG00000257298.1	RP3-405J10.3	4.42	1.55e-05	0.00732	0.28	0.28	Fibrinogen;	chr12:50661925	chr12:50185580~50191363:-
OV	cis	rs72615157	0.664	rs6953580	ENSG00000242294.5	STAG3L5P	4.42	1.55e-05	0.00733	0.27	0.28	Lung function (FEV1/FVC);	chr7:100227652	chr7:100336079~100351900:+
OV	cis	rs9287719	0.967	rs10206225	ENSG00000234818.1	AC092687.5	4.42	1.55e-05	0.00733	0.3	0.28	Prostate cancer;	chr2:10618531	chr2:10589166~10604830:+
OV	cis	rs8062405	1	rs8062405	ENSG00000278665.1	RP11-666O2.4	-4.42	1.55e-05	0.00733	-0.3	-0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28826585	chr16:28599241~28601881:-
OV	cis	rs7017914	0.69	rs2732117	ENSG00000223220.1	Y_RNA	4.42	1.55e-05	0.00734	0.3	0.28	Bone mineral density;	chr8:70996843	chr8:70780914~70781008:-
OV	cis	rs7746199	0.668	rs7749305	ENSG00000220721.1	OR1F12	4.42	1.55e-05	0.00734	0.5	0.28	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27478787	chr6:28073316~28074233:+
OV	cis	rs7746199	0.668	rs34864796	ENSG00000220721.1	OR1F12	4.42	1.55e-05	0.00734	0.5	0.28	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27492144	chr6:28073316~28074233:+
OV	cis	rs6822297	0.504	rs9291487	ENSG00000240005.4	RP11-293A21.1	4.42	1.55e-05	0.00734	0.32	0.28	Obesity-related traits;	chr4:26965862	chr4:26859806~26860599:-
OV	cis	rs62184315	0.52	rs62184268	ENSG00000253559.1	OSGEPL1-AS1	-4.42	1.55e-05	0.00734	-0.39	-0.28	Alcohol dependence (age at onset);	chr2:189767451	chr2:189762704~189765556:+
OV	cis	rs2263638	0.565	rs2488794	ENSG00000228701.1	TNKS2-AS1	-4.42	1.55e-05	0.00734	-0.33	-0.28	Airflow obstruction;	chr10:92408060	chr10:91782839~91798291:-
OV	cis	rs8100891	0.537	rs73036023	ENSG00000267213.4	AC007773.2	-4.42	1.55e-05	0.00735	-0.44	-0.28	Neuroticism;	chr19:32457414	chr19:32390050~32405560:-
OV	cis	rs1198872	0.563	rs1106185	ENSG00000272275.1	RP11-791G15.2	4.42	1.55e-05	0.00735	0.35	0.28	Cardiac Troponin-T levels;	chr2:10823444	chr2:10767875~10770058:-
OV	cis	rs8062405	0.964	rs11860513	ENSG00000278665.1	RP11-666O2.4	4.42	1.55e-05	0.00735	0.3	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814099	chr16:28599241~28601881:-
OV	cis	rs9393813	0.605	rs12529458	ENSG00000124549.13	BTN2A3P	4.42	1.56e-05	0.00736	0.27	0.28	Bipolar disorder;	chr6:27393902	chr6:26421391~26432383:+
OV	cis	rs7520050	0.807	rs5021934	ENSG00000281133.1	AL355480.3	4.42	1.56e-05	0.00736	0.31	0.28	Reticulocyte count;Red blood cell count;	chr1:45643632	chr1:45580892~45580996:-
OV	cis	rs67340775	0.541	rs200973	ENSG00000226314.6	ZNF192P1	-4.42	1.56e-05	0.00738	-0.41	-0.28	Lung cancer in ever smokers;	chr6:27890643	chr6:28161781~28169594:+
OV	cis	rs934734	0.752	rs1039764	ENSG00000234255.7	AC012370.3	-4.41	1.56e-05	0.00739	-0.3	-0.28	Rheumatoid arthritis;	chr2:65387479	chr2:65439888~65456571:-
OV	cis	rs875971	0.545	rs75840613	ENSG00000237310.1	GS1-124K5.4	4.41	1.56e-05	0.0074	0.33	0.28	Aortic root size;	chr7:66376399	chr7:66493706~66495474:+
OV	cis	rs2243480	0.831	rs57294491	ENSG00000226824.5	RP4-756H11.3	4.41	1.57e-05	0.0074	0.46	0.28	Diabetic kidney disease;	chr7:66219914	chr7:66654538~66669855:+
OV	cis	rs992157	0.732	rs10932771	ENSG00000261338.2	RP11-378A13.1	4.41	1.57e-05	0.0074	0.33	0.28	Colorectal cancer;	chr2:218305513	chr2:218255319~218257366:+
OV	cis	rs2919917	0.915	rs10957897	ENSG00000254352.1	RP11-578O24.2	4.41	1.57e-05	0.00741	0.34	0.28	Lymphocyte counts;	chr8:78695658	chr8:78723796~78724136:-
OV	cis	rs1707322	0.627	rs3014213	ENSG00000234329.1	RP11-767N6.2	-4.41	1.57e-05	0.00741	-0.3	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45651039~45651826:-
OV	cis	rs1707322	0.686	rs2152078	ENSG00000234329.1	RP11-767N6.2	-4.41	1.57e-05	0.00741	-0.3	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45651039~45651826:-
OV	cis	rs1707322	0.686	rs2991979	ENSG00000234329.1	RP11-767N6.2	-4.41	1.57e-05	0.00741	-0.3	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45651039~45651826:-
OV	cis	rs9291683	0.546	rs6820188	ENSG00000250413.1	RP11-448G15.1	-4.41	1.57e-05	0.00742	-0.32	-0.28	Bone mineral density;	chr4:10050031	chr4:10006482~10009725:+
OV	cis	rs9287719	0.649	rs12621977	ENSG00000243819.4	RN7SL832P	4.41	1.57e-05	0.00742	0.28	0.28	Prostate cancer;	chr2:10581805	chr2:10690344~10692099:+
OV	cis	rs9287719	0.649	rs12617968	ENSG00000243819.4	RN7SL832P	4.41	1.57e-05	0.00742	0.28	0.28	Prostate cancer;	chr2:10581819	chr2:10690344~10692099:+
OV	cis	rs9287719	0.614	rs12622053	ENSG00000243819.4	RN7SL832P	4.41	1.57e-05	0.00742	0.28	0.28	Prostate cancer;	chr2:10582014	chr2:10690344~10692099:+
OV	cis	rs9287719	0.614	rs12329184	ENSG00000243819.4	RN7SL832P	4.41	1.57e-05	0.00742	0.28	0.28	Prostate cancer;	chr2:10582638	chr2:10690344~10692099:+
OV	cis	rs9287719	0.614	rs10929679	ENSG00000243819.4	RN7SL832P	4.41	1.57e-05	0.00742	0.28	0.28	Prostate cancer;	chr2:10582982	chr2:10690344~10692099:+
OV	cis	rs9287719	0.614	rs10929680	ENSG00000243819.4	RN7SL832P	4.41	1.57e-05	0.00742	0.28	0.28	Prostate cancer;	chr2:10583000	chr2:10690344~10692099:+
OV	cis	rs9287719	0.614	rs10929681	ENSG00000243819.4	RN7SL832P	4.41	1.57e-05	0.00742	0.28	0.28	Prostate cancer;	chr2:10583157	chr2:10690344~10692099:+
OV	cis	rs9287719	0.614	rs6711473	ENSG00000243819.4	RN7SL832P	4.41	1.57e-05	0.00742	0.28	0.28	Prostate cancer;	chr2:10583248	chr2:10690344~10692099:+
OV	cis	rs9287719	0.686	rs10174605	ENSG00000243819.4	RN7SL832P	4.41	1.57e-05	0.00742	0.28	0.28	Prostate cancer;	chr2:10585106	chr2:10690344~10692099:+
OV	cis	rs9287719	0.624	rs10211190	ENSG00000243819.4	RN7SL832P	4.41	1.57e-05	0.00742	0.28	0.28	Prostate cancer;	chr2:10585302	chr2:10690344~10692099:+
OV	cis	rs9287719	0.649	rs10166765	ENSG00000243819.4	RN7SL832P	4.41	1.57e-05	0.00742	0.28	0.28	Prostate cancer;	chr2:10585547	chr2:10690344~10692099:+
OV	cis	rs9287719	0.649	rs6720112	ENSG00000243819.4	RN7SL832P	4.41	1.57e-05	0.00742	0.28	0.28	Prostate cancer;	chr2:10585593	chr2:10690344~10692099:+
OV	cis	rs9287719	0.649	rs6730247	ENSG00000243819.4	RN7SL832P	4.41	1.57e-05	0.00742	0.28	0.28	Prostate cancer;	chr2:10585762	chr2:10690344~10692099:+
OV	cis	rs9287719	0.649	rs10184776	ENSG00000243819.4	RN7SL832P	4.41	1.57e-05	0.00742	0.28	0.28	Prostate cancer;	chr2:10586320	chr2:10690344~10692099:+
OV	cis	rs9287719	0.6	rs10197187	ENSG00000243819.4	RN7SL832P	4.41	1.57e-05	0.00742	0.28	0.28	Prostate cancer;	chr2:10586513	chr2:10690344~10692099:+
OV	cis	rs9287719	0.624	rs10199635	ENSG00000243819.4	RN7SL832P	4.41	1.57e-05	0.00742	0.28	0.28	Prostate cancer;	chr2:10586514	chr2:10690344~10692099:+
OV	cis	rs9287719	0.624	rs10199831	ENSG00000243819.4	RN7SL832P	4.41	1.57e-05	0.00742	0.28	0.28	Prostate cancer;	chr2:10586737	chr2:10690344~10692099:+
OV	cis	rs9287719	0.624	rs10187659	ENSG00000243819.4	RN7SL832P	4.41	1.57e-05	0.00742	0.28	0.28	Prostate cancer;	chr2:10586834	chr2:10690344~10692099:+
OV	cis	rs9287719	0.649	rs10202370	ENSG00000243819.4	RN7SL832P	4.41	1.57e-05	0.00742	0.28	0.28	Prostate cancer;	chr2:10586917	chr2:10690344~10692099:+
OV	cis	rs9287719	0.649	rs12618726	ENSG00000243819.4	RN7SL832P	4.41	1.57e-05	0.00742	0.28	0.28	Prostate cancer;	chr2:10588249	chr2:10690344~10692099:+
OV	cis	rs9287719	0.649	rs6714787	ENSG00000243819.4	RN7SL832P	4.41	1.57e-05	0.00742	0.28	0.28	Prostate cancer;	chr2:10588906	chr2:10690344~10692099:+
OV	cis	rs9287719	0.649	rs2024432	ENSG00000243819.4	RN7SL832P	4.41	1.57e-05	0.00742	0.28	0.28	Prostate cancer;	chr2:10591348	chr2:10690344~10692099:+
OV	cis	rs9287719	0.649	rs12104950	ENSG00000243819.4	RN7SL832P	4.41	1.57e-05	0.00742	0.28	0.28	Prostate cancer;	chr2:10591979	chr2:10690344~10692099:+
OV	cis	rs9287719	0.649	rs10803724	ENSG00000243819.4	RN7SL832P	4.41	1.57e-05	0.00742	0.28	0.28	Prostate cancer;	chr2:10592197	chr2:10690344~10692099:+
OV	cis	rs9287719	0.649	rs10803725	ENSG00000243819.4	RN7SL832P	4.41	1.57e-05	0.00742	0.28	0.28	Prostate cancer;	chr2:10592220	chr2:10690344~10692099:+
OV	cis	rs9287719	0.649	rs10929685	ENSG00000243819.4	RN7SL832P	4.41	1.57e-05	0.00742	0.28	0.28	Prostate cancer;	chr2:10592673	chr2:10690344~10692099:+
OV	cis	rs9287719	0.649	rs10183359	ENSG00000243819.4	RN7SL832P	4.41	1.57e-05	0.00742	0.28	0.28	Prostate cancer;	chr2:10592918	chr2:10690344~10692099:+
OV	cis	rs9287719	0.624	rs10172926	ENSG00000243819.4	RN7SL832P	4.41	1.57e-05	0.00742	0.28	0.28	Prostate cancer;	chr2:10593128	chr2:10690344~10692099:+
OV	cis	rs7520050	0.966	rs10890363	ENSG00000281133.1	AL355480.3	-4.41	1.58e-05	0.00743	-0.31	-0.28	Reticulocyte count;Red blood cell count;	chr1:45890476	chr1:45580892~45580996:-
OV	cis	rs992157	0.687	rs35271699	ENSG00000237281.1	CATIP-AS2	-4.41	1.58e-05	0.00744	-0.33	-0.28	Colorectal cancer;	chr2:218252759	chr2:218326889~218357966:-
OV	cis	rs1823913	0.637	rs4853578	ENSG00000227542.1	AC092614.2	4.41	1.58e-05	0.00744	0.31	0.28	Obesity-related traits;	chr2:191297215	chr2:191229165~191246172:-
OV	cis	rs35851103	0.6	rs4841662	ENSG00000254423.1	RP11-351I21.7	-4.41	1.58e-05	0.00744	-0.28	-0.28	Neuroticism;	chr8:11986249	chr8:12374366~12375546:-
OV	cis	rs7043114	0.507	rs7856204	ENSG00000281156.1	MIR3651	-4.41	1.58e-05	0.00744	-0.31	-0.28	Height;	chr9:92411532	chr9:92292458~92292547:-
OV	cis	rs7043114	0.525	rs2516567	ENSG00000281156.1	MIR3651	-4.41	1.58e-05	0.00744	-0.31	-0.28	Height;	chr9:92425136	chr9:92292458~92292547:-
OV	cis	rs875971	0.862	rs7786892	ENSG00000236529.1	RP13-254B10.1	-4.41	1.58e-05	0.00745	-0.29	-0.28	Aortic root size;	chr7:66163889	chr7:65840212~65840596:+
OV	cis	rs295490	0.748	rs10513063	ENSG00000272656.1	RP11-219D15.3	4.41	1.58e-05	0.00745	0.53	0.28	PR interval in Tripanosoma cruzi seropositivity;	chr3:139341586	chr3:139349024~139349371:-
OV	cis	rs875971	0.545	rs316305	ENSG00000237310.1	GS1-124K5.4	-4.41	1.58e-05	0.00745	-0.32	-0.28	Aortic root size;	chr7:66152984	chr7:66493706~66495474:+
OV	cis	rs875971	0.545	rs316306	ENSG00000237310.1	GS1-124K5.4	-4.41	1.58e-05	0.00745	-0.32	-0.28	Aortic root size;	chr7:66153687	chr7:66493706~66495474:+
OV	cis	rs1790761	0.505	rs7927657	ENSG00000184224.3	C11orf72	-4.41	1.58e-05	0.00745	-0.3	-0.28	Mean corpuscular volume;	chr11:67579517	chr11:67602880~67606706:-
OV	cis	rs1790761	0.505	rs7941395	ENSG00000184224.3	C11orf72	-4.41	1.58e-05	0.00745	-0.3	-0.28	Mean corpuscular volume;	chr11:67579946	chr11:67602880~67606706:-
OV	cis	rs1790761	0.505	rs7941648	ENSG00000184224.3	C11orf72	-4.41	1.58e-05	0.00745	-0.3	-0.28	Mean corpuscular volume;	chr11:67580124	chr11:67602880~67606706:-
OV	cis	rs1790761	0.505	rs7945035	ENSG00000184224.3	C11orf72	-4.41	1.58e-05	0.00745	-0.3	-0.28	Mean corpuscular volume;	chr11:67580691	chr11:67602880~67606706:-
OV	cis	rs1790761	0.505	rs2370141	ENSG00000184224.3	C11orf72	-4.41	1.58e-05	0.00745	-0.3	-0.28	Mean corpuscular volume;	chr11:67581058	chr11:67602880~67606706:-
OV	cis	rs4845570	0.834	rs1196467	ENSG00000238711.1	RNY4P25	4.41	1.58e-05	0.00746	0.39	0.28	Coronary artery disease;	chr1:151737562	chr1:151439000~151439095:+
OV	cis	rs12130219	0.5	rs4845737	ENSG00000237975.5	FLG-AS1	-4.41	1.58e-05	0.00746	-0.37	-0.28	Inflammatory skin disease;	chr1:152205063	chr1:152168125~152445456:+
OV	cis	rs10992471	0.63	rs10453241	ENSG00000281156.1	MIR3651	-4.41	1.58e-05	0.00747	-0.31	-0.28	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92436605	chr9:92292458~92292547:-
OV	cis	rs10924970	0.555	rs12403167	ENSG00000236863.2	RPL23AP23	4.41	1.58e-05	0.00747	0.29	0.28	Asthma;	chr1:235275020	chr1:235295865~235296335:+
OV	cis	rs11096990	0.656	rs9993224	ENSG00000249207.1	RP11-360F5.1	4.41	1.59e-05	0.00748	0.3	0.28	Cognitive function;	chr4:39298578	chr4:39112677~39126818:-
OV	cis	rs10462065	1	rs10462065	ENSG00000249779.1	RP11-447H19.3	-4.41	1.59e-05	0.00748	-0.53	-0.28	Nonsyndromic cleft lip with cleft palate;	chr5:44068744	chr5:43206709~43207811:+
OV	cis	rs853679	0.517	rs868987	ENSG00000226314.6	ZNF192P1	4.41	1.59e-05	0.00749	0.4	0.28	Depression;	chr6:28142370	chr6:28161781~28169594:+
OV	cis	rs35141484	1	rs35141484	ENSG00000255458.4	RP11-539G18.3	-4.41	1.59e-05	0.00749	-0.48	-0.28	Asthma (childhood onset);	chr4:39086721	chr4:39639140~39666644:+
OV	cis	rs9287719	0.967	rs6712304	ENSG00000234818.1	AC092687.5	4.41	1.59e-05	0.00749	0.3	0.28	Prostate cancer;	chr2:10614249	chr2:10589166~10604830:+
OV	cis	rs1113500	0.73	rs1781077	ENSG00000226822.1	RP11-356N1.2	-4.41	1.59e-05	0.0075	-0.33	-0.28	Growth-regulated protein alpha levels;	chr1:108046967	chr1:108071482~108074519:+
OV	cis	rs858239	0.899	rs10262243	ENSG00000230042.1	AK3P3	-4.41	1.59e-05	0.0075	-0.3	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23251368	chr7:23129178~23129841:+
OV	cis	rs858239	0.899	rs1881203	ENSG00000230042.1	AK3P3	-4.41	1.59e-05	0.0075	-0.3	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23253189	chr7:23129178~23129841:+
OV	cis	rs858239	0.899	rs28458177	ENSG00000230042.1	AK3P3	-4.41	1.59e-05	0.0075	-0.3	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23255253	chr7:23129178~23129841:+
OV	cis	rs10246939	0.544	rs6957037	ENSG00000228775.6	WEE2-AS1	4.41	1.59e-05	0.00751	0.3	0.28	Bitter taste perception;	chr7:141865557	chr7:141704338~141738346:-
OV	cis	rs9309473	1	rs10184268	ENSG00000163016.8	ALMS1P	4.41	1.6e-05	0.00752	0.34	0.28	Metabolite levels;	chr2:73399916	chr2:73644919~73685576:+
OV	cis	rs12073359	0.955	rs4926412	ENSG00000223945.2	RP11-458I7.1	4.41	1.6e-05	0.00752	0.42	0.28	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150166237	chr1:150053864~150055034:+
OV	cis	rs1211375	0.607	rs1203978	ENSG00000268836.1	LA16c-OS12.2	-4.41	1.6e-05	0.00753	-0.3	-0.28	Mean corpuscular volume;Hematology traits;Mean corpuscular hemoglobin;	chr16:207212	chr16:185748~186294:-
OV	cis	rs9287719	0.649	rs6722126	ENSG00000243819.4	RN7SL832P	4.41	1.6e-05	0.00753	0.28	0.28	Prostate cancer;	chr2:10581516	chr2:10690344~10692099:+
OV	cis	rs9287719	0.967	rs3814388	ENSG00000234818.1	AC092687.5	4.41	1.6e-05	0.00755	0.3	0.28	Prostate cancer;	chr2:10561973	chr2:10589166~10604830:+
OV	cis	rs9925964	0.933	rs11150604	ENSG00000278922.1	AC002310.14	-4.41	1.61e-05	0.00756	-0.32	-0.28	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31025699	chr16:30526918~30528294:+
OV	cis	rs73201462	1	rs57699322	ENSG00000242551.2	POU5F1P6	4.41	1.61e-05	0.00756	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128346470	chr3:128674735~128677005:-
OV	cis	rs11157436	1	rs11157436	ENSG00000211812.1	TRAV26-2	4.41	1.61e-05	0.00756	0.33	0.28	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22168978	chr14:22202583~22203368:+
OV	cis	rs9287719	0.839	rs11683335	ENSG00000234818.1	AC092687.5	4.41	1.61e-05	0.00756	0.3	0.28	Prostate cancer;	chr2:10616539	chr2:10589166~10604830:+
OV	cis	rs9309473	1	rs1534471	ENSG00000163016.8	ALMS1P	4.41	1.61e-05	0.00756	0.34	0.28	Metabolite levels;	chr2:73420380	chr2:73644919~73685576:+
OV	cis	rs7267979	0.899	rs2179459	ENSG00000274973.1	RP13-401N8.7	-4.41	1.61e-05	0.00756	-0.32	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25475505	chr20:25845497~25845862:+
OV	cis	rs72615157	0.612	rs7786505	ENSG00000242294.5	STAG3L5P	4.41	1.61e-05	0.00757	0.27	0.28	Lung function (FEV1/FVC);	chr7:100219962	chr7:100336079~100351900:+
OV	cis	rs72615157	0.613	rs56089143	ENSG00000242294.5	STAG3L5P	4.41	1.61e-05	0.00757	0.27	0.28	Lung function (FEV1/FVC);	chr7:100222221	chr7:100336079~100351900:+
OV	cis	rs875971	0.545	rs1796226	ENSG00000236529.1	RP13-254B10.1	4.41	1.61e-05	0.00757	0.33	0.28	Aortic root size;	chr7:66622723	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs6971059	ENSG00000236529.1	RP13-254B10.1	-4.41	1.61e-05	0.00757	-0.29	-0.28	Aortic root size;	chr7:66602045	chr7:65840212~65840596:+
OV	cis	rs875971	0.789	rs7808013	ENSG00000236529.1	RP13-254B10.1	-4.41	1.61e-05	0.00757	-0.29	-0.28	Aortic root size;	chr7:66606209	chr7:65840212~65840596:+
OV	cis	rs875971	0.825	rs7384021	ENSG00000236529.1	RP13-254B10.1	-4.41	1.61e-05	0.00757	-0.29	-0.28	Aortic root size;	chr7:66612917	chr7:65840212~65840596:+
OV	cis	rs875971	0.825	rs66981195	ENSG00000236529.1	RP13-254B10.1	-4.41	1.61e-05	0.00757	-0.29	-0.28	Aortic root size;	chr7:66614048	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs3926380	ENSG00000236529.1	RP13-254B10.1	-4.41	1.61e-05	0.00757	-0.29	-0.28	Aortic root size;	chr7:66615658	chr7:65840212~65840596:+
OV	cis	rs875971	0.825	rs1860472	ENSG00000236529.1	RP13-254B10.1	-4.41	1.61e-05	0.00757	-0.29	-0.28	Aortic root size;	chr7:66617736	chr7:65840212~65840596:+
OV	cis	rs2243480	1	rs316326	ENSG00000226824.5	RP4-756H11.3	-4.41	1.61e-05	0.00757	-0.45	-0.28	Diabetic kidney disease;	chr7:66144466	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs316325	ENSG00000226824.5	RP4-756H11.3	-4.41	1.61e-05	0.00757	-0.45	-0.28	Diabetic kidney disease;	chr7:66144531	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs316321	ENSG00000226824.5	RP4-756H11.3	-4.41	1.61e-05	0.00757	-0.45	-0.28	Diabetic kidney disease;	chr7:66146626	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs316318	ENSG00000226824.5	RP4-756H11.3	-4.41	1.61e-05	0.00757	-0.45	-0.28	Diabetic kidney disease;	chr7:66147917	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs316317	ENSG00000226824.5	RP4-756H11.3	-4.41	1.61e-05	0.00757	-0.45	-0.28	Diabetic kidney disease;	chr7:66148650	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs316304	ENSG00000226824.5	RP4-756H11.3	-4.41	1.61e-05	0.00757	-0.45	-0.28	Diabetic kidney disease;	chr7:66151907	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs2465120	ENSG00000226824.5	RP4-756H11.3	-4.41	1.61e-05	0.00757	-0.45	-0.28	Diabetic kidney disease;	chr7:66155987	chr7:66654538~66669855:+
OV	cis	rs2243480	0.908	rs2460431	ENSG00000226824.5	RP4-756H11.3	4.41	1.61e-05	0.00757	0.45	0.28	Diabetic kidney disease;	chr7:66157859	chr7:66654538~66669855:+
OV	cis	rs2243480	0.711	rs2460426	ENSG00000226824.5	RP4-756H11.3	4.41	1.61e-05	0.00757	0.45	0.28	Diabetic kidney disease;	chr7:66158142	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs4718309	ENSG00000226824.5	RP4-756H11.3	4.41	1.61e-05	0.00757	0.45	0.28	Diabetic kidney disease;	chr7:66162777	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs6460274	ENSG00000226824.5	RP4-756H11.3	4.41	1.61e-05	0.00757	0.45	0.28	Diabetic kidney disease;	chr7:66163497	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs7787230	ENSG00000226824.5	RP4-756H11.3	4.41	1.61e-05	0.00757	0.45	0.28	Diabetic kidney disease;	chr7:66164112	chr7:66654538~66669855:+
OV	cis	rs6052484	0.523	rs56309952	ENSG00000229539.1	RP11-119B16.2	4.41	1.61e-05	0.00758	0.32	0.28	Sense of smell;	chr20:4342230	chr20:3888239~3888868:-
OV	cis	rs1661178	0.826	rs1623156	ENSG00000277806.1	RP11-15A1.8	4.41	1.61e-05	0.00759	0.46	0.28	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr19:44540600	chr19:43976815~43977448:+
OV	cis	rs11096990	0.855	rs75746161	ENSG00000249207.1	RP11-360F5.1	4.41	1.61e-05	0.00759	0.33	0.28	Cognitive function;	chr4:39167481	chr4:39112677~39126818:-
OV	cis	rs4853012	0.941	rs78128123	ENSG00000257800.1	FNBP1P1	4.41	1.61e-05	0.00759	0.44	0.28	Gestational age at birth (maternal effect);	chr2:74120398	chr2:74120680~74123218:+
OV	cis	rs809367	1	rs809367	ENSG00000223482.6	NUTM2A-AS1	4.41	1.62e-05	0.00759	0.47	0.28	Parental extreme longevity (95 years and older);	chr10:87982049	chr10:87203875~87342612:-
OV	cis	rs853679	0.882	rs9461432	ENSG00000219392.1	RP1-265C24.5	-4.41	1.62e-05	0.00759	-0.47	-0.28	Depression;	chr6:28119105	chr6:28115628~28116551:+
OV	cis	rs10924970	0.649	rs12753233	ENSG00000236863.2	RPL23AP23	4.41	1.62e-05	0.0076	0.29	0.28	Asthma;	chr1:235323779	chr1:235295865~235296335:+
OV	cis	rs1950626	0.833	rs67456801	ENSG00000258399.5	MEG8	-4.41	1.62e-05	0.00761	-0.29	-0.28	Pelvic organ prolapse (moderate/severe);	chr14:100932832	chr14:100894770~100935999:+
OV	cis	rs7968440	0.933	rs2684889	ENSG00000257298.1	RP3-405J10.3	4.41	1.62e-05	0.00761	0.27	0.28	Fibrinogen;	chr12:50686091	chr12:50185580~50191363:-
OV	cis	rs7968440	1	rs2700482	ENSG00000257298.1	RP3-405J10.3	4.41	1.62e-05	0.00761	0.27	0.28	Fibrinogen;	chr12:50689482	chr12:50185580~50191363:-
OV	cis	rs7617773	0.78	rs13079728	ENSG00000228638.1	FCF1P2	-4.41	1.62e-05	0.00761	-0.36	-0.28	Coronary artery disease;	chr3:48297870	chr3:48290793~48291375:-
OV	cis	rs1823913	0.599	rs34100174	ENSG00000227542.1	AC092614.2	4.41	1.62e-05	0.00761	0.31	0.28	Obesity-related traits;	chr2:191283579	chr2:191229165~191246172:-
OV	cis	rs116095464	0.51	rs7714944	ENSG00000250848.1	CTD-2083E4.5	-4.41	1.62e-05	0.00761	-0.34	-0.28	Breast cancer;	chr5:231650	chr5:288833~290321:-
OV	cis	rs875971	0.545	rs13311962	ENSG00000226824.5	RP4-756H11.3	4.41	1.62e-05	0.00762	0.34	0.28	Aortic root size;	chr7:66603142	chr7:66654538~66669855:+
OV	cis	rs7017914	0.69	rs6992048	ENSG00000223220.1	Y_RNA	4.41	1.63e-05	0.00763	0.3	0.28	Bone mineral density;	chr8:70911636	chr8:70780914~70781008:-
OV	cis	rs7017914	0.69	rs6984663	ENSG00000223220.1	Y_RNA	4.41	1.63e-05	0.00763	0.3	0.28	Bone mineral density;	chr8:70915430	chr8:70780914~70781008:-
OV	cis	rs9287719	0.556	rs10168351	ENSG00000243819.4	RN7SL832P	4.41	1.63e-05	0.00763	0.29	0.28	Prostate cancer;	chr2:10596684	chr2:10690344~10692099:+
OV	cis	rs10924970	0.624	rs12755851	ENSG00000236863.2	RPL23AP23	4.41	1.63e-05	0.00765	0.29	0.28	Asthma;	chr1:235314491	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs4659492	ENSG00000236863.2	RPL23AP23	4.41	1.63e-05	0.00765	0.29	0.28	Asthma;	chr1:235318892	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs4659493	ENSG00000236863.2	RPL23AP23	4.41	1.63e-05	0.00765	0.29	0.28	Asthma;	chr1:235318957	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs6697580	ENSG00000236863.2	RPL23AP23	4.41	1.63e-05	0.00765	0.29	0.28	Asthma;	chr1:235321294	chr1:235295865~235296335:+
OV	cis	rs11105298	0.891	rs10858890	ENSG00000257194.2	RP11-567C2.1	-4.4	1.63e-05	0.00766	-0.41	-0.28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89513389	chr12:90107739~90112779:+
OV	cis	rs1538970	1	rs2050884	ENSG00000280836.1	AL355480.1	-4.4	1.63e-05	0.00766	-0.38	-0.28	Platelet count;	chr1:45365152	chr1:45581219~45581321:-
OV	cis	rs1538970	1	rs7417107	ENSG00000280836.1	AL355480.1	-4.4	1.63e-05	0.00766	-0.38	-0.28	Platelet count;	chr1:45366243	chr1:45581219~45581321:-
OV	cis	rs7043114	0.563	rs10820990	ENSG00000281156.1	MIR3651	4.4	1.63e-05	0.00767	0.3	0.28	Height;	chr9:92561015	chr9:92292458~92292547:-
OV	cis	rs11157436	0.918	rs12437004	ENSG00000211812.1	TRAV26-2	-4.4	1.64e-05	0.00768	-0.31	-0.28	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22149461	chr14:22202583~22203368:+
OV	cis	rs7043114	0.525	rs2274966	ENSG00000281156.1	MIR3651	-4.4	1.64e-05	0.00768	-0.31	-0.28	Height;	chr9:92393281	chr9:92292458~92292547:-
OV	cis	rs10992471	0.63	rs10992322	ENSG00000281156.1	MIR3651	-4.4	1.64e-05	0.00768	-0.31	-0.28	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92396914	chr9:92292458~92292547:-
OV	cis	rs4908768	0.906	rs12122851	ENSG00000228423.2	RP4-633I8.4	-4.4	1.64e-05	0.00769	-0.33	-0.28	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8574231	chr1:8805860~8807051:-
OV	cis	rs514406	0.607	rs11206000	ENSG00000206627.1	RNU6-969P	-4.4	1.64e-05	0.00769	-0.3	-0.28	Monocyte count;	chr1:52740251	chr1:52805108~52805212:-
OV	cis	rs11083475	1	rs10421560	ENSG00000267892.1	CTD-2540F13.2	4.4	1.64e-05	0.0077	0.31	0.28	Heart rate;	chr19:38695973	chr19:38738284~38739863:+
OV	cis	rs638893	0.842	rs480791	ENSG00000255239.1	AP002954.6	4.4	1.64e-05	0.0077	0.44	0.28	Vitiligo;	chr11:118833546	chr11:118688039~118690600:-
OV	cis	rs12073359	1	rs11205316	ENSG00000223945.2	RP11-458I7.1	4.4	1.64e-05	0.00771	0.42	0.28	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150035140	chr1:150053864~150055034:+
OV	cis	rs17767294	0.708	rs72848776	ENSG00000220721.1	OR1F12	4.4	1.65e-05	0.00772	0.56	0.28	Parkinson's disease;	chr6:27987048	chr6:28073316~28074233:+
OV	cis	rs2243480	0.711	rs2420172	ENSG00000226824.5	RP4-756H11.3	4.4	1.65e-05	0.00773	0.45	0.28	Diabetic kidney disease;	chr7:66170354	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs2420171	ENSG00000226824.5	RP4-756H11.3	4.4	1.65e-05	0.00773	0.45	0.28	Diabetic kidney disease;	chr7:66172773	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs6974723	ENSG00000226824.5	RP4-756H11.3	4.4	1.65e-05	0.00773	0.45	0.28	Diabetic kidney disease;	chr7:66172952	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs9769882	ENSG00000226824.5	RP4-756H11.3	4.4	1.65e-05	0.00773	0.45	0.28	Diabetic kidney disease;	chr7:66177938	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs6966322	ENSG00000226824.5	RP4-756H11.3	4.4	1.65e-05	0.00773	0.45	0.28	Diabetic kidney disease;	chr7:66181767	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs4145008	ENSG00000226824.5	RP4-756H11.3	4.4	1.65e-05	0.00773	0.45	0.28	Diabetic kidney disease;	chr7:66182524	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs4718315	ENSG00000226824.5	RP4-756H11.3	4.4	1.65e-05	0.00773	0.45	0.28	Diabetic kidney disease;	chr7:66183554	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs4718316	ENSG00000226824.5	RP4-756H11.3	4.4	1.65e-05	0.00773	0.45	0.28	Diabetic kidney disease;	chr7:66183744	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs1873494	ENSG00000226824.5	RP4-756H11.3	4.4	1.65e-05	0.00773	0.45	0.28	Diabetic kidney disease;	chr7:66184912	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs6959002	ENSG00000226824.5	RP4-756H11.3	4.4	1.65e-05	0.00773	0.45	0.28	Diabetic kidney disease;	chr7:66185509	chr7:66654538~66669855:+
OV	cis	rs11096990	0.613	rs4974996	ENSG00000249207.1	RP11-360F5.1	-4.4	1.65e-05	0.00773	-0.3	-0.28	Cognitive function;	chr4:39225928	chr4:39112677~39126818:-
OV	cis	rs6052484	0.523	rs61330129	ENSG00000229539.1	RP11-119B16.2	4.4	1.65e-05	0.00774	0.32	0.28	Sense of smell;	chr20:4343931	chr20:3888239~3888868:-
OV	cis	rs2999052	0.673	rs1735538	ENSG00000242551.2	POU5F1P6	4.4	1.65e-05	0.00774	0.35	0.28	Hypospadias;	chr3:128373259	chr3:128674735~128677005:-
OV	cis	rs4853012	0.838	rs4563249	ENSG00000257800.1	FNBP1P1	4.4	1.65e-05	0.00775	0.38	0.28	Gestational age at birth (maternal effect);	chr2:74126889	chr2:74120680~74123218:+
OV	cis	rs4763879	0.634	rs2098298	ENSG00000278635.1	CTD-2318O12.1	4.4	1.66e-05	0.00775	0.24	0.28	Type 1 diabetes;	chr12:9707473	chr12:9415641~9416718:+
OV	cis	rs4763879	0.594	rs12427310	ENSG00000278635.1	CTD-2318O12.1	4.4	1.66e-05	0.00775	0.24	0.28	Type 1 diabetes;	chr12:9707539	chr12:9415641~9416718:+
OV	cis	rs9660180	0.967	rs2272908	ENSG00000215914.4	MMP23A	4.4	1.66e-05	0.00776	0.32	0.28	Body mass index;	chr1:1790040	chr1:1699942~1701782:+
OV	cis	rs11118620	0.535	rs1389750	ENSG00000238078.1	LINC01352	4.4	1.66e-05	0.00776	0.32	0.28	Heart failure;	chr1:220866829	chr1:220829255~220832429:+
OV	cis	rs17711722	0.51	rs11767457	ENSG00000226824.5	RP4-756H11.3	-4.4	1.66e-05	0.00776	-0.32	-0.28	Calcium levels;	chr7:65825628	chr7:66654538~66669855:+
OV	cis	rs67311347	1	rs4973898	ENSG00000223797.4	ENTPD3-AS1	-4.4	1.66e-05	0.00776	-0.3	-0.28	Renal cell carcinoma;	chr3:40418041	chr3:40313802~40453329:-
OV	cis	rs73201462	1	rs7374952	ENSG00000277250.1	Metazoa_SRP	4.4	1.66e-05	0.00777	0.42	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128282524	chr3:128673681~128674021:-
OV	cis	rs2274471	0.678	rs7867965	ENSG00000234534.1	CSNK1G2P1	4.4	1.66e-05	0.00777	0.36	0.28	Crohn's disease;	chr9:5104574	chr9:5040945~5041940:+
OV	cis	rs11700536	0.54	rs8132259	ENSG00000236663.1	AP001631.9	4.4	1.66e-05	0.00778	0.31	0.28	Interleukin-18 levels;	chr21:43129548	chr21:43140523~43141092:-
OV	cis	rs2919917	0.628	rs2717544	ENSG00000254352.1	RP11-578O24.2	-4.4	1.66e-05	0.00778	-0.37	-0.28	Lymphocyte counts;	chr8:78724307	chr8:78723796~78724136:-
OV	cis	rs6088590	0.687	rs6088580	ENSG00000206582.1	Y_RNA	-4.4	1.66e-05	0.00778	-0.34	-0.28	Coronary artery disease;	chr20:34697249	chr20:34526510~34526606:-
OV	cis	rs6088590	0.813	rs1884668	ENSG00000206582.1	Y_RNA	-4.4	1.66e-05	0.00778	-0.34	-0.28	Coronary artery disease;	chr20:34697710	chr20:34526510~34526606:-
OV	cis	rs7829975	0.686	rs907180	ENSG00000253981.4	ALG1L13P	4.4	1.66e-05	0.00778	0.29	0.28	Mood instability;	chr8:8845317	chr8:8236003~8244667:-
OV	cis	rs992157	0.798	rs7587220	ENSG00000261338.2	RP11-378A13.1	-4.4	1.66e-05	0.00778	-0.34	-0.28	Colorectal cancer;	chr2:218296141	chr2:218255319~218257366:+
OV	cis	rs992157	0.798	rs4674284	ENSG00000261338.2	RP11-378A13.1	-4.4	1.66e-05	0.00778	-0.34	-0.28	Colorectal cancer;	chr2:218296518	chr2:218255319~218257366:+
OV	cis	rs67311347	0.955	rs60554147	ENSG00000223797.4	ENTPD3-AS1	4.4	1.66e-05	0.00778	0.3	0.28	Renal cell carcinoma;	chr3:40431012	chr3:40313802~40453329:-
OV	cis	rs1823913	0.599	rs13015653	ENSG00000227542.1	AC092614.2	4.4	1.66e-05	0.00778	0.31	0.28	Obesity-related traits;	chr2:191306813	chr2:191229165~191246172:-
OV	cis	rs1823913	0.599	rs12994212	ENSG00000227542.1	AC092614.2	4.4	1.66e-05	0.00778	0.31	0.28	Obesity-related traits;	chr2:191306910	chr2:191229165~191246172:-
OV	cis	rs1823913	0.599	rs12994236	ENSG00000227542.1	AC092614.2	4.4	1.66e-05	0.00778	0.31	0.28	Obesity-related traits;	chr2:191306991	chr2:191229165~191246172:-
OV	cis	rs1823913	0.599	rs35495506	ENSG00000227542.1	AC092614.2	4.4	1.66e-05	0.00778	0.31	0.28	Obesity-related traits;	chr2:191307551	chr2:191229165~191246172:-
OV	cis	rs1823913	0.599	rs34691559	ENSG00000227542.1	AC092614.2	4.4	1.66e-05	0.00778	0.31	0.28	Obesity-related traits;	chr2:191307688	chr2:191229165~191246172:-
OV	cis	rs1823913	0.561	rs55790432	ENSG00000227542.1	AC092614.2	4.4	1.66e-05	0.00778	0.31	0.28	Obesity-related traits;	chr2:191307722	chr2:191229165~191246172:-
OV	cis	rs13113518	0.812	rs12648271	ENSG00000223305.1	RN7SKP30	4.4	1.66e-05	0.00778	0.34	0.28	Height;	chr4:55501955	chr4:55540502~55540835:-
OV	cis	rs1823913	0.637	rs4613316	ENSG00000227542.1	AC092614.2	4.4	1.66e-05	0.00778	0.32	0.28	Obesity-related traits;	chr2:191326074	chr2:191229165~191246172:-
OV	cis	rs8177876	0.749	rs10459871	ENSG00000261838.4	RP11-303E16.6	4.4	1.66e-05	0.00779	0.53	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81059462	chr16:81069854~81076598:+
OV	cis	rs2070488	0.965	rs7372849	ENSG00000229589.1	ACVR2B-AS1	4.4	1.67e-05	0.0078	0.31	0.28	Electrocardiographic conduction measures;	chr3:38482837	chr3:38451027~38454820:-
OV	cis	rs10895987	0.531	rs11227118	ENSG00000254614.2	AP003068.23	4.4	1.67e-05	0.00781	0.35	0.28	Blood protein levels;	chr11:65093183	chr11:65177606~65181834:-
OV	cis	rs10895987	0.531	rs11227120	ENSG00000254614.2	AP003068.23	4.4	1.67e-05	0.00781	0.35	0.28	Blood protein levels;	chr11:65097387	chr11:65177606~65181834:-
OV	cis	rs6844153	1	rs57686546	ENSG00000240005.4	RP11-293A21.1	-4.4	1.67e-05	0.00782	-0.4	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26915162	chr4:26859806~26860599:-
OV	cis	rs116095464	0.558	rs10055993	ENSG00000250848.1	CTD-2083E4.5	-4.4	1.67e-05	0.00782	-0.37	-0.28	Breast cancer;	chr5:264181	chr5:288833~290321:-
OV	cis	rs7567389	0.638	rs12105051	ENSG00000236682.1	AC068282.3	4.4	1.67e-05	0.00782	0.39	0.28	Self-rated health;	chr2:127232601	chr2:127389130~127400580:+
OV	cis	rs7927592	0.513	rs689075	ENSG00000212093.1	AP000807.1	4.4	1.67e-05	0.00782	0.32	0.28	Total body bone mineral density;	chr11:68426964	chr11:68506083~68506166:-
OV	cis	rs7927592	0.513	rs608343	ENSG00000212093.1	AP000807.1	4.4	1.67e-05	0.00782	0.32	0.28	Total body bone mineral density;	chr11:68429362	chr11:68506083~68506166:-
OV	cis	rs6772849	1	rs2734037	ENSG00000277250.1	Metazoa_SRP	-4.4	1.67e-05	0.00782	-0.33	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128590041	chr3:128673681~128674021:-
OV	cis	rs7267979	0.932	rs6115214	ENSG00000274973.1	RP13-401N8.7	4.4	1.67e-05	0.00782	0.32	0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25576790	chr20:25845497~25845862:+
OV	cis	rs1555322	0.53	rs6058224	ENSG00000269202.1	RP4-614O4.12	-4.4	1.67e-05	0.00782	-0.31	-0.28	Attention deficit hyperactivity disorder;	chr20:35293971	chr20:35201747~35203288:-
OV	cis	rs10888838	0.618	rs13571	ENSG00000198711.5	SSBP3-AS1	-4.4	1.67e-05	0.00783	-0.23	-0.28	Mitochondrial DNA levels;	chr1:54216247	chr1:54236440~54239063:+
OV	cis	rs875971	0.545	rs73378304	ENSG00000237310.1	GS1-124K5.4	4.4	1.68e-05	0.00783	0.32	0.28	Aortic root size;	chr7:66175760	chr7:66493706~66495474:+
OV	cis	rs14027	0.921	rs3812463	ENSG00000279347.1	RP11-85I17.2	-4.4	1.68e-05	0.00783	-0.29	-0.28	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119839860	chr8:119838736~119840385:-
OV	cis	rs7520050	0.807	rs28378621	ENSG00000280836.1	AL355480.1	-4.4	1.68e-05	0.00784	-0.34	-0.28	Reticulocyte count;Red blood cell count;	chr1:45723882	chr1:45581219~45581321:-
OV	cis	rs9473147	0.798	rs4711895	ENSG00000270761.1	RP11-385F7.1	4.4	1.68e-05	0.00784	0.32	0.28	Platelet distribution width;Mean platelet volume;	chr6:47659291	chr6:47477243~47477572:-
OV	cis	rs853679	0.607	rs13199772	ENSG00000220721.1	OR1F12	4.4	1.68e-05	0.00785	0.55	0.28	Depression;	chr6:27866307	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs13199906	ENSG00000220721.1	OR1F12	4.4	1.68e-05	0.00785	0.55	0.28	Depression;	chr6:27866361	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs17763089	ENSG00000220721.1	OR1F12	4.4	1.68e-05	0.00785	0.55	0.28	Depression;	chr6:27867440	chr6:28073316~28074233:+
OV	cis	rs853679	0.546	rs17695758	ENSG00000220721.1	OR1F12	4.4	1.68e-05	0.00785	0.55	0.28	Depression;	chr6:27869405	chr6:28073316~28074233:+
OV	cis	rs732716	0.785	rs11085073	ENSG00000267769.1	CTB-50L17.9	4.4	1.68e-05	0.00785	0.3	0.28	Mean corpuscular volume;	chr19:4375165	chr19:4454014~4455286:+
OV	cis	rs964184	0.564	rs2266788	ENSG00000254851.1	RP11-109L13.1	-4.4	1.68e-05	0.00785	-0.64	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116789970	chr11:117135528~117138582:+
OV	cis	rs9298506	1	rs10104003	ENSG00000254142.2	RP11-53M11.3	4.4	1.68e-05	0.00785	0.36	0.28	Intracranial aneurysm;	chr8:54509880	chr8:54554361~54561927:+
OV	cis	rs783540	0.967	rs1864699	ENSG00000278603.1	RP13-608F4.5	4.4	1.68e-05	0.00786	0.32	0.28	Schizophrenia;	chr15:82654567	chr15:82472203~82472426:+
OV	cis	rs875971	0.545	rs6460298	ENSG00000237310.1	GS1-124K5.4	4.4	1.68e-05	0.00786	0.33	0.28	Aortic root size;	chr7:66442783	chr7:66493706~66495474:+
OV	cis	rs875971	0.545	rs75577046	ENSG00000237310.1	GS1-124K5.4	4.4	1.68e-05	0.00786	0.33	0.28	Aortic root size;	chr7:66493729	chr7:66493706~66495474:+
OV	cis	rs875971	0.545	rs3735147	ENSG00000237310.1	GS1-124K5.4	4.4	1.68e-05	0.00786	0.33	0.28	Aortic root size;	chr7:66505541	chr7:66493706~66495474:+
OV	cis	rs875971	0.619	rs2302918	ENSG00000224316.1	RP11-479O9.2	4.4	1.68e-05	0.00786	0.3	0.28	Aortic root size;	chr7:66535945	chr7:65773620~65802067:+
OV	cis	rs6500602	0.584	rs11646063	ENSG00000280063.1	RP11-295D4.3	-4.4	1.68e-05	0.00787	-0.23	-0.28	Schizophrenia;	chr16:4389208	chr16:4346694~4348648:-
OV	cis	rs10829156	0.898	rs7923072	ENSG00000225527.1	RP11-383B4.4	-4.4	1.68e-05	0.00787	-0.38	-0.28	Sudden cardiac arrest;	chr10:18649305	chr10:18531849~18533336:-
OV	cis	rs3814244	0.933	rs10878725	ENSG00000255733.4	IFNG-AS1	-4.4	1.68e-05	0.00787	-0.27	-0.28	Itch intensity from mosquito bite adjusted by bite size;	chr12:68020930	chr12:67989445~68234686:+
OV	cis	rs934734	0.789	rs11689314	ENSG00000234255.7	AC012370.3	-4.4	1.69e-05	0.00787	-0.31	-0.28	Rheumatoid arthritis;	chr2:65378274	chr2:65439888~65456571:-
OV	cis	rs73201462	0.908	rs2999083	ENSG00000277250.1	Metazoa_SRP	-4.4	1.69e-05	0.00787	-0.41	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128235591	chr3:128673681~128674021:-
OV	cis	rs73201462	0.901	rs2999080	ENSG00000277250.1	Metazoa_SRP	-4.4	1.69e-05	0.00787	-0.41	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128237865	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2999077	ENSG00000277250.1	Metazoa_SRP	-4.4	1.69e-05	0.00787	-0.41	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128239571	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2955077	ENSG00000277250.1	Metazoa_SRP	-4.4	1.69e-05	0.00787	-0.41	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128240026	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2955078	ENSG00000277250.1	Metazoa_SRP	-4.4	1.69e-05	0.00787	-0.41	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128240343	chr3:128673681~128674021:-
OV	cis	rs2955081	1	rs2955081	ENSG00000277250.1	Metazoa_SRP	-4.4	1.69e-05	0.00787	-0.41	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128241456	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2955085	ENSG00000277250.1	Metazoa_SRP	-4.4	1.69e-05	0.00787	-0.41	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128243914	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2999072	ENSG00000277250.1	Metazoa_SRP	-4.4	1.69e-05	0.00787	-0.41	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128244033	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2955088	ENSG00000277250.1	Metazoa_SRP	-4.4	1.69e-05	0.00787	-0.41	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128244867	chr3:128673681~128674021:-
OV	cis	rs4591358	0.871	rs6434780	ENSG00000223466.1	AC064834.2	4.4	1.69e-05	0.00788	0.35	0.28	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195470558	chr2:195533035~195538681:+
OV	cis	rs5742933	1	rs5743052	ENSG00000253559.1	OSGEPL1-AS1	-4.4	1.69e-05	0.00788	-0.32	-0.28	Ferritin levels;	chr2:189824558	chr2:189762704~189765556:+
OV	cis	rs55692468	0.883	rs6714213	ENSG00000213197.3	AC012066.1	-4.4	1.69e-05	0.00788	-0.29	-0.28	Intraocular pressure;	chr2:152500869	chr2:152389937~152390630:+
OV	cis	rs875971	0.545	rs6979636	ENSG00000236529.1	RP13-254B10.1	4.4	1.69e-05	0.00789	0.32	0.28	Aortic root size;	chr7:66276638	chr7:65840212~65840596:+
OV	cis	rs7829975	0.742	rs12547493	ENSG00000253893.2	FAM85B	4.4	1.69e-05	0.00789	0.37	0.28	Mood instability;	chr8:8804024	chr8:8167819~8226614:-
OV	cis	rs7267979	0.932	rs2387891	ENSG00000274973.1	RP13-401N8.7	-4.4	1.69e-05	0.00789	-0.31	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25489692	chr20:25845497~25845862:+
OV	cis	rs55879323	1	rs55879323	ENSG00000237975.5	FLG-AS1	-4.4	1.69e-05	0.0079	-0.37	-0.28	Inflammatory skin disease;	chr1:152196264	chr1:152168125~152445456:+
OV	cis	rs881375	0.967	rs1930780	ENSG00000226752.6	PSMD5-AS1	-4.4	1.69e-05	0.0079	-0.31	-0.28	Rheumatoid arthritis;	chr9:120923941	chr9:120824828~120854385:+
OV	cis	rs6088590	0.687	rs8115656	ENSG00000206582.1	Y_RNA	-4.4	1.69e-05	0.0079	-0.34	-0.28	Coronary artery disease;	chr20:34694976	chr20:34526510~34526606:-
OV	cis	rs875971	0.502	rs1796227	ENSG00000226824.5	RP4-756H11.3	4.4	1.69e-05	0.0079	0.34	0.28	Aortic root size;	chr7:66622032	chr7:66654538~66669855:+
OV	cis	rs9925964	0.622	rs8046707	ENSG00000278922.1	AC002310.14	-4.4	1.69e-05	0.0079	-0.32	-0.28	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30904912	chr16:30526918~30528294:+
OV	cis	rs2243480	1	rs427044	ENSG00000226824.5	RP4-756H11.3	-4.4	1.69e-05	0.0079	-0.46	-0.28	Diabetic kidney disease;	chr7:66043558	chr7:66654538~66669855:+
OV	cis	rs853679	0.599	rs188015	ENSG00000280107.1	AL022393.9	-4.4	1.7e-05	0.00791	-0.48	-0.28	Depression;	chr6:27909668	chr6:28170845~28172521:+
OV	cis	rs4814920	0.756	rs6075586	ENSG00000275142.1	RP5-999L4.2	-4.4	1.7e-05	0.00792	-0.5	-0.28	Bipolar disorder (body mass index interaction);	chr20:19874650	chr20:19871891~19872284:+
OV	cis	rs11159086	1	rs8006958	ENSG00000270000.1	RP3-449M8.9	4.4	1.7e-05	0.00792	0.42	0.28	Advanced glycation end-product levels;	chr14:74478148	chr14:74471930~74472360:-
OV	cis	rs2243480	1	rs2420170	ENSG00000226824.5	RP4-756H11.3	4.4	1.7e-05	0.00792	0.46	0.28	Diabetic kidney disease;	chr7:66191066	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs7804223	ENSG00000226824.5	RP4-756H11.3	4.4	1.7e-05	0.00792	0.46	0.28	Diabetic kidney disease;	chr7:66199572	chr7:66654538~66669855:+
OV	cis	rs1120787	0.546	rs9963681	ENSG00000267787.4	RP11-35G9.5	-4.4	1.7e-05	0.00792	-0.39	-0.28	HIV-1 control;	chr18:57295823	chr18:57639455~57738044:+
OV	cis	rs4713118	0.621	rs4713132	ENSG00000226314.6	ZNF192P1	-4.4	1.7e-05	0.00792	-0.37	-0.28	Parkinson's disease;	chr6:28066257	chr6:28161781~28169594:+
OV	cis	rs4713118	0.621	rs4713133	ENSG00000226314.6	ZNF192P1	-4.4	1.7e-05	0.00792	-0.37	-0.28	Parkinson's disease;	chr6:28066263	chr6:28161781~28169594:+
OV	cis	rs4713118	0.621	rs4713134	ENSG00000226314.6	ZNF192P1	-4.4	1.7e-05	0.00792	-0.37	-0.28	Parkinson's disease;	chr6:28066343	chr6:28161781~28169594:+
OV	cis	rs56114371	0.777	rs200481	ENSG00000280107.1	AL022393.9	-4.39	1.7e-05	0.00793	-0.48	-0.28	Breast cancer;	chr6:27806054	chr6:28170845~28172521:+
OV	cis	rs638893	1	rs636736	ENSG00000255239.1	AP002954.6	4.39	1.7e-05	0.00793	0.43	0.28	Vitiligo;	chr11:118834436	chr11:118688039~118690600:-
OV	cis	rs7968440	1	rs7968440	ENSG00000257298.1	RP3-405J10.3	4.39	1.7e-05	0.00794	0.27	0.28	Fibrinogen;	chr12:50740958	chr12:50185580~50191363:-
OV	cis	rs853679	0.55	rs1233699	ENSG00000226314.6	ZNF192P1	-4.39	1.7e-05	0.00794	-0.37	-0.28	Depression;	chr6:28201380	chr6:28161781~28169594:+
OV	cis	rs73201462	1	rs2811537	ENSG00000242551.2	POU5F1P6	4.39	1.71e-05	0.00794	0.41	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128269081	chr3:128674735~128677005:-
OV	cis	rs4747241	0.962	rs11000248	ENSG00000226163.1	RP11-167P22.3	4.39	1.71e-05	0.00794	0.31	0.28	Heschl's gyrus morphology;	chr10:72282843	chr10:72501746~72502956:+
OV	cis	rs8054556	1	rs11150579	ENSG00000261367.1	RP11-455F5.4	-4.39	1.71e-05	0.00794	-0.31	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29989009	chr16:30107675~30110541:+
OV	cis	rs8054556	1	rs9924686	ENSG00000261367.1	RP11-455F5.4	-4.39	1.71e-05	0.00794	-0.31	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29991755	chr16:30107675~30110541:+
OV	cis	rs2412819	0.571	rs62018900	ENSG00000205771.5	CATSPER2P1	-4.39	1.71e-05	0.00794	-0.43	-0.28	Lung cancer;	chr15:43633252	chr15:43726918~43747094:-
OV	cis	rs7267979	0.932	rs1541061	ENSG00000274973.1	RP13-401N8.7	-4.39	1.71e-05	0.00794	-0.32	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25540421	chr20:25845497~25845862:+
OV	cis	rs7267979	0.932	rs6138600	ENSG00000274973.1	RP13-401N8.7	-4.39	1.71e-05	0.00794	-0.32	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25540710	chr20:25845497~25845862:+
OV	cis	rs7267979	0.899	rs2104734	ENSG00000274973.1	RP13-401N8.7	-4.39	1.71e-05	0.00794	-0.32	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25546032	chr20:25845497~25845862:+
OV	cis	rs599083	0.59	rs661988	ENSG00000212093.1	AP000807.1	4.39	1.71e-05	0.00795	0.38	0.28	Bone mineral density (spine);	chr11:68421783	chr11:68506083~68506166:-
OV	cis	rs6772849	0.83	rs4857917	ENSG00000277250.1	Metazoa_SRP	-4.39	1.71e-05	0.00795	-0.33	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128657335	chr3:128673681~128674021:-
OV	cis	rs11719079	1	rs11719079	ENSG00000277250.1	Metazoa_SRP	4.39	1.71e-05	0.00795	0.46	0.28	Post bronchodilator FEV1;	chr3:128105206	chr3:128673681~128674021:-
OV	cis	rs10486158	1	rs6955140	ENSG00000234141.1	AC009473.1	-4.39	1.71e-05	0.00796	-0.43	-0.28	Bipolar disorder and schizophrenia;	chr7:7335192	chr7:7949853~7950709:-
OV	cis	rs1979679	0.573	rs6487693	ENSG00000278733.1	RP11-425D17.1	-4.39	1.71e-05	0.00796	-0.34	-0.28	Ossification of the posterior longitudinal ligament of the spine;	chr12:28574158	chr12:28185625~28186190:-
OV	cis	rs1979679	0.573	rs6487694	ENSG00000278733.1	RP11-425D17.1	-4.39	1.71e-05	0.00796	-0.34	-0.28	Ossification of the posterior longitudinal ligament of the spine;	chr12:28574801	chr12:28185625~28186190:-
OV	cis	rs875971	0.862	rs6460302	ENSG00000236529.1	RP13-254B10.1	4.39	1.71e-05	0.00796	0.29	0.28	Aortic root size;	chr7:66495270	chr7:65840212~65840596:+
OV	cis	rs62244186	0.773	rs6809116	ENSG00000214820.3	MPRIPP1	4.39	1.71e-05	0.00796	0.26	0.28	Depressive symptoms;	chr3:44670605	chr3:44579938~44581026:-
OV	cis	rs2919917	1	rs1384804	ENSG00000254352.1	RP11-578O24.2	4.39	1.71e-05	0.00796	0.34	0.28	Lymphocyte counts;	chr8:78659987	chr8:78723796~78724136:-
OV	cis	rs2919917	1	rs10093654	ENSG00000254352.1	RP11-578O24.2	4.39	1.71e-05	0.00796	0.34	0.28	Lymphocyte counts;	chr8:78660360	chr8:78723796~78724136:-
OV	cis	rs2919917	1	rs10093797	ENSG00000254352.1	RP11-578O24.2	4.39	1.71e-05	0.00796	0.34	0.28	Lymphocyte counts;	chr8:78660478	chr8:78723796~78724136:-
OV	cis	rs2919917	1	rs3808619	ENSG00000254352.1	RP11-578O24.2	4.39	1.71e-05	0.00796	0.34	0.28	Lymphocyte counts;	chr8:78665491	chr8:78723796~78724136:-
OV	cis	rs2919917	1	rs13269243	ENSG00000254352.1	RP11-578O24.2	4.39	1.71e-05	0.00796	0.34	0.28	Lymphocyte counts;	chr8:78669501	chr8:78723796~78724136:-
OV	cis	rs2919917	1	rs7839152	ENSG00000254352.1	RP11-578O24.2	4.39	1.71e-05	0.00796	0.34	0.28	Lymphocyte counts;	chr8:78677777	chr8:78723796~78724136:-
OV	cis	rs2919917	1	rs28429528	ENSG00000254352.1	RP11-578O24.2	4.39	1.71e-05	0.00796	0.34	0.28	Lymphocyte counts;	chr8:78678782	chr8:78723796~78724136:-
OV	cis	rs2919917	1	rs9298316	ENSG00000254352.1	RP11-578O24.2	4.39	1.71e-05	0.00796	0.34	0.28	Lymphocyte counts;	chr8:78680191	chr8:78723796~78724136:-
OV	cis	rs2919917	1	rs7842142	ENSG00000254352.1	RP11-578O24.2	4.39	1.71e-05	0.00796	0.34	0.28	Lymphocyte counts;	chr8:78681501	chr8:78723796~78724136:-
OV	cis	rs2919917	1	rs11785966	ENSG00000254352.1	RP11-578O24.2	4.39	1.71e-05	0.00796	0.34	0.28	Lymphocyte counts;	chr8:78681851	chr8:78723796~78724136:-
OV	cis	rs2919917	1	rs10092335	ENSG00000254352.1	RP11-578O24.2	4.39	1.71e-05	0.00796	0.34	0.28	Lymphocyte counts;	chr8:78686218	chr8:78723796~78724136:-
OV	cis	rs8054556	1	rs7204797	ENSG00000261367.1	RP11-455F5.4	-4.39	1.71e-05	0.00796	-0.31	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29956694	chr16:30107675~30110541:+
OV	cis	rs2999052	0.713	rs1702119	ENSG00000242551.2	POU5F1P6	4.39	1.71e-05	0.00796	0.36	0.28	Hypospadias;	chr3:128375650	chr3:128674735~128677005:-
OV	cis	rs6772849	1	rs6772849	ENSG00000277250.1	Metazoa_SRP	-4.39	1.71e-05	0.00796	-0.34	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128587575	chr3:128673681~128674021:-
OV	cis	rs78545713	0.649	rs16891464	ENSG00000241549.7	GUSBP2	-4.39	1.71e-05	0.00796	-0.43	-0.28	Iron status biomarkers (total iron binding capacity);	chr6:26235072	chr6:26871484~26956554:-
OV	cis	rs2880765	0.835	rs4281668	ENSG00000229212.6	RP11-561C5.4	4.39	1.71e-05	0.00797	0.32	0.28	Coronary artery disease;	chr15:85504055	chr15:85205440~85234795:-
OV	cis	rs4908768	0.906	rs11121182	ENSG00000228423.2	RP4-633I8.4	4.39	1.71e-05	0.00797	0.35	0.28	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8462493	chr1:8805860~8807051:-
OV	cis	rs1969253	0.712	rs843368	ENSG00000243584.1	RP11-14I2.2	-4.39	1.71e-05	0.00797	-0.32	-0.28	Major depressive disorder;	chr3:184179837	chr3:183613620~183616742:+
OV	cis	rs295490	0.748	rs78652857	ENSG00000272656.1	RP11-219D15.3	4.39	1.71e-05	0.00797	0.53	0.28	PR interval in Tripanosoma cruzi seropositivity;	chr3:139509107	chr3:139349024~139349371:-
OV	cis	rs62458065	0.85	rs7804998	ENSG00000226468.2	AC018641.7	4.39	1.72e-05	0.00798	0.4	0.28	Metabolite levels (HVA/MHPG ratio);	chr7:32421585	chr7:32456963~32457758:-
OV	cis	rs858239	0.601	rs7805206	ENSG00000230042.1	AK3P3	-4.39	1.72e-05	0.00798	-0.29	-0.28	Cerebrospinal fluid biomarker levels;	chr7:23120591	chr7:23129178~23129841:+
OV	cis	rs1823913	0.614	rs12616167	ENSG00000227542.1	AC092614.2	-4.39	1.72e-05	0.00798	-0.32	-0.28	Obesity-related traits;	chr2:191311274	chr2:191229165~191246172:-
OV	cis	rs7520050	0.966	rs7550746	ENSG00000281133.1	AL355480.3	4.39	1.72e-05	0.00798	0.32	0.28	Reticulocyte count;Red blood cell count;	chr1:45886047	chr1:45580892~45580996:-
OV	cis	rs992157	0.798	rs12053514	ENSG00000261338.2	RP11-378A13.1	-4.39	1.72e-05	0.00799	-0.34	-0.28	Colorectal cancer;	chr2:218303242	chr2:218255319~218257366:+
OV	cis	rs73186030	0.92	rs2001548	ENSG00000272758.4	RP11-299J3.8	4.39	1.72e-05	0.008	0.31	0.28	Serum parathyroid hormone levels;	chr3:122313942	chr3:122416207~122443180:+
OV	cis	rs1861353	0.863	rs16952252	ENSG00000279344.1	RP11-44F14.7	4.39	1.72e-05	0.008	0.26	0.28	Intelligence (multi-trait analysis);	chr16:53450068	chr16:53478957~53481550:-
OV	cis	rs1020064	0.636	rs2679883	ENSG00000235319.1	AC012360.4	-4.39	1.72e-05	0.008	-0.36	-0.28	AIDS;	chr2:105333211	chr2:105324210~105330529:+
OV	cis	rs853679	0.55	rs1233701	ENSG00000226314.6	ZNF192P1	4.39	1.72e-05	0.00801	0.38	0.28	Depression;	chr6:28200948	chr6:28161781~28169594:+
OV	cis	rs6940638	0.688	rs9393790	ENSG00000220721.1	OR1F12	-4.39	1.72e-05	0.00802	-0.3	-0.28	Intelligence (multi-trait analysis);	chr6:27146273	chr6:28073316~28074233:+
OV	cis	rs1113500	0.614	rs11185243	ENSG00000226822.1	RP11-356N1.2	4.39	1.73e-05	0.00802	0.35	0.28	Growth-regulated protein alpha levels;	chr1:108054519	chr1:108071482~108074519:+
OV	cis	rs9880211	0.898	rs9870825	ENSG00000239213.4	NCK1-AS1	4.39	1.73e-05	0.00802	0.35	0.28	Height;Body mass index;	chr3:136346878	chr3:136841726~136862054:-
OV	cis	rs2919917	0.628	rs2583759	ENSG00000254352.1	RP11-578O24.2	-4.39	1.73e-05	0.00803	-0.38	-0.28	Lymphocyte counts;	chr8:78732729	chr8:78723796~78724136:-
OV	cis	rs2919917	0.628	rs2583778	ENSG00000254352.1	RP11-578O24.2	-4.39	1.73e-05	0.00803	-0.38	-0.28	Lymphocyte counts;	chr8:78738906	chr8:78723796~78724136:-
OV	cis	rs796364	0.589	rs6743217	ENSG00000232732.8	AC073043.1	4.39	1.73e-05	0.00804	0.37	0.28	Schizophrenia;	chr2:200270191	chr2:199867396~199911159:-
OV	cis	rs796364	0.589	rs55700082	ENSG00000232732.8	AC073043.1	4.39	1.73e-05	0.00804	0.37	0.28	Schizophrenia;	chr2:200270946	chr2:199867396~199911159:-
OV	cis	rs6940638	0.744	rs858964	ENSG00000220721.1	OR1F12	-4.39	1.73e-05	0.00805	-0.29	-0.28	Intelligence (multi-trait analysis);	chr6:27174835	chr6:28073316~28074233:+
OV	cis	rs2562784	0.638	rs12437593	ENSG00000235370.6	DNM1P51	4.39	1.73e-05	0.00805	0.51	0.28	Height;	chr15:83594945	chr15:84398316~84411701:-
OV	cis	rs881375	0.678	rs7031752	ENSG00000226752.6	PSMD5-AS1	-4.39	1.74e-05	0.00806	-0.3	-0.28	Rheumatoid arthritis;	chr9:120901204	chr9:120824828~120854385:+
OV	cis	rs6991838	0.831	rs11992528	ENSG00000200714.1	Y_RNA	4.39	1.74e-05	0.00806	0.34	0.28	Intelligence (multi-trait analysis);	chr8:65561644	chr8:65592731~65592820:+
OV	cis	rs6890270	1	rs6890270	ENSG00000271828.1	CTD-2310F14.1	4.39	1.74e-05	0.00807	0.5	0.28	Breast cancer;	chr5:56964779	chr5:56927874~56929573:+
OV	cis	rs62244186	0.606	rs6798590	ENSG00000214820.3	MPRIPP1	4.39	1.74e-05	0.00807	0.25	0.28	Depressive symptoms;	chr3:44515369	chr3:44579938~44581026:-
OV	cis	rs757081	0.648	rs10832750	ENSG00000213779.4	RP11-452G18.1	-4.39	1.74e-05	0.00808	-0.3	-0.28	Systolic blood pressure;	chr11:17239371	chr11:17193489~17194308:+
OV	cis	rs7927592	0.912	rs55767696	ENSG00000212093.1	AP000807.1	4.39	1.74e-05	0.00808	0.35	0.28	Total body bone mineral density;	chr11:68607652	chr11:68506083~68506166:-
OV	cis	rs11122895	0.716	rs7605443	ENSG00000228251.1	AC012442.6	4.39	1.75e-05	0.0081	0.27	0.28	Allergic sensitization;	chr2:111716295	chr2:112590796~112591939:+
OV	cis	rs757081	0.648	rs7940253	ENSG00000213779.4	RP11-452G18.1	4.39	1.75e-05	0.00811	0.3	0.28	Systolic blood pressure;	chr11:17259049	chr11:17193489~17194308:+
OV	cis	rs881375	1	rs1953126	ENSG00000226752.6	PSMD5-AS1	-4.39	1.75e-05	0.00812	-0.31	-0.28	Rheumatoid arthritis;	chr9:120878222	chr9:120824828~120854385:+
OV	cis	rs2732480	0.538	rs2468943	ENSG00000226413.2	OR8T1P	-4.39	1.75e-05	0.00812	-0.35	-0.28	Red blood cell count;Hematocrit;Hemoglobin concentration;	chr12:48353466	chr12:48442030~48442947:-
OV	cis	rs67311347	1	rs9842564	ENSG00000223797.4	ENTPD3-AS1	-4.39	1.75e-05	0.00812	-0.29	-0.28	Renal cell carcinoma;	chr3:40364319	chr3:40313802~40453329:-
OV	cis	rs881375	0.967	rs1014529	ENSG00000226752.6	PSMD5-AS1	-4.39	1.75e-05	0.00812	-0.31	-0.28	Rheumatoid arthritis;	chr9:120922665	chr9:120824828~120854385:+
OV	cis	rs2015599	0.514	rs10843376	ENSG00000257176.2	RP11-996F15.2	4.39	1.75e-05	0.00813	0.35	0.28	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29280418~29317848:-
OV	cis	rs7829975	0.742	rs1533059	ENSG00000253981.4	ALG1L13P	-4.39	1.75e-05	0.00814	-0.29	-0.28	Mood instability;	chr8:8827443	chr8:8236003~8244667:-
OV	cis	rs9287719	0.674	rs12620209	ENSG00000243819.4	RN7SL832P	4.39	1.76e-05	0.00814	0.28	0.28	Prostate cancer;	chr2:10580315	chr2:10690344~10692099:+
OV	cis	rs62458065	0.85	rs10273165	ENSG00000226468.2	AC018641.7	4.39	1.76e-05	0.00815	0.4	0.28	Metabolite levels (HVA/MHPG ratio);	chr7:32421228	chr7:32456963~32457758:-
OV	cis	rs62458065	0.85	rs7785659	ENSG00000226468.2	AC018641.7	4.39	1.76e-05	0.00815	0.4	0.28	Metabolite levels (HVA/MHPG ratio);	chr7:32421403	chr7:32456963~32457758:-
OV	cis	rs853679	0.517	rs9380052	ENSG00000226314.6	ZNF192P1	-4.39	1.76e-05	0.00815	-0.37	-0.28	Depression;	chr6:28096845	chr6:28161781~28169594:+
OV	cis	rs9880211	0.948	rs13321721	ENSG00000239213.4	NCK1-AS1	4.39	1.76e-05	0.00815	0.34	0.28	Height;Body mass index;	chr3:136490708	chr3:136841726~136862054:-
OV	cis	rs1823913	0.637	rs2067610	ENSG00000227542.1	AC092614.2	4.39	1.76e-05	0.00815	0.31	0.28	Obesity-related traits;	chr2:191299251	chr2:191229165~191246172:-
OV	cis	rs7520050	0.751	rs2230657	ENSG00000280836.1	AL355480.1	4.39	1.76e-05	0.00816	0.34	0.28	Reticulocyte count;Red blood cell count;	chr1:45607817	chr1:45581219~45581321:-
OV	cis	rs62244186	0.748	rs13319803	ENSG00000214820.3	MPRIPP1	4.39	1.76e-05	0.00816	0.25	0.28	Depressive symptoms;	chr3:44593969	chr3:44579938~44581026:-
OV	cis	rs9287719	0.674	rs12622551	ENSG00000243819.4	RN7SL832P	4.39	1.76e-05	0.00816	0.28	0.28	Prostate cancer;	chr2:10580317	chr2:10690344~10692099:+
OV	cis	rs9287719	0.649	rs10182589	ENSG00000243819.4	RN7SL832P	4.39	1.76e-05	0.00816	0.28	0.28	Prostate cancer;	chr2:10580538	chr2:10690344~10692099:+
OV	cis	rs9287719	0.649	rs10208103	ENSG00000243819.4	RN7SL832P	4.39	1.76e-05	0.00816	0.28	0.28	Prostate cancer;	chr2:10580741	chr2:10690344~10692099:+
OV	cis	rs67311347	0.956	rs11714871	ENSG00000223797.4	ENTPD3-AS1	4.39	1.76e-05	0.00816	0.3	0.28	Renal cell carcinoma;	chr3:40387447	chr3:40313802~40453329:-
OV	cis	rs67311347	1	rs2305521	ENSG00000223797.4	ENTPD3-AS1	4.39	1.76e-05	0.00816	0.3	0.28	Renal cell carcinoma;	chr3:40387692	chr3:40313802~40453329:-
OV	cis	rs2688608	0.62	rs11000767	ENSG00000271816.1	BMS1P4	4.39	1.76e-05	0.00816	0.26	0.28	Inflammatory bowel disease;	chr10:73756868	chr10:73699151~73730487:-
OV	cis	rs12130219	0.5	rs1552991	ENSG00000237975.5	FLG-AS1	-4.39	1.76e-05	0.00817	-0.37	-0.28	Inflammatory skin disease;	chr1:152193402	chr1:152168125~152445456:+
OV	cis	rs4964805	0.657	rs73192049	ENSG00000257681.1	RP11-341G23.4	4.39	1.77e-05	0.00818	0.31	0.28	Attention deficit hyperactivity disorder;	chr12:103794215	chr12:103746315~103768858:-
OV	cis	rs4964805	0.632	rs9706225	ENSG00000257681.1	RP11-341G23.4	4.39	1.77e-05	0.00818	0.31	0.28	Attention deficit hyperactivity disorder;	chr12:103794308	chr12:103746315~103768858:-
OV	cis	rs7746199	0.673	rs35501037	ENSG00000220721.1	OR1F12	4.39	1.77e-05	0.00818	0.58	0.28	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27771787	chr6:28073316~28074233:+
OV	cis	rs7043114	0.507	rs2007837	ENSG00000281156.1	MIR3651	-4.39	1.77e-05	0.00818	-0.31	-0.28	Height;	chr9:92427485	chr9:92292458~92292547:-
OV	cis	rs1862618	0.853	rs252921	ENSG00000271828.1	CTD-2310F14.1	4.39	1.77e-05	0.00818	0.44	0.28	Initial pursuit acceleration;	chr5:56841960	chr5:56927874~56929573:+
OV	cis	rs12073359	1	rs7553622	ENSG00000223945.2	RP11-458I7.1	4.39	1.77e-05	0.0082	0.42	0.28	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150092668	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs3850838	ENSG00000223945.2	RP11-458I7.1	4.39	1.77e-05	0.0082	0.42	0.28	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150093282	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs11205326	ENSG00000223945.2	RP11-458I7.1	4.39	1.77e-05	0.0082	0.42	0.28	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150104428	chr1:150053864~150055034:+
OV	cis	rs992157	0.56	rs6738394	ENSG00000237281.1	CATIP-AS2	4.39	1.77e-05	0.0082	0.33	0.28	Colorectal cancer;	chr2:218245902	chr2:218326889~218357966:-
OV	cis	rs1075265	0.791	rs1833498	ENSG00000233266.1	HMGB1P31	4.39	1.77e-05	0.0082	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54080801	chr2:54051334~54051760:+
OV	cis	rs875971	0.545	rs1638724	ENSG00000237310.1	GS1-124K5.4	-4.39	1.77e-05	0.00821	-0.32	-0.28	Aortic root size;	chr7:66575494	chr7:66493706~66495474:+
OV	cis	rs10510102	0.872	rs3862129	ENSG00000226864.1	ATE1-AS1	4.38	1.78e-05	0.00822	0.44	0.28	Breast cancer;	chr10:121824460	chr10:121928312~121951965:+
OV	cis	rs9287719	0.901	rs55861579	ENSG00000234818.1	AC092687.5	4.38	1.78e-05	0.00822	0.3	0.28	Prostate cancer;	chr2:10623214	chr2:10589166~10604830:+
OV	cis	rs7968440	1	rs2731442	ENSG00000257298.1	RP3-405J10.3	4.38	1.78e-05	0.00824	0.27	0.28	Fibrinogen;	chr12:50660872	chr12:50185580~50191363:-
OV	cis	rs1858037	0.765	rs67404371	ENSG00000234255.7	AC012370.3	4.38	1.78e-05	0.00825	0.31	0.28	Rheumatoid arthritis;	chr2:65370137	chr2:65439888~65456571:-
OV	cis	rs10899021	0.915	rs11236198	ENSG00000279353.1	RP11-864N7.4	4.38	1.78e-05	0.00825	0.52	0.28	Response to metformin (IC50);	chr11:74661155	chr11:74698231~74699658:-
OV	cis	rs1511299	0.516	rs34464850	ENSG00000249417.1	RP11-438D8.2	-4.38	1.79e-05	0.00826	-0.41	-0.28	Glomerular filtration rate;	chr3:142002920	chr3:141267353~141367137:-
OV	cis	rs9287719	0.601	rs6751436	ENSG00000243819.4	RN7SL832P	4.38	1.79e-05	0.00827	0.29	0.28	Prostate cancer;	chr2:10583736	chr2:10690344~10692099:+
OV	cis	rs9287719	0.578	rs13425171	ENSG00000243819.4	RN7SL832P	4.38	1.79e-05	0.00827	0.29	0.28	Prostate cancer;	chr2:10591840	chr2:10690344~10692099:+
OV	cis	rs67311347	1	rs6599094	ENSG00000223797.4	ENTPD3-AS1	4.38	1.79e-05	0.00828	0.29	0.28	Renal cell carcinoma;	chr3:40358102	chr3:40313802~40453329:-
OV	cis	rs853679	0.517	rs6932109	ENSG00000226314.6	ZNF192P1	4.38	1.79e-05	0.00828	0.38	0.28	Depression;	chr6:28110525	chr6:28161781~28169594:+
OV	cis	rs7520050	0.807	rs3013595	ENSG00000280836.1	AL355480.1	-4.38	1.8e-05	0.00829	-0.34	-0.28	Reticulocyte count;Red blood cell count;	chr1:45687531	chr1:45581219~45581321:-
OV	cis	rs10129255	0.5	rs10143242	ENSG00000223648.3	IGHV3-64	4.38	1.8e-05	0.00829	0.29	0.28	Kawasaki disease;	chr14:106681814	chr14:106643132~106658258:-
OV	cis	rs1436109	0.809	rs2155293	ENSG00000255129.4	RP11-839D17.3	-4.38	1.8e-05	0.0083	-0.48	-0.28	Cardiac muscle measurement;	chr11:113030372	chr11:113278437~113314437:-
OV	cis	rs4964805	0.594	rs751448	ENSG00000257681.1	RP11-341G23.4	4.38	1.8e-05	0.0083	0.31	0.28	Attention deficit hyperactivity disorder;	chr12:103773407	chr12:103746315~103768858:-
OV	cis	rs4713118	0.621	rs10484403	ENSG00000226314.6	ZNF192P1	-4.38	1.8e-05	0.0083	-0.38	-0.28	Parkinson's disease;	chr6:28065745	chr6:28161781~28169594:+
OV	cis	rs1555322	0.53	rs2297789	ENSG00000269202.1	RP4-614O4.12	-4.38	1.8e-05	0.00831	-0.32	-0.28	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35201747~35203288:-
OV	cis	rs62355901	0.505	rs72759712	ENSG00000271828.1	CTD-2310F14.1	4.38	1.8e-05	0.00831	0.55	0.28	Breast cancer;	chr5:56906519	chr5:56927874~56929573:+
OV	cis	rs73201462	0.615	rs2293947	ENSG00000242551.2	POU5F1P6	4.38	1.8e-05	0.00832	0.6	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128378653	chr3:128674735~128677005:-
OV	cis	rs67311347	1	rs7648952	ENSG00000223797.4	ENTPD3-AS1	-4.38	1.8e-05	0.00832	-0.3	-0.28	Renal cell carcinoma;	chr3:40415547	chr3:40313802~40453329:-
OV	cis	rs295490	0.748	rs17395611	ENSG00000272656.1	RP11-219D15.3	-4.38	1.8e-05	0.00833	-0.49	-0.28	PR interval in Tripanosoma cruzi seropositivity;	chr3:139425773	chr3:139349024~139349371:-
OV	cis	rs4908768	0.906	rs56305243	ENSG00000228423.2	RP4-633I8.4	4.38	1.81e-05	0.00834	0.34	0.28	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8665361	chr1:8805860~8807051:-
OV	cis	rs2919917	1	rs2046338	ENSG00000254352.1	RP11-578O24.2	4.38	1.81e-05	0.00834	0.33	0.28	Lymphocyte counts;	chr8:78723734	chr8:78723796~78724136:-
OV	cis	rs11083475	1	rs7251903	ENSG00000267892.1	CTD-2540F13.2	4.38	1.81e-05	0.00834	0.31	0.28	Heart rate;	chr19:38694171	chr19:38738284~38739863:+
OV	cis	rs7688540	0.723	rs80316648	ENSG00000275426.1	CH17-262A2.1	4.38	1.81e-05	0.00834	0.44	0.28	Facial morphology (factor 6, height of vermillion lower lip);	chr4:238426	chr4:149738~150317:+
OV	cis	rs4948102	0.642	rs6593297	ENSG00000275875.1	RP11-613E4.5	4.38	1.81e-05	0.00834	0.3	0.28	Plasma homocysteine levels (post-methionine load test);	chr7:56054365	chr7:55741525~55741869:+
OV	cis	rs1075265	0.836	rs1421622	ENSG00000233266.1	HMGB1P31	-4.38	1.81e-05	0.00835	-0.34	-0.28	Chronotype;Morning vs. evening chronotype;	chr2:54062644	chr2:54051334~54051760:+
OV	cis	rs473651	0.904	rs472247	ENSG00000229915.1	AC016999.2	-4.38	1.81e-05	0.00835	-0.36	-0.28	Multiple system atrophy;	chr2:238453932	chr2:238427077~238427729:-
OV	cis	rs73201462	0.708	rs34862979	ENSG00000242551.2	POU5F1P6	4.38	1.81e-05	0.00836	0.42	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128131521	chr3:128674735~128677005:-
OV	cis	rs1862618	0.853	rs252902	ENSG00000271828.1	CTD-2310F14.1	4.38	1.81e-05	0.00836	0.43	0.28	Initial pursuit acceleration;	chr5:56820258	chr5:56927874~56929573:+
OV	cis	rs2919917	1	rs1872072	ENSG00000254352.1	RP11-578O24.2	4.38	1.82e-05	0.00839	0.33	0.28	Lymphocyte counts;	chr8:78689185	chr8:78723796~78724136:-
OV	cis	rs2933343	0.953	rs2933344	ENSG00000231305.3	RP11-723O4.2	4.38	1.82e-05	0.00839	0.35	0.28	IgG glycosylation;	chr3:128939872	chr3:128861313~128871540:-
OV	cis	rs2239547	0.562	rs6794389	ENSG00000242142.1	SERBP1P3	4.38	1.82e-05	0.0084	0.35	0.28	Schizophrenia;	chr3:53062378	chr3:53064283~53065091:-
OV	cis	rs4908768	0.906	rs114812780	ENSG00000228423.2	RP4-633I8.4	4.38	1.82e-05	0.0084	0.35	0.28	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8468794	chr1:8805860~8807051:-
OV	cis	rs1823913	0.599	rs55786000	ENSG00000227542.1	AC092614.2	4.38	1.82e-05	0.00841	0.31	0.28	Obesity-related traits;	chr2:191284500	chr2:191229165~191246172:-
OV	cis	rs7043114	0.525	rs12353096	ENSG00000281156.1	MIR3651	-4.38	1.83e-05	0.00841	-0.31	-0.28	Height;	chr9:92268862	chr9:92292458~92292547:-
OV	cis	rs7043114	0.507	rs10992291	ENSG00000281156.1	MIR3651	-4.38	1.83e-05	0.00841	-0.31	-0.28	Height;	chr9:92270727	chr9:92292458~92292547:-
OV	cis	rs7043114	0.525	rs10820964	ENSG00000281156.1	MIR3651	-4.38	1.83e-05	0.00841	-0.31	-0.28	Height;	chr9:92279354	chr9:92292458~92292547:-
OV	cis	rs7043114	0.525	rs10739927	ENSG00000281156.1	MIR3651	-4.38	1.83e-05	0.00841	-0.31	-0.28	Height;	chr9:92289799	chr9:92292458~92292547:-
OV	cis	rs7043114	0.525	rs7863406	ENSG00000281156.1	MIR3651	-4.38	1.83e-05	0.00841	-0.31	-0.28	Height;	chr9:92291099	chr9:92292458~92292547:-
OV	cis	rs7043114	0.525	rs6479416	ENSG00000281156.1	MIR3651	-4.38	1.83e-05	0.00841	-0.31	-0.28	Height;	chr9:92291589	chr9:92292458~92292547:-
OV	cis	rs673078	0.66	rs17512574	ENSG00000275759.1	RP11-131L12.3	-4.38	1.83e-05	0.00842	-0.41	-0.28	Glucose homeostasis traits;	chr12:118350198	chr12:118428281~118428870:+
OV	cis	rs2919917	0.628	rs13267679	ENSG00000254352.1	RP11-578O24.2	-4.38	1.83e-05	0.00844	-0.38	-0.28	Lymphocyte counts;	chr8:78711603	chr8:78723796~78724136:-
OV	cis	rs4718428	1	rs1830070	ENSG00000222364.1	RNU6-96P	-4.38	1.83e-05	0.00845	-0.31	-0.28	Corneal structure;	chr7:66884684	chr7:66395191~66395286:+
OV	cis	rs2980436	1	rs2980436	ENSG00000254153.1	CTA-398F10.2	-4.38	1.83e-05	0.00845	-0.38	-0.28	Schizophrenia;	chr8:8234503	chr8:8456909~8461337:-
OV	cis	rs801193	0.66	rs974239	ENSG00000236529.1	RP13-254B10.1	4.38	1.84e-05	0.00845	0.29	0.28	Aortic root size;	chr7:66748504	chr7:65840212~65840596:+
OV	cis	rs801193	0.66	rs1016265	ENSG00000236529.1	RP13-254B10.1	4.38	1.84e-05	0.00845	0.29	0.28	Aortic root size;	chr7:66749580	chr7:65840212~65840596:+
OV	cis	rs801193	0.66	rs4610622	ENSG00000236529.1	RP13-254B10.1	4.38	1.84e-05	0.00845	0.29	0.28	Aortic root size;	chr7:66759510	chr7:65840212~65840596:+
OV	cis	rs1823913	0.599	rs7598639	ENSG00000227542.1	AC092614.2	4.38	1.84e-05	0.00845	0.3	0.28	Obesity-related traits;	chr2:191267958	chr2:191229165~191246172:-
OV	cis	rs6772849	0.931	rs60825080	ENSG00000277250.1	Metazoa_SRP	-4.38	1.84e-05	0.00846	-0.33	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128665991	chr3:128673681~128674021:-
OV	cis	rs8054556	1	rs11901	ENSG00000261367.1	RP11-455F5.4	-4.38	1.84e-05	0.00846	-0.31	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29972749	chr16:30107675~30110541:+
OV	cis	rs8054556	1	rs4318227	ENSG00000261367.1	RP11-455F5.4	-4.38	1.84e-05	0.00846	-0.31	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29973518	chr16:30107675~30110541:+
OV	cis	rs853679	0.882	rs9380069	ENSG00000280107.1	AL022393.9	-4.38	1.84e-05	0.00846	-0.51	-0.28	Depression;	chr6:28235522	chr6:28170845~28172521:+
OV	cis	rs1150668	0.796	rs1005125	ENSG00000204709.4	LINC01556	4.38	1.84e-05	0.00846	0.32	0.28	Pubertal anthropometrics;	chr6:28399578	chr6:28943877~28944537:+
OV	cis	rs2550374	0.807	rs1820235	ENSG00000260467.1	RP11-405F3.4	-4.38	1.84e-05	0.00847	-0.3	-0.28	Primary biliary cholangitis;	chr16:58230508	chr16:57681124~57701730:-
OV	cis	rs67340775	0.541	rs169287	ENSG00000226314.6	ZNF192P1	-4.38	1.84e-05	0.00848	-0.41	-0.28	Lung cancer in ever smokers;	chr6:27886982	chr6:28161781~28169594:+
OV	cis	rs67340775	0.541	rs200966	ENSG00000226314.6	ZNF192P1	-4.38	1.84e-05	0.00848	-0.41	-0.28	Lung cancer in ever smokers;	chr6:27894374	chr6:28161781~28169594:+
OV	cis	rs10978777	0.805	rs10739234	ENSG00000276883.1	AL137852.1	-4.38	1.84e-05	0.00848	-0.31	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107285035	chr9:107292369~107292456:-
OV	cis	rs875971	0.545	rs73142245	ENSG00000237310.1	GS1-124K5.4	4.38	1.84e-05	0.00848	0.32	0.28	Aortic root size;	chr7:66226662	chr7:66493706~66495474:+
OV	cis	rs62184315	0.536	rs62183651	ENSG00000253559.1	OSGEPL1-AS1	-4.38	1.84e-05	0.00848	-0.38	-0.28	Alcohol dependence (age at onset);	chr2:189647251	chr2:189762704~189765556:+
OV	cis	rs875971	0.545	rs1909508	ENSG00000237310.1	GS1-124K5.4	4.38	1.84e-05	0.00849	0.32	0.28	Aortic root size;	chr7:66301366	chr7:66493706~66495474:+
OV	cis	rs7512898	0.5	rs6691268	ENSG00000260088.1	RP11-92G12.3	-4.38	1.84e-05	0.00849	-0.31	-0.28	Electrocardiographic conduction measures;	chr1:200786938	chr1:200669507~200694250:+
OV	cis	rs9660180	0.967	rs11260623	ENSG00000215914.4	MMP23A	-4.38	1.85e-05	0.00849	-0.32	-0.28	Body mass index;	chr1:1850017	chr1:1699942~1701782:+
OV	cis	rs10759883	0.563	rs682682	ENSG00000175611.10	LINC00476	4.38	1.85e-05	0.00849	0.34	0.28	Nicotine dependence;	chr9:95939980	chr9:95759231~95875977:-
OV	cis	rs1020064	0.636	rs1529974	ENSG00000235319.1	AC012360.4	-4.38	1.85e-05	0.0085	-0.34	-0.28	AIDS;	chr2:105311539	chr2:105324210~105330529:+
OV	cis	rs1020064	0.636	rs2576726	ENSG00000235319.1	AC012360.4	-4.38	1.85e-05	0.0085	-0.34	-0.28	AIDS;	chr2:105319955	chr2:105324210~105330529:+
OV	cis	rs11096990	0.855	rs2711935	ENSG00000249207.1	RP11-360F5.1	4.38	1.85e-05	0.0085	0.32	0.28	Cognitive function;	chr4:39160837	chr4:39112677~39126818:-
OV	cis	rs1538970	0.962	rs9429158	ENSG00000280836.1	AL355480.1	-4.38	1.85e-05	0.00851	-0.38	-0.28	Platelet count;	chr1:45355721	chr1:45581219~45581321:-
OV	cis	rs10924970	0.588	rs61836189	ENSG00000236863.2	RPL23AP23	4.38	1.85e-05	0.00851	0.29	0.28	Asthma;	chr1:235349015	chr1:235295865~235296335:+
OV	cis	rs2243480	0.522	rs1638736	ENSG00000222364.1	RNU6-96P	-4.37	1.85e-05	0.00852	-0.45	-0.28	Diabetic kidney disease;	chr7:66627321	chr7:66395191~66395286:+
OV	cis	rs10924970	0.625	rs3806394	ENSG00000236863.2	RPL23AP23	4.37	1.85e-05	0.00853	0.29	0.28	Asthma;	chr1:235326535	chr1:235295865~235296335:+
OV	cis	rs7429990	0.864	rs61620099	ENSG00000229759.1	MRPS18AP1	-4.37	1.85e-05	0.00853	-0.3	-0.28	Educational attainment (years of education);	chr3:47600755	chr3:48256350~48256938:-
OV	cis	rs2898290	0.5	rs11998678	ENSG00000206014.6	OR7E161P	4.37	1.86e-05	0.00853	0.36	0.28	Systolic blood pressure;	chr8:11972641	chr8:11928597~11929563:-
OV	cis	rs7968440	1	rs2731440	ENSG00000257298.1	RP3-405J10.3	4.37	1.86e-05	0.00854	0.27	0.28	Fibrinogen;	chr12:50663844	chr12:50185580~50191363:-
OV	cis	rs7968440	1	rs2731439	ENSG00000257298.1	RP3-405J10.3	4.37	1.86e-05	0.00854	0.27	0.28	Fibrinogen;	chr12:50666567	chr12:50185580~50191363:-
OV	cis	rs4713118	0.955	rs9468203	ENSG00000280107.1	AL022393.9	-4.37	1.86e-05	0.00854	-0.33	-0.28	Parkinson's disease;	chr6:27720888	chr6:28170845~28172521:+
OV	cis	rs7927592	0.956	rs7126340	ENSG00000212093.1	AP000807.1	4.37	1.86e-05	0.00855	0.35	0.28	Total body bone mineral density;	chr11:68489825	chr11:68506083~68506166:-
OV	cis	rs73201462	0.901	rs16843876	ENSG00000277250.1	Metazoa_SRP	4.37	1.86e-05	0.00855	0.41	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128313697	chr3:128673681~128674021:-
OV	cis	rs853679	1	rs7740487	ENSG00000219392.1	RP1-265C24.5	-4.37	1.86e-05	0.00856	-0.45	-0.28	Depression;	chr6:28248708	chr6:28115628~28116551:+
OV	cis	rs593531	0.614	rs596976	ENSG00000280269.1	AP000577.2	4.37	1.86e-05	0.00856	0.33	0.28	Neuroticism;	chr11:74332663	chr11:74204869~74205746:+
OV	cis	rs1858037	0.867	rs953312	ENSG00000234255.7	AC012370.3	4.37	1.86e-05	0.00857	0.31	0.28	Rheumatoid arthritis;	chr2:65340556	chr2:65439888~65456571:-
OV	cis	rs1858037	0.867	rs9789444	ENSG00000234255.7	AC012370.3	4.37	1.86e-05	0.00857	0.31	0.28	Rheumatoid arthritis;	chr2:65342093	chr2:65439888~65456571:-
OV	cis	rs875971	0.628	rs6974355	ENSG00000224316.1	RP11-479O9.2	4.37	1.87e-05	0.00857	0.3	0.28	Aortic root size;	chr7:66376994	chr7:65773620~65802067:+
OV	cis	rs13113518	0.557	rs13142096	ENSG00000223305.1	RN7SKP30	4.37	1.87e-05	0.00857	0.34	0.28	Height;	chr4:55566291	chr4:55540502~55540835:-
OV	cis	rs13113518	0.812	rs13140590	ENSG00000223305.1	RN7SKP30	4.37	1.87e-05	0.00857	0.33	0.28	Height;	chr4:55548666	chr4:55540502~55540835:-
OV	cis	rs6788497	0.643	rs11709536	ENSG00000242551.2	POU5F1P6	4.37	1.87e-05	0.00858	0.55	0.28	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr3:128392270	chr3:128674735~128677005:-
OV	cis	rs11083475	0.967	rs13343794	ENSG00000267892.1	CTD-2540F13.2	4.37	1.87e-05	0.00858	0.3	0.28	Heart rate;	chr19:38688631	chr19:38738284~38739863:+
OV	cis	rs9309473	1	rs6753344	ENSG00000163016.8	ALMS1P	-4.37	1.87e-05	0.00858	-0.34	-0.28	Metabolite levels;	chr2:73426010	chr2:73644919~73685576:+
OV	cis	rs2522056	1	rs62385693	ENSG00000233006.5	AC034220.3	-4.37	1.87e-05	0.00858	-0.33	-0.28	Fibrinogen;Lymphocyte counts;	chr5:132437982	chr5:132311285~132369916:-
OV	cis	rs7968440	1	rs11832315	ENSG00000257298.1	RP3-405J10.3	4.37	1.87e-05	0.00858	0.27	0.28	Fibrinogen;	chr12:50550149	chr12:50185580~50191363:-
OV	cis	rs7968440	1	rs66597435	ENSG00000257298.1	RP3-405J10.3	4.37	1.87e-05	0.00858	0.27	0.28	Fibrinogen;	chr12:50551486	chr12:50185580~50191363:-
OV	cis	rs1511299	0.546	rs34486172	ENSG00000249417.1	RP11-438D8.2	-4.37	1.87e-05	0.00859	-0.41	-0.28	Glomerular filtration rate;	chr3:141984480	chr3:141267353~141367137:-
OV	cis	rs7746199	0.736	rs35848276	ENSG00000220721.1	OR1F12	4.37	1.87e-05	0.0086	0.54	0.28	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:28073316~28074233:+
OV	cis	rs116095464	0.558	rs56081398	ENSG00000250848.1	CTD-2083E4.5	-4.37	1.87e-05	0.0086	-0.36	-0.28	Breast cancer;	chr5:247203	chr5:288833~290321:-
OV	cis	rs4814920	0.818	rs4813377	ENSG00000275142.1	RP5-999L4.2	-4.37	1.88e-05	0.00862	-0.43	-0.28	Bipolar disorder (body mass index interaction);	chr20:19870822	chr20:19871891~19872284:+
OV	cis	rs7684253	1	rs7684253	ENSG00000269949.1	RP11-738E22.3	4.37	1.88e-05	0.00863	0.33	0.28	Migraine;	chr4:56861145	chr4:56960927~56961373:-
OV	cis	rs1113500	0.73	rs1777457	ENSG00000226822.1	RP11-356N1.2	-4.37	1.88e-05	0.00864	-0.33	-0.28	Growth-regulated protein alpha levels;	chr1:108045573	chr1:108071482~108074519:+
OV	cis	rs9287719	0.967	rs10929688	ENSG00000234818.1	AC092687.5	4.37	1.89e-05	0.00865	0.3	0.28	Prostate cancer;	chr2:10616524	chr2:10589166~10604830:+
OV	cis	rs9291683	0.546	rs13120348	ENSG00000250413.1	RP11-448G15.1	4.37	1.89e-05	0.00866	0.31	0.28	Bone mineral density;	chr4:10051531	chr4:10006482~10009725:+
OV	cis	rs2919917	0.554	rs2086755	ENSG00000254352.1	RP11-578O24.2	4.37	1.89e-05	0.00866	0.38	0.28	Lymphocyte counts;	chr8:78701809	chr8:78723796~78724136:-
OV	cis	rs992157	0.835	rs2292550	ENSG00000261338.2	RP11-378A13.1	-4.37	1.89e-05	0.00867	-0.33	-0.28	Colorectal cancer;	chr2:218275565	chr2:218255319~218257366:+
OV	cis	rs1113500	0.933	rs61797345	ENSG00000226822.1	RP11-356N1.2	4.37	1.89e-05	0.00867	0.33	0.28	Growth-regulated protein alpha levels;	chr1:108081106	chr1:108071482~108074519:+
OV	cis	rs1823913	0.637	rs4853574	ENSG00000227542.1	AC092614.2	-4.37	1.89e-05	0.00868	-0.31	-0.28	Obesity-related traits;	chr2:191296113	chr2:191229165~191246172:-
OV	cis	rs9880211	1	rs13071220	ENSG00000239213.4	NCK1-AS1	4.37	1.89e-05	0.00868	0.34	0.28	Height;Body mass index;	chr3:136595277	chr3:136841726~136862054:-
OV	cis	rs1559040	1	rs72800725	ENSG00000272156.1	RP11-477N3.1	-4.37	1.89e-05	0.00869	-0.49	-0.28	Sudden cardiac arrest;	chr2:54074000	chr2:54082554~54085066:+
OV	cis	rs11105298	0.891	rs10858881	ENSG00000257194.2	RP11-567C2.1	-4.37	1.89e-05	0.00869	-0.41	-0.28	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89497697	chr12:90107739~90112779:+
OV	cis	rs7267979	0.966	rs7270835	ENSG00000274973.1	RP13-401N8.7	-4.37	1.9e-05	0.00869	-0.32	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25454431	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6115191	ENSG00000274973.1	RP13-401N8.7	-4.37	1.9e-05	0.00869	-0.32	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25459842	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6107045	ENSG00000274973.1	RP13-401N8.7	-4.37	1.9e-05	0.00869	-0.32	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25461300	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6107046	ENSG00000274973.1	RP13-401N8.7	-4.37	1.9e-05	0.00869	-0.32	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25461413	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6107047	ENSG00000274973.1	RP13-401N8.7	-4.37	1.9e-05	0.00869	-0.32	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25461461	chr20:25845497~25845862:+
OV	cis	rs10462065	0.818	rs72750180	ENSG00000249779.1	RP11-447H19.3	-4.37	1.9e-05	0.00869	-0.53	-0.28	Nonsyndromic cleft lip with cleft palate;	chr5:44052515	chr5:43206709~43207811:+
OV	cis	rs7746199	0.736	rs17750424	ENSG00000220721.1	OR1F12	4.37	1.9e-05	0.00869	0.53	0.28	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:28073316~28074233:+
OV	cis	rs9287719	0.837	rs4233882	ENSG00000234818.1	AC092687.5	4.37	1.9e-05	0.00869	0.3	0.28	Prostate cancer;	chr2:10615438	chr2:10589166~10604830:+
OV	cis	rs4938303	0.718	rs3212282	ENSG00000254851.1	RP11-109L13.1	-4.37	1.9e-05	0.0087	-0.42	-0.28	Triglycerides;	chr11:116731229	chr11:117135528~117138582:+
OV	cis	rs875971	0.545	rs10950025	ENSG00000237310.1	GS1-124K5.4	4.37	1.9e-05	0.00871	0.32	0.28	Aortic root size;	chr7:66158946	chr7:66493706~66495474:+
OV	cis	rs875971	0.52	rs12666485	ENSG00000237310.1	GS1-124K5.4	4.37	1.9e-05	0.00871	0.32	0.28	Aortic root size;	chr7:66160135	chr7:66493706~66495474:+
OV	cis	rs875971	0.545	rs67688847	ENSG00000237310.1	GS1-124K5.4	4.37	1.9e-05	0.00871	0.32	0.28	Aortic root size;	chr7:66161064	chr7:66493706~66495474:+
OV	cis	rs875971	0.545	rs7787063	ENSG00000237310.1	GS1-124K5.4	4.37	1.9e-05	0.00871	0.32	0.28	Aortic root size;	chr7:66164012	chr7:66493706~66495474:+
OV	cis	rs875971	0.545	rs2460427	ENSG00000237310.1	GS1-124K5.4	-4.37	1.9e-05	0.00871	-0.32	-0.28	Aortic root size;	chr7:66154218	chr7:66493706~66495474:+
OV	cis	rs1850744	1	rs1850744	ENSG00000163612.10	FAM86KP	-4.37	1.9e-05	0.00871	-0.64	-0.28	Economic and political preferences;	chr4:9789088	chr4:9153296~9165451:+
OV	cis	rs9660180	0.839	rs12040826	ENSG00000215914.4	MMP23A	-4.37	1.9e-05	0.00871	-0.32	-0.28	Body mass index;	chr1:1773848	chr1:1699942~1701782:+
OV	cis	rs7927592	0.956	rs12365160	ENSG00000212093.1	AP000807.1	4.37	1.9e-05	0.00872	0.35	0.28	Total body bone mineral density;	chr11:68482951	chr11:68506083~68506166:-
OV	cis	rs7927592	0.956	rs11228256	ENSG00000212093.1	AP000807.1	4.37	1.9e-05	0.00872	0.35	0.28	Total body bone mineral density;	chr11:68483992	chr11:68506083~68506166:-
OV	cis	rs964184	0.63	rs10750096	ENSG00000254851.1	RP11-109L13.1	-4.37	1.9e-05	0.00872	-0.63	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116786072	chr11:117135528~117138582:+
OV	cis	rs7811142	1	rs11771419	ENSG00000242294.5	STAG3L5P	4.37	1.91e-05	0.00873	0.28	0.28	Platelet count;	chr7:100390780	chr7:100336079~100351900:+
OV	cis	rs10924970	0.649	rs12029822	ENSG00000236863.2	RPL23AP23	4.37	1.91e-05	0.00873	0.29	0.28	Asthma;	chr1:235218027	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs12403014	ENSG00000236863.2	RPL23AP23	4.37	1.91e-05	0.00873	0.29	0.28	Asthma;	chr1:235230648	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs12753166	ENSG00000236863.2	RPL23AP23	4.37	1.91e-05	0.00873	0.29	0.28	Asthma;	chr1:235230963	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs12745603	ENSG00000236863.2	RPL23AP23	4.37	1.91e-05	0.00873	0.29	0.28	Asthma;	chr1:235241896	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs4412584	ENSG00000236863.2	RPL23AP23	4.37	1.91e-05	0.00873	0.29	0.28	Asthma;	chr1:235254831	chr1:235295865~235296335:+
OV	cis	rs11992162	1	rs7460395	ENSG00000251402.3	FAM90A25P	4.37	1.91e-05	0.00873	0.33	0.28	Monocyte count;	chr8:11977866	chr8:12415080~12418090:-
OV	cis	rs9287719	0.578	rs10168852	ENSG00000243819.4	RN7SL832P	4.37	1.91e-05	0.00873	0.29	0.28	Prostate cancer;	chr2:10606197	chr2:10690344~10692099:+
OV	cis	rs10899021	0.92	rs12287097	ENSG00000279353.1	RP11-864N7.4	4.37	1.91e-05	0.00873	0.47	0.28	Response to metformin (IC50);	chr11:74621619	chr11:74698231~74699658:-
OV	cis	rs10899021	0.92	rs11236174	ENSG00000279353.1	RP11-864N7.4	4.37	1.91e-05	0.00873	0.47	0.28	Response to metformin (IC50);	chr11:74623156	chr11:74698231~74699658:-
OV	cis	rs4591358	0.705	rs12994849	ENSG00000223466.1	AC064834.2	-4.37	1.91e-05	0.00874	-0.32	-0.28	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195447620	chr2:195533035~195538681:+
OV	cis	rs1823913	0.637	rs4853573	ENSG00000227542.1	AC092614.2	-4.37	1.91e-05	0.00874	-0.31	-0.28	Obesity-related traits;	chr2:191295866	chr2:191229165~191246172:-
OV	cis	rs1823913	0.614	rs4853466	ENSG00000227542.1	AC092614.2	-4.37	1.91e-05	0.00874	-0.31	-0.28	Obesity-related traits;	chr2:191295943	chr2:191229165~191246172:-
OV	cis	rs9880211	1	rs67949818	ENSG00000239213.4	NCK1-AS1	4.37	1.91e-05	0.00874	0.33	0.28	Height;Body mass index;	chr3:136494136	chr3:136841726~136862054:-
OV	cis	rs17301013	0.606	rs6666588	ENSG00000227373.4	RP11-160H22.5	4.37	1.91e-05	0.00874	0.38	0.28	Systemic lupus erythematosus;	chr1:174248972	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs72713504	ENSG00000227373.4	RP11-160H22.5	4.37	1.91e-05	0.00874	0.38	0.28	Systemic lupus erythematosus;	chr1:174251916	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs72713505	ENSG00000227373.4	RP11-160H22.5	4.37	1.91e-05	0.00874	0.38	0.28	Systemic lupus erythematosus;	chr1:174255911	chr1:174115300~174160004:-
OV	cis	rs17301013	0.606	rs55698100	ENSG00000227373.4	RP11-160H22.5	4.37	1.91e-05	0.00874	0.38	0.28	Systemic lupus erythematosus;	chr1:174258295	chr1:174115300~174160004:-
OV	cis	rs6991838	0.584	rs2175810	ENSG00000200714.1	Y_RNA	-4.37	1.91e-05	0.00874	-0.37	-0.28	Intelligence (multi-trait analysis);	chr8:65643583	chr8:65592731~65592820:+
OV	cis	rs11159086	1	rs8006909	ENSG00000270000.1	RP3-449M8.9	4.37	1.91e-05	0.00875	0.43	0.28	Advanced glycation end-product levels;	chr14:74478085	chr14:74471930~74472360:-
OV	cis	rs10129255	0.536	rs8004835	ENSG00000223648.3	IGHV3-64	4.37	1.91e-05	0.00875	0.28	0.28	Kawasaki disease;	chr14:106686361	chr14:106643132~106658258:-
OV	cis	rs7302981	0.899	rs1862043	ENSG00000257298.1	RP3-405J10.3	-4.37	1.91e-05	0.00875	-0.26	-0.28	Systolic blood pressure;	chr12:50182533	chr12:50185580~50191363:-
OV	cis	rs3758911	0.751	rs590699	ENSG00000261098.1	RP11-819C21.1	4.37	1.91e-05	0.00876	0.27	0.28	Coronary artery disease;	chr11:107447553	chr11:107312132~107316271:-
OV	cis	rs875971	0.597	rs11763224	ENSG00000237310.1	GS1-124K5.4	4.37	1.92e-05	0.00878	0.33	0.28	Aortic root size;	chr7:66518628	chr7:66493706~66495474:+
OV	cis	rs638893	0.717	rs622690	ENSG00000255239.1	AP002954.6	4.37	1.92e-05	0.0088	0.43	0.28	Vitiligo;	chr11:118833556	chr11:118688039~118690600:-
OV	cis	rs6822297	0.522	rs7700108	ENSG00000240005.4	RP11-293A21.1	4.37	1.92e-05	0.0088	0.32	0.28	Obesity-related traits;	chr4:26967785	chr4:26859806~26860599:-
OV	cis	rs62244186	0.748	rs12635624	ENSG00000214820.3	MPRIPP1	4.37	1.92e-05	0.0088	0.26	0.28	Depressive symptoms;	chr3:44637006	chr3:44579938~44581026:-
OV	cis	rs4908768	0.871	rs7553298	ENSG00000228423.2	RP4-633I8.4	4.37	1.92e-05	0.0088	0.32	0.28	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8710824	chr1:8805860~8807051:-
OV	cis	rs3733585	0.699	rs6839490	ENSG00000250413.1	RP11-448G15.1	-4.37	1.92e-05	0.0088	-0.33	-0.28	Cleft plate (environmental tobacco smoke interaction);	chr4:9963376	chr4:10006482~10009725:+
OV	cis	rs10899021	1	rs11236193	ENSG00000279353.1	RP11-864N7.4	4.36	1.93e-05	0.00882	0.52	0.28	Response to metformin (IC50);	chr11:74657262	chr11:74698231~74699658:-
OV	cis	rs9326248	0.817	rs6589598	ENSG00000280143.1	AP000892.6	4.36	1.93e-05	0.00882	0.34	0.28	Blood protein levels;	chr11:117131687	chr11:117204967~117210292:+
OV	cis	rs1538970	0.962	rs7532762	ENSG00000280836.1	AL355480.1	-4.36	1.93e-05	0.00883	-0.38	-0.28	Platelet count;	chr1:45399023	chr1:45581219~45581321:-
OV	cis	rs1113500	0.933	rs61797344	ENSG00000226822.1	RP11-356N1.2	4.36	1.93e-05	0.00883	0.33	0.28	Growth-regulated protein alpha levels;	chr1:108079958	chr1:108071482~108074519:+
OV	cis	rs9880211	0.613	rs6439629	ENSG00000261758.1	RP11-102M11.2	-4.36	1.94e-05	0.00883	-0.34	-0.28	Height;Body mass index;	chr3:136182428	chr3:136752630~136755780:+
OV	cis	rs1075265	0.756	rs2160931	ENSG00000233266.1	HMGB1P31	4.36	1.94e-05	0.00883	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53712411	chr2:54051334~54051760:+
OV	cis	rs875971	0.862	rs801204	ENSG00000236529.1	RP13-254B10.1	-4.36	1.94e-05	0.00885	-0.29	-0.28	Aortic root size;	chr7:66557934	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs801203	ENSG00000236529.1	RP13-254B10.1	-4.36	1.94e-05	0.00885	-0.29	-0.28	Aortic root size;	chr7:66558025	chr7:65840212~65840596:+
OV	cis	rs875971	0.545	rs1796219	ENSG00000237310.1	GS1-124K5.4	-4.36	1.94e-05	0.00885	-0.33	-0.28	Aortic root size;	chr7:66645977	chr7:66493706~66495474:+
OV	cis	rs12815613	0.961	rs1134464	ENSG00000200795.1	RNU4-1	4.36	1.94e-05	0.00885	0.35	0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr12:120968771	chr12:120293097~120293237:-
OV	cis	rs62244186	0.748	rs4682987	ENSG00000214820.3	MPRIPP1	4.36	1.94e-05	0.00885	0.26	0.28	Depressive symptoms;	chr3:44633504	chr3:44579938~44581026:-
OV	cis	rs7671266	0.532	rs28730480	ENSG00000250413.1	RP11-448G15.1	-4.36	1.94e-05	0.00886	-0.4	-0.28	Cardiovascular disease risk factors;	chr4:10047243	chr4:10006482~10009725:+
OV	cis	rs9309473	0.847	rs4547554	ENSG00000163016.8	ALMS1P	4.36	1.94e-05	0.00886	0.34	0.28	Metabolite levels;	chr2:73640735	chr2:73644919~73685576:+
OV	cis	rs9287719	0.967	rs6432121	ENSG00000234818.1	AC092687.5	4.36	1.94e-05	0.00887	0.3	0.28	Prostate cancer;	chr2:10613678	chr2:10589166~10604830:+
OV	cis	rs4664293	0.625	rs4665102	ENSG00000226266.5	AC009961.3	4.36	1.95e-05	0.00887	0.33	0.28	Monocyte percentage of white cells;	chr2:159666076	chr2:159670708~159712435:-
OV	cis	rs7726839	0.794	rs10474792	ENSG00000271781.1	CTD-2589H19.6	-4.36	1.95e-05	0.00887	-0.36	-0.28	Obesity-related traits;	chr5:599943	chr5:675826~676616:+
OV	cis	rs1862618	0.529	rs978406	ENSG00000271828.1	CTD-2310F14.1	-4.36	1.95e-05	0.00888	-0.47	-0.28	Initial pursuit acceleration;	chr5:56963981	chr5:56927874~56929573:+
OV	cis	rs2243480	1	rs316332	ENSG00000226824.5	RP4-756H11.3	-4.36	1.95e-05	0.00889	-0.44	-0.28	Diabetic kidney disease;	chr7:66139312	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs316330	ENSG00000226824.5	RP4-756H11.3	-4.36	1.95e-05	0.00889	-0.44	-0.28	Diabetic kidney disease;	chr7:66140385	chr7:66654538~66669855:+
OV	cis	rs6772849	0.896	rs4557179	ENSG00000277250.1	Metazoa_SRP	-4.36	1.95e-05	0.00889	-0.32	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128647883	chr3:128673681~128674021:-
OV	cis	rs6964833	0.554	rs112506907	ENSG00000277072.3	STAG3L2	4.36	1.95e-05	0.00889	0.3	0.28	Menarche (age at onset);	chr7:74654407	chr7:74882163~74890610:-
OV	cis	rs7829975	0.682	rs7013471	ENSG00000253893.2	FAM85B	4.36	1.95e-05	0.0089	0.31	0.28	Mood instability;	chr8:8829815	chr8:8167819~8226614:-
OV	cis	rs6940638	0.688	rs2022272	ENSG00000220721.1	OR1F12	4.36	1.95e-05	0.0089	0.29	0.28	Intelligence (multi-trait analysis);	chr6:27135801	chr6:28073316~28074233:+
OV	cis	rs6101567	0.623	rs13042328	ENSG00000261431.1	RP4-616B8.4	4.36	1.95e-05	0.0089	0.28	0.28	Nose size;	chr20:39359885	chr20:38961925~38962111:-
OV	cis	rs875971	0.66	rs2191268	ENSG00000224316.1	RP11-479O9.2	4.36	1.96e-05	0.00891	0.29	0.28	Aortic root size;	chr7:66645237	chr7:65773620~65802067:+
OV	cis	rs295490	0.748	rs41399544	ENSG00000272656.1	RP11-219D15.3	4.36	1.96e-05	0.00891	0.51	0.28	PR interval in Tripanosoma cruzi seropositivity;	chr3:139356303	chr3:139349024~139349371:-
OV	cis	rs13113518	0.513	rs13147861	ENSG00000223305.1	RN7SKP30	4.36	1.96e-05	0.00891	0.33	0.28	Height;	chr4:55611014	chr4:55540502~55540835:-
OV	cis	rs7932354	0.502	rs10769244	ENSG00000271543.1	RP11-692M12.5	4.36	1.96e-05	0.00892	0.36	0.28	Bone mineral density (hip);Bone mineral density;	chr11:47160817	chr11:47796169~47796379:+
OV	cis	rs875971	0.964	rs6945019	ENSG00000237310.1	GS1-124K5.4	4.36	1.96e-05	0.00892	0.29	0.28	Aortic root size;	chr7:66457471	chr7:66493706~66495474:+
OV	cis	rs1950626	0.796	rs7152870	ENSG00000258399.5	MEG8	4.36	1.96e-05	0.00892	0.29	0.28	Pelvic organ prolapse (moderate/severe);	chr14:100923650	chr14:100894770~100935999:+
OV	cis	rs1555322	0.53	rs2425053	ENSG00000269202.1	RP4-614O4.12	-4.36	1.96e-05	0.00892	-0.32	-0.28	Attention deficit hyperactivity disorder;	chr20:35294017	chr20:35201747~35203288:-
OV	cis	rs8054556	1	rs12921996	ENSG00000261367.1	RP11-455F5.4	-4.36	1.96e-05	0.00893	-0.31	-0.28	Autism spectrum disorder or schizophrenia;	chr16:30000297	chr16:30107675~30110541:+
OV	cis	rs8054556	1	rs4788209	ENSG00000261367.1	RP11-455F5.4	-4.36	1.96e-05	0.00893	-0.31	-0.28	Autism spectrum disorder or schizophrenia;	chr16:30001945	chr16:30107675~30110541:+
OV	cis	rs8054556	1	rs4788210	ENSG00000261367.1	RP11-455F5.4	-4.36	1.96e-05	0.00893	-0.31	-0.28	Autism spectrum disorder or schizophrenia;	chr16:30002353	chr16:30107675~30110541:+
OV	cis	rs8054556	1	rs11150580	ENSG00000261367.1	RP11-455F5.4	-4.36	1.96e-05	0.00893	-0.31	-0.28	Autism spectrum disorder or schizophrenia;	chr16:30003243	chr16:30107675~30110541:+
OV	cis	rs8054556	1	rs3814880	ENSG00000261367.1	RP11-455F5.4	-4.36	1.96e-05	0.00893	-0.31	-0.28	Autism spectrum disorder or schizophrenia;	chr16:30006574	chr16:30107675~30110541:+
OV	cis	rs3814244	0.897	rs4141135	ENSG00000255733.4	IFNG-AS1	4.36	1.96e-05	0.00893	0.27	0.28	Itch intensity from mosquito bite adjusted by bite size;	chr12:68025050	chr12:67989445~68234686:+
OV	cis	rs5742933	1	rs1317751	ENSG00000253559.1	OSGEPL1-AS1	-4.36	1.96e-05	0.00893	-0.32	-0.28	Ferritin levels;	chr2:189807898	chr2:189762704~189765556:+
OV	cis	rs5742933	1	rs3791770	ENSG00000253559.1	OSGEPL1-AS1	-4.36	1.96e-05	0.00893	-0.32	-0.28	Ferritin levels;	chr2:189809109	chr2:189762704~189765556:+
OV	cis	rs5742933	0.948	rs62184286	ENSG00000253559.1	OSGEPL1-AS1	-4.36	1.96e-05	0.00893	-0.32	-0.28	Ferritin levels;	chr2:189812147	chr2:189762704~189765556:+
OV	cis	rs5742933	1	rs5743032	ENSG00000253559.1	OSGEPL1-AS1	-4.36	1.96e-05	0.00893	-0.32	-0.28	Ferritin levels;	chr2:189814077	chr2:189762704~189765556:+
OV	cis	rs4713118	0.955	rs34752872	ENSG00000280107.1	AL022393.9	-4.36	1.96e-05	0.00893	-0.34	-0.28	Parkinson's disease;	chr6:27715465	chr6:28170845~28172521:+
OV	cis	rs4713118	0.955	rs9380010	ENSG00000280107.1	AL022393.9	-4.36	1.96e-05	0.00893	-0.34	-0.28	Parkinson's disease;	chr6:27715793	chr6:28170845~28172521:+
OV	cis	rs4713118	0.955	rs9368528	ENSG00000280107.1	AL022393.9	-4.36	1.96e-05	0.00893	-0.34	-0.28	Parkinson's disease;	chr6:27716019	chr6:28170845~28172521:+
OV	cis	rs4713118	0.955	rs9380011	ENSG00000280107.1	AL022393.9	-4.36	1.96e-05	0.00893	-0.34	-0.28	Parkinson's disease;	chr6:27716145	chr6:28170845~28172521:+
OV	cis	rs4713118	0.955	rs9368529	ENSG00000280107.1	AL022393.9	-4.36	1.96e-05	0.00893	-0.34	-0.28	Parkinson's disease;	chr6:27716852	chr6:28170845~28172521:+
OV	cis	rs4713118	0.955	rs9380012	ENSG00000280107.1	AL022393.9	-4.36	1.96e-05	0.00893	-0.34	-0.28	Parkinson's disease;	chr6:27716875	chr6:28170845~28172521:+
OV	cis	rs4713118	0.911	rs2394000	ENSG00000280107.1	AL022393.9	-4.36	1.96e-05	0.00893	-0.34	-0.28	Parkinson's disease;	chr6:27719212	chr6:28170845~28172521:+
OV	cis	rs4713118	0.955	rs9393847	ENSG00000280107.1	AL022393.9	-4.36	1.96e-05	0.00893	-0.34	-0.28	Parkinson's disease;	chr6:27720194	chr6:28170845~28172521:+
OV	cis	rs10924970	0.649	rs12727616	ENSG00000236863.2	RPL23AP23	4.36	1.97e-05	0.00895	0.29	0.28	Asthma;	chr1:235258315	chr1:235295865~235296335:+
OV	cis	rs853679	0.513	rs13437444	ENSG00000226314.6	ZNF192P1	-4.36	1.97e-05	0.00895	-0.42	-0.28	Depression;	chr6:28103220	chr6:28161781~28169594:+
OV	cis	rs4713118	0.662	rs149961	ENSG00000226314.6	ZNF192P1	-4.36	1.97e-05	0.00896	-0.38	-0.28	Parkinson's disease;	chr6:28047791	chr6:28161781~28169594:+
OV	cis	rs964184	0.507	rs6589565	ENSG00000254851.1	RP11-109L13.1	-4.36	1.97e-05	0.00896	-0.64	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116769521	chr11:117135528~117138582:+
OV	cis	rs875971	0.545	rs73142265	ENSG00000237310.1	GS1-124K5.4	4.36	1.97e-05	0.00896	0.32	0.28	Aortic root size;	chr7:66234510	chr7:66493706~66495474:+
OV	cis	rs116095464	0.558	rs7708515	ENSG00000250848.1	CTD-2083E4.5	-4.36	1.97e-05	0.00897	-0.34	-0.28	Breast cancer;	chr5:234874	chr5:288833~290321:-
OV	cis	rs6940638	0.688	rs9393791	ENSG00000220721.1	OR1F12	4.36	1.98e-05	0.00898	0.3	0.28	Intelligence (multi-trait analysis);	chr6:27164750	chr6:28073316~28074233:+
OV	cis	rs5742933	1	rs3791773	ENSG00000253559.1	OSGEPL1-AS1	-4.36	1.98e-05	0.00898	-0.32	-0.28	Ferritin levels;	chr2:189817906	chr2:189762704~189765556:+
OV	cis	rs9287719	0.837	rs4233883	ENSG00000234818.1	AC092687.5	4.36	1.98e-05	0.00899	0.3	0.28	Prostate cancer;	chr2:10615470	chr2:10589166~10604830:+
OV	cis	rs9386630	0.691	rs2500589	ENSG00000271734.1	RP1-111B22.3	4.36	1.98e-05	0.00899	0.31	0.28	Coffee consumption;	chr6:107303136	chr6:108030249~108030718:-
OV	cis	rs1511299	0.597	rs34514405	ENSG00000249417.1	RP11-438D8.2	-4.36	1.98e-05	0.00901	-0.41	-0.28	Glomerular filtration rate;	chr3:141998599	chr3:141267353~141367137:-
OV	cis	rs17711722	0.522	rs62469933	ENSG00000226824.5	RP4-756H11.3	-4.36	1.98e-05	0.00902	-0.31	-0.28	Calcium levels;	chr7:65800652	chr7:66654538~66669855:+
OV	cis	rs6844153	0.887	rs62302532	ENSG00000240005.4	RP11-293A21.1	-4.36	1.99e-05	0.00902	-0.38	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26947150	chr4:26859806~26860599:-
OV	cis	rs6844153	0.887	rs6448488	ENSG00000240005.4	RP11-293A21.1	-4.36	1.99e-05	0.00902	-0.38	-0.28	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26949365	chr4:26859806~26860599:-
OV	cis	rs4296809	0.505	rs72751880	ENSG00000249779.1	RP11-447H19.3	-4.36	1.99e-05	0.00902	-0.52	-0.28	Brain structure;	chr5:44082496	chr5:43206709~43207811:+
OV	cis	rs4296809	0.505	rs72751887	ENSG00000249779.1	RP11-447H19.3	-4.36	1.99e-05	0.00902	-0.52	-0.28	Brain structure;	chr5:44089810	chr5:43206709~43207811:+
OV	cis	rs4296809	0.505	rs4866764	ENSG00000249779.1	RP11-447H19.3	-4.36	1.99e-05	0.00902	-0.52	-0.28	Brain structure;	chr5:44109335	chr5:43206709~43207811:+
OV	cis	rs4296809	0.505	rs72753635	ENSG00000249779.1	RP11-447H19.3	-4.36	1.99e-05	0.00902	-0.52	-0.28	Brain structure;	chr5:44111649	chr5:43206709~43207811:+
OV	cis	rs4296809	0.505	rs72753700	ENSG00000249779.1	RP11-447H19.3	-4.36	1.99e-05	0.00902	-0.52	-0.28	Brain structure;	chr5:44117575	chr5:43206709~43207811:+
OV	cis	rs4296809	0.505	rs4866766	ENSG00000249779.1	RP11-447H19.3	-4.36	1.99e-05	0.00902	-0.52	-0.28	Brain structure;	chr5:44119423	chr5:43206709~43207811:+
OV	cis	rs4296809	0.505	rs72755311	ENSG00000249779.1	RP11-447H19.3	-4.36	1.99e-05	0.00902	-0.52	-0.28	Brain structure;	chr5:44125765	chr5:43206709~43207811:+
OV	cis	rs4296809	0.505	rs72755312	ENSG00000249779.1	RP11-447H19.3	-4.36	1.99e-05	0.00902	-0.52	-0.28	Brain structure;	chr5:44127167	chr5:43206709~43207811:+
OV	cis	rs4296809	0.505	rs72755313	ENSG00000249779.1	RP11-447H19.3	-4.36	1.99e-05	0.00902	-0.52	-0.28	Brain structure;	chr5:44127576	chr5:43206709~43207811:+
OV	cis	rs4296809	0.505	rs4131426	ENSG00000249779.1	RP11-447H19.3	-4.36	1.99e-05	0.00902	-0.52	-0.28	Brain structure;	chr5:44129608	chr5:43206709~43207811:+
OV	cis	rs8062405	1	rs4451951	ENSG00000278665.1	RP11-666O2.4	4.36	1.99e-05	0.00903	0.3	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28824884	chr16:28599241~28601881:-
OV	cis	rs1950626	0.833	rs1951025	ENSG00000258399.5	MEG8	-4.36	1.99e-05	0.00903	-0.28	-0.28	Pelvic organ prolapse (moderate/severe);	chr14:100939685	chr14:100894770~100935999:+
OV	cis	rs1950626	0.827	rs35829821	ENSG00000258399.5	MEG8	-4.36	1.99e-05	0.00903	-0.28	-0.28	Pelvic organ prolapse (moderate/severe);	chr14:100943426	chr14:100894770~100935999:+
OV	cis	rs1950626	0.833	rs34463495	ENSG00000258399.5	MEG8	-4.36	1.99e-05	0.00903	-0.28	-0.28	Pelvic organ prolapse (moderate/severe);	chr14:100944849	chr14:100894770~100935999:+
OV	cis	rs1950626	0.833	rs12891189	ENSG00000258399.5	MEG8	-4.36	1.99e-05	0.00903	-0.28	-0.28	Pelvic organ prolapse (moderate/severe);	chr14:100949186	chr14:100894770~100935999:+
OV	cis	rs1950626	0.833	rs72700524	ENSG00000258399.5	MEG8	-4.36	1.99e-05	0.00903	-0.28	-0.28	Pelvic organ prolapse (moderate/severe);	chr14:100950972	chr14:100894770~100935999:+
OV	cis	rs9506514	0.509	rs9509279	ENSG00000275964.1	RP11-61K9.3	-4.36	1.99e-05	0.00904	-0.3	-0.28	Coronary artery calcification;	chr13:20559580	chr13:19863858~19865048:+
OV	cis	rs7043114	0.525	rs6479417	ENSG00000281156.1	MIR3651	-4.36	1.99e-05	0.00904	-0.3	-0.28	Height;	chr9:92302280	chr9:92292458~92292547:-
OV	cis	rs10992471	0.605	rs7872375	ENSG00000281156.1	MIR3651	-4.36	1.99e-05	0.00904	-0.3	-0.28	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92302561	chr9:92292458~92292547:-
OV	cis	rs7043114	0.525	rs1133908	ENSG00000281156.1	MIR3651	-4.36	1.99e-05	0.00904	-0.3	-0.28	Height;	chr9:92305764	chr9:92292458~92292547:-
OV	cis	rs853679	0.882	rs9380064	ENSG00000219392.1	RP1-265C24.5	-4.36	1.99e-05	0.00904	-0.47	-0.28	Depression;	chr6:28175340	chr6:28115628~28116551:+
OV	cis	rs116095464	0.614	rs10059220	ENSG00000250848.1	CTD-2083E4.5	-4.36	1.99e-05	0.00904	-0.36	-0.28	Breast cancer;	chr5:242698	chr5:288833~290321:-
OV	cis	rs881375	0.678	rs10985102	ENSG00000226752.6	PSMD5-AS1	-4.36	1.99e-05	0.00905	-0.29	-0.28	Rheumatoid arthritis;	chr9:120945219	chr9:120824828~120854385:+
OV	cis	rs4713118	0.869	rs9366700	ENSG00000219392.1	RP1-265C24.5	-4.36	2e-05	0.00906	-0.31	-0.28	Parkinson's disease;	chr6:27729172	chr6:28115628~28116551:+
OV	cis	rs4713118	0.869	rs6456802	ENSG00000219392.1	RP1-265C24.5	-4.36	2e-05	0.00906	-0.31	-0.28	Parkinson's disease;	chr6:27730576	chr6:28115628~28116551:+
OV	cis	rs4713118	0.869	rs9393851	ENSG00000219392.1	RP1-265C24.5	-4.36	2e-05	0.00906	-0.31	-0.28	Parkinson's disease;	chr6:27731802	chr6:28115628~28116551:+
OV	cis	rs4713118	0.869	rs9461400	ENSG00000219392.1	RP1-265C24.5	-4.36	2e-05	0.00906	-0.31	-0.28	Parkinson's disease;	chr6:27732780	chr6:28115628~28116551:+
OV	cis	rs4713118	0.869	rs9295742	ENSG00000219392.1	RP1-265C24.5	-4.36	2e-05	0.00906	-0.31	-0.28	Parkinson's disease;	chr6:27735053	chr6:28115628~28116551:+
OV	cis	rs4713118	0.869	rs9461401	ENSG00000219392.1	RP1-265C24.5	-4.36	2e-05	0.00906	-0.31	-0.28	Parkinson's disease;	chr6:27735512	chr6:28115628~28116551:+
OV	cis	rs4713118	0.869	rs6914924	ENSG00000219392.1	RP1-265C24.5	-4.36	2e-05	0.00906	-0.31	-0.28	Parkinson's disease;	chr6:27743751	chr6:28115628~28116551:+
OV	cis	rs4713118	0.869	rs6930992	ENSG00000219392.1	RP1-265C24.5	-4.36	2e-05	0.00906	-0.31	-0.28	Parkinson's disease;	chr6:27744341	chr6:28115628~28116551:+
OV	cis	rs4713118	0.869	rs6901520	ENSG00000219392.1	RP1-265C24.5	-4.36	2e-05	0.00906	-0.31	-0.28	Parkinson's disease;	chr6:27746796	chr6:28115628~28116551:+
OV	cis	rs4930103	0.904	rs4929984	ENSG00000232987.1	LINC01219	4.36	2e-05	0.00907	0.3	0.28	DNA methylation (variation);DNA methylation (parent-of-origin);	chr11:2003453	chr11:1991096~1993469:+
OV	cis	rs3764021	1	rs7977720	ENSG00000256673.1	RP11-599J14.2	-4.36	2e-05	0.00907	-0.26	-0.28	Type 1 diabetes;	chr12:9713753	chr12:9398355~9414851:-
OV	cis	rs7520050	0.778	rs3014238	ENSG00000281133.1	AL355480.3	4.36	2e-05	0.00907	0.31	0.28	Reticulocyte count;Red blood cell count;	chr1:45624542	chr1:45580892~45580996:-
OV	cis	rs7512898	0.522	rs7520287	ENSG00000260088.1	RP11-92G12.3	-4.36	2e-05	0.00907	-0.31	-0.28	Electrocardiographic conduction measures;	chr1:200781448	chr1:200669507~200694250:+
OV	cis	rs1797885	0.564	rs2596822	ENSG00000251774.1	RNU6-377P	-4.36	2e-05	0.00908	-0.27	-0.28	Immature fraction of reticulocytes;	chr3:12555345	chr3:12514706~12514807:+
OV	cis	rs2117029	0.767	rs10875912	ENSG00000258017.1	RP11-386G11.10	-4.36	2e-05	0.00908	-0.36	-0.28	Intelligence (multi-trait analysis);	chr12:49023161	chr12:49127782~49147869:+
OV	cis	rs73201462	1	rs2999076	ENSG00000277250.1	Metazoa_SRP	-4.36	2e-05	0.00908	-0.4	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128239849	chr3:128673681~128674021:-
OV	cis	rs11159086	1	rs4903232	ENSG00000270000.1	RP3-449M8.9	4.36	2e-05	0.00909	0.43	0.28	Advanced glycation end-product levels;	chr14:74496585	chr14:74471930~74472360:-
OV	cis	rs8062405	0.755	rs4149398	ENSG00000278665.1	RP11-666O2.4	4.36	2e-05	0.00909	0.3	0.28	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28597617	chr16:28599241~28601881:-
OV	cis	rs2070488	0.965	rs4679060	ENSG00000229589.1	ACVR2B-AS1	-4.36	2.01e-05	0.00909	-0.31	-0.28	Electrocardiographic conduction measures;	chr3:38494770	chr3:38451027~38454820:-
OV	cis	rs2070488	1	rs4147024	ENSG00000229589.1	ACVR2B-AS1	4.36	2.01e-05	0.00909	0.31	0.28	Electrocardiographic conduction measures;	chr3:38415173	chr3:38451027~38454820:-
OV	cis	rs875971	0.545	rs4718325	ENSG00000237310.1	GS1-124K5.4	4.36	2.01e-05	0.00909	0.32	0.28	Aortic root size;	chr7:66215323	chr7:66493706~66495474:+
OV	cis	rs17301013	0.507	rs1754352	ENSG00000227373.4	RP11-160H22.5	4.36	2.01e-05	0.0091	0.36	0.28	Systemic lupus erythematosus;	chr1:174835984	chr1:174115300~174160004:-
OV	cis	rs1198872	0.563	rs2005011	ENSG00000272275.1	RP11-791G15.2	-4.36	2.01e-05	0.0091	-0.35	-0.28	Cardiac Troponin-T levels;	chr2:10823799	chr2:10767875~10770058:-
OV	cis	rs1198872	0.563	rs2008967	ENSG00000272275.1	RP11-791G15.2	-4.36	2.01e-05	0.0091	-0.35	-0.28	Cardiac Troponin-T levels;	chr2:10824167	chr2:10767875~10770058:-
OV	cis	rs9309473	0.95	rs6756885	ENSG00000163016.8	ALMS1P	4.36	2.01e-05	0.00911	0.32	0.28	Metabolite levels;	chr2:73578045	chr2:73644919~73685576:+
OV	cis	rs1979679	0.573	rs4930825	ENSG00000278733.1	RP11-425D17.1	-4.36	2.01e-05	0.00911	-0.34	-0.28	Ossification of the posterior longitudinal ligament of the spine;	chr12:28574174	chr12:28185625~28186190:-
OV	cis	rs1979679	0.541	rs4931085	ENSG00000278733.1	RP11-425D17.1	-4.36	2.01e-05	0.00911	-0.34	-0.28	Ossification of the posterior longitudinal ligament of the spine;	chr12:28574577	chr12:28185625~28186190:-
OV	cis	rs1979679	0.573	rs7316056	ENSG00000278733.1	RP11-425D17.1	-4.36	2.01e-05	0.00911	-0.34	-0.28	Ossification of the posterior longitudinal ligament of the spine;	chr12:28575743	chr12:28185625~28186190:-
OV	cis	rs9309473	0.948	rs13391552	ENSG00000163016.8	ALMS1P	4.36	2.01e-05	0.00911	0.33	0.28	Metabolite levels;	chr2:73591809	chr2:73644919~73685576:+
OV	cis	rs514406	0.505	rs146750	ENSG00000206627.1	RNU6-969P	4.36	2.01e-05	0.00912	0.29	0.28	Monocyte count;	chr1:52717775	chr1:52805108~52805212:-
OV	cis	rs73201462	0.522	rs36069551	ENSG00000277250.1	Metazoa_SRP	4.35	2.01e-05	0.00913	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128095234	chr3:128673681~128674021:-
OV	cis	rs1850744	1	rs2867388	ENSG00000163612.10	FAM86KP	-4.35	2.02e-05	0.00913	-0.65	-0.28	Economic and political preferences;	chr4:9794871	chr4:9153296~9165451:+
OV	cis	rs7043114	0.507	rs10992340	ENSG00000281156.1	MIR3651	-4.35	2.02e-05	0.00913	-0.3	-0.28	Height;	chr9:92447411	chr9:92292458~92292547:-
OV	cis	rs1862618	0.853	rs43184	ENSG00000271828.1	CTD-2310F14.1	4.35	2.02e-05	0.00914	0.44	0.28	Initial pursuit acceleration;	chr5:56845950	chr5:56927874~56929573:+
OV	cis	rs1862618	0.853	rs33326	ENSG00000271828.1	CTD-2310F14.1	4.35	2.02e-05	0.00914	0.44	0.28	Initial pursuit acceleration;	chr5:56846774	chr5:56927874~56929573:+
OV	cis	rs1862618	0.802	rs33327	ENSG00000271828.1	CTD-2310F14.1	4.35	2.02e-05	0.00914	0.44	0.28	Initial pursuit acceleration;	chr5:56846866	chr5:56927874~56929573:+
OV	cis	rs1555322	0.53	rs2425047	ENSG00000269202.1	RP4-614O4.12	4.35	2.02e-05	0.00914	0.31	0.28	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35201747~35203288:-
OV	cis	rs4908768	0.906	rs10492966	ENSG00000228423.2	RP4-633I8.4	4.35	2.02e-05	0.00914	0.34	0.28	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8537946	chr1:8805860~8807051:-
OV	cis	rs5742933	1	rs12619808	ENSG00000253559.1	OSGEPL1-AS1	-4.35	2.02e-05	0.00914	-0.32	-0.28	Ferritin levels;	chr2:189776458	chr2:189762704~189765556:+
OV	cis	rs875971	0.862	rs1968126	ENSG00000236529.1	RP13-254B10.1	-4.35	2.02e-05	0.00914	-0.29	-0.28	Aortic root size;	chr7:66592017	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs6460306	ENSG00000236529.1	RP13-254B10.1	-4.35	2.02e-05	0.00914	-0.29	-0.28	Aortic root size;	chr7:66595806	chr7:65840212~65840596:+
OV	cis	rs12073359	1	rs72694919	ENSG00000223945.2	RP11-458I7.1	-4.35	2.02e-05	0.00914	-0.42	-0.28	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150104694	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs72694927	ENSG00000223945.2	RP11-458I7.1	-4.35	2.02e-05	0.00914	-0.42	-0.28	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150108545	chr1:150053864~150055034:+
OV	cis	rs4938303	0.756	rs4938301	ENSG00000254851.1	RP11-109L13.1	4.35	2.02e-05	0.00915	0.42	0.28	Triglycerides;	chr11:116704757	chr11:117135528~117138582:+
OV	cis	rs11119805	0.649	rs12562791	ENSG00000260805.2	RP11-61J19.5	-4.35	2.02e-05	0.00915	-0.43	-0.28	Stearic acid (18:0) levels;	chr1:211826964	chr1:212557833~212559731:-
OV	cis	rs11119805	0.649	rs12145721	ENSG00000260805.2	RP11-61J19.5	-4.35	2.02e-05	0.00915	-0.43	-0.28	Stearic acid (18:0) levels;	chr1:211828011	chr1:212557833~212559731:-
OV	cis	rs11119805	0.649	rs72746569	ENSG00000260805.2	RP11-61J19.5	-4.35	2.02e-05	0.00915	-0.43	-0.28	Stearic acid (18:0) levels;	chr1:211828678	chr1:212557833~212559731:-
OV	cis	rs295490	0.748	rs80249265	ENSG00000272656.1	RP11-219D15.3	4.35	2.02e-05	0.00915	0.55	0.28	PR interval in Tripanosoma cruzi seropositivity;	chr3:139371856	chr3:139349024~139349371:-
OV	cis	rs7617773	0.925	rs35942721	ENSG00000228638.1	FCF1P2	-4.35	2.02e-05	0.00915	-0.39	-0.28	Coronary artery disease;	chr3:48131579	chr3:48290793~48291375:-
OV	cis	rs72615157	0.634	rs7789890	ENSG00000242294.5	STAG3L5P	4.35	2.02e-05	0.00915	0.26	0.28	Lung function (FEV1/FVC);	chr7:100202936	chr7:100336079~100351900:+
OV	cis	rs72615157	0.634	rs79986079	ENSG00000242294.5	STAG3L5P	4.35	2.02e-05	0.00915	0.26	0.28	Lung function (FEV1/FVC);	chr7:100204421	chr7:100336079~100351900:+
OV	cis	rs17767294	0.708	rs41269275	ENSG00000220721.1	OR1F12	4.35	2.02e-05	0.00916	0.54	0.28	Parkinson's disease;	chr6:27865537	chr6:28073316~28074233:+
OV	cis	rs17767294	0.708	rs72847361	ENSG00000220721.1	OR1F12	4.35	2.02e-05	0.00916	0.54	0.28	Parkinson's disease;	chr6:27866438	chr6:28073316~28074233:+
OV	cis	rs17767294	0.708	rs34144478	ENSG00000220721.1	OR1F12	4.35	2.02e-05	0.00916	0.54	0.28	Parkinson's disease;	chr6:27866899	chr6:28073316~28074233:+
OV	cis	rs17767294	0.708	rs72847365	ENSG00000220721.1	OR1F12	4.35	2.02e-05	0.00916	0.54	0.28	Parkinson's disease;	chr6:27869449	chr6:28073316~28074233:+
OV	cis	rs9468199	0.51	rs77576207	ENSG00000220721.1	OR1F12	4.35	2.02e-05	0.00916	0.54	0.28	Parkinson's disease;	chr6:27874377	chr6:28073316~28074233:+
OV	cis	rs17767294	0.708	rs115736281	ENSG00000220721.1	OR1F12	4.35	2.02e-05	0.00916	0.54	0.28	Parkinson's disease;	chr6:27875110	chr6:28073316~28074233:+
OV	cis	rs17767294	0.522	rs78037434	ENSG00000220721.1	OR1F12	4.35	2.02e-05	0.00916	0.54	0.28	Parkinson's disease;	chr6:27881120	chr6:28073316~28074233:+
OV	cis	rs2015599	0.623	rs3782505	ENSG00000275476.1	RP11-996F15.4	4.35	2.03e-05	0.00917	0.36	0.28	Platelet count;Mean platelet volume;	chr12:29292236	chr12:29277397~29277882:-
OV	cis	rs875971	0.545	rs73376394	ENSG00000236529.1	RP13-254B10.1	4.35	2.03e-05	0.00918	0.32	0.28	Aortic root size;	chr7:66172694	chr7:65840212~65840596:+
OV	cis	rs7811142	0.943	rs67196635	ENSG00000242294.5	STAG3L5P	4.35	2.03e-05	0.00918	0.28	0.28	Platelet count;	chr7:100427941	chr7:100336079~100351900:+
OV	cis	rs7811142	1	rs6962151	ENSG00000242294.5	STAG3L5P	4.35	2.03e-05	0.00918	0.28	0.28	Platelet count;	chr7:100430861	chr7:100336079~100351900:+
OV	cis	rs7811142	0.943	rs67483801	ENSG00000242294.5	STAG3L5P	4.35	2.03e-05	0.00918	0.28	0.28	Platelet count;	chr7:100434135	chr7:100336079~100351900:+
OV	cis	rs7811142	1	rs11761784	ENSG00000242294.5	STAG3L5P	4.35	2.03e-05	0.00918	0.28	0.28	Platelet count;	chr7:100442347	chr7:100336079~100351900:+
OV	cis	rs7811142	1	rs112317829	ENSG00000242294.5	STAG3L5P	4.35	2.03e-05	0.00918	0.28	0.28	Platelet count;	chr7:100445550	chr7:100336079~100351900:+
OV	cis	rs7811142	0.943	rs28578163	ENSG00000242294.5	STAG3L5P	4.35	2.03e-05	0.00918	0.28	0.28	Platelet count;	chr7:100447131	chr7:100336079~100351900:+
OV	cis	rs7811142	1	rs67239991	ENSG00000242294.5	STAG3L5P	4.35	2.03e-05	0.00918	0.28	0.28	Platelet count;	chr7:100448881	chr7:100336079~100351900:+
OV	cis	rs7811142	0.943	rs111493473	ENSG00000242294.5	STAG3L5P	4.35	2.03e-05	0.00918	0.28	0.28	Platelet count;	chr7:100452119	chr7:100336079~100351900:+
OV	cis	rs7811142	1	rs4472444	ENSG00000242294.5	STAG3L5P	4.35	2.03e-05	0.00918	0.28	0.28	Platelet count;	chr7:100473135	chr7:100336079~100351900:+
OV	cis	rs7811142	1	rs7809801	ENSG00000242294.5	STAG3L5P	4.35	2.03e-05	0.00918	0.28	0.28	Platelet count;	chr7:100474408	chr7:100336079~100351900:+
OV	cis	rs7811142	1	rs11766752	ENSG00000242294.5	STAG3L5P	4.35	2.03e-05	0.00918	0.28	0.28	Platelet count;	chr7:100475669	chr7:100336079~100351900:+
OV	cis	rs17301013	0.606	rs4650968	ENSG00000227373.4	RP11-160H22.5	4.35	2.03e-05	0.00918	0.38	0.28	Systemic lupus erythematosus;	chr1:174223322	chr1:174115300~174160004:-
OV	cis	rs9309473	0.95	rs11126412	ENSG00000163016.8	ALMS1P	4.35	2.03e-05	0.00919	0.34	0.28	Metabolite levels;	chr2:73660507	chr2:73644919~73685576:+
OV	cis	rs7617773	0.815	rs9825637	ENSG00000228638.1	FCF1P2	-4.35	2.03e-05	0.00919	-0.35	-0.28	Coronary artery disease;	chr3:48330792	chr3:48290793~48291375:-
OV	cis	rs11715604	1	rs11715604	ENSG00000239213.4	NCK1-AS1	-4.35	2.03e-05	0.0092	-0.42	-0.28	B-cell malignancies (chronic lymphocytic leukemia, Hodgkin lymphoma or multiple myeloma) (pleiotropy);	chr3:136870707	chr3:136841726~136862054:-
OV	cis	rs10129255	0.5	rs10142931	ENSG00000223648.3	IGHV3-64	4.35	2.04e-05	0.0092	0.28	0.28	Kawasaki disease;	chr14:106782288	chr14:106643132~106658258:-
OV	cis	rs6772849	1	rs66910450	ENSG00000242551.2	POU5F1P6	-4.35	2.04e-05	0.0092	-0.33	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128585050	chr3:128674735~128677005:-
OV	cis	rs7927771	0.524	rs1056387	ENSG00000280615.1	Y_RNA	4.35	2.04e-05	0.00921	0.29	0.28	Subjective well-being;	chr11:47659818	chr11:47614898~47614994:-
OV	cis	rs9473147	0.571	rs9463335	ENSG00000270761.1	RP11-385F7.1	-4.35	2.04e-05	0.00921	-0.32	-0.28	Platelet distribution width;Mean platelet volume;	chr6:47511400	chr6:47477243~47477572:-
OV	cis	rs4713118	0.869	rs9295743	ENSG00000219392.1	RP1-265C24.5	-4.35	2.04e-05	0.00921	-0.31	-0.28	Parkinson's disease;	chr6:27747323	chr6:28115628~28116551:+
OV	cis	rs4296809	0.505	rs72753627	ENSG00000249779.1	RP11-447H19.3	-4.35	2.04e-05	0.00922	-0.52	-0.28	Brain structure;	chr5:44109810	chr5:43206709~43207811:+
OV	cis	rs2070488	1	rs7373805	ENSG00000229589.1	ACVR2B-AS1	4.35	2.04e-05	0.00922	0.31	0.28	Electrocardiographic conduction measures;	chr3:38413948	chr3:38451027~38454820:-
OV	cis	rs2070488	1	rs13074160	ENSG00000229589.1	ACVR2B-AS1	4.35	2.04e-05	0.00922	0.31	0.28	Electrocardiographic conduction measures;	chr3:38414159	chr3:38451027~38454820:-
OV	cis	rs2070488	1	rs13074025	ENSG00000229589.1	ACVR2B-AS1	4.35	2.04e-05	0.00922	0.31	0.28	Electrocardiographic conduction measures;	chr3:38414213	chr3:38451027~38454820:-
OV	cis	rs13068223	0.663	rs12107178	ENSG00000243926.1	TIPARP-AS1	4.35	2.04e-05	0.00922	0.26	0.28	Age-related hearing impairment (SNP x SNP interaction);	chr3:156756735	chr3:156671862~156674378:-
OV	cis	rs11673344	0.73	rs475026	ENSG00000226686.6	LINC01535	4.35	2.04e-05	0.00923	0.35	0.28	Obesity-related traits;	chr19:36968115	chr19:37251912~37265535:+
OV	cis	rs2243480	1	rs316313	ENSG00000226824.5	RP4-756H11.3	-4.35	2.04e-05	0.00923	-0.44	-0.28	Diabetic kidney disease;	chr7:66128561	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs316312	ENSG00000226824.5	RP4-756H11.3	-4.35	2.04e-05	0.00923	-0.44	-0.28	Diabetic kidney disease;	chr7:66131504	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs419603	ENSG00000226824.5	RP4-756H11.3	-4.35	2.04e-05	0.00923	-0.44	-0.28	Diabetic kidney disease;	chr7:66132354	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs387676	ENSG00000226824.5	RP4-756H11.3	-4.35	2.04e-05	0.00923	-0.44	-0.28	Diabetic kidney disease;	chr7:66133233	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs13310597	ENSG00000226824.5	RP4-756H11.3	-4.35	2.04e-05	0.00923	-0.44	-0.28	Diabetic kidney disease;	chr7:66133553	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs431076	ENSG00000226824.5	RP4-756H11.3	-4.35	2.04e-05	0.00923	-0.44	-0.28	Diabetic kidney disease;	chr7:66135333	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs2257790	ENSG00000226824.5	RP4-756H11.3	-4.35	2.04e-05	0.00923	-0.44	-0.28	Diabetic kidney disease;	chr7:66135463	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs2460422	ENSG00000226824.5	RP4-756H11.3	-4.35	2.04e-05	0.00923	-0.44	-0.28	Diabetic kidney disease;	chr7:66136518	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs316334	ENSG00000226824.5	RP4-756H11.3	-4.35	2.04e-05	0.00923	-0.44	-0.28	Diabetic kidney disease;	chr7:66137139	chr7:66654538~66669855:+
OV	cis	rs3733585	0.699	rs11724510	ENSG00000250413.1	RP11-448G15.1	4.35	2.04e-05	0.00923	0.31	0.28	Cleft plate (environmental tobacco smoke interaction);	chr4:9956959	chr4:10006482~10009725:+
OV	cis	rs3733585	0.699	rs28837683	ENSG00000250413.1	RP11-448G15.1	4.35	2.04e-05	0.00923	0.31	0.28	Cleft plate (environmental tobacco smoke interaction);	chr4:9958184	chr4:10006482~10009725:+
OV	cis	rs3733585	0.699	rs6449157	ENSG00000250413.1	RP11-448G15.1	4.35	2.04e-05	0.00923	0.31	0.28	Cleft plate (environmental tobacco smoke interaction);	chr4:9958818	chr4:10006482~10009725:+
OV	cis	rs3733585	0.699	rs6823361	ENSG00000250413.1	RP11-448G15.1	4.35	2.04e-05	0.00923	0.31	0.28	Cleft plate (environmental tobacco smoke interaction);	chr4:9961503	chr4:10006482~10009725:+
OV	cis	rs1823913	0.599	rs34262638	ENSG00000227542.1	AC092614.2	4.35	2.04e-05	0.00923	0.31	0.28	Obesity-related traits;	chr2:191279442	chr2:191229165~191246172:-
OV	cis	rs7829975	0.539	rs940031	ENSG00000253893.2	FAM85B	4.35	2.05e-05	0.00924	0.32	0.28	Mood instability;	chr8:8689338	chr8:8167819~8226614:-
OV	cis	rs1555322	0.53	rs8122819	ENSG00000269202.1	RP4-614O4.12	-4.35	2.05e-05	0.00924	-0.31	-0.28	Attention deficit hyperactivity disorder;	chr20:35293783	chr20:35201747~35203288:-
OV	cis	rs6772849	1	rs60228913	ENSG00000277250.1	Metazoa_SRP	-4.35	2.05e-05	0.00925	-0.33	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128592488	chr3:128673681~128674021:-
OV	cis	rs9473147	0.516	rs9395279	ENSG00000270761.1	RP11-385F7.1	-4.35	2.05e-05	0.00925	-0.31	-0.28	Platelet distribution width;Mean platelet volume;	chr6:47575128	chr6:47477243~47477572:-
OV	cis	rs9473147	0.516	rs9357546	ENSG00000270761.1	RP11-385F7.1	-4.35	2.05e-05	0.00925	-0.31	-0.28	Platelet distribution width;Mean platelet volume;	chr6:47581759	chr6:47477243~47477572:-
OV	cis	rs1823913	0.599	rs56328712	ENSG00000227542.1	AC092614.2	4.35	2.05e-05	0.00926	0.31	0.28	Obesity-related traits;	chr2:191273807	chr2:191229165~191246172:-
OV	cis	rs1823913	0.599	rs55862924	ENSG00000227542.1	AC092614.2	4.35	2.05e-05	0.00926	0.31	0.28	Obesity-related traits;	chr2:191273809	chr2:191229165~191246172:-
OV	cis	rs1823913	0.561	rs60479498	ENSG00000227542.1	AC092614.2	4.35	2.05e-05	0.00926	0.31	0.28	Obesity-related traits;	chr2:191275197	chr2:191229165~191246172:-
OV	cis	rs1823913	0.599	rs12989203	ENSG00000227542.1	AC092614.2	4.35	2.05e-05	0.00926	0.31	0.28	Obesity-related traits;	chr2:191276617	chr2:191229165~191246172:-
OV	cis	rs853679	0.766	rs9368561	ENSG00000219392.1	RP1-265C24.5	-4.35	2.05e-05	0.00927	-0.47	-0.28	Depression;	chr6:28200565	chr6:28115628~28116551:+
OV	cis	rs2239547	0.603	rs4687698	ENSG00000242142.1	SERBP1P3	4.35	2.06e-05	0.00927	0.35	0.28	Schizophrenia;	chr3:53063092	chr3:53064283~53065091:-
OV	cis	rs62184315	0.536	rs62183652	ENSG00000253559.1	OSGEPL1-AS1	-4.35	2.06e-05	0.00928	-0.38	-0.28	Alcohol dependence (age at onset);	chr2:189648877	chr2:189762704~189765556:+
OV	cis	rs62184315	0.536	rs62183653	ENSG00000253559.1	OSGEPL1-AS1	-4.35	2.06e-05	0.00928	-0.38	-0.28	Alcohol dependence (age at onset);	chr2:189650099	chr2:189762704~189765556:+
OV	cis	rs62184315	0.536	rs72920421	ENSG00000253559.1	OSGEPL1-AS1	-4.35	2.06e-05	0.00928	-0.38	-0.28	Alcohol dependence (age at onset);	chr2:189650292	chr2:189762704~189765556:+
OV	cis	rs10924970	0.649	rs9787250	ENSG00000236863.2	RPL23AP23	4.35	2.06e-05	0.00929	0.28	0.28	Asthma;	chr1:235224539	chr1:235295865~235296335:+
OV	cis	rs17741873	0.614	rs16931042	ENSG00000224195.1	RP11-574K11.5	4.35	2.06e-05	0.00929	0.42	0.28	Paclitaxel disposition in epithelial ovarian cancer;	chr10:73933165	chr10:73813518~73814737:+
OV	cis	rs2070488	0.699	rs6599205	ENSG00000229589.1	ACVR2B-AS1	4.35	2.06e-05	0.00931	0.32	0.28	Electrocardiographic conduction measures;	chr3:38487949	chr3:38451027~38454820:-
OV	cis	rs1823913	0.549	rs4516458	ENSG00000227542.1	AC092614.2	4.35	2.07e-05	0.00933	0.32	0.28	Obesity-related traits;	chr2:191325177	chr2:191229165~191246172:-
OV	cis	rs2015599	0.563	rs11050168	ENSG00000275476.1	RP11-996F15.4	4.35	2.07e-05	0.00934	0.35	0.28	Platelet count;Mean platelet volume;	chr12:29273760	chr12:29277397~29277882:-
OV	cis	rs1790761	0.505	rs17593068	ENSG00000184224.3	C11orf72	-4.35	2.07e-05	0.00934	-0.3	-0.28	Mean corpuscular volume;	chr11:67583461	chr11:67602880~67606706:-
OV	cis	rs8114671	0.967	rs6142322	ENSG00000269202.1	RP4-614O4.12	4.35	2.07e-05	0.00934	0.27	0.28	Height;	chr20:35200735	chr20:35201747~35203288:-
OV	cis	rs8114671	0.967	rs6142324	ENSG00000269202.1	RP4-614O4.12	4.35	2.07e-05	0.00934	0.27	0.28	Height;	chr20:35201240	chr20:35201747~35203288:-
OV	cis	rs7927592	0.913	rs6591346	ENSG00000212093.1	AP000807.1	4.35	2.07e-05	0.00934	0.34	0.28	Total body bone mineral density;	chr11:68617150	chr11:68506083~68506166:-
OV	cis	rs1113500	0.862	rs2336129	ENSG00000226822.1	RP11-356N1.2	-4.35	2.08e-05	0.00936	-0.33	-0.28	Growth-regulated protein alpha levels;	chr1:108098047	chr1:108071482~108074519:+
OV	cis	rs853679	0.607	rs13208096	ENSG00000220721.1	OR1F12	4.35	2.08e-05	0.00936	0.55	0.28	Depression;	chr6:28257533	chr6:28073316~28074233:+
OV	cis	rs8059260	0.668	rs8055893	ENSG00000274038.1	RP11-66H6.4	-4.35	2.08e-05	0.00936	-0.51	-0.28	Alcohol consumption over the past year;	chr16:10977938	chr16:11056556~11057034:+
OV	cis	rs2243480	1	rs437889	ENSG00000226824.5	RP4-756H11.3	-4.35	2.08e-05	0.00938	-0.46	-0.28	Diabetic kidney disease;	chr7:66044247	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs402418	ENSG00000226824.5	RP4-756H11.3	-4.35	2.08e-05	0.00938	-0.46	-0.28	Diabetic kidney disease;	chr7:66044482	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs431318	ENSG00000226824.5	RP4-756H11.3	-4.35	2.08e-05	0.00938	-0.46	-0.28	Diabetic kidney disease;	chr7:66046610	chr7:66654538~66669855:+
OV	cis	rs9393777	0.92	rs34071253	ENSG00000243307.2	POM121L6P	-4.35	2.09e-05	0.00939	-0.47	-0.28	Intelligence (multi-trait analysis);	chr6:27424023	chr6:26896952~26898777:+
OV	cis	rs10924970	0.687	rs61836127	ENSG00000236863.2	RPL23AP23	4.35	2.09e-05	0.00939	0.29	0.28	Asthma;	chr1:235200425	chr1:235295865~235296335:+
OV	cis	rs6545883	0.965	rs11887205	ENSG00000273302.1	RP11-493E12.2	4.35	2.09e-05	0.0094	0.23	0.28	Tuberculosis;	chr2:61547338	chr2:61199979~61200769:+
OV	cis	rs11673344	0.73	rs1644641	ENSG00000226686.6	LINC01535	4.35	2.09e-05	0.0094	0.35	0.28	Obesity-related traits;	chr19:36971237	chr19:37251912~37265535:+
OV	cis	rs7746199	0.611	rs17750747	ENSG00000220721.1	OR1F12	4.35	2.09e-05	0.00941	0.55	0.28	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr6:28073316~28074233:+
OV	cis	rs6126019	1	rs6126019	ENSG00000231715.1	COX6CP2	4.35	2.09e-05	0.00941	0.32	0.28	Hematocrit;Red blood cell count;	chr20:50485053	chr20:50479767~50479991:+
OV	cis	rs7968440	1	rs67701624	ENSG00000257298.1	RP3-405J10.3	4.35	2.09e-05	0.00942	0.27	0.28	Fibrinogen;	chr12:50535155	chr12:50185580~50191363:-
OV	cis	rs7968440	0.966	rs68171620	ENSG00000257298.1	RP3-405J10.3	4.35	2.09e-05	0.00942	0.27	0.28	Fibrinogen;	chr12:50543755	chr12:50185580~50191363:-
OV	cis	rs9287719	0.649	rs2024433	ENSG00000243819.4	RN7SL832P	4.35	2.09e-05	0.00942	0.28	0.28	Prostate cancer;	chr2:10591378	chr2:10690344~10692099:+
OV	cis	rs12364620	1	rs12364620	ENSG00000212093.1	AP000807.1	4.35	2.09e-05	0.00942	0.35	0.28	Total body bone mineral density (age 0-15);	chr11:68484655	chr11:68506083~68506166:-
OV	cis	rs10759883	0.651	rs7852346	ENSG00000175611.10	LINC00476	-4.35	2.1e-05	0.00942	-0.34	-0.28	Nicotine dependence;	chr9:95786167	chr9:95759231~95875977:-
OV	cis	rs9393777	0.92	rs67859638	ENSG00000220721.1	OR1F12	4.35	2.1e-05	0.00943	0.52	0.28	Intelligence (multi-trait analysis);	chr6:27390199	chr6:28073316~28074233:+
OV	cis	rs875971	0.755	rs76288834	ENSG00000237310.1	GS1-124K5.4	-4.35	2.1e-05	0.00943	-0.28	-0.28	Aortic root size;	chr7:66604815	chr7:66493706~66495474:+
OV	cis	rs56114371	0.53	rs9348774	ENSG00000220721.1	OR1F12	4.35	2.1e-05	0.00943	0.34	0.28	Breast cancer;	chr6:27721151	chr6:28073316~28074233:+
OV	cis	rs11096990	0.634	rs11947159	ENSG00000249207.1	RP11-360F5.1	4.35	2.1e-05	0.00943	0.29	0.28	Cognitive function;	chr4:39286900	chr4:39112677~39126818:-
OV	cis	rs6558530	0.932	rs7846610	ENSG00000253982.1	CTD-2336O2.1	4.35	2.1e-05	0.00944	0.3	0.28	Systolic blood pressure;	chr8:1758509	chr8:1761990~1764502:-
OV	cis	rs11083475	1	rs56113315	ENSG00000267892.1	CTD-2540F13.2	4.35	2.1e-05	0.00944	0.31	0.28	Heart rate;	chr19:38693526	chr19:38738284~38739863:+
OV	cis	rs2098713	0.535	rs4869538	ENSG00000250155.1	CTD-2353F22.1	4.34	2.11e-05	0.00946	0.33	0.28	Telomere length;	chr5:37624065	chr5:36666214~36725195:-
OV	cis	rs11673344	0.536	rs62108291	ENSG00000267422.1	CTD-2554C21.1	4.34	2.11e-05	0.00946	0.28	0.28	Obesity-related traits;	chr19:37659457	chr19:37779686~37792865:+
OV	cis	rs7617773	0.78	rs13090538	ENSG00000228638.1	FCF1P2	-4.34	2.11e-05	0.00946	-0.35	-0.28	Coronary artery disease;	chr3:48329279	chr3:48290793~48291375:-
OV	cis	rs8114671	0.967	rs4911478	ENSG00000269202.1	RP4-614O4.12	4.34	2.11e-05	0.00947	0.27	0.28	Height;	chr20:35194822	chr20:35201747~35203288:-
OV	cis	rs1979679	0.801	rs1463571	ENSG00000278733.1	RP11-425D17.1	4.34	2.11e-05	0.00947	0.32	0.28	Ossification of the posterior longitudinal ligament of the spine;	chr12:28144514	chr12:28185625~28186190:-
OV	cis	rs1723838	0.826	rs1792157	ENSG00000255928.1	RP11-456I15.2	4.34	2.11e-05	0.00947	0.65	0.28	Obesity-related traits;	chr11:73818909	chr11:73722349~73722694:+
OV	cis	rs6940638	0.688	rs7744759	ENSG00000220721.1	OR1F12	4.34	2.11e-05	0.00947	0.29	0.28	Intelligence (multi-trait analysis);	chr6:27152047	chr6:28073316~28074233:+
OV	cis	rs73201462	1	rs11709611	ENSG00000277250.1	Metazoa_SRP	4.34	2.12e-05	0.0095	0.44	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128348432	chr3:128673681~128674021:-
OV	cis	rs588177	1	rs588177	ENSG00000236935.1	AP003774.1	4.34	2.12e-05	0.0095	0.34	0.28	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr11:64256584	chr11:64325050~64329504:-
OV	cis	rs588177	0.919	rs2244625	ENSG00000236935.1	AP003774.1	4.34	2.12e-05	0.0095	0.34	0.28	High light scatter reticulocyte count;High light scatter reticulocyte percentage of red cells;	chr11:64258672	chr11:64325050~64329504:-
OV	cis	rs13068223	0.617	rs13061457	ENSG00000243926.1	TIPARP-AS1	4.34	2.12e-05	0.00951	0.26	0.28	Age-related hearing impairment (SNP x SNP interaction);	chr3:156725596	chr3:156671862~156674378:-
OV	cis	rs1584120	0.57	rs17361776	ENSG00000274885.1	RP11-268P4.6	4.34	2.12e-05	0.00951	0.32	0.28	Pelvic organ prolapse (moderate/severe);	chr12:23108719	chr12:22638464~22638943:+
OV	cis	rs5742933	1	rs55792400	ENSG00000253559.1	OSGEPL1-AS1	-4.34	2.12e-05	0.00951	-0.32	-0.28	Ferritin levels;	chr2:189686708	chr2:189762704~189765556:+
OV	cis	rs5742933	0.947	rs62185871	ENSG00000253559.1	OSGEPL1-AS1	-4.34	2.12e-05	0.00951	-0.32	-0.28	Ferritin levels;	chr2:189686980	chr2:189762704~189765556:+
OV	cis	rs875971	0.862	rs10274883	ENSG00000237310.1	GS1-124K5.4	-4.34	2.12e-05	0.00952	-0.28	-0.28	Aortic root size;	chr7:66651104	chr7:66493706~66495474:+
OV	cis	rs801193	0.569	rs881285	ENSG00000237310.1	GS1-124K5.4	-4.34	2.12e-05	0.00952	-0.28	-0.28	Aortic root size;	chr7:66654433	chr7:66493706~66495474:+
OV	cis	rs801193	0.569	rs3846973	ENSG00000237310.1	GS1-124K5.4	-4.34	2.12e-05	0.00952	-0.28	-0.28	Aortic root size;	chr7:66655048	chr7:66493706~66495474:+
OV	cis	rs801193	0.569	rs2013908	ENSG00000237310.1	GS1-124K5.4	-4.34	2.12e-05	0.00952	-0.28	-0.28	Aortic root size;	chr7:66656082	chr7:66493706~66495474:+
OV	cis	rs801193	0.548	rs2109297	ENSG00000237310.1	GS1-124K5.4	-4.34	2.12e-05	0.00952	-0.28	-0.28	Aortic root size;	chr7:66657397	chr7:66493706~66495474:+
OV	cis	rs801193	0.569	rs6978178	ENSG00000237310.1	GS1-124K5.4	-4.34	2.12e-05	0.00952	-0.28	-0.28	Aortic root size;	chr7:66658097	chr7:66493706~66495474:+
OV	cis	rs1979679	0.918	rs1533142	ENSG00000278733.1	RP11-425D17.1	-4.34	2.12e-05	0.00953	-0.35	-0.28	Ossification of the posterior longitudinal ligament of the spine;	chr12:28461206	chr12:28185625~28186190:-
OV	cis	rs7968440	1	rs7307815	ENSG00000257298.1	RP3-405J10.3	4.34	2.12e-05	0.00953	0.27	0.28	Fibrinogen;	chr12:50528927	chr12:50185580~50191363:-
OV	cis	rs9326248	1	rs9326248	ENSG00000280143.1	AP000892.6	4.34	2.12e-05	0.00953	0.32	0.28	Blood protein levels;	chr11:117128509	chr11:117204967~117210292:+
OV	cis	rs2070488	0.804	rs13092164	ENSG00000229589.1	ACVR2B-AS1	4.34	2.13e-05	0.00953	0.31	0.28	Electrocardiographic conduction measures;	chr3:38417042	chr3:38451027~38454820:-
OV	cis	rs4908768	0.629	rs4908517	ENSG00000228423.2	RP4-633I8.4	4.34	2.13e-05	0.00953	0.32	0.28	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8826946	chr1:8805860~8807051:-
OV	cis	rs4814920	0.756	rs6046400	ENSG00000275142.1	RP5-999L4.2	-4.34	2.13e-05	0.00954	-0.49	-0.28	Bipolar disorder (body mass index interaction);	chr20:19878482	chr20:19871891~19872284:+
OV	cis	rs7429990	0.864	rs7631950	ENSG00000229759.1	MRPS18AP1	-4.34	2.13e-05	0.00954	-0.3	-0.28	Educational attainment (years of education);	chr3:47591865	chr3:48256350~48256938:-
OV	cis	rs7429990	0.833	rs11716582	ENSG00000229759.1	MRPS18AP1	-4.34	2.13e-05	0.00954	-0.3	-0.28	Educational attainment (years of education);	chr3:47592269	chr3:48256350~48256938:-
OV	cis	rs7429990	0.833	rs4858801	ENSG00000229759.1	MRPS18AP1	-4.34	2.13e-05	0.00954	-0.3	-0.28	Educational attainment (years of education);	chr3:47599432	chr3:48256350~48256938:-
OV	cis	rs62244186	0.683	rs6766334	ENSG00000214820.3	MPRIPP1	4.34	2.13e-05	0.00954	0.25	0.28	Depressive symptoms;	chr3:44525573	chr3:44579938~44581026:-
OV	cis	rs9326248	0.817	rs1242127	ENSG00000280143.1	AP000892.6	-4.34	2.13e-05	0.00955	-0.32	-0.28	Blood protein levels;	chr11:117205848	chr11:117204967~117210292:+
OV	cis	rs2253762	0.54	rs11200324	ENSG00000276742.1	RP11-500G22.4	-4.34	2.13e-05	0.00955	-0.48	-0.28	Breast cancer;	chr10:122009999	chr10:121956782~121957098:+
OV	cis	rs875971	0.545	rs4441996	ENSG00000237310.1	GS1-124K5.4	-4.34	2.13e-05	0.00956	-0.32	-0.28	Aortic root size;	chr7:66123233	chr7:66493706~66495474:+
OV	cis	rs7617773	0.746	rs4371540	ENSG00000228638.1	FCF1P2	-4.34	2.13e-05	0.00956	-0.36	-0.28	Coronary artery disease;	chr3:48312053	chr3:48290793~48291375:-
OV	cis	rs7746199	0.736	rs35848276	ENSG00000280107.1	AL022393.9	-4.34	2.13e-05	0.00956	-0.58	-0.28	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27553317	chr6:28170845~28172521:+
OV	cis	rs11096990	0.819	rs2711992	ENSG00000249207.1	RP11-360F5.1	4.34	2.13e-05	0.00956	0.32	0.28	Cognitive function;	chr4:39148651	chr4:39112677~39126818:-
OV	cis	rs10986311	0.747	rs2026190	ENSG00000227200.1	RP11-121A14.3	-4.34	2.13e-05	0.00956	-0.24	-0.28	Vitiligo;	chr9:124260984	chr9:124262876~124265809:+
OV	cis	rs4728142	0.604	rs2272347	ENSG00000275106.1	RP11-309L24.10	4.34	2.14e-05	0.00957	0.35	0.28	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128979361	chr7:128952527~128953316:-
OV	cis	rs2243480	1	rs422164	ENSG00000226824.5	RP4-756H11.3	-4.34	2.14e-05	0.00958	-0.44	-0.28	Diabetic kidney disease;	chr7:66121618	chr7:66654538~66669855:+
OV	cis	rs853679	0.607	rs13207345	ENSG00000220721.1	OR1F12	4.34	2.14e-05	0.00958	0.55	0.28	Depression;	chr6:28297795	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs72854513	ENSG00000220721.1	OR1F12	4.34	2.14e-05	0.00958	0.55	0.28	Depression;	chr6:28298177	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs33932084	ENSG00000220721.1	OR1F12	4.34	2.14e-05	0.00958	0.55	0.28	Depression;	chr6:28301047	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs56189111	ENSG00000220721.1	OR1F12	4.34	2.14e-05	0.00958	0.55	0.28	Depression;	chr6:28304196	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs35072899	ENSG00000220721.1	OR1F12	4.34	2.14e-05	0.00958	0.55	0.28	Depression;	chr6:28313764	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs56075693	ENSG00000220721.1	OR1F12	4.34	2.14e-05	0.00958	0.55	0.28	Depression;	chr6:28322551	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs34218844	ENSG00000220721.1	OR1F12	4.34	2.14e-05	0.00958	0.55	0.28	Depression;	chr6:28322870	chr6:28073316~28074233:+
OV	cis	rs1113500	0.805	rs11185248	ENSG00000226822.1	RP11-356N1.2	-4.34	2.14e-05	0.00958	-0.32	-0.28	Growth-regulated protein alpha levels;	chr1:108068379	chr1:108071482~108074519:+
OV	cis	rs7017914	0.69	rs13255749	ENSG00000223220.1	Y_RNA	4.34	2.14e-05	0.00958	0.29	0.28	Bone mineral density;	chr8:70889586	chr8:70780914~70781008:-
OV	cis	rs7017914	0.69	rs11985482	ENSG00000223220.1	Y_RNA	4.34	2.14e-05	0.00958	0.29	0.28	Bone mineral density;	chr8:70898343	chr8:70780914~70781008:-
OV	cis	rs7017914	0.583	rs7838671	ENSG00000223220.1	Y_RNA	4.34	2.14e-05	0.00958	0.29	0.28	Bone mineral density;	chr8:70899057	chr8:70780914~70781008:-
OV	cis	rs1979679	1	rs1979679	ENSG00000278733.1	RP11-425D17.1	4.34	2.14e-05	0.00958	0.33	0.28	Ossification of the posterior longitudinal ligament of the spine;	chr12:28253582	chr12:28185625~28186190:-
OV	cis	rs1979679	1	rs11049487	ENSG00000278733.1	RP11-425D17.1	4.34	2.14e-05	0.00958	0.33	0.28	Ossification of the posterior longitudinal ligament of the spine;	chr12:28254157	chr12:28185625~28186190:-
OV	cis	rs1850744	1	rs1533615	ENSG00000163612.10	FAM86KP	4.34	2.14e-05	0.00959	0.69	0.28	Economic and political preferences;	chr4:9802900	chr4:9153296~9165451:+
OV	cis	rs6772849	0.896	rs9816260	ENSG00000277250.1	Metazoa_SRP	-4.34	2.14e-05	0.00959	-0.32	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128633240	chr3:128673681~128674021:-
OV	cis	rs7968440	1	rs2700485	ENSG00000272368.2	RP4-605O3.4	4.34	2.14e-05	0.00959	0.32	0.28	Fibrinogen;	chr12:50710209	chr12:50112197~50165618:+
OV	cis	rs7968440	1	rs2250752	ENSG00000272368.2	RP4-605O3.4	4.34	2.14e-05	0.00959	0.32	0.28	Fibrinogen;	chr12:50712308	chr12:50112197~50165618:+
OV	cis	rs7968440	1	rs2731434	ENSG00000272368.2	RP4-605O3.4	4.34	2.14e-05	0.00959	0.32	0.28	Fibrinogen;	chr12:50716092	chr12:50112197~50165618:+
OV	cis	rs881375	0.715	rs10985073	ENSG00000226752.6	PSMD5-AS1	-4.34	2.14e-05	0.0096	-0.29	-0.28	Rheumatoid arthritis;	chr9:120881577	chr9:120824828~120854385:+
OV	cis	rs783540	0.934	rs4779053	ENSG00000278603.1	RP13-608F4.5	4.34	2.14e-05	0.0096	0.32	0.28	Schizophrenia;	chr15:82702846	chr15:82472203~82472426:+
OV	cis	rs3733585	0.699	rs6449174	ENSG00000250413.1	RP11-448G15.1	4.34	2.15e-05	0.00962	0.31	0.28	Cleft plate (environmental tobacco smoke interaction);	chr4:9964798	chr4:10006482~10009725:+
OV	cis	rs10924970	0.967	rs12027832	ENSG00000236863.2	RPL23AP23	4.34	2.15e-05	0.00962	0.28	0.28	Asthma;	chr1:235222619	chr1:235295865~235296335:+
OV	cis	rs1113500	0.933	rs11185250	ENSG00000226822.1	RP11-356N1.2	4.34	2.15e-05	0.00962	0.33	0.28	Growth-regulated protein alpha levels;	chr1:108073795	chr1:108071482~108074519:+
OV	cis	rs1113500	0.933	rs1419003	ENSG00000226822.1	RP11-356N1.2	4.34	2.15e-05	0.00962	0.33	0.28	Growth-regulated protein alpha levels;	chr1:108074333	chr1:108071482~108074519:+
OV	cis	rs2524005	1	rs2524005	ENSG00000176998.4	HCG4	-4.34	2.15e-05	0.00963	-0.41	-0.28	Bipolar disorder and schizophrenia;	chr6:29931900	chr6:29791753~29792750:-
OV	cis	rs1823913	0.599	rs1454754	ENSG00000227542.1	AC092614.2	4.34	2.15e-05	0.00963	0.31	0.28	Obesity-related traits;	chr2:191303562	chr2:191229165~191246172:-
OV	cis	rs1823913	0.637	rs13010441	ENSG00000227542.1	AC092614.2	4.34	2.15e-05	0.00963	0.31	0.28	Obesity-related traits;	chr2:191303903	chr2:191229165~191246172:-
OV	cis	rs875971	0.545	rs10950025	ENSG00000273024.4	INTS4P2	-4.34	2.15e-05	0.00964	-0.33	-0.28	Aortic root size;	chr7:66158946	chr7:65647864~65715661:+
OV	cis	rs875971	0.52	rs12666485	ENSG00000273024.4	INTS4P2	-4.34	2.15e-05	0.00964	-0.33	-0.28	Aortic root size;	chr7:66160135	chr7:65647864~65715661:+
OV	cis	rs875971	0.545	rs67688847	ENSG00000273024.4	INTS4P2	-4.34	2.15e-05	0.00964	-0.33	-0.28	Aortic root size;	chr7:66161064	chr7:65647864~65715661:+
OV	cis	rs875971	0.545	rs7787063	ENSG00000273024.4	INTS4P2	-4.34	2.15e-05	0.00964	-0.33	-0.28	Aortic root size;	chr7:66164012	chr7:65647864~65715661:+
OV	cis	rs875971	0.545	rs2460427	ENSG00000273024.4	INTS4P2	4.34	2.15e-05	0.00964	0.33	0.28	Aortic root size;	chr7:66154218	chr7:65647864~65715661:+
OV	cis	rs9549260	0.604	rs7330618	ENSG00000229456.1	RLIMP1	4.34	2.15e-05	0.00964	0.32	0.28	Red blood cell count;	chr13:40717570	chr13:40618738~40621348:+
OV	cis	rs1979679	0.918	rs7135922	ENSG00000278733.1	RP11-425D17.1	-4.34	2.15e-05	0.00964	-0.34	-0.28	Ossification of the posterior longitudinal ligament of the spine;	chr12:28469148	chr12:28185625~28186190:-
OV	cis	rs964184	0.63	rs2160669	ENSG00000254851.1	RP11-109L13.1	-4.34	2.16e-05	0.00964	-0.64	-0.28	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116776891	chr11:117135528~117138582:+
OV	cis	rs7617773	0.78	rs3197223	ENSG00000228638.1	FCF1P2	-4.34	2.16e-05	0.00964	-0.35	-0.28	Coronary artery disease;	chr3:48294367	chr3:48290793~48291375:-
OV	cis	rs8054556	1	rs4788197	ENSG00000261367.1	RP11-455F5.4	-4.34	2.16e-05	0.00965	-0.31	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29959513	chr16:30107675~30110541:+
OV	cis	rs8054556	1	rs4788198	ENSG00000261367.1	RP11-455F5.4	-4.34	2.16e-05	0.00965	-0.31	-0.28	Autism spectrum disorder or schizophrenia;	chr16:29959514	chr16:30107675~30110541:+
OV	cis	rs8005677	0.741	rs1043675	ENSG00000279656.1	RP11-298I3.6	-4.34	2.16e-05	0.00965	-0.31	-0.28	Cognitive ability (multi-trait analysis);	chr14:22987106	chr14:23023083~23024217:-
OV	cis	rs1075265	0.868	rs4671872	ENSG00000233266.1	HMGB1P31	4.34	2.16e-05	0.00965	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:54134035	chr2:54051334~54051760:+
OV	cis	rs7017914	0.69	rs13269690	ENSG00000223220.1	Y_RNA	4.34	2.16e-05	0.00965	0.29	0.28	Bone mineral density;	chr8:70732572	chr8:70780914~70781008:-
OV	cis	rs9287719	0.934	rs6706763	ENSG00000234818.1	AC092687.5	4.34	2.16e-05	0.00965	0.29	0.28	Prostate cancer;	chr2:10611281	chr2:10589166~10604830:+
OV	cis	rs9287719	1	rs9679122	ENSG00000234818.1	AC092687.5	4.34	2.16e-05	0.00965	0.29	0.28	Prostate cancer;	chr2:10611584	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs9679581	ENSG00000234818.1	AC092687.5	4.34	2.16e-05	0.00965	0.29	0.28	Prostate cancer;	chr2:10611610	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs10203664	ENSG00000234818.1	AC092687.5	4.34	2.16e-05	0.00965	0.29	0.28	Prostate cancer;	chr2:10612251	chr2:10589166~10604830:+
OV	cis	rs9287719	0.934	rs10201077	ENSG00000234818.1	AC092687.5	4.34	2.16e-05	0.00965	0.29	0.28	Prostate cancer;	chr2:10612300	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs10203785	ENSG00000234818.1	AC092687.5	4.34	2.16e-05	0.00965	0.29	0.28	Prostate cancer;	chr2:10612382	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs9287720	ENSG00000234818.1	AC092687.5	4.34	2.16e-05	0.00965	0.29	0.28	Prostate cancer;	chr2:10612538	chr2:10589166~10604830:+
OV	cis	rs9287719	0.87	rs10167676	ENSG00000234818.1	AC092687.5	4.34	2.16e-05	0.00965	0.29	0.28	Prostate cancer;	chr2:10613014	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs12995159	ENSG00000234818.1	AC092687.5	4.34	2.16e-05	0.00965	0.29	0.28	Prostate cancer;	chr2:10613197	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs12995602	ENSG00000234818.1	AC092687.5	4.34	2.16e-05	0.00965	0.29	0.28	Prostate cancer;	chr2:10613416	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs6432119	ENSG00000234818.1	AC092687.5	4.34	2.16e-05	0.00965	0.29	0.28	Prostate cancer;	chr2:10613561	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs6432120	ENSG00000234818.1	AC092687.5	4.34	2.16e-05	0.00965	0.29	0.28	Prostate cancer;	chr2:10613645	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs6432122	ENSG00000234818.1	AC092687.5	4.34	2.16e-05	0.00965	0.29	0.28	Prostate cancer;	chr2:10613718	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs6712406	ENSG00000234818.1	AC092687.5	4.34	2.16e-05	0.00965	0.29	0.28	Prostate cancer;	chr2:10614294	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs10195802	ENSG00000234818.1	AC092687.5	4.34	2.16e-05	0.00965	0.29	0.28	Prostate cancer;	chr2:10614406	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs7563894	ENSG00000234818.1	AC092687.5	4.34	2.16e-05	0.00965	0.29	0.28	Prostate cancer;	chr2:10614523	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs7566767	ENSG00000234818.1	AC092687.5	4.34	2.16e-05	0.00965	0.29	0.28	Prostate cancer;	chr2:10614537	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs7566875	ENSG00000234818.1	AC092687.5	4.34	2.16e-05	0.00965	0.29	0.28	Prostate cancer;	chr2:10614666	chr2:10589166~10604830:+
OV	cis	rs9287719	0.934	rs4371336	ENSG00000234818.1	AC092687.5	4.34	2.16e-05	0.00965	0.29	0.28	Prostate cancer;	chr2:10615597	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs4405729	ENSG00000234818.1	AC092687.5	4.34	2.16e-05	0.00965	0.29	0.28	Prostate cancer;	chr2:10615653	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs6432126	ENSG00000234818.1	AC092687.5	4.34	2.16e-05	0.00965	0.29	0.28	Prostate cancer;	chr2:10616975	chr2:10589166~10604830:+
OV	cis	rs9287719	0.904	rs55738250	ENSG00000234818.1	AC092687.5	4.34	2.16e-05	0.00965	0.29	0.28	Prostate cancer;	chr2:10617006	chr2:10589166~10604830:+
OV	cis	rs9287719	0.934	rs6710033	ENSG00000234818.1	AC092687.5	4.34	2.16e-05	0.00965	0.29	0.28	Prostate cancer;	chr2:10617551	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs4669598	ENSG00000234818.1	AC092687.5	4.34	2.16e-05	0.00965	0.29	0.28	Prostate cancer;	chr2:10617712	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs4669599	ENSG00000234818.1	AC092687.5	4.34	2.16e-05	0.00965	0.29	0.28	Prostate cancer;	chr2:10617903	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs10167129	ENSG00000234818.1	AC092687.5	4.34	2.16e-05	0.00965	0.29	0.28	Prostate cancer;	chr2:10618449	chr2:10589166~10604830:+
OV	cis	rs1511299	0.597	rs35787200	ENSG00000249417.1	RP11-438D8.2	-4.34	2.16e-05	0.00965	-0.41	-0.28	Glomerular filtration rate;	chr3:141998913	chr3:141267353~141367137:-
OV	cis	rs17301013	0.606	rs10798307	ENSG00000227373.4	RP11-160H22.5	4.34	2.16e-05	0.00966	0.36	0.28	Systemic lupus erythematosus;	chr1:174264172	chr1:174115300~174160004:-
OV	cis	rs10829156	0.732	rs10828834	ENSG00000225527.1	RP11-383B4.4	-4.34	2.16e-05	0.00966	-0.38	-0.28	Sudden cardiac arrest;	chr10:18523505	chr10:18531849~18533336:-
OV	cis	rs10829156	0.732	rs7100884	ENSG00000225527.1	RP11-383B4.4	-4.34	2.16e-05	0.00966	-0.38	-0.28	Sudden cardiac arrest;	chr10:18523768	chr10:18531849~18533336:-
OV	cis	rs6772849	0.93	rs55987729	ENSG00000277250.1	Metazoa_SRP	-4.34	2.16e-05	0.00966	-0.32	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128621267	chr3:128673681~128674021:-
OV	cis	rs934734	0.752	rs1876518	ENSG00000234255.7	AC012370.3	-4.34	2.16e-05	0.00967	-0.3	-0.28	Rheumatoid arthritis;	chr2:65381775	chr2:65439888~65456571:-
OV	cis	rs9287719	0.649	rs6717431	ENSG00000243819.4	RN7SL832P	4.34	2.16e-05	0.00967	0.28	0.28	Prostate cancer;	chr2:10585920	chr2:10690344~10692099:+
OV	cis	rs7267979	0.899	rs6115213	ENSG00000274973.1	RP13-401N8.7	-4.34	2.16e-05	0.00967	-0.31	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25569736	chr20:25845497~25845862:+
OV	cis	rs9309473	0.904	rs78450880	ENSG00000163016.8	ALMS1P	4.34	2.17e-05	0.00968	0.33	0.28	Metabolite levels;	chr2:73594254	chr2:73644919~73685576:+
OV	cis	rs9309473	0.904	rs79145598	ENSG00000163016.8	ALMS1P	4.34	2.17e-05	0.00968	0.33	0.28	Metabolite levels;	chr2:73594255	chr2:73644919~73685576:+
OV	cis	rs9309473	0.904	rs62149783	ENSG00000163016.8	ALMS1P	4.34	2.17e-05	0.00968	0.33	0.28	Metabolite levels;	chr2:73594257	chr2:73644919~73685576:+
OV	cis	rs10924970	0.625	rs10925482	ENSG00000236863.2	RPL23AP23	4.34	2.17e-05	0.00968	0.29	0.28	Asthma;	chr1:235335948	chr1:235295865~235296335:+
OV	cis	rs853679	0.882	rs4713139	ENSG00000226314.6	ZNF192P1	-4.34	2.17e-05	0.00969	-0.49	-0.28	Depression;	chr6:28124907	chr6:28161781~28169594:+
OV	cis	rs8177876	0.749	rs75923695	ENSG00000261838.4	RP11-303E16.6	4.34	2.17e-05	0.0097	0.51	0.28	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81060289	chr16:81069854~81076598:+
OV	cis	rs3733585	0.673	rs4314284	ENSG00000250413.1	RP11-448G15.1	4.34	2.17e-05	0.0097	0.31	0.28	Cleft plate (environmental tobacco smoke interaction);	chr4:9954472	chr4:10006482~10009725:+
OV	cis	rs73019876	0.686	rs1989119	ENSG00000269742.1	BNIP3P29	-4.34	2.17e-05	0.00971	-0.32	-0.28	Testicular germ cell tumor;	chr19:22022863	chr19:22065828~22066398:-
OV	cis	rs783540	1	rs11631963	ENSG00000278603.1	RP13-608F4.5	4.34	2.17e-05	0.00971	0.32	0.28	Schizophrenia;	chr15:82649451	chr15:82472203~82472426:+
OV	cis	rs73201462	1	rs11721213	ENSG00000242551.2	POU5F1P6	-4.34	2.18e-05	0.00972	-0.43	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128348598	chr3:128674735~128677005:-
OV	cis	rs1075265	0.756	rs2542576	ENSG00000233266.1	HMGB1P31	4.34	2.18e-05	0.00972	0.34	0.28	Chronotype;Morning vs. evening chronotype;	chr2:53821659	chr2:54051334~54051760:+
OV	cis	rs1576263	0.764	rs4960453	ENSG00000230939.1	RP11-314C16.1	4.34	2.18e-05	0.00973	0.29	0.28	Photic sneeze reflex;	chr6:8692183	chr6:8784178~8785445:+
OV	cis	rs1707322	0.717	rs3014237	ENSG00000234329.1	RP11-767N6.2	-4.34	2.18e-05	0.00974	-0.3	-0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45624580	chr1:45651039~45651826:-
OV	cis	rs853679	0.882	rs9468287	ENSG00000226314.6	ZNF192P1	-4.34	2.18e-05	0.00974	-0.5	-0.28	Depression;	chr6:28111963	chr6:28161781~28169594:+
OV	cis	rs7302981	0.967	rs35549836	ENSG00000257298.1	RP3-405J10.3	4.34	2.18e-05	0.00974	0.26	0.28	Systolic blood pressure;	chr12:50159419	chr12:50185580~50191363:-
OV	cis	rs7302981	0.967	rs35998534	ENSG00000257298.1	RP3-405J10.3	4.34	2.18e-05	0.00974	0.26	0.28	Systolic blood pressure;	chr12:50162999	chr12:50185580~50191363:-
OV	cis	rs62184315	0.536	rs62185897	ENSG00000253559.1	OSGEPL1-AS1	-4.34	2.18e-05	0.00975	-0.38	-0.28	Alcohol dependence (age at onset);	chr2:189721279	chr2:189762704~189765556:+
OV	cis	rs73201462	1	rs13077913	ENSG00000277250.1	Metazoa_SRP	4.34	2.19e-05	0.00976	0.44	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128163761	chr3:128673681~128674021:-
OV	cis	rs2307022	0.671	rs9889191	ENSG00000263126.1	CTC-479C5.10	-4.34	2.19e-05	0.00977	-0.28	-0.28	Body mass index;	chr16:68343945	chr16:67882461~67886367:+
OV	cis	rs801193	0.591	rs9986881	ENSG00000237310.1	GS1-124K5.4	4.34	2.19e-05	0.00977	0.32	0.28	Aortic root size;	chr7:66708053	chr7:66493706~66495474:+
OV	cis	rs7811142	1	rs68116612	ENSG00000242294.5	STAG3L5P	4.34	2.19e-05	0.00977	0.28	0.28	Platelet count;	chr7:100408870	chr7:100336079~100351900:+
OV	cis	rs796364	0.806	rs203767	ENSG00000232732.8	AC073043.1	4.34	2.19e-05	0.00977	0.44	0.28	Schizophrenia;	chr2:200037688	chr2:199867396~199911159:-
OV	cis	rs796364	0.755	rs203762	ENSG00000232732.8	AC073043.1	4.34	2.19e-05	0.00977	0.44	0.28	Schizophrenia;	chr2:200040413	chr2:199867396~199911159:-
OV	cis	rs796364	0.806	rs12619136	ENSG00000232732.8	AC073043.1	4.34	2.19e-05	0.00977	0.44	0.28	Schizophrenia;	chr2:200045624	chr2:199867396~199911159:-
OV	cis	rs796364	0.76	rs56225698	ENSG00000232732.8	AC073043.1	4.34	2.19e-05	0.00977	0.44	0.28	Schizophrenia;	chr2:200045930	chr2:199867396~199911159:-
OV	cis	rs796364	0.806	rs78527234	ENSG00000232732.8	AC073043.1	4.34	2.19e-05	0.00977	0.44	0.28	Schizophrenia;	chr2:200048730	chr2:199867396~199911159:-
OV	cis	rs796364	0.806	rs74771155	ENSG00000232732.8	AC073043.1	4.34	2.19e-05	0.00977	0.44	0.28	Schizophrenia;	chr2:200049020	chr2:199867396~199911159:-
OV	cis	rs796364	0.806	rs79156935	ENSG00000232732.8	AC073043.1	4.34	2.19e-05	0.00977	0.44	0.28	Schizophrenia;	chr2:200049099	chr2:199867396~199911159:-
OV	cis	rs796364	0.806	rs79333757	ENSG00000232732.8	AC073043.1	4.34	2.19e-05	0.00977	0.44	0.28	Schizophrenia;	chr2:200050993	chr2:199867396~199911159:-
OV	cis	rs796364	0.806	rs11688168	ENSG00000232732.8	AC073043.1	4.34	2.19e-05	0.00977	0.44	0.28	Schizophrenia;	chr2:200051281	chr2:199867396~199911159:-
OV	cis	rs796364	0.806	rs11694236	ENSG00000232732.8	AC073043.1	4.34	2.19e-05	0.00977	0.44	0.28	Schizophrenia;	chr2:200051507	chr2:199867396~199911159:-
OV	cis	rs796364	0.806	rs11688194	ENSG00000232732.8	AC073043.1	4.34	2.19e-05	0.00977	0.44	0.28	Schizophrenia;	chr2:200051516	chr2:199867396~199911159:-
OV	cis	rs796364	0.806	rs34381014	ENSG00000232732.8	AC073043.1	4.34	2.19e-05	0.00977	0.44	0.28	Schizophrenia;	chr2:200051680	chr2:199867396~199911159:-
OV	cis	rs796364	0.76	rs56285751	ENSG00000232732.8	AC073043.1	4.34	2.19e-05	0.00977	0.44	0.28	Schizophrenia;	chr2:200055113	chr2:199867396~199911159:-
OV	cis	rs796364	0.806	rs11679658	ENSG00000232732.8	AC073043.1	4.34	2.19e-05	0.00977	0.44	0.28	Schizophrenia;	chr2:200058358	chr2:199867396~199911159:-
OV	cis	rs796364	0.806	rs1509832	ENSG00000232732.8	AC073043.1	-4.34	2.19e-05	0.00977	-0.44	-0.28	Schizophrenia;	chr2:200009720	chr2:199867396~199911159:-
OV	cis	rs796364	0.76	rs2202922	ENSG00000232732.8	AC073043.1	-4.34	2.19e-05	0.00977	-0.44	-0.28	Schizophrenia;	chr2:200017887	chr2:199867396~199911159:-
OV	cis	rs796364	0.664	rs3106089	ENSG00000232732.8	AC073043.1	-4.34	2.19e-05	0.00977	-0.44	-0.28	Schizophrenia;	chr2:200019892	chr2:199867396~199911159:-
OV	cis	rs2070488	0.775	rs6599204	ENSG00000229589.1	ACVR2B-AS1	4.33	2.19e-05	0.00977	0.32	0.28	Electrocardiographic conduction measures;	chr3:38484243	chr3:38451027~38454820:-
OV	cis	rs834811	0.523	rs1346208	ENSG00000232053.5	AC009784.3	-4.33	2.19e-05	0.00977	-0.34	-0.28	Post-traumatic stress disorder;	chr7:136219623	chr7:136092925~136437426:+
OV	cis	rs4908768	0.906	rs11121223	ENSG00000228423.2	RP4-633I8.4	4.33	2.19e-05	0.00977	0.34	0.28	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8712786	chr1:8805860~8807051:-
OV	cis	rs4296809	0.505	rs72751899	ENSG00000249779.1	RP11-447H19.3	-4.33	2.19e-05	0.00977	-0.53	-0.28	Brain structure;	chr5:44095762	chr5:43206709~43207811:+
OV	cis	rs853679	0.599	rs13193295	ENSG00000220721.1	OR1F12	4.33	2.19e-05	0.00978	0.56	0.28	Depression;	chr6:28035450	chr6:28073316~28074233:+
OV	cis	rs1729407	0.814	rs2542051	ENSG00000254851.1	RP11-109L13.1	4.33	2.19e-05	0.00978	0.35	0.28	Apolipoprotein A-IV levels;	chr11:116827022	chr11:117135528~117138582:+
OV	cis	rs9287719	0.967	rs6709466	ENSG00000234818.1	AC092687.5	4.33	2.19e-05	0.00978	0.29	0.28	Prostate cancer;	chr2:10608131	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs6719701	ENSG00000234818.1	AC092687.5	4.33	2.19e-05	0.00978	0.29	0.28	Prostate cancer;	chr2:10608157	chr2:10589166~10604830:+
OV	cis	rs9287719	0.934	rs6432115	ENSG00000234818.1	AC092687.5	4.33	2.19e-05	0.00978	0.29	0.28	Prostate cancer;	chr2:10608217	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs6432116	ENSG00000234818.1	AC092687.5	4.33	2.19e-05	0.00978	0.29	0.28	Prostate cancer;	chr2:10608489	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs2110776	ENSG00000234818.1	AC092687.5	4.33	2.19e-05	0.00978	0.29	0.28	Prostate cancer;	chr2:10608684	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs2110778	ENSG00000234818.1	AC092687.5	4.33	2.19e-05	0.00978	0.29	0.28	Prostate cancer;	chr2:10608844	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs6432117	ENSG00000234818.1	AC092687.5	4.33	2.19e-05	0.00978	0.29	0.28	Prostate cancer;	chr2:10609233	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs6432118	ENSG00000234818.1	AC092687.5	4.33	2.19e-05	0.00978	0.29	0.28	Prostate cancer;	chr2:10609315	chr2:10589166~10604830:+
OV	cis	rs9287719	0.935	rs728283	ENSG00000234818.1	AC092687.5	4.33	2.19e-05	0.00978	0.29	0.28	Prostate cancer;	chr2:10609964	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs728282	ENSG00000234818.1	AC092687.5	4.33	2.19e-05	0.00978	0.29	0.28	Prostate cancer;	chr2:10610177	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs728281	ENSG00000234818.1	AC092687.5	4.33	2.19e-05	0.00978	0.29	0.28	Prostate cancer;	chr2:10610229	chr2:10589166~10604830:+
OV	cis	rs9287719	0.934	rs6721510	ENSG00000234818.1	AC092687.5	4.33	2.19e-05	0.00978	0.29	0.28	Prostate cancer;	chr2:10610920	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs6721514	ENSG00000234818.1	AC092687.5	4.33	2.19e-05	0.00978	0.29	0.28	Prostate cancer;	chr2:10610936	chr2:10589166~10604830:+
OV	cis	rs875971	1	rs6963646	ENSG00000236529.1	RP13-254B10.1	-4.33	2.2e-05	0.0098	-0.29	-0.28	Aortic root size;	chr7:66220780	chr7:65840212~65840596:+
OV	cis	rs2070488	0.775	rs7374458	ENSG00000229589.1	ACVR2B-AS1	4.33	2.2e-05	0.0098	0.31	0.28	Electrocardiographic conduction measures;	chr3:38489720	chr3:38451027~38454820:-
OV	cis	rs4763879	0.634	rs917913	ENSG00000256673.1	RP11-599J14.2	4.33	2.2e-05	0.0098	0.26	0.28	Type 1 diabetes;	chr12:9707040	chr12:9398355~9414851:-
OV	cis	rs4763879	0.634	rs2012643	ENSG00000256673.1	RP11-599J14.2	4.33	2.2e-05	0.0098	0.26	0.28	Type 1 diabetes;	chr12:9707128	chr12:9398355~9414851:-
OV	cis	rs13113518	0.783	rs34534635	ENSG00000223305.1	RN7SKP30	4.33	2.2e-05	0.00981	0.32	0.28	Height;	chr4:55573424	chr4:55540502~55540835:-
OV	cis	rs1823913	0.503	rs6434464	ENSG00000227542.1	AC092614.2	-4.33	2.2e-05	0.00981	-0.31	-0.28	Obesity-related traits;	chr2:191341120	chr2:191229165~191246172:-
OV	cis	rs4814920	0.818	rs6046403	ENSG00000275142.1	RP5-999L4.2	-4.33	2.2e-05	0.00981	-0.49	-0.28	Bipolar disorder (body mass index interaction);	chr20:19882329	chr20:19871891~19872284:+
OV	cis	rs3758911	1	rs11212153	ENSG00000261098.1	RP11-819C21.1	-4.33	2.2e-05	0.00981	-0.26	-0.28	Coronary artery disease;	chr11:107319234	chr11:107312132~107316271:-
OV	cis	rs2243480	1	rs316322	ENSG00000226824.5	RP4-756H11.3	-4.33	2.2e-05	0.00981	-0.46	-0.28	Diabetic kidney disease;	chr7:66146246	chr7:66654538~66669855:+
OV	cis	rs2898681	0.561	rs2200225	ENSG00000248375.1	RP11-177B4.1	-4.33	2.21e-05	0.00982	-0.43	-0.28	Optic nerve measurement (cup area);	chr4:52872244	chr4:52720081~52720831:-
OV	cis	rs73201462	1	rs35724792	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128090773	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs34403909	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128091602	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs13060453	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128091895	chr3:128673681~128674021:-
OV	cis	rs73201462	0.901	rs13091198	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128093194	chr3:128673681~128674021:-
OV	cis	rs73201462	0.764	rs13092202	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128093506	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs55684215	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128093949	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs35515217	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128094968	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs11714052	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128095614	chr3:128673681~128674021:-
OV	cis	rs11709377	1	rs11709377	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1;	chr3:128096827	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs36059338	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128097084	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs34228187	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128097590	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs34562493	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128098179	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs6787614	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128098635	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs11720239	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128099112	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs34709844	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128100026	chr3:128673681~128674021:-
OV	cis	rs73201462	0.901	rs11715661	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128102003	chr3:128673681~128674021:-
OV	cis	rs73201462	0.809	rs55777628	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128103178	chr3:128673681~128674021:-
OV	cis	rs73201462	0.803	rs57897513	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128105816	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs67674204	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128105935	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs35437840	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128106463	chr3:128673681~128674021:-
OV	cis	rs73201462	0.908	rs35804055	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128107736	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs13082038	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128109613	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs13062252	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128109788	chr3:128673681~128674021:-
OV	cis	rs73201462	0.901	rs60387553	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128110125	chr3:128673681~128674021:-
OV	cis	rs35421223	1	rs35421223	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128111036	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs33998546	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128112195	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs35947214	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128114388	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs67940364	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128114510	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs6785535	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128115852	chr3:128673681~128674021:-
OV	cis	rs73201462	0.708	rs34545799	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128118665	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs11707462	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128119787	chr3:128673681~128674021:-
OV	cis	rs138573550	1	rs138573550	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1;	chr3:128121182	chr3:128673681~128674021:-
OV	cis	rs112434347	1	rs112434347	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1;	chr3:128121604	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs35531186	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128122217	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs66987356	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128122255	chr3:128673681~128674021:-
OV	cis	rs73201462	0.901	rs34172752	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128122901	chr3:128673681~128674021:-
OV	cis	rs73201462	0.901	rs60464856	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128123377	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs6784159	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128124535	chr3:128673681~128674021:-
OV	cis	rs73201462	0.901	rs56050323	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128128455	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs35145572	ENSG00000277250.1	Metazoa_SRP	4.33	2.21e-05	0.00983	0.45	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128128575	chr3:128673681~128674021:-
OV	cis	rs7927592	0.513	rs531163	ENSG00000212093.1	AP000807.1	4.33	2.21e-05	0.00985	0.32	0.28	Total body bone mineral density;	chr11:68427028	chr11:68506083~68506166:-
OV	cis	rs7520050	0.771	rs4660882	ENSG00000281133.1	AL355480.3	-4.33	2.21e-05	0.00985	-0.31	-0.28	Reticulocyte count;Red blood cell count;	chr1:45650620	chr1:45580892~45580996:-
OV	cis	rs7520050	0.778	rs3013597	ENSG00000281133.1	AL355480.3	-4.33	2.21e-05	0.00985	-0.31	-0.28	Reticulocyte count;Red blood cell count;	chr1:45662684	chr1:45580892~45580996:-
OV	cis	rs67311347	0.577	rs2371129	ENSG00000223797.4	ENTPD3-AS1	-4.33	2.21e-05	0.00985	-0.29	-0.28	Renal cell carcinoma;	chr3:40206902	chr3:40313802~40453329:-
OV	cis	rs1979679	0.918	rs7314502	ENSG00000278733.1	RP11-425D17.1	-4.33	2.21e-05	0.00985	-0.34	-0.28	Ossification of the posterior longitudinal ligament of the spine;	chr12:28462300	chr12:28185625~28186190:-
OV	cis	rs853679	1	rs68141011	ENSG00000219392.1	RP1-265C24.5	-4.33	2.22e-05	0.00986	-0.44	-0.28	Depression;	chr6:28250019	chr6:28115628~28116551:+
OV	cis	rs853679	1	rs13200462	ENSG00000219392.1	RP1-265C24.5	-4.33	2.22e-05	0.00986	-0.44	-0.28	Depression;	chr6:28250421	chr6:28115628~28116551:+
OV	cis	rs1707322	0.752	rs12062535	ENSG00000234329.1	RP11-767N6.2	4.33	2.22e-05	0.00987	0.29	0.28	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr1:45651039~45651826:-
OV	cis	rs7520050	0.966	rs4660317	ENSG00000281133.1	AL355480.3	4.33	2.22e-05	0.00987	0.31	0.28	Reticulocyte count;Red blood cell count;	chr1:45860554	chr1:45580892~45580996:-
OV	cis	rs7520050	0.931	rs6688365	ENSG00000281133.1	AL355480.3	4.33	2.22e-05	0.00987	0.31	0.28	Reticulocyte count;Red blood cell count;	chr1:45864212	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs6656992	ENSG00000281133.1	AL355480.3	4.33	2.22e-05	0.00987	0.31	0.28	Reticulocyte count;Red blood cell count;	chr1:45867396	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs61783220	ENSG00000281133.1	AL355480.3	4.33	2.22e-05	0.00987	0.31	0.28	Reticulocyte count;Red blood cell count;	chr1:45869640	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs7540325	ENSG00000281133.1	AL355480.3	4.33	2.22e-05	0.00987	0.31	0.28	Reticulocyte count;Red blood cell count;	chr1:45872545	chr1:45580892~45580996:-
OV	cis	rs7520050	1	rs7540699	ENSG00000281133.1	AL355480.3	4.33	2.22e-05	0.00987	0.31	0.28	Reticulocyte count;Red blood cell count;	chr1:45872913	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs4660319	ENSG00000281133.1	AL355480.3	4.33	2.22e-05	0.00987	0.31	0.28	Reticulocyte count;Red blood cell count;	chr1:45875951	chr1:45580892~45580996:-
OV	cis	rs7520050	0.931	rs11211213	ENSG00000281133.1	AL355480.3	4.33	2.22e-05	0.00987	0.31	0.28	Reticulocyte count;Red blood cell count;	chr1:45876845	chr1:45580892~45580996:-
OV	cis	rs1823913	0.599	rs1823912	ENSG00000227542.1	AC092614.2	4.33	2.22e-05	0.00987	0.3	0.28	Obesity-related traits;	chr2:191266388	chr2:191229165~191246172:-
OV	cis	rs3758911	0.894	rs11212179	ENSG00000261098.1	RP11-819C21.1	-4.33	2.22e-05	0.00988	-0.27	-0.28	Coronary artery disease;	chr11:107357254	chr11:107312132~107316271:-
OV	cis	rs3758911	0.856	rs11212180	ENSG00000261098.1	RP11-819C21.1	-4.33	2.22e-05	0.00988	-0.27	-0.28	Coronary artery disease;	chr11:107358630	chr11:107312132~107316271:-
OV	cis	rs3758911	0.856	rs11212181	ENSG00000261098.1	RP11-819C21.1	-4.33	2.22e-05	0.00988	-0.27	-0.28	Coronary artery disease;	chr11:107360169	chr11:107312132~107316271:-
OV	cis	rs3758911	0.894	rs11212182	ENSG00000261098.1	RP11-819C21.1	-4.33	2.22e-05	0.00988	-0.27	-0.28	Coronary artery disease;	chr11:107360879	chr11:107312132~107316271:-
OV	cis	rs3758911	0.894	rs11607304	ENSG00000261098.1	RP11-819C21.1	-4.33	2.22e-05	0.00988	-0.27	-0.28	Coronary artery disease;	chr11:107361870	chr11:107312132~107316271:-
OV	cis	rs10899021	0.92	rs11236172	ENSG00000279353.1	RP11-864N7.4	4.33	2.22e-05	0.00989	0.47	0.28	Response to metformin (IC50);	chr11:74619843	chr11:74698231~74699658:-
OV	cis	rs62229266	0.804	rs998383	ENSG00000231106.2	LINC01436	4.33	2.23e-05	0.00989	0.33	0.28	Mitral valve prolapse;	chr21:36073441	chr21:36005338~36007838:+
OV	cis	rs4722166	0.541	rs1800795	ENSG00000179428.2	AC073072.5	-4.33	2.23e-05	0.0099	-0.34	-0.28	Lung cancer;	chr7:22727026	chr7:22725395~22727620:-
OV	cis	rs4728142	0.604	rs10954215	ENSG00000275106.1	RP11-309L24.10	-4.33	2.23e-05	0.0099	-0.36	-0.28	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129005459	chr7:128952527~128953316:-
OV	cis	rs7520050	0.807	rs3013595	ENSG00000281133.1	AL355480.3	-4.33	2.23e-05	0.0099	-0.31	-0.28	Reticulocyte count;Red blood cell count;	chr1:45687531	chr1:45580892~45580996:-
OV	cis	rs7567389	0.677	rs6757492	ENSG00000236682.1	AC068282.3	4.33	2.23e-05	0.00991	0.38	0.28	Self-rated health;	chr2:127237756	chr2:127389130~127400580:+
OV	cis	rs11098499	0.863	rs1383532	ENSG00000245958.5	RP11-33B1.1	4.33	2.23e-05	0.00992	0.33	0.28	Corneal astigmatism;	chr4:119513249	chr4:119454791~119552025:+
OV	cis	rs6772849	1	rs9848975	ENSG00000277250.1	Metazoa_SRP	-4.33	2.23e-05	0.00992	-0.33	-0.28	Monocyte percentage of white cells;Monocyte count;	chr3:128593140	chr3:128673681~128674021:-
OV	cis	rs2070488	1	rs17733640	ENSG00000229589.1	ACVR2B-AS1	4.33	2.24e-05	0.00994	0.3	0.28	Electrocardiographic conduction measures;	chr3:38405251	chr3:38451027~38454820:-
OV	cis	rs1979679	0.719	rs11049489	ENSG00000278733.1	RP11-425D17.1	4.33	2.24e-05	0.00994	0.33	0.28	Ossification of the posterior longitudinal ligament of the spine;	chr12:28259482	chr12:28185625~28186190:-
OV	cis	rs11673344	0.536	rs62108291	ENSG00000226686.6	LINC01535	4.33	2.24e-05	0.00995	0.36	0.28	Obesity-related traits;	chr19:37659457	chr19:37251912~37265535:+
OV	cis	rs992157	0.835	rs11677953	ENSG00000261338.2	RP11-378A13.1	-4.33	2.24e-05	0.00995	-0.33	-0.28	Colorectal cancer;	chr2:218256940	chr2:218255319~218257366:+
OV	cis	rs10121140	0.576	rs10961466	ENSG00000234297.2	RP11-54D18.4	-4.33	2.24e-05	0.00995	-0.32	-0.28	Coronary artery disease;	chr9:14292881	chr9:15055057~15056052:+
OV	cis	rs2070488	0.965	rs2126534	ENSG00000229589.1	ACVR2B-AS1	4.33	2.24e-05	0.00996	0.3	0.28	Electrocardiographic conduction measures;	chr3:38403674	chr3:38451027~38454820:-
OV	cis	rs2243480	1	rs313803	ENSG00000226824.5	RP4-756H11.3	-4.33	2.25e-05	0.00997	-0.46	-0.28	Diabetic kidney disease;	chr7:66049744	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs313802	ENSG00000226824.5	RP4-756H11.3	-4.33	2.25e-05	0.00997	-0.46	-0.28	Diabetic kidney disease;	chr7:66051386	chr7:66654538~66669855:+
OV	cis	rs2243480	0.803	rs403089	ENSG00000226824.5	RP4-756H11.3	-4.33	2.25e-05	0.00997	-0.46	-0.28	Diabetic kidney disease;	chr7:66052736	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs458291	ENSG00000226824.5	RP4-756H11.3	-4.33	2.25e-05	0.00997	-0.46	-0.28	Diabetic kidney disease;	chr7:66055492	chr7:66654538~66669855:+
OV	cis	rs14027	0.921	rs7813651	ENSG00000279347.1	RP11-85I17.2	-4.33	2.25e-05	0.00997	-0.29	-0.28	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119839119	chr8:119838736~119840385:-
OV	cis	rs9287719	0.614	rs10929678	ENSG00000243819.4	RN7SL832P	4.33	2.25e-05	0.00997	0.29	0.28	Prostate cancer;	chr2:10582969	chr2:10690344~10692099:+
OV	cis	rs1329650	1	rs1329650	ENSG00000228701.1	TNKS2-AS1	4.33	2.25e-05	0.00998	0.31	0.28	Smoking behavior;	chr10:91588363	chr10:91782839~91798291:-
OV	cis	rs796364	0.951	rs12996313	ENSG00000232732.8	AC073043.1	4.33	2.25e-05	0.00998	0.41	0.28	Schizophrenia;	chr2:200133193	chr2:199867396~199911159:-
OV	cis	rs7968440	0.933	rs7308872	ENSG00000272368.2	RP4-605O3.4	-4.33	2.25e-05	0.00998	-0.31	-0.28	Fibrinogen;	chr12:50726391	chr12:50112197~50165618:+
OV	cis	rs7746199	0.736	rs34573979	ENSG00000280107.1	AL022393.9	-4.33	2.25e-05	0.00999	-0.58	-0.28	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr6:28170845~28172521:+
OV	cis	rs4938303	0.589	rs11601584	ENSG00000254851.1	RP11-109L13.1	4.33	2.26e-05	0.01	0.38	0.28	Triglycerides;	chr11:116700568	chr11:117135528~117138582:+
OV	cis	rs801193	1	rs10234018	ENSG00000224316.1	RP11-479O9.2	-4.33	2.26e-05	0.01	-0.29	-0.28	Aortic root size;	chr7:66681297	chr7:65773620~65802067:+
OV	cis	rs9287719	0.649	rs10929684	ENSG00000243819.4	RN7SL832P	-4.33	2.26e-05	0.01	-0.28	-0.28	Prostate cancer;	chr2:10592098	chr2:10690344~10692099:+
OV	cis	rs7302981	0.899	rs4883481	ENSG00000257298.1	RP3-405J10.3	-4.33	2.26e-05	0.01	-0.26	-0.28	Systolic blood pressure;	chr12:50180528	chr12:50185580~50191363:-
OV	cis	rs9828933	0.752	rs13434089	ENSG00000280620.1	SCAANT1	-4.33	2.26e-05	0.01	-0.51	-0.28	Type 2 diabetes;	chr3:63962890	chr3:63911518~63911772:-
OV	cis	rs10924970	0.625	rs12730441	ENSG00000236863.2	RPL23AP23	4.33	2.26e-05	0.01	0.29	0.28	Asthma;	chr1:235334744	chr1:235295865~235296335:+
OV	cis	rs4654783	0.521	rs59709264	ENSG00000228397.1	RP1-224A6.3	4.33	2.26e-05	0.01	0.31	0.28	Endometriosis;	chr1:22122832	chr1:22023994~22024968:-
OV	cis	rs7267979	0.932	rs6132848	ENSG00000274973.1	RP13-401N8.7	-4.33	2.26e-05	0.01	-0.31	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25581009	chr20:25845497~25845862:+
OV	cis	rs7267979	0.932	rs6115215	ENSG00000274973.1	RP13-401N8.7	-4.33	2.26e-05	0.01	-0.31	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25581864	chr20:25845497~25845862:+
OV	cis	rs7267979	0.866	rs6138609	ENSG00000274973.1	RP13-401N8.7	-4.33	2.26e-05	0.01	-0.31	-0.28	Liver enzyme levels (alkaline phosphatase);	chr20:25590349	chr20:25845497~25845862:+
OV	cis	rs7617773	0.817	rs11130163	ENSG00000228638.1	FCF1P2	-4.33	2.27e-05	0.01	-0.33	-0.28	Coronary artery disease;	chr3:48271168	chr3:48290793~48291375:-
OV	cis	rs10924970	0.687	rs10802286	ENSG00000236863.2	RPL23AP23	-4.33	2.27e-05	0.01	-0.29	-0.28	Asthma;	chr1:235185924	chr1:235295865~235296335:+
OV	cis	rs6460942	0.778	rs17444259	ENSG00000226690.5	AC005281.1	4.33	2.27e-05	0.01	0.42	0.28	Coronary artery disease;	chr7:12422802	chr7:12496429~12541910:+
OV	cis	rs1113500	0.933	rs4593854	ENSG00000226822.1	RP11-356N1.2	4.33	2.27e-05	0.0101	0.32	0.28	Growth-regulated protein alpha levels;	chr1:108095897	chr1:108071482~108074519:+
OV	cis	rs1723838	0.826	rs2462617	ENSG00000255928.1	RP11-456I15.2	4.33	2.27e-05	0.0101	0.64	0.28	Obesity-related traits;	chr11:73800651	chr11:73722349~73722694:+
OV	cis	rs7615952	0.736	rs9866347	ENSG00000171084.14	FAM86JP	4.33	2.27e-05	0.0101	0.6	0.28	Blood pressure (smoking interaction);	chr3:125951082	chr3:125916620~125930024:+
OV	cis	rs1823913	0.599	rs17511410	ENSG00000227542.1	AC092614.2	4.33	2.27e-05	0.0101	0.31	0.28	Obesity-related traits;	chr2:191278043	chr2:191229165~191246172:-
OV	cis	rs181553	0.664	rs1838963	ENSG00000266696.1	RP11-30L3.2	4.33	2.27e-05	0.0101	0.34	0.28	Hip circumference adjusted for BMI;	chr18:49153498	chr18:49205912~49208781:+
OV	cis	rs7635879	0.702	rs4687494	ENSG00000230102.6	RP11-407B7.1	-4.33	2.28e-05	0.0101	-0.31	-0.28	Breastfeeding duration;	chr3:194010581	chr3:194005259~194070970:-
OV	cis	rs7043114	0.525	rs7847929	ENSG00000281156.1	MIR3651	-4.33	2.28e-05	0.0101	-0.3	-0.28	Height;	chr9:92391962	chr9:92292458~92292547:-
OV	cis	rs7043114	0.507	rs10820971	ENSG00000281156.1	MIR3651	-4.33	2.28e-05	0.0101	-0.3	-0.28	Height;	chr9:92399458	chr9:92292458~92292547:-
OV	cis	rs7646881	0.544	rs16847130	ENSG00000272440.1	RP11-379F4.6	4.33	2.28e-05	0.0101	0.41	0.28	Tetralogy of Fallot;	chr3:158705785	chr3:158695367~158695581:+
OV	cis	rs2015599	0.514	rs10843376	ENSG00000275476.1	RP11-996F15.4	4.33	2.28e-05	0.0101	0.35	0.28	Platelet count;Mean platelet volume;	chr12:29283651	chr12:29277397~29277882:-
OV	cis	rs2274471	0.645	rs3780376	ENSG00000234534.1	CSNK1G2P1	4.33	2.28e-05	0.0101	0.34	0.28	Crohn's disease;	chr9:5109485	chr9:5040945~5041940:+
OV	cis	rs11096990	0.656	rs6531709	ENSG00000249207.1	RP11-360F5.1	4.33	2.28e-05	0.0101	0.29	0.28	Cognitive function;	chr4:39300629	chr4:39112677~39126818:-
OV	cis	rs7555523	0.887	rs4657475	ENSG00000224358.1	RP11-466F5.8	-4.32	2.29e-05	0.0101	-0.37	-0.28	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165717938	chr1:165768929~165775176:+
OV	cis	rs7555523	0.887	rs4656461	ENSG00000224358.1	RP11-466F5.8	-4.32	2.29e-05	0.0101	-0.37	-0.28	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165717968	chr1:165768929~165775176:+
OV	cis	rs934734	0.563	rs955903	ENSG00000234255.7	AC012370.3	4.32	2.29e-05	0.0101	0.3	0.28	Rheumatoid arthritis;	chr2:65348419	chr2:65439888~65456571:-
OV	cis	rs7520050	0.966	rs2486447	ENSG00000281133.1	AL355480.3	4.32	2.29e-05	0.0101	0.32	0.28	Reticulocyte count;Red blood cell count;	chr1:46080052	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs1085244	ENSG00000281133.1	AL355480.3	4.32	2.29e-05	0.0101	0.32	0.28	Reticulocyte count;Red blood cell count;	chr1:46098008	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs6662641	ENSG00000281133.1	AL355480.3	4.32	2.29e-05	0.0101	0.32	0.28	Reticulocyte count;Red blood cell count;	chr1:46105837	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs1707335	ENSG00000281133.1	AL355480.3	4.32	2.29e-05	0.0101	0.32	0.28	Reticulocyte count;Red blood cell count;	chr1:46106249	chr1:45580892~45580996:-
OV	cis	rs4814920	0.818	rs6035467	ENSG00000275142.1	RP5-999L4.2	-4.32	2.29e-05	0.0101	-0.49	-0.28	Bipolar disorder (body mass index interaction);	chr20:19879602	chr20:19871891~19872284:+
OV	cis	rs853679	0.824	rs34712084	ENSG00000226314.6	ZNF192P1	-4.32	2.29e-05	0.0101	-0.5	-0.28	Depression;	chr6:28076050	chr6:28161781~28169594:+
OV	cis	rs853679	0.824	rs1321505	ENSG00000226314.6	ZNF192P1	-4.32	2.29e-05	0.0101	-0.5	-0.28	Depression;	chr6:28085045	chr6:28161781~28169594:+
OV	cis	rs17767294	0.708	rs72847370	ENSG00000219392.1	RP1-265C24.5	-4.32	2.29e-05	0.0101	-0.55	-0.28	Parkinson's disease;	chr6:27881646	chr6:28115628~28116551:+
OV	cis	rs17767294	0.708	rs113741085	ENSG00000219392.1	RP1-265C24.5	-4.32	2.29e-05	0.0101	-0.55	-0.28	Parkinson's disease;	chr6:27882204	chr6:28115628~28116551:+
OV	cis	rs4296809	0.505	rs10434608	ENSG00000249779.1	RP11-447H19.3	-4.32	2.29e-05	0.0101	-0.53	-0.28	Brain structure;	chr5:44053514	chr5:43206709~43207811:+
OV	cis	rs9979383	0.576	rs719301	ENSG00000228107.1	AP000692.9	4.32	2.29e-05	0.0101	0.29	0.28	Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr21:35430205	chr21:36360630~36362040:+
OV	cis	rs9979383	0.538	rs1882766	ENSG00000228107.1	AP000692.9	4.32	2.29e-05	0.0101	0.29	0.28	Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr21:35438861	chr21:36360630~36362040:+
OV	cis	rs514406	0.571	rs11206004	ENSG00000206627.1	RNU6-969P	-4.32	2.29e-05	0.0101	-0.29	-0.28	Monocyte count;	chr1:52745286	chr1:52805108~52805212:-
OV	cis	rs1723838	1	rs1723846	ENSG00000255928.1	RP11-456I15.2	4.32	2.3e-05	0.0102	0.57	0.28	Obesity-related traits;	chr11:73788869	chr11:73722349~73722694:+
OV	cis	rs11903757	1	rs6759665	ENSG00000281467.1	Clostridiales-1	-4.32	2.3e-05	0.0102	-0.47	-0.28	Colorectal cancer;	chr2:191724728	chr2:191699476~191699631:-
OV	cis	rs56114371	0.53	rs9357045	ENSG00000220721.1	OR1F12	4.32	2.3e-05	0.0102	0.34	0.28	Breast cancer;	chr6:27721148	chr6:28073316~28074233:+
OV	cis	rs8054556	1	rs4283241	ENSG00000261367.1	RP11-455F5.4	4.32	2.3e-05	0.0102	0.3	0.28	Autism spectrum disorder or schizophrenia;	chr16:29977028	chr16:30107675~30110541:+
OV	cis	rs10924970	0.601	rs2803847	ENSG00000236863.2	RPL23AP23	4.32	2.3e-05	0.0102	0.29	0.28	Asthma;	chr1:235340296	chr1:235295865~235296335:+
OV	cis	rs73201462	1	rs11706908	ENSG00000277250.1	Metazoa_SRP	4.32	2.3e-05	0.0102	0.41	0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128314205	chr3:128673681~128674021:-
OV	cis	rs9309473	1	rs56672945	ENSG00000163016.8	ALMS1P	4.32	2.3e-05	0.0102	0.32	0.28	Metabolite levels;	chr2:73395535	chr2:73644919~73685576:+
OV	cis	rs9309473	1	rs60844734	ENSG00000163016.8	ALMS1P	4.32	2.3e-05	0.0102	0.32	0.28	Metabolite levels;	chr2:73396077	chr2:73644919~73685576:+
OV	cis	rs9309473	1	rs11899902	ENSG00000163016.8	ALMS1P	4.32	2.3e-05	0.0102	0.32	0.28	Metabolite levels;	chr2:73404436	chr2:73644919~73685576:+
OV	cis	rs763121	0.962	rs2071887	ENSG00000273076.1	RP3-508I15.22	4.32	2.31e-05	0.0102	0.28	0.28	Menopause (age at onset);	chr22:38483005	chr22:38743495~38743910:+
OV	cis	rs796364	0.951	rs72932280	ENSG00000232732.8	AC073043.1	4.32	2.31e-05	0.0102	0.41	0.28	Schizophrenia;	chr2:200132128	chr2:199867396~199911159:-
OV	cis	rs7429990	0.864	rs12492915	ENSG00000229759.1	MRPS18AP1	-4.32	2.31e-05	0.0102	-0.3	-0.28	Educational attainment (years of education);	chr3:47636545	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs12636863	ENSG00000229759.1	MRPS18AP1	-4.32	2.31e-05	0.0102	-0.3	-0.28	Educational attainment (years of education);	chr3:47638629	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs7613934	ENSG00000229759.1	MRPS18AP1	-4.32	2.31e-05	0.0102	-0.3	-0.28	Educational attainment (years of education);	chr3:47640681	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs7621236	ENSG00000229759.1	MRPS18AP1	-4.32	2.31e-05	0.0102	-0.3	-0.28	Educational attainment (years of education);	chr3:47646677	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs7624474	ENSG00000229759.1	MRPS18AP1	-4.32	2.31e-05	0.0102	-0.3	-0.28	Educational attainment (years of education);	chr3:47647786	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs4858846	ENSG00000229759.1	MRPS18AP1	-4.32	2.31e-05	0.0102	-0.3	-0.28	Educational attainment (years of education);	chr3:47654591	chr3:48256350~48256938:-
OV	cis	rs7429990	0.803	rs13081356	ENSG00000229759.1	MRPS18AP1	-4.32	2.31e-05	0.0102	-0.3	-0.28	Educational attainment (years of education);	chr3:47660067	chr3:48256350~48256938:-
OV	cis	rs7429990	0.803	rs11130145	ENSG00000229759.1	MRPS18AP1	-4.32	2.31e-05	0.0102	-0.3	-0.28	Educational attainment (years of education);	chr3:47661780	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs11130146	ENSG00000229759.1	MRPS18AP1	-4.32	2.31e-05	0.0102	-0.3	-0.28	Educational attainment (years of education);	chr3:47666322	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs12633604	ENSG00000229759.1	MRPS18AP1	-4.32	2.31e-05	0.0102	-0.3	-0.28	Educational attainment (years of education);	chr3:47673308	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs6772301	ENSG00000229759.1	MRPS18AP1	-4.32	2.31e-05	0.0102	-0.3	-0.28	Educational attainment (years of education);	chr3:47682366	chr3:48256350~48256938:-
OV	cis	rs4787491	0.729	rs11642399	ENSG00000261367.1	RP11-455F5.4	-4.32	2.31e-05	0.0102	-0.3	-0.28	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30048272	chr16:30107675~30110541:+
OV	cis	rs1150668	0.83	rs2531831	ENSG00000204709.4	LINC01556	4.32	2.31e-05	0.0102	0.31	0.28	Pubertal anthropometrics;	chr6:28420988	chr6:28943877~28944537:+
OV	cis	rs853679	0.517	rs2273564	ENSG00000226314.6	ZNF192P1	-4.32	2.31e-05	0.0102	-0.36	-0.28	Depression;	chr6:28089816	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs1853097	ENSG00000226314.6	ZNF192P1	-4.32	2.31e-05	0.0102	-0.36	-0.28	Depression;	chr6:28090857	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9393887	ENSG00000226314.6	ZNF192P1	-4.32	2.31e-05	0.0102	-0.36	-0.28	Depression;	chr6:28091242	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9393888	ENSG00000226314.6	ZNF192P1	-4.32	2.31e-05	0.0102	-0.36	-0.28	Depression;	chr6:28091439	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs3734573	ENSG00000226314.6	ZNF192P1	-4.32	2.31e-05	0.0102	-0.36	-0.28	Depression;	chr6:28091659	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9368551	ENSG00000226314.6	ZNF192P1	-4.32	2.31e-05	0.0102	-0.36	-0.28	Depression;	chr6:28094014	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9393890	ENSG00000226314.6	ZNF192P1	-4.32	2.31e-05	0.0102	-0.36	-0.28	Depression;	chr6:28096077	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9366715	ENSG00000226314.6	ZNF192P1	-4.32	2.31e-05	0.0102	-0.36	-0.28	Depression;	chr6:28096855	chr6:28161781~28169594:+
OV	cis	rs853679	0.598	rs9380054	ENSG00000226314.6	ZNF192P1	-4.32	2.31e-05	0.0102	-0.36	-0.28	Depression;	chr6:28099759	chr6:28161781~28169594:+
OV	cis	rs4713118	0.547	rs2116981	ENSG00000226314.6	ZNF192P1	-4.32	2.31e-05	0.0102	-0.36	-0.28	Parkinson's disease;	chr6:28100173	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9368552	ENSG00000226314.6	ZNF192P1	-4.32	2.31e-05	0.0102	-0.36	-0.28	Depression;	chr6:28100648	chr6:28161781~28169594:+
OV	cis	rs853679	0.542	rs34131763	ENSG00000226314.6	ZNF192P1	-4.32	2.31e-05	0.0102	-0.36	-0.28	Depression;	chr6:28107222	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs35193936	ENSG00000226314.6	ZNF192P1	-4.32	2.31e-05	0.0102	-0.36	-0.28	Depression;	chr6:28108492	chr6:28161781~28169594:+
OV	cis	rs875971	0.898	rs6977501	ENSG00000236529.1	RP13-254B10.1	-4.32	2.31e-05	0.0102	-0.29	-0.28	Aortic root size;	chr7:66228355	chr7:65840212~65840596:+
OV	cis	rs7259376	0.875	rs9304996	ENSG00000269742.1	BNIP3P29	4.32	2.31e-05	0.0102	0.32	0.28	Menopause (age at onset);	chr19:22303733	chr19:22065828~22066398:-
OV	cis	rs7259376	0.875	rs4932755	ENSG00000269742.1	BNIP3P29	4.32	2.31e-05	0.0102	0.32	0.28	Menopause (age at onset);	chr19:22312014	chr19:22065828~22066398:-
OV	cis	rs7259376	0.807	rs7254434	ENSG00000269742.1	BNIP3P29	4.32	2.31e-05	0.0102	0.32	0.28	Menopause (age at onset);	chr19:22317231	chr19:22065828~22066398:-
OV	cis	rs7116641	0.961	rs35243581	ENSG00000246250.2	RP11-613D13.5	4.32	2.31e-05	0.0102	0.31	0.28	Coronary artery disease;	chr11:43685814	chr11:43829709~43880726:-
OV	cis	rs2239557	0.961	rs10133356	ENSG00000259065.1	RP5-1021I20.1	4.32	2.31e-05	0.0102	0.33	0.28	Common traits (Other);	chr14:74181056	chr14:73787360~73803270:+
OV	cis	rs2239557	1	rs10144220	ENSG00000259065.1	RP5-1021I20.1	4.32	2.31e-05	0.0102	0.33	0.28	Common traits (Other);	chr14:74181201	chr14:73787360~73803270:+
OV	cis	rs2239557	0.961	rs10135858	ENSG00000259065.1	RP5-1021I20.1	4.32	2.31e-05	0.0102	0.33	0.28	Common traits (Other);	chr14:74181259	chr14:73787360~73803270:+
OV	cis	rs3758911	0.796	rs56753250	ENSG00000261098.1	RP11-819C21.1	-4.32	2.31e-05	0.0102	-0.28	-0.28	Coronary artery disease;	chr11:107338499	chr11:107312132~107316271:-
OV	cis	rs896854	0.631	rs10097617	ENSG00000253528.2	RP11-347C18.4	4.32	2.31e-05	0.0102	0.26	0.28	Type 2 diabetes;	chr8:94949398	chr8:94974573~94974853:-
OV	cis	rs78545713	1	rs41266821	ENSG00000241549.7	GUSBP2	-4.32	2.32e-05	0.0102	-0.39	-0.28	Iron status biomarkers (total iron binding capacity);	chr6:26246970	chr6:26871484~26956554:-
OV	cis	rs7116641	0.524	rs4755743	ENSG00000246250.2	RP11-613D13.5	-4.32	2.32e-05	0.0102	-0.37	-0.28	Coronary artery disease;	chr11:43792226	chr11:43829709~43880726:-
OV	cis	rs12073359	1	rs1339494	ENSG00000223945.2	RP11-458I7.1	4.32	2.32e-05	0.0102	0.41	0.28	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150029512	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs7550350	ENSG00000223945.2	RP11-458I7.1	4.32	2.32e-05	0.0102	0.41	0.28	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150031555	chr1:150053864~150055034:+
OV	cis	rs875971	0.545	rs6970498	ENSG00000236529.1	RP13-254B10.1	4.32	2.32e-05	0.0102	0.33	0.28	Aortic root size;	chr7:66275908	chr7:65840212~65840596:+
OV	cis	rs11159086	1	rs3759745	ENSG00000270000.1	RP3-449M8.9	4.32	2.32e-05	0.0102	0.42	0.28	Advanced glycation end-product levels;	chr14:74495967	chr14:74471930~74472360:-
OV	cis	rs1823913	0.599	rs17346412	ENSG00000227542.1	AC092614.2	4.32	2.32e-05	0.0102	0.31	0.28	Obesity-related traits;	chr2:191285902	chr2:191229165~191246172:-
OV	cis	rs1823913	0.599	rs17412239	ENSG00000227542.1	AC092614.2	4.32	2.32e-05	0.0102	0.31	0.28	Obesity-related traits;	chr2:191285937	chr2:191229165~191246172:-
OV	cis	rs1823913	0.599	rs35098152	ENSG00000227542.1	AC092614.2	4.32	2.32e-05	0.0102	0.31	0.28	Obesity-related traits;	chr2:191286658	chr2:191229165~191246172:-
OV	cis	rs1823913	0.599	rs35150635	ENSG00000227542.1	AC092614.2	4.32	2.32e-05	0.0102	0.31	0.28	Obesity-related traits;	chr2:191287303	chr2:191229165~191246172:-
OV	cis	rs875971	0.545	rs73378304	ENSG00000273024.4	INTS4P2	-4.32	2.32e-05	0.0102	-0.33	-0.28	Aortic root size;	chr7:66175760	chr7:65647864~65715661:+
OV	cis	rs2243480	0.803	rs423187	ENSG00000226824.5	RP4-756H11.3	-4.32	2.32e-05	0.0102	-0.46	-0.28	Diabetic kidney disease;	chr7:66044512	chr7:66654538~66669855:+
OV	cis	rs10246939	0.553	rs34894166	ENSG00000228775.6	WEE2-AS1	4.32	2.32e-05	0.0102	0.28	0.28	Bitter taste perception;	chr7:141852158	chr7:141704338~141738346:-
OV	cis	rs514406	0.893	rs6588446	ENSG00000206627.1	RNU6-969P	-4.32	2.32e-05	0.0102	-0.29	-0.28	Monocyte count;	chr1:52959588	chr1:52805108~52805212:-
OV	cis	rs13113518	0.812	rs12500601	ENSG00000223305.1	RN7SKP30	4.32	2.32e-05	0.0102	0.32	0.28	Height;	chr4:55451489	chr4:55540502~55540835:-
OV	cis	rs11673344	0.734	rs1644638	ENSG00000226686.6	LINC01535	4.32	2.32e-05	0.0102	0.35	0.28	Obesity-related traits;	chr19:36970513	chr19:37251912~37265535:+
OV	cis	rs17301013	0.606	rs10912751	ENSG00000227373.4	RP11-160H22.5	4.32	2.32e-05	0.0102	0.37	0.28	Systemic lupus erythematosus;	chr1:174262992	chr1:174115300~174160004:-
OV	cis	rs801193	0.569	rs13242290	ENSG00000236529.1	RP13-254B10.1	-4.32	2.32e-05	0.0102	-0.29	-0.28	Aortic root size;	chr7:66656898	chr7:65840212~65840596:+
OV	cis	rs2015599	0.623	rs2288128	ENSG00000257176.2	RP11-996F15.2	4.32	2.32e-05	0.0102	0.34	0.28	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29280418~29317848:-
OV	cis	rs2015599	0.584	rs2288129	ENSG00000257176.2	RP11-996F15.2	4.32	2.32e-05	0.0102	0.34	0.28	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29280418~29317848:-
OV	cis	rs1823913	0.637	rs979967	ENSG00000227542.1	AC092614.2	4.32	2.32e-05	0.0102	0.31	0.28	Obesity-related traits;	chr2:191304695	chr2:191229165~191246172:-
OV	cis	rs4747241	0.626	rs10762510	ENSG00000226163.1	RP11-167P22.3	4.32	2.33e-05	0.0102	0.31	0.28	Heschl's gyrus morphology;	chr10:72307528	chr10:72501746~72502956:+
OV	cis	rs4747241	0.626	rs10762511	ENSG00000226163.1	RP11-167P22.3	4.32	2.33e-05	0.0102	0.31	0.28	Heschl's gyrus morphology;	chr10:72307554	chr10:72501746~72502956:+
OV	cis	rs4747241	0.591	rs10823913	ENSG00000226163.1	RP11-167P22.3	4.32	2.33e-05	0.0102	0.31	0.28	Heschl's gyrus morphology;	chr10:72307586	chr10:72501746~72502956:+
OV	cis	rs3758911	0.894	rs10890698	ENSG00000261098.1	RP11-819C21.1	-4.32	2.33e-05	0.0103	-0.27	-0.28	Coronary artery disease;	chr11:107308080	chr11:107312132~107316271:-
OV	cis	rs3758911	0.929	rs10890700	ENSG00000261098.1	RP11-819C21.1	-4.32	2.33e-05	0.0103	-0.27	-0.28	Coronary artery disease;	chr11:107308243	chr11:107312132~107316271:-
OV	cis	rs3758911	0.964	rs10789599	ENSG00000261098.1	RP11-819C21.1	-4.32	2.33e-05	0.0103	-0.27	-0.28	Coronary artery disease;	chr11:107309145	chr11:107312132~107316271:-
OV	cis	rs3758911	0.929	rs10749894	ENSG00000261098.1	RP11-819C21.1	-4.32	2.33e-05	0.0103	-0.27	-0.28	Coronary artery disease;	chr11:107309586	chr11:107312132~107316271:-
OV	cis	rs7429990	0.864	rs13086149	ENSG00000229759.1	MRPS18AP1	-4.32	2.33e-05	0.0103	-0.3	-0.28	Educational attainment (years of education);	chr3:47784158	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs3915654	ENSG00000229759.1	MRPS18AP1	-4.32	2.33e-05	0.0103	-0.3	-0.28	Educational attainment (years of education);	chr3:47827132	chr3:48256350~48256938:-
OV	cis	rs73201462	1	rs2999086	ENSG00000277250.1	Metazoa_SRP	-4.32	2.33e-05	0.0103	-0.4	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128232405	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2999085	ENSG00000277250.1	Metazoa_SRP	-4.32	2.33e-05	0.0103	-0.4	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128232716	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2999084	ENSG00000277250.1	Metazoa_SRP	-4.32	2.33e-05	0.0103	-0.4	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128233645	chr3:128673681~128674021:-
OV	cis	rs73201462	0.536	rs56397996	ENSG00000277250.1	Metazoa_SRP	-4.32	2.33e-05	0.0103	-0.4	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128235867	chr3:128673681~128674021:-
OV	cis	rs73201462	0.901	rs2999082	ENSG00000277250.1	Metazoa_SRP	-4.32	2.33e-05	0.0103	-0.4	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128237345	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2999079	ENSG00000277250.1	Metazoa_SRP	-4.32	2.33e-05	0.0103	-0.4	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128238389	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2955079	ENSG00000277250.1	Metazoa_SRP	-4.32	2.33e-05	0.0103	-0.4	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128240981	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2955080	ENSG00000277250.1	Metazoa_SRP	-4.32	2.33e-05	0.0103	-0.4	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128241022	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2955082	ENSG00000277250.1	Metazoa_SRP	-4.32	2.33e-05	0.0103	-0.4	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128241491	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2999073	ENSG00000277250.1	Metazoa_SRP	-4.32	2.33e-05	0.0103	-0.4	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128243486	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2955086	ENSG00000277250.1	Metazoa_SRP	-4.32	2.33e-05	0.0103	-0.4	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128244348	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2999071	ENSG00000277250.1	Metazoa_SRP	-4.32	2.33e-05	0.0103	-0.4	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128244772	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs2999070	ENSG00000277250.1	Metazoa_SRP	-4.32	2.33e-05	0.0103	-0.4	-0.28	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128245808	chr3:128673681~128674021:-
OV	cis	rs853679	0.517	rs9283884	ENSG00000226314.6	ZNF192P1	4.32	2.33e-05	0.0103	0.38	0.28	Depression;	chr6:28167882	chr6:28161781~28169594:+
OV	cis	rs11157436	0.874	rs35951144	ENSG00000211812.1	TRAV26-2	-4.32	2.33e-05	0.0103	-0.31	-0.28	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22149973	chr14:22202583~22203368:+
OV	cis	rs3733585	0.577	rs28558552	ENSG00000250413.1	RP11-448G15.1	4.32	2.33e-05	0.0103	0.32	0.28	Cleft plate (environmental tobacco smoke interaction);	chr4:9963289	chr4:10006482~10009725:+
OV	cis	rs5742933	1	rs5742933	ENSG00000253559.1	OSGEPL1-AS1	-4.32	2.33e-05	0.0103	-0.32	-0.28	Ferritin levels;	chr2:189784590	chr2:189762704~189765556:+
OV	cis	rs9880211	1	rs9880211	ENSG00000239213.4	NCK1-AS1	4.32	2.33e-05	0.0103	0.34	0.28	Height;Body mass index;	chr3:136388707	chr3:136841726~136862054:-
OV	cis	rs9880211	1	rs9841529	ENSG00000239213.4	NCK1-AS1	4.32	2.33e-05	0.0103	0.34	0.28	Height;Body mass index;	chr3:136418441	chr3:136841726~136862054:-
OV	cis	rs934734	0.563	rs11684155	ENSG00000234255.7	AC012370.3	4.32	2.34e-05	0.0103	0.3	0.28	Rheumatoid arthritis;	chr2:65354166	chr2:65439888~65456571:-
OV	cis	rs2243480	1	rs958550	ENSG00000226824.5	RP4-756H11.3	4.32	2.34e-05	0.0103	0.43	0.28	Diabetic kidney disease;	chr7:66170692	chr7:66654538~66669855:+
OV	cis	rs7927592	0.763	rs10791982	ENSG00000212093.1	AP000807.1	-4.32	2.34e-05	0.0103	-0.32	-0.28	Total body bone mineral density;	chr11:68570196	chr11:68506083~68506166:-
OV	cis	rs7811142	0.943	rs3900792	ENSG00000242294.5	STAG3L5P	4.32	2.34e-05	0.0103	0.28	0.28	Platelet count;	chr7:100406954	chr7:100336079~100351900:+
OV	cis	rs9880211	0.948	rs13316214	ENSG00000239213.4	NCK1-AS1	4.32	2.34e-05	0.0103	0.34	0.28	Height;Body mass index;	chr3:136439379	chr3:136841726~136862054:-
OV	cis	rs189798	0.807	rs12785	ENSG00000253981.4	ALG1L13P	4.32	2.34e-05	0.0103	0.38	0.28	Myopia (pathological);	chr8:9137426	chr8:8236003~8244667:-
OV	cis	rs881375	0.631	rs2416808	ENSG00000226752.6	PSMD5-AS1	-4.32	2.35e-05	0.0103	-0.28	-0.28	Rheumatoid arthritis;	chr9:120944005	chr9:120824828~120854385:+
OV	cis	rs7520050	0.966	rs785492	ENSG00000281133.1	AL355480.3	4.32	2.35e-05	0.0103	0.32	0.28	Reticulocyte count;Red blood cell count;	chr1:46117935	chr1:45580892~45580996:-
OV	cis	rs7617773	0.817	rs6787500	ENSG00000228638.1	FCF1P2	-4.32	2.35e-05	0.0103	-0.33	-0.28	Coronary artery disease;	chr3:48257949	chr3:48290793~48291375:-
OV	cis	rs4296809	0.505	rs4866763	ENSG00000249779.1	RP11-447H19.3	-4.32	2.35e-05	0.0103	-0.53	-0.28	Brain structure;	chr5:44073368	chr5:43206709~43207811:+
OV	cis	rs17767294	0.708	rs6908688	ENSG00000219392.1	RP1-265C24.5	-4.32	2.35e-05	0.0103	-0.6	-0.28	Parkinson's disease;	chr6:27918273	chr6:28115628~28116551:+
OV	cis	rs11992162	1	rs7460395	ENSG00000254423.1	RP11-351I21.7	4.32	2.35e-05	0.0103	0.3	0.28	Monocyte count;	chr8:11977866	chr8:12374366~12375546:-
OV	cis	rs1790761	0.505	rs6591245	ENSG00000184224.3	C11orf72	-4.32	2.36e-05	0.0104	-0.31	-0.28	Mean corpuscular volume;	chr11:67543465	chr11:67602880~67606706:-
OV	cis	rs10810935	0.77	rs16936469	ENSG00000232176.1	RP11-146N23.1	4.32	2.36e-05	0.0104	0.3	0.28	Alcohol dependence (age at onset);	chr9:18250239	chr9:19200335~19201046:-
OV	cis	rs9291683	0.546	rs6829727	ENSG00000250413.1	RP11-448G15.1	-4.32	2.36e-05	0.0104	-0.33	-0.28	Bone mineral density;	chr4:10050048	chr4:10006482~10009725:+
OV	cis	rs7927592	0.717	rs7126451	ENSG00000222339.1	AP000807.2	-4.32	2.36e-05	0.0104	-0.28	-0.28	Total body bone mineral density;	chr11:68489918	chr11:68505572~68505651:-
OV	cis	rs473651	0.935	rs483166	ENSG00000229915.1	AC016999.2	4.32	2.36e-05	0.0104	0.35	0.28	Multiple system atrophy;	chr2:238438000	chr2:238427077~238427729:-
OV	cis	rs875971	0.545	rs6979636	ENSG00000237310.1	GS1-124K5.4	4.32	2.36e-05	0.0104	0.31	0.28	Aortic root size;	chr7:66276638	chr7:66493706~66495474:+
OV	cis	rs7927592	0.913	rs10896330	ENSG00000212093.1	AP000807.1	4.32	2.36e-05	0.0104	0.35	0.28	Total body bone mineral density;	chr11:68487530	chr11:68506083~68506166:-
OV	cis	rs7927592	0.956	rs12274114	ENSG00000212093.1	AP000807.1	4.32	2.36e-05	0.0104	0.35	0.28	Total body bone mineral density;	chr11:68488109	chr11:68506083~68506166:-
OV	cis	rs7927592	0.913	rs12294029	ENSG00000212093.1	AP000807.1	4.32	2.36e-05	0.0104	0.35	0.28	Total body bone mineral density;	chr11:68489591	chr11:68506083~68506166:-
OV	cis	rs2070488	1	rs1002675	ENSG00000229589.1	ACVR2B-AS1	4.32	2.36e-05	0.0104	0.3	0.28	Electrocardiographic conduction measures;	chr3:38403735	chr3:38451027~38454820:-
OV	cis	rs80168506	0.748	rs35078032	ENSG00000272519.1	RP11-105N14.2	4.32	2.36e-05	0.0104	0.41	0.28	Selective IgA deficiency;	chr2:213208992	chr2:213266995~213276152:-
OV	cis	rs1538970	0.924	rs4660851	ENSG00000280836.1	AL355480.1	-4.32	2.37e-05	0.0104	-0.38	-0.28	Platelet count;	chr1:45378138	chr1:45581219~45581321:-
OV	cis	rs7580658	0.55	rs62160290	ENSG00000236682.1	AC068282.3	-4.32	2.37e-05	0.0104	-0.38	-0.28	Protein C levels;	chr2:127443119	chr2:127389130~127400580:+
OV	cis	rs783540	1	rs698500	ENSG00000278603.1	RP13-608F4.5	-4.32	2.37e-05	0.0104	-0.31	-0.28	Schizophrenia;	chr15:82569019	chr15:82472203~82472426:+
OV	cis	rs4761702	0.527	rs12824664	ENSG00000257322.4	RP11-511B23.2	-4.32	2.37e-05	0.0104	-0.3	-0.28	Immature fraction of reticulocytes;	chr12:93343125	chr12:93003415~93215679:-
OV	cis	rs9309473	0.948	rs13392691	ENSG00000163016.8	ALMS1P	4.32	2.37e-05	0.0104	0.35	0.28	Metabolite levels;	chr2:73521853	chr2:73644919~73685576:+
OV	cis	rs7968440	1	rs2252589	ENSG00000257298.1	RP3-405J10.3	4.32	2.37e-05	0.0104	0.26	0.28	Fibrinogen;	chr12:50648174	chr12:50185580~50191363:-
OV	cis	rs66887589	0.967	rs1480933	ENSG00000245958.5	RP11-33B1.1	-4.32	2.37e-05	0.0104	-0.33	-0.28	Diastolic blood pressure;	chr4:119512093	chr4:119454791~119552025:+
OV	cis	rs6788497	0.643	rs11705891	ENSG00000242551.2	POU5F1P6	4.32	2.37e-05	0.0104	0.52	0.28	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr3:128401512	chr3:128674735~128677005:-
OV	cis	rs9287719	0.601	rs13427815	ENSG00000243819.4	RN7SL832P	4.32	2.37e-05	0.0104	0.28	0.28	Prostate cancer;	chr2:10567859	chr2:10690344~10692099:+
OV	cis	rs1823913	0.637	rs921737	ENSG00000227542.1	AC092614.2	-4.32	2.37e-05	0.0104	-0.31	-0.28	Obesity-related traits;	chr2:191286097	chr2:191229165~191246172:-
OV	cis	rs1823913	0.599	rs6736071	ENSG00000227542.1	AC092614.2	-4.32	2.37e-05	0.0104	-0.31	-0.28	Obesity-related traits;	chr2:191287265	chr2:191229165~191246172:-
OV	cis	rs896854	0.714	rs6471503	ENSG00000253528.2	RP11-347C18.4	4.32	2.37e-05	0.0104	0.26	0.28	Type 2 diabetes;	chr8:94978055	chr8:94974573~94974853:-
OV	cis	rs875971	0.895	rs12698520	ENSG00000237310.1	GS1-124K5.4	4.32	2.37e-05	0.0104	0.28	0.28	Aortic root size;	chr7:66453720	chr7:66493706~66495474:+
OV	cis	rs934734	0.789	rs2661798	ENSG00000234255.7	AC012370.3	-4.32	2.38e-05	0.0104	-0.29	-0.28	Rheumatoid arthritis;	chr2:65408554	chr2:65439888~65456571:-
OV	cis	rs853679	1	rs9986596	ENSG00000219392.1	RP1-265C24.5	-4.32	2.38e-05	0.0104	-0.44	-0.28	Depression;	chr6:28251883	chr6:28115628~28116551:+
OV	cis	rs7587476	0.548	rs35982594	ENSG00000229267.2	AC072062.1	-4.32	2.38e-05	0.0104	-0.39	-0.28	Neuroblastoma;	chr2:214841351	chr2:214810229~214963274:+
OV	cis	rs7520050	0.966	rs10890361	ENSG00000281133.1	AL355480.3	4.32	2.38e-05	0.0104	0.3	0.28	Reticulocyte count;Red blood cell count;	chr1:45880562	chr1:45580892~45580996:-
OV	cis	rs4296809	0.505	rs12513463	ENSG00000249779.1	RP11-447H19.3	-4.32	2.38e-05	0.0104	-0.51	-0.28	Brain structure;	chr5:44072744	chr5:43206709~43207811:+
OV	cis	rs7520050	0.966	rs10749860	ENSG00000281133.1	AL355480.3	4.31	2.38e-05	0.0105	0.31	0.28	Reticulocyte count;Red blood cell count;	chr1:45862538	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs12139630	ENSG00000281133.1	AL355480.3	4.31	2.38e-05	0.0105	0.31	0.28	Reticulocyte count;Red blood cell count;	chr1:45885263	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs12144263	ENSG00000281133.1	AL355480.3	4.31	2.38e-05	0.0105	0.31	0.28	Reticulocyte count;Red blood cell count;	chr1:45886774	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs6668284	ENSG00000281133.1	AL355480.3	4.31	2.38e-05	0.0105	0.31	0.28	Reticulocyte count;Red blood cell count;	chr1:45888838	chr1:45580892~45580996:-
OV	cis	rs7107356	1	rs7107356	ENSG00000280615.1	Y_RNA	4.31	2.39e-05	0.0105	0.29	0.28	Neuroticism (multi-trait analysis);Neuroticism;	chr11:47654618	chr11:47614898~47614994:-
OV	cis	rs7429990	0.864	rs6806860	ENSG00000229759.1	MRPS18AP1	-4.31	2.39e-05	0.0105	-0.3	-0.28	Educational attainment (years of education);	chr3:47708218	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs6768699	ENSG00000229759.1	MRPS18AP1	-4.31	2.39e-05	0.0105	-0.3	-0.28	Educational attainment (years of education);	chr3:47711258	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs6786001	ENSG00000229759.1	MRPS18AP1	-4.31	2.39e-05	0.0105	-0.3	-0.28	Educational attainment (years of education);	chr3:47718500	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs12495204	ENSG00000229759.1	MRPS18AP1	-4.31	2.39e-05	0.0105	-0.3	-0.28	Educational attainment (years of education);	chr3:47720540	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs7618758	ENSG00000229759.1	MRPS18AP1	-4.31	2.39e-05	0.0105	-0.3	-0.28	Educational attainment (years of education);	chr3:47720993	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs7612219	ENSG00000229759.1	MRPS18AP1	-4.31	2.39e-05	0.0105	-0.3	-0.28	Educational attainment (years of education);	chr3:47739676	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs35148469	ENSG00000229759.1	MRPS18AP1	-4.31	2.39e-05	0.0105	-0.3	-0.28	Educational attainment (years of education);	chr3:47739873	chr3:48256350~48256938:-
OV	cis	rs7429990	0.694	rs7645846	ENSG00000229759.1	MRPS18AP1	-4.31	2.39e-05	0.0105	-0.3	-0.28	Educational attainment (years of education);	chr3:47740829	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs17079785	ENSG00000229759.1	MRPS18AP1	-4.31	2.39e-05	0.0105	-0.3	-0.28	Educational attainment (years of education);	chr3:47743160	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs6442082	ENSG00000229759.1	MRPS18AP1	-4.31	2.39e-05	0.0105	-0.3	-0.28	Educational attainment (years of education);	chr3:47743991	chr3:48256350~48256938:-
OV	cis	rs7429990	0.747	rs6442083	ENSG00000229759.1	MRPS18AP1	-4.31	2.39e-05	0.0105	-0.3	-0.28	Educational attainment (years of education);	chr3:47744305	chr3:48256350~48256938:-
OV	cis	rs7429990	0.786	rs13064183	ENSG00000229759.1	MRPS18AP1	-4.31	2.39e-05	0.0105	-0.3	-0.28	Educational attainment (years of education);	chr3:47745405	chr3:48256350~48256938:-
OV	cis	rs7429990	0.833	rs6777632	ENSG00000229759.1	MRPS18AP1	-4.31	2.39e-05	0.0105	-0.3	-0.28	Educational attainment (years of education);	chr3:47748775	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs7637372	ENSG00000229759.1	MRPS18AP1	-4.31	2.39e-05	0.0105	-0.3	-0.28	Educational attainment (years of education);	chr3:47750385	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs13098128	ENSG00000229759.1	MRPS18AP1	-4.31	2.39e-05	0.0105	-0.3	-0.28	Educational attainment (years of education);	chr3:47756066	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs7637950	ENSG00000229759.1	MRPS18AP1	-4.31	2.39e-05	0.0105	-0.3	-0.28	Educational attainment (years of education);	chr3:47758204	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs6442085	ENSG00000229759.1	MRPS18AP1	-4.31	2.39e-05	0.0105	-0.3	-0.28	Educational attainment (years of education);	chr3:47760080	chr3:48256350~48256938:-
OV	cis	rs1823913	0.637	rs6722183	ENSG00000227542.1	AC092614.2	-4.31	2.39e-05	0.0105	-0.31	-0.28	Obesity-related traits;	chr2:191333203	chr2:191229165~191246172:-
OV	cis	rs11096990	0.656	rs2066786	ENSG00000249207.1	RP11-360F5.1	-4.31	2.39e-05	0.0105	-0.29	-0.28	Cognitive function;	chr4:39300409	chr4:39112677~39126818:-
OV	cis	rs9880211	1	rs9812579	ENSG00000239213.4	NCK1-AS1	4.31	2.39e-05	0.0105	0.34	0.28	Height;Body mass index;	chr3:136432408	chr3:136841726~136862054:-
OV	cis	rs9880211	0.948	rs1604793	ENSG00000239213.4	NCK1-AS1	4.31	2.39e-05	0.0105	0.34	0.28	Height;Body mass index;	chr3:136462228	chr3:136841726~136862054:-
OV	cis	rs6052484	0.523	rs4569542	ENSG00000229539.1	RP11-119B16.2	4.31	2.39e-05	0.0105	0.31	0.28	Sense of smell;	chr20:4338546	chr20:3888239~3888868:-
OV	cis	rs6052484	0.523	rs4283491	ENSG00000229539.1	RP11-119B16.2	4.31	2.39e-05	0.0105	0.31	0.28	Sense of smell;	chr20:4338575	chr20:3888239~3888868:-
OV	cis	rs10129255	0.5	rs1024350	ENSG00000223648.3	IGHV3-64	4.31	2.39e-05	0.0105	0.27	0.28	Kawasaki disease;	chr14:106685105	chr14:106643132~106658258:-
OV	cis	rs10978777	0.676	rs4625087	ENSG00000276883.1	AL137852.1	-4.31	2.39e-05	0.0105	-0.3	-0.28	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107298562	chr9:107292369~107292456:-
OV	cis	rs3823536	0.583	rs10156169	ENSG00000275106.1	RP11-309L24.10	-4.31	2.4e-05	0.0105	-0.39	-0.28	Sjögren's syndrome;	chr7:129044517	chr7:128952527~128953316:-
OV	cis	rs17301013	0.507	rs11810824	ENSG00000227373.4	RP11-160H22.5	-4.31	2.4e-05	0.0105	-0.36	-0.28	Systemic lupus erythematosus;	chr1:174408223	chr1:174115300~174160004:-
OV	cis	rs11239930	0.538	rs4950361	ENSG00000278811.3	LINC00624	-4.31	2.4e-05	0.0105	-0.34	-0.28	AIDS progression;	chr1:147087618	chr1:147258885~147517875:-
OV	cis	rs732765	0.734	rs7152804	ENSG00000258439.1	RP11-173A8.2	4.31	2.4e-05	0.0105	0.36	0.28	Non-small cell lung cancer;	chr14:74697305	chr14:74658049~74658590:+
OV	cis	rs4713118	0.513	rs149954	ENSG00000280107.1	AL022393.9	-4.31	2.4e-05	0.0105	-0.32	-0.28	Parkinson's disease;	chr6:28067468	chr6:28170845~28172521:+
OV	cis	rs832187	0.665	rs7627690	ENSG00000280620.1	SCAANT1	4.31	2.4e-05	0.0105	0.34	0.28	Schizophrenia;	chr3:63914801	chr3:63911518~63911772:-
OV	cis	rs8114671	0.967	rs12481169	ENSG00000269202.1	RP4-614O4.12	4.31	2.4e-05	0.0105	0.27	0.28	Height;	chr20:35206707	chr20:35201747~35203288:-
OV	cis	rs6840360	0.642	rs2724577	ENSG00000270265.1	RP11-731D1.4	-4.31	2.41e-05	0.0105	-0.33	-0.28	Intelligence (multi-trait analysis);	chr4:151433753	chr4:151333775~151353224:-
OV	cis	rs878830	1	rs878830	ENSG00000255027.2	RP11-680F20.9	-4.31	2.41e-05	0.0105	-0.33	-0.28	Gut microbiome composition (winter);	chr11:126440187	chr11:125903247~125938916:-
OV	cis	rs9287719	0.967	rs1541573	ENSG00000234818.1	AC092687.5	4.31	2.41e-05	0.0105	0.3	0.28	Prostate cancer;	chr2:10633259	chr2:10589166~10604830:+
OV	cis	rs9287719	0.967	rs1541574	ENSG00000234818.1	AC092687.5	4.31	2.41e-05	0.0105	0.3	0.28	Prostate cancer;	chr2:10633382	chr2:10589166~10604830:+
OV	cis	rs10924970	0.601	rs34636135	ENSG00000236863.2	RPL23AP23	4.31	2.41e-05	0.0105	0.29	0.28	Asthma;	chr1:235301985	chr1:235295865~235296335:+
OV	cis	rs7968440	0.707	rs1109726	ENSG00000272368.2	RP4-605O3.4	4.31	2.41e-05	0.0105	0.34	0.28	Fibrinogen;	chr12:50764765	chr12:50112197~50165618:+
OV	cis	rs7567389	0.534	rs72845982	ENSG00000236682.1	AC068282.3	-4.31	2.41e-05	0.0105	-0.38	-0.28	Self-rated health;	chr2:127340994	chr2:127389130~127400580:+
OV	cis	rs2919917	0.628	rs10113703	ENSG00000254352.1	RP11-578O24.2	4.31	2.41e-05	0.0106	0.36	0.28	Lymphocyte counts;	chr8:78688404	chr8:78723796~78724136:-
OV	cis	rs67311347	0.866	rs1454491	ENSG00000223797.4	ENTPD3-AS1	4.31	2.41e-05	0.0106	0.3	0.28	Renal cell carcinoma;	chr3:40311156	chr3:40313802~40453329:-
OV	cis	rs4938303	0.718	rs4938300	ENSG00000254851.1	RP11-109L13.1	4.31	2.41e-05	0.0106	0.45	0.28	Triglycerides;	chr11:116696903	chr11:117135528~117138582:+
OV	cis	rs35542019	1	rs35542019	ENSG00000273102.1	AP000569.9	4.31	2.42e-05	0.0106	0.29	0.28	Hemoglobin concentration;Hematocrit;Red blood cell count;	chr21:33974555	chr21:33967101~33968573:-
OV	cis	rs11673344	0.502	rs62108306	ENSG00000226686.6	LINC01535	4.31	2.42e-05	0.0106	0.36	0.28	Obesity-related traits;	chr19:37691789	chr19:37251912~37265535:+
OV	cis	rs7520050	0.807	rs72688483	ENSG00000280836.1	AL355480.1	-4.31	2.42e-05	0.0106	-0.34	-0.28	Reticulocyte count;Red blood cell count;	chr1:45683537	chr1:45581219~45581321:-
OV	cis	rs1823913	0.637	rs2883912	ENSG00000227542.1	AC092614.2	-4.31	2.42e-05	0.0106	-0.31	-0.28	Obesity-related traits;	chr2:191284290	chr2:191229165~191246172:-
OV	cis	rs4950322	1	rs4950429	ENSG00000278811.3	LINC00624	4.31	2.42e-05	0.0106	0.38	0.28	Protein quantitative trait loci;	chr1:147400227	chr1:147258885~147517875:-
OV	cis	rs4950322	1	rs59498179	ENSG00000278811.3	LINC00624	4.31	2.42e-05	0.0106	0.38	0.28	Protein quantitative trait loci;	chr1:147400417	chr1:147258885~147517875:-
OV	cis	rs4950322	0.947	rs58671552	ENSG00000278811.3	LINC00624	4.31	2.42e-05	0.0106	0.38	0.28	Protein quantitative trait loci;	chr1:147409534	chr1:147258885~147517875:-
OV	cis	rs875971	0.929	rs34406470	ENSG00000237310.1	GS1-124K5.4	4.31	2.42e-05	0.0106	0.28	0.28	Aortic root size;	chr7:66464969	chr7:66493706~66495474:+
OV	cis	rs1511299	0.597	rs2063453	ENSG00000249417.1	RP11-438D8.2	4.31	2.43e-05	0.0106	0.4	0.28	Glomerular filtration rate;	chr3:141996701	chr3:141267353~141367137:-
OV	cis	rs35491132	1	rs35491132	ENSG00000220721.1	OR1F12	4.31	2.43e-05	0.0106	0.52	0.28	Urinary tract infection frequency;	chr6:27559449	chr6:28073316~28074233:+
OV	cis	rs7811142	0.943	rs111757992	ENSG00000242294.5	STAG3L5P	4.31	2.43e-05	0.0106	0.28	0.28	Platelet count;	chr7:100418731	chr7:100336079~100351900:+
OV	cis	rs7811142	1	rs28490152	ENSG00000242294.5	STAG3L5P	4.31	2.43e-05	0.0106	0.28	0.28	Platelet count;	chr7:100423359	chr7:100336079~100351900:+
OV	cis	rs7811142	0.943	rs28660238	ENSG00000242294.5	STAG3L5P	4.31	2.43e-05	0.0106	0.28	0.28	Platelet count;	chr7:100425685	chr7:100336079~100351900:+
OV	cis	rs71520386	0.632	rs12535331	ENSG00000221740.1	SNORD93	4.31	2.43e-05	0.0106	0.33	0.28	Fibrinogen levels;	chr7:22838485	chr7:22856613~22856686:+
OV	cis	rs11096990	0.819	rs2381225	ENSG00000249207.1	RP11-360F5.1	4.31	2.43e-05	0.0106	0.32	0.28	Cognitive function;	chr4:39158915	chr4:39112677~39126818:-
OV	cis	rs9467773	0.62	rs2101582	ENSG00000261584.1	RP11-457M11.5	4.31	2.43e-05	0.0106	0.3	0.28	Intelligence (multi-trait analysis);	chr6:26622506	chr6:26686241~26687964:+
OV	cis	rs9309473	1	rs7598419	ENSG00000163016.8	ALMS1P	4.31	2.43e-05	0.0106	0.33	0.28	Metabolite levels;	chr2:73571096	chr2:73644919~73685576:+
OV	cis	rs295137	0.725	rs1729413	ENSG00000232732.8	AC073043.1	-4.31	2.43e-05	0.0106	-0.32	-0.28	Asthma (bronchodilator response);	chr2:200221940	chr2:199867396~199911159:-
OV	cis	rs4713118	0.869	rs2056925	ENSG00000219392.1	RP1-265C24.5	-4.31	2.44e-05	0.0106	-0.31	-0.28	Parkinson's disease;	chr6:27723126	chr6:28115628~28116551:+
OV	cis	rs1823913	0.599	rs6732976	ENSG00000227542.1	AC092614.2	-4.31	2.44e-05	0.0106	-0.3	-0.28	Obesity-related traits;	chr2:191281004	chr2:191229165~191246172:-
OV	cis	rs2070488	1	rs13072809	ENSG00000229589.1	ACVR2B-AS1	4.31	2.44e-05	0.0106	0.3	0.28	Electrocardiographic conduction measures;	chr3:38426680	chr3:38451027~38454820:-
OV	cis	rs7811142	1	rs7783550	ENSG00000242294.5	STAG3L5P	-4.31	2.44e-05	0.0106	-0.27	-0.28	Platelet count;	chr7:100390182	chr7:100336079~100351900:+
OV	cis	rs10462065	0.818	rs10434607	ENSG00000249779.1	RP11-447H19.3	-4.31	2.44e-05	0.0107	-0.53	-0.27	Nonsyndromic cleft lip with cleft palate;	chr5:44053250	chr5:43206709~43207811:+
OV	cis	rs1030877	0.515	rs17030766	ENSG00000235319.1	AC012360.4	4.31	2.44e-05	0.0107	0.38	0.27	Obesity-related traits;	chr2:105295448	chr2:105324210~105330529:+
OV	cis	rs7688540	0.771	rs2353605	ENSG00000275426.1	CH17-262A2.1	4.31	2.44e-05	0.0107	0.43	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:225749	chr4:149738~150317:+
OV	cis	rs7688540	0.739	rs11729659	ENSG00000275426.1	CH17-262A2.1	4.31	2.44e-05	0.0107	0.43	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:243495	chr4:149738~150317:+
OV	cis	rs7688540	0.665	rs11731933	ENSG00000275426.1	CH17-262A2.1	4.31	2.44e-05	0.0107	0.43	0.27	Facial morphology (factor 6, height of vermillion lower lip);	chr4:245370	chr4:149738~150317:+
OV	cis	rs7429990	0.965	rs319692	ENSG00000229759.1	MRPS18AP1	4.31	2.44e-05	0.0107	0.29	0.27	Educational attainment (years of education);	chr3:47882827	chr3:48256350~48256938:-
OV	cis	rs1555322	0.53	rs6060347	ENSG00000269202.1	RP4-614O4.12	-4.31	2.45e-05	0.0107	-0.32	-0.27	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35201747~35203288:-
OV	cis	rs17301013	0.606	rs12076453	ENSG00000227373.4	RP11-160H22.5	4.31	2.45e-05	0.0107	0.36	0.27	Systemic lupus erythematosus;	chr1:174230438	chr1:174115300~174160004:-
OV	cis	rs875971	0.619	rs10278371	ENSG00000224316.1	RP11-479O9.2	-4.31	2.45e-05	0.0107	-0.29	-0.27	Aortic root size;	chr7:66586553	chr7:65773620~65802067:+
OV	cis	rs10829156	0.66	rs7910506	ENSG00000225527.1	RP11-383B4.4	4.31	2.45e-05	0.0107	0.34	0.27	Sudden cardiac arrest;	chr10:18518128	chr10:18531849~18533336:-
OV	cis	rs10924970	0.649	rs4659763	ENSG00000236863.2	RPL23AP23	4.31	2.45e-05	0.0107	0.29	0.27	Asthma;	chr1:235284464	chr1:235295865~235296335:+
OV	cis	rs875971	0.965	rs6971509	ENSG00000236529.1	RP13-254B10.1	-4.31	2.45e-05	0.0107	-0.29	-0.27	Aortic root size;	chr7:66249983	chr7:65840212~65840596:+
OV	cis	rs7121800	0.888	rs10835673	ENSG00000254532.1	RP11-624D11.2	-4.31	2.45e-05	0.0107	-0.32	-0.27	Pit-and-Fissure caries;	chr11:30490118	chr11:30044058~30084343:-
OV	cis	rs9291683	0.53	rs998675	ENSG00000250413.1	RP11-448G15.1	-4.31	2.45e-05	0.0107	-0.31	-0.27	Bone mineral density;	chr4:9947205	chr4:10006482~10009725:+
OV	cis	rs12073359	0.954	rs116203299	ENSG00000223945.2	RP11-458I7.1	-4.31	2.45e-05	0.0107	-0.42	-0.27	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150117189	chr1:150053864~150055034:+
OV	cis	rs11096990	0.613	rs9997015	ENSG00000249207.1	RP11-360F5.1	4.31	2.46e-05	0.0107	0.29	0.27	Cognitive function;	chr4:39222677	chr4:39112677~39126818:-
OV	cis	rs11250098	0.547	rs2409764	ENSG00000254527.1	ENPP7P12	4.31	2.46e-05	0.0107	0.29	0.27	Morning vs. evening chronotype;	chr8:11423764	chr8:12205759~12206389:-
OV	cis	rs11096990	0.634	rs10019594	ENSG00000249207.1	RP11-360F5.1	4.31	2.46e-05	0.0107	0.29	0.27	Cognitive function;	chr4:39287127	chr4:39112677~39126818:-
OV	cis	rs12999373	0.523	rs9678953	ENSG00000223751.1	AC116609.2	-4.31	2.46e-05	0.0107	-0.35	-0.27	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:694759	chr2:742488~747767:+
OV	cis	rs875971	0.862	rs2420174	ENSG00000236529.1	RP13-254B10.1	-4.31	2.46e-05	0.0107	-0.28	-0.27	Aortic root size;	chr7:66180374	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs2420173	ENSG00000236529.1	RP13-254B10.1	-4.31	2.46e-05	0.0107	-0.28	-0.27	Aortic root size;	chr7:66180412	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs4718319	ENSG00000236529.1	RP13-254B10.1	-4.31	2.46e-05	0.0107	-0.28	-0.27	Aortic root size;	chr7:66187797	chr7:65840212~65840596:+
OV	cis	rs875971	0.723	rs28391294	ENSG00000236529.1	RP13-254B10.1	-4.31	2.46e-05	0.0107	-0.28	-0.27	Aortic root size;	chr7:66189328	chr7:65840212~65840596:+
OV	cis	rs875971	0.83	rs6967708	ENSG00000236529.1	RP13-254B10.1	-4.31	2.46e-05	0.0107	-0.28	-0.27	Aortic root size;	chr7:66192326	chr7:65840212~65840596:+
OV	cis	rs875971	0.895	rs7782806	ENSG00000236529.1	RP13-254B10.1	-4.31	2.46e-05	0.0107	-0.28	-0.27	Aortic root size;	chr7:66192910	chr7:65840212~65840596:+
OV	cis	rs4591358	0.559	rs2133858	ENSG00000223466.1	AC064834.2	4.31	2.46e-05	0.0107	0.33	0.27	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195519925	chr2:195533035~195538681:+
OV	cis	rs4578769	0.55	rs4517887	ENSG00000242182.3	RN7SL745P	-4.31	2.47e-05	0.0107	-0.31	-0.27	Eosinophil percentage of white cells;	chr18:22994715	chr18:23004564~23004862:+
OV	cis	rs4578769	0.55	rs4635434	ENSG00000242182.3	RN7SL745P	-4.31	2.47e-05	0.0107	-0.31	-0.27	Eosinophil percentage of white cells;	chr18:22996032	chr18:23004564~23004862:+
OV	cis	rs1555322	0.53	rs2425043	ENSG00000126005.14	MMP24-AS1	-4.31	2.47e-05	0.0107	-0.37	-0.27	Attention deficit hyperactivity disorder;	chr20:35280899	chr20:35216462~35278131:-
OV	cis	rs35160687	0.901	rs7571424	ENSG00000273080.1	RP11-301O19.1	4.31	2.47e-05	0.0107	0.28	0.27	Night sleep phenotypes;	chr2:86312037	chr2:86195590~86196049:+
OV	cis	rs853679	0.517	rs2281588	ENSG00000226314.6	ZNF192P1	-4.31	2.47e-05	0.0107	-0.36	-0.27	Depression;	chr6:28104824	chr6:28161781~28169594:+
OV	cis	rs7017914	0.69	rs7844508	ENSG00000223220.1	Y_RNA	4.31	2.47e-05	0.0107	0.29	0.27	Bone mineral density;	chr8:70690760	chr8:70780914~70781008:-
OV	cis	rs4908768	0.822	rs12122737	ENSG00000228423.2	RP4-633I8.4	4.31	2.47e-05	0.0108	0.33	0.27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8556345	chr1:8805860~8807051:-
OV	cis	rs10771431	0.935	rs1988852	ENSG00000111788.10	RP11-22B23.1	4.31	2.47e-05	0.0108	0.25	0.27	Breast size;	chr12:9220266	chr12:9277235~9313241:+
OV	cis	rs7605378	1	rs769954	ENSG00000232732.8	AC073043.1	4.31	2.47e-05	0.0108	0.33	0.27	Osteoporosis;	chr2:199827436	chr2:199867396~199911159:-
OV	cis	rs1707322	0.752	rs6662164	ENSG00000234329.1	RP11-767N6.2	4.31	2.47e-05	0.0108	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680558	chr1:45651039~45651826:-
OV	cis	rs1723838	0.826	rs2515091	ENSG00000255928.1	RP11-456I15.2	4.31	2.47e-05	0.0108	0.64	0.27	Obesity-related traits;	chr11:73823409	chr11:73722349~73722694:+
OV	cis	rs17023223	0.581	rs10923750	ENSG00000231365.4	RP11-418J17.1	-4.31	2.48e-05	0.0108	-0.37	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119108172	chr1:119140396~119275973:+
OV	cis	rs853679	0.517	rs9357063	ENSG00000226314.6	ZNF192P1	-4.31	2.48e-05	0.0108	-0.36	-0.27	Depression;	chr6:28092227	chr6:28161781~28169594:+
OV	cis	rs934734	0.563	rs11673956	ENSG00000234255.7	AC012370.3	4.31	2.48e-05	0.0108	0.3	0.27	Rheumatoid arthritis;	chr2:65370523	chr2:65439888~65456571:-
OV	cis	rs934734	0.563	rs11673987	ENSG00000234255.7	AC012370.3	4.31	2.48e-05	0.0108	0.3	0.27	Rheumatoid arthritis;	chr2:65370537	chr2:65439888~65456571:-
OV	cis	rs853679	0.882	rs9461432	ENSG00000226314.6	ZNF192P1	-4.3	2.49e-05	0.0108	-0.5	-0.27	Depression;	chr6:28119105	chr6:28161781~28169594:+
OV	cis	rs7927592	0.763	rs10896326	ENSG00000222339.1	AP000807.2	4.3	2.49e-05	0.0108	0.28	0.27	Total body bone mineral density;	chr11:68467103	chr11:68505572~68505651:-
OV	cis	rs7927771	1	rs4752797	ENSG00000271350.1	CTD-2384B9.1	-4.3	2.49e-05	0.0108	-0.33	-0.27	Subjective well-being;	chr11:47852812	chr11:47041027~47041945:-
OV	cis	rs35491132	1	rs35491132	ENSG00000280107.1	AL022393.9	-4.3	2.49e-05	0.0108	-0.56	-0.27	Urinary tract infection frequency;	chr6:27559449	chr6:28170845~28172521:+
OV	cis	rs875971	0.619	rs12533585	ENSG00000224316.1	RP11-479O9.2	4.3	2.49e-05	0.0108	0.29	0.27	Aortic root size;	chr7:66519618	chr7:65773620~65802067:+
OV	cis	rs6940638	0.688	rs1028308	ENSG00000220721.1	OR1F12	4.3	2.49e-05	0.0108	0.29	0.27	Intelligence (multi-trait analysis);	chr6:27161978	chr6:28073316~28074233:+
OV	cis	rs992157	0.643	rs10191283	ENSG00000237281.1	CATIP-AS2	-4.3	2.49e-05	0.0108	-0.32	-0.27	Colorectal cancer;	chr2:218192032	chr2:218326889~218357966:-
OV	cis	rs853679	0.517	rs9380047	ENSG00000226314.6	ZNF192P1	-4.3	2.49e-05	0.0108	-0.36	-0.27	Depression;	chr6:28070115	chr6:28161781~28169594:+
OV	cis	rs2243480	1	rs466983	ENSG00000226824.5	RP4-756H11.3	-4.3	2.5e-05	0.0108	-0.46	-0.27	Diabetic kidney disease;	chr7:66055509	chr7:66654538~66669855:+
OV	cis	rs3764021	1	rs7977720	ENSG00000278635.1	CTD-2318O12.1	-4.3	2.5e-05	0.0108	-0.23	-0.27	Type 1 diabetes;	chr12:9713753	chr12:9415641~9416718:+
OV	cis	rs875971	0.66	rs801217	ENSG00000224316.1	RP11-479O9.2	-4.3	2.5e-05	0.0108	-0.29	-0.27	Aortic root size;	chr7:66545590	chr7:65773620~65802067:+
OV	cis	rs875971	0.638	rs801216	ENSG00000224316.1	RP11-479O9.2	-4.3	2.5e-05	0.0108	-0.29	-0.27	Aortic root size;	chr7:66546680	chr7:65773620~65802067:+
OV	cis	rs875971	0.66	rs801211	ENSG00000224316.1	RP11-479O9.2	-4.3	2.5e-05	0.0108	-0.29	-0.27	Aortic root size;	chr7:66550702	chr7:65773620~65802067:+
OV	cis	rs875971	0.638	rs801205	ENSG00000224316.1	RP11-479O9.2	-4.3	2.5e-05	0.0108	-0.29	-0.27	Aortic root size;	chr7:66557157	chr7:65773620~65802067:+
OV	cis	rs875971	0.617	rs810400	ENSG00000224316.1	RP11-479O9.2	-4.3	2.5e-05	0.0108	-0.29	-0.27	Aortic root size;	chr7:66557902	chr7:65773620~65802067:+
OV	cis	rs875971	0.66	rs801192	ENSG00000224316.1	RP11-479O9.2	-4.3	2.5e-05	0.0108	-0.29	-0.27	Aortic root size;	chr7:66566965	chr7:65773620~65802067:+
OV	cis	rs875971	0.66	rs801190	ENSG00000224316.1	RP11-479O9.2	-4.3	2.5e-05	0.0108	-0.29	-0.27	Aortic root size;	chr7:66568046	chr7:65773620~65802067:+
OV	cis	rs875971	0.66	rs3857686	ENSG00000224316.1	RP11-479O9.2	-4.3	2.5e-05	0.0108	-0.29	-0.27	Aortic root size;	chr7:66571204	chr7:65773620~65802067:+
OV	cis	rs875971	0.638	rs3898855	ENSG00000224316.1	RP11-479O9.2	-4.3	2.5e-05	0.0108	-0.29	-0.27	Aortic root size;	chr7:66571411	chr7:65773620~65802067:+
OV	cis	rs875971	0.638	rs10278816	ENSG00000224316.1	RP11-479O9.2	-4.3	2.5e-05	0.0108	-0.29	-0.27	Aortic root size;	chr7:66572000	chr7:65773620~65802067:+
OV	cis	rs875971	0.66	rs10281080	ENSG00000224316.1	RP11-479O9.2	-4.3	2.5e-05	0.0108	-0.29	-0.27	Aortic root size;	chr7:66577454	chr7:65773620~65802067:+
OV	cis	rs875971	0.66	rs10950044	ENSG00000224316.1	RP11-479O9.2	-4.3	2.5e-05	0.0108	-0.29	-0.27	Aortic root size;	chr7:66577989	chr7:65773620~65802067:+
OV	cis	rs875971	0.638	rs10249404	ENSG00000224316.1	RP11-479O9.2	-4.3	2.5e-05	0.0108	-0.29	-0.27	Aortic root size;	chr7:66581737	chr7:65773620~65802067:+
OV	cis	rs875971	0.66	rs10215132	ENSG00000224316.1	RP11-479O9.2	-4.3	2.5e-05	0.0108	-0.29	-0.27	Aortic root size;	chr7:66589419	chr7:65773620~65802067:+
OV	cis	rs875971	0.522	rs1968127	ENSG00000224316.1	RP11-479O9.2	-4.3	2.5e-05	0.0108	-0.29	-0.27	Aortic root size;	chr7:66591816	chr7:65773620~65802067:+
OV	cis	rs875971	0.638	rs6460305	ENSG00000224316.1	RP11-479O9.2	-4.3	2.5e-05	0.0108	-0.29	-0.27	Aortic root size;	chr7:66595421	chr7:65773620~65802067:+
OV	cis	rs875971	0.66	rs10272357	ENSG00000224316.1	RP11-479O9.2	-4.3	2.5e-05	0.0108	-0.29	-0.27	Aortic root size;	chr7:66598087	chr7:65773620~65802067:+
OV	cis	rs875971	0.66	rs28698552	ENSG00000224316.1	RP11-479O9.2	4.3	2.5e-05	0.0108	0.29	0.27	Aortic root size;	chr7:66540031	chr7:65773620~65802067:+
OV	cis	rs875971	0.66	rs62465434	ENSG00000224316.1	RP11-479O9.2	4.3	2.5e-05	0.0108	0.29	0.27	Aortic root size;	chr7:66540165	chr7:65773620~65802067:+
OV	cis	rs875971	0.66	rs13224319	ENSG00000224316.1	RP11-479O9.2	4.3	2.5e-05	0.0108	0.29	0.27	Aortic root size;	chr7:66542376	chr7:65773620~65802067:+
OV	cis	rs2070488	0.804	rs13092539	ENSG00000229589.1	ACVR2B-AS1	4.3	2.5e-05	0.0109	0.31	0.27	Electrocardiographic conduction measures;	chr3:38417234	chr3:38451027~38454820:-
OV	cis	rs2070488	0.804	rs13092473	ENSG00000229589.1	ACVR2B-AS1	4.3	2.5e-05	0.0109	0.31	0.27	Electrocardiographic conduction measures;	chr3:38417467	chr3:38451027~38454820:-
OV	cis	rs2070488	0.804	rs7646429	ENSG00000229589.1	ACVR2B-AS1	4.3	2.5e-05	0.0109	0.31	0.27	Electrocardiographic conduction measures;	chr3:38426222	chr3:38451027~38454820:-
OV	cis	rs992157	0.835	rs7559416	ENSG00000237281.1	CATIP-AS2	4.3	2.5e-05	0.0109	0.31	0.27	Colorectal cancer;	chr2:218285488	chr2:218326889~218357966:-
OV	cis	rs375066	0.935	rs368089	ENSG00000267058.1	RP11-15A1.3	-4.3	2.5e-05	0.0109	-0.32	-0.27	Breast cancer;	chr19:43894932	chr19:43891804~43901805:-
OV	cis	rs13201294	1	rs13201294	ENSG00000280107.1	AL022393.9	-4.3	2.5e-05	0.0109	-0.5	-0.27	Squamous cell lung carcinoma;	chr6:27588362	chr6:28170845~28172521:+
OV	cis	rs11649653	0.502	rs11864054	ENSG00000278922.1	AC002310.14	4.3	2.5e-05	0.0109	0.32	0.27	Triglycerides;	chr16:30834813	chr16:30526918~30528294:+
OV	cis	rs11649653	0.502	rs4889490	ENSG00000278922.1	AC002310.14	4.3	2.5e-05	0.0109	0.31	0.27	Triglycerides;	chr16:30811726	chr16:30526918~30528294:+
OV	cis	rs5754266	0.545	rs713685	ENSG00000273325.1	RP1-90G24.11	-4.3	2.51e-05	0.0109	-0.48	-0.27	Blood protein levels;	chr22:32812451	chr22:32284683~32285131:+
OV	cis	rs875971	0.66	rs79009421	ENSG00000224316.1	RP11-479O9.2	-4.3	2.51e-05	0.0109	-0.29	-0.27	Aortic root size;	chr7:66603522	chr7:65773620~65802067:+
OV	cis	rs875971	0.66	rs6460308	ENSG00000224316.1	RP11-479O9.2	-4.3	2.51e-05	0.0109	-0.29	-0.27	Aortic root size;	chr7:66619753	chr7:65773620~65802067:+
OV	cis	rs875971	0.66	rs7807930	ENSG00000224316.1	RP11-479O9.2	-4.3	2.51e-05	0.0109	-0.29	-0.27	Aortic root size;	chr7:66622178	chr7:65773620~65802067:+
OV	cis	rs875971	0.66	rs7807944	ENSG00000224316.1	RP11-479O9.2	-4.3	2.51e-05	0.0109	-0.29	-0.27	Aortic root size;	chr7:66622208	chr7:65773620~65802067:+
OV	cis	rs12073359	0.954	rs55909733	ENSG00000223945.2	RP11-458I7.1	-4.3	2.51e-05	0.0109	-0.42	-0.27	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150139439	chr1:150053864~150055034:+
OV	cis	rs2239557	1	rs2239557	ENSG00000259065.1	RP5-1021I20.1	-4.3	2.51e-05	0.0109	-0.33	-0.27	Common traits (Other);	chr14:74085267	chr14:73787360~73803270:+
OV	cis	rs2239557	0.961	rs11159061	ENSG00000259065.1	RP5-1021I20.1	-4.3	2.51e-05	0.0109	-0.33	-0.27	Common traits (Other);	chr14:74089560	chr14:73787360~73803270:+
OV	cis	rs2239557	1	rs17096228	ENSG00000259065.1	RP5-1021I20.1	-4.3	2.51e-05	0.0109	-0.33	-0.27	Common traits (Other);	chr14:74091966	chr14:73787360~73803270:+
OV	cis	rs62244186	0.627	rs3935212	ENSG00000214820.3	MPRIPP1	4.3	2.51e-05	0.0109	0.25	0.27	Depressive symptoms;	chr3:44419462	chr3:44579938~44581026:-
OV	cis	rs3733585	0.605	rs4697708	ENSG00000250413.1	RP11-448G15.1	4.3	2.51e-05	0.0109	0.34	0.27	Cleft plate (environmental tobacco smoke interaction);	chr4:10119565	chr4:10006482~10009725:+
OV	cis	rs4639966	0.589	rs480958	ENSG00000278376.1	RP11-158I9.8	-4.3	2.52e-05	0.0109	-0.27	-0.27	Systemic lupus erythematosus;	chr11:118707281	chr11:118791254~118793137:+
OV	cis	rs6991838	0.806	rs4285523	ENSG00000272010.1	CTD-3025N20.3	4.3	2.52e-05	0.0109	0.34	0.27	Intelligence (multi-trait analysis);	chr8:65552095	chr8:65591850~65592472:-
OV	cis	rs7267979	1	rs6138572	ENSG00000274973.1	RP13-401N8.7	-4.3	2.52e-05	0.0109	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25455298	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6138575	ENSG00000274973.1	RP13-401N8.7	-4.3	2.52e-05	0.0109	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25458316	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs11087521	ENSG00000274973.1	RP13-401N8.7	-4.3	2.52e-05	0.0109	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25460012	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs13038834	ENSG00000274973.1	RP13-401N8.7	-4.3	2.52e-05	0.0109	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25460797	chr20:25845497~25845862:+
OV	cis	rs7520050	0.966	rs61783200	ENSG00000281133.1	AL355480.3	4.3	2.52e-05	0.0109	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:45831731	chr1:45580892~45580996:-
OV	cis	rs17767294	0.708	rs76223516	ENSG00000220721.1	OR1F12	4.3	2.52e-05	0.0109	0.56	0.27	Parkinson's disease;	chr6:27971697	chr6:28073316~28074233:+
OV	cis	rs7617773	0.78	rs11718350	ENSG00000228638.1	FCF1P2	-4.3	2.52e-05	0.0109	-0.35	-0.27	Coronary artery disease;	chr3:48319502	chr3:48290793~48291375:-
OV	cis	rs6772849	0.896	rs4857859	ENSG00000277250.1	Metazoa_SRP	-4.3	2.52e-05	0.0109	-0.32	-0.27	Monocyte percentage of white cells;Monocyte count;	chr3:128629171	chr3:128673681~128674021:-
OV	cis	rs875971	0.862	rs2901152	ENSG00000236529.1	RP13-254B10.1	-4.3	2.52e-05	0.0109	-0.29	-0.27	Aortic root size;	chr7:66300017	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs10263690	ENSG00000236529.1	RP13-254B10.1	-4.3	2.52e-05	0.0109	-0.29	-0.27	Aortic root size;	chr7:66301466	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs10250544	ENSG00000236529.1	RP13-254B10.1	-4.3	2.52e-05	0.0109	-0.29	-0.27	Aortic root size;	chr7:66301574	chr7:65840212~65840596:+
OV	cis	rs875971	0.895	rs12531677	ENSG00000236529.1	RP13-254B10.1	-4.3	2.52e-05	0.0109	-0.29	-0.27	Aortic root size;	chr7:66304099	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs7798630	ENSG00000236529.1	RP13-254B10.1	-4.3	2.52e-05	0.0109	-0.29	-0.27	Aortic root size;	chr7:66306492	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs11984115	ENSG00000236529.1	RP13-254B10.1	-4.3	2.52e-05	0.0109	-0.29	-0.27	Aortic root size;	chr7:66308872	chr7:65840212~65840596:+
OV	cis	rs875971	0.755	rs10228885	ENSG00000236529.1	RP13-254B10.1	-4.3	2.52e-05	0.0109	-0.29	-0.27	Aortic root size;	chr7:66315542	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs3893216	ENSG00000236529.1	RP13-254B10.1	-4.3	2.52e-05	0.0109	-0.29	-0.27	Aortic root size;	chr7:66325720	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs6958294	ENSG00000236529.1	RP13-254B10.1	-4.3	2.52e-05	0.0109	-0.29	-0.27	Aortic root size;	chr7:66329809	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs2088655	ENSG00000236529.1	RP13-254B10.1	-4.3	2.52e-05	0.0109	-0.29	-0.27	Aortic root size;	chr7:66330724	chr7:65840212~65840596:+
OV	cis	rs875971	0.895	rs10447522	ENSG00000236529.1	RP13-254B10.1	-4.3	2.52e-05	0.0109	-0.29	-0.27	Aortic root size;	chr7:66331087	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs2088653	ENSG00000236529.1	RP13-254B10.1	-4.3	2.52e-05	0.0109	-0.29	-0.27	Aortic root size;	chr7:66343621	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs6460293	ENSG00000236529.1	RP13-254B10.1	-4.3	2.52e-05	0.0109	-0.29	-0.27	Aortic root size;	chr7:66345205	chr7:65840212~65840596:+
OV	cis	rs3733585	0.699	rs12498150	ENSG00000250413.1	RP11-448G15.1	4.3	2.52e-05	0.0109	0.3	0.27	Cleft plate (environmental tobacco smoke interaction);	chr4:9948913	chr4:10006482~10009725:+
OV	cis	rs11903757	0.738	rs71414946	ENSG00000281467.1	Clostridiales-1	-4.3	2.52e-05	0.0109	-0.39	-0.27	Colorectal cancer;	chr2:191692418	chr2:191699476~191699631:-
OV	cis	rs4934494	0.911	rs7081788	ENSG00000240996.1	RP11-80H5.7	-4.3	2.53e-05	0.0109	-0.36	-0.27	Red blood cell count;	chr10:89648999	chr10:89694295~89697928:-
OV	cis	rs747650	0.926	rs11039119	ENSG00000271543.1	RP11-692M12.5	4.3	2.53e-05	0.0109	0.35	0.27	Acne (severe);	chr11:47180373	chr11:47796169~47796379:+
OV	cis	rs7555523	0.887	rs7518099	ENSG00000224358.1	RP11-466F5.8	-4.3	2.53e-05	0.0109	-0.39	-0.27	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165767643	chr1:165768929~165775176:+
OV	cis	rs73201462	0.831	rs2999036	ENSG00000242551.2	POU5F1P6	-4.3	2.53e-05	0.0109	-0.42	-0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128301858	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2811390	ENSG00000242551.2	POU5F1P6	-4.3	2.53e-05	0.0109	-0.42	-0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128302638	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2811391	ENSG00000242551.2	POU5F1P6	-4.3	2.53e-05	0.0109	-0.42	-0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128303525	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2811393	ENSG00000242551.2	POU5F1P6	-4.3	2.53e-05	0.0109	-0.42	-0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128305156	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2037965	ENSG00000242551.2	POU5F1P6	-4.3	2.53e-05	0.0109	-0.42	-0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128306201	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2811397	ENSG00000242551.2	POU5F1P6	-4.3	2.53e-05	0.0109	-0.42	-0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128308394	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs6805582	ENSG00000242551.2	POU5F1P6	4.3	2.53e-05	0.0109	0.42	0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128310165	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs6805621	ENSG00000242551.2	POU5F1P6	4.3	2.53e-05	0.0109	0.42	0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128310361	chr3:128674735~128677005:-
OV	cis	rs17023223	0.537	rs10923754	ENSG00000231365.4	RP11-418J17.1	-4.3	2.53e-05	0.0109	-0.37	-0.27	Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for BMI in active individuals;	chr1:119126017	chr1:119140396~119275973:+
OV	cis	rs4950322	1	rs72694750	ENSG00000278811.3	LINC00624	4.3	2.53e-05	0.0109	0.38	0.27	Protein quantitative trait loci;	chr1:147396856	chr1:147258885~147517875:-
OV	cis	rs4950322	1	rs1986987	ENSG00000278811.3	LINC00624	4.3	2.53e-05	0.0109	0.38	0.27	Protein quantitative trait loci;	chr1:147397553	chr1:147258885~147517875:-
OV	cis	rs4950322	1	rs61230354	ENSG00000278811.3	LINC00624	4.3	2.53e-05	0.0109	0.38	0.27	Protein quantitative trait loci;	chr1:147398161	chr1:147258885~147517875:-
OV	cis	rs4805272	1	rs8104550	ENSG00000267243.4	AC005307.3	-4.3	2.53e-05	0.011	-0.35	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28840826	chr19:28435388~28727777:-
OV	cis	rs1075265	0.655	rs13432632	ENSG00000233266.1	HMGB1P31	4.3	2.53e-05	0.011	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53713586	chr2:54051334~54051760:+
OV	cis	rs10986311	0.713	rs10986292	ENSG00000227200.1	RP11-121A14.3	-4.3	2.53e-05	0.011	-0.24	-0.27	Vitiligo;	chr9:124254597	chr9:124262876~124265809:+
OV	cis	rs7520050	0.966	rs6661910	ENSG00000281133.1	AL355480.3	4.3	2.53e-05	0.011	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:45824960	chr1:45580892~45580996:-
OV	cis	rs11723261	0.664	rs4627799	ENSG00000275426.1	CH17-262A2.1	4.3	2.53e-05	0.011	0.4	0.27	Immune response to smallpox vaccine (IL-6);	chr4:138608	chr4:149738~150317:+
OV	cis	rs7267979	0.932	rs367666	ENSG00000274973.1	RP13-401N8.7	-4.3	2.54e-05	0.011	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25469182	chr20:25845497~25845862:+
OV	cis	rs801193	0.66	rs10950049	ENSG00000236529.1	RP13-254B10.1	4.3	2.54e-05	0.011	0.29	0.27	Aortic root size;	chr7:66765873	chr7:65840212~65840596:+
OV	cis	rs2239547	0.603	rs34230854	ENSG00000242142.1	SERBP1P3	4.3	2.54e-05	0.011	0.35	0.27	Schizophrenia;	chr3:53044574	chr3:53064283~53065091:-
OV	cis	rs62184315	0.536	rs16831873	ENSG00000253559.1	OSGEPL1-AS1	-4.3	2.54e-05	0.011	-0.37	-0.27	Alcohol dependence (age at onset);	chr2:189692172	chr2:189762704~189765556:+
OV	cis	rs9287719	0.753	rs1990613	ENSG00000234818.1	AC092687.5	-4.3	2.54e-05	0.011	-0.31	-0.27	Prostate cancer;	chr2:10641849	chr2:10589166~10604830:+
OV	cis	rs875971	1	rs2077593	ENSG00000237310.1	GS1-124K5.4	4.3	2.54e-05	0.011	0.28	0.27	Aortic root size;	chr7:66427543	chr7:66493706~66495474:+
OV	cis	rs4563143	0.663	rs10406794	ENSG00000260725.1	AC005307.1	-4.3	2.55e-05	0.011	-0.39	-0.27	Methadone dose in opioid dependence;	chr19:28737149	chr19:28418483~28429490:-
OV	cis	rs853679	0.882	rs9393908	ENSG00000280107.1	AL022393.9	-4.3	2.55e-05	0.011	-0.5	-0.27	Depression;	chr6:28223052	chr6:28170845~28172521:+
OV	cis	rs853679	0.882	rs9366717	ENSG00000280107.1	AL022393.9	-4.3	2.55e-05	0.011	-0.5	-0.27	Depression;	chr6:28223279	chr6:28170845~28172521:+
OV	cis	rs1075265	0.756	rs809280	ENSG00000233266.1	HMGB1P31	4.3	2.55e-05	0.011	0.34	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53921270	chr2:54051334~54051760:+
OV	cis	rs11096990	0.821	rs76235093	ENSG00000249207.1	RP11-360F5.1	4.3	2.55e-05	0.011	0.3	0.27	Cognitive function;	chr4:39281157	chr4:39112677~39126818:-
OV	cis	rs11039216	1	rs11039216	ENSG00000280615.1	Y_RNA	4.3	2.55e-05	0.011	0.3	0.27	Neuroticism;	chr11:47385041	chr11:47614898~47614994:-
OV	cis	rs875971	0.825	rs801202	ENSG00000236529.1	RP13-254B10.1	-4.3	2.55e-05	0.011	-0.28	-0.27	Aortic root size;	chr7:66558942	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs801195	ENSG00000236529.1	RP13-254B10.1	-4.3	2.55e-05	0.011	-0.28	-0.27	Aortic root size;	chr7:66561128	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs801194	ENSG00000236529.1	RP13-254B10.1	-4.3	2.55e-05	0.011	-0.28	-0.27	Aortic root size;	chr7:66563508	chr7:65840212~65840596:+
OV	cis	rs7121800	0.962	rs11031113	ENSG00000254532.1	RP11-624D11.2	-4.3	2.55e-05	0.011	-0.32	-0.27	Pit-and-Fissure caries;	chr11:30494410	chr11:30044058~30084343:-
OV	cis	rs6893300	0.785	rs6887507	ENSG00000254035.1	RP11-281O15.4	4.3	2.55e-05	0.011	0.32	0.27	Resting heart rate;	chr5:179759236	chr5:178969390~178990116:+
OV	cis	rs7617773	0.539	rs6779517	ENSG00000228638.1	FCF1P2	-4.3	2.55e-05	0.011	-0.33	-0.27	Coronary artery disease;	chr3:48342898	chr3:48290793~48291375:-
OV	cis	rs1922233	0.657	rs1919225	ENSG00000249049.1	RP11-763F8.1	-4.3	2.55e-05	0.011	-0.37	-0.27	Gut microbiome composition (summer and winter);	chr4:91365454	chr4:91319034~91325306:-
OV	cis	rs875971	0.755	rs76288834	ENSG00000236529.1	RP13-254B10.1	-4.3	2.56e-05	0.011	-0.29	-0.27	Aortic root size;	chr7:66604815	chr7:65840212~65840596:+
OV	cis	rs1979679	0.842	rs11049380	ENSG00000278733.1	RP11-425D17.1	4.3	2.56e-05	0.011	0.33	0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28160904	chr12:28185625~28186190:-
OV	cis	rs1979679	0.842	rs2035271	ENSG00000278733.1	RP11-425D17.1	4.3	2.56e-05	0.011	0.33	0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28165638	chr12:28185625~28186190:-
OV	cis	rs1979679	0.842	rs60025108	ENSG00000278733.1	RP11-425D17.1	4.3	2.56e-05	0.011	0.33	0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28168238	chr12:28185625~28186190:-
OV	cis	rs1979679	0.842	rs7487773	ENSG00000278733.1	RP11-425D17.1	4.3	2.56e-05	0.011	0.33	0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28168418	chr12:28185625~28186190:-
OV	cis	rs7927592	0.763	rs7120876	ENSG00000212093.1	AP000807.1	4.3	2.56e-05	0.011	0.32	0.27	Total body bone mineral density;	chr11:68493930	chr11:68506083~68506166:-
OV	cis	rs2919917	0.628	rs6997255	ENSG00000254352.1	RP11-578O24.2	4.3	2.56e-05	0.011	0.36	0.27	Lymphocyte counts;	chr8:78694850	chr8:78723796~78724136:-
OV	cis	rs2919917	0.628	rs7017898	ENSG00000254352.1	RP11-578O24.2	4.3	2.56e-05	0.011	0.36	0.27	Lymphocyte counts;	chr8:78697147	chr8:78723796~78724136:-
OV	cis	rs2919917	0.628	rs7010299	ENSG00000254352.1	RP11-578O24.2	4.3	2.56e-05	0.011	0.36	0.27	Lymphocyte counts;	chr8:78707786	chr8:78723796~78724136:-
OV	cis	rs2919917	0.628	rs2625663	ENSG00000254352.1	RP11-578O24.2	4.3	2.56e-05	0.011	0.36	0.27	Lymphocyte counts;	chr8:78718106	chr8:78723796~78724136:-
OV	cis	rs7726839	0.54	rs12517638	ENSG00000271781.1	CTD-2589H19.6	-4.3	2.56e-05	0.011	-0.43	-0.27	Obesity-related traits;	chr5:645369	chr5:675826~676616:+
OV	cis	rs7726839	0.54	rs72705030	ENSG00000271781.1	CTD-2589H19.6	-4.3	2.56e-05	0.011	-0.43	-0.27	Obesity-related traits;	chr5:645447	chr5:675826~676616:+
OV	cis	rs11048434	0.761	rs2110192	ENSG00000245105.2	A2M-AS1	4.3	2.56e-05	0.0111	0.24	0.27	Sjögren's syndrome;	chr12:8983755	chr12:9065177~9068060:+
OV	cis	rs12815613	1	rs7961554	ENSG00000200795.1	RNU4-1	-4.3	2.56e-05	0.0111	-0.33	-0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr12:120962441	chr12:120293097~120293237:-
OV	cis	rs7812879	0.636	rs2618455	ENSG00000255052.4	FAM66D	4.3	2.56e-05	0.0111	0.39	0.27	Systemic lupus erythematosus;	chr8:11513369	chr8:12115782~12177550:+
OV	cis	rs7512898	0.522	rs7534184	ENSG00000260088.1	RP11-92G12.3	-4.3	2.57e-05	0.0111	-0.3	-0.27	Electrocardiographic conduction measures;	chr1:200708502	chr1:200669507~200694250:+
OV	cis	rs1823913	0.503	rs35672076	ENSG00000227542.1	AC092614.2	4.3	2.57e-05	0.0111	0.31	0.27	Obesity-related traits;	chr2:191343907	chr2:191229165~191246172:-
OV	cis	rs1823913	0.503	rs35282329	ENSG00000227542.1	AC092614.2	4.3	2.57e-05	0.0111	0.31	0.27	Obesity-related traits;	chr2:191343925	chr2:191229165~191246172:-
OV	cis	rs6088590	0.687	rs6088582	ENSG00000206582.1	Y_RNA	-4.3	2.57e-05	0.0111	-0.33	-0.27	Coronary artery disease;	chr20:34698994	chr20:34526510~34526606:-
OV	cis	rs7131987	0.622	rs7294598	ENSG00000257176.2	RP11-996F15.2	4.3	2.57e-05	0.0111	0.35	0.27	QT interval;	chr12:29379056	chr12:29280418~29317848:-
OV	cis	rs7567389	0.744	rs6430934	ENSG00000236682.1	AC068282.3	4.3	2.57e-05	0.0111	0.37	0.27	Self-rated health;	chr2:127243257	chr2:127389130~127400580:+
OV	cis	rs3733585	0.605	rs56178126	ENSG00000250413.1	RP11-448G15.1	4.3	2.57e-05	0.0111	0.35	0.27	Cleft plate (environmental tobacco smoke interaction);	chr4:10121957	chr4:10006482~10009725:+
OV	cis	rs9880211	0.948	rs34282798	ENSG00000239213.4	NCK1-AS1	4.3	2.57e-05	0.0111	0.34	0.27	Height;Body mass index;	chr3:136424515	chr3:136841726~136862054:-
OV	cis	rs9880211	1	rs34757183	ENSG00000239213.4	NCK1-AS1	4.3	2.57e-05	0.0111	0.34	0.27	Height;Body mass index;	chr3:136424826	chr3:136841726~136862054:-
OV	cis	rs8054556	1	rs4787486	ENSG00000261367.1	RP11-455F5.4	-4.3	2.57e-05	0.0111	-0.3	-0.27	Autism spectrum disorder or schizophrenia;	chr16:29966241	chr16:30107675~30110541:+
OV	cis	rs7017914	0.818	rs13252808	ENSG00000223220.1	Y_RNA	4.3	2.57e-05	0.0111	0.29	0.27	Bone mineral density;	chr8:70704420	chr8:70780914~70781008:-
OV	cis	rs1823913	0.637	rs6741454	ENSG00000227542.1	AC092614.2	-4.3	2.57e-05	0.0111	-0.31	-0.27	Obesity-related traits;	chr2:191269520	chr2:191229165~191246172:-
OV	cis	rs1823913	0.614	rs6755243	ENSG00000227542.1	AC092614.2	-4.3	2.57e-05	0.0111	-0.31	-0.27	Obesity-related traits;	chr2:191269810	chr2:191229165~191246172:-
OV	cis	rs7429990	0.864	rs12497826	ENSG00000229759.1	MRPS18AP1	-4.3	2.58e-05	0.0111	-0.3	-0.27	Educational attainment (years of education);	chr3:47628059	chr3:48256350~48256938:-
OV	cis	rs4296809	0.505	rs72753614	ENSG00000249779.1	RP11-447H19.3	-4.3	2.58e-05	0.0111	-0.52	-0.27	Brain structure;	chr5:44101578	chr5:43206709~43207811:+
OV	cis	rs7520050	0.933	rs11211203	ENSG00000281133.1	AL355480.3	4.3	2.58e-05	0.0111	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:45849920	chr1:45580892~45580996:-
OV	cis	rs638893	0.853	rs4938549	ENSG00000255239.1	AP002954.6	4.3	2.58e-05	0.0111	0.42	0.27	Vitiligo;	chr11:118830888	chr11:118688039~118690600:-
OV	cis	rs638893	0.898	rs530646	ENSG00000255239.1	AP002954.6	4.3	2.58e-05	0.0111	0.42	0.27	Vitiligo;	chr11:118830959	chr11:118688039~118690600:-
OV	cis	rs638893	0.947	rs12808822	ENSG00000255239.1	AP002954.6	4.3	2.58e-05	0.0111	0.42	0.27	Vitiligo;	chr11:118831560	chr11:118688039~118690600:-
OV	cis	rs638893	0.947	rs1170396	ENSG00000255239.1	AP002954.6	4.3	2.58e-05	0.0111	0.42	0.27	Vitiligo;	chr11:118833108	chr11:118688039~118690600:-
OV	cis	rs7773456	1	rs7773456	ENSG00000240869.3	RN7SL128P	-4.3	2.58e-05	0.0111	-0.31	-0.27	Lupus nephritis in systemic lupus erythematosus;	chr6:19823007	chr6:20421583~20421887:-
OV	cis	rs7520050	0.966	rs11211199	ENSG00000281133.1	AL355480.3	4.3	2.59e-05	0.0111	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:45822197	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs4376778	ENSG00000281133.1	AL355480.3	4.3	2.59e-05	0.0111	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:45823174	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs6672898	ENSG00000281133.1	AL355480.3	4.3	2.59e-05	0.0111	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:45824916	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs7539932	ENSG00000281133.1	AL355480.3	4.3	2.59e-05	0.0111	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:45826682	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs6680380	ENSG00000281133.1	AL355480.3	4.3	2.59e-05	0.0111	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:45834517	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs10890354	ENSG00000281133.1	AL355480.3	4.3	2.59e-05	0.0111	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:45839675	chr1:45580892~45580996:-
OV	cis	rs7520050	0.931	rs6697557	ENSG00000281133.1	AL355480.3	4.3	2.59e-05	0.0111	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:45842137	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs6701614	ENSG00000281133.1	AL355480.3	4.3	2.59e-05	0.0111	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:45843748	chr1:45580892~45580996:-
OV	cis	rs8177876	0.915	rs8059692	ENSG00000261838.4	RP11-303E16.6	4.3	2.59e-05	0.0112	0.46	0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81096889	chr16:81069854~81076598:+
OV	cis	rs10462065	0.818	rs72750176	ENSG00000249779.1	RP11-447H19.3	-4.3	2.59e-05	0.0112	-0.53	-0.27	Nonsyndromic cleft lip with cleft palate;	chr5:44049836	chr5:43206709~43207811:+
OV	cis	rs853679	0.607	rs13211507	ENSG00000220721.1	OR1F12	4.29	2.59e-05	0.0112	0.53	0.27	Depression;	chr6:28289600	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs34691223	ENSG00000220721.1	OR1F12	4.29	2.59e-05	0.0112	0.53	0.27	Depression;	chr6:28290431	chr6:28073316~28074233:+
OV	cis	rs9813712	0.597	rs62281648	ENSG00000253540.4	FAM86HP	-4.29	2.59e-05	0.0112	-0.29	-0.27	Response to amphetamines;	chr3:130244794	chr3:130099092~130111472:-
OV	cis	rs2227564	0.62	rs10740418	ENSG00000271816.1	BMS1P4	4.29	2.59e-05	0.0112	0.27	0.27	Crohn's disease;Inflammatory bowel disease;	chr10:73759564	chr10:73699151~73730487:-
OV	cis	rs1150668	0.699	rs2394049	ENSG00000204709.4	LINC01556	4.29	2.59e-05	0.0112	0.31	0.27	Pubertal anthropometrics;	chr6:28271903	chr6:28943877~28944537:+
OV	cis	rs1150668	0.699	rs1531681	ENSG00000204709.4	LINC01556	4.29	2.6e-05	0.0112	0.31	0.27	Pubertal anthropometrics;	chr6:28259100	chr6:28943877~28944537:+
OV	cis	rs7267979	0.866	rs437635	ENSG00000274973.1	RP13-401N8.7	-4.29	2.6e-05	0.0112	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25476252	chr20:25845497~25845862:+
OV	cis	rs7267979	0.899	rs442834	ENSG00000274973.1	RP13-401N8.7	-4.29	2.6e-05	0.0112	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25477460	chr20:25845497~25845862:+
OV	cis	rs7267979	0.932	rs417110	ENSG00000274973.1	RP13-401N8.7	-4.29	2.6e-05	0.0112	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25477661	chr20:25845497~25845862:+
OV	cis	rs7267979	0.932	rs417130	ENSG00000274973.1	RP13-401N8.7	-4.29	2.6e-05	0.0112	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25477684	chr20:25845497~25845862:+
OV	cis	rs7267979	0.932	rs449703	ENSG00000274973.1	RP13-401N8.7	-4.29	2.6e-05	0.0112	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25477923	chr20:25845497~25845862:+
OV	cis	rs7267979	0.932	rs6037125	ENSG00000274973.1	RP13-401N8.7	-4.29	2.6e-05	0.0112	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25482746	chr20:25845497~25845862:+
OV	cis	rs7267979	0.932	rs372678	ENSG00000274973.1	RP13-401N8.7	-4.29	2.6e-05	0.0112	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25484612	chr20:25845497~25845862:+
OV	cis	rs7267979	0.932	rs431579	ENSG00000274973.1	RP13-401N8.7	-4.29	2.6e-05	0.0112	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25489420	chr20:25845497~25845862:+
OV	cis	rs1555322	0.53	rs2425049	ENSG00000279253.1	RP4-614O4.13	-4.29	2.6e-05	0.0112	-0.34	-0.27	Attention deficit hyperactivity disorder;	chr20:35286917	chr20:35262727~35264187:-
OV	cis	rs7520050	0.743	rs61789988	ENSG00000281133.1	AL355480.3	4.29	2.6e-05	0.0112	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:45619570	chr1:45580892~45580996:-
OV	cis	rs801193	0.527	rs2707837	ENSG00000237310.1	GS1-124K5.4	4.29	2.61e-05	0.0112	0.28	0.27	Aortic root size;	chr7:66716086	chr7:66493706~66495474:+
OV	cis	rs34421088	0.506	rs2117616	ENSG00000255495.1	AC145124.2	-4.29	2.61e-05	0.0112	-0.3	-0.27	Neuroticism;	chr8:11288402	chr8:12194467~12196280:+
OV	cis	rs3733585	0.699	rs13328050	ENSG00000250413.1	RP11-448G15.1	4.29	2.61e-05	0.0112	0.3	0.27	Cleft plate (environmental tobacco smoke interaction);	chr4:9949496	chr4:10006482~10009725:+
OV	cis	rs2522056	1	rs1003533	ENSG00000233006.5	AC034220.3	-4.29	2.61e-05	0.0112	-0.32	-0.27	Fibrinogen;Lymphocyte counts;	chr5:132419959	chr5:132311285~132369916:-
OV	cis	rs7267979	0.932	rs1985737	ENSG00000274973.1	RP13-401N8.7	-4.29	2.61e-05	0.0112	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25610832	chr20:25845497~25845862:+
OV	cis	rs4934494	0.911	rs34486602	ENSG00000240996.1	RP11-80H5.7	-4.29	2.62e-05	0.0113	-0.36	-0.27	Red blood cell count;	chr10:89655895	chr10:89694295~89697928:-
OV	cis	rs4934494	0.911	rs6586213	ENSG00000240996.1	RP11-80H5.7	-4.29	2.62e-05	0.0113	-0.36	-0.27	Red blood cell count;	chr10:89656327	chr10:89694295~89697928:-
OV	cis	rs801193	0.591	rs9986881	ENSG00000224316.1	RP11-479O9.2	4.29	2.62e-05	0.0113	0.32	0.27	Aortic root size;	chr7:66708053	chr7:65773620~65802067:+
OV	cis	rs2522056	1	rs2106854	ENSG00000233006.5	AC034220.3	-4.29	2.62e-05	0.0113	-0.33	-0.27	Fibrinogen;Lymphocyte counts;	chr5:132433482	chr5:132311285~132369916:-
OV	cis	rs11673344	0.764	rs1644643	ENSG00000226686.6	LINC01535	4.29	2.62e-05	0.0113	0.35	0.27	Obesity-related traits;	chr19:36972269	chr19:37251912~37265535:+
OV	cis	rs11157436	0.83	rs61972214	ENSG00000211812.1	TRAV26-2	-4.29	2.62e-05	0.0113	-0.31	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22152416	chr14:22202583~22203368:+
OV	cis	rs7302981	0.746	rs646782	ENSG00000272368.2	RP4-605O3.4	4.29	2.62e-05	0.0113	0.3	0.27	Systolic blood pressure;	chr12:50088428	chr12:50112197~50165618:+
OV	cis	rs2599510	0.811	rs2710625	ENSG00000279544.1	AL133243.4	-4.29	2.62e-05	0.0113	-0.25	-0.27	Interleukin-18 levels;	chr2:32597890	chr2:32563328~32566436:+
OV	cis	rs992157	0.798	rs10932772	ENSG00000237281.1	CATIP-AS2	-4.29	2.62e-05	0.0113	-0.32	-0.27	Colorectal cancer;	chr2:218312425	chr2:218326889~218357966:-
OV	cis	rs2015599	0.623	rs7313552	ENSG00000257176.2	RP11-996F15.2	4.29	2.63e-05	0.0113	0.34	0.27	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29280418~29317848:-
OV	cis	rs2015599	0.584	rs7299283	ENSG00000257176.2	RP11-996F15.2	4.29	2.63e-05	0.0113	0.34	0.27	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29280418~29317848:-
OV	cis	rs7968440	1	rs66644594	ENSG00000257298.1	RP3-405J10.3	4.29	2.63e-05	0.0113	0.27	0.27	Fibrinogen;	chr12:50539200	chr12:50185580~50191363:-
OV	cis	rs17301013	0.507	rs12091076	ENSG00000227373.4	RP11-160H22.5	4.29	2.63e-05	0.0113	0.37	0.27	Systemic lupus erythematosus;	chr1:174321545	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs16846861	ENSG00000227373.4	RP11-160H22.5	4.29	2.63e-05	0.0113	0.37	0.27	Systemic lupus erythematosus;	chr1:174338731	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs2860954	ENSG00000227373.4	RP11-160H22.5	4.29	2.63e-05	0.0113	0.37	0.27	Systemic lupus erythematosus;	chr1:174344313	chr1:174115300~174160004:-
OV	cis	rs17301013	0.507	rs60864659	ENSG00000227373.4	RP11-160H22.5	4.29	2.63e-05	0.0113	0.37	0.27	Systemic lupus erythematosus;	chr1:174344641	chr1:174115300~174160004:-
OV	cis	rs2880765	0.835	rs12708553	ENSG00000229212.6	RP11-561C5.4	-4.29	2.63e-05	0.0113	-0.31	-0.27	Coronary artery disease;	chr15:85503602	chr15:85205440~85234795:-
OV	cis	rs7520050	0.966	rs10890383	ENSG00000280836.1	AL355480.1	4.29	2.63e-05	0.0113	0.35	0.27	Reticulocyte count;Red blood cell count;	chr1:46122831	chr1:45581219~45581321:-
OV	cis	rs12962334	0.555	rs9959556	ENSG00000242182.3	RN7SL745P	4.29	2.63e-05	0.0113	0.31	0.27	Breast cancer;	chr18:23011982	chr18:23004564~23004862:+
OV	cis	rs4578769	0.531	rs4800443	ENSG00000242182.3	RN7SL745P	4.29	2.63e-05	0.0113	0.31	0.27	Eosinophil percentage of white cells;	chr18:23015139	chr18:23004564~23004862:+
OV	cis	rs2243480	1	rs6958289	ENSG00000226824.5	RP4-756H11.3	4.29	2.63e-05	0.0113	0.44	0.27	Diabetic kidney disease;	chr7:66192124	chr7:66654538~66669855:+
OV	cis	rs181553	0.664	rs2166670	ENSG00000266696.1	RP11-30L3.2	4.29	2.63e-05	0.0113	0.34	0.27	Hip circumference adjusted for BMI;	chr18:49158540	chr18:49205912~49208781:+
OV	cis	rs12073359	0.954	rs12061565	ENSG00000223945.2	RP11-458I7.1	-4.29	2.63e-05	0.0113	-0.44	-0.27	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150039388	chr1:150053864~150055034:+
OV	cis	rs7968440	0.933	rs4768885	ENSG00000257298.1	RP3-405J10.3	-4.29	2.63e-05	0.0113	-0.25	-0.27	Fibrinogen;	chr12:50527989	chr12:50185580~50191363:-
OV	cis	rs7968440	0.902	rs4768886	ENSG00000257298.1	RP3-405J10.3	-4.29	2.63e-05	0.0113	-0.25	-0.27	Fibrinogen;	chr12:50528196	chr12:50185580~50191363:-
OV	cis	rs9287719	0.601	rs10177062	ENSG00000243819.4	RN7SL832P	4.29	2.63e-05	0.0113	0.29	0.27	Prostate cancer;	chr2:10573572	chr2:10690344~10692099:+
OV	cis	rs694739	1	rs646153	ENSG00000236935.1	AP003774.1	4.29	2.63e-05	0.0113	0.37	0.27	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64322116	chr11:64325050~64329504:-
OV	cis	rs10228465	0.953	rs1034836	ENSG00000234999.1	SNRPCP19	4.29	2.64e-05	0.0113	0.32	0.27	Lobe attachment (rater-scored or self-reported);	chr7:25408328	chr7:24906135~24906594:-
OV	cis	rs514406	0.56	rs1889033	ENSG00000206627.1	RNU6-969P	-4.29	2.64e-05	0.0113	-0.29	-0.27	Monocyte count;	chr1:52746215	chr1:52805108~52805212:-
OV	cis	rs514406	0.548	rs6670871	ENSG00000206627.1	RNU6-969P	-4.29	2.64e-05	0.0113	-0.29	-0.27	Monocyte count;	chr1:52746410	chr1:52805108~52805212:-
OV	cis	rs9660180	0.967	rs6687065	ENSG00000215914.4	MMP23A	-4.29	2.64e-05	0.0113	-0.32	-0.27	Body mass index;	chr1:1847030	chr1:1699942~1701782:+
OV	cis	rs7520050	0.966	rs785479	ENSG00000281133.1	AL355480.3	4.29	2.64e-05	0.0113	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:46026472	chr1:45580892~45580996:-
OV	cis	rs7555523	0.887	rs4657476	ENSG00000224358.1	RP11-466F5.8	4.29	2.64e-05	0.0114	0.38	0.27	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165763424	chr1:165768929~165775176:+
OV	cis	rs7121800	0.888	rs12800941	ENSG00000254532.1	RP11-624D11.2	4.29	2.64e-05	0.0114	0.32	0.27	Pit-and-Fissure caries;	chr11:30491179	chr11:30044058~30084343:-
OV	cis	rs5742933	1	rs3762545	ENSG00000253559.1	OSGEPL1-AS1	-4.29	2.64e-05	0.0114	-0.31	-0.27	Ferritin levels;	chr2:189790835	chr2:189762704~189765556:+
OV	cis	rs5742933	1	rs5742998	ENSG00000253559.1	OSGEPL1-AS1	-4.29	2.64e-05	0.0114	-0.31	-0.27	Ferritin levels;	chr2:189799626	chr2:189762704~189765556:+
OV	cis	rs9880211	0.898	rs9866840	ENSG00000239213.4	NCK1-AS1	4.29	2.64e-05	0.0114	0.34	0.27	Height;Body mass index;	chr3:136310416	chr3:136841726~136862054:-
OV	cis	rs1862618	0.853	rs860580	ENSG00000271828.1	CTD-2310F14.1	-4.29	2.64e-05	0.0114	-0.43	-0.27	Initial pursuit acceleration;	chr5:56853602	chr5:56927874~56929573:+
OV	cis	rs801193	0.569	rs2659908	ENSG00000237310.1	GS1-124K5.4	4.29	2.65e-05	0.0114	0.28	0.27	Aortic root size;	chr7:66695835	chr7:66493706~66495474:+
OV	cis	rs801193	0.569	rs7782587	ENSG00000237310.1	GS1-124K5.4	4.29	2.65e-05	0.0114	0.28	0.27	Aortic root size;	chr7:66701485	chr7:66493706~66495474:+
OV	cis	rs801193	0.569	rs4717315	ENSG00000237310.1	GS1-124K5.4	4.29	2.65e-05	0.0114	0.28	0.27	Aortic root size;	chr7:66713338	chr7:66493706~66495474:+
OV	cis	rs6940638	0.688	rs9461335	ENSG00000220721.1	OR1F12	4.29	2.65e-05	0.0114	0.29	0.27	Intelligence (multi-trait analysis);	chr6:27170750	chr6:28073316~28074233:+
OV	cis	rs1979679	0.879	rs55996833	ENSG00000278733.1	RP11-425D17.1	4.29	2.65e-05	0.0114	0.33	0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28313303	chr12:28185625~28186190:-
OV	cis	rs8114671	0.967	rs4911476	ENSG00000269202.1	RP4-614O4.12	4.29	2.65e-05	0.0114	0.27	0.27	Height;	chr20:35192965	chr20:35201747~35203288:-
OV	cis	rs934734	0.752	rs2661795	ENSG00000234255.7	AC012370.3	-4.29	2.65e-05	0.0114	-0.29	-0.27	Rheumatoid arthritis;	chr2:65399672	chr2:65439888~65456571:-
OV	cis	rs934734	0.752	rs2661797	ENSG00000234255.7	AC012370.3	-4.29	2.65e-05	0.0114	-0.29	-0.27	Rheumatoid arthritis;	chr2:65406056	chr2:65439888~65456571:-
OV	cis	rs4938303	0.718	rs10892023	ENSG00000254851.1	RP11-109L13.1	-4.29	2.65e-05	0.0114	-0.42	-0.27	Triglycerides;	chr11:116727532	chr11:117135528~117138582:+
OV	cis	rs9992667	0.955	rs73232876	ENSG00000231160.8	KLF3-AS1	4.29	2.66e-05	0.0114	0.32	0.27	Eosinophil percentage of granulocytes;	chr4:38645888	chr4:38612701~38664883:-
OV	cis	rs13113518	0.812	rs13107810	ENSG00000223305.1	RN7SKP30	4.29	2.66e-05	0.0114	0.32	0.27	Height;	chr4:55542243	chr4:55540502~55540835:-
OV	cis	rs1930961	0.85	rs5996945	ENSG00000272942.1	CTA-246H3.12	4.29	2.66e-05	0.0114	0.34	0.27	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25434324~25435070:-
OV	cis	rs11951515	0.738	rs10805674	ENSG00000278487.1	RP11-447H19.4	-4.29	2.66e-05	0.0114	-0.32	-0.27	Metabolite levels  (X-11787);	chr5:43349758	chr5:43143362~43143514:-
OV	cis	rs1075265	0.756	rs3821081	ENSG00000233266.1	HMGB1P31	-4.29	2.66e-05	0.0114	-0.33	-0.27	Chronotype;Morning vs. evening chronotype;	chr2:53738252	chr2:54051334~54051760:+
OV	cis	rs13236243	0.502	rs3802083	ENSG00000237773.4	AC003075.4	4.29	2.66e-05	0.0114	0.28	0.27	Sensory disturbances after bilateral sagittal split ramus osteotomy;	chr7:17309283	chr7:17279834~17299357:-
OV	cis	rs1584120	0.57	rs10842120	ENSG00000274885.1	RP11-268P4.6	4.29	2.66e-05	0.0114	0.31	0.27	Pelvic organ prolapse (moderate/severe);	chr12:23105069	chr12:22638464~22638943:+
OV	cis	rs638893	1	rs113641235	ENSG00000255239.1	AP002954.6	-4.29	2.66e-05	0.0114	-0.46	-0.27	Vitiligo;	chr11:118829555	chr11:118688039~118690600:-
OV	cis	rs1020064	0.636	rs2576750	ENSG00000235319.1	AC012360.4	-4.29	2.66e-05	0.0114	-0.34	-0.27	AIDS;	chr2:105300178	chr2:105324210~105330529:+
OV	cis	rs6844153	1	rs6844153	ENSG00000240005.4	RP11-293A21.1	-4.29	2.67e-05	0.0114	-0.39	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26942692	chr4:26859806~26860599:-
OV	cis	rs2274471	0.645	rs3780375	ENSG00000234534.1	CSNK1G2P1	4.29	2.67e-05	0.0114	0.34	0.27	Crohn's disease;	chr9:5109431	chr9:5040945~5041940:+
OV	cis	rs875971	0.545	rs73142233	ENSG00000237310.1	GS1-124K5.4	4.29	2.67e-05	0.0114	0.32	0.27	Aortic root size;	chr7:66221293	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs6971059	ENSG00000237310.1	GS1-124K5.4	-4.29	2.67e-05	0.0115	-0.28	-0.27	Aortic root size;	chr7:66602045	chr7:66493706~66495474:+
OV	cis	rs875971	0.789	rs7808013	ENSG00000237310.1	GS1-124K5.4	-4.29	2.67e-05	0.0115	-0.28	-0.27	Aortic root size;	chr7:66606209	chr7:66493706~66495474:+
OV	cis	rs875971	0.825	rs7384021	ENSG00000237310.1	GS1-124K5.4	-4.29	2.67e-05	0.0115	-0.28	-0.27	Aortic root size;	chr7:66612917	chr7:66493706~66495474:+
OV	cis	rs875971	0.825	rs66981195	ENSG00000237310.1	GS1-124K5.4	-4.29	2.67e-05	0.0115	-0.28	-0.27	Aortic root size;	chr7:66614048	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs3926380	ENSG00000237310.1	GS1-124K5.4	-4.29	2.67e-05	0.0115	-0.28	-0.27	Aortic root size;	chr7:66615658	chr7:66493706~66495474:+
OV	cis	rs875971	0.825	rs1860472	ENSG00000237310.1	GS1-124K5.4	-4.29	2.67e-05	0.0115	-0.28	-0.27	Aortic root size;	chr7:66617736	chr7:66493706~66495474:+
OV	cis	rs897984	0.762	rs7204459	ENSG00000260911.2	RP11-196G11.2	-4.29	2.67e-05	0.0115	-0.25	-0.27	Dementia with Lewy bodies;	chr16:30972891	chr16:31043150~31049868:+
OV	cis	rs897984	0.762	rs4889604	ENSG00000260911.2	RP11-196G11.2	-4.29	2.67e-05	0.0115	-0.25	-0.27	Dementia with Lewy bodies;	chr16:30974673	chr16:31043150~31049868:+
OV	cis	rs897984	0.762	rs12931046	ENSG00000260911.2	RP11-196G11.2	-4.29	2.67e-05	0.0115	-0.25	-0.27	Dementia with Lewy bodies;	chr16:30975823	chr16:31043150~31049868:+
OV	cis	rs6088580	0.567	rs6088520	ENSG00000206582.1	Y_RNA	4.29	2.67e-05	0.0115	0.33	0.27	Glomerular filtration rate (creatinine);	chr20:34544560	chr20:34526510~34526606:-
OV	cis	rs2243480	1	rs56016656	ENSG00000226824.5	RP4-756H11.3	-4.29	2.67e-05	0.0115	-0.44	-0.27	Diabetic kidney disease;	chr7:65918494	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs56291018	ENSG00000226824.5	RP4-756H11.3	-4.29	2.67e-05	0.0115	-0.44	-0.27	Diabetic kidney disease;	chr7:65925352	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs36033484	ENSG00000226824.5	RP4-756H11.3	-4.29	2.67e-05	0.0115	-0.44	-0.27	Diabetic kidney disease;	chr7:65925571	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs34193460	ENSG00000226824.5	RP4-756H11.3	-4.29	2.67e-05	0.0115	-0.44	-0.27	Diabetic kidney disease;	chr7:65928123	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs34560516	ENSG00000226824.5	RP4-756H11.3	-4.29	2.67e-05	0.0115	-0.44	-0.27	Diabetic kidney disease;	chr7:65939105	chr7:66654538~66669855:+
OV	cis	rs10129255	0.5	rs8021941	ENSG00000223648.3	IGHV3-64	4.29	2.68e-05	0.0115	0.27	0.27	Kawasaki disease;	chr14:106781490	chr14:106643132~106658258:-
OV	cis	rs9318086	0.712	rs12875437	ENSG00000205861.10	C1QTNF9B-AS1	-4.29	2.68e-05	0.0115	-0.34	-0.27	Myopia (pathological);	chr13:23879817	chr13:23888889~23897263:+
OV	cis	rs875971	1	rs6460296	ENSG00000237310.1	GS1-124K5.4	4.29	2.68e-05	0.0115	0.28	0.27	Aortic root size;	chr7:66430152	chr7:66493706~66495474:+
OV	cis	rs875971	1	rs4717292	ENSG00000237310.1	GS1-124K5.4	4.29	2.68e-05	0.0115	0.28	0.27	Aortic root size;	chr7:66430611	chr7:66493706~66495474:+
OV	cis	rs875971	0.895	rs4718349	ENSG00000237310.1	GS1-124K5.4	4.29	2.68e-05	0.0115	0.28	0.27	Aortic root size;	chr7:66444024	chr7:66493706~66495474:+
OV	cis	rs875971	1	rs2420591	ENSG00000237310.1	GS1-124K5.4	4.29	2.68e-05	0.0115	0.28	0.27	Aortic root size;	chr7:66447394	chr7:66493706~66495474:+
OV	cis	rs875971	0.895	rs10755833	ENSG00000237310.1	GS1-124K5.4	4.29	2.68e-05	0.0115	0.28	0.27	Aortic root size;	chr7:66448930	chr7:66493706~66495474:+
OV	cis	rs875971	0.964	rs12668936	ENSG00000237310.1	GS1-124K5.4	4.29	2.68e-05	0.0115	0.28	0.27	Aortic root size;	chr7:66449417	chr7:66493706~66495474:+
OV	cis	rs875971	0.895	rs7788984	ENSG00000237310.1	GS1-124K5.4	4.29	2.68e-05	0.0115	0.28	0.27	Aortic root size;	chr7:66450629	chr7:66493706~66495474:+
OV	cis	rs875971	0.895	rs1833495	ENSG00000237310.1	GS1-124K5.4	4.29	2.68e-05	0.0115	0.28	0.27	Aortic root size;	chr7:66456608	chr7:66493706~66495474:+
OV	cis	rs875971	0.964	rs6945032	ENSG00000237310.1	GS1-124K5.4	4.29	2.68e-05	0.0115	0.28	0.27	Aortic root size;	chr7:66457499	chr7:66493706~66495474:+
OV	cis	rs875971	0.929	rs12673810	ENSG00000237310.1	GS1-124K5.4	4.29	2.68e-05	0.0115	0.28	0.27	Aortic root size;	chr7:66458866	chr7:66493706~66495474:+
OV	cis	rs875971	1	rs35149210	ENSG00000237310.1	GS1-124K5.4	4.29	2.68e-05	0.0115	0.28	0.27	Aortic root size;	chr7:66464938	chr7:66493706~66495474:+
OV	cis	rs875971	1	rs2042133	ENSG00000237310.1	GS1-124K5.4	4.29	2.68e-05	0.0115	0.28	0.27	Aortic root size;	chr7:66466935	chr7:66493706~66495474:+
OV	cis	rs875971	0.964	rs2161065	ENSG00000237310.1	GS1-124K5.4	4.29	2.68e-05	0.0115	0.28	0.27	Aortic root size;	chr7:66467918	chr7:66493706~66495474:+
OV	cis	rs875971	1	rs6961155	ENSG00000237310.1	GS1-124K5.4	4.29	2.68e-05	0.0115	0.28	0.27	Aortic root size;	chr7:66468308	chr7:66493706~66495474:+
OV	cis	rs875971	1	rs7789768	ENSG00000237310.1	GS1-124K5.4	4.29	2.68e-05	0.0115	0.28	0.27	Aortic root size;	chr7:66473993	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs12698521	ENSG00000237310.1	GS1-124K5.4	4.29	2.68e-05	0.0115	0.28	0.27	Aortic root size;	chr7:66474502	chr7:66493706~66495474:+
OV	cis	rs875971	1	rs1363055	ENSG00000237310.1	GS1-124K5.4	4.29	2.68e-05	0.0115	0.28	0.27	Aortic root size;	chr7:66478288	chr7:66493706~66495474:+
OV	cis	rs875971	0.964	rs9691480	ENSG00000237310.1	GS1-124K5.4	4.29	2.68e-05	0.0115	0.28	0.27	Aortic root size;	chr7:66479319	chr7:66493706~66495474:+
OV	cis	rs875971	1	rs7789554	ENSG00000237310.1	GS1-124K5.4	4.29	2.68e-05	0.0115	0.28	0.27	Aortic root size;	chr7:66481051	chr7:66493706~66495474:+
OV	cis	rs875971	1	rs4717300	ENSG00000237310.1	GS1-124K5.4	4.29	2.68e-05	0.0115	0.28	0.27	Aortic root size;	chr7:66482393	chr7:66493706~66495474:+
OV	cis	rs875971	0.895	rs1974769	ENSG00000237310.1	GS1-124K5.4	4.29	2.68e-05	0.0115	0.28	0.27	Aortic root size;	chr7:66485627	chr7:66493706~66495474:+
OV	cis	rs875971	0.895	rs6460300	ENSG00000237310.1	GS1-124K5.4	4.29	2.68e-05	0.0115	0.28	0.27	Aortic root size;	chr7:66487937	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs7803416	ENSG00000237310.1	GS1-124K5.4	4.29	2.68e-05	0.0115	0.28	0.27	Aortic root size;	chr7:66489212	chr7:66493706~66495474:+
OV	cis	rs875971	1	rs1981798	ENSG00000237310.1	GS1-124K5.4	4.29	2.68e-05	0.0115	0.28	0.27	Aortic root size;	chr7:66489916	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs1981799	ENSG00000237310.1	GS1-124K5.4	4.29	2.68e-05	0.0115	0.28	0.27	Aortic root size;	chr7:66490572	chr7:66493706~66495474:+
OV	cis	rs875971	0.964	rs2277911	ENSG00000237310.1	GS1-124K5.4	4.29	2.68e-05	0.0115	0.28	0.27	Aortic root size;	chr7:66493638	chr7:66493706~66495474:+
OV	cis	rs7927592	0.763	rs1193699	ENSG00000212093.1	AP000807.1	4.29	2.68e-05	0.0115	0.32	0.27	Total body bone mineral density;	chr11:68482012	chr11:68506083~68506166:-
OV	cis	rs1790761	0.587	rs4930430	ENSG00000184224.3	C11orf72	4.29	2.68e-05	0.0115	0.31	0.27	Mean corpuscular volume;	chr11:67526727	chr11:67602880~67606706:-
OV	cis	rs1707322	0.752	rs11488313	ENSG00000234329.1	RP11-767N6.2	4.29	2.68e-05	0.0115	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr1:45651039~45651826:-
OV	cis	rs2070488	0.965	rs13097628	ENSG00000229589.1	ACVR2B-AS1	4.29	2.69e-05	0.0115	0.3	0.27	Electrocardiographic conduction measures;	chr3:38479665	chr3:38451027~38454820:-
OV	cis	rs2070488	0.965	rs4679053	ENSG00000229589.1	ACVR2B-AS1	4.29	2.69e-05	0.0115	0.3	0.27	Electrocardiographic conduction measures;	chr3:38482004	chr3:38451027~38454820:-
OV	cis	rs944801	0.587	rs10965212	ENSG00000234840.1	LINC01239	4.29	2.69e-05	0.0115	0.31	0.27	Type 2 diabetes;	chr9:22023796	chr9:22646200~22824213:+
OV	cis	rs875971	0.545	rs1796219	ENSG00000236529.1	RP13-254B10.1	-4.29	2.69e-05	0.0115	-0.33	-0.27	Aortic root size;	chr7:66645977	chr7:65840212~65840596:+
OV	cis	rs7512898	0.5	rs10733063	ENSG00000260088.1	RP11-92G12.3	-4.29	2.69e-05	0.0115	-0.3	-0.27	Electrocardiographic conduction measures;	chr1:200821181	chr1:200669507~200694250:+
OV	cis	rs6088590	0.687	rs13044899	ENSG00000206582.1	Y_RNA	-4.29	2.69e-05	0.0115	-0.34	-0.27	Coronary artery disease;	chr20:34699274	chr20:34526510~34526606:-
OV	cis	rs62184315	0.58	rs62185872	ENSG00000253559.1	OSGEPL1-AS1	-4.29	2.69e-05	0.0115	-0.37	-0.27	Alcohol dependence (age at onset);	chr2:189690033	chr2:189762704~189765556:+
OV	cis	rs514406	0.644	rs1855127	ENSG00000206627.1	RNU6-969P	-4.29	2.69e-05	0.0115	-0.29	-0.27	Monocyte count;	chr1:52733922	chr1:52805108~52805212:-
OV	cis	rs7429990	0.864	rs35698005	ENSG00000229759.1	MRPS18AP1	-4.29	2.69e-05	0.0115	-0.3	-0.27	Educational attainment (years of education);	chr3:47800558	chr3:48256350~48256938:-
OV	cis	rs4591358	0.705	rs11897464	ENSG00000223466.1	AC064834.2	-4.29	2.69e-05	0.0115	-0.32	-0.27	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195478572	chr2:195533035~195538681:+
OV	cis	rs1823913	0.637	rs4853465	ENSG00000227542.1	AC092614.2	-4.29	2.69e-05	0.0115	-0.3	-0.27	Obesity-related traits;	chr2:191294768	chr2:191229165~191246172:-
OV	cis	rs1823913	0.599	rs1378156	ENSG00000227542.1	AC092614.2	-4.29	2.69e-05	0.0115	-0.3	-0.27	Obesity-related traits;	chr2:191272466	chr2:191229165~191246172:-
OV	cis	rs2243480	1	rs73142162	ENSG00000226824.5	RP4-756H11.3	-4.29	2.69e-05	0.0115	-0.44	-0.27	Diabetic kidney disease;	chr7:65909309	chr7:66654538~66669855:+
OV	cis	rs7267979	0.932	rs6115200	ENSG00000274973.1	RP13-401N8.7	-4.29	2.7e-05	0.0115	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25506741	chr20:25845497~25845862:+
OV	cis	rs7267979	0.932	rs6138588	ENSG00000274973.1	RP13-401N8.7	-4.29	2.7e-05	0.0115	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25506887	chr20:25845497~25845862:+
OV	cis	rs55692468	0.883	rs6434068	ENSG00000213197.3	AC012066.1	4.29	2.7e-05	0.0115	0.28	0.27	Intraocular pressure;	chr2:152501027	chr2:152389937~152390630:+
OV	cis	rs7083	0.716	rs574603	ENSG00000278768.1	BACE1-AS	4.29	2.7e-05	0.0115	0.28	0.27	Blood protein levels;	chr11:117307025	chr11:117290874~117293571:+
OV	cis	rs1823913	0.614	rs4853576	ENSG00000227542.1	AC092614.2	-4.28	2.7e-05	0.0116	-0.3	-0.27	Obesity-related traits;	chr2:191296618	chr2:191229165~191246172:-
OV	cis	rs875971	0.545	rs73142245	ENSG00000236529.1	RP13-254B10.1	4.28	2.7e-05	0.0116	0.32	0.27	Aortic root size;	chr7:66226662	chr7:65840212~65840596:+
OV	cis	rs9867325	1	rs9867325	ENSG00000239213.4	NCK1-AS1	4.28	2.7e-05	0.0116	0.34	0.27	Body mass index;	chr3:136900067	chr3:136841726~136862054:-
OV	cis	rs9867325	1	rs9840500	ENSG00000239213.4	NCK1-AS1	4.28	2.7e-05	0.0116	0.34	0.27	Body mass index;	chr3:136902496	chr3:136841726~136862054:-
OV	cis	rs875971	0.862	rs1860469	ENSG00000237310.1	GS1-124K5.4	-4.28	2.71e-05	0.0116	-0.28	-0.27	Aortic root size;	chr7:66641888	chr7:66493706~66495474:+
OV	cis	rs7429990	0.864	rs883662	ENSG00000229759.1	MRPS18AP1	4.28	2.71e-05	0.0116	0.3	0.27	Educational attainment (years of education);	chr3:47619342	chr3:48256350~48256938:-
OV	cis	rs514406	0.667	rs10788942	ENSG00000206627.1	RNU6-969P	-4.28	2.71e-05	0.0116	-0.29	-0.27	Monocyte count;	chr1:52744849	chr1:52805108~52805212:-
OV	cis	rs2243480	1	rs160639	ENSG00000226824.5	RP4-756H11.3	-4.28	2.71e-05	0.0116	-0.43	-0.27	Diabetic kidney disease;	chr7:66115000	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs313824	ENSG00000226824.5	RP4-756H11.3	-4.28	2.71e-05	0.0116	-0.43	-0.27	Diabetic kidney disease;	chr7:66116220	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs186378	ENSG00000226824.5	RP4-756H11.3	-4.28	2.71e-05	0.0116	-0.43	-0.27	Diabetic kidney disease;	chr7:66117071	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs160637	ENSG00000226824.5	RP4-756H11.3	-4.28	2.71e-05	0.0116	-0.43	-0.27	Diabetic kidney disease;	chr7:66119331	chr7:66654538~66669855:+
OV	cis	rs73201462	1	rs55762931	ENSG00000277250.1	Metazoa_SRP	4.28	2.71e-05	0.0116	0.44	0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128128832	chr3:128673681~128674021:-
OV	cis	rs10181042	0.612	rs1177282	ENSG00000271889.1	RP11-493E12.1	4.28	2.71e-05	0.0116	0.31	0.27	Crohn's disease;	chr2:61130642	chr2:61151433~61162105:-
OV	cis	rs875971	0.862	rs2024192	ENSG00000236529.1	RP13-254B10.1	-4.28	2.71e-05	0.0116	-0.28	-0.27	Aortic root size;	chr7:66576460	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs4718377	ENSG00000236529.1	RP13-254B10.1	-4.28	2.71e-05	0.0116	-0.28	-0.27	Aortic root size;	chr7:66584691	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs10278014	ENSG00000236529.1	RP13-254B10.1	-4.28	2.71e-05	0.0116	-0.28	-0.27	Aortic root size;	chr7:66586277	chr7:65840212~65840596:+
OV	cis	rs7520050	0.966	rs1707336	ENSG00000281133.1	AL355480.3	4.28	2.71e-05	0.0116	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:46027788	chr1:45580892~45580996:-
OV	cis	rs10759883	0.563	rs671058	ENSG00000175611.10	LINC00476	4.28	2.71e-05	0.0116	0.33	0.27	Nicotine dependence;	chr9:95931728	chr9:95759231~95875977:-
OV	cis	rs875971	0.66	rs2013222	ENSG00000224316.1	RP11-479O9.2	-4.28	2.71e-05	0.0116	-0.29	-0.27	Aortic root size;	chr7:66570949	chr7:65773620~65802067:+
OV	cis	rs3823536	0.583	rs10279821	ENSG00000275106.1	RP11-309L24.10	-4.28	2.72e-05	0.0116	-0.39	-0.27	Sjögren's syndrome;	chr7:129043493	chr7:128952527~128953316:-
OV	cis	rs7189233	0.531	rs8049033	ENSG00000279344.1	RP11-44F14.7	4.28	2.73e-05	0.0117	0.25	0.27	Intelligence (multi-trait analysis);	chr16:53479143	chr16:53478957~53481550:-
OV	cis	rs9992667	0.91	rs10019144	ENSG00000231160.8	KLF3-AS1	4.28	2.73e-05	0.0117	0.32	0.27	Eosinophil percentage of granulocytes;	chr4:38684784	chr4:38612701~38664883:-
OV	cis	rs796364	0.951	rs12463436	ENSG00000232732.8	AC073043.1	-4.28	2.73e-05	0.0117	-0.36	-0.27	Schizophrenia;	chr2:200197239	chr2:199867396~199911159:-
OV	cis	rs4948102	0.642	rs4948104	ENSG00000275875.1	RP11-613E4.5	-4.28	2.73e-05	0.0117	-0.3	-0.27	Plasma homocysteine levels (post-methionine load test);	chr7:56074826	chr7:55741525~55741869:+
OV	cis	rs2117029	0.767	rs11168838	ENSG00000258017.1	RP11-386G11.10	-4.28	2.73e-05	0.0117	-0.36	-0.27	Intelligence (multi-trait analysis);	chr12:49061223	chr12:49127782~49147869:+
OV	cis	rs944801	0.506	rs10811640	ENSG00000234840.1	LINC01239	-4.28	2.73e-05	0.0117	-0.31	-0.27	Type 2 diabetes;	chr9:22013412	chr9:22646200~22824213:+
OV	cis	rs944801	0.506	rs10757263	ENSG00000234840.1	LINC01239	-4.28	2.73e-05	0.0117	-0.31	-0.27	Type 2 diabetes;	chr9:22013806	chr9:22646200~22824213:+
OV	cis	rs7927592	0.83	rs10896339	ENSG00000212093.1	AP000807.1	4.28	2.73e-05	0.0117	0.34	0.27	Total body bone mineral density;	chr11:68535378	chr11:68506083~68506166:-
OV	cis	rs2492286	0.673	rs17255991	ENSG00000277250.1	Metazoa_SRP	4.28	2.73e-05	0.0117	0.47	0.27	Eosinophil counts;	chr3:128637371	chr3:128673681~128674021:-
OV	cis	rs8114671	0.935	rs35193912	ENSG00000269202.1	RP4-614O4.12	4.28	2.74e-05	0.0117	0.27	0.27	Height;	chr20:35197247	chr20:35201747~35203288:-
OV	cis	rs8114671	0.967	rs34515766	ENSG00000269202.1	RP4-614O4.12	4.28	2.74e-05	0.0117	0.27	0.27	Height;	chr20:35197418	chr20:35201747~35203288:-
OV	cis	rs9309473	0.95	rs11689588	ENSG00000163016.8	ALMS1P	4.28	2.74e-05	0.0117	0.33	0.27	Metabolite levels;	chr2:73546564	chr2:73644919~73685576:+
OV	cis	rs2243480	1	rs1267820	ENSG00000226824.5	RP4-756H11.3	-4.28	2.74e-05	0.0117	-0.44	-0.27	Diabetic kidney disease;	chr7:66585308	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs2533288	ENSG00000226824.5	RP4-756H11.3	-4.28	2.74e-05	0.0117	-0.44	-0.27	Diabetic kidney disease;	chr7:66591724	chr7:66654538~66669855:+
OV	cis	rs10978777	0.805	rs7035611	ENSG00000276883.1	AL137852.1	-4.28	2.74e-05	0.0117	-0.31	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107287547	chr9:107292369~107292456:-
OV	cis	rs801193	0.569	rs10950050	ENSG00000237310.1	GS1-124K5.4	4.28	2.74e-05	0.0117	0.27	0.27	Aortic root size;	chr7:66774601	chr7:66493706~66495474:+
OV	cis	rs6772849	0.896	rs61112519	ENSG00000277250.1	Metazoa_SRP	-4.28	2.74e-05	0.0117	-0.32	-0.27	Monocyte percentage of white cells;Monocyte count;	chr3:128619333	chr3:128673681~128674021:-
OV	cis	rs12073359	1	rs1339495	ENSG00000223945.2	RP11-458I7.1	4.28	2.74e-05	0.0117	0.41	0.27	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150029275	chr1:150053864~150055034:+
OV	cis	rs2070488	0.804	rs6764551	ENSG00000229589.1	ACVR2B-AS1	4.28	2.75e-05	0.0117	0.3	0.27	Electrocardiographic conduction measures;	chr3:38418814	chr3:38451027~38454820:-
OV	cis	rs7267979	0.966	rs2482918	ENSG00000274973.1	RP13-401N8.7	4.28	2.75e-05	0.0117	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25431499	chr20:25845497~25845862:+
OV	cis	rs1150668	0.699	rs12214383	ENSG00000204709.4	LINC01556	-4.28	2.75e-05	0.0117	-0.31	-0.27	Pubertal anthropometrics;	chr6:28255953	chr6:28943877~28944537:+
OV	cis	rs34421088	0.576	rs2572437	ENSG00000255495.1	AC145124.2	-4.28	2.75e-05	0.0117	-0.32	-0.27	Neuroticism;	chr8:11240932	chr8:12194467~12196280:+
OV	cis	rs1979679	0.801	rs7977538	ENSG00000278733.1	RP11-425D17.1	4.28	2.75e-05	0.0117	0.32	0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28143503	chr12:28185625~28186190:-
OV	cis	rs1979679	0.801	rs1965280	ENSG00000278733.1	RP11-425D17.1	4.28	2.75e-05	0.0117	0.32	0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28143639	chr12:28185625~28186190:-
OV	cis	rs514406	0.893	rs522287	ENSG00000206627.1	RNU6-969P	4.28	2.75e-05	0.0117	0.28	0.27	Monocyte count;	chr1:52899821	chr1:52805108~52805212:-
OV	cis	rs514406	0.823	rs501006	ENSG00000206627.1	RNU6-969P	4.28	2.75e-05	0.0117	0.28	0.27	Monocyte count;	chr1:52902620	chr1:52805108~52805212:-
OV	cis	rs853679	0.607	rs34950484	ENSG00000220721.1	OR1F12	4.28	2.76e-05	0.0117	0.53	0.27	Depression;	chr6:28310911	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs34661125	ENSG00000220721.1	OR1F12	4.28	2.76e-05	0.0117	0.53	0.27	Depression;	chr6:28314117	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs13190888	ENSG00000220721.1	OR1F12	4.28	2.76e-05	0.0117	0.53	0.27	Depression;	chr6:28318208	chr6:28073316~28074233:+
OV	cis	rs9309473	1	rs6755217	ENSG00000163016.8	ALMS1P	4.28	2.76e-05	0.0118	0.34	0.27	Metabolite levels;	chr2:73414157	chr2:73644919~73685576:+
OV	cis	rs514406	0.607	rs6696940	ENSG00000206627.1	RNU6-969P	-4.28	2.76e-05	0.0118	-0.3	-0.27	Monocyte count;	chr1:52737755	chr1:52805108~52805212:-
OV	cis	rs17711722	0.503	rs453835	ENSG00000273024.4	INTS4P2	4.28	2.76e-05	0.0118	0.32	0.27	Calcium levels;	chr7:66046172	chr7:65647864~65715661:+
OV	cis	rs10924970	0.625	rs2789366	ENSG00000236863.2	RPL23AP23	4.28	2.76e-05	0.0118	0.29	0.27	Asthma;	chr1:235344955	chr1:235295865~235296335:+
OV	cis	rs9880211	1	rs28634226	ENSG00000239213.4	NCK1-AS1	4.28	2.76e-05	0.0118	0.34	0.27	Height;Body mass index;	chr3:136411040	chr3:136841726~136862054:-
OV	cis	rs9880211	0.898	rs1052620	ENSG00000239213.4	NCK1-AS1	4.28	2.76e-05	0.0118	0.34	0.27	Height;Body mass index;	chr3:136855679	chr3:136841726~136862054:-
OV	cis	rs7520050	0.966	rs6695809	ENSG00000281133.1	AL355480.3	4.28	2.77e-05	0.0118	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:45819789	chr1:45580892~45580996:-
OV	cis	rs747650	0.892	rs7937101	ENSG00000271543.1	RP11-692M12.5	-4.28	2.77e-05	0.0118	-0.35	-0.27	Acne (severe);	chr11:47204937	chr11:47796169~47796379:+
OV	cis	rs7017914	0.69	rs11989644	ENSG00000223220.1	Y_RNA	4.28	2.77e-05	0.0118	0.28	0.27	Bone mineral density;	chr8:70728961	chr8:70780914~70781008:-
OV	cis	rs7017914	0.568	rs13272884	ENSG00000223220.1	Y_RNA	4.28	2.77e-05	0.0118	0.28	0.27	Bone mineral density;	chr8:70729413	chr8:70780914~70781008:-
OV	cis	rs7017914	0.667	rs13281864	ENSG00000223220.1	Y_RNA	4.28	2.77e-05	0.0118	0.28	0.27	Bone mineral density;	chr8:70730338	chr8:70780914~70781008:-
OV	cis	rs2243480	1	rs160646	ENSG00000226824.5	RP4-756H11.3	-4.28	2.77e-05	0.0118	-0.44	-0.27	Diabetic kidney disease;	chr7:66091293	chr7:66654538~66669855:+
OV	cis	rs1979679	0.573	rs7134807	ENSG00000278733.1	RP11-425D17.1	4.28	2.78e-05	0.0118	0.33	0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28576317	chr12:28185625~28186190:-
OV	cis	rs514406	0.683	rs6588440	ENSG00000206627.1	RNU6-969P	-4.28	2.78e-05	0.0118	-0.29	-0.27	Monocyte count;	chr1:52743915	chr1:52805108~52805212:-
OV	cis	rs7121800	0.888	rs34344304	ENSG00000254532.1	RP11-624D11.2	4.28	2.78e-05	0.0118	0.32	0.27	Pit-and-Fissure caries;	chr11:30491046	chr11:30044058~30084343:-
OV	cis	rs8054556	1	rs3935873	ENSG00000261367.1	RP11-455F5.4	4.28	2.78e-05	0.0118	0.31	0.27	Autism spectrum disorder or schizophrenia;	chr16:30007179	chr16:30107675~30110541:+
OV	cis	rs7927592	0.513	rs3853616	ENSG00000212093.1	AP000807.1	4.28	2.78e-05	0.0118	0.31	0.27	Total body bone mineral density;	chr11:68430784	chr11:68506083~68506166:-
OV	cis	rs12073359	0.955	rs12124898	ENSG00000223945.2	RP11-458I7.1	-4.28	2.78e-05	0.0118	-0.41	-0.27	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150182112	chr1:150053864~150055034:+
OV	cis	rs12440434	1	rs12440434	ENSG00000259488.2	RP11-154J22.1	4.28	2.79e-05	0.0119	0.31	0.27	Major depressive disorder;	chr15:48930049	chr15:48312353~48331856:-
OV	cis	rs757081	0.676	rs567033	ENSG00000213779.4	RP11-452G18.1	4.28	2.79e-05	0.0119	0.3	0.27	Systolic blood pressure;	chr11:17185463	chr11:17193489~17194308:+
OV	cis	rs757081	0.676	rs677042	ENSG00000213779.4	RP11-452G18.1	4.28	2.79e-05	0.0119	0.3	0.27	Systolic blood pressure;	chr11:17185533	chr11:17193489~17194308:+
OV	cis	rs10510102	1	rs11200181	ENSG00000226864.1	ATE1-AS1	4.28	2.79e-05	0.0119	0.43	0.27	Breast cancer;	chr10:121828528	chr10:121928312~121951965:+
OV	cis	rs10510102	1	rs7923678	ENSG00000226864.1	ATE1-AS1	4.28	2.79e-05	0.0119	0.43	0.27	Breast cancer;	chr10:121832546	chr10:121928312~121951965:+
OV	cis	rs10510102	1	rs6585764	ENSG00000226864.1	ATE1-AS1	4.28	2.79e-05	0.0119	0.43	0.27	Breast cancer;	chr10:121837308	chr10:121928312~121951965:+
OV	cis	rs1150668	0.768	rs1150709	ENSG00000204709.4	LINC01556	-4.28	2.79e-05	0.0119	-0.31	-0.27	Pubertal anthropometrics;	chr6:28239585	chr6:28943877~28944537:+
OV	cis	rs1797885	0.524	rs2255648	ENSG00000251774.1	RNU6-377P	4.28	2.79e-05	0.0119	0.26	0.27	Immature fraction of reticulocytes;	chr3:12557464	chr3:12514706~12514807:+
OV	cis	rs55692468	0.848	rs2346206	ENSG00000213197.3	AC012066.1	4.28	2.79e-05	0.0119	0.29	0.27	Intraocular pressure;	chr2:152506465	chr2:152389937~152390630:+
OV	cis	rs14027	0.64	rs10096846	ENSG00000279347.1	RP11-85I17.2	-4.28	2.79e-05	0.0119	-0.25	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119760884	chr8:119838736~119840385:-
OV	cis	rs6460942	0.597	rs10273045	ENSG00000226690.5	AC005281.1	4.28	2.79e-05	0.0119	0.48	0.27	Coronary artery disease;	chr7:12479745	chr7:12496429~12541910:+
OV	cis	rs2070488	0.775	rs13072731	ENSG00000229589.1	ACVR2B-AS1	4.28	2.79e-05	0.0119	0.3	0.27	Electrocardiographic conduction measures;	chr3:38491844	chr3:38451027~38454820:-
OV	cis	rs270601	0.909	rs2569265	ENSG00000233006.5	AC034220.3	-4.28	2.8e-05	0.0119	-0.29	-0.27	Acylcarnitine levels;	chr5:132368827	chr5:132311285~132369916:-
OV	cis	rs875971	0.545	rs73142265	ENSG00000236529.1	RP13-254B10.1	4.28	2.8e-05	0.0119	0.32	0.27	Aortic root size;	chr7:66234510	chr7:65840212~65840596:+
OV	cis	rs9309473	0.95	rs10206899	ENSG00000163016.8	ALMS1P	4.28	2.8e-05	0.0119	0.32	0.27	Metabolite levels;	chr2:73673773	chr2:73644919~73685576:+
OV	cis	rs957448	0.554	rs12541408	ENSG00000253175.1	RP11-267M23.6	4.28	2.8e-05	0.0119	0.31	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94573579	chr8:94565036~94565715:+
OV	cis	rs4763879	0.593	rs7960328	ENSG00000278635.1	CTD-2318O12.1	4.28	2.8e-05	0.0119	0.23	0.27	Type 1 diabetes;	chr12:9699584	chr12:9415641~9416718:+
OV	cis	rs7077415	0.818	rs12255028	ENSG00000235618.6	FAM21EP	4.28	2.8e-05	0.0119	0.52	0.27	Cerebrospinal fluid biomarker levels;	chr10:50264922	chr10:50021182~50067803:-
OV	cis	rs11673344	0.764	rs1644645	ENSG00000226686.6	LINC01535	4.28	2.8e-05	0.0119	0.35	0.27	Obesity-related traits;	chr19:36972528	chr19:37251912~37265535:+
OV	cis	rs875971	0.862	rs6955837	ENSG00000236529.1	RP13-254B10.1	-4.28	2.8e-05	0.0119	-0.28	-0.27	Aortic root size;	chr7:66578155	chr7:65840212~65840596:+
OV	cis	rs875971	0.825	rs10281499	ENSG00000236529.1	RP13-254B10.1	-4.28	2.8e-05	0.0119	-0.28	-0.27	Aortic root size;	chr7:66583979	chr7:65840212~65840596:+
OV	cis	rs9880211	1	rs9823373	ENSG00000239213.4	NCK1-AS1	4.28	2.8e-05	0.0119	0.33	0.27	Height;Body mass index;	chr3:136448185	chr3:136841726~136862054:-
OV	cis	rs7746199	0.736	rs58616630	ENSG00000226314.6	ZNF192P1	-4.28	2.81e-05	0.0119	-0.6	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:28161781~28169594:+
OV	cis	rs1499614	1	rs1267817	ENSG00000226824.5	RP4-756H11.3	-4.28	2.81e-05	0.0119	-0.45	-0.27	Gout;	chr7:66645053	chr7:66654538~66669855:+
OV	cis	rs2919917	0.628	rs4739135	ENSG00000254352.1	RP11-578O24.2	4.28	2.81e-05	0.0119	0.36	0.27	Lymphocyte counts;	chr8:78656057	chr8:78723796~78724136:-
OV	cis	rs2617170	0.922	rs1049172	ENSG00000256667.5	KLRAP1	4.28	2.81e-05	0.0119	0.28	0.27	Behcet's disease;	chr12:10373141	chr12:10588063~10599669:-
OV	cis	rs7520050	0.931	rs11211189	ENSG00000281133.1	AL355480.3	4.28	2.81e-05	0.0119	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:45795912	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs7524495	ENSG00000281133.1	AL355480.3	4.28	2.81e-05	0.0119	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:45801260	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs12411269	ENSG00000281133.1	AL355480.3	4.28	2.81e-05	0.0119	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:45805380	chr1:45580892~45580996:-
OV	cis	rs7520050	0.931	rs11211198	ENSG00000281133.1	AL355480.3	4.28	2.81e-05	0.0119	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:45817001	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs10890352	ENSG00000281133.1	AL355480.3	4.28	2.81e-05	0.0119	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:45817956	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs6700597	ENSG00000281133.1	AL355480.3	4.28	2.81e-05	0.0119	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:45818574	chr1:45580892~45580996:-
OV	cis	rs494459	0.536	rs57719838	ENSG00000255422.1	AP002954.4	-4.27	2.82e-05	0.0119	-0.32	-0.27	Height;	chr11:118854014	chr11:118704607~118750263:+
OV	cis	rs9880211	0.948	rs9820621	ENSG00000239213.4	NCK1-AS1	4.27	2.82e-05	0.0119	0.33	0.27	Height;Body mass index;	chr3:136391671	chr3:136841726~136862054:-
OV	cis	rs9880211	0.948	rs34913797	ENSG00000239213.4	NCK1-AS1	4.27	2.82e-05	0.0119	0.33	0.27	Height;Body mass index;	chr3:136408728	chr3:136841726~136862054:-
OV	cis	rs89107	0.575	rs10872167	ENSG00000169075.7	RP3-509L4.3	-4.27	2.82e-05	0.0119	-0.28	-0.27	Cardiac structure and function;	chr6:118667199	chr6:118501430~118502906:+
OV	cis	rs4713118	0.539	rs200951	ENSG00000219392.1	RP1-265C24.5	-4.27	2.82e-05	0.012	-0.31	-0.27	Parkinson's disease;	chr6:27868152	chr6:28115628~28116551:+
OV	cis	rs514406	0.893	rs479569	ENSG00000206627.1	RNU6-969P	4.27	2.82e-05	0.012	0.28	0.27	Monocyte count;	chr1:52886735	chr1:52805108~52805212:-
OV	cis	rs4713118	0.629	rs149899	ENSG00000226314.6	ZNF192P1	-4.27	2.82e-05	0.012	-0.37	-0.27	Parkinson's disease;	chr6:28052201	chr6:28161781~28169594:+
OV	cis	rs4713118	0.629	rs172165	ENSG00000226314.6	ZNF192P1	-4.27	2.82e-05	0.012	-0.37	-0.27	Parkinson's disease;	chr6:28053036	chr6:28161781~28169594:+
OV	cis	rs4713118	0.597	rs172166	ENSG00000226314.6	ZNF192P1	-4.27	2.82e-05	0.012	-0.37	-0.27	Parkinson's disease;	chr6:28053042	chr6:28161781~28169594:+
OV	cis	rs801193	0.591	rs4506088	ENSG00000236529.1	RP13-254B10.1	-4.27	2.82e-05	0.012	-0.29	-0.27	Aortic root size;	chr7:66670470	chr7:65840212~65840596:+
OV	cis	rs853679	0.599	rs149949	ENSG00000226314.6	ZNF192P1	-4.27	2.82e-05	0.012	-0.49	-0.27	Depression;	chr6:28043738	chr6:28161781~28169594:+
OV	cis	rs9473147	0.516	rs7754282	ENSG00000270761.1	RP11-385F7.1	4.27	2.83e-05	0.012	0.31	0.27	Platelet distribution width;Mean platelet volume;	chr6:47534288	chr6:47477243~47477572:-
OV	cis	rs4908768	0.906	rs2144463	ENSG00000228423.2	RP4-633I8.4	4.27	2.83e-05	0.012	0.34	0.27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8523234	chr1:8805860~8807051:-
OV	cis	rs8114671	0.933	rs6142327	ENSG00000269202.1	RP4-614O4.12	4.27	2.83e-05	0.012	0.27	0.27	Height;	chr20:35205344	chr20:35201747~35203288:-
OV	cis	rs2070488	0.804	rs13085153	ENSG00000229589.1	ACVR2B-AS1	4.27	2.83e-05	0.012	0.3	0.27	Electrocardiographic conduction measures;	chr3:38419788	chr3:38451027~38454820:-
OV	cis	rs2070488	1	rs4147025	ENSG00000229589.1	ACVR2B-AS1	4.27	2.84e-05	0.012	0.3	0.27	Electrocardiographic conduction measures;	chr3:38415040	chr3:38451027~38454820:-
OV	cis	rs1823913	0.503	rs34716486	ENSG00000227542.1	AC092614.2	4.27	2.84e-05	0.012	0.31	0.27	Obesity-related traits;	chr2:191343335	chr2:191229165~191246172:-
OV	cis	rs875971	1	rs7781698	ENSG00000237310.1	GS1-124K5.4	4.27	2.84e-05	0.012	0.28	0.27	Aortic root size;	chr7:66431325	chr7:66493706~66495474:+
OV	cis	rs10829156	0.607	rs7908550	ENSG00000225527.1	RP11-383B4.4	-4.27	2.84e-05	0.012	-0.38	-0.27	Sudden cardiac arrest;	chr10:18573282	chr10:18531849~18533336:-
OV	cis	rs992157	0.767	rs2382822	ENSG00000261338.2	RP11-378A13.1	-4.27	2.84e-05	0.012	-0.33	-0.27	Colorectal cancer;	chr2:218308604	chr2:218255319~218257366:+
OV	cis	rs7927592	0.513	rs7950129	ENSG00000212093.1	AP000807.1	4.27	2.84e-05	0.012	0.32	0.27	Total body bone mineral density;	chr11:68435435	chr11:68506083~68506166:-
OV	cis	rs694739	0.894	rs11601860	ENSG00000236935.1	AP003774.1	4.27	2.84e-05	0.012	0.36	0.27	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64342950	chr11:64325050~64329504:-
OV	cis	rs7121800	0.632	rs1870360	ENSG00000254532.1	RP11-624D11.2	4.27	2.84e-05	0.012	0.36	0.27	Pit-and-Fissure caries;	chr11:30518717	chr11:30044058~30084343:-
OV	cis	rs858239	0.669	rs1990365	ENSG00000230042.1	AK3P3	-4.27	2.85e-05	0.0121	-0.3	-0.27	Cerebrospinal fluid biomarker levels;	chr7:23076347	chr7:23129178~23129841:+
OV	cis	rs8114671	1	rs8114671	ENSG00000269202.1	RP4-614O4.12	4.27	2.85e-05	0.0121	0.27	0.27	Height;	chr20:35201339	chr20:35201747~35203288:-
OV	cis	rs10129255	0.5	rs8011115	ENSG00000223648.3	IGHV3-64	4.27	2.85e-05	0.0121	0.27	0.27	Kawasaki disease;	chr14:106786292	chr14:106643132~106658258:-
OV	cis	rs116095464	0.558	rs9654453	ENSG00000250848.1	CTD-2083E4.5	-4.27	2.85e-05	0.0121	-0.36	-0.27	Breast cancer;	chr5:299506	chr5:288833~290321:-
OV	cis	rs7927592	0.956	rs11228277	ENSG00000212093.1	AP000807.1	4.27	2.85e-05	0.0121	0.34	0.27	Total body bone mineral density;	chr11:68540856	chr11:68506083~68506166:-
OV	cis	rs7927592	0.956	rs11228278	ENSG00000212093.1	AP000807.1	4.27	2.85e-05	0.0121	0.34	0.27	Total body bone mineral density;	chr11:68541062	chr11:68506083~68506166:-
OV	cis	rs3758911	0.894	rs10890717	ENSG00000261098.1	RP11-819C21.1	-4.27	2.85e-05	0.0121	-0.27	-0.27	Coronary artery disease;	chr11:107324666	chr11:107312132~107316271:-
OV	cis	rs11096990	0.855	rs56275407	ENSG00000249207.1	RP11-360F5.1	4.27	2.85e-05	0.0121	0.32	0.27	Cognitive function;	chr4:39177224	chr4:39112677~39126818:-
OV	cis	rs4763879	0.593	rs7960328	ENSG00000256673.1	RP11-599J14.2	4.27	2.85e-05	0.0121	0.26	0.27	Type 1 diabetes;	chr12:9699584	chr12:9398355~9414851:-
OV	cis	rs1823913	0.599	rs13427761	ENSG00000227542.1	AC092614.2	-4.27	2.85e-05	0.0121	-0.3	-0.27	Obesity-related traits;	chr2:191269256	chr2:191229165~191246172:-
OV	cis	rs875971	0.965	rs28682868	ENSG00000236529.1	RP13-254B10.1	-4.27	2.85e-05	0.0121	-0.28	-0.27	Aortic root size;	chr7:66224822	chr7:65840212~65840596:+
OV	cis	rs4578769	0.55	rs4471804	ENSG00000242182.3	RN7SL745P	-4.27	2.85e-05	0.0121	-0.31	-0.27	Eosinophil percentage of white cells;	chr18:22996218	chr18:23004564~23004862:+
OV	cis	rs4578769	0.55	rs9945620	ENSG00000242182.3	RN7SL745P	4.27	2.85e-05	0.0121	0.31	0.27	Eosinophil percentage of white cells;	chr18:22997367	chr18:23004564~23004862:+
OV	cis	rs4578769	0.55	rs2305886	ENSG00000242182.3	RN7SL745P	4.27	2.85e-05	0.0121	0.31	0.27	Eosinophil percentage of white cells;	chr18:22997493	chr18:23004564~23004862:+
OV	cis	rs7927592	0.731	rs2840367	ENSG00000212093.1	AP000807.1	-4.27	2.85e-05	0.0121	-0.32	-0.27	Total body bone mineral density;	chr11:68534633	chr11:68506083~68506166:-
OV	cis	rs4763879	0.634	rs11052582	ENSG00000256673.1	RP11-599J14.2	4.27	2.85e-05	0.0121	0.26	0.27	Type 1 diabetes;	chr12:9706714	chr12:9398355~9414851:-
OV	cis	rs12928939	0.815	rs1345868	ENSG00000260886.1	TAT-AS1	4.27	2.86e-05	0.0121	0.35	0.27	Post bronchodilator FEV1;	chr16:71635721	chr16:71565789~71578187:+
OV	cis	rs8114671	0.935	rs6142313	ENSG00000269202.1	RP4-614O4.12	4.27	2.86e-05	0.0121	0.27	0.27	Height;	chr20:35192624	chr20:35201747~35203288:-
OV	cis	rs1030877	0.515	rs2679893	ENSG00000235319.1	AC012360.4	-4.27	2.86e-05	0.0121	-0.37	-0.27	Obesity-related traits;	chr2:105293097	chr2:105324210~105330529:+
OV	cis	rs10027350	0.927	rs1035091	ENSG00000281501.1	SEPSECS-AS1	4.27	2.86e-05	0.0121	0.3	0.27	Childhood ear infection;	chr4:25150252	chr4:25160641~25201440:+
OV	cis	rs73201462	1	rs11706826	ENSG00000277250.1	Metazoa_SRP	4.27	2.86e-05	0.0121	0.41	0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128314148	chr3:128673681~128674021:-
OV	cis	rs7520050	0.751	rs592214	ENSG00000281133.1	AL355480.3	4.27	2.87e-05	0.0121	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:45558833	chr1:45580892~45580996:-
OV	cis	rs308447	0.576	rs10005301	ENSG00000273007.1	RP11-170N16.3	4.27	2.87e-05	0.0121	0.31	0.27	Perceived unattractiveness to mosquitoes;	chr4:122793900	chr4:122881878~122884712:-
OV	cis	rs181553	0.664	rs4567802	ENSG00000266696.1	RP11-30L3.2	4.27	2.87e-05	0.0121	0.33	0.27	Hip circumference adjusted for BMI;	chr18:49170994	chr18:49205912~49208781:+
OV	cis	rs62244186	0.659	rs56231820	ENSG00000214820.3	MPRIPP1	4.27	2.87e-05	0.0121	0.25	0.27	Depressive symptoms;	chr3:44488837	chr3:44579938~44581026:-
OV	cis	rs11096990	0.855	rs6855008	ENSG00000249207.1	RP11-360F5.1	4.27	2.87e-05	0.0121	0.32	0.27	Cognitive function;	chr4:39172006	chr4:39112677~39126818:-
OV	cis	rs6101567	0.623	rs12625021	ENSG00000261431.1	RP4-616B8.4	4.27	2.87e-05	0.0121	0.27	0.27	Nose size;	chr20:39361201	chr20:38961925~38962111:-
OV	cis	rs853679	0.599	rs202906	ENSG00000226314.6	ZNF192P1	4.27	2.87e-05	0.0121	0.46	0.27	Depression;	chr6:28043874	chr6:28161781~28169594:+
OV	cis	rs1823913	0.599	rs2124093	ENSG00000227542.1	AC092614.2	4.27	2.87e-05	0.0121	0.3	0.27	Obesity-related traits;	chr2:191288280	chr2:191229165~191246172:-
OV	cis	rs7520050	0.808	rs11211195	ENSG00000281133.1	AL355480.3	4.27	2.87e-05	0.0121	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:45816623	chr1:45580892~45580996:-
OV	cis	rs7520050	0.808	rs11211196	ENSG00000281133.1	AL355480.3	4.27	2.87e-05	0.0121	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:45816624	chr1:45580892~45580996:-
OV	cis	rs7429990	0.864	rs2140335	ENSG00000229759.1	MRPS18AP1	-4.27	2.87e-05	0.0121	-0.29	-0.27	Educational attainment (years of education);	chr3:47663625	chr3:48256350~48256938:-
OV	cis	rs1150668	0.799	rs1150707	ENSG00000204709.4	LINC01556	4.27	2.87e-05	0.0121	0.31	0.27	Pubertal anthropometrics;	chr6:28229827	chr6:28943877~28944537:+
OV	cis	rs1150668	0.799	rs7206	ENSG00000204709.4	LINC01556	4.27	2.87e-05	0.0121	0.31	0.27	Pubertal anthropometrics;	chr6:28233360	chr6:28943877~28944537:+
OV	cis	rs6964833	0.554	rs2527366	ENSG00000277072.3	STAG3L2	-4.27	2.88e-05	0.0122	-0.29	-0.27	Menarche (age at onset);	chr7:74684615	chr7:74882163~74890610:-
OV	cis	rs853679	0.882	rs9468287	ENSG00000219392.1	RP1-265C24.5	-4.27	2.88e-05	0.0122	-0.46	-0.27	Depression;	chr6:28111963	chr6:28115628~28116551:+
OV	cis	rs7267979	0.932	rs449370	ENSG00000274973.1	RP13-401N8.7	4.27	2.88e-05	0.0122	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25470544	chr20:25845497~25845862:+
OV	cis	rs11159086	1	rs17100451	ENSG00000270000.1	RP3-449M8.9	4.27	2.88e-05	0.0122	0.41	0.27	Advanced glycation end-product levels;	chr14:74476210	chr14:74471930~74472360:-
OV	cis	rs4713118	0.955	rs9468201	ENSG00000280107.1	AL022393.9	-4.27	2.89e-05	0.0122	-0.33	-0.27	Parkinson's disease;	chr6:27719256	chr6:28170845~28172521:+
OV	cis	rs6772849	1	rs66910450	ENSG00000277250.1	Metazoa_SRP	-4.27	2.89e-05	0.0122	-0.33	-0.27	Monocyte percentage of white cells;Monocyte count;	chr3:128585050	chr3:128673681~128674021:-
OV	cis	rs5742933	1	rs12622902	ENSG00000253559.1	OSGEPL1-AS1	-4.27	2.89e-05	0.0122	-0.31	-0.27	Ferritin levels;	chr2:189776263	chr2:189762704~189765556:+
OV	cis	rs1823913	0.599	rs13027086	ENSG00000227542.1	AC092614.2	4.27	2.9e-05	0.0122	0.3	0.27	Obesity-related traits;	chr2:191294058	chr2:191229165~191246172:-
OV	cis	rs11159086	1	rs58384818	ENSG00000270000.1	RP3-449M8.9	4.27	2.9e-05	0.0122	0.41	0.27	Advanced glycation end-product levels;	chr14:74487045	chr14:74471930~74472360:-
OV	cis	rs11159086	1	rs17100588	ENSG00000270000.1	RP3-449M8.9	4.27	2.9e-05	0.0122	0.41	0.27	Advanced glycation end-product levels;	chr14:74487624	chr14:74471930~74472360:-
OV	cis	rs853679	0.546	rs483143	ENSG00000280107.1	AL022393.9	-4.27	2.9e-05	0.0122	-0.46	-0.27	Depression;	chr6:27878966	chr6:28170845~28172521:+
OV	cis	rs7017914	0.714	rs1982884	ENSG00000223220.1	Y_RNA	4.27	2.9e-05	0.0122	0.29	0.27	Bone mineral density;	chr8:70877318	chr8:70780914~70781008:-
OV	cis	rs189798	0.807	rs9949	ENSG00000253981.4	ALG1L13P	4.27	2.9e-05	0.0122	0.42	0.27	Myopia (pathological);	chr8:9137002	chr8:8236003~8244667:-
OV	cis	rs412658	0.67	rs1912576	ENSG00000269742.1	BNIP3P29	4.27	2.9e-05	0.0122	0.34	0.27	Telomere length;	chr19:21938491	chr19:22065828~22066398:-
OV	cis	rs10924970	0.649	rs11590729	ENSG00000236863.2	RPL23AP23	4.27	2.9e-05	0.0123	0.29	0.27	Asthma;	chr1:235258862	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs12409696	ENSG00000236863.2	RPL23AP23	4.27	2.9e-05	0.0123	0.29	0.27	Asthma;	chr1:235260292	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs12748629	ENSG00000236863.2	RPL23AP23	4.27	2.9e-05	0.0123	0.29	0.27	Asthma;	chr1:235262644	chr1:235295865~235296335:+
OV	cis	rs11157436	0.918	rs1983520	ENSG00000211812.1	TRAV26-2	-4.27	2.91e-05	0.0123	-0.31	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150390	chr14:22202583~22203368:+
OV	cis	rs11157436	0.918	rs1983522	ENSG00000211812.1	TRAV26-2	-4.27	2.91e-05	0.0123	-0.31	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150588	chr14:22202583~22203368:+
OV	cis	rs11157436	0.918	rs12586393	ENSG00000211812.1	TRAV26-2	-4.27	2.91e-05	0.0123	-0.31	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150815	chr14:22202583~22203368:+
OV	cis	rs11157436	0.918	rs2178788	ENSG00000211812.1	TRAV26-2	-4.27	2.91e-05	0.0123	-0.31	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22150916	chr14:22202583~22203368:+
OV	cis	rs6101567	0.623	rs6129261	ENSG00000261431.1	RP4-616B8.4	4.27	2.91e-05	0.0123	0.27	0.27	Nose size;	chr20:39329615	chr20:38961925~38962111:-
OV	cis	rs7429990	0.931	rs62262084	ENSG00000229759.1	MRPS18AP1	4.27	2.91e-05	0.0123	0.32	0.27	Educational attainment (years of education);	chr3:47612332	chr3:48256350~48256938:-
OV	cis	rs853679	0.607	rs34788973	ENSG00000220721.1	OR1F12	4.27	2.91e-05	0.0123	0.58	0.27	Depression;	chr6:27911422	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs61742093	ENSG00000220721.1	OR1F12	4.27	2.91e-05	0.0123	0.58	0.27	Depression;	chr6:27912204	chr6:28073316~28074233:+
OV	cis	rs200986	1	rs200986	ENSG00000219392.1	RP1-265C24.5	-4.27	2.92e-05	0.0123	-0.31	-0.27	Autism spectrum disorder or schizophrenia;	chr6:27856988	chr6:28115628~28116551:+
OV	cis	rs7617773	0.817	rs17647717	ENSG00000228638.1	FCF1P2	-4.27	2.92e-05	0.0123	-0.36	-0.27	Coronary artery disease;	chr3:48263966	chr3:48290793~48291375:-
OV	cis	rs7267979	1	rs6132835	ENSG00000274973.1	RP13-401N8.7	-4.27	2.92e-05	0.0123	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25454031	chr20:25845497~25845862:+
OV	cis	rs7267979	0.933	rs11699203	ENSG00000274973.1	RP13-401N8.7	-4.27	2.92e-05	0.0123	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25454533	chr20:25845497~25845862:+
OV	cis	rs7267979	0.933	rs6138571	ENSG00000274973.1	RP13-401N8.7	-4.27	2.92e-05	0.0123	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25454752	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs11087520	ENSG00000274973.1	RP13-401N8.7	-4.27	2.92e-05	0.0123	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25456191	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs416745	ENSG00000274973.1	RP13-401N8.7	-4.27	2.92e-05	0.0123	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25458232	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs454723	ENSG00000274973.1	RP13-401N8.7	-4.27	2.92e-05	0.0123	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25458292	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs398036	ENSG00000274973.1	RP13-401N8.7	-4.27	2.92e-05	0.0123	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25459214	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs397119	ENSG00000274973.1	RP13-401N8.7	-4.27	2.92e-05	0.0123	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25459551	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs448396	ENSG00000274973.1	RP13-401N8.7	-4.27	2.92e-05	0.0123	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25459633	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs453329	ENSG00000274973.1	RP13-401N8.7	-4.27	2.92e-05	0.0123	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25459957	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs447722	ENSG00000274973.1	RP13-401N8.7	-4.27	2.92e-05	0.0123	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25462874	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs422424	ENSG00000274973.1	RP13-401N8.7	-4.27	2.92e-05	0.0123	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25464810	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs422844	ENSG00000274973.1	RP13-401N8.7	-4.27	2.92e-05	0.0123	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25464955	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs401166	ENSG00000274973.1	RP13-401N8.7	-4.27	2.92e-05	0.0123	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25465672	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs404394	ENSG00000274973.1	RP13-401N8.7	-4.27	2.92e-05	0.0123	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25467260	chr20:25845497~25845862:+
OV	cis	rs875971	0.571	rs160647	ENSG00000236529.1	RP13-254B10.1	-4.27	2.92e-05	0.0123	-0.32	-0.27	Aortic root size;	chr7:66089365	chr7:65840212~65840596:+
OV	cis	rs875971	0.502	rs6460311	ENSG00000237310.1	GS1-124K5.4	-4.27	2.92e-05	0.0123	-0.32	-0.27	Aortic root size;	chr7:66646886	chr7:66493706~66495474:+
OV	cis	rs6101567	0.595	rs1534975	ENSG00000261431.1	RP4-616B8.4	4.27	2.92e-05	0.0123	0.27	0.27	Nose size;	chr20:39361629	chr20:38961925~38962111:-
OV	cis	rs2919917	0.628	rs979564	ENSG00000254352.1	RP11-578O24.2	4.27	2.92e-05	0.0123	0.36	0.27	Lymphocyte counts;	chr8:78663924	chr8:78723796~78724136:-
OV	cis	rs1113500	0.614	rs6677839	ENSG00000226822.1	RP11-356N1.2	-4.27	2.93e-05	0.0123	-0.33	-0.27	Growth-regulated protein alpha levels;	chr1:108056719	chr1:108071482~108074519:+
OV	cis	rs7193541	1	rs7193541	ENSG00000276822.1	RP11-252A24.8	-4.27	2.93e-05	0.0123	-0.3	-0.27	Multiple myeloma;	chr16:74630845	chr16:74393076~74393183:-
OV	cis	rs1499614	0.803	rs1796229	ENSG00000226824.5	RP4-756H11.3	-4.26	2.94e-05	0.0124	-0.45	-0.27	Gout;	chr7:66654674	chr7:66654538~66669855:+
OV	cis	rs1499614	0.901	rs3936	ENSG00000226824.5	RP4-756H11.3	-4.26	2.94e-05	0.0124	-0.45	-0.27	Gout;	chr7:66661502	chr7:66654538~66669855:+
OV	cis	rs875971	0.825	rs28480509	ENSG00000237310.1	GS1-124K5.4	-4.26	2.94e-05	0.0124	-0.28	-0.27	Aortic root size;	chr7:66634237	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs9791712	ENSG00000237310.1	GS1-124K5.4	-4.26	2.94e-05	0.0124	-0.28	-0.27	Aortic root size;	chr7:66640176	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs9791713	ENSG00000237310.1	GS1-124K5.4	-4.26	2.94e-05	0.0124	-0.28	-0.27	Aortic root size;	chr7:66640211	chr7:66493706~66495474:+
OV	cis	rs853679	0.607	rs66868086	ENSG00000220721.1	OR1F12	4.26	2.94e-05	0.0124	0.55	0.27	Depression;	chr6:27898124	chr6:28073316~28074233:+
OV	cis	rs2239547	0.523	rs6803486	ENSG00000242142.1	SERBP1P3	4.26	2.94e-05	0.0124	0.34	0.27	Schizophrenia;	chr3:53064193	chr3:53064283~53065091:-
OV	cis	rs1979679	0.608	rs1581075	ENSG00000278733.1	RP11-425D17.1	-4.26	2.94e-05	0.0124	-0.35	-0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28570992	chr12:28185625~28186190:-
OV	cis	rs1850744	1	rs2280208	ENSG00000163612.10	FAM86KP	-4.26	2.94e-05	0.0124	-0.66	-0.27	Economic and political preferences;	chr4:9798419	chr4:9153296~9165451:+
OV	cis	rs9880211	0.948	rs17298525	ENSG00000239213.4	NCK1-AS1	4.26	2.94e-05	0.0124	0.33	0.27	Height;Body mass index;	chr3:136474183	chr3:136841726~136862054:-
OV	cis	rs7927771	0.524	rs7933184	ENSG00000280615.1	Y_RNA	4.26	2.95e-05	0.0124	0.29	0.27	Subjective well-being;	chr11:47660850	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs12362318	ENSG00000280615.1	Y_RNA	4.26	2.95e-05	0.0124	0.29	0.27	Subjective well-being;	chr11:47661119	chr11:47614898~47614994:-
OV	cis	rs881375	0.678	rs10760128	ENSG00000226752.6	PSMD5-AS1	-4.26	2.95e-05	0.0124	-0.28	-0.27	Rheumatoid arthritis;	chr9:120934047	chr9:120824828~120854385:+
OV	cis	rs7267979	1	rs2424700	ENSG00000274973.1	RP13-401N8.7	-4.26	2.95e-05	0.0124	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25285877	chr20:25845497~25845862:+
OV	cis	rs801193	0.967	rs34356500	ENSG00000224316.1	RP11-479O9.2	4.26	2.95e-05	0.0124	0.3	0.27	Aortic root size;	chr7:66771620	chr7:65773620~65802067:+
OV	cis	rs73201462	1	rs56328893	ENSG00000277250.1	Metazoa_SRP	4.26	2.95e-05	0.0124	0.42	0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128322987	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs11706304	ENSG00000277250.1	Metazoa_SRP	4.26	2.95e-05	0.0124	0.42	0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128331771	chr3:128673681~128674021:-
OV	cis	rs6545883	0.868	rs2518933	ENSG00000273302.1	RP11-493E12.2	4.26	2.96e-05	0.0124	0.22	0.27	Tuberculosis;	chr2:61569895	chr2:61199979~61200769:+
OV	cis	rs6545883	0.783	rs7579651	ENSG00000273302.1	RP11-493E12.2	4.26	2.96e-05	0.0124	0.22	0.27	Tuberculosis;	chr2:61573144	chr2:61199979~61200769:+
OV	cis	rs7580658	0.891	rs3768866	ENSG00000236682.1	AC068282.3	-4.26	2.96e-05	0.0124	-0.36	-0.27	Protein C levels;	chr2:127287839	chr2:127389130~127400580:+
OV	cis	rs1823913	0.637	rs4853577	ENSG00000227542.1	AC092614.2	-4.26	2.96e-05	0.0124	-0.3	-0.27	Obesity-related traits;	chr2:191297118	chr2:191229165~191246172:-
OV	cis	rs1823913	0.637	rs4853579	ENSG00000227542.1	AC092614.2	-4.26	2.96e-05	0.0124	-0.3	-0.27	Obesity-related traits;	chr2:191297413	chr2:191229165~191246172:-
OV	cis	rs1823913	0.637	rs12622194	ENSG00000227542.1	AC092614.2	-4.26	2.96e-05	0.0124	-0.3	-0.27	Obesity-related traits;	chr2:191298680	chr2:191229165~191246172:-
OV	cis	rs1823913	0.637	rs13019567	ENSG00000227542.1	AC092614.2	-4.26	2.96e-05	0.0124	-0.3	-0.27	Obesity-related traits;	chr2:191298736	chr2:191229165~191246172:-
OV	cis	rs1823913	0.637	rs1947456	ENSG00000227542.1	AC092614.2	-4.26	2.96e-05	0.0124	-0.3	-0.27	Obesity-related traits;	chr2:191298759	chr2:191229165~191246172:-
OV	cis	rs1823913	0.614	rs11693878	ENSG00000227542.1	AC092614.2	-4.26	2.96e-05	0.0124	-0.3	-0.27	Obesity-related traits;	chr2:191299399	chr2:191229165~191246172:-
OV	cis	rs1823913	0.637	rs10931494	ENSG00000227542.1	AC092614.2	-4.26	2.96e-05	0.0124	-0.3	-0.27	Obesity-related traits;	chr2:191299442	chr2:191229165~191246172:-
OV	cis	rs1823913	0.637	rs10931495	ENSG00000227542.1	AC092614.2	-4.26	2.96e-05	0.0124	-0.3	-0.27	Obesity-related traits;	chr2:191299447	chr2:191229165~191246172:-
OV	cis	rs1823913	0.637	rs12623156	ENSG00000227542.1	AC092614.2	-4.26	2.96e-05	0.0124	-0.3	-0.27	Obesity-related traits;	chr2:191299661	chr2:191229165~191246172:-
OV	cis	rs6673267	0.869	rs6700264	ENSG00000223774.4	RP11-307B6.3	4.26	2.96e-05	0.0124	0.3	0.27	Lobe attachment (rater-scored or self-reported);	chr1:201014894	chr1:201893842~201899978:+
OV	cis	rs7811142	1	rs67471932	ENSG00000242294.5	STAG3L5P	4.26	2.96e-05	0.0125	0.28	0.27	Platelet count;	chr7:100412362	chr7:100336079~100351900:+
OV	cis	rs6076065	0.748	rs2253834	ENSG00000273838.1	RP3-333B15.5	-4.26	2.97e-05	0.0125	-0.31	-0.27	Facial morphology (factor 15, philtrum width);	chr20:23407179	chr20:23458529~23459459:+
OV	cis	rs10462065	0.71	rs55969046	ENSG00000249779.1	RP11-447H19.3	-4.26	2.97e-05	0.0125	-0.52	-0.27	Nonsyndromic cleft lip with cleft palate;	chr5:44055301	chr5:43206709~43207811:+
OV	cis	rs4578769	0.55	rs9961760	ENSG00000242182.3	RN7SL745P	4.26	2.97e-05	0.0125	0.31	0.27	Eosinophil percentage of white cells;	chr18:23021545	chr18:23004564~23004862:+
OV	cis	rs875971	0.545	rs1796217	ENSG00000226824.5	RP4-756H11.3	4.26	2.97e-05	0.0125	0.33	0.27	Aortic root size;	chr7:66620931	chr7:66654538~66669855:+
OV	cis	rs6921919	0.583	rs7764722	ENSG00000204709.4	LINC01556	4.26	2.97e-05	0.0125	0.32	0.27	Autism spectrum disorder or schizophrenia;	chr6:28386756	chr6:28943877~28944537:+
OV	cis	rs514406	0.893	rs1242317	ENSG00000206627.1	RNU6-969P	4.26	2.98e-05	0.0125	0.28	0.27	Monocyte count;	chr1:52949094	chr1:52805108~52805212:-
OV	cis	rs7617773	0.743	rs6804986	ENSG00000228638.1	FCF1P2	-4.26	2.98e-05	0.0125	-0.34	-0.27	Coronary artery disease;	chr3:48322105	chr3:48290793~48291375:-
OV	cis	rs7968440	0.933	rs2700480	ENSG00000257298.1	RP3-405J10.3	4.26	2.98e-05	0.0125	0.26	0.27	Fibrinogen;	chr12:50628648	chr12:50185580~50191363:-
OV	cis	rs10759883	0.627	rs816672	ENSG00000175611.10	LINC00476	4.26	2.98e-05	0.0125	0.33	0.27	Nicotine dependence;	chr9:95812171	chr9:95759231~95875977:-
OV	cis	rs11168618	0.904	rs11495273	ENSG00000222635.1	RNU6-1203P	-4.26	2.98e-05	0.0125	-0.32	-0.27	Adiponectin levels;	chr12:48535407	chr12:48081319~48081428:+
OV	cis	rs13217239	0.646	rs7451149	ENSG00000241549.7	GUSBP2	-4.26	2.98e-05	0.0125	-0.27	-0.27	Schizophrenia;	chr6:27089739	chr6:26871484~26956554:-
OV	cis	rs853679	0.517	rs7755442	ENSG00000226314.6	ZNF192P1	-4.26	2.98e-05	0.0125	-0.35	-0.27	Depression;	chr6:28071237	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs12174753	ENSG00000226314.6	ZNF192P1	-4.26	2.98e-05	0.0125	-0.35	-0.27	Depression;	chr6:28074687	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs55747925	ENSG00000226314.6	ZNF192P1	-4.26	2.98e-05	0.0125	-0.35	-0.27	Depression;	chr6:28076559	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs56310871	ENSG00000226314.6	ZNF192P1	-4.26	2.98e-05	0.0125	-0.35	-0.27	Depression;	chr6:28076704	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs34716816	ENSG00000226314.6	ZNF192P1	-4.26	2.98e-05	0.0125	-0.35	-0.27	Depression;	chr6:28078391	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9393884	ENSG00000226314.6	ZNF192P1	-4.26	2.98e-05	0.0125	-0.35	-0.27	Depression;	chr6:28079011	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9380049	ENSG00000226314.6	ZNF192P1	-4.26	2.98e-05	0.0125	-0.35	-0.27	Depression;	chr6:28080757	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9380050	ENSG00000226314.6	ZNF192P1	-4.26	2.98e-05	0.0125	-0.35	-0.27	Depression;	chr6:28080760	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9393885	ENSG00000226314.6	ZNF192P1	-4.26	2.98e-05	0.0125	-0.35	-0.27	Depression;	chr6:28082231	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9393886	ENSG00000226314.6	ZNF192P1	-4.26	2.98e-05	0.0125	-0.35	-0.27	Depression;	chr6:28082261	chr6:28161781~28169594:+
OV	cis	rs4713118	0.515	rs9368549	ENSG00000226314.6	ZNF192P1	-4.26	2.98e-05	0.0125	-0.35	-0.27	Parkinson's disease;	chr6:28082269	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs56364346	ENSG00000226314.6	ZNF192P1	-4.26	2.98e-05	0.0125	-0.35	-0.27	Depression;	chr6:28082984	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9357061	ENSG00000226314.6	ZNF192P1	-4.26	2.98e-05	0.0125	-0.35	-0.27	Depression;	chr6:28083994	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9368550	ENSG00000226314.6	ZNF192P1	-4.26	2.98e-05	0.0125	-0.35	-0.27	Depression;	chr6:28084025	chr6:28161781~28169594:+
OV	cis	rs853679	0.542	rs2295594	ENSG00000226314.6	ZNF192P1	-4.26	2.98e-05	0.0125	-0.35	-0.27	Depression;	chr6:28085319	chr6:28161781~28169594:+
OV	cis	rs2950393	0.895	rs2958154	ENSG00000241217.3	RN7SL809P	-4.26	2.98e-05	0.0125	-0.27	-0.27	Platelet distribution width;	chr12:56671929	chr12:56670450~56670746:-
OV	cis	rs853679	0.76	rs9393910	ENSG00000219392.1	RP1-265C24.5	-4.26	2.98e-05	0.0125	-0.39	-0.27	Depression;	chr6:28240414	chr6:28115628~28116551:+
OV	cis	rs853679	0.76	rs9368563	ENSG00000219392.1	RP1-265C24.5	-4.26	2.98e-05	0.0125	-0.39	-0.27	Depression;	chr6:28240780	chr6:28115628~28116551:+
OV	cis	rs853679	0.76	rs9295768	ENSG00000219392.1	RP1-265C24.5	-4.26	2.98e-05	0.0125	-0.39	-0.27	Depression;	chr6:28241324	chr6:28115628~28116551:+
OV	cis	rs853679	0.699	rs9468318	ENSG00000219392.1	RP1-265C24.5	-4.26	2.98e-05	0.0125	-0.39	-0.27	Depression;	chr6:28241753	chr6:28115628~28116551:+
OV	cis	rs853679	0.76	rs9357067	ENSG00000219392.1	RP1-265C24.5	-4.26	2.98e-05	0.0125	-0.39	-0.27	Depression;	chr6:28242515	chr6:28115628~28116551:+
OV	cis	rs853679	0.76	rs967005	ENSG00000219392.1	RP1-265C24.5	-4.26	2.98e-05	0.0125	-0.39	-0.27	Depression;	chr6:28242910	chr6:28115628~28116551:+
OV	cis	rs10924970	0.649	rs1933247	ENSG00000236863.2	RPL23AP23	4.26	2.99e-05	0.0125	0.29	0.27	Asthma;	chr1:235269452	chr1:235295865~235296335:+
OV	cis	rs10924970	0.601	rs12402448	ENSG00000236863.2	RPL23AP23	4.26	2.99e-05	0.0125	0.29	0.27	Asthma;	chr1:235284780	chr1:235295865~235296335:+
OV	cis	rs10924970	0.649	rs11805093	ENSG00000236863.2	RPL23AP23	4.26	2.99e-05	0.0125	0.29	0.27	Asthma;	chr1:235298353	chr1:235295865~235296335:+
OV	cis	rs10924970	0.578	rs12025973	ENSG00000236863.2	RPL23AP23	4.26	2.99e-05	0.0125	0.29	0.27	Asthma;	chr1:235300573	chr1:235295865~235296335:+
OV	cis	rs10924970	0.534	rs10925362	ENSG00000236863.2	RPL23AP23	4.26	2.99e-05	0.0125	0.29	0.27	Asthma;	chr1:235301065	chr1:235295865~235296335:+
OV	cis	rs10486158	0.901	rs1294614	ENSG00000234141.1	AC009473.1	-4.26	2.99e-05	0.0125	-0.42	-0.27	Bipolar disorder and schizophrenia;	chr7:7327333	chr7:7949853~7950709:-
OV	cis	rs804280	0.509	rs13276433	ENSG00000206014.6	OR7E161P	-4.26	2.99e-05	0.0125	-0.31	-0.27	Myopia (pathological);	chr8:11925527	chr8:11928597~11929563:-
OV	cis	rs181553	0.664	rs1893529	ENSG00000266696.1	RP11-30L3.2	-4.26	2.99e-05	0.0125	-0.39	-0.27	Hip circumference adjusted for BMI;	chr18:49169906	chr18:49205912~49208781:+
OV	cis	rs10895987	0.531	rs2282498	ENSG00000254614.2	AP003068.23	4.26	2.99e-05	0.0125	0.33	0.27	Blood protein levels;	chr11:65088514	chr11:65177606~65181834:-
OV	cis	rs11710845	1	rs11710139	ENSG00000243885.1	RP11-278L15.2	4.26	2.99e-05	0.0125	0.42	0.27	Intraocular pressure;	chr3:150341555	chr3:149384179~149385800:-
OV	cis	rs11710845	0.961	rs4681609	ENSG00000243885.1	RP11-278L15.2	4.26	2.99e-05	0.0125	0.42	0.27	Intraocular pressure;	chr3:150346033	chr3:149384179~149385800:-
OV	cis	rs11710845	1	rs4681610	ENSG00000243885.1	RP11-278L15.2	4.26	2.99e-05	0.0125	0.42	0.27	Intraocular pressure;	chr3:150346328	chr3:149384179~149385800:-
OV	cis	rs4664293	0.51	rs72961751	ENSG00000226266.5	AC009961.3	4.26	2.99e-05	0.0126	0.33	0.27	Monocyte percentage of white cells;	chr2:159738067	chr2:159670708~159712435:-
OV	cis	rs7246657	0.943	rs1035479	ENSG00000226686.6	LINC01535	4.26	2.99e-05	0.0126	0.4	0.27	Coronary artery calcification;	chr19:37402398	chr19:37251912~37265535:+
OV	cis	rs1020064	0.636	rs12476328	ENSG00000235319.1	AC012360.4	-4.26	2.99e-05	0.0126	-0.35	-0.27	AIDS;	chr2:105359887	chr2:105324210~105330529:+
OV	cis	rs2239557	1	rs11159067	ENSG00000259065.1	RP5-1021I20.1	-4.26	3e-05	0.0126	-0.32	-0.27	Common traits (Other);	chr14:74170741	chr14:73787360~73803270:+
OV	cis	rs853679	0.517	rs9295761	ENSG00000226314.6	ZNF192P1	-4.26	3e-05	0.0126	-0.38	-0.27	Depression;	chr6:28180209	chr6:28161781~28169594:+
OV	cis	rs7746199	0.736	rs13195636	ENSG00000280107.1	AL022393.9	-4.26	3e-05	0.0126	-0.6	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27541714	chr6:28170845~28172521:+
OV	cis	rs62244186	0.659	rs6441844	ENSG00000214820.3	MPRIPP1	4.26	3e-05	0.0126	0.24	0.27	Depressive symptoms;	chr3:44462087	chr3:44579938~44581026:-
OV	cis	rs62244186	0.659	rs4431151	ENSG00000214820.3	MPRIPP1	4.26	3e-05	0.0126	0.24	0.27	Depressive symptoms;	chr3:44469414	chr3:44579938~44581026:-
OV	cis	rs62244186	0.608	rs2888390	ENSG00000214820.3	MPRIPP1	4.26	3e-05	0.0126	0.24	0.27	Depressive symptoms;	chr3:44469913	chr3:44579938~44581026:-
OV	cis	rs62244186	0.659	rs9819766	ENSG00000214820.3	MPRIPP1	4.26	3e-05	0.0126	0.24	0.27	Depressive symptoms;	chr3:44479488	chr3:44579938~44581026:-
OV	cis	rs10129255	0.518	rs2006284	ENSG00000223648.3	IGHV3-64	4.26	3e-05	0.0126	0.27	0.27	Kawasaki disease;	chr14:106676185	chr14:106643132~106658258:-
OV	cis	rs8054556	0.967	rs9932702	ENSG00000261367.1	RP11-455F5.4	-4.26	3e-05	0.0126	-0.3	-0.27	Autism spectrum disorder or schizophrenia;	chr16:29971640	chr16:30107675~30110541:+
OV	cis	rs8054556	1	rs9932196	ENSG00000261367.1	RP11-455F5.4	-4.26	3e-05	0.0126	-0.3	-0.27	Autism spectrum disorder or schizophrenia;	chr16:29971798	chr16:30107675~30110541:+
OV	cis	rs8054556	1	rs9925102	ENSG00000261367.1	RP11-455F5.4	-4.26	3e-05	0.0126	-0.3	-0.27	Autism spectrum disorder or schizophrenia;	chr16:29971827	chr16:30107675~30110541:+
OV	cis	rs7646881	0.544	rs16847135	ENSG00000272440.1	RP11-379F4.6	4.26	3.01e-05	0.0126	0.42	0.27	Tetralogy of Fallot;	chr3:158706064	chr3:158695367~158695581:+
OV	cis	rs2282300	0.956	rs1717779	ENSG00000242353.1	RP4-710M3.1	-4.26	3.01e-05	0.0126	-0.39	-0.27	Morning vs. evening chronotype;	chr11:30355151	chr11:30368148~30368646:+
OV	cis	rs6128907	0.8	rs6129020	ENSG00000224635.1	RP4-564F22.5	-4.26	3.01e-05	0.0126	-0.42	-0.27	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38786294	chr20:38406011~38416797:-
OV	cis	rs992157	1	rs992157	ENSG00000261338.2	RP11-378A13.1	-4.26	3.01e-05	0.0126	-0.31	-0.27	Colorectal cancer;	chr2:218290058	chr2:218255319~218257366:+
OV	cis	rs875971	0.862	rs4718383	ENSG00000237310.1	GS1-124K5.4	-4.26	3.01e-05	0.0126	-0.28	-0.27	Aortic root size;	chr7:66643422	chr7:66493706~66495474:+
OV	cis	rs7200543	1	rs1121	ENSG00000270580.4	PKD1P6	4.26	3.01e-05	0.0126	0.28	0.27	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037219	chr16:15104723~15131601:-
OV	cis	rs7267979	1	rs12428	ENSG00000274973.1	RP13-401N8.7	4.26	3.01e-05	0.0126	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25453185	chr20:25845497~25845862:+
OV	cis	rs4964805	0.606	rs7312606	ENSG00000257681.1	RP11-341G23.4	4.26	3.02e-05	0.0126	0.3	0.27	Attention deficit hyperactivity disorder;	chr12:103794607	chr12:103746315~103768858:-
OV	cis	rs4964805	0.581	rs7312825	ENSG00000257681.1	RP11-341G23.4	4.26	3.02e-05	0.0126	0.3	0.27	Attention deficit hyperactivity disorder;	chr12:103794610	chr12:103746315~103768858:-
OV	cis	rs12073359	1	rs10888569	ENSG00000223945.2	RP11-458I7.1	4.26	3.02e-05	0.0127	0.4	0.27	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150053690	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs7520930	ENSG00000223945.2	RP11-458I7.1	4.26	3.02e-05	0.0127	0.4	0.27	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150065560	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs2027349	ENSG00000223945.2	RP11-458I7.1	4.26	3.02e-05	0.0127	0.4	0.27	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150067621	chr1:150053864~150055034:+
OV	cis	rs11118620	0.81	rs1603047	ENSG00000238078.1	LINC01352	4.26	3.02e-05	0.0127	0.36	0.27	Heart failure;	chr1:220849953	chr1:220829255~220832429:+
OV	cis	rs11118620	1	rs11118620	ENSG00000238078.1	LINC01352	4.26	3.02e-05	0.0127	0.36	0.27	Heart failure;	chr1:220855166	chr1:220829255~220832429:+
OV	cis	rs2898681	1	rs6833096	ENSG00000248375.1	RP11-177B4.1	-4.26	3.03e-05	0.0127	-0.41	-0.27	Optic nerve measurement (cup area);	chr4:52878108	chr4:52720081~52720831:-
OV	cis	rs8059260	0.668	rs16957855	ENSG00000274038.1	RP11-66H6.4	-4.26	3.03e-05	0.0127	-0.52	-0.27	Alcohol consumption over the past year;	chr16:10977116	chr16:11056556~11057034:+
OV	cis	rs4787491	0.729	rs11150584	ENSG00000261367.1	RP11-455F5.4	-4.26	3.03e-05	0.0127	-0.3	-0.27	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30028357	chr16:30107675~30110541:+
OV	cis	rs2243480	1	rs316307	ENSG00000226824.5	RP4-756H11.3	-4.26	3.03e-05	0.0127	-0.43	-0.27	Diabetic kidney disease;	chr7:66105184	chr7:66654538~66669855:+
OV	cis	rs2243480	0.908	rs313822	ENSG00000226824.5	RP4-756H11.3	-4.26	3.03e-05	0.0127	-0.43	-0.27	Diabetic kidney disease;	chr7:66108952	chr7:66654538~66669855:+
OV	cis	rs11673344	0.536	rs7259272	ENSG00000226686.6	LINC01535	4.26	3.03e-05	0.0127	0.36	0.27	Obesity-related traits;	chr19:37692214	chr19:37251912~37265535:+
OV	cis	rs4296809	0.505	rs12521430	ENSG00000249779.1	RP11-447H19.3	-4.26	3.03e-05	0.0127	-0.51	-0.27	Brain structure;	chr5:44120134	chr5:43206709~43207811:+
OV	cis	rs4713118	0.869	rs9461405	ENSG00000219392.1	RP1-265C24.5	-4.26	3.03e-05	0.0127	-0.31	-0.27	Parkinson's disease;	chr6:27751596	chr6:28115628~28116551:+
OV	cis	rs9287719	0.601	rs759401	ENSG00000243819.4	RN7SL832P	4.26	3.04e-05	0.0127	0.28	0.27	Prostate cancer;	chr2:10569796	chr2:10690344~10692099:+
OV	cis	rs1823913	0.549	rs4465792	ENSG00000227542.1	AC092614.2	4.26	3.04e-05	0.0127	0.32	0.27	Obesity-related traits;	chr2:191328884	chr2:191229165~191246172:-
OV	cis	rs1823913	0.513	rs4334520	ENSG00000227542.1	AC092614.2	4.26	3.04e-05	0.0127	0.32	0.27	Obesity-related traits;	chr2:191329200	chr2:191229165~191246172:-
OV	cis	rs7259965	0.804	rs2054675	ENSG00000277744.1	CTC-435M10.12	4.26	3.04e-05	0.0127	0.27	0.27	Midgestational circulating levels of organochlorine pesticides;Midgestational circulating levels of PBDEs;	chr19:40989850	chr19:41373971~41374419:+
OV	cis	rs62184315	0.536	rs62183659	ENSG00000253559.1	OSGEPL1-AS1	-4.26	3.04e-05	0.0127	-0.38	-0.27	Alcohol dependence (age at onset);	chr2:189672131	chr2:189762704~189765556:+
OV	cis	rs62184315	0.536	rs62185869	ENSG00000253559.1	OSGEPL1-AS1	-4.26	3.04e-05	0.0127	-0.38	-0.27	Alcohol dependence (age at onset);	chr2:189672330	chr2:189762704~189765556:+
OV	cis	rs853679	0.607	rs13199649	ENSG00000220721.1	OR1F12	4.26	3.04e-05	0.0127	0.58	0.27	Depression;	chr6:27901014	chr6:28073316~28074233:+
OV	cis	rs6683071	1	rs6683071	ENSG00000272750.1	RP11-378J18.8	-4.26	3.04e-05	0.0127	-0.33	-0.27	Cognitive performance;	chr1:222750009	chr1:222658867~222661512:-
OV	cis	rs7615952	0.641	rs4490307	ENSG00000171084.14	FAM86JP	4.26	3.04e-05	0.0127	0.38	0.27	Blood pressure (smoking interaction);	chr3:125993833	chr3:125916620~125930024:+
OV	cis	rs7927592	0.956	rs7113287	ENSG00000212093.1	AP000807.1	4.26	3.05e-05	0.0127	0.34	0.27	Total body bone mineral density;	chr11:68604718	chr11:68506083~68506166:-
OV	cis	rs2898681	0.618	rs79471207	ENSG00000248375.1	RP11-177B4.1	-4.26	3.05e-05	0.0127	-0.5	-0.27	Optic nerve measurement (cup area);	chr4:52872357	chr4:52720081~52720831:-
OV	cis	rs12073359	1	rs2318763	ENSG00000223945.2	RP11-458I7.1	-4.26	3.05e-05	0.0127	-0.42	-0.27	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150143798	chr1:150053864~150055034:+
OV	cis	rs12073359	0.954	rs72694950	ENSG00000223945.2	RP11-458I7.1	-4.26	3.05e-05	0.0127	-0.42	-0.27	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150146961	chr1:150053864~150055034:+
OV	cis	rs4908768	0.906	rs10492965	ENSG00000228423.2	RP4-633I8.4	4.26	3.05e-05	0.0127	0.34	0.27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8538068	chr1:8805860~8807051:-
OV	cis	rs4908768	0.906	rs12401496	ENSG00000228423.2	RP4-633I8.4	4.26	3.05e-05	0.0127	0.34	0.27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8540342	chr1:8805860~8807051:-
OV	cis	rs9813712	0.571	rs9824426	ENSG00000253540.4	FAM86HP	-4.26	3.05e-05	0.0127	-0.3	-0.27	Response to amphetamines;	chr3:130226115	chr3:130099092~130111472:-
OV	cis	rs8100891	0.537	rs11883143	ENSG00000267213.4	AC007773.2	-4.26	3.05e-05	0.0127	-0.4	-0.27	Neuroticism;	chr19:32478350	chr19:32390050~32405560:-
OV	cis	rs4938303	0.633	rs77835865	ENSG00000254851.1	RP11-109L13.1	4.26	3.05e-05	0.0128	0.44	0.27	Triglycerides;	chr11:116684713	chr11:117135528~117138582:+
OV	cis	rs10829156	0.945	rs10741131	ENSG00000225527.1	RP11-383B4.4	-4.26	3.05e-05	0.0128	-0.36	-0.27	Sudden cardiac arrest;	chr10:18683130	chr10:18531849~18533336:-
OV	cis	rs950169	0.614	rs765524	ENSG00000225151.9	GOLGA2P7	-4.26	3.06e-05	0.0128	-0.38	-0.27	Schizophrenia;	chr15:84013030	chr15:84199311~84230136:-
OV	cis	rs11105298	0.891	rs10858879	ENSG00000257194.2	RP11-567C2.1	4.26	3.06e-05	0.0128	0.38	0.27	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492801	chr12:90107739~90112779:+
OV	cis	rs6772849	0.93	rs12630379	ENSG00000277250.1	Metazoa_SRP	-4.25	3.06e-05	0.0128	-0.32	-0.27	Monocyte percentage of white cells;Monocyte count;	chr3:128651361	chr3:128673681~128674021:-
OV	cis	rs875971	0.756	rs2901210	ENSG00000237310.1	GS1-124K5.4	-4.25	3.06e-05	0.0128	-0.28	-0.27	Aortic root size;	chr7:66552518	chr7:66493706~66495474:+
OV	cis	rs4763879	0.634	rs7974396	ENSG00000278635.1	CTD-2318O12.1	4.25	3.06e-05	0.0128	0.23	0.27	Type 1 diabetes;	chr12:9708101	chr12:9415641~9416718:+
OV	cis	rs7520050	0.807	rs28378621	ENSG00000281133.1	AL355480.3	-4.25	3.06e-05	0.0128	-0.31	-0.27	Reticulocyte count;Red blood cell count;	chr1:45723882	chr1:45580892~45580996:-
OV	cis	rs73201462	1	rs61044849	ENSG00000242551.2	POU5F1P6	4.25	3.06e-05	0.0128	0.44	0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128346623	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs57735707	ENSG00000242551.2	POU5F1P6	4.25	3.06e-05	0.0128	0.44	0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128346972	chr3:128674735~128677005:-
OV	cis	rs7267979	0.932	rs4280527	ENSG00000274973.1	RP13-401N8.7	-4.25	3.07e-05	0.0128	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25563378	chr20:25845497~25845862:+
OV	cis	rs801193	0.569	rs2707847	ENSG00000236529.1	RP13-254B10.1	4.25	3.07e-05	0.0128	0.28	0.27	Aortic root size;	chr7:66737884	chr7:65840212~65840596:+
OV	cis	rs1823913	0.622	rs55787447	ENSG00000227542.1	AC092614.2	4.25	3.07e-05	0.0128	0.3	0.27	Obesity-related traits;	chr2:191288596	chr2:191229165~191246172:-
OV	cis	rs11072089	0.509	rs1504626	ENSG00000259215.1	RP11-253M7.4	4.25	3.07e-05	0.0128	0.55	0.27	Bipolar disorder and schizophrenia;	chr15:69407431	chr15:69458522~69461806:-
OV	cis	rs12681420	0.665	rs67705199	ENSG00000223220.1	Y_RNA	4.25	3.07e-05	0.0128	0.28	0.27	Erythrocyte cadmium concentration in never smokers;	chr8:70695170	chr8:70780914~70781008:-
OV	cis	rs10740039	0.768	rs10761549	ENSG00000254271.1	RP11-131N11.4	4.25	3.07e-05	0.0128	0.35	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60701902	chr10:60734342~60741828:+
OV	cis	rs7918232	0.574	rs10458708	ENSG00000262412.1	RP11-85G18.6	4.25	3.07e-05	0.0128	0.33	0.27	Breast cancer;	chr10:27166676	chr10:27243130~27250804:+
OV	cis	rs7429990	0.52	rs78838427	ENSG00000229759.1	MRPS18AP1	-4.25	3.07e-05	0.0128	-0.29	-0.27	Educational attainment (years of education);	chr3:47595561	chr3:48256350~48256938:-
OV	cis	rs6844153	0.887	rs3792685	ENSG00000240005.4	RP11-293A21.1	-4.25	3.07e-05	0.0128	-0.38	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26957585	chr4:26859806~26860599:-
OV	cis	rs1823913	0.637	rs897197	ENSG00000227542.1	AC092614.2	-4.25	3.08e-05	0.0128	-0.3	-0.27	Obesity-related traits;	chr2:191281456	chr2:191229165~191246172:-
OV	cis	rs11118620	0.853	rs11118622	ENSG00000238078.1	LINC01352	4.25	3.08e-05	0.0128	0.36	0.27	Heart failure;	chr1:220868833	chr1:220829255~220832429:+
OV	cis	rs2286503	0.78	rs12113458	ENSG00000228649.7	AC005682.5	4.25	3.08e-05	0.0128	0.34	0.27	Fibrinogen;	chr7:22816009	chr7:22854178~22861579:+
OV	cis	rs2839627	0.561	rs8126478	ENSG00000225218.1	AP001628.6	4.25	3.08e-05	0.0128	0.28	0.27	Information processing speed;	chr21:42898558	chr21:42831040~42836477:-
OV	cis	rs8114671	0.545	rs2378335	ENSG00000269202.1	RP4-614O4.12	-4.25	3.08e-05	0.0129	-0.31	-0.27	Height;	chr20:35169027	chr20:35201747~35203288:-
OV	cis	rs6940638	0.688	rs9379960	ENSG00000220721.1	OR1F12	4.25	3.08e-05	0.0129	0.29	0.27	Intelligence (multi-trait analysis);	chr6:27153546	chr6:28073316~28074233:+
OV	cis	rs7520050	0.807	rs28647556	ENSG00000281133.1	AL355480.3	-4.25	3.08e-05	0.0129	-0.31	-0.27	Reticulocyte count;Red blood cell count;	chr1:45740727	chr1:45580892~45580996:-
OV	cis	rs7520050	0.807	rs4274104	ENSG00000281133.1	AL355480.3	-4.25	3.08e-05	0.0129	-0.31	-0.27	Reticulocyte count;Red blood cell count;	chr1:45752269	chr1:45580892~45580996:-
OV	cis	rs7520050	0.751	rs2991975	ENSG00000281133.1	AL355480.3	4.25	3.09e-05	0.0129	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:45558854	chr1:45580892~45580996:-
OV	cis	rs1823913	0.637	rs4853583	ENSG00000227542.1	AC092614.2	-4.25	3.09e-05	0.0129	-0.3	-0.27	Obesity-related traits;	chr2:191304648	chr2:191229165~191246172:-
OV	cis	rs4718428	1	rs1830070	ENSG00000226824.5	RP4-756H11.3	-4.25	3.09e-05	0.0129	-0.31	-0.27	Corneal structure;	chr7:66884684	chr7:66654538~66669855:+
OV	cis	rs875971	0.862	rs7786892	ENSG00000237310.1	GS1-124K5.4	-4.25	3.09e-05	0.0129	-0.27	-0.27	Aortic root size;	chr7:66163889	chr7:66493706~66495474:+
OV	cis	rs7429990	0.833	rs35582375	ENSG00000229759.1	MRPS18AP1	-4.25	3.09e-05	0.0129	-0.3	-0.27	Educational attainment (years of education);	chr3:47829639	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs13077230	ENSG00000229759.1	MRPS18AP1	-4.25	3.09e-05	0.0129	-0.3	-0.27	Educational attainment (years of education);	chr3:47832232	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs11130150	ENSG00000229759.1	MRPS18AP1	-4.25	3.09e-05	0.0129	-0.3	-0.27	Educational attainment (years of education);	chr3:47832449	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs11710199	ENSG00000229759.1	MRPS18AP1	-4.25	3.09e-05	0.0129	-0.3	-0.27	Educational attainment (years of education);	chr3:47836588	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs17290490	ENSG00000229759.1	MRPS18AP1	-4.25	3.09e-05	0.0129	-0.3	-0.27	Educational attainment (years of education);	chr3:47841237	chr3:48256350~48256938:-
OV	cis	rs6991838	0.806	rs11781358	ENSG00000272010.1	CTD-3025N20.3	4.25	3.09e-05	0.0129	0.34	0.27	Intelligence (multi-trait analysis);	chr8:65557691	chr8:65591850~65592472:-
OV	cis	rs73201462	1	rs16844002	ENSG00000277250.1	Metazoa_SRP	4.25	3.09e-05	0.0129	0.39	0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128334644	chr3:128673681~128674021:-
OV	cis	rs7200543	1	rs16966953	ENSG00000270580.4	PKD1P6	4.25	3.09e-05	0.0129	0.28	0.27	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15041997	chr16:15104723~15131601:-
OV	cis	rs1823913	0.637	rs10931497	ENSG00000227542.1	AC092614.2	-4.25	3.09e-05	0.0129	-0.3	-0.27	Obesity-related traits;	chr2:191306254	chr2:191229165~191246172:-
OV	cis	rs591584	0.583	rs57607909	ENSG00000255893.1	RP11-685N10.1	-4.25	3.09e-05	0.0129	-0.35	-0.27	Macrophage Migration Inhibitory Factor levels;	chr11:94593599	chr11:94472908~94473570:-
OV	cis	rs12220777	0.681	rs117394476	ENSG00000230091.5	TMEM254-AS1	4.25	3.1e-05	0.0129	0.52	0.27	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80103000	chr10:80046860~80078912:-
OV	cis	rs7429990	1	rs7429990	ENSG00000229759.1	MRPS18AP1	4.25	3.1e-05	0.0129	0.29	0.27	Educational attainment (years of education);	chr3:47860313	chr3:48256350~48256938:-
OV	cis	rs853679	0.517	rs1340004	ENSG00000226314.6	ZNF192P1	-4.25	3.1e-05	0.0129	-0.36	-0.27	Depression;	chr6:28135913	chr6:28161781~28169594:+
OV	cis	rs9660180	0.967	rs10907191	ENSG00000215914.4	MMP23A	-4.25	3.1e-05	0.0129	-0.32	-0.27	Body mass index;	chr1:1843381	chr1:1699942~1701782:+
OV	cis	rs709400	0.691	rs12888077	ENSG00000244691.1	RPL10AP1	-4.25	3.1e-05	0.0129	-0.28	-0.27	Body mass index;	chr14:103406216	chr14:103412119~103412761:-
OV	cis	rs801193	0.844	rs2244022	ENSG00000224316.1	RP11-479O9.2	4.25	3.1e-05	0.0129	0.29	0.27	Aortic root size;	chr7:66737443	chr7:65773620~65802067:+
OV	cis	rs7968440	0.808	rs6580769	ENSG00000272368.2	RP4-605O3.4	4.25	3.1e-05	0.0129	0.33	0.27	Fibrinogen;	chr12:50801738	chr12:50112197~50165618:+
OV	cis	rs7968440	0.808	rs66838741	ENSG00000272368.2	RP4-605O3.4	4.25	3.1e-05	0.0129	0.33	0.27	Fibrinogen;	chr12:50805231	chr12:50112197~50165618:+
OV	cis	rs2286503	0.78	rs2286506	ENSG00000228649.7	AC005682.5	4.25	3.11e-05	0.0129	0.34	0.27	Fibrinogen;	chr7:22815196	chr7:22854178~22861579:+
OV	cis	rs2286503	0.752	rs2286504	ENSG00000228649.7	AC005682.5	4.25	3.11e-05	0.0129	0.34	0.27	Fibrinogen;	chr7:22815228	chr7:22854178~22861579:+
OV	cis	rs591584	0.63	rs72965819	ENSG00000255893.1	RP11-685N10.1	-4.25	3.11e-05	0.013	-0.35	-0.27	Macrophage Migration Inhibitory Factor levels;	chr11:94599244	chr11:94472908~94473570:-
OV	cis	rs7429990	0.833	rs869508	ENSG00000229759.1	MRPS18AP1	4.25	3.11e-05	0.013	0.3	0.27	Educational attainment (years of education);	chr3:47571812	chr3:48256350~48256938:-
OV	cis	rs2243480	1	rs1796228	ENSG00000226824.5	RP4-756H11.3	-4.25	3.11e-05	0.013	-0.44	-0.27	Diabetic kidney disease;	chr7:66568097	chr7:66654538~66669855:+
OV	cis	rs9660180	1	rs3737628	ENSG00000215914.4	MMP23A	-4.25	3.11e-05	0.013	-0.3	-0.27	Body mass index;	chr1:1791493	chr1:1699942~1701782:+
OV	cis	rs1816752	0.819	rs7400583	ENSG00000273628.1	RP11-756A22.7	4.25	3.11e-05	0.013	0.26	0.27	Obesity-related traits;	chr13:24415916	chr13:24933006~24936796:+
OV	cis	rs10829156	0.945	rs8181345	ENSG00000225527.1	RP11-383B4.4	-4.25	3.11e-05	0.013	-0.37	-0.27	Sudden cardiac arrest;	chr10:18678689	chr10:18531849~18533336:-
OV	cis	rs9992667	0.955	rs6858772	ENSG00000231160.8	KLF3-AS1	4.25	3.11e-05	0.013	0.32	0.27	Eosinophil percentage of granulocytes;	chr4:38649382	chr4:38612701~38664883:-
OV	cis	rs9828933	1	rs1060897	ENSG00000280620.1	SCAANT1	-4.25	3.12e-05	0.013	-0.39	-0.27	Type 2 diabetes;	chr3:64012196	chr3:63911518~63911772:-
OV	cis	rs7189233	0.592	rs2024449	ENSG00000279344.1	RP11-44F14.7	4.25	3.12e-05	0.013	0.25	0.27	Intelligence (multi-trait analysis);	chr16:53460705	chr16:53478957~53481550:-
OV	cis	rs2919917	1	rs2919936	ENSG00000254352.1	RP11-578O24.2	4.25	3.12e-05	0.013	0.32	0.27	Lymphocyte counts;	chr8:78721772	chr8:78723796~78724136:-
OV	cis	rs10129255	0.518	rs7143784	ENSG00000223648.3	IGHV3-64	4.25	3.12e-05	0.013	0.27	0.27	Kawasaki disease;	chr14:106687277	chr14:106643132~106658258:-
OV	cis	rs4948102	0.595	rs7793921	ENSG00000226278.1	PSPHP1	-4.25	3.12e-05	0.013	-0.3	-0.27	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr7:55764797~55773288:+
OV	cis	rs4948102	0.595	rs10255049	ENSG00000226278.1	PSPHP1	-4.25	3.12e-05	0.013	-0.3	-0.27	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr7:55764797~55773288:+
OV	cis	rs2239557	1	rs10150201	ENSG00000259065.1	RP5-1021I20.1	4.25	3.12e-05	0.013	0.32	0.27	Common traits (Other);	chr14:74182454	chr14:73787360~73803270:+
OV	cis	rs9287719	0.649	rs10175884	ENSG00000243819.4	RN7SL832P	4.25	3.12e-05	0.013	0.28	0.27	Prostate cancer;	chr2:10578408	chr2:10690344~10692099:+
OV	cis	rs9287719	0.649	rs10190673	ENSG00000243819.4	RN7SL832P	4.25	3.12e-05	0.013	0.28	0.27	Prostate cancer;	chr2:10578492	chr2:10690344~10692099:+
OV	cis	rs9287719	0.649	rs10198971	ENSG00000243819.4	RN7SL832P	4.25	3.12e-05	0.013	0.28	0.27	Prostate cancer;	chr2:10578573	chr2:10690344~10692099:+
OV	cis	rs9287719	0.649	rs10190774	ENSG00000243819.4	RN7SL832P	4.25	3.12e-05	0.013	0.28	0.27	Prostate cancer;	chr2:10578620	chr2:10690344~10692099:+
OV	cis	rs9287719	0.649	rs10188373	ENSG00000243819.4	RN7SL832P	4.25	3.12e-05	0.013	0.28	0.27	Prostate cancer;	chr2:10578676	chr2:10690344~10692099:+
OV	cis	rs9287719	0.649	rs2884232	ENSG00000243819.4	RN7SL832P	4.25	3.12e-05	0.013	0.28	0.27	Prostate cancer;	chr2:10579553	chr2:10690344~10692099:+
OV	cis	rs881375	0.692	rs2072438	ENSG00000226752.6	PSMD5-AS1	-4.25	3.12e-05	0.013	-0.28	-0.27	Rheumatoid arthritis;	chr9:120889023	chr9:120824828~120854385:+
OV	cis	rs13030978	0.505	rs72916554	ENSG00000227542.1	AC092614.2	4.25	3.12e-05	0.013	0.32	0.27	Liver enzyme levels (gamma-glutamyl transferase);	chr2:191330532	chr2:191229165~191246172:-
OV	cis	rs9880211	0.948	rs9872178	ENSG00000239213.4	NCK1-AS1	4.25	3.13e-05	0.013	0.34	0.27	Height;Body mass index;	chr3:136267596	chr3:136841726~136862054:-
OV	cis	rs853679	0.517	rs9380058	ENSG00000226314.6	ZNF192P1	-4.25	3.13e-05	0.013	-0.38	-0.27	Depression;	chr6:28159666	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9393898	ENSG00000226314.6	ZNF192P1	-4.25	3.13e-05	0.013	-0.38	-0.27	Depression;	chr6:28162598	chr6:28161781~28169594:+
OV	cis	rs4763879	0.634	rs917913	ENSG00000278635.1	CTD-2318O12.1	4.25	3.13e-05	0.013	0.23	0.27	Type 1 diabetes;	chr12:9707040	chr12:9415641~9416718:+
OV	cis	rs4763879	0.634	rs2012643	ENSG00000278635.1	CTD-2318O12.1	4.25	3.13e-05	0.013	0.23	0.27	Type 1 diabetes;	chr12:9707128	chr12:9415641~9416718:+
OV	cis	rs992157	0.735	rs2271541	ENSG00000237281.1	CATIP-AS2	-4.25	3.13e-05	0.013	-0.32	-0.27	Colorectal cancer;	chr2:218217396	chr2:218326889~218357966:-
OV	cis	rs992157	0.71	rs12694432	ENSG00000237281.1	CATIP-AS2	-4.25	3.13e-05	0.013	-0.32	-0.27	Colorectal cancer;	chr2:218217607	chr2:218326889~218357966:-
OV	cis	rs992157	0.735	rs12990082	ENSG00000237281.1	CATIP-AS2	-4.25	3.13e-05	0.013	-0.32	-0.27	Colorectal cancer;	chr2:218237609	chr2:218326889~218357966:-
OV	cis	rs17767294	0.708	rs115714358	ENSG00000220721.1	OR1F12	4.25	3.13e-05	0.013	0.54	0.27	Parkinson's disease;	chr6:27996554	chr6:28073316~28074233:+
OV	cis	rs1707322	0.721	rs11211149	ENSG00000234329.1	RP11-767N6.2	4.25	3.13e-05	0.013	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45646546	chr1:45651039~45651826:-
OV	cis	rs1707322	0.752	rs11211152	ENSG00000234329.1	RP11-767N6.2	4.25	3.13e-05	0.013	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648485	chr1:45651039~45651826:-
OV	cis	rs1707322	0.752	rs4607935	ENSG00000234329.1	RP11-767N6.2	4.25	3.13e-05	0.013	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651489	chr1:45651039~45651826:-
OV	cis	rs1707322	0.681	rs12048866	ENSG00000234329.1	RP11-767N6.2	4.25	3.13e-05	0.013	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651820	chr1:45651039~45651826:-
OV	cis	rs1707322	0.752	rs3811436	ENSG00000234329.1	RP11-767N6.2	4.25	3.13e-05	0.013	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660208	chr1:45651039~45651826:-
OV	cis	rs1707322	0.752	rs12024590	ENSG00000234329.1	RP11-767N6.2	4.25	3.13e-05	0.013	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45661824	chr1:45651039~45651826:-
OV	cis	rs1707322	0.752	rs12027622	ENSG00000234329.1	RP11-767N6.2	4.25	3.13e-05	0.013	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664580	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs4415615	ENSG00000234329.1	RP11-767N6.2	4.25	3.13e-05	0.013	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45666437	chr1:45651039~45651826:-
OV	cis	rs1707322	0.752	rs7529699	ENSG00000234329.1	RP11-767N6.2	4.25	3.13e-05	0.013	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668962	chr1:45651039~45651826:-
OV	cis	rs1707322	0.716	rs6699444	ENSG00000234329.1	RP11-767N6.2	4.25	3.13e-05	0.013	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669448	chr1:45651039~45651826:-
OV	cis	rs1707322	0.752	rs10430105	ENSG00000234329.1	RP11-767N6.2	4.25	3.13e-05	0.013	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45673204	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs10890341	ENSG00000234329.1	RP11-767N6.2	4.25	3.13e-05	0.013	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45681568	chr1:45651039~45651826:-
OV	cis	rs17301013	0.606	rs4650969	ENSG00000227373.4	RP11-160H22.5	4.25	3.13e-05	0.013	0.37	0.27	Systemic lupus erythematosus;	chr1:174229622	chr1:174115300~174160004:-
OV	cis	rs17301013	0.581	rs72711501	ENSG00000227373.4	RP11-160H22.5	4.25	3.13e-05	0.013	0.37	0.27	Systemic lupus erythematosus;	chr1:174233081	chr1:174115300~174160004:-
OV	cis	rs7119038	0.609	rs11216998	ENSG00000255422.1	AP002954.4	4.25	3.14e-05	0.013	0.35	0.27	Sjögren's syndrome;	chr11:118734128	chr11:118704607~118750263:+
OV	cis	rs9925964	0.804	rs4889606	ENSG00000278922.1	AC002310.14	4.25	3.14e-05	0.013	0.31	0.27	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:30999862	chr16:30526918~30528294:+
OV	cis	rs11673344	0.764	rs472226	ENSG00000226686.6	LINC01535	4.25	3.14e-05	0.0131	0.35	0.27	Obesity-related traits;	chr19:36967811	chr19:37251912~37265535:+
OV	cis	rs7927592	0.956	rs6591341	ENSG00000212093.1	AP000807.1	4.25	3.14e-05	0.0131	0.34	0.27	Total body bone mineral density;	chr11:68568010	chr11:68506083~68506166:-
OV	cis	rs7520050	0.966	rs785471	ENSG00000281133.1	AL355480.3	4.25	3.15e-05	0.0131	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:46053005	chr1:45580892~45580996:-
OV	cis	rs10771431	0.967	rs7137443	ENSG00000111788.10	RP11-22B23.1	4.25	3.15e-05	0.0131	0.24	0.27	Breast size;	chr12:9219433	chr12:9277235~9313241:+
OV	cis	rs10771431	0.935	rs1117735	ENSG00000111788.10	RP11-22B23.1	4.25	3.15e-05	0.0131	0.24	0.27	Breast size;	chr12:9220132	chr12:9277235~9313241:+
OV	cis	rs4713118	0.619	rs200486	ENSG00000220721.1	OR1F12	4.25	3.15e-05	0.0131	0.34	0.27	Parkinson's disease;	chr6:27811728	chr6:28073316~28074233:+
OV	cis	rs7267979	0.966	rs2263204	ENSG00000274973.1	RP13-401N8.7	4.25	3.15e-05	0.0131	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25397052	chr20:25845497~25845862:+
OV	cis	rs1979679	0.573	rs4931087	ENSG00000278733.1	RP11-425D17.1	4.25	3.15e-05	0.0131	0.33	0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28582158	chr12:28185625~28186190:-
OV	cis	rs801193	0.548	rs7805152	ENSG00000236529.1	RP13-254B10.1	4.25	3.15e-05	0.0131	0.28	0.27	Aortic root size;	chr7:66744266	chr7:65840212~65840596:+
OV	cis	rs2919917	1	rs13280202	ENSG00000254352.1	RP11-578O24.2	-4.25	3.16e-05	0.0131	-0.32	-0.27	Lymphocyte counts;	chr8:78700238	chr8:78723796~78724136:-
OV	cis	rs10510102	0.623	rs10159856	ENSG00000226864.1	ATE1-AS1	4.25	3.16e-05	0.0131	0.49	0.27	Breast cancer;	chr10:121988292	chr10:121928312~121951965:+
OV	cis	rs4665809	0.878	rs4665826	ENSG00000231655.1	AC011742.3	-4.25	3.16e-05	0.0131	-0.42	-0.27	Gut microbiome composition (summer);	chr2:26144634	chr2:26140263~26141264:-
OV	cis	rs875971	0.929	rs4122249	ENSG00000237310.1	GS1-124K5.4	4.25	3.16e-05	0.0131	0.28	0.27	Aortic root size;	chr7:66455949	chr7:66493706~66495474:+
OV	cis	rs7617773	0.817	rs6796490	ENSG00000228638.1	FCF1P2	-4.25	3.16e-05	0.0131	-0.33	-0.27	Coronary artery disease;	chr3:48195614	chr3:48290793~48291375:-
OV	cis	rs7267979	1	rs1047171	ENSG00000274973.1	RP13-401N8.7	-4.25	3.16e-05	0.0131	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25448150	chr20:25845497~25845862:+
OV	cis	rs783540	0.521	rs28719490	ENSG00000259429.4	UBE2Q2P2	-4.25	3.16e-05	0.0131	-0.32	-0.27	Schizophrenia;	chr15:82720688	chr15:82355142~82420075:+
OV	cis	rs7520050	0.807	rs3013594	ENSG00000281133.1	AL355480.3	-4.25	3.16e-05	0.0131	-0.3	-0.27	Reticulocyte count;Red blood cell count;	chr1:45672328	chr1:45580892~45580996:-
OV	cis	rs2153535	0.585	rs7762631	ENSG00000230939.1	RP11-314C16.1	4.25	3.16e-05	0.0131	0.29	0.27	Motion sickness;	chr6:8635339	chr6:8784178~8785445:+
OV	cis	rs7568498	1	rs13004784	ENSG00000227403.1	AC009299.3	-4.25	3.17e-05	0.0131	-0.45	-0.27	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161022320	chr2:161244739~161249050:+
OV	cis	rs12073359	1	rs58426216	ENSG00000223945.2	RP11-458I7.1	-4.25	3.17e-05	0.0132	-0.41	-0.27	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150152425	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs56349882	ENSG00000223945.2	RP11-458I7.1	-4.25	3.17e-05	0.0132	-0.41	-0.27	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150157804	chr1:150053864~150055034:+
OV	cis	rs8177876	0.749	rs10459872	ENSG00000261838.4	RP11-303E16.6	-4.25	3.17e-05	0.0132	-0.45	-0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81061346	chr16:81069854~81076598:+
OV	cis	rs10978777	0.805	rs4978844	ENSG00000276883.1	AL137852.1	-4.25	3.17e-05	0.0132	-0.29	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107308902	chr9:107292369~107292456:-
OV	cis	rs992157	0.732	rs10932771	ENSG00000237281.1	CATIP-AS2	-4.25	3.17e-05	0.0132	-0.31	-0.27	Colorectal cancer;	chr2:218305513	chr2:218326889~218357966:-
OV	cis	rs853679	0.556	rs45509595	ENSG00000220721.1	OR1F12	4.25	3.18e-05	0.0132	0.55	0.27	Depression;	chr6:27873148	chr6:28073316~28074233:+
OV	cis	rs4713118	0.516	rs7739216	ENSG00000226314.6	ZNF192P1	-4.25	3.18e-05	0.0132	-0.36	-0.27	Parkinson's disease;	chr6:28112168	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs35512245	ENSG00000226314.6	ZNF192P1	-4.25	3.18e-05	0.0132	-0.36	-0.27	Depression;	chr6:28112175	chr6:28161781~28169594:+
OV	cis	rs10246939	0.543	rs11765106	ENSG00000228775.6	WEE2-AS1	4.25	3.18e-05	0.0132	0.3	0.27	Bitter taste perception;	chr7:141902676	chr7:141704338~141738346:-
OV	cis	rs10246939	0.543	rs7802271	ENSG00000228775.6	WEE2-AS1	4.25	3.18e-05	0.0132	0.3	0.27	Bitter taste perception;	chr7:141909624	chr7:141704338~141738346:-
OV	cis	rs10246939	0.52	rs7782886	ENSG00000228775.6	WEE2-AS1	4.25	3.18e-05	0.0132	0.3	0.27	Bitter taste perception;	chr7:141909958	chr7:141704338~141738346:-
OV	cis	rs10246939	0.543	rs994808	ENSG00000228775.6	WEE2-AS1	4.25	3.18e-05	0.0132	0.3	0.27	Bitter taste perception;	chr7:141911091	chr7:141704338~141738346:-
OV	cis	rs10246939	0.543	rs7808421	ENSG00000228775.6	WEE2-AS1	4.25	3.18e-05	0.0132	0.3	0.27	Bitter taste perception;	chr7:141911592	chr7:141704338~141738346:-
OV	cis	rs10246939	0.543	rs7789123	ENSG00000228775.6	WEE2-AS1	4.25	3.18e-05	0.0132	0.3	0.27	Bitter taste perception;	chr7:141911699	chr7:141704338~141738346:-
OV	cis	rs10246939	0.543	rs11767119	ENSG00000228775.6	WEE2-AS1	4.25	3.18e-05	0.0132	0.3	0.27	Bitter taste perception;	chr7:141912316	chr7:141704338~141738346:-
OV	cis	rs10246939	0.543	rs11767947	ENSG00000228775.6	WEE2-AS1	4.25	3.18e-05	0.0132	0.3	0.27	Bitter taste perception;	chr7:141912821	chr7:141704338~141738346:-
OV	cis	rs10246939	0.543	rs11769089	ENSG00000228775.6	WEE2-AS1	4.25	3.18e-05	0.0132	0.3	0.27	Bitter taste perception;	chr7:141914310	chr7:141704338~141738346:-
OV	cis	rs10246939	0.543	rs11765974	ENSG00000228775.6	WEE2-AS1	4.25	3.18e-05	0.0132	0.3	0.27	Bitter taste perception;	chr7:141914390	chr7:141704338~141738346:-
OV	cis	rs7617773	0.78	rs35297395	ENSG00000228638.1	FCF1P2	-4.24	3.19e-05	0.0132	-0.35	-0.27	Coronary artery disease;	chr3:48301392	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs36075665	ENSG00000228638.1	FCF1P2	-4.24	3.19e-05	0.0132	-0.35	-0.27	Coronary artery disease;	chr3:48301597	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs35190747	ENSG00000228638.1	FCF1P2	-4.24	3.19e-05	0.0132	-0.35	-0.27	Coronary artery disease;	chr3:48301800	chr3:48290793~48291375:-
OV	cis	rs7617773	0.743	rs7621785	ENSG00000228638.1	FCF1P2	-4.24	3.19e-05	0.0132	-0.35	-0.27	Coronary artery disease;	chr3:48302218	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs4511915	ENSG00000228638.1	FCF1P2	-4.24	3.19e-05	0.0132	-0.35	-0.27	Coronary artery disease;	chr3:48302368	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs13066758	ENSG00000228638.1	FCF1P2	-4.24	3.19e-05	0.0132	-0.35	-0.27	Coronary artery disease;	chr3:48302387	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs4392440	ENSG00000228638.1	FCF1P2	-4.24	3.19e-05	0.0132	-0.35	-0.27	Coronary artery disease;	chr3:48302430	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs13082859	ENSG00000228638.1	FCF1P2	-4.24	3.19e-05	0.0132	-0.35	-0.27	Coronary artery disease;	chr3:48303185	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs36121690	ENSG00000228638.1	FCF1P2	-4.24	3.19e-05	0.0132	-0.35	-0.27	Coronary artery disease;	chr3:48304021	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs35778847	ENSG00000228638.1	FCF1P2	-4.24	3.19e-05	0.0132	-0.35	-0.27	Coronary artery disease;	chr3:48305495	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs34749846	ENSG00000228638.1	FCF1P2	-4.24	3.19e-05	0.0132	-0.35	-0.27	Coronary artery disease;	chr3:48305678	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs7632297	ENSG00000228638.1	FCF1P2	-4.24	3.19e-05	0.0132	-0.35	-0.27	Coronary artery disease;	chr3:48306673	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs79089926	ENSG00000228638.1	FCF1P2	-4.24	3.19e-05	0.0132	-0.35	-0.27	Coronary artery disease;	chr3:48307074	chr3:48290793~48291375:-
OV	cis	rs7617773	0.643	rs78159520	ENSG00000228638.1	FCF1P2	-4.24	3.19e-05	0.0132	-0.35	-0.27	Coronary artery disease;	chr3:48307533	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs4511916	ENSG00000228638.1	FCF1P2	-4.24	3.19e-05	0.0132	-0.35	-0.27	Coronary artery disease;	chr3:48308876	chr3:48290793~48291375:-
OV	cis	rs7617773	0.815	rs7624450	ENSG00000228638.1	FCF1P2	-4.24	3.19e-05	0.0132	-0.35	-0.27	Coronary artery disease;	chr3:48308885	chr3:48290793~48291375:-
OV	cis	rs7617773	0.815	rs6793150	ENSG00000228638.1	FCF1P2	-4.24	3.19e-05	0.0132	-0.35	-0.27	Coronary artery disease;	chr3:48310070	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs6793239	ENSG00000228638.1	FCF1P2	-4.24	3.19e-05	0.0132	-0.35	-0.27	Coronary artery disease;	chr3:48310128	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs6782166	ENSG00000228638.1	FCF1P2	-4.24	3.19e-05	0.0132	-0.35	-0.27	Coronary artery disease;	chr3:48310193	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs4130522	ENSG00000228638.1	FCF1P2	-4.24	3.19e-05	0.0132	-0.35	-0.27	Coronary artery disease;	chr3:48310823	chr3:48290793~48291375:-
OV	cis	rs7617773	0.674	rs13069029	ENSG00000228638.1	FCF1P2	-4.24	3.19e-05	0.0132	-0.35	-0.27	Coronary artery disease;	chr3:48313534	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs13081169	ENSG00000228638.1	FCF1P2	-4.24	3.19e-05	0.0132	-0.35	-0.27	Coronary artery disease;	chr3:48315307	chr3:48290793~48291375:-
OV	cis	rs1062177	0.855	rs6884630	ENSG00000253921.1	CTB-113P19.3	-4.24	3.19e-05	0.0132	-0.35	-0.27	Preschool internalizing problems;	chr5:151889436	chr5:151753992~151767247:+
OV	cis	rs62244186	0.659	rs12108134	ENSG00000214820.3	MPRIPP1	-4.24	3.21e-05	0.0133	-0.24	-0.27	Depressive symptoms;	chr3:44501538	chr3:44579938~44581026:-
OV	cis	rs5742933	1	rs62184283	ENSG00000253559.1	OSGEPL1-AS1	-4.24	3.21e-05	0.0133	-0.31	-0.27	Ferritin levels;	chr2:189801179	chr2:189762704~189765556:+
OV	cis	rs709400	0.628	rs6575983	ENSG00000244691.1	RPL10AP1	4.24	3.21e-05	0.0133	0.26	0.27	Body mass index;	chr14:103403512	chr14:103412119~103412761:-
OV	cis	rs4934494	0.727	rs2418929	ENSG00000240996.1	RP11-80H5.7	-4.24	3.21e-05	0.0133	-0.37	-0.27	Red blood cell count;	chr10:89741720	chr10:89694295~89697928:-
OV	cis	rs9979383	0.576	rs11701941	ENSG00000228107.1	AP000692.9	4.24	3.21e-05	0.0133	0.29	0.27	Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr21:35410834	chr21:36360630~36362040:+
OV	cis	rs4972806	0.849	rs1542180	ENSG00000226363.3	HAGLROS	-4.24	3.21e-05	0.0133	-0.34	-0.27	IgG glycosylation;	chr2:176164039	chr2:176177717~176179008:+
OV	cis	rs1823913	0.599	rs13002286	ENSG00000227542.1	AC092614.2	-4.24	3.21e-05	0.0133	-0.3	-0.27	Obesity-related traits;	chr2:191285626	chr2:191229165~191246172:-
OV	cis	rs7267979	1	rs7019	ENSG00000274973.1	RP13-401N8.7	-4.24	3.21e-05	0.0133	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25297642	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2424710	ENSG00000274973.1	RP13-401N8.7	-4.24	3.21e-05	0.0133	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25303250	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6115140	ENSG00000274973.1	RP13-401N8.7	-4.24	3.21e-05	0.0133	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25304871	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs1888997	ENSG00000274973.1	RP13-401N8.7	4.24	3.21e-05	0.0133	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25318352	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs3002698	ENSG00000274973.1	RP13-401N8.7	4.24	3.21e-05	0.0133	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25322743	chr20:25845497~25845862:+
OV	cis	rs67340775	0.834	rs13218875	ENSG00000220721.1	OR1F12	4.24	3.22e-05	0.0133	0.57	0.27	Lung cancer in ever smokers;	chr6:27916234	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs67040724	ENSG00000220721.1	OR1F12	4.24	3.22e-05	0.0133	0.57	0.27	Depression;	chr6:27937731	chr6:28073316~28074233:+
OV	cis	rs7555523	0.887	rs6696454	ENSG00000224358.1	RP11-466F5.8	-4.24	3.22e-05	0.0133	-0.38	-0.27	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165738686	chr1:165768929~165775176:+
OV	cis	rs7555523	0.943	rs4537525	ENSG00000224358.1	RP11-466F5.8	-4.24	3.22e-05	0.0133	-0.38	-0.27	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165741852	chr1:165768929~165775176:+
OV	cis	rs7555523	0.887	rs4269750	ENSG00000224358.1	RP11-466F5.8	-4.24	3.22e-05	0.0133	-0.38	-0.27	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165742273	chr1:165768929~165775176:+
OV	cis	rs7555523	0.887	rs10918274	ENSG00000224358.1	RP11-466F5.8	-4.24	3.22e-05	0.0133	-0.38	-0.27	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165745179	chr1:165768929~165775176:+
OV	cis	rs7555523	0.779	rs6662839	ENSG00000224358.1	RP11-466F5.8	-4.24	3.22e-05	0.0133	-0.38	-0.27	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165753409	chr1:165768929~165775176:+
OV	cis	rs7555523	0.887	rs2790053	ENSG00000224358.1	RP11-466F5.8	-4.24	3.22e-05	0.0133	-0.38	-0.27	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165768467	chr1:165768929~165775176:+
OV	cis	rs7555523	0.778	rs2790052	ENSG00000224358.1	RP11-466F5.8	-4.24	3.22e-05	0.0133	-0.38	-0.27	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165769226	chr1:165768929~165775176:+
OV	cis	rs1950626	0.787	rs34857222	ENSG00000258399.5	MEG8	-4.24	3.22e-05	0.0133	-0.28	-0.27	Pelvic organ prolapse (moderate/severe);	chr14:100925017	chr14:100894770~100935999:+
OV	cis	rs1950626	0.833	rs12897114	ENSG00000258399.5	MEG8	-4.24	3.22e-05	0.0133	-0.28	-0.27	Pelvic organ prolapse (moderate/severe);	chr14:100928803	chr14:100894770~100935999:+
OV	cis	rs11122895	0.839	rs12999970	ENSG00000228251.1	AC012442.6	-4.24	3.22e-05	0.0133	-0.26	-0.27	Allergic sensitization;	chr2:111689254	chr2:112590796~112591939:+
OV	cis	rs896854	0.684	rs10099059	ENSG00000253528.2	RP11-347C18.4	4.24	3.22e-05	0.0133	0.26	0.27	Type 2 diabetes;	chr8:94974744	chr8:94974573~94974853:-
OV	cis	rs896854	0.684	rs10099941	ENSG00000253528.2	RP11-347C18.4	4.24	3.22e-05	0.0133	0.26	0.27	Type 2 diabetes;	chr8:94974780	chr8:94974573~94974853:-
OV	cis	rs8059260	0.604	rs16957984	ENSG00000274038.1	RP11-66H6.4	-4.24	3.23e-05	0.0133	-0.56	-0.27	Alcohol consumption over the past year;	chr16:11051105	chr16:11056556~11057034:+
OV	cis	rs875971	0.862	rs6460307	ENSG00000236529.1	RP13-254B10.1	4.24	3.23e-05	0.0133	0.28	0.27	Aortic root size;	chr7:66595884	chr7:65840212~65840596:+
OV	cis	rs9309473	1	rs11899740	ENSG00000163016.8	ALMS1P	4.24	3.23e-05	0.0133	0.34	0.27	Metabolite levels;	chr2:73404084	chr2:73644919~73685576:+
OV	cis	rs875971	0.666	rs13242072	ENSG00000224316.1	RP11-479O9.2	-4.24	3.23e-05	0.0133	-0.29	-0.27	Aortic root size;	chr7:66301001	chr7:65773620~65802067:+
OV	cis	rs7429990	0.864	rs12495520	ENSG00000229759.1	MRPS18AP1	-4.24	3.23e-05	0.0134	-0.3	-0.27	Educational attainment (years of education);	chr3:47766269	chr3:48256350~48256938:-
OV	cis	rs7927592	0.956	rs10896348	ENSG00000212093.1	AP000807.1	4.24	3.23e-05	0.0134	0.34	0.27	Total body bone mineral density;	chr11:68589900	chr11:68506083~68506166:-
OV	cis	rs853679	0.517	rs36078605	ENSG00000226314.6	ZNF192P1	-4.24	3.23e-05	0.0134	-0.36	-0.27	Depression;	chr6:28110254	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9393891	ENSG00000226314.6	ZNF192P1	-4.24	3.23e-05	0.0134	-0.36	-0.27	Depression;	chr6:28111382	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9468286	ENSG00000226314.6	ZNF192P1	-4.24	3.23e-05	0.0134	-0.36	-0.27	Depression;	chr6:28111650	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9380055	ENSG00000226314.6	ZNF192P1	-4.24	3.23e-05	0.0134	-0.36	-0.27	Depression;	chr6:28113851	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9368553	ENSG00000226314.6	ZNF192P1	-4.24	3.23e-05	0.0134	-0.36	-0.27	Depression;	chr6:28114487	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9368554	ENSG00000226314.6	ZNF192P1	-4.24	3.23e-05	0.0134	-0.36	-0.27	Depression;	chr6:28114933	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs4713137	ENSG00000226314.6	ZNF192P1	-4.24	3.23e-05	0.0134	-0.36	-0.27	Depression;	chr6:28115743	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9348793	ENSG00000226314.6	ZNF192P1	-4.24	3.23e-05	0.0134	-0.36	-0.27	Depression;	chr6:28116411	chr6:28161781~28169594:+
OV	cis	rs4713118	0.586	rs6905516	ENSG00000226314.6	ZNF192P1	-4.24	3.23e-05	0.0134	-0.36	-0.27	Parkinson's disease;	chr6:28118700	chr6:28161781~28169594:+
OV	cis	rs4713118	0.586	rs6905522	ENSG00000226314.6	ZNF192P1	-4.24	3.23e-05	0.0134	-0.36	-0.27	Parkinson's disease;	chr6:28118701	chr6:28161781~28169594:+
OV	cis	rs4713118	0.586	rs9468290	ENSG00000226314.6	ZNF192P1	-4.24	3.23e-05	0.0134	-0.36	-0.27	Parkinson's disease;	chr6:28119896	chr6:28161781~28169594:+
OV	cis	rs9287719	0.601	rs10084172	ENSG00000243819.4	RN7SL832P	4.24	3.24e-05	0.0134	0.28	0.27	Prostate cancer;	chr2:10631102	chr2:10690344~10692099:+
OV	cis	rs9847710	0.708	rs2581811	ENSG00000242142.1	SERBP1P3	4.24	3.24e-05	0.0134	0.33	0.27	Ulcerative colitis;	chr3:53051785	chr3:53064283~53065091:-
OV	cis	rs9880211	1	rs12695645	ENSG00000239213.4	NCK1-AS1	4.24	3.24e-05	0.0134	0.34	0.27	Height;Body mass index;	chr3:136272039	chr3:136841726~136862054:-
OV	cis	rs10510102	0.516	rs12256693	ENSG00000226864.1	ATE1-AS1	4.24	3.24e-05	0.0134	0.5	0.27	Breast cancer;	chr10:121976839	chr10:121928312~121951965:+
OV	cis	rs10510102	0.516	rs11200300	ENSG00000226864.1	ATE1-AS1	4.24	3.24e-05	0.0134	0.5	0.27	Breast cancer;	chr10:121977489	chr10:121928312~121951965:+
OV	cis	rs875971	0.862	rs1612452	ENSG00000237310.1	GS1-124K5.4	-4.24	3.24e-05	0.0134	-0.27	-0.27	Aortic root size;	chr7:66108909	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs1167390	ENSG00000237310.1	GS1-124K5.4	-4.24	3.24e-05	0.0134	-0.27	-0.27	Aortic root size;	chr7:66110906	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs35034167	ENSG00000237310.1	GS1-124K5.4	-4.24	3.24e-05	0.0134	-0.27	-0.27	Aortic root size;	chr7:66115179	chr7:66493706~66495474:+
OV	cis	rs2303745	0.589	rs11882562	ENSG00000269815.1	CTD-2278I10.4	4.24	3.25e-05	0.0134	0.36	0.27	Systemic lupus erythematosus;	chr19:17284246	chr19:17296196~17296695:-
OV	cis	rs2153535	0.935	rs11243254	ENSG00000230939.1	RP11-314C16.1	4.24	3.25e-05	0.0134	0.31	0.27	Motion sickness;	chr6:8381009	chr6:8784178~8785445:+
OV	cis	rs8100891	0.614	rs6510243	ENSG00000267213.4	AC007773.2	-4.24	3.25e-05	0.0134	-0.33	-0.27	Neuroticism;	chr19:32342765	chr19:32390050~32405560:-
OV	cis	rs7812879	0.852	rs998682	ENSG00000254866.2	DEFB109P3	4.24	3.25e-05	0.0134	0.42	0.27	Systemic lupus erythematosus;	chr8:11495543	chr8:12150895~12151134:-
OV	cis	rs7043114	0.525	rs7045409	ENSG00000281156.1	MIR3651	-4.24	3.27e-05	0.0135	-0.3	-0.27	Height;	chr9:92439258	chr9:92292458~92292547:-
OV	cis	rs2070488	0.965	rs13079145	ENSG00000229589.1	ACVR2B-AS1	4.24	3.27e-05	0.0135	0.3	0.27	Electrocardiographic conduction measures;	chr3:38476501	chr3:38451027~38454820:-
OV	cis	rs1823913	0.599	rs13399251	ENSG00000227542.1	AC092614.2	4.24	3.27e-05	0.0135	0.3	0.27	Obesity-related traits;	chr2:191268758	chr2:191229165~191246172:-
OV	cis	rs1707322	0.752	rs4660880	ENSG00000234329.1	RP11-767N6.2	4.24	3.28e-05	0.0135	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645368	chr1:45651039~45651826:-
OV	cis	rs4845570	0.831	rs11588258	ENSG00000203288.3	RP11-98D18.9	-4.24	3.28e-05	0.0135	-0.45	-0.27	Coronary artery disease;	chr1:151808252	chr1:151790804~151794402:+
OV	cis	rs2243480	1	rs73142166	ENSG00000226824.5	RP4-756H11.3	-4.24	3.28e-05	0.0135	-0.44	-0.27	Diabetic kidney disease;	chr7:65910845	chr7:66654538~66669855:+
OV	cis	rs2243480	0.908	rs55876148	ENSG00000226824.5	RP4-756H11.3	-4.24	3.28e-05	0.0135	-0.44	-0.27	Diabetic kidney disease;	chr7:65914813	chr7:66654538~66669855:+
OV	cis	rs5769707	0.967	rs763126	ENSG00000188511.11	C22orf34	-4.24	3.28e-05	0.0135	-0.28	-0.27	Monocyte percentage of white cells;Monocyte count;	chr22:49594926	chr22:49414524~49657542:-
OV	cis	rs9847710	0.733	rs2581808	ENSG00000242142.1	SERBP1P3	4.24	3.28e-05	0.0135	0.33	0.27	Ulcerative colitis;	chr3:53055429	chr3:53064283~53065091:-
OV	cis	rs62244186	0.659	rs9311358	ENSG00000214820.3	MPRIPP1	4.24	3.29e-05	0.0135	0.24	0.27	Depressive symptoms;	chr3:44497256	chr3:44579938~44581026:-
OV	cis	rs992157	0.798	rs4996257	ENSG00000237281.1	CATIP-AS2	-4.24	3.29e-05	0.0135	-0.32	-0.27	Colorectal cancer;	chr2:218298113	chr2:218326889~218357966:-
OV	cis	rs7017914	0.69	rs7016334	ENSG00000223220.1	Y_RNA	4.24	3.29e-05	0.0135	0.28	0.27	Bone mineral density;	chr8:70742171	chr8:70780914~70781008:-
OV	cis	rs7017914	0.714	rs28376252	ENSG00000223220.1	Y_RNA	4.24	3.29e-05	0.0135	0.28	0.27	Bone mineral density;	chr8:70747652	chr8:70780914~70781008:-
OV	cis	rs10978777	0.737	rs1535765	ENSG00000276883.1	AL137852.1	-4.24	3.29e-05	0.0135	-0.3	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107291226	chr9:107292369~107292456:-
OV	cis	rs10978777	0.664	rs7029997	ENSG00000276883.1	AL137852.1	-4.24	3.29e-05	0.0135	-0.3	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107291456	chr9:107292369~107292456:-
OV	cis	rs10978777	0.616	rs7030631	ENSG00000276883.1	AL137852.1	-4.24	3.29e-05	0.0135	-0.3	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107291959	chr9:107292369~107292456:-
OV	cis	rs10978777	0.677	rs2147071	ENSG00000276883.1	AL137852.1	-4.24	3.29e-05	0.0135	-0.3	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107292418	chr9:107292369~107292456:-
OV	cis	rs10978777	0.737	rs7038737	ENSG00000276883.1	AL137852.1	-4.24	3.29e-05	0.0135	-0.3	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107293740	chr9:107292369~107292456:-
OV	cis	rs10978777	0.737	rs7039041	ENSG00000276883.1	AL137852.1	-4.24	3.29e-05	0.0135	-0.3	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107293985	chr9:107292369~107292456:-
OV	cis	rs875971	0.706	rs1643374	ENSG00000224316.1	RP11-479O9.2	4.24	3.29e-05	0.0135	0.29	0.27	Aortic root size;	chr7:66407695	chr7:65773620~65802067:+
OV	cis	rs4908768	0.906	rs6656249	ENSG00000228423.2	RP4-633I8.4	4.24	3.29e-05	0.0135	0.32	0.27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8520956	chr1:8805860~8807051:-
OV	cis	rs9473147	0.571	rs9395285	ENSG00000270761.1	RP11-385F7.1	-4.24	3.3e-05	0.0136	-0.31	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47586441	chr6:47477243~47477572:-
OV	cis	rs875971	0.545	rs316324	ENSG00000237310.1	GS1-124K5.4	-4.24	3.3e-05	0.0136	-0.31	-0.27	Aortic root size;	chr7:66145627	chr7:66493706~66495474:+
OV	cis	rs875971	0.545	rs316323	ENSG00000237310.1	GS1-124K5.4	-4.24	3.3e-05	0.0136	-0.31	-0.27	Aortic root size;	chr7:66146002	chr7:66493706~66495474:+
OV	cis	rs875971	0.545	rs316316	ENSG00000237310.1	GS1-124K5.4	-4.24	3.3e-05	0.0136	-0.31	-0.27	Aortic root size;	chr7:66149270	chr7:66493706~66495474:+
OV	cis	rs875971	0.545	rs1796226	ENSG00000273024.4	INTS4P2	-4.24	3.3e-05	0.0136	-0.33	-0.27	Aortic root size;	chr7:66622723	chr7:65647864~65715661:+
OV	cis	rs1538970	0.962	rs2153607	ENSG00000280836.1	AL355480.1	-4.24	3.3e-05	0.0136	-0.37	-0.27	Platelet count;	chr1:45348148	chr1:45581219~45581321:-
OV	cis	rs853679	0.546	rs493161	ENSG00000280107.1	AL022393.9	-4.24	3.31e-05	0.0136	-0.49	-0.27	Depression;	chr6:27882936	chr6:28170845~28172521:+
OV	cis	rs4934494	0.768	rs12771413	ENSG00000240996.1	RP11-80H5.7	4.24	3.31e-05	0.0136	0.35	0.27	Red blood cell count;	chr10:89633010	chr10:89694295~89697928:-
OV	cis	rs7520050	0.778	rs2088102	ENSG00000280836.1	AL355480.1	4.24	3.31e-05	0.0136	0.33	0.27	Reticulocyte count;Red blood cell count;	chr1:45567302	chr1:45581219~45581321:-
OV	cis	rs3733585	0.605	rs4697710	ENSG00000250413.1	RP11-448G15.1	4.24	3.31e-05	0.0136	0.35	0.27	Cleft plate (environmental tobacco smoke interaction);	chr4:10121025	chr4:10006482~10009725:+
OV	cis	rs11157436	0.918	rs1076546	ENSG00000211812.1	TRAV26-2	-4.24	3.31e-05	0.0136	-0.3	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22159015	chr14:22202583~22203368:+
OV	cis	rs853679	0.517	rs9393895	ENSG00000226314.6	ZNF192P1	-4.24	3.31e-05	0.0136	-0.37	-0.27	Depression;	chr6:28159843	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9357066	ENSG00000226314.6	ZNF192P1	-4.24	3.31e-05	0.0136	-0.37	-0.27	Depression;	chr6:28162053	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9368556	ENSG00000226314.6	ZNF192P1	-4.24	3.31e-05	0.0136	-0.37	-0.27	Depression;	chr6:28163375	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9368557	ENSG00000226314.6	ZNF192P1	-4.24	3.31e-05	0.0136	-0.37	-0.27	Depression;	chr6:28163759	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9380059	ENSG00000226314.6	ZNF192P1	-4.24	3.31e-05	0.0136	-0.37	-0.27	Depression;	chr6:28164580	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9380060	ENSG00000226314.6	ZNF192P1	-4.24	3.31e-05	0.0136	-0.37	-0.27	Depression;	chr6:28164825	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs35227624	ENSG00000226314.6	ZNF192P1	-4.24	3.31e-05	0.0136	-0.37	-0.27	Depression;	chr6:28164948	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9380061	ENSG00000226314.6	ZNF192P1	-4.24	3.31e-05	0.0136	-0.37	-0.27	Depression;	chr6:28165025	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9368558	ENSG00000226314.6	ZNF192P1	-4.24	3.31e-05	0.0136	-0.37	-0.27	Depression;	chr6:28165528	chr6:28161781~28169594:+
OV	cis	rs4713118	0.587	rs9393899	ENSG00000226314.6	ZNF192P1	-4.24	3.31e-05	0.0136	-0.37	-0.27	Parkinson's disease;	chr6:28165750	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs4713150	ENSG00000226314.6	ZNF192P1	-4.24	3.31e-05	0.0136	-0.37	-0.27	Depression;	chr6:28168434	chr6:28161781~28169594:+
OV	cis	rs4713118	0.527	rs4713151	ENSG00000226314.6	ZNF192P1	-4.24	3.31e-05	0.0136	-0.37	-0.27	Parkinson's disease;	chr6:28168578	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9393901	ENSG00000226314.6	ZNF192P1	-4.24	3.31e-05	0.0136	-0.37	-0.27	Depression;	chr6:28169019	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs3173443	ENSG00000226314.6	ZNF192P1	-4.24	3.31e-05	0.0136	-0.37	-0.27	Depression;	chr6:28169249	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs4713152	ENSG00000226314.6	ZNF192P1	-4.24	3.31e-05	0.0136	-0.37	-0.27	Depression;	chr6:28169676	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9348797	ENSG00000226314.6	ZNF192P1	-4.24	3.31e-05	0.0136	-0.37	-0.27	Depression;	chr6:28169755	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9380062	ENSG00000226314.6	ZNF192P1	-4.24	3.31e-05	0.0136	-0.37	-0.27	Depression;	chr6:28169791	chr6:28161781~28169594:+
OV	cis	rs853679	0.542	rs9380063	ENSG00000226314.6	ZNF192P1	-4.24	3.31e-05	0.0136	-0.37	-0.27	Depression;	chr6:28170075	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs12332979	ENSG00000226314.6	ZNF192P1	-4.24	3.31e-05	0.0136	-0.37	-0.27	Depression;	chr6:28173770	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs67878650	ENSG00000226314.6	ZNF192P1	-4.24	3.31e-05	0.0136	-0.37	-0.27	Depression;	chr6:28174809	chr6:28161781~28169594:+
OV	cis	rs853679	0.569	rs9348798	ENSG00000226314.6	ZNF192P1	-4.24	3.31e-05	0.0136	-0.37	-0.27	Depression;	chr6:28175233	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9380065	ENSG00000226314.6	ZNF192P1	-4.24	3.31e-05	0.0136	-0.37	-0.27	Depression;	chr6:28176973	chr6:28161781~28169594:+
OV	cis	rs5769707	0.609	rs2007024	ENSG00000188511.11	C22orf34	4.24	3.31e-05	0.0136	0.32	0.27	Monocyte percentage of white cells;Monocyte count;	chr22:49595167	chr22:49414524~49657542:-
OV	cis	rs853679	0.513	rs9468296	ENSG00000226314.6	ZNF192P1	-4.24	3.31e-05	0.0136	-0.37	-0.27	Depression;	chr6:28145952	chr6:28161781~28169594:+
OV	cis	rs1823913	0.525	rs7424440	ENSG00000227542.1	AC092614.2	4.24	3.31e-05	0.0136	0.31	0.27	Obesity-related traits;	chr2:191337919	chr2:191229165~191246172:-
OV	cis	rs1823913	0.526	rs35340557	ENSG00000227542.1	AC092614.2	4.24	3.31e-05	0.0136	0.31	0.27	Obesity-related traits;	chr2:191338688	chr2:191229165~191246172:-
OV	cis	rs1823913	0.503	rs35562914	ENSG00000227542.1	AC092614.2	4.24	3.31e-05	0.0136	0.31	0.27	Obesity-related traits;	chr2:191338969	chr2:191229165~191246172:-
OV	cis	rs3733585	0.673	rs4580649	ENSG00000250413.1	RP11-448G15.1	4.24	3.31e-05	0.0136	0.3	0.27	Cleft plate (environmental tobacco smoke interaction);	chr4:9946837	chr4:10006482~10009725:+
OV	cis	rs17301013	0.507	rs10489255	ENSG00000227373.4	RP11-160H22.5	4.24	3.32e-05	0.0136	0.36	0.27	Systemic lupus erythematosus;	chr1:174341985	chr1:174115300~174160004:-
OV	cis	rs875971	0.862	rs10276077	ENSG00000236529.1	RP13-254B10.1	-4.23	3.32e-05	0.0136	-0.28	-0.27	Aortic root size;	chr7:66263424	chr7:65840212~65840596:+
OV	cis	rs9876781	0.539	rs9809695	ENSG00000229759.1	MRPS18AP1	-4.23	3.32e-05	0.0136	-0.28	-0.27	Longevity;	chr3:48364654	chr3:48256350~48256938:-
OV	cis	rs514406	0.722	rs7552139	ENSG00000206627.1	RNU6-969P	4.23	3.32e-05	0.0137	0.28	0.27	Monocyte count;	chr1:52921707	chr1:52805108~52805212:-
OV	cis	rs7200543	1	rs4985154	ENSG00000270580.4	PKD1P6	4.23	3.32e-05	0.0137	0.28	0.27	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15037785	chr16:15104723~15131601:-
OV	cis	rs853679	0.556	rs13200214	ENSG00000220721.1	OR1F12	4.23	3.32e-05	0.0137	0.53	0.27	Depression;	chr6:28049472	chr6:28073316~28074233:+
OV	cis	rs7773456	0.74	rs6917179	ENSG00000228412.5	RP4-625H18.2	-4.23	3.33e-05	0.0137	-0.34	-0.27	Lupus nephritis in systemic lupus erythematosus;	chr6:19817570	chr6:19802164~19804752:-
OV	cis	rs7267979	0.966	rs2261698	ENSG00000274973.1	RP13-401N8.7	-4.23	3.33e-05	0.0137	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25279274	chr20:25845497~25845862:+
OV	cis	rs7429990	0.864	rs13085978	ENSG00000229759.1	MRPS18AP1	4.23	3.33e-05	0.0137	0.3	0.27	Educational attainment (years of education);	chr3:47608585	chr3:48256350~48256938:-
OV	cis	rs7429990	0.727	rs61675361	ENSG00000229759.1	MRPS18AP1	4.23	3.33e-05	0.0137	0.3	0.27	Educational attainment (years of education);	chr3:47610630	chr3:48256350~48256938:-
OV	cis	rs7567389	0.6	rs11691088	ENSG00000236682.1	AC068282.3	-4.23	3.33e-05	0.0137	-0.37	-0.27	Self-rated health;	chr2:127374277	chr2:127389130~127400580:+
OV	cis	rs4578769	0.55	rs12958492	ENSG00000242182.3	RN7SL745P	4.23	3.33e-05	0.0137	0.3	0.27	Eosinophil percentage of white cells;	chr18:22988974	chr18:23004564~23004862:+
OV	cis	rs10899021	0.92	rs11236171	ENSG00000279353.1	RP11-864N7.4	4.23	3.33e-05	0.0137	0.46	0.27	Response to metformin (IC50);	chr11:74606473	chr11:74698231~74699658:-
OV	cis	rs10899021	0.92	rs61901541	ENSG00000279353.1	RP11-864N7.4	4.23	3.33e-05	0.0137	0.46	0.27	Response to metformin (IC50);	chr11:74606940	chr11:74698231~74699658:-
OV	cis	rs73201462	0.908	rs2999081	ENSG00000277250.1	Metazoa_SRP	4.23	3.33e-05	0.0137	0.41	0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128237429	chr3:128673681~128674021:-
OV	cis	rs73186030	0.546	rs55857899	ENSG00000272758.4	RP11-299J3.8	4.23	3.34e-05	0.0137	0.32	0.27	Serum parathyroid hormone levels;	chr3:122390705	chr3:122416207~122443180:+
OV	cis	rs73186030	0.546	rs73188320	ENSG00000272758.4	RP11-299J3.8	4.23	3.34e-05	0.0137	0.32	0.27	Serum parathyroid hormone levels;	chr3:122391694	chr3:122416207~122443180:+
OV	cis	rs10899021	0.92	rs7122710	ENSG00000279353.1	RP11-864N7.4	4.23	3.34e-05	0.0137	0.47	0.27	Response to metformin (IC50);	chr11:74612130	chr11:74698231~74699658:-
OV	cis	rs10129255	0.509	rs756583	ENSG00000223648.3	IGHV3-64	4.23	3.34e-05	0.0137	0.27	0.27	Kawasaki disease;	chr14:106680002	chr14:106643132~106658258:-
OV	cis	rs6991838	0.778	rs11779602	ENSG00000272010.1	CTD-3025N20.3	4.23	3.34e-05	0.0137	0.33	0.27	Intelligence (multi-trait analysis);	chr8:65550247	chr8:65591850~65592472:-
OV	cis	rs10978777	0.765	rs7043962	ENSG00000276883.1	AL137852.1	-4.23	3.34e-05	0.0137	-0.3	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107310320	chr9:107292369~107292456:-
OV	cis	rs10978777	0.805	rs7856227	ENSG00000276883.1	AL137852.1	-4.23	3.34e-05	0.0137	-0.3	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107310714	chr9:107292369~107292456:-
OV	cis	rs1979679	0.918	rs10843187	ENSG00000278733.1	RP11-425D17.1	-4.23	3.35e-05	0.0137	-0.33	-0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28483586	chr12:28185625~28186190:-
OV	cis	rs7267979	0.903	rs2500400	ENSG00000274973.1	RP13-401N8.7	4.23	3.35e-05	0.0137	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25374069	chr20:25845497~25845862:+
OV	cis	rs4908768	0.555	rs4908777	ENSG00000228423.2	RP4-633I8.4	4.23	3.35e-05	0.0137	0.31	0.27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8744178	chr1:8805860~8807051:-
OV	cis	rs9329221	0.662	rs13254942	ENSG00000254936.4	AF131215.3	4.23	3.36e-05	0.0138	0.28	0.27	Neuroticism;	chr8:10400168	chr8:11123381~11126064:-
OV	cis	rs6101567	0.594	rs6129260	ENSG00000261431.1	RP4-616B8.4	4.23	3.36e-05	0.0138	0.27	0.27	Nose size;	chr20:39329548	chr20:38961925~38962111:-
OV	cis	rs896854	1	rs13255935	ENSG00000253528.2	RP11-347C18.4	4.23	3.36e-05	0.0138	0.26	0.27	Type 2 diabetes;	chr8:94953457	chr8:94974573~94974853:-
OV	cis	rs7520050	0.807	rs28647556	ENSG00000280836.1	AL355480.1	-4.23	3.36e-05	0.0138	-0.33	-0.27	Reticulocyte count;Red blood cell count;	chr1:45740727	chr1:45581219~45581321:-
OV	cis	rs7520050	0.807	rs4274104	ENSG00000280836.1	AL355480.1	-4.23	3.36e-05	0.0138	-0.33	-0.27	Reticulocyte count;Red blood cell count;	chr1:45752269	chr1:45581219~45581321:-
OV	cis	rs801193	0.569	rs11772819	ENSG00000236529.1	RP13-254B10.1	4.23	3.36e-05	0.0138	0.28	0.27	Aortic root size;	chr7:66752983	chr7:65840212~65840596:+
OV	cis	rs801193	0.569	rs11761542	ENSG00000236529.1	RP13-254B10.1	4.23	3.36e-05	0.0138	0.28	0.27	Aortic root size;	chr7:66753209	chr7:65840212~65840596:+
OV	cis	rs801193	0.569	rs7800620	ENSG00000236529.1	RP13-254B10.1	4.23	3.36e-05	0.0138	0.28	0.27	Aortic root size;	chr7:66758701	chr7:65840212~65840596:+
OV	cis	rs1707322	0.656	rs3014210	ENSG00000234329.1	RP11-767N6.2	-4.23	3.37e-05	0.0138	-0.28	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45651039~45651826:-
OV	cis	rs3733585	0.605	rs4235355	ENSG00000250413.1	RP11-448G15.1	4.23	3.37e-05	0.0138	0.33	0.27	Cleft plate (environmental tobacco smoke interaction);	chr4:10121454	chr4:10006482~10009725:+
OV	cis	rs3733585	0.579	rs4235356	ENSG00000250413.1	RP11-448G15.1	4.23	3.37e-05	0.0138	0.33	0.27	Cleft plate (environmental tobacco smoke interaction);	chr4:10121482	chr4:10006482~10009725:+
OV	cis	rs11159086	1	rs4899516	ENSG00000270000.1	RP3-449M8.9	4.23	3.37e-05	0.0138	0.42	0.27	Advanced glycation end-product levels;	chr14:74492825	chr14:74471930~74472360:-
OV	cis	rs11159086	1	rs12433848	ENSG00000270000.1	RP3-449M8.9	4.23	3.37e-05	0.0138	0.42	0.27	Advanced glycation end-product levels;	chr14:74497570	chr14:74471930~74472360:-
OV	cis	rs992157	0.804	rs6758540	ENSG00000261338.2	RP11-378A13.1	-4.23	3.37e-05	0.0138	-0.32	-0.27	Colorectal cancer;	chr2:218273902	chr2:218255319~218257366:+
OV	cis	rs7789940	1	rs76024966	ENSG00000230305.2	AC004980.9	4.23	3.37e-05	0.0138	0.38	0.27	Multiple sclerosis;	chr7:76365704	chr7:76524515~76532692:+
OV	cis	rs7121800	0.632	rs7944883	ENSG00000254532.1	RP11-624D11.2	4.23	3.37e-05	0.0138	0.36	0.27	Pit-and-Fissure caries;	chr11:30509936	chr11:30044058~30084343:-
OV	cis	rs8059260	0.736	rs7195509	ENSG00000274038.1	RP11-66H6.4	-4.23	3.38e-05	0.0138	-0.49	-0.27	Alcohol consumption over the past year;	chr16:10951572	chr16:11056556~11057034:+
OV	cis	rs7121800	0.962	rs12417588	ENSG00000254532.1	RP11-624D11.2	4.23	3.38e-05	0.0138	0.31	0.27	Pit-and-Fissure caries;	chr11:30500116	chr11:30044058~30084343:-
OV	cis	rs2015599	0.623	rs1006410	ENSG00000257176.2	RP11-996F15.2	4.23	3.38e-05	0.0138	0.33	0.27	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29280418~29317848:-
OV	cis	rs2239547	0.603	rs7644973	ENSG00000242142.1	SERBP1P3	4.23	3.38e-05	0.0138	0.34	0.27	Schizophrenia;	chr3:53048921	chr3:53064283~53065091:-
OV	cis	rs944801	0.566	rs1333036	ENSG00000234840.1	LINC01239	-4.23	3.38e-05	0.0138	-0.31	-0.27	Type 2 diabetes;	chr9:22043820	chr9:22646200~22824213:+
OV	cis	rs1030877	0.557	rs2278501	ENSG00000235319.1	AC012360.4	4.23	3.38e-05	0.0138	0.31	0.27	Obesity-related traits;	chr2:105363049	chr2:105324210~105330529:+
OV	cis	rs11168618	0.904	rs7135125	ENSG00000222635.1	RNU6-1203P	-4.23	3.39e-05	0.0139	-0.32	-0.27	Adiponectin levels;	chr12:48532485	chr12:48081319~48081428:+
OV	cis	rs11168618	0.904	rs10875829	ENSG00000222635.1	RNU6-1203P	-4.23	3.39e-05	0.0139	-0.32	-0.27	Adiponectin levels;	chr12:48533414	chr12:48081319~48081428:+
OV	cis	rs4964805	0.657	rs11111787	ENSG00000257681.1	RP11-341G23.4	4.23	3.39e-05	0.0139	0.3	0.27	Attention deficit hyperactivity disorder;	chr12:103795721	chr12:103746315~103768858:-
OV	cis	rs9992667	0.91	rs28681431	ENSG00000231160.8	KLF3-AS1	4.23	3.39e-05	0.0139	0.33	0.27	Eosinophil percentage of granulocytes;	chr4:38686307	chr4:38612701~38664883:-
OV	cis	rs792448	0.506	rs12567517	ENSG00000201544.1	SNORA16B	-4.23	3.39e-05	0.0139	-0.31	-0.27	White blood cell count (basophil);	chr1:212444081	chr1:212352816~212352950:+
OV	cis	rs10899021	1	rs10899025	ENSG00000279353.1	RP11-864N7.4	4.23	3.39e-05	0.0139	0.5	0.27	Response to metformin (IC50);	chr11:74655995	chr11:74698231~74699658:-
OV	cis	rs853679	0.546	rs200977	ENSG00000280107.1	AL022393.9	-4.23	3.39e-05	0.0139	-0.49	-0.27	Depression;	chr6:27886523	chr6:28170845~28172521:+
OV	cis	rs1823913	0.614	rs4853463	ENSG00000227542.1	AC092614.2	-4.23	3.4e-05	0.0139	-0.31	-0.27	Obesity-related traits;	chr2:191278699	chr2:191229165~191246172:-
OV	cis	rs14027	0.843	rs1828238	ENSG00000279347.1	RP11-85I17.2	4.23	3.4e-05	0.0139	0.28	0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119848105	chr8:119838736~119840385:-
OV	cis	rs14027	0.921	rs1960438	ENSG00000279347.1	RP11-85I17.2	4.23	3.4e-05	0.0139	0.28	0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119848193	chr8:119838736~119840385:-
OV	cis	rs7932354	0.502	rs57323109	ENSG00000271543.1	RP11-692M12.5	4.23	3.4e-05	0.0139	0.35	0.27	Bone mineral density (hip);Bone mineral density;	chr11:47171816	chr11:47796169~47796379:+
OV	cis	rs7932354	0.502	rs11600668	ENSG00000271543.1	RP11-692M12.5	4.23	3.4e-05	0.0139	0.35	0.27	Bone mineral density (hip);Bone mineral density;	chr11:47172015	chr11:47796169~47796379:+
OV	cis	rs708547	0.575	rs6847086	ENSG00000269949.1	RP11-738E22.3	-4.23	3.4e-05	0.0139	-0.35	-0.27	Response to bleomycin (chromatid breaks);	chr4:56925698	chr4:56960927~56961373:-
OV	cis	rs875971	0.862	rs11773628	ENSG00000236529.1	RP13-254B10.1	-4.23	3.41e-05	0.0139	-0.28	-0.27	Aortic root size;	chr7:66517644	chr7:65840212~65840596:+
OV	cis	rs7116641	0.524	rs2176598	ENSG00000246250.2	RP11-613D13.5	-4.23	3.41e-05	0.0139	-0.34	-0.27	Coronary artery disease;	chr11:43842728	chr11:43829709~43880726:-
OV	cis	rs7968440	0.966	rs1521516	ENSG00000272368.2	RP4-605O3.4	4.23	3.42e-05	0.014	0.32	0.27	Fibrinogen;	chr12:50661925	chr12:50112197~50165618:+
OV	cis	rs1404100	0.51	rs2140573	ENSG00000249274.1	PDLIM1P4	4.23	3.42e-05	0.014	0.32	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:99071376	chr3:98782188~98783193:+
OV	cis	rs6545883	0.868	rs6752938	ENSG00000270820.4	RP11-355B11.2	4.23	3.42e-05	0.014	0.31	0.27	Tuberculosis;	chr2:61614453	chr2:61471188~61484130:+
OV	cis	rs73201462	1	rs6794591	ENSG00000277250.1	Metazoa_SRP	4.23	3.43e-05	0.014	0.41	0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128312376	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs11706852	ENSG00000277250.1	Metazoa_SRP	4.23	3.43e-05	0.014	0.41	0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128314044	chr3:128673681~128674021:-
OV	cis	rs73201462	0.901	rs6771646	ENSG00000277250.1	Metazoa_SRP	4.23	3.43e-05	0.014	0.41	0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128315692	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs55989768	ENSG00000277250.1	Metazoa_SRP	4.23	3.43e-05	0.014	0.41	0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128324161	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs55675294	ENSG00000277250.1	Metazoa_SRP	4.23	3.43e-05	0.014	0.41	0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128324207	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs6772407	ENSG00000277250.1	Metazoa_SRP	4.23	3.43e-05	0.014	0.41	0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128325529	chr3:128673681~128674021:-
OV	cis	rs757081	0.648	rs10832752	ENSG00000213779.4	RP11-452G18.1	4.23	3.43e-05	0.014	0.3	0.27	Systolic blood pressure;	chr11:17263940	chr11:17193489~17194308:+
OV	cis	rs295140	0.507	rs13019821	ENSG00000232732.8	AC073043.1	4.23	3.44e-05	0.014	0.32	0.27	QT interval;	chr2:200242092	chr2:199867396~199911159:-
OV	cis	rs6673267	0.869	rs957957	ENSG00000223774.4	RP11-307B6.3	4.23	3.44e-05	0.014	0.29	0.27	Lobe attachment (rater-scored or self-reported);	chr1:201018670	chr1:201893842~201899978:+
OV	cis	rs4938303	0.633	rs17092638	ENSG00000254851.1	RP11-109L13.1	4.23	3.44e-05	0.014	0.43	0.27	Triglycerides;	chr11:116685520	chr11:117135528~117138582:+
OV	cis	rs1823913	0.599	rs55685315	ENSG00000227542.1	AC092614.2	4.23	3.44e-05	0.014	0.31	0.27	Obesity-related traits;	chr2:191306451	chr2:191229165~191246172:-
OV	cis	rs14027	0.921	rs6469852	ENSG00000279347.1	RP11-85I17.2	4.23	3.44e-05	0.014	0.27	0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119848495	chr8:119838736~119840385:-
OV	cis	rs7520050	0.778	rs3014218	ENSG00000281133.1	AL355480.3	4.23	3.44e-05	0.014	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:45560656	chr1:45580892~45580996:-
OV	cis	rs4774565	0.762	rs34565064	ENSG00000244879.4	GABPB1-AS1	-4.23	3.44e-05	0.014	-0.26	-0.27	Breast cancer;	chr15:50371706	chr15:50354959~50372202:+
OV	cis	rs7172809	0.573	rs7182221	ENSG00000230459.3	RP11-741G21.1	-4.23	3.44e-05	0.014	-0.34	-0.27	Glucose homeostasis traits;	chr15:77297193	chr15:77278465~77278774:+
OV	cis	rs7429990	0.864	rs13063042	ENSG00000229759.1	MRPS18AP1	-4.23	3.45e-05	0.0141	-0.29	-0.27	Educational attainment (years of education);	chr3:47683825	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs2133601	ENSG00000229759.1	MRPS18AP1	-4.23	3.45e-05	0.0141	-0.29	-0.27	Educational attainment (years of education);	chr3:47692525	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs6792497	ENSG00000229759.1	MRPS18AP1	-4.23	3.45e-05	0.0141	-0.29	-0.27	Educational attainment (years of education);	chr3:47693684	chr3:48256350~48256938:-
OV	cis	rs7429990	0.833	rs2030596	ENSG00000229759.1	MRPS18AP1	-4.23	3.45e-05	0.0141	-0.29	-0.27	Educational attainment (years of education);	chr3:47701712	chr3:48256350~48256938:-
OV	cis	rs7520050	0.833	rs1085242	ENSG00000281133.1	AL355480.3	4.23	3.45e-05	0.0141	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:46078552	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs1085243	ENSG00000281133.1	AL355480.3	4.23	3.45e-05	0.0141	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:46079096	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs1768803	ENSG00000281133.1	AL355480.3	4.23	3.45e-05	0.0141	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:46080536	chr1:45580892~45580996:-
OV	cis	rs7520050	0.931	rs1707333	ENSG00000281133.1	AL355480.3	4.23	3.45e-05	0.0141	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:46081363	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs4660910	ENSG00000281133.1	AL355480.3	4.23	3.45e-05	0.0141	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:46082730	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs785481	ENSG00000281133.1	AL355480.3	4.23	3.45e-05	0.0141	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:46088846	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs6675726	ENSG00000281133.1	AL355480.3	4.23	3.45e-05	0.0141	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:46094971	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs785520	ENSG00000281133.1	AL355480.3	4.23	3.45e-05	0.0141	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:46103164	chr1:45580892~45580996:-
OV	cis	rs2243480	0.706	rs34466769	ENSG00000226824.5	RP4-756H11.3	-4.23	3.45e-05	0.0141	-0.39	-0.27	Diabetic kidney disease;	chr7:65988305	chr7:66654538~66669855:+
OV	cis	rs12713280	1	rs12713280	ENSG00000272156.1	RP11-477N3.1	-4.23	3.45e-05	0.0141	-0.36	-0.27	Economic and political preferences;	chr2:54854239	chr2:54082554~54085066:+
OV	cis	rs853679	0.517	rs4713146	ENSG00000226314.6	ZNF192P1	-4.23	3.46e-05	0.0141	-0.37	-0.27	Depression;	chr6:28143758	chr6:28161781~28169594:+
OV	cis	rs642743	0.517	rs157077	ENSG00000228261.1	RP11-127L20.3	4.23	3.46e-05	0.0141	0.29	0.27	Left ventricular obstructive tract defect (maternal effect);	chr10:104278136	chr10:104323369~104327004:+
OV	cis	rs7726839	0.54	rs4957081	ENSG00000271781.1	CTD-2589H19.6	-4.23	3.46e-05	0.0141	-0.42	-0.27	Obesity-related traits;	chr5:646303	chr5:675826~676616:+
OV	cis	rs7726839	0.54	rs72705097	ENSG00000271781.1	CTD-2589H19.6	-4.23	3.46e-05	0.0141	-0.42	-0.27	Obesity-related traits;	chr5:654952	chr5:675826~676616:+
OV	cis	rs17428076	0.556	rs12692976	ENSG00000228389.1	AC068039.4	4.23	3.46e-05	0.0141	0.28	0.27	Myopia;	chr2:171827893	chr2:171773482~171775844:+
OV	cis	rs3733585	0.673	rs7375587	ENSG00000250413.1	RP11-448G15.1	-4.22	3.46e-05	0.0141	-0.3	-0.27	Cleft plate (environmental tobacco smoke interaction);	chr4:9953134	chr4:10006482~10009725:+
OV	cis	rs4845570	0.834	rs7007	ENSG00000203288.3	RP11-98D18.9	-4.22	3.46e-05	0.0141	-0.47	-0.27	Coronary artery disease;	chr1:151763100	chr1:151790804~151794402:+
OV	cis	rs56114371	0.777	rs200482	ENSG00000280107.1	AL022393.9	-4.22	3.47e-05	0.0141	-0.47	-0.27	Breast cancer;	chr6:27806126	chr6:28170845~28172521:+
OV	cis	rs1850744	0.826	rs7685513	ENSG00000250268.3	ALG1L14P	4.22	3.47e-05	0.0141	0.67	0.27	Economic and political preferences;	chr4:9726975	chr4:9166297~9170270:-
OV	cis	rs796364	0.525	rs10931895	ENSG00000232732.8	AC073043.1	-4.22	3.47e-05	0.0141	-0.36	-0.27	Schizophrenia;	chr2:200278519	chr2:199867396~199911159:-
OV	cis	rs6860806	0.507	rs272854	ENSG00000233006.5	AC034220.3	4.22	3.47e-05	0.0141	0.28	0.27	Breast cancer;	chr5:132352324	chr5:132311285~132369916:-
OV	cis	rs10829156	0.945	rs10829199	ENSG00000225527.1	RP11-383B4.4	-4.22	3.47e-05	0.0142	-0.36	-0.27	Sudden cardiac arrest;	chr10:18679012	chr10:18531849~18533336:-
OV	cis	rs2239557	1	rs4903201	ENSG00000259065.1	RP5-1021I20.1	4.22	3.48e-05	0.0142	0.32	0.27	Common traits (Other);	chr14:74192987	chr14:73787360~73803270:+
OV	cis	rs9291683	0.546	rs4575994	ENSG00000250413.1	RP11-448G15.1	-4.22	3.48e-05	0.0142	-0.31	-0.27	Bone mineral density;	chr4:9996355	chr4:10006482~10009725:+
OV	cis	rs853679	0.517	rs9357065	ENSG00000226314.6	ZNF192P1	-4.22	3.48e-05	0.0142	-0.37	-0.27	Depression;	chr6:28161802	chr6:28161781~28169594:+
OV	cis	rs853679	1	rs2799079	ENSG00000280107.1	AL022393.9	-4.22	3.48e-05	0.0142	-0.42	-0.27	Depression;	chr6:28267398	chr6:28170845~28172521:+
OV	cis	rs4728142	0.604	rs10239340	ENSG00000275106.1	RP11-309L24.10	-4.22	3.49e-05	0.0142	-0.35	-0.27	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129028456	chr7:128952527~128953316:-
OV	cis	rs4728142	0.604	rs6467222	ENSG00000275106.1	RP11-309L24.10	-4.22	3.49e-05	0.0142	-0.35	-0.27	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129034365	chr7:128952527~128953316:-
OV	cis	rs896854	1	rs896854	ENSG00000253528.2	RP11-347C18.4	4.22	3.49e-05	0.0142	0.26	0.27	Type 2 diabetes;	chr8:94948283	chr8:94974573~94974853:-
OV	cis	rs896854	0.967	rs1320164	ENSG00000253528.2	RP11-347C18.4	4.22	3.49e-05	0.0142	0.26	0.27	Type 2 diabetes;	chr8:94948539	chr8:94974573~94974853:-
OV	cis	rs896854	0.902	rs896852	ENSG00000253528.2	RP11-347C18.4	4.22	3.49e-05	0.0142	0.26	0.27	Type 2 diabetes;	chr8:94948658	chr8:94974573~94974853:-
OV	cis	rs896854	1	rs7003387	ENSG00000253528.2	RP11-347C18.4	4.22	3.49e-05	0.0142	0.26	0.27	Type 2 diabetes;	chr8:94949751	chr8:94974573~94974853:-
OV	cis	rs1511299	0.546	rs12495978	ENSG00000249417.1	RP11-438D8.2	-4.22	3.49e-05	0.0142	-0.41	-0.27	Glomerular filtration rate;	chr3:141988271	chr3:141267353~141367137:-
OV	cis	rs1511299	0.546	rs3811708	ENSG00000249417.1	RP11-438D8.2	-4.22	3.49e-05	0.0142	-0.41	-0.27	Glomerular filtration rate;	chr3:141989329	chr3:141267353~141367137:-
OV	cis	rs1511299	0.597	rs62283132	ENSG00000249417.1	RP11-438D8.2	-4.22	3.49e-05	0.0142	-0.41	-0.27	Glomerular filtration rate;	chr3:141990194	chr3:141267353~141367137:-
OV	cis	rs3808502	0.549	rs1382563	ENSG00000255556.2	RP11-351I21.6	4.22	3.49e-05	0.0142	0.33	0.27	Neuroticism;	chr8:11569281	chr8:12378679~12380265:-
OV	cis	rs6745190	0.953	rs4510177	ENSG00000236153.1	AC104076.3	4.22	3.49e-05	0.0142	0.33	0.27	White blood cell count;	chr2:180976518	chr2:180979427~180980090:-
OV	cis	rs7927771	0.524	rs7129797	ENSG00000280615.1	Y_RNA	4.22	3.49e-05	0.0142	0.29	0.27	Subjective well-being;	chr11:47645615	chr11:47614898~47614994:-
OV	cis	rs1576263	0.967	rs9378560	ENSG00000230939.1	RP11-314C16.1	4.22	3.5e-05	0.0142	0.29	0.27	Photic sneeze reflex;	chr6:8551317	chr6:8784178~8785445:+
OV	cis	rs7829975	0.514	rs2979151	ENSG00000173295.6	FAM86B3P	-4.22	3.5e-05	0.0142	-0.26	-0.27	Mood instability;	chr8:8400509	chr8:8228595~8244865:+
OV	cis	rs7017914	0.677	rs7010889	ENSG00000223220.1	Y_RNA	4.22	3.5e-05	0.0142	0.28	0.27	Bone mineral density;	chr8:70741136	chr8:70780914~70781008:-
OV	cis	rs7520050	0.966	rs785488	ENSG00000281133.1	AL355480.3	4.22	3.51e-05	0.0143	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:46110423	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs785489	ENSG00000281133.1	AL355480.3	4.22	3.51e-05	0.0143	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:46110718	chr1:45580892~45580996:-
OV	cis	rs1858037	0.867	rs67453645	ENSG00000234255.7	AC012370.3	4.22	3.51e-05	0.0143	0.3	0.27	Rheumatoid arthritis;	chr2:65358908	chr2:65439888~65456571:-
OV	cis	rs1858037	0.867	rs57913336	ENSG00000234255.7	AC012370.3	4.22	3.51e-05	0.0143	0.3	0.27	Rheumatoid arthritis;	chr2:65360485	chr2:65439888~65456571:-
OV	cis	rs17301013	0.507	rs12072050	ENSG00000227373.4	RP11-160H22.5	4.22	3.51e-05	0.0143	0.38	0.27	Systemic lupus erythematosus;	chr1:174269648	chr1:174115300~174160004:-
OV	cis	rs7746199	0.736	rs13212093	ENSG00000220721.1	OR1F12	4.22	3.51e-05	0.0143	0.53	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:28073316~28074233:+
OV	cis	rs4664293	0.51	rs12469374	ENSG00000226266.5	AC009961.3	4.22	3.52e-05	0.0143	0.33	0.27	Monocyte percentage of white cells;	chr2:159720393	chr2:159670708~159712435:-
OV	cis	rs12358699	0.546	rs17157322	ENSG00000165511.6	C10orf25	4.22	3.52e-05	0.0143	0.68	0.27	Lung function (FEV1/FVC);	chr10:44986714	chr10:44997698~45000888:-
OV	cis	rs12358699	0.546	rs78763507	ENSG00000165511.6	C10orf25	4.22	3.52e-05	0.0143	0.68	0.27	Lung function (FEV1/FVC);	chr10:44987421	chr10:44997698~45000888:-
OV	cis	rs992157	0.71	rs6719789	ENSG00000237281.1	CATIP-AS2	4.22	3.52e-05	0.0143	0.3	0.27	Colorectal cancer;	chr2:218193087	chr2:218326889~218357966:-
OV	cis	rs2015599	0.623	rs1072724	ENSG00000275476.1	RP11-996F15.4	4.22	3.52e-05	0.0143	0.35	0.27	Platelet count;Mean platelet volume;	chr12:29289205	chr12:29277397~29277882:-
OV	cis	rs2015599	0.623	rs7358667	ENSG00000275476.1	RP11-996F15.4	4.22	3.52e-05	0.0143	0.35	0.27	Platelet count;Mean platelet volume;	chr12:29290236	chr12:29277397~29277882:-
OV	cis	rs8059260	0.544	rs7205916	ENSG00000274038.1	RP11-66H6.4	-4.22	3.52e-05	0.0143	-0.47	-0.27	Alcohol consumption over the past year;	chr16:11095399	chr16:11056556~11057034:+
OV	cis	rs4578769	0.55	rs6417085	ENSG00000242182.3	RN7SL745P	4.22	3.52e-05	0.0143	0.31	0.27	Eosinophil percentage of white cells;	chr18:23041335	chr18:23004564~23004862:+
OV	cis	rs4578769	0.55	rs6507456	ENSG00000242182.3	RN7SL745P	4.22	3.52e-05	0.0143	0.31	0.27	Eosinophil percentage of white cells;	chr18:23042023	chr18:23004564~23004862:+
OV	cis	rs4578769	0.513	rs9956441	ENSG00000242182.3	RN7SL745P	4.22	3.52e-05	0.0143	0.31	0.27	Eosinophil percentage of white cells;	chr18:23042524	chr18:23004564~23004862:+
OV	cis	rs9287719	0.935	rs61424402	ENSG00000234818.1	AC092687.5	4.22	3.52e-05	0.0143	0.29	0.27	Prostate cancer;	chr2:10618245	chr2:10589166~10604830:+
OV	cis	rs7520050	0.898	rs785502	ENSG00000281133.1	AL355480.3	4.22	3.52e-05	0.0143	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:46115772	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs785491	ENSG00000281133.1	AL355480.3	4.22	3.52e-05	0.0143	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:46117746	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs785503	ENSG00000281133.1	AL355480.3	4.22	3.52e-05	0.0143	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:46130196	chr1:45580892~45580996:-
OV	cis	rs10483853	0.887	rs2269967	ENSG00000258695.2	RP3-414A15.2	4.22	3.53e-05	0.0143	0.36	0.27	Coronary artery calcification;	chr14:73271334	chr14:73522878~73530610:+
OV	cis	rs4908768	0.906	rs55858268	ENSG00000228423.2	RP4-633I8.4	4.22	3.53e-05	0.0143	0.33	0.27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8494636	chr1:8805860~8807051:-
OV	cis	rs4908768	0.906	rs12117910	ENSG00000228423.2	RP4-633I8.4	4.22	3.53e-05	0.0143	0.33	0.27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8496893	chr1:8805860~8807051:-
OV	cis	rs4908768	0.906	rs12403339	ENSG00000228423.2	RP4-633I8.4	4.22	3.53e-05	0.0143	0.33	0.27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8498232	chr1:8805860~8807051:-
OV	cis	rs4908768	0.906	rs11584261	ENSG00000228423.2	RP4-633I8.4	4.22	3.53e-05	0.0143	0.33	0.27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8500306	chr1:8805860~8807051:-
OV	cis	rs1075265	0.783	rs805439	ENSG00000233266.1	HMGB1P31	4.22	3.53e-05	0.0143	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53829437	chr2:54051334~54051760:+
OV	cis	rs9979383	0.538	rs2049811	ENSG00000228107.1	AP000692.9	4.22	3.53e-05	0.0143	0.28	0.27	Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr21:35435962	chr21:36360630~36362040:+
OV	cis	rs6860806	0.507	rs2631369	ENSG00000233006.5	AC034220.3	-4.22	3.53e-05	0.0143	-0.28	-0.27	Breast cancer;	chr5:132369574	chr5:132311285~132369916:-
OV	cis	rs274567	0.501	rs2631368	ENSG00000233006.5	AC034220.3	-4.22	3.53e-05	0.0143	-0.28	-0.27	Blood metabolite levels;	chr5:132369605	chr5:132311285~132369916:-
OV	cis	rs1979679	0.766	rs10843197	ENSG00000278733.1	RP11-425D17.1	-4.22	3.53e-05	0.0143	-0.33	-0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28518308	chr12:28185625~28186190:-
OV	cis	rs7726839	0.574	rs11134149	ENSG00000271781.1	CTD-2589H19.6	-4.22	3.53e-05	0.0143	-0.4	-0.27	Obesity-related traits;	chr5:637162	chr5:675826~676616:+
OV	cis	rs6128907	0.8	rs6129026	ENSG00000224635.1	RP4-564F22.5	4.22	3.54e-05	0.0143	0.44	0.27	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38787252	chr20:38406011~38416797:-
OV	cis	rs7829975	0.522	rs6601689	ENSG00000253893.2	FAM85B	-4.22	3.54e-05	0.0144	-0.3	-0.27	Mood instability;	chr8:8314761	chr8:8167819~8226614:-
OV	cis	rs2919917	1	rs1021156	ENSG00000254352.1	RP11-578O24.2	4.22	3.54e-05	0.0144	0.32	0.27	Lymphocyte counts;	chr8:78663569	chr8:78723796~78724136:-
OV	cis	rs853679	0.599	rs149990	ENSG00000226314.6	ZNF192P1	-4.22	3.54e-05	0.0144	-0.48	-0.27	Depression;	chr6:28030480	chr6:28161781~28169594:+
OV	cis	rs853679	0.599	rs149943	ENSG00000226314.6	ZNF192P1	-4.22	3.54e-05	0.0144	-0.48	-0.27	Depression;	chr6:28034610	chr6:28161781~28169594:+
OV	cis	rs1862618	0.573	rs185220	ENSG00000271828.1	CTD-2310F14.1	4.22	3.54e-05	0.0144	0.46	0.27	Initial pursuit acceleration;	chr5:56909530	chr5:56927874~56929573:+
OV	cis	rs7646881	0.544	rs13315529	ENSG00000272087.1	RP11-379F4.7	4.22	3.55e-05	0.0144	0.39	0.27	Tetralogy of Fallot;	chr3:158610485	chr3:158693120~158693768:-
OV	cis	rs7727544	0.684	rs274561	ENSG00000233006.5	AC034220.3	4.22	3.55e-05	0.0144	0.27	0.27	Blood metabolite levels;	chr5:132383536	chr5:132311285~132369916:-
OV	cis	rs17767294	0.708	rs78094982	ENSG00000220721.1	OR1F12	4.22	3.55e-05	0.0144	0.55	0.27	Parkinson's disease;	chr6:28000572	chr6:28073316~28074233:+
OV	cis	rs17767294	0.708	rs72848785	ENSG00000220721.1	OR1F12	4.22	3.55e-05	0.0144	0.55	0.27	Parkinson's disease;	chr6:28009825	chr6:28073316~28074233:+
OV	cis	rs593531	0.614	rs655719	ENSG00000280269.1	AP000577.2	-4.22	3.55e-05	0.0144	-0.32	-0.27	Neuroticism;	chr11:74331196	chr11:74204869~74205746:+
OV	cis	rs1979679	0.541	rs7956757	ENSG00000278733.1	RP11-425D17.1	-4.22	3.56e-05	0.0144	-0.33	-0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28570071	chr12:28185625~28186190:-
OV	cis	rs1979679	0.608	rs1581073	ENSG00000278733.1	RP11-425D17.1	-4.22	3.56e-05	0.0144	-0.33	-0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28571106	chr12:28185625~28186190:-
OV	cis	rs1979679	0.608	rs6487691	ENSG00000278733.1	RP11-425D17.1	-4.22	3.56e-05	0.0144	-0.33	-0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28571283	chr12:28185625~28186190:-
OV	cis	rs1979679	0.572	rs6487692	ENSG00000278733.1	RP11-425D17.1	-4.22	3.56e-05	0.0144	-0.33	-0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28573109	chr12:28185625~28186190:-
OV	cis	rs1979679	0.608	rs3803087	ENSG00000278733.1	RP11-425D17.1	-4.22	3.56e-05	0.0144	-0.33	-0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28573701	chr12:28185625~28186190:-
OV	cis	rs6088590	0.55	rs12624640	ENSG00000206582.1	Y_RNA	-4.22	3.56e-05	0.0144	-0.36	-0.27	Coronary artery disease;	chr20:34364319	chr20:34526510~34526606:-
OV	cis	rs801193	0.548	rs2659904	ENSG00000236529.1	RP13-254B10.1	4.22	3.56e-05	0.0144	0.29	0.27	Aortic root size;	chr7:66713615	chr7:65840212~65840596:+
OV	cis	rs1823913	0.637	rs1349938	ENSG00000227542.1	AC092614.2	-4.22	3.56e-05	0.0144	-0.3	-0.27	Obesity-related traits;	chr2:191299970	chr2:191229165~191246172:-
OV	cis	rs1823913	0.592	rs1349939	ENSG00000227542.1	AC092614.2	-4.22	3.56e-05	0.0144	-0.3	-0.27	Obesity-related traits;	chr2:191300079	chr2:191229165~191246172:-
OV	cis	rs1823913	0.614	rs6434459	ENSG00000227542.1	AC092614.2	-4.22	3.56e-05	0.0144	-0.3	-0.27	Obesity-related traits;	chr2:191300886	chr2:191229165~191246172:-
OV	cis	rs1823913	0.592	rs7588555	ENSG00000227542.1	AC092614.2	-4.22	3.56e-05	0.0144	-0.3	-0.27	Obesity-related traits;	chr2:191300912	chr2:191229165~191246172:-
OV	cis	rs1823913	0.637	rs4853581	ENSG00000227542.1	AC092614.2	-4.22	3.56e-05	0.0144	-0.3	-0.27	Obesity-related traits;	chr2:191301533	chr2:191229165~191246172:-
OV	cis	rs1823913	0.614	rs7565987	ENSG00000227542.1	AC092614.2	-4.22	3.56e-05	0.0144	-0.3	-0.27	Obesity-related traits;	chr2:191301815	chr2:191229165~191246172:-
OV	cis	rs1823913	0.614	rs1973067	ENSG00000227542.1	AC092614.2	-4.22	3.56e-05	0.0144	-0.3	-0.27	Obesity-related traits;	chr2:191302021	chr2:191229165~191246172:-
OV	cis	rs1823913	0.637	rs1973068	ENSG00000227542.1	AC092614.2	-4.22	3.56e-05	0.0144	-0.3	-0.27	Obesity-related traits;	chr2:191302227	chr2:191229165~191246172:-
OV	cis	rs1823913	0.637	rs7569231	ENSG00000227542.1	AC092614.2	-4.22	3.56e-05	0.0144	-0.3	-0.27	Obesity-related traits;	chr2:191302373	chr2:191229165~191246172:-
OV	cis	rs1823913	0.637	rs6434461	ENSG00000227542.1	AC092614.2	-4.22	3.56e-05	0.0144	-0.3	-0.27	Obesity-related traits;	chr2:191302661	chr2:191229165~191246172:-
OV	cis	rs1823913	0.614	rs6434462	ENSG00000227542.1	AC092614.2	-4.22	3.56e-05	0.0144	-0.3	-0.27	Obesity-related traits;	chr2:191302705	chr2:191229165~191246172:-
OV	cis	rs1823913	0.637	rs6750360	ENSG00000227542.1	AC092614.2	-4.22	3.56e-05	0.0144	-0.3	-0.27	Obesity-related traits;	chr2:191303089	chr2:191229165~191246172:-
OV	cis	rs1823913	0.637	rs11677694	ENSG00000227542.1	AC092614.2	-4.22	3.56e-05	0.0144	-0.3	-0.27	Obesity-related traits;	chr2:191303203	chr2:191229165~191246172:-
OV	cis	rs1823913	0.571	rs6737307	ENSG00000227542.1	AC092614.2	-4.22	3.56e-05	0.0144	-0.3	-0.27	Obesity-related traits;	chr2:191303247	chr2:191229165~191246172:-
OV	cis	rs1823913	0.637	rs4853582	ENSG00000227542.1	AC092614.2	-4.22	3.56e-05	0.0144	-0.3	-0.27	Obesity-related traits;	chr2:191303483	chr2:191229165~191246172:-
OV	cis	rs1823913	0.637	rs35200176	ENSG00000227542.1	AC092614.2	-4.22	3.56e-05	0.0144	-0.3	-0.27	Obesity-related traits;	chr2:191303534	chr2:191229165~191246172:-
OV	cis	rs1823913	0.637	rs17348013	ENSG00000227542.1	AC092614.2	-4.22	3.56e-05	0.0144	-0.3	-0.27	Obesity-related traits;	chr2:191303726	chr2:191229165~191246172:-
OV	cis	rs2239557	1	rs4903203	ENSG00000259065.1	RP5-1021I20.1	4.22	3.56e-05	0.0144	0.32	0.27	Common traits (Other);	chr14:74193805	chr14:73787360~73803270:+
OV	cis	rs733592	0.507	rs10875739	ENSG00000258273.1	RP11-370I10.4	-4.22	3.56e-05	0.0144	-0.33	-0.27	Plateletcrit;	chr12:48087136	chr12:48333755~48333901:-
OV	cis	rs7267979	1	rs10966	ENSG00000274973.1	RP13-401N8.7	-4.22	3.56e-05	0.0144	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25302308	chr20:25845497~25845862:+
OV	cis	rs2243480	1	rs313807	ENSG00000226824.5	RP4-756H11.3	-4.22	3.56e-05	0.0144	-0.44	-0.27	Diabetic kidney disease;	chr7:66034494	chr7:66654538~66669855:+
OV	cis	rs4938303	0.633	rs12800436	ENSG00000254851.1	RP11-109L13.1	4.22	3.57e-05	0.0144	0.47	0.27	Triglycerides;	chr11:116688086	chr11:117135528~117138582:+
OV	cis	rs2243480	1	rs313820	ENSG00000226824.5	RP4-756H11.3	-4.22	3.57e-05	0.0144	-0.42	-0.27	Diabetic kidney disease;	chr7:66109479	chr7:66654538~66669855:+
OV	cis	rs10899021	0.92	rs61901540	ENSG00000279353.1	RP11-864N7.4	4.22	3.57e-05	0.0145	0.46	0.27	Response to metformin (IC50);	chr11:74603820	chr11:74698231~74699658:-
OV	cis	rs10899021	0.92	rs10899014	ENSG00000279353.1	RP11-864N7.4	4.22	3.57e-05	0.0145	0.46	0.27	Response to metformin (IC50);	chr11:74614064	chr11:74698231~74699658:-
OV	cis	rs115769866	0.569	rs2859358	ENSG00000216901.1	AL022393.7	4.22	3.57e-05	0.0145	0.4	0.27	Bipolar disorder;	chr6:28505044	chr6:28176188~28176674:+
OV	cis	rs6673267	0.904	rs6701469	ENSG00000223774.4	RP11-307B6.3	4.22	3.57e-05	0.0145	0.29	0.27	Lobe attachment (rater-scored or self-reported);	chr1:201029691	chr1:201893842~201899978:+
OV	cis	rs758324	0.606	rs247276	ENSG00000234290.2	AC116366.6	-4.22	3.57e-05	0.0145	-0.23	-0.27	Alzheimer's disease in APOE e4- carriers;	chr5:132133311	chr5:132468890~132473043:-
OV	cis	rs3743772	0.5	rs28671196	ENSG00000279722.1	RP11-44F14.6	4.22	3.57e-05	0.0145	0.43	0.27	Depressive symptoms (SSRI exposure interaction);	chr16:53404024	chr16:53487607~53489943:-
OV	cis	rs6772849	0.93	rs4467479	ENSG00000277250.1	Metazoa_SRP	-4.22	3.58e-05	0.0145	-0.31	-0.27	Monocyte percentage of white cells;Monocyte count;	chr3:128650212	chr3:128673681~128674021:-
OV	cis	rs1823913	0.599	rs12988037	ENSG00000227542.1	AC092614.2	4.22	3.58e-05	0.0145	0.3	0.27	Obesity-related traits;	chr2:191306419	chr2:191229165~191246172:-
OV	cis	rs1330225	0.962	rs11580755	ENSG00000232952.1	RP11-90H3.1	-4.22	3.58e-05	0.0145	-0.34	-0.27	Blood pressure measurement (low sodium intervention);	chr1:106293628	chr1:105891739~105893517:+
OV	cis	rs1707322	0.662	rs11211160	ENSG00000234329.1	RP11-767N6.2	4.22	3.58e-05	0.0145	0.27	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45680557	chr1:45651039~45651826:-
OV	cis	rs4713118	0.513	rs9368547	ENSG00000280107.1	AL022393.9	-4.22	3.58e-05	0.0145	-0.31	-0.27	Parkinson's disease;	chr6:28060289	chr6:28170845~28172521:+
OV	cis	rs4713118	0.513	rs183244	ENSG00000280107.1	AL022393.9	-4.22	3.58e-05	0.0145	-0.31	-0.27	Parkinson's disease;	chr6:28064060	chr6:28170845~28172521:+
OV	cis	rs10759883	0.563	rs690063	ENSG00000175611.10	LINC00476	4.22	3.58e-05	0.0145	0.33	0.27	Nicotine dependence;	chr9:95931019	chr9:95759231~95875977:-
OV	cis	rs11096990	0.656	rs3796513	ENSG00000249207.1	RP11-360F5.1	4.22	3.58e-05	0.0145	0.28	0.27	Cognitive function;	chr4:39289462	chr4:39112677~39126818:-
OV	cis	rs11096990	0.656	rs2123027	ENSG00000249207.1	RP11-360F5.1	4.22	3.58e-05	0.0145	0.28	0.27	Cognitive function;	chr4:39289493	chr4:39112677~39126818:-
OV	cis	rs11096990	0.634	rs10029074	ENSG00000249207.1	RP11-360F5.1	4.22	3.58e-05	0.0145	0.28	0.27	Cognitive function;	chr4:39290882	chr4:39112677~39126818:-
OV	cis	rs11096990	0.634	rs1564710	ENSG00000249207.1	RP11-360F5.1	4.22	3.58e-05	0.0145	0.28	0.27	Cognitive function;	chr4:39291178	chr4:39112677~39126818:-
OV	cis	rs11096990	0.634	rs2839765	ENSG00000249207.1	RP11-360F5.1	4.22	3.58e-05	0.0145	0.28	0.27	Cognitive function;	chr4:39293933	chr4:39112677~39126818:-
OV	cis	rs11096990	0.634	rs6531706	ENSG00000249207.1	RP11-360F5.1	4.22	3.58e-05	0.0145	0.28	0.27	Cognitive function;	chr4:39294547	chr4:39112677~39126818:-
OV	cis	rs11096990	0.634	rs6815855	ENSG00000249207.1	RP11-360F5.1	4.22	3.58e-05	0.0145	0.28	0.27	Cognitive function;	chr4:39294926	chr4:39112677~39126818:-
OV	cis	rs62244186	0.659	rs62251383	ENSG00000214820.3	MPRIPP1	4.22	3.59e-05	0.0145	0.25	0.27	Depressive symptoms;	chr3:44510929	chr3:44579938~44581026:-
OV	cis	rs944801	0.566	rs10115049	ENSG00000234840.1	LINC01239	-4.22	3.59e-05	0.0145	-0.31	-0.27	Type 2 diabetes;	chr9:22032120	chr9:22646200~22824213:+
OV	cis	rs875971	0.66	rs12698534	ENSG00000224316.1	RP11-479O9.2	4.22	3.59e-05	0.0145	0.29	0.27	Aortic root size;	chr7:66521858	chr7:65773620~65802067:+
OV	cis	rs858239	0.509	rs6962213	ENSG00000230042.1	AK3P3	-4.22	3.59e-05	0.0145	-0.28	-0.27	Cerebrospinal fluid biomarker levels;	chr7:23148490	chr7:23129178~23129841:+
OV	cis	rs992157	0.71	rs12612347	ENSG00000237281.1	CATIP-AS2	4.22	3.59e-05	0.0145	0.32	0.27	Colorectal cancer;	chr2:218192615	chr2:218326889~218357966:-
OV	cis	rs12358699	0.546	rs76143312	ENSG00000165511.6	C10orf25	4.22	3.59e-05	0.0145	0.67	0.27	Lung function (FEV1/FVC);	chr10:44985673	chr10:44997698~45000888:-
OV	cis	rs1538970	1	rs4520450	ENSG00000280836.1	AL355480.1	-4.22	3.6e-05	0.0145	-0.37	-0.27	Platelet count;	chr1:45369101	chr1:45581219~45581321:-
OV	cis	rs12468226	1	rs16839077	ENSG00000272966.1	RP11-686O6.1	4.22	3.6e-05	0.0145	0.45	0.27	Urate levels;	chr2:202343970	chr2:202336739~202337200:+
OV	cis	rs1499614	0.522	rs13247442	ENSG00000222364.1	RNU6-96P	-4.22	3.6e-05	0.0146	-0.51	-0.27	Gout;	chr7:66723871	chr7:66395191~66395286:+
OV	cis	rs7927592	0.701	rs12226585	ENSG00000212093.1	AP000807.1	-4.22	3.6e-05	0.0146	-0.31	-0.27	Total body bone mineral density;	chr11:68490393	chr11:68506083~68506166:-
OV	cis	rs1723838	0.702	rs4944865	ENSG00000255928.1	RP11-456I15.2	-4.22	3.6e-05	0.0146	-0.57	-0.27	Obesity-related traits;	chr11:73745459	chr11:73722349~73722694:+
OV	cis	rs1836229	0.594	rs1434256	ENSG00000225706.1	PTPRD-AS1	-4.22	3.61e-05	0.0146	-0.27	-0.27	Restless legs syndrome;	chr9:8830796	chr9:8858130~8862255:+
OV	cis	rs6545883	0.868	rs7594191	ENSG00000270820.4	RP11-355B11.2	-4.21	3.61e-05	0.0146	-0.31	-0.27	Tuberculosis;	chr2:61612883	chr2:61471188~61484130:+
OV	cis	rs62244186	0.566	rs2135531	ENSG00000214820.3	MPRIPP1	4.21	3.61e-05	0.0146	0.25	0.27	Depressive symptoms;	chr3:44839666	chr3:44579938~44581026:-
OV	cis	rs7968440	0.722	rs11609941	ENSG00000272368.2	RP4-605O3.4	4.21	3.61e-05	0.0146	0.33	0.27	Fibrinogen;	chr12:50773835	chr12:50112197~50165618:+
OV	cis	rs7968440	0.75	rs67356137	ENSG00000272368.2	RP4-605O3.4	4.21	3.61e-05	0.0146	0.33	0.27	Fibrinogen;	chr12:50778044	chr12:50112197~50165618:+
OV	cis	rs80168506	0.748	rs11694899	ENSG00000272519.1	RP11-105N14.2	4.21	3.61e-05	0.0146	0.41	0.27	Selective IgA deficiency;	chr2:213203018	chr2:213266995~213276152:-
OV	cis	rs801193	1	rs10234018	ENSG00000237310.1	GS1-124K5.4	-4.21	3.61e-05	0.0146	-0.27	-0.27	Aortic root size;	chr7:66681297	chr7:66493706~66495474:+
OV	cis	rs11037575	0.739	rs7482725	ENSG00000246250.2	RP11-613D13.5	-4.21	3.61e-05	0.0146	-0.29	-0.27	Neuroblastoma;	chr11:43702082	chr11:43829709~43880726:-
OV	cis	rs853679	0.607	rs35001169	ENSG00000220721.1	OR1F12	4.21	3.62e-05	0.0146	0.57	0.27	Depression;	chr6:28219854	chr6:28073316~28074233:+
OV	cis	rs853679	0.546	rs35656932	ENSG00000220721.1	OR1F12	4.21	3.62e-05	0.0146	0.57	0.27	Depression;	chr6:28223510	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs34243448	ENSG00000220721.1	OR1F12	4.21	3.62e-05	0.0146	0.57	0.27	Depression;	chr6:28225324	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs13204012	ENSG00000220721.1	OR1F12	4.21	3.62e-05	0.0146	0.57	0.27	Depression;	chr6:28233753	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs13205211	ENSG00000220721.1	OR1F12	4.21	3.62e-05	0.0146	0.57	0.27	Depression;	chr6:28235278	chr6:28073316~28074233:+
OV	cis	rs853679	0.585	rs201001	ENSG00000220721.1	OR1F12	4.21	3.62e-05	0.0146	0.33	0.27	Depression;	chr6:27841121	chr6:28073316~28074233:+
OV	cis	rs853679	0.585	rs201000	ENSG00000220721.1	OR1F12	4.21	3.62e-05	0.0146	0.33	0.27	Depression;	chr6:27841381	chr6:28073316~28074233:+
OV	cis	rs4664293	0.51	rs72961735	ENSG00000226266.5	AC009961.3	4.21	3.62e-05	0.0146	0.32	0.27	Monocyte percentage of white cells;	chr2:159708009	chr2:159670708~159712435:-
OV	cis	rs9287719	0.649	rs7589694	ENSG00000243819.4	RN7SL832P	4.21	3.62e-05	0.0146	0.27	0.27	Prostate cancer;	chr2:10560748	chr2:10690344~10692099:+
OV	cis	rs7267979	1	rs4813562	ENSG00000274973.1	RP13-401N8.7	4.21	3.62e-05	0.0146	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25371952	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs6050567	ENSG00000274973.1	RP13-401N8.7	4.21	3.62e-05	0.0146	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25373925	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6037099	ENSG00000274973.1	RP13-401N8.7	4.21	3.62e-05	0.0146	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25376240	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs4815414	ENSG00000274973.1	RP13-401N8.7	4.21	3.62e-05	0.0146	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25381065	chr20:25845497~25845862:+
OV	cis	rs1765142	0.55	rs654893	ENSG00000254532.1	RP11-624D11.2	-4.21	3.63e-05	0.0146	-0.32	-0.27	Schizophrenia;	chr11:30387407	chr11:30044058~30084343:-
OV	cis	rs56114371	0.777	rs200483	ENSG00000280107.1	AL022393.9	-4.21	3.63e-05	0.0146	-0.48	-0.27	Breast cancer;	chr6:27807046	chr6:28170845~28172521:+
OV	cis	rs7932354	0.528	rs747650	ENSG00000271543.1	RP11-692M12.5	4.21	3.63e-05	0.0147	0.35	0.27	Bone mineral density (hip);Bone mineral density;	chr11:47154454	chr11:47796169~47796379:+
OV	cis	rs7520050	0.966	rs785485	ENSG00000281133.1	AL355480.3	4.21	3.63e-05	0.0147	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:46108752	chr1:45580892~45580996:-
OV	cis	rs2070488	1	rs13089394	ENSG00000229589.1	ACVR2B-AS1	4.21	3.63e-05	0.0147	0.3	0.27	Electrocardiographic conduction measures;	chr3:38404818	chr3:38451027~38454820:-
OV	cis	rs11118620	0.81	rs4587570	ENSG00000238078.1	LINC01352	4.21	3.64e-05	0.0147	0.35	0.27	Heart failure;	chr1:220860693	chr1:220829255~220832429:+
OV	cis	rs11118620	0.853	rs12037861	ENSG00000238078.1	LINC01352	4.21	3.64e-05	0.0147	0.35	0.27	Heart failure;	chr1:220864835	chr1:220829255~220832429:+
OV	cis	rs801193	0.569	rs13242290	ENSG00000237310.1	GS1-124K5.4	-4.21	3.64e-05	0.0147	-0.28	-0.27	Aortic root size;	chr7:66656898	chr7:66493706~66495474:+
OV	cis	rs17301013	0.502	rs6703836	ENSG00000227373.4	RP11-160H22.5	4.21	3.64e-05	0.0147	0.37	0.27	Systemic lupus erythematosus;	chr1:174099675	chr1:174115300~174160004:-
OV	cis	rs7617773	0.78	rs13067450	ENSG00000228638.1	FCF1P2	-4.21	3.64e-05	0.0147	-0.34	-0.27	Coronary artery disease;	chr3:48295716	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs4479622	ENSG00000228638.1	FCF1P2	-4.21	3.64e-05	0.0147	-0.34	-0.27	Coronary artery disease;	chr3:48296683	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs34946886	ENSG00000228638.1	FCF1P2	-4.21	3.64e-05	0.0147	-0.34	-0.27	Coronary artery disease;	chr3:48296997	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs34589064	ENSG00000228638.1	FCF1P2	-4.21	3.64e-05	0.0147	-0.34	-0.27	Coronary artery disease;	chr3:48298059	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs2541	ENSG00000228638.1	FCF1P2	-4.21	3.64e-05	0.0147	-0.34	-0.27	Coronary artery disease;	chr3:48298128	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs13085251	ENSG00000228638.1	FCF1P2	-4.21	3.64e-05	0.0147	-0.34	-0.27	Coronary artery disease;	chr3:48298555	chr3:48290793~48291375:-
OV	cis	rs2239557	1	rs4903202	ENSG00000259065.1	RP5-1021I20.1	4.21	3.64e-05	0.0147	0.32	0.27	Common traits (Other);	chr14:74193599	chr14:73787360~73803270:+
OV	cis	rs4578769	0.55	rs11082258	ENSG00000242182.3	RN7SL745P	4.21	3.64e-05	0.0147	0.31	0.27	Eosinophil percentage of white cells;	chr18:23037401	chr18:23004564~23004862:+
OV	cis	rs4578769	0.55	rs4280358	ENSG00000242182.3	RN7SL745P	4.21	3.64e-05	0.0147	0.31	0.27	Eosinophil percentage of white cells;	chr18:23037844	chr18:23004564~23004862:+
OV	cis	rs897984	0.645	rs9938550	ENSG00000260911.2	RP11-196G11.2	-4.21	3.65e-05	0.0147	-0.24	-0.27	Dementia with Lewy bodies;	chr16:30987821	chr16:31043150~31049868:+
OV	cis	rs957448	0.503	rs752460	ENSG00000253704.1	RP11-267M23.4	4.21	3.65e-05	0.0147	0.36	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94477994	chr8:94553722~94569745:+
OV	cis	rs12681366	0.801	rs4735293	ENSG00000253704.1	RP11-267M23.4	4.21	3.65e-05	0.0147	0.36	0.27	Nonsyndromic cleft lip with cleft palate;	chr8:94478175	chr8:94553722~94569745:+
OV	cis	rs9467773	0.804	rs2073526	ENSG00000243307.2	POM121L6P	-4.21	3.65e-05	0.0147	-0.28	-0.27	Intelligence (multi-trait analysis);	chr6:26374430	chr6:26896952~26898777:+
OV	cis	rs853679	0.882	rs3757188	ENSG00000226314.6	ZNF192P1	-4.21	3.65e-05	0.0147	-0.48	-0.27	Depression;	chr6:28139579	chr6:28161781~28169594:+
OV	cis	rs1765142	0.55	rs640494	ENSG00000254532.1	RP11-624D11.2	-4.21	3.65e-05	0.0147	-0.33	-0.27	Schizophrenia;	chr11:30386514	chr11:30044058~30084343:-
OV	cis	rs1707322	0.752	rs7541962	ENSG00000234329.1	RP11-767N6.2	4.21	3.65e-05	0.0147	0.29	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769445	chr1:45651039~45651826:-
OV	cis	rs3764021	1	rs3764021	ENSG00000278635.1	CTD-2318O12.1	-4.21	3.65e-05	0.0147	-0.22	-0.27	Type 1 diabetes;	chr12:9681032	chr12:9415641~9416718:+
OV	cis	rs1538970	0.962	rs2298018	ENSG00000280836.1	AL355480.1	-4.21	3.66e-05	0.0147	-0.37	-0.27	Platelet count;	chr1:45347769	chr1:45581219~45581321:-
OV	cis	rs9393777	0.528	rs35982103	ENSG00000243307.2	POM121L6P	-4.21	3.66e-05	0.0147	-0.33	-0.27	Intelligence (multi-trait analysis);	chr6:27275355	chr6:26896952~26898777:+
OV	cis	rs12701220	0.895	rs12534778	ENSG00000229043.2	AC091729.9	4.21	3.66e-05	0.0147	0.37	0.27	Bronchopulmonary dysplasia;	chr7:1026225	chr7:1160374~1165267:+
OV	cis	rs11903757	1	rs12463776	ENSG00000281467.1	Clostridiales-1	-4.21	3.66e-05	0.0148	-0.45	-0.27	Colorectal cancer;	chr2:191723608	chr2:191699476~191699631:-
OV	cis	rs2348418	0.579	rs2126896	ENSG00000247934.4	RP11-967K21.1	-4.21	3.66e-05	0.0148	-0.26	-0.27	Lung function (FEV1);Lung function (FVC);	chr12:28239701	chr12:28163298~28190738:-
OV	cis	rs2617170	0.922	rs2617149	ENSG00000256667.5	KLRAP1	-4.21	3.67e-05	0.0148	-0.28	-0.27	Behcet's disease;	chr12:10375734	chr12:10588063~10599669:-
OV	cis	rs10246939	0.543	rs10952509	ENSG00000228775.6	WEE2-AS1	4.21	3.67e-05	0.0148	0.3	0.27	Bitter taste perception;	chr7:141890884	chr7:141704338~141738346:-
OV	cis	rs10246939	0.543	rs12538701	ENSG00000228775.6	WEE2-AS1	4.21	3.67e-05	0.0148	0.3	0.27	Bitter taste perception;	chr7:141893634	chr7:141704338~141738346:-
OV	cis	rs875971	0.895	rs6460278	ENSG00000236529.1	RP13-254B10.1	-4.21	3.67e-05	0.0148	-0.28	-0.27	Aortic root size;	chr7:66197749	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs6460279	ENSG00000236529.1	RP13-254B10.1	-4.21	3.67e-05	0.0148	-0.28	-0.27	Aortic root size;	chr7:66197774	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs28491091	ENSG00000236529.1	RP13-254B10.1	-4.21	3.67e-05	0.0148	-0.28	-0.27	Aortic root size;	chr7:66204077	chr7:65840212~65840596:+
OV	cis	rs7746199	0.736	rs13209332	ENSG00000220721.1	OR1F12	4.21	3.67e-05	0.0148	0.51	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:28073316~28074233:+
OV	cis	rs7746199	0.736	rs34965299	ENSG00000220721.1	OR1F12	4.21	3.67e-05	0.0148	0.51	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr6:28073316~28074233:+
OV	cis	rs73201462	1	rs55925538	ENSG00000277250.1	Metazoa_SRP	4.21	3.67e-05	0.0148	0.41	0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128324034	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs73197388	ENSG00000277250.1	Metazoa_SRP	4.21	3.67e-05	0.0148	0.41	0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128325077	chr3:128673681~128674021:-
OV	cis	rs73201462	1	rs11710627	ENSG00000277250.1	Metazoa_SRP	4.21	3.67e-05	0.0148	0.41	0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128328166	chr3:128673681~128674021:-
OV	cis	rs11009175	0.725	rs11009195	ENSG00000273038.2	RP11-479G22.8	-4.21	3.67e-05	0.0148	-0.37	-0.27	Depression (quantitative trait);	chr10:33045345	chr10:32887255~32889311:-
OV	cis	rs62244186	0.659	rs9835270	ENSG00000214820.3	MPRIPP1	4.21	3.67e-05	0.0148	0.25	0.27	Depressive symptoms;	chr3:44512230	chr3:44579938~44581026:-
OV	cis	rs9660180	0.967	rs12044597	ENSG00000215914.4	MMP23A	-4.21	3.68e-05	0.0148	-0.31	-0.27	Body mass index;	chr1:1777362	chr1:1699942~1701782:+
OV	cis	rs875971	0.571	rs160641	ENSG00000237310.1	GS1-124K5.4	-4.21	3.68e-05	0.0148	-0.31	-0.27	Aortic root size;	chr7:66112359	chr7:66493706~66495474:+
OV	cis	rs896854	0.967	rs896853	ENSG00000253528.2	RP11-347C18.4	4.21	3.68e-05	0.0148	0.26	0.27	Type 2 diabetes;	chr8:94948627	chr8:94974573~94974853:-
OV	cis	rs896854	0.967	rs2879813	ENSG00000253528.2	RP11-347C18.4	4.21	3.68e-05	0.0148	0.26	0.27	Type 2 diabetes;	chr8:94948719	chr8:94974573~94974853:-
OV	cis	rs7267979	1	rs4815412	ENSG00000274973.1	RP13-401N8.7	-4.21	3.68e-05	0.0148	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25369689	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs6107031	ENSG00000274973.1	RP13-401N8.7	4.21	3.68e-05	0.0148	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25370041	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6115159	ENSG00000274973.1	RP13-401N8.7	4.21	3.68e-05	0.0148	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25370308	chr20:25845497~25845862:+
OV	cis	rs853679	0.517	rs1904840	ENSG00000226314.6	ZNF192P1	-4.21	3.68e-05	0.0148	-0.37	-0.27	Depression;	chr6:28140454	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9368555	ENSG00000226314.6	ZNF192P1	-4.21	3.68e-05	0.0148	-0.37	-0.27	Depression;	chr6:28141189	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9393893	ENSG00000226314.6	ZNF192P1	-4.21	3.68e-05	0.0148	-0.37	-0.27	Depression;	chr6:28141484	chr6:28161781~28169594:+
OV	cis	rs875971	0.502	rs1796227	ENSG00000236529.1	RP13-254B10.1	-4.21	3.69e-05	0.0148	-0.32	-0.27	Aortic root size;	chr7:66622032	chr7:65840212~65840596:+
OV	cis	rs6951245	0.744	rs10265736	ENSG00000229043.2	AC091729.9	-4.21	3.69e-05	0.0148	-0.43	-0.27	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1132829	chr7:1160374~1165267:+
OV	cis	rs4908768	0.906	rs78110809	ENSG00000228423.2	RP4-633I8.4	4.21	3.69e-05	0.0148	0.33	0.27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8512949	chr1:8805860~8807051:-
OV	cis	rs4908768	0.906	rs6678982	ENSG00000228423.2	RP4-633I8.4	4.21	3.69e-05	0.0148	0.33	0.27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8517126	chr1:8805860~8807051:-
OV	cis	rs881375	0.678	rs7021049	ENSG00000226752.6	PSMD5-AS1	-4.21	3.69e-05	0.0148	-0.28	-0.27	Rheumatoid arthritis;	chr9:120921704	chr9:120824828~120854385:+
OV	cis	rs1723838	0.826	rs1880642	ENSG00000255928.1	RP11-456I15.2	-4.21	3.69e-05	0.0148	-0.58	-0.27	Obesity-related traits;	chr11:73701723	chr11:73722349~73722694:+
OV	cis	rs853679	0.607	rs35030260	ENSG00000220721.1	OR1F12	4.21	3.69e-05	0.0148	0.51	0.27	Depression;	chr6:28337731	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs13217619	ENSG00000220721.1	OR1F12	4.21	3.69e-05	0.0148	0.51	0.27	Depression;	chr6:28338894	chr6:28073316~28074233:+
OV	cis	rs255758	0.813	rs194281	ENSG00000272123.1	CTD-2366F13.2	-4.21	3.69e-05	0.0148	-0.37	-0.27	Rheumatoid arthritis;	chr5:54024373	chr5:53089016~53089468:-
OV	cis	rs875971	0.545	rs316305	ENSG00000273024.4	INTS4P2	4.21	3.69e-05	0.0149	0.32	0.27	Aortic root size;	chr7:66152984	chr7:65647864~65715661:+
OV	cis	rs875971	0.545	rs316306	ENSG00000273024.4	INTS4P2	4.21	3.69e-05	0.0149	0.32	0.27	Aortic root size;	chr7:66153687	chr7:65647864~65715661:+
OV	cis	rs8062405	0.558	rs231976	ENSG00000259982.1	CDC37P1	4.21	3.7e-05	0.0149	0.31	0.27	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28534266	chr16:28700294~28701540:-
OV	cis	rs10978777	0.706	rs10739238	ENSG00000276883.1	AL137852.1	-4.21	3.7e-05	0.0149	-0.29	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107295525	chr9:107292369~107292456:-
OV	cis	rs944801	0.545	rs4977753	ENSG00000234840.1	LINC01239	-4.21	3.7e-05	0.0149	-0.3	-0.27	Type 2 diabetes;	chr9:22030028	chr9:22646200~22824213:+
OV	cis	rs6991838	0.612	rs7842162	ENSG00000200714.1	Y_RNA	4.21	3.7e-05	0.0149	0.35	0.27	Intelligence (multi-trait analysis);	chr8:65644057	chr8:65592731~65592820:+
OV	cis	rs2239547	0.603	rs59989280	ENSG00000242142.1	SERBP1P3	4.21	3.7e-05	0.0149	0.34	0.27	Schizophrenia;	chr3:53064859	chr3:53064283~53065091:-
OV	cis	rs2239547	0.603	rs6789219	ENSG00000242142.1	SERBP1P3	4.21	3.7e-05	0.0149	0.34	0.27	Schizophrenia;	chr3:53064922	chr3:53064283~53065091:-
OV	cis	rs10504130	0.569	rs12678646	ENSG00000272024.1	RP11-546K22.3	-4.21	3.7e-05	0.0149	-0.38	-0.27	Venous thromboembolism (SNP x SNP interaction);	chr8:51755611	chr8:51950284~51950690:+
OV	cis	rs2919917	0.628	rs9643739	ENSG00000254352.1	RP11-578O24.2	4.21	3.71e-05	0.0149	0.35	0.27	Lymphocyte counts;	chr8:78679535	chr8:78723796~78724136:-
OV	cis	rs2919917	0.628	rs2170732	ENSG00000254352.1	RP11-578O24.2	4.21	3.71e-05	0.0149	0.35	0.27	Lymphocyte counts;	chr8:78684261	chr8:78723796~78724136:-
OV	cis	rs6991838	0.673	rs7462352	ENSG00000200714.1	Y_RNA	4.21	3.71e-05	0.0149	0.34	0.27	Intelligence (multi-trait analysis);	chr8:65584378	chr8:65592731~65592820:+
OV	cis	rs875971	0.638	rs6960778	ENSG00000224316.1	RP11-479O9.2	-4.21	3.71e-05	0.0149	-0.29	-0.27	Aortic root size;	chr7:66606610	chr7:65773620~65802067:+
OV	cis	rs2919917	0.628	rs1384803	ENSG00000254352.1	RP11-578O24.2	-4.21	3.71e-05	0.0149	-0.35	-0.27	Lymphocyte counts;	chr8:78669393	chr8:78723796~78724136:-
OV	cis	rs7646881	0.544	rs13315529	ENSG00000272440.1	RP11-379F4.6	4.21	3.71e-05	0.0149	0.41	0.27	Tetralogy of Fallot;	chr3:158610485	chr3:158695367~158695581:+
OV	cis	rs11096990	0.634	rs6829064	ENSG00000249207.1	RP11-360F5.1	4.21	3.71e-05	0.0149	0.28	0.27	Cognitive function;	chr4:39290192	chr4:39112677~39126818:-
OV	cis	rs4763879	0.502	rs11052552	ENSG00000278635.1	CTD-2318O12.1	-4.21	3.71e-05	0.0149	-0.22	-0.27	Type 1 diabetes;	chr12:9703362	chr12:9415641~9416718:+
OV	cis	rs11096990	0.928	rs2008681	ENSG00000249207.1	RP11-360F5.1	4.21	3.71e-05	0.0149	0.3	0.27	Cognitive function;	chr4:39266396	chr4:39112677~39126818:-
OV	cis	rs847845	0.535	rs3734261	ENSG00000220643.1	RP3-391O22.1	4.21	3.72e-05	0.0149	0.59	0.27	Non-small cell lung cancer;	chr6:34872621	chr6:34686602~34687106:+
OV	cis	rs4763879	0.634	rs11052582	ENSG00000278635.1	CTD-2318O12.1	4.21	3.72e-05	0.0149	0.23	0.27	Type 1 diabetes;	chr12:9706714	chr12:9415641~9416718:+
OV	cis	rs7617773	0.707	rs13061269	ENSG00000228638.1	FCF1P2	-4.21	3.72e-05	0.015	-0.35	-0.27	Coronary artery disease;	chr3:48331853	chr3:48290793~48291375:-
OV	cis	rs6860806	0.507	rs273901	ENSG00000233006.5	AC034220.3	4.21	3.73e-05	0.015	0.28	0.27	Breast cancer;	chr5:132358667	chr5:132311285~132369916:-
OV	cis	rs270601	0.913	rs273899	ENSG00000233006.5	AC034220.3	4.21	3.73e-05	0.015	0.28	0.27	Acylcarnitine levels;	chr5:132359485	chr5:132311285~132369916:-
OV	cis	rs6860806	0.507	rs200837	ENSG00000233006.5	AC034220.3	4.21	3.73e-05	0.015	0.28	0.27	Breast cancer;	chr5:132364266	chr5:132311285~132369916:-
OV	cis	rs9880211	1	rs9818056	ENSG00000239213.4	NCK1-AS1	4.21	3.73e-05	0.015	0.33	0.27	Height;Body mass index;	chr3:136491232	chr3:136841726~136862054:-
OV	cis	rs875971	0.862	rs28470208	ENSG00000237310.1	GS1-124K5.4	-4.21	3.73e-05	0.015	-0.27	-0.27	Aortic root size;	chr7:66119713	chr7:66493706~66495474:+
OV	cis	rs1584120	0.594	rs2243559	ENSG00000274885.1	RP11-268P4.6	4.21	3.73e-05	0.015	0.32	0.27	Pelvic organ prolapse (moderate/severe);	chr12:23128620	chr12:22638464~22638943:+
OV	cis	rs1555322	0.53	rs2425049	ENSG00000269202.1	RP4-614O4.12	-4.21	3.73e-05	0.015	-0.31	-0.27	Attention deficit hyperactivity disorder;	chr20:35286917	chr20:35201747~35203288:-
OV	cis	rs950169	0.58	rs11634320	ENSG00000225151.9	GOLGA2P7	4.21	3.73e-05	0.015	0.34	0.27	Schizophrenia;	chr15:84628952	chr15:84199311~84230136:-
OV	cis	rs1511299	0.546	rs4315664	ENSG00000249417.1	RP11-438D8.2	-4.21	3.73e-05	0.015	-0.4	-0.27	Glomerular filtration rate;	chr3:141975255	chr3:141267353~141367137:-
OV	cis	rs1511299	0.546	rs4315665	ENSG00000249417.1	RP11-438D8.2	-4.21	3.73e-05	0.015	-0.4	-0.27	Glomerular filtration rate;	chr3:141975297	chr3:141267353~141367137:-
OV	cis	rs7017914	0.642	rs2732143	ENSG00000223220.1	Y_RNA	4.21	3.73e-05	0.015	0.28	0.27	Bone mineral density;	chr8:70963007	chr8:70780914~70781008:-
OV	cis	rs858239	0.669	rs1006709	ENSG00000230042.1	AK3P3	-4.21	3.74e-05	0.015	-0.28	-0.27	Cerebrospinal fluid biomarker levels;	chr7:23100480	chr7:23129178~23129841:+
OV	cis	rs7746199	0.736	rs13210634	ENSG00000220721.1	OR1F12	4.21	3.75e-05	0.015	0.52	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:28073316~28074233:+
OV	cis	rs7746199	0.736	rs13215275	ENSG00000220721.1	OR1F12	4.21	3.75e-05	0.015	0.52	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:28073316~28074233:+
OV	cis	rs7746199	0.736	rs17749927	ENSG00000220721.1	OR1F12	4.21	3.75e-05	0.015	0.52	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:28073316~28074233:+
OV	cis	rs7746199	0.736	rs13192965	ENSG00000220721.1	OR1F12	4.21	3.75e-05	0.015	0.52	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:28073316~28074233:+
OV	cis	rs11122895	0.716	rs11122898	ENSG00000228251.1	AC012442.6	-4.21	3.75e-05	0.015	-0.25	-0.27	Allergic sensitization;	chr2:111716597	chr2:112590796~112591939:+
OV	cis	rs11122895	0.716	rs11122899	ENSG00000228251.1	AC012442.6	-4.21	3.75e-05	0.015	-0.25	-0.27	Allergic sensitization;	chr2:111716993	chr2:112590796~112591939:+
OV	cis	rs1075265	0.572	rs62139835	ENSG00000233266.1	HMGB1P31	4.21	3.75e-05	0.015	0.31	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53682307	chr2:54051334~54051760:+
OV	cis	rs6772849	0.93	rs68090762	ENSG00000277250.1	Metazoa_SRP	-4.21	3.75e-05	0.015	-0.31	-0.27	Monocyte percentage of white cells;Monocyte count;	chr3:128625064	chr3:128673681~128674021:-
OV	cis	rs4934494	0.768	rs11330	ENSG00000240996.1	RP11-80H5.7	4.21	3.75e-05	0.015	0.35	0.27	Red blood cell count;	chr10:89634322	chr10:89694295~89697928:-
OV	cis	rs12073359	0.955	rs72694960	ENSG00000223945.2	RP11-458I7.1	-4.21	3.75e-05	0.015	-0.45	-0.27	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150174687	chr1:150053864~150055034:+
OV	cis	rs6673267	0.904	rs6427870	ENSG00000223774.4	RP11-307B6.3	4.21	3.75e-05	0.015	0.29	0.27	Lobe attachment (rater-scored or self-reported);	chr1:201027061	chr1:201893842~201899978:+
OV	cis	rs7968440	1	rs2684900	ENSG00000257298.1	RP3-405J10.3	4.21	3.75e-05	0.015	0.26	0.27	Fibrinogen;	chr12:50625773	chr12:50185580~50191363:-
OV	cis	rs7968440	1	rs2700479	ENSG00000257298.1	RP3-405J10.3	4.21	3.75e-05	0.015	0.26	0.27	Fibrinogen;	chr12:50626688	chr12:50185580~50191363:-
OV	cis	rs4578769	0.55	rs4474794	ENSG00000242182.3	RN7SL745P	4.21	3.75e-05	0.015	0.31	0.27	Eosinophil percentage of white cells;	chr18:22987010	chr18:23004564~23004862:+
OV	cis	rs2919917	0.628	rs9298314	ENSG00000254352.1	RP11-578O24.2	4.21	3.76e-05	0.0151	0.35	0.27	Lymphocyte counts;	chr8:78660874	chr8:78723796~78724136:-
OV	cis	rs944801	0.566	rs10965219	ENSG00000234840.1	LINC01239	4.21	3.76e-05	0.0151	0.3	0.27	Type 2 diabetes;	chr9:22053688	chr9:22646200~22824213:+
OV	cis	rs7746199	0.736	rs34105070	ENSG00000220721.1	OR1F12	4.2	3.76e-05	0.0151	0.52	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:28073316~28074233:+
OV	cis	rs7746199	0.673	rs72845046	ENSG00000220721.1	OR1F12	4.2	3.76e-05	0.0151	0.52	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:28073316~28074233:+
OV	cis	rs7746199	0.736	rs67652222	ENSG00000220721.1	OR1F12	4.2	3.76e-05	0.0151	0.52	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:28073316~28074233:+
OV	cis	rs7746199	0.736	rs34038546	ENSG00000220721.1	OR1F12	4.2	3.76e-05	0.0151	0.52	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:28073316~28074233:+
OV	cis	rs141342723	1	rs141342723	ENSG00000220721.1	OR1F12	4.2	3.76e-05	0.0151	0.52	0.27	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:28073316~28074233:+
OV	cis	rs7746199	0.736	rs34543938	ENSG00000220721.1	OR1F12	4.2	3.76e-05	0.0151	0.52	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:28073316~28074233:+
OV	cis	rs7746199	0.736	rs56405707	ENSG00000220721.1	OR1F12	4.2	3.76e-05	0.0151	0.52	0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:28073316~28074233:+
OV	cis	rs9992667	1	rs10032639	ENSG00000231160.8	KLF3-AS1	4.2	3.76e-05	0.0151	0.33	0.27	Eosinophil percentage of granulocytes;	chr4:38673107	chr4:38612701~38664883:-
OV	cis	rs1823913	0.66	rs1454752	ENSG00000227542.1	AC092614.2	-4.2	3.76e-05	0.0151	-0.3	-0.27	Obesity-related traits;	chr2:191298668	chr2:191229165~191246172:-
OV	cis	rs5742933	0.69	rs16831821	ENSG00000253559.1	OSGEPL1-AS1	-4.2	3.76e-05	0.0151	-0.37	-0.27	Ferritin levels;	chr2:189641087	chr2:189762704~189765556:+
OV	cis	rs514406	0.584	rs7524702	ENSG00000206627.1	RNU6-969P	-4.2	3.76e-05	0.0151	-0.29	-0.27	Monocyte count;	chr1:52732158	chr1:52805108~52805212:-
OV	cis	rs875971	0.545	rs12673308	ENSG00000273024.4	INTS4P2	-4.2	3.77e-05	0.0151	-0.32	-0.27	Aortic root size;	chr7:66166374	chr7:65647864~65715661:+
OV	cis	rs875971	0.545	rs67397473	ENSG00000273024.4	INTS4P2	-4.2	3.77e-05	0.0151	-0.32	-0.27	Aortic root size;	chr7:66168318	chr7:65647864~65715661:+
OV	cis	rs875971	0.545	rs10950027	ENSG00000273024.4	INTS4P2	-4.2	3.77e-05	0.0151	-0.32	-0.27	Aortic root size;	chr7:66169164	chr7:65647864~65715661:+
OV	cis	rs73201462	1	rs58986862	ENSG00000242551.2	POU5F1P6	4.2	3.77e-05	0.0151	0.43	0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128342846	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs56850662	ENSG00000242551.2	POU5F1P6	4.2	3.77e-05	0.0151	0.43	0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128343079	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs60399786	ENSG00000242551.2	POU5F1P6	4.2	3.77e-05	0.0151	0.43	0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128343227	chr3:128674735~128677005:-
OV	cis	rs11017221	0.891	rs7905219	ENSG00000233122.2	CTAGE7P	-4.2	3.77e-05	0.0151	-0.26	-0.27	Migraine;	chr10:130364448	chr10:130106046~130108481:+
OV	cis	rs8054556	0.539	rs12596543	ENSG00000261367.1	RP11-455F5.4	-4.2	3.77e-05	0.0151	-0.3	-0.27	Autism spectrum disorder or schizophrenia;	chr16:30017814	chr16:30107675~30110541:+
OV	cis	rs7267979	1	rs2257432	ENSG00000274973.1	RP13-401N8.7	-4.2	3.77e-05	0.0151	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25290450	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2258066	ENSG00000274973.1	RP13-401N8.7	-4.2	3.77e-05	0.0151	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25290690	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2258135	ENSG00000274973.1	RP13-401N8.7	-4.2	3.77e-05	0.0151	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25291687	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2258201	ENSG00000274973.1	RP13-401N8.7	-4.2	3.77e-05	0.0151	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25291854	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2258563	ENSG00000274973.1	RP13-401N8.7	-4.2	3.77e-05	0.0151	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25292799	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2258617	ENSG00000274973.1	RP13-401N8.7	-4.2	3.77e-05	0.0151	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25293682	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2257420	ENSG00000274973.1	RP13-401N8.7	-4.2	3.77e-05	0.0151	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25295254	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2258769	ENSG00000274973.1	RP13-401N8.7	-4.2	3.77e-05	0.0151	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25296044	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs7018	ENSG00000274973.1	RP13-401N8.7	-4.2	3.77e-05	0.0151	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25297625	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2258879	ENSG00000274973.1	RP13-401N8.7	-4.2	3.77e-05	0.0151	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25298577	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2257496	ENSG00000274973.1	RP13-401N8.7	-4.2	3.77e-05	0.0151	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25298679	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2258884	ENSG00000274973.1	RP13-401N8.7	-4.2	3.77e-05	0.0151	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25298903	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2259837	ENSG00000274973.1	RP13-401N8.7	-4.2	3.77e-05	0.0151	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25299569	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2259873	ENSG00000274973.1	RP13-401N8.7	-4.2	3.77e-05	0.0151	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25300145	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs11100	ENSG00000274973.1	RP13-401N8.7	-4.2	3.77e-05	0.0151	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25300548	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs1046073	ENSG00000274973.1	RP13-401N8.7	-4.2	3.77e-05	0.0151	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25300697	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2259926	ENSG00000274973.1	RP13-401N8.7	-4.2	3.77e-05	0.0151	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25301097	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2259928	ENSG00000274973.1	RP13-401N8.7	-4.2	3.77e-05	0.0151	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25301198	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2259956	ENSG00000274973.1	RP13-401N8.7	-4.2	3.77e-05	0.0151	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25301797	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs6037083	ENSG00000274973.1	RP13-401N8.7	4.2	3.77e-05	0.0151	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25309907	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs4813557	ENSG00000274973.1	RP13-401N8.7	4.2	3.77e-05	0.0151	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25311909	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2297496	ENSG00000274973.1	RP13-401N8.7	4.2	3.77e-05	0.0151	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25315151	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs7343481	ENSG00000274973.1	RP13-401N8.7	4.2	3.77e-05	0.0151	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25319477	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs4815404	ENSG00000274973.1	RP13-401N8.7	4.2	3.77e-05	0.0151	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25321209	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6115146	ENSG00000274973.1	RP13-401N8.7	4.2	3.77e-05	0.0151	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25323871	chr20:25845497~25845862:+
OV	cis	rs7267979	0.934	rs6037085	ENSG00000274973.1	RP13-401N8.7	4.2	3.77e-05	0.0151	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25324566	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs6050532	ENSG00000274973.1	RP13-401N8.7	4.2	3.77e-05	0.0151	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25328157	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6083804	ENSG00000274973.1	RP13-401N8.7	4.2	3.77e-05	0.0151	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25336424	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6083805	ENSG00000274973.1	RP13-401N8.7	4.2	3.77e-05	0.0151	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25336720	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs4815405	ENSG00000274973.1	RP13-401N8.7	4.2	3.77e-05	0.0151	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25336856	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6050542	ENSG00000274973.1	RP13-401N8.7	4.2	3.77e-05	0.0151	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25338243	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6076336	ENSG00000274973.1	RP13-401N8.7	4.2	3.77e-05	0.0151	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25338576	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6050544	ENSG00000274973.1	RP13-401N8.7	4.2	3.77e-05	0.0151	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25339592	chr20:25845497~25845862:+
OV	cis	rs11673344	0.526	rs17305823	ENSG00000226686.6	LINC01535	-4.2	3.77e-05	0.0151	-0.36	-0.27	Obesity-related traits;	chr19:37644145	chr19:37251912~37265535:+
OV	cis	rs9473147	0.602	rs9296567	ENSG00000270761.1	RP11-385F7.1	-4.2	3.78e-05	0.0151	-0.31	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47585666	chr6:47477243~47477572:-
OV	cis	rs9473147	0.571	rs9369717	ENSG00000270761.1	RP11-385F7.1	-4.2	3.78e-05	0.0151	-0.31	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47586732	chr6:47477243~47477572:-
OV	cis	rs2227564	0.597	rs12256103	ENSG00000271816.1	BMS1P4	4.2	3.78e-05	0.0151	0.27	0.27	Crohn's disease;Inflammatory bowel disease;	chr10:73785493	chr10:73699151~73730487:-
OV	cis	rs2227564	0.62	rs3911887	ENSG00000271816.1	BMS1P4	4.2	3.78e-05	0.0151	0.27	0.27	Crohn's disease;Inflammatory bowel disease;	chr10:73788268	chr10:73699151~73730487:-
OV	cis	rs875971	0.862	rs880166	ENSG00000236529.1	RP13-254B10.1	-4.2	3.78e-05	0.0151	-0.28	-0.27	Aortic root size;	chr7:66205775	chr7:65840212~65840596:+
OV	cis	rs2282300	0.956	rs1222212	ENSG00000242353.1	RP4-710M3.1	-4.2	3.78e-05	0.0151	-0.39	-0.27	Morning vs. evening chronotype;	chr11:30353096	chr11:30368148~30368646:+
OV	cis	rs694739	1	rs499425	ENSG00000236935.1	AP003774.1	-4.2	3.78e-05	0.0151	-0.35	-0.27	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338457	chr11:64325050~64329504:-
OV	cis	rs9326248	1	rs7107152	ENSG00000280143.1	AP000892.6	-4.2	3.78e-05	0.0151	-0.29	-0.27	Blood protein levels;	chr11:117185364	chr11:117204967~117210292:+
OV	cis	rs1862618	0.853	rs832565	ENSG00000271828.1	CTD-2310F14.1	4.2	3.78e-05	0.0151	0.43	0.27	Initial pursuit acceleration;	chr5:56854976	chr5:56927874~56929573:+
OV	cis	rs6860806	0.507	rs273912	ENSG00000233006.5	AC034220.3	-4.2	3.78e-05	0.0151	-0.28	-0.27	Breast cancer;	chr5:132325656	chr5:132311285~132369916:-
OV	cis	rs10759883	0.563	rs589362	ENSG00000175611.10	LINC00476	4.2	3.79e-05	0.0151	0.33	0.27	Nicotine dependence;	chr9:95966906	chr9:95759231~95875977:-
OV	cis	rs1823913	0.637	rs13382985	ENSG00000227542.1	AC092614.2	-4.2	3.79e-05	0.0151	-0.3	-0.27	Obesity-related traits;	chr2:191306335	chr2:191229165~191246172:-
OV	cis	rs78545713	0.536	rs80202565	ENSG00000241549.7	GUSBP2	-4.2	3.79e-05	0.0152	-0.45	-0.27	Iron status biomarkers (total iron binding capacity);	chr6:26233654	chr6:26871484~26956554:-
OV	cis	rs7520050	0.807	rs4468203	ENSG00000280836.1	AL355480.1	-4.2	3.79e-05	0.0152	-0.32	-0.27	Reticulocyte count;Red blood cell count;	chr1:45647600	chr1:45581219~45581321:-
OV	cis	rs7520050	0.807	rs6656279	ENSG00000280836.1	AL355480.1	-4.2	3.79e-05	0.0152	-0.32	-0.27	Reticulocyte count;Red blood cell count;	chr1:45658416	chr1:45581219~45581321:-
OV	cis	rs7520050	0.807	rs6671802	ENSG00000280836.1	AL355480.1	-4.2	3.79e-05	0.0152	-0.32	-0.27	Reticulocyte count;Red blood cell count;	chr1:45658991	chr1:45581219~45581321:-
OV	cis	rs80168506	0.748	rs12474158	ENSG00000272519.1	RP11-105N14.2	4.2	3.79e-05	0.0152	0.4	0.27	Selective IgA deficiency;	chr2:213208463	chr2:213266995~213276152:-
OV	cis	rs1044826	1	rs9834607	ENSG00000250433.1	CLSTN2-AS1	-4.2	3.79e-05	0.0152	-0.32	-0.27	Obesity-related traits;	chr3:139515342	chr3:140505611~140508789:-
OV	cis	rs11096990	0.656	rs3733284	ENSG00000249207.1	RP11-360F5.1	4.2	3.79e-05	0.0152	0.29	0.27	Cognitive function;	chr4:39299714	chr4:39112677~39126818:-
OV	cis	rs7267979	0.932	rs433352	ENSG00000274973.1	RP13-401N8.7	4.2	3.79e-05	0.0152	0.3	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25487356	chr20:25845497~25845862:+
OV	cis	rs2741335	0.876	rs2741338	ENSG00000253567.1	RP11-181B11.2	-4.2	3.8e-05	0.0152	-0.33	-0.27	Response to zileuton treatment in asthma (FEV1 change interaction);	chr8:27478217	chr8:28447264~28455902:+
OV	cis	rs4713118	0.621	rs9368548	ENSG00000226314.6	ZNF192P1	-4.2	3.8e-05	0.0152	-0.36	-0.27	Parkinson's disease;	chr6:28066959	chr6:28161781~28169594:+
OV	cis	rs6745190	0.953	rs4595925	ENSG00000236153.1	AC104076.3	4.2	3.8e-05	0.0152	0.33	0.27	White blood cell count;	chr2:180979589	chr2:180979427~180980090:-
OV	cis	rs7968440	1	rs7305655	ENSG00000257298.1	RP3-405J10.3	-4.2	3.8e-05	0.0152	-0.26	-0.27	Fibrinogen;	chr12:50611506	chr12:50185580~50191363:-
OV	cis	rs1723838	0.702	rs2056649	ENSG00000255928.1	RP11-456I15.2	-4.2	3.8e-05	0.0152	-0.58	-0.27	Obesity-related traits;	chr11:73730296	chr11:73722349~73722694:+
OV	cis	rs1707322	0.827	rs10890347	ENSG00000234329.1	RP11-767N6.2	-4.2	3.81e-05	0.0152	-0.27	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45651039~45651826:-
OV	cis	rs1569175	1	rs17591301	ENSG00000232732.8	AC073043.1	4.2	3.81e-05	0.0152	0.54	0.27	Response to treatment for acute lymphoblastic leukemia;	chr2:199989492	chr2:199867396~199911159:-
OV	cis	rs9287719	0.649	rs9973456	ENSG00000243819.4	RN7SL832P	4.2	3.81e-05	0.0152	0.27	0.27	Prostate cancer;	chr2:10578004	chr2:10690344~10692099:+
OV	cis	rs7017914	0.69	rs2008517	ENSG00000223220.1	Y_RNA	4.2	3.82e-05	0.0152	0.28	0.27	Bone mineral density;	chr8:70944285	chr8:70780914~70781008:-
OV	cis	rs7520050	0.966	rs4660321	ENSG00000281133.1	AL355480.3	4.2	3.82e-05	0.0153	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45901088	chr1:45580892~45580996:-
OV	cis	rs7520050	0.931	rs6698247	ENSG00000281133.1	AL355480.3	4.2	3.82e-05	0.0153	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45905814	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs6675946	ENSG00000281133.1	AL355480.3	4.2	3.82e-05	0.0153	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45906102	chr1:45580892~45580996:-
OV	cis	rs7520050	0.931	rs7526678	ENSG00000281133.1	AL355480.3	4.2	3.82e-05	0.0153	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45908487	chr1:45580892~45580996:-
OV	cis	rs7520050	0.931	rs6686134	ENSG00000281133.1	AL355480.3	4.2	3.82e-05	0.0153	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45912596	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs12564541	ENSG00000281133.1	AL355480.3	4.2	3.82e-05	0.0153	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45914565	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs61102033	ENSG00000281133.1	AL355480.3	4.2	3.82e-05	0.0153	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45916769	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs12405451	ENSG00000281133.1	AL355480.3	4.2	3.82e-05	0.0153	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45918654	chr1:45580892~45580996:-
OV	cis	rs7520050	0.931	rs11211224	ENSG00000281133.1	AL355480.3	4.2	3.82e-05	0.0153	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45918716	chr1:45580892~45580996:-
OV	cis	rs7520050	0.933	rs6656022	ENSG00000281133.1	AL355480.3	4.2	3.82e-05	0.0153	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45928643	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs4134386	ENSG00000281133.1	AL355480.3	4.2	3.82e-05	0.0153	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45929417	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs12561806	ENSG00000281133.1	AL355480.3	4.2	3.82e-05	0.0153	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45931104	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs6669522	ENSG00000281133.1	AL355480.3	4.2	3.82e-05	0.0153	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45932269	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs6677007	ENSG00000281133.1	AL355480.3	4.2	3.82e-05	0.0153	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45934918	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs4660898	ENSG00000281133.1	AL355480.3	4.2	3.82e-05	0.0153	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45936499	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs11211230	ENSG00000281133.1	AL355480.3	4.2	3.82e-05	0.0153	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45941095	chr1:45580892~45580996:-
OV	cis	rs7520050	0.931	rs35743647	ENSG00000281133.1	AL355480.3	4.2	3.82e-05	0.0153	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45941580	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs7522601	ENSG00000281133.1	AL355480.3	4.2	3.82e-05	0.0153	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45953349	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs10789487	ENSG00000281133.1	AL355480.3	4.2	3.82e-05	0.0153	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45954549	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs11211234	ENSG00000281133.1	AL355480.3	4.2	3.82e-05	0.0153	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45973115	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs11211241	ENSG00000281133.1	AL355480.3	4.2	3.82e-05	0.0153	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45987011	chr1:45580892~45580996:-
OV	cis	rs7520050	0.933	rs4504835	ENSG00000281133.1	AL355480.3	4.2	3.82e-05	0.0153	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45989899	chr1:45580892~45580996:-
OV	cis	rs7520050	0.902	rs4638056	ENSG00000281133.1	AL355480.3	4.2	3.82e-05	0.0153	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45992481	chr1:45580892~45580996:-
OV	cis	rs7520050	0.931	rs11576305	ENSG00000281133.1	AL355480.3	4.2	3.82e-05	0.0153	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45994374	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs7556615	ENSG00000281133.1	AL355480.3	4.2	3.82e-05	0.0153	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45995697	chr1:45580892~45580996:-
OV	cis	rs1862618	0.853	rs252922	ENSG00000271828.1	CTD-2310F14.1	4.2	3.82e-05	0.0153	0.42	0.27	Initial pursuit acceleration;	chr5:56840516	chr5:56927874~56929573:+
OV	cis	rs67311347	0.544	rs12635762	ENSG00000223797.4	ENTPD3-AS1	-4.2	3.82e-05	0.0153	-0.28	-0.27	Renal cell carcinoma;	chr3:40291268	chr3:40313802~40453329:-
OV	cis	rs72615157	0.634	rs2272343	ENSG00000242294.5	STAG3L5P	4.2	3.83e-05	0.0153	0.25	0.27	Lung function (FEV1/FVC);	chr7:100180662	chr7:100336079~100351900:+
OV	cis	rs72615157	0.634	rs74742883	ENSG00000242294.5	STAG3L5P	4.2	3.83e-05	0.0153	0.25	0.27	Lung function (FEV1/FVC);	chr7:100188142	chr7:100336079~100351900:+
OV	cis	rs6462411	0.818	rs10244636	ENSG00000236708.1	AC073316.1	-4.2	3.83e-05	0.0153	-0.33	-0.27	Quantitative traits;	chr7:3870858	chr7:3264032~3302452:-
OV	cis	rs1862618	0.853	rs252904	ENSG00000271828.1	CTD-2310F14.1	4.2	3.83e-05	0.0153	0.41	0.27	Initial pursuit acceleration;	chr5:56822906	chr5:56927874~56929573:+
OV	cis	rs801193	0.591	rs721717	ENSG00000237310.1	GS1-124K5.4	-4.2	3.83e-05	0.0153	-0.27	-0.27	Aortic root size;	chr7:66665305	chr7:66493706~66495474:+
OV	cis	rs801193	0.569	rs6951302	ENSG00000237310.1	GS1-124K5.4	-4.2	3.83e-05	0.0153	-0.27	-0.27	Aortic root size;	chr7:66667525	chr7:66493706~66495474:+
OV	cis	rs1790761	0.587	rs7934075	ENSG00000184224.3	C11orf72	-4.2	3.83e-05	0.0153	-0.3	-0.27	Mean corpuscular volume;	chr11:67528478	chr11:67602880~67606706:-
OV	cis	rs9828933	0.766	rs3774725	ENSG00000280620.1	SCAANT1	4.2	3.83e-05	0.0153	0.44	0.27	Type 2 diabetes;	chr3:63988582	chr3:63911518~63911772:-
OV	cis	rs853679	0.546	rs200490	ENSG00000280107.1	AL022393.9	-4.2	3.83e-05	0.0153	-0.47	-0.27	Depression;	chr6:27829157	chr6:28170845~28172521:+
OV	cis	rs1765142	0.55	rs592328	ENSG00000254532.1	RP11-624D11.2	-4.2	3.83e-05	0.0153	-0.32	-0.27	Schizophrenia;	chr11:30390627	chr11:30044058~30084343:-
OV	cis	rs12468226	1	rs7597469	ENSG00000272966.1	RP11-686O6.1	4.2	3.84e-05	0.0153	0.44	0.27	Urate levels;	chr2:202329547	chr2:202336739~202337200:+
OV	cis	rs12468226	1	rs113877751	ENSG00000272966.1	RP11-686O6.1	4.2	3.84e-05	0.0153	0.44	0.27	Urate levels;	chr2:202329998	chr2:202336739~202337200:+
OV	cis	rs12468226	0.935	rs113021930	ENSG00000272966.1	RP11-686O6.1	4.2	3.84e-05	0.0153	0.44	0.27	Urate levels;	chr2:202330448	chr2:202336739~202337200:+
OV	cis	rs12468226	1	rs113491584	ENSG00000272966.1	RP11-686O6.1	4.2	3.84e-05	0.0153	0.44	0.27	Urate levels;	chr2:202331724	chr2:202336739~202337200:+
OV	cis	rs12468226	1	rs112306637	ENSG00000272966.1	RP11-686O6.1	4.2	3.84e-05	0.0153	0.44	0.27	Urate levels;	chr2:202334195	chr2:202336739~202337200:+
OV	cis	rs12468226	1	rs111252524	ENSG00000272966.1	RP11-686O6.1	4.2	3.84e-05	0.0153	0.44	0.27	Urate levels;	chr2:202334465	chr2:202336739~202337200:+
OV	cis	rs12468226	1	rs112753638	ENSG00000272966.1	RP11-686O6.1	4.2	3.84e-05	0.0153	0.44	0.27	Urate levels;	chr2:202334496	chr2:202336739~202337200:+
OV	cis	rs12468226	0.935	rs113188021	ENSG00000272966.1	RP11-686O6.1	4.2	3.84e-05	0.0153	0.44	0.27	Urate levels;	chr2:202336237	chr2:202336739~202337200:+
OV	cis	rs12468226	1	rs6731027	ENSG00000272966.1	RP11-686O6.1	4.2	3.84e-05	0.0153	0.44	0.27	Urate levels;	chr2:202337443	chr2:202336739~202337200:+
OV	cis	rs1707322	0.682	rs10890334	ENSG00000234329.1	RP11-767N6.2	4.2	3.84e-05	0.0153	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634706	chr1:45651039~45651826:-
OV	cis	rs1707322	0.682	rs10890335	ENSG00000234329.1	RP11-767N6.2	4.2	3.84e-05	0.0153	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634722	chr1:45651039~45651826:-
OV	cis	rs7811142	1	rs74460138	ENSG00000242294.5	STAG3L5P	4.2	3.84e-05	0.0153	0.28	0.27	Platelet count;	chr7:100429716	chr7:100336079~100351900:+
OV	cis	rs7811142	1	rs6975729	ENSG00000242294.5	STAG3L5P	4.2	3.84e-05	0.0153	0.28	0.27	Platelet count;	chr7:100430564	chr7:100336079~100351900:+
OV	cis	rs7811142	1	rs1073	ENSG00000242294.5	STAG3L5P	4.2	3.84e-05	0.0153	0.28	0.27	Platelet count;	chr7:100433989	chr7:100336079~100351900:+
OV	cis	rs7811142	1	rs4989959	ENSG00000242294.5	STAG3L5P	4.2	3.84e-05	0.0153	0.28	0.27	Platelet count;	chr7:100434665	chr7:100336079~100351900:+
OV	cis	rs7811142	0.887	rs4074838	ENSG00000242294.5	STAG3L5P	4.2	3.84e-05	0.0153	0.28	0.27	Platelet count;	chr7:100435042	chr7:100336079~100351900:+
OV	cis	rs7811142	1	rs11764818	ENSG00000242294.5	STAG3L5P	4.2	3.84e-05	0.0153	0.28	0.27	Platelet count;	chr7:100445432	chr7:100336079~100351900:+
OV	cis	rs7811142	0.945	rs6955362	ENSG00000242294.5	STAG3L5P	4.2	3.84e-05	0.0153	0.28	0.27	Platelet count;	chr7:100458543	chr7:100336079~100351900:+
OV	cis	rs7811142	1	rs6975514	ENSG00000242294.5	STAG3L5P	4.2	3.84e-05	0.0153	0.28	0.27	Platelet count;	chr7:100458597	chr7:100336079~100351900:+
OV	cis	rs7811142	1	rs7811142	ENSG00000242294.5	STAG3L5P	4.2	3.84e-05	0.0153	0.28	0.27	Platelet count;	chr7:100467820	chr7:100336079~100351900:+
OV	cis	rs7811142	1	rs11773661	ENSG00000242294.5	STAG3L5P	4.2	3.84e-05	0.0153	0.28	0.27	Platelet count;	chr7:100475446	chr7:100336079~100351900:+
OV	cis	rs7811142	0.943	rs66958101	ENSG00000242294.5	STAG3L5P	4.2	3.84e-05	0.0153	0.28	0.27	Platelet count;	chr7:100476397	chr7:100336079~100351900:+
OV	cis	rs1198872	0.503	rs1627163	ENSG00000272275.1	RP11-791G15.2	-4.2	3.84e-05	0.0153	-0.33	-0.27	Cardiac Troponin-T levels;	chr2:10814718	chr2:10767875~10770058:-
OV	cis	rs3733585	0.673	rs9993410	ENSG00000250413.1	RP11-448G15.1	4.2	3.84e-05	0.0153	0.29	0.27	Cleft plate (environmental tobacco smoke interaction);	chr4:9949640	chr4:10006482~10009725:+
OV	cis	rs7267979	0.933	rs2261109	ENSG00000274973.1	RP13-401N8.7	-4.2	3.84e-05	0.0153	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25278564	chr20:25845497~25845862:+
OV	cis	rs7267979	0.934	rs2261115	ENSG00000274973.1	RP13-401N8.7	-4.2	3.84e-05	0.0153	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25279171	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs2261720	ENSG00000274973.1	RP13-401N8.7	-4.2	3.84e-05	0.0153	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25280005	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs2227890	ENSG00000274973.1	RP13-401N8.7	-4.2	3.84e-05	0.0153	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25280295	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs2261747	ENSG00000274973.1	RP13-401N8.7	-4.2	3.84e-05	0.0153	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25281148	chr20:25845497~25845862:+
OV	cis	rs7267979	0.934	rs2261753	ENSG00000274973.1	RP13-401N8.7	-4.2	3.84e-05	0.0153	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25281655	chr20:25845497~25845862:+
OV	cis	rs875971	0.502	rs2465121	ENSG00000273024.4	INTS4P2	4.2	3.84e-05	0.0153	0.32	0.27	Aortic root size;	chr7:66156017	chr7:65647864~65715661:+
OV	cis	rs17428076	0.514	rs3821095	ENSG00000228389.1	AC068039.4	4.2	3.84e-05	0.0153	0.28	0.27	Myopia;	chr2:171827496	chr2:171773482~171775844:+
OV	cis	rs783540	0.5	rs7178459	ENSG00000259429.4	UBE2Q2P2	-4.2	3.84e-05	0.0153	-0.32	-0.27	Schizophrenia;	chr15:82729632	chr15:82355142~82420075:+
OV	cis	rs875971	0.862	rs1983372	ENSG00000237310.1	GS1-124K5.4	-4.2	3.84e-05	0.0153	-0.27	-0.27	Aortic root size;	chr7:66146364	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs908915	ENSG00000237310.1	GS1-124K5.4	-4.2	3.84e-05	0.0153	-0.27	-0.27	Aortic root size;	chr7:66149664	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs7809814	ENSG00000237310.1	GS1-124K5.4	-4.2	3.84e-05	0.0153	-0.27	-0.27	Aortic root size;	chr7:66150410	chr7:66493706~66495474:+
OV	cis	rs10924970	0.649	rs12048686	ENSG00000236863.2	RPL23AP23	4.2	3.85e-05	0.0153	0.28	0.27	Asthma;	chr1:235271295	chr1:235295865~235296335:+
OV	cis	rs7617773	0.817	rs11720622	ENSG00000228638.1	FCF1P2	-4.2	3.85e-05	0.0153	-0.32	-0.27	Coronary artery disease;	chr3:48205189	chr3:48290793~48291375:-
OV	cis	rs6545883	0.965	rs3771258	ENSG00000273302.1	RP11-493E12.2	4.2	3.85e-05	0.0153	0.22	0.27	Tuberculosis;	chr2:61537005	chr2:61199979~61200769:+
OV	cis	rs6545883	0.899	rs1562309	ENSG00000273302.1	RP11-493E12.2	4.2	3.85e-05	0.0153	0.22	0.27	Tuberculosis;	chr2:61542991	chr2:61199979~61200769:+
OV	cis	rs1030877	0.515	rs920217	ENSG00000235319.1	AC012360.4	4.2	3.86e-05	0.0154	0.37	0.27	Obesity-related traits;	chr2:105288205	chr2:105324210~105330529:+
OV	cis	rs4948102	0.667	rs7811270	ENSG00000273720.1	RP11-613E4.4	-4.2	3.86e-05	0.0154	-0.31	-0.27	Plasma homocysteine levels (post-methionine load test);	chr7:56072297	chr7:55743073~55743457:+
OV	cis	rs2708377	0.789	rs3911150	ENSG00000256981.1	TAS2R18	-4.2	3.86e-05	0.0154	-0.37	-0.27	Bitter taste perception;	chr12:11049649	chr12:11158785~11159694:-
OV	cis	rs7520050	0.966	rs1768816	ENSG00000281133.1	AL355480.3	4.2	3.86e-05	0.0154	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:46062927	chr1:45580892~45580996:-
OV	cis	rs7520050	1	rs785511	ENSG00000281133.1	AL355480.3	4.2	3.86e-05	0.0154	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:46068826	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs809775	ENSG00000281133.1	AL355480.3	4.2	3.86e-05	0.0154	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:46072368	chr1:45580892~45580996:-
OV	cis	rs9393777	0.841	rs13191474	ENSG00000243307.2	POM121L6P	-4.2	3.86e-05	0.0154	-0.47	-0.27	Intelligence (multi-trait analysis);	chr6:27445566	chr6:26896952~26898777:+
OV	cis	rs7617773	0.817	rs6806112	ENSG00000228638.1	FCF1P2	-4.2	3.86e-05	0.0154	-0.32	-0.27	Coronary artery disease;	chr3:48234587	chr3:48290793~48291375:-
OV	cis	rs4787491	0.765	rs4788216	ENSG00000261367.1	RP11-455F5.4	-4.2	3.86e-05	0.0154	-0.29	-0.27	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30036756	chr16:30107675~30110541:+
OV	cis	rs4787491	0.704	rs67218159	ENSG00000261367.1	RP11-455F5.4	-4.2	3.86e-05	0.0154	-0.29	-0.27	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30039184	chr16:30107675~30110541:+
OV	cis	rs1765142	0.55	rs487336	ENSG00000254532.1	RP11-624D11.2	-4.2	3.86e-05	0.0154	-0.31	-0.27	Schizophrenia;	chr11:30380558	chr11:30044058~30084343:-
OV	cis	rs1765142	0.55	rs488220	ENSG00000254532.1	RP11-624D11.2	-4.2	3.86e-05	0.0154	-0.31	-0.27	Schizophrenia;	chr11:30380632	chr11:30044058~30084343:-
OV	cis	rs1584120	0.57	rs11046795	ENSG00000274885.1	RP11-268P4.6	4.2	3.86e-05	0.0154	0.31	0.27	Pelvic organ prolapse (moderate/severe);	chr12:23109161	chr12:22638464~22638943:+
OV	cis	rs9813712	0.953	rs12635811	ENSG00000228252.7	COL6A4P2	-4.2	3.86e-05	0.0154	-0.36	-0.27	Response to amphetamines;	chr3:130262534	chr3:130212823~130273806:+
OV	cis	rs992157	0.735	rs10932765	ENSG00000237281.1	CATIP-AS2	-4.2	3.86e-05	0.0154	-0.32	-0.27	Colorectal cancer;	chr2:218234761	chr2:218326889~218357966:-
OV	cis	rs4763879	0.634	rs61915473	ENSG00000256673.1	RP11-599J14.2	4.2	3.87e-05	0.0154	0.25	0.27	Type 1 diabetes;	chr12:9705282	chr12:9398355~9414851:-
OV	cis	rs7771547	0.788	rs10214849	ENSG00000240733.3	RN7SL502P	4.2	3.87e-05	0.0154	0.3	0.27	Platelet distribution width;	chr6:36633668	chr6:36450912~36451201:-
OV	cis	rs10783487	0.895	rs4761848	ENSG00000258279.2	LINC00592	4.2	3.87e-05	0.0154	0.37	0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr12:52079209	chr12:52210930~52223804:+
OV	cis	rs12815613	1	rs55913575	ENSG00000200795.1	RNU4-1	4.2	3.87e-05	0.0154	0.33	0.27	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr12:120967485	chr12:120293097~120293237:-
OV	cis	rs7204230	1	rs12598049	ENSG00000261291.1	RP11-295M3.2	-4.2	3.87e-05	0.0154	-0.33	-0.27	Fibrinogen;	chr16:53282942	chr16:53168522~53169450:+
OV	cis	rs7927592	0.763	rs10896327	ENSG00000222339.1	AP000807.2	4.2	3.87e-05	0.0154	0.27	0.27	Total body bone mineral density;	chr11:68467807	chr11:68505572~68505651:-
OV	cis	rs1113500	0.524	rs11185270	ENSG00000226822.1	RP11-356N1.2	4.2	3.87e-05	0.0154	0.34	0.27	Growth-regulated protein alpha levels;	chr1:108111740	chr1:108071482~108074519:+
OV	cis	rs62244186	0.711	rs6778410	ENSG00000214820.3	MPRIPP1	4.2	3.87e-05	0.0154	0.24	0.27	Depressive symptoms;	chr3:44702501	chr3:44579938~44581026:-
OV	cis	rs11157436	0.918	rs1983518	ENSG00000211812.1	TRAV26-2	-4.2	3.88e-05	0.0154	-0.3	-0.27	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22149336	chr14:22202583~22203368:+
OV	cis	rs10759883	0.539	rs10115110	ENSG00000175611.10	LINC00476	4.2	3.88e-05	0.0154	0.36	0.27	Nicotine dependence;	chr9:96033023	chr9:95759231~95875977:-
OV	cis	rs7429990	0.965	rs11709289	ENSG00000229759.1	MRPS18AP1	4.2	3.88e-05	0.0154	0.33	0.27	Educational attainment (years of education);	chr3:47765159	chr3:48256350~48256938:-
OV	cis	rs7727544	0.735	rs273913	ENSG00000233006.5	AC034220.3	4.2	3.88e-05	0.0154	0.27	0.27	Blood metabolite levels;	chr5:132325463	chr5:132311285~132369916:-
OV	cis	rs6700559	0.74	rs11582610	ENSG00000260088.1	RP11-92G12.3	4.2	3.88e-05	0.0154	0.28	0.27	Coronary artery disease;	chr1:200675973	chr1:200669507~200694250:+
OV	cis	rs6700559	0.74	rs10919997	ENSG00000260088.1	RP11-92G12.3	4.2	3.88e-05	0.0154	0.28	0.27	Coronary artery disease;	chr1:200677522	chr1:200669507~200694250:+
OV	cis	rs6700559	0.74	rs4437908	ENSG00000260088.1	RP11-92G12.3	4.2	3.88e-05	0.0154	0.28	0.27	Coronary artery disease;	chr1:200679311	chr1:200669507~200694250:+
OV	cis	rs6700559	0.74	rs4072551	ENSG00000260088.1	RP11-92G12.3	4.2	3.88e-05	0.0154	0.28	0.27	Coronary artery disease;	chr1:200679993	chr1:200669507~200694250:+
OV	cis	rs6700559	0.74	rs4072554	ENSG00000260088.1	RP11-92G12.3	4.2	3.88e-05	0.0154	0.28	0.27	Coronary artery disease;	chr1:200680238	chr1:200669507~200694250:+
OV	cis	rs6700559	0.74	rs10919999	ENSG00000260088.1	RP11-92G12.3	4.2	3.88e-05	0.0154	0.28	0.27	Coronary artery disease;	chr1:200680631	chr1:200669507~200694250:+
OV	cis	rs6700559	0.654	rs12061556	ENSG00000260088.1	RP11-92G12.3	4.2	3.88e-05	0.0154	0.28	0.27	Coronary artery disease;	chr1:200681111	chr1:200669507~200694250:+
OV	cis	rs977987	0.872	rs4888422	ENSG00000261783.1	RP11-252K23.2	-4.2	3.88e-05	0.0154	-0.36	-0.27	Dupuytren's disease;	chr16:75436678	chr16:75379818~75381260:-
OV	cis	rs2239557	1	rs10140433	ENSG00000259065.1	RP5-1021I20.1	4.2	3.88e-05	0.0154	0.32	0.27	Common traits (Other);	chr14:74193286	chr14:73787360~73803270:+
OV	cis	rs7746199	0.668	rs7749305	ENSG00000280107.1	AL022393.9	-4.2	3.89e-05	0.0154	-0.52	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27478787	chr6:28170845~28172521:+
OV	cis	rs7746199	0.668	rs34864796	ENSG00000280107.1	AL022393.9	-4.2	3.89e-05	0.0154	-0.52	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27492144	chr6:28170845~28172521:+
OV	cis	rs3018712	0.532	rs2513289	ENSG00000212093.1	AP000807.1	-4.2	3.89e-05	0.0155	-0.38	-0.27	Total body bone mineral density;	chr11:68652187	chr11:68506083~68506166:-
OV	cis	rs881375	1	rs10117059	ENSG00000226752.6	PSMD5-AS1	-4.2	3.89e-05	0.0155	-0.3	-0.27	Rheumatoid arthritis;	chr9:120891199	chr9:120824828~120854385:+
OV	cis	rs2239547	0.563	rs4687699	ENSG00000242142.1	SERBP1P3	4.2	3.89e-05	0.0155	0.33	0.27	Schizophrenia;	chr3:53067208	chr3:53064283~53065091:-
OV	cis	rs853679	0.527	rs9461443	ENSG00000280107.1	AL022393.9	-4.2	3.89e-05	0.0155	-0.34	-0.27	Depression;	chr6:28226851	chr6:28170845~28172521:+
OV	cis	rs853679	0.55	rs34477097	ENSG00000280107.1	AL022393.9	-4.2	3.89e-05	0.0155	-0.34	-0.27	Depression;	chr6:28229408	chr6:28170845~28172521:+
OV	cis	rs45509595	0.841	rs200485	ENSG00000280107.1	AL022393.9	-4.2	3.9e-05	0.0155	-0.46	-0.27	Breast cancer;	chr6:27807919	chr6:28170845~28172521:+
OV	cis	rs45509595	0.841	rs370155	ENSG00000280107.1	AL022393.9	-4.2	3.9e-05	0.0155	-0.46	-0.27	Breast cancer;	chr6:27814253	chr6:28170845~28172521:+
OV	cis	rs7520050	0.807	rs3013594	ENSG00000280836.1	AL355480.1	-4.2	3.9e-05	0.0155	-0.32	-0.27	Reticulocyte count;Red blood cell count;	chr1:45672328	chr1:45581219~45581321:-
OV	cis	rs7968440	1	rs66644594	ENSG00000272368.2	RP4-605O3.4	4.2	3.9e-05	0.0155	0.32	0.27	Fibrinogen;	chr12:50539200	chr12:50112197~50165618:+
OV	cis	rs875971	0.756	rs4718328	ENSG00000236529.1	RP13-254B10.1	-4.2	3.9e-05	0.0155	-0.28	-0.27	Aortic root size;	chr7:66228350	chr7:65840212~65840596:+
OV	cis	rs14027	1	rs14027	ENSG00000279347.1	RP11-85I17.2	-4.2	3.9e-05	0.0155	-0.28	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119834349	chr8:119838736~119840385:-
OV	cis	rs115769866	0.609	rs974334	ENSG00000216901.1	AL022393.7	4.2	3.91e-05	0.0155	0.38	0.27	Bipolar disorder;	chr6:28506441	chr6:28176188~28176674:+
OV	cis	rs992157	0.71	rs10167446	ENSG00000237281.1	CATIP-AS2	-4.2	3.91e-05	0.0155	-0.31	-0.27	Colorectal cancer;	chr2:218192143	chr2:218326889~218357966:-
OV	cis	rs2239547	0.603	rs71301807	ENSG00000242142.1	SERBP1P3	4.2	3.91e-05	0.0155	0.34	0.27	Schizophrenia;	chr3:53051459	chr3:53064283~53065091:-
OV	cis	rs801193	0.591	rs4506088	ENSG00000237310.1	GS1-124K5.4	-4.2	3.91e-05	0.0155	-0.27	-0.27	Aortic root size;	chr7:66670470	chr7:66493706~66495474:+
OV	cis	rs853679	0.517	rs9393896	ENSG00000226314.6	ZNF192P1	-4.2	3.91e-05	0.0155	-0.37	-0.27	Depression;	chr6:28159925	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9393897	ENSG00000226314.6	ZNF192P1	-4.2	3.91e-05	0.0155	-0.37	-0.27	Depression;	chr6:28159932	chr6:28161781~28169594:+
OV	cis	rs7267979	1	rs3002702	ENSG00000274973.1	RP13-401N8.7	-4.2	3.91e-05	0.0155	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25288284	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2257982	ENSG00000274973.1	RP13-401N8.7	-4.2	3.91e-05	0.0155	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25288994	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2257985	ENSG00000274973.1	RP13-401N8.7	-4.2	3.91e-05	0.0155	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25289107	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2257988	ENSG00000274973.1	RP13-401N8.7	-4.2	3.91e-05	0.0155	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25289367	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6050566	ENSG00000274973.1	RP13-401N8.7	4.2	3.91e-05	0.0155	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25370435	chr20:25845497~25845862:+
OV	cis	rs1075265	0.73	rs805392	ENSG00000233266.1	HMGB1P31	4.19	3.92e-05	0.0155	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53877594	chr2:54051334~54051760:+
OV	cis	rs6545883	0.965	rs1562308	ENSG00000273302.1	RP11-493E12.2	4.19	3.92e-05	0.0155	0.22	0.27	Tuberculosis;	chr2:61541286	chr2:61199979~61200769:+
OV	cis	rs7536700	1	rs7536700	ENSG00000272030.1	RP1-178F15.4	-4.19	3.92e-05	0.0156	-0.59	-0.27	Multiple myeloma (IgH translocation);	chr1:153668351	chr1:153631438~153634397:-
OV	cis	rs599083	0.829	rs23691	ENSG00000212093.1	AP000807.1	-4.19	3.92e-05	0.0156	-0.31	-0.27	Bone mineral density (spine);	chr11:68411200	chr11:68506083~68506166:-
OV	cis	rs599083	0.793	rs314750	ENSG00000212093.1	AP000807.1	-4.19	3.92e-05	0.0156	-0.31	-0.27	Bone mineral density (spine);	chr11:68414560	chr11:68506083~68506166:-
OV	cis	rs599083	0.829	rs23691	ENSG00000222339.1	AP000807.2	-4.19	3.92e-05	0.0156	-0.27	-0.27	Bone mineral density (spine);	chr11:68411200	chr11:68505572~68505651:-
OV	cis	rs599083	0.793	rs314750	ENSG00000222339.1	AP000807.2	-4.19	3.92e-05	0.0156	-0.27	-0.27	Bone mineral density (spine);	chr11:68414560	chr11:68505572~68505651:-
OV	cis	rs9393813	0.626	rs12664996	ENSG00000124549.13	BTN2A3P	4.19	3.92e-05	0.0156	0.27	0.27	Bipolar disorder;	chr6:27395865	chr6:26421391~26432383:+
OV	cis	rs7968440	0.808	rs66947035	ENSG00000272368.2	RP4-605O3.4	4.19	3.92e-05	0.0156	0.33	0.27	Fibrinogen;	chr12:50781260	chr12:50112197~50165618:+
OV	cis	rs7121800	0.888	rs1336516	ENSG00000254532.1	RP11-624D11.2	4.19	3.93e-05	0.0156	0.31	0.27	Pit-and-Fissure caries;	chr11:30490264	chr11:30044058~30084343:-
OV	cis	rs7646881	0.544	rs17630785	ENSG00000272440.1	RP11-379F4.6	4.19	3.93e-05	0.0156	0.41	0.27	Tetralogy of Fallot;	chr3:158674437	chr3:158695367~158695581:+
OV	cis	rs7646881	0.544	rs12638363	ENSG00000272440.1	RP11-379F4.6	4.19	3.93e-05	0.0156	0.41	0.27	Tetralogy of Fallot;	chr3:158686969	chr3:158695367~158695581:+
OV	cis	rs7646881	0.544	rs59492803	ENSG00000272440.1	RP11-379F4.6	4.19	3.93e-05	0.0156	0.41	0.27	Tetralogy of Fallot;	chr3:158702908	chr3:158695367~158695581:+
OV	cis	rs8059260	0.668	rs74737820	ENSG00000274038.1	RP11-66H6.4	-4.19	3.93e-05	0.0156	-0.51	-0.27	Alcohol consumption over the past year;	chr16:10972240	chr16:11056556~11057034:+
OV	cis	rs853679	0.607	rs201002	ENSG00000226314.6	ZNF192P1	-4.19	3.93e-05	0.0156	-0.48	-0.27	Depression;	chr6:27840414	chr6:28161781~28169594:+
OV	cis	rs3758911	0.822	rs10749903	ENSG00000261098.1	RP11-819C21.1	-4.19	3.94e-05	0.0156	-0.25	-0.27	Coronary artery disease;	chr11:107336840	chr11:107312132~107316271:-
OV	cis	rs1185460	0.546	rs592190	ENSG00000271751.1	RP11-110I1.14	4.19	3.94e-05	0.0156	0.32	0.27	Coronary artery disease;	chr11:119084604	chr11:119065263~119065677:-
OV	cis	rs1185460	0.546	rs589925	ENSG00000271751.1	RP11-110I1.14	4.19	3.94e-05	0.0156	0.32	0.27	Coronary artery disease;	chr11:119084969	chr11:119065263~119065677:-
OV	cis	rs2950393	0.804	rs1466382	ENSG00000241217.3	RN7SL809P	-4.19	3.95e-05	0.0157	-0.25	-0.27	Platelet distribution width;	chr12:56723050	chr12:56670450~56670746:-
OV	cis	rs7121800	0.888	rs10835672	ENSG00000254532.1	RP11-624D11.2	4.19	3.95e-05	0.0157	0.31	0.27	Pit-and-Fissure caries;	chr11:30481166	chr11:30044058~30084343:-
OV	cis	rs181553	0.699	rs8092003	ENSG00000266696.1	RP11-30L3.2	4.19	3.95e-05	0.0157	0.34	0.27	Hip circumference adjusted for BMI;	chr18:49165560	chr18:49205912~49208781:+
OV	cis	rs7874604	1	rs7874604	ENSG00000234840.1	LINC01239	-4.19	3.95e-05	0.0157	-0.31	-0.27	Basal cell carcinoma;	chr9:22054691	chr9:22646200~22824213:+
OV	cis	rs12073359	1	rs59607464	ENSG00000223945.2	RP11-458I7.1	-4.19	3.95e-05	0.0157	-0.41	-0.27	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150157887	chr1:150053864~150055034:+
OV	cis	rs853679	0.882	rs9380069	ENSG00000226314.6	ZNF192P1	-4.19	3.96e-05	0.0157	-0.52	-0.27	Depression;	chr6:28235522	chr6:28161781~28169594:+
OV	cis	rs7267979	1	rs1077889	ENSG00000274973.1	RP13-401N8.7	-4.19	3.96e-05	0.0157	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25287257	chr20:25845497~25845862:+
OV	cis	rs4591358	0.587	rs7604146	ENSG00000223466.1	AC064834.2	4.19	3.96e-05	0.0157	0.32	0.27	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195522900	chr2:195533035~195538681:+
OV	cis	rs62184315	0.629	rs6753164	ENSG00000253559.1	OSGEPL1-AS1	-4.19	3.96e-05	0.0157	-0.33	-0.27	Alcohol dependence (age at onset);	chr2:189837146	chr2:189762704~189765556:+
OV	cis	rs7267979	0.966	rs2261784	ENSG00000274973.1	RP13-401N8.7	-4.19	3.96e-05	0.0157	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25281760	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs2261785	ENSG00000274973.1	RP13-401N8.7	-4.19	3.96e-05	0.0157	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25281767	chr20:25845497~25845862:+
OV	cis	rs12701220	0.655	rs34344742	ENSG00000229043.2	AC091729.9	-4.19	3.96e-05	0.0157	-0.34	-0.27	Bronchopulmonary dysplasia;	chr7:1109652	chr7:1160374~1165267:+
OV	cis	rs9880211	0.699	rs9809269	ENSG00000239213.4	NCK1-AS1	4.19	3.96e-05	0.0157	0.36	0.27	Height;Body mass index;	chr3:136711064	chr3:136841726~136862054:-
OV	cis	rs2243480	1	rs35421653	ENSG00000226824.5	RP4-756H11.3	-4.19	3.97e-05	0.0157	-0.43	-0.27	Diabetic kidney disease;	chr7:65898442	chr7:66654538~66669855:+
OV	cis	rs7520050	0.898	rs4660885	ENSG00000281133.1	AL355480.3	4.19	3.97e-05	0.0157	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45778084	chr1:45580892~45580996:-
OV	cis	rs4908768	0.906	rs55860300	ENSG00000228423.2	RP4-633I8.4	4.19	3.97e-05	0.0157	0.33	0.27	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8536276	chr1:8805860~8807051:-
OV	cis	rs1723838	0.826	rs4944854	ENSG00000255928.1	RP11-456I15.2	-4.19	3.97e-05	0.0157	-0.61	-0.27	Obesity-related traits;	chr11:73667576	chr11:73722349~73722694:+
OV	cis	rs2286503	0.752	rs6461669	ENSG00000221740.1	SNORD93	4.19	3.97e-05	0.0157	0.34	0.27	Fibrinogen;	chr7:22818447	chr7:22856613~22856686:+
OV	cis	rs4934494	0.813	rs12775783	ENSG00000240996.1	RP11-80H5.7	-4.19	3.97e-05	0.0157	-0.39	-0.27	Red blood cell count;	chr10:89646494	chr10:89694295~89697928:-
OV	cis	rs1823913	0.637	rs11686185	ENSG00000227542.1	AC092614.2	-4.19	3.97e-05	0.0157	-0.3	-0.27	Obesity-related traits;	chr2:191289282	chr2:191229165~191246172:-
OV	cis	rs7520050	0.966	rs4076006	ENSG00000281133.1	AL355480.3	4.19	3.97e-05	0.0157	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45972404	chr1:45580892~45580996:-
OV	cis	rs7267979	1	rs2257808	ENSG00000274973.1	RP13-401N8.7	-4.19	3.97e-05	0.0157	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25285814	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2257809	ENSG00000274973.1	RP13-401N8.7	-4.19	3.97e-05	0.0157	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25285840	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs910997	ENSG00000274973.1	RP13-401N8.7	-4.19	3.97e-05	0.0157	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25286665	chr20:25845497~25845862:+
OV	cis	rs9650657	0.529	rs6601521	ENSG00000280294.1	RP11-177H2.1	4.19	3.98e-05	0.0157	0.31	0.27	Neuroticism;	chr8:10771437	chr8:10856085~10859436:-
OV	cis	rs950169	0.58	rs2271431	ENSG00000225151.9	GOLGA2P7	-4.19	3.98e-05	0.0157	-0.34	-0.27	Schizophrenia;	chr15:84646233	chr15:84199311~84230136:-
OV	cis	rs4845570	0.764	rs12141652	ENSG00000203288.3	RP11-98D18.9	-4.19	3.98e-05	0.0157	-0.47	-0.27	Coronary artery disease;	chr1:151744235	chr1:151790804~151794402:+
OV	cis	rs4845570	0.764	rs12122917	ENSG00000203288.3	RP11-98D18.9	-4.19	3.98e-05	0.0157	-0.47	-0.27	Coronary artery disease;	chr1:151744236	chr1:151790804~151794402:+
OV	cis	rs853679	0.546	rs200996	ENSG00000280107.1	AL022393.9	-4.19	3.98e-05	0.0158	-0.47	-0.27	Depression;	chr6:27844050	chr6:28170845~28172521:+
OV	cis	rs9287719	0.566	rs34595606	ENSG00000243819.4	RN7SL832P	4.19	3.98e-05	0.0158	0.28	0.27	Prostate cancer;	chr2:10582392	chr2:10690344~10692099:+
OV	cis	rs4713118	0.587	rs61471148	ENSG00000226314.6	ZNF192P1	-4.19	3.98e-05	0.0158	-0.36	-0.27	Parkinson's disease;	chr6:28069254	chr6:28161781~28169594:+
OV	cis	rs494459	0.504	rs7929520	ENSG00000255422.1	AP002954.4	-4.19	3.99e-05	0.0158	-0.31	-0.27	Height;	chr11:118859432	chr11:118704607~118750263:+
OV	cis	rs494459	0.536	rs34561290	ENSG00000255422.1	AP002954.4	-4.19	3.99e-05	0.0158	-0.31	-0.27	Height;	chr11:118860890	chr11:118704607~118750263:+
OV	cis	rs494459	0.536	rs11217072	ENSG00000255422.1	AP002954.4	-4.19	3.99e-05	0.0158	-0.31	-0.27	Height;	chr11:118861053	chr11:118704607~118750263:+
OV	cis	rs801193	0.591	rs9986881	ENSG00000226824.5	RP4-756H11.3	-4.19	3.99e-05	0.0158	-0.31	-0.27	Aortic root size;	chr7:66708053	chr7:66654538~66669855:+
OV	cis	rs34787248	1	rs34787248	ENSG00000219392.1	RP1-265C24.5	-4.19	3.99e-05	0.0158	-0.39	-0.27	Autism spectrum disorder or schizophrenia;	chr6:28230108	chr6:28115628~28116551:+
OV	cis	rs853679	0.76	rs2299029	ENSG00000219392.1	RP1-265C24.5	-4.19	3.99e-05	0.0158	-0.39	-0.27	Depression;	chr6:28231053	chr6:28115628~28116551:+
OV	cis	rs853679	0.76	rs11967137	ENSG00000219392.1	RP1-265C24.5	-4.19	3.99e-05	0.0158	-0.39	-0.27	Depression;	chr6:28231986	chr6:28115628~28116551:+
OV	cis	rs853679	0.76	rs11962305	ENSG00000219392.1	RP1-265C24.5	-4.19	3.99e-05	0.0158	-0.39	-0.27	Depression;	chr6:28232159	chr6:28115628~28116551:+
OV	cis	rs6860806	0.507	rs2631371	ENSG00000233006.5	AC034220.3	-4.19	3.99e-05	0.0158	-0.28	-0.27	Breast cancer;	chr5:132367999	chr5:132311285~132369916:-
OV	cis	rs1661178	0.826	rs1623156	ENSG00000267282.1	CTB-129P6.4	4.19	3.99e-05	0.0158	0.44	0.27	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr19:44540600	chr19:44882027~44890876:-
OV	cis	rs7617773	0.817	rs11130162	ENSG00000228638.1	FCF1P2	-4.19	4e-05	0.0158	-0.32	-0.27	Coronary artery disease;	chr3:48256121	chr3:48290793~48291375:-
OV	cis	rs804280	0.509	rs12719915	ENSG00000251402.3	FAM90A25P	-4.19	4e-05	0.0158	-0.34	-0.27	Myopia (pathological);	chr8:11928746	chr8:12415080~12418090:-
OV	cis	rs7536700	0.908	rs6692298	ENSG00000272030.1	RP1-178F15.4	-4.19	4.01e-05	0.0159	-0.59	-0.27	Multiple myeloma (IgH translocation);	chr1:153659663	chr1:153631438~153634397:-
OV	cis	rs10178409	1	rs10178409	ENSG00000163016.8	ALMS1P	4.19	4.01e-05	0.0159	0.33	0.27	Urinary metabolites;	chr2:73628380	chr2:73644919~73685576:+
OV	cis	rs2239547	0.603	rs9870898	ENSG00000242142.1	SERBP1P3	4.19	4.02e-05	0.0159	0.34	0.27	Schizophrenia;	chr3:53058359	chr3:53064283~53065091:-
OV	cis	rs17711722	0.528	rs73138179	ENSG00000226824.5	RP4-756H11.3	-4.19	4.02e-05	0.0159	-0.31	-0.27	Calcium levels;	chr7:65829495	chr7:66654538~66669855:+
OV	cis	rs514406	0.644	rs6662414	ENSG00000206627.1	RNU6-969P	-4.19	4.02e-05	0.0159	-0.29	-0.27	Monocyte count;	chr1:52733221	chr1:52805108~52805212:-
OV	cis	rs4948102	0.595	rs7793921	ENSG00000273720.1	RP11-613E4.4	-4.19	4.02e-05	0.0159	-0.3	-0.27	Plasma homocysteine levels (post-methionine load test);	chr7:56053188	chr7:55743073~55743457:+
OV	cis	rs4948102	0.595	rs10255049	ENSG00000273720.1	RP11-613E4.4	-4.19	4.02e-05	0.0159	-0.3	-0.27	Plasma homocysteine levels (post-methionine load test);	chr7:56053611	chr7:55743073~55743457:+
OV	cis	rs17711722	0.51	rs11767457	ENSG00000273024.4	INTS4P2	-4.19	4.03e-05	0.0159	-0.31	-0.27	Calcium levels;	chr7:65825628	chr7:65647864~65715661:+
OV	cis	rs7121800	0.632	rs7114662	ENSG00000254532.1	RP11-624D11.2	4.19	4.03e-05	0.0159	0.36	0.27	Pit-and-Fissure caries;	chr11:30507967	chr11:30044058~30084343:-
OV	cis	rs2239557	0.961	rs4903200	ENSG00000259065.1	RP5-1021I20.1	4.19	4.03e-05	0.0159	0.32	0.27	Common traits (Other);	chr14:74192934	chr14:73787360~73803270:+
OV	cis	rs1723838	0.702	rs6592529	ENSG00000255928.1	RP11-456I15.2	-4.19	4.03e-05	0.0159	-0.57	-0.27	Obesity-related traits;	chr11:73687235	chr11:73722349~73722694:+
OV	cis	rs1723838	0.826	rs4944026	ENSG00000255928.1	RP11-456I15.2	-4.19	4.03e-05	0.0159	-0.57	-0.27	Obesity-related traits;	chr11:73694199	chr11:73722349~73722694:+
OV	cis	rs1723838	0.702	rs2366944	ENSG00000255928.1	RP11-456I15.2	-4.19	4.03e-05	0.0159	-0.57	-0.27	Obesity-related traits;	chr11:73694534	chr11:73722349~73722694:+
OV	cis	rs1723838	0.702	rs7942515	ENSG00000255928.1	RP11-456I15.2	-4.19	4.03e-05	0.0159	-0.57	-0.27	Obesity-related traits;	chr11:73694843	chr11:73722349~73722694:+
OV	cis	rs1723838	0.702	rs4944027	ENSG00000255928.1	RP11-456I15.2	-4.19	4.03e-05	0.0159	-0.57	-0.27	Obesity-related traits;	chr11:73696343	chr11:73722349~73722694:+
OV	cis	rs1723838	0.702	rs4944030	ENSG00000255928.1	RP11-456I15.2	-4.19	4.03e-05	0.0159	-0.57	-0.27	Obesity-related traits;	chr11:73697922	chr11:73722349~73722694:+
OV	cis	rs1723838	0.826	rs7108695	ENSG00000255928.1	RP11-456I15.2	-4.19	4.03e-05	0.0159	-0.57	-0.27	Obesity-related traits;	chr11:73703126	chr11:73722349~73722694:+
OV	cis	rs1723838	0.609	rs1723849	ENSG00000255928.1	RP11-456I15.2	-4.19	4.03e-05	0.0159	-0.57	-0.27	Obesity-related traits;	chr11:73747980	chr11:73722349~73722694:+
OV	cis	rs1723838	0.826	rs1792196	ENSG00000255928.1	RP11-456I15.2	-4.19	4.03e-05	0.0159	-0.57	-0.27	Obesity-related traits;	chr11:73749981	chr11:73722349~73722694:+
OV	cis	rs11098499	0.691	rs10028773	ENSG00000249244.1	RP11-548H18.2	-4.19	4.03e-05	0.0159	-0.33	-0.27	Corneal astigmatism;	chr4:119344104	chr4:119391831~119395335:-
OV	cis	rs6921919	0.583	rs7764737	ENSG00000204709.4	LINC01556	4.19	4.03e-05	0.0159	0.32	0.27	Autism spectrum disorder or schizophrenia;	chr6:28386838	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs9461458	ENSG00000204709.4	LINC01556	4.19	4.03e-05	0.0159	0.32	0.27	Autism spectrum disorder or schizophrenia;	chr6:28388098	chr6:28943877~28944537:+
OV	cis	rs6921919	0.609	rs9468365	ENSG00000204709.4	LINC01556	4.19	4.03e-05	0.0159	0.32	0.27	Autism spectrum disorder or schizophrenia;	chr6:28390189	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs1361385	ENSG00000204709.4	LINC01556	4.19	4.03e-05	0.0159	0.32	0.27	Autism spectrum disorder or schizophrenia;	chr6:28390543	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs1416918	ENSG00000204709.4	LINC01556	4.19	4.03e-05	0.0159	0.32	0.27	Autism spectrum disorder or schizophrenia;	chr6:28390558	chr6:28943877~28944537:+
OV	cis	rs4950322	0.947	rs72694723	ENSG00000278811.3	LINC00624	4.19	4.04e-05	0.0159	0.37	0.27	Protein quantitative trait loci;	chr1:147373174	chr1:147258885~147517875:-
OV	cis	rs4950322	1	rs1806618	ENSG00000278811.3	LINC00624	4.19	4.04e-05	0.0159	0.37	0.27	Protein quantitative trait loci;	chr1:147377075	chr1:147258885~147517875:-
OV	cis	rs4950322	1	rs4448568	ENSG00000278811.3	LINC00624	4.19	4.04e-05	0.0159	0.37	0.27	Protein quantitative trait loci;	chr1:147377296	chr1:147258885~147517875:-
OV	cis	rs4950322	0.895	rs17356735	ENSG00000278811.3	LINC00624	4.19	4.04e-05	0.0159	0.37	0.27	Protein quantitative trait loci;	chr1:147378328	chr1:147258885~147517875:-
OV	cis	rs992157	0.798	rs10193383	ENSG00000237281.1	CATIP-AS2	-4.19	4.04e-05	0.016	-0.32	-0.27	Colorectal cancer;	chr2:218292969	chr2:218326889~218357966:-
OV	cis	rs992157	0.798	rs10206064	ENSG00000237281.1	CATIP-AS2	-4.19	4.04e-05	0.016	-0.32	-0.27	Colorectal cancer;	chr2:218293236	chr2:218326889~218357966:-
OV	cis	rs992157	0.7	rs10165153	ENSG00000237281.1	CATIP-AS2	-4.19	4.04e-05	0.016	-0.32	-0.27	Colorectal cancer;	chr2:218294906	chr2:218326889~218357966:-
OV	cis	rs9368481	0.761	rs9357030	ENSG00000241549.7	GUSBP2	-4.19	4.05e-05	0.016	-0.27	-0.27	Autism spectrum disorder or schizophrenia;	chr6:27017247	chr6:26871484~26956554:-
OV	cis	rs2834288	0.613	rs2040113	ENSG00000273102.1	AP000569.9	4.19	4.05e-05	0.016	0.28	0.27	Gut microbiota (bacterial taxa);	chr21:33908879	chr21:33967101~33968573:-
OV	cis	rs801193	0.591	rs721717	ENSG00000236529.1	RP13-254B10.1	-4.19	4.05e-05	0.016	-0.28	-0.27	Aortic root size;	chr7:66665305	chr7:65840212~65840596:+
OV	cis	rs801193	0.569	rs6951302	ENSG00000236529.1	RP13-254B10.1	-4.19	4.05e-05	0.016	-0.28	-0.27	Aortic root size;	chr7:66667525	chr7:65840212~65840596:+
OV	cis	rs2239557	0.961	rs8003212	ENSG00000259065.1	RP5-1021I20.1	4.19	4.05e-05	0.016	0.33	0.27	Common traits (Other);	chr14:74158260	chr14:73787360~73803270:+
OV	cis	rs7520050	0.966	rs11211208	ENSG00000281133.1	AL355480.3	4.19	4.05e-05	0.016	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45868584	chr1:45580892~45580996:-
OV	cis	rs801193	0.569	rs2707847	ENSG00000237310.1	GS1-124K5.4	4.19	4.05e-05	0.016	0.27	0.27	Aortic root size;	chr7:66737884	chr7:66493706~66495474:+
OV	cis	rs1538970	1	rs4660852	ENSG00000280836.1	AL355480.1	4.19	4.05e-05	0.016	0.35	0.27	Platelet count;	chr1:45383259	chr1:45581219~45581321:-
OV	cis	rs12468226	1	rs7587234	ENSG00000272966.1	RP11-686O6.1	4.19	4.05e-05	0.016	0.45	0.27	Urate levels;	chr2:202351699	chr2:202336739~202337200:+
OV	cis	rs1458175	0.967	rs7975094	ENSG00000257674.1	RP11-76E16.2	4.19	4.05e-05	0.016	0.27	0.27	Multiple sclerosis;	chr12:41569106	chr12:42286911~42288560:+
OV	cis	rs7121800	0.888	rs3781846	ENSG00000254532.1	RP11-624D11.2	4.19	4.05e-05	0.016	0.31	0.27	Pit-and-Fissure caries;	chr11:30487765	chr11:30044058~30084343:-
OV	cis	rs10924970	0.967	rs2152953	ENSG00000236863.2	RPL23AP23	4.19	4.05e-05	0.016	0.27	0.27	Asthma;	chr1:235254486	chr1:235295865~235296335:+
OV	cis	rs1458175	1	rs1458175	ENSG00000257674.1	RP11-76E16.2	4.19	4.06e-05	0.016	0.27	0.27	Multiple sclerosis;	chr12:41572059	chr12:42286911~42288560:+
OV	cis	rs7811142	1	rs76913697	ENSG00000242294.5	STAG3L5P	4.19	4.06e-05	0.016	0.28	0.27	Platelet count;	chr7:100405149	chr7:100336079~100351900:+
OV	cis	rs1167827	0.68	rs1167796	ENSG00000205583.12	STAG3L1	-4.19	4.06e-05	0.016	-0.32	-0.27	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75543861	chr7:75359194~75395383:+
OV	cis	rs11083475	0.967	rs2287729	ENSG00000267892.1	CTD-2540F13.2	4.19	4.06e-05	0.016	0.3	0.27	Heart rate;	chr19:38704674	chr19:38738284~38739863:+
OV	cis	rs801193	0.569	rs11772819	ENSG00000237310.1	GS1-124K5.4	4.19	4.07e-05	0.016	0.27	0.27	Aortic root size;	chr7:66752983	chr7:66493706~66495474:+
OV	cis	rs801193	0.569	rs11761542	ENSG00000237310.1	GS1-124K5.4	4.19	4.07e-05	0.016	0.27	0.27	Aortic root size;	chr7:66753209	chr7:66493706~66495474:+
OV	cis	rs801193	0.569	rs7800620	ENSG00000237310.1	GS1-124K5.4	4.19	4.07e-05	0.016	0.27	0.27	Aortic root size;	chr7:66758701	chr7:66493706~66495474:+
OV	cis	rs6460942	0.544	rs4719292	ENSG00000226690.5	AC005281.1	4.19	4.07e-05	0.016	0.51	0.27	Coronary artery disease;	chr7:12099990	chr7:12496429~12541910:+
OV	cis	rs4964805	0.657	rs4964813	ENSG00000257681.1	RP11-341G23.4	4.19	4.07e-05	0.016	0.29	0.27	Attention deficit hyperactivity disorder;	chr12:103795776	chr12:103746315~103768858:-
OV	cis	rs4713118	0.516	rs6931858	ENSG00000226314.6	ZNF192P1	-4.18	4.08e-05	0.0161	-0.36	-0.27	Parkinson's disease;	chr6:28110633	chr6:28161781~28169594:+
OV	cis	rs2736345	0.755	rs2736340	ENSG00000270154.1	RP11-419I17.1	4.18	4.08e-05	0.0161	0.33	0.27	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11486464	chr8:12476462~12477122:+
OV	cis	rs4787491	0.704	rs35605010	ENSG00000261367.1	RP11-455F5.4	-4.18	4.08e-05	0.0161	-0.29	-0.27	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30022107	chr16:30107675~30110541:+
OV	cis	rs4787491	0.729	rs4238960	ENSG00000261367.1	RP11-455F5.4	-4.18	4.08e-05	0.0161	-0.29	-0.27	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30027327	chr16:30107675~30110541:+
OV	cis	rs1075265	0.73	rs4413193	ENSG00000233266.1	HMGB1P31	4.18	4.08e-05	0.0161	0.33	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53710901	chr2:54051334~54051760:+
OV	cis	rs7512898	0.5	rs4915457	ENSG00000260088.1	RP11-92G12.3	-4.18	4.09e-05	0.0161	-0.3	-0.27	Electrocardiographic conduction measures;	chr1:200771742	chr1:200669507~200694250:+
OV	cis	rs821470	0.568	rs13330423	ENSG00000272372.1	RP11-441F2.5	4.18	4.09e-05	0.0161	0.32	0.27	Bipolar disorder and schizophrenia;	chr16:57017589	chr16:56351886~56353524:-
OV	cis	rs3734266	0.702	rs16895659	ENSG00000220643.1	RP3-391O22.1	-4.18	4.09e-05	0.0161	-0.42	-0.27	Systemic lupus erythematosus;	chr6:34923091	chr6:34686602~34687106:+
OV	cis	rs3734266	0.702	rs28360525	ENSG00000220643.1	RP3-391O22.1	-4.18	4.09e-05	0.0161	-0.42	-0.27	Systemic lupus erythematosus;	chr6:34923261	chr6:34686602~34687106:+
OV	cis	rs3734266	0.702	rs6457797	ENSG00000220643.1	RP3-391O22.1	-4.18	4.09e-05	0.0161	-0.42	-0.27	Systemic lupus erythematosus;	chr6:34929397	chr6:34686602~34687106:+
OV	cis	rs3734266	0.702	rs6457798	ENSG00000220643.1	RP3-391O22.1	-4.18	4.09e-05	0.0161	-0.42	-0.27	Systemic lupus erythematosus;	chr6:34929422	chr6:34686602~34687106:+
OV	cis	rs11109072	0.655	rs1420395	ENSG00000257167.2	TMPO-AS1	4.18	4.09e-05	0.0161	0.46	0.27	Obesity (early onset extreme);	chr12:97682225	chr12:98512973~98516422:-
OV	cis	rs12073359	0.955	rs1964542	ENSG00000223945.2	RP11-458I7.1	-4.18	4.09e-05	0.0161	-0.39	-0.27	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150053851	chr1:150053864~150055034:+
OV	cis	rs875971	0.862	rs4718330	ENSG00000236529.1	RP13-254B10.1	-4.18	4.1e-05	0.0161	-0.28	-0.27	Aortic root size;	chr7:66250256	chr7:65840212~65840596:+
OV	cis	rs4664293	0.51	rs3903306	ENSG00000226266.5	AC009961.3	4.18	4.1e-05	0.0161	0.32	0.27	Monocyte percentage of white cells;	chr2:159592171	chr2:159670708~159712435:-
OV	cis	rs9992667	1	rs68191221	ENSG00000231160.8	KLF3-AS1	4.18	4.1e-05	0.0161	0.33	0.27	Eosinophil percentage of granulocytes;	chr4:38675441	chr4:38612701~38664883:-
OV	cis	rs10740039	0.768	rs7895268	ENSG00000254271.1	RP11-131N11.4	4.18	4.1e-05	0.0161	0.34	0.27	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60703479	chr10:60734342~60741828:+
OV	cis	rs9287719	0.601	rs6755281	ENSG00000243819.4	RN7SL832P	4.18	4.1e-05	0.0161	0.28	0.27	Prostate cancer;	chr2:10629729	chr2:10690344~10692099:+
OV	cis	rs733592	0.507	rs7304428	ENSG00000240399.1	RP1-228P16.1	-4.18	4.1e-05	0.0161	-0.29	-0.27	Plateletcrit;	chr12:48100492	chr12:48054813~48055591:-
OV	cis	rs2070488	1	rs7433707	ENSG00000229589.1	ACVR2B-AS1	4.18	4.1e-05	0.0161	0.3	0.27	Electrocardiographic conduction measures;	chr3:38401689	chr3:38451027~38454820:-
OV	cis	rs2070488	0.932	rs4678604	ENSG00000229589.1	ACVR2B-AS1	4.18	4.1e-05	0.0161	0.3	0.27	Electrocardiographic conduction measures;	chr3:38402782	chr3:38451027~38454820:-
OV	cis	rs78545713	0.649	rs79662647	ENSG00000241549.7	GUSBP2	-4.18	4.1e-05	0.0161	-0.46	-0.27	Iron status biomarkers (total iron binding capacity);	chr6:26217617	chr6:26871484~26956554:-
OV	cis	rs78545713	0.649	rs114015443	ENSG00000241549.7	GUSBP2	-4.18	4.1e-05	0.0161	-0.46	-0.27	Iron status biomarkers (total iron binding capacity);	chr6:26221751	chr6:26871484~26956554:-
OV	cis	rs78545713	0.649	rs77727979	ENSG00000241549.7	GUSBP2	-4.18	4.1e-05	0.0161	-0.46	-0.27	Iron status biomarkers (total iron binding capacity);	chr6:26221798	chr6:26871484~26956554:-
OV	cis	rs78545713	0.541	rs111465843	ENSG00000241549.7	GUSBP2	-4.18	4.1e-05	0.0161	-0.46	-0.27	Iron status biomarkers (total iron binding capacity);	chr6:26222595	chr6:26871484~26956554:-
OV	cis	rs78545713	0.649	rs113407109	ENSG00000241549.7	GUSBP2	-4.18	4.1e-05	0.0161	-0.46	-0.27	Iron status biomarkers (total iron binding capacity);	chr6:26224175	chr6:26871484~26956554:-
OV	cis	rs78545713	0.649	rs77362785	ENSG00000241549.7	GUSBP2	-4.18	4.1e-05	0.0161	-0.46	-0.27	Iron status biomarkers (total iron binding capacity);	chr6:26232123	chr6:26871484~26956554:-
OV	cis	rs4927850	1	rs4927850	ENSG00000207650.1	MIR570	-4.18	4.1e-05	0.0161	-0.31	-0.27	Pancreatic cancer;	chr3:196024759	chr3:195699401~195699497:+
OV	cis	rs881375	1	rs1609810	ENSG00000226752.6	PSMD5-AS1	-4.18	4.1e-05	0.0161	-0.29	-0.27	Rheumatoid arthritis;	chr9:120880073	chr9:120824828~120854385:+
OV	cis	rs881375	1	rs10818480	ENSG00000226752.6	PSMD5-AS1	-4.18	4.1e-05	0.0161	-0.29	-0.27	Rheumatoid arthritis;	chr9:120880892	chr9:120824828~120854385:+
OV	cis	rs7617773	0.709	rs4404473	ENSG00000228638.1	FCF1P2	-4.18	4.1e-05	0.0161	-0.35	-0.27	Coronary artery disease;	chr3:48312136	chr3:48290793~48291375:-
OV	cis	rs853679	0.517	rs4713135	ENSG00000226314.6	ZNF192P1	-4.18	4.11e-05	0.0162	-0.35	-0.27	Depression;	chr6:28071808	chr6:28161781~28169594:+
OV	cis	rs7267979	1	rs2500436	ENSG00000274973.1	RP13-401N8.7	4.18	4.11e-05	0.0162	0.3	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25425730	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6083856	ENSG00000274973.1	RP13-401N8.7	4.18	4.11e-05	0.0162	0.3	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25426949	chr20:25845497~25845862:+
OV	cis	rs9810089	0.708	rs619605	ENSG00000261758.1	RP11-102M11.2	4.18	4.11e-05	0.0162	0.31	0.27	Gestational age at birth (child effect);	chr3:136368170	chr3:136752630~136755780:+
OV	cis	rs4787491	0.679	rs12933575	ENSG00000261367.1	RP11-455F5.4	-4.18	4.11e-05	0.0162	-0.3	-0.27	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30011243	chr16:30107675~30110541:+
OV	cis	rs4787491	0.729	rs7191849	ENSG00000261367.1	RP11-455F5.4	-4.18	4.11e-05	0.0162	-0.3	-0.27	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30011836	chr16:30107675~30110541:+
OV	cis	rs1707322	0.716	rs10890342	ENSG00000234329.1	RP11-767N6.2	4.18	4.12e-05	0.0162	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45691415	chr1:45651039~45651826:-
OV	cis	rs1707322	0.752	rs6658700	ENSG00000234329.1	RP11-767N6.2	4.18	4.12e-05	0.0162	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45694588	chr1:45651039~45651826:-
OV	cis	rs1707322	0.752	rs12047629	ENSG00000234329.1	RP11-767N6.2	4.18	4.12e-05	0.0162	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697130	chr1:45651039~45651826:-
OV	cis	rs1707322	0.752	rs11211168	ENSG00000234329.1	RP11-767N6.2	4.18	4.12e-05	0.0162	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697975	chr1:45651039~45651826:-
OV	cis	rs1707322	0.752	rs11211169	ENSG00000234329.1	RP11-767N6.2	4.18	4.12e-05	0.0162	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701037	chr1:45651039~45651826:-
OV	cis	rs1707322	0.752	rs11211171	ENSG00000234329.1	RP11-767N6.2	4.18	4.12e-05	0.0162	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45702970	chr1:45651039~45651826:-
OV	cis	rs1707322	0.716	rs28370457	ENSG00000234329.1	RP11-767N6.2	4.18	4.12e-05	0.0162	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706390	chr1:45651039~45651826:-
OV	cis	rs10770152	0.932	rs12226859	ENSG00000177112.6	MRVI1-AS1	-4.18	4.12e-05	0.0162	-0.32	-0.27	Caudate activity during reward;	chr11:10995017	chr11:10541272~10599932:+
OV	cis	rs4718428	1	rs12534637	ENSG00000222364.1	RNU6-96P	-4.18	4.12e-05	0.0162	-0.3	-0.27	Corneal structure;	chr7:66862667	chr7:66395191~66395286:+
OV	cis	rs7567389	0.6	rs72845979	ENSG00000236682.1	AC068282.3	-4.18	4.12e-05	0.0162	-0.37	-0.27	Self-rated health;	chr2:127338178	chr2:127389130~127400580:+
OV	cis	rs9326248	0.954	rs4938349	ENSG00000280143.1	AP000892.6	4.18	4.12e-05	0.0162	0.3	0.27	Blood protein levels;	chr11:117151207	chr11:117204967~117210292:+
OV	cis	rs12073359	1	rs1545762	ENSG00000223945.2	RP11-458I7.1	4.18	4.12e-05	0.0162	0.4	0.27	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150156231	chr1:150053864~150055034:+
OV	cis	rs7017914	0.69	rs7003794	ENSG00000223220.1	Y_RNA	4.18	4.12e-05	0.0162	0.28	0.27	Bone mineral density;	chr8:70876911	chr8:70780914~70781008:-
OV	cis	rs10992471	0.603	rs10116813	ENSG00000281156.1	MIR3651	-4.18	4.13e-05	0.0162	-0.31	-0.27	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92328078	chr9:92292458~92292547:-
OV	cis	rs9287719	0.601	rs12995465	ENSG00000243819.4	RN7SL832P	4.18	4.13e-05	0.0162	0.28	0.27	Prostate cancer;	chr2:10576702	chr2:10690344~10692099:+
OV	cis	rs732765	0.819	rs2058920	ENSG00000258439.1	RP11-173A8.2	-4.18	4.13e-05	0.0162	-0.35	-0.27	Non-small cell lung cancer;	chr14:74844626	chr14:74658049~74658590:+
OV	cis	rs2243480	1	rs465359	ENSG00000226824.5	RP4-756H11.3	-4.18	4.13e-05	0.0162	-0.43	-0.27	Diabetic kidney disease;	chr7:66093177	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs462853	ENSG00000226824.5	RP4-756H11.3	-4.18	4.13e-05	0.0162	-0.43	-0.27	Diabetic kidney disease;	chr7:66093180	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs160644	ENSG00000226824.5	RP4-756H11.3	-4.18	4.13e-05	0.0162	-0.43	-0.27	Diabetic kidney disease;	chr7:66093199	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs160642	ENSG00000226824.5	RP4-756H11.3	-4.18	4.13e-05	0.0162	-0.43	-0.27	Diabetic kidney disease;	chr7:66093386	chr7:66654538~66669855:+
OV	cis	rs2243480	0.614	rs34032527	ENSG00000226824.5	RP4-756H11.3	-4.18	4.13e-05	0.0162	-0.43	-0.27	Diabetic kidney disease;	chr7:66100154	chr7:66654538~66669855:+
OV	cis	rs1723838	0.826	rs1723844	ENSG00000255928.1	RP11-456I15.2	4.18	4.13e-05	0.0162	0.57	0.27	Obesity-related traits;	chr11:73758532	chr11:73722349~73722694:+
OV	cis	rs1723838	0.826	rs1525751	ENSG00000255928.1	RP11-456I15.2	4.18	4.13e-05	0.0162	0.57	0.27	Obesity-related traits;	chr11:73758816	chr11:73722349~73722694:+
OV	cis	rs1723838	0.826	rs1525750	ENSG00000255928.1	RP11-456I15.2	4.18	4.13e-05	0.0162	0.57	0.27	Obesity-related traits;	chr11:73758831	chr11:73722349~73722694:+
OV	cis	rs1723838	0.826	rs1723842	ENSG00000255928.1	RP11-456I15.2	4.18	4.13e-05	0.0162	0.57	0.27	Obesity-related traits;	chr11:73760340	chr11:73722349~73722694:+
OV	cis	rs1723838	0.826	rs1723839	ENSG00000255928.1	RP11-456I15.2	4.18	4.13e-05	0.0162	0.57	0.27	Obesity-related traits;	chr11:73765678	chr11:73722349~73722694:+
OV	cis	rs1723838	0.609	rs4944857	ENSG00000255928.1	RP11-456I15.2	-4.18	4.13e-05	0.0162	-0.57	-0.27	Obesity-related traits;	chr11:73706243	chr11:73722349~73722694:+
OV	cis	rs1723838	0.702	rs4944859	ENSG00000255928.1	RP11-456I15.2	-4.18	4.13e-05	0.0162	-0.57	-0.27	Obesity-related traits;	chr11:73713090	chr11:73722349~73722694:+
OV	cis	rs1723838	0.826	rs4944860	ENSG00000255928.1	RP11-456I15.2	-4.18	4.13e-05	0.0162	-0.57	-0.27	Obesity-related traits;	chr11:73716081	chr11:73722349~73722694:+
OV	cis	rs1723838	0.826	rs1404975	ENSG00000255928.1	RP11-456I15.2	-4.18	4.13e-05	0.0162	-0.57	-0.27	Obesity-related traits;	chr11:73722089	chr11:73722349~73722694:+
OV	cis	rs1723838	0.623	rs9634024	ENSG00000255928.1	RP11-456I15.2	-4.18	4.13e-05	0.0162	-0.57	-0.27	Obesity-related traits;	chr11:73728714	chr11:73722349~73722694:+
OV	cis	rs11673344	0.502	rs62108306	ENSG00000267422.1	CTD-2554C21.1	4.18	4.14e-05	0.0162	0.27	0.27	Obesity-related traits;	chr19:37691789	chr19:37779686~37792865:+
OV	cis	rs10978777	0.805	rs7031904	ENSG00000276883.1	AL137852.1	-4.18	4.14e-05	0.0162	-0.29	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107287195	chr9:107292369~107292456:-
OV	cis	rs10978777	0.805	rs7031906	ENSG00000276883.1	AL137852.1	-4.18	4.14e-05	0.0162	-0.29	-0.27	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107287196	chr9:107292369~107292456:-
OV	cis	rs801193	0.967	rs2707853	ENSG00000224316.1	RP11-479O9.2	4.18	4.14e-05	0.0163	0.29	0.27	Aortic root size;	chr7:66749023	chr7:65773620~65802067:+
OV	cis	rs7520050	1	rs12143096	ENSG00000281133.1	AL355480.3	4.18	4.14e-05	0.0163	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:46004091	chr1:45580892~45580996:-
OV	cis	rs7520050	0.897	rs4440807	ENSG00000281133.1	AL355480.3	4.18	4.14e-05	0.0163	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:46005206	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs12049588	ENSG00000281133.1	AL355480.3	4.18	4.14e-05	0.0163	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:46006750	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs12021587	ENSG00000281133.1	AL355480.3	4.18	4.14e-05	0.0163	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:46007087	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs11810993	ENSG00000281133.1	AL355480.3	4.18	4.14e-05	0.0163	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:46013121	chr1:45580892~45580996:-
OV	cis	rs7520050	0.898	rs34175029	ENSG00000281133.1	AL355480.3	4.18	4.14e-05	0.0163	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:46018199	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs946529	ENSG00000281133.1	AL355480.3	4.18	4.14e-05	0.0163	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:46019876	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs2275426	ENSG00000281133.1	AL355480.3	4.18	4.14e-05	0.0163	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:46021880	chr1:45580892~45580996:-
OV	cis	rs7267979	1	rs6050565	ENSG00000274973.1	RP13-401N8.7	4.18	4.15e-05	0.0163	0.3	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25366927	chr20:25845497~25845862:+
OV	cis	rs1979679	0.573	rs7315906	ENSG00000278733.1	RP11-425D17.1	-4.18	4.15e-05	0.0163	-0.32	-0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28575612	chr12:28185625~28186190:-
OV	cis	rs875971	0.825	rs6951503	ENSG00000236529.1	RP13-254B10.1	-4.18	4.15e-05	0.0163	-0.28	-0.27	Aortic root size;	chr7:66253949	chr7:65840212~65840596:+
OV	cis	rs1363119	1	rs59384167	ENSG00000268199.2	CTD-3137H5.1	-4.18	4.15e-05	0.0163	-0.27	-0.27	Intelligence (multi-trait analysis);	chr19:18333708	chr19:18441419~18443597:+
OV	cis	rs1797885	0.564	rs2596819	ENSG00000251774.1	RNU6-377P	4.18	4.15e-05	0.0163	0.25	0.27	Immature fraction of reticulocytes;	chr3:12559030	chr3:12514706~12514807:+
OV	cis	rs514406	0.683	rs10157120	ENSG00000206627.1	RNU6-969P	4.18	4.16e-05	0.0163	0.29	0.27	Monocyte count;	chr1:52745216	chr1:52805108~52805212:-
OV	cis	rs853679	0.517	rs4711164	ENSG00000226314.6	ZNF192P1	-4.18	4.16e-05	0.0163	-0.37	-0.27	Depression;	chr6:28147378	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs4711165	ENSG00000226314.6	ZNF192P1	-4.18	4.16e-05	0.0163	-0.37	-0.27	Depression;	chr6:28147406	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs4713148	ENSG00000226314.6	ZNF192P1	-4.18	4.16e-05	0.0163	-0.37	-0.27	Depression;	chr6:28148143	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9348794	ENSG00000226314.6	ZNF192P1	-4.18	4.16e-05	0.0163	-0.37	-0.27	Depression;	chr6:28149979	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9468297	ENSG00000226314.6	ZNF192P1	-4.18	4.16e-05	0.0163	-0.37	-0.27	Depression;	chr6:28151096	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9295758	ENSG00000226314.6	ZNF192P1	-4.18	4.16e-05	0.0163	-0.37	-0.27	Depression;	chr6:28152885	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs17774663	ENSG00000226314.6	ZNF192P1	-4.18	4.16e-05	0.0163	-0.37	-0.27	Depression;	chr6:28153120	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9468298	ENSG00000226314.6	ZNF192P1	-4.18	4.16e-05	0.0163	-0.37	-0.27	Depression;	chr6:28154567	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9295759	ENSG00000226314.6	ZNF192P1	-4.18	4.16e-05	0.0163	-0.37	-0.27	Depression;	chr6:28156691	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9348796	ENSG00000226314.6	ZNF192P1	-4.18	4.16e-05	0.0163	-0.37	-0.27	Depression;	chr6:28158424	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs11552219	ENSG00000226314.6	ZNF192P1	-4.18	4.16e-05	0.0163	-0.37	-0.27	Depression;	chr6:28159056	chr6:28161781~28169594:+
OV	cis	rs7512898	0.5	rs7519783	ENSG00000260088.1	RP11-92G12.3	-4.18	4.16e-05	0.0163	-0.29	-0.27	Electrocardiographic conduction measures;	chr1:200715929	chr1:200669507~200694250:+
OV	cis	rs17767294	0.708	rs72848766	ENSG00000219392.1	RP1-265C24.5	-4.18	4.17e-05	0.0163	-0.58	-0.27	Parkinson's disease;	chr6:27940978	chr6:28115628~28116551:+
OV	cis	rs17767294	0.708	rs72848772	ENSG00000219392.1	RP1-265C24.5	-4.18	4.17e-05	0.0163	-0.58	-0.27	Parkinson's disease;	chr6:27953170	chr6:28115628~28116551:+
OV	cis	rs295490	0.748	rs1602626	ENSG00000272656.1	RP11-219D15.3	-4.18	4.17e-05	0.0163	-0.49	-0.27	PR interval in Tripanosoma cruzi seropositivity;	chr3:139364928	chr3:139349024~139349371:-
OV	cis	rs4763879	0.778	rs9332411	ENSG00000256673.1	RP11-599J14.2	4.18	4.17e-05	0.0163	0.26	0.27	Type 1 diabetes;	chr12:9681749	chr12:9398355~9414851:-
OV	cis	rs875971	0.929	rs34406470	ENSG00000224316.1	RP11-479O9.2	4.18	4.17e-05	0.0163	0.29	0.27	Aortic root size;	chr7:66464969	chr7:65773620~65802067:+
OV	cis	rs875971	0.545	rs73376394	ENSG00000237310.1	GS1-124K5.4	4.18	4.17e-05	0.0163	0.3	0.27	Aortic root size;	chr7:66172694	chr7:66493706~66495474:+
OV	cis	rs2117029	0.727	rs10875910	ENSG00000258017.1	RP11-386G11.10	-4.18	4.17e-05	0.0163	-0.36	-0.27	Intelligence (multi-trait analysis);	chr12:49008610	chr12:49127782~49147869:+
OV	cis	rs10462065	0.748	rs72750185	ENSG00000249779.1	RP11-447H19.3	-4.18	4.17e-05	0.0164	-0.51	-0.27	Nonsyndromic cleft lip with cleft palate;	chr5:44054018	chr5:43206709~43207811:+
OV	cis	rs853679	0.766	rs9368561	ENSG00000226314.6	ZNF192P1	-4.18	4.17e-05	0.0164	-0.49	-0.27	Depression;	chr6:28200565	chr6:28161781~28169594:+
OV	cis	rs4938303	0.671	rs2008915	ENSG00000254851.1	RP11-109L13.1	-4.18	4.17e-05	0.0164	-0.41	-0.27	Triglycerides;	chr11:116732418	chr11:117135528~117138582:+
OV	cis	rs72615157	0.697	rs2056726	ENSG00000242294.5	STAG3L5P	4.18	4.17e-05	0.0164	0.25	0.27	Lung function (FEV1/FVC);	chr7:100182660	chr7:100336079~100351900:+
OV	cis	rs13118159	1	rs13118159	ENSG00000272927.1	RP11-1191J2.5	4.18	4.18e-05	0.0164	0.31	0.27	Longevity;	chr4:1371339	chr4:661209~661945:-
OV	cis	rs1823913	1	rs12623832	ENSG00000227542.1	AC092614.2	-4.18	4.18e-05	0.0164	-0.31	-0.27	Obesity-related traits;	chr2:191260918	chr2:191229165~191246172:-
OV	cis	rs1030877	0.515	rs2679895	ENSG00000235319.1	AC012360.4	-4.18	4.18e-05	0.0164	-0.37	-0.27	Obesity-related traits;	chr2:105290023	chr2:105324210~105330529:+
OV	cis	rs11159086	1	rs11159086	ENSG00000270000.1	RP3-449M8.9	4.18	4.18e-05	0.0164	0.41	0.27	Advanced glycation end-product levels;	chr14:74495572	chr14:74471930~74472360:-
OV	cis	rs881375	0.934	rs1468671	ENSG00000226752.6	PSMD5-AS1	-4.18	4.18e-05	0.0164	-0.3	-0.27	Rheumatoid arthritis;	chr9:120895224	chr9:120824828~120854385:+
OV	cis	rs6128386	0.597	rs6100139	ENSG00000268941.2	RP5-907D15.4	4.18	4.18e-05	0.0164	0.4	0.27	Response to cytadine analogues (cytosine arabinoside);	chr20:58620413	chr20:58634772~58635738:+
OV	cis	rs61784830	0.539	rs61784820	ENSG00000280836.1	AL355480.1	-4.18	4.19e-05	0.0164	-0.61	-0.27	Iron status biomarkers (total iron binding capacity);	chr1:45732541	chr1:45581219~45581321:-
OV	cis	rs1823913	0.538	rs11892998	ENSG00000227542.1	AC092614.2	4.18	4.19e-05	0.0164	0.31	0.27	Obesity-related traits;	chr2:191340159	chr2:191229165~191246172:-
OV	cis	rs1823913	0.538	rs13432697	ENSG00000227542.1	AC092614.2	4.18	4.19e-05	0.0164	0.31	0.27	Obesity-related traits;	chr2:191345944	chr2:191229165~191246172:-
OV	cis	rs4664293	0.625	rs4665102	ENSG00000224152.1	AC009506.1	4.18	4.19e-05	0.0164	0.27	0.27	Monocyte percentage of white cells;	chr2:159666076	chr2:159615296~159617082:+
OV	cis	rs6569038	0.533	rs12526935	ENSG00000253194.1	RP11-351A11.1	-4.18	4.19e-05	0.0164	-0.3	-0.27	Epstein-Barr virus copy number in lymphoblastoid cell lines;	chr6:119052747	chr6:118934785~119031541:+
OV	cis	rs6088590	0.735	rs6060003	ENSG00000206582.1	Y_RNA	-4.18	4.19e-05	0.0164	-0.33	-0.27	Coronary artery disease;	chr20:34707141	chr20:34526510~34526606:-
OV	cis	rs2117029	0.965	rs2293446	ENSG00000258017.1	RP11-386G11.10	-4.18	4.2e-05	0.0164	-0.34	-0.27	Intelligence (multi-trait analysis);	chr12:49018926	chr12:49127782~49147869:+
OV	cis	rs2185570	0.543	rs34254643	ENSG00000234724.1	HDAC1P1	4.18	4.2e-05	0.0164	0.49	0.27	Dehydroepiandrosterone sulphate levels;	chr10:95122875	chr10:94137748~94139500:+
OV	cis	rs992157	0.798	rs1017698	ENSG00000237281.1	CATIP-AS2	4.18	4.2e-05	0.0164	0.31	0.27	Colorectal cancer;	chr2:218305802	chr2:218326889~218357966:-
OV	cis	rs11083475	1	rs3786845	ENSG00000267892.1	CTD-2540F13.2	4.18	4.2e-05	0.0164	0.3	0.27	Heart rate;	chr19:38704443	chr19:38738284~38739863:+
OV	cis	rs853679	0.76	rs9468317	ENSG00000219392.1	RP1-265C24.5	-4.18	4.2e-05	0.0165	-0.39	-0.27	Depression;	chr6:28230678	chr6:28115628~28116551:+
OV	cis	rs875971	0.862	rs10282433	ENSG00000236529.1	RP13-254B10.1	-4.18	4.2e-05	0.0165	-0.28	-0.27	Aortic root size;	chr7:66256452	chr7:65840212~65840596:+
OV	cis	rs11951515	0.7	rs7714027	ENSG00000278487.1	RP11-447H19.4	-4.18	4.21e-05	0.0165	-0.31	-0.27	Metabolite levels  (X-11787);	chr5:43373116	chr5:43143362~43143514:-
OV	cis	rs875971	1	rs9986696	ENSG00000236529.1	RP13-254B10.1	-4.18	4.21e-05	0.0165	-0.28	-0.27	Aortic root size;	chr7:66239589	chr7:65840212~65840596:+
OV	cis	rs7200543	1	rs1135999	ENSG00000270580.4	PKD1P6	4.18	4.21e-05	0.0165	0.28	0.27	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038105	chr16:15104723~15131601:-
OV	cis	rs7200543	1	rs34614532	ENSG00000270580.4	PKD1P6	4.18	4.21e-05	0.0165	0.28	0.27	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15039051	chr16:15104723~15131601:-
OV	cis	rs7017914	0.69	rs6984056	ENSG00000223220.1	Y_RNA	4.18	4.21e-05	0.0165	0.28	0.27	Bone mineral density;	chr8:70858886	chr8:70780914~70781008:-
OV	cis	rs875971	0.545	rs1796222	ENSG00000236529.1	RP13-254B10.1	-4.18	4.21e-05	0.0165	-0.32	-0.27	Aortic root size;	chr7:66592167	chr7:65840212~65840596:+
OV	cis	rs11951515	0.738	rs55759097	ENSG00000278487.1	RP11-447H19.4	-4.18	4.21e-05	0.0165	-0.31	-0.27	Metabolite levels  (X-11787);	chr5:43371762	chr5:43143362~43143514:-
OV	cis	rs11951515	0.714	rs11956635	ENSG00000278487.1	RP11-447H19.4	-4.18	4.21e-05	0.0165	-0.31	-0.27	Metabolite levels  (X-11787);	chr5:43371926	chr5:43143362~43143514:-
OV	cis	rs11951515	0.738	rs11950040	ENSG00000278487.1	RP11-447H19.4	-4.18	4.21e-05	0.0165	-0.31	-0.27	Metabolite levels  (X-11787);	chr5:43372087	chr5:43143362~43143514:-
OV	cis	rs801193	0.548	rs7805152	ENSG00000237310.1	GS1-124K5.4	4.18	4.21e-05	0.0165	0.27	0.27	Aortic root size;	chr7:66744266	chr7:66493706~66495474:+
OV	cis	rs73186030	1	rs73186044	ENSG00000272758.4	RP11-299J3.8	4.18	4.21e-05	0.0165	0.33	0.27	Serum parathyroid hormone levels;	chr3:122309629	chr3:122416207~122443180:+
OV	cis	rs638893	0.842	rs480791	ENSG00000278376.1	RP11-158I9.8	-4.18	4.21e-05	0.0165	-0.35	-0.27	Vitiligo;	chr11:118833546	chr11:118791254~118793137:+
OV	cis	rs9876781	0.559	rs7610524	ENSG00000244380.1	RP11-24C3.2	4.18	4.21e-05	0.0165	0.33	0.27	Longevity;	chr3:48353882	chr3:48440352~48446656:-
OV	cis	rs2898681	1	rs2046364	ENSG00000248375.1	RP11-177B4.1	-4.18	4.22e-05	0.0165	-0.39	-0.27	Optic nerve measurement (cup area);	chr4:52877051	chr4:52720081~52720831:-
OV	cis	rs14027	0.921	rs13261032	ENSG00000279347.1	RP11-85I17.2	-4.18	4.22e-05	0.0165	-0.28	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119733117	chr8:119838736~119840385:-
OV	cis	rs14027	0.921	rs2048239	ENSG00000279347.1	RP11-85I17.2	-4.18	4.22e-05	0.0165	-0.28	-0.27	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119735701	chr8:119838736~119840385:-
OV	cis	rs11992162	0.56	rs13256329	ENSG00000270154.1	RP11-419I17.1	-4.18	4.23e-05	0.0165	-0.27	-0.27	Monocyte count;	chr8:11924705	chr8:12476462~12477122:+
OV	cis	rs10435719	0.638	rs67146188	ENSG00000270154.1	RP11-419I17.1	-4.18	4.23e-05	0.0165	-0.27	-0.27	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11924924	chr8:12476462~12477122:+
OV	cis	rs10435719	0.58	rs13260712	ENSG00000270154.1	RP11-419I17.1	-4.18	4.23e-05	0.0165	-0.27	-0.27	C-reactive protein levels or triglyceride levels (pleiotropy);	chr8:11925061	chr8:12476462~12477122:+
OV	cis	rs11992162	0.551	rs13268217	ENSG00000270154.1	RP11-419I17.1	-4.18	4.23e-05	0.0165	-0.27	-0.27	Monocyte count;	chr8:11925100	chr8:12476462~12477122:+
OV	cis	rs11992162	0.573	rs13264994	ENSG00000270154.1	RP11-419I17.1	-4.18	4.23e-05	0.0165	-0.27	-0.27	Monocyte count;	chr8:11925250	chr8:12476462~12477122:+
OV	cis	rs11992162	0.573	rs13275808	ENSG00000270154.1	RP11-419I17.1	-4.18	4.23e-05	0.0165	-0.27	-0.27	Monocyte count;	chr8:11925306	chr8:12476462~12477122:+
OV	cis	rs7554511	0.555	rs11807626	ENSG00000223774.4	RP11-307B6.3	-4.18	4.23e-05	0.0165	-0.3	-0.27	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201031226	chr1:201893842~201899978:+
OV	cis	rs295137	0.752	rs10931892	ENSG00000232732.8	AC073043.1	4.18	4.23e-05	0.0165	0.31	0.27	Asthma (bronchodilator response);	chr2:200240274	chr2:199867396~199911159:-
OV	cis	rs2239557	1	rs75824542	ENSG00000259065.1	RP5-1021I20.1	-4.18	4.23e-05	0.0165	-0.33	-0.27	Common traits (Other);	chr14:74056344	chr14:73787360~73803270:+
OV	cis	rs2239557	1	rs2072293	ENSG00000259065.1	RP5-1021I20.1	-4.18	4.23e-05	0.0165	-0.33	-0.27	Common traits (Other);	chr14:74071182	chr14:73787360~73803270:+
OV	cis	rs12073359	1	rs4058847	ENSG00000223945.2	RP11-458I7.1	4.18	4.23e-05	0.0166	0.4	0.27	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150086641	chr1:150053864~150055034:+
OV	cis	rs875971	0.545	rs2420612	ENSG00000237310.1	GS1-124K5.4	4.18	4.24e-05	0.0166	0.31	0.27	Aortic root size;	chr7:66536825	chr7:66493706~66495474:+
OV	cis	rs10924970	0.625	rs2789370	ENSG00000236863.2	RPL23AP23	4.18	4.24e-05	0.0166	0.28	0.27	Asthma;	chr1:235339941	chr1:235295865~235296335:+
OV	cis	rs2919917	0.628	rs1021157	ENSG00000254352.1	RP11-578O24.2	4.18	4.24e-05	0.0166	0.35	0.27	Lymphocyte counts;	chr8:78662938	chr8:78723796~78724136:-
OV	cis	rs494459	0.536	rs11217063	ENSG00000255422.1	AP002954.4	-4.18	4.24e-05	0.0166	-0.31	-0.27	Height;	chr11:118855233	chr11:118704607~118750263:+
OV	cis	rs72622154	1	rs57907751	ENSG00000275981.1	EGOT	-4.18	4.24e-05	0.0166	-0.59	-0.27	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr3:4614972	chr3:4750333~4750685:+
OV	cis	rs13113518	0.812	rs7667741	ENSG00000223305.1	RN7SKP30	4.18	4.24e-05	0.0166	0.32	0.27	Height;	chr4:55544621	chr4:55540502~55540835:-
OV	cis	rs4845570	1	rs11585294	ENSG00000203288.3	RP11-98D18.9	-4.18	4.24e-05	0.0166	-0.46	-0.27	Coronary artery disease;	chr1:151797411	chr1:151790804~151794402:+
OV	cis	rs801193	1	rs2707850	ENSG00000224316.1	RP11-479O9.2	4.18	4.24e-05	0.0166	0.29	0.27	Aortic root size;	chr7:66738883	chr7:65773620~65802067:+
OV	cis	rs801193	0.967	rs1110414	ENSG00000224316.1	RP11-479O9.2	4.18	4.24e-05	0.0166	0.29	0.27	Aortic root size;	chr7:66740595	chr7:65773620~65802067:+
OV	cis	rs801193	1	rs7783924	ENSG00000224316.1	RP11-479O9.2	4.18	4.24e-05	0.0166	0.29	0.27	Aortic root size;	chr7:66744070	chr7:65773620~65802067:+
OV	cis	rs801193	1	rs7789184	ENSG00000224316.1	RP11-479O9.2	4.18	4.24e-05	0.0166	0.29	0.27	Aortic root size;	chr7:66745208	chr7:65773620~65802067:+
OV	cis	rs801193	1	rs2707856	ENSG00000224316.1	RP11-479O9.2	4.18	4.24e-05	0.0166	0.29	0.27	Aortic root size;	chr7:66746023	chr7:65773620~65802067:+
OV	cis	rs801193	1	rs2707854	ENSG00000224316.1	RP11-479O9.2	4.18	4.24e-05	0.0166	0.29	0.27	Aortic root size;	chr7:66747610	chr7:65773620~65802067:+
OV	cis	rs7200543	1	rs6498540	ENSG00000270580.4	PKD1P6	4.18	4.25e-05	0.0166	0.28	0.27	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036737	chr16:15104723~15131601:-
OV	cis	rs2288061	0.676	rs9937270	ENSG00000244485.1	RPL18P13	4.18	4.25e-05	0.0166	0.33	0.27	Delta-5 desaturase activity;	chr16:76061037	chr16:76235055~76235623:-
OV	cis	rs17767294	0.708	rs72848766	ENSG00000220721.1	OR1F12	4.18	4.25e-05	0.0166	0.55	0.27	Parkinson's disease;	chr6:27940978	chr6:28073316~28074233:+
OV	cis	rs17767294	0.708	rs72848772	ENSG00000220721.1	OR1F12	4.18	4.25e-05	0.0166	0.55	0.27	Parkinson's disease;	chr6:27953170	chr6:28073316~28074233:+
OV	cis	rs11700536	1	rs11700536	ENSG00000236663.1	AP001631.9	-4.18	4.25e-05	0.0166	-0.29	-0.27	Interleukin-18 levels;	chr21:43138577	chr21:43140523~43141092:-
OV	cis	rs801193	0.569	rs13226966	ENSG00000237310.1	GS1-124K5.4	4.18	4.25e-05	0.0166	0.27	0.27	Aortic root size;	chr7:66768636	chr7:66493706~66495474:+
OV	cis	rs9287719	0.601	rs9287718	ENSG00000243819.4	RN7SL832P	-4.18	4.25e-05	0.0166	-0.27	-0.27	Prostate cancer;	chr2:10561503	chr2:10690344~10692099:+
OV	cis	rs12073359	0.913	rs4926406	ENSG00000223945.2	RP11-458I7.1	4.17	4.25e-05	0.0166	0.4	0.27	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150074899	chr1:150053864~150055034:+
OV	cis	rs6907340	0.517	rs6939160	ENSG00000227116.1	RP3-471C18.1	-4.17	4.25e-05	0.0166	-0.32	-0.27	Endometriosis;	chr6:19802086	chr6:19730427~19734567:-
OV	cis	rs11673344	0.536	rs7259272	ENSG00000267422.1	CTD-2554C21.1	4.17	4.26e-05	0.0166	0.27	0.27	Obesity-related traits;	chr19:37692214	chr19:37779686~37792865:+
OV	cis	rs733592	0.524	rs10875741	ENSG00000240399.1	RP1-228P16.1	-4.17	4.26e-05	0.0166	-0.29	-0.27	Plateletcrit;	chr12:48099139	chr12:48054813~48055591:-
OV	cis	rs13113518	0.783	rs11943206	ENSG00000223305.1	RN7SKP30	4.17	4.26e-05	0.0166	0.31	0.27	Height;	chr4:55570843	chr4:55540502~55540835:-
OV	cis	rs2919917	0.628	rs10111658	ENSG00000254352.1	RP11-578O24.2	4.17	4.26e-05	0.0166	0.35	0.27	Lymphocyte counts;	chr8:78652834	chr8:78723796~78724136:-
OV	cis	rs2919917	0.59	rs10098472	ENSG00000254352.1	RP11-578O24.2	4.17	4.26e-05	0.0166	0.35	0.27	Lymphocyte counts;	chr8:78652955	chr8:78723796~78724136:-
OV	cis	rs2919917	0.628	rs13251931	ENSG00000254352.1	RP11-578O24.2	4.17	4.26e-05	0.0166	0.35	0.27	Lymphocyte counts;	chr8:78653990	chr8:78723796~78724136:-
OV	cis	rs6907340	0.517	rs9465531	ENSG00000227116.1	RP3-471C18.1	-4.17	4.26e-05	0.0166	-0.32	-0.27	Endometriosis;	chr6:19798418	chr6:19730427~19734567:-
OV	cis	rs34421088	0.56	rs1478898	ENSG00000255052.4	FAM66D	4.17	4.26e-05	0.0166	0.31	0.27	Neuroticism;	chr8:11537570	chr8:12115782~12177550:+
OV	cis	rs875971	0.893	rs62465470	ENSG00000237310.1	GS1-124K5.4	-4.17	4.26e-05	0.0166	-0.26	-0.27	Aortic root size;	chr7:66136231	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs4368860	ENSG00000237310.1	GS1-124K5.4	-4.17	4.26e-05	0.0166	-0.26	-0.27	Aortic root size;	chr7:66143495	chr7:66493706~66495474:+
OV	cis	rs4934494	0.768	rs2094214	ENSG00000240996.1	RP11-80H5.7	-4.17	4.27e-05	0.0166	-0.39	-0.27	Red blood cell count;	chr10:89649624	chr10:89694295~89697928:-
OV	cis	rs1723838	0.826	rs2037709	ENSG00000255928.1	RP11-456I15.2	-4.17	4.27e-05	0.0166	-0.57	-0.27	Obesity-related traits;	chr11:73730727	chr11:73722349~73722694:+
OV	cis	rs17150703	0.722	rs473034	ENSG00000272505.1	RP11-981G7.6	-4.17	4.27e-05	0.0166	-0.39	-0.27	Obesity (early onset extreme);	chr8:9918006	chr8:10486807~10489666:+
OV	cis	rs1044826	0.692	rs295484	ENSG00000178631.7	ACTG1P1	-4.17	4.27e-05	0.0166	-0.28	-0.27	Obesity-related traits;	chr3:139512940	chr3:139493809~139494937:+
OV	cis	rs73201462	1	rs56287882	ENSG00000242551.2	POU5F1P6	4.17	4.27e-05	0.0166	0.42	0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128311500	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs73197383	ENSG00000242551.2	POU5F1P6	4.17	4.27e-05	0.0166	0.42	0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128311631	chr3:128674735~128677005:-
OV	cis	rs7520050	0.966	rs4545281	ENSG00000281133.1	AL355480.3	4.17	4.27e-05	0.0167	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45894382	chr1:45580892~45580996:-
OV	cis	rs116095464	0.558	rs9312957	ENSG00000250848.1	CTD-2083E4.5	-4.17	4.27e-05	0.0167	-0.34	-0.27	Breast cancer;	chr5:202079	chr5:288833~290321:-
OV	cis	rs10783487	0.947	rs7138000	ENSG00000258279.2	LINC00592	4.17	4.27e-05	0.0167	0.37	0.27	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr12:52076325	chr12:52210930~52223804:+
OV	cis	rs255758	0.813	rs255760	ENSG00000272123.1	CTD-2366F13.2	-4.17	4.27e-05	0.0167	-0.37	-0.27	Rheumatoid arthritis;	chr5:54026357	chr5:53089016~53089468:-
OV	cis	rs255758	0.813	rs406517	ENSG00000272123.1	CTD-2366F13.2	-4.17	4.27e-05	0.0167	-0.37	-0.27	Rheumatoid arthritis;	chr5:54026399	chr5:53089016~53089468:-
OV	cis	rs599083	0.793	rs471966	ENSG00000212093.1	AP000807.1	-4.17	4.27e-05	0.0167	-0.31	-0.27	Bone mineral density (spine);	chr11:68406393	chr11:68506083~68506166:-
OV	cis	rs7267979	1	rs2257991	ENSG00000274973.1	RP13-401N8.7	4.17	4.27e-05	0.0167	0.3	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25289703	chr20:25845497~25845862:+
OV	cis	rs1426063	0.541	rs58959724	ENSG00000260265.1	RP11-44F21.5	4.17	4.28e-05	0.0167	0.61	0.27	QT interval;	chr4:75073543	chr4:75081702~75084717:-
OV	cis	rs4763879	0.865	rs4763839	ENSG00000278635.1	CTD-2318O12.1	4.17	4.28e-05	0.0167	0.23	0.27	Type 1 diabetes;	chr12:9730104	chr12:9415641~9416718:+
OV	cis	rs7746199	0.736	rs10484399	ENSG00000280107.1	AL022393.9	-4.17	4.29e-05	0.0167	-0.51	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:28170845~28172521:+
OV	cis	rs8059260	0.736	rs3871209	ENSG00000274038.1	RP11-66H6.4	-4.17	4.29e-05	0.0167	-0.49	-0.27	Alcohol consumption over the past year;	chr16:10962907	chr16:11056556~11057034:+
OV	cis	rs2599510	0.703	rs762023	ENSG00000279544.1	AL133243.4	-4.17	4.29e-05	0.0167	-0.26	-0.27	Interleukin-18 levels;	chr2:32488103	chr2:32563328~32566436:+
OV	cis	rs1723838	0.826	rs1723845	ENSG00000255928.1	RP11-456I15.2	4.17	4.29e-05	0.0167	0.57	0.27	Obesity-related traits;	chr11:73786879	chr11:73722349~73722694:+
OV	cis	rs10754283	0.84	rs1215500	ENSG00000231613.1	RP5-943J3.1	4.17	4.29e-05	0.0167	0.28	0.27	Amyotrophic lateral sclerosis (sporadic);	chr1:89631695	chr1:89788914~89790492:+
OV	cis	rs1862618	0.853	rs3099459	ENSG00000271828.1	CTD-2310F14.1	4.17	4.29e-05	0.0167	0.43	0.27	Initial pursuit acceleration;	chr5:56841343	chr5:56927874~56929573:+
OV	cis	rs2117029	0.767	rs12580349	ENSG00000258017.1	RP11-386G11.10	4.17	4.3e-05	0.0167	0.35	0.27	Intelligence (multi-trait analysis);	chr12:49042941	chr12:49127782~49147869:+
OV	cis	rs9287719	0.649	rs6721857	ENSG00000243819.4	RN7SL832P	-4.17	4.3e-05	0.0168	-0.26	-0.27	Prostate cancer;	chr2:10581084	chr2:10690344~10692099:+
OV	cis	rs7555523	0.887	rs4657477	ENSG00000224358.1	RP11-466F5.8	-4.17	4.31e-05	0.0168	-0.36	-0.27	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165766938	chr1:165768929~165775176:+
OV	cis	rs11122895	0.716	rs11679110	ENSG00000228251.1	AC012442.6	-4.17	4.31e-05	0.0168	-0.25	-0.27	Allergic sensitization;	chr2:111710778	chr2:112590796~112591939:+
OV	cis	rs2933343	0.953	rs2933344	ENSG00000261159.1	RP11-723O4.9	4.17	4.31e-05	0.0168	0.34	0.27	IgG glycosylation;	chr3:128939872	chr3:128859716~128860526:-
OV	cis	rs2243480	1	rs4718269	ENSG00000226824.5	RP4-756H11.3	4.17	4.31e-05	0.0168	0.47	0.27	Diabetic kidney disease;	chr7:65735810	chr7:66654538~66669855:+
OV	cis	rs9309473	0.66	rs10496192	ENSG00000163016.8	ALMS1P	4.17	4.31e-05	0.0168	0.36	0.27	Metabolite levels;	chr2:73452739	chr2:73644919~73685576:+
OV	cis	rs881375	0.9	rs1930786	ENSG00000226752.6	PSMD5-AS1	-4.17	4.31e-05	0.0168	-0.29	-0.27	Rheumatoid arthritis;	chr9:120929191	chr9:120824828~120854385:+
OV	cis	rs881375	0.967	rs7864019	ENSG00000226752.6	PSMD5-AS1	-4.17	4.31e-05	0.0168	-0.29	-0.27	Rheumatoid arthritis;	chr9:120930590	chr9:120824828~120854385:+
OV	cis	rs881375	0.967	rs10739579	ENSG00000226752.6	PSMD5-AS1	-4.17	4.31e-05	0.0168	-0.29	-0.27	Rheumatoid arthritis;	chr9:120932510	chr9:120824828~120854385:+
OV	cis	rs881375	0.933	rs7031096	ENSG00000226752.6	PSMD5-AS1	-4.17	4.31e-05	0.0168	-0.29	-0.27	Rheumatoid arthritis;	chr9:120932664	chr9:120824828~120854385:+
OV	cis	rs881375	0.967	rs10739580	ENSG00000226752.6	PSMD5-AS1	-4.17	4.31e-05	0.0168	-0.29	-0.27	Rheumatoid arthritis;	chr9:120933004	chr9:120824828~120854385:+
OV	cis	rs2492286	0.597	rs2712384	ENSG00000242551.2	POU5F1P6	-4.17	4.32e-05	0.0168	-0.35	-0.27	Eosinophil counts;	chr3:128615429	chr3:128674735~128677005:-
OV	cis	rs1020064	0.583	rs2576775	ENSG00000235319.1	AC012360.4	-4.17	4.32e-05	0.0168	-0.35	-0.27	AIDS;	chr2:105356755	chr2:105324210~105330529:+
OV	cis	rs853679	0.517	rs9393894	ENSG00000226314.6	ZNF192P1	-4.17	4.32e-05	0.0168	-0.36	-0.27	Depression;	chr6:28144784	chr6:28161781~28169594:+
OV	cis	rs27434	0.602	rs2927620	ENSG00000272109.1	CTD-2260A17.3	-4.17	4.33e-05	0.0168	-0.43	-0.27	Ankylosing spondylitis;	chr5:96845594	chr5:96804353~96806105:+
OV	cis	rs944801	0.587	rs1591136	ENSG00000234840.1	LINC01239	-4.17	4.33e-05	0.0168	-0.3	-0.27	Type 2 diabetes;	chr9:22026835	chr9:22646200~22824213:+
OV	cis	rs7429990	0.965	rs17785248	ENSG00000229759.1	MRPS18AP1	4.17	4.33e-05	0.0168	0.32	0.27	Educational attainment (years of education);	chr3:47631425	chr3:48256350~48256938:-
OV	cis	rs7429990	0.965	rs35012836	ENSG00000229759.1	MRPS18AP1	4.17	4.33e-05	0.0168	0.32	0.27	Educational attainment (years of education);	chr3:47670000	chr3:48256350~48256938:-
OV	cis	rs17711722	0.523	rs313812	ENSG00000226824.5	RP4-756H11.3	4.17	4.33e-05	0.0169	0.3	0.27	Calcium levels;	chr7:66040056	chr7:66654538~66669855:+
OV	cis	rs1707322	0.752	rs28623463	ENSG00000234329.1	RP11-767N6.2	4.17	4.33e-05	0.0169	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45705086	chr1:45651039~45651826:-
OV	cis	rs62296447	0.514	rs6858545	ENSG00000241612.1	RP13-585F24.1	4.17	4.33e-05	0.0169	0.28	0.27	Schizophrenia;	chr4:19417747	chr4:19813749~19814231:+
OV	cis	rs7520050	0.807	rs5021934	ENSG00000280836.1	AL355480.1	4.17	4.34e-05	0.0169	0.32	0.27	Reticulocyte count;Red blood cell count;	chr1:45643632	chr1:45581219~45581321:-
OV	cis	rs2239557	1	rs7153587	ENSG00000259065.1	RP5-1021I20.1	-4.17	4.34e-05	0.0169	-0.33	-0.27	Common traits (Other);	chr14:74042957	chr14:73787360~73803270:+
OV	cis	rs2243480	1	rs313832	ENSG00000226824.5	RP4-756H11.3	-4.17	4.34e-05	0.0169	-0.43	-0.27	Diabetic kidney disease;	chr7:66085904	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs313831	ENSG00000226824.5	RP4-756H11.3	-4.17	4.34e-05	0.0169	-0.43	-0.27	Diabetic kidney disease;	chr7:66086239	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs2462569	ENSG00000226824.5	RP4-756H11.3	4.17	4.34e-05	0.0169	0.42	0.27	Diabetic kidney disease;	chr7:66009859	chr7:66654538~66669855:+
OV	cis	rs10986311	0.747	rs2282085	ENSG00000227200.1	RP11-121A14.3	-4.17	4.34e-05	0.0169	-0.23	-0.27	Vitiligo;	chr9:124262761	chr9:124262876~124265809:+
OV	cis	rs7520050	0.966	rs10890383	ENSG00000281133.1	AL355480.3	4.17	4.34e-05	0.0169	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:46122831	chr1:45580892~45580996:-
OV	cis	rs6828577	0.56	rs2631147	ENSG00000245958.5	RP11-33B1.1	4.17	4.34e-05	0.0169	0.33	0.27	Perioperative myocardial infarction in coronary artery bypass surgery;	chr4:118534699	chr4:119454791~119552025:+
OV	cis	rs897984	0.721	rs28360557	ENSG00000260911.2	RP11-196G11.2	-4.17	4.35e-05	0.0169	-0.24	-0.27	Dementia with Lewy bodies;	chr16:30971939	chr16:31043150~31049868:+
OV	cis	rs897984	0.721	rs4889525	ENSG00000260911.2	RP11-196G11.2	-4.17	4.35e-05	0.0169	-0.24	-0.27	Dementia with Lewy bodies;	chr16:30978537	chr16:31043150~31049868:+
OV	cis	rs897984	0.684	rs6950	ENSG00000260911.2	RP11-196G11.2	-4.17	4.35e-05	0.0169	-0.24	-0.27	Dementia with Lewy bodies;	chr16:30984348	chr16:31043150~31049868:+
OV	cis	rs897984	0.762	rs2305880	ENSG00000260911.2	RP11-196G11.2	-4.17	4.35e-05	0.0169	-0.24	-0.27	Dementia with Lewy bodies;	chr16:30988141	chr16:31043150~31049868:+
OV	cis	rs897984	0.759	rs13708	ENSG00000260911.2	RP11-196G11.2	-4.17	4.35e-05	0.0169	-0.24	-0.27	Dementia with Lewy bodies;	chr16:30989488	chr16:31043150~31049868:+
OV	cis	rs11587682	0.785	rs72694993	ENSG00000223945.2	RP11-458I7.1	-4.17	4.35e-05	0.0169	-0.47	-0.27	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150270203	chr1:150053864~150055034:+
OV	cis	rs4665809	0.759	rs62128394	ENSG00000231655.1	AC011742.3	-4.17	4.35e-05	0.0169	-0.42	-0.27	Gut microbiome composition (summer);	chr2:26141157	chr2:26140263~26141264:-
OV	cis	rs4296809	0.66	rs4866865	ENSG00000249779.1	RP11-447H19.3	-4.17	4.35e-05	0.0169	-0.47	-0.27	Brain structure;	chr5:44115014	chr5:43206709~43207811:+
OV	cis	rs4296809	0.607	rs113376202	ENSG00000249779.1	RP11-447H19.3	-4.17	4.35e-05	0.0169	-0.47	-0.27	Brain structure;	chr5:44120070	chr5:43206709~43207811:+
OV	cis	rs10462065	0.605	rs4632804	ENSG00000249779.1	RP11-447H19.3	-4.17	4.35e-05	0.0169	-0.47	-0.27	Nonsyndromic cleft lip with cleft palate;	chr5:44125112	chr5:43206709~43207811:+
OV	cis	rs10924970	0.967	rs6677573	ENSG00000236863.2	RPL23AP23	4.17	4.35e-05	0.0169	0.26	0.27	Asthma;	chr1:235214664	chr1:235295865~235296335:+
OV	cis	rs10924970	0.967	rs10495362	ENSG00000236863.2	RPL23AP23	4.17	4.35e-05	0.0169	0.26	0.27	Asthma;	chr1:235227081	chr1:235295865~235296335:+
OV	cis	rs10924970	0.935	rs4659674	ENSG00000236863.2	RPL23AP23	4.17	4.35e-05	0.0169	0.26	0.27	Asthma;	chr1:235229039	chr1:235295865~235296335:+
OV	cis	rs10924970	0.935	rs12731746	ENSG00000236863.2	RPL23AP23	4.17	4.35e-05	0.0169	0.26	0.27	Asthma;	chr1:235229231	chr1:235295865~235296335:+
OV	cis	rs10924970	0.967	rs7518225	ENSG00000236863.2	RPL23AP23	4.17	4.35e-05	0.0169	0.26	0.27	Asthma;	chr1:235231226	chr1:235295865~235296335:+
OV	cis	rs10924970	0.967	rs4659678	ENSG00000236863.2	RPL23AP23	4.17	4.35e-05	0.0169	0.26	0.27	Asthma;	chr1:235233382	chr1:235295865~235296335:+
OV	cis	rs10924970	0.967	rs12030186	ENSG00000236863.2	RPL23AP23	4.17	4.35e-05	0.0169	0.26	0.27	Asthma;	chr1:235234162	chr1:235295865~235296335:+
OV	cis	rs10924970	0.967	rs10925192	ENSG00000236863.2	RPL23AP23	4.17	4.35e-05	0.0169	0.26	0.27	Asthma;	chr1:235237511	chr1:235295865~235296335:+
OV	cis	rs10924970	0.967	rs12035746	ENSG00000236863.2	RPL23AP23	4.17	4.35e-05	0.0169	0.26	0.27	Asthma;	chr1:235242339	chr1:235295865~235296335:+
OV	cis	rs1075265	0.933	rs7573491	ENSG00000233266.1	HMGB1P31	4.17	4.36e-05	0.0169	0.32	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54115875	chr2:54051334~54051760:+
OV	cis	rs1075265	0.933	rs2042143	ENSG00000233266.1	HMGB1P31	4.17	4.36e-05	0.0169	0.32	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54116377	chr2:54051334~54051760:+
OV	cis	rs4296809	0.556	rs72755324	ENSG00000249779.1	RP11-447H19.3	-4.17	4.36e-05	0.0169	-0.52	-0.27	Brain structure;	chr5:44139235	chr5:43206709~43207811:+
OV	cis	rs10462065	1	rs12519758	ENSG00000249779.1	RP11-447H19.3	-4.17	4.36e-05	0.0169	-0.52	-0.27	Nonsyndromic cleft lip with cleft palate;	chr5:44146729	chr5:43206709~43207811:+
OV	cis	rs73201462	1	rs2811392	ENSG00000242551.2	POU5F1P6	-4.17	4.36e-05	0.0169	-0.41	-0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128305133	chr3:128674735~128677005:-
OV	cis	rs875971	0.862	rs778736	ENSG00000236529.1	RP13-254B10.1	4.17	4.36e-05	0.0169	0.28	0.27	Aortic root size;	chr7:66348861	chr7:65840212~65840596:+
OV	cis	rs9287719	0.967	rs6721739	ENSG00000234818.1	AC092687.5	-4.17	4.36e-05	0.0169	-0.28	-0.27	Prostate cancer;	chr2:10611120	chr2:10589166~10604830:+
OV	cis	rs7336933	1	rs7336933	ENSG00000278390.3	RP11-74J13.8	4.17	4.37e-05	0.017	0.32	0.27	Calcium levels;	chr13:41984940	chr13:41132939~41236686:+
OV	cis	rs11096990	0.679	rs6531707	ENSG00000249207.1	RP11-360F5.1	4.17	4.37e-05	0.017	0.28	0.27	Cognitive function;	chr4:39296064	chr4:39112677~39126818:-
OV	cis	rs1555322	0.53	rs6060341	ENSG00000279253.1	RP4-614O4.13	4.17	4.37e-05	0.017	0.33	0.27	Attention deficit hyperactivity disorder;	chr20:35275830	chr20:35262727~35264187:-
OV	cis	rs56114371	0.777	rs200481	ENSG00000226314.6	ZNF192P1	-4.17	4.37e-05	0.017	-0.48	-0.27	Breast cancer;	chr6:27806054	chr6:28161781~28169594:+
OV	cis	rs9311474	0.607	rs11711421	ENSG00000243224.1	RP5-1157M23.2	-4.17	4.37e-05	0.017	-0.27	-0.27	Electroencephalogram traits;	chr3:52527763	chr3:52239258~52241097:+
OV	cis	rs853679	0.585	rs201004	ENSG00000220721.1	OR1F12	4.17	4.37e-05	0.017	0.33	0.27	Depression;	chr6:27837156	chr6:28073316~28074233:+
OV	cis	rs4805272	0.962	rs4805277	ENSG00000267243.4	AC005307.3	-4.17	4.38e-05	0.017	-0.35	-0.27	Plasma omega-3 polyunsaturated fatty acid levels (docosahexaenoic acid);	chr19:28840036	chr19:28435388~28727777:-
OV	cis	rs10895987	0.531	rs7943007	ENSG00000254614.2	AP003068.23	-4.17	4.38e-05	0.017	-0.33	-0.27	Blood protein levels;	chr11:65089626	chr11:65177606~65181834:-
OV	cis	rs4713118	0.539	rs200988	ENSG00000219392.1	RP1-265C24.5	-4.17	4.38e-05	0.017	-0.31	-0.27	Parkinson's disease;	chr6:27851575	chr6:28115628~28116551:+
OV	cis	rs722782	1	rs722782	ENSG00000223508.5	RPL23AP53	4.17	4.38e-05	0.017	0.5	0.27	Age-related macular degeneration (geographic atrophy);	chr8:566479	chr8:213186~232231:-
OV	cis	rs9473147	0.543	rs9296559	ENSG00000270761.1	RP11-385F7.1	-4.17	4.38e-05	0.017	-0.3	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47484534	chr6:47477243~47477572:-
OV	cis	rs9473147	0.516	rs2151975	ENSG00000270761.1	RP11-385F7.1	-4.17	4.39e-05	0.017	-0.3	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47547927	chr6:47477243~47477572:-
OV	cis	rs9473147	0.516	rs9395283	ENSG00000270761.1	RP11-385F7.1	-4.17	4.39e-05	0.017	-0.3	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47583708	chr6:47477243~47477572:-
OV	cis	rs9473147	0.516	rs9349415	ENSG00000270761.1	RP11-385F7.1	-4.17	4.39e-05	0.017	-0.3	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47584125	chr6:47477243~47477572:-
OV	cis	rs9473147	0.516	rs9349416	ENSG00000270761.1	RP11-385F7.1	-4.17	4.39e-05	0.017	-0.3	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47584202	chr6:47477243~47477572:-
OV	cis	rs4296809	0.505	rs4866859	ENSG00000249779.1	RP11-447H19.3	-4.17	4.39e-05	0.017	-0.5	-0.27	Brain structure;	chr5:44073433	chr5:43206709~43207811:+
OV	cis	rs10462065	0.892	rs10462066	ENSG00000249779.1	RP11-447H19.3	-4.17	4.39e-05	0.017	-0.5	-0.27	Nonsyndromic cleft lip with cleft palate;	chr5:44080407	chr5:43206709~43207811:+
OV	cis	rs4296809	0.505	rs72751881	ENSG00000249779.1	RP11-447H19.3	-4.17	4.39e-05	0.017	-0.5	-0.27	Brain structure;	chr5:44084240	chr5:43206709~43207811:+
OV	cis	rs7267979	0.933	rs2424708	ENSG00000274973.1	RP13-401N8.7	-4.17	4.39e-05	0.017	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25300762	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs884613	ENSG00000274973.1	RP13-401N8.7	4.17	4.39e-05	0.017	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25307869	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs1888998	ENSG00000274973.1	RP13-401N8.7	4.17	4.39e-05	0.017	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25311190	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs2500433	ENSG00000274973.1	RP13-401N8.7	4.17	4.39e-05	0.017	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25315699	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs2482948	ENSG00000274973.1	RP13-401N8.7	4.17	4.39e-05	0.017	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25315863	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2482919	ENSG00000274973.1	RP13-401N8.7	4.17	4.39e-05	0.017	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25319120	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6037086	ENSG00000274973.1	RP13-401N8.7	4.17	4.39e-05	0.017	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25325702	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs2482923	ENSG00000274973.1	RP13-401N8.7	4.17	4.39e-05	0.017	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25328345	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2482927	ENSG00000274973.1	RP13-401N8.7	4.17	4.39e-05	0.017	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25346515	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2482931	ENSG00000274973.1	RP13-401N8.7	4.17	4.39e-05	0.017	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25353809	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2482940	ENSG00000274973.1	RP13-401N8.7	4.17	4.39e-05	0.017	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25369194	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2027003	ENSG00000274973.1	RP13-401N8.7	4.17	4.39e-05	0.017	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25369862	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2027004	ENSG00000274973.1	RP13-401N8.7	4.17	4.39e-05	0.017	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25369982	chr20:25845497~25845862:+
OV	cis	rs7267979	0.934	rs2500399	ENSG00000274973.1	RP13-401N8.7	4.17	4.39e-05	0.017	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25374058	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2500404	ENSG00000274973.1	RP13-401N8.7	4.17	4.39e-05	0.017	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25379122	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2500405	ENSG00000274973.1	RP13-401N8.7	4.17	4.39e-05	0.017	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25380190	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2482941	ENSG00000274973.1	RP13-401N8.7	4.17	4.39e-05	0.017	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25380580	chr20:25845497~25845862:+
OV	cis	rs7267979	0.903	rs2500423	ENSG00000274973.1	RP13-401N8.7	4.17	4.39e-05	0.017	0.31	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25394246	chr20:25845497~25845862:+
OV	cis	rs2839627	0.561	rs9977774	ENSG00000225218.1	AP001628.6	4.17	4.39e-05	0.017	0.28	0.27	Information processing speed;	chr21:42922366	chr21:42831040~42836477:-
OV	cis	rs1075265	0.575	rs2692531	ENSG00000233266.1	HMGB1P31	4.17	4.39e-05	0.017	0.32	0.27	Chronotype;Morning vs. evening chronotype;	chr2:53776640	chr2:54051334~54051760:+
OV	cis	rs1933112	1	rs1933109	ENSG00000227777.1	RP4-738P11.3	-4.17	4.4e-05	0.0171	-0.3	-0.27	Blood protein levels;	chr1:168554386	chr1:168542737~168543354:+
OV	cis	rs7267979	0.706	rs6138542	ENSG00000274973.1	RP13-401N8.7	-4.17	4.4e-05	0.0171	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25227137	chr20:25845497~25845862:+
OV	cis	rs9311474	1	rs1060330	ENSG00000243224.1	RP5-1157M23.2	-4.17	4.4e-05	0.0171	-0.29	-0.27	Electroencephalogram traits;	chr3:52254929	chr3:52239258~52241097:+
OV	cis	rs858239	0.669	rs6461687	ENSG00000230042.1	AK3P3	-4.17	4.41e-05	0.0171	-0.29	-0.27	Cerebrospinal fluid biomarker levels;	chr7:23076961	chr7:23129178~23129841:+
OV	cis	rs9987353	0.84	rs329994	ENSG00000254340.1	RP11-10A14.3	-4.17	4.41e-05	0.0171	-0.31	-0.27	Recombination measurement;	chr8:9265723	chr8:9141424~9145435:+
OV	cis	rs7520050	0.807	rs28844317	ENSG00000281133.1	AL355480.3	-4.17	4.41e-05	0.0171	-0.3	-0.27	Reticulocyte count;Red blood cell count;	chr1:45743535	chr1:45580892~45580996:-
OV	cis	rs7520050	0.807	rs6429576	ENSG00000281133.1	AL355480.3	-4.17	4.41e-05	0.0171	-0.3	-0.27	Reticulocyte count;Red blood cell count;	chr1:45750903	chr1:45580892~45580996:-
OV	cis	rs4934494	0.635	rs12572869	ENSG00000240996.1	RP11-80H5.7	-4.17	4.41e-05	0.0171	-0.39	-0.27	Red blood cell count;	chr10:89653611	chr10:89694295~89697928:-
OV	cis	rs1797885	0.564	rs2454422	ENSG00000251774.1	RNU6-377P	4.17	4.42e-05	0.0171	0.25	0.27	Immature fraction of reticulocytes;	chr3:12562401	chr3:12514706~12514807:+
OV	cis	rs2811415	0.531	rs13099396	ENSG00000277250.1	Metazoa_SRP	4.17	4.42e-05	0.0171	0.36	0.27	Lung function (FEV1/FVC);	chr3:128077129	chr3:128673681~128674021:-
OV	cis	rs7932354	0.528	rs2018527	ENSG00000271543.1	RP11-692M12.5	4.17	4.42e-05	0.0171	0.34	0.27	Bone mineral density (hip);Bone mineral density;	chr11:47154258	chr11:47796169~47796379:+
OV	cis	rs2021786	0.93	rs2269023	ENSG00000199719.1	RN7SKP74	4.17	4.42e-05	0.0171	0.29	0.27	Preschool internalizing problems;	chr20:17452434	chr20:18295143~18295451:-
OV	cis	rs853679	0.546	rs200990	ENSG00000280107.1	AL022393.9	-4.17	4.42e-05	0.0171	-0.45	-0.27	Depression;	chr6:27848045	chr6:28170845~28172521:+
OV	cis	rs12539814	0.929	rs12671701	ENSG00000170356.8	OR2A20P	4.17	4.42e-05	0.0171	0.54	0.27	Diastolic blood pressure;	chr7:144459893	chr7:144250045~144252957:-
OV	cis	rs12073359	1	rs1975957	ENSG00000223945.2	RP11-458I7.1	4.17	4.42e-05	0.0171	0.39	0.27	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150132108	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs4926408	ENSG00000223945.2	RP11-458I7.1	4.17	4.42e-05	0.0171	0.39	0.27	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150134065	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs11205333	ENSG00000223945.2	RP11-458I7.1	4.17	4.42e-05	0.0171	0.39	0.27	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150134975	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs4926409	ENSG00000223945.2	RP11-458I7.1	4.17	4.42e-05	0.0171	0.39	0.27	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150138272	chr1:150053864~150055034:+
OV	cis	rs9992667	0.955	rs28664852	ENSG00000231160.8	KLF3-AS1	4.16	4.43e-05	0.0171	0.31	0.27	Eosinophil percentage of granulocytes;	chr4:38644479	chr4:38612701~38664883:-
OV	cis	rs2522056	0.808	rs7704457	ENSG00000233006.5	AC034220.3	4.16	4.43e-05	0.0172	0.31	0.27	Fibrinogen;Lymphocyte counts;	chr5:132409098	chr5:132311285~132369916:-
OV	cis	rs853679	0.542	rs9393892	ENSG00000226314.6	ZNF192P1	-4.16	4.43e-05	0.0172	-0.35	-0.27	Depression;	chr6:28113616	chr6:28161781~28169594:+
OV	cis	rs9473147	0.516	rs6904764	ENSG00000270761.1	RP11-385F7.1	-4.16	4.43e-05	0.0172	-0.3	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47535761	chr6:47477243~47477572:-
OV	cis	rs9369695	0.883	rs9473128	ENSG00000270761.1	RP11-385F7.1	-4.16	4.43e-05	0.0172	-0.3	-0.27	Reticulocyte count;	chr6:47537274	chr6:47477243~47477572:-
OV	cis	rs1823913	0.637	rs1470962	ENSG00000227542.1	AC092614.2	-4.16	4.43e-05	0.0172	-0.29	-0.27	Obesity-related traits;	chr2:191270271	chr2:191229165~191246172:-
OV	cis	rs858239	0.72	rs10227559	ENSG00000230042.1	AK3P3	-4.16	4.43e-05	0.0172	-0.29	-0.27	Cerebrospinal fluid biomarker levels;	chr7:23232525	chr7:23129178~23129841:+
OV	cis	rs9311474	0.581	rs13621	ENSG00000243224.1	RP5-1157M23.2	-4.16	4.43e-05	0.0172	-0.27	-0.27	Electroencephalogram traits;	chr3:52524117	chr3:52239258~52241097:+
OV	cis	rs4787491	0.704	rs66467443	ENSG00000261367.1	RP11-455F5.4	-4.16	4.44e-05	0.0172	-0.29	-0.27	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30039173	chr16:30107675~30110541:+
OV	cis	rs9992667	0.955	rs11096953	ENSG00000231160.8	KLF3-AS1	-4.16	4.44e-05	0.0172	-0.3	-0.27	Eosinophil percentage of granulocytes;	chr4:38642171	chr4:38612701~38664883:-
OV	cis	rs7121800	0.962	rs4923641	ENSG00000254532.1	RP11-624D11.2	4.16	4.44e-05	0.0172	0.31	0.27	Pit-and-Fissure caries;	chr11:30501598	chr11:30044058~30084343:-
OV	cis	rs3930017	1	rs7783809	ENSG00000225726.1	AC007000.10	-4.16	4.45e-05	0.0172	-0.26	-0.27	Body mass index;	chr7:77090234	chr7:77071751~77072237:-
OV	cis	rs10759883	0.563	rs686048	ENSG00000175611.10	LINC00476	4.16	4.45e-05	0.0172	0.32	0.27	Nicotine dependence;	chr9:95967100	chr9:95759231~95875977:-
OV	cis	rs10759883	0.539	rs649819	ENSG00000175611.10	LINC00476	4.16	4.45e-05	0.0172	0.32	0.27	Nicotine dependence;	chr9:95969323	chr9:95759231~95875977:-
OV	cis	rs801193	0.569	rs13226966	ENSG00000236529.1	RP13-254B10.1	4.16	4.45e-05	0.0172	0.27	0.27	Aortic root size;	chr7:66768636	chr7:65840212~65840596:+
OV	cis	rs7968440	1	rs2684898	ENSG00000257298.1	RP3-405J10.3	4.16	4.45e-05	0.0172	0.25	0.27	Fibrinogen;	chr12:50653042	chr12:50185580~50191363:-
OV	cis	rs7968440	0.902	rs2684901	ENSG00000257298.1	RP3-405J10.3	4.16	4.45e-05	0.0172	0.25	0.27	Fibrinogen;	chr12:50657985	chr12:50185580~50191363:-
OV	cis	rs3734266	0.702	rs6900426	ENSG00000220643.1	RP3-391O22.1	4.16	4.46e-05	0.0172	0.43	0.27	Systemic lupus erythematosus;	chr6:34656371	chr6:34686602~34687106:+
OV	cis	rs6128907	1	rs16987583	ENSG00000224635.1	RP4-564F22.5	4.16	4.46e-05	0.0173	0.38	0.27	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38766975	chr20:38406011~38416797:-
OV	cis	rs1538970	0.781	rs34768551	ENSG00000280836.1	AL355480.1	-4.16	4.46e-05	0.0173	-0.41	-0.27	Platelet count;	chr1:45554736	chr1:45581219~45581321:-
OV	cis	rs7017914	0.69	rs12674838	ENSG00000223220.1	Y_RNA	4.16	4.46e-05	0.0173	0.31	0.27	Bone mineral density;	chr8:71078045	chr8:70780914~70781008:-
OV	cis	rs801193	1	rs2286684	ENSG00000224316.1	RP11-479O9.2	-4.16	4.46e-05	0.0173	-0.29	-0.27	Aortic root size;	chr7:66664843	chr7:65773620~65802067:+
OV	cis	rs801193	0.935	rs2286683	ENSG00000224316.1	RP11-479O9.2	-4.16	4.46e-05	0.0173	-0.29	-0.27	Aortic root size;	chr7:66664856	chr7:65773620~65802067:+
OV	cis	rs801193	0.613	rs2659900	ENSG00000236529.1	RP13-254B10.1	4.16	4.46e-05	0.0173	0.28	0.27	Aortic root size;	chr7:66719456	chr7:65840212~65840596:+
OV	cis	rs1707322	0.716	rs6694889	ENSG00000234329.1	RP11-767N6.2	4.16	4.47e-05	0.0173	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45636134	chr1:45651039~45651826:-
OV	cis	rs1707322	0.682	rs12041197	ENSG00000234329.1	RP11-767N6.2	4.16	4.47e-05	0.0173	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638792	chr1:45651039~45651826:-
OV	cis	rs1707322	0.717	rs12023439	ENSG00000234329.1	RP11-767N6.2	4.16	4.47e-05	0.0173	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45638964	chr1:45651039~45651826:-
OV	cis	rs853679	0.542	rs6934769	ENSG00000226314.6	ZNF192P1	-4.16	4.47e-05	0.0173	-0.35	-0.27	Depression;	chr6:28123153	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs17711801	ENSG00000226314.6	ZNF192P1	-4.16	4.47e-05	0.0173	-0.35	-0.27	Depression;	chr6:28124529	chr6:28161781~28169594:+
OV	cis	rs4713118	0.527	rs9461433	ENSG00000226314.6	ZNF192P1	-4.16	4.47e-05	0.0173	-0.35	-0.27	Parkinson's disease;	chr6:28127394	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9468292	ENSG00000226314.6	ZNF192P1	-4.16	4.47e-05	0.0173	-0.35	-0.27	Depression;	chr6:28127577	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs1947863	ENSG00000226314.6	ZNF192P1	-4.16	4.47e-05	0.0173	-0.35	-0.27	Depression;	chr6:28131566	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs4713141	ENSG00000226314.6	ZNF192P1	-4.16	4.47e-05	0.0173	-0.35	-0.27	Depression;	chr6:28133900	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9380056	ENSG00000226314.6	ZNF192P1	-4.16	4.47e-05	0.0173	-0.35	-0.27	Depression;	chr6:28136698	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs9380057	ENSG00000226314.6	ZNF192P1	-4.16	4.47e-05	0.0173	-0.35	-0.27	Depression;	chr6:28136856	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs6941992	ENSG00000226314.6	ZNF192P1	-4.16	4.47e-05	0.0173	-0.35	-0.27	Depression;	chr6:28138363	chr6:28161781~28169594:+
OV	cis	rs4713118	0.516	rs4713142	ENSG00000226314.6	ZNF192P1	-4.16	4.47e-05	0.0173	-0.35	-0.27	Parkinson's disease;	chr6:28138569	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs4713143	ENSG00000226314.6	ZNF192P1	-4.16	4.47e-05	0.0173	-0.35	-0.27	Depression;	chr6:28138981	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs4713144	ENSG00000226314.6	ZNF192P1	-4.16	4.47e-05	0.0173	-0.35	-0.27	Depression;	chr6:28139012	chr6:28161781~28169594:+
OV	cis	rs2185570	0.605	rs67851687	ENSG00000234724.1	HDAC1P1	4.16	4.47e-05	0.0173	0.49	0.27	Dehydroepiandrosterone sulphate levels;	chr10:95126375	chr10:94137748~94139500:+
OV	cis	rs2185570	0.605	rs35238981	ENSG00000234724.1	HDAC1P1	4.16	4.47e-05	0.0173	0.49	0.27	Dehydroepiandrosterone sulphate levels;	chr10:95126551	chr10:94137748~94139500:+
OV	cis	rs2185570	0.605	rs34320910	ENSG00000234724.1	HDAC1P1	4.16	4.47e-05	0.0173	0.49	0.27	Dehydroepiandrosterone sulphate levels;	chr10:95126582	chr10:94137748~94139500:+
OV	cis	rs9473147	0.516	rs10948367	ENSG00000270761.1	RP11-385F7.1	-4.16	4.47e-05	0.0173	-0.3	-0.27	Platelet distribution width;Mean platelet volume;	chr6:47617879	chr6:47477243~47477572:-
OV	cis	rs41271951	0.542	rs113775984	ENSG00000223945.2	RP11-458I7.1	-4.16	4.47e-05	0.0173	-0.48	-0.27	Blood protein levels;	chr1:150275044	chr1:150053864~150055034:+
OV	cis	rs9309473	1	rs6710438	ENSG00000163016.8	ALMS1P	-4.16	4.47e-05	0.0173	-0.32	-0.27	Metabolite levels;	chr2:73592981	chr2:73644919~73685576:+
OV	cis	rs6893300	0.785	rs58386410	ENSG00000254035.1	RP11-281O15.4	4.16	4.47e-05	0.0173	0.31	0.27	Resting heart rate;	chr5:179778703	chr5:178969390~178990116:+
OV	cis	rs6893300	0.785	rs17617710	ENSG00000254035.1	RP11-281O15.4	4.16	4.47e-05	0.0173	0.31	0.27	Resting heart rate;	chr5:179779106	chr5:178969390~178990116:+
OV	cis	rs10924970	0.649	rs12021964	ENSG00000236863.2	RPL23AP23	4.16	4.48e-05	0.0173	0.28	0.27	Asthma;	chr1:235271228	chr1:235295865~235296335:+
OV	cis	rs10924970	0.613	rs12027933	ENSG00000236863.2	RPL23AP23	4.16	4.48e-05	0.0173	0.28	0.27	Asthma;	chr1:235277096	chr1:235295865~235296335:+
OV	cis	rs10924970	0.601	rs12024609	ENSG00000236863.2	RPL23AP23	4.16	4.48e-05	0.0173	0.28	0.27	Asthma;	chr1:235288852	chr1:235295865~235296335:+
OV	cis	rs7520050	0.933	rs12045165	ENSG00000281133.1	AL355480.3	4.16	4.48e-05	0.0173	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:45790350	chr1:45580892~45580996:-
OV	cis	rs2919917	0.59	rs2919919	ENSG00000254352.1	RP11-578O24.2	-4.16	4.48e-05	0.0173	-0.38	-0.27	Lymphocyte counts;	chr8:78745274	chr8:78723796~78724136:-
OV	cis	rs7267979	0.873	rs6115093	ENSG00000274973.1	RP13-401N8.7	-4.16	4.49e-05	0.0173	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25230094	chr20:25845497~25845862:+
OV	cis	rs944801	0.608	rs7027950	ENSG00000234840.1	LINC01239	-4.16	4.49e-05	0.0173	-0.31	-0.27	Type 2 diabetes;	chr9:22048392	chr9:22646200~22824213:+
OV	cis	rs35740288	0.753	rs4843095	ENSG00000259295.5	CSPG4P12	4.16	4.49e-05	0.0173	0.35	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85731900	chr15:85191438~85213905:+
OV	cis	rs35740288	0.822	rs11630549	ENSG00000259295.5	CSPG4P12	4.16	4.49e-05	0.0173	0.35	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85732565	chr15:85191438~85213905:+
OV	cis	rs35740288	0.822	rs56322219	ENSG00000259295.5	CSPG4P12	4.16	4.49e-05	0.0173	0.35	0.27	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85733109	chr15:85191438~85213905:+
OV	cis	rs8054556	1	rs11150577	ENSG00000261367.1	RP11-455F5.4	-4.16	4.49e-05	0.0173	-0.3	-0.27	Autism spectrum disorder or schizophrenia;	chr16:29975204	chr16:30107675~30110541:+
OV	cis	rs9992667	0.955	rs2078179	ENSG00000231160.8	KLF3-AS1	4.16	4.49e-05	0.0173	0.33	0.27	Eosinophil percentage of granulocytes;	chr4:38662878	chr4:38612701~38664883:-
OV	cis	rs9992667	0.664	rs112691446	ENSG00000231160.8	KLF3-AS1	4.16	4.49e-05	0.0173	0.33	0.27	Eosinophil percentage of granulocytes;	chr4:38663521	chr4:38612701~38664883:-
OV	cis	rs7429990	0.864	rs4274776	ENSG00000229759.1	MRPS18AP1	4.16	4.49e-05	0.0173	0.29	0.27	Educational attainment (years of education);	chr3:47605868	chr3:48256350~48256938:-
OV	cis	rs7746199	0.736	rs17750424	ENSG00000280107.1	AL022393.9	-4.16	4.49e-05	0.0173	-0.55	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27733343	chr6:28170845~28172521:+
OV	cis	rs7811142	1	rs73161759	ENSG00000242294.5	STAG3L5P	4.16	4.49e-05	0.0173	0.27	0.27	Platelet count;	chr7:100412371	chr7:100336079~100351900:+
OV	cis	rs7811142	1	rs67315960	ENSG00000242294.5	STAG3L5P	4.16	4.49e-05	0.0173	0.27	0.27	Platelet count;	chr7:100417501	chr7:100336079~100351900:+
OV	cis	rs7811142	1	rs11763414	ENSG00000242294.5	STAG3L5P	4.16	4.49e-05	0.0173	0.27	0.27	Platelet count;	chr7:100419221	chr7:100336079~100351900:+
OV	cis	rs7811142	1	rs66632384	ENSG00000242294.5	STAG3L5P	4.16	4.49e-05	0.0173	0.27	0.27	Platelet count;	chr7:100421281	chr7:100336079~100351900:+
OV	cis	rs7811142	1	rs67163493	ENSG00000242294.5	STAG3L5P	4.16	4.49e-05	0.0173	0.27	0.27	Platelet count;	chr7:100426215	chr7:100336079~100351900:+
OV	cis	rs7811142	0.943	rs73403312	ENSG00000242294.5	STAG3L5P	4.16	4.49e-05	0.0173	0.27	0.27	Platelet count;	chr7:100426530	chr7:100336079~100351900:+
OV	cis	rs10924970	0.687	rs946027	ENSG00000236863.2	RPL23AP23	4.16	4.49e-05	0.0174	0.28	0.27	Asthma;	chr1:235182971	chr1:235295865~235296335:+
OV	cis	rs801193	0.844	rs2244022	ENSG00000237310.1	GS1-124K5.4	4.16	4.49e-05	0.0174	0.28	0.27	Aortic root size;	chr7:66737443	chr7:66493706~66495474:+
OV	cis	rs357894	0.519	rs357893	ENSG00000266696.1	RP11-30L3.2	4.16	4.5e-05	0.0174	0.33	0.27	Dental caries;	chr18:49050848	chr18:49205912~49208781:+
OV	cis	rs1538970	0.884	rs1771551	ENSG00000280836.1	AL355480.1	-4.16	4.5e-05	0.0174	-0.36	-0.27	Platelet count;	chr1:45417971	chr1:45581219~45581321:-
OV	cis	rs1538970	1	rs4660853	ENSG00000280836.1	AL355480.1	-4.16	4.5e-05	0.0174	-0.37	-0.27	Platelet count;	chr1:45383418	chr1:45581219~45581321:-
OV	cis	rs801193	1	rs10274773	ENSG00000224316.1	RP11-479O9.2	-4.16	4.5e-05	0.0174	-0.29	-0.27	Aortic root size;	chr7:66668591	chr7:65773620~65802067:+
OV	cis	rs801193	1	rs7785213	ENSG00000224316.1	RP11-479O9.2	-4.16	4.5e-05	0.0174	-0.29	-0.27	Aortic root size;	chr7:66673991	chr7:65773620~65802067:+
OV	cis	rs6893300	0.785	rs7705530	ENSG00000254035.1	RP11-281O15.4	4.16	4.5e-05	0.0174	0.31	0.27	Resting heart rate;	chr5:179763993	chr5:178969390~178990116:+
OV	cis	rs6893300	0.785	rs7704520	ENSG00000254035.1	RP11-281O15.4	4.16	4.5e-05	0.0174	0.31	0.27	Resting heart rate;	chr5:179764053	chr5:178969390~178990116:+
OV	cis	rs9828933	0.752	rs17069507	ENSG00000280620.1	SCAANT1	4.16	4.5e-05	0.0174	0.51	0.27	Type 2 diabetes;	chr3:63939280	chr3:63911518~63911772:-
OV	cis	rs9291683	0.61	rs993172	ENSG00000250413.1	RP11-448G15.1	-4.16	4.5e-05	0.0174	-0.3	-0.27	Bone mineral density;	chr4:10322737	chr4:10006482~10009725:+
OV	cis	rs875971	1	rs3981131	ENSG00000237310.1	GS1-124K5.4	4.16	4.5e-05	0.0174	0.27	0.27	Aortic root size;	chr7:66486690	chr7:66493706~66495474:+
OV	cis	rs896854	0.715	rs12548874	ENSG00000253528.2	RP11-347C18.4	-4.16	4.5e-05	0.0174	-0.25	-0.27	Type 2 diabetes;	chr8:94922936	chr8:94974573~94974853:-
OV	cis	rs9291683	0.575	rs3756223	ENSG00000250413.1	RP11-448G15.1	-4.16	4.5e-05	0.0174	-0.29	-0.27	Bone mineral density;	chr4:10104173	chr4:10006482~10009725:+
OV	cis	rs2574704	1	rs2574716	ENSG00000251774.1	RNU6-377P	4.16	4.5e-05	0.0174	0.26	0.27	Body mass index;	chr3:11620648	chr3:12514706~12514807:+
OV	cis	rs1979679	0.801	rs2881787	ENSG00000278733.1	RP11-425D17.1	-4.16	4.5e-05	0.0174	-0.29	-0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28145489	chr12:28185625~28186190:-
OV	cis	rs10510102	0.516	rs10887034	ENSG00000226864.1	ATE1-AS1	4.16	4.5e-05	0.0174	0.49	0.27	Breast cancer;	chr10:121973996	chr10:121928312~121951965:+
OV	cis	rs650258	1	rs650258	ENSG00000256196.1	RP11-881M11.4	4.16	4.51e-05	0.0174	0.36	0.27	Gut microbiota (bacterial taxa);Multiple sclerosis;Gut microbiota (functional units);	chr11:61064810	chr11:60918469~60925397:-
OV	cis	rs5742933	1	rs2289404	ENSG00000253559.1	OSGEPL1-AS1	-4.16	4.51e-05	0.0174	-0.3	-0.27	Ferritin levels;	chr2:189771288	chr2:189762704~189765556:+
OV	cis	rs7536700	0.643	rs59770064	ENSG00000272030.1	RP1-178F15.4	-4.16	4.51e-05	0.0174	-0.6	-0.27	Multiple myeloma (IgH translocation);	chr1:153672987	chr1:153631438~153634397:-
OV	cis	rs853679	0.882	rs9380064	ENSG00000226314.6	ZNF192P1	-4.16	4.51e-05	0.0174	-0.49	-0.27	Depression;	chr6:28175340	chr6:28161781~28169594:+
OV	cis	rs1790761	0.505	rs34721562	ENSG00000184224.3	C11orf72	-4.16	4.51e-05	0.0174	-0.3	-0.27	Mean corpuscular volume;	chr11:67545237	chr11:67602880~67606706:-
OV	cis	rs801193	1	rs6975195	ENSG00000224316.1	RP11-479O9.2	-4.16	4.51e-05	0.0174	-0.29	-0.27	Aortic root size;	chr7:66659787	chr7:65773620~65802067:+
OV	cis	rs801193	1	rs3857688	ENSG00000224316.1	RP11-479O9.2	-4.16	4.51e-05	0.0174	-0.29	-0.27	Aortic root size;	chr7:66662819	chr7:65773620~65802067:+
OV	cis	rs12468226	0.938	rs116109808	ENSG00000272966.1	RP11-686O6.1	4.16	4.52e-05	0.0174	0.44	0.27	Urate levels;	chr2:202287356	chr2:202336739~202337200:+
OV	cis	rs12468226	0.873	rs78175596	ENSG00000272966.1	RP11-686O6.1	4.16	4.52e-05	0.0174	0.44	0.27	Urate levels;	chr2:202287993	chr2:202336739~202337200:+
OV	cis	rs12468226	0.938	rs74454549	ENSG00000272966.1	RP11-686O6.1	4.16	4.52e-05	0.0174	0.44	0.27	Urate levels;	chr2:202288044	chr2:202336739~202337200:+
OV	cis	rs12468226	0.938	rs56684065	ENSG00000272966.1	RP11-686O6.1	4.16	4.52e-05	0.0174	0.44	0.27	Urate levels;	chr2:202289528	chr2:202336739~202337200:+
OV	cis	rs12468226	0.938	rs1474001	ENSG00000272966.1	RP11-686O6.1	4.16	4.52e-05	0.0174	0.44	0.27	Urate levels;	chr2:202290230	chr2:202336739~202337200:+
OV	cis	rs12468226	0.938	rs76664732	ENSG00000272966.1	RP11-686O6.1	4.16	4.52e-05	0.0174	0.44	0.27	Urate levels;	chr2:202296298	chr2:202336739~202337200:+
OV	cis	rs7267979	1	rs2387880	ENSG00000274973.1	RP13-401N8.7	4.16	4.52e-05	0.0174	0.3	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25397151	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs2387882	ENSG00000274973.1	RP13-401N8.7	4.16	4.52e-05	0.0174	0.3	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25398166	chr20:25845497~25845862:+
OV	cis	rs6445967	1	rs6445967	ENSG00000272360.1	RP11-359I18.5	4.16	4.52e-05	0.0174	0.28	0.27	Platelet count;	chr3:58296849	chr3:58490830~58491291:-
OV	cis	rs853679	0.517	rs3757187	ENSG00000226314.6	ZNF192P1	-4.16	4.52e-05	0.0174	-0.36	-0.27	Depression;	chr6:28139876	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs3757185	ENSG00000226314.6	ZNF192P1	-4.16	4.52e-05	0.0174	-0.36	-0.27	Depression;	chr6:28139998	chr6:28161781~28169594:+
OV	cis	rs9880211	1	rs28811905	ENSG00000239213.4	NCK1-AS1	4.16	4.52e-05	0.0174	0.32	0.27	Height;Body mass index;	chr3:136533210	chr3:136841726~136862054:-
OV	cis	rs9880211	0.948	rs9813691	ENSG00000239213.4	NCK1-AS1	4.16	4.52e-05	0.0174	0.32	0.27	Height;Body mass index;	chr3:136541880	chr3:136841726~136862054:-
OV	cis	rs7429990	0.965	rs319686	ENSG00000229759.1	MRPS18AP1	4.16	4.53e-05	0.0175	0.28	0.27	Educational attainment (years of education);	chr3:47888930	chr3:48256350~48256938:-
OV	cis	rs7580658	0.929	rs4662575	ENSG00000236682.1	AC068282.3	-4.16	4.53e-05	0.0175	-0.35	-0.27	Protein C levels;	chr2:127264639	chr2:127389130~127400580:+
OV	cis	rs7580658	0.929	rs11886231	ENSG00000236682.1	AC068282.3	-4.16	4.53e-05	0.0175	-0.35	-0.27	Protein C levels;	chr2:127270554	chr2:127389130~127400580:+
OV	cis	rs10266483	0.656	rs670966	ENSG00000232727.2	YWHAEP1	4.16	4.53e-05	0.0175	0.31	0.27	Response to statin therapy;	chr7:64302521	chr7:64433830~64434592:+
OV	cis	rs10266483	0.739	rs682662	ENSG00000232727.2	YWHAEP1	4.16	4.53e-05	0.0175	0.31	0.27	Response to statin therapy;	chr7:64306107	chr7:64433830~64434592:+
OV	cis	rs10266483	0.739	rs679966	ENSG00000232727.2	YWHAEP1	4.16	4.53e-05	0.0175	0.31	0.27	Response to statin therapy;	chr7:64306688	chr7:64433830~64434592:+
OV	cis	rs10266483	0.739	rs2692099	ENSG00000232727.2	YWHAEP1	4.16	4.53e-05	0.0175	0.31	0.27	Response to statin therapy;	chr7:64307384	chr7:64433830~64434592:+
OV	cis	rs45509595	0.841	rs200485	ENSG00000226314.6	ZNF192P1	-4.16	4.54e-05	0.0175	-0.49	-0.27	Breast cancer;	chr6:27807919	chr6:28161781~28169594:+
OV	cis	rs45509595	0.841	rs370155	ENSG00000226314.6	ZNF192P1	-4.16	4.54e-05	0.0175	-0.49	-0.27	Breast cancer;	chr6:27814253	chr6:28161781~28169594:+
OV	cis	rs9880211	1	rs9826454	ENSG00000239213.4	NCK1-AS1	4.16	4.54e-05	0.0175	0.33	0.27	Height;Body mass index;	chr3:136234378	chr3:136841726~136862054:-
OV	cis	rs5742933	0.842	rs1225101	ENSG00000253559.1	OSGEPL1-AS1	-4.16	4.54e-05	0.0175	-0.29	-0.27	Ferritin levels;	chr2:189740695	chr2:189762704~189765556:+
OV	cis	rs6052484	0.523	rs605191	ENSG00000229539.1	RP11-119B16.2	4.16	4.54e-05	0.0175	0.3	0.27	Sense of smell;	chr20:4342329	chr20:3888239~3888868:-
OV	cis	rs11096990	0.656	rs6531710	ENSG00000249207.1	RP11-360F5.1	4.16	4.54e-05	0.0175	0.28	0.27	Cognitive function;	chr4:39300658	chr4:39112677~39126818:-
OV	cis	rs2919917	1	rs4739134	ENSG00000254352.1	RP11-578O24.2	4.16	4.54e-05	0.0175	0.34	0.27	Lymphocyte counts;	chr8:78643913	chr8:78723796~78724136:-
OV	cis	rs801193	0.66	rs2659914	ENSG00000236529.1	RP13-254B10.1	4.16	4.54e-05	0.0175	0.28	0.27	Aortic root size;	chr7:66691927	chr7:65840212~65840596:+
OV	cis	rs5742933	0.51	rs10182631	ENSG00000253559.1	OSGEPL1-AS1	-4.16	4.54e-05	0.0175	-0.34	-0.27	Ferritin levels;	chr2:189635233	chr2:189762704~189765556:+
OV	cis	rs367615	0.661	rs9326773	ENSG00000249476.1	CTD-2587M2.1	4.16	4.54e-05	0.0175	0.31	0.27	Colorectal cancer (SNP x SNP interaction);	chr5:109497822	chr5:109237120~109326369:-
OV	cis	rs8027521	0.871	rs7169118	ENSG00000280362.1	RP11-643A5.3	4.16	4.54e-05	0.0175	0.32	0.27	Circulating chemerin levels;	chr15:53969733	chr15:53910769~53914712:+
OV	cis	rs3758911	0.894	rs10502087	ENSG00000261098.1	RP11-819C21.1	-4.16	4.54e-05	0.0175	-0.25	-0.27	Coronary artery disease;	chr11:107381482	chr11:107312132~107316271:-
OV	cis	rs992157	0.798	rs10193383	ENSG00000261338.2	RP11-378A13.1	4.16	4.55e-05	0.0175	0.32	0.27	Colorectal cancer;	chr2:218292969	chr2:218255319~218257366:+
OV	cis	rs992157	0.798	rs10206064	ENSG00000261338.2	RP11-378A13.1	4.16	4.55e-05	0.0175	0.32	0.27	Colorectal cancer;	chr2:218293236	chr2:218255319~218257366:+
OV	cis	rs992157	0.7	rs10165153	ENSG00000261338.2	RP11-378A13.1	4.16	4.55e-05	0.0175	0.32	0.27	Colorectal cancer;	chr2:218294906	chr2:218255319~218257366:+
OV	cis	rs12999373	0.501	rs2867134	ENSG00000223751.1	AC116609.2	-4.16	4.55e-05	0.0175	-0.3	-0.27	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:697499	chr2:742488~747767:+
OV	cis	rs783540	0.967	rs783523	ENSG00000278603.1	RP13-608F4.5	4.16	4.55e-05	0.0175	0.3	0.27	Schizophrenia;	chr15:82614804	chr15:82472203~82472426:+
OV	cis	rs7200543	1	rs6498541	ENSG00000270580.4	PKD1P6	4.16	4.55e-05	0.0175	0.28	0.27	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046800	chr16:15104723~15131601:-
OV	cis	rs2015599	0.623	rs10843385	ENSG00000257176.2	RP11-996F15.2	-4.16	4.55e-05	0.0175	-0.34	-0.27	Platelet count;Mean platelet volume;	chr12:29323100	chr12:29280418~29317848:-
OV	cis	rs2015599	0.601	rs17715086	ENSG00000257176.2	RP11-996F15.2	-4.16	4.55e-05	0.0175	-0.34	-0.27	Platelet count;Mean platelet volume;	chr12:29329073	chr12:29280418~29317848:-
OV	cis	rs1528149	0.504	rs10950600	ENSG00000224683.1	RPL36AP29	-4.16	4.55e-05	0.0175	-0.31	-0.27	Sitting height ratio;	chr7:16063823	chr7:16208945~16209265:+
OV	cis	rs7246657	0.943	rs10426666	ENSG00000226686.6	LINC01535	-4.16	4.55e-05	0.0175	-0.4	-0.27	Coronary artery calcification;	chr19:37337612	chr19:37251912~37265535:+
OV	cis	rs5742933	1	rs3791767	ENSG00000253559.1	OSGEPL1-AS1	4.16	4.55e-05	0.0175	0.3	0.27	Ferritin levels;	chr2:189775189	chr2:189762704~189765556:+
OV	cis	rs1979679	1	rs6487672	ENSG00000278733.1	RP11-425D17.1	4.16	4.55e-05	0.0175	0.32	0.27	Ossification of the posterior longitudinal ligament of the spine;	chr12:28270413	chr12:28185625~28186190:-
OV	cis	rs757110	0.745	rs2074311	ENSG00000213779.4	RP11-452G18.1	-4.16	4.56e-05	0.0175	-0.3	-0.27	Type 2 diabetes;	chr11:17400313	chr11:17193489~17194308:+
OV	cis	rs4578769	0.55	rs9956087	ENSG00000242182.3	RN7SL745P	4.16	4.56e-05	0.0176	0.31	0.27	Eosinophil percentage of white cells;	chr18:23030538	chr18:23004564~23004862:+
OV	cis	rs4578769	0.55	rs6507452	ENSG00000242182.3	RN7SL745P	4.16	4.56e-05	0.0176	0.31	0.27	Eosinophil percentage of white cells;	chr18:23032275	chr18:23004564~23004862:+
OV	cis	rs12962334	0.555	rs9954649	ENSG00000242182.3	RN7SL745P	4.16	4.56e-05	0.0176	0.31	0.27	Breast cancer;	chr18:23033307	chr18:23004564~23004862:+
OV	cis	rs4578769	0.505	rs9946743	ENSG00000242182.3	RN7SL745P	4.16	4.56e-05	0.0176	0.31	0.27	Eosinophil percentage of white cells;	chr18:23033394	chr18:23004564~23004862:+
OV	cis	rs6673267	0.874	rs6427871	ENSG00000223774.4	RP11-307B6.3	4.16	4.56e-05	0.0176	0.29	0.27	Lobe attachment (rater-scored or self-reported);	chr1:201028188	chr1:201893842~201899978:+
OV	cis	rs7927771	0.524	rs10838782	ENSG00000280615.1	Y_RNA	4.16	4.57e-05	0.0176	0.28	0.27	Subjective well-being;	chr11:47856248	chr11:47614898~47614994:-
OV	cis	rs1950626	0.743	rs1956734	ENSG00000258399.5	MEG8	4.16	4.57e-05	0.0176	0.26	0.27	Pelvic organ prolapse (moderate/severe);	chr14:100933493	chr14:100894770~100935999:+
OV	cis	rs7789940	0.904	rs7459185	ENSG00000230305.2	AC004980.9	-4.16	4.57e-05	0.0176	-0.34	-0.27	Multiple sclerosis;	chr7:76305323	chr7:76524515~76532692:+
OV	cis	rs4845570	1	rs11586946	ENSG00000203288.3	RP11-98D18.9	-4.16	4.57e-05	0.0176	-0.45	-0.27	Coronary artery disease;	chr1:151797330	chr1:151790804~151794402:+
OV	cis	rs7119	0.717	rs12901471	ENSG00000259362.2	RP11-307C19.1	-4.16	4.57e-05	0.0176	-0.31	-0.27	Type 2 diabetes;	chr15:77526650	chr15:77525540~77534110:+
OV	cis	rs7520050	0.966	rs1707304	ENSG00000281133.1	AL355480.3	4.16	4.58e-05	0.0176	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:46132597	chr1:45580892~45580996:-
OV	cis	rs7017914	0.69	rs10453108	ENSG00000223220.1	Y_RNA	4.16	4.58e-05	0.0176	0.28	0.27	Bone mineral density;	chr8:70870705	chr8:70780914~70781008:-
OV	cis	rs2185570	0.543	rs72820645	ENSG00000234724.1	HDAC1P1	4.16	4.59e-05	0.0176	0.49	0.27	Dehydroepiandrosterone sulphate levels;	chr10:95117681	chr10:94137748~94139500:+
OV	cis	rs2070488	0.775	rs2070489	ENSG00000229589.1	ACVR2B-AS1	4.16	4.59e-05	0.0176	0.3	0.27	Electrocardiographic conduction measures;	chr3:38477933	chr3:38451027~38454820:-
OV	cis	rs80226907	0.634	rs713473	ENSG00000186615.9	KTN1-AS1	-4.16	4.59e-05	0.0176	-0.5	-0.27	Mean platelet volume;	chr14:55437978	chr14:55499278~55580110:-
OV	cis	rs62229266	0.804	rs2835241	ENSG00000231106.2	LINC01436	-4.16	4.59e-05	0.0177	-0.32	-0.27	Mitral valve prolapse;	chr21:36039082	chr21:36005338~36007838:+
OV	cis	rs853679	0.546	rs13195291	ENSG00000220721.1	OR1F12	4.16	4.6e-05	0.0177	0.55	0.27	Depression;	chr6:28201463	chr6:28073316~28074233:+
OV	cis	rs853679	0.556	rs13197633	ENSG00000220721.1	OR1F12	4.16	4.6e-05	0.0177	0.55	0.27	Depression;	chr6:28206979	chr6:28073316~28074233:+
OV	cis	rs801193	1	rs10252765	ENSG00000237310.1	GS1-124K5.4	4.16	4.6e-05	0.0177	0.28	0.27	Aortic root size;	chr7:66763745	chr7:66493706~66495474:+
OV	cis	rs593531	0.614	rs486758	ENSG00000280269.1	AP000577.2	-4.16	4.6e-05	0.0177	-0.32	-0.27	Neuroticism;	chr11:74347887	chr11:74204869~74205746:+
OV	cis	rs593531	0.614	rs623065	ENSG00000280269.1	AP000577.2	-4.16	4.6e-05	0.0177	-0.32	-0.27	Neuroticism;	chr11:74360165	chr11:74204869~74205746:+
OV	cis	rs7267979	0.933	rs1130694	ENSG00000274973.1	RP13-401N8.7	-4.16	4.6e-05	0.0177	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25295661	chr20:25845497~25845862:+
OV	cis	rs7267979	0.933	rs2258728	ENSG00000274973.1	RP13-401N8.7	-4.16	4.6e-05	0.0177	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25295707	chr20:25845497~25845862:+
OV	cis	rs9660180	0.967	rs9660106	ENSG00000215914.4	MMP23A	-4.16	4.6e-05	0.0177	-0.31	-0.27	Body mass index;	chr1:1866508	chr1:1699942~1701782:+
OV	cis	rs7520050	0.807	rs4660312	ENSG00000280836.1	AL355480.1	-4.16	4.6e-05	0.0177	-0.32	-0.27	Reticulocyte count;Red blood cell count;	chr1:45644900	chr1:45581219~45581321:-
OV	cis	rs7267979	1	rs7020	ENSG00000274973.1	RP13-401N8.7	-4.16	4.6e-05	0.0177	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25297964	chr20:25845497~25845862:+
OV	cis	rs6860806	0.507	rs273915	ENSG00000233006.5	AC034220.3	4.16	4.61e-05	0.0177	0.28	0.27	Breast cancer;	chr5:132324426	chr5:132311285~132369916:-
OV	cis	rs7520050	0.966	rs1707340	ENSG00000281133.1	AL355480.3	4.16	4.61e-05	0.0177	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:46049270	chr1:45580892~45580996:-
OV	cis	rs7520050	1	rs785473	ENSG00000281133.1	AL355480.3	4.16	4.61e-05	0.0177	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:46051191	chr1:45580892~45580996:-
OV	cis	rs7520050	0.931	rs785472	ENSG00000281133.1	AL355480.3	4.16	4.61e-05	0.0177	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:46052616	chr1:45580892~45580996:-
OV	cis	rs7968440	0.933	rs4768885	ENSG00000272368.2	RP4-605O3.4	-4.16	4.61e-05	0.0177	-0.29	-0.27	Fibrinogen;	chr12:50527989	chr12:50112197~50165618:+
OV	cis	rs7968440	0.902	rs4768886	ENSG00000272368.2	RP4-605O3.4	-4.16	4.61e-05	0.0177	-0.29	-0.27	Fibrinogen;	chr12:50528196	chr12:50112197~50165618:+
OV	cis	rs62244186	0.659	rs12489887	ENSG00000214820.3	MPRIPP1	4.15	4.61e-05	0.0177	0.24	0.27	Depressive symptoms;	chr3:44505632	chr3:44579938~44581026:-
OV	cis	rs274567	0.602	rs272853	ENSG00000233006.5	AC034220.3	4.15	4.62e-05	0.0177	0.27	0.27	Blood metabolite levels;	chr5:132352868	chr5:132311285~132369916:-
OV	cis	rs1075265	0.87	rs10207537	ENSG00000233266.1	HMGB1P31	4.15	4.62e-05	0.0177	0.32	0.27	Chronotype;Morning vs. evening chronotype;	chr2:54101700	chr2:54051334~54051760:+
OV	cis	rs853679	0.666	rs200956	ENSG00000220721.1	OR1F12	4.15	4.62e-05	0.0177	0.35	0.27	Depression;	chr6:27871968	chr6:28073316~28074233:+
OV	cis	rs11083475	1	rs11083475	ENSG00000267892.1	CTD-2540F13.2	4.15	4.62e-05	0.0177	0.29	0.27	Heart rate;	chr19:38697472	chr19:38738284~38739863:+
OV	cis	rs7267979	0.966	rs2261795	ENSG00000274973.1	RP13-401N8.7	-4.15	4.62e-05	0.0177	-0.3	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25282500	chr20:25845497~25845862:+
OV	cis	rs7927771	0.524	rs11039329	ENSG00000280615.1	Y_RNA	4.15	4.63e-05	0.0178	0.28	0.27	Subjective well-being;	chr11:47663356	chr11:47614898~47614994:-
OV	cis	rs7124681	0.528	rs74608150	ENSG00000280615.1	Y_RNA	4.15	4.63e-05	0.0178	0.28	0.27	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47674662	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs3758655	ENSG00000280615.1	Y_RNA	4.15	4.63e-05	0.0178	0.28	0.27	Subjective well-being;	chr11:47682391	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs7936948	ENSG00000280615.1	Y_RNA	4.15	4.63e-05	0.0178	0.28	0.27	Subjective well-being;	chr11:47682648	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs10838746	ENSG00000280615.1	Y_RNA	4.15	4.63e-05	0.0178	0.28	0.27	Subjective well-being;	chr11:47684739	chr11:47614898~47614994:-
OV	cis	rs7124681	0.584	rs10769285	ENSG00000280615.1	Y_RNA	4.15	4.63e-05	0.0178	0.28	0.27	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47687660	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs7943213	ENSG00000280615.1	Y_RNA	4.15	4.63e-05	0.0178	0.28	0.27	Subjective well-being;	chr11:47693972	chr11:47614898~47614994:-
OV	cis	rs7555523	0.83	rs6426936	ENSG00000224358.1	RP11-466F5.8	4.15	4.63e-05	0.0178	0.38	0.27	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165715470	chr1:165768929~165775176:+
OV	cis	rs10986311	0.681	rs10986291	ENSG00000227200.1	RP11-121A14.3	-4.15	4.63e-05	0.0178	-0.24	-0.27	Vitiligo;	chr9:124253992	chr9:124262876~124265809:+
OV	cis	rs6893300	0.785	rs3797762	ENSG00000254035.1	RP11-281O15.4	4.15	4.64e-05	0.0178	0.31	0.27	Resting heart rate;	chr5:179775687	chr5:178969390~178990116:+
OV	cis	rs3733585	0.699	rs12498956	ENSG00000250413.1	RP11-448G15.1	4.15	4.64e-05	0.0178	0.29	0.27	Cleft plate (environmental tobacco smoke interaction);	chr4:9949081	chr4:10006482~10009725:+
OV	cis	rs6088590	0.735	rs2273684	ENSG00000206582.1	Y_RNA	4.15	4.65e-05	0.0178	0.32	0.27	Coronary artery disease;	chr20:34941963	chr20:34526510~34526606:-
OV	cis	rs853679	0.882	rs9380069	ENSG00000220721.1	OR1F12	4.15	4.65e-05	0.0178	0.44	0.27	Depression;	chr6:28235522	chr6:28073316~28074233:+
OV	cis	rs2348418	0.639	rs10459086	ENSG00000247934.4	RP11-967K21.1	-4.15	4.65e-05	0.0178	-0.26	-0.27	Lung function (FEV1);Lung function (FVC);	chr12:28115511	chr12:28163298~28190738:-
OV	cis	rs66887589	0.777	rs10015883	ENSG00000245958.5	RP11-33B1.1	-4.15	4.65e-05	0.0178	-0.28	-0.27	Diastolic blood pressure;	chr4:119346991	chr4:119454791~119552025:+
OV	cis	rs875971	0.862	rs6460282	ENSG00000236529.1	RP13-254B10.1	-4.15	4.65e-05	0.0178	-0.28	-0.27	Aortic root size;	chr7:66226259	chr7:65840212~65840596:+
OV	cis	rs7520050	0.966	rs785495	ENSG00000281133.1	AL355480.3	4.15	4.65e-05	0.0178	0.31	0.27	Reticulocyte count;Red blood cell count;	chr1:46122215	chr1:45580892~45580996:-
OV	cis	rs7555523	0.83	rs6660601	ENSG00000224358.1	RP11-466F5.8	-4.15	4.65e-05	0.0178	-0.39	-0.27	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165726618	chr1:165768929~165775176:+
OV	cis	rs6061231	0.798	rs2427308	ENSG00000273619.1	RP5-908M14.9	-4.15	4.66e-05	0.0179	-0.29	-0.27	Colorectal cancer;	chr20:62394395	chr20:62386303~62386970:-
OV	cis	rs7520050	0.807	rs28844317	ENSG00000280836.1	AL355480.1	-4.15	4.66e-05	0.0179	-0.32	-0.27	Reticulocyte count;Red blood cell count;	chr1:45743535	chr1:45581219~45581321:-
OV	cis	rs7520050	0.807	rs6429576	ENSG00000280836.1	AL355480.1	-4.15	4.66e-05	0.0179	-0.32	-0.27	Reticulocyte count;Red blood cell count;	chr1:45750903	chr1:45581219~45581321:-
OV	cis	rs10759883	0.627	rs10125109	ENSG00000175611.10	LINC00476	-4.15	4.67e-05	0.0179	-0.33	-0.27	Nicotine dependence;	chr9:95799228	chr9:95759231~95875977:-
OV	cis	rs62244186	0.659	rs9855433	ENSG00000214820.3	MPRIPP1	4.15	4.67e-05	0.0179	0.24	0.27	Depressive symptoms;	chr3:44426573	chr3:44579938~44581026:-
OV	cis	rs1797885	0.763	rs709160	ENSG00000251774.1	RNU6-377P	4.15	4.67e-05	0.0179	0.24	0.27	Immature fraction of reticulocytes;	chr3:12484903	chr3:12514706~12514807:+
OV	cis	rs11083475	0.935	rs28488032	ENSG00000267892.1	CTD-2540F13.2	4.15	4.67e-05	0.0179	0.3	0.27	Heart rate;	chr19:38712248	chr19:38738284~38739863:+
OV	cis	rs7520050	0.966	rs785464	ENSG00000281133.1	AL355480.3	4.15	4.67e-05	0.0179	0.3	0.27	Reticulocyte count;Red blood cell count;	chr1:46057417	chr1:45580892~45580996:-
OV	cis	rs8177876	0.731	rs74878296	ENSG00000261838.4	RP11-303E16.6	4.15	4.67e-05	0.0179	0.56	0.27	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81071940	chr16:81069854~81076598:+
OV	cis	rs7188445	0.592	rs7199794	ENSG00000261390.4	RP11-345M22.2	4.15	4.67e-05	0.0179	0.29	0.27	Urate levels;	chr16:79708296	chr16:79715232~79770563:-
OV	cis	rs7200543	1	rs1136001	ENSG00000270580.4	PKD1P6	4.15	4.68e-05	0.0179	0.27	0.27	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038117	chr16:15104723~15131601:-
OV	cis	rs1862618	0.627	rs744023	ENSG00000271828.1	CTD-2310F14.1	4.15	4.68e-05	0.0179	0.46	0.27	Initial pursuit acceleration;	chr5:56901251	chr5:56927874~56929573:+
OV	cis	rs879620	1	rs2531995	ENSG00000275515.1	RP11-295D4.7	4.15	4.69e-05	0.018	0.3	0.27	Hip circumference;Body mass index;	chr16:3963466	chr16:4433202~4433387:-
OV	cis	rs853679	0.607	rs67340775	ENSG00000220721.1	OR1F12	4.15	4.69e-05	0.018	0.49	0.27	Depression;	chr6:28336607	chr6:28073316~28074233:+
OV	cis	rs7649443	0.959	rs12374173	ENSG00000235897.1	TM4SF19-AS1	4.15	4.69e-05	0.018	0.3	0.27	Nonsyndromic cleft lip with cleft palate;	chr3:197089418	chr3:196318330~196325570:+
OV	cis	rs2412819	0.571	rs112667279	ENSG00000205771.5	CATSPER2P1	-4.15	4.7e-05	0.018	-0.4	-0.27	Lung cancer;	chr15:43649258	chr15:43726918~43747094:-
OV	cis	rs55692468	0.804	rs1579050	ENSG00000213197.3	AC012066.1	4.15	4.7e-05	0.018	0.27	0.27	Intraocular pressure;	chr2:152508013	chr2:152389937~152390630:+
OV	cis	rs853679	1	rs1778508	ENSG00000220721.1	OR1F12	-4.15	4.7e-05	0.018	-0.37	-0.27	Depression;	chr6:28262103	chr6:28073316~28074233:+
OV	cis	rs2839627	0.561	rs2839601	ENSG00000225218.1	AP001628.6	4.15	4.7e-05	0.018	0.28	0.27	Information processing speed;	chr21:42897271	chr21:42831040~42836477:-
OV	cis	rs13113518	0.783	rs7690837	ENSG00000223305.1	RN7SKP30	4.15	4.7e-05	0.018	0.31	0.27	Height;	chr4:55575856	chr4:55540502~55540835:-
OV	cis	rs13113518	0.783	rs12510400	ENSG00000223305.1	RN7SKP30	4.15	4.7e-05	0.018	0.31	0.27	Height;	chr4:55577294	chr4:55540502~55540835:-
OV	cis	rs13113518	0.783	rs13111128	ENSG00000223305.1	RN7SKP30	4.15	4.7e-05	0.018	0.31	0.27	Height;	chr4:55578154	chr4:55540502~55540835:-
OV	cis	rs7555523	1	rs7555523	ENSG00000224358.1	RP11-466F5.8	-4.15	4.7e-05	0.018	-0.38	-0.27	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165749742	chr1:165768929~165775176:+
OV	cis	rs7555523	0.887	rs10800155	ENSG00000224358.1	RP11-466F5.8	-4.15	4.7e-05	0.018	-0.38	-0.27	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165754533	chr1:165768929~165775176:+
OV	cis	rs7555523	0.887	rs2251768	ENSG00000224358.1	RP11-466F5.8	-4.15	4.7e-05	0.018	-0.38	-0.27	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165769074	chr1:165768929~165775176:+
OV	cis	rs2070488	1	rs2268757	ENSG00000229589.1	ACVR2B-AS1	4.15	4.7e-05	0.018	0.29	0.27	Electrocardiographic conduction measures;	chr3:38464362	chr3:38451027~38454820:-
OV	cis	rs7726839	0.794	rs10474792	ENSG00000225138.6	CTD-2228K2.7	4.15	4.7e-05	0.018	0.33	0.27	Obesity-related traits;	chr5:599943	chr5:473236~480884:+
OV	cis	rs78545713	0.536	rs116337444	ENSG00000241549.7	GUSBP2	-4.15	4.7e-05	0.018	-0.46	-0.27	Iron status biomarkers (total iron binding capacity);	chr6:26208041	chr6:26871484~26956554:-
OV	cis	rs763121	0.853	rs138712	ENSG00000273076.1	RP3-508I15.22	4.15	4.71e-05	0.018	0.36	0.27	Menopause (age at onset);	chr22:38745595	chr22:38743495~38743910:+
OV	cis	rs12701220	0.504	rs12702092	ENSG00000229043.2	AC091729.9	-4.15	4.71e-05	0.018	-0.34	-0.27	Bronchopulmonary dysplasia;	chr7:1106232	chr7:1160374~1165267:+
OV	cis	rs7267979	1	rs2258719	ENSG00000274973.1	RP13-401N8.7	-4.15	4.71e-05	0.018	-0.31	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25295207	chr20:25845497~25845862:+
OV	cis	rs599083	0.793	rs471966	ENSG00000222339.1	AP000807.2	-4.15	4.72e-05	0.018	-0.27	-0.27	Bone mineral density (spine);	chr11:68406393	chr11:68505572~68505651:-
OV	cis	rs1559040	0.932	rs28368466	ENSG00000272156.1	RP11-477N3.1	-4.15	4.72e-05	0.0181	-0.46	-0.27	Sudden cardiac arrest;	chr2:54061824	chr2:54082554~54085066:+
OV	cis	rs853679	0.556	rs34706883	ENSG00000280107.1	AL022393.9	-4.15	4.73e-05	0.0181	-0.56	-0.27	Depression;	chr6:27837477	chr6:28170845~28172521:+
OV	cis	rs67340775	0.748	rs13212651	ENSG00000280107.1	AL022393.9	-4.15	4.73e-05	0.0181	-0.56	-0.27	Lung cancer in ever smokers;	chr6:27839207	chr6:28170845~28172521:+
OV	cis	rs6661961	0.752	rs4636462	ENSG00000237975.5	FLG-AS1	-4.15	4.73e-05	0.0181	-0.34	-0.27	Atopic dermatitis;	chr1:152442732	chr1:152168125~152445456:+
OV	cis	rs7267979	1	rs6083825	ENSG00000274973.1	RP13-401N8.7	4.15	4.73e-05	0.0181	0.3	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25385788	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs34645895	ENSG00000274973.1	RP13-401N8.7	4.15	4.73e-05	0.0181	0.3	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25387737	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6083828	ENSG00000274973.1	RP13-401N8.7	4.15	4.73e-05	0.0181	0.3	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25389282	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6115168	ENSG00000274973.1	RP13-401N8.7	4.15	4.73e-05	0.0181	0.3	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25392255	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6037105	ENSG00000274973.1	RP13-401N8.7	4.15	4.73e-05	0.0181	0.3	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25393563	chr20:25845497~25845862:+
OV	cis	rs58785573	1	rs58785573	ENSG00000231160.8	KLF3-AS1	-4.15	4.73e-05	0.0181	-0.24	-0.27	Lymphocyte percentage of white cells;	chr4:38652152	chr4:38612701~38664883:-
OV	cis	rs7017914	0.653	rs2732130	ENSG00000223220.1	Y_RNA	4.15	4.73e-05	0.0181	0.28	0.27	Bone mineral density;	chr8:70981238	chr8:70780914~70781008:-
OV	cis	rs7746199	0.736	rs13202295	ENSG00000280107.1	AL022393.9	-4.15	4.73e-05	0.0181	-0.54	-0.27	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:28170845~28172521:+
OV	cis	rs8005677	0.828	rs57822749	ENSG00000279656.1	RP11-298I3.6	4.15	4.74e-05	0.0181	0.3	0.27	Cognitive ability (multi-trait analysis);	chr14:22940758	chr14:23023083~23024217:-
OV	cis	rs17264034	0.5	rs10475468	ENSG00000250786.1	SNHG18	-4.15	4.74e-05	0.0181	-0.34	-0.27	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9538645	chr5:9546200~9550609:+
OV	cis	rs7927771	0.507	rs12366244	ENSG00000280615.1	Y_RNA	4.15	4.74e-05	0.0181	0.28	0.27	Subjective well-being;	chr11:47860578	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs10838784	ENSG00000280615.1	Y_RNA	4.15	4.74e-05	0.0181	0.28	0.27	Subjective well-being;	chr11:47860789	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs7933896	ENSG00000280615.1	Y_RNA	4.15	4.74e-05	0.0181	0.28	0.27	Subjective well-being;	chr11:47861230	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs7943464	ENSG00000280615.1	Y_RNA	4.15	4.74e-05	0.0181	0.28	0.27	Subjective well-being;	chr11:47865087	chr11:47614898~47614994:-
OV	cis	rs7124681	0.546	rs7941399	ENSG00000280615.1	Y_RNA	4.15	4.74e-05	0.0181	0.28	0.27	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47868869	chr11:47614898~47614994:-
OV	cis	rs4664293	0.51	rs2042781	ENSG00000226266.5	AC009961.3	4.15	4.74e-05	0.0181	0.32	0.27	Monocyte percentage of white cells;	chr2:159789899	chr2:159670708~159712435:-
OV	cis	rs9309473	1	rs3813227	ENSG00000163016.8	ALMS1P	-4.15	4.74e-05	0.0181	-0.31	-0.27	Metabolite levels;	chr2:73424839	chr2:73644919~73685576:+
OV	cis	rs1723838	0.826	rs4548648	ENSG00000255928.1	RP11-456I15.2	4.15	4.74e-05	0.0181	0.63	0.27	Obesity-related traits;	chr11:73790730	chr11:73722349~73722694:+
OV	cis	rs875971	0.789	rs10260426	ENSG00000236529.1	RP13-254B10.1	-4.15	4.75e-05	0.0181	-0.28	-0.27	Aortic root size;	chr7:66271055	chr7:65840212~65840596:+
OV	cis	rs875971	0.79	rs10257911	ENSG00000236529.1	RP13-254B10.1	-4.15	4.75e-05	0.0181	-0.28	-0.27	Aortic root size;	chr7:66278783	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs7796162	ENSG00000236529.1	RP13-254B10.1	-4.15	4.75e-05	0.0181	-0.28	-0.27	Aortic root size;	chr7:66280771	chr7:65840212~65840596:+
OV	cis	rs9660180	0.837	rs915292	ENSG00000215914.4	MMP23A	-4.15	4.75e-05	0.0181	-0.31	-0.27	Body mass index;	chr1:1860718	chr1:1699942~1701782:+
OV	cis	rs2282300	0.956	rs1717773	ENSG00000242353.1	RP4-710M3.1	-4.15	4.75e-05	0.0181	-0.39	-0.27	Morning vs. evening chronotype;	chr11:30361607	chr11:30368148~30368646:+
OV	cis	rs2999052	1	rs4857877	ENSG00000277250.1	Metazoa_SRP	4.15	4.75e-05	0.0182	0.31	0.27	Hypospadias;	chr3:128229217	chr3:128673681~128674021:-
OV	cis	rs11083475	1	rs9304578	ENSG00000267892.1	CTD-2540F13.2	-4.15	4.76e-05	0.0182	-0.29	-0.27	Heart rate;	chr19:38759697	chr19:38738284~38739863:+
OV	cis	rs1707322	0.752	rs28550303	ENSG00000234329.1	RP11-767N6.2	4.15	4.76e-05	0.0182	0.28	0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723242	chr1:45651039~45651826:-
OV	cis	rs1933112	1	rs1933112	ENSG00000227777.1	RP4-738P11.3	-4.15	4.76e-05	0.0182	-0.3	-0.27	Blood protein levels;	chr1:168552179	chr1:168542737~168543354:+
OV	cis	rs853679	0.882	rs9468300	ENSG00000226314.6	ZNF192P1	-4.15	4.76e-05	0.0182	-0.48	-0.27	Depression;	chr6:28159062	chr6:28161781~28169594:+
OV	cis	rs853679	0.825	rs8180562	ENSG00000226314.6	ZNF192P1	-4.15	4.76e-05	0.0182	-0.48	-0.27	Depression;	chr6:28173682	chr6:28161781~28169594:+
OV	cis	rs853679	0.607	rs200489	ENSG00000280107.1	AL022393.9	-4.15	4.76e-05	0.0182	-0.48	-0.27	Depression;	chr6:27830479	chr6:28170845~28172521:+
OV	cis	rs1797885	0.714	rs709161	ENSG00000251774.1	RNU6-377P	4.15	4.76e-05	0.0182	0.24	0.27	Immature fraction of reticulocytes;	chr3:12484689	chr3:12514706~12514807:+
OV	cis	rs4660456	0.504	rs491619	ENSG00000237899.1	RP4-739H11.3	4.15	4.76e-05	0.0182	0.39	0.27	Platelet count;	chr1:40641688	chr1:40669089~40687588:-
OV	cis	rs4660456	0.542	rs850009	ENSG00000237899.1	RP4-739H11.3	4.15	4.76e-05	0.0182	0.39	0.27	Platelet count;	chr1:40643593	chr1:40669089~40687588:-
OV	cis	rs11951515	0.663	rs35231094	ENSG00000278487.1	RP11-447H19.4	-4.15	4.77e-05	0.0182	-0.31	-0.27	Metabolite levels  (X-11787);	chr5:43281983	chr5:43143362~43143514:-
OV	cis	rs7017914	0.69	rs13280922	ENSG00000223220.1	Y_RNA	4.15	4.77e-05	0.0182	0.27	0.27	Bone mineral density;	chr8:70713163	chr8:70780914~70781008:-
OV	cis	rs4934494	0.689	rs17127588	ENSG00000240996.1	RP11-80H5.7	-4.15	4.77e-05	0.0182	-0.36	-0.27	Red blood cell count;	chr10:89815887	chr10:89694295~89697928:-
OV	cis	rs9847710	0.733	rs2581809	ENSG00000242142.1	SERBP1P3	4.15	4.77e-05	0.0182	0.32	0.27	Ulcerative colitis;	chr3:53055667	chr3:53064283~53065091:-
OV	cis	rs801193	0.569	rs35070132	ENSG00000237310.1	GS1-124K5.4	4.15	4.78e-05	0.0182	0.27	0.27	Aortic root size;	chr7:66773096	chr7:66493706~66495474:+
OV	cis	rs7824557	0.527	rs2572449	ENSG00000255556.2	RP11-351I21.6	4.15	4.78e-05	0.0182	0.28	0.27	Retinal vascular caliber;	chr8:11381628	chr8:12378679~12380265:-
OV	cis	rs9649213	0.574	rs12873	ENSG00000272950.1	RP11-307C18.1	4.15	4.78e-05	0.0182	0.31	0.27	Prostate cancer (SNP x SNP interaction);	chr7:98293461	chr7:98322853~98323430:+
OV	cis	rs853679	0.517	rs1947862	ENSG00000226314.6	ZNF192P1	-4.15	4.78e-05	0.0182	-0.35	-0.27	Depression;	chr6:28137418	chr6:28161781~28169594:+
OV	cis	rs2070488	0.804	rs7372452	ENSG00000229589.1	ACVR2B-AS1	4.15	4.78e-05	0.0182	0.3	0.27	Electrocardiographic conduction measures;	chr3:38402807	chr3:38451027~38454820:-
OV	cis	rs4296809	0.556	rs72755333	ENSG00000249779.1	RP11-447H19.3	-4.15	4.78e-05	0.0183	-0.53	-0.27	Brain structure;	chr5:44144087	chr5:43206709~43207811:+
OV	cis	rs12073359	1	rs72694954	ENSG00000223945.2	RP11-458I7.1	-4.15	4.78e-05	0.0183	-0.43	-0.27	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150151572	chr1:150053864~150055034:+
OV	cis	rs9880211	0.613	rs6786582	ENSG00000261758.1	RP11-102M11.2	4.15	4.79e-05	0.0183	0.33	0.27	Height;Body mass index;	chr3:136180142	chr3:136752630~136755780:+
OV	cis	rs694739	0.857	rs574835	ENSG00000236935.1	AP003774.1	4.15	4.79e-05	0.0183	0.35	0.27	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64343196	chr11:64325050~64329504:-
OV	cis	rs7617773	0.78	rs35297486	ENSG00000228638.1	FCF1P2	-4.15	4.79e-05	0.0183	-0.34	-0.27	Coronary artery disease;	chr3:48336657	chr3:48290793~48291375:-
OV	cis	rs7246657	0.943	rs10424574	ENSG00000226686.6	LINC01535	-4.15	4.79e-05	0.0183	-0.4	-0.27	Coronary artery calcification;	chr19:37347491	chr19:37251912~37265535:+
OV	cis	rs4763879	0.634	rs61915473	ENSG00000278635.1	CTD-2318O12.1	4.15	4.79e-05	0.0183	0.22	0.27	Type 1 diabetes;	chr12:9705282	chr12:9415641~9416718:+
OV	cis	rs4639966	0.589	rs480958	ENSG00000255422.1	AP002954.4	-4.15	4.8e-05	0.0183	-0.3	-0.27	Systemic lupus erythematosus;	chr11:118707281	chr11:118704607~118750263:+
OV	cis	rs9880211	0.948	rs34135127	ENSG00000239213.4	NCK1-AS1	4.14	4.8e-05	0.0183	0.32	0.27	Height;Body mass index;	chr3:136507656	chr3:136841726~136862054:-
OV	cis	rs73201462	0.908	rs2811388	ENSG00000277250.1	Metazoa_SRP	4.14	4.8e-05	0.0183	0.41	0.27	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128299604	chr3:128673681~128674021:-
OV	cis	rs2243480	0.901	rs73142137	ENSG00000226824.5	RP4-756H11.3	-4.14	4.81e-05	0.0183	-0.43	-0.27	Diabetic kidney disease;	chr7:65878455	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs13247184	ENSG00000226824.5	RP4-756H11.3	-4.14	4.81e-05	0.0183	-0.43	-0.27	Diabetic kidney disease;	chr7:65893941	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs35283677	ENSG00000226824.5	RP4-756H11.3	-4.14	4.81e-05	0.0183	-0.43	-0.27	Diabetic kidney disease;	chr7:65894246	chr7:66654538~66669855:+
OV	cis	rs2185570	0.605	rs67918795	ENSG00000234724.1	HDAC1P1	4.14	4.81e-05	0.0183	0.49	0.27	Dehydroepiandrosterone sulphate levels;	chr10:95116382	chr10:94137748~94139500:+
OV	cis	rs7726839	0.794	rs10053310	ENSG00000225138.6	CTD-2228K2.7	4.14	4.81e-05	0.0183	0.33	0.27	Obesity-related traits;	chr5:595546	chr5:473236~480884:+
OV	cis	rs7726839	0.718	rs6887972	ENSG00000225138.6	CTD-2228K2.7	4.14	4.81e-05	0.0183	0.33	0.27	Obesity-related traits;	chr5:597159	chr5:473236~480884:+
OV	cis	rs1167827	1	rs1167827	ENSG00000127957.15	PMS2P3	-4.14	4.81e-05	0.0183	-0.26	-0.27	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75502930~75528148:-
OV	cis	rs1723838	0.536	rs4944858	ENSG00000255928.1	RP11-456I15.2	-4.14	4.81e-05	0.0183	-0.57	-0.27	Obesity-related traits;	chr11:73708012	chr11:73722349~73722694:+
OV	cis	rs7267979	1	rs2387881	ENSG00000274973.1	RP13-401N8.7	4.14	4.81e-05	0.0183	0.3	0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25397536	chr20:25845497~25845862:+
OV	cis	rs1847134	0.674	rs4121401	ENSG00000280367.1	RP11-121L10.2	4.14	4.82e-05	0.0184	0.25	0.27	Eye color;Melanoma;	chr11:89246678	chr11:90223153~90226538:+
OV	cis	rs829883	0.664	rs249833	ENSG00000227825.4	SLC9A7P1	4.14	4.82e-05	0.0184	0.28	0.27	Colorectal adenoma (advanced);	chr12:98438411	chr12:98453835~98457145:-
OV	cis	rs829883	0.616	rs249832	ENSG00000227825.4	SLC9A7P1	4.14	4.82e-05	0.0184	0.28	0.27	Colorectal adenoma (advanced);	chr12:98438609	chr12:98453835~98457145:-
OV	cis	rs17767294	0.708	rs72848760	ENSG00000220721.1	OR1F12	4.14	4.82e-05	0.0184	0.55	0.27	Parkinson's disease;	chr6:27919099	chr6:28073316~28074233:+
OV	cis	rs17767294	0.708	rs72848763	ENSG00000220721.1	OR1F12	4.14	4.82e-05	0.0184	0.55	0.27	Parkinson's disease;	chr6:27934710	chr6:28073316~28074233:+
OV	cis	rs17767294	0.708	rs72848767	ENSG00000220721.1	OR1F12	4.14	4.82e-05	0.0184	0.55	0.27	Parkinson's disease;	chr6:27941509	chr6:28073316~28074233:+
OV	cis	rs17767294	0.708	rs72848769	ENSG00000220721.1	OR1F12	4.14	4.82e-05	0.0184	0.55	0.27	Parkinson's disease;	chr6:27950601	chr6:28073316~28074233:+
OV	cis	rs17767294	0.708	rs72848770	ENSG00000220721.1	OR1F12	4.14	4.82e-05	0.0184	0.55	0.27	Parkinson's disease;	chr6:27951371	chr6:28073316~28074233:+
OV	cis	rs2726040	0.902	rs33957528	ENSG00000259982.1	CDC37P1	-4.14	4.83e-05	0.0184	-0.32	-0.27	Hip circumference;	chr16:28296619	chr16:28700294~28701540:-
OV	cis	rs6921919	0.887	rs7766356	ENSG00000216901.1	AL022393.7	4.14	4.83e-05	0.0184	0.42	0.27	Autism spectrum disorder or schizophrenia;	chr6:28432761	chr6:28176188~28176674:+
OV	cis	rs270601	0.913	rs273916	ENSG00000233006.5	AC034220.3	4.14	4.84e-05	0.0184	0.28	0.27	Acylcarnitine levels;	chr5:132324137	chr5:132311285~132369916:-
OV	cis	rs1707322	0.686	rs2991977	ENSG00000234329.1	RP11-767N6.2	-4.14	4.84e-05	0.0184	-0.28	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45588011	chr1:45651039~45651826:-
OV	cis	rs1707322	0.656	rs2991981	ENSG00000234329.1	RP11-767N6.2	-4.14	4.84e-05	0.0184	-0.28	-0.27	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45591472	chr1:45651039~45651826:-
OV	cis	rs5742933	0.948	rs10195109	ENSG00000253559.1	OSGEPL1-AS1	4.14	4.84e-05	0.0184	0.29	0.27	Ferritin levels;	chr2:189704465	chr2:189762704~189765556:+
OV	cis	rs7520050	0.966	rs4073846	ENSG00000281133.1	AL355480.3	-4.14	4.85e-05	0.0184	-0.3	-0.27	Reticulocyte count;Red blood cell count;	chr1:45997209	chr1:45580892~45580996:-
OV	cis	rs62229266	0.804	rs2255858	ENSG00000231106.2	LINC01436	4.14	4.85e-05	0.0184	0.32	0.27	Mitral valve prolapse;	chr21:36040454	chr21:36005338~36007838:+
OV	cis	rs11083475	1	rs883433	ENSG00000267892.1	CTD-2540F13.2	-4.14	4.85e-05	0.0184	-0.3	-0.27	Heart rate;	chr19:38715648	chr19:38738284~38739863:+
OV	cis	rs7121800	0.962	rs1336515	ENSG00000254532.1	RP11-624D11.2	4.14	4.85e-05	0.0185	0.31	0.27	Pit-and-Fissure caries;	chr11:30503157	chr11:30044058~30084343:-
OV	cis	rs3758911	0.828	rs10890697	ENSG00000261098.1	RP11-819C21.1	-4.14	4.85e-05	0.0185	-0.26	-0.27	Coronary artery disease;	chr11:107307915	chr11:107312132~107316271:-
OV	cis	rs8059260	0.604	rs78753859	ENSG00000274038.1	RP11-66H6.4	-4.14	4.85e-05	0.0185	-0.54	-0.27	Alcohol consumption over the past year;	chr16:11052774	chr16:11056556~11057034:+
OV	cis	rs10246939	0.505	rs13236432	ENSG00000228775.6	WEE2-AS1	4.14	4.86e-05	0.0185	0.29	0.27	Bitter taste perception;	chr7:141850980	chr7:141704338~141738346:-
OV	cis	rs6545883	0.868	rs7608483	ENSG00000273302.1	RP11-493E12.2	4.14	4.86e-05	0.0185	0.22	0.27	Tuberculosis;	chr2:61609100	chr2:61199979~61200769:+
OV	cis	rs7968440	1	rs11609231	ENSG00000257298.1	RP3-405J10.3	4.14	4.86e-05	0.0185	0.26	0.27	Fibrinogen;	chr12:50538647	chr12:50185580~50191363:-
OV	cis	rs2185570	0.605	rs35564280	ENSG00000234724.1	HDAC1P1	4.14	4.86e-05	0.0185	0.47	0.27	Dehydroepiandrosterone sulphate levels;	chr10:95102164	chr10:94137748~94139500:+
OV	cis	rs2880765	0.835	rs7180923	ENSG00000259295.5	CSPG4P12	4.14	4.87e-05	0.0185	0.31	0.27	Coronary artery disease;	chr15:85507659	chr15:85191438~85213905:+
OV	cis	rs62229266	0.804	rs12483151	ENSG00000231106.2	LINC01436	4.14	4.87e-05	0.0185	0.32	0.27	Mitral valve prolapse;	chr21:36047280	chr21:36005338~36007838:+
OV	cis	rs62229266	0.804	rs880221	ENSG00000231106.2	LINC01436	4.14	4.87e-05	0.0185	0.32	0.27	Mitral valve prolapse;	chr21:36048487	chr21:36005338~36007838:+
OV	cis	rs12468226	1	rs16839090	ENSG00000272966.1	RP11-686O6.1	4.14	4.87e-05	0.0185	0.43	0.27	Urate levels;	chr2:202348338	chr2:202336739~202337200:+
OV	cis	rs7176527	1	rs3762169	ENSG00000229212.6	RP11-561C5.4	4.14	4.87e-05	0.0185	0.4	0.27	Waist circumference adjusted for BMI (joint analysis main effects and physical activity interaction);Waist circumference adjusted for body mass index;Waist circumference adjusted for BMI in active individuals;	chr15:84598728	chr15:85205440~85234795:-
OV	cis	rs897984	0.609	rs55979739	ENSG00000232748.3	RP11-196G11.6	-4.14	4.88e-05	0.0185	-0.28	-0.27	Dementia with Lewy bodies;	chr16:31037834	chr16:31056460~31062803:+
OV	cis	rs897984	0.609	rs732173	ENSG00000232748.3	RP11-196G11.6	-4.14	4.88e-05	0.0185	-0.28	-0.27	Dementia with Lewy bodies;	chr16:31038702	chr16:31056460~31062803:+
OV	cis	rs897984	0.609	rs732172	ENSG00000232748.3	RP11-196G11.6	-4.14	4.88e-05	0.0185	-0.28	-0.27	Dementia with Lewy bodies;	chr16:31038712	chr16:31056460~31062803:+
OV	cis	rs897984	0.609	rs1108431	ENSG00000232748.3	RP11-196G11.6	-4.14	4.88e-05	0.0185	-0.28	-0.27	Dementia with Lewy bodies;	chr16:31043286	chr16:31056460~31062803:+
OV	cis	rs9649213	0.593	rs6969731	ENSG00000272950.1	RP11-307C18.1	4.14	4.88e-05	0.0185	0.31	0.27	Prostate cancer (SNP x SNP interaction);	chr7:98295259	chr7:98322853~98323430:+
OV	cis	rs1538970	1	rs11211101	ENSG00000280836.1	AL355480.1	-4.14	4.88e-05	0.0185	-0.37	-0.27	Platelet count;	chr1:45383639	chr1:45581219~45581321:-
OV	cis	rs7267979	0.866	rs2424698	ENSG00000274973.1	RP13-401N8.7	-4.14	4.88e-05	0.0185	-0.3	-0.27	Liver enzyme levels (alkaline phosphatase);	chr20:25275470	chr20:25845497~25845862:+
OV	cis	rs7429990	0.803	rs13319205	ENSG00000229759.1	MRPS18AP1	4.14	4.88e-05	0.0186	0.3	0.27	Educational attainment (years of education);	chr3:47758726	chr3:48256350~48256938:-
OV	cis	rs2243480	1	rs1039664	ENSG00000226824.5	RP4-756H11.3	-4.14	4.88e-05	0.0186	-0.42	-0.27	Diabetic kidney disease;	chr7:65984729	chr7:66654538~66669855:+
OV	cis	rs4272382	1	rs4272382	ENSG00000253981.4	ALG1L13P	-4.14	4.89e-05	0.0186	-0.42	-0.26	Response to cytidine analogues (gemcitabine);	chr8:8575978	chr8:8236003~8244667:-
OV	cis	rs7771547	0.855	rs4713987	ENSG00000240733.3	RN7SL502P	4.14	4.89e-05	0.0186	0.29	0.26	Platelet distribution width;	chr6:36631233	chr6:36450912~36451201:-
OV	cis	rs394563	0.967	rs438852	ENSG00000231760.4	RP11-350J20.5	-4.14	4.89e-05	0.0186	-0.3	-0.26	Dupuytren's disease;	chr6:149473397	chr6:149796151~149826294:-
OV	cis	rs853679	0.546	rs175597	ENSG00000280107.1	AL022393.9	-4.14	4.89e-05	0.0186	-0.47	-0.26	Depression;	chr6:27842848	chr6:28170845~28172521:+
OV	cis	rs7536700	1	rs61806716	ENSG00000272030.1	RP1-178F15.4	-4.14	4.89e-05	0.0186	-0.6	-0.26	Multiple myeloma (IgH translocation);	chr1:153676671	chr1:153631438~153634397:-
OV	cis	rs7726839	0.794	rs10053310	ENSG00000271781.1	CTD-2589H19.6	-4.14	4.89e-05	0.0186	-0.34	-0.26	Obesity-related traits;	chr5:595546	chr5:675826~676616:+
OV	cis	rs7726839	0.718	rs6887972	ENSG00000271781.1	CTD-2589H19.6	-4.14	4.89e-05	0.0186	-0.34	-0.26	Obesity-related traits;	chr5:597159	chr5:675826~676616:+
OV	cis	rs913678	0.513	rs4811034	ENSG00000237595.3	RP11-112L6.3	-4.14	4.89e-05	0.0186	-0.37	-0.26	Granulocyte percentage of myeloid white cells;Inflammatory bowel disease;Ulcerative colitis;Monocyte percentage of white cells;Monocyte count;	chr20:50342928	chr20:50162765~50166102:-
OV	cis	rs9309473	1	rs13384952	ENSG00000163016.8	ALMS1P	-4.14	4.89e-05	0.0186	-0.34	-0.26	Metabolite levels;	chr2:73496832	chr2:73644919~73685576:+
OV	cis	rs45509595	0.822	rs200484	ENSG00000280107.1	AL022393.9	-4.14	4.9e-05	0.0186	-0.48	-0.26	Breast cancer;	chr6:27807896	chr6:28170845~28172521:+
OV	cis	rs45509595	0.841	rs9368531	ENSG00000280107.1	AL022393.9	-4.14	4.9e-05	0.0186	-0.48	-0.26	Breast cancer;	chr6:27814094	chr6:28170845~28172521:+
OV	cis	rs45509595	0.749	rs401763	ENSG00000280107.1	AL022393.9	-4.14	4.9e-05	0.0186	-0.48	-0.26	Breast cancer;	chr6:27814750	chr6:28170845~28172521:+
OV	cis	rs45509595	0.659	rs390764	ENSG00000280107.1	AL022393.9	-4.14	4.9e-05	0.0186	-0.48	-0.26	Breast cancer;	chr6:27814757	chr6:28170845~28172521:+
OV	cis	rs45509595	0.841	rs401754	ENSG00000280107.1	AL022393.9	-4.14	4.9e-05	0.0186	-0.48	-0.26	Breast cancer;	chr6:27814760	chr6:28170845~28172521:+
OV	cis	rs45509595	0.841	rs2747054	ENSG00000280107.1	AL022393.9	-4.14	4.9e-05	0.0186	-0.48	-0.26	Breast cancer;	chr6:27815581	chr6:28170845~28172521:+
OV	cis	rs45509595	0.841	rs200501	ENSG00000280107.1	AL022393.9	-4.14	4.9e-05	0.0186	-0.48	-0.26	Breast cancer;	chr6:27821164	chr6:28170845~28172521:+
OV	cis	rs2243480	1	rs313809	ENSG00000226824.5	RP4-756H11.3	-4.14	4.9e-05	0.0186	-0.43	-0.26	Diabetic kidney disease;	chr7:66034996	chr7:66654538~66669855:+
OV	cis	rs7520050	0.831	rs61783170	ENSG00000281133.1	AL355480.3	4.14	4.9e-05	0.0186	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45790657	chr1:45580892~45580996:-
OV	cis	rs694739	1	rs11231757	ENSG00000236935.1	AP003774.1	4.14	4.9e-05	0.0186	0.35	0.26	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338845	chr11:64325050~64329504:-
OV	cis	rs801193	1	rs2420824	ENSG00000224316.1	RP11-479O9.2	-4.14	4.91e-05	0.0186	-0.28	-0.26	Aortic root size;	chr7:66666129	chr7:65773620~65802067:+
OV	cis	rs10829156	0.607	rs4293025	ENSG00000225527.1	RP11-383B4.4	4.14	4.91e-05	0.0186	0.34	0.26	Sudden cardiac arrest;	chr10:18693315	chr10:18531849~18533336:-
OV	cis	rs875971	1	rs709597	ENSG00000236529.1	RP13-254B10.1	-4.14	4.92e-05	0.0187	-0.28	-0.26	Aortic root size;	chr7:66360996	chr7:65840212~65840596:+
OV	cis	rs7429990	0.864	rs11712464	ENSG00000229759.1	MRPS18AP1	4.14	4.92e-05	0.0187	0.3	0.26	Educational attainment (years of education);	chr3:47724057	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs56376646	ENSG00000229759.1	MRPS18AP1	4.14	4.92e-05	0.0187	0.3	0.26	Educational attainment (years of education);	chr3:47732588	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs11927129	ENSG00000229759.1	MRPS18AP1	4.14	4.92e-05	0.0187	0.3	0.26	Educational attainment (years of education);	chr3:47745413	chr3:48256350~48256938:-
OV	cis	rs7429990	0.828	rs55823596	ENSG00000229759.1	MRPS18AP1	4.14	4.92e-05	0.0187	0.3	0.26	Educational attainment (years of education);	chr3:47758541	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs4858853	ENSG00000229759.1	MRPS18AP1	4.14	4.92e-05	0.0187	0.3	0.26	Educational attainment (years of education);	chr3:47760605	chr3:48256350~48256938:-
OV	cis	rs7200543	1	rs14347	ENSG00000270580.4	PKD1P6	4.14	4.92e-05	0.0187	0.27	0.26	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15040032	chr16:15104723~15131601:-
OV	cis	rs11951515	0.738	rs7720681	ENSG00000278487.1	RP11-447H19.4	4.14	4.92e-05	0.0187	0.31	0.26	Metabolite levels  (X-11787);	chr5:43373205	chr5:43143362~43143514:-
OV	cis	rs10214930	0.671	rs9639553	ENSG00000235574.1	AC073150.6	4.14	4.92e-05	0.0187	0.31	0.26	Hypospadias;	chr7:27538548	chr7:27491682~27492765:-
OV	cis	rs9992667	0.955	rs73232881	ENSG00000231160.8	KLF3-AS1	4.14	4.92e-05	0.0187	0.32	0.26	Eosinophil percentage of granulocytes;	chr4:38662510	chr4:38612701~38664883:-
OV	cis	rs11122895	0.846	rs11692656	ENSG00000228251.1	AC012442.6	-4.14	4.92e-05	0.0187	-0.26	-0.26	Allergic sensitization;	chr2:111685147	chr2:112590796~112591939:+
OV	cis	rs875971	0.862	rs1875057	ENSG00000236529.1	RP13-254B10.1	-4.14	4.92e-05	0.0187	-0.27	-0.26	Aortic root size;	chr7:66266868	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs6960446	ENSG00000236529.1	RP13-254B10.1	-4.14	4.92e-05	0.0187	-0.27	-0.26	Aortic root size;	chr7:66268272	chr7:65840212~65840596:+
OV	cis	rs10266483	0.739	rs2692104	ENSG00000232727.2	YWHAEP1	4.14	4.93e-05	0.0187	0.31	0.26	Response to statin therapy;	chr7:64300577	chr7:64433830~64434592:+
OV	cis	rs7267979	0.966	rs2261790	ENSG00000274973.1	RP13-401N8.7	-4.14	4.93e-05	0.0187	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25282153	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs2261794	ENSG00000274973.1	RP13-401N8.7	-4.14	4.93e-05	0.0187	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25282426	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs2145126	ENSG00000274973.1	RP13-401N8.7	-4.14	4.93e-05	0.0187	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25283012	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs910996	ENSG00000274973.1	RP13-401N8.7	-4.14	4.93e-05	0.0187	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25283560	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs2257705	ENSG00000274973.1	RP13-401N8.7	-4.14	4.93e-05	0.0187	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25284028	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs2227892	ENSG00000274973.1	RP13-401N8.7	-4.14	4.93e-05	0.0187	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25284178	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs2257712	ENSG00000274973.1	RP13-401N8.7	-4.14	4.93e-05	0.0187	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25284274	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs2257461	ENSG00000274973.1	RP13-401N8.7	-4.14	4.93e-05	0.0187	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25284918	chr20:25845497~25845862:+
OV	cis	rs6788497	0.708	rs72977381	ENSG00000242551.2	POU5F1P6	4.14	4.93e-05	0.0187	0.48	0.26	Post bronchodilator FEV1;Post bronchodilator FEV1/FVC ratio;	chr3:128397055	chr3:128674735~128677005:-
OV	cis	rs8059260	0.604	rs9940096	ENSG00000274038.1	RP11-66H6.4	-4.14	4.93e-05	0.0187	-0.52	-0.26	Alcohol consumption over the past year;	chr16:11045737	chr16:11056556~11057034:+
OV	cis	rs62229266	0.804	rs2835263	ENSG00000231106.2	LINC01436	-4.14	4.93e-05	0.0187	-0.32	-0.26	Mitral valve prolapse;	chr21:36057947	chr21:36005338~36007838:+
OV	cis	rs1113500	0.862	rs2336128	ENSG00000226822.1	RP11-356N1.2	4.14	4.93e-05	0.0187	0.32	0.26	Growth-regulated protein alpha levels;	chr1:108098117	chr1:108071482~108074519:+
OV	cis	rs7520050	0.966	rs785494	ENSG00000281133.1	AL355480.3	4.14	4.94e-05	0.0187	0.3	0.26	Reticulocyte count;Red blood cell count;	chr1:46120954	chr1:45580892~45580996:-
OV	cis	rs3733585	0.699	rs4408959	ENSG00000250413.1	RP11-448G15.1	4.14	4.94e-05	0.0187	0.29	0.26	Cleft plate (environmental tobacco smoke interaction);	chr4:9947244	chr4:10006482~10009725:+
OV	cis	rs3733585	0.699	rs4276278	ENSG00000250413.1	RP11-448G15.1	4.14	4.94e-05	0.0187	0.29	0.26	Cleft plate (environmental tobacco smoke interaction);	chr4:9947246	chr4:10006482~10009725:+
OV	cis	rs7121800	0.962	rs11031119	ENSG00000254532.1	RP11-624D11.2	4.14	4.95e-05	0.0187	0.31	0.26	Pit-and-Fissure caries;	chr11:30504226	chr11:30044058~30084343:-
OV	cis	rs12073359	1	rs72692901	ENSG00000223945.2	RP11-458I7.1	-4.14	4.95e-05	0.0188	-0.41	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150084424	chr1:150053864~150055034:+
OV	cis	rs7726839	0.794	rs6883536	ENSG00000271781.1	CTD-2589H19.6	-4.14	4.95e-05	0.0188	-0.34	-0.26	Obesity-related traits;	chr5:599159	chr5:675826~676616:+
OV	cis	rs4414128	0.832	rs2386649	ENSG00000232807.2	RP11-536K7.3	4.14	4.95e-05	0.0188	0.37	0.26	Breast cancer;	chr10:5638879	chr10:5934270~5945900:-
OV	cis	rs7079041	1	rs7079041	ENSG00000273038.2	RP11-479G22.8	-4.14	4.95e-05	0.0188	-0.3	-0.26	Suicide in bipolar disorder;	chr10:32704340	chr10:32887255~32889311:-
OV	cis	rs11951515	0.738	rs10941630	ENSG00000278487.1	RP11-447H19.4	-4.14	4.96e-05	0.0188	-0.31	-0.26	Metabolite levels  (X-11787);	chr5:43350116	chr5:43143362~43143514:-
OV	cis	rs11951515	0.738	rs6887351	ENSG00000278487.1	RP11-447H19.4	-4.14	4.96e-05	0.0188	-0.31	-0.26	Metabolite levels  (X-11787);	chr5:43350203	chr5:43143362~43143514:-
OV	cis	rs11951515	0.738	rs11738086	ENSG00000278487.1	RP11-447H19.4	-4.14	4.96e-05	0.0188	-0.31	-0.26	Metabolite levels  (X-11787);	chr5:43352399	chr5:43143362~43143514:-
OV	cis	rs4266144	0.562	rs2086667	ENSG00000244515.1	KRT18P34	-4.14	4.96e-05	0.0188	-0.34	-0.26	Coronary artery disease;	chr3:157118728	chr3:157162663~157163932:-
OV	cis	rs67311347	0.544	rs4974040	ENSG00000223797.4	ENTPD3-AS1	4.14	4.96e-05	0.0188	0.27	0.26	Renal cell carcinoma;	chr3:40289568	chr3:40313802~40453329:-
OV	cis	rs7555523	0.887	rs2814471	ENSG00000224358.1	RP11-466F5.8	-4.14	4.96e-05	0.0188	-0.38	-0.26	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165770361	chr1:165768929~165775176:+
OV	cis	rs6921919	0.583	rs7759191	ENSG00000204709.4	LINC01556	4.14	4.96e-05	0.0188	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28385657	chr6:28943877~28944537:+
OV	cis	rs7267979	0.934	rs2257464	ENSG00000274973.1	RP13-401N8.7	-4.14	4.96e-05	0.0188	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25285236	chr20:25845497~25845862:+
OV	cis	rs801193	1	rs2659915	ENSG00000224316.1	RP11-479O9.2	4.14	4.96e-05	0.0188	0.28	0.26	Aortic root size;	chr7:66688114	chr7:65773620~65802067:+
OV	cis	rs2492286	0.597	rs2712372	ENSG00000242551.2	POU5F1P6	-4.14	4.97e-05	0.0188	-0.35	-0.26	Eosinophil counts;	chr3:128604994	chr3:128674735~128677005:-
OV	cis	rs2492286	0.597	rs2712407	ENSG00000242551.2	POU5F1P6	-4.14	4.97e-05	0.0188	-0.35	-0.26	Eosinophil counts;	chr3:128607964	chr3:128674735~128677005:-
OV	cis	rs4591358	0.765	rs16836629	ENSG00000223466.1	AC064834.2	4.14	4.97e-05	0.0188	0.31	0.26	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195499385	chr2:195533035~195538681:+
OV	cis	rs12468226	1	rs13389798	ENSG00000272966.1	RP11-686O6.1	4.14	4.98e-05	0.0188	0.44	0.26	Urate levels;	chr2:202348370	chr2:202336739~202337200:+
OV	cis	rs7017914	0.69	rs4446768	ENSG00000223220.1	Y_RNA	4.14	4.98e-05	0.0189	0.28	0.26	Bone mineral density;	chr8:70865354	chr8:70780914~70781008:-
OV	cis	rs6142102	0.812	rs761238	ENSG00000264616.1	MIR4755	-4.14	4.98e-05	0.0189	-0.32	-0.26	Skin pigmentation;	chr20:33932182	chr20:34049119~34049190:+
OV	cis	rs992157	0.71	rs10169718	ENSG00000237281.1	CATIP-AS2	4.14	4.99e-05	0.0189	0.31	0.26	Colorectal cancer;	chr2:218238857	chr2:218326889~218357966:-
OV	cis	rs9992667	0.955	rs66709517	ENSG00000231160.8	KLF3-AS1	4.14	4.99e-05	0.0189	0.31	0.26	Eosinophil percentage of granulocytes;	chr4:38647772	chr4:38612701~38664883:-
OV	cis	rs2919917	0.628	rs1351742	ENSG00000254352.1	RP11-578O24.2	4.14	4.99e-05	0.0189	0.35	0.26	Lymphocyte counts;	chr8:78655823	chr8:78723796~78724136:-
OV	cis	rs2919917	0.666	rs982032	ENSG00000254352.1	RP11-578O24.2	4.14	4.99e-05	0.0189	0.35	0.26	Lymphocyte counts;	chr8:78655825	chr8:78723796~78724136:-
OV	cis	rs2919917	0.628	rs13265305	ENSG00000254352.1	RP11-578O24.2	4.14	4.99e-05	0.0189	0.35	0.26	Lymphocyte counts;	chr8:78656575	chr8:78723796~78724136:-
OV	cis	rs886448	1	rs886448	ENSG00000232818.2	RPS2P32	-4.14	4.99e-05	0.0189	-0.59	-0.26	Asthma (childhood onset);	chr7:24200546	chr7:23490473~23491364:+
OV	cis	rs757081	0.648	rs7108316	ENSG00000213779.4	RP11-452G18.1	4.14	5e-05	0.0189	0.29	0.26	Systolic blood pressure;	chr11:17253488	chr11:17193489~17194308:+
OV	cis	rs944801	0.545	rs10811643	ENSG00000234840.1	LINC01239	-4.14	5e-05	0.0189	-0.29	-0.26	Type 2 diabetes;	chr9:22024967	chr9:22646200~22824213:+
OV	cis	rs944801	0.545	rs10811644	ENSG00000234840.1	LINC01239	-4.14	5e-05	0.0189	-0.29	-0.26	Type 2 diabetes;	chr9:22025068	chr9:22646200~22824213:+
OV	cis	rs944801	0.526	rs7035484	ENSG00000234840.1	LINC01239	-4.14	5e-05	0.0189	-0.29	-0.26	Type 2 diabetes;	chr9:22025241	chr9:22646200~22824213:+
OV	cis	rs112744032	1	rs112744032	ENSG00000240350.2	AC017002.1	-4.13	5e-05	0.0189	-0.38	-0.26	Mean corpuscular hemoglobin;	chr2:111521757	chr2:111491273~111570974:+
OV	cis	rs62162297	1	rs62162297	ENSG00000240350.2	AC017002.1	-4.13	5e-05	0.0189	-0.38	-0.26	Red blood cell count;	chr2:111521758	chr2:111491273~111570974:+
OV	cis	rs1933112	1	rs2223583	ENSG00000227777.1	RP4-738P11.3	-4.13	5e-05	0.0189	-0.3	-0.26	Blood protein levels;	chr1:168556178	chr1:168542737~168543354:+
OV	cis	rs1933112	0.966	rs4656605	ENSG00000227777.1	RP4-738P11.3	-4.13	5e-05	0.0189	-0.3	-0.26	Blood protein levels;	chr1:168556659	chr1:168542737~168543354:+
OV	cis	rs1933112	1	rs1024176	ENSG00000227777.1	RP4-738P11.3	-4.13	5e-05	0.0189	-0.3	-0.26	Blood protein levels;	chr1:168556865	chr1:168542737~168543354:+
OV	cis	rs4296809	0.556	rs12054795	ENSG00000249779.1	RP11-447H19.3	-4.13	5e-05	0.0189	-0.52	-0.26	Brain structure;	chr5:44134991	chr5:43206709~43207811:+
OV	cis	rs4296809	0.556	rs72755325	ENSG00000249779.1	RP11-447H19.3	-4.13	5e-05	0.0189	-0.52	-0.26	Brain structure;	chr5:44139570	chr5:43206709~43207811:+
OV	cis	rs4296809	0.556	rs72755336	ENSG00000249779.1	RP11-447H19.3	-4.13	5e-05	0.0189	-0.52	-0.26	Brain structure;	chr5:44145753	chr5:43206709~43207811:+
OV	cis	rs4296809	0.505	rs56401540	ENSG00000249779.1	RP11-447H19.3	-4.13	5e-05	0.0189	-0.52	-0.26	Brain structure;	chr5:44147510	chr5:43206709~43207811:+
OV	cis	rs7267979	1	rs6107033	ENSG00000274973.1	RP13-401N8.7	4.13	5e-05	0.0189	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25382955	chr20:25845497~25845862:+
OV	cis	rs9438901	0.614	rs2375278	ENSG00000259984.1	RP11-335G20.7	-4.13	5.01e-05	0.0189	-0.3	-0.26	Red cell distribution width;	chr1:25202547	chr1:25336429~25337465:-
OV	cis	rs4845570	0.834	rs13376155	ENSG00000203288.3	RP11-98D18.9	-4.13	5.01e-05	0.0189	-0.46	-0.26	Coronary artery disease;	chr1:151748794	chr1:151790804~151794402:+
OV	cis	rs2243480	0.803	rs36127118	ENSG00000226824.5	RP4-756H11.3	-4.13	5.01e-05	0.0189	-0.43	-0.26	Diabetic kidney disease;	chr7:66100518	chr7:66654538~66669855:+
OV	cis	rs6860806	0.507	rs272892	ENSG00000233006.5	AC034220.3	4.13	5.01e-05	0.0189	0.28	0.26	Breast cancer;	chr5:132328656	chr5:132311285~132369916:-
OV	cis	rs7246657	1	rs35398388	ENSG00000226686.6	LINC01535	-4.13	5.01e-05	0.0189	-0.41	-0.26	Coronary artery calcification;	chr19:37249456	chr19:37251912~37265535:+
OV	cis	rs7200543	1	rs2740	ENSG00000270580.4	PKD1P6	4.13	5.02e-05	0.019	0.28	0.26	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15038251	chr16:15104723~15131601:-
OV	cis	rs1113500	0.805	rs11185244	ENSG00000226822.1	RP11-356N1.2	4.13	5.02e-05	0.019	0.31	0.26	Growth-regulated protein alpha levels;	chr1:108058525	chr1:108071482~108074519:+
OV	cis	rs1113500	0.814	rs1592282	ENSG00000226822.1	RP11-356N1.2	4.13	5.02e-05	0.019	0.31	0.26	Growth-regulated protein alpha levels;	chr1:108058743	chr1:108071482~108074519:+
OV	cis	rs801193	0.548	rs6975044	ENSG00000237310.1	GS1-124K5.4	4.13	5.02e-05	0.019	0.27	0.26	Aortic root size;	chr7:66762495	chr7:66493706~66495474:+
OV	cis	rs11159086	0.941	rs12434836	ENSG00000270000.1	RP3-449M8.9	4.13	5.02e-05	0.019	0.41	0.26	Advanced glycation end-product levels;	chr14:74468887	chr14:74471930~74472360:-
OV	cis	rs11159086	1	rs11626856	ENSG00000270000.1	RP3-449M8.9	4.13	5.02e-05	0.019	0.41	0.26	Advanced glycation end-product levels;	chr14:74469665	chr14:74471930~74472360:-
OV	cis	rs6558530	0.836	rs11136424	ENSG00000253982.1	CTD-2336O2.1	4.13	5.02e-05	0.019	0.32	0.26	Systolic blood pressure;	chr8:1768870	chr8:1761990~1764502:-
OV	cis	rs2348418	0.801	rs7298379	ENSG00000247934.4	RP11-967K21.1	4.13	5.02e-05	0.019	0.26	0.26	Lung function (FEV1);Lung function (FVC);	chr12:28270541	chr12:28163298~28190738:-
OV	cis	rs7811142	0.943	rs10241492	ENSG00000242294.5	STAG3L5P	4.13	5.02e-05	0.019	0.28	0.26	Platelet count;	chr7:100397190	chr7:100336079~100351900:+
OV	cis	rs427941	0.632	rs201503	ENSG00000272219.1	CTB-181H17.1	-4.13	5.02e-05	0.019	-0.22	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr7:102116315	chr7:101960116~101961894:+
OV	cis	rs875971	0.545	rs73376394	ENSG00000273024.4	INTS4P2	-4.13	5.02e-05	0.019	-0.31	-0.26	Aortic root size;	chr7:66172694	chr7:65647864~65715661:+
OV	cis	rs12073359	0.955	rs2319280	ENSG00000223945.2	RP11-458I7.1	4.13	5.02e-05	0.019	0.43	0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150042041	chr1:150053864~150055034:+
OV	cis	rs757081	0.648	rs7108315	ENSG00000213779.4	RP11-452G18.1	4.13	5.03e-05	0.019	0.29	0.26	Systolic blood pressure;	chr11:17245617	chr11:17193489~17194308:+
OV	cis	rs11083475	1	rs3745859	ENSG00000267892.1	CTD-2540F13.2	4.13	5.03e-05	0.019	0.3	0.26	Heart rate;	chr19:38706105	chr19:38738284~38739863:+
OV	cis	rs9992667	0.911	rs28656945	ENSG00000231160.8	KLF3-AS1	4.13	5.03e-05	0.019	0.32	0.26	Eosinophil percentage of granulocytes;	chr4:38665125	chr4:38612701~38664883:-
OV	cis	rs12480328	1	rs6091237	ENSG00000233077.1	LINC01271	4.13	5.03e-05	0.019	0.62	0.26	Prostate cancer;	chr20:50909450	chr20:50310711~50321342:-
OV	cis	rs757081	0.648	rs214102	ENSG00000213779.4	RP11-452G18.1	4.13	5.03e-05	0.019	0.3	0.26	Systolic blood pressure;	chr11:17266751	chr11:17193489~17194308:+
OV	cis	rs7520050	0.966	rs9429183	ENSG00000281133.1	AL355480.3	4.13	5.03e-05	0.019	0.3	0.26	Reticulocyte count;Red blood cell count;	chr1:46058910	chr1:45580892~45580996:-
OV	cis	rs1538970	0.962	rs3219489	ENSG00000280836.1	AL355480.1	-4.13	5.03e-05	0.019	-0.37	-0.26	Platelet count;	chr1:45331833	chr1:45581219~45581321:-
OV	cis	rs11903757	1	rs6731095	ENSG00000281467.1	Clostridiales-1	4.13	5.04e-05	0.019	0.43	0.26	Colorectal cancer;	chr2:191724716	chr2:191699476~191699631:-
OV	cis	rs7746199	0.736	rs6904596	ENSG00000280107.1	AL022393.9	-4.13	5.04e-05	0.019	-0.55	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27523520	chr6:28170845~28172521:+
OV	cis	rs8023445	0.85	rs16961733	ENSG00000259488.2	RP11-154J22.1	-4.13	5.04e-05	0.019	-0.27	-0.26	Major depressive disorder;	chr15:48856159	chr15:48312353~48331856:-
OV	cis	rs7520050	0.966	rs11579634	ENSG00000281133.1	AL355480.3	-4.13	5.04e-05	0.019	-0.3	-0.26	Reticulocyte count;Red blood cell count;	chr1:46000719	chr1:45580892~45580996:-
OV	cis	rs6860806	0.507	rs270601	ENSG00000233006.5	AC034220.3	4.13	5.04e-05	0.019	0.28	0.26	Breast cancer;	chr5:132321304	chr5:132311285~132369916:-
OV	cis	rs2412819	0.571	rs17727853	ENSG00000205771.5	CATSPER2P1	-4.13	5.05e-05	0.0191	-0.4	-0.26	Lung cancer;	chr15:43630299	chr15:43726918~43747094:-
OV	cis	rs67311347	1	rs9848083	ENSG00000223797.4	ENTPD3-AS1	-4.13	5.05e-05	0.0191	-0.29	-0.26	Renal cell carcinoma;	chr3:40425488	chr3:40313802~40453329:-
OV	cis	rs9992667	0.955	rs1491199	ENSG00000231160.8	KLF3-AS1	4.13	5.05e-05	0.0191	0.3	0.26	Eosinophil percentage of granulocytes;	chr4:38641393	chr4:38612701~38664883:-
OV	cis	rs9326248	1	rs4938344	ENSG00000280143.1	AP000892.6	4.13	5.05e-05	0.0191	0.31	0.26	Blood protein levels;	chr11:117133033	chr11:117204967~117210292:+
OV	cis	rs7746199	0.736	rs13202291	ENSG00000280107.1	AL022393.9	-4.13	5.06e-05	0.0191	-0.53	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:28170845~28172521:+
OV	cis	rs801193	0.935	rs2659916	ENSG00000224316.1	RP11-479O9.2	4.13	5.06e-05	0.0191	0.28	0.26	Aortic root size;	chr7:66686365	chr7:65773620~65802067:+
OV	cis	rs35160687	0.736	rs6746198	ENSG00000273080.1	RP11-301O19.1	-4.13	5.07e-05	0.0191	-0.25	-0.26	Night sleep phenotypes;	chr2:86314990	chr2:86195590~86196049:+
OV	cis	rs11168351	0.591	rs4258439	ENSG00000240399.1	RP1-228P16.1	-4.13	5.07e-05	0.0191	-0.29	-0.26	Bipolar disorder and schizophrenia;	chr12:48074869	chr12:48054813~48055591:-
OV	cis	rs733592	0.507	rs10747529	ENSG00000240399.1	RP1-228P16.1	-4.13	5.07e-05	0.0191	-0.29	-0.26	Plateletcrit;	chr12:48079586	chr12:48054813~48055591:-
OV	cis	rs6700559	0.74	rs4387211	ENSG00000260088.1	RP11-92G12.3	-4.13	5.07e-05	0.0191	-0.27	-0.26	Coronary artery disease;	chr1:200676810	chr1:200669507~200694250:+
OV	cis	rs13068223	0.84	rs1469536	ENSG00000243926.1	TIPARP-AS1	4.13	5.07e-05	0.0191	0.24	0.26	Age-related hearing impairment (SNP x SNP interaction);	chr3:156710038	chr3:156671862~156674378:-
OV	cis	rs875971	0.545	rs6970498	ENSG00000237310.1	GS1-124K5.4	4.13	5.08e-05	0.0191	0.31	0.26	Aortic root size;	chr7:66275908	chr7:66493706~66495474:+
OV	cis	rs7267979	1	rs4813563	ENSG00000274973.1	RP13-401N8.7	4.13	5.08e-05	0.0191	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25384704	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs6037103	ENSG00000274973.1	RP13-401N8.7	4.13	5.08e-05	0.0191	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25388459	chr20:25845497~25845862:+
OV	cis	rs7927771	0.507	rs1483988	ENSG00000280615.1	Y_RNA	4.13	5.08e-05	0.0191	0.28	0.26	Subjective well-being;	chr11:47877478	chr11:47614898~47614994:-
OV	cis	rs6445967	0.966	rs9857570	ENSG00000272360.1	RP11-359I18.5	4.13	5.08e-05	0.0191	0.28	0.26	Platelet count;	chr3:58294963	chr3:58490830~58491291:-
OV	cis	rs4703129	0.506	rs1002268	ENSG00000249448.1	RP11-474J18.1	4.13	5.08e-05	0.0192	0.3	0.26	Asperger disorder;	chr5:98431093	chr5:98410235~98411792:-
OV	cis	rs10783487	0.895	rs10876232	ENSG00000258279.2	LINC00592	4.13	5.08e-05	0.0192	0.36	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr12:52072572	chr12:52210930~52223804:+
OV	cis	rs367615	0.704	rs60538082	ENSG00000249476.1	CTD-2587M2.1	4.13	5.09e-05	0.0192	0.32	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109493400	chr5:109237120~109326369:-
OV	cis	rs7927592	0.546	rs638076	ENSG00000212093.1	AP000807.1	4.13	5.09e-05	0.0192	0.31	0.26	Total body bone mineral density;	chr11:68435112	chr11:68506083~68506166:-
OV	cis	rs17767294	0.708	rs41269275	ENSG00000219392.1	RP1-265C24.5	-4.13	5.09e-05	0.0192	-0.55	-0.26	Parkinson's disease;	chr6:27865537	chr6:28115628~28116551:+
OV	cis	rs17767294	0.708	rs72847361	ENSG00000219392.1	RP1-265C24.5	-4.13	5.09e-05	0.0192	-0.55	-0.26	Parkinson's disease;	chr6:27866438	chr6:28115628~28116551:+
OV	cis	rs17767294	0.708	rs34144478	ENSG00000219392.1	RP1-265C24.5	-4.13	5.09e-05	0.0192	-0.55	-0.26	Parkinson's disease;	chr6:27866899	chr6:28115628~28116551:+
OV	cis	rs17767294	0.708	rs72847365	ENSG00000219392.1	RP1-265C24.5	-4.13	5.09e-05	0.0192	-0.55	-0.26	Parkinson's disease;	chr6:27869449	chr6:28115628~28116551:+
OV	cis	rs9468199	0.51	rs77576207	ENSG00000219392.1	RP1-265C24.5	-4.13	5.09e-05	0.0192	-0.55	-0.26	Parkinson's disease;	chr6:27874377	chr6:28115628~28116551:+
OV	cis	rs17767294	0.708	rs115736281	ENSG00000219392.1	RP1-265C24.5	-4.13	5.09e-05	0.0192	-0.55	-0.26	Parkinson's disease;	chr6:27875110	chr6:28115628~28116551:+
OV	cis	rs17767294	0.522	rs78037434	ENSG00000219392.1	RP1-265C24.5	-4.13	5.09e-05	0.0192	-0.55	-0.26	Parkinson's disease;	chr6:27881120	chr6:28115628~28116551:+
OV	cis	rs853679	0.546	rs200490	ENSG00000226314.6	ZNF192P1	-4.13	5.09e-05	0.0192	-0.48	-0.26	Depression;	chr6:27829157	chr6:28161781~28169594:+
OV	cis	rs9880211	0.821	rs9832813	ENSG00000239213.4	NCK1-AS1	4.13	5.09e-05	0.0192	0.32	0.26	Height;Body mass index;	chr3:136346723	chr3:136841726~136862054:-
OV	cis	rs56114371	0.777	rs200482	ENSG00000226314.6	ZNF192P1	-4.13	5.1e-05	0.0192	-0.49	-0.26	Breast cancer;	chr6:27806126	chr6:28161781~28169594:+
OV	cis	rs1933112	1	rs1933110	ENSG00000227777.1	RP4-738P11.3	-4.13	5.1e-05	0.0192	-0.3	-0.26	Blood protein levels;	chr1:168554217	chr1:168542737~168543354:+
OV	cis	rs2227564	0.62	rs4746148	ENSG00000271816.1	BMS1P4	4.13	5.1e-05	0.0192	0.27	0.26	Crohn's disease;Inflammatory bowel disease;	chr10:73774730	chr10:73699151~73730487:-
OV	cis	rs7267979	0.966	rs3827014	ENSG00000274973.1	RP13-401N8.7	4.13	5.1e-05	0.0192	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25390923	chr20:25845497~25845862:+
OV	cis	rs6589563	0.609	rs12280724	ENSG00000278768.1	BACE1-AS	4.13	5.1e-05	0.0192	0.45	0.26	Eosinophil counts;	chr11:116742707	chr11:117290874~117293571:+
OV	cis	rs1113500	0.548	rs17020971	ENSG00000226822.1	RP11-356N1.2	4.13	5.1e-05	0.0192	0.33	0.26	Growth-regulated protein alpha levels;	chr1:108112666	chr1:108071482~108074519:+
OV	cis	rs35934224	0.891	rs34249993	ENSG00000232926.1	AC000078.5	4.13	5.1e-05	0.0192	0.4	0.26	Glaucoma (primary open-angle);	chr22:19884647	chr22:19887289~19887970:+
OV	cis	rs7267979	1	rs6076339	ENSG00000274973.1	RP13-401N8.7	4.13	5.11e-05	0.0192	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25368076	chr20:25845497~25845862:+
OV	cis	rs1707322	0.691	rs61784799	ENSG00000234329.1	RP11-767N6.2	-4.13	5.11e-05	0.0192	-0.28	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45712076	chr1:45651039~45651826:-
OV	cis	rs1707322	0.752	rs28890893	ENSG00000234329.1	RP11-767N6.2	4.13	5.11e-05	0.0192	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720904	chr1:45651039~45651826:-
OV	cis	rs1707322	0.716	rs28375469	ENSG00000234329.1	RP11-767N6.2	4.13	5.11e-05	0.0192	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45729703	chr1:45651039~45651826:-
OV	cis	rs1707322	0.752	rs28545085	ENSG00000234329.1	RP11-767N6.2	4.13	5.11e-05	0.0192	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736278	chr1:45651039~45651826:-
OV	cis	rs1707322	0.752	rs28719889	ENSG00000234329.1	RP11-767N6.2	4.13	5.11e-05	0.0192	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45736611	chr1:45651039~45651826:-
OV	cis	rs1707322	0.752	rs28812624	ENSG00000234329.1	RP11-767N6.2	4.13	5.11e-05	0.0192	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45738064	chr1:45651039~45651826:-
OV	cis	rs1707322	0.752	rs28507722	ENSG00000234329.1	RP11-767N6.2	4.13	5.11e-05	0.0192	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45740868	chr1:45651039~45651826:-
OV	cis	rs1707322	0.752	rs28568986	ENSG00000234329.1	RP11-767N6.2	4.13	5.11e-05	0.0192	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45742071	chr1:45651039~45651826:-
OV	cis	rs1707322	0.717	rs28396194	ENSG00000234329.1	RP11-767N6.2	4.13	5.11e-05	0.0192	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747555	chr1:45651039~45651826:-
OV	cis	rs1707322	0.717	rs28752166	ENSG00000234329.1	RP11-767N6.2	4.13	5.11e-05	0.0192	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747637	chr1:45651039~45651826:-
OV	cis	rs1707322	0.717	rs10890345	ENSG00000234329.1	RP11-767N6.2	4.13	5.11e-05	0.0192	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45748255	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs10789471	ENSG00000234329.1	RP11-767N6.2	4.13	5.11e-05	0.0192	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45749947	chr1:45651039~45651826:-
OV	cis	rs1707322	0.752	rs11211173	ENSG00000234329.1	RP11-767N6.2	4.13	5.11e-05	0.0192	0.28	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45753704	chr1:45651039~45651826:-
OV	cis	rs6907340	0.517	rs9465533	ENSG00000227116.1	RP3-471C18.1	-4.13	5.12e-05	0.0193	-0.32	-0.26	Endometriosis;	chr6:19801477	chr6:19730427~19734567:-
OV	cis	rs494459	0.536	rs11217065	ENSG00000255422.1	AP002954.4	-4.13	5.12e-05	0.0193	-0.31	-0.26	Height;	chr11:118855938	chr11:118704607~118750263:+
OV	cis	rs17711722	0.565	rs73372653	ENSG00000226824.5	RP4-756H11.3	-4.13	5.12e-05	0.0193	-0.29	-0.26	Calcium levels;	chr7:65977808	chr7:66654538~66669855:+
OV	cis	rs7927592	0.763	rs1193699	ENSG00000222339.1	AP000807.2	4.13	5.12e-05	0.0193	0.27	0.26	Total body bone mineral density;	chr11:68482012	chr11:68505572~68505651:-
OV	cis	rs115769866	0.609	rs2191037	ENSG00000216901.1	AL022393.7	4.13	5.12e-05	0.0193	0.36	0.26	Bipolar disorder;	chr6:28499211	chr6:28176188~28176674:+
OV	cis	rs858267	1	rs858267	ENSG00000230658.1	KLHL7-AS1	-4.13	5.12e-05	0.0193	-0.67	-0.26	Blood protein levels;	chr7:23170510	chr7:23101228~23105703:-
OV	cis	rs7829975	0.522	rs6601689	ENSG00000253981.4	ALG1L13P	4.13	5.12e-05	0.0193	0.28	0.26	Mood instability;	chr8:8314761	chr8:8236003~8244667:-
OV	cis	rs2999052	0.661	rs3021461	ENSG00000277250.1	Metazoa_SRP	4.13	5.13e-05	0.0193	0.37	0.26	Hypospadias;	chr3:128376809	chr3:128673681~128674021:-
OV	cis	rs2999052	0.661	rs2977565	ENSG00000277250.1	Metazoa_SRP	4.13	5.13e-05	0.0193	0.37	0.26	Hypospadias;	chr3:128376924	chr3:128673681~128674021:-
OV	cis	rs12073359	1	rs12058090	ENSG00000223945.2	RP11-458I7.1	-4.13	5.13e-05	0.0193	-0.41	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150039173	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs12060211	ENSG00000223945.2	RP11-458I7.1	-4.13	5.13e-05	0.0193	-0.41	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150039351	chr1:150053864~150055034:+
OV	cis	rs12073359	0.954	rs12063059	ENSG00000223945.2	RP11-458I7.1	-4.13	5.13e-05	0.0193	-0.41	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150041153	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs12065681	ENSG00000223945.2	RP11-458I7.1	-4.13	5.13e-05	0.0193	-0.41	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150041680	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs12064532	ENSG00000223945.2	RP11-458I7.1	-4.13	5.13e-05	0.0193	-0.41	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150042102	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs72692865	ENSG00000223945.2	RP11-458I7.1	-4.13	5.13e-05	0.0193	-0.41	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150043194	chr1:150053864~150055034:+
OV	cis	rs12073359	0.909	rs12066132	ENSG00000223945.2	RP11-458I7.1	-4.13	5.13e-05	0.0193	-0.41	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150043281	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs12066293	ENSG00000223945.2	RP11-458I7.1	-4.13	5.13e-05	0.0193	-0.41	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150043653	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs12067422	ENSG00000223945.2	RP11-458I7.1	-4.13	5.13e-05	0.0193	-0.41	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150043833	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs72692866	ENSG00000223945.2	RP11-458I7.1	-4.13	5.13e-05	0.0193	-0.41	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150045258	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs11205319	ENSG00000223945.2	RP11-458I7.1	-4.13	5.13e-05	0.0193	-0.41	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150045847	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs28753817	ENSG00000223945.2	RP11-458I7.1	-4.13	5.13e-05	0.0193	-0.41	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150046397	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs9662055	ENSG00000223945.2	RP11-458I7.1	-4.13	5.13e-05	0.0193	-0.41	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150046744	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs72692869	ENSG00000223945.2	RP11-458I7.1	-4.13	5.13e-05	0.0193	-0.41	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150047061	chr1:150053864~150055034:+
OV	cis	rs7927771	0.524	rs11039345	ENSG00000280615.1	Y_RNA	4.13	5.13e-05	0.0193	0.28	0.26	Subjective well-being;	chr11:47698676	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs7942074	ENSG00000280615.1	Y_RNA	4.13	5.13e-05	0.0193	0.28	0.26	Subjective well-being;	chr11:47698957	chr11:47614898~47614994:-
OV	cis	rs1858037	0.806	rs12612780	ENSG00000234255.7	AC012370.3	4.13	5.13e-05	0.0193	0.3	0.26	Rheumatoid arthritis;	chr2:65355967	chr2:65439888~65456571:-
OV	cis	rs7267979	0.932	rs13040655	ENSG00000274973.1	RP13-401N8.7	-4.13	5.14e-05	0.0193	-0.31	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25601561	chr20:25845497~25845862:+
OV	cis	rs2117029	1	rs2293445	ENSG00000258017.1	RP11-386G11.10	-4.13	5.14e-05	0.0193	-0.34	-0.26	Intelligence (multi-trait analysis);	chr12:49005079	chr12:49127782~49147869:+
OV	cis	rs875971	0.545	rs73142233	ENSG00000236529.1	RP13-254B10.1	4.13	5.14e-05	0.0193	0.31	0.26	Aortic root size;	chr7:66221293	chr7:65840212~65840596:+
OV	cis	rs7520050	0.966	rs2486447	ENSG00000280836.1	AL355480.1	4.13	5.14e-05	0.0193	0.33	0.26	Reticulocyte count;Red blood cell count;	chr1:46080052	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs1085244	ENSG00000280836.1	AL355480.1	4.13	5.14e-05	0.0193	0.33	0.26	Reticulocyte count;Red blood cell count;	chr1:46098008	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs6662641	ENSG00000280836.1	AL355480.1	4.13	5.14e-05	0.0193	0.33	0.26	Reticulocyte count;Red blood cell count;	chr1:46105837	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs1707335	ENSG00000280836.1	AL355480.1	4.13	5.14e-05	0.0193	0.33	0.26	Reticulocyte count;Red blood cell count;	chr1:46106249	chr1:45581219~45581321:-
OV	cis	rs9649213	0.593	rs12728	ENSG00000272950.1	RP11-307C18.1	4.13	5.14e-05	0.0193	0.31	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98293539	chr7:98322853~98323430:+
OV	cis	rs10129255	0.536	rs17113249	ENSG00000223648.3	IGHV3-64	4.13	5.14e-05	0.0193	0.26	0.26	Kawasaki disease;	chr14:106678273	chr14:106643132~106658258:-
OV	cis	rs2243480	0.901	rs1701759	ENSG00000226824.5	RP4-756H11.3	-4.13	5.14e-05	0.0193	-0.42	-0.26	Diabetic kidney disease;	chr7:66005945	chr7:66654538~66669855:+
OV	cis	rs944801	0.608	rs7028570	ENSG00000234840.1	LINC01239	-4.13	5.14e-05	0.0193	-0.3	-0.26	Type 2 diabetes;	chr9:22048684	chr9:22646200~22824213:+
OV	cis	rs62244186	1	rs62244186	ENSG00000214820.3	MPRIPP1	4.13	5.15e-05	0.0193	0.24	0.26	Depressive symptoms;	chr3:44698291	chr3:44579938~44581026:-
OV	cis	rs2564921	0.57	rs3821831	ENSG00000242142.1	SERBP1P3	-4.13	5.15e-05	0.0194	-0.33	-0.26	Height;	chr3:52819385	chr3:53064283~53065091:-
OV	cis	rs72700829	0.518	rs34755378	ENSG00000223945.2	RP11-458I7.1	-4.13	5.16e-05	0.0194	-0.46	-0.26	Schizophrenia;	chr1:150269940	chr1:150053864~150055034:+
OV	cis	rs41271951	0.542	rs12138787	ENSG00000223945.2	RP11-458I7.1	-4.13	5.16e-05	0.0194	-0.46	-0.26	Blood protein levels;	chr1:150273667	chr1:150053864~150055034:+
OV	cis	rs801193	1	rs11773829	ENSG00000224316.1	RP11-479O9.2	-4.13	5.16e-05	0.0194	-0.28	-0.26	Aortic root size;	chr7:66676087	chr7:65773620~65802067:+
OV	cis	rs9393777	0.557	rs7759741	ENSG00000243307.2	POM121L6P	-4.13	5.16e-05	0.0194	-0.32	-0.26	Intelligence (multi-trait analysis);	chr6:27273264	chr6:26896952~26898777:+
OV	cis	rs7520050	0.771	rs4660882	ENSG00000280836.1	AL355480.1	-4.13	5.17e-05	0.0194	-0.31	-0.26	Reticulocyte count;Red blood cell count;	chr1:45650620	chr1:45581219~45581321:-
OV	cis	rs7520050	0.778	rs3013597	ENSG00000280836.1	AL355480.1	-4.13	5.17e-05	0.0194	-0.31	-0.26	Reticulocyte count;Red blood cell count;	chr1:45662684	chr1:45581219~45581321:-
OV	cis	rs2243480	1	rs10807702	ENSG00000273142.1	RP11-458F8.4	-4.13	5.17e-05	0.0194	-0.32	-0.26	Diabetic kidney disease;	chr7:66302856	chr7:66902857~66906297:+
OV	cis	rs35160687	0.842	rs7593440	ENSG00000273080.1	RP11-301O19.1	-4.13	5.17e-05	0.0194	-0.25	-0.26	Night sleep phenotypes;	chr2:86323534	chr2:86195590~86196049:+
OV	cis	rs35160687	0.814	rs4392258	ENSG00000273080.1	RP11-301O19.1	-4.13	5.17e-05	0.0194	-0.25	-0.26	Night sleep phenotypes;	chr2:86325454	chr2:86195590~86196049:+
OV	cis	rs35160687	0.842	rs11685863	ENSG00000273080.1	RP11-301O19.1	-4.13	5.17e-05	0.0194	-0.25	-0.26	Night sleep phenotypes;	chr2:86327361	chr2:86195590~86196049:+
OV	cis	rs12701220	0.655	rs12702117	ENSG00000229043.2	AC091729.9	-4.13	5.18e-05	0.0194	-0.34	-0.26	Bronchopulmonary dysplasia;	chr7:1109066	chr7:1160374~1165267:+
OV	cis	rs12701220	0.604	rs12702122	ENSG00000229043.2	AC091729.9	-4.13	5.18e-05	0.0194	-0.34	-0.26	Bronchopulmonary dysplasia;	chr7:1109858	chr7:1160374~1165267:+
OV	cis	rs875971	0.545	rs316324	ENSG00000273024.4	INTS4P2	4.13	5.18e-05	0.0194	0.32	0.26	Aortic root size;	chr7:66145627	chr7:65647864~65715661:+
OV	cis	rs875971	0.545	rs316323	ENSG00000273024.4	INTS4P2	4.13	5.18e-05	0.0194	0.32	0.26	Aortic root size;	chr7:66146002	chr7:65647864~65715661:+
OV	cis	rs875971	0.545	rs316316	ENSG00000273024.4	INTS4P2	4.13	5.18e-05	0.0194	0.32	0.26	Aortic root size;	chr7:66149270	chr7:65647864~65715661:+
OV	cis	rs9880211	1	rs35899944	ENSG00000239213.4	NCK1-AS1	4.13	5.18e-05	0.0195	0.32	0.26	Height;Body mass index;	chr3:136510215	chr3:136841726~136862054:-
OV	cis	rs9880211	1	rs9878078	ENSG00000239213.4	NCK1-AS1	4.13	5.18e-05	0.0195	0.32	0.26	Height;Body mass index;	chr3:136518731	chr3:136841726~136862054:-
OV	cis	rs1979679	0.608	rs1355472	ENSG00000278733.1	RP11-425D17.1	4.13	5.18e-05	0.0195	0.33	0.26	Ossification of the posterior longitudinal ligament of the spine;	chr12:28568481	chr12:28185625~28186190:-
OV	cis	rs1979679	0.608	rs4931084	ENSG00000278733.1	RP11-425D17.1	-4.13	5.18e-05	0.0195	-0.33	-0.26	Ossification of the posterior longitudinal ligament of the spine;	chr12:28569378	chr12:28185625~28186190:-
OV	cis	rs11233413	0.587	rs4944421	ENSG00000274004.1	H19_3	4.13	5.18e-05	0.0195	0.32	0.26	Economic and political preferences (feminism/equality);	chr11:82978127	chr11:83386988~83387102:+
OV	cis	rs4132509	1	rs9287269	ENSG00000227230.1	RP11-261C10.5	-4.13	5.18e-05	0.0195	-0.33	-0.26	RR interval (heart rate);	chr1:243791249	chr1:243135898~243140588:+
OV	cis	rs1020064	0.945	rs1030878	ENSG00000235319.1	AC012360.4	-4.13	5.19e-05	0.0195	-0.36	-0.26	AIDS;	chr2:105294141	chr2:105324210~105330529:+
OV	cis	rs9467773	1	rs9295695	ENSG00000243307.2	POM121L6P	-4.13	5.19e-05	0.0195	-0.25	-0.26	Intelligence (multi-trait analysis);	chr6:26528022	chr6:26896952~26898777:+
OV	cis	rs2070488	0.965	rs1058945	ENSG00000229589.1	ACVR2B-AS1	-4.13	5.19e-05	0.0195	-0.29	-0.26	Electrocardiographic conduction measures;	chr3:38491020	chr3:38451027~38454820:-
OV	cis	rs2243480	1	rs6964530	ENSG00000273142.1	RP11-458F8.4	4.13	5.19e-05	0.0195	0.31	0.26	Diabetic kidney disease;	chr7:66253864	chr7:66902857~66906297:+
OV	cis	rs8062405	0.54	rs480400	ENSG00000259982.1	CDC37P1	4.13	5.2e-05	0.0195	0.31	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28563294	chr16:28700294~28701540:-
OV	cis	rs875971	0.502	rs11769702	ENSG00000236529.1	RP13-254B10.1	4.13	5.2e-05	0.0195	0.31	0.26	Aortic root size;	chr7:66255529	chr7:65840212~65840596:+
OV	cis	rs1930961	0.85	rs5996945	ENSG00000100058.11	CRYBB2P1	-4.13	5.2e-05	0.0195	-0.37	-0.26	Bipolar disorder with mood-incongruent psychosis;	chr22:25479606	chr22:25448105~25520854:+
OV	cis	rs853679	0.824	rs34712084	ENSG00000219392.1	RP1-265C24.5	-4.13	5.2e-05	0.0195	-0.45	-0.26	Depression;	chr6:28076050	chr6:28115628~28116551:+
OV	cis	rs853679	0.824	rs1321505	ENSG00000219392.1	RP1-265C24.5	-4.13	5.2e-05	0.0195	-0.45	-0.26	Depression;	chr6:28085045	chr6:28115628~28116551:+
OV	cis	rs10851478	0.54	rs1904316	ENSG00000259545.2	RP11-325E5.4	4.13	5.2e-05	0.0195	0.29	0.26	Oral cavity cancer;	chr15:49416513	chr15:49177610~49178741:-
OV	cis	rs7429990	0.864	rs34616865	ENSG00000229759.1	MRPS18AP1	-4.12	5.21e-05	0.0195	-0.28	-0.26	Educational attainment (years of education);	chr3:47608508	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs1014228	ENSG00000229759.1	MRPS18AP1	-4.12	5.21e-05	0.0195	-0.28	-0.26	Educational attainment (years of education);	chr3:47611149	chr3:48256350~48256938:-
OV	cis	rs853679	0.723	rs9366718	ENSG00000219392.1	RP1-265C24.5	-4.12	5.21e-05	0.0195	-0.39	-0.26	Depression;	chr6:28237724	chr6:28115628~28116551:+
OV	cis	rs7746199	0.736	rs34064842	ENSG00000220721.1	OR1F12	4.12	5.21e-05	0.0195	0.5	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr6:28073316~28074233:+
OV	cis	rs7746199	0.736	rs13212318	ENSG00000220721.1	OR1F12	4.12	5.21e-05	0.0195	0.5	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:28073316~28074233:+
OV	cis	rs1707322	0.827	rs10890347	ENSG00000225447.1	RPS15AP10	-4.12	5.21e-05	0.0195	-0.24	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45776660	chr1:45645816~45646197:-
OV	cis	rs12713280	0.69	rs6756933	ENSG00000272156.1	RP11-477N3.1	4.12	5.21e-05	0.0195	0.34	0.26	Economic and political preferences;	chr2:54846946	chr2:54082554~54085066:+
OV	cis	rs9880211	1	rs9883189	ENSG00000239213.4	NCK1-AS1	4.12	5.21e-05	0.0195	0.32	0.26	Height;Body mass index;	chr3:136570624	chr3:136841726~136862054:-
OV	cis	rs9880211	1	rs28641809	ENSG00000239213.4	NCK1-AS1	4.12	5.21e-05	0.0195	0.32	0.26	Height;Body mass index;	chr3:136571647	chr3:136841726~136862054:-
OV	cis	rs4853012	0.941	rs7571083	ENSG00000257800.1	FNBP1P1	4.12	5.21e-05	0.0195	0.4	0.26	Gestational age at birth (maternal effect);	chr2:74115133	chr2:74120680~74123218:+
OV	cis	rs7824557	0.564	rs13260727	ENSG00000227888.4	FAM66A	4.12	5.22e-05	0.0195	0.31	0.26	Retinal vascular caliber;	chr8:11375351	chr8:12362019~12388296:+
OV	cis	rs1823913	0.599	rs1378155	ENSG00000227542.1	AC092614.2	4.12	5.22e-05	0.0196	0.29	0.26	Obesity-related traits;	chr2:191266610	chr2:191229165~191246172:-
OV	cis	rs1823913	0.576	rs13011608	ENSG00000227542.1	AC092614.2	4.12	5.22e-05	0.0196	0.29	0.26	Obesity-related traits;	chr2:191267097	chr2:191229165~191246172:-
OV	cis	rs7520050	0.902	rs9429088	ENSG00000281133.1	AL355480.3	4.12	5.22e-05	0.0196	0.3	0.26	Reticulocyte count;Red blood cell count;	chr1:46031828	chr1:45580892~45580996:-
OV	cis	rs875971	0.83	rs809025	ENSG00000237310.1	GS1-124K5.4	4.12	5.22e-05	0.0196	0.26	0.26	Aortic root size;	chr7:66384832	chr7:66493706~66495474:+
OV	cis	rs1707322	0.721	rs10890346	ENSG00000234329.1	RP11-767N6.2	-4.12	5.22e-05	0.0196	-0.27	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45758220	chr1:45651039~45651826:-
OV	cis	rs2348418	0.767	rs1478332	ENSG00000247934.4	RP11-967K21.1	-4.12	5.22e-05	0.0196	-0.26	-0.26	Lung function (FEV1);Lung function (FVC);	chr12:28255432	chr12:28163298~28190738:-
OV	cis	rs7927771	0.524	rs10838740	ENSG00000280615.1	Y_RNA	4.12	5.22e-05	0.0196	0.28	0.26	Subjective well-being;	chr11:47658428	chr11:47614898~47614994:-
OV	cis	rs6061231	0.793	rs2427320	ENSG00000273619.1	RP5-908M14.9	-4.12	5.22e-05	0.0196	-0.29	-0.26	Colorectal cancer;	chr20:62401667	chr20:62386303~62386970:-
OV	cis	rs6061231	0.793	rs6061512	ENSG00000273619.1	RP5-908M14.9	-4.12	5.22e-05	0.0196	-0.29	-0.26	Colorectal cancer;	chr20:62401873	chr20:62386303~62386970:-
OV	cis	rs6061231	0.837	rs6061235	ENSG00000273619.1	RP5-908M14.9	-4.12	5.22e-05	0.0196	-0.29	-0.26	Colorectal cancer;	chr20:62403468	chr20:62386303~62386970:-
OV	cis	rs9992667	0.868	rs113071828	ENSG00000231160.8	KLF3-AS1	4.12	5.22e-05	0.0196	0.32	0.26	Eosinophil percentage of granulocytes;	chr4:38664197	chr4:38612701~38664883:-
OV	cis	rs733592	0.507	rs56129148	ENSG00000240399.1	RP1-228P16.1	-4.12	5.23e-05	0.0196	-0.29	-0.26	Plateletcrit;	chr12:48091747	chr12:48054813~48055591:-
OV	cis	rs2070488	1	rs36006749	ENSG00000229589.1	ACVR2B-AS1	4.12	5.23e-05	0.0196	0.29	0.26	Electrocardiographic conduction measures;	chr3:38401821	chr3:38451027~38454820:-
OV	cis	rs6071524	0.508	rs2255213	ENSG00000277581.1	RP4-616B8.6	4.12	5.23e-05	0.0196	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr20:38757734	chr20:38962472~38962993:+
OV	cis	rs13113518	0.783	rs1586555	ENSG00000223305.1	RN7SKP30	4.12	5.23e-05	0.0196	0.31	0.26	Height;	chr4:55587104	chr4:55540502~55540835:-
OV	cis	rs1555322	0.505	rs639763	ENSG00000269202.1	RP4-614O4.12	-4.12	5.23e-05	0.0196	-0.31	-0.26	Attention deficit hyperactivity disorder;	chr20:35274101	chr20:35201747~35203288:-
OV	cis	rs4774565	0.762	rs8041193	ENSG00000244879.4	GABPB1-AS1	-4.12	5.23e-05	0.0196	-0.26	-0.26	Breast cancer;	chr15:50369960	chr15:50354959~50372202:+
OV	cis	rs11951515	0.7	rs66585077	ENSG00000278487.1	RP11-447H19.4	-4.12	5.23e-05	0.0196	-0.31	-0.26	Metabolite levels  (X-11787);	chr5:43281754	chr5:43143362~43143514:-
OV	cis	rs7246657	0.941	rs7259618	ENSG00000226686.6	LINC01535	-4.12	5.24e-05	0.0196	-0.41	-0.26	Coronary artery calcification;	chr19:37259817	chr19:37251912~37265535:+
OV	cis	rs897984	0.762	rs4889599	ENSG00000260911.2	RP11-196G11.2	-4.12	5.24e-05	0.0196	-0.24	-0.26	Dementia with Lewy bodies;	chr16:30957268	chr16:31043150~31049868:+
OV	cis	rs897984	0.721	rs2305884	ENSG00000260911.2	RP11-196G11.2	-4.12	5.24e-05	0.0196	-0.24	-0.26	Dementia with Lewy bodies;	chr16:30959420	chr16:31043150~31049868:+
OV	cis	rs897984	0.762	rs11150601	ENSG00000260911.2	RP11-196G11.2	-4.12	5.24e-05	0.0196	-0.24	-0.26	Dementia with Lewy bodies;	chr16:30966478	chr16:31043150~31049868:+
OV	cis	rs897984	0.762	rs897986	ENSG00000260911.2	RP11-196G11.2	-4.12	5.24e-05	0.0196	-0.24	-0.26	Dementia with Lewy bodies;	chr16:30969581	chr16:31043150~31049868:+
OV	cis	rs61990749	0.511	rs724263	ENSG00000239272.1	RPL21P10	4.12	5.25e-05	0.0197	0.39	0.26	Fibroblast growth factor basic levels;	chr14:77855531	chr14:77683202~77683989:-
OV	cis	rs61990749	0.511	rs10130790	ENSG00000239272.1	RPL21P10	4.12	5.25e-05	0.0197	0.39	0.26	Fibroblast growth factor basic levels;	chr14:77857849	chr14:77683202~77683989:-
OV	cis	rs61990749	0.511	rs10146144	ENSG00000239272.1	RPL21P10	4.12	5.25e-05	0.0197	0.39	0.26	Fibroblast growth factor basic levels;	chr14:77858957	chr14:77683202~77683989:-
OV	cis	rs514406	0.584	rs12095247	ENSG00000206627.1	RNU6-969P	-4.12	5.25e-05	0.0197	-0.28	-0.26	Monocyte count;	chr1:52728124	chr1:52805108~52805212:-
OV	cis	rs7646881	0.544	rs73030851	ENSG00000272440.1	RP11-379F4.6	4.12	5.26e-05	0.0197	0.4	0.26	Tetralogy of Fallot;	chr3:158699163	chr3:158695367~158695581:+
OV	cis	rs7017914	0.667	rs2639925	ENSG00000223220.1	Y_RNA	4.12	5.26e-05	0.0197	0.28	0.26	Bone mineral density;	chr8:70991937	chr8:70780914~70781008:-
OV	cis	rs9438901	0.655	rs609320	ENSG00000224183.1	SDHDP6	4.12	5.26e-05	0.0197	0.42	0.26	Red cell distribution width;	chr1:25390874	chr1:25294164~25294643:-
OV	cis	rs12928939	0.774	rs7205340	ENSG00000260886.1	TAT-AS1	-4.12	5.26e-05	0.0197	-0.32	-0.26	Post bronchodilator FEV1;	chr16:71611767	chr16:71565789~71578187:+
OV	cis	rs9326248	0.954	rs10790177	ENSG00000280143.1	AP000892.6	4.12	5.27e-05	0.0197	0.29	0.26	Blood protein levels;	chr11:117177701	chr11:117204967~117210292:+
OV	cis	rs896854	0.684	rs2340534	ENSG00000253528.2	RP11-347C18.4	4.12	5.27e-05	0.0197	0.25	0.26	Type 2 diabetes;	chr8:94980102	chr8:94974573~94974853:-
OV	cis	rs944801	0.608	rs10757265	ENSG00000234840.1	LINC01239	-4.12	5.27e-05	0.0197	-0.3	-0.26	Type 2 diabetes;	chr9:22048860	chr9:22646200~22824213:+
OV	cis	rs4132509	1	rs10927067	ENSG00000227230.1	RP11-261C10.5	-4.12	5.27e-05	0.0197	-0.32	-0.26	RR interval (heart rate);	chr1:243759942	chr1:243135898~243140588:+
OV	cis	rs73201462	0.908	rs2811388	ENSG00000242551.2	POU5F1P6	4.12	5.27e-05	0.0197	0.41	0.26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128299604	chr3:128674735~128677005:-
OV	cis	rs9291683	0.692	rs1558489	ENSG00000250413.1	RP11-448G15.1	4.12	5.27e-05	0.0197	0.3	0.26	Bone mineral density;	chr4:10323865	chr4:10006482~10009725:+
OV	cis	rs2243480	1	rs1638734	ENSG00000226824.5	RP4-756H11.3	-4.12	5.27e-05	0.0197	-0.43	-0.26	Diabetic kidney disease;	chr7:66632552	chr7:66654538~66669855:+
OV	cis	rs4666360	1	rs4666295	ENSG00000234378.1	AC098828.2	-4.12	5.28e-05	0.0197	-0.27	-0.26	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);	chr2:20137383	chr2:20063856~20106829:-
OV	cis	rs881375	0.967	rs7039505	ENSG00000226752.6	PSMD5-AS1	-4.12	5.28e-05	0.0197	-0.29	-0.26	Rheumatoid arthritis;	chr9:120943667	chr9:120824828~120854385:+
OV	cis	rs2243480	1	rs709607	ENSG00000226824.5	RP4-756H11.3	4.12	5.28e-05	0.0197	0.45	0.26	Diabetic kidney disease;	chr7:65984554	chr7:66654538~66669855:+
OV	cis	rs61990749	0.511	rs2052444	ENSG00000239272.1	RPL21P10	4.12	5.28e-05	0.0197	0.38	0.26	Fibroblast growth factor basic levels;	chr14:77846575	chr14:77683202~77683989:-
OV	cis	rs2113334	0.765	rs231130	ENSG00000260009.1	RP11-65J21.1	-4.12	5.28e-05	0.0198	-0.29	-0.26	Metabolic syndrome;	chr16:13864415	chr16:14363109~14370266:-
OV	cis	rs494459	0.536	rs10790267	ENSG00000255422.1	AP002954.4	-4.12	5.29e-05	0.0198	-0.31	-0.26	Height;	chr11:118856460	chr11:118704607~118750263:+
OV	cis	rs494459	0.536	rs11217067	ENSG00000255422.1	AP002954.4	-4.12	5.29e-05	0.0198	-0.31	-0.26	Height;	chr11:118856623	chr11:118704607~118750263:+
OV	cis	rs2510897	0.675	rs4936442	ENSG00000255422.1	AP002954.4	-4.12	5.29e-05	0.0198	-0.31	-0.26	Height;	chr11:118857611	chr11:118704607~118750263:+
OV	cis	rs7945705	0.869	rs11042154	ENSG00000254860.4	TMEM9B-AS1	4.12	5.29e-05	0.0198	0.28	0.26	Hemoglobin concentration;	chr11:9008153	chr11:8964675~8977527:+
OV	cis	rs7246657	0.943	rs713256	ENSG00000226686.6	LINC01535	-4.12	5.29e-05	0.0198	-0.41	-0.26	Coronary artery calcification;	chr19:37374463	chr19:37251912~37265535:+
OV	cis	rs853679	0.546	rs200981	ENSG00000280107.1	AL022393.9	-4.12	5.29e-05	0.0198	-0.44	-0.26	Depression;	chr6:27865396	chr6:28170845~28172521:+
OV	cis	rs2767713	0.5	rs1855608	ENSG00000233926.1	RP11-154D17.1	4.12	5.29e-05	0.0198	0.37	0.26	Autism spectrum disorder or schizophrenia;Schizophrenia;	chr9:81906466	chr9:81689713~81776900:+
OV	cis	rs1555322	0.53	rs2297789	ENSG00000279253.1	RP4-614O4.13	-4.12	5.29e-05	0.0198	-0.33	-0.26	Attention deficit hyperactivity disorder;	chr20:35279445	chr20:35262727~35264187:-
OV	cis	rs853679	0.599	rs156743	ENSG00000226314.6	ZNF192P1	-4.12	5.3e-05	0.0198	-0.46	-0.26	Depression;	chr6:27999311	chr6:28161781~28169594:+
OV	cis	rs733592	0.524	rs10875744	ENSG00000240399.1	RP1-228P16.1	4.12	5.3e-05	0.0198	0.29	0.26	Plateletcrit;	chr12:48104657	chr12:48054813~48055591:-
OV	cis	rs9649213	0.574	rs7790229	ENSG00000272950.1	RP11-307C18.1	4.12	5.31e-05	0.0198	0.31	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98290026	chr7:98322853~98323430:+
OV	cis	rs1198872	0.563	rs1686497	ENSG00000272275.1	RP11-791G15.2	-4.12	5.31e-05	0.0198	-0.33	-0.26	Cardiac Troponin-T levels;	chr2:10821058	chr2:10767875~10770058:-
OV	cis	rs9311474	0.967	rs11717383	ENSG00000243224.1	RP5-1157M23.2	-4.12	5.31e-05	0.0198	-0.29	-0.26	Electroencephalogram traits;	chr3:52253452	chr3:52239258~52241097:+
OV	cis	rs10759883	0.563	rs624075	ENSG00000175611.10	LINC00476	4.12	5.31e-05	0.0199	0.32	0.26	Nicotine dependence;	chr9:95902665	chr9:95759231~95875977:-
OV	cis	rs10759883	0.563	rs1327997	ENSG00000175611.10	LINC00476	4.12	5.31e-05	0.0199	0.32	0.26	Nicotine dependence;	chr9:95913600	chr9:95759231~95875977:-
OV	cis	rs10759883	0.563	rs1327996	ENSG00000175611.10	LINC00476	4.12	5.31e-05	0.0199	0.32	0.26	Nicotine dependence;	chr9:95913710	chr9:95759231~95875977:-
OV	cis	rs10759883	0.563	rs617187	ENSG00000175611.10	LINC00476	4.12	5.31e-05	0.0199	0.32	0.26	Nicotine dependence;	chr9:95917359	chr9:95759231~95875977:-
OV	cis	rs10759883	0.563	rs689619	ENSG00000175611.10	LINC00476	4.12	5.31e-05	0.0199	0.32	0.26	Nicotine dependence;	chr9:95921689	chr9:95759231~95875977:-
OV	cis	rs10759883	0.563	rs10512245	ENSG00000175611.10	LINC00476	4.12	5.31e-05	0.0199	0.32	0.26	Nicotine dependence;	chr9:95929529	chr9:95759231~95875977:-
OV	cis	rs2436845	0.651	rs2513912	ENSG00000253385.1	KB-1254G8.1	4.12	5.32e-05	0.0199	0.32	0.26	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102809260	chr8:102854455~102856075:+
OV	cis	rs875971	0.502	rs2946580	ENSG00000234500.1	GS1-124K5.10	4.12	5.32e-05	0.0199	0.22	0.26	Aortic root size;	chr7:66066855	chr7:66511556~66545066:+
OV	cis	rs2243480	1	rs57057549	ENSG00000226824.5	RP4-756H11.3	-4.12	5.32e-05	0.0199	-0.42	-0.26	Diabetic kidney disease;	chr7:65940751	chr7:66654538~66669855:+
OV	cis	rs2243480	0.808	rs12698508	ENSG00000226824.5	RP4-756H11.3	-4.12	5.32e-05	0.0199	-0.42	-0.26	Diabetic kidney disease;	chr7:65946971	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs2961102	ENSG00000226824.5	RP4-756H11.3	-4.12	5.32e-05	0.0199	-0.42	-0.26	Diabetic kidney disease;	chr7:65959671	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs34970380	ENSG00000226824.5	RP4-756H11.3	-4.12	5.32e-05	0.0199	-0.42	-0.26	Diabetic kidney disease;	chr7:65966506	chr7:66654538~66669855:+
OV	cis	rs2243480	0.901	rs73148097	ENSG00000226824.5	RP4-756H11.3	-4.12	5.32e-05	0.0199	-0.42	-0.26	Diabetic kidney disease;	chr7:65966800	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs35820085	ENSG00000226824.5	RP4-756H11.3	-4.12	5.32e-05	0.0199	-0.42	-0.26	Diabetic kidney disease;	chr7:65977771	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs906134	ENSG00000226824.5	RP4-756H11.3	-4.12	5.32e-05	0.0199	-0.42	-0.26	Diabetic kidney disease;	chr7:65979301	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs1723270	ENSG00000226824.5	RP4-756H11.3	-4.12	5.32e-05	0.0199	-0.42	-0.26	Diabetic kidney disease;	chr7:66004843	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs1723269	ENSG00000226824.5	RP4-756H11.3	-4.12	5.32e-05	0.0199	-0.42	-0.26	Diabetic kidney disease;	chr7:66007799	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs781150	ENSG00000226824.5	RP4-756H11.3	-4.12	5.32e-05	0.0199	-0.42	-0.26	Diabetic kidney disease;	chr7:66015986	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs313798	ENSG00000226824.5	RP4-756H11.3	-4.12	5.32e-05	0.0199	-0.42	-0.26	Diabetic kidney disease;	chr7:66028044	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs35396113	ENSG00000226824.5	RP4-756H11.3	-4.12	5.32e-05	0.0199	-0.42	-0.26	Diabetic kidney disease;	chr7:66030474	chr7:66654538~66669855:+
OV	cis	rs7131987	0.683	rs7954278	ENSG00000257176.2	RP11-996F15.2	-4.12	5.32e-05	0.0199	-0.33	-0.26	QT interval;	chr12:29306357	chr12:29280418~29317848:-
OV	cis	rs10992471	0.603	rs12341817	ENSG00000281156.1	MIR3651	-4.12	5.32e-05	0.0199	-0.3	-0.26	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92489870	chr9:92292458~92292547:-
OV	cis	rs10181042	0.565	rs62150982	ENSG00000270820.4	RP11-355B11.2	-4.12	5.32e-05	0.0199	-0.29	-0.26	Crohn's disease;	chr2:61053540	chr2:61471188~61484130:+
OV	cis	rs7429990	0.864	rs2047559	ENSG00000229759.1	MRPS18AP1	-4.12	5.33e-05	0.0199	-0.29	-0.26	Educational attainment (years of education);	chr3:47704695	chr3:48256350~48256938:-
OV	cis	rs7121800	0.888	rs4923639	ENSG00000254532.1	RP11-624D11.2	4.12	5.33e-05	0.0199	0.3	0.26	Pit-and-Fissure caries;	chr11:30477804	chr11:30044058~30084343:-
OV	cis	rs7121800	0.926	rs7927408	ENSG00000254532.1	RP11-624D11.2	4.12	5.33e-05	0.0199	0.3	0.26	Pit-and-Fissure caries;	chr11:30478764	chr11:30044058~30084343:-
OV	cis	rs7121800	0.888	rs1870358	ENSG00000254532.1	RP11-624D11.2	4.12	5.33e-05	0.0199	0.3	0.26	Pit-and-Fissure caries;	chr11:30486493	chr11:30044058~30084343:-
OV	cis	rs10759883	0.563	rs690286	ENSG00000175611.10	LINC00476	4.12	5.33e-05	0.0199	0.36	0.26	Nicotine dependence;	chr9:96034685	chr9:95759231~95875977:-
OV	cis	rs7429990	0.965	rs7651237	ENSG00000229759.1	MRPS18AP1	-4.12	5.33e-05	0.0199	-0.29	-0.26	Educational attainment (years of education);	chr3:48064038	chr3:48256350~48256938:-
OV	cis	rs9287719	0.578	rs7598541	ENSG00000243819.4	RN7SL832P	4.12	5.34e-05	0.0199	0.27	0.26	Prostate cancer;	chr2:10560390	chr2:10690344~10692099:+
OV	cis	rs9649213	0.555	rs6968193	ENSG00000272950.1	RP11-307C18.1	4.12	5.34e-05	0.0199	0.31	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98286590	chr7:98322853~98323430:+
OV	cis	rs4938303	0.589	rs11216100	ENSG00000254851.1	RP11-109L13.1	4.12	5.34e-05	0.0199	0.35	0.26	Triglycerides;	chr11:116701814	chr11:117135528~117138582:+
OV	cis	rs9298506	0.948	rs72648770	ENSG00000254142.2	RP11-53M11.3	4.12	5.35e-05	0.02	0.4	0.26	Intracranial aneurysm;	chr8:54542004	chr8:54554361~54561927:+
OV	cis	rs12073359	1	rs72694917	ENSG00000223945.2	RP11-458I7.1	-4.12	5.35e-05	0.02	-0.41	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150104499	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs72694918	ENSG00000223945.2	RP11-458I7.1	-4.12	5.35e-05	0.02	-0.41	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150104549	chr1:150053864~150055034:+
OV	cis	rs9649213	0.593	rs13246725	ENSG00000272950.1	RP11-307C18.1	4.12	5.35e-05	0.02	0.31	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98285586	chr7:98322853~98323430:+
OV	cis	rs9649213	0.593	rs11766808	ENSG00000272950.1	RP11-307C18.1	4.12	5.35e-05	0.02	0.31	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98286064	chr7:98322853~98323430:+
OV	cis	rs9649213	0.593	rs35941058	ENSG00000272950.1	RP11-307C18.1	4.12	5.35e-05	0.02	0.31	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98288847	chr7:98322853~98323430:+
OV	cis	rs9649213	0.593	rs7778015	ENSG00000272950.1	RP11-307C18.1	4.12	5.35e-05	0.02	0.31	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98290958	chr7:98322853~98323430:+
OV	cis	rs9649213	0.593	rs1132971	ENSG00000272950.1	RP11-307C18.1	4.12	5.35e-05	0.02	0.31	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98292221	chr7:98322853~98323430:+
OV	cis	rs9649213	0.593	rs6465664	ENSG00000272950.1	RP11-307C18.1	4.12	5.35e-05	0.02	0.31	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98292522	chr7:98322853~98323430:+
OV	cis	rs1723838	0.826	rs2037706	ENSG00000255928.1	RP11-456I15.2	-4.12	5.35e-05	0.02	-0.59	-0.26	Obesity-related traits;	chr11:73666418	chr11:73722349~73722694:+
OV	cis	rs801193	0.591	rs2707839	ENSG00000236529.1	RP13-254B10.1	4.12	5.35e-05	0.02	0.28	0.26	Aortic root size;	chr7:66728097	chr7:65840212~65840596:+
OV	cis	rs757081	0.648	rs214923	ENSG00000213779.4	RP11-452G18.1	4.12	5.35e-05	0.02	0.29	0.26	Systolic blood pressure;	chr11:17215533	chr11:17193489~17194308:+
OV	cis	rs10759883	0.539	rs10117340	ENSG00000175611.10	LINC00476	-4.12	5.36e-05	0.02	-0.36	-0.26	Nicotine dependence;	chr9:96032530	chr9:95759231~95875977:-
OV	cis	rs3018712	0.532	rs2513281	ENSG00000212093.1	AP000807.1	-4.12	5.36e-05	0.02	-0.39	-0.26	Total body bone mineral density;	chr11:68649626	chr11:68506083~68506166:-
OV	cis	rs8099594	0.565	rs1893527	ENSG00000266696.1	RP11-30L3.2	-4.12	5.37e-05	0.02	-0.36	-0.26	Height;	chr18:49185738	chr18:49205912~49208781:+
OV	cis	rs12073359	0.908	rs11589801	ENSG00000223945.2	RP11-458I7.1	-4.12	5.37e-05	0.02	-0.43	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150168635	chr1:150053864~150055034:+
OV	cis	rs12073359	0.955	rs78676616	ENSG00000223945.2	RP11-458I7.1	-4.12	5.37e-05	0.02	-0.43	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150171103	chr1:150053864~150055034:+
OV	cis	rs7267979	1	rs2500448	ENSG00000274973.1	RP13-401N8.7	4.12	5.37e-05	0.02	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25423391	chr20:25845497~25845862:+
OV	cis	rs7267979	0.873	rs6083853	ENSG00000274973.1	RP13-401N8.7	4.12	5.37e-05	0.02	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25423905	chr20:25845497~25845862:+
OV	cis	rs7267979	0.934	rs2482913	ENSG00000274973.1	RP13-401N8.7	4.12	5.37e-05	0.02	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25424450	chr20:25845497~25845862:+
OV	cis	rs757081	0.648	rs11024223	ENSG00000213779.4	RP11-452G18.1	-4.12	5.37e-05	0.02	-0.29	-0.26	Systolic blood pressure;	chr11:17256146	chr11:17193489~17194308:+
OV	cis	rs1030877	0.557	rs2576752	ENSG00000235319.1	AC012360.4	-4.12	5.38e-05	0.02	-0.3	-0.26	Obesity-related traits;	chr2:105362304	chr2:105324210~105330529:+
OV	cis	rs611744	0.573	rs1457210	ENSG00000253754.1	RP11-35G22.1	4.12	5.38e-05	0.02	0.29	0.26	Dupuytren's disease;	chr8:108249333	chr8:108226200~108227544:+
OV	cis	rs80168506	0.748	rs12694298	ENSG00000272519.1	RP11-105N14.2	-4.12	5.38e-05	0.0201	-0.4	-0.26	Selective IgA deficiency;	chr2:213197183	chr2:213266995~213276152:-
OV	cis	rs9649213	0.593	rs35983874	ENSG00000272950.1	RP11-307C18.1	4.12	5.38e-05	0.0201	0.31	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98287149	chr7:98322853~98323430:+
OV	cis	rs7829975	0.659	rs4382480	ENSG00000254340.1	RP11-10A14.3	4.12	5.38e-05	0.0201	0.3	0.26	Mood instability;	chr8:8863963	chr8:9141424~9145435:+
OV	cis	rs7131987	0.621	rs57803026	ENSG00000257176.2	RP11-996F15.2	-4.12	5.38e-05	0.0201	-0.33	-0.26	QT interval;	chr12:29344573	chr12:29280418~29317848:-
OV	cis	rs7131987	0.617	rs3764953	ENSG00000257176.2	RP11-996F15.2	-4.12	5.38e-05	0.0201	-0.33	-0.26	QT interval;	chr12:29349303	chr12:29280418~29317848:-
OV	cis	rs1150668	0.768	rs1233713	ENSG00000204709.4	LINC01556	4.12	5.38e-05	0.0201	0.3	0.26	Pubertal anthropometrics;	chr6:28230503	chr6:28943877~28944537:+
OV	cis	rs12073359	0.909	rs72692870	ENSG00000223945.2	RP11-458I7.1	-4.12	5.38e-05	0.0201	-0.41	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150047081	chr1:150053864~150055034:+
OV	cis	rs11096990	0.964	rs6835064	ENSG00000249207.1	RP11-360F5.1	4.12	5.39e-05	0.0201	0.29	0.26	Cognitive function;	chr4:39264346	chr4:39112677~39126818:-
OV	cis	rs14027	0.921	rs13262434	ENSG00000279347.1	RP11-85I17.2	-4.12	5.39e-05	0.0201	-0.27	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119733423	chr8:119838736~119840385:-
OV	cis	rs9925964	0.933	rs8050894	ENSG00000278922.1	AC002310.14	-4.12	5.39e-05	0.0201	-0.29	-0.26	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31093188	chr16:30526918~30528294:+
OV	cis	rs1538970	0.962	rs9429072	ENSG00000280836.1	AL355480.1	4.12	5.39e-05	0.0201	0.36	0.26	Platelet count;	chr1:45344419	chr1:45581219~45581321:-
OV	cis	rs2522056	0.935	rs1981524	ENSG00000233006.5	AC034220.3	-4.12	5.39e-05	0.0201	-0.32	-0.26	Fibrinogen;Lymphocyte counts;	chr5:132420814	chr5:132311285~132369916:-
OV	cis	rs4713118	0.955	rs9468200	ENSG00000280107.1	AL022393.9	-4.12	5.39e-05	0.0201	-0.32	-0.26	Parkinson's disease;	chr6:27715284	chr6:28170845~28172521:+
OV	cis	rs1850744	1	rs1850744	ENSG00000250268.3	ALG1L14P	-4.12	5.4e-05	0.0201	-0.62	-0.26	Economic and political preferences;	chr4:9789088	chr4:9166297~9170270:-
OV	cis	rs7927771	0.524	rs10838739	ENSG00000280615.1	Y_RNA	-4.12	5.4e-05	0.0201	-0.28	-0.26	Subjective well-being;	chr11:47651191	chr11:47614898~47614994:-
OV	cis	rs8054556	1	rs10871451	ENSG00000261367.1	RP11-455F5.4	-4.12	5.4e-05	0.0201	-0.29	-0.26	Autism spectrum disorder or schizophrenia;	chr16:29974884	chr16:30107675~30110541:+
OV	cis	rs73186030	0.92	rs73186059	ENSG00000272758.4	RP11-299J3.8	4.12	5.41e-05	0.0201	0.32	0.26	Serum parathyroid hormone levels;	chr3:122332336	chr3:122416207~122443180:+
OV	cis	rs73186030	0.92	rs73186060	ENSG00000272758.4	RP11-299J3.8	4.12	5.41e-05	0.0201	0.32	0.26	Serum parathyroid hormone levels;	chr3:122333507	chr3:122416207~122443180:+
OV	cis	rs73186030	0.841	rs112779893	ENSG00000272758.4	RP11-299J3.8	4.12	5.41e-05	0.0201	0.32	0.26	Serum parathyroid hormone levels;	chr3:122334433	chr3:122416207~122443180:+
OV	cis	rs10486158	1	rs7786515	ENSG00000234141.1	AC009473.1	-4.12	5.41e-05	0.0201	-0.4	-0.26	Bipolar disorder and schizophrenia;	chr7:7360608	chr7:7949853~7950709:-
OV	cis	rs11105306	1	rs11105306	ENSG00000257194.2	RP11-567C2.1	-4.12	5.41e-05	0.0201	-0.38	-0.26	NT-proBNP levels in acute coronary syndrome;	chr12:89503611	chr12:90107739~90112779:+
OV	cis	rs7726839	0.794	rs6883536	ENSG00000225138.6	CTD-2228K2.7	4.12	5.41e-05	0.0201	0.33	0.26	Obesity-related traits;	chr5:599159	chr5:473236~480884:+
OV	cis	rs7927592	0.546	rs497261	ENSG00000222339.1	AP000807.2	4.12	5.41e-05	0.0201	0.27	0.26	Total body bone mineral density;	chr11:68424776	chr11:68505572~68505651:-
OV	cis	rs7927592	0.546	rs599083	ENSG00000222339.1	AP000807.2	4.12	5.41e-05	0.0201	0.27	0.26	Total body bone mineral density;	chr11:68424878	chr11:68505572~68505651:-
OV	cis	rs7927592	0.546	rs683978	ENSG00000222339.1	AP000807.2	4.12	5.41e-05	0.0201	0.27	0.26	Total body bone mineral density;	chr11:68424953	chr11:68505572~68505651:-
OV	cis	rs7927592	0.546	rs554734	ENSG00000222339.1	AP000807.2	4.12	5.41e-05	0.0201	0.27	0.26	Total body bone mineral density;	chr11:68425050	chr11:68505572~68505651:-
OV	cis	rs9992667	0.955	rs1000571	ENSG00000231160.8	KLF3-AS1	4.12	5.41e-05	0.0201	0.32	0.26	Eosinophil percentage of granulocytes;	chr4:38661274	chr4:38612701~38664883:-
OV	cis	rs9992667	0.955	rs12507197	ENSG00000231160.8	KLF3-AS1	4.12	5.41e-05	0.0201	0.32	0.26	Eosinophil percentage of granulocytes;	chr4:38662039	chr4:38612701~38664883:-
OV	cis	rs9992667	0.955	rs60029573	ENSG00000231160.8	KLF3-AS1	4.12	5.41e-05	0.0201	0.32	0.26	Eosinophil percentage of granulocytes;	chr4:38662242	chr4:38612701~38664883:-
OV	cis	rs9880211	0.948	rs13326151	ENSG00000239213.4	NCK1-AS1	4.12	5.41e-05	0.0202	0.32	0.26	Height;Body mass index;	chr3:136542902	chr3:136841726~136862054:-
OV	cis	rs853679	0.546	rs200953	ENSG00000280107.1	AL022393.9	-4.12	5.41e-05	0.0202	-0.44	-0.26	Depression;	chr6:27869489	chr6:28170845~28172521:+
OV	cis	rs7617773	0.78	rs13084616	ENSG00000228638.1	FCF1P2	4.12	5.42e-05	0.0202	0.34	0.26	Coronary artery disease;	chr3:48298209	chr3:48290793~48291375:-
OV	cis	rs6772849	1	rs9839508	ENSG00000277250.1	Metazoa_SRP	4.12	5.42e-05	0.0202	0.32	0.26	Monocyte percentage of white cells;Monocyte count;	chr3:128591951	chr3:128673681~128674021:-
OV	cis	rs10740039	0.846	rs10761529	ENSG00000254271.1	RP11-131N11.4	4.11	5.42e-05	0.0202	0.33	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60627052	chr10:60734342~60741828:+
OV	cis	rs17767294	0.708	rs72848786	ENSG00000220721.1	OR1F12	4.11	5.43e-05	0.0202	0.52	0.26	Parkinson's disease;	chr6:28012239	chr6:28073316~28074233:+
OV	cis	rs709400	0.593	rs12898029	ENSG00000244691.1	RPL10AP1	-4.11	5.43e-05	0.0202	-0.27	-0.26	Body mass index;	chr14:103411547	chr14:103412119~103412761:-
OV	cis	rs7267979	1	rs2500443	ENSG00000274973.1	RP13-401N8.7	4.11	5.43e-05	0.0202	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25350806	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2482928	ENSG00000274973.1	RP13-401N8.7	4.11	5.43e-05	0.0202	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25350894	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2482930	ENSG00000274973.1	RP13-401N8.7	4.11	5.43e-05	0.0202	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25353479	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2500446	ENSG00000274973.1	RP13-401N8.7	4.11	5.43e-05	0.0202	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25359028	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2482937	ENSG00000274973.1	RP13-401N8.7	4.11	5.43e-05	0.0202	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25360150	chr20:25845497~25845862:+
OV	cis	rs1979679	0.682	rs4359252	ENSG00000278733.1	RP11-425D17.1	-4.11	5.44e-05	0.0202	-0.34	-0.26	Ossification of the posterior longitudinal ligament of the spine;	chr12:28434298	chr12:28185625~28186190:-
OV	cis	rs1979679	0.686	rs4348940	ENSG00000278733.1	RP11-425D17.1	-4.11	5.44e-05	0.0202	-0.34	-0.26	Ossification of the posterior longitudinal ligament of the spine;	chr12:28437804	chr12:28185625~28186190:-
OV	cis	rs78545713	1	rs3734534	ENSG00000241549.7	GUSBP2	4.11	5.44e-05	0.0202	0.37	0.26	Iron status biomarkers (total iron binding capacity);	chr6:26240421	chr6:26871484~26956554:-
OV	cis	rs149866169	1	rs149866169	ENSG00000280107.1	AL022393.9	-4.11	5.44e-05	0.0202	-0.52	-0.26	Subjective well-being (multi-trait analysis);Lung cancer;Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Squamous cell lung carcinoma;	chr6:27473944	chr6:28170845~28172521:+
OV	cis	rs514406	0.76	rs475969	ENSG00000206627.1	RNU6-969P	4.11	5.45e-05	0.0203	0.28	0.26	Monocyte count;	chr1:52826935	chr1:52805108~52805212:-
OV	cis	rs61990749	0.571	rs11628049	ENSG00000239272.1	RPL21P10	-4.11	5.45e-05	0.0203	-0.4	-0.26	Fibroblast growth factor basic levels;	chr14:77842108	chr14:77683202~77683989:-
OV	cis	rs1707322	0.752	rs11211146	ENSG00000234329.1	RP11-767N6.2	4.11	5.45e-05	0.0203	0.27	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644122	chr1:45651039~45651826:-
OV	cis	rs1707322	0.752	rs11211147	ENSG00000234329.1	RP11-767N6.2	4.11	5.45e-05	0.0203	0.27	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45644422	chr1:45651039~45651826:-
OV	cis	rs7267979	0.833	rs6138556	ENSG00000274973.1	RP13-401N8.7	-4.11	5.45e-05	0.0203	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25262674	chr20:25845497~25845862:+
OV	cis	rs2015599	0.623	rs2288128	ENSG00000275476.1	RP11-996F15.4	4.11	5.46e-05	0.0203	0.34	0.26	Platelet count;Mean platelet volume;	chr12:29316054	chr12:29277397~29277882:-
OV	cis	rs2015599	0.584	rs2288129	ENSG00000275476.1	RP11-996F15.4	4.11	5.46e-05	0.0203	0.34	0.26	Platelet count;Mean platelet volume;	chr12:29316355	chr12:29277397~29277882:-
OV	cis	rs6661961	0.752	rs1885529	ENSG00000237975.5	FLG-AS1	-4.11	5.46e-05	0.0203	-0.34	-0.26	Atopic dermatitis;	chr1:152448570	chr1:152168125~152445456:+
OV	cis	rs6661961	0.752	rs1885528	ENSG00000237975.5	FLG-AS1	-4.11	5.46e-05	0.0203	-0.34	-0.26	Atopic dermatitis;	chr1:152448978	chr1:152168125~152445456:+
OV	cis	rs6661961	0.752	rs1885527	ENSG00000237975.5	FLG-AS1	-4.11	5.46e-05	0.0203	-0.34	-0.26	Atopic dermatitis;	chr1:152449069	chr1:152168125~152445456:+
OV	cis	rs6661961	0.752	rs4991216	ENSG00000237975.5	FLG-AS1	-4.11	5.46e-05	0.0203	-0.34	-0.26	Atopic dermatitis;	chr1:152449124	chr1:152168125~152445456:+
OV	cis	rs11951515	0.7	rs1545753	ENSG00000278487.1	RP11-447H19.4	-4.11	5.46e-05	0.0203	-0.31	-0.26	Metabolite levels  (X-11787);	chr5:43288264	chr5:43143362~43143514:-
OV	cis	rs11951515	0.7	rs6814	ENSG00000278487.1	RP11-447H19.4	-4.11	5.46e-05	0.0203	-0.31	-0.26	Metabolite levels  (X-11787);	chr5:43289606	chr5:43143362~43143514:-
OV	cis	rs801193	0.569	rs2659907	ENSG00000237310.1	GS1-124K5.4	4.11	5.46e-05	0.0203	0.27	0.26	Aortic root size;	chr7:66699045	chr7:66493706~66495474:+
OV	cis	rs73201462	1	rs11709066	ENSG00000277250.1	Metazoa_SRP	-4.11	5.46e-05	0.0203	-0.39	-0.26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128156069	chr3:128673681~128674021:-
OV	cis	rs14027	0.921	rs7833112	ENSG00000279347.1	RP11-85I17.2	-4.11	5.46e-05	0.0203	-0.28	-0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119835842	chr8:119838736~119840385:-
OV	cis	rs7932354	0.528	rs1965952	ENSG00000271543.1	RP11-692M12.5	4.11	5.47e-05	0.0203	0.34	0.26	Bone mineral density (hip);Bone mineral density;	chr11:47159489	chr11:47796169~47796379:+
OV	cis	rs354033	0.837	rs6949316	ENSG00000280992.1	AC004932.1	4.11	5.47e-05	0.0203	0.29	0.26	Multiple sclerosis;	chr7:149483534	chr7:149541747~149541846:-
OV	cis	rs1030877	0.521	rs2576747	ENSG00000235319.1	AC012360.4	-4.11	5.47e-05	0.0203	-0.3	-0.26	Obesity-related traits;	chr2:105362219	chr2:105324210~105330529:+
OV	cis	rs7017914	0.69	rs7838421	ENSG00000223220.1	Y_RNA	4.11	5.47e-05	0.0203	0.28	0.26	Bone mineral density;	chr8:70760088	chr8:70780914~70781008:-
OV	cis	rs9649213	0.593	rs11760930	ENSG00000272950.1	RP11-307C18.1	4.11	5.47e-05	0.0203	0.31	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98286477	chr7:98322853~98323430:+
OV	cis	rs7968440	0.808	rs2554862	ENSG00000272368.2	RP4-605O3.4	4.11	5.48e-05	0.0204	0.32	0.26	Fibrinogen;	chr12:50808263	chr12:50112197~50165618:+
OV	cis	rs1979679	0.608	rs4931082	ENSG00000278733.1	RP11-425D17.1	-4.11	5.48e-05	0.0204	-0.33	-0.26	Ossification of the posterior longitudinal ligament of the spine;	chr12:28567087	chr12:28185625~28186190:-
OV	cis	rs7017914	0.69	rs6991708	ENSG00000223220.1	Y_RNA	4.11	5.48e-05	0.0204	0.28	0.26	Bone mineral density;	chr8:70756293	chr8:70780914~70781008:-
OV	cis	rs1075265	0.547	rs7557799	ENSG00000233266.1	HMGB1P31	-4.11	5.48e-05	0.0204	-0.3	-0.26	Chronotype;Morning vs. evening chronotype;	chr2:53674760	chr2:54051334~54051760:+
OV	cis	rs720475	0.732	rs62483106	ENSG00000204959.4	ARHGEF34P	-4.11	5.48e-05	0.0204	-0.4	-0.26	Breast cancer;	chr7:144439533	chr7:144272445~144286966:-
OV	cis	rs796364	1	rs71424239	ENSG00000232732.8	AC073043.1	4.11	5.49e-05	0.0204	0.41	0.26	Schizophrenia;	chr2:199860750	chr2:199867396~199911159:-
OV	cis	rs796364	1	rs11694369	ENSG00000232732.8	AC073043.1	4.11	5.49e-05	0.0204	0.41	0.26	Schizophrenia;	chr2:199876997	chr2:199867396~199911159:-
OV	cis	rs2117029	0.965	rs1138908	ENSG00000258017.1	RP11-386G11.10	-4.11	5.49e-05	0.0204	-0.34	-0.26	Intelligence (multi-trait analysis);	chr12:49008516	chr12:49127782~49147869:+
OV	cis	rs2117029	1	rs2117029	ENSG00000258017.1	RP11-386G11.10	-4.11	5.49e-05	0.0204	-0.34	-0.26	Intelligence (multi-trait analysis);	chr12:49014657	chr12:49127782~49147869:+
OV	cis	rs372883	0.648	rs11088117	ENSG00000226935.5	LINC00161	-4.11	5.49e-05	0.0204	-0.28	-0.26	Pancreatic cancer;	chr21:29365495	chr21:28539318~28540355:+
OV	cis	rs10129255	0.53	rs11624912	ENSG00000223648.3	IGHV3-64	4.11	5.49e-05	0.0204	0.26	0.26	Kawasaki disease;	chr14:106673891	chr14:106643132~106658258:-
OV	cis	rs6715284	1	rs6711127	ENSG00000183308.6	AC005037.3	4.11	5.49e-05	0.0204	0.6	0.26	Rheumatoid arthritis;	chr2:201348792	chr2:200963263~201009102:+
OV	cis	rs6715284	1	rs72934973	ENSG00000183308.6	AC005037.3	4.11	5.49e-05	0.0204	0.6	0.26	Rheumatoid arthritis;	chr2:201349211	chr2:200963263~201009102:+
OV	cis	rs3743772	0.5	rs11866060	ENSG00000279722.1	RP11-44F14.6	4.11	5.49e-05	0.0204	0.4	0.26	Depressive symptoms (SSRI exposure interaction);	chr16:53394937	chr16:53487607~53489943:-
OV	cis	rs6061231	0.724	rs1570027	ENSG00000273619.1	RP5-908M14.9	-4.11	5.51e-05	0.0204	-0.29	-0.26	Colorectal cancer;	chr20:62393540	chr20:62386303~62386970:-
OV	cis	rs4853012	0.887	rs6737314	ENSG00000257800.1	FNBP1P1	4.11	5.51e-05	0.0205	0.4	0.26	Gestational age at birth (maternal effect);	chr2:74112459	chr2:74120680~74123218:+
OV	cis	rs1914816	1	rs2255408	ENSG00000259422.1	RP11-593F23.1	-4.11	5.51e-05	0.0205	-0.36	-0.26	Response to tocilizumab in rheumatoid arthritis;	chr15:76210954	chr15:76174891~76181486:-
OV	cis	rs7617773	0.78	rs35411187	ENSG00000228638.1	FCF1P2	-4.11	5.52e-05	0.0205	-0.33	-0.26	Coronary artery disease;	chr3:48318527	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs11714176	ENSG00000228638.1	FCF1P2	-4.11	5.52e-05	0.0205	-0.33	-0.26	Coronary artery disease;	chr3:48319372	chr3:48290793~48291375:-
OV	cis	rs35851103	0.507	rs6601649	ENSG00000255046.1	RP11-297N6.4	4.11	5.52e-05	0.0205	0.34	0.26	Neuroticism;	chr8:11999808	chr8:11797928~11802568:-
OV	cis	rs6661961	0.752	rs4845770	ENSG00000237975.5	FLG-AS1	-4.11	5.53e-05	0.0205	-0.34	-0.26	Atopic dermatitis;	chr1:152451191	chr1:152168125~152445456:+
OV	cis	rs3814244	0.515	rs3015002	ENSG00000255733.4	IFNG-AS1	-4.11	5.53e-05	0.0205	-0.27	-0.26	Itch intensity from mosquito bite adjusted by bite size;	chr12:68010853	chr12:67989445~68234686:+
OV	cis	rs72700829	0.518	rs72694990	ENSG00000223945.2	RP11-458I7.1	-4.11	5.53e-05	0.0205	-0.46	-0.26	Schizophrenia;	chr1:150251390	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs12074281	ENSG00000223945.2	RP11-458I7.1	-4.11	5.54e-05	0.0205	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150053395	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs7540847	ENSG00000223945.2	RP11-458I7.1	-4.11	5.54e-05	0.0205	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150054837	chr1:150053864~150055034:+
OV	cis	rs9880211	0.898	rs73230099	ENSG00000239213.4	NCK1-AS1	4.11	5.54e-05	0.0205	0.34	0.26	Height;Body mass index;	chr3:136833785	chr3:136841726~136862054:-
OV	cis	rs4869419	0.502	rs6861722	ENSG00000272406.1	RP11-185E12.2	-4.11	5.54e-05	0.0205	-0.38	-0.26	Natriuretic peptide levels;	chr5:93028722	chr5:93741640~93743500:+
OV	cis	rs2562784	0.638	rs2562762	ENSG00000235370.6	DNM1P51	4.11	5.55e-05	0.0206	0.47	0.26	Height;	chr15:83598835	chr15:84398316~84411701:-
OV	cis	rs2562784	0.638	rs2730097	ENSG00000235370.6	DNM1P51	4.11	5.55e-05	0.0206	0.47	0.26	Height;	chr15:83599198	chr15:84398316~84411701:-
OV	cis	rs8113142	0.551	rs4805262	ENSG00000261824.5	LINC00662	-4.11	5.55e-05	0.0206	-0.38	-0.26	Femoral neck bone geometry and menarche (age at onset);	chr19:28722536	chr19:27684580~27793940:-
OV	cis	rs4713118	0.581	rs200504	ENSG00000220721.1	OR1F12	4.11	5.56e-05	0.0206	0.33	0.26	Parkinson's disease;	chr6:27818042	chr6:28073316~28074233:+
OV	cis	rs9545047	0.604	rs1856997	ENSG00000227676.3	LINC01068	4.11	5.56e-05	0.0206	0.31	0.26	Schizophrenia;	chr13:79287487	chr13:79566727~79571436:+
OV	cis	rs7302981	0.719	rs844347	ENSG00000272368.2	RP4-605O3.4	4.11	5.56e-05	0.0206	0.31	0.26	Systolic blood pressure;	chr12:50067893	chr12:50112197~50165618:+
OV	cis	rs7267979	0.966	rs2387885	ENSG00000274973.1	RP13-401N8.7	4.11	5.56e-05	0.0206	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25434588	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2424713	ENSG00000274973.1	RP13-401N8.7	-4.11	5.56e-05	0.0206	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25437846	chr20:25845497~25845862:+
OV	cis	rs7500067	1	rs13329835	ENSG00000260495.1	RP11-55K13.1	4.11	5.56e-05	0.0206	0.27	0.26	Breast cancer;	chr16:80616908	chr16:81310731~81313423:-
OV	cis	rs7587476	0.906	rs17487792	ENSG00000229267.2	AC072062.1	4.11	5.56e-05	0.0206	0.33	0.26	Neuroblastoma;	chr2:214778776	chr2:214810229~214963274:+
OV	cis	rs67311347	0.544	rs12633295	ENSG00000223797.4	ENTPD3-AS1	-4.11	5.56e-05	0.0206	-0.28	-0.26	Renal cell carcinoma;	chr3:40293801	chr3:40313802~40453329:-
OV	cis	rs2243480	1	rs1546059	ENSG00000226824.5	RP4-756H11.3	4.11	5.57e-05	0.0206	0.43	0.26	Diabetic kidney disease;	chr7:66189722	chr7:66654538~66669855:+
OV	cis	rs7042370	0.835	rs12377159	ENSG00000234740.1	RP11-272P10.2	4.11	5.57e-05	0.0206	0.35	0.26	Pediatric autoimmune diseases;	chr9:12790263	chr9:13274510~13279187:-
OV	cis	rs6052484	0.523	rs17315511	ENSG00000229539.1	RP11-119B16.2	4.11	5.57e-05	0.0206	0.29	0.26	Sense of smell;	chr20:4334714	chr20:3888239~3888868:-
OV	cis	rs7520050	0.966	rs785492	ENSG00000280836.1	AL355480.1	4.11	5.57e-05	0.0206	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:46117935	chr1:45581219~45581321:-
OV	cis	rs9733	0.791	rs11204693	ENSG00000277452.1	Metazoa_SRP	-4.11	5.57e-05	0.0206	-0.28	-0.26	Tonsillectomy;	chr1:150675511	chr1:150566562~150566860:-
OV	cis	rs6545883	0.783	rs12713442	ENSG00000273302.1	RP11-493E12.2	4.11	5.57e-05	0.0206	0.21	0.26	Tuberculosis;	chr2:61620943	chr2:61199979~61200769:+
OV	cis	rs801193	0.967	rs3800823	ENSG00000224316.1	RP11-479O9.2	-4.11	5.57e-05	0.0206	-0.28	-0.26	Aortic root size;	chr7:66682123	chr7:65773620~65802067:+
OV	cis	rs875971	0.767	rs61348003	ENSG00000237310.1	GS1-124K5.4	4.11	5.57e-05	0.0206	0.26	0.26	Aortic root size;	chr7:66540947	chr7:66493706~66495474:+
OV	cis	rs6442522	0.737	rs905640	ENSG00000249786.6	EAF1-AS1	4.11	5.57e-05	0.0206	0.26	0.26	Uric acid levels;	chr3:15454333	chr3:15436171~15455940:-
OV	cis	rs875971	0.862	rs6952182	ENSG00000236529.1	RP13-254B10.1	-4.11	5.57e-05	0.0206	-0.27	-0.26	Aortic root size;	chr7:66218330	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs6964437	ENSG00000236529.1	RP13-254B10.1	-4.11	5.57e-05	0.0206	-0.27	-0.26	Aortic root size;	chr7:66221457	chr7:65840212~65840596:+
OV	cis	rs9925964	0.933	rs2303222	ENSG00000278922.1	AC002310.14	-4.11	5.57e-05	0.0206	-0.29	-0.26	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31074149	chr16:30526918~30528294:+
OV	cis	rs12468226	0.938	rs114177656	ENSG00000272966.1	RP11-686O6.1	4.11	5.58e-05	0.0206	0.44	0.26	Urate levels;	chr2:202291596	chr2:202336739~202337200:+
OV	cis	rs2243480	1	rs4718317	ENSG00000226824.5	RP4-756H11.3	4.11	5.58e-05	0.0206	0.41	0.26	Diabetic kidney disease;	chr7:66183914	chr7:66654538~66669855:+
OV	cis	rs5742933	1	rs1966729	ENSG00000253559.1	OSGEPL1-AS1	-4.11	5.58e-05	0.0207	-0.29	-0.26	Ferritin levels;	chr2:189721105	chr2:189762704~189765556:+
OV	cis	rs7512898	0.5	rs10753882	ENSG00000260088.1	RP11-92G12.3	-4.11	5.58e-05	0.0207	-0.29	-0.26	Electrocardiographic conduction measures;	chr1:200821492	chr1:200669507~200694250:+
OV	cis	rs11671005	0.611	rs56026876	ENSG00000269600.1	AC016629.3	-4.11	5.58e-05	0.0207	-0.38	-0.26	Mean platelet volume;	chr19:58494790	chr19:58593896~58599355:-
OV	cis	rs2243480	0.522	rs778717	ENSG00000226824.5	RP4-756H11.3	-4.11	5.58e-05	0.0207	-0.48	-0.26	Diabetic kidney disease;	chr7:66383164	chr7:66654538~66669855:+
OV	cis	rs1584120	0.62	rs11046805	ENSG00000274885.1	RP11-268P4.6	-4.11	5.59e-05	0.0207	-0.31	-0.26	Pelvic organ prolapse (moderate/severe);	chr12:23119544	chr12:22638464~22638943:+
OV	cis	rs12073359	1	rs7519918	ENSG00000223945.2	RP11-458I7.1	4.11	5.59e-05	0.0207	0.39	0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150041043	chr1:150053864~150055034:+
OV	cis	rs12073359	0.788	rs4926388	ENSG00000223945.2	RP11-458I7.1	4.11	5.59e-05	0.0207	0.39	0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150044686	chr1:150053864~150055034:+
OV	cis	rs7771547	0.692	rs9296192	ENSG00000240733.3	RN7SL502P	4.11	5.59e-05	0.0207	0.28	0.26	Platelet distribution width;	chr6:36633426	chr6:36450912~36451201:-
OV	cis	rs875971	0.545	rs221986	ENSG00000273024.4	INTS4P2	4.11	5.59e-05	0.0207	0.31	0.26	Aortic root size;	chr7:66105323	chr7:65647864~65715661:+
OV	cis	rs4713118	0.869	rs9283883	ENSG00000219392.1	RP1-265C24.5	-4.11	5.59e-05	0.0207	-0.3	-0.26	Parkinson's disease;	chr6:27747691	chr6:28115628~28116551:+
OV	cis	rs9311474	0.632	rs6445528	ENSG00000243224.1	RP5-1157M23.2	4.11	5.6e-05	0.0207	0.26	0.26	Electroencephalogram traits;	chr3:52538431	chr3:52239258~52241097:+
OV	cis	rs992157	0.798	rs7587220	ENSG00000237281.1	CATIP-AS2	4.11	5.6e-05	0.0207	0.32	0.26	Colorectal cancer;	chr2:218296141	chr2:218326889~218357966:-
OV	cis	rs992157	0.798	rs4674284	ENSG00000237281.1	CATIP-AS2	4.11	5.6e-05	0.0207	0.32	0.26	Colorectal cancer;	chr2:218296518	chr2:218326889~218357966:-
OV	cis	rs2070488	0.775	rs762318	ENSG00000229589.1	ACVR2B-AS1	4.11	5.6e-05	0.0207	0.3	0.26	Electrocardiographic conduction measures;	chr3:38474878	chr3:38451027~38454820:-
OV	cis	rs7598759	0.527	rs12987949	ENSG00000181798.2	LINC00471	-4.11	5.6e-05	0.0207	-0.26	-0.26	Noise-induced hearing loss;	chr2:231502800	chr2:231508426~231514339:-
OV	cis	rs9393777	0.92	rs35716472	ENSG00000243307.2	POM121L6P	-4.11	5.61e-05	0.0207	-0.46	-0.26	Intelligence (multi-trait analysis);	chr6:27438828	chr6:26896952~26898777:+
OV	cis	rs2599510	0.934	rs2710634	ENSG00000279544.1	AL133243.4	-4.11	5.61e-05	0.0207	-0.24	-0.26	Interleukin-18 levels;	chr2:32583737	chr2:32563328~32566436:+
OV	cis	rs853679	1	rs1679732	ENSG00000219392.1	RP1-265C24.5	4.11	5.61e-05	0.0207	0.4	0.26	Depression;	chr6:28253486	chr6:28115628~28116551:+
OV	cis	rs2274471	0.582	rs57839907	ENSG00000234534.1	CSNK1G2P1	4.11	5.61e-05	0.0207	0.34	0.26	Crohn's disease;	chr9:5082671	chr9:5040945~5041940:+
OV	cis	rs7520050	0.933	rs11211203	ENSG00000280836.1	AL355480.1	4.11	5.61e-05	0.0208	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45849920	chr1:45581219~45581321:-
OV	cis	rs2739330	0.76	rs5751761	ENSG00000235689.1	AP000351.13	-4.11	5.62e-05	0.0208	-0.27	-0.26	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23901549	chr22:24006305~24008258:-
OV	cis	rs9291683	0.61	rs993173	ENSG00000250413.1	RP11-448G15.1	4.11	5.62e-05	0.0208	0.29	0.26	Bone mineral density;	chr4:10322311	chr4:10006482~10009725:+
OV	cis	rs11157436	0.602	rs11157435	ENSG00000211812.1	TRAV26-2	-4.11	5.62e-05	0.0208	-0.28	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22168888	chr14:22202583~22203368:+
OV	cis	rs9879311	1	rs9879311	ENSG00000240288.6	GHRLOS	4.11	5.63e-05	0.0208	0.25	0.26	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10373659	chr3:10285754~10293449:+
OV	cis	rs1584120	0.62	rs11046814	ENSG00000274885.1	RP11-268P4.6	-4.11	5.63e-05	0.0208	-0.31	-0.26	Pelvic organ prolapse (moderate/severe);	chr12:23127707	chr12:22638464~22638943:+
OV	cis	rs9649213	0.593	rs7796611	ENSG00000272950.1	RP11-307C18.1	4.11	5.63e-05	0.0208	0.31	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98278911	chr7:98322853~98323430:+
OV	cis	rs9649213	0.574	rs13238610	ENSG00000272950.1	RP11-307C18.1	4.11	5.63e-05	0.0208	0.31	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98279965	chr7:98322853~98323430:+
OV	cis	rs2919917	0.578	rs11783804	ENSG00000254352.1	RP11-578O24.2	4.11	5.63e-05	0.0208	0.35	0.26	Lymphocyte counts;	chr8:78652776	chr8:78723796~78724136:-
OV	cis	rs473651	0.935	rs515412	ENSG00000229915.1	AC016999.2	-4.11	5.63e-05	0.0208	-0.33	-0.26	Multiple system atrophy;	chr2:238436753	chr2:238427077~238427729:-
OV	cis	rs10129255	0.5	rs6576231	ENSG00000223648.3	IGHV3-64	4.11	5.64e-05	0.0208	0.27	0.26	Kawasaki disease;	chr14:106783693	chr14:106643132~106658258:-
OV	cis	rs875971	0.862	rs6952182	ENSG00000237310.1	GS1-124K5.4	-4.11	5.64e-05	0.0208	-0.26	-0.26	Aortic root size;	chr7:66218330	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs6964437	ENSG00000237310.1	GS1-124K5.4	-4.11	5.64e-05	0.0208	-0.26	-0.26	Aortic root size;	chr7:66221457	chr7:66493706~66495474:+
OV	cis	rs9309473	1	rs10187192	ENSG00000163016.8	ALMS1P	4.1	5.65e-05	0.0209	0.32	0.26	Metabolite levels;	chr2:73486373	chr2:73644919~73685576:+
OV	cis	rs9309473	0.948	rs10183818	ENSG00000163016.8	ALMS1P	4.1	5.65e-05	0.0209	0.32	0.26	Metabolite levels;	chr2:73487429	chr2:73644919~73685576:+
OV	cis	rs12073359	0.955	rs7521768	ENSG00000223945.2	RP11-458I7.1	4.1	5.65e-05	0.0209	0.4	0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150170954	chr1:150053864~150055034:+
OV	cis	rs9828933	0.626	rs73119018	ENSG00000280620.1	SCAANT1	4.1	5.66e-05	0.0209	0.49	0.26	Type 2 diabetes;	chr3:63989652	chr3:63911518~63911772:-
OV	cis	rs12073359	1	rs72692897	ENSG00000223945.2	RP11-458I7.1	-4.1	5.66e-05	0.0209	-0.41	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150077856	chr1:150053864~150055034:+
OV	cis	rs4908768	0.906	rs7539382	ENSG00000228423.2	RP4-633I8.4	4.1	5.66e-05	0.0209	0.32	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8519242	chr1:8805860~8807051:-
OV	cis	rs1555322	0.872	rs2425046	ENSG00000269202.1	RP4-614O4.12	-4.1	5.66e-05	0.0209	-0.38	-0.26	Attention deficit hyperactivity disorder;	chr20:35283858	chr20:35201747~35203288:-
OV	cis	rs295490	0.748	rs2291555	ENSG00000272656.1	RP11-219D15.3	4.1	5.66e-05	0.0209	0.5	0.26	PR interval in Tripanosoma cruzi seropositivity;	chr3:139355352	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs17335312	ENSG00000272656.1	RP11-219D15.3	4.1	5.66e-05	0.0209	0.5	0.26	PR interval in Tripanosoma cruzi seropositivity;	chr3:139356544	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs58060926	ENSG00000272656.1	RP11-219D15.3	4.1	5.66e-05	0.0209	0.5	0.26	PR interval in Tripanosoma cruzi seropositivity;	chr3:139356577	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs78116750	ENSG00000272656.1	RP11-219D15.3	4.1	5.66e-05	0.0209	0.5	0.26	PR interval in Tripanosoma cruzi seropositivity;	chr3:139356886	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs74365525	ENSG00000272656.1	RP11-219D15.3	4.1	5.66e-05	0.0209	0.5	0.26	PR interval in Tripanosoma cruzi seropositivity;	chr3:139357107	chr3:139349024~139349371:-
OV	cis	rs295490	0.667	rs80049554	ENSG00000272656.1	RP11-219D15.3	4.1	5.66e-05	0.0209	0.5	0.26	PR interval in Tripanosoma cruzi seropositivity;	chr3:139357161	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs2307031	ENSG00000272656.1	RP11-219D15.3	4.1	5.66e-05	0.0209	0.5	0.26	PR interval in Tripanosoma cruzi seropositivity;	chr3:139357978	chr3:139349024~139349371:-
OV	cis	rs295490	0.915	rs79695313	ENSG00000272656.1	RP11-219D15.3	4.1	5.66e-05	0.0209	0.5	0.26	PR interval in Tripanosoma cruzi seropositivity;	chr3:139358335	chr3:139349024~139349371:-
OV	cis	rs4948102	0.597	rs12669623	ENSG00000273720.1	RP11-613E4.4	-4.1	5.66e-05	0.0209	-0.3	-0.26	Plasma homocysteine levels (post-methionine load test);	chr7:56071486	chr7:55743073~55743457:+
OV	cis	rs9880211	0.948	rs9857966	ENSG00000239213.4	NCK1-AS1	4.1	5.66e-05	0.0209	0.32	0.26	Height;Body mass index;	chr3:136560548	chr3:136841726~136862054:-
OV	cis	rs2070488	0.689	rs6809352	ENSG00000229589.1	ACVR2B-AS1	-4.1	5.66e-05	0.0209	-0.29	-0.26	Electrocardiographic conduction measures;	chr3:38502858	chr3:38451027~38454820:-
OV	cis	rs10486158	0.582	rs887605	ENSG00000230825.1	AC005532.5	-4.1	5.66e-05	0.0209	-0.4	-0.26	Bipolar disorder and schizophrenia;	chr7:7348302	chr7:7255154~7277779:+
OV	cis	rs4865169	0.595	rs4865165	ENSG00000269949.1	RP11-738E22.3	-4.1	5.66e-05	0.0209	-0.31	-0.26	Breast cancer;	chr4:56899380	chr4:56960927~56961373:-
OV	cis	rs10759883	0.563	rs10739705	ENSG00000175611.10	LINC00476	4.1	5.67e-05	0.0209	0.32	0.26	Nicotine dependence;	chr9:95900857	chr9:95759231~95875977:-
OV	cis	rs10759883	0.539	rs10987963	ENSG00000175611.10	LINC00476	4.1	5.67e-05	0.0209	0.32	0.26	Nicotine dependence;	chr9:95903798	chr9:95759231~95875977:-
OV	cis	rs10486158	1	rs7385925	ENSG00000234141.1	AC009473.1	-4.1	5.67e-05	0.0209	-0.4	-0.26	Bipolar disorder and schizophrenia;	chr7:7336725	chr7:7949853~7950709:-
OV	cis	rs73186030	0.92	rs73186050	ENSG00000272758.4	RP11-299J3.8	4.1	5.67e-05	0.0209	0.32	0.26	Serum parathyroid hormone levels;	chr3:122321081	chr3:122416207~122443180:+
OV	cis	rs7968440	0.808	rs67934435	ENSG00000272368.2	RP4-605O3.4	4.1	5.67e-05	0.0209	0.31	0.26	Fibrinogen;	chr12:50823401	chr12:50112197~50165618:+
OV	cis	rs970548	1	rs11239545	ENSG00000223462.2	RP11-285G1.9	-4.1	5.67e-05	0.0209	-0.32	-0.26	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45516797	chr10:44937508~44955725:+
OV	cis	rs6661961	0.752	rs4845771	ENSG00000237975.5	FLG-AS1	-4.1	5.67e-05	0.0209	-0.34	-0.26	Atopic dermatitis;	chr1:152458204	chr1:152168125~152445456:+
OV	cis	rs6661961	0.752	rs7529997	ENSG00000237975.5	FLG-AS1	-4.1	5.67e-05	0.0209	-0.34	-0.26	Atopic dermatitis;	chr1:152458670	chr1:152168125~152445456:+
OV	cis	rs17772222	0.682	rs7142053	ENSG00000258789.1	RP11-507K2.3	-4.1	5.67e-05	0.0209	-0.27	-0.26	Coronary artery calcification;	chr14:88511594	chr14:88551597~88552493:+
OV	cis	rs4908768	0.906	rs74324642	ENSG00000228423.2	RP4-633I8.4	4.1	5.68e-05	0.0209	0.32	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8560113	chr1:8805860~8807051:-
OV	cis	rs4908768	0.906	rs12410336	ENSG00000228423.2	RP4-633I8.4	4.1	5.68e-05	0.0209	0.32	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8563605	chr1:8805860~8807051:-
OV	cis	rs9291683	0.53	rs4697698	ENSG00000250413.1	RP11-448G15.1	-4.1	5.68e-05	0.021	-0.29	-0.26	Bone mineral density;	chr4:9940953	chr4:10006482~10009725:+
OV	cis	rs34421088	0.56	rs1478898	ENSG00000255046.1	RP11-297N6.4	4.1	5.68e-05	0.021	0.28	0.26	Neuroticism;	chr8:11537570	chr8:11797928~11802568:-
OV	cis	rs2574704	0.886	rs13066755	ENSG00000251774.1	RNU6-377P	4.1	5.68e-05	0.021	0.26	0.26	Body mass index;	chr3:11590615	chr3:12514706~12514807:+
OV	cis	rs6669119	0.668	rs75509607	ENSG00000200403.1	RNU6-1099P	-4.1	5.69e-05	0.021	-0.36	-0.26	Percentage gas trapping;	chr1:18767269	chr1:19305076~19305182:-
OV	cis	rs2015599	0.623	rs1006410	ENSG00000275476.1	RP11-996F15.4	4.1	5.69e-05	0.021	0.34	0.26	Platelet count;Mean platelet volume;	chr12:29282682	chr12:29277397~29277882:-
OV	cis	rs9473147	0.543	rs9367279	ENSG00000270761.1	RP11-385F7.1	-4.1	5.69e-05	0.021	-0.3	-0.26	Platelet distribution width;Mean platelet volume;	chr6:47480600	chr6:47477243~47477572:-
OV	cis	rs9473147	0.543	rs9473119	ENSG00000270761.1	RP11-385F7.1	-4.1	5.69e-05	0.021	-0.3	-0.26	Platelet distribution width;Mean platelet volume;	chr6:47482882	chr6:47477243~47477572:-
OV	cis	rs7520050	0.553	rs2993263	ENSG00000280836.1	AL355480.1	-4.1	5.69e-05	0.021	-0.34	-0.26	Reticulocyte count;Red blood cell count;	chr1:45555958	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs61783200	ENSG00000280836.1	AL355480.1	4.1	5.7e-05	0.021	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45831731	chr1:45581219~45581321:-
OV	cis	rs4713118	0.629	rs203890	ENSG00000226314.6	ZNF192P1	-4.1	5.7e-05	0.021	-0.35	-0.26	Parkinson's disease;	chr6:28054470	chr6:28161781~28169594:+
OV	cis	rs7158300	1	rs11849778	ENSG00000260711.2	RP11-747H7.3	-4.1	5.7e-05	0.021	-0.29	-0.26	Height;	chr14:92017883	chr14:91752856~91759798:-
OV	cis	rs10078	0.898	rs2241598	ENSG00000221990.4	EXOC3-AS1	-4.1	5.71e-05	0.021	-0.28	-0.26	Fat distribution (HIV);	chr5:438449	chr5:441498~443160:-
OV	cis	rs992157	0.767	rs2014615	ENSG00000261338.2	RP11-378A13.1	4.1	5.71e-05	0.0211	0.31	0.26	Colorectal cancer;	chr2:218306468	chr2:218255319~218257366:+
OV	cis	rs78545713	0.502	rs57145038	ENSG00000241549.7	GUSBP2	-4.1	5.72e-05	0.0211	-0.33	-0.26	Iron status biomarkers (total iron binding capacity);	chr6:26311282	chr6:26871484~26956554:-
OV	cis	rs6445035	0.556	rs17519507	ENSG00000224962.4	PSAT1P4	-4.1	5.72e-05	0.0211	-0.44	-0.26	Aspirin hydrolysis (plasma);	chr3:165727769	chr3:166691187~166691712:+
OV	cis	rs7122539	0.646	rs594313	ENSG00000199325.1	RNU4-39P	-4.1	5.72e-05	0.0211	-0.28	-0.26	HIV-1 susceptibility;	chr11:66841520	chr11:66614964~66615090:-
OV	cis	rs801193	0.636	rs2659895	ENSG00000236529.1	RP13-254B10.1	4.1	5.72e-05	0.0211	0.28	0.26	Aortic root size;	chr7:66731484	chr7:65840212~65840596:+
OV	cis	rs875971	0.862	rs13232191	ENSG00000237310.1	GS1-124K5.4	4.1	5.73e-05	0.0211	0.26	0.26	Aortic root size;	chr7:66521661	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs35378740	ENSG00000237310.1	GS1-124K5.4	4.1	5.73e-05	0.0211	0.26	0.26	Aortic root size;	chr7:66522725	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs10950043	ENSG00000237310.1	GS1-124K5.4	4.1	5.73e-05	0.0211	0.26	0.26	Aortic root size;	chr7:66523623	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs17747530	ENSG00000237310.1	GS1-124K5.4	4.1	5.73e-05	0.0211	0.26	0.26	Aortic root size;	chr7:66529742	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs13226170	ENSG00000237310.1	GS1-124K5.4	4.1	5.73e-05	0.0211	0.26	0.26	Aortic root size;	chr7:66534311	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs2420611	ENSG00000237310.1	GS1-124K5.4	4.1	5.73e-05	0.0211	0.26	0.26	Aortic root size;	chr7:66534333	chr7:66493706~66495474:+
OV	cis	rs875971	0.861	rs801215	ENSG00000237310.1	GS1-124K5.4	-4.1	5.73e-05	0.0211	-0.26	-0.26	Aortic root size;	chr7:66546951	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs13536	ENSG00000237310.1	GS1-124K5.4	-4.1	5.73e-05	0.0211	-0.26	-0.26	Aortic root size;	chr7:66554203	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs801209	ENSG00000237310.1	GS1-124K5.4	-4.1	5.73e-05	0.0211	-0.26	-0.26	Aortic root size;	chr7:66554403	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs801206	ENSG00000237310.1	GS1-124K5.4	-4.1	5.73e-05	0.0211	-0.26	-0.26	Aortic root size;	chr7:66556979	chr7:66493706~66495474:+
OV	cis	rs6669119	0.668	rs75088145	ENSG00000200403.1	RNU6-1099P	-4.1	5.73e-05	0.0211	-0.36	-0.26	Percentage gas trapping;	chr1:18765874	chr1:19305076~19305182:-
OV	cis	rs11105298	0.891	rs6538189	ENSG00000257194.2	RP11-567C2.1	-4.1	5.73e-05	0.0211	-0.39	-0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492146	chr12:90107739~90112779:+
OV	cis	rs11105298	0.891	rs6538190	ENSG00000257194.2	RP11-567C2.1	-4.1	5.73e-05	0.0211	-0.39	-0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89492165	chr12:90107739~90112779:+
OV	cis	rs1167832	0.645	rs1167829	ENSG00000278416.1	PMS2L2	-4.1	5.73e-05	0.0211	-0.41	-0.26	Ankle injury;	chr7:75535697	chr7:75344015~75359550:-
OV	cis	rs6921919	0.583	rs2041230	ENSG00000204709.4	LINC01556	4.1	5.73e-05	0.0211	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28397738	chr6:28943877~28944537:+
OV	cis	rs4132509	1	rs57824597	ENSG00000227230.1	RP11-261C10.5	-4.1	5.74e-05	0.0211	-0.32	-0.26	RR interval (heart rate);	chr1:243767097	chr1:243135898~243140588:+
OV	cis	rs10783487	0.947	rs10876233	ENSG00000258279.2	LINC00592	4.1	5.74e-05	0.0211	0.36	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr12:52082084	chr12:52210930~52223804:+
OV	cis	rs12699921	0.632	rs2723501	ENSG00000279048.1	RP11-511H23.2	4.1	5.74e-05	0.0211	0.23	0.26	Fibrinogen levels;	chr7:17814909	chr7:17940503~17942922:+
OV	cis	rs4787491	0.729	rs4788215	ENSG00000261367.1	RP11-455F5.4	-4.1	5.74e-05	0.0211	-0.29	-0.26	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30036609	chr16:30107675~30110541:+
OV	cis	rs116095464	0.558	rs6962	ENSG00000250848.1	CTD-2083E4.5	-4.1	5.75e-05	0.0212	-0.34	-0.26	Breast cancer;	chr5:256394	chr5:288833~290321:-
OV	cis	rs9287719	0.934	rs6727884	ENSG00000234818.1	AC092687.5	-4.1	5.75e-05	0.0212	-0.28	-0.26	Prostate cancer;	chr2:10617431	chr2:10589166~10604830:+
OV	cis	rs9880211	0.613	rs13079205	ENSG00000239213.4	NCK1-AS1	4.1	5.75e-05	0.0212	0.32	0.26	Height;Body mass index;	chr3:136081851	chr3:136841726~136862054:-
OV	cis	rs9880211	0.644	rs6799320	ENSG00000239213.4	NCK1-AS1	4.1	5.75e-05	0.0212	0.32	0.26	Height;Body mass index;	chr3:136083597	chr3:136841726~136862054:-
OV	cis	rs9880211	0.613	rs9834966	ENSG00000239213.4	NCK1-AS1	4.1	5.75e-05	0.0212	0.32	0.26	Height;Body mass index;	chr3:136089778	chr3:136841726~136862054:-
OV	cis	rs9880211	0.613	rs9653930	ENSG00000239213.4	NCK1-AS1	4.1	5.75e-05	0.0212	0.32	0.26	Height;Body mass index;	chr3:136091472	chr3:136841726~136862054:-
OV	cis	rs9287719	0.649	rs10929677	ENSG00000243819.4	RN7SL832P	4.1	5.75e-05	0.0212	0.27	0.26	Prostate cancer;	chr2:10577422	chr2:10690344~10692099:+
OV	cis	rs1823913	0.599	rs13035132	ENSG00000227542.1	AC092614.2	4.1	5.75e-05	0.0212	0.28	0.26	Obesity-related traits;	chr2:191265275	chr2:191229165~191246172:-
OV	cis	rs4787491	0.729	rs11544328	ENSG00000261367.1	RP11-455F5.4	-4.1	5.75e-05	0.0212	-0.29	-0.26	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30025807	chr16:30107675~30110541:+
OV	cis	rs10486158	0.817	rs3752644	ENSG00000234141.1	AC009473.1	-4.1	5.76e-05	0.0212	-0.39	-0.26	Bipolar disorder and schizophrenia;	chr7:7360152	chr7:7949853~7950709:-
OV	cis	rs12468226	1	rs58288071	ENSG00000272966.1	RP11-686O6.1	4.1	5.76e-05	0.0212	0.44	0.26	Urate levels;	chr2:202350016	chr2:202336739~202337200:+
OV	cis	rs2153535	1	rs2153535	ENSG00000230939.1	RP11-314C16.1	4.1	5.77e-05	0.0212	0.3	0.26	Motion sickness;	chr6:8369446	chr6:8784178~8785445:+
OV	cis	rs593531	0.55	rs592644	ENSG00000280269.1	AP000577.2	-4.1	5.77e-05	0.0212	-0.31	-0.26	Neuroticism;	chr11:74342502	chr11:74204869~74205746:+
OV	cis	rs7267979	0.966	rs6083855	ENSG00000274973.1	RP13-401N8.7	4.1	5.77e-05	0.0212	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25424482	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs4815426	ENSG00000274973.1	RP13-401N8.7	4.1	5.77e-05	0.0212	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25424550	chr20:25845497~25845862:+
OV	cis	rs7246657	1	rs1529957	ENSG00000226686.6	LINC01535	-4.1	5.78e-05	0.0212	-0.4	-0.26	Coronary artery calcification;	chr19:37248899	chr19:37251912~37265535:+
OV	cis	rs6445967	0.933	rs6796069	ENSG00000272360.1	RP11-359I18.5	4.1	5.78e-05	0.0212	0.29	0.26	Platelet count;	chr3:58346781	chr3:58490830~58491291:-
OV	cis	rs7927592	0.763	rs7120876	ENSG00000222339.1	AP000807.2	4.1	5.78e-05	0.0212	0.27	0.26	Total body bone mineral density;	chr11:68493930	chr11:68505572~68505651:-
OV	cis	rs10986311	0.747	rs2282084	ENSG00000227200.1	RP11-121A14.3	-4.1	5.78e-05	0.0213	-0.23	-0.26	Vitiligo;	chr9:124259253	chr9:124262876~124265809:+
OV	cis	rs2243480	1	rs73150014	ENSG00000226824.5	RP4-756H11.3	-4.1	5.78e-05	0.0213	-0.42	-0.26	Diabetic kidney disease;	chr7:65985932	chr7:66654538~66669855:+
OV	cis	rs7649443	0.959	rs12631126	ENSG00000235897.1	TM4SF19-AS1	4.1	5.78e-05	0.0213	0.3	0.26	Nonsyndromic cleft lip with cleft palate;	chr3:197061567	chr3:196318330~196325570:+
OV	cis	rs9675999	1	rs9675999	ENSG00000242182.3	RN7SL745P	4.1	5.79e-05	0.0213	0.3	0.26	Breast cancer;	chr18:23047728	chr18:23004564~23004862:+
OV	cis	rs10992471	0.603	rs10118939	ENSG00000281156.1	MIR3651	-4.1	5.79e-05	0.0213	-0.3	-0.26	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92531359	chr9:92292458~92292547:-
OV	cis	rs853679	1	rs1679732	ENSG00000220721.1	OR1F12	-4.1	5.79e-05	0.0213	-0.37	-0.26	Depression;	chr6:28253486	chr6:28073316~28074233:+
OV	cis	rs6101567	0.623	rs4812376	ENSG00000261431.1	RP4-616B8.4	4.1	5.8e-05	0.0213	0.26	0.26	Nose size;	chr20:39328752	chr20:38961925~38962111:-
OV	cis	rs745109	0.504	rs76654460	ENSG00000273080.1	RP11-301O19.1	4.1	5.8e-05	0.0213	0.35	0.26	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86378757	chr2:86195590~86196049:+
OV	cis	rs801193	1	rs13239306	ENSG00000237310.1	GS1-124K5.4	-4.1	5.8e-05	0.0213	-0.28	-0.26	Aortic root size;	chr7:66671030	chr7:66493706~66495474:+
OV	cis	rs1765142	0.55	rs475477	ENSG00000254532.1	RP11-624D11.2	-4.1	5.81e-05	0.0213	-0.31	-0.26	Schizophrenia;	chr11:30387218	chr11:30044058~30084343:-
OV	cis	rs9992667	1	rs9992667	ENSG00000231160.8	KLF3-AS1	4.1	5.81e-05	0.0213	0.32	0.26	Eosinophil percentage of granulocytes;	chr4:38678565	chr4:38612701~38664883:-
OV	cis	rs9847710	0.733	rs9818819	ENSG00000242142.1	SERBP1P3	4.1	5.81e-05	0.0213	0.31	0.26	Ulcerative colitis;	chr3:53042739	chr3:53064283~53065091:-
OV	cis	rs2839627	0.598	rs2246573	ENSG00000225218.1	AP001628.6	-4.1	5.81e-05	0.0213	-0.26	-0.26	Information processing speed;	chr21:42832906	chr21:42831040~42836477:-
OV	cis	rs12073359	0.954	rs72692895	ENSG00000223945.2	RP11-458I7.1	-4.1	5.81e-05	0.0213	-0.41	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150075781	chr1:150053864~150055034:+
OV	cis	rs2348418	0.765	rs4931734	ENSG00000247934.4	RP11-967K21.1	-4.1	5.82e-05	0.0214	-0.25	-0.26	Lung function (FEV1);Lung function (FVC);	chr12:28196661	chr12:28163298~28190738:-
OV	cis	rs2348418	0.733	rs1904386	ENSG00000247934.4	RP11-967K21.1	-4.1	5.82e-05	0.0214	-0.25	-0.26	Lung function (FEV1);Lung function (FVC);	chr12:28202321	chr12:28163298~28190738:-
OV	cis	rs2348418	0.733	rs1824769	ENSG00000247934.4	RP11-967K21.1	-4.1	5.82e-05	0.0214	-0.25	-0.26	Lung function (FEV1);Lung function (FVC);	chr12:28202322	chr12:28163298~28190738:-
OV	cis	rs2348418	0.671	rs2169753	ENSG00000247934.4	RP11-967K21.1	-4.1	5.82e-05	0.0214	-0.25	-0.26	Lung function (FEV1);Lung function (FVC);	chr12:28203481	chr12:28163298~28190738:-
OV	cis	rs7520050	0.966	rs6661910	ENSG00000280836.1	AL355480.1	4.1	5.82e-05	0.0214	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45824960	chr1:45581219~45581321:-
OV	cis	rs7267979	1	rs6115153	ENSG00000274973.1	RP13-401N8.7	4.1	5.82e-05	0.0214	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25344931	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs7268053	ENSG00000274973.1	RP13-401N8.7	4.1	5.82e-05	0.0214	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25347650	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6083809	ENSG00000274973.1	RP13-401N8.7	4.1	5.82e-05	0.0214	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25348673	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6050561	ENSG00000274973.1	RP13-401N8.7	4.1	5.82e-05	0.0214	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25354219	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6083813	ENSG00000274973.1	RP13-401N8.7	4.1	5.82e-05	0.0214	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25357035	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs4815406	ENSG00000274973.1	RP13-401N8.7	4.1	5.82e-05	0.0214	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25360680	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs6083817	ENSG00000274973.1	RP13-401N8.7	4.1	5.82e-05	0.0214	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25363362	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6050564	ENSG00000274973.1	RP13-401N8.7	4.1	5.82e-05	0.0214	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25363595	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs6083818	ENSG00000274973.1	RP13-401N8.7	4.1	5.82e-05	0.0214	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25365446	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs4815409	ENSG00000274973.1	RP13-401N8.7	4.1	5.82e-05	0.0214	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25366061	chr20:25845497~25845862:+
OV	cis	rs2599510	0.807	rs176416	ENSG00000279544.1	AL133243.4	4.1	5.82e-05	0.0214	0.24	0.26	Interleukin-18 levels;	chr2:32427155	chr2:32563328~32566436:+
OV	cis	rs6128907	1	rs6124014	ENSG00000224635.1	RP4-564F22.5	4.1	5.82e-05	0.0214	0.38	0.26	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38763855	chr20:38406011~38416797:-
OV	cis	rs6128907	1	rs6124015	ENSG00000224635.1	RP4-564F22.5	-4.1	5.82e-05	0.0214	-0.38	-0.26	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38764146	chr20:38406011~38416797:-
OV	cis	rs4728142	0.593	rs7808907	ENSG00000275106.1	RP11-309L24.10	4.1	5.82e-05	0.0214	0.31	0.26	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:128944030	chr7:128952527~128953316:-
OV	cis	rs7246657	0.941	rs10418729	ENSG00000226686.6	LINC01535	-4.1	5.83e-05	0.0214	-0.41	-0.26	Coronary artery calcification;	chr19:37246163	chr19:37251912~37265535:+
OV	cis	rs73186030	1	rs5008830	ENSG00000272758.4	RP11-299J3.8	4.1	5.83e-05	0.0214	0.32	0.26	Serum parathyroid hormone levels;	chr3:122311615	chr3:122416207~122443180:+
OV	cis	rs6723108	0.603	rs1374289	ENSG00000224043.6	CCNT2-AS1	4.1	5.83e-05	0.0214	0.31	0.26	Type 2 diabetes;	chr2:134936809	chr2:134735464~134918710:-
OV	cis	rs875971	0.545	rs316328	ENSG00000236529.1	RP13-254B10.1	-4.1	5.83e-05	0.0214	-0.3	-0.26	Aortic root size;	chr7:66143851	chr7:65840212~65840596:+
OV	cis	rs59042687	1	rs59042687	ENSG00000234629.1	WDR82P1	-4.1	5.83e-05	0.0214	-0.32	-0.26	Gut microbiota (bacterial taxa);	chr3:95804156	chr3:94937086~94938024:-
OV	cis	rs17708984	0.606	rs3786576	ENSG00000270802.2	AC005776.1	-4.1	5.84e-05	0.0214	-0.29	-0.26	Platelet distribution width;Platelet count;	chr19:16082527	chr19:15338948~15339237:+
OV	cis	rs1707322	0.686	rs1084086	ENSG00000225447.1	RPS15AP10	-4.1	5.84e-05	0.0214	-0.25	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45575428	chr1:45645816~45646197:-
OV	cis	rs73562014	0.938	rs73564142	ENSG00000254416.4	RP11-347E10.1	-4.1	5.84e-05	0.0214	-0.47	-0.26	Coronary artery disease;	chr11:110437200	chr11:110355130~110406400:+
OV	cis	rs73562014	0.938	rs73564147	ENSG00000254416.4	RP11-347E10.1	-4.1	5.84e-05	0.0214	-0.47	-0.26	Coronary artery disease;	chr11:110437521	chr11:110355130~110406400:+
OV	cis	rs2015599	0.623	rs7313552	ENSG00000275476.1	RP11-996F15.4	4.1	5.84e-05	0.0214	0.34	0.26	Platelet count;Mean platelet volume;	chr12:29277302	chr12:29277397~29277882:-
OV	cis	rs2015599	0.584	rs7299283	ENSG00000275476.1	RP11-996F15.4	4.1	5.84e-05	0.0214	0.34	0.26	Platelet count;Mean platelet volume;	chr12:29277442	chr12:29277397~29277882:-
OV	cis	rs6764050	1	rs7640320	ENSG00000263826.1	RP11-573D15.9	-4.1	5.84e-05	0.0214	-0.47	-0.26	Response to citalopram treatment;	chr3:187712742	chr3:186781780~186784179:-
OV	cis	rs73019876	0.72	rs1989118	ENSG00000269742.1	BNIP3P29	-4.1	5.85e-05	0.0214	-0.31	-0.26	Testicular germ cell tumor;	chr19:22022877	chr19:22065828~22066398:-
OV	cis	rs62458065	0.713	rs1597560	ENSG00000226468.2	AC018641.7	4.1	5.85e-05	0.0215	0.39	0.26	Metabolite levels (HVA/MHPG ratio);	chr7:32454274	chr7:32456963~32457758:-
OV	cis	rs9867325	0.895	rs9879531	ENSG00000239213.4	NCK1-AS1	4.1	5.85e-05	0.0215	0.33	0.26	Body mass index;	chr3:136920133	chr3:136841726~136862054:-
OV	cis	rs10783487	0.947	rs4762048	ENSG00000258279.2	LINC00592	4.1	5.85e-05	0.0215	0.36	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr12:52074492	chr12:52210930~52223804:+
OV	cis	rs10783487	0.947	rs12830246	ENSG00000258279.2	LINC00592	4.1	5.85e-05	0.0215	0.36	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr12:52074787	chr12:52210930~52223804:+
OV	cis	rs10783487	0.947	rs1882120	ENSG00000258279.2	LINC00592	4.1	5.85e-05	0.0215	0.36	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr12:52074972	chr12:52210930~52223804:+
OV	cis	rs10783487	0.947	rs11521	ENSG00000258279.2	LINC00592	4.1	5.85e-05	0.0215	0.36	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr12:52077375	chr12:52210930~52223804:+
OV	cis	rs7615952	0.515	rs7637246	ENSG00000171084.14	FAM86JP	4.1	5.85e-05	0.0215	0.45	0.26	Blood pressure (smoking interaction);	chr3:125959863	chr3:125916620~125930024:+
OV	cis	rs62458065	1	rs10246687	ENSG00000226468.2	AC018641.7	4.1	5.85e-05	0.0215	0.37	0.26	Metabolite levels (HVA/MHPG ratio);	chr7:32425571	chr7:32456963~32457758:-
OV	cis	rs62458065	1	rs10231294	ENSG00000226468.2	AC018641.7	4.1	5.85e-05	0.0215	0.37	0.26	Metabolite levels (HVA/MHPG ratio);	chr7:32425745	chr7:32456963~32457758:-
OV	cis	rs62458065	1	rs10250808	ENSG00000226468.2	AC018641.7	4.1	5.85e-05	0.0215	0.37	0.26	Metabolite levels (HVA/MHPG ratio);	chr7:32426541	chr7:32456963~32457758:-
OV	cis	rs7667	0.812	rs12042004	ENSG00000240490.3	RN7SL277P	-4.1	5.85e-05	0.0215	-0.32	-0.26	Crohn's disease and psoriasis;	chr1:19437546	chr1:19424384~19424671:+
OV	cis	rs3758911	0.765	rs609821	ENSG00000261098.1	RP11-819C21.1	4.1	5.86e-05	0.0215	0.26	0.26	Coronary artery disease;	chr11:107468429	chr11:107312132~107316271:-
OV	cis	rs941207	0.526	rs11171916	ENSG00000241217.3	RN7SL809P	-4.1	5.86e-05	0.0215	-0.26	-0.26	Platelet count;	chr12:56653236	chr12:56670450~56670746:-
OV	cis	rs875971	0.545	rs2279757	ENSG00000237310.1	GS1-124K5.4	4.1	5.86e-05	0.0215	0.31	0.26	Aortic root size;	chr7:66363676	chr7:66493706~66495474:+
OV	cis	rs875971	0.545	rs11766183	ENSG00000237310.1	GS1-124K5.4	4.1	5.86e-05	0.0215	0.31	0.26	Aortic root size;	chr7:66374173	chr7:66493706~66495474:+
OV	cis	rs875971	0.545	rs1065265	ENSG00000237310.1	GS1-124K5.4	4.1	5.86e-05	0.0215	0.31	0.26	Aortic root size;	chr7:66376216	chr7:66493706~66495474:+
OV	cis	rs875971	0.545	rs7811204	ENSG00000237310.1	GS1-124K5.4	4.1	5.86e-05	0.0215	0.31	0.26	Aortic root size;	chr7:66387213	chr7:66493706~66495474:+
OV	cis	rs801193	1	rs6958520	ENSG00000224316.1	RP11-479O9.2	4.1	5.86e-05	0.0215	0.28	0.26	Aortic root size;	chr7:66686466	chr7:65773620~65802067:+
OV	cis	rs801193	1	rs7788576	ENSG00000224316.1	RP11-479O9.2	-4.1	5.86e-05	0.0215	-0.28	-0.26	Aortic root size;	chr7:66683315	chr7:65773620~65802067:+
OV	cis	rs992157	0.56	rs6436047	ENSG00000237281.1	CATIP-AS2	-4.1	5.86e-05	0.0215	-0.3	-0.26	Colorectal cancer;	chr2:218244190	chr2:218326889~218357966:-
OV	cis	rs2617170	0.885	rs7978962	ENSG00000245648.1	RP11-277P12.20	4.1	5.87e-05	0.0215	0.34	0.26	Behcet's disease;	chr12:10372225	chr12:10363769~10398506:+
OV	cis	rs7746199	0.736	rs34064842	ENSG00000280107.1	AL022393.9	-4.1	5.87e-05	0.0215	-0.55	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27720846	chr6:28170845~28172521:+
OV	cis	rs7746199	0.736	rs13212318	ENSG00000280107.1	AL022393.9	-4.1	5.87e-05	0.0215	-0.55	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27721062	chr6:28170845~28172521:+
OV	cis	rs2288061	0.723	rs2113187	ENSG00000244485.1	RPL18P13	-4.1	5.87e-05	0.0215	-0.32	-0.26	Delta-5 desaturase activity;	chr16:76066011	chr16:76235055~76235623:-
OV	cis	rs73201462	1	rs2999061	ENSG00000242551.2	POU5F1P6	4.09	5.88e-05	0.0215	0.39	0.26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128274780	chr3:128674735~128677005:-
OV	cis	rs1823913	0.637	rs4853569	ENSG00000227542.1	AC092614.2	-4.09	5.88e-05	0.0216	-0.29	-0.26	Obesity-related traits;	chr2:191266970	chr2:191229165~191246172:-
OV	cis	rs709400	0.628	rs12879085	ENSG00000244691.1	RPL10AP1	-4.09	5.88e-05	0.0216	-0.26	-0.26	Body mass index;	chr14:103408083	chr14:103412119~103412761:-
OV	cis	rs17772222	0.71	rs1028455	ENSG00000258789.1	RP11-507K2.3	-4.09	5.89e-05	0.0216	-0.27	-0.26	Coronary artery calcification;	chr14:88363631	chr14:88551597~88552493:+
OV	cis	rs4713118	0.513	rs149972	ENSG00000280107.1	AL022393.9	-4.09	5.89e-05	0.0216	-0.33	-0.26	Parkinson's disease;	chr6:28015449	chr6:28170845~28172521:+
OV	cis	rs12073359	1	rs7530922	ENSG00000223945.2	RP11-458I7.1	4.09	5.89e-05	0.0216	0.4	0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150051427	chr1:150053864~150055034:+
OV	cis	rs7829975	0.742	rs1533058	ENSG00000254153.1	CTA-398F10.2	4.09	5.89e-05	0.0216	0.32	0.26	Mood instability;	chr8:8827680	chr8:8456909~8461337:-
OV	cis	rs11976180	1	rs6464573	ENSG00000204959.4	ARHGEF34P	-4.09	5.9e-05	0.0216	-0.34	-0.26	Obesity-related traits;	chr7:144051005	chr7:144272445~144286966:-
OV	cis	rs1113500	0.548	rs7541433	ENSG00000226822.1	RP11-356N1.2	4.09	5.9e-05	0.0216	0.33	0.26	Growth-regulated protein alpha levels;	chr1:108103019	chr1:108071482~108074519:+
OV	cis	rs7267979	1	rs2424712	ENSG00000274973.1	RP13-401N8.7	-4.09	5.9e-05	0.0216	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25436306	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs2424714	ENSG00000274973.1	RP13-401N8.7	-4.09	5.9e-05	0.0216	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25438045	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs2424715	ENSG00000274973.1	RP13-401N8.7	-4.09	5.9e-05	0.0216	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25439441	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6050617	ENSG00000274973.1	RP13-401N8.7	-4.09	5.9e-05	0.0216	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25441012	chr20:25845497~25845862:+
OV	cis	rs7267979	0.933	rs2387887	ENSG00000274973.1	RP13-401N8.7	-4.09	5.9e-05	0.0216	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25446445	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6050626	ENSG00000274973.1	RP13-401N8.7	-4.09	5.9e-05	0.0216	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25447625	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6037121	ENSG00000274973.1	RP13-401N8.7	-4.09	5.9e-05	0.0216	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25447675	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6050629	ENSG00000274973.1	RP13-401N8.7	-4.09	5.9e-05	0.0216	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25450044	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6050630	ENSG00000274973.1	RP13-401N8.7	-4.09	5.9e-05	0.0216	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25450109	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6050632	ENSG00000274973.1	RP13-401N8.7	-4.09	5.9e-05	0.0216	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25451965	chr20:25845497~25845862:+
OV	cis	rs992969	0.506	rs10119713	ENSG00000231967.1	RP11-12D24.6	4.09	5.9e-05	0.0216	0.3	0.26	Asthma;	chr9:6163823	chr9:5356312~5356525:-
OV	cis	rs10759883	0.563	rs625105	ENSG00000175611.10	LINC00476	4.09	5.9e-05	0.0216	0.32	0.26	Nicotine dependence;	chr9:96007466	chr9:95759231~95875977:-
OV	cis	rs8059260	0.604	rs9302458	ENSG00000274038.1	RP11-66H6.4	-4.09	5.9e-05	0.0216	-0.47	-0.26	Alcohol consumption over the past year;	chr16:11050352	chr16:11056556~11057034:+
OV	cis	rs875971	0.571	rs160641	ENSG00000273024.4	INTS4P2	4.09	5.9e-05	0.0216	0.31	0.26	Aortic root size;	chr7:66112359	chr7:65647864~65715661:+
OV	cis	rs7520050	0.966	rs12409773	ENSG00000281133.1	AL355480.3	4.09	5.9e-05	0.0216	0.3	0.26	Reticulocyte count;Red blood cell count;	chr1:45893159	chr1:45580892~45580996:-
OV	cis	rs7520050	1	rs12410070	ENSG00000281133.1	AL355480.3	4.09	5.9e-05	0.0216	0.3	0.26	Reticulocyte count;Red blood cell count;	chr1:45893210	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs12410071	ENSG00000281133.1	AL355480.3	4.09	5.9e-05	0.0216	0.3	0.26	Reticulocyte count;Red blood cell count;	chr1:45893214	chr1:45580892~45580996:-
OV	cis	rs9813712	0.595	rs6439226	ENSG00000228252.7	COL6A4P2	4.09	5.9e-05	0.0216	0.31	0.26	Response to amphetamines;	chr3:130283686	chr3:130212823~130273806:+
OV	cis	rs4703129	0.506	rs10043462	ENSG00000249448.1	RP11-474J18.1	4.09	5.91e-05	0.0216	0.3	0.26	Asperger disorder;	chr5:98430152	chr5:98410235~98411792:-
OV	cis	rs9880211	1	rs9809988	ENSG00000239213.4	NCK1-AS1	4.09	5.91e-05	0.0216	0.33	0.26	Height;Body mass index;	chr3:136803379	chr3:136841726~136862054:-
OV	cis	rs9880211	1	rs9828976	ENSG00000239213.4	NCK1-AS1	4.09	5.91e-05	0.0216	0.33	0.26	Height;Body mass index;	chr3:136817993	chr3:136841726~136862054:-
OV	cis	rs9880211	0.898	rs73231903	ENSG00000239213.4	NCK1-AS1	4.09	5.91e-05	0.0216	0.33	0.26	Height;Body mass index;	chr3:136842783	chr3:136841726~136862054:-
OV	cis	rs1933112	1	rs1933104	ENSG00000227777.1	RP4-738P11.3	-4.09	5.91e-05	0.0216	-0.29	-0.26	Blood protein levels;	chr1:168559648	chr1:168542737~168543354:+
OV	cis	rs7811142	1	rs11771241	ENSG00000242294.5	STAG3L5P	4.09	5.91e-05	0.0216	0.27	0.26	Platelet count;	chr7:100397162	chr7:100336079~100351900:+
OV	cis	rs7598759	0.548	rs1584462	ENSG00000181798.2	LINC00471	-4.09	5.91e-05	0.0216	-0.26	-0.26	Noise-induced hearing loss;	chr2:231505087	chr2:231508426~231514339:-
OV	cis	rs934734	1	rs934734	ENSG00000234255.7	AC012370.3	-4.09	5.91e-05	0.0216	-0.28	-0.26	Rheumatoid arthritis;	chr2:65368452	chr2:65439888~65456571:-
OV	cis	rs7746199	0.736	rs34573979	ENSG00000226314.6	ZNF192P1	-4.09	5.92e-05	0.0217	-0.58	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr6:28161781~28169594:+
OV	cis	rs875971	0.508	rs10950045	ENSG00000237310.1	GS1-124K5.4	-4.09	5.92e-05	0.0217	-0.27	-0.26	Aortic root size;	chr7:66601386	chr7:66493706~66495474:+
OV	cis	rs801193	0.839	rs6968619	ENSG00000237310.1	GS1-124K5.4	-4.09	5.92e-05	0.0217	-0.27	-0.26	Aortic root size;	chr7:66603880	chr7:66493706~66495474:+
OV	cis	rs801193	0.839	rs12534943	ENSG00000237310.1	GS1-124K5.4	-4.09	5.92e-05	0.0217	-0.27	-0.26	Aortic root size;	chr7:66605533	chr7:66493706~66495474:+
OV	cis	rs801193	0.805	rs12532355	ENSG00000237310.1	GS1-124K5.4	-4.09	5.92e-05	0.0217	-0.27	-0.26	Aortic root size;	chr7:66605597	chr7:66493706~66495474:+
OV	cis	rs7429990	0.828	rs11712152	ENSG00000229759.1	MRPS18AP1	4.09	5.92e-05	0.0217	0.29	0.26	Educational attainment (years of education);	chr3:47655314	chr3:48256350~48256938:-
OV	cis	rs853356	0.532	rs861209	ENSG00000272209.1	RP3-500L14.2	4.09	5.92e-05	0.0217	0.33	0.26	Height;	chr6:14194233	chr6:13825432~13826574:+
OV	cis	rs875971	0.508	rs10242423	ENSG00000237310.1	GS1-124K5.4	-4.09	5.92e-05	0.0217	-0.27	-0.26	Aortic root size;	chr7:66594188	chr7:66493706~66495474:+
OV	cis	rs875971	0.508	rs10253883	ENSG00000237310.1	GS1-124K5.4	-4.09	5.92e-05	0.0217	-0.27	-0.26	Aortic root size;	chr7:66596151	chr7:66493706~66495474:+
OV	cis	rs6921919	0.583	rs11755942	ENSG00000204709.4	LINC01556	4.09	5.92e-05	0.0217	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28401760	chr6:28943877~28944537:+
OV	cis	rs7267979	0.932	rs446649	ENSG00000274973.1	RP13-401N8.7	-4.09	5.92e-05	0.0217	-0.29	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25486723	chr20:25845497~25845862:+
OV	cis	rs11096990	0.656	rs4580661	ENSG00000249207.1	RP11-360F5.1	4.09	5.92e-05	0.0217	0.28	0.26	Cognitive function;	chr4:39294730	chr4:39112677~39126818:-
OV	cis	rs7520050	0.966	rs11211199	ENSG00000280836.1	AL355480.1	4.09	5.92e-05	0.0217	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45822197	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs4376778	ENSG00000280836.1	AL355480.1	4.09	5.92e-05	0.0217	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45823174	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs6672898	ENSG00000280836.1	AL355480.1	4.09	5.92e-05	0.0217	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45824916	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs7539932	ENSG00000280836.1	AL355480.1	4.09	5.92e-05	0.0217	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45826682	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs6680380	ENSG00000280836.1	AL355480.1	4.09	5.92e-05	0.0217	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45834517	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs10890354	ENSG00000280836.1	AL355480.1	4.09	5.92e-05	0.0217	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45839675	chr1:45581219~45581321:-
OV	cis	rs7520050	0.931	rs6697557	ENSG00000280836.1	AL355480.1	4.09	5.92e-05	0.0217	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45842137	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs6701614	ENSG00000280836.1	AL355480.1	4.09	5.92e-05	0.0217	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45843748	chr1:45581219~45581321:-
OV	cis	rs7968440	0.838	rs7979165	ENSG00000272368.2	RP4-605O3.4	4.09	5.93e-05	0.0217	0.32	0.26	Fibrinogen;	chr12:50754774	chr12:50112197~50165618:+
OV	cis	rs1008375	1	rs2058338	ENSG00000249502.1	AC006160.5	4.09	5.93e-05	0.0217	0.27	0.26	Parasitemia in Tripanosoma cruzi seropositivity;	chr4:17676977	chr4:17587467~17614571:-
OV	cis	rs17708984	0.606	rs3786573	ENSG00000270802.2	AC005776.1	-4.09	5.93e-05	0.0217	-0.29	-0.26	Platelet distribution width;Platelet count;	chr19:16082975	chr19:15338948~15339237:+
OV	cis	rs2777491	0.872	rs7176588	ENSG00000259617.1	RP11-540O11.6	-4.09	5.93e-05	0.0217	-0.25	-0.26	Ulcerative colitis;	chr15:41296674	chr15:40999274~41004865:+
OV	cis	rs4908768	0.906	rs12405049	ENSG00000228423.2	RP4-633I8.4	4.09	5.93e-05	0.0217	0.32	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8566058	chr1:8805860~8807051:-
OV	cis	rs2243480	1	rs1964692	ENSG00000226824.5	RP4-756H11.3	-4.09	5.93e-05	0.0217	-0.42	-0.26	Diabetic kidney disease;	chr7:65989196	chr7:66654538~66669855:+
OV	cis	rs2243480	0.901	rs2456483	ENSG00000226824.5	RP4-756H11.3	-4.09	5.93e-05	0.0217	-0.42	-0.26	Diabetic kidney disease;	chr7:65996588	chr7:66654538~66669855:+
OV	cis	rs2243480	0.901	rs2949697	ENSG00000226824.5	RP4-756H11.3	-4.09	5.93e-05	0.0217	-0.42	-0.26	Diabetic kidney disease;	chr7:65999249	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs1701750	ENSG00000226824.5	RP4-756H11.3	-4.09	5.93e-05	0.0217	-0.42	-0.26	Diabetic kidney disease;	chr7:66002158	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs1701758	ENSG00000226824.5	RP4-756H11.3	-4.09	5.93e-05	0.0217	-0.42	-0.26	Diabetic kidney disease;	chr7:66005214	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs781157	ENSG00000226824.5	RP4-756H11.3	-4.09	5.93e-05	0.0217	-0.42	-0.26	Diabetic kidney disease;	chr7:66013324	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs781156	ENSG00000226824.5	RP4-756H11.3	-4.09	5.93e-05	0.0217	-0.42	-0.26	Diabetic kidney disease;	chr7:66014154	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs781149	ENSG00000226824.5	RP4-756H11.3	-4.09	5.93e-05	0.0217	-0.42	-0.26	Diabetic kidney disease;	chr7:66016297	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs451396	ENSG00000226824.5	RP4-756H11.3	-4.09	5.93e-05	0.0217	-0.42	-0.26	Diabetic kidney disease;	chr7:66019087	chr7:66654538~66669855:+
OV	cis	rs2243480	0.901	rs58207111	ENSG00000226824.5	RP4-756H11.3	-4.09	5.93e-05	0.0217	-0.42	-0.26	Diabetic kidney disease;	chr7:66021736	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs1167613	ENSG00000226824.5	RP4-756H11.3	-4.09	5.93e-05	0.0217	-0.42	-0.26	Diabetic kidney disease;	chr7:66022452	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs1715235	ENSG00000226824.5	RP4-756H11.3	-4.09	5.93e-05	0.0217	-0.42	-0.26	Diabetic kidney disease;	chr7:66023407	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs313799	ENSG00000226824.5	RP4-756H11.3	-4.09	5.93e-05	0.0217	-0.42	-0.26	Diabetic kidney disease;	chr7:66029343	chr7:66654538~66669855:+
OV	cis	rs7727544	0.684	rs272889	ENSG00000233006.5	AC034220.3	4.09	5.93e-05	0.0217	0.26	0.26	Blood metabolite levels;	chr5:132329685	chr5:132311285~132369916:-
OV	cis	rs875971	0.545	rs10261710	ENSG00000236529.1	RP13-254B10.1	4.09	5.94e-05	0.0217	0.32	0.26	Aortic root size;	chr7:66249202	chr7:65840212~65840596:+
OV	cis	rs9506514	0.509	rs9509279	ENSG00000238286.1	SLC35E1P1	4.09	5.94e-05	0.0217	0.3	0.26	Coronary artery calcification;	chr13:20559580	chr13:20607268~20608131:+
OV	cis	rs17428076	0.536	rs62182438	ENSG00000228389.1	AC068039.4	-4.09	5.94e-05	0.0217	-0.31	-0.26	Myopia;	chr2:171940254	chr2:171773482~171775844:+
OV	cis	rs11083475	1	rs10403540	ENSG00000267892.1	CTD-2540F13.2	4.09	5.94e-05	0.0217	0.3	0.26	Heart rate;	chr19:38714206	chr19:38738284~38739863:+
OV	cis	rs11083475	1	rs3786848	ENSG00000267892.1	CTD-2540F13.2	4.09	5.94e-05	0.0217	0.3	0.26	Heart rate;	chr19:38716689	chr19:38738284~38739863:+
OV	cis	rs11083475	1	rs8111746	ENSG00000267892.1	CTD-2540F13.2	4.09	5.94e-05	0.0217	0.3	0.26	Heart rate;	chr19:38722219	chr19:38738284~38739863:+
OV	cis	rs11083475	1	rs3786851	ENSG00000267892.1	CTD-2540F13.2	4.09	5.94e-05	0.0217	0.3	0.26	Heart rate;	chr19:38724693	chr19:38738284~38739863:+
OV	cis	rs6901317	1	rs6901317	ENSG00000231628.1	RP3-355L5.4	-4.09	5.94e-05	0.0217	-0.26	-0.26	Beard thickness;	chr6:105588276	chr6:105279016~105281755:+
OV	cis	rs17772222	0.606	rs1955598	ENSG00000258789.1	RP11-507K2.3	-4.09	5.94e-05	0.0217	-0.26	-0.26	Coronary artery calcification;	chr14:88357311	chr14:88551597~88552493:+
OV	cis	rs1113500	0.548	rs11185271	ENSG00000226822.1	RP11-356N1.2	4.09	5.94e-05	0.0217	0.33	0.26	Growth-regulated protein alpha levels;	chr1:108117311	chr1:108071482~108074519:+
OV	cis	rs2348418	0.767	rs7972954	ENSG00000247934.4	RP11-967K21.1	4.09	5.95e-05	0.0217	0.26	0.26	Lung function (FEV1);Lung function (FVC);	chr12:28260273	chr12:28163298~28190738:-
OV	cis	rs9992667	0.955	rs9992076	ENSG00000231160.8	KLF3-AS1	4.09	5.95e-05	0.0217	0.3	0.26	Eosinophil percentage of granulocytes;	chr4:38643046	chr4:38612701~38664883:-
OV	cis	rs2919917	0.628	rs2887482	ENSG00000254352.1	RP11-578O24.2	4.09	5.95e-05	0.0217	0.34	0.26	Lymphocyte counts;	chr8:78659633	chr8:78723796~78724136:-
OV	cis	rs2919917	0.628	rs1905364	ENSG00000254352.1	RP11-578O24.2	4.09	5.95e-05	0.0217	0.34	0.26	Lymphocyte counts;	chr8:78660244	chr8:78723796~78724136:-
OV	cis	rs10986311	0.802	rs6478659	ENSG00000232630.1	PRPS1P2	-4.09	5.95e-05	0.0217	-0.28	-0.26	Vitiligo;	chr9:124365995	chr9:125150653~125151589:+
OV	cis	rs7746199	0.736	rs10484399	ENSG00000226314.6	ZNF192P1	-4.09	5.95e-05	0.0217	-0.53	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27566749	chr6:28161781~28169594:+
OV	cis	rs875971	0.862	rs6955837	ENSG00000237310.1	GS1-124K5.4	-4.09	5.95e-05	0.0217	-0.26	-0.26	Aortic root size;	chr7:66578155	chr7:66493706~66495474:+
OV	cis	rs875971	0.825	rs10281499	ENSG00000237310.1	GS1-124K5.4	-4.09	5.95e-05	0.0217	-0.26	-0.26	Aortic root size;	chr7:66583979	chr7:66493706~66495474:+
OV	cis	rs3858145	0.588	rs61854837	ENSG00000233590.1	RP11-153K11.3	-4.09	5.96e-05	0.0217	-0.39	-0.26	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68282613	chr10:68233251~68242379:-
OV	cis	rs11233413	0.587	rs2170008	ENSG00000274004.1	H19_3	4.09	5.96e-05	0.0218	0.32	0.26	Economic and political preferences (feminism/equality);	chr11:82979391	chr11:83386988~83387102:+
OV	cis	rs1436109	0.831	rs4366519	ENSG00000255710.2	RP11-667M19.9	-4.09	5.96e-05	0.0218	-0.35	-0.26	Cardiac muscle measurement;	chr11:113149860	chr11:113820856~113821885:-
OV	cis	rs4654783	0.671	rs3765351	ENSG00000228397.1	RP1-224A6.3	4.09	5.96e-05	0.0218	0.3	0.26	Endometriosis;	chr1:22119498	chr1:22023994~22024968:-
OV	cis	rs875971	0.862	rs11763189	ENSG00000237310.1	GS1-124K5.4	4.09	5.96e-05	0.0218	0.26	0.26	Aortic root size;	chr7:66518542	chr7:66493706~66495474:+
OV	cis	rs72615157	0.634	rs11762932	ENSG00000242294.5	STAG3L5P	-4.09	5.96e-05	0.0218	-0.24	-0.26	Lung function (FEV1/FVC);	chr7:100195043	chr7:100336079~100351900:+
OV	cis	rs11122895	0.716	rs3952774	ENSG00000228251.1	AC012442.6	-4.09	5.96e-05	0.0218	-0.25	-0.26	Allergic sensitization;	chr2:111711830	chr2:112590796~112591939:+
OV	cis	rs1979679	0.918	rs786711	ENSG00000278733.1	RP11-425D17.1	4.09	5.97e-05	0.0218	0.32	0.26	Ossification of the posterior longitudinal ligament of the spine;	chr12:28406330	chr12:28185625~28186190:-
OV	cis	rs1979679	0.918	rs786707	ENSG00000278733.1	RP11-425D17.1	4.09	5.97e-05	0.0218	0.32	0.26	Ossification of the posterior longitudinal ligament of the spine;	chr12:28420714	chr12:28185625~28186190:-
OV	cis	rs4908768	0.906	rs751790	ENSG00000228423.2	RP4-633I8.4	-4.09	5.97e-05	0.0218	-0.32	-0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8469081	chr1:8805860~8807051:-
OV	cis	rs8062405	1	rs2008514	ENSG00000278665.1	RP11-666O2.4	-4.09	5.97e-05	0.0218	-0.28	-0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814284	chr16:28599241~28601881:-
OV	cis	rs7017914	0.667	rs2732124	ENSG00000223220.1	Y_RNA	4.09	5.97e-05	0.0218	0.28	0.26	Bone mineral density;	chr8:70986447	chr8:70780914~70781008:-
OV	cis	rs10129255	0.518	rs8004895	ENSG00000223648.3	IGHV3-64	4.09	5.97e-05	0.0218	0.26	0.26	Kawasaki disease;	chr14:106785139	chr14:106643132~106658258:-
OV	cis	rs7789940	1	rs2072435	ENSG00000230305.2	AC004980.9	4.09	5.98e-05	0.0218	0.37	0.26	Multiple sclerosis;	chr7:76329871	chr7:76524515~76532692:+
OV	cis	rs694739	1	rs1783521	ENSG00000236935.1	AP003774.1	4.09	5.98e-05	0.0218	0.34	0.26	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64338819	chr11:64325050~64329504:-
OV	cis	rs9649213	0.593	rs13246942	ENSG00000272950.1	RP11-307C18.1	4.09	5.98e-05	0.0218	0.31	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98285709	chr7:98322853~98323430:+
OV	cis	rs9649213	0.593	rs6968144	ENSG00000272950.1	RP11-307C18.1	4.09	5.98e-05	0.0218	0.31	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98286385	chr7:98322853~98323430:+
OV	cis	rs9649213	0.574	rs62479853	ENSG00000272950.1	RP11-307C18.1	4.09	5.98e-05	0.0218	0.31	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98287846	chr7:98322853~98323430:+
OV	cis	rs2227564	0.62	rs11000765	ENSG00000271816.1	BMS1P4	4.09	5.98e-05	0.0218	0.26	0.26	Crohn's disease;Inflammatory bowel disease;	chr10:73752694	chr10:73699151~73730487:-
OV	cis	rs1979679	0.573	rs2348417	ENSG00000278733.1	RP11-425D17.1	-4.09	5.99e-05	0.0218	-0.32	-0.26	Ossification of the posterior longitudinal ligament of the spine;	chr12:28582663	chr12:28185625~28186190:-
OV	cis	rs6673267	0.874	rs10753887	ENSG00000223774.4	RP11-307B6.3	4.09	5.99e-05	0.0218	0.29	0.26	Lobe attachment (rater-scored or self-reported);	chr1:201020313	chr1:201893842~201899978:+
OV	cis	rs7927592	0.513	rs653056	ENSG00000212093.1	AP000807.1	4.09	5.99e-05	0.0218	0.31	0.26	Total body bone mineral density;	chr11:68436157	chr11:68506083~68506166:-
OV	cis	rs4713118	0.629	rs203888	ENSG00000226314.6	ZNF192P1	-4.09	5.99e-05	0.0219	-0.34	-0.26	Parkinson's disease;	chr6:28053811	chr6:28161781~28169594:+
OV	cis	rs10462065	0.685	rs75318003	ENSG00000249779.1	RP11-447H19.3	-4.09	6e-05	0.0219	-0.48	-0.26	Nonsyndromic cleft lip with cleft palate;	chr5:44115281	chr5:43206709~43207811:+
OV	cis	rs10783487	0.895	rs10876230	ENSG00000258279.2	LINC00592	4.09	6e-05	0.0219	0.36	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr12:52072398	chr12:52210930~52223804:+
OV	cis	rs10783487	0.895	rs10876231	ENSG00000258279.2	LINC00592	4.09	6e-05	0.0219	0.36	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr12:52072421	chr12:52210930~52223804:+
OV	cis	rs10740039	0.81	rs10159646	ENSG00000254271.1	RP11-131N11.4	4.09	6e-05	0.0219	0.33	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60620366	chr10:60734342~60741828:+
OV	cis	rs7927592	0.626	rs11228279	ENSG00000222339.1	AP000807.2	-4.09	6e-05	0.0219	-0.26	-0.26	Total body bone mineral density;	chr11:68542212	chr11:68505572~68505651:-
OV	cis	rs8100891	0.734	rs8104048	ENSG00000267213.4	AC007773.2	-4.09	6e-05	0.0219	-0.33	-0.26	Neuroticism;	chr19:32338400	chr19:32390050~32405560:-
OV	cis	rs875971	0.545	rs73136346	ENSG00000273024.4	INTS4P2	4.09	6e-05	0.0219	0.32	0.26	Aortic root size;	chr7:66101095	chr7:65647864~65715661:+
OV	cis	rs6120849	0.951	rs6120848	ENSG00000206582.1	Y_RNA	-4.09	6.01e-05	0.0219	-0.35	-0.26	Protein C levels;	chr20:35140875	chr20:34526510~34526606:-
OV	cis	rs881375	0.933	rs4837804	ENSG00000226752.6	PSMD5-AS1	-4.09	6.01e-05	0.0219	-0.28	-0.26	Rheumatoid arthritis;	chr9:120943026	chr9:120824828~120854385:+
OV	cis	rs801193	0.636	rs10233806	ENSG00000237310.1	GS1-124K5.4	-4.09	6.01e-05	0.0219	-0.27	-0.26	Aortic root size;	chr7:66653261	chr7:66493706~66495474:+
OV	cis	rs7119038	0.615	rs10892274	ENSG00000255422.1	AP002954.4	4.09	6.02e-05	0.0219	0.34	0.26	Sjögren's syndrome;	chr11:118734754	chr11:118704607~118750263:+
OV	cis	rs709400	0.628	rs7155014	ENSG00000244691.1	RPL10AP1	4.09	6.02e-05	0.0219	0.26	0.26	Body mass index;	chr14:103397633	chr14:103412119~103412761:-
OV	cis	rs62184315	0.938	rs17806132	ENSG00000253559.1	OSGEPL1-AS1	4.09	6.03e-05	0.022	0.35	0.26	Alcohol dependence (age at onset);	chr2:189843561	chr2:189762704~189765556:+
OV	cis	rs4296809	0.714	rs57879248	ENSG00000249779.1	RP11-447H19.3	-4.09	6.03e-05	0.022	-0.46	-0.26	Brain structure;	chr5:44100653	chr5:43206709~43207811:+
OV	cis	rs11122895	0.716	rs7580929	ENSG00000228251.1	AC012442.6	-4.09	6.03e-05	0.022	-0.25	-0.26	Allergic sensitization;	chr2:111713904	chr2:112590796~112591939:+
OV	cis	rs11105298	0.891	rs3825330	ENSG00000257194.2	RP11-567C2.1	-4.09	6.03e-05	0.022	-0.39	-0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89539933	chr12:90107739~90112779:+
OV	cis	rs11105298	0.891	rs10858909	ENSG00000257194.2	RP11-567C2.1	-4.09	6.03e-05	0.022	-0.39	-0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89541610	chr12:90107739~90112779:+
OV	cis	rs944801	0.631	rs2383204	ENSG00000234840.1	LINC01239	-4.09	6.04e-05	0.022	-0.3	-0.26	Type 2 diabetes;	chr9:22055049	chr9:22646200~22824213:+
OV	cis	rs5742933	1	rs7557519	ENSG00000253559.1	OSGEPL1-AS1	-4.09	6.04e-05	0.022	-0.29	-0.26	Ferritin levels;	chr2:189718461	chr2:189762704~189765556:+
OV	cis	rs4266144	0.562	rs56357317	ENSG00000244515.1	KRT18P34	-4.09	6.04e-05	0.022	-0.34	-0.26	Coronary artery disease;	chr3:157117385	chr3:157162663~157163932:-
OV	cis	rs73186030	0.92	rs73186053	ENSG00000272758.4	RP11-299J3.8	4.09	6.04e-05	0.022	0.32	0.26	Serum parathyroid hormone levels;	chr3:122322009	chr3:122416207~122443180:+
OV	cis	rs73186030	0.92	rs73186057	ENSG00000272758.4	RP11-299J3.8	4.09	6.04e-05	0.022	0.32	0.26	Serum parathyroid hormone levels;	chr3:122325058	chr3:122416207~122443180:+
OV	cis	rs2282300	0.956	rs2685286	ENSG00000242353.1	RP4-710M3.1	-4.09	6.04e-05	0.022	-0.38	-0.26	Morning vs. evening chronotype;	chr11:30360041	chr11:30368148~30368646:+
OV	cis	rs3758911	0.964	rs10789603	ENSG00000261098.1	RP11-819C21.1	-4.09	6.05e-05	0.022	-0.25	-0.26	Coronary artery disease;	chr11:107311050	chr11:107312132~107316271:-
OV	cis	rs4908768	0.906	rs12409937	ENSG00000228423.2	RP4-633I8.4	4.09	6.05e-05	0.022	0.32	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8478242	chr1:8805860~8807051:-
OV	cis	rs4908768	0.906	rs12402539	ENSG00000228423.2	RP4-633I8.4	4.09	6.05e-05	0.022	0.32	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8478243	chr1:8805860~8807051:-
OV	cis	rs2243480	0.522	rs73150635	ENSG00000226824.5	RP4-756H11.3	-4.09	6.05e-05	0.022	-0.48	-0.26	Diabetic kidney disease;	chr7:66507503	chr7:66654538~66669855:+
OV	cis	rs9287719	0.601	rs62128635	ENSG00000243819.4	RN7SL832P	4.09	6.05e-05	0.022	0.27	0.26	Prostate cancer;	chr2:10585208	chr2:10690344~10692099:+
OV	cis	rs6750795	0.765	rs6742387	ENSG00000181798.2	LINC00471	-4.09	6.05e-05	0.022	-0.26	-0.26	Height;	chr2:231490121	chr2:231508426~231514339:-
OV	cis	rs7598759	0.548	rs1823328	ENSG00000181798.2	LINC00471	-4.09	6.05e-05	0.022	-0.26	-0.26	Noise-induced hearing loss;	chr2:231490473	chr2:231508426~231514339:-
OV	cis	rs2117029	1	rs11168839	ENSG00000258017.1	RP11-386G11.10	4.09	6.05e-05	0.022	0.31	0.26	Intelligence (multi-trait analysis);	chr12:49063852	chr12:49127782~49147869:+
OV	cis	rs7267979	1	rs6115182	ENSG00000274973.1	RP13-401N8.7	4.09	6.06e-05	0.022	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25429623	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6050609	ENSG00000274973.1	RP13-401N8.7	4.09	6.06e-05	0.022	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25431115	chr20:25845497~25845862:+
OV	cis	rs2910756	1	rs2973116	ENSG00000248216.1	KCTD9P5	-4.09	6.06e-05	0.022	-0.36	-0.26	World class endurance athleticism;	chr5:37854636	chr5:37505688~37506857:-
OV	cis	rs6545883	1	rs778758	ENSG00000273302.1	RP11-493E12.2	4.09	6.06e-05	0.022	0.21	0.26	Tuberculosis;	chr2:61555026	chr2:61199979~61200769:+
OV	cis	rs897984	0.762	rs2054213	ENSG00000260911.2	RP11-196G11.2	-4.09	6.06e-05	0.022	-0.24	-0.26	Dementia with Lewy bodies;	chr16:30960489	chr16:31043150~31049868:+
OV	cis	rs57221529	0.664	rs72704802	ENSG00000271781.1	CTD-2589H19.6	-4.09	6.06e-05	0.022	-0.47	-0.26	Lung disease severity in cystic fibrosis;	chr5:554096	chr5:675826~676616:+
OV	cis	rs13201294	1	rs13201294	ENSG00000220721.1	OR1F12	4.09	6.06e-05	0.022	0.44	0.26	Squamous cell lung carcinoma;	chr6:27588362	chr6:28073316~28074233:+
OV	cis	rs4908768	0.906	rs12145445	ENSG00000228423.2	RP4-633I8.4	4.09	6.06e-05	0.022	0.32	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8544311	chr1:8805860~8807051:-
OV	cis	rs4908768	0.906	rs28422051	ENSG00000228423.2	RP4-633I8.4	4.09	6.06e-05	0.022	0.32	0.26	Neuroticism (multi-trait analysis);Subjective well-being (multi-trait analysis);	chr1:8558278	chr1:8805860~8807051:-
OV	cis	rs1823913	0.637	rs4853575	ENSG00000227542.1	AC092614.2	-4.09	6.06e-05	0.0221	-0.28	-0.26	Obesity-related traits;	chr2:191296149	chr2:191229165~191246172:-
OV	cis	rs76210638	1	rs76210638	ENSG00000232986.1	RP11-179A7.2	4.09	6.06e-05	0.0221	0.62	0.26	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);	chr13:33928046	chr13:33657436~33659928:+
OV	cis	rs6921919	0.583	rs9468367	ENSG00000204709.4	LINC01556	4.09	6.06e-05	0.0221	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28392469	chr6:28943877~28944537:+
OV	cis	rs9326248	1	rs4938354	ENSG00000280143.1	AP000892.6	4.09	6.06e-05	0.0221	0.29	0.26	Blood protein levels;	chr11:117180449	chr11:117204967~117210292:+
OV	cis	rs875971	0.862	rs778724	ENSG00000237310.1	GS1-124K5.4	4.09	6.07e-05	0.0221	0.26	0.26	Aortic root size;	chr7:66364304	chr7:66493706~66495474:+
OV	cis	rs875971	0.767	rs1643394	ENSG00000237310.1	GS1-124K5.4	4.09	6.07e-05	0.0221	0.26	0.26	Aortic root size;	chr7:66371107	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs778684	ENSG00000237310.1	GS1-124K5.4	4.09	6.07e-05	0.0221	0.26	0.26	Aortic root size;	chr7:66371416	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs778680	ENSG00000237310.1	GS1-124K5.4	4.09	6.07e-05	0.0221	0.26	0.26	Aortic root size;	chr7:66375427	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs11769079	ENSG00000237310.1	GS1-124K5.4	4.09	6.07e-05	0.0221	0.26	0.26	Aortic root size;	chr7:66377141	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs1695820	ENSG00000237310.1	GS1-124K5.4	4.09	6.07e-05	0.0221	0.26	0.26	Aortic root size;	chr7:66379576	chr7:66493706~66495474:+
OV	cis	rs875971	0.83	rs778715	ENSG00000237310.1	GS1-124K5.4	4.09	6.07e-05	0.0221	0.26	0.26	Aortic root size;	chr7:66384222	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs778702	ENSG00000237310.1	GS1-124K5.4	4.09	6.07e-05	0.0221	0.26	0.26	Aortic root size;	chr7:66399848	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs1643375	ENSG00000237310.1	GS1-124K5.4	4.09	6.07e-05	0.0221	0.26	0.26	Aortic root size;	chr7:66407690	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs6962717	ENSG00000237310.1	GS1-124K5.4	4.09	6.07e-05	0.0221	0.26	0.26	Aortic root size;	chr7:66418748	chr7:66493706~66495474:+
OV	cis	rs12073359	1	rs11205321	ENSG00000223945.2	RP11-458I7.1	-4.09	6.08e-05	0.0221	-0.4	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150054225	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs7550323	ENSG00000223945.2	RP11-458I7.1	-4.09	6.08e-05	0.0221	-0.4	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150055018	chr1:150053864~150055034:+
OV	cis	rs4934494	0.689	rs11185895	ENSG00000240996.1	RP11-80H5.7	4.09	6.08e-05	0.0221	0.34	0.26	Red blood cell count;	chr10:89817482	chr10:89694295~89697928:-
OV	cis	rs16895768	0.685	rs4700171	ENSG00000249894.1	RP11-434D9.2	-4.09	6.08e-05	0.0221	-0.38	-0.26	Selective IgA deficiency;	chr5:66906403	chr5:67800740~67890096:-
OV	cis	rs4787491	0.729	rs4788213	ENSG00000261367.1	RP11-455F5.4	-4.09	6.08e-05	0.0221	-0.29	-0.26	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30023203	chr16:30107675~30110541:+
OV	cis	rs4787491	0.679	rs7204852	ENSG00000261367.1	RP11-455F5.4	-4.09	6.08e-05	0.0221	-0.29	-0.26	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30028857	chr16:30107675~30110541:+
OV	cis	rs4787491	0.729	rs12446378	ENSG00000261367.1	RP11-455F5.4	-4.09	6.08e-05	0.0221	-0.29	-0.26	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30031789	chr16:30107675~30110541:+
OV	cis	rs4787491	0.729	rs8043883	ENSG00000261367.1	RP11-455F5.4	-4.09	6.08e-05	0.0221	-0.29	-0.26	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30033260	chr16:30107675~30110541:+
OV	cis	rs4787491	0.765	rs8054507	ENSG00000261367.1	RP11-455F5.4	-4.09	6.08e-05	0.0221	-0.29	-0.26	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30034721	chr16:30107675~30110541:+
OV	cis	rs6683071	0.894	rs12073392	ENSG00000272750.1	RP11-378J18.8	-4.09	6.08e-05	0.0221	-0.32	-0.26	Cognitive performance;	chr1:222753336	chr1:222658867~222661512:-
OV	cis	rs2070488	1	rs34258593	ENSG00000229589.1	ACVR2B-AS1	4.09	6.09e-05	0.0221	0.29	0.26	Electrocardiographic conduction measures;	chr3:38423074	chr3:38451027~38454820:-
OV	cis	rs4761702	0.551	rs11106987	ENSG00000257322.4	RP11-511B23.2	-4.09	6.09e-05	0.0221	-0.29	-0.26	Immature fraction of reticulocytes;	chr12:93339760	chr12:93003415~93215679:-
OV	cis	rs10783487	0.895	rs7979353	ENSG00000258279.2	LINC00592	4.09	6.09e-05	0.0221	0.36	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr12:52072655	chr12:52210930~52223804:+
OV	cis	rs73186030	0.546	rs55780469	ENSG00000272758.4	RP11-299J3.8	4.09	6.09e-05	0.0221	0.31	0.26	Serum parathyroid hormone levels;	chr3:122388590	chr3:122416207~122443180:+
OV	cis	rs1707322	0.752	rs4660313	ENSG00000234329.1	RP11-767N6.2	-4.09	6.09e-05	0.0221	-0.27	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645169	chr1:45651039~45651826:-
OV	cis	rs9287719	0.578	rs10175555	ENSG00000243819.4	RN7SL832P	4.09	6.09e-05	0.0221	0.27	0.26	Prostate cancer;	chr2:10563107	chr2:10690344~10692099:+
OV	cis	rs8062405	0.54	rs151226	ENSG00000259982.1	CDC37P1	4.09	6.09e-05	0.0221	0.3	0.26	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28538502	chr16:28700294~28701540:-
OV	cis	rs3734266	0.702	rs4646933	ENSG00000220643.1	RP3-391O22.1	-4.09	6.1e-05	0.0221	-0.43	-0.26	Systemic lupus erythematosus;	chr6:34882883	chr6:34686602~34687106:+
OV	cis	rs5742933	1	rs4666783	ENSG00000253559.1	OSGEPL1-AS1	-4.09	6.1e-05	0.0221	-0.3	-0.26	Ferritin levels;	chr2:189748254	chr2:189762704~189765556:+
OV	cis	rs10129255	0.5	rs8014529	ENSG00000223648.3	IGHV3-64	4.09	6.1e-05	0.0222	0.26	0.26	Kawasaki disease;	chr14:106784065	chr14:106643132~106658258:-
OV	cis	rs10129255	0.5	rs12101190	ENSG00000223648.3	IGHV3-64	4.09	6.1e-05	0.0222	0.26	0.26	Kawasaki disease;	chr14:106784149	chr14:106643132~106658258:-
OV	cis	rs6673267	0.904	rs10800751	ENSG00000223774.4	RP11-307B6.3	4.09	6.11e-05	0.0222	0.28	0.26	Lobe attachment (rater-scored or self-reported);	chr1:201030798	chr1:201893842~201899978:+
OV	cis	rs6661961	0.78	rs11803629	ENSG00000237975.5	FLG-AS1	-4.09	6.11e-05	0.0222	-0.34	-0.26	Atopic dermatitis;	chr1:152445670	chr1:152168125~152445456:+
OV	cis	rs6661961	0.714	rs12125681	ENSG00000237975.5	FLG-AS1	-4.09	6.11e-05	0.0222	-0.34	-0.26	Atopic dermatitis;	chr1:152445737	chr1:152168125~152445456:+
OV	cis	rs6661961	0.714	rs11205004	ENSG00000237975.5	FLG-AS1	-4.09	6.11e-05	0.0222	-0.34	-0.26	Atopic dermatitis;	chr1:152446586	chr1:152168125~152445456:+
OV	cis	rs7302981	0.51	rs860698	ENSG00000272368.2	RP4-605O3.4	4.09	6.11e-05	0.0222	0.29	0.26	Systolic blood pressure;	chr12:50092539	chr12:50112197~50165618:+
OV	cis	rs4713118	0.513	rs149989	ENSG00000280107.1	AL022393.9	-4.09	6.11e-05	0.0222	-0.33	-0.26	Parkinson's disease;	chr6:28030406	chr6:28170845~28172521:+
OV	cis	rs10181042	0.535	rs2441465	ENSG00000270820.4	RP11-355B11.2	4.08	6.12e-05	0.0222	0.29	0.26	Crohn's disease;	chr2:61084052	chr2:61471188~61484130:+
OV	cis	rs2919917	0.915	rs3899796	ENSG00000254352.1	RP11-578O24.2	4.08	6.12e-05	0.0222	0.32	0.26	Lymphocyte counts;	chr8:78655847	chr8:78723796~78724136:-
OV	cis	rs7824557	0.815	rs958648	ENSG00000254866.2	DEFB109P3	4.08	6.12e-05	0.0222	0.32	0.26	Retinal vascular caliber;	chr8:11246386	chr8:12150895~12151134:-
OV	cis	rs9326248	1	rs7946257	ENSG00000280143.1	AP000892.6	4.08	6.12e-05	0.0222	0.29	0.26	Blood protein levels;	chr11:117182449	chr11:117204967~117210292:+
OV	cis	rs970548	0.721	rs57491883	ENSG00000228462.1	RP11-445N18.3	-4.08	6.13e-05	0.0222	-0.29	-0.26	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45604653	chr10:45073146~45073541:-
OV	cis	rs7017914	0.582	rs7012796	ENSG00000223220.1	Y_RNA	4.08	6.13e-05	0.0223	0.28	0.26	Bone mineral density;	chr8:70763958	chr8:70780914~70781008:-
OV	cis	rs1561296	0.529	rs10497860	ENSG00000232732.8	AC073043.1	-4.08	6.14e-05	0.0223	-0.3	-0.26	Schizophrenia;	chr2:200407982	chr2:199867396~199911159:-
OV	cis	rs255758	0.768	rs255750	ENSG00000272123.1	CTD-2366F13.2	-4.08	6.14e-05	0.0223	-0.36	-0.26	Rheumatoid arthritis;	chr5:54023645	chr5:53089016~53089468:-
OV	cis	rs7124681	0.584	rs11039448	ENSG00000280615.1	Y_RNA	-4.08	6.14e-05	0.0223	-0.28	-0.26	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47896864	chr11:47614898~47614994:-
OV	cis	rs7429990	0.965	rs5016900	ENSG00000229759.1	MRPS18AP1	4.08	6.15e-05	0.0223	0.31	0.26	Educational attainment (years of education);	chr3:47781387	chr3:48256350~48256938:-
OV	cis	rs7429990	0.896	rs34448818	ENSG00000229759.1	MRPS18AP1	4.08	6.15e-05	0.0223	0.31	0.26	Educational attainment (years of education);	chr3:47799822	chr3:48256350~48256938:-
OV	cis	rs7429990	0.93	rs13072132	ENSG00000229759.1	MRPS18AP1	4.08	6.15e-05	0.0223	0.31	0.26	Educational attainment (years of education);	chr3:47824671	chr3:48256350~48256938:-
OV	cis	rs1555322	0.505	rs591590	ENSG00000279253.1	RP4-614O4.13	4.08	6.15e-05	0.0223	0.33	0.26	Attention deficit hyperactivity disorder;	chr20:35278225	chr20:35262727~35264187:-
OV	cis	rs1707322	0.686	rs2050376	ENSG00000234329.1	RP11-767N6.2	4.08	6.16e-05	0.0223	0.26	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45651039~45651826:-
OV	cis	rs73186030	0.92	rs55784797	ENSG00000272758.4	RP11-299J3.8	4.08	6.16e-05	0.0223	0.32	0.26	Serum parathyroid hormone levels;	chr3:122335788	chr3:122416207~122443180:+
OV	cis	rs10992471	0.58	rs10992304	ENSG00000281156.1	MIR3651	-4.08	6.16e-05	0.0223	-0.3	-0.26	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92323083	chr9:92292458~92292547:-
OV	cis	rs40363	0.729	rs6501176	ENSG00000260176.1	CTD-3126B10.4	-4.08	6.16e-05	0.0223	-0.36	-0.26	Tuberculosis;	chr16:3472197	chr16:2644084~2645214:-
OV	cis	rs6921919	0.525	rs11760133	ENSG00000204709.4	LINC01556	4.08	6.17e-05	0.0224	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28418962	chr6:28943877~28944537:+
OV	cis	rs2679053	0.534	rs7118770	ENSG00000246250.2	RP11-613D13.5	4.08	6.17e-05	0.0224	0.29	0.26	Coronary artery disease;	chr11:43700631	chr11:43829709~43880726:-
OV	cis	rs10246939	0.544	rs6955562	ENSG00000228775.6	WEE2-AS1	4.08	6.17e-05	0.0224	0.28	0.26	Bitter taste perception;	chr7:141886641	chr7:141704338~141738346:-
OV	cis	rs709400	0.628	rs12889639	ENSG00000244691.1	RPL10AP1	-4.08	6.17e-05	0.0224	-0.26	-0.26	Body mass index;	chr14:103393869	chr14:103412119~103412761:-
OV	cis	rs7789940	0.951	rs7779014	ENSG00000230305.2	AC004980.9	4.08	6.17e-05	0.0224	0.36	0.26	Multiple sclerosis;	chr7:76346269	chr7:76524515~76532692:+
OV	cis	rs9992667	0.955	rs12331049	ENSG00000231160.8	KLF3-AS1	4.08	6.17e-05	0.0224	0.31	0.26	Eosinophil percentage of granulocytes;	chr4:38654151	chr4:38612701~38664883:-
OV	cis	rs172166	0.561	rs149976	ENSG00000204709.4	LINC01556	-4.08	6.17e-05	0.0224	-0.3	-0.26	Cardiac Troponin-T levels;	chr6:28019998	chr6:28943877~28944537:+
OV	cis	rs10246939	0.579	rs13232651	ENSG00000228775.6	WEE2-AS1	4.08	6.18e-05	0.0224	0.27	0.26	Bitter taste perception;	chr7:141862624	chr7:141704338~141738346:-
OV	cis	rs62296447	0.514	rs12646839	ENSG00000241612.1	RP13-585F24.1	4.08	6.18e-05	0.0224	0.27	0.26	Schizophrenia;	chr4:19494936	chr4:19813749~19814231:+
OV	cis	rs7246657	0.943	rs4969487	ENSG00000226686.6	LINC01535	-4.08	6.18e-05	0.0224	-0.4	-0.26	Coronary artery calcification;	chr19:37340137	chr19:37251912~37265535:+
OV	cis	rs7246657	0.943	rs28402338	ENSG00000226686.6	LINC01535	-4.08	6.18e-05	0.0224	-0.4	-0.26	Coronary artery calcification;	chr19:37343021	chr19:37251912~37265535:+
OV	cis	rs7246657	0.943	rs10417503	ENSG00000226686.6	LINC01535	-4.08	6.18e-05	0.0224	-0.4	-0.26	Coronary artery calcification;	chr19:37351833	chr19:37251912~37265535:+
OV	cis	rs7246657	0.943	rs10403613	ENSG00000226686.6	LINC01535	-4.08	6.18e-05	0.0224	-0.4	-0.26	Coronary artery calcification;	chr19:37353404	chr19:37251912~37265535:+
OV	cis	rs7246657	0.943	rs9304566	ENSG00000226686.6	LINC01535	-4.08	6.18e-05	0.0224	-0.4	-0.26	Coronary artery calcification;	chr19:37354602	chr19:37251912~37265535:+
OV	cis	rs7246657	0.943	rs10422967	ENSG00000226686.6	LINC01535	-4.08	6.18e-05	0.0224	-0.4	-0.26	Coronary artery calcification;	chr19:37359235	chr19:37251912~37265535:+
OV	cis	rs7246657	0.943	rs4417644	ENSG00000226686.6	LINC01535	-4.08	6.18e-05	0.0224	-0.4	-0.26	Coronary artery calcification;	chr19:37361570	chr19:37251912~37265535:+
OV	cis	rs9649213	0.593	rs6947208	ENSG00000272950.1	RP11-307C18.1	4.08	6.18e-05	0.0224	0.31	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98282892	chr7:98322853~98323430:+
OV	cis	rs7131987	0.65	rs16934135	ENSG00000257176.2	RP11-996F15.2	-4.08	6.19e-05	0.0224	-0.33	-0.26	QT interval;	chr12:29331030	chr12:29280418~29317848:-
OV	cis	rs944801	0.587	rs7049105	ENSG00000234840.1	LINC01239	4.08	6.19e-05	0.0224	0.29	0.26	Type 2 diabetes;	chr9:22028802	chr9:22646200~22824213:+
OV	cis	rs496547	0.756	rs562059	ENSG00000255422.1	AP002954.4	-4.08	6.19e-05	0.0224	-0.31	-0.26	Hip minimal joint space width;	chr11:118731349	chr11:118704607~118750263:+
OV	cis	rs875971	0.545	rs73376401	ENSG00000273024.4	INTS4P2	-4.08	6.2e-05	0.0224	-0.31	-0.26	Aortic root size;	chr7:66174841	chr7:65647864~65715661:+
OV	cis	rs875971	0.545	rs6460276	ENSG00000273024.4	INTS4P2	-4.08	6.2e-05	0.0224	-0.31	-0.26	Aortic root size;	chr7:66182290	chr7:65647864~65715661:+
OV	cis	rs9393777	0.844	rs35909544	ENSG00000220721.1	OR1F12	4.08	6.2e-05	0.0224	0.45	0.26	Intelligence (multi-trait analysis);	chr6:27195677	chr6:28073316~28074233:+
OV	cis	rs6750047	0.585	rs4670235	ENSG00000235848.3	RMDN2-AS1	-4.08	6.2e-05	0.0224	-0.3	-0.26	Cutaneous malignant melanoma;Melanoma;	chr2:38045385	chr2:37949911~38067041:-
OV	cis	rs7043114	0.525	rs7853859	ENSG00000281156.1	MIR3651	-4.08	6.2e-05	0.0225	-0.3	-0.26	Height;	chr9:92389095	chr9:92292458~92292547:-
OV	cis	rs73186030	0.92	rs73186048	ENSG00000272758.4	RP11-299J3.8	4.08	6.2e-05	0.0225	0.32	0.26	Serum parathyroid hormone levels;	chr3:122316515	chr3:122416207~122443180:+
OV	cis	rs11671005	0.571	rs56243535	ENSG00000269600.1	AC016629.3	-4.08	6.2e-05	0.0225	-0.38	-0.26	Mean platelet volume;	chr19:58494783	chr19:58593896~58599355:-
OV	cis	rs8059260	0.668	rs16957894	ENSG00000274038.1	RP11-66H6.4	-4.08	6.21e-05	0.0225	-0.51	-0.26	Alcohol consumption over the past year;	chr16:10996501	chr16:11056556~11057034:+
OV	cis	rs7078012	0.504	rs17886602	ENSG00000225484.5	NUTM2B-AS1	-4.08	6.21e-05	0.0225	-0.68	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79937421	chr10:79663088~79826594:-
OV	cis	rs875971	0.862	rs6460282	ENSG00000237310.1	GS1-124K5.4	-4.08	6.21e-05	0.0225	-0.27	-0.26	Aortic root size;	chr7:66226259	chr7:66493706~66495474:+
OV	cis	rs7746199	0.673	rs72847313	ENSG00000220721.1	OR1F12	4.08	6.21e-05	0.0225	0.53	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762303	chr6:28073316~28074233:+
OV	cis	rs343496	0.941	rs10975412	ENSG00000231509.1	RP11-574F11.3	-4.08	6.21e-05	0.0225	-0.33	-0.26	Asthma and hay fever;	chr9:6049547	chr9:5584490~5588994:+
OV	cis	rs8059260	0.736	rs113120936	ENSG00000274038.1	RP11-66H6.4	-4.08	6.22e-05	0.0225	-0.53	-0.26	Alcohol consumption over the past year;	chr16:10989474	chr16:11056556~11057034:+
OV	cis	rs7124681	0.584	rs1471712	ENSG00000280615.1	Y_RNA	-4.08	6.22e-05	0.0225	-0.28	-0.26	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47890598	chr11:47614898~47614994:-
OV	cis	rs894157	0.92	rs8030720	ENSG00000255571.5	LINC00925	-4.08	6.22e-05	0.0225	-0.41	-0.26	Obesity-related traits;	chr15:89600336	chr15:89361579~89398487:+
OV	cis	rs11083475	0.967	rs28624276	ENSG00000267892.1	CTD-2540F13.2	4.08	6.22e-05	0.0225	0.29	0.26	Heart rate;	chr19:38712257	chr19:38738284~38739863:+
OV	cis	rs6921919	0.583	rs9468368	ENSG00000204709.4	LINC01556	4.08	6.22e-05	0.0225	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28397172	chr6:28943877~28944537:+
OV	cis	rs875971	0.571	rs78668714	ENSG00000237310.1	GS1-124K5.4	4.08	6.23e-05	0.0225	0.3	0.26	Aortic root size;	chr7:66474464	chr7:66493706~66495474:+
OV	cis	rs875971	0.545	rs73150604	ENSG00000237310.1	GS1-124K5.4	4.08	6.23e-05	0.0225	0.3	0.26	Aortic root size;	chr7:66480545	chr7:66493706~66495474:+
OV	cis	rs875971	0.545	rs7810213	ENSG00000237310.1	GS1-124K5.4	4.08	6.23e-05	0.0225	0.3	0.26	Aortic root size;	chr7:66481592	chr7:66493706~66495474:+
OV	cis	rs4950322	0.744	rs2353987	ENSG00000278811.3	LINC00624	4.08	6.23e-05	0.0225	0.33	0.26	Protein quantitative trait loci;	chr1:147355845	chr1:147258885~147517875:-
OV	cis	rs12681366	1	rs2960122	ENSG00000253704.1	RP11-267M23.4	4.08	6.23e-05	0.0226	0.33	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94419858	chr8:94553722~94569745:+
OV	cis	rs12681366	1	rs2930971	ENSG00000253704.1	RP11-267M23.4	4.08	6.23e-05	0.0226	0.33	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94420319	chr8:94553722~94569745:+
OV	cis	rs9813712	0.83	rs9755184	ENSG00000228252.7	COL6A4P2	-4.08	6.24e-05	0.0226	-0.35	-0.26	Response to amphetamines;	chr3:130262278	chr3:130212823~130273806:+
OV	cis	rs9287719	0.649	rs10207885	ENSG00000243819.4	RN7SL832P	4.08	6.24e-05	0.0226	0.27	0.26	Prostate cancer;	chr2:10593062	chr2:10690344~10692099:+
OV	cis	rs10759883	0.563	rs12345187	ENSG00000175611.10	LINC00476	4.08	6.24e-05	0.0226	0.32	0.26	Nicotine dependence;	chr9:95906088	chr9:95759231~95875977:-
OV	cis	rs7267979	1	rs8125868	ENSG00000274973.1	RP13-401N8.7	4.08	6.25e-05	0.0226	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25343774	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6037095	ENSG00000274973.1	RP13-401N8.7	4.08	6.25e-05	0.0226	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25355051	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6050562	ENSG00000274973.1	RP13-401N8.7	4.08	6.25e-05	0.0226	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25355550	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs4815407	ENSG00000274973.1	RP13-401N8.7	4.08	6.25e-05	0.0226	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25360842	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs4815408	ENSG00000274973.1	RP13-401N8.7	4.08	6.25e-05	0.0226	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25366042	chr20:25845497~25845862:+
OV	cis	rs8027521	0.846	rs1841945	ENSG00000280362.1	RP11-643A5.3	-4.08	6.26e-05	0.0226	-0.3	-0.26	Circulating chemerin levels;	chr15:53978200	chr15:53910769~53914712:+
OV	cis	rs11105298	0.786	rs10858867	ENSG00000257194.2	RP11-567C2.1	-4.08	6.26e-05	0.0226	-0.4	-0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89457389	chr12:90107739~90112779:+
OV	cis	rs11105298	0.891	rs10858869	ENSG00000257194.2	RP11-567C2.1	-4.08	6.26e-05	0.0226	-0.4	-0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89463834	chr12:90107739~90112779:+
OV	cis	rs11105298	0.786	rs3803128	ENSG00000257194.2	RP11-567C2.1	-4.08	6.26e-05	0.0226	-0.4	-0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89466542	chr12:90107739~90112779:+
OV	cis	rs11105298	0.891	rs10506972	ENSG00000257194.2	RP11-567C2.1	-4.08	6.26e-05	0.0226	-0.4	-0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89467752	chr12:90107739~90112779:+
OV	cis	rs11105298	0.891	rs12228177	ENSG00000257194.2	RP11-567C2.1	-4.08	6.26e-05	0.0226	-0.4	-0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89468253	chr12:90107739~90112779:+
OV	cis	rs11105298	0.891	rs10858871	ENSG00000257194.2	RP11-567C2.1	-4.08	6.26e-05	0.0226	-0.4	-0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89477836	chr12:90107739~90112779:+
OV	cis	rs11105298	0.891	rs10858872	ENSG00000257194.2	RP11-567C2.1	-4.08	6.26e-05	0.0226	-0.4	-0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89479155	chr12:90107739~90112779:+
OV	cis	rs7520050	0.966	rs7515491	ENSG00000281133.1	AL355480.3	4.08	6.27e-05	0.0227	0.3	0.26	Reticulocyte count;Red blood cell count;	chr1:45889407	chr1:45580892~45580996:-
OV	cis	rs7267979	1	rs4815411	ENSG00000274973.1	RP13-401N8.7	4.08	6.27e-05	0.0227	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25369587	chr20:25845497~25845862:+
OV	cis	rs881375	0.934	rs2159778	ENSG00000226752.6	PSMD5-AS1	-4.08	6.27e-05	0.0227	-0.28	-0.26	Rheumatoid arthritis;	chr9:120915851	chr9:120824828~120854385:+
OV	cis	rs1075265	0.783	rs6708095	ENSG00000233266.1	HMGB1P31	4.08	6.27e-05	0.0227	0.31	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53710365	chr2:54051334~54051760:+
OV	cis	rs992157	0.661	rs10171839	ENSG00000237281.1	CATIP-AS2	-4.08	6.28e-05	0.0227	-0.3	-0.26	Colorectal cancer;	chr2:218186591	chr2:218326889~218357966:-
OV	cis	rs7267979	0.966	rs6050611	ENSG00000274973.1	RP13-401N8.7	-4.08	6.28e-05	0.0227	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25433783	chr20:25845497~25845862:+
OV	cis	rs9393777	0.546	rs35589403	ENSG00000243307.2	POM121L6P	-4.08	6.28e-05	0.0227	-0.33	-0.26	Intelligence (multi-trait analysis);	chr6:27251712	chr6:26896952~26898777:+
OV	cis	rs6723108	0.627	rs1374292	ENSG00000224043.6	CCNT2-AS1	-4.08	6.29e-05	0.0227	-0.31	-0.26	Type 2 diabetes;	chr2:134896598	chr2:134735464~134918710:-
OV	cis	rs4702131	0.603	rs861259	ENSG00000248699.1	CTD-2313D3.1	4.08	6.29e-05	0.0227	0.29	0.26	Breast cancer;	chr5:16285989	chr5:15450701~15451811:+
OV	cis	rs7567389	0.626	rs11683344	ENSG00000236682.1	AC068282.3	-4.08	6.29e-05	0.0227	-0.36	-0.26	Self-rated health;	chr2:127198676	chr2:127389130~127400580:+
OV	cis	rs9467773	1	rs9467791	ENSG00000243307.2	POM121L6P	-4.08	6.29e-05	0.0227	-0.25	-0.26	Intelligence (multi-trait analysis);	chr6:26562258	chr6:26896952~26898777:+
OV	cis	rs35160687	0.814	rs6547673	ENSG00000273080.1	RP11-301O19.1	4.08	6.29e-05	0.0227	0.25	0.26	Night sleep phenotypes;	chr2:86301815	chr2:86195590~86196049:+
OV	cis	rs875971	0.545	rs1796222	ENSG00000237310.1	GS1-124K5.4	-4.08	6.3e-05	0.0227	-0.31	-0.26	Aortic root size;	chr7:66592167	chr7:66493706~66495474:+
OV	cis	rs4763879	0.739	rs2114871	ENSG00000256673.1	RP11-599J14.2	4.08	6.3e-05	0.0228	0.26	0.26	Type 1 diabetes;	chr12:9676842	chr12:9398355~9414851:-
OV	cis	rs875971	0.895	rs6460278	ENSG00000237310.1	GS1-124K5.4	-4.08	6.3e-05	0.0228	-0.26	-0.26	Aortic root size;	chr7:66197749	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs6460279	ENSG00000237310.1	GS1-124K5.4	-4.08	6.3e-05	0.0228	-0.26	-0.26	Aortic root size;	chr7:66197774	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs28491091	ENSG00000237310.1	GS1-124K5.4	-4.08	6.3e-05	0.0228	-0.26	-0.26	Aortic root size;	chr7:66204077	chr7:66493706~66495474:+
OV	cis	rs6921919	0.583	rs6908137	ENSG00000204709.4	LINC01556	4.08	6.3e-05	0.0228	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28402616	chr6:28943877~28944537:+
OV	cis	rs1850744	1	rs7664572	ENSG00000163612.10	FAM86KP	4.08	6.31e-05	0.0228	0.67	0.26	Economic and political preferences;	chr4:9807085	chr4:9153296~9165451:+
OV	cis	rs57221529	0.766	rs12522303	ENSG00000271781.1	CTD-2589H19.6	-4.08	6.31e-05	0.0228	-0.43	-0.26	Lung disease severity in cystic fibrosis;	chr5:555449	chr5:675826~676616:+
OV	cis	rs57221529	0.766	rs12521988	ENSG00000271781.1	CTD-2589H19.6	-4.08	6.31e-05	0.0228	-0.43	-0.26	Lung disease severity in cystic fibrosis;	chr5:556306	chr5:675826~676616:+
OV	cis	rs57221529	0.766	rs17497684	ENSG00000271781.1	CTD-2589H19.6	-4.08	6.31e-05	0.0228	-0.43	-0.26	Lung disease severity in cystic fibrosis;	chr5:558192	chr5:675826~676616:+
OV	cis	rs57221529	0.766	rs72706606	ENSG00000271781.1	CTD-2589H19.6	-4.08	6.31e-05	0.0228	-0.43	-0.26	Lung disease severity in cystic fibrosis;	chr5:558494	chr5:675826~676616:+
OV	cis	rs57221529	0.766	rs12519763	ENSG00000271781.1	CTD-2589H19.6	-4.08	6.31e-05	0.0228	-0.43	-0.26	Lung disease severity in cystic fibrosis;	chr5:559030	chr5:675826~676616:+
OV	cis	rs57221529	0.766	rs72706608	ENSG00000271781.1	CTD-2589H19.6	-4.08	6.31e-05	0.0228	-0.43	-0.26	Lung disease severity in cystic fibrosis;	chr5:559088	chr5:675826~676616:+
OV	cis	rs8059260	0.736	rs8059156	ENSG00000274038.1	RP11-66H6.4	-4.08	6.31e-05	0.0228	-0.48	-0.26	Alcohol consumption over the past year;	chr16:10952135	chr16:11056556~11057034:+
OV	cis	rs8059260	0.736	rs8044180	ENSG00000274038.1	RP11-66H6.4	-4.08	6.31e-05	0.0228	-0.48	-0.26	Alcohol consumption over the past year;	chr16:10952531	chr16:11056556~11057034:+
OV	cis	rs8059260	0.736	rs7192171	ENSG00000274038.1	RP11-66H6.4	-4.08	6.31e-05	0.0228	-0.48	-0.26	Alcohol consumption over the past year;	chr16:10955262	chr16:11056556~11057034:+
OV	cis	rs8059260	0.736	rs16957836	ENSG00000274038.1	RP11-66H6.4	-4.08	6.31e-05	0.0228	-0.48	-0.26	Alcohol consumption over the past year;	chr16:10959229	chr16:11056556~11057034:+
OV	cis	rs6860806	0.531	rs272888	ENSG00000233006.5	AC034220.3	4.08	6.31e-05	0.0228	0.27	0.26	Breast cancer;	chr5:132329730	chr5:132311285~132369916:-
OV	cis	rs7119038	0.609	rs11216999	ENSG00000255422.1	AP002954.4	4.08	6.31e-05	0.0228	0.34	0.26	Sjögren's syndrome;	chr11:118734232	chr11:118704607~118750263:+
OV	cis	rs881375	0.669	rs73541868	ENSG00000226752.6	PSMD5-AS1	-4.08	6.32e-05	0.0228	-0.27	-0.26	Rheumatoid arthritis;	chr9:120876986	chr9:120824828~120854385:+
OV	cis	rs9876781	0.559	rs13073692	ENSG00000229759.1	MRPS18AP1	4.08	6.32e-05	0.0228	0.27	0.26	Longevity;	chr3:48361812	chr3:48256350~48256938:-
OV	cis	rs733592	0.56	rs2158515	ENSG00000240399.1	RP1-228P16.1	-4.08	6.33e-05	0.0228	-0.28	-0.26	Plateletcrit;	chr12:48113885	chr12:48054813~48055591:-
OV	cis	rs593531	0.614	rs10793080	ENSG00000280269.1	AP000577.2	-4.08	6.33e-05	0.0228	-0.31	-0.26	Neuroticism;	chr11:74377698	chr11:74204869~74205746:+
OV	cis	rs593531	0.571	rs7934621	ENSG00000280269.1	AP000577.2	-4.08	6.33e-05	0.0228	-0.31	-0.26	Neuroticism;	chr11:74379883	chr11:74204869~74205746:+
OV	cis	rs3018712	0.532	rs2510396	ENSG00000212093.1	AP000807.1	-4.08	6.33e-05	0.0228	-0.39	-0.26	Total body bone mineral density;	chr11:68650184	chr11:68506083~68506166:-
OV	cis	rs3018712	0.532	rs2510397	ENSG00000212093.1	AP000807.1	-4.08	6.33e-05	0.0228	-0.39	-0.26	Total body bone mineral density;	chr11:68652091	chr11:68506083~68506166:-
OV	cis	rs12073359	0.955	rs72694959	ENSG00000223945.2	RP11-458I7.1	-4.08	6.33e-05	0.0228	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150165955	chr1:150053864~150055034:+
OV	cis	rs3731896	0.607	rs7600417	ENSG00000272644.1	RP11-33O4.1	4.08	6.33e-05	0.0228	0.4	0.26	Educational attainment;	chr2:219304770	chr2:219069354~219069809:-
OV	cis	rs7267979	1	rs7267979	ENSG00000274973.1	RP13-401N8.7	-4.08	6.33e-05	0.0228	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25317451	chr20:25845497~25845862:+
OV	cis	rs875971	0.862	rs880166	ENSG00000237310.1	GS1-124K5.4	-4.08	6.34e-05	0.0229	-0.26	-0.26	Aortic root size;	chr7:66205775	chr7:66493706~66495474:+
OV	cis	rs6429082	0.509	rs2789362	ENSG00000236863.2	RPL23AP23	4.08	6.34e-05	0.0229	0.26	0.26	Adiposity;	chr1:235357920	chr1:235295865~235296335:+
OV	cis	rs7267979	1	rs6515651	ENSG00000274973.1	RP13-401N8.7	4.08	6.35e-05	0.0229	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25433903	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs2151144	ENSG00000274973.1	RP13-401N8.7	4.08	6.35e-05	0.0229	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25434288	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2424716	ENSG00000274973.1	RP13-401N8.7	-4.08	6.35e-05	0.0229	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25442902	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs761025	ENSG00000274973.1	RP13-401N8.7	-4.08	6.35e-05	0.0229	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25446332	chr20:25845497~25845862:+
OV	cis	rs295490	0.748	rs74846775	ENSG00000272656.1	RP11-219D15.3	4.08	6.36e-05	0.0229	0.5	0.26	PR interval in Tripanosoma cruzi seropositivity;	chr3:139354736	chr3:139349024~139349371:-
OV	cis	rs73201462	0.708	rs2811477	ENSG00000277250.1	Metazoa_SRP	4.08	6.36e-05	0.0229	0.55	0.26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128179940	chr3:128673681~128674021:-
OV	cis	rs6687758	0.735	rs12032653	ENSG00000238042.4	RP11-815M8.1	4.08	6.36e-05	0.0229	0.36	0.26	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221975457	chr1:221880981~221978523:-
OV	cis	rs6687758	0.679	rs12029332	ENSG00000238042.4	RP11-815M8.1	4.08	6.36e-05	0.0229	0.36	0.26	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221975480	chr1:221880981~221978523:-
OV	cis	rs514406	0.893	rs499195	ENSG00000206627.1	RNU6-969P	4.07	6.36e-05	0.0229	0.27	0.26	Monocyte count;	chr1:52879235	chr1:52805108~52805212:-
OV	cis	rs6700559	0.679	rs7520407	ENSG00000260088.1	RP11-92G12.3	4.07	6.37e-05	0.0229	0.28	0.26	Coronary artery disease;	chr1:200686600	chr1:200669507~200694250:+
OV	cis	rs6700559	0.679	rs12076946	ENSG00000260088.1	RP11-92G12.3	4.07	6.37e-05	0.0229	0.28	0.26	Coronary artery disease;	chr1:200693707	chr1:200669507~200694250:+
OV	cis	rs5742933	1	rs16831939	ENSG00000253559.1	OSGEPL1-AS1	-4.07	6.37e-05	0.023	-0.29	-0.26	Ferritin levels;	chr2:189739282	chr2:189762704~189765556:+
OV	cis	rs5742933	1	rs12052909	ENSG00000253559.1	OSGEPL1-AS1	-4.07	6.37e-05	0.023	-0.29	-0.26	Ferritin levels;	chr2:189742484	chr2:189762704~189765556:+
OV	cis	rs5742933	1	rs16831955	ENSG00000253559.1	OSGEPL1-AS1	-4.07	6.37e-05	0.023	-0.29	-0.26	Ferritin levels;	chr2:189745811	chr2:189762704~189765556:+
OV	cis	rs73201462	1	rs10934850	ENSG00000242551.2	POU5F1P6	4.07	6.37e-05	0.023	0.4	0.26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128168114	chr3:128674735~128677005:-
OV	cis	rs62244186	0.659	rs4682745	ENSG00000214820.3	MPRIPP1	4.07	6.38e-05	0.023	0.24	0.26	Depressive symptoms;	chr3:44467475	chr3:44579938~44581026:-
OV	cis	rs62244186	0.659	rs1806579	ENSG00000214820.3	MPRIPP1	4.07	6.38e-05	0.023	0.24	0.26	Depressive symptoms;	chr3:44467789	chr3:44579938~44581026:-
OV	cis	rs62244186	0.659	rs56234157	ENSG00000214820.3	MPRIPP1	4.07	6.38e-05	0.023	0.24	0.26	Depressive symptoms;	chr3:44474729	chr3:44579938~44581026:-
OV	cis	rs62244186	0.659	rs9850129	ENSG00000214820.3	MPRIPP1	4.07	6.38e-05	0.023	0.24	0.26	Depressive symptoms;	chr3:44490555	chr3:44579938~44581026:-
OV	cis	rs7927771	0.507	rs11039432	ENSG00000280615.1	Y_RNA	4.07	6.38e-05	0.023	0.28	0.26	Subjective well-being;	chr11:47851775	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs2170815	ENSG00000280615.1	Y_RNA	4.07	6.38e-05	0.023	0.28	0.26	Subjective well-being;	chr11:47854358	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs7929725	ENSG00000280615.1	Y_RNA	4.07	6.38e-05	0.023	0.28	0.26	Subjective well-being;	chr11:47860188	chr11:47614898~47614994:-
OV	cis	rs2117029	0.767	rs11614738	ENSG00000258017.1	RP11-386G11.10	-4.07	6.38e-05	0.023	-0.36	-0.26	Intelligence (multi-trait analysis);	chr12:49030833	chr12:49127782~49147869:+
OV	cis	rs3124314	1	rs6700989	ENSG00000237975.5	FLG-AS1	-4.07	6.38e-05	0.023	-0.33	-0.26	Hair morphology;	chr1:152166833	chr1:152168125~152445456:+
OV	cis	rs7143963	0.943	rs10133111	ENSG00000272444.1	RP11-1017G21.6	-4.07	6.38e-05	0.023	-0.37	-0.26	Body mass index;	chr14:102910984	chr14:101952416~101953063:+
OV	cis	rs8054556	0.787	rs1140239	ENSG00000261367.1	RP11-455F5.4	-4.07	6.38e-05	0.023	-0.31	-0.26	Autism spectrum disorder or schizophrenia;	chr16:30010081	chr16:30107675~30110541:+
OV	cis	rs8054556	0.787	rs12325400	ENSG00000261367.1	RP11-455F5.4	-4.07	6.38e-05	0.023	-0.31	-0.26	Autism spectrum disorder or schizophrenia;	chr16:30012465	chr16:30107675~30110541:+
OV	cis	rs8054556	0.787	rs11649274	ENSG00000261367.1	RP11-455F5.4	-4.07	6.38e-05	0.023	-0.31	-0.26	Autism spectrum disorder or schizophrenia;	chr16:30015148	chr16:30107675~30110541:+
OV	cis	rs8054556	0.787	rs12935701	ENSG00000261367.1	RP11-455F5.4	-4.07	6.38e-05	0.023	-0.31	-0.26	Autism spectrum disorder or schizophrenia;	chr16:30015427	chr16:30107675~30110541:+
OV	cis	rs55665837	1	rs12804549	ENSG00000251991.1	RNU7-49P	4.07	6.39e-05	0.023	0.28	0.26	Vitamin D levels;	chr11:14416212	chr11:14478892~14478953:+
OV	cis	rs295490	0.748	rs78681436	ENSG00000272656.1	RP11-219D15.3	4.07	6.39e-05	0.023	0.48	0.26	PR interval in Tripanosoma cruzi seropositivity;	chr3:139510715	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs79854429	ENSG00000272656.1	RP11-219D15.3	4.07	6.39e-05	0.023	0.48	0.26	PR interval in Tripanosoma cruzi seropositivity;	chr3:139512550	chr3:139349024~139349371:-
OV	cis	rs3124314	1	rs12033735	ENSG00000237975.5	FLG-AS1	-4.07	6.39e-05	0.023	-0.33	-0.26	Hair morphology;	chr1:152167815	chr1:152168125~152445456:+
OV	cis	rs7746199	0.736	rs34573979	ENSG00000220721.1	OR1F12	4.07	6.39e-05	0.023	0.51	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27512747	chr6:28073316~28074233:+
OV	cis	rs796364	0.756	rs2949006	ENSG00000232732.8	AC073043.1	-4.07	6.39e-05	0.023	-0.39	-0.26	Schizophrenia;	chr2:199850665	chr2:199867396~199911159:-
OV	cis	rs875971	0.545	rs313828	ENSG00000273024.4	INTS4P2	4.07	6.39e-05	0.023	0.32	0.26	Aortic root size;	chr7:66087627	chr7:65647864~65715661:+
OV	cis	rs875971	0.52	rs160645	ENSG00000273024.4	INTS4P2	4.07	6.39e-05	0.023	0.32	0.26	Aortic root size;	chr7:66091320	chr7:65647864~65715661:+
OV	cis	rs875971	0.789	rs28815324	ENSG00000273024.4	INTS4P2	4.07	6.39e-05	0.023	0.32	0.26	Aortic root size;	chr7:66100789	chr7:65647864~65715661:+
OV	cis	rs7520050	0.966	rs6695809	ENSG00000280836.1	AL355480.1	4.07	6.4e-05	0.023	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45819789	chr1:45581219~45581321:-
OV	cis	rs10924970	0.967	rs2891015	ENSG00000236863.2	RPL23AP23	4.07	6.4e-05	0.023	0.26	0.26	Asthma;	chr1:235296194	chr1:235295865~235296335:+
OV	cis	rs6723108	0.603	rs12469411	ENSG00000224043.6	CCNT2-AS1	-4.07	6.4e-05	0.023	-0.31	-0.26	Type 2 diabetes;	chr2:134906986	chr2:134735464~134918710:-
OV	cis	rs6723108	0.592	rs10928523	ENSG00000224043.6	CCNT2-AS1	-4.07	6.4e-05	0.023	-0.31	-0.26	Type 2 diabetes;	chr2:134907891	chr2:134735464~134918710:-
OV	cis	rs6723108	0.627	rs1374288	ENSG00000224043.6	CCNT2-AS1	-4.07	6.4e-05	0.023	-0.31	-0.26	Type 2 diabetes;	chr2:134909483	chr2:134735464~134918710:-
OV	cis	rs62229266	0.804	rs11088331	ENSG00000231106.2	LINC01436	4.07	6.4e-05	0.023	0.32	0.26	Mitral valve prolapse;	chr21:36049574	chr21:36005338~36007838:+
OV	cis	rs62229266	0.804	rs62230821	ENSG00000231106.2	LINC01436	4.07	6.4e-05	0.023	0.32	0.26	Mitral valve prolapse;	chr21:36052818	chr21:36005338~36007838:+
OV	cis	rs62229266	0.804	rs2835259	ENSG00000231106.2	LINC01436	4.07	6.4e-05	0.023	0.32	0.26	Mitral valve prolapse;	chr21:36053004	chr21:36005338~36007838:+
OV	cis	rs2702164	0.962	rs1259290	ENSG00000240661.1	RP11-174O3.3	-4.07	6.4e-05	0.023	-0.33	-0.26	Gut microbiome composition (winter);	chr3:120357902	chr3:120349510~120367998:+
OV	cis	rs6128386	0.859	rs6026408	ENSG00000268941.2	RP5-907D15.4	4.07	6.4e-05	0.023	0.35	0.26	Response to cytadine analogues (cytosine arabinoside);	chr20:58617994	chr20:58634772~58635738:+
OV	cis	rs9393777	0.92	rs13196692	ENSG00000280107.1	AL022393.9	-4.07	6.4e-05	0.023	-0.51	-0.26	Intelligence (multi-trait analysis);	chr6:27411340	chr6:28170845~28172521:+
OV	cis	rs12073359	0.909	rs72694905	ENSG00000223945.2	RP11-458I7.1	-4.07	6.41e-05	0.0231	-0.41	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150090550	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs72694906	ENSG00000223945.2	RP11-458I7.1	-4.07	6.41e-05	0.0231	-0.41	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150093191	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs72694908	ENSG00000223945.2	RP11-458I7.1	-4.07	6.41e-05	0.0231	-0.41	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150095972	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs56188926	ENSG00000223945.2	RP11-458I7.1	-4.07	6.41e-05	0.0231	-0.41	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150101152	chr1:150053864~150055034:+
OV	cis	rs941207	0.526	rs2950390	ENSG00000241217.3	RN7SL809P	4.07	6.42e-05	0.0231	0.26	0.26	Platelet count;	chr12:56661507	chr12:56670450~56670746:-
OV	cis	rs12962334	0.518	rs4800141	ENSG00000242182.3	RN7SL745P	4.07	6.42e-05	0.0231	0.29	0.26	Breast cancer;	chr18:22984312	chr18:23004564~23004862:+
OV	cis	rs1113500	0.575	rs1781070	ENSG00000226822.1	RP11-356N1.2	-4.07	6.42e-05	0.0231	-0.3	-0.26	Growth-regulated protein alpha levels;	chr1:108027076	chr1:108071482~108074519:+
OV	cis	rs1044826	1	rs9835241	ENSG00000250433.1	CLSTN2-AS1	-4.07	6.43e-05	0.0231	-0.32	-0.26	Obesity-related traits;	chr3:139515713	chr3:140505611~140508789:-
OV	cis	rs12468226	0.938	rs116601501	ENSG00000272966.1	RP11-686O6.1	4.07	6.43e-05	0.0231	0.43	0.26	Urate levels;	chr2:202274567	chr2:202336739~202337200:+
OV	cis	rs12468226	0.938	rs76658848	ENSG00000272966.1	RP11-686O6.1	4.07	6.43e-05	0.0231	0.43	0.26	Urate levels;	chr2:202275548	chr2:202336739~202337200:+
OV	cis	rs12468226	0.938	rs57571703	ENSG00000272966.1	RP11-686O6.1	4.07	6.43e-05	0.0231	0.43	0.26	Urate levels;	chr2:202281997	chr2:202336739~202337200:+
OV	cis	rs12468226	0.938	rs78928733	ENSG00000272966.1	RP11-686O6.1	4.07	6.43e-05	0.0231	0.43	0.26	Urate levels;	chr2:202283787	chr2:202336739~202337200:+
OV	cis	rs12468226	0.938	rs77062060	ENSG00000272966.1	RP11-686O6.1	4.07	6.43e-05	0.0231	0.43	0.26	Urate levels;	chr2:202285639	chr2:202336739~202337200:+
OV	cis	rs12468226	0.938	rs16841867	ENSG00000272966.1	RP11-686O6.1	4.07	6.43e-05	0.0231	0.43	0.26	Urate levels;	chr2:202303512	chr2:202336739~202337200:+
OV	cis	rs12468226	0.938	rs79117531	ENSG00000272966.1	RP11-686O6.1	4.07	6.43e-05	0.0231	0.43	0.26	Urate levels;	chr2:202307690	chr2:202336739~202337200:+
OV	cis	rs12468226	0.938	rs16839065	ENSG00000272966.1	RP11-686O6.1	4.07	6.43e-05	0.0231	0.43	0.26	Urate levels;	chr2:202308774	chr2:202336739~202337200:+
OV	cis	rs12468226	0.938	rs115418918	ENSG00000272966.1	RP11-686O6.1	4.07	6.43e-05	0.0231	0.43	0.26	Urate levels;	chr2:202315145	chr2:202336739~202337200:+
OV	cis	rs12468226	0.938	rs114922024	ENSG00000272966.1	RP11-686O6.1	4.07	6.43e-05	0.0231	0.43	0.26	Urate levels;	chr2:202315958	chr2:202336739~202337200:+
OV	cis	rs12468226	0.938	rs77261109	ENSG00000272966.1	RP11-686O6.1	4.07	6.43e-05	0.0231	0.43	0.26	Urate levels;	chr2:202316233	chr2:202336739~202337200:+
OV	cis	rs12468226	0.938	rs12466003	ENSG00000272966.1	RP11-686O6.1	4.07	6.43e-05	0.0231	0.43	0.26	Urate levels;	chr2:202317317	chr2:202336739~202337200:+
OV	cis	rs12468226	0.938	rs76501067	ENSG00000272966.1	RP11-686O6.1	4.07	6.43e-05	0.0231	0.43	0.26	Urate levels;	chr2:202318042	chr2:202336739~202337200:+
OV	cis	rs10483554	0.671	rs12887190	ENSG00000243038.1	RP11-58E21.1	4.07	6.43e-05	0.0231	0.43	0.26	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr14:49342124	chr14:50052857~50053569:+
OV	cis	rs7569084	0.663	rs10190233	ENSG00000204929.10	AC074391.1	-4.07	6.44e-05	0.0231	-0.33	-0.26	Sum eosinophil basophil counts;	chr2:65413095	chr2:65436711~66084639:+
OV	cis	rs10992471	0.528	rs10429459	ENSG00000281156.1	MIR3651	4.07	6.44e-05	0.0231	0.29	0.26	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92495837	chr9:92292458~92292547:-
OV	cis	rs3758911	0.861	rs11212175	ENSG00000261098.1	RP11-819C21.1	-4.07	6.44e-05	0.0231	-0.26	-0.26	Coronary artery disease;	chr11:107348581	chr11:107312132~107316271:-
OV	cis	rs3758911	0.894	rs72990443	ENSG00000261098.1	RP11-819C21.1	-4.07	6.44e-05	0.0231	-0.26	-0.26	Coronary artery disease;	chr11:107352050	chr11:107312132~107316271:-
OV	cis	rs61774743	0.557	rs4660192	ENSG00000229901.1	RP11-399E6.4	-4.07	6.44e-05	0.0231	-0.31	-0.26	Intelligence (multi-trait analysis);	chr1:41376678	chr1:41375004~41375669:-
OV	cis	rs76210638	1	rs17080209	ENSG00000232986.1	RP11-179A7.2	4.07	6.45e-05	0.0232	0.61	0.26	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);	chr13:33928762	chr13:33657436~33659928:+
OV	cis	rs3758911	0.861	rs10890721	ENSG00000261098.1	RP11-819C21.1	-4.07	6.45e-05	0.0232	-0.26	-0.26	Coronary artery disease;	chr11:107336876	chr11:107312132~107316271:-
OV	cis	rs3758911	0.828	rs11212173	ENSG00000261098.1	RP11-819C21.1	-4.07	6.45e-05	0.0232	-0.26	-0.26	Coronary artery disease;	chr11:107343881	chr11:107312132~107316271:-
OV	cis	rs7246657	1	rs7247672	ENSG00000226686.6	LINC01535	-4.07	6.45e-05	0.0232	-0.4	-0.26	Coronary artery calcification;	chr19:37253026	chr19:37251912~37265535:+
OV	cis	rs7246657	1	rs8110011	ENSG00000226686.6	LINC01535	-4.07	6.45e-05	0.0232	-0.4	-0.26	Coronary artery calcification;	chr19:37254911	chr19:37251912~37265535:+
OV	cis	rs875971	0.825	rs801202	ENSG00000237310.1	GS1-124K5.4	-4.07	6.45e-05	0.0232	-0.26	-0.26	Aortic root size;	chr7:66558942	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs801195	ENSG00000237310.1	GS1-124K5.4	-4.07	6.45e-05	0.0232	-0.26	-0.26	Aortic root size;	chr7:66561128	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs801194	ENSG00000237310.1	GS1-124K5.4	-4.07	6.45e-05	0.0232	-0.26	-0.26	Aortic root size;	chr7:66563508	chr7:66493706~66495474:+
OV	cis	rs6928977	0.5	rs11154810	ENSG00000231028.7	LINC00271	4.07	6.45e-05	0.0232	0.27	0.26	Nodular sclerosis Hodgkin lymphoma;Hodgkin's lymphoma;	chr6:135629234	chr6:135497801~135716055:+
OV	cis	rs4845570	1	rs3811415	ENSG00000203288.3	RP11-98D18.9	-4.07	6.45e-05	0.0232	-0.44	-0.26	Coronary artery disease;	chr1:151791291	chr1:151790804~151794402:+
OV	cis	rs9880211	1	rs9828088	ENSG00000239213.4	NCK1-AS1	4.07	6.45e-05	0.0232	0.32	0.26	Height;Body mass index;	chr3:136528948	chr3:136841726~136862054:-
OV	cis	rs13217239	0.646	rs10946897	ENSG00000261584.1	RP11-457M11.5	4.07	6.46e-05	0.0232	0.29	0.26	Schizophrenia;	chr6:27027472	chr6:26686241~26687964:+
OV	cis	rs13217239	0.646	rs4403259	ENSG00000261584.1	RP11-457M11.5	4.07	6.46e-05	0.0232	0.29	0.26	Schizophrenia;	chr6:27029838	chr6:26686241~26687964:+
OV	cis	rs57221529	0.766	rs28563961	ENSG00000271781.1	CTD-2589H19.6	-4.07	6.46e-05	0.0232	-0.45	-0.26	Lung disease severity in cystic fibrosis;	chr5:554383	chr5:675826~676616:+
OV	cis	rs7927592	0.763	rs596494	ENSG00000212093.1	AP000807.1	4.07	6.46e-05	0.0232	0.3	0.26	Total body bone mineral density;	chr11:68483586	chr11:68506083~68506166:-
OV	cis	rs433852	0.898	rs376524	ENSG00000232871.7	SEC1P	-4.07	6.47e-05	0.0232	-0.37	-0.26	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48613181	chr19:48638071~48682245:+
OV	cis	rs4512344	0.509	rs2409784	ENSG00000255052.4	FAM66D	4.07	6.47e-05	0.0232	0.34	0.26	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11539347	chr8:12115782~12177550:+
OV	cis	rs801193	0.935	rs3800820	ENSG00000224316.1	RP11-479O9.2	-4.07	6.48e-05	0.0232	-0.28	-0.26	Aortic root size;	chr7:66682191	chr7:65773620~65802067:+
OV	cis	rs9992667	0.955	rs12499028	ENSG00000231160.8	KLF3-AS1	4.07	6.48e-05	0.0233	0.31	0.26	Eosinophil percentage of granulocytes;	chr4:38638087	chr4:38612701~38664883:-
OV	cis	rs9992667	0.955	rs28491682	ENSG00000231160.8	KLF3-AS1	4.07	6.48e-05	0.0233	0.31	0.26	Eosinophil percentage of granulocytes;	chr4:38639268	chr4:38612701~38664883:-
OV	cis	rs9992667	0.826	rs7656708	ENSG00000231160.8	KLF3-AS1	4.07	6.48e-05	0.0233	0.31	0.26	Eosinophil percentage of granulocytes;	chr4:38640041	chr4:38612701~38664883:-
OV	cis	rs9925964	0.933	rs2303223	ENSG00000279196.1	RP11-1072A3.3	-4.07	6.48e-05	0.0233	-0.29	-0.26	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31063854	chr16:30984630~30988270:-
OV	cis	rs9925964	0.933	rs881929	ENSG00000279196.1	RP11-1072A3.3	-4.07	6.48e-05	0.0233	-0.29	-0.26	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31068050	chr16:30984630~30988270:-
OV	cis	rs801193	0.569	rs2707824	ENSG00000237310.1	GS1-124K5.4	4.07	6.48e-05	0.0233	0.26	0.26	Aortic root size;	chr7:66724256	chr7:66493706~66495474:+
OV	cis	rs875971	0.545	rs6969224	ENSG00000237310.1	GS1-124K5.4	4.07	6.49e-05	0.0233	0.31	0.26	Aortic root size;	chr7:66370011	chr7:66493706~66495474:+
OV	cis	rs4934494	0.768	rs67111731	ENSG00000240996.1	RP11-80H5.7	-4.07	6.49e-05	0.0233	-0.38	-0.26	Red blood cell count;	chr10:89659528	chr10:89694295~89697928:-
OV	cis	rs1561570	1	rs1561570	ENSG00000228330.1	RP11-730A19.5	4.07	6.49e-05	0.0233	0.29	0.26	Paget's disease;	chr10:13113726	chr10:13142185~13142977:-
OV	cis	rs12073359	0.909	rs7554367	ENSG00000223945.2	RP11-458I7.1	4.07	6.49e-05	0.0233	0.41	0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150047605	chr1:150053864~150055034:+
OV	cis	rs6723108	0.627	rs766271	ENSG00000224043.6	CCNT2-AS1	-4.07	6.5e-05	0.0233	-0.3	-0.26	Type 2 diabetes;	chr2:134909561	chr2:134735464~134918710:-
OV	cis	rs7927592	0.956	rs55816191	ENSG00000212093.1	AP000807.1	4.07	6.51e-05	0.0233	0.32	0.26	Total body bone mineral density;	chr11:68495511	chr11:68506083~68506166:-
OV	cis	rs10978777	0.805	rs10816493	ENSG00000276883.1	AL137852.1	-4.07	6.51e-05	0.0233	-0.27	-0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107338464	chr9:107292369~107292456:-
OV	cis	rs4713118	0.911	rs9461406	ENSG00000226314.6	ZNF192P1	4.07	6.52e-05	0.0234	0.35	0.26	Parkinson's disease;	chr6:27751985	chr6:28161781~28169594:+
OV	cis	rs897984	0.647	rs8060857	ENSG00000260911.2	RP11-196G11.2	-4.07	6.52e-05	0.0234	-0.24	-0.26	Dementia with Lewy bodies;	chr16:30991399	chr16:31043150~31049868:+
OV	cis	rs7267979	0.903	rs2474766	ENSG00000274973.1	RP13-401N8.7	-4.07	6.52e-05	0.0234	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25265517	chr20:25845497~25845862:+
OV	cis	rs7267979	0.903	rs2474769	ENSG00000274973.1	RP13-401N8.7	-4.07	6.52e-05	0.0234	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25268089	chr20:25845497~25845862:+
OV	cis	rs9309473	0.615	rs62151562	ENSG00000163016.8	ALMS1P	4.07	6.52e-05	0.0234	0.36	0.26	Metabolite levels;	chr2:73376412	chr2:73644919~73685576:+
OV	cis	rs5742933	1	rs6719224	ENSG00000253559.1	OSGEPL1-AS1	-4.07	6.53e-05	0.0234	-0.29	-0.26	Ferritin levels;	chr2:189769545	chr2:189762704~189765556:+
OV	cis	rs17767294	0.708	rs72848786	ENSG00000219392.1	RP1-265C24.5	-4.07	6.53e-05	0.0234	-0.55	-0.26	Parkinson's disease;	chr6:28012239	chr6:28115628~28116551:+
OV	cis	rs7811142	1	rs6972167	ENSG00000242294.5	STAG3L5P	4.07	6.54e-05	0.0234	0.27	0.26	Platelet count;	chr7:100482390	chr7:100336079~100351900:+
OV	cis	rs1075265	0.756	rs1075264	ENSG00000233266.1	HMGB1P31	4.07	6.54e-05	0.0234	0.32	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54127916	chr2:54051334~54051760:+
OV	cis	rs1538970	0.961	rs7543428	ENSG00000280836.1	AL355480.1	-4.07	6.54e-05	0.0234	-0.35	-0.26	Platelet count;	chr1:45373971	chr1:45581219~45581321:-
OV	cis	rs10246939	0.505	rs10952508	ENSG00000228775.6	WEE2-AS1	4.07	6.54e-05	0.0234	0.29	0.26	Bitter taste perception;	chr7:141879415	chr7:141704338~141738346:-
OV	cis	rs10992471	0.528	rs4744135	ENSG00000281156.1	MIR3651	4.07	6.54e-05	0.0234	0.28	0.26	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92489592	chr9:92292458~92292547:-
OV	cis	rs6860806	0.531	rs2631359	ENSG00000233006.5	AC034220.3	-4.07	6.55e-05	0.0235	-0.28	-0.26	Breast cancer;	chr5:132372200	chr5:132311285~132369916:-
OV	cis	rs6860806	0.507	rs582490	ENSG00000233006.5	AC034220.3	-4.07	6.55e-05	0.0235	-0.28	-0.26	Breast cancer;	chr5:132374403	chr5:132311285~132369916:-
OV	cis	rs274567	0.501	rs581968	ENSG00000233006.5	AC034220.3	-4.07	6.55e-05	0.0235	-0.28	-0.26	Blood metabolite levels;	chr5:132374510	chr5:132311285~132369916:-
OV	cis	rs12073359	1	rs11577346	ENSG00000223945.2	RP11-458I7.1	-4.07	6.55e-05	0.0235	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150094433	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs112521467	ENSG00000223945.2	RP11-458I7.1	-4.07	6.55e-05	0.0235	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150101194	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs112245786	ENSG00000223945.2	RP11-458I7.1	-4.07	6.55e-05	0.0235	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150102532	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs112814713	ENSG00000223945.2	RP11-458I7.1	-4.07	6.55e-05	0.0235	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150102647	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs72694914	ENSG00000223945.2	RP11-458I7.1	-4.07	6.55e-05	0.0235	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150102833	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs72694915	ENSG00000223945.2	RP11-458I7.1	-4.07	6.55e-05	0.0235	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150102876	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs72694923	ENSG00000223945.2	RP11-458I7.1	-4.07	6.55e-05	0.0235	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150105152	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs72694926	ENSG00000223945.2	RP11-458I7.1	-4.07	6.55e-05	0.0235	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150107999	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs72694928	ENSG00000223945.2	RP11-458I7.1	-4.07	6.55e-05	0.0235	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150109454	chr1:150053864~150055034:+
OV	cis	rs12073359	0.954	rs113082139	ENSG00000223945.2	RP11-458I7.1	-4.07	6.55e-05	0.0235	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150117796	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs72694933	ENSG00000223945.2	RP11-458I7.1	-4.07	6.55e-05	0.0235	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150122414	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs55840680	ENSG00000223945.2	RP11-458I7.1	-4.07	6.55e-05	0.0235	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150125477	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs72694936	ENSG00000223945.2	RP11-458I7.1	-4.07	6.55e-05	0.0235	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150125986	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs11584091	ENSG00000223945.2	RP11-458I7.1	-4.07	6.55e-05	0.0235	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150129018	chr1:150053864~150055034:+
OV	cis	rs8027521	0.54	rs11639036	ENSG00000280362.1	RP11-643A5.3	4.07	6.55e-05	0.0235	0.34	0.26	Circulating chemerin levels;	chr15:53944693	chr15:53910769~53914712:+
OV	cis	rs66561647	0.661	rs7835090	ENSG00000207110.1	RNU1-106P	-4.07	6.55e-05	0.0235	-0.3	-0.26	Hemoglobin concentration;	chr8:127927931	chr8:127999131~127999294:+
OV	cis	rs4660456	0.504	rs587963	ENSG00000237899.1	RP4-739H11.3	4.07	6.55e-05	0.0235	0.39	0.26	Platelet count;	chr1:40640045	chr1:40669089~40687588:-
OV	cis	rs2274471	0.645	rs73395330	ENSG00000234534.1	CSNK1G2P1	4.07	6.55e-05	0.0235	0.34	0.26	Crohn's disease;	chr9:5082839	chr9:5040945~5041940:+
OV	cis	rs2880765	0.835	rs12708553	ENSG00000259295.5	CSPG4P12	-4.07	6.56e-05	0.0235	-0.29	-0.26	Coronary artery disease;	chr15:85503602	chr15:85191438~85213905:+
OV	cis	rs7746199	0.668	rs7749305	ENSG00000226314.6	ZNF192P1	-4.07	6.56e-05	0.0235	-0.54	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27478787	chr6:28161781~28169594:+
OV	cis	rs7746199	0.668	rs34864796	ENSG00000226314.6	ZNF192P1	-4.07	6.56e-05	0.0235	-0.54	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27492144	chr6:28161781~28169594:+
OV	cis	rs10504130	0.569	rs9650179	ENSG00000272024.1	RP11-546K22.3	-4.07	6.56e-05	0.0235	-0.34	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51912127	chr8:51950284~51950690:+
OV	cis	rs7259376	0.84	rs3862494	ENSG00000269742.1	BNIP3P29	4.07	6.56e-05	0.0235	0.3	0.26	Menopause (age at onset);	chr19:22336720	chr19:22065828~22066398:-
OV	cis	rs801193	0.527	rs2707837	ENSG00000236529.1	RP13-254B10.1	4.07	6.57e-05	0.0235	0.27	0.26	Aortic root size;	chr7:66716086	chr7:65840212~65840596:+
OV	cis	rs7927592	0.763	rs10896351	ENSG00000222339.1	AP000807.2	4.07	6.57e-05	0.0235	0.27	0.26	Total body bone mineral density;	chr11:68619428	chr11:68505572~68505651:-
OV	cis	rs10510102	0.516	rs78586895	ENSG00000226864.1	ATE1-AS1	4.07	6.58e-05	0.0235	0.47	0.26	Breast cancer;	chr10:121977081	chr10:121928312~121951965:+
OV	cis	rs6045612	0.821	rs13042195	ENSG00000232528.3	RP4-673D20.3	4.07	6.58e-05	0.0235	0.37	0.26	White blood cell count (basophil);	chr20:1950531	chr20:1767957~1779995:-
OV	cis	rs4665809	0.816	rs2384359	ENSG00000231655.1	AC011742.3	4.07	6.58e-05	0.0235	0.4	0.26	Gut microbiome composition (summer);	chr2:26148495	chr2:26140263~26141264:-
OV	cis	rs4713118	0.568	rs9468213	ENSG00000219392.1	RP1-265C24.5	-4.07	6.58e-05	0.0235	-0.28	-0.26	Parkinson's disease;	chr6:27738401	chr6:28115628~28116551:+
OV	cis	rs7870657	0.777	rs10869867	ENSG00000279706.1	RP11-561O23.9	4.07	6.59e-05	0.0236	0.31	0.26	Seasonality;	chr9:69101139	chr9:68250469~68251656:-
OV	cis	rs372883	0.648	rs1003772	ENSG00000226935.5	LINC00161	-4.07	6.59e-05	0.0236	-0.28	-0.26	Pancreatic cancer;	chr21:29363824	chr21:28539318~28540355:+
OV	cis	rs10800713	0.954	rs6427835	ENSG00000260088.1	RP11-92G12.3	-4.07	6.59e-05	0.0236	-0.32	-0.26	Tandem gait;	chr1:200591725	chr1:200669507~200694250:+
OV	cis	rs10800713	0.954	rs6667081	ENSG00000260088.1	RP11-92G12.3	-4.07	6.59e-05	0.0236	-0.32	-0.26	Tandem gait;	chr1:200593366	chr1:200669507~200694250:+
OV	cis	rs10800713	0.954	rs6673474	ENSG00000260088.1	RP11-92G12.3	-4.07	6.59e-05	0.0236	-0.32	-0.26	Tandem gait;	chr1:200594991	chr1:200669507~200694250:+
OV	cis	rs875971	0.862	rs1968126	ENSG00000237310.1	GS1-124K5.4	-4.07	6.59e-05	0.0236	-0.26	-0.26	Aortic root size;	chr7:66592017	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs6460306	ENSG00000237310.1	GS1-124K5.4	-4.07	6.59e-05	0.0236	-0.26	-0.26	Aortic root size;	chr7:66595806	chr7:66493706~66495474:+
OV	cis	rs1862618	0.802	rs7733041	ENSG00000271828.1	CTD-2310F14.1	4.07	6.59e-05	0.0236	0.42	0.26	Initial pursuit acceleration;	chr5:56811550	chr5:56927874~56929573:+
OV	cis	rs172166	0.637	rs1071893	ENSG00000280107.1	AL022393.9	-4.07	6.6e-05	0.0236	-0.32	-0.26	Cardiac Troponin-T levels;	chr6:28199857	chr6:28170845~28172521:+
OV	cis	rs9402743	0.634	rs2327647	ENSG00000231028.7	LINC00271	4.07	6.6e-05	0.0236	0.27	0.26	Systemic lupus erythematosus;	chr6:135597296	chr6:135497801~135716055:+
OV	cis	rs8054556	0.708	rs2278557	ENSG00000261367.1	RP11-455F5.4	-4.07	6.6e-05	0.0236	-0.31	-0.26	Autism spectrum disorder or schizophrenia;	chr16:30082458	chr16:30107675~30110541:+
OV	cis	rs2117029	0.767	rs3741622	ENSG00000258017.1	RP11-386G11.10	-4.07	6.6e-05	0.0236	-0.35	-0.26	Intelligence (multi-trait analysis);	chr12:49032195	chr12:49127782~49147869:+
OV	cis	rs274567	0.501	rs272856	ENSG00000233006.5	AC034220.3	4.07	6.6e-05	0.0236	0.27	0.26	Blood metabolite levels;	chr5:132351388	chr5:132311285~132369916:-
OV	cis	rs10754283	0.84	rs1215504	ENSG00000231613.1	RP5-943J3.1	4.07	6.6e-05	0.0236	0.27	0.26	Amyotrophic lateral sclerosis (sporadic);	chr1:89626331	chr1:89788914~89790492:+
OV	cis	rs9309473	1	rs11893881	ENSG00000163016.8	ALMS1P	4.07	6.61e-05	0.0236	0.31	0.26	Metabolite levels;	chr2:73597246	chr2:73644919~73685576:+
OV	cis	rs1015213	0.609	rs79629306	ENSG00000253844.1	RP11-546K22.1	-4.07	6.61e-05	0.0236	-0.67	-0.26	Glaucoma (primary angle closure);	chr8:51947789	chr8:51961458~52022974:+
OV	cis	rs1015213	0.609	rs75088902	ENSG00000253844.1	RP11-546K22.1	-4.07	6.61e-05	0.0236	-0.67	-0.26	Glaucoma (primary angle closure);	chr8:51948979	chr8:51961458~52022974:+
OV	cis	rs12073359	1	rs72694943	ENSG00000223945.2	RP11-458I7.1	-4.07	6.61e-05	0.0236	-0.4	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150139816	chr1:150053864~150055034:+
OV	cis	rs7568498	0.517	rs11678856	ENSG00000227403.1	AC009299.3	4.07	6.61e-05	0.0236	0.39	0.26	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161068932	chr2:161244739~161249050:+
OV	cis	rs7267979	1	rs6050631	ENSG00000274973.1	RP13-401N8.7	-4.07	6.61e-05	0.0236	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25451113	chr20:25845497~25845862:+
OV	cis	rs1850744	1	rs2867388	ENSG00000250268.3	ALG1L14P	-4.07	6.61e-05	0.0236	-0.61	-0.26	Economic and political preferences;	chr4:9794871	chr4:9166297~9170270:-
OV	cis	rs7829975	0.56	rs56094035	ENSG00000253893.2	FAM85B	4.07	6.61e-05	0.0236	0.29	0.26	Mood instability;	chr8:8694112	chr8:8167819~8226614:-
OV	cis	rs7829975	0.539	rs4841012	ENSG00000253893.2	FAM85B	4.07	6.61e-05	0.0236	0.29	0.26	Mood instability;	chr8:8694200	chr8:8167819~8226614:-
OV	cis	rs7829975	0.56	rs4841013	ENSG00000253893.2	FAM85B	4.07	6.61e-05	0.0236	0.29	0.26	Mood instability;	chr8:8694503	chr8:8167819~8226614:-
OV	cis	rs9309473	0.95	rs1052162	ENSG00000163016.8	ALMS1P	-4.07	6.61e-05	0.0236	-0.31	-0.26	Metabolite levels;	chr2:73602245	chr2:73644919~73685576:+
OV	cis	rs9660180	0.967	rs6603802	ENSG00000215914.4	MMP23A	-4.07	6.62e-05	0.0236	-0.31	-0.26	Body mass index;	chr1:1881082	chr1:1699942~1701782:+
OV	cis	rs2679053	0.556	rs11037564	ENSG00000246250.2	RP11-613D13.5	4.06	6.63e-05	0.0237	0.29	0.26	Coronary artery disease;	chr11:43687175	chr11:43829709~43880726:-
OV	cis	rs875971	0.862	rs801204	ENSG00000237310.1	GS1-124K5.4	-4.06	6.63e-05	0.0237	-0.26	-0.26	Aortic root size;	chr7:66557934	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs801203	ENSG00000237310.1	GS1-124K5.4	-4.06	6.63e-05	0.0237	-0.26	-0.26	Aortic root size;	chr7:66558025	chr7:66493706~66495474:+
OV	cis	rs12073359	0.908	rs72694964	ENSG00000223945.2	RP11-458I7.1	-4.06	6.63e-05	0.0237	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150177071	chr1:150053864~150055034:+
OV	cis	rs2880765	0.525	rs2062234	ENSG00000259295.5	CSPG4P12	4.06	6.63e-05	0.0237	0.32	0.26	Coronary artery disease;	chr15:85511259	chr15:85191438~85213905:+
OV	cis	rs853679	0.546	rs200989	ENSG00000280107.1	AL022393.9	-4.06	6.64e-05	0.0237	-0.46	-0.26	Depression;	chr6:27848664	chr6:28170845~28172521:+
OV	cis	rs9287719	0.625	rs12473787	ENSG00000243819.4	RN7SL832P	4.06	6.65e-05	0.0237	0.26	0.26	Prostate cancer;	chr2:10577068	chr2:10690344~10692099:+
OV	cis	rs9287719	0.649	rs2160258	ENSG00000243819.4	RN7SL832P	4.06	6.65e-05	0.0237	0.26	0.26	Prostate cancer;	chr2:10577095	chr2:10690344~10692099:+
OV	cis	rs427941	0.632	rs201509	ENSG00000272219.1	CTB-181H17.1	-4.06	6.65e-05	0.0237	-0.22	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr7:102121722	chr7:101960116~101961894:+
OV	cis	rs12073359	1	rs72694946	ENSG00000223945.2	RP11-458I7.1	-4.06	6.65e-05	0.0237	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150143308	chr1:150053864~150055034:+
OV	cis	rs4787491	0.729	rs3814878	ENSG00000261367.1	RP11-455F5.4	-4.06	6.65e-05	0.0237	-0.29	-0.26	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30030645	chr16:30107675~30110541:+
OV	cis	rs7520050	0.931	rs11211189	ENSG00000280836.1	AL355480.1	4.06	6.65e-05	0.0237	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45795912	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs7524495	ENSG00000280836.1	AL355480.1	4.06	6.65e-05	0.0237	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45801260	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs12411269	ENSG00000280836.1	AL355480.1	4.06	6.65e-05	0.0237	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45805380	chr1:45581219~45581321:-
OV	cis	rs7520050	0.931	rs11211198	ENSG00000280836.1	AL355480.1	4.06	6.65e-05	0.0237	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45817001	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs10890352	ENSG00000280836.1	AL355480.1	4.06	6.65e-05	0.0237	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45817956	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs6700597	ENSG00000280836.1	AL355480.1	4.06	6.65e-05	0.0237	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45818574	chr1:45581219~45581321:-
OV	cis	rs514406	0.584	rs11205997	ENSG00000206627.1	RNU6-969P	-4.06	6.66e-05	0.0238	-0.28	-0.26	Monocyte count;	chr1:52729599	chr1:52805108~52805212:-
OV	cis	rs514406	0.607	rs1930305	ENSG00000206627.1	RNU6-969P	-4.06	6.66e-05	0.0238	-0.28	-0.26	Monocyte count;	chr1:52729809	chr1:52805108~52805212:-
OV	cis	rs514406	0.644	rs928451	ENSG00000206627.1	RNU6-969P	-4.06	6.66e-05	0.0238	-0.28	-0.26	Monocyte count;	chr1:52730128	chr1:52805108~52805212:-
OV	cis	rs514406	0.621	rs928452	ENSG00000206627.1	RNU6-969P	-4.06	6.66e-05	0.0238	-0.28	-0.26	Monocyte count;	chr1:52730254	chr1:52805108~52805212:-
OV	cis	rs514406	0.621	rs2003250	ENSG00000206627.1	RNU6-969P	-4.06	6.66e-05	0.0238	-0.28	-0.26	Monocyte count;	chr1:52730994	chr1:52805108~52805212:-
OV	cis	rs7267979	0.966	rs2500417	ENSG00000274973.1	RP13-401N8.7	4.06	6.66e-05	0.0238	0.3	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25402651	chr20:25845497~25845862:+
OV	cis	rs7927592	0.763	rs10896327	ENSG00000212093.1	AP000807.1	4.06	6.66e-05	0.0238	0.31	0.26	Total body bone mineral density;	chr11:68467807	chr11:68506083~68506166:-
OV	cis	rs6745190	0.953	rs4990275	ENSG00000236153.1	AC104076.3	4.06	6.67e-05	0.0238	0.32	0.26	White blood cell count;	chr2:181008934	chr2:180979427~180980090:-
OV	cis	rs7567389	0.6	rs7590030	ENSG00000236682.1	AC068282.3	4.06	6.67e-05	0.0238	0.35	0.26	Self-rated health;	chr2:127298391	chr2:127389130~127400580:+
OV	cis	rs3731896	0.7	rs2271593	ENSG00000272644.1	RP11-33O4.1	-4.06	6.67e-05	0.0238	-0.4	-0.26	Educational attainment;	chr2:219303885	chr2:219069354~219069809:-
OV	cis	rs7587476	0.906	rs2070096	ENSG00000229267.2	AC072062.1	-4.06	6.67e-05	0.0238	-0.35	-0.26	Neuroblastoma;	chr2:214780821	chr2:214810229~214963274:+
OV	cis	rs7587476	0.906	rs16852750	ENSG00000229267.2	AC072062.1	-4.06	6.67e-05	0.0238	-0.35	-0.26	Neuroblastoma;	chr2:214781959	chr2:214810229~214963274:+
OV	cis	rs7017914	0.653	rs6983845	ENSG00000223220.1	Y_RNA	4.06	6.68e-05	0.0238	0.28	0.26	Bone mineral density;	chr8:70834245	chr8:70780914~70781008:-
OV	cis	rs10829156	0.773	rs7909552	ENSG00000225527.1	RP11-383B4.4	-4.06	6.68e-05	0.0238	-0.35	-0.26	Sudden cardiac arrest;	chr10:18620407	chr10:18531849~18533336:-
OV	cis	rs7017914	0.714	rs13273979	ENSG00000223220.1	Y_RNA	4.06	6.68e-05	0.0238	0.28	0.26	Bone mineral density;	chr8:70825087	chr8:70780914~70781008:-
OV	cis	rs7017914	0.69	rs62508859	ENSG00000223220.1	Y_RNA	4.06	6.68e-05	0.0238	0.28	0.26	Bone mineral density;	chr8:70828699	chr8:70780914~70781008:-
OV	cis	rs7017914	0.69	rs13255849	ENSG00000223220.1	Y_RNA	4.06	6.68e-05	0.0238	0.28	0.26	Bone mineral density;	chr8:70840518	chr8:70780914~70781008:-
OV	cis	rs7017914	0.653	rs6472548	ENSG00000223220.1	Y_RNA	4.06	6.68e-05	0.0238	0.28	0.26	Bone mineral density;	chr8:70842064	chr8:70780914~70781008:-
OV	cis	rs34779708	0.766	rs7913451	ENSG00000230534.5	RP11-297A16.2	4.06	6.68e-05	0.0238	0.36	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35262597	chr10:35098006~35127020:-
OV	cis	rs7927771	0.524	rs7116346	ENSG00000280615.1	Y_RNA	-4.06	6.68e-05	0.0238	-0.27	-0.26	Subjective well-being;	chr11:47862328	chr11:47614898~47614994:-
OV	cis	rs1555322	0.53	rs2250205	ENSG00000126005.14	MMP24-AS1	-4.06	6.68e-05	0.0238	-0.35	-0.26	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35216462~35278131:-
OV	cis	rs10857712	0.528	rs2265638	ENSG00000214279.11	SCART1	-4.06	6.69e-05	0.0238	-0.26	-0.26	Systemic lupus erythematosus;	chr10:133403671	chr10:133453928~133523558:+
OV	cis	rs73201462	1	rs2811523	ENSG00000242551.2	POU5F1P6	4.06	6.69e-05	0.0238	0.4	0.26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128292554	chr3:128674735~128677005:-
OV	cis	rs1499614	1	rs1267818	ENSG00000226824.5	RP4-756H11.3	-4.06	6.69e-05	0.0238	-0.42	-0.26	Gout;	chr7:66642037	chr7:66654538~66669855:+
OV	cis	rs10510102	0.935	rs11200201	ENSG00000226864.1	ATE1-AS1	4.06	6.69e-05	0.0239	0.46	0.26	Breast cancer;	chr10:121864790	chr10:121928312~121951965:+
OV	cis	rs2185570	0.544	rs9332155	ENSG00000234724.1	HDAC1P1	4.06	6.69e-05	0.0239	0.47	0.26	Dehydroepiandrosterone sulphate levels;	chr10:94964239	chr10:94137748~94139500:+
OV	cis	rs4918798	0.696	rs9332163	ENSG00000234724.1	HDAC1P1	4.06	6.69e-05	0.0239	0.47	0.26	Warfarin maintenance dose;	chr10:94965081	chr10:94137748~94139500:+
OV	cis	rs1765142	0.55	rs605193	ENSG00000254532.1	RP11-624D11.2	-4.06	6.7e-05	0.0239	-0.3	-0.26	Schizophrenia;	chr11:30383031	chr11:30044058~30084343:-
OV	cis	rs7968440	0.933	rs2684889	ENSG00000272368.2	RP4-605O3.4	4.06	6.7e-05	0.0239	0.3	0.26	Fibrinogen;	chr12:50686091	chr12:50112197~50165618:+
OV	cis	rs7968440	1	rs2700482	ENSG00000272368.2	RP4-605O3.4	4.06	6.7e-05	0.0239	0.3	0.26	Fibrinogen;	chr12:50689482	chr12:50112197~50165618:+
OV	cis	rs875971	0.545	rs73136346	ENSG00000237310.1	GS1-124K5.4	-4.06	6.7e-05	0.0239	-0.3	-0.26	Aortic root size;	chr7:66101095	chr7:66493706~66495474:+
OV	cis	rs875971	1	rs10244498	ENSG00000237310.1	GS1-124K5.4	4.06	6.71e-05	0.0239	0.27	0.26	Aortic root size;	chr7:66651069	chr7:66493706~66495474:+
OV	cis	rs62184315	0.536	rs5743047	ENSG00000253559.1	OSGEPL1-AS1	4.06	6.71e-05	0.0239	0.34	0.26	Alcohol dependence (age at onset);	chr2:189819942	chr2:189762704~189765556:+
OV	cis	rs10986311	0.708	rs34011920	ENSG00000227200.1	RP11-121A14.3	-4.06	6.71e-05	0.0239	-0.23	-0.26	Vitiligo;	chr9:124265133	chr9:124262876~124265809:+
OV	cis	rs9880211	0.948	rs9844666	ENSG00000239213.4	NCK1-AS1	4.06	6.71e-05	0.0239	0.33	0.26	Height;Body mass index;	chr3:136255374	chr3:136841726~136862054:-
OV	cis	rs7789940	1	rs758944	ENSG00000230305.2	AC004980.9	4.06	6.71e-05	0.0239	0.36	0.26	Multiple sclerosis;	chr7:76323980	chr7:76524515~76532692:+
OV	cis	rs1950626	0.833	rs35151884	ENSG00000258399.5	MEG8	-4.06	6.72e-05	0.0239	-0.27	-0.26	Pelvic organ prolapse (moderate/severe);	chr14:100927859	chr14:100894770~100935999:+
OV	cis	rs9876781	0.559	rs7611415	ENSG00000229759.1	MRPS18AP1	4.06	6.72e-05	0.0239	0.27	0.26	Longevity;	chr3:48363659	chr3:48256350~48256938:-
OV	cis	rs7332672	0.962	rs2182885	ENSG00000260992.1	DOCK9-AS2	-4.06	6.72e-05	0.0239	-0.3	-0.26	Eosinophil counts;	chr13:99202870	chr13:99087819~99088625:+
OV	cis	rs10462065	0.818	rs72753613	ENSG00000249779.1	RP11-447H19.3	-4.06	6.73e-05	0.024	-0.48	-0.26	Nonsyndromic cleft lip with cleft palate;	chr5:44100982	chr5:43206709~43207811:+
OV	cis	rs2111504	0.806	rs2903738	ENSG00000267213.4	AC007773.2	-4.06	6.73e-05	0.024	-0.35	-0.26	Bipolar disorder;	chr19:32455137	chr19:32390050~32405560:-
OV	cis	rs2111504	0.806	rs10421787	ENSG00000267213.4	AC007773.2	-4.06	6.73e-05	0.024	-0.35	-0.26	Bipolar disorder;	chr19:32460316	chr19:32390050~32405560:-
OV	cis	rs7520050	0.933	rs6694340	ENSG00000281133.1	AL355480.3	4.06	6.73e-05	0.024	0.3	0.26	Reticulocyte count;Red blood cell count;	chr1:45823744	chr1:45580892~45580996:-
OV	cis	rs7520050	0.933	rs12565042	ENSG00000281133.1	AL355480.3	4.06	6.73e-05	0.024	0.3	0.26	Reticulocyte count;Red blood cell count;	chr1:45833438	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs10789475	ENSG00000281133.1	AL355480.3	4.06	6.73e-05	0.024	0.3	0.26	Reticulocyte count;Red blood cell count;	chr1:45838505	chr1:45580892~45580996:-
OV	cis	rs7520050	0.933	rs6666743	ENSG00000281133.1	AL355480.3	4.06	6.73e-05	0.024	0.3	0.26	Reticulocyte count;Red blood cell count;	chr1:45845603	chr1:45580892~45580996:-
OV	cis	rs7520050	0.933	rs9787208	ENSG00000281133.1	AL355480.3	4.06	6.73e-05	0.024	0.3	0.26	Reticulocyte count;Red blood cell count;	chr1:45848944	chr1:45580892~45580996:-
OV	cis	rs7429990	0.803	rs6776963	ENSG00000229759.1	MRPS18AP1	-4.06	6.73e-05	0.024	-0.29	-0.26	Educational attainment (years of education);	chr3:47789251	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs4858863	ENSG00000229759.1	MRPS18AP1	-4.06	6.73e-05	0.024	-0.29	-0.26	Educational attainment (years of education);	chr3:47814143	chr3:48256350~48256938:-
OV	cis	rs7429990	0.864	rs7629850	ENSG00000229759.1	MRPS18AP1	-4.06	6.73e-05	0.024	-0.29	-0.26	Educational attainment (years of education);	chr3:47815592	chr3:48256350~48256938:-
OV	cis	rs9309473	0.615	rs62153183	ENSG00000163016.8	ALMS1P	4.06	6.74e-05	0.024	0.35	0.26	Metabolite levels;	chr2:73536239	chr2:73644919~73685576:+
OV	cis	rs7927771	0.524	rs4752798	ENSG00000280615.1	Y_RNA	-4.06	6.74e-05	0.024	-0.27	-0.26	Subjective well-being;	chr11:47864812	chr11:47614898~47614994:-
OV	cis	rs2665103	0.715	rs16973457	ENSG00000278202.1	RP11-152F13.8	4.06	6.75e-05	0.024	0.24	0.26	Intelligence (multi-trait analysis);	chr15:82271650	chr15:82418651~82434235:+
OV	cis	rs853679	0.546	rs34295134	ENSG00000280107.1	AL022393.9	-4.06	6.75e-05	0.024	-0.46	-0.26	Depression;	chr6:27860373	chr6:28170845~28172521:+
OV	cis	rs853679	0.546	rs200948	ENSG00000280107.1	AL022393.9	-4.06	6.75e-05	0.024	-0.46	-0.26	Depression;	chr6:27867494	chr6:28170845~28172521:+
OV	cis	rs853679	0.546	rs200950	ENSG00000280107.1	AL022393.9	-4.06	6.75e-05	0.024	-0.46	-0.26	Depression;	chr6:27867994	chr6:28170845~28172521:+
OV	cis	rs11096990	0.964	rs7678689	ENSG00000249207.1	RP11-360F5.1	4.06	6.75e-05	0.024	0.3	0.26	Cognitive function;	chr4:39261140	chr4:39112677~39126818:-
OV	cis	rs433852	0.904	rs8102492	ENSG00000232871.7	SEC1P	4.06	6.75e-05	0.024	0.37	0.26	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48637552	chr19:48638071~48682245:+
OV	cis	rs875971	0.862	rs2024192	ENSG00000237310.1	GS1-124K5.4	-4.06	6.76e-05	0.024	-0.26	-0.26	Aortic root size;	chr7:66576460	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs4718377	ENSG00000237310.1	GS1-124K5.4	-4.06	6.76e-05	0.024	-0.26	-0.26	Aortic root size;	chr7:66584691	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs10278014	ENSG00000237310.1	GS1-124K5.4	-4.06	6.76e-05	0.024	-0.26	-0.26	Aortic root size;	chr7:66586277	chr7:66493706~66495474:+
OV	cis	rs2117029	0.965	rs2241726	ENSG00000258017.1	RP11-386G11.10	-4.06	6.76e-05	0.0241	-0.33	-0.26	Intelligence (multi-trait analysis);	chr12:49050762	chr12:49127782~49147869:+
OV	cis	rs875971	0.619	rs2302918	ENSG00000237310.1	GS1-124K5.4	4.06	6.76e-05	0.0241	0.27	0.26	Aortic root size;	chr7:66535945	chr7:66493706~66495474:+
OV	cis	rs6741892	0.536	rs6761563	ENSG00000213594.4	GAPDHP25	4.06	6.77e-05	0.0241	0.39	0.26	5-HTT brain serotonin transporter levels;	chr2:38664264	chr2:38285410~38286410:+
OV	cis	rs35160687	0.814	rs1863063	ENSG00000273080.1	RP11-301O19.1	4.06	6.77e-05	0.0241	0.25	0.26	Night sleep phenotypes;	chr2:86291126	chr2:86195590~86196049:+
OV	cis	rs9992667	0.744	rs7657152	ENSG00000231160.8	KLF3-AS1	4.06	6.77e-05	0.0241	0.3	0.26	Eosinophil percentage of granulocytes;	chr4:38640315	chr4:38612701~38664883:-
OV	cis	rs875971	0.66	rs2191268	ENSG00000237310.1	GS1-124K5.4	4.06	6.78e-05	0.0241	0.26	0.26	Aortic root size;	chr7:66645237	chr7:66493706~66495474:+
OV	cis	rs9393777	0.841	rs34332556	ENSG00000280107.1	AL022393.9	-4.06	6.78e-05	0.0241	-0.49	-0.26	Intelligence (multi-trait analysis);	chr6:27389635	chr6:28170845~28172521:+
OV	cis	rs8114671	0.935	rs633198	ENSG00000269202.1	RP4-614O4.12	4.06	6.79e-05	0.0241	0.26	0.26	Height;	chr20:35190631	chr20:35201747~35203288:-
OV	cis	rs9649213	0.593	rs6967457	ENSG00000272950.1	RP11-307C18.1	4.06	6.79e-05	0.0241	0.3	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98282909	chr7:98322853~98323430:+
OV	cis	rs1167827	1	rs1167827	ENSG00000278416.1	PMS2L2	4.06	6.79e-05	0.0241	0.35	0.26	Body mass index;Body mass index (joint analysis main effects and smoking interaction);Body mass index in physically active individuals;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index (joint analysis main effects and physical activity interaction);	chr7:75533848	chr7:75344015~75359550:-
OV	cis	rs6893300	1	rs62406176	ENSG00000242979.1	RPS15AP18	4.06	6.8e-05	0.0242	0.35	0.26	Resting heart rate;	chr5:179737142	chr5:179933805~179934196:-
OV	cis	rs6893300	1	rs62406177	ENSG00000242979.1	RPS15AP18	4.06	6.8e-05	0.0242	0.35	0.26	Resting heart rate;	chr5:179737208	chr5:179933805~179934196:-
OV	cis	rs6893300	1	rs62406178	ENSG00000242979.1	RPS15AP18	4.06	6.8e-05	0.0242	0.35	0.26	Resting heart rate;	chr5:179737217	chr5:179933805~179934196:-
OV	cis	rs2617170	0.922	rs1351113	ENSG00000256667.5	KLRAP1	-4.06	6.8e-05	0.0242	-0.27	-0.26	Behcet's disease;	chr12:10373045	chr12:10588063~10599669:-
OV	cis	rs7520050	0.808	rs11211195	ENSG00000280836.1	AL355480.1	4.06	6.8e-05	0.0242	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45816623	chr1:45581219~45581321:-
OV	cis	rs7520050	0.808	rs11211196	ENSG00000280836.1	AL355480.1	4.06	6.8e-05	0.0242	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45816624	chr1:45581219~45581321:-
OV	cis	rs9287719	0.593	rs13009015	ENSG00000243819.4	RN7SL832P	4.06	6.81e-05	0.0242	0.28	0.26	Prostate cancer;	chr2:10622992	chr2:10690344~10692099:+
OV	cis	rs10462794	0.853	rs1562825	ENSG00000250579.1	CTD-2297D10.2	4.06	6.81e-05	0.0242	0.31	0.26	DNA methylation (variation);	chr5:4510870	chr5:5132780~5140054:-
OV	cis	rs2113334	0.732	rs231128	ENSG00000260009.1	RP11-65J21.1	4.06	6.81e-05	0.0242	0.28	0.26	Metabolic syndrome;	chr16:13861724	chr16:14363109~14370266:-
OV	cis	rs944801	0.608	rs10811645	ENSG00000234840.1	LINC01239	-4.06	6.81e-05	0.0242	-0.3	-0.26	Type 2 diabetes;	chr9:22049657	chr9:22646200~22824213:+
OV	cis	rs4763879	0.739	rs2895988	ENSG00000256673.1	RP11-599J14.2	4.06	6.82e-05	0.0242	0.25	0.26	Type 1 diabetes;	chr12:9675831	chr12:9398355~9414851:-
OV	cis	rs1823913	0.503	rs35868016	ENSG00000227542.1	AC092614.2	4.06	6.83e-05	0.0243	0.3	0.26	Obesity-related traits;	chr2:191344082	chr2:191229165~191246172:-
OV	cis	rs944801	0.631	rs7027048	ENSG00000234840.1	LINC01239	-4.06	6.83e-05	0.0243	-0.3	-0.26	Type 2 diabetes;	chr9:22053710	chr9:22646200~22824213:+
OV	cis	rs11037575	0.654	rs7129029	ENSG00000246250.2	RP11-613D13.5	4.06	6.83e-05	0.0243	0.29	0.26	Neuroblastoma;	chr11:43720927	chr11:43829709~43880726:-
OV	cis	rs875971	0.862	rs7783779	ENSG00000237310.1	GS1-124K5.4	-4.06	6.84e-05	0.0243	-0.27	-0.26	Aortic root size;	chr7:66331639	chr7:66493706~66495474:+
OV	cis	rs35160687	0.842	rs10200619	ENSG00000273080.1	RP11-301O19.1	-4.06	6.84e-05	0.0243	-0.25	-0.26	Night sleep phenotypes;	chr2:86321725	chr2:86195590~86196049:+
OV	cis	rs4761702	0.527	rs11106988	ENSG00000257322.4	RP11-511B23.2	-4.06	6.84e-05	0.0243	-0.29	-0.26	Immature fraction of reticulocytes;	chr12:93340674	chr12:93003415~93215679:-
OV	cis	rs745109	0.504	rs80252327	ENSG00000273080.1	RP11-301O19.1	4.06	6.85e-05	0.0243	0.35	0.26	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86385089	chr2:86195590~86196049:+
OV	cis	rs745109	0.504	rs74432925	ENSG00000273080.1	RP11-301O19.1	4.06	6.85e-05	0.0243	0.35	0.26	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86386592	chr2:86195590~86196049:+
OV	cis	rs853679	0.55	rs1233707	ENSG00000226314.6	ZNF192P1	-4.06	6.85e-05	0.0243	-0.35	-0.26	Depression;	chr6:28205175	chr6:28161781~28169594:+
OV	cis	rs7567389	0.6	rs3732209	ENSG00000236682.1	AC068282.3	-4.06	6.85e-05	0.0243	-0.35	-0.26	Self-rated health;	chr2:127322230	chr2:127389130~127400580:+
OV	cis	rs801193	0.66	rs2659897	ENSG00000236529.1	RP13-254B10.1	-4.06	6.86e-05	0.0243	-0.27	-0.26	Aortic root size;	chr7:66722728	chr7:65840212~65840596:+
OV	cis	rs4296809	0.653	rs6859263	ENSG00000249779.1	RP11-447H19.3	4.06	6.86e-05	0.0243	0.43	0.26	Brain structure;	chr5:44065991	chr5:43206709~43207811:+
OV	cis	rs7176093	1	rs7176093	ENSG00000259416.2	RP11-158M2.5	4.06	6.86e-05	0.0243	0.27	0.26	Aging traits;	chr15:85826199	chr15:85754941~85756237:-
OV	cis	rs10759883	0.563	rs12348051	ENSG00000175611.10	LINC00476	4.06	6.86e-05	0.0243	0.32	0.26	Nicotine dependence;	chr9:95905928	chr9:95759231~95875977:-
OV	cis	rs10759883	0.563	rs689710	ENSG00000175611.10	LINC00476	4.06	6.86e-05	0.0243	0.32	0.26	Nicotine dependence;	chr9:95908339	chr9:95759231~95875977:-
OV	cis	rs7246657	0.943	rs7257672	ENSG00000226686.6	LINC01535	-4.06	6.86e-05	0.0243	-0.38	-0.26	Coronary artery calcification;	chr19:37332957	chr19:37251912~37265535:+
OV	cis	rs7246657	0.891	rs7257495	ENSG00000226686.6	LINC01535	-4.06	6.86e-05	0.0243	-0.38	-0.26	Coronary artery calcification;	chr19:37332974	chr19:37251912~37265535:+
OV	cis	rs7246967	0.673	rs937078	ENSG00000267920.1	SNX6P1	-4.06	6.86e-05	0.0243	-0.41	-0.26	Bronchopulmonary dysplasia;	chr19:22628865	chr19:23126569~23127792:-
OV	cis	rs7246967	0.673	rs12978794	ENSG00000267920.1	SNX6P1	-4.06	6.86e-05	0.0243	-0.41	-0.26	Bronchopulmonary dysplasia;	chr19:22629332	chr19:23126569~23127792:-
OV	cis	rs7246967	0.673	rs4932782	ENSG00000267920.1	SNX6P1	-4.06	6.86e-05	0.0243	-0.41	-0.26	Bronchopulmonary dysplasia;	chr19:22629999	chr19:23126569~23127792:-
OV	cis	rs7246967	0.673	rs4933017	ENSG00000267920.1	SNX6P1	-4.06	6.86e-05	0.0243	-0.41	-0.26	Bronchopulmonary dysplasia;	chr19:22630178	chr19:23126569~23127792:-
OV	cis	rs7246967	0.611	rs66866654	ENSG00000267920.1	SNX6P1	-4.06	6.86e-05	0.0243	-0.41	-0.26	Bronchopulmonary dysplasia;	chr19:22630937	chr19:23126569~23127792:-
OV	cis	rs7246967	0.673	rs73028776	ENSG00000267920.1	SNX6P1	-4.06	6.86e-05	0.0243	-0.41	-0.26	Bronchopulmonary dysplasia;	chr19:22630938	chr19:23126569~23127792:-
OV	cis	rs7246967	0.551	rs56968124	ENSG00000267920.1	SNX6P1	-4.06	6.86e-05	0.0243	-0.41	-0.26	Bronchopulmonary dysplasia;	chr19:22631647	chr19:23126569~23127792:-
OV	cis	rs7246967	0.551	rs57775631	ENSG00000267920.1	SNX6P1	-4.06	6.86e-05	0.0243	-0.41	-0.26	Bronchopulmonary dysplasia;	chr19:22631659	chr19:23126569~23127792:-
OV	cis	rs7246967	0.673	rs2361021	ENSG00000267920.1	SNX6P1	-4.06	6.86e-05	0.0243	-0.41	-0.26	Bronchopulmonary dysplasia;	chr19:22633522	chr19:23126569~23127792:-
OV	cis	rs7078012	0.504	rs78496266	ENSG00000225484.5	NUTM2B-AS1	-4.06	6.86e-05	0.0243	-0.65	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79927006	chr10:79663088~79826594:-
OV	cis	rs7078012	0.504	rs11815922	ENSG00000225484.5	NUTM2B-AS1	-4.06	6.86e-05	0.0243	-0.65	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79928323	chr10:79663088~79826594:-
OV	cis	rs7078012	0.504	rs17879405	ENSG00000225484.5	NUTM2B-AS1	-4.06	6.86e-05	0.0243	-0.65	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79929784	chr10:79663088~79826594:-
OV	cis	rs6921919	0.609	rs1005127	ENSG00000204709.4	LINC01556	4.06	6.86e-05	0.0243	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28399881	chr6:28943877~28944537:+
OV	cis	rs853679	0.515	rs4580862	ENSG00000204709.4	LINC01556	4.06	6.86e-05	0.0243	0.32	0.26	Depression;	chr6:28399886	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs4357130	ENSG00000204709.4	LINC01556	4.06	6.86e-05	0.0243	0.32	0.26	Autism spectrum disorder or schizophrenia;	chr6:28399906	chr6:28943877~28944537:+
OV	cis	rs881375	0.715	rs10818482	ENSG00000226752.6	PSMD5-AS1	4.06	6.86e-05	0.0243	0.28	0.26	Rheumatoid arthritis;	chr9:120885807	chr9:120824828~120854385:+
OV	cis	rs875971	0.545	rs313830	ENSG00000273024.4	INTS4P2	4.06	6.86e-05	0.0243	0.31	0.26	Aortic root size;	chr7:66086944	chr7:65647864~65715661:+
OV	cis	rs7520050	0.933	rs6680211	ENSG00000281133.1	AL355480.3	4.06	6.88e-05	0.0244	0.3	0.26	Reticulocyte count;Red blood cell count;	chr1:45849335	chr1:45580892~45580996:-
OV	cis	rs1979679	0.877	rs6487684	ENSG00000278733.1	RP11-425D17.1	-4.06	6.88e-05	0.0244	-0.32	-0.26	Ossification of the posterior longitudinal ligament of the spine;	chr12:28490280	chr12:28185625~28186190:-
OV	cis	rs2243480	1	rs1723267	ENSG00000226824.5	RP4-756H11.3	-4.06	6.88e-05	0.0244	-0.41	-0.26	Diabetic kidney disease;	chr7:66008327	chr7:66654538~66669855:+
OV	cis	rs1797885	0.763	rs299630	ENSG00000251774.1	RNU6-377P	4.05	6.89e-05	0.0244	0.24	0.26	Immature fraction of reticulocytes;	chr3:12526926	chr3:12514706~12514807:+
OV	cis	rs514406	0.644	rs4926928	ENSG00000206627.1	RNU6-969P	4.05	6.9e-05	0.0244	0.27	0.26	Monocyte count;	chr1:52744491	chr1:52805108~52805212:-
OV	cis	rs7520050	0.966	rs6429582	ENSG00000280836.1	AL355480.1	-4.05	6.9e-05	0.0244	-0.31	-0.26	Reticulocyte count;Red blood cell count;	chr1:45856171	chr1:45581219~45581321:-
OV	cis	rs1789	0.592	rs1125378	ENSG00000273133.1	RP11-799M12.2	-4.05	6.9e-05	0.0245	-0.32	-0.26	Blood protein levels;	chr4:15538867	chr4:15563698~15564253:-
OV	cis	rs12134151	0.87	rs6672864	ENSG00000237416.5	RP11-465K1.2	4.05	6.9e-05	0.0245	0.3	0.26	Educational attainment (years of education);	chr1:95730540	chr1:94836748~94855426:-
OV	cis	rs7587476	0.861	rs17488049	ENSG00000229267.2	AC072062.1	-4.05	6.9e-05	0.0245	-0.36	-0.26	Neuroblastoma;	chr2:214787026	chr2:214810229~214963274:+
OV	cis	rs6693388	0.548	rs2999539	ENSG00000237975.5	FLG-AS1	-4.05	6.9e-05	0.0245	-0.34	-0.26	Blood metabolite ratios;	chr1:152014151	chr1:152168125~152445456:+
OV	cis	rs875971	0.862	rs709596	ENSG00000237310.1	GS1-124K5.4	4.05	6.9e-05	0.0245	0.26	0.26	Aortic root size;	chr7:66360926	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs778686	ENSG00000237310.1	GS1-124K5.4	4.05	6.9e-05	0.0245	0.26	0.26	Aortic root size;	chr7:66370923	chr7:66493706~66495474:+
OV	cis	rs593531	0.571	rs3862799	ENSG00000280269.1	AP000577.2	-4.05	6.9e-05	0.0245	-0.31	-0.26	Neuroticism;	chr11:74339217	chr11:74204869~74205746:+
OV	cis	rs853679	0.546	rs200952	ENSG00000280107.1	AL022393.9	-4.05	6.91e-05	0.0245	-0.46	-0.26	Depression;	chr6:27869198	chr6:28170845~28172521:+
OV	cis	rs853679	0.546	rs200954	ENSG00000280107.1	AL022393.9	-4.05	6.91e-05	0.0245	-0.46	-0.26	Depression;	chr6:27870986	chr6:28170845~28172521:+
OV	cis	rs2348418	0.832	rs12303069	ENSG00000247934.4	RP11-967K21.1	4.05	6.91e-05	0.0245	0.26	0.26	Lung function (FEV1);Lung function (FVC);	chr12:28294319	chr12:28163298~28190738:-
OV	cis	rs2919917	1	rs3736169	ENSG00000254352.1	RP11-578O24.2	4.05	6.91e-05	0.0245	0.3	0.26	Lymphocyte counts;	chr8:78675620	chr8:78723796~78724136:-
OV	cis	rs2919917	1	rs10093127	ENSG00000254352.1	RP11-578O24.2	4.05	6.91e-05	0.0245	0.3	0.26	Lymphocyte counts;	chr8:78686869	chr8:78723796~78724136:-
OV	cis	rs7811142	0.887	rs111972532	ENSG00000242294.5	STAG3L5P	4.05	6.92e-05	0.0245	0.27	0.26	Platelet count;	chr7:100471465	chr7:100336079~100351900:+
OV	cis	rs11105298	0.891	rs1008764	ENSG00000257194.2	RP11-567C2.1	-4.05	6.92e-05	0.0245	-0.39	-0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89493872	chr12:90107739~90112779:+
OV	cis	rs9880211	0.731	rs116443932	ENSG00000239213.4	NCK1-AS1	4.05	6.92e-05	0.0245	0.33	0.26	Height;Body mass index;	chr3:136252908	chr3:136841726~136862054:-
OV	cis	rs2243480	0.666	rs1880311	ENSG00000226824.5	RP4-756H11.3	4.05	6.92e-05	0.0245	0.43	0.26	Diabetic kidney disease;	chr7:65811765	chr7:66654538~66669855:+
OV	cis	rs2243480	0.901	rs3813708	ENSG00000226824.5	RP4-756H11.3	-4.05	6.93e-05	0.0245	-0.42	-0.26	Diabetic kidney disease;	chr7:65840645	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs73142122	ENSG00000226824.5	RP4-756H11.3	-4.05	6.93e-05	0.0245	-0.42	-0.26	Diabetic kidney disease;	chr7:65846311	chr7:66654538~66669855:+
OV	cis	rs7121800	0.962	rs11031117	ENSG00000254532.1	RP11-624D11.2	4.05	6.93e-05	0.0245	0.3	0.26	Pit-and-Fissure caries;	chr11:30498512	chr11:30044058~30084343:-
OV	cis	rs875971	0.545	rs73146609	ENSG00000237310.1	GS1-124K5.4	4.05	6.93e-05	0.0245	0.3	0.26	Aortic root size;	chr7:66302477	chr7:66493706~66495474:+
OV	cis	rs875971	0.545	rs2173571	ENSG00000237310.1	GS1-124K5.4	4.05	6.93e-05	0.0245	0.3	0.26	Aortic root size;	chr7:66305392	chr7:66493706~66495474:+
OV	cis	rs875971	0.545	rs11770063	ENSG00000237310.1	GS1-124K5.4	4.05	6.93e-05	0.0245	0.3	0.26	Aortic root size;	chr7:66318029	chr7:66493706~66495474:+
OV	cis	rs875971	0.545	rs3936065	ENSG00000237310.1	GS1-124K5.4	4.05	6.93e-05	0.0245	0.3	0.26	Aortic root size;	chr7:66325577	chr7:66493706~66495474:+
OV	cis	rs875971	0.545	rs4718335	ENSG00000237310.1	GS1-124K5.4	4.05	6.93e-05	0.0245	0.3	0.26	Aortic root size;	chr7:66339619	chr7:66493706~66495474:+
OV	cis	rs7520050	0.933	rs12045165	ENSG00000280836.1	AL355480.1	4.05	6.93e-05	0.0245	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:45790350	chr1:45581219~45581321:-
OV	cis	rs7968440	0.966	rs7977742	ENSG00000272368.2	RP4-605O3.4	4.05	6.94e-05	0.0246	0.32	0.26	Fibrinogen;	chr12:50736424	chr12:50112197~50165618:+
OV	cis	rs10783487	0.947	rs1920606	ENSG00000258279.2	LINC00592	4.05	6.94e-05	0.0246	0.35	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr12:52088244	chr12:52210930~52223804:+
OV	cis	rs11096990	0.964	rs4974999	ENSG00000249207.1	RP11-360F5.1	-4.05	6.94e-05	0.0246	-0.29	-0.26	Cognitive function;	chr4:39262294	chr4:39112677~39126818:-
OV	cis	rs140174	0.763	rs131421	ENSG00000234353.2	AP000347.4	4.05	6.95e-05	0.0246	0.23	0.26	Migraine;	chr22:23579015	chr22:23638492~23640762:-
OV	cis	rs875971	0.862	rs2909688	ENSG00000237310.1	GS1-124K5.4	4.05	6.95e-05	0.0246	0.26	0.26	Aortic root size;	chr7:66376625	chr7:66493706~66495474:+
OV	cis	rs875971	0.83	rs778711	ENSG00000237310.1	GS1-124K5.4	4.05	6.95e-05	0.0246	0.26	0.26	Aortic root size;	chr7:66386670	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs1083554	ENSG00000237310.1	GS1-124K5.4	4.05	6.95e-05	0.0246	0.26	0.26	Aortic root size;	chr7:66387354	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs778707	ENSG00000237310.1	GS1-124K5.4	4.05	6.95e-05	0.0246	0.26	0.26	Aortic root size;	chr7:66392040	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs778705	ENSG00000237310.1	GS1-124K5.4	4.05	6.95e-05	0.0246	0.26	0.26	Aortic root size;	chr7:66396128	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs778697	ENSG00000237310.1	GS1-124K5.4	4.05	6.95e-05	0.0246	0.26	0.26	Aortic root size;	chr7:66405439	chr7:66493706~66495474:+
OV	cis	rs875971	0.798	rs7789615	ENSG00000237310.1	GS1-124K5.4	4.05	6.95e-05	0.0246	0.26	0.26	Aortic root size;	chr7:66413674	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs6978028	ENSG00000237310.1	GS1-124K5.4	4.05	6.95e-05	0.0246	0.26	0.26	Aortic root size;	chr7:66421313	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs6947339	ENSG00000237310.1	GS1-124K5.4	4.05	6.95e-05	0.0246	0.26	0.26	Aortic root size;	chr7:66423483	chr7:66493706~66495474:+
OV	cis	rs7598759	0.548	rs11693738	ENSG00000181798.2	LINC00471	-4.05	6.96e-05	0.0246	-0.25	-0.26	Noise-induced hearing loss;	chr2:231495773	chr2:231508426~231514339:-
OV	cis	rs1015213	0.609	rs117534993	ENSG00000253844.1	RP11-546K22.1	-4.05	6.96e-05	0.0246	-0.67	-0.26	Glaucoma (primary angle closure);	chr8:51952056	chr8:51961458~52022974:+
OV	cis	rs10858047	0.883	rs2137365	ENSG00000236480.1	PKMP1	4.05	6.96e-05	0.0246	0.37	0.26	Autism;	chr1:114536064	chr1:114535995~114537840:+
OV	cis	rs875971	0.862	rs12537823	ENSG00000236529.1	RP13-254B10.1	4.05	6.97e-05	0.0246	0.27	0.26	Aortic root size;	chr7:66255897	chr7:65840212~65840596:+
OV	cis	rs514406	0.505	rs374849	ENSG00000206627.1	RNU6-969P	4.05	6.97e-05	0.0247	0.28	0.26	Monocyte count;	chr1:52719959	chr1:52805108~52805212:-
OV	cis	rs934734	0.789	rs174847	ENSG00000234255.7	AC012370.3	-4.05	6.98e-05	0.0247	-0.3	-0.26	Rheumatoid arthritis;	chr2:65378060	chr2:65439888~65456571:-
OV	cis	rs62229266	0.835	rs998384	ENSG00000231106.2	LINC01436	4.05	6.98e-05	0.0247	0.32	0.26	Mitral valve prolapse;	chr21:36073228	chr21:36005338~36007838:+
OV	cis	rs10078	1	rs10078	ENSG00000221990.4	EXOC3-AS1	4.05	6.98e-05	0.0247	0.29	0.26	Fat distribution (HIV);	chr5:437987	chr5:441498~443160:-
OV	cis	rs2702164	0.962	rs1147682	ENSG00000240661.1	RP11-174O3.3	-4.05	6.98e-05	0.0247	-0.33	-0.26	Gut microbiome composition (winter);	chr3:120363948	chr3:120349510~120367998:+
OV	cis	rs73201462	1	rs2955091	ENSG00000242551.2	POU5F1P6	-4.05	6.98e-05	0.0247	-0.41	-0.26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128252518	chr3:128674735~128677005:-
OV	cis	rs944801	0.631	rs10757267	ENSG00000234840.1	LINC01239	-4.05	6.98e-05	0.0247	-0.29	-0.26	Type 2 diabetes;	chr9:22052811	chr9:22646200~22824213:+
OV	cis	rs6429082	0.509	rs6699315	ENSG00000236863.2	RPL23AP23	-4.05	6.99e-05	0.0247	-0.26	-0.26	Adiposity;	chr1:235361938	chr1:235295865~235296335:+
OV	cis	rs3930017	0.513	rs3930018	ENSG00000225726.1	AC007000.10	-4.05	6.99e-05	0.0247	-0.27	-0.26	Body mass index;	chr7:77091318	chr7:77071751~77072237:-
OV	cis	rs1113500	0.548	rs3853495	ENSG00000226822.1	RP11-356N1.2	4.05	6.99e-05	0.0247	0.33	0.26	Growth-regulated protein alpha levels;	chr1:108100623	chr1:108071482~108074519:+
OV	cis	rs1113500	0.548	rs9970655	ENSG00000226822.1	RP11-356N1.2	4.05	6.99e-05	0.0247	0.33	0.26	Growth-regulated protein alpha levels;	chr1:108100915	chr1:108071482~108074519:+
OV	cis	rs3823536	0.583	rs2280714	ENSG00000275106.1	RP11-309L24.10	-4.05	7e-05	0.0247	-0.36	-0.26	Sjögren's syndrome;	chr7:128954671	chr7:128952527~128953316:-
OV	cis	rs853679	0.76	rs9393909	ENSG00000219392.1	RP1-265C24.5	4.05	7e-05	0.0247	0.39	0.26	Depression;	chr6:28239422	chr6:28115628~28116551:+
OV	cis	rs13217239	0.574	rs9366680	ENSG00000261584.1	RP11-457M11.5	4.05	7e-05	0.0247	0.29	0.26	Schizophrenia;	chr6:27038344	chr6:26686241~26687964:+
OV	cis	rs10129255	0.5	rs2105991	ENSG00000223648.3	IGHV3-64	4.05	7e-05	0.0247	0.26	0.26	Kawasaki disease;	chr14:106682022	chr14:106643132~106658258:-
OV	cis	rs801193	0.773	rs801207	ENSG00000237310.1	GS1-124K5.4	-4.05	7.01e-05	0.0248	-0.26	-0.26	Aortic root size;	chr7:66555603	chr7:66493706~66495474:+
OV	cis	rs875971	0.543	rs801191	ENSG00000237310.1	GS1-124K5.4	-4.05	7.01e-05	0.0248	-0.26	-0.26	Aortic root size;	chr7:66567968	chr7:66493706~66495474:+
OV	cis	rs875971	0.508	rs6947808	ENSG00000237310.1	GS1-124K5.4	-4.05	7.01e-05	0.0248	-0.26	-0.26	Aortic root size;	chr7:66580095	chr7:66493706~66495474:+
OV	cis	rs801193	0.844	rs732465	ENSG00000237310.1	GS1-124K5.4	4.05	7.01e-05	0.0248	0.26	0.26	Aortic root size;	chr7:66533463	chr7:66493706~66495474:+
OV	cis	rs13068223	0.503	rs34277251	ENSG00000243926.1	TIPARP-AS1	4.05	7.01e-05	0.0248	0.24	0.26	Age-related hearing impairment (SNP x SNP interaction);	chr3:156703736	chr3:156671862~156674378:-
OV	cis	rs9473147	0.516	rs2151974	ENSG00000270761.1	RP11-385F7.1	-4.05	7.02e-05	0.0248	-0.3	-0.26	Platelet distribution width;Mean platelet volume;	chr6:47547894	chr6:47477243~47477572:-
OV	cis	rs9473147	0.516	rs9367284	ENSG00000270761.1	RP11-385F7.1	-4.05	7.02e-05	0.0248	-0.3	-0.26	Platelet distribution width;Mean platelet volume;	chr6:47548633	chr6:47477243~47477572:-
OV	cis	rs9473147	0.516	rs9381575	ENSG00000270761.1	RP11-385F7.1	-4.05	7.02e-05	0.0248	-0.3	-0.26	Platelet distribution width;Mean platelet volume;	chr6:47561028	chr6:47477243~47477572:-
OV	cis	rs1555322	0.53	rs2250205	ENSG00000269202.1	RP4-614O4.12	-4.05	7.02e-05	0.0248	-0.3	-0.26	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35201747~35203288:-
OV	cis	rs11157436	0.56	rs11623957	ENSG00000211812.1	TRAV26-2	-4.05	7.02e-05	0.0248	-0.26	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22224735	chr14:22202583~22203368:+
OV	cis	rs875971	0.545	rs4441996	ENSG00000273024.4	INTS4P2	4.05	7.03e-05	0.0248	0.31	0.26	Aortic root size;	chr7:66123233	chr7:65647864~65715661:+
OV	cis	rs875971	0.862	rs2420174	ENSG00000237310.1	GS1-124K5.4	-4.05	7.05e-05	0.0249	-0.26	-0.26	Aortic root size;	chr7:66180374	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs2420173	ENSG00000237310.1	GS1-124K5.4	-4.05	7.05e-05	0.0249	-0.26	-0.26	Aortic root size;	chr7:66180412	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs4718319	ENSG00000237310.1	GS1-124K5.4	-4.05	7.05e-05	0.0249	-0.26	-0.26	Aortic root size;	chr7:66187797	chr7:66493706~66495474:+
OV	cis	rs875971	0.723	rs28391294	ENSG00000237310.1	GS1-124K5.4	-4.05	7.05e-05	0.0249	-0.26	-0.26	Aortic root size;	chr7:66189328	chr7:66493706~66495474:+
OV	cis	rs875971	0.83	rs6967708	ENSG00000237310.1	GS1-124K5.4	-4.05	7.05e-05	0.0249	-0.26	-0.26	Aortic root size;	chr7:66192326	chr7:66493706~66495474:+
OV	cis	rs875971	0.895	rs7782806	ENSG00000237310.1	GS1-124K5.4	-4.05	7.05e-05	0.0249	-0.26	-0.26	Aortic root size;	chr7:66192910	chr7:66493706~66495474:+
OV	cis	rs73562014	0.938	rs59834028	ENSG00000254416.4	RP11-347E10.1	-4.05	7.05e-05	0.0249	-0.46	-0.26	Coronary artery disease;	chr11:110450976	chr11:110355130~110406400:+
OV	cis	rs73562014	0.882	rs10891118	ENSG00000254416.4	RP11-347E10.1	-4.05	7.05e-05	0.0249	-0.46	-0.26	Coronary artery disease;	chr11:110458142	chr11:110355130~110406400:+
OV	cis	rs10924970	0.935	rs6667150	ENSG00000236863.2	RPL23AP23	4.05	7.05e-05	0.0249	0.26	0.26	Asthma;	chr1:235191929	chr1:235295865~235296335:+
OV	cis	rs7395581	1	rs7395581	ENSG00000271350.1	CTD-2384B9.1	-4.05	7.05e-05	0.0249	-0.32	-0.26	HDL cholesterol;	chr11:47224846	chr11:47041027~47041945:-
OV	cis	rs853679	0.55	rs9295762	ENSG00000226314.6	ZNF192P1	4.05	7.05e-05	0.0249	0.33	0.26	Depression;	chr6:28187640	chr6:28161781~28169594:+
OV	cis	rs6071524	0.508	rs2244797	ENSG00000277581.1	RP4-616B8.6	4.05	7.05e-05	0.0249	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr20:38763546	chr20:38962472~38962993:+
OV	cis	rs7267979	1	rs1888999	ENSG00000274973.1	RP13-401N8.7	-4.05	7.07e-05	0.0249	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25311212	chr20:25845497~25845862:+
OV	cis	rs944801	0.608	rs10738605	ENSG00000234840.1	LINC01239	-4.05	7.07e-05	0.0249	-0.3	-0.26	Type 2 diabetes;	chr9:22049131	chr9:22646200~22824213:+
OV	cis	rs944801	0.506	rs2106119	ENSG00000234840.1	LINC01239	-4.05	7.07e-05	0.0249	-0.29	-0.26	Type 2 diabetes;	chr9:22017551	chr9:22646200~22824213:+
OV	cis	rs2239557	1	rs7157566	ENSG00000259065.1	RP5-1021I20.1	4.05	7.08e-05	0.025	0.3	0.26	Common traits (Other);	chr14:74182426	chr14:73787360~73803270:+
OV	cis	rs9879311	0.966	rs7619385	ENSG00000240288.6	GHRLOS	4.05	7.08e-05	0.025	0.25	0.26	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10373225	chr3:10285754~10293449:+
OV	cis	rs2243480	0.615	rs34363376	ENSG00000226824.5	RP4-756H11.3	-4.05	7.08e-05	0.025	-0.44	-0.26	Diabetic kidney disease;	chr7:66474549	chr7:66654538~66669855:+
OV	cis	rs11903757	1	rs78893166	ENSG00000281467.1	Clostridiales-1	-4.05	7.08e-05	0.025	-0.45	-0.26	Colorectal cancer;	chr2:191713930	chr2:191699476~191699631:-
OV	cis	rs829883	0.738	rs249846	ENSG00000227825.4	SLC9A7P1	4.05	7.08e-05	0.025	0.27	0.26	Colorectal adenoma (advanced);	chr12:98474961	chr12:98453835~98457145:-
OV	cis	rs4845570	1	rs4845570	ENSG00000203288.3	RP11-98D18.9	4.05	7.09e-05	0.025	0.4	0.26	Coronary artery disease;	chr1:151786628	chr1:151790804~151794402:+
OV	cis	rs4845570	1	rs4845356	ENSG00000203288.3	RP11-98D18.9	4.05	7.09e-05	0.025	0.4	0.26	Coronary artery disease;	chr1:151786747	chr1:151790804~151794402:+
OV	cis	rs4927850	0.723	rs7630825	ENSG00000229178.1	AC069513.4	-4.05	7.09e-05	0.025	-0.3	-0.26	Pancreatic cancer;	chr3:196026869	chr3:195655565~195657927:-
OV	cis	rs6545883	0.931	rs7557230	ENSG00000273302.1	RP11-493E12.2	4.05	7.09e-05	0.025	0.21	0.26	Tuberculosis;	chr2:61509517	chr2:61199979~61200769:+
OV	cis	rs17122278	1	rs1047079	ENSG00000255422.1	AP002954.4	4.05	7.11e-05	0.0251	0.42	0.26	Total cholesterol levels;	chr11:118602516	chr11:118704607~118750263:+
OV	cis	rs4666360	1	rs4233757	ENSG00000234378.1	AC098828.2	4.05	7.11e-05	0.0251	0.26	0.26	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);	chr2:20136316	chr2:20063856~20106829:-
OV	cis	rs4666360	1	rs4666361	ENSG00000234378.1	AC098828.2	4.05	7.11e-05	0.0251	0.26	0.26	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);	chr2:20136454	chr2:20063856~20106829:-
OV	cis	rs10888838	0.618	rs15921	ENSG00000198711.5	SSBP3-AS1	4.05	7.11e-05	0.0251	0.21	0.26	Mitochondrial DNA levels;	chr1:54218183	chr1:54236440~54239063:+
OV	cis	rs6687758	1	rs6695584	ENSG00000238042.4	RP11-815M8.1	4.05	7.11e-05	0.0251	0.36	0.26	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221988647	chr1:221880981~221978523:-
OV	cis	rs76210638	1	rs77201671	ENSG00000232986.1	RP11-179A7.2	4.05	7.11e-05	0.0251	0.61	0.26	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);	chr13:33921926	chr13:33657436~33659928:+
OV	cis	rs4713118	0.866	rs9468217	ENSG00000226314.6	ZNF192P1	-4.05	7.11e-05	0.0251	-0.34	-0.26	Parkinson's disease;	chr6:27758688	chr6:28161781~28169594:+
OV	cis	rs428445	1	rs428445	ENSG00000228995.1	MTND1P9	-4.05	7.11e-05	0.0251	-0.28	-0.26	Refractive astigmatism;	chr20:56461491	chr20:57357426~57358369:-
OV	cis	rs7200543	0.961	rs3803573	ENSG00000270580.4	PKD1P6	4.05	7.11e-05	0.0251	0.27	0.26	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044556	chr16:15104723~15131601:-
OV	cis	rs2950393	0.895	rs2926740	ENSG00000241217.3	RN7SL809P	4.05	7.11e-05	0.0251	0.26	0.26	Platelet distribution width;	chr12:56666751	chr12:56670450~56670746:-
OV	cis	rs113835537	0.529	rs80100524	ENSG00000255517.5	CTD-3074O7.5	-4.05	7.11e-05	0.0251	-0.37	-0.26	Airway imaging phenotypes;	chr11:66478465	chr11:66473490~66480233:-
OV	cis	rs113835537	0.529	rs2279864	ENSG00000255517.5	CTD-3074O7.5	-4.05	7.11e-05	0.0251	-0.37	-0.26	Airway imaging phenotypes;	chr11:66480373	chr11:66473490~66480233:-
OV	cis	rs113835537	0.529	rs78999944	ENSG00000255517.5	CTD-3074O7.5	-4.05	7.11e-05	0.0251	-0.37	-0.26	Airway imaging phenotypes;	chr11:66483757	chr11:66473490~66480233:-
OV	cis	rs113835537	0.529	rs11550299	ENSG00000255517.5	CTD-3074O7.5	-4.05	7.11e-05	0.0251	-0.37	-0.26	Airway imaging phenotypes;	chr11:66486614	chr11:66473490~66480233:-
OV	cis	rs113835537	0.529	rs4930379	ENSG00000255517.5	CTD-3074O7.5	-4.05	7.11e-05	0.0251	-0.37	-0.26	Airway imaging phenotypes;	chr11:66488203	chr11:66473490~66480233:-
OV	cis	rs113835537	0.529	rs4930183	ENSG00000255517.5	CTD-3074O7.5	-4.05	7.11e-05	0.0251	-0.37	-0.26	Airway imaging phenotypes;	chr11:66488261	chr11:66473490~66480233:-
OV	cis	rs4964805	0.626	rs869993	ENSG00000257681.1	RP11-341G23.4	4.05	7.11e-05	0.0251	0.3	0.26	Attention deficit hyperactivity disorder;	chr12:103781360	chr12:103746315~103768858:-
OV	cis	rs428445	1	rs13037594	ENSG00000228995.1	MTND1P9	4.05	7.12e-05	0.0251	0.28	0.26	Refractive astigmatism;	chr20:56465112	chr20:57357426~57358369:-
OV	cis	rs9925964	0.9	rs56813533	ENSG00000279196.1	RP11-1072A3.3	-4.05	7.12e-05	0.0251	-0.28	-0.26	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31059160	chr16:30984630~30988270:-
OV	cis	rs1113500	0.73	rs1781080	ENSG00000226822.1	RP11-356N1.2	-4.05	7.12e-05	0.0251	-0.31	-0.26	Growth-regulated protein alpha levels;	chr1:108050793	chr1:108071482~108074519:+
OV	cis	rs848490	0.651	rs12113119	ENSG00000214293.7	APTR	4.05	7.12e-05	0.0251	0.32	0.26	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685501	chr7:77657660~77696265:-
OV	cis	rs881375	0.933	rs7021206	ENSG00000226752.6	PSMD5-AS1	4.05	7.13e-05	0.0251	0.29	0.26	Rheumatoid arthritis;	chr9:120921879	chr9:120824828~120854385:+
OV	cis	rs1559040	0.932	rs10208690	ENSG00000272156.1	RP11-477N3.1	4.05	7.13e-05	0.0251	0.44	0.26	Sudden cardiac arrest;	chr2:54066783	chr2:54082554~54085066:+
OV	cis	rs465969	0.744	rs574056	ENSG00000255389.1	C6orf3	-4.05	7.13e-05	0.0251	-0.51	-0.26	Psoriasis;	chr6:111305787	chr6:111599875~111602295:+
OV	cis	rs6673267	0.869	rs6687260	ENSG00000223774.4	RP11-307B6.3	4.05	7.14e-05	0.0251	0.28	0.26	Lobe attachment (rater-scored or self-reported);	chr1:201011570	chr1:201893842~201899978:+
OV	cis	rs10754283	0.84	rs1215501	ENSG00000231613.1	RP5-943J3.1	4.05	7.14e-05	0.0251	0.28	0.26	Amyotrophic lateral sclerosis (sporadic);	chr1:89630131	chr1:89788914~89790492:+
OV	cis	rs28567906	0.551	rs764967	ENSG00000234380.1	LINC01426	4.05	7.15e-05	0.0252	0.44	0.26	Sum eosinophil basophil counts;Eosinophil percentage of white cells;Eosinophil counts;Eosinophil percentage of granulocytes;	chr21:34927368	chr21:34745757~34784886:+
OV	cis	rs2599510	0.783	rs2710626	ENSG00000279544.1	AL133243.4	-4.05	7.15e-05	0.0252	-0.24	-0.26	Interleukin-18 levels;	chr2:32533687	chr2:32563328~32566436:+
OV	cis	rs9473147	0.543	rs9349407	ENSG00000270761.1	RP11-385F7.1	-4.05	7.15e-05	0.0252	-0.29	-0.26	Platelet distribution width;Mean platelet volume;	chr6:47485642	chr6:47477243~47477572:-
OV	cis	rs801193	0.569	rs2659893	ENSG00000237310.1	GS1-124K5.4	4.05	7.15e-05	0.0252	0.26	0.26	Aortic root size;	chr7:66735006	chr7:66493706~66495474:+
OV	cis	rs801193	0.569	rs2659892	ENSG00000237310.1	GS1-124K5.4	4.05	7.15e-05	0.0252	0.26	0.26	Aortic root size;	chr7:66735318	chr7:66493706~66495474:+
OV	cis	rs2348418	0.765	rs6487665	ENSG00000247934.4	RP11-967K21.1	4.05	7.16e-05	0.0252	0.25	0.26	Lung function (FEV1);Lung function (FVC);	chr12:28177726	chr12:28163298~28190738:-
OV	cis	rs354033	0.837	rs6971236	ENSG00000280992.1	AC004932.1	-4.05	7.16e-05	0.0252	-0.28	-0.26	Multiple sclerosis;	chr7:149487759	chr7:149541747~149541846:-
OV	cis	rs9979383	0.576	rs2091890	ENSG00000228107.1	AP000692.9	4.05	7.16e-05	0.0252	0.26	0.26	Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr21:35421587	chr21:36360630~36362040:+
OV	cis	rs113835537	0.529	rs17147644	ENSG00000255517.5	CTD-3074O7.5	-4.05	7.16e-05	0.0252	-0.37	-0.26	Airway imaging phenotypes;	chr11:66489189	chr11:66473490~66480233:-
OV	cis	rs5743077	1	rs5743077	ENSG00000253559.1	OSGEPL1-AS1	-4.05	7.17e-05	0.0252	-0.34	-0.26	Iron status biomarkers (ferritin levels);	chr2:189832613	chr2:189762704~189765556:+
OV	cis	rs4664293	0.605	rs12474082	ENSG00000226266.5	AC009961.3	4.05	7.17e-05	0.0252	0.31	0.26	Monocyte percentage of white cells;	chr2:159657403	chr2:159670708~159712435:-
OV	cis	rs4664293	0.585	rs1991372	ENSG00000226266.5	AC009961.3	4.05	7.17e-05	0.0252	0.31	0.26	Monocyte percentage of white cells;	chr2:159659556	chr2:159670708~159712435:-
OV	cis	rs4664293	0.546	rs1991373	ENSG00000226266.5	AC009961.3	4.05	7.17e-05	0.0252	0.31	0.26	Monocyte percentage of white cells;	chr2:159659714	chr2:159670708~159712435:-
OV	cis	rs4664293	0.625	rs6707985	ENSG00000226266.5	AC009961.3	4.05	7.17e-05	0.0252	0.31	0.26	Monocyte percentage of white cells;	chr2:159659877	chr2:159670708~159712435:-
OV	cis	rs4664293	0.625	rs62171641	ENSG00000226266.5	AC009961.3	4.05	7.17e-05	0.0252	0.31	0.26	Monocyte percentage of white cells;	chr2:159659994	chr2:159670708~159712435:-
OV	cis	rs4664293	0.585	rs35293435	ENSG00000226266.5	AC009961.3	4.05	7.17e-05	0.0252	0.31	0.26	Monocyte percentage of white cells;	chr2:159662396	chr2:159670708~159712435:-
OV	cis	rs4664293	0.625	rs62171646	ENSG00000226266.5	AC009961.3	4.05	7.17e-05	0.0252	0.31	0.26	Monocyte percentage of white cells;	chr2:159662563	chr2:159670708~159712435:-
OV	cis	rs4664293	0.625	rs4664295	ENSG00000226266.5	AC009961.3	4.05	7.17e-05	0.0252	0.31	0.26	Monocyte percentage of white cells;	chr2:159663807	chr2:159670708~159712435:-
OV	cis	rs73186030	1	rs55838400	ENSG00000272758.4	RP11-299J3.8	4.05	7.17e-05	0.0252	0.32	0.26	Serum parathyroid hormone levels;	chr3:122313446	chr3:122416207~122443180:+
OV	cis	rs875971	0.798	rs12698522	ENSG00000237310.1	GS1-124K5.4	4.05	7.17e-05	0.0252	0.26	0.26	Aortic root size;	chr7:66502354	chr7:66493706~66495474:+
OV	cis	rs875971	0.83	rs28714531	ENSG00000237310.1	GS1-124K5.4	4.05	7.17e-05	0.0252	0.26	0.26	Aortic root size;	chr7:66503250	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs12698526	ENSG00000237310.1	GS1-124K5.4	4.05	7.17e-05	0.0252	0.26	0.26	Aortic root size;	chr7:66504118	chr7:66493706~66495474:+
OV	cis	rs9810089	0.967	rs7372313	ENSG00000261758.1	RP11-102M11.2	4.04	7.18e-05	0.0252	0.3	0.26	Gestational age at birth (child effect);	chr3:136154116	chr3:136752630~136755780:+
OV	cis	rs10246939	0.579	rs17133534	ENSG00000228775.6	WEE2-AS1	4.04	7.19e-05	0.0253	0.27	0.26	Bitter taste perception;	chr7:141860855	chr7:141704338~141738346:-
OV	cis	rs9649213	0.593	rs10953255	ENSG00000272950.1	RP11-307C18.1	4.04	7.19e-05	0.0253	0.31	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98293886	chr7:98322853~98323430:+
OV	cis	rs4950322	1	rs4950322	ENSG00000278811.3	LINC00624	-4.04	7.19e-05	0.0253	-0.35	-0.26	Protein quantitative trait loci;	chr1:147383114	chr1:147258885~147517875:-
OV	cis	rs9393777	0.92	rs67859638	ENSG00000280107.1	AL022393.9	-4.04	7.19e-05	0.0253	-0.54	-0.26	Intelligence (multi-trait analysis);	chr6:27390199	chr6:28170845~28172521:+
OV	cis	rs9828933	0.752	rs13433909	ENSG00000280620.1	SCAANT1	4.04	7.19e-05	0.0253	0.42	0.26	Type 2 diabetes;	chr3:63962933	chr3:63911518~63911772:-
OV	cis	rs9386630	0.728	rs2500595	ENSG00000271734.1	RP1-111B22.3	-4.04	7.19e-05	0.0253	-0.29	-0.26	Coffee consumption;	chr6:107300273	chr6:108030249~108030718:-
OV	cis	rs10783487	0.895	rs7964071	ENSG00000258279.2	LINC00592	4.04	7.19e-05	0.0253	0.36	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr12:52072266	chr12:52210930~52223804:+
OV	cis	rs9992667	0.911	rs12332031	ENSG00000231160.8	KLF3-AS1	4.04	7.19e-05	0.0253	0.31	0.26	Eosinophil percentage of granulocytes;	chr4:38651881	chr4:38612701~38664883:-
OV	cis	rs599083	0.59	rs10791984	ENSG00000212093.1	AP000807.1	-4.04	7.19e-05	0.0253	-0.29	-0.26	Bone mineral density (spine);	chr11:68640367	chr11:68506083~68506166:-
OV	cis	rs7927592	0.956	rs12281742	ENSG00000212093.1	AP000807.1	-4.04	7.2e-05	0.0253	-0.32	-0.26	Total body bone mineral density;	chr11:68536161	chr11:68506083~68506166:-
OV	cis	rs796364	0.951	rs13029537	ENSG00000232732.8	AC073043.1	4.04	7.2e-05	0.0253	0.37	0.26	Schizophrenia;	chr2:200134227	chr2:199867396~199911159:-
OV	cis	rs801193	0.548	rs2659891	ENSG00000237310.1	GS1-124K5.4	4.04	7.2e-05	0.0253	0.26	0.26	Aortic root size;	chr7:66736127	chr7:66493706~66495474:+
OV	cis	rs7083	0.84	rs509565	ENSG00000278768.1	BACE1-AS	4.04	7.2e-05	0.0253	0.26	0.26	Blood protein levels;	chr11:117249757	chr11:117290874~117293571:+
OV	cis	rs1933112	1	rs1024177	ENSG00000227777.1	RP4-738P11.3	-4.04	7.21e-05	0.0253	-0.29	-0.26	Blood protein levels;	chr1:168557477	chr1:168542737~168543354:+
OV	cis	rs12460587	0.587	rs55899235	ENSG00000275055.1	CTC-471J1.11	-4.04	7.21e-05	0.0253	-0.28	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52099871	chr19:52049007~52049754:+
OV	cis	rs72700829	0.518	rs11548267	ENSG00000223945.2	RP11-458I7.1	-4.04	7.21e-05	0.0253	-0.45	-0.26	Schizophrenia;	chr1:150266299	chr1:150053864~150055034:+
OV	cis	rs1790761	0.505	rs6591256	ENSG00000184224.3	C11orf72	-4.04	7.22e-05	0.0253	-0.28	-0.26	Mean corpuscular volume;	chr11:67582428	chr11:67602880~67606706:-
OV	cis	rs2303745	0.589	rs891018	ENSG00000269815.1	CTD-2278I10.4	4.04	7.22e-05	0.0254	0.34	0.26	Systemic lupus erythematosus;	chr19:17285952	chr19:17296196~17296695:-
OV	cis	rs3823536	0.583	rs10236569	ENSG00000275106.1	RP11-309L24.10	-4.04	7.22e-05	0.0254	-0.36	-0.26	Sjögren's syndrome;	chr7:128957533	chr7:128952527~128953316:-
OV	cis	rs1836229	0.594	rs10758998	ENSG00000225706.1	PTPRD-AS1	-4.04	7.23e-05	0.0254	-0.26	-0.26	Restless legs syndrome;	chr9:8833943	chr9:8858130~8862255:+
OV	cis	rs12073359	0.954	rs12061856	ENSG00000223945.2	RP11-458I7.1	-4.04	7.23e-05	0.0254	-0.39	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150029941	chr1:150053864~150055034:+
OV	cis	rs2111504	0.806	rs10403559	ENSG00000267213.4	AC007773.2	-4.04	7.23e-05	0.0254	-0.34	-0.26	Bipolar disorder;	chr19:32462195	chr19:32390050~32405560:-
OV	cis	rs17807185	0.676	rs4273781	ENSG00000214293.7	APTR	4.04	7.23e-05	0.0254	0.32	0.26	Height;	chr7:77671806	chr7:77657660~77696265:-
OV	cis	rs2950393	0.927	rs11171914	ENSG00000241217.3	RN7SL809P	-4.04	7.24e-05	0.0254	-0.26	-0.26	Platelet distribution width;	chr12:56649462	chr12:56670450~56670746:-
OV	cis	rs7267979	0.903	rs6050482	ENSG00000274973.1	RP13-401N8.7	-4.04	7.24e-05	0.0254	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25245691	chr20:25845497~25845862:+
OV	cis	rs7267979	0.706	rs6037069	ENSG00000274973.1	RP13-401N8.7	-4.04	7.24e-05	0.0254	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25253530	chr20:25845497~25845862:+
OV	cis	rs881375	0.867	rs6478487	ENSG00000226752.6	PSMD5-AS1	-4.04	7.24e-05	0.0254	-0.29	-0.26	Rheumatoid arthritis;	chr9:120910499	chr9:120824828~120854385:+
OV	cis	rs944801	0.506	rs2106120	ENSG00000234840.1	LINC01239	-4.04	7.24e-05	0.0254	-0.29	-0.26	Type 2 diabetes;	chr9:22017102	chr9:22646200~22824213:+
OV	cis	rs494453	0.6	rs575208	ENSG00000227811.2	FAM212B-AS1	-4.04	7.24e-05	0.0254	-0.29	-0.26	Osteoporosis-related phenotypes;	chr1:111663769	chr1:111739841~111747798:+
OV	cis	rs12446632	0.551	rs56344690	ENSG00000261939.1	LARP7P2	4.04	7.24e-05	0.0254	0.49	0.26	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19730908	chr16:19819504~19819628:-
OV	cis	rs7746199	0.736	rs58616630	ENSG00000220721.1	OR1F12	4.04	7.25e-05	0.0254	0.49	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27506936	chr6:28073316~28074233:+
OV	cis	rs7520050	0.902	rs1355642	ENSG00000281133.1	AL355480.3	4.04	7.25e-05	0.0254	0.3	0.26	Reticulocyte count;Red blood cell count;	chr1:46133231	chr1:45580892~45580996:-
OV	cis	rs7789940	1	rs7789940	ENSG00000230305.2	AC004980.9	4.04	7.25e-05	0.0254	0.36	0.26	Multiple sclerosis;	chr7:76321913	chr7:76524515~76532692:+
OV	cis	rs1436109	0.809	rs60244972	ENSG00000255129.4	RP11-839D17.3	4.04	7.25e-05	0.0255	0.45	0.26	Cardiac muscle measurement;	chr11:113009653	chr11:113278437~113314437:-
OV	cis	rs1436109	0.809	rs4322430	ENSG00000255129.4	RP11-839D17.3	4.04	7.25e-05	0.0255	0.45	0.26	Cardiac muscle measurement;	chr11:113009984	chr11:113278437~113314437:-
OV	cis	rs1436109	0.809	rs2155289	ENSG00000255129.4	RP11-839D17.3	4.04	7.25e-05	0.0255	0.45	0.26	Cardiac muscle measurement;	chr11:113014359	chr11:113278437~113314437:-
OV	cis	rs4761702	0.922	rs11106975	ENSG00000257252.4	RP11-486A14.2	-4.04	7.26e-05	0.0255	-0.31	-0.26	Immature fraction of reticulocytes;	chr12:93327178	chr12:93317135~93377736:-
OV	cis	rs6921919	0.609	rs67211468	ENSG00000204709.4	LINC01556	4.04	7.26e-05	0.0255	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28424210	chr6:28943877~28944537:+
OV	cis	rs7649443	0.917	rs13099700	ENSG00000235897.1	TM4SF19-AS1	4.04	7.27e-05	0.0255	0.29	0.26	Nonsyndromic cleft lip with cleft palate;	chr3:197091982	chr3:196318330~196325570:+
OV	cis	rs7927592	0.513	rs3853616	ENSG00000222339.1	AP000807.2	4.04	7.27e-05	0.0255	0.26	0.26	Total body bone mineral density;	chr11:68430784	chr11:68505572~68505651:-
OV	cis	rs1707322	0.717	rs1547925	ENSG00000234329.1	RP11-767N6.2	-4.04	7.28e-05	0.0255	-0.28	-0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45619684	chr1:45651039~45651826:-
OV	cis	rs7131987	0.65	rs7954871	ENSG00000257176.2	RP11-996F15.2	-4.04	7.28e-05	0.0255	-0.32	-0.26	QT interval;	chr12:29306799	chr12:29280418~29317848:-
OV	cis	rs1113500	0.73	rs1618693	ENSG00000226822.1	RP11-356N1.2	-4.04	7.28e-05	0.0255	-0.31	-0.26	Growth-regulated protein alpha levels;	chr1:108048961	chr1:108071482~108074519:+
OV	cis	rs1113500	0.698	rs1781078	ENSG00000226822.1	RP11-356N1.2	-4.04	7.28e-05	0.0255	-0.31	-0.26	Growth-regulated protein alpha levels;	chr1:108049020	chr1:108071482~108074519:+
OV	cis	rs4934494	0.573	rs67157720	ENSG00000240996.1	RP11-80H5.7	-4.04	7.28e-05	0.0255	-0.38	-0.26	Red blood cell count;	chr10:89820415	chr10:89694295~89697928:-
OV	cis	rs4664293	0.585	rs35081473	ENSG00000224152.1	AC009506.1	4.04	7.29e-05	0.0255	0.27	0.26	Monocyte percentage of white cells;	chr2:159679970	chr2:159615296~159617082:+
OV	cis	rs4664293	0.605	rs7556888	ENSG00000224152.1	AC009506.1	4.04	7.29e-05	0.0255	0.27	0.26	Monocyte percentage of white cells;	chr2:159683750	chr2:159615296~159617082:+
OV	cis	rs4243830	0.737	rs6692747	ENSG00000229519.2	RP11-58A11.2	-4.04	7.29e-05	0.0255	-0.38	-0.26	Body mass index;	chr1:6549989	chr1:6547905~6548619:+
OV	cis	rs10800713	0.954	rs6665951	ENSG00000260088.1	RP11-92G12.3	-4.04	7.29e-05	0.0255	-0.31	-0.26	Tandem gait;	chr1:200589235	chr1:200669507~200694250:+
OV	cis	rs848490	0.651	rs7810273	ENSG00000214293.7	APTR	4.04	7.29e-05	0.0256	0.32	0.26	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685327	chr7:77657660~77696265:-
OV	cis	rs992157	0.698	rs6746089	ENSG00000261338.2	RP11-378A13.1	4.04	7.29e-05	0.0256	0.31	0.26	Colorectal cancer;	chr2:218305654	chr2:218255319~218257366:+
OV	cis	rs7927592	0.731	rs10896350	ENSG00000222339.1	AP000807.2	4.04	7.3e-05	0.0256	0.26	0.26	Total body bone mineral density;	chr11:68618905	chr11:68505572~68505651:-
OV	cis	rs1823913	1	rs4853568	ENSG00000227542.1	AC092614.2	-4.04	7.3e-05	0.0256	-0.3	-0.26	Obesity-related traits;	chr2:191261464	chr2:191229165~191246172:-
OV	cis	rs10986311	0.681	rs35068124	ENSG00000227200.1	RP11-121A14.3	-4.04	7.31e-05	0.0256	-0.23	-0.26	Vitiligo;	chr9:124265531	chr9:124262876~124265809:+
OV	cis	rs11083475	1	rs883394	ENSG00000267892.1	CTD-2540F13.2	4.04	7.31e-05	0.0256	0.29	0.26	Heart rate;	chr19:38714973	chr19:38738284~38739863:+
OV	cis	rs796364	0.951	rs1105964	ENSG00000232732.8	AC073043.1	4.04	7.31e-05	0.0256	0.37	0.26	Schizophrenia;	chr2:200136053	chr2:199867396~199911159:-
OV	cis	rs4853012	0.941	rs4852329	ENSG00000257800.1	FNBP1P1	4.04	7.31e-05	0.0256	0.39	0.26	Gestational age at birth (maternal effect);	chr2:74127417	chr2:74120680~74123218:+
OV	cis	rs514406	0.505	rs6703127	ENSG00000206627.1	RNU6-969P	4.04	7.31e-05	0.0256	0.28	0.26	Monocyte count;	chr1:52714893	chr1:52805108~52805212:-
OV	cis	rs4664293	0.528	rs56027129	ENSG00000226266.5	AC009961.3	4.04	7.32e-05	0.0256	0.31	0.26	Monocyte percentage of white cells;	chr2:159600091	chr2:159670708~159712435:-
OV	cis	rs858239	0.899	rs10085838	ENSG00000230042.1	AK3P3	-4.04	7.32e-05	0.0256	-0.28	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23258796	chr7:23129178~23129841:+
OV	cis	rs2342371	0.756	rs4916492	ENSG00000235897.1	TM4SF19-AS1	4.04	7.32e-05	0.0256	0.3	0.26	Fat distribution (HIV);	chr3:196379435	chr3:196318330~196325570:+
OV	cis	rs67311347	0.544	rs6599088	ENSG00000223797.4	ENTPD3-AS1	4.04	7.32e-05	0.0256	0.27	0.26	Renal cell carcinoma;	chr3:40287797	chr3:40313802~40453329:-
OV	cis	rs4713118	0.955	rs9468203	ENSG00000219392.1	RP1-265C24.5	-4.04	7.32e-05	0.0256	-0.3	-0.26	Parkinson's disease;	chr6:27720888	chr6:28115628~28116551:+
OV	cis	rs7580658	0.929	rs2276583	ENSG00000236682.1	AC068282.3	-4.04	7.33e-05	0.0257	-0.34	-0.26	Protein C levels;	chr2:127257108	chr2:127389130~127400580:+
OV	cis	rs7927592	0.513	rs607887	ENSG00000222339.1	AP000807.2	4.04	7.33e-05	0.0257	0.26	0.26	Total body bone mineral density;	chr11:68429493	chr11:68505572~68505651:-
OV	cis	rs9923856	0.614	rs62026377	ENSG00000262636.1	CTD-3088G3.4	4.04	7.33e-05	0.0257	0.38	0.26	Atopic dermatitis;Adult asthma;	chr16:11135271	chr16:11380859~11381118:-
OV	cis	rs10129255	0.5	rs11628999	ENSG00000223648.3	IGHV3-64	4.04	7.33e-05	0.0257	0.26	0.26	Kawasaki disease;	chr14:106800208	chr14:106643132~106658258:-
OV	cis	rs9309473	0.66	rs11679594	ENSG00000163016.8	ALMS1P	4.04	7.33e-05	0.0257	0.34	0.26	Metabolite levels;	chr2:73552380	chr2:73644919~73685576:+
OV	cis	rs2828520	0.606	rs2408786	ENSG00000223822.2	EEF1A1P1	4.04	7.34e-05	0.0257	0.24	0.26	Major depressive disorder;	chr21:23750235	chr21:23390258~23390996:+
OV	cis	rs2828520	0.647	rs2828499	ENSG00000223822.2	EEF1A1P1	4.04	7.34e-05	0.0257	0.24	0.26	Major depressive disorder;	chr21:23750973	chr21:23390258~23390996:+
OV	cis	rs295140	0.546	rs295134	ENSG00000232732.8	AC073043.1	4.04	7.34e-05	0.0257	0.3	0.26	QT interval;	chr2:200245500	chr2:199867396~199911159:-
OV	cis	rs7789940	0.904	rs6948661	ENSG00000230305.2	AC004980.9	4.04	7.35e-05	0.0257	0.36	0.26	Multiple sclerosis;	chr7:76332330	chr7:76524515~76532692:+
OV	cis	rs6661961	0.752	rs4845768	ENSG00000237975.5	FLG-AS1	-4.04	7.35e-05	0.0257	-0.33	-0.26	Atopic dermatitis;	chr1:152442997	chr1:152168125~152445456:+
OV	cis	rs897984	0.572	rs112906665	ENSG00000232748.3	RP11-196G11.6	-4.04	7.36e-05	0.0257	-0.27	-0.26	Dementia with Lewy bodies;	chr16:31028818	chr16:31056460~31062803:+
OV	cis	rs897984	0.645	rs58726213	ENSG00000232748.3	RP11-196G11.6	-4.04	7.36e-05	0.0257	-0.27	-0.26	Dementia with Lewy bodies;	chr16:31033362	chr16:31056460~31062803:+
OV	cis	rs897984	0.609	rs12445650	ENSG00000232748.3	RP11-196G11.6	-4.04	7.36e-05	0.0257	-0.27	-0.26	Dementia with Lewy bodies;	chr16:31033576	chr16:31056460~31062803:+
OV	cis	rs62229266	0.804	rs56279140	ENSG00000231106.2	LINC01436	4.04	7.36e-05	0.0257	0.32	0.26	Mitral valve prolapse;	chr21:36052063	chr21:36005338~36007838:+
OV	cis	rs6500602	0.702	rs9929475	ENSG00000280063.1	RP11-295D4.3	-4.04	7.36e-05	0.0257	-0.21	-0.26	Schizophrenia;	chr16:4490884	chr16:4346694~4348648:-
OV	cis	rs7520050	0.778	rs2991985	ENSG00000280836.1	AL355480.1	4.04	7.37e-05	0.0258	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45614858	chr1:45581219~45581321:-
OV	cis	rs3814244	0.751	rs12832728	ENSG00000255733.4	IFNG-AS1	-4.04	7.37e-05	0.0258	-0.25	-0.26	Itch intensity from mosquito bite adjusted by bite size;	chr12:68026623	chr12:67989445~68234686:+
OV	cis	rs796364	0.806	rs35200468	ENSG00000232732.8	AC073043.1	4.04	7.37e-05	0.0258	0.41	0.26	Schizophrenia;	chr2:200245645	chr2:199867396~199911159:-
OV	cis	rs875971	0.798	rs6460304	ENSG00000237310.1	GS1-124K5.4	4.04	7.38e-05	0.0258	0.26	0.26	Aortic root size;	chr7:66499741	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs6945775	ENSG00000237310.1	GS1-124K5.4	4.04	7.38e-05	0.0258	0.26	0.26	Aortic root size;	chr7:66503987	chr7:66493706~66495474:+
OV	cis	rs1511299	0.597	rs2271386	ENSG00000249417.1	RP11-438D8.2	4.04	7.39e-05	0.0258	0.4	0.26	Glomerular filtration rate;	chr3:141993866	chr3:141267353~141367137:-
OV	cis	rs7789940	1	rs11765693	ENSG00000230305.2	AC004980.9	4.04	7.39e-05	0.0258	0.36	0.26	Multiple sclerosis;	chr7:76356056	chr7:76524515~76532692:+
OV	cis	rs7789940	1	rs73140069	ENSG00000230305.2	AC004980.9	4.04	7.39e-05	0.0258	0.36	0.26	Multiple sclerosis;	chr7:76357473	chr7:76524515~76532692:+
OV	cis	rs57709857	0.957	rs11985168	ENSG00000272092.1	RP11-350N15.5	-4.04	7.39e-05	0.0258	-0.35	-0.26	Autism spectrum disorder or schizophrenia;	chr8:38302525	chr8:38382364~38383461:+
OV	cis	rs8113142	0.551	rs60227266	ENSG00000267243.4	AC005307.3	-4.04	7.39e-05	0.0258	-0.38	-0.26	Femoral neck bone geometry and menarche (age at onset);	chr19:28722748	chr19:28435388~28727777:-
OV	cis	rs853679	0.607	rs71559070	ENSG00000220721.1	OR1F12	4.04	7.39e-05	0.0258	0.54	0.26	Depression;	chr6:28071151	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs35902873	ENSG00000220721.1	OR1F12	4.04	7.39e-05	0.0258	0.54	0.26	Depression;	chr6:28091171	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs13197574	ENSG00000220721.1	OR1F12	4.04	7.39e-05	0.0258	0.54	0.26	Depression;	chr6:28092461	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs34166054	ENSG00000220721.1	OR1F12	4.04	7.39e-05	0.0258	0.54	0.26	Depression;	chr6:28098023	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs34662244	ENSG00000220721.1	OR1F12	4.04	7.39e-05	0.0258	0.54	0.26	Depression;	chr6:28106103	chr6:28073316~28074233:+
OV	cis	rs35952432	1	rs35952432	ENSG00000220721.1	OR1F12	4.04	7.39e-05	0.0258	0.54	0.26	Lung cancer;	chr6:28107123	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs13203816	ENSG00000220721.1	OR1F12	4.04	7.39e-05	0.0258	0.54	0.26	Depression;	chr6:28111820	chr6:28073316~28074233:+
OV	cis	rs853679	0.556	rs34588114	ENSG00000220721.1	OR1F12	4.04	7.39e-05	0.0258	0.54	0.26	Depression;	chr6:28112850	chr6:28073316~28074233:+
OV	cis	rs853679	0.546	rs34371502	ENSG00000220721.1	OR1F12	4.04	7.39e-05	0.0258	0.54	0.26	Depression;	chr6:28113980	chr6:28073316~28074233:+
OV	cis	rs5742933	0.948	rs2264018	ENSG00000253559.1	OSGEPL1-AS1	-4.04	7.39e-05	0.0258	-0.28	-0.26	Ferritin levels;	chr2:189712052	chr2:189762704~189765556:+
OV	cis	rs9326248	0.59	rs2542063	ENSG00000280143.1	AP000892.6	4.04	7.4e-05	0.0258	0.26	0.26	Blood protein levels;	chr11:116814051	chr11:117204967~117210292:+
OV	cis	rs11105298	0.891	rs10858854	ENSG00000257194.2	RP11-567C2.1	-4.04	7.4e-05	0.0259	-0.4	-0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89441951	chr12:90107739~90112779:+
OV	cis	rs9467773	1	rs9467787	ENSG00000243307.2	POM121L6P	4.04	7.41e-05	0.0259	0.25	0.26	Intelligence (multi-trait analysis);	chr6:26556541	chr6:26896952~26898777:+
OV	cis	rs9638182	0.848	rs55747707	ENSG00000106133.16	NSUN5P2	-4.04	7.41e-05	0.0259	-0.41	-0.26	Triglycerides;	chr7:73623036	chr7:72947581~72954790:-
OV	cis	rs9638182	0.848	rs35493868	ENSG00000106133.16	NSUN5P2	-4.04	7.41e-05	0.0259	-0.41	-0.26	Triglycerides;	chr7:73625076	chr7:72947581~72954790:-
OV	cis	rs9638182	0.848	rs34121855	ENSG00000106133.16	NSUN5P2	-4.04	7.41e-05	0.0259	-0.41	-0.26	Triglycerides;	chr7:73626484	chr7:72947581~72954790:-
OV	cis	rs2239557	1	rs7153160	ENSG00000259065.1	RP5-1021I20.1	-4.04	7.42e-05	0.0259	-0.32	-0.26	Common traits (Other);	chr14:74042674	chr14:73787360~73803270:+
OV	cis	rs9876781	0.559	rs7630053	ENSG00000229759.1	MRPS18AP1	4.04	7.43e-05	0.0259	0.26	0.26	Longevity;	chr3:48357096	chr3:48256350~48256938:-
OV	cis	rs2999052	1	rs2811476	ENSG00000277250.1	Metazoa_SRP	4.04	7.43e-05	0.0259	0.32	0.26	Hypospadias;	chr3:128179658	chr3:128673681~128674021:-
OV	cis	rs7017914	0.69	rs2732133	ENSG00000223220.1	Y_RNA	4.04	7.43e-05	0.0259	0.27	0.26	Bone mineral density;	chr8:70978741	chr8:70780914~70781008:-
OV	cis	rs7520050	0.933	rs6661163	ENSG00000281133.1	AL355480.3	4.04	7.43e-05	0.0259	0.29	0.26	Reticulocyte count;Red blood cell count;	chr1:45789332	chr1:45580892~45580996:-
OV	cis	rs7536700	0.915	rs7533987	ENSG00000272030.1	RP1-178F15.4	-4.04	7.43e-05	0.0259	-0.54	-0.26	Multiple myeloma (IgH translocation);	chr1:153688513	chr1:153631438~153634397:-
OV	cis	rs3733585	0.699	rs2018643	ENSG00000250413.1	RP11-448G15.1	-4.04	7.43e-05	0.0259	-0.29	-0.26	Cleft plate (environmental tobacco smoke interaction);	chr4:9945497	chr4:10006482~10009725:+
OV	cis	rs11122895	1	rs11691123	ENSG00000228251.1	AC012442.6	-4.04	7.44e-05	0.026	-0.24	-0.26	Allergic sensitization;	chr2:111705533	chr2:112590796~112591939:+
OV	cis	rs12073359	1	rs77391665	ENSG00000223945.2	RP11-458I7.1	-4.04	7.44e-05	0.026	-0.39	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150036614	chr1:150053864~150055034:+
OV	cis	rs9309473	0.606	rs79234109	ENSG00000163016.8	ALMS1P	4.04	7.44e-05	0.026	0.35	0.26	Metabolite levels;	chr2:73621227	chr2:73644919~73685576:+
OV	cis	rs801193	0.569	rs2659908	ENSG00000236529.1	RP13-254B10.1	4.04	7.44e-05	0.026	0.27	0.26	Aortic root size;	chr7:66695835	chr7:65840212~65840596:+
OV	cis	rs801193	0.569	rs7782587	ENSG00000236529.1	RP13-254B10.1	4.04	7.44e-05	0.026	0.27	0.26	Aortic root size;	chr7:66701485	chr7:65840212~65840596:+
OV	cis	rs801193	0.569	rs4717315	ENSG00000236529.1	RP13-254B10.1	4.04	7.44e-05	0.026	0.27	0.26	Aortic root size;	chr7:66713338	chr7:65840212~65840596:+
OV	cis	rs12446632	0.509	rs72769533	ENSG00000261939.1	LARP7P2	4.04	7.45e-05	0.026	0.49	0.26	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19739888	chr16:19819504~19819628:-
OV	cis	rs7520050	0.966	rs4660317	ENSG00000280836.1	AL355480.1	4.04	7.46e-05	0.026	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45860554	chr1:45581219~45581321:-
OV	cis	rs7520050	0.931	rs6688365	ENSG00000280836.1	AL355480.1	4.04	7.46e-05	0.026	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45864212	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs6656992	ENSG00000280836.1	AL355480.1	4.04	7.46e-05	0.026	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45867396	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs61783220	ENSG00000280836.1	AL355480.1	4.04	7.46e-05	0.026	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45869640	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs7540325	ENSG00000280836.1	AL355480.1	4.04	7.46e-05	0.026	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45872545	chr1:45581219~45581321:-
OV	cis	rs7520050	1	rs7540699	ENSG00000280836.1	AL355480.1	4.04	7.46e-05	0.026	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45872913	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs4660319	ENSG00000280836.1	AL355480.1	4.04	7.46e-05	0.026	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45875951	chr1:45581219~45581321:-
OV	cis	rs7520050	0.931	rs11211213	ENSG00000280836.1	AL355480.1	4.04	7.46e-05	0.026	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45876845	chr1:45581219~45581321:-
OV	cis	rs7131987	0.621	rs6487805	ENSG00000257176.2	RP11-996F15.2	4.04	7.46e-05	0.026	0.32	0.26	QT interval;	chr12:29304617	chr12:29280418~29317848:-
OV	cis	rs4918798	0.641	rs61886773	ENSG00000234724.1	HDAC1P1	4.04	7.46e-05	0.026	0.47	0.26	Warfarin maintenance dose;	chr10:94953587	chr10:94137748~94139500:+
OV	cis	rs4918798	0.547	rs2860968	ENSG00000234724.1	HDAC1P1	4.04	7.46e-05	0.026	0.47	0.26	Warfarin maintenance dose;	chr10:94953824	chr10:94137748~94139500:+
OV	cis	rs4918798	0.696	rs55804705	ENSG00000234724.1	HDAC1P1	4.04	7.46e-05	0.026	0.47	0.26	Warfarin maintenance dose;	chr10:94960857	chr10:94137748~94139500:+
OV	cis	rs642743	0.901	rs674850	ENSG00000228261.1	RP11-127L20.3	-4.03	7.47e-05	0.026	-0.27	-0.26	Left ventricular obstructive tract defect (maternal effect);	chr10:104201669	chr10:104323369~104327004:+
OV	cis	rs425277	1	rs262641	ENSG00000231050.1	RP1-140A9.1	-4.03	7.47e-05	0.0261	-0.3	-0.26	Height;	chr1:2173542	chr1:1891471~1892658:+
OV	cis	rs9876781	0.559	rs11130167	ENSG00000229759.1	MRPS18AP1	4.03	7.47e-05	0.0261	0.26	0.26	Longevity;	chr3:48358570	chr3:48256350~48256938:-
OV	cis	rs760794	0.577	rs17483277	ENSG00000227116.1	RP3-471C18.1	-4.03	7.47e-05	0.0261	-0.29	-0.26	Endometriosis;	chr6:19790340	chr6:19730427~19734567:-
OV	cis	rs7649443	0.876	rs12638001	ENSG00000235897.1	TM4SF19-AS1	4.03	7.48e-05	0.0261	0.29	0.26	Nonsyndromic cleft lip with cleft palate;	chr3:197090304	chr3:196318330~196325570:+
OV	cis	rs9393777	0.92	rs35120058	ENSG00000280107.1	AL022393.9	-4.03	7.48e-05	0.0261	-0.49	-0.26	Intelligence (multi-trait analysis);	chr6:27390387	chr6:28170845~28172521:+
OV	cis	rs16843372	0.576	rs10184397	ENSG00000251491.2	OR7E28P	-4.03	7.48e-05	0.0261	-0.32	-0.26	Obesity-related traits;	chr2:158838730	chr2:158862311~158863285:+
OV	cis	rs6921919	0.583	rs9468355	ENSG00000204709.4	LINC01556	4.03	7.48e-05	0.0261	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28374100	chr6:28943877~28944537:+
OV	cis	rs6429082	0.509	rs7516807	ENSG00000236863.2	RPL23AP23	4.03	7.48e-05	0.0261	0.25	0.26	Adiposity;	chr1:235360240	chr1:235295865~235296335:+
OV	cis	rs7726839	0.54	rs12520279	ENSG00000271781.1	CTD-2589H19.6	-4.03	7.48e-05	0.0261	-0.41	-0.26	Obesity-related traits;	chr5:657176	chr5:675826~676616:+
OV	cis	rs7726839	0.54	rs7558	ENSG00000271781.1	CTD-2589H19.6	-4.03	7.49e-05	0.0261	-0.41	-0.26	Obesity-related traits;	chr5:660376	chr5:675826~676616:+
OV	cis	rs78547569	1	rs981071	ENSG00000230793.1	SMARCE1P5	-4.03	7.49e-05	0.0261	-0.38	-0.26	Response to paliperidone in schizophrenia (negative Marder score);Response to paliperidone in schizophrenia (Multivariate);	chr13:43820758	chr13:44594858~44596082:+
OV	cis	rs934734	0.967	rs17534670	ENSG00000234255.7	AC012370.3	-4.03	7.49e-05	0.0261	-0.27	-0.26	Rheumatoid arthritis;	chr2:65388294	chr2:65439888~65456571:-
OV	cis	rs62553886	1	rs905358	ENSG00000227638.2	HNRNPA1P14	4.03	7.49e-05	0.0261	0.36	0.26	Lymphocyte percentage of white cells;	chr9:88890719	chr9:88410529~88411463:-
OV	cis	rs7512898	0.5	rs7520984	ENSG00000260088.1	RP11-92G12.3	-4.03	7.49e-05	0.0261	-0.29	-0.26	Electrocardiographic conduction measures;	chr1:200741190	chr1:200669507~200694250:+
OV	cis	rs7131987	0.65	rs7957339	ENSG00000257176.2	RP11-996F15.2	-4.03	7.49e-05	0.0261	-0.32	-0.26	QT interval;	chr12:29303562	chr12:29280418~29317848:-
OV	cis	rs7131987	0.65	rs7973786	ENSG00000257176.2	RP11-996F15.2	-4.03	7.49e-05	0.0261	-0.32	-0.26	QT interval;	chr12:29309811	chr12:29280418~29317848:-
OV	cis	rs7131987	0.718	rs7976961	ENSG00000257176.2	RP11-996F15.2	-4.03	7.49e-05	0.0261	-0.32	-0.26	QT interval;	chr12:29310155	chr12:29280418~29317848:-
OV	cis	rs7131987	0.621	rs11050181	ENSG00000257176.2	RP11-996F15.2	-4.03	7.49e-05	0.0261	-0.32	-0.26	QT interval;	chr12:29314736	chr12:29280418~29317848:-
OV	cis	rs7131987	0.65	rs10843384	ENSG00000257176.2	RP11-996F15.2	-4.03	7.49e-05	0.0261	-0.32	-0.26	QT interval;	chr12:29319476	chr12:29280418~29317848:-
OV	cis	rs7131987	0.65	rs11050187	ENSG00000257176.2	RP11-996F15.2	-4.03	7.49e-05	0.0261	-0.32	-0.26	QT interval;	chr12:29319943	chr12:29280418~29317848:-
OV	cis	rs7131987	0.65	rs11050188	ENSG00000257176.2	RP11-996F15.2	-4.03	7.49e-05	0.0261	-0.32	-0.26	QT interval;	chr12:29320175	chr12:29280418~29317848:-
OV	cis	rs7131987	0.683	rs12366505	ENSG00000257176.2	RP11-996F15.2	-4.03	7.49e-05	0.0261	-0.32	-0.26	QT interval;	chr12:29321177	chr12:29280418~29317848:-
OV	cis	rs7131987	0.65	rs12366527	ENSG00000257176.2	RP11-996F15.2	-4.03	7.49e-05	0.0261	-0.32	-0.26	QT interval;	chr12:29321323	chr12:29280418~29317848:-
OV	cis	rs7131987	0.65	rs7311912	ENSG00000257176.2	RP11-996F15.2	-4.03	7.49e-05	0.0261	-0.32	-0.26	QT interval;	chr12:29322770	chr12:29280418~29317848:-
OV	cis	rs7520050	0.807	rs12025621	ENSG00000281133.1	AL355480.3	4.03	7.5e-05	0.0261	0.29	0.26	Reticulocyte count;Red blood cell count;	chr1:45762719	chr1:45580892~45580996:-
OV	cis	rs7520050	0.778	rs12404197	ENSG00000281133.1	AL355480.3	4.03	7.5e-05	0.0261	0.29	0.26	Reticulocyte count;Red blood cell count;	chr1:45766748	chr1:45580892~45580996:-
OV	cis	rs7520050	0.801	rs6703960	ENSG00000281133.1	AL355480.3	4.03	7.5e-05	0.0261	0.29	0.26	Reticulocyte count;Red blood cell count;	chr1:45767051	chr1:45580892~45580996:-
OV	cis	rs1075265	0.611	rs3770403	ENSG00000233266.1	HMGB1P31	4.03	7.51e-05	0.0262	0.31	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53695688	chr2:54051334~54051760:+
OV	cis	rs10978777	0.726	rs10816473	ENSG00000276883.1	AL137852.1	4.03	7.51e-05	0.0262	0.32	0.26	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr9:107242013	chr9:107292369~107292456:-
OV	cis	rs853679	0.607	rs67662114	ENSG00000220721.1	OR1F12	4.03	7.51e-05	0.0262	0.6	0.26	Depression;	chr6:27964523	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs13216117	ENSG00000220721.1	OR1F12	4.03	7.51e-05	0.0262	0.6	0.26	Depression;	chr6:27970706	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs36101351	ENSG00000220721.1	OR1F12	4.03	7.51e-05	0.0262	0.6	0.26	Depression;	chr6:27975591	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs28360499	ENSG00000220721.1	OR1F12	4.03	7.51e-05	0.0262	0.6	0.26	Depression;	chr6:27977618	chr6:28073316~28074233:+
OV	cis	rs1150668	0.835	rs203869	ENSG00000204709.4	LINC01556	4.03	7.51e-05	0.0262	0.29	0.26	Pubertal anthropometrics;	chr6:28073041	chr6:28943877~28944537:+
OV	cis	rs172166	0.56	rs203878	ENSG00000204709.4	LINC01556	4.03	7.51e-05	0.0262	0.29	0.26	Cardiac Troponin-T levels;	chr6:28081218	chr6:28943877~28944537:+
OV	cis	rs6128386	0.741	rs6100138	ENSG00000268941.2	RP5-907D15.4	4.03	7.51e-05	0.0262	0.36	0.26	Response to cytadine analogues (cytosine arabinoside);	chr20:58618232	chr20:58634772~58635738:+
OV	cis	rs525592	1	rs525592	ENSG00000222339.1	AP000807.2	4.03	7.51e-05	0.0262	0.26	0.26	Bone mineral density;	chr11:68427636	chr11:68505572~68505651:-
OV	cis	rs694739	0.734	rs663743	ENSG00000236935.1	AP003774.1	4.03	7.51e-05	0.0262	0.36	0.26	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64340263	chr11:64325050~64329504:-
OV	cis	rs7646881	0.544	rs7638518	ENSG00000272440.1	RP11-379F4.6	-4.03	7.52e-05	0.0262	-0.39	-0.26	Tetralogy of Fallot;	chr3:158568953	chr3:158695367~158695581:+
OV	cis	rs73201462	1	rs2811527	ENSG00000242551.2	POU5F1P6	-4.03	7.52e-05	0.0262	-0.38	-0.26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128275761	chr3:128674735~128677005:-
OV	cis	rs875971	0.502	rs11769702	ENSG00000237310.1	GS1-124K5.4	4.03	7.52e-05	0.0262	0.3	0.26	Aortic root size;	chr7:66255529	chr7:66493706~66495474:+
OV	cis	rs1933112	1	rs2179500	ENSG00000227777.1	RP4-738P11.3	-4.03	7.52e-05	0.0262	-0.29	-0.26	Blood protein levels;	chr1:168546589	chr1:168542737~168543354:+
OV	cis	rs172166	0.516	rs1225710	ENSG00000204709.4	LINC01556	-4.03	7.52e-05	0.0262	-0.3	-0.26	Cardiac Troponin-T levels;	chr6:28132862	chr6:28943877~28944537:+
OV	cis	rs2492286	0.597	rs2811487	ENSG00000242551.2	POU5F1P6	-4.03	7.53e-05	0.0262	-0.33	-0.26	Eosinophil counts;	chr3:128613036	chr3:128674735~128677005:-
OV	cis	rs4713118	0.869	rs10214440	ENSG00000219392.1	RP1-265C24.5	-4.03	7.53e-05	0.0262	-0.3	-0.26	Parkinson's disease;	chr6:27734661	chr6:28115628~28116551:+
OV	cis	rs709400	0.628	rs6575984	ENSG00000244691.1	RPL10AP1	-4.03	7.54e-05	0.0262	-0.26	-0.26	Body mass index;	chr14:103410117	chr14:103412119~103412761:-
OV	cis	rs709400	0.628	rs7154246	ENSG00000244691.1	RPL10AP1	-4.03	7.54e-05	0.0262	-0.26	-0.26	Body mass index;	chr14:103410457	chr14:103412119~103412761:-
OV	cis	rs8114671	0.967	rs2069948	ENSG00000269202.1	RP4-614O4.12	-4.03	7.54e-05	0.0262	-0.26	-0.26	Height;	chr20:35174686	chr20:35201747~35203288:-
OV	cis	rs8114671	0.935	rs945960	ENSG00000269202.1	RP4-614O4.12	-4.03	7.54e-05	0.0262	-0.26	-0.26	Height;	chr20:35175051	chr20:35201747~35203288:-
OV	cis	rs8114671	0.967	rs2069952	ENSG00000269202.1	RP4-614O4.12	-4.03	7.54e-05	0.0262	-0.26	-0.26	Height;	chr20:35176148	chr20:35201747~35203288:-
OV	cis	rs8114671	0.967	rs9574	ENSG00000269202.1	RP4-614O4.12	-4.03	7.54e-05	0.0262	-0.26	-0.26	Height;	chr20:35176829	chr20:35201747~35203288:-
OV	cis	rs8114671	0.967	rs1415773	ENSG00000269202.1	RP4-614O4.12	-4.03	7.54e-05	0.0262	-0.26	-0.26	Height;	chr20:35177782	chr20:35201747~35203288:-
OV	cis	rs8114671	0.935	rs6060282	ENSG00000269202.1	RP4-614O4.12	-4.03	7.54e-05	0.0262	-0.26	-0.26	Height;	chr20:35179263	chr20:35201747~35203288:-
OV	cis	rs8114671	0.967	rs2065978	ENSG00000269202.1	RP4-614O4.12	-4.03	7.54e-05	0.0262	-0.26	-0.26	Height;	chr20:35179488	chr20:35201747~35203288:-
OV	cis	rs8114671	0.967	rs2065979	ENSG00000269202.1	RP4-614O4.12	-4.03	7.54e-05	0.0262	-0.26	-0.26	Height;	chr20:35179887	chr20:35201747~35203288:-
OV	cis	rs7116641	0.524	rs10838184	ENSG00000246250.2	RP11-613D13.5	4.03	7.54e-05	0.0263	0.34	0.26	Coronary artery disease;	chr11:43848310	chr11:43829709~43880726:-
OV	cis	rs6921919	0.583	rs4254981	ENSG00000204709.4	LINC01556	4.03	7.54e-05	0.0263	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28403625	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs6928771	ENSG00000204709.4	LINC01556	4.03	7.54e-05	0.0263	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28407432	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs6928773	ENSG00000204709.4	LINC01556	4.03	7.54e-05	0.0263	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28407433	chr6:28943877~28944537:+
OV	cis	rs6921919	0.525	rs6929825	ENSG00000204709.4	LINC01556	4.03	7.54e-05	0.0263	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28411182	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs35599905	ENSG00000204709.4	LINC01556	4.03	7.54e-05	0.0263	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28411886	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs1124131	ENSG00000204709.4	LINC01556	4.03	7.54e-05	0.0263	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28412471	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs6899389	ENSG00000204709.4	LINC01556	4.03	7.54e-05	0.0263	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28413363	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs6922374	ENSG00000204709.4	LINC01556	4.03	7.54e-05	0.0263	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28413495	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs6899603	ENSG00000204709.4	LINC01556	4.03	7.54e-05	0.0263	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28413528	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs6922429	ENSG00000204709.4	LINC01556	4.03	7.54e-05	0.0263	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28413568	chr6:28943877~28944537:+
OV	cis	rs2999052	0.865	rs10934853	ENSG00000277250.1	Metazoa_SRP	-4.03	7.54e-05	0.0263	-0.32	-0.26	Hypospadias;	chr3:128319530	chr3:128673681~128674021:-
OV	cis	rs6657613	0.68	rs6690919	ENSG00000186715.9	MST1L	-4.03	7.55e-05	0.0263	-0.28	-0.26	Hip circumference adjusted for BMI;	chr1:17046710	chr1:16754910~16770237:-
OV	cis	rs6657613	0.621	rs9435749	ENSG00000186715.9	MST1L	-4.03	7.55e-05	0.0263	-0.28	-0.26	Hip circumference adjusted for BMI;	chr1:17047464	chr1:16754910~16770237:-
OV	cis	rs12517906	0.848	rs12719877	ENSG00000242979.1	RPS15AP18	-4.03	7.55e-05	0.0263	-0.37	-0.26	Weight;Body mass index;	chr5:180744030	chr5:179933805~179934196:-
OV	cis	rs1584120	0.57	rs10842122	ENSG00000274885.1	RP11-268P4.6	4.03	7.55e-05	0.0263	0.29	0.26	Pelvic organ prolapse (moderate/severe);	chr12:23112929	chr12:22638464~22638943:+
OV	cis	rs4722166	0.63	rs6461667	ENSG00000179428.2	AC073072.5	-4.03	7.56e-05	0.0263	-0.33	-0.26	Lung cancer;	chr7:22757124	chr7:22725395~22727620:-
OV	cis	rs950169	0.512	rs4374136	ENSG00000256278.1	RP11-182J1.5	4.03	7.57e-05	0.0263	0.35	0.26	Schizophrenia;	chr15:83976255	chr15:84611689~84614969:-
OV	cis	rs2243480	0.901	rs313808	ENSG00000226824.5	RP4-756H11.3	-4.03	7.57e-05	0.0263	-0.42	-0.26	Diabetic kidney disease;	chr7:66034886	chr7:66654538~66669855:+
OV	cis	rs4950322	0.857	rs72693002	ENSG00000278811.3	LINC00624	4.03	7.58e-05	0.0263	0.34	0.26	Protein quantitative trait loci;	chr1:147357593	chr1:147258885~147517875:-
OV	cis	rs4950322	0.857	rs72694703	ENSG00000278811.3	LINC00624	4.03	7.58e-05	0.0263	0.34	0.26	Protein quantitative trait loci;	chr1:147358427	chr1:147258885~147517875:-
OV	cis	rs10129255	0.536	rs6576201	ENSG00000223648.3	IGHV3-64	-4.03	7.59e-05	0.0264	-0.25	-0.26	Kawasaki disease;	chr14:106683696	chr14:106643132~106658258:-
OV	cis	rs9880211	0.718	rs28631273	ENSG00000261758.1	RP11-102M11.2	-4.03	7.59e-05	0.0264	-0.31	-0.26	Height;Body mass index;	chr3:136215869	chr3:136752630~136755780:+
OV	cis	rs11105298	0.891	rs10777163	ENSG00000257194.2	RP11-567C2.1	-4.03	7.6e-05	0.0264	-0.41	-0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89436943	chr12:90107739~90112779:+
OV	cis	rs6128907	0.615	rs116490114	ENSG00000224635.1	RP4-564F22.5	4.03	7.6e-05	0.0264	0.38	0.26	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38779527	chr20:38406011~38416797:-
OV	cis	rs73186030	0.687	rs55636509	ENSG00000272758.4	RP11-299J3.8	4.03	7.61e-05	0.0264	0.31	0.26	Serum parathyroid hormone levels;	chr3:122351816	chr3:122416207~122443180:+
OV	cis	rs2070488	1	rs1841777	ENSG00000229589.1	ACVR2B-AS1	4.03	7.61e-05	0.0265	0.29	0.26	Electrocardiographic conduction measures;	chr3:38443328	chr3:38451027~38454820:-
OV	cis	rs12073359	1	rs1382573	ENSG00000223945.2	RP11-458I7.1	-4.03	7.63e-05	0.0265	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150160129	chr1:150053864~150055034:+
OV	cis	rs6657613	0.68	rs7545499	ENSG00000186715.9	MST1L	4.03	7.63e-05	0.0265	0.28	0.26	Hip circumference adjusted for BMI;	chr1:17048193	chr1:16754910~16770237:-
OV	cis	rs62296447	0.514	rs4697123	ENSG00000241612.1	RP13-585F24.1	4.03	7.63e-05	0.0265	0.27	0.26	Schizophrenia;	chr4:19440656	chr4:19813749~19814231:+
OV	cis	rs7587476	0.906	rs3768713	ENSG00000229267.2	AC072062.1	-4.03	7.63e-05	0.0265	-0.35	-0.26	Neuroblastoma;	chr2:214772781	chr2:214810229~214963274:+
OV	cis	rs7789940	1	rs17149161	ENSG00000230305.2	AC004980.9	4.03	7.64e-05	0.0265	0.36	0.26	Multiple sclerosis;	chr7:76348912	chr7:76524515~76532692:+
OV	cis	rs9925964	0.933	rs10871454	ENSG00000279196.1	RP11-1072A3.3	-4.03	7.65e-05	0.0265	-0.28	-0.26	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31036758	chr16:30984630~30988270:-
OV	cis	rs9925964	0.933	rs12448321	ENSG00000279196.1	RP11-1072A3.3	-4.03	7.65e-05	0.0265	-0.28	-0.26	BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);Body mass index;	chr16:31036959	chr16:30984630~30988270:-
OV	cis	rs7927771	0.524	rs7118747	ENSG00000280615.1	Y_RNA	-4.03	7.65e-05	0.0266	-0.27	-0.26	Subjective well-being;	chr11:47867993	chr11:47614898~47614994:-
OV	cis	rs9309473	0.528	rs79799178	ENSG00000163016.8	ALMS1P	4.03	7.66e-05	0.0266	0.34	0.26	Metabolite levels;	chr2:73564108	chr2:73644919~73685576:+
OV	cis	rs1568889	1	rs1568889	ENSG00000255322.1	RP11-22P4.1	4.03	7.66e-05	0.0266	0.39	0.26	Bipolar disorder;	chr11:27987916	chr11:28352107~28527041:+
OV	cis	rs897984	0.609	rs35468353	ENSG00000232748.3	RP11-196G11.6	-4.03	7.67e-05	0.0266	-0.27	-0.26	Dementia with Lewy bodies;	chr16:31045112	chr16:31056460~31062803:+
OV	cis	rs11951515	0.738	rs11951584	ENSG00000278487.1	RP11-447H19.4	-4.03	7.67e-05	0.0266	-0.3	-0.26	Metabolite levels  (X-11787);	chr5:43348904	chr5:43143362~43143514:-
OV	cis	rs11951515	0.738	rs6863246	ENSG00000278487.1	RP11-447H19.4	-4.03	7.67e-05	0.0266	-0.3	-0.26	Metabolite levels  (X-11787);	chr5:43349398	chr5:43143362~43143514:-
OV	cis	rs853356	0.532	rs853387	ENSG00000272209.1	RP3-500L14.2	4.03	7.68e-05	0.0266	0.33	0.26	Height;	chr6:14187817	chr6:13825432~13826574:+
OV	cis	rs1559040	0.86	rs72800775	ENSG00000272156.1	RP11-477N3.1	-4.03	7.68e-05	0.0266	-0.48	-0.26	Sudden cardiac arrest;	chr2:54152457	chr2:54082554~54085066:+
OV	cis	rs992157	0.798	rs12053514	ENSG00000237281.1	CATIP-AS2	4.03	7.68e-05	0.0266	0.31	0.26	Colorectal cancer;	chr2:218303242	chr2:218326889~218357966:-
OV	cis	rs7927592	0.956	rs11228258	ENSG00000222339.1	AP000807.2	-4.03	7.68e-05	0.0266	-0.28	-0.26	Total body bone mineral density;	chr11:68486860	chr11:68505572~68505651:-
OV	cis	rs1862618	0.853	rs832568	ENSG00000271828.1	CTD-2310F14.1	4.03	7.68e-05	0.0266	0.41	0.26	Initial pursuit acceleration;	chr5:56857949	chr5:56927874~56929573:+
OV	cis	rs1862618	0.853	rs832569	ENSG00000271828.1	CTD-2310F14.1	4.03	7.68e-05	0.0266	0.41	0.26	Initial pursuit acceleration;	chr5:56858757	chr5:56927874~56929573:+
OV	cis	rs6661961	0.714	rs12069640	ENSG00000237975.5	FLG-AS1	-4.03	7.68e-05	0.0266	-0.33	-0.26	Atopic dermatitis;	chr1:152444300	chr1:152168125~152445456:+
OV	cis	rs1538970	0.962	rs2153608	ENSG00000280836.1	AL355480.1	4.03	7.69e-05	0.0267	0.36	0.26	Platelet count;	chr1:45348269	chr1:45581219~45581321:-
OV	cis	rs2336384	1	rs6672267	ENSG00000229484.1	RP5-888M10.2	-4.03	7.69e-05	0.0267	-0.28	-0.26	Platelet count;	chr1:11994854	chr1:12527724~12528420:+
OV	cis	rs11096990	0.855	rs2711990	ENSG00000249207.1	RP11-360F5.1	4.03	7.7e-05	0.0267	0.3	0.26	Cognitive function;	chr4:39150116	chr4:39112677~39126818:-
OV	cis	rs6951245	0.678	rs28600085	ENSG00000229043.2	AC091729.9	-4.03	7.7e-05	0.0267	-0.42	-0.26	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1130000	chr7:1160374~1165267:+
OV	cis	rs62184315	0.629	rs5743072	ENSG00000253559.1	OSGEPL1-AS1	-4.03	7.71e-05	0.0267	-0.32	-0.26	Alcohol dependence (age at onset);	chr2:189832198	chr2:189762704~189765556:+
OV	cis	rs9660180	0.934	rs12729990	ENSG00000215914.4	MMP23A	-4.03	7.71e-05	0.0267	-0.31	-0.26	Body mass index;	chr1:1880596	chr1:1699942~1701782:+
OV	cis	rs7824557	0.564	rs13260727	ENSG00000255495.1	AC145124.2	4.03	7.71e-05	0.0267	0.29	0.26	Retinal vascular caliber;	chr8:11375351	chr8:12194467~12196280:+
OV	cis	rs758324	0.606	rs247276	ENSG00000202533.1	Y_RNA	-4.03	7.71e-05	0.0267	-0.24	-0.26	Alzheimer's disease in APOE e4- carriers;	chr5:132133311	chr5:132468147~132468257:+
OV	cis	rs10924970	0.934	rs2891026	ENSG00000236863.2	RPL23AP23	4.03	7.72e-05	0.0268	0.26	0.26	Asthma;	chr1:235266592	chr1:235295865~235296335:+
OV	cis	rs6921919	0.583	rs7740351	ENSG00000204709.4	LINC01556	4.03	7.72e-05	0.0268	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28431635	chr6:28943877~28944537:+
OV	cis	rs7246657	0.943	rs10415937	ENSG00000226686.6	LINC01535	-4.03	7.72e-05	0.0268	-0.38	-0.26	Coronary artery calcification;	chr19:37339162	chr19:37251912~37265535:+
OV	cis	rs745109	0.504	rs75610186	ENSG00000273080.1	RP11-301O19.1	4.03	7.72e-05	0.0268	0.34	0.26	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86372933	chr2:86195590~86196049:+
OV	cis	rs853679	0.505	rs200992	ENSG00000280107.1	AL022393.9	-4.03	7.73e-05	0.0268	-0.44	-0.26	Depression;	chr6:27846899	chr6:28170845~28172521:+
OV	cis	rs2835345	0.507	rs7280011	ENSG00000230479.1	AP000695.6	4.03	7.73e-05	0.0268	0.33	0.26	Pulmonary function;	chr21:36455256	chr21:36430360~36481070:+
OV	cis	rs62244186	0.659	rs9873072	ENSG00000214820.3	MPRIPP1	4.03	7.73e-05	0.0268	0.23	0.26	Depressive symptoms;	chr3:44475004	chr3:44579938~44581026:-
OV	cis	rs62458065	1	rs1450868	ENSG00000226468.2	AC018641.7	4.03	7.74e-05	0.0268	0.36	0.26	Metabolite levels (HVA/MHPG ratio);	chr7:32424054	chr7:32456963~32457758:-
OV	cis	rs10043228	1	rs12520568	ENSG00000248445.4	SEMA6A-AS1	-4.03	7.74e-05	0.0268	-0.36	-0.26	Asthma or chronic obstructive pulmonary disease;	chr5:116285808	chr5:116447547~116508276:+
OV	cis	rs4845570	1	rs3790514	ENSG00000238711.1	RNY4P25	-4.03	7.75e-05	0.0268	-0.35	-0.26	Coronary artery disease;	chr1:151771692	chr1:151439000~151439095:+
OV	cis	rs7927592	0.513	rs630225	ENSG00000222339.1	AP000807.2	4.03	7.75e-05	0.0268	0.26	0.26	Total body bone mineral density;	chr11:68427143	chr11:68505572~68505651:-
OV	cis	rs8054556	0.787	rs12921753	ENSG00000261367.1	RP11-455F5.4	-4.03	7.75e-05	0.0268	-0.31	-0.26	Autism spectrum disorder or schizophrenia;	chr16:30007399	chr16:30107675~30110541:+
OV	cis	rs5742933	1	rs6717922	ENSG00000253559.1	OSGEPL1-AS1	-4.03	7.75e-05	0.0269	-0.29	-0.26	Ferritin levels;	chr2:189721497	chr2:189762704~189765556:+
OV	cis	rs5742933	1	rs4667306	ENSG00000253559.1	OSGEPL1-AS1	-4.03	7.75e-05	0.0269	-0.29	-0.26	Ferritin levels;	chr2:189725630	chr2:189762704~189765556:+
OV	cis	rs5742933	1	rs16831925	ENSG00000253559.1	OSGEPL1-AS1	-4.03	7.75e-05	0.0269	-0.29	-0.26	Ferritin levels;	chr2:189731178	chr2:189762704~189765556:+
OV	cis	rs7520050	0.807	rs72688483	ENSG00000281133.1	AL355480.3	-4.03	7.75e-05	0.0269	-0.29	-0.26	Reticulocyte count;Red blood cell count;	chr1:45683537	chr1:45580892~45580996:-
OV	cis	rs875971	0.798	rs57739047	ENSG00000237310.1	GS1-124K5.4	4.03	7.76e-05	0.0269	0.26	0.26	Aortic root size;	chr7:66507579	chr7:66493706~66495474:+
OV	cis	rs875971	0.83	rs6950137	ENSG00000237310.1	GS1-124K5.4	4.03	7.76e-05	0.0269	0.26	0.26	Aortic root size;	chr7:66511623	chr7:66493706~66495474:+
OV	cis	rs1075265	0.572	rs2193682	ENSG00000233266.1	HMGB1P31	4.03	7.76e-05	0.0269	0.3	0.26	Chronotype;Morning vs. evening chronotype;	chr2:53695119	chr2:54051334~54051760:+
OV	cis	rs428445	0.966	rs6064397	ENSG00000228995.1	MTND1P9	4.02	7.77e-05	0.0269	0.27	0.26	Refractive astigmatism;	chr20:56465552	chr20:57357426~57358369:-
OV	cis	rs11700536	1	rs2839636	ENSG00000236663.1	AP001631.9	4.02	7.77e-05	0.0269	0.29	0.26	Interleukin-18 levels;	chr21:43139085	chr21:43140523~43141092:-
OV	cis	rs7395581	0.918	rs3816725	ENSG00000271350.1	CTD-2384B9.1	4.02	7.78e-05	0.0269	0.3	0.26	HDL cholesterol;	chr11:47284118	chr11:47041027~47041945:-
OV	cis	rs7520050	0.966	rs11579634	ENSG00000280836.1	AL355480.1	-4.02	7.78e-05	0.0269	-0.32	-0.26	Reticulocyte count;Red blood cell count;	chr1:46000719	chr1:45581219~45581321:-
OV	cis	rs7829975	0.617	rs4841071	ENSG00000254340.1	RP11-10A14.3	4.02	7.78e-05	0.0269	0.3	0.26	Mood instability;	chr8:8933634	chr8:9141424~9145435:+
OV	cis	rs9309473	0.606	rs77962988	ENSG00000163016.8	ALMS1P	4.02	7.79e-05	0.0269	0.35	0.26	Metabolite levels;	chr2:73658963	chr2:73644919~73685576:+
OV	cis	rs7626444	1	rs7626444	ENSG00000272359.1	U4	-4.02	7.79e-05	0.0269	-0.27	-0.26	Monocyte count;	chr3:196778031	chr3:196747192~196747324:-
OV	cis	rs1823913	0.599	rs17346475	ENSG00000227542.1	AC092614.2	-4.02	7.79e-05	0.0269	-0.28	-0.26	Obesity-related traits;	chr2:191288488	chr2:191229165~191246172:-
OV	cis	rs4713118	0.869	rs6902689	ENSG00000219392.1	RP1-265C24.5	-4.02	7.79e-05	0.027	-0.3	-0.26	Parkinson's disease;	chr6:27741662	chr6:28115628~28116551:+
OV	cis	rs4713118	0.869	rs9468214	ENSG00000219392.1	RP1-265C24.5	-4.02	7.79e-05	0.027	-0.3	-0.26	Parkinson's disease;	chr6:27745520	chr6:28115628~28116551:+
OV	cis	rs1823913	0.599	rs35892286	ENSG00000227542.1	AC092614.2	4.02	7.79e-05	0.027	0.28	0.26	Obesity-related traits;	chr2:191269010	chr2:191229165~191246172:-
OV	cis	rs6657613	0.649	rs9435746	ENSG00000186715.9	MST1L	-4.02	7.79e-05	0.027	-0.28	-0.26	Hip circumference adjusted for BMI;	chr1:17045622	chr1:16754910~16770237:-
OV	cis	rs6657613	0.68	rs9435747	ENSG00000186715.9	MST1L	-4.02	7.79e-05	0.027	-0.28	-0.26	Hip circumference adjusted for BMI;	chr1:17045972	chr1:16754910~16770237:-
OV	cis	rs6657613	0.68	rs11582579	ENSG00000186715.9	MST1L	-4.02	7.79e-05	0.027	-0.28	-0.26	Hip circumference adjusted for BMI;	chr1:17046016	chr1:16754910~16770237:-
OV	cis	rs9880211	0.562	rs13068210	ENSG00000261758.1	RP11-102M11.2	-4.02	7.79e-05	0.027	-0.32	-0.26	Height;Body mass index;	chr3:136186704	chr3:136752630~136755780:+
OV	cis	rs6844153	1	rs74601981	ENSG00000240005.4	RP11-293A21.1	-4.02	7.8e-05	0.027	-0.39	-0.26	Plasma omega-3 polyunsaturated fatty acid levels (docosapentaenoic acid);	chr4:26915639	chr4:26859806~26860599:-
OV	cis	rs62458065	1	rs6462363	ENSG00000226468.2	AC018641.7	4.02	7.8e-05	0.027	0.36	0.26	Metabolite levels (HVA/MHPG ratio);	chr7:32425147	chr7:32456963~32457758:-
OV	cis	rs62458065	1	rs6462364	ENSG00000226468.2	AC018641.7	4.02	7.8e-05	0.027	0.36	0.26	Metabolite levels (HVA/MHPG ratio);	chr7:32425164	chr7:32456963~32457758:-
OV	cis	rs941207	0.507	rs73337030	ENSG00000241217.3	RN7SL809P	-4.02	7.81e-05	0.027	-0.25	-0.26	Platelet count;	chr12:56652410	chr12:56670450~56670746:-
OV	cis	rs4563143	0.704	rs16961809	ENSG00000260725.1	AC005307.1	-4.02	7.81e-05	0.027	-0.37	-0.26	Methadone dose in opioid dependence;	chr19:28735392	chr19:28418483~28429490:-
OV	cis	rs11951515	0.738	rs17244818	ENSG00000278487.1	RP11-447H19.4	4.02	7.82e-05	0.027	0.3	0.26	Metabolite levels  (X-11787);	chr5:43339433	chr5:43143362~43143514:-
OV	cis	rs11105298	0.891	rs11105299	ENSG00000257194.2	RP11-567C2.1	-4.02	7.83e-05	0.0271	-0.39	-0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89484166	chr12:90107739~90112779:+
OV	cis	rs950173	1	rs950173	ENSG00000228389.1	AC068039.4	4.02	7.83e-05	0.0271	0.44	0.26	Hippocampal volume;	chr2:171713909	chr2:171773482~171775844:+
OV	cis	rs10924970	0.87	rs12095886	ENSG00000236863.2	RPL23AP23	4.02	7.83e-05	0.0271	0.26	0.26	Asthma;	chr1:235268934	chr1:235295865~235296335:+
OV	cis	rs1511299	0.546	rs2861421	ENSG00000249417.1	RP11-438D8.2	-4.02	7.83e-05	0.0271	-0.39	-0.26	Glomerular filtration rate;	chr3:141971598	chr3:141267353~141367137:-
OV	cis	rs6545883	0.718	rs6715259	ENSG00000273302.1	RP11-493E12.2	4.02	7.84e-05	0.0271	0.21	0.26	Tuberculosis;	chr2:61624710	chr2:61199979~61200769:+
OV	cis	rs9992667	0.91	rs4535339	ENSG00000231160.8	KLF3-AS1	4.02	7.84e-05	0.0271	0.31	0.26	Eosinophil percentage of granulocytes;	chr4:38687607	chr4:38612701~38664883:-
OV	cis	rs1979679	0.879	rs1002863	ENSG00000278733.1	RP11-425D17.1	-4.02	7.84e-05	0.0271	-0.31	-0.26	Ossification of the posterior longitudinal ligament of the spine;	chr12:28500768	chr12:28185625~28186190:-
OV	cis	rs9880211	0.718	rs35320690	ENSG00000261758.1	RP11-102M11.2	4.02	7.84e-05	0.0271	0.32	0.26	Height;Body mass index;	chr3:136213652	chr3:136752630~136755780:+
OV	cis	rs804280	0.509	rs13276433	ENSG00000270154.1	RP11-419I17.1	4.02	7.84e-05	0.0271	0.25	0.26	Myopia (pathological);	chr8:11925527	chr8:12476462~12477122:+
OV	cis	rs875971	0.545	rs10950029	ENSG00000273024.4	INTS4P2	-4.02	7.84e-05	0.0271	-0.3	-0.26	Aortic root size;	chr7:66169334	chr7:65647864~65715661:+
OV	cis	rs12681366	0.881	rs3019155	ENSG00000253704.1	RP11-267M23.4	4.02	7.85e-05	0.0271	0.37	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94405359	chr8:94553722~94569745:+
OV	cis	rs62229266	0.804	rs2835231	ENSG00000231106.2	LINC01436	4.02	7.85e-05	0.0271	0.32	0.26	Mitral valve prolapse;	chr21:36018300	chr21:36005338~36007838:+
OV	cis	rs7395581	1	rs830085	ENSG00000271350.1	CTD-2384B9.1	-4.02	7.85e-05	0.0271	-0.31	-0.26	HDL cholesterol;	chr11:47229648	chr11:47041027~47041945:-
OV	cis	rs7246657	0.943	rs10414904	ENSG00000226686.6	LINC01535	-4.02	7.85e-05	0.0271	-0.38	-0.26	Coronary artery calcification;	chr19:37339186	chr19:37251912~37265535:+
OV	cis	rs7246657	0.943	rs10417844	ENSG00000226686.6	LINC01535	-4.02	7.85e-05	0.0271	-0.38	-0.26	Coronary artery calcification;	chr19:37346685	chr19:37251912~37265535:+
OV	cis	rs7246657	0.943	rs1373991	ENSG00000226686.6	LINC01535	-4.02	7.85e-05	0.0271	-0.38	-0.26	Coronary artery calcification;	chr19:37348009	chr19:37251912~37265535:+
OV	cis	rs7246657	0.943	rs10405407	ENSG00000226686.6	LINC01535	-4.02	7.85e-05	0.0271	-0.38	-0.26	Coronary artery calcification;	chr19:37348262	chr19:37251912~37265535:+
OV	cis	rs7246657	0.943	rs12709813	ENSG00000226686.6	LINC01535	-4.02	7.85e-05	0.0271	-0.38	-0.26	Coronary artery calcification;	chr19:37354081	chr19:37251912~37265535:+
OV	cis	rs7246657	0.943	rs13345116	ENSG00000226686.6	LINC01535	-4.02	7.85e-05	0.0271	-0.38	-0.26	Coronary artery calcification;	chr19:37356196	chr19:37251912~37265535:+
OV	cis	rs7246657	0.765	rs7247259	ENSG00000226686.6	LINC01535	-4.02	7.85e-05	0.0271	-0.38	-0.26	Coronary artery calcification;	chr19:37360188	chr19:37251912~37265535:+
OV	cis	rs1823913	1	rs4853562	ENSG00000227542.1	AC092614.2	-4.02	7.85e-05	0.0271	-0.3	-0.26	Obesity-related traits;	chr2:191253696	chr2:191229165~191246172:-
OV	cis	rs1823913	1	rs4853461	ENSG00000227542.1	AC092614.2	-4.02	7.85e-05	0.0271	-0.3	-0.26	Obesity-related traits;	chr2:191254572	chr2:191229165~191246172:-
OV	cis	rs1823913	1	rs4853563	ENSG00000227542.1	AC092614.2	-4.02	7.85e-05	0.0271	-0.3	-0.26	Obesity-related traits;	chr2:191254808	chr2:191229165~191246172:-
OV	cis	rs1823913	0.895	rs10931491	ENSG00000227542.1	AC092614.2	-4.02	7.85e-05	0.0271	-0.3	-0.26	Obesity-related traits;	chr2:191256087	chr2:191229165~191246172:-
OV	cis	rs1823913	1	rs11681777	ENSG00000227542.1	AC092614.2	-4.02	7.85e-05	0.0271	-0.3	-0.26	Obesity-related traits;	chr2:191256741	chr2:191229165~191246172:-
OV	cis	rs1823913	1	rs1840377	ENSG00000227542.1	AC092614.2	-4.02	7.85e-05	0.0271	-0.3	-0.26	Obesity-related traits;	chr2:191257992	chr2:191229165~191246172:-
OV	cis	rs1823913	1	rs4853564	ENSG00000227542.1	AC092614.2	-4.02	7.85e-05	0.0271	-0.3	-0.26	Obesity-related traits;	chr2:191258939	chr2:191229165~191246172:-
OV	cis	rs1823913	1	rs4853565	ENSG00000227542.1	AC092614.2	-4.02	7.85e-05	0.0271	-0.3	-0.26	Obesity-related traits;	chr2:191259020	chr2:191229165~191246172:-
OV	cis	rs1823913	1	rs4853462	ENSG00000227542.1	AC092614.2	-4.02	7.85e-05	0.0271	-0.3	-0.26	Obesity-related traits;	chr2:191259078	chr2:191229165~191246172:-
OV	cis	rs11671005	0.572	rs11669127	ENSG00000269600.1	AC016629.3	4.02	7.85e-05	0.0271	0.38	0.26	Mean platelet volume;	chr19:58492463	chr19:58593896~58599355:-
OV	cis	rs12681366	0.96	rs2930961	ENSG00000253704.1	RP11-267M23.4	4.02	7.85e-05	0.0271	0.32	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94431578	chr8:94553722~94569745:+
OV	cis	rs1075265	0.756	rs6751105	ENSG00000233266.1	HMGB1P31	4.02	7.85e-05	0.0271	0.31	0.26	Chronotype;Morning vs. evening chronotype;	chr2:54129214	chr2:54051334~54051760:+
OV	cis	rs11157436	0.56	rs988997	ENSG00000211812.1	TRAV26-2	-4.02	7.86e-05	0.0271	-0.26	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22225937	chr14:22202583~22203368:+
OV	cis	rs11157436	0.56	rs2242543	ENSG00000211812.1	TRAV26-2	-4.02	7.86e-05	0.0271	-0.26	-0.26	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22226436	chr14:22202583~22203368:+
OV	cis	rs944801	0.608	rs10757266	ENSG00000234840.1	LINC01239	-4.02	7.86e-05	0.0272	-0.29	-0.26	Type 2 diabetes;	chr9:22049556	chr9:22646200~22824213:+
OV	cis	rs7520050	0.743	rs61789988	ENSG00000280836.1	AL355480.1	4.02	7.86e-05	0.0272	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45619570	chr1:45581219~45581321:-
OV	cis	rs7617773	0.676	rs13060020	ENSG00000228638.1	FCF1P2	-4.02	7.87e-05	0.0272	-0.33	-0.26	Coronary artery disease;	chr3:48331156	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs11710257	ENSG00000228638.1	FCF1P2	-4.02	7.87e-05	0.0272	-0.33	-0.26	Coronary artery disease;	chr3:48331724	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs71323395	ENSG00000228638.1	FCF1P2	-4.02	7.87e-05	0.0272	-0.33	-0.26	Coronary artery disease;	chr3:48332587	chr3:48290793~48291375:-
OV	cis	rs7617773	0.743	rs71323397	ENSG00000228638.1	FCF1P2	-4.02	7.87e-05	0.0272	-0.33	-0.26	Coronary artery disease;	chr3:48333384	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs13066044	ENSG00000228638.1	FCF1P2	-4.02	7.87e-05	0.0272	-0.33	-0.26	Coronary artery disease;	chr3:48335786	chr3:48290793~48291375:-
OV	cis	rs7617773	0.778	rs11715776	ENSG00000228638.1	FCF1P2	-4.02	7.87e-05	0.0272	-0.33	-0.26	Coronary artery disease;	chr3:48336121	chr3:48290793~48291375:-
OV	cis	rs7617773	0.778	rs11707997	ENSG00000228638.1	FCF1P2	-4.02	7.87e-05	0.0272	-0.33	-0.26	Coronary artery disease;	chr3:48336385	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs11716848	ENSG00000228638.1	FCF1P2	-4.02	7.87e-05	0.0272	-0.33	-0.26	Coronary artery disease;	chr3:48337010	chr3:48290793~48291375:-
OV	cis	rs57221529	0.766	rs12521051	ENSG00000271781.1	CTD-2589H19.6	4.02	7.87e-05	0.0272	0.42	0.26	Lung disease severity in cystic fibrosis;	chr5:560325	chr5:675826~676616:+
OV	cis	rs992969	0.506	rs4637906	ENSG00000231967.1	RP11-12D24.6	-4.02	7.87e-05	0.0272	-0.29	-0.26	Asthma;	chr9:6160049	chr9:5356312~5356525:-
OV	cis	rs4713118	0.513	rs149975	ENSG00000280107.1	AL022393.9	-4.02	7.87e-05	0.0272	-0.33	-0.26	Parkinson's disease;	chr6:28018562	chr6:28170845~28172521:+
OV	cis	rs10740039	0.81	rs1372709	ENSG00000254271.1	RP11-131N11.4	4.02	7.88e-05	0.0272	0.34	0.26	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60621666	chr10:60734342~60741828:+
OV	cis	rs4950322	0.857	rs55790545	ENSG00000278811.3	LINC00624	4.02	7.88e-05	0.0272	0.34	0.26	Protein quantitative trait loci;	chr1:147366649	chr1:147258885~147517875:-
OV	cis	rs4950322	0.857	rs7522219	ENSG00000278811.3	LINC00624	4.02	7.88e-05	0.0272	0.34	0.26	Protein quantitative trait loci;	chr1:147366904	chr1:147258885~147517875:-
OV	cis	rs295490	1	rs295490	ENSG00000272656.1	RP11-219D15.3	-4.02	7.89e-05	0.0272	-0.36	-0.26	PR interval in Tripanosoma cruzi seropositivity;	chr3:139522529	chr3:139349024~139349371:-
OV	cis	rs8114671	0.933	rs2103971	ENSG00000269202.1	RP4-614O4.12	4.02	7.9e-05	0.0273	0.26	0.26	Height;	chr20:35198453	chr20:35201747~35203288:-
OV	cis	rs7617773	0.539	rs13094496	ENSG00000228638.1	FCF1P2	-4.02	7.9e-05	0.0273	-0.32	-0.26	Coronary artery disease;	chr3:48345560	chr3:48290793~48291375:-
OV	cis	rs7267979	1	rs6050559	ENSG00000274973.1	RP13-401N8.7	-4.02	7.9e-05	0.0273	-0.29	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25349279	chr20:25845497~25845862:+
OV	cis	rs4639966	0.569	rs603486	ENSG00000255422.1	AP002954.4	-4.02	7.9e-05	0.0273	-0.28	-0.26	Systemic lupus erythematosus;	chr11:118716638	chr11:118704607~118750263:+
OV	cis	rs10754283	0.84	rs1229992	ENSG00000231613.1	RP5-943J3.1	4.02	7.9e-05	0.0273	0.27	0.26	Amyotrophic lateral sclerosis (sporadic);	chr1:89628669	chr1:89788914~89790492:+
OV	cis	rs10754283	0.84	rs990040	ENSG00000231613.1	RP5-943J3.1	4.02	7.9e-05	0.0273	0.27	0.26	Amyotrophic lateral sclerosis (sporadic);	chr1:89628800	chr1:89788914~89790492:+
OV	cis	rs6772849	0.93	rs4857912	ENSG00000277250.1	Metazoa_SRP	-4.02	7.91e-05	0.0273	-0.31	-0.26	Monocyte percentage of white cells;Monocyte count;	chr3:128610381	chr3:128673681~128674021:-
OV	cis	rs6723108	0.627	rs1348790	ENSG00000224043.6	CCNT2-AS1	-4.02	7.91e-05	0.0273	-0.3	-0.26	Type 2 diabetes;	chr2:134882405	chr2:134735464~134918710:-
OV	cis	rs6723108	0.627	rs4954193	ENSG00000224043.6	CCNT2-AS1	-4.02	7.91e-05	0.0273	-0.3	-0.26	Type 2 diabetes;	chr2:134884610	chr2:134735464~134918710:-
OV	cis	rs3934047	0.682	rs12915429	ENSG00000252690.3	SCARNA15	-4.02	7.92e-05	0.0273	-0.21	-0.26	Response to paliperidone in schizophrenia (positive Marder score);	chr15:81813559	chr15:82752884~82757208:+
OV	cis	rs7121800	0.63	rs551935	ENSG00000254532.1	RP11-624D11.2	4.02	7.92e-05	0.0273	0.29	0.26	Pit-and-Fissure caries;	chr11:30479285	chr11:30044058~30084343:-
OV	cis	rs2070488	0.775	rs6780349	ENSG00000229589.1	ACVR2B-AS1	-4.02	7.92e-05	0.0273	-0.29	-0.26	Electrocardiographic conduction measures;	chr3:38513687	chr3:38451027~38454820:-
OV	cis	rs7267979	1	rs2424704	ENSG00000274973.1	RP13-401N8.7	-4.02	7.92e-05	0.0273	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25293293	chr20:25845497~25845862:+
OV	cis	rs2303745	0.589	rs1864116	ENSG00000269815.1	CTD-2278I10.4	-4.02	7.93e-05	0.0273	-0.33	-0.26	Systemic lupus erythematosus;	chr19:17282206	chr19:17296196~17296695:-
OV	cis	rs2303745	0.589	rs1864115	ENSG00000269815.1	CTD-2278I10.4	-4.02	7.93e-05	0.0273	-0.33	-0.26	Systemic lupus erythematosus;	chr19:17282518	chr19:17296196~17296695:-
OV	cis	rs2303745	0.622	rs1864113	ENSG00000269815.1	CTD-2278I10.4	-4.02	7.93e-05	0.0273	-0.33	-0.26	Systemic lupus erythematosus;	chr19:17282695	chr19:17296196~17296695:-
OV	cis	rs7968440	1	rs2731440	ENSG00000272368.2	RP4-605O3.4	4.02	7.93e-05	0.0273	0.3	0.26	Fibrinogen;	chr12:50663844	chr12:50112197~50165618:+
OV	cis	rs7968440	1	rs2731439	ENSG00000272368.2	RP4-605O3.4	4.02	7.93e-05	0.0273	0.3	0.26	Fibrinogen;	chr12:50666567	chr12:50112197~50165618:+
OV	cis	rs881375	1	rs4323544	ENSG00000226752.6	PSMD5-AS1	-4.02	7.93e-05	0.0273	-0.28	-0.26	Rheumatoid arthritis;	chr9:120885099	chr9:120824828~120854385:+
OV	cis	rs11951515	0.663	rs10462048	ENSG00000278487.1	RP11-447H19.4	-4.02	7.94e-05	0.0274	-0.3	-0.26	Metabolite levels  (X-11787);	chr5:43258426	chr5:43143362~43143514:-
OV	cis	rs17711722	0.503	rs453835	ENSG00000237310.1	GS1-124K5.4	-4.02	7.94e-05	0.0274	-0.29	-0.26	Calcium levels;	chr7:66046172	chr7:66493706~66495474:+
OV	cis	rs9309473	0.66	rs56131703	ENSG00000163016.8	ALMS1P	4.02	7.95e-05	0.0274	0.35	0.26	Metabolite levels;	chr2:73620133	chr2:73644919~73685576:+
OV	cis	rs9649213	0.593	rs7807555	ENSG00000272950.1	RP11-307C18.1	4.02	7.95e-05	0.0274	0.3	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98328205	chr7:98322853~98323430:+
OV	cis	rs9649213	0.593	rs7807455	ENSG00000272950.1	RP11-307C18.1	4.02	7.95e-05	0.0274	0.3	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98328310	chr7:98322853~98323430:+
OV	cis	rs9649213	0.593	rs6465667	ENSG00000272950.1	RP11-307C18.1	4.02	7.95e-05	0.0274	0.3	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98328573	chr7:98322853~98323430:+
OV	cis	rs9649213	0.593	rs6949214	ENSG00000272950.1	RP11-307C18.1	4.02	7.95e-05	0.0274	0.3	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98330921	chr7:98322853~98323430:+
OV	cis	rs62244186	0.659	rs7649834	ENSG00000214820.3	MPRIPP1	4.02	7.95e-05	0.0274	0.23	0.26	Depressive symptoms;	chr3:44462240	chr3:44579938~44581026:-
OV	cis	rs9810089	1	rs9810089	ENSG00000261758.1	RP11-102M11.2	-4.02	7.96e-05	0.0274	-0.29	-0.26	Gestational age at birth (child effect);	chr3:136088767	chr3:136752630~136755780:+
OV	cis	rs853679	0.882	rs9380069	ENSG00000219392.1	RP1-265C24.5	-4.02	7.96e-05	0.0274	-0.46	-0.26	Depression;	chr6:28235522	chr6:28115628~28116551:+
OV	cis	rs1765142	0.55	rs808152	ENSG00000254532.1	RP11-624D11.2	-4.02	7.97e-05	0.0274	-0.3	-0.26	Schizophrenia;	chr11:30397414	chr11:30044058~30084343:-
OV	cis	rs6062509	0.895	rs6062497	ENSG00000232442.1	CTD-3184A7.4	-4.02	7.97e-05	0.0274	-0.26	-0.26	Prostate cancer;	chr20:63704906	chr20:63627227~63628824:+
OV	cis	rs2243480	0.908	rs4718273	ENSG00000226824.5	RP4-756H11.3	4.02	7.97e-05	0.0275	0.46	0.26	Diabetic kidney disease;	chr7:65751112	chr7:66654538~66669855:+
OV	cis	rs757081	0.547	rs11024220	ENSG00000213779.4	RP11-452G18.1	4.02	7.97e-05	0.0275	0.28	0.26	Systolic blood pressure;	chr11:17252987	chr11:17193489~17194308:+
OV	cis	rs757081	0.579	rs11024221	ENSG00000213779.4	RP11-452G18.1	4.02	7.97e-05	0.0275	0.28	0.26	Systolic blood pressure;	chr11:17253003	chr11:17193489~17194308:+
OV	cis	rs1979679	0.65	rs3963302	ENSG00000278733.1	RP11-425D17.1	4.02	7.98e-05	0.0275	0.33	0.26	Ossification of the posterior longitudinal ligament of the spine;	chr12:28367813	chr12:28185625~28186190:-
OV	cis	rs7617773	0.78	rs7653152	ENSG00000228638.1	FCF1P2	-4.02	7.98e-05	0.0275	-0.33	-0.26	Coronary artery disease;	chr3:48320607	chr3:48290793~48291375:-
OV	cis	rs2919917	0.628	rs7823970	ENSG00000254352.1	RP11-578O24.2	4.02	7.98e-05	0.0275	0.33	0.26	Lymphocyte counts;	chr8:78681364	chr8:78723796~78724136:-
OV	cis	rs2919917	0.616	rs7823723	ENSG00000254352.1	RP11-578O24.2	4.02	7.98e-05	0.0275	0.33	0.26	Lymphocyte counts;	chr8:78681390	chr8:78723796~78724136:-
OV	cis	rs12477438	0.501	rs34272114	ENSG00000231822.1	AC019097.7	4.02	7.98e-05	0.0275	0.27	0.26	Chronic sinus infection;	chr2:99120980	chr2:99102018~99102752:+
OV	cis	rs9549260	0.604	rs7330618	ENSG00000239827.7	SUGT1P3	-4.02	7.98e-05	0.0275	-0.34	-0.26	Red blood cell count;	chr13:40717570	chr13:40908159~40921774:-
OV	cis	rs7726839	0.794	rs11739663	ENSG00000225138.6	CTD-2228K2.7	4.02	7.98e-05	0.0275	0.32	0.26	Obesity-related traits;	chr5:593968	chr5:473236~480884:+
OV	cis	rs12468226	1	rs16824599	ENSG00000272966.1	RP11-686O6.1	4.02	7.99e-05	0.0275	0.43	0.26	Urate levels;	chr2:202358243	chr2:202336739~202337200:+
OV	cis	rs10510102	0.516	rs10219133	ENSG00000226864.1	ATE1-AS1	4.02	7.99e-05	0.0275	0.48	0.26	Breast cancer;	chr10:121987898	chr10:121928312~121951965:+
OV	cis	rs61677309	0.638	rs17122021	ENSG00000207185.1	RNU6-1157P	-4.02	7.99e-05	0.0275	-0.27	-0.26	Lung cancer in ever smokers;	chr11:118274971	chr11:118593988~118594093:+
OV	cis	rs10924970	1	rs10157739	ENSG00000236863.2	RPL23AP23	4.02	8e-05	0.0275	0.25	0.26	Asthma;	chr1:235191240	chr1:235295865~235296335:+
OV	cis	rs7649443	0.959	rs2341225	ENSG00000235897.1	TM4SF19-AS1	4.02	8e-05	0.0275	0.29	0.26	Nonsyndromic cleft lip with cleft palate;	chr3:197098527	chr3:196318330~196325570:+
OV	cis	rs17711722	0.523	rs313812	ENSG00000222364.1	RNU6-96P	4.02	8e-05	0.0275	0.28	0.26	Calcium levels;	chr7:66040056	chr7:66395191~66395286:+
OV	cis	rs145729347	1	rs145729347	ENSG00000254731.1	CTD-2005H7.1	-4.02	8e-05	0.0275	-0.43	-0.26	Lung function (FEV1);	chr11:86731691	chr11:86703099~86714092:+
OV	cis	rs2599510	0.811	rs176410	ENSG00000279544.1	AL133243.4	4.02	8e-05	0.0276	0.24	0.26	Interleukin-18 levels;	chr2:32418369	chr2:32563328~32566436:+
OV	cis	rs375066	0.935	rs368089	ENSG00000279095.1	AC092066.1	-4.02	8.01e-05	0.0276	-0.25	-0.26	Breast cancer;	chr19:43894932	chr19:44664131~44666158:+
OV	cis	rs9393777	0.92	rs34150729	ENSG00000226314.6	ZNF192P1	-4.02	8.02e-05	0.0276	-0.55	-0.26	Intelligence (multi-trait analysis);	chr6:27420975	chr6:28161781~28169594:+
OV	cis	rs9393777	0.92	rs13191227	ENSG00000226314.6	ZNF192P1	-4.02	8.02e-05	0.0276	-0.55	-0.26	Intelligence (multi-trait analysis);	chr6:27422336	chr6:28161781~28169594:+
OV	cis	rs4763879	0.634	rs7974396	ENSG00000256673.1	RP11-599J14.2	4.02	8.02e-05	0.0276	0.24	0.26	Type 1 diabetes;	chr12:9708101	chr12:9398355~9414851:-
OV	cis	rs9810089	1	rs1278493	ENSG00000261758.1	RP11-102M11.2	-4.02	8.02e-05	0.0276	-0.29	-0.26	Gestational age at birth (child effect);	chr3:136095167	chr3:136752630~136755780:+
OV	cis	rs757081	0.578	rs7109536	ENSG00000213779.4	RP11-452G18.1	4.02	8.02e-05	0.0276	0.28	0.26	Systolic blood pressure;	chr11:17233965	chr11:17193489~17194308:+
OV	cis	rs1950626	0.75	rs72700530	ENSG00000258399.5	MEG8	-4.02	8.03e-05	0.0276	-0.26	-0.26	Pelvic organ prolapse (moderate/severe);	chr14:100963122	chr14:100894770~100935999:+
OV	cis	rs1950626	0.75	rs34144313	ENSG00000258399.5	MEG8	-4.02	8.03e-05	0.0276	-0.26	-0.26	Pelvic organ prolapse (moderate/severe);	chr14:100964879	chr14:100894770~100935999:+
OV	cis	rs1950626	0.705	rs34991312	ENSG00000258399.5	MEG8	-4.02	8.03e-05	0.0276	-0.26	-0.26	Pelvic organ prolapse (moderate/severe);	chr14:100968830	chr14:100894770~100935999:+
OV	cis	rs1950626	0.75	rs34061904	ENSG00000258399.5	MEG8	-4.02	8.03e-05	0.0276	-0.26	-0.26	Pelvic organ prolapse (moderate/severe);	chr14:100969637	chr14:100894770~100935999:+
OV	cis	rs1950626	0.75	rs34228453	ENSG00000258399.5	MEG8	-4.02	8.03e-05	0.0276	-0.26	-0.26	Pelvic organ prolapse (moderate/severe);	chr14:100973984	chr14:100894770~100935999:+
OV	cis	rs1950626	0.662	rs72700538	ENSG00000258399.5	MEG8	-4.02	8.03e-05	0.0276	-0.26	-0.26	Pelvic organ prolapse (moderate/severe);	chr14:100975574	chr14:100894770~100935999:+
OV	cis	rs1950626	0.75	rs12895798	ENSG00000258399.5	MEG8	-4.02	8.03e-05	0.0276	-0.26	-0.26	Pelvic organ prolapse (moderate/severe);	chr14:100976456	chr14:100894770~100935999:+
OV	cis	rs1933112	1	rs10753777	ENSG00000227777.1	RP4-738P11.3	-4.02	8.03e-05	0.0276	-0.29	-0.26	Blood protein levels;	chr1:168558549	chr1:168542737~168543354:+
OV	cis	rs10783487	0.947	rs12582462	ENSG00000258279.2	LINC00592	4.02	8.03e-05	0.0276	0.36	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr12:52085409	chr12:52210930~52223804:+
OV	cis	rs10783487	0.947	rs10467108	ENSG00000258279.2	LINC00592	4.02	8.03e-05	0.0276	0.36	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr12:52085585	chr12:52210930~52223804:+
OV	cis	rs7267979	0.903	rs6115101	ENSG00000274973.1	RP13-401N8.7	-4.02	8.03e-05	0.0276	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25248928	chr20:25845497~25845862:+
OV	cis	rs7267979	0.868	rs6107019	ENSG00000274973.1	RP13-401N8.7	-4.02	8.03e-05	0.0276	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25253349	chr20:25845497~25845862:+
OV	cis	rs7267979	0.868	rs6138553	ENSG00000274973.1	RP13-401N8.7	-4.02	8.03e-05	0.0276	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25258597	chr20:25845497~25845862:+
OV	cis	rs7267979	0.903	rs6115109	ENSG00000274973.1	RP13-401N8.7	-4.02	8.03e-05	0.0276	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25259031	chr20:25845497~25845862:+
OV	cis	rs7267979	0.833	rs4619688	ENSG00000274973.1	RP13-401N8.7	-4.02	8.03e-05	0.0276	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25263465	chr20:25845497~25845862:+
OV	cis	rs7267979	0.903	rs6115118	ENSG00000274973.1	RP13-401N8.7	-4.02	8.03e-05	0.0276	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25266098	chr20:25845497~25845862:+
OV	cis	rs7267979	0.903	rs1118963	ENSG00000274973.1	RP13-401N8.7	-4.02	8.03e-05	0.0276	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25266813	chr20:25845497~25845862:+
OV	cis	rs34779708	0.766	rs7897088	ENSG00000230534.5	RP11-297A16.2	4.02	8.03e-05	0.0276	0.35	0.26	Inflammatory bowel disease;Crohn's disease;	chr10:35262639	chr10:35098006~35127020:-
OV	cis	rs801193	0.569	rs2707824	ENSG00000236529.1	RP13-254B10.1	4.02	8.04e-05	0.0276	0.27	0.26	Aortic root size;	chr7:66724256	chr7:65840212~65840596:+
OV	cis	rs55692468	0.848	rs3811574	ENSG00000213197.3	AC012066.1	-4.02	8.04e-05	0.0276	-0.26	-0.26	Intraocular pressure;	chr2:152490331	chr2:152389937~152390630:+
OV	cis	rs7927771	0.965	rs12787112	ENSG00000271350.1	CTD-2384B9.1	-4.02	8.04e-05	0.0277	-0.31	-0.26	Subjective well-being;	chr11:47665595	chr11:47041027~47041945:-
OV	cis	rs875971	0.545	rs10261710	ENSG00000237310.1	GS1-124K5.4	4.02	8.05e-05	0.0277	0.31	0.26	Aortic root size;	chr7:66249202	chr7:66493706~66495474:+
OV	cis	rs853679	0.769	rs17720293	ENSG00000220721.1	OR1F12	4.02	8.05e-05	0.0277	0.48	0.26	Depression;	chr6:28246920	chr6:28073316~28074233:+
OV	cis	rs2153535	0.869	rs11962457	ENSG00000230939.1	RP11-314C16.1	4.02	8.05e-05	0.0277	0.3	0.26	Motion sickness;	chr6:8375622	chr6:8784178~8785445:+
OV	cis	rs875971	0.862	rs1167408	ENSG00000237310.1	GS1-124K5.4	-4.02	8.05e-05	0.0277	-0.26	-0.26	Aortic root size;	chr7:66091121	chr7:66493706~66495474:+
OV	cis	rs875971	0.83	rs1167406	ENSG00000237310.1	GS1-124K5.4	-4.02	8.05e-05	0.0277	-0.26	-0.26	Aortic root size;	chr7:66091949	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs709609	ENSG00000237310.1	GS1-124K5.4	-4.02	8.05e-05	0.0277	-0.26	-0.26	Aortic root size;	chr7:66095574	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs1167399	ENSG00000237310.1	GS1-124K5.4	-4.02	8.05e-05	0.0277	-0.26	-0.26	Aortic root size;	chr7:66096890	chr7:66493706~66495474:+
OV	cis	rs875971	0.825	rs59466412	ENSG00000237310.1	GS1-124K5.4	-4.02	8.05e-05	0.0277	-0.26	-0.26	Aortic root size;	chr7:66100371	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs57866200	ENSG00000237310.1	GS1-124K5.4	-4.02	8.05e-05	0.0277	-0.26	-0.26	Aortic root size;	chr7:66100405	chr7:66493706~66495474:+
OV	cis	rs853679	0.607	rs67340775	ENSG00000226314.6	ZNF192P1	-4.02	8.05e-05	0.0277	-0.55	-0.26	Depression;	chr6:28336607	chr6:28161781~28169594:+
OV	cis	rs4934494	0.822	rs3962370	ENSG00000240996.1	RP11-80H5.7	-4.02	8.06e-05	0.0277	-0.32	-0.26	Red blood cell count;	chr10:89777763	chr10:89694295~89697928:-
OV	cis	rs4934494	0.727	rs1590566	ENSG00000240996.1	RP11-80H5.7	-4.02	8.06e-05	0.0277	-0.32	-0.26	Red blood cell count;	chr10:89778781	chr10:89694295~89697928:-
OV	cis	rs11009175	0.929	rs6481825	ENSG00000273038.2	RP11-479G22.8	-4.02	8.06e-05	0.0277	-0.34	-0.26	Depression (quantitative trait);	chr10:33050595	chr10:32887255~32889311:-
OV	cis	rs853679	0.55	rs1150689	ENSG00000226314.6	ZNF192P1	-4.02	8.06e-05	0.0277	-0.36	-0.26	Depression;	chr6:28197321	chr6:28161781~28169594:+
OV	cis	rs853679	0.55	rs1225599	ENSG00000226314.6	ZNF192P1	-4.02	8.06e-05	0.0277	-0.36	-0.26	Depression;	chr6:28197412	chr6:28161781~28169594:+
OV	cis	rs853679	0.574	rs1233705	ENSG00000226314.6	ZNF192P1	-4.02	8.06e-05	0.0277	-0.36	-0.26	Depression;	chr6:28198669	chr6:28161781~28169594:+
OV	cis	rs9649213	0.593	rs6970801	ENSG00000272950.1	RP11-307C18.1	4.02	8.06e-05	0.0277	0.3	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98295928	chr7:98322853~98323430:+
OV	cis	rs9649213	0.593	rs12704982	ENSG00000272950.1	RP11-307C18.1	4.02	8.06e-05	0.0277	0.3	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98296741	chr7:98322853~98323430:+
OV	cis	rs9649213	0.593	rs34129434	ENSG00000272950.1	RP11-307C18.1	4.02	8.06e-05	0.0277	0.3	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98297152	chr7:98322853~98323430:+
OV	cis	rs9649213	0.593	rs12704983	ENSG00000272950.1	RP11-307C18.1	4.02	8.06e-05	0.0277	0.3	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98297733	chr7:98322853~98323430:+
OV	cis	rs9649213	0.593	rs7781916	ENSG00000272950.1	RP11-307C18.1	4.02	8.06e-05	0.0277	0.3	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98300426	chr7:98322853~98323430:+
OV	cis	rs9649213	0.593	rs736753	ENSG00000272950.1	RP11-307C18.1	4.02	8.06e-05	0.0277	0.3	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98302177	chr7:98322853~98323430:+
OV	cis	rs9649213	0.593	rs736754	ENSG00000272950.1	RP11-307C18.1	4.02	8.06e-05	0.0277	0.3	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98302247	chr7:98322853~98323430:+
OV	cis	rs2288884	0.636	rs6509620	ENSG00000275055.1	CTC-471J1.11	-4.02	8.06e-05	0.0277	-0.27	-0.26	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:52077543	chr19:52049007~52049754:+
OV	cis	rs1549733	0.73	rs6714412	ENSG00000222714.1	RN7SKP38	-4.02	8.06e-05	0.0277	-0.3	-0.26	Optic disc area;	chr2:217584816	chr2:218500729~218501037:-
OV	cis	rs853679	0.599	rs188015	ENSG00000226314.6	ZNF192P1	-4.02	8.06e-05	0.0277	-0.47	-0.26	Depression;	chr6:27909668	chr6:28161781~28169594:+
OV	cis	rs897984	0.609	rs4889609	ENSG00000232748.3	RP11-196G11.6	-4.02	8.06e-05	0.0277	-0.27	-0.26	Dementia with Lewy bodies;	chr16:31015106	chr16:31056460~31062803:+
OV	cis	rs897984	0.572	rs4889526	ENSG00000232748.3	RP11-196G11.6	-4.02	8.06e-05	0.0277	-0.27	-0.26	Dementia with Lewy bodies;	chr16:31019023	chr16:31056460~31062803:+
OV	cis	rs897984	0.609	rs57576577	ENSG00000232748.3	RP11-196G11.6	-4.02	8.06e-05	0.0277	-0.27	-0.26	Dementia with Lewy bodies;	chr16:31025046	chr16:31056460~31062803:+
OV	cis	rs2839627	0.561	rs6586250	ENSG00000225218.1	AP001628.6	4.02	8.07e-05	0.0277	0.25	0.26	Information processing speed;	chr21:42850119	chr21:42831040~42836477:-
OV	cis	rs4964805	0.672	rs4964823	ENSG00000257681.1	RP11-341G23.4	4.02	8.07e-05	0.0277	0.31	0.26	Attention deficit hyperactivity disorder;	chr12:103787642	chr12:103746315~103768858:-
OV	cis	rs4918798	0.641	rs61886771	ENSG00000234724.1	HDAC1P1	4.02	8.07e-05	0.0277	0.46	0.26	Warfarin maintenance dose;	chr10:94951688	chr10:94137748~94139500:+
OV	cis	rs1584120	0.501	rs2204780	ENSG00000274885.1	RP11-268P4.6	-4.02	8.08e-05	0.0277	-0.29	-0.26	Pelvic organ prolapse (moderate/severe);	chr12:23099483	chr12:22638464~22638943:+
OV	cis	rs7968440	1	rs67701624	ENSG00000272368.2	RP4-605O3.4	4.01	8.08e-05	0.0278	0.3	0.26	Fibrinogen;	chr12:50535155	chr12:50112197~50165618:+
OV	cis	rs7968440	0.966	rs68171620	ENSG00000272368.2	RP4-605O3.4	4.01	8.08e-05	0.0278	0.3	0.26	Fibrinogen;	chr12:50543755	chr12:50112197~50165618:+
OV	cis	rs12908161	0.96	rs17599989	ENSG00000225151.9	GOLGA2P7	-4.01	8.08e-05	0.0278	-0.32	-0.26	Schizophrenia;	chr15:84742305	chr15:84199311~84230136:-
OV	cis	rs7520050	0.966	rs10749860	ENSG00000280836.1	AL355480.1	4.01	8.09e-05	0.0278	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45862538	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs12139630	ENSG00000280836.1	AL355480.1	4.01	8.09e-05	0.0278	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45885263	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs12144263	ENSG00000280836.1	AL355480.1	4.01	8.09e-05	0.0278	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45886774	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs6668284	ENSG00000280836.1	AL355480.1	4.01	8.09e-05	0.0278	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45888838	chr1:45581219~45581321:-
OV	cis	rs17708984	0.606	rs3786574	ENSG00000270802.2	AC005776.1	-4.01	8.09e-05	0.0278	-0.28	-0.26	Platelet distribution width;Platelet count;	chr19:16082807	chr19:15338948~15339237:+
OV	cis	rs12681366	0.881	rs12674614	ENSG00000253704.1	RP11-267M23.4	4.01	8.1e-05	0.0278	0.37	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94396605	chr8:94553722~94569745:+
OV	cis	rs6921919	0.583	rs6922169	ENSG00000204709.4	LINC01556	4.01	8.1e-05	0.0278	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28415155	chr6:28943877~28944537:+
OV	cis	rs6921919	0.559	rs13210866	ENSG00000204709.4	LINC01556	4.01	8.1e-05	0.0278	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28416065	chr6:28943877~28944537:+
OV	cis	rs6921919	0.609	rs36018474	ENSG00000204709.4	LINC01556	4.01	8.1e-05	0.0278	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28417752	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs13201726	ENSG00000204709.4	LINC01556	4.01	8.1e-05	0.0278	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28417774	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs740622	ENSG00000204709.4	LINC01556	4.01	8.1e-05	0.0278	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28430514	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs16894108	ENSG00000204709.4	LINC01556	4.01	8.1e-05	0.0278	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28434013	chr6:28943877~28944537:+
OV	cis	rs14027	0.961	rs7017279	ENSG00000279347.1	RP11-85I17.2	4.01	8.11e-05	0.0278	0.26	0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119847580	chr8:119838736~119840385:-
OV	cis	rs2303745	0.589	rs7246262	ENSG00000269815.1	CTD-2278I10.4	-4.01	8.11e-05	0.0278	-0.33	-0.26	Systemic lupus erythematosus;	chr19:17281674	chr19:17296196~17296695:-
OV	cis	rs11105298	0.891	rs4842661	ENSG00000257194.2	RP11-567C2.1	-4.01	8.11e-05	0.0278	-0.4	-0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89536622	chr12:90107739~90112779:+
OV	cis	rs2348418	0.733	rs9651832	ENSG00000247934.4	RP11-967K21.1	-4.01	8.11e-05	0.0278	-0.25	-0.26	Lung function (FEV1);Lung function (FVC);	chr12:28242489	chr12:28163298~28190738:-
OV	cis	rs4296809	0.556	rs12517503	ENSG00000249779.1	RP11-447H19.3	-4.01	8.12e-05	0.0278	-0.51	-0.26	Brain structure;	chr5:44134285	chr5:43206709~43207811:+
OV	cis	rs4763879	0.593	rs2080206	ENSG00000256673.1	RP11-599J14.2	4.01	8.12e-05	0.0279	0.25	0.26	Type 1 diabetes;	chr12:9715370	chr12:9398355~9414851:-
OV	cis	rs4290604	0.748	rs4663241	ENSG00000224132.2	AC112715.2	-4.01	8.12e-05	0.0279	-0.48	-0.26	Asthma;	chr2:237177317	chr2:237257091~237257676:+
OV	cis	rs4290604	0.665	rs4316893	ENSG00000224132.2	AC112715.2	-4.01	8.12e-05	0.0279	-0.48	-0.26	Asthma;	chr2:237181124	chr2:237257091~237257676:+
OV	cis	rs9880211	1	rs9869630	ENSG00000239213.4	NCK1-AS1	4.01	8.12e-05	0.0279	0.31	0.26	Height;Body mass index;	chr3:136529177	chr3:136841726~136862054:-
OV	cis	rs465969	1	rs9387010	ENSG00000255389.1	C6orf3	4.01	8.13e-05	0.0279	0.39	0.26	Psoriasis;	chr6:111384741	chr6:111599875~111602295:+
OV	cis	rs11951515	0.714	rs12520895	ENSG00000278487.1	RP11-447H19.4	-4.01	8.13e-05	0.0279	-0.3	-0.26	Metabolite levels  (X-11787);	chr5:43369447	chr5:43143362~43143514:-
OV	cis	rs7927592	0.513	rs689075	ENSG00000222339.1	AP000807.2	4.01	8.13e-05	0.0279	0.26	0.26	Total body bone mineral density;	chr11:68426964	chr11:68505572~68505651:-
OV	cis	rs7927592	0.513	rs608343	ENSG00000222339.1	AP000807.2	4.01	8.13e-05	0.0279	0.26	0.26	Total body bone mineral density;	chr11:68429362	chr11:68505572~68505651:-
OV	cis	rs1979679	0.744	rs2348236	ENSG00000278733.1	RP11-425D17.1	-4.01	8.13e-05	0.0279	-0.32	-0.26	Ossification of the posterior longitudinal ligament of the spine;	chr12:28441640	chr12:28185625~28186190:-
OV	cis	rs7665090	1	rs4586937	ENSG00000246560.2	RP11-10L12.4	-4.01	8.14e-05	0.0279	-0.27	-0.26	Primary biliary cholangitis;	chr4:102635305	chr4:102828055~102844075:+
OV	cis	rs1979679	0.918	rs11049513	ENSG00000278733.1	RP11-425D17.1	4.01	8.14e-05	0.0279	0.31	0.26	Ossification of the posterior longitudinal ligament of the spine;	chr12:28297218	chr12:28185625~28186190:-
OV	cis	rs10510102	0.516	rs10437506	ENSG00000226864.1	ATE1-AS1	4.01	8.15e-05	0.0279	0.47	0.26	Breast cancer;	chr10:121984011	chr10:121928312~121951965:+
OV	cis	rs10510102	0.516	rs74461504	ENSG00000226864.1	ATE1-AS1	4.01	8.15e-05	0.0279	0.47	0.26	Breast cancer;	chr10:121986077	chr10:121928312~121951965:+
OV	cis	rs10510102	0.516	rs61071865	ENSG00000226864.1	ATE1-AS1	4.01	8.15e-05	0.0279	0.47	0.26	Breast cancer;	chr10:121986236	chr10:121928312~121951965:+
OV	cis	rs10510102	0.516	rs10159589	ENSG00000226864.1	ATE1-AS1	4.01	8.15e-05	0.0279	0.47	0.26	Breast cancer;	chr10:121986659	chr10:121928312~121951965:+
OV	cis	rs875971	0.545	rs313830	ENSG00000237310.1	GS1-124K5.4	-4.01	8.15e-05	0.0279	-0.3	-0.26	Aortic root size;	chr7:66086944	chr7:66493706~66495474:+
OV	cis	rs10510102	0.516	rs3936070	ENSG00000226864.1	ATE1-AS1	4.01	8.15e-05	0.0279	0.47	0.26	Breast cancer;	chr10:121974440	chr10:121928312~121951965:+
OV	cis	rs7267979	0.966	rs6037097	ENSG00000274973.1	RP13-401N8.7	-4.01	8.15e-05	0.0279	-0.29	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25366585	chr20:25845497~25845862:+
OV	cis	rs9979383	0.502	rs11088320	ENSG00000228107.1	AP000692.9	4.01	8.16e-05	0.028	0.27	0.26	Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr21:35442792	chr21:36360630~36362040:+
OV	cis	rs12681366	0.843	rs3019147	ENSG00000253704.1	RP11-267M23.4	4.01	8.16e-05	0.028	0.36	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94412804	chr8:94553722~94569745:+
OV	cis	rs10924970	1	rs55969096	ENSG00000236863.2	RPL23AP23	4.01	8.16e-05	0.028	0.26	0.26	Asthma;	chr1:235189050	chr1:235295865~235296335:+
OV	cis	rs1707322	0.721	rs11211178	ENSG00000234329.1	RP11-767N6.2	4.01	8.16e-05	0.028	0.27	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45761894	chr1:45651039~45651826:-
OV	cis	rs4835473	0.932	rs11724752	ENSG00000251600.4	RP11-673E1.1	-4.01	8.17e-05	0.028	-0.29	-0.26	Immature fraction of reticulocytes;	chr4:143769473	chr4:143912331~143982454:+
OV	cis	rs1823913	0.637	rs12624271	ENSG00000227542.1	AC092614.2	-4.01	8.17e-05	0.028	-0.29	-0.26	Obesity-related traits;	chr2:191288586	chr2:191229165~191246172:-
OV	cis	rs11951515	0.527	rs10462047	ENSG00000278487.1	RP11-447H19.4	4.01	8.17e-05	0.028	0.3	0.26	Metabolite levels  (X-11787);	chr5:43258358	chr5:43143362~43143514:-
OV	cis	rs12073359	1	rs72692893	ENSG00000223945.2	RP11-458I7.1	-4.01	8.17e-05	0.028	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150075047	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs72692898	ENSG00000223945.2	RP11-458I7.1	-4.01	8.17e-05	0.028	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150077904	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs72692900	ENSG00000223945.2	RP11-458I7.1	-4.01	8.17e-05	0.028	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150078190	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs56212907	ENSG00000223945.2	RP11-458I7.1	-4.01	8.17e-05	0.028	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150086719	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs11587963	ENSG00000223945.2	RP11-458I7.1	-4.01	8.17e-05	0.028	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150134393	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs56369603	ENSG00000223945.2	RP11-458I7.1	-4.01	8.17e-05	0.028	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150134673	chr1:150053864~150055034:+
OV	cis	rs12073359	0.955	rs72694942	ENSG00000223945.2	RP11-458I7.1	-4.01	8.17e-05	0.028	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150138317	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs72694944	ENSG00000223945.2	RP11-458I7.1	-4.01	8.17e-05	0.028	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150140312	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs72694945	ENSG00000223945.2	RP11-458I7.1	-4.01	8.17e-05	0.028	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150141312	chr1:150053864~150055034:+
OV	cis	rs12073359	0.954	rs72694951	ENSG00000223945.2	RP11-458I7.1	-4.01	8.17e-05	0.028	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150146987	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs72694953	ENSG00000223945.2	RP11-458I7.1	-4.01	8.17e-05	0.028	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150147539	chr1:150053864~150055034:+
OV	cis	rs7584330	0.554	rs6705908	ENSG00000234949.2	AC104667.3	-4.01	8.17e-05	0.028	-0.3	-0.26	Prostate cancer;	chr2:237525322	chr2:237591020~237595981:+
OV	cis	rs10829156	0.66	rs4338439	ENSG00000225527.1	RP11-383B4.4	-4.01	8.18e-05	0.028	-0.36	-0.26	Sudden cardiac arrest;	chr10:18594220	chr10:18531849~18533336:-
OV	cis	rs7968440	0.736	rs1561422	ENSG00000272368.2	RP4-605O3.4	-4.01	8.18e-05	0.028	-0.3	-0.26	Fibrinogen;	chr12:50794614	chr12:50112197~50165618:+
OV	cis	rs792448	0.506	rs2275712	ENSG00000201544.1	SNORA16B	4.01	8.19e-05	0.028	0.3	0.26	White blood cell count (basophil);	chr1:212444487	chr1:212352816~212352950:+
OV	cis	rs4713118	0.513	rs149941	ENSG00000280107.1	AL022393.9	-4.01	8.19e-05	0.028	-0.33	-0.26	Parkinson's disease;	chr6:28033255	chr6:28170845~28172521:+
OV	cis	rs17772222	0.839	rs2274735	ENSG00000258789.1	RP11-507K2.3	-4.01	8.19e-05	0.028	-0.26	-0.26	Coronary artery calcification;	chr14:88505414	chr14:88551597~88552493:+
OV	cis	rs62229266	0.74	rs4817759	ENSG00000231106.2	LINC01436	4.01	8.19e-05	0.028	0.32	0.26	Mitral valve prolapse;	chr21:36017261	chr21:36005338~36007838:+
OV	cis	rs62229266	0.771	rs2835232	ENSG00000231106.2	LINC01436	4.01	8.19e-05	0.028	0.32	0.26	Mitral valve prolapse;	chr21:36021129	chr21:36005338~36007838:+
OV	cis	rs62229266	0.74	rs2835233	ENSG00000231106.2	LINC01436	4.01	8.19e-05	0.028	0.32	0.26	Mitral valve prolapse;	chr21:36021284	chr21:36005338~36007838:+
OV	cis	rs7267979	0.903	rs6107015	ENSG00000274973.1	RP13-401N8.7	-4.01	8.19e-05	0.028	-0.3	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25236128	chr20:25845497~25845862:+
OV	cis	rs4713118	0.513	rs149962	ENSG00000280107.1	AL022393.9	-4.01	8.19e-05	0.028	-0.31	-0.26	Parkinson's disease;	chr6:28048140	chr6:28170845~28172521:+
OV	cis	rs172166	0.769	rs149965	ENSG00000280107.1	AL022393.9	-4.01	8.19e-05	0.028	-0.31	-0.26	Cardiac Troponin-T levels;	chr6:28050911	chr6:28170845~28172521:+
OV	cis	rs853679	0.666	rs200956	ENSG00000280107.1	AL022393.9	-4.01	8.19e-05	0.028	-0.37	-0.26	Depression;	chr6:27871968	chr6:28170845~28172521:+
OV	cis	rs11096990	0.656	rs2123028	ENSG00000249207.1	RP11-360F5.1	4.01	8.19e-05	0.0281	0.27	0.26	Cognitive function;	chr4:39301859	chr4:39112677~39126818:-
OV	cis	rs7267979	1	rs2482911	ENSG00000274973.1	RP13-401N8.7	4.01	8.19e-05	0.0281	0.29	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25414892	chr20:25845497~25845862:+
OV	cis	rs2021786	0.93	rs4504064	ENSG00000199719.1	RN7SKP74	4.01	8.19e-05	0.0281	0.29	0.26	Preschool internalizing problems;	chr20:17448715	chr20:18295143~18295451:-
OV	cis	rs1113500	0.73	rs1361829	ENSG00000226822.1	RP11-356N1.2	-4.01	8.2e-05	0.0281	-0.31	-0.26	Growth-regulated protein alpha levels;	chr1:108051273	chr1:108071482~108074519:+
OV	cis	rs8114671	0.967	rs6142320	ENSG00000269202.1	RP4-614O4.12	4.01	8.2e-05	0.0281	0.26	0.26	Height;	chr20:35200390	chr20:35201747~35203288:-
OV	cis	rs8114671	0.967	rs6142321	ENSG00000269202.1	RP4-614O4.12	4.01	8.2e-05	0.0281	0.26	0.26	Height;	chr20:35200671	chr20:35201747~35203288:-
OV	cis	rs8114671	0.967	rs6142323	ENSG00000269202.1	RP4-614O4.12	4.01	8.2e-05	0.0281	0.26	0.26	Height;	chr20:35201180	chr20:35201747~35203288:-
OV	cis	rs992157	0.798	rs7557709	ENSG00000261338.2	RP11-378A13.1	4.01	8.2e-05	0.0281	0.3	0.26	Colorectal cancer;	chr2:218302806	chr2:218255319~218257366:+
OV	cis	rs9847710	0.683	rs2581818	ENSG00000242142.1	SERBP1P3	4.01	8.21e-05	0.0281	0.31	0.26	Ulcerative colitis;	chr3:53037636	chr3:53064283~53065091:-
OV	cis	rs7968440	0.736	rs7978559	ENSG00000272368.2	RP4-605O3.4	4.01	8.21e-05	0.0281	0.32	0.26	Fibrinogen;	chr12:50794855	chr12:50112197~50165618:+
OV	cis	rs7968440	0.808	rs7958114	ENSG00000272368.2	RP4-605O3.4	4.01	8.21e-05	0.0281	0.32	0.26	Fibrinogen;	chr12:50796909	chr12:50112197~50165618:+
OV	cis	rs2015599	0.623	rs12581107	ENSG00000257176.2	RP11-996F15.2	-4.01	8.22e-05	0.0281	-0.33	-0.26	Platelet count;Mean platelet volume;	chr12:29352358	chr12:29280418~29317848:-
OV	cis	rs7968440	0.931	rs2251024	ENSG00000272368.2	RP4-605O3.4	4.01	8.22e-05	0.0281	0.3	0.26	Fibrinogen;	chr12:50709850	chr12:50112197~50165618:+
OV	cis	rs10783487	0.749	rs11169998	ENSG00000258279.2	LINC00592	4.01	8.22e-05	0.0281	0.31	0.26	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr12:52092733	chr12:52210930~52223804:+
OV	cis	rs9287719	0.649	rs9973374	ENSG00000243819.4	RN7SL832P	4.01	8.23e-05	0.0281	0.26	0.26	Prostate cancer;	chr2:10576258	chr2:10690344~10692099:+
OV	cis	rs2492286	0.597	rs1126828	ENSG00000242551.2	POU5F1P6	-4.01	8.23e-05	0.0281	-0.32	-0.26	Eosinophil counts;	chr3:128625943	chr3:128674735~128677005:-
OV	cis	rs881375	0.678	rs10818488	ENSG00000226752.6	PSMD5-AS1	-4.01	8.23e-05	0.0282	-0.26	-0.26	Rheumatoid arthritis;	chr9:120942809	chr9:120824828~120854385:+
OV	cis	rs1765142	0.55	rs562103	ENSG00000254532.1	RP11-624D11.2	-4.01	8.23e-05	0.0282	-0.31	-0.26	Schizophrenia;	chr11:30396409	chr11:30044058~30084343:-
OV	cis	rs12073359	1	rs11589922	ENSG00000223945.2	RP11-458I7.1	-4.01	8.23e-05	0.0282	-0.39	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150161125	chr1:150053864~150055034:+
OV	cis	rs4845570	0.749	rs11576810	ENSG00000203288.3	RP11-98D18.9	-4.01	8.24e-05	0.0282	-0.45	-0.26	Coronary artery disease;	chr1:151739725	chr1:151790804~151794402:+
OV	cis	rs774359	0.75	rs2477521	ENSG00000234676.1	IFT74-AS1	4.01	8.24e-05	0.0282	0.31	0.26	Amyotrophic lateral sclerosis;	chr9:27509947	chr9:26955780~26956295:-
OV	cis	rs7746199	0.736	rs13212093	ENSG00000280107.1	AL022393.9	-4.01	8.24e-05	0.0282	-0.55	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27638937	chr6:28170845~28172521:+
OV	cis	rs801193	0.548	rs2659891	ENSG00000236529.1	RP13-254B10.1	4.01	8.25e-05	0.0282	0.27	0.26	Aortic root size;	chr7:66736127	chr7:65840212~65840596:+
OV	cis	rs12073359	0.954	rs72694956	ENSG00000223945.2	RP11-458I7.1	-4.01	8.25e-05	0.0282	-0.42	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150162023	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs11591200	ENSG00000223945.2	RP11-458I7.1	4.01	8.25e-05	0.0282	0.42	0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150161365	chr1:150053864~150055034:+
OV	cis	rs3768716	0.5	rs777329	ENSG00000229267.2	AC072062.1	4.01	8.25e-05	0.0282	0.35	0.26	Neuroblastoma;	chr2:214877871	chr2:214810229~214963274:+
OV	cis	rs875971	0.756	rs4718328	ENSG00000237310.1	GS1-124K5.4	-4.01	8.26e-05	0.0282	-0.26	-0.26	Aortic root size;	chr7:66228350	chr7:66493706~66495474:+
OV	cis	rs12477438	0.501	rs11692336	ENSG00000231822.1	AC019097.7	4.01	8.26e-05	0.0282	0.27	0.26	Chronic sinus infection;	chr2:99124143	chr2:99102018~99102752:+
OV	cis	rs12477438	0.52	rs1133978	ENSG00000231822.1	AC019097.7	4.01	8.26e-05	0.0282	0.27	0.26	Chronic sinus infection;	chr2:99125501	chr2:99102018~99102752:+
OV	cis	rs2919917	0.578	rs922928	ENSG00000254352.1	RP11-578O24.2	4.01	8.26e-05	0.0282	0.36	0.26	Lymphocyte counts;	chr8:78645085	chr8:78723796~78724136:-
OV	cis	rs757110	0.866	rs5215	ENSG00000213779.4	RP11-452G18.1	-4.01	8.26e-05	0.0282	-0.32	-0.26	Type 2 diabetes;	chr11:17387083	chr11:17193489~17194308:+
OV	cis	rs9309473	0.513	rs62149782	ENSG00000163016.8	ALMS1P	4.01	8.27e-05	0.0283	0.36	0.26	Metabolite levels;	chr2:73591901	chr2:73644919~73685576:+
OV	cis	rs858239	0.665	rs858305	ENSG00000230042.1	AK3P3	4.01	8.27e-05	0.0283	0.3	0.26	Cerebrospinal fluid biomarker levels;	chr7:23203211	chr7:23129178~23129841:+
OV	cis	rs2227564	0.597	rs2271271	ENSG00000271816.1	BMS1P4	4.01	8.28e-05	0.0283	0.26	0.26	Crohn's disease;Inflammatory bowel disease;	chr10:73799109	chr10:73699151~73730487:-
OV	cis	rs2348418	0.733	rs10771414	ENSG00000247934.4	RP11-967K21.1	4.01	8.29e-05	0.0283	0.24	0.26	Lung function (FEV1);Lung function (FVC);	chr12:28241369	chr12:28163298~28190738:-
OV	cis	rs4296809	0.714	rs58649795	ENSG00000249779.1	RP11-447H19.3	-4.01	8.3e-05	0.0283	-0.43	-0.26	Brain structure;	chr5:44068020	chr5:43206709~43207811:+
OV	cis	rs4296809	0.714	rs10461752	ENSG00000249779.1	RP11-447H19.3	-4.01	8.3e-05	0.0283	-0.43	-0.26	Brain structure;	chr5:44068276	chr5:43206709~43207811:+
OV	cis	rs992969	0.506	rs2225537	ENSG00000231967.1	RP11-12D24.6	-4.01	8.3e-05	0.0284	-0.29	-0.26	Asthma;	chr9:6160578	chr9:5356312~5356525:-
OV	cis	rs2834288	0.613	rs2834297	ENSG00000273102.1	AP000569.9	-4.01	8.3e-05	0.0284	-0.27	-0.26	Gut microbiota (bacterial taxa);	chr21:33910534	chr21:33967101~33968573:-
OV	cis	rs12681366	0.881	rs2931631	ENSG00000253704.1	RP11-267M23.4	4.01	8.3e-05	0.0284	0.37	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94401415	chr8:94553722~94569745:+
OV	cis	rs12134151	0.87	rs6662729	ENSG00000237416.5	RP11-465K1.2	4.01	8.31e-05	0.0284	0.29	0.26	Educational attainment (years of education);	chr1:95730007	chr1:94836748~94855426:-
OV	cis	rs10992471	0.603	rs1980848	ENSG00000281156.1	MIR3651	4.01	8.31e-05	0.0284	0.29	0.26	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92486289	chr9:92292458~92292547:-
OV	cis	rs4948102	0.686	rs11771788	ENSG00000275875.1	RP11-613E4.5	-4.01	8.31e-05	0.0284	-0.29	-0.26	Plasma homocysteine levels (post-methionine load test);	chr7:56090347	chr7:55741525~55741869:+
OV	cis	rs4948102	0.686	rs7801467	ENSG00000275875.1	RP11-613E4.5	-4.01	8.31e-05	0.0284	-0.29	-0.26	Plasma homocysteine levels (post-methionine load test);	chr7:56093284	chr7:55741525~55741869:+
OV	cis	rs10924970	0.967	rs10925270	ENSG00000236863.2	RPL23AP23	4.01	8.31e-05	0.0284	0.26	0.26	Asthma;	chr1:235262560	chr1:235295865~235296335:+
OV	cis	rs10924970	0.934	rs10802572	ENSG00000236863.2	RPL23AP23	4.01	8.31e-05	0.0284	0.26	0.26	Asthma;	chr1:235262806	chr1:235295865~235296335:+
OV	cis	rs11992162	1	rs7460395	ENSG00000254527.1	ENPP7P12	4.01	8.32e-05	0.0284	0.3	0.26	Monocyte count;	chr8:11977866	chr8:12205759~12206389:-
OV	cis	rs3823536	0.583	rs7800687	ENSG00000275106.1	RP11-309L24.10	-4.01	8.32e-05	0.0284	-0.36	-0.26	Sjögren's syndrome;	chr7:128953665	chr7:128952527~128953316:-
OV	cis	rs7617773	0.78	rs13082158	ENSG00000228638.1	FCF1P2	-4.01	8.32e-05	0.0284	-0.33	-0.26	Coronary artery disease;	chr3:48330980	chr3:48290793~48291375:-
OV	cis	rs295490	0.831	rs3772871	ENSG00000272656.1	RP11-219D15.3	-4.01	8.33e-05	0.0284	-0.45	-0.26	PR interval in Tripanosoma cruzi seropositivity;	chr3:139522774	chr3:139349024~139349371:-
OV	cis	rs12480328	1	rs12480328	ENSG00000233077.1	LINC01271	4.01	8.33e-05	0.0284	0.54	0.26	Prostate cancer;	chr20:50911385	chr20:50310711~50321342:-
OV	cis	rs7615952	0.515	rs4441610	ENSG00000171084.14	FAM86JP	4.01	8.33e-05	0.0284	0.38	0.26	Blood pressure (smoking interaction);	chr3:125962464	chr3:125916620~125930024:+
OV	cis	rs4711350	0.765	rs2182658	ENSG00000224557.6	HLA-DPB2	4.01	8.33e-05	0.0284	0.36	0.26	Schizophrenia;	chr6:33781054	chr6:33112451~33129084:+
OV	cis	rs2117029	0.737	rs34436857	ENSG00000258017.1	RP11-386G11.10	-4.01	8.34e-05	0.0285	-0.33	-0.26	Intelligence (multi-trait analysis);	chr12:49045738	chr12:49127782~49147869:+
OV	cis	rs12654437	0.506	rs35082563	ENSG00000270442.1	CTB-95D12.1	4.01	8.34e-05	0.0285	0.35	0.26	Cognitive decline (age-related);	chr5:155428926	chr5:155491336~155493598:+
OV	cis	rs17767294	0.708	rs72848774	ENSG00000220721.1	OR1F12	4.01	8.34e-05	0.0285	0.53	0.26	Parkinson's disease;	chr6:27977862	chr6:28073316~28074233:+
OV	cis	rs17767294	0.708	rs72848775	ENSG00000220721.1	OR1F12	4.01	8.34e-05	0.0285	0.53	0.26	Parkinson's disease;	chr6:27982052	chr6:28073316~28074233:+
OV	cis	rs7267979	0.868	rs6138550	ENSG00000274973.1	RP13-401N8.7	-4.01	8.35e-05	0.0285	-0.29	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25242794	chr20:25845497~25845862:+
OV	cis	rs7267979	0.903	rs6050481	ENSG00000274973.1	RP13-401N8.7	-4.01	8.35e-05	0.0285	-0.29	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25243944	chr20:25845497~25845862:+
OV	cis	rs7267979	0.834	rs6115100	ENSG00000274973.1	RP13-401N8.7	-4.01	8.35e-05	0.0285	-0.29	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25245302	chr20:25845497~25845862:+
OV	cis	rs10759883	0.587	rs6478977	ENSG00000175611.10	LINC00476	-4.01	8.35e-05	0.0285	-0.31	-0.26	Nicotine dependence;	chr9:95797994	chr9:95759231~95875977:-
OV	cis	rs897984	0.542	rs59061704	ENSG00000232748.3	RP11-196G11.6	-4.01	8.35e-05	0.0285	-0.28	-0.26	Dementia with Lewy bodies;	chr16:31051383	chr16:31056460~31062803:+
OV	cis	rs1823913	0.637	rs12992372	ENSG00000227542.1	AC092614.2	4.01	8.36e-05	0.0285	0.28	0.26	Obesity-related traits;	chr2:191289251	chr2:191229165~191246172:-
OV	cis	rs11119805	0.649	rs11119816	ENSG00000260805.2	RP11-61J19.5	-4.01	8.37e-05	0.0285	-0.4	-0.26	Stearic acid (18:0) levels;	chr1:211826146	chr1:212557833~212559731:-
OV	cis	rs10992471	0.603	rs987553	ENSG00000281156.1	MIR3651	-4.01	8.37e-05	0.0286	-0.29	-0.26	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92536412	chr9:92292458~92292547:-
OV	cis	rs10992471	0.603	rs7872610	ENSG00000281156.1	MIR3651	-4.01	8.37e-05	0.0286	-0.29	-0.26	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92536855	chr9:92292458~92292547:-
OV	cis	rs987724	0.511	rs386736	ENSG00000243926.1	TIPARP-AS1	4.01	8.37e-05	0.0286	0.26	0.26	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr3:156795619	chr3:156671862~156674378:-
OV	cis	rs7246657	0.943	rs10404602	ENSG00000226686.6	LINC01535	-4.01	8.38e-05	0.0286	-0.39	-0.26	Coronary artery calcification;	chr19:37334731	chr19:37251912~37265535:+
OV	cis	rs944801	0.526	rs7044859	ENSG00000234840.1	LINC01239	4.01	8.38e-05	0.0286	0.29	0.26	Type 2 diabetes;	chr9:22018782	chr9:22646200~22824213:+
OV	cis	rs80168506	0.748	rs935093	ENSG00000272519.1	RP11-105N14.2	4.01	8.38e-05	0.0286	0.4	0.26	Selective IgA deficiency;	chr2:213182904	chr2:213266995~213276152:-
OV	cis	rs62025270	0.547	rs1026722	ENSG00000229212.6	RP11-561C5.4	4.01	8.39e-05	0.0286	0.33	0.26	Idiopathic pulmonary fibrosis;	chr15:85576168	chr15:85205440~85234795:-
OV	cis	rs2436845	0.627	rs1019976	ENSG00000253385.1	KB-1254G8.1	4.01	8.39e-05	0.0286	0.33	0.26	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102852043	chr8:102854455~102856075:+
OV	cis	rs8177876	0.642	rs4454990	ENSG00000261838.4	RP11-303E16.6	-4.01	8.4e-05	0.0286	-0.49	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81106550	chr16:81069854~81076598:+
OV	cis	rs4948102	0.599	rs2230197	ENSG00000273720.1	RP11-613E4.4	-4.01	8.4e-05	0.0286	-0.29	-0.26	Plasma homocysteine levels (post-methionine load test);	chr7:56058667	chr7:55743073~55743457:+
OV	cis	rs9393777	0.841	rs34332556	ENSG00000220721.1	OR1F12	4.01	8.4e-05	0.0286	0.45	0.26	Intelligence (multi-trait analysis);	chr6:27389635	chr6:28073316~28074233:+
OV	cis	rs6545883	0.965	rs778752	ENSG00000273302.1	RP11-493E12.2	4	8.41e-05	0.0287	0.21	0.26	Tuberculosis;	chr2:61549767	chr2:61199979~61200769:+
OV	cis	rs7267979	1	rs2297497	ENSG00000274973.1	RP13-401N8.7	4	8.42e-05	0.0287	0.29	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25317273	chr20:25845497~25845862:+
OV	cis	rs853679	0.546	rs483143	ENSG00000226314.6	ZNF192P1	-4	8.42e-05	0.0287	-0.46	-0.26	Depression;	chr6:27878966	chr6:28161781~28169594:+
OV	cis	rs809367	1	rs809367	ENSG00000272508.1	RP11-96C23.14	4	8.42e-05	0.0287	0.4	0.26	Parental extreme longevity (95 years and older);	chr10:87982049	chr10:86993432~87024732:+
OV	cis	rs7617773	0.539	rs35460860	ENSG00000228638.1	FCF1P2	-4	8.43e-05	0.0287	-0.31	-0.26	Coronary artery disease;	chr3:48350595	chr3:48290793~48291375:-
OV	cis	rs78663649	0.908	rs76338861	ENSG00000269480.1	CTD-3032J10.3	-4	8.43e-05	0.0287	-0.44	-0.26	White blood cell count;	chr19:16423227	chr19:17207138~17208010:-
OV	cis	rs7595412	1	rs992603	ENSG00000222017.1	AC011997.1	-4	8.44e-05	0.0287	-0.44	-0.26	Hip bone size;	chr2:198162300	chr2:197693106~197774823:+
OV	cis	rs255758	0.727	rs255748	ENSG00000272123.1	CTD-2366F13.2	-4	8.44e-05	0.0288	-0.35	-0.26	Rheumatoid arthritis;	chr5:54022546	chr5:53089016~53089468:-
OV	cis	rs7746199	0.736	rs13193542	ENSG00000280107.1	AL022393.9	-4	8.44e-05	0.0288	-0.54	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734646	chr6:28170845~28172521:+
OV	cis	rs7746199	0.736	rs13193480	ENSG00000280107.1	AL022393.9	-4	8.44e-05	0.0288	-0.54	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27734782	chr6:28170845~28172521:+
OV	cis	rs12468226	0.938	rs80282360	ENSG00000272966.1	RP11-686O6.1	4	8.45e-05	0.0288	0.43	0.26	Urate levels;	chr2:202275121	chr2:202336739~202337200:+
OV	cis	rs12468226	0.938	rs3731700	ENSG00000272966.1	RP11-686O6.1	4	8.45e-05	0.0288	0.43	0.26	Urate levels;	chr2:202291213	chr2:202336739~202337200:+
OV	cis	rs12468226	0.938	rs12464254	ENSG00000272966.1	RP11-686O6.1	4	8.45e-05	0.0288	0.43	0.26	Urate levels;	chr2:202301641	chr2:202336739~202337200:+
OV	cis	rs12468226	0.938	rs12471060	ENSG00000272966.1	RP11-686O6.1	4	8.45e-05	0.0288	0.43	0.26	Urate levels;	chr2:202309597	chr2:202336739~202337200:+
OV	cis	rs12468226	0.938	rs80315897	ENSG00000272966.1	RP11-686O6.1	4	8.45e-05	0.0288	0.43	0.26	Urate levels;	chr2:202318044	chr2:202336739~202337200:+
OV	cis	rs2274471	0.699	rs10758672	ENSG00000234534.1	CSNK1G2P1	4	8.45e-05	0.0288	0.32	0.26	Crohn's disease;	chr9:5116369	chr9:5040945~5041940:+
OV	cis	rs745109	0.504	rs113679164	ENSG00000273080.1	RP11-301O19.1	4	8.45e-05	0.0288	0.34	0.26	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86411479	chr2:86195590~86196049:+
OV	cis	rs2999052	1	rs2492285	ENSG00000277250.1	Metazoa_SRP	4	8.45e-05	0.0288	0.31	0.26	Hypospadias;	chr3:128199157	chr3:128673681~128674021:-
OV	cis	rs11105298	0.891	rs10777184	ENSG00000257194.2	RP11-567C2.1	-4	8.45e-05	0.0288	-0.4	-0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89525791	chr12:90107739~90112779:+
OV	cis	rs11105298	0.891	rs10858896	ENSG00000257194.2	RP11-567C2.1	-4	8.45e-05	0.0288	-0.4	-0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89526407	chr12:90107739~90112779:+
OV	cis	rs11105298	0.786	rs10777186	ENSG00000257194.2	RP11-567C2.1	-4	8.45e-05	0.0288	-0.4	-0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89527500	chr12:90107739~90112779:+
OV	cis	rs12477438	0.501	rs13008171	ENSG00000231822.1	AC019097.7	4	8.45e-05	0.0288	0.27	0.26	Chronic sinus infection;	chr2:99126956	chr2:99102018~99102752:+
OV	cis	rs12477438	0.52	rs4850897	ENSG00000231822.1	AC019097.7	4	8.45e-05	0.0288	0.27	0.26	Chronic sinus infection;	chr2:99151956	chr2:99102018~99102752:+
OV	cis	rs733592	0.507	rs7138917	ENSG00000240399.1	RP1-228P16.1	-4	8.45e-05	0.0288	-0.28	-0.26	Plateletcrit;	chr12:48061472	chr12:48054813~48055591:-
OV	cis	rs853679	0.546	rs200995	ENSG00000280107.1	AL022393.9	4	8.45e-05	0.0288	0.45	0.26	Depression;	chr6:27845916	chr6:28170845~28172521:+
OV	cis	rs10510102	0.516	rs10159759	ENSG00000226864.1	ATE1-AS1	4	8.46e-05	0.0288	0.47	0.26	Breast cancer;	chr10:121986533	chr10:121928312~121951965:+
OV	cis	rs7267979	0.868	rs6138546	ENSG00000274973.1	RP13-401N8.7	-4	8.46e-05	0.0288	-0.29	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25235898	chr20:25845497~25845862:+
OV	cis	rs4761702	0.661	rs12423139	ENSG00000257252.4	RP11-486A14.2	-4	8.46e-05	0.0288	-0.31	-0.26	Immature fraction of reticulocytes;	chr12:93336482	chr12:93317135~93377736:-
OV	cis	rs7811142	1	rs11559117	ENSG00000242294.5	STAG3L5P	4	8.46e-05	0.0288	0.27	0.26	Platelet count;	chr7:100478991	chr7:100336079~100351900:+
OV	cis	rs7811142	1	rs2406253	ENSG00000242294.5	STAG3L5P	4	8.46e-05	0.0288	0.27	0.26	Platelet count;	chr7:100479650	chr7:100336079~100351900:+
OV	cis	rs7811142	1	rs4463351	ENSG00000242294.5	STAG3L5P	4	8.46e-05	0.0288	0.27	0.26	Platelet count;	chr7:100480603	chr7:100336079~100351900:+
OV	cis	rs7811142	1	rs60844404	ENSG00000242294.5	STAG3L5P	4	8.46e-05	0.0288	0.27	0.26	Platelet count;	chr7:100482851	chr7:100336079~100351900:+
OV	cis	rs7811142	1	rs113738841	ENSG00000242294.5	STAG3L5P	4	8.46e-05	0.0288	0.27	0.26	Platelet count;	chr7:100483683	chr7:100336079~100351900:+
OV	cis	rs7811142	1	rs11763511	ENSG00000242294.5	STAG3L5P	4	8.46e-05	0.0288	0.27	0.26	Platelet count;	chr7:100484321	chr7:100336079~100351900:+
OV	cis	rs667920	0.573	rs9682783	ENSG00000239213.4	NCK1-AS1	4	8.47e-05	0.0288	0.32	0.26	Coronary artery disease;	chr3:136820847	chr3:136841726~136862054:-
OV	cis	rs9467773	0.62	rs2101582	ENSG00000243307.2	POM121L6P	4	8.47e-05	0.0288	0.25	0.26	Intelligence (multi-trait analysis);	chr6:26622506	chr6:26896952~26898777:+
OV	cis	rs9326248	0.953	rs488962	ENSG00000280143.1	AP000892.6	-4	8.47e-05	0.0288	-0.29	-0.26	Blood protein levels;	chr11:117201809	chr11:117204967~117210292:+
OV	cis	rs9326248	0.953	rs634960	ENSG00000280143.1	AP000892.6	-4	8.47e-05	0.0288	-0.29	-0.26	Blood protein levels;	chr11:117202247	chr11:117204967~117210292:+
OV	cis	rs8177876	0.597	rs1048194	ENSG00000261838.4	RP11-303E16.6	-4	8.47e-05	0.0288	-0.47	-0.26	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81031097	chr16:81069854~81076598:+
OV	cis	rs11105298	0.838	rs4842488	ENSG00000257194.2	RP11-567C2.1	-4	8.47e-05	0.0288	-0.39	-0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89487787	chr12:90107739~90112779:+
OV	cis	rs3761847	0.622	rs10818500	ENSG00000226752.6	PSMD5-AS1	4	8.48e-05	0.0289	0.28	0.26	Rheumatoid arthritis;	chr9:121048605	chr9:120824828~120854385:+
OV	cis	rs11105298	0.891	rs11105325	ENSG00000257194.2	RP11-567C2.1	-4	8.49e-05	0.0289	-0.38	-0.26	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89544813	chr12:90107739~90112779:+
OV	cis	rs1422189	0.925	rs16903340	ENSG00000250705.1	CTC-470C15.1	-4	8.49e-05	0.0289	-0.46	-0.26	Intelligence (multi-trait analysis);	chr5:88768123	chr5:88602780~88603117:+
OV	cis	rs2839627	0.561	rs7281655	ENSG00000225218.1	AP001628.6	4	8.49e-05	0.0289	0.25	0.26	Information processing speed;	chr21:42849633	chr21:42831040~42836477:-
OV	cis	rs10986311	0.851	rs10818940	ENSG00000227200.1	RP11-121A14.3	4	8.49e-05	0.0289	0.23	0.26	Vitiligo;	chr9:124301180	chr9:124262876~124265809:+
OV	cis	rs11096990	0.656	rs7693837	ENSG00000249207.1	RP11-360F5.1	-4	8.49e-05	0.0289	-0.27	-0.26	Cognitive function;	chr4:39301481	chr4:39112677~39126818:-
OV	cis	rs2303745	0.589	rs11086065	ENSG00000269815.1	CTD-2278I10.4	-4	8.49e-05	0.0289	-0.33	-0.26	Systemic lupus erythematosus;	chr19:17284194	chr19:17296196~17296695:-
OV	cis	rs848490	0.894	rs17233275	ENSG00000214293.7	APTR	4	8.49e-05	0.0289	0.32	0.26	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77680725	chr7:77657660~77696265:-
OV	cis	rs6919534	0.646	rs2071920	ENSG00000265123.2	RN7SL200P	4	8.49e-05	0.0289	0.29	0.26	Height;	chr6:35248519	chr6:34685355~34685642:-
OV	cis	rs801193	0.569	rs2659893	ENSG00000236529.1	RP13-254B10.1	4	8.5e-05	0.0289	0.27	0.26	Aortic root size;	chr7:66735006	chr7:65840212~65840596:+
OV	cis	rs801193	0.569	rs2659892	ENSG00000236529.1	RP13-254B10.1	4	8.5e-05	0.0289	0.27	0.26	Aortic root size;	chr7:66735318	chr7:65840212~65840596:+
OV	cis	rs4296809	0.505	rs55886751	ENSG00000249779.1	RP11-447H19.3	-4	8.51e-05	0.0289	-0.44	-0.26	Brain structure;	chr5:44108490	chr5:43206709~43207811:+
OV	cis	rs2111504	0.583	rs10853921	ENSG00000267213.4	AC007773.2	-4	8.51e-05	0.0289	-0.35	-0.26	Bipolar disorder;	chr19:32370899	chr19:32390050~32405560:-
OV	cis	rs2581794	1	rs2581794	ENSG00000242142.1	SERBP1P3	4	8.51e-05	0.0289	0.31	0.26	Schizophrenia;	chr3:53002190	chr3:53064283~53065091:-
OV	cis	rs6921919	0.945	rs61289879	ENSG00000220721.1	OR1F12	4	8.51e-05	0.0289	0.33	0.26	Autism spectrum disorder or schizophrenia;	chr6:28451385	chr6:28073316~28074233:+
OV	cis	rs12681366	0.843	rs3019156	ENSG00000253704.1	RP11-267M23.4	4	8.51e-05	0.0289	0.36	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94409552	chr8:94553722~94569745:+
OV	cis	rs10759883	0.58	rs690495	ENSG00000175611.10	LINC00476	4	8.52e-05	0.029	0.31	0.26	Nicotine dependence;	chr9:95893511	chr9:95759231~95875977:-
OV	cis	rs9867325	0.778	rs9877089	ENSG00000239213.4	NCK1-AS1	4	8.52e-05	0.029	0.33	0.26	Body mass index;	chr3:136937751	chr3:136841726~136862054:-
OV	cis	rs6128907	1	rs6128959	ENSG00000224635.1	RP4-564F22.5	4	8.52e-05	0.029	0.38	0.26	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38773752	chr20:38406011~38416797:-
OV	cis	rs6128907	0.898	rs9636527	ENSG00000224635.1	RP4-564F22.5	4	8.52e-05	0.029	0.38	0.26	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38774270	chr20:38406011~38416797:-
OV	cis	rs73201462	1	rs2955126	ENSG00000242551.2	POU5F1P6	-4	8.53e-05	0.029	-0.39	-0.26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128207411	chr3:128674735~128677005:-
OV	cis	rs2999052	1	rs2687729	ENSG00000277250.1	Metazoa_SRP	4	8.53e-05	0.029	0.31	0.26	Hypospadias;	chr3:128176383	chr3:128673681~128674021:-
OV	cis	rs2999052	1	rs2999049	ENSG00000277250.1	Metazoa_SRP	4	8.53e-05	0.029	0.31	0.26	Hypospadias;	chr3:128159974	chr3:128673681~128674021:-
OV	cis	rs35160687	0.787	rs10186289	ENSG00000273080.1	RP11-301O19.1	4	8.54e-05	0.029	0.25	0.26	Night sleep phenotypes;	chr2:86285865	chr2:86195590~86196049:+
OV	cis	rs7200543	0.961	rs1741	ENSG00000270580.4	PKD1P6	4	8.54e-05	0.029	0.27	0.26	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15036494	chr16:15104723~15131601:-
OV	cis	rs11951515	0.738	rs11950448	ENSG00000278487.1	RP11-447H19.4	4	8.55e-05	0.029	0.31	0.26	Metabolite levels  (X-11787);	chr5:43360163	chr5:43143362~43143514:-
OV	cis	rs875971	0.545	rs313828	ENSG00000237310.1	GS1-124K5.4	-4	8.55e-05	0.029	-0.3	-0.26	Aortic root size;	chr7:66087627	chr7:66493706~66495474:+
OV	cis	rs875971	0.52	rs160645	ENSG00000237310.1	GS1-124K5.4	-4	8.55e-05	0.029	-0.3	-0.26	Aortic root size;	chr7:66091320	chr7:66493706~66495474:+
OV	cis	rs875971	0.789	rs28815324	ENSG00000237310.1	GS1-124K5.4	-4	8.55e-05	0.029	-0.3	-0.26	Aortic root size;	chr7:66100789	chr7:66493706~66495474:+
OV	cis	rs7746199	0.736	rs17693963	ENSG00000220721.1	OR1F12	4	8.55e-05	0.029	0.46	0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27742386	chr6:28073316~28074233:+
OV	cis	rs4934494	1	rs4934494	ENSG00000240996.1	RP11-80H5.7	-4	8.55e-05	0.029	-0.33	-0.26	Red blood cell count;	chr10:89687662	chr10:89694295~89697928:-
OV	cis	rs35824328	0.571	rs1949049	ENSG00000197585.8	AC107218.3	4	8.56e-05	0.0291	0.4	0.26	HIV-associated neurocognitive disorder (mild neurocognitive disorder);	chr2:214359625	chr2:214250040~214684246:-
OV	cis	rs12477438	0.52	rs1453563	ENSG00000231822.1	AC019097.7	4	8.56e-05	0.0291	0.27	0.26	Chronic sinus infection;	chr2:99103804	chr2:99102018~99102752:+
OV	cis	rs875971	1	rs55962648	ENSG00000237310.1	GS1-124K5.4	-4	8.56e-05	0.0291	-0.26	-0.26	Aortic root size;	chr7:66160764	chr7:66493706~66495474:+
OV	cis	rs875971	1	rs11971949	ENSG00000237310.1	GS1-124K5.4	-4	8.56e-05	0.0291	-0.26	-0.26	Aortic root size;	chr7:66161027	chr7:66493706~66495474:+
OV	cis	rs875971	1	rs2420168	ENSG00000237310.1	GS1-124K5.4	-4	8.56e-05	0.0291	-0.26	-0.26	Aortic root size;	chr7:66165644	chr7:66493706~66495474:+
OV	cis	rs7646881	0.544	rs16847135	ENSG00000272087.1	RP11-379F4.7	4	8.56e-05	0.0291	0.38	0.26	Tetralogy of Fallot;	chr3:158706064	chr3:158693120~158693768:-
OV	cis	rs367615	0.66	rs10477972	ENSG00000249476.1	CTD-2587M2.1	4	8.56e-05	0.0291	0.31	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109496250	chr5:109237120~109326369:-
OV	cis	rs367615	0.66	rs4632850	ENSG00000249476.1	CTD-2587M2.1	4	8.56e-05	0.0291	0.31	0.26	Colorectal cancer (SNP x SNP interaction);	chr5:109497182	chr5:109237120~109326369:-
OV	cis	rs172166	0.561	rs149971	ENSG00000204709.4	LINC01556	4	8.56e-05	0.0291	0.3	0.26	Cardiac Troponin-T levels;	chr6:28014374	chr6:28943877~28944537:+
OV	cis	rs7771547	0.519	rs12663882	ENSG00000224666.3	RP1-50J22.4	-4	8.56e-05	0.0291	-0.28	-0.26	Platelet distribution width;	chr6:36394664	chr6:36386831~36393462:+
OV	cis	rs10486158	0.948	rs7807595	ENSG00000234141.1	AC009473.1	-4	8.57e-05	0.0291	-0.38	-0.26	Bipolar disorder and schizophrenia;	chr7:7360707	chr7:7949853~7950709:-
OV	cis	rs7246657	0.943	rs10420430	ENSG00000226686.6	LINC01535	-4	8.57e-05	0.0291	-0.4	-0.26	Coronary artery calcification;	chr19:37403292	chr19:37251912~37265535:+
OV	cis	rs72627509	0.857	rs2227901	ENSG00000269949.1	RP11-738E22.3	-4	8.57e-05	0.0291	-0.39	-0.26	Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr4:56932023	chr4:56960927~56961373:-
OV	cis	rs1584120	0.648	rs11046820	ENSG00000274885.1	RP11-268P4.6	-4	8.57e-05	0.0291	-0.32	-0.26	Pelvic organ prolapse (moderate/severe);	chr12:23134309	chr12:22638464~22638943:+
OV	cis	rs875971	0.862	rs10256544	ENSG00000236529.1	RP13-254B10.1	4	8.57e-05	0.0291	0.27	0.26	Aortic root size;	chr7:66210141	chr7:65840212~65840596:+
OV	cis	rs67180937	0.583	rs3008622	ENSG00000272750.1	RP11-378J18.8	4	8.57e-05	0.0291	0.34	0.26	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222632356	chr1:222658867~222661512:-
OV	cis	rs2919917	0.628	rs12680932	ENSG00000254352.1	RP11-578O24.2	-4	8.57e-05	0.0291	-0.34	-0.26	Lymphocyte counts;	chr8:78685516	chr8:78723796~78724136:-
OV	cis	rs1436109	0.711	rs12287147	ENSG00000255129.4	RP11-839D17.3	4	8.57e-05	0.0291	0.44	0.26	Cardiac muscle measurement;	chr11:113027488	chr11:113278437~113314437:-
OV	cis	rs1436109	0.711	rs12288908	ENSG00000255129.4	RP11-839D17.3	4	8.57e-05	0.0291	0.44	0.26	Cardiac muscle measurement;	chr11:113028273	chr11:113278437~113314437:-
OV	cis	rs4296809	0.556	rs4866870	ENSG00000249779.1	RP11-447H19.3	4	8.57e-05	0.0291	0.48	0.26	Brain structure;	chr5:44150320	chr5:43206709~43207811:+
OV	cis	rs9847710	0.733	rs2581806	ENSG00000242142.1	SERBP1P3	4	8.57e-05	0.0291	0.31	0.26	Ulcerative colitis;	chr3:53029344	chr3:53064283~53065091:-
OV	cis	rs1836229	0.571	rs1972798	ENSG00000225706.1	PTPRD-AS1	-4	8.57e-05	0.0291	-0.26	-0.26	Restless legs syndrome;	chr9:8835579	chr9:8858130~8862255:+
OV	cis	rs10504130	0.569	rs13265006	ENSG00000272024.1	RP11-546K22.3	-4	8.57e-05	0.0291	-0.33	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51877963	chr8:51950284~51950690:+
OV	cis	rs10504130	0.597	rs34058697	ENSG00000272024.1	RP11-546K22.3	-4	8.57e-05	0.0291	-0.33	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51882392	chr8:51950284~51950690:+
OV	cis	rs10504130	0.569	rs12681734	ENSG00000272024.1	RP11-546K22.3	-4	8.57e-05	0.0291	-0.33	-0.26	Venous thromboembolism (SNP x SNP interaction);	chr8:51893635	chr8:51950284~51950690:+
OV	cis	rs2243480	1	rs6460260	ENSG00000226824.5	RP4-756H11.3	4	8.58e-05	0.0291	0.46	0.26	Diabetic kidney disease;	chr7:65750468	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs6460261	ENSG00000226824.5	RP4-756H11.3	4	8.58e-05	0.0291	0.46	0.26	Diabetic kidney disease;	chr7:65750593	chr7:66654538~66669855:+
OV	cis	rs10829156	0.741	rs9731044	ENSG00000225527.1	RP11-383B4.4	-4	8.59e-05	0.0291	-0.36	-0.26	Sudden cardiac arrest;	chr10:18605356	chr10:18531849~18533336:-
OV	cis	rs10829156	0.538	rs61840846	ENSG00000225527.1	RP11-383B4.4	-4	8.59e-05	0.0291	-0.36	-0.26	Sudden cardiac arrest;	chr10:18606393	chr10:18531849~18533336:-
OV	cis	rs7520050	0.966	rs785495	ENSG00000280836.1	AL355480.1	4	8.59e-05	0.0291	0.32	0.26	Reticulocyte count;Red blood cell count;	chr1:46122215	chr1:45581219~45581321:-
OV	cis	rs11992162	1	rs7460395	ENSG00000227888.4	FAM66A	4	8.59e-05	0.0291	0.33	0.26	Monocyte count;	chr8:11977866	chr8:12362019~12388296:+
OV	cis	rs755249	0.727	rs12028034	ENSG00000237624.1	OXCT2P1	-4	8.6e-05	0.0292	-0.3	-0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39574035	chr1:39514956~39516490:+
OV	cis	rs4664293	0.528	rs72960224	ENSG00000226266.5	AC009961.3	4	8.6e-05	0.0292	0.31	0.26	Monocyte percentage of white cells;	chr2:159563993	chr2:159670708~159712435:-
OV	cis	rs875971	0.862	rs6959268	ENSG00000237310.1	GS1-124K5.4	-4	8.6e-05	0.0292	-0.26	-0.26	Aortic root size;	chr7:66347979	chr7:66493706~66495474:+
OV	cis	rs3105491	0.586	rs1118559	ENSG00000240356.5	RP11-395L14.11	-4	8.6e-05	0.0292	-0.33	-0.26	Systolic blood pressure in sickle cell anemia;	chr2:114170646	chr2:113610502~113627090:-
OV	cis	rs8114671	0.967	rs6060285	ENSG00000269202.1	RP4-614O4.12	-4	8.61e-05	0.0292	-0.26	-0.26	Height;	chr20:35182684	chr20:35201747~35203288:-
OV	cis	rs8114671	0.967	rs2378337	ENSG00000269202.1	RP4-614O4.12	-4	8.61e-05	0.0292	-0.26	-0.26	Height;	chr20:35183632	chr20:35201747~35203288:-
OV	cis	rs8114671	0.901	rs6119581	ENSG00000269202.1	RP4-614O4.12	-4	8.61e-05	0.0292	-0.26	-0.26	Height;	chr20:35185886	chr20:35201747~35203288:-
OV	cis	rs8114671	0.933	rs6087683	ENSG00000269202.1	RP4-614O4.12	-4	8.61e-05	0.0292	-0.26	-0.26	Height;	chr20:35186641	chr20:35201747~35203288:-
OV	cis	rs8114671	0.967	rs4911472	ENSG00000269202.1	RP4-614O4.12	-4	8.61e-05	0.0292	-0.26	-0.26	Height;	chr20:35187574	chr20:35201747~35203288:-
OV	cis	rs8114671	0.967	rs6058202	ENSG00000269202.1	RP4-614O4.12	-4	8.61e-05	0.0292	-0.26	-0.26	Height;	chr20:35190180	chr20:35201747~35203288:-
OV	cis	rs9326248	1	rs3736120	ENSG00000280143.1	AP000892.6	4	8.62e-05	0.0292	0.28	0.26	Blood protein levels;	chr11:117161409	chr11:117204967~117210292:+
OV	cis	rs6142102	0.923	rs2268078	ENSG00000264616.1	MIR4755	4	8.62e-05	0.0292	0.32	0.26	Skin pigmentation;	chr20:34008898	chr20:34049119~34049190:+
OV	cis	rs73186030	0.623	rs16832958	ENSG00000272758.4	RP11-299J3.8	4	8.62e-05	0.0292	0.26	0.26	Serum parathyroid hormone levels;	chr3:122299646	chr3:122416207~122443180:+
OV	cis	rs992157	0.735	rs13430006	ENSG00000237281.1	CATIP-AS2	4	8.62e-05	0.0292	0.3	0.26	Colorectal cancer;	chr2:218248366	chr2:218326889~218357966:-
OV	cis	rs4713118	0.868	rs2893928	ENSG00000226314.6	ZNF192P1	-4	8.62e-05	0.0292	-0.34	-0.26	Parkinson's disease;	chr6:27770651	chr6:28161781~28169594:+
OV	cis	rs7259376	0.623	rs3926992	ENSG00000269742.1	BNIP3P29	4	8.62e-05	0.0292	0.3	0.26	Menopause (age at onset);	chr19:22323074	chr19:22065828~22066398:-
OV	cis	rs875971	0.862	rs778736	ENSG00000237310.1	GS1-124K5.4	4	8.63e-05	0.0293	0.26	0.26	Aortic root size;	chr7:66348861	chr7:66493706~66495474:+
OV	cis	rs875971	0.502	rs2946580	ENSG00000273024.4	INTS4P2	4	8.64e-05	0.0293	0.31	0.26	Aortic root size;	chr7:66066855	chr7:65647864~65715661:+
OV	cis	rs6673267	0.869	rs11583140	ENSG00000223774.4	RP11-307B6.3	4	8.66e-05	0.0293	0.28	0.26	Lobe attachment (rater-scored or self-reported);	chr1:201007970	chr1:201893842~201899978:+
OV	cis	rs3733585	0.579	rs4235353	ENSG00000250413.1	RP11-448G15.1	4	8.67e-05	0.0293	0.33	0.26	Cleft plate (environmental tobacco smoke interaction);	chr4:10121310	chr4:10006482~10009725:+
OV	cis	rs3733585	0.605	rs4235354	ENSG00000250413.1	RP11-448G15.1	4	8.67e-05	0.0293	0.33	0.26	Cleft plate (environmental tobacco smoke interaction);	chr4:10121318	chr4:10006482~10009725:+
OV	cis	rs10214930	0.697	rs12539707	ENSG00000235574.1	AC073150.6	-4	8.67e-05	0.0293	-0.31	-0.26	Hypospadias;	chr7:27586546	chr7:27491682~27492765:-
OV	cis	rs10214930	0.697	rs7783447	ENSG00000235574.1	AC073150.6	-4	8.67e-05	0.0293	-0.31	-0.26	Hypospadias;	chr7:27587236	chr7:27491682~27492765:-
OV	cis	rs10214930	0.697	rs6462034	ENSG00000235574.1	AC073150.6	-4	8.67e-05	0.0293	-0.31	-0.26	Hypospadias;	chr7:27588965	chr7:27491682~27492765:-
OV	cis	rs10214930	0.65	rs4348389	ENSG00000235574.1	AC073150.6	-4	8.67e-05	0.0293	-0.31	-0.26	Hypospadias;	chr7:27589331	chr7:27491682~27492765:-
OV	cis	rs10214930	0.697	rs1980329	ENSG00000235574.1	AC073150.6	-4	8.67e-05	0.0293	-0.31	-0.26	Hypospadias;	chr7:27590681	chr7:27491682~27492765:-
OV	cis	rs10214930	0.697	rs12667235	ENSG00000235574.1	AC073150.6	-4	8.67e-05	0.0293	-0.31	-0.26	Hypospadias;	chr7:27592012	chr7:27491682~27492765:-
OV	cis	rs10214930	0.723	rs6948814	ENSG00000235574.1	AC073150.6	-4	8.67e-05	0.0293	-0.31	-0.26	Hypospadias;	chr7:27593782	chr7:27491682~27492765:-
OV	cis	rs10214930	0.697	rs12668430	ENSG00000235574.1	AC073150.6	-4	8.67e-05	0.0293	-0.31	-0.26	Hypospadias;	chr7:27593899	chr7:27491682~27492765:-
OV	cis	rs10214930	0.671	rs28416309	ENSG00000235574.1	AC073150.6	-4	8.67e-05	0.0293	-0.31	-0.26	Hypospadias;	chr7:27594123	chr7:27491682~27492765:-
OV	cis	rs10214930	0.697	rs28429439	ENSG00000235574.1	AC073150.6	-4	8.67e-05	0.0293	-0.31	-0.26	Hypospadias;	chr7:27594180	chr7:27491682~27492765:-
OV	cis	rs10214930	0.697	rs1404278	ENSG00000235574.1	AC073150.6	-4	8.67e-05	0.0293	-0.31	-0.26	Hypospadias;	chr7:27595107	chr7:27491682~27492765:-
OV	cis	rs10214930	0.697	rs2110526	ENSG00000235574.1	AC073150.6	-4	8.67e-05	0.0293	-0.31	-0.26	Hypospadias;	chr7:27596061	chr7:27491682~27492765:-
OV	cis	rs10214930	0.723	rs6960834	ENSG00000235574.1	AC073150.6	-4	8.67e-05	0.0293	-0.31	-0.26	Hypospadias;	chr7:27596367	chr7:27491682~27492765:-
OV	cis	rs10214930	0.697	rs6980382	ENSG00000235574.1	AC073150.6	-4	8.67e-05	0.0293	-0.31	-0.26	Hypospadias;	chr7:27598043	chr7:27491682~27492765:-
OV	cis	rs10214930	0.697	rs6947731	ENSG00000235574.1	AC073150.6	-4	8.67e-05	0.0293	-0.31	-0.26	Hypospadias;	chr7:27599076	chr7:27491682~27492765:-
OV	cis	rs10214930	0.697	rs1030003	ENSG00000235574.1	AC073150.6	-4	8.67e-05	0.0293	-0.31	-0.26	Hypospadias;	chr7:27600240	chr7:27491682~27492765:-
OV	cis	rs10214930	0.697	rs6462036	ENSG00000235574.1	AC073150.6	-4	8.67e-05	0.0293	-0.31	-0.26	Hypospadias;	chr7:27601444	chr7:27491682~27492765:-
OV	cis	rs10214930	0.625	rs6462037	ENSG00000235574.1	AC073150.6	-4	8.67e-05	0.0293	-0.31	-0.26	Hypospadias;	chr7:27601481	chr7:27491682~27492765:-
OV	cis	rs10214930	0.697	rs7811436	ENSG00000235574.1	AC073150.6	-4	8.67e-05	0.0293	-0.31	-0.26	Hypospadias;	chr7:27601667	chr7:27491682~27492765:-
OV	cis	rs10214930	0.697	rs2110528	ENSG00000235574.1	AC073150.6	-4	8.67e-05	0.0293	-0.31	-0.26	Hypospadias;	chr7:27603400	chr7:27491682~27492765:-
OV	cis	rs7587476	0.505	rs777323	ENSG00000229267.2	AC072062.1	4	8.67e-05	0.0294	0.35	0.26	Neuroblastoma;	chr2:214873761	chr2:214810229~214963274:+
OV	cis	rs1584120	0.62	rs11046812	ENSG00000274885.1	RP11-268P4.6	-4	8.67e-05	0.0294	-0.3	-0.26	Pelvic organ prolapse (moderate/severe);	chr12:23126673	chr12:22638464~22638943:+
OV	cis	rs1950626	0.833	rs2400963	ENSG00000258399.5	MEG8	-4	8.67e-05	0.0294	-0.25	-0.26	Pelvic organ prolapse (moderate/severe);	chr14:100929369	chr14:100894770~100935999:+
OV	cis	rs10829156	0.898	rs6482565	ENSG00000225527.1	RP11-383B4.4	-4	8.68e-05	0.0294	-0.36	-0.26	Sudden cardiac arrest;	chr10:18611664	chr10:18531849~18533336:-
OV	cis	rs2021786	0.965	rs2300927	ENSG00000199719.1	RN7SKP74	4	8.7e-05	0.0294	0.29	0.26	Preschool internalizing problems;	chr20:17447110	chr20:18295143~18295451:-
OV	cis	rs4713118	0.868	rs10484401	ENSG00000226314.6	ZNF192P1	4	8.7e-05	0.0294	0.33	0.26	Parkinson's disease;	chr6:27778811	chr6:28161781~28169594:+
OV	cis	rs7598759	0.548	rs11686485	ENSG00000181798.2	LINC00471	-4	8.7e-05	0.0294	-0.25	-0.26	Noise-induced hearing loss;	chr2:231495986	chr2:231508426~231514339:-
OV	cis	rs1797885	0.763	rs9862177	ENSG00000251774.1	RNU6-377P	4	8.7e-05	0.0294	0.24	0.26	Immature fraction of reticulocytes;	chr3:12477703	chr3:12514706~12514807:+
OV	cis	rs1707322	0.721	rs4559551	ENSG00000234329.1	RP11-767N6.2	4	8.7e-05	0.0294	0.27	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701861	chr1:45651039~45651826:-
OV	cis	rs6921919	0.583	rs2027361	ENSG00000204709.4	LINC01556	4	8.71e-05	0.0295	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28420531	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs4642462	ENSG00000204709.4	LINC01556	4	8.71e-05	0.0295	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28421474	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs3800328	ENSG00000204709.4	LINC01556	4	8.71e-05	0.0295	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28423066	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs35560946	ENSG00000204709.4	LINC01556	4	8.71e-05	0.0295	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28427660	chr6:28943877~28944537:+
OV	cis	rs4296809	0.714	rs76606202	ENSG00000249779.1	RP11-447H19.3	-4	8.71e-05	0.0295	-0.45	-0.26	Brain structure;	chr5:44122163	chr5:43206709~43207811:+
OV	cis	rs295490	0.748	rs79654016	ENSG00000272656.1	RP11-219D15.3	4	8.71e-05	0.0295	0.52	0.26	PR interval in Tripanosoma cruzi seropositivity;	chr3:139374644	chr3:139349024~139349371:-
OV	cis	rs10924970	0.967	rs61836169	ENSG00000236863.2	RPL23AP23	4	8.72e-05	0.0295	0.25	0.26	Asthma;	chr1:235303483	chr1:235295865~235296335:+
OV	cis	rs2239557	1	rs11628710	ENSG00000259065.1	RP5-1021I20.1	-4	8.73e-05	0.0295	-0.31	-0.26	Common traits (Other);	chr14:74182577	chr14:73787360~73803270:+
OV	cis	rs638893	0.673	rs538645	ENSG00000255239.1	AP002954.6	-4	8.73e-05	0.0295	-0.34	-0.26	Vitiligo;	chr11:118840360	chr11:118688039~118690600:-
OV	cis	rs7617773	0.539	rs12486935	ENSG00000228638.1	FCF1P2	-4	8.73e-05	0.0295	-0.32	-0.26	Coronary artery disease;	chr3:48348674	chr3:48290793~48291375:-
OV	cis	rs8113142	0.551	rs8110450	ENSG00000267243.4	AC005307.3	-4	8.73e-05	0.0295	-0.36	-0.26	Femoral neck bone geometry and menarche (age at onset);	chr19:28723143	chr19:28435388~28727777:-
OV	cis	rs220324	0.683	rs220323	ENSG00000237232.6	ZNF295-AS1	-4	8.73e-05	0.0295	-0.33	-0.26	Idiopathic osteonecrosis of the femoral head;	chr21:42166548	chr21:42009194~42024924:+
OV	cis	rs875971	0.571	rs160647	ENSG00000273024.4	INTS4P2	4	8.73e-05	0.0295	0.31	0.26	Aortic root size;	chr7:66089365	chr7:65647864~65715661:+
OV	cis	rs7520050	0.902	rs4626927	ENSG00000281133.1	AL355480.3	3.99	8.75e-05	0.0296	0.29	0.26	Reticulocyte count;Red blood cell count;	chr1:45782973	chr1:45580892~45580996:-
OV	cis	rs7520050	0.902	rs7514192	ENSG00000281133.1	AL355480.3	3.99	8.75e-05	0.0296	0.29	0.26	Reticulocyte count;Red blood cell count;	chr1:45783305	chr1:45580892~45580996:-
OV	cis	rs7520050	0.966	rs785479	ENSG00000280836.1	AL355480.1	3.99	8.75e-05	0.0296	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:46026472	chr1:45581219~45581321:-
OV	cis	rs494453	0.583	rs559981	ENSG00000227811.2	FAM212B-AS1	-3.99	8.75e-05	0.0296	-0.35	-0.26	Osteoporosis-related phenotypes;	chr1:111676716	chr1:111739841~111747798:+
OV	cis	rs9368481	0.761	rs4358615	ENSG00000261584.1	RP11-457M11.5	3.99	8.75e-05	0.0296	0.28	0.26	Autism spectrum disorder or schizophrenia;	chr6:27030788	chr6:26686241~26687964:+
OV	cis	rs7726839	0.574	rs12517345	ENSG00000271781.1	CTD-2589H19.6	-3.99	8.76e-05	0.0296	-0.39	-0.26	Obesity-related traits;	chr5:628179	chr5:675826~676616:+
OV	cis	rs7726839	0.574	rs11739866	ENSG00000271781.1	CTD-2589H19.6	-3.99	8.76e-05	0.0296	-0.39	-0.26	Obesity-related traits;	chr5:636184	chr5:675826~676616:+
OV	cis	rs57481061	1	rs57481061	ENSG00000258302.2	RP11-981P6.1	3.99	8.77e-05	0.0296	0.36	0.26	Coronary artery disease;	chr12:89625401	chr12:89561129~89594878:+
OV	cis	rs67311347	0.544	rs9877105	ENSG00000223797.4	ENTPD3-AS1	3.99	8.77e-05	0.0296	0.26	0.26	Renal cell carcinoma;	chr3:40291875	chr3:40313802~40453329:-
OV	cis	rs2303745	0.589	rs10401700	ENSG00000269815.1	CTD-2278I10.4	-3.99	8.78e-05	0.0296	-0.34	-0.26	Systemic lupus erythematosus;	chr19:17286891	chr19:17296196~17296695:-
OV	cis	rs2243480	0.708	rs13242216	ENSG00000226824.5	RP4-756H11.3	-3.99	8.78e-05	0.0296	-0.43	-0.26	Diabetic kidney disease;	chr7:66433290	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs67536397	ENSG00000226824.5	RP4-756H11.3	-3.99	8.78e-05	0.0296	-0.43	-0.26	Diabetic kidney disease;	chr7:66482930	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs58669269	ENSG00000226824.5	RP4-756H11.3	-3.99	8.78e-05	0.0296	-0.43	-0.26	Diabetic kidney disease;	chr7:66486966	chr7:66654538~66669855:+
OV	cis	rs35824328	0.634	rs1912202	ENSG00000197585.8	AC107218.3	3.99	8.79e-05	0.0297	0.4	0.26	HIV-associated neurocognitive disorder (mild neurocognitive disorder);	chr2:214361854	chr2:214250040~214684246:-
OV	cis	rs11822910	0.654	rs2439450	ENSG00000265566.2	RN7SL605P	3.99	8.79e-05	0.0297	0.36	0.26	Platelet distribution width;	chr11:57445588	chr11:57528085~57528365:-
OV	cis	rs3198697	0.663	rs12928099	ENSG00000263335.1	AF001548.5	-3.99	8.79e-05	0.0297	-0.36	-0.26	Triglycerides;	chr16:15056648	chr16:15726674~15732993:+
OV	cis	rs1707322	0.685	rs56177313	ENSG00000234329.1	RP11-767N6.2	3.99	8.79e-05	0.0297	0.27	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760134	chr1:45651039~45651826:-
OV	cis	rs11951515	0.7	rs56023994	ENSG00000278487.1	RP11-447H19.4	-3.99	8.79e-05	0.0297	-0.3	-0.26	Metabolite levels  (X-11787);	chr5:43285291	chr5:43143362~43143514:-
OV	cis	rs11951515	0.676	rs55647314	ENSG00000278487.1	RP11-447H19.4	-3.99	8.79e-05	0.0297	-0.3	-0.26	Metabolite levels  (X-11787);	chr5:43285294	chr5:43143362~43143514:-
OV	cis	rs1823913	0.637	rs10931493	ENSG00000227542.1	AC092614.2	3.99	8.79e-05	0.0297	0.28	0.26	Obesity-related traits;	chr2:191288142	chr2:191229165~191246172:-
OV	cis	rs12681366	0.839	rs2931632	ENSG00000253704.1	RP11-267M23.4	3.99	8.8e-05	0.0297	0.36	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94406560	chr8:94553722~94569745:+
OV	cis	rs514406	0.505	rs431459	ENSG00000206627.1	RNU6-969P	3.99	8.8e-05	0.0297	0.28	0.26	Monocyte count;	chr1:52717558	chr1:52805108~52805212:-
OV	cis	rs4591358	0.734	rs16836256	ENSG00000223466.1	AC064834.2	3.99	8.81e-05	0.0297	0.3	0.26	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195470381	chr2:195533035~195538681:+
OV	cis	rs6128907	1	rs6128913	ENSG00000224635.1	RP4-564F22.5	3.99	8.81e-05	0.0297	0.37	0.26	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38761531	chr20:38406011~38416797:-
OV	cis	rs1560104	0.556	rs59670495	ENSG00000259899.1	CTD-3037G24.3	-3.99	8.81e-05	0.0297	-0.3	-0.26	Obesity-related traits;	chr16:12617241	chr16:12560756~12611044:-
OV	cis	rs9733	0.818	rs4970926	ENSG00000277452.1	Metazoa_SRP	-3.99	8.81e-05	0.0297	-0.28	-0.26	Tonsillectomy;	chr1:150701208	chr1:150566562~150566860:-
OV	cis	rs12701220	0.655	rs7784403	ENSG00000229043.2	AC091729.9	-3.99	8.81e-05	0.0297	-0.33	-0.26	Bronchopulmonary dysplasia;	chr7:1113441	chr7:1160374~1165267:+
OV	cis	rs7957197	0.628	rs692902	ENSG00000200795.1	RNU4-1	-3.99	8.81e-05	0.0297	-0.38	-0.26	Type 2 diabetes;	chr12:120759321	chr12:120293097~120293237:-
OV	cis	rs853679	0.55	rs1225598	ENSG00000226314.6	ZNF192P1	-3.99	8.81e-05	0.0297	-0.35	-0.26	Depression;	chr6:28193021	chr6:28161781~28169594:+
OV	cis	rs7246967	0.611	rs73030508	ENSG00000267920.1	SNX6P1	-3.99	8.82e-05	0.0297	-0.41	-0.26	Bronchopulmonary dysplasia;	chr19:22643230	chr19:23126569~23127792:-
OV	cis	rs7246967	0.611	rs73030511	ENSG00000267920.1	SNX6P1	-3.99	8.82e-05	0.0297	-0.41	-0.26	Bronchopulmonary dysplasia;	chr19:22643232	chr19:23126569~23127792:-
OV	cis	rs9309473	0.66	rs79370894	ENSG00000163016.8	ALMS1P	3.99	8.82e-05	0.0297	0.35	0.26	Metabolite levels;	chr2:73456388	chr2:73644919~73685576:+
OV	cis	rs9287719	0.578	rs62127189	ENSG00000243819.4	RN7SL832P	3.99	8.83e-05	0.0298	0.27	0.26	Prostate cancer;	chr2:10621200	chr2:10690344~10692099:+
OV	cis	rs9287719	0.601	rs1861299	ENSG00000243819.4	RN7SL832P	3.99	8.83e-05	0.0298	0.27	0.26	Prostate cancer;	chr2:10623631	chr2:10690344~10692099:+
OV	cis	rs9287719	0.601	rs1861300	ENSG00000243819.4	RN7SL832P	3.99	8.83e-05	0.0298	0.27	0.26	Prostate cancer;	chr2:10623835	chr2:10690344~10692099:+
OV	cis	rs12468226	0.873	rs60722019	ENSG00000272966.1	RP11-686O6.1	3.99	8.83e-05	0.0298	0.43	0.26	Urate levels;	chr2:202282060	chr2:202336739~202337200:+
OV	cis	rs16843372	0.599	rs1807921	ENSG00000251491.2	OR7E28P	3.99	8.84e-05	0.0298	0.31	0.26	Obesity-related traits;	chr2:158838237	chr2:158862311~158863285:+
OV	cis	rs9326248	1	rs664922	ENSG00000280143.1	AP000892.6	3.99	8.84e-05	0.0298	0.28	0.26	Blood protein levels;	chr11:117200179	chr11:117204967~117210292:+
OV	cis	rs9326248	1	rs664082	ENSG00000280143.1	AP000892.6	3.99	8.84e-05	0.0298	0.28	0.26	Blood protein levels;	chr11:117200354	chr11:117204967~117210292:+
OV	cis	rs7520050	0.966	rs7550746	ENSG00000280836.1	AL355480.1	3.99	8.85e-05	0.0298	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:45886047	chr1:45581219~45581321:-
OV	cis	rs2243480	1	rs2707844	ENSG00000226824.5	RP4-756H11.3	-3.99	8.85e-05	0.0298	-0.42	-0.26	Diabetic kidney disease;	chr7:66594522	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs1796220	ENSG00000226824.5	RP4-756H11.3	-3.99	8.85e-05	0.0298	-0.42	-0.26	Diabetic kidney disease;	chr7:66597113	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs2707831	ENSG00000226824.5	RP4-756H11.3	-3.99	8.85e-05	0.0298	-0.42	-0.26	Diabetic kidney disease;	chr7:66597524	chr7:66654538~66669855:+
OV	cis	rs57221529	0.608	rs11749927	ENSG00000271781.1	CTD-2589H19.6	-3.99	8.85e-05	0.0298	-0.39	-0.26	Lung disease severity in cystic fibrosis;	chr5:668727	chr5:675826~676616:+
OV	cis	rs2070488	0.965	rs2366119	ENSG00000229589.1	ACVR2B-AS1	3.99	8.85e-05	0.0298	0.29	0.26	Electrocardiographic conduction measures;	chr3:38442962	chr3:38451027~38454820:-
OV	cis	rs7536700	0.915	rs3891075	ENSG00000272030.1	RP1-178F15.4	3.99	8.85e-05	0.0298	0.51	0.26	Multiple myeloma (IgH translocation);	chr1:153685711	chr1:153631438~153634397:-
OV	cis	rs858239	0.899	rs7794684	ENSG00000230042.1	AK3P3	-3.99	8.86e-05	0.0298	-0.27	-0.26	Cerebrospinal fluid biomarker levels;	chr7:23271186	chr7:23129178~23129841:+
OV	cis	rs9287719	0.601	rs12996735	ENSG00000243819.4	RN7SL832P	3.99	8.86e-05	0.0299	0.27	0.26	Prostate cancer;	chr2:10576590	chr2:10690344~10692099:+
OV	cis	rs73201462	1	rs11706908	ENSG00000242551.2	POU5F1P6	3.99	8.86e-05	0.0299	0.38	0.26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128314205	chr3:128674735~128677005:-
OV	cis	rs7746199	0.736	rs34105070	ENSG00000280107.1	AL022393.9	-3.99	8.86e-05	0.0299	-0.54	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27593026	chr6:28170845~28172521:+
OV	cis	rs7746199	0.673	rs72845046	ENSG00000280107.1	AL022393.9	-3.99	8.86e-05	0.0299	-0.54	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27607489	chr6:28170845~28172521:+
OV	cis	rs7746199	0.736	rs67652222	ENSG00000280107.1	AL022393.9	-3.99	8.86e-05	0.0299	-0.54	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27618441	chr6:28170845~28172521:+
OV	cis	rs7746199	0.736	rs34038546	ENSG00000280107.1	AL022393.9	-3.99	8.86e-05	0.0299	-0.54	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27639881	chr6:28170845~28172521:+
OV	cis	rs141342723	1	rs141342723	ENSG00000280107.1	AL022393.9	-3.99	8.86e-05	0.0299	-0.54	-0.26	Autism spectrum disorder or schizophrenia;	chr6:27654305	chr6:28170845~28172521:+
OV	cis	rs7746199	0.736	rs34543938	ENSG00000280107.1	AL022393.9	-3.99	8.86e-05	0.0299	-0.54	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27656861	chr6:28170845~28172521:+
OV	cis	rs7746199	0.736	rs56405707	ENSG00000280107.1	AL022393.9	-3.99	8.86e-05	0.0299	-0.54	-0.26	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27672467	chr6:28170845~28172521:+
OV	cis	rs2058350	0.773	rs7975273	ENSG00000250770.2	RP5-1063M23.1	-3.99	8.87e-05	0.0299	-0.33	-0.26	Cognitive performance;	chr12:3822900	chr12:3296202~3300224:-
OV	cis	rs2999052	1	rs2955102	ENSG00000277250.1	Metazoa_SRP	3.99	8.87e-05	0.0299	0.31	0.26	Hypospadias;	chr3:128146667	chr3:128673681~128674021:-
OV	cis	rs2999052	1	rs67451924	ENSG00000277250.1	Metazoa_SRP	3.99	8.87e-05	0.0299	0.31	0.26	Hypospadias;	chr3:128148554	chr3:128673681~128674021:-
OV	cis	rs6088590	0.735	rs6060001	ENSG00000206582.1	Y_RNA	3.99	8.87e-05	0.0299	0.31	0.26	Coronary artery disease;	chr20:34706549	chr20:34526510~34526606:-
OV	cis	rs11951515	0.7	rs57392430	ENSG00000278487.1	RP11-447H19.4	-3.99	8.88e-05	0.0299	-0.3	-0.26	Metabolite levels  (X-11787);	chr5:43284329	chr5:43143362~43143514:-
OV	cis	rs11951515	0.7	rs56029402	ENSG00000278487.1	RP11-447H19.4	-3.99	8.88e-05	0.0299	-0.3	-0.26	Metabolite levels  (X-11787);	chr5:43284353	chr5:43143362~43143514:-
OV	cis	rs10760123	1	rs10760123	ENSG00000226752.6	PSMD5-AS1	-3.99	8.88e-05	0.0299	-0.28	-0.26	Allergic disease (asthma, hay fever or eczema);	chr9:120888256	chr9:120824828~120854385:+
OV	cis	rs881375	0.967	rs2270231	ENSG00000226752.6	PSMD5-AS1	-3.99	8.88e-05	0.0299	-0.28	-0.26	Rheumatoid arthritis;	chr9:120888704	chr9:120824828~120854385:+
OV	cis	rs881375	1	rs6478484	ENSG00000226752.6	PSMD5-AS1	-3.99	8.88e-05	0.0299	-0.28	-0.26	Rheumatoid arthritis;	chr9:120890102	chr9:120824828~120854385:+
OV	cis	rs881375	1	rs881375	ENSG00000226752.6	PSMD5-AS1	-3.99	8.88e-05	0.0299	-0.28	-0.26	Rheumatoid arthritis;	chr9:120890620	chr9:120824828~120854385:+
OV	cis	rs9309473	0.615	rs74523560	ENSG00000163016.8	ALMS1P	3.99	8.89e-05	0.03	0.34	0.26	Metabolite levels;	chr2:73537058	chr2:73644919~73685576:+
OV	cis	rs10754283	0.901	rs10047070	ENSG00000231613.1	RP5-943J3.1	3.99	8.9e-05	0.03	0.28	0.26	Amyotrophic lateral sclerosis (sporadic);	chr1:89633156	chr1:89788914~89790492:+
OV	cis	rs73201462	1	rs2999089	ENSG00000277250.1	Metazoa_SRP	-3.99	8.9e-05	0.03	-0.42	-0.26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128216316	chr3:128673681~128674021:-
OV	cis	rs10771431	0.738	rs11049697	ENSG00000111788.10	RP11-22B23.1	3.99	8.9e-05	0.03	0.25	0.26	Breast size;	chr12:9232743	chr12:9277235~9313241:+
OV	cis	rs9473147	0.543	rs4715019	ENSG00000270761.1	RP11-385F7.1	-3.99	8.9e-05	0.03	-0.29	-0.26	Platelet distribution width;Mean platelet volume;	chr6:47479305	chr6:47477243~47477572:-
OV	cis	rs73201462	1	rs2955095	ENSG00000242551.2	POU5F1P6	3.99	8.91e-05	0.03	0.38	0.26	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128258822	chr3:128674735~128677005:-
OV	cis	rs7204230	1	rs16952044	ENSG00000261291.1	RP11-295M3.2	-3.99	8.91e-05	0.03	-0.31	-0.26	Fibrinogen;	chr16:53166370	chr16:53168522~53169450:+
OV	cis	rs11992162	0.636	rs4841642	ENSG00000270154.1	RP11-419I17.1	3.99	8.91e-05	0.03	0.27	0.26	Monocyte count;	chr8:11940825	chr8:12476462~12477122:+
OV	cis	rs11992162	0.636	rs4841646	ENSG00000270154.1	RP11-419I17.1	3.99	8.91e-05	0.03	0.27	0.26	Monocyte count;	chr8:11941198	chr8:12476462~12477122:+
OV	cis	rs1538970	1	rs1538970	ENSG00000280836.1	AL355480.1	-3.99	8.92e-05	0.03	-0.36	-0.26	Platelet count;	chr1:45381890	chr1:45581219~45581321:-
OV	cis	rs7789940	0.857	rs12532935	ENSG00000230305.2	AC004980.9	3.99	8.93e-05	0.03	0.37	0.26	Multiple sclerosis;	chr7:76310381	chr7:76524515~76532692:+
OV	cis	rs2919917	1	rs2717547	ENSG00000254352.1	RP11-578O24.2	-3.99	8.93e-05	0.03	-0.31	-0.26	Lymphocyte counts;	chr8:78744754	chr8:78723796~78724136:-
OV	cis	rs67311347	0.544	rs1902073	ENSG00000223797.4	ENTPD3-AS1	3.99	8.93e-05	0.0301	0.27	0.26	Renal cell carcinoma;	chr3:40292006	chr3:40313802~40453329:-
OV	cis	rs7927592	0.763	rs10896326	ENSG00000212093.1	AP000807.1	3.99	8.93e-05	0.0301	0.3	0.26	Total body bone mineral density;	chr11:68467103	chr11:68506083~68506166:-
OV	cis	rs10829156	0.786	rs7093907	ENSG00000225527.1	RP11-383B4.4	-3.99	8.94e-05	0.0301	-0.36	-0.26	Sudden cardiac arrest;	chr10:18587225	chr10:18531849~18533336:-
OV	cis	rs6429082	0.509	rs2246554	ENSG00000236863.2	RPL23AP23	3.99	8.94e-05	0.0301	0.25	0.26	Adiposity;	chr1:235356861	chr1:235295865~235296335:+
OV	cis	rs6429082	0.509	rs2803845	ENSG00000236863.2	RPL23AP23	3.99	8.94e-05	0.0301	0.25	0.26	Adiposity;	chr1:235356913	chr1:235295865~235296335:+
OV	cis	rs10924970	0.687	rs12737933	ENSG00000236863.2	RPL23AP23	-3.99	8.95e-05	0.0301	-0.27	-0.26	Asthma;	chr1:235200593	chr1:235295865~235296335:+
OV	cis	rs7267979	0.744	rs6050464	ENSG00000274973.1	RP13-401N8.7	-3.99	8.95e-05	0.0301	-0.29	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25228663	chr20:25845497~25845862:+
OV	cis	rs6052484	0.523	rs17315630	ENSG00000229539.1	RP11-119B16.2	3.99	8.96e-05	0.0301	0.29	0.26	Sense of smell;	chr20:4336810	chr20:3888239~3888868:-
OV	cis	rs1979679	0.581	rs1405812	ENSG00000278733.1	RP11-425D17.1	-3.99	8.96e-05	0.0301	-0.34	-0.26	Ossification of the posterior longitudinal ligament of the spine;	chr12:28476043	chr12:28185625~28186190:-
OV	cis	rs6545883	0.868	rs2518933	ENSG00000270820.4	RP11-355B11.2	3.99	8.96e-05	0.0301	0.29	0.26	Tuberculosis;	chr2:61569895	chr2:61471188~61484130:+
OV	cis	rs6545883	0.783	rs7579651	ENSG00000270820.4	RP11-355B11.2	3.99	8.96e-05	0.0301	0.29	0.26	Tuberculosis;	chr2:61573144	chr2:61471188~61484130:+
OV	cis	rs7246657	0.943	rs4803347	ENSG00000226686.6	LINC01535	-3.99	8.96e-05	0.0302	-0.38	-0.26	Coronary artery calcification;	chr19:37357115	chr19:37251912~37265535:+
OV	cis	rs9828933	0.882	rs3816156	ENSG00000280620.1	SCAANT1	3.99	8.96e-05	0.0302	0.38	0.26	Type 2 diabetes;	chr3:64014036	chr3:63911518~63911772:-
OV	cis	rs3733585	0.699	rs1122142	ENSG00000250413.1	RP11-448G15.1	3.99	8.97e-05	0.0302	0.29	0.26	Cleft plate (environmental tobacco smoke interaction);	chr4:9945924	chr4:10006482~10009725:+
OV	cis	rs3733585	0.699	rs4339211	ENSG00000250413.1	RP11-448G15.1	3.99	8.97e-05	0.0302	0.29	0.26	Cleft plate (environmental tobacco smoke interaction);	chr4:9946034	chr4:10006482~10009725:+
OV	cis	rs11992162	0.613	rs6998690	ENSG00000270154.1	RP11-419I17.1	3.99	8.98e-05	0.0302	0.27	0.26	Monocyte count;	chr8:11941287	chr8:12476462~12477122:+
OV	cis	rs7246657	0.891	rs7253114	ENSG00000226686.6	LINC01535	-3.99	8.98e-05	0.0302	-0.38	-0.26	Coronary artery calcification;	chr19:37497823	chr19:37251912~37265535:+
OV	cis	rs9879311	0.932	rs7427473	ENSG00000240288.6	GHRLOS	3.99	8.98e-05	0.0302	0.25	0.26	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10371513	chr3:10285754~10293449:+
OV	cis	rs2999052	1	rs2811508	ENSG00000277250.1	Metazoa_SRP	3.99	8.98e-05	0.0302	0.31	0.26	Hypospadias;	chr3:128201180	chr3:128673681~128674021:-
OV	cis	rs7968440	0.808	rs67218241	ENSG00000272368.2	RP4-605O3.4	3.99	8.98e-05	0.0302	0.32	0.26	Fibrinogen;	chr12:50761639	chr12:50112197~50165618:+
OV	cis	rs7968440	0.778	rs111941917	ENSG00000272368.2	RP4-605O3.4	3.99	8.98e-05	0.0302	0.32	0.26	Fibrinogen;	chr12:50764479	chr12:50112197~50165618:+
OV	cis	rs67311347	0.544	rs60329764	ENSG00000223797.4	ENTPD3-AS1	-3.99	8.98e-05	0.0302	-0.27	-0.26	Renal cell carcinoma;	chr3:40293130	chr3:40313802~40453329:-
OV	cis	rs9649213	0.593	rs6949718	ENSG00000272950.1	RP11-307C18.1	3.99	8.99e-05	0.0302	0.3	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98295171	chr7:98322853~98323430:+
OV	cis	rs9649213	0.593	rs6970990	ENSG00000272950.1	RP11-307C18.1	3.99	8.99e-05	0.0302	0.3	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98296070	chr7:98322853~98323430:+
OV	cis	rs9649213	0.555	rs34695842	ENSG00000272950.1	RP11-307C18.1	3.99	8.99e-05	0.0302	0.3	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98301750	chr7:98322853~98323430:+
OV	cis	rs9649213	0.574	rs7791321	ENSG00000272950.1	RP11-307C18.1	3.99	8.99e-05	0.0302	0.3	0.26	Prostate cancer (SNP x SNP interaction);	chr7:98314813	chr7:98322853~98323430:+
OV	cis	rs7429990	0.864	rs12635438	ENSG00000229759.1	MRPS18AP1	3.99	8.99e-05	0.0302	0.29	0.26	Educational attainment (years of education);	chr3:47693210	chr3:48256350~48256938:-
OV	cis	rs6921919	0.583	rs1054372	ENSG00000204709.4	LINC01556	3.99	8.99e-05	0.0302	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28368965	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs9468354	ENSG00000204709.4	LINC01556	3.99	8.99e-05	0.0302	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28370024	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs7773051	ENSG00000204709.4	LINC01556	3.99	8.99e-05	0.0302	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28372539	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs12697938	ENSG00000204709.4	LINC01556	3.99	8.99e-05	0.0302	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28373322	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs13437294	ENSG00000204709.4	LINC01556	3.99	8.99e-05	0.0302	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28373758	chr6:28943877~28944537:+
OV	cis	rs6921919	0.609	rs9468357	ENSG00000204709.4	LINC01556	3.99	8.99e-05	0.0302	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28374276	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs34513104	ENSG00000204709.4	LINC01556	3.99	8.99e-05	0.0302	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28375566	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs9461456	ENSG00000204709.4	LINC01556	3.99	8.99e-05	0.0302	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28376039	chr6:28943877~28944537:+
OV	cis	rs6921919	0.525	rs9468360	ENSG00000204709.4	LINC01556	3.99	8.99e-05	0.0302	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28376661	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs16894021	ENSG00000204709.4	LINC01556	3.99	8.99e-05	0.0302	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28377249	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs11751693	ENSG00000204709.4	LINC01556	3.99	8.99e-05	0.0302	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28377306	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs7749736	ENSG00000204709.4	LINC01556	3.99	8.99e-05	0.0302	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28378254	chr6:28943877~28944537:+
OV	cis	rs7580658	0.613	rs12478656	ENSG00000236682.1	AC068282.3	-3.99	9e-05	0.0303	-0.35	-0.26	Protein C levels;	chr2:127438944	chr2:127389130~127400580:+
OV	cis	rs7580658	0.613	rs12463538	ENSG00000236682.1	AC068282.3	-3.99	9e-05	0.0303	-0.35	-0.26	Protein C levels;	chr2:127439278	chr2:127389130~127400580:+
OV	cis	rs507080	0.922	rs4589335	ENSG00000278376.1	RP11-158I9.8	-3.99	9.01e-05	0.0303	-0.25	-0.26	Serum metabolite levels;	chr11:118668431	chr11:118791254~118793137:+
OV	cis	rs881375	0.715	rs7858209	ENSG00000226752.6	PSMD5-AS1	-3.99	9.01e-05	0.0303	-0.26	-0.26	Rheumatoid arthritis;	chr9:120883482	chr9:120824828~120854385:+
OV	cis	rs881375	0.715	rs10760119	ENSG00000226752.6	PSMD5-AS1	-3.99	9.01e-05	0.0303	-0.26	-0.26	Rheumatoid arthritis;	chr9:120883782	chr9:120824828~120854385:+
OV	cis	rs13217239	0.572	rs9379958	ENSG00000261584.1	RP11-457M11.5	-3.99	9.01e-05	0.0303	-0.28	-0.26	Schizophrenia;	chr6:27098384	chr6:26686241~26687964:+
OV	cis	rs7267979	1	rs6083844	ENSG00000274973.1	RP13-401N8.7	3.99	9.01e-05	0.0303	0.29	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25406196	chr20:25845497~25845862:+
OV	cis	rs9733	0.818	rs12403609	ENSG00000277452.1	Metazoa_SRP	-3.99	9.01e-05	0.0303	-0.27	-0.26	Tonsillectomy;	chr1:150704009	chr1:150566562~150566860:-
OV	cis	rs710913	0.618	rs6587	ENSG00000237624.1	OXCT2P1	3.99	9.01e-05	0.0303	0.32	0.26	Peripheral arterial disease (traffic-related air pollution interaction);	chr1:39624273	chr1:39514956~39516490:+
OV	cis	rs7726839	0.54	rs72703078	ENSG00000271781.1	CTD-2589H19.6	-3.99	9.01e-05	0.0303	-0.39	-0.26	Obesity-related traits;	chr5:594872	chr5:675826~676616:+
OV	cis	rs4703129	0.506	rs1563317	ENSG00000249448.1	RP11-474J18.1	3.99	9.02e-05	0.0303	0.29	0.26	Asperger disorder;	chr5:98432782	chr5:98410235~98411792:-
OV	cis	rs4703129	0.532	rs59941249	ENSG00000249448.1	RP11-474J18.1	3.99	9.02e-05	0.0303	0.29	0.26	Asperger disorder;	chr5:98437789	chr5:98410235~98411792:-
OV	cis	rs7131987	0.65	rs11050208	ENSG00000257176.2	RP11-996F15.2	-3.99	9.02e-05	0.0303	-0.34	-0.26	QT interval;	chr12:29357436	chr12:29280418~29317848:-
OV	cis	rs2999052	0.542	rs729847	ENSG00000277250.1	Metazoa_SRP	3.99	9.02e-05	0.0303	0.32	0.26	Hypospadias;	chr3:128391927	chr3:128673681~128674021:-
OV	cis	rs7520050	0.966	rs1707336	ENSG00000280836.1	AL355480.1	3.99	9.02e-05	0.0303	0.31	0.26	Reticulocyte count;Red blood cell count;	chr1:46027788	chr1:45581219~45581321:-
OV	cis	rs2999052	1	rs2811479	ENSG00000277250.1	Metazoa_SRP	3.99	9.02e-05	0.0303	0.31	0.26	Hypospadias;	chr3:128182943	chr3:128673681~128674021:-
OV	cis	rs2999052	1	rs2811480	ENSG00000277250.1	Metazoa_SRP	3.99	9.02e-05	0.0303	0.31	0.26	Hypospadias;	chr3:128183248	chr3:128673681~128674021:-
OV	cis	rs4591358	0.705	rs6741348	ENSG00000223466.1	AC064834.2	-3.99	9.02e-05	0.0303	-0.3	-0.26	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195466190	chr2:195533035~195538681:+
OV	cis	rs2839627	0.638	rs73366794	ENSG00000225218.1	AP001628.6	3.99	9.02e-05	0.0303	0.3	0.26	Information processing speed;	chr21:42849070	chr21:42831040~42836477:-
OV	cis	rs6657613	0.68	rs7545518	ENSG00000186715.9	MST1L	3.99	9.03e-05	0.0303	0.28	0.26	Hip circumference adjusted for BMI;	chr1:17048247	chr1:16754910~16770237:-
OV	cis	rs801193	1	rs2003301	ENSG00000224316.1	RP11-479O9.2	-3.99	9.03e-05	0.0303	-0.27	-0.26	Aortic root size;	chr7:66682669	chr7:65773620~65802067:+
OV	cis	rs9393777	0.777	rs56114371	ENSG00000220721.1	OR1F12	3.99	9.03e-05	0.0303	0.52	0.26	Intelligence (multi-trait analysis);	chr6:27307055	chr6:28073316~28074233:+
OV	cis	rs7945705	0.902	rs1560569	ENSG00000254860.4	TMEM9B-AS1	3.99	9.03e-05	0.0303	0.28	0.26	Hemoglobin concentration;	chr11:8918340	chr11:8964675~8977527:+
OV	cis	rs27434	0.605	rs152468	ENSG00000272109.1	CTD-2260A17.3	-3.99	9.03e-05	0.0303	-0.42	-0.26	Ankylosing spondylitis;	chr5:96831833	chr5:96804353~96806105:+
OV	cis	rs372883	0.648	rs382732	ENSG00000226935.5	LINC00161	-3.99	9.03e-05	0.0303	-0.27	-0.26	Pancreatic cancer;	chr21:29346689	chr21:28539318~28540355:+
OV	cis	rs76210638	0.803	rs57089201	ENSG00000232986.1	RP11-179A7.2	3.99	9.03e-05	0.0303	0.46	0.26	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);	chr13:33916843	chr13:33657436~33659928:+
OV	cis	rs9393813	1	rs12663650	ENSG00000124549.13	BTN2A3P	3.99	9.04e-05	0.0303	0.26	0.26	Bipolar disorder;	chr6:27399042	chr6:26421391~26432383:+
OV	cis	rs4703129	0.506	rs56870134	ENSG00000249448.1	RP11-474J18.1	3.99	9.04e-05	0.0303	0.29	0.26	Asperger disorder;	chr5:98437819	chr5:98410235~98411792:-
OV	cis	rs9393777	0.92	rs35120058	ENSG00000220721.1	OR1F12	3.99	9.04e-05	0.0304	0.44	0.26	Intelligence (multi-trait analysis);	chr6:27390387	chr6:28073316~28074233:+
OV	cis	rs2070488	0.965	rs2284819	ENSG00000229589.1	ACVR2B-AS1	3.99	9.05e-05	0.0304	0.28	0.26	Electrocardiographic conduction measures;	chr3:38515670	chr3:38451027~38454820:-
OV	cis	rs4591358	0.765	rs979821	ENSG00000223466.1	AC064834.2	3.99	9.05e-05	0.0304	0.3	0.26	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195456015	chr2:195533035~195538681:+
OV	cis	rs760794	0.577	rs7752808	ENSG00000227116.1	RP3-471C18.1	-3.99	9.05e-05	0.0304	-0.29	-0.26	Endometriosis;	chr6:19792665	chr6:19730427~19734567:-
OV	cis	rs7259965	0.654	rs71358950	ENSG00000277744.1	CTC-435M10.12	3.99	9.06e-05	0.0304	0.25	0.26	Midgestational circulating levels of organochlorine pesticides;Midgestational circulating levels of PBDEs;	chr19:40952529	chr19:41373971~41374419:+
OV	cis	rs809367	1	rs809367	ENSG00000224914.2	LINC00863	3.99	9.06e-05	0.0304	0.38	0.26	Parental extreme longevity (95 years and older);	chr10:87982049	chr10:87342736~87357882:+
OV	cis	rs3858145	0.588	rs731063	ENSG00000233590.1	RP11-153K11.3	3.99	9.07e-05	0.0304	0.38	0.26	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68283433	chr10:68233251~68242379:-
OV	cis	rs10829156	1	rs10829157	ENSG00000225527.1	RP11-383B4.4	-3.99	9.07e-05	0.0304	-0.35	-0.26	Sudden cardiac arrest;	chr10:18662534	chr10:18531849~18533336:-
OV	cis	rs2999052	0.737	rs3849531	ENSG00000277250.1	Metazoa_SRP	3.99	9.07e-05	0.0304	0.33	0.26	Hypospadias;	chr3:128339774	chr3:128673681~128674021:-
OV	cis	rs2070488	1	rs2268758	ENSG00000229589.1	ACVR2B-AS1	3.99	9.07e-05	0.0304	0.28	0.26	Electrocardiographic conduction measures;	chr3:38472558	chr3:38451027~38454820:-
OV	cis	rs7267979	1	rs2387884	ENSG00000274973.1	RP13-401N8.7	3.99	9.07e-05	0.0304	0.29	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25398433	chr20:25845497~25845862:+
OV	cis	rs12477438	0.501	rs11683188	ENSG00000231822.1	AC019097.7	3.99	9.07e-05	0.0304	0.26	0.26	Chronic sinus infection;	chr2:99108049	chr2:99102018~99102752:+
OV	cis	rs12477438	0.559	rs6733285	ENSG00000231822.1	AC019097.7	3.99	9.07e-05	0.0304	0.26	0.26	Chronic sinus infection;	chr2:99109112	chr2:99102018~99102752:+
OV	cis	rs7200543	1	rs3803575	ENSG00000270580.4	PKD1P6	3.99	9.07e-05	0.0304	0.26	0.26	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15044590	chr16:15104723~15131601:-
OV	cis	rs6052484	0.523	rs11698498	ENSG00000229539.1	RP11-119B16.2	3.99	9.08e-05	0.0305	0.29	0.26	Sense of smell;	chr20:4342528	chr20:3888239~3888868:-
OV	cis	rs71386921	1	rs71386921	ENSG00000262412.1	RP11-85G18.6	3.99	9.08e-05	0.0305	0.36	0.26	Breast cancer;	chr10:27189786	chr10:27243130~27250804:+
OV	cis	rs3823536	0.583	rs10954214	ENSG00000275106.1	RP11-309L24.10	-3.99	9.08e-05	0.0305	-0.36	-0.26	Sjögren's syndrome;	chr7:128949579	chr7:128952527~128953316:-
OV	cis	rs7927771	0.524	rs12785949	ENSG00000280615.1	Y_RNA	3.99	9.09e-05	0.0305	0.27	0.26	Subjective well-being;	chr11:47708218	chr11:47614898~47614994:-
OV	cis	rs7927771	0.542	rs7102205	ENSG00000280615.1	Y_RNA	3.99	9.09e-05	0.0305	0.27	0.26	Subjective well-being;	chr11:47723822	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs10838777	ENSG00000280615.1	Y_RNA	3.99	9.09e-05	0.0305	0.27	0.26	Subjective well-being;	chr11:47839402	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs10458915	ENSG00000280615.1	Y_RNA	3.99	9.09e-05	0.0305	0.27	0.26	Subjective well-being;	chr11:47842840	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs10742824	ENSG00000280615.1	Y_RNA	3.99	9.09e-05	0.0305	0.27	0.26	Subjective well-being;	chr11:47843290	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs10769299	ENSG00000280615.1	Y_RNA	3.99	9.09e-05	0.0305	0.27	0.26	Subjective well-being;	chr11:47843608	chr11:47614898~47614994:-
OV	cis	rs7927771	0.542	rs10769300	ENSG00000280615.1	Y_RNA	3.99	9.09e-05	0.0305	0.27	0.26	Subjective well-being;	chr11:47844008	chr11:47614898~47614994:-
OV	cis	rs7124681	0.584	rs7950674	ENSG00000280615.1	Y_RNA	3.99	9.09e-05	0.0305	0.27	0.26	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47849465	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs11039431	ENSG00000280615.1	Y_RNA	3.99	9.09e-05	0.0305	0.27	0.26	Subjective well-being;	chr11:47850460	chr11:47614898~47614994:-
OV	cis	rs4853012	0.887	rs77148265	ENSG00000257800.1	FNBP1P1	3.98	9.1e-05	0.0305	0.39	0.26	Gestational age at birth (maternal effect);	chr2:74112392	chr2:74120680~74123218:+
OV	cis	rs875971	1	rs4718307	ENSG00000237310.1	GS1-124K5.4	-3.98	9.1e-05	0.0305	-0.26	-0.26	Aortic root size;	chr7:66146001	chr7:66493706~66495474:+
OV	cis	rs875971	1	rs7801282	ENSG00000237310.1	GS1-124K5.4	-3.98	9.1e-05	0.0305	-0.26	-0.26	Aortic root size;	chr7:66148700	chr7:66493706~66495474:+
OV	cis	rs12073837	0.784	rs35730037	ENSG00000238078.1	LINC01352	-3.98	9.1e-05	0.0305	-0.35	-0.26	F-cell distribution;	chr1:220815403	chr1:220829255~220832429:+
OV	cis	rs875971	0.651	rs2420596	ENSG00000224316.1	RP11-479O9.2	3.98	9.11e-05	0.0305	0.27	0.26	Aortic root size;	chr7:66450996	chr7:65773620~65802067:+
OV	cis	rs875971	0.52	rs2420597	ENSG00000224316.1	RP11-479O9.2	3.98	9.11e-05	0.0305	0.27	0.26	Aortic root size;	chr7:66450999	chr7:65773620~65802067:+
OV	cis	rs3823536	0.505	rs3925323	ENSG00000275106.1	RP11-309L24.10	-3.98	9.11e-05	0.0305	-0.36	-0.26	Sjögren's syndrome;	chr7:128952187	chr7:128952527~128953316:-
OV	cis	rs7927771	0.524	rs7107792	ENSG00000280615.1	Y_RNA	3.98	9.11e-05	0.0305	0.27	0.26	Subjective well-being;	chr11:47647697	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs7107922	ENSG00000280615.1	Y_RNA	3.98	9.11e-05	0.0305	0.27	0.26	Subjective well-being;	chr11:47647737	chr11:47614898~47614994:-
OV	cis	rs7122539	0.646	rs6591222	ENSG00000199325.1	RNU4-39P	-3.98	9.11e-05	0.0305	-0.32	-0.26	HIV-1 susceptibility;	chr11:66783672	chr11:66614964~66615090:-
OV	cis	rs11239930	0.538	rs3011810	ENSG00000229828.2	PDE4DIP1	3.98	9.11e-05	0.0305	0.34	0.26	AIDS progression;	chr1:147082079	chr1:148080598~148093883:+
OV	cis	rs9473147	0.503	rs2171086	ENSG00000270761.1	RP11-385F7.1	-3.98	9.11e-05	0.0305	-0.29	-0.26	Platelet distribution width;Mean platelet volume;	chr6:47622368	chr6:47477243~47477572:-
OV	cis	rs6921919	0.583	rs9461459	ENSG00000204709.4	LINC01556	3.98	9.11e-05	0.0305	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28394139	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs28360638	ENSG00000204709.4	LINC01556	3.98	9.11e-05	0.0305	0.31	0.26	Autism spectrum disorder or schizophrenia;	chr6:28394552	chr6:28943877~28944537:+
OV	cis	rs3758086	0.542	rs1731273	ENSG00000246582.2	RP11-1149O23.3	-3.98	9.12e-05	0.0306	-0.33	-0.26	Glomerular filtration rate (creatinine);	chr8:23901742	chr8:23224471~23230926:+
OV	cis	rs7811142	1	rs2897358	ENSG00000242294.5	STAG3L5P	3.98	9.12e-05	0.0306	0.27	0.26	Platelet count;	chr7:100491017	chr7:100336079~100351900:+
OV	cis	rs76076331	0.517	rs1734367	ENSG00000271952.1	RP11-245G13.2	3.98	9.12e-05	0.0306	0.31	0.26	Educational attainment (college completion);Educational attainment (years of education);	chr2:10838036	chr2:10878269~10885118:+
OV	cis	rs274567	0.55	rs272885	ENSG00000233006.5	AC034220.3	3.98	9.13e-05	0.0306	0.27	0.26	Blood metabolite levels;	chr5:132332043	chr5:132311285~132369916:-
OV	cis	rs6860806	0.507	rs272883	ENSG00000233006.5	AC034220.3	3.98	9.13e-05	0.0306	0.27	0.26	Breast cancer;	chr5:132333005	chr5:132311285~132369916:-
OV	cis	rs6860806	0.507	rs272882	ENSG00000233006.5	AC034220.3	3.98	9.13e-05	0.0306	0.27	0.26	Breast cancer;	chr5:132333468	chr5:132311285~132369916:-
OV	cis	rs7302981	0.967	rs7972842	ENSG00000257298.1	RP3-405J10.3	-3.98	9.13e-05	0.0306	-0.24	-0.26	Systolic blood pressure;	chr12:50122540	chr12:50185580~50191363:-
OV	cis	rs9813712	0.548	rs9880123	ENSG00000253540.4	FAM86HP	-3.98	9.14e-05	0.0306	-0.28	-0.26	Response to amphetamines;	chr3:130215275	chr3:130099092~130111472:-
OV	cis	rs1790761	0.505	rs7103713	ENSG00000184224.3	C11orf72	-3.98	9.14e-05	0.0306	-0.28	-0.26	Mean corpuscular volume;	chr11:67570771	chr11:67602880~67606706:-
OV	cis	rs728616	0.867	rs61860041	ENSG00000234382.2	RP11-40F6.1	-3.98	9.14e-05	0.0306	-0.6	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80184575	chr10:80233664~80245367:+
OV	cis	rs728616	0.867	rs61860042	ENSG00000234382.2	RP11-40F6.1	-3.98	9.14e-05	0.0306	-0.6	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80186482	chr10:80233664~80245367:+
OV	cis	rs728616	0.867	rs12415870	ENSG00000234382.2	RP11-40F6.1	-3.98	9.14e-05	0.0306	-0.6	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80189714	chr10:80233664~80245367:+
OV	cis	rs4761702	0.922	rs7976742	ENSG00000257252.4	RP11-486A14.2	-3.98	9.14e-05	0.0306	-0.31	-0.26	Immature fraction of reticulocytes;	chr12:93328025	chr12:93317135~93377736:-
OV	cis	rs12681366	0.734	rs1872889	ENSG00000253704.1	RP11-267M23.4	3.98	9.14e-05	0.0306	0.3	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94406193	chr8:94553722~94569745:+
OV	cis	rs9473147	0.543	rs7738044	ENSG00000270761.1	RP11-385F7.1	-3.98	9.14e-05	0.0306	-0.29	-0.26	Platelet distribution width;Mean platelet volume;	chr6:47501537	chr6:47477243~47477572:-
OV	cis	rs9473147	0.543	rs9473122	ENSG00000270761.1	RP11-385F7.1	-3.98	9.14e-05	0.0306	-0.29	-0.26	Platelet distribution width;Mean platelet volume;	chr6:47507226	chr6:47477243~47477572:-
OV	cis	rs9473147	0.503	rs9473123	ENSG00000270761.1	RP11-385F7.1	-3.98	9.14e-05	0.0306	-0.29	-0.26	Platelet distribution width;Mean platelet volume;	chr6:47507603	chr6:47477243~47477572:-
OV	cis	rs9473147	0.543	rs13211285	ENSG00000270761.1	RP11-385F7.1	-3.98	9.14e-05	0.0306	-0.29	-0.26	Platelet distribution width;Mean platelet volume;	chr6:47511882	chr6:47477243~47477572:-
OV	cis	rs9473147	0.543	rs1872505	ENSG00000270761.1	RP11-385F7.1	-3.98	9.14e-05	0.0306	-0.29	-0.26	Platelet distribution width;Mean platelet volume;	chr6:47513239	chr6:47477243~47477572:-
OV	cis	rs9473147	0.516	rs9296561	ENSG00000270761.1	RP11-385F7.1	-3.98	9.14e-05	0.0306	-0.29	-0.26	Platelet distribution width;Mean platelet volume;	chr6:47521202	chr6:47477243~47477572:-
OV	cis	rs9473147	0.516	rs7749167	ENSG00000270761.1	RP11-385F7.1	-3.98	9.14e-05	0.0306	-0.29	-0.26	Platelet distribution width;Mean platelet volume;	chr6:47526204	chr6:47477243~47477572:-
OV	cis	rs9473147	0.516	rs9296564	ENSG00000270761.1	RP11-385F7.1	-3.98	9.14e-05	0.0306	-0.29	-0.26	Platelet distribution width;Mean platelet volume;	chr6:47527023	chr6:47477243~47477572:-
OV	cis	rs10129255	0.5	rs10131875	ENSG00000223648.3	IGHV3-64	3.98	9.14e-05	0.0306	0.25	0.26	Kawasaki disease;	chr14:106792798	chr14:106643132~106658258:-
OV	cis	rs11710845	1	rs11710845	ENSG00000243885.1	RP11-278L15.2	3.98	9.15e-05	0.0306	0.4	0.26	Intraocular pressure;	chr3:150347493	chr3:149384179~149385800:-
OV	cis	rs801193	1	rs13239306	ENSG00000224316.1	RP11-479O9.2	-3.98	9.15e-05	0.0306	-0.28	-0.26	Aortic root size;	chr7:66671030	chr7:65773620~65802067:+
OV	cis	rs4720575	1	rs4720574	ENSG00000223829.4	AC004870.4	-3.98	9.15e-05	0.0306	-0.34	-0.26	Angiotensin-converting enzyme inhibitor intolerance;	chr7:47045999	chr7:46969702~47027481:+
OV	cis	rs7395581	0.877	rs10838691	ENSG00000271350.1	CTD-2384B9.1	3.98	9.15e-05	0.0306	0.29	0.26	HDL cholesterol;	chr11:47320178	chr11:47041027~47041945:-
OV	cis	rs804292	1	rs804292	ENSG00000255046.1	RP11-297N6.4	-3.98	9.15e-05	0.0306	-0.35	-0.26	Nicotine use;Alcohol dependence;	chr8:11786406	chr8:11797928~11802568:-
OV	cis	rs11971779	0.715	rs10954646	ENSG00000273391.1	RP11-634H22.1	-3.98	9.16e-05	0.0306	-0.25	-0.26	Diisocyanate-induced asthma;	chr7:139376323	chr7:139359032~139359566:-
OV	cis	rs17711722	0.528	rs73138179	ENSG00000273024.4	INTS4P2	-3.98	9.16e-05	0.0306	-0.3	-0.26	Calcium levels;	chr7:65829495	chr7:65647864~65715661:+
OV	cis	rs9473147	0.543	rs9296558	ENSG00000270761.1	RP11-385F7.1	-3.98	9.16e-05	0.0307	-0.29	-0.26	Platelet distribution width;Mean platelet volume;	chr6:47484147	chr6:47477243~47477572:-
OV	cis	rs1707322	0.717	rs1972410	ENSG00000234329.1	RP11-767N6.2	3.98	9.16e-05	0.0307	0.27	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45615275	chr1:45651039~45651826:-
OV	cis	rs4698036	0.586	rs7672759	ENSG00000250413.1	RP11-448G15.1	-3.98	9.17e-05	0.0307	-0.3	-0.26	Cardiovascular disease risk factors;	chr4:10283391	chr4:10006482~10009725:+
OV	cis	rs11971779	0.68	rs4728467	ENSG00000273391.1	RP11-634H22.1	3.98	9.17e-05	0.0307	0.28	0.26	Diisocyanate-induced asthma;	chr7:139435816	chr7:139359032~139359566:-
OV	cis	rs9425326	0.6	rs9425615	ENSG00000232860.6	SMG7-AS1	-3.98	9.17e-05	0.0307	-0.42	-0.26	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr1:183869981	chr1:183460874~183472265:-
OV	cis	rs2274471	0.699	rs73395341	ENSG00000234534.1	CSNK1G2P1	3.98	9.17e-05	0.0307	0.33	0.26	Crohn's disease;	chr9:5085549	chr9:5040945~5041940:+
OV	cis	rs12477438	0.501	rs6727749	ENSG00000231822.1	AC019097.7	3.98	9.17e-05	0.0307	0.26	0.26	Chronic sinus infection;	chr2:99177127	chr2:99102018~99102752:+
OV	cis	rs12477438	0.501	rs13033012	ENSG00000231822.1	AC019097.7	3.98	9.17e-05	0.0307	0.26	0.26	Chronic sinus infection;	chr2:99178686	chr2:99102018~99102752:+
OV	cis	rs12477438	0.501	rs13000731	ENSG00000231822.1	AC019097.7	3.98	9.17e-05	0.0307	0.26	0.26	Chronic sinus infection;	chr2:99178768	chr2:99102018~99102752:+
OV	cis	rs12477438	0.501	rs6708878	ENSG00000231822.1	AC019097.7	3.98	9.17e-05	0.0307	0.26	0.26	Chronic sinus infection;	chr2:99185101	chr2:99102018~99102752:+
OV	cis	rs7267979	1	rs6076345	ENSG00000274973.1	RP13-401N8.7	3.98	9.17e-05	0.0307	0.29	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25401259	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs4815420	ENSG00000274973.1	RP13-401N8.7	3.98	9.17e-05	0.0307	0.29	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25403343	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6050590	ENSG00000274973.1	RP13-401N8.7	3.98	9.17e-05	0.0307	0.29	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25404358	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs4813566	ENSG00000274973.1	RP13-401N8.7	3.98	9.17e-05	0.0307	0.29	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25405829	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs4815421	ENSG00000274973.1	RP13-401N8.7	3.98	9.17e-05	0.0307	0.29	0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25405873	chr20:25845497~25845862:+
OV	cis	rs733592	0.723	rs10875766	ENSG00000258273.1	RP11-370I10.4	-3.98	9.18e-05	0.0307	-0.33	-0.26	Plateletcrit;	chr12:48199797	chr12:48333755~48333901:-
OV	cis	rs7246967	0.611	rs2361022	ENSG00000267920.1	SNX6P1	-3.98	9.18e-05	0.0307	-0.41	-0.26	Bronchopulmonary dysplasia;	chr19:22633731	chr19:23126569~23127792:-
OV	cis	rs7246967	0.673	rs2361023	ENSG00000267920.1	SNX6P1	-3.98	9.18e-05	0.0307	-0.41	-0.26	Bronchopulmonary dysplasia;	chr19:22634065	chr19:23126569~23127792:-
OV	cis	rs7246967	0.673	rs118059742	ENSG00000267920.1	SNX6P1	-3.98	9.18e-05	0.0307	-0.41	-0.26	Bronchopulmonary dysplasia;	chr19:22636644	chr19:23126569~23127792:-
OV	cis	rs7246967	0.673	rs56663398	ENSG00000267920.1	SNX6P1	-3.98	9.18e-05	0.0307	-0.41	-0.26	Bronchopulmonary dysplasia;	chr19:22637398	chr19:23126569~23127792:-
OV	cis	rs7246967	0.673	rs35731237	ENSG00000267920.1	SNX6P1	-3.98	9.18e-05	0.0307	-0.41	-0.26	Bronchopulmonary dysplasia;	chr19:22637708	chr19:23126569~23127792:-
OV	cis	rs7246967	0.673	rs12979173	ENSG00000267920.1	SNX6P1	-3.98	9.18e-05	0.0307	-0.41	-0.26	Bronchopulmonary dysplasia;	chr19:22637879	chr19:23126569~23127792:-
OV	cis	rs7246967	0.673	rs12979848	ENSG00000267920.1	SNX6P1	-3.98	9.18e-05	0.0307	-0.41	-0.26	Bronchopulmonary dysplasia;	chr19:22637996	chr19:23126569~23127792:-
OV	cis	rs7246967	0.551	rs6511367	ENSG00000267920.1	SNX6P1	-3.98	9.18e-05	0.0307	-0.41	-0.26	Bronchopulmonary dysplasia;	chr19:22638468	chr19:23126569~23127792:-
OV	cis	rs7246967	0.611	rs7250964	ENSG00000267920.1	SNX6P1	-3.98	9.18e-05	0.0307	-0.41	-0.26	Bronchopulmonary dysplasia;	chr19:22639692	chr19:23126569~23127792:-
OV	cis	rs7246967	0.673	rs7250343	ENSG00000267920.1	SNX6P1	-3.98	9.18e-05	0.0307	-0.41	-0.26	Bronchopulmonary dysplasia;	chr19:22640043	chr19:23126569~23127792:-
OV	cis	rs7246967	0.673	rs35007247	ENSG00000267920.1	SNX6P1	-3.98	9.18e-05	0.0307	-0.41	-0.26	Bronchopulmonary dysplasia;	chr19:22640121	chr19:23126569~23127792:-
OV	cis	rs12654437	0.574	rs2872328	ENSG00000270442.1	CTB-95D12.1	3.98	9.18e-05	0.0307	0.34	0.26	Cognitive decline (age-related);	chr5:155420959	chr5:155491336~155493598:+
OV	cis	rs9393777	0.92	rs13207689	ENSG00000226314.6	ZNF192P1	-3.98	9.18e-05	0.0307	-0.55	-0.26	Intelligence (multi-trait analysis);	chr6:27401925	chr6:28161781~28169594:+
OV	cis	rs514406	0.505	rs425520	ENSG00000206627.1	RNU6-969P	3.98	9.18e-05	0.0307	0.28	0.26	Monocyte count;	chr1:52714133	chr1:52805108~52805212:-
OV	cis	rs875971	0.83	rs6976714	ENSG00000224316.1	RP11-479O9.2	3.98	9.18e-05	0.0307	0.27	0.26	Aortic root size;	chr7:66426474	chr7:65773620~65802067:+
OV	cis	rs881827	0.962	rs2839329	ENSG00000223692.1	DIP2A-IT1	3.98	9.19e-05	0.0307	0.3	0.26	Lymphocyte counts;	chr21:46564650	chr21:46462471~46469306:+
OV	cis	rs2253762	0.609	rs10887057	ENSG00000226864.1	ATE1-AS1	3.98	9.19e-05	0.0307	0.4	0.26	Breast cancer;	chr10:122043799	chr10:121928312~121951965:+
OV	cis	rs2070488	0.804	rs1870914	ENSG00000229589.1	ACVR2B-AS1	3.98	9.19e-05	0.0307	0.29	0.26	Electrocardiographic conduction measures;	chr3:38452729	chr3:38451027~38454820:-
OV	cis	rs6071524	0.508	rs2243520	ENSG00000277581.1	RP4-616B8.6	-3.98	9.19e-05	0.0307	-0.31	-0.26	Autism spectrum disorder or schizophrenia;	chr20:38766469	chr20:38962472~38962993:+
OV	cis	rs6445967	1	rs13325699	ENSG00000272360.1	RP11-359I18.5	3.98	9.19e-05	0.0307	0.28	0.26	Platelet count;	chr3:58301143	chr3:58490830~58491291:-
OV	cis	rs732765	0.657	rs17782749	ENSG00000258439.1	RP11-173A8.2	3.98	9.2e-05	0.0307	0.39	0.26	Non-small cell lung cancer;	chr14:74831646	chr14:74658049~74658590:+
OV	cis	rs1707322	0.721	rs10890336	ENSG00000234329.1	RP11-767N6.2	3.98	9.21e-05	0.0308	0.26	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45645384	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs11211151	ENSG00000234329.1	RP11-767N6.2	3.98	9.21e-05	0.0308	0.26	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45647080	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs12045096	ENSG00000234329.1	RP11-767N6.2	3.98	9.21e-05	0.0308	0.26	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45648756	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs4609469	ENSG00000234329.1	RP11-767N6.2	3.98	9.21e-05	0.0308	0.26	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45651513	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs12049027	ENSG00000234329.1	RP11-767N6.2	3.98	9.21e-05	0.0308	0.26	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45652512	chr1:45651039~45651826:-
OV	cis	rs1707322	0.752	rs10789467	ENSG00000234329.1	RP11-767N6.2	3.98	9.21e-05	0.0308	0.26	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45653073	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs10890337	ENSG00000234329.1	RP11-767N6.2	3.98	9.21e-05	0.0308	0.26	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45658855	chr1:45651039~45651826:-
OV	cis	rs1707322	0.752	rs3811435	ENSG00000234329.1	RP11-767N6.2	3.98	9.21e-05	0.0308	0.26	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45660118	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs9793568	ENSG00000234329.1	RP11-767N6.2	3.98	9.21e-05	0.0308	0.26	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45664701	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs11211157	ENSG00000234329.1	RP11-767N6.2	3.98	9.21e-05	0.0308	0.26	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667172	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs11211158	ENSG00000234329.1	RP11-767N6.2	3.98	9.21e-05	0.0308	0.26	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45667178	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs6429575	ENSG00000234329.1	RP11-767N6.2	3.98	9.21e-05	0.0308	0.26	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45668544	chr1:45651039~45651826:-
OV	cis	rs1707322	0.685	rs6690926	ENSG00000234329.1	RP11-767N6.2	3.98	9.21e-05	0.0308	0.26	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45669306	chr1:45651039~45651826:-
OV	cis	rs1707322	0.752	rs8179402	ENSG00000234329.1	RP11-767N6.2	3.98	9.21e-05	0.0308	0.26	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45676794	chr1:45651039~45651826:-
OV	cis	rs1707322	0.752	rs8179296	ENSG00000234329.1	RP11-767N6.2	3.98	9.21e-05	0.0308	0.26	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45678119	chr1:45651039~45651826:-
OV	cis	rs1823913	0.503	rs6706578	ENSG00000227542.1	AC092614.2	3.98	9.21e-05	0.0308	0.29	0.26	Obesity-related traits;	chr2:191346992	chr2:191229165~191246172:-
OV	cis	rs11673344	0.704	rs510757	ENSG00000226686.6	LINC01535	-3.98	9.23e-05	0.0308	-0.32	-0.26	Obesity-related traits;	chr19:36931900	chr19:37251912~37265535:+
OV	cis	rs45509595	0.556	rs34409918	ENSG00000220721.1	OR1F12	3.98	9.23e-05	0.0308	0.5	0.26	Breast cancer;	chr6:27717569	chr6:28073316~28074233:+
OV	cis	rs11951515	0.738	rs6886499	ENSG00000278487.1	RP11-447H19.4	-3.98	9.24e-05	0.0308	-0.3	-0.26	Metabolite levels  (X-11787);	chr5:43362976	chr5:43143362~43143514:-
OV	cis	rs11951515	0.738	rs10941631	ENSG00000278487.1	RP11-447H19.4	-3.98	9.24e-05	0.0308	-0.3	-0.26	Metabolite levels  (X-11787);	chr5:43363907	chr5:43143362~43143514:-
OV	cis	rs11951515	0.714	rs10805675	ENSG00000278487.1	RP11-447H19.4	-3.98	9.24e-05	0.0308	-0.3	-0.26	Metabolite levels  (X-11787);	chr5:43363942	chr5:43143362~43143514:-
OV	cis	rs1979679	0.918	rs786712	ENSG00000278733.1	RP11-425D17.1	3.98	9.24e-05	0.0308	0.31	0.26	Ossification of the posterior longitudinal ligament of the spine;	chr12:28399664	chr12:28185625~28186190:-
OV	cis	rs12468226	0.882	rs116437099	ENSG00000272966.1	RP11-686O6.1	3.98	9.25e-05	0.0309	0.39	0.26	Urate levels;	chr2:202299250	chr2:202336739~202337200:+
OV	cis	rs860818	0.793	rs4722233	ENSG00000230658.1	KLHL7-AS1	3.98	9.26e-05	0.0309	0.73	0.26	Initial pursuit acceleration;	chr7:23157792	chr7:23101228~23105703:-
OV	cis	rs860818	0.655	rs6968416	ENSG00000230658.1	KLHL7-AS1	3.98	9.26e-05	0.0309	0.73	0.26	Initial pursuit acceleration;	chr7:23158042	chr7:23101228~23105703:-
OV	cis	rs860818	0.793	rs9639457	ENSG00000230658.1	KLHL7-AS1	3.98	9.26e-05	0.0309	0.73	0.26	Initial pursuit acceleration;	chr7:23158090	chr7:23101228~23105703:-
OV	cis	rs860818	0.655	rs6461696	ENSG00000230658.1	KLHL7-AS1	3.98	9.26e-05	0.0309	0.73	0.26	Initial pursuit acceleration;	chr7:23158225	chr7:23101228~23105703:-
OV	cis	rs860818	0.793	rs6461697	ENSG00000230658.1	KLHL7-AS1	3.98	9.26e-05	0.0309	0.73	0.26	Initial pursuit acceleration;	chr7:23158468	chr7:23101228~23105703:-
OV	cis	rs860818	0.793	rs6949272	ENSG00000230658.1	KLHL7-AS1	3.98	9.26e-05	0.0309	0.73	0.26	Initial pursuit acceleration;	chr7:23158750	chr7:23101228~23105703:-
OV	cis	rs860818	0.793	rs12700419	ENSG00000230658.1	KLHL7-AS1	3.98	9.26e-05	0.0309	0.73	0.26	Initial pursuit acceleration;	chr7:23158881	chr7:23101228~23105703:-
OV	cis	rs860818	1	rs6960118	ENSG00000230658.1	KLHL7-AS1	3.98	9.26e-05	0.0309	0.73	0.26	Initial pursuit acceleration;	chr7:23160709	chr7:23101228~23105703:-
OV	cis	rs860818	1	rs6964671	ENSG00000230658.1	KLHL7-AS1	3.98	9.26e-05	0.0309	0.73	0.26	Initial pursuit acceleration;	chr7:23161183	chr7:23101228~23105703:-
OV	cis	rs860818	1	rs6461699	ENSG00000230658.1	KLHL7-AS1	3.98	9.26e-05	0.0309	0.73	0.26	Initial pursuit acceleration;	chr7:23162679	chr7:23101228~23105703:-
OV	cis	rs860818	0.793	rs7807516	ENSG00000230658.1	KLHL7-AS1	3.98	9.26e-05	0.0309	0.73	0.26	Initial pursuit acceleration;	chr7:23163147	chr7:23101228~23105703:-
OV	cis	rs860818	1	rs858316	ENSG00000230658.1	KLHL7-AS1	-3.98	9.26e-05	0.0309	-0.73	-0.26	Initial pursuit acceleration;	chr7:23163511	chr7:23101228~23105703:-
OV	cis	rs860818	1	rs1621012	ENSG00000230658.1	KLHL7-AS1	-3.98	9.26e-05	0.0309	-0.73	-0.26	Initial pursuit acceleration;	chr7:23163714	chr7:23101228~23105703:-
OV	cis	rs860818	1	rs1637244	ENSG00000230658.1	KLHL7-AS1	-3.98	9.26e-05	0.0309	-0.73	-0.26	Initial pursuit acceleration;	chr7:23163715	chr7:23101228~23105703:-
OV	cis	rs860818	1	rs858315	ENSG00000230658.1	KLHL7-AS1	-3.98	9.26e-05	0.0309	-0.73	-0.26	Initial pursuit acceleration;	chr7:23164348	chr7:23101228~23105703:-
OV	cis	rs860818	1	rs858314	ENSG00000230658.1	KLHL7-AS1	-3.98	9.26e-05	0.0309	-0.73	-0.26	Initial pursuit acceleration;	chr7:23164932	chr7:23101228~23105703:-
OV	cis	rs860818	1	rs858313	ENSG00000230658.1	KLHL7-AS1	-3.98	9.26e-05	0.0309	-0.73	-0.26	Initial pursuit acceleration;	chr7:23165118	chr7:23101228~23105703:-
OV	cis	rs1707322	0.685	rs11211177	ENSG00000225447.1	RPS15AP10	3.98	9.26e-05	0.0309	0.23	0.26	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45760677	chr1:45645816~45646197:-
OV	cis	rs11903757	1	rs77399531	ENSG00000281467.1	Clostridiales-1	-3.98	9.26e-05	0.0309	-0.45	-0.26	Colorectal cancer;	chr2:191724338	chr2:191699476~191699631:-
OV	cis	rs11903757	1	rs79858889	ENSG00000281467.1	Clostridiales-1	-3.98	9.26e-05	0.0309	-0.45	-0.26	Colorectal cancer;	chr2:191724366	chr2:191699476~191699631:-
OV	cis	rs62458065	1	rs10275978	ENSG00000226468.2	AC018641.7	3.98	9.26e-05	0.0309	0.37	0.26	Metabolite levels (HVA/MHPG ratio);	chr7:32427107	chr7:32456963~32457758:-
OV	cis	rs7267979	1	rs2500432	ENSG00000274973.1	RP13-401N8.7	-3.98	9.26e-05	0.0309	-0.29	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25309876	chr20:25845497~25845862:+
OV	cis	rs1950626	0.716	rs34572720	ENSG00000258399.5	MEG8	-3.98	9.27e-05	0.0309	-0.26	-0.26	Pelvic organ prolapse (moderate/severe);	chr14:100980813	chr14:100894770~100935999:+
OV	cis	rs1950626	0.716	rs34158896	ENSG00000258399.5	MEG8	-3.98	9.27e-05	0.0309	-0.26	-0.26	Pelvic organ prolapse (moderate/severe);	chr14:100981036	chr14:100894770~100935999:+
OV	cis	rs1950626	0.75	rs35683125	ENSG00000258399.5	MEG8	-3.98	9.27e-05	0.0309	-0.26	-0.26	Pelvic organ prolapse (moderate/severe);	chr14:100988413	chr14:100894770~100935999:+
OV	cis	rs3734266	0.702	rs1051115	ENSG00000220643.1	RP3-391O22.1	-3.98	9.28e-05	0.0309	-0.42	-0.26	Systemic lupus erythematosus;	chr6:34887971	chr6:34686602~34687106:+
OV	cis	rs12681366	0.734	rs3019146	ENSG00000253704.1	RP11-267M23.4	3.98	9.28e-05	0.031	0.3	0.26	Nonsyndromic cleft lip with cleft palate;	chr8:94401878	chr8:94553722~94569745:+
OV	cis	rs6860806	0.507	rs272868	ENSG00000233006.5	AC034220.3	3.98	9.3e-05	0.031	0.27	0.26	Breast cancer;	chr5:132345058	chr5:132311285~132369916:-
OV	cis	rs1029966	0.697	rs2908662	ENSG00000280063.1	RP11-295D4.3	3.98	9.3e-05	0.031	0.23	0.26	Cancer;	chr16:4932012	chr16:4346694~4348648:-
OV	cis	rs62229266	0.804	rs62230822	ENSG00000231106.2	LINC01436	3.98	9.31e-05	0.031	0.32	0.26	Mitral valve prolapse;	chr21:36057647	chr21:36005338~36007838:+
OV	cis	rs7688540	0.713	rs4624608	ENSG00000275426.1	CH17-262A2.1	3.98	9.31e-05	0.031	0.4	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:213204	chr4:149738~150317:+
OV	cis	rs6052484	0.523	rs62212299	ENSG00000229539.1	RP11-119B16.2	3.98	9.31e-05	0.031	0.29	0.26	Sense of smell;	chr20:4347401	chr20:3888239~3888868:-
OV	cis	rs9635963	0.673	rs4595868	ENSG00000279332.1	RP11-799B12.1	3.98	9.33e-05	0.0311	0.43	0.26	Protein quantitative trait loci;	chr18:24113928	chr18:24135468~24135829:-
OV	cis	rs7726839	0.54	rs3749615	ENSG00000271781.1	CTD-2589H19.6	-3.98	9.33e-05	0.0311	-0.39	-0.26	Obesity-related traits;	chr5:601370	chr5:675826~676616:+
OV	cis	rs6906287	0.694	rs11968293	ENSG00000169075.7	RP3-509L4.3	3.98	9.34e-05	0.0311	0.26	0.26	Electrocardiographic conduction measures;	chr6:118313535	chr6:118501430~118502906:+
OV	cis	rs970548	0.688	rs2082110	ENSG00000230869.1	CTGLF10P	3.98	9.34e-05	0.0311	0.4	0.26	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45435622	chr10:45678692~45700532:+
OV	cis	rs970548	0.688	rs2082109	ENSG00000230869.1	CTGLF10P	3.98	9.34e-05	0.0311	0.4	0.26	Total cholesterol levels;HDL cholesterol;HDL cholesterol levels;Cholesterol, total;	chr10:45435654	chr10:45678692~45700532:+
OV	cis	rs11037575	0.739	rs10838149	ENSG00000246250.2	RP11-613D13.5	3.98	9.34e-05	0.0311	0.28	0.26	Neuroblastoma;	chr11:43684073	chr11:43829709~43880726:-
OV	cis	rs758324	0.947	rs7708140	ENSG00000233006.5	AC034220.3	3.98	9.35e-05	0.0311	0.3	0.26	Alzheimer's disease in APOE e4- carriers;	chr5:131916703	chr5:132311285~132369916:-
OV	cis	rs3758911	0.929	rs10789600	ENSG00000261098.1	RP11-819C21.1	-3.98	9.35e-05	0.0311	-0.25	-0.26	Coronary artery disease;	chr11:107310335	chr11:107312132~107316271:-
OV	cis	rs10129255	0.556	rs9324093	ENSG00000223648.3	IGHV3-64	3.98	9.35e-05	0.0312	0.25	0.26	Kawasaki disease;	chr14:106683893	chr14:106643132~106658258:-
OV	cis	rs875971	0.508	rs10258739	ENSG00000273024.4	INTS4P2	3.98	9.35e-05	0.0312	0.27	0.26	Aortic root size;	chr7:66597948	chr7:65647864~65715661:+
OV	cis	rs56071727	1	rs56071727	ENSG00000280836.1	AL355480.1	-3.98	9.36e-05	0.0312	-0.57	-0.26	Iron status biomarkers (total iron binding capacity);	chr1:45625172	chr1:45581219~45581321:-
OV	cis	rs2348418	0.703	rs10843122	ENSG00000247934.4	RP11-967K21.1	-3.98	9.36e-05	0.0312	-0.25	-0.26	Lung function (FEV1);Lung function (FVC);	chr12:28174153	chr12:28163298~28190738:-
OV	cis	rs2348418	0.765	rs2078016	ENSG00000247934.4	RP11-967K21.1	-3.98	9.36e-05	0.0312	-0.25	-0.26	Lung function (FEV1);Lung function (FVC);	chr12:28180174	chr12:28163298~28190738:-
OV	cis	rs6545883	0.929	rs55806663	ENSG00000273302.1	RP11-493E12.2	3.98	9.37e-05	0.0312	0.21	0.26	Tuberculosis;	chr2:61513352	chr2:61199979~61200769:+
OV	cis	rs6545883	0.929	rs6545877	ENSG00000273302.1	RP11-493E12.2	3.98	9.37e-05	0.0312	0.21	0.26	Tuberculosis;	chr2:61514812	chr2:61199979~61200769:+
OV	cis	rs6545883	0.929	rs7606167	ENSG00000273302.1	RP11-493E12.2	3.98	9.37e-05	0.0312	0.21	0.26	Tuberculosis;	chr2:61515519	chr2:61199979~61200769:+
OV	cis	rs6545883	0.929	rs3732170	ENSG00000273302.1	RP11-493E12.2	3.98	9.37e-05	0.0312	0.21	0.26	Tuberculosis;	chr2:61522581	chr2:61199979~61200769:+
OV	cis	rs6545883	0.831	rs9309336	ENSG00000273302.1	RP11-493E12.2	3.98	9.37e-05	0.0312	0.21	0.26	Tuberculosis;	chr2:61536030	chr2:61199979~61200769:+
OV	cis	rs80168506	0.748	rs12464768	ENSG00000272519.1	RP11-105N14.2	3.98	9.37e-05	0.0312	0.38	0.26	Selective IgA deficiency;	chr2:213214013	chr2:213266995~213276152:-
OV	cis	rs4964805	0.594	rs3751204	ENSG00000257681.1	RP11-341G23.4	3.98	9.37e-05	0.0312	0.29	0.26	Attention deficit hyperactivity disorder;	chr12:103777677	chr12:103746315~103768858:-
OV	cis	rs757081	0.648	rs10766382	ENSG00000213779.4	RP11-452G18.1	3.98	9.38e-05	0.0312	0.28	0.26	Systolic blood pressure;	chr11:17252894	chr11:17193489~17194308:+
OV	cis	rs757081	0.648	rs12276859	ENSG00000213779.4	RP11-452G18.1	3.98	9.38e-05	0.0312	0.28	0.26	Systolic blood pressure;	chr11:17255418	chr11:17193489~17194308:+
OV	cis	rs709400	0.628	rs1989565	ENSG00000244691.1	RPL10AP1	-3.98	9.38e-05	0.0312	-0.25	-0.26	Body mass index;	chr14:103395856	chr14:103412119~103412761:-
OV	cis	rs9813712	0.672	rs73210789	ENSG00000228252.7	COL6A4P2	3.98	9.38e-05	0.0312	0.34	0.26	Response to amphetamines;	chr3:130243418	chr3:130212823~130273806:+
OV	cis	rs9813712	1	rs57804141	ENSG00000228252.7	COL6A4P2	3.98	9.38e-05	0.0312	0.34	0.26	Response to amphetamines;	chr3:130243669	chr3:130212823~130273806:+
OV	cis	rs1511299	0.597	rs11569198	ENSG00000249417.1	RP11-438D8.2	-3.98	9.39e-05	0.0312	-0.39	-0.26	Glomerular filtration rate;	chr3:141995526	chr3:141267353~141367137:-
OV	cis	rs9880211	0.613	rs12330335	ENSG00000239213.4	NCK1-AS1	3.98	9.39e-05	0.0313	0.31	0.26	Height;Body mass index;	chr3:136134690	chr3:136841726~136862054:-
OV	cis	rs9880211	0.613	rs1393786	ENSG00000239213.4	NCK1-AS1	3.98	9.39e-05	0.0313	0.31	0.26	Height;Body mass index;	chr3:136135193	chr3:136841726~136862054:-
OV	cis	rs12500482	0.5	rs2269493	ENSG00000249673.5	NOP14-AS1	-3.98	9.39e-05	0.0313	-0.29	-0.26	Cognitive function;	chr4:2426736	chr4:2934899~2961738:+
OV	cis	rs7590255	0.876	rs4629139	ENSG00000279519.1	RP11-288C18.1	3.98	9.39e-05	0.0313	0.31	0.26	Nonsyndromic cleft lip with cleft palate;	chr2:37758344	chr2:36839922~36842539:-
OV	cis	rs7267979	0.744	rs6050463	ENSG00000274973.1	RP13-401N8.7	-3.98	9.4e-05	0.0313	-0.29	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25228354	chr20:25845497~25845862:+
OV	cis	rs11951515	0.7	rs11956936	ENSG00000278487.1	RP11-447H19.4	-3.98	9.4e-05	0.0313	-0.3	-0.26	Metabolite levels  (X-11787);	chr5:43367247	chr5:43143362~43143514:-
OV	cis	rs11951515	0.7	rs11956988	ENSG00000278487.1	RP11-447H19.4	-3.98	9.4e-05	0.0313	-0.3	-0.26	Metabolite levels  (X-11787);	chr5:43367267	chr5:43143362~43143514:-
OV	cis	rs11951515	0.738	rs11960415	ENSG00000278487.1	RP11-447H19.4	-3.98	9.4e-05	0.0313	-0.3	-0.26	Metabolite levels  (X-11787);	chr5:43367407	chr5:43143362~43143514:-
OV	cis	rs11951515	0.738	rs10512827	ENSG00000278487.1	RP11-447H19.4	-3.98	9.4e-05	0.0313	-0.3	-0.26	Metabolite levels  (X-11787);	chr5:43367964	chr5:43143362~43143514:-
OV	cis	rs11951515	0.738	rs12517362	ENSG00000278487.1	RP11-447H19.4	-3.98	9.4e-05	0.0313	-0.3	-0.26	Metabolite levels  (X-11787);	chr5:43368060	chr5:43143362~43143514:-
OV	cis	rs61990749	0.571	rs4448861	ENSG00000239272.1	RPL21P10	3.98	9.41e-05	0.0313	0.37	0.26	Fibroblast growth factor basic levels;	chr14:77841392	chr14:77683202~77683989:-
OV	cis	rs10838687	0.932	rs4752973	ENSG00000271350.1	CTD-2384B9.1	3.98	9.41e-05	0.0313	0.34	0.26	Proinsulin levels;	chr11:47247608	chr11:47041027~47041945:-
OV	cis	rs10129255	0.5	rs7157975	ENSG00000223648.3	IGHV3-64	3.98	9.41e-05	0.0313	0.25	0.26	Kawasaki disease;	chr14:106804049	chr14:106643132~106658258:-
OV	cis	rs9287719	0.649	rs12473957	ENSG00000243819.4	RN7SL832P	-3.98	9.41e-05	0.0313	-0.26	-0.26	Prostate cancer;	chr2:10577588	chr2:10690344~10692099:+
OV	cis	rs2243480	1	rs3885839	ENSG00000226824.5	RP4-756H11.3	-3.98	9.41e-05	0.0313	-0.41	-0.26	Diabetic kidney disease;	chr7:65825416	chr7:66654538~66669855:+
OV	cis	rs853679	0.55	rs1233704	ENSG00000226314.6	ZNF192P1	3.98	9.42e-05	0.0313	0.36	0.26	Depression;	chr6:28199145	chr6:28161781~28169594:+
OV	cis	rs4713118	0.614	rs9468209	ENSG00000216901.1	AL022393.7	3.98	9.42e-05	0.0313	0.29	0.26	Parkinson's disease;	chr6:27726642	chr6:28176188~28176674:+
OV	cis	rs7078012	0.504	rs10400059	ENSG00000225484.5	NUTM2B-AS1	-3.98	9.43e-05	0.0314	-0.59	-0.26	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79920782	chr10:79663088~79826594:-
OV	cis	rs9311474	0.659	rs7638808	ENSG00000243224.1	RP5-1157M23.2	3.98	9.43e-05	0.0314	0.26	0.26	Electroencephalogram traits;	chr3:52538040	chr3:52239258~52241097:+
OV	cis	rs2828520	0.606	rs2828497	ENSG00000223822.2	EEF1A1P1	3.98	9.43e-05	0.0314	0.23	0.26	Major depressive disorder;	chr21:23748187	chr21:23390258~23390996:+
OV	cis	rs11122895	0.716	rs3860383	ENSG00000228251.1	AC012442.6	-3.98	9.44e-05	0.0314	-0.24	-0.26	Allergic sensitization;	chr2:111715291	chr2:112590796~112591939:+
OV	cis	rs71520386	0.632	rs10224419	ENSG00000228649.7	AC005682.5	3.98	9.45e-05	0.0314	0.31	0.26	Fibrinogen levels;	chr7:22830397	chr7:22854178~22861579:+
OV	cis	rs490608	0.608	rs11264360	ENSG00000225855.5	RUSC1-AS1	3.98	9.45e-05	0.0314	0.23	0.26	Inflammatory bowel disease;	chr1:155314795	chr1:155316863~155324176:-
OV	cis	rs6101567	0.623	rs6129279	ENSG00000261431.1	RP4-616B8.4	3.98	9.45e-05	0.0314	0.26	0.26	Nose size;	chr20:39367446	chr20:38961925~38962111:-
OV	cis	rs295490	0.667	rs78259171	ENSG00000272656.1	RP11-219D15.3	3.98	9.46e-05	0.0315	0.51	0.26	PR interval in Tripanosoma cruzi seropositivity;	chr3:139323866	chr3:139349024~139349371:-
OV	cis	rs7259965	0.839	rs1872124	ENSG00000277744.1	CTC-435M10.12	3.97	9.46e-05	0.0315	0.25	0.26	Midgestational circulating levels of organochlorine pesticides;Midgestational circulating levels of PBDEs;	chr19:40995755	chr19:41373971~41374419:+
OV	cis	rs730566	0.64	rs6442112	ENSG00000229759.1	MRPS18AP1	3.97	9.46e-05	0.0315	0.28	0.26	Prion diseases;	chr3:48274544	chr3:48256350~48256938:-
OV	cis	rs2070488	1	rs3792528	ENSG00000229589.1	ACVR2B-AS1	3.97	9.46e-05	0.0315	0.29	0.26	Electrocardiographic conduction measures;	chr3:38451812	chr3:38451027~38454820:-
OV	cis	rs62184315	0.536	rs56324258	ENSG00000253559.1	OSGEPL1-AS1	-3.97	9.47e-05	0.0315	-0.34	-0.26	Alcohol dependence (age at onset);	chr2:189811589	chr2:189762704~189765556:+
OV	cis	rs514406	0.621	rs1930306	ENSG00000206627.1	RNU6-969P	-3.97	9.47e-05	0.0315	-0.27	-0.26	Monocyte count;	chr1:52730014	chr1:52805108~52805212:-
OV	cis	rs13217239	0.646	rs9393789	ENSG00000261584.1	RP11-457M11.5	-3.97	9.47e-05	0.0315	-0.29	-0.26	Schizophrenia;	chr6:27099249	chr6:26686241~26687964:+
OV	cis	rs13217239	0.646	rs6456767	ENSG00000261584.1	RP11-457M11.5	-3.97	9.47e-05	0.0315	-0.29	-0.26	Schizophrenia;	chr6:27102764	chr6:26686241~26687964:+
OV	cis	rs9532669	0.926	rs9525418	ENSG00000239827.7	SUGT1P3	3.97	9.48e-05	0.0315	0.33	0.26	Cervical cancer;	chr13:40879081	chr13:40908159~40921774:-
OV	cis	rs3823536	0.583	rs1874327	ENSG00000275106.1	RP11-309L24.10	-3.97	9.48e-05	0.0315	-0.36	-0.26	Sjögren's syndrome;	chr7:128945322	chr7:128952527~128953316:-
OV	cis	rs897984	0.542	rs750952	ENSG00000232748.3	RP11-196G11.6	-3.97	9.49e-05	0.0315	-0.27	-0.26	Dementia with Lewy bodies;	chr16:31082633	chr16:31056460~31062803:+
OV	cis	rs4304977	0.645	rs1993938	ENSG00000272888.4	LINC01578	3.97	9.49e-05	0.0315	0.29	0.26	DNA methylation (variation);	chr15:92226166	chr15:92882707~92899701:+
OV	cis	rs7267979	0.873	rs7453	ENSG00000274973.1	RP13-401N8.7	-3.97	9.49e-05	0.0315	-0.29	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25226438	chr20:25845497~25845862:+
OV	cis	rs6545883	0.965	rs12713439	ENSG00000273302.1	RP11-493E12.2	3.97	9.49e-05	0.0315	0.21	0.26	Tuberculosis;	chr2:61525019	chr2:61199979~61200769:+
OV	cis	rs6545883	0.965	rs7421663	ENSG00000273302.1	RP11-493E12.2	3.97	9.49e-05	0.0315	0.21	0.26	Tuberculosis;	chr2:61526651	chr2:61199979~61200769:+
OV	cis	rs6545883	0.931	rs11125885	ENSG00000273302.1	RP11-493E12.2	3.97	9.49e-05	0.0315	0.21	0.26	Tuberculosis;	chr2:61528593	chr2:61199979~61200769:+
OV	cis	rs6545883	0.965	rs9989775	ENSG00000273302.1	RP11-493E12.2	3.97	9.49e-05	0.0315	0.21	0.26	Tuberculosis;	chr2:61534639	chr2:61199979~61200769:+
OV	cis	rs12073359	1	rs12060027	ENSG00000223945.2	RP11-458I7.1	-3.97	9.5e-05	0.0316	-0.39	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150043510	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs28660389	ENSG00000223945.2	RP11-458I7.1	-3.97	9.5e-05	0.0316	-0.39	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150047352	chr1:150053864~150055034:+
OV	cis	rs7726839	0.54	rs72703083	ENSG00000271781.1	CTD-2589H19.6	-3.97	9.5e-05	0.0316	-0.39	-0.26	Obesity-related traits;	chr5:595250	chr5:675826~676616:+
OV	cis	rs7726839	0.54	rs55929359	ENSG00000271781.1	CTD-2589H19.6	-3.97	9.5e-05	0.0316	-0.39	-0.26	Obesity-related traits;	chr5:595841	chr5:675826~676616:+
OV	cis	rs7726839	0.54	rs58599998	ENSG00000271781.1	CTD-2589H19.6	-3.97	9.5e-05	0.0316	-0.39	-0.26	Obesity-related traits;	chr5:595972	chr5:675826~676616:+
OV	cis	rs7726839	0.507	rs56282020	ENSG00000271781.1	CTD-2589H19.6	-3.97	9.5e-05	0.0316	-0.39	-0.26	Obesity-related traits;	chr5:596586	chr5:675826~676616:+
OV	cis	rs7726839	0.507	rs60068988	ENSG00000271781.1	CTD-2589H19.6	-3.97	9.5e-05	0.0316	-0.39	-0.26	Obesity-related traits;	chr5:597553	chr5:675826~676616:+
OV	cis	rs7726839	0.54	rs72703087	ENSG00000271781.1	CTD-2589H19.6	-3.97	9.5e-05	0.0316	-0.39	-0.26	Obesity-related traits;	chr5:597914	chr5:675826~676616:+
OV	cis	rs57221529	0.709	rs72703090	ENSG00000271781.1	CTD-2589H19.6	-3.97	9.5e-05	0.0316	-0.39	-0.26	Lung disease severity in cystic fibrosis;	chr5:598199	chr5:675826~676616:+
OV	cis	rs7726839	0.54	rs11750321	ENSG00000271781.1	CTD-2589H19.6	-3.97	9.5e-05	0.0316	-0.39	-0.26	Obesity-related traits;	chr5:599081	chr5:675826~676616:+
OV	cis	rs7726839	0.54	rs72703092	ENSG00000271781.1	CTD-2589H19.6	-3.97	9.5e-05	0.0316	-0.39	-0.26	Obesity-related traits;	chr5:599154	chr5:675826~676616:+
OV	cis	rs7267979	1	rs6050573	ENSG00000274973.1	RP13-401N8.7	-3.97	9.5e-05	0.0316	-0.29	-0.26	Liver enzyme levels (alkaline phosphatase);	chr20:25385429	chr20:25845497~25845862:+
OV	cis	rs12815613	1	rs12815613	ENSG00000202538.1	RNU4-2	3.97	9.5e-05	0.0316	0.31	0.26	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr12:120969453	chr12:120291763~120291903:-
OV	cis	rs4604732	0.642	rs4489599	ENSG00000227135.1	GCSAML-AS1	3.97	9.52e-05	0.0316	0.41	0.26	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247471911	chr1:247524679~247526752:-
OV	cis	rs8054556	0.787	rs12444108	ENSG00000261367.1	RP11-455F5.4	-3.97	9.52e-05	0.0316	-0.3	-0.26	Autism spectrum disorder or schizophrenia;	chr16:30016373	chr16:30107675~30110541:+
OV	cis	rs6076065	0.802	rs2424527	ENSG00000273838.1	RP3-333B15.5	3.97	9.52e-05	0.0316	0.31	0.26	Facial morphology (factor 15, philtrum width);	chr20:23376692	chr20:23458529~23459459:+
OV	cis	rs7688540	0.771	rs11737268	ENSG00000275426.1	CH17-262A2.1	3.97	9.52e-05	0.0316	0.38	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:230663	chr4:149738~150317:+
OV	cis	rs7688540	0.771	rs11726829	ENSG00000275426.1	CH17-262A2.1	3.97	9.52e-05	0.0316	0.38	0.26	Facial morphology (factor 6, height of vermillion lower lip);	chr4:231159	chr4:149738~150317:+
OV	cis	rs6715284	0.892	rs72937112	ENSG00000183308.6	AC005037.3	3.97	9.52e-05	0.0316	0.59	0.26	Rheumatoid arthritis;	chr2:201363385	chr2:200963263~201009102:+
OV	cis	rs12073359	0.954	rs72692899	ENSG00000223945.2	RP11-458I7.1	-3.97	9.52e-05	0.0316	-0.41	-0.26	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150077980	chr1:150053864~150055034:+
OV	cis	rs1015213	0.609	rs78364597	ENSG00000253844.1	RP11-546K22.1	-3.97	9.52e-05	0.0316	-0.67	-0.25	Glaucoma (primary angle closure);	chr8:51960839	chr8:51961458~52022974:+
OV	cis	rs1015213	0.609	rs117118889	ENSG00000253844.1	RP11-546K22.1	-3.97	9.52e-05	0.0316	-0.67	-0.25	Glaucoma (primary angle closure);	chr8:51960998	chr8:51961458~52022974:+
OV	cis	rs1015213	0.609	rs77334030	ENSG00000253844.1	RP11-546K22.1	-3.97	9.52e-05	0.0316	-0.67	-0.25	Glaucoma (primary angle closure);	chr8:51961090	chr8:51961458~52022974:+
OV	cis	rs1015213	0.609	rs116867982	ENSG00000253844.1	RP11-546K22.1	-3.97	9.52e-05	0.0316	-0.67	-0.25	Glaucoma (primary angle closure);	chr8:51961295	chr8:51961458~52022974:+
OV	cis	rs1015213	0.609	rs80295940	ENSG00000253844.1	RP11-546K22.1	-3.97	9.52e-05	0.0316	-0.67	-0.25	Glaucoma (primary angle closure);	chr8:51963004	chr8:51961458~52022974:+
OV	cis	rs1015213	0.609	rs76288806	ENSG00000253844.1	RP11-546K22.1	-3.97	9.52e-05	0.0316	-0.67	-0.25	Glaucoma (primary angle closure);	chr8:51964609	chr8:51961458~52022974:+
OV	cis	rs1015213	0.609	rs78232489	ENSG00000253844.1	RP11-546K22.1	-3.97	9.52e-05	0.0316	-0.67	-0.25	Glaucoma (primary angle closure);	chr8:51964689	chr8:51961458~52022974:+
OV	cis	rs1015213	0.609	rs75774497	ENSG00000253844.1	RP11-546K22.1	-3.97	9.52e-05	0.0316	-0.67	-0.25	Glaucoma (primary angle closure);	chr8:51964868	chr8:51961458~52022974:+
OV	cis	rs1015213	0.609	rs75473483	ENSG00000253844.1	RP11-546K22.1	-3.97	9.52e-05	0.0316	-0.67	-0.25	Glaucoma (primary angle closure);	chr8:51965017	chr8:51961458~52022974:+
OV	cis	rs1015213	0.609	rs74830652	ENSG00000253844.1	RP11-546K22.1	-3.97	9.52e-05	0.0316	-0.67	-0.25	Glaucoma (primary angle closure);	chr8:51965936	chr8:51961458~52022974:+
OV	cis	rs1015213	0.609	rs115398091	ENSG00000253844.1	RP11-546K22.1	-3.97	9.52e-05	0.0316	-0.67	-0.25	Glaucoma (primary angle closure);	chr8:51966515	chr8:51961458~52022974:+
OV	cis	rs2834288	0.5	rs766425	ENSG00000273102.1	AP000569.9	3.97	9.52e-05	0.0316	0.27	0.25	Gut microbiota (bacterial taxa);	chr21:33962264	chr21:33967101~33968573:-
OV	cis	rs7520050	0.966	rs34102169	ENSG00000281133.1	AL355480.3	3.97	9.52e-05	0.0316	0.29	0.25	Reticulocyte count;Red blood cell count;	chr1:45959192	chr1:45580892~45580996:-
OV	cis	rs433852	1	rs433852	ENSG00000232871.7	SEC1P	-3.97	9.52e-05	0.0316	-0.36	-0.25	Elevated serum carcinoembryonic antigen levels;Posterior cortical atrophy and Alzheimer's disease;	chr19:48613847	chr19:48638071~48682245:+
OV	cis	rs801193	0.844	rs732465	ENSG00000273024.4	INTS4P2	-3.97	9.52e-05	0.0316	-0.27	-0.25	Aortic root size;	chr7:66533463	chr7:65647864~65715661:+
OV	cis	rs801193	0.773	rs801207	ENSG00000273024.4	INTS4P2	3.97	9.52e-05	0.0316	0.27	0.25	Aortic root size;	chr7:66555603	chr7:65647864~65715661:+
OV	cis	rs875971	0.543	rs801191	ENSG00000273024.4	INTS4P2	3.97	9.52e-05	0.0316	0.27	0.25	Aortic root size;	chr7:66567968	chr7:65647864~65715661:+
OV	cis	rs875971	0.508	rs6947808	ENSG00000273024.4	INTS4P2	3.97	9.52e-05	0.0316	0.27	0.25	Aortic root size;	chr7:66580095	chr7:65647864~65715661:+
OV	cis	rs7395581	0.959	rs35879051	ENSG00000271350.1	CTD-2384B9.1	3.97	9.53e-05	0.0316	0.3	0.25	HDL cholesterol;	chr11:47254331	chr11:47041027~47041945:-
OV	cis	rs7395581	0.959	rs59663860	ENSG00000271350.1	CTD-2384B9.1	3.97	9.53e-05	0.0316	0.3	0.25	HDL cholesterol;	chr11:47254799	chr11:47041027~47041945:-
OV	cis	rs7395581	0.879	rs3758673	ENSG00000271350.1	CTD-2384B9.1	3.97	9.53e-05	0.0316	0.3	0.25	HDL cholesterol;	chr11:47257366	chr11:47041027~47041945:-
OV	cis	rs7395581	0.959	rs2279239	ENSG00000271350.1	CTD-2384B9.1	3.97	9.53e-05	0.0316	0.3	0.25	HDL cholesterol;	chr11:47260229	chr11:47041027~47041945:-
OV	cis	rs11105298	0.891	rs12369685	ENSG00000257194.2	RP11-567C2.1	-3.97	9.53e-05	0.0316	-0.39	-0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89535128	chr12:90107739~90112779:+
OV	cis	rs7968440	0.801	rs7960015	ENSG00000272368.2	RP4-605O3.4	3.97	9.53e-05	0.0316	0.31	0.25	Fibrinogen;	chr12:50751411	chr12:50112197~50165618:+
OV	cis	rs73201462	0.908	rs2955098	ENSG00000242551.2	POU5F1P6	-3.97	9.53e-05	0.0316	-0.37	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128260658	chr3:128674735~128677005:-
OV	cis	rs73201462	0.901	rs2811400	ENSG00000242551.2	POU5F1P6	-3.97	9.53e-05	0.0316	-0.37	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128269024	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2955096	ENSG00000242551.2	POU5F1P6	3.97	9.53e-05	0.0316	0.37	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128259023	chr3:128674735~128677005:-
OV	cis	rs7520050	0.831	rs61783170	ENSG00000280836.1	AL355480.1	3.97	9.54e-05	0.0316	0.32	0.25	Reticulocyte count;Red blood cell count;	chr1:45790657	chr1:45581219~45581321:-
OV	cis	rs10895275	0.51	rs1942683	ENSG00000260008.1	RP11-732A21.2	-3.97	9.54e-05	0.0316	-0.28	-0.25	Migraine;	chr11:102173916	chr11:102107886~102109842:+
OV	cis	rs7932354	0.528	rs1060573	ENSG00000271543.1	RP11-692M12.5	-3.97	9.54e-05	0.0317	-0.32	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:47158278	chr11:47796169~47796379:+
OV	cis	rs34460569	0.648	rs6749789	ENSG00000234193.1	AC097461.4	3.97	9.56e-05	0.0317	0.41	0.25	Nose size;	chr2:222129502	chr2:222917387~222919363:-
OV	cis	rs7173064	0.617	rs6497106	ENSG00000272888.4	LINC01578	3.97	9.56e-05	0.0317	0.33	0.25	White matter hyperintensity burden;	chr15:93682592	chr15:92882707~92899701:+
OV	cis	rs757081	0.648	rs1488933	ENSG00000213779.4	RP11-452G18.1	3.97	9.56e-05	0.0317	0.28	0.25	Systolic blood pressure;	chr11:17245482	chr11:17193489~17194308:+
OV	cis	rs2243480	1	rs4718270	ENSG00000226824.5	RP4-756H11.3	-3.97	9.56e-05	0.0317	-0.45	-0.25	Diabetic kidney disease;	chr7:65737415	chr7:66654538~66669855:+
OV	cis	rs2243480	0.901	rs2900904	ENSG00000226824.5	RP4-756H11.3	-3.97	9.56e-05	0.0317	-0.45	-0.25	Diabetic kidney disease;	chr7:65739282	chr7:66654538~66669855:+
OV	cis	rs4664293	0.51	rs890096	ENSG00000226266.5	AC009961.3	3.97	9.56e-05	0.0317	0.31	0.25	Monocyte percentage of white cells;	chr2:159604849	chr2:159670708~159712435:-
OV	cis	rs4664293	0.51	rs747707	ENSG00000226266.5	AC009961.3	3.97	9.56e-05	0.0317	0.31	0.25	Monocyte percentage of white cells;	chr2:159609003	chr2:159670708~159712435:-
OV	cis	rs4664293	0.51	rs6731277	ENSG00000226266.5	AC009961.3	3.97	9.56e-05	0.0317	0.31	0.25	Monocyte percentage of white cells;	chr2:159610606	chr2:159670708~159712435:-
OV	cis	rs697003	0.966	rs701929	ENSG00000231057.3	RP11-122M14.1	3.97	9.56e-05	0.0317	0.25	0.25	Red cell distribution width;	chr1:211673534	chr1:211675762~211690103:+
OV	cis	rs1555322	0.53	rs2425053	ENSG00000261582.1	RP4-614O4.11	-3.97	9.57e-05	0.0317	-0.29	-0.25	Attention deficit hyperactivity disorder;	chr20:35294017	chr20:35267885~35280043:-
OV	cis	rs853679	0.556	rs45509595	ENSG00000280107.1	AL022393.9	-3.97	9.59e-05	0.0318	-0.56	-0.25	Depression;	chr6:27873148	chr6:28170845~28172521:+
OV	cis	rs6452524	0.508	rs256795	ENSG00000271862.1	RP11-343L5.2	-3.97	9.59e-05	0.0318	-0.3	-0.25	Hypertension (SNP x SNP interaction);	chr5:83001543	chr5:83049376~83050964:-
OV	cis	rs6921919	0.525	rs9468361	ENSG00000204709.4	LINC01556	3.97	9.59e-05	0.0318	0.31	0.25	Autism spectrum disorder or schizophrenia;	chr6:28378541	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs7775132	ENSG00000204709.4	LINC01556	3.97	9.59e-05	0.0318	0.31	0.25	Autism spectrum disorder or schizophrenia;	chr6:28379236	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs3734563	ENSG00000204709.4	LINC01556	3.97	9.59e-05	0.0318	0.31	0.25	Autism spectrum disorder or schizophrenia;	chr6:28381948	chr6:28943877~28944537:+
OV	cis	rs6921919	0.583	rs1591913	ENSG00000204709.4	LINC01556	3.97	9.59e-05	0.0318	0.31	0.25	Autism spectrum disorder or schizophrenia;	chr6:28383951	chr6:28943877~28944537:+
OV	cis	rs7520050	0.778	rs3014238	ENSG00000280836.1	AL355480.1	3.97	9.59e-05	0.0318	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45624542	chr1:45581219~45581321:-
OV	cis	rs7246657	0.943	rs12981532	ENSG00000226686.6	LINC01535	-3.97	9.6e-05	0.0318	-0.4	-0.25	Coronary artery calcification;	chr19:37398378	chr19:37251912~37265535:+
OV	cis	rs7246657	0.943	rs7246993	ENSG00000226686.6	LINC01535	-3.97	9.6e-05	0.0318	-0.4	-0.25	Coronary artery calcification;	chr19:37399252	chr19:37251912~37265535:+
OV	cis	rs7246657	0.943	rs10413602	ENSG00000226686.6	LINC01535	-3.97	9.6e-05	0.0318	-0.4	-0.25	Coronary artery calcification;	chr19:37400590	chr19:37251912~37265535:+
OV	cis	rs7246657	0.943	rs10422074	ENSG00000226686.6	LINC01535	-3.97	9.6e-05	0.0318	-0.4	-0.25	Coronary artery calcification;	chr19:37403334	chr19:37251912~37265535:+
OV	cis	rs9309473	0.66	rs62151564	ENSG00000163016.8	ALMS1P	3.97	9.6e-05	0.0318	0.36	0.25	Metabolite levels;	chr2:73388321	chr2:73644919~73685576:+
OV	cis	rs929354	1	rs1182389	ENSG00000235029.1	MNX1-AS2	-3.97	9.6e-05	0.0318	-0.29	-0.25	Body mass index;	chr7:157246109	chr7:157006307~157007132:+
OV	cis	rs796364	0.806	rs78037592	ENSG00000232732.8	AC073043.1	3.97	9.6e-05	0.0318	0.43	0.25	Schizophrenia;	chr2:200241011	chr2:199867396~199911159:-
OV	cis	rs1584120	0.678	rs11046821	ENSG00000274885.1	RP11-268P4.6	-3.97	9.61e-05	0.0318	-0.32	-0.25	Pelvic organ prolapse (moderate/severe);	chr12:23134388	chr12:22638464~22638943:+
OV	cis	rs80285556	1	rs17661933	ENSG00000161643.11	SIGLEC16	-3.97	9.62e-05	0.0319	-0.55	-0.25	antipsychotic drug dosage in schizophrenia or schizoaffective disorder;	chr19:50031263	chr19:49969673~49975814:+
OV	cis	rs6128907	0.948	rs6128952	ENSG00000224635.1	RP4-564F22.5	3.97	9.63e-05	0.0319	0.37	0.25	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38771847	chr20:38406011~38416797:-
OV	cis	rs2243480	1	rs2243480	ENSG00000226824.5	RP4-756H11.3	-3.97	9.63e-05	0.0319	-0.39	-0.25	Diabetic kidney disease;	chr7:66134209	chr7:66654538~66669855:+
OV	cis	rs875971	0.571	rs160647	ENSG00000234500.1	GS1-124K5.10	3.97	9.63e-05	0.0319	0.21	0.25	Aortic root size;	chr7:66089365	chr7:66511556~66545066:+
OV	cis	rs7646881	0.544	rs7638518	ENSG00000272087.1	RP11-379F4.7	-3.97	9.63e-05	0.0319	-0.37	-0.25	Tetralogy of Fallot;	chr3:158568953	chr3:158693120~158693768:-
OV	cis	rs7927592	0.763	rs10896340	ENSG00000222339.1	AP000807.2	-3.97	9.63e-05	0.0319	-0.26	-0.25	Total body bone mineral density;	chr11:68545177	chr11:68505572~68505651:-
OV	cis	rs694739	0.541	rs61886926	ENSG00000236935.1	AP003774.1	3.97	9.65e-05	0.0319	0.32	0.25	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64366080	chr11:64325050~64329504:-
OV	cis	rs694739	0.628	rs617051	ENSG00000236935.1	AP003774.1	3.97	9.65e-05	0.0319	0.32	0.25	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64366166	chr11:64325050~64329504:-
OV	cis	rs12480328	1	rs73909829	ENSG00000233077.1	LINC01271	3.97	9.65e-05	0.0319	0.54	0.25	Prostate cancer;	chr20:50909760	chr20:50310711~50321342:-
OV	cis	rs12480328	1	rs73909831	ENSG00000233077.1	LINC01271	3.97	9.65e-05	0.0319	0.54	0.25	Prostate cancer;	chr20:50909948	chr20:50310711~50321342:-
OV	cis	rs12480328	1	rs78860779	ENSG00000233077.1	LINC01271	3.97	9.65e-05	0.0319	0.54	0.25	Prostate cancer;	chr20:50910834	chr20:50310711~50321342:-
OV	cis	rs12480328	1	rs41274692	ENSG00000233077.1	LINC01271	3.97	9.65e-05	0.0319	0.54	0.25	Prostate cancer;	chr20:50914391	chr20:50310711~50321342:-
OV	cis	rs732765	0.734	rs12892937	ENSG00000258439.1	RP11-173A8.2	3.97	9.65e-05	0.0319	0.33	0.25	Non-small cell lung cancer;	chr14:74702224	chr14:74658049~74658590:+
OV	cis	rs732765	0.734	rs12323361	ENSG00000258439.1	RP11-173A8.2	3.97	9.65e-05	0.0319	0.33	0.25	Non-small cell lung cancer;	chr14:74705003	chr14:74658049~74658590:+
OV	cis	rs732765	0.734	rs7153812	ENSG00000258439.1	RP11-173A8.2	3.97	9.65e-05	0.0319	0.33	0.25	Non-small cell lung cancer;	chr14:74706787	chr14:74658049~74658590:+
OV	cis	rs13201294	1	rs13201294	ENSG00000226314.6	ZNF192P1	-3.97	9.65e-05	0.0319	-0.49	-0.25	Squamous cell lung carcinoma;	chr6:27588362	chr6:28161781~28169594:+
OV	cis	rs1113500	0.509	rs17020915	ENSG00000226822.1	RP11-356N1.2	3.97	9.66e-05	0.032	0.32	0.25	Growth-regulated protein alpha levels;	chr1:108104384	chr1:108071482~108074519:+
OV	cis	rs1862618	0.853	rs6450409	ENSG00000271828.1	CTD-2310F14.1	3.97	9.66e-05	0.032	0.4	0.25	Initial pursuit acceleration;	chr5:56805572	chr5:56927874~56929573:+
OV	cis	rs6545883	0.791	rs2600665	ENSG00000270820.4	RP11-355B11.2	3.97	9.66e-05	0.032	0.29	0.25	Tuberculosis;	chr2:61178660	chr2:61471188~61484130:+
OV	cis	rs3758911	0.894	rs4343000	ENSG00000261098.1	RP11-819C21.1	-3.97	9.66e-05	0.032	-0.25	-0.25	Coronary artery disease;	chr11:107353992	chr11:107312132~107316271:-
OV	cis	rs875971	0.825	rs4587224	ENSG00000237310.1	GS1-124K5.4	-3.97	9.67e-05	0.032	-0.26	-0.25	Aortic root size;	chr7:66271195	chr7:66493706~66495474:+
OV	cis	rs875971	0.792	rs6971752	ENSG00000237310.1	GS1-124K5.4	-3.97	9.67e-05	0.032	-0.26	-0.25	Aortic root size;	chr7:66272999	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs10950033	ENSG00000237310.1	GS1-124K5.4	-3.97	9.67e-05	0.032	-0.26	-0.25	Aortic root size;	chr7:66274686	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs11760844	ENSG00000237310.1	GS1-124K5.4	-3.97	9.67e-05	0.032	-0.26	-0.25	Aortic root size;	chr7:66274896	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs4149461	ENSG00000237310.1	GS1-124K5.4	-3.97	9.67e-05	0.032	-0.26	-0.25	Aortic root size;	chr7:66279745	chr7:66493706~66495474:+
OV	cis	rs1436109	0.615	rs12273652	ENSG00000255129.4	RP11-839D17.3	3.97	9.67e-05	0.032	0.45	0.25	Cardiac muscle measurement;	chr11:113003813	chr11:113278437~113314437:-
OV	cis	rs7546668	1	rs45619934	ENSG00000272510.1	RP4-680D5.8	3.97	9.67e-05	0.032	0.28	0.25	Glomerular filtration rate (creatinine);	chr1:15585452	chr1:15565611~15565956:-
OV	cis	rs1538970	0.961	rs7553318	ENSG00000280836.1	AL355480.1	-3.97	9.69e-05	0.032	-0.35	-0.25	Platelet count;	chr1:45377414	chr1:45581219~45581321:-
OV	cis	rs1538970	0.961	rs884962	ENSG00000280836.1	AL355480.1	-3.97	9.69e-05	0.032	-0.35	-0.25	Platelet count;	chr1:45382309	chr1:45581219~45581321:-
OV	cis	rs35824328	0.517	rs1912203	ENSG00000197585.8	AC107218.3	3.97	9.69e-05	0.032	0.39	0.25	HIV-associated neurocognitive disorder (mild neurocognitive disorder);	chr2:214360552	chr2:214250040~214684246:-
OV	cis	rs7204230	1	rs8057688	ENSG00000261291.1	RP11-295M3.2	-3.97	9.69e-05	0.032	-0.3	-0.25	Fibrinogen;	chr16:53294067	chr16:53168522~53169450:+
OV	cis	rs4290604	0.748	rs10754942	ENSG00000224132.2	AC112715.2	-3.97	9.69e-05	0.032	-0.47	-0.25	Asthma;	chr2:237166544	chr2:237257091~237257676:+
OV	cis	rs4290604	0.748	rs4621125	ENSG00000224132.2	AC112715.2	-3.97	9.69e-05	0.032	-0.47	-0.25	Asthma;	chr2:237171571	chr2:237257091~237257676:+
OV	cis	rs4290604	0.748	rs10929216	ENSG00000224132.2	AC112715.2	-3.97	9.69e-05	0.032	-0.47	-0.25	Asthma;	chr2:237172295	chr2:237257091~237257676:+
OV	cis	rs9368481	0.761	rs12661756	ENSG00000261584.1	RP11-457M11.5	3.97	9.7e-05	0.0321	0.29	0.25	Autism spectrum disorder or schizophrenia;	chr6:27035704	chr6:26686241~26687964:+
OV	cis	rs875971	0.54	rs35510581	ENSG00000237310.1	GS1-124K5.4	-3.97	9.7e-05	0.0321	-0.26	-0.25	Aortic root size;	chr7:66113790	chr7:66493706~66495474:+
OV	cis	rs2492286	0.597	rs7647337	ENSG00000242551.2	POU5F1P6	-3.97	9.71e-05	0.0321	-0.33	-0.25	Eosinophil counts;	chr3:128628353	chr3:128674735~128677005:-
OV	cis	rs2492286	0.569	rs9848287	ENSG00000242551.2	POU5F1P6	-3.97	9.71e-05	0.0321	-0.33	-0.25	Eosinophil counts;	chr3:128628799	chr3:128674735~128677005:-
OV	cis	rs2492286	0.569	rs2712383	ENSG00000242551.2	POU5F1P6	-3.97	9.71e-05	0.0321	-0.33	-0.25	Eosinophil counts;	chr3:128629033	chr3:128674735~128677005:-
OV	cis	rs11098499	0.863	rs10019674	ENSG00000249244.1	RP11-548H18.2	-3.97	9.71e-05	0.0321	-0.33	-0.25	Corneal astigmatism;	chr4:119522334	chr4:119391831~119395335:-
OV	cis	rs7520050	0.831	rs61783169	ENSG00000280836.1	AL355480.1	3.97	9.71e-05	0.0321	0.32	0.25	Reticulocyte count;Red blood cell count;	chr1:45790655	chr1:45581219~45581321:-
OV	cis	rs1538970	0.962	rs9429160	ENSG00000280836.1	AL355480.1	-3.97	9.71e-05	0.0321	-0.35	-0.25	Platelet count;	chr1:45362296	chr1:45581219~45581321:-
OV	cis	rs796364	0.806	rs55985986	ENSG00000232732.8	AC073043.1	3.97	9.71e-05	0.0321	0.41	0.25	Schizophrenia;	chr2:200256264	chr2:199867396~199911159:-
OV	cis	rs2243480	0.706	rs6460257	ENSG00000226824.5	RP4-756H11.3	-3.97	9.72e-05	0.0321	-0.38	-0.25	Diabetic kidney disease;	chr7:65731813	chr7:66654538~66669855:+
OV	cis	rs9649213	0.574	rs34817002	ENSG00000223402.1	AC074121.4	-3.97	9.72e-05	0.0321	-0.3	-0.25	Prostate cancer (SNP x SNP interaction);	chr7:98257739	chr7:98478551~98479225:-
OV	cis	rs12073359	1	rs72692862	ENSG00000223945.2	RP11-458I7.1	-3.97	9.72e-05	0.0321	-0.41	-0.25	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150037246	chr1:150053864~150055034:+
OV	cis	rs1499614	1	rs2707832	ENSG00000226824.5	RP4-756H11.3	-3.97	9.72e-05	0.0321	-0.42	-0.25	Gout;	chr7:66671562	chr7:66654538~66669855:+
OV	cis	rs2239547	0.522	rs2336669	ENSG00000242142.1	SERBP1P3	-3.97	9.73e-05	0.0321	-0.32	-0.25	Schizophrenia;	chr3:52960122	chr3:53064283~53065091:-
OV	cis	rs875971	0.508	rs10258739	ENSG00000237310.1	GS1-124K5.4	-3.97	9.73e-05	0.0321	-0.26	-0.25	Aortic root size;	chr7:66597948	chr7:66493706~66495474:+
OV	cis	rs888405	0.541	rs697287	ENSG00000239926.1	PRDX3P4	3.97	9.73e-05	0.0321	0.36	0.25	Gestational age at birth in premature rupture of membrane-initiated deliveries (child effect);	chr3:64225426	chr3:64174401~64175147:+
OV	cis	rs6142102	0.886	rs6059583	ENSG00000264616.1	MIR4755	3.97	9.75e-05	0.0322	0.32	0.25	Skin pigmentation;	chr20:33944308	chr20:34049119~34049190:+
OV	cis	rs6545883	0.931	rs9807965	ENSG00000270820.4	RP11-355B11.2	3.97	9.76e-05	0.0322	0.29	0.25	Tuberculosis;	chr2:61505024	chr2:61471188~61484130:+
OV	cis	rs2070488	0.965	rs6599206	ENSG00000229589.1	ACVR2B-AS1	-3.97	9.77e-05	0.0323	-0.28	-0.25	Electrocardiographic conduction measures;	chr3:38503858	chr3:38451027~38454820:-
OV	cis	rs853679	0.628	rs9368560	ENSG00000226314.6	ZNF192P1	-3.97	9.78e-05	0.0323	-0.37	-0.25	Depression;	chr6:28192182	chr6:28161781~28169594:+
OV	cis	rs4664293	0.51	rs1968343	ENSG00000224152.1	AC009506.1	3.97	9.79e-05	0.0323	0.26	0.25	Monocyte percentage of white cells;	chr2:159712247	chr2:159615296~159617082:+
OV	cis	rs73198271	0.813	rs17697237	ENSG00000253981.4	ALG1L13P	3.97	9.79e-05	0.0323	0.28	0.25	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8758364	chr8:8236003~8244667:-
OV	cis	rs2999052	0.865	rs4857841	ENSG00000277250.1	Metazoa_SRP	3.97	9.8e-05	0.0323	0.31	0.25	Hypospadias;	chr3:128327800	chr3:128673681~128674021:-
OV	cis	rs1790761	0.505	rs34802338	ENSG00000184224.3	C11orf72	-3.97	9.8e-05	0.0323	-0.28	-0.25	Mean corpuscular volume;	chr11:67544995	chr11:67602880~67606706:-
OV	cis	rs2999052	1	rs2999052	ENSG00000277250.1	Metazoa_SRP	3.97	9.8e-05	0.0323	0.31	0.25	Hypospadias;	chr3:128173194	chr3:128673681~128674021:-
OV	cis	rs7267979	1	rs6050547	ENSG00000274973.1	RP13-401N8.7	3.97	9.81e-05	0.0324	0.29	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25345376	chr20:25845497~25845862:+
OV	cis	rs1707322	0.647	rs6686944	ENSG00000234329.1	RP11-767N6.2	3.97	9.81e-05	0.0324	0.27	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690636	chr1:45651039~45651826:-
OV	cis	rs7017914	0.69	rs1156956	ENSG00000223220.1	Y_RNA	3.97	9.81e-05	0.0324	0.27	0.25	Bone mineral density;	chr8:70842803	chr8:70780914~70781008:-
OV	cis	rs4763879	0.739	rs7310460	ENSG00000256673.1	RP11-599J14.2	3.97	9.81e-05	0.0324	0.23	0.25	Type 1 diabetes;	chr12:9688177	chr12:9398355~9414851:-
OV	cis	rs3758785	0.621	rs7128673	ENSG00000255893.1	RP11-685N10.1	-3.97	9.82e-05	0.0324	-0.3	-0.25	Response to angiotensin II receptor blocker therapy (opposite direction w/ diuretic therapy);	chr11:94453072	chr11:94472908~94473570:-
OV	cis	rs12815613	0.961	rs1134464	ENSG00000202538.1	RNU4-2	3.97	9.82e-05	0.0324	0.31	0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);	chr12:120968771	chr12:120291763~120291903:-
OV	cis	rs6545883	0.899	rs12473030	ENSG00000273302.1	RP11-493E12.2	3.97	9.82e-05	0.0324	0.21	0.25	Tuberculosis;	chr2:61493362	chr2:61199979~61200769:+
OV	cis	rs6545883	0.931	rs12713437	ENSG00000273302.1	RP11-493E12.2	3.97	9.82e-05	0.0324	0.21	0.25	Tuberculosis;	chr2:61495769	chr2:61199979~61200769:+
OV	cis	rs6545883	0.965	rs6545872	ENSG00000273302.1	RP11-493E12.2	3.97	9.82e-05	0.0324	0.21	0.25	Tuberculosis;	chr2:61497433	chr2:61199979~61200769:+
OV	cis	rs7119	0.651	rs12902898	ENSG00000259362.2	RP11-307C19.1	-3.97	9.82e-05	0.0324	-0.29	-0.25	Type 2 diabetes;	chr15:77556849	chr15:77525540~77534110:+
OV	cis	rs73019876	0.868	rs2262908	ENSG00000269742.1	BNIP3P29	-3.97	9.82e-05	0.0324	-0.29	-0.25	Testicular germ cell tumor;	chr19:21951998	chr19:22065828~22066398:-
OV	cis	rs7927592	0.731	rs643609	ENSG00000222339.1	AP000807.2	3.97	9.83e-05	0.0324	0.26	0.25	Total body bone mineral density;	chr11:68474365	chr11:68505572~68505651:-
OV	cis	rs35740288	0.822	rs2241268	ENSG00000259295.5	CSPG4P12	3.97	9.83e-05	0.0324	0.34	0.25	Eosinophil percentage of white cells;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr15:85735078	chr15:85191438~85213905:+
OV	cis	rs10486158	1	rs10952052	ENSG00000234141.1	AC009473.1	-3.97	9.83e-05	0.0324	-0.38	-0.25	Bipolar disorder and schizophrenia;	chr7:7359849	chr7:7949853~7950709:-
OV	cis	rs11239930	0.538	rs618575	ENSG00000229828.2	PDE4DIP1	3.96	9.84e-05	0.0324	0.34	0.25	AIDS progression;	chr1:147080759	chr1:148080598~148093883:+
OV	cis	rs7246967	0.673	rs8103012	ENSG00000267920.1	SNX6P1	-3.96	9.85e-05	0.0325	-0.4	-0.25	Bronchopulmonary dysplasia;	chr19:22696483	chr19:23126569~23127792:-
OV	cis	rs7116641	0.557	rs939016	ENSG00000246250.2	RP11-613D13.5	-3.96	9.85e-05	0.0325	-0.33	-0.25	Coronary artery disease;	chr11:43846818	chr11:43829709~43880726:-
OV	cis	rs6128907	1	rs6128947	ENSG00000224635.1	RP4-564F22.5	3.96	9.86e-05	0.0325	0.37	0.25	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38770845	chr20:38406011~38416797:-
OV	cis	rs875971	0.545	rs221986	ENSG00000237310.1	GS1-124K5.4	-3.96	9.86e-05	0.0325	-0.29	-0.25	Aortic root size;	chr7:66105323	chr7:66493706~66495474:+
OV	cis	rs2307022	0.671	rs9889191	ENSG00000263276.1	RP11-96D1.10	-3.96	9.86e-05	0.0325	-0.28	-0.25	Body mass index;	chr16:68343945	chr16:68224713~68227734:+
OV	cis	rs1458175	1	rs7304173	ENSG00000257674.1	RP11-76E16.2	3.96	9.87e-05	0.0325	0.26	0.25	Multiple sclerosis;	chr12:41570961	chr12:42286911~42288560:+
OV	cis	rs1458175	0.844	rs7133573	ENSG00000257674.1	RP11-76E16.2	3.96	9.87e-05	0.0325	0.26	0.25	Multiple sclerosis;	chr12:41570963	chr12:42286911~42288560:+
OV	cis	rs6071166	1	rs6071166	ENSG00000174365.18	SNHG11	-3.96	9.88e-05	0.0325	-0.33	-0.25	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38704369	chr20:38446578~38450921:+
OV	cis	rs10740039	0.81	rs6479720	ENSG00000254271.1	RP11-131N11.4	3.96	9.88e-05	0.0326	0.33	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60610935	chr10:60734342~60741828:+
OV	cis	rs3764021	0.933	rs2268146	ENSG00000256673.1	RP11-599J14.2	-3.96	9.89e-05	0.0326	-0.24	-0.25	Type 1 diabetes;	chr12:9716675	chr12:9398355~9414851:-
OV	cis	rs1707322	0.752	rs6678444	ENSG00000234329.1	RP11-767N6.2	3.96	9.91e-05	0.0326	0.27	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45764175	chr1:45651039~45651826:-
OV	cis	rs875971	1	rs2087647	ENSG00000237310.1	GS1-124K5.4	-3.96	9.92e-05	0.0326	-0.26	-0.25	Aortic root size;	chr7:66128201	chr7:66493706~66495474:+
OV	cis	rs875971	1	rs6958484	ENSG00000237310.1	GS1-124K5.4	-3.96	9.92e-05	0.0326	-0.26	-0.25	Aortic root size;	chr7:66134459	chr7:66493706~66495474:+
OV	cis	rs4713118	0.868	rs760587	ENSG00000226314.6	ZNF192P1	-3.96	9.92e-05	0.0327	-0.34	-0.25	Parkinson's disease;	chr6:27772521	chr6:28161781~28169594:+
OV	cis	rs1850744	1	rs2280208	ENSG00000250268.3	ALG1L14P	-3.96	9.93e-05	0.0327	-0.62	-0.25	Economic and political preferences;	chr4:9798419	chr4:9166297~9170270:-
OV	cis	rs2282300	0.637	rs10767841	ENSG00000242353.1	RP4-710M3.1	-3.96	9.93e-05	0.0327	-0.31	-0.25	Morning vs. evening chronotype;	chr11:30406728	chr11:30368148~30368646:+
OV	cis	rs2282300	0.637	rs7941828	ENSG00000242353.1	RP4-710M3.1	-3.96	9.93e-05	0.0327	-0.31	-0.25	Morning vs. evening chronotype;	chr11:30408784	chr11:30368148~30368646:+
OV	cis	rs2282300	0.637	rs7942037	ENSG00000242353.1	RP4-710M3.1	-3.96	9.93e-05	0.0327	-0.31	-0.25	Morning vs. evening chronotype;	chr11:30408785	chr11:30368148~30368646:+
OV	cis	rs6750795	0.502	rs11685196	ENSG00000223198.1	RNU2-22P	-3.96	9.94e-05	0.0327	-0.24	-0.25	Height;	chr2:231516587	chr2:231501990~231502201:-
OV	cis	rs9880211	1	rs12695649	ENSG00000239213.4	NCK1-AS1	3.96	9.94e-05	0.0327	0.3	0.25	Height;Body mass index;	chr3:136553074	chr3:136841726~136862054:-
OV	cis	rs11119805	0.649	rs12568179	ENSG00000260805.2	RP11-61J19.5	-3.96	9.95e-05	0.0327	-0.4	-0.25	Stearic acid (18:0) levels;	chr1:211826015	chr1:212557833~212559731:-
OV	cis	rs11119805	0.649	rs12138188	ENSG00000260805.2	RP11-61J19.5	-3.96	9.95e-05	0.0327	-0.4	-0.25	Stearic acid (18:0) levels;	chr1:211826215	chr1:212557833~212559731:-
OV	cis	rs11119805	0.649	rs12120603	ENSG00000260805.2	RP11-61J19.5	-3.96	9.95e-05	0.0327	-0.4	-0.25	Stearic acid (18:0) levels;	chr1:211827447	chr1:212557833~212559731:-
OV	cis	rs11119805	0.649	rs12139319	ENSG00000260805.2	RP11-61J19.5	-3.96	9.95e-05	0.0327	-0.4	-0.25	Stearic acid (18:0) levels;	chr1:211827470	chr1:212557833~212559731:-
OV	cis	rs6128907	1	rs62202464	ENSG00000224635.1	RP4-564F22.5	3.96	9.95e-05	0.0327	0.38	0.25	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38750439	chr20:38406011~38416797:-
OV	cis	rs7121800	0.603	rs2085612	ENSG00000254532.1	RP11-624D11.2	3.96	9.95e-05	0.0327	0.35	0.25	Pit-and-Fissure caries;	chr11:30522875	chr11:30044058~30084343:-
OV	cis	rs10986311	0.722	rs944339	ENSG00000227200.1	RP11-121A14.3	-3.96	9.95e-05	0.0327	-0.22	-0.25	Vitiligo;	chr9:124278699	chr9:124262876~124265809:+
OV	cis	rs7746199	0.736	rs13210634	ENSG00000280107.1	AL022393.9	-3.96	9.95e-05	0.0327	-0.54	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27678713	chr6:28170845~28172521:+
OV	cis	rs7746199	0.736	rs13215275	ENSG00000280107.1	AL022393.9	-3.96	9.95e-05	0.0327	-0.54	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27679730	chr6:28170845~28172521:+
OV	cis	rs7746199	0.736	rs17749927	ENSG00000280107.1	AL022393.9	-3.96	9.95e-05	0.0327	-0.54	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27702197	chr6:28170845~28172521:+
OV	cis	rs7746199	0.736	rs13192965	ENSG00000280107.1	AL022393.9	-3.96	9.95e-05	0.0327	-0.54	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27704046	chr6:28170845~28172521:+
OV	cis	rs875971	0.789	rs10260426	ENSG00000237310.1	GS1-124K5.4	-3.96	9.95e-05	0.0327	-0.26	-0.25	Aortic root size;	chr7:66271055	chr7:66493706~66495474:+
OV	cis	rs875971	0.79	rs10257911	ENSG00000237310.1	GS1-124K5.4	-3.96	9.95e-05	0.0327	-0.26	-0.25	Aortic root size;	chr7:66278783	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs7796162	ENSG00000237310.1	GS1-124K5.4	-3.96	9.95e-05	0.0327	-0.26	-0.25	Aortic root size;	chr7:66280771	chr7:66493706~66495474:+
OV	cis	rs1075265	0.522	rs7584474	ENSG00000233266.1	HMGB1P31	3.96	9.95e-05	0.0327	0.3	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53674874	chr2:54051334~54051760:+
OV	cis	rs1555322	0.53	rs8122819	ENSG00000261582.1	RP4-614O4.11	-3.96	9.96e-05	0.0327	-0.29	-0.25	Attention deficit hyperactivity disorder;	chr20:35293783	chr20:35267885~35280043:-
OV	cis	rs875971	0.502	rs2465121	ENSG00000237310.1	GS1-124K5.4	-3.96	9.96e-05	0.0327	-0.29	-0.25	Aortic root size;	chr7:66156017	chr7:66493706~66495474:+
OV	cis	rs80168506	0.748	rs1020195	ENSG00000272519.1	RP11-105N14.2	3.96	9.96e-05	0.0328	0.39	0.25	Selective IgA deficiency;	chr2:213224514	chr2:213266995~213276152:-
OV	cis	rs80168506	0.748	rs7600041	ENSG00000272519.1	RP11-105N14.2	3.96	9.96e-05	0.0328	0.39	0.25	Selective IgA deficiency;	chr2:213224557	chr2:213266995~213276152:-
OV	cis	rs80168506	0.748	rs6435759	ENSG00000272519.1	RP11-105N14.2	3.96	9.96e-05	0.0328	0.39	0.25	Selective IgA deficiency;	chr2:213224809	chr2:213266995~213276152:-
OV	cis	rs875971	0.545	rs4718325	ENSG00000236529.1	RP13-254B10.1	3.96	9.96e-05	0.0328	0.3	0.25	Aortic root size;	chr7:66215323	chr7:65840212~65840596:+
OV	cis	rs17772222	0.651	rs12586714	ENSG00000258789.1	RP11-507K2.3	-3.96	9.96e-05	0.0328	-0.27	-0.25	Coronary artery calcification;	chr14:88360497	chr14:88551597~88552493:+
OV	cis	rs1979679	0.801	rs6487686	ENSG00000278733.1	RP11-425D17.1	-3.96	9.96e-05	0.0328	-0.3	-0.25	Ossification of the posterior longitudinal ligament of the spine;	chr12:28548362	chr12:28185625~28186190:-
OV	cis	rs992157	0.698	rs6746089	ENSG00000237281.1	CATIP-AS2	-3.96	9.96e-05	0.0328	-0.3	-0.25	Colorectal cancer;	chr2:218305654	chr2:218326889~218357966:-
OV	cis	rs7617773	0.539	rs2017858	ENSG00000228638.1	FCF1P2	-3.96	9.97e-05	0.0328	-0.32	-0.25	Coronary artery disease;	chr3:48340792	chr3:48290793~48291375:-
OV	cis	rs7746199	0.736	rs35037868	ENSG00000220721.1	OR1F12	3.96	9.97e-05	0.0328	0.54	0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27791336	chr6:28073316~28074233:+
OV	cis	rs7246657	0.722	rs1291	ENSG00000276846.1	CTD-3220F14.3	-3.96	9.97e-05	0.0328	-0.32	-0.25	Coronary artery calcification;	chr19:37738477	chr19:37314868~37315620:-
OV	cis	rs1015213	0.609	rs80348021	ENSG00000253844.1	RP11-546K22.1	-3.96	9.98e-05	0.0328	-0.67	-0.25	Glaucoma (primary angle closure);	chr8:51954432	chr8:51961458~52022974:+
OV	cis	rs1015213	0.609	rs78373786	ENSG00000253844.1	RP11-546K22.1	-3.96	9.98e-05	0.0328	-0.67	-0.25	Glaucoma (primary angle closure);	chr8:51955599	chr8:51961458~52022974:+
OV	cis	rs1015213	0.609	rs79440584	ENSG00000253844.1	RP11-546K22.1	-3.96	9.98e-05	0.0328	-0.67	-0.25	Glaucoma (primary angle closure);	chr8:51958054	chr8:51961458~52022974:+
OV	cis	rs1015213	0.609	rs77456701	ENSG00000253844.1	RP11-546K22.1	-3.96	9.98e-05	0.0328	-0.67	-0.25	Glaucoma (primary angle closure);	chr8:51958120	chr8:51961458~52022974:+
OV	cis	rs1015213	0.609	rs17212845	ENSG00000253844.1	RP11-546K22.1	-3.96	9.98e-05	0.0328	-0.67	-0.25	Glaucoma (primary angle closure);	chr8:51959353	chr8:51961458~52022974:+
OV	cis	rs1015213	0.609	rs117407615	ENSG00000253844.1	RP11-546K22.1	-3.96	9.98e-05	0.0328	-0.67	-0.25	Glaucoma (primary angle closure);	chr8:51959626	chr8:51961458~52022974:+
OV	cis	rs1015213	0.609	rs76209356	ENSG00000253844.1	RP11-546K22.1	-3.96	9.98e-05	0.0328	-0.67	-0.25	Glaucoma (primary angle closure);	chr8:51960149	chr8:51961458~52022974:+
OV	cis	rs10851478	0.54	rs16962440	ENSG00000259545.2	RP11-325E5.4	3.96	9.98e-05	0.0328	0.29	0.25	Oral cavity cancer;	chr15:49424648	chr15:49177610~49178741:-
OV	cis	rs72904190	0.748	rs72904173	ENSG00000238069.1	RPLP0P7	3.96	9.98e-05	0.0328	0.49	0.25	Intelligence (multi-trait analysis);	chr2:156014494	chr2:156777706~156778372:-
OV	cis	rs73201462	1	rs67575175	ENSG00000242551.2	POU5F1P6	3.96	9.99e-05	0.0328	0.38	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128161383	chr3:128674735~128677005:-
OV	cis	rs992157	0.767	rs2014615	ENSG00000237281.1	CATIP-AS2	-3.96	9.99e-05	0.0328	-0.3	-0.25	Colorectal cancer;	chr2:218306468	chr2:218326889~218357966:-
OV	cis	rs774359	0.789	rs17779457	ENSG00000234676.1	IFT74-AS1	-3.96	9.99e-05	0.0328	-0.3	-0.25	Amyotrophic lateral sclerosis;	chr9:27488094	chr9:26955780~26956295:-
OV	cis	rs1707322	0.752	rs11211145	ENSG00000225447.1	RPS15AP10	3.96	9.99e-05	0.0328	0.24	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642819	chr1:45645816~45646197:-
OV	cis	rs2070488	0.775	rs2300669	ENSG00000229589.1	ACVR2B-AS1	-3.96	9.99e-05	0.0328	-0.28	-0.25	Electrocardiographic conduction measures;	chr3:38499827	chr3:38451027~38454820:-
OV	cis	rs1892094	0.905	rs1200157	ENSG00000239494.2	RN7SL333P	3.96	1e-04	0.0328	0.29	0.25	Coronary artery disease;	chr1:169129823	chr1:169859756~169860052:+
OV	cis	rs10027350	0.757	rs4459977	ENSG00000281501.1	SEPSECS-AS1	3.96	1e-04	0.0328	0.32	0.25	Childhood ear infection;	chr4:25183937	chr4:25160641~25201440:+
OV	cis	rs3734266	0.702	rs13196983	ENSG00000220643.1	RP3-391O22.1	-3.96	1e-04	0.0328	-0.43	-0.25	Systemic lupus erythematosus;	chr6:34712698	chr6:34686602~34687106:+
OV	cis	rs73201462	1	rs2811396	ENSG00000242551.2	POU5F1P6	-3.96	1e-04	0.0329	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128268513	chr3:128674735~128677005:-
OV	cis	rs10514805	0.557	rs12614309	ENSG00000234690.5	AC073283.4	-3.96	1e-04	0.0329	-0.46	-0.25	Electroencephalogram traits;	chr2:47508732	chr2:47192405~47345074:-
OV	cis	rs4845570	0.749	rs11586446	ENSG00000238711.1	RNY4P25	-3.96	1e-04	0.0329	-0.38	-0.25	Coronary artery disease;	chr1:151740012	chr1:151439000~151439095:+
OV	cis	rs7267979	0.816	rs8115257	ENSG00000274973.1	RP13-401N8.7	-3.96	1e-04	0.0329	-0.29	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25227295	chr20:25845497~25845862:+
OV	cis	rs7927771	1	rs10838747	ENSG00000271350.1	CTD-2384B9.1	-3.96	1e-04	0.0329	-0.3	-0.25	Subjective well-being;	chr11:47694772	chr11:47041027~47041945:-
OV	cis	rs12134151	0.905	rs11586170	ENSG00000237416.5	RP11-465K1.2	3.96	1e-04	0.0329	0.29	0.25	Educational attainment (years of education);	chr1:95731220	chr1:94836748~94855426:-
OV	cis	rs7246657	0.882	rs10412043	ENSG00000226686.6	LINC01535	-3.96	1e-04	0.0329	-0.38	-0.25	Coronary artery calcification;	chr19:37335724	chr19:37251912~37265535:+
OV	cis	rs2111504	0.559	rs12460112	ENSG00000267213.4	AC007773.2	3.96	1e-04	0.0329	0.34	0.25	Bipolar disorder;	chr19:32363928	chr19:32390050~32405560:-
OV	cis	rs7078012	0.504	rs117047841	ENSG00000225484.5	NUTM2B-AS1	-3.96	1e-04	0.0329	-0.65	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79905900	chr10:79663088~79826594:-
OV	cis	rs7267979	0.932	rs2260997	ENSG00000274973.1	RP13-401N8.7	3.96	1e-04	0.0329	0.29	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25275630	chr20:25845497~25845862:+
OV	cis	rs2617170	0.885	rs7975996	ENSG00000256667.5	KLRAP1	3.96	1e-04	0.0329	0.27	0.25	Behcet's disease;	chr12:10372324	chr12:10588063~10599669:-
OV	cis	rs1538970	0.748	rs11211137	ENSG00000280836.1	AL355480.1	-3.96	1e-04	0.033	-0.39	-0.25	Platelet count;	chr1:45548220	chr1:45581219~45581321:-
OV	cis	rs875971	0.862	rs1875057	ENSG00000237310.1	GS1-124K5.4	-3.96	1e-04	0.033	-0.26	-0.25	Aortic root size;	chr7:66266868	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs6960446	ENSG00000237310.1	GS1-124K5.4	-3.96	1e-04	0.033	-0.26	-0.25	Aortic root size;	chr7:66268272	chr7:66493706~66495474:+
OV	cis	rs8059260	0.736	rs8049278	ENSG00000274038.1	RP11-66H6.4	-3.96	1e-04	0.033	-0.48	-0.25	Alcohol consumption over the past year;	chr16:10968766	chr16:11056556~11057034:+
OV	cis	rs7587476	0.954	rs3768708	ENSG00000229267.2	AC072062.1	3.96	0.000101	0.033	0.32	0.25	Neuroblastoma;	chr2:214780322	chr2:214810229~214963274:+
OV	cis	rs1979679	0.527	rs12809834	ENSG00000278733.1	RP11-425D17.1	3.96	0.000101	0.033	0.37	0.25	Ossification of the posterior longitudinal ligament of the spine;	chr12:28180573	chr12:28185625~28186190:-
OV	cis	rs1538970	0.781	rs11211139	ENSG00000280836.1	AL355480.1	-3.96	0.000101	0.033	-0.39	-0.25	Platelet count;	chr1:45550079	chr1:45581219~45581321:-
OV	cis	rs875971	0.862	rs4718330	ENSG00000237310.1	GS1-124K5.4	-3.96	0.000101	0.033	-0.26	-0.25	Aortic root size;	chr7:66250256	chr7:66493706~66495474:+
OV	cis	rs1404100	0.51	rs2341683	ENSG00000249274.1	PDLIM1P4	3.96	0.000101	0.033	0.29	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:99069807	chr3:98782188~98783193:+
OV	cis	rs1404100	0.51	rs6768480	ENSG00000249274.1	PDLIM1P4	3.96	0.000101	0.033	0.29	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:99070070	chr3:98782188~98783193:+
OV	cis	rs1707322	0.656	rs3014210	ENSG00000225447.1	RPS15AP10	-3.96	0.000101	0.0331	-0.24	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45600936	chr1:45645816~45646197:-
OV	cis	rs2828520	0.647	rs1910980	ENSG00000223822.2	EEF1A1P1	-3.96	0.000101	0.0331	-0.22	-0.25	Major depressive disorder;	chr21:23765372	chr21:23390258~23390996:+
OV	cis	rs151227923	1	rs151227923	ENSG00000273117.1	AC144652.1	3.96	0.000101	0.0331	0.32	0.25	Stem cell growth factor beta levels;	chr7:155314854	chr7:155295918~155297541:-
OV	cis	rs140365914	1	rs140365914	ENSG00000273117.1	AC144652.1	3.96	0.000101	0.0331	0.32	0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr7:155314860	chr7:155295918~155297541:-
OV	cis	rs507080	0.961	rs607527	ENSG00000278376.1	RP11-158I9.8	3.96	0.000101	0.0331	0.25	0.25	Serum metabolite levels;	chr11:118667478	chr11:118791254~118793137:+
OV	cis	rs733592	0.507	rs3825403	ENSG00000240399.1	RP1-228P16.1	-3.96	0.000101	0.0331	-0.28	-0.25	Plateletcrit;	chr12:48063376	chr12:48054813~48055591:-
OV	cis	rs9309473	0.514	rs62149659	ENSG00000163016.8	ALMS1P	3.96	0.000101	0.0331	0.35	0.25	Metabolite levels;	chr2:73358068	chr2:73644919~73685576:+
OV	cis	rs12468226	0.938	rs12463937	ENSG00000272966.1	RP11-686O6.1	3.96	0.000101	0.0331	0.43	0.25	Urate levels;	chr2:202246543	chr2:202336739~202337200:+
OV	cis	rs67311347	0.544	rs9864664	ENSG00000223797.4	ENTPD3-AS1	3.96	0.000101	0.0331	0.26	0.25	Renal cell carcinoma;	chr3:40294735	chr3:40313802~40453329:-
OV	cis	rs67311347	0.544	rs35112505	ENSG00000223797.4	ENTPD3-AS1	3.96	0.000101	0.0331	0.26	0.25	Renal cell carcinoma;	chr3:40295584	chr3:40313802~40453329:-
OV	cis	rs67311347	0.544	rs67533651	ENSG00000223797.4	ENTPD3-AS1	3.96	0.000101	0.0331	0.26	0.25	Renal cell carcinoma;	chr3:40296876	chr3:40313802~40453329:-
OV	cis	rs7569084	0.687	rs11126038	ENSG00000204929.10	AC074391.1	3.96	0.000101	0.0331	0.32	0.25	Sum eosinophil basophil counts;	chr2:65436100	chr2:65436711~66084639:+
OV	cis	rs4664293	0.605	rs6745815	ENSG00000226266.5	AC009961.3	3.96	0.000101	0.0332	0.3	0.25	Monocyte percentage of white cells;	chr2:159693558	chr2:159670708~159712435:-
OV	cis	rs4664293	0.551	rs11898293	ENSG00000226266.5	AC009961.3	3.96	0.000101	0.0332	0.3	0.25	Monocyte percentage of white cells;	chr2:159696082	chr2:159670708~159712435:-
OV	cis	rs7520050	0.966	rs4073846	ENSG00000280836.1	AL355480.1	-3.96	0.000101	0.0332	-0.31	-0.25	Reticulocyte count;Red blood cell count;	chr1:45997209	chr1:45581219~45581321:-
OV	cis	rs853679	0.546	rs200990	ENSG00000226314.6	ZNF192P1	-3.96	0.000101	0.0332	-0.45	-0.25	Depression;	chr6:27848045	chr6:28161781~28169594:+
OV	cis	rs11992162	0.591	rs4240678	ENSG00000255495.1	AC145124.2	-3.96	0.000101	0.0332	-0.32	-0.25	Monocyte count;	chr8:11944917	chr8:12194467~12196280:+
OV	cis	rs11037575	0.715	rs7926355	ENSG00000246250.2	RP11-613D13.5	3.96	0.000101	0.0332	0.28	0.25	Neuroblastoma;	chr11:43682965	chr11:43829709~43880726:-
OV	cis	rs875971	1	rs7781698	ENSG00000224316.1	RP11-479O9.2	3.96	0.000101	0.0332	0.27	0.25	Aortic root size;	chr7:66431325	chr7:65773620~65802067:+
OV	cis	rs9473147	0.516	rs6931478	ENSG00000270761.1	RP11-385F7.1	-3.96	0.000101	0.0332	-0.29	-0.25	Platelet distribution width;Mean platelet volume;	chr6:47494177	chr6:47477243~47477572:-
OV	cis	rs2288884	0.579	rs6509603	ENSG00000275055.1	CTC-471J1.11	-3.96	0.000101	0.0332	-0.32	-0.25	Bronchodilator response in asthma (inhaled corticosteroid treatment interaction);	chr19:51960977	chr19:52049007~52049754:+
OV	cis	rs941207	0.756	rs1465081	ENSG00000241217.3	RN7SL809P	-3.96	0.000101	0.0332	-0.28	-0.25	Platelet count;	chr12:56656390	chr12:56670450~56670746:-
OV	cis	rs4666360	1	rs6725416	ENSG00000234378.1	AC098828.2	3.96	0.000102	0.0332	0.26	0.25	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);	chr2:20137012	chr2:20063856~20106829:-
OV	cis	rs13217239	0.646	rs10946888	ENSG00000261584.1	RP11-457M11.5	3.96	0.000102	0.0332	0.28	0.25	Schizophrenia;	chr6:26983899	chr6:26686241~26687964:+
OV	cis	rs1836229	0.594	rs10121702	ENSG00000225706.1	PTPRD-AS1	-3.96	0.000102	0.0332	-0.26	-0.25	Restless legs syndrome;	chr9:8825375	chr9:8858130~8862255:+
OV	cis	rs9326248	0.798	rs10892079	ENSG00000280143.1	AP000892.6	3.96	0.000102	0.0333	0.29	0.25	Blood protein levels;	chr11:117146108	chr11:117204967~117210292:+
OV	cis	rs4713118	0.824	rs2179095	ENSG00000226314.6	ZNF192P1	3.96	0.000102	0.0333	0.32	0.25	Parkinson's disease;	chr6:27783079	chr6:28161781~28169594:+
OV	cis	rs4664293	0.625	rs6722715	ENSG00000226266.5	AC009961.3	3.96	0.000102	0.0333	0.3	0.25	Monocyte percentage of white cells;	chr2:159668515	chr2:159670708~159712435:-
OV	cis	rs4664293	0.669	rs2042778	ENSG00000226266.5	AC009961.3	3.96	0.000102	0.0333	0.3	0.25	Monocyte percentage of white cells;	chr2:159672119	chr2:159670708~159712435:-
OV	cis	rs4664293	0.625	rs62171654	ENSG00000226266.5	AC009961.3	3.96	0.000102	0.0333	0.3	0.25	Monocyte percentage of white cells;	chr2:159675107	chr2:159670708~159712435:-
OV	cis	rs4664293	0.625	rs11903816	ENSG00000226266.5	AC009961.3	3.96	0.000102	0.0333	0.3	0.25	Monocyte percentage of white cells;	chr2:159675347	chr2:159670708~159712435:-
OV	cis	rs4664293	0.625	rs6738523	ENSG00000226266.5	AC009961.3	3.96	0.000102	0.0333	0.3	0.25	Monocyte percentage of white cells;	chr2:159681203	chr2:159670708~159712435:-
OV	cis	rs4664293	0.585	rs11893106	ENSG00000226266.5	AC009961.3	3.96	0.000102	0.0333	0.3	0.25	Monocyte percentage of white cells;	chr2:159684294	chr2:159670708~159712435:-
OV	cis	rs295490	0.748	rs78069957	ENSG00000272656.1	RP11-219D15.3	3.96	0.000102	0.0333	0.52	0.25	PR interval in Tripanosoma cruzi seropositivity;	chr3:139375970	chr3:139349024~139349371:-
OV	cis	rs853679	0.546	rs200953	ENSG00000226314.6	ZNF192P1	-3.96	0.000102	0.0333	-0.45	-0.25	Depression;	chr6:27869489	chr6:28161781~28169594:+
OV	cis	rs9992667	0.955	rs7654470	ENSG00000231160.8	KLF3-AS1	3.96	0.000102	0.0333	0.29	0.25	Eosinophil percentage of granulocytes;	chr4:38634608	chr4:38612701~38664883:-
OV	cis	rs2736345	0.788	rs2618476	ENSG00000270154.1	RP11-419I17.1	3.96	0.000102	0.0333	0.27	0.25	Systemic lupus erythematosus;Sjögren's syndrome;	chr8:11495032	chr8:12476462~12477122:+
OV	cis	rs950027	0.538	rs635205	ENSG00000259520.4	CTD-2651B20.3	-3.96	0.000102	0.0333	-0.29	-0.25	Response to fenofibrate (adiponectin levels);	chr15:45656186	chr15:45251580~45279251:-
OV	cis	rs1560104	0.597	rs735819	ENSG00000259899.1	CTD-3037G24.3	3.96	0.000102	0.0333	0.3	0.25	Obesity-related traits;	chr16:12618370	chr16:12560756~12611044:-
OV	cis	rs113507773	1	rs113507773	ENSG00000241549.7	GUSBP2	-3.96	0.000102	0.0333	-0.37	-0.25	Iron status biomarkers (iron levels);Iron status biomarkers (transferrin saturation);	chr6:26255511	chr6:26871484~26956554:-
OV	cis	rs11951515	0.7	rs4443426	ENSG00000278487.1	RP11-447H19.4	-3.96	0.000102	0.0333	-0.3	-0.25	Metabolite levels  (X-11787);	chr5:43279470	chr5:43143362~43143514:-
OV	cis	rs673078	0.571	rs7954330	ENSG00000275759.1	RP11-131L12.3	-3.96	0.000102	0.0333	-0.39	-0.25	Glucose homeostasis traits;	chr12:118275284	chr12:118428281~118428870:+
OV	cis	rs4713118	0.629	rs203890	ENSG00000204709.4	LINC01556	3.96	0.000102	0.0333	0.33	0.25	Parkinson's disease;	chr6:28054470	chr6:28943877~28944537:+
OV	cis	rs4713118	0.699	rs573179	ENSG00000226314.6	ZNF192P1	-3.96	0.000102	0.0334	-0.34	-0.25	Parkinson's disease;	chr6:27881898	chr6:28161781~28169594:+
OV	cis	rs7927771	0.524	rs3816605	ENSG00000280615.1	Y_RNA	3.96	0.000102	0.0334	0.27	0.25	Subjective well-being;	chr11:47835701	chr11:47614898~47614994:-
OV	cis	rs3758911	0.765	rs687991	ENSG00000261098.1	RP11-819C21.1	3.96	0.000102	0.0334	0.25	0.25	Coronary artery disease;	chr11:107449918	chr11:107312132~107316271:-
OV	cis	rs7429990	0.965	rs34507589	ENSG00000229759.1	MRPS18AP1	3.96	0.000102	0.0334	0.3	0.25	Educational attainment (years of education);	chr3:47832552	chr3:48256350~48256938:-
OV	cis	rs67311347	0.568	rs9864544	ENSG00000223797.4	ENTPD3-AS1	3.96	0.000102	0.0334	0.26	0.25	Renal cell carcinoma;	chr3:40294713	chr3:40313802~40453329:-
OV	cis	rs67311347	0.544	rs13062243	ENSG00000223797.4	ENTPD3-AS1	3.96	0.000102	0.0334	0.26	0.25	Renal cell carcinoma;	chr3:40295298	chr3:40313802~40453329:-
OV	cis	rs67311347	0.544	rs12054197	ENSG00000223797.4	ENTPD3-AS1	3.96	0.000102	0.0334	0.26	0.25	Renal cell carcinoma;	chr3:40296071	chr3:40313802~40453329:-
OV	cis	rs73201462	1	rs13095660	ENSG00000242551.2	POU5F1P6	3.96	0.000102	0.0334	0.39	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128129313	chr3:128674735~128677005:-
OV	cis	rs73201462	0.708	rs6788497	ENSG00000242551.2	POU5F1P6	3.96	0.000102	0.0334	0.39	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128129545	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs6439116	ENSG00000242551.2	POU5F1P6	3.96	0.000102	0.0334	0.39	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128130224	chr3:128674735~128677005:-
OV	cis	rs13059975	1	rs13059975	ENSG00000242551.2	POU5F1P6	3.96	0.000102	0.0334	0.39	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128130841	chr3:128674735~128677005:-
OV	cis	rs34174370	1	rs34174370	ENSG00000242551.2	POU5F1P6	3.96	0.000102	0.0334	0.39	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128130901	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs11714619	ENSG00000242551.2	POU5F1P6	3.96	0.000102	0.0334	0.39	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128131233	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs6783253	ENSG00000242551.2	POU5F1P6	3.96	0.000102	0.0334	0.39	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128132718	chr3:128674735~128677005:-
OV	cis	rs73201462	0.901	rs35347185	ENSG00000242551.2	POU5F1P6	3.96	0.000102	0.0334	0.39	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128135684	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs6797834	ENSG00000242551.2	POU5F1P6	3.96	0.000102	0.0334	0.39	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128137557	chr3:128674735~128677005:-
OV	cis	rs73201462	0.708	rs11709725	ENSG00000242551.2	POU5F1P6	3.96	0.000102	0.0334	0.39	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128139090	chr3:128674735~128677005:-
OV	cis	rs73201462	0.808	rs34689870	ENSG00000242551.2	POU5F1P6	3.96	0.000102	0.0334	0.39	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128141636	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs34817706	ENSG00000242551.2	POU5F1P6	3.96	0.000102	0.0334	0.39	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128142215	chr3:128674735~128677005:-
OV	cis	rs6800225	1	rs6800225	ENSG00000242551.2	POU5F1P6	3.96	0.000102	0.0334	0.39	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128143335	chr3:128674735~128677005:-
OV	cis	rs10027350	0.765	rs6838393	ENSG00000281501.1	SEPSECS-AS1	3.96	0.000102	0.0334	0.32	0.25	Childhood ear infection;	chr4:25172629	chr4:25160641~25201440:+
OV	cis	rs7726839	0.574	rs72705017	ENSG00000271781.1	CTD-2589H19.6	-3.96	0.000102	0.0334	-0.39	-0.25	Obesity-related traits;	chr5:623618	chr5:675826~676616:+
OV	cis	rs1511299	0.546	rs34092379	ENSG00000249417.1	RP11-438D8.2	-3.96	0.000102	0.0334	-0.37	-0.25	Glomerular filtration rate;	chr3:141980617	chr3:141267353~141367137:-
OV	cis	rs1823913	0.538	rs6732537	ENSG00000227542.1	AC092614.2	3.96	0.000102	0.0334	0.29	0.25	Obesity-related traits;	chr2:191346755	chr2:191229165~191246172:-
OV	cis	rs12681366	0.734	rs4735292	ENSG00000253704.1	RP11-267M23.4	3.96	0.000102	0.0334	0.3	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94396503	chr8:94553722~94569745:+
OV	cis	rs12477438	0.52	rs2516830	ENSG00000231822.1	AC019097.7	3.95	0.000102	0.0334	0.26	0.25	Chronic sinus infection;	chr2:99157239	chr2:99102018~99102752:+
OV	cis	rs12477438	0.52	rs2632283	ENSG00000231822.1	AC019097.7	3.95	0.000102	0.0334	0.26	0.25	Chronic sinus infection;	chr2:99159537	chr2:99102018~99102752:+
OV	cis	rs12477438	0.501	rs2516833	ENSG00000231822.1	AC019097.7	3.95	0.000102	0.0334	0.26	0.25	Chronic sinus infection;	chr2:99160942	chr2:99102018~99102752:+
OV	cis	rs12477438	0.52	rs2516835	ENSG00000231822.1	AC019097.7	3.95	0.000102	0.0334	0.26	0.25	Chronic sinus infection;	chr2:99162668	chr2:99102018~99102752:+
OV	cis	rs12477438	0.501	rs7608938	ENSG00000231822.1	AC019097.7	3.95	0.000102	0.0334	0.26	0.25	Chronic sinus infection;	chr2:99165763	chr2:99102018~99102752:+
OV	cis	rs12477438	0.501	rs6542868	ENSG00000231822.1	AC019097.7	3.95	0.000102	0.0334	0.26	0.25	Chronic sinus infection;	chr2:99166385	chr2:99102018~99102752:+
OV	cis	rs2898681	1	rs2003198	ENSG00000248375.1	RP11-177B4.1	-3.95	0.000102	0.0335	-0.39	-0.25	Optic nerve measurement (cup area);	chr4:52882416	chr4:52720081~52720831:-
OV	cis	rs9952991	0.566	rs34846641	ENSG00000266146.1	MIR5190	-3.95	0.000102	0.0335	-0.32	-0.25	Inflammatory skin disease;	chr18:12875976	chr18:13459947~13460026:+
OV	cis	rs7520050	0.966	rs10789481	ENSG00000281133.1	AL355480.3	3.95	0.000102	0.0335	0.29	0.25	Reticulocyte count;Red blood cell count;	chr1:45917911	chr1:45580892~45580996:-
OV	cis	rs4763879	0.593	rs2080206	ENSG00000278635.1	CTD-2318O12.1	3.95	0.000103	0.0335	0.22	0.25	Type 1 diabetes;	chr12:9715370	chr12:9415641~9416718:+
OV	cis	rs7587476	0.861	rs3768716	ENSG00000229267.2	AC072062.1	-3.95	0.000103	0.0335	-0.35	-0.25	Neuroblastoma;	chr2:214771070	chr2:214810229~214963274:+
OV	cis	rs11072089	0.818	rs9635370	ENSG00000259215.1	RP11-253M7.4	-3.95	0.000103	0.0335	-0.65	-0.25	Bipolar disorder and schizophrenia;	chr15:69372921	chr15:69458522~69461806:-
OV	cis	rs743757	0.878	rs35986136	ENSG00000228008.1	CTD-2330K9.3	-3.95	0.000103	0.0335	-0.42	-0.25	Diastolic blood pressure;	chr3:50497790	chr3:49903845~49916937:+
OV	cis	rs875971	0.862	rs778734	ENSG00000237310.1	GS1-124K5.4	3.95	0.000103	0.0335	0.26	0.25	Aortic root size;	chr7:66349862	chr7:66493706~66495474:+
OV	cis	rs12073359	1	rs12063281	ENSG00000223945.2	RP11-458I7.1	-3.95	0.000103	0.0335	-0.38	-0.25	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150030335	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs55840906	ENSG00000223945.2	RP11-458I7.1	-3.95	0.000103	0.0335	-0.38	-0.25	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150031159	chr1:150053864~150055034:+
OV	cis	rs7246657	0.943	rs2126977	ENSG00000226686.6	LINC01535	3.95	0.000103	0.0335	0.39	0.25	Coronary artery calcification;	chr19:37504845	chr19:37251912~37265535:+
OV	cis	rs950173	1	rs13000153	ENSG00000228389.1	AC068039.4	3.95	0.000103	0.0335	0.4	0.25	Hippocampal volume;	chr2:171729557	chr2:171773482~171775844:+
OV	cis	rs7162943	1	rs7162943	ENSG00000265871.1	MIR3174	-3.95	0.000103	0.0335	-0.26	-0.25	Mean platelet volume;	chr15:89072044	chr15:90006755~90006841:+
OV	cis	rs11976180	1	rs1540894	ENSG00000204959.4	ARHGEF34P	3.95	0.000103	0.0335	0.34	0.25	Obesity-related traits;	chr7:144070583	chr7:144272445~144286966:-
OV	cis	rs1538970	1	rs9326141	ENSG00000280836.1	AL355480.1	3.95	0.000103	0.0335	0.35	0.25	Platelet count;	chr1:45363271	chr1:45581219~45581321:-
OV	cis	rs439731	0.518	rs2260241	ENSG00000260051.1	LA16c-390E6.4	3.95	0.000103	0.0336	0.31	0.25	Itch intensity from mosquito bite adjusted by bite size;	chr16:1025147	chr16:1451760~1452653:+
OV	cis	rs4853012	0.941	rs2421752	ENSG00000257800.1	FNBP1P1	3.95	0.000103	0.0336	0.39	0.25	Gestational age at birth (maternal effect);	chr2:74114488	chr2:74120680~74123218:+
OV	cis	rs7395581	0.918	rs3781622	ENSG00000271350.1	CTD-2384B9.1	3.95	0.000103	0.0336	0.29	0.25	HDL cholesterol;	chr11:47327151	chr11:47041027~47041945:-
OV	cis	rs6661961	0.752	rs1923496	ENSG00000237975.5	FLG-AS1	3.95	0.000103	0.0336	0.32	0.25	Atopic dermatitis;	chr1:152452372	chr1:152168125~152445456:+
OV	cis	rs6142102	0.812	rs761236	ENSG00000264616.1	MIR4755	3.95	0.000103	0.0336	0.31	0.25	Skin pigmentation;	chr20:33932245	chr20:34049119~34049190:+
OV	cis	rs7931462	0.655	rs6483208	ENSG00000202314.1	SNORD6	-3.95	0.000103	0.0336	-0.46	-0.25	DNA methylation (parent-of-origin);	chr11:92972678	chr11:93731502~93731574:-
OV	cis	rs7927592	0.763	rs3740628	ENSG00000222339.1	AP000807.2	3.95	0.000103	0.0336	0.26	0.25	Total body bone mineral density;	chr11:68613947	chr11:68505572~68505651:-
OV	cis	rs1862618	0.853	rs832582	ENSG00000271828.1	CTD-2310F14.1	3.95	0.000103	0.0336	0.42	0.25	Initial pursuit acceleration;	chr5:56881916	chr5:56927874~56929573:+
OV	cis	rs860295	0.54	rs11264426	ENSG00000225855.5	RUSC1-AS1	-3.95	0.000103	0.0336	-0.21	-0.25	Body mass index;	chr1:155971157	chr1:155316863~155324176:-
OV	cis	rs1975197	0.515	rs2814723	ENSG00000225706.1	PTPRD-AS1	-3.95	0.000103	0.0336	-0.27	-0.25	Restless legs syndrome;	chr9:8846151	chr9:8858130~8862255:+
OV	cis	rs3733585	0.699	rs7694997	ENSG00000250413.1	RP11-448G15.1	3.95	0.000103	0.0337	0.28	0.25	Cleft plate (environmental tobacco smoke interaction);	chr4:9946187	chr4:10006482~10009725:+
OV	cis	rs757081	0.648	rs214907	ENSG00000213779.4	RP11-452G18.1	3.95	0.000103	0.0337	0.28	0.25	Systolic blood pressure;	chr11:17223232	chr11:17193489~17194308:+
OV	cis	rs2070488	1	rs2268753	ENSG00000229589.1	ACVR2B-AS1	3.95	0.000103	0.0337	0.28	0.25	Electrocardiographic conduction measures;	chr3:38458698	chr3:38451027~38454820:-
OV	cis	rs10129255	0.5	rs8004923	ENSG00000223648.3	IGHV3-64	3.95	0.000103	0.0337	0.25	0.25	Kawasaki disease;	chr14:106785926	chr14:106643132~106658258:-
OV	cis	rs10129255	0.5	rs6576232	ENSG00000223648.3	IGHV3-64	3.95	0.000103	0.0337	0.25	0.25	Kawasaki disease;	chr14:106787090	chr14:106643132~106658258:-
OV	cis	rs9847710	0.733	rs7613013	ENSG00000242142.1	SERBP1P3	3.95	0.000103	0.0337	0.3	0.25	Ulcerative colitis;	chr3:53043790	chr3:53064283~53065091:-
OV	cis	rs7520050	0.902	rs4626927	ENSG00000280836.1	AL355480.1	3.95	0.000103	0.0337	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45782973	chr1:45581219~45581321:-
OV	cis	rs7520050	0.902	rs7514192	ENSG00000280836.1	AL355480.1	3.95	0.000103	0.0337	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45783305	chr1:45581219~45581321:-
OV	cis	rs12220777	1	rs11201799	ENSG00000230091.5	TMEM254-AS1	-3.95	0.000103	0.0337	-0.45	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80122198	chr10:80046860~80078912:-
OV	cis	rs14027	0.843	rs6469849	ENSG00000279347.1	RP11-85I17.2	-3.95	0.000103	0.0337	-0.26	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119844929	chr8:119838736~119840385:-
OV	cis	rs2239547	0.522	rs6771610	ENSG00000242142.1	SERBP1P3	3.95	0.000103	0.0337	0.33	0.25	Schizophrenia;	chr3:52992088	chr3:53064283~53065091:-
OV	cis	rs599083	0.53	rs576118	ENSG00000212093.1	AP000807.1	-3.95	0.000103	0.0337	-0.31	-0.25	Bone mineral density (spine);	chr11:68410240	chr11:68506083~68506166:-
OV	cis	rs6545883	0.868	rs7608483	ENSG00000270820.4	RP11-355B11.2	3.95	0.000104	0.0337	0.29	0.25	Tuberculosis;	chr2:61609100	chr2:61471188~61484130:+
OV	cis	rs16953946	1	rs9932033	ENSG00000260213.4	RP11-303E16.3	-3.95	0.000104	0.0337	-0.36	-0.25	Inflammatory bowel disease;	chr16:80747455	chr16:81016792~81035759:-
OV	cis	rs3733585	0.699	rs7686538	ENSG00000250413.1	RP11-448G15.1	3.95	0.000104	0.0338	0.28	0.25	Cleft plate (environmental tobacco smoke interaction);	chr4:9946453	chr4:10006482~10009725:+
OV	cis	rs2286503	0.839	rs4722189	ENSG00000221740.1	SNORD93	3.95	0.000104	0.0338	0.32	0.25	Fibrinogen;	chr7:22820855	chr7:22856613~22856686:+
OV	cis	rs7246967	0.673	rs12978964	ENSG00000267920.1	SNX6P1	-3.95	0.000104	0.0338	-0.41	-0.25	Bronchopulmonary dysplasia;	chr19:22636442	chr19:23126569~23127792:-
OV	cis	rs7259376	0.714	rs4358065	ENSG00000269742.1	BNIP3P29	3.95	0.000104	0.0338	0.3	0.25	Menopause (age at onset);	chr19:22338330	chr19:22065828~22066398:-
OV	cis	rs1797885	0.651	rs1552484	ENSG00000251774.1	RNU6-377P	3.95	0.000104	0.0338	0.24	0.25	Immature fraction of reticulocytes;	chr3:12538747	chr3:12514706~12514807:+
OV	cis	rs785830	0.749	rs2479325	ENSG00000227914.3	RP11-130C19.3	3.95	0.000104	0.0338	0.25	0.25	Platelet distribution width;	chr9:253282	chr9:673478~685555:-
OV	cis	rs330071	0.549	rs11785593	ENSG00000253426.4	RP11-10A14.4	3.95	0.000104	0.0338	0.32	0.25	Acne (severe);	chr8:9398814	chr8:9151742~9168136:+
OV	cis	rs875971	1	rs1544549	ENSG00000237310.1	GS1-124K5.4	-3.95	0.000104	0.0338	-0.26	-0.25	Aortic root size;	chr7:66625676	chr7:66493706~66495474:+
OV	cis	rs11951515	0.7	rs7720165	ENSG00000278487.1	RP11-447H19.4	3.95	0.000104	0.0338	0.3	0.25	Metabolite levels  (X-11787);	chr5:43301442	chr5:43143362~43143514:-
OV	cis	rs9880211	0.718	rs28631273	ENSG00000239213.4	NCK1-AS1	3.95	0.000104	0.0339	0.3	0.25	Height;Body mass index;	chr3:136215869	chr3:136841726~136862054:-
OV	cis	rs4703129	0.506	rs59060802	ENSG00000249448.1	RP11-474J18.1	3.95	0.000104	0.0339	0.28	0.25	Asperger disorder;	chr5:98432546	chr5:98410235~98411792:-
OV	cis	rs73201462	1	rs13071740	ENSG00000242551.2	POU5F1P6	3.95	0.000104	0.0339	0.39	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128162725	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs13077790	ENSG00000242551.2	POU5F1P6	3.95	0.000104	0.0339	0.39	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128163815	chr3:128674735~128677005:-
OV	cis	rs73201462	0.901	rs2955133	ENSG00000242551.2	POU5F1P6	-3.95	0.000104	0.0339	-0.38	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128226479	chr3:128674735~128677005:-
OV	cis	rs140505938	1	rs140505938	ENSG00000223945.2	RP11-458I7.1	-3.95	0.000104	0.0339	-0.4	-0.25	Schizophrenia;	chr1:150059494	chr1:150053864~150055034:+
OV	cis	rs12073359	0.865	rs72692886	ENSG00000223945.2	RP11-458I7.1	-3.95	0.000104	0.0339	-0.4	-0.25	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150060225	chr1:150053864~150055034:+
OV	cis	rs12073359	0.955	rs11584354	ENSG00000223945.2	RP11-458I7.1	-3.95	0.000104	0.0339	-0.4	-0.25	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150066990	chr1:150053864~150055034:+
OV	cis	rs12073359	0.955	rs112287706	ENSG00000223945.2	RP11-458I7.1	-3.95	0.000104	0.0339	-0.4	-0.25	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150074061	chr1:150053864~150055034:+
OV	cis	rs2070488	0.965	rs13093640	ENSG00000229589.1	ACVR2B-AS1	3.95	0.000104	0.0339	0.28	0.25	Electrocardiographic conduction measures;	chr3:38445685	chr3:38451027~38454820:-
OV	cis	rs2070488	1	rs762317	ENSG00000229589.1	ACVR2B-AS1	3.95	0.000104	0.0339	0.28	0.25	Electrocardiographic conduction measures;	chr3:38456168	chr3:38451027~38454820:-
OV	cis	rs7646881	0.544	rs7638606	ENSG00000272087.1	RP11-379F4.7	3.95	0.000104	0.0339	0.36	0.25	Tetralogy of Fallot;	chr3:158569050	chr3:158693120~158693768:-
OV	cis	rs7646881	0.544	rs9881679	ENSG00000272087.1	RP11-379F4.7	3.95	0.000104	0.0339	0.36	0.25	Tetralogy of Fallot;	chr3:158580643	chr3:158693120~158693768:-
OV	cis	rs7646881	0.544	rs9849437	ENSG00000272087.1	RP11-379F4.7	3.95	0.000104	0.0339	0.36	0.25	Tetralogy of Fallot;	chr3:158581612	chr3:158693120~158693768:-
OV	cis	rs9828933	0.808	rs3733125	ENSG00000280620.1	SCAANT1	3.95	0.000104	0.0339	0.49	0.25	Type 2 diabetes;	chr3:63995959	chr3:63911518~63911772:-
OV	cis	rs2574704	0.961	rs11712416	ENSG00000251774.1	RNU6-377P	3.95	0.000104	0.034	0.25	0.25	Body mass index;	chr3:11607860	chr3:12514706~12514807:+
OV	cis	rs1538970	0.816	rs868351	ENSG00000234329.1	RP11-767N6.2	3.95	0.000104	0.034	0.26	0.25	Platelet count;	chr1:45544146	chr1:45651039~45651826:-
OV	cis	rs6700559	0.595	rs11581339	ENSG00000260088.1	RP11-92G12.3	3.95	0.000104	0.034	0.27	0.25	Coronary artery disease;	chr1:200686105	chr1:200669507~200694250:+
OV	cis	rs2828520	0.606	rs2828502	ENSG00000223822.2	EEF1A1P1	3.95	0.000105	0.034	0.23	0.25	Major depressive disorder;	chr21:23752956	chr21:23390258~23390996:+
OV	cis	rs2015599	0.645	rs12578931	ENSG00000257176.2	RP11-996F15.2	-3.95	0.000105	0.034	-0.32	-0.25	Platelet count;Mean platelet volume;	chr12:29358608	chr12:29280418~29317848:-
OV	cis	rs2015599	0.623	rs4931174	ENSG00000257176.2	RP11-996F15.2	-3.95	0.000105	0.034	-0.32	-0.25	Platelet count;Mean platelet volume;	chr12:29360545	chr12:29280418~29317848:-
OV	cis	rs6661961	0.752	rs4845436	ENSG00000237975.5	FLG-AS1	-3.95	0.000105	0.034	-0.33	-0.25	Atopic dermatitis;	chr1:152451483	chr1:152168125~152445456:+
OV	cis	rs2599510	0.811	rs2243844	ENSG00000279544.1	AL133243.4	-3.95	0.000105	0.034	-0.23	-0.25	Interleukin-18 levels;	chr2:32550917	chr2:32563328~32566436:+
OV	cis	rs7121800	0.962	rs10835675	ENSG00000242353.1	RP4-710M3.1	-3.95	0.000105	0.034	-0.31	-0.25	Pit-and-Fissure caries;	chr11:30498306	chr11:30368148~30368646:+
OV	cis	rs6687758	1	rs12140604	ENSG00000238042.4	RP11-815M8.1	3.95	0.000105	0.034	0.36	0.25	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221985808	chr1:221880981~221978523:-
OV	cis	rs4927850	1	rs7630875	ENSG00000229178.1	AC069513.4	-3.95	0.000105	0.034	-0.3	-0.25	Pancreatic cancer;	chr3:196026895	chr3:195655565~195657927:-
OV	cis	rs4713118	0.629	rs203888	ENSG00000204709.4	LINC01556	3.95	0.000105	0.0341	0.32	0.25	Parkinson's disease;	chr6:28053811	chr6:28943877~28944537:+
OV	cis	rs7927592	0.701	rs12226585	ENSG00000222339.1	AP000807.2	-3.95	0.000105	0.0341	-0.26	-0.25	Total body bone mineral density;	chr11:68490393	chr11:68505572~68505651:-
OV	cis	rs10992471	0.627	rs10820980	ENSG00000281156.1	MIR3651	-3.95	0.000105	0.0341	-0.29	-0.25	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92491060	chr9:92292458~92292547:-
OV	cis	rs10992471	0.603	rs11788523	ENSG00000281156.1	MIR3651	-3.95	0.000105	0.0341	-0.29	-0.25	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92494311	chr9:92292458~92292547:-
OV	cis	rs514406	0.505	rs427319	ENSG00000206627.1	RNU6-969P	3.95	0.000105	0.0341	0.28	0.25	Monocyte count;	chr1:52713135	chr1:52805108~52805212:-
OV	cis	rs514406	0.505	rs431427	ENSG00000206627.1	RNU6-969P	3.95	0.000105	0.0341	0.28	0.25	Monocyte count;	chr1:52713422	chr1:52805108~52805212:-
OV	cis	rs7017914	0.69	rs7013495	ENSG00000223220.1	Y_RNA	3.95	0.000105	0.0341	0.27	0.25	Bone mineral density;	chr8:70781282	chr8:70780914~70781008:-
OV	cis	rs7017914	0.69	rs10429277	ENSG00000223220.1	Y_RNA	3.95	0.000105	0.0341	0.27	0.25	Bone mineral density;	chr8:70789156	chr8:70780914~70781008:-
OV	cis	rs189798	0.807	rs12785	ENSG00000254340.1	RP11-10A14.3	3.95	0.000105	0.0341	0.39	0.25	Myopia (pathological);	chr8:9137426	chr8:9141424~9145435:+
OV	cis	rs10924970	1	rs12095653	ENSG00000236863.2	RPL23AP23	3.95	0.000105	0.0341	0.26	0.25	Asthma;	chr1:235163823	chr1:235295865~235296335:+
OV	cis	rs875971	1	rs6961717	ENSG00000237310.1	GS1-124K5.4	-3.95	0.000105	0.0341	-0.25	-0.25	Aortic root size;	chr7:66122550	chr7:66493706~66495474:+
OV	cis	rs12134151	0.806	rs1931245	ENSG00000237416.5	RP11-465K1.2	3.95	0.000105	0.0341	0.29	0.25	Educational attainment (years of education);	chr1:95712981	chr1:94836748~94855426:-
OV	cis	rs11105298	0.891	rs10858852	ENSG00000257194.2	RP11-567C2.1	-3.95	0.000105	0.0341	-0.39	-0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89439561	chr12:90107739~90112779:+
OV	cis	rs11105298	0.891	rs4842653	ENSG00000257194.2	RP11-567C2.1	-3.95	0.000105	0.0341	-0.39	-0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89440336	chr12:90107739~90112779:+
OV	cis	rs11105298	0.891	rs4842654	ENSG00000257194.2	RP11-567C2.1	-3.95	0.000105	0.0341	-0.39	-0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89440651	chr12:90107739~90112779:+
OV	cis	rs11105298	0.838	rs10858862	ENSG00000257194.2	RP11-567C2.1	-3.95	0.000105	0.0341	-0.39	-0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89448276	chr12:90107739~90112779:+
OV	cis	rs11105298	0.891	rs10858864	ENSG00000257194.2	RP11-567C2.1	-3.95	0.000105	0.0341	-0.39	-0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89452453	chr12:90107739~90112779:+
OV	cis	rs11105298	0.891	rs10858865	ENSG00000257194.2	RP11-567C2.1	-3.95	0.000105	0.0341	-0.39	-0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89452699	chr12:90107739~90112779:+
OV	cis	rs5742933	0.948	rs6434363	ENSG00000253559.1	OSGEPL1-AS1	-3.95	0.000105	0.0341	-0.29	-0.25	Ferritin levels;	chr2:189707565	chr2:189762704~189765556:+
OV	cis	rs5742933	0.948	rs6434365	ENSG00000253559.1	OSGEPL1-AS1	-3.95	0.000105	0.0341	-0.29	-0.25	Ferritin levels;	chr2:189707695	chr2:189762704~189765556:+
OV	cis	rs9813712	1	rs9864582	ENSG00000228252.7	COL6A4P2	3.95	0.000105	0.0341	0.34	0.25	Response to amphetamines;	chr3:130251619	chr3:130212823~130273806:+
OV	cis	rs9473147	0.516	rs7754971	ENSG00000270761.1	RP11-385F7.1	-3.95	0.000105	0.0341	-0.29	-0.25	Platelet distribution width;Mean platelet volume;	chr6:47622740	chr6:47477243~47477572:-
OV	cis	rs17597773	0.638	rs11118609	ENSG00000238078.1	LINC01352	3.95	0.000105	0.0341	0.34	0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220815148	chr1:220829255~220832429:+
OV	cis	rs848490	0.674	rs62460676	ENSG00000214293.7	APTR	3.95	0.000105	0.0341	0.32	0.25	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77680405	chr7:77657660~77696265:-
OV	cis	rs642743	0.967	rs581686	ENSG00000228261.1	RP11-127L20.3	-3.95	0.000105	0.0341	-0.26	-0.25	Left ventricular obstructive tract defect (maternal effect);	chr10:104223598	chr10:104323369~104327004:+
OV	cis	rs7726839	0.794	rs11739663	ENSG00000271781.1	CTD-2589H19.6	-3.95	0.000105	0.0341	-0.32	-0.25	Obesity-related traits;	chr5:593968	chr5:675826~676616:+
OV	cis	rs4296809	0.505	rs72753629	ENSG00000249779.1	RP11-447H19.3	-3.95	0.000105	0.0342	-0.46	-0.25	Brain structure;	chr5:44110329	chr5:43206709~43207811:+
OV	cis	rs4296809	0.505	rs72753631	ENSG00000249779.1	RP11-447H19.3	-3.95	0.000105	0.0342	-0.46	-0.25	Brain structure;	chr5:44110361	chr5:43206709~43207811:+
OV	cis	rs4296809	0.505	rs72753633	ENSG00000249779.1	RP11-447H19.3	-3.95	0.000105	0.0342	-0.46	-0.25	Brain structure;	chr5:44110382	chr5:43206709~43207811:+
OV	cis	rs4296809	0.505	rs116558399	ENSG00000249779.1	RP11-447H19.3	-3.95	0.000105	0.0342	-0.46	-0.25	Brain structure;	chr5:44118115	chr5:43206709~43207811:+
OV	cis	rs4296809	0.505	rs4473774	ENSG00000249779.1	RP11-447H19.3	-3.95	0.000105	0.0342	-0.46	-0.25	Brain structure;	chr5:44125290	chr5:43206709~43207811:+
OV	cis	rs16843372	0.562	rs10194836	ENSG00000251491.2	OR7E28P	-3.95	0.000105	0.0342	-0.31	-0.25	Obesity-related traits;	chr2:158838428	chr2:158862311~158863285:+
OV	cis	rs4664293	0.605	rs12991516	ENSG00000224152.1	AC009506.1	-3.95	0.000105	0.0342	-0.26	-0.25	Monocyte percentage of white cells;	chr2:159585554	chr2:159615296~159617082:+
OV	cis	rs7968440	1	rs2731442	ENSG00000272368.2	RP4-605O3.4	3.95	0.000105	0.0342	0.3	0.25	Fibrinogen;	chr12:50660872	chr12:50112197~50165618:+
OV	cis	rs12999373	0.501	rs11127496	ENSG00000223751.1	AC116609.2	3.95	0.000105	0.0342	0.28	0.25	Response to fenofibrate (adiponectin levels);Uric acid levels;	chr2:694063	chr2:742488~747767:+
OV	cis	rs6860806	0.531	rs272887	ENSG00000233006.5	AC034220.3	3.95	0.000105	0.0342	0.26	0.25	Breast cancer;	chr5:132330020	chr5:132311285~132369916:-
OV	cis	rs73198271	0.531	rs112930476	ENSG00000253893.2	FAM85B	3.95	0.000105	0.0342	0.39	0.25	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8814041	chr8:8167819~8226614:-
OV	cis	rs6062509	0.895	rs6011040	ENSG00000232442.1	CTD-3184A7.4	3.95	0.000105	0.0343	0.25	0.25	Prostate cancer;	chr20:63706054	chr20:63627227~63628824:+
OV	cis	rs7927592	0.763	rs596494	ENSG00000222339.1	AP000807.2	3.95	0.000106	0.0343	0.26	0.25	Total body bone mineral density;	chr11:68483586	chr11:68505572~68505651:-
OV	cis	rs6545883	1	rs6545883	ENSG00000273302.1	RP11-493E12.2	3.95	0.000106	0.0343	0.2	0.25	Tuberculosis;	chr2:61545122	chr2:61199979~61200769:+
OV	cis	rs4918798	0.696	rs2185570	ENSG00000234724.1	HDAC1P1	3.95	0.000106	0.0343	0.47	0.25	Warfarin maintenance dose;	chr10:94991513	chr10:94137748~94139500:+
OV	cis	rs2828520	0.647	rs9636727	ENSG00000223822.2	EEF1A1P1	3.95	0.000106	0.0343	0.22	0.25	Major depressive disorder;	chr21:23764494	chr21:23390258~23390996:+
OV	cis	rs9369695	0.881	rs9349409	ENSG00000270761.1	RP11-385F7.1	-3.95	0.000106	0.0343	-0.29	-0.25	Reticulocyte count;	chr6:47495390	chr6:47477243~47477572:-
OV	cis	rs9369695	0.842	rs9395262	ENSG00000270761.1	RP11-385F7.1	-3.95	0.000106	0.0343	-0.29	-0.25	Reticulocyte count;	chr6:47497531	chr6:47477243~47477572:-
OV	cis	rs9393777	0.92	rs13196692	ENSG00000226314.6	ZNF192P1	-3.95	0.000106	0.0343	-0.52	-0.25	Intelligence (multi-trait analysis);	chr6:27411340	chr6:28161781~28169594:+
OV	cis	rs5015933	0.832	rs2841332	ENSG00000232630.1	PRPS1P2	-3.95	0.000106	0.0343	-0.24	-0.25	Body mass index;	chr9:125367578	chr9:125150653~125151589:+
OV	cis	rs2590816	0.648	rs1126328	ENSG00000226950.5	DANCR	-3.95	0.000106	0.0343	-0.32	-0.25	Lobe attachment (rater-scored or self-reported);	chr4:53595556	chr4:52712404~52720351:+
OV	cis	rs2243480	1	rs12698509	ENSG00000226824.5	RP4-756H11.3	-3.95	0.000106	0.0343	-0.4	-0.25	Diabetic kidney disease;	chr7:65953889	chr7:66654538~66669855:+
OV	cis	rs18122	0.549	rs605980	ENSG00000236605.1	AC023115.4	3.95	0.000106	0.0343	0.32	0.25	Waist-to-hip ratio adjusted for body mass index;	chr2:67456571	chr2:67324627~67325304:+
OV	cis	rs7520050	0.966	rs785471	ENSG00000280836.1	AL355480.1	3.95	0.000106	0.0343	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:46053005	chr1:45581219~45581321:-
OV	cis	rs11083475	1	rs12462270	ENSG00000267892.1	CTD-2540F13.2	3.95	0.000106	0.0344	0.29	0.25	Heart rate;	chr19:38710848	chr19:38738284~38739863:+
OV	cis	rs11083475	1	rs2279144	ENSG00000267892.1	CTD-2540F13.2	3.95	0.000106	0.0344	0.29	0.25	Heart rate;	chr19:38711141	chr19:38738284~38739863:+
OV	cis	rs2253762	0.527	rs11200323	ENSG00000276742.1	RP11-500G22.4	-3.95	0.000106	0.0344	-0.4	-0.25	Breast cancer;	chr10:122008869	chr10:121956782~121957098:+
OV	cis	rs7646881	0.544	rs28856044	ENSG00000272087.1	RP11-379F4.7	3.95	0.000106	0.0344	0.36	0.25	Tetralogy of Fallot;	chr3:158584970	chr3:158693120~158693768:-
OV	cis	rs7646881	0.508	rs6779054	ENSG00000272087.1	RP11-379F4.7	3.95	0.000106	0.0344	0.36	0.25	Tetralogy of Fallot;	chr3:158587658	chr3:158693120~158693768:-
OV	cis	rs7646881	0.544	rs9872682	ENSG00000272087.1	RP11-379F4.7	3.95	0.000106	0.0344	0.36	0.25	Tetralogy of Fallot;	chr3:158592117	chr3:158693120~158693768:-
OV	cis	rs7646881	0.544	rs13318109	ENSG00000272087.1	RP11-379F4.7	3.95	0.000106	0.0344	0.36	0.25	Tetralogy of Fallot;	chr3:158595417	chr3:158693120~158693768:-
OV	cis	rs9309473	0.95	rs10189885	ENSG00000163016.8	ALMS1P	3.95	0.000106	0.0344	0.31	0.25	Metabolite levels;	chr2:73649928	chr2:73644919~73685576:+
OV	cis	rs62458065	0.85	rs62458099	ENSG00000226468.2	AC018641.7	3.95	0.000106	0.0344	0.41	0.25	Metabolite levels (HVA/MHPG ratio);	chr7:32432783	chr7:32456963~32457758:-
OV	cis	rs9649213	0.555	rs6955259	ENSG00000223402.1	AC074121.4	-3.95	0.000106	0.0344	-0.3	-0.25	Prostate cancer (SNP x SNP interaction);	chr7:98263044	chr7:98478551~98479225:-
OV	cis	rs6919534	0.688	rs9469964	ENSG00000265123.2	RN7SL200P	3.95	0.000106	0.0344	0.29	0.25	Height;	chr6:35223742	chr6:34685355~34685642:-
OV	cis	rs12073837	0.784	rs61830288	ENSG00000238078.1	LINC01352	-3.95	0.000106	0.0345	-0.34	-0.25	F-cell distribution;	chr1:220815399	chr1:220829255~220832429:+
OV	cis	rs12073837	0.784	rs61830289	ENSG00000238078.1	LINC01352	-3.95	0.000106	0.0345	-0.34	-0.25	F-cell distribution;	chr1:220815400	chr1:220829255~220832429:+
OV	cis	rs2239547	0.603	rs17304995	ENSG00000242142.1	SERBP1P3	3.95	0.000106	0.0345	0.32	0.25	Schizophrenia;	chr3:53036739	chr3:53064283~53065091:-
OV	cis	rs12980942	0.81	rs8105901	ENSG00000279539.1	AC006486.10	3.95	0.000106	0.0345	0.52	0.25	Coronary artery disease;	chr19:41286187	chr19:42242775~42244973:+
OV	cis	rs9902453	1	rs4465650	ENSG00000240074.1	RPL9P30	3.94	0.000106	0.0345	0.3	0.25	Coffee consumption (cups per day);	chr17:30069703	chr17:29855759~29856332:+
OV	cis	rs9992667	0.956	rs73232890	ENSG00000231160.8	KLF3-AS1	3.94	0.000106	0.0345	0.31	0.25	Eosinophil percentage of granulocytes;	chr4:38683420	chr4:38612701~38664883:-
OV	cis	rs2070488	0.932	rs1841776	ENSG00000229589.1	ACVR2B-AS1	3.94	0.000106	0.0345	0.28	0.25	Electrocardiographic conduction measures;	chr3:38439236	chr3:38451027~38454820:-
OV	cis	rs2070488	1	rs7373816	ENSG00000229589.1	ACVR2B-AS1	3.94	0.000106	0.0345	0.28	0.25	Electrocardiographic conduction measures;	chr3:38448952	chr3:38451027~38454820:-
OV	cis	rs2070488	1	rs13079757	ENSG00000229589.1	ACVR2B-AS1	3.94	0.000106	0.0345	0.28	0.25	Electrocardiographic conduction measures;	chr3:38449953	chr3:38451027~38454820:-
OV	cis	rs2070488	0.965	rs2366123	ENSG00000229589.1	ACVR2B-AS1	3.94	0.000106	0.0345	0.28	0.25	Electrocardiographic conduction measures;	chr3:38451662	chr3:38451027~38454820:-
OV	cis	rs2070488	1	rs3792527	ENSG00000229589.1	ACVR2B-AS1	3.94	0.000106	0.0345	0.28	0.25	Electrocardiographic conduction measures;	chr3:38451721	chr3:38451027~38454820:-
OV	cis	rs2070488	0.965	rs3762788	ENSG00000229589.1	ACVR2B-AS1	3.94	0.000106	0.0345	0.28	0.25	Electrocardiographic conduction measures;	chr3:38452361	chr3:38451027~38454820:-
OV	cis	rs875971	0.825	rs6951503	ENSG00000237310.1	GS1-124K5.4	-3.94	0.000106	0.0345	-0.26	-0.25	Aortic root size;	chr7:66253949	chr7:66493706~66495474:+
OV	cis	rs11157436	0.918	rs11157426	ENSG00000211812.1	TRAV26-2	-3.94	0.000107	0.0345	-0.28	-0.25	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22153691	chr14:22202583~22203368:+
OV	cis	rs11157436	0.918	rs11157427	ENSG00000211812.1	TRAV26-2	-3.94	0.000107	0.0345	-0.28	-0.25	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22154291	chr14:22202583~22203368:+
OV	cis	rs11157436	0.792	rs12433875	ENSG00000211812.1	TRAV26-2	-3.94	0.000107	0.0345	-0.28	-0.25	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22154490	chr14:22202583~22203368:+
OV	cis	rs732765	0.657	rs17782737	ENSG00000258439.1	RP11-173A8.2	3.94	0.000107	0.0345	0.39	0.25	Non-small cell lung cancer;	chr14:74826123	chr14:74658049~74658590:+
OV	cis	rs2111504	0.583	rs2868082	ENSG00000267213.4	AC007773.2	3.94	0.000107	0.0346	0.33	0.25	Bipolar disorder;	chr19:32368475	chr19:32390050~32405560:-
OV	cis	rs1765142	0.55	rs594207	ENSG00000254532.1	RP11-624D11.2	-3.94	0.000107	0.0346	-0.3	-0.25	Schizophrenia;	chr11:30399226	chr11:30044058~30084343:-
OV	cis	rs2273788	0.793	rs34492085	ENSG00000204173.9	LRRC37A5P	3.94	0.000107	0.0346	0.3	0.25	Monocyte count;	chr9:111584381	chr9:111602831~111631289:-
OV	cis	rs1436109	0.809	rs55657838	ENSG00000255129.4	RP11-839D17.3	3.94	0.000107	0.0346	0.46	0.25	Cardiac muscle measurement;	chr11:112974217	chr11:113278437~113314437:-
OV	cis	rs1436109	0.809	rs56049549	ENSG00000255129.4	RP11-839D17.3	3.94	0.000107	0.0346	0.46	0.25	Cardiac muscle measurement;	chr11:112974311	chr11:113278437~113314437:-
OV	cis	rs9326248	0.954	rs8521	ENSG00000280143.1	AP000892.6	3.94	0.000107	0.0346	0.27	0.25	Blood protein levels;	chr11:117196983	chr11:117204967~117210292:+
OV	cis	rs9880211	0.613	rs28519617	ENSG00000261758.1	RP11-102M11.2	-3.94	0.000107	0.0346	-0.32	-0.25	Height;Body mass index;	chr3:136156088	chr3:136752630~136755780:+
OV	cis	rs9880211	0.613	rs28669017	ENSG00000261758.1	RP11-102M11.2	-3.94	0.000107	0.0346	-0.32	-0.25	Height;Body mass index;	chr3:136156090	chr3:136752630~136755780:+
OV	cis	rs9880211	0.613	rs10222451	ENSG00000261758.1	RP11-102M11.2	-3.94	0.000107	0.0346	-0.32	-0.25	Height;Body mass index;	chr3:136158571	chr3:136752630~136755780:+
OV	cis	rs10759883	0.539	rs7847393	ENSG00000175611.10	LINC00476	3.94	0.000107	0.0346	0.34	0.25	Nicotine dependence;	chr9:96033431	chr9:95759231~95875977:-
OV	cis	rs2282300	0.637	rs10742240	ENSG00000242353.1	RP4-710M3.1	-3.94	0.000107	0.0346	-0.3	-0.25	Morning vs. evening chronotype;	chr11:30407891	chr11:30368148~30368646:+
OV	cis	rs1404100	0.51	rs1038272	ENSG00000249274.1	PDLIM1P4	3.94	0.000107	0.0346	0.29	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:99067685	chr3:98782188~98783193:+
OV	cis	rs7688540	0.61	rs6830496	ENSG00000275426.1	CH17-262A2.1	3.94	0.000107	0.0346	0.41	0.25	Facial morphology (factor 6, height of vermillion lower lip);	chr4:221985	chr4:149738~150317:+
OV	cis	rs4787491	0.729	rs4788212	ENSG00000261367.1	RP11-455F5.4	3.94	0.000107	0.0346	0.28	0.25	Body mass index;BMI (adjusted for smoking behaviour);BMI in non-smokers;Body mass index (joint analysis main effects and smoking interaction);	chr16:30023148	chr16:30107675~30110541:+
OV	cis	rs1979679	0.879	rs2061759	ENSG00000278733.1	RP11-425D17.1	3.94	0.000107	0.0346	0.3	0.25	Ossification of the posterior longitudinal ligament of the spine;	chr12:28310394	chr12:28185625~28186190:-
OV	cis	rs10483554	0.671	rs72675940	ENSG00000243038.1	RP11-58E21.1	3.94	0.000107	0.0346	0.4	0.25	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr14:49345444	chr14:50052857~50053569:+
OV	cis	rs1823913	0.599	rs17412094	ENSG00000227542.1	AC092614.2	3.94	0.000107	0.0346	0.28	0.25	Obesity-related traits;	chr2:191284202	chr2:191229165~191246172:-
OV	cis	rs5742933	0.725	rs1132360	ENSG00000273240.1	RP11-455J20.3	3.94	0.000107	0.0347	0.27	0.25	Ferritin levels;	chr2:189661498	chr2:189763859~189764456:-
OV	cis	rs733592	0.56	rs61918773	ENSG00000240399.1	RP1-228P16.1	-3.94	0.000107	0.0347	-0.27	-0.25	Plateletcrit;	chr12:48027991	chr12:48054813~48055591:-
OV	cis	rs941207	0.789	rs2958145	ENSG00000241217.3	RN7SL809P	-3.94	0.000107	0.0347	-0.28	-0.25	Platelet count;	chr12:56662290	chr12:56670450~56670746:-
OV	cis	rs881375	0.967	rs10733648	ENSG00000226752.6	PSMD5-AS1	-3.94	0.000107	0.0347	-0.28	-0.25	Rheumatoid arthritis;	chr9:120938501	chr9:120824828~120854385:+
OV	cis	rs9880211	0.563	rs67589653	ENSG00000239213.4	NCK1-AS1	3.94	0.000107	0.0347	0.31	0.25	Height;Body mass index;	chr3:136092732	chr3:136841726~136862054:-
OV	cis	rs9880211	0.563	rs10512990	ENSG00000239213.4	NCK1-AS1	3.94	0.000107	0.0347	0.31	0.25	Height;Body mass index;	chr3:136095785	chr3:136841726~136862054:-
OV	cis	rs67311347	0.544	rs13097602	ENSG00000223797.4	ENTPD3-AS1	-3.94	0.000107	0.0347	-0.27	-0.25	Renal cell carcinoma;	chr3:40297756	chr3:40313802~40453329:-
OV	cis	rs7646881	0.544	rs10154917	ENSG00000272440.1	RP11-379F4.6	3.94	0.000107	0.0347	0.37	0.25	Tetralogy of Fallot;	chr3:158614911	chr3:158695367~158695581:+
OV	cis	rs10992471	0.676	rs13286566	ENSG00000281156.1	MIR3651	-3.94	0.000107	0.0348	-0.29	-0.25	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92710896	chr9:92292458~92292547:-
OV	cis	rs2242663	0.705	rs551708	ENSG00000199325.1	RNU4-39P	3.94	0.000107	0.0348	0.28	0.25	Bipolar disorder;	chr11:66718672	chr11:66614964~66615090:-
OV	cis	rs1062177	0.855	rs6892117	ENSG00000253921.1	CTB-113P19.3	3.94	0.000107	0.0348	0.32	0.25	Preschool internalizing problems;	chr5:151885424	chr5:151753992~151767247:+
OV	cis	rs2708377	0.79	rs73051387	ENSG00000256981.1	TAS2R18	3.94	0.000108	0.0348	0.36	0.25	Bitter taste perception;	chr12:11161864	chr12:11158785~11159694:-
OV	cis	rs11122895	1	rs11685349	ENSG00000228251.1	AC012442.6	-3.94	0.000108	0.0348	-0.24	-0.25	Allergic sensitization;	chr2:111705548	chr2:112590796~112591939:+
OV	cis	rs6951245	0.706	rs28483034	ENSG00000229043.2	AC091729.9	-3.94	0.000108	0.0348	-0.41	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1130535	chr7:1160374~1165267:+
OV	cis	rs62458065	0.85	rs62458100	ENSG00000226468.2	AC018641.7	3.94	0.000108	0.0348	0.4	0.25	Metabolite levels (HVA/MHPG ratio);	chr7:32433530	chr7:32456963~32457758:-
OV	cis	rs10510102	0.516	rs12242799	ENSG00000226864.1	ATE1-AS1	3.94	0.000108	0.0348	0.46	0.25	Breast cancer;	chr10:121980067	chr10:121928312~121951965:+
OV	cis	rs1436109	0.809	rs13328864	ENSG00000255129.4	RP11-839D17.3	3.94	0.000108	0.0348	0.47	0.25	Cardiac muscle measurement;	chr11:112972688	chr11:113278437~113314437:-
OV	cis	rs3734266	0.639	rs7739385	ENSG00000220643.1	RP3-391O22.1	-3.94	0.000108	0.0348	-0.4	-0.25	Systemic lupus erythematosus;	chr6:34899701	chr6:34686602~34687106:+
OV	cis	rs7520050	0.966	rs10890363	ENSG00000280836.1	AL355480.1	-3.94	0.000108	0.0348	-0.3	-0.25	Reticulocyte count;Red blood cell count;	chr1:45890476	chr1:45581219~45581321:-
OV	cis	rs7569084	1	rs7569084	ENSG00000204929.10	AC074391.1	-3.94	0.000108	0.0348	-0.32	-0.25	Sum eosinophil basophil counts;	chr2:65429835	chr2:65436711~66084639:+
OV	cis	rs853679	0.546	rs200981	ENSG00000226314.6	ZNF192P1	-3.94	0.000108	0.0348	-0.45	-0.25	Depression;	chr6:27865396	chr6:28161781~28169594:+
OV	cis	rs6914704	0.605	rs1013303	ENSG00000250903.7	GMDS-AS1	3.94	0.000108	0.0348	0.26	0.25	Late-onset myasthenia gravis;	chr6:1749694	chr6:2245748~2482022:+
OV	cis	rs2302729	0.515	rs10161158	ENSG00000246627.5	CACNA1C-AS1	3.94	0.000108	0.0348	0.27	0.25	Sleep quality;	chr12:2659806	chr12:2676001~2691200:-
OV	cis	rs10214930	0.697	rs5009225	ENSG00000235574.1	AC073150.6	-3.94	0.000108	0.0348	-0.3	-0.25	Hypospadias;	chr7:27577166	chr7:27491682~27492765:-
OV	cis	rs10214930	0.697	rs10807841	ENSG00000235574.1	AC073150.6	-3.94	0.000108	0.0348	-0.3	-0.25	Hypospadias;	chr7:27580132	chr7:27491682~27492765:-
OV	cis	rs10214930	0.671	rs1009252	ENSG00000235574.1	AC073150.6	-3.94	0.000108	0.0348	-0.3	-0.25	Hypospadias;	chr7:27582054	chr7:27491682~27492765:-
OV	cis	rs10214930	0.697	rs7789788	ENSG00000235574.1	AC073150.6	-3.94	0.000108	0.0348	-0.3	-0.25	Hypospadias;	chr7:27582992	chr7:27491682~27492765:-
OV	cis	rs10214930	0.697	rs1608664	ENSG00000235574.1	AC073150.6	-3.94	0.000108	0.0348	-0.3	-0.25	Hypospadias;	chr7:27584309	chr7:27491682~27492765:-
OV	cis	rs10214930	0.697	rs4140899	ENSG00000235574.1	AC073150.6	-3.94	0.000108	0.0348	-0.3	-0.25	Hypospadias;	chr7:27585408	chr7:27491682~27492765:-
OV	cis	rs10214930	0.697	rs1524532	ENSG00000235574.1	AC073150.6	-3.94	0.000108	0.0348	-0.3	-0.25	Hypospadias;	chr7:27586067	chr7:27491682~27492765:-
OV	cis	rs10214930	0.697	rs1524533	ENSG00000235574.1	AC073150.6	-3.94	0.000108	0.0348	-0.3	-0.25	Hypospadias;	chr7:27586177	chr7:27491682~27492765:-
OV	cis	rs10214930	0.697	rs2391443	ENSG00000235574.1	AC073150.6	-3.94	0.000108	0.0348	-0.3	-0.25	Hypospadias;	chr7:27586310	chr7:27491682~27492765:-
OV	cis	rs7617773	0.539	rs17593974	ENSG00000228638.1	FCF1P2	-3.94	0.000108	0.0348	-0.31	-0.25	Coronary artery disease;	chr3:48345844	chr3:48290793~48291375:-
OV	cis	rs7617773	0.514	rs11130166	ENSG00000228638.1	FCF1P2	-3.94	0.000108	0.0348	-0.31	-0.25	Coronary artery disease;	chr3:48346566	chr3:48290793~48291375:-
OV	cis	rs7617773	0.563	rs62263035	ENSG00000228638.1	FCF1P2	-3.94	0.000108	0.0348	-0.31	-0.25	Coronary artery disease;	chr3:48350079	chr3:48290793~48291375:-
OV	cis	rs9880211	0.635	rs6775778	ENSG00000261758.1	RP11-102M11.2	3.94	0.000108	0.0349	0.32	0.25	Height;Body mass index;	chr3:136007837	chr3:136752630~136755780:+
OV	cis	rs17739794	0.967	rs3860880	ENSG00000254207.1	RP11-43A14.1	-3.94	0.000108	0.0349	-0.27	-0.25	Clozapine-induced cytotoxicity;	chr8:859497	chr8:725188~725877:-
OV	cis	rs10129255	0.5	rs59939897	ENSG00000223648.3	IGHV3-64	3.94	0.000108	0.0349	0.25	0.25	Kawasaki disease;	chr14:106783414	chr14:106643132~106658258:-
OV	cis	rs514406	0.505	rs269293	ENSG00000206627.1	RNU6-969P	3.94	0.000108	0.0349	0.28	0.25	Monocyte count;	chr1:52722095	chr1:52805108~52805212:-
OV	cis	rs514406	0.505	rs269292	ENSG00000206627.1	RNU6-969P	3.94	0.000108	0.0349	0.28	0.25	Monocyte count;	chr1:52722239	chr1:52805108~52805212:-
OV	cis	rs78663649	0.908	rs79641498	ENSG00000269480.1	CTD-3032J10.3	-3.94	0.000108	0.0349	-0.44	-0.25	White blood cell count;	chr19:16410332	chr19:17207138~17208010:-
OV	cis	rs1850744	1	rs1533615	ENSG00000250268.3	ALG1L14P	3.94	0.000108	0.0349	0.64	0.25	Economic and political preferences;	chr4:9802900	chr4:9166297~9170270:-
OV	cis	rs801193	0.548	rs2659904	ENSG00000237310.1	GS1-124K5.4	3.94	0.000108	0.0349	0.26	0.25	Aortic root size;	chr7:66713615	chr7:66493706~66495474:+
OV	cis	rs2070488	0.775	rs2268762	ENSG00000229589.1	ACVR2B-AS1	3.94	0.000108	0.035	0.28	0.25	Electrocardiographic conduction measures;	chr3:38474584	chr3:38451027~38454820:-
OV	cis	rs2070488	0.775	rs13098946	ENSG00000229589.1	ACVR2B-AS1	3.94	0.000108	0.035	0.28	0.25	Electrocardiographic conduction measures;	chr3:38476293	chr3:38451027~38454820:-
OV	cis	rs2070488	0.699	rs13078966	ENSG00000229589.1	ACVR2B-AS1	3.94	0.000108	0.035	0.28	0.25	Electrocardiographic conduction measures;	chr3:38476423	chr3:38451027~38454820:-
OV	cis	rs2348418	0.733	rs2169754	ENSG00000247934.4	RP11-967K21.1	-3.94	0.000108	0.035	-0.25	-0.25	Lung function (FEV1);Lung function (FVC);	chr12:28187712	chr12:28163298~28190738:-
OV	cis	rs881375	0.967	rs1008381	ENSG00000226752.6	PSMD5-AS1	-3.94	0.000108	0.035	-0.28	-0.25	Rheumatoid arthritis;	chr9:120918838	chr9:120824828~120854385:+
OV	cis	rs4761702	0.922	rs7960229	ENSG00000257252.4	RP11-486A14.2	-3.94	0.000108	0.035	-0.3	-0.25	Immature fraction of reticulocytes;	chr12:93323943	chr12:93317135~93377736:-
OV	cis	rs11009175	0.799	rs2457703	ENSG00000273038.2	RP11-479G22.8	-3.94	0.000108	0.035	-0.34	-0.25	Depression (quantitative trait);	chr10:33050611	chr10:32887255~32889311:-
OV	cis	rs11009175	0.746	rs2756023	ENSG00000273038.2	RP11-479G22.8	-3.94	0.000108	0.035	-0.34	-0.25	Depression (quantitative trait);	chr10:33050726	chr10:32887255~32889311:-
OV	cis	rs11009175	0.799	rs2756022	ENSG00000273038.2	RP11-479G22.8	-3.94	0.000108	0.035	-0.34	-0.25	Depression (quantitative trait);	chr10:33051028	chr10:32887255~32889311:-
OV	cis	rs801193	0.613	rs2659900	ENSG00000237310.1	GS1-124K5.4	3.94	0.000108	0.035	0.26	0.25	Aortic root size;	chr7:66719456	chr7:66493706~66495474:+
OV	cis	rs6101567	0.623	rs4810261	ENSG00000261431.1	RP4-616B8.4	3.94	0.000109	0.035	0.25	0.25	Nose size;	chr20:39331352	chr20:38961925~38962111:-
OV	cis	rs6071524	0.508	rs2263750	ENSG00000277581.1	RP4-616B8.6	-3.94	0.000109	0.0351	-0.3	-0.25	Autism spectrum disorder or schizophrenia;	chr20:38768515	chr20:38962472~38962993:+
OV	cis	rs7246967	0.673	rs16999519	ENSG00000267920.1	SNX6P1	3.94	0.000109	0.0351	0.4	0.25	Bronchopulmonary dysplasia;	chr19:22631274	chr19:23126569~23127792:-
OV	cis	rs4948102	0.642	rs4948104	ENSG00000273720.1	RP11-613E4.4	-3.94	0.000109	0.0351	-0.3	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56074826	chr7:55743073~55743457:+
OV	cis	rs4728142	0.604	rs12155080	ENSG00000275106.1	RP11-309L24.10	-3.94	0.000109	0.0351	-0.32	-0.25	Ulcerative colitis;Inflammatory bowel disease;Systemic lupus erythematosus;	chr7:129018685	chr7:128952527~128953316:-
OV	cis	rs2599510	0.748	rs6718214	ENSG00000279544.1	AL133243.4	3.94	0.000109	0.0351	0.24	0.25	Interleukin-18 levels;	chr2:32325416	chr2:32563328~32566436:+
OV	cis	rs7246657	0.943	rs7408563	ENSG00000226686.6	LINC01535	-3.94	0.000109	0.0351	-0.38	-0.25	Coronary artery calcification;	chr19:37317683	chr19:37251912~37265535:+
OV	cis	rs7246657	0.943	rs7258692	ENSG00000226686.6	LINC01535	-3.94	0.000109	0.0351	-0.38	-0.25	Coronary artery calcification;	chr19:37327927	chr19:37251912~37265535:+
OV	cis	rs8100891	0.665	rs7259259	ENSG00000267213.4	AC007773.2	-3.94	0.000109	0.0351	-0.32	-0.25	Neuroticism;	chr19:32328935	chr19:32390050~32405560:-
OV	cis	rs1075265	0.656	rs2542574	ENSG00000233266.1	HMGB1P31	3.94	0.000109	0.0351	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53820295	chr2:54051334~54051760:+
OV	cis	rs7259965	0.839	rs62109048	ENSG00000277744.1	CTC-435M10.12	3.94	0.000109	0.0351	0.25	0.25	Midgestational circulating levels of organochlorine pesticides;Midgestational circulating levels of PBDEs;	chr19:40997352	chr19:41373971~41374419:+
OV	cis	rs1007358	0.597	rs10266929	ENSG00000229459.1	AC023669.1	-3.94	0.000109	0.0352	-0.29	-0.25	Height;	chr7:46172773	chr7:46261064~46294469:+
OV	cis	rs2574704	1	rs7433453	ENSG00000251774.1	RNU6-377P	-3.94	0.000109	0.0352	-0.24	-0.25	Body mass index;	chr3:11605942	chr3:12514706~12514807:+
OV	cis	rs1765142	0.55	rs529056	ENSG00000254532.1	RP11-624D11.2	-3.94	0.000109	0.0352	-0.3	-0.25	Schizophrenia;	chr11:30401636	chr11:30044058~30084343:-
OV	cis	rs4703129	0.506	rs751882	ENSG00000249448.1	RP11-474J18.1	-3.94	0.000109	0.0352	-0.3	-0.25	Asperger disorder;	chr5:98443705	chr5:98410235~98411792:-
OV	cis	rs61542988	1	rs61542988	ENSG00000221740.1	SNORD93	3.94	0.000109	0.0352	0.34	0.25	Fibrinogen levels;	chr7:22842672	chr7:22856613~22856686:+
OV	cis	rs2070488	0.775	rs961179	ENSG00000229589.1	ACVR2B-AS1	3.94	0.000109	0.0352	0.28	0.25	Electrocardiographic conduction measures;	chr3:38468127	chr3:38451027~38454820:-
OV	cis	rs2070488	0.804	rs2276541	ENSG00000229589.1	ACVR2B-AS1	3.94	0.000109	0.0352	0.28	0.25	Electrocardiographic conduction measures;	chr3:38471288	chr3:38451027~38454820:-
OV	cis	rs829883	0.714	rs249847	ENSG00000227825.4	SLC9A7P1	3.94	0.000109	0.0352	0.26	0.25	Colorectal adenoma (advanced);	chr12:98473938	chr12:98453835~98457145:-
OV	cis	rs9880211	0.563	rs6769762	ENSG00000261758.1	RP11-102M11.2	-3.94	0.000109	0.0352	-0.32	-0.25	Height;Body mass index;	chr3:136189336	chr3:136752630~136755780:+
OV	cis	rs367615	0.918	rs10067984	ENSG00000249476.1	CTD-2587M2.1	3.94	0.000109	0.0353	0.33	0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109536983	chr5:109237120~109326369:-
OV	cis	rs367615	0.918	rs4270746	ENSG00000249476.1	CTD-2587M2.1	3.94	0.000109	0.0353	0.33	0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109541138	chr5:109237120~109326369:-
OV	cis	rs367615	0.84	rs113540823	ENSG00000249476.1	CTD-2587M2.1	3.94	0.000109	0.0353	0.33	0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109543383	chr5:109237120~109326369:-
OV	cis	rs7246657	0.943	rs10420722	ENSG00000226686.6	LINC01535	-3.94	0.000109	0.0353	-0.39	-0.25	Coronary artery calcification;	chr19:37482872	chr19:37251912~37265535:+
OV	cis	rs9393777	0.92	rs67859638	ENSG00000226314.6	ZNF192P1	-3.94	0.000109	0.0353	-0.55	-0.25	Intelligence (multi-trait analysis);	chr6:27390199	chr6:28161781~28169594:+
OV	cis	rs2111504	0.583	rs1015839	ENSG00000267213.4	AC007773.2	3.94	0.000109	0.0353	0.33	0.25	Bipolar disorder;	chr19:32390365	chr19:32390050~32405560:-
OV	cis	rs10754283	0.967	rs6428559	ENSG00000231613.1	RP5-943J3.1	3.94	0.00011	0.0353	0.27	0.25	Amyotrophic lateral sclerosis (sporadic);	chr1:89633477	chr1:89788914~89790492:+
OV	cis	rs9309473	0.95	rs6546854	ENSG00000163016.8	ALMS1P	3.94	0.00011	0.0353	0.31	0.25	Metabolite levels;	chr2:73606907	chr2:73644919~73685576:+
OV	cis	rs4713118	0.869	rs6922574	ENSG00000219392.1	RP1-265C24.5	-3.94	0.00011	0.0353	-0.29	-0.25	Parkinson's disease;	chr6:27725224	chr6:28115628~28116551:+
OV	cis	rs1707322	0.752	rs4586014	ENSG00000234329.1	RP11-767N6.2	3.94	0.00011	0.0353	0.27	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45684771	chr1:45651039~45651826:-
OV	cis	rs1707322	0.648	rs4439382	ENSG00000234329.1	RP11-767N6.2	3.94	0.00011	0.0353	0.27	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45685133	chr1:45651039~45651826:-
OV	cis	rs748404	0.55	rs12912505	ENSG00000205771.5	CATSPER2P1	-3.94	0.00011	0.0353	-0.38	-0.25	Lung cancer;	chr15:43525206	chr15:43726918~43747094:-
OV	cis	rs7116641	0.961	rs6485443	ENSG00000246250.2	RP11-613D13.5	-3.94	0.00011	0.0353	-0.29	-0.25	Coronary artery disease;	chr11:43674766	chr11:43829709~43880726:-
OV	cis	rs4927850	1	rs7630875	ENSG00000242086.7	LINC00969	3.94	0.00011	0.0353	0.26	0.25	Pancreatic cancer;	chr3:196026895	chr3:195658062~195739964:+
OV	cis	rs1538970	0.962	rs9429076	ENSG00000280836.1	AL355480.1	-3.94	0.00011	0.0353	-0.32	-0.25	Platelet count;	chr1:45353817	chr1:45581219~45581321:-
OV	cis	rs792448	0.534	rs66912346	ENSG00000201544.1	SNORA16B	3.94	0.00011	0.0353	0.31	0.25	White blood cell count (basophil);	chr1:212444178	chr1:212352816~212352950:+
OV	cis	rs858239	0.73	rs10255155	ENSG00000230042.1	AK3P3	3.94	0.00011	0.0353	0.26	0.25	Cerebrospinal fluid biomarker levels;	chr7:23362528	chr7:23129178~23129841:+
OV	cis	rs4845570	1	rs7416415	ENSG00000203288.3	RP11-98D18.9	3.94	0.00011	0.0353	0.4	0.25	Coronary artery disease;	chr1:151785322	chr1:151790804~151794402:+
OV	cis	rs4845570	0.92	rs10788809	ENSG00000203288.3	RP11-98D18.9	3.94	0.00011	0.0353	0.4	0.25	Coronary artery disease;	chr1:151788316	chr1:151790804~151794402:+
OV	cis	rs6545883	0.929	rs7563678	ENSG00000270820.4	RP11-355B11.2	-3.94	0.00011	0.0354	-0.29	-0.25	Tuberculosis;	chr2:61514676	chr2:61471188~61484130:+
OV	cis	rs1584120	0.648	rs11046823	ENSG00000274885.1	RP11-268P4.6	-3.94	0.00011	0.0354	-0.32	-0.25	Pelvic organ prolapse (moderate/severe);	chr12:23135871	chr12:22638464~22638943:+
OV	cis	rs330071	0.557	rs405001	ENSG00000279949.1	RP11-10A14.9	-3.94	0.00011	0.0354	-0.28	-0.25	Acne (severe);	chr8:9307870	chr8:9158063~9158621:+
OV	cis	rs62458065	0.85	rs7808992	ENSG00000226468.2	AC018641.7	3.94	0.00011	0.0354	0.41	0.25	Metabolite levels (HVA/MHPG ratio);	chr7:32431065	chr7:32456963~32457758:-
OV	cis	rs62458065	0.85	rs62458098	ENSG00000226468.2	AC018641.7	3.94	0.00011	0.0354	0.41	0.25	Metabolite levels (HVA/MHPG ratio);	chr7:32431517	chr7:32456963~32457758:-
OV	cis	rs62458065	0.85	rs73096034	ENSG00000226468.2	AC018641.7	3.94	0.00011	0.0354	0.41	0.25	Metabolite levels (HVA/MHPG ratio);	chr7:32432436	chr7:32456963~32457758:-
OV	cis	rs6142102	0.961	rs8119937	ENSG00000276073.1	RP5-1125A11.7	-3.94	0.00011	0.0354	-0.3	-0.25	Skin pigmentation;	chr20:34057745	chr20:33985617~33988989:-
OV	cis	rs11951515	0.691	rs36050992	ENSG00000278487.1	RP11-447H19.4	-3.94	0.00011	0.0354	-0.29	-0.25	Metabolite levels  (X-11787);	chr5:43364305	chr5:43143362~43143514:-
OV	cis	rs1113500	0.548	rs11185269	ENSG00000226822.1	RP11-356N1.2	3.94	0.00011	0.0354	0.32	0.25	Growth-regulated protein alpha levels;	chr1:108105014	chr1:108071482~108074519:+
OV	cis	rs4356975	0.563	rs7676472	ENSG00000251284.2	RP13-644M16.1	-3.94	0.00011	0.0354	-0.26	-0.25	Obesity-related traits;	chr4:69090226	chr4:69125274~69126451:+
OV	cis	rs853679	0.882	rs9393908	ENSG00000226314.6	ZNF192P1	-3.94	0.00011	0.0354	-0.48	-0.25	Depression;	chr6:28223052	chr6:28161781~28169594:+
OV	cis	rs853679	0.882	rs9366717	ENSG00000226314.6	ZNF192P1	-3.94	0.00011	0.0354	-0.48	-0.25	Depression;	chr6:28223279	chr6:28161781~28169594:+
OV	cis	rs73201462	1	rs2811414	ENSG00000242551.2	POU5F1P6	-3.94	0.00011	0.0354	-0.37	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128272334	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2811530	ENSG00000242551.2	POU5F1P6	-3.94	0.00011	0.0354	-0.37	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128274323	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2811528	ENSG00000242551.2	POU5F1P6	-3.94	0.00011	0.0354	-0.37	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128275593	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2811381	ENSG00000242551.2	POU5F1P6	-3.94	0.00011	0.0354	-0.37	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128279069	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs6765233	ENSG00000242551.2	POU5F1P6	-3.94	0.00011	0.0354	-0.37	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128284007	chr3:128674735~128677005:-
OV	cis	rs593531	0.531	rs662393	ENSG00000280269.1	AP000577.2	-3.94	0.00011	0.0354	-0.3	-0.25	Neuroticism;	chr11:74375263	chr11:74204869~74205746:+
OV	cis	rs2243480	1	rs6964245	ENSG00000273142.1	RP11-458F8.4	3.94	0.00011	0.0355	0.3	0.25	Diabetic kidney disease;	chr7:66253730	chr7:66902857~66906297:+
OV	cis	rs2243480	1	rs10807701	ENSG00000273142.1	RP11-458F8.4	3.94	0.00011	0.0355	0.3	0.25	Diabetic kidney disease;	chr7:66259699	chr7:66902857~66906297:+
OV	cis	rs2919917	0.617	rs4641056	ENSG00000254352.1	RP11-578O24.2	3.94	0.00011	0.0355	0.33	0.25	Lymphocyte counts;	chr8:78670261	chr8:78723796~78724136:-
OV	cis	rs7927771	1	rs2290850	ENSG00000271350.1	CTD-2384B9.1	-3.94	0.00011	0.0355	-0.3	-0.25	Subjective well-being;	chr11:47786222	chr11:47041027~47041945:-
OV	cis	rs2933343	0.951	rs789217	ENSG00000231305.3	RP11-723O4.2	3.94	0.00011	0.0355	0.32	0.25	IgG glycosylation;	chr3:128874358	chr3:128861313~128871540:-
OV	cis	rs10486158	0.779	rs3890981	ENSG00000234141.1	AC009473.1	-3.94	0.00011	0.0355	-0.38	-0.25	Bipolar disorder and schizophrenia;	chr7:7362041	chr7:7949853~7950709:-
OV	cis	rs9880211	0.752	rs9838884	ENSG00000239213.4	NCK1-AS1	3.94	0.00011	0.0355	0.33	0.25	Height;Body mass index;	chr3:136736862	chr3:136841726~136862054:-
OV	cis	rs9880211	0.8	rs9873536	ENSG00000239213.4	NCK1-AS1	3.94	0.00011	0.0355	0.33	0.25	Height;Body mass index;	chr3:136755425	chr3:136841726~136862054:-
OV	cis	rs6496932	0.563	rs2344083	ENSG00000229212.6	RP11-561C5.4	-3.94	0.00011	0.0355	-0.3	-0.25	Central corneal thickness;Corneal structure;	chr15:85354201	chr15:85205440~85234795:-
OV	cis	rs2811474	0.535	rs2999045	ENSG00000277250.1	Metazoa_SRP	3.94	0.00011	0.0355	0.3	0.25	Schizophrenia;	chr3:128146554	chr3:128673681~128674021:-
OV	cis	rs35110281	0.693	rs2251253	ENSG00000213440.2	H2AFZP1	3.94	0.00011	0.0355	0.28	0.25	Mean corpuscular volume;	chr21:43672376	chr21:44046347~44047041:-
OV	cis	rs35110281	0.693	rs2838345	ENSG00000213440.2	H2AFZP1	3.94	0.00011	0.0355	0.28	0.25	Mean corpuscular volume;	chr21:43672834	chr21:44046347~44047041:-
OV	cis	rs9393777	0.92	rs13195040	ENSG00000243307.2	POM121L6P	3.94	0.00011	0.0355	0.43	0.25	Intelligence (multi-trait analysis);	chr6:27446145	chr6:26896952~26898777:+
OV	cis	rs858267	0.661	rs7786708	ENSG00000230658.1	KLHL7-AS1	-3.94	0.000111	0.0355	-0.69	-0.25	Blood protein levels;	chr7:23075797	chr7:23101228~23105703:-
OV	cis	rs774359	0.789	rs2477520	ENSG00000234676.1	IFT74-AS1	3.94	0.000111	0.0355	0.3	0.25	Amyotrophic lateral sclerosis;	chr9:27509872	chr9:26955780~26956295:-
OV	cis	rs9649213	0.574	rs7789440	ENSG00000223402.1	AC074121.4	-3.94	0.000111	0.0356	-0.3	-0.25	Prostate cancer (SNP x SNP interaction);	chr7:98259486	chr7:98478551~98479225:-
OV	cis	rs14027	0.883	rs1469755	ENSG00000279347.1	RP11-85I17.2	-3.94	0.000111	0.0356	-0.26	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119728107	chr8:119838736~119840385:-
OV	cis	rs14027	0.883	rs35449013	ENSG00000279347.1	RP11-85I17.2	-3.94	0.000111	0.0356	-0.26	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119729239	chr8:119838736~119840385:-
OV	cis	rs11903757	0.945	rs77282295	ENSG00000281467.1	Clostridiales-1	-3.94	0.000111	0.0356	-0.44	-0.25	Colorectal cancer;	chr2:191709580	chr2:191699476~191699631:-
OV	cis	rs881375	0.967	rs2416805	ENSG00000226752.6	PSMD5-AS1	-3.93	0.000111	0.0356	-0.28	-0.25	Rheumatoid arthritis;	chr9:120914204	chr9:120824828~120854385:+
OV	cis	rs881375	0.967	rs758959	ENSG00000226752.6	PSMD5-AS1	-3.93	0.000111	0.0356	-0.28	-0.25	Rheumatoid arthritis;	chr9:120914421	chr9:120824828~120854385:+
OV	cis	rs881375	0.967	rs876445	ENSG00000226752.6	PSMD5-AS1	-3.93	0.000111	0.0356	-0.28	-0.25	Rheumatoid arthritis;	chr9:120914824	chr9:120824828~120854385:+
OV	cis	rs881375	0.967	rs2109895	ENSG00000226752.6	PSMD5-AS1	-3.93	0.000111	0.0356	-0.28	-0.25	Rheumatoid arthritis;	chr9:120915549	chr9:120824828~120854385:+
OV	cis	rs9880211	0.752	rs9847427	ENSG00000239213.4	NCK1-AS1	3.93	0.000111	0.0356	0.33	0.25	Height;Body mass index;	chr3:136632708	chr3:136841726~136862054:-
OV	cis	rs9880211	0.752	rs9881831	ENSG00000239213.4	NCK1-AS1	3.93	0.000111	0.0356	0.33	0.25	Height;Body mass index;	chr3:136670876	chr3:136841726~136862054:-
OV	cis	rs10097215	1	rs10097215	ENSG00000253982.1	CTD-2336O2.1	3.93	0.000111	0.0356	0.39	0.25	Plasma omega-6 polyunsaturated fatty acid levels (gamma-linolenic acid);	chr8:2649382	chr8:1761990~1764502:-
OV	cis	rs12480328	1	rs2870025	ENSG00000233077.1	LINC01271	3.93	0.000111	0.0356	0.53	0.25	Prostate cancer;	chr20:50922521	chr20:50310711~50321342:-
OV	cis	rs1580019	0.587	rs7805311	ENSG00000231952.3	DPY19L1P2	3.93	0.000111	0.0356	0.32	0.25	Cognitive ability;	chr7:32518690	chr7:32812757~32838570:+
OV	cis	rs4842666	0.915	rs73437338	ENSG00000258302.2	RP11-981P6.1	3.93	0.000111	0.0356	0.35	0.25	Blood pressure;	chr12:89660842	chr12:89561129~89594878:+
OV	cis	rs992969	0.524	rs10124250	ENSG00000231967.1	RP11-12D24.6	-3.93	0.000111	0.0356	-0.29	-0.25	Asthma;	chr9:6161686	chr9:5356312~5356525:-
OV	cis	rs7927771	0.524	rs1563821	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Subjective well-being;	chr11:47735016	chr11:47614898~47614994:-
OV	cis	rs7927771	0.507	rs10838754	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Subjective well-being;	chr11:47736980	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs6485773	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Subjective well-being;	chr11:47741957	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs7932703	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Subjective well-being;	chr11:47748384	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs10838758	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Subjective well-being;	chr11:47749924	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs7929014	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Subjective well-being;	chr11:47754731	chr11:47614898~47614994:-
OV	cis	rs7927771	0.542	rs7108479	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Subjective well-being;	chr11:47759908	chr11:47614898~47614994:-
OV	cis	rs7927771	0.507	rs10838759	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Subjective well-being;	chr11:47763795	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs10838760	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Subjective well-being;	chr11:47764862	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs7111576	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Subjective well-being;	chr11:47765893	chr11:47614898~47614994:-
OV	cis	rs7927771	0.507	rs7111606	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Subjective well-being;	chr11:47765986	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs11039377	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Subjective well-being;	chr11:47768224	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs61895760	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Subjective well-being;	chr11:47772986	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs10838763	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Subjective well-being;	chr11:47773250	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs7101597	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Subjective well-being;	chr11:47776365	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs11039392	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Subjective well-being;	chr11:47777201	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs7114813	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Subjective well-being;	chr11:47779549	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs12226431	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Subjective well-being;	chr11:47784304	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs754434	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Subjective well-being;	chr11:47792728	chr11:47614898~47614994:-
OV	cis	rs7927771	0.542	rs3886262	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Subjective well-being;	chr11:47795458	chr11:47614898~47614994:-
OV	cis	rs7124681	0.565	rs2904127	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47795738	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs11039402	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Subjective well-being;	chr11:47804538	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs6485786	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Subjective well-being;	chr11:47815856	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs11039415	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Subjective well-being;	chr11:47824262	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs7110300	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Subjective well-being;	chr11:47826890	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs9633830	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Subjective well-being;	chr11:47827918	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs11039419	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Subjective well-being;	chr11:47829802	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs7123952	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Subjective well-being;	chr11:47830505	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs10838775	ENSG00000280615.1	Y_RNA	3.93	0.000111	0.0356	0.27	0.25	Subjective well-being;	chr11:47834830	chr11:47614898~47614994:-
OV	cis	rs875971	0.638	rs7793569	ENSG00000237310.1	GS1-124K5.4	-3.93	0.000111	0.0356	-0.26	-0.25	Aortic root size;	chr7:66651646	chr7:66493706~66495474:+
OV	cis	rs1538970	0.81	rs12067642	ENSG00000280836.1	AL355480.1	-3.93	0.000111	0.0356	-0.36	-0.25	Platelet count;	chr1:45461845	chr1:45581219~45581321:-
OV	cis	rs514406	0.505	rs440871	ENSG00000206627.1	RNU6-969P	3.93	0.000111	0.0356	0.27	0.25	Monocyte count;	chr1:52707380	chr1:52805108~52805212:-
OV	cis	rs1707322	0.721	rs7519900	ENSG00000234329.1	RP11-767N6.2	3.93	0.000111	0.0356	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45769275	chr1:45651039~45651826:-
OV	cis	rs7932354	0.528	rs4752967	ENSG00000271543.1	RP11-692M12.5	3.93	0.000111	0.0356	0.32	0.25	Bone mineral density (hip);Bone mineral density;	chr11:47147825	chr11:47796169~47796379:+
OV	cis	rs4934494	0.768	rs17125834	ENSG00000240996.1	RP11-80H5.7	-3.93	0.000111	0.0357	-0.37	-0.25	Red blood cell count;	chr10:89673405	chr10:89694295~89697928:-
OV	cis	rs4934494	0.768	rs12571918	ENSG00000240996.1	RP11-80H5.7	-3.93	0.000111	0.0357	-0.37	-0.25	Red blood cell count;	chr10:89674920	chr10:89694295~89697928:-
OV	cis	rs4934494	0.768	rs12776306	ENSG00000240996.1	RP11-80H5.7	-3.93	0.000111	0.0357	-0.37	-0.25	Red blood cell count;	chr10:89676300	chr10:89694295~89697928:-
OV	cis	rs4934494	0.768	rs7078321	ENSG00000240996.1	RP11-80H5.7	-3.93	0.000111	0.0357	-0.37	-0.25	Red blood cell count;	chr10:89678341	chr10:89694295~89697928:-
OV	cis	rs4934494	0.768	rs34379399	ENSG00000240996.1	RP11-80H5.7	-3.93	0.000111	0.0357	-0.37	-0.25	Red blood cell count;	chr10:89683526	chr10:89694295~89697928:-
OV	cis	rs2286503	0.78	rs1304431	ENSG00000221740.1	SNORD93	3.93	0.000111	0.0357	0.32	0.25	Fibrinogen;	chr7:22825793	chr7:22856613~22856686:+
OV	cis	rs2070488	0.804	rs13059256	ENSG00000229589.1	ACVR2B-AS1	3.93	0.000111	0.0357	0.28	0.25	Electrocardiographic conduction measures;	chr3:38462824	chr3:38451027~38454820:-
OV	cis	rs45509595	0.822	rs200484	ENSG00000226314.6	ZNF192P1	-3.93	0.000111	0.0357	-0.48	-0.25	Breast cancer;	chr6:27807896	chr6:28161781~28169594:+
OV	cis	rs45509595	0.841	rs9368531	ENSG00000226314.6	ZNF192P1	-3.93	0.000111	0.0357	-0.48	-0.25	Breast cancer;	chr6:27814094	chr6:28161781~28169594:+
OV	cis	rs45509595	0.749	rs401763	ENSG00000226314.6	ZNF192P1	-3.93	0.000111	0.0357	-0.48	-0.25	Breast cancer;	chr6:27814750	chr6:28161781~28169594:+
OV	cis	rs45509595	0.659	rs390764	ENSG00000226314.6	ZNF192P1	-3.93	0.000111	0.0357	-0.48	-0.25	Breast cancer;	chr6:27814757	chr6:28161781~28169594:+
OV	cis	rs45509595	0.841	rs401754	ENSG00000226314.6	ZNF192P1	-3.93	0.000111	0.0357	-0.48	-0.25	Breast cancer;	chr6:27814760	chr6:28161781~28169594:+
OV	cis	rs45509595	0.841	rs2747054	ENSG00000226314.6	ZNF192P1	-3.93	0.000111	0.0357	-0.48	-0.25	Breast cancer;	chr6:27815581	chr6:28161781~28169594:+
OV	cis	rs45509595	0.841	rs200501	ENSG00000226314.6	ZNF192P1	-3.93	0.000111	0.0357	-0.48	-0.25	Breast cancer;	chr6:27821164	chr6:28161781~28169594:+
OV	cis	rs7968440	0.808	rs829112	ENSG00000272368.2	RP4-605O3.4	-3.93	0.000111	0.0357	-0.3	-0.25	Fibrinogen;	chr12:50813921	chr12:50112197~50165618:+
OV	cis	rs5015933	0.966	rs10986724	ENSG00000232630.1	PRPS1P2	3.93	0.000111	0.0357	0.26	0.25	Body mass index;	chr9:125369240	chr9:125150653~125151589:+
OV	cis	rs2070488	0.965	rs9877282	ENSG00000229589.1	ACVR2B-AS1	-3.93	0.000111	0.0357	-0.28	-0.25	Electrocardiographic conduction measures;	chr3:38499961	chr3:38451027~38454820:-
OV	cis	rs10992471	0.603	rs7864575	ENSG00000281156.1	MIR3651	-3.93	0.000111	0.0358	-0.29	-0.25	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92542365	chr9:92292458~92292547:-
OV	cis	rs295490	0.748	rs77423224	ENSG00000272656.1	RP11-219D15.3	3.93	0.000111	0.0358	0.52	0.25	PR interval in Tripanosoma cruzi seropositivity;	chr3:139384020	chr3:139349024~139349371:-
OV	cis	rs514406	0.798	rs4351588	ENSG00000206627.1	RNU6-969P	-3.93	0.000112	0.0358	-0.27	-0.25	Monocyte count;	chr1:52798154	chr1:52805108~52805212:-
OV	cis	rs7195386	0.783	rs11642328	ENSG00000261266.2	CTD-2196E14.5	-3.93	0.000112	0.0358	-0.29	-0.25	Obesity-related traits;Body mass index;	chr16:24529117	chr16:23687049~23687689:-
OV	cis	rs6959887	0.926	rs4723399	ENSG00000271122.1	RP11-379H18.1	-3.93	0.000112	0.0358	-0.32	-0.25	Birth weight;	chr7:35233504	chr7:35695214~35699413:+
OV	cis	rs9309473	0.606	rs6759452	ENSG00000163016.8	ALMS1P	3.93	0.000112	0.0358	0.33	0.25	Metabolite levels;	chr2:73651225	chr2:73644919~73685576:+
OV	cis	rs2243480	1	rs34136756	ENSG00000226824.5	RP4-756H11.3	-3.93	0.000112	0.0358	-0.4	-0.25	Diabetic kidney disease;	chr7:65916269	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs78803505	ENSG00000226824.5	RP4-756H11.3	-3.93	0.000112	0.0358	-0.4	-0.25	Diabetic kidney disease;	chr7:65917585	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs34933526	ENSG00000226824.5	RP4-756H11.3	-3.93	0.000112	0.0358	-0.4	-0.25	Diabetic kidney disease;	chr7:65918212	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs34577383	ENSG00000226824.5	RP4-756H11.3	-3.93	0.000112	0.0358	-0.4	-0.25	Diabetic kidney disease;	chr7:65920739	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs6949812	ENSG00000226824.5	RP4-756H11.3	-3.93	0.000112	0.0358	-0.4	-0.25	Diabetic kidney disease;	chr7:65922114	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs55895244	ENSG00000226824.5	RP4-756H11.3	-3.93	0.000112	0.0358	-0.4	-0.25	Diabetic kidney disease;	chr7:65922691	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs6970243	ENSG00000226824.5	RP4-756H11.3	-3.93	0.000112	0.0358	-0.4	-0.25	Diabetic kidney disease;	chr7:65923503	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs7794661	ENSG00000226824.5	RP4-756H11.3	-3.93	0.000112	0.0358	-0.4	-0.25	Diabetic kidney disease;	chr7:65924743	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs7795242	ENSG00000226824.5	RP4-756H11.3	-3.93	0.000112	0.0358	-0.4	-0.25	Diabetic kidney disease;	chr7:65925107	chr7:66654538~66669855:+
OV	cis	rs2243480	0.708	rs35310401	ENSG00000226824.5	RP4-756H11.3	-3.93	0.000112	0.0358	-0.4	-0.25	Diabetic kidney disease;	chr7:65925372	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs35058610	ENSG00000226824.5	RP4-756H11.3	-3.93	0.000112	0.0358	-0.4	-0.25	Diabetic kidney disease;	chr7:65925938	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs2177703	ENSG00000226824.5	RP4-756H11.3	-3.93	0.000112	0.0358	-0.4	-0.25	Diabetic kidney disease;	chr7:65926730	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs35432774	ENSG00000226824.5	RP4-756H11.3	-3.93	0.000112	0.0358	-0.4	-0.25	Diabetic kidney disease;	chr7:65928032	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs56985706	ENSG00000226824.5	RP4-756H11.3	-3.93	0.000112	0.0358	-0.4	-0.25	Diabetic kidney disease;	chr7:65929575	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs60683927	ENSG00000226824.5	RP4-756H11.3	-3.93	0.000112	0.0358	-0.4	-0.25	Diabetic kidney disease;	chr7:65929781	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs58062456	ENSG00000226824.5	RP4-756H11.3	-3.93	0.000112	0.0358	-0.4	-0.25	Diabetic kidney disease;	chr7:65929865	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs34529418	ENSG00000226824.5	RP4-756H11.3	-3.93	0.000112	0.0358	-0.4	-0.25	Diabetic kidney disease;	chr7:65938222	chr7:66654538~66669855:+
OV	cis	rs2243480	0.831	rs7806717	ENSG00000226824.5	RP4-756H11.3	3.93	0.000112	0.0358	0.4	0.25	Diabetic kidney disease;	chr7:65928187	chr7:66654538~66669855:+
OV	cis	rs6991838	0.806	rs17302392	ENSG00000272010.1	CTD-3025N20.3	3.93	0.000112	0.0358	0.31	0.25	Intelligence (multi-trait analysis);	chr8:65551073	chr8:65591850~65592472:-
OV	cis	rs7726839	0.54	rs72703095	ENSG00000271781.1	CTD-2589H19.6	-3.93	0.000112	0.0358	-0.38	-0.25	Obesity-related traits;	chr5:601674	chr5:675826~676616:+
OV	cis	rs7726839	0.54	rs3749618	ENSG00000271781.1	CTD-2589H19.6	-3.93	0.000112	0.0358	-0.38	-0.25	Obesity-related traits;	chr5:602535	chr5:675826~676616:+
OV	cis	rs7726839	0.54	rs11739847	ENSG00000271781.1	CTD-2589H19.6	-3.93	0.000112	0.0358	-0.38	-0.25	Obesity-related traits;	chr5:609546	chr5:675826~676616:+
OV	cis	rs875971	0.508	rs10950045	ENSG00000273024.4	INTS4P2	3.93	0.000112	0.0358	0.27	0.25	Aortic root size;	chr7:66601386	chr7:65647864~65715661:+
OV	cis	rs801193	0.839	rs6968619	ENSG00000273024.4	INTS4P2	3.93	0.000112	0.0358	0.27	0.25	Aortic root size;	chr7:66603880	chr7:65647864~65715661:+
OV	cis	rs801193	0.839	rs12534943	ENSG00000273024.4	INTS4P2	3.93	0.000112	0.0358	0.27	0.25	Aortic root size;	chr7:66605533	chr7:65647864~65715661:+
OV	cis	rs801193	0.805	rs12532355	ENSG00000273024.4	INTS4P2	3.93	0.000112	0.0358	0.27	0.25	Aortic root size;	chr7:66605597	chr7:65647864~65715661:+
OV	cis	rs830124	0.866	rs4760099	ENSG00000256811.1	RP11-7M8.2	3.93	0.000112	0.0358	0.37	0.25	Urinary metabolites;	chr12:121880817	chr12:121856259~121857059:+
OV	cis	rs1404100	0.531	rs1038271	ENSG00000249274.1	PDLIM1P4	3.93	0.000112	0.0359	0.29	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:99067399	chr3:98782188~98783193:+
OV	cis	rs10214930	0.697	rs12700819	ENSG00000235574.1	AC073150.6	-3.93	0.000112	0.0359	-0.3	-0.25	Hypospadias;	chr7:27560271	chr7:27491682~27492765:-
OV	cis	rs10214930	0.697	rs12670415	ENSG00000235574.1	AC073150.6	-3.93	0.000112	0.0359	-0.3	-0.25	Hypospadias;	chr7:27562604	chr7:27491682~27492765:-
OV	cis	rs10214930	0.624	rs6959126	ENSG00000235574.1	AC073150.6	-3.93	0.000112	0.0359	-0.3	-0.25	Hypospadias;	chr7:27564631	chr7:27491682~27492765:-
OV	cis	rs10214930	0.671	rs1005128	ENSG00000235574.1	AC073150.6	-3.93	0.000112	0.0359	-0.3	-0.25	Hypospadias;	chr7:27569057	chr7:27491682~27492765:-
OV	cis	rs10924970	0.967	rs4659721	ENSG00000236863.2	RPL23AP23	3.93	0.000112	0.0359	0.25	0.25	Asthma;	chr1:235263602	chr1:235295865~235296335:+
OV	cis	rs2999052	1	rs3122173	ENSG00000277250.1	Metazoa_SRP	3.93	0.000112	0.0359	0.31	0.25	Hypospadias;	chr3:128170444	chr3:128673681~128674021:-
OV	cis	rs897984	0.76	rs11076	ENSG00000260911.2	RP11-196G11.2	-3.93	0.000112	0.0359	-0.23	-0.25	Dementia with Lewy bodies;	chr16:30984207	chr16:31043150~31049868:+
OV	cis	rs875971	0.508	rs10242423	ENSG00000273024.4	INTS4P2	3.93	0.000112	0.0359	0.27	0.25	Aortic root size;	chr7:66594188	chr7:65647864~65715661:+
OV	cis	rs875971	0.508	rs10253883	ENSG00000273024.4	INTS4P2	3.93	0.000112	0.0359	0.27	0.25	Aortic root size;	chr7:66596151	chr7:65647864~65715661:+
OV	cis	rs4664293	0.625	rs3821300	ENSG00000226266.5	AC009961.3	3.93	0.000112	0.0359	0.29	0.25	Monocyte percentage of white cells;	chr2:159710719	chr2:159670708~159712435:-
OV	cis	rs4665809	0.878	rs6720312	ENSG00000231655.1	AC011742.3	-3.93	0.000112	0.0359	-0.39	-0.25	Gut microbiome composition (summer);	chr2:26142065	chr2:26140263~26141264:-
OV	cis	rs732765	0.734	rs2270425	ENSG00000258439.1	RP11-173A8.2	3.93	0.000112	0.0359	0.33	0.25	Non-small cell lung cancer;	chr14:74713031	chr14:74658049~74658590:+
OV	cis	rs638893	0.636	rs1784295	ENSG00000278376.1	RP11-158I9.8	-3.93	0.000112	0.0359	-0.35	-0.25	Vitiligo;	chr11:118790223	chr11:118791254~118793137:+
OV	cis	rs9393777	0.92	rs34150729	ENSG00000280107.1	AL022393.9	-3.93	0.000112	0.036	-0.51	-0.25	Intelligence (multi-trait analysis);	chr6:27420975	chr6:28170845~28172521:+
OV	cis	rs9393777	0.92	rs13191227	ENSG00000280107.1	AL022393.9	-3.93	0.000112	0.036	-0.51	-0.25	Intelligence (multi-trait analysis);	chr6:27422336	chr6:28170845~28172521:+
OV	cis	rs7267979	1	rs3761117	ENSG00000274973.1	RP13-401N8.7	3.93	0.000112	0.036	0.29	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25407434	chr20:25845497~25845862:+
OV	cis	rs7267979	0.966	rs8123949	ENSG00000274973.1	RP13-401N8.7	3.93	0.000112	0.036	0.29	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25407497	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs2184000	ENSG00000274973.1	RP13-401N8.7	3.93	0.000112	0.036	0.29	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25415242	chr20:25845497~25845862:+
OV	cis	rs11096990	0.964	rs6831700	ENSG00000249207.1	RP11-360F5.1	-3.93	0.000112	0.036	-0.28	-0.25	Cognitive function;	chr4:39255344	chr4:39112677~39126818:-
OV	cis	rs7124681	0.585	rs10838773	ENSG00000280615.1	Y_RNA	3.93	0.000112	0.036	0.27	0.25	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47812794	chr11:47614898~47614994:-
OV	cis	rs1113500	0.897	rs2336127	ENSG00000226822.1	RP11-356N1.2	3.93	0.000112	0.036	0.31	0.25	Growth-regulated protein alpha levels;	chr1:108098248	chr1:108071482~108074519:+
OV	cis	rs875971	0.862	rs10276077	ENSG00000237310.1	GS1-124K5.4	-3.93	0.000112	0.036	-0.25	-0.25	Aortic root size;	chr7:66263424	chr7:66493706~66495474:+
OV	cis	rs7927771	0.965	rs17788930	ENSG00000271350.1	CTD-2384B9.1	-3.93	0.000112	0.036	-0.3	-0.25	Subjective well-being;	chr11:47731223	chr11:47041027~47041945:-
OV	cis	rs6723108	0.604	rs1374291	ENSG00000224043.6	CCNT2-AS1	-3.93	0.000112	0.036	-0.3	-0.25	Type 2 diabetes;	chr2:134896768	chr2:134735464~134918710:-
OV	cis	rs11105298	0.891	rs11105309	ENSG00000257194.2	RP11-567C2.1	-3.93	0.000113	0.036	-0.37	-0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89516073	chr12:90107739~90112779:+
OV	cis	rs7429990	0.774	rs3772402	ENSG00000229759.1	MRPS18AP1	-3.93	0.000113	0.036	-0.26	-0.25	Educational attainment (years of education);	chr3:47574661	chr3:48256350~48256938:-
OV	cis	rs7429990	0.833	rs3755637	ENSG00000229759.1	MRPS18AP1	-3.93	0.000113	0.036	-0.26	-0.25	Educational attainment (years of education);	chr3:47580720	chr3:48256350~48256938:-
OV	cis	rs2348418	0.639	rs61301264	ENSG00000247934.4	RP11-967K21.1	-3.93	0.000113	0.0361	-0.25	-0.25	Lung function (FEV1);Lung function (FVC);	chr12:28112922	chr12:28163298~28190738:-
OV	cis	rs875971	0.66	rs801193	ENSG00000237310.1	GS1-124K5.4	-3.93	0.000113	0.0361	-0.26	-0.25	Aortic root size;	chr7:66565625	chr7:66493706~66495474:+
OV	cis	rs694739	0.628	rs508168	ENSG00000236935.1	AP003774.1	3.93	0.000113	0.0361	0.31	0.25	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64367963	chr11:64325050~64329504:-
OV	cis	rs694739	0.595	rs11606015	ENSG00000236935.1	AP003774.1	3.93	0.000113	0.0361	0.31	0.25	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64369405	chr11:64325050~64329504:-
OV	cis	rs694739	0.628	rs11606081	ENSG00000236935.1	AP003774.1	3.93	0.000113	0.0361	0.31	0.25	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64370403	chr11:64325050~64329504:-
OV	cis	rs34119086	1	rs34119086	ENSG00000280107.1	AL022393.9	-3.93	0.000113	0.0361	-0.6	-0.25	Breast cancer;	chr6:28594471	chr6:28170845~28172521:+
OV	cis	rs354033	0.837	rs4727075	ENSG00000280992.1	AC004932.1	3.93	0.000113	0.0361	0.28	0.25	Multiple sclerosis;	chr7:149490647	chr7:149541747~149541846:-
OV	cis	rs7932354	0.528	rs12224096	ENSG00000271543.1	RP11-692M12.5	3.93	0.000113	0.0361	0.32	0.25	Bone mineral density (hip);Bone mineral density;	chr11:47152810	chr11:47796169~47796379:+
OV	cis	rs2348418	0.639	rs2347595	ENSG00000247934.4	RP11-967K21.1	-3.93	0.000113	0.0361	-0.26	-0.25	Lung function (FEV1);Lung function (FVC);	chr12:28109947	chr12:28163298~28190738:-
OV	cis	rs13113518	0.513	rs13132085	ENSG00000249700.7	SRD5A3-AS1	-3.93	0.000113	0.0361	-0.31	-0.25	Height;	chr4:55593918	chr4:55363971~55395847:-
OV	cis	rs9733	0.818	rs6694531	ENSG00000277452.1	Metazoa_SRP	-3.93	0.000113	0.0361	-0.27	-0.25	Tonsillectomy;	chr1:150711036	chr1:150566562~150566860:-
OV	cis	rs9733	0.818	rs10888388	ENSG00000277452.1	Metazoa_SRP	-3.93	0.000113	0.0361	-0.27	-0.25	Tonsillectomy;	chr1:150714820	chr1:150566562~150566860:-
OV	cis	rs9733	0.818	rs12130363	ENSG00000277452.1	Metazoa_SRP	-3.93	0.000113	0.0361	-0.27	-0.25	Tonsillectomy;	chr1:150716120	chr1:150566562~150566860:-
OV	cis	rs62027291	0.898	rs17465755	ENSG00000230459.3	RP11-741G21.1	-3.93	0.000113	0.0361	-0.34	-0.25	Plateletcrit;	chr15:77015411	chr15:77278465~77278774:+
OV	cis	rs801193	0.66	rs2659914	ENSG00000237310.1	GS1-124K5.4	3.93	0.000113	0.0361	0.26	0.25	Aortic root size;	chr7:66691927	chr7:66493706~66495474:+
OV	cis	rs514406	0.798	rs575138	ENSG00000206627.1	RNU6-969P	3.93	0.000113	0.0361	0.26	0.25	Monocyte count;	chr1:52862722	chr1:52805108~52805212:-
OV	cis	rs7580658	0.68	rs2069931	ENSG00000236682.1	AC068282.3	-3.93	0.000113	0.0361	-0.35	-0.25	Protein C levels;	chr2:127427993	chr2:127389130~127400580:+
OV	cis	rs853679	0.607	rs34950484	ENSG00000226314.6	ZNF192P1	-3.93	0.000113	0.0361	-0.57	-0.25	Depression;	chr6:28310911	chr6:28161781~28169594:+
OV	cis	rs853679	0.607	rs34661125	ENSG00000226314.6	ZNF192P1	-3.93	0.000113	0.0361	-0.57	-0.25	Depression;	chr6:28314117	chr6:28161781~28169594:+
OV	cis	rs853679	0.607	rs13190888	ENSG00000226314.6	ZNF192P1	-3.93	0.000113	0.0361	-0.57	-0.25	Depression;	chr6:28318208	chr6:28161781~28169594:+
OV	cis	rs34779708	0.766	rs16935949	ENSG00000230534.5	RP11-297A16.2	3.93	0.000113	0.0361	0.35	0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35262887	chr10:35098006~35127020:-
OV	cis	rs295490	0.831	rs57707457	ENSG00000272656.1	RP11-219D15.3	3.93	0.000113	0.0362	0.48	0.25	PR interval in Tripanosoma cruzi seropositivity;	chr3:139520256	chr3:139349024~139349371:-
OV	cis	rs2136690	0.51	rs4273327	ENSG00000243926.1	TIPARP-AS1	3.93	0.000113	0.0362	0.24	0.25	Breast cancer;	chr3:156654883	chr3:156671862~156674378:-
OV	cis	rs7302981	0.967	rs2178173	ENSG00000257298.1	RP3-405J10.3	-3.93	0.000113	0.0362	-0.23	-0.25	Systolic blood pressure;	chr12:50124146	chr12:50185580~50191363:-
OV	cis	rs7302981	0.967	rs7297421	ENSG00000257298.1	RP3-405J10.3	-3.93	0.000113	0.0362	-0.23	-0.25	Systolic blood pressure;	chr12:50125143	chr12:50185580~50191363:-
OV	cis	rs7302981	0.934	rs7279	ENSG00000257298.1	RP3-405J10.3	-3.93	0.000113	0.0362	-0.23	-0.25	Systolic blood pressure;	chr12:50130164	chr12:50185580~50191363:-
OV	cis	rs7302981	0.934	rs7532	ENSG00000257298.1	RP3-405J10.3	-3.93	0.000113	0.0362	-0.23	-0.25	Systolic blood pressure;	chr12:50130181	chr12:50185580~50191363:-
OV	cis	rs10514805	0.557	rs77310289	ENSG00000234690.5	AC073283.4	-3.93	0.000113	0.0362	-0.46	-0.25	Electroencephalogram traits;	chr2:47498073	chr2:47192405~47345074:-
OV	cis	rs67311347	0.568	rs57287242	ENSG00000223797.4	ENTPD3-AS1	3.93	0.000113	0.0362	0.26	0.25	Renal cell carcinoma;	chr3:40294047	chr3:40313802~40453329:-
OV	cis	rs6025590	1	rs6025590	ENSG00000124097.7	HMGB1P1	-3.93	0.000113	0.0362	-0.33	-0.25	Obesity-related traits;	chr20:57495449	chr20:57488392~57489027:-
OV	cis	rs2239547	0.603	rs2276825	ENSG00000280003.1	RP11-330H6.6	3.93	0.000113	0.0362	0.32	0.25	Schizophrenia;	chr3:52852589	chr3:52217016~52219012:-
OV	cis	rs2239547	0.521	rs9682464	ENSG00000280003.1	RP11-330H6.6	3.93	0.000113	0.0362	0.32	0.25	Schizophrenia;	chr3:52854469	chr3:52217016~52219012:-
OV	cis	rs1329650	1	rs10881926	ENSG00000228701.1	TNKS2-AS1	-3.93	0.000113	0.0362	-0.29	-0.25	Smoking behavior;	chr10:91584497	chr10:91782839~91798291:-
OV	cis	rs7771547	0.755	rs6937430	ENSG00000240733.3	RN7SL502P	3.93	0.000113	0.0362	0.28	0.25	Platelet distribution width;	chr6:36634120	chr6:36450912~36451201:-
OV	cis	rs78663649	0.908	rs113779505	ENSG00000269480.1	CTD-3032J10.3	-3.93	0.000113	0.0362	-0.44	-0.25	White blood cell count;	chr19:16417171	chr19:17207138~17208010:-
OV	cis	rs4934494	0.768	rs58163515	ENSG00000240996.1	RP11-80H5.7	-3.93	0.000113	0.0362	-0.36	-0.25	Red blood cell count;	chr10:89637807	chr10:89694295~89697928:-
OV	cis	rs2070488	1	rs2276540	ENSG00000229589.1	ACVR2B-AS1	3.93	0.000113	0.0362	0.28	0.25	Electrocardiographic conduction measures;	chr3:38471016	chr3:38451027~38454820:-
OV	cis	rs73201462	1	rs2999069	ENSG00000242551.2	POU5F1P6	-3.93	0.000113	0.0362	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128252766	chr3:128674735~128677005:-
OV	cis	rs73201462	0.908	rs2955092	ENSG00000242551.2	POU5F1P6	-3.93	0.000113	0.0362	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128253685	chr3:128674735~128677005:-
OV	cis	rs73201462	0.908	rs2955094	ENSG00000242551.2	POU5F1P6	-3.93	0.000113	0.0362	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128258080	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2999068	ENSG00000242551.2	POU5F1P6	-3.93	0.000113	0.0362	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128259135	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2955097	ENSG00000242551.2	POU5F1P6	-3.93	0.000113	0.0362	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128259662	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2999067	ENSG00000242551.2	POU5F1P6	-3.93	0.000113	0.0362	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128259688	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2955099	ENSG00000242551.2	POU5F1P6	-3.93	0.000113	0.0362	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128260811	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2999066	ENSG00000242551.2	POU5F1P6	-3.93	0.000113	0.0362	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128261443	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2999065	ENSG00000242551.2	POU5F1P6	-3.93	0.000113	0.0362	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128262595	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2811545	ENSG00000242551.2	POU5F1P6	-3.93	0.000113	0.0362	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128264305	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2811544	ENSG00000242551.2	POU5F1P6	-3.93	0.000113	0.0362	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128264652	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2811543	ENSG00000242551.2	POU5F1P6	-3.93	0.000113	0.0362	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128264953	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2811542	ENSG00000242551.2	POU5F1P6	-3.93	0.000113	0.0362	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128264957	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2811541	ENSG00000242551.2	POU5F1P6	-3.93	0.000113	0.0362	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128265951	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2811540	ENSG00000242551.2	POU5F1P6	-3.93	0.000113	0.0362	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128266726	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2811538	ENSG00000242551.2	POU5F1P6	-3.93	0.000113	0.0362	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128267788	chr3:128674735~128677005:-
OV	cis	rs62184315	1	rs62184315	ENSG00000253559.1	OSGEPL1-AS1	-3.93	0.000113	0.0362	-0.34	-0.25	Alcohol dependence (age at onset);	chr2:189907219	chr2:189762704~189765556:+
OV	cis	rs4713118	0.955	rs9468206	ENSG00000226314.6	ZNF192P1	-3.93	0.000113	0.0362	-0.32	-0.25	Parkinson's disease;	chr6:27722674	chr6:28161781~28169594:+
OV	cis	rs2617170	0.885	rs7975996	ENSG00000245648.1	RP11-277P12.20	3.93	0.000113	0.0362	0.34	0.25	Behcet's disease;	chr12:10372324	chr12:10363769~10398506:+
OV	cis	rs7520050	0.966	rs4660321	ENSG00000280836.1	AL355480.1	3.93	0.000113	0.0362	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45901088	chr1:45581219~45581321:-
OV	cis	rs7520050	0.931	rs6698247	ENSG00000280836.1	AL355480.1	3.93	0.000113	0.0362	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45905814	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs6675946	ENSG00000280836.1	AL355480.1	3.93	0.000113	0.0362	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45906102	chr1:45581219~45581321:-
OV	cis	rs7520050	0.931	rs7526678	ENSG00000280836.1	AL355480.1	3.93	0.000113	0.0362	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45908487	chr1:45581219~45581321:-
OV	cis	rs7520050	0.931	rs6686134	ENSG00000280836.1	AL355480.1	3.93	0.000113	0.0362	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45912596	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs12564541	ENSG00000280836.1	AL355480.1	3.93	0.000113	0.0362	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45914565	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs61102033	ENSG00000280836.1	AL355480.1	3.93	0.000113	0.0362	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45916769	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs12405451	ENSG00000280836.1	AL355480.1	3.93	0.000113	0.0362	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45918654	chr1:45581219~45581321:-
OV	cis	rs7520050	0.931	rs11211224	ENSG00000280836.1	AL355480.1	3.93	0.000113	0.0362	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45918716	chr1:45581219~45581321:-
OV	cis	rs7520050	0.933	rs6656022	ENSG00000280836.1	AL355480.1	3.93	0.000113	0.0362	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45928643	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs4134386	ENSG00000280836.1	AL355480.1	3.93	0.000113	0.0362	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45929417	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs12561806	ENSG00000280836.1	AL355480.1	3.93	0.000113	0.0362	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45931104	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs6669522	ENSG00000280836.1	AL355480.1	3.93	0.000113	0.0362	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45932269	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs6677007	ENSG00000280836.1	AL355480.1	3.93	0.000113	0.0362	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45934918	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs4660898	ENSG00000280836.1	AL355480.1	3.93	0.000113	0.0362	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45936499	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs11211230	ENSG00000280836.1	AL355480.1	3.93	0.000113	0.0362	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45941095	chr1:45581219~45581321:-
OV	cis	rs7520050	0.931	rs35743647	ENSG00000280836.1	AL355480.1	3.93	0.000113	0.0362	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45941580	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs7522601	ENSG00000280836.1	AL355480.1	3.93	0.000113	0.0362	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45953349	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs10789487	ENSG00000280836.1	AL355480.1	3.93	0.000113	0.0362	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45954549	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs11211234	ENSG00000280836.1	AL355480.1	3.93	0.000113	0.0362	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45973115	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs11211241	ENSG00000280836.1	AL355480.1	3.93	0.000113	0.0362	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45987011	chr1:45581219~45581321:-
OV	cis	rs7520050	0.933	rs4504835	ENSG00000280836.1	AL355480.1	3.93	0.000113	0.0362	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45989899	chr1:45581219~45581321:-
OV	cis	rs7520050	0.902	rs4638056	ENSG00000280836.1	AL355480.1	3.93	0.000113	0.0362	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45992481	chr1:45581219~45581321:-
OV	cis	rs7520050	0.931	rs11576305	ENSG00000280836.1	AL355480.1	3.93	0.000113	0.0362	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45994374	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs7556615	ENSG00000280836.1	AL355480.1	3.93	0.000113	0.0362	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45995697	chr1:45581219~45581321:-
OV	cis	rs4296809	0.505	rs4492117	ENSG00000249779.1	RP11-447H19.3	-3.93	0.000113	0.0362	-0.46	-0.25	Brain structure;	chr5:44129275	chr5:43206709~43207811:+
OV	cis	rs2617170	0.885	rs7978962	ENSG00000256667.5	KLRAP1	3.93	0.000114	0.0363	0.26	0.25	Behcet's disease;	chr12:10372225	chr12:10588063~10599669:-
OV	cis	rs7520050	0.966	rs6429582	ENSG00000281133.1	AL355480.3	-3.93	0.000114	0.0363	-0.28	-0.25	Reticulocyte count;Red blood cell count;	chr1:45856171	chr1:45580892~45580996:-
OV	cis	rs7646881	0.5	rs2082838	ENSG00000272087.1	RP11-379F4.7	-3.93	0.000114	0.0363	-0.37	-0.25	Tetralogy of Fallot;	chr3:158588105	chr3:158693120~158693768:-
OV	cis	rs875971	0.545	rs1909508	ENSG00000273024.4	INTS4P2	-3.93	0.000114	0.0363	-0.31	-0.25	Aortic root size;	chr7:66301366	chr7:65647864~65715661:+
OV	cis	rs7811142	1	rs7783159	ENSG00000242294.5	STAG3L5P	3.93	0.000114	0.0363	0.27	0.25	Platelet count;	chr7:100419831	chr7:100336079~100351900:+
OV	cis	rs2286503	0.839	rs2270105	ENSG00000228649.7	AC005682.5	3.93	0.000114	0.0363	0.32	0.25	Fibrinogen;	chr7:22822848	chr7:22854178~22861579:+
OV	cis	rs3858145	0.588	rs61854833	ENSG00000233590.1	RP11-153K11.3	-3.93	0.000114	0.0363	-0.37	-0.25	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68277570	chr10:68233251~68242379:-
OV	cis	rs73201462	1	rs11715394	ENSG00000277250.1	Metazoa_SRP	3.93	0.000114	0.0363	0.42	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128174721	chr3:128673681~128674021:-
OV	cis	rs73201462	0.803	rs2811478	ENSG00000242551.2	POU5F1P6	3.93	0.000114	0.0363	0.38	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128180781	chr3:128674735~128677005:-
OV	cis	rs6071524	0.508	rs911721	ENSG00000277581.1	RP4-616B8.6	-3.93	0.000114	0.0363	-0.31	-0.25	Autism spectrum disorder or schizophrenia;	chr20:38771231	chr20:38962472~38962993:+
OV	cis	rs2021786	0.93	rs2328145	ENSG00000199719.1	RN7SKP74	3.93	0.000114	0.0363	0.28	0.25	Preschool internalizing problems;	chr20:17440580	chr20:18295143~18295451:-
OV	cis	rs2021786	0.93	rs2021787	ENSG00000199719.1	RN7SKP74	3.93	0.000114	0.0363	0.28	0.25	Preschool internalizing problems;	chr20:17441323	chr20:18295143~18295451:-
OV	cis	rs2021786	1	rs2021786	ENSG00000199719.1	RN7SKP74	3.93	0.000114	0.0363	0.28	0.25	Preschool internalizing problems;	chr20:17441333	chr20:18295143~18295451:-
OV	cis	rs2021786	0.965	rs2021785	ENSG00000199719.1	RN7SKP74	3.93	0.000114	0.0363	0.28	0.25	Preschool internalizing problems;	chr20:17441418	chr20:18295143~18295451:-
OV	cis	rs2021786	0.965	rs6034825	ENSG00000199719.1	RN7SKP74	3.93	0.000114	0.0363	0.28	0.25	Preschool internalizing problems;	chr20:17441811	chr20:18295143~18295451:-
OV	cis	rs2021786	0.965	rs6034826	ENSG00000199719.1	RN7SKP74	3.93	0.000114	0.0363	0.28	0.25	Preschool internalizing problems;	chr20:17442062	chr20:18295143~18295451:-
OV	cis	rs2021786	0.965	rs6034827	ENSG00000199719.1	RN7SKP74	3.93	0.000114	0.0363	0.28	0.25	Preschool internalizing problems;	chr20:17442163	chr20:18295143~18295451:-
OV	cis	rs2021786	0.965	rs2269017	ENSG00000199719.1	RN7SKP74	3.93	0.000114	0.0363	0.28	0.25	Preschool internalizing problems;	chr20:17444348	chr20:18295143~18295451:-
OV	cis	rs2021786	0.965	rs1010291	ENSG00000199719.1	RN7SKP74	3.93	0.000114	0.0363	0.28	0.25	Preschool internalizing problems;	chr20:17446042	chr20:18295143~18295451:-
OV	cis	rs2021786	0.965	rs2269020	ENSG00000199719.1	RN7SKP74	3.93	0.000114	0.0363	0.28	0.25	Preschool internalizing problems;	chr20:17446584	chr20:18295143~18295451:-
OV	cis	rs2021786	0.897	rs2300925	ENSG00000199719.1	RN7SKP74	3.93	0.000114	0.0363	0.28	0.25	Preschool internalizing problems;	chr20:17446706	chr20:18295143~18295451:-
OV	cis	rs2021786	0.965	rs2300926	ENSG00000199719.1	RN7SKP74	3.93	0.000114	0.0363	0.28	0.25	Preschool internalizing problems;	chr20:17447082	chr20:18295143~18295451:-
OV	cis	rs2021786	0.965	rs12625275	ENSG00000199719.1	RN7SKP74	3.93	0.000114	0.0363	0.28	0.25	Preschool internalizing problems;	chr20:17447432	chr20:18295143~18295451:-
OV	cis	rs2021786	0.93	rs2328146	ENSG00000199719.1	RN7SKP74	3.93	0.000114	0.0363	0.28	0.25	Preschool internalizing problems;	chr20:17447943	chr20:18295143~18295451:-
OV	cis	rs2021786	0.965	rs2328147	ENSG00000199719.1	RN7SKP74	3.93	0.000114	0.0363	0.28	0.25	Preschool internalizing problems;	chr20:17448923	chr20:18295143~18295451:-
OV	cis	rs2021786	0.965	rs2876457	ENSG00000199719.1	RN7SKP74	3.93	0.000114	0.0363	0.28	0.25	Preschool internalizing problems;	chr20:17448993	chr20:18295143~18295451:-
OV	cis	rs2021786	0.897	rs2328148	ENSG00000199719.1	RN7SKP74	3.93	0.000114	0.0363	0.28	0.25	Preschool internalizing problems;	chr20:17449008	chr20:18295143~18295451:-
OV	cis	rs2021786	0.965	rs4450680	ENSG00000199719.1	RN7SKP74	3.93	0.000114	0.0363	0.28	0.25	Preschool internalizing problems;	chr20:17449131	chr20:18295143~18295451:-
OV	cis	rs2021786	0.965	rs6131953	ENSG00000199719.1	RN7SKP74	3.93	0.000114	0.0363	0.28	0.25	Preschool internalizing problems;	chr20:17449207	chr20:18295143~18295451:-
OV	cis	rs2021786	0.965	rs6131954	ENSG00000199719.1	RN7SKP74	3.93	0.000114	0.0363	0.28	0.25	Preschool internalizing problems;	chr20:17449268	chr20:18295143~18295451:-
OV	cis	rs2021786	0.965	rs6131955	ENSG00000199719.1	RN7SKP74	3.93	0.000114	0.0363	0.28	0.25	Preschool internalizing problems;	chr20:17449348	chr20:18295143~18295451:-
OV	cis	rs11992162	0.636	rs11250182	ENSG00000270154.1	RP11-419I17.1	-3.93	0.000114	0.0363	-0.26	-0.25	Monocyte count;	chr8:11950067	chr8:12476462~12477122:+
OV	cis	rs2070488	1	rs6772046	ENSG00000229589.1	ACVR2B-AS1	3.93	0.000114	0.0363	0.28	0.25	Electrocardiographic conduction measures;	chr3:38438169	chr3:38451027~38454820:-
OV	cis	rs2070488	0.965	rs7372386	ENSG00000229589.1	ACVR2B-AS1	3.93	0.000114	0.0363	0.28	0.25	Electrocardiographic conduction measures;	chr3:38442684	chr3:38451027~38454820:-
OV	cis	rs7646881	0.544	rs59973861	ENSG00000272440.1	RP11-379F4.6	3.93	0.000114	0.0363	0.39	0.25	Tetralogy of Fallot;	chr3:158570314	chr3:158695367~158695581:+
OV	cis	rs7588746	0.621	rs10497859	ENSG00000232732.8	AC073043.1	3.93	0.000114	0.0363	0.31	0.25	Bipolar disorder lithium response (continuous) or schizophrenia;	chr2:200279723	chr2:199867396~199911159:-
OV	cis	rs853679	0.882	rs9393908	ENSG00000219392.1	RP1-265C24.5	-3.93	0.000114	0.0364	-0.45	-0.25	Depression;	chr6:28223052	chr6:28115628~28116551:+
OV	cis	rs853679	0.882	rs9366717	ENSG00000219392.1	RP1-265C24.5	-3.93	0.000114	0.0364	-0.45	-0.25	Depression;	chr6:28223279	chr6:28115628~28116551:+
OV	cis	rs6101567	0.623	rs4810262	ENSG00000261431.1	RP4-616B8.4	3.93	0.000114	0.0364	0.25	0.25	Nose size;	chr20:39335078	chr20:38961925~38962111:-
OV	cis	rs875971	0.862	rs2460432	ENSG00000237310.1	GS1-124K5.4	-3.93	0.000114	0.0364	-0.25	-0.25	Aortic root size;	chr7:66089398	chr7:66493706~66495474:+
OV	cis	rs78545713	0.536	rs11755618	ENSG00000241549.7	GUSBP2	3.93	0.000114	0.0364	0.41	0.25	Iron status biomarkers (total iron binding capacity);	chr6:26215574	chr6:26871484~26956554:-
OV	cis	rs875971	0.66	rs801193	ENSG00000224316.1	RP11-479O9.2	-3.93	0.000114	0.0364	-0.27	-0.25	Aortic root size;	chr7:66565625	chr7:65773620~65802067:+
OV	cis	rs11159086	0.941	rs11846588	ENSG00000270000.1	RP3-449M8.9	3.93	0.000114	0.0364	0.41	0.25	Advanced glycation end-product levels;	chr14:74505398	chr14:74471930~74472360:-
OV	cis	rs41271951	0.518	rs72696901	ENSG00000223945.2	RP11-458I7.1	-3.93	0.000114	0.0364	-0.43	-0.25	Blood protein levels;	chr1:150453647	chr1:150053864~150055034:+
OV	cis	rs7429990	0.864	rs883663	ENSG00000229759.1	MRPS18AP1	-3.93	0.000114	0.0364	-0.27	-0.25	Educational attainment (years of education);	chr3:47619306	chr3:48256350~48256938:-
OV	cis	rs13191038	1	rs13191038	ENSG00000280107.1	AL022393.9	-3.93	0.000114	0.0364	-0.6	-0.25	Urinary tract infection frequency;	chr6:28515140	chr6:28170845~28172521:+
OV	cis	rs10829156	0.947	rs7081435	ENSG00000225527.1	RP11-383B4.4	-3.93	0.000114	0.0364	-0.34	-0.25	Sudden cardiac arrest;	chr10:18667411	chr10:18531849~18533336:-
OV	cis	rs1075265	0.756	rs698854	ENSG00000233266.1	HMGB1P31	3.93	0.000114	0.0364	0.31	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53826784	chr2:54051334~54051760:+
OV	cis	rs6429082	0.511	rs12748957	ENSG00000236863.2	RPL23AP23	3.93	0.000114	0.0364	0.25	0.25	Adiposity;	chr1:235262818	chr1:235295865~235296335:+
OV	cis	rs9425326	0.568	rs9425323	ENSG00000232860.6	SMG7-AS1	-3.93	0.000114	0.0364	-0.41	-0.25	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr1:183865142	chr1:183460874~183472265:-
OV	cis	rs4948102	0.642	rs766333	ENSG00000273720.1	RP11-613E4.4	-3.93	0.000114	0.0364	-0.29	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56059011	chr7:55743073~55743457:+
OV	cis	rs4927850	0.881	rs7630489	ENSG00000229178.1	AC069513.4	-3.93	0.000114	0.0364	-0.3	-0.25	Pancreatic cancer;	chr3:196026530	chr3:195655565~195657927:-
OV	cis	rs4927850	1	rs7627868	ENSG00000229178.1	AC069513.4	-3.93	0.000114	0.0364	-0.3	-0.25	Pancreatic cancer;	chr3:196026602	chr3:195655565~195657927:-
OV	cis	rs4591358	0.651	rs66489016	ENSG00000223466.1	AC064834.2	3.93	0.000114	0.0364	0.29	0.25	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195431900	chr2:195533035~195538681:+
OV	cis	rs62445005	1	rs62445005	ENSG00000211698.2	TRGV4	3.93	0.000114	0.0364	0.32	0.25	Shingles;	chr7:38346957	chr7:38353715~38354517:-
OV	cis	rs682331	0.503	rs9425339	ENSG00000231084.2	CTA-253N17.1	-3.93	0.000114	0.0364	-0.29	-0.25	Obesity-related traits;	chr1:184678248	chr1:185171335~185171710:-
OV	cis	rs11951515	0.738	rs10805673	ENSG00000278487.1	RP11-447H19.4	-3.93	0.000114	0.0364	-0.29	-0.25	Metabolite levels  (X-11787);	chr5:43347921	chr5:43143362~43143514:-
OV	cis	rs6723108	0.627	rs766270	ENSG00000224043.6	CCNT2-AS1	-3.93	0.000114	0.0364	-0.3	-0.25	Type 2 diabetes;	chr2:134909356	chr2:134735464~134918710:-
OV	cis	rs897984	0.609	rs11862744	ENSG00000232748.3	RP11-196G11.6	-3.93	0.000114	0.0365	-0.27	-0.25	Dementia with Lewy bodies;	chr16:31046479	chr16:31056460~31062803:+
OV	cis	rs80168506	0.748	rs10173605	ENSG00000272519.1	RP11-105N14.2	3.93	0.000114	0.0365	0.39	0.25	Selective IgA deficiency;	chr2:213196288	chr2:213266995~213276152:-
OV	cis	rs889312	0.923	rs12697152	ENSG00000271828.1	CTD-2310F14.1	3.93	0.000114	0.0365	0.34	0.25	Breast cancer (early onset);Breast cancer;	chr5:56729889	chr5:56927874~56929573:+
OV	cis	rs6715284	0.892	rs72934991	ENSG00000183308.6	AC005037.3	3.93	0.000114	0.0365	0.58	0.25	Rheumatoid arthritis;	chr2:201352338	chr2:200963263~201009102:+
OV	cis	rs1499614	0.522	rs13247442	ENSG00000226824.5	RP4-756H11.3	-3.93	0.000115	0.0365	-0.49	-0.25	Gout;	chr7:66723871	chr7:66654538~66669855:+
OV	cis	rs7017914	0.69	rs2732127	ENSG00000223220.1	Y_RNA	3.93	0.000115	0.0365	0.27	0.25	Bone mineral density;	chr8:70984584	chr8:70780914~70781008:-
OV	cis	rs7555523	0.778	rs4233408	ENSG00000224358.1	RP11-466F5.8	-3.93	0.000115	0.0365	-0.34	-0.25	Glaucoma (high intraocular pressure);Intraocular pressure;	chr1:165743723	chr1:165768929~165775176:+
OV	cis	rs9847710	0.696	rs2244461	ENSG00000242142.1	SERBP1P3	3.93	0.000115	0.0365	0.31	0.25	Ulcerative colitis;	chr3:53021826	chr3:53064283~53065091:-
OV	cis	rs6715284	1	rs13398075	ENSG00000183308.6	AC005037.3	-3.93	0.000115	0.0365	-0.55	-0.25	Rheumatoid arthritis;	chr2:201511546	chr2:200963263~201009102:+
OV	cis	rs9309473	0.95	rs6546859	ENSG00000163016.8	ALMS1P	3.93	0.000115	0.0366	0.3	0.25	Metabolite levels;	chr2:73614928	chr2:73644919~73685576:+
OV	cis	rs11098499	0.863	rs6534139	ENSG00000245958.5	RP11-33B1.1	3.93	0.000115	0.0366	0.3	0.25	Corneal astigmatism;	chr4:119528301	chr4:119454791~119552025:+
OV	cis	rs2834288	0.5	rs2834305	ENSG00000273102.1	AP000569.9	3.93	0.000115	0.0366	0.26	0.25	Gut microbiota (bacterial taxa);	chr21:33955321	chr21:33967101~33968573:-
OV	cis	rs2834288	0.5	rs7277248	ENSG00000273102.1	AP000569.9	3.93	0.000115	0.0366	0.26	0.25	Gut microbiota (bacterial taxa);	chr21:33957948	chr21:33967101~33968573:-
OV	cis	rs2574704	0.851	rs2574720	ENSG00000251774.1	RNU6-377P	-3.93	0.000115	0.0366	-0.24	-0.25	Body mass index;	chr3:11618938	chr3:12514706~12514807:+
OV	cis	rs7727544	0.684	rs274567	ENSG00000233006.5	AC034220.3	-3.93	0.000115	0.0366	-0.26	-0.25	Blood metabolite levels;	chr5:132378717	chr5:132311285~132369916:-
OV	cis	rs4845570	0.92	rs1196456	ENSG00000238711.1	RNY4P25	3.93	0.000115	0.0366	0.33	0.25	Coronary artery disease;	chr1:151764873	chr1:151439000~151439095:+
OV	cis	rs2070488	0.804	rs1817364	ENSG00000229589.1	ACVR2B-AS1	3.93	0.000115	0.0366	0.28	0.25	Electrocardiographic conduction measures;	chr3:38433022	chr3:38451027~38454820:-
OV	cis	rs2070488	0.804	rs13063978	ENSG00000229589.1	ACVR2B-AS1	3.93	0.000115	0.0366	0.28	0.25	Electrocardiographic conduction measures;	chr3:38435047	chr3:38451027~38454820:-
OV	cis	rs2070488	0.766	rs4679050	ENSG00000229589.1	ACVR2B-AS1	3.93	0.000115	0.0366	0.28	0.25	Electrocardiographic conduction measures;	chr3:38440516	chr3:38451027~38454820:-
OV	cis	rs2070488	0.804	rs13100195	ENSG00000229589.1	ACVR2B-AS1	3.93	0.000115	0.0366	0.28	0.25	Electrocardiographic conduction measures;	chr3:38441048	chr3:38451027~38454820:-
OV	cis	rs7646881	0.544	rs58034569	ENSG00000272440.1	RP11-379F4.6	3.93	0.000115	0.0366	0.39	0.25	Tetralogy of Fallot;	chr3:158569900	chr3:158695367~158695581:+
OV	cis	rs7646881	0.544	rs16829116	ENSG00000272440.1	RP11-379F4.6	3.93	0.000115	0.0366	0.39	0.25	Tetralogy of Fallot;	chr3:158570012	chr3:158695367~158695581:+
OV	cis	rs8059260	0.673	rs74985998	ENSG00000274038.1	RP11-66H6.4	-3.93	0.000115	0.0366	-0.48	-0.25	Alcohol consumption over the past year;	chr16:10967208	chr16:11056556~11057034:+
OV	cis	rs4927850	1	rs7614767	ENSG00000229178.1	AC069513.4	-3.93	0.000115	0.0366	-0.3	-0.25	Pancreatic cancer;	chr3:196026580	chr3:195655565~195657927:-
OV	cis	rs7200543	1	rs4500751	ENSG00000270580.4	PKD1P6	3.93	0.000115	0.0366	0.26	0.25	Triglyceride levels;Body mass index;Metabolic traits;Glycerophospholipid levels;	chr16:15046354	chr16:15104723~15131601:-
OV	cis	rs7267979	0.966	rs4815425	ENSG00000274973.1	RP13-401N8.7	3.92	0.000115	0.0366	0.28	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25418240	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6050599	ENSG00000274973.1	RP13-401N8.7	3.92	0.000115	0.0366	0.28	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25419604	chr20:25845497~25845862:+
OV	cis	rs7267979	1	rs6050602	ENSG00000274973.1	RP13-401N8.7	3.92	0.000115	0.0366	0.28	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25420567	chr20:25845497~25845862:+
OV	cis	rs7554511	0.535	rs1995681	ENSG00000223774.4	RP11-307B6.3	-3.92	0.000115	0.0366	-0.28	-0.25	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201036678	chr1:201893842~201899978:+
OV	cis	rs1015213	0.609	rs115542794	ENSG00000253844.1	RP11-546K22.1	-3.92	0.000115	0.0367	-0.65	-0.25	Glaucoma (primary angle closure);	chr8:51955551	chr8:51961458~52022974:+
OV	cis	rs2999052	0.737	rs3849531	ENSG00000242551.2	POU5F1P6	3.92	0.000115	0.0367	0.32	0.25	Hypospadias;	chr3:128339774	chr3:128674735~128677005:-
OV	cis	rs34779708	0.733	rs3936503	ENSG00000230534.5	RP11-297A16.2	-3.92	0.000115	0.0367	-0.33	-0.25	Inflammatory bowel disease;Crohn's disease;	chr10:35260329	chr10:35098006~35127020:-
OV	cis	rs12073359	1	rs55647342	ENSG00000223945.2	RP11-458I7.1	-3.92	0.000115	0.0367	-0.38	-0.25	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150057947	chr1:150053864~150055034:+
OV	cis	rs12073359	1	rs11583720	ENSG00000223945.2	RP11-458I7.1	-3.92	0.000115	0.0367	-0.38	-0.25	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150071406	chr1:150053864~150055034:+
OV	cis	rs10992471	0.603	rs13301537	ENSG00000281156.1	MIR3651	-3.92	0.000115	0.0367	-0.3	-0.25	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92466765	chr9:92292458~92292547:-
OV	cis	rs10992471	0.603	rs10992349	ENSG00000281156.1	MIR3651	-3.92	0.000115	0.0367	-0.3	-0.25	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92471605	chr9:92292458~92292547:-
OV	cis	rs17711722	0.528	rs73138179	ENSG00000234500.1	GS1-124K5.10	-3.92	0.000115	0.0367	-0.2	-0.25	Calcium levels;	chr7:65829495	chr7:66511556~66545066:+
OV	cis	rs8062405	1	rs62036616	ENSG00000270424.1	RP11-1348G14.6	3.92	0.000115	0.0367	0.29	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28814986	chr16:28749959~28750595:-
OV	cis	rs4713118	0.696	rs2394002	ENSG00000226314.6	ZNF192P1	-3.92	0.000115	0.0367	-0.32	-0.25	Parkinson's disease;	chr6:27780236	chr6:28161781~28169594:+
OV	cis	rs720475	0.732	rs17195725	ENSG00000204959.4	ARHGEF34P	3.92	0.000115	0.0367	0.37	0.25	Breast cancer;	chr7:144440044	chr7:144272445~144286966:-
OV	cis	rs6128907	1	rs6128906	ENSG00000224635.1	RP4-564F22.5	3.92	0.000115	0.0367	0.37	0.25	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38758939	chr20:38406011~38416797:-
OV	cis	rs6128907	1	rs6128907	ENSG00000224635.1	RP4-564F22.5	3.92	0.000115	0.0367	0.37	0.25	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38759219	chr20:38406011~38416797:-
OV	cis	rs4761702	1	rs4761702	ENSG00000257252.4	RP11-486A14.2	-3.92	0.000116	0.0368	-0.3	-0.25	Immature fraction of reticulocytes;	chr12:93316116	chr12:93317135~93377736:-
OV	cis	rs10483554	0.671	rs12879293	ENSG00000243038.1	RP11-58E21.1	3.92	0.000116	0.0368	0.4	0.25	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr14:49345790	chr14:50052857~50053569:+
OV	cis	rs10483554	0.671	rs12878304	ENSG00000243038.1	RP11-58E21.1	3.92	0.000116	0.0368	0.4	0.25	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr14:49346041	chr14:50052857~50053569:+
OV	cis	rs10486158	1	rs1541502	ENSG00000234141.1	AC009473.1	-3.92	0.000116	0.0368	-0.38	-0.25	Bipolar disorder and schizophrenia;	chr7:7360855	chr7:7949853~7950709:-
OV	cis	rs10486158	0.947	rs758910	ENSG00000234141.1	AC009473.1	-3.92	0.000116	0.0368	-0.38	-0.25	Bipolar disorder and schizophrenia;	chr7:7361188	chr7:7949853~7950709:-
OV	cis	rs6661961	0.752	rs11579085	ENSG00000237975.5	FLG-AS1	-3.92	0.000116	0.0368	-0.33	-0.25	Atopic dermatitis;	chr1:152447965	chr1:152168125~152445456:+
OV	cis	rs2676917	0.935	rs2676920	ENSG00000271662.1	RP11-141C7.3	-3.92	0.000116	0.0368	-0.27	-0.25	Metabolite levels (Pyroglutamine);	chr3:195017866	chr3:195650146~195651472:-
OV	cis	rs875971	0.502	rs2946580	ENSG00000237310.1	GS1-124K5.4	-3.92	0.000116	0.0368	-0.29	-0.25	Aortic root size;	chr7:66066855	chr7:66493706~66495474:+
OV	cis	rs7726839	0.54	rs4957080	ENSG00000271781.1	CTD-2589H19.6	3.92	0.000116	0.0368	0.39	0.25	Obesity-related traits;	chr5:644437	chr5:675826~676616:+
OV	cis	rs6142102	0.812	rs6059558	ENSG00000264616.1	MIR4755	3.92	0.000116	0.0368	0.31	0.25	Skin pigmentation;	chr20:33929024	chr20:34049119~34049190:+
OV	cis	rs6142102	0.659	rs6057945	ENSG00000264616.1	MIR4755	3.92	0.000116	0.0368	0.31	0.25	Skin pigmentation;	chr20:33929374	chr20:34049119~34049190:+
OV	cis	rs7246657	1	rs6508710	ENSG00000226686.6	LINC01535	-3.92	0.000116	0.0368	-0.39	-0.25	Coronary artery calcification;	chr19:37258984	chr19:37251912~37265535:+
OV	cis	rs3823536	0.583	rs3778750	ENSG00000275106.1	RP11-309L24.10	-3.92	0.000116	0.0368	-0.35	-0.25	Sjögren's syndrome;	chr7:128977035	chr7:128952527~128953316:-
OV	cis	rs7617773	0.78	rs71323396	ENSG00000228638.1	FCF1P2	-3.92	0.000116	0.0368	-0.32	-0.25	Coronary artery disease;	chr3:48333244	chr3:48290793~48291375:-
OV	cis	rs875971	0.862	rs949930	ENSG00000237310.1	GS1-124K5.4	-3.92	0.000116	0.0368	-0.25	-0.25	Aortic root size;	chr7:66301835	chr7:66493706~66495474:+
OV	cis	rs875971	0.928	rs2036263	ENSG00000237310.1	GS1-124K5.4	-3.92	0.000116	0.0368	-0.25	-0.25	Aortic root size;	chr7:66335210	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs10240949	ENSG00000237310.1	GS1-124K5.4	-3.92	0.000116	0.0368	-0.25	-0.25	Aortic root size;	chr7:66339430	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs7782704	ENSG00000237310.1	GS1-124K5.4	-3.92	0.000116	0.0368	-0.25	-0.25	Aortic root size;	chr7:66340379	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs6460290	ENSG00000237310.1	GS1-124K5.4	-3.92	0.000116	0.0368	-0.25	-0.25	Aortic root size;	chr7:66344119	chr7:66493706~66495474:+
OV	cis	rs35160687	0.842	rs1863051	ENSG00000273080.1	RP11-301O19.1	3.92	0.000116	0.0368	0.24	0.25	Night sleep phenotypes;	chr2:86332025	chr2:86195590~86196049:+
OV	cis	rs295140	0.546	rs295119	ENSG00000232732.8	AC073043.1	-3.92	0.000116	0.0368	-0.3	-0.25	QT interval;	chr2:200253221	chr2:199867396~199911159:-
OV	cis	rs6673267	0.869	rs10920094	ENSG00000223774.4	RP11-307B6.3	3.92	0.000116	0.0368	0.27	0.25	Lobe attachment (rater-scored or self-reported);	chr1:201011868	chr1:201893842~201899978:+
OV	cis	rs2273788	0.837	rs13297520	ENSG00000204173.9	LRRC37A5P	3.92	0.000116	0.0369	0.3	0.25	Monocyte count;	chr9:111588861	chr9:111602831~111631289:-
OV	cis	rs6919534	0.688	rs9394283	ENSG00000265123.2	RN7SL200P	3.92	0.000116	0.0369	0.29	0.25	Height;	chr6:35221859	chr6:34685355~34685642:-
OV	cis	rs7617773	0.78	rs7645425	ENSG00000228638.1	FCF1P2	-3.92	0.000116	0.0369	-0.32	-0.25	Coronary artery disease;	chr3:48320879	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs6793223	ENSG00000228638.1	FCF1P2	-3.92	0.000116	0.0369	-0.32	-0.25	Coronary artery disease;	chr3:48322611	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs4541431	ENSG00000228638.1	FCF1P2	-3.92	0.000116	0.0369	-0.32	-0.25	Coronary artery disease;	chr3:48323728	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs11714944	ENSG00000228638.1	FCF1P2	-3.92	0.000116	0.0369	-0.32	-0.25	Coronary artery disease;	chr3:48325481	chr3:48290793~48291375:-
OV	cis	rs7617773	0.743	rs13071960	ENSG00000228638.1	FCF1P2	-3.92	0.000116	0.0369	-0.32	-0.25	Coronary artery disease;	chr3:48326047	chr3:48290793~48291375:-
OV	cis	rs7617773	0.743	rs4632568	ENSG00000228638.1	FCF1P2	-3.92	0.000116	0.0369	-0.32	-0.25	Coronary artery disease;	chr3:48326329	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs11130164	ENSG00000228638.1	FCF1P2	-3.92	0.000116	0.0369	-0.32	-0.25	Coronary artery disease;	chr3:48327544	chr3:48290793~48291375:-
OV	cis	rs7617773	0.78	rs7653336	ENSG00000228638.1	FCF1P2	-3.92	0.000116	0.0369	-0.32	-0.25	Coronary artery disease;	chr3:48327974	chr3:48290793~48291375:-
OV	cis	rs7617773	0.747	rs34076262	ENSG00000228638.1	FCF1P2	-3.92	0.000116	0.0369	-0.32	-0.25	Coronary artery disease;	chr3:48328926	chr3:48290793~48291375:-
OV	cis	rs12681366	0.801	rs12682524	ENSG00000253704.1	RP11-267M23.4	3.92	0.000116	0.0369	0.35	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94472071	chr8:94553722~94569745:+
OV	cis	rs6496044	0.568	rs3743321	ENSG00000229212.6	RP11-561C5.4	3.92	0.000116	0.0369	0.29	0.25	Interstitial lung disease;	chr15:85521737	chr15:85205440~85234795:-
OV	cis	rs2708377	0.858	rs115781584	ENSG00000256981.1	TAS2R18	3.92	0.000116	0.0369	0.36	0.25	Bitter taste perception;	chr12:11151961	chr12:11158785~11159694:-
OV	cis	rs73201462	1	rs13069054	ENSG00000242551.2	POU5F1P6	3.92	0.000116	0.037	0.38	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128137139	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs6810006	ENSG00000242551.2	POU5F1P6	3.92	0.000116	0.037	0.38	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128137215	chr3:128674735~128677005:-
OV	cis	rs73201462	0.901	rs56175090	ENSG00000242551.2	POU5F1P6	3.92	0.000116	0.037	0.38	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128141237	chr3:128674735~128677005:-
OV	cis	rs73201462	0.808	rs34372443	ENSG00000242551.2	POU5F1P6	3.92	0.000116	0.037	0.38	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128141651	chr3:128674735~128677005:-
OV	cis	rs4290604	0.748	rs7594554	ENSG00000224132.2	AC112715.2	-3.92	0.000116	0.037	-0.46	-0.25	Asthma;	chr2:237157338	chr2:237257091~237257676:+
OV	cis	rs12480328	1	rs16995568	ENSG00000259456.3	ADNP-AS1	-3.92	0.000116	0.037	-0.49	-0.25	Prostate cancer;	chr20:50884357	chr20:50930984~50945134:+
OV	cis	rs2999052	0.95	rs2461794	ENSG00000277250.1	Metazoa_SRP	3.92	0.000116	0.037	0.31	0.25	Hypospadias;	chr3:128151217	chr3:128673681~128674021:-
OV	cis	rs4918798	0.641	rs17443251	ENSG00000234724.1	HDAC1P1	3.92	0.000117	0.037	0.45	0.25	Warfarin maintenance dose;	chr10:94948133	chr10:94137748~94139500:+
OV	cis	rs4713118	0.868	rs7756968	ENSG00000226314.6	ZNF192P1	-3.92	0.000117	0.037	-0.33	-0.25	Parkinson's disease;	chr6:27767175	chr6:28161781~28169594:+
OV	cis	rs6122940	0.554	rs3787335	ENSG00000237788.1	RP5-1041C10.3	-3.92	0.000117	0.037	-0.47	-0.25	Lymphocyte counts;	chr20:50526498	chr20:49829125~49831085:+
OV	cis	rs1560104	0.576	rs7186185	ENSG00000259899.1	CTD-3037G24.3	-3.92	0.000117	0.037	-0.29	-0.25	Obesity-related traits;	chr16:12614985	chr16:12560756~12611044:-
OV	cis	rs255758	0.627	rs255749	ENSG00000272123.1	CTD-2366F13.2	-3.92	0.000117	0.037	-0.31	-0.25	Rheumatoid arthritis;	chr5:54022766	chr5:53089016~53089468:-
OV	cis	rs1511299	0.597	rs3817176	ENSG00000249417.1	RP11-438D8.2	-3.92	0.000117	0.037	-0.38	-0.25	Glomerular filtration rate;	chr3:141993938	chr3:141267353~141367137:-
OV	cis	rs2950393	0.804	rs2958132	ENSG00000241217.3	RN7SL809P	3.92	0.000117	0.0371	0.25	0.25	Platelet distribution width;	chr12:56750749	chr12:56670450~56670746:-
OV	cis	rs2274471	0.645	rs2031907	ENSG00000234534.1	CSNK1G2P1	3.92	0.000117	0.0371	0.32	0.25	Crohn's disease;	chr9:5087596	chr9:5040945~5041940:+
OV	cis	rs35094601	0.731	rs4954928	ENSG00000232915.1	AC097721.1	3.92	0.000117	0.0371	0.26	0.25	Schizophrenia;	chr2:138455193	chr2:138412066~138413318:-
OV	cis	rs5742933	0.696	rs17271246	ENSG00000253559.1	OSGEPL1-AS1	-3.92	0.000117	0.0371	-0.34	-0.25	Ferritin levels;	chr2:189781481	chr2:189762704~189765556:+
OV	cis	rs2904967	0.598	rs2904978	ENSG00000254614.2	AP003068.23	3.92	0.000117	0.0371	0.33	0.25	Mean corpuscular volume;	chr11:65233007	chr11:65177606~65181834:-
OV	cis	rs2898290	0.617	rs13278965	ENSG00000255556.2	RP11-351I21.6	3.92	0.000117	0.0371	0.26	0.25	Systolic blood pressure;	chr8:11609236	chr8:12378679~12380265:-
OV	cis	rs6921919	0.583	rs740621	ENSG00000204709.4	LINC01556	3.92	0.000117	0.0371	0.31	0.25	Autism spectrum disorder or schizophrenia;	chr6:28430010	chr6:28943877~28944537:+
OV	cis	rs7107770	0.629	rs7104313	ENSG00000254833.1	RP11-50B3.2	3.92	0.000117	0.0371	0.34	0.25	Photic sneeze reflex;	chr11:125200301	chr11:126160714~126176035:+
OV	cis	rs875971	0.545	rs67775320	ENSG00000273024.4	INTS4P2	-3.92	0.000117	0.0371	-0.3	-0.25	Aortic root size;	chr7:66193792	chr7:65647864~65715661:+
OV	cis	rs12681366	0.881	rs3019149	ENSG00000253704.1	RP11-267M23.4	3.92	0.000117	0.0371	0.35	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94418351	chr8:94553722~94569745:+
OV	cis	rs4918798	0.696	rs56386142	ENSG00000234724.1	HDAC1P1	3.92	0.000117	0.0371	0.45	0.25	Warfarin maintenance dose;	chr10:94873116	chr10:94137748~94139500:+
OV	cis	rs7726839	0.574	rs11134148	ENSG00000271781.1	CTD-2589H19.6	-3.92	0.000117	0.0371	-0.39	-0.25	Obesity-related traits;	chr5:636992	chr5:675826~676616:+
OV	cis	rs10504130	0.569	rs13275967	ENSG00000272024.1	RP11-546K22.3	-3.92	0.000117	0.0372	-0.34	-0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:51761316	chr8:51950284~51950690:+
OV	cis	rs10504130	0.569	rs13274159	ENSG00000272024.1	RP11-546K22.3	-3.92	0.000117	0.0372	-0.34	-0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:51761450	chr8:51950284~51950690:+
OV	cis	rs10504130	0.569	rs4436115	ENSG00000272024.1	RP11-546K22.3	-3.92	0.000117	0.0372	-0.34	-0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:51761932	chr8:51950284~51950690:+
OV	cis	rs10504130	0.569	rs4573262	ENSG00000272024.1	RP11-546K22.3	-3.92	0.000117	0.0372	-0.34	-0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:51762249	chr8:51950284~51950690:+
OV	cis	rs10504130	0.569	rs11785467	ENSG00000272024.1	RP11-546K22.3	-3.92	0.000117	0.0372	-0.34	-0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:51763108	chr8:51950284~51950690:+
OV	cis	rs17122278	1	rs2277292	ENSG00000255422.1	AP002954.4	3.92	0.000117	0.0372	0.38	0.25	Total cholesterol levels;	chr11:118554704	chr11:118704607~118750263:+
OV	cis	rs934734	0.752	rs1194849	ENSG00000234255.7	AC012370.3	-3.92	0.000117	0.0372	-0.27	-0.25	Rheumatoid arthritis;	chr2:65379519	chr2:65439888~65456571:-
OV	cis	rs934734	0.752	rs198478	ENSG00000234255.7	AC012370.3	-3.92	0.000117	0.0372	-0.27	-0.25	Rheumatoid arthritis;	chr2:65379877	chr2:65439888~65456571:-
OV	cis	rs934734	0.752	rs268136	ENSG00000234255.7	AC012370.3	-3.92	0.000117	0.0372	-0.27	-0.25	Rheumatoid arthritis;	chr2:65380409	chr2:65439888~65456571:-
OV	cis	rs7932354	0.554	rs6485721	ENSG00000271543.1	RP11-692M12.5	-3.92	0.000117	0.0372	-0.32	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:47019303	chr11:47796169~47796379:+
OV	cis	rs4761702	1	rs4761701	ENSG00000257252.4	RP11-486A14.2	-3.92	0.000117	0.0372	-0.3	-0.25	Immature fraction of reticulocytes;	chr12:93315956	chr12:93317135~93377736:-
OV	cis	rs6545883	0.965	rs6734830	ENSG00000270820.4	RP11-355B11.2	3.92	0.000118	0.0373	0.29	0.25	Tuberculosis;	chr2:61503977	chr2:61471188~61484130:+
OV	cis	rs944801	0.608	rs944799	ENSG00000234840.1	LINC01239	-3.92	0.000118	0.0373	-0.29	-0.25	Type 2 diabetes;	chr9:22050614	chr9:22646200~22824213:+
OV	cis	rs7746199	0.736	rs6904596	ENSG00000220721.1	OR1F12	3.92	0.000118	0.0373	0.48	0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27523520	chr6:28073316~28074233:+
OV	cis	rs4964805	1	rs12228207	ENSG00000257681.1	RP11-341G23.4	3.92	0.000118	0.0373	0.32	0.25	Attention deficit hyperactivity disorder;	chr12:103802956	chr12:103746315~103768858:-
OV	cis	rs875971	0.929	rs4122249	ENSG00000265600.1	AC006480.1	-3.92	0.000118	0.0373	-0.25	-0.25	Aortic root size;	chr7:66455949	chr7:67356680~67356779:+
OV	cis	rs7302981	0.719	rs844347	ENSG00000257298.1	RP3-405J10.3	3.92	0.000118	0.0373	0.24	0.25	Systolic blood pressure;	chr12:50067893	chr12:50185580~50191363:-
OV	cis	rs7267979	0.816	rs6115094	ENSG00000274973.1	RP13-401N8.7	-3.92	0.000118	0.0373	-0.29	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25230191	chr20:25845497~25845862:+
OV	cis	rs957448	1	rs72674855	ENSG00000253175.1	RP11-267M23.6	3.92	0.000118	0.0373	0.3	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94536706	chr8:94565036~94565715:+
OV	cis	rs875971	0.862	rs11773628	ENSG00000237310.1	GS1-124K5.4	-3.92	0.000118	0.0373	-0.25	-0.25	Aortic root size;	chr7:66517644	chr7:66493706~66495474:+
OV	cis	rs9879311	0.966	rs6442165	ENSG00000240288.6	GHRLOS	3.92	0.000118	0.0373	0.24	0.25	Schizophrenia;Autism spectrum disorder or schizophrenia;	chr3:10373424	chr3:10285754~10293449:+
OV	cis	rs4950322	0.802	rs72694705	ENSG00000278811.3	LINC00624	3.92	0.000118	0.0373	0.33	0.25	Protein quantitative trait loci;	chr1:147362313	chr1:147258885~147517875:-
OV	cis	rs4713118	0.699	rs200978	ENSG00000226314.6	ZNF192P1	-3.92	0.000118	0.0373	-0.34	-0.25	Parkinson's disease;	chr6:27885390	chr6:28161781~28169594:+
OV	cis	rs6545883	0.868	rs28749199	ENSG00000273302.1	RP11-493E12.2	3.92	0.000118	0.0373	0.21	0.25	Tuberculosis;	chr2:61599917	chr2:61199979~61200769:+
OV	cis	rs881375	0.9	rs1008383	ENSG00000226752.6	PSMD5-AS1	-3.92	0.000118	0.0373	-0.28	-0.25	Rheumatoid arthritis;	chr9:120921301	chr9:120824828~120854385:+
OV	cis	rs1568889	1	rs34667360	ENSG00000255322.1	RP11-22P4.1	3.92	0.000118	0.0373	0.37	0.25	Bipolar disorder;	chr11:28034103	chr11:28352107~28527041:+
OV	cis	rs7646881	0.509	rs56321207	ENSG00000272440.1	RP11-379F4.6	3.92	0.000118	0.0373	0.38	0.25	Tetralogy of Fallot;	chr3:158666944	chr3:158695367~158695581:+
OV	cis	rs7646881	0.544	rs16829283	ENSG00000272440.1	RP11-379F4.6	3.92	0.000118	0.0373	0.38	0.25	Tetralogy of Fallot;	chr3:158671339	chr3:158695367~158695581:+
OV	cis	rs7520050	0.872	rs2486445	ENSG00000281133.1	AL355480.3	3.92	0.000118	0.0373	0.28	0.25	Reticulocyte count;Red blood cell count;	chr1:46139697	chr1:45580892~45580996:-
OV	cis	rs4664293	0.546	rs72956113	ENSG00000226266.5	AC009961.3	3.92	0.000118	0.0374	0.31	0.25	Monocyte percentage of white cells;	chr2:159631132	chr2:159670708~159712435:-
OV	cis	rs881375	0.678	rs10739581	ENSG00000226752.6	PSMD5-AS1	-3.92	0.000118	0.0374	-0.26	-0.25	Rheumatoid arthritis;	chr9:120934593	chr9:120824828~120854385:+
OV	cis	rs4713118	0.868	rs35069907	ENSG00000226314.6	ZNF192P1	-3.92	0.000118	0.0374	-0.33	-0.25	Parkinson's disease;	chr6:27778913	chr6:28161781~28169594:+
OV	cis	rs80168506	0.748	rs10197379	ENSG00000272519.1	RP11-105N14.2	3.92	0.000118	0.0374	0.38	0.25	Selective IgA deficiency;	chr2:213196515	chr2:213266995~213276152:-
OV	cis	rs4713118	0.826	rs2893929	ENSG00000226314.6	ZNF192P1	-3.92	0.000118	0.0374	-0.33	-0.25	Parkinson's disease;	chr6:27770953	chr6:28161781~28169594:+
OV	cis	rs4713118	0.666	rs4140646	ENSG00000226314.6	ZNF192P1	-3.92	0.000118	0.0374	-0.33	-0.25	Parkinson's disease;	chr6:27771022	chr6:28161781~28169594:+
OV	cis	rs4713118	0.666	rs2893930	ENSG00000226314.6	ZNF192P1	-3.92	0.000118	0.0374	-0.33	-0.25	Parkinson's disease;	chr6:27771027	chr6:28161781~28169594:+
OV	cis	rs427941	0.585	rs201511	ENSG00000272219.1	CTB-181H17.1	-3.92	0.000118	0.0374	-0.22	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr7:102124373	chr7:101960116~101961894:+
OV	cis	rs860295	0.58	rs2297480	ENSG00000225855.5	RUSC1-AS1	3.92	0.000118	0.0374	0.22	0.25	Body mass index;	chr1:155309691	chr1:155316863~155324176:-
OV	cis	rs860295	0.58	rs11264358	ENSG00000225855.5	RUSC1-AS1	3.92	0.000118	0.0374	0.22	0.25	Body mass index;	chr1:155310373	chr1:155316863~155324176:-
OV	cis	rs12776158	0.901	rs79980322	ENSG00000229261.1	RP11-227H15.4	3.92	0.000118	0.0374	0.47	0.25	Age-related hearing impairment (SNP x SNP interaction);	chr10:69441959	chr10:69215333~69232490:-
OV	cis	rs12776158	0.792	rs12413268	ENSG00000229261.1	RP11-227H15.4	3.92	0.000118	0.0374	0.47	0.25	Age-related hearing impairment (SNP x SNP interaction);	chr10:69445748	chr10:69215333~69232490:-
OV	cis	rs1538970	0.962	rs4660301	ENSG00000280836.1	AL355480.1	-3.92	0.000118	0.0374	-0.35	-0.25	Platelet count;	chr1:45354477	chr1:45581219~45581321:-
OV	cis	rs1538970	0.962	rs9429077	ENSG00000280836.1	AL355480.1	-3.92	0.000118	0.0374	-0.35	-0.25	Platelet count;	chr1:45354995	chr1:45581219~45581321:-
OV	cis	rs6460942	1	rs7808819	ENSG00000226690.5	AC005281.1	3.92	0.000118	0.0374	0.45	0.25	Coronary artery disease;	chr7:12257814	chr7:12496429~12541910:+
OV	cis	rs2282300	0.956	rs594937	ENSG00000242353.1	RP4-710M3.1	3.92	0.000118	0.0374	0.37	0.25	Morning vs. evening chronotype;	chr11:30368585	chr11:30368148~30368646:+
OV	cis	rs295490	1	rs397940	ENSG00000272656.1	RP11-219D15.3	-3.92	0.000118	0.0374	-0.37	-0.25	PR interval in Tripanosoma cruzi seropositivity;	chr3:139520429	chr3:139349024~139349371:-
OV	cis	rs17711722	0.51	rs11767457	ENSG00000234500.1	GS1-124K5.10	-3.92	0.000118	0.0374	-0.2	-0.25	Calcium levels;	chr7:65825628	chr7:66511556~66545066:+
OV	cis	rs4713118	0.824	rs9366702	ENSG00000226314.6	ZNF192P1	-3.92	0.000119	0.0375	-0.31	-0.25	Parkinson's disease;	chr6:27766691	chr6:28161781~28169594:+
OV	cis	rs7520050	0.807	rs12025621	ENSG00000280836.1	AL355480.1	3.92	0.000119	0.0375	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:45762719	chr1:45581219~45581321:-
OV	cis	rs7520050	0.778	rs12404197	ENSG00000280836.1	AL355480.1	3.92	0.000119	0.0375	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:45766748	chr1:45581219~45581321:-
OV	cis	rs7520050	0.801	rs6703960	ENSG00000280836.1	AL355480.1	3.92	0.000119	0.0375	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:45767051	chr1:45581219~45581321:-
OV	cis	rs7617773	0.539	rs13069884	ENSG00000228638.1	FCF1P2	-3.92	0.000119	0.0375	-0.31	-0.25	Coronary artery disease;	chr3:48339658	chr3:48290793~48291375:-
OV	cis	rs7617773	0.539	rs2017859	ENSG00000228638.1	FCF1P2	-3.92	0.000119	0.0375	-0.31	-0.25	Coronary artery disease;	chr3:48340771	chr3:48290793~48291375:-
OV	cis	rs7617773	0.501	rs12185901	ENSG00000228638.1	FCF1P2	-3.92	0.000119	0.0375	-0.31	-0.25	Coronary artery disease;	chr3:48341429	chr3:48290793~48291375:-
OV	cis	rs7617773	0.539	rs13082217	ENSG00000228638.1	FCF1P2	-3.92	0.000119	0.0375	-0.31	-0.25	Coronary artery disease;	chr3:48341774	chr3:48290793~48291375:-
OV	cis	rs7617773	0.539	rs11706939	ENSG00000228638.1	FCF1P2	-3.92	0.000119	0.0375	-0.31	-0.25	Coronary artery disease;	chr3:48342502	chr3:48290793~48291375:-
OV	cis	rs7617773	0.539	rs11130165	ENSG00000228638.1	FCF1P2	-3.92	0.000119	0.0375	-0.31	-0.25	Coronary artery disease;	chr3:48343231	chr3:48290793~48291375:-
OV	cis	rs881375	0.678	rs1014530	ENSG00000226752.6	PSMD5-AS1	-3.92	0.000119	0.0375	-0.26	-0.25	Rheumatoid arthritis;	chr9:120922814	chr9:120824828~120854385:+
OV	cis	rs9386630	0.554	rs3002709	ENSG00000271734.1	RP1-111B22.3	3.92	0.000119	0.0376	0.28	0.25	Coffee consumption;	chr6:107322216	chr6:108030249~108030718:-
OV	cis	rs897984	0.571	rs7184567	ENSG00000232748.3	RP11-196G11.6	-3.92	0.000119	0.0376	-0.27	-0.25	Dementia with Lewy bodies;	chr16:31009757	chr16:31056460~31062803:+
OV	cis	rs7980799	0.689	rs4142890	ENSG00000276148.1	RP11-278C7.4	3.92	0.000119	0.0376	0.27	0.25	Heart rate variability traits (RMSSD);Heart rate;	chr12:33293695	chr12:32725248~32725660:-
OV	cis	rs1107366	0.637	rs2044575	ENSG00000280053.1	RP11-61K12.2	3.92	0.000119	0.0376	0.25	0.25	Metabolite levels;	chr3:126257525	chr3:126973065~126976426:+
OV	cis	rs7726839	0.507	rs72703100	ENSG00000271781.1	CTD-2589H19.6	-3.92	0.000119	0.0376	-0.38	-0.25	Obesity-related traits;	chr5:614176	chr5:675826~676616:+
OV	cis	rs7726839	0.574	rs72705014	ENSG00000271781.1	CTD-2589H19.6	-3.92	0.000119	0.0376	-0.38	-0.25	Obesity-related traits;	chr5:619700	chr5:675826~676616:+
OV	cis	rs9847710	0.696	rs2581777	ENSG00000242142.1	SERBP1P3	3.92	0.000119	0.0376	0.31	0.25	Ulcerative colitis;	chr3:53020711	chr3:53064283~53065091:-
OV	cis	rs1823913	1	rs1823913	ENSG00000227542.1	AC092614.2	3.92	0.000119	0.0376	0.29	0.25	Obesity-related traits;	chr2:191253321	chr2:191229165~191246172:-
OV	cis	rs61931739	0.511	rs2035659	ENSG00000274976.1	RP11-8P13.5	-3.92	0.000119	0.0376	-0.31	-0.25	Morning vs. evening chronotype;	chr12:33673306	chr12:32820142~32820567:-
OV	cis	rs7512898	0.5	rs10920046	ENSG00000260088.1	RP11-92G12.3	-3.92	0.000119	0.0376	-0.28	-0.25	Electrocardiographic conduction measures;	chr1:200840100	chr1:200669507~200694250:+
OV	cis	rs7512898	0.522	rs10800743	ENSG00000260088.1	RP11-92G12.3	-3.92	0.000119	0.0376	-0.28	-0.25	Electrocardiographic conduction measures;	chr1:200852408	chr1:200669507~200694250:+
OV	cis	rs1862618	0.525	rs832403	ENSG00000271828.1	CTD-2310F14.1	-3.92	0.000119	0.0376	-0.44	-0.25	Initial pursuit acceleration;	chr5:56970165	chr5:56927874~56929573:+
OV	cis	rs7195386	0.869	rs7206159	ENSG00000261266.2	CTD-2196E14.5	-3.92	0.000119	0.0376	-0.3	-0.25	Obesity-related traits;Body mass index;	chr16:24551137	chr16:23687049~23687689:-
OV	cis	rs6545883	0.862	rs1880866	ENSG00000270820.4	RP11-355B11.2	3.92	0.000119	0.0377	0.28	0.25	Tuberculosis;	chr2:61471837	chr2:61471188~61484130:+
OV	cis	rs7927771	0.507	rs7119517	ENSG00000280615.1	Y_RNA	3.92	0.000119	0.0377	0.27	0.25	Subjective well-being;	chr11:47653764	chr11:47614898~47614994:-
OV	cis	rs9467773	0.804	rs2073526	ENSG00000261584.1	RP11-457M11.5	-3.92	0.000119	0.0377	-0.29	-0.25	Intelligence (multi-trait analysis);	chr6:26374430	chr6:26686241~26687964:+
OV	cis	rs9880211	0.752	rs13062352	ENSG00000239213.4	NCK1-AS1	3.92	0.000119	0.0377	0.33	0.25	Height;Body mass index;	chr3:136745920	chr3:136841726~136862054:-
OV	cis	rs9880211	0.8	rs9813376	ENSG00000239213.4	NCK1-AS1	3.92	0.000119	0.0377	0.33	0.25	Height;Body mass index;	chr3:136756584	chr3:136841726~136862054:-
OV	cis	rs11122895	1	rs11122891	ENSG00000228251.1	AC012442.6	-3.92	0.000119	0.0377	-0.24	-0.25	Allergic sensitization;	chr2:111710024	chr2:112590796~112591939:+
OV	cis	rs6545883	0.895	rs7588814	ENSG00000270820.4	RP11-355B11.2	3.92	0.000119	0.0377	0.29	0.25	Tuberculosis;	chr2:61468454	chr2:61471188~61484130:+
OV	cis	rs35110281	0.659	rs11702544	ENSG00000213440.2	H2AFZP1	3.92	0.000119	0.0377	0.28	0.25	Mean corpuscular volume;	chr21:43671980	chr21:44046347~44047041:-
OV	cis	rs9880211	0.8	rs28390205	ENSG00000239213.4	NCK1-AS1	3.92	0.000119	0.0377	0.33	0.25	Height;Body mass index;	chr3:136646008	chr3:136841726~136862054:-
OV	cis	rs9880211	0.706	rs67382287	ENSG00000239213.4	NCK1-AS1	3.92	0.000119	0.0377	0.33	0.25	Height;Body mass index;	chr3:136661617	chr3:136841726~136862054:-
OV	cis	rs9880211	0.752	rs35428413	ENSG00000239213.4	NCK1-AS1	3.92	0.000119	0.0377	0.33	0.25	Height;Body mass index;	chr3:136661856	chr3:136841726~136862054:-
OV	cis	rs9880211	0.699	rs13433688	ENSG00000239213.4	NCK1-AS1	3.92	0.000119	0.0377	0.33	0.25	Height;Body mass index;	chr3:136690329	chr3:136841726~136862054:-
OV	cis	rs7520050	0.966	rs4076006	ENSG00000280836.1	AL355480.1	3.92	0.000119	0.0377	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45972404	chr1:45581219~45581321:-
OV	cis	rs7927771	0.56	rs4752858	ENSG00000280615.1	Y_RNA	-3.92	0.000119	0.0377	-0.27	-0.25	Subjective well-being;	chr11:47664277	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs4539273	ENSG00000280615.1	Y_RNA	-3.92	0.000119	0.0377	-0.27	-0.25	Subjective well-being;	chr11:47673147	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs4752860	ENSG00000280615.1	Y_RNA	-3.92	0.000119	0.0377	-0.27	-0.25	Subjective well-being;	chr11:47683463	chr11:47614898~47614994:-
OV	cis	rs7927771	0.542	rs11039336	ENSG00000280615.1	Y_RNA	-3.92	0.000119	0.0377	-0.27	-0.25	Subjective well-being;	chr11:47684589	chr11:47614898~47614994:-
OV	cis	rs1568889	1	rs12800354	ENSG00000255322.1	RP11-22P4.1	3.92	0.000119	0.0377	0.37	0.25	Bipolar disorder;	chr11:28026176	chr11:28352107~28527041:+
OV	cis	rs149866169	1	rs149866169	ENSG00000226314.6	ZNF192P1	-3.92	0.000119	0.0377	-0.53	-0.25	Subjective well-being (multi-trait analysis);Lung cancer;Neuroticism (multi-trait analysis);Lung cancer in ever smokers;Squamous cell lung carcinoma;	chr6:27473944	chr6:28161781~28169594:+
OV	cis	rs7195386	0.783	rs17767765	ENSG00000261266.2	CTD-2196E14.5	3.92	0.000119	0.0377	0.29	0.25	Obesity-related traits;Body mass index;	chr16:24528472	chr16:23687049~23687689:-
OV	cis	rs2070488	0.695	rs6599201	ENSG00000229589.1	ACVR2B-AS1	3.92	0.00012	0.0377	0.28	0.25	Electrocardiographic conduction measures;	chr3:38435123	chr3:38451027~38454820:-
OV	cis	rs10829156	0.51	rs1490197	ENSG00000225527.1	RP11-383B4.4	-3.92	0.00012	0.0378	-0.33	-0.25	Sudden cardiac arrest;	chr10:18696785	chr10:18531849~18533336:-
OV	cis	rs73201462	1	rs2955129	ENSG00000242551.2	POU5F1P6	-3.91	0.00012	0.0378	-0.39	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128210364	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2955130	ENSG00000242551.2	POU5F1P6	-3.91	0.00012	0.0378	-0.39	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128218971	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2811549	ENSG00000242551.2	POU5F1P6	-3.91	0.00012	0.0378	-0.39	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128219865	chr3:128674735~128677005:-
OV	cis	rs7267979	1	rs6050598	ENSG00000274973.1	RP13-401N8.7	-3.91	0.00012	0.0378	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25416621	chr20:25845497~25845862:+
OV	cis	rs2436845	0.627	rs1991928	ENSG00000253385.1	KB-1254G8.1	-3.91	0.00012	0.0378	-0.31	-0.25	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102860863	chr8:102854455~102856075:+
OV	cis	rs7432375	0.901	rs1729951	ENSG00000261758.1	RP11-102M11.2	-3.91	0.00012	0.0378	-0.31	-0.25	Schizophrenia;Neuroticism;Autism spectrum disorder or schizophrenia;	chr3:136781891	chr3:136752630~136755780:+
OV	cis	rs6693388	0.52	rs2932570	ENSG00000237975.5	FLG-AS1	3.91	0.00012	0.0378	0.33	0.25	Blood metabolite ratios;	chr1:152014344	chr1:152168125~152445456:+
OV	cis	rs6128907	1	rs1535431	ENSG00000224635.1	RP4-564F22.5	3.91	0.00012	0.0378	0.37	0.25	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38775776	chr20:38406011~38416797:-
OV	cis	rs6128907	1	rs62202485	ENSG00000224635.1	RP4-564F22.5	3.91	0.00012	0.0378	0.37	0.25	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38779925	chr20:38406011~38416797:-
OV	cis	rs7267979	1	rs2856	ENSG00000274973.1	RP13-401N8.7	-3.91	0.00012	0.0378	-0.29	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25452900	chr20:25845497~25845862:+
OV	cis	rs12358699	0.546	rs59381196	ENSG00000165511.6	C10orf25	3.91	0.00012	0.0378	0.66	0.25	Lung function (FEV1/FVC);	chr10:44983560	chr10:44997698~45000888:-
OV	cis	rs12358699	0.546	rs41306546	ENSG00000165511.6	C10orf25	3.91	0.00012	0.0378	0.66	0.25	Lung function (FEV1/FVC);	chr10:44983598	chr10:44997698~45000888:-
OV	cis	rs12358699	0.546	rs41306544	ENSG00000165511.6	C10orf25	3.91	0.00012	0.0378	0.66	0.25	Lung function (FEV1/FVC);	chr10:44983677	chr10:44997698~45000888:-
OV	cis	rs1015213	0.609	rs2894453	ENSG00000253844.1	RP11-546K22.1	-3.91	0.00012	0.0379	-0.66	-0.25	Glaucoma (primary angle closure);	chr8:51944596	chr8:51961458~52022974:+
OV	cis	rs7131987	0.683	rs3782511	ENSG00000257176.2	RP11-996F15.2	-3.91	0.00012	0.0379	-0.32	-0.25	QT interval;	chr12:29343291	chr12:29280418~29317848:-
OV	cis	rs2286503	0.839	rs2270105	ENSG00000221740.1	SNORD93	3.91	0.00012	0.0379	0.31	0.25	Fibrinogen;	chr7:22822848	chr7:22856613~22856686:+
OV	cis	rs2999052	1	rs2999048	ENSG00000277250.1	Metazoa_SRP	3.91	0.00012	0.0379	0.3	0.25	Hypospadias;	chr3:128159573	chr3:128673681~128674021:-
OV	cis	rs4845570	1	rs7542898	ENSG00000203288.3	RP11-98D18.9	-3.91	0.00012	0.0379	-0.4	-0.25	Coronary artery disease;	chr1:151781146	chr1:151790804~151794402:+
OV	cis	rs4934494	0.768	rs1409357	ENSG00000240996.1	RP11-80H5.7	-3.91	0.00012	0.0379	-0.36	-0.25	Red blood cell count;	chr10:89669719	chr10:89694295~89697928:-
OV	cis	rs720475	0.695	rs62483108	ENSG00000204959.4	ARHGEF34P	-3.91	0.00012	0.0379	-0.38	-0.25	Breast cancer;	chr7:144442326	chr7:144272445~144286966:-
OV	cis	rs73201462	1	rs11710704	ENSG00000242551.2	POU5F1P6	3.91	0.00012	0.0379	0.39	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128328393	chr3:128674735~128677005:-
OV	cis	rs11951515	0.7	rs13659	ENSG00000278487.1	RP11-447H19.4	-3.91	0.00012	0.0379	-0.3	-0.25	Metabolite levels  (X-11787);	chr5:43290598	chr5:43143362~43143514:-
OV	cis	rs11951515	0.7	rs55794239	ENSG00000278487.1	RP11-447H19.4	-3.91	0.00012	0.0379	-0.3	-0.25	Metabolite levels  (X-11787);	chr5:43292806	chr5:43143362~43143514:-
OV	cis	rs11951515	0.7	rs12520012	ENSG00000278487.1	RP11-447H19.4	-3.91	0.00012	0.0379	-0.3	-0.25	Metabolite levels  (X-11787);	chr5:43296063	chr5:43143362~43143514:-
OV	cis	rs372883	0.624	rs1153286	ENSG00000226935.5	LINC00161	3.91	0.00012	0.0379	0.27	0.25	Pancreatic cancer;	chr21:29312062	chr21:28539318~28540355:+
OV	cis	rs858239	0.899	rs2268747	ENSG00000230042.1	AK3P3	-3.91	0.00012	0.0379	-0.27	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23273843	chr7:23129178~23129841:+
OV	cis	rs2254546	0.516	rs7014565	ENSG00000254866.2	DEFB109P3	-3.91	0.00012	0.0379	-0.42	-0.25	Systemic lupus erythematosus;Kawasaki disease;	chr8:11539309	chr8:12150895~12151134:-
OV	cis	rs8062405	0.558	rs151228	ENSG00000259982.1	CDC37P1	3.91	0.00012	0.0379	0.29	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28551705	chr16:28700294~28701540:-
OV	cis	rs7520050	1	rs12143096	ENSG00000280836.1	AL355480.1	3.91	0.00012	0.0379	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:46004091	chr1:45581219~45581321:-
OV	cis	rs7520050	0.897	rs4440807	ENSG00000280836.1	AL355480.1	3.91	0.00012	0.0379	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:46005206	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs12049588	ENSG00000280836.1	AL355480.1	3.91	0.00012	0.0379	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:46006750	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs12021587	ENSG00000280836.1	AL355480.1	3.91	0.00012	0.0379	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:46007087	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs11810993	ENSG00000280836.1	AL355480.1	3.91	0.00012	0.0379	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:46013121	chr1:45581219~45581321:-
OV	cis	rs7520050	0.898	rs34175029	ENSG00000280836.1	AL355480.1	3.91	0.00012	0.0379	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:46018199	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs946529	ENSG00000280836.1	AL355480.1	3.91	0.00012	0.0379	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:46019876	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs2275426	ENSG00000280836.1	AL355480.1	3.91	0.00012	0.0379	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:46021880	chr1:45581219~45581321:-
OV	cis	rs4713118	0.824	rs9468223	ENSG00000226314.6	ZNF192P1	-3.91	0.00012	0.0379	-0.31	-0.25	Parkinson's disease;	chr6:27772887	chr6:28161781~28169594:+
OV	cis	rs2898290	0.592	rs2736342	ENSG00000254527.1	ENPP7P12	-3.91	0.00012	0.038	-0.27	-0.25	Systolic blood pressure;	chr8:11489780	chr8:12205759~12206389:-
OV	cis	rs3858145	0.588	rs78041174	ENSG00000233590.1	RP11-153K11.3	-3.91	0.00012	0.038	-0.38	-0.25	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68279014	chr10:68233251~68242379:-
OV	cis	rs514406	0.798	rs576650	ENSG00000206627.1	RNU6-969P	3.91	0.00012	0.038	0.26	0.25	Monocyte count;	chr1:52861535	chr1:52805108~52805212:-
OV	cis	rs35160687	0.814	rs7563887	ENSG00000273080.1	RP11-301O19.1	3.91	0.00012	0.038	0.25	0.25	Night sleep phenotypes;	chr2:86288998	chr2:86195590~86196049:+
OV	cis	rs55692468	0.959	rs10931146	ENSG00000213197.3	AC012066.1	3.91	0.00012	0.038	0.27	0.25	Intraocular pressure;	chr2:152495196	chr2:152389937~152390630:+
OV	cis	rs8027521	1	rs8027521	ENSG00000280362.1	RP11-643A5.3	3.91	0.00012	0.038	0.29	0.25	Circulating chemerin levels;	chr15:53964061	chr15:53910769~53914712:+
OV	cis	rs7267979	1	rs4815424	ENSG00000274973.1	RP13-401N8.7	3.91	0.000121	0.038	0.28	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25409648	chr20:25845497~25845862:+
OV	cis	rs733592	0.504	rs2261608	ENSG00000258273.1	RP11-370I10.4	-3.91	0.000121	0.038	-0.32	-0.25	Plateletcrit;	chr12:48327851	chr12:48333755~48333901:-
OV	cis	rs12073359	1	rs72692896	ENSG00000223945.2	RP11-458I7.1	-3.91	0.000121	0.038	-0.39	-0.25	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150076793	chr1:150053864~150055034:+
OV	cis	rs4761702	1	rs4761702	ENSG00000257512.1	RP11-486A14.1	-3.91	0.000121	0.038	-0.29	-0.25	Immature fraction of reticulocytes;	chr12:93316116	chr12:93314809~93315941:+
OV	cis	rs1560104	0.576	rs11640886	ENSG00000259899.1	CTD-3037G24.3	-3.91	0.000121	0.038	-0.29	-0.25	Obesity-related traits;	chr16:12615377	chr16:12560756~12611044:-
OV	cis	rs6142102	0.602	rs10485503	ENSG00000276073.1	RP5-1125A11.7	-3.91	0.000121	0.038	-0.29	-0.25	Skin pigmentation;	chr20:33970036	chr20:33985617~33988989:-
OV	cis	rs6429082	0.51	rs2789369	ENSG00000236863.2	RPL23AP23	3.91	0.000121	0.038	0.25	0.25	Adiposity;	chr1:235340200	chr1:235295865~235296335:+
OV	cis	rs2306032	0.669	rs10838622	ENSG00000271543.1	RP11-692M12.5	-3.91	0.000121	0.038	-0.33	-0.25	Total body bone mineral density;	chr11:46834985	chr11:47796169~47796379:+
OV	cis	rs6071524	0.508	rs2245237	ENSG00000277581.1	RP4-616B8.6	-3.91	0.000121	0.0381	-0.3	-0.25	Autism spectrum disorder or schizophrenia;	chr20:38767619	chr20:38962472~38962993:+
OV	cis	rs2070488	0.804	rs4678605	ENSG00000229589.1	ACVR2B-AS1	3.91	0.000121	0.0381	0.28	0.25	Electrocardiographic conduction measures;	chr3:38402998	chr3:38451027~38454820:-
OV	cis	rs2999052	1	rs4857878	ENSG00000277250.1	Metazoa_SRP	-3.91	0.000121	0.0381	-0.31	-0.25	Hypospadias;	chr3:128229306	chr3:128673681~128674021:-
OV	cis	rs189798	0.807	rs9949	ENSG00000254340.1	RP11-10A14.3	3.91	0.000121	0.0381	0.44	0.25	Myopia (pathological);	chr8:9137002	chr8:9141424~9145435:+
OV	cis	rs8113142	0.723	rs61394367	ENSG00000267243.4	AC005307.3	-3.91	0.000121	0.0381	-0.45	-0.25	Femoral neck bone geometry and menarche (age at onset);	chr19:28551094	chr19:28435388~28727777:-
OV	cis	rs7246967	0.611	rs12978511	ENSG00000267920.1	SNX6P1	-3.91	0.000121	0.0381	-0.4	-0.25	Bronchopulmonary dysplasia;	chr19:22636414	chr19:23126569~23127792:-
OV	cis	rs6071524	0.508	rs2748663	ENSG00000277581.1	RP4-616B8.6	-3.91	0.000121	0.0381	-0.3	-0.25	Autism spectrum disorder or schizophrenia;	chr20:38754997	chr20:38962472~38962993:+
OV	cis	rs801193	0.967	rs2420827	ENSG00000224316.1	RP11-479O9.2	-3.91	0.000121	0.0381	-0.26	-0.25	Aortic root size;	chr7:66682114	chr7:65773620~65802067:+
OV	cis	rs2286503	0.752	rs6461669	ENSG00000228649.7	AC005682.5	3.91	0.000121	0.0381	0.32	0.25	Fibrinogen;	chr7:22818447	chr7:22854178~22861579:+
OV	cis	rs7727544	0.735	rs272842	ENSG00000233006.5	AC034220.3	3.91	0.000121	0.0382	0.26	0.25	Blood metabolite levels;	chr5:132320824	chr5:132311285~132369916:-
OV	cis	rs1876905	0.764	rs4947106	ENSG00000255389.1	C6orf3	-3.91	0.000121	0.0382	-0.31	-0.25	Mean corpuscular hemoglobin;	chr6:111100163	chr6:111599875~111602295:+
OV	cis	rs2070488	0.965	rs1984312	ENSG00000229589.1	ACVR2B-AS1	-3.91	0.000121	0.0382	-0.28	-0.25	Electrocardiographic conduction measures;	chr3:38496975	chr3:38451027~38454820:-
OV	cis	rs9813712	0.571	rs9855777	ENSG00000253540.4	FAM86HP	3.91	0.000121	0.0382	0.26	0.25	Response to amphetamines;	chr3:130214805	chr3:130099092~130111472:-
OV	cis	rs9847710	0.733	rs11923593	ENSG00000242142.1	SERBP1P3	3.91	0.000121	0.0382	0.31	0.25	Ulcerative colitis;	chr3:53054774	chr3:53064283~53065091:-
OV	cis	rs745109	0.504	rs76526816	ENSG00000273080.1	RP11-301O19.1	3.91	0.000121	0.0382	0.33	0.25	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86370509	chr2:86195590~86196049:+
OV	cis	rs745109	0.504	rs77013753	ENSG00000273080.1	RP11-301O19.1	3.91	0.000121	0.0382	0.33	0.25	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr2:86371654	chr2:86195590~86196049:+
OV	cis	rs111226991	0.505	rs77207476	ENSG00000273080.1	RP11-301O19.1	3.91	0.000121	0.0382	0.33	0.25	Glomerular filtration rate in chronic kidney disease;	chr2:86371847	chr2:86195590~86196049:+
OV	cis	rs56233836	1	rs56233836	ENSG00000235358.1	RP11-399E6.1	3.91	0.000121	0.0382	0.46	0.25	Intelligence (multi-trait analysis);	chr1:41371501	chr1:41242373~41284861:+
OV	cis	rs12477438	0.52	rs4347885	ENSG00000231822.1	AC019097.7	3.91	0.000121	0.0382	0.26	0.25	Chronic sinus infection;	chr2:99187544	chr2:99102018~99102752:+
OV	cis	rs6745190	0.953	rs6704750	ENSG00000236153.1	AC104076.3	3.91	0.000122	0.0383	0.3	0.25	White blood cell count;	chr2:180964847	chr2:180979427~180980090:-
OV	cis	rs3124314	1	rs1496036	ENSG00000237975.5	FLG-AS1	-3.91	0.000122	0.0383	-0.31	-0.25	Hair morphology;	chr1:152167540	chr1:152168125~152445456:+
OV	cis	rs638893	0.636	rs548167	ENSG00000255239.1	AP002954.6	3.91	0.000122	0.0383	0.42	0.25	Vitiligo;	chr11:118777687	chr11:118688039~118690600:-
OV	cis	rs638893	0.685	rs486651	ENSG00000255239.1	AP002954.6	3.91	0.000122	0.0383	0.42	0.25	Vitiligo;	chr11:118779150	chr11:118688039~118690600:-
OV	cis	rs12480328	1	rs2870024	ENSG00000233077.1	LINC01271	3.91	0.000122	0.0383	0.53	0.25	Prostate cancer;	chr20:50922384	chr20:50310711~50321342:-
OV	cis	rs875971	0.862	rs4236208	ENSG00000237310.1	GS1-124K5.4	-3.91	0.000122	0.0383	-0.25	-0.25	Aortic root size;	chr7:66284091	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs10261398	ENSG00000237310.1	GS1-124K5.4	-3.91	0.000122	0.0383	-0.25	-0.25	Aortic root size;	chr7:66285177	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs10224872	ENSG00000237310.1	GS1-124K5.4	-3.91	0.000122	0.0383	-0.25	-0.25	Aortic root size;	chr7:66294786	chr7:66493706~66495474:+
OV	cis	rs7267979	0.934	rs4815423	ENSG00000274973.1	RP13-401N8.7	3.91	0.000122	0.0383	0.28	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25406885	chr20:25845497~25845862:+
OV	cis	rs12681366	0.708	rs2930962	ENSG00000253704.1	RP11-267M23.4	3.91	0.000122	0.0383	0.29	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94433277	chr8:94553722~94569745:+
OV	cis	rs12681366	0.708	rs3019154	ENSG00000253704.1	RP11-267M23.4	3.91	0.000122	0.0383	0.29	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94434280	chr8:94553722~94569745:+
OV	cis	rs12681366	0.708	rs3019279	ENSG00000253704.1	RP11-267M23.4	3.91	0.000122	0.0383	0.29	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94435677	chr8:94553722~94569745:+
OV	cis	rs6009527	1	rs4315635	ENSG00000279345.1	RP3-522J7.7	3.91	0.000122	0.0383	0.31	0.25	Plasma omega-3 polyunsaturated fatty acid levels (alphalinolenic acid);	chr22:49175604	chr22:49805452~49807208:+
OV	cis	rs7927771	0.524	rs12286721	ENSG00000280615.1	Y_RNA	-3.91	0.000122	0.0383	-0.27	-0.25	Subjective well-being;	chr11:47679976	chr11:47614898~47614994:-
OV	cis	rs673078	0.66	rs17440364	ENSG00000275759.1	RP11-131L12.3	-3.91	0.000122	0.0383	-0.38	-0.25	Glucose homeostasis traits;	chr12:118186613	chr12:118428281~118428870:+
OV	cis	rs4964805	1	rs4964805	ENSG00000257681.1	RP11-341G23.4	3.91	0.000122	0.0383	0.33	0.25	Attention deficit hyperactivity disorder;	chr12:103799046	chr12:103746315~103768858:-
OV	cis	rs6545883	0.894	rs2167566	ENSG00000270820.4	RP11-355B11.2	3.91	0.000122	0.0383	0.27	0.25	Tuberculosis;	chr2:61292273	chr2:61471188~61484130:+
OV	cis	rs73201462	1	rs2811525	ENSG00000242551.2	POU5F1P6	-3.91	0.000122	0.0383	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128280587	chr3:128674735~128677005:-
OV	cis	rs7560018	0.898	rs6544933	ENSG00000253515.1	RP11-417F21.2	-3.91	0.000122	0.0384	-0.33	-0.25	Response to efavirenz-containing treatment in HIV 1 infection (virologic failure);	chr2:46884036	chr2:46499731~46501278:+
OV	cis	rs57221529	0.766	rs4081846	ENSG00000271781.1	CTD-2589H19.6	-3.91	0.000122	0.0384	-0.41	-0.25	Lung disease severity in cystic fibrosis;	chr5:573904	chr5:675826~676616:+
OV	cis	rs11903757	1	rs4076769	ENSG00000281467.1	Clostridiales-1	3.91	0.000122	0.0384	0.43	0.25	Colorectal cancer;	chr2:191719480	chr2:191699476~191699631:-
OV	cis	rs8059260	1	rs7205474	ENSG00000274038.1	RP11-66H6.4	-3.91	0.000122	0.0384	-0.43	-0.25	Alcohol consumption over the past year;	chr16:10949556	chr16:11056556~11057034:+
OV	cis	rs6919534	0.607	rs7763946	ENSG00000265123.2	RN7SL200P	3.91	0.000122	0.0384	0.29	0.25	Height;	chr6:35223049	chr6:34685355~34685642:-
OV	cis	rs7598759	0.527	rs4973417	ENSG00000181798.2	LINC00471	-3.91	0.000122	0.0384	-0.25	-0.25	Noise-induced hearing loss;	chr2:231484925	chr2:231508426~231514339:-
OV	cis	rs72622154	1	rs35054010	ENSG00000275981.1	EGOT	3.91	0.000122	0.0384	0.52	0.25	3-hydroxy-1-methylpropylmercapturic acid levels in smokers;	chr3:4615806	chr3:4750333~4750685:+
OV	cis	rs2839440	1	rs2839440	ENSG00000227702.1	LINC00111	-3.91	0.000122	0.0384	-0.37	-0.25	Preeclampsia;	chr21:42023389	chr21:41679181~41697336:+
OV	cis	rs7520050	0.966	rs11211208	ENSG00000280836.1	AL355480.1	3.91	0.000122	0.0384	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45868584	chr1:45581219~45581321:-
OV	cis	rs7646881	0.544	rs28856044	ENSG00000272440.1	RP11-379F4.6	3.91	0.000122	0.0384	0.37	0.25	Tetralogy of Fallot;	chr3:158584970	chr3:158695367~158695581:+
OV	cis	rs7646881	0.508	rs6779054	ENSG00000272440.1	RP11-379F4.6	3.91	0.000122	0.0384	0.37	0.25	Tetralogy of Fallot;	chr3:158587658	chr3:158695367~158695581:+
OV	cis	rs7646881	0.544	rs9872682	ENSG00000272440.1	RP11-379F4.6	3.91	0.000122	0.0384	0.37	0.25	Tetralogy of Fallot;	chr3:158592117	chr3:158695367~158695581:+
OV	cis	rs7646881	0.544	rs13318109	ENSG00000272440.1	RP11-379F4.6	3.91	0.000122	0.0384	0.37	0.25	Tetralogy of Fallot;	chr3:158595417	chr3:158695367~158695581:+
OV	cis	rs16843372	0.599	rs10207728	ENSG00000251491.2	OR7E28P	-3.91	0.000122	0.0384	-0.3	-0.25	Obesity-related traits;	chr2:158819604	chr2:158862311~158863285:+
OV	cis	rs12073359	0.908	rs7521783	ENSG00000223945.2	RP11-458I7.1	-3.91	0.000122	0.0384	-0.39	-0.25	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150170994	chr1:150053864~150055034:+
OV	cis	rs1707322	0.721	rs11211163	ENSG00000234329.1	RP11-767N6.2	3.91	0.000122	0.0384	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45687876	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs12037803	ENSG00000234329.1	RP11-767N6.2	3.91	0.000122	0.0384	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45690820	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs11211165	ENSG00000234329.1	RP11-767N6.2	3.91	0.000122	0.0384	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692234	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs11211166	ENSG00000234329.1	RP11-767N6.2	3.91	0.000122	0.0384	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692270	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs10789470	ENSG00000234329.1	RP11-767N6.2	3.91	0.000122	0.0384	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45692659	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs61784796	ENSG00000234329.1	RP11-767N6.2	3.91	0.000122	0.0384	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45697584	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs10749856	ENSG00000234329.1	RP11-767N6.2	3.91	0.000122	0.0384	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45699174	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs10890344	ENSG00000234329.1	RP11-767N6.2	3.91	0.000122	0.0384	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45700418	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs4564187	ENSG00000234329.1	RP11-767N6.2	3.91	0.000122	0.0384	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45701189	chr1:45651039~45651826:-
OV	cis	rs1707322	0.752	rs28438704	ENSG00000234329.1	RP11-767N6.2	3.91	0.000122	0.0384	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45704872	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs28442079	ENSG00000234329.1	RP11-767N6.2	3.91	0.000122	0.0384	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45706329	chr1:45651039~45651826:-
OV	cis	rs2663905	0.611	rs2663920	ENSG00000259445.1	RP11-276M12.1	3.91	0.000122	0.0385	0.26	0.25	QT interval (drug interaction);	chr15:81104063	chr15:81953303~81995666:-
OV	cis	rs2243480	0.901	rs12530490	ENSG00000273142.1	RP11-458F8.4	3.91	0.000122	0.0385	0.3	0.25	Diabetic kidney disease;	chr7:66226660	chr7:66902857~66906297:+
OV	cis	rs2243480	1	rs7778911	ENSG00000273142.1	RP11-458F8.4	3.91	0.000122	0.0385	0.3	0.25	Diabetic kidney disease;	chr7:66229519	chr7:66902857~66906297:+
OV	cis	rs2243480	1	rs1979823	ENSG00000273142.1	RP11-458F8.4	3.91	0.000122	0.0385	0.3	0.25	Diabetic kidney disease;	chr7:66239626	chr7:66902857~66906297:+
OV	cis	rs7259376	0.601	rs7251483	ENSG00000269742.1	BNIP3P29	3.91	0.000122	0.0385	0.29	0.25	Menopause (age at onset);	chr19:22311334	chr19:22065828~22066398:-
OV	cis	rs944801	0.55	rs2151280	ENSG00000234840.1	LINC01239	-3.91	0.000123	0.0385	-0.29	-0.25	Type 2 diabetes;	chr9:22034720	chr9:22646200~22824213:+
OV	cis	rs10170846	0.924	rs3768973	ENSG00000261428.2	RP11-16P6.1	3.91	0.000123	0.0385	0.28	0.25	Schizophrenia (inflammation and infection response interaction);	chr2:222571683	chr2:222566899~222569719:-
OV	cis	rs7824557	0.603	rs2249804	ENSG00000254866.2	DEFB109P3	-3.91	0.000123	0.0385	-0.31	-0.25	Retinal vascular caliber;	chr8:11358108	chr8:12150895~12151134:-
OV	cis	rs11903757	1	rs74747990	ENSG00000281467.1	Clostridiales-1	-3.91	0.000123	0.0385	-0.43	-0.25	Colorectal cancer;	chr2:191709742	chr2:191699476~191699631:-
OV	cis	rs11903757	1	rs75823023	ENSG00000281467.1	Clostridiales-1	-3.91	0.000123	0.0385	-0.43	-0.25	Colorectal cancer;	chr2:191712122	chr2:191699476~191699631:-
OV	cis	rs11903757	1	rs80201920	ENSG00000281467.1	Clostridiales-1	-3.91	0.000123	0.0385	-0.43	-0.25	Colorectal cancer;	chr2:191712510	chr2:191699476~191699631:-
OV	cis	rs796364	0.806	rs76112266	ENSG00000232732.8	AC073043.1	3.91	0.000123	0.0385	0.42	0.25	Schizophrenia;	chr2:200222434	chr2:199867396~199911159:-
OV	cis	rs4964805	1	rs4964806	ENSG00000257681.1	RP11-341G23.4	3.91	0.000123	0.0385	0.31	0.25	Attention deficit hyperactivity disorder;	chr12:103798982	chr12:103746315~103768858:-
OV	cis	rs4964805	1	rs4964794	ENSG00000257681.1	RP11-341G23.4	3.91	0.000123	0.0385	0.31	0.25	Attention deficit hyperactivity disorder;	chr12:103800640	chr12:103746315~103768858:-
OV	cis	rs6128907	1	rs6128918	ENSG00000224635.1	RP4-564F22.5	3.91	0.000123	0.0385	0.37	0.25	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38762789	chr20:38406011~38416797:-
OV	cis	rs2999052	0.865	rs10934853	ENSG00000242551.2	POU5F1P6	-3.91	0.000123	0.0385	-0.31	-0.25	Hypospadias;	chr3:128319530	chr3:128674735~128677005:-
OV	cis	rs12073359	0.955	rs72694965	ENSG00000223945.2	RP11-458I7.1	-3.91	0.000123	0.0386	-0.4	-0.25	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150186473	chr1:150053864~150055034:+
OV	cis	rs6545883	0.965	rs2305156	ENSG00000273302.1	RP11-493E12.2	3.91	0.000123	0.0386	0.2	0.25	Tuberculosis;	chr2:61502133	chr2:61199979~61200769:+
OV	cis	rs2070488	0.804	rs13094715	ENSG00000229589.1	ACVR2B-AS1	3.91	0.000123	0.0386	0.28	0.25	Electrocardiographic conduction measures;	chr3:38462939	chr3:38451027~38454820:-
OV	cis	rs11951515	0.7	rs10941620	ENSG00000278487.1	RP11-447H19.4	-3.91	0.000123	0.0386	-0.29	-0.25	Metabolite levels  (X-11787);	chr5:43283594	chr5:43143362~43143514:-
OV	cis	rs13217239	0.621	rs12527231	ENSG00000261584.1	RP11-457M11.5	3.91	0.000123	0.0386	0.28	0.25	Schizophrenia;	chr6:27033509	chr6:26686241~26687964:+
OV	cis	rs13217239	0.646	rs12523820	ENSG00000261584.1	RP11-457M11.5	3.91	0.000123	0.0386	0.28	0.25	Schizophrenia;	chr6:27033723	chr6:26686241~26687964:+
OV	cis	rs7615952	0.546	rs16836896	ENSG00000241278.1	ENPP7P4	3.91	0.000123	0.0386	0.33	0.25	Blood pressure (smoking interaction);	chr3:125592418	chr3:125848223~125909372:+
OV	cis	rs9326248	0.861	rs11216172	ENSG00000280143.1	AP000892.6	3.91	0.000123	0.0386	0.29	0.25	Blood protein levels;	chr11:116879162	chr11:117204967~117210292:+
OV	cis	rs1862618	0.853	rs33322	ENSG00000271828.1	CTD-2310F14.1	3.91	0.000123	0.0386	0.41	0.25	Initial pursuit acceleration;	chr5:56879399	chr5:56927874~56929573:+
OV	cis	rs11951515	0.7	rs35239179	ENSG00000278487.1	RP11-447H19.4	-3.91	0.000123	0.0386	-0.3	-0.25	Metabolite levels  (X-11787);	chr5:43298455	chr5:43143362~43143514:-
OV	cis	rs11951515	0.637	rs4866813	ENSG00000278487.1	RP11-447H19.4	-3.91	0.000123	0.0386	-0.3	-0.25	Metabolite levels  (X-11787);	chr5:43300642	chr5:43143362~43143514:-
OV	cis	rs11951515	0.7	rs11739665	ENSG00000278487.1	RP11-447H19.4	-3.91	0.000123	0.0386	-0.3	-0.25	Metabolite levels  (X-11787);	chr5:43301791	chr5:43143362~43143514:-
OV	cis	rs11951515	0.7	rs10805672	ENSG00000278487.1	RP11-447H19.4	-3.91	0.000123	0.0386	-0.3	-0.25	Metabolite levels  (X-11787);	chr5:43303646	chr5:43143362~43143514:-
OV	cis	rs11951515	0.675	rs9790987	ENSG00000278487.1	RP11-447H19.4	-3.91	0.000123	0.0386	-0.3	-0.25	Metabolite levels  (X-11787);	chr5:43306131	chr5:43143362~43143514:-
OV	cis	rs11951515	0.663	rs66691321	ENSG00000278487.1	RP11-447H19.4	-3.91	0.000123	0.0386	-0.3	-0.25	Metabolite levels  (X-11787);	chr5:43308353	chr5:43143362~43143514:-
OV	cis	rs11951515	0.638	rs10941621	ENSG00000278487.1	RP11-447H19.4	-3.91	0.000123	0.0386	-0.3	-0.25	Metabolite levels  (X-11787);	chr5:43308533	chr5:43143362~43143514:-
OV	cis	rs11951515	0.676	rs10941622	ENSG00000278487.1	RP11-447H19.4	-3.91	0.000123	0.0386	-0.3	-0.25	Metabolite levels  (X-11787);	chr5:43308588	chr5:43143362~43143514:-
OV	cis	rs11951515	0.676	rs10941623	ENSG00000278487.1	RP11-447H19.4	-3.91	0.000123	0.0386	-0.3	-0.25	Metabolite levels  (X-11787);	chr5:43308739	chr5:43143362~43143514:-
OV	cis	rs11951515	0.7	rs10512825	ENSG00000278487.1	RP11-447H19.4	-3.91	0.000123	0.0386	-0.3	-0.25	Metabolite levels  (X-11787);	chr5:43309088	chr5:43143362~43143514:-
OV	cis	rs11951515	0.7	rs1548097	ENSG00000278487.1	RP11-447H19.4	-3.91	0.000123	0.0386	-0.3	-0.25	Metabolite levels  (X-11787);	chr5:43310713	chr5:43143362~43143514:-
OV	cis	rs11951515	0.7	rs12518032	ENSG00000278487.1	RP11-447H19.4	-3.91	0.000123	0.0386	-0.3	-0.25	Metabolite levels  (X-11787);	chr5:43311252	chr5:43143362~43143514:-
OV	cis	rs4493873	0.785	rs7841266	ENSG00000253738.1	OTUD6B-AS1	3.91	0.000123	0.0387	0.31	0.25	Migraine - clinic-based;	chr8:91105586	chr8:91059909~91070189:-
OV	cis	rs73198271	0.74	rs1039912	ENSG00000253893.2	FAM85B	3.91	0.000123	0.0387	0.32	0.25	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:8790719	chr8:8167819~8226614:-
OV	cis	rs2282300	0.739	rs1222210	ENSG00000242353.1	RP4-710M3.1	3.91	0.000123	0.0387	0.35	0.25	Morning vs. evening chronotype;	chr11:30340578	chr11:30368148~30368646:+
OV	cis	rs1867631	0.585	rs6694782	ENSG00000248458.2	RP4-598P13.1	-3.91	0.000123	0.0387	-0.26	-0.25	Menopause (age at onset);	chr1:66661079	chr1:66665864~66677027:-
OV	cis	rs853679	0.607	rs200489	ENSG00000226314.6	ZNF192P1	-3.91	0.000124	0.0388	-0.48	-0.25	Depression;	chr6:27830479	chr6:28161781~28169594:+
OV	cis	rs7927771	1	rs4752873	ENSG00000271350.1	CTD-2384B9.1	-3.91	0.000124	0.0388	-0.3	-0.25	Subjective well-being;	chr11:47835968	chr11:47041027~47041945:-
OV	cis	rs11157436	0.918	rs3811285	ENSG00000211812.1	TRAV26-2	-3.91	0.000124	0.0388	-0.28	-0.25	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22155322	chr14:22202583~22203368:+
OV	cis	rs875971	0.862	rs6460302	ENSG00000237310.1	GS1-124K5.4	3.91	0.000124	0.0388	0.25	0.25	Aortic root size;	chr7:66495270	chr7:66493706~66495474:+
OV	cis	rs11105298	0.891	rs11105310	ENSG00000257194.2	RP11-567C2.1	-3.91	0.000124	0.0388	-0.39	-0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89524900	chr12:90107739~90112779:+
OV	cis	rs13217239	0.646	rs6937880	ENSG00000261584.1	RP11-457M11.5	3.91	0.000124	0.0388	0.28	0.25	Schizophrenia;	chr6:27032457	chr6:26686241~26687964:+
OV	cis	rs10759883	0.651	rs816670	ENSG00000175611.10	LINC00476	-3.91	0.000124	0.0388	-0.31	-0.25	Nicotine dependence;	chr9:95813152	chr9:95759231~95875977:-
OV	cis	rs10992471	0.603	rs7045572	ENSG00000281156.1	MIR3651	-3.91	0.000124	0.0388	-0.29	-0.25	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92375682	chr9:92292458~92292547:-
OV	cis	rs7121800	0.962	rs10835675	ENSG00000254532.1	RP11-624D11.2	3.91	0.000124	0.0388	0.29	0.25	Pit-and-Fissure caries;	chr11:30498306	chr11:30044058~30084343:-
OV	cis	rs10754283	0.967	rs10737706	ENSG00000231613.1	RP5-943J3.1	3.91	0.000124	0.0388	0.27	0.25	Amyotrophic lateral sclerosis (sporadic);	chr1:89647020	chr1:89788914~89790492:+
OV	cis	rs2282300	0.739	rs35229181	ENSG00000242353.1	RP4-710M3.1	-3.91	0.000124	0.0388	-0.35	-0.25	Morning vs. evening chronotype;	chr11:30220151	chr11:30368148~30368646:+
OV	cis	rs2282300	0.739	rs34234618	ENSG00000242353.1	RP4-710M3.1	-3.91	0.000124	0.0388	-0.35	-0.25	Morning vs. evening chronotype;	chr11:30220154	chr11:30368148~30368646:+
OV	cis	rs8059260	0.604	rs741176	ENSG00000274038.1	RP11-66H6.4	3.91	0.000124	0.0389	0.49	0.25	Alcohol consumption over the past year;	chr16:11051953	chr16:11056556~11057034:+
OV	cis	rs34421088	0.585	rs10101661	ENSG00000270154.1	RP11-419I17.1	-3.91	0.000124	0.0389	-0.26	-0.25	Neuroticism;	chr8:11735995	chr8:12476462~12477122:+
OV	cis	rs720475	0.732	rs7784282	ENSG00000204959.4	ARHGEF34P	-3.91	0.000124	0.0389	-0.37	-0.25	Breast cancer;	chr7:144431561	chr7:144272445~144286966:-
OV	cis	rs4493873	0.812	rs7820904	ENSG00000253738.1	OTUD6B-AS1	3.91	0.000124	0.0389	0.31	0.25	Migraine - clinic-based;	chr8:91098708	chr8:91059909~91070189:-
OV	cis	rs17264034	0.948	rs112941079	ENSG00000250786.1	SNHG18	3.91	0.000124	0.0389	0.43	0.25	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9545986	chr5:9546200~9550609:+
OV	cis	rs17264034	0.796	rs113140904	ENSG00000250786.1	SNHG18	3.91	0.000124	0.0389	0.43	0.25	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9546023	chr5:9546200~9550609:+
OV	cis	rs2950393	0.804	rs1026565	ENSG00000241217.3	RN7SL809P	3.91	0.000124	0.0389	0.23	0.25	Platelet distribution width;	chr12:56744044	chr12:56670450~56670746:-
OV	cis	rs7927592	0.763	rs11822059	ENSG00000222339.1	AP000807.2	3.91	0.000124	0.0389	0.26	0.25	Total body bone mineral density;	chr11:68533354	chr11:68505572~68505651:-
OV	cis	rs7927771	1	rs11039426	ENSG00000271350.1	CTD-2384B9.1	-3.91	0.000124	0.0389	-0.3	-0.25	Subjective well-being;	chr11:47841567	chr11:47041027~47041945:-
OV	cis	rs7927771	1	rs12418852	ENSG00000271350.1	CTD-2384B9.1	-3.91	0.000124	0.0389	-0.3	-0.25	Subjective well-being;	chr11:47847301	chr11:47041027~47041945:-
OV	cis	rs17711722	0.523	rs365896	ENSG00000226824.5	RP4-756H11.3	3.9	0.000124	0.039	0.28	0.25	Calcium levels;	chr7:66045710	chr7:66654538~66669855:+
OV	cis	rs9649213	0.574	rs34830366	ENSG00000223402.1	AC074121.4	-3.9	0.000124	0.039	-0.3	-0.25	Prostate cancer (SNP x SNP interaction);	chr7:98270223	chr7:98478551~98479225:-
OV	cis	rs9649213	0.593	rs34776142	ENSG00000223402.1	AC074121.4	-3.9	0.000124	0.039	-0.3	-0.25	Prostate cancer (SNP x SNP interaction);	chr7:98270561	chr7:98478551~98479225:-
OV	cis	rs10483554	0.671	rs8023061	ENSG00000243038.1	RP11-58E21.1	3.9	0.000124	0.039	0.34	0.25	Oppositional defiant disorder dimensions in attention-deficit hyperactivity disorder;	chr14:49345712	chr14:50052857~50053569:+
OV	cis	rs1862618	0.802	rs4389648	ENSG00000271828.1	CTD-2310F14.1	3.9	0.000125	0.039	0.4	0.25	Initial pursuit acceleration;	chr5:56807775	chr5:56927874~56929573:+
OV	cis	rs61784830	0.642	rs61782915	ENSG00000280836.1	AL355480.1	-3.9	0.000125	0.039	-0.56	-0.25	Iron status biomarkers (total iron binding capacity);	chr1:46108067	chr1:45581219~45581321:-
OV	cis	rs11951515	0.663	rs11746629	ENSG00000278487.1	RP11-447H19.4	-3.9	0.000125	0.039	-0.29	-0.25	Metabolite levels  (X-11787);	chr5:43284109	chr5:43143362~43143514:-
OV	cis	rs10986311	0.681	rs10818937	ENSG00000227200.1	RP11-121A14.3	-3.9	0.000125	0.039	-0.23	-0.25	Vitiligo;	chr9:124253161	chr9:124262876~124265809:+
OV	cis	rs2999052	1	rs2687720	ENSG00000277250.1	Metazoa_SRP	3.9	0.000125	0.0391	0.3	0.25	Hypospadias;	chr3:128200112	chr3:128673681~128674021:-
OV	cis	rs4927850	1	rs7627706	ENSG00000242086.7	LINC00969	3.9	0.000125	0.0391	0.26	0.25	Pancreatic cancer;	chr3:196026482	chr3:195658062~195739964:+
OV	cis	rs8059260	0.877	rs111352543	ENSG00000274038.1	RP11-66H6.4	-3.9	0.000125	0.0391	-0.43	-0.25	Alcohol consumption over the past year;	chr16:10949603	chr16:11056556~11057034:+
OV	cis	rs11122895	0.967	rs11677976	ENSG00000228251.1	AC012442.6	-3.9	0.000125	0.0391	-0.24	-0.25	Allergic sensitization;	chr2:111710641	chr2:112590796~112591939:+
OV	cis	rs8059260	1	rs8057540	ENSG00000274038.1	RP11-66H6.4	-3.9	0.000125	0.0391	-0.42	-0.25	Alcohol consumption over the past year;	chr16:10951985	chr16:11056556~11057034:+
OV	cis	rs934734	0.752	rs268139	ENSG00000234255.7	AC012370.3	-3.9	0.000125	0.0391	-0.27	-0.25	Rheumatoid arthritis;	chr2:65379857	chr2:65439888~65456571:-
OV	cis	rs1823913	0.637	rs11688994	ENSG00000227542.1	AC092614.2	3.9	0.000125	0.0391	0.27	0.25	Obesity-related traits;	chr2:191266242	chr2:191229165~191246172:-
OV	cis	rs875971	1	rs6946143	ENSG00000237310.1	GS1-124K5.4	3.9	0.000125	0.0391	0.25	0.25	Aortic root size;	chr7:66114735	chr7:66493706~66495474:+
OV	cis	rs6120849	0.951	rs55670307	ENSG00000206582.1	Y_RNA	-3.9	0.000125	0.0391	-0.34	-0.25	Protein C levels;	chr20:35132691	chr20:34526510~34526606:-
OV	cis	rs853679	0.607	rs66868086	ENSG00000280107.1	AL022393.9	-3.9	0.000125	0.0391	-0.55	-0.25	Depression;	chr6:27898124	chr6:28170845~28172521:+
OV	cis	rs172166	0.694	rs2791332	ENSG00000204709.4	LINC01556	3.9	0.000125	0.0391	0.32	0.25	Cardiac Troponin-T levels;	chr6:28141010	chr6:28943877~28944537:+
OV	cis	rs6545883	0.862	rs11691734	ENSG00000270820.4	RP11-355B11.2	3.9	0.000125	0.0391	0.28	0.25	Tuberculosis;	chr2:61475331	chr2:61471188~61484130:+
OV	cis	rs2070488	0.574	rs57754356	ENSG00000229589.1	ACVR2B-AS1	3.9	0.000125	0.0391	0.28	0.25	Electrocardiographic conduction measures;	chr3:38447215	chr3:38451027~38454820:-
OV	cis	rs2070488	0.766	rs6808093	ENSG00000229589.1	ACVR2B-AS1	3.9	0.000125	0.0391	0.28	0.25	Electrocardiographic conduction measures;	chr3:38456669	chr3:38451027~38454820:-
OV	cis	rs2070488	0.804	rs35463537	ENSG00000229589.1	ACVR2B-AS1	3.9	0.000125	0.0391	0.28	0.25	Electrocardiographic conduction measures;	chr3:38456757	chr3:38451027~38454820:-
OV	cis	rs9368481	0.729	rs9379948	ENSG00000241549.7	GUSBP2	3.9	0.000125	0.0392	0.25	0.25	Autism spectrum disorder or schizophrenia;	chr6:26977004	chr6:26871484~26956554:-
OV	cis	rs1829883	0.607	rs10076841	ENSG00000227762.4	GUSBP8	3.9	0.000125	0.0392	0.27	0.25	Hemostatic factors and hematological phenotypes;	chr5:99699546	chr5:99532628~99534611:+
OV	cis	rs73201462	1	rs2687723	ENSG00000242551.2	POU5F1P6	3.9	0.000125	0.0392	0.37	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128146716	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs73192978	ENSG00000242551.2	POU5F1P6	3.9	0.000125	0.0392	0.37	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128149432	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs73192979	ENSG00000242551.2	POU5F1P6	3.9	0.000125	0.0392	0.37	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128149478	chr3:128674735~128677005:-
OV	cis	rs73201462	0.901	rs34749881	ENSG00000242551.2	POU5F1P6	3.9	0.000125	0.0392	0.37	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128151426	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs11711710	ENSG00000242551.2	POU5F1P6	3.9	0.000125	0.0392	0.37	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128153663	chr3:128674735~128677005:-
OV	cis	rs11719546	1	rs11719546	ENSG00000242551.2	POU5F1P6	3.9	0.000125	0.0392	0.37	0.25	Post bronchodilator FEV1;	chr3:128153759	chr3:128674735~128677005:-
OV	cis	rs17428076	0.874	rs12619041	ENSG00000228389.1	AC068039.4	3.9	0.000125	0.0392	0.34	0.25	Myopia;	chr2:171744206	chr2:171773482~171775844:+
OV	cis	rs41271951	0.542	rs66464034	ENSG00000223945.2	RP11-458I7.1	-3.9	0.000125	0.0392	-0.44	-0.25	Blood protein levels;	chr1:150523912	chr1:150053864~150055034:+
OV	cis	rs7829975	0.617	rs4841071	ENSG00000253893.2	FAM85B	-3.9	0.000125	0.0392	-0.27	-0.25	Mood instability;	chr8:8933634	chr8:8167819~8226614:-
OV	cis	rs9309473	0.615	rs62149774	ENSG00000163016.8	ALMS1P	3.9	0.000125	0.0392	0.33	0.25	Metabolite levels;	chr2:73560525	chr2:73644919~73685576:+
OV	cis	rs12358699	0.546	rs41301601	ENSG00000165511.6	C10orf25	3.9	0.000125	0.0392	0.66	0.25	Lung function (FEV1/FVC);	chr10:44983428	chr10:44997698~45000888:-
OV	cis	rs2117029	1	rs10783301	ENSG00000258017.1	RP11-386G11.10	-3.9	0.000125	0.0392	-0.31	-0.25	Intelligence (multi-trait analysis);	chr12:49045593	chr12:49127782~49147869:+
OV	cis	rs8177876	0.822	rs16954582	ENSG00000259867.4	RP11-525K10.3	-3.9	0.000125	0.0392	-0.45	-0.25	Plasma omega-3 polyunsaturated fatty acid level (eicosapentaenoic acid);	chr16:81080552	chr16:80155053~80563135:-
OV	cis	rs4713118	0.699	rs200969	ENSG00000226314.6	ZNF192P1	-3.9	0.000125	0.0392	-0.34	-0.25	Parkinson's disease;	chr6:27891675	chr6:28161781~28169594:+
OV	cis	rs507080	0.961	rs520543	ENSG00000278376.1	RP11-158I9.8	-3.9	0.000126	0.0392	-0.25	-0.25	Serum metabolite levels;	chr11:118667448	chr11:118791254~118793137:+
OV	cis	rs6545883	0.868	rs28749199	ENSG00000270820.4	RP11-355B11.2	3.9	0.000126	0.0392	0.29	0.25	Tuberculosis;	chr2:61599917	chr2:61471188~61484130:+
OV	cis	rs9393777	0.513	rs9379893	ENSG00000243307.2	POM121L6P	3.9	0.000126	0.0392	0.31	0.25	Intelligence (multi-trait analysis);	chr6:26584440	chr6:26896952~26898777:+
OV	cis	rs683250	1	rs662545	ENSG00000255541.1	RP11-727A23.8	-3.9	0.000126	0.0392	-0.32	-0.25	Subcortical brain region volumes;	chr11:83556843	chr11:83209399~83209634:+
OV	cis	rs774359	0.789	rs868857	ENSG00000234676.1	IFT74-AS1	3.9	0.000126	0.0392	0.31	0.25	Amyotrophic lateral sclerosis;	chr9:27488908	chr9:26955780~26956295:-
OV	cis	rs7927771	1	rs34910028	ENSG00000271350.1	CTD-2384B9.1	-3.9	0.000126	0.0392	-0.3	-0.25	Subjective well-being;	chr11:47736897	chr11:47041027~47041945:-
OV	cis	rs11602339	1	rs11602339	ENSG00000271350.1	CTD-2384B9.1	-3.9	0.000126	0.0392	-0.3	-0.25	Body mass index;	chr11:47739919	chr11:47041027~47041945:-
OV	cis	rs7927771	1	rs12421210	ENSG00000271350.1	CTD-2384B9.1	-3.9	0.000126	0.0392	-0.3	-0.25	Subjective well-being;	chr11:47758034	chr11:47041027~47041945:-
OV	cis	rs7927771	1	rs7927771	ENSG00000271350.1	CTD-2384B9.1	-3.9	0.000126	0.0392	-0.3	-0.25	Subjective well-being;	chr11:47759754	chr11:47041027~47041945:-
OV	cis	rs7927771	1	rs12361031	ENSG00000271350.1	CTD-2384B9.1	-3.9	0.000126	0.0392	-0.3	-0.25	Subjective well-being;	chr11:47761524	chr11:47041027~47041945:-
OV	cis	rs7927771	1	rs7947730	ENSG00000271350.1	CTD-2384B9.1	-3.9	0.000126	0.0392	-0.3	-0.25	Subjective well-being;	chr11:47764632	chr11:47041027~47041945:-
OV	cis	rs7927771	1	rs35902101	ENSG00000271350.1	CTD-2384B9.1	-3.9	0.000126	0.0392	-0.3	-0.25	Subjective well-being;	chr11:47773617	chr11:47041027~47041945:-
OV	cis	rs11039389	1	rs11039389	ENSG00000271350.1	CTD-2384B9.1	-3.9	0.000126	0.0392	-0.3	-0.25	Neuroticism;	chr11:47774510	chr11:47041027~47041945:-
OV	cis	rs7927771	1	rs11039390	ENSG00000271350.1	CTD-2384B9.1	-3.9	0.000126	0.0392	-0.3	-0.25	Subjective well-being;	chr11:47774743	chr11:47041027~47041945:-
OV	cis	rs7927771	1	rs9909	ENSG00000271350.1	CTD-2384B9.1	-3.9	0.000126	0.0392	-0.3	-0.25	Subjective well-being;	chr11:47778223	chr11:47041027~47041945:-
OV	cis	rs7927771	1	rs7105282	ENSG00000271350.1	CTD-2384B9.1	-3.9	0.000126	0.0392	-0.3	-0.25	Subjective well-being;	chr11:47784062	chr11:47041027~47041945:-
OV	cis	rs7927771	1	rs12787330	ENSG00000271350.1	CTD-2384B9.1	-3.9	0.000126	0.0392	-0.3	-0.25	Subjective well-being;	chr11:47790759	chr11:47041027~47041945:-
OV	cis	rs7927771	1	rs7120333	ENSG00000271350.1	CTD-2384B9.1	-3.9	0.000126	0.0392	-0.3	-0.25	Subjective well-being;	chr11:47795889	chr11:47041027~47041945:-
OV	cis	rs7927771	1	rs11605774	ENSG00000271350.1	CTD-2384B9.1	-3.9	0.000126	0.0392	-0.3	-0.25	Subjective well-being;	chr11:47811241	chr11:47041027~47041945:-
OV	cis	rs7927771	1	rs11039412	ENSG00000271350.1	CTD-2384B9.1	-3.9	0.000126	0.0392	-0.3	-0.25	Subjective well-being;	chr11:47820029	chr11:47041027~47041945:-
OV	cis	rs7927771	0.965	rs11039416	ENSG00000271350.1	CTD-2384B9.1	-3.9	0.000126	0.0392	-0.3	-0.25	Subjective well-being;	chr11:47825159	chr11:47041027~47041945:-
OV	cis	rs7927771	0.965	rs35985502	ENSG00000271350.1	CTD-2384B9.1	-3.9	0.000126	0.0392	-0.3	-0.25	Subjective well-being;	chr11:47825876	chr11:47041027~47041945:-
OV	cis	rs6657613	0.68	rs6698160	ENSG00000186715.9	MST1L	-3.9	0.000126	0.0393	-0.27	-0.25	Hip circumference adjusted for BMI;	chr1:17049067	chr1:16754910~16770237:-
OV	cis	rs6657613	0.68	rs6701200	ENSG00000186715.9	MST1L	-3.9	0.000126	0.0393	-0.27	-0.25	Hip circumference adjusted for BMI;	chr1:17049085	chr1:16754910~16770237:-
OV	cis	rs6657613	0.68	rs12122144	ENSG00000186715.9	MST1L	-3.9	0.000126	0.0393	-0.27	-0.25	Hip circumference adjusted for BMI;	chr1:17049279	chr1:16754910~16770237:-
OV	cis	rs6657613	0.68	rs1546925	ENSG00000186715.9	MST1L	-3.9	0.000126	0.0393	-0.27	-0.25	Hip circumference adjusted for BMI;	chr1:17049801	chr1:16754910~16770237:-
OV	cis	rs6657613	0.68	rs6700594	ENSG00000186715.9	MST1L	-3.9	0.000126	0.0393	-0.27	-0.25	Hip circumference adjusted for BMI;	chr1:17050016	chr1:16754910~16770237:-
OV	cis	rs7635879	0.693	rs4687496	ENSG00000230102.6	RP11-407B7.1	3.9	0.000126	0.0393	0.28	0.25	Breastfeeding duration;	chr3:194011436	chr3:194005259~194070970:-
OV	cis	rs1950626	0.75	rs35820579	ENSG00000258399.5	MEG8	-3.9	0.000126	0.0393	-0.26	-0.25	Pelvic organ prolapse (moderate/severe);	chr14:100969178	chr14:100894770~100935999:+
OV	cis	rs3743102	1	rs3743102	ENSG00000278603.1	RP13-608F4.5	3.9	0.000126	0.0393	0.37	0.25	Colorectal adenoma (advanced);	chr15:82758642	chr15:82472203~82472426:+
OV	cis	rs13178541	0.745	rs4976326	ENSG00000250378.1	RP11-119J18.1	3.9	0.000126	0.0393	0.36	0.25	IgG glycosylation;	chr5:135728800	chr5:135812667~135826582:+
OV	cis	rs992157	0.56	rs6436048	ENSG00000237281.1	CATIP-AS2	-3.9	0.000126	0.0393	-0.3	-0.25	Colorectal cancer;	chr2:218244310	chr2:218326889~218357966:-
OV	cis	rs7771547	0.589	rs6941918	ENSG00000240733.3	RN7SL502P	3.9	0.000126	0.0393	0.3	0.25	Platelet distribution width;	chr6:36546944	chr6:36450912~36451201:-
OV	cis	rs853679	0.607	rs13211507	ENSG00000226314.6	ZNF192P1	-3.9	0.000126	0.0393	-0.56	-0.25	Depression;	chr6:28289600	chr6:28161781~28169594:+
OV	cis	rs853679	0.607	rs34691223	ENSG00000226314.6	ZNF192P1	-3.9	0.000126	0.0393	-0.56	-0.25	Depression;	chr6:28290431	chr6:28161781~28169594:+
OV	cis	rs73201462	1	rs34409786	ENSG00000242551.2	POU5F1P6	3.9	0.000126	0.0393	0.38	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128169332	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs13067650	ENSG00000242551.2	POU5F1P6	3.9	0.000126	0.0393	0.38	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128170699	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs11706455	ENSG00000242551.2	POU5F1P6	3.9	0.000126	0.0393	0.38	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128173148	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs11712798	ENSG00000242551.2	POU5F1P6	3.9	0.000126	0.0393	0.38	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128175451	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2811511	ENSG00000242551.2	POU5F1P6	3.9	0.000126	0.0393	0.38	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128194145	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2687730	ENSG00000242551.2	POU5F1P6	3.9	0.000126	0.0393	0.38	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128196614	chr3:128674735~128677005:-
OV	cis	rs73201462	0.901	rs2811486	ENSG00000242551.2	POU5F1P6	3.9	0.000126	0.0393	0.38	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128201232	chr3:128674735~128677005:-
OV	cis	rs2239547	0.522	rs2581780	ENSG00000242142.1	SERBP1P3	-3.9	0.000126	0.0393	-0.33	-0.25	Schizophrenia;	chr3:53024944	chr3:53064283~53065091:-
OV	cis	rs853679	0.527	rs853693	ENSG00000204709.4	LINC01556	3.9	0.000126	0.0393	0.3	0.25	Depression;	chr6:28314871	chr6:28943877~28944537:+
OV	cis	rs934734	0.789	rs4303705	ENSG00000234255.7	AC012370.3	-3.9	0.000126	0.0394	-0.27	-0.25	Rheumatoid arthritis;	chr2:65392576	chr2:65439888~65456571:-
OV	cis	rs934734	0.752	rs2661796	ENSG00000234255.7	AC012370.3	-3.9	0.000126	0.0394	-0.27	-0.25	Rheumatoid arthritis;	chr2:65400272	chr2:65439888~65456571:-
OV	cis	rs9880211	0.8	rs9819856	ENSG00000239213.4	NCK1-AS1	3.9	0.000126	0.0394	0.33	0.25	Height;Body mass index;	chr3:136773307	chr3:136841726~136862054:-
OV	cis	rs9880211	0.8	rs75901823	ENSG00000239213.4	NCK1-AS1	3.9	0.000126	0.0394	0.33	0.25	Height;Body mass index;	chr3:136775309	chr3:136841726~136862054:-
OV	cis	rs9880211	0.706	rs35716521	ENSG00000239213.4	NCK1-AS1	3.9	0.000126	0.0394	0.33	0.25	Height;Body mass index;	chr3:136775828	chr3:136841726~136862054:-
OV	cis	rs9880211	0.8	rs17365792	ENSG00000239213.4	NCK1-AS1	3.9	0.000126	0.0394	0.33	0.25	Height;Body mass index;	chr3:136778550	chr3:136841726~136862054:-
OV	cis	rs858239	0.932	rs1728320	ENSG00000230042.1	AK3P3	-3.9	0.000126	0.0394	-0.26	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23280170	chr7:23129178~23129841:+
OV	cis	rs4295627	0.621	rs10100356	ENSG00000243402.1	RP11-473O4.1	-3.9	0.000126	0.0394	-0.28	-0.25	Glioma;	chr8:129613918	chr8:129864478~129865052:+
OV	cis	rs6921919	0.583	rs2071965	ENSG00000204709.4	LINC01556	3.9	0.000126	0.0394	0.3	0.25	Autism spectrum disorder or schizophrenia;	chr6:28435448	chr6:28943877~28944537:+
OV	cis	rs4664293	0.605	rs890095	ENSG00000224152.1	AC009506.1	3.9	0.000126	0.0394	0.26	0.25	Monocyte percentage of white cells;	chr2:159604708	chr2:159615296~159617082:+
OV	cis	rs9309473	0.514	rs62149630	ENSG00000163016.8	ALMS1P	3.9	0.000126	0.0394	0.35	0.25	Metabolite levels;	chr2:73354627	chr2:73644919~73685576:+
OV	cis	rs9649213	0.555	rs7785612	ENSG00000272950.1	RP11-307C18.1	3.9	0.000126	0.0394	0.29	0.25	Prostate cancer (SNP x SNP interaction);	chr7:98304555	chr7:98322853~98323430:+
OV	cis	rs1881797	0.527	rs1852908	ENSG00000227135.1	GCSAML-AS1	-3.9	0.000126	0.0394	-0.56	-0.25	Acute lymphoblastic leukemia (childhood);	chr1:247514958	chr1:247524679~247526752:-
OV	cis	rs10829156	0.732	rs7075678	ENSG00000225527.1	RP11-383B4.4	-3.9	0.000126	0.0394	-0.35	-0.25	Sudden cardiac arrest;	chr10:18585174	chr10:18531849~18533336:-
OV	cis	rs7246657	0.943	rs8109038	ENSG00000226686.6	LINC01535	3.9	0.000126	0.0394	0.38	0.25	Coronary artery calcification;	chr19:37524807	chr19:37251912~37265535:+
OV	cis	rs9473147	0.516	rs13212790	ENSG00000270761.1	RP11-385F7.1	-3.9	0.000126	0.0394	-0.29	-0.25	Platelet distribution width;Mean platelet volume;	chr6:47608631	chr6:47477243~47477572:-
OV	cis	rs7726839	0.54	rs4957083	ENSG00000271781.1	CTD-2589H19.6	-3.9	0.000126	0.0395	-0.39	-0.25	Obesity-related traits;	chr5:659228	chr5:675826~676616:+
OV	cis	rs10992471	0.702	rs10120915	ENSG00000281156.1	MIR3651	-3.9	0.000126	0.0395	-0.28	-0.25	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92785443	chr9:92292458~92292547:-
OV	cis	rs7980799	0.662	rs10844534	ENSG00000276148.1	RP11-278C7.4	3.9	0.000126	0.0395	0.27	0.25	Heart rate variability traits (RMSSD);Heart rate;	chr12:33293230	chr12:32725248~32725660:-
OV	cis	rs1555322	0.53	rs6060347	ENSG00000261582.1	RP4-614O4.11	-3.9	0.000127	0.0395	-0.29	-0.25	Attention deficit hyperactivity disorder;	chr20:35286348	chr20:35267885~35280043:-
OV	cis	rs2834288	0.535	rs881228	ENSG00000273102.1	AP000569.9	3.9	0.000127	0.0395	0.28	0.25	Gut microbiota (bacterial taxa);	chr21:33950387	chr21:33967101~33968573:-
OV	cis	rs853679	0.607	rs35030260	ENSG00000226314.6	ZNF192P1	-3.9	0.000127	0.0395	-0.55	-0.25	Depression;	chr6:28337731	chr6:28161781~28169594:+
OV	cis	rs853679	0.607	rs13217619	ENSG00000226314.6	ZNF192P1	-3.9	0.000127	0.0395	-0.55	-0.25	Depression;	chr6:28338894	chr6:28161781~28169594:+
OV	cis	rs73201462	1	rs2955089	ENSG00000242551.2	POU5F1P6	-3.9	0.000127	0.0395	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128250487	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2955090	ENSG00000242551.2	POU5F1P6	-3.9	0.000127	0.0395	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128250528	chr3:128674735~128677005:-
OV	cis	rs1568889	1	rs12797689	ENSG00000255322.1	RP11-22P4.1	3.9	0.000127	0.0395	0.37	0.25	Bipolar disorder;	chr11:28054495	chr11:28352107~28527041:+
OV	cis	rs4356975	0.563	rs12512526	ENSG00000251284.2	RP13-644M16.1	-3.9	0.000127	0.0396	-0.26	-0.25	Obesity-related traits;	chr4:69100700	chr4:69125274~69126451:+
OV	cis	rs4356975	0.522	rs34386959	ENSG00000251284.2	RP13-644M16.1	-3.9	0.000127	0.0396	-0.26	-0.25	Obesity-related traits;	chr4:69100837	chr4:69125274~69126451:+
OV	cis	rs4356975	0.563	rs55834557	ENSG00000251284.2	RP13-644M16.1	-3.9	0.000127	0.0396	-0.26	-0.25	Obesity-related traits;	chr4:69100876	chr4:69125274~69126451:+
OV	cis	rs4356975	0.522	rs56388229	ENSG00000251284.2	RP13-644M16.1	-3.9	0.000127	0.0396	-0.26	-0.25	Obesity-related traits;	chr4:69100940	chr4:69125274~69126451:+
OV	cis	rs4356975	0.563	rs34318523	ENSG00000251284.2	RP13-644M16.1	-3.9	0.000127	0.0396	-0.26	-0.25	Obesity-related traits;	chr4:69101135	chr4:69125274~69126451:+
OV	cis	rs2153535	1	rs11243251	ENSG00000230939.1	RP11-314C16.1	3.9	0.000127	0.0396	0.28	0.25	Motion sickness;	chr6:8367974	chr6:8784178~8785445:+
OV	cis	rs12073359	0.913	rs12138231	ENSG00000223945.2	RP11-458I7.1	3.9	0.000127	0.0396	0.37	0.25	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150143220	chr1:150053864~150055034:+
OV	cis	rs858239	0.896	rs1637193	ENSG00000230042.1	AK3P3	-3.9	0.000127	0.0396	-0.27	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23220632	chr7:23129178~23129841:+
OV	cis	rs4910157	1	rs4910157	ENSG00000254860.4	TMEM9B-AS1	-3.9	0.000127	0.0396	-0.27	-0.25	Tonsillectomy;	chr11:8919668	chr11:8964675~8977527:+
OV	cis	rs13631	0.894	rs7856589	ENSG00000268996.3	MAN1B1-AS1	-3.9	0.000127	0.0396	-0.21	-0.25	Cerebrospinal fluid biomarker levels;	chr9:137109469	chr9:137084946~137086817:-
OV	cis	rs3743772	0.5	rs8045574	ENSG00000279722.1	RP11-44F14.6	-3.9	0.000127	0.0396	-0.38	-0.25	Depressive symptoms (SSRI exposure interaction);	chr16:53395293	chr16:53487607~53489943:-
OV	cis	rs2058350	0.812	rs2072386	ENSG00000250770.2	RP5-1063M23.1	-3.9	0.000127	0.0396	-0.32	-0.25	Cognitive performance;	chr12:3841016	chr12:3296202~3300224:-
OV	cis	rs2058350	0.773	rs2072387	ENSG00000250770.2	RP5-1063M23.1	-3.9	0.000127	0.0396	-0.32	-0.25	Cognitive performance;	chr12:3841018	chr12:3296202~3300224:-
OV	cis	rs3733585	0.673	rs10000983	ENSG00000250413.1	RP11-448G15.1	3.9	0.000127	0.0397	0.27	0.25	Cleft plate (environmental tobacco smoke interaction);	chr4:9949982	chr4:10006482~10009725:+
OV	cis	rs3733585	0.699	rs1079128	ENSG00000250413.1	RP11-448G15.1	3.9	0.000127	0.0397	0.27	0.25	Cleft plate (environmental tobacco smoke interaction);	chr4:9949597	chr4:10006482~10009725:+
OV	cis	rs78545713	1	rs114970164	ENSG00000241549.7	GUSBP2	-3.9	0.000127	0.0397	-0.36	-0.25	Iron status biomarkers (total iron binding capacity);	chr6:26241765	chr6:26871484~26956554:-
OV	cis	rs934734	0.752	rs268131	ENSG00000234255.7	AC012370.3	-3.9	0.000127	0.0397	-0.27	-0.25	Rheumatoid arthritis;	chr2:65383337	chr2:65439888~65456571:-
OV	cis	rs2286503	0.809	rs4719716	ENSG00000228649.7	AC005682.5	3.9	0.000127	0.0397	0.31	0.25	Fibrinogen;	chr7:22821750	chr7:22854178~22861579:+
OV	cis	rs2286503	0.839	rs2270108	ENSG00000228649.7	AC005682.5	3.9	0.000127	0.0397	0.31	0.25	Fibrinogen;	chr7:22822512	chr7:22854178~22861579:+
OV	cis	rs2286503	0.839	rs2270107	ENSG00000228649.7	AC005682.5	3.9	0.000127	0.0397	0.31	0.25	Fibrinogen;	chr7:22822564	chr7:22854178~22861579:+
OV	cis	rs2286503	0.839	rs2270103	ENSG00000228649.7	AC005682.5	3.9	0.000127	0.0397	0.31	0.25	Fibrinogen;	chr7:22823103	chr7:22854178~22861579:+
OV	cis	rs10783487	0.749	rs3817606	ENSG00000258279.2	LINC00592	3.9	0.000127	0.0397	0.31	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr12:52091857	chr12:52210930~52223804:+
OV	cis	rs55665837	1	rs4412729	ENSG00000251991.1	RNU7-49P	3.9	0.000128	0.0397	0.28	0.25	Vitamin D levels;	chr11:14417454	chr11:14478892~14478953:+
OV	cis	rs897984	0.647	rs7203999	ENSG00000232748.3	RP11-196G11.6	3.9	0.000128	0.0398	0.27	0.25	Dementia with Lewy bodies;	chr16:31006233	chr16:31056460~31062803:+
OV	cis	rs2117029	0.862	rs10875915	ENSG00000258017.1	RP11-386G11.10	-3.9	0.000128	0.0398	-0.32	-0.25	Intelligence (multi-trait analysis);	chr12:49036311	chr12:49127782~49147869:+
OV	cis	rs853679	0.546	rs200949	ENSG00000280107.1	AL022393.9	-3.9	0.000128	0.0398	-0.4	-0.25	Depression;	chr6:27867657	chr6:28170845~28172521:+
OV	cis	rs992157	0.835	rs6707559	ENSG00000261338.2	RP11-378A13.1	3.9	0.000128	0.0398	0.29	0.25	Colorectal cancer;	chr2:218278050	chr2:218255319~218257366:+
OV	cis	rs801193	1	rs2707845	ENSG00000224316.1	RP11-479O9.2	3.9	0.000128	0.0398	0.27	0.25	Aortic root size;	chr7:66733811	chr7:65773620~65802067:+
OV	cis	rs7617773	0.539	rs12486944	ENSG00000228638.1	FCF1P2	-3.9	0.000128	0.0398	-0.3	-0.25	Coronary artery disease;	chr3:48348526	chr3:48290793~48291375:-
OV	cis	rs10214930	0.697	rs2041714	ENSG00000235574.1	AC073150.6	-3.9	0.000128	0.0398	-0.3	-0.25	Hypospadias;	chr7:27559228	chr7:27491682~27492765:-
OV	cis	rs9649213	0.574	rs7802541	ENSG00000272950.1	RP11-307C18.1	3.9	0.000128	0.0398	0.29	0.25	Prostate cancer (SNP x SNP interaction);	chr7:98304543	chr7:98322853~98323430:+
OV	cis	rs941207	0.756	rs2950394	ENSG00000241217.3	RN7SL809P	-3.9	0.000128	0.0398	-0.28	-0.25	Platelet count;	chr12:56644548	chr12:56670450~56670746:-
OV	cis	rs4266144	1	rs4561781	ENSG00000244515.1	KRT18P34	3.9	0.000128	0.0399	0.3	0.25	Coronary artery disease;	chr3:157135154	chr3:157162663~157163932:-
OV	cis	rs61990749	0.511	rs7146020	ENSG00000239272.1	RPL21P10	3.9	0.000128	0.0399	0.37	0.25	Fibroblast growth factor basic levels;	chr14:77891976	chr14:77683202~77683989:-
OV	cis	rs354033	1	rs354033	ENSG00000280992.1	AC004932.1	-3.9	0.000128	0.0399	-0.26	-0.25	Multiple sclerosis;	chr7:149592373	chr7:149541747~149541846:-
OV	cis	rs858239	0.899	rs28635122	ENSG00000230042.1	AK3P3	-3.9	0.000128	0.0399	-0.27	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23270562	chr7:23129178~23129841:+
OV	cis	rs7646881	0.5	rs73022762	ENSG00000272087.1	RP11-379F4.7	3.9	0.000128	0.0399	0.36	0.25	Tetralogy of Fallot;	chr3:158572516	chr3:158693120~158693768:-
OV	cis	rs4664293	0.585	rs34385495	ENSG00000226266.5	AC009961.3	3.9	0.000128	0.0399	0.3	0.25	Monocyte percentage of white cells;	chr2:159656372	chr2:159670708~159712435:-
OV	cis	rs4761702	1	rs4761701	ENSG00000257512.1	RP11-486A14.1	-3.9	0.000128	0.0399	-0.29	-0.25	Immature fraction of reticulocytes;	chr12:93315956	chr12:93314809~93315941:+
OV	cis	rs7927771	0.542	rs7122217	ENSG00000280615.1	Y_RNA	-3.9	0.000128	0.0399	-0.26	-0.25	Subjective well-being;	chr11:47756368	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs12421563	ENSG00000280615.1	Y_RNA	-3.9	0.000128	0.0399	-0.26	-0.25	Subjective well-being;	chr11:47758670	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs10742820	ENSG00000280615.1	Y_RNA	-3.9	0.000128	0.0399	-0.26	-0.25	Subjective well-being;	chr11:47759505	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs7124396	ENSG00000280615.1	Y_RNA	-3.9	0.000128	0.0399	-0.26	-0.25	Subjective well-being;	chr11:47765882	chr11:47614898~47614994:-
OV	cis	rs7124681	0.584	rs4752792	ENSG00000280615.1	Y_RNA	-3.9	0.000128	0.0399	-0.26	-0.25	Body mass index;Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:47794150	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs10838769	ENSG00000280615.1	Y_RNA	-3.9	0.000128	0.0399	-0.26	-0.25	Subjective well-being;	chr11:47803781	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs1563820	ENSG00000280615.1	Y_RNA	-3.9	0.000128	0.0399	-0.26	-0.25	Subjective well-being;	chr11:47811846	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs4752796	ENSG00000280615.1	Y_RNA	-3.9	0.000128	0.0399	-0.26	-0.25	Subjective well-being;	chr11:47820310	chr11:47614898~47614994:-
OV	cis	rs7927771	0.524	rs7122182	ENSG00000280615.1	Y_RNA	-3.9	0.000128	0.0399	-0.26	-0.25	Subjective well-being;	chr11:47821581	chr11:47614898~47614994:-
OV	cis	rs7651736	1	rs7651736	ENSG00000261758.1	RP11-102M11.2	3.9	0.000129	0.04	0.27	0.25	Neuroticism;	chr3:137041756	chr3:136752630~136755780:+
OV	cis	rs7569084	0.687	rs1344891	ENSG00000204929.10	AC074391.1	3.9	0.000129	0.04	0.31	0.25	Sum eosinophil basophil counts;	chr2:65458890	chr2:65436711~66084639:+
OV	cis	rs1580019	0.539	rs11769109	ENSG00000231952.3	DPY19L1P2	-3.9	0.000129	0.04	-0.31	-0.25	Cognitive ability;	chr7:32531740	chr7:32812757~32838570:+
OV	cis	rs78545713	1	rs11753610	ENSG00000241549.7	GUSBP2	3.9	0.000129	0.04	0.35	0.25	Iron status biomarkers (total iron binding capacity);	chr6:26251373	chr6:26871484~26956554:-
OV	cis	rs7144018	1	rs7144018	ENSG00000259969.1	RP11-999E24.3	3.9	0.000129	0.04	0.39	0.25	Multiple myeloma (IgH translocation);	chr14:57140349	chr14:57993545~57994525:-
OV	cis	rs801193	1	rs1553609	ENSG00000224316.1	RP11-479O9.2	3.9	0.000129	0.04	0.27	0.25	Aortic root size;	chr7:66732152	chr7:65773620~65802067:+
OV	cis	rs801193	1	rs1553610	ENSG00000224316.1	RP11-479O9.2	3.9	0.000129	0.04	0.27	0.25	Aortic root size;	chr7:66732246	chr7:65773620~65802067:+
OV	cis	rs11951515	0.7	rs3733769	ENSG00000278487.1	RP11-447H19.4	-3.9	0.000129	0.04	-0.3	-0.25	Metabolite levels  (X-11787);	chr5:43297042	chr5:43143362~43143514:-
OV	cis	rs4132509	1	rs10927050	ENSG00000227230.1	RP11-261C10.5	-3.9	0.000129	0.04	-0.3	-0.25	RR interval (heart rate);	chr1:243642605	chr1:243135898~243140588:+
OV	cis	rs801193	0.66	rs1962050	ENSG00000236529.1	RP13-254B10.1	-3.9	0.000129	0.0401	-0.26	-0.25	Aortic root size;	chr7:66775021	chr7:65840212~65840596:+
OV	cis	rs11239930	0.517	rs4950354	ENSG00000229828.2	PDE4DIP1	3.9	0.000129	0.0401	0.33	0.25	AIDS progression;	chr1:147082674	chr1:148080598~148093883:+
OV	cis	rs11239930	0.538	rs4950355	ENSG00000229828.2	PDE4DIP1	3.9	0.000129	0.0401	0.33	0.25	AIDS progression;	chr1:147082700	chr1:148080598~148093883:+
OV	cis	rs11239930	0.538	rs9663073	ENSG00000229828.2	PDE4DIP1	3.9	0.000129	0.0401	0.33	0.25	AIDS progression;	chr1:147083022	chr1:148080598~148093883:+
OV	cis	rs6723108	0.627	rs7593370	ENSG00000224043.6	CCNT2-AS1	3.9	0.000129	0.0401	0.3	0.25	Type 2 diabetes;	chr2:134865947	chr2:134735464~134918710:-
OV	cis	rs853679	0.599	rs13193295	ENSG00000226314.6	ZNF192P1	-3.9	0.000129	0.0401	-0.59	-0.25	Depression;	chr6:28035450	chr6:28161781~28169594:+
OV	cis	rs4761702	0.857	rs1135400	ENSG00000257252.4	RP11-486A14.2	3.9	0.000129	0.0401	0.28	0.25	Immature fraction of reticulocytes;	chr12:93315763	chr12:93317135~93377736:-
OV	cis	rs7646881	0.544	rs16829273	ENSG00000272087.1	RP11-379F4.7	-3.9	0.000129	0.0401	-0.36	-0.25	Tetralogy of Fallot;	chr3:158664831	chr3:158693120~158693768:-
OV	cis	rs12220898	0.85	rs2889782	ENSG00000235939.1	RP11-123B3.2	-3.9	0.000129	0.0401	-0.48	-0.25	Inflammatory biomarkers;	chr10:49351731	chr10:49419277~49472903:+
OV	cis	rs7395581	0.918	rs11039166	ENSG00000271350.1	CTD-2384B9.1	3.9	0.000129	0.0401	0.29	0.25	HDL cholesterol;	chr11:47295140	chr11:47041027~47041945:-
OV	cis	rs9880211	0.679	rs9818740	ENSG00000261758.1	RP11-102M11.2	-3.9	0.000129	0.0401	-0.31	-0.25	Height;Body mass index;	chr3:136220744	chr3:136752630~136755780:+
OV	cis	rs6593680	0.523	rs6678734	ENSG00000237416.5	RP11-465K1.2	3.9	0.000129	0.0401	0.28	0.25	Intelligence (multi-trait analysis);	chr1:95711007	chr1:94836748~94855426:-
OV	cis	rs6593680	0.523	rs12128772	ENSG00000237416.5	RP11-465K1.2	3.9	0.000129	0.0401	0.28	0.25	Intelligence (multi-trait analysis);	chr1:95711153	chr1:94836748~94855426:-
OV	cis	rs6593680	0.523	rs12128864	ENSG00000237416.5	RP11-465K1.2	3.9	0.000129	0.0401	0.28	0.25	Intelligence (multi-trait analysis);	chr1:95711458	chr1:94836748~94855426:-
OV	cis	rs6593680	0.523	rs34701878	ENSG00000237416.5	RP11-465K1.2	3.9	0.000129	0.0401	0.28	0.25	Intelligence (multi-trait analysis);	chr1:95711517	chr1:94836748~94855426:-
OV	cis	rs9309473	0.66	rs11686541	ENSG00000163016.8	ALMS1P	3.9	0.000129	0.0401	0.32	0.25	Metabolite levels;	chr2:73477348	chr2:73644919~73685576:+
OV	cis	rs801193	0.569	rs2659907	ENSG00000236529.1	RP13-254B10.1	3.9	0.000129	0.0401	0.26	0.25	Aortic root size;	chr7:66699045	chr7:65840212~65840596:+
OV	cis	rs10486158	1	rs3857760	ENSG00000234141.1	AC009473.1	-3.9	0.000129	0.0401	-0.38	-0.25	Bipolar disorder and schizophrenia;	chr7:7362048	chr7:7949853~7950709:-
OV	cis	rs11719079	1	rs11719079	ENSG00000242551.2	POU5F1P6	3.9	0.000129	0.0401	0.41	0.25	Post bronchodilator FEV1;	chr3:128105206	chr3:128674735~128677005:-
OV	cis	rs17277593	0.628	rs13294545	ENSG00000229268.1	PES1P2	-3.89	0.000129	0.0401	-0.34	-0.25	Endometriosis;	chr9:13965922	chr9:13986175~13987909:+
OV	cis	rs6759004	1	rs6759004	ENSG00000183308.6	AC005037.3	3.89	0.000129	0.0402	0.45	0.25	Triptolide cytotoxicity;	chr2:201139953	chr2:200963263~201009102:+
OV	cis	rs9649213	0.531	rs35216698	ENSG00000223402.1	AC074121.4	-3.89	0.000129	0.0402	-0.3	-0.25	Prostate cancer (SNP x SNP interaction);	chr7:98266863	chr7:98478551~98479225:-
OV	cis	rs6951245	0.638	rs74976697	ENSG00000229043.2	AC091729.9	-3.89	0.000129	0.0402	-0.42	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1120869	chr7:1160374~1165267:+
OV	cis	rs3858145	0.588	rs76854765	ENSG00000233590.1	RP11-153K11.3	-3.89	0.000129	0.0402	-0.37	-0.25	Optic nerve measurement (cup area);Optic nerve measurement (disc area);Optic cup area;	chr10:68277699	chr10:68233251~68242379:-
OV	cis	rs7927771	0.524	rs4752865	ENSG00000280615.1	Y_RNA	-3.89	0.000129	0.0402	-0.26	-0.25	Subjective well-being;	chr11:47738289	chr11:47614898~47614994:-
OV	cis	rs7615952	0.599	rs6803160	ENSG00000250012.1	RP11-124N2.1	-3.89	0.000129	0.0402	-0.3	-0.25	Blood pressure (smoking interaction);	chr3:125990711	chr3:126084220~126095349:+
OV	cis	rs7615952	0.688	rs12485622	ENSG00000250012.1	RP11-124N2.1	-3.89	0.000129	0.0402	-0.3	-0.25	Blood pressure (smoking interaction);	chr3:125991896	chr3:126084220~126095349:+
OV	cis	rs2599510	0.811	rs2754520	ENSG00000279544.1	AL133243.4	-3.89	0.000129	0.0402	-0.23	-0.25	Interleukin-18 levels;	chr2:32585226	chr2:32563328~32566436:+
OV	cis	rs56114371	0.777	rs200483	ENSG00000226314.6	ZNF192P1	-3.89	0.000129	0.0402	-0.47	-0.25	Breast cancer;	chr6:27807046	chr6:28161781~28169594:+
OV	cis	rs6071524	0.508	rs2254492	ENSG00000277581.1	RP4-616B8.6	-3.89	0.00013	0.0402	-0.3	-0.25	Autism spectrum disorder or schizophrenia;	chr20:38751676	chr20:38962472~38962993:+
OV	cis	rs881375	0.967	rs2109896	ENSG00000226752.6	PSMD5-AS1	-3.89	0.00013	0.0402	-0.28	-0.25	Rheumatoid arthritis;	chr9:120920828	chr9:120824828~120854385:+
OV	cis	rs6703335	0.87	rs10803142	ENSG00000227230.1	RP11-261C10.5	-3.89	0.00013	0.0402	-0.26	-0.25	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;	chr1:243434932	chr1:243135898~243140588:+
OV	cis	rs7667	0.812	rs12049394	ENSG00000240490.3	RN7SL277P	-3.89	0.00013	0.0402	-0.3	-0.25	Crohn's disease and psoriasis;	chr1:19455455	chr1:19424384~19424671:+
OV	cis	rs6142102	0.778	rs6059581	ENSG00000271803.1	RP1-63M2.5	3.89	0.00013	0.0402	0.32	0.25	Skin pigmentation;	chr20:33940582	chr20:33674517~33675380:+
OV	cis	rs10510102	0.516	rs11200301	ENSG00000226864.1	ATE1-AS1	3.89	0.00013	0.0402	0.45	0.25	Breast cancer;	chr10:121977976	chr10:121928312~121951965:+
OV	cis	rs7923609	0.756	rs6479908	ENSG00000232075.1	MRPL35P2	3.89	0.00013	0.0402	0.26	0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63573888	chr10:63634317~63634827:-
OV	cis	rs9473147	0.543	rs9349417	ENSG00000270761.1	RP11-385F7.1	-3.89	0.00013	0.0402	-0.29	-0.25	Platelet distribution width;Mean platelet volume;	chr6:47612921	chr6:47477243~47477572:-
OV	cis	rs9369695	0.883	rs9381581	ENSG00000270761.1	RP11-385F7.1	-3.89	0.00013	0.0402	-0.29	-0.25	Reticulocyte count;	chr6:47612959	chr6:47477243~47477572:-
OV	cis	rs1707322	0.721	rs10890333	ENSG00000234329.1	RP11-767N6.2	3.89	0.00013	0.0402	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45634650	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs12043945	ENSG00000234329.1	RP11-767N6.2	3.89	0.00013	0.0402	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45641250	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs12091503	ENSG00000234329.1	RP11-767N6.2	3.89	0.00013	0.0402	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45642196	chr1:45651039~45651826:-
OV	cis	rs9640161	0.789	rs6964110	ENSG00000261305.1	RP4-584D14.7	3.89	0.00013	0.0402	0.31	0.25	Blood protein levels;Circulating chemerin levels;	chr7:150344747	chr7:150341771~150342607:+
OV	cis	rs73201462	1	rs34955225	ENSG00000242551.2	POU5F1P6	3.89	0.00013	0.0402	0.4	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128106235	chr3:128674735~128677005:-
OV	cis	rs62184315	0.536	rs5742985	ENSG00000253559.1	OSGEPL1-AS1	-3.89	0.00013	0.0403	-0.34	-0.25	Alcohol dependence (age at onset);	chr2:189796383	chr2:189762704~189765556:+
OV	cis	rs694739	0.595	rs11542299	ENSG00000236935.1	AP003774.1	3.89	0.00013	0.0403	0.31	0.25	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64371333	chr11:64325050~64329504:-
OV	cis	rs9311474	1	rs7629072	ENSG00000243224.1	RP5-1157M23.2	-3.89	0.00013	0.0403	-0.27	-0.25	Electroencephalogram traits;	chr3:52271617	chr3:52239258~52241097:+
OV	cis	rs6792584	0.637	rs2634741	ENSG00000241316.5	SUCLG2-AS1	3.89	0.00013	0.0403	0.35	0.25	Corneal astigmatism;	chr3:67560847	chr3:67654697~67947713:+
OV	cis	rs9880211	0.613	rs34864445	ENSG00000239213.4	NCK1-AS1	3.89	0.00013	0.0403	0.3	0.25	Height;Body mass index;	chr3:136104082	chr3:136841726~136862054:-
OV	cis	rs10214930	0.697	rs10951171	ENSG00000235574.1	AC073150.6	-3.89	0.00013	0.0403	-0.3	-0.25	Hypospadias;	chr7:27571988	chr7:27491682~27492765:-
OV	cis	rs10214930	0.697	rs986706	ENSG00000235574.1	AC073150.6	-3.89	0.00013	0.0403	-0.3	-0.25	Hypospadias;	chr7:27573133	chr7:27491682~27492765:-
OV	cis	rs10214930	0.697	rs7806605	ENSG00000235574.1	AC073150.6	-3.89	0.00013	0.0403	-0.3	-0.25	Hypospadias;	chr7:27573966	chr7:27491682~27492765:-
OV	cis	rs10214930	0.697	rs4722719	ENSG00000235574.1	AC073150.6	-3.89	0.00013	0.0403	-0.3	-0.25	Hypospadias;	chr7:27575303	chr7:27491682~27492765:-
OV	cis	rs4927850	1	rs7614767	ENSG00000242086.7	LINC00969	3.89	0.00013	0.0403	0.25	0.25	Pancreatic cancer;	chr3:196026580	chr3:195658062~195739964:+
OV	cis	rs736408	0.5	rs2878762	ENSG00000242142.1	SERBP1P3	3.89	0.00013	0.0403	0.33	0.25	Bipolar disorder;	chr3:52884986	chr3:53064283~53065091:-
OV	cis	rs4664293	0.546	rs12469866	ENSG00000224152.1	AC009506.1	3.89	0.00013	0.0403	0.26	0.25	Monocyte percentage of white cells;	chr2:159766119	chr2:159615296~159617082:+
OV	cis	rs2348418	0.832	rs1907692	ENSG00000247934.4	RP11-967K21.1	3.89	0.00013	0.0403	0.24	0.25	Lung function (FEV1);Lung function (FVC);	chr12:28385178	chr12:28163298~28190738:-
OV	cis	rs12134151	0.905	rs1931243	ENSG00000237416.5	RP11-465K1.2	3.89	0.00013	0.0403	0.28	0.25	Educational attainment (years of education);	chr1:95733482	chr1:94836748~94855426:-
OV	cis	rs6128907	0.898	rs62202466	ENSG00000224635.1	RP4-564F22.5	3.89	0.00013	0.0403	0.37	0.25	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38753004	chr20:38406011~38416797:-
OV	cis	rs6128907	1	rs62202467	ENSG00000224635.1	RP4-564F22.5	3.89	0.00013	0.0403	0.37	0.25	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38753138	chr20:38406011~38416797:-
OV	cis	rs2950393	0.777	rs7966391	ENSG00000241217.3	RN7SL809P	3.89	0.00013	0.0403	0.24	0.25	Platelet distribution width;	chr12:56745272	chr12:56670450~56670746:-
OV	cis	rs494453	0.583	rs564807	ENSG00000227811.2	FAM212B-AS1	-3.89	0.00013	0.0403	-0.34	-0.25	Osteoporosis-related phenotypes;	chr1:111669679	chr1:111739841~111747798:+
OV	cis	rs9876781	1	rs4858793	ENSG00000229759.1	MRPS18AP1	-3.89	0.00013	0.0403	-0.28	-0.25	Longevity;	chr3:48373517	chr3:48256350~48256938:-
OV	cis	rs2999052	0.95	rs1554535	ENSG00000277250.1	Metazoa_SRP	3.89	0.00013	0.0403	0.3	0.25	Hypospadias;	chr3:128177143	chr3:128673681~128674021:-
OV	cis	rs875971	0.862	rs2901152	ENSG00000237310.1	GS1-124K5.4	-3.89	0.00013	0.0403	-0.25	-0.25	Aortic root size;	chr7:66300017	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs10263690	ENSG00000237310.1	GS1-124K5.4	-3.89	0.00013	0.0403	-0.25	-0.25	Aortic root size;	chr7:66301466	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs10250544	ENSG00000237310.1	GS1-124K5.4	-3.89	0.00013	0.0403	-0.25	-0.25	Aortic root size;	chr7:66301574	chr7:66493706~66495474:+
OV	cis	rs875971	0.895	rs12531677	ENSG00000237310.1	GS1-124K5.4	-3.89	0.00013	0.0403	-0.25	-0.25	Aortic root size;	chr7:66304099	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs7798630	ENSG00000237310.1	GS1-124K5.4	-3.89	0.00013	0.0403	-0.25	-0.25	Aortic root size;	chr7:66306492	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs11984115	ENSG00000237310.1	GS1-124K5.4	-3.89	0.00013	0.0403	-0.25	-0.25	Aortic root size;	chr7:66308872	chr7:66493706~66495474:+
OV	cis	rs875971	0.755	rs10228885	ENSG00000237310.1	GS1-124K5.4	-3.89	0.00013	0.0403	-0.25	-0.25	Aortic root size;	chr7:66315542	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs3893216	ENSG00000237310.1	GS1-124K5.4	-3.89	0.00013	0.0403	-0.25	-0.25	Aortic root size;	chr7:66325720	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs6958294	ENSG00000237310.1	GS1-124K5.4	-3.89	0.00013	0.0403	-0.25	-0.25	Aortic root size;	chr7:66329809	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs2088655	ENSG00000237310.1	GS1-124K5.4	-3.89	0.00013	0.0403	-0.25	-0.25	Aortic root size;	chr7:66330724	chr7:66493706~66495474:+
OV	cis	rs875971	0.895	rs10447522	ENSG00000237310.1	GS1-124K5.4	-3.89	0.00013	0.0403	-0.25	-0.25	Aortic root size;	chr7:66331087	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs2088653	ENSG00000237310.1	GS1-124K5.4	-3.89	0.00013	0.0403	-0.25	-0.25	Aortic root size;	chr7:66343621	chr7:66493706~66495474:+
OV	cis	rs875971	0.862	rs6460293	ENSG00000237310.1	GS1-124K5.4	-3.89	0.00013	0.0403	-0.25	-0.25	Aortic root size;	chr7:66345205	chr7:66493706~66495474:+
OV	cis	rs10740039	0.81	rs9415605	ENSG00000254271.1	RP11-131N11.4	-3.89	0.00013	0.0403	-0.34	-0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60616809	chr10:60734342~60741828:+
OV	cis	rs11951515	0.714	rs56071328	ENSG00000278487.1	RP11-447H19.4	-3.89	0.00013	0.0404	-0.29	-0.25	Metabolite levels  (X-11787);	chr5:43341225	chr5:43143362~43143514:-
OV	cis	rs67311347	0.544	rs6769627	ENSG00000223797.4	ENTPD3-AS1	3.89	0.00013	0.0404	0.26	0.25	Renal cell carcinoma;	chr3:40286354	chr3:40313802~40453329:-
OV	cis	rs6921919	0.832	rs17312661	ENSG00000216901.1	AL022393.7	3.89	0.00013	0.0404	0.39	0.25	Autism spectrum disorder or schizophrenia;	chr6:28332559	chr6:28176188~28176674:+
OV	cis	rs1538970	0.816	rs61788356	ENSG00000280836.1	AL355480.1	-3.89	0.00013	0.0404	-0.38	-0.25	Platelet count;	chr1:45541003	chr1:45581219~45581321:-
OV	cis	rs4702131	0.603	rs11956879	ENSG00000248699.1	CTD-2313D3.1	-3.89	0.00013	0.0404	-0.28	-0.25	Breast cancer;	chr5:16258685	chr5:15450701~15451811:+
OV	cis	rs12073359	1	rs12058502	ENSG00000223945.2	RP11-458I7.1	-3.89	0.00013	0.0404	-0.38	-0.25	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150037869	chr1:150053864~150055034:+
OV	cis	rs34421088	0.585	rs10101661	ENSG00000254423.1	RP11-351I21.7	-3.89	0.00013	0.0404	-0.26	-0.25	Neuroticism;	chr8:11735995	chr8:12374366~12375546:-
OV	cis	rs7017914	0.69	rs1838392	ENSG00000223220.1	Y_RNA	3.89	0.00013	0.0404	0.27	0.25	Bone mineral density;	chr8:70770348	chr8:70780914~70781008:-
OV	cis	rs9813712	0.78	rs7625942	ENSG00000228252.7	COL6A4P2	3.89	0.00013	0.0404	0.34	0.25	Response to amphetamines;	chr3:130232611	chr3:130212823~130273806:+
OV	cis	rs6737205	1	rs7577389	ENSG00000234945.6	GTF3C2-AS1	3.89	0.000131	0.0404	0.45	0.25	RR interval (tricyclic/tetracyclic antidepressant use interaction);	chr2:28099170	chr2:27335535~27342599:+
OV	cis	rs3758911	0.828	rs10890695	ENSG00000261098.1	RP11-819C21.1	-3.89	0.000131	0.0404	-0.25	-0.25	Coronary artery disease;	chr11:107294923	chr11:107312132~107316271:-
OV	cis	rs3758911	0.861	rs11212142	ENSG00000261098.1	RP11-819C21.1	-3.89	0.000131	0.0404	-0.25	-0.25	Coronary artery disease;	chr11:107302994	chr11:107312132~107316271:-
OV	cis	rs3758911	0.861	rs10789597	ENSG00000261098.1	RP11-819C21.1	-3.89	0.000131	0.0404	-0.25	-0.25	Coronary artery disease;	chr11:107304314	chr11:107312132~107316271:-
OV	cis	rs3758911	0.861	rs12285607	ENSG00000261098.1	RP11-819C21.1	-3.89	0.000131	0.0404	-0.25	-0.25	Coronary artery disease;	chr11:107304608	chr11:107312132~107316271:-
OV	cis	rs3758911	0.861	rs10890696	ENSG00000261098.1	RP11-819C21.1	-3.89	0.000131	0.0404	-0.25	-0.25	Coronary artery disease;	chr11:107306487	chr11:107312132~107316271:-
OV	cis	rs6921919	0.583	rs16894060	ENSG00000204709.4	LINC01556	3.89	0.000131	0.0405	0.31	0.25	Autism spectrum disorder or schizophrenia;	chr6:28394694	chr6:28943877~28944537:+
OV	cis	rs9310736	0.898	rs869784	ENSG00000233544.1	EIF3KP2	-3.89	0.000131	0.0405	-0.26	-0.25	Red blood cell traits;Mean corpuscular hemoglobin;Mean corpuscular volume;	chr3:24306517	chr3:24555834~24556459:+
OV	cis	rs6775745	1	rs6775745	ENSG00000248724.5	NPHP3-AS1	3.89	0.000131	0.0405	0.34	0.25	Neutrophil count;	chr3:132095056	chr3:132721750~132874223:+
OV	cis	rs10514805	0.557	rs77356752	ENSG00000234690.5	AC073283.4	-3.89	0.000131	0.0405	-0.45	-0.25	Electroencephalogram traits;	chr2:47499364	chr2:47192405~47345074:-
OV	cis	rs2898681	0.874	rs59649036	ENSG00000248375.1	RP11-177B4.1	-3.89	0.000131	0.0405	-0.35	-0.25	Optic nerve measurement (cup area);	chr4:52875008	chr4:52720081~52720831:-
OV	cis	rs17708984	0.585	rs7247875	ENSG00000270802.2	AC005776.1	3.89	0.000131	0.0405	0.27	0.25	Platelet distribution width;Platelet count;	chr19:16081815	chr19:15338948~15339237:+
OV	cis	rs9393777	0.92	rs13207689	ENSG00000280107.1	AL022393.9	-3.89	0.000131	0.0405	-0.51	-0.25	Intelligence (multi-trait analysis);	chr6:27401925	chr6:28170845~28172521:+
OV	cis	rs7567389	0.504	rs13030463	ENSG00000236682.1	AC068282.3	-3.89	0.000131	0.0405	-0.32	-0.25	Self-rated health;	chr2:127431295	chr2:127389130~127400580:+
OV	cis	rs12681366	0.839	rs3019278	ENSG00000253704.1	RP11-267M23.4	3.89	0.000131	0.0405	0.34	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94434339	chr8:94553722~94569745:+
OV	cis	rs12681366	0.839	rs2930964	ENSG00000253704.1	RP11-267M23.4	3.89	0.000131	0.0405	0.34	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94435906	chr8:94553722~94569745:+
OV	cis	rs801193	1	rs62466793	ENSG00000224316.1	RP11-479O9.2	3.89	0.000131	0.0405	0.27	0.25	Aortic root size;	chr7:66726530	chr7:65773620~65802067:+
OV	cis	rs801193	1	rs62466794	ENSG00000224316.1	RP11-479O9.2	3.89	0.000131	0.0405	0.27	0.25	Aortic root size;	chr7:66726592	chr7:65773620~65802067:+
OV	cis	rs7811142	1	rs60478351	ENSG00000242294.5	STAG3L5P	3.89	0.000131	0.0405	0.26	0.25	Platelet count;	chr7:100491394	chr7:100336079~100351900:+
OV	cis	rs7811142	1	rs7787620	ENSG00000242294.5	STAG3L5P	3.89	0.000131	0.0405	0.26	0.25	Platelet count;	chr7:100491611	chr7:100336079~100351900:+
OV	cis	rs7811142	1	rs11769700	ENSG00000242294.5	STAG3L5P	3.89	0.000131	0.0405	0.26	0.25	Platelet count;	chr7:100492426	chr7:100336079~100351900:+
OV	cis	rs2016586	0.796	rs5995166	ENSG00000237406.1	NDUFA9P1	3.89	0.000131	0.0406	0.31	0.25	Body mass index;	chr22:35732403	chr22:35897270~35898404:-
OV	cis	rs2999052	1	rs2811516	ENSG00000277250.1	Metazoa_SRP	3.89	0.000131	0.0406	0.31	0.25	Hypospadias;	chr3:128186608	chr3:128673681~128674021:-
OV	cis	rs2999052	1	rs2811515	ENSG00000277250.1	Metazoa_SRP	3.89	0.000131	0.0406	0.31	0.25	Hypospadias;	chr3:128186675	chr3:128673681~128674021:-
OV	cis	rs2999052	1	rs2811513	ENSG00000277250.1	Metazoa_SRP	3.89	0.000131	0.0406	0.31	0.25	Hypospadias;	chr3:128190721	chr3:128673681~128674021:-
OV	cis	rs4713118	0.868	rs742047	ENSG00000226314.6	ZNF192P1	-3.89	0.000131	0.0406	-0.33	-0.25	Parkinson's disease;	chr6:27771601	chr6:28161781~28169594:+
OV	cis	rs9309473	0.615	rs11680965	ENSG00000163016.8	ALMS1P	3.89	0.000131	0.0406	0.32	0.25	Metabolite levels;	chr2:73498789	chr2:73644919~73685576:+
OV	cis	rs992157	0.798	rs2382817	ENSG00000261338.2	RP11-378A13.1	3.89	0.000131	0.0406	0.29	0.25	Colorectal cancer;	chr2:218286495	chr2:218255319~218257366:+
OV	cis	rs251891	0.755	rs424347	ENSG00000249167.1	CTB-118N6.2	-3.89	0.000131	0.0407	-0.28	-0.25	Liver injury in combined anti-retroviral and anti-tuberculosis drug-treated HIV with tuberculosis;	chr5:115671727	chr5:116574482~116591398:+
OV	cis	rs12134151	0.87	rs11583841	ENSG00000237416.5	RP11-465K1.2	3.89	0.000131	0.0407	0.28	0.25	Educational attainment (years of education);	chr1:95722320	chr1:94836748~94855426:-
OV	cis	rs4934494	0.588	rs2026554	ENSG00000240996.1	RP11-80H5.7	-3.89	0.000131	0.0407	-0.34	-0.25	Red blood cell count;	chr10:89829699	chr10:89694295~89697928:-
OV	cis	rs12134151	0.905	rs6668127	ENSG00000237416.5	RP11-465K1.2	3.89	0.000131	0.0407	0.28	0.25	Educational attainment (years of education);	chr1:95734140	chr1:94836748~94855426:-
OV	cis	rs941207	0.756	rs7313074	ENSG00000241217.3	RN7SL809P	-3.89	0.000131	0.0407	-0.29	-0.25	Platelet count;	chr12:56760705	chr12:56670450~56670746:-
OV	cis	rs10754283	0.934	rs10493829	ENSG00000231613.1	RP5-943J3.1	3.89	0.000132	0.0407	0.27	0.25	Amyotrophic lateral sclerosis (sporadic);	chr1:89652274	chr1:89788914~89790492:+
OV	cis	rs73201462	1	rs2811522	ENSG00000242551.2	POU5F1P6	-3.89	0.000132	0.0407	-0.37	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128292580	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs7374227	ENSG00000242551.2	POU5F1P6	3.89	0.000132	0.0407	0.37	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128282672	chr3:128674735~128677005:-
OV	cis	rs10924970	1	rs7339903	ENSG00000236863.2	RPL23AP23	3.89	0.000132	0.0407	0.25	0.25	Asthma;	chr1:235174418	chr1:235295865~235296335:+
OV	cis	rs9309473	0.66	rs17349321	ENSG00000163016.8	ALMS1P	3.89	0.000132	0.0407	0.34	0.25	Metabolite levels;	chr2:73416625	chr2:73644919~73685576:+
OV	cis	rs2070488	0.73	rs2268759	ENSG00000229589.1	ACVR2B-AS1	3.89	0.000132	0.0407	0.28	0.25	Electrocardiographic conduction measures;	chr3:38472836	chr3:38451027~38454820:-
OV	cis	rs694739	0.628	rs645078	ENSG00000236935.1	AP003774.1	3.89	0.000132	0.0407	0.31	0.25	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64367826	chr11:64325050~64329504:-
OV	cis	rs911186	0.786	rs3800307	ENSG00000243307.2	POM121L6P	-3.89	0.000132	0.0407	-0.3	-0.25	Autism spectrum disorder or schizophrenia;	chr6:27218013	chr6:26896952~26898777:+
OV	cis	rs172166	0.694	rs1225716	ENSG00000204709.4	LINC01556	3.89	0.000132	0.0407	0.31	0.25	Cardiac Troponin-T levels;	chr6:28145968	chr6:28943877~28944537:+
OV	cis	rs1015213	0.609	rs77749278	ENSG00000253844.1	RP11-546K22.1	-3.89	0.000132	0.0407	-0.65	-0.25	Glaucoma (primary angle closure);	chr8:51941322	chr8:51961458~52022974:+
OV	cis	rs1015213	0.609	rs80308549	ENSG00000253844.1	RP11-546K22.1	-3.89	0.000132	0.0407	-0.65	-0.25	Glaucoma (primary angle closure);	chr8:51941385	chr8:51961458~52022974:+
OV	cis	rs1015213	0.609	rs76138168	ENSG00000253844.1	RP11-546K22.1	-3.89	0.000132	0.0407	-0.65	-0.25	Glaucoma (primary angle closure);	chr8:51942836	chr8:51961458~52022974:+
OV	cis	rs2828520	0.606	rs6516580	ENSG00000223822.2	EEF1A1P1	3.89	0.000132	0.0408	0.22	0.25	Major depressive disorder;	chr21:23760869	chr21:23390258~23390996:+
OV	cis	rs2828520	0.606	rs9979807	ENSG00000223822.2	EEF1A1P1	3.89	0.000132	0.0408	0.22	0.25	Major depressive disorder;	chr21:23761284	chr21:23390258~23390996:+
OV	cis	rs6071524	0.508	rs2244791	ENSG00000277581.1	RP4-616B8.6	-3.89	0.000132	0.0408	-0.3	-0.25	Autism spectrum disorder or schizophrenia;	chr20:38763463	chr20:38962472~38962993:+
OV	cis	rs12701220	0.655	rs6463317	ENSG00000229043.2	AC091729.9	-3.89	0.000132	0.0408	-0.32	-0.25	Bronchopulmonary dysplasia;	chr7:1119607	chr7:1160374~1165267:+
OV	cis	rs4665809	1	rs4233709	ENSG00000231655.1	AC011742.3	-3.89	0.000132	0.0408	-0.35	-0.25	Gut microbiome composition (summer);	chr2:26068624	chr2:26140263~26141264:-
OV	cis	rs394563	0.591	rs237018	ENSG00000231760.4	RP11-350J20.5	3.89	0.000132	0.0409	0.28	0.25	Dupuytren's disease;	chr6:149422794	chr6:149796151~149826294:-
OV	cis	rs73201462	1	rs2811534	ENSG00000242551.2	POU5F1P6	-3.89	0.000132	0.0409	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128272265	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2811533	ENSG00000242551.2	POU5F1P6	-3.89	0.000132	0.0409	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128272886	chr3:128674735~128677005:-
OV	cis	rs73201462	0.901	rs2811532	ENSG00000242551.2	POU5F1P6	-3.89	0.000132	0.0409	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128273327	chr3:128674735~128677005:-
OV	cis	rs73201462	0.908	rs2811531	ENSG00000242551.2	POU5F1P6	-3.89	0.000132	0.0409	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128273652	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2955100	ENSG00000242551.2	POU5F1P6	-3.89	0.000132	0.0409	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128274482	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2999062	ENSG00000242551.2	POU5F1P6	-3.89	0.000132	0.0409	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128274763	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2811526	ENSG00000242551.2	POU5F1P6	-3.89	0.000132	0.0409	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128276875	chr3:128674735~128677005:-
OV	cis	rs73201462	0.908	rs2811373	ENSG00000242551.2	POU5F1P6	-3.89	0.000132	0.0409	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128278586	chr3:128674735~128677005:-
OV	cis	rs73201462	0.831	rs2811524	ENSG00000242551.2	POU5F1P6	-3.89	0.000132	0.0409	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128281112	chr3:128674735~128677005:-
OV	cis	rs73201462	0.908	rs2811386	ENSG00000242551.2	POU5F1P6	-3.89	0.000132	0.0409	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128281172	chr3:128674735~128677005:-
OV	cis	rs73201462	0.908	rs4593050	ENSG00000242551.2	POU5F1P6	-3.89	0.000132	0.0409	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128285688	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs6439124	ENSG00000242551.2	POU5F1P6	-3.89	0.000132	0.0409	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128288623	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs7373998	ENSG00000242551.2	POU5F1P6	-3.89	0.000132	0.0409	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128289380	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2955101	ENSG00000242551.2	POU5F1P6	-3.89	0.000132	0.0409	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128290769	chr3:128674735~128677005:-
OV	cis	rs73201462	0.908	rs2811520	ENSG00000242551.2	POU5F1P6	-3.89	0.000132	0.0409	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128293434	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2811519	ENSG00000242551.2	POU5F1P6	-3.89	0.000132	0.0409	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128294033	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2811518	ENSG00000242551.2	POU5F1P6	-3.89	0.000132	0.0409	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128294802	chr3:128674735~128677005:-
OV	cis	rs1829883	0.701	rs1462430	ENSG00000227762.4	GUSBP8	3.89	0.000132	0.0409	0.27	0.25	Hemostatic factors and hematological phenotypes;	chr5:99676846	chr5:99532628~99534611:+
OV	cis	rs2303745	0.544	rs12710308	ENSG00000269815.1	CTD-2278I10.4	-3.89	0.000132	0.0409	-0.33	-0.25	Systemic lupus erythematosus;	chr19:17285070	chr19:17296196~17296695:-
OV	cis	rs801193	1	rs2659915	ENSG00000237310.1	GS1-124K5.4	3.89	0.000132	0.0409	0.25	0.25	Aortic root size;	chr7:66688114	chr7:66493706~66495474:+
OV	cis	rs7131987	0.65	rs10843377	ENSG00000257176.2	RP11-996F15.2	3.89	0.000133	0.0409	0.31	0.25	QT interval;	chr12:29284120	chr12:29280418~29317848:-
OV	cis	rs4934494	0.681	rs1129777	ENSG00000240996.1	RP11-80H5.7	-3.89	0.000133	0.0409	-0.34	-0.25	Red blood cell count;	chr10:89709168	chr10:89694295~89697928:-
OV	cis	rs4934494	0.727	rs3824607	ENSG00000240996.1	RP11-80H5.7	-3.89	0.000133	0.0409	-0.34	-0.25	Red blood cell count;	chr10:89711258	chr10:89694295~89697928:-
OV	cis	rs4934494	0.681	rs3740035	ENSG00000240996.1	RP11-80H5.7	-3.89	0.000133	0.0409	-0.34	-0.25	Red blood cell count;	chr10:89716708	chr10:89694295~89697928:-
OV	cis	rs4934494	0.681	rs34591435	ENSG00000240996.1	RP11-80H5.7	-3.89	0.000133	0.0409	-0.34	-0.25	Red blood cell count;	chr10:89721691	chr10:89694295~89697928:-
OV	cis	rs4934494	0.727	rs12783845	ENSG00000240996.1	RP11-80H5.7	-3.89	0.000133	0.0409	-0.34	-0.25	Red blood cell count;	chr10:89722872	chr10:89694295~89697928:-
OV	cis	rs10472076	0.561	rs10461656	ENSG00000247345.2	RP11-266N13.2	3.89	0.000133	0.0409	0.32	0.25	Breast cancer;	chr5:58980523	chr5:59039761~59063503:+
OV	cis	rs12073359	1	rs72692857	ENSG00000223945.2	RP11-458I7.1	-3.89	0.000133	0.0409	-0.41	-0.25	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150029674	chr1:150053864~150055034:+
OV	cis	rs860295	0.58	rs10908463	ENSG00000225855.5	RUSC1-AS1	3.89	0.000133	0.041	0.22	0.25	Body mass index;	chr1:155316467	chr1:155316863~155324176:-
OV	cis	rs10514805	0.557	rs75752731	ENSG00000234690.5	AC073283.4	-3.89	0.000133	0.041	-0.45	-0.25	Electroencephalogram traits;	chr2:47496354	chr2:47192405~47345074:-
OV	cis	rs375092	0.611	rs75733834	ENSG00000230658.1	KLHL7-AS1	3.89	0.000133	0.041	0.61	0.25	Personality dimensions;	chr7:23375762	chr7:23101228~23105703:-
OV	cis	rs1030877	0.515	rs3828300	ENSG00000235319.1	AC012360.4	3.89	0.000133	0.041	0.36	0.25	Obesity-related traits;	chr2:105284650	chr2:105324210~105330529:+
OV	cis	rs7302981	0.967	rs7136570	ENSG00000257298.1	RP3-405J10.3	-3.89	0.000133	0.041	-0.23	-0.25	Systolic blood pressure;	chr12:50136153	chr12:50185580~50191363:-
OV	cis	rs7568498	1	rs13013777	ENSG00000227403.1	AC009299.3	3.89	0.000133	0.041	0.48	0.25	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161074601	chr2:161244739~161249050:+
OV	cis	rs6545883	0.965	rs2305155	ENSG00000273302.1	RP11-493E12.2	3.89	0.000133	0.041	0.2	0.25	Tuberculosis;	chr2:61502123	chr2:61199979~61200769:+
OV	cis	rs853679	0.505	rs200992	ENSG00000226314.6	ZNF192P1	-3.89	0.000133	0.041	-0.45	-0.25	Depression;	chr6:27846899	chr6:28161781~28169594:+
OV	cis	rs853679	0.517	rs1340004	ENSG00000204709.4	LINC01556	3.89	0.000133	0.041	0.33	0.25	Depression;	chr6:28135913	chr6:28943877~28944537:+
OV	cis	rs796364	0.951	rs12613687	ENSG00000232732.8	AC073043.1	3.89	0.000133	0.041	0.37	0.25	Schizophrenia;	chr2:200134533	chr2:199867396~199911159:-
OV	cis	rs73201462	0.803	rs2955084	ENSG00000277250.1	Metazoa_SRP	-3.89	0.000133	0.041	-0.52	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128242462	chr3:128673681~128674021:-
OV	cis	rs9992667	0.91	rs17428945	ENSG00000231160.8	KLF3-AS1	3.89	0.000133	0.0411	0.3	0.25	Eosinophil percentage of granulocytes;	chr4:38688124	chr4:38612701~38664883:-
OV	cis	rs11951515	0.675	rs72754530	ENSG00000278487.1	RP11-447H19.4	-3.89	0.000133	0.0411	-0.29	-0.25	Metabolite levels  (X-11787);	chr5:43339370	chr5:43143362~43143514:-
OV	cis	rs11951515	0.738	rs55673816	ENSG00000278487.1	RP11-447H19.4	-3.89	0.000133	0.0411	-0.29	-0.25	Metabolite levels  (X-11787);	chr5:43339682	chr5:43143362~43143514:-
OV	cis	rs4964805	0.626	rs11111767	ENSG00000257681.1	RP11-341G23.4	-3.89	0.000133	0.0411	-0.29	-0.25	Attention deficit hyperactivity disorder;	chr12:103782468	chr12:103746315~103768858:-
OV	cis	rs4906332	1	rs7155822	ENSG00000244691.1	RPL10AP1	-3.89	0.000133	0.0411	-0.27	-0.25	Coronary artery disease;	chr14:103456053	chr14:103412119~103412761:-
OV	cis	rs6545883	0.868	rs7594191	ENSG00000273302.1	RP11-493E12.2	-3.89	0.000133	0.0411	-0.2	-0.25	Tuberculosis;	chr2:61612883	chr2:61199979~61200769:+
OV	cis	rs4878497	0.588	rs11795343	ENSG00000237437.1	ASS1P12	-3.89	0.000133	0.0411	-0.28	-0.25	Inflammatory skin disease;	chr9:32523739	chr9:32945996~32947222:+
OV	cis	rs853679	0.567	rs1005126	ENSG00000204709.4	LINC01556	3.89	0.000133	0.0411	0.31	0.25	Depression;	chr6:28399846	chr6:28943877~28944537:+
OV	cis	rs7927592	0.672	rs10501398	ENSG00000222339.1	AP000807.2	-3.89	0.000133	0.0411	-0.25	-0.25	Total body bone mineral density;	chr11:68564247	chr11:68505572~68505651:-
OV	cis	rs2070488	1	rs2070488	ENSG00000229589.1	ACVR2B-AS1	-3.89	0.000134	0.0411	-0.27	-0.25	Electrocardiographic conduction measures;	chr3:38400999	chr3:38451027~38454820:-
OV	cis	rs7621025	0.505	rs13063893	ENSG00000239213.4	NCK1-AS1	-3.89	0.000134	0.0411	-0.4	-0.25	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136668796	chr3:136841726~136862054:-
OV	cis	rs7621025	0.505	rs34613715	ENSG00000239213.4	NCK1-AS1	-3.89	0.000134	0.0411	-0.4	-0.25	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136736165	chr3:136841726~136862054:-
OV	cis	rs7621025	0.505	rs34281413	ENSG00000239213.4	NCK1-AS1	-3.89	0.000134	0.0411	-0.4	-0.25	C-reactive protein levels or HDL-cholesterol levels (pleiotropy);Body mass index;	chr3:136743018	chr3:136841726~136862054:-
OV	cis	rs941207	0.756	rs7315472	ENSG00000241217.3	RN7SL809P	-3.89	0.000134	0.0412	-0.27	-0.25	Platelet count;	chr12:56648276	chr12:56670450~56670746:-
OV	cis	rs941207	0.756	rs67046307	ENSG00000241217.3	RN7SL809P	-3.89	0.000134	0.0412	-0.27	-0.25	Platelet count;	chr12:56651152	chr12:56670450~56670746:-
OV	cis	rs941207	0.756	rs10876915	ENSG00000241217.3	RN7SL809P	-3.89	0.000134	0.0412	-0.27	-0.25	Platelet count;	chr12:56655280	chr12:56670450~56670746:-
OV	cis	rs11951515	0.663	rs7734293	ENSG00000278487.1	RP11-447H19.4	-3.89	0.000134	0.0412	-0.29	-0.25	Metabolite levels  (X-11787);	chr5:43283100	chr5:43143362~43143514:-
OV	cis	rs792448	0.534	rs6702347	ENSG00000201544.1	SNORA16B	3.89	0.000134	0.0412	0.31	0.25	White blood cell count (basophil);	chr1:212439569	chr1:212352816~212352950:+
OV	cis	rs11585357	0.947	rs2977303	ENSG00000226457.1	RP11-430L17.1	-3.89	0.000134	0.0412	-0.41	-0.25	Hair shape;	chr1:17285053	chr1:16369150~16369530:-
OV	cis	rs9638182	0.945	rs35368205	ENSG00000106133.16	NSUN5P2	-3.89	0.000134	0.0412	-0.39	-0.25	Triglycerides;	chr7:73603327	chr7:72947581~72954790:-
OV	cis	rs7771547	0.855	rs9366911	ENSG00000240733.3	RN7SL502P	-3.89	0.000134	0.0412	-0.26	-0.25	Platelet distribution width;	chr6:36621563	chr6:36450912~36451201:-
OV	cis	rs1569175	0.522	rs3094771	ENSG00000232732.8	AC073043.1	3.89	0.000134	0.0412	0.41	0.25	Response to treatment for acute lymphoblastic leukemia;	chr2:200021335	chr2:199867396~199911159:-
OV	cis	rs11168618	0.626	rs11514105	ENSG00000258273.1	RP11-370I10.4	-3.89	0.000134	0.0412	-0.31	-0.25	Adiponectin levels;	chr12:48427151	chr12:48333755~48333901:-
OV	cis	rs2999052	0.805	rs1735549	ENSG00000277250.1	Metazoa_SRP	3.89	0.000134	0.0412	0.35	0.25	Hypospadias;	chr3:128352966	chr3:128673681~128674021:-
OV	cis	rs7246657	0.943	rs7255785	ENSG00000226686.6	LINC01535	-3.89	0.000134	0.0412	-0.37	-0.25	Coronary artery calcification;	chr19:37480781	chr19:37251912~37265535:+
OV	cis	rs7246657	0.943	rs7255996	ENSG00000226686.6	LINC01535	-3.89	0.000134	0.0412	-0.37	-0.25	Coronary artery calcification;	chr19:37480797	chr19:37251912~37265535:+
OV	cis	rs1506403	0.735	rs315281	ENSG00000275743.1	TRBV14	-3.89	0.000134	0.0412	-0.33	-0.25	Cancer;	chr7:143134546	chr7:142587868~142588359:+
OV	cis	rs6860806	0.507	rs274572	ENSG00000233006.5	AC034220.3	-3.89	0.000134	0.0412	-0.27	-0.25	Breast cancer;	chr5:132375225	chr5:132311285~132369916:-
OV	cis	rs274567	0.501	rs274571	ENSG00000233006.5	AC034220.3	-3.89	0.000134	0.0412	-0.27	-0.25	Blood metabolite levels;	chr5:132376433	chr5:132311285~132369916:-
OV	cis	rs6687758	0.945	rs12033415	ENSG00000238042.4	RP11-815M8.1	3.89	0.000134	0.0412	0.35	0.25	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221981726	chr1:221880981~221978523:-
OV	cis	rs703108	0.868	rs3011641	ENSG00000279623.1	RP11-399C16.3	3.89	0.000134	0.0412	0.36	0.25	Monocyte percentage of white cells;	chr10:22104761	chr10:21865335~21865921:-
OV	cis	rs12893668	0.703	rs34186780	ENSG00000201184.1	RNU4-68P	-3.89	0.000134	0.0413	-0.3	-0.25	Reticulocyte count;	chr14:103561258	chr14:103567405~103567545:+
OV	cis	rs11903757	1	rs75521628	ENSG00000281467.1	Clostridiales-1	-3.89	0.000134	0.0413	-0.44	-0.25	Colorectal cancer;	chr2:191717363	chr2:191699476~191699631:-
OV	cis	rs12446632	0.599	rs72769553	ENSG00000261939.1	LARP7P2	3.89	0.000134	0.0413	0.47	0.25	Hip circumference;Body mass index (joint analysis main effects and smoking interaction);BMI in smokers;Menarche (age at onset);Obesity;Childhood body mass index;Waist circumference;BMI in non-smokers;BMI (adjusted for smoking behaviour);Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);Body mass index;	chr16:19789701	chr16:19819504~19819628:-
OV	cis	rs2348418	0.733	rs7137557	ENSG00000247934.4	RP11-967K21.1	3.89	0.000134	0.0413	0.25	0.25	Lung function (FEV1);Lung function (FVC);	chr12:28221259	chr12:28163298~28190738:-
OV	cis	rs2348418	0.733	rs12425200	ENSG00000247934.4	RP11-967K21.1	3.89	0.000134	0.0413	0.25	0.25	Lung function (FEV1);Lung function (FVC);	chr12:28237896	chr12:28163298~28190738:-
OV	cis	rs694739	0.726	rs17857342	ENSG00000236935.1	AP003774.1	3.89	0.000134	0.0413	0.31	0.25	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64371433	chr11:64325050~64329504:-
OV	cis	rs1797885	0.763	rs299649	ENSG00000251774.1	RNU6-377P	3.89	0.000134	0.0413	0.23	0.25	Immature fraction of reticulocytes;	chr3:12497220	chr3:12514706~12514807:+
OV	cis	rs8062405	1	rs7187776	ENSG00000278665.1	RP11-666O2.4	3.89	0.000134	0.0413	0.26	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28846324	chr16:28599241~28601881:-
OV	cis	rs1765142	0.542	rs640245	ENSG00000254532.1	RP11-624D11.2	-3.89	0.000134	0.0413	-0.28	-0.25	Schizophrenia;	chr11:30371813	chr11:30044058~30084343:-
OV	cis	rs62025270	0.547	rs338540	ENSG00000229212.6	RP11-561C5.4	3.88	0.000134	0.0413	0.32	0.25	Idiopathic pulmonary fibrosis;	chr15:85652500	chr15:85205440~85234795:-
OV	cis	rs2117029	1	rs3782357	ENSG00000258017.1	RP11-386G11.10	-3.88	0.000134	0.0413	-0.32	-0.25	Intelligence (multi-trait analysis);	chr12:49033869	chr12:49127782~49147869:+
OV	cis	rs2243480	1	rs67728539	ENSG00000226824.5	RP4-756H11.3	-3.88	0.000134	0.0413	-0.39	-0.25	Diabetic kidney disease;	chr7:65913137	chr7:66654538~66669855:+
OV	cis	rs1113500	0.548	rs6583062	ENSG00000226822.1	RP11-356N1.2	3.88	0.000134	0.0414	0.32	0.25	Growth-regulated protein alpha levels;	chr1:108113841	chr1:108071482~108074519:+
OV	cis	rs9473147	0.516	rs7749271	ENSG00000270761.1	RP11-385F7.1	-3.88	0.000135	0.0414	-0.28	-0.25	Platelet distribution width;Mean platelet volume;	chr6:47517266	chr6:47477243~47477572:-
OV	cis	rs7554511	0.535	rs10920090	ENSG00000223774.4	RP11-307B6.3	3.88	0.000135	0.0414	0.28	0.25	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201003326	chr1:201893842~201899978:+
OV	cis	rs1836229	0.594	rs7864464	ENSG00000225706.1	PTPRD-AS1	-3.88	0.000135	0.0414	-0.26	-0.25	Restless legs syndrome;	chr9:8824274	chr9:8858130~8862255:+
OV	cis	rs354033	0.837	rs56402950	ENSG00000280992.1	AC004932.1	3.88	0.000135	0.0414	0.28	0.25	Multiple sclerosis;	chr7:149483128	chr7:149541747~149541846:-
OV	cis	rs7968440	1	rs11832315	ENSG00000272368.2	RP4-605O3.4	3.88	0.000135	0.0414	0.29	0.25	Fibrinogen;	chr12:50550149	chr12:50112197~50165618:+
OV	cis	rs7968440	1	rs66597435	ENSG00000272368.2	RP4-605O3.4	3.88	0.000135	0.0414	0.29	0.25	Fibrinogen;	chr12:50551486	chr12:50112197~50165618:+
OV	cis	rs1404100	0.51	rs1038273	ENSG00000249274.1	PDLIM1P4	3.88	0.000135	0.0414	0.29	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr3:99067757	chr3:98782188~98783193:+
OV	cis	rs12483148	0.877	rs28733798	ENSG00000231106.2	LINC01436	3.88	0.000135	0.0414	0.51	0.25	Obesity-related traits;	chr21:35642201	chr21:36005338~36007838:+
OV	cis	rs801193	0.66	rs974239	ENSG00000237310.1	GS1-124K5.4	3.88	0.000135	0.0414	0.26	0.25	Aortic root size;	chr7:66748504	chr7:66493706~66495474:+
OV	cis	rs801193	0.66	rs1016265	ENSG00000237310.1	GS1-124K5.4	3.88	0.000135	0.0414	0.26	0.25	Aortic root size;	chr7:66749580	chr7:66493706~66495474:+
OV	cis	rs801193	0.66	rs4610622	ENSG00000237310.1	GS1-124K5.4	3.88	0.000135	0.0414	0.26	0.25	Aortic root size;	chr7:66759510	chr7:66493706~66495474:+
OV	cis	rs7587928	0.593	rs59743691	ENSG00000225642.1	SNRPEP5	3.88	0.000135	0.0415	0.29	0.25	Neutrophil count;	chr2:8831464	chr2:8603082~8603359:+
OV	cis	rs2834288	0.535	rs4816469	ENSG00000273102.1	AP000569.9	3.88	0.000135	0.0415	0.28	0.25	Gut microbiota (bacterial taxa);	chr21:33952321	chr21:33967101~33968573:-
OV	cis	rs6101567	0.623	rs6129265	ENSG00000261431.1	RP4-616B8.4	3.88	0.000135	0.0415	0.25	0.25	Nose size;	chr20:39333713	chr20:38961925~38962111:-
OV	cis	rs111342015	0.686	rs79630229	ENSG00000240625.3	RN7SL403P	3.88	0.000135	0.0415	0.42	0.25	Breast cancer;	chr6:43217825	chr6:43036196~43036500:-
OV	cis	rs62458065	1	rs979355	ENSG00000226468.2	AC018641.7	-3.88	0.000135	0.0415	-0.34	-0.25	Metabolite levels (HVA/MHPG ratio);	chr7:32424321	chr7:32456963~32457758:-
OV	cis	rs6071166	0.967	rs6027419	ENSG00000174365.18	SNHG11	-3.88	0.000135	0.0415	-0.32	-0.25	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38703562	chr20:38446578~38450921:+
OV	cis	rs7646881	0.544	rs73028934	ENSG00000272440.1	RP11-379F4.6	3.88	0.000135	0.0415	0.38	0.25	Tetralogy of Fallot;	chr3:158655761	chr3:158695367~158695581:+
OV	cis	rs7131987	0.65	rs4331146	ENSG00000257176.2	RP11-996F15.2	-3.88	0.000135	0.0415	-0.31	-0.25	QT interval;	chr12:29287150	chr12:29280418~29317848:-
OV	cis	rs9325389	0.648	rs12630378	ENSG00000271662.1	RP11-141C7.3	3.88	0.000135	0.0415	0.32	0.25	Facial morphology (factor 17, height of vermillion upper lip);	chr3:195832418	chr3:195650146~195651472:-
OV	cis	rs10504130	0.569	rs4626585	ENSG00000272024.1	RP11-546K22.3	3.88	0.000135	0.0415	0.33	0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:51767380	chr8:51950284~51950690:+
OV	cis	rs846111	1	rs846111	ENSG00000225077.2	LINC00337	-3.88	0.000135	0.0415	-0.31	-0.25	QT interval;	chr1:6219310	chr1:6236240~6239444:+
OV	cis	rs4934494	0.689	rs17127596	ENSG00000240996.1	RP11-80H5.7	3.88	0.000135	0.0415	0.34	0.25	Red blood cell count;	chr10:89816128	chr10:89694295~89697928:-
OV	cis	rs7246967	0.611	rs35355374	ENSG00000267920.1	SNX6P1	-3.88	0.000135	0.0415	-0.42	-0.25	Bronchopulmonary dysplasia;	chr19:22654899	chr19:23126569~23127792:-
OV	cis	rs7771547	0.521	rs2180929	ENSG00000240733.3	RN7SL502P	3.88	0.000135	0.0416	0.3	0.25	Platelet distribution width;	chr6:36426310	chr6:36450912~36451201:-
OV	cis	rs1707322	0.717	rs3014246	ENSG00000234329.1	RP11-767N6.2	-3.88	0.000135	0.0416	-0.27	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620405	chr1:45651039~45651826:-
OV	cis	rs801193	1	rs2659889	ENSG00000237310.1	GS1-124K5.4	3.88	0.000135	0.0416	0.26	0.25	Aortic root size;	chr7:66752125	chr7:66493706~66495474:+
OV	cis	rs801193	1	rs3800812	ENSG00000237310.1	GS1-124K5.4	3.88	0.000135	0.0416	0.26	0.25	Aortic root size;	chr7:66758474	chr7:66493706~66495474:+
OV	cis	rs801193	1	rs4279493	ENSG00000237310.1	GS1-124K5.4	3.88	0.000135	0.0416	0.26	0.25	Aortic root size;	chr7:66761633	chr7:66493706~66495474:+
OV	cis	rs9813712	0.595	rs1453240	ENSG00000228252.7	COL6A4P2	-3.88	0.000135	0.0416	-0.3	-0.25	Response to amphetamines;	chr3:130282849	chr3:130212823~130273806:+
OV	cis	rs4918798	0.641	rs61888394	ENSG00000234724.1	HDAC1P1	3.88	0.000135	0.0416	0.44	0.25	Warfarin maintenance dose;	chr10:94880683	chr10:94137748~94139500:+
OV	cis	rs4918798	0.649	rs61888396	ENSG00000234724.1	HDAC1P1	3.88	0.000135	0.0416	0.44	0.25	Warfarin maintenance dose;	chr10:94884013	chr10:94137748~94139500:+
OV	cis	rs10992471	0.603	rs1121978	ENSG00000281156.1	MIR3651	-3.88	0.000136	0.0416	-0.29	-0.25	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92378069	chr9:92292458~92292547:-
OV	cis	rs1015213	0.609	rs75550511	ENSG00000253844.1	RP11-546K22.1	-3.88	0.000136	0.0417	-0.66	-0.25	Glaucoma (primary angle closure);	chr8:51955846	chr8:51961458~52022974:+
OV	cis	rs1015213	0.609	rs74435722	ENSG00000253844.1	RP11-546K22.1	-3.88	0.000136	0.0417	-0.66	-0.25	Glaucoma (primary angle closure);	chr8:51958279	chr8:51961458~52022974:+
OV	cis	rs4272382	1	rs4272382	ENSG00000233609.3	RP11-62H7.2	-3.88	0.000136	0.0417	-0.42	-0.25	Response to cytidine analogues (gemcitabine);	chr8:8575978	chr8:8961200~8979025:+
OV	cis	rs10504130	0.569	rs9650305	ENSG00000272024.1	RP11-546K22.3	-3.88	0.000136	0.0417	-0.32	-0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:51912113	chr8:51950284~51950690:+
OV	cis	rs17122278	1	rs17122269	ENSG00000255422.1	AP002954.4	3.88	0.000136	0.0417	0.38	0.25	Total cholesterol levels;	chr11:118574560	chr11:118704607~118750263:+
OV	cis	rs875971	0.571	rs160647	ENSG00000237310.1	GS1-124K5.4	-3.88	0.000136	0.0417	-0.29	-0.25	Aortic root size;	chr7:66089365	chr7:66493706~66495474:+
OV	cis	rs6576132	0.56	rs4322586	ENSG00000257869.1	CTD-2591A6.2	3.88	0.000136	0.0417	0.24	0.25	Resting oxygen saturation in chronic osbtructive pulmonary disease (pulse oxymetry);	chr14:28247815	chr14:28318141~28418612:+
OV	cis	rs11951515	0.738	rs2330242	ENSG00000278487.1	RP11-447H19.4	-3.88	0.000136	0.0417	-0.29	-0.25	Metabolite levels  (X-11787);	chr5:43361566	chr5:43143362~43143514:-
OV	cis	rs62229266	0.771	rs11701590	ENSG00000231106.2	LINC01436	3.88	0.000136	0.0417	0.31	0.25	Mitral valve prolapse;	chr21:36012432	chr21:36005338~36007838:+
OV	cis	rs10754283	0.84	rs1215502	ENSG00000231613.1	RP5-943J3.1	3.88	0.000136	0.0417	0.27	0.25	Amyotrophic lateral sclerosis (sporadic);	chr1:89627456	chr1:89788914~89790492:+
OV	cis	rs6951245	0.744	rs10265758	ENSG00000229043.2	AC091729.9	-3.88	0.000136	0.0418	-0.38	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr7:1132882	chr7:1160374~1165267:+
OV	cis	rs12073359	0.954	rs28366567	ENSG00000223945.2	RP11-458I7.1	-3.88	0.000136	0.0418	-0.41	-0.25	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150032389	chr1:150053864~150055034:+
OV	cis	rs7246657	0.943	rs10415358	ENSG00000226686.6	LINC01535	-3.88	0.000136	0.0418	-0.38	-0.25	Coronary artery calcification;	chr19:37317961	chr19:37251912~37265535:+
OV	cis	rs11168618	0.567	rs7314569	ENSG00000258273.1	RP11-370I10.4	-3.88	0.000136	0.0418	-0.31	-0.25	Adiponectin levels;	chr12:48423198	chr12:48333755~48333901:-
OV	cis	rs7968440	1	rs7305655	ENSG00000272368.2	RP4-605O3.4	-3.88	0.000136	0.0418	-0.29	-0.25	Fibrinogen;	chr12:50611506	chr12:50112197~50165618:+
OV	cis	rs6919534	0.688	rs2395614	ENSG00000265123.2	RN7SL200P	3.88	0.000136	0.0418	0.28	0.25	Height;	chr6:35235106	chr6:34685355~34685642:-
OV	cis	rs6919534	0.688	rs13214290	ENSG00000265123.2	RN7SL200P	3.88	0.000136	0.0418	0.28	0.25	Height;	chr6:35235426	chr6:34685355~34685642:-
OV	cis	rs6919534	0.688	rs4711411	ENSG00000265123.2	RN7SL200P	3.88	0.000136	0.0418	0.28	0.25	Height;	chr6:35248127	chr6:34685355~34685642:-
OV	cis	rs6919534	0.607	rs4713845	ENSG00000265123.2	RN7SL200P	3.88	0.000136	0.0418	0.28	0.25	Height;	chr6:35260610	chr6:34685355~34685642:-
OV	cis	rs6919534	0.688	rs1888825	ENSG00000265123.2	RN7SL200P	3.88	0.000136	0.0418	0.28	0.25	Height;	chr6:35262763	chr6:34685355~34685642:-
OV	cis	rs6919534	0.736	rs9462065	ENSG00000265123.2	RN7SL200P	3.88	0.000136	0.0418	0.28	0.25	Height;	chr6:35263391	chr6:34685355~34685642:-
OV	cis	rs6919534	0.688	rs2267657	ENSG00000265123.2	RN7SL200P	3.88	0.000136	0.0418	0.28	0.25	Height;	chr6:35268081	chr6:34685355~34685642:-
OV	cis	rs6120849	0.901	rs11696967	ENSG00000206582.1	Y_RNA	-3.88	0.000136	0.0418	-0.34	-0.25	Protein C levels;	chr20:35155806	chr20:34526510~34526606:-
OV	cis	rs7395581	0.959	rs7120118	ENSG00000271350.1	CTD-2384B9.1	3.88	0.000136	0.0418	0.29	0.25	HDL cholesterol;	chr11:47264739	chr11:47041027~47041945:-
OV	cis	rs801193	0.66	rs10950049	ENSG00000237310.1	GS1-124K5.4	3.88	0.000136	0.0418	0.25	0.25	Aortic root size;	chr7:66765873	chr7:66493706~66495474:+
OV	cis	rs7617773	0.563	rs13082269	ENSG00000228638.1	FCF1P2	-3.88	0.000136	0.0419	-0.3	-0.25	Coronary artery disease;	chr3:48350784	chr3:48290793~48291375:-
OV	cis	rs11951515	0.738	rs12518127	ENSG00000278487.1	RP11-447H19.4	3.88	0.000136	0.0419	0.29	0.25	Metabolite levels  (X-11787);	chr5:43369286	chr5:43143362~43143514:-
OV	cis	rs6545883	0.859	rs2694644	ENSG00000270820.4	RP11-355B11.2	-3.88	0.000136	0.0419	-0.28	-0.25	Tuberculosis;	chr2:61377721	chr2:61471188~61484130:+
OV	cis	rs743757	1	rs2236979	ENSG00000228008.1	CTD-2330K9.3	3.88	0.000137	0.0419	0.34	0.25	Diastolic blood pressure;	chr3:50449464	chr3:49903845~49916937:+
OV	cis	rs743757	0.938	rs2236981	ENSG00000228008.1	CTD-2330K9.3	3.88	0.000137	0.0419	0.34	0.25	Diastolic blood pressure;	chr3:50451414	chr3:49903845~49916937:+
OV	cis	rs743757	1	rs743857	ENSG00000228008.1	CTD-2330K9.3	3.88	0.000137	0.0419	0.34	0.25	Diastolic blood pressure;	chr3:50456119	chr3:49903845~49916937:+
OV	cis	rs2274471	0.645	rs73639261	ENSG00000234534.1	CSNK1G2P1	3.88	0.000137	0.0419	0.33	0.25	Crohn's disease;	chr9:5084215	chr9:5040945~5041940:+
OV	cis	rs6673267	0.967	rs10494827	ENSG00000223774.4	RP11-307B6.3	3.88	0.000137	0.0419	0.27	0.25	Lobe attachment (rater-scored or self-reported);	chr1:201044819	chr1:201893842~201899978:+
OV	cis	rs6128907	1	rs62202470	ENSG00000224635.1	RP4-564F22.5	3.88	0.000137	0.0419	0.36	0.25	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38755510	chr20:38406011~38416797:-
OV	cis	rs6128907	1	rs62202471	ENSG00000224635.1	RP4-564F22.5	3.88	0.000137	0.0419	0.36	0.25	Liver fibrosis in pediatric non-alcoholic fatty acid liver disease;	chr20:38757278	chr20:38406011~38416797:-
OV	cis	rs55665837	1	rs7121171	ENSG00000251991.1	RNU7-49P	3.88	0.000137	0.042	0.26	0.25	Vitamin D levels;	chr11:14424874	chr11:14478892~14478953:+
OV	cis	rs7189233	0.955	rs8054299	ENSG00000279722.1	RP11-44F14.6	3.88	0.000137	0.042	0.29	0.25	Intelligence (multi-trait analysis);	chr16:53464743	chr16:53487607~53489943:-
OV	cis	rs6952407	1	rs6952407	ENSG00000237310.1	GS1-124K5.4	-3.88	0.000137	0.042	-0.26	-0.25	Cotinine glucuronidation;	chr7:66580525	chr7:66493706~66495474:+
OV	cis	rs7267979	1	rs6050555	ENSG00000274973.1	RP13-401N8.7	3.88	0.000137	0.042	0.29	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25347907	chr20:25845497~25845862:+
OV	cis	rs10759883	0.612	rs2943532	ENSG00000175611.10	LINC00476	3.88	0.000137	0.042	0.33	0.25	Nicotine dependence;	chr9:96024975	chr9:95759231~95875977:-
OV	cis	rs4664293	0.51	rs2113861	ENSG00000226266.5	AC009961.3	3.88	0.000137	0.042	0.3	0.25	Monocyte percentage of white cells;	chr2:159585233	chr2:159670708~159712435:-
OV	cis	rs7968440	1	rs11609231	ENSG00000272368.2	RP4-605O3.4	3.88	0.000137	0.042	0.29	0.25	Fibrinogen;	chr12:50538647	chr12:50112197~50165618:+
OV	cis	rs7255066	0.556	rs13344893	ENSG00000279103.1	CTC-204F22.1	-3.88	0.000137	0.042	-0.3	-0.25	Multiple sclerosis;	chr19:44634946	chr19:44246478~44248374:-
OV	cis	rs10992471	0.603	rs10820968	ENSG00000281156.1	MIR3651	-3.88	0.000137	0.042	-0.29	-0.25	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92344161	chr9:92292458~92292547:-
OV	cis	rs10992471	0.58	rs7030920	ENSG00000281156.1	MIR3651	-3.88	0.000137	0.042	-0.29	-0.25	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92360670	chr9:92292458~92292547:-
OV	cis	rs881375	0.678	rs7037195	ENSG00000226752.6	PSMD5-AS1	-3.88	0.000137	0.042	-0.25	-0.25	Rheumatoid arthritis;	chr9:120921722	chr9:120824828~120854385:+
OV	cis	rs9393777	0.92	rs13195040	ENSG00000220721.1	OR1F12	-3.88	0.000137	0.0421	-0.41	-0.25	Intelligence (multi-trait analysis);	chr6:27446145	chr6:28073316~28074233:+
OV	cis	rs2070488	0.965	rs35553573	ENSG00000229589.1	ACVR2B-AS1	3.88	0.000137	0.0421	0.28	0.25	Electrocardiographic conduction measures;	chr3:38399948	chr3:38451027~38454820:-
OV	cis	rs45509595	0.556	rs34409918	ENSG00000280107.1	AL022393.9	-3.88	0.000137	0.0421	-0.53	-0.25	Breast cancer;	chr6:27717569	chr6:28170845~28172521:+
OV	cis	rs4356975	0.563	rs6600893	ENSG00000251284.2	RP13-644M16.1	-3.88	0.000137	0.0421	-0.26	-0.25	Obesity-related traits;	chr4:69113183	chr4:69125274~69126451:+
OV	cis	rs6964833	1	rs36044436	ENSG00000277053.3	GTF2IP1	-3.88	0.000137	0.0421	-0.28	-0.25	Menarche (age at onset);	chr7:74675495	chr7:75185385~75237696:-
OV	cis	rs2927438	0.571	rs2965106	ENSG00000266903.1	CTB-171A8.1	-3.88	0.000137	0.0421	-0.31	-0.25	Digestive system disease (Barrett's esophagus and esophageal adenocarcinoma combined);	chr19:44729108	chr19:44632199~44718759:-
OV	cis	rs12908161	0.959	rs2175567	ENSG00000225151.9	GOLGA2P7	-3.88	0.000137	0.0421	-0.32	-0.25	Schizophrenia;	chr15:84657715	chr15:84199311~84230136:-
OV	cis	rs774359	0.789	rs2453552	ENSG00000234676.1	IFT74-AS1	3.88	0.000137	0.0421	0.29	0.25	Amyotrophic lateral sclerosis;	chr9:27527514	chr9:26955780~26956295:-
OV	cis	rs367615	0.704	rs4320313	ENSG00000249476.1	CTD-2587M2.1	3.88	0.000138	0.0421	0.31	0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109492986	chr5:109237120~109326369:-
OV	cis	rs6500265	0.64	rs9944315	ENSG00000260024.1	MRPS21P7	-3.88	0.000138	0.0421	-0.25	-0.25	Cold medicine-related Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) with severe ocular complications;	chr16:49909893	chr16:49708006~49708243:+
OV	cis	rs12701220	0.503	rs13222294	ENSG00000229043.2	AC091729.9	-3.88	0.000138	0.0422	-0.33	-0.25	Bronchopulmonary dysplasia;	chr7:1133333	chr7:1160374~1165267:+
OV	cis	rs6919534	0.688	rs9469972	ENSG00000265123.2	RN7SL200P	3.88	0.000138	0.0422	0.28	0.25	Height;	chr6:35243434	chr6:34685355~34685642:-
OV	cis	rs7246967	0.673	rs4933026	ENSG00000267920.1	SNX6P1	-3.88	0.000138	0.0422	-0.39	-0.25	Bronchopulmonary dysplasia;	chr19:22691690	chr19:23126569~23127792:-
OV	cis	rs6673267	0.967	rs6675915	ENSG00000223774.4	RP11-307B6.3	3.88	0.000138	0.0422	0.27	0.25	Lobe attachment (rater-scored or self-reported);	chr1:201041734	chr1:201893842~201899978:+
OV	cis	rs7615952	0.576	rs66671308	ENSG00000250012.1	RP11-124N2.1	-3.88	0.000138	0.0422	-0.31	-0.25	Blood pressure (smoking interaction);	chr3:126074683	chr3:126084220~126095349:+
OV	cis	rs6673267	0.967	rs2297906	ENSG00000223774.4	RP11-307B6.3	3.88	0.000138	0.0422	0.27	0.25	Lobe attachment (rater-scored or self-reported);	chr1:201044208	chr1:201893842~201899978:+
OV	cis	rs853679	0.546	rs493161	ENSG00000226314.6	ZNF192P1	-3.88	0.000138	0.0422	-0.48	-0.25	Depression;	chr6:27882936	chr6:28161781~28169594:+
OV	cis	rs7746199	0.736	rs13202291	ENSG00000226314.6	ZNF192P1	-3.88	0.000138	0.0422	-0.53	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731078	chr6:28161781~28169594:+
OV	cis	rs7927592	0.731	rs2156463	ENSG00000222339.1	AP000807.2	3.88	0.000138	0.0422	0.25	0.25	Total body bone mineral density;	chr11:68618843	chr11:68505572~68505651:-
OV	cis	rs7667	0.812	rs12041311	ENSG00000240490.3	RN7SL277P	-3.88	0.000138	0.0422	-0.29	-0.25	Crohn's disease and psoriasis;	chr1:19439754	chr1:19424384~19424671:+
OV	cis	rs853679	0.607	rs35749575	ENSG00000220721.1	OR1F12	3.88	0.000138	0.0422	0.52	0.25	Depression;	chr6:28147040	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs72846780	ENSG00000220721.1	OR1F12	3.88	0.000138	0.0422	0.52	0.25	Depression;	chr6:28151277	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs13205911	ENSG00000220721.1	OR1F12	3.88	0.000138	0.0422	0.52	0.25	Depression;	chr6:28156336	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs13197176	ENSG00000220721.1	OR1F12	3.88	0.000138	0.0422	0.52	0.25	Depression;	chr6:28161454	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs13201308	ENSG00000220721.1	OR1F12	3.88	0.000138	0.0422	0.52	0.25	Depression;	chr6:28162311	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs34765154	ENSG00000220721.1	OR1F12	3.88	0.000138	0.0422	0.52	0.25	Depression;	chr6:28162672	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs34505829	ENSG00000220721.1	OR1F12	3.88	0.000138	0.0422	0.52	0.25	Depression;	chr6:28165461	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs35098436	ENSG00000220721.1	OR1F12	3.88	0.000138	0.0422	0.52	0.25	Depression;	chr6:28166443	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs72846794	ENSG00000220721.1	OR1F12	3.88	0.000138	0.0422	0.52	0.25	Depression;	chr6:28169721	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs13217984	ENSG00000220721.1	OR1F12	3.88	0.000138	0.0422	0.52	0.25	Depression;	chr6:28171932	chr6:28073316~28074233:+
OV	cis	rs853679	0.556	rs67297533	ENSG00000220721.1	OR1F12	3.88	0.000138	0.0422	0.52	0.25	Depression;	chr6:28173475	chr6:28073316~28074233:+
OV	cis	rs853679	0.505	rs35781323	ENSG00000220721.1	OR1F12	3.88	0.000138	0.0422	0.52	0.25	Depression;	chr6:28177054	chr6:28073316~28074233:+
OV	cis	rs1560104	0.518	rs11645483	ENSG00000259899.1	CTD-3037G24.3	-3.88	0.000138	0.0422	-0.29	-0.25	Obesity-related traits;	chr16:12615400	chr16:12560756~12611044:-
OV	cis	rs7395581	0.918	rs61896050	ENSG00000271350.1	CTD-2384B9.1	3.88	0.000138	0.0422	0.28	0.25	HDL cholesterol;	chr11:47287512	chr11:47041027~47041945:-
OV	cis	rs12681366	0.734	rs2291439	ENSG00000253704.1	RP11-267M23.4	3.88	0.000138	0.0422	0.3	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94407470	chr8:94553722~94569745:+
OV	cis	rs4591358	0.684	rs17177643	ENSG00000223466.1	AC064834.2	3.88	0.000138	0.0423	0.3	0.25	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195510796	chr2:195533035~195538681:+
OV	cis	rs10924970	0.967	rs7512798	ENSG00000236863.2	RPL23AP23	3.88	0.000138	0.0423	0.25	0.25	Asthma;	chr1:235193110	chr1:235295865~235296335:+
OV	cis	rs6545883	0.826	rs2694651	ENSG00000270820.4	RP11-355B11.2	-3.88	0.000138	0.0423	-0.28	-0.25	Tuberculosis;	chr2:61361507	chr2:61471188~61484130:+
OV	cis	rs7918232	0.882	rs788211	ENSG00000262412.1	RP11-85G18.6	-3.88	0.000138	0.0423	-0.36	-0.25	Breast cancer;	chr10:27190141	chr10:27243130~27250804:+
OV	cis	rs732765	0.657	rs3764920	ENSG00000258439.1	RP11-173A8.2	3.88	0.000138	0.0423	0.39	0.25	Non-small cell lung cancer;	chr14:74824728	chr14:74658049~74658590:+
OV	cis	rs7615952	0.576	rs2276729	ENSG00000250012.1	RP11-124N2.1	-3.88	0.000138	0.0423	-0.31	-0.25	Blood pressure (smoking interaction);	chr3:126107371	chr3:126084220~126095349:+
OV	cis	rs1661178	0.826	rs1623156	ENSG00000279095.1	AC092066.1	3.88	0.000138	0.0423	0.39	0.25	Exploratory eye movement dysfunction in schizophrenia (responsive search score);	chr19:44540600	chr19:44664131~44666158:+
OV	cis	rs514406	0.505	rs387436	ENSG00000206627.1	RNU6-969P	-3.88	0.000138	0.0423	-0.26	-0.25	Monocyte count;	chr1:52713704	chr1:52805108~52805212:-
OV	cis	rs743757	1	rs929047	ENSG00000228008.1	CTD-2330K9.3	3.88	0.000138	0.0423	0.38	0.25	Diastolic blood pressure;	chr3:50465739	chr3:49903845~49916937:+
OV	cis	rs743757	0.877	rs11130250	ENSG00000228008.1	CTD-2330K9.3	3.88	0.000138	0.0423	0.38	0.25	Diastolic blood pressure;	chr3:50470895	chr3:49903845~49916937:+
OV	cis	rs9473147	0.516	rs2171089	ENSG00000270761.1	RP11-385F7.1	-3.88	0.000139	0.0424	-0.29	-0.25	Platelet distribution width;Mean platelet volume;	chr6:47548075	chr6:47477243~47477572:-
OV	cis	rs673078	0.66	rs16948234	ENSG00000275759.1	RP11-131L12.3	3.88	0.000139	0.0424	0.39	0.25	Glucose homeostasis traits;	chr12:118282464	chr12:118428281~118428870:+
OV	cis	rs2108622	0.727	rs3093216	ENSG00000267453.5	AC004791.2	-3.88	0.000139	0.0424	-0.29	-0.25	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15876927	chr19:15851993~15864904:-
OV	cis	rs2108622	0.701	rs3093209	ENSG00000267453.5	AC004791.2	-3.88	0.000139	0.0424	-0.29	-0.25	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15877610	chr19:15851993~15864904:-
OV	cis	rs3734266	0.702	rs6909637	ENSG00000220643.1	RP3-391O22.1	-3.88	0.000139	0.0424	-0.41	-0.25	Systemic lupus erythematosus;	chr6:34645853	chr6:34686602~34687106:+
OV	cis	rs3734266	0.702	rs9469837	ENSG00000220643.1	RP3-391O22.1	-3.88	0.000139	0.0424	-0.41	-0.25	Systemic lupus erythematosus;	chr6:34647755	chr6:34686602~34687106:+
OV	cis	rs3734266	0.702	rs16892384	ENSG00000220643.1	RP3-391O22.1	-3.88	0.000139	0.0424	-0.41	-0.25	Systemic lupus erythematosus;	chr6:34651226	chr6:34686602~34687106:+
OV	cis	rs3734266	0.702	rs7765969	ENSG00000220643.1	RP3-391O22.1	-3.88	0.000139	0.0424	-0.41	-0.25	Systemic lupus erythematosus;	chr6:34667078	chr6:34686602~34687106:+
OV	cis	rs3734266	0.702	rs9462002	ENSG00000220643.1	RP3-391O22.1	-3.88	0.000139	0.0424	-0.41	-0.25	Systemic lupus erythematosus;	chr6:34691457	chr6:34686602~34687106:+
OV	cis	rs3734266	0.702	rs72910111	ENSG00000220643.1	RP3-391O22.1	-3.88	0.000139	0.0424	-0.41	-0.25	Systemic lupus erythematosus;	chr6:34699627	chr6:34686602~34687106:+
OV	cis	rs3734266	0.591	rs7749750	ENSG00000220643.1	RP3-391O22.1	-3.88	0.000139	0.0424	-0.41	-0.25	Systemic lupus erythematosus;	chr6:34709268	chr6:34686602~34687106:+
OV	cis	rs3734266	0.702	rs6908462	ENSG00000220643.1	RP3-391O22.1	3.88	0.000139	0.0424	0.41	0.25	Systemic lupus erythematosus;	chr6:34705372	chr6:34686602~34687106:+
OV	cis	rs10992471	0.603	rs10114912	ENSG00000281156.1	MIR3651	-3.88	0.000139	0.0424	-0.28	-0.25	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92545581	chr9:92292458~92292547:-
OV	cis	rs10992471	0.603	rs10114932	ENSG00000281156.1	MIR3651	-3.88	0.000139	0.0424	-0.28	-0.25	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92545619	chr9:92292458~92292547:-
OV	cis	rs10992471	0.603	rs10761163	ENSG00000281156.1	MIR3651	-3.88	0.000139	0.0424	-0.28	-0.25	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92551005	chr9:92292458~92292547:-
OV	cis	rs3734266	0.702	rs13196785	ENSG00000220643.1	RP3-391O22.1	-3.88	0.000139	0.0424	-0.43	-0.25	Systemic lupus erythematosus;	chr6:34841044	chr6:34686602~34687106:+
OV	cis	rs11623436	0.552	rs4899401	ENSG00000258300.2	NUTF2P2	3.88	0.000139	0.0424	0.29	0.25	Lobe attachment (rater-scored or self-reported);	chr14:36535344	chr14:35819837~35820220:+
OV	cis	rs2442825	0.693	rs2258768	ENSG00000206573.7	THUMPD3-AS1	3.88	0.000139	0.0424	0.27	0.25	Cerebrospinal fluid clusterin levels;	chr3:9363193	chr3:9349689~9398579:-
OV	cis	rs875971	1	rs2420820	ENSG00000237310.1	GS1-124K5.4	-3.88	0.000139	0.0425	-0.26	-0.25	Aortic root size;	chr7:66626920	chr7:66493706~66495474:+
OV	cis	rs2070488	0.775	rs11926767	ENSG00000229589.1	ACVR2B-AS1	-3.88	0.000139	0.0425	-0.29	-0.25	Electrocardiographic conduction measures;	chr3:38486422	chr3:38451027~38454820:-
OV	cis	rs4713118	0.866	rs2179094	ENSG00000226314.6	ZNF192P1	-3.88	0.000139	0.0425	-0.31	-0.25	Parkinson's disease;	chr6:27774046	chr6:28161781~28169594:+
OV	cis	rs7246657	0.943	rs13343502	ENSG00000226686.6	LINC01535	-3.88	0.000139	0.0425	-0.39	-0.25	Coronary artery calcification;	chr19:37471390	chr19:37251912~37265535:+
OV	cis	rs9473147	0.516	rs9463342	ENSG00000270761.1	RP11-385F7.1	-3.88	0.000139	0.0425	-0.28	-0.25	Platelet distribution width;Mean platelet volume;	chr6:47617370	chr6:47477243~47477572:-
OV	cis	rs1353899	0.784	rs7615202	ENSG00000231310.3	TBL1XR1-AS1	-3.88	0.000139	0.0425	-0.3	-0.25	Alcohol consumption;	chr3:177505279	chr3:177037405~177047923:+
OV	cis	rs4845570	1	rs6673002	ENSG00000238711.1	RNY4P25	3.88	0.000139	0.0425	0.33	0.25	Coronary artery disease;	chr1:151770799	chr1:151439000~151439095:+
OV	cis	rs11951515	0.738	rs4866821	ENSG00000278487.1	RP11-447H19.4	-3.88	0.000139	0.0425	-0.29	-0.25	Metabolite levels  (X-11787);	chr5:43353719	chr5:43143362~43143514:-
OV	cis	rs11951515	0.603	rs58358642	ENSG00000278487.1	RP11-447H19.4	-3.88	0.000139	0.0425	-0.29	-0.25	Metabolite levels  (X-11787);	chr5:43355066	chr5:43143362~43143514:-
OV	cis	rs11951515	0.628	rs57066570	ENSG00000278487.1	RP11-447H19.4	-3.88	0.000139	0.0425	-0.29	-0.25	Metabolite levels  (X-11787);	chr5:43355217	chr5:43143362~43143514:-
OV	cis	rs11951515	0.603	rs59625262	ENSG00000278487.1	RP11-447H19.4	-3.88	0.000139	0.0425	-0.29	-0.25	Metabolite levels  (X-11787);	chr5:43355270	chr5:43143362~43143514:-
OV	cis	rs7927592	0.83	rs7120635	ENSG00000212093.1	AP000807.1	3.88	0.000139	0.0425	0.31	0.25	Total body bone mineral density;	chr11:68493825	chr11:68506083~68506166:-
OV	cis	rs1075265	0.901	rs1058320	ENSG00000233266.1	HMGB1P31	3.88	0.000139	0.0425	0.3	0.25	Chronotype;Morning vs. evening chronotype;	chr2:54085016	chr2:54051334~54051760:+
OV	cis	rs6657613	0.68	rs6690934	ENSG00000186715.9	MST1L	-3.88	0.000139	0.0425	-0.27	-0.25	Hip circumference adjusted for BMI;	chr1:17046127	chr1:16754910~16770237:-
OV	cis	rs858239	0.899	rs2268745	ENSG00000230042.1	AK3P3	-3.88	0.000139	0.0426	-0.27	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23277981	chr7:23129178~23129841:+
OV	cis	rs9473147	0.516	rs1485780	ENSG00000270761.1	RP11-385F7.1	-3.88	0.000139	0.0426	-0.28	-0.25	Platelet distribution width;Mean platelet volume;	chr6:47588894	chr6:47477243~47477572:-
OV	cis	rs9473147	0.543	rs9381578	ENSG00000270761.1	RP11-385F7.1	-3.88	0.000139	0.0426	-0.28	-0.25	Platelet distribution width;Mean platelet volume;	chr6:47588898	chr6:47477243~47477572:-
OV	cis	rs9473147	0.516	rs9381579	ENSG00000270761.1	RP11-385F7.1	-3.88	0.000139	0.0426	-0.28	-0.25	Platelet distribution width;Mean platelet volume;	chr6:47588944	chr6:47477243~47477572:-
OV	cis	rs9473147	0.516	rs10456570	ENSG00000270761.1	RP11-385F7.1	-3.88	0.000139	0.0426	-0.28	-0.25	Platelet distribution width;Mean platelet volume;	chr6:47591715	chr6:47477243~47477572:-
OV	cis	rs9473147	0.516	rs6903331	ENSG00000270761.1	RP11-385F7.1	-3.88	0.000139	0.0426	-0.28	-0.25	Platelet distribution width;Mean platelet volume;	chr6:47595179	chr6:47477243~47477572:-
OV	cis	rs6071524	0.508	rs2254377	ENSG00000277581.1	RP4-616B8.6	-3.88	0.00014	0.0426	-0.29	-0.25	Autism spectrum disorder or schizophrenia;	chr20:38750986	chr20:38962472~38962993:+
OV	cis	rs853679	1	rs7740487	ENSG00000226314.6	ZNF192P1	-3.87	0.00014	0.0426	-0.43	-0.25	Depression;	chr6:28248708	chr6:28161781~28169594:+
OV	cis	rs73201462	1	rs2811536	ENSG00000242551.2	POU5F1P6	-3.87	0.00014	0.0426	-0.37	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128270076	chr3:128674735~128677005:-
OV	cis	rs3758911	0.964	rs10890702	ENSG00000261098.1	RP11-819C21.1	3.87	0.00014	0.0426	0.25	0.25	Coronary artery disease;	chr11:107310159	chr11:107312132~107316271:-
OV	cis	rs11667325	1	rs4802867	ENSG00000268316.1	AC006272.2	-3.87	0.00014	0.0427	-0.24	-0.25	Neutrophil percentage of granulocytes;	chr19:51796632	chr19:51839771~51840945:-
OV	cis	rs9847710	0.696	rs2581821	ENSG00000242142.1	SERBP1P3	3.87	0.00014	0.0427	0.3	0.25	Ulcerative colitis;	chr3:52987572	chr3:53064283~53065091:-
OV	cis	rs11685222	0.668	rs61642940	ENSG00000229867.1	STEAP3-AS1	-3.87	0.00014	0.0427	-0.4	-0.25	Response to chemotherapy in breast cancer hypertensive cases (cumulative dose) (bevacizumab);	chr2:119708850	chr2:119244422~119249071:-
OV	cis	rs6142102	0.58	rs761233	ENSG00000276073.1	RP5-1125A11.7	-3.87	0.00014	0.0427	-0.29	-0.25	Skin pigmentation;	chr20:33981080	chr20:33985617~33988989:-
OV	cis	rs6142102	0.602	rs4911395	ENSG00000276073.1	RP5-1125A11.7	-3.87	0.00014	0.0427	-0.29	-0.25	Skin pigmentation;	chr20:33992095	chr20:33985617~33988989:-
OV	cis	rs6142102	0.602	rs2268079	ENSG00000276073.1	RP5-1125A11.7	-3.87	0.00014	0.0427	-0.29	-0.25	Skin pigmentation;	chr20:34008944	chr20:33985617~33988989:-
OV	cis	rs6142102	0.602	rs1054534	ENSG00000276073.1	RP5-1125A11.7	-3.87	0.00014	0.0427	-0.29	-0.25	Skin pigmentation;	chr20:34017521	chr20:33985617~33988989:-
OV	cis	rs6723108	0.581	rs1446525	ENSG00000224043.6	CCNT2-AS1	-3.87	0.00014	0.0427	-0.29	-0.25	Type 2 diabetes;	chr2:134880277	chr2:134735464~134918710:-
OV	cis	rs6723108	0.627	rs6430554	ENSG00000224043.6	CCNT2-AS1	-3.87	0.00014	0.0427	-0.29	-0.25	Type 2 diabetes;	chr2:134880891	chr2:134735464~134918710:-
OV	cis	rs6723108	0.603	rs6430555	ENSG00000224043.6	CCNT2-AS1	-3.87	0.00014	0.0427	-0.29	-0.25	Type 2 diabetes;	chr2:134890089	chr2:134735464~134918710:-
OV	cis	rs11673344	0.523	rs1402468	ENSG00000226686.6	LINC01535	3.87	0.00014	0.0427	0.31	0.25	Obesity-related traits;	chr19:37129346	chr19:37251912~37265535:+
OV	cis	rs7789940	0.951	rs7787526	ENSG00000230305.2	AC004980.9	3.87	0.00014	0.0427	0.36	0.25	Multiple sclerosis;	chr7:76318236	chr7:76524515~76532692:+
OV	cis	rs1538970	0.962	rs7544178	ENSG00000280836.1	AL355480.1	-3.87	0.00014	0.0427	-0.35	-0.25	Platelet count;	chr1:45353397	chr1:45581219~45581321:-
OV	cis	rs860295	0.58	rs12032720	ENSG00000225855.5	RUSC1-AS1	3.87	0.00014	0.0427	0.22	0.25	Body mass index;	chr1:155305169	chr1:155316863~155324176:-
OV	cis	rs4493873	0.785	rs7832592	ENSG00000253738.1	OTUD6B-AS1	3.87	0.00014	0.0428	0.31	0.25	Migraine - clinic-based;	chr8:91091059	chr8:91059909~91070189:-
OV	cis	rs4493873	0.812	rs10956790	ENSG00000253738.1	OTUD6B-AS1	3.87	0.00014	0.0428	0.31	0.25	Migraine - clinic-based;	chr8:91093238	chr8:91059909~91070189:-
OV	cis	rs7246657	0.943	rs4801803	ENSG00000226686.6	LINC01535	3.87	0.00014	0.0428	0.39	0.25	Coronary artery calcification;	chr19:37476021	chr19:37251912~37265535:+
OV	cis	rs2436845	0.603	rs2679753	ENSG00000253385.1	KB-1254G8.1	-3.87	0.00014	0.0428	-0.31	-0.25	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102855232	chr8:102854455~102856075:+
OV	cis	rs4356203	0.905	rs17472886	ENSG00000213779.4	RP11-452G18.1	3.87	0.00014	0.0428	0.27	0.25	Schizophrenia;Schizophrenia or bipolar disorder;	chr11:17064620	chr11:17193489~17194308:+
OV	cis	rs8054556	0.733	rs35467921	ENSG00000261367.1	RP11-455F5.4	-3.87	0.00014	0.0428	-0.3	-0.25	Autism spectrum disorder or schizophrenia;	chr16:30037232	chr16:30107675~30110541:+
OV	cis	rs35160687	0.829	rs13017143	ENSG00000273196.1	RP11-717A5.2	-3.87	0.00014	0.0428	-0.27	-0.25	Night sleep phenotypes;	chr2:86239426	chr2:85387074~85387146:-
OV	cis	rs7646881	0.544	rs41272617	ENSG00000272440.1	RP11-379F4.6	3.87	0.000141	0.0428	0.36	0.25	Tetralogy of Fallot;	chr3:158603103	chr3:158695367~158695581:+
OV	cis	rs7646881	0.544	rs73024790	ENSG00000272440.1	RP11-379F4.6	3.87	0.000141	0.0428	0.36	0.25	Tetralogy of Fallot;	chr3:158606615	chr3:158695367~158695581:+
OV	cis	rs7646881	0.544	rs16829135	ENSG00000272440.1	RP11-379F4.6	3.87	0.000141	0.0428	0.36	0.25	Tetralogy of Fallot;	chr3:158608049	chr3:158695367~158695581:+
OV	cis	rs11587682	0.956	rs114537627	ENSG00000223945.2	RP11-458I7.1	-3.87	0.000141	0.0428	-0.43	-0.25	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150421758	chr1:150053864~150055034:+
OV	cis	rs41271951	0.518	rs72696873	ENSG00000223945.2	RP11-458I7.1	-3.87	0.000141	0.0428	-0.43	-0.25	Blood protein levels;	chr1:150423354	chr1:150053864~150055034:+
OV	cis	rs41271951	0.518	rs12144958	ENSG00000223945.2	RP11-458I7.1	-3.87	0.000141	0.0428	-0.43	-0.25	Blood protein levels;	chr1:150430903	chr1:150053864~150055034:+
OV	cis	rs72700829	0.507	rs11205374	ENSG00000223945.2	RP11-458I7.1	-3.87	0.000141	0.0428	-0.43	-0.25	Schizophrenia;	chr1:150434823	chr1:150053864~150055034:+
OV	cis	rs11587682	0.955	rs12119320	ENSG00000223945.2	RP11-458I7.1	-3.87	0.000141	0.0428	-0.43	-0.25	Autism spectrum disorder, attention deficit-hyperactivity disorder, bipolar disorder, major depressive disorder, and schizophrenia (combined);	chr1:150440123	chr1:150053864~150055034:+
OV	cis	rs41271951	0.542	rs11580764	ENSG00000223945.2	RP11-458I7.1	-3.87	0.000141	0.0428	-0.43	-0.25	Blood protein levels;	chr1:150445741	chr1:150053864~150055034:+
OV	cis	rs875971	0.502	rs2465121	ENSG00000236529.1	RP13-254B10.1	-3.87	0.000141	0.0428	-0.29	-0.25	Aortic root size;	chr7:66156017	chr7:65840212~65840596:+
OV	cis	rs2739330	0.587	rs4820571	ENSG00000228039.3	KB-1125A3.10	3.87	0.000141	0.0428	0.29	0.25	Liver enzyme levels (gamma-glutamyl transferase);	chr22:23900786	chr22:23963780~23964374:+
OV	cis	rs3018712	0.59	rs4930236	ENSG00000212093.1	AP000807.1	-3.87	0.000141	0.0429	-0.35	-0.25	Total body bone mineral density;	chr11:68646532	chr11:68506083~68506166:-
OV	cis	rs6683071	0.643	rs35507977	ENSG00000272750.1	RP11-378J18.8	-3.87	0.000141	0.0429	-0.35	-0.25	Cognitive performance;	chr1:222700776	chr1:222658867~222661512:-
OV	cis	rs6683071	0.738	rs2030076	ENSG00000272750.1	RP11-378J18.8	-3.87	0.000141	0.0429	-0.35	-0.25	Cognitive performance;	chr1:222701624	chr1:222658867~222661512:-
OV	cis	rs67180937	0.553	rs11485123	ENSG00000272750.1	RP11-378J18.8	-3.87	0.000141	0.0429	-0.35	-0.25	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222704833	chr1:222658867~222661512:-
OV	cis	rs6683071	0.643	rs34433664	ENSG00000272750.1	RP11-378J18.8	-3.87	0.000141	0.0429	-0.35	-0.25	Cognitive performance;	chr1:222709607	chr1:222658867~222661512:-
OV	cis	rs14027	0.921	rs2289011	ENSG00000279347.1	RP11-85I17.2	3.87	0.000141	0.0429	0.25	0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119744768	chr8:119838736~119840385:-
OV	cis	rs853679	0.545	rs35949109	ENSG00000220721.1	OR1F12	3.87	0.000141	0.0429	0.37	0.25	Depression;	chr6:28058148	chr6:28073316~28074233:+
OV	cis	rs1797885	0.524	rs2596823	ENSG00000251774.1	RNU6-377P	3.87	0.000141	0.0429	0.24	0.25	Immature fraction of reticulocytes;	chr3:12566846	chr3:12514706~12514807:+
OV	cis	rs300032	1	rs1867486	ENSG00000260750.4	RP11-482M8.1	3.87	0.000141	0.0429	0.35	0.25	IgG glycosylation;	chr16:86647549	chr16:87492555~87515635:+
OV	cis	rs642743	0.967	rs789970	ENSG00000228261.1	RP11-127L20.3	-3.87	0.000141	0.0429	-0.26	-0.25	Left ventricular obstructive tract defect (maternal effect);	chr10:104217963	chr10:104323369~104327004:+
OV	cis	rs929354	0.566	rs6979947	ENSG00000224629.1	RP5-1142J19.2	3.87	0.000141	0.0429	0.24	0.25	Body mass index;	chr7:157213169	chr7:157263022~157263229:-
OV	cis	rs9287719	0.601	rs62128635	ENSG00000234818.1	AC092687.5	3.87	0.000141	0.0429	0.28	0.25	Prostate cancer;	chr2:10585208	chr2:10589166~10604830:+
OV	cis	rs711355	0.967	rs813676	ENSG00000270016.1	RP11-932O9.8	3.87	0.000141	0.0429	0.28	0.25	Response to antipsychotic treatment;	chr15:29901113	chr15:30607695~30608193:-
OV	cis	rs255758	0.654	rs255751	ENSG00000272123.1	CTD-2366F13.2	-3.87	0.000141	0.0429	-0.31	-0.25	Rheumatoid arthritis;	chr5:54023687	chr5:53089016~53089468:-
OV	cis	rs2919917	1	rs1483573	ENSG00000254352.1	RP11-578O24.2	3.87	0.000141	0.0429	0.29	0.25	Lymphocyte counts;	chr8:78711382	chr8:78723796~78724136:-
OV	cis	rs9847710	0.696	rs2564932	ENSG00000242142.1	SERBP1P3	-3.87	0.000141	0.0429	-0.3	-0.25	Ulcerative colitis;	chr3:52987994	chr3:53064283~53065091:-
OV	cis	rs2999052	1	rs6414310	ENSG00000277250.1	Metazoa_SRP	-3.87	0.000141	0.0429	-0.3	-0.25	Hypospadias;	chr3:128137730	chr3:128673681~128674021:-
OV	cis	rs2999052	1	rs6777054	ENSG00000277250.1	Metazoa_SRP	-3.87	0.000141	0.0429	-0.31	-0.25	Hypospadias;	chr3:128226506	chr3:128673681~128674021:-
OV	cis	rs7968440	1	rs2252589	ENSG00000272368.2	RP4-605O3.4	3.87	0.000141	0.0429	0.29	0.25	Fibrinogen;	chr12:50648174	chr12:50112197~50165618:+
OV	cis	rs7568498	1	rs13387779	ENSG00000227403.1	AC009299.3	3.87	0.000141	0.043	0.46	0.25	Response to anti-retroviral therapy (ddI/d4T) in HIV-1 infection (Grade 3 peripheral neuropathy);	chr2:161082846	chr2:161244739~161249050:+
OV	cis	rs6460942	0.597	rs13221702	ENSG00000226690.5	AC005281.1	-3.87	0.000141	0.043	-0.45	-0.25	Coronary artery disease;	chr7:12479450	chr7:12496429~12541910:+
OV	cis	rs7927771	1	rs10838748	ENSG00000271350.1	CTD-2384B9.1	-3.87	0.000141	0.043	-0.3	-0.25	Subjective well-being;	chr11:47694829	chr11:47041027~47041945:-
OV	cis	rs4604732	0.642	rs4400652	ENSG00000227135.1	GCSAML-AS1	-3.87	0.000141	0.043	-0.4	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247473177	chr1:247524679~247526752:-
OV	cis	rs4604732	0.642	rs4472786	ENSG00000227135.1	GCSAML-AS1	-3.87	0.000141	0.043	-0.4	-0.25	Plasma omega-6 polyunsaturated fatty acid levels (dihomo-gamma-linolenic acid);	chr1:247473216	chr1:247524679~247526752:-
OV	cis	rs1105307	0.628	rs10780507	ENSG00000229312.2	RP11-470P21.2	-3.87	0.000141	0.043	-0.3	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr9:69530359	chr9:69472466~69494513:+
OV	cis	rs9393692	0.676	rs806977	ENSG00000241549.7	GUSBP2	-3.87	0.000141	0.043	-0.28	-0.25	Educational attainment;	chr6:26189387	chr6:26871484~26956554:-
OV	cis	rs11239930	0.517	rs590286	ENSG00000278811.3	LINC00624	3.87	0.000141	0.043	0.3	0.25	AIDS progression;	chr1:147074056	chr1:147258885~147517875:-
OV	cis	rs860295	0.557	rs10796941	ENSG00000225855.5	RUSC1-AS1	3.87	0.000141	0.043	0.22	0.25	Body mass index;	chr1:155314470	chr1:155316863~155324176:-
OV	cis	rs11951515	0.579	rs58966636	ENSG00000278487.1	RP11-447H19.4	-3.87	0.000141	0.043	-0.29	-0.25	Metabolite levels  (X-11787);	chr5:43355264	chr5:43143362~43143514:-
OV	cis	rs7520050	0.751	rs2991975	ENSG00000280836.1	AL355480.1	3.87	0.000142	0.0431	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:45558854	chr1:45581219~45581321:-
OV	cis	rs9880211	0.706	rs9289513	ENSG00000239213.4	NCK1-AS1	3.87	0.000142	0.0431	0.32	0.25	Height;Body mass index;	chr3:136732904	chr3:136841726~136862054:-
OV	cis	rs9880211	0.8	rs35100027	ENSG00000239213.4	NCK1-AS1	3.87	0.000142	0.0431	0.32	0.25	Height;Body mass index;	chr3:136748719	chr3:136841726~136862054:-
OV	cis	rs1889899	0.966	rs10967533	ENSG00000254261.1	RP11-18A15.1	-3.87	0.000142	0.0431	-0.25	-0.25	Smoking behavior;	chr9:26781147	chr9:26746953~26786874:+
OV	cis	rs7587928	0.593	rs10187714	ENSG00000225642.1	SNRPEP5	3.87	0.000142	0.0431	0.28	0.25	Neutrophil count;	chr2:8720770	chr2:8603082~8603359:+
OV	cis	rs2303745	0.589	rs8103523	ENSG00000269815.1	CTD-2278I10.4	-3.87	0.000142	0.0431	-0.33	-0.25	Systemic lupus erythematosus;	chr19:17287460	chr19:17296196~17296695:-
OV	cis	rs897984	0.762	rs7204459	ENSG00000278922.1	AC002310.14	-3.87	0.000142	0.0431	-0.27	-0.25	Dementia with Lewy bodies;	chr16:30972891	chr16:30526918~30528294:+
OV	cis	rs897984	0.762	rs4889604	ENSG00000278922.1	AC002310.14	-3.87	0.000142	0.0431	-0.27	-0.25	Dementia with Lewy bodies;	chr16:30974673	chr16:30526918~30528294:+
OV	cis	rs897984	0.762	rs12931046	ENSG00000278922.1	AC002310.14	-3.87	0.000142	0.0431	-0.27	-0.25	Dementia with Lewy bodies;	chr16:30975823	chr16:30526918~30528294:+
OV	cis	rs9847710	0.838	rs2581795	ENSG00000242142.1	SERBP1P3	-3.87	0.000142	0.0431	-0.27	-0.25	Ulcerative colitis;	chr3:53004770	chr3:53064283~53065091:-
OV	cis	rs9880211	0.752	rs9820717	ENSG00000239213.4	NCK1-AS1	3.87	0.000142	0.0431	0.32	0.25	Height;Body mass index;	chr3:136627771	chr3:136841726~136862054:-
OV	cis	rs7246657	0.943	rs34603719	ENSG00000226686.6	LINC01535	-3.87	0.000142	0.0431	-0.4	-0.25	Coronary artery calcification;	chr19:37303626	chr19:37251912~37265535:+
OV	cis	rs5015933	0.902	rs2291858	ENSG00000232630.1	PRPS1P2	-3.87	0.000142	0.0432	-0.24	-0.25	Body mass index;	chr9:125366503	chr9:125150653~125151589:+
OV	cis	rs4296809	0.505	rs72755343	ENSG00000249779.1	RP11-447H19.3	-3.87	0.000142	0.0432	-0.48	-0.25	Brain structure;	chr5:44151662	chr5:43206709~43207811:+
OV	cis	rs7208859	0.623	rs122898	ENSG00000263603.1	CTD-2349P21.5	3.87	0.000142	0.0432	0.25	0.25	Mean corpuscular hemoglobin;Mean corpuscular volume;	chr17:30578236	chr17:30729469~30731202:+
OV	cis	rs61160187	0.583	rs6449503	ENSG00000152931.7	PART1	3.87	0.000142	0.0432	0.29	0.25	Educational attainment (years of education);Educational attainment (college completion);	chr5:60799445	chr5:60487713~60547657:+
OV	cis	rs8059260	1	rs8059260	ENSG00000274038.1	RP11-66H6.4	-3.87	0.000142	0.0433	-0.41	-0.25	Alcohol consumption over the past year;	chr16:10966294	chr16:11056556~11057034:+
OV	cis	rs11673344	0.526	rs1871196	ENSG00000267422.1	CTD-2554C21.1	3.87	0.000142	0.0433	0.26	0.25	Obesity-related traits;	chr19:37656022	chr19:37779686~37792865:+
OV	cis	rs853679	0.666	rs200956	ENSG00000226314.6	ZNF192P1	-3.87	0.000142	0.0433	-0.38	-0.25	Depression;	chr6:27871968	chr6:28161781~28169594:+
OV	cis	rs7615952	0.576	rs6780025	ENSG00000250012.1	RP11-124N2.1	-3.87	0.000142	0.0433	-0.31	-0.25	Blood pressure (smoking interaction);	chr3:126096781	chr3:126084220~126095349:+
OV	cis	rs7615952	0.576	rs6804482	ENSG00000250012.1	RP11-124N2.1	-3.87	0.000142	0.0433	-0.31	-0.25	Blood pressure (smoking interaction);	chr3:126096919	chr3:126084220~126095349:+
OV	cis	rs11918654	0.628	rs11707472	ENSG00000235831.5	BHLHE40-AS1	3.87	0.000142	0.0433	0.35	0.25	Disc degeneration (lumbar);	chr3:5142215	chr3:4896809~4979961:-
OV	cis	rs9979383	0.576	rs4817722	ENSG00000228107.1	AP000692.9	3.87	0.000142	0.0433	0.25	0.25	Sum eosinophil basophil counts;Eosinophil percentage of granulocytes;Neutrophil percentage of granulocytes;	chr21:35421042	chr21:36360630~36362040:+
OV	cis	rs801193	0.935	rs2659916	ENSG00000237310.1	GS1-124K5.4	3.87	0.000142	0.0433	0.26	0.25	Aortic root size;	chr7:66686365	chr7:66493706~66495474:+
OV	cis	rs848490	0.508	rs6975810	ENSG00000214293.7	APTR	3.87	0.000142	0.0433	0.31	0.25	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77659701	chr7:77657660~77696265:-
OV	cis	rs11951515	0.738	rs56185290	ENSG00000278487.1	RP11-447H19.4	-3.87	0.000143	0.0433	-0.29	-0.25	Metabolite levels  (X-11787);	chr5:43356604	chr5:43143362~43143514:-
OV	cis	rs11951515	0.789	rs55759722	ENSG00000278487.1	RP11-447H19.4	-3.87	0.000143	0.0433	-0.29	-0.25	Metabolite levels  (X-11787);	chr5:43356812	chr5:43143362~43143514:-
OV	cis	rs11951515	0.738	rs4866822	ENSG00000278487.1	RP11-447H19.4	-3.87	0.000143	0.0433	-0.29	-0.25	Metabolite levels  (X-11787);	chr5:43357992	chr5:43143362~43143514:-
OV	cis	rs11951515	0.663	rs11742171	ENSG00000278487.1	RP11-447H19.4	-3.87	0.000143	0.0433	-0.29	-0.25	Metabolite levels  (X-11787);	chr5:43358607	chr5:43143362~43143514:-
OV	cis	rs11951515	0.738	rs7708779	ENSG00000278487.1	RP11-447H19.4	-3.87	0.000143	0.0433	-0.29	-0.25	Metabolite levels  (X-11787);	chr5:43359181	chr5:43143362~43143514:-
OV	cis	rs11951515	0.738	rs4866824	ENSG00000278487.1	RP11-447H19.4	-3.87	0.000143	0.0433	-0.29	-0.25	Metabolite levels  (X-11787);	chr5:43359343	chr5:43143362~43143514:-
OV	cis	rs11951515	0.738	rs59814709	ENSG00000278487.1	RP11-447H19.4	-3.87	0.000143	0.0433	-0.29	-0.25	Metabolite levels  (X-11787);	chr5:43359992	chr5:43143362~43143514:-
OV	cis	rs428445	1	rs6069758	ENSG00000228995.1	MTND1P9	3.87	0.000143	0.0433	0.26	0.25	Refractive astigmatism;	chr20:56471679	chr20:57357426~57358369:-
OV	cis	rs12893668	0.703	rs34896432	ENSG00000201184.1	RNU4-68P	-3.87	0.000143	0.0433	-0.3	-0.25	Reticulocyte count;	chr14:103561658	chr14:103567405~103567545:+
OV	cis	rs6715284	0.892	rs56828879	ENSG00000183308.6	AC005037.3	3.87	0.000143	0.0433	0.58	0.25	Rheumatoid arthritis;	chr2:201376600	chr2:200963263~201009102:+
OV	cis	rs2021786	0.965	rs13039651	ENSG00000199719.1	RN7SKP74	3.87	0.000143	0.0433	0.27	0.25	Preschool internalizing problems;	chr20:17442395	chr20:18295143~18295451:-
OV	cis	rs10214930	0.671	rs10951172	ENSG00000235574.1	AC073150.6	-3.87	0.000143	0.0433	-0.3	-0.25	Hypospadias;	chr7:27574492	chr7:27491682~27492765:-
OV	cis	rs10461617	0.617	rs79742142	ENSG00000271828.1	CTD-2310F14.1	3.87	0.000143	0.0433	0.39	0.25	Type 2 diabetes;	chr5:56808550	chr5:56927874~56929573:+
OV	cis	rs6545883	0.929	rs10200055	ENSG00000270820.4	RP11-355B11.2	-3.87	0.000143	0.0433	-0.28	-0.25	Tuberculosis;	chr2:61400882	chr2:61471188~61484130:+
OV	cis	rs6545883	0.929	rs10193666	ENSG00000270820.4	RP11-355B11.2	-3.87	0.000143	0.0433	-0.28	-0.25	Tuberculosis;	chr2:61402273	chr2:61471188~61484130:+
OV	cis	rs11037575	0.739	rs12294299	ENSG00000246250.2	RP11-613D13.5	3.87	0.000143	0.0434	0.27	0.25	Neuroblastoma;	chr11:43686010	chr11:43829709~43880726:-
OV	cis	rs11037575	0.739	rs11037565	ENSG00000246250.2	RP11-613D13.5	3.87	0.000143	0.0434	0.27	0.25	Neuroblastoma;	chr11:43687202	chr11:43829709~43880726:-
OV	cis	rs5015933	0.902	rs10819047	ENSG00000232630.1	PRPS1P2	-3.87	0.000143	0.0434	-0.24	-0.25	Body mass index;	chr9:125365133	chr9:125150653~125151589:+
OV	cis	rs593531	0.592	rs598869	ENSG00000280269.1	AP000577.2	-3.87	0.000143	0.0434	-0.29	-0.25	Neuroticism;	chr11:74335930	chr11:74204869~74205746:+
OV	cis	rs1765142	0.55	rs589338	ENSG00000254532.1	RP11-624D11.2	-3.87	0.000143	0.0434	-0.3	-0.25	Schizophrenia;	chr11:30396604	chr11:30044058~30084343:-
OV	cis	rs67180937	0.621	rs2068814	ENSG00000272750.1	RP11-378J18.8	-3.87	0.000143	0.0434	-0.26	-0.25	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222749659	chr1:222658867~222661512:-
OV	cis	rs804280	1	rs804280	ENSG00000227888.4	FAM66A	3.87	0.000143	0.0434	0.31	0.25	Myopia (pathological);	chr8:11755189	chr8:12362019~12388296:+
OV	cis	rs7520050	0.933	rs6680211	ENSG00000280836.1	AL355480.1	3.87	0.000143	0.0434	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:45849335	chr1:45581219~45581321:-
OV	cis	rs12134151	0.84	rs1931253	ENSG00000237416.5	RP11-465K1.2	3.87	0.000143	0.0434	0.28	0.25	Educational attainment (years of education);	chr1:95716507	chr1:94836748~94855426:-
OV	cis	rs6593680	0.523	rs11583189	ENSG00000237416.5	RP11-465K1.2	3.87	0.000143	0.0435	0.28	0.25	Intelligence (multi-trait analysis);	chr1:95714636	chr1:94836748~94855426:-
OV	cis	rs1765142	0.55	rs588350	ENSG00000254532.1	RP11-624D11.2	-3.87	0.000143	0.0435	-0.3	-0.25	Schizophrenia;	chr11:30396361	chr11:30044058~30084343:-
OV	cis	rs7789940	1	rs76024966	ENSG00000250778.1	AC004980.8	3.87	0.000143	0.0435	0.33	0.25	Multiple sclerosis;	chr7:76365704	chr7:76521611~76522074:+
OV	cis	rs3823536	0.583	rs11760442	ENSG00000275106.1	RP11-309L24.10	-3.87	0.000143	0.0435	-0.35	-0.25	Sjögren's syndrome;	chr7:129016066	chr7:128952527~128953316:-
OV	cis	rs3823536	0.583	rs3847099	ENSG00000275106.1	RP11-309L24.10	-3.87	0.000143	0.0435	-0.35	-0.25	Sjögren's syndrome;	chr7:129016777	chr7:128952527~128953316:-
OV	cis	rs3823536	0.604	rs3857852	ENSG00000275106.1	RP11-309L24.10	-3.87	0.000143	0.0435	-0.35	-0.25	Sjögren's syndrome;	chr7:129017223	chr7:128952527~128953316:-
OV	cis	rs7617773	0.78	rs11720026	ENSG00000228638.1	FCF1P2	-3.87	0.000143	0.0435	-0.32	-0.25	Coronary artery disease;	chr3:48336431	chr3:48290793~48291375:-
OV	cis	rs7617773	0.743	rs11715876	ENSG00000228638.1	FCF1P2	-3.87	0.000143	0.0435	-0.32	-0.25	Coronary artery disease;	chr3:48336432	chr3:48290793~48291375:-
OV	cis	rs10266483	0.96	rs13221291	ENSG00000232727.2	YWHAEP1	3.87	0.000143	0.0435	0.28	0.25	Response to statin therapy;	chr7:64279114	chr7:64433830~64434592:+
OV	cis	rs1436109	0.809	rs17114705	ENSG00000255129.4	RP11-839D17.3	-3.87	0.000143	0.0435	-0.43	-0.25	Cardiac muscle measurement;	chr11:113029110	chr11:113278437~113314437:-
OV	cis	rs73019876	0.901	rs2666448	ENSG00000269742.1	BNIP3P29	-3.87	0.000143	0.0435	-0.28	-0.25	Testicular germ cell tumor;	chr19:21949706	chr19:22065828~22066398:-
OV	cis	rs3824867	0.804	rs12419342	ENSG00000280615.1	Y_RNA	-3.87	0.000143	0.0435	-0.29	-0.25	Mean corpuscular hemoglobin;	chr11:47446993	chr11:47614898~47614994:-
OV	cis	rs7267979	1	rs2474777	ENSG00000274973.1	RP13-401N8.7	-3.87	0.000143	0.0435	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25291997	chr20:25845497~25845862:+
OV	cis	rs3764021	0.933	rs2268146	ENSG00000278635.1	CTD-2318O12.1	-3.87	0.000143	0.0435	-0.21	-0.25	Type 1 diabetes;	chr12:9716675	chr12:9415641~9416718:+
OV	cis	rs599083	0.569	rs685095	ENSG00000212093.1	AP000807.1	-3.87	0.000143	0.0435	-0.31	-0.25	Bone mineral density (spine);	chr11:68402908	chr11:68506083~68506166:-
OV	cis	rs6546550	0.867	rs7592647	ENSG00000228034.1	HMGN2P21	3.87	0.000143	0.0435	0.3	0.25	Prevalent atrial fibrillation;	chr2:69912002	chr2:70803157~70803426:+
OV	cis	rs412658	0.504	rs10404322	ENSG00000269742.1	BNIP3P29	3.87	0.000144	0.0435	0.3	0.25	Telomere length;	chr19:21927867	chr19:22065828~22066398:-
OV	cis	rs10740039	0.81	rs10761528	ENSG00000254271.1	RP11-131N11.4	3.87	0.000144	0.0435	0.32	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60607902	chr10:60734342~60741828:+
OV	cis	rs2950393	0.804	rs2926752	ENSG00000241217.3	RN7SL809P	3.87	0.000144	0.0435	0.24	0.25	Platelet distribution width;	chr12:56710144	chr12:56670450~56670746:-
OV	cis	rs2950393	0.777	rs2958148	ENSG00000241217.3	RN7SL809P	3.87	0.000144	0.0435	0.24	0.25	Platelet distribution width;	chr12:56710153	chr12:56670450~56670746:-
OV	cis	rs875971	0.545	rs10950036	ENSG00000273024.4	INTS4P2	-3.87	0.000144	0.0436	-0.3	-0.25	Aortic root size;	chr7:66353241	chr7:65647864~65715661:+
OV	cis	rs875971	0.545	rs73148639	ENSG00000273024.4	INTS4P2	-3.87	0.000144	0.0436	-0.3	-0.25	Aortic root size;	chr7:66390342	chr7:65647864~65715661:+
OV	cis	rs796364	0.951	rs10931888	ENSG00000232732.8	AC073043.1	3.87	0.000144	0.0436	0.38	0.25	Schizophrenia;	chr2:200158229	chr2:199867396~199911159:-
OV	cis	rs2281636	0.754	rs4919364	ENSG00000235823.1	OLMALINC	-3.87	0.000144	0.0436	-0.31	-0.25	Obesity-related traits;	chr10:99604947	chr10:100373615~100383368:+
OV	cis	rs10924970	1	rs4660145	ENSG00000236863.2	RPL23AP23	3.87	0.000144	0.0436	0.25	0.25	Asthma;	chr1:235186892	chr1:235295865~235296335:+
OV	cis	rs10924970	1	rs10924501	ENSG00000236863.2	RPL23AP23	3.87	0.000144	0.0436	0.25	0.25	Asthma;	chr1:235188132	chr1:235295865~235296335:+
OV	cis	rs6940116	1	rs6940116	ENSG00000220721.1	OR1F12	3.87	0.000144	0.0436	0.34	0.25	Intelligence (multi-trait analysis);Autism spectrum disorder or schizophrenia;	chr6:27740953	chr6:28073316~28074233:+
OV	cis	rs6683071	0.54	rs1391558	ENSG00000272750.1	RP11-378J18.8	3.87	0.000144	0.0436	0.35	0.25	Cognitive performance;	chr1:222674687	chr1:222658867~222661512:-
OV	cis	rs7832232	1	rs7832232	ENSG00000255201.1	RP11-350N15.4	-3.87	0.000144	0.0436	-0.28	-0.25	Pancreatic cancer;	chr8:38611785	chr8:38421889~38426096:+
OV	cis	rs4665809	1	rs4665809	ENSG00000231655.1	AC011742.3	-3.87	0.000144	0.0436	-0.36	-0.25	Gut microbiome composition (summer);	chr2:26028492	chr2:26140263~26141264:-
OV	cis	rs2282300	0.739	rs7942129	ENSG00000242353.1	RP4-710M3.1	-3.87	0.000144	0.0436	-0.35	-0.25	Morning vs. evening chronotype;	chr11:30203145	chr11:30368148~30368646:+
OV	cis	rs2282300	0.739	rs34855782	ENSG00000242353.1	RP4-710M3.1	-3.87	0.000144	0.0436	-0.35	-0.25	Morning vs. evening chronotype;	chr11:30203923	chr11:30368148~30368646:+
OV	cis	rs11096990	0.964	rs11096987	ENSG00000249207.1	RP11-360F5.1	3.87	0.000144	0.0436	0.28	0.25	Cognitive function;	chr4:39257570	chr4:39112677~39126818:-
OV	cis	rs8054556	0.787	rs12325539	ENSG00000261367.1	RP11-455F5.4	-3.87	0.000144	0.0436	-0.3	-0.25	Autism spectrum disorder or schizophrenia;	chr16:30022312	chr16:30107675~30110541:+
OV	cis	rs8054556	0.751	rs11642430	ENSG00000261367.1	RP11-455F5.4	-3.87	0.000144	0.0436	-0.3	-0.25	Autism spectrum disorder or schizophrenia;	chr16:30034468	chr16:30107675~30110541:+
OV	cis	rs2492286	0.569	rs9289331	ENSG00000242551.2	POU5F1P6	-3.87	0.000144	0.0436	-0.32	-0.25	Eosinophil counts;	chr3:128635173	chr3:128674735~128677005:-
OV	cis	rs67517081	1	rs67517081	ENSG00000260911.2	RP11-196G11.2	-3.87	0.000144	0.0436	-0.22	-0.25	Mean corpuscular hemoglobin;	chr16:30976060	chr16:31043150~31049868:+
OV	cis	rs1950626	0.671	rs34675695	ENSG00000258399.5	MEG8	-3.87	0.000144	0.0437	-0.25	-0.25	Pelvic organ prolapse (moderate/severe);	chr14:100981576	chr14:100894770~100935999:+
OV	cis	rs7646881	0.544	rs6792976	ENSG00000272440.1	RP11-379F4.6	3.87	0.000144	0.0437	0.38	0.25	Tetralogy of Fallot;	chr3:158608781	chr3:158695367~158695581:+
OV	cis	rs2669010	0.796	rs2632212	ENSG00000243071.1	RP11-613M5.2	-3.87	0.000144	0.0437	-0.22	-0.25	Systemic lupus erythematosus;	chr12:76650111	chr12:76660405~76660884:+
OV	cis	rs13174863	1	rs13174863	ENSG00000250635.1	CTD-3224K15.2	3.87	0.000144	0.0437	0.37	0.25	Body mass index;	chr5:139701160	chr5:139648999~139649728:-
OV	cis	rs2185570	0.669	rs11572064	ENSG00000234724.1	HDAC1P1	3.87	0.000144	0.0437	0.44	0.25	Dehydroepiandrosterone sulphate levels;	chr10:95070609	chr10:94137748~94139500:+
OV	cis	rs2185570	0.605	rs72820608	ENSG00000234724.1	HDAC1P1	3.87	0.000144	0.0437	0.44	0.25	Dehydroepiandrosterone sulphate levels;	chr10:95075177	chr10:94137748~94139500:+
OV	cis	rs12477438	0.501	rs12613624	ENSG00000231822.1	AC019097.7	-3.87	0.000144	0.0437	-0.25	-0.25	Chronic sinus infection;	chr2:99116278	chr2:99102018~99102752:+
OV	cis	rs367615	0.537	rs17161729	ENSG00000249476.1	CTD-2587M2.1	-3.87	0.000144	0.0437	-0.27	-0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109324827	chr5:109237120~109326369:-
OV	cis	rs4664293	0.625	rs2114625	ENSG00000226266.5	AC009961.3	-3.87	0.000144	0.0437	-0.29	-0.25	Monocyte percentage of white cells;	chr2:159687297	chr2:159670708~159712435:-
OV	cis	rs2282300	0.653	rs12800124	ENSG00000242353.1	RP4-710M3.1	-3.87	0.000144	0.0437	-0.35	-0.25	Morning vs. evening chronotype;	chr11:30218318	chr11:30368148~30368646:+
OV	cis	rs2282300	0.739	rs35883696	ENSG00000242353.1	RP4-710M3.1	-3.87	0.000144	0.0437	-0.35	-0.25	Morning vs. evening chronotype;	chr11:30224860	chr11:30368148~30368646:+
OV	cis	rs2282300	0.696	rs12578061	ENSG00000242353.1	RP4-710M3.1	-3.87	0.000144	0.0437	-0.35	-0.25	Morning vs. evening chronotype;	chr11:30227818	chr11:30368148~30368646:+
OV	cis	rs2282300	0.739	rs34224414	ENSG00000242353.1	RP4-710M3.1	-3.87	0.000144	0.0437	-0.35	-0.25	Morning vs. evening chronotype;	chr11:30229494	chr11:30368148~30368646:+
OV	cis	rs2282300	0.739	rs12577729	ENSG00000242353.1	RP4-710M3.1	-3.87	0.000144	0.0437	-0.35	-0.25	Morning vs. evening chronotype;	chr11:30235830	chr11:30368148~30368646:+
OV	cis	rs2282300	0.739	rs34044331	ENSG00000242353.1	RP4-710M3.1	-3.87	0.000144	0.0437	-0.35	-0.25	Morning vs. evening chronotype;	chr11:30242939	chr11:30368148~30368646:+
OV	cis	rs2282300	0.739	rs7925340	ENSG00000242353.1	RP4-710M3.1	3.87	0.000144	0.0437	0.35	0.25	Morning vs. evening chronotype;	chr11:30258861	chr11:30368148~30368646:+
OV	cis	rs2282300	0.702	rs4379811	ENSG00000242353.1	RP4-710M3.1	3.87	0.000144	0.0437	0.35	0.25	Morning vs. evening chronotype;	chr11:30273213	chr11:30368148~30368646:+
OV	cis	rs2282300	0.739	rs3858428	ENSG00000242353.1	RP4-710M3.1	3.87	0.000144	0.0437	0.35	0.25	Morning vs. evening chronotype;	chr11:30275003	chr11:30368148~30368646:+
OV	cis	rs7569084	0.663	rs4671128	ENSG00000204929.10	AC074391.1	3.87	0.000144	0.0437	0.32	0.25	Sum eosinophil basophil counts;	chr2:65438130	chr2:65436711~66084639:+
OV	cis	rs6121246	0.567	rs7266471	ENSG00000230613.1	HM13-AS1	3.87	0.000144	0.0437	0.38	0.25	Mean corpuscular hemoglobin;	chr20:31632796	chr20:31567707~31573263:-
OV	cis	rs6121246	0.567	rs6060399	ENSG00000230613.1	HM13-AS1	3.87	0.000144	0.0437	0.38	0.25	Mean corpuscular hemoglobin;	chr20:31633020	chr20:31567707~31573263:-
OV	cis	rs7726839	0.54	rs3762951	ENSG00000271781.1	CTD-2589H19.6	-3.87	0.000144	0.0437	-0.39	-0.25	Obesity-related traits;	chr5:662498	chr5:675826~676616:+
OV	cis	rs4964805	1	rs11111791	ENSG00000257681.1	RP11-341G23.4	3.87	0.000144	0.0437	0.32	0.25	Attention deficit hyperactivity disorder;	chr12:103799493	chr12:103746315~103768858:-
OV	cis	rs7610761	0.967	rs1426271	ENSG00000236182.1	RP11-297K7.1	3.87	0.000144	0.0438	0.28	0.25	Schizophrenia;	chr3:188469462	chr3:188989382~188990135:-
OV	cis	rs6715284	1	rs72937120	ENSG00000183308.6	AC005037.3	3.87	0.000145	0.0438	0.58	0.25	Rheumatoid arthritis;	chr2:201367888	chr2:200963263~201009102:+
OV	cis	rs1623523	1	rs1623523	ENSG00000262001.1	DLGAP1-AS2	-3.87	0.000145	0.0438	-0.35	-0.25	Antineutrophil cytoplasmic antibody-associated vasculitis;	chr18:3328748	chr18:3603000~3608336:+
OV	cis	rs7567389	0.6	rs11679414	ENSG00000236682.1	AC068282.3	-3.87	0.000145	0.0438	-0.35	-0.25	Self-rated health;	chr2:127393427	chr2:127389130~127400580:+
OV	cis	rs7968440	1	rs7307815	ENSG00000272368.2	RP4-605O3.4	3.87	0.000145	0.0438	0.29	0.25	Fibrinogen;	chr12:50528927	chr12:50112197~50165618:+
OV	cis	rs57221529	0.766	rs4081847	ENSG00000271781.1	CTD-2589H19.6	-3.87	0.000145	0.0438	-0.4	-0.25	Lung disease severity in cystic fibrosis;	chr5:573957	chr5:675826~676616:+
OV	cis	rs4356975	0.563	rs7657423	ENSG00000251284.2	RP13-644M16.1	3.87	0.000145	0.0438	0.26	0.25	Obesity-related traits;	chr4:69090196	chr4:69125274~69126451:+
OV	cis	rs12713280	1	rs12713281	ENSG00000272156.1	RP11-477N3.1	3.87	0.000145	0.0439	0.34	0.25	Economic and political preferences;	chr2:54854625	chr2:54082554~54085066:+
OV	cis	rs7904519	0.55	rs4073288	ENSG00000260917.1	RP11-57H14.4	-3.87	0.000145	0.0439	-0.24	-0.25	Breast cancer (estrogen-receptor negative);Breast cancer;	chr10:112987518	chr10:112823490~112827726:+
OV	cis	rs78663649	0.908	rs12461349	ENSG00000269480.1	CTD-3032J10.3	-3.87	0.000145	0.0439	-0.45	-0.25	White blood cell count;	chr19:16385697	chr19:17207138~17208010:-
OV	cis	rs4356975	0.563	rs4455491	ENSG00000251284.2	RP13-644M16.1	-3.87	0.000145	0.0439	-0.26	-0.25	Obesity-related traits;	chr4:69095215	chr4:69125274~69126451:+
OV	cis	rs4356975	0.522	rs11940220	ENSG00000251284.2	RP13-644M16.1	-3.87	0.000145	0.0439	-0.26	-0.25	Obesity-related traits;	chr4:69095222	chr4:69125274~69126451:+
OV	cis	rs7246657	0.943	rs2303131	ENSG00000226686.6	LINC01535	-3.87	0.000145	0.0439	-0.39	-0.25	Coronary artery calcification;	chr19:37445123	chr19:37251912~37265535:+
OV	cis	rs7246657	0.943	rs1015848	ENSG00000226686.6	LINC01535	-3.87	0.000145	0.0439	-0.39	-0.25	Coronary artery calcification;	chr19:37454372	chr19:37251912~37265535:+
OV	cis	rs7246657	0.943	rs4801759	ENSG00000226686.6	LINC01535	-3.87	0.000145	0.0439	-0.39	-0.25	Coronary artery calcification;	chr19:37464083	chr19:37251912~37265535:+
OV	cis	rs10716881	1	rs10716881	ENSG00000241217.3	RN7SL809P	-3.87	0.000145	0.0439	-0.24	-0.25	High light scatter reticulocyte count;	chr12:56644387	chr12:56670450~56670746:-
OV	cis	rs6593680	0.558	rs1931263	ENSG00000237416.5	RP11-465K1.2	3.87	0.000145	0.0439	0.28	0.25	Intelligence (multi-trait analysis);	chr1:95709545	chr1:94836748~94855426:-
OV	cis	rs11992162	0.591	rs4240678	ENSG00000227888.4	FAM66A	-3.86	0.000145	0.0439	-0.34	-0.25	Monocyte count;	chr8:11944917	chr8:12362019~12388296:+
OV	cis	rs73562014	0.938	rs12221694	ENSG00000254416.4	RP11-347E10.1	-3.86	0.000145	0.0439	-0.4	-0.25	Coronary artery disease;	chr11:110460523	chr11:110355130~110406400:+
OV	cis	rs6715284	1	rs72934999	ENSG00000183308.6	AC005037.3	3.86	0.000145	0.0439	0.58	0.25	Rheumatoid arthritis;	chr2:201358801	chr2:200963263~201009102:+
OV	cis	rs6715284	1	rs72937106	ENSG00000183308.6	AC005037.3	3.86	0.000145	0.0439	0.58	0.25	Rheumatoid arthritis;	chr2:201360797	chr2:200963263~201009102:+
OV	cis	rs6715284	1	rs72937118	ENSG00000183308.6	AC005037.3	3.86	0.000145	0.0439	0.58	0.25	Rheumatoid arthritis;	chr2:201364804	chr2:200963263~201009102:+
OV	cis	rs4664293	0.585	rs13019325	ENSG00000224152.1	AC009506.1	3.86	0.000145	0.0439	0.26	0.25	Monocyte percentage of white cells;	chr2:159772479	chr2:159615296~159617082:+
OV	cis	rs7267979	0.789	rs9927	ENSG00000274973.1	RP13-401N8.7	-3.86	0.000145	0.044	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25296608	chr20:25845497~25845862:+
OV	cis	rs1862618	0.853	rs2113079	ENSG00000271828.1	CTD-2310F14.1	3.86	0.000145	0.044	0.4	0.25	Initial pursuit acceleration;	chr5:56862124	chr5:56927874~56929573:+
OV	cis	rs10504130	0.569	rs34364864	ENSG00000272024.1	RP11-546K22.3	-3.86	0.000145	0.044	-0.32	-0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:51817086	chr8:51950284~51950690:+
OV	cis	rs6142102	0.812	rs6059578	ENSG00000264616.1	MIR4755	3.86	0.000145	0.044	0.31	0.25	Skin pigmentation;	chr20:33939900	chr20:34049119~34049190:+
OV	cis	rs2239547	0.603	rs12489490	ENSG00000242142.1	SERBP1P3	3.86	0.000145	0.044	0.32	0.25	Schizophrenia;	chr3:53030006	chr3:53064283~53065091:-
OV	cis	rs4493873	0.812	rs10956793	ENSG00000253738.1	OTUD6B-AS1	3.86	0.000145	0.044	0.3	0.25	Migraine - clinic-based;	chr8:91097696	chr8:91059909~91070189:-
OV	cis	rs62184315	0.832	rs12466395	ENSG00000253559.1	OSGEPL1-AS1	-3.86	0.000146	0.044	-0.28	-0.25	Alcohol dependence (age at onset);	chr2:189915972	chr2:189762704~189765556:+
OV	cis	rs2240395	0.754	rs10242990	ENSG00000252332.1	RNU6-911P	3.86	0.000146	0.044	0.31	0.25	Drug-induced liver injury (nonsteroidal anti-inflammatory drugs);	chr7:140030700	chr7:139448740~139448843:+
OV	cis	rs372883	0.648	rs2832297	ENSG00000226935.5	LINC00161	-3.86	0.000146	0.044	-0.27	-0.25	Pancreatic cancer;	chr21:29370675	chr21:28539318~28540355:+
OV	cis	rs964184	0.63	rs2075290	ENSG00000254851.1	RP11-109L13.1	-3.86	0.000146	0.044	-0.55	-0.25	Very long-chain saturated fatty acid levels (fatty acid 20:0);Response to Vitamin E supplementation;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);Metabolite levels (lipoprotein measures);LDL cholesterol levels;Vitamin E levels;Platelet distribution width;Mean corpuscular hemoglobin concentration;Metabolic syndrome;HDL cholesterol;Coronary artery disease;Hypertriglyceridemia;LDL cholesterol;High light scatter reticulocyte percentage of red cells;High light scatter reticulocyte count;Metabolite levels;Age-related disease endophenotypes;Age-related diseases, mortality and associated endophenotypes;Reticulocyte fraction of red cells;Blood metabolite levels;Red cell distribution width;Lipoprotein-associated phospholipase A2 activity and mass;Reticulocyte count;Triglyceride levels;Circulating phylloquinone levels;Coronary heart disease;Triglycerides;Postprandial triglyceride response to high fat diet meal;Coronary artery disease or large artery stroke;Phospholipid levels (plasma);Total cholesterol levels;Very low density lipoprotein cholesterol levels;Mean platelet volume;Cholesterol, total;	chr11:116782580	chr11:117135528~117138582:+
OV	cis	rs9326248	0.954	rs521171	ENSG00000280143.1	AP000892.6	3.86	0.000146	0.044	0.27	0.25	Blood protein levels;	chr11:117193977	chr11:117204967~117210292:+
OV	cis	rs801193	0.967	rs2707841	ENSG00000224316.1	RP11-479O9.2	3.86	0.000146	0.044	0.27	0.25	Aortic root size;	chr7:66692033	chr7:65773620~65802067:+
OV	cis	rs801193	1	rs2659912	ENSG00000224316.1	RP11-479O9.2	3.86	0.000146	0.044	0.27	0.25	Aortic root size;	chr7:66693012	chr7:65773620~65802067:+
OV	cis	rs801193	1	rs2707836	ENSG00000224316.1	RP11-479O9.2	3.86	0.000146	0.044	0.27	0.25	Aortic root size;	chr7:66695448	chr7:65773620~65802067:+
OV	cis	rs801193	1	rs4717310	ENSG00000224316.1	RP11-479O9.2	3.86	0.000146	0.044	0.27	0.25	Aortic root size;	chr7:66696020	chr7:65773620~65802067:+
OV	cis	rs801193	0.844	rs7779971	ENSG00000224316.1	RP11-479O9.2	3.86	0.000146	0.044	0.27	0.25	Aortic root size;	chr7:66696803	chr7:65773620~65802067:+
OV	cis	rs4664293	0.625	rs6713600	ENSG00000226266.5	AC009961.3	3.86	0.000146	0.044	0.29	0.25	Monocyte percentage of white cells;	chr2:159706559	chr2:159670708~159712435:-
OV	cis	rs4664293	0.625	rs7607394	ENSG00000226266.5	AC009961.3	3.86	0.000146	0.044	0.29	0.25	Monocyte percentage of white cells;	chr2:159707286	chr2:159670708~159712435:-
OV	cis	rs4665809	0.878	rs6748745	ENSG00000231655.1	AC011742.3	3.86	0.000146	0.0441	0.37	0.25	Gut microbiome composition (summer);	chr2:26141321	chr2:26140263~26141264:-
OV	cis	rs7520050	0.933	rs6694340	ENSG00000280836.1	AL355480.1	3.86	0.000146	0.0441	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:45823744	chr1:45581219~45581321:-
OV	cis	rs7520050	0.933	rs12565042	ENSG00000280836.1	AL355480.1	3.86	0.000146	0.0441	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:45833438	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs10789475	ENSG00000280836.1	AL355480.1	3.86	0.000146	0.0441	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:45838505	chr1:45581219~45581321:-
OV	cis	rs7520050	0.933	rs6666743	ENSG00000280836.1	AL355480.1	3.86	0.000146	0.0441	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:45845603	chr1:45581219~45581321:-
OV	cis	rs7520050	0.933	rs9787208	ENSG00000280836.1	AL355480.1	3.86	0.000146	0.0441	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:45848944	chr1:45581219~45581321:-
OV	cis	rs514406	0.621	rs881198	ENSG00000206627.1	RNU6-969P	-3.86	0.000146	0.0441	-0.27	-0.25	Monocyte count;	chr1:52730768	chr1:52805108~52805212:-
OV	cis	rs7927771	0.929	rs12787646	ENSG00000271350.1	CTD-2384B9.1	-3.86	0.000146	0.0441	-0.3	-0.25	Subjective well-being;	chr11:47648113	chr11:47041027~47041945:-
OV	cis	rs4664293	0.585	rs10460301	ENSG00000224152.1	AC009506.1	3.86	0.000146	0.0441	0.26	0.25	Monocyte percentage of white cells;	chr2:159778566	chr2:159615296~159617082:+
OV	cis	rs6545883	0.718	rs2694624	ENSG00000273302.1	RP11-493E12.2	3.86	0.000146	0.0441	0.2	0.25	Tuberculosis;	chr2:61445178	chr2:61199979~61200769:+
OV	cis	rs7927771	0.524	rs2290851	ENSG00000280615.1	Y_RNA	-3.86	0.000146	0.0441	-0.26	-0.25	Subjective well-being;	chr11:47731818	chr11:47614898~47614994:-
OV	cis	rs6661961	0.752	rs11205003	ENSG00000237975.5	FLG-AS1	-3.86	0.000146	0.0442	-0.32	-0.25	Atopic dermatitis;	chr1:152444154	chr1:152168125~152445456:+
OV	cis	rs7569084	1	rs13385171	ENSG00000204929.10	AC074391.1	-3.86	0.000146	0.0442	-0.31	-0.25	Sum eosinophil basophil counts;	chr2:65434709	chr2:65436711~66084639:+
OV	cis	rs875971	0.545	rs313828	ENSG00000234500.1	GS1-124K5.10	3.86	0.000146	0.0442	0.21	0.25	Aortic root size;	chr7:66087627	chr7:66511556~66545066:+
OV	cis	rs875971	0.52	rs160645	ENSG00000234500.1	GS1-124K5.10	3.86	0.000146	0.0442	0.21	0.25	Aortic root size;	chr7:66091320	chr7:66511556~66545066:+
OV	cis	rs875971	0.789	rs28815324	ENSG00000234500.1	GS1-124K5.10	3.86	0.000146	0.0442	0.21	0.25	Aortic root size;	chr7:66100789	chr7:66511556~66545066:+
OV	cis	rs6142102	0.602	rs6142069	ENSG00000276073.1	RP5-1125A11.7	-3.86	0.000146	0.0442	-0.29	-0.25	Skin pigmentation;	chr20:33972736	chr20:33985617~33988989:-
OV	cis	rs67180937	0.621	rs34885880	ENSG00000272750.1	RP11-378J18.8	-3.86	0.000146	0.0442	-0.26	-0.25	Coronary artery disease;Coronary artery disease (myocardial infartum, percutaneous transluminal coronary angioplasty, coronary artery bypass grafting, angina or chromic ischemic heart disease);	chr1:222752593	chr1:222658867~222661512:-
OV	cis	rs12681366	0.839	rs3019280	ENSG00000253704.1	RP11-267M23.4	3.86	0.000146	0.0442	0.34	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94437804	chr8:94553722~94569745:+
OV	cis	rs12681366	0.839	rs3019281	ENSG00000253704.1	RP11-267M23.4	3.86	0.000146	0.0442	0.34	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94438061	chr8:94553722~94569745:+
OV	cis	rs11951515	0.663	rs4395639	ENSG00000278487.1	RP11-447H19.4	-3.86	0.000146	0.0442	-0.29	-0.25	Metabolite levels  (X-11787);	chr5:43286361	chr5:43143362~43143514:-
OV	cis	rs3764021	1	rs3764021	ENSG00000256673.1	RP11-599J14.2	-3.86	0.000147	0.0443	-0.23	-0.25	Type 1 diabetes;	chr12:9681032	chr12:9398355~9414851:-
OV	cis	rs12037343	0.867	rs619430	ENSG00000228536.1	RP11-392O17.1	-3.86	0.000147	0.0443	-0.54	-0.25	Smooth-surface caries;	chr1:218862691	chr1:219409681~219411941:-
OV	cis	rs73186030	0.687	rs16833080	ENSG00000272758.4	RP11-299J3.8	-3.86	0.000147	0.0443	-0.29	-0.25	Serum parathyroid hormone levels;	chr3:122382060	chr3:122416207~122443180:+
OV	cis	rs9918079	0.56	rs10008376	ENSG00000249930.1	AC007016.3	3.86	0.000147	0.0443	0.28	0.25	Obesity-related traits;	chr4:15622332	chr4:15492729~15492972:-
OV	cis	rs875971	0.545	rs12671152	ENSG00000237310.1	GS1-124K5.4	3.86	0.000147	0.0443	0.3	0.25	Aortic root size;	chr7:66311140	chr7:66493706~66495474:+
OV	cis	rs12134151	0.87	rs953401	ENSG00000237416.5	RP11-465K1.2	3.86	0.000147	0.0443	0.28	0.25	Educational attainment (years of education);	chr1:95721115	chr1:94836748~94855426:-
OV	cis	rs747650	0.699	rs4237547	ENSG00000271543.1	RP11-692M12.5	-3.86	0.000147	0.0443	-0.32	-0.25	Acne (severe);	chr11:47214854	chr11:47796169~47796379:+
OV	cis	rs4664293	0.625	rs11899419	ENSG00000226266.5	AC009961.3	3.86	0.000147	0.0443	0.29	0.25	Monocyte percentage of white cells;	chr2:159688858	chr2:159670708~159712435:-
OV	cis	rs8059260	0.604	rs16957966	ENSG00000274038.1	RP11-66H6.4	-3.86	0.000147	0.0443	-0.46	-0.25	Alcohol consumption over the past year;	chr16:11046280	chr16:11056556~11057034:+
OV	cis	rs853679	0.607	rs67998226	ENSG00000220721.1	OR1F12	3.86	0.000147	0.0443	0.5	0.25	Depression;	chr6:28270281	chr6:28073316~28074233:+
OV	cis	rs10986311	0.713	rs944337	ENSG00000227200.1	RP11-121A14.3	-3.86	0.000147	0.0444	-0.22	-0.25	Vitiligo;	chr9:124259987	chr9:124262876~124265809:+
OV	cis	rs10986311	0.747	rs944338	ENSG00000227200.1	RP11-121A14.3	-3.86	0.000147	0.0444	-0.22	-0.25	Vitiligo;	chr9:124259988	chr9:124262876~124265809:+
OV	cis	rs2243480	0.708	rs781141	ENSG00000226824.5	RP4-756H11.3	-3.86	0.000147	0.0444	-0.39	-0.25	Diabetic kidney disease;	chr7:65973566	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs781142	ENSG00000226824.5	RP4-756H11.3	-3.86	0.000147	0.0444	-0.39	-0.25	Diabetic kidney disease;	chr7:65973791	chr7:66654538~66669855:+
OV	cis	rs2021786	0.93	rs2023423	ENSG00000199719.1	RN7SKP74	3.86	0.000147	0.0444	0.28	0.25	Preschool internalizing problems;	chr20:17459833	chr20:18295143~18295451:-
OV	cis	rs796364	0.806	rs11679676	ENSG00000232732.8	AC073043.1	3.86	0.000147	0.0444	0.43	0.25	Schizophrenia;	chr2:200176258	chr2:199867396~199911159:-
OV	cis	rs4927850	0.881	rs7630489	ENSG00000242086.7	LINC00969	3.86	0.000147	0.0444	0.25	0.25	Pancreatic cancer;	chr3:196026530	chr3:195658062~195739964:+
OV	cis	rs4927850	1	rs7627868	ENSG00000242086.7	LINC00969	3.86	0.000147	0.0444	0.25	0.25	Pancreatic cancer;	chr3:196026602	chr3:195658062~195739964:+
OV	cis	rs3731896	0.653	rs10932799	ENSG00000272644.1	RP11-33O4.1	-3.86	0.000147	0.0444	-0.38	-0.25	Educational attainment;	chr2:219335983	chr2:219069354~219069809:-
OV	cis	rs9473147	0.543	rs9369716	ENSG00000270761.1	RP11-385F7.1	-3.86	0.000147	0.0444	-0.29	-0.25	Platelet distribution width;Mean platelet volume;	chr6:47584444	chr6:47477243~47477572:-
OV	cis	rs7267979	0.844	rs8184820	ENSG00000274973.1	RP13-401N8.7	3.86	0.000147	0.0444	0.28	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25269941	chr20:25845497~25845862:+
OV	cis	rs12468226	1	rs116635509	ENSG00000272966.1	RP11-686O6.1	3.86	0.000147	0.0444	0.42	0.25	Urate levels;	chr2:202460027	chr2:202336739~202337200:+
OV	cis	rs11951515	0.663	rs67415672	ENSG00000278487.1	RP11-447H19.4	-3.86	0.000147	0.0444	-0.29	-0.25	Metabolite levels  (X-11787);	chr5:43287059	chr5:43143362~43143514:-
OV	cis	rs875971	0.545	rs2707851	ENSG00000273024.4	INTS4P2	3.86	0.000147	0.0444	0.3	0.25	Aortic root size;	chr7:66624178	chr7:65647864~65715661:+
OV	cis	rs11118620	0.853	rs11118622	ENSG00000257551.1	HLX-AS1	3.86	0.000147	0.0444	0.31	0.25	Heart failure;	chr1:220868833	chr1:220832763~220880140:-
OV	cis	rs801193	1	rs2659906	ENSG00000224316.1	RP11-479O9.2	3.86	0.000148	0.0445	0.27	0.25	Aortic root size;	chr7:66700323	chr7:65773620~65802067:+
OV	cis	rs801193	0.935	rs2659899	ENSG00000224316.1	RP11-479O9.2	3.86	0.000148	0.0445	0.27	0.25	Aortic root size;	chr7:66721734	chr7:65773620~65802067:+
OV	cis	rs6460942	0.514	rs118124486	ENSG00000226690.5	AC005281.1	3.86	0.000148	0.0445	0.33	0.25	Coronary artery disease;	chr7:12430755	chr7:12496429~12541910:+
OV	cis	rs853679	0.607	rs34878803	ENSG00000220721.1	OR1F12	3.86	0.000148	0.0445	0.5	0.25	Depression;	chr6:28282402	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs34396849	ENSG00000220721.1	OR1F12	3.86	0.000148	0.0445	0.5	0.25	Depression;	chr6:28283178	chr6:28073316~28074233:+
OV	cis	rs11673344	0.526	rs73035160	ENSG00000267422.1	CTD-2554C21.1	3.86	0.000148	0.0445	0.26	0.25	Obesity-related traits;	chr19:37655135	chr19:37779686~37792865:+
OV	cis	rs73186030	0.546	rs73188327	ENSG00000272758.4	RP11-299J3.8	3.86	0.000148	0.0445	0.29	0.25	Serum parathyroid hormone levels;	chr3:122394819	chr3:122416207~122443180:+
OV	cis	rs11096990	0.964	rs6842390	ENSG00000249207.1	RP11-360F5.1	3.86	0.000148	0.0445	0.27	0.25	Cognitive function;	chr4:39261862	chr4:39112677~39126818:-
OV	cis	rs11037575	0.739	rs12283558	ENSG00000246250.2	RP11-613D13.5	3.86	0.000148	0.0445	0.27	0.25	Neuroblastoma;	chr11:43691144	chr11:43829709~43880726:-
OV	cis	rs12701220	0.553	rs7782024	ENSG00000229043.2	AC091729.9	-3.86	0.000148	0.0445	-0.32	-0.25	Bronchopulmonary dysplasia;	chr7:1117866	chr7:1160374~1165267:+
OV	cis	rs4356975	0.563	rs3924192	ENSG00000251284.2	RP13-644M16.1	3.86	0.000148	0.0445	0.25	0.25	Obesity-related traits;	chr4:69105246	chr4:69125274~69126451:+
OV	cis	rs1862618	0.853	rs252887	ENSG00000271828.1	CTD-2310F14.1	3.86	0.000148	0.0445	0.41	0.25	Initial pursuit acceleration;	chr5:56870361	chr5:56927874~56929573:+
OV	cis	rs17711722	0.523	rs365896	ENSG00000222364.1	RNU6-96P	3.86	0.000148	0.0445	0.27	0.25	Calcium levels;	chr7:66045710	chr7:66395191~66395286:+
OV	cis	rs7569084	0.687	rs4671663	ENSG00000204929.10	AC074391.1	3.86	0.000148	0.0446	0.32	0.25	Sum eosinophil basophil counts;	chr2:65434400	chr2:65436711~66084639:+
OV	cis	rs7569084	0.687	rs11692813	ENSG00000204929.10	AC074391.1	3.86	0.000148	0.0446	0.32	0.25	Sum eosinophil basophil counts;	chr2:65435172	chr2:65436711~66084639:+
OV	cis	rs957448	1	rs957448	ENSG00000253175.1	RP11-267M23.6	3.86	0.000148	0.0446	0.29	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94529074	chr8:94565036~94565715:+
OV	cis	rs7587928	0.548	rs62104392	ENSG00000225642.1	SNRPEP5	3.86	0.000148	0.0446	0.29	0.25	Neutrophil count;	chr2:8816302	chr2:8603082~8603359:+
OV	cis	rs3731896	0.653	rs1514748	ENSG00000272644.1	RP11-33O4.1	3.86	0.000148	0.0446	0.37	0.25	Educational attainment;	chr2:219328293	chr2:219069354~219069809:-
OV	cis	rs2839627	0.598	rs9975526	ENSG00000225218.1	AP001628.6	3.86	0.000148	0.0446	0.25	0.25	Information processing speed;	chr21:42846463	chr21:42831040~42836477:-
OV	cis	rs11098499	0.863	rs7699064	ENSG00000249244.1	RP11-548H18.2	-3.86	0.000148	0.0446	-0.32	-0.25	Corneal astigmatism;	chr4:119507154	chr4:119391831~119395335:-
OV	cis	rs812925	0.511	rs11886950	ENSG00000271889.1	RP11-493E12.1	3.86	0.000148	0.0447	0.28	0.25	Immature fraction of reticulocytes;	chr2:61172182	chr2:61151433~61162105:-
OV	cis	rs875971	0.767	rs12668005	ENSG00000224316.1	RP11-479O9.2	3.86	0.000148	0.0447	0.26	0.25	Aortic root size;	chr7:66444034	chr7:65773620~65802067:+
OV	cis	rs7923609	0.841	rs10761786	ENSG00000232075.1	MRPL35P2	-3.86	0.000148	0.0447	-0.26	-0.25	Liver enzyme levels (alkaline phosphatase);Educational attainment;	chr10:63576447	chr10:63634317~63634827:-
OV	cis	rs13113518	0.812	rs12649507	ENSG00000223305.1	RN7SKP30	-3.86	0.000148	0.0447	-0.3	-0.25	Height;	chr4:55514317	chr4:55540502~55540835:-
OV	cis	rs10214930	0.697	rs1554641	ENSG00000235574.1	AC073150.6	-3.86	0.000149	0.0447	-0.3	-0.25	Hypospadias;	chr7:27555068	chr7:27491682~27492765:-
OV	cis	rs1862618	0.853	rs10461617	ENSG00000271828.1	CTD-2310F14.1	3.86	0.000149	0.0447	0.38	0.25	Initial pursuit acceleration;	chr5:56808481	chr5:56927874~56929573:+
OV	cis	rs372883	0.648	rs1153288	ENSG00000226935.5	LINC00161	-3.86	0.000149	0.0448	-0.26	-0.25	Pancreatic cancer;	chr21:29313770	chr21:28539318~28540355:+
OV	cis	rs7646881	0.544	rs7638606	ENSG00000272440.1	RP11-379F4.6	3.86	0.000149	0.0448	0.37	0.25	Tetralogy of Fallot;	chr3:158569050	chr3:158695367~158695581:+
OV	cis	rs7646881	0.544	rs9881679	ENSG00000272440.1	RP11-379F4.6	3.86	0.000149	0.0448	0.37	0.25	Tetralogy of Fallot;	chr3:158580643	chr3:158695367~158695581:+
OV	cis	rs7646881	0.544	rs9849437	ENSG00000272440.1	RP11-379F4.6	3.86	0.000149	0.0448	0.37	0.25	Tetralogy of Fallot;	chr3:158581612	chr3:158695367~158695581:+
OV	cis	rs7615952	0.576	rs2276726	ENSG00000250012.1	RP11-124N2.1	-3.86	0.000149	0.0448	-0.3	-0.25	Blood pressure (smoking interaction);	chr3:126107444	chr3:126084220~126095349:+
OV	cis	rs6775745	0.793	rs9826324	ENSG00000248724.5	NPHP3-AS1	-3.86	0.000149	0.0448	-0.36	-0.25	Neutrophil count;	chr3:132108747	chr3:132721750~132874223:+
OV	cis	rs6545883	0.894	rs778148	ENSG00000270820.4	RP11-355B11.2	-3.86	0.000149	0.0448	-0.28	-0.25	Tuberculosis;	chr2:61379731	chr2:61471188~61484130:+
OV	cis	rs6545883	0.929	rs2600663	ENSG00000270820.4	RP11-355B11.2	-3.86	0.000149	0.0448	-0.29	-0.25	Tuberculosis;	chr2:61313552	chr2:61471188~61484130:+
OV	cis	rs4713118	0.513	rs149944	ENSG00000280107.1	AL022393.9	-3.86	0.000149	0.0448	-0.3	-0.25	Parkinson's disease;	chr6:28035040	chr6:28170845~28172521:+
OV	cis	rs736408	0.562	rs1014969	ENSG00000243224.1	RP5-1157M23.2	-3.86	0.000149	0.0448	-0.25	-0.25	Bipolar disorder;	chr3:52774325	chr3:52239258~52241097:+
OV	cis	rs5742933	0.857	rs893784	ENSG00000273240.1	RP11-455J20.3	-3.86	0.000149	0.0448	-0.27	-0.25	Ferritin levels;	chr2:189671557	chr2:189763859~189764456:-
OV	cis	rs514406	0.584	rs7548832	ENSG00000206627.1	RNU6-969P	3.86	0.000149	0.0448	0.26	0.25	Monocyte count;	chr1:52727904	chr1:52805108~52805212:-
OV	cis	rs12893668	0.673	rs2296482	ENSG00000201184.1	RNU4-68P	-3.86	0.000149	0.0448	-0.29	-0.25	Reticulocyte count;	chr14:103563482	chr14:103567405~103567545:+
OV	cis	rs736408	0.562	rs1014969	ENSG00000275956.1	RP5-966M1.7	-3.86	0.000149	0.0448	-0.24	-0.25	Bipolar disorder;	chr3:52774325	chr3:52732547~52733867:+
OV	cis	rs1979679	0.918	rs3858544	ENSG00000278733.1	RP11-425D17.1	-3.86	0.000149	0.0448	-0.3	-0.25	Ossification of the posterior longitudinal ligament of the spine;	chr12:28442911	chr12:28185625~28186190:-
OV	cis	rs9649213	0.537	rs6465663	ENSG00000272950.1	RP11-307C18.1	3.86	0.000149	0.0448	0.29	0.25	Prostate cancer (SNP x SNP interaction);	chr7:98289571	chr7:98322853~98323430:+
OV	cis	rs7927771	1	rs34128973	ENSG00000271350.1	CTD-2384B9.1	-3.86	0.000149	0.0449	-0.3	-0.25	Subjective well-being;	chr11:47829824	chr11:47041027~47041945:-
OV	cis	rs12073359	0.955	rs72694962	ENSG00000223945.2	RP11-458I7.1	-3.86	0.000149	0.0449	-0.38	-0.25	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150175740	chr1:150053864~150055034:+
OV	cis	rs7121800	0.962	rs1336515	ENSG00000242353.1	RP4-710M3.1	-3.86	0.000149	0.0449	-0.3	-0.25	Pit-and-Fissure caries;	chr11:30503157	chr11:30368148~30368646:+
OV	cis	rs10129255	0.518	rs12590732	ENSG00000223648.3	IGHV3-64	-3.86	0.000149	0.0449	-0.24	-0.25	Kawasaki disease;	chr14:106779612	chr14:106643132~106658258:-
OV	cis	rs7395581	0.797	rs10742801	ENSG00000271350.1	CTD-2384B9.1	3.86	0.000149	0.0449	0.28	0.25	HDL cholesterol;	chr11:47320669	chr11:47041027~47041945:-
OV	cis	rs641862	1	rs641862	ENSG00000229152.2	ANKRD10-IT1	3.86	0.000149	0.0449	0.44	0.25	Obesity-related traits;	chr13:110137885	chr13:110894639~110899172:-
OV	cis	rs2282300	0.667	rs10734405	ENSG00000242353.1	RP4-710M3.1	3.86	0.00015	0.0449	0.35	0.25	Morning vs. evening chronotype;	chr11:30252203	chr11:30368148~30368646:+
OV	cis	rs1707322	0.691	rs61784803	ENSG00000234329.1	RP11-767N6.2	-3.86	0.00015	0.0449	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45713599	chr1:45651039~45651826:-
OV	cis	rs1707322	0.663	rs3935296	ENSG00000234329.1	RP11-767N6.2	-3.86	0.00015	0.0449	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45714798	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs28817701	ENSG00000234329.1	RP11-767N6.2	3.86	0.00015	0.0449	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45720378	chr1:45651039~45651826:-
OV	cis	rs1707322	0.691	rs28495425	ENSG00000234329.1	RP11-767N6.2	3.86	0.00015	0.0449	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45721648	chr1:45651039~45651826:-
OV	cis	rs1707322	0.685	rs28617418	ENSG00000234329.1	RP11-767N6.2	3.86	0.00015	0.0449	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45723854	chr1:45651039~45651826:-
OV	cis	rs1707322	0.682	rs28490344	ENSG00000234329.1	RP11-767N6.2	3.86	0.00015	0.0449	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45732276	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs28501477	ENSG00000234329.1	RP11-767N6.2	3.86	0.00015	0.0449	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45733412	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs28641748	ENSG00000234329.1	RP11-767N6.2	3.86	0.00015	0.0449	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45747164	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs6697821	ENSG00000234329.1	RP11-767N6.2	3.86	0.00015	0.0449	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751050	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs4330955	ENSG00000234329.1	RP11-767N6.2	3.86	0.00015	0.0449	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45751813	chr1:45651039~45651826:-
OV	cis	rs1707322	0.691	rs11211174	ENSG00000234329.1	RP11-767N6.2	3.86	0.00015	0.0449	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755144	chr1:45651039~45651826:-
OV	cis	rs1707322	0.691	rs12031182	ENSG00000234329.1	RP11-767N6.2	3.86	0.00015	0.0449	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755327	chr1:45651039~45651826:-
OV	cis	rs1707322	0.721	rs10430123	ENSG00000234329.1	RP11-767N6.2	3.86	0.00015	0.0449	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45755768	chr1:45651039~45651826:-
OV	cis	rs732765	0.657	rs2287404	ENSG00000258439.1	RP11-173A8.2	-3.86	0.00015	0.045	-0.38	-0.25	Non-small cell lung cancer;	chr14:74792580	chr14:74658049~74658590:+
OV	cis	rs7649443	0.921	rs35624335	ENSG00000235897.1	TM4SF19-AS1	3.86	0.00015	0.045	0.28	0.25	Nonsyndromic cleft lip with cleft palate;	chr3:197156210	chr3:196318330~196325570:+
OV	cis	rs1829883	0.614	rs10042540	ENSG00000227762.4	GUSBP8	3.86	0.00015	0.045	0.27	0.25	Hemostatic factors and hematological phenotypes;	chr5:99681455	chr5:99532628~99534611:+
OV	cis	rs694739	0.726	rs516124	ENSG00000236935.1	AP003774.1	3.86	0.00015	0.045	0.32	0.25	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64360951	chr11:64325050~64329504:-
OV	cis	rs13256369	0.901	rs12681298	ENSG00000272267.2	RP11-375N15.2	3.86	0.00015	0.045	0.31	0.25	Obesity-related traits;	chr8:8708725	chr8:9555144~9556520:-
OV	cis	rs41271951	0.542	rs11205377	ENSG00000223945.2	RP11-458I7.1	-3.86	0.00015	0.045	-0.43	-0.25	Blood protein levels;	chr1:150448615	chr1:150053864~150055034:+
OV	cis	rs6593680	0.558	rs1931262	ENSG00000237416.5	RP11-465K1.2	3.86	0.00015	0.045	0.28	0.25	Intelligence (multi-trait analysis);	chr1:95709356	chr1:94836748~94855426:-
OV	cis	rs7617773	0.539	rs1471217	ENSG00000228638.1	FCF1P2	-3.86	0.00015	0.045	-0.3	-0.25	Coronary artery disease;	chr3:48343405	chr3:48290793~48291375:-
OV	cis	rs7520050	0.778	rs2934857	ENSG00000280836.1	AL355480.1	-3.86	0.00015	0.045	-0.29	-0.25	Reticulocyte count;Red blood cell count;	chr1:45573940	chr1:45581219~45581321:-
OV	cis	rs848490	0.651	rs11489586	ENSG00000214293.7	APTR	3.86	0.00015	0.0451	0.31	0.25	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77685900	chr7:77657660~77696265:-
OV	cis	rs4664293	0.528	rs12477092	ENSG00000226266.5	AC009961.3	3.86	0.00015	0.0451	0.3	0.25	Monocyte percentage of white cells;	chr2:159577170	chr2:159670708~159712435:-
OV	cis	rs9393777	0.92	rs72839445	ENSG00000220721.1	OR1F12	3.86	0.00015	0.0451	0.52	0.25	Intelligence (multi-trait analysis);	chr6:27281907	chr6:28073316~28074233:+
OV	cis	rs2302729	0.545	rs216047	ENSG00000246627.5	CACNA1C-AS1	-3.86	0.00015	0.0451	-0.27	-0.25	Sleep quality;	chr12:2656694	chr12:2676001~2691200:-
OV	cis	rs295137	0.836	rs10804097	ENSG00000232732.8	AC073043.1	-3.86	0.00015	0.0451	-0.28	-0.25	Asthma (bronchodilator response);	chr2:200240201	chr2:199867396~199911159:-
OV	cis	rs4948102	0.551	rs4275190	ENSG00000226278.1	PSPHP1	-3.86	0.00015	0.0451	-0.29	-0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56036695	chr7:55764797~55773288:+
OV	cis	rs9318086	0.578	rs2077709	ENSG00000205861.10	C1QTNF9B-AS1	3.86	0.00015	0.0451	0.32	0.25	Myopia (pathological);	chr13:23901934	chr13:23888889~23897263:+
OV	cis	rs3758911	0.964	rs10789602	ENSG00000261098.1	RP11-819C21.1	-3.86	0.00015	0.0451	-0.25	-0.25	Coronary artery disease;	chr11:107310729	chr11:107312132~107316271:-
OV	cis	rs6723226	0.572	rs176411	ENSG00000279544.1	AL133243.4	-3.86	0.00015	0.0451	-0.23	-0.25	Intelligence (multi-trait analysis);	chr2:32418460	chr2:32563328~32566436:+
OV	cis	rs11903757	1	rs4299283	ENSG00000281467.1	Clostridiales-1	-3.86	0.00015	0.0451	-0.43	-0.25	Colorectal cancer;	chr2:191716161	chr2:191699476~191699631:-
OV	cis	rs7932354	0.528	rs11039105	ENSG00000271543.1	RP11-692M12.5	3.86	0.00015	0.0451	0.32	0.25	Bone mineral density (hip);Bone mineral density;	chr11:47136126	chr11:47796169~47796379:+
OV	cis	rs4296809	0.505	rs72755339	ENSG00000249779.1	RP11-447H19.3	-3.86	0.00015	0.0452	-0.48	-0.25	Brain structure;	chr5:44148325	chr5:43206709~43207811:+
OV	cis	rs4296809	0.556	rs4596388	ENSG00000249779.1	RP11-447H19.3	-3.86	0.00015	0.0452	-0.48	-0.25	Brain structure;	chr5:44148683	chr5:43206709~43207811:+
OV	cis	rs7968440	1	rs2684900	ENSG00000272368.2	RP4-605O3.4	3.86	0.00015	0.0452	0.29	0.25	Fibrinogen;	chr12:50625773	chr12:50112197~50165618:+
OV	cis	rs7968440	1	rs2700479	ENSG00000272368.2	RP4-605O3.4	3.86	0.00015	0.0452	0.29	0.25	Fibrinogen;	chr12:50626688	chr12:50112197~50165618:+
OV	cis	rs6921919	0.583	rs6907950	ENSG00000204709.4	LINC01556	3.86	0.00015	0.0452	0.31	0.25	Autism spectrum disorder or schizophrenia;	chr6:28402469	chr6:28943877~28944537:+
OV	cis	rs2070488	0.775	rs9838614	ENSG00000229589.1	ACVR2B-AS1	-3.86	0.00015	0.0452	-0.28	-0.25	Electrocardiographic conduction measures;	chr3:38496180	chr3:38451027~38454820:-
OV	cis	rs73201462	0.908	rs2999083	ENSG00000242551.2	POU5F1P6	-3.86	0.000151	0.0452	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128235591	chr3:128674735~128677005:-
OV	cis	rs73201462	0.901	rs2999080	ENSG00000242551.2	POU5F1P6	-3.86	0.000151	0.0452	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128237865	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2999077	ENSG00000242551.2	POU5F1P6	-3.86	0.000151	0.0452	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128239571	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2955077	ENSG00000242551.2	POU5F1P6	-3.86	0.000151	0.0452	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128240026	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2955078	ENSG00000242551.2	POU5F1P6	-3.86	0.000151	0.0452	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128240343	chr3:128674735~128677005:-
OV	cis	rs2955081	1	rs2955081	ENSG00000242551.2	POU5F1P6	-3.86	0.000151	0.0452	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128241456	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2955085	ENSG00000242551.2	POU5F1P6	-3.86	0.000151	0.0452	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128243914	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2999072	ENSG00000242551.2	POU5F1P6	-3.86	0.000151	0.0452	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128244033	chr3:128674735~128677005:-
OV	cis	rs73201462	1	rs2955088	ENSG00000242551.2	POU5F1P6	-3.86	0.000151	0.0452	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128244867	chr3:128674735~128677005:-
OV	cis	rs4713118	0.869	rs9348775	ENSG00000219392.1	RP1-265C24.5	-3.86	0.000151	0.0452	-0.29	-0.25	Parkinson's disease;	chr6:27727550	chr6:28115628~28116551:+
OV	cis	rs875971	1	rs7792762	ENSG00000237310.1	GS1-124K5.4	3.86	0.000151	0.0452	0.25	0.25	Aortic root size;	chr7:66539151	chr7:66493706~66495474:+
OV	cis	rs9923856	0.614	rs7203459	ENSG00000262636.1	CTD-3088G3.4	3.86	0.000151	0.0452	0.36	0.25	Atopic dermatitis;Adult asthma;	chr16:11136846	chr16:11380859~11381118:-
OV	cis	rs1933112	1	rs10918925	ENSG00000227777.1	RP4-738P11.3	3.85	0.000151	0.0452	0.28	0.25	Blood protein levels;	chr1:168556009	chr1:168542737~168543354:+
OV	cis	rs875971	0.545	rs6460281	ENSG00000273024.4	INTS4P2	-3.85	0.000151	0.0452	-0.3	-0.25	Aortic root size;	chr7:66216128	chr7:65647864~65715661:+
OV	cis	rs11098499	0.954	rs11098524	ENSG00000249244.1	RP11-548H18.2	3.85	0.000151	0.0452	0.3	0.25	Corneal astigmatism;	chr4:119468877	chr4:119391831~119395335:-
OV	cis	rs944801	0.608	rs10120806	ENSG00000234840.1	LINC01239	-3.85	0.000151	0.0452	-0.29	-0.25	Type 2 diabetes;	chr9:22047946	chr9:22646200~22824213:+
OV	cis	rs7646881	0.544	rs16829118	ENSG00000272087.1	RP11-379F4.7	3.85	0.000151	0.0452	0.36	0.25	Tetralogy of Fallot;	chr3:158571033	chr3:158693120~158693768:-
OV	cis	rs7204230	1	rs16952141	ENSG00000261291.1	RP11-295M3.2	3.85	0.000151	0.0452	0.3	0.25	Fibrinogen;	chr16:53294875	chr16:53168522~53169450:+
OV	cis	rs7204230	1	rs12596211	ENSG00000261291.1	RP11-295M3.2	3.85	0.000151	0.0452	0.3	0.25	Fibrinogen;	chr16:53298530	chr16:53168522~53169450:+
OV	cis	rs2243480	1	rs1499613	ENSG00000273142.1	RP11-458F8.4	3.85	0.000151	0.0452	0.29	0.25	Diabetic kidney disease;	chr7:66265873	chr7:66902857~66906297:+
OV	cis	rs2243480	1	rs1553174	ENSG00000273142.1	RP11-458F8.4	3.85	0.000151	0.0452	0.29	0.25	Diabetic kidney disease;	chr7:66266207	chr7:66902857~66906297:+
OV	cis	rs2243480	1	rs10950032	ENSG00000273142.1	RP11-458F8.4	3.85	0.000151	0.0452	0.29	0.25	Diabetic kidney disease;	chr7:66273604	chr7:66902857~66906297:+
OV	cis	rs2243480	1	rs6958420	ENSG00000273142.1	RP11-458F8.4	3.85	0.000151	0.0452	0.29	0.25	Diabetic kidney disease;	chr7:66286184	chr7:66902857~66906297:+
OV	cis	rs2243480	1	rs1392104	ENSG00000273142.1	RP11-458F8.4	3.85	0.000151	0.0452	0.29	0.25	Diabetic kidney disease;	chr7:66294120	chr7:66902857~66906297:+
OV	cis	rs2243480	1	rs4718333	ENSG00000273142.1	RP11-458F8.4	3.85	0.000151	0.0452	0.29	0.25	Diabetic kidney disease;	chr7:66307771	chr7:66902857~66906297:+
OV	cis	rs2243480	1	rs7792391	ENSG00000273142.1	RP11-458F8.4	3.85	0.000151	0.0452	0.29	0.25	Diabetic kidney disease;	chr7:66308442	chr7:66902857~66906297:+
OV	cis	rs2243480	1	rs10247526	ENSG00000273142.1	RP11-458F8.4	3.85	0.000151	0.0452	0.29	0.25	Diabetic kidney disease;	chr7:66315709	chr7:66902857~66906297:+
OV	cis	rs2243480	0.908	rs1532573	ENSG00000273142.1	RP11-458F8.4	3.85	0.000151	0.0452	0.29	0.25	Diabetic kidney disease;	chr7:66333815	chr7:66902857~66906297:+
OV	cis	rs1555322	0.872	rs6579227	ENSG00000269202.1	RP4-614O4.12	-3.85	0.000151	0.0452	-0.37	-0.25	Attention deficit hyperactivity disorder;	chr20:35291403	chr20:35201747~35203288:-
OV	cis	rs6964833	1	rs4717907	ENSG00000277072.3	STAG3L2	3.85	0.000151	0.0452	0.28	0.25	Menarche (age at onset);	chr7:74672169	chr7:74882163~74890610:-
OV	cis	rs1797885	0.763	rs796291	ENSG00000251774.1	RNU6-377P	3.85	0.000151	0.0453	0.23	0.25	Immature fraction of reticulocytes;	chr3:12480072	chr3:12514706~12514807:+
OV	cis	rs1797885	0.763	rs1797886	ENSG00000251774.1	RNU6-377P	3.85	0.000151	0.0453	0.23	0.25	Immature fraction of reticulocytes;	chr3:12480199	chr3:12514706~12514807:+
OV	cis	rs10181042	0.565	rs3108630	ENSG00000270820.4	RP11-355B11.2	-3.85	0.000151	0.0453	-0.28	-0.25	Crohn's disease;	chr2:61041025	chr2:61471188~61484130:+
OV	cis	rs4713118	0.868	rs9468220	ENSG00000226314.6	ZNF192P1	3.85	0.000151	0.0453	0.34	0.25	Parkinson's disease;	chr6:27765197	chr6:28161781~28169594:+
OV	cis	rs8056893	0.61	rs3803650	ENSG00000263276.1	RP11-96D1.10	3.85	0.000151	0.0453	0.2	0.25	Blood metabolite levels;Blood metabolite ratios;Glomerular filtration rate (creatinine);	chr16:68310793	chr16:68224713~68227734:+
OV	cis	rs913678	0.513	rs6020461	ENSG00000237595.3	RP11-112L6.3	-3.85	0.000151	0.0453	-0.36	-0.25	Granulocyte percentage of myeloid white cells;Inflammatory bowel disease;Ulcerative colitis;Monocyte percentage of white cells;Monocyte count;	chr20:50344686	chr20:50162765~50166102:-
OV	cis	rs2282300	0.739	rs1631451	ENSG00000242353.1	RP4-710M3.1	-3.85	0.000151	0.0453	-0.35	-0.25	Morning vs. evening chronotype;	chr11:30327586	chr11:30368148~30368646:+
OV	cis	rs2282300	0.739	rs1717775	ENSG00000242353.1	RP4-710M3.1	-3.85	0.000151	0.0453	-0.35	-0.25	Morning vs. evening chronotype;	chr11:30328707	chr11:30368148~30368646:+
OV	cis	rs2282300	0.739	rs1222208	ENSG00000242353.1	RP4-710M3.1	-3.85	0.000151	0.0453	-0.35	-0.25	Morning vs. evening chronotype;	chr11:30339830	chr11:30368148~30368646:+
OV	cis	rs1829883	0.668	rs7705557	ENSG00000227762.4	GUSBP8	3.85	0.000151	0.0453	0.27	0.25	Hemostatic factors and hematological phenotypes;	chr5:99688866	chr5:99532628~99534611:+
OV	cis	rs6142102	0.923	rs3787230	ENSG00000276073.1	RP5-1125A11.7	-3.85	0.000151	0.0453	-0.29	-0.25	Skin pigmentation;	chr20:34052466	chr20:33985617~33988989:-
OV	cis	rs7520050	0.966	rs12760175	ENSG00000280836.1	AL355480.1	3.85	0.000151	0.0454	0.31	0.25	Reticulocyte count;Red blood cell count;	chr1:45982168	chr1:45581219~45581321:-
OV	cis	rs7429990	0.864	rs3772399	ENSG00000229759.1	MRPS18AP1	-3.85	0.000151	0.0454	-0.27	-0.25	Educational attainment (years of education);	chr3:47826237	chr3:48256350~48256938:-
OV	cis	rs7246657	0.943	rs6508732	ENSG00000226686.6	LINC01535	-3.85	0.000151	0.0454	-0.37	-0.25	Coronary artery calcification;	chr19:37509566	chr19:37251912~37265535:+
OV	cis	rs12264252	0.623	rs12773636	ENSG00000226659.1	RP11-137H2.4	3.85	0.000151	0.0454	0.43	0.25	Coronary artery disease;	chr10:80502651	chr10:80529597~80535942:-
OV	cis	rs7957197	0.938	rs55879344	ENSG00000202538.1	RNU4-2	3.85	0.000151	0.0454	0.35	0.25	Type 2 diabetes;	chr12:121007193	chr12:120291763~120291903:-
OV	cis	rs8062405	0.964	rs62036614	ENSG00000270424.1	RP11-1348G14.6	3.85	0.000151	0.0454	0.28	0.25	Cognitive ability (multi-trait analysis);Cognitive ability;	chr16:28813364	chr16:28749959~28750595:-
OV	cis	rs6545883	1	rs6545883	ENSG00000270820.4	RP11-355B11.2	3.85	0.000151	0.0454	0.28	0.25	Tuberculosis;	chr2:61545122	chr2:61471188~61484130:+
OV	cis	rs2271920	0.626	rs2241661	ENSG00000253875.1	RP11-16P20.3	-3.85	0.000152	0.0454	-0.32	-0.25	Alzheimer's disease in APOE e4- carriers;	chr8:27443104	chr8:27733338~27756426:+
OV	cis	rs17767294	0.612	rs9461424	ENSG00000219392.1	RP1-265C24.5	-3.85	0.000152	0.0454	-0.42	-0.25	Parkinson's disease;	chr6:27951623	chr6:28115628~28116551:+
OV	cis	rs17767294	0.612	rs9461425	ENSG00000219392.1	RP1-265C24.5	-3.85	0.000152	0.0454	-0.42	-0.25	Parkinson's disease;	chr6:27951910	chr6:28115628~28116551:+
OV	cis	rs597539	0.652	rs514296	ENSG00000250508.1	RP11-757G1.6	-3.85	0.000152	0.0454	-0.35	-0.25	Coronary artery calcified atherosclerotic plaque score in type 2 diabetes;	chr11:68886714	chr11:68870664~68874542:+
OV	cis	rs7746199	0.736	rs13209332	ENSG00000226314.6	ZNF192P1	-3.85	0.000152	0.0454	-0.54	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27552973	chr6:28161781~28169594:+
OV	cis	rs7746199	0.736	rs34965299	ENSG00000226314.6	ZNF192P1	-3.85	0.000152	0.0454	-0.54	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27554077	chr6:28161781~28169594:+
OV	cis	rs7429990	0.864	rs2049301	ENSG00000229759.1	MRPS18AP1	-3.85	0.000152	0.0454	-0.27	-0.25	Educational attainment (years of education);	chr3:47681369	chr3:48256350~48256938:-
OV	cis	rs6142102	0.812	rs2377955	ENSG00000271803.1	RP1-63M2.5	3.85	0.000152	0.0454	0.31	0.25	Skin pigmentation;	chr20:33937564	chr20:33674517~33675380:+
OV	cis	rs7569084	0.687	rs963539	ENSG00000204929.10	AC074391.1	-3.85	0.000152	0.0454	-0.32	-0.25	Sum eosinophil basophil counts;	chr2:65421413	chr2:65436711~66084639:+
OV	cis	rs1862618	0.853	rs832553	ENSG00000271828.1	CTD-2310F14.1	3.85	0.000152	0.0454	0.4	0.25	Initial pursuit acceleration;	chr5:56818959	chr5:56927874~56929573:+
OV	cis	rs881375	0.678	rs2269060	ENSG00000226752.6	PSMD5-AS1	-3.85	0.000152	0.0455	-0.25	-0.25	Rheumatoid arthritis;	chr9:120921291	chr9:120824828~120854385:+
OV	cis	rs897984	0.542	rs8061047	ENSG00000232748.3	RP11-196G11.6	-3.85	0.000152	0.0455	-0.26	-0.25	Dementia with Lewy bodies;	chr16:31057639	chr16:31056460~31062803:+
OV	cis	rs4889609	0.834	rs72785520	ENSG00000232748.3	RP11-196G11.6	-3.85	0.000152	0.0455	-0.26	-0.25	Response to metformin (IC50);	chr16:31059457	chr16:31056460~31062803:+
OV	cis	rs867186	0.748	rs6060238	ENSG00000230155.5	RP3-477O4.14	3.85	0.000152	0.0455	0.37	0.25	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35106737	chr20:35476203~35490982:-
OV	cis	rs867186	0.748	rs6060239	ENSG00000230155.5	RP3-477O4.14	3.85	0.000152	0.0455	0.37	0.25	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35106777	chr20:35476203~35490982:-
OV	cis	rs867186	0.748	rs6060240	ENSG00000230155.5	RP3-477O4.14	3.85	0.000152	0.0455	0.37	0.25	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35106896	chr20:35476203~35490982:-
OV	cis	rs9880211	1	rs6805316	ENSG00000239213.4	NCK1-AS1	3.85	0.000152	0.0455	0.3	0.25	Height;Body mass index;	chr3:136233270	chr3:136841726~136862054:-
OV	cis	rs7746199	0.736	rs13202295	ENSG00000226314.6	ZNF192P1	-3.85	0.000152	0.0455	-0.53	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27731058	chr6:28161781~28169594:+
OV	cis	rs733592	1	rs1859440	ENSG00000240399.1	RP1-228P16.1	-3.85	0.000152	0.0455	-0.27	-0.25	Plateletcrit;	chr12:48033546	chr12:48054813~48055591:-
OV	cis	rs7520050	0.778	rs3014218	ENSG00000280836.1	AL355480.1	3.85	0.000152	0.0455	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:45560656	chr1:45581219~45581321:-
OV	cis	rs860295	0.729	rs4971072	ENSG00000225855.5	RUSC1-AS1	-3.85	0.000152	0.0455	-0.2	-0.25	Body mass index;	chr1:155304078	chr1:155316863~155324176:-
OV	cis	rs4591358	0.734	rs11904194	ENSG00000223466.1	AC064834.2	3.85	0.000152	0.0455	0.29	0.25	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195495211	chr2:195533035~195538681:+
OV	cis	rs2274471	0.591	rs7034539	ENSG00000234534.1	CSNK1G2P1	-3.85	0.000152	0.0455	-0.31	-0.25	Crohn's disease;	chr9:5081585	chr9:5040945~5041940:+
OV	cis	rs16858868	0.964	rs1282944	ENSG00000242308.2	RP11-572C15.3	-3.85	0.000152	0.0455	-0.27	-0.25	Lobe attachment (rater-scored or self-reported);	chr3:111916556	chr3:112696908~112697706:-
OV	cis	rs853679	0.55	rs1237875	ENSG00000226314.6	ZNF192P1	3.85	0.000152	0.0455	0.33	0.25	Depression;	chr6:28205232	chr6:28161781~28169594:+
OV	cis	rs17767294	0.708	rs6908688	ENSG00000220721.1	OR1F12	3.85	0.000152	0.0455	0.5	0.25	Parkinson's disease;	chr6:27918273	chr6:28073316~28074233:+
OV	cis	rs1538970	1	rs61791368	ENSG00000280836.1	AL355480.1	-3.85	0.000152	0.0456	-0.35	-0.25	Platelet count;	chr1:45402272	chr1:45581219~45581321:-
OV	cis	rs1823913	0.637	rs2356354	ENSG00000227542.1	AC092614.2	-3.85	0.000152	0.0456	-0.28	-0.25	Obesity-related traits;	chr2:191270970	chr2:191229165~191246172:-
OV	cis	rs6101567	0.623	rs13040896	ENSG00000261431.1	RP4-616B8.4	3.85	0.000152	0.0456	0.25	0.25	Nose size;	chr20:39363122	chr20:38961925~38962111:-
OV	cis	rs875971	0.545	rs313830	ENSG00000234500.1	GS1-124K5.10	3.85	0.000152	0.0456	0.21	0.25	Aortic root size;	chr7:66086944	chr7:66511556~66545066:+
OV	cis	rs7302981	0.809	rs66768395	ENSG00000257298.1	RP3-405J10.3	3.85	0.000152	0.0456	0.23	0.25	Systolic blood pressure;	chr12:50174482	chr12:50185580~50191363:-
OV	cis	rs7302981	0.809	rs1044370	ENSG00000257298.1	RP3-405J10.3	3.85	0.000152	0.0456	0.23	0.25	Systolic blood pressure;	chr12:50176827	chr12:50185580~50191363:-
OV	cis	rs7569084	0.663	rs11126037	ENSG00000204929.10	AC074391.1	3.85	0.000152	0.0456	0.32	0.25	Sum eosinophil basophil counts;	chr2:65436024	chr2:65436711~66084639:+
OV	cis	rs7569084	0.663	rs11694714	ENSG00000204929.10	AC074391.1	3.85	0.000152	0.0456	0.32	0.25	Sum eosinophil basophil counts;	chr2:65436802	chr2:65436711~66084639:+
OV	cis	rs17711722	0.523	rs365896	ENSG00000273142.1	RP11-458F8.4	-3.85	0.000152	0.0456	-0.2	-0.25	Calcium levels;	chr7:66045710	chr7:66902857~66906297:+
OV	cis	rs8396	1	rs8396	ENSG00000271817.2	U3	-3.85	0.000152	0.0456	-0.3	-0.25	Blood metabolite levels;Blood protein levels;Acylcarnitine levels;Metabolite levels;Metabolic traits;	chr4:158709665	chr4:158700691~158700909:+
OV	cis	rs889312	0.924	rs1910020	ENSG00000271828.1	CTD-2310F14.1	-3.85	0.000153	0.0456	-0.33	-0.25	Breast cancer (early onset);Breast cancer;	chr5:56730673	chr5:56927874~56929573:+
OV	cis	rs1881797	0.527	rs78398999	ENSG00000227135.1	GCSAML-AS1	-3.85	0.000153	0.0456	-0.55	-0.25	Acute lymphoblastic leukemia (childhood);	chr1:247523668	chr1:247524679~247526752:-
OV	cis	rs10485879	1	rs17150464	ENSG00000214293.7	APTR	-3.85	0.000153	0.0456	-0.37	-0.25	Colonoscopy-negative controls vs population controls;	chr7:78268667	chr7:77657660~77696265:-
OV	cis	rs7246657	0.943	rs10405064	ENSG00000226686.6	LINC01535	-3.85	0.000153	0.0456	-0.38	-0.25	Coronary artery calcification;	chr19:37370959	chr19:37251912~37265535:+
OV	cis	rs7246657	0.943	rs8111782	ENSG00000226686.6	LINC01535	-3.85	0.000153	0.0456	-0.38	-0.25	Coronary artery calcification;	chr19:37377002	chr19:37251912~37265535:+
OV	cis	rs7246657	0.943	rs10404920	ENSG00000226686.6	LINC01535	-3.85	0.000153	0.0456	-0.38	-0.25	Coronary artery calcification;	chr19:37390654	chr19:37251912~37265535:+
OV	cis	rs12787909	1	rs12787909	ENSG00000235910.1	APOA1-AS	3.85	0.000153	0.0456	0.48	0.25	Lipoprotein (a) - cholesterol levels;	chr11:117675767	chr11:116836117~116855729:+
OV	cis	rs11037575	0.647	rs7948942	ENSG00000246250.2	RP11-613D13.5	3.85	0.000153	0.0457	0.27	0.25	Neuroblastoma;	chr11:43702916	chr11:43829709~43880726:-
OV	cis	rs11037575	0.739	rs10838154	ENSG00000246250.2	RP11-613D13.5	3.85	0.000153	0.0457	0.27	0.25	Neuroblastoma;	chr11:43704069	chr11:43829709~43880726:-
OV	cis	rs9929218	0.52	rs1078621	ENSG00000274698.1	RP11-71L14.4	3.85	0.000153	0.0457	0.28	0.25	Colorectal cancer;	chr16:68745093	chr16:68450283~68452318:+
OV	cis	rs801193	0.967	rs34356500	ENSG00000237310.1	GS1-124K5.4	3.85	0.000153	0.0457	0.26	0.25	Aortic root size;	chr7:66771620	chr7:66493706~66495474:+
OV	cis	rs2108622	0.727	rs12609900	ENSG00000267453.5	AC004791.2	-3.85	0.000153	0.0457	-0.29	-0.25	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871604	chr19:15851993~15864904:-
OV	cis	rs2108622	0.727	rs62107763	ENSG00000267453.5	AC004791.2	-3.85	0.000153	0.0457	-0.29	-0.25	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871788	chr19:15851993~15864904:-
OV	cis	rs2108622	0.727	rs62107764	ENSG00000267453.5	AC004791.2	-3.85	0.000153	0.0457	-0.29	-0.25	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871848	chr19:15851993~15864904:-
OV	cis	rs2108622	0.727	rs76984410	ENSG00000267453.5	AC004791.2	-3.85	0.000153	0.0457	-0.29	-0.25	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871890	chr19:15851993~15864904:-
OV	cis	rs2108622	0.727	rs77780918	ENSG00000267453.5	AC004791.2	-3.85	0.000153	0.0457	-0.29	-0.25	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871897	chr19:15851993~15864904:-
OV	cis	rs2108622	0.727	rs8104311	ENSG00000267453.5	AC004791.2	-3.85	0.000153	0.0457	-0.29	-0.25	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15871950	chr19:15851993~15864904:-
OV	cis	rs2108622	0.727	rs8101038	ENSG00000267453.5	AC004791.2	-3.85	0.000153	0.0457	-0.29	-0.25	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872054	chr19:15851993~15864904:-
OV	cis	rs35738462	0.777	rs927614	ENSG00000185839.3	RP4-592A1.2	-3.85	0.000153	0.0457	-0.34	-0.25	Alcohol dependence (age at onset);	chr1:57788645	chr1:58630841~58631530:-
OV	cis	rs4700393	0.52	rs206789	ENSG00000250461.1	RP11-631M6.2	-3.85	0.000153	0.0457	-0.26	-0.25	Intelligence (multi-trait analysis);	chr5:60608144	chr5:61375112~61375855:+
OV	cis	rs896854	0.738	rs2515226	ENSG00000253528.2	RP11-347C18.4	-3.85	0.000153	0.0457	-0.25	-0.25	Type 2 diabetes;	chr8:94953515	chr8:94974573~94974853:-
OV	cis	rs896854	0.714	rs572547	ENSG00000253528.2	RP11-347C18.4	-3.85	0.000153	0.0457	-0.25	-0.25	Type 2 diabetes;	chr8:94954058	chr8:94974573~94974853:-
OV	cis	rs896854	0.738	rs509594	ENSG00000253528.2	RP11-347C18.4	-3.85	0.000153	0.0457	-0.25	-0.25	Type 2 diabetes;	chr8:94954928	chr8:94974573~94974853:-
OV	cis	rs9309711	0.643	rs4535074	ENSG00000225234.1	TRAPPC12-AS1	-3.85	0.000153	0.0457	-0.26	-0.25	Neurofibrillary tangles;	chr2:3477866	chr2:3481242~3482409:-
OV	cis	rs11976180	1	rs2961134	ENSG00000204959.4	ARHGEF34P	3.85	0.000153	0.0457	0.31	0.25	Obesity-related traits;	chr7:144073969	chr7:144272445~144286966:-
OV	cis	rs12073359	0.954	rs72692902	ENSG00000223945.2	RP11-458I7.1	-3.85	0.000153	0.0457	-0.39	-0.25	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150086491	chr1:150053864~150055034:+
OV	cis	rs7932354	0.71	rs10838621	ENSG00000271543.1	RP11-692M12.5	-3.85	0.000153	0.0458	-0.32	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:46829908	chr11:47796169~47796379:+
OV	cis	rs2282300	0.739	rs1765139	ENSG00000242353.1	RP4-710M3.1	-3.85	0.000153	0.0458	-0.35	-0.25	Morning vs. evening chronotype;	chr11:30332178	chr11:30368148~30368646:+
OV	cis	rs4950322	1	rs72694720	ENSG00000278811.3	LINC00624	3.85	0.000153	0.0458	0.35	0.25	Protein quantitative trait loci;	chr1:147371939	chr1:147258885~147517875:-
OV	cis	rs367615	0.68	rs385728	ENSG00000272523.1	LINC01023	-3.85	0.000153	0.0458	-0.35	-0.25	Colorectal cancer (SNP x SNP interaction);	chr5:109630308	chr5:108727825~108728260:-
OV	cis	rs62151617	1	rs17005905	ENSG00000233870.1	AC007881.4	3.85	0.000153	0.0458	0.33	0.25	Hair shape;	chr2:70581780	chr2:71178587~71178773:+
OV	cis	rs3743102	1	rs8023873	ENSG00000278603.1	RP13-608F4.5	-3.85	0.000153	0.0458	-0.38	-0.25	Colorectal adenoma (advanced);	chr15:82758932	chr15:82472203~82472426:+
OV	cis	rs2111504	0.583	rs2111503	ENSG00000267213.4	AC007773.2	3.85	0.000153	0.0458	0.32	0.25	Bipolar disorder;	chr19:32383819	chr19:32390050~32405560:-
OV	cis	rs10214930	0.697	rs12537499	ENSG00000235574.1	AC073150.6	3.85	0.000153	0.0458	0.3	0.25	Hypospadias;	chr7:27551976	chr7:27491682~27492765:-
OV	cis	rs10214930	0.697	rs759269	ENSG00000235574.1	AC073150.6	-3.85	0.000153	0.0458	-0.3	-0.25	Hypospadias;	chr7:27552728	chr7:27491682~27492765:-
OV	cis	rs10214930	0.56	rs1015750	ENSG00000235574.1	AC073150.6	-3.85	0.000153	0.0458	-0.3	-0.25	Hypospadias;	chr7:27553600	chr7:27491682~27492765:-
OV	cis	rs10214930	0.697	rs7780431	ENSG00000235574.1	AC073150.6	-3.85	0.000153	0.0458	-0.3	-0.25	Hypospadias;	chr7:27553749	chr7:27491682~27492765:-
OV	cis	rs7259376	0.514	rs11673221	ENSG00000269742.1	BNIP3P29	3.85	0.000153	0.0458	0.29	0.25	Menopause (age at onset);	chr19:22309233	chr19:22065828~22066398:-
OV	cis	rs2251381	0.606	rs8129515	ENSG00000226935.5	LINC00161	-3.85	0.000154	0.0459	-0.26	-0.25	Selective IgA deficiency;	chr21:29147846	chr21:28539318~28540355:+
OV	cis	rs875971	0.545	rs316328	ENSG00000237310.1	GS1-124K5.4	-3.85	0.000154	0.0459	-0.27	-0.25	Aortic root size;	chr7:66143851	chr7:66493706~66495474:+
OV	cis	rs875971	0.965	rs697968	ENSG00000237310.1	GS1-124K5.4	-3.85	0.000154	0.0459	-0.26	-0.25	Aortic root size;	chr7:66070046	chr7:66493706~66495474:+
OV	cis	rs875971	1	rs1167411	ENSG00000237310.1	GS1-124K5.4	-3.85	0.000154	0.0459	-0.26	-0.25	Aortic root size;	chr7:66074277	chr7:66493706~66495474:+
OV	cis	rs875971	1	rs1183245	ENSG00000237310.1	GS1-124K5.4	-3.85	0.000154	0.0459	-0.26	-0.25	Aortic root size;	chr7:66076198	chr7:66493706~66495474:+
OV	cis	rs875971	1	rs1144895	ENSG00000237310.1	GS1-124K5.4	-3.85	0.000154	0.0459	-0.26	-0.25	Aortic root size;	chr7:66076320	chr7:66493706~66495474:+
OV	cis	rs875971	1	rs1144894	ENSG00000237310.1	GS1-124K5.4	-3.85	0.000154	0.0459	-0.26	-0.25	Aortic root size;	chr7:66077907	chr7:66493706~66495474:+
OV	cis	rs860818	0.793	rs1881202	ENSG00000230658.1	KLHL7-AS1	3.85	0.000154	0.0459	0.65	0.25	Initial pursuit acceleration;	chr7:23153889	chr7:23101228~23105703:-
OV	cis	rs10851478	0.591	rs11634786	ENSG00000259545.2	RP11-325E5.4	3.85	0.000154	0.0459	0.27	0.25	Oral cavity cancer;	chr15:49452370	chr15:49177610~49178741:-
OV	cis	rs6919534	0.646	rs10080361	ENSG00000265123.2	RN7SL200P	3.85	0.000154	0.0459	0.28	0.25	Height;	chr6:35260466	chr6:34685355~34685642:-
OV	cis	rs875971	0.545	rs1796226	ENSG00000237310.1	GS1-124K5.4	3.85	0.000154	0.0459	0.29	0.25	Aortic root size;	chr7:66622723	chr7:66493706~66495474:+
OV	cis	rs875971	0.577	rs34888281	ENSG00000237310.1	GS1-124K5.4	-3.85	0.000154	0.0459	-0.25	-0.25	Aortic root size;	chr7:66120784	chr7:66493706~66495474:+
OV	cis	rs7789940	0.904	rs6953281	ENSG00000230305.2	AC004980.9	3.85	0.000154	0.046	0.35	0.25	Multiple sclerosis;	chr7:76317626	chr7:76524515~76532692:+
OV	cis	rs73562014	0.938	rs111760901	ENSG00000254416.4	RP11-347E10.1	-3.85	0.000154	0.046	-0.42	-0.25	Coronary artery disease;	chr11:110469931	chr11:110355130~110406400:+
OV	cis	rs11037575	0.715	rs11037572	ENSG00000246250.2	RP11-613D13.5	3.85	0.000154	0.046	0.27	0.25	Neuroblastoma;	chr11:43702618	chr11:43829709~43880726:-
OV	cis	rs13144136	0.862	rs4582144	ENSG00000250413.1	RP11-448G15.1	3.85	0.000154	0.046	0.28	0.25	Resistance to antihypertensive treatment in hypertension;	chr4:10672383	chr4:10006482~10009725:+
OV	cis	rs2834288	0.5	rs2834304	ENSG00000273102.1	AP000569.9	3.85	0.000154	0.046	0.26	0.25	Gut microbiota (bacterial taxa);	chr21:33949550	chr21:33967101~33968573:-
OV	cis	rs1584120	0.628	rs11046835	ENSG00000274885.1	RP11-268P4.6	-3.85	0.000154	0.046	-0.31	-0.25	Pelvic organ prolapse (moderate/severe);	chr12:23166860	chr12:22638464~22638943:+
OV	cis	rs4713118	0.739	rs2893931	ENSG00000226314.6	ZNF192P1	-3.85	0.000154	0.046	-0.31	-0.25	Parkinson's disease;	chr6:27780231	chr6:28161781~28169594:+
OV	cis	rs73201462	0.901	rs16843876	ENSG00000242551.2	POU5F1P6	3.85	0.000154	0.046	0.36	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128313697	chr3:128674735~128677005:-
OV	cis	rs4356975	0.563	rs4538548	ENSG00000251284.2	RP13-644M16.1	-3.85	0.000154	0.046	-0.26	-0.25	Obesity-related traits;	chr4:69094951	chr4:69125274~69126451:+
OV	cis	rs4356975	0.563	rs6600883	ENSG00000251284.2	RP13-644M16.1	-3.85	0.000154	0.046	-0.26	-0.25	Obesity-related traits;	chr4:69094953	chr4:69125274~69126451:+
OV	cis	rs4356975	0.563	rs7662029	ENSG00000251284.2	RP13-644M16.1	-3.85	0.000154	0.046	-0.26	-0.25	Obesity-related traits;	chr4:69096194	chr4:69125274~69126451:+
OV	cis	rs1707322	0.721	rs4660883	ENSG00000234329.1	RP11-767N6.2	3.85	0.000154	0.046	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45770426	chr1:45651039~45651826:-
OV	cis	rs1723838	0.826	rs1723834	ENSG00000255928.1	RP11-456I15.2	-3.85	0.000154	0.046	-0.6	-0.25	Obesity-related traits;	chr11:73801603	chr11:73722349~73722694:+
OV	cis	rs7259376	0.623	rs7252078	ENSG00000269742.1	BNIP3P29	3.85	0.000155	0.0461	0.29	0.25	Menopause (age at onset);	chr19:22320213	chr19:22065828~22066398:-
OV	cis	rs7615952	0.641	rs7632497	ENSG00000250012.1	RP11-124N2.1	-3.85	0.000155	0.0461	-0.31	-0.25	Blood pressure (smoking interaction);	chr3:126064243	chr3:126084220~126095349:+
OV	cis	rs7615952	0.641	rs12487875	ENSG00000250012.1	RP11-124N2.1	-3.85	0.000155	0.0461	-0.31	-0.25	Blood pressure (smoking interaction);	chr3:126068381	chr3:126084220~126095349:+
OV	cis	rs6545883	0.894	rs778144	ENSG00000270820.4	RP11-355B11.2	-3.85	0.000155	0.0461	-0.28	-0.25	Tuberculosis;	chr2:61355993	chr2:61471188~61484130:+
OV	cis	rs9393777	0.557	rs36034627	ENSG00000243307.2	POM121L6P	-3.85	0.000155	0.0461	-0.31	-0.25	Intelligence (multi-trait analysis);	chr6:27269584	chr6:26896952~26898777:+
OV	cis	rs3823536	0.583	rs7789423	ENSG00000275106.1	RP11-309L24.10	-3.85	0.000155	0.0461	-0.34	-0.25	Sjögren's syndrome;	chr7:128981150	chr7:128952527~128953316:-
OV	cis	rs3823536	0.583	rs6948928	ENSG00000275106.1	RP11-309L24.10	-3.85	0.000155	0.0461	-0.34	-0.25	Sjögren's syndrome;	chr7:128983043	chr7:128952527~128953316:-
OV	cis	rs760794	0.577	rs17483277	ENSG00000228412.5	RP4-625H18.2	3.85	0.000155	0.0461	0.31	0.25	Endometriosis;	chr6:19790340	chr6:19802164~19804752:-
OV	cis	rs10504130	0.597	rs4598243	ENSG00000272024.1	RP11-546K22.3	-3.85	0.000155	0.0461	-0.33	-0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:51797158	chr8:51950284~51950690:+
OV	cis	rs17711722	0.565	rs4275112	ENSG00000222364.1	RNU6-96P	3.85	0.000155	0.0461	0.27	0.25	Calcium levels;	chr7:65733651	chr7:66395191~66395286:+
OV	cis	rs10078	0.848	rs890985	ENSG00000221990.4	EXOC3-AS1	3.85	0.000155	0.0461	0.26	0.25	Fat distribution (HIV);	chr5:479631	chr5:441498~443160:-
OV	cis	rs259282	0.524	rs731674	ENSG00000267213.4	AC007773.2	3.85	0.000155	0.0461	0.31	0.25	Schizophrenia;	chr19:32641489	chr19:32390050~32405560:-
OV	cis	rs6142102	0.602	rs2300209	ENSG00000276073.1	RP5-1125A11.7	-3.85	0.000155	0.0462	-0.29	-0.25	Skin pigmentation;	chr20:34055294	chr20:33985617~33988989:-
OV	cis	rs7512898	0.5	rs7516036	ENSG00000260088.1	RP11-92G12.3	-3.85	0.000155	0.0462	-0.27	-0.25	Electrocardiographic conduction measures;	chr1:200727825	chr1:200669507~200694250:+
OV	cis	rs853679	0.567	rs3799499	ENSG00000204709.4	LINC01556	3.85	0.000155	0.0462	0.31	0.25	Depression;	chr6:28386473	chr6:28943877~28944537:+
OV	cis	rs73201462	1	rs11709611	ENSG00000242551.2	POU5F1P6	3.85	0.000155	0.0462	0.39	0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128348432	chr3:128674735~128677005:-
OV	cis	rs2950393	0.929	rs2958155	ENSG00000241217.3	RN7SL809P	3.85	0.000155	0.0462	0.23	0.25	Platelet distribution width;	chr12:56670761	chr12:56670450~56670746:-
OV	cis	rs540254	0.578	rs3817407	ENSG00000225217.1	HSPA7	3.85	0.000155	0.0462	0.23	0.25	Blood protein levels;	chr1:160818341	chr1:161606291~161608217:+
OV	cis	rs2284378	0.515	rs6059579	ENSG00000271803.1	RP1-63M2.5	3.85	0.000155	0.0462	0.3	0.25	Breast cancer;	chr20:33940059	chr20:33674517~33675380:+
OV	cis	rs13272623	0.536	rs11985127	ENSG00000223220.1	Y_RNA	-3.85	0.000155	0.0462	-0.36	-0.25	IgG glycosylation;	chr8:70831708	chr8:70780914~70781008:-
OV	cis	rs6893300	0.785	rs58386410	ENSG00000229721.3	RP11-252I14.1	3.85	0.000155	0.0462	0.3	0.25	Resting heart rate;	chr5:179778703	chr5:180226378~180227000:-
OV	cis	rs6893300	0.785	rs17617710	ENSG00000229721.3	RP11-252I14.1	3.85	0.000155	0.0462	0.3	0.25	Resting heart rate;	chr5:179779106	chr5:180226378~180227000:-
OV	cis	rs2227564	0.62	rs11000785	ENSG00000271816.1	BMS1P4	3.85	0.000155	0.0462	0.25	0.25	Crohn's disease;Inflammatory bowel disease;	chr10:73816205	chr10:73699151~73730487:-
OV	cis	rs2302729	0.578	rs7315556	ENSG00000246627.5	CACNA1C-AS1	3.85	0.000155	0.0462	0.26	0.25	Sleep quality;	chr12:2664689	chr12:2676001~2691200:-
OV	cis	rs10754283	0.901	rs10922684	ENSG00000231613.1	RP5-943J3.1	3.85	0.000155	0.0462	0.27	0.25	Amyotrophic lateral sclerosis (sporadic);	chr1:89652375	chr1:89788914~89790492:+
OV	cis	rs7121800	0.962	rs11031119	ENSG00000242353.1	RP4-710M3.1	-3.85	0.000155	0.0462	-0.3	-0.25	Pit-and-Fissure caries;	chr11:30504226	chr11:30368148~30368646:+
OV	cis	rs41271951	0.542	rs66866430	ENSG00000223945.2	RP11-458I7.1	-3.85	0.000155	0.0462	-0.44	-0.25	Blood protein levels;	chr1:150527609	chr1:150053864~150055034:+
OV	cis	rs2282300	0.637	rs13642	ENSG00000242353.1	RP4-710M3.1	-3.85	0.000155	0.0462	-0.3	-0.25	Morning vs. evening chronotype;	chr11:30410673	chr11:30368148~30368646:+
OV	cis	rs6723108	0.603	rs6733130	ENSG00000224043.6	CCNT2-AS1	-3.85	0.000155	0.0462	-0.3	-0.25	Type 2 diabetes;	chr2:134908983	chr2:134735464~134918710:-
OV	cis	rs6723108	0.627	rs1374287	ENSG00000224043.6	CCNT2-AS1	-3.85	0.000155	0.0462	-0.3	-0.25	Type 2 diabetes;	chr2:134909631	chr2:134735464~134918710:-
OV	cis	rs7267979	0.773	rs6132821	ENSG00000274973.1	RP13-401N8.7	-3.85	0.000155	0.0462	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25245556	chr20:25845497~25845862:+
OV	cis	rs7267979	0.873	rs6132822	ENSG00000274973.1	RP13-401N8.7	-3.85	0.000155	0.0462	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25248059	chr20:25845497~25845862:+
OV	cis	rs7267979	0.844	rs1555330	ENSG00000274973.1	RP13-401N8.7	-3.85	0.000155	0.0462	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25251461	chr20:25845497~25845862:+
OV	cis	rs7267979	0.844	rs6107017	ENSG00000274973.1	RP13-401N8.7	-3.85	0.000155	0.0462	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25251664	chr20:25845497~25845862:+
OV	cis	rs7267979	0.844	rs6132824	ENSG00000274973.1	RP13-401N8.7	-3.85	0.000155	0.0462	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25257537	chr20:25845497~25845862:+
OV	cis	rs7267979	0.739	rs6138555	ENSG00000274973.1	RP13-401N8.7	-3.85	0.000155	0.0462	-0.28	-0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25262274	chr20:25845497~25845862:+
OV	cis	rs10754283	0.901	rs10922683	ENSG00000231613.1	RP5-943J3.1	3.85	0.000155	0.0463	0.26	0.25	Amyotrophic lateral sclerosis (sporadic);	chr1:89650509	chr1:89788914~89790492:+
OV	cis	rs10754283	0.967	rs4658307	ENSG00000231613.1	RP5-943J3.1	3.85	0.000155	0.0463	0.26	0.25	Amyotrophic lateral sclerosis (sporadic);	chr1:89652027	chr1:89788914~89790492:+
OV	cis	rs2599510	0.811	rs62136345	ENSG00000279544.1	AL133243.4	-3.85	0.000156	0.0463	-0.23	-0.25	Interleukin-18 levels;	chr2:32582156	chr2:32563328~32566436:+
OV	cis	rs6101567	0.623	rs6129277	ENSG00000261431.1	RP4-616B8.4	3.85	0.000156	0.0463	0.25	0.25	Nose size;	chr20:39359811	chr20:38961925~38962111:-
OV	cis	rs7259376	0.623	rs59533346	ENSG00000269742.1	BNIP3P29	3.85	0.000156	0.0463	0.29	0.25	Menopause (age at onset);	chr19:22301380	chr19:22065828~22066398:-
OV	cis	rs7259376	0.593	rs1091180	ENSG00000269742.1	BNIP3P29	-3.85	0.000156	0.0463	-0.29	-0.25	Menopause (age at onset);	chr19:22294080	chr19:22065828~22066398:-
OV	cis	rs9733	0.818	rs11204702	ENSG00000277452.1	Metazoa_SRP	-3.85	0.000156	0.0463	-0.27	-0.25	Tonsillectomy;	chr1:150691031	chr1:150566562~150566860:-
OV	cis	rs638893	1	rs583905	ENSG00000278376.1	RP11-158I9.8	-3.85	0.000156	0.0463	-0.31	-0.25	Vitiligo;	chr11:118825199	chr11:118791254~118793137:+
OV	cis	rs7646881	0.544	rs41272617	ENSG00000272087.1	RP11-379F4.7	3.85	0.000156	0.0463	0.35	0.25	Tetralogy of Fallot;	chr3:158603103	chr3:158693120~158693768:-
OV	cis	rs7646881	0.544	rs73024790	ENSG00000272087.1	RP11-379F4.7	3.85	0.000156	0.0463	0.35	0.25	Tetralogy of Fallot;	chr3:158606615	chr3:158693120~158693768:-
OV	cis	rs7646881	0.544	rs16829135	ENSG00000272087.1	RP11-379F4.7	3.85	0.000156	0.0463	0.35	0.25	Tetralogy of Fallot;	chr3:158608049	chr3:158693120~158693768:-
OV	cis	rs4722166	0.695	rs7808122	ENSG00000179428.2	AC073072.5	-3.85	0.000156	0.0463	-0.31	-0.25	Lung cancer;	chr7:22758461	chr7:22725395~22727620:-
OV	cis	rs1153858	1	rs11858495	ENSG00000179523.4	EIF3J-AS1	3.85	0.000156	0.0463	0.26	0.25	Homoarginine levels;	chr15:45345464	chr15:44527257~44536923:-
OV	cis	rs6142102	0.923	rs6059635	ENSG00000264616.1	MIR4755	3.85	0.000156	0.0463	0.31	0.25	Skin pigmentation;	chr20:34025687	chr20:34049119~34049190:+
OV	cis	rs5754266	0.545	rs713685	ENSG00000224050.1	RP1-90G24.6	-3.85	0.000156	0.0463	-0.47	-0.25	Blood protein levels;	chr22:32812451	chr22:32273420~32277186:+
OV	cis	rs853679	0.556	rs13200214	ENSG00000226314.6	ZNF192P1	-3.85	0.000156	0.0463	-0.56	-0.25	Depression;	chr6:28049472	chr6:28161781~28169594:+
OV	cis	rs9649213	0.593	rs6945554	ENSG00000272950.1	RP11-307C18.1	3.85	0.000156	0.0464	0.29	0.25	Prostate cancer (SNP x SNP interaction);	chr7:98343634	chr7:98322853~98323430:+
OV	cis	rs9649213	0.537	rs6971825	ENSG00000272950.1	RP11-307C18.1	3.85	0.000156	0.0464	0.29	0.25	Prostate cancer (SNP x SNP interaction);	chr7:98350236	chr7:98322853~98323430:+
OV	cis	rs7646881	0.544	rs61107068	ENSG00000272440.1	RP11-379F4.6	3.85	0.000156	0.0464	0.38	0.25	Tetralogy of Fallot;	chr3:158665915	chr3:158695367~158695581:+
OV	cis	rs2834288	0.5	rs7280837	ENSG00000273102.1	AP000569.9	3.85	0.000156	0.0464	0.26	0.25	Gut microbiota (bacterial taxa);	chr21:33951533	chr21:33967101~33968573:-
OV	cis	rs4964805	0.657	rs4964814	ENSG00000257681.1	RP11-341G23.4	-3.85	0.000156	0.0464	-0.27	-0.25	Attention deficit hyperactivity disorder;	chr12:103795606	chr12:103746315~103768858:-
OV	cis	rs9368481	0.645	rs10456350	ENSG00000241549.7	GUSBP2	3.85	0.000156	0.0464	0.24	0.25	Autism spectrum disorder or schizophrenia;	chr6:27007802	chr6:26871484~26956554:-
OV	cis	rs7520050	0.966	rs1768816	ENSG00000280836.1	AL355480.1	3.85	0.000156	0.0464	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:46062927	chr1:45581219~45581321:-
OV	cis	rs7520050	1	rs785511	ENSG00000280836.1	AL355480.1	3.85	0.000156	0.0464	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:46068826	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs809775	ENSG00000280836.1	AL355480.1	3.85	0.000156	0.0464	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:46072368	chr1:45581219~45581321:-
OV	cis	rs7927771	0.524	rs7939420	ENSG00000280615.1	Y_RNA	-3.85	0.000156	0.0464	-0.26	-0.25	Subjective well-being;	chr11:47702386	chr11:47614898~47614994:-
OV	cis	rs4950322	0.518	rs11811023	ENSG00000278811.3	LINC00624	-3.85	0.000156	0.0464	-0.3	-0.25	Protein quantitative trait loci;	chr1:147109536	chr1:147258885~147517875:-
OV	cis	rs7927592	0.763	rs7119422	ENSG00000222339.1	AP000807.2	-3.85	0.000156	0.0465	-0.25	-0.25	Total body bone mineral density;	chr11:68563686	chr11:68505572~68505651:-
OV	cis	rs7395581	0.918	rs10838693	ENSG00000271350.1	CTD-2384B9.1	3.85	0.000156	0.0465	0.28	0.25	HDL cholesterol;	chr11:47329002	chr11:47041027~47041945:-
OV	cis	rs7927592	0.513	rs531163	ENSG00000222339.1	AP000807.2	3.85	0.000156	0.0465	0.25	0.25	Total body bone mineral density;	chr11:68427028	chr11:68505572~68505651:-
OV	cis	rs4266144	1	rs12487629	ENSG00000244515.1	KRT18P34	-3.85	0.000156	0.0465	-0.31	-0.25	Coronary artery disease;	chr3:157134416	chr3:157162663~157163932:-
OV	cis	rs9649213	0.593	rs2240349	ENSG00000272950.1	RP11-307C18.1	3.85	0.000156	0.0465	0.29	0.25	Prostate cancer (SNP x SNP interaction);	chr7:98355351	chr7:98322853~98323430:+
OV	cis	rs9649213	0.593	rs6944262	ENSG00000272950.1	RP11-307C18.1	3.85	0.000156	0.0465	0.29	0.25	Prostate cancer (SNP x SNP interaction);	chr7:98356103	chr7:98322853~98323430:+
OV	cis	rs9649213	0.593	rs13307593	ENSG00000272950.1	RP11-307C18.1	3.85	0.000156	0.0465	0.29	0.25	Prostate cancer (SNP x SNP interaction);	chr7:98356834	chr7:98322853~98323430:+
OV	cis	rs7927592	0.913	rs10047412	ENSG00000212093.1	AP000807.1	3.85	0.000156	0.0465	0.31	0.25	Total body bone mineral density;	chr11:68465444	chr11:68506083~68506166:-
OV	cis	rs9687846	0.674	rs6867983	ENSG00000234553.1	AC022431.3	3.85	0.000157	0.0465	0.37	0.25	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);	chr5:56558326	chr5:56536583~56537826:-
OV	cis	rs4356975	0.563	rs7439152	ENSG00000251284.2	RP13-644M16.1	-3.84	0.000157	0.0465	-0.25	-0.25	Obesity-related traits;	chr4:69103288	chr4:69125274~69126451:+
OV	cis	rs11168618	0.567	rs12372687	ENSG00000258273.1	RP11-370I10.4	-3.84	0.000157	0.0465	-0.3	-0.25	Adiponectin levels;	chr12:48418016	chr12:48333755~48333901:-
OV	cis	rs801193	0.935	rs3800820	ENSG00000237310.1	GS1-124K5.4	-3.84	0.000157	0.0465	-0.26	-0.25	Aortic root size;	chr7:66682191	chr7:66493706~66495474:+
OV	cis	rs593531	0.614	rs10736795	ENSG00000280269.1	AP000577.2	-3.84	0.000157	0.0465	-0.29	-0.25	Neuroticism;	chr11:74328501	chr11:74204869~74205746:+
OV	cis	rs944801	0.631	rs10120688	ENSG00000234840.1	LINC01239	3.84	0.000157	0.0466	0.28	0.25	Type 2 diabetes;	chr9:22056500	chr9:22646200~22824213:+
OV	cis	rs8114671	0.967	rs1415774	ENSG00000269202.1	RP4-614O4.12	3.84	0.000157	0.0466	0.25	0.25	Height;	chr20:35177813	chr20:35201747~35203288:-
OV	cis	rs1560104	0.597	rs12162027	ENSG00000259899.1	CTD-3037G24.3	-3.84	0.000157	0.0466	-0.29	-0.25	Obesity-related traits;	chr16:12616235	chr16:12560756~12611044:-
OV	cis	rs9368481	0.645	rs10456350	ENSG00000261584.1	RP11-457M11.5	3.84	0.000157	0.0466	0.27	0.25	Autism spectrum disorder or schizophrenia;	chr6:27007802	chr6:26686241~26687964:+
OV	cis	rs7932354	0.666	rs6485696	ENSG00000271543.1	RP11-692M12.5	-3.84	0.000157	0.0466	-0.32	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:46820494	chr11:47796169~47796379:+
OV	cis	rs1923539	0.545	rs11201034	ENSG00000244733.5	RP11-506M13.3	3.84	0.000157	0.0466	0.3	0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79985611	chr10:79660891~79677996:+
OV	cis	rs4934494	0.727	rs67827533	ENSG00000240996.1	RP11-80H5.7	-3.84	0.000157	0.0466	-0.34	-0.25	Red blood cell count;	chr10:89745626	chr10:89694295~89697928:-
OV	cis	rs4934494	0.768	rs1926139	ENSG00000240996.1	RP11-80H5.7	-3.84	0.000157	0.0466	-0.34	-0.25	Red blood cell count;	chr10:89753395	chr10:89694295~89697928:-
OV	cis	rs4934494	0.727	rs55823491	ENSG00000240996.1	RP11-80H5.7	-3.84	0.000157	0.0466	-0.34	-0.25	Red blood cell count;	chr10:89757598	chr10:89694295~89697928:-
OV	cis	rs4934494	0.727	rs12570750	ENSG00000240996.1	RP11-80H5.7	-3.84	0.000157	0.0466	-0.34	-0.25	Red blood cell count;	chr10:89761273	chr10:89694295~89697928:-
OV	cis	rs4934494	0.723	rs17127001	ENSG00000240996.1	RP11-80H5.7	-3.84	0.000157	0.0466	-0.34	-0.25	Red blood cell count;	chr10:89762932	chr10:89694295~89697928:-
OV	cis	rs4934494	0.727	rs36019294	ENSG00000240996.1	RP11-80H5.7	-3.84	0.000157	0.0466	-0.34	-0.25	Red blood cell count;	chr10:89777822	chr10:89694295~89697928:-
OV	cis	rs12480328	1	rs76685994	ENSG00000233077.1	LINC01271	3.84	0.000157	0.0466	0.53	0.25	Prostate cancer;	chr20:50947674	chr20:50310711~50321342:-
OV	cis	rs3750965	0.959	rs4930265	ENSG00000260895.1	RP11-554A11.7	3.84	0.000157	0.0466	0.29	0.25	Hair color;	chr11:69088486	chr11:69103493~69109094:+
OV	cis	rs12468226	0.872	rs1061157	ENSG00000272966.1	RP11-686O6.1	3.84	0.000157	0.0467	0.45	0.25	Urate levels;	chr2:202556476	chr2:202336739~202337200:+
OV	cis	rs9287719	0.649	rs10186984	ENSG00000243819.4	RN7SL832P	-3.84	0.000157	0.0467	-0.24	-0.25	Prostate cancer;	chr2:10594066	chr2:10690344~10692099:+
OV	cis	rs7927592	0.913	rs7106339	ENSG00000212093.1	AP000807.1	3.84	0.000157	0.0467	0.31	0.25	Total body bone mineral density;	chr11:68472773	chr11:68506083~68506166:-
OV	cis	rs1707322	0.627	rs3014213	ENSG00000225447.1	RPS15AP10	-3.84	0.000157	0.0467	-0.24	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45579850	chr1:45645816~45646197:-
OV	cis	rs1707322	0.686	rs2152078	ENSG00000225447.1	RPS15AP10	-3.84	0.000157	0.0467	-0.24	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45589928	chr1:45645816~45646197:-
OV	cis	rs1707322	0.686	rs2991979	ENSG00000225447.1	RPS15AP10	-3.84	0.000157	0.0467	-0.24	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45590186	chr1:45645816~45646197:-
OV	cis	rs459193	0.636	rs455660	ENSG00000271828.1	CTD-2310F14.1	-3.84	0.000157	0.0467	-0.35	-0.25	Waist-to-hip ratio adjusted for BMI in non-smokers;Waist-to-hip ratio adjusted for BMI (joint analysis main effects and smoking interaction);Waist-hip ratio;Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (smoking interaction);Coronary artery disease;Type 2 diabetes;Waist-to-hip ratio adjusted for BMI (adjusted for smoking behaviour);	chr5:56521061	chr5:56927874~56929573:+
OV	cis	rs9880211	0.613	rs6767060	ENSG00000261758.1	RP11-102M11.2	-3.84	0.000157	0.0467	-0.31	-0.25	Height;Body mass index;	chr3:136148248	chr3:136752630~136755780:+
OV	cis	rs2243480	1	rs13220979	ENSG00000226824.5	RP4-756H11.3	-3.84	0.000158	0.0467	-0.39	-0.25	Diabetic kidney disease;	chr7:65898217	chr7:66654538~66669855:+
OV	cis	rs2243480	1	rs34974928	ENSG00000226824.5	RP4-756H11.3	-3.84	0.000158	0.0467	-0.39	-0.25	Diabetic kidney disease;	chr7:65899019	chr7:66654538~66669855:+
OV	cis	rs4430311	0.688	rs12142652	ENSG00000227230.1	RP11-261C10.5	3.84	0.000158	0.0467	0.27	0.25	Post-traumatic stress disorder (asjusted for relatedness);	chr1:243790281	chr1:243135898~243140588:+
OV	cis	rs9733	0.818	rs11204695	ENSG00000277452.1	Metazoa_SRP	-3.84	0.000158	0.0467	-0.27	-0.25	Tonsillectomy;	chr1:150684535	chr1:150566562~150566860:-
OV	cis	rs2834288	0.5	rs881231	ENSG00000273102.1	AP000569.9	3.84	0.000158	0.0467	0.26	0.25	Gut microbiota (bacterial taxa);	chr21:33950526	chr21:33967101~33968573:-
OV	cis	rs1061377	1	rs4974931	ENSG00000249685.1	RP11-360F5.3	3.84	0.000158	0.0468	0.29	0.25	Uric acid levels;	chr4:39108896	chr4:39133913~39135608:+
OV	cis	rs2274471	0.645	rs2104685	ENSG00000234534.1	CSNK1G2P1	3.84	0.000158	0.0468	0.31	0.25	Crohn's disease;	chr9:5106023	chr9:5040945~5041940:+
OV	cis	rs4591358	0.765	rs2063838	ENSG00000223466.1	AC064834.2	3.84	0.000158	0.0468	0.29	0.25	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195493578	chr2:195533035~195538681:+
OV	cis	rs2058350	0.773	rs719352	ENSG00000250770.2	RP5-1063M23.1	-3.84	0.000158	0.0468	-0.32	-0.25	Cognitive performance;	chr12:3833417	chr12:3296202~3300224:-
OV	cis	rs591584	0.59	rs7120587	ENSG00000255893.1	RP11-685N10.1	-3.84	0.000158	0.0468	-0.29	-0.25	Macrophage Migration Inhibitory Factor levels;	chr11:94586307	chr11:94472908~94473570:-
OV	cis	rs720475	0.732	rs73159066	ENSG00000204959.4	ARHGEF34P	-3.84	0.000158	0.0468	-0.37	-0.25	Breast cancer;	chr7:144426495	chr7:144272445~144286966:-
OV	cis	rs3750965	0.959	rs3376	ENSG00000260895.1	RP11-554A11.7	3.84	0.000158	0.0468	0.29	0.25	Hair color;	chr11:69089212	chr11:69103493~69109094:+
OV	cis	rs3750965	0.959	rs2253658	ENSG00000260895.1	RP11-554A11.7	3.84	0.000158	0.0468	0.29	0.25	Hair color;	chr11:69089336	chr11:69103493~69109094:+
OV	cis	rs71520386	0.632	rs10224419	ENSG00000221740.1	SNORD93	3.84	0.000158	0.0468	0.3	0.25	Fibrinogen levels;	chr7:22830397	chr7:22856613~22856686:+
OV	cis	rs875971	0.965	rs7794930	ENSG00000237310.1	GS1-124K5.4	-3.84	0.000158	0.0468	-0.25	-0.25	Aortic root size;	chr7:66313559	chr7:66493706~66495474:+
OV	cis	rs9649213	0.537	rs35997266	ENSG00000272950.1	RP11-307C18.1	3.84	0.000158	0.0468	0.29	0.25	Prostate cancer (SNP x SNP interaction);	chr7:98336254	chr7:98322853~98323430:+
OV	cis	rs4713118	0.869	rs7773070	ENSG00000226314.6	ZNF192P1	-3.84	0.000158	0.0468	-0.3	-0.25	Parkinson's disease;	chr6:27761048	chr6:28161781~28169594:+
OV	cis	rs1075265	0.611	rs11684084	ENSG00000233266.1	HMGB1P31	3.84	0.000158	0.0468	0.3	0.25	Chronotype;Morning vs. evening chronotype;	chr2:53695806	chr2:54051334~54051760:+
OV	cis	rs10992471	0.603	rs4743873	ENSG00000281156.1	MIR3651	3.84	0.000158	0.0468	0.28	0.25	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92508499	chr9:92292458~92292547:-
OV	cis	rs10504130	0.569	rs10958305	ENSG00000272024.1	RP11-546K22.3	-3.84	0.000158	0.0468	-0.32	-0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:51906464	chr8:51950284~51950690:+
OV	cis	rs10504130	0.569	rs11784869	ENSG00000272024.1	RP11-546K22.3	-3.84	0.000158	0.0468	-0.32	-0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:51906951	chr8:51950284~51950690:+
OV	cis	rs4964805	1	rs11111792	ENSG00000257681.1	RP11-341G23.4	3.84	0.000158	0.0469	0.31	0.25	Attention deficit hyperactivity disorder;	chr12:103801079	chr12:103746315~103768858:-
OV	cis	rs1105307	0.798	rs7851858	ENSG00000229312.2	RP11-470P21.2	-3.84	0.000158	0.0469	-0.29	-0.25	Cognitive ability;Cognitive ability (multi-trait analysis);	chr9:69533576	chr9:69472466~69494513:+
OV	cis	rs4132509	0.947	rs320339	ENSG00000227230.1	RP11-261C10.5	-3.84	0.000158	0.0469	-0.3	-0.25	RR interval (heart rate);	chr1:243707608	chr1:243135898~243140588:+
OV	cis	rs11037575	0.739	rs10838151	ENSG00000246250.2	RP11-613D13.5	3.84	0.000158	0.0469	0.27	0.25	Neuroblastoma;	chr11:43686859	chr11:43829709~43880726:-
OV	cis	rs941207	0.526	rs7303216	ENSG00000241217.3	RN7SL809P	3.84	0.000158	0.0469	0.25	0.25	Platelet count;	chr12:56680909	chr12:56670450~56670746:-
OV	cis	rs941207	0.507	rs7297289	ENSG00000241217.3	RN7SL809P	3.84	0.000158	0.0469	0.25	0.25	Platelet count;	chr12:56682703	chr12:56670450~56670746:-
OV	cis	rs941207	0.526	rs4759028	ENSG00000241217.3	RN7SL809P	3.84	0.000158	0.0469	0.25	0.25	Platelet count;	chr12:56686399	chr12:56670450~56670746:-
OV	cis	rs10924970	0.805	rs12030234	ENSG00000236863.2	RPL23AP23	3.84	0.000158	0.0469	0.24	0.25	Asthma;	chr1:235354242	chr1:235295865~235296335:+
OV	cis	rs6429082	0.509	rs12027995	ENSG00000236863.2	RPL23AP23	3.84	0.000158	0.0469	0.24	0.25	Adiposity;	chr1:235354292	chr1:235295865~235296335:+
OV	cis	rs2999052	0.708	rs6785384	ENSG00000277250.1	Metazoa_SRP	3.84	0.000158	0.0469	0.35	0.25	Hypospadias;	chr3:128358759	chr3:128673681~128674021:-
OV	cis	rs2999052	0.708	rs1735545	ENSG00000277250.1	Metazoa_SRP	3.84	0.000158	0.0469	0.35	0.25	Hypospadias;	chr3:128362417	chr3:128673681~128674021:-
OV	cis	rs66530629	0.874	rs6667299	ENSG00000264443.1	RP4-594I10.3	-3.84	0.000158	0.0469	-0.29	-0.25	Plateletcrit;	chr1:24832009	chr1:24538802~24556024:-
OV	cis	rs4512344	0.509	rs2409784	ENSG00000254866.2	DEFB109P3	3.84	0.000158	0.0469	0.34	0.25	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11539347	chr8:12150895~12151134:-
OV	cis	rs11951515	0.738	rs4866825	ENSG00000278487.1	RP11-447H19.4	-3.84	0.000158	0.0469	-0.29	-0.25	Metabolite levels  (X-11787);	chr5:43359517	chr5:43143362~43143514:-
OV	cis	rs7395581	0.918	rs1449627	ENSG00000271350.1	CTD-2384B9.1	3.84	0.000158	0.0469	0.28	0.25	HDL cholesterol;	chr11:47269433	chr11:47041027~47041945:-
OV	cis	rs7395581	0.918	rs1055510	ENSG00000271350.1	CTD-2384B9.1	3.84	0.000158	0.0469	0.28	0.25	HDL cholesterol;	chr11:47270686	chr11:47041027~47041945:-
OV	cis	rs7395581	0.918	rs10742799	ENSG00000271350.1	CTD-2384B9.1	3.84	0.000158	0.0469	0.28	0.25	HDL cholesterol;	chr11:47272151	chr11:47041027~47041945:-
OV	cis	rs6691738	0.959	rs7553711	ENSG00000203739.3	RP11-296O14.3	3.84	0.000159	0.0469	0.26	0.25	Asthma;	chr1:173162769	chr1:173417793~173461362:-
OV	cis	rs514406	0.505	rs436363	ENSG00000206627.1	RNU6-969P	3.84	0.000159	0.0469	0.26	0.25	Monocyte count;	chr1:52706491	chr1:52805108~52805212:-
OV	cis	rs896854	0.818	rs13262110	ENSG00000253528.2	RP11-347C18.4	3.84	0.000159	0.047	0.24	0.25	Type 2 diabetes;	chr8:94914662	chr8:94974573~94974853:-
OV	cis	rs8114671	0.967	rs6088753	ENSG00000269202.1	RP4-614O4.12	-3.84	0.000159	0.047	-0.25	-0.25	Height;	chr20:35180449	chr20:35201747~35203288:-
OV	cis	rs7615952	0.515	rs4267608	ENSG00000171084.14	FAM86JP	3.84	0.000159	0.047	0.4	0.25	Blood pressure (smoking interaction);	chr3:125961657	chr3:125916620~125930024:+
OV	cis	rs853679	0.546	rs35353359	ENSG00000226314.6	ZNF192P1	-3.84	0.000159	0.047	-0.59	-0.25	Depression;	chr6:28356601	chr6:28161781~28169594:+
OV	cis	rs17401966	0.931	rs11585794	ENSG00000199562.1	RNU6-37P	3.84	0.000159	0.047	0.28	0.25	Hepatocellular carcinoma;	chr1:10383809	chr1:10298966~10299072:+
OV	cis	rs853679	0.546	rs35353359	ENSG00000280107.1	AL022393.9	-3.84	0.000159	0.0471	-0.56	-0.25	Depression;	chr6:28356601	chr6:28170845~28172521:+
OV	cis	rs7246657	0.714	rs12972195	ENSG00000226686.6	LINC01535	-3.84	0.000159	0.0471	-0.38	-0.25	Coronary artery calcification;	chr19:37261603	chr19:37251912~37265535:+
OV	cis	rs6445967	1	rs62259324	ENSG00000272360.1	RP11-359I18.5	3.84	0.000159	0.0471	0.27	0.25	Platelet count;	chr3:58305380	chr3:58490830~58491291:-
OV	cis	rs10504130	0.502	rs12674620	ENSG00000272024.1	RP11-546K22.3	3.84	0.000159	0.0471	0.33	0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:51755043	chr8:51950284~51950690:+
OV	cis	rs3734266	0.702	rs11966100	ENSG00000220643.1	RP3-391O22.1	-3.84	0.000159	0.0471	-0.42	-0.25	Systemic lupus erythematosus;	chr6:34839740	chr6:34686602~34687106:+
OV	cis	rs3734266	0.702	rs34480956	ENSG00000220643.1	RP3-391O22.1	-3.84	0.000159	0.0471	-0.42	-0.25	Systemic lupus erythematosus;	chr6:34840324	chr6:34686602~34687106:+
OV	cis	rs875971	0.66	rs7807930	ENSG00000237310.1	GS1-124K5.4	-3.84	0.000159	0.0471	-0.25	-0.25	Aortic root size;	chr7:66622178	chr7:66493706~66495474:+
OV	cis	rs875971	0.66	rs7807944	ENSG00000237310.1	GS1-124K5.4	-3.84	0.000159	0.0471	-0.25	-0.25	Aortic root size;	chr7:66622208	chr7:66493706~66495474:+
OV	cis	rs10214930	0.602	rs2098315	ENSG00000235574.1	AC073150.6	-3.84	0.000159	0.0471	-0.3	-0.25	Hypospadias;	chr7:27541026	chr7:27491682~27492765:-
OV	cis	rs7646881	0.544	rs3817373	ENSG00000272087.1	RP11-379F4.7	3.84	0.000159	0.0471	0.36	0.25	Tetralogy of Fallot;	chr3:158571246	chr3:158693120~158693768:-
OV	cis	rs7646881	0.544	rs4368546	ENSG00000272087.1	RP11-379F4.7	3.84	0.000159	0.0471	0.36	0.25	Tetralogy of Fallot;	chr3:158574361	chr3:158693120~158693768:-
OV	cis	rs7646881	0.544	rs73022770	ENSG00000272087.1	RP11-379F4.7	3.84	0.000159	0.0471	0.36	0.25	Tetralogy of Fallot;	chr3:158576506	chr3:158693120~158693768:-
OV	cis	rs875971	0.545	rs17138156	ENSG00000273024.4	INTS4P2	-3.84	0.000159	0.0471	-0.3	-0.25	Aortic root size;	chr7:66249708	chr7:65647864~65715661:+
OV	cis	rs2436845	0.627	rs2679750	ENSG00000253385.1	KB-1254G8.1	-3.84	0.000159	0.0471	-0.31	-0.25	Granulocyte count;Sum basophil neutrophil counts;Neutrophil count;Sum neutrophil eosinophil counts;	chr8:102848164	chr8:102854455~102856075:+
OV	cis	rs4478239	1	rs6553051	ENSG00000213332.4	SLC25A5P6	-3.84	0.000159	0.0471	-0.52	-0.25	Major depressive disorder;	chr4:187268963	chr4:186328716~186329601:-
OV	cis	rs4665809	1	rs4665811	ENSG00000231655.1	AC011742.3	3.84	0.000159	0.0471	0.36	0.25	Gut microbiome composition (summer);	chr2:26037148	chr2:26140263~26141264:-
OV	cis	rs4665809	1	rs1371553	ENSG00000231655.1	AC011742.3	3.84	0.000159	0.0471	0.36	0.25	Gut microbiome composition (summer);	chr2:26040079	chr2:26140263~26141264:-
OV	cis	rs4665809	0.887	rs6546716	ENSG00000231655.1	AC011742.3	3.84	0.000159	0.0471	0.36	0.25	Gut microbiome composition (summer);	chr2:26040967	chr2:26140263~26141264:-
OV	cis	rs9880211	0.563	rs1393787	ENSG00000239213.4	NCK1-AS1	3.84	0.000159	0.0471	0.3	0.25	Height;Body mass index;	chr3:136135359	chr3:136841726~136862054:-
OV	cis	rs72820985	1	rs16954075	ENSG00000260213.4	RP11-303E16.3	-3.84	0.000159	0.0472	-0.28	-0.25	Breast cancer;	chr16:80813665	chr16:81016792~81035759:-
OV	cis	rs295140	0.507	rs4673814	ENSG00000232732.8	AC073043.1	3.84	0.000159	0.0472	0.29	0.25	QT interval;	chr2:200243410	chr2:199867396~199911159:-
OV	cis	rs896854	0.738	rs481887	ENSG00000253528.2	RP11-347C18.4	-3.84	0.000159	0.0472	-0.25	-0.25	Type 2 diabetes;	chr8:94955610	chr8:94974573~94974853:-
OV	cis	rs3124314	1	rs4845420	ENSG00000237975.5	FLG-AS1	3.84	0.00016	0.0472	0.32	0.25	Hair morphology;	chr1:152168728	chr1:152168125~152445456:+
OV	cis	rs1707322	0.655	rs3014240	ENSG00000234329.1	RP11-767N6.2	-3.84	0.00016	0.0472	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45623553	chr1:45651039~45651826:-
OV	cis	rs1707322	0.686	rs3014235	ENSG00000234329.1	RP11-767N6.2	-3.84	0.00016	0.0472	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45625840	chr1:45651039~45651826:-
OV	cis	rs1707322	0.656	rs9429172	ENSG00000234329.1	RP11-767N6.2	-3.84	0.00016	0.0472	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45626804	chr1:45651039~45651826:-
OV	cis	rs1707322	0.717	rs1135850	ENSG00000234329.1	RP11-767N6.2	3.84	0.00016	0.0472	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45628020	chr1:45651039~45651826:-
OV	cis	rs12681366	0.734	rs16916802	ENSG00000253704.1	RP11-267M23.4	3.84	0.00016	0.0472	0.29	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94397280	chr8:94553722~94569745:+
OV	cis	rs2286503	0.78	rs1304431	ENSG00000228649.7	AC005682.5	3.84	0.00016	0.0472	0.31	0.25	Fibrinogen;	chr7:22825793	chr7:22854178~22861579:+
OV	cis	rs9880211	0.8	rs36109616	ENSG00000239213.4	NCK1-AS1	3.84	0.00016	0.0472	0.31	0.25	Height;Body mass index;	chr3:136773561	chr3:136841726~136862054:-
OV	cis	rs9880211	0.8	rs35198484	ENSG00000239213.4	NCK1-AS1	3.84	0.00016	0.0472	0.31	0.25	Height;Body mass index;	chr3:136773795	chr3:136841726~136862054:-
OV	cis	rs9880211	0.66	rs9289514	ENSG00000239213.4	NCK1-AS1	3.84	0.00016	0.0472	0.31	0.25	Height;Body mass index;	chr3:136774361	chr3:136841726~136862054:-
OV	cis	rs9880211	0.8	rs79876804	ENSG00000239213.4	NCK1-AS1	3.84	0.00016	0.0472	0.31	0.25	Height;Body mass index;	chr3:136775308	chr3:136841726~136862054:-
OV	cis	rs9880211	0.8	rs35210994	ENSG00000239213.4	NCK1-AS1	3.84	0.00016	0.0472	0.31	0.25	Height;Body mass index;	chr3:136777294	chr3:136841726~136862054:-
OV	cis	rs853679	1	rs7740487	ENSG00000220721.1	OR1F12	3.84	0.00016	0.0472	0.37	0.25	Depression;	chr6:28248708	chr6:28073316~28074233:+
OV	cis	rs4713118	0.869	rs9283883	ENSG00000226314.6	ZNF192P1	-3.84	0.00016	0.0472	-0.3	-0.25	Parkinson's disease;	chr6:27747691	chr6:28161781~28169594:+
OV	cis	rs732765	0.657	rs1143454	ENSG00000258439.1	RP11-173A8.2	3.84	0.00016	0.0472	0.38	0.25	Non-small cell lung cancer;	chr14:74803030	chr14:74658049~74658590:+
OV	cis	rs732765	0.657	rs2270429	ENSG00000258439.1	RP11-173A8.2	3.84	0.00016	0.0472	0.38	0.25	Non-small cell lung cancer;	chr14:74803306	chr14:74658049~74658590:+
OV	cis	rs732765	0.657	rs11159103	ENSG00000258439.1	RP11-173A8.2	3.84	0.00016	0.0472	0.38	0.25	Non-small cell lung cancer;	chr14:74804651	chr14:74658049~74658590:+
OV	cis	rs732765	0.657	rs28499170	ENSG00000258439.1	RP11-173A8.2	3.84	0.00016	0.0472	0.38	0.25	Non-small cell lung cancer;	chr14:74807450	chr14:74658049~74658590:+
OV	cis	rs732765	0.657	rs1057552	ENSG00000258439.1	RP11-173A8.2	3.84	0.00016	0.0472	0.38	0.25	Non-small cell lung cancer;	chr14:74828415	chr14:74658049~74658590:+
OV	cis	rs732765	0.657	rs59187510	ENSG00000258439.1	RP11-173A8.2	3.84	0.00016	0.0472	0.38	0.25	Non-small cell lung cancer;	chr14:74831073	chr14:74658049~74658590:+
OV	cis	rs732765	0.657	rs17782755	ENSG00000258439.1	RP11-173A8.2	3.84	0.00016	0.0472	0.38	0.25	Non-small cell lung cancer;	chr14:74837612	chr14:74658049~74658590:+
OV	cis	rs732765	0.657	rs17183215	ENSG00000258439.1	RP11-173A8.2	3.84	0.00016	0.0472	0.38	0.25	Non-small cell lung cancer;	chr14:74839724	chr14:74658049~74658590:+
OV	cis	rs6142102	0.602	rs4911396	ENSG00000276073.1	RP5-1125A11.7	-3.84	0.00016	0.0472	-0.29	-0.25	Skin pigmentation;	chr20:33992139	chr20:33985617~33988989:-
OV	cis	rs1707322	0.686	rs2050376	ENSG00000225447.1	RPS15AP10	3.84	0.00016	0.0472	0.23	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45612958	chr1:45645816~45646197:-
OV	cis	rs514406	0.547	rs377808	ENSG00000206627.1	RNU6-969P	3.84	0.00016	0.0472	0.27	0.25	Monocyte count;	chr1:52724687	chr1:52805108~52805212:-
OV	cis	rs8054556	0.787	rs11642612	ENSG00000261367.1	RP11-455F5.4	-3.84	0.00016	0.0472	-0.3	-0.25	Autism spectrum disorder or schizophrenia;	chr16:30018874	chr16:30107675~30110541:+
OV	cis	rs8054556	0.787	rs11150581	ENSG00000261367.1	RP11-455F5.4	-3.84	0.00016	0.0472	-0.3	-0.25	Autism spectrum disorder or schizophrenia;	chr16:30019378	chr16:30107675~30110541:+
OV	cis	rs875971	0.825	rs1000464	ENSG00000237310.1	GS1-124K5.4	-3.84	0.00016	0.0472	-0.25	-0.25	Aortic root size;	chr7:66312922	chr7:66493706~66495474:+
OV	cis	rs7667	0.846	rs12405176	ENSG00000240490.3	RN7SL277P	-3.84	0.00016	0.0473	-0.3	-0.25	Crohn's disease and psoriasis;	chr1:19431012	chr1:19424384~19424671:+
OV	cis	rs11105298	0.891	rs10858889	ENSG00000257194.2	RP11-567C2.1	-3.84	0.00016	0.0473	-0.36	-0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89508827	chr12:90107739~90112779:+
OV	cis	rs3124314	1	rs10788821	ENSG00000237975.5	FLG-AS1	3.84	0.00016	0.0473	0.32	0.25	Hair morphology;	chr1:152168905	chr1:152168125~152445456:+
OV	cis	rs4918798	0.901	rs17442946	ENSG00000234724.1	HDAC1P1	3.84	0.00016	0.0473	0.36	0.25	Warfarin maintenance dose;	chr10:94874432	chr10:94137748~94139500:+
OV	cis	rs4918798	0.901	rs61888393	ENSG00000234724.1	HDAC1P1	3.84	0.00016	0.0473	0.36	0.25	Warfarin maintenance dose;	chr10:94877333	chr10:94137748~94139500:+
OV	cis	rs10740039	0.81	rs1006956	ENSG00000254271.1	RP11-131N11.4	-3.84	0.00016	0.0473	-0.32	-0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60608218	chr10:60734342~60741828:+
OV	cis	rs1765142	0.55	rs667511	ENSG00000254532.1	RP11-624D11.2	3.84	0.00016	0.0474	0.3	0.25	Schizophrenia;	chr11:30404108	chr11:30044058~30084343:-
OV	cis	rs76210638	1	rs12430966	ENSG00000232986.1	RP11-179A7.2	-3.84	0.00016	0.0474	-0.54	-0.25	Facial morphology (factor 13, vertical position of alar curvature relative to upper lip);	chr13:33933896	chr13:33657436~33659928:+
OV	cis	rs801193	1	rs2659909	ENSG00000224316.1	RP11-479O9.2	3.84	0.00016	0.0474	0.26	0.25	Aortic root size;	chr7:66695292	chr7:65773620~65802067:+
OV	cis	rs10754283	0.84	rs6428560	ENSG00000231613.1	RP5-943J3.1	3.84	0.00016	0.0474	0.26	0.25	Amyotrophic lateral sclerosis (sporadic);	chr1:89636903	chr1:89788914~89790492:+
OV	cis	rs12681366	0.881	rs2960121	ENSG00000253704.1	RP11-267M23.4	3.84	0.000161	0.0474	0.35	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94417678	chr8:94553722~94569745:+
OV	cis	rs9847710	0.901	rs2564964	ENSG00000242142.1	SERBP1P3	3.84	0.000161	0.0474	0.3	0.25	Ulcerative colitis;	chr3:53004102	chr3:53064283~53065091:-
OV	cis	rs2111504	0.559	rs7250813	ENSG00000267213.4	AC007773.2	3.84	0.000161	0.0474	0.33	0.25	Bipolar disorder;	chr19:32358815	chr19:32390050~32405560:-
OV	cis	rs2243480	1	rs383402	ENSG00000226824.5	RP4-756H11.3	3.84	0.000161	0.0474	0.37	0.25	Diabetic kidney disease;	chr7:66121666	chr7:66654538~66669855:+
OV	cis	rs6445967	1	rs6777105	ENSG00000272360.1	RP11-359I18.5	3.84	0.000161	0.0475	0.26	0.25	Platelet count;	chr3:58321917	chr3:58490830~58491291:-
OV	cis	rs1799810	0.64	rs55998444	ENSG00000236682.1	AC068282.3	-3.84	0.000161	0.0475	-0.33	-0.25	Self-rated health;	chr2:127362270	chr2:127389130~127400580:+
OV	cis	rs867186	0.748	rs6058181	ENSG00000230155.5	RP3-477O4.14	3.84	0.000161	0.0475	0.37	0.25	Factor VII levels;D-dimer levels;Blood protein levels;Anticoagulant levels;Coronary artery disease;Hemostatic factors and hematological phenotypes;Protein C levels;	chr20:35106998	chr20:35476203~35490982:-
OV	cis	rs7395581	0.877	rs7127907	ENSG00000271350.1	CTD-2384B9.1	3.84	0.000161	0.0475	0.28	0.25	HDL cholesterol;	chr11:47302921	chr11:47041027~47041945:-
OV	cis	rs78905543	1	rs4872049	ENSG00000253616.4	RP11-875O11.3	-3.84	0.000161	0.0475	-0.29	-0.25	Mean corpuscular volume;	chr8:23074266	chr8:23071377~23074488:-
OV	cis	rs4664293	0.625	rs11899419	ENSG00000224152.1	AC009506.1	3.84	0.000161	0.0475	0.25	0.25	Monocyte percentage of white cells;	chr2:159688858	chr2:159615296~159617082:+
OV	cis	rs1113500	0.548	rs3853497	ENSG00000226822.1	RP11-356N1.2	3.84	0.000161	0.0475	0.31	0.25	Growth-regulated protein alpha levels;	chr1:108114562	chr1:108071482~108074519:+
OV	cis	rs7246657	0.943	rs10409204	ENSG00000226686.6	LINC01535	-3.84	0.000161	0.0475	-0.39	-0.25	Coronary artery calcification;	chr19:37426790	chr19:37251912~37265535:+
OV	cis	rs12973620	1	rs12973620	ENSG00000268660.1	LETM1P2	3.84	0.000161	0.0475	0.35	0.25	Allergic rhinitis;	chr19:57738275	chr19:58044592~58046769:+
OV	cis	rs507080	0.922	rs592280	ENSG00000278376.1	RP11-158I9.8	-3.84	0.000161	0.0475	-0.25	-0.25	Serum metabolite levels;	chr11:118682509	chr11:118791254~118793137:+
OV	cis	rs8059260	0.604	rs741177	ENSG00000274038.1	RP11-66H6.4	-3.84	0.000161	0.0475	-0.49	-0.25	Alcohol consumption over the past year;	chr16:11051791	chr16:11056556~11057034:+
OV	cis	rs78545713	0.536	rs2179516	ENSG00000241549.7	GUSBP2	-3.84	0.000161	0.0475	-0.4	-0.25	Iron status biomarkers (total iron binding capacity);	chr6:26229183	chr6:26871484~26956554:-
OV	cis	rs73019876	0.68	rs807951	ENSG00000269742.1	BNIP3P29	3.84	0.000161	0.0475	0.28	0.25	Testicular germ cell tumor;	chr19:21937561	chr19:22065828~22066398:-
OV	cis	rs591584	0.73	rs72963846	ENSG00000255893.1	RP11-685N10.1	-3.84	0.000161	0.0475	-0.3	-0.25	Macrophage Migration Inhibitory Factor levels;	chr11:94574596	chr11:94472908~94473570:-
OV	cis	rs591584	0.73	rs10765688	ENSG00000255893.1	RP11-685N10.1	-3.84	0.000161	0.0475	-0.3	-0.25	Macrophage Migration Inhibitory Factor levels;	chr11:94576693	chr11:94472908~94473570:-
OV	cis	rs591584	0.73	rs72963850	ENSG00000255893.1	RP11-685N10.1	-3.84	0.000161	0.0475	-0.3	-0.25	Macrophage Migration Inhibitory Factor levels;	chr11:94577566	chr11:94472908~94473570:-
OV	cis	rs10501568	0.609	rs17807611	ENSG00000213305.3	HNRNPCP6	3.84	0.000161	0.0476	0.42	0.25	Chronic periodontitis;	chr11:84527856	chr11:85020785~85021655:-
OV	cis	rs9880211	0.8	rs9845862	ENSG00000239213.4	NCK1-AS1	3.84	0.000161	0.0476	0.32	0.25	Height;Body mass index;	chr3:136753731	chr3:136841726~136862054:-
OV	cis	rs6121246	0.529	rs2889528	ENSG00000230613.1	HM13-AS1	3.84	0.000161	0.0476	0.37	0.25	Mean corpuscular hemoglobin;	chr20:31622218	chr20:31567707~31573263:-
OV	cis	rs6121246	0.567	rs6088796	ENSG00000230613.1	HM13-AS1	3.84	0.000161	0.0476	0.37	0.25	Mean corpuscular hemoglobin;	chr20:31625426	chr20:31567707~31573263:-
OV	cis	rs6121246	0.567	rs6087700	ENSG00000230613.1	HM13-AS1	3.84	0.000161	0.0476	0.37	0.25	Mean corpuscular hemoglobin;	chr20:31629757	chr20:31567707~31573263:-
OV	cis	rs6121246	0.567	rs6087701	ENSG00000230613.1	HM13-AS1	3.84	0.000161	0.0476	0.37	0.25	Mean corpuscular hemoglobin;	chr20:31629905	chr20:31567707~31573263:-
OV	cis	rs6121246	0.529	rs6088814	ENSG00000230613.1	HM13-AS1	3.84	0.000161	0.0476	0.37	0.25	Mean corpuscular hemoglobin;	chr20:31630369	chr20:31567707~31573263:-
OV	cis	rs6121246	0.567	rs6120937	ENSG00000230613.1	HM13-AS1	3.84	0.000161	0.0476	0.37	0.25	Mean corpuscular hemoglobin;	chr20:31631918	chr20:31567707~31573263:-
OV	cis	rs506597	0.573	rs221780	ENSG00000263672.2	RN7SL750P	3.84	0.000161	0.0476	0.32	0.25	Pursuit maintenance gain in psychotic disorders;	chr7:100699412	chr7:100821027~100821264:-
OV	cis	rs4296809	0.505	rs4866862	ENSG00000249779.1	RP11-447H19.3	-3.84	0.000161	0.0476	-0.45	-0.25	Brain structure;	chr5:44109471	chr5:43206709~43207811:+
OV	cis	rs4296809	0.505	rs72753701	ENSG00000249779.1	RP11-447H19.3	-3.84	0.000161	0.0476	-0.45	-0.25	Brain structure;	chr5:44117797	chr5:43206709~43207811:+
OV	cis	rs10838687	1	rs10838687	ENSG00000271350.1	CTD-2384B9.1	3.84	0.000161	0.0476	0.32	0.25	Proinsulin levels;	chr11:47291341	chr11:47041027~47041945:-
OV	cis	rs7078012	1	rs7078012	ENSG00000244733.5	RP11-506M13.3	-3.84	0.000161	0.0476	-0.41	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:79945677	chr10:79660891~79677996:+
OV	cis	rs2286503	0.839	rs10276099	ENSG00000228649.7	AC005682.5	3.84	0.000161	0.0476	0.31	0.25	Fibrinogen;	chr7:22823331	chr7:22854178~22861579:+
OV	cis	rs6071524	0.508	rs2248447	ENSG00000277581.1	RP4-616B8.6	-3.84	0.000161	0.0476	-0.3	-0.25	Autism spectrum disorder or schizophrenia;	chr20:38772624	chr20:38962472~38962993:+
OV	cis	rs6071524	0.508	rs941513	ENSG00000277581.1	RP4-616B8.6	-3.84	0.000161	0.0476	-0.3	-0.25	Autism spectrum disorder or schizophrenia;	chr20:38774586	chr20:38962472~38962993:+
OV	cis	rs6071524	0.508	rs2748665	ENSG00000277581.1	RP4-616B8.6	-3.84	0.000161	0.0476	-0.3	-0.25	Autism spectrum disorder or schizophrenia;	chr20:38776701	chr20:38962472~38962993:+
OV	cis	rs6723108	0.627	rs7589297	ENSG00000224043.6	CCNT2-AS1	-3.84	0.000161	0.0476	-0.29	-0.25	Type 2 diabetes;	chr2:134894829	chr2:134735464~134918710:-
OV	cis	rs747650	0.884	rs7128325	ENSG00000271543.1	RP11-692M12.5	-3.84	0.000161	0.0476	-0.32	-0.25	Acne (severe);	chr11:47025003	chr11:47796169~47796379:+
OV	cis	rs7646881	0.583	rs2115942	ENSG00000272087.1	RP11-379F4.7	3.84	0.000161	0.0476	0.36	0.25	Tetralogy of Fallot;	chr3:158588841	chr3:158693120~158693768:-
OV	cis	rs7646881	0.544	rs73022798	ENSG00000272087.1	RP11-379F4.7	3.84	0.000161	0.0476	0.36	0.25	Tetralogy of Fallot;	chr3:158590099	chr3:158693120~158693768:-
OV	cis	rs2999052	1	rs872267	ENSG00000277250.1	Metazoa_SRP	3.84	0.000162	0.0476	0.3	0.25	Hypospadias;	chr3:128169224	chr3:128673681~128674021:-
OV	cis	rs2999052	1	rs2955120	ENSG00000277250.1	Metazoa_SRP	3.84	0.000162	0.0476	0.3	0.25	Hypospadias;	chr3:128169504	chr3:128673681~128674021:-
OV	cis	rs6723108	0.603	rs10187990	ENSG00000224043.6	CCNT2-AS1	-3.84	0.000162	0.0477	-0.29	-0.25	Type 2 diabetes;	chr2:134939987	chr2:134735464~134918710:-
OV	cis	rs992157	0.767	rs2382822	ENSG00000237281.1	CATIP-AS2	3.84	0.000162	0.0477	0.29	0.25	Colorectal cancer;	chr2:218308604	chr2:218326889~218357966:-
OV	cis	rs4132509	1	rs1458024	ENSG00000227230.1	RP11-261C10.5	-3.84	0.000162	0.0477	-0.3	-0.25	RR interval (heart rate);	chr1:243774143	chr1:243135898~243140588:+
OV	cis	rs2836974	0.604	rs2854727	ENSG00000237373.1	BRWD1-IT1	-3.84	0.000162	0.0477	-0.28	-0.25	Cognitive function;	chr21:39341861	chr21:39217093~39219805:-
OV	cis	rs11037575	0.933	rs10768970	ENSG00000246250.2	RP11-613D13.5	-3.84	0.000162	0.0477	-0.27	-0.25	Neuroblastoma;	chr11:43642966	chr11:43829709~43880726:-
OV	cis	rs2898681	1	rs2898681	ENSG00000248375.1	RP11-177B4.1	-3.84	0.000162	0.0477	-0.36	-0.25	Optic nerve measurement (cup area);	chr4:52890833	chr4:52720081~52720831:-
OV	cis	rs9386630	0.728	rs2430474	ENSG00000271734.1	RP1-111B22.3	-3.84	0.000162	0.0477	-0.27	-0.25	Coffee consumption;	chr6:107293464	chr6:108030249~108030718:-
OV	cis	rs1836229	0.57	rs7863423	ENSG00000225706.1	PTPRD-AS1	-3.84	0.000162	0.0477	-0.26	-0.25	Restless legs syndrome;	chr9:8824111	chr9:8858130~8862255:+
OV	cis	rs634537	0.525	rs496892	ENSG00000234840.1	LINC01239	-3.84	0.000162	0.0478	-0.28	-0.25	Glioma;Non-glioblastoma glioma;Glioblastoma;	chr9:22024352	chr9:22646200~22824213:+
OV	cis	rs858239	0.67	rs6967526	ENSG00000230042.1	AK3P3	-3.84	0.000162	0.0478	-0.25	-0.25	Cerebrospinal fluid biomarker levels;	chr7:23119622	chr7:23129178~23129841:+
OV	cis	rs6661961	0.752	rs7548609	ENSG00000237975.5	FLG-AS1	-3.84	0.000162	0.0478	-0.32	-0.25	Atopic dermatitis;	chr1:152457705	chr1:152168125~152445456:+
OV	cis	rs6661961	0.752	rs4845438	ENSG00000237975.5	FLG-AS1	-3.84	0.000162	0.0478	-0.32	-0.25	Atopic dermatitis;	chr1:152458037	chr1:152168125~152445456:+
OV	cis	rs4845570	1	rs3790514	ENSG00000203288.3	RP11-98D18.9	-3.84	0.000162	0.0478	-0.4	-0.25	Coronary artery disease;	chr1:151771692	chr1:151790804~151794402:+
OV	cis	rs6071166	0.774	rs6027213	ENSG00000174365.18	SNHG11	-3.84	0.000162	0.0478	-0.3	-0.25	circulating leptin levels adjusted for BMI;circulating leptin levels;	chr20:38676778	chr20:38446578~38450921:+
OV	cis	rs9393777	0.92	rs35120058	ENSG00000243307.2	POM121L6P	-3.84	0.000162	0.0478	-0.44	-0.25	Intelligence (multi-trait analysis);	chr6:27390387	chr6:26896952~26898777:+
OV	cis	rs599083	0.53	rs491347	ENSG00000212093.1	AP000807.1	-3.84	0.000162	0.0478	-0.3	-0.25	Bone mineral density (spine);	chr11:68402220	chr11:68506083~68506166:-
OV	cis	rs9733	0.791	rs11800059	ENSG00000277452.1	Metazoa_SRP	-3.84	0.000162	0.0478	-0.27	-0.25	Tonsillectomy;	chr1:150678699	chr1:150566562~150566860:-
OV	cis	rs7932354	0.528	rs11039112	ENSG00000271543.1	RP11-692M12.5	3.84	0.000162	0.0478	0.32	0.25	Bone mineral density (hip);Bone mineral density;	chr11:47152745	chr11:47796169~47796379:+
OV	cis	rs7246967	0.611	rs62118780	ENSG00000267920.1	SNX6P1	-3.84	0.000162	0.0478	-0.41	-0.25	Bronchopulmonary dysplasia;	chr19:22648312	chr19:23126569~23127792:-
OV	cis	rs7246967	0.611	rs4933019	ENSG00000267920.1	SNX6P1	-3.84	0.000162	0.0478	-0.41	-0.25	Bronchopulmonary dysplasia;	chr19:22649184	chr19:23126569~23127792:-
OV	cis	rs7246967	0.611	rs12983761	ENSG00000267920.1	SNX6P1	-3.84	0.000162	0.0478	-0.41	-0.25	Bronchopulmonary dysplasia;	chr19:22657795	chr19:23126569~23127792:-
OV	cis	rs11214589	1	rs11214589	ENSG00000270179.1	RP11-159N11.4	-3.84	0.000163	0.0479	-0.25	-0.25	Neuroticism;	chr11:113374326	chr11:113368478~113369117:+
OV	cis	rs1555322	0.53	rs2250205	ENSG00000279253.1	RP4-614O4.13	-3.84	0.000163	0.0479	-0.3	-0.25	Attention deficit hyperactivity disorder;	chr20:35280121	chr20:35262727~35264187:-
OV	cis	rs11951515	0.844	rs7727047	ENSG00000278487.1	RP11-447H19.4	-3.84	0.000163	0.0479	-0.29	-0.25	Metabolite levels  (X-11787);	chr5:43374831	chr5:43143362~43143514:-
OV	cis	rs9876781	1	rs9812647	ENSG00000228638.1	FCF1P2	3.84	0.000163	0.0479	0.27	0.25	Longevity;	chr3:48407507	chr3:48290793~48291375:-
OV	cis	rs801193	0.761	rs2659888	ENSG00000237310.1	GS1-124K5.4	3.83	0.000163	0.0479	0.26	0.25	Aortic root size;	chr7:66765184	chr7:66493706~66495474:+
OV	cis	rs7246967	0.611	rs62118770	ENSG00000267920.1	SNX6P1	-3.83	0.000163	0.0479	-0.41	-0.25	Bronchopulmonary dysplasia;	chr19:22641227	chr19:23126569~23127792:-
OV	cis	rs7246967	0.611	rs62118771	ENSG00000267920.1	SNX6P1	-3.83	0.000163	0.0479	-0.41	-0.25	Bronchopulmonary dysplasia;	chr19:22641496	chr19:23126569~23127792:-
OV	cis	rs11683197	1	rs11683197	ENSG00000223739.1	AC007389.2	-3.83	0.000163	0.0479	-0.31	-0.25	Visceral fat;	chr2:64800490	chr2:65511771~65512076:-
OV	cis	rs11037575	0.739	rs12277307	ENSG00000246250.2	RP11-613D13.5	3.83	0.000163	0.048	0.27	0.25	Neuroblastoma;	chr11:43700122	chr11:43829709~43880726:-
OV	cis	rs11037575	0.715	rs7118766	ENSG00000246250.2	RP11-613D13.5	3.83	0.000163	0.048	0.27	0.25	Neuroblastoma;	chr11:43700663	chr11:43829709~43880726:-
OV	cis	rs2108622	0.727	rs9305069	ENSG00000267453.5	AC004791.2	-3.83	0.000163	0.048	-0.29	-0.25	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15872576	chr19:15851993~15864904:-
OV	cis	rs17767294	0.708	rs115714358	ENSG00000219392.1	RP1-265C24.5	-3.83	0.000163	0.048	-0.53	-0.25	Parkinson's disease;	chr6:27996554	chr6:28115628~28116551:+
OV	cis	rs801193	0.967	rs2707849	ENSG00000224316.1	RP11-479O9.2	3.83	0.000163	0.048	0.26	0.25	Aortic root size;	chr7:66687725	chr7:65773620~65802067:+
OV	cis	rs1862618	0.853	rs6450408	ENSG00000271828.1	CTD-2310F14.1	3.83	0.000163	0.048	0.39	0.25	Initial pursuit acceleration;	chr5:56802319	chr5:56927874~56929573:+
OV	cis	rs2070488	0.775	rs7649984	ENSG00000229589.1	ACVR2B-AS1	-3.83	0.000163	0.048	-0.28	-0.25	Electrocardiographic conduction measures;	chr3:38528730	chr3:38451027~38454820:-
OV	cis	rs17767294	0.708	rs72848760	ENSG00000219392.1	RP1-265C24.5	-3.83	0.000163	0.048	-0.54	-0.25	Parkinson's disease;	chr6:27919099	chr6:28115628~28116551:+
OV	cis	rs17767294	0.708	rs72848763	ENSG00000219392.1	RP1-265C24.5	-3.83	0.000163	0.048	-0.54	-0.25	Parkinson's disease;	chr6:27934710	chr6:28115628~28116551:+
OV	cis	rs17767294	0.708	rs72848767	ENSG00000219392.1	RP1-265C24.5	-3.83	0.000163	0.048	-0.54	-0.25	Parkinson's disease;	chr6:27941509	chr6:28115628~28116551:+
OV	cis	rs17767294	0.708	rs72848769	ENSG00000219392.1	RP1-265C24.5	-3.83	0.000163	0.048	-0.54	-0.25	Parkinson's disease;	chr6:27950601	chr6:28115628~28116551:+
OV	cis	rs17767294	0.708	rs72848770	ENSG00000219392.1	RP1-265C24.5	-3.83	0.000163	0.048	-0.54	-0.25	Parkinson's disease;	chr6:27951371	chr6:28115628~28116551:+
OV	cis	rs1528149	0.521	rs6959719	ENSG00000224683.1	RPL36AP29	3.83	0.000163	0.048	0.3	0.25	Sitting height ratio;	chr7:16064461	chr7:16208945~16209265:+
OV	cis	rs1559040	1	rs56374740	ENSG00000272156.1	RP11-477N3.1	-3.83	0.000163	0.048	-0.43	-0.25	Sudden cardiac arrest;	chr2:54092380	chr2:54082554~54085066:+
OV	cis	rs7536700	0.915	rs12097725	ENSG00000272030.1	RP1-178F15.4	-3.83	0.000163	0.048	-0.49	-0.25	Multiple myeloma (IgH translocation);	chr1:153684696	chr1:153631438~153634397:-
OV	cis	rs4934494	0.727	rs12572012	ENSG00000240996.1	RP11-80H5.7	-3.83	0.000163	0.048	-0.34	-0.25	Red blood cell count;	chr10:89727892	chr10:89694295~89697928:-
OV	cis	rs4934494	0.727	rs3758388	ENSG00000240996.1	RP11-80H5.7	-3.83	0.000163	0.048	-0.34	-0.25	Red blood cell count;	chr10:89729222	chr10:89694295~89697928:-
OV	cis	rs4934494	0.727	rs12783582	ENSG00000240996.1	RP11-80H5.7	-3.83	0.000163	0.048	-0.34	-0.25	Red blood cell count;	chr10:89735210	chr10:89694295~89697928:-
OV	cis	rs4654783	0.627	rs2092322	ENSG00000228397.1	RP1-224A6.3	-3.83	0.000163	0.048	-0.28	-0.25	Endometriosis;	chr1:22109230	chr1:22023994~22024968:-
OV	cis	rs1555322	0.53	rs2425044	ENSG00000261582.1	RP4-614O4.11	-3.83	0.000163	0.0481	-0.29	-0.25	Attention deficit hyperactivity disorder;	chr20:35281932	chr20:35267885~35280043:-
OV	cis	rs4774565	0.762	rs17431150	ENSG00000244879.4	GABPB1-AS1	-3.83	0.000163	0.0481	-0.24	-0.25	Breast cancer;	chr15:50371385	chr15:50354959~50372202:+
OV	cis	rs4774565	0.762	rs17431171	ENSG00000244879.4	GABPB1-AS1	-3.83	0.000163	0.0481	-0.24	-0.25	Breast cancer;	chr15:50371424	chr15:50354959~50372202:+
OV	cis	rs4774565	0.762	rs720599	ENSG00000244879.4	GABPB1-AS1	-3.83	0.000163	0.0481	-0.24	-0.25	Breast cancer;	chr15:50372318	chr15:50354959~50372202:+
OV	cis	rs7246657	0.943	rs10405325	ENSG00000226686.6	LINC01535	-3.83	0.000164	0.0481	-0.38	-0.25	Coronary artery calcification;	chr19:37392575	chr19:37251912~37265535:+
OV	cis	rs6715284	1	rs6715380	ENSG00000183308.6	AC005037.3	3.83	0.000164	0.0481	0.56	0.25	Rheumatoid arthritis;	chr2:201349782	chr2:200963263~201009102:+
OV	cis	rs7746199	0.611	rs17750747	ENSG00000226314.6	ZNF192P1	-3.83	0.000164	0.0481	-0.57	-0.25	Gait speed in old age;Autism spectrum disorder or schizophrenia;	chr6:27762555	chr6:28161781~28169594:+
OV	cis	rs12701220	0.655	rs6955290	ENSG00000229043.2	AC091729.9	3.83	0.000164	0.0481	0.31	0.25	Bronchopulmonary dysplasia;	chr7:1111430	chr7:1160374~1165267:+
OV	cis	rs6893300	0.961	rs11741570	ENSG00000242979.1	RPS15AP18	3.83	0.000164	0.0481	0.31	0.25	Resting heart rate;	chr5:179781909	chr5:179933805~179934196:-
OV	cis	rs6893300	0.961	rs11744616	ENSG00000242979.1	RPS15AP18	3.83	0.000164	0.0481	0.31	0.25	Resting heart rate;	chr5:179782112	chr5:179933805~179934196:-
OV	cis	rs17264034	0.95	rs11951006	ENSG00000250786.1	SNHG18	3.83	0.000164	0.0481	0.41	0.25	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:9539123	chr5:9546200~9550609:+
OV	cis	rs3734266	0.702	rs34377413	ENSG00000220643.1	RP3-391O22.1	-3.83	0.000164	0.0481	-0.42	-0.25	Systemic lupus erythematosus;	chr6:34730524	chr6:34686602~34687106:+
OV	cis	rs3734266	0.646	rs35369977	ENSG00000220643.1	RP3-391O22.1	-3.83	0.000164	0.0481	-0.42	-0.25	Systemic lupus erythematosus;	chr6:34731564	chr6:34686602~34687106:+
OV	cis	rs3734266	0.639	rs66672772	ENSG00000220643.1	RP3-391O22.1	-3.83	0.000164	0.0481	-0.42	-0.25	Systemic lupus erythematosus;	chr6:34738160	chr6:34686602~34687106:+
OV	cis	rs3734266	0.702	rs71542490	ENSG00000220643.1	RP3-391O22.1	-3.83	0.000164	0.0481	-0.42	-0.25	Systemic lupus erythematosus;	chr6:34740699	chr6:34686602~34687106:+
OV	cis	rs3734266	0.702	rs11961041	ENSG00000220643.1	RP3-391O22.1	-3.83	0.000164	0.0481	-0.42	-0.25	Systemic lupus erythematosus;	chr6:34742132	chr6:34686602~34687106:+
OV	cis	rs6963495	0.818	rs116845562	ENSG00000272604.1	RP11-251G23.5	-3.83	0.000164	0.0481	-0.34	-0.25	Bipolar disorder (body mass index interaction);	chr7:105576591	chr7:105571083~105573660:+
OV	cis	rs12681366	0.881	rs3019145	ENSG00000253704.1	RP11-267M23.4	3.83	0.000164	0.0481	0.35	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94401324	chr8:94553722~94569745:+
OV	cis	rs673078	0.66	rs16948197	ENSG00000275759.1	RP11-131L12.3	3.83	0.000164	0.0481	0.39	0.25	Glucose homeostasis traits;	chr12:118239135	chr12:118428281~118428870:+
OV	cis	rs4947962	0.651	rs17172433	ENSG00000275875.1	RP11-613E4.5	3.83	0.000164	0.0481	0.34	0.25	Subjective response to lithium treatment;	chr7:55074742	chr7:55741525~55741869:+
OV	cis	rs11157436	0.602	rs4982569	ENSG00000211812.1	TRAV26-2	-3.83	0.000164	0.0481	-0.26	-0.25	Neurocognitive impairment in HIV-1 infection (continuous);	chr14:22169716	chr14:22202583~22203368:+
OV	cis	rs1707322	0.752	rs12062535	ENSG00000225447.1	RPS15AP10	3.83	0.000164	0.0482	0.24	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45757208	chr1:45645816~45646197:-
OV	cis	rs7646881	0.544	rs16829118	ENSG00000272440.1	RP11-379F4.6	3.83	0.000164	0.0482	0.38	0.25	Tetralogy of Fallot;	chr3:158571033	chr3:158695367~158695581:+
OV	cis	rs7824557	0.564	rs2736295	ENSG00000255495.1	AC145124.2	3.83	0.000164	0.0482	0.27	0.25	Retinal vascular caliber;	chr8:11377271	chr8:12194467~12196280:+
OV	cis	rs6723108	0.627	rs62168872	ENSG00000224043.6	CCNT2-AS1	-3.83	0.000164	0.0482	-0.29	-0.25	Type 2 diabetes;	chr2:134904177	chr2:134735464~134918710:-
OV	cis	rs6723108	0.627	rs4954196	ENSG00000224043.6	CCNT2-AS1	-3.83	0.000164	0.0482	-0.29	-0.25	Type 2 diabetes;	chr2:134904446	chr2:134735464~134918710:-
OV	cis	rs6723108	0.627	rs4954197	ENSG00000224043.6	CCNT2-AS1	-3.83	0.000164	0.0482	-0.29	-0.25	Type 2 diabetes;	chr2:134904674	chr2:134735464~134918710:-
OV	cis	rs6723108	0.604	rs2322251	ENSG00000224043.6	CCNT2-AS1	-3.83	0.000164	0.0482	-0.29	-0.25	Type 2 diabetes;	chr2:134913732	chr2:134735464~134918710:-
OV	cis	rs2669010	0.796	rs2632211	ENSG00000243071.1	RP11-613M5.2	3.83	0.000164	0.0482	0.22	0.25	Systemic lupus erythematosus;	chr12:76652109	chr12:76660405~76660884:+
OV	cis	rs783540	0.5	rs7163840	ENSG00000259429.4	UBE2Q2P2	3.83	0.000164	0.0482	0.29	0.25	Schizophrenia;	chr15:82729551	chr15:82355142~82420075:+
OV	cis	rs17597773	0.638	rs6541161	ENSG00000238078.1	LINC01352	-3.83	0.000164	0.0482	-0.33	-0.25	C-reactive protein levels or total cholesterol levels (pleiotropy);	chr1:220820922	chr1:220829255~220832429:+
OV	cis	rs7131987	0.65	rs7301398	ENSG00000257176.2	RP11-996F15.2	-3.83	0.000164	0.0482	-0.31	-0.25	QT interval;	chr12:29302457	chr12:29280418~29317848:-
OV	cis	rs7131987	0.65	rs7301188	ENSG00000257176.2	RP11-996F15.2	-3.83	0.000164	0.0482	-0.31	-0.25	QT interval;	chr12:29302458	chr12:29280418~29317848:-
OV	cis	rs13217239	0.646	rs10946898	ENSG00000261584.1	RP11-457M11.5	3.83	0.000164	0.0482	0.27	0.25	Schizophrenia;	chr6:27036105	chr6:26686241~26687964:+
OV	cis	rs12654437	0.612	rs10036440	ENSG00000270442.1	CTB-95D12.1	-3.83	0.000164	0.0482	-0.33	-0.25	Cognitive decline (age-related);	chr5:155409275	chr5:155491336~155493598:+
OV	cis	rs7649443	0.878	rs7642604	ENSG00000235897.1	TM4SF19-AS1	3.83	0.000164	0.0482	0.28	0.25	Nonsyndromic cleft lip with cleft palate;	chr3:197165115	chr3:196318330~196325570:+
OV	cis	rs7649443	0.878	rs7634994	ENSG00000235897.1	TM4SF19-AS1	3.83	0.000164	0.0482	0.28	0.25	Nonsyndromic cleft lip with cleft palate;	chr3:197165142	chr3:196318330~196325570:+
OV	cis	rs77669868	0.866	rs2735195	ENSG00000256452.1	RP11-667M19.10	3.83	0.000164	0.0482	0.29	0.25	Monocyte percentage of white cells;	chr11:114180470	chr11:113818077~113822458:+
OV	cis	rs10986311	0.802	rs6478659	ENSG00000214593.3	RP11-65N13.6	3.83	0.000164	0.0482	0.23	0.25	Vitiligo;	chr9:124365995	chr9:125263845~125264090:-
OV	cis	rs6142102	0.961	rs4911144	ENSG00000264616.1	MIR4755	3.83	0.000164	0.0482	0.31	0.25	Skin pigmentation;	chr20:34026565	chr20:34049119~34049190:+
OV	cis	rs10740039	0.729	rs6479721	ENSG00000254271.1	RP11-131N11.4	3.83	0.000164	0.0482	0.32	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60613364	chr10:60734342~60741828:+
OV	cis	rs6723108	0.603	rs62168891	ENSG00000224043.6	CCNT2-AS1	-3.83	0.000164	0.0482	-0.29	-0.25	Type 2 diabetes;	chr2:134914617	chr2:134735464~134918710:-
OV	cis	rs4722166	0.63	rs10950916	ENSG00000179428.2	AC073072.5	-3.83	0.000164	0.0482	-0.32	-0.25	Lung cancer;	chr7:22760048	chr7:22725395~22727620:-
OV	cis	rs1707322	0.752	rs11488313	ENSG00000225447.1	RPS15AP10	3.83	0.000164	0.0482	0.24	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45759108	chr1:45645816~45646197:-
OV	cis	rs3750965	0.959	rs11228490	ENSG00000260895.1	RP11-554A11.7	-3.83	0.000164	0.0483	-0.29	-0.25	Hair color;	chr11:69093404	chr11:69103493~69109094:+
OV	cis	rs73186030	0.546	rs9857972	ENSG00000272758.4	RP11-299J3.8	3.83	0.000164	0.0483	0.29	0.25	Serum parathyroid hormone levels;	chr3:122390602	chr3:122416207~122443180:+
OV	cis	rs4948102	0.642	rs6593297	ENSG00000273720.1	RP11-613E4.4	3.83	0.000164	0.0483	0.28	0.25	Plasma homocysteine levels (post-methionine load test);	chr7:56054365	chr7:55743073~55743457:+
OV	cis	rs6120849	1	rs6120849	ENSG00000206582.1	Y_RNA	-3.83	0.000164	0.0483	-0.33	-0.25	Protein C levels;	chr20:35142584	chr20:34526510~34526606:-
OV	cis	rs12220898	0.749	rs17009669	ENSG00000228754.1	RP11-534L6.3	3.83	0.000164	0.0483	0.46	0.25	Inflammatory biomarkers;	chr10:49262064	chr10:48745545~48746128:-
OV	cis	rs12220898	0.749	rs74912367	ENSG00000228754.1	RP11-534L6.3	3.83	0.000164	0.0483	0.46	0.25	Inflammatory biomarkers;	chr10:49262967	chr10:48745545~48746128:-
OV	cis	rs12220898	0.749	rs4297382	ENSG00000228754.1	RP11-534L6.3	3.83	0.000164	0.0483	0.46	0.25	Inflammatory biomarkers;	chr10:49263510	chr10:48745545~48746128:-
OV	cis	rs12220898	0.749	rs77898932	ENSG00000228754.1	RP11-534L6.3	3.83	0.000164	0.0483	0.46	0.25	Inflammatory biomarkers;	chr10:49268050	chr10:48745545~48746128:-
OV	cis	rs12220898	0.749	rs78757939	ENSG00000228754.1	RP11-534L6.3	3.83	0.000164	0.0483	0.46	0.25	Inflammatory biomarkers;	chr10:49268572	chr10:48745545~48746128:-
OV	cis	rs858239	0.67	rs3807452	ENSG00000230042.1	AK3P3	3.83	0.000164	0.0483	0.25	0.25	Cerebrospinal fluid biomarker levels;	chr7:23122462	chr7:23129178~23129841:+
OV	cis	rs9473147	0.543	rs4711878	ENSG00000270761.1	RP11-385F7.1	-3.83	0.000165	0.0483	-0.28	-0.25	Platelet distribution width;Mean platelet volume;	chr6:47488382	chr6:47477243~47477572:-
OV	cis	rs6071524	0.508	rs2248100	ENSG00000277581.1	RP4-616B8.6	-3.83	0.000165	0.0483	-0.3	-0.25	Autism spectrum disorder or schizophrenia;	chr20:38769589	chr20:38962472~38962993:+
OV	cis	rs642743	0.967	rs686441	ENSG00000228261.1	RP11-127L20.3	-3.83	0.000165	0.0483	-0.26	-0.25	Left ventricular obstructive tract defect (maternal effect);	chr10:104190475	chr10:104323369~104327004:+
OV	cis	rs1113500	0.58	rs1781058	ENSG00000226822.1	RP11-356N1.2	3.83	0.000165	0.0483	0.3	0.25	Growth-regulated protein alpha levels;	chr1:108021437	chr1:108071482~108074519:+
OV	cis	rs941207	0.756	rs7978685	ENSG00000241217.3	RN7SL809P	3.83	0.000165	0.0483	0.27	0.25	Platelet count;	chr12:56709370	chr12:56670450~56670746:-
OV	cis	rs2348418	0.832	rs11049512	ENSG00000247934.4	RP11-967K21.1	3.83	0.000165	0.0484	0.25	0.25	Lung function (FEV1);Lung function (FVC);	chr12:28295880	chr12:28163298~28190738:-
OV	cis	rs6964833	1	rs36044436	ENSG00000277072.3	STAG3L2	3.83	0.000165	0.0484	0.29	0.25	Menarche (age at onset);	chr7:74675495	chr7:74882163~74890610:-
OV	cis	rs6687758	1	rs6687758	ENSG00000238042.4	RP11-815M8.1	3.83	0.000165	0.0484	0.33	0.25	Colorectal cancer;Progressive supranuclear palsy;Colorectal cancer (SNP x SNP interaction);	chr1:221991606	chr1:221880981~221978523:-
OV	cis	rs4321386	1	rs3218872	ENSG00000271532.1	RP11-426K3.1	-3.83	0.000165	0.0484	-0.41	-0.25	Hormone measurements;	chr2:102012047	chr2:101068378~101068656:+
OV	cis	rs7267979	1	rs2500424	ENSG00000274973.1	RP13-401N8.7	3.83	0.000165	0.0484	0.28	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25411333	chr20:25845497~25845862:+
OV	cis	rs73201462	1	rs2999076	ENSG00000242551.2	POU5F1P6	-3.83	0.000165	0.0484	-0.36	-0.25	Post bronchodilator FEV1/FVC ratio;Post bronchodilator FEV1;	chr3:128239849	chr3:128674735~128677005:-
OV	cis	rs9369695	0.842	rs2396825	ENSG00000270761.1	RP11-385F7.1	-3.83	0.000165	0.0484	-0.28	-0.25	Reticulocyte count;	chr6:47600960	chr6:47477243~47477572:-
OV	cis	rs7246657	0.943	rs9676967	ENSG00000226686.6	LINC01535	-3.83	0.000165	0.0484	-0.37	-0.25	Coronary artery calcification;	chr19:37437187	chr19:37251912~37265535:+
OV	cis	rs2286503	0.809	rs4719716	ENSG00000221740.1	SNORD93	3.83	0.000165	0.0484	0.31	0.25	Fibrinogen;	chr7:22821750	chr7:22856613~22856686:+
OV	cis	rs2286503	0.839	rs2270108	ENSG00000221740.1	SNORD93	3.83	0.000165	0.0484	0.31	0.25	Fibrinogen;	chr7:22822512	chr7:22856613~22856686:+
OV	cis	rs2286503	0.839	rs2270107	ENSG00000221740.1	SNORD93	3.83	0.000165	0.0484	0.31	0.25	Fibrinogen;	chr7:22822564	chr7:22856613~22856686:+
OV	cis	rs2286503	0.839	rs2270103	ENSG00000221740.1	SNORD93	3.83	0.000165	0.0484	0.31	0.25	Fibrinogen;	chr7:22823103	chr7:22856613~22856686:+
OV	cis	rs1584120	0.62	rs1406770	ENSG00000274885.1	RP11-268P4.6	3.83	0.000165	0.0484	0.28	0.25	Pelvic organ prolapse (moderate/severe);	chr12:23123682	chr12:22638464~22638943:+
OV	cis	rs1584120	0.594	rs12317093	ENSG00000274885.1	RP11-268P4.6	3.83	0.000165	0.0484	0.28	0.25	Pelvic organ prolapse (moderate/severe);	chr12:23123909	chr12:22638464~22638943:+
OV	cis	rs7520050	0.872	rs1707308	ENSG00000281133.1	AL355480.3	3.83	0.000165	0.0484	0.28	0.25	Reticulocyte count;Red blood cell count;	chr1:46138643	chr1:45580892~45580996:-
OV	cis	rs3731896	0.653	rs58269809	ENSG00000272644.1	RP11-33O4.1	-3.83	0.000165	0.0485	-0.37	-0.25	Educational attainment;	chr2:219331291	chr2:219069354~219069809:-
OV	cis	rs3731896	0.653	rs908194	ENSG00000272644.1	RP11-33O4.1	-3.83	0.000165	0.0485	-0.37	-0.25	Educational attainment;	chr2:219333525	chr2:219069354~219069809:-
OV	cis	rs3731896	0.653	rs1567931	ENSG00000272644.1	RP11-33O4.1	-3.83	0.000165	0.0485	-0.37	-0.25	Educational attainment;	chr2:219334345	chr2:219069354~219069809:-
OV	cis	rs4290604	0.748	rs4549025	ENSG00000224132.2	AC112715.2	3.83	0.000165	0.0485	0.45	0.25	Asthma;	chr2:237144268	chr2:237257091~237257676:+
OV	cis	rs2853333	0.6	rs916147	ENSG00000268947.1	AD000684.2	3.83	0.000165	0.0485	0.21	0.25	Red blood cell count;	chr19:35266347	chr19:35262846~35264804:+
OV	cis	rs860295	0.58	rs10908461	ENSG00000225855.5	RUSC1-AS1	3.83	0.000165	0.0485	0.21	0.25	Body mass index;	chr1:155305936	chr1:155316863~155324176:-
OV	cis	rs1707322	0.506	rs2991983	ENSG00000234329.1	RP11-767N6.2	-3.83	0.000165	0.0485	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613719	chr1:45651039~45651826:-
OV	cis	rs1707322	0.717	rs3014249	ENSG00000234329.1	RP11-767N6.2	-3.83	0.000165	0.0485	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45613821	chr1:45651039~45651826:-
OV	cis	rs7246967	0.673	rs8106180	ENSG00000267920.1	SNX6P1	-3.83	0.000166	0.0486	-0.39	-0.25	Bronchopulmonary dysplasia;	chr19:22696558	chr19:23126569~23127792:-
OV	cis	rs6691738	0.959	rs6665456	ENSG00000203739.3	RP11-296O14.3	3.83	0.000166	0.0486	0.27	0.25	Asthma;	chr1:173171626	chr1:173417793~173461362:-
OV	cis	rs2688482	0.557	rs2550236	ENSG00000207650.1	MIR570	3.83	0.000166	0.0486	0.35	0.25	Lung disease severity in cystic fibrosis;	chr3:195795450	chr3:195699401~195699497:+
OV	cis	rs9876781	0.53	rs35516531	ENSG00000229759.1	MRPS18AP1	3.83	0.000166	0.0486	0.26	0.25	Longevity;	chr3:48364275	chr3:48256350~48256938:-
OV	cis	rs9810089	0.708	rs711977	ENSG00000261758.1	RP11-102M11.2	3.83	0.000166	0.0486	0.3	0.25	Gestational age at birth (child effect);	chr3:136508545	chr3:136752630~136755780:+
OV	cis	rs1538970	0.851	rs2055145	ENSG00000280836.1	AL355480.1	-3.83	0.000166	0.0486	-0.36	-0.25	Platelet count;	chr1:45460823	chr1:45581219~45581321:-
OV	cis	rs7017914	0.677	rs1973364	ENSG00000223220.1	Y_RNA	-3.83	0.000166	0.0486	-0.26	-0.25	Bone mineral density;	chr8:70955007	chr8:70780914~70781008:-
OV	cis	rs2834288	0.5	rs4817602	ENSG00000273102.1	AP000569.9	3.83	0.000166	0.0486	0.26	0.25	Gut microbiota (bacterial taxa);	chr21:33952354	chr21:33967101~33968573:-
OV	cis	rs1061377	1	rs3796509	ENSG00000249685.1	RP11-360F5.3	3.83	0.000166	0.0486	0.29	0.25	Uric acid levels;	chr4:39108566	chr4:39133913~39135608:+
OV	cis	rs35491132	1	rs35491132	ENSG00000226314.6	ZNF192P1	-3.83	0.000166	0.0486	-0.53	-0.25	Urinary tract infection frequency;	chr6:27559449	chr6:28161781~28169594:+
OV	cis	rs801193	1	rs3778909	ENSG00000237310.1	GS1-124K5.4	3.83	0.000166	0.0486	0.26	0.25	Aortic root size;	chr7:66790659	chr7:66493706~66495474:+
OV	cis	rs57221529	0.545	rs55955015	ENSG00000271781.1	CTD-2589H19.6	-3.83	0.000166	0.0486	-0.4	-0.25	Lung disease severity in cystic fibrosis;	chr5:575067	chr5:675826~676616:+
OV	cis	rs1015213	0.609	rs78162380	ENSG00000253844.1	RP11-546K22.1	-3.83	0.000166	0.0486	-0.66	-0.25	Glaucoma (primary angle closure);	chr8:51940653	chr8:51961458~52022974:+
OV	cis	rs2980439	0.525	rs2980508	ENSG00000253893.2	FAM85B	-3.83	0.000166	0.0486	-0.29	-0.25	Neuroticism;	chr8:8314210	chr8:8167819~8226614:-
OV	cis	rs903027	1	rs903027	ENSG00000255321.1	RP11-91I20.4	-3.83	0.000166	0.0486	-0.41	-0.25	Whole-brain volume;	chr8:61496869	chr8:60551957~60553036:-
OV	cis	rs9733	0.818	rs4970924	ENSG00000277452.1	Metazoa_SRP	-3.83	0.000166	0.0487	-0.27	-0.25	Tonsillectomy;	chr1:150660603	chr1:150566562~150566860:-
OV	cis	rs12073359	1	rs12063329	ENSG00000223945.2	RP11-458I7.1	-3.83	0.000166	0.0487	-0.39	-0.25	Obesity in adult survivors of childhood cancer not exposed to cranial radiation;	chr1:150030478	chr1:150053864~150055034:+
OV	cis	rs743757	1	rs2236984	ENSG00000228008.1	CTD-2330K9.3	3.83	0.000166	0.0487	0.33	0.25	Diastolic blood pressure;	chr3:50458056	chr3:49903845~49916937:+
OV	cis	rs6703335	0.632	rs10927025	ENSG00000227230.1	RP11-261C10.5	-3.83	0.000166	0.0487	-0.25	-0.25	Schizophrenia;Schizophrenia, schizoaffective disorder or bipolar disorder;	chr1:243475916	chr1:243135898~243140588:+
OV	cis	rs1850744	0.826	rs10939514	ENSG00000163612.10	FAM86KP	-3.83	0.000166	0.0487	-0.63	-0.25	Economic and political preferences;	chr4:9771572	chr4:9153296~9165451:+
OV	cis	rs10754283	0.967	rs10922685	ENSG00000231613.1	RP5-943J3.1	3.83	0.000166	0.0487	0.27	0.25	Amyotrophic lateral sclerosis (sporadic);	chr1:89652761	chr1:89788914~89790492:+
OV	cis	rs599083	0.53	rs546803	ENSG00000212093.1	AP000807.1	-3.83	0.000166	0.0488	-0.3	-0.25	Bone mineral density (spine);	chr11:68418924	chr11:68506083~68506166:-
OV	cis	rs2286503	0.839	rs4722188	ENSG00000221740.1	SNORD93	3.83	0.000166	0.0488	0.31	0.25	Fibrinogen;	chr7:22820592	chr7:22856613~22856686:+
OV	cis	rs634537	0.559	rs643319	ENSG00000234840.1	LINC01239	-3.83	0.000167	0.0488	-0.29	-0.25	Glioma;Non-glioblastoma glioma;Glioblastoma;	chr9:22017837	chr9:22646200~22824213:+
OV	cis	rs12681366	0.762	rs3019148	ENSG00000253704.1	RP11-267M23.4	3.83	0.000167	0.0488	0.3	0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94417407	chr8:94553722~94569745:+
OV	cis	rs12545912	0.609	rs633777	ENSG00000280294.1	RP11-177H2.1	-3.83	0.000167	0.0488	-0.32	-0.25	Multiple myeloma (hyperdiploidy);	chr8:9942505	chr8:10856085~10859436:-
OV	cis	rs78545713	1	rs77281308	ENSG00000241549.7	GUSBP2	-3.83	0.000167	0.0488	-0.36	-0.25	Iron status biomarkers (total iron binding capacity);	chr6:26249801	chr6:26871484~26956554:-
OV	cis	rs78545713	1	rs78661760	ENSG00000241549.7	GUSBP2	-3.83	0.000167	0.0488	-0.36	-0.25	Iron status biomarkers (total iron binding capacity);	chr6:26249805	chr6:26871484~26956554:-
OV	cis	rs6429082	0.51	rs3806393	ENSG00000236863.2	RPL23AP23	3.83	0.000167	0.0488	0.25	0.25	Adiposity;	chr1:235329231	chr1:235295865~235296335:+
OV	cis	rs7598759	0.527	rs7571691	ENSG00000181798.2	LINC00471	-3.83	0.000167	0.0488	-0.24	-0.25	Noise-induced hearing loss;	chr2:231504690	chr2:231508426~231514339:-
OV	cis	rs6545883	0.929	rs6707830	ENSG00000270820.4	RP11-355B11.2	3.83	0.000167	0.0488	0.28	0.25	Tuberculosis;	chr2:61522337	chr2:61471188~61484130:+
OV	cis	rs8087799	0.83	rs8097170	ENSG00000265943.1	RP11-739L10.1	3.83	0.000167	0.0489	0.31	0.25	Intracranial, abdominal aortic or thoracic aortic aneurysm (pleiotropy);	chr18:22612140	chr18:22699481~22933764:-
OV	cis	rs62151617	1	rs17005910	ENSG00000233870.1	AC007881.4	3.83	0.000167	0.0489	0.32	0.25	Hair shape;	chr2:70582114	chr2:71178587~71178773:+
OV	cis	rs7204230	1	rs1133261	ENSG00000261291.1	RP11-295M3.2	3.83	0.000167	0.0489	0.29	0.25	Fibrinogen;	chr16:53298166	chr16:53168522~53169450:+
OV	cis	rs9473147	0.516	rs9395286	ENSG00000270761.1	RP11-385F7.1	-3.83	0.000167	0.0489	-0.28	-0.25	Platelet distribution width;Mean platelet volume;	chr6:47607596	chr6:47477243~47477572:-
OV	cis	rs4578769	0.569	rs4800433	ENSG00000242182.3	RN7SL745P	3.83	0.000167	0.0489	0.28	0.25	Eosinophil percentage of white cells;	chr18:22816691	chr18:23004564~23004862:+
OV	cis	rs4578769	0.569	rs11082155	ENSG00000242182.3	RN7SL745P	3.83	0.000167	0.0489	0.28	0.25	Eosinophil percentage of white cells;	chr18:22824527	chr18:23004564~23004862:+
OV	cis	rs4578769	0.569	rs4289091	ENSG00000242182.3	RN7SL745P	3.83	0.000167	0.0489	0.28	0.25	Eosinophil percentage of white cells;	chr18:22825856	chr18:23004564~23004862:+
OV	cis	rs4578769	0.569	rs12956367	ENSG00000242182.3	RN7SL745P	3.83	0.000167	0.0489	0.28	0.25	Eosinophil percentage of white cells;	chr18:22833742	chr18:23004564~23004862:+
OV	cis	rs4918798	0.901	rs17521564	ENSG00000234724.1	HDAC1P1	3.83	0.000167	0.0489	0.36	0.25	Warfarin maintenance dose;	chr10:94874553	chr10:94137748~94139500:+
OV	cis	rs7121800	0.962	rs4923641	ENSG00000242353.1	RP4-710M3.1	-3.83	0.000167	0.0489	-0.3	-0.25	Pit-and-Fissure caries;	chr11:30501598	chr11:30368148~30368646:+
OV	cis	rs4927850	1	rs7627706	ENSG00000229178.1	AC069513.4	-3.83	0.000167	0.0489	-0.3	-0.25	Pancreatic cancer;	chr3:196026482	chr3:195655565~195657927:-
OV	cis	rs11119805	0.649	rs55648545	ENSG00000260805.2	RP11-61J19.5	-3.83	0.000167	0.0489	-0.39	-0.25	Stearic acid (18:0) levels;	chr1:211793898	chr1:212557833~212559731:-
OV	cis	rs11119805	0.649	rs56074728	ENSG00000260805.2	RP11-61J19.5	-3.83	0.000167	0.0489	-0.39	-0.25	Stearic acid (18:0) levels;	chr1:211795263	chr1:212557833~212559731:-
OV	cis	rs11119805	0.649	rs12123135	ENSG00000260805.2	RP11-61J19.5	-3.83	0.000167	0.0489	-0.39	-0.25	Stearic acid (18:0) levels;	chr1:211801371	chr1:212557833~212559731:-
OV	cis	rs11119805	0.649	rs12134302	ENSG00000260805.2	RP11-61J19.5	-3.83	0.000167	0.0489	-0.39	-0.25	Stearic acid (18:0) levels;	chr1:211801568	chr1:212557833~212559731:-
OV	cis	rs11119805	0.649	rs12138283	ENSG00000260805.2	RP11-61J19.5	-3.83	0.000167	0.0489	-0.39	-0.25	Stearic acid (18:0) levels;	chr1:211805197	chr1:212557833~212559731:-
OV	cis	rs6479891	0.643	rs2565187	ENSG00000232075.1	MRPL35P2	-3.83	0.000167	0.0489	-0.41	-0.25	Arthritis (juvenile idiopathic);	chr10:63632093	chr10:63634317~63634827:-
OV	cis	rs6479891	0.643	rs2565186	ENSG00000232075.1	MRPL35P2	-3.83	0.000167	0.0489	-0.41	-0.25	Arthritis (juvenile idiopathic);	chr10:63632270	chr10:63634317~63634827:-
OV	cis	rs6479891	0.643	rs1268639	ENSG00000232075.1	MRPL35P2	-3.83	0.000167	0.0489	-0.41	-0.25	Arthritis (juvenile idiopathic);	chr10:63632720	chr10:63634317~63634827:-
OV	cis	rs6545883	0.794	rs778152	ENSG00000270820.4	RP11-355B11.2	-3.83	0.000167	0.0489	-0.28	-0.25	Tuberculosis;	chr2:61381405	chr2:61471188~61484130:+
OV	cis	rs801193	1	rs2707850	ENSG00000237310.1	GS1-124K5.4	3.83	0.000167	0.0489	0.26	0.25	Aortic root size;	chr7:66738883	chr7:66493706~66495474:+
OV	cis	rs801193	0.967	rs1110414	ENSG00000237310.1	GS1-124K5.4	3.83	0.000167	0.0489	0.26	0.25	Aortic root size;	chr7:66740595	chr7:66493706~66495474:+
OV	cis	rs801193	1	rs7783924	ENSG00000237310.1	GS1-124K5.4	3.83	0.000167	0.0489	0.26	0.25	Aortic root size;	chr7:66744070	chr7:66493706~66495474:+
OV	cis	rs801193	1	rs7789184	ENSG00000237310.1	GS1-124K5.4	3.83	0.000167	0.0489	0.26	0.25	Aortic root size;	chr7:66745208	chr7:66493706~66495474:+
OV	cis	rs801193	1	rs2707856	ENSG00000237310.1	GS1-124K5.4	3.83	0.000167	0.0489	0.26	0.25	Aortic root size;	chr7:66746023	chr7:66493706~66495474:+
OV	cis	rs801193	1	rs2707854	ENSG00000237310.1	GS1-124K5.4	3.83	0.000167	0.0489	0.26	0.25	Aortic root size;	chr7:66747610	chr7:66493706~66495474:+
OV	cis	rs9386630	0.554	rs2250383	ENSG00000271734.1	RP1-111B22.3	3.83	0.000167	0.0489	0.27	0.25	Coffee consumption;	chr6:107317680	chr6:108030249~108030718:-
OV	cis	rs14027	0.705	rs13265683	ENSG00000279347.1	RP11-85I17.2	-3.83	0.000167	0.0489	-0.26	-0.25	Venous thromboembolism adjusted for sickle cell variant rs77121243-T;	chr8:119729926	chr8:119838736~119840385:-
OV	cis	rs801193	1	rs4717319	ENSG00000237310.1	GS1-124K5.4	3.83	0.000167	0.0489	0.26	0.25	Aortic root size;	chr7:66777606	chr7:66493706~66495474:+
OV	cis	rs801193	0.904	rs4718403	ENSG00000237310.1	GS1-124K5.4	3.83	0.000167	0.0489	0.26	0.25	Aortic root size;	chr7:66777742	chr7:66493706~66495474:+
OV	cis	rs599083	0.573	rs3018713	ENSG00000222339.1	AP000807.2	3.83	0.000167	0.0489	0.25	0.25	Bone mineral density (spine);	chr11:68623518	chr11:68505572~68505651:-
OV	cis	rs35851103	0.6	rs4841662	ENSG00000251402.3	FAM90A25P	-3.83	0.000167	0.049	-0.27	-0.25	Neuroticism;	chr8:11986249	chr8:12415080~12418090:-
OV	cis	rs189798	0.807	rs12785	ENSG00000253893.2	FAM85B	-3.83	0.000167	0.049	-0.35	-0.25	Myopia (pathological);	chr8:9137426	chr8:8167819~8226614:-
OV	cis	rs9425326	0.537	rs9425617	ENSG00000232860.6	SMG7-AS1	-3.83	0.000168	0.049	-0.44	-0.25	Antipsychotic drug-induced QTc interval change in schizophrenia;	chr1:183872650	chr1:183460874~183472265:-
OV	cis	rs4493873	0.758	rs56306245	ENSG00000253738.1	OTUD6B-AS1	3.83	0.000168	0.049	0.3	0.25	Migraine - clinic-based;	chr8:91105866	chr8:91059909~91070189:-
OV	cis	rs2898290	0.54	rs12677146	ENSG00000255556.2	RP11-351I21.6	-3.83	0.000168	0.049	-0.27	-0.25	Systolic blood pressure;	chr8:11593228	chr8:12378679~12380265:-
OV	cis	rs875971	0.577	rs35072105	ENSG00000237310.1	GS1-124K5.4	-3.83	0.000168	0.049	-0.25	-0.25	Aortic root size;	chr7:66144830	chr7:66493706~66495474:+
OV	cis	rs6142102	0.961	rs2284387	ENSG00000264616.1	MIR4755	3.83	0.000168	0.049	0.31	0.25	Skin pigmentation;	chr20:34056782	chr20:34049119~34049190:+
OV	cis	rs7726839	0.54	rs72705102	ENSG00000271781.1	CTD-2589H19.6	-3.83	0.000168	0.049	-0.39	-0.25	Obesity-related traits;	chr5:659322	chr5:675826~676616:+
OV	cis	rs2115630	1	rs6496441	ENSG00000259295.5	CSPG4P12	-3.83	0.000168	0.049	-0.28	-0.25	P wave terminal force;	chr15:84820117	chr15:85191438~85213905:+
OV	cis	rs1707322	0.682	rs3014241	ENSG00000234329.1	RP11-767N6.2	-3.83	0.000168	0.049	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45622207	chr1:45651039~45651826:-
OV	cis	rs2021786	0.93	rs919189	ENSG00000199719.1	RN7SKP74	-3.83	0.000168	0.049	-0.26	-0.25	Preschool internalizing problems;	chr20:17456844	chr20:18295143~18295451:-
OV	cis	rs8059260	1	rs7185978	ENSG00000274038.1	RP11-66H6.4	-3.83	0.000168	0.049	-0.41	-0.25	Alcohol consumption over the past year;	chr16:10954417	chr16:11056556~11057034:+
OV	cis	rs603446	1	rs603446	ENSG00000254851.1	RP11-109L13.1	-3.83	0.000168	0.049	-0.29	-0.25	Triglycerides;	chr11:116783719	chr11:117135528~117138582:+
OV	cis	rs10924970	0.967	rs2152955	ENSG00000236863.2	RPL23AP23	3.83	0.000168	0.0491	0.24	0.25	Asthma;	chr1:235254458	chr1:235295865~235296335:+
OV	cis	rs10924970	0.967	rs2152954	ENSG00000236863.2	RPL23AP23	3.83	0.000168	0.0491	0.24	0.25	Asthma;	chr1:235254465	chr1:235295865~235296335:+
OV	cis	rs1707322	0.717	rs2275086	ENSG00000234329.1	RP11-767N6.2	-3.83	0.000168	0.0491	-0.26	-0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45620207	chr1:45651039~45651826:-
OV	cis	rs4713118	0.512	rs2622319	ENSG00000204709.4	LINC01556	3.83	0.000168	0.0491	0.31	0.25	Parkinson's disease;	chr6:28152623	chr6:28943877~28944537:+
OV	cis	rs8100891	0.537	rs7258196	ENSG00000267213.4	AC007773.2	-3.83	0.000168	0.0491	-0.37	-0.25	Neuroticism;	chr19:32453659	chr19:32390050~32405560:-
OV	cis	rs8100891	0.537	rs4805762	ENSG00000267213.4	AC007773.2	-3.83	0.000168	0.0491	-0.37	-0.25	Neuroticism;	chr19:32473048	chr19:32390050~32405560:-
OV	cis	rs8100891	0.537	rs7253039	ENSG00000267213.4	AC007773.2	-3.83	0.000168	0.0491	-0.37	-0.25	Neuroticism;	chr19:32482171	chr19:32390050~32405560:-
OV	cis	rs10754283	0.967	rs7523046	ENSG00000231613.1	RP5-943J3.1	3.83	0.000168	0.0491	0.27	0.25	Amyotrophic lateral sclerosis (sporadic);	chr1:89643940	chr1:89788914~89790492:+
OV	cis	rs10754283	0.967	rs7546518	ENSG00000231613.1	RP5-943J3.1	3.83	0.000168	0.0491	0.27	0.25	Amyotrophic lateral sclerosis (sporadic);	chr1:89644397	chr1:89788914~89790492:+
OV	cis	rs10754283	0.967	rs7523518	ENSG00000231613.1	RP5-943J3.1	3.83	0.000168	0.0491	0.27	0.25	Amyotrophic lateral sclerosis (sporadic);	chr1:89644451	chr1:89788914~89790492:+
OV	cis	rs61784830	1	rs61784830	ENSG00000280836.1	AL355480.1	-3.83	0.000168	0.0492	-0.54	-0.25	Iron status biomarkers (total iron binding capacity);	chr1:45763401	chr1:45581219~45581321:-
OV	cis	rs728616	0.867	rs34870056	ENSG00000234382.2	RP11-40F6.1	-3.83	0.000168	0.0492	-0.57	-0.25	Chronic obstructive pulmonary disease-related biomarkers;	chr10:80188299	chr10:80233664~80245367:+
OV	cis	rs1538970	1	rs17395553	ENSG00000280836.1	AL355480.1	-3.83	0.000168	0.0492	-0.35	-0.25	Platelet count;	chr1:45399089	chr1:45581219~45581321:-
OV	cis	rs10800713	0.954	rs10800710	ENSG00000260088.1	RP11-92G12.3	-3.83	0.000168	0.0492	-0.3	-0.25	Tandem gait;	chr1:200569240	chr1:200669507~200694250:+
OV	cis	rs10800713	0.954	rs10800711	ENSG00000260088.1	RP11-92G12.3	-3.83	0.000168	0.0492	-0.3	-0.25	Tandem gait;	chr1:200569757	chr1:200669507~200694250:+
OV	cis	rs10800713	0.954	rs12092148	ENSG00000260088.1	RP11-92G12.3	-3.83	0.000168	0.0492	-0.3	-0.25	Tandem gait;	chr1:200570655	chr1:200669507~200694250:+
OV	cis	rs10800713	0.826	rs11586257	ENSG00000260088.1	RP11-92G12.3	-3.83	0.000168	0.0492	-0.3	-0.25	Tandem gait;	chr1:200572236	chr1:200669507~200694250:+
OV	cis	rs10800713	0.954	rs10800712	ENSG00000260088.1	RP11-92G12.3	-3.83	0.000168	0.0492	-0.3	-0.25	Tandem gait;	chr1:200576059	chr1:200669507~200694250:+
OV	cis	rs10800713	0.908	rs10919978	ENSG00000260088.1	RP11-92G12.3	-3.83	0.000168	0.0492	-0.3	-0.25	Tandem gait;	chr1:200576923	chr1:200669507~200694250:+
OV	cis	rs10800713	0.954	rs4353125	ENSG00000260088.1	RP11-92G12.3	-3.83	0.000168	0.0492	-0.3	-0.25	Tandem gait;	chr1:200582178	chr1:200669507~200694250:+
OV	cis	rs10800713	0.908	rs6670625	ENSG00000260088.1	RP11-92G12.3	-3.83	0.000168	0.0492	-0.3	-0.25	Tandem gait;	chr1:200587514	chr1:200669507~200694250:+
OV	cis	rs7932354	0.528	rs7479189	ENSG00000271543.1	RP11-692M12.5	-3.83	0.000168	0.0492	-0.32	-0.25	Bone mineral density (hip);Bone mineral density;	chr11:47035458	chr11:47796169~47796379:+
OV	cis	rs9326246	0.643	rs2072560	ENSG00000254851.1	RP11-109L13.1	-3.83	0.000168	0.0492	-0.56	-0.25	Coronary artery disease;	chr11:116791110	chr11:117135528~117138582:+
OV	cis	rs1061377	1	rs6829450	ENSG00000249685.1	RP11-360F5.3	3.83	0.000168	0.0492	0.3	0.25	Uric acid levels;	chr4:39114721	chr4:39133913~39135608:+
OV	cis	rs17401966	1	rs12118323	ENSG00000199562.1	RNU6-37P	3.83	0.000168	0.0492	0.3	0.25	Hepatocellular carcinoma;	chr1:10409584	chr1:10298966~10299072:+
OV	cis	rs4950322	0.57	rs72691012	ENSG00000278811.3	LINC00624	3.83	0.000168	0.0492	0.31	0.25	Protein quantitative trait loci;	chr1:147239751	chr1:147258885~147517875:-
OV	cis	rs9309473	0.606	rs62149777	ENSG00000163016.8	ALMS1P	3.83	0.000168	0.0492	0.32	0.25	Metabolite levels;	chr2:73568237	chr2:73644919~73685576:+
OV	cis	rs6088580	0.524	rs7274854	ENSG00000206582.1	Y_RNA	-3.83	0.000169	0.0492	-0.3	-0.25	Glomerular filtration rate (creatinine);	chr20:34640868	chr20:34526510~34526606:-
OV	cis	rs909341	0.859	rs2297441	ENSG00000232442.1	CTD-3184A7.4	3.83	0.000169	0.0492	0.26	0.25	Atopic dermatitis;	chr20:63696229	chr20:63627227~63628824:+
OV	cis	rs6142102	0.517	rs6059580	ENSG00000271803.1	RP1-63M2.5	3.83	0.000169	0.0492	0.3	0.25	Skin pigmentation;	chr20:33940067	chr20:33674517~33675380:+
OV	cis	rs8031584	0.56	rs7171208	ENSG00000259845.1	HERC2P10	-3.83	0.000169	0.0492	-0.27	-0.25	Huntington's disease progression;	chr15:30906726	chr15:30815271~30844153:+
OV	cis	rs13022357	0.59	rs4665040	ENSG00000230783.1	AC009961.2	-3.83	0.000169	0.0492	-0.58	-0.25	Sudden cardiac arrest;	chr2:159209305	chr2:159689217~159690291:-
OV	cis	rs8133949	1	rs871546	ENSG00000236384.6	LINC00479	-3.83	0.000169	0.0492	-0.33	-0.25	Hand grip strength;	chr21:41993444	chr21:41711520~41715775:-
OV	cis	rs73186030	0.546	rs67931976	ENSG00000272758.4	RP11-299J3.8	3.83	0.000169	0.0492	0.28	0.25	Serum parathyroid hormone levels;	chr3:122386868	chr3:122416207~122443180:+
OV	cis	rs13179617	0.887	rs12188685	ENSG00000272308.1	RP11-231G3.1	-3.83	0.000169	0.0493	-0.3	-0.25	Intelligence (multi-trait analysis);	chr5:61548097	chr5:60866457~60866935:-
OV	cis	rs2043599	1	rs7259764	ENSG00000269793.4	ZIM2-AS1	3.83	0.000169	0.0493	0.64	0.25	Exploratory eye movement dysfunction in schizophrenia (number of eye fixations);Exploratory eye movement dysfunction in schizophrenia (responsive search score);Immune reponse to smallpox (secreted IFN-alpha);	chr19:55954861	chr19:56690686~56799646:+
OV	cis	rs4478239	1	rs6841945	ENSG00000213332.4	SLC25A5P6	-3.83	0.000169	0.0493	-0.54	-0.25	Major depressive disorder;	chr4:187249012	chr4:186328716~186329601:-
OV	cis	rs4478239	1	rs2126376	ENSG00000213332.4	SLC25A5P6	-3.83	0.000169	0.0493	-0.54	-0.25	Major depressive disorder;	chr4:187253321	chr4:186328716~186329601:-
OV	cis	rs11105298	0.891	rs10858898	ENSG00000257194.2	RP11-567C2.1	-3.83	0.000169	0.0493	-0.37	-0.25	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr12:89528334	chr12:90107739~90112779:+
OV	cis	rs17253792	0.822	rs12323476	ENSG00000186615.9	KTN1-AS1	3.83	0.000169	0.0493	0.4	0.25	Putamen volume;	chr14:55706004	chr14:55499278~55580110:-
OV	cis	rs10829156	0.755	rs10732437	ENSG00000225527.1	RP11-383B4.4	-3.83	0.000169	0.0493	-0.34	-0.25	Sudden cardiac arrest;	chr10:18626973	chr10:18531849~18533336:-
OV	cis	rs62229266	0.771	rs62230790	ENSG00000231106.2	LINC01436	3.82	0.000169	0.0493	0.3	0.25	Mitral valve prolapse;	chr21:36016613	chr21:36005338~36007838:+
OV	cis	rs6661961	0.752	rs4557976	ENSG00000237975.5	FLG-AS1	-3.82	0.000169	0.0494	-0.32	-0.25	Atopic dermatitis;	chr1:152442590	chr1:152168125~152445456:+
OV	cis	rs5015933	1	rs10760395	ENSG00000232630.1	PRPS1P2	-3.82	0.000169	0.0494	-0.23	-0.25	Body mass index;	chr9:125369582	chr9:125150653~125151589:+
OV	cis	rs10759883	0.563	rs10819720	ENSG00000175611.10	LINC00476	3.82	0.000169	0.0494	0.31	0.25	Nicotine dependence;	chr9:96021506	chr9:95759231~95875977:-
OV	cis	rs1555322	0.53	rs2425047	ENSG00000279253.1	RP4-614O4.13	3.82	0.000169	0.0494	0.3	0.25	Attention deficit hyperactivity disorder;	chr20:35283872	chr20:35262727~35264187:-
OV	cis	rs10924970	0.781	rs10754614	ENSG00000236863.2	RPL23AP23	3.82	0.000169	0.0494	0.25	0.25	Asthma;	chr1:235330489	chr1:235295865~235296335:+
OV	cis	rs4845570	0.749	rs11576810	ENSG00000238711.1	RNY4P25	-3.82	0.000169	0.0494	-0.36	-0.25	Coronary artery disease;	chr1:151739725	chr1:151439000~151439095:+
OV	cis	rs17253792	0.732	rs8017891	ENSG00000186615.9	KTN1-AS1	3.82	0.000169	0.0494	0.38	0.25	Putamen volume;	chr14:55706249	chr14:55499278~55580110:-
OV	cis	rs4713118	0.628	rs12179134	ENSG00000220721.1	OR1F12	3.82	0.000169	0.0494	0.34	0.25	Parkinson's disease;	chr6:27707690	chr6:28073316~28074233:+
OV	cis	rs6772849	0.93	rs4857914	ENSG00000277250.1	Metazoa_SRP	-3.82	0.000169	0.0494	-0.28	-0.25	Monocyte percentage of white cells;Monocyte count;	chr3:128631841	chr3:128673681~128674021:-
OV	cis	rs2286503	0.839	rs4722189	ENSG00000228649.7	AC005682.5	3.82	0.000169	0.0494	0.31	0.25	Fibrinogen;	chr7:22820855	chr7:22854178~22861579:+
OV	cis	rs4591358	0.765	rs4355137	ENSG00000223466.1	AC064834.2	3.82	0.000169	0.0494	0.29	0.25	Adverse response to chemotherapy (neutropenia/leucopenia) (all antimicrotubule drugs);	chr2:195486465	chr2:195533035~195538681:+
OV	cis	rs4665809	1	rs7599132	ENSG00000231655.1	AC011742.3	-3.82	0.000169	0.0494	-0.36	-0.25	Gut microbiome composition (summer);	chr2:26056941	chr2:26140263~26141264:-
OV	cis	rs2282300	0.739	rs1616223	ENSG00000242353.1	RP4-710M3.1	-3.82	0.000169	0.0494	-0.35	-0.25	Morning vs. evening chronotype;	chr11:30317236	chr11:30368148~30368646:+
OV	cis	rs2282300	0.739	rs1717772	ENSG00000242353.1	RP4-710M3.1	-3.82	0.000169	0.0494	-0.35	-0.25	Morning vs. evening chronotype;	chr11:30318586	chr11:30368148~30368646:+
OV	cis	rs2282300	0.739	rs1933342	ENSG00000242353.1	RP4-710M3.1	3.82	0.000169	0.0494	0.35	0.25	Morning vs. evening chronotype;	chr11:30291278	chr11:30368148~30368646:+
OV	cis	rs2282300	0.739	rs2225909	ENSG00000242353.1	RP4-710M3.1	3.82	0.000169	0.0494	0.35	0.25	Morning vs. evening chronotype;	chr11:30308197	chr11:30368148~30368646:+
OV	cis	rs2282300	0.702	rs2211018	ENSG00000242353.1	RP4-710M3.1	3.82	0.000169	0.0494	0.35	0.25	Morning vs. evening chronotype;	chr11:30308532	chr11:30368148~30368646:+
OV	cis	rs2282300	0.739	rs7926465	ENSG00000242353.1	RP4-710M3.1	3.82	0.000169	0.0494	0.35	0.25	Morning vs. evening chronotype;	chr11:30311469	chr11:30368148~30368646:+
OV	cis	rs67311347	0.544	rs4974047	ENSG00000223797.4	ENTPD3-AS1	3.82	0.00017	0.0494	0.25	0.25	Renal cell carcinoma;	chr3:40298162	chr3:40313802~40453329:-
OV	cis	rs801193	0.967	rs2707853	ENSG00000237310.1	GS1-124K5.4	3.82	0.00017	0.0494	0.26	0.25	Aortic root size;	chr7:66749023	chr7:66493706~66495474:+
OV	cis	rs4950322	0.515	rs72691016	ENSG00000278811.3	LINC00624	3.82	0.00017	0.0494	0.31	0.25	Protein quantitative trait loci;	chr1:147245375	chr1:147258885~147517875:-
OV	cis	rs338419	0.617	rs2414660	ENSG00000240238.1	RP11-112N19.2	-3.82	0.00017	0.0494	-0.24	-0.25	Blood protein levels;	chr15:60183143	chr15:59552615~59553093:-
OV	cis	rs80168506	0.748	rs12463958	ENSG00000272519.1	RP11-105N14.2	3.82	0.00017	0.0494	0.36	0.25	Selective IgA deficiency;	chr2:213213812	chr2:213266995~213276152:-
OV	cis	rs80168506	0.748	rs6435758	ENSG00000272519.1	RP11-105N14.2	3.82	0.00017	0.0494	0.36	0.25	Selective IgA deficiency;	chr2:213215638	chr2:213266995~213276152:-
OV	cis	rs80168506	0.748	rs10204931	ENSG00000272519.1	RP11-105N14.2	3.82	0.00017	0.0494	0.36	0.25	Selective IgA deficiency;	chr2:213216140	chr2:213266995~213276152:-
OV	cis	rs80168506	0.748	rs56020963	ENSG00000272519.1	RP11-105N14.2	3.82	0.00017	0.0494	0.36	0.25	Selective IgA deficiency;	chr2:213217656	chr2:213266995~213276152:-
OV	cis	rs80168506	1	rs35925141	ENSG00000272519.1	RP11-105N14.2	3.82	0.00017	0.0494	0.36	0.25	Selective IgA deficiency;	chr2:213217808	chr2:213266995~213276152:-
OV	cis	rs507080	0.922	rs558907	ENSG00000278376.1	RP11-158I9.8	-3.82	0.00017	0.0494	-0.25	-0.25	Serum metabolite levels;	chr11:118687746	chr11:118791254~118793137:+
OV	cis	rs507080	0.885	rs7926959	ENSG00000278376.1	RP11-158I9.8	-3.82	0.00017	0.0494	-0.25	-0.25	Serum metabolite levels;	chr11:118689157	chr11:118791254~118793137:+
OV	cis	rs507080	0.663	rs7926970	ENSG00000278376.1	RP11-158I9.8	-3.82	0.00017	0.0494	-0.25	-0.25	Serum metabolite levels;	chr11:118689172	chr11:118791254~118793137:+
OV	cis	rs507080	0.885	rs4938530	ENSG00000278376.1	RP11-158I9.8	-3.82	0.00017	0.0494	-0.25	-0.25	Serum metabolite levels;	chr11:118689861	chr11:118791254~118793137:+
OV	cis	rs10754283	0.967	rs1934045	ENSG00000231613.1	RP5-943J3.1	-3.82	0.00017	0.0494	-0.27	-0.25	Amyotrophic lateral sclerosis (sporadic);	chr1:89642240	chr1:89788914~89790492:+
OV	cis	rs6142102	0.961	rs761235	ENSG00000264616.1	MIR4755	3.82	0.00017	0.0495	0.3	0.25	Skin pigmentation;	chr20:33946602	chr20:34049119~34049190:+
OV	cis	rs9813712	0.597	rs10934931	ENSG00000249846.5	RP11-77P16.4	-3.82	0.00017	0.0495	-0.31	-0.25	Response to amphetamines;	chr3:130261365	chr3:130112550~130120579:+
OV	cis	rs853679	0.76	rs9393910	ENSG00000220721.1	OR1F12	3.82	0.00017	0.0495	0.33	0.25	Depression;	chr6:28240414	chr6:28073316~28074233:+
OV	cis	rs853679	0.76	rs9368563	ENSG00000220721.1	OR1F12	3.82	0.00017	0.0495	0.33	0.25	Depression;	chr6:28240780	chr6:28073316~28074233:+
OV	cis	rs853679	0.76	rs9295768	ENSG00000220721.1	OR1F12	3.82	0.00017	0.0495	0.33	0.25	Depression;	chr6:28241324	chr6:28073316~28074233:+
OV	cis	rs853679	0.699	rs9468318	ENSG00000220721.1	OR1F12	3.82	0.00017	0.0495	0.33	0.25	Depression;	chr6:28241753	chr6:28073316~28074233:+
OV	cis	rs853679	0.76	rs9357067	ENSG00000220721.1	OR1F12	3.82	0.00017	0.0495	0.33	0.25	Depression;	chr6:28242515	chr6:28073316~28074233:+
OV	cis	rs853679	0.76	rs967005	ENSG00000220721.1	OR1F12	3.82	0.00017	0.0495	0.33	0.25	Depression;	chr6:28242910	chr6:28073316~28074233:+
OV	cis	rs853679	0.607	rs67101035	ENSG00000280107.1	AL022393.9	-3.82	0.00017	0.0495	-0.55	-0.25	Depression;	chr6:27831109	chr6:28170845~28172521:+
OV	cis	rs2070488	0.699	rs13064938	ENSG00000229589.1	ACVR2B-AS1	3.82	0.00017	0.0495	0.28	0.25	Electrocardiographic conduction measures;	chr3:38398746	chr3:38451027~38454820:-
OV	cis	rs7667	0.812	rs12045440	ENSG00000240490.3	RN7SL277P	3.82	0.00017	0.0495	0.29	0.25	Crohn's disease and psoriasis;	chr1:19439024	chr1:19424384~19424671:+
OV	cis	rs694739	0.964	rs2510066	ENSG00000236935.1	AP003774.1	3.82	0.00017	0.0495	0.32	0.25	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64284975	chr11:64325050~64329504:-
OV	cis	rs694739	0.894	rs887314	ENSG00000236935.1	AP003774.1	3.82	0.00017	0.0495	0.32	0.25	Alopecia areata;Crohn's disease;Psoriasis vulgaris;	chr11:64285685	chr11:64325050~64329504:-
OV	cis	rs295490	0.748	rs116416768	ENSG00000272656.1	RP11-219D15.3	3.82	0.00017	0.0495	0.49	0.25	PR interval in Tripanosoma cruzi seropositivity;	chr3:139382294	chr3:139349024~139349371:-
OV	cis	rs295490	0.748	rs56993164	ENSG00000272656.1	RP11-219D15.3	3.82	0.00017	0.0495	0.49	0.25	PR interval in Tripanosoma cruzi seropositivity;	chr3:139388391	chr3:139349024~139349371:-
OV	cis	rs4664293	0.51	rs66537229	ENSG00000226266.5	AC009961.3	3.82	0.00017	0.0495	0.3	0.25	Monocyte percentage of white cells;	chr2:159624095	chr2:159670708~159712435:-
OV	cis	rs4664293	0.51	rs66571608	ENSG00000226266.5	AC009961.3	3.82	0.00017	0.0495	0.3	0.25	Monocyte percentage of white cells;	chr2:159635851	chr2:159670708~159712435:-
OV	cis	rs4664293	0.51	rs66589863	ENSG00000226266.5	AC009961.3	3.82	0.00017	0.0495	0.3	0.25	Monocyte percentage of white cells;	chr2:159649684	chr2:159670708~159712435:-
OV	cis	rs875971	0.619	rs10278371	ENSG00000237310.1	GS1-124K5.4	-3.82	0.00017	0.0495	-0.25	-0.25	Aortic root size;	chr7:66586553	chr7:66493706~66495474:+
OV	cis	rs6071524	0.508	rs1406856	ENSG00000277581.1	RP4-616B8.6	-3.82	0.00017	0.0495	-0.29	-0.25	Autism spectrum disorder or schizophrenia;	chr20:38753759	chr20:38962472~38962993:+
OV	cis	rs6071524	0.508	rs2255202	ENSG00000277581.1	RP4-616B8.6	-3.82	0.00017	0.0495	-0.29	-0.25	Autism spectrum disorder or schizophrenia;	chr20:38757476	chr20:38962472~38962993:+
OV	cis	rs9326248	1	rs664971	ENSG00000280143.1	AP000892.6	-3.82	0.00017	0.0495	-0.26	-0.25	Blood protein levels;	chr11:117200141	chr11:117204967~117210292:+
OV	cis	rs6657613	0.68	rs10887994	ENSG00000186715.9	MST1L	3.82	0.00017	0.0495	0.27	0.25	Hip circumference adjusted for BMI;	chr1:17045260	chr1:16754910~16770237:-
OV	cis	rs7580658	0.613	rs6754999	ENSG00000236682.1	AC068282.3	-3.82	0.00017	0.0495	-0.34	-0.25	Protein C levels;	chr2:127437811	chr2:127389130~127400580:+
OV	cis	rs2999052	1	rs2811509	ENSG00000277250.1	Metazoa_SRP	3.82	0.00017	0.0495	0.3	0.25	Hypospadias;	chr3:128197708	chr3:128673681~128674021:-
OV	cis	rs6919534	0.688	rs9366882	ENSG00000265123.2	RN7SL200P	3.82	0.00017	0.0495	0.28	0.25	Height;	chr6:35248246	chr6:34685355~34685642:-
OV	cis	rs10992471	0.729	rs2181585	ENSG00000281156.1	MIR3651	-3.82	0.00017	0.0495	-0.27	-0.25	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92789548	chr9:92292458~92292547:-
OV	cis	rs7246657	0.943	rs10407084	ENSG00000226686.6	LINC01535	-3.82	0.00017	0.0495	-0.38	-0.25	Coronary artery calcification;	chr19:37416890	chr19:37251912~37265535:+
OV	cis	rs7246657	0.943	rs7252099	ENSG00000226686.6	LINC01535	-3.82	0.00017	0.0495	-0.38	-0.25	Coronary artery calcification;	chr19:37442878	chr19:37251912~37265535:+
OV	cis	rs7246657	0.943	rs7255972	ENSG00000226686.6	LINC01535	-3.82	0.00017	0.0495	-0.38	-0.25	Coronary artery calcification;	chr19:37442939	chr19:37251912~37265535:+
OV	cis	rs7246657	0.943	rs1015849	ENSG00000226686.6	LINC01535	-3.82	0.00017	0.0495	-0.38	-0.25	Coronary artery calcification;	chr19:37455278	chr19:37251912~37265535:+
OV	cis	rs10992471	0.528	rs4744133	ENSG00000281156.1	MIR3651	-3.82	0.00017	0.0496	-0.28	-0.25	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr9:92464420	chr9:92292458~92292547:-
OV	cis	rs1862618	0.853	rs832583	ENSG00000271828.1	CTD-2310F14.1	3.82	0.00017	0.0496	0.4	0.25	Initial pursuit acceleration;	chr5:56882390	chr5:56927874~56929573:+
OV	cis	rs1862618	0.713	rs832550	ENSG00000271828.1	CTD-2310F14.1	3.82	0.00017	0.0496	0.4	0.25	Initial pursuit acceleration;	chr5:56886762	chr5:56927874~56929573:+
OV	cis	rs1862618	0.756	rs832548	ENSG00000271828.1	CTD-2310F14.1	3.82	0.00017	0.0496	0.4	0.25	Initial pursuit acceleration;	chr5:56887810	chr5:56927874~56929573:+
OV	cis	rs1862618	0.802	rs832547	ENSG00000271828.1	CTD-2310F14.1	3.82	0.00017	0.0496	0.4	0.25	Initial pursuit acceleration;	chr5:56888114	chr5:56927874~56929573:+
OV	cis	rs1862618	0.853	rs866222	ENSG00000271828.1	CTD-2310F14.1	3.82	0.00017	0.0496	0.4	0.25	Initial pursuit acceleration;	chr5:56888617	chr5:56927874~56929573:+
OV	cis	rs1862618	0.853	rs861283	ENSG00000271828.1	CTD-2310F14.1	3.82	0.00017	0.0496	0.4	0.25	Initial pursuit acceleration;	chr5:56888783	chr5:56927874~56929573:+
OV	cis	rs1862618	0.802	rs252900	ENSG00000271828.1	CTD-2310F14.1	3.82	0.00017	0.0496	0.4	0.25	Initial pursuit acceleration;	chr5:56889454	chr5:56927874~56929573:+
OV	cis	rs17772222	0.727	rs3179969	ENSG00000258789.1	RP11-507K2.3	-3.82	0.00017	0.0496	-0.25	-0.25	Coronary artery calcification;	chr14:88396185	chr14:88551597~88552493:+
OV	cis	rs9393777	0.513	rs7740197	ENSG00000243307.2	POM121L6P	3.82	0.00017	0.0496	0.29	0.25	Intelligence (multi-trait analysis);	chr6:26663250	chr6:26896952~26898777:+
OV	cis	rs650258	0.815	rs506616	ENSG00000256196.1	RP11-881M11.4	-3.82	0.00017	0.0496	-0.35	-0.25	Gut microbiota (bacterial taxa);Multiple sclerosis;Gut microbiota (functional units);	chr11:61067571	chr11:60918469~60925397:-
OV	cis	rs10504130	0.569	rs34004633	ENSG00000272024.1	RP11-546K22.3	-3.82	0.00017	0.0496	-0.33	-0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:51764279	chr8:51950284~51950690:+
OV	cis	rs10759883	0.612	rs816675	ENSG00000175611.10	LINC00476	-3.82	0.000171	0.0496	-0.3	-0.25	Nicotine dependence;	chr9:95806799	chr9:95759231~95875977:-
OV	cis	rs10759883	0.627	rs816674	ENSG00000175611.10	LINC00476	-3.82	0.000171	0.0496	-0.3	-0.25	Nicotine dependence;	chr9:95807835	chr9:95759231~95875977:-
OV	cis	rs957448	1	rs1055800	ENSG00000253175.1	RP11-267M23.6	-3.82	0.000171	0.0497	-0.28	-0.25	Nonsyndromic cleft lip with cleft palate;	chr8:94510810	chr8:94565036~94565715:+
OV	cis	rs3758911	0.929	rs1843	ENSG00000261098.1	RP11-819C21.1	-3.82	0.000171	0.0497	-0.25	-0.25	Coronary artery disease;	chr11:107312219	chr11:107312132~107316271:-
OV	cis	rs1560104	0.597	rs12708758	ENSG00000259899.1	CTD-3037G24.3	-3.82	0.000171	0.0497	-0.28	-0.25	Obesity-related traits;	chr16:12616844	chr16:12560756~12611044:-
OV	cis	rs514406	0.525	rs269291	ENSG00000206627.1	RNU6-969P	3.82	0.000171	0.0497	0.27	0.25	Monocyte count;	chr1:52723625	chr1:52805108~52805212:-
OV	cis	rs9649213	0.593	rs3801255	ENSG00000272950.1	RP11-307C18.1	3.82	0.000171	0.0497	0.29	0.25	Prostate cancer (SNP x SNP interaction);	chr7:98371617	chr7:98322853~98323430:+
OV	cis	rs67311347	0.544	rs7644181	ENSG00000223797.4	ENTPD3-AS1	-3.82	0.000171	0.0497	-0.26	-0.25	Renal cell carcinoma;	chr3:40314174	chr3:40313802~40453329:-
OV	cis	rs2108622	0.727	rs62106155	ENSG00000267453.5	AC004791.2	-3.82	0.000171	0.0497	-0.28	-0.25	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869550	chr19:15851993~15864904:-
OV	cis	rs2108622	0.727	rs62106157	ENSG00000267453.5	AC004791.2	-3.82	0.000171	0.0497	-0.28	-0.25	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869638	chr19:15851993~15864904:-
OV	cis	rs2108622	0.727	rs62106158	ENSG00000267453.5	AC004791.2	-3.82	0.000171	0.0497	-0.28	-0.25	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869682	chr19:15851993~15864904:-
OV	cis	rs2108622	0.727	rs7256877	ENSG00000267453.5	AC004791.2	-3.82	0.000171	0.0497	-0.28	-0.25	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15869873	chr19:15851993~15864904:-
OV	cis	rs2108622	0.559	rs7252638	ENSG00000267453.5	AC004791.2	-3.82	0.000171	0.0497	-0.28	-0.25	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870215	chr19:15851993~15864904:-
OV	cis	rs2108622	0.727	rs7253684	ENSG00000267453.5	AC004791.2	-3.82	0.000171	0.0497	-0.28	-0.25	Response to Vitamin E supplementation;Acenocoumarol maintenance dosage;Circulating phylloquinone levels;Metabolite levels;Warfarin maintenance dose;Vitamin E levels;	chr19:15870316	chr19:15851993~15864904:-
OV	cis	rs7267979	0.727	rs4815431	ENSG00000274973.1	RP13-401N8.7	3.82	0.000171	0.0497	0.29	0.25	Liver enzyme levels (alkaline phosphatase);	chr20:25551769	chr20:25845497~25845862:+
OV	cis	rs875971	0.929	rs4122249	ENSG00000224316.1	RP11-479O9.2	3.82	0.000171	0.0497	0.26	0.25	Aortic root size;	chr7:66455949	chr7:65773620~65802067:+
OV	cis	rs9952991	0.566	rs7234029	ENSG00000266146.1	MIR5190	3.82	0.000171	0.0497	0.32	0.25	Inflammatory skin disease;	chr18:12877061	chr18:13459947~13460026:+
OV	cis	rs634537	0.525	rs504318	ENSG00000234840.1	LINC01239	3.82	0.000171	0.0498	0.27	0.25	Glioma;Non-glioblastoma glioma;Glioblastoma;	chr9:22024024	chr9:22646200~22824213:+
OV	cis	rs1707322	0.717	rs11211161	ENSG00000234329.1	RP11-767N6.2	3.82	0.000171	0.0498	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45682466	chr1:45651039~45651826:-
OV	cis	rs1707322	0.752	rs61784793	ENSG00000234329.1	RP11-767N6.2	3.82	0.000171	0.0498	0.26	0.25	Body mass index;Body mass index in physically active individuals;Body mass index (joint analysis main effects and physical activity interaction);	chr1:45683613	chr1:45651039~45651826:-
OV	cis	rs9467711	0.606	rs9379859	ENSG00000243307.2	POM121L6P	-3.82	0.000171	0.0498	-0.43	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26369321	chr6:26896952~26898777:+
OV	cis	rs9467711	0.606	rs9358935	ENSG00000243307.2	POM121L6P	-3.82	0.000171	0.0498	-0.43	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26369359	chr6:26896952~26898777:+
OV	cis	rs9467711	0.539	rs34436535	ENSG00000243307.2	POM121L6P	-3.82	0.000171	0.0498	-0.43	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26370137	chr6:26896952~26898777:+
OV	cis	rs9467711	0.606	rs35307327	ENSG00000243307.2	POM121L6P	-3.82	0.000171	0.0498	-0.43	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26370246	chr6:26896952~26898777:+
OV	cis	rs9467711	0.606	rs34878490	ENSG00000243307.2	POM121L6P	-3.82	0.000171	0.0498	-0.43	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26370344	chr6:26896952~26898777:+
OV	cis	rs9467711	0.606	rs9358936	ENSG00000243307.2	POM121L6P	-3.82	0.000171	0.0498	-0.43	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26370429	chr6:26896952~26898777:+
OV	cis	rs9467711	0.606	rs9393711	ENSG00000243307.2	POM121L6P	-3.82	0.000171	0.0498	-0.43	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26370431	chr6:26896952~26898777:+
OV	cis	rs9467711	0.606	rs9393712	ENSG00000243307.2	POM121L6P	-3.82	0.000171	0.0498	-0.43	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26370772	chr6:26896952~26898777:+
OV	cis	rs9467711	0.606	rs12173854	ENSG00000243307.2	POM121L6P	-3.82	0.000171	0.0498	-0.43	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26371451	chr6:26896952~26898777:+
OV	cis	rs9467711	0.606	rs9379863	ENSG00000243307.2	POM121L6P	-3.82	0.000171	0.0498	-0.43	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26372199	chr6:26896952~26898777:+
OV	cis	rs9467711	0.606	rs9379864	ENSG00000243307.2	POM121L6P	-3.82	0.000171	0.0498	-0.43	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26372356	chr6:26896952~26898777:+
OV	cis	rs9467711	0.606	rs12176317	ENSG00000243307.2	POM121L6P	-3.82	0.000171	0.0498	-0.43	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26372558	chr6:26896952~26898777:+
OV	cis	rs9467711	0.606	rs12174602	ENSG00000243307.2	POM121L6P	-3.82	0.000171	0.0498	-0.43	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26372599	chr6:26896952~26898777:+
OV	cis	rs9467711	0.606	rs12174623	ENSG00000243307.2	POM121L6P	-3.82	0.000171	0.0498	-0.43	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26372858	chr6:26896952~26898777:+
OV	cis	rs9467711	0.606	rs12174631	ENSG00000243307.2	POM121L6P	-3.82	0.000171	0.0498	-0.43	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26372922	chr6:26896952~26898777:+
OV	cis	rs9467711	0.659	rs13216828	ENSG00000243307.2	POM121L6P	-3.82	0.000171	0.0498	-0.43	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26373279	chr6:26896952~26898777:+
OV	cis	rs9467711	0.606	rs9393714	ENSG00000243307.2	POM121L6P	-3.82	0.000171	0.0498	-0.43	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26373512	chr6:26896952~26898777:+
OV	cis	rs9467711	0.606	rs9358937	ENSG00000243307.2	POM121L6P	-3.82	0.000171	0.0498	-0.43	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26374046	chr6:26896952~26898777:+
OV	cis	rs9467711	0.606	rs2073527	ENSG00000243307.2	POM121L6P	-3.82	0.000171	0.0498	-0.43	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26374750	chr6:26896952~26898777:+
OV	cis	rs9467711	0.606	rs2073530	ENSG00000243307.2	POM121L6P	-3.82	0.000171	0.0498	-0.43	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26375015	chr6:26896952~26898777:+
OV	cis	rs9467711	0.606	rs2073531	ENSG00000243307.2	POM121L6P	-3.82	0.000171	0.0498	-0.43	-0.25	Autism spectrum disorder or schizophrenia;	chr6:26375028	chr6:26896952~26898777:+
OV	cis	rs4296809	0.556	rs5007472	ENSG00000249779.1	RP11-447H19.3	-3.82	0.000171	0.0498	-0.48	-0.25	Brain structure;	chr5:44148554	chr5:43206709~43207811:+
OV	cis	rs10504130	0.569	rs34372756	ENSG00000272024.1	RP11-546K22.3	-3.82	0.000171	0.0498	-0.32	-0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:51908796	chr8:51950284~51950690:+
OV	cis	rs10504130	0.569	rs9650180	ENSG00000272024.1	RP11-546K22.3	-3.82	0.000171	0.0498	-0.32	-0.25	Venous thromboembolism (SNP x SNP interaction);	chr8:51912306	chr8:51950284~51950690:+
OV	cis	rs2999052	1	rs9873786	ENSG00000277250.1	Metazoa_SRP	3.82	0.000171	0.0498	0.29	0.25	Hypospadias;	chr3:128223536	chr3:128673681~128674021:-
OV	cis	rs10266483	0.654	rs6962076	ENSG00000232727.2	YWHAEP1	-3.82	0.000171	0.0498	-0.29	-0.25	Response to statin therapy;	chr7:64559214	chr7:64433830~64434592:+
OV	cis	rs1559040	0.858	rs11695936	ENSG00000272156.1	RP11-477N3.1	-3.82	0.000171	0.0498	-0.43	-0.25	Sudden cardiac arrest;	chr2:54090135	chr2:54082554~54085066:+
OV	cis	rs8028182	0.636	rs4886707	ENSG00000260269.4	CTD-2323K18.1	-3.82	0.000171	0.0498	-0.3	-0.25	Sudden cardiac arrest;	chr15:75463126	chr15:75527150~75601205:-
OV	cis	rs6545883	0.894	rs12620105	ENSG00000270820.4	RP11-355B11.2	-3.82	0.000171	0.0498	-0.28	-0.25	Tuberculosis;	chr2:61285186	chr2:61471188~61484130:+
OV	cis	rs4666360	1	rs4666359	ENSG00000234378.1	AC098828.2	3.82	0.000171	0.0498	0.25	0.25	Adverse response to chemotherapy (neutropenia/leucopenia) (paclitaxel);	chr2:20135853	chr2:20063856~20106829:-
OV	cis	rs6424270	0.569	rs6424272	ENSG00000251508.1	RP5-862P8.3	3.82	0.000171	0.0498	0.32	0.25	Bone mineral density (Ward's triangle area);	chr1:233055622	chr1:233295325~233295727:-
OV	cis	rs6893300	0.785	rs3797762	ENSG00000229721.3	RP11-252I14.1	3.82	0.000171	0.0498	0.29	0.25	Resting heart rate;	chr5:179775687	chr5:180226378~180227000:-
OV	cis	rs7254114	0.568	rs8111456	ENSG00000278897.1	AC020951.1	-3.82	0.000171	0.0498	-0.22	-0.25	Immature fraction of reticulocytes;	chr19:11190471	chr19:11856032~11858302:+
OV	cis	rs9649213	0.593	rs6465666	ENSG00000272950.1	RP11-307C18.1	-3.82	0.000172	0.0499	-0.29	-0.25	Prostate cancer (SNP x SNP interaction);	chr7:98307946	chr7:98322853~98323430:+
OV	cis	rs848490	0.674	rs7803449	ENSG00000214293.7	APTR	3.82	0.000172	0.0499	0.3	0.25	Glomerular filtration rate (creatinine);Glomerular filtration rate in non diabetics (creatinine);	chr7:77679660	chr7:77657660~77696265:-
OV	cis	rs7674212	1	rs7691873	ENSG00000246560.2	RP11-10L12.4	-3.82	0.000172	0.0499	-0.3	-0.25	Type 2 diabetes;	chr4:103066742	chr4:102828055~102844075:+
OV	cis	rs9649213	0.511	rs6950994	ENSG00000223402.1	AC074121.4	-3.82	0.000172	0.0499	-0.3	-0.25	Prostate cancer (SNP x SNP interaction);	chr7:98258560	chr7:98478551~98479225:-
OV	cis	rs944797	0.935	rs1333046	ENSG00000234840.1	LINC01239	-3.82	0.000172	0.05	-0.27	-0.25	Coronary heart disease;	chr9:22124124	chr9:22646200~22824213:+
OV	cis	rs4287000	0.615	rs11793637	ENSG00000237679.2	VDAC1P11	3.82	0.000172	0.05	0.27	0.25	Itch intensity from mosquito bite adjusted by bite size;	chr9:93653617	chr9:94287699~94288550:-
OV	cis	rs251130	1	rs251130	ENSG00000224032.5	EPB41L4A-AS1	3.82	0.000172	0.05	0.23	0.25	Menarche (age at onset);	chr5:111524099	chr5:112160526~112164276:+
OV	cis	rs7520050	0.833	rs1085242	ENSG00000280836.1	AL355480.1	3.82	0.000172	0.05	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:46078552	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs1085243	ENSG00000280836.1	AL355480.1	3.82	0.000172	0.05	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:46079096	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs1768803	ENSG00000280836.1	AL355480.1	3.82	0.000172	0.05	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:46080536	chr1:45581219~45581321:-
OV	cis	rs7520050	0.931	rs1707333	ENSG00000280836.1	AL355480.1	3.82	0.000172	0.05	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:46081363	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs4660910	ENSG00000280836.1	AL355480.1	3.82	0.000172	0.05	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:46082730	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs785481	ENSG00000280836.1	AL355480.1	3.82	0.000172	0.05	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:46088846	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs6675726	ENSG00000280836.1	AL355480.1	3.82	0.000172	0.05	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:46094971	chr1:45581219~45581321:-
OV	cis	rs7520050	0.966	rs785520	ENSG00000280836.1	AL355480.1	3.82	0.000172	0.05	0.3	0.25	Reticulocyte count;Red blood cell count;	chr1:46103164	chr1:45581219~45581321:-
OV	cis	rs9393777	0.841	rs34332556	ENSG00000243307.2	POM121L6P	-3.82	0.000172	0.05	-0.44	-0.25	Intelligence (multi-trait analysis);	chr6:27389635	chr6:26896952~26898777:+
OV	cis	rs743757	1	rs2236973	ENSG00000228008.1	CTD-2330K9.3	3.82	0.000172	0.05	0.34	0.25	Diastolic blood pressure;	chr3:50436853	chr3:49903845~49916937:+
OV	cis	rs10740039	0.81	rs2165691	ENSG00000254271.1	RP11-131N11.4	3.82	0.000172	0.05	0.32	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60611891	chr10:60734342~60741828:+
OV	cis	rs10740039	0.768	rs10821801	ENSG00000254271.1	RP11-131N11.4	3.82	0.000172	0.05	0.32	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60612017	chr10:60734342~60741828:+
OV	cis	rs10740039	0.81	rs1442543	ENSG00000254271.1	RP11-131N11.4	3.82	0.000172	0.05	0.32	0.25	Coronary artery calcified atherosclerotic plaque (130 HU threshold) in type 2 diabetes;	chr10:60613704	chr10:60734342~60741828:+
OV	trans	rs3749237	0.595	rs17595772	ENSG00000197582.5	GPX1P1	24.48	1.28e-65	5.25e-56	1.06	0.85	Resting heart rate;	chr3:49372271	chrX:13378735~13379340:-
OV	trans	rs3749237	0.595	rs7621003	ENSG00000197582.5	GPX1P1	24.48	1.28e-65	5.25e-56	1.06	0.85	Resting heart rate;	chr3:49373971	chrX:13378735~13379340:-
OV	trans	rs3749237	0.595	rs4955412	ENSG00000197582.5	GPX1P1	24.48	1.28e-65	5.25e-56	1.06	0.85	Resting heart rate;	chr3:49380735	chrX:13378735~13379340:-
OV	trans	rs3749237	0.557	rs7631908	ENSG00000197582.5	GPX1P1	24.48	1.28e-65	5.25e-56	1.06	0.85	Resting heart rate;	chr3:49388274	chrX:13378735~13379340:-
OV	trans	rs3749237	0.615	rs55957735	ENSG00000197582.5	GPX1P1	24.48	1.28e-65	5.25e-56	1.06	0.85	Resting heart rate;	chr3:49400725	chrX:13378735~13379340:-
OV	trans	rs3749237	0.595	rs4855877	ENSG00000197582.5	GPX1P1	24.48	1.28e-65	5.25e-56	1.06	0.85	Resting heart rate;	chr3:49411094	chrX:13378735~13379340:-
OV	trans	rs3749237	0.595	rs2878298	ENSG00000197582.5	GPX1P1	24.46	1.42e-65	5.41e-56	1.07	0.85	Resting heart rate;	chr3:49368647	chrX:13378735~13379340:-
OV	trans	rs13177918	0.557	rs12520101	ENSG00000224114.1	RP11-343H5.4	24.22	7.36e-65	2.38e-55	1.14	0.85	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:206695837~206696269:-
OV	trans	rs3749237	0.595	rs12489092	ENSG00000197582.5	GPX1P1	24.2	8.69e-65	2.38e-55	1.07	0.85	Resting heart rate;	chr3:49513481	chrX:13378735~13379340:-
OV	trans	rs3749237	0.595	rs3870337	ENSG00000197582.5	GPX1P1	24.2	8.69e-65	2.38e-55	1.07	0.85	Resting heart rate;	chr3:49519662	chrX:13378735~13379340:-
OV	trans	rs3749237	0.595	rs4855873	ENSG00000197582.5	GPX1P1	24.07	2.01e-64	3.54e-55	1.06	0.85	Resting heart rate;	chr3:49421681	chrX:13378735~13379340:-
OV	trans	rs3749237	0.595	rs1464566	ENSG00000197582.5	GPX1P1	24.07	2.01e-64	3.54e-55	1.06	0.85	Resting heart rate;	chr3:49421943	chrX:13378735~13379340:-
OV	trans	rs3749237	0.537	rs4459909	ENSG00000197582.5	GPX1P1	24.07	2.01e-64	3.54e-55	1.06	0.85	Resting heart rate;	chr3:49431784	chrX:13378735~13379340:-
OV	trans	rs3749237	0.595	rs11130196	ENSG00000197582.5	GPX1P1	24.07	2.01e-64	3.54e-55	1.06	0.85	Resting heart rate;	chr3:49452716	chrX:13378735~13379340:-
OV	trans	rs3749237	0.595	rs4855839	ENSG00000197582.5	GPX1P1	24.07	2.01e-64	3.54e-55	1.06	0.85	Resting heart rate;	chr3:49470414	chrX:13378735~13379340:-
OV	trans	rs3749237	0.595	rs4855864	ENSG00000197582.5	GPX1P1	24.07	2.01e-64	3.54e-55	1.06	0.85	Resting heart rate;	chr3:49484541	chrX:13378735~13379340:-
OV	trans	rs3749237	0.595	rs11130199	ENSG00000197582.5	GPX1P1	24.07	2.01e-64	3.54e-55	1.06	0.85	Resting heart rate;	chr3:49501366	chrX:13378735~13379340:-
OV	trans	rs3749237	0.595	rs3870338	ENSG00000197582.5	GPX1P1	23.85	9.36e-64	1.59e-54	1.08	0.85	Resting heart rate;	chr3:49519618	chrX:13378735~13379340:-
OV	trans	rs3749237	0.576	rs4241406	ENSG00000197582.5	GPX1P1	23.73	2.04e-63	3.35e-54	1.07	0.84	Resting heart rate;	chr3:49562993	chrX:13378735~13379340:-
OV	trans	rs13177918	0.557	rs12520101	ENSG00000239528.1	RPS14P8	22.54	7.75e-60	6.18e-51	1.12	0.83	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr5:116562562~116562930:+
OV	trans	rs3749237	0.555	rs7637665	ENSG00000197582.5	GPX1P1	22.22	7.23e-59	2.33e-50	1.04	0.83	Resting heart rate;	chr3:49514862	chrX:13378735~13379340:-
OV	trans	rs3749237	0.555	rs2117939	ENSG00000197582.5	GPX1P1	22.17	1.04e-58	3.28e-50	1.03	0.83	Resting heart rate;	chr3:49377746	chrX:13378735~13379340:-
OV	trans	rs3749237	0.595	rs6797765	ENSG00000197582.5	GPX1P1	22.17	1.04e-58	3.28e-50	1.03	0.83	Resting heart rate;	chr3:49386543	chrX:13378735~13379340:-
OV	trans	rs3749237	0.595	rs35701831	ENSG00000197582.5	GPX1P1	22.09	1.73e-58	5.31e-50	1.04	0.83	Resting heart rate;	chr3:49477567	chrX:13378735~13379340:-
OV	trans	rs3749237	0.595	rs1464568	ENSG00000197582.5	GPX1P1	21.53	9.42e-57	2.54e-48	1.03	0.82	Resting heart rate;	chr3:49420833	chrX:13378735~13379340:-
OV	trans	rs3749237	0.595	rs17650792	ENSG00000197582.5	GPX1P1	21.46	1.49e-56	3.91e-48	1.02	0.82	Resting heart rate;	chr3:49352817	chrX:13378735~13379340:-
OV	trans	rs3749237	0.595	rs1568661	ENSG00000197582.5	GPX1P1	21.33	3.95e-56	1.03e-47	1.02	0.82	Resting heart rate;	chr3:49483525	chrX:13378735~13379340:-
OV	trans	rs3749237	0.595	rs1464567	ENSG00000197582.5	GPX1P1	-21.04	3.05e-55	7.77e-47	-1.02	-0.81	Resting heart rate;	chr3:49421819	chrX:13378735~13379340:-
OV	trans	rs3749237	0.595	rs10865955	ENSG00000197582.5	GPX1P1	20.62	6.2e-54	1.52e-45	1.02	0.81	Resting heart rate;	chr3:49462396	chrX:13378735~13379340:-
OV	trans	rs3749237	0.576	rs3877784	ENSG00000197582.5	GPX1P1	20.62	6.2e-54	1.52e-45	1.02	0.81	Resting heart rate;	chr3:49501984	chrX:13378735~13379340:-
OV	trans	rs3749237	0.595	rs1050088	ENSG00000197582.5	GPX1P1	-20.54	1.09e-53	2.63e-45	-1.02	-0.81	Resting heart rate;	chr3:49533449	chrX:13378735~13379340:-
OV	trans	rs3749237	0.595	rs11720264	ENSG00000197582.5	GPX1P1	20.44	2.3e-53	5.54e-45	1.02	0.8	Resting heart rate;	chr3:49542914	chrX:13378735~13379340:-
OV	trans	rs3749237	0.615	rs11130202	ENSG00000197582.5	GPX1P1	20.4	2.96e-53	7.07e-45	1.01	0.8	Resting heart rate;	chr3:49529282	chrX:13378735~13379340:-
OV	trans	rs3749237	0.615	rs6792911	ENSG00000197582.5	GPX1P1	20.4	3.07e-53	7.29e-45	1	0.8	Resting heart rate;	chr3:49392423	chrX:13378735~13379340:-
OV	trans	rs3749237	0.595	rs11130192	ENSG00000197582.5	GPX1P1	20.32	5.42e-53	1.2e-44	1.01	0.8	Resting heart rate;	chr3:49429773	chrX:13378735~13379340:-
OV	trans	rs13096760	1	rs13096760	ENSG00000197582.5	GPX1P1	20.32	5.42e-53	1.2e-44	1.01	0.8	Intelligence (multi-trait analysis);	chr3:49439373	chrX:13378735~13379340:-
OV	trans	rs3749237	0.595	rs885592	ENSG00000197582.5	GPX1P1	20.32	5.42e-53	1.2e-44	1.01	0.8	Resting heart rate;	chr3:49460450	chrX:13378735~13379340:-
OV	trans	rs3749237	0.636	rs1568662	ENSG00000197582.5	GPX1P1	20.32	5.42e-53	1.2e-44	1.01	0.8	Resting heart rate;	chr3:49483830	chrX:13378735~13379340:-
OV	trans	rs3749237	0.595	rs3924462	ENSG00000197582.5	GPX1P1	20.32	5.42e-53	1.2e-44	1.01	0.8	Resting heart rate;	chr3:49486803	chrX:13378735~13379340:-
OV	trans	rs3749237	0.595	rs4855861	ENSG00000197582.5	GPX1P1	20.32	5.42e-53	1.2e-44	1.01	0.8	Resting heart rate;	chr3:49488529	chrX:13378735~13379340:-
OV	trans	rs3749237	0.595	rs4855859	ENSG00000197582.5	GPX1P1	20.32	5.42e-53	1.2e-44	1.01	0.8	Resting heart rate;	chr3:49488867	chrX:13378735~13379340:-
OV	trans	rs3749237	0.595	rs7643845	ENSG00000197582.5	GPX1P1	20.32	5.42e-53	1.2e-44	1.01	0.8	Resting heart rate;	chr3:49493278	chrX:13378735~13379340:-
OV	trans	rs3749237	0.595	rs7637999	ENSG00000197582.5	GPX1P1	20.32	5.42e-53	1.2e-44	1.01	0.8	Resting heart rate;	chr3:49497682	chrX:13378735~13379340:-
OV	trans	rs13177918	0.557	rs12520101	ENSG00000213058.3	RP4-765C7.2	20.29	6.68e-53	1.47e-44	1.11	0.8	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:178411616~178411972:+
OV	trans	rs3749237	0.595	rs6784820	ENSG00000197582.5	GPX1P1	-20.23	1.07e-52	2.33e-44	-1.01	-0.8	Resting heart rate;	chr3:49413431	chrX:13378735~13379340:-
OV	trans	rs3749237	0.576	rs62259939	ENSG00000197582.5	GPX1P1	19.81	2.22e-51	4.7e-43	0.99	0.8	Resting heart rate;	chr3:49348614	chrX:13378735~13379340:-
OV	trans	rs928391	0.681	rs12145743	ENSG00000227183.3	HDGFP1	19.61	9.18e-51	1.89e-42	1.07	0.79	Platelet count;	chr1:156730859	chrX:131646639~131646890:+
OV	trans	rs1816752	0.819	rs7400583	ENSG00000237917.1	PARP4P1	19.39	4.57e-50	9.06e-42	0.94	0.79	Obesity-related traits;	chr13:24415916	chrY:26594851~26634652:-
OV	trans	rs928391	0.681	rs3806417	ENSG00000227183.3	HDGFP1	19.31	8.36e-50	1.65e-41	1.07	0.79	Platelet count;	chr1:156741831	chrX:131646639~131646890:+
OV	trans	rs928391	0.624	rs4399146	ENSG00000227183.3	HDGFP1	19.31	8.36e-50	1.65e-41	1.07	0.79	Platelet count;	chr1:156743766	chrX:131646639~131646890:+
OV	trans	rs928391	0.681	rs12161427	ENSG00000227183.3	HDGFP1	19.31	8.53e-50	1.66e-41	1.07	0.79	Platelet count;	chr1:156736030	chrX:131646639~131646890:+
OV	trans	rs928391	0.681	rs11264533	ENSG00000227183.3	HDGFP1	19.26	1.21e-49	2.35e-41	1.07	0.79	Platelet count;	chr1:156748656	chrX:131646639~131646890:+
OV	trans	rs7949030	0.591	rs35880596	ENSG00000186676.3	EEF1GP1	19.1	4.05e-49	7.6e-41	1	0.79	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602412	chr7:125033453~125035301:+
OV	trans	rs928391	0.681	rs4501833	ENSG00000227183.3	HDGFP1	19.09	4.16e-49	7.75e-41	1.07	0.79	Platelet count;	chr1:156746806	chrX:131646639~131646890:+
OV	trans	rs928391	0.681	rs11264535	ENSG00000227183.3	HDGFP1	18.83	2.77e-48	5.12e-40	1.06	0.78	Platelet count;	chr1:156752632	chrX:131646639~131646890:+
OV	trans	rs7949030	0.626	rs11231154	ENSG00000186676.3	EEF1GP1	18.83	2.88e-48	5.24e-40	0.98	0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62594821	chr7:125033453~125035301:+
OV	trans	rs7949030	0.591	rs11231156	ENSG00000186676.3	EEF1GP1	18.83	2.88e-48	5.24e-40	0.98	0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598982	chr7:125033453~125035301:+
OV	trans	rs7949030	0.591	rs12049914	ENSG00000186676.3	EEF1GP1	18.83	2.88e-48	5.24e-40	0.98	0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601964	chr7:125033453~125035301:+
OV	trans	rs7949030	0.591	rs35156678	ENSG00000186676.3	EEF1GP1	18.83	2.88e-48	5.24e-40	0.98	0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602409	chr7:125033453~125035301:+
OV	trans	rs7949030	0.596	rs71490394	ENSG00000186676.3	EEF1GP1	18.83	2.88e-48	5.24e-40	0.98	0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62602683	chr7:125033453~125035301:+
OV	trans	rs7949030	0.626	rs11231144	ENSG00000186676.3	EEF1GP1	18.73	6.1e-48	1.09e-39	0.97	0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62560566	chr7:125033453~125035301:+
OV	trans	rs7949030	0.626	rs7943191	ENSG00000186676.3	EEF1GP1	18.61	1.46e-47	2.59e-39	0.97	0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561079	chr7:125033453~125035301:+
OV	trans	rs7949030	0.626	rs1061093	ENSG00000186676.3	EEF1GP1	18.57	1.97e-47	3.49e-39	0.97	0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62567436	chr7:125033453~125035301:+
OV	trans	rs7949030	0.626	rs11231145	ENSG00000186676.3	EEF1GP1	18.56	2.05e-47	3.53e-39	0.97	0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561382	chr7:125033453~125035301:+
OV	trans	rs7949030	0.626	rs71490390	ENSG00000186676.3	EEF1GP1	18.56	2.05e-47	3.53e-39	0.97	0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62561713	chr7:125033453~125035301:+
OV	trans	rs7949030	0.626	rs7124057	ENSG00000186676.3	EEF1GP1	18.56	2.05e-47	3.53e-39	0.97	0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62566624	chr7:125033453~125035301:+
OV	trans	rs7949030	0.626	rs72927213	ENSG00000186676.3	EEF1GP1	18.56	2.05e-47	3.53e-39	0.97	0.78	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62583726	chr7:125033453~125035301:+
OV	trans	rs928391	0.681	rs11264534	ENSG00000227183.3	HDGFP1	18.14	4.83e-46	7.52e-38	1.06	0.77	Platelet count;	chr1:156750758	chrX:131646639~131646890:+
OV	trans	rs928391	0.652	rs12030654	ENSG00000227183.3	HDGFP1	18.14	4.83e-46	7.52e-38	1.06	0.77	Platelet count;	chr1:156751240	chrX:131646639~131646890:+
OV	trans	rs7949030	0.626	rs11231141	ENSG00000186676.3	EEF1GP1	18.13	5.14e-46	7.96e-38	0.96	0.77	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62558793	chr7:125033453~125035301:+
OV	trans	rs7949030	0.59	rs12225213	ENSG00000186676.3	EEF1GP1	18.06	8.84e-46	1.35e-37	0.96	0.77	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62582776	chr7:125033453~125035301:+
OV	trans	rs7949030	0.626	rs7930896	ENSG00000186676.3	EEF1GP1	17.86	3.85e-45	5.73e-37	0.95	0.76	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62557800	chr7:125033453~125035301:+
OV	trans	rs13177918	0.557	rs12520101	ENSG00000226396.1	RP5-1056L3.3	17.73	1.03e-44	1.51e-36	0.87	0.76	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150431360	chr1:19608114~19608568:+
OV	trans	rs7949030	0.653	rs2516634	ENSG00000186676.3	EEF1GP1	-17.64	1.97e-44	2.83e-36	-0.95	-0.76	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62599714	chr7:125033453~125035301:+
OV	trans	rs7949030	0.62	rs2428551	ENSG00000186676.3	EEF1GP1	17.49	5.99e-44	8.36e-36	0.93	0.76	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62562286	chr7:125033453~125035301:+
OV	trans	rs7949030	0.688	rs2849031	ENSG00000186676.3	EEF1GP1	-17.31	2.34e-43	3.21e-35	-0.94	-0.75	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598193	chr7:125033453~125035301:+
OV	trans	rs7949030	0.653	rs2849030	ENSG00000186676.3	EEF1GP1	-17.31	2.34e-43	3.21e-35	-0.94	-0.75	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62599514	chr7:125033453~125035301:+
OV	trans	rs7949030	0.688	rs11231155	ENSG00000186676.3	EEF1GP1	17.18	6.22e-43	8.11e-35	0.94	0.75	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62598147	chr7:125033453~125035301:+
OV	trans	rs7949030	0.626	rs61296092	ENSG00000186676.3	EEF1GP1	17.14	8.4e-43	1.08e-34	0.95	0.75	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62553366	chr7:125033453~125035301:+
OV	trans	rs928391	0.681	rs9427242	ENSG00000227183.3	HDGFP1	-16.8	1.04e-41	1.28e-33	-0.98	-0.74	Platelet count;	chr1:156755209	chrX:131646639~131646890:+
OV	trans	rs13177918	0.798	rs12514700	ENSG00000224114.1	RP11-343H5.4	16.34	3.41e-40	3.58e-32	1	0.74	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:206695837~206696269:-
OV	trans	rs7943191	0.805	rs12226821	ENSG00000186676.3	EEF1GP1	16.02	3.87e-39	3.97e-31	0.97	0.73	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62601546	chr7:125033453~125035301:+
OV	trans	rs7943191	0.81	rs7942154	ENSG00000186676.3	EEF1GP1	15.84	1.42e-38	1.43e-30	0.95	0.72	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569691	chr7:125033453~125035301:+
OV	trans	rs7949030	0.523	rs12223627	ENSG00000186676.3	EEF1GP1	15.78	2.28e-38	2.29e-30	0.95	0.72	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62601085	chr7:125033453~125035301:+
OV	trans	rs7949030	0.596	rs11231138	ENSG00000186676.3	EEF1GP1	15.64	6.81e-38	6.64e-30	0.92	0.72	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62548723	chr7:125033453~125035301:+
OV	trans	rs13177918	0.798	rs12514700	ENSG00000239528.1	RPS14P8	15.62	7.65e-38	7.45e-30	0.99	0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr5:116562562~116562930:+
OV	trans	rs13177918	0.798	rs13182116	ENSG00000224114.1	RP11-343H5.4	-15.59	9.45e-38	9.17e-30	-0.96	-0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:206695837~206696269:-
OV	trans	rs7943191	0.768	rs34065644	ENSG00000186676.3	EEF1GP1	15.53	1.52e-37	1.45e-29	0.95	0.72	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62604466	chr7:125033453~125035301:+
OV	trans	rs13177918	0.798	rs13182116	ENSG00000239528.1	RPS14P8	-15.42	3.44e-37	3.23e-29	-0.96	-0.72	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr5:116562562~116562930:+
OV	trans	rs7943191	0.81	rs7942991	ENSG00000186676.3	EEF1GP1	-15.36	5.44e-37	5.1e-29	-0.93	-0.71	Waist-to-hip ratio adjusted for BMI in active individuals;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);Waist-to-hip ratio adjusted for body mass index;	chr11:62569731	chr7:125033453~125035301:+
OV	trans	rs7949030	0.653	rs17773169	ENSG00000186676.3	EEF1GP1	14.91	1.66e-35	1.45e-27	0.89	0.7	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551058	chr7:125033453~125035301:+
OV	trans	rs13177918	0.798	rs12514700	ENSG00000213058.3	RP4-765C7.2	14.79	4.17e-35	3.59e-27	0.98	0.7	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:178411616~178411972:+
OV	trans	rs7949030	0.626	rs35587183	ENSG00000186676.3	EEF1GP1	14.52	3.24e-34	2.63e-26	0.92	0.69	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62551184	chr7:125033453~125035301:+
OV	trans	rs7949030	0.504	rs2516633	ENSG00000186676.3	EEF1GP1	-14.46	4.96e-34	4.02e-26	-0.9	-0.69	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62604301	chr7:125033453~125035301:+
OV	trans	rs877636	0.692	rs11171739	ENSG00000204652.6	RPS26P8	14.35	1.13e-33	9.03e-26	0.69	0.69	Cognitive function;	chr12:56076841	chr17:45608571~45608918:+
OV	trans	rs877636	0.692	rs11171739	ENSG00000235459.5	RPS26P31	14.22	3.09e-33	2.43e-25	0.68	0.69	Cognitive function;	chr12:56076841	chr7:122681315~122681662:+
OV	trans	rs877636	0.692	rs11171739	ENSG00000227586.5	RP11-162A23.5	14.09	7.91e-33	6.04e-25	0.65	0.68	Cognitive function;	chr12:56076841	chr10:123171535~123171875:-
OV	trans	rs877636	0.692	rs10876870	ENSG00000204652.6	RPS26P8	-14.08	8.94e-33	6.76e-25	-0.7	-0.68	Cognitive function;	chr12:56084218	chr17:45608571~45608918:+
OV	trans	rs877636	0.692	rs7971751	ENSG00000204652.6	RPS26P8	-14.08	8.94e-33	6.76e-25	-0.7	-0.68	Cognitive function;	chr12:56084874	chr17:45608571~45608918:+
OV	trans	rs13177918	0.798	rs13182116	ENSG00000213058.3	RP4-765C7.2	-14.06	9.88e-33	7.43e-25	-0.94	-0.68	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:178411616~178411972:+
OV	trans	rs877636	0.692	rs11171739	ENSG00000224553.1	AC008065.1	13.92	3.01e-32	2.18e-24	0.69	0.68	Cognitive function;	chr12:56076841	chr2:171374931~171375278:-
OV	trans	rs877636	0.692	rs11171739	ENSG00000234513.1	AC073072.7	13.89	3.79e-32	2.73e-24	0.67	0.68	Cognitive function;	chr12:56076841	chr7:22773646~22773993:-
OV	trans	rs877636	0.669	rs7297175	ENSG00000204652.6	RPS26P8	-13.82	6.29e-32	4.49e-24	-0.69	-0.68	Cognitive function;	chr12:56080024	chr17:45608571~45608918:+
OV	trans	rs877636	0.692	rs11171739	ENSG00000242970.2	AC068522.4	13.81	6.98e-32	4.95e-24	0.67	0.68	Cognitive function;	chr12:56076841	chr8:58588420~58588764:-
OV	trans	rs7312770	0.612	rs773114	ENSG00000242970.2	AC068522.4	13.76	9.6e-32	6.75e-24	0.66	0.67	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:58588420~58588764:-
OV	trans	rs877636	0.692	rs2271194	ENSG00000204652.6	RPS26P8	-13.68	1.8e-31	1.24e-23	-0.69	-0.67	Cognitive function;	chr12:56083910	chr17:45608571~45608918:+
OV	trans	rs877636	0.669	rs7297175	ENSG00000224553.1	AC008065.1	-13.65	2.34e-31	1.61e-23	-0.7	-0.67	Cognitive function;	chr12:56080024	chr2:171374931~171375278:-
OV	trans	rs877636	0.692	rs10876870	ENSG00000224553.1	AC008065.1	-13.62	2.78e-31	1.9e-23	-0.7	-0.67	Cognitive function;	chr12:56084218	chr2:171374931~171375278:-
OV	trans	rs877636	0.692	rs7971751	ENSG00000224553.1	AC008065.1	-13.62	2.78e-31	1.9e-23	-0.7	-0.67	Cognitive function;	chr12:56084874	chr2:171374931~171375278:-
OV	trans	rs7312770	0.612	rs773114	ENSG00000235459.5	RPS26P31	13.57	4.2e-31	2.87e-23	0.66	0.67	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr7:122681315~122681662:+
OV	trans	rs7312770	0.612	rs1873914	ENSG00000224553.1	AC008065.1	13.56	4.39e-31	2.99e-23	0.68	0.67	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr2:171374931~171375278:-
OV	trans	rs7312770	0.612	rs773114	ENSG00000212829.8	RPS26P3	13.53	5.73e-31	3.89e-23	0.64	0.67	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr9:9090898~9091245:+
OV	trans	rs877636	0.669	rs7297175	ENSG00000235459.5	RPS26P31	-13.44	1.08e-30	7.22e-23	-0.68	-0.67	Cognitive function;	chr12:56080024	chr7:122681315~122681662:+
OV	trans	rs877636	0.692	rs11171739	ENSG00000212829.8	RPS26P3	13.43	1.22e-30	8.12e-23	0.64	0.67	Cognitive function;	chr12:56076841	chr9:9090898~9091245:+
OV	trans	rs877636	0.692	rs10876870	ENSG00000235459.5	RPS26P31	-13.39	1.59e-30	1.04e-22	-0.68	-0.66	Cognitive function;	chr12:56084218	chr7:122681315~122681662:+
OV	trans	rs877636	0.692	rs7971751	ENSG00000235459.5	RPS26P31	-13.39	1.59e-30	1.04e-22	-0.68	-0.66	Cognitive function;	chr12:56084874	chr7:122681315~122681662:+
OV	trans	rs877636	0.692	rs2271194	ENSG00000224553.1	AC008065.1	-13.39	1.6e-30	1.05e-22	-0.69	-0.66	Cognitive function;	chr12:56083910	chr2:171374931~171375278:-
OV	trans	rs877636	0.669	rs7297175	ENSG00000243403.1	RP11-330L19.1	-13.36	2e-30	1.3e-22	-0.66	-0.66	Cognitive function;	chr12:56080024	chr15:64592979~64593326:+
OV	trans	rs7312770	0.612	rs773114	ENSG00000224553.1	AC008065.1	13.28	3.77e-30	2.41e-22	0.67	0.66	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr2:171374931~171375278:-
OV	trans	rs7312770	0.612	rs1873914	ENSG00000243403.1	RP11-330L19.1	13.25	4.46e-30	2.82e-22	0.64	0.66	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr15:64592979~64593326:+
OV	trans	rs7312770	0.612	rs1873914	ENSG00000235459.5	RPS26P31	13.23	5.45e-30	3.44e-22	0.65	0.66	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr7:122681315~122681662:+
OV	trans	rs877636	0.692	rs10876870	ENSG00000227586.5	RP11-162A23.5	-13.2	6.45e-30	4.05e-22	-0.65	-0.66	Cognitive function;	chr12:56084218	chr10:123171535~123171875:-
OV	trans	rs877636	0.692	rs7971751	ENSG00000227586.5	RP11-162A23.5	-13.2	6.45e-30	4.05e-22	-0.65	-0.66	Cognitive function;	chr12:56084874	chr10:123171535~123171875:-
OV	trans	rs7312770	0.612	rs773114	ENSG00000243403.1	RP11-330L19.1	13.19	7.03e-30	4.38e-22	0.63	0.66	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr15:64592979~64593326:+
OV	trans	rs7312770	0.612	rs1873914	ENSG00000204652.6	RPS26P8	13.18	7.49e-30	4.66e-22	0.66	0.66	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr17:45608571~45608918:+
OV	trans	rs877636	0.692	rs10876870	ENSG00000212829.8	RPS26P3	-13.17	8.53e-30	5.29e-22	-0.65	-0.66	Cognitive function;	chr12:56084218	chr9:9090898~9091245:+
OV	trans	rs877636	0.692	rs7971751	ENSG00000212829.8	RPS26P3	-13.17	8.53e-30	5.29e-22	-0.65	-0.66	Cognitive function;	chr12:56084874	chr9:9090898~9091245:+
OV	trans	rs877636	0.692	rs10876870	ENSG00000243403.1	RP11-330L19.1	-13.14	1.07e-29	6.5e-22	-0.66	-0.66	Cognitive function;	chr12:56084218	chr15:64592979~64593326:+
OV	trans	rs877636	0.692	rs7971751	ENSG00000243403.1	RP11-330L19.1	-13.14	1.07e-29	6.5e-22	-0.66	-0.66	Cognitive function;	chr12:56084874	chr15:64592979~64593326:+
OV	trans	rs7312770	0.612	rs773114	ENSG00000227586.5	RP11-162A23.5	13.09	1.51e-29	9.02e-22	0.62	0.66	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr10:123171535~123171875:-
OV	trans	rs7312770	0.612	rs773114	ENSG00000204652.6	RPS26P8	13.09	1.54e-29	9.22e-22	0.65	0.66	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr17:45608571~45608918:+
OV	trans	rs7312770	0.612	rs773114	ENSG00000212994.5	RPS26P6	13.09	1.58e-29	9.43e-22	0.67	0.66	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:100895771~100896118:+
OV	trans	rs7312770	0.612	rs1873914	ENSG00000242970.2	AC068522.4	13.08	1.65e-29	9.83e-22	0.65	0.66	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:58588420~58588764:-
OV	trans	rs928391	0.895	rs12042999	ENSG00000227183.3	HDGFP1	13.06	1.93e-29	1.14e-21	0.97	0.65	Platelet count;	chr1:156768636	chrX:131646639~131646890:+
OV	trans	rs928391	0.895	rs11264547	ENSG00000227183.3	HDGFP1	13.06	1.93e-29	1.14e-21	0.97	0.65	Platelet count;	chr1:156776326	chrX:131646639~131646890:+
OV	trans	rs928391	0.947	rs11264549	ENSG00000227183.3	HDGFP1	13.06	1.93e-29	1.14e-21	0.97	0.65	Platelet count;	chr1:156781017	chrX:131646639~131646890:+
OV	trans	rs928391	1	rs12134991	ENSG00000227183.3	HDGFP1	13.06	1.93e-29	1.14e-21	0.97	0.65	Platelet count;	chr1:156781285	chrX:131646639~131646890:+
OV	trans	rs928391	1	rs2274501	ENSG00000227183.3	HDGFP1	13.06	1.93e-29	1.14e-21	0.97	0.65	Platelet count;	chr1:156782460	chrX:131646639~131646890:+
OV	trans	rs13177918	0.798	rs12514700	ENSG00000226396.1	RP5-1056L3.3	13.05	1.98e-29	1.16e-21	0.76	0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150466096	chr1:19608114~19608568:+
OV	trans	rs877636	0.692	rs2271194	ENSG00000235459.5	RPS26P31	-13.04	2.14e-29	1.25e-21	-0.67	-0.65	Cognitive function;	chr12:56083910	chr7:122681315~122681662:+
OV	trans	rs928391	1	rs61816272	ENSG00000227183.3	HDGFP1	13.04	2.23e-29	1.3e-21	0.97	0.65	Platelet count;	chr1:156778073	chrX:131646639~131646890:+
OV	trans	rs13177918	0.798	rs13182116	ENSG00000226396.1	RP5-1056L3.3	-13.04	2.28e-29	1.33e-21	-0.74	-0.65	Visceral adipose tissue/subcutaneous adipose tissue ratio;	chr5:150465963	chr1:19608114~19608568:+
OV	trans	rs7312770	0.612	rs1873914	ENSG00000212829.8	RPS26P3	13.02	2.54e-29	1.48e-21	0.62	0.65	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr9:9090898~9091245:+
OV	trans	rs877636	0.692	rs11171739	ENSG00000243403.1	RP11-330L19.1	13	2.98e-29	1.73e-21	0.64	0.65	Cognitive function;	chr12:56076841	chr15:64592979~64593326:+
OV	trans	rs928391	1	rs2777929	ENSG00000227183.3	HDGFP1	12.96	4.02e-29	2.31e-21	0.96	0.65	Platelet count;	chr1:156797879	chrX:131646639~131646890:+
OV	trans	rs928391	1	rs2768767	ENSG00000227183.3	HDGFP1	12.96	4.02e-29	2.31e-21	0.96	0.65	Platelet count;	chr1:156797933	chrX:131646639~131646890:+
OV	trans	rs877636	0.669	rs7297175	ENSG00000242970.2	AC068522.4	-12.96	4.03e-29	2.31e-21	-0.66	-0.65	Cognitive function;	chr12:56080024	chr8:58588420~58588764:-
OV	trans	rs1816752	0.875	rs3783076	ENSG00000237917.1	PARP4P1	12.94	4.8e-29	2.74e-21	0.79	0.65	Obesity-related traits;	chr13:24490319	chrY:26594851~26634652:-
OV	trans	rs877636	0.692	rs10876870	ENSG00000242970.2	AC068522.4	-12.93	4.98e-29	2.83e-21	-0.67	-0.65	Cognitive function;	chr12:56084218	chr8:58588420~58588764:-
OV	trans	rs877636	0.692	rs7971751	ENSG00000242970.2	AC068522.4	-12.93	4.98e-29	2.83e-21	-0.67	-0.65	Cognitive function;	chr12:56084874	chr8:58588420~58588764:-
OV	trans	rs877636	0.692	rs10876870	ENSG00000234513.1	AC073072.7	-12.93	5e-29	2.83e-21	-0.67	-0.65	Cognitive function;	chr12:56084218	chr7:22773646~22773993:-
OV	trans	rs877636	0.692	rs7971751	ENSG00000234513.1	AC073072.7	-12.93	5e-29	2.83e-21	-0.67	-0.65	Cognitive function;	chr12:56084874	chr7:22773646~22773993:-
OV	trans	rs877636	0.692	rs2271194	ENSG00000212829.8	RPS26P3	-12.9	6.45e-29	3.64e-21	-0.64	-0.65	Cognitive function;	chr12:56083910	chr9:9090898~9091245:+
OV	trans	rs877636	0.692	rs10876870	ENSG00000212994.5	RPS26P6	-12.84	1.03e-28	5.71e-21	-0.69	-0.65	Cognitive function;	chr12:56084218	chr8:100895771~100896118:+
OV	trans	rs877636	0.692	rs7971751	ENSG00000212994.5	RPS26P6	-12.84	1.03e-28	5.71e-21	-0.69	-0.65	Cognitive function;	chr12:56084874	chr8:100895771~100896118:+
OV	trans	rs928391	1	rs12043405	ENSG00000227183.3	HDGFP1	12.83	1.05e-28	5.86e-21	0.96	0.65	Platelet count;	chr1:156784508	chrX:131646639~131646890:+
OV	trans	rs928391	1	rs2644615	ENSG00000227183.3	HDGFP1	12.82	1.18e-28	6.46e-21	0.95	0.65	Platelet count;	chr1:156791826	chrX:131646639~131646890:+
OV	trans	rs877636	0.692	rs2271194	ENSG00000227586.5	RP11-162A23.5	-12.79	1.49e-28	8.11e-21	-0.63	-0.65	Cognitive function;	chr12:56083910	chr10:123171535~123171875:-
OV	trans	rs877636	0.669	rs7297175	ENSG00000212829.8	RPS26P3	-12.75	2.01e-28	1.09e-20	-0.64	-0.65	Cognitive function;	chr12:56080024	chr9:9090898~9091245:+
OV	trans	rs877636	0.669	rs7297175	ENSG00000227586.5	RP11-162A23.5	-12.74	2.17e-28	1.17e-20	-0.63	-0.65	Cognitive function;	chr12:56080024	chr10:123171535~123171875:-
OV	trans	rs7949030	1	rs10897289	ENSG00000186676.3	EEF1GP1	12.72	2.44e-28	1.31e-20	0.83	0.65	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62632544	chr7:125033453~125035301:+
OV	trans	rs7949030	1	rs3018561	ENSG00000186676.3	EEF1GP1	-12.71	2.64e-28	1.42e-20	-0.84	-0.64	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62624757	chr7:125033453~125035301:+
OV	trans	rs877636	0.692	rs2271194	ENSG00000243403.1	RP11-330L19.1	-12.7	2.73e-28	1.46e-20	-0.64	-0.64	Cognitive function;	chr12:56083910	chr15:64592979~64593326:+
OV	trans	rs3749237	1	rs11130214	ENSG00000197582.5	GPX1P1	-12.67	3.61e-28	1.91e-20	-0.88	-0.64	Resting heart rate;	chr3:49698313	chrX:13378735~13379340:-
OV	trans	rs877636	0.692	rs10876870	ENSG00000196933.5	RPS26P11	-12.64	4.32e-28	2.27e-20	-0.68	-0.64	Cognitive function;	chr12:56084218	chrX:72044545~72044892:+
OV	trans	rs877636	0.692	rs7971751	ENSG00000196933.5	RPS26P11	-12.64	4.32e-28	2.27e-20	-0.68	-0.64	Cognitive function;	chr12:56084874	chrX:72044545~72044892:+
OV	trans	rs7949030	1	rs2956993	ENSG00000186676.3	EEF1GP1	-12.59	6.27e-28	3.25e-20	-0.83	-0.64	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62638690	chr7:125033453~125035301:+
OV	trans	rs7312770	0.612	rs1873914	ENSG00000227586.5	RP11-162A23.5	12.58	6.76e-28	3.48e-20	0.61	0.64	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr10:123171535~123171875:-
OV	trans	rs877636	0.692	rs2271194	ENSG00000196933.5	RPS26P11	-12.56	7.74e-28	3.97e-20	-0.68	-0.64	Cognitive function;	chr12:56083910	chrX:72044545~72044892:+
OV	trans	rs7949030	0.964	rs2957122	ENSG00000186676.3	EEF1GP1	-12.56	7.87e-28	4.03e-20	-0.82	-0.64	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62624628	chr7:125033453~125035301:+
OV	trans	rs928391	1	rs12129173	ENSG00000227183.3	HDGFP1	12.54	9.03e-28	4.6e-20	0.96	0.64	Platelet count;	chr1:156803833	chrX:131646639~131646890:+
OV	trans	rs3749237	1	rs11710675	ENSG00000197582.5	GPX1P1	12.54	9.2e-28	4.68e-20	0.87	0.64	Resting heart rate;	chr3:49714467	chrX:13378735~13379340:-
OV	trans	rs877636	0.692	rs2271194	ENSG00000242970.2	AC068522.4	-12.53	9.92e-28	5.03e-20	-0.65	-0.64	Cognitive function;	chr12:56083910	chr8:58588420~58588764:-
OV	trans	rs7647973	0.506	rs11920251	ENSG00000197582.5	GPX1P1	12.53	1.01e-27	5.11e-20	0.81	0.64	Menarche (age at onset);	chr3:49319238	chrX:13378735~13379340:-
OV	trans	rs877636	0.692	rs11171739	ENSG00000196933.5	RPS26P11	12.52	1.08e-27	5.49e-20	0.66	0.64	Cognitive function;	chr12:56076841	chrX:72044545~72044892:+
OV	trans	rs877636	0.692	rs2271194	ENSG00000212994.5	RPS26P6	-12.51	1.18e-27	5.92e-20	-0.68	-0.64	Cognitive function;	chr12:56083910	chr8:100895771~100896118:+
OV	trans	rs7949030	1	rs7949030	ENSG00000186676.3	EEF1GP1	12.5	1.28e-27	6.42e-20	0.81	0.64	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62627409	chr7:125033453~125035301:+
OV	trans	rs7312770	0.612	rs773114	ENSG00000196656.7	AC004057.1	12.49	1.31e-27	6.57e-20	0.66	0.64	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr4:113214046~113217170:-
OV	trans	rs877636	0.692	rs11171739	ENSG00000233778.3	RP11-777J24.1	12.49	1.33e-27	6.64e-20	0.64	0.64	Cognitive function;	chr12:56076841	chr8:92144088~92144435:-
OV	trans	rs928391	1	rs928391	ENSG00000227183.3	HDGFP1	12.49	1.34e-27	6.69e-20	0.94	0.64	Platelet count;	chr1:156806925	chrX:131646639~131646890:+
OV	trans	rs877636	0.669	rs7297175	ENSG00000234513.1	AC073072.7	-12.49	1.36e-27	6.77e-20	-0.65	-0.64	Cognitive function;	chr12:56080024	chr7:22773646~22773993:-
OV	trans	rs3749237	0.964	rs1799845	ENSG00000197582.5	GPX1P1	12.48	1.44e-27	7.19e-20	0.87	0.64	Resting heart rate;	chr3:49810190	chrX:13378735~13379340:-
OV	trans	rs3749237	1	rs11717256	ENSG00000197582.5	GPX1P1	12.48	1.5e-27	7.45e-20	0.86	0.64	Resting heart rate;	chr3:49831087	chrX:13378735~13379340:-
OV	trans	rs3749237	0.964	rs2234385	ENSG00000197582.5	GPX1P1	12.47	1.57e-27	7.79e-20	0.86	0.64	Resting heart rate;	chr3:49808608	chrX:13378735~13379340:-
OV	trans	rs3749237	0.964	rs1799843	ENSG00000197582.5	GPX1P1	12.47	1.57e-27	7.79e-20	0.86	0.64	Resting heart rate;	chr3:49812290	chrX:13378735~13379340:-
OV	trans	rs7312770	0.612	rs773114	ENSG00000234513.1	AC073072.7	12.47	1.61e-27	7.96e-20	0.63	0.64	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr7:22773646~22773993:-
OV	trans	rs877636	0.692	rs2271194	ENSG00000234513.1	AC073072.7	-12.46	1.72e-27	8.48e-20	-0.65	-0.64	Cognitive function;	chr12:56083910	chr7:22773646~22773993:-
OV	trans	rs877636	0.669	rs7297175	ENSG00000212994.5	RPS26P6	-12.45	1.76e-27	8.66e-20	-0.68	-0.64	Cognitive function;	chr12:56080024	chr8:100895771~100896118:+
OV	trans	rs7312770	1	rs7312770	ENSG00000204652.6	RPS26P8	-12.44	1.9e-27	9.27e-20	-0.64	-0.64	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr17:45608571~45608918:+
OV	trans	rs3749237	0.929	rs62260715	ENSG00000197582.5	GPX1P1	12.43	2.15e-27	1.04e-19	0.89	0.64	Resting heart rate;	chr3:49791893	chrX:13378735~13379340:-
OV	trans	rs877636	0.692	rs11171739	ENSG00000212994.5	RPS26P6	12.43	2.16e-27	1.04e-19	0.66	0.64	Cognitive function;	chr12:56076841	chr8:100895771~100896118:+
OV	trans	rs3749237	0.964	rs2352967	ENSG00000197582.5	GPX1P1	12.42	2.26e-27	1.08e-19	0.86	0.64	Resting heart rate;	chr3:49834208	chrX:13378735~13379340:-
OV	trans	rs7949030	0.754	rs36104523	ENSG00000186676.3	EEF1GP1	-12.41	2.43e-27	1.16e-19	-0.81	-0.64	Waist-to-hip ratio adjusted for body mass index;Waist-to-hip ratio adjusted for BMI (joint analysis for main effect and physical activity interaction);	chr11:62628268	chr7:125033453~125035301:+
OV	trans	rs7312770	0.612	rs1873914	ENSG00000234513.1	AC073072.7	12.39	2.83e-27	1.32e-19	0.63	0.64	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr7:22773646~22773993:-
OV	trans	rs877636	0.692	rs10876870	ENSG00000223416.3	RPS26P15	-12.38	3.15e-27	1.45e-19	-0.66	-0.63	Cognitive function;	chr12:56084218	chr1:58056133~58056480:-
OV	trans	rs877636	0.692	rs7971751	ENSG00000223416.3	RPS26P15	-12.38	3.15e-27	1.45e-19	-0.66	-0.63	Cognitive function;	chr12:56084874	chr1:58056133~58056480:-
OV	trans	rs928391	1	rs2644606	ENSG00000227183.3	HDGFP1	12.36	3.5e-27	1.55e-19	0.93	0.63	Platelet count;	chr1:156808053	chrX:131646639~131646890:+
OV	trans	rs7312770	0.612	rs1873914	ENSG00000212994.5	RPS26P6	12.29	5.8e-27	2.49e-19	0.65	0.63	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:100895771~100896118:+
OV	trans	rs3749237	0.964	rs34522271	ENSG00000197582.5	GPX1P1	12.29	5.9e-27	2.53e-19	0.87	0.63	Resting heart rate;	chr3:49771084	chrX:13378735~13379340:-
OV	trans	rs7312770	0.612	rs773114	ENSG00000233778.3	RP11-777J24.1	12.25	8.08e-27	3.4e-19	0.62	0.63	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:92144088~92144435:-
OV	trans	rs877636	0.692	rs10876870	ENSG00000196656.7	AC004057.1	-12.24	8.49e-27	3.57e-19	-0.68	-0.63	Cognitive function;	chr12:56084218	chr4:113214046~113217170:-
OV	trans	rs877636	0.692	rs7971751	ENSG00000196656.7	AC004057.1	-12.24	8.49e-27	3.57e-19	-0.68	-0.63	Cognitive function;	chr12:56084874	chr4:113214046~113217170:-
OV	trans	rs877636	0.692	rs10876870	ENSG00000225071.1	GS1-184P14.2	-12.23	9.18e-27	3.83e-19	-0.69	-0.63	Cognitive function;	chr12:56084218	chrX:24429573~24429920:-
OV	trans	rs877636	0.692	rs7971751	ENSG00000225071.1	GS1-184P14.2	-12.23	9.18e-27	3.83e-19	-0.69	-0.63	Cognitive function;	chr12:56084874	chrX:24429573~24429920:-
OV	trans	rs877636	0.669	rs7297175	ENSG00000196656.7	AC004057.1	-12.2	1.16e-26	4.8e-19	-0.67	-0.63	Cognitive function;	chr12:56080024	chr4:113214046~113217170:-
OV	trans	rs7312770	0.612	rs773114	ENSG00000196933.5	RPS26P11	12.19	1.27e-26	5.24e-19	0.64	0.63	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chrX:72044545~72044892:+
OV	trans	rs928391	0.948	rs2735657	ENSG00000227183.3	HDGFP1	12.17	1.49e-26	6.07e-19	0.91	0.63	Platelet count;	chr1:156810514	chrX:131646639~131646890:+
OV	trans	rs3749237	0.964	rs7431078	ENSG00000197582.5	GPX1P1	12.16	1.62e-26	6.56e-19	0.86	0.63	Resting heart rate;	chr3:49770757	chrX:13378735~13379340:-
OV	trans	rs3749237	0.964	rs35210174	ENSG00000197582.5	GPX1P1	12.16	1.62e-26	6.56e-19	0.86	0.63	Resting heart rate;	chr3:49775173	chrX:13378735~13379340:-
OV	trans	rs877636	0.692	rs11171739	ENSG00000223416.3	RPS26P15	12.15	1.68e-26	6.78e-19	0.63	0.63	Cognitive function;	chr12:56076841	chr1:58056133~58056480:-
OV	trans	rs3749237	1	rs11130216	ENSG00000197582.5	GPX1P1	12.15	1.7e-26	6.88e-19	0.87	0.63	Resting heart rate;	chr3:49698739	chrX:13378735~13379340:-
OV	trans	rs3749237	1	rs6804655	ENSG00000197582.5	GPX1P1	12.15	1.7e-26	6.88e-19	0.87	0.63	Resting heart rate;	chr3:49701512	chrX:13378735~13379340:-
OV	trans	rs877636	0.692	rs2271194	ENSG00000223416.3	RPS26P15	-12.13	1.97e-26	7.87e-19	-0.65	-0.63	Cognitive function;	chr12:56083910	chr1:58056133~58056480:-
OV	trans	rs3749237	0.964	rs10865959	ENSG00000197582.5	GPX1P1	12.11	2.23e-26	8.85e-19	0.86	0.63	Resting heart rate;	chr3:49853569	chrX:13378735~13379340:-
OV	trans	rs3749237	1	rs4768	ENSG00000197582.5	GPX1P1	12.1	2.5e-26	9.85e-19	0.87	0.63	Resting heart rate;	chr3:49721331	chrX:13378735~13379340:-
OV	trans	rs7312770	0.612	rs773114	ENSG00000225071.1	GS1-184P14.2	12.09	2.67e-26	1.04e-18	0.66	0.63	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chrX:24429573~24429920:-
OV	trans	rs877636	0.692	rs11171739	ENSG00000196656.7	AC004057.1	12.08	2.88e-26	1.12e-18	0.65	0.63	Cognitive function;	chr12:56076841	chr4:113214046~113217170:-
OV	trans	rs877636	0.692	rs10876870	ENSG00000233778.3	RP11-777J24.1	-12.07	3.08e-26	1.2e-18	-0.64	-0.63	Cognitive function;	chr12:56084218	chr8:92144088~92144435:-
OV	trans	rs877636	0.692	rs7971751	ENSG00000233778.3	RP11-777J24.1	-12.07	3.08e-26	1.2e-18	-0.64	-0.63	Cognitive function;	chr12:56084874	chr8:92144088~92144435:-
OV	trans	rs3749237	0.964	rs13084243	ENSG00000197582.5	GPX1P1	12.07	3.14e-26	1.22e-18	0.86	0.63	Resting heart rate;	chr3:49784445	chrX:13378735~13379340:-
OV	trans	rs3749237	1	rs11920900	ENSG00000197582.5	GPX1P1	12.07	3.14e-26	1.22e-18	0.86	0.63	Resting heart rate;	chr3:49785591	chrX:13378735~13379340:-
OV	trans	rs877636	0.692	rs2271194	ENSG00000196656.7	AC004057.1	-12.05	3.53e-26	1.36e-18	-0.67	-0.62	Cognitive function;	chr12:56083910	chr4:113214046~113217170:-
OV	trans	rs3749237	0.964	rs11714957	ENSG00000197582.5	GPX1P1	12.02	4.6e-26	1.76e-18	0.87	0.62	Resting heart rate;	chr3:49738745	chrX:13378735~13379340:-
OV	trans	rs7312770	0.612	rs773114	ENSG00000223416.3	RPS26P15	12	4.97e-26	1.89e-18	0.62	0.62	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr1:58056133~58056480:-
OV	trans	rs3749237	1	rs2307021	ENSG00000197582.5	GPX1P1	12	5e-26	1.91e-18	0.87	0.62	Resting heart rate;	chr3:49728050	chrX:13378735~13379340:-
OV	trans	rs877636	0.692	rs2271194	ENSG00000225071.1	GS1-184P14.2	-11.97	6.49e-26	2.45e-18	-0.68	-0.62	Cognitive function;	chr12:56083910	chrX:24429573~24429920:-
OV	trans	rs7312770	0.612	rs1873914	ENSG00000196933.5	RPS26P11	11.96	7e-26	2.62e-18	0.64	0.62	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chrX:72044545~72044892:+
OV	trans	rs7312770	0.612	rs1873914	ENSG00000196656.7	AC004057.1	11.93	8.74e-26	3.24e-18	0.65	0.62	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr4:113214046~113217170:-
OV	trans	rs7312770	0.612	rs773114	ENSG00000227887.1	RPS26P13	11.9	1.09e-25	4.03e-18	0.61	0.62	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr1:208697369~208697698:-
OV	trans	rs3749237	1	rs2291542	ENSG00000197582.5	GPX1P1	11.89	1.16e-25	4.25e-18	0.85	0.62	Resting heart rate;	chr3:49714152	chrX:13378735~13379340:-
OV	trans	rs3749237	0.964	rs62260719	ENSG00000197582.5	GPX1P1	11.88	1.27e-25	4.66e-18	0.87	0.62	Resting heart rate;	chr3:49814986	chrX:13378735~13379340:-
OV	trans	rs877636	0.692	rs2271194	ENSG00000233778.3	RP11-777J24.1	-11.79	2.49e-25	8.85e-18	-0.63	-0.62	Cognitive function;	chr12:56083910	chr8:92144088~92144435:-
OV	trans	rs877636	0.692	rs11171739	ENSG00000225071.1	GS1-184P14.2	11.78	2.68e-25	9.51e-18	0.66	0.62	Cognitive function;	chr12:56076841	chrX:24429573~24429920:-
OV	trans	rs877636	0.669	rs7297175	ENSG00000223416.3	RPS26P15	-11.77	2.71e-25	9.58e-18	-0.63	-0.62	Cognitive function;	chr12:56080024	chr1:58056133~58056480:-
OV	trans	rs7312770	0.612	rs1873914	ENSG00000233778.3	RP11-777J24.1	11.76	3.07e-25	1.08e-17	0.61	0.62	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:92144088~92144435:-
OV	trans	rs877636	0.692	rs11171739	ENSG00000233278.1	RPS26P2	11.73	3.66e-25	1.28e-17	0.62	0.61	Cognitive function;	chr12:56076841	chr9:30831878~30832225:-
OV	trans	rs928391	1	rs2768766	ENSG00000227183.3	HDGFP1	11.7	4.59e-25	1.59e-17	0.88	0.61	Platelet count;	chr1:156805842	chrX:131646639~131646890:+
OV	trans	rs7312770	0.612	rs1873914	ENSG00000223416.3	RPS26P15	11.64	7.08e-25	2.42e-17	0.61	0.61	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr1:58056133~58056480:-
OV	trans	rs7312770	0.612	rs1873914	ENSG00000227887.1	RPS26P13	11.64	7.48e-25	2.55e-17	0.61	0.61	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr1:208697369~208697698:-
OV	trans	rs877636	0.669	rs7297175	ENSG00000233778.3	RP11-777J24.1	-11.63	8.08e-25	2.75e-17	-0.63	-0.61	Cognitive function;	chr12:56080024	chr8:92144088~92144435:-
OV	trans	rs877636	0.669	rs7297175	ENSG00000196933.5	RPS26P11	-11.62	8.22e-25	2.79e-17	-0.65	-0.61	Cognitive function;	chr12:56080024	chrX:72044545~72044892:+
OV	trans	rs3749237	1	rs3749237	ENSG00000197582.5	GPX1P1	11.59	1.02e-24	3.43e-17	0.84	0.61	Resting heart rate;	chr3:49732599	chrX:13378735~13379340:-
OV	trans	rs3749237	0.964	rs11717463	ENSG00000197582.5	GPX1P1	11.54	1.54e-24	5.09e-17	0.84	0.61	Resting heart rate;	chr3:49771548	chrX:13378735~13379340:-
OV	trans	rs877636	0.692	rs11171739	ENSG00000227887.1	RPS26P13	11.53	1.61e-24	5.31e-17	0.61	0.61	Cognitive function;	chr12:56076841	chr1:208697369~208697698:-
OV	trans	rs877636	0.669	rs7297175	ENSG00000225071.1	GS1-184P14.2	-11.53	1.65e-24	5.46e-17	-0.67	-0.61	Cognitive function;	chr12:56080024	chrX:24429573~24429920:-
OV	trans	rs7312770	1	rs7312770	ENSG00000212829.8	RPS26P3	-11.5	2.01e-24	6.56e-17	-0.59	-0.61	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr9:9090898~9091245:+
OV	trans	rs7312770	1	rs7312770	ENSG00000224553.1	AC008065.1	-11.45	2.88e-24	9.35e-17	-0.62	-0.61	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr2:171374931~171375278:-
OV	trans	rs7312770	0.612	rs1873914	ENSG00000225071.1	GS1-184P14.2	11.44	3.16e-24	1.02e-16	0.64	0.6	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chrX:24429573~24429920:-
OV	trans	rs7647973	0.516	rs4536858	ENSG00000197582.5	GPX1P1	11.43	3.51e-24	1.13e-16	0.76	0.6	Menarche (age at onset);	chr3:49155648	chrX:13378735~13379340:-
OV	trans	rs7647973	0.516	rs4955418	ENSG00000197582.5	GPX1P1	11.43	3.51e-24	1.13e-16	0.76	0.6	Menarche (age at onset);	chr3:49163194	chrX:13378735~13379340:-
OV	trans	rs7647973	0.516	rs4499638	ENSG00000197582.5	GPX1P1	11.43	3.51e-24	1.13e-16	0.76	0.6	Menarche (age at onset);	chr3:49165349	chrX:13378735~13379340:-
OV	trans	rs7312770	0.612	rs1873914	ENSG00000244604.1	RP11-713H12.1	11.4	4.15e-24	1.33e-16	0.62	0.6	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr17:8561230~8561576:+
OV	trans	rs7647973	0.516	rs12490393	ENSG00000197582.5	GPX1P1	11.35	5.96e-24	1.88e-16	0.75	0.6	Menarche (age at onset);	chr3:49158699	chrX:13378735~13379340:-
OV	trans	rs7312770	1	rs7312770	ENSG00000235459.5	RPS26P31	-11.31	8.12e-24	2.55e-16	-0.6	-0.6	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr7:122681315~122681662:+
OV	trans	rs877636	0.692	rs10876870	ENSG00000233278.1	RPS26P2	-11.31	8.42e-24	2.64e-16	-0.63	-0.6	Cognitive function;	chr12:56084218	chr9:30831878~30832225:-
OV	trans	rs877636	0.692	rs7971751	ENSG00000233278.1	RPS26P2	-11.31	8.42e-24	2.64e-16	-0.63	-0.6	Cognitive function;	chr12:56084874	chr9:30831878~30832225:-
OV	trans	rs877636	0.669	rs7297175	ENSG00000233278.1	RPS26P2	-11.3	8.66e-24	2.71e-16	-0.62	-0.6	Cognitive function;	chr12:56080024	chr9:30831878~30832225:-
OV	trans	rs7312770	1	rs7312770	ENSG00000227586.5	RP11-162A23.5	-11.25	1.22e-23	3.76e-16	-0.58	-0.6	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr10:123171535~123171875:-
OV	trans	rs7312770	1	rs7312770	ENSG00000234513.1	AC073072.7	-11.24	1.35e-23	4.13e-16	-0.6	-0.6	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr7:22773646~22773993:-
OV	trans	rs1816752	0.646	rs9511309	ENSG00000237917.1	PARP4P1	-11.23	1.42e-23	4.34e-16	-0.69	-0.6	Obesity-related traits;	chr13:24515435	chrY:26594851~26634652:-
OV	trans	rs877636	0.692	rs2271194	ENSG00000233278.1	RPS26P2	-11.23	1.48e-23	4.53e-16	-0.62	-0.6	Cognitive function;	chr12:56083910	chr9:30831878~30832225:-
OV	trans	rs877636	0.692	rs10876870	ENSG00000227887.1	RPS26P13	-11.23	1.5e-23	4.56e-16	-0.61	-0.6	Cognitive function;	chr12:56084218	chr1:208697369~208697698:-
OV	trans	rs877636	0.692	rs7971751	ENSG00000227887.1	RPS26P13	-11.23	1.5e-23	4.56e-16	-0.61	-0.6	Cognitive function;	chr12:56084874	chr1:208697369~208697698:-
OV	trans	rs12497850	0.931	rs6442130	ENSG00000197582.5	GPX1P1	11.15	2.65e-23	7.85e-16	0.78	0.59	Parkinson's disease;	chr3:48740594	chrX:13378735~13379340:-
OV	trans	rs877636	0.692	rs2271194	ENSG00000227887.1	RPS26P13	-11.1	3.73e-23	1.08e-15	-0.61	-0.59	Cognitive function;	chr12:56083910	chr1:208697369~208697698:-
OV	trans	rs7312770	0.612	rs1873914	ENSG00000233278.1	RPS26P2	11.06	5.17e-23	1.49e-15	0.6	0.59	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr9:30831878~30832225:-
OV	trans	rs877636	0.669	rs7297175	ENSG00000227887.1	RPS26P13	-11.04	5.81e-23	1.59e-15	-0.6	-0.59	Cognitive function;	chr12:56080024	chr1:208697369~208697698:-
OV	trans	rs80033912	0.713	rs7629936	ENSG00000197582.5	GPX1P1	11.04	5.9e-23	1.61e-15	0.83	0.59	Intelligence (multi-trait analysis);	chr3:49799274	chrX:13378735~13379340:-
OV	trans	rs877636	0.669	rs7297175	ENSG00000244604.1	RP11-713H12.1	-11.01	7.05e-23	1.92e-15	-0.62	-0.59	Cognitive function;	chr12:56080024	chr17:8561230~8561576:+
OV	trans	rs7312770	1	rs7312770	ENSG00000233778.3	RP11-777J24.1	-10.97	9.59e-23	2.57e-15	-0.59	-0.59	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:92144088~92144435:-
OV	trans	rs7312770	1	rs7312770	ENSG00000243403.1	RP11-330L19.1	-10.97	9.95e-23	2.66e-15	-0.58	-0.59	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr15:64592979~64593326:+
OV	trans	rs7647973	0.621	rs3774800	ENSG00000197582.5	GPX1P1	-10.94	1.2e-22	3.19e-15	-0.74	-0.59	Menarche (age at onset);	chr3:49297335	chrX:13378735~13379340:-
OV	trans	rs7312770	1	rs7312770	ENSG00000242970.2	AC068522.4	-10.9	1.57e-22	4.13e-15	-0.59	-0.59	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:58588420~58588764:-
OV	trans	rs7312770	1	rs7312770	ENSG00000212994.5	RPS26P6	-10.88	1.89e-22	4.94e-15	-0.61	-0.59	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:100895771~100896118:+
OV	trans	rs877636	0.692	rs10876870	ENSG00000234192.1	RP11-57C13.5	-10.77	3.93e-22	1e-14	-0.59	-0.58	Cognitive function;	chr12:56084218	chr10:87642607~87642954:+
OV	trans	rs877636	0.692	rs7971751	ENSG00000234192.1	RP11-57C13.5	-10.77	3.93e-22	1e-14	-0.59	-0.58	Cognitive function;	chr12:56084874	chr10:87642607~87642954:+
OV	trans	rs877636	0.692	rs11171739	ENSG00000234192.1	RP11-57C13.5	10.76	4.32e-22	1.1e-14	0.57	0.58	Cognitive function;	chr12:56076841	chr10:87642607~87642954:+
OV	trans	rs7647973	0.58	rs4955432	ENSG00000197582.5	GPX1P1	10.71	6.28e-22	1.57e-14	0.72	0.58	Menarche (age at onset);	chr3:49229339	chrX:13378735~13379340:-
OV	trans	rs7647973	0.6	rs11920267	ENSG00000197582.5	GPX1P1	10.71	6.28e-22	1.57e-14	0.72	0.58	Menarche (age at onset);	chr3:49238531	chrX:13378735~13379340:-
OV	trans	rs7312770	0.612	rs773114	ENSG00000244604.1	RP11-713H12.1	10.7	6.82e-22	1.71e-14	0.59	0.58	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr17:8561230~8561576:+
OV	trans	rs877636	0.692	rs2271194	ENSG00000234192.1	RP11-57C13.5	-10.64	1.02e-21	2.53e-14	-0.58	-0.58	Cognitive function;	chr12:56083910	chr10:87642607~87642954:+
OV	trans	rs7312770	0.612	rs773114	ENSG00000233278.1	RPS26P2	10.6	1.33e-21	3.25e-14	0.58	0.58	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr9:30831878~30832225:-
OV	trans	rs7312770	1	rs7312770	ENSG00000223416.3	RPS26P15	-10.56	1.85e-21	4.46e-14	-0.58	-0.57	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr1:58056133~58056480:-
OV	trans	rs877636	0.692	rs11171739	ENSG00000244604.1	RP11-713H12.1	10.55	2.03e-21	4.88e-14	0.59	0.57	Cognitive function;	chr12:56076841	chr17:8561230~8561576:+
OV	trans	rs7647973	0.516	rs4955419	ENSG00000197582.5	GPX1P1	10.51	2.6e-21	6.23e-14	0.71	0.57	Menarche (age at onset);	chr3:49163259	chrX:13378735~13379340:-
OV	trans	rs12497850	0.764	rs6784111	ENSG00000197582.5	GPX1P1	10.49	2.99e-21	7.13e-14	0.75	0.57	Parkinson's disease;	chr3:49141413	chrX:13378735~13379340:-
OV	trans	rs12497850	0.864	rs12493001	ENSG00000197582.5	GPX1P1	10.49	2.99e-21	7.13e-14	0.75	0.57	Parkinson's disease;	chr3:49144452	chrX:13378735~13379340:-
OV	trans	rs12497850	0.829	rs12636030	ENSG00000197582.5	GPX1P1	10.49	2.99e-21	7.13e-14	0.75	0.57	Parkinson's disease;	chr3:49144804	chrX:13378735~13379340:-
OV	trans	rs7647973	0.516	rs4308307	ENSG00000197582.5	GPX1P1	10.46	3.72e-21	8.81e-14	0.7	0.57	Menarche (age at onset);	chr3:49155783	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs6446205	ENSG00000197582.5	GPX1P1	10.45	3.98e-21	9.41e-14	0.74	0.57	Parkinson's disease;	chr3:48997778	chrX:13378735~13379340:-
OV	trans	rs7312770	0.612	rs773114	ENSG00000234192.1	RP11-57C13.5	10.43	4.65e-21	1.09e-13	0.55	0.57	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr10:87642607~87642954:+
OV	trans	rs12497850	0.864	rs6779394	ENSG00000197582.5	GPX1P1	10.43	4.78e-21	1.12e-13	0.74	0.57	Parkinson's disease;	chr3:49120338	chrX:13378735~13379340:-
OV	trans	rs7312770	1	rs7312770	ENSG00000196656.7	AC004057.1	-10.42	4.9e-21	1.15e-13	-0.6	-0.57	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr4:113214046~113217170:-
OV	trans	rs12497850	0.931	rs9876848	ENSG00000197582.5	GPX1P1	10.4	5.8e-21	1.35e-13	0.73	0.57	Parkinson's disease;	chr3:48806626	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs9682444	ENSG00000197582.5	GPX1P1	10.4	5.8e-21	1.35e-13	0.73	0.57	Parkinson's disease;	chr3:48815206	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs9835307	ENSG00000197582.5	GPX1P1	10.4	5.8e-21	1.35e-13	0.73	0.57	Parkinson's disease;	chr3:48820372	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs9755490	ENSG00000197582.5	GPX1P1	10.4	5.8e-21	1.35e-13	0.73	0.57	Parkinson's disease;	chr3:48834231	chrX:13378735~13379340:-
OV	trans	rs12497850	0.897	rs9681717	ENSG00000197582.5	GPX1P1	10.4	5.8e-21	1.35e-13	0.73	0.57	Parkinson's disease;	chr3:48835565	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs9840684	ENSG00000197582.5	GPX1P1	10.4	5.8e-21	1.35e-13	0.73	0.57	Parkinson's disease;	chr3:48856347	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs4974079	ENSG00000197582.5	GPX1P1	10.4	5.8e-21	1.35e-13	0.73	0.57	Parkinson's disease;	chr3:48869036	chrX:13378735~13379340:-
OV	trans	rs12497850	0.897	rs6446252	ENSG00000197582.5	GPX1P1	10.4	5.8e-21	1.35e-13	0.73	0.57	Parkinson's disease;	chr3:48873692	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs4974087	ENSG00000197582.5	GPX1P1	10.4	5.8e-21	1.35e-13	0.73	0.57	Parkinson's disease;	chr3:48881799	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs28642807	ENSG00000197582.5	GPX1P1	10.4	5.8e-21	1.35e-13	0.73	0.57	Parkinson's disease;	chr3:48889383	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs7627404	ENSG00000197582.5	GPX1P1	10.38	6.41e-21	1.48e-13	0.73	0.57	Parkinson's disease;	chr3:48782235	chrX:13378735~13379340:-
OV	trans	rs12497850	0.897	rs7373778	ENSG00000197582.5	GPX1P1	10.37	7.34e-21	1.64e-13	0.74	0.57	Parkinson's disease;	chr3:48798959	chrX:13378735~13379340:-
OV	trans	rs928391	1	rs10157555	ENSG00000227183.3	HDGFP1	-10.36	7.57e-21	1.69e-13	-0.8	-0.57	Platelet count;	chr1:156802060	chrX:131646639~131646890:+
OV	trans	rs12497850	0.931	rs62262517	ENSG00000197582.5	GPX1P1	10.34	8.72e-21	1.91e-13	0.74	0.57	Parkinson's disease;	chr3:49097481	chrX:13378735~13379340:-
OV	trans	rs7312770	1	rs7312770	ENSG00000196933.5	RPS26P11	-10.34	8.8e-21	1.92e-13	-0.59	-0.57	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chrX:72044545~72044892:+
OV	trans	rs7312770	1	rs7312770	ENSG00000233278.1	RPS26P2	-10.32	9.77e-21	2.13e-13	-0.58	-0.57	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr9:30831878~30832225:-
OV	trans	rs877636	0.701	rs34415530	ENSG00000204652.6	RPS26P8	10.31	1.07e-20	2.32e-13	0.6	0.56	Cognitive function;	chr12:56050848	chr17:45608571~45608918:+
OV	trans	rs877636	0.702	rs773111	ENSG00000204652.6	RPS26P8	10.3	1.13e-20	2.43e-13	0.59	0.56	Cognitive function;	chr12:55981956	chr17:45608571~45608918:+
OV	trans	rs877636	0.702	rs773112	ENSG00000204652.6	RPS26P8	10.3	1.13e-20	2.43e-13	0.59	0.56	Cognitive function;	chr12:55982097	chr17:45608571~45608918:+
OV	trans	rs877636	0.702	rs773109	ENSG00000204652.6	RPS26P8	10.3	1.17e-20	2.52e-13	0.59	0.56	Cognitive function;	chr12:55980911	chr17:45608571~45608918:+
OV	trans	rs7312770	1	rs7312770	ENSG00000227887.1	RPS26P13	-10.29	1.27e-20	2.73e-13	-0.57	-0.56	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr1:208697369~208697698:-
OV	trans	rs12497850	0.931	rs13064911	ENSG00000197582.5	GPX1P1	10.26	1.51e-20	3.25e-13	0.73	0.56	Parkinson's disease;	chr3:48914952	chrX:13378735~13379340:-
OV	trans	rs877636	0.692	rs10876870	ENSG00000244604.1	RP11-713H12.1	-10.25	1.71e-20	3.65e-13	-0.6	-0.56	Cognitive function;	chr12:56084218	chr17:8561230~8561576:+
OV	trans	rs877636	0.692	rs7971751	ENSG00000244604.1	RP11-713H12.1	-10.25	1.71e-20	3.65e-13	-0.6	-0.56	Cognitive function;	chr12:56084874	chr17:8561230~8561576:+
OV	trans	rs877636	0.702	rs773110	ENSG00000204652.6	RPS26P8	10.24	1.73e-20	3.7e-13	0.59	0.56	Cognitive function;	chr12:55981353	chr17:45608571~45608918:+
OV	trans	rs7647973	0.58	rs12637576	ENSG00000197582.5	GPX1P1	10.24	1.82e-20	3.88e-13	0.71	0.56	Menarche (age at onset);	chr3:49199901	chrX:13378735~13379340:-
OV	trans	rs877636	0.74	rs705702	ENSG00000235459.5	RPS26P31	-10.23	1.85e-20	3.95e-13	-0.59	-0.56	Cognitive function;	chr12:55996852	chr7:122681315~122681662:+
OV	trans	rs928391	1	rs3765787	ENSG00000227183.3	HDGFP1	-10.22	2e-20	4.23e-13	-0.8	-0.56	Platelet count;	chr1:156784673	chrX:131646639~131646890:+
OV	trans	rs928391	1	rs928392	ENSG00000227183.3	HDGFP1	10.22	2.12e-20	4.47e-13	0.79	0.56	Platelet count;	chr1:156801024	chrX:131646639~131646890:+
OV	trans	rs12497850	0.931	rs7430198	ENSG00000197582.5	GPX1P1	10.21	2.26e-20	4.76e-13	0.73	0.56	Parkinson's disease;	chr3:48951327	chrX:13378735~13379340:-
OV	trans	rs12497850	0.866	rs6791234	ENSG00000197582.5	GPX1P1	10.21	2.26e-20	4.76e-13	0.73	0.56	Parkinson's disease;	chr3:48958704	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs6446196	ENSG00000197582.5	GPX1P1	10.21	2.26e-20	4.76e-13	0.73	0.56	Parkinson's disease;	chr3:48967290	chrX:13378735~13379340:-
OV	trans	rs12497850	0.805	rs6446198	ENSG00000197582.5	GPX1P1	10.21	2.26e-20	4.76e-13	0.73	0.56	Parkinson's disease;	chr3:48970205	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs4072859	ENSG00000197582.5	GPX1P1	10.21	2.26e-20	4.76e-13	0.73	0.56	Parkinson's disease;	chr3:48994772	chrX:13378735~13379340:-
OV	trans	rs7312770	0.612	rs773114	ENSG00000239210.2	RPS26P55	10.21	2.27e-20	4.76e-13	0.54	0.56	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr19:34533427~34534084:-
OV	trans	rs12497850	0.897	rs7432989	ENSG00000197582.5	GPX1P1	10.18	2.79e-20	5.82e-13	0.72	0.56	Parkinson's disease;	chr3:49067703	chrX:13378735~13379340:-
OV	trans	rs877636	0.702	rs61937249	ENSG00000235459.5	RPS26P31	10.17	2.9e-20	6.02e-13	0.58	0.56	Cognitive function;	chr12:55988132	chr7:122681315~122681662:+
OV	trans	rs877636	0.702	rs61937249	ENSG00000204652.6	RPS26P8	10.17	2.91e-20	6.04e-13	0.58	0.56	Cognitive function;	chr12:55988132	chr17:45608571~45608918:+
OV	trans	rs877636	0.702	rs773111	ENSG00000235459.5	RPS26P31	10.17	3e-20	6.19e-13	0.58	0.56	Cognitive function;	chr12:55981956	chr7:122681315~122681662:+
OV	trans	rs877636	0.702	rs773112	ENSG00000235459.5	RPS26P31	10.17	3e-20	6.19e-13	0.58	0.56	Cognitive function;	chr12:55982097	chr7:122681315~122681662:+
OV	trans	rs877636	0.74	rs705702	ENSG00000204652.6	RPS26P8	-10.15	3.31e-20	6.81e-13	-0.59	-0.56	Cognitive function;	chr12:55996852	chr17:45608571~45608918:+
OV	trans	rs12497850	0.543	rs6446218	ENSG00000197582.5	GPX1P1	10.14	3.67e-20	7.51e-13	0.72	0.56	Parkinson's disease;	chr3:49038080	chrX:13378735~13379340:-
OV	trans	rs12497850	0.897	rs6795025	ENSG00000197582.5	GPX1P1	10.14	3.67e-20	7.51e-13	0.72	0.56	Parkinson's disease;	chr3:49043814	chrX:13378735~13379340:-
OV	trans	rs7647973	0.56	rs7638154	ENSG00000197582.5	GPX1P1	10.13	3.78e-20	7.74e-13	0.69	0.56	Menarche (age at onset);	chr3:49261942	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs13316620	ENSG00000197582.5	GPX1P1	10.11	4.51e-20	9.17e-13	0.72	0.56	Parkinson's disease;	chr3:49007922	chrX:13378735~13379340:-
OV	trans	rs877636	0.702	rs773109	ENSG00000243403.1	RP11-330L19.1	10.1	4.86e-20	9.87e-13	0.56	0.56	Cognitive function;	chr12:55980911	chr15:64592979~64593326:+
OV	trans	rs877636	0.702	rs773109	ENSG00000235459.5	RPS26P31	10.1	4.89e-20	9.91e-13	0.58	0.56	Cognitive function;	chr12:55980911	chr7:122681315~122681662:+
OV	trans	rs7312770	0.612	rs1873914	ENSG00000219993.1	RP11-288G3.3	10.08	5.69e-20	1.12e-12	0.53	0.56	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr6:7506203~7506549:+
OV	trans	rs877636	0.859	rs3741499	ENSG00000204652.6	RPS26P8	-10.04	7.21e-20	1.41e-12	-0.58	-0.55	Cognitive function;	chr12:56080595	chr17:45608571~45608918:+
OV	trans	rs877636	0.74	rs705702	ENSG00000243403.1	RP11-330L19.1	-10.04	7.22e-20	1.41e-12	-0.57	-0.55	Cognitive function;	chr12:55996852	chr15:64592979~64593326:+
OV	trans	rs877636	0.702	rs773111	ENSG00000243403.1	RP11-330L19.1	10.02	8.66e-20	1.69e-12	0.56	0.55	Cognitive function;	chr12:55981956	chr15:64592979~64593326:+
OV	trans	rs877636	0.702	rs773112	ENSG00000243403.1	RP11-330L19.1	10.02	8.66e-20	1.69e-12	0.56	0.55	Cognitive function;	chr12:55982097	chr15:64592979~64593326:+
OV	trans	rs877636	0.702	rs773110	ENSG00000235459.5	RPS26P31	10.01	8.68e-20	1.69e-12	0.57	0.55	Cognitive function;	chr12:55981353	chr7:122681315~122681662:+
OV	trans	rs877636	0.702	rs773110	ENSG00000243403.1	RP11-330L19.1	10.01	8.74e-20	1.7e-12	0.56	0.55	Cognitive function;	chr12:55981353	chr15:64592979~64593326:+
OV	trans	rs7647973	0.58	rs7652746	ENSG00000197582.5	GPX1P1	-10.01	9.14e-20	1.78e-12	-0.71	-0.55	Menarche (age at onset);	chr3:49224874	chrX:13378735~13379340:-
OV	trans	rs877636	0.74	rs705702	ENSG00000224553.1	AC008065.1	-10	9.84e-20	1.91e-12	-0.59	-0.55	Cognitive function;	chr12:55996852	chr2:171374931~171375278:-
OV	trans	rs877636	0.702	rs773111	ENSG00000224553.1	AC008065.1	9.98	1.12e-19	2.16e-12	0.58	0.55	Cognitive function;	chr12:55981956	chr2:171374931~171375278:-
OV	trans	rs877636	0.702	rs773112	ENSG00000224553.1	AC008065.1	9.98	1.12e-19	2.16e-12	0.58	0.55	Cognitive function;	chr12:55982097	chr2:171374931~171375278:-
OV	trans	rs12497850	0.931	rs4974080	ENSG00000197582.5	GPX1P1	9.96	1.3e-19	2.5e-12	0.72	0.55	Parkinson's disease;	chr3:48993395	chrX:13378735~13379340:-
OV	trans	rs7647973	0.6	rs35174559	ENSG00000197582.5	GPX1P1	9.96	1.3e-19	2.51e-12	0.68	0.55	Menarche (age at onset);	chr3:49250326	chrX:13378735~13379340:-
OV	trans	rs7647973	0.6	rs12631989	ENSG00000197582.5	GPX1P1	9.95	1.33e-19	2.56e-12	0.68	0.55	Menarche (age at onset);	chr3:49236563	chrX:13378735~13379340:-
OV	trans	rs7647973	0.6	rs13064780	ENSG00000197582.5	GPX1P1	9.95	1.33e-19	2.56e-12	0.68	0.55	Menarche (age at onset);	chr3:49237393	chrX:13378735~13379340:-
OV	trans	rs877636	0.702	rs61937249	ENSG00000243403.1	RP11-330L19.1	9.95	1.35e-19	2.59e-12	0.56	0.55	Cognitive function;	chr12:55988132	chr15:64592979~64593326:+
OV	trans	rs877636	1	rs877636	ENSG00000204652.6	RPS26P8	-9.94	1.45e-19	2.78e-12	-0.57	-0.55	Cognitive function;	chr12:56086799	chr17:45608571~45608918:+
OV	trans	rs877636	0.702	rs773109	ENSG00000224553.1	AC008065.1	9.94	1.45e-19	2.78e-12	0.58	0.55	Cognitive function;	chr12:55980911	chr2:171374931~171375278:-
OV	trans	rs877636	0.702	rs61937249	ENSG00000224553.1	AC008065.1	9.92	1.66e-19	3.17e-12	0.58	0.55	Cognitive function;	chr12:55988132	chr2:171374931~171375278:-
OV	trans	rs7647973	0.58	rs35218722	ENSG00000197582.5	GPX1P1	9.92	1.71e-19	3.26e-12	0.68	0.55	Menarche (age at onset);	chr3:49238372	chrX:13378735~13379340:-
OV	trans	rs877636	0.692	rs2271194	ENSG00000244604.1	RP11-713H12.1	-9.91	1.85e-19	3.52e-12	-0.58	-0.55	Cognitive function;	chr12:56083910	chr17:8561230~8561576:+
OV	trans	rs877636	0.74	rs772920	ENSG00000204652.6	RPS26P8	9.9	1.92e-19	3.66e-12	0.58	0.55	Cognitive function;	chr12:55996580	chr17:45608571~45608918:+
OV	trans	rs7312770	0.612	rs773114	ENSG00000219993.1	RP11-288G3.3	9.9	1.98e-19	3.75e-12	0.52	0.55	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr6:7506203~7506549:+
OV	trans	rs12497850	0.863	rs4974084	ENSG00000197582.5	GPX1P1	9.88	2.18e-19	4.14e-12	0.71	0.55	Parkinson's disease;	chr3:48901647	chrX:13378735~13379340:-
OV	trans	rs877636	1	rs4759229	ENSG00000204652.6	RPS26P8	-9.87	2.46e-19	4.65e-12	-0.57	-0.55	Cognitive function;	chr12:56080696	chr17:45608571~45608918:+
OV	trans	rs12497850	0.805	rs11130176	ENSG00000197582.5	GPX1P1	9.84	2.91e-19	5.46e-12	0.7	0.55	Parkinson's disease;	chr3:48806644	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs9311430	ENSG00000197582.5	GPX1P1	9.84	2.91e-19	5.46e-12	0.7	0.55	Parkinson's disease;	chr3:48807818	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs9311432	ENSG00000197582.5	GPX1P1	9.84	2.91e-19	5.46e-12	0.7	0.55	Parkinson's disease;	chr3:48813010	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs9311433	ENSG00000197582.5	GPX1P1	9.84	2.91e-19	5.46e-12	0.7	0.55	Parkinson's disease;	chr3:48826402	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs7430501	ENSG00000197582.5	GPX1P1	9.84	2.91e-19	5.46e-12	0.7	0.55	Parkinson's disease;	chr3:48852686	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs10780033	ENSG00000197582.5	GPX1P1	9.84	2.91e-19	5.46e-12	0.7	0.55	Parkinson's disease;	chr3:48853842	chrX:13378735~13379340:-
OV	trans	rs12497850	0.864	rs7431857	ENSG00000197582.5	GPX1P1	9.84	2.91e-19	5.46e-12	0.7	0.55	Parkinson's disease;	chr3:48862914	chrX:13378735~13379340:-
OV	trans	rs877636	1	rs705696	ENSG00000204652.6	RPS26P8	9.84	3.02e-19	5.66e-12	0.59	0.55	Cognitive function;	chr12:56086864	chr17:45608571~45608918:+
OV	trans	rs12497850	0.864	rs3212	ENSG00000197582.5	GPX1P1	9.83	3.06e-19	5.73e-12	0.71	0.55	Parkinson's disease;	chr3:49108308	chrX:13378735~13379340:-
OV	trans	rs877636	0.702	rs773110	ENSG00000224553.1	AC008065.1	9.83	3.06e-19	5.73e-12	0.58	0.55	Cognitive function;	chr12:55981353	chr2:171374931~171375278:-
OV	trans	rs12497850	0.765	rs12487580	ENSG00000197582.5	GPX1P1	9.82	3.3e-19	6.15e-12	0.7	0.55	Parkinson's disease;	chr3:49145499	chrX:13378735~13379340:-
OV	trans	rs12497850	0.797	rs61583136	ENSG00000197582.5	GPX1P1	9.82	3.3e-19	6.15e-12	0.7	0.55	Parkinson's disease;	chr3:49151762	chrX:13378735~13379340:-
OV	trans	rs7647973	0.58	rs11716334	ENSG00000197582.5	GPX1P1	9.82	3.36e-19	6.25e-12	0.68	0.55	Menarche (age at onset);	chr3:49192663	chrX:13378735~13379340:-
OV	trans	rs877636	0.702	rs773109	ENSG00000242970.2	AC068522.4	9.81	3.52e-19	6.55e-12	0.56	0.55	Cognitive function;	chr12:55980911	chr8:58588420~58588764:-
OV	trans	rs877636	0.74	rs772920	ENSG00000235459.5	RPS26P31	9.81	3.71e-19	6.9e-12	0.57	0.55	Cognitive function;	chr12:55996580	chr7:122681315~122681662:+
OV	trans	rs877636	0.702	rs773111	ENSG00000242970.2	AC068522.4	9.8	3.86e-19	7.16e-12	0.56	0.55	Cognitive function;	chr12:55981956	chr8:58588420~58588764:-
OV	trans	rs877636	0.702	rs773112	ENSG00000242970.2	AC068522.4	9.8	3.86e-19	7.16e-12	0.56	0.55	Cognitive function;	chr12:55982097	chr8:58588420~58588764:-
OV	trans	rs12497850	0.931	rs6791542	ENSG00000197582.5	GPX1P1	9.8	3.99e-19	7.39e-12	0.7	0.55	Parkinson's disease;	chr3:48749786	chrX:13378735~13379340:-
OV	trans	rs7647973	0.58	rs2334958	ENSG00000197582.5	GPX1P1	9.8	4.03e-19	7.45e-12	0.68	0.55	Menarche (age at onset);	chr3:49214931	chrX:13378735~13379340:-
OV	trans	rs877636	0.702	rs61937249	ENSG00000242970.2	AC068522.4	9.79	4.06e-19	7.5e-12	0.56	0.55	Cognitive function;	chr12:55988132	chr8:58588420~58588764:-
OV	trans	rs7312770	1	rs7312770	ENSG00000244604.1	RP11-713H12.1	-9.78	4.35e-19	8e-12	-0.57	-0.54	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr17:8561230~8561576:+
OV	trans	rs877636	1	rs2292239	ENSG00000204652.6	RPS26P8	9.77	4.74e-19	8.71e-12	0.57	0.54	Cognitive function;	chr12:56088396	chr17:45608571~45608918:+
OV	trans	rs877636	0.701	rs34415530	ENSG00000235459.5	RPS26P31	9.77	4.83e-19	8.86e-12	0.58	0.54	Cognitive function;	chr12:56050848	chr7:122681315~122681662:+
OV	trans	rs7647973	0.58	rs11130184	ENSG00000197582.5	GPX1P1	9.76	5.01e-19	9.17e-12	0.68	0.54	Menarche (age at onset);	chr3:49192497	chrX:13378735~13379340:-
OV	trans	rs12497850	0.864	rs4521268	ENSG00000197582.5	GPX1P1	9.75	5.62e-19	1.02e-11	0.7	0.54	Parkinson's disease;	chr3:49100471	chrX:13378735~13379340:-
OV	trans	rs7647973	0.58	rs2117938	ENSG00000197582.5	GPX1P1	-9.74	5.76e-19	1.05e-11	-0.68	-0.54	Menarche (age at onset);	chr3:49226417	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs9840050	ENSG00000197582.5	GPX1P1	9.73	6.21e-19	1.13e-11	0.7	0.54	Parkinson's disease;	chr3:49095877	chrX:13378735~13379340:-
OV	trans	rs877636	0.702	rs773110	ENSG00000242970.2	AC068522.4	9.73	6.52e-19	1.18e-11	0.56	0.54	Cognitive function;	chr12:55981353	chr8:58588420~58588764:-
OV	trans	rs12497850	0.931	rs11924597	ENSG00000197582.5	GPX1P1	9.7	7.91e-19	1.41e-11	0.7	0.54	Parkinson's disease;	chr3:48900357	chrX:13378735~13379340:-
OV	trans	rs12497850	0.897	rs9850134	ENSG00000197582.5	GPX1P1	9.7	7.91e-19	1.41e-11	0.7	0.54	Parkinson's disease;	chr3:48919714	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs9867373	ENSG00000197582.5	GPX1P1	9.7	7.91e-19	1.41e-11	0.7	0.54	Parkinson's disease;	chr3:48923505	chrX:13378735~13379340:-
OV	trans	rs877636	1	rs2292239	ENSG00000224553.1	AC008065.1	9.69	8.42e-19	1.5e-11	0.57	0.54	Cognitive function;	chr12:56088396	chr2:171374931~171375278:-
OV	trans	rs877636	0.74	rs772920	ENSG00000243403.1	RP11-330L19.1	9.69	8.46e-19	1.51e-11	0.55	0.54	Cognitive function;	chr12:55996580	chr15:64592979~64593326:+
OV	trans	rs877636	1	rs2292239	ENSG00000235459.5	RPS26P31	9.68	8.87e-19	1.58e-11	0.56	0.54	Cognitive function;	chr12:56088396	chr7:122681315~122681662:+
OV	trans	rs12497850	0.897	rs9884022	ENSG00000197582.5	GPX1P1	9.68	8.9e-19	1.58e-11	0.7	0.54	Parkinson's disease;	chr3:48919429	chrX:13378735~13379340:-
OV	trans	rs7617480	0.519	rs6790914	ENSG00000197582.5	GPX1P1	9.68	9.1e-19	1.61e-11	0.71	0.54	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49168885	chrX:13378735~13379340:-
OV	trans	rs7312770	1	rs7312770	ENSG00000225071.1	GS1-184P14.2	-9.67	9.92e-19	1.75e-11	-0.58	-0.54	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chrX:24429573~24429920:-
OV	trans	rs877636	0.74	rs705702	ENSG00000227586.5	RP11-162A23.5	-9.64	1.18e-18	2.07e-11	-0.54	-0.54	Cognitive function;	chr12:55996852	chr10:123171535~123171875:-
OV	trans	rs12497850	0.864	rs4513485	ENSG00000197582.5	GPX1P1	9.62	1.37e-18	2.4e-11	0.69	0.54	Parkinson's disease;	chr3:49102533	chrX:13378735~13379340:-
OV	trans	rs928391	0.592	rs6427332	ENSG00000227183.3	HDGFP1	-9.61	1.46e-18	2.54e-11	-0.79	-0.54	Platelet count;	chr1:156827052	chrX:131646639~131646890:+
OV	trans	rs928391	0.592	rs7522395	ENSG00000227183.3	HDGFP1	-9.6	1.59e-18	2.76e-11	-0.79	-0.54	Platelet count;	chr1:156826905	chrX:131646639~131646890:+
OV	trans	rs12497850	0.931	rs12493289	ENSG00000197582.5	GPX1P1	9.59	1.64e-18	2.85e-11	0.68	0.54	Parkinson's disease;	chr3:48867728	chrX:13378735~13379340:-
OV	trans	rs12497850	0.865	rs7649458	ENSG00000197582.5	GPX1P1	9.59	1.64e-18	2.85e-11	0.68	0.54	Parkinson's disease;	chr3:48882694	chrX:13378735~13379340:-
OV	trans	rs12497850	0.864	rs4279134	ENSG00000197582.5	GPX1P1	9.59	1.68e-18	2.91e-11	0.69	0.54	Parkinson's disease;	chr3:49119243	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs13315711	ENSG00000197582.5	GPX1P1	9.58	1.73e-18	2.99e-11	0.69	0.54	Parkinson's disease;	chr3:48948966	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs7636057	ENSG00000197582.5	GPX1P1	9.58	1.73e-18	2.99e-11	0.69	0.54	Parkinson's disease;	chr3:48955149	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs7643368	ENSG00000197582.5	GPX1P1	9.58	1.73e-18	2.99e-11	0.69	0.54	Parkinson's disease;	chr3:48955422	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs7621015	ENSG00000197582.5	GPX1P1	9.58	1.73e-18	2.99e-11	0.69	0.54	Parkinson's disease;	chr3:48978623	chrX:13378735~13379340:-
OV	trans	rs7312770	0.612	rs1873914	ENSG00000234354.3	RPS26P47	9.58	1.81e-18	3.12e-11	0.61	0.54	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr13:100539901~100540248:-
OV	trans	rs12497850	0.931	rs9311434	ENSG00000197582.5	GPX1P1	9.58	1.83e-18	3.14e-11	0.68	0.54	Parkinson's disease;	chr3:48846714	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs7623023	ENSG00000197582.5	GPX1P1	9.58	1.83e-18	3.14e-11	0.68	0.54	Parkinson's disease;	chr3:48876805	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs7431710	ENSG00000197582.5	GPX1P1	9.58	1.83e-18	3.14e-11	0.68	0.54	Parkinson's disease;	chr3:48898150	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs11705888	ENSG00000197582.5	GPX1P1	9.58	1.84e-18	3.17e-11	0.68	0.54	Parkinson's disease;	chr3:48779856	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs7647813	ENSG00000197582.5	GPX1P1	9.58	1.84e-18	3.17e-11	0.68	0.54	Parkinson's disease;	chr3:48795915	chrX:13378735~13379340:-
OV	trans	rs7647973	0.58	rs12629759	ENSG00000197582.5	GPX1P1	9.56	2.09e-18	3.58e-11	0.68	0.54	Menarche (age at onset);	chr3:49199961	chrX:13378735~13379340:-
OV	trans	rs12497850	0.966	rs6792510	ENSG00000197582.5	GPX1P1	9.55	2.23e-18	3.82e-11	0.68	0.54	Parkinson's disease;	chr3:48685869	chrX:13378735~13379340:-
OV	trans	rs7312770	0.612	rs1873914	ENSG00000239210.2	RPS26P55	9.55	2.23e-18	3.82e-11	0.52	0.54	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr19:34533427~34534084:-
OV	trans	rs12497850	0.931	rs3774628	ENSG00000197582.5	GPX1P1	9.54	2.3e-18	3.94e-11	0.68	0.54	Parkinson's disease;	chr3:48764407	chrX:13378735~13379340:-
OV	trans	rs877636	1	rs705696	ENSG00000224553.1	AC008065.1	9.54	2.38e-18	4.07e-11	0.58	0.53	Cognitive function;	chr12:56086864	chr2:171374931~171375278:-
OV	trans	rs877636	0.692	rs11171739	ENSG00000219993.1	RP11-288G3.3	9.53	2.47e-18	4.23e-11	0.51	0.53	Cognitive function;	chr12:56076841	chr6:7506203~7506549:+
OV	trans	rs877636	0.74	rs705702	ENSG00000242970.2	AC068522.4	-9.53	2.59e-18	4.43e-11	-0.56	-0.53	Cognitive function;	chr12:55996852	chr8:58588420~58588764:-
OV	trans	rs877636	0.701	rs34415530	ENSG00000224553.1	AC008065.1	9.52	2.63e-18	4.48e-11	0.58	0.53	Cognitive function;	chr12:56050848	chr2:171374931~171375278:-
OV	trans	rs877636	0.74	rs772920	ENSG00000227586.5	RP11-162A23.5	9.51	2.96e-18	5.04e-11	0.54	0.53	Cognitive function;	chr12:55996580	chr10:123171535~123171875:-
OV	trans	rs12497850	0.931	rs7626445	ENSG00000197582.5	GPX1P1	9.5	3.15e-18	5.36e-11	0.67	0.53	Parkinson's disease;	chr3:49077111	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs13064784	ENSG00000197582.5	GPX1P1	9.49	3.38e-18	5.74e-11	0.68	0.53	Parkinson's disease;	chr3:49098528	chrX:13378735~13379340:-
OV	trans	rs12497850	0.897	rs6781790	ENSG00000197582.5	GPX1P1	9.49	3.42e-18	5.8e-11	0.68	0.53	Parkinson's disease;	chr3:49007334	chrX:13378735~13379340:-
OV	trans	rs877636	0.74	rs705702	ENSG00000234513.1	AC073072.7	-9.48	3.65e-18	6.18e-11	-0.55	-0.53	Cognitive function;	chr12:55996852	chr7:22773646~22773993:-
OV	trans	rs877636	0.74	rs705702	ENSG00000212994.5	RPS26P6	-9.48	3.65e-18	6.18e-11	-0.58	-0.53	Cognitive function;	chr12:55996852	chr8:100895771~100896118:+
OV	trans	rs877636	0.74	rs772920	ENSG00000224553.1	AC008065.1	9.47	3.78e-18	6.4e-11	0.57	0.53	Cognitive function;	chr12:55996580	chr2:171374931~171375278:-
OV	trans	rs877636	0.692	rs10876870	ENSG00000219993.1	RP11-288G3.3	-9.46	3.96e-18	6.7e-11	-0.52	-0.53	Cognitive function;	chr12:56084218	chr6:7506203~7506549:+
OV	trans	rs877636	0.692	rs7971751	ENSG00000219993.1	RP11-288G3.3	-9.46	3.96e-18	6.7e-11	-0.52	-0.53	Cognitive function;	chr12:56084874	chr6:7506203~7506549:+
OV	trans	rs877636	0.702	rs773109	ENSG00000196656.7	AC004057.1	9.46	4.04e-18	6.82e-11	0.58	0.53	Cognitive function;	chr12:55980911	chr4:113214046~113217170:-
OV	trans	rs877636	0.859	rs3741499	ENSG00000224553.1	AC008065.1	-9.44	4.56e-18	7.69e-11	-0.56	-0.53	Cognitive function;	chr12:56080595	chr2:171374931~171375278:-
OV	trans	rs12497850	0.931	rs9846123	ENSG00000197582.5	GPX1P1	-9.44	4.69e-18	7.92e-11	-0.68	-0.53	Parkinson's disease;	chr3:49050679	chrX:13378735~13379340:-
OV	trans	rs877636	1	rs877636	ENSG00000224553.1	AC008065.1	-9.43	4.92e-18	8.28e-11	-0.56	-0.53	Cognitive function;	chr12:56086799	chr2:171374931~171375278:-
OV	trans	rs877636	0.74	rs772920	ENSG00000212994.5	RPS26P6	9.43	5.02e-18	8.45e-11	0.58	0.53	Cognitive function;	chr12:55996580	chr8:100895771~100896118:+
OV	trans	rs12497850	0.829	rs8926	ENSG00000197582.5	GPX1P1	9.42	5.43e-18	9.13e-11	0.68	0.53	Parkinson's disease;	chr3:49015352	chrX:13378735~13379340:-
OV	trans	rs877636	0.702	rs61937249	ENSG00000227586.5	RP11-162A23.5	9.42	5.53e-18	9.29e-11	0.53	0.53	Cognitive function;	chr12:55988132	chr10:123171535~123171875:-
OV	trans	rs12497850	0.931	rs11920534	ENSG00000197582.5	GPX1P1	9.41	5.61e-18	9.41e-11	0.68	0.53	Parkinson's disease;	chr3:48900328	chrX:13378735~13379340:-
OV	trans	rs12497850	0.865	rs13072911	ENSG00000197582.5	GPX1P1	9.4	6.01e-18	1.01e-10	0.68	0.53	Parkinson's disease;	chr3:48924695	chrX:13378735~13379340:-
OV	trans	rs877636	1	rs705696	ENSG00000235459.5	RPS26P31	9.4	6.3e-18	1.05e-10	0.57	0.53	Cognitive function;	chr12:56086864	chr7:122681315~122681662:+
OV	trans	rs877636	0.692	rs11171739	ENSG00000242206.2	RPS26P35	9.4	6.33e-18	1.06e-10	0.53	0.53	Cognitive function;	chr12:56076841	chr8:118761856~118762201:-
OV	trans	rs877636	1	rs705696	ENSG00000243403.1	RP11-330L19.1	9.39	6.44e-18	1.07e-10	0.55	0.53	Cognitive function;	chr12:56086864	chr15:64592979~64593326:+
OV	trans	rs877636	0.702	rs773109	ENSG00000227586.5	RP11-162A23.5	9.39	6.71e-18	1.12e-10	0.53	0.53	Cognitive function;	chr12:55980911	chr10:123171535~123171875:-
OV	trans	rs877636	0.692	rs11171739	ENSG00000239210.2	RPS26P55	9.38	6.87e-18	1.14e-10	0.52	0.53	Cognitive function;	chr12:56076841	chr19:34533427~34534084:-
OV	trans	rs12497850	0.931	rs4974085	ENSG00000197582.5	GPX1P1	9.38	7.11e-18	1.18e-10	0.67	0.53	Parkinson's disease;	chr3:48887467	chrX:13378735~13379340:-
OV	trans	rs12497850	1	rs4858798	ENSG00000197582.5	GPX1P1	9.38	7.26e-18	1.21e-10	0.67	0.53	Parkinson's disease;	chr3:48689679	chrX:13378735~13379340:-
OV	trans	rs877636	1	rs4759229	ENSG00000224553.1	AC008065.1	-9.38	7.28e-18	1.21e-10	-0.56	-0.53	Cognitive function;	chr12:56080696	chr2:171374931~171375278:-
OV	trans	rs12497850	0.644	rs11928552	ENSG00000197582.5	GPX1P1	9.37	7.79e-18	1.29e-10	0.68	0.53	Parkinson's disease;	chr3:48702450	chrX:13378735~13379340:-
OV	trans	rs7647973	1	rs13096474	ENSG00000197582.5	GPX1P1	-9.37	7.82e-18	1.3e-10	-0.72	-0.53	Menarche (age at onset);	chr3:49405648	chrX:13378735~13379340:-
OV	trans	rs877636	0.74	rs705702	ENSG00000212829.8	RPS26P3	-9.34	8.99e-18	1.49e-10	-0.53	-0.53	Cognitive function;	chr12:55996852	chr9:9090898~9091245:+
OV	trans	rs877636	0.702	rs773111	ENSG00000196656.7	AC004057.1	9.34	9.35e-18	1.54e-10	0.57	0.53	Cognitive function;	chr12:55981956	chr4:113214046~113217170:-
OV	trans	rs877636	0.702	rs773112	ENSG00000196656.7	AC004057.1	9.34	9.35e-18	1.54e-10	0.57	0.53	Cognitive function;	chr12:55982097	chr4:113214046~113217170:-
OV	trans	rs877636	0.702	rs773110	ENSG00000196656.7	AC004057.1	9.34	9.42e-18	1.55e-10	0.57	0.53	Cognitive function;	chr12:55981353	chr4:113214046~113217170:-
OV	trans	rs877636	0.702	rs773109	ENSG00000212829.8	RPS26P3	9.33	9.7e-18	1.6e-10	0.53	0.53	Cognitive function;	chr12:55980911	chr9:9090898~9091245:+
OV	trans	rs12497850	0.931	rs6414613	ENSG00000197582.5	GPX1P1	9.32	1.06e-17	1.75e-10	0.67	0.53	Parkinson's disease;	chr3:48998452	chrX:13378735~13379340:-
OV	trans	rs877636	0.701	rs34415530	ENSG00000243403.1	RP11-330L19.1	9.32	1.06e-17	1.75e-10	0.55	0.53	Cognitive function;	chr12:56050848	chr15:64592979~64593326:+
OV	trans	rs877636	0.702	rs773111	ENSG00000227586.5	RP11-162A23.5	9.32	1.07e-17	1.75e-10	0.52	0.53	Cognitive function;	chr12:55981956	chr10:123171535~123171875:-
OV	trans	rs877636	0.702	rs773112	ENSG00000227586.5	RP11-162A23.5	9.32	1.07e-17	1.75e-10	0.52	0.53	Cognitive function;	chr12:55982097	chr10:123171535~123171875:-
OV	trans	rs12497850	0.931	rs1134591	ENSG00000197582.5	GPX1P1	9.32	1.08e-17	1.77e-10	0.68	0.53	Parkinson's disease;	chr3:48935459	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs7628719	ENSG00000197582.5	GPX1P1	9.32	1.09e-17	1.79e-10	0.67	0.53	Parkinson's disease;	chr3:48958054	chrX:13378735~13379340:-
OV	trans	rs12497850	0.931	rs4974082	ENSG00000197582.5	GPX1P1	9.32	1.09e-17	1.79e-10	0.67	0.53	Parkinson's disease;	chr3:48961890	chrX:13378735~13379340:-
OV	trans	rs877636	0.702	rs773109	ENSG00000234513.1	AC073072.7	9.31	1.11e-17	1.82e-10	0.54	0.53	Cognitive function;	chr12:55980911	chr7:22773646~22773993:-
OV	trans	rs877636	0.859	rs3741499	ENSG00000235459.5	RPS26P31	-9.31	1.15e-17	1.89e-10	-0.55	-0.53	Cognitive function;	chr12:56080595	chr7:122681315~122681662:+
OV	trans	rs877636	1	rs877636	ENSG00000235459.5	RPS26P31	-9.3	1.21e-17	1.98e-10	-0.54	-0.53	Cognitive function;	chr12:56086799	chr7:122681315~122681662:+
OV	trans	rs12497850	0.931	rs7616815	ENSG00000197582.5	GPX1P1	9.3	1.21e-17	1.98e-10	0.67	0.53	Parkinson's disease;	chr3:48742282	chrX:13378735~13379340:-
OV	trans	rs877636	0.859	rs3741499	ENSG00000243403.1	RP11-330L19.1	-9.29	1.27e-17	2.07e-10	-0.53	-0.53	Cognitive function;	chr12:56080595	chr15:64592979~64593326:+
OV	trans	rs877636	0.669	rs7297175	ENSG00000234192.1	RP11-57C13.5	-9.29	1.33e-17	2.17e-10	-0.53	-0.52	Cognitive function;	chr12:56080024	chr10:87642607~87642954:+
OV	trans	rs877636	1	rs2292239	ENSG00000243403.1	RP11-330L19.1	9.28	1.37e-17	2.24e-10	0.53	0.52	Cognitive function;	chr12:56088396	chr15:64592979~64593326:+
OV	trans	rs877636	0.702	rs773110	ENSG00000212994.5	RPS26P6	9.28	1.37e-17	2.24e-10	0.57	0.52	Cognitive function;	chr12:55981353	chr8:100895771~100896118:+
OV	trans	rs877636	0.702	rs773110	ENSG00000212829.8	RPS26P3	9.28	1.4e-17	2.28e-10	0.52	0.52	Cognitive function;	chr12:55981353	chr9:9090898~9091245:+
OV	trans	rs877636	0.702	rs773110	ENSG00000234513.1	AC073072.7	9.27	1.45e-17	2.35e-10	0.54	0.52	Cognitive function;	chr12:55981353	chr7:22773646~22773993:-
OV	trans	rs877636	0.692	rs2271194	ENSG00000219993.1	RP11-288G3.3	-9.27	1.45e-17	2.35e-10	-0.51	-0.52	Cognitive function;	chr12:56083910	chr6:7506203~7506549:+
OV	trans	rs877636	0.74	rs772920	ENSG00000242970.2	AC068522.4	9.27	1.48e-17	2.41e-10	0.55	0.52	Cognitive function;	chr12:55996580	chr8:58588420~58588764:-
OV	trans	rs877636	0.702	rs773109	ENSG00000212994.5	RPS26P6	9.26	1.56e-17	2.53e-10	0.56	0.52	Cognitive function;	chr12:55980911	chr8:100895771~100896118:+
OV	trans	rs877636	0.702	rs773110	ENSG00000227586.5	RP11-162A23.5	9.26	1.56e-17	2.53e-10	0.52	0.52	Cognitive function;	chr12:55981353	chr10:123171535~123171875:-
OV	trans	rs877636	0.74	rs705702	ENSG00000196656.7	AC004057.1	-9.26	1.58e-17	2.55e-10	-0.57	-0.52	Cognitive function;	chr12:55996852	chr4:113214046~113217170:-
OV	trans	rs8010715	1	rs8010715	ENSG00000248988.1	RP11-815N9.2	9.26	1.63e-17	2.63e-10	0.69	0.52	IgG glycosylation;	chr14:24139938	chr4:159007119~159007835:+
OV	trans	rs877636	0.702	rs61937249	ENSG00000196656.7	AC004057.1	9.25	1.7e-17	2.75e-10	0.57	0.52	Cognitive function;	chr12:55988132	chr4:113214046~113217170:-
OV	trans	rs928391	0.592	rs7516856	ENSG00000227183.3	HDGFP1	-9.25	1.74e-17	2.8e-10	-0.77	-0.52	Platelet count;	chr1:156828324	chrX:131646639~131646890:+
OV	trans	rs928391	0.541	rs1888863	ENSG00000227183.3	HDGFP1	-9.24	1.79e-17	2.89e-10	-0.77	-0.52	Platelet count;	chr1:156828046	chrX:131646639~131646890:+
OV	trans	rs877636	0.74	rs772920	ENSG00000234513.1	AC073072.7	9.23	1.95e-17	3.15e-10	0.55	0.52	Cognitive function;	chr12:55996580	chr7:22773646~22773993:-
OV	trans	rs12497850	1	rs12493578	ENSG00000197582.5	GPX1P1	-9.22	2.15e-17	3.45e-10	-0.68	-0.52	Parkinson's disease;	chr3:48692683	chrX:13378735~13379340:-
OV	trans	rs877636	0.702	rs773111	ENSG00000212829.8	RPS26P3	9.22	2.16e-17	3.45e-10	0.52	0.52	Cognitive function;	chr12:55981956	chr9:9090898~9091245:+
OV	trans	rs877636	0.702	rs773112	ENSG00000212829.8	RPS26P3	9.22	2.16e-17	3.45e-10	0.52	0.52	Cognitive function;	chr12:55982097	chr9:9090898~9091245:+
OV	trans	rs928391	0.592	rs6689750	ENSG00000227183.3	HDGFP1	-9.21	2.3e-17	3.67e-10	-0.79	-0.52	Platelet count;	chr1:156828933	chrX:131646639~131646890:+
OV	trans	rs8010715	1	rs3742500	ENSG00000248988.1	RP11-815N9.2	9.2	2.37e-17	3.79e-10	0.69	0.52	IgG glycosylation;	chr14:24142769	chr4:159007119~159007835:+
OV	trans	rs928391	0.592	rs1888861	ENSG00000227183.3	HDGFP1	-9.2	2.42e-17	3.87e-10	-0.77	-0.52	Platelet count;	chr1:156828169	chrX:131646639~131646890:+
OV	trans	rs877636	0.702	rs773111	ENSG00000212994.5	RPS26P6	9.19	2.58e-17	4.11e-10	0.56	0.52	Cognitive function;	chr12:55981956	chr8:100895771~100896118:+
OV	trans	rs877636	0.702	rs773112	ENSG00000212994.5	RPS26P6	9.19	2.58e-17	4.11e-10	0.56	0.52	Cognitive function;	chr12:55982097	chr8:100895771~100896118:+
OV	trans	rs877636	0.702	rs773111	ENSG00000234513.1	AC073072.7	9.18	2.72e-17	4.33e-10	0.54	0.52	Cognitive function;	chr12:55981956	chr7:22773646~22773993:-
OV	trans	rs877636	0.702	rs773112	ENSG00000234513.1	AC073072.7	9.18	2.72e-17	4.33e-10	0.54	0.52	Cognitive function;	chr12:55982097	chr7:22773646~22773993:-
OV	trans	rs877636	0.702	rs61937249	ENSG00000212829.8	RPS26P3	9.18	2.83e-17	4.49e-10	0.52	0.52	Cognitive function;	chr12:55988132	chr9:9090898~9091245:+
OV	trans	rs80033912	0.64	rs6785832	ENSG00000197582.5	GPX1P1	9.16	3.08e-17	4.88e-10	0.65	0.52	Intelligence (multi-trait analysis);	chr3:49186883	chrX:13378735~13379340:-
OV	trans	rs877636	1	rs877636	ENSG00000243403.1	RP11-330L19.1	-9.16	3.08e-17	4.89e-10	-0.52	-0.52	Cognitive function;	chr12:56086799	chr15:64592979~64593326:+
OV	trans	rs7312770	0.612	rs1873914	ENSG00000234192.1	RP11-57C13.5	9.16	3.19e-17	5.05e-10	0.51	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr10:87642607~87642954:+
OV	trans	rs877636	1	rs4759229	ENSG00000235459.5	RPS26P31	-9.16	3.21e-17	5.09e-10	-0.54	-0.52	Cognitive function;	chr12:56080696	chr7:122681315~122681662:+
OV	trans	rs877636	0.74	rs772920	ENSG00000196656.7	AC004057.1	9.15	3.3e-17	5.23e-10	0.57	0.52	Cognitive function;	chr12:55996580	chr4:113214046~113217170:-
OV	trans	rs877636	0.702	rs61937249	ENSG00000234513.1	AC073072.7	9.15	3.4e-17	5.38e-10	0.54	0.52	Cognitive function;	chr12:55988132	chr7:22773646~22773993:-
OV	trans	rs877636	0.702	rs61937249	ENSG00000212994.5	RPS26P6	9.15	3.42e-17	5.41e-10	0.56	0.52	Cognitive function;	chr12:55988132	chr8:100895771~100896118:+
OV	trans	rs7312770	0.612	rs1873914	ENSG00000242206.2	RPS26P35	9.13	3.94e-17	6.21e-10	0.51	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:118761856~118762201:-
OV	trans	rs7617480	0.61	rs4955420	ENSG00000197582.5	GPX1P1	9.1	4.63e-17	7.27e-10	0.66	0.52	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49171432	chrX:13378735~13379340:-
OV	trans	rs877636	1	rs2292239	ENSG00000242970.2	AC068522.4	9.1	4.69e-17	7.37e-10	0.54	0.52	Cognitive function;	chr12:56088396	chr8:58588420~58588764:-
OV	trans	rs877636	0.669	rs7297175	ENSG00000242206.2	RPS26P35	-9.1	4.82e-17	7.57e-10	-0.53	-0.52	Cognitive function;	chr12:56080024	chr8:118761856~118762201:-
OV	trans	rs877636	0.692	rs11171739	ENSG00000243538.1	CTB-55B8.1	9.1	4.88e-17	7.66e-10	0.53	0.52	Cognitive function;	chr12:56076841	chr5:16902294~16902641:-
OV	trans	rs6477998	0.535	rs4979232	ENSG00000238072.1	RP11-305M3.2	-9.09	5.05e-17	7.91e-10	-0.65	-0.52	Hematology traits;	chr9:113286594	chr7:129410113~129410370:-
OV	trans	rs7312770	0.612	rs773114	ENSG00000234354.3	RPS26P47	9.08	5.49e-17	8.59e-10	0.58	0.52	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr13:100539901~100540248:-
OV	trans	rs877636	1	rs4759229	ENSG00000243403.1	RP11-330L19.1	-9.07	5.63e-17	8.79e-10	-0.52	-0.52	Cognitive function;	chr12:56080696	chr15:64592979~64593326:+
OV	trans	rs877636	0.701	rs34415530	ENSG00000234513.1	AC073072.7	9.07	5.76e-17	8.98e-10	0.55	0.52	Cognitive function;	chr12:56050848	chr7:22773646~22773993:-
OV	trans	rs928391	0.592	rs1888862	ENSG00000227183.3	HDGFP1	-9.07	5.77e-17	9e-10	-0.76	-0.52	Platelet count;	chr1:156828113	chrX:131646639~131646890:+
OV	trans	rs877636	0.701	rs34415530	ENSG00000196656.7	AC004057.1	9.06	6.12e-17	9.51e-10	0.57	0.52	Cognitive function;	chr12:56050848	chr4:113214046~113217170:-
OV	trans	rs12497850	1	rs4858828	ENSG00000197582.5	GPX1P1	9.05	6.66e-17	1.03e-09	0.64	0.51	Parkinson's disease;	chr3:48687378	chrX:13378735~13379340:-
OV	trans	rs12497850	0.863	rs4858799	ENSG00000197582.5	GPX1P1	9.05	6.66e-17	1.03e-09	0.64	0.51	Parkinson's disease;	chr3:48690771	chrX:13378735~13379340:-
OV	trans	rs877636	0.701	rs34415530	ENSG00000212994.5	RPS26P6	9.04	7.32e-17	1.13e-09	0.57	0.51	Cognitive function;	chr12:56050848	chr8:100895771~100896118:+
OV	trans	rs12497850	1	rs10865952	ENSG00000197582.5	GPX1P1	9.03	7.45e-17	1.15e-09	0.65	0.51	Parkinson's disease;	chr3:48707051	chrX:13378735~13379340:-
OV	trans	rs877636	0.74	rs772920	ENSG00000212829.8	RPS26P3	9.02	8.25e-17	1.28e-09	0.52	0.51	Cognitive function;	chr12:55996580	chr9:9090898~9091245:+
OV	trans	rs877636	0.701	rs34415530	ENSG00000242970.2	AC068522.4	9.01	8.4e-17	1.29e-09	0.54	0.51	Cognitive function;	chr12:56050848	chr8:58588420~58588764:-
OV	trans	rs877636	0.692	rs10876870	ENSG00000242206.2	RPS26P35	-9.01	8.85e-17	1.36e-09	-0.53	-0.51	Cognitive function;	chr12:56084218	chr8:118761856~118762201:-
OV	trans	rs877636	0.692	rs7971751	ENSG00000242206.2	RPS26P35	-9.01	8.85e-17	1.36e-09	-0.53	-0.51	Cognitive function;	chr12:56084874	chr8:118761856~118762201:-
OV	trans	rs7554511	1	rs7522462	ENSG00000244144.1	RP11-757F18.3	9	9.07e-17	1.39e-09	0.7	0.51	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200912467	chr3:112185480~112185998:-
OV	trans	rs877636	0.692	rs10876870	ENSG00000239210.2	RPS26P55	-9	9.09e-17	1.39e-09	-0.52	-0.51	Cognitive function;	chr12:56084218	chr19:34533427~34534084:-
OV	trans	rs877636	0.692	rs7971751	ENSG00000239210.2	RPS26P55	-9	9.09e-17	1.39e-09	-0.52	-0.51	Cognitive function;	chr12:56084874	chr19:34533427~34534084:-
OV	trans	rs7312770	0.612	rs773114	ENSG00000242206.2	RPS26P35	8.97	1.14e-16	1.72e-09	0.51	0.51	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:118761856~118762201:-
OV	trans	rs7399018	0.643	rs6580810	ENSG00000223825.5	DAZAP2P1	8.97	1.14e-16	1.73e-09	0.89	0.51	Cisplatin-induced ototoxicity;	chr12:51216694	chr2:202201384~202201886:-
OV	trans	rs12497850	1	rs6788650	ENSG00000197582.5	GPX1P1	8.96	1.25e-16	1.89e-09	0.65	0.51	Parkinson's disease;	chr3:48712110	chrX:13378735~13379340:-
OV	trans	rs7647973	0.961	rs7638750	ENSG00000197582.5	GPX1P1	-8.95	1.3e-16	1.97e-09	-0.7	-0.51	Menarche (age at onset);	chr3:49415524	chrX:13378735~13379340:-
OV	trans	rs877636	0.859	rs3741499	ENSG00000242970.2	AC068522.4	-8.95	1.33e-16	2e-09	-0.53	-0.51	Cognitive function;	chr12:56080595	chr8:58588420~58588764:-
OV	trans	rs877636	0.692	rs2271194	ENSG00000242206.2	RPS26P35	-8.94	1.38e-16	2.07e-09	-0.52	-0.51	Cognitive function;	chr12:56083910	chr8:118761856~118762201:-
OV	trans	rs11039798	0.512	rs28453037	ENSG00000134612.10	FOLH1B	8.92	1.62e-16	2.43e-09	0.76	0.51	Axial length;	chr11:48985377	chr11:89639227~89698718:+
OV	trans	rs877636	1	rs877636	ENSG00000242970.2	AC068522.4	-8.9	1.87e-16	2.77e-09	-0.52	-0.51	Cognitive function;	chr12:56086799	chr8:58588420~58588764:-
OV	trans	rs877636	0.692	rs2271194	ENSG00000239210.2	RPS26P55	-8.88	2.02e-16	2.98e-09	-0.51	-0.51	Cognitive function;	chr12:56083910	chr19:34533427~34534084:-
OV	trans	rs877636	0.669	rs7297175	ENSG00000219993.1	RP11-288G3.3	-8.88	2.07e-16	3.05e-09	-0.5	-0.51	Cognitive function;	chr12:56080024	chr6:7506203~7506549:+
OV	trans	rs12497850	1	rs1352420	ENSG00000197582.5	GPX1P1	8.87	2.28e-16	3.35e-09	0.65	0.51	Parkinson's disease;	chr3:48719858	chrX:13378735~13379340:-
OV	trans	rs877636	1	rs2292239	ENSG00000196656.7	AC004057.1	8.86	2.35e-16	3.45e-09	0.55	0.51	Cognitive function;	chr12:56088396	chr4:113214046~113217170:-
OV	trans	rs11039798	0.528	rs10839208	ENSG00000134612.10	FOLH1B	8.85	2.48e-16	3.64e-09	0.75	0.51	Axial length;	chr11:49008904	chr11:89639227~89698718:+
OV	trans	rs11039798	0.528	rs10769559	ENSG00000134612.10	FOLH1B	8.85	2.48e-16	3.64e-09	0.75	0.51	Axial length;	chr11:49010894	chr11:89639227~89698718:+
OV	trans	rs6477998	0.535	rs10981712	ENSG00000238072.1	RP11-305M3.2	8.85	2.49e-16	3.64e-09	0.61	0.51	Hematology traits;	chr9:113283846	chr7:129410113~129410370:-
OV	trans	rs877636	0.701	rs34415530	ENSG00000212829.8	RPS26P3	8.85	2.58e-16	3.77e-09	0.52	0.51	Cognitive function;	chr12:56050848	chr9:9090898~9091245:+
OV	trans	rs877636	0.669	rs7297175	ENSG00000243538.1	CTB-55B8.1	-8.82	3.13e-16	4.53e-09	-0.53	-0.51	Cognitive function;	chr12:56080024	chr5:16902294~16902641:-
OV	trans	rs7554511	1	rs41299637	ENSG00000244144.1	RP11-757F18.3	-8.81	3.21e-16	4.61e-09	-0.7	-0.5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200908722	chr3:112185480~112185998:-
OV	trans	rs877636	1	rs2292239	ENSG00000234513.1	AC073072.7	8.81	3.22e-16	4.63e-09	0.52	0.5	Cognitive function;	chr12:56088396	chr7:22773646~22773993:-
OV	trans	rs12497850	0.864	rs4955410	ENSG00000197582.5	GPX1P1	8.81	3.25e-16	4.67e-09	0.64	0.5	Parkinson's disease;	chr3:49143785	chrX:13378735~13379340:-
OV	trans	rs877636	0.701	rs34415530	ENSG00000227586.5	RP11-162A23.5	8.81	3.31e-16	4.75e-09	0.51	0.5	Cognitive function;	chr12:56050848	chr10:123171535~123171875:-
OV	trans	rs7647973	1	rs6446275	ENSG00000197582.5	GPX1P1	-8.81	3.39e-16	4.86e-09	-0.69	-0.5	Menarche (age at onset);	chr3:49429438	chrX:13378735~13379340:-
OV	trans	rs7647973	1	rs62259933	ENSG00000197582.5	GPX1P1	-8.81	3.39e-16	4.86e-09	-0.69	-0.5	Menarche (age at onset);	chr3:49432270	chrX:13378735~13379340:-
OV	trans	rs7647973	0.922	rs7620024	ENSG00000197582.5	GPX1P1	-8.8	3.55e-16	5.08e-09	-0.69	-0.5	Menarche (age at onset);	chr3:49414258	chrX:13378735~13379340:-
OV	trans	rs7647973	1	rs1464569	ENSG00000197582.5	GPX1P1	8.8	3.56e-16	5.1e-09	0.69	0.5	Menarche (age at onset);	chr3:49422917	chrX:13378735~13379340:-
OV	trans	rs877636	1	rs877636	ENSG00000227586.5	RP11-162A23.5	-8.8	3.62e-16	5.17e-09	-0.5	-0.5	Cognitive function;	chr12:56086799	chr10:123171535~123171875:-
OV	trans	rs877636	1	rs705696	ENSG00000196656.7	AC004057.1	8.8	3.64e-16	5.2e-09	0.57	0.5	Cognitive function;	chr12:56086864	chr4:113214046~113217170:-
OV	trans	rs7554511	1	rs12131796	ENSG00000244144.1	RP11-757F18.3	-8.79	3.73e-16	5.33e-09	-0.69	-0.5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200909599	chr3:112185480~112185998:-
OV	trans	rs7399018	0.739	rs6580811	ENSG00000223825.5	DAZAP2P1	8.79	3.85e-16	5.5e-09	0.89	0.5	Cisplatin-induced ototoxicity;	chr12:51218717	chr2:202201384~202201886:-
OV	trans	rs11220237	0.92	rs1365081	ENSG00000236257.1	EI24P2	-8.77	4.44e-16	6.31e-09	-0.71	-0.5	Itch intensity from mosquito bite adjusted by bite size;	chr11:125778087	chr1:158454198~158455273:+
OV	trans	rs7554511	1	rs7554511	ENSG00000244144.1	RP11-757F18.3	8.76	4.48e-16	6.36e-09	0.69	0.5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200908434	chr3:112185480~112185998:-
OV	trans	rs7647973	1	rs9842132	ENSG00000197582.5	GPX1P1	-8.76	4.63e-16	6.55e-09	-0.68	-0.5	Menarche (age at onset);	chr3:49390500	chrX:13378735~13379340:-
OV	trans	rs7647973	1	rs6785045	ENSG00000197582.5	GPX1P1	-8.76	4.63e-16	6.55e-09	-0.68	-0.5	Menarche (age at onset);	chr3:49397810	chrX:13378735~13379340:-
OV	trans	rs7647973	1	rs56127630	ENSG00000197582.5	GPX1P1	-8.76	4.63e-16	6.55e-09	-0.68	-0.5	Menarche (age at onset);	chr3:49400603	chrX:13378735~13379340:-
OV	trans	rs7647973	1	rs7648995	ENSG00000197582.5	GPX1P1	-8.76	4.63e-16	6.55e-09	-0.68	-0.5	Menarche (age at onset);	chr3:49401370	chrX:13378735~13379340:-
OV	trans	rs7647973	1	rs2140270	ENSG00000197582.5	GPX1P1	-8.76	4.63e-16	6.55e-09	-0.68	-0.5	Menarche (age at onset);	chr3:49402007	chrX:13378735~13379340:-
OV	trans	rs7647973	1	rs2177268	ENSG00000197582.5	GPX1P1	-8.76	4.63e-16	6.55e-09	-0.68	-0.5	Menarche (age at onset);	chr3:49402292	chrX:13378735~13379340:-
OV	trans	rs7647973	1	rs3448	ENSG00000197582.5	GPX1P1	8.76	4.63e-16	6.55e-09	0.68	0.5	Menarche (age at onset);	chr3:49359318	chrX:13378735~13379340:-
OV	trans	rs7647973	1	rs11130190	ENSG00000197582.5	GPX1P1	8.76	4.63e-16	6.55e-09	0.68	0.5	Menarche (age at onset);	chr3:49364704	chrX:13378735~13379340:-
OV	trans	rs877636	1	rs877636	ENSG00000196656.7	AC004057.1	-8.76	4.65e-16	6.58e-09	-0.55	-0.5	Cognitive function;	chr12:56086799	chr4:113214046~113217170:-
OV	trans	rs877636	0.702	rs773109	ENSG00000233278.1	RPS26P2	8.75	4.77e-16	6.74e-09	0.53	0.5	Cognitive function;	chr12:55980911	chr9:30831878~30832225:-
OV	trans	rs877636	1	rs4759229	ENSG00000242970.2	AC068522.4	-8.75	4.87e-16	6.84e-09	-0.52	-0.5	Cognitive function;	chr12:56080696	chr8:58588420~58588764:-
OV	trans	rs12497850	1	rs4858831	ENSG00000197582.5	GPX1P1	8.75	4.99e-16	7.01e-09	0.63	0.5	Parkinson's disease;	chr3:48698125	chrX:13378735~13379340:-
OV	trans	rs12497850	1	rs12497850	ENSG00000197582.5	GPX1P1	8.74	5.14e-16	7.22e-09	0.64	0.5	Parkinson's disease;	chr3:48711556	chrX:13378735~13379340:-
OV	trans	rs7647973	1	rs6446262	ENSG00000197582.5	GPX1P1	8.73	5.55e-16	7.75e-09	0.69	0.5	Menarche (age at onset);	chr3:49363720	chrX:13378735~13379340:-
OV	trans	rs7647973	0.961	rs62259943	ENSG00000197582.5	GPX1P1	-8.73	5.55e-16	7.75e-09	-0.69	-0.5	Menarche (age at onset);	chr3:49387734	chrX:13378735~13379340:-
OV	trans	rs7647973	1	rs62259947	ENSG00000197582.5	GPX1P1	-8.73	5.55e-16	7.75e-09	-0.69	-0.5	Menarche (age at onset);	chr3:49402491	chrX:13378735~13379340:-
OV	trans	rs7647973	1	rs73088137	ENSG00000197582.5	GPX1P1	-8.73	5.55e-16	7.75e-09	-0.69	-0.5	Menarche (age at onset);	chr3:49410990	chrX:13378735~13379340:-
OV	trans	rs2069408	1	rs2069408	ENSG00000212994.5	RPS26P6	-8.73	5.69e-16	7.94e-09	-0.56	-0.5	Asthma;	chr12:55970537	chr8:100895771~100896118:+
OV	trans	rs877636	0.74	rs705702	ENSG00000233278.1	RPS26P2	-8.7	6.89e-16	9.56e-09	-0.53	-0.5	Cognitive function;	chr12:55996852	chr9:30831878~30832225:-
OV	trans	rs11039798	0.512	rs3974936	ENSG00000134612.10	FOLH1B	8.7	6.91e-16	9.59e-09	0.76	0.5	Axial length;	chr11:48983460	chr11:89639227~89698718:+
OV	trans	rs7647973	1	rs7613491	ENSG00000197582.5	GPX1P1	-8.69	7.14e-16	9.88e-09	-0.69	-0.5	Menarche (age at onset);	chr3:49471543	chrX:13378735~13379340:-
OV	trans	rs7647973	1	rs7647973	ENSG00000197582.5	GPX1P1	-8.69	7.14e-16	9.88e-09	-0.69	-0.5	Menarche (age at onset);	chr3:49473498	chrX:13378735~13379340:-
OV	trans	rs7647973	1	rs6783003	ENSG00000197582.5	GPX1P1	-8.69	7.14e-16	9.88e-09	-0.69	-0.5	Menarche (age at onset);	chr3:49487345	chrX:13378735~13379340:-
OV	trans	rs877636	0.702	rs773110	ENSG00000233778.3	RP11-777J24.1	8.69	7.22e-16	9.99e-09	0.52	0.5	Cognitive function;	chr12:55981353	chr8:92144088~92144435:-
OV	trans	rs11039798	0.588	rs61932767	ENSG00000134612.10	FOLH1B	8.69	7.27e-16	1.01e-08	0.72	0.5	Axial length;	chr11:48683254	chr11:89639227~89698718:+
OV	trans	rs877636	0.692	rs10876870	ENSG00000234354.3	RPS26P47	-8.69	7.4e-16	1.02e-08	-0.58	-0.5	Cognitive function;	chr12:56084218	chr13:100539901~100540248:-
OV	trans	rs877636	0.692	rs7971751	ENSG00000234354.3	RPS26P47	-8.69	7.4e-16	1.02e-08	-0.58	-0.5	Cognitive function;	chr12:56084874	chr13:100539901~100540248:-
OV	trans	rs877636	1	rs705696	ENSG00000212994.5	RPS26P6	8.68	7.63e-16	1.05e-08	0.56	0.5	Cognitive function;	chr12:56086864	chr8:100895771~100896118:+
OV	trans	rs877636	0.702	rs773111	ENSG00000233778.3	RP11-777J24.1	8.67	8.23e-16	1.13e-08	0.52	0.5	Cognitive function;	chr12:55981956	chr8:92144088~92144435:-
OV	trans	rs877636	0.702	rs773112	ENSG00000233778.3	RP11-777J24.1	8.67	8.23e-16	1.13e-08	0.52	0.5	Cognitive function;	chr12:55982097	chr8:92144088~92144435:-
OV	trans	rs877636	0.859	rs3741499	ENSG00000196656.7	AC004057.1	-8.65	9.22e-16	1.26e-08	-0.54	-0.5	Cognitive function;	chr12:56080595	chr4:113214046~113217170:-
OV	trans	rs877636	0.74	rs705702	ENSG00000233778.3	RP11-777J24.1	-8.65	9.4e-16	1.29e-08	-0.52	-0.5	Cognitive function;	chr12:55996852	chr8:92144088~92144435:-
OV	trans	rs877636	0.702	rs773110	ENSG00000233278.1	RPS26P2	8.65	9.61e-16	1.31e-08	0.53	0.5	Cognitive function;	chr12:55981353	chr9:30831878~30832225:-
OV	trans	rs7617480	0.61	rs10865954	ENSG00000197582.5	GPX1P1	8.65	9.69e-16	1.32e-08	0.65	0.5	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:49174556	chrX:13378735~13379340:-
OV	trans	rs877636	0.669	rs7297175	ENSG00000239210.2	RPS26P55	-8.64	1e-15	1.37e-08	-0.5	-0.5	Cognitive function;	chr12:56080024	chr19:34533427~34534084:-
OV	trans	rs877636	0.702	rs773109	ENSG00000233778.3	RP11-777J24.1	8.64	1.03e-15	1.4e-08	0.52	0.5	Cognitive function;	chr12:55980911	chr8:92144088~92144435:-
OV	trans	rs11220237	1	rs10893444	ENSG00000236257.1	EI24P2	8.64	1.03e-15	1.41e-08	0.71	0.5	Itch intensity from mosquito bite adjusted by bite size;	chr11:125875652	chr1:158454198~158455273:+
OV	trans	rs11220237	1	rs3824921	ENSG00000236257.1	EI24P2	8.63	1.09e-15	1.48e-08	0.74	0.5	Itch intensity from mosquito bite adjusted by bite size;	chr11:125891563	chr1:158454198~158455273:+
OV	trans	rs877636	0.669	rs7297175	ENSG00000234354.3	RPS26P47	-8.63	1.09e-15	1.48e-08	-0.58	-0.5	Cognitive function;	chr12:56080024	chr13:100539901~100540248:-
OV	trans	rs877636	0.702	rs61937249	ENSG00000233778.3	RP11-777J24.1	8.62	1.14e-15	1.55e-08	0.52	0.5	Cognitive function;	chr12:55988132	chr8:92144088~92144435:-
OV	trans	rs11220237	1	rs11220218	ENSG00000236257.1	EI24P2	8.62	1.15e-15	1.56e-08	0.71	0.5	Itch intensity from mosquito bite adjusted by bite size;	chr11:125793961	chr1:158454198~158455273:+
OV	trans	rs877636	0.692	rs2271194	ENSG00000234354.3	RPS26P47	-8.61	1.24e-15	1.68e-08	-0.58	-0.5	Cognitive function;	chr12:56083910	chr13:100539901~100540248:-
OV	trans	rs7930295	0.632	rs12271647	ENSG00000236257.1	EI24P2	8.6	1.29e-15	1.74e-08	0.73	0.5	Schizophrenia;	chr11:125754161	chr1:158454198~158455273:+
OV	trans	rs7647973	1	rs9860055	ENSG00000197582.5	GPX1P1	-8.6	1.29e-15	1.74e-08	-0.68	-0.5	Menarche (age at onset);	chr3:49469467	chrX:13378735~13379340:-
OV	trans	rs7647973	1	rs74471041	ENSG00000197582.5	GPX1P1	-8.6	1.29e-15	1.74e-08	-0.68	-0.5	Menarche (age at onset);	chr3:49505110	chrX:13378735~13379340:-
OV	trans	rs7647973	1	rs7644148	ENSG00000197582.5	GPX1P1	-8.6	1.29e-15	1.74e-08	-0.68	-0.5	Menarche (age at onset);	chr3:49507808	chrX:13378735~13379340:-
OV	trans	rs877636	1	rs705696	ENSG00000212829.8	RPS26P3	8.6	1.33e-15	1.79e-08	0.51	0.5	Cognitive function;	chr12:56086864	chr9:9090898~9091245:+
OV	trans	rs877636	1	rs4759229	ENSG00000196656.7	AC004057.1	-8.6	1.36e-15	1.84e-08	-0.54	-0.5	Cognitive function;	chr12:56080696	chr4:113214046~113217170:-
OV	trans	rs11220237	1	rs3862623	ENSG00000236257.1	EI24P2	8.59	1.38e-15	1.86e-08	0.71	0.5	Itch intensity from mosquito bite adjusted by bite size;	chr11:125850351	chr1:158454198~158455273:+
OV	trans	rs11220237	0.92	rs11220263	ENSG00000236257.1	EI24P2	8.59	1.4e-15	1.88e-08	0.71	0.5	Itch intensity from mosquito bite adjusted by bite size;	chr11:125885375	chr1:158454198~158455273:+
OV	trans	rs7554511	1	rs55838263	ENSG00000244144.1	RP11-757F18.3	-8.59	1.42e-15	1.91e-08	-0.7	-0.5	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200905600	chr3:112185480~112185998:-
OV	trans	rs11220237	1	rs11220261	ENSG00000236257.1	EI24P2	8.58	1.46e-15	1.96e-08	0.7	0.5	Itch intensity from mosquito bite adjusted by bite size;	chr11:125877574	chr1:158454198~158455273:+
OV	trans	rs6477998	0.513	rs10981720	ENSG00000238072.1	RP11-305M3.2	8.58	1.48e-15	1.98e-08	0.64	0.49	Hematology traits;	chr9:113293831	chr7:129410113~129410370:-
OV	trans	rs11220237	1	rs56338707	ENSG00000236257.1	EI24P2	8.58	1.48e-15	1.99e-08	0.72	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr11:125883330	chr1:158454198~158455273:+
OV	trans	rs7647973	1	rs6446268	ENSG00000197582.5	GPX1P1	-8.58	1.51e-15	2.02e-08	-0.68	-0.49	Menarche (age at onset);	chr3:49408262	chrX:13378735~13379340:-
OV	trans	rs11220237	0.841	rs7118459	ENSG00000236257.1	EI24P2	8.58	1.51e-15	2.03e-08	0.7	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr11:125867837	chr1:158454198~158455273:+
OV	trans	rs11220237	1	rs12288151	ENSG00000236257.1	EI24P2	8.58	1.51e-15	2.03e-08	0.7	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr11:125873344	chr1:158454198~158455273:+
OV	trans	rs7647973	1	rs892974	ENSG00000197582.5	GPX1P1	8.57	1.56e-15	2.08e-08	0.68	0.49	Menarche (age at onset);	chr3:49361081	chrX:13378735~13379340:-
OV	trans	rs877636	0.702	rs773111	ENSG00000233278.1	RPS26P2	8.57	1.59e-15	2.13e-08	0.52	0.49	Cognitive function;	chr12:55981956	chr9:30831878~30832225:-
OV	trans	rs877636	0.702	rs773112	ENSG00000233278.1	RPS26P2	8.57	1.59e-15	2.13e-08	0.52	0.49	Cognitive function;	chr12:55982097	chr9:30831878~30832225:-
OV	trans	rs6790105	1	rs6790105	ENSG00000197582.5	GPX1P1	8.56	1.67e-15	2.23e-08	0.68	0.49	Childhood ear infection;	chr3:49355976	chrX:13378735~13379340:-
OV	trans	rs2069408	1	rs2069408	ENSG00000204652.6	RPS26P8	-8.56	1.7e-15	2.27e-08	-0.53	-0.49	Asthma;	chr12:55970537	chr17:45608571~45608918:+
OV	trans	rs7554511	1	rs35730213	ENSG00000244144.1	RP11-757F18.3	-8.56	1.72e-15	2.3e-08	-0.69	-0.49	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200905101	chr3:112185480~112185998:-
OV	trans	rs7647973	1	rs974495	ENSG00000197582.5	GPX1P1	8.56	1.77e-15	2.36e-08	0.67	0.49	Menarche (age at onset);	chr3:49363049	chrX:13378735~13379340:-
OV	trans	rs7647973	1	rs11719762	ENSG00000197582.5	GPX1P1	8.56	1.77e-15	2.36e-08	0.67	0.49	Menarche (age at onset);	chr3:49371569	chrX:13378735~13379340:-
OV	trans	rs7647973	1	rs10155014	ENSG00000197582.5	GPX1P1	8.56	1.77e-15	2.36e-08	0.67	0.49	Menarche (age at onset);	chr3:49394888	chrX:13378735~13379340:-
OV	trans	rs7647973	1	rs940045	ENSG00000197582.5	GPX1P1	8.56	1.77e-15	2.36e-08	0.67	0.49	Menarche (age at onset);	chr3:49412205	chrX:13378735~13379340:-
OV	trans	rs8010715	0.816	rs11574503	ENSG00000248988.1	RP11-815N9.2	-8.55	1.78e-15	2.37e-08	-0.63	-0.49	IgG glycosylation;	chr14:24132109	chr4:159007119~159007835:+
OV	trans	rs7647973	1	rs8897	ENSG00000197582.5	GPX1P1	8.55	1.82e-15	2.42e-08	0.69	0.49	Menarche (age at onset);	chr3:49422974	chrX:13378735~13379340:-
OV	trans	rs11220237	1	rs7124578	ENSG00000236257.1	EI24P2	8.55	1.85e-15	2.45e-08	0.7	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr11:125850600	chr1:158454198~158455273:+
OV	trans	rs877636	1	rs877636	ENSG00000234513.1	AC073072.7	-8.55	1.86e-15	2.46e-08	-0.51	-0.49	Cognitive function;	chr12:56086799	chr7:22773646~22773993:-
OV	trans	rs11220237	1	rs11220221	ENSG00000236257.1	EI24P2	8.54	1.95e-15	2.59e-08	0.71	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr11:125796232	chr1:158454198~158455273:+
OV	trans	rs11039798	0.623	rs588700	ENSG00000134612.10	FOLH1B	-8.54	1.95e-15	2.59e-08	-0.74	-0.49	Axial length;	chr11:48428337	chr11:89639227~89698718:+
OV	trans	rs7554511	1	rs12132298	ENSG00000244144.1	RP11-757F18.3	-8.54	1.97e-15	2.6e-08	-0.69	-0.49	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200905967	chr3:112185480~112185998:-
OV	trans	rs7554511	1	rs12132349	ENSG00000244144.1	RP11-757F18.3	-8.54	1.97e-15	2.6e-08	-0.69	-0.49	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200906114	chr3:112185480~112185998:-
OV	trans	rs7554511	0.964	rs59655222	ENSG00000244144.1	RP11-757F18.3	-8.54	1.97e-15	2.6e-08	-0.69	-0.49	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200906769	chr3:112185480~112185998:-
OV	trans	rs6477998	0.58	rs11552582	ENSG00000238072.1	RP11-305M3.2	8.54	1.98e-15	2.62e-08	0.57	0.49	Hematology traits;	chr9:113282718	chr7:129410113~129410370:-
OV	trans	rs11220237	1	rs7121477	ENSG00000236257.1	EI24P2	8.53	2.03e-15	2.69e-08	0.7	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr11:125853528	chr1:158454198~158455273:+
OV	trans	rs11220237	0.925	rs6590178	ENSG00000236257.1	EI24P2	8.53	2.03e-15	2.69e-08	0.7	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr11:125853735	chr1:158454198~158455273:+
OV	trans	rs877636	0.692	rs10876870	ENSG00000243538.1	CTB-55B8.1	-8.53	2.05e-15	2.71e-08	-0.52	-0.49	Cognitive function;	chr12:56084218	chr5:16902294~16902641:-
OV	trans	rs877636	0.692	rs7971751	ENSG00000243538.1	CTB-55B8.1	-8.53	2.05e-15	2.71e-08	-0.52	-0.49	Cognitive function;	chr12:56084874	chr5:16902294~16902641:-
OV	trans	rs2069408	1	rs2069408	ENSG00000235459.5	RPS26P31	-8.53	2.1e-15	2.77e-08	-0.53	-0.49	Asthma;	chr12:55970537	chr7:122681315~122681662:+
OV	trans	rs877636	1	rs877636	ENSG00000212829.8	RPS26P3	-8.53	2.12e-15	2.79e-08	-0.49	-0.49	Cognitive function;	chr12:56086799	chr9:9090898~9091245:+
OV	trans	rs877636	0.702	rs61937249	ENSG00000233278.1	RPS26P2	8.52	2.16e-15	2.84e-08	0.52	0.49	Cognitive function;	chr12:55988132	chr9:30831878~30832225:-
OV	trans	rs877636	1	rs877636	ENSG00000212994.5	RPS26P6	-8.52	2.19e-15	2.87e-08	-0.53	-0.49	Cognitive function;	chr12:56086799	chr8:100895771~100896118:+
OV	trans	rs877636	0.702	rs773109	ENSG00000225071.1	GS1-184P14.2	8.52	2.21e-15	2.91e-08	0.55	0.49	Cognitive function;	chr12:55980911	chrX:24429573~24429920:-
OV	trans	rs877636	1	rs2292239	ENSG00000212829.8	RPS26P3	8.51	2.44e-15	3.2e-08	0.49	0.49	Cognitive function;	chr12:56088396	chr9:9090898~9091245:+
OV	trans	rs7395662	1	rs9645642	ENSG00000134612.10	FOLH1B	-8.5	2.49e-15	3.26e-08	-0.59	-0.49	HDL cholesterol;	chr11:48683903	chr11:89639227~89698718:+
OV	trans	rs11220237	1	rs7934485	ENSG00000236257.1	EI24P2	8.5	2.57e-15	3.36e-08	0.7	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr11:125804339	chr1:158454198~158455273:+
OV	trans	rs7647973	1	rs10865956	ENSG00000197582.5	GPX1P1	8.5	2.61e-15	3.4e-08	0.66	0.49	Menarche (age at onset);	chr3:49544126	chrX:13378735~13379340:-
OV	trans	rs877636	0.859	rs3741499	ENSG00000234513.1	AC073072.7	-8.49	2.67e-15	3.48e-08	-0.51	-0.49	Cognitive function;	chr12:56080595	chr7:22773646~22773993:-
OV	trans	rs877636	0.74	rs705702	ENSG00000223416.3	RPS26P15	-8.49	2.72e-15	3.53e-08	-0.52	-0.49	Cognitive function;	chr12:55996852	chr1:58056133~58056480:-
OV	trans	rs11220237	1	rs59868022	ENSG00000236257.1	EI24P2	8.48	2.86e-15	3.71e-08	0.69	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr11:125850985	chr1:158454198~158455273:+
OV	trans	rs877636	0.74	rs772920	ENSG00000233278.1	RPS26P2	8.48	2.96e-15	3.83e-08	0.52	0.49	Cognitive function;	chr12:55996580	chr9:30831878~30832225:-
OV	trans	rs2069408	1	rs2069408	ENSG00000243403.1	RP11-330L19.1	-8.47	3.08e-15	3.97e-08	-0.51	-0.49	Asthma;	chr12:55970537	chr15:64592979~64593326:+
OV	trans	rs877636	0.859	rs3741499	ENSG00000227586.5	RP11-162A23.5	-8.47	3.14e-15	4.05e-08	-0.49	-0.49	Cognitive function;	chr12:56080595	chr10:123171535~123171875:-
OV	trans	rs877636	1	rs2292239	ENSG00000227586.5	RP11-162A23.5	8.46	3.23e-15	4.17e-08	0.49	0.49	Cognitive function;	chr12:56088396	chr10:123171535~123171875:-
OV	trans	rs11220237	0.925	rs9651705	ENSG00000236257.1	EI24P2	8.46	3.25e-15	4.19e-08	0.69	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr11:125798921	chr1:158454198~158455273:+
OV	trans	rs877636	0.702	rs773111	ENSG00000227887.1	RPS26P13	8.46	3.37e-15	4.33e-08	0.51	0.49	Cognitive function;	chr12:55981956	chr1:208697369~208697698:-
OV	trans	rs877636	0.702	rs773112	ENSG00000227887.1	RPS26P13	8.46	3.37e-15	4.33e-08	0.51	0.49	Cognitive function;	chr12:55982097	chr1:208697369~208697698:-
OV	trans	rs877636	0.702	rs773109	ENSG00000227887.1	RPS26P13	8.46	3.37e-15	4.33e-08	0.51	0.49	Cognitive function;	chr12:55980911	chr1:208697369~208697698:-
OV	trans	rs2069408	1	rs2069408	ENSG00000224553.1	AC008065.1	-8.46	3.4e-15	4.37e-08	-0.54	-0.49	Asthma;	chr12:55970537	chr2:171374931~171375278:-
OV	trans	rs7395662	1	rs11039890	ENSG00000134612.10	FOLH1B	-8.45	3.48e-15	4.47e-08	-0.59	-0.49	HDL cholesterol;	chr11:48631916	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs6485906	ENSG00000134612.10	FOLH1B	-8.45	3.57e-15	4.57e-08	-0.58	-0.49	HDL cholesterol;	chr11:48630109	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs6485907	ENSG00000134612.10	FOLH1B	-8.45	3.57e-15	4.57e-08	-0.58	-0.49	HDL cholesterol;	chr11:48630143	chr11:89639227~89698718:+
OV	trans	rs7647973	1	rs1982861	ENSG00000197582.5	GPX1P1	8.45	3.58e-15	4.58e-08	0.66	0.49	Menarche (age at onset);	chr3:49540232	chrX:13378735~13379340:-
OV	trans	rs877636	1	rs705696	ENSG00000234513.1	AC073072.7	8.44	3.64e-15	4.67e-08	0.52	0.49	Cognitive function;	chr12:56086864	chr7:22773646~22773993:-
OV	trans	rs877636	0.702	rs773110	ENSG00000225071.1	GS1-184P14.2	8.44	3.69e-15	4.72e-08	0.54	0.49	Cognitive function;	chr12:55981353	chrX:24429573~24429920:-
OV	trans	rs7647973	1	rs12583	ENSG00000197582.5	GPX1P1	-8.44	3.77e-15	4.82e-08	-0.66	-0.49	Menarche (age at onset);	chr3:49534029	chrX:13378735~13379340:-
OV	trans	rs7395662	0.791	rs11040136	ENSG00000134612.10	FOLH1B	8.43	4e-15	5.11e-08	0.58	0.49	HDL cholesterol;	chr11:48918239	chr11:89639227~89698718:+
OV	trans	rs11220237	1	rs7938074	ENSG00000236257.1	EI24P2	8.43	4.02e-15	5.12e-08	0.69	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr11:125804743	chr1:158454198~158455273:+
OV	trans	rs7395662	1	rs2221559	ENSG00000134612.10	FOLH1B	8.43	4.04e-15	5.12e-08	0.58	0.49	HDL cholesterol;	chr11:48686421	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs11499897	ENSG00000134612.10	FOLH1B	8.43	4.04e-15	5.12e-08	0.58	0.49	HDL cholesterol;	chr11:48696314	chr11:89639227~89698718:+
OV	trans	rs7395662	0.895	rs3903506	ENSG00000134612.10	FOLH1B	8.43	4.04e-15	5.12e-08	0.58	0.49	HDL cholesterol;	chr11:48696961	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs9666932	ENSG00000134612.10	FOLH1B	8.43	4.04e-15	5.12e-08	0.58	0.49	HDL cholesterol;	chr11:48704688	chr11:89639227~89698718:+
OV	trans	rs7395662	0.926	rs7122869	ENSG00000134612.10	FOLH1B	8.43	4.04e-15	5.12e-08	0.58	0.49	HDL cholesterol;	chr11:48706447	chr11:89639227~89698718:+
OV	trans	rs7395662	0.892	rs9667579	ENSG00000134612.10	FOLH1B	8.43	4.04e-15	5.12e-08	0.58	0.49	HDL cholesterol;	chr11:48708596	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs8189076	ENSG00000134612.10	FOLH1B	8.43	4.04e-15	5.12e-08	0.58	0.49	HDL cholesterol;	chr11:48711423	chr11:89639227~89698718:+
OV	trans	rs7395662	0.857	rs3902433	ENSG00000134612.10	FOLH1B	8.43	4.04e-15	5.12e-08	0.58	0.49	HDL cholesterol;	chr11:48711772	chr11:89639227~89698718:+
OV	trans	rs7395662	0.889	rs11039972	ENSG00000134612.10	FOLH1B	8.43	4.04e-15	5.12e-08	0.58	0.49	HDL cholesterol;	chr11:48737700	chr11:89639227~89698718:+
OV	trans	rs7395662	0.892	rs11040010	ENSG00000134612.10	FOLH1B	8.43	4.04e-15	5.12e-08	0.58	0.49	HDL cholesterol;	chr11:48755377	chr11:89639227~89698718:+
OV	trans	rs7647973	1	rs7619789	ENSG00000197582.5	GPX1P1	8.43	4.06e-15	5.13e-08	0.68	0.49	Menarche (age at onset);	chr3:49438830	chrX:13378735~13379340:-
OV	trans	rs7647973	0.922	rs57273516	ENSG00000197582.5	GPX1P1	8.43	4.06e-15	5.13e-08	0.68	0.49	Menarche (age at onset);	chr3:49445641	chrX:13378735~13379340:-
OV	trans	rs7647973	1	rs1009051	ENSG00000197582.5	GPX1P1	8.43	4.06e-15	5.13e-08	0.68	0.49	Menarche (age at onset);	chr3:49484116	chrX:13378735~13379340:-
OV	trans	rs7647973	1	rs3870339	ENSG00000197582.5	GPX1P1	8.43	4.06e-15	5.13e-08	0.68	0.49	Menarche (age at onset);	chr3:49499430	chrX:13378735~13379340:-
OV	trans	rs8010715	0.771	rs2277481	ENSG00000248988.1	RP11-815N9.2	8.43	4.11e-15	5.19e-08	0.61	0.49	IgG glycosylation;	chr14:24118336	chr4:159007119~159007835:+
OV	trans	rs877636	0.692	rs11171739	ENSG00000234354.3	RPS26P47	8.42	4.16e-15	5.25e-08	0.56	0.49	Cognitive function;	chr12:56076841	chr13:100539901~100540248:-
OV	trans	rs877636	0.702	rs61937249	ENSG00000227887.1	RPS26P13	8.42	4.2e-15	5.3e-08	0.51	0.49	Cognitive function;	chr12:55988132	chr1:208697369~208697698:-
OV	trans	rs7395662	0.784	rs75694945	ENSG00000134612.10	FOLH1B	8.42	4.2e-15	5.3e-08	0.58	0.49	HDL cholesterol;	chr11:48843911	chr11:89639227~89698718:+
OV	trans	rs7395662	0.784	rs79037165	ENSG00000134612.10	FOLH1B	8.42	4.2e-15	5.3e-08	0.58	0.49	HDL cholesterol;	chr11:48843912	chr11:89639227~89698718:+
OV	trans	rs877636	0.74	rs772920	ENSG00000233778.3	RP11-777J24.1	8.41	4.44e-15	5.6e-08	0.51	0.49	Cognitive function;	chr12:55996580	chr8:92144088~92144435:-
OV	trans	rs11220237	0.92	rs10893426	ENSG00000236257.1	EI24P2	8.41	4.62e-15	5.81e-08	0.69	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr11:125778426	chr1:158454198~158455273:+
OV	trans	rs11220237	1	rs12273204	ENSG00000236257.1	EI24P2	8.41	4.62e-15	5.81e-08	0.69	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr11:125784704	chr1:158454198~158455273:+
OV	trans	rs7647973	1	rs2312462	ENSG00000197582.5	GPX1P1	8.4	4.84e-15	6.07e-08	0.65	0.49	Menarche (age at onset);	chr3:49563822	chrX:13378735~13379340:-
OV	trans	rs877636	0.74	rs705702	ENSG00000227887.1	RPS26P13	-8.4	4.97e-15	6.22e-08	-0.51	-0.49	Cognitive function;	chr12:55996852	chr1:208697369~208697698:-
OV	trans	rs10242455	0.557	rs73403272	ENSG00000228834.1	RP11-249L21.4	8.4	5e-15	6.26e-08	1.07	0.49	Blood metabolite levels;	chr7:99536585	chr6:108907615~108907873:-
OV	trans	rs11220237	1	rs34506449	ENSG00000236257.1	EI24P2	8.4	5.01e-15	6.26e-08	0.7	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr11:125833712	chr1:158454198~158455273:+
OV	trans	rs11220237	1	rs7937508	ENSG00000236257.1	EI24P2	8.4	5.01e-15	6.26e-08	0.7	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr11:125834587	chr1:158454198~158455273:+
OV	trans	rs11220237	1	rs10893434	ENSG00000236257.1	EI24P2	8.4	5.01e-15	6.26e-08	0.7	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr11:125836029	chr1:158454198~158455273:+
OV	trans	rs11220237	1	rs10893435	ENSG00000236257.1	EI24P2	8.4	5.01e-15	6.26e-08	0.7	0.49	Itch intensity from mosquito bite adjusted by bite size;	chr11:125838890	chr1:158454198~158455273:+
OV	trans	rs10242455	0.702	rs73713507	ENSG00000228834.1	RP11-249L21.4	8.4	5.03e-15	6.29e-08	1.13	0.49	Blood metabolite levels;	chr7:99540980	chr6:108907615~108907873:-
OV	trans	rs10242455	0.702	rs78218664	ENSG00000228834.1	RP11-249L21.4	8.4	5.03e-15	6.29e-08	1.13	0.49	Blood metabolite levels;	chr7:99556758	chr6:108907615~108907873:-
OV	trans	rs8010715	0.816	rs1134340	ENSG00000248988.1	RP11-815N9.2	8.39	5.08e-15	6.34e-08	0.59	0.49	IgG glycosylation;	chr14:24125004	chr4:159007119~159007835:+
OV	trans	rs877636	0.702	rs773109	ENSG00000223416.3	RPS26P15	8.39	5.09e-15	6.36e-08	0.51	0.49	Cognitive function;	chr12:55980911	chr1:58056133~58056480:-
OV	trans	rs877636	1	rs877636	ENSG00000233778.3	RP11-777J24.1	-8.39	5.17e-15	6.45e-08	-0.5	-0.49	Cognitive function;	chr12:56086799	chr8:92144088~92144435:-
OV	trans	rs877636	1	rs705696	ENSG00000242970.2	AC068522.4	8.39	5.28e-15	6.59e-08	0.52	0.49	Cognitive function;	chr12:56086864	chr8:58588420~58588764:-
OV	trans	rs877636	0.859	rs3741499	ENSG00000212994.5	RPS26P6	-8.38	5.4e-15	6.74e-08	-0.52	-0.49	Cognitive function;	chr12:56080595	chr8:100895771~100896118:+
OV	trans	rs11039798	0.582	rs60764175	ENSG00000134612.10	FOLH1B	8.38	5.67e-15	7.04e-08	0.73	0.49	Axial length;	chr11:48754304	chr11:89639227~89698718:+
OV	trans	rs7312770	0.612	rs773114	ENSG00000243538.1	CTB-55B8.1	8.37	5.83e-15	7.23e-08	0.49	0.49	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr5:16902294~16902641:-
OV	trans	rs7647973	1	rs9871024	ENSG00000197582.5	GPX1P1	-8.37	6.06e-15	7.5e-08	-0.65	-0.49	Menarche (age at onset);	chr3:49516808	chrX:13378735~13379340:-
OV	trans	rs7647973	1	rs13322887	ENSG00000197582.5	GPX1P1	-8.37	6.06e-15	7.5e-08	-0.65	-0.49	Menarche (age at onset);	chr3:49518150	chrX:13378735~13379340:-
OV	trans	rs877636	0.702	rs773111	ENSG00000225071.1	GS1-184P14.2	8.37	6.08e-15	7.52e-08	0.54	0.49	Cognitive function;	chr12:55981956	chrX:24429573~24429920:-
OV	trans	rs877636	0.702	rs773112	ENSG00000225071.1	GS1-184P14.2	8.37	6.08e-15	7.52e-08	0.54	0.49	Cognitive function;	chr12:55982097	chrX:24429573~24429920:-
OV	trans	rs7312770	0.612	rs1873914	ENSG00000243538.1	CTB-55B8.1	8.36	6.21e-15	7.67e-08	0.5	0.49	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr5:16902294~16902641:-
OV	trans	rs7395662	0.963	rs11039950	ENSG00000134612.10	FOLH1B	8.36	6.42e-15	7.92e-08	0.57	0.49	HDL cholesterol;	chr11:48715919	chr11:89639227~89698718:+
OV	trans	rs7395662	0.617	rs1976509	ENSG00000134612.10	FOLH1B	8.36	6.46e-15	7.97e-08	0.58	0.49	HDL cholesterol;	chr11:48943051	chr11:89639227~89698718:+
OV	trans	rs11039798	0.557	rs4436575	ENSG00000134612.10	FOLH1B	-8.35	6.53e-15	8.04e-08	-0.72	-0.48	Axial length;	chr11:48377342	chr11:89639227~89698718:+
OV	trans	rs11039798	0.623	rs635632	ENSG00000134612.10	FOLH1B	-8.35	6.53e-15	8.04e-08	-0.72	-0.48	Axial length;	chr11:48377980	chr11:89639227~89698718:+
OV	trans	rs11039798	0.623	rs594615	ENSG00000134612.10	FOLH1B	-8.35	6.53e-15	8.04e-08	-0.72	-0.48	Axial length;	chr11:48381252	chr11:89639227~89698718:+
OV	trans	rs877636	0.74	rs772920	ENSG00000223416.3	RPS26P15	8.35	6.55e-15	8.06e-08	0.51	0.48	Cognitive function;	chr12:55996580	chr1:58056133~58056480:-
OV	trans	rs8010715	0.816	rs6573565	ENSG00000248988.1	RP11-815N9.2	-8.35	6.56e-15	8.07e-08	-0.59	-0.48	IgG glycosylation;	chr14:24125524	chr4:159007119~159007835:+
OV	trans	rs877636	1	rs705696	ENSG00000227586.5	RP11-162A23.5	8.35	6.78e-15	8.33e-08	0.5	0.48	Cognitive function;	chr12:56086864	chr10:123171535~123171875:-
OV	trans	rs877636	0.859	rs3741499	ENSG00000212829.8	RPS26P3	-8.35	6.86e-15	8.41e-08	-0.49	-0.48	Cognitive function;	chr12:56080595	chr9:9090898~9091245:+
OV	trans	rs8010715	0.816	rs762093	ENSG00000248988.1	RP11-815N9.2	8.34	6.99e-15	8.57e-08	0.59	0.48	IgG glycosylation;	chr14:24122709	chr4:159007119~159007835:+
OV	trans	rs877636	0.74	rs705702	ENSG00000225071.1	GS1-184P14.2	-8.34	7.03e-15	8.61e-08	-0.54	-0.48	Cognitive function;	chr12:55996852	chrX:24429573~24429920:-
OV	trans	rs7395662	1	rs7479498	ENSG00000134612.10	FOLH1B	-8.34	7.17e-15	8.78e-08	-0.58	-0.48	HDL cholesterol;	chr11:48638947	chr11:89639227~89698718:+
OV	trans	rs877636	0.702	rs773110	ENSG00000227887.1	RPS26P13	8.34	7.18e-15	8.78e-08	0.5	0.48	Cognitive function;	chr12:55981353	chr1:208697369~208697698:-
OV	trans	rs2069408	1	rs2069408	ENSG00000227586.5	RP11-162A23.5	-8.34	7.18e-15	8.78e-08	-0.5	-0.48	Asthma;	chr12:55970537	chr10:123171535~123171875:-
OV	trans	rs7312770	0.612	rs773114	ENSG00000240427.1	RPS26P34	8.34	7.29e-15	8.91e-08	0.48	0.48	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr8:81627269~81627617:+
OV	trans	rs7395662	0.624	rs11040162	ENSG00000134612.10	FOLH1B	8.33	7.69e-15	9.37e-08	0.58	0.48	HDL cholesterol;	chr11:48938439	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs10839171	ENSG00000134612.10	FOLH1B	8.33	7.71e-15	9.39e-08	0.58	0.48	HDL cholesterol;	chr11:48901482	chr11:89639227~89698718:+
OV	trans	rs7395662	0.791	rs7945791	ENSG00000134612.10	FOLH1B	8.33	7.71e-15	9.39e-08	0.58	0.48	HDL cholesterol;	chr11:48914788	chr11:89639227~89698718:+
OV	trans	rs11039798	0.582	rs1483119	ENSG00000134612.10	FOLH1B	-8.32	7.99e-15	9.72e-08	-0.72	-0.48	Axial length;	chr11:48360782	chr11:89639227~89698718:+
OV	trans	rs7395662	0.929	rs11039903	ENSG00000134612.10	FOLH1B	-8.32	8.2e-15	9.96e-08	-0.58	-0.48	HDL cholesterol;	chr11:48658153	chr11:89639227~89698718:+
OV	trans	rs11039798	0.512	rs1588069	ENSG00000134612.10	FOLH1B	8.31	8.51e-15	1.03e-07	0.72	0.48	Axial length;	chr11:48673319	chr11:89639227~89698718:+
OV	trans	rs11039798	0.623	rs7294273	ENSG00000134612.10	FOLH1B	8.31	8.51e-15	1.03e-07	0.72	0.48	Axial length;	chr11:48683822	chr11:89639227~89698718:+
OV	trans	rs877636	1	rs2292239	ENSG00000212994.5	RPS26P6	8.31	8.57e-15	1.04e-07	0.52	0.48	Cognitive function;	chr12:56088396	chr8:100895771~100896118:+
OV	trans	rs7647973	1	rs62261249	ENSG00000197582.5	GPX1P1	-8.31	8.63e-15	1.04e-07	-0.67	-0.48	Menarche (age at onset);	chr3:49556627	chrX:13378735~13379340:-
OV	trans	rs11039798	0.557	rs4441015	ENSG00000134612.10	FOLH1B	8.31	8.72e-15	1.05e-07	0.75	0.48	Axial length;	chr11:49005518	chr11:89639227~89698718:+
OV	trans	rs877636	0.702	rs61937249	ENSG00000225071.1	GS1-184P14.2	8.31	8.9e-15	1.07e-07	0.54	0.48	Cognitive function;	chr12:55988132	chrX:24429573~24429920:-
OV	trans	rs877636	0.701	rs34415530	ENSG00000233278.1	RPS26P2	8.3	9.03e-15	1.09e-07	0.52	0.48	Cognitive function;	chr12:56050848	chr9:30831878~30832225:-
OV	trans	rs7395662	0.963	rs4882146	ENSG00000134612.10	FOLH1B	-8.3	9.07e-15	1.09e-07	-0.58	-0.48	HDL cholesterol;	chr11:48638617	chr11:89639227~89698718:+
OV	trans	rs877636	0.702	rs773110	ENSG00000223416.3	RPS26P15	8.3	9.09e-15	1.09e-07	0.51	0.48	Cognitive function;	chr12:55981353	chr1:58056133~58056480:-
OV	trans	rs7647973	1	rs4241407	ENSG00000197582.5	GPX1P1	8.3	9.5e-15	1.14e-07	0.65	0.48	Menarche (age at onset);	chr3:49562886	chrX:13378735~13379340:-
OV	trans	rs2069408	1	rs2069408	ENSG00000234513.1	AC073072.7	-8.3	9.5e-15	1.14e-07	-0.52	-0.48	Asthma;	chr12:55970537	chr7:22773646~22773993:-
OV	trans	rs6477998	0.58	rs10981715	ENSG00000238072.1	RP11-305M3.2	8.29	9.72e-15	1.17e-07	0.59	0.48	Hematology traits;	chr9:113287218	chr7:129410113~129410370:-
OV	trans	rs7930295	0.632	rs12287044	ENSG00000236257.1	EI24P2	8.29	9.84e-15	1.18e-07	0.7	0.48	Schizophrenia;	chr11:125772649	chr1:158454198~158455273:+
OV	trans	rs7930295	0.632	rs2081502	ENSG00000236257.1	EI24P2	8.29	9.84e-15	1.18e-07	0.7	0.48	Schizophrenia;	chr11:125773374	chr1:158454198~158455273:+
OV	trans	rs11220237	1	rs11518432	ENSG00000236257.1	EI24P2	8.29	1.02e-14	1.22e-07	0.68	0.48	Itch intensity from mosquito bite adjusted by bite size;	chr11:125814838	chr1:158454198~158455273:+
OV	trans	rs11220237	0.92	rs12272767	ENSG00000236257.1	EI24P2	8.29	1.02e-14	1.22e-07	0.68	0.48	Itch intensity from mosquito bite adjusted by bite size;	chr11:125824748	chr1:158454198~158455273:+
OV	trans	rs11220237	1	rs11220238	ENSG00000236257.1	EI24P2	8.29	1.02e-14	1.22e-07	0.68	0.48	Itch intensity from mosquito bite adjusted by bite size;	chr11:125839807	chr1:158454198~158455273:+
OV	trans	rs11220237	1	rs11220239	ENSG00000236257.1	EI24P2	8.29	1.02e-14	1.22e-07	0.68	0.48	Itch intensity from mosquito bite adjusted by bite size;	chr11:125840630	chr1:158454198~158455273:+
OV	trans	rs877636	0.74	rs772920	ENSG00000227887.1	RPS26P13	8.29	1.02e-14	1.22e-07	0.51	0.48	Cognitive function;	chr12:55996580	chr1:208697369~208697698:-
OV	trans	rs7647973	1	rs3870341	ENSG00000197582.5	GPX1P1	8.28	1.03e-14	1.23e-07	0.66	0.48	Menarche (age at onset);	chr3:49547312	chrX:13378735~13379340:-
OV	trans	rs7395662	0.895	rs2221553	ENSG00000134612.10	FOLH1B	-8.28	1.04e-14	1.24e-07	-0.58	-0.48	HDL cholesterol;	chr11:48667232	chr11:89639227~89698718:+
OV	trans	rs7395662	0.817	rs1848151	ENSG00000134612.10	FOLH1B	-8.28	1.04e-14	1.24e-07	-0.58	-0.48	HDL cholesterol;	chr11:48671106	chr11:89639227~89698718:+
OV	trans	rs7395662	0.889	rs1848158	ENSG00000134612.10	FOLH1B	-8.28	1.04e-14	1.24e-07	-0.58	-0.48	HDL cholesterol;	chr11:48675742	chr11:89639227~89698718:+
OV	trans	rs7395662	0.553	rs11040122	ENSG00000134612.10	FOLH1B	8.28	1.05e-14	1.24e-07	0.57	0.48	HDL cholesterol;	chr11:48879486	chr11:89639227~89698718:+
OV	trans	rs11039798	0.507	rs56994343	ENSG00000134612.10	FOLH1B	8.28	1.07e-14	1.27e-07	0.72	0.48	Axial length;	chr11:48875418	chr11:89639227~89698718:+
OV	trans	rs7930295	0.632	rs35245130	ENSG00000236257.1	EI24P2	8.28	1.09e-14	1.29e-07	0.68	0.48	Schizophrenia;	chr11:125771018	chr1:158454198~158455273:+
OV	trans	rs7930295	0.632	rs11220215	ENSG00000236257.1	EI24P2	8.27	1.1e-14	1.3e-07	0.68	0.48	Schizophrenia;	chr11:125771766	chr1:158454198~158455273:+
OV	trans	rs877636	1	rs4759229	ENSG00000227586.5	RP11-162A23.5	-8.27	1.1e-14	1.31e-07	-0.48	-0.48	Cognitive function;	chr12:56080696	chr10:123171535~123171875:-
OV	trans	rs11220237	1	rs12795730	ENSG00000236257.1	EI24P2	8.27	1.13e-14	1.34e-07	0.72	0.48	Itch intensity from mosquito bite adjusted by bite size;	chr11:125846182	chr1:158454198~158455273:+
OV	trans	rs877636	0.692	rs2271194	ENSG00000243538.1	CTB-55B8.1	-8.27	1.15e-14	1.36e-07	-0.51	-0.48	Cognitive function;	chr12:56083910	chr5:16902294~16902641:-
OV	trans	rs877636	0.702	rs773111	ENSG00000223416.3	RPS26P15	8.27	1.15e-14	1.36e-07	0.5	0.48	Cognitive function;	chr12:55981956	chr1:58056133~58056480:-
OV	trans	rs877636	0.702	rs773112	ENSG00000223416.3	RPS26P15	8.27	1.15e-14	1.36e-07	0.5	0.48	Cognitive function;	chr12:55982097	chr1:58056133~58056480:-
OV	trans	rs7647973	1	rs3866330	ENSG00000197582.5	GPX1P1	8.26	1.18e-14	1.39e-07	0.66	0.48	Menarche (age at onset);	chr3:49545561	chrX:13378735~13379340:-
OV	trans	rs7647973	1	rs11928090	ENSG00000197582.5	GPX1P1	8.26	1.2e-14	1.41e-07	0.66	0.48	Menarche (age at onset);	chr3:49567471	chrX:13378735~13379340:-
OV	trans	rs7647973	1	rs62259944	ENSG00000197582.5	GPX1P1	-8.26	1.23e-14	1.45e-07	-0.68	-0.48	Menarche (age at onset);	chr3:49393450	chrX:13378735~13379340:-
OV	trans	rs7312770	1	rs7312770	ENSG00000234192.1	RP11-57C13.5	-8.26	1.23e-14	1.45e-07	-0.48	-0.48	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr10:87642607~87642954:+
OV	trans	rs6477998	0.557	rs11789755	ENSG00000238072.1	RP11-305M3.2	8.26	1.24e-14	1.46e-07	0.56	0.48	Hematology traits;	chr9:113292796	chr7:129410113~129410370:-
OV	trans	rs877636	1	rs4759229	ENSG00000234513.1	AC073072.7	-8.25	1.28e-14	1.5e-07	-0.5	-0.48	Cognitive function;	chr12:56080696	chr7:22773646~22773993:-
OV	trans	rs877636	1	rs4759229	ENSG00000212829.8	RPS26P3	-8.25	1.28e-14	1.51e-07	-0.48	-0.48	Cognitive function;	chr12:56080696	chr9:9090898~9091245:+
OV	trans	rs11039798	0.588	rs11039818	ENSG00000134612.10	FOLH1B	8.25	1.29e-14	1.52e-07	0.71	0.48	Axial length;	chr11:48540568	chr11:89639227~89698718:+
OV	trans	rs877636	0.702	rs61937249	ENSG00000223416.3	RPS26P15	8.24	1.33e-14	1.56e-07	0.5	0.48	Cognitive function;	chr12:55988132	chr1:58056133~58056480:-
OV	trans	rs877636	1	rs4759229	ENSG00000212994.5	RPS26P6	-8.24	1.34e-14	1.57e-07	-0.52	-0.48	Cognitive function;	chr12:56080696	chr8:100895771~100896118:+
OV	trans	rs877636	0.692	rs10876870	ENSG00000224161.3	RPS26P54	-8.24	1.36e-14	1.59e-07	-0.52	-0.48	Cognitive function;	chr12:56084218	chr18:59761558~59761905:+
OV	trans	rs877636	0.692	rs7971751	ENSG00000224161.3	RPS26P54	-8.24	1.36e-14	1.59e-07	-0.52	-0.48	Cognitive function;	chr12:56084874	chr18:59761558~59761905:+
OV	trans	rs877636	1	rs877636	ENSG00000225071.1	GS1-184P14.2	-8.24	1.39e-14	1.62e-07	-0.53	-0.48	Cognitive function;	chr12:56086799	chrX:24429573~24429920:-
OV	trans	rs11039798	0.591	rs74992349	ENSG00000134612.10	FOLH1B	8.24	1.41e-14	1.65e-07	0.75	0.48	Axial length;	chr11:48997700	chr11:89639227~89698718:+
OV	trans	rs7395662	0.597	rs2135684	ENSG00000134612.10	FOLH1B	-8.23	1.5e-14	1.75e-07	-0.58	-0.48	HDL cholesterol;	chr11:48726917	chr11:89639227~89698718:+
OV	trans	rs11039798	0.588	rs1814768	ENSG00000134612.10	FOLH1B	8.22	1.53e-14	1.78e-07	0.73	0.48	Axial length;	chr11:48965903	chr11:89639227~89698718:+
OV	trans	rs7395662	0.895	rs1121000	ENSG00000134612.10	FOLH1B	-8.22	1.54e-14	1.79e-07	-0.57	-0.48	HDL cholesterol;	chr11:48690238	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs8189397	ENSG00000134612.10	FOLH1B	-8.22	1.54e-14	1.79e-07	-0.57	-0.48	HDL cholesterol;	chr11:48690318	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs11039937	ENSG00000134612.10	FOLH1B	-8.22	1.54e-14	1.79e-07	-0.57	-0.48	HDL cholesterol;	chr11:48691030	chr11:89639227~89698718:+
OV	trans	rs7395662	0.895	rs1827971	ENSG00000134612.10	FOLH1B	-8.22	1.54e-14	1.79e-07	-0.57	-0.48	HDL cholesterol;	chr11:48696950	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs60772766	ENSG00000134612.10	FOLH1B	-8.22	1.54e-14	1.79e-07	-0.57	-0.48	HDL cholesterol;	chr11:48699459	chr11:89639227~89698718:+
OV	trans	rs7395662	0.929	rs11493665	ENSG00000134612.10	FOLH1B	-8.22	1.54e-14	1.79e-07	-0.57	-0.48	HDL cholesterol;	chr11:48699483	chr11:89639227~89698718:+
OV	trans	rs11039798	0.512	rs11040205	ENSG00000134612.10	FOLH1B	8.22	1.55e-14	1.8e-07	0.74	0.48	Axial length;	chr11:48985808	chr11:89639227~89698718:+
OV	trans	rs11039798	0.512	rs1988465	ENSG00000134612.10	FOLH1B	8.22	1.55e-14	1.8e-07	0.74	0.48	Axial length;	chr11:48989751	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs7925955	ENSG00000134612.10	FOLH1B	-8.22	1.55e-14	1.8e-07	-0.57	-0.48	HDL cholesterol;	chr11:48625981	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs12806328	ENSG00000134612.10	FOLH1B	-8.22	1.55e-14	1.8e-07	-0.57	-0.48	HDL cholesterol;	chr11:48626419	chr11:89639227~89698718:+
OV	trans	rs7395662	0.857	rs11040074	ENSG00000134612.10	FOLH1B	-8.22	1.56e-14	1.81e-07	-0.58	-0.48	HDL cholesterol;	chr11:48835174	chr11:89639227~89698718:+
OV	trans	rs7647973	1	rs11710434	ENSG00000197582.5	GPX1P1	8.22	1.58e-14	1.83e-07	0.64	0.48	Menarche (age at onset);	chr3:49308697	chrX:13378735~13379340:-
OV	trans	rs877636	0.702	rs773109	ENSG00000244604.1	RP11-713H12.1	8.21	1.67e-14	1.93e-07	0.51	0.48	Cognitive function;	chr12:55980911	chr17:8561230~8561576:+
OV	trans	rs10242455	0.702	rs73403290	ENSG00000228834.1	RP11-249L21.4	8.21	1.7e-14	1.97e-07	1.07	0.48	Blood metabolite levels;	chr7:99560205	chr6:108907615~108907873:-
OV	trans	rs10242455	0.702	rs74416635	ENSG00000228834.1	RP11-249L21.4	8.21	1.7e-14	1.97e-07	1.07	0.48	Blood metabolite levels;	chr7:99582946	chr6:108907615~108907873:-
OV	trans	rs7312770	1	rs7312770	ENSG00000219993.1	RP11-288G3.3	-8.2	1.75e-14	2.02e-07	-0.46	-0.48	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr6:7506203~7506549:+
OV	trans	rs11039798	0.588	rs584899	ENSG00000134612.10	FOLH1B	-8.2	1.75e-14	2.02e-07	-0.69	-0.48	Axial length;	chr11:48409856	chr11:89639227~89698718:+
OV	trans	rs2069408	1	rs2069408	ENSG00000244604.1	RP11-713H12.1	-8.2	1.8e-14	2.07e-07	-0.53	-0.48	Asthma;	chr12:55970537	chr17:8561230~8561576:+
OV	trans	rs7395662	0.791	rs4347396	ENSG00000134612.10	FOLH1B	8.2	1.81e-14	2.08e-07	0.57	0.48	HDL cholesterol;	chr11:48874377	chr11:89639227~89698718:+
OV	trans	rs7395662	0.759	rs4347397	ENSG00000134612.10	FOLH1B	8.2	1.81e-14	2.08e-07	0.57	0.48	HDL cholesterol;	chr11:48874394	chr11:89639227~89698718:+
OV	trans	rs877636	1	rs2292239	ENSG00000233278.1	RPS26P2	8.19	1.86e-14	2.14e-07	0.51	0.48	Cognitive function;	chr12:56088396	chr9:30831878~30832225:-
OV	trans	rs8010715	0.785	rs2877611	ENSG00000248988.1	RP11-815N9.2	8.19	1.92e-14	2.18e-07	0.59	0.48	IgG glycosylation;	chr14:24126221	chr4:159007119~159007835:+
OV	trans	rs7395662	0.963	rs4882170	ENSG00000134612.10	FOLH1B	-8.19	1.92e-14	2.18e-07	-0.57	-0.48	HDL cholesterol;	chr11:48702662	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs2865923	ENSG00000134612.10	FOLH1B	-8.19	1.92e-14	2.18e-07	-0.57	-0.48	HDL cholesterol;	chr11:48703403	chr11:89639227~89698718:+
OV	trans	rs7395662	0.7	rs11493668	ENSG00000134612.10	FOLH1B	-8.19	1.92e-14	2.18e-07	-0.57	-0.48	HDL cholesterol;	chr11:48706030	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs2135681	ENSG00000134612.10	FOLH1B	-8.19	1.92e-14	2.18e-07	-0.57	-0.48	HDL cholesterol;	chr11:48706836	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs2135680	ENSG00000134612.10	FOLH1B	-8.19	1.92e-14	2.18e-07	-0.57	-0.48	HDL cholesterol;	chr11:48706873	chr11:89639227~89698718:+
OV	trans	rs7395662	0.895	rs8186350	ENSG00000134612.10	FOLH1B	-8.19	1.92e-14	2.18e-07	-0.57	-0.48	HDL cholesterol;	chr11:48717709	chr11:89639227~89698718:+
OV	trans	rs7395662	0.781	rs11499902	ENSG00000134612.10	FOLH1B	-8.19	1.92e-14	2.18e-07	-0.57	-0.48	HDL cholesterol;	chr11:48721179	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs10454482	ENSG00000134612.10	FOLH1B	-8.19	1.92e-14	2.18e-07	-0.57	-0.48	HDL cholesterol;	chr11:48733425	chr11:89639227~89698718:+
OV	trans	rs7395662	0.895	rs4882238	ENSG00000134612.10	FOLH1B	-8.19	1.92e-14	2.18e-07	-0.57	-0.48	HDL cholesterol;	chr11:48733988	chr11:89639227~89698718:+
OV	trans	rs7395662	0.547	rs10769442	ENSG00000134612.10	FOLH1B	-8.19	1.92e-14	2.18e-07	-0.57	-0.48	HDL cholesterol;	chr11:48743475	chr11:89639227~89698718:+
OV	trans	rs7395662	0.746	rs8186207	ENSG00000134612.10	FOLH1B	-8.19	1.92e-14	2.18e-07	-0.57	-0.48	HDL cholesterol;	chr11:48743813	chr11:89639227~89698718:+
OV	trans	rs7395662	0.622	rs2865620	ENSG00000134612.10	FOLH1B	-8.19	1.92e-14	2.18e-07	-0.57	-0.48	HDL cholesterol;	chr11:48786359	chr11:89639227~89698718:+
OV	trans	rs11039798	0.511	rs717896	ENSG00000134612.10	FOLH1B	-8.18	2.01e-14	2.27e-07	-0.71	-0.48	Axial length;	chr11:48353783	chr11:89639227~89698718:+
OV	trans	rs11039798	0.588	rs589834	ENSG00000134612.10	FOLH1B	-8.18	2.05e-14	2.31e-07	-0.69	-0.48	Axial length;	chr11:48397830	chr11:89639227~89698718:+
OV	trans	rs877636	0.74	rs772920	ENSG00000225071.1	GS1-184P14.2	8.18	2.05e-14	2.32e-07	0.54	0.48	Cognitive function;	chr12:55996580	chrX:24429573~24429920:-
OV	trans	rs2069408	1	rs2069408	ENSG00000242970.2	AC068522.4	-8.17	2.11e-14	2.38e-07	-0.51	-0.48	Asthma;	chr12:55970537	chr8:58588420~58588764:-
OV	trans	rs7395662	0.667	rs2865612	ENSG00000134612.10	FOLH1B	8.17	2.13e-14	2.4e-07	0.57	0.48	HDL cholesterol;	chr11:48758670	chr11:89639227~89698718:+
OV	trans	rs7399018	0.739	rs10747608	ENSG00000223825.5	DAZAP2P1	8.17	2.16e-14	2.43e-07	0.74	0.48	Cisplatin-induced ototoxicity;	chr12:51222798	chr2:202201384~202201886:-
OV	trans	rs8010715	0.816	rs7153156	ENSG00000248988.1	RP11-815N9.2	8.16	2.27e-14	2.55e-07	0.59	0.48	IgG glycosylation;	chr14:24129637	chr4:159007119~159007835:+
OV	trans	rs8010715	0.816	rs6573572	ENSG00000248988.1	RP11-815N9.2	8.16	2.27e-14	2.55e-07	0.59	0.48	IgG glycosylation;	chr14:24130021	chr4:159007119~159007835:+
OV	trans	rs11039798	0.588	rs59777067	ENSG00000134612.10	FOLH1B	8.16	2.29e-14	2.57e-07	0.74	0.48	Axial length;	chr11:48993798	chr11:89639227~89698718:+
OV	trans	rs7395662	0.697	rs11530291	ENSG00000134612.10	FOLH1B	8.16	2.3e-14	2.58e-07	0.57	0.48	HDL cholesterol;	chr11:48742651	chr11:89639227~89698718:+
OV	trans	rs7113874	0.659	rs7935453	ENSG00000266891.1	RP11-692N5.2	8.16	2.33e-14	2.61e-07	0.6	0.48	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8625216	chr18:9734882~9735602:-
OV	trans	rs877636	0.702	rs773110	ENSG00000244604.1	RP11-713H12.1	8.15	2.44e-14	2.73e-07	0.51	0.48	Cognitive function;	chr12:55981353	chr17:8561230~8561576:+
OV	trans	rs8010715	0.816	rs6573573	ENSG00000248988.1	RP11-815N9.2	8.15	2.47e-14	2.77e-07	0.59	0.48	IgG glycosylation;	chr14:24130048	chr4:159007119~159007835:+
OV	trans	rs877636	0.692	rs2271194	ENSG00000224161.3	RPS26P54	-8.15	2.5e-14	2.8e-07	-0.51	-0.48	Cognitive function;	chr12:56083910	chr18:59761558~59761905:+
OV	trans	rs7312770	1	rs7312770	ENSG00000234354.3	RPS26P47	-8.14	2.58e-14	2.87e-07	-0.54	-0.48	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr13:100539901~100540248:-
OV	trans	rs7647973	1	rs3905330	ENSG00000197582.5	GPX1P1	8.14	2.63e-14	2.92e-07	0.64	0.48	Menarche (age at onset);	chr3:49513341	chrX:13378735~13379340:-
OV	trans	rs877636	0.692	rs11171739	ENSG00000240427.1	RPS26P34	8.14	2.65e-14	2.95e-07	0.48	0.48	Cognitive function;	chr12:56076841	chr8:81627269~81627617:+
OV	trans	rs7647973	0.925	rs9881860	ENSG00000197582.5	GPX1P1	8.13	2.69e-14	2.99e-07	0.63	0.48	Menarche (age at onset);	chr3:49315089	chrX:13378735~13379340:-
OV	trans	rs7395662	0.929	rs8186263	ENSG00000134612.10	FOLH1B	-8.13	2.82e-14	3.13e-07	-0.56	-0.47	HDL cholesterol;	chr11:48716383	chr11:89639227~89698718:+
OV	trans	rs8010715	0.816	rs8015168	ENSG00000248988.1	RP11-815N9.2	8.12	2.94e-14	3.26e-07	0.59	0.47	IgG glycosylation;	chr14:24130663	chr4:159007119~159007835:+
OV	trans	rs7930295	0.556	rs9704355	ENSG00000236257.1	EI24P2	8.11	3.09e-14	3.42e-07	0.72	0.47	Schizophrenia;	chr11:125478435	chr1:158454198~158455273:+
OV	trans	rs7395662	1	rs4882017	ENSG00000134612.10	FOLH1B	8.11	3.1e-14	3.43e-07	0.58	0.47	HDL cholesterol;	chr11:48548630	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs1857786	ENSG00000134612.10	FOLH1B	-8.1	3.28e-14	3.62e-07	-0.57	-0.47	HDL cholesterol;	chr11:48945872	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs11040172	ENSG00000134612.10	FOLH1B	-8.1	3.28e-14	3.62e-07	-0.57	-0.47	HDL cholesterol;	chr11:48946945	chr11:89639227~89698718:+
OV	trans	rs7395662	0.824	rs12787989	ENSG00000134612.10	FOLH1B	-8.1	3.28e-14	3.62e-07	-0.57	-0.47	HDL cholesterol;	chr11:48949335	chr11:89639227~89698718:+
OV	trans	rs877636	0.692	rs11171739	ENSG00000224161.3	RPS26P54	8.1	3.33e-14	3.67e-07	0.5	0.47	Cognitive function;	chr12:56076841	chr18:59761558~59761905:+
OV	trans	rs877636	1	rs705696	ENSG00000233278.1	RPS26P2	8.1	3.46e-14	3.81e-07	0.52	0.47	Cognitive function;	chr12:56086864	chr9:30831878~30832225:-
OV	trans	rs11039798	0.588	rs643668	ENSG00000134612.10	FOLH1B	-8.09	3.58e-14	3.95e-07	-0.69	-0.47	Axial length;	chr11:48391847	chr11:89639227~89698718:+
OV	trans	rs877636	1	rs705696	ENSG00000233778.3	RP11-777J24.1	8.09	3.59e-14	3.95e-07	0.51	0.47	Cognitive function;	chr12:56086864	chr8:92144088~92144435:-
OV	trans	rs6477998	0.58	rs7027833	ENSG00000238072.1	RP11-305M3.2	8.09	3.6e-14	3.96e-07	0.55	0.47	Hematology traits;	chr9:113301377	chr7:129410113~129410370:-
OV	trans	rs7395662	0.963	rs7120743	ENSG00000134612.10	FOLH1B	-8.08	3.75e-14	4.12e-07	-0.57	-0.47	HDL cholesterol;	chr11:48901093	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs7119550	ENSG00000134612.10	FOLH1B	-8.08	3.75e-14	4.12e-07	-0.57	-0.47	HDL cholesterol;	chr11:48906102	chr11:89639227~89698718:+
OV	trans	rs7395662	0.929	rs10839173	ENSG00000134612.10	FOLH1B	-8.08	3.75e-14	4.12e-07	-0.57	-0.47	HDL cholesterol;	chr11:48909206	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs6485900	ENSG00000134612.10	FOLH1B	-8.08	3.76e-14	4.13e-07	-0.56	-0.47	HDL cholesterol;	chr11:48615863	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs6485903	ENSG00000134612.10	FOLH1B	-8.08	3.76e-14	4.13e-07	-0.56	-0.47	HDL cholesterol;	chr11:48617452	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs7938880	ENSG00000134612.10	FOLH1B	-8.08	3.76e-14	4.13e-07	-0.56	-0.47	HDL cholesterol;	chr11:48620602	chr11:89639227~89698718:+
OV	trans	rs7395662	0.593	rs8188975	ENSG00000134612.10	FOLH1B	8.08	3.79e-14	4.15e-07	0.56	0.47	HDL cholesterol;	chr11:48870325	chr11:89639227~89698718:+
OV	trans	rs11039798	0.545	rs7118670	ENSG00000134612.10	FOLH1B	8.08	3.88e-14	4.25e-07	0.71	0.47	Axial length;	chr11:48510504	chr11:89639227~89698718:+
OV	trans	rs877636	0.702	rs773111	ENSG00000244604.1	RP11-713H12.1	8.06	4.22e-14	4.59e-07	0.51	0.47	Cognitive function;	chr12:55981956	chr17:8561230~8561576:+
OV	trans	rs877636	0.702	rs773112	ENSG00000244604.1	RP11-713H12.1	8.06	4.22e-14	4.59e-07	0.51	0.47	Cognitive function;	chr12:55982097	chr17:8561230~8561576:+
OV	trans	rs7395662	1	rs11039820	ENSG00000134612.10	FOLH1B	-8.06	4.34e-14	4.72e-07	-0.57	-0.47	HDL cholesterol;	chr11:48540700	chr11:89639227~89698718:+
OV	trans	rs7395662	0.819	rs11039913	ENSG00000134612.10	FOLH1B	-8.06	4.41e-14	4.78e-07	-0.56	-0.47	HDL cholesterol;	chr11:48670529	chr11:89639227~89698718:+
OV	trans	rs7395662	0.864	rs11039917	ENSG00000134612.10	FOLH1B	-8.06	4.41e-14	4.78e-07	-0.56	-0.47	HDL cholesterol;	chr11:48673876	chr11:89639227~89698718:+
OV	trans	rs2069408	1	rs2069408	ENSG00000225071.1	GS1-184P14.2	-8.06	4.48e-14	4.85e-07	-0.54	-0.47	Asthma;	chr12:55970537	chrX:24429573~24429920:-
OV	trans	rs7930295	0.556	rs6590146	ENSG00000236257.1	EI24P2	8.05	4.55e-14	4.92e-07	0.72	0.47	Schizophrenia;	chr11:125479933	chr1:158454198~158455273:+
OV	trans	rs2069408	1	rs2069408	ENSG00000212829.8	RPS26P3	-8.04	4.82e-14	5.2e-07	-0.49	-0.47	Asthma;	chr12:55970537	chr9:9090898~9091245:+
OV	trans	rs11039571	0.588	rs61917001	ENSG00000134612.10	FOLH1B	8.04	4.9e-14	5.29e-07	0.74	0.47	D-dimer levels;	chr11:48212115	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs7482528	ENSG00000134612.10	FOLH1B	-8.04	4.96e-14	5.35e-07	-0.56	-0.47	HDL cholesterol;	chr11:48618500	chr11:89639227~89698718:+
OV	trans	rs7395662	0.791	rs12273724	ENSG00000134612.10	FOLH1B	8.04	4.97e-14	5.36e-07	0.57	0.47	HDL cholesterol;	chr11:48824158	chr11:89639227~89698718:+
OV	trans	rs877636	0.692	rs10876870	ENSG00000240427.1	RPS26P34	-8.04	5.03e-14	5.42e-07	-0.49	-0.47	Cognitive function;	chr12:56084218	chr8:81627269~81627617:+
OV	trans	rs877636	0.692	rs7971751	ENSG00000240427.1	RPS26P34	-8.04	5.03e-14	5.42e-07	-0.49	-0.47	Cognitive function;	chr12:56084874	chr8:81627269~81627617:+
OV	trans	rs7930295	0.556	rs35904963	ENSG00000236257.1	EI24P2	8.04	5.07e-14	5.46e-07	0.71	0.47	Schizophrenia;	chr11:125476956	chr1:158454198~158455273:+
OV	trans	rs7395662	0.711	rs11512405	ENSG00000134612.10	FOLH1B	-8.03	5.24e-14	5.63e-07	-0.56	-0.47	HDL cholesterol;	chr11:48914805	chr11:89639227~89698718:+
OV	trans	rs877636	0.692	rs2271194	ENSG00000240427.1	RPS26P34	-8.03	5.29e-14	5.68e-07	-0.48	-0.47	Cognitive function;	chr12:56083910	chr8:81627269~81627617:+
OV	trans	rs877636	1	rs705696	ENSG00000223416.3	RPS26P15	8.02	5.46e-14	5.85e-07	0.51	0.47	Cognitive function;	chr12:56086864	chr1:58056133~58056480:-
OV	trans	rs877636	0.701	rs34415530	ENSG00000233778.3	RP11-777J24.1	8.01	5.8e-14	6.18e-07	0.5	0.47	Cognitive function;	chr12:56050848	chr8:92144088~92144435:-
OV	trans	rs877636	0.669	rs7297175	ENSG00000224161.3	RPS26P54	-8.01	5.83e-14	6.21e-07	-0.51	-0.47	Cognitive function;	chr12:56080024	chr18:59761558~59761905:+
OV	trans	rs7395662	1	rs7395662	ENSG00000134612.10	FOLH1B	8.01	5.88e-14	6.26e-07	0.58	0.47	HDL cholesterol;	chr11:48497341	chr11:89639227~89698718:+
OV	trans	rs877636	0.701	rs34415530	ENSG00000223416.3	RPS26P15	8.01	5.93e-14	6.31e-07	0.5	0.47	Cognitive function;	chr12:56050848	chr1:58056133~58056480:-
OV	trans	rs7647973	1	rs11130189	ENSG00000197582.5	GPX1P1	8.01	5.94e-14	6.31e-07	0.62	0.47	Menarche (age at onset);	chr3:49309924	chrX:13378735~13379340:-
OV	trans	rs877636	1	rs2292239	ENSG00000233778.3	RP11-777J24.1	8.01	6.04e-14	6.42e-07	0.49	0.47	Cognitive function;	chr12:56088396	chr8:92144088~92144435:-
OV	trans	rs11039798	0.588	rs6485869	ENSG00000134612.10	FOLH1B	8	6.5e-14	6.88e-07	0.69	0.47	Axial length;	chr11:48555351	chr11:89639227~89698718:+
OV	trans	rs11039798	0.588	rs12294395	ENSG00000134612.10	FOLH1B	8	6.53e-14	6.91e-07	0.71	0.47	Axial length;	chr11:48455308	chr11:89639227~89698718:+
OV	trans	rs7395662	0.687	rs11602892	ENSG00000134612.10	FOLH1B	-7.99	6.66e-14	7.04e-07	-0.57	-0.47	HDL cholesterol;	chr11:48937600	chr11:89639227~89698718:+
OV	trans	rs7395662	0.724	rs10400308	ENSG00000134612.10	FOLH1B	-7.99	6.73e-14	7.1e-07	-0.56	-0.47	HDL cholesterol;	chr11:48869694	chr11:89639227~89698718:+
OV	trans	rs11039798	0.588	rs11039807	ENSG00000134612.10	FOLH1B	7.99	6.81e-14	7.19e-07	0.7	0.47	Axial length;	chr11:48527839	chr11:89639227~89698718:+
OV	trans	rs7395662	0.609	rs10839190	ENSG00000134612.10	FOLH1B	7.99	6.87e-14	7.24e-07	0.57	0.47	HDL cholesterol;	chr11:48935456	chr11:89639227~89698718:+
OV	trans	rs7395662	0.819	rs12269855	ENSG00000134612.10	FOLH1B	-7.99	6.88e-14	7.25e-07	-0.57	-0.47	HDL cholesterol;	chr11:48757100	chr11:89639227~89698718:+
OV	trans	rs7395662	0.889	rs11517696	ENSG00000134612.10	FOLH1B	-7.98	7.08e-14	7.44e-07	-0.56	-0.47	HDL cholesterol;	chr11:48918521	chr11:89639227~89698718:+
OV	trans	rs7786410	1	rs7786410	ENSG00000204894.4	RP11-208G20.2	7.98	7.2e-14	7.57e-07	0.89	0.47	Age-related hearing impairment;	chr7:55854630	chr7:152367171~152367260:+
OV	trans	rs7395662	0.824	rs4882180	ENSG00000134612.10	FOLH1B	-7.97	7.44e-14	7.82e-07	-0.56	-0.47	HDL cholesterol;	chr11:48727805	chr11:89639227~89698718:+
OV	trans	rs11039571	0.588	rs10734564	ENSG00000134612.10	FOLH1B	-7.97	7.47e-14	7.84e-07	-0.77	-0.47	D-dimer levels;	chr11:48138877	chr11:89639227~89698718:+
OV	trans	rs11039798	0.588	rs11039781	ENSG00000134612.10	FOLH1B	7.97	7.78e-14	8.15e-07	0.69	0.47	Axial length;	chr11:48501533	chr11:89639227~89698718:+
OV	trans	rs11039798	0.588	rs11039782	ENSG00000134612.10	FOLH1B	7.97	7.78e-14	8.15e-07	0.69	0.47	Axial length;	chr11:48503233	chr11:89639227~89698718:+
OV	trans	rs7647973	1	rs13088309	ENSG00000197582.5	GPX1P1	7.96	8.01e-14	8.39e-07	0.62	0.47	Menarche (age at onset);	chr3:49330884	chrX:13378735~13379340:-
OV	trans	rs7647973	0.961	rs4955430	ENSG00000197582.5	GPX1P1	7.96	8.01e-14	8.39e-07	0.62	0.47	Menarche (age at onset);	chr3:49340655	chrX:13378735~13379340:-
OV	trans	rs11220237	1	rs11220237	ENSG00000236257.1	EI24P2	7.96	8.12e-14	8.49e-07	0.69	0.47	Itch intensity from mosquito bite adjusted by bite size;	chr11:125838942	chr1:158454198~158455273:+
OV	trans	rs877636	1	rs877636	ENSG00000233278.1	RPS26P2	-7.96	8.26e-14	8.63e-07	-0.49	-0.47	Cognitive function;	chr12:56086799	chr9:30831878~30832225:-
OV	trans	rs7395662	1	rs4881994	ENSG00000134612.10	FOLH1B	-7.95	8.45e-14	8.81e-07	-0.57	-0.47	HDL cholesterol;	chr11:48476587	chr11:89639227~89698718:+
OV	trans	rs7395662	0.709	rs11040113	ENSG00000134612.10	FOLH1B	-7.95	8.52e-14	8.84e-07	-0.56	-0.47	HDL cholesterol;	chr11:48874101	chr11:89639227~89698718:+
OV	trans	rs11039798	0.588	rs12284168	ENSG00000134612.10	FOLH1B	7.95	8.65e-14	8.97e-07	0.71	0.47	Axial length;	chr11:48534075	chr11:89639227~89698718:+
OV	trans	rs11039798	0.588	rs666165	ENSG00000134612.10	FOLH1B	-7.95	8.66e-14	8.98e-07	-0.7	-0.47	Axial length;	chr11:48435887	chr11:89639227~89698718:+
OV	trans	rs11039798	0.557	rs683180	ENSG00000134612.10	FOLH1B	-7.95	8.66e-14	8.98e-07	-0.7	-0.47	Axial length;	chr11:48442397	chr11:89639227~89698718:+
OV	trans	rs11039798	0.511	rs7948129	ENSG00000134612.10	FOLH1B	-7.95	8.7e-14	9.03e-07	-0.72	-0.47	Axial length;	chr11:48146276	chr11:89639227~89698718:+
OV	trans	rs11039798	0.588	rs7946443	ENSG00000134612.10	FOLH1B	7.95	8.8e-14	9.12e-07	0.69	0.47	Axial length;	chr11:48523952	chr11:89639227~89698718:+
OV	trans	rs877636	1	rs2292239	ENSG00000225071.1	GS1-184P14.2	7.95	8.99e-14	9.31e-07	0.52	0.47	Cognitive function;	chr12:56088396	chrX:24429573~24429920:-
OV	trans	rs2727020	0.637	rs1164673	ENSG00000134612.10	FOLH1B	7.94	9.07e-14	9.39e-07	0.57	0.47	Coronary artery disease;	chr11:49306804	chr11:89639227~89698718:+
OV	trans	rs7121616	0.576	rs4936767	ENSG00000234176.1	HSPA8P1	7.94	9.08e-14	9.4e-07	0.56	0.47	Breast cancer;	chr11:123047451	chrX:121203182~121205014:-
OV	trans	rs7121616	0.563	rs1461494	ENSG00000234176.1	HSPA8P1	7.94	9.3e-14	9.62e-07	0.56	0.47	Breast cancer;	chr11:123055777	chrX:121203182~121205014:-
OV	trans	rs11039798	0.565	rs7118675	ENSG00000134612.10	FOLH1B	7.94	9.38e-14	9.69e-07	0.69	0.47	Axial length;	chr11:48510511	chr11:89639227~89698718:+
OV	trans	rs7554511	0.894	rs404339	ENSG00000244144.1	RP11-757F18.3	-7.94	9.57e-14	9.88e-07	-0.62	-0.47	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200917763	chr3:112185480~112185998:-
OV	trans	rs877636	0.701	rs34415530	ENSG00000227887.1	RPS26P13	7.93	9.66e-14	9.95e-07	0.5	0.47	Cognitive function;	chr12:56050848	chr1:208697369~208697698:-
OV	trans	rs7647973	1	rs6774724	ENSG00000197582.5	GPX1P1	7.93	9.69e-14	9.96e-07	0.62	0.47	Menarche (age at onset);	chr3:49344478	chrX:13378735~13379340:-
OV	trans	rs7395662	0.658	rs2865610	ENSG00000134612.10	FOLH1B	-7.93	9.69e-14	9.96e-07	-0.56	-0.47	HDL cholesterol;	chr11:48751065	chr11:89639227~89698718:+
OV	trans	rs7395662	0.818	rs34486360	ENSG00000134612.10	FOLH1B	-7.93	9.69e-14	9.96e-07	-0.56	-0.47	HDL cholesterol;	chr11:48760920	chr11:89639227~89698718:+
OV	trans	rs877636	1	rs877636	ENSG00000223416.3	RPS26P15	-7.93	9.7e-14	9.97e-07	-0.49	-0.47	Cognitive function;	chr12:56086799	chr1:58056133~58056480:-
OV	trans	rs1814175	0.654	rs1164676	ENSG00000134612.10	FOLH1B	7.93	9.79e-14	1e-06	0.58	0.47	Height;	chr11:49303316	chr11:89639227~89698718:+
OV	trans	rs10242455	0.702	rs7794068	ENSG00000228834.1	RP11-249L21.4	7.93	1.01e-13	1.03e-06	1.01	0.47	Blood metabolite levels;	chr7:99549250	chr6:108907615~108907873:-
OV	trans	rs10242455	0.571	rs56167514	ENSG00000228834.1	RP11-249L21.4	7.93	1.01e-13	1.03e-06	1.01	0.47	Blood metabolite levels;	chr7:99563724	chr6:108907615~108907873:-
OV	trans	rs10242455	0.571	rs7805661	ENSG00000228834.1	RP11-249L21.4	7.93	1.01e-13	1.03e-06	1.01	0.47	Blood metabolite levels;	chr7:99573899	chr6:108907615~108907873:-
OV	trans	rs877636	1	rs877636	ENSG00000234192.1	RP11-57C13.5	-7.92	1.04e-13	1.06e-06	-0.48	-0.47	Cognitive function;	chr12:56086799	chr10:87642607~87642954:+
OV	trans	rs11039798	0.588	rs1847640	ENSG00000134612.10	FOLH1B	7.92	1.07e-13	1.09e-06	0.67	0.47	Axial length;	chr11:48982473	chr11:89639227~89698718:+
OV	trans	rs6477998	0.58	rs2296073	ENSG00000238072.1	RP11-305M3.2	7.92	1.08e-13	1.11e-06	0.54	0.47	Hematology traits;	chr9:113299348	chr7:129410113~129410370:-
OV	trans	rs10242455	0.702	rs58348977	ENSG00000228834.1	RP11-249L21.4	7.91	1.09e-13	1.11e-06	1.1	0.47	Blood metabolite levels;	chr7:99590391	chr6:108907615~108907873:-
OV	trans	rs7647973	0.925	rs6769821	ENSG00000197582.5	GPX1P1	7.91	1.09e-13	1.11e-06	0.65	0.47	Menarche (age at onset);	chr3:49207224	chrX:13378735~13379340:-
OV	trans	rs2727020	0.558	rs1164675	ENSG00000134612.10	FOLH1B	7.91	1.1e-13	1.12e-06	0.58	0.46	Coronary artery disease;	chr11:49304420	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs10742862	ENSG00000134612.10	FOLH1B	-7.91	1.12e-13	1.14e-06	-0.56	-0.46	HDL cholesterol;	chr11:48627764	chr11:89639227~89698718:+
OV	trans	rs877636	0.74	rs705702	ENSG00000244604.1	RP11-713H12.1	-7.91	1.12e-13	1.14e-06	-0.5	-0.46	Cognitive function;	chr12:55996852	chr17:8561230~8561576:+
OV	trans	rs7395662	1	rs11039871	ENSG00000134612.10	FOLH1B	7.9	1.16e-13	1.18e-06	0.57	0.46	HDL cholesterol;	chr11:48605068	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs6485911	ENSG00000134612.10	FOLH1B	-7.9	1.17e-13	1.19e-06	-0.56	-0.46	HDL cholesterol;	chr11:48633232	chr11:89639227~89698718:+
OV	trans	rs6477998	0.58	rs10759638	ENSG00000238072.1	RP11-305M3.2	-7.9	1.2e-13	1.22e-06	-0.53	-0.46	Hematology traits;	chr9:113280212	chr7:129410113~129410370:-
OV	trans	rs941207	0.789	rs2958145	ENSG00000121089.4	NACA3P	-7.9	1.2e-13	1.22e-06	-0.49	-0.46	Platelet count;	chr12:56662290	chr4:164943290~164943937:+
OV	trans	rs11039798	0.588	rs7479642	ENSG00000134612.10	FOLH1B	7.9	1.2e-13	1.22e-06	0.7	0.46	Axial length;	chr11:48532256	chr11:89639227~89698718:+
OV	trans	rs877636	0.859	rs3741499	ENSG00000233778.3	RP11-777J24.1	-7.9	1.22e-13	1.23e-06	-0.48	-0.46	Cognitive function;	chr12:56080595	chr8:92144088~92144435:-
OV	trans	rs7395662	0.895	rs1945183	ENSG00000134612.10	FOLH1B	-7.89	1.24e-13	1.25e-06	-0.57	-0.46	HDL cholesterol;	chr11:48480875	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs10838917	ENSG00000134612.10	FOLH1B	-7.89	1.24e-13	1.25e-06	-0.57	-0.46	HDL cholesterol;	chr11:48481575	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs11039774	ENSG00000134612.10	FOLH1B	-7.89	1.24e-13	1.25e-06	-0.57	-0.46	HDL cholesterol;	chr11:48492407	chr11:89639227~89698718:+
OV	trans	rs6477998	0.535	rs10817475	ENSG00000238072.1	RP11-305M3.2	7.89	1.26e-13	1.27e-06	0.59	0.46	Hematology traits;	chr9:113296774	chr7:129410113~129410370:-
OV	trans	rs877636	1	rs877636	ENSG00000196933.5	RPS26P11	-7.89	1.27e-13	1.28e-06	-0.5	-0.46	Cognitive function;	chr12:56086799	chrX:72044545~72044892:+
OV	trans	rs11039798	0.588	rs7116858	ENSG00000134612.10	FOLH1B	7.89	1.28e-13	1.29e-06	0.69	0.46	Axial length;	chr11:48522368	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs12366208	ENSG00000134612.10	FOLH1B	-7.89	1.29e-13	1.29e-06	-0.56	-0.46	HDL cholesterol;	chr11:48541576	chr11:89639227~89698718:+
OV	trans	rs7395662	0.864	rs12366262	ENSG00000134612.10	FOLH1B	-7.89	1.29e-13	1.29e-06	-0.56	-0.46	HDL cholesterol;	chr11:48541920	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs4882117	ENSG00000134612.10	FOLH1B	-7.89	1.29e-13	1.29e-06	-0.56	-0.46	HDL cholesterol;	chr11:48543916	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs4882015	ENSG00000134612.10	FOLH1B	-7.89	1.29e-13	1.29e-06	-0.56	-0.46	HDL cholesterol;	chr11:48544021	chr11:89639227~89698718:+
OV	trans	rs11039798	0.66	rs717897	ENSG00000134612.10	FOLH1B	-7.88	1.31e-13	1.32e-06	-0.69	-0.46	Axial length;	chr11:48354052	chr11:89639227~89698718:+
OV	trans	rs7395662	0.713	rs11512404	ENSG00000134612.10	FOLH1B	-7.88	1.33e-13	1.33e-06	-0.55	-0.46	HDL cholesterol;	chr11:48914619	chr11:89639227~89698718:+
OV	trans	rs877636	0.702	rs61937249	ENSG00000244604.1	RP11-713H12.1	7.88	1.33e-13	1.33e-06	0.5	0.46	Cognitive function;	chr12:55988132	chr17:8561230~8561576:+
OV	trans	rs7121616	0.563	rs4936770	ENSG00000234176.1	HSPA8P1	7.88	1.35e-13	1.35e-06	0.56	0.46	Breast cancer;	chr11:123058167	chrX:121203182~121205014:-
OV	trans	rs11220237	0.62	rs11220184	ENSG00000236257.1	EI24P2	7.88	1.35e-13	1.35e-06	0.7	0.46	Itch intensity from mosquito bite adjusted by bite size;	chr11:125681713	chr1:158454198~158455273:+
OV	trans	rs7395662	0.824	rs12785858	ENSG00000134612.10	FOLH1B	-7.88	1.36e-13	1.36e-06	-0.55	-0.46	HDL cholesterol;	chr11:48757254	chr11:89639227~89698718:+
OV	trans	rs7395662	0.655	rs2202458	ENSG00000134612.10	FOLH1B	7.88	1.37e-13	1.37e-06	0.56	0.46	HDL cholesterol;	chr11:48834995	chr11:89639227~89698718:+
OV	trans	rs7121616	0.545	rs11600517	ENSG00000241478.1	HSPA8P9	7.88	1.39e-13	1.39e-06	0.58	0.46	Breast cancer;	chr11:123047247	chr3:137880295~137882237:+
OV	trans	rs7121616	0.576	rs7111590	ENSG00000241478.1	HSPA8P9	7.87	1.42e-13	1.41e-06	0.58	0.46	Breast cancer;	chr11:123055419	chr3:137880295~137882237:+
OV	trans	rs7121616	0.576	rs7123232	ENSG00000241478.1	HSPA8P9	7.87	1.42e-13	1.41e-06	0.58	0.46	Breast cancer;	chr11:123056237	chr3:137880295~137882237:+
OV	trans	rs877636	1	rs2292239	ENSG00000223416.3	RPS26P15	7.87	1.46e-13	1.45e-06	0.49	0.46	Cognitive function;	chr12:56088396	chr1:58056133~58056480:-
OV	trans	rs7312770	0.612	rs773114	ENSG00000224161.3	RPS26P54	7.87	1.46e-13	1.45e-06	0.48	0.46	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr18:59761558~59761905:+
OV	trans	rs2069408	1	rs2069408	ENSG00000196933.5	RPS26P11	-7.86	1.49e-13	1.48e-06	-0.51	-0.46	Asthma;	chr12:55970537	chrX:72044545~72044892:+
OV	trans	rs7395662	0.963	rs11039826	ENSG00000134612.10	FOLH1B	-7.86	1.58e-13	1.56e-06	-0.56	-0.46	HDL cholesterol;	chr11:48550846	chr11:89639227~89698718:+
OV	trans	rs2069408	1	rs2069408	ENSG00000223416.3	RPS26P15	-7.85	1.59e-13	1.58e-06	-0.5	-0.46	Asthma;	chr12:55970537	chr1:58056133~58056480:-
OV	trans	rs7554511	0.894	rs296543	ENSG00000244144.1	RP11-757F18.3	7.85	1.6e-13	1.59e-06	0.62	0.46	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200920705	chr3:112185480~112185998:-
OV	trans	rs7554511	0.894	rs296545	ENSG00000244144.1	RP11-757F18.3	7.85	1.6e-13	1.59e-06	0.62	0.46	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200921564	chr3:112185480~112185998:-
OV	trans	rs7554511	0.894	rs296546	ENSG00000244144.1	RP11-757F18.3	7.85	1.6e-13	1.59e-06	0.62	0.46	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200921963	chr3:112185480~112185998:-
OV	trans	rs7395662	0.963	rs4882072	ENSG00000134612.10	FOLH1B	-7.85	1.61e-13	1.6e-06	-0.57	-0.46	HDL cholesterol;	chr11:48458339	chr11:89639227~89698718:+
OV	trans	rs7395662	0.816	rs11039764	ENSG00000134612.10	FOLH1B	-7.85	1.61e-13	1.6e-06	-0.57	-0.46	HDL cholesterol;	chr11:48463064	chr11:89639227~89698718:+
OV	trans	rs7395662	0.927	rs12793888	ENSG00000134612.10	FOLH1B	-7.85	1.61e-13	1.6e-06	-0.57	-0.46	HDL cholesterol;	chr11:48466504	chr11:89639227~89698718:+
OV	trans	rs7647973	1	rs11720542	ENSG00000197582.5	GPX1P1	7.85	1.63e-13	1.62e-06	0.62	0.46	Menarche (age at onset);	chr3:49319994	chrX:13378735~13379340:-
OV	trans	rs7121616	0.576	rs7111598	ENSG00000241478.1	HSPA8P9	7.85	1.65e-13	1.64e-06	0.57	0.46	Breast cancer;	chr11:123055438	chr3:137880295~137882237:+
OV	trans	rs877636	1	rs4759229	ENSG00000233278.1	RPS26P2	-7.84	1.71e-13	1.7e-06	-0.49	-0.46	Cognitive function;	chr12:56080696	chr9:30831878~30832225:-
OV	trans	rs7395662	0.963	rs6485865	ENSG00000134612.10	FOLH1B	-7.84	1.72e-13	1.7e-06	-0.56	-0.46	HDL cholesterol;	chr11:48554437	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs7107184	ENSG00000134612.10	FOLH1B	-7.84	1.72e-13	1.7e-06	-0.56	-0.46	HDL cholesterol;	chr11:48555517	chr11:89639227~89698718:+
OV	trans	rs11039798	0.511	rs2047812	ENSG00000134612.10	FOLH1B	-7.84	1.74e-13	1.72e-06	-0.71	-0.46	Axial length;	chr11:48140490	chr11:89639227~89698718:+
OV	trans	rs7121616	0.576	rs73610510	ENSG00000241478.1	HSPA8P9	7.84	1.79e-13	1.76e-06	0.58	0.46	Breast cancer;	chr11:123049365	chr3:137880295~137882237:+
OV	trans	rs7647973	0.925	rs4955439	ENSG00000197582.5	GPX1P1	-7.83	1.83e-13	1.8e-06	-0.6	-0.46	Menarche (age at onset);	chr3:49208212	chrX:13378735~13379340:-
OV	trans	rs11039571	0.544	rs7947811	ENSG00000134612.10	FOLH1B	-7.83	1.84e-13	1.81e-06	-0.7	-0.46	D-dimer levels;	chr11:48146186	chr11:89639227~89698718:+
OV	trans	rs2727020	0.553	rs11040400	ENSG00000134612.10	FOLH1B	-7.83	1.86e-13	1.83e-06	-0.58	-0.46	Coronary artery disease;	chr11:49496744	chr11:89639227~89698718:+
OV	trans	rs7395662	0.927	rs2135690	ENSG00000134612.10	FOLH1B	7.83	1.86e-13	1.83e-06	0.55	0.46	HDL cholesterol;	chr11:48712049	chr11:89639227~89698718:+
OV	trans	rs7395662	0.658	rs8189235	ENSG00000134612.10	FOLH1B	7.83	1.86e-13	1.83e-06	0.55	0.46	HDL cholesterol;	chr11:48718512	chr11:89639227~89698718:+
OV	trans	rs7395662	0.581	rs10769445	ENSG00000134612.10	FOLH1B	7.83	1.86e-13	1.83e-06	0.55	0.46	HDL cholesterol;	chr11:48744042	chr11:89639227~89698718:+
OV	trans	rs877636	0.859	rs3741499	ENSG00000233278.1	RPS26P2	-7.83	1.88e-13	1.85e-06	-0.49	-0.46	Cognitive function;	chr12:56080595	chr9:30831878~30832225:-
OV	trans	rs7395662	1	rs7949348	ENSG00000134612.10	FOLH1B	-7.82	1.92e-13	1.89e-06	-0.57	-0.46	HDL cholesterol;	chr11:48472249	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs10838912	ENSG00000134612.10	FOLH1B	-7.82	1.92e-13	1.89e-06	-0.57	-0.46	HDL cholesterol;	chr11:48474925	chr11:89639227~89698718:+
OV	trans	rs941207	0.756	rs2958153	ENSG00000121089.4	NACA3P	7.82	1.93e-13	1.89e-06	0.5	0.46	Platelet count;	chr12:56687733	chr4:164943290~164943937:+
OV	trans	rs11039798	0.588	rs6485857	ENSG00000134612.10	FOLH1B	7.82	1.97e-13	1.93e-06	0.68	0.46	Axial length;	chr11:48534959	chr11:89639227~89698718:+
OV	trans	rs11039798	0.544	rs114343057	ENSG00000134612.10	FOLH1B	7.82	1.97e-13	1.93e-06	0.68	0.46	Axial length;	chr11:48536620	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs11039819	ENSG00000134612.10	FOLH1B	-7.82	1.98e-13	1.93e-06	-0.56	-0.46	HDL cholesterol;	chr11:48540629	chr11:89639227~89698718:+
OV	trans	rs7930295	1	rs34238592	ENSG00000236257.1	EI24P2	7.82	2.02e-13	1.97e-06	0.71	0.46	Schizophrenia;	chr11:125445059	chr1:158454198~158455273:+
OV	trans	rs7930295	1	rs34504992	ENSG00000236257.1	EI24P2	7.82	2.02e-13	1.97e-06	0.71	0.46	Schizophrenia;	chr11:125446177	chr1:158454198~158455273:+
OV	trans	rs7930295	1	rs28593289	ENSG00000236257.1	EI24P2	7.82	2.02e-13	1.97e-06	0.71	0.46	Schizophrenia;	chr11:125446628	chr1:158454198~158455273:+
OV	trans	rs7930295	1	rs6590145	ENSG00000236257.1	EI24P2	7.82	2.02e-13	1.97e-06	0.71	0.46	Schizophrenia;	chr11:125448020	chr1:158454198~158455273:+
OV	trans	rs7312770	1	rs7312770	ENSG00000242206.2	RPS26P35	-7.81	2.15e-13	2.09e-06	-0.46	-0.46	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr8:118761856~118762201:-
OV	trans	rs7121616	0.576	rs73610509	ENSG00000241478.1	HSPA8P9	7.81	2.17e-13	2.1e-06	0.57	0.46	Breast cancer;	chr11:123048564	chr3:137880295~137882237:+
OV	trans	rs7121616	0.576	rs7942164	ENSG00000241478.1	HSPA8P9	7.81	2.17e-13	2.1e-06	0.57	0.46	Breast cancer;	chr11:123050459	chr3:137880295~137882237:+
OV	trans	rs7121616	0.576	rs56131320	ENSG00000241478.1	HSPA8P9	7.81	2.17e-13	2.1e-06	0.57	0.46	Breast cancer;	chr11:123053058	chr3:137880295~137882237:+
OV	trans	rs7647973	0.922	rs6809851	ENSG00000197582.5	GPX1P1	7.8	2.18e-13	2.12e-06	0.61	0.46	Menarche (age at onset);	chr3:49272354	chrX:13378735~13379340:-
OV	trans	rs2069408	1	rs2069408	ENSG00000227887.1	RPS26P13	-7.8	2.23e-13	2.16e-06	-0.49	-0.46	Asthma;	chr12:55970537	chr1:208697369~208697698:-
OV	trans	rs877636	0.74	rs772920	ENSG00000244604.1	RP11-713H12.1	7.8	2.27e-13	2.2e-06	0.5	0.46	Cognitive function;	chr12:55996580	chr17:8561230~8561576:+
OV	trans	rs941207	0.724	rs4788	ENSG00000121089.4	NACA3P	7.79	2.37e-13	2.29e-06	0.48	0.46	Platelet count;	chr12:56712876	chr4:164943290~164943937:+
OV	trans	rs877636	0.702	rs773109	ENSG00000196933.5	RPS26P11	7.78	2.49e-13	2.4e-06	0.49	0.46	Cognitive function;	chr12:55980911	chrX:72044545~72044892:+
OV	trans	rs6477998	0.557	rs3750534	ENSG00000238072.1	RP11-305M3.2	7.78	2.51e-13	2.41e-06	0.54	0.46	Hematology traits;	chr9:113297844	chr7:129410113~129410370:-
OV	trans	rs7395662	0.816	rs12420341	ENSG00000134612.10	FOLH1B	-7.78	2.55e-13	2.45e-06	-0.54	-0.46	HDL cholesterol;	chr11:48871832	chr11:89639227~89698718:+
OV	trans	rs8010715	0.816	rs2332224	ENSG00000248988.1	RP11-815N9.2	7.77	2.67e-13	2.56e-06	0.57	0.46	IgG glycosylation;	chr14:24129335	chr4:159007119~159007835:+
OV	trans	rs877636	1	rs4759229	ENSG00000233778.3	RP11-777J24.1	-7.77	2.7e-13	2.59e-06	-0.48	-0.46	Cognitive function;	chr12:56080696	chr8:92144088~92144435:-
OV	trans	rs7395662	0.794	rs11511967	ENSG00000134612.10	FOLH1B	-7.77	2.77e-13	2.65e-06	-0.56	-0.46	HDL cholesterol;	chr11:48798901	chr11:89639227~89698718:+
OV	trans	rs7395662	0.927	rs8188938	ENSG00000134612.10	FOLH1B	7.77	2.77e-13	2.65e-06	0.55	0.46	HDL cholesterol;	chr11:48669314	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs7952491	ENSG00000134612.10	FOLH1B	-7.77	2.77e-13	2.65e-06	-0.55	-0.46	HDL cholesterol;	chr11:48641743	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs1588068	ENSG00000134612.10	FOLH1B	-7.77	2.77e-13	2.65e-06	-0.55	-0.46	HDL cholesterol;	chr11:48650193	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs1605364	ENSG00000134612.10	FOLH1B	-7.77	2.77e-13	2.65e-06	-0.55	-0.46	HDL cholesterol;	chr11:48663291	chr11:89639227~89698718:+
OV	trans	rs7395662	0.926	rs12288788	ENSG00000134612.10	FOLH1B	-7.77	2.77e-13	2.65e-06	-0.55	-0.46	HDL cholesterol;	chr11:48665311	chr11:89639227~89698718:+
OV	trans	rs6477998	0.58	rs3750532	ENSG00000238072.1	RP11-305M3.2	7.76	2.83e-13	2.7e-06	0.54	0.46	Hematology traits;	chr9:113298207	chr7:129410113~129410370:-
OV	trans	rs11039798	0.588	rs3924476	ENSG00000134612.10	FOLH1B	7.76	2.93e-13	2.8e-06	0.68	0.46	Axial length;	chr11:48560181	chr11:89639227~89698718:+
OV	trans	rs7647973	0.826	rs9834535	ENSG00000197582.5	GPX1P1	7.75	2.97e-13	2.83e-06	0.62	0.46	Menarche (age at onset);	chr3:49341364	chrX:13378735~13379340:-
OV	trans	rs7647973	0.961	rs6778080	ENSG00000197582.5	GPX1P1	-7.75	2.98e-13	2.84e-06	-0.61	-0.46	Menarche (age at onset);	chr3:49279905	chrX:13378735~13379340:-
OV	trans	rs6477998	0.58	rs4979233	ENSG00000238072.1	RP11-305M3.2	7.75	2.99e-13	2.85e-06	0.55	0.46	Hematology traits;	chr9:113295501	chr7:129410113~129410370:-
OV	trans	rs7395662	0.658	rs11493304	ENSG00000134612.10	FOLH1B	-7.75	3.03e-13	2.89e-06	-0.54	-0.46	HDL cholesterol;	chr11:48874039	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs7121460	ENSG00000134612.10	FOLH1B	-7.75	3.04e-13	2.89e-06	-0.56	-0.46	HDL cholesterol;	chr11:48523680	chr11:89639227~89698718:+
OV	trans	rs7395662	0.929	rs10838934	ENSG00000134612.10	FOLH1B	-7.75	3.04e-13	2.89e-06	-0.56	-0.46	HDL cholesterol;	chr11:48525520	chr11:89639227~89698718:+
OV	trans	rs877636	1	rs2292239	ENSG00000227887.1	RPS26P13	7.75	3.11e-13	2.95e-06	0.48	0.46	Cognitive function;	chr12:56088396	chr1:208697369~208697698:-
OV	trans	rs7395662	1	rs11039777	ENSG00000134612.10	FOLH1B	-7.74	3.18e-13	3.02e-06	-0.56	-0.46	HDL cholesterol;	chr11:48495497	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs11039779	ENSG00000134612.10	FOLH1B	-7.74	3.18e-13	3.02e-06	-0.56	-0.46	HDL cholesterol;	chr11:48496343	chr11:89639227~89698718:+
OV	trans	rs7121616	0.576	rs7929869	ENSG00000241478.1	HSPA8P9	7.74	3.18e-13	3.02e-06	0.57	0.46	Breast cancer;	chr11:123054435	chr3:137880295~137882237:+
OV	trans	rs7121616	0.576	rs1841580	ENSG00000241478.1	HSPA8P9	7.74	3.18e-13	3.02e-06	0.57	0.46	Breast cancer;	chr11:123055956	chr3:137880295~137882237:+
OV	trans	rs7395662	0.864	rs11039872	ENSG00000134612.10	FOLH1B	-7.74	3.22e-13	3.05e-06	-0.55	-0.46	HDL cholesterol;	chr11:48607981	chr11:89639227~89698718:+
OV	trans	rs7554511	0.861	rs11583546	ENSG00000244144.1	RP11-757F18.3	-7.74	3.24e-13	3.06e-06	-0.65	-0.46	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200933479	chr3:112185480~112185998:-
OV	trans	rs7395662	0.926	rs10742848	ENSG00000134612.10	FOLH1B	-7.74	3.26e-13	3.09e-06	-0.57	-0.46	HDL cholesterol;	chr11:48447236	chr11:89639227~89698718:+
OV	trans	rs7395662	0.889	rs11039754	ENSG00000134612.10	FOLH1B	-7.74	3.26e-13	3.09e-06	-0.57	-0.46	HDL cholesterol;	chr11:48453661	chr11:89639227~89698718:+
OV	trans	rs941207	0.756	rs2926743	ENSG00000121089.4	NACA3P	7.74	3.26e-13	3.09e-06	0.49	0.46	Platelet count;	chr12:56720316	chr4:164943290~164943937:+
OV	trans	rs7121616	0.595	rs7949414	ENSG00000234176.1	HSPA8P1	7.74	3.32e-13	3.14e-06	0.54	0.46	Breast cancer;	chr11:123072787	chrX:121203182~121205014:-
OV	trans	rs11039798	0.588	rs7483361	ENSG00000134612.10	FOLH1B	7.73	3.41e-13	3.22e-06	0.68	0.46	Axial length;	chr11:48572234	chr11:89639227~89698718:+
OV	trans	rs11039798	0.588	rs10160381	ENSG00000134612.10	FOLH1B	7.73	3.41e-13	3.22e-06	0.68	0.46	Axial length;	chr11:48577939	chr11:89639227~89698718:+
OV	trans	rs877636	0.859	rs3741499	ENSG00000223416.3	RPS26P15	-7.73	3.46e-13	3.26e-06	-0.48	-0.46	Cognitive function;	chr12:56080595	chr1:58056133~58056480:-
OV	trans	rs7395662	0.963	rs11039772	ENSG00000134612.10	FOLH1B	-7.73	3.54e-13	3.32e-06	-0.56	-0.46	HDL cholesterol;	chr11:48492340	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs11039773	ENSG00000134612.10	FOLH1B	-7.73	3.54e-13	3.32e-06	-0.56	-0.46	HDL cholesterol;	chr11:48492379	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs10838954	ENSG00000134612.10	FOLH1B	-7.72	3.64e-13	3.41e-06	-0.55	-0.46	HDL cholesterol;	chr11:48557771	chr11:89639227~89698718:+
OV	trans	rs7395662	0.5	rs7947055	ENSG00000134612.10	FOLH1B	7.72	3.66e-13	3.42e-06	0.55	0.46	HDL cholesterol;	chr11:48955534	chr11:89639227~89698718:+
OV	trans	rs10242455	0.702	rs73711293	ENSG00000228834.1	RP11-249L21.4	7.72	3.79e-13	3.54e-06	1.04	0.46	Blood metabolite levels;	chr7:99483972	chr6:108907615~108907873:-
OV	trans	rs11039798	0.623	rs6485879	ENSG00000134612.10	FOLH1B	7.71	3.83e-13	3.57e-06	0.68	0.46	Axial length;	chr11:48566432	chr11:89639227~89698718:+
OV	trans	rs7312770	1	rs7312770	ENSG00000243538.1	CTB-55B8.1	-7.71	3.84e-13	3.58e-06	-0.47	-0.46	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr5:16902294~16902641:-
OV	trans	rs7395662	1	rs11039745	ENSG00000134612.10	FOLH1B	-7.71	3.96e-13	3.68e-06	-0.57	-0.46	HDL cholesterol;	chr11:48442259	chr11:89639227~89698718:+
OV	trans	rs7647973	0.961	rs7626076	ENSG00000197582.5	GPX1P1	7.71	3.97e-13	3.69e-06	0.6	0.46	Menarche (age at onset);	chr3:49260706	chrX:13378735~13379340:-
OV	trans	rs7395662	1	rs4882016	ENSG00000134612.10	FOLH1B	-7.71	4.02e-13	3.73e-06	-0.55	-0.46	HDL cholesterol;	chr11:48548573	chr11:89639227~89698718:+
OV	trans	rs7395662	0.611	rs11040073	ENSG00000134612.10	FOLH1B	7.7	4.08e-13	3.79e-06	0.55	0.46	HDL cholesterol;	chr11:48834072	chr11:89639227~89698718:+
OV	trans	rs877636	0.702	rs773110	ENSG00000196933.5	RPS26P11	7.7	4.14e-13	3.84e-06	0.49	0.46	Cognitive function;	chr12:55981353	chrX:72044545~72044892:+
OV	trans	rs941207	0.756	rs7978685	ENSG00000121089.4	NACA3P	7.7	4.27e-13	3.96e-06	0.48	0.45	Platelet count;	chr12:56709370	chr4:164943290~164943937:+
OV	trans	rs7395662	1	rs6485872	ENSG00000134612.10	FOLH1B	-7.69	4.42e-13	4.09e-06	-0.55	-0.45	HDL cholesterol;	chr11:48558158	chr11:89639227~89698718:+
OV	trans	rs11039798	0.588	rs10437592	ENSG00000134612.10	FOLH1B	7.69	4.46e-13	4.13e-06	0.67	0.45	Axial length;	chr11:48577307	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs12365014	ENSG00000134612.10	FOLH1B	-7.69	4.47e-13	4.13e-06	-0.54	-0.45	HDL cholesterol;	chr11:48607882	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs55834832	ENSG00000134612.10	FOLH1B	-7.68	4.59e-13	4.23e-06	-0.55	-0.45	HDL cholesterol;	chr11:48541031	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs11039821	ENSG00000134612.10	FOLH1B	-7.68	4.59e-13	4.23e-06	-0.55	-0.45	HDL cholesterol;	chr11:48541323	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs12361812	ENSG00000134612.10	FOLH1B	-7.68	4.59e-13	4.23e-06	-0.55	-0.45	HDL cholesterol;	chr11:48541552	chr11:89639227~89698718:+
OV	trans	rs7395662	0.864	rs10838951	ENSG00000134612.10	FOLH1B	-7.68	4.64e-13	4.28e-06	-0.55	-0.45	HDL cholesterol;	chr11:48549536	chr11:89639227~89698718:+
OV	trans	rs7395662	0.864	rs7483617	ENSG00000134612.10	FOLH1B	-7.68	4.76e-13	4.38e-06	-0.55	-0.45	HDL cholesterol;	chr11:48530107	chr11:89639227~89698718:+
OV	trans	rs941207	0.756	rs2950394	ENSG00000121089.4	NACA3P	-7.68	4.81e-13	4.43e-06	-0.49	-0.45	Platelet count;	chr12:56644548	chr4:164943290~164943937:+
OV	trans	rs877636	0.74	rs705702	ENSG00000196933.5	RPS26P11	-7.68	4.81e-13	4.43e-06	-0.49	-0.45	Cognitive function;	chr12:55996852	chrX:72044545~72044892:+
OV	trans	rs7113874	0.659	rs1867810	ENSG00000266891.1	RP11-692N5.2	7.68	4.81e-13	4.43e-06	0.61	0.45	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8483981	chr18:9734882~9735602:-
OV	trans	rs11039798	0.588	rs10838970	ENSG00000134612.10	FOLH1B	7.67	5.01e-13	4.6e-06	0.66	0.45	Axial length;	chr11:48584715	chr11:89639227~89698718:+
OV	trans	rs11039798	0.588	rs11039855	ENSG00000134612.10	FOLH1B	7.67	5.01e-13	4.6e-06	0.66	0.45	Axial length;	chr11:48588539	chr11:89639227~89698718:+
OV	trans	rs11039798	0.588	rs7108164	ENSG00000134612.10	FOLH1B	7.67	5.01e-13	4.6e-06	0.66	0.45	Axial length;	chr11:48604811	chr11:89639227~89698718:+
OV	trans	rs11039798	0.588	rs10838979	ENSG00000134612.10	FOLH1B	7.67	5.01e-13	4.6e-06	0.66	0.45	Axial length;	chr11:48605258	chr11:89639227~89698718:+
OV	trans	rs941207	0.756	rs1465081	ENSG00000121089.4	NACA3P	-7.67	5.14e-13	4.71e-06	-0.49	-0.45	Platelet count;	chr12:56656390	chr4:164943290~164943937:+
OV	trans	rs877636	0.859	rs3741499	ENSG00000225071.1	GS1-184P14.2	-7.66	5.19e-13	4.76e-06	-0.51	-0.45	Cognitive function;	chr12:56080595	chrX:24429573~24429920:-
OV	trans	rs877636	0.702	rs773111	ENSG00000196933.5	RPS26P11	7.66	5.32e-13	4.87e-06	0.49	0.45	Cognitive function;	chr12:55981956	chrX:72044545~72044892:+
OV	trans	rs877636	0.702	rs773112	ENSG00000196933.5	RPS26P11	7.66	5.32e-13	4.87e-06	0.49	0.45	Cognitive function;	chr12:55982097	chrX:72044545~72044892:+
OV	trans	rs6477998	0.58	rs12343629	ENSG00000238072.1	RP11-305M3.2	7.65	5.81e-13	5.29e-06	0.52	0.45	Hematology traits;	chr9:113279301	chr7:129410113~129410370:-
OV	trans	rs877636	1	rs4759229	ENSG00000223416.3	RPS26P15	-7.64	6.1e-13	5.54e-06	-0.47	-0.45	Cognitive function;	chr12:56080696	chr1:58056133~58056480:-
OV	trans	rs941207	0.756	rs2958149	ENSG00000121089.4	NACA3P	7.64	6.1e-13	5.54e-06	0.48	0.45	Platelet count;	chr12:56716008	chr4:164943290~164943937:+
OV	trans	rs941207	0.724	rs1979325	ENSG00000121089.4	NACA3P	7.64	6.1e-13	5.54e-06	0.48	0.45	Platelet count;	chr12:56728152	chr4:164943290~164943937:+
OV	trans	rs941207	0.756	rs7315472	ENSG00000121089.4	NACA3P	-7.64	6.17e-13	5.59e-06	-0.48	-0.45	Platelet count;	chr12:56648276	chr4:164943290~164943937:+
OV	trans	rs941207	0.756	rs67046307	ENSG00000121089.4	NACA3P	-7.64	6.17e-13	5.59e-06	-0.48	-0.45	Platelet count;	chr12:56651152	chr4:164943290~164943937:+
OV	trans	rs941207	0.756	rs10876915	ENSG00000121089.4	NACA3P	-7.64	6.17e-13	5.59e-06	-0.48	-0.45	Platelet count;	chr12:56655280	chr4:164943290~164943937:+
OV	trans	rs877636	1	rs877636	ENSG00000227887.1	RPS26P13	-7.64	6.23e-13	5.64e-06	-0.47	-0.45	Cognitive function;	chr12:56086799	chr1:208697369~208697698:-
OV	trans	rs877636	0.702	rs61937249	ENSG00000196933.5	RPS26P11	7.63	6.25e-13	5.66e-06	0.49	0.45	Cognitive function;	chr12:55988132	chrX:72044545~72044892:+
OV	trans	rs7395662	1	rs4882120	ENSG00000134612.10	FOLH1B	-7.63	6.3e-13	5.69e-06	-0.55	-0.45	HDL cholesterol;	chr11:48551977	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs4882123	ENSG00000134612.10	FOLH1B	-7.63	6.3e-13	5.69e-06	-0.55	-0.45	HDL cholesterol;	chr11:48554187	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs12420372	ENSG00000134612.10	FOLH1B	7.63	6.35e-13	5.74e-06	0.55	0.45	HDL cholesterol;	chr11:48476051	chr11:89639227~89698718:+
OV	trans	rs7647973	1	rs9862534	ENSG00000197582.5	GPX1P1	7.63	6.4e-13	5.77e-06	0.6	0.45	Menarche (age at onset);	chr3:49560631	chrX:13378735~13379340:-
OV	trans	rs11039798	0.66	rs28435129	ENSG00000134612.10	FOLH1B	7.63	6.44e-13	5.8e-06	0.66	0.45	Axial length;	chr11:48608243	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs10838931	ENSG00000134612.10	FOLH1B	-7.63	6.46e-13	5.81e-06	-0.55	-0.45	HDL cholesterol;	chr11:48519421	chr11:89639227~89698718:+
OV	trans	rs7395662	0.929	rs12366252	ENSG00000134612.10	FOLH1B	-7.63	6.46e-13	5.81e-06	-0.55	-0.45	HDL cholesterol;	chr11:48520766	chr11:89639227~89698718:+
OV	trans	rs7395662	0.853	rs10838885	ENSG00000134612.10	FOLH1B	-7.62	6.66e-13	5.98e-06	-0.56	-0.45	HDL cholesterol;	chr11:48377254	chr11:89639227~89698718:+
OV	trans	rs7121616	0.576	rs7111590	ENSG00000234176.1	HSPA8P1	7.62	6.92e-13	6.2e-06	0.58	0.45	Breast cancer;	chr11:123055419	chrX:121203182~121205014:-
OV	trans	rs7121616	0.576	rs7123232	ENSG00000234176.1	HSPA8P1	7.62	6.92e-13	6.2e-06	0.58	0.45	Breast cancer;	chr11:123056237	chrX:121203182~121205014:-
OV	trans	rs941207	0.756	rs9634246	ENSG00000121089.4	NACA3P	-7.62	6.92e-13	6.2e-06	-0.49	-0.45	Platelet count;	chr12:56640604	chr4:164943290~164943937:+
OV	trans	rs7395662	0.654	rs12289625	ENSG00000134612.10	FOLH1B	7.62	7e-13	6.28e-06	0.54	0.45	HDL cholesterol;	chr11:48795690	chr11:89639227~89698718:+
OV	trans	rs10242455	0.702	rs73401510	ENSG00000228834.1	RP11-249L21.4	7.61	7.06e-13	6.32e-06	1.03	0.45	Blood metabolite levels;	chr7:99468189	chr6:108907615~108907873:-
OV	trans	rs7647973	0.848	rs4955426	ENSG00000197582.5	GPX1P1	7.61	7.08e-13	6.34e-06	0.69	0.45	Menarche (age at onset);	chr3:49106005	chrX:13378735~13379340:-
OV	trans	rs7121616	0.545	rs11600517	ENSG00000234176.1	HSPA8P1	7.61	7.24e-13	6.48e-06	0.58	0.45	Breast cancer;	chr11:123047247	chrX:121203182~121205014:-
OV	trans	rs7395662	0.759	rs11529442	ENSG00000134612.10	FOLH1B	7.61	7.43e-13	6.64e-06	0.54	0.45	HDL cholesterol;	chr11:48798434	chr11:89639227~89698718:+
OV	trans	rs7647973	0.771	rs9865051	ENSG00000197582.5	GPX1P1	7.61	7.47e-13	6.68e-06	0.64	0.45	Menarche (age at onset);	chr3:49128636	chrX:13378735~13379340:-
OV	trans	rs7395662	1	rs7948486	ENSG00000134612.10	FOLH1B	7.61	7.5e-13	6.69e-06	0.54	0.45	HDL cholesterol;	chr11:48890588	chr11:89639227~89698718:+
OV	trans	rs7395662	0.625	rs11040006	ENSG00000134612.10	FOLH1B	7.6	7.86e-13	7e-06	0.54	0.45	HDL cholesterol;	chr11:48752750	chr11:89639227~89698718:+
OV	trans	rs7395662	0.892	rs11040014	ENSG00000134612.10	FOLH1B	7.6	7.86e-13	7e-06	0.54	0.45	HDL cholesterol;	chr11:48761505	chr11:89639227~89698718:+
OV	trans	rs7113874	0.625	rs10743073	ENSG00000266891.1	RP11-692N5.2	-7.6	7.88e-13	7.02e-06	-0.59	-0.45	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8483072	chr18:9734882~9735602:-
OV	trans	rs7395662	0.818	rs2200181	ENSG00000134612.10	FOLH1B	-7.6	7.95e-13	7.08e-06	-0.56	-0.45	HDL cholesterol;	chr11:48391623	chr11:89639227~89698718:+
OV	trans	rs2727020	0.553	rs3907576	ENSG00000134612.10	FOLH1B	-7.6	7.96e-13	7.09e-06	-0.56	-0.45	Coronary artery disease;	chr11:49515087	chr11:89639227~89698718:+
OV	trans	rs2727020	0.553	rs10839295	ENSG00000134612.10	FOLH1B	-7.59	8.08e-13	7.19e-06	-0.56	-0.45	Coronary artery disease;	chr11:49505793	chr11:89639227~89698718:+
OV	trans	rs877636	0.701	rs34415530	ENSG00000225071.1	GS1-184P14.2	7.59	8.33e-13	7.39e-06	0.51	0.45	Cognitive function;	chr12:56050848	chrX:24429573~24429920:-
OV	trans	rs10242455	0.702	rs6974831	ENSG00000228834.1	RP11-249L21.4	7.59	8.39e-13	7.43e-06	1	0.45	Blood metabolite levels;	chr7:99533982	chr6:108907615~108907873:-
OV	trans	rs877636	1	rs705696	ENSG00000225071.1	GS1-184P14.2	7.59	8.4e-13	7.44e-06	0.52	0.45	Cognitive function;	chr12:56086864	chrX:24429573~24429920:-
OV	trans	rs7121616	0.576	rs73610509	ENSG00000234176.1	HSPA8P1	7.58	8.5e-13	7.52e-06	0.58	0.45	Breast cancer;	chr11:123048564	chrX:121203182~121205014:-
OV	trans	rs7121616	0.576	rs7942164	ENSG00000234176.1	HSPA8P1	7.58	8.5e-13	7.52e-06	0.58	0.45	Breast cancer;	chr11:123050459	chrX:121203182~121205014:-
OV	trans	rs7121616	0.576	rs56131320	ENSG00000234176.1	HSPA8P1	7.58	8.5e-13	7.52e-06	0.58	0.45	Breast cancer;	chr11:123053058	chrX:121203182~121205014:-
OV	trans	rs7395662	0.864	rs7482764	ENSG00000134612.10	FOLH1B	-7.58	8.54e-13	7.56e-06	-0.54	-0.45	HDL cholesterol;	chr11:48604306	chr11:89639227~89698718:+
OV	trans	rs7395662	0.929	rs34584314	ENSG00000134612.10	FOLH1B	-7.58	8.54e-13	7.56e-06	-0.54	-0.45	HDL cholesterol;	chr11:48606134	chr11:89639227~89698718:+
OV	trans	rs7395662	0.853	rs4882054	ENSG00000134612.10	FOLH1B	-7.58	8.61e-13	7.61e-06	-0.55	-0.45	HDL cholesterol;	chr11:48378347	chr11:89639227~89698718:+
OV	trans	rs7647973	0.925	rs7429661	ENSG00000197582.5	GPX1P1	7.58	8.66e-13	7.65e-06	0.6	0.45	Menarche (age at onset);	chr3:49191367	chrX:13378735~13379340:-
OV	trans	rs7121616	0.576	rs73610510	ENSG00000234176.1	HSPA8P1	7.58	8.78e-13	7.75e-06	0.58	0.45	Breast cancer;	chr11:123049365	chrX:121203182~121205014:-
OV	trans	rs7121616	0.576	rs4802	ENSG00000234176.1	HSPA8P1	7.58	8.88e-13	7.84e-06	0.54	0.45	Breast cancer;	chr11:123057914	chrX:121203182~121205014:-
OV	trans	rs7554511	0.792	rs12126806	ENSG00000244144.1	RP11-757F18.3	-7.57	9.07e-13	8e-06	-0.6	-0.45	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200994697	chr3:112185480~112185998:-
OV	trans	rs7554511	0.893	rs12122721	ENSG00000244144.1	RP11-757F18.3	7.57	9.51e-13	8.37e-06	0.6	0.45	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201015352	chr3:112185480~112185998:-
OV	trans	rs2727020	0.553	rs7479975	ENSG00000134612.10	FOLH1B	-7.57	9.58e-13	8.44e-06	-0.56	-0.45	Coronary artery disease;	chr11:49560412	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs12800770	ENSG00000134612.10	FOLH1B	-7.56	9.83e-13	8.64e-06	-0.54	-0.45	HDL cholesterol;	chr11:48583375	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs6485888	ENSG00000134612.10	FOLH1B	-7.56	9.83e-13	8.64e-06	-0.54	-0.45	HDL cholesterol;	chr11:48583787	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs10838971	ENSG00000134612.10	FOLH1B	-7.56	9.83e-13	8.64e-06	-0.54	-0.45	HDL cholesterol;	chr11:48585072	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs7944356	ENSG00000134612.10	FOLH1B	-7.56	9.83e-13	8.64e-06	-0.54	-0.45	HDL cholesterol;	chr11:48588602	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs11039857	ENSG00000134612.10	FOLH1B	-7.56	9.83e-13	8.64e-06	-0.54	-0.45	HDL cholesterol;	chr11:48589301	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs11039859	ENSG00000134612.10	FOLH1B	-7.56	9.83e-13	8.64e-06	-0.54	-0.45	HDL cholesterol;	chr11:48590436	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs7928083	ENSG00000134612.10	FOLH1B	-7.56	9.83e-13	8.64e-06	-0.54	-0.45	HDL cholesterol;	chr11:48591596	chr11:89639227~89698718:+
OV	trans	rs877636	0.701	rs34415530	ENSG00000196933.5	RPS26P11	7.56	9.87e-13	8.66e-06	0.49	0.45	Cognitive function;	chr12:56050848	chrX:72044545~72044892:+
OV	trans	rs877636	1	rs4759229	ENSG00000225071.1	GS1-184P14.2	-7.56	9.98e-13	8.76e-06	-0.5	-0.45	Cognitive function;	chr12:56080696	chrX:24429573~24429920:-
OV	trans	rs7395662	1	rs1809986	ENSG00000134612.10	FOLH1B	-7.56	1e-12	8.81e-06	-0.55	-0.45	HDL cholesterol;	chr11:48965987	chr11:89639227~89698718:+
OV	trans	rs10242455	0.557	rs73401516	ENSG00000228834.1	RP11-249L21.4	7.55	1.02e-12	8.93e-06	0.99	0.45	Blood metabolite levels;	chr7:99470728	chr6:108907615~108907873:-
OV	trans	rs10242455	0.557	rs77997620	ENSG00000228834.1	RP11-249L21.4	7.55	1.02e-12	8.93e-06	0.99	0.45	Blood metabolite levels;	chr7:99472792	chr6:108907615~108907873:-
OV	trans	rs10242455	0.702	rs59240302	ENSG00000228834.1	RP11-249L21.4	7.55	1.02e-12	8.93e-06	0.99	0.45	Blood metabolite levels;	chr7:99475368	chr6:108907615~108907873:-
OV	trans	rs10242455	0.702	rs73403247	ENSG00000228834.1	RP11-249L21.4	7.55	1.02e-12	8.93e-06	0.99	0.45	Blood metabolite levels;	chr7:99491107	chr6:108907615~108907873:-
OV	trans	rs7312770	0.612	rs773114	ENSG00000226339.1	RPS26P56	7.55	1.02e-12	8.93e-06	0.44	0.45	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chrX:129408382~129408621:+
OV	trans	rs7395662	0.963	rs12418254	ENSG00000134612.10	FOLH1B	-7.55	1.02e-12	8.97e-06	-0.55	-0.45	HDL cholesterol;	chr11:48966710	chr11:89639227~89698718:+
OV	trans	rs2069408	1	rs2069408	ENSG00000233278.1	RPS26P2	-7.55	1.04e-12	9.09e-06	-0.49	-0.45	Asthma;	chr12:55970537	chr9:30831878~30832225:-
OV	trans	rs7395662	1	rs4882021	ENSG00000134612.10	FOLH1B	-7.55	1.05e-12	9.19e-06	-0.54	-0.45	HDL cholesterol;	chr11:48594414	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs7129386	ENSG00000134612.10	FOLH1B	-7.55	1.05e-12	9.19e-06	-0.54	-0.45	HDL cholesterol;	chr11:48595142	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs10838975	ENSG00000134612.10	FOLH1B	-7.55	1.05e-12	9.19e-06	-0.54	-0.45	HDL cholesterol;	chr11:48596063	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs12418721	ENSG00000134612.10	FOLH1B	-7.55	1.05e-12	9.19e-06	-0.54	-0.45	HDL cholesterol;	chr11:48596899	chr11:89639227~89698718:+
OV	trans	rs7395662	0.929	rs7108559	ENSG00000134612.10	FOLH1B	-7.55	1.05e-12	9.19e-06	-0.54	-0.45	HDL cholesterol;	chr11:48597599	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs2089209	ENSG00000134612.10	FOLH1B	-7.55	1.07e-12	9.37e-06	-0.55	-0.45	HDL cholesterol;	chr11:48965568	chr11:89639227~89698718:+
OV	trans	rs877636	1	rs705696	ENSG00000196933.5	RPS26P11	7.55	1.08e-12	9.39e-06	0.5	0.45	Cognitive function;	chr12:56086864	chrX:72044545~72044892:+
OV	trans	rs7395662	0.929	rs7952580	ENSG00000134612.10	FOLH1B	-7.55	1.08e-12	9.41e-06	-0.54	-0.45	HDL cholesterol;	chr11:48573654	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs4882019	ENSG00000134612.10	FOLH1B	-7.55	1.08e-12	9.41e-06	-0.54	-0.45	HDL cholesterol;	chr11:48577196	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs4882134	ENSG00000134612.10	FOLH1B	-7.55	1.08e-12	9.41e-06	-0.54	-0.45	HDL cholesterol;	chr11:48577243	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs7483920	ENSG00000134612.10	FOLH1B	-7.55	1.08e-12	9.41e-06	-0.54	-0.45	HDL cholesterol;	chr11:48578417	chr11:89639227~89698718:+
OV	trans	rs877636	1	rs705696	ENSG00000227887.1	RPS26P13	7.54	1.09e-12	9.45e-06	0.48	0.45	Cognitive function;	chr12:56086864	chr1:208697369~208697698:-
OV	trans	rs7121616	0.576	rs7929869	ENSG00000234176.1	HSPA8P1	7.54	1.09e-12	9.47e-06	0.57	0.45	Breast cancer;	chr11:123054435	chrX:121203182~121205014:-
OV	trans	rs7121616	0.576	rs1841580	ENSG00000234176.1	HSPA8P1	7.54	1.09e-12	9.47e-06	0.57	0.45	Breast cancer;	chr11:123055956	chrX:121203182~121205014:-
OV	trans	rs1814175	0.935	rs11040462	ENSG00000134612.10	FOLH1B	-7.54	1.09e-12	9.51e-06	-0.57	-0.45	Height;	chr11:49661606	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs7125110	ENSG00000134612.10	FOLH1B	-7.54	1.11e-12	9.65e-06	-0.54	-0.45	HDL cholesterol;	chr11:48523955	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs4882002	ENSG00000134612.10	FOLH1B	-7.54	1.11e-12	9.65e-06	-0.54	-0.45	HDL cholesterol;	chr11:48525179	chr11:89639227~89698718:+
OV	trans	rs7395662	0.89	rs11039806	ENSG00000134612.10	FOLH1B	-7.54	1.11e-12	9.65e-06	-0.54	-0.45	HDL cholesterol;	chr11:48526164	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs11039817	ENSG00000134612.10	FOLH1B	-7.54	1.14e-12	9.86e-06	-0.54	-0.45	HDL cholesterol;	chr11:48539928	chr11:89639227~89698718:+
OV	trans	rs7554511	0.893	rs55862304	ENSG00000244144.1	RP11-757F18.3	-7.54	1.15e-12	9.95e-06	-0.63	-0.45	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201020647	chr3:112185480~112185998:-
OV	trans	rs7647973	0.848	rs4955411	ENSG00000197582.5	GPX1P1	7.53	1.16e-12	1e-05	0.65	0.45	Menarche (age at onset);	chr3:49107871	chrX:13378735~13379340:-
OV	trans	rs7647973	0.848	rs4292260	ENSG00000197582.5	GPX1P1	7.53	1.16e-12	1e-05	0.65	0.45	Menarche (age at onset);	chr3:49111457	chrX:13378735~13379340:-
OV	trans	rs877636	0.859	rs3741499	ENSG00000244604.1	RP11-713H12.1	-7.53	1.17e-12	1.01e-05	-0.48	-0.45	Cognitive function;	chr12:56080595	chr17:8561230~8561576:+
OV	trans	rs10242455	0.571	rs13438288	ENSG00000228834.1	RP11-249L21.4	7.53	1.17e-12	1.01e-05	1	0.45	Blood metabolite levels;	chr7:99318791	chr6:108907615~108907873:-
OV	trans	rs7395662	1	rs7931984	ENSG00000134612.10	FOLH1B	-7.53	1.17e-12	1.02e-05	-0.54	-0.45	HDL cholesterol;	chr11:48559283	chr11:89639227~89698718:+
OV	trans	rs877636	0.692	rs11171739	ENSG00000226339.1	RPS26P56	7.53	1.18e-12	1.02e-05	0.45	0.45	Cognitive function;	chr12:56076841	chrX:129408382~129408621:+
OV	trans	rs7554511	0.893	rs11580823	ENSG00000244144.1	RP11-757F18.3	-7.53	1.18e-12	1.02e-05	-0.63	-0.45	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201014361	chr3:112185480~112185998:-
OV	trans	rs941207	0.756	rs2950388	ENSG00000121089.4	NACA3P	-7.53	1.19e-12	1.02e-05	-0.48	-0.45	Platelet count;	chr12:56639569	chr4:164943290~164943937:+
OV	trans	rs7647973	0.961	rs4955417	ENSG00000197582.5	GPX1P1	7.53	1.22e-12	1.05e-05	0.6	0.45	Menarche (age at onset);	chr3:49260772	chrX:13378735~13379340:-
OV	trans	rs7395662	1	rs6485875	ENSG00000134612.10	FOLH1B	-7.53	1.22e-12	1.06e-05	-0.54	-0.45	HDL cholesterol;	chr11:48559482	chr11:89639227~89698718:+
OV	trans	rs7113874	0.592	rs10500703	ENSG00000266891.1	RP11-692N5.2	7.52	1.25e-12	1.08e-05	0.62	0.45	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8412317	chr18:9734882~9735602:-
OV	trans	rs877636	0.701	rs34415530	ENSG00000244604.1	RP11-713H12.1	7.52	1.27e-12	1.1e-05	0.49	0.45	Cognitive function;	chr12:56050848	chr17:8561230~8561576:+
OV	trans	rs7395662	0.853	rs10769356	ENSG00000134612.10	FOLH1B	-7.52	1.29e-12	1.11e-05	-0.56	-0.45	HDL cholesterol;	chr11:48423102	chr11:89639227~89698718:+
OV	trans	rs877636	0.859	rs3741499	ENSG00000227887.1	RPS26P13	-7.52	1.3e-12	1.11e-05	-0.46	-0.45	Cognitive function;	chr12:56080595	chr1:208697369~208697698:-
OV	trans	rs7395662	0.963	rs11040016	ENSG00000134612.10	FOLH1B	7.52	1.3e-12	1.12e-05	0.53	0.45	HDL cholesterol;	chr11:48761945	chr11:89639227~89698718:+
OV	trans	rs10242455	0.557	rs59672032	ENSG00000228834.1	RP11-249L21.4	7.51	1.32e-12	1.14e-05	0.99	0.45	Blood metabolite levels;	chr7:99461074	chr6:108907615~108907873:-
OV	trans	rs673253	0.581	rs2152113	ENSG00000231007.5	CDC20P1	-7.51	1.33e-12	1.14e-05	-0.59	-0.45	Intelligence (multi-trait analysis);	chr1:43517898	chr9:87011652~87013151:+
OV	trans	rs7395662	1	rs12365220	ENSG00000134612.10	FOLH1B	-7.51	1.34e-12	1.15e-05	-0.54	-0.45	HDL cholesterol;	chr11:48534405	chr11:89639227~89698718:+
OV	trans	rs7395662	0.929	rs12363679	ENSG00000134612.10	FOLH1B	-7.51	1.34e-12	1.15e-05	-0.54	-0.45	HDL cholesterol;	chr11:48534471	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs10838943	ENSG00000134612.10	FOLH1B	-7.51	1.34e-12	1.15e-05	-0.54	-0.45	HDL cholesterol;	chr11:48535890	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs4882109	ENSG00000134612.10	FOLH1B	-7.51	1.34e-12	1.15e-05	-0.54	-0.45	HDL cholesterol;	chr11:48536133	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs4882111	ENSG00000134612.10	FOLH1B	-7.51	1.34e-12	1.15e-05	-0.54	-0.45	HDL cholesterol;	chr11:48536895	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs4882010	ENSG00000134612.10	FOLH1B	-7.51	1.34e-12	1.15e-05	-0.54	-0.45	HDL cholesterol;	chr11:48537621	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs10838944	ENSG00000134612.10	FOLH1B	-7.51	1.34e-12	1.15e-05	-0.54	-0.45	HDL cholesterol;	chr11:48538019	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs4882112	ENSG00000134612.10	FOLH1B	-7.51	1.34e-12	1.15e-05	-0.54	-0.45	HDL cholesterol;	chr11:48539531	chr11:89639227~89698718:+
OV	trans	rs7395662	0.75	rs10838985	ENSG00000134612.10	FOLH1B	-7.51	1.35e-12	1.16e-05	-0.53	-0.45	HDL cholesterol;	chr11:48623533	chr11:89639227~89698718:+
OV	trans	rs7554511	0.893	rs11589573	ENSG00000244144.1	RP11-757F18.3	-7.51	1.37e-12	1.17e-05	-0.63	-0.45	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201005987	chr3:112185480~112185998:-
OV	trans	rs877636	0.74	rs705702	ENSG00000242206.2	RPS26P35	-7.51	1.37e-12	1.17e-05	-0.47	-0.45	Cognitive function;	chr12:55996852	chr8:118761856~118762201:-
OV	trans	rs7312770	0.612	rs1873914	ENSG00000224161.3	RPS26P54	7.51	1.38e-12	1.18e-05	0.47	0.45	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr18:59761558~59761905:+
OV	trans	rs2069408	1	rs2069408	ENSG00000196656.7	AC004057.1	-7.5	1.41e-12	1.2e-05	-0.5	-0.45	Asthma;	chr12:55970537	chr4:113214046~113217170:-
OV	trans	rs877636	1	rs4759229	ENSG00000227887.1	RPS26P13	-7.49	1.5e-12	1.27e-05	-0.46	-0.45	Cognitive function;	chr12:56080696	chr1:208697369~208697698:-
OV	trans	rs673253	0.556	rs11577403	ENSG00000231007.5	CDC20P1	7.49	1.52e-12	1.3e-05	0.6	0.45	Intelligence (multi-trait analysis);	chr1:43524102	chr9:87011652~87013151:+
OV	trans	rs877636	0.74	rs772920	ENSG00000196933.5	RPS26P11	7.48	1.61e-12	1.36e-05	0.48	0.44	Cognitive function;	chr12:55996580	chrX:72044545~72044892:+
OV	trans	rs7395662	1	rs8189391	ENSG00000134612.10	FOLH1B	7.48	1.64e-12	1.39e-05	0.54	0.44	HDL cholesterol;	chr11:48838237	chr11:89639227~89698718:+
OV	trans	rs7395662	0.747	rs11040106	ENSG00000134612.10	FOLH1B	7.48	1.65e-12	1.4e-05	0.53	0.44	HDL cholesterol;	chr11:48867574	chr11:89639227~89698718:+
OV	trans	rs7121616	0.576	rs7102045	ENSG00000241478.1	HSPA8P9	7.48	1.65e-12	1.4e-05	0.56	0.44	Breast cancer;	chr11:123052713	chr3:137880295~137882237:+
OV	trans	rs7647973	0.769	rs7434187	ENSG00000197582.5	GPX1P1	7.48	1.66e-12	1.41e-05	0.64	0.44	Menarche (age at onset);	chr3:48995534	chrX:13378735~13379340:-
OV	trans	rs7647973	0.577	rs6446247	ENSG00000197582.5	GPX1P1	7.47	1.69e-12	1.43e-05	0.63	0.44	Menarche (age at onset);	chr3:49064568	chrX:13378735~13379340:-
OV	trans	rs1814175	0.935	rs11040465	ENSG00000134612.10	FOLH1B	-7.47	1.76e-12	1.49e-05	-0.57	-0.44	Height;	chr11:49667771	chr11:89639227~89698718:+
OV	trans	rs7395662	0.853	rs35255233	ENSG00000134612.10	FOLH1B	-7.47	1.77e-12	1.49e-05	-0.56	-0.44	HDL cholesterol;	chr11:48421318	chr11:89639227~89698718:+
OV	trans	rs7554511	0.893	rs17419032	ENSG00000244144.1	RP11-757F18.3	7.47	1.77e-12	1.49e-05	0.61	0.44	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201029403	chr3:112185480~112185998:-
OV	trans	rs7395662	0.963	rs4882094	ENSG00000134612.10	FOLH1B	-7.46	1.83e-12	1.55e-05	-0.54	-0.44	HDL cholesterol;	chr11:48510908	chr11:89639227~89698718:+
OV	trans	rs7554511	0.893	rs11586763	ENSG00000244144.1	RP11-757F18.3	-7.46	1.87e-12	1.58e-05	-0.62	-0.44	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201020316	chr3:112185480~112185998:-
OV	trans	rs7395662	0.784	rs2170661	ENSG00000134612.10	FOLH1B	-7.45	1.91e-12	1.61e-05	-0.55	-0.44	HDL cholesterol;	chr11:48356634	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs6485882	ENSG00000134612.10	FOLH1B	7.45	1.92e-12	1.62e-05	0.54	0.44	HDL cholesterol;	chr11:48570883	chr11:89639227~89698718:+
OV	trans	rs928391	0.572	rs11264548	ENSG00000227183.3	HDGFP1	-7.45	1.94e-12	1.64e-05	-0.58	-0.44	Platelet count;	chr1:156779339	chrX:131646639~131646890:+
OV	trans	rs928391	0.744	rs2274503	ENSG00000227183.3	HDGFP1	-7.45	1.94e-12	1.64e-05	-0.58	-0.44	Platelet count;	chr1:156782256	chrX:131646639~131646890:+
OV	trans	rs7647973	0.961	rs4955443	ENSG00000197582.5	GPX1P1	7.45	1.97e-12	1.66e-05	0.59	0.44	Menarche (age at onset);	chr3:49249185	chrX:13378735~13379340:-
OV	trans	rs7647973	0.961	rs11130187	ENSG00000197582.5	GPX1P1	7.45	1.97e-12	1.66e-05	0.59	0.44	Menarche (age at onset);	chr3:49270439	chrX:13378735~13379340:-
OV	trans	rs36022378	0.504	rs4688688	ENSG00000197582.5	GPX1P1	-7.45	1.98e-12	1.67e-05	-0.74	-0.44	Diastolic blood pressure;	chr3:50005257	chrX:13378735~13379340:-
OV	trans	rs1814175	0.869	rs10769600	ENSG00000134612.10	FOLH1B	-7.45	1.99e-12	1.67e-05	-0.56	-0.44	Height;	chr11:49660280	chr11:89639227~89698718:+
OV	trans	rs1814175	0.935	rs11040463	ENSG00000134612.10	FOLH1B	-7.45	1.99e-12	1.67e-05	-0.56	-0.44	Height;	chr11:49664022	chr11:89639227~89698718:+
OV	trans	rs2727020	0.553	rs61904166	ENSG00000134612.10	FOLH1B	-7.44	2.03e-12	1.7e-05	-0.56	-0.44	Coronary artery disease;	chr11:49559909	chr11:89639227~89698718:+
OV	trans	rs2727020	0.576	rs1814175	ENSG00000134612.10	FOLH1B	-7.44	2.03e-12	1.71e-05	-0.55	-0.44	Coronary artery disease;	chr11:49537620	chr11:89639227~89698718:+
OV	trans	rs7554511	0.893	rs72749166	ENSG00000244144.1	RP11-757F18.3	-7.44	2.04e-12	1.71e-05	-0.61	-0.44	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201031177	chr3:112185480~112185998:-
OV	trans	rs7121616	0.562	rs7131452	ENSG00000234176.1	HSPA8P1	7.44	2.05e-12	1.71e-05	0.54	0.44	Breast cancer;	chr11:123065314	chrX:121203182~121205014:-
OV	trans	rs1814175	0.935	rs28586931	ENSG00000134612.10	FOLH1B	-7.43	2.14e-12	1.79e-05	-0.56	-0.44	Height;	chr11:49672320	chr11:89639227~89698718:+
OV	trans	rs2727020	0.575	rs10769587	ENSG00000134612.10	FOLH1B	-7.43	2.16e-12	1.8e-05	-0.55	-0.44	Coronary artery disease;	chr11:49528297	chr11:89639227~89698718:+
OV	trans	rs2727020	0.514	rs4980444	ENSG00000134612.10	FOLH1B	-7.43	2.16e-12	1.8e-05	-0.55	-0.44	Coronary artery disease;	chr11:49529212	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs10769371	ENSG00000134612.10	FOLH1B	-7.43	2.22e-12	1.85e-05	-0.54	-0.44	HDL cholesterol;	chr11:48509632	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs4882096	ENSG00000134612.10	FOLH1B	-7.43	2.22e-12	1.85e-05	-0.54	-0.44	HDL cholesterol;	chr11:48512550	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs7478900	ENSG00000134612.10	FOLH1B	-7.43	2.22e-12	1.85e-05	-0.54	-0.44	HDL cholesterol;	chr11:48522451	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs7483713	ENSG00000134612.10	FOLH1B	-7.42	2.33e-12	1.94e-05	-0.53	-0.44	HDL cholesterol;	chr11:48607662	chr11:89639227~89698718:+
OV	trans	rs877636	1	rs2292239	ENSG00000196933.5	RPS26P11	7.41	2.4e-12	1.99e-05	0.48	0.44	Cognitive function;	chr12:56088396	chrX:72044545~72044892:+
OV	trans	rs1814175	0.715	rs7479622	ENSG00000134612.10	FOLH1B	-7.41	2.45e-12	2.03e-05	-0.56	-0.44	Height;	chr11:49651788	chr11:89639227~89698718:+
OV	trans	rs7617480	0.648	rs9864243	ENSG00000197582.5	GPX1P1	7.41	2.5e-12	2.08e-05	0.63	0.44	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48945299	chrX:13378735~13379340:-
OV	trans	rs7121616	0.576	rs11218967	ENSG00000234176.1	HSPA8P1	7.4	2.63e-12	2.18e-05	0.54	0.44	Breast cancer;	chr11:123087551	chrX:121203182~121205014:-
OV	trans	rs7647973	0.925	rs4384984	ENSG00000197582.5	GPX1P1	7.4	2.64e-12	2.19e-05	0.59	0.44	Menarche (age at onset);	chr3:49252445	chrX:13378735~13379340:-
OV	trans	rs7395662	1	rs4882129	ENSG00000134612.10	FOLH1B	-7.4	2.68e-12	2.21e-05	-0.53	-0.44	HDL cholesterol;	chr11:48567222	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs4882130	ENSG00000134612.10	FOLH1B	-7.4	2.68e-12	2.21e-05	-0.53	-0.44	HDL cholesterol;	chr11:48567402	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs10838966	ENSG00000134612.10	FOLH1B	-7.4	2.68e-12	2.21e-05	-0.53	-0.44	HDL cholesterol;	chr11:48568171	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs34636547	ENSG00000134612.10	FOLH1B	-7.4	2.68e-12	2.21e-05	-0.53	-0.44	HDL cholesterol;	chr11:48568551	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs10769382	ENSG00000134612.10	FOLH1B	-7.4	2.68e-12	2.21e-05	-0.53	-0.44	HDL cholesterol;	chr11:48568863	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs11039800	ENSG00000134612.10	FOLH1B	7.39	2.79e-12	2.3e-05	0.53	0.44	HDL cholesterol;	chr11:48521027	chr11:89639227~89698718:+
OV	trans	rs6477998	0.58	rs4979231	ENSG00000238072.1	RP11-305M3.2	7.39	2.84e-12	2.34e-05	0.52	0.44	Hematology traits;	chr9:113286475	chr7:129410113~129410370:-
OV	trans	rs7554511	0.861	rs10920074	ENSG00000244144.1	RP11-757F18.3	-7.39	2.86e-12	2.36e-05	-0.6	-0.44	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200943599	chr3:112185480~112185998:-
OV	trans	rs7121616	0.576	rs7111598	ENSG00000234176.1	HSPA8P1	7.39	2.86e-12	2.36e-05	0.56	0.44	Breast cancer;	chr11:123055438	chrX:121203182~121205014:-
OV	trans	rs928391	0.744	rs11264555	ENSG00000227183.3	HDGFP1	-7.38	2.89e-12	2.38e-05	-0.57	-0.44	Platelet count;	chr1:156794246	chrX:131646639~131646890:+
OV	trans	rs1814175	0.935	rs10839329	ENSG00000134612.10	FOLH1B	-7.38	2.92e-12	2.4e-05	-0.56	-0.44	Height;	chr11:49672654	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs12419576	ENSG00000134612.10	FOLH1B	-7.38	2.97e-12	2.44e-05	-0.53	-0.44	HDL cholesterol;	chr11:48560092	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs61930968	ENSG00000134612.10	FOLH1B	-7.38	2.97e-12	2.44e-05	-0.53	-0.44	HDL cholesterol;	chr11:48560097	chr11:89639227~89698718:+
OV	trans	rs7395662	0.929	rs10838956	ENSG00000134612.10	FOLH1B	-7.38	2.97e-12	2.44e-05	-0.53	-0.44	HDL cholesterol;	chr11:48560213	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs7949554	ENSG00000134612.10	FOLH1B	-7.38	2.97e-12	2.44e-05	-0.53	-0.44	HDL cholesterol;	chr11:48560440	chr11:89639227~89698718:+
OV	trans	rs7395662	0.895	rs7924481	ENSG00000134612.10	FOLH1B	-7.38	2.97e-12	2.44e-05	-0.53	-0.44	HDL cholesterol;	chr11:48560905	chr11:89639227~89698718:+
OV	trans	rs7395662	0.929	rs10838959	ENSG00000134612.10	FOLH1B	-7.38	2.97e-12	2.44e-05	-0.53	-0.44	HDL cholesterol;	chr11:48563180	chr11:89639227~89698718:+
OV	trans	rs877636	1	rs4759229	ENSG00000196933.5	RPS26P11	-7.38	3.04e-12	2.49e-05	-0.47	-0.44	Cognitive function;	chr12:56080696	chrX:72044545~72044892:+
OV	trans	rs877636	0.74	rs705702	ENSG00000234192.1	RP11-57C13.5	-7.38	3.04e-12	2.5e-05	-0.45	-0.44	Cognitive function;	chr12:55996852	chr10:87642607~87642954:+
OV	trans	rs7395662	1	rs7479134	ENSG00000134612.10	FOLH1B	-7.37	3.19e-12	2.61e-05	-0.52	-0.44	HDL cholesterol;	chr11:48603857	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs11039870	ENSG00000134612.10	FOLH1B	-7.37	3.19e-12	2.61e-05	-0.52	-0.44	HDL cholesterol;	chr11:48604926	chr11:89639227~89698718:+
OV	trans	rs7121616	0.562	rs2061602	ENSG00000234176.1	HSPA8P1	7.36	3.25e-12	2.66e-05	0.53	0.44	Breast cancer;	chr11:123065079	chrX:121203182~121205014:-
OV	trans	rs11039798	0.588	rs10838923	ENSG00000134612.10	FOLH1B	7.36	3.29e-12	2.69e-05	0.64	0.44	Axial length;	chr11:48513312	chr11:89639227~89698718:+
OV	trans	rs673253	0.581	rs11210860	ENSG00000231007.5	CDC20P1	-7.36	3.31e-12	2.71e-05	-0.58	-0.44	Intelligence (multi-trait analysis);	chr1:43516856	chr9:87011652~87013151:+
OV	trans	rs11220082	0.666	rs12789687	ENSG00000236257.1	EI24P2	-7.36	3.4e-12	2.78e-05	-0.56	-0.44	Schizophrenia;	chr11:125461254	chr1:158454198~158455273:+
OV	trans	rs877636	0.859	rs3741499	ENSG00000196933.5	RPS26P11	-7.35	3.48e-12	2.84e-05	-0.47	-0.44	Cognitive function;	chr12:56080595	chrX:72044545~72044892:+
OV	trans	rs928391	0.744	rs3765783	ENSG00000227183.3	HDGFP1	-7.35	3.56e-12	2.9e-05	-0.56	-0.44	Platelet count;	chr1:156796181	chrX:131646639~131646890:+
OV	trans	rs7647973	0.925	rs6808036	ENSG00000197582.5	GPX1P1	7.35	3.58e-12	2.91e-05	0.59	0.44	Menarche (age at onset);	chr3:49199006	chrX:13378735~13379340:-
OV	trans	rs877636	0.74	rs772920	ENSG00000242206.2	RPS26P35	7.35	3.59e-12	2.93e-05	0.46	0.44	Cognitive function;	chr12:55996580	chr8:118761856~118762201:-
OV	trans	rs1814175	0.935	rs7479914	ENSG00000134612.10	FOLH1B	-7.35	3.63e-12	2.96e-05	-0.56	-0.44	Height;	chr11:49639799	chr11:89639227~89698718:+
OV	trans	rs877636	0.702	rs61937249	ENSG00000234192.1	RP11-57C13.5	7.35	3.65e-12	2.97e-05	0.45	0.44	Cognitive function;	chr12:55988132	chr10:87642607~87642954:+
OV	trans	rs7395662	1	rs4882132	ENSG00000134612.10	FOLH1B	-7.35	3.65e-12	2.97e-05	-0.53	-0.44	HDL cholesterol;	chr11:48571573	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs7951432	ENSG00000134612.10	FOLH1B	-7.35	3.66e-12	2.97e-05	-0.53	-0.44	HDL cholesterol;	chr11:48569728	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs7121992	ENSG00000134612.10	FOLH1B	-7.35	3.66e-12	2.97e-05	-0.53	-0.44	HDL cholesterol;	chr11:48571030	chr11:89639227~89698718:+
OV	trans	rs7395662	0.89	rs4882133	ENSG00000134612.10	FOLH1B	-7.35	3.66e-12	2.97e-05	-0.53	-0.44	HDL cholesterol;	chr11:48571898	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs10838967	ENSG00000134612.10	FOLH1B	-7.35	3.66e-12	2.97e-05	-0.53	-0.44	HDL cholesterol;	chr11:48573455	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs7481308	ENSG00000134612.10	FOLH1B	-7.35	3.66e-12	2.97e-05	-0.53	-0.44	HDL cholesterol;	chr11:48578515	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs11039851	ENSG00000134612.10	FOLH1B	-7.35	3.66e-12	2.97e-05	-0.53	-0.44	HDL cholesterol;	chr11:48579287	chr11:89639227~89698718:+
OV	trans	rs7647973	0.696	rs3087866	ENSG00000197582.5	GPX1P1	7.34	3.7e-12	3.01e-05	0.61	0.44	Menarche (age at onset);	chr3:49017259	chrX:13378735~13379340:-
OV	trans	rs7395662	1	rs11039854	ENSG00000134612.10	FOLH1B	-7.34	3.74e-12	3.04e-05	-0.53	-0.44	HDL cholesterol;	chr11:48586136	chr11:89639227~89698718:+
OV	trans	rs7395662	0.777	rs7114291	ENSG00000134612.10	FOLH1B	-7.34	3.74e-12	3.04e-05	-0.53	-0.44	HDL cholesterol;	chr11:48586699	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs6485889	ENSG00000134612.10	FOLH1B	-7.34	3.74e-12	3.04e-05	-0.53	-0.44	HDL cholesterol;	chr11:48587233	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs7481880	ENSG00000134612.10	FOLH1B	-7.34	3.74e-12	3.04e-05	-0.53	-0.44	HDL cholesterol;	chr11:48587795	chr11:89639227~89698718:+
OV	trans	rs928391	0.531	rs7517728	ENSG00000227183.3	HDGFP1	-7.34	3.77e-12	3.05e-05	-0.58	-0.44	Platelet count;	chr1:156823340	chrX:131646639~131646890:+
OV	trans	rs877636	0.702	rs773111	ENSG00000234192.1	RP11-57C13.5	7.34	3.78e-12	3.06e-05	0.45	0.44	Cognitive function;	chr12:55981956	chr10:87642607~87642954:+
OV	trans	rs877636	0.702	rs773112	ENSG00000234192.1	RP11-57C13.5	7.34	3.78e-12	3.06e-05	0.45	0.44	Cognitive function;	chr12:55982097	chr10:87642607~87642954:+
OV	trans	rs7647973	0.696	rs7100	ENSG00000197582.5	GPX1P1	7.34	3.8e-12	3.08e-05	0.63	0.44	Menarche (age at onset);	chr3:49015786	chrX:13378735~13379340:-
OV	trans	rs928391	0.744	rs6700964	ENSG00000227183.3	HDGFP1	-7.33	3.93e-12	3.18e-05	-0.56	-0.44	Platelet count;	chr1:156790244	chrX:131646639~131646890:+
OV	trans	rs11039798	0.588	rs12278284	ENSG00000134612.10	FOLH1B	7.33	3.98e-12	3.21e-05	0.67	0.44	Axial length;	chr11:48590511	chr11:89639227~89698718:+
OV	trans	rs7395662	0.929	rs7946248	ENSG00000134612.10	FOLH1B	-7.33	4.05e-12	3.26e-05	-0.52	-0.44	HDL cholesterol;	chr11:48591964	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs4882136	ENSG00000134612.10	FOLH1B	-7.33	4.05e-12	3.26e-05	-0.52	-0.44	HDL cholesterol;	chr11:48593759	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs4882137	ENSG00000134612.10	FOLH1B	-7.33	4.05e-12	3.26e-05	-0.52	-0.44	HDL cholesterol;	chr11:48594119	chr11:89639227~89698718:+
OV	trans	rs7395662	0.963	rs10769389	ENSG00000134612.10	FOLH1B	-7.33	4.05e-12	3.26e-05	-0.52	-0.44	HDL cholesterol;	chr11:48596459	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs10769390	ENSG00000134612.10	FOLH1B	-7.33	4.05e-12	3.26e-05	-0.52	-0.44	HDL cholesterol;	chr11:48596670	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs11039868	ENSG00000134612.10	FOLH1B	-7.33	4.05e-12	3.26e-05	-0.52	-0.44	HDL cholesterol;	chr11:48600594	chr11:89639227~89698718:+
OV	trans	rs7395662	0.895	rs11039869	ENSG00000134612.10	FOLH1B	-7.33	4.05e-12	3.26e-05	-0.52	-0.44	HDL cholesterol;	chr11:48600760	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs12421159	ENSG00000134612.10	FOLH1B	-7.33	4.05e-12	3.26e-05	-0.52	-0.44	HDL cholesterol;	chr11:48603289	chr11:89639227~89698718:+
OV	trans	rs7617480	0.648	rs9859473	ENSG00000197582.5	GPX1P1	7.33	4.13e-12	3.32e-05	0.6	0.44	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48799749	chrX:13378735~13379340:-
OV	trans	rs877636	1	rs4759229	ENSG00000244604.1	RP11-713H12.1	-7.33	4.13e-12	3.32e-05	-0.47	-0.44	Cognitive function;	chr12:56080696	chr17:8561230~8561576:+
OV	trans	rs10242455	0.571	rs11734	ENSG00000228834.1	RP11-249L21.4	-7.32	4.15e-12	3.33e-05	-0.85	-0.44	Blood metabolite levels;	chr7:99632145	chr6:108907615~108907873:-
OV	trans	rs9467773	0.62	rs2451741	ENSG00000242375.1	RP11-498P14.3	7.32	4.24e-12	3.4e-05	0.52	0.44	Intelligence (multi-trait analysis);	chr6:26629176	chr9:97195351~97197687:-
OV	trans	rs2898290	0.5	rs11998678	ENSG00000253893.2	FAM85B	7.32	4.25e-12	3.41e-05	0.53	0.44	Systolic blood pressure;	chr8:11972641	chr8:8167819~8226614:-
OV	trans	rs7121616	0.576	rs7102045	ENSG00000234176.1	HSPA8P1	7.32	4.32e-12	3.46e-05	0.56	0.44	Breast cancer;	chr11:123052713	chrX:121203182~121205014:-
OV	trans	rs7647973	0.925	rs9834003	ENSG00000197582.5	GPX1P1	7.31	4.46e-12	3.55e-05	0.59	0.44	Menarche (age at onset);	chr3:49179039	chrX:13378735~13379340:-
OV	trans	rs7647973	0.925	rs4955421	ENSG00000197582.5	GPX1P1	7.31	4.46e-12	3.55e-05	0.59	0.44	Menarche (age at onset);	chr3:49181455	chrX:13378735~13379340:-
OV	trans	rs7647973	0.925	rs4955423	ENSG00000197582.5	GPX1P1	7.31	4.46e-12	3.55e-05	0.59	0.44	Menarche (age at onset);	chr3:49183015	chrX:13378735~13379340:-
OV	trans	rs7647973	0.925	rs11130183	ENSG00000197582.5	GPX1P1	7.31	4.46e-12	3.55e-05	0.59	0.44	Menarche (age at onset);	chr3:49191513	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs7646366	ENSG00000197582.5	GPX1P1	-7.31	4.47e-12	3.55e-05	-0.6	-0.44	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49433235	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs67216675	ENSG00000197582.5	GPX1P1	-7.31	4.47e-12	3.55e-05	-0.6	-0.44	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49455718	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs9853683	ENSG00000197582.5	GPX1P1	-7.31	4.47e-12	3.55e-05	-0.6	-0.44	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49475155	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs12330269	ENSG00000197582.5	GPX1P1	-7.31	4.47e-12	3.55e-05	-0.6	-0.44	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49476477	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs9827021	ENSG00000197582.5	GPX1P1	-7.31	4.47e-12	3.55e-05	-0.6	-0.44	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49477331	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs9818590	ENSG00000197582.5	GPX1P1	-7.31	4.47e-12	3.55e-05	-0.6	-0.44	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49487663	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs11719996	ENSG00000197582.5	GPX1P1	-7.31	4.47e-12	3.55e-05	-0.6	-0.44	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49488525	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs34363169	ENSG00000197582.5	GPX1P1	-7.31	4.47e-12	3.55e-05	-0.6	-0.44	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49500279	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs35261698	ENSG00000197582.5	GPX1P1	-7.31	4.47e-12	3.55e-05	-0.6	-0.44	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49500406	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs6766131	ENSG00000197582.5	GPX1P1	-7.31	4.47e-12	3.55e-05	-0.6	-0.44	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49501499	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs6766581	ENSG00000197582.5	GPX1P1	-7.31	4.47e-12	3.55e-05	-0.6	-0.44	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49501968	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs9821311	ENSG00000197582.5	GPX1P1	-7.31	4.47e-12	3.55e-05	-0.6	-0.44	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49506223	chrX:13378735~13379340:-
OV	trans	rs1814175	0.904	rs1846289	ENSG00000134612.10	FOLH1B	-7.31	4.55e-12	3.62e-05	-0.57	-0.44	Height;	chr11:49598701	chr11:89639227~89698718:+
OV	trans	rs7647973	0.566	rs57630346	ENSG00000197582.5	GPX1P1	7.31	4.59e-12	3.64e-05	0.62	0.44	Menarche (age at onset);	chr3:49048782	chrX:13378735~13379340:-
OV	trans	rs10917477	0.624	rs2745217	ENSG00000224237.1	MINOS1P3	-7.31	4.66e-12	3.69e-05	-0.47	-0.44	Thyroid function;	chr1:19595253	chr3:27214816~27215018:-
OV	trans	rs1814175	0.717	rs11040450	ENSG00000134612.10	FOLH1B	-7.3	4.75e-12	3.76e-05	-0.56	-0.44	Height;	chr11:49629086	chr11:89639227~89698718:+
OV	trans	rs1814175	0.803	rs11040451	ENSG00000134612.10	FOLH1B	-7.3	4.75e-12	3.76e-05	-0.56	-0.44	Height;	chr11:49629087	chr11:89639227~89698718:+
OV	trans	rs1814175	0.935	rs10839317	ENSG00000134612.10	FOLH1B	-7.3	4.84e-12	3.83e-05	-0.56	-0.44	Height;	chr11:49635676	chr11:89639227~89698718:+
OV	trans	rs1814175	0.935	rs6485999	ENSG00000134612.10	FOLH1B	-7.3	4.84e-12	3.83e-05	-0.56	-0.44	Height;	chr11:49637434	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs11039862	ENSG00000134612.10	FOLH1B	-7.29	4.95e-12	3.91e-05	-0.52	-0.44	HDL cholesterol;	chr11:48596754	chr11:89639227~89698718:+
OV	trans	rs9858542	0.953	rs9814873	ENSG00000197582.5	GPX1P1	-7.29	5.02e-12	3.96e-05	-0.57	-0.44	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49416679	chrX:13378735~13379340:-
OV	trans	rs1814175	0.935	rs7925863	ENSG00000134612.10	FOLH1B	-7.29	5.08e-12	4.01e-05	-0.57	-0.44	Height;	chr11:49594250	chr11:89639227~89698718:+
OV	trans	rs7395662	0.782	rs4882064	ENSG00000134612.10	FOLH1B	7.29	5.18e-12	4.08e-05	0.53	0.44	HDL cholesterol;	chr11:48434205	chr11:89639227~89698718:+
OV	trans	rs11039798	0.588	rs6485891	ENSG00000134612.10	FOLH1B	7.29	5.18e-12	4.08e-05	0.67	0.44	Axial length;	chr11:48590472	chr11:89639227~89698718:+
OV	trans	rs1814175	0.904	rs7924371	ENSG00000134612.10	FOLH1B	-7.29	5.26e-12	4.14e-05	-0.56	-0.44	Height;	chr11:49599043	chr11:89639227~89698718:+
OV	trans	rs1814175	0.935	rs11040438	ENSG00000134612.10	FOLH1B	-7.29	5.26e-12	4.14e-05	-0.56	-0.44	Height;	chr11:49600969	chr11:89639227~89698718:+
OV	trans	rs1814175	0.935	rs1827017	ENSG00000134612.10	FOLH1B	-7.29	5.26e-12	4.14e-05	-0.56	-0.44	Height;	chr11:49611040	chr11:89639227~89698718:+
OV	trans	rs1814175	0.935	rs7482690	ENSG00000134612.10	FOLH1B	-7.28	5.27e-12	4.14e-05	-0.56	-0.44	Height;	chr11:49627262	chr11:89639227~89698718:+
OV	trans	rs3942852	0.545	rs10838798	ENSG00000134612.10	FOLH1B	-7.28	5.29e-12	4.15e-05	-0.57	-0.44	Acute lymphoblastic leukemia (childhood);	chr11:48069751	chr11:89639227~89698718:+
OV	trans	rs3942852	0.545	rs7395231	ENSG00000134612.10	FOLH1B	-7.28	5.29e-12	4.15e-05	-0.57	-0.44	Acute lymphoblastic leukemia (childhood);	chr11:48070137	chr11:89639227~89698718:+
OV	trans	rs7617480	0.558	rs12715430	ENSG00000197582.5	GPX1P1	7.28	5.38e-12	4.22e-05	0.62	0.44	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48905422	chrX:13378735~13379340:-
OV	trans	rs877636	0.702	rs773109	ENSG00000234192.1	RP11-57C13.5	7.28	5.45e-12	4.27e-05	0.45	0.44	Cognitive function;	chr12:55980911	chr10:87642607~87642954:+
OV	trans	rs7121616	0.545	rs7109336	ENSG00000241478.1	HSPA8P9	7.28	5.57e-12	4.36e-05	0.55	0.43	Breast cancer;	chr11:123056530	chr3:137880295~137882237:+
OV	trans	rs7121616	0.576	rs7948948	ENSG00000241478.1	HSPA8P9	7.28	5.57e-12	4.36e-05	0.55	0.43	Breast cancer;	chr11:123057467	chr3:137880295~137882237:+
OV	trans	rs9858542	0.953	rs35115732	ENSG00000197582.5	GPX1P1	-7.27	5.66e-12	4.42e-05	-0.59	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49437722	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs9841110	ENSG00000197582.5	GPX1P1	-7.27	5.66e-12	4.42e-05	-0.59	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49455048	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs7622302	ENSG00000197582.5	GPX1P1	-7.27	5.66e-12	4.42e-05	-0.59	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49510128	chrX:13378735~13379340:-
OV	trans	rs11220082	0.666	rs12223186	ENSG00000236257.1	EI24P2	-7.27	5.69e-12	4.45e-05	-0.57	-0.43	Schizophrenia;	chr11:125461743	chr1:158454198~158455273:+
OV	trans	rs10242455	0.702	rs59574285	ENSG00000228834.1	RP11-249L21.4	7.27	5.74e-12	4.48e-05	0.96	0.43	Blood metabolite levels;	chr7:99638528	chr6:108907615~108907873:-
OV	trans	rs10242455	0.702	rs6956305	ENSG00000228834.1	RP11-249L21.4	7.27	5.74e-12	4.48e-05	0.96	0.43	Blood metabolite levels;	chr7:99643687	chr6:108907615~108907873:-
OV	trans	rs10242455	0.702	rs73713580	ENSG00000228834.1	RP11-249L21.4	7.27	5.74e-12	4.48e-05	0.96	0.43	Blood metabolite levels;	chr7:99643987	chr6:108907615~108907873:-
OV	trans	rs10242455	0.702	rs6976017	ENSG00000228834.1	RP11-249L21.4	7.27	5.74e-12	4.48e-05	0.96	0.43	Blood metabolite levels;	chr7:99652376	chr6:108907615~108907873:-
OV	trans	rs877636	0.702	rs773109	ENSG00000242206.2	RPS26P35	7.26	5.97e-12	4.65e-05	0.45	0.43	Cognitive function;	chr12:55980911	chr8:118761856~118762201:-
OV	trans	rs9858542	0.953	rs4625	ENSG00000197582.5	GPX1P1	-7.26	6e-12	4.67e-05	-0.59	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49534707	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs3811697	ENSG00000197582.5	GPX1P1	-7.26	6e-12	4.67e-05	-0.59	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49553337	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs9837027	ENSG00000197582.5	GPX1P1	-7.26	6e-12	4.67e-05	-0.59	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49559580	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs9858280	ENSG00000197582.5	GPX1P1	-7.26	6e-12	4.67e-05	-0.59	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49560304	chrX:13378735~13379340:-
OV	trans	rs7647973	0.807	rs4955416	ENSG00000197582.5	GPX1P1	7.26	6.03e-12	4.69e-05	0.62	0.43	Menarche (age at onset);	chr3:49070995	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs11713474	ENSG00000197582.5	GPX1P1	-7.26	6.06e-12	4.71e-05	-0.59	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49574024	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs71324979	ENSG00000197582.5	GPX1P1	-7.26	6.06e-12	4.71e-05	-0.59	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49582218	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs9811982	ENSG00000197582.5	GPX1P1	-7.26	6.06e-12	4.71e-05	-0.59	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49586944	chrX:13378735~13379340:-
OV	trans	rs9858542	0.903	rs9875617	ENSG00000197582.5	GPX1P1	-7.26	6.06e-12	4.71e-05	-0.59	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49597263	chrX:13378735~13379340:-
OV	trans	rs7121616	0.531	rs1461497	ENSG00000241478.1	HSPA8P9	7.26	6.13e-12	4.76e-05	0.55	0.43	Breast cancer;	chr11:123060505	chr3:137880295~137882237:+
OV	trans	rs7121616	0.531	rs41361350	ENSG00000241478.1	HSPA8P9	7.26	6.13e-12	4.76e-05	0.55	0.43	Breast cancer;	chr11:123060917	chr3:137880295~137882237:+
OV	trans	rs7312770	0.612	rs1873914	ENSG00000226339.1	RPS26P56	7.26	6.22e-12	4.82e-05	0.43	0.43	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chrX:129408382~129408621:+
OV	trans	rs9858542	0.953	rs11711485	ENSG00000197582.5	GPX1P1	-7.24	6.99e-12	5.41e-05	-0.59	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49454550	chrX:13378735~13379340:-
OV	trans	rs7647973	1	rs6805609	ENSG00000197582.5	GPX1P1	-7.24	7.06e-12	5.46e-05	-0.65	-0.43	Menarche (age at onset);	chr3:49434089	chrX:13378735~13379340:-
OV	trans	rs7554511	0.929	rs55757739	ENSG00000244144.1	RP11-757F18.3	-7.23	7.1e-12	5.49e-05	-0.61	-0.43	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200997848	chr3:112185480~112185998:-
OV	trans	rs1814175	0.867	rs7926002	ENSG00000134612.10	FOLH1B	-7.23	7.14e-12	5.51e-05	-0.56	-0.43	Height;	chr11:49594466	chr11:89639227~89698718:+
OV	trans	rs7554511	0.825	rs11576681	ENSG00000244144.1	RP11-757F18.3	-7.23	7.16e-12	5.53e-05	-0.59	-0.43	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201034923	chr3:112185480~112185998:-
OV	trans	rs2727020	0.553	rs3862350	ENSG00000134612.10	FOLH1B	-7.23	7.21e-12	5.57e-05	-0.55	-0.43	Coronary artery disease;	chr11:49574360	chr11:89639227~89698718:+
OV	trans	rs877636	0.702	rs773110	ENSG00000234192.1	RP11-57C13.5	7.23	7.32e-12	5.65e-05	0.44	0.43	Cognitive function;	chr12:55981353	chr10:87642607~87642954:+
OV	trans	rs877636	0.74	rs772920	ENSG00000234192.1	RP11-57C13.5	7.23	7.37e-12	5.69e-05	0.45	0.43	Cognitive function;	chr12:55996580	chr10:87642607~87642954:+
OV	trans	rs7647973	0.769	rs4974081	ENSG00000197582.5	GPX1P1	-7.23	7.39e-12	5.7e-05	-0.61	-0.43	Menarche (age at onset);	chr3:49033066	chrX:13378735~13379340:-
OV	trans	rs9858542	0.903	rs35999162	ENSG00000197582.5	GPX1P1	-7.23	7.46e-12	5.74e-05	-0.59	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49559797	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs11926781	ENSG00000197582.5	GPX1P1	-7.23	7.48e-12	5.76e-05	-0.59	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49565856	chrX:13378735~13379340:-
OV	trans	rs13091206	1	rs13091206	ENSG00000197582.5	GPX1P1	7.22	7.57e-12	5.83e-05	0.66	0.43	Mean corpuscular volume;Mean corpuscular hemoglobin;	chr3:49201285	chrX:13378735~13379340:-
OV	trans	rs11220082	0.627	rs34912904	ENSG00000236257.1	EI24P2	-7.22	7.95e-12	6.1e-05	-0.56	-0.43	Schizophrenia;	chr11:125475460	chr1:158454198~158455273:+
OV	trans	rs7121616	0.545	rs7109348	ENSG00000241478.1	HSPA8P9	7.21	8.36e-12	6.39e-05	0.54	0.43	Breast cancer;	chr11:123056555	chr3:137880295~137882237:+
OV	trans	rs7121616	0.576	rs7949127	ENSG00000241478.1	HSPA8P9	7.21	8.36e-12	6.39e-05	0.54	0.43	Breast cancer;	chr11:123057408	chr3:137880295~137882237:+
OV	trans	rs7121616	0.576	rs7949220	ENSG00000241478.1	HSPA8P9	7.21	8.36e-12	6.39e-05	0.54	0.43	Breast cancer;	chr11:123057418	chr3:137880295~137882237:+
OV	trans	rs1568889	0.838	rs7943538	ENSG00000174912.7	METTL15P1	7.2	8.5e-12	6.49e-05	0.47	0.43	Bipolar disorder;	chr11:28267408	chr3:156713884~156714928:-
OV	trans	rs877636	1	rs2292239	ENSG00000244604.1	RP11-713H12.1	7.2	8.58e-12	6.56e-05	0.47	0.43	Cognitive function;	chr12:56088396	chr17:8561230~8561576:+
OV	trans	rs9858542	0.953	rs11922013	ENSG00000197582.5	GPX1P1	-7.2	8.74e-12	6.67e-05	-0.59	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49420922	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs6446272	ENSG00000197582.5	GPX1P1	-7.2	8.74e-12	6.67e-05	-0.59	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49425854	chrX:13378735~13379340:-
OV	trans	rs877636	1	rs705696	ENSG00000244604.1	RP11-713H12.1	7.2	8.74e-12	6.67e-05	0.48	0.43	Cognitive function;	chr12:56086864	chr17:8561230~8561576:+
OV	trans	rs673253	0.557	rs34898652	ENSG00000231007.5	CDC20P1	7.2	8.89e-12	6.78e-05	0.57	0.43	Intelligence (multi-trait analysis);	chr1:43508420	chr9:87011652~87013151:+
OV	trans	rs9858542	0.953	rs7633271	ENSG00000197582.5	GPX1P1	-7.2	8.92e-12	6.8e-05	-0.58	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49518530	chrX:13378735~13379340:-
OV	trans	rs10242455	0.702	rs6977165	ENSG00000228834.1	RP11-249L21.4	7.19	9.06e-12	6.9e-05	0.96	0.43	Blood metabolite levels;	chr7:99671774	chr6:108907615~108907873:-
OV	trans	rs877636	0.702	rs61937249	ENSG00000242206.2	RPS26P35	7.19	9.1e-12	6.93e-05	0.45	0.43	Cognitive function;	chr12:55988132	chr8:118761856~118762201:-
OV	trans	rs7647973	0.961	rs11130186	ENSG00000197582.5	GPX1P1	7.18	9.85e-12	7.48e-05	0.58	0.43	Menarche (age at onset);	chr3:49238395	chrX:13378735~13379340:-
OV	trans	rs7647973	0.769	rs11130181	ENSG00000197582.5	GPX1P1	7.18	9.87e-12	7.49e-05	0.6	0.43	Menarche (age at onset);	chr3:49072486	chrX:13378735~13379340:-
OV	trans	rs7121616	0.545	rs7109336	ENSG00000234176.1	HSPA8P1	7.18	9.92e-12	7.53e-05	0.56	0.43	Breast cancer;	chr11:123056530	chrX:121203182~121205014:-
OV	trans	rs7121616	0.576	rs7948948	ENSG00000234176.1	HSPA8P1	7.18	9.92e-12	7.53e-05	0.56	0.43	Breast cancer;	chr11:123057467	chrX:121203182~121205014:-
OV	trans	rs7121616	0.576	rs1064585	ENSG00000241478.1	HSPA8P9	7.18	1e-11	7.61e-05	0.54	0.43	Breast cancer;	chr11:123058699	chr3:137880295~137882237:+
OV	trans	rs877636	0.702	rs773111	ENSG00000242206.2	RPS26P35	7.17	1.02e-11	7.7e-05	0.45	0.43	Cognitive function;	chr12:55981956	chr8:118761856~118762201:-
OV	trans	rs877636	0.702	rs773112	ENSG00000242206.2	RPS26P35	7.17	1.02e-11	7.7e-05	0.45	0.43	Cognitive function;	chr12:55982097	chr8:118761856~118762201:-
OV	trans	rs877636	0.702	rs773110	ENSG00000239210.2	RPS26P55	7.17	1.02e-11	7.73e-05	0.44	0.43	Cognitive function;	chr12:55981353	chr19:34533427~34534084:-
OV	trans	rs7647973	0.925	rs6446256	ENSG00000197582.5	GPX1P1	7.17	1.03e-11	7.83e-05	0.58	0.43	Menarche (age at onset);	chr3:49186777	chrX:13378735~13379340:-
OV	trans	rs7395662	1	rs7482176	ENSG00000134612.10	FOLH1B	-7.17	1.04e-11	7.84e-05	-0.52	-0.43	HDL cholesterol;	chr11:48583068	chr11:89639227~89698718:+
OV	trans	rs7121616	0.595	rs7941144	ENSG00000234176.1	HSPA8P1	7.17	1.04e-11	7.89e-05	0.5	0.43	Breast cancer;	chr11:123079805	chrX:121203182~121205014:-
OV	trans	rs7312770	1	rs7312770	ENSG00000239210.2	RPS26P55	-7.17	1.06e-11	8.02e-05	-0.42	-0.43	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr19:34533427~34534084:-
OV	trans	rs9858542	0.903	rs11921590	ENSG00000197582.5	GPX1P1	-7.17	1.06e-11	8.03e-05	-0.59	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49606760	chrX:13378735~13379340:-
OV	trans	rs877636	0.702	rs773110	ENSG00000242206.2	RPS26P35	7.16	1.08e-11	8.17e-05	0.45	0.43	Cognitive function;	chr12:55981353	chr8:118761856~118762201:-
OV	trans	rs7121616	0.531	rs1461497	ENSG00000234176.1	HSPA8P1	7.16	1.08e-11	8.18e-05	0.55	0.43	Breast cancer;	chr11:123060505	chrX:121203182~121205014:-
OV	trans	rs7121616	0.531	rs41361350	ENSG00000234176.1	HSPA8P1	7.16	1.08e-11	8.18e-05	0.55	0.43	Breast cancer;	chr11:123060917	chrX:121203182~121205014:-
OV	trans	rs9858542	0.953	rs9859556	ENSG00000197582.5	GPX1P1	-7.16	1.09e-11	8.23e-05	-0.59	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49418553	chrX:13378735~13379340:-
OV	trans	rs877636	0.702	rs773109	ENSG00000239210.2	RPS26P55	7.16	1.1e-11	8.3e-05	0.44	0.43	Cognitive function;	chr12:55980911	chr19:34533427~34534084:-
OV	trans	rs877636	0.74	rs705702	ENSG00000219993.1	RP11-288G3.3	-7.16	1.11e-11	8.37e-05	-0.43	-0.43	Cognitive function;	chr12:55996852	chr6:7506203~7506549:+
OV	trans	rs9858542	0.953	rs1801143	ENSG00000197582.5	GPX1P1	-7.15	1.15e-11	8.63e-05	-0.57	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49532767	chrX:13378735~13379340:-
OV	trans	rs7121616	0.545	rs7109348	ENSG00000234176.1	HSPA8P1	7.15	1.16e-11	8.72e-05	0.55	0.43	Breast cancer;	chr11:123056555	chrX:121203182~121205014:-
OV	trans	rs7121616	0.576	rs7949127	ENSG00000234176.1	HSPA8P1	7.15	1.16e-11	8.72e-05	0.55	0.43	Breast cancer;	chr11:123057408	chrX:121203182~121205014:-
OV	trans	rs7121616	0.576	rs7949220	ENSG00000234176.1	HSPA8P1	7.15	1.16e-11	8.72e-05	0.55	0.43	Breast cancer;	chr11:123057418	chrX:121203182~121205014:-
OV	trans	rs3942852	0.568	rs10769313	ENSG00000134612.10	FOLH1B	-7.15	1.21e-11	9.09e-05	-0.56	-0.43	Acute lymphoblastic leukemia (childhood);	chr11:48075914	chr11:89639227~89698718:+
OV	trans	rs3942852	0.568	rs10769314	ENSG00000134612.10	FOLH1B	-7.15	1.21e-11	9.09e-05	-0.56	-0.43	Acute lymphoblastic leukemia (childhood);	chr11:48076068	chr11:89639227~89698718:+
OV	trans	rs3942852	0.568	rs1039484	ENSG00000134612.10	FOLH1B	-7.15	1.21e-11	9.09e-05	-0.56	-0.43	Acute lymphoblastic leukemia (childhood);	chr11:48076396	chr11:89639227~89698718:+
OV	trans	rs3942852	0.594	rs10769311	ENSG00000134612.10	FOLH1B	-7.14	1.22e-11	9.13e-05	-0.56	-0.43	Acute lymphoblastic leukemia (childhood);	chr11:48072457	chr11:89639227~89698718:+
OV	trans	rs3942852	0.568	rs10838800	ENSG00000134612.10	FOLH1B	-7.14	1.22e-11	9.13e-05	-0.56	-0.43	Acute lymphoblastic leukemia (childhood);	chr11:48073327	chr11:89639227~89698718:+
OV	trans	rs7554511	0.858	rs12140420	ENSG00000244144.1	RP11-757F18.3	-7.14	1.22e-11	9.13e-05	-0.59	-0.43	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200993159	chr3:112185480~112185998:-
OV	trans	rs10242455	0.702	rs55927283	ENSG00000228834.1	RP11-249L21.4	7.14	1.27e-11	9.45e-05	0.94	0.43	Blood metabolite levels;	chr7:99459568	chr6:108907615~108907873:-
OV	trans	rs877636	0.702	rs61937249	ENSG00000219993.1	RP11-288G3.3	7.14	1.28e-11	9.54e-05	0.43	0.43	Cognitive function;	chr12:55988132	chr6:7506203~7506549:+
OV	trans	rs9858542	0.903	rs11917431	ENSG00000197582.5	GPX1P1	-7.13	1.3e-11	9.66e-05	-0.59	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49606579	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs10640	ENSG00000197582.5	GPX1P1	-7.13	1.32e-11	9.79e-05	-0.58	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49416844	chrX:13378735~13379340:-
OV	trans	rs877636	0.692	rs11171739	ENSG00000244641.2	RPS26P43	7.13	1.35e-11	1e-04	0.44	0.43	Cognitive function;	chr12:56076841	chr11:123049787~123050353:-
OV	trans	rs7121616	0.576	rs1064585	ENSG00000234176.1	HSPA8P1	7.12	1.37e-11	0.000102	0.55	0.43	Breast cancer;	chr11:123058699	chrX:121203182~121205014:-
OV	trans	rs3942852	0.568	rs2904315	ENSG00000134612.10	FOLH1B	7.12	1.4e-11	0.000104	0.57	0.43	Acute lymphoblastic leukemia (childhood);	chr11:48088396	chr11:89639227~89698718:+
OV	trans	rs7647973	0.961	rs10154992	ENSG00000197582.5	GPX1P1	7.12	1.44e-11	0.000107	0.57	0.43	Menarche (age at onset);	chr3:49238644	chrX:13378735~13379340:-
OV	trans	rs148734725	1	rs148734725	ENSG00000197582.5	GPX1P1	-7.11	1.46e-11	0.000107	-0.58	-0.43	Educational attainment (college completion);	chr3:49369275	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs34588335	ENSG00000197582.5	GPX1P1	-7.11	1.46e-11	0.000107	-0.58	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49370227	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs6809216	ENSG00000197582.5	GPX1P1	-7.11	1.46e-11	0.000107	-0.58	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49375126	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs7623659	ENSG00000197582.5	GPX1P1	-7.11	1.46e-11	0.000107	-0.58	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49377358	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs7648841	ENSG00000197582.5	GPX1P1	-7.11	1.46e-11	0.000107	-0.58	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49379392	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs6446264	ENSG00000197582.5	GPX1P1	-7.11	1.46e-11	0.000107	-0.58	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49379810	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs35169793	ENSG00000197582.5	GPX1P1	-7.11	1.46e-11	0.000107	-0.58	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49385841	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs9878943	ENSG00000197582.5	GPX1P1	-7.11	1.46e-11	0.000107	-0.58	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49397221	chrX:13378735~13379340:-
OV	trans	rs7617480	0.585	rs7373072	ENSG00000197582.5	GPX1P1	7.11	1.48e-11	0.000109	0.61	0.43	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48922584	chrX:13378735~13379340:-
OV	trans	rs877636	0.669	rs7297175	ENSG00000226339.1	RPS26P56	-7.1	1.59e-11	0.000116	-0.43	-0.43	Cognitive function;	chr12:56080024	chrX:129408382~129408621:+
OV	trans	rs7617480	0.648	rs6766238	ENSG00000197582.5	GPX1P1	7.1	1.6e-11	0.000118	0.6	0.43	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48764496	chrX:13378735~13379340:-
OV	trans	rs7617480	0.549	rs9879978	ENSG00000197582.5	GPX1P1	7.1	1.63e-11	0.000119	0.6	0.43	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48809167	chrX:13378735~13379340:-
OV	trans	rs3942852	0.568	rs4412719	ENSG00000134612.10	FOLH1B	-7.09	1.67e-11	0.000122	-0.55	-0.43	Acute lymphoblastic leukemia (childhood);	chr11:48080108	chr11:89639227~89698718:+
OV	trans	rs9858542	0.953	rs6779524	ENSG00000197582.5	GPX1P1	-7.09	1.7e-11	0.000124	-0.58	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49413016	chrX:13378735~13379340:-
OV	trans	rs877636	0.702	rs61937249	ENSG00000239210.2	RPS26P55	7.08	1.8e-11	0.000131	0.43	0.43	Cognitive function;	chr12:55988132	chr19:34533427~34534084:-
OV	trans	rs9858542	0.951	rs1800668	ENSG00000197582.5	GPX1P1	-7.08	1.82e-11	0.000133	-0.58	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49358324	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs1987628	ENSG00000197582.5	GPX1P1	-7.08	1.82e-11	0.000133	-0.58	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49361826	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs11706370	ENSG00000197582.5	GPX1P1	-7.08	1.82e-11	0.000133	-0.58	-0.43	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49403658	chrX:13378735~13379340:-
OV	trans	rs7554511	0.858	rs11583328	ENSG00000244144.1	RP11-757F18.3	7.07	1.88e-11	0.000136	0.57	0.42	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201033045	chr3:112185480~112185998:-
OV	trans	rs7647973	0.961	rs56324858	ENSG00000197582.5	GPX1P1	-7.07	1.9e-11	0.000138	-0.65	-0.42	Menarche (age at onset);	chr3:49506796	chrX:13378735~13379340:-
OV	trans	rs11220082	0.602	rs10893383	ENSG00000236257.1	EI24P2	-7.06	1.99e-11	0.000144	-0.55	-0.42	Schizophrenia;	chr11:125466237	chr1:158454198~158455273:+
OV	trans	rs877636	0.74	rs705702	ENSG00000239210.2	RPS26P55	-7.06	2.03e-11	0.000147	-0.44	-0.42	Cognitive function;	chr12:55996852	chr19:34533427~34534084:-
OV	trans	rs7617480	0.648	rs4974083	ENSG00000197582.5	GPX1P1	7.05	2.09e-11	0.000151	0.62	0.42	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48963193	chrX:13378735~13379340:-
OV	trans	rs7647973	0.769	rs6446204	ENSG00000197582.5	GPX1P1	7.05	2.09e-11	0.000151	0.62	0.42	Menarche (age at onset);	chr3:48997446	chrX:13378735~13379340:-
OV	trans	rs3942852	0.568	rs6485807	ENSG00000134612.10	FOLH1B	-7.05	2.12e-11	0.000153	-0.55	-0.42	Acute lymphoblastic leukemia (childhood);	chr11:48081315	chr11:89639227~89698718:+
OV	trans	rs877636	0.702	rs773111	ENSG00000239210.2	RPS26P55	7.05	2.13e-11	0.000153	0.43	0.42	Cognitive function;	chr12:55981956	chr19:34533427~34534084:-
OV	trans	rs877636	0.702	rs773112	ENSG00000239210.2	RPS26P55	7.05	2.13e-11	0.000153	0.43	0.42	Cognitive function;	chr12:55982097	chr19:34533427~34534084:-
OV	trans	rs8010715	0.848	rs8009511	ENSG00000248988.1	RP11-815N9.2	7.05	2.16e-11	0.000155	0.53	0.42	IgG glycosylation;	chr14:24124771	chr4:159007119~159007835:+
OV	trans	rs8010715	0.804	rs1134334	ENSG00000248988.1	RP11-815N9.2	7.05	2.16e-11	0.000155	0.53	0.42	IgG glycosylation;	chr14:24124905	chr4:159007119~159007835:+
OV	trans	rs877636	0.74	rs772920	ENSG00000219993.1	RP11-288G3.3	7.05	2.18e-11	0.000156	0.43	0.42	Cognitive function;	chr12:55996580	chr6:7506203~7506549:+
OV	trans	rs9858542	0.953	rs3811699	ENSG00000197582.5	GPX1P1	-7.05	2.19e-11	0.000157	-0.58	-0.42	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49358927	chrX:13378735~13379340:-
OV	trans	rs7554511	0.894	rs11579874	ENSG00000244144.1	RP11-757F18.3	7.03	2.36e-11	0.000168	0.56	0.42	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200951234	chr3:112185480~112185998:-
OV	trans	rs877636	1	rs705696	ENSG00000234192.1	RP11-57C13.5	7.03	2.4e-11	0.000171	0.45	0.42	Cognitive function;	chr12:56086864	chr10:87642607~87642954:+
OV	trans	rs10838801	1	rs10838801	ENSG00000134612.10	FOLH1B	-7.03	2.42e-11	0.000172	-0.55	-0.42	Height;	chr11:48076728	chr11:89639227~89698718:+
OV	trans	rs9329221	0.967	rs7005363	ENSG00000253981.4	ALG1L13P	-7.02	2.57e-11	0.000183	-0.44	-0.42	Neuroticism;	chr8:10426238	chr8:8236003~8244667:-
OV	trans	rs7395662	0.745	rs10838830	ENSG00000134612.10	FOLH1B	7.01	2.63e-11	0.000187	0.52	0.42	HDL cholesterol;	chr11:48212380	chr11:89639227~89698718:+
OV	trans	rs7647973	0.961	rs7619016	ENSG00000197582.5	GPX1P1	7.01	2.65e-11	0.000188	0.56	0.42	Menarche (age at onset);	chr3:49235156	chrX:13378735~13379340:-
OV	trans	rs7554511	0.825	rs12122809	ENSG00000244144.1	RP11-757F18.3	-7.01	2.7e-11	0.000192	-0.57	-0.42	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201045838	chr3:112185480~112185998:-
OV	trans	rs877636	0.702	rs773111	ENSG00000219993.1	RP11-288G3.3	7.01	2.7e-11	0.000192	0.42	0.42	Cognitive function;	chr12:55981956	chr6:7506203~7506549:+
OV	trans	rs877636	0.702	rs773112	ENSG00000219993.1	RP11-288G3.3	7.01	2.7e-11	0.000192	0.42	0.42	Cognitive function;	chr12:55982097	chr6:7506203~7506549:+
OV	trans	rs1568889	0.838	rs12273631	ENSG00000174912.7	METTL15P1	7	2.82e-11	2e-04	0.49	0.42	Bipolar disorder;	chr11:28020588	chr3:156713884~156714928:-
OV	trans	rs7554511	0.894	rs11589638	ENSG00000244144.1	RP11-757F18.3	-7	2.85e-11	0.000201	-0.58	-0.42	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200925807	chr3:112185480~112185998:-
OV	trans	rs1568889	0.838	rs11030187	ENSG00000174912.7	METTL15P1	7	2.87e-11	0.000203	0.48	0.42	Bipolar disorder;	chr11:28022844	chr3:156713884~156714928:-
OV	trans	rs877636	0.702	rs773110	ENSG00000219993.1	RP11-288G3.3	6.99	2.99e-11	0.000211	0.42	0.42	Cognitive function;	chr12:55981353	chr6:7506203~7506549:+
OV	trans	rs877636	0.701	rs34415530	ENSG00000234192.1	RP11-57C13.5	6.99	3.06e-11	0.000216	0.44	0.42	Cognitive function;	chr12:56050848	chr10:87642607~87642954:+
OV	trans	rs11220082	0.666	rs35203305	ENSG00000236257.1	EI24P2	-6.98	3.23e-11	0.000227	-0.55	-0.42	Schizophrenia;	chr11:125468987	chr1:158454198~158455273:+
OV	trans	rs11220082	0.666	rs12224788	ENSG00000236257.1	EI24P2	-6.98	3.29e-11	0.000231	-0.53	-0.42	Schizophrenia;	chr11:125459165	chr1:158454198~158455273:+
OV	trans	rs7554511	0.893	rs6427868	ENSG00000244144.1	RP11-757F18.3	-6.98	3.3e-11	0.000231	-0.59	-0.42	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200960354	chr3:112185480~112185998:-
OV	trans	rs11098499	0.866	rs10518329	ENSG00000275858.1	RP11-291L22.8	6.98	3.31e-11	0.000232	0.43	0.42	Corneal astigmatism;	chr4:119480680	chr10:38450738~38451069:-
OV	trans	rs11220082	0.644	rs34435097	ENSG00000236257.1	EI24P2	-6.97	3.48e-11	0.000243	-0.55	-0.42	Schizophrenia;	chr11:125469075	chr1:158454198~158455273:+
OV	trans	rs2069408	1	rs2069408	ENSG00000239210.2	RPS26P55	-6.96	3.53e-11	0.000247	-0.44	-0.42	Asthma;	chr12:55970537	chr19:34533427~34534084:-
OV	trans	rs7554511	0.763	rs3913893	ENSG00000244144.1	RP11-757F18.3	-6.96	3.56e-11	0.000249	-0.56	-0.42	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201046655	chr3:112185480~112185998:-
OV	trans	rs8010715	0.848	rs2277483	ENSG00000248988.1	RP11-815N9.2	6.96	3.65e-11	0.000254	0.53	0.42	IgG glycosylation;	chr14:24122683	chr4:159007119~159007835:+
OV	trans	rs2727020	0.638	rs1164668	ENSG00000134612.10	FOLH1B	6.96	3.71e-11	0.000258	0.53	0.42	Coronary artery disease;	chr11:49309075	chr11:89639227~89698718:+
OV	trans	rs10242455	0.702	rs3823813	ENSG00000228834.1	RP11-249L21.4	6.96	3.72e-11	0.000259	1	0.42	Blood metabolite levels;	chr7:99451766	chr6:108907615~108907873:-
OV	trans	rs1568889	0.838	rs11030185	ENSG00000174912.7	METTL15P1	6.95	3.73e-11	0.000259	0.49	0.42	Bipolar disorder;	chr11:28020357	chr3:156713884~156714928:-
OV	trans	rs7554511	0.858	rs6701496	ENSG00000244144.1	RP11-757F18.3	-6.95	3.75e-11	0.000261	-0.58	-0.42	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201038700	chr3:112185480~112185998:-
OV	trans	rs877636	0.701	rs34415530	ENSG00000242206.2	RPS26P35	6.95	3.9e-11	0.000271	0.45	0.42	Cognitive function;	chr12:56050848	chr8:118761856~118762201:-
OV	trans	rs9858542	0.953	rs6997	ENSG00000197582.5	GPX1P1	-6.94	4.09e-11	0.000283	-0.57	-0.42	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49416401	chrX:13378735~13379340:-
OV	trans	rs11220082	0.666	rs7103665	ENSG00000236257.1	EI24P2	-6.93	4.33e-11	0.000299	-0.55	-0.42	Schizophrenia;	chr11:125472998	chr1:158454198~158455273:+
OV	trans	rs11220082	0.644	rs61917855	ENSG00000236257.1	EI24P2	-6.93	4.33e-11	0.000299	-0.55	-0.42	Schizophrenia;	chr11:125473652	chr1:158454198~158455273:+
OV	trans	rs2898290	0.506	rs2736311	ENSG00000253893.2	FAM85B	6.92	4.44e-11	0.000305	0.45	0.42	Systolic blood pressure;	chr8:11394661	chr8:8167819~8226614:-
OV	trans	rs7554511	0.763	rs55734382	ENSG00000244144.1	RP11-757F18.3	-6.92	4.57e-11	0.000314	-0.56	-0.42	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201049931	chr3:112185480~112185998:-
OV	trans	rs9858542	0.903	rs17080528	ENSG00000197582.5	GPX1P1	-6.92	4.61e-11	0.000316	-0.57	-0.42	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49352409	chrX:13378735~13379340:-
OV	trans	rs7617480	0.648	rs9284885	ENSG00000197582.5	GPX1P1	6.92	4.62e-11	0.000317	0.59	0.42	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48845667	chrX:13378735~13379340:-
OV	trans	rs616147	0.627	rs816487	ENSG00000214263.2	RPSAP53	-6.92	4.64e-11	0.000318	-0.54	-0.42	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39445999	chr13:67266845~67267706:-
OV	trans	rs877636	1	rs2292239	ENSG00000234192.1	RP11-57C13.5	6.91	4.73e-11	0.000324	0.43	0.42	Cognitive function;	chr12:56088396	chr10:87642607~87642954:+
OV	trans	rs7554511	0.858	rs7539693	ENSG00000244144.1	RP11-757F18.3	-6.91	4.86e-11	0.000332	-0.59	-0.42	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200986438	chr3:112185480~112185998:-
OV	trans	rs7554511	0.893	rs10494828	ENSG00000244144.1	RP11-757F18.3	-6.91	4.86e-11	0.000332	-0.59	-0.42	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200987904	chr3:112185480~112185998:-
OV	trans	rs877636	0.702	rs773109	ENSG00000219993.1	RP11-288G3.3	6.91	4.97e-11	0.000339	0.42	0.42	Cognitive function;	chr12:55980911	chr6:7506203~7506549:+
OV	trans	rs7647973	0.89	rs73073004	ENSG00000197582.5	GPX1P1	-6.91	4.97e-11	0.000339	-0.65	-0.42	Menarche (age at onset);	chr3:49452587	chrX:13378735~13379340:-
OV	trans	rs7617480	0.648	rs6801211	ENSG00000197582.5	GPX1P1	6.91	4.98e-11	0.000339	0.59	0.42	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48736987	chrX:13378735~13379340:-
OV	trans	rs7617480	0.648	rs6796790	ENSG00000197582.5	GPX1P1	6.91	4.98e-11	0.000339	0.59	0.42	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48742884	chrX:13378735~13379340:-
OV	trans	rs2727020	0.702	rs609054	ENSG00000134612.10	FOLH1B	6.9	5.01e-11	0.000341	0.52	0.42	Coronary artery disease;	chr11:49198173	chr11:89639227~89698718:+
OV	trans	rs7647973	0.731	rs13084037	ENSG00000197582.5	GPX1P1	6.9	5.05e-11	0.000344	0.61	0.42	Menarche (age at onset);	chr3:49176633	chrX:13378735~13379340:-
OV	trans	rs11220237	0.688	rs3913027	ENSG00000236257.1	EI24P2	6.9	5.13e-11	0.000349	0.66	0.42	Itch intensity from mosquito bite adjusted by bite size;	chr11:125735038	chr1:158454198~158455273:+
OV	trans	rs2727020	0.729	rs685789	ENSG00000134612.10	FOLH1B	6.89	5.55e-11	0.000376	0.53	0.42	Coronary artery disease;	chr11:49219676	chr11:89639227~89698718:+
OV	trans	rs11098499	0.954	rs11098524	ENSG00000275858.1	RP11-291L22.8	6.89	5.59e-11	0.000378	0.43	0.42	Corneal astigmatism;	chr4:119468877	chr10:38450738~38451069:-
OV	trans	rs877636	0.692	rs10876870	ENSG00000226339.1	RPS26P56	-6.87	6.05e-11	0.000408	-0.42	-0.41	Cognitive function;	chr12:56084218	chrX:129408382~129408621:+
OV	trans	rs877636	0.692	rs7971751	ENSG00000226339.1	RPS26P56	-6.87	6.05e-11	0.000408	-0.42	-0.41	Cognitive function;	chr12:56084874	chrX:129408382~129408621:+
OV	trans	rs11220237	0.544	rs10893412	ENSG00000236257.1	EI24P2	-6.87	6.08e-11	0.00041	-0.6	-0.41	Itch intensity from mosquito bite adjusted by bite size;	chr11:125669307	chr1:158454198~158455273:+
OV	trans	rs13090388	1	rs13090388	ENSG00000197582.5	GPX1P1	-6.87	6.14e-11	0.000413	-0.57	-0.41	Educational attainment (years of education);Intelligence (multi-trait analysis);	chr3:49353649	chrX:13378735~13379340:-
OV	trans	rs7395662	0.525	rs1945189	ENSG00000134612.10	FOLH1B	-6.87	6.19e-11	0.000416	-0.53	-0.41	HDL cholesterol;	chr11:48397337	chr11:89639227~89698718:+
OV	trans	rs11220237	0.764	rs9943542	ENSG00000236257.1	EI24P2	6.86	6.3e-11	0.000423	0.66	0.41	Itch intensity from mosquito bite adjusted by bite size;	chr11:125707970	chr1:158454198~158455273:+
OV	trans	rs2069408	1	rs2069408	ENSG00000233778.3	RP11-777J24.1	-6.86	6.32e-11	0.000425	-0.45	-0.41	Asthma;	chr12:55970537	chr8:92144088~92144435:-
OV	trans	rs3096299	0.685	rs4329923	ENSG00000215030.5	RPL13P12	-6.86	6.47e-11	0.000434	-0.4	-0.41	Multiple myeloma (IgH translocation);	chr16:89493770	chr17:17383377~17384012:-
OV	trans	rs7554511	0.707	rs3767501	ENSG00000244144.1	RP11-757F18.3	6.86	6.49e-11	0.000435	0.54	0.41	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201053951	chr3:112185480~112185998:-
OV	trans	rs877636	0.701	rs34415530	ENSG00000239210.2	RPS26P55	6.86	6.58e-11	0.00044	0.43	0.41	Cognitive function;	chr12:56050848	chr19:34533427~34534084:-
OV	trans	rs2727020	0.729	rs34647977	ENSG00000134612.10	FOLH1B	-6.85	6.67e-11	0.000447	-0.52	-0.41	Coronary artery disease;	chr11:49173991	chr11:89639227~89698718:+
OV	trans	rs7554511	0.858	rs3208703	ENSG00000244144.1	RP11-757F18.3	-6.84	7.21e-11	0.000481	-0.58	-0.41	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200970514	chr3:112185480~112185998:-
OV	trans	rs11220237	0.764	rs34125226	ENSG00000236257.1	EI24P2	6.84	7.29e-11	0.000486	0.65	0.41	Itch intensity from mosquito bite adjusted by bite size;	chr11:125738705	chr1:158454198~158455273:+
OV	trans	rs2950393	0.509	rs10459247	ENSG00000121089.4	NACA3P	-6.83	7.57e-11	0.000504	-0.45	-0.41	Platelet distribution width;	chr12:56777732	chr4:164943290~164943937:+
OV	trans	rs9467773	0.62	rs2101582	ENSG00000242375.1	RP11-498P14.3	6.82	8.06e-11	0.000536	0.49	0.41	Intelligence (multi-trait analysis);	chr6:26622506	chr9:97195351~97197687:-
OV	trans	rs7647973	0.922	rs56049603	ENSG00000197582.5	GPX1P1	-6.82	8.18e-11	0.000543	-0.64	-0.41	Menarche (age at onset);	chr3:49547810	chrX:13378735~13379340:-
OV	trans	rs2727020	0.729	rs1164666	ENSG00000134612.10	FOLH1B	-6.82	8.32e-11	0.000552	-0.52	-0.41	Coronary artery disease;	chr11:49274315	chr11:89639227~89698718:+
OV	trans	rs7617480	0.648	rs7653408	ENSG00000197582.5	GPX1P1	6.81	8.46e-11	0.00056	0.58	0.41	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48934918	chrX:13378735~13379340:-
OV	trans	rs2069408	1	rs2069408	ENSG00000219993.1	RP11-288G3.3	-6.81	8.52e-11	0.000564	-0.42	-0.41	Asthma;	chr12:55970537	chr6:7506203~7506549:+
OV	trans	rs7554511	0.707	rs10800755	ENSG00000244144.1	RP11-757F18.3	6.81	8.68e-11	0.000574	0.54	0.41	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201054852	chr3:112185480~112185998:-
OV	trans	rs7554511	0.707	rs10800756	ENSG00000244144.1	RP11-757F18.3	6.81	8.68e-11	0.000574	0.54	0.41	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201054931	chr3:112185480~112185998:-
OV	trans	rs10242455	0.702	rs73713531	ENSG00000228834.1	RP11-249L21.4	6.8	8.99e-11	0.000593	0.97	0.41	Blood metabolite levels;	chr7:99624756	chr6:108907615~108907873:-
OV	trans	rs7395662	0.926	rs11039893	ENSG00000134612.10	FOLH1B	-6.8	9.01e-11	0.000595	-0.5	-0.41	HDL cholesterol;	chr11:48636202	chr11:89639227~89698718:+
OV	trans	rs2727020	0.729	rs588458	ENSG00000134612.10	FOLH1B	6.8	9.15e-11	0.000603	0.52	0.41	Coronary artery disease;	chr11:49192496	chr11:89639227~89698718:+
OV	trans	rs2727020	0.729	rs4315497	ENSG00000134612.10	FOLH1B	6.8	9.15e-11	0.000603	0.52	0.41	Coronary artery disease;	chr11:49192947	chr11:89639227~89698718:+
OV	trans	rs7554511	0.858	rs10920084	ENSG00000244144.1	RP11-757F18.3	-6.79	9.57e-11	0.000629	-0.54	-0.41	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200993667	chr3:112185480~112185998:-
OV	trans	rs7824557	0.547	rs2409745	ENSG00000253981.4	ALG1L13P	6.79	9.64e-11	0.000634	0.43	0.41	Retinal vascular caliber;	chr8:11219126	chr8:8236003~8244667:-
OV	trans	rs11098499	0.954	rs13145352	ENSG00000275858.1	RP11-291L22.8	-6.79	9.68e-11	0.000636	-0.44	-0.41	Corneal astigmatism;	chr4:119488808	chr10:38450738~38451069:-
OV	trans	rs7647973	0.731	rs7617480	ENSG00000197582.5	GPX1P1	-6.79	9.76e-11	0.000641	-0.59	-0.41	Menarche (age at onset);	chr3:49173299	chrX:13378735~13379340:-
OV	trans	rs7617480	0.648	rs14018	ENSG00000197582.5	GPX1P1	6.79	9.78e-11	0.000642	0.6	0.41	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48746837	chrX:13378735~13379340:-
OV	trans	rs877636	0.669	rs7297175	ENSG00000244641.2	RPS26P43	-6.79	9.85e-11	0.000647	-0.43	-0.41	Cognitive function;	chr12:56080024	chr11:123049787~123050353:-
OV	trans	rs877636	1	rs877636	ENSG00000244604.1	RP11-713H12.1	-6.78	1.04e-10	0.000683	-0.44	-0.41	Cognitive function;	chr12:56086799	chr17:8561230~8561576:+
OV	trans	rs7554511	0.823	rs67602696	ENSG00000244144.1	RP11-757F18.3	-6.77	1.08e-10	0.000702	-0.56	-0.41	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201043809	chr3:112185480~112185998:-
OV	trans	rs616147	0.627	rs9871799	ENSG00000214263.2	RPSAP53	6.77	1.1e-10	0.000718	0.51	0.41	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39442829	chr13:67266845~67267706:-
OV	trans	rs7554511	0.858	rs12118735	ENSG00000244144.1	RP11-757F18.3	-6.76	1.16e-10	0.000751	-0.58	-0.41	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200981832	chr3:112185480~112185998:-
OV	trans	rs3942852	0.568	rs7479361	ENSG00000134612.10	FOLH1B	-6.76	1.17e-10	0.000762	-0.56	-0.41	Acute lymphoblastic leukemia (childhood);	chr11:48088241	chr11:89639227~89698718:+
OV	trans	rs11098499	0.954	rs6849561	ENSG00000275858.1	RP11-291L22.8	-6.76	1.18e-10	0.000765	-0.45	-0.41	Corneal astigmatism;	chr4:119488539	chr10:38450738~38451069:-
OV	trans	rs10242455	0.557	rs2404487	ENSG00000228834.1	RP11-249L21.4	6.75	1.19e-10	0.00077	0.94	0.41	Blood metabolite levels;	chr7:99440434	chr6:108907615~108907873:-
OV	trans	rs10242455	0.702	rs73711280	ENSG00000228834.1	RP11-249L21.4	6.75	1.19e-10	0.00077	0.94	0.41	Blood metabolite levels;	chr7:99441981	chr6:108907615~108907873:-
OV	trans	rs10242455	0.702	rs73397499	ENSG00000228834.1	RP11-249L21.4	6.75	1.19e-10	0.00077	0.94	0.41	Blood metabolite levels;	chr7:99442004	chr6:108907615~108907873:-
OV	trans	rs10242455	0.702	rs45448997	ENSG00000228834.1	RP11-249L21.4	6.75	1.19e-10	0.00077	0.94	0.41	Blood metabolite levels;	chr7:99443975	chr6:108907615~108907873:-
OV	trans	rs10242455	0.557	rs45492501	ENSG00000228834.1	RP11-249L21.4	6.75	1.19e-10	0.00077	0.94	0.41	Blood metabolite levels;	chr7:99449407	chr6:108907615~108907873:-
OV	trans	rs10242455	0.702	rs17854665	ENSG00000228834.1	RP11-249L21.4	6.75	1.19e-10	0.00077	0.94	0.41	Blood metabolite levels;	chr7:99452416	chr6:108907615~108907873:-
OV	trans	rs10242455	0.702	rs45461000	ENSG00000228834.1	RP11-249L21.4	6.75	1.19e-10	0.00077	0.94	0.41	Blood metabolite levels;	chr7:99455087	chr6:108907615~108907873:-
OV	trans	rs11220237	0.764	rs11220207	ENSG00000236257.1	EI24P2	6.75	1.21e-10	0.000781	0.65	0.41	Itch intensity from mosquito bite adjusted by bite size;	chr11:125747298	chr1:158454198~158455273:+
OV	trans	rs7312770	0.612	rs773114	ENSG00000229032.1	RP11-91A18.1	6.75	1.22e-10	0.000789	0.42	0.41	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr1:51980473~51980814:+
OV	trans	rs9858542	1	rs11718165	ENSG00000197582.5	GPX1P1	-6.75	1.24e-10	0.000798	-0.57	-0.41	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49659364	chrX:13378735~13379340:-
OV	trans	rs7399018	0.739	rs7953955	ENSG00000223825.5	DAZAP2P1	6.74	1.33e-10	0.000855	0.67	0.41	Cisplatin-induced ototoxicity;	chr12:51214683	chr2:202201384~202201886:-
OV	trans	rs7395662	0.591	rs4882085	ENSG00000134612.10	FOLH1B	-6.73	1.34e-10	0.000859	-0.53	-0.41	HDL cholesterol;	chr11:48483017	chr11:89639227~89698718:+
OV	trans	rs7395662	0.571	rs4881998	ENSG00000134612.10	FOLH1B	-6.73	1.34e-10	0.000859	-0.53	-0.41	HDL cholesterol;	chr11:48503634	chr11:89639227~89698718:+
OV	trans	rs6477998	0.58	rs3750533	ENSG00000238072.1	RP11-305M3.2	6.73	1.34e-10	0.000861	0.5	0.41	Hematology traits;	chr9:113297941	chr7:129410113~129410370:-
OV	trans	rs2727020	0.688	rs4929894	ENSG00000134612.10	FOLH1B	-6.73	1.35e-10	0.000867	-0.52	-0.41	Coronary artery disease;	chr11:49174781	chr11:89639227~89698718:+
OV	trans	rs2727020	0.731	rs10450572	ENSG00000134612.10	FOLH1B	6.73	1.36e-10	0.000868	0.52	0.41	Coronary artery disease;	chr11:49259521	chr11:89639227~89698718:+
OV	trans	rs2727020	0.729	rs2866328	ENSG00000134612.10	FOLH1B	6.73	1.36e-10	0.000868	0.52	0.41	Coronary artery disease;	chr11:49260869	chr11:89639227~89698718:+
OV	trans	rs7395662	0.611	rs4882089	ENSG00000134612.10	FOLH1B	-6.73	1.36e-10	0.000868	-0.52	-0.41	HDL cholesterol;	chr11:48494060	chr11:89639227~89698718:+
OV	trans	rs7395662	0.591	rs11039776	ENSG00000134612.10	FOLH1B	-6.73	1.36e-10	0.000868	-0.52	-0.41	HDL cholesterol;	chr11:48495154	chr11:89639227~89698718:+
OV	trans	rs8010715	0.848	rs927494	ENSG00000248988.1	RP11-815N9.2	6.73	1.39e-10	0.000892	0.51	0.41	IgG glycosylation;	chr14:24131181	chr4:159007119~159007835:+
OV	trans	rs877636	0.74	rs772920	ENSG00000239210.2	RPS26P55	6.72	1.42e-10	0.000905	0.42	0.41	Cognitive function;	chr12:55996580	chr19:34533427~34534084:-
OV	trans	rs7617480	0.616	rs9873227	ENSG00000197582.5	GPX1P1	6.72	1.45e-10	0.000927	0.59	0.41	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48735675	chrX:13378735~13379340:-
OV	trans	rs7617480	0.616	rs7429596	ENSG00000197582.5	GPX1P1	6.72	1.45e-10	0.000927	0.59	0.41	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48771098	chrX:13378735~13379340:-
OV	trans	rs7617480	0.587	rs9311431	ENSG00000197582.5	GPX1P1	6.72	1.45e-10	0.000927	0.59	0.41	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48811354	chrX:13378735~13379340:-
OV	trans	rs7617480	0.648	rs4974088	ENSG00000197582.5	GPX1P1	6.72	1.45e-10	0.000927	0.59	0.41	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48861316	chrX:13378735~13379340:-
OV	trans	rs11220237	0.764	rs7940086	ENSG00000236257.1	EI24P2	6.72	1.48e-10	0.00094	0.64	0.41	Itch intensity from mosquito bite adjusted by bite size;	chr11:125722518	chr1:158454198~158455273:+
OV	trans	rs877636	0.701	rs34415530	ENSG00000219993.1	RP11-288G3.3	6.72	1.48e-10	0.000942	0.42	0.41	Cognitive function;	chr12:56050848	chr6:7506203~7506549:+
OV	trans	rs2727020	0.688	rs11040338	ENSG00000134612.10	FOLH1B	6.71	1.52e-10	0.000967	0.51	0.41	Coronary artery disease;	chr11:49339049	chr11:89639227~89698718:+
OV	trans	rs10242455	0.702	rs112475236	ENSG00000228834.1	RP11-249L21.4	6.71	1.53e-10	0.000974	0.93	0.41	Blood metabolite levels;	chr7:99447056	chr6:108907615~108907873:-
OV	trans	rs10242455	0.557	rs45529541	ENSG00000228834.1	RP11-249L21.4	6.71	1.53e-10	0.000974	0.93	0.41	Blood metabolite levels;	chr7:99450520	chr6:108907615~108907873:-
OV	trans	rs10242455	0.702	rs3528	ENSG00000228834.1	RP11-249L21.4	6.71	1.53e-10	0.000974	0.93	0.41	Blood metabolite levels;	chr7:99458317	chr6:108907615~108907873:-
OV	trans	rs7395662	0.929	rs10838982	ENSG00000134612.10	FOLH1B	-6.71	1.55e-10	0.000985	-0.49	-0.41	HDL cholesterol;	chr11:48618616	chr11:89639227~89698718:+
OV	trans	rs616147	0.627	rs816510	ENSG00000214263.2	RPSAP53	-6.71	1.57e-10	0.000994	-0.52	-0.41	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39430804	chr13:67266845~67267706:-
OV	trans	rs11098499	0.863	rs1383532	ENSG00000275858.1	RP11-291L22.8	-6.71	1.57e-10	0.000996	-0.45	-0.41	Corneal astigmatism;	chr4:119513249	chr10:38450738~38451069:-
OV	trans	rs2727020	0.755	rs652655	ENSG00000134612.10	FOLH1B	6.7	1.58e-10	0.001	0.51	0.41	Coronary artery disease;	chr11:49229741	chr11:89639227~89698718:+
OV	trans	rs7944735	0.517	rs12274550	ENSG00000134612.10	FOLH1B	6.7	1.61e-10	0.00102	0.67	0.41	Intraocular pressure;	chr11:48175200	chr11:89639227~89698718:+
OV	trans	rs7944735	0.517	rs7952205	ENSG00000134612.10	FOLH1B	6.7	1.61e-10	0.00102	0.67	0.41	Intraocular pressure;	chr11:48177675	chr11:89639227~89698718:+
OV	trans	rs747782	0.582	rs11039571	ENSG00000134612.10	FOLH1B	6.7	1.61e-10	0.00102	0.67	0.41	Intraocular pressure;	chr11:48185707	chr11:89639227~89698718:+
OV	trans	rs2727020	0.566	rs10839234	ENSG00000134612.10	FOLH1B	-6.7	1.64e-10	0.00104	-0.51	-0.41	Coronary artery disease;	chr11:49163972	chr11:89639227~89698718:+
OV	trans	rs10838798	0.523	rs11039543	ENSG00000134612.10	FOLH1B	-6.69	1.7e-10	0.00107	-0.51	-0.41	Height;	chr11:48146551	chr11:89639227~89698718:+
OV	trans	rs2727020	0.729	rs1164685	ENSG00000134612.10	FOLH1B	6.69	1.72e-10	0.00108	0.51	0.41	Coronary artery disease;	chr11:49272108	chr11:89639227~89698718:+
OV	trans	rs4979906	1	rs7086586	ENSG00000230585.2	PHBP12	6.69	1.72e-10	0.00108	0.63	0.41	Mortality in heart failure;	chr10:77699766	chr1:50780340~50781150:+
OV	trans	rs2727020	0.729	rs7924782	ENSG00000134612.10	FOLH1B	-6.68	1.78e-10	0.00112	-0.52	-0.41	Coronary artery disease;	chr11:49245697	chr11:89639227~89698718:+
OV	trans	rs877636	0.74	rs705702	ENSG00000234354.3	RPS26P47	-6.68	1.8e-10	0.00113	-0.48	-0.41	Cognitive function;	chr12:55996852	chr13:100539901~100540248:-
OV	trans	rs7554511	0.858	rs12142704	ENSG00000244144.1	RP11-757F18.3	-6.68	1.82e-10	0.00114	-0.59	-0.41	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200988569	chr3:112185480~112185998:-
OV	trans	rs2727020	0.729	rs4980439	ENSG00000134612.10	FOLH1B	-6.68	1.83e-10	0.00115	-0.52	-0.41	Coronary artery disease;	chr11:49320694	chr11:89639227~89698718:+
OV	trans	rs2727020	0.681	rs1976901	ENSG00000134612.10	FOLH1B	-6.67	1.92e-10	0.0012	-0.51	-0.4	Coronary artery disease;	chr11:49357145	chr11:89639227~89698718:+
OV	trans	rs2727020	0.681	rs2866362	ENSG00000134612.10	FOLH1B	-6.67	1.92e-10	0.0012	-0.51	-0.4	Coronary artery disease;	chr11:49357764	chr11:89639227~89698718:+
OV	trans	rs2727020	0.729	rs10839268	ENSG00000134612.10	FOLH1B	-6.67	1.92e-10	0.0012	-0.51	-0.4	Coronary artery disease;	chr11:49358776	chr11:89639227~89698718:+
OV	trans	rs2727020	0.729	rs1917325	ENSG00000134612.10	FOLH1B	-6.67	1.94e-10	0.00121	-0.51	-0.4	Coronary artery disease;	chr11:49348452	chr11:89639227~89698718:+
OV	trans	rs2727020	0.704	rs4144700	ENSG00000134612.10	FOLH1B	-6.67	1.94e-10	0.00121	-0.51	-0.4	Coronary artery disease;	chr11:49349282	chr11:89639227~89698718:+
OV	trans	rs7554511	0.666	rs2221581	ENSG00000244144.1	RP11-757F18.3	-6.67	1.95e-10	0.00122	-0.52	-0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201012797	chr3:112185480~112185998:-
OV	trans	rs877636	1	rs705696	ENSG00000239210.2	RPS26P55	6.65	2.14e-10	0.00133	0.42	0.4	Cognitive function;	chr12:56086864	chr19:34533427~34534084:-
OV	trans	rs7554511	0.707	rs3767498	ENSG00000244144.1	RP11-757F18.3	-6.65	2.17e-10	0.00135	-0.53	-0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201051599	chr3:112185480~112185998:-
OV	trans	rs9858542	1	rs9882740	ENSG00000197582.5	GPX1P1	-6.64	2.25e-10	0.0014	-0.56	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49665051	chrX:13378735~13379340:-
OV	trans	rs3942852	0.568	rs10769312	ENSG00000134612.10	FOLH1B	6.64	2.26e-10	0.0014	0.52	0.4	Acute lymphoblastic leukemia (childhood);	chr11:48073217	chr11:89639227~89698718:+
OV	trans	rs7395662	0.504	rs2019666	ENSG00000134612.10	FOLH1B	-6.64	2.3e-10	0.00143	-0.51	-0.4	HDL cholesterol;	chr11:48416177	chr11:89639227~89698718:+
OV	trans	rs2727020	0.658	rs4980431	ENSG00000134612.10	FOLH1B	-6.63	2.4e-10	0.00148	-0.51	-0.4	Coronary artery disease;	chr11:49328519	chr11:89639227~89698718:+
OV	trans	rs1568889	0.838	rs10767708	ENSG00000174912.7	METTL15P1	6.63	2.41e-10	0.00149	0.45	0.4	Bipolar disorder;	chr11:28273300	chr3:156713884~156714928:-
OV	trans	rs1568889	0.838	rs11030265	ENSG00000174912.7	METTL15P1	6.63	2.41e-10	0.00149	0.45	0.4	Bipolar disorder;	chr11:28274621	chr3:156713884~156714928:-
OV	trans	rs1568889	0.838	rs10835304	ENSG00000174912.7	METTL15P1	6.63	2.41e-10	0.00149	0.45	0.4	Bipolar disorder;	chr11:28274982	chr3:156713884~156714928:-
OV	trans	rs7554511	0.655	rs3767502	ENSG00000244144.1	RP11-757F18.3	6.63	2.47e-10	0.00152	0.53	0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201053970	chr3:112185480~112185998:-
OV	trans	rs11220082	0.666	rs56398391	ENSG00000236257.1	EI24P2	-6.62	2.5e-10	0.00154	-0.54	-0.4	Schizophrenia;	chr11:125444220	chr1:158454198~158455273:+
OV	trans	rs877636	0.859	rs3741499	ENSG00000234192.1	RP11-57C13.5	-6.62	2.5e-10	0.00154	-0.41	-0.4	Cognitive function;	chr12:56080595	chr10:87642607~87642954:+
OV	trans	rs7554511	0.707	rs6702590	ENSG00000244144.1	RP11-757F18.3	6.62	2.52e-10	0.00155	0.52	0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201050977	chr3:112185480~112185998:-
OV	trans	rs7554511	0.858	rs11584383	ENSG00000244144.1	RP11-757F18.3	6.62	2.52e-10	0.00155	0.54	0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200966738	chr3:112185480~112185998:-
OV	trans	rs7554511	0.691	rs10920091	ENSG00000244144.1	RP11-757F18.3	-6.62	2.6e-10	0.0016	-0.51	-0.4	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201005936	chr3:112185480~112185998:-
OV	trans	rs2727020	0.587	rs1164658	ENSG00000134612.10	FOLH1B	6.62	2.62e-10	0.00161	0.51	0.4	Coronary artery disease;	chr11:49276999	chr11:89639227~89698718:+
OV	trans	rs7617480	0.648	rs10865953	ENSG00000197582.5	GPX1P1	6.61	2.64e-10	0.00162	0.57	0.4	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48722129	chrX:13378735~13379340:-
OV	trans	rs7395662	0.571	rs1605358	ENSG00000134612.10	FOLH1B	-6.61	2.67e-10	0.00164	-0.48	-0.4	HDL cholesterol;	chr11:48667766	chr11:89639227~89698718:+
OV	trans	rs3770081	0.826	rs1019591	ENSG00000229880.1	IMMTP1	6.61	2.67e-10	0.00164	1.1	0.4	Facial emotion recognition (sad faces);	chr2:86071476	chr21:44675868~44678086:-
OV	trans	rs4512344	0.509	rs2409784	ENSG00000253893.2	FAM85B	6.61	2.69e-10	0.00164	0.49	0.4	Bone ultrasound measurement (broadband ultrasound attenuation);	chr8:11539347	chr8:8167819~8226614:-
OV	trans	rs3770081	1	rs6750765	ENSG00000229880.1	IMMTP1	6.6	2.83e-10	0.00173	1.1	0.4	Facial emotion recognition (sad faces);	chr2:86073185	chr21:44675868~44678086:-
OV	trans	rs1568889	0.838	rs7933991	ENSG00000174912.7	METTL15P1	6.6	2.84e-10	0.00173	0.46	0.4	Bipolar disorder;	chr11:28038214	chr3:156713884~156714928:-
OV	trans	rs1568889	1	rs10767693	ENSG00000174912.7	METTL15P1	6.6	2.86e-10	0.00175	0.46	0.4	Bipolar disorder;	chr11:28072379	chr3:156713884~156714928:-
OV	trans	rs7395662	0.591	rs11039766	ENSG00000134612.10	FOLH1B	-6.6	2.88e-10	0.00176	-0.52	-0.4	HDL cholesterol;	chr11:48467163	chr11:89639227~89698718:+
OV	trans	rs9858542	1	rs9822268	ENSG00000197582.5	GPX1P1	-6.6	2.93e-10	0.00178	-0.55	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49682296	chrX:13378735~13379340:-
OV	trans	rs9858542	1	rs13085791	ENSG00000197582.5	GPX1P1	-6.6	2.93e-10	0.00178	-0.55	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49684365	chrX:13378735~13379340:-
OV	trans	rs1568889	0.838	rs6484347	ENSG00000174912.7	METTL15P1	-6.6	2.93e-10	0.00178	-0.46	-0.4	Bipolar disorder;	chr11:28019422	chr3:156713884~156714928:-
OV	trans	rs7647973	0.925	rs6446257	ENSG00000197582.5	GPX1P1	-6.6	2.93e-10	0.00178	-0.56	-0.4	Menarche (age at onset);	chr3:49216059	chrX:13378735~13379340:-
OV	trans	rs11098499	0.863	rs10019674	ENSG00000275858.1	RP11-291L22.8	-6.6	2.94e-10	0.00178	-0.44	-0.4	Corneal astigmatism;	chr4:119522334	chr10:38450738~38451069:-
OV	trans	rs1568889	0.838	rs11030206	ENSG00000174912.7	METTL15P1	6.59	2.98e-10	0.0018	0.46	0.4	Bipolar disorder;	chr11:28078200	chr3:156713884~156714928:-
OV	trans	rs877636	1	rs4759229	ENSG00000234192.1	RP11-57C13.5	-6.59	3.01e-10	0.00182	-0.41	-0.4	Cognitive function;	chr12:56080696	chr10:87642607~87642954:+
OV	trans	rs1568889	0.838	rs10458896	ENSG00000174912.7	METTL15P1	6.59	3.09e-10	0.00187	0.46	0.4	Bipolar disorder;	chr11:28036410	chr3:156713884~156714928:-
OV	trans	rs9858542	1	rs4283605	ENSG00000197582.5	GPX1P1	-6.59	3.1e-10	0.00187	-0.55	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49641218	chrX:13378735~13379340:-
OV	trans	rs9858542	1	rs9812791	ENSG00000197582.5	GPX1P1	-6.59	3.1e-10	0.00187	-0.55	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49644878	chrX:13378735~13379340:-
OV	trans	rs9858542	1	rs13316695	ENSG00000197582.5	GPX1P1	-6.59	3.1e-10	0.00187	-0.55	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49647484	chrX:13378735~13379340:-
OV	trans	rs9858542	1	rs6770670	ENSG00000197582.5	GPX1P1	-6.59	3.1e-10	0.00187	-0.55	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49649249	chrX:13378735~13379340:-
OV	trans	rs9858542	1	rs34762726	ENSG00000197582.5	GPX1P1	-6.59	3.1e-10	0.00187	-0.55	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49651777	chrX:13378735~13379340:-
OV	trans	rs1568889	0.838	rs1525717	ENSG00000174912.7	METTL15P1	6.59	3.12e-10	0.00188	0.46	0.4	Bipolar disorder;	chr11:28059658	chr3:156713884~156714928:-
OV	trans	rs1568889	0.838	rs7131379	ENSG00000174912.7	METTL15P1	6.59	3.12e-10	0.00188	0.46	0.4	Bipolar disorder;	chr11:28064242	chr3:156713884~156714928:-
OV	trans	rs877636	1	rs705696	ENSG00000242206.2	RPS26P35	6.58	3.14e-10	0.00189	0.43	0.4	Cognitive function;	chr12:56086864	chr8:118761856~118762201:-
OV	trans	rs9858542	0.953	rs6803222	ENSG00000197582.5	GPX1P1	-6.58	3.14e-10	0.00189	-0.56	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49628543	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs9824092	ENSG00000197582.5	GPX1P1	-6.58	3.2e-10	0.00193	-0.56	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49636714	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs9862080	ENSG00000197582.5	GPX1P1	-6.58	3.2e-10	0.00193	-0.56	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49637025	chrX:13378735~13379340:-
OV	trans	rs9858542	0.953	rs11710037	ENSG00000197582.5	GPX1P1	-6.58	3.2e-10	0.00193	-0.56	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49637901	chrX:13378735~13379340:-
OV	trans	rs1568889	0.887	rs2062269	ENSG00000174912.7	METTL15P1	6.58	3.21e-10	0.00193	0.46	0.4	Bipolar disorder;	chr11:28094990	chr3:156713884~156714928:-
OV	trans	rs877636	0.692	rs2271194	ENSG00000226339.1	RPS26P56	-6.58	3.27e-10	0.00197	-0.41	-0.4	Cognitive function;	chr12:56083910	chrX:129408382~129408621:+
OV	trans	rs1568889	0.838	rs3812738	ENSG00000174912.7	METTL15P1	6.58	3.28e-10	0.00197	0.46	0.4	Bipolar disorder;	chr11:28108435	chr3:156713884~156714928:-
OV	trans	rs1568889	0.838	rs7131053	ENSG00000174912.7	METTL15P1	6.58	3.28e-10	0.00197	0.46	0.4	Bipolar disorder;	chr11:28121765	chr3:156713884~156714928:-
OV	trans	rs1568889	0.73	rs6484350	ENSG00000174912.7	METTL15P1	-6.58	3.3e-10	0.00198	-0.46	-0.4	Bipolar disorder;	chr11:28092111	chr3:156713884~156714928:-
OV	trans	rs1568889	0.887	rs7102237	ENSG00000174912.7	METTL15P1	6.58	3.3e-10	0.00198	0.46	0.4	Bipolar disorder;	chr11:28322749	chr3:156713884~156714928:-
OV	trans	rs7395662	0.57	rs11039737	ENSG00000134612.10	FOLH1B	-6.57	3.35e-10	0.00201	-0.51	-0.4	HDL cholesterol;	chr11:48428648	chr11:89639227~89698718:+
OV	trans	rs7395662	0.591	rs4882012	ENSG00000134612.10	FOLH1B	-6.57	3.36e-10	0.00202	-0.51	-0.4	HDL cholesterol;	chr11:48539045	chr11:89639227~89698718:+
OV	trans	rs7395662	0.571	rs10838947	ENSG00000134612.10	FOLH1B	-6.57	3.37e-10	0.00202	-0.51	-0.4	HDL cholesterol;	chr11:48547141	chr11:89639227~89698718:+
OV	trans	rs9858542	0.953	rs9837341	ENSG00000197582.5	GPX1P1	-6.57	3.41e-10	0.00204	-0.56	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49627334	chrX:13378735~13379340:-
OV	trans	rs9858213	1	rs9858213	ENSG00000197582.5	GPX1P1	-6.57	3.44e-10	0.00206	-0.55	-0.4	Educational attainment;	chr3:49694428	chrX:13378735~13379340:-
OV	trans	rs941207	0.855	rs2256341	ENSG00000121089.4	NACA3P	-6.56	3.52e-10	0.0021	-0.44	-0.4	Platelet count;	chr12:56599930	chr4:164943290~164943937:+
OV	trans	rs941207	0.805	rs2958139	ENSG00000121089.4	NACA3P	-6.56	3.52e-10	0.0021	-0.44	-0.4	Platelet count;	chr12:56610884	chr4:164943290~164943937:+
OV	trans	rs9858542	1	rs2172252	ENSG00000197582.5	GPX1P1	-6.56	3.55e-10	0.00212	-0.55	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49640874	chrX:13378735~13379340:-
OV	trans	rs7395662	0.681	rs2865641	ENSG00000134612.10	FOLH1B	-6.56	3.57e-10	0.00213	-0.48	-0.4	HDL cholesterol;	chr11:48919547	chr11:89639227~89698718:+
OV	trans	rs1568889	0.838	rs11030220	ENSG00000174912.7	METTL15P1	6.56	3.65e-10	0.00218	0.46	0.4	Bipolar disorder;	chr11:28124222	chr3:156713884~156714928:-
OV	trans	rs1568889	0.838	rs7125749	ENSG00000174912.7	METTL15P1	6.56	3.65e-10	0.00218	0.46	0.4	Bipolar disorder;	chr11:28133145	chr3:156713884~156714928:-
OV	trans	rs1568889	0.838	rs10835273	ENSG00000174912.7	METTL15P1	6.56	3.65e-10	0.00218	0.46	0.4	Bipolar disorder;	chr11:28135051	chr3:156713884~156714928:-
OV	trans	rs7395662	0.804	rs8186428	ENSG00000134612.10	FOLH1B	-6.56	3.67e-10	0.00218	-0.48	-0.4	HDL cholesterol;	chr11:48713125	chr11:89639227~89698718:+
OV	trans	rs7395662	0.736	rs4882036	ENSG00000134612.10	FOLH1B	-6.56	3.67e-10	0.00218	-0.48	-0.4	HDL cholesterol;	chr11:48727832	chr11:89639227~89698718:+
OV	trans	rs616147	0.548	rs2370965	ENSG00000214263.2	RPSAP53	-6.55	3.7e-10	0.0022	-0.51	-0.4	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39448996	chr13:67266845~67267706:-
OV	trans	rs1568889	0.838	rs716366	ENSG00000174912.7	METTL15P1	6.55	3.71e-10	0.00221	0.46	0.4	Bipolar disorder;	chr11:28099989	chr3:156713884~156714928:-
OV	trans	rs7312770	1	rs7312770	ENSG00000224161.3	RPS26P54	-6.55	3.74e-10	0.00222	-0.42	-0.4	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr18:59761558~59761905:+
OV	trans	rs9858542	0.953	rs1873625	ENSG00000197582.5	GPX1P1	-6.55	3.75e-10	0.00223	-0.56	-0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49629531	chrX:13378735~13379340:-
OV	trans	rs7819412	0.745	rs4841498	ENSG00000253981.4	ALG1L13P	-6.55	3.77e-10	0.00224	-0.41	-0.4	Triglycerides;	chr8:11127922	chr8:8236003~8244667:-
OV	trans	rs1568889	0.838	rs7127069	ENSG00000174912.7	METTL15P1	6.55	3.81e-10	0.00227	0.45	0.4	Bipolar disorder;	chr11:28303865	chr3:156713884~156714928:-
OV	trans	rs9858542	0.953	rs11715915	ENSG00000197582.5	GPX1P1	6.55	3.87e-10	0.0023	0.57	0.4	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49417897	chrX:13378735~13379340:-
OV	trans	rs7312770	0.612	rs1873914	ENSG00000240427.1	RPS26P34	6.55	3.89e-10	0.00231	0.4	0.4	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr8:81627269~81627617:+
OV	trans	rs1568889	0.838	rs11030229	ENSG00000174912.7	METTL15P1	6.55	3.9e-10	0.00231	0.45	0.4	Bipolar disorder;	chr11:28152087	chr3:156713884~156714928:-
OV	trans	rs1568889	0.838	rs10835276	ENSG00000174912.7	METTL15P1	6.54	3.98e-10	0.00236	0.46	0.4	Bipolar disorder;	chr11:28145600	chr3:156713884~156714928:-
OV	trans	rs1568889	0.775	rs35243076	ENSG00000174912.7	METTL15P1	6.53	4.15e-10	0.00245	0.45	0.4	Bipolar disorder;	chr11:28229071	chr3:156713884~156714928:-
OV	trans	rs877636	1	rs877636	ENSG00000239210.2	RPS26P55	-6.53	4.2e-10	0.00248	-0.4	-0.4	Cognitive function;	chr12:56086799	chr19:34533427~34534084:-
OV	trans	rs1568889	0.838	rs11030230	ENSG00000174912.7	METTL15P1	6.53	4.34e-10	0.00256	0.46	0.4	Bipolar disorder;	chr11:28153084	chr3:156713884~156714928:-
OV	trans	rs3770081	1	rs12612513	ENSG00000229880.1	IMMTP1	6.53	4.35e-10	0.00256	1.16	0.4	Facial emotion recognition (sad faces);	chr2:86074102	chr21:44675868~44678086:-
OV	trans	rs4979906	1	rs7915428	ENSG00000230585.2	PHBP12	6.53	4.37e-10	0.00258	0.61	0.4	Mortality in heart failure;	chr10:77700855	chr1:50780340~50781150:+
OV	trans	rs7395662	0.833	rs1963073	ENSG00000134612.10	FOLH1B	-6.52	4.52e-10	0.00266	-0.48	-0.4	HDL cholesterol;	chr11:48953542	chr11:89639227~89698718:+
OV	trans	rs673253	0.662	rs11586016	ENSG00000231007.5	CDC20P1	6.52	4.52e-10	0.00266	0.54	0.4	Intelligence (multi-trait analysis);	chr1:43566122	chr9:87011652~87013151:+
OV	trans	rs1517114	1	rs1517114	ENSG00000233340.1	RP11-25C19.3	-6.52	4.55e-10	0.00268	-0.41	-0.4	Response to irinotecan in non-small-cell lung cancer;	chr8:68476982	chr10:112671812~112677819:-
OV	trans	rs877636	0.74	rs772920	ENSG00000234354.3	RPS26P47	6.52	4.59e-10	0.0027	0.48	0.4	Cognitive function;	chr12:55996580	chr13:100539901~100540248:-
OV	trans	rs7312770	1	rs7312770	ENSG00000244641.2	RPS26P43	-6.52	4.61e-10	0.00271	-0.41	-0.4	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chr11:123049787~123050353:-
OV	trans	rs7395662	0.782	rs66468703	ENSG00000134612.10	FOLH1B	-6.51	4.67e-10	0.00274	-0.48	-0.4	HDL cholesterol;	chr11:48717221	chr11:89639227~89698718:+
OV	trans	rs2727020	0.664	rs4929893	ENSG00000134612.10	FOLH1B	-6.51	4.7e-10	0.00276	-0.5	-0.4	Coronary artery disease;	chr11:49174780	chr11:89639227~89698718:+
OV	trans	rs1568889	1	rs9783375	ENSG00000174912.7	METTL15P1	6.51	4.77e-10	0.0028	0.55	0.4	Bipolar disorder;	chr11:28012120	chr3:156713884~156714928:-
OV	trans	rs7647973	0.769	rs6772452	ENSG00000197582.5	GPX1P1	6.51	4.81e-10	0.00282	0.54	0.4	Menarche (age at onset);	chr3:49003029	chrX:13378735~13379340:-
OV	trans	rs73108077	0.736	rs7273790	ENSG00000279352.1	RP11-411B10.7	-6.51	4.86e-10	0.00285	-0.77	-0.4	Red blood cell density in sickle cell anemia;	chr20:31312478	chr18:14010054~14010917:+
OV	trans	rs1568889	0.838	rs4614434	ENSG00000174912.7	METTL15P1	6.5	4.96e-10	0.00291	0.45	0.4	Bipolar disorder;	chr11:28280687	chr3:156713884~156714928:-
OV	trans	rs1568889	0.712	rs10835306	ENSG00000174912.7	METTL15P1	6.5	4.96e-10	0.00291	0.45	0.4	Bipolar disorder;	chr11:28280863	chr3:156713884~156714928:-
OV	trans	rs7395662	0.504	rs1814158	ENSG00000134612.10	FOLH1B	-6.5	5.01e-10	0.00294	-0.51	-0.4	HDL cholesterol;	chr11:48416385	chr11:89639227~89698718:+
OV	trans	rs4851250	0.565	rs60473748	ENSG00000221990.4	EXOC3-AS1	-6.5	5.05e-10	0.00295	-0.51	-0.4	Intelligence (multi-trait analysis);	chr2:100003323	chr5:441498~443160:-
OV	trans	rs11039798	0.687	rs11499938	ENSG00000134612.10	FOLH1B	6.49	5.22e-10	0.00305	0.64	0.4	Axial length;	chr11:48935745	chr11:89639227~89698718:+
OV	trans	rs3942852	0.524	rs7118665	ENSG00000134612.10	FOLH1B	6.49	5.22e-10	0.00305	0.53	0.4	Acute lymphoblastic leukemia (childhood);	chr11:48056875	chr11:89639227~89698718:+
OV	trans	rs10242455	0.571	rs41258334	ENSG00000228834.1	RP11-249L21.4	6.49	5.27e-10	0.00308	0.87	0.4	Blood metabolite levels;	chr7:99674185	chr6:108907615~108907873:-
OV	trans	rs10242455	0.571	rs28365067	ENSG00000228834.1	RP11-249L21.4	6.49	5.27e-10	0.00308	0.87	0.4	Blood metabolite levels;	chr7:99674687	chr6:108907615~108907873:-
OV	trans	rs1568889	0.838	rs6484359	ENSG00000174912.7	METTL15P1	6.49	5.37e-10	0.00313	0.45	0.4	Bipolar disorder;	chr11:28240781	chr3:156713884~156714928:-
OV	trans	rs11039798	0.778	rs7944523	ENSG00000134612.10	FOLH1B	6.49	5.38e-10	0.00313	0.64	0.4	Axial length;	chr11:48889467	chr11:89639227~89698718:+
OV	trans	rs11039798	0.925	rs12277669	ENSG00000134612.10	FOLH1B	6.49	5.38e-10	0.00313	0.64	0.4	Axial length;	chr11:48903764	chr11:89639227~89698718:+
OV	trans	rs11039798	0.841	rs10839174	ENSG00000134612.10	FOLH1B	6.49	5.38e-10	0.00313	0.64	0.4	Axial length;	chr11:48909633	chr11:89639227~89698718:+
OV	trans	rs11039798	0.925	rs7929225	ENSG00000134612.10	FOLH1B	6.49	5.38e-10	0.00313	0.64	0.4	Axial length;	chr11:48910187	chr11:89639227~89698718:+
OV	trans	rs11039798	0.764	rs76882342	ENSG00000134612.10	FOLH1B	6.49	5.38e-10	0.00313	0.64	0.4	Axial length;	chr11:48917539	chr11:89639227~89698718:+
OV	trans	rs11039798	0.844	rs7126949	ENSG00000134612.10	FOLH1B	6.49	5.38e-10	0.00313	0.64	0.4	Axial length;	chr11:48950614	chr11:89639227~89698718:+
OV	trans	rs11039798	0.844	rs11040177	ENSG00000134612.10	FOLH1B	6.49	5.38e-10	0.00313	0.64	0.4	Axial length;	chr11:48954659	chr11:89639227~89698718:+
OV	trans	rs11039798	0.92	rs116109043	ENSG00000134612.10	FOLH1B	6.49	5.38e-10	0.00313	0.64	0.4	Axial length;	chr11:48955388	chr11:89639227~89698718:+
OV	trans	rs13086611	1	rs13086611	ENSG00000197582.5	GPX1P1	-6.48	5.48e-10	0.00319	-0.53	-0.4	Educational attainment;	chr3:49347984	chrX:13378735~13379340:-
OV	trans	rs7395662	0.526	rs4882001	ENSG00000134612.10	FOLH1B	-6.48	5.5e-10	0.00319	-0.5	-0.4	HDL cholesterol;	chr11:48525123	chr11:89639227~89698718:+
OV	trans	rs7819412	0.525	rs10086521	ENSG00000253893.2	FAM85B	6.48	5.69e-10	0.0033	0.43	0.4	Triglycerides;	chr8:10926259	chr8:8167819~8226614:-
OV	trans	rs877636	0.692	rs10876870	ENSG00000244641.2	RPS26P43	-6.48	5.73e-10	0.00332	-0.42	-0.39	Cognitive function;	chr12:56084218	chr11:123049787~123050353:-
OV	trans	rs877636	0.692	rs7971751	ENSG00000244641.2	RPS26P43	-6.48	5.73e-10	0.00332	-0.42	-0.39	Cognitive function;	chr12:56084874	chr11:123049787~123050353:-
OV	trans	rs3770081	1	rs74607112	ENSG00000229880.1	IMMTP1	6.47	5.82e-10	0.00337	1.08	0.39	Facial emotion recognition (sad faces);	chr2:86078411	chr21:44675868~44678086:-
OV	trans	rs7395662	0.548	rs4882000	ENSG00000134612.10	FOLH1B	-6.47	5.87e-10	0.0034	-0.5	-0.39	HDL cholesterol;	chr11:48524944	chr11:89639227~89698718:+
OV	trans	rs7121616	0.531	rs10892958	ENSG00000241478.1	HSPA8P9	6.47	5.89e-10	0.00341	0.47	0.39	Breast cancer;	chr11:123061415	chr3:137880295~137882237:+
OV	trans	rs7395662	0.591	rs4882093	ENSG00000134612.10	FOLH1B	-6.47	5.91e-10	0.00342	-0.51	-0.39	HDL cholesterol;	chr11:48509268	chr11:89639227~89698718:+
OV	trans	rs7395662	0.611	rs7478698	ENSG00000134612.10	FOLH1B	-6.47	5.91e-10	0.00342	-0.51	-0.39	HDL cholesterol;	chr11:48527587	chr11:89639227~89698718:+
OV	trans	rs2069408	1	rs2069408	ENSG00000242206.2	RPS26P35	-6.47	6.06e-10	0.0035	-0.42	-0.39	Asthma;	chr12:55970537	chr8:118761856~118762201:-
OV	trans	rs1814175	0.538	rs1684260	ENSG00000134612.10	FOLH1B	6.46	6.13e-10	0.00354	0.5	0.39	Height;	chr11:49202679	chr11:89639227~89698718:+
OV	trans	rs2727020	0.688	rs2734002	ENSG00000134612.10	FOLH1B	6.46	6.13e-10	0.00354	0.5	0.39	Coronary artery disease;	chr11:49212610	chr11:89639227~89698718:+
OV	trans	rs2727020	0.612	rs603672	ENSG00000134612.10	FOLH1B	6.46	6.13e-10	0.00354	0.5	0.39	Coronary artery disease;	chr11:49213014	chr11:89639227~89698718:+
OV	trans	rs11098499	0.863	rs7699064	ENSG00000275858.1	RP11-291L22.8	-6.46	6.47e-10	0.00372	-0.43	-0.39	Corneal astigmatism;	chr4:119507154	chr10:38450738~38451069:-
OV	trans	rs1814175	0.817	rs10769617	ENSG00000134612.10	FOLH1B	-6.46	6.48e-10	0.00373	-0.5	-0.39	Height;	chr11:49788869	chr11:89639227~89698718:+
OV	trans	rs1814175	0.817	rs4881648	ENSG00000134612.10	FOLH1B	-6.46	6.48e-10	0.00373	-0.5	-0.39	Height;	chr11:49791349	chr11:89639227~89698718:+
OV	trans	rs7395662	0.591	rs4882110	ENSG00000134612.10	FOLH1B	-6.45	6.51e-10	0.00374	-0.5	-0.39	HDL cholesterol;	chr11:48536697	chr11:89639227~89698718:+
OV	trans	rs7395662	0.517	rs10838960	ENSG00000134612.10	FOLH1B	-6.45	6.51e-10	0.00374	-0.5	-0.39	HDL cholesterol;	chr11:48563189	chr11:89639227~89698718:+
OV	trans	rs7617480	0.648	rs9882443	ENSG00000197582.5	GPX1P1	6.45	6.55e-10	0.00376	0.56	0.39	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48711631	chrX:13378735~13379340:-
OV	trans	rs7617480	0.648	rs9848268	ENSG00000197582.5	GPX1P1	6.45	6.59e-10	0.00378	0.59	0.39	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48724838	chrX:13378735~13379340:-
OV	trans	rs7121616	0.531	rs11218941	ENSG00000241478.1	HSPA8P9	6.45	6.62e-10	0.00379	0.47	0.39	Breast cancer;	chr11:123061701	chr3:137880295~137882237:+
OV	trans	rs877636	0.702	rs773110	ENSG00000243538.1	CTB-55B8.1	6.45	6.69e-10	0.00383	0.42	0.39	Cognitive function;	chr12:55981353	chr5:16902294~16902641:-
OV	trans	rs2069408	1	rs2069408	ENSG00000234192.1	RP11-57C13.5	-6.45	6.74e-10	0.00386	-0.42	-0.39	Asthma;	chr12:55970537	chr10:87642607~87642954:+
OV	trans	rs7647973	0.731	rs9831648	ENSG00000197582.5	GPX1P1	6.45	6.79e-10	0.00389	0.57	0.39	Menarche (age at onset);	chr3:49176870	chrX:13378735~13379340:-
OV	trans	rs1568889	0.838	rs1483858	ENSG00000174912.7	METTL15P1	6.44	7.12e-10	0.00406	0.45	0.39	Bipolar disorder;	chr11:28168092	chr3:156713884~156714928:-
OV	trans	rs11039798	0.698	rs78553793	ENSG00000134612.10	FOLH1B	6.44	7.14e-10	0.00407	0.72	0.39	Axial length;	chr11:48925784	chr11:89639227~89698718:+
OV	trans	rs7121616	0.515	rs11218966	ENSG00000234176.1	HSPA8P1	6.44	7.19e-10	0.00409	0.6	0.39	Breast cancer;	chr11:123086510	chrX:121203182~121205014:-
OV	trans	rs9650657	0.645	rs4841409	ENSG00000253981.4	ALG1L13P	6.43	7.3e-10	0.00414	0.4	0.39	Neuroticism;	chr8:10658864	chr8:8236003~8244667:-
OV	trans	rs877636	0.692	rs10876870	ENSG00000229032.1	RP11-91A18.1	-6.43	7.35e-10	0.00417	-0.42	-0.39	Cognitive function;	chr12:56084218	chr1:51980473~51980814:+
OV	trans	rs877636	0.692	rs7971751	ENSG00000229032.1	RP11-91A18.1	-6.43	7.35e-10	0.00417	-0.42	-0.39	Cognitive function;	chr12:56084874	chr1:51980473~51980814:+
OV	trans	rs2727020	0.729	rs2299650	ENSG00000134612.10	FOLH1B	-6.43	7.39e-10	0.00419	-0.51	-0.39	Coronary artery disease;	chr11:49152455	chr11:89639227~89698718:+
OV	trans	rs7395662	0.819	rs1473579	ENSG00000134612.10	FOLH1B	-6.43	7.49e-10	0.00424	-0.47	-0.39	HDL cholesterol;	chr11:48880001	chr11:89639227~89698718:+
OV	trans	rs7395662	1	rs4929903	ENSG00000134612.10	FOLH1B	-6.43	7.49e-10	0.00424	-0.47	-0.39	HDL cholesterol;	chr11:48891780	chr11:89639227~89698718:+
OV	trans	rs7554511	0.894	rs2297909	ENSG00000244144.1	RP11-757F18.3	-6.43	7.5e-10	0.00424	-0.52	-0.39	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200991179	chr3:112185480~112185998:-
OV	trans	rs941207	0.526	rs2950390	ENSG00000121089.4	NACA3P	6.42	7.7e-10	0.00435	0.38	0.39	Platelet count;	chr12:56661507	chr4:164943290~164943937:+
OV	trans	rs9858542	1	rs11709525	ENSG00000197582.5	GPX1P1	-6.42	7.75e-10	0.00438	-0.55	-0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49653063	chrX:13378735~13379340:-
OV	trans	rs7312770	0.612	rs1873914	ENSG00000244641.2	RPS26P43	6.42	7.79e-10	0.0044	0.4	0.39	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985643	chr11:123049787~123050353:-
OV	trans	rs877636	0.702	rs773109	ENSG00000243538.1	CTB-55B8.1	6.42	7.86e-10	0.00444	0.42	0.39	Cognitive function;	chr12:55980911	chr5:16902294~16902641:-
OV	trans	rs877636	0.692	rs2271194	ENSG00000244641.2	RPS26P43	-6.42	7.87e-10	0.00444	-0.41	-0.39	Cognitive function;	chr12:56083910	chr11:123049787~123050353:-
OV	trans	rs877636	0.692	rs2271194	ENSG00000229032.1	RP11-91A18.1	-6.42	7.91e-10	0.00446	-0.42	-0.39	Cognitive function;	chr12:56083910	chr1:51980473~51980814:+
OV	trans	rs12709013	0.636	rs6499976	ENSG00000230849.2	GOT2P2	6.42	7.97e-10	0.0045	0.46	0.39	Blood metabolite ratios;	chr16:58770330	chr1:173141100~173142350:-
OV	trans	rs673253	0.638	rs552638	ENSG00000231007.5	CDC20P1	6.42	8.06e-10	0.00453	0.53	0.39	Intelligence (multi-trait analysis);	chr1:43577721	chr9:87011652~87013151:+
OV	trans	rs673253	0.686	rs1887402	ENSG00000231007.5	CDC20P1	6.42	8.07e-10	0.00454	0.53	0.39	Intelligence (multi-trait analysis);	chr1:43570414	chr9:87011652~87013151:+
OV	trans	rs7395662	0.927	rs4882141	ENSG00000134612.10	FOLH1B	-6.42	8.08e-10	0.00454	-0.46	-0.39	HDL cholesterol;	chr11:48605973	chr11:89639227~89698718:+
OV	trans	rs2727020	0.729	rs2204366	ENSG00000134612.10	FOLH1B	6.42	8.09e-10	0.00455	0.51	0.39	Coronary artery disease;	chr11:49327815	chr11:89639227~89698718:+
OV	trans	rs7944735	0.517	rs74763661	ENSG00000134612.10	FOLH1B	6.41	8.35e-10	0.00469	0.65	0.39	Intraocular pressure;	chr11:48212220	chr11:89639227~89698718:+
OV	trans	rs877636	1	rs705696	ENSG00000219993.1	RP11-288G3.3	6.41	8.35e-10	0.00469	0.4	0.39	Cognitive function;	chr12:56086864	chr6:7506203~7506549:+
OV	trans	rs7617480	0.648	rs4858830	ENSG00000197582.5	GPX1P1	6.41	8.54e-10	0.00479	0.54	0.39	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48696569	chrX:13378735~13379340:-
OV	trans	rs7617480	0.544	rs6442129	ENSG00000197582.5	GPX1P1	6.41	8.54e-10	0.00479	0.54	0.39	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48697823	chrX:13378735~13379340:-
OV	trans	rs7617480	0.617	rs7610519	ENSG00000197582.5	GPX1P1	6.41	8.54e-10	0.00479	0.54	0.39	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48708994	chrX:13378735~13379340:-
OV	trans	rs7617480	0.648	rs4858800	ENSG00000197582.5	GPX1P1	6.41	8.54e-10	0.00479	0.54	0.39	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48718387	chrX:13378735~13379340:-
OV	trans	rs11098499	0.863	rs17050695	ENSG00000275858.1	RP11-291L22.8	6.41	8.55e-10	0.00479	0.42	0.39	Corneal astigmatism;	chr4:119568372	chr10:38450738~38451069:-
OV	trans	rs877636	1	rs877636	ENSG00000242206.2	RPS26P35	-6.4	8.61e-10	0.00482	-0.41	-0.39	Cognitive function;	chr12:56086799	chr8:118761856~118762201:-
OV	trans	rs11220082	0.627	rs35102191	ENSG00000236257.1	EI24P2	-6.4	8.69e-10	0.00487	-0.52	-0.39	Schizophrenia;	chr11:125455250	chr1:158454198~158455273:+
OV	trans	rs747782	0.527	rs12289516	ENSG00000134612.10	FOLH1B	6.4	8.99e-10	0.00501	0.65	0.39	Intraocular pressure;	chr11:48213128	chr11:89639227~89698718:+
OV	trans	rs11039798	0.62	rs10838833	ENSG00000134612.10	FOLH1B	6.4	8.99e-10	0.00501	0.65	0.39	Axial length;	chr11:48217328	chr11:89639227~89698718:+
OV	trans	rs877636	0.702	rs773111	ENSG00000243538.1	CTB-55B8.1	6.4	9.03e-10	0.00503	0.42	0.39	Cognitive function;	chr12:55981956	chr5:16902294~16902641:-
OV	trans	rs877636	0.702	rs773112	ENSG00000243538.1	CTB-55B8.1	6.4	9.03e-10	0.00503	0.42	0.39	Cognitive function;	chr12:55982097	chr5:16902294~16902641:-
OV	trans	rs747782	0.527	rs75915859	ENSG00000134612.10	FOLH1B	6.4	9.04e-10	0.00503	0.65	0.39	Intraocular pressure;	chr11:48211379	chr11:89639227~89698718:+
OV	trans	rs7395662	0.591	rs12807777	ENSG00000134612.10	FOLH1B	-6.39	9.29e-10	0.00515	-0.49	-0.39	HDL cholesterol;	chr11:48572202	chr11:89639227~89698718:+
OV	trans	rs7395662	0.591	rs10838968	ENSG00000134612.10	FOLH1B	-6.39	9.29e-10	0.00515	-0.49	-0.39	HDL cholesterol;	chr11:48573494	chr11:89639227~89698718:+
OV	trans	rs10838798	0.523	rs4752907	ENSG00000134612.10	FOLH1B	-6.39	9.41e-10	0.00521	-0.5	-0.39	Height;	chr11:48149029	chr11:89639227~89698718:+
OV	trans	rs1568889	1	rs9783281	ENSG00000174912.7	METTL15P1	6.39	9.46e-10	0.00523	0.53	0.39	Bipolar disorder;	chr11:28012239	chr3:156713884~156714928:-
OV	trans	rs877636	0.859	rs3741499	ENSG00000242206.2	RPS26P35	-6.39	9.55e-10	0.00528	-0.41	-0.39	Cognitive function;	chr12:56080595	chr8:118761856~118762201:-
OV	trans	rs877636	1	rs4759229	ENSG00000242206.2	RPS26P35	-6.38	9.59e-10	0.0053	-0.41	-0.39	Cognitive function;	chr12:56080696	chr8:118761856~118762201:-
OV	trans	rs877636	0.74	rs705702	ENSG00000243538.1	CTB-55B8.1	-6.38	9.61e-10	0.00531	-0.42	-0.39	Cognitive function;	chr12:55996852	chr5:16902294~16902641:-
OV	trans	rs1814175	0.817	rs10839358	ENSG00000134612.10	FOLH1B	-6.38	9.85e-10	0.00543	-0.48	-0.39	Height;	chr11:49749420	chr11:89639227~89698718:+
OV	trans	rs1814175	0.791	rs11040513	ENSG00000134612.10	FOLH1B	-6.38	9.85e-10	0.00543	-0.48	-0.39	Height;	chr11:49756601	chr11:89639227~89698718:+
OV	trans	rs1814175	0.817	rs4881645	ENSG00000134612.10	FOLH1B	-6.38	9.85e-10	0.00543	-0.48	-0.39	Height;	chr11:49769616	chr11:89639227~89698718:+
OV	trans	rs1814175	0.817	rs4881623	ENSG00000134612.10	FOLH1B	-6.38	9.85e-10	0.00543	-0.48	-0.39	Height;	chr11:49783439	chr11:89639227~89698718:+
OV	trans	rs7944735	0.517	rs1827503	ENSG00000134612.10	FOLH1B	6.38	9.99e-10	0.00549	0.65	0.39	Intraocular pressure;	chr11:48203563	chr11:89639227~89698718:+
OV	trans	rs11039798	0.698	rs76315297	ENSG00000134612.10	FOLH1B	6.38	9.99e-10	0.00549	0.65	0.39	Axial length;	chr11:48218923	chr11:89639227~89698718:+
OV	trans	rs9858542	1	rs9823546	ENSG00000197582.5	GPX1P1	-6.38	1e-09	0.00551	-0.54	-0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49668079	chrX:13378735~13379340:-
OV	trans	rs673253	0.686	rs596522	ENSG00000231007.5	CDC20P1	6.38	1e-09	0.00552	0.53	0.39	Intelligence (multi-trait analysis);	chr1:43600753	chr9:87011652~87013151:+
OV	trans	rs11098499	0.863	rs1552095	ENSG00000275858.1	RP11-291L22.8	6.37	1.01e-09	0.00558	0.47	0.39	Corneal astigmatism;	chr4:119539151	chr10:38450738~38451069:-
OV	trans	rs1814175	0.791	rs11040472	ENSG00000134612.10	FOLH1B	-6.37	1.03e-09	0.00565	-0.48	-0.39	Height;	chr11:49681564	chr11:89639227~89698718:+
OV	trans	rs1814175	0.817	rs11040474	ENSG00000134612.10	FOLH1B	-6.37	1.03e-09	0.00565	-0.48	-0.39	Height;	chr11:49686889	chr11:89639227~89698718:+
OV	trans	rs1814175	0.817	rs10839351	ENSG00000134612.10	FOLH1B	-6.37	1.03e-09	0.00565	-0.48	-0.39	Height;	chr11:49736601	chr11:89639227~89698718:+
OV	trans	rs1568889	0.774	rs11030235	ENSG00000174912.7	METTL15P1	6.37	1.04e-09	0.00573	0.44	0.39	Bipolar disorder;	chr11:28190828	chr3:156713884~156714928:-
OV	trans	rs6132905	0.52	rs2422824	ENSG00000235559.1	NOP56P1	6.36	1.07e-09	0.00586	0.49	0.39	Mumps;	chr20:2666724	chr6:28783633~28784004:-
OV	trans	rs941207	0.756	rs7313074	ENSG00000121089.4	NACA3P	-6.36	1.1e-09	0.00603	-0.44	-0.39	Platelet count;	chr12:56760705	chr4:164943290~164943937:+
OV	trans	rs7312770	1	rs7312770	ENSG00000226339.1	RPS26P56	-6.36	1.11e-09	0.00605	-0.39	-0.39	Polycystic ovary syndrome;Hypothyroidism;	chr12:56073803	chrX:129408382~129408621:+
OV	trans	rs673253	0.686	rs943513	ENSG00000231007.5	CDC20P1	6.36	1.11e-09	0.00606	0.53	0.39	Intelligence (multi-trait analysis);	chr1:43569801	chr9:87011652~87013151:+
OV	trans	rs7312770	0.612	rs773114	ENSG00000231366.1	RP11-399N22.3	6.35	1.13e-09	0.00616	0.44	0.39	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr10:70794230~70794523:-
OV	trans	rs2727020	0.729	rs6485965	ENSG00000134612.10	FOLH1B	6.35	1.15e-09	0.00624	0.5	0.39	Coronary artery disease;	chr11:49145178	chr11:89639227~89698718:+
OV	trans	rs2727020	0.595	rs10839286	ENSG00000134612.10	FOLH1B	-6.35	1.15e-09	0.00626	-0.49	-0.39	Coronary artery disease;	chr11:49475511	chr11:89639227~89698718:+
OV	trans	rs2727020	0.595	rs10466496	ENSG00000134612.10	FOLH1B	-6.35	1.15e-09	0.00626	-0.49	-0.39	Coronary artery disease;	chr11:49479962	chr11:89639227~89698718:+
OV	trans	rs2727020	0.595	rs7924311	ENSG00000134612.10	FOLH1B	-6.35	1.15e-09	0.00626	-0.49	-0.39	Coronary artery disease;	chr11:49486021	chr11:89639227~89698718:+
OV	trans	rs12643440	0.96	rs16894625	ENSG00000270171.1	RP11-338N10.1	6.35	1.16e-09	0.00632	0.51	0.39	Metabolite levels (Pyroglutamine);	chr4:17196624	chr1:7693124~7694844:-
OV	trans	rs2727020	0.595	rs10769583	ENSG00000134612.10	FOLH1B	-6.35	1.18e-09	0.00639	-0.49	-0.39	Coronary artery disease;	chr11:49461641	chr11:89639227~89698718:+
OV	trans	rs2727020	0.595	rs10839281	ENSG00000134612.10	FOLH1B	-6.35	1.18e-09	0.00639	-0.49	-0.39	Coronary artery disease;	chr11:49461821	chr11:89639227~89698718:+
OV	trans	rs11098499	0.863	rs6534139	ENSG00000275858.1	RP11-291L22.8	-6.35	1.19e-09	0.00647	-0.43	-0.39	Corneal astigmatism;	chr4:119528301	chr10:38450738~38451069:-
OV	trans	rs1814175	0.653	rs10839480	ENSG00000134612.10	FOLH1B	-6.34	1.21e-09	0.00658	-0.49	-0.39	Height;	chr11:50013036	chr11:89639227~89698718:+
OV	trans	rs7617480	0.648	rs6806356	ENSG00000197582.5	GPX1P1	6.34	1.24e-09	0.00671	0.54	0.39	Menarche (age at onset);Subjective well-being (multi-trait analysis);	chr3:48690203	chrX:13378735~13379340:-
OV	trans	rs877636	1	rs2292239	ENSG00000242206.2	RPS26P35	6.33	1.26e-09	0.00684	0.4	0.39	Cognitive function;	chr12:56088396	chr8:118761856~118762201:-
OV	trans	rs11220082	0.644	rs36143594	ENSG00000236257.1	EI24P2	-6.33	1.28e-09	0.00692	-0.5	-0.39	Schizophrenia;	chr11:125457076	chr1:158454198~158455273:+
OV	trans	rs1568889	0.838	rs10835283	ENSG00000174912.7	METTL15P1	6.33	1.32e-09	0.00713	0.44	0.39	Bipolar disorder;	chr11:28193438	chr3:156713884~156714928:-
OV	trans	rs1814175	0.817	rs28679516	ENSG00000134612.10	FOLH1B	-6.33	1.32e-09	0.00713	-0.49	-0.39	Height;	chr11:50096826	chr11:89639227~89698718:+
OV	trans	rs1814175	0.817	rs1390676	ENSG00000134612.10	FOLH1B	-6.33	1.32e-09	0.00713	-0.49	-0.39	Height;	chr11:50097606	chr11:89639227~89698718:+
OV	trans	rs2950393	0.895	rs2926740	ENSG00000121089.4	NACA3P	6.32	1.33e-09	0.00718	0.37	0.39	Platelet distribution width;	chr12:56666751	chr4:164943290~164943937:+
OV	trans	rs7554511	0.861	rs965321	ENSG00000244144.1	RP11-757F18.3	6.32	1.33e-09	0.00718	0.5	0.39	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201036374	chr3:112185480~112185998:-
OV	trans	rs7395662	0.591	rs11039858	ENSG00000134612.10	FOLH1B	-6.32	1.35e-09	0.00726	-0.5	-0.39	HDL cholesterol;	chr11:48590099	chr11:89639227~89698718:+
OV	trans	rs9858542	1	rs9858542	ENSG00000197582.5	GPX1P1	6.32	1.35e-09	0.00728	0.54	0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49664550	chrX:13378735~13379340:-
OV	trans	rs12643440	0.919	rs13143674	ENSG00000270171.1	RP11-338N10.1	6.32	1.38e-09	0.0074	0.53	0.39	Metabolite levels (Pyroglutamine);	chr4:17196100	chr1:7693124~7694844:-
OV	trans	rs12492269	0.702	rs41381644	ENSG00000258608.1	DNAJC19P9	6.32	1.38e-09	0.00743	0.62	0.39	Plasma clusterin levels;	chr3:178443826	chr14:45290036~45290386:+
OV	trans	rs877636	0.692	rs11171739	ENSG00000229032.1	RP11-91A18.1	6.32	1.38e-09	0.00745	0.4	0.39	Cognitive function;	chr12:56076841	chr1:51980473~51980814:+
OV	trans	rs73108077	0.736	rs73105954	ENSG00000279352.1	RP11-411B10.7	6.32	1.4e-09	0.00751	0.8	0.39	Red blood cell density in sickle cell anemia;	chr20:31355903	chr18:14010054~14010917:+
OV	trans	rs877636	0.702	rs773111	ENSG00000234354.3	RPS26P47	6.32	1.41e-09	0.00756	0.46	0.39	Cognitive function;	chr12:55981956	chr13:100539901~100540248:-
OV	trans	rs877636	0.702	rs773112	ENSG00000234354.3	RPS26P47	6.32	1.41e-09	0.00756	0.46	0.39	Cognitive function;	chr12:55982097	chr13:100539901~100540248:-
OV	trans	rs877636	0.702	rs773110	ENSG00000234354.3	RPS26P47	6.31	1.41e-09	0.00758	0.46	0.39	Cognitive function;	chr12:55981353	chr13:100539901~100540248:-
OV	trans	rs877636	0.702	rs61937249	ENSG00000243538.1	CTB-55B8.1	6.31	1.41e-09	0.00758	0.41	0.39	Cognitive function;	chr12:55988132	chr5:16902294~16902641:-
OV	trans	rs16869212	0.71	rs6882539	ENSG00000237404.1	RP3-471C18.2	6.31	1.44e-09	0.00773	0.67	0.39	Body mass index (change over time) in lung cancer or chronic obstructive pulmonary disease;	chr5:16880011	chr6:19689825~19753113:-
OV	trans	rs1814175	0.817	rs11493756	ENSG00000134612.10	FOLH1B	-6.31	1.47e-09	0.00788	-0.49	-0.39	Height;	chr11:49996346	chr11:89639227~89698718:+
OV	trans	rs7395662	0.571	rs4882020	ENSG00000134612.10	FOLH1B	-6.31	1.47e-09	0.0079	-0.49	-0.39	HDL cholesterol;	chr11:48594106	chr11:89639227~89698718:+
OV	trans	rs7395662	0.591	rs4882138	ENSG00000134612.10	FOLH1B	-6.31	1.47e-09	0.0079	-0.49	-0.39	HDL cholesterol;	chr11:48597769	chr11:89639227~89698718:+
OV	trans	rs3942852	0.712	rs10742828	ENSG00000134612.10	FOLH1B	-6.31	1.48e-09	0.00793	-0.51	-0.39	Acute lymphoblastic leukemia (childhood);	chr11:48083003	chr11:89639227~89698718:+
OV	trans	rs7395662	0.591	rs7483212	ENSG00000134612.10	FOLH1B	-6.31	1.48e-09	0.00794	-0.49	-0.39	HDL cholesterol;	chr11:48585630	chr11:89639227~89698718:+
OV	trans	rs7395662	0.591	rs7482521	ENSG00000134612.10	FOLH1B	-6.31	1.48e-09	0.00794	-0.49	-0.39	HDL cholesterol;	chr11:48588183	chr11:89639227~89698718:+
OV	trans	rs7395662	0.591	rs10838972	ENSG00000134612.10	FOLH1B	-6.31	1.48e-09	0.00794	-0.49	-0.39	HDL cholesterol;	chr11:48589848	chr11:89639227~89698718:+
OV	trans	rs10242455	0.557	rs57830676	ENSG00000228834.1	RP11-249L21.4	6.3	1.49e-09	0.008	0.77	0.39	Blood metabolite levels;	chr7:99683740	chr6:108907615~108907873:-
OV	trans	rs10242455	0.571	rs55830753	ENSG00000228834.1	RP11-249L21.4	6.3	1.49e-09	0.008	0.77	0.39	Blood metabolite levels;	chr7:99694599	chr6:108907615~108907873:-
OV	trans	rs1814175	0.817	rs12295885	ENSG00000134612.10	FOLH1B	-6.3	1.5e-09	0.00803	-0.49	-0.39	Height;	chr11:50015241	chr11:89639227~89698718:+
OV	trans	rs7395662	0.674	rs7124275	ENSG00000134612.10	FOLH1B	-6.3	1.52e-09	0.00812	-0.47	-0.39	HDL cholesterol;	chr11:48140753	chr11:89639227~89698718:+
OV	trans	rs673253	1	rs673253	ENSG00000231007.5	CDC20P1	6.3	1.53e-09	0.00819	0.53	0.39	Intelligence (multi-trait analysis);	chr1:43596483	chr9:87011652~87013151:+
OV	trans	rs877636	0.692	rs11171739	ENSG00000231366.1	RP11-399N22.3	6.3	1.54e-09	0.00822	0.44	0.39	Cognitive function;	chr12:56076841	chr10:70794230~70794523:-
OV	trans	rs9858542	1	rs11130213	ENSG00000197582.5	GPX1P1	-6.3	1.54e-09	0.00822	-0.53	-0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49674864	chrX:13378735~13379340:-
OV	trans	rs9858542	1	rs1131095	ENSG00000197582.5	GPX1P1	-6.3	1.54e-09	0.00822	-0.53	-0.39	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49676792	chrX:13378735~13379340:-
OV	trans	rs73108077	0.92	rs73248560	ENSG00000279352.1	RP11-411B10.7	6.3	1.54e-09	0.00823	0.85	0.39	Red blood cell density in sickle cell anemia;	chr20:31436938	chr18:14010054~14010917:+
OV	trans	rs7647973	0.559	rs9586	ENSG00000197582.5	GPX1P1	6.3	1.55e-09	0.00829	0.56	0.39	Menarche (age at onset);	chr3:49176204	chrX:13378735~13379340:-
OV	trans	rs877636	1	rs2292239	ENSG00000239210.2	RPS26P55	6.29	1.57e-09	0.00838	0.39	0.39	Cognitive function;	chr12:56088396	chr19:34533427~34534084:-
OV	trans	rs2950393	0.895	rs2958154	ENSG00000121089.4	NACA3P	-6.29	1.57e-09	0.0084	-0.37	-0.39	Platelet distribution width;	chr12:56671929	chr4:164943290~164943937:+
OV	trans	rs1814175	0.754	rs28593359	ENSG00000134612.10	FOLH1B	-6.29	1.6e-09	0.00853	-0.49	-0.39	Height;	chr11:50083198	chr11:89639227~89698718:+
OV	trans	rs1814175	0.817	rs28594987	ENSG00000134612.10	FOLH1B	-6.29	1.6e-09	0.00853	-0.49	-0.39	Height;	chr11:50086022	chr11:89639227~89698718:+
OV	trans	rs1814175	0.817	rs28502006	ENSG00000134612.10	FOLH1B	-6.29	1.6e-09	0.00853	-0.49	-0.39	Height;	chr11:50090770	chr11:89639227~89698718:+
OV	trans	rs1814175	0.781	rs28681334	ENSG00000134612.10	FOLH1B	-6.29	1.6e-09	0.00853	-0.49	-0.39	Height;	chr11:50092006	chr11:89639227~89698718:+
OV	trans	rs3770081	1	rs56104203	ENSG00000229880.1	IMMTP1	6.29	1.62e-09	0.00864	1.16	0.39	Facial emotion recognition (sad faces);	chr2:86109133	chr21:44675868~44678086:-
OV	trans	rs3770081	1	rs12617717	ENSG00000229880.1	IMMTP1	6.29	1.62e-09	0.00864	1.16	0.39	Facial emotion recognition (sad faces);	chr2:86115180	chr21:44675868~44678086:-
OV	trans	rs7395662	0.525	rs4882060	ENSG00000134612.10	FOLH1B	-6.28	1.68e-09	0.00893	-0.49	-0.38	HDL cholesterol;	chr11:48420322	chr11:89639227~89698718:+
OV	trans	rs11039798	0.92	rs61448762	ENSG00000134612.10	FOLH1B	6.28	1.71e-09	0.00907	0.66	0.38	Axial length;	chr11:48902204	chr11:89639227~89698718:+
OV	trans	rs1814175	0.511	rs61905634	ENSG00000134612.10	FOLH1B	-6.28	1.72e-09	0.00912	-0.49	-0.38	Height;	chr11:49798184	chr11:89639227~89698718:+
OV	trans	rs877636	0.702	rs61937249	ENSG00000234354.3	RPS26P47	6.28	1.72e-09	0.00912	0.46	0.38	Cognitive function;	chr12:55988132	chr13:100539901~100540248:-
OV	trans	rs3770081	1	rs2278086	ENSG00000229880.1	IMMTP1	6.28	1.74e-09	0.0092	1.12	0.38	Facial emotion recognition (sad faces);	chr2:86054782	chr21:44675868~44678086:-
OV	trans	rs3770081	1	rs78646493	ENSG00000229880.1	IMMTP1	6.28	1.74e-09	0.0092	1.12	0.38	Facial emotion recognition (sad faces);	chr2:86056072	chr21:44675868~44678086:-
OV	trans	rs3770081	1	rs111295372	ENSG00000229880.1	IMMTP1	6.28	1.74e-09	0.0092	1.12	0.38	Facial emotion recognition (sad faces);	chr2:86056234	chr21:44675868~44678086:-
OV	trans	rs4979906	1	rs1609790	ENSG00000230585.2	PHBP12	6.28	1.75e-09	0.00924	0.57	0.38	Mortality in heart failure;	chr10:77704320	chr1:50780340~50781150:+
OV	trans	rs12643440	0.919	rs7687526	ENSG00000270171.1	RP11-338N10.1	6.27	1.8e-09	0.00949	0.54	0.38	Metabolite levels (Pyroglutamine);	chr4:17195376	chr1:7693124~7694844:-
OV	trans	rs4981053	0.807	rs76881309	ENSG00000234203.1	RP5-1050D4.2	6.27	1.8e-09	0.00952	0.42	0.38	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr14:20023016	chr17:4972851~4974681:+
OV	trans	rs73108077	0.736	rs73104095	ENSG00000279352.1	RP11-411B10.7	6.27	1.83e-09	0.00964	0.79	0.38	Red blood cell density in sickle cell anemia;	chr20:31312074	chr18:14010054~14010917:+
OV	trans	rs73108077	0.79	rs73105930	ENSG00000279352.1	RP11-411B10.7	6.27	1.83e-09	0.00964	0.79	0.38	Red blood cell density in sickle cell anemia;	chr20:31327265	chr18:14010054~14010917:+
OV	trans	rs73108077	0.79	rs8122544	ENSG00000279352.1	RP11-411B10.7	6.27	1.83e-09	0.00964	0.79	0.38	Red blood cell density in sickle cell anemia;	chr20:31346428	chr18:14010054~14010917:+
OV	trans	rs8010715	0.636	rs2277482	ENSG00000248988.1	RP11-815N9.2	6.27	1.83e-09	0.00965	0.49	0.38	IgG glycosylation;	chr14:24118586	chr4:159007119~159007835:+
OV	trans	rs11039798	0.844	rs41431447	ENSG00000134612.10	FOLH1B	6.27	1.84e-09	0.00968	0.68	0.38	Axial length;	chr11:48961647	chr11:89639227~89698718:+
OV	trans	rs4744901	1	rs4744902	ENSG00000245812.2	RP11-175K6.1	6.26	1.86e-09	0.00978	1.01	0.38	Schizophrenia;	chr9:69483321	chr5:159100483~159117478:+
OV	trans	rs4744901	1	rs1331979	ENSG00000245812.2	RP11-175K6.1	6.26	1.86e-09	0.00978	1.01	0.38	Schizophrenia;	chr9:69487853	chr5:159100483~159117478:+
OV	trans	rs4744901	1	rs7357615	ENSG00000245812.2	RP11-175K6.1	6.26	1.86e-09	0.00978	1.01	0.38	Schizophrenia;	chr9:69488332	chr5:159100483~159117478:+
OV	trans	rs1814175	0.817	rs12287396	ENSG00000134612.10	FOLH1B	-6.26	1.86e-09	0.00978	-0.49	-0.38	Height;	chr11:49798246	chr11:89639227~89698718:+
OV	trans	rs3770081	0.793	rs60719866	ENSG00000229880.1	IMMTP1	6.26	1.88e-09	0.00985	1.14	0.38	Facial emotion recognition (sad faces);	chr2:86057255	chr21:44675868~44678086:-
OV	trans	rs3770081	1	rs76081054	ENSG00000229880.1	IMMTP1	6.26	1.88e-09	0.00985	1.14	0.38	Facial emotion recognition (sad faces);	chr2:86057914	chr21:44675868~44678086:-
OV	trans	rs3770081	1	rs59947468	ENSG00000229880.1	IMMTP1	6.26	1.88e-09	0.00985	1.14	0.38	Facial emotion recognition (sad faces);	chr2:86062313	chr21:44675868~44678086:-
OV	trans	rs10242455	0.571	rs45532337	ENSG00000228834.1	RP11-249L21.4	6.26	1.88e-09	0.00985	0.77	0.38	Blood metabolite levels;	chr7:99712696	chr6:108907615~108907873:-
OV	trans	rs2727020	0.595	rs11040416	ENSG00000134612.10	FOLH1B	-6.26	1.88e-09	0.00986	-0.48	-0.38	Coronary artery disease;	chr11:49544877	chr11:89639227~89698718:+
OV	trans	rs11039798	0.92	rs11040015	ENSG00000134612.10	FOLH1B	6.26	1.9e-09	0.00997	0.64	0.38	Axial length;	chr11:48761578	chr11:89639227~89698718:+
OV	trans	rs4979906	1	rs4979910	ENSG00000230585.2	PHBP12	6.26	1.94e-09	0.0101	0.58	0.38	Mortality in heart failure;	chr10:77696803	chr1:50780340~50781150:+
OV	trans	rs8010715	0.636	rs2277480	ENSG00000248988.1	RP11-815N9.2	6.25	1.99e-09	0.0104	0.49	0.38	IgG glycosylation;	chr14:24118306	chr4:159007119~159007835:+
OV	trans	rs11098499	0.955	rs11944880	ENSG00000275858.1	RP11-291L22.8	-6.25	2.04e-09	0.0105	-0.39	-0.38	Corneal astigmatism;	chr4:119238179	chr10:38450738~38451069:-
OV	trans	rs877636	0.702	rs773109	ENSG00000234354.3	RPS26P47	6.24	2.08e-09	0.0108	0.45	0.38	Cognitive function;	chr12:55980911	chr13:100539901~100540248:-
OV	trans	rs1814175	0.754	rs10219245	ENSG00000134612.10	FOLH1B	-6.24	2.1e-09	0.0109	-0.5	-0.38	Height;	chr11:49623500	chr11:89639227~89698718:+
OV	trans	rs9858542	0.953	rs9827708	ENSG00000197582.5	GPX1P1	-6.24	2.11e-09	0.0109	-0.52	-0.38	Blood protein levels;Ulcerative colitis;Crohn's disease;	chr3:49612556	chrX:13378735~13379340:-
OV	trans	rs1568889	1	rs35343234	ENSG00000174912.7	METTL15P1	6.24	2.11e-09	0.0109	0.53	0.38	Bipolar disorder;	chr11:28012832	chr3:156713884~156714928:-
OV	trans	rs941207	0.526	rs7303216	ENSG00000121089.4	NACA3P	6.24	2.15e-09	0.0111	0.37	0.38	Platelet count;	chr12:56680909	chr4:164943290~164943937:+
OV	trans	rs941207	0.507	rs7297289	ENSG00000121089.4	NACA3P	6.24	2.15e-09	0.0111	0.37	0.38	Platelet count;	chr12:56682703	chr4:164943290~164943937:+
OV	trans	rs941207	0.526	rs4759028	ENSG00000121089.4	NACA3P	6.24	2.15e-09	0.0111	0.37	0.38	Platelet count;	chr12:56686399	chr4:164943290~164943937:+
OV	trans	rs7554511	0.861	rs10753888	ENSG00000244144.1	RP11-757F18.3	-6.24	2.17e-09	0.0112	-0.5	-0.38	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201037057	chr3:112185480~112185998:-
OV	trans	rs3942852	0.712	rs2174129	ENSG00000134612.10	FOLH1B	-6.24	2.17e-09	0.0112	-0.51	-0.38	Acute lymphoblastic leukemia (childhood);	chr11:48087005	chr11:89639227~89698718:+
OV	trans	rs73108077	0.79	rs73104055	ENSG00000279352.1	RP11-411B10.7	6.23	2.18e-09	0.0112	0.78	0.38	Red blood cell density in sickle cell anemia;	chr20:31293082	chr18:14010054~14010917:+
OV	trans	rs73108077	0.79	rs73104064	ENSG00000279352.1	RP11-411B10.7	6.23	2.18e-09	0.0112	0.78	0.38	Red blood cell density in sickle cell anemia;	chr20:31297920	chr18:14010054~14010917:+
OV	trans	rs73108077	0.79	rs73104067	ENSG00000279352.1	RP11-411B10.7	6.23	2.18e-09	0.0112	0.78	0.38	Red blood cell density in sickle cell anemia;	chr20:31298693	chr18:14010054~14010917:+
OV	trans	rs2980436	1	rs2980436	ENSG00000270154.1	RP11-419I17.1	-6.23	2.2e-09	0.0113	-0.45	-0.38	Schizophrenia;	chr8:8234503	chr8:12476462~12477122:+
OV	trans	rs6132905	0.52	rs2422823	ENSG00000235559.1	NOP56P1	-6.23	2.2e-09	0.0113	-0.51	-0.38	Mumps;	chr20:2665687	chr6:28783633~28784004:-
OV	trans	rs877636	0.74	rs772920	ENSG00000243538.1	CTB-55B8.1	6.23	2.24e-09	0.0115	0.41	0.38	Cognitive function;	chr12:55996580	chr5:16902294~16902641:-
OV	trans	rs1517114	1	rs1400550	ENSG00000233340.1	RP11-25C19.3	-6.22	2.36e-09	0.012	-0.4	-0.38	Response to irinotecan in non-small-cell lung cancer;	chr8:68482747	chr10:112671812~112677819:-
OV	trans	rs1517114	1	rs10105022	ENSG00000233340.1	RP11-25C19.3	-6.22	2.36e-09	0.012	-0.4	-0.38	Response to irinotecan in non-small-cell lung cancer;	chr8:68483386	chr10:112671812~112677819:-
OV	trans	rs1517114	0.932	rs4737261	ENSG00000233340.1	RP11-25C19.3	-6.22	2.36e-09	0.012	-0.4	-0.38	Response to irinotecan in non-small-cell lung cancer;	chr8:68480977	chr10:112671812~112677819:-
OV	trans	rs1517114	0.562	rs34472413	ENSG00000233340.1	RP11-25C19.3	-6.22	2.36e-09	0.012	-0.4	-0.38	Response to irinotecan in non-small-cell lung cancer;	chr8:68481357	chr10:112671812~112677819:-
OV	trans	rs1517114	1	rs2380461	ENSG00000233340.1	RP11-25C19.3	6.22	2.36e-09	0.012	0.4	0.38	Response to irinotecan in non-small-cell lung cancer;	chr8:68485962	chr10:112671812~112677819:-
OV	trans	rs1517114	0.898	rs4466385	ENSG00000233340.1	RP11-25C19.3	6.22	2.36e-09	0.012	0.4	0.38	Response to irinotecan in non-small-cell lung cancer;	chr8:68486575	chr10:112671812~112677819:-
OV	trans	rs1517114	0.965	rs4481578	ENSG00000233340.1	RP11-25C19.3	6.22	2.36e-09	0.012	0.4	0.38	Response to irinotecan in non-small-cell lung cancer;	chr8:68486745	chr10:112671812~112677819:-
OV	trans	rs4851250	0.58	rs56909870	ENSG00000221990.4	EXOC3-AS1	-6.22	2.43e-09	0.0123	-0.5	-0.38	Intelligence (multi-trait analysis);	chr2:100003555	chr5:441498~443160:-
OV	trans	rs3770081	1	rs2303339	ENSG00000229880.1	IMMTP1	-6.21	2.49e-09	0.0126	-1.1	-0.38	Facial emotion recognition (sad faces);	chr2:86119057	chr21:44675868~44678086:-
OV	trans	rs3770081	1	rs12620810	ENSG00000229880.1	IMMTP1	6.21	2.49e-09	0.0126	1.1	0.38	Facial emotion recognition (sad faces);	chr2:86164358	chr21:44675868~44678086:-
OV	trans	rs2039485	0.889	rs4981922	ENSG00000224650.2	IGHV3-74	6.21	2.5e-09	0.0127	0.44	0.38	Brain lesion load;	chr14:31868219	chr14:106810442~106811131:-
OV	trans	rs2727020	0.615	rs35423199	ENSG00000134612.10	FOLH1B	-6.21	2.54e-09	0.0129	-0.48	-0.38	Coronary artery disease;	chr11:49493362	chr11:89639227~89698718:+
OV	trans	rs2727020	0.658	rs1851992	ENSG00000134612.10	FOLH1B	-6.21	2.54e-09	0.0129	-0.47	-0.38	Coronary artery disease;	chr11:49416558	chr11:89639227~89698718:+
OV	trans	rs2727020	0.636	rs10839275	ENSG00000134612.10	FOLH1B	-6.21	2.54e-09	0.0129	-0.47	-0.38	Coronary artery disease;	chr11:49417410	chr11:89639227~89698718:+
OV	trans	rs2727020	0.658	rs4980442	ENSG00000134612.10	FOLH1B	-6.21	2.54e-09	0.0129	-0.47	-0.38	Coronary artery disease;	chr11:49423464	chr11:89639227~89698718:+
OV	trans	rs3770081	1	rs17584578	ENSG00000229880.1	IMMTP1	-6.2	2.59e-09	0.0131	-1.02	-0.38	Facial emotion recognition (sad faces);	chr2:86080501	chr21:44675868~44678086:-
OV	trans	rs7554511	0.707	rs3861928	ENSG00000244144.1	RP11-757F18.3	-6.2	2.68e-09	0.0135	-0.49	-0.38	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201051446	chr3:112185480~112185998:-
OV	trans	rs2727020	0.658	rs10839278	ENSG00000134612.10	FOLH1B	-6.2	2.69e-09	0.0135	-0.47	-0.38	Coronary artery disease;	chr11:49429295	chr11:89639227~89698718:+
OV	trans	rs2727020	0.636	rs11040368	ENSG00000134612.10	FOLH1B	-6.2	2.69e-09	0.0135	-0.47	-0.38	Coronary artery disease;	chr11:49432050	chr11:89639227~89698718:+
OV	trans	rs11220082	0.666	rs2241514	ENSG00000236257.1	EI24P2	-6.19	2.75e-09	0.0138	-0.49	-0.38	Schizophrenia;	chr11:125456130	chr1:158454198~158455273:+
OV	trans	rs73108077	1	rs73108077	ENSG00000279352.1	RP11-411B10.7	6.19	2.8e-09	0.014	0.87	0.38	Red blood cell density in sickle cell anemia;	chr20:31419056	chr18:14010054~14010917:+
OV	trans	rs7260598	0.535	rs13343732	ENSG00000261770.1	CTC-459F4.1	6.19	2.84e-09	0.0142	0.45	0.38	Response to taxane treatment (placlitaxel);	chr19:23928479	chr19:27757184~27760849:-
OV	trans	rs7121616	0.515	rs76088419	ENSG00000234176.1	HSPA8P1	6.19	2.86e-09	0.0143	0.57	0.38	Breast cancer;	chr11:123066813	chrX:121203182~121205014:-
OV	trans	rs10838798	0.523	rs2019093	ENSG00000134612.10	FOLH1B	-6.19	2.86e-09	0.0143	-0.48	-0.38	Height;	chr11:48175001	chr11:89639227~89698718:+
OV	trans	rs616147	0.671	rs674192	ENSG00000214263.2	RPSAP53	-6.18	2.88e-09	0.0144	-0.5	-0.38	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458653	chr13:67266845~67267706:-
OV	trans	rs7121616	0.531	rs10892958	ENSG00000234176.1	HSPA8P1	6.18	2.91e-09	0.0145	0.46	0.38	Breast cancer;	chr11:123061415	chrX:121203182~121205014:-
OV	trans	rs10838798	0.504	rs11039673	ENSG00000134612.10	FOLH1B	-6.18	2.92e-09	0.0146	-0.49	-0.38	Height;	chr11:48313604	chr11:89639227~89698718:+
OV	trans	rs2950393	0.857	rs1563896	ENSG00000121089.4	NACA3P	6.18	2.95e-09	0.0147	0.37	0.38	Platelet distribution width;	chr12:56699312	chr4:164943290~164943937:+
OV	trans	rs877636	0.701	rs34415530	ENSG00000243538.1	CTB-55B8.1	6.18	2.98e-09	0.0148	0.41	0.38	Cognitive function;	chr12:56050848	chr5:16902294~16902641:-
OV	trans	rs1814175	0.817	rs1851858	ENSG00000134612.10	FOLH1B	-6.18	3.01e-09	0.0149	-0.48	-0.38	Height;	chr11:49834086	chr11:89639227~89698718:+
OV	trans	rs2727020	0.576	rs12293522	ENSG00000134612.10	FOLH1B	-6.17	3.04e-09	0.0151	-0.47	-0.38	Coronary artery disease;	chr11:49536873	chr11:89639227~89698718:+
OV	trans	rs2727020	0.658	rs7111215	ENSG00000134612.10	FOLH1B	-6.17	3.07e-09	0.0152	-0.47	-0.38	Coronary artery disease;	chr11:49409000	chr11:89639227~89698718:+
OV	trans	rs1814175	0.817	rs2866863	ENSG00000134612.10	FOLH1B	-6.17	3.08e-09	0.0152	-0.48	-0.38	Height;	chr11:49931690	chr11:89639227~89698718:+
OV	trans	rs1814175	0.817	rs4881627	ENSG00000134612.10	FOLH1B	-6.17	3.08e-09	0.0152	-0.48	-0.38	Height;	chr11:49932403	chr11:89639227~89698718:+
OV	trans	rs1814175	0.781	rs12286395	ENSG00000134612.10	FOLH1B	-6.17	3.08e-09	0.0152	-0.48	-0.38	Height;	chr11:49932510	chr11:89639227~89698718:+
OV	trans	rs1814175	0.817	rs7927373	ENSG00000134612.10	FOLH1B	-6.17	3.08e-09	0.0152	-0.48	-0.38	Height;	chr11:49936088	chr11:89639227~89698718:+
OV	trans	rs1814175	0.817	rs10769641	ENSG00000134612.10	FOLH1B	-6.17	3.08e-09	0.0152	-0.48	-0.38	Height;	chr11:49938589	chr11:89639227~89698718:+
OV	trans	rs1814175	0.817	rs7109440	ENSG00000134612.10	FOLH1B	-6.17	3.08e-09	0.0152	-0.48	-0.38	Height;	chr11:49944744	chr11:89639227~89698718:+
OV	trans	rs1814175	0.781	rs11040681	ENSG00000134612.10	FOLH1B	-6.17	3.08e-09	0.0152	-0.48	-0.38	Height;	chr11:49960104	chr11:89639227~89698718:+
OV	trans	rs1814175	0.817	rs6486044	ENSG00000134612.10	FOLH1B	-6.17	3.08e-09	0.0152	-0.48	-0.38	Height;	chr11:49961168	chr11:89639227~89698718:+
OV	trans	rs1814175	0.817	rs11518158	ENSG00000134612.10	FOLH1B	-6.17	3.08e-09	0.0152	-0.48	-0.38	Height;	chr11:49964083	chr11:89639227~89698718:+
OV	trans	rs1814175	0.791	rs10839468	ENSG00000134612.10	FOLH1B	-6.17	3.08e-09	0.0152	-0.48	-0.38	Height;	chr11:49964738	chr11:89639227~89698718:+
OV	trans	rs1814175	0.817	rs6486046	ENSG00000134612.10	FOLH1B	-6.17	3.08e-09	0.0152	-0.48	-0.38	Height;	chr11:49975471	chr11:89639227~89698718:+
OV	trans	rs7395662	0.853	rs4882062	ENSG00000134612.10	FOLH1B	6.16	3.19e-09	0.0158	0.53	0.38	HDL cholesterol;	chr11:48431719	chr11:89639227~89698718:+
OV	trans	rs16937956	0.597	rs16937958	ENSG00000266891.1	RP11-692N5.2	6.16	3.22e-09	0.0159	0.5	0.38	Body mass index;	chr11:8382988	chr18:9734882~9735602:-
OV	trans	rs4981053	0.749	rs952535	ENSG00000234203.1	RP5-1050D4.2	-6.16	3.26e-09	0.0161	-0.41	-0.38	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr14:20022757	chr17:4972851~4974681:+
OV	trans	rs877636	0.859	rs3741499	ENSG00000239210.2	RPS26P55	-6.16	3.27e-09	0.0161	-0.39	-0.38	Cognitive function;	chr12:56080595	chr19:34533427~34534084:-
OV	trans	rs11220082	0.644	rs12577961	ENSG00000236257.1	EI24P2	-6.16	3.28e-09	0.0161	-0.51	-0.38	Schizophrenia;	chr11:125438943	chr1:158454198~158455273:+
OV	trans	rs73108077	0.79	rs73102082	ENSG00000279352.1	RP11-411B10.7	6.16	3.28e-09	0.0161	0.78	0.38	Red blood cell density in sickle cell anemia;	chr20:31288687	chr18:14010054~14010917:+
OV	trans	rs7395662	0.864	rs10839201	ENSG00000134612.10	FOLH1B	6.15	3.37e-09	0.0165	0.47	0.38	HDL cholesterol;	chr11:48967865	chr11:89639227~89698718:+
OV	trans	rs1517114	1	rs10089645	ENSG00000233340.1	RP11-25C19.3	-6.15	3.43e-09	0.0168	-0.39	-0.38	Response to irinotecan in non-small-cell lung cancer;	chr8:68479910	chr10:112671812~112677819:-
OV	trans	rs7142881	0.815	rs4981891	ENSG00000211625.2	IGKV3D-20	6.15	3.54e-09	0.0173	0.36	0.38	Response to iloperidone treatment (QT prolongation);	chr14:31724753	chr2:90038848~90039479:+
OV	trans	rs11220082	0.542	rs11220079	ENSG00000236257.1	EI24P2	-6.14	3.58e-09	0.0175	-0.5	-0.38	Schizophrenia;	chr11:125450033	chr1:158454198~158455273:+
OV	trans	rs2950393	0.927	rs11171914	ENSG00000121089.4	NACA3P	-6.14	3.64e-09	0.0178	-0.37	-0.38	Platelet distribution width;	chr12:56649462	chr4:164943290~164943937:+
OV	trans	rs4981053	0.775	rs7141391	ENSG00000234203.1	RP5-1050D4.2	6.14	3.66e-09	0.0178	0.42	0.38	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr14:20029578	chr17:4972851~4974681:+
OV	trans	rs1814175	0.647	rs10839394	ENSG00000134612.10	FOLH1B	-6.14	3.69e-09	0.018	-0.48	-0.38	Height;	chr11:49823195	chr11:89639227~89698718:+
OV	trans	rs166820	0.793	rs256518	ENSG00000280020.1	CTD-2095E4.4	-6.14	3.69e-09	0.018	-0.49	-0.38	Intelligence (multi-trait analysis);	chr5:90080254	chr17:32178946~32180074:-
OV	trans	rs9329221	0.537	rs6986911	ENSG00000253893.2	FAM85B	-6.14	3.74e-09	0.0182	-0.43	-0.38	Neuroticism;	chr8:10121013	chr8:8167819~8226614:-
OV	trans	rs1814175	0.647	rs61306292	ENSG00000134612.10	FOLH1B	-6.13	3.77e-09	0.0183	-0.48	-0.38	Height;	chr11:49834488	chr11:89639227~89698718:+
OV	trans	rs2727020	0.615	rs4980435	ENSG00000134612.10	FOLH1B	-6.13	3.81e-09	0.0185	-0.47	-0.38	Coronary artery disease;	chr11:49570024	chr11:89639227~89698718:+
OV	trans	rs7395662	0.504	rs11039701	ENSG00000134612.10	FOLH1B	-6.13	3.91e-09	0.019	-0.48	-0.38	HDL cholesterol;	chr11:48368286	chr11:89639227~89698718:+
OV	trans	rs673253	0.686	rs2842185	ENSG00000231007.5	CDC20P1	-6.12	3.97e-09	0.0192	-0.52	-0.38	Intelligence (multi-trait analysis);	chr1:43554060	chr9:87011652~87013151:+
OV	trans	rs673253	0.662	rs11210869	ENSG00000231007.5	CDC20P1	6.12	3.97e-09	0.0192	0.52	0.38	Intelligence (multi-trait analysis);	chr1:43560369	chr9:87011652~87013151:+
OV	trans	rs9650657	0.65	rs2898248	ENSG00000253981.4	ALG1L13P	6.12	4e-09	0.0193	0.47	0.38	Neuroticism;	chr8:10779240	chr8:8236003~8244667:-
OV	trans	rs73108077	0.79	rs73102048	ENSG00000279352.1	RP11-411B10.7	6.12	4.01e-09	0.0194	0.77	0.38	Red blood cell density in sickle cell anemia;	chr20:31277508	chr18:14010054~14010917:+
OV	trans	rs73108077	0.704	rs7273922	ENSG00000279352.1	RP11-411B10.7	6.12	4.01e-09	0.0194	0.77	0.38	Red blood cell density in sickle cell anemia;	chr20:31282601	chr18:14010054~14010917:+
OV	trans	rs73108077	0.79	rs73104050	ENSG00000279352.1	RP11-411B10.7	6.12	4.01e-09	0.0194	0.77	0.38	Red blood cell density in sickle cell anemia;	chr20:31289961	chr18:14010054~14010917:+
OV	trans	rs877636	0.701	rs34415530	ENSG00000234354.3	RPS26P47	6.12	4.02e-09	0.0194	0.46	0.38	Cognitive function;	chr12:56050848	chr13:100539901~100540248:-
OV	trans	rs1814175	0.754	rs28663627	ENSG00000134612.10	FOLH1B	-6.12	4.02e-09	0.0194	-0.47	-0.38	Height;	chr11:50089669	chr11:89639227~89698718:+
OV	trans	rs2727020	0.658	rs7120136	ENSG00000134612.10	FOLH1B	-6.12	4.09e-09	0.0197	-0.47	-0.38	Coronary artery disease;	chr11:49362806	chr11:89639227~89698718:+
OV	trans	rs2727020	0.658	rs10839269	ENSG00000134612.10	FOLH1B	-6.12	4.09e-09	0.0197	-0.47	-0.38	Coronary artery disease;	chr11:49364044	chr11:89639227~89698718:+
OV	trans	rs9650657	0.538	rs11250093	ENSG00000253981.4	ALG1L13P	6.12	4.1e-09	0.0197	0.4	0.38	Neuroticism;	chr8:10941318	chr8:8236003~8244667:-
OV	trans	rs11039798	0.844	rs6485820	ENSG00000134612.10	FOLH1B	6.12	4.13e-09	0.0198	0.62	0.38	Axial length;	chr11:48243159	chr11:89639227~89698718:+
OV	trans	rs11039798	0.699	rs7120775	ENSG00000134612.10	FOLH1B	6.12	4.13e-09	0.0198	0.62	0.38	Axial length;	chr11:48245184	chr11:89639227~89698718:+
OV	trans	rs747782	0.585	rs1604655	ENSG00000134612.10	FOLH1B	6.12	4.13e-09	0.0198	0.62	0.38	Intraocular pressure;	chr11:48253226	chr11:89639227~89698718:+
OV	trans	rs747782	0.585	rs1316604	ENSG00000134612.10	FOLH1B	6.12	4.13e-09	0.0198	0.62	0.38	Intraocular pressure;	chr11:48258244	chr11:89639227~89698718:+
OV	trans	rs877636	1	rs4759229	ENSG00000239210.2	RPS26P55	-6.12	4.14e-09	0.0199	-0.38	-0.38	Cognitive function;	chr12:56080696	chr19:34533427~34534084:-
OV	trans	rs1517114	1	rs4590428	ENSG00000233340.1	RP11-25C19.3	-6.11	4.21e-09	0.0202	-0.38	-0.38	Response to irinotecan in non-small-cell lung cancer;	chr8:68497294	chr10:112671812~112677819:-
OV	trans	rs1814175	0.817	rs1818890	ENSG00000134612.10	FOLH1B	-6.11	4.22e-09	0.0202	-0.47	-0.38	Height;	chr11:49835330	chr11:89639227~89698718:+
OV	trans	rs1814175	0.817	rs10839397	ENSG00000134612.10	FOLH1B	-6.11	4.22e-09	0.0202	-0.47	-0.38	Height;	chr11:49835522	chr11:89639227~89698718:+
OV	trans	rs73108077	1	rs73108061	ENSG00000279352.1	RP11-411B10.7	6.11	4.22e-09	0.0202	0.87	0.38	Red blood cell density in sickle cell anemia;	chr20:31413650	chr18:14010054~14010917:+
OV	trans	rs1878007	0.502	rs2673504	ENSG00000180539.7	C9orf139	6.11	4.23e-09	0.0202	0.46	0.38	Preschool internalizing problems;	chr3:173014815	chr9:137027464~137037957:+
OV	trans	rs1814175	0.817	rs10769618	ENSG00000134612.10	FOLH1B	-6.11	4.26e-09	0.0204	-0.47	-0.38	Height;	chr11:49800784	chr11:89639227~89698718:+
OV	trans	rs1568889	0.838	rs7121937	ENSG00000174912.7	METTL15P1	6.11	4.3e-09	0.0205	0.43	0.38	Bipolar disorder;	chr11:28338311	chr3:156713884~156714928:-
OV	trans	rs616147	0.616	rs1768234	ENSG00000214263.2	RPSAP53	-6.11	4.3e-09	0.0206	-0.51	-0.38	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39459821	chr13:67266845~67267706:-
OV	trans	rs616147	0.72	rs1768209	ENSG00000214263.2	RPSAP53	-6.11	4.31e-09	0.0206	-0.5	-0.38	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461184	chr13:67266845~67267706:-
OV	trans	rs616147	0.72	rs2965067	ENSG00000214263.2	RPSAP53	-6.11	4.31e-09	0.0206	-0.5	-0.38	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461546	chr13:67266845~67267706:-
OV	trans	rs4383453	0.513	rs7627445	ENSG00000260781.1	ARHGAP23P1	-6.11	4.36e-09	0.0208	-0.62	-0.38	Gestational age at birth (maternal effect);	chr3:123188368	chr16:33907419~33937167:-
OV	trans	rs7121616	0.531	rs11218941	ENSG00000234176.1	HSPA8P1	6.11	4.4e-09	0.0209	0.46	0.38	Breast cancer;	chr11:123061701	chrX:121203182~121205014:-
OV	trans	rs12643440	0.919	rs555912	ENSG00000270171.1	RP11-338N10.1	-6.1	4.43e-09	0.0211	-0.5	-0.38	Metabolite levels (Pyroglutamine);	chr4:17195559	chr1:7693124~7694844:-
OV	trans	rs2727020	0.617	rs1917311	ENSG00000134612.10	FOLH1B	-6.1	4.45e-09	0.0212	-0.47	-0.38	Coronary artery disease;	chr11:49401113	chr11:89639227~89698718:+
OV	trans	rs4415084	0.932	rs2218080	ENSG00000248208.1	RP11-153M7.1	6.1	4.47e-09	0.0213	0.44	0.38	Breast cancer;	chr5:44714228	chr4:153658572~153659653:+
OV	trans	rs747782	0.582	rs7949865	ENSG00000134612.10	FOLH1B	-6.1	4.49e-09	0.0214	-0.62	-0.38	Intraocular pressure;	chr11:48324650	chr11:89639227~89698718:+
OV	trans	rs673253	0.686	rs11580258	ENSG00000231007.5	CDC20P1	6.1	4.5e-09	0.0214	0.51	0.38	Intelligence (multi-trait analysis);	chr1:43550344	chr9:87011652~87013151:+
OV	trans	rs747782	0.528	rs16905753	ENSG00000134612.10	FOLH1B	6.1	4.51e-09	0.0214	0.62	0.38	Intraocular pressure;	chr11:48264354	chr11:89639227~89698718:+
OV	trans	rs11039798	0.764	rs4357721	ENSG00000134612.10	FOLH1B	-6.1	4.52e-09	0.0215	-0.62	-0.38	Axial length;	chr11:48333355	chr11:89639227~89698718:+
OV	trans	rs10838798	0.504	rs11039634	ENSG00000134612.10	FOLH1B	-6.1	4.54e-09	0.0215	-0.48	-0.38	Height;	chr11:48276291	chr11:89639227~89698718:+
OV	trans	rs7554511	0.624	rs5010839	ENSG00000244144.1	RP11-757F18.3	-6.1	4.57e-09	0.0217	-0.5	-0.38	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:201042916	chr3:112185480~112185998:-
OV	trans	rs8010715	0.636	rs3825584	ENSG00000248988.1	RP11-815N9.2	6.1	4.62e-09	0.0219	0.49	0.38	IgG glycosylation;	chr14:24118430	chr4:159007119~159007835:+
OV	trans	rs12145833	0.748	rs11807162	ENSG00000154608.12	CEP170P1	-6.1	4.65e-09	0.022	-0.56	-0.38	Obesity (early onset extreme);	chr1:243291378	chr4:118467590~118554204:+
OV	trans	rs941207	0.526	rs11171916	ENSG00000121089.4	NACA3P	-6.09	4.69e-09	0.0221	-0.37	-0.37	Platelet count;	chr12:56653236	chr4:164943290~164943937:+
OV	trans	rs2727020	0.658	rs4980440	ENSG00000134612.10	FOLH1B	-6.09	4.76e-09	0.0225	-0.47	-0.37	Coronary artery disease;	chr11:49364465	chr11:89639227~89698718:+
OV	trans	rs3096299	0.685	rs12935112	ENSG00000215030.5	RPL13P12	6.09	4.77e-09	0.0225	0.35	0.37	Multiple myeloma (IgH translocation);	chr16:89476450	chr17:17383377~17384012:-
OV	trans	rs11039798	0.925	rs6485831	ENSG00000134612.10	FOLH1B	6.09	4.8e-09	0.0226	0.62	0.37	Axial length;	chr11:48433479	chr11:89639227~89698718:+
OV	trans	rs73108077	0.764	rs75475053	ENSG00000279352.1	RP11-411B10.7	6.09	4.82e-09	0.0227	0.83	0.37	Red blood cell density in sickle cell anemia;	chr20:31217143	chr18:14010054~14010917:+
OV	trans	rs73108077	0.621	rs7261582	ENSG00000279352.1	RP11-411B10.7	6.09	4.82e-09	0.0227	0.83	0.37	Red blood cell density in sickle cell anemia;	chr20:31226977	chr18:14010054~14010917:+
OV	trans	rs73108077	0.57	rs73119526	ENSG00000279352.1	RP11-411B10.7	6.09	4.82e-09	0.0227	0.83	0.37	Red blood cell density in sickle cell anemia;	chr20:31252117	chr18:14010054~14010917:+
OV	trans	rs12709013	0.636	rs6499976	ENSG00000233719.3	GOT2P3	6.09	4.85e-09	0.0229	0.44	0.37	Blood metabolite ratios;	chr16:58770330	chr12:9641802~9643007:+
OV	trans	rs7647973	0.583	rs55935606	ENSG00000197582.5	GPX1P1	-6.09	4.86e-09	0.0229	-0.58	-0.37	Menarche (age at onset);	chr3:49528072	chrX:13378735~13379340:-
OV	trans	rs2727020	0.729	rs10742932	ENSG00000134612.10	FOLH1B	-6.09	4.87e-09	0.0229	-0.48	-0.37	Coronary artery disease;	chr11:49151682	chr11:89639227~89698718:+
OV	trans	rs747782	0.528	rs4370963	ENSG00000134612.10	FOLH1B	6.08	4.95e-09	0.0232	0.6	0.37	Intraocular pressure;	chr11:48412391	chr11:89639227~89698718:+
OV	trans	rs73108077	0.736	rs73104088	ENSG00000279352.1	RP11-411B10.7	6.08	5.01e-09	0.0235	0.77	0.37	Red blood cell density in sickle cell anemia;	chr20:31311110	chr18:14010054~14010917:+
OV	trans	rs7824557	0.815	rs958648	ENSG00000253893.2	FAM85B	6.08	5.04e-09	0.0236	0.4	0.37	Retinal vascular caliber;	chr8:11246386	chr8:8167819~8226614:-
OV	trans	rs7121616	0.576	rs4936767	ENSG00000241478.1	HSPA8P9	6.08	5.14e-09	0.024	0.44	0.37	Breast cancer;	chr11:123047451	chr3:137880295~137882237:+
OV	trans	rs1814175	0.765	rs11493326	ENSG00000134612.10	FOLH1B	-6.08	5.16e-09	0.0241	-0.48	-0.37	Height;	chr11:49996524	chr11:89639227~89698718:+
OV	trans	rs1351696	1	rs1351696	ENSG00000134612.10	FOLH1B	-6.07	5.3e-09	0.0247	-0.6	-0.37	D-dimer levels;	chr11:48360919	chr11:89639227~89698718:+
OV	trans	rs747782	0.528	rs624348	ENSG00000134612.10	FOLH1B	-6.07	5.3e-09	0.0247	-0.6	-0.37	Intraocular pressure;	chr11:48379243	chr11:89639227~89698718:+
OV	trans	rs11039798	0.623	rs584851	ENSG00000134612.10	FOLH1B	-6.07	5.3e-09	0.0247	-0.6	-0.37	Axial length;	chr11:48394769	chr11:89639227~89698718:+
OV	trans	rs747782	0.528	rs10838881	ENSG00000134612.10	FOLH1B	6.07	5.3e-09	0.0247	0.6	0.37	Intraocular pressure;	chr11:48365723	chr11:89639227~89698718:+
OV	trans	rs11039798	0.764	rs10838882	ENSG00000134612.10	FOLH1B	6.07	5.3e-09	0.0247	0.6	0.37	Axial length;	chr11:48371483	chr11:89639227~89698718:+
OV	trans	rs11039798	1	rs12223271	ENSG00000134612.10	FOLH1B	6.07	5.3e-09	0.0247	0.6	0.37	Axial length;	chr11:48395868	chr11:89639227~89698718:+
OV	trans	rs747782	0.639	rs17198985	ENSG00000134612.10	FOLH1B	6.07	5.36e-09	0.0249	0.62	0.37	Intraocular pressure;	chr11:48162013	chr11:89639227~89698718:+
OV	trans	rs7395662	0.786	rs12791074	ENSG00000134612.10	FOLH1B	-6.07	5.36e-09	0.0249	-0.46	-0.37	HDL cholesterol;	chr11:48983471	chr11:89639227~89698718:+
OV	trans	rs7824557	0.767	rs6985460	ENSG00000253981.4	ALG1L13P	6.07	5.4e-09	0.0251	0.42	0.37	Retinal vascular caliber;	chr8:11313578	chr8:8236003~8244667:-
OV	trans	rs11039798	1	rs7125559	ENSG00000134612.10	FOLH1B	6.07	5.43e-09	0.0252	0.62	0.37	Axial length;	chr11:48962655	chr11:89639227~89698718:+
OV	trans	rs11039798	1	rs7125913	ENSG00000134612.10	FOLH1B	6.07	5.43e-09	0.0252	0.62	0.37	Axial length;	chr11:48962766	chr11:89639227~89698718:+
OV	trans	rs6708331	0.504	rs2169837	ENSG00000232654.1	FAM136BP	6.07	5.44e-09	0.0252	0.47	0.37	Obesity-related traits;	chr2:70324775	chr6:3045384~3045800:+
OV	trans	rs7121616	0.563	rs1461494	ENSG00000241478.1	HSPA8P9	6.07	5.45e-09	0.0253	0.44	0.37	Breast cancer;	chr11:123055777	chr3:137880295~137882237:+
OV	trans	rs11039798	0.858	rs11039730	ENSG00000134612.10	FOLH1B	6.07	5.46e-09	0.0253	0.67	0.37	Axial length;	chr11:48418943	chr11:89639227~89698718:+
OV	trans	rs4851250	0.559	rs13032879	ENSG00000221990.4	EXOC3-AS1	-6.07	5.46e-09	0.0253	-0.48	-0.37	Intelligence (multi-trait analysis);	chr2:99986297	chr5:441498~443160:-
OV	trans	rs1517114	0.965	rs4009125	ENSG00000233340.1	RP11-25C19.3	-6.06	5.51e-09	0.0255	-0.39	-0.37	Response to irinotecan in non-small-cell lung cancer;	chr8:68478847	chr10:112671812~112677819:-
OV	trans	rs34421088	0.56	rs1478898	ENSG00000253893.2	FAM85B	6.06	5.64e-09	0.0261	0.4	0.37	Neuroticism;	chr8:11537570	chr8:8167819~8226614:-
OV	trans	rs7312770	0.612	rs773114	ENSG00000244641.2	RPS26P43	6.06	5.75e-09	0.0265	0.38	0.37	Polycystic ovary syndrome;Hypothyroidism;	chr12:55985276	chr11:123049787~123050353:-
OV	trans	rs7121616	0.595	rs7949414	ENSG00000241478.1	HSPA8P9	6.05	5.78e-09	0.0266	0.43	0.37	Breast cancer;	chr11:123072787	chr3:137880295~137882237:+
OV	trans	rs7512769	0.691	rs12136161	ENSG00000229786.1	SNRPFP2	-6.05	5.82e-09	0.0268	-0.44	-0.37	Bipolar disorder and schizophrenia;	chr1:196129224	chr1:25887360~25887610:+
OV	trans	rs1814175	0.654	rs7482446	ENSG00000134612.10	FOLH1B	-6.05	5.84e-09	0.0269	-0.46	-0.37	Height;	chr11:49757468	chr11:89639227~89698718:+
OV	trans	rs747782	0.583	rs11039666	ENSG00000134612.10	FOLH1B	6.05	5.85e-09	0.0269	0.68	0.37	Intraocular pressure;	chr11:48303289	chr11:89639227~89698718:+
OV	trans	rs10838798	0.504	rs11039627	ENSG00000134612.10	FOLH1B	-6.05	6.05e-09	0.0277	-0.48	-0.37	Height;	chr11:48272379	chr11:89639227~89698718:+
OV	trans	rs11039798	0.614	rs2174703	ENSG00000134612.10	FOLH1B	6.04	6.1e-09	0.0279	0.62	0.37	Axial length;	chr11:48766690	chr11:89639227~89698718:+
OV	trans	rs7142881	0.873	rs8020397	ENSG00000211625.2	IGKV3D-20	-6.04	6.15e-09	0.0281	-0.35	-0.37	Response to iloperidone treatment (QT prolongation);	chr14:31727036	chr2:90038848~90039479:+
OV	trans	rs9650657	0.524	rs2163379	ENSG00000253981.4	ALG1L13P	6.04	6.16e-09	0.0281	0.45	0.37	Neuroticism;	chr8:10874540	chr8:8236003~8244667:-
OV	trans	rs12643440	0.919	rs616878	ENSG00000270171.1	RP11-338N10.1	-6.04	6.21e-09	0.0283	-0.51	-0.37	Metabolite levels (Pyroglutamine);	chr4:17195379	chr1:7693124~7694844:-
OV	trans	rs7142881	0.873	rs36092827	ENSG00000211625.2	IGKV3D-20	-6.04	6.27e-09	0.0285	-0.36	-0.37	Response to iloperidone treatment (QT prolongation);	chr14:31623484	chr2:90038848~90039479:+
OV	trans	rs2727020	0.563	rs10769582	ENSG00000134612.10	FOLH1B	-6.04	6.32e-09	0.0287	-0.46	-0.37	Coronary artery disease;	chr11:49452488	chr11:89639227~89698718:+
OV	trans	rs12709013	0.636	rs10852565	ENSG00000230849.2	GOT2P2	6.04	6.36e-09	0.0289	0.45	0.37	Blood metabolite ratios;	chr16:58771277	chr1:173141100~173142350:-
OV	trans	rs2458413	0.542	rs2514670	ENSG00000279569.1	RP11-394B2.1	6.04	6.37e-09	0.029	0.33	0.37	Paget's disease;	chr8:104351224	chr16:70661667~70665836:+
OV	trans	rs877636	1	rs877636	ENSG00000219993.1	RP11-288G3.3	-6.04	6.4e-09	0.0291	-0.37	-0.37	Cognitive function;	chr12:56086799	chr6:7506203~7506549:+
OV	trans	rs6777098	0.793	rs28559571	ENSG00000276934.1	RP11-231E4.5	6.03	6.43e-09	0.0292	0.5	0.37	Response to paliperidone in schizophrenia (positive Marder score);	chr3:167123219	chr18:74504766~74505248:+
OV	trans	rs6777098	0.793	rs2139487	ENSG00000276934.1	RP11-231E4.5	-6.03	6.43e-09	0.0292	-0.5	-0.37	Response to paliperidone in schizophrenia (positive Marder score);	chr3:167114978	chr18:74504766~74505248:+
OV	trans	rs6777098	0.793	rs4109150	ENSG00000276934.1	RP11-231E4.5	-6.03	6.43e-09	0.0292	-0.5	-0.37	Response to paliperidone in schizophrenia (positive Marder score);	chr3:167116773	chr18:74504766~74505248:+
OV	trans	rs6777098	0.793	rs7617026	ENSG00000276934.1	RP11-231E4.5	-6.03	6.43e-09	0.0292	-0.5	-0.37	Response to paliperidone in schizophrenia (positive Marder score);	chr3:167118070	chr18:74504766~74505248:+
OV	trans	rs6777098	0.793	rs7627588	ENSG00000276934.1	RP11-231E4.5	-6.03	6.43e-09	0.0292	-0.5	-0.37	Response to paliperidone in schizophrenia (positive Marder score);	chr3:167118840	chr18:74504766~74505248:+
OV	trans	rs6777098	0.793	rs12493760	ENSG00000276934.1	RP11-231E4.5	-6.03	6.43e-09	0.0292	-0.5	-0.37	Response to paliperidone in schizophrenia (positive Marder score);	chr3:167119044	chr18:74504766~74505248:+
OV	trans	rs6777098	0.793	rs11917614	ENSG00000276934.1	RP11-231E4.5	-6.03	6.43e-09	0.0292	-0.5	-0.37	Response to paliperidone in schizophrenia (positive Marder score);	chr3:167119271	chr18:74504766~74505248:+
OV	trans	rs2069408	1	rs2069408	ENSG00000243538.1	CTB-55B8.1	-6.03	6.52e-09	0.0295	-0.41	-0.37	Asthma;	chr12:55970537	chr5:16902294~16902641:-
OV	trans	rs1814175	0.817	rs11040700	ENSG00000134612.10	FOLH1B	-6.03	6.54e-09	0.0296	-0.46	-0.37	Height;	chr11:50002293	chr11:89639227~89698718:+
OV	trans	rs1814175	0.712	rs9665784	ENSG00000134612.10	FOLH1B	-6.03	6.54e-09	0.0296	-0.46	-0.37	Height;	chr11:50009095	chr11:89639227~89698718:+
OV	trans	rs1568889	0.838	rs4572130	ENSG00000174912.7	METTL15P1	6.03	6.56e-09	0.0297	0.42	0.37	Bipolar disorder;	chr11:28350247	chr3:156713884~156714928:-
OV	trans	rs12643440	0.879	rs62294495	ENSG00000270171.1	RP11-338N10.1	6.03	6.6e-09	0.0298	0.52	0.37	Metabolite levels (Pyroglutamine);	chr4:17230280	chr1:7693124~7694844:-
OV	trans	rs616147	1	rs1768208	ENSG00000214263.2	RPSAP53	-6.03	6.62e-09	0.0299	-0.49	-0.37	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39481512	chr13:67266845~67267706:-
OV	trans	rs330048	0.545	rs11781008	ENSG00000253981.4	ALG1L13P	6.02	6.95e-09	0.0312	0.42	0.37	Systemic lupus erythematosus;	chr8:9295729	chr8:8236003~8244667:-
OV	trans	rs4981053	0.807	rs11626279	ENSG00000234203.1	RP5-1050D4.2	6.02	6.96e-09	0.0312	0.41	0.37	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr14:20021973	chr17:4972851~4974681:+
OV	trans	rs616147	0.671	rs675595	ENSG00000214263.2	RPSAP53	-6.02	7.04e-09	0.0315	-0.5	-0.37	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39458987	chr13:67266845~67267706:-
OV	trans	rs7142881	0.873	rs2378944	ENSG00000211625.2	IGKV3D-20	6.02	7.08e-09	0.0317	0.35	0.37	Response to iloperidone treatment (QT prolongation);	chr14:31733272	chr2:90038848~90039479:+
OV	trans	rs7142881	0.873	rs8020980	ENSG00000211625.2	IGKV3D-20	6.01	7.17e-09	0.0321	0.36	0.37	Response to iloperidone treatment (QT prolongation);	chr14:31735802	chr2:90038848~90039479:+
OV	trans	rs62413470	0.935	rs28808332	ENSG00000261357.1	RP11-626G11.1	6.01	7.23e-09	0.0323	0.7	0.37	Joint mobility (Beighton score);	chr6:56134115	chr16:19065991~19066694:+
OV	trans	rs62413470	1	rs28836882	ENSG00000261357.1	RP11-626G11.1	6.01	7.23e-09	0.0323	0.7	0.37	Joint mobility (Beighton score);	chr6:56134120	chr16:19065991~19066694:+
OV	trans	rs4851250	0.518	rs34490534	ENSG00000221990.4	EXOC3-AS1	-6.01	7.3e-09	0.0326	-0.47	-0.37	Intelligence (multi-trait analysis);	chr2:99999598	chr5:441498~443160:-
OV	trans	rs673253	0.686	rs2842187	ENSG00000231007.5	CDC20P1	-6.01	7.32e-09	0.0327	-0.48	-0.37	Intelligence (multi-trait analysis);	chr1:43549278	chr9:87011652~87013151:+
OV	trans	rs4979906	1	rs2395494	ENSG00000230585.2	PHBP12	6.01	7.46e-09	0.0331	0.51	0.37	Mortality in heart failure;	chr10:77698582	chr1:50780340~50781150:+
OV	trans	rs12538804	1	rs12538804	ENSG00000279198.1	CTD-2231E14.2	6	7.55e-09	0.0335	0.35	0.37	Urate levels in obese individuals;	chr7:7654288	chr19:16074293~16077395:-
OV	trans	rs6919210	0.948	rs6914372	ENSG00000257847.1	LSM3P2	6	7.6e-09	0.0337	0.56	0.37	Subjective well-being;	chr6:69871437	chr12:94590821~94591093:+
OV	trans	rs7113874	1	rs4929925	ENSG00000266891.1	RP11-692N5.2	-6	7.6e-09	0.0337	-0.43	-0.37	Body mass index (joint analysis main effects and physical activity interaction);Body mass index in physically active individuals;	chr11:8633640	chr18:9734882~9735602:-
OV	trans	rs7142881	0.708	rs35756264	ENSG00000211625.2	IGKV3D-20	6	7.71e-09	0.0342	0.36	0.37	Response to iloperidone treatment (QT prolongation);	chr14:31734757	chr2:90038848~90039479:+
OV	trans	rs7142881	0.873	rs12436187	ENSG00000211625.2	IGKV3D-20	6	7.71e-09	0.0342	0.36	0.37	Response to iloperidone treatment (QT prolongation);	chr14:31734797	chr2:90038848~90039479:+
OV	trans	rs4398173	0.522	rs6506459	ENSG00000274717.1	RP1-47A17.1	-6	7.78e-09	0.0344	-0.47	-0.37	Response to citalopram treatment;	chr18:6940558	chr22:42791814~42794313:-
OV	trans	rs1517114	1	rs1850386	ENSG00000233340.1	RP11-25C19.3	-6	7.81e-09	0.0345	-0.39	-0.37	Response to irinotecan in non-small-cell lung cancer;	chr8:68477868	chr10:112671812~112677819:-
OV	trans	rs4398173	0.561	rs7244230	ENSG00000274717.1	RP1-47A17.1	5.99	7.94e-09	0.035	0.49	0.37	Response to citalopram treatment;	chr18:6939756	chr22:42791814~42794313:-
OV	trans	rs10875976	0.525	rs67723963	ENSG00000264311.1	CCDC58P1	5.99	7.95e-09	0.035	0.44	0.37	Obesity;	chr12:49864759	chr18:10623876~10624305:-
OV	trans	rs941207	0.526	rs2950393	ENSG00000121089.4	NACA3P	-5.99	8.01e-09	0.0353	-0.37	-0.37	Platelet count;	chr12:56642239	chr4:164943290~164943937:+
OV	trans	rs7618501	0.933	rs1128535	ENSG00000197582.5	GPX1P1	5.99	8.26e-09	0.0361	0.45	0.37	Intelligence (multi-trait analysis);	chr3:49828959	chrX:13378735~13379340:-
OV	trans	rs7618501	0.902	rs7645061	ENSG00000197582.5	GPX1P1	5.99	8.26e-09	0.0361	0.45	0.37	Intelligence (multi-trait analysis);	chr3:49831409	chrX:13378735~13379340:-
OV	trans	rs7618501	1	rs695238	ENSG00000197582.5	GPX1P1	5.99	8.26e-09	0.0361	0.45	0.37	Intelligence (multi-trait analysis);	chr3:49831725	chrX:13378735~13379340:-
OV	trans	rs1814175	0.817	rs4084376	ENSG00000134612.10	FOLH1B	-5.99	8.27e-09	0.0362	-0.47	-0.37	Height;	chr11:49809608	chr11:89639227~89698718:+
OV	trans	rs877636	0.702	rs61937249	ENSG00000226339.1	RPS26P56	5.99	8.31e-09	0.0363	0.38	0.37	Cognitive function;	chr12:55988132	chrX:129408382~129408621:+
OV	trans	rs7647973	0.71	rs2029591	ENSG00000197582.5	GPX1P1	-5.98	8.48e-09	0.037	-0.61	-0.37	Menarche (age at onset);	chr3:49609548	chrX:13378735~13379340:-
OV	trans	rs258677	0.888	rs258667	ENSG00000207053.1	RNU6-937P	5.98	8.55e-09	0.0372	0.45	0.37	Positive affect;	chr7:82099057	chr20:35928570~35928675:-
OV	trans	rs673253	0.686	rs17371903	ENSG00000231007.5	CDC20P1	5.98	8.57e-09	0.0373	0.51	0.37	Intelligence (multi-trait analysis);	chr1:43605020	chr9:87011652~87013151:+
OV	trans	rs1814175	0.817	rs10839318	ENSG00000134612.10	FOLH1B	-5.98	8.58e-09	0.0373	-0.48	-0.37	Height;	chr11:49635959	chr11:89639227~89698718:+
OV	trans	rs7819412	0.595	rs10106914	ENSG00000253893.2	FAM85B	5.98	8.6e-09	0.0373	0.47	0.37	Triglycerides;	chr8:11130141	chr8:8167819~8226614:-
OV	trans	rs11039798	1	rs11039904	ENSG00000134612.10	FOLH1B	5.98	8.6e-09	0.0373	0.61	0.37	Axial length;	chr11:48661045	chr11:89639227~89698718:+
OV	trans	rs11039798	1	rs8188963	ENSG00000134612.10	FOLH1B	5.98	8.6e-09	0.0373	0.61	0.37	Axial length;	chr11:48664141	chr11:89639227~89698718:+
OV	trans	rs11039798	0.92	rs9667596	ENSG00000134612.10	FOLH1B	5.98	8.6e-09	0.0373	0.61	0.37	Axial length;	chr11:48669641	chr11:89639227~89698718:+
OV	trans	rs11039798	0.841	rs11500573	ENSG00000134612.10	FOLH1B	5.98	8.6e-09	0.0373	0.61	0.37	Axial length;	chr11:48692348	chr11:89639227~89698718:+
OV	trans	rs11039798	0.92	rs11500574	ENSG00000134612.10	FOLH1B	5.98	8.6e-09	0.0373	0.61	0.37	Axial length;	chr11:48692434	chr11:89639227~89698718:+
OV	trans	rs11039798	0.92	rs11039940	ENSG00000134612.10	FOLH1B	5.98	8.6e-09	0.0373	0.61	0.37	Axial length;	chr11:48694764	chr11:89639227~89698718:+
OV	trans	rs11039798	0.614	rs11039954	ENSG00000134612.10	FOLH1B	5.98	8.6e-09	0.0373	0.61	0.37	Axial length;	chr11:48720266	chr11:89639227~89698718:+
OV	trans	rs11039798	0.688	rs8188953	ENSG00000134612.10	FOLH1B	5.98	8.6e-09	0.0373	0.61	0.37	Axial length;	chr11:48727649	chr11:89639227~89698718:+
OV	trans	rs11039798	1	rs12225599	ENSG00000134612.10	FOLH1B	5.98	8.6e-09	0.0373	0.61	0.37	Axial length;	chr11:48734316	chr11:89639227~89698718:+
OV	trans	rs11039798	1	rs11039978	ENSG00000134612.10	FOLH1B	5.98	8.6e-09	0.0373	0.61	0.37	Axial length;	chr11:48738685	chr11:89639227~89698718:+
OV	trans	rs11039798	1	rs115429994	ENSG00000134612.10	FOLH1B	5.98	8.6e-09	0.0373	0.61	0.37	Axial length;	chr11:48739631	chr11:89639227~89698718:+
OV	trans	rs11039798	0.764	rs7294013	ENSG00000134612.10	FOLH1B	5.98	8.6e-09	0.0373	0.61	0.37	Axial length;	chr11:48740864	chr11:89639227~89698718:+
OV	trans	rs11039798	0.92	rs11040013	ENSG00000134612.10	FOLH1B	5.98	8.6e-09	0.0373	0.61	0.37	Axial length;	chr11:48761310	chr11:89639227~89698718:+
OV	trans	rs11039798	0.541	rs12283728	ENSG00000134612.10	FOLH1B	5.98	8.6e-09	0.0373	0.61	0.37	Axial length;	chr11:48774855	chr11:89639227~89698718:+
OV	trans	rs11039798	0.92	rs8186465	ENSG00000134612.10	FOLH1B	5.98	8.6e-09	0.0373	0.61	0.37	Axial length;	chr11:48775219	chr11:89639227~89698718:+
OV	trans	rs11039798	0.764	rs11040030	ENSG00000134612.10	FOLH1B	5.98	8.6e-09	0.0373	0.61	0.37	Axial length;	chr11:48779433	chr11:89639227~89698718:+
OV	trans	rs877636	0.692	rs10876870	ENSG00000231366.1	RP11-399N22.3	-5.98	8.64e-09	0.0374	-0.43	-0.37	Cognitive function;	chr12:56084218	chr10:70794230~70794523:-
OV	trans	rs877636	0.692	rs7971751	ENSG00000231366.1	RP11-399N22.3	-5.98	8.64e-09	0.0374	-0.43	-0.37	Cognitive function;	chr12:56084874	chr10:70794230~70794523:-
OV	trans	rs616147	0.655	rs1707981	ENSG00000214263.2	RPSAP53	-5.98	8.66e-09	0.0375	-0.5	-0.37	Amyotrophic lateral sclerosis (sporadic);Amyotrophic lateral sclerosis;	chr3:39461015	chr13:67266845~67267706:-
OV	trans	rs7121616	0.563	rs4936770	ENSG00000241478.1	HSPA8P9	5.98	8.67e-09	0.0376	0.43	0.37	Breast cancer;	chr11:123058167	chr3:137880295~137882237:+
OV	trans	rs13253073	0.723	rs1130569	ENSG00000260318.1	COX6CP1	5.98	8.7e-09	0.0377	0.47	0.37	Glucose homeostasis traits;	chr8:99887565	chr16:11903923~11904137:-
OV	trans	rs7000551	0.688	rs2948145	ENSG00000235488.1	JARID2-AS1	5.97	8.86e-09	0.0383	0.36	0.37	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr8:22510279	chr6:15247815~15248634:-
OV	trans	rs1814175	0.817	rs7924619	ENSG00000134612.10	FOLH1B	-5.97	8.89e-09	0.0384	-0.48	-0.37	Height;	chr11:49599080	chr11:89639227~89698718:+
OV	trans	rs1814175	0.817	rs7947526	ENSG00000134612.10	FOLH1B	-5.97	8.9e-09	0.0384	-0.47	-0.37	Height;	chr11:49962104	chr11:89639227~89698718:+
OV	trans	rs877636	0.702	rs773111	ENSG00000226339.1	RPS26P56	5.97	9e-09	0.0387	0.38	0.37	Cognitive function;	chr12:55981956	chrX:129408382~129408621:+
OV	trans	rs877636	0.702	rs773112	ENSG00000226339.1	RPS26P56	5.97	9e-09	0.0387	0.38	0.37	Cognitive function;	chr12:55982097	chrX:129408382~129408621:+
OV	trans	rs1814175	0.817	rs1996982	ENSG00000134612.10	FOLH1B	-5.97	9.01e-09	0.0387	-0.46	-0.37	Height;	chr11:49951067	chr11:89639227~89698718:+
OV	trans	rs1814175	0.817	rs7950856	ENSG00000134612.10	FOLH1B	-5.97	9.01e-09	0.0387	-0.46	-0.37	Height;	chr11:49954842	chr11:89639227~89698718:+
OV	trans	rs1814175	0.817	rs10839465	ENSG00000134612.10	FOLH1B	-5.97	9.01e-09	0.0387	-0.46	-0.37	Height;	chr11:49960004	chr11:89639227~89698718:+
OV	trans	rs1814175	0.817	rs7932683	ENSG00000134612.10	FOLH1B	-5.97	9.01e-09	0.0387	-0.46	-0.37	Height;	chr11:49962090	chr11:89639227~89698718:+
OV	trans	rs4981053	0.717	rs8014743	ENSG00000234203.1	RP5-1050D4.2	5.97	9.04e-09	0.0389	0.4	0.37	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr14:20030379	chr17:4972851~4974681:+
OV	trans	rs4415084	1	rs13155752	ENSG00000248208.1	RP11-153M7.1	5.97	9.05e-09	0.0389	0.42	0.37	Breast cancer;	chr5:44680585	chr4:153658572~153659653:+
OV	trans	rs1814175	0.817	rs2866545	ENSG00000134612.10	FOLH1B	-5.97	9.07e-09	0.039	-0.48	-0.37	Height;	chr11:49609272	chr11:89639227~89698718:+
OV	trans	rs1814175	0.817	rs12290508	ENSG00000134612.10	FOLH1B	-5.97	9.11e-09	0.0391	-0.48	-0.37	Height;	chr11:49599485	chr11:89639227~89698718:+
OV	trans	rs4383453	0.515	rs7616757	ENSG00000260781.1	ARHGAP23P1	-5.97	9.16e-09	0.0393	-0.61	-0.37	Gestational age at birth (maternal effect);	chr3:123257164	chr16:33907419~33937167:-
OV	trans	rs4383453	0.515	rs7616689	ENSG00000260781.1	ARHGAP23P1	-5.97	9.16e-09	0.0393	-0.61	-0.37	Gestational age at birth (maternal effect);	chr3:123257213	chr16:33907419~33937167:-
OV	trans	rs4869313	0.837	rs27998	ENSG00000272632.1	RP11-362F19.3	5.97	9.19e-09	0.0394	0.4	0.37	Pediatric autoimmune diseases;	chr5:97031704	chr4:141430831~141431284:+
OV	trans	rs6777098	0.793	rs6807388	ENSG00000276934.1	RP11-231E4.5	-5.97	9.21e-09	0.0395	-0.5	-0.37	Response to paliperidone in schizophrenia (positive Marder score);	chr3:167120148	chr18:74504766~74505248:+
OV	trans	rs8007846	0.631	rs8014475	ENSG00000200003.1	RNU6-986P	-5.97	9.24e-09	0.0396	-0.4	-0.37	Multiple sclerosis--Brain Glutamate Levels;	chr14:65344819	chr2:27475494~27475595:-
OV	trans	rs1360123	0.595	rs4459183	ENSG00000218676.1	BRD7P4	-5.97	9.25e-09	0.0396	-0.45	-0.37	Intelligence (multi-trait analysis);	chr10:25529848	chr6:111430260~111431781:+
OV	trans	rs4981053	0.745	rs17277003	ENSG00000234203.1	RP5-1050D4.2	5.97	9.28e-09	0.0398	0.4	0.37	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr14:20028666	chr17:4972851~4974681:+
OV	trans	rs4981053	0.775	rs12587722	ENSG00000234203.1	RP5-1050D4.2	5.97	9.28e-09	0.0398	0.4	0.37	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr14:20029327	chr17:4972851~4974681:+
OV	trans	rs7142881	0.873	rs11156703	ENSG00000211625.2	IGKV3D-20	5.96	9.31e-09	0.0398	0.35	0.37	Response to iloperidone treatment (QT prolongation);	chr14:31734215	chr2:90038848~90039479:+
OV	trans	rs7142881	0.873	rs6571459	ENSG00000211625.2	IGKV3D-20	5.96	9.31e-09	0.0398	0.35	0.37	Response to iloperidone treatment (QT prolongation);	chr14:31735401	chr2:90038848~90039479:+
OV	trans	rs7142881	0.873	rs919521	ENSG00000211625.2	IGKV3D-20	5.96	9.31e-09	0.0398	0.35	0.37	Response to iloperidone treatment (QT prolongation);	chr14:31738684	chr2:90038848~90039479:+
OV	trans	rs6919210	0.948	rs1572898	ENSG00000257847.1	LSM3P2	5.96	9.32e-09	0.0399	0.54	0.37	Subjective well-being;	chr6:69869212	chr12:94590821~94591093:+
OV	trans	rs4238010	0.541	rs17772352	ENSG00000260809.1	CTD-2144E22.10	5.96	9.35e-09	0.04	0.96	0.37	Major depressive disorder;	chr12:4015000	chr16:35090501~35104834:+
OV	trans	rs10783779	0.647	rs705708	ENSG00000243403.1	RP11-330L19.1	5.96	9.46e-09	0.0403	0.36	0.37	Educational attainment;	chr12:56095129	chr15:64592979~64593326:+
OV	trans	rs2458413	0.542	rs2002812	ENSG00000279569.1	RP11-394B2.1	-5.96	9.47e-09	0.0403	-0.32	-0.37	Paget's disease;	chr8:104353006	chr16:70661667~70665836:+
OV	trans	rs10242455	0.571	rs45527841	ENSG00000228834.1	RP11-249L21.4	5.96	9.54e-09	0.0406	0.75	0.37	Blood metabolite levels;	chr7:99713342	chr6:108907615~108907873:-
OV	trans	rs10242455	0.571	rs73713595	ENSG00000228834.1	RP11-249L21.4	5.96	9.54e-09	0.0406	0.75	0.37	Blood metabolite levels;	chr7:99729036	chr6:108907615~108907873:-
OV	trans	rs941207	0.542	rs11171978	ENSG00000121089.4	NACA3P	5.96	9.54e-09	0.0406	0.37	0.37	Platelet count;	chr12:56800015	chr4:164943290~164943937:+
OV	trans	rs877636	0.702	rs773110	ENSG00000226339.1	RPS26P56	5.96	9.56e-09	0.0407	0.38	0.37	Cognitive function;	chr12:55981353	chrX:129408382~129408621:+
OV	trans	rs4981053	0.745	rs56396302	ENSG00000234203.1	RP5-1050D4.2	5.96	9.6e-09	0.0409	0.4	0.37	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr14:20027032	chr17:4972851~4974681:+
OV	trans	rs4496150	0.531	rs11642216	ENSG00000205847.5	OR7E91P	-5.96	9.66e-09	0.0411	-0.47	-0.37	Breast cancer;	chr16:87064273	chr2:71029028~71029893:+
OV	trans	rs11039798	0.614	rs8188910	ENSG00000134612.10	FOLH1B	5.96	9.7e-09	0.0412	0.61	0.37	Axial length;	chr11:48804188	chr11:89639227~89698718:+
OV	trans	rs11039798	0.61	rs11530356	ENSG00000134612.10	FOLH1B	5.96	9.7e-09	0.0412	0.61	0.37	Axial length;	chr11:48814738	chr11:89639227~89698718:+
OV	trans	rs11039798	0.688	rs12277029	ENSG00000134612.10	FOLH1B	5.96	9.7e-09	0.0412	0.61	0.37	Axial length;	chr11:48831281	chr11:89639227~89698718:+
OV	trans	rs11039798	0.764	rs2089208	ENSG00000134612.10	FOLH1B	5.96	9.7e-09	0.0412	0.61	0.37	Axial length;	chr11:48878308	chr11:89639227~89698718:+
OV	trans	rs4981053	0.685	rs11621354	ENSG00000234203.1	RP5-1050D4.2	5.96	9.76e-09	0.0414	0.4	0.37	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr14:20030680	chr17:4972851~4974681:+
OV	trans	rs4981053	0.841	rs11627640	ENSG00000234203.1	RP5-1050D4.2	5.96	9.76e-09	0.0414	0.4	0.37	Acute graft versus host disease in bone marrow transplantation (recipient effect);	chr14:20031031	chr17:4972851~4974681:+
OV	trans	rs1814175	0.817	rs28525029	ENSG00000134612.10	FOLH1B	-5.95	9.96e-09	0.0421	-0.46	-0.37	Height;	chr11:50086656	chr11:89639227~89698718:+
OV	trans	rs1814175	0.817	rs28544182	ENSG00000134612.10	FOLH1B	-5.95	9.96e-09	0.0421	-0.46	-0.37	Height;	chr11:50090417	chr11:89639227~89698718:+
OV	trans	rs6601327	0.602	rs7829463	ENSG00000253893.2	FAM85B	5.95	1e-08	0.0422	0.42	0.37	Multiple myeloma (hyperdiploidy);	chr8:9792181	chr8:8167819~8226614:-
OV	trans	rs7554511	0.861	rs296563	ENSG00000244144.1	RP11-757F18.3	5.95	1.01e-08	0.0427	0.49	0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200975712	chr3:112185480~112185998:-
OV	trans	rs858239	0.863	rs274058	ENSG00000273010.1	RP11-96K19.5	-5.95	1.01e-08	0.0427	-0.45	-0.37	Cerebrospinal fluid biomarker levels;	chr7:23351890	chr1:110963302~110964649:+
OV	trans	rs12643440	0.96	rs34891733	ENSG00000270171.1	RP11-338N10.1	5.95	1.03e-08	0.0432	0.5	0.37	Metabolite levels (Pyroglutamine);	chr4:17202934	chr1:7693124~7694844:-
OV	trans	rs1814175	0.754	rs10839453	ENSG00000134612.10	FOLH1B	-5.95	1.03e-08	0.0433	-0.46	-0.37	Height;	chr11:49934263	chr11:89639227~89698718:+
OV	trans	rs747782	0.528	rs11039669	ENSG00000134612.10	FOLH1B	5.94	1.04e-08	0.0437	0.6	0.37	Intraocular pressure;	chr11:48307266	chr11:89639227~89698718:+
OV	trans	rs11039798	0.858	rs7121333	ENSG00000134612.10	FOLH1B	5.94	1.04e-08	0.0437	0.6	0.37	Axial length;	chr11:48310586	chr11:89639227~89698718:+
OV	trans	rs747782	0.528	rs11039674	ENSG00000134612.10	FOLH1B	5.94	1.04e-08	0.0437	0.6	0.37	Intraocular pressure;	chr11:48314564	chr11:89639227~89698718:+
OV	trans	rs10242455	0.571	rs73713594	ENSG00000228834.1	RP11-249L21.4	5.94	1.06e-08	0.0443	0.74	0.37	Blood metabolite levels;	chr7:99728875	chr6:108907615~108907873:-
OV	trans	rs1517114	1	rs6982746	ENSG00000233340.1	RP11-25C19.3	-5.94	1.07e-08	0.0444	-0.36	-0.37	Response to irinotecan in non-small-cell lung cancer;	chr8:68479210	chr10:112671812~112677819:-
OV	trans	rs6777098	0.788	rs56239365	ENSG00000276934.1	RP11-231E4.5	5.94	1.08e-08	0.0446	0.5	0.37	Response to paliperidone in schizophrenia (positive Marder score);	chr3:167122737	chr18:74504766~74505248:+
OV	trans	rs2039485	0.924	rs2039483	ENSG00000224650.2	IGHV3-74	5.94	1.08e-08	0.0447	0.42	0.37	Brain lesion load;	chr14:31876019	chr14:106810442~106811131:-
OV	trans	rs7554511	0.861	rs378672	ENSG00000244144.1	RP11-757F18.3	5.94	1.09e-08	0.045	0.47	0.37	Ulcerative colitis;Crohn's disease;Inflammatory bowel disease;	chr1:200917205	chr3:112185480~112185998:-
OV	trans	rs11146838	1	rs11146838	ENSG00000276997.3	RP11-378J18.9	5.93	1.09e-08	0.045	0.39	0.37	Breast cancer;	chr10:38856846	chr1:222477252~222504622:-
OV	trans	rs7944735	0.517	rs11039538	ENSG00000134612.10	FOLH1B	5.93	1.1e-08	0.0453	0.62	0.37	Intraocular pressure;	chr11:48133438	chr11:89639227~89698718:+
OV	trans	rs10908521	0.611	rs7516736	ENSG00000227183.3	HDGFP1	-5.93	1.11e-08	0.0456	-0.46	-0.37	Uric acid clearance;	chr1:156825994	chrX:131646639~131646890:+
OV	trans	rs7000551	0.675	rs2443503	ENSG00000235488.1	JARID2-AS1	5.93	1.11e-08	0.0457	0.37	0.37	B-type natriuretic peptide to N-terminal pro B-type natriuretic peptide ratio;	chr8:22524337	chr6:15247815~15248634:-
OV	trans	rs17040773	1	rs17040773	ENSG00000259366.1	CTD-2647L4.4	5.93	1.12e-08	0.0459	0.39	0.37	Bone mineral density;	chr2:111742458	chr8:29055935~29056685:+
OV	trans	rs9447700	0.725	rs12527804	ENSG00000176912.3	TYMSOS	5.93	1.12e-08	0.0459	0.39	0.37	Menarche (age at onset);	chr6:76304792	chr18:641320~658340:-
OV	trans	rs4415084	0.834	rs10043344	ENSG00000248208.1	RP11-153M7.1	-5.93	1.12e-08	0.0461	-0.43	-0.37	Breast cancer;	chr5:44926416	chr4:153658572~153659653:+
OV	trans	rs1517114	1	rs4737910	ENSG00000233340.1	RP11-25C19.3	-5.93	1.13e-08	0.0462	-0.4	-0.37	Response to irinotecan in non-small-cell lung cancer;	chr8:68480974	chr10:112671812~112677819:-
OV	trans	rs7512898	0.5	rs10733063	ENSG00000244144.1	RP11-757F18.3	-5.93	1.13e-08	0.0462	-0.51	-0.37	Electrocardiographic conduction measures;	chr1:200821181	chr3:112185480~112185998:-
OV	trans	rs7047280	0.683	rs13295645	ENSG00000254065.1	RP11-697N18.2	-5.93	1.13e-08	0.0463	-0.44	-0.37	Plasma t-tau levels;	chr9:23328667	chr8:47592147~47592609:-
OV	trans	rs1814175	0.817	rs10769598	ENSG00000134612.10	FOLH1B	-5.93	1.14e-08	0.0464	-0.46	-0.37	Height;	chr11:49647774	chr11:89639227~89698718:+
OV	trans	rs12643440	0.96	rs474634	ENSG00000270171.1	RP11-338N10.1	-5.93	1.14e-08	0.0467	-0.48	-0.37	Metabolite levels (Pyroglutamine);	chr4:17196420	chr1:7693124~7694844:-
OV	trans	rs2727020	0.573	rs7925419	ENSG00000134612.10	FOLH1B	-5.93	1.15e-08	0.0468	-0.46	-0.37	Coronary artery disease;	chr11:49210307	chr11:89639227~89698718:+
OV	trans	rs10838798	0.517	rs1967210	ENSG00000134612.10	FOLH1B	-5.92	1.15e-08	0.0469	-0.56	-0.37	Height;	chr11:48075140	chr11:89639227~89698718:+
OV	trans	rs6777098	0.793	rs12494179	ENSG00000276934.1	RP11-231E4.5	5.92	1.16e-08	0.0473	0.5	0.37	Response to paliperidone in schizophrenia (positive Marder score);	chr3:167226517	chr18:74504766~74505248:+
OV	trans	rs1360123	0.617	rs1932148	ENSG00000218676.1	BRD7P4	-5.92	1.17e-08	0.0475	-0.45	-0.37	Intelligence (multi-trait analysis);	chr10:25528737	chr6:111430260~111431781:+
OV	trans	rs1814175	0.791	rs7395713	ENSG00000134612.10	FOLH1B	-5.92	1.17e-08	0.0478	-0.46	-0.37	Height;	chr11:49856335	chr11:89639227~89698718:+
OV	trans	rs6777098	0.793	rs13084399	ENSG00000276934.1	RP11-231E4.5	-5.92	1.18e-08	0.0479	-0.49	-0.37	Response to paliperidone in schizophrenia (positive Marder score);	chr3:167229900	chr18:74504766~74505248:+
OV	trans	rs1814175	0.791	rs10769593	ENSG00000134612.10	FOLH1B	-5.92	1.18e-08	0.0481	-0.47	-0.37	Height;	chr11:49594665	chr11:89639227~89698718:+
OV	trans	rs6777098	0.537	rs4352376	ENSG00000276934.1	RP11-231E4.5	-5.92	1.19e-08	0.0482	-0.49	-0.37	Response to paliperidone in schizophrenia (positive Marder score);	chr3:167218379	chr18:74504766~74505248:+
OV	trans	rs6777098	0.793	rs9830639	ENSG00000276934.1	RP11-231E4.5	5.92	1.19e-08	0.0482	0.49	0.37	Response to paliperidone in schizophrenia (positive Marder score);	chr3:167208229	chr18:74504766~74505248:+
OV	trans	rs1814175	0.541	rs12287397	ENSG00000134612.10	FOLH1B	-5.92	1.19e-08	0.0484	-0.47	-0.37	Height;	chr11:49798247	chr11:89639227~89698718:+
OV	trans	rs2281680	1	rs2281680	ENSG00000278594.1	RP11-146E13.5	5.92	1.19e-08	0.0484	0.61	0.37	Sudden cardiac arrest;	chr14:23563861	chr14:19131842~19132890:-
OV	trans	rs2458413	0.5	rs2251930	ENSG00000279569.1	RP11-394B2.1	-5.92	1.19e-08	0.0484	-0.33	-0.37	Paget's disease;	chr8:104345536	chr16:70661667~70665836:+
OV	trans	rs2458413	0.5	rs2514665	ENSG00000279569.1	RP11-394B2.1	-5.92	1.19e-08	0.0485	-0.33	-0.37	Paget's disease;	chr8:104339303	chr16:70661667~70665836:+
OV	trans	rs1814175	0.791	rs10769625	ENSG00000134612.10	FOLH1B	-5.92	1.2e-08	0.0486	-0.46	-0.37	Height;	chr11:49848335	chr11:89639227~89698718:+
OV	trans	rs1814175	0.817	rs7947286	ENSG00000134612.10	FOLH1B	-5.92	1.2e-08	0.0486	-0.46	-0.37	Height;	chr11:49853105	chr11:89639227~89698718:+
OV	trans	rs1814175	0.715	rs10839409	ENSG00000134612.10	FOLH1B	-5.92	1.2e-08	0.0486	-0.46	-0.37	Height;	chr11:49863095	chr11:89639227~89698718:+
OV	trans	rs1814175	0.781	rs2866734	ENSG00000134612.10	FOLH1B	-5.92	1.2e-08	0.0486	-0.46	-0.37	Height;	chr11:49864786	chr11:89639227~89698718:+
OV	trans	rs1814175	0.817	rs1615305	ENSG00000134612.10	FOLH1B	-5.92	1.2e-08	0.0486	-0.46	-0.37	Height;	chr11:49873670	chr11:89639227~89698718:+
OV	trans	rs1814175	0.817	rs1621090	ENSG00000134612.10	FOLH1B	-5.92	1.2e-08	0.0486	-0.46	-0.37	Height;	chr11:49874316	chr11:89639227~89698718:+
OV	trans	rs6777098	0.757	rs4245910	ENSG00000276934.1	RP11-231E4.5	-5.92	1.2e-08	0.0486	-0.49	-0.37	Response to paliperidone in schizophrenia (positive Marder score);	chr3:167239018	chr18:74504766~74505248:+
OV	trans	rs7142881	0.873	rs7144102	ENSG00000211625.2	IGKV3D-20	-5.92	1.21e-08	0.0487	-0.35	-0.37	Response to iloperidone treatment (QT prolongation);	chr14:31619021	chr2:90038848~90039479:+
OV	trans	rs11039798	0.764	rs1121450	ENSG00000134612.10	FOLH1B	5.92	1.21e-08	0.0489	0.61	0.37	Axial length;	chr11:48875924	chr11:89639227~89698718:+
OV	trans	rs877636	1	rs2292239	ENSG00000243538.1	CTB-55B8.1	5.91	1.22e-08	0.0491	0.39	0.37	Cognitive function;	chr12:56088396	chr5:16902294~16902641:-
OV	trans	rs6777098	0.881	rs7647942	ENSG00000276934.1	RP11-231E4.5	-5.91	1.22e-08	0.0492	-0.49	-0.37	Response to paliperidone in schizophrenia (positive Marder score);	chr3:167118549	chr18:74504766~74505248:+
OV	trans	rs4918814	0.518	rs569586	ENSG00000274494.1	MIR6832	-5.91	1.22e-08	0.0494	-0.53	-0.37	Neuroticism (multi-trait analysis);	chr10:113336731	chr6:31633787~31633858:+
OV	trans	rs7121616	0.515	rs11218966	ENSG00000241478.1	HSPA8P9	5.91	1.23e-08	0.0496	0.54	0.37	Breast cancer;	chr11:123086510	chr3:137880295~137882237:+